In POS N
sildenafil POS N
versus POS N
placebo POS N
arms, POS N
week-12 POS N
6MWD POS N
increases POS N
were POS N
similar POS N
(least POS N
squares POS N
mean POS N
difference POS N
[sildenafil-placebo], POS N
-2.4 POS N
m POS N
[90% POS N
CI: POS N
-21.8 POS N
to POS N
17.1 POS N
m]; POS N
P POS N
= POS N
0.6); POS N
mean POS N
± POS N
SD POS N
changes POS N
from POS N
baseline POS N
were POS N
26.4 POS N
± POS N
45.7 POS N
versus POS N
11.8 POS N
± POS N
57.4 POS N
m, POS N
respectively, POS N
in POS N
IPAH POS N
(65% POS N
of POS N
population) POS N
and POS N
-18.3 POS N
± POS N
82.0 POS N
versus POS N
17.5 POS N
± POS N
59.1 POS N
m POS N
in POS N
APAH-CTD POS N
(35% POS N
of POS N
population). POS N

Changes POS N
in POS N
WHO POS N
functional POS N
class POS N
and POS N
Borg POS N
dyspnoea POS N
score POS N
and POS N
incidence POS N
of POS N
clinical POS N
worsening POS N
did POS N
not POS N
differ. POS N

In POS N
sildenafil POS N
versus POS N
placebo POS N
arms, POS N
week-12 POS N
6MWD POS N
increases POS N
were POS N
similar POS N
(least POS N
squares POS N
mean POS N
difference POS N
[sildenafil-placebo], POS N
-2.4 POS N
m POS N
[90% POS N
CI: POS N
-21.8 POS N
to POS N
17.1 POS N
m]; POS N
P POS N
= POS N
0.6); POS N
mean POS N
± POS N
SD POS N
changes POS N
from POS N
baseline POS N
were POS N
26.4 POS N
± POS N
45.7 POS N
versus POS N
11.8 POS N
± POS N
57.4 POS N
m, POS N
respectively, POS N
in POS N
IPAH POS N
(65% POS N
of POS N
population) POS N
and POS N
-18.3 POS N
± POS N
82.0 POS N
versus POS N
17.5 POS N
± POS N
59.1 POS N
m POS N
in POS N
APAH-CTD POS N
(35% POS N
of POS N
population). POS N

Headache, POS N
diarrhoea, POS N
and POS N
flushing POS N
were POS N
more POS N
common POS N
with POS N
sildenafil. POS N

In POS N
sildenafil POS N
versus POS N
placebo POS N
arms, POS N
week-12 POS N
6MWD POS N
increases POS N
were POS N
similar POS N
(least POS N
squares POS N
mean POS N
difference POS N
[sildenafil-placebo], POS N
-2.4 POS N
m POS N
[90% POS N
CI: POS N
-21.8 POS N
to POS N
17.1 POS N
m]; POS N
P POS N
= POS N
0.6); POS N
mean POS N
± POS N
SD POS N
changes POS N
from POS N
baseline POS N
were POS N
26.4 POS N
± POS N
45.7 POS N
versus POS N
11.8 POS N
± POS N
57.4 POS N
m, POS N
respectively, POS N
in POS N
IPAH POS N
(65% POS N
of POS N
population) POS N
and POS N
-18.3 POS N
± POS N
82.0 POS N
versus POS N
17.5 POS N
± POS N
59.1 POS N
m POS N
in POS N
APAH-CTD POS N
(35% POS N
of POS N
population). POS N

Sildenafil, POS N
in POS N
addition POS N
to POS N
stable POS N
(≥3 POS N
months) POS N
bosentan POS N
therapy, POS N
had POS N
no POS N
benefit POS N
over POS N
placebo POS N
for POS N
12-week POS N
change POS N
from POS N
baseline POS N
in POS N
6MWD. POS N

Changes POS N
in POS N
WHO POS N
functional POS N
class POS N
and POS N
Borg POS N
dyspnoea POS N
score POS N
and POS N
incidence POS N
of POS N
clinical POS N
worsening POS N
did POS N
not POS N
differ. POS N

In POS N
sildenafil POS N
versus POS N
placebo POS N
arms, POS N
week-12 POS N
6MWD POS N
increases POS N
were POS N
similar POS N
(least POS N
squares POS N
mean POS N
difference POS N
[sildenafil-placebo], POS N
-2.4 POS N
m POS N
[90% POS N
CI: POS N
-21.8 POS N
to POS N
17.1 POS N
m]; POS N
P POS N
= POS N
0.6); POS N
mean POS N
± POS N
SD POS N
changes POS N
from POS N
baseline POS N
were POS N
26.4 POS N
± POS N
45.7 POS N
versus POS N
11.8 POS N
± POS N
57.4 POS N
m, POS N
respectively, POS N
in POS N
IPAH POS N
(65% POS N
of POS N
population) POS N
and POS N
-18.3 POS N
± POS N
82.0 POS N
versus POS N
17.5 POS N
± POS N
59.1 POS N
m POS N
in POS N
APAH-CTD POS N
(35% POS N
of POS N
population). POS N

Changes POS N
in POS N
WHO POS N
functional POS N
class POS N
and POS N
Borg POS N
dyspnoea POS N
score POS N
and POS N
incidence POS N
of POS N
clinical POS N
worsening POS N
did POS N
not POS N
differ. POS N

Headache, POS N
diarrhoea, POS N
and POS N
flushing POS N
were POS N
more POS N
common POS N
with POS N
sildenafil. POS N

Changes POS N
in POS N
WHO POS N
functional POS N
class POS N
and POS N
Borg POS N
dyspnoea POS N
score POS N
and POS N
incidence POS N
of POS N
clinical POS N
worsening POS N
did POS N
not POS N
differ. POS N

Sildenafil, POS N
in POS N
addition POS N
to POS N
stable POS N
(≥3 POS N
months) POS N
bosentan POS N
therapy, POS N
had POS N
no POS N
benefit POS N
over POS N
placebo POS N
for POS N
12-week POS N
change POS N
from POS N
baseline POS N
in POS N
6MWD. POS N

Headache, POS N
diarrhoea, POS N
and POS N
flushing POS N
were POS N
more POS N
common POS N
with POS N
sildenafil. POS N

In POS N
sildenafil POS N
versus POS N
placebo POS N
arms, POS N
week-12 POS N
6MWD POS N
increases POS N
were POS N
similar POS N
(least POS N
squares POS N
mean POS N
difference POS N
[sildenafil-placebo], POS N
-2.4 POS N
m POS N
[90% POS N
CI: POS N
-21.8 POS N
to POS N
17.1 POS N
m]; POS N
P POS N
= POS N
0.6); POS N
mean POS N
± POS N
SD POS N
changes POS N
from POS N
baseline POS N
were POS N
26.4 POS N
± POS N
45.7 POS N
versus POS N
11.8 POS N
± POS N
57.4 POS N
m, POS N
respectively, POS N
in POS N
IPAH POS N
(65% POS N
of POS N
population) POS N
and POS N
-18.3 POS N
± POS N
82.0 POS N
versus POS N
17.5 POS N
± POS N
59.1 POS N
m POS N
in POS N
APAH-CTD POS N
(35% POS N
of POS N
population). POS N

Headache, POS N
diarrhoea, POS N
and POS N
flushing POS N
were POS N
more POS N
common POS N
with POS N
sildenafil. POS N

Changes POS N
in POS N
WHO POS N
functional POS N
class POS N
and POS N
Borg POS N
dyspnoea POS N
score POS N
and POS N
incidence POS N
of POS N
clinical POS N
worsening POS N
did POS N
not POS N
differ. POS N

Headache, POS N
diarrhoea, POS N
and POS N
flushing POS N
were POS N
more POS N
common POS N
with POS N
sildenafil. POS N

Sildenafil, POS N
in POS N
addition POS N
to POS N
stable POS N
(≥3 POS N
months) POS N
bosentan POS N
therapy, POS N
had POS N
no POS N
benefit POS N
over POS N
placebo POS N
for POS N
12-week POS N
change POS N
from POS N
baseline POS N
in POS N
6MWD. POS N

Sildenafil, POS N
in POS N
addition POS N
to POS N
stable POS N
(≥3 POS N
months) POS N
bosentan POS N
therapy, POS N
had POS N
no POS N
benefit POS N
over POS N
placebo POS N
for POS N
12-week POS N
change POS N
from POS N
baseline POS N
in POS N
6MWD. POS N

In POS N
sildenafil POS N
versus POS N
placebo POS N
arms, POS N
week-12 POS N
6MWD POS N
increases POS N
were POS N
similar POS N
(least POS N
squares POS N
mean POS N
difference POS N
[sildenafil-placebo], POS N
-2.4 POS N
m POS N
[90% POS N
CI: POS N
-21.8 POS N
to POS N
17.1 POS N
m]; POS N
P POS N
= POS N
0.6); POS N
mean POS N
± POS N
SD POS N
changes POS N
from POS N
baseline POS N
were POS N
26.4 POS N
± POS N
45.7 POS N
versus POS N
11.8 POS N
± POS N
57.4 POS N
m, POS N
respectively, POS N
in POS N
IPAH POS N
(65% POS N
of POS N
population) POS N
and POS N
-18.3 POS N
± POS N
82.0 POS N
versus POS N
17.5 POS N
± POS N
59.1 POS N
m POS N
in POS N
APAH-CTD POS N
(35% POS N
of POS N
population). POS N

Sildenafil, POS N
in POS N
addition POS N
to POS N
stable POS N
(≥3 POS N
months) POS N
bosentan POS N
therapy, POS N
had POS N
no POS N
benefit POS N
over POS N
placebo POS N
for POS N
12-week POS N
change POS N
from POS N
baseline POS N
in POS N
6MWD. POS N

Changes POS N
in POS N
WHO POS N
functional POS N
class POS N
and POS N
Borg POS N
dyspnoea POS N
score POS N
and POS N
incidence POS N
of POS N
clinical POS N
worsening POS N
did POS N
not POS N
differ. POS N

Sildenafil, POS N
in POS N
addition POS N
to POS N
stable POS N
(≥3 POS N
months) POS N
bosentan POS N
therapy, POS N
had POS N
no POS N
benefit POS N
over POS N
placebo POS N
for POS N
12-week POS N
change POS N
from POS N
baseline POS N
in POS N
6MWD. POS N

Headache, POS N
diarrhoea, POS N
and POS N
flushing POS N
were POS N
more POS N
common POS N
with POS N
sildenafil. POS N

Responses POS N
(> POS N
or POS N
= POS N
50% POS N
improvement) POS N
were POS N
seen POS N
in POS N
3 POS N
(20%) POS N
of POS N
15 POS N
patients POS N
with POS N
an POS N
initial POS N
dose POS N
at POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0%-40%), POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
35%-72%), POS N
and POS N
10 POS N
(67%) POS N
of POS N
15 POS N
patients POS N
at POS N
above POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
43%-91%). POS N

The POS N
rate POS N
of POS N
progressive POS N
disease POS N
was POS N
47%, POS N
21%, POS N
and POS N
13% POS N
at POS N
the POS N
same POS N
dose POS N
levels, POS N
respectively. POS N

Responses POS N
(> POS N
or POS N
= POS N
50% POS N
improvement) POS N
were POS N
seen POS N
in POS N
3 POS N
(20%) POS N
of POS N
15 POS N
patients POS N
with POS N
an POS N
initial POS N
dose POS N
at POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0%-40%), POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
35%-72%), POS N
and POS N
10 POS N
(67%) POS N
of POS N
15 POS N
patients POS N
at POS N
above POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
43%-91%). POS N

Eight POS N
(73%) POS N
of POS N
11 POS N
patients POS N
crossing POS N
over POS N
from POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
to POS N
higher POS N
doses POS N
subsequently POS N
responded. POS N

Responses POS N
(> POS N
or POS N
= POS N
50% POS N
improvement) POS N
were POS N
seen POS N
in POS N
3 POS N
(20%) POS N
of POS N
15 POS N
patients POS N
with POS N
an POS N
initial POS N
dose POS N
at POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0%-40%), POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
35%-72%), POS N
and POS N
10 POS N
(67%) POS N
of POS N
15 POS N
patients POS N
at POS N
above POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
43%-91%). POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
from POS N
start POS N
of POS N
therapy POS N
could POS N
not POS N
be POS N
estimated POS N
for POS N
the POS N
15 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
owing POS N
to POS N
low POS N
relapse POS N
rates POS N
in POS N
2 POS N
patients POS N
(13%); POS N
at POS N
higher POS N
doses POS N
it POS N
was POS N
516 POS N
days. POS N

Responses POS N
(> POS N
or POS N
= POS N
50% POS N
improvement) POS N
were POS N
seen POS N
in POS N
3 POS N
(20%) POS N
of POS N
15 POS N
patients POS N
with POS N
an POS N
initial POS N
dose POS N
at POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0%-40%), POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
35%-72%), POS N
and POS N
10 POS N
(67%) POS N
of POS N
15 POS N
patients POS N
at POS N
above POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
43%-91%). POS N

The POS N
following POS N
drug-related POS N
adverse POS N
effects POS N
were POS N
reversible POS N
and POS N
treatable: POS N
hypertriglyceridemia POS N
(46 POS N
patients POS N
[79%]), POS N
hypercholesterolemia POS N
(28 POS N
patients POS N
[48%]), POS N
headache POS N
(27 POS N
patients POS N
[47%]), POS N
central POS N
hypothyroidism POS N
(23 POS N
patients POS N
[40%]), POS N
asthenia POS N
(21 POS N
patients POS N
[36%]), POS N
and POS N
leukopenia POS N
(16 POS N
patients POS N
[28%]). POS N

Responses POS N
(> POS N
or POS N
= POS N
50% POS N
improvement) POS N
were POS N
seen POS N
in POS N
3 POS N
(20%) POS N
of POS N
15 POS N
patients POS N
with POS N
an POS N
initial POS N
dose POS N
at POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0%-40%), POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
35%-72%), POS N
and POS N
10 POS N
(67%) POS N
of POS N
15 POS N
patients POS N
at POS N
above POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
43%-91%). POS N

No POS N
cases POS N
of POS N
drug-related POS N
neutropenic POS N
fever, POS N
sepsis, POS N
or POS N
death POS N
occurred. POS N

Responses POS N
(> POS N
or POS N
= POS N
50% POS N
improvement) POS N
were POS N
seen POS N
in POS N
3 POS N
(20%) POS N
of POS N
15 POS N
patients POS N
with POS N
an POS N
initial POS N
dose POS N
at POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0%-40%), POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
35%-72%), POS N
and POS N
10 POS N
(67%) POS N
of POS N
15 POS N
patients POS N
at POS N
above POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
43%-91%). POS N

Pancreatitis POS N
occurred POS N
in POS N
3 POS N
patients POS N
with POS N
triglyceride POS N
levels POS N
higher POS N
than POS N
14.69 POS N
mmol/L POS N
(1300 POS N
mg/dL), POS N
all POS N
of POS N
whom POS N
were POS N
taking POS N
300 POS N
mg/m(2) POS N
or POS N
more POS N
of POS N
oral POS N
bexarotene POS N
per POS N
day. POS N

Responses POS N
(> POS N
or POS N
= POS N
50% POS N
improvement) POS N
were POS N
seen POS N
in POS N
3 POS N
(20%) POS N
of POS N
15 POS N
patients POS N
with POS N
an POS N
initial POS N
dose POS N
at POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0%-40%), POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
35%-72%), POS N
and POS N
10 POS N
(67%) POS N
of POS N
15 POS N
patients POS N
at POS N
above POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
43%-91%). POS N

Bexarotene POS N
(Targretin POS N
capsules) POS N
(the POS N
first POS N
retinoid POS N
X POS N
receptor-selective POS N
rexinoid) POS N
was POS N
well POS N
tolerated POS N
and POS N
effective POS N
as POS N
an POS N
oral POS N
treatment POS N
for POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
with POS N
refractory POS N
or POS N
persistent POS N
early-stage POS N
cutaneous POS N
T-cell POS N
lymphoma POS N
at POS N
doses POS N
of POS N
300 POS N
mg/m(2) POS N
per POS N
day. POS N

Responses POS N
(> POS N
or POS N
= POS N
50% POS N
improvement) POS N
were POS N
seen POS N
in POS N
3 POS N
(20%) POS N
of POS N
15 POS N
patients POS N
with POS N
an POS N
initial POS N
dose POS N
at POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0%-40%), POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
35%-72%), POS N
and POS N
10 POS N
(67%) POS N
of POS N
15 POS N
patients POS N
at POS N
above POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
43%-91%). POS N

Hypertriglyceridemia POS N
and POS N
hypothyroidism POS N
require POS N
monitoring POS N
but POS N
are POS N
reversible POS N
and POS N
manageable POS N
with POS N
concomitant POS N
medication. POS N

The POS N
rate POS N
of POS N
progressive POS N
disease POS N
was POS N
47%, POS N
21%, POS N
and POS N
13% POS N
at POS N
the POS N
same POS N
dose POS N
levels, POS N
respectively. POS N

Responses POS N
(> POS N
or POS N
= POS N
50% POS N
improvement) POS N
were POS N
seen POS N
in POS N
3 POS N
(20%) POS N
of POS N
15 POS N
patients POS N
with POS N
an POS N
initial POS N
dose POS N
at POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0%-40%), POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
35%-72%), POS N
and POS N
10 POS N
(67%) POS N
of POS N
15 POS N
patients POS N
at POS N
above POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
43%-91%). POS N

The POS N
rate POS N
of POS N
progressive POS N
disease POS N
was POS N
47%, POS N
21%, POS N
and POS N
13% POS N
at POS N
the POS N
same POS N
dose POS N
levels, POS N
respectively. POS N

Eight POS N
(73%) POS N
of POS N
11 POS N
patients POS N
crossing POS N
over POS N
from POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
to POS N
higher POS N
doses POS N
subsequently POS N
responded. POS N

The POS N
rate POS N
of POS N
progressive POS N
disease POS N
was POS N
47%, POS N
21%, POS N
and POS N
13% POS N
at POS N
the POS N
same POS N
dose POS N
levels, POS N
respectively. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
from POS N
start POS N
of POS N
therapy POS N
could POS N
not POS N
be POS N
estimated POS N
for POS N
the POS N
15 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
owing POS N
to POS N
low POS N
relapse POS N
rates POS N
in POS N
2 POS N
patients POS N
(13%); POS N
at POS N
higher POS N
doses POS N
it POS N
was POS N
516 POS N
days. POS N

The POS N
rate POS N
of POS N
progressive POS N
disease POS N
was POS N
47%, POS N
21%, POS N
and POS N
13% POS N
at POS N
the POS N
same POS N
dose POS N
levels, POS N
respectively. POS N

The POS N
following POS N
drug-related POS N
adverse POS N
effects POS N
were POS N
reversible POS N
and POS N
treatable: POS N
hypertriglyceridemia POS N
(46 POS N
patients POS N
[79%]), POS N
hypercholesterolemia POS N
(28 POS N
patients POS N
[48%]), POS N
headache POS N
(27 POS N
patients POS N
[47%]), POS N
central POS N
hypothyroidism POS N
(23 POS N
patients POS N
[40%]), POS N
asthenia POS N
(21 POS N
patients POS N
[36%]), POS N
and POS N
leukopenia POS N
(16 POS N
patients POS N
[28%]). POS N

The POS N
rate POS N
of POS N
progressive POS N
disease POS N
was POS N
47%, POS N
21%, POS N
and POS N
13% POS N
at POS N
the POS N
same POS N
dose POS N
levels, POS N
respectively. POS N

No POS N
cases POS N
of POS N
drug-related POS N
neutropenic POS N
fever, POS N
sepsis, POS N
or POS N
death POS N
occurred. POS N

The POS N
rate POS N
of POS N
progressive POS N
disease POS N
was POS N
47%, POS N
21%, POS N
and POS N
13% POS N
at POS N
the POS N
same POS N
dose POS N
levels, POS N
respectively. POS N

Pancreatitis POS N
occurred POS N
in POS N
3 POS N
patients POS N
with POS N
triglyceride POS N
levels POS N
higher POS N
than POS N
14.69 POS N
mmol/L POS N
(1300 POS N
mg/dL), POS N
all POS N
of POS N
whom POS N
were POS N
taking POS N
300 POS N
mg/m(2) POS N
or POS N
more POS N
of POS N
oral POS N
bexarotene POS N
per POS N
day. POS N

The POS N
rate POS N
of POS N
progressive POS N
disease POS N
was POS N
47%, POS N
21%, POS N
and POS N
13% POS N
at POS N
the POS N
same POS N
dose POS N
levels, POS N
respectively. POS N

Bexarotene POS N
(Targretin POS N
capsules) POS N
(the POS N
first POS N
retinoid POS N
X POS N
receptor-selective POS N
rexinoid) POS N
was POS N
well POS N
tolerated POS N
and POS N
effective POS N
as POS N
an POS N
oral POS N
treatment POS N
for POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
with POS N
refractory POS N
or POS N
persistent POS N
early-stage POS N
cutaneous POS N
T-cell POS N
lymphoma POS N
at POS N
doses POS N
of POS N
300 POS N
mg/m(2) POS N
per POS N
day. POS N

The POS N
rate POS N
of POS N
progressive POS N
disease POS N
was POS N
47%, POS N
21%, POS N
and POS N
13% POS N
at POS N
the POS N
same POS N
dose POS N
levels, POS N
respectively. POS N

Hypertriglyceridemia POS N
and POS N
hypothyroidism POS N
require POS N
monitoring POS N
but POS N
are POS N
reversible POS N
and POS N
manageable POS N
with POS N
concomitant POS N
medication. POS N

Eight POS N
(73%) POS N
of POS N
11 POS N
patients POS N
crossing POS N
over POS N
from POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
to POS N
higher POS N
doses POS N
subsequently POS N
responded. POS N

Responses POS N
(> POS N
or POS N
= POS N
50% POS N
improvement) POS N
were POS N
seen POS N
in POS N
3 POS N
(20%) POS N
of POS N
15 POS N
patients POS N
with POS N
an POS N
initial POS N
dose POS N
at POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0%-40%), POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
35%-72%), POS N
and POS N
10 POS N
(67%) POS N
of POS N
15 POS N
patients POS N
at POS N
above POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
43%-91%). POS N

Eight POS N
(73%) POS N
of POS N
11 POS N
patients POS N
crossing POS N
over POS N
from POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
to POS N
higher POS N
doses POS N
subsequently POS N
responded. POS N

The POS N
rate POS N
of POS N
progressive POS N
disease POS N
was POS N
47%, POS N
21%, POS N
and POS N
13% POS N
at POS N
the POS N
same POS N
dose POS N
levels, POS N
respectively. POS N

Eight POS N
(73%) POS N
of POS N
11 POS N
patients POS N
crossing POS N
over POS N
from POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
to POS N
higher POS N
doses POS N
subsequently POS N
responded. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
from POS N
start POS N
of POS N
therapy POS N
could POS N
not POS N
be POS N
estimated POS N
for POS N
the POS N
15 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
owing POS N
to POS N
low POS N
relapse POS N
rates POS N
in POS N
2 POS N
patients POS N
(13%); POS N
at POS N
higher POS N
doses POS N
it POS N
was POS N
516 POS N
days. POS N

Eight POS N
(73%) POS N
of POS N
11 POS N
patients POS N
crossing POS N
over POS N
from POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
to POS N
higher POS N
doses POS N
subsequently POS N
responded. POS N

The POS N
following POS N
drug-related POS N
adverse POS N
effects POS N
were POS N
reversible POS N
and POS N
treatable: POS N
hypertriglyceridemia POS N
(46 POS N
patients POS N
[79%]), POS N
hypercholesterolemia POS N
(28 POS N
patients POS N
[48%]), POS N
headache POS N
(27 POS N
patients POS N
[47%]), POS N
central POS N
hypothyroidism POS N
(23 POS N
patients POS N
[40%]), POS N
asthenia POS N
(21 POS N
patients POS N
[36%]), POS N
and POS N
leukopenia POS N
(16 POS N
patients POS N
[28%]). POS N

Eight POS N
(73%) POS N
of POS N
11 POS N
patients POS N
crossing POS N
over POS N
from POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
to POS N
higher POS N
doses POS N
subsequently POS N
responded. POS N

No POS N
cases POS N
of POS N
drug-related POS N
neutropenic POS N
fever, POS N
sepsis, POS N
or POS N
death POS N
occurred. POS N

Eight POS N
(73%) POS N
of POS N
11 POS N
patients POS N
crossing POS N
over POS N
from POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
to POS N
higher POS N
doses POS N
subsequently POS N
responded. POS N

Pancreatitis POS N
occurred POS N
in POS N
3 POS N
patients POS N
with POS N
triglyceride POS N
levels POS N
higher POS N
than POS N
14.69 POS N
mmol/L POS N
(1300 POS N
mg/dL), POS N
all POS N
of POS N
whom POS N
were POS N
taking POS N
300 POS N
mg/m(2) POS N
or POS N
more POS N
of POS N
oral POS N
bexarotene POS N
per POS N
day. POS N

Eight POS N
(73%) POS N
of POS N
11 POS N
patients POS N
crossing POS N
over POS N
from POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
to POS N
higher POS N
doses POS N
subsequently POS N
responded. POS N

Bexarotene POS N
(Targretin POS N
capsules) POS N
(the POS N
first POS N
retinoid POS N
X POS N
receptor-selective POS N
rexinoid) POS N
was POS N
well POS N
tolerated POS N
and POS N
effective POS N
as POS N
an POS N
oral POS N
treatment POS N
for POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
with POS N
refractory POS N
or POS N
persistent POS N
early-stage POS N
cutaneous POS N
T-cell POS N
lymphoma POS N
at POS N
doses POS N
of POS N
300 POS N
mg/m(2) POS N
per POS N
day. POS N

Eight POS N
(73%) POS N
of POS N
11 POS N
patients POS N
crossing POS N
over POS N
from POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
to POS N
higher POS N
doses POS N
subsequently POS N
responded. POS N

Hypertriglyceridemia POS N
and POS N
hypothyroidism POS N
require POS N
monitoring POS N
but POS N
are POS N
reversible POS N
and POS N
manageable POS N
with POS N
concomitant POS N
medication. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
from POS N
start POS N
of POS N
therapy POS N
could POS N
not POS N
be POS N
estimated POS N
for POS N
the POS N
15 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
owing POS N
to POS N
low POS N
relapse POS N
rates POS N
in POS N
2 POS N
patients POS N
(13%); POS N
at POS N
higher POS N
doses POS N
it POS N
was POS N
516 POS N
days. POS N

Responses POS N
(> POS N
or POS N
= POS N
50% POS N
improvement) POS N
were POS N
seen POS N
in POS N
3 POS N
(20%) POS N
of POS N
15 POS N
patients POS N
with POS N
an POS N
initial POS N
dose POS N
at POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0%-40%), POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
35%-72%), POS N
and POS N
10 POS N
(67%) POS N
of POS N
15 POS N
patients POS N
at POS N
above POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
43%-91%). POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
from POS N
start POS N
of POS N
therapy POS N
could POS N
not POS N
be POS N
estimated POS N
for POS N
the POS N
15 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
owing POS N
to POS N
low POS N
relapse POS N
rates POS N
in POS N
2 POS N
patients POS N
(13%); POS N
at POS N
higher POS N
doses POS N
it POS N
was POS N
516 POS N
days. POS N

The POS N
rate POS N
of POS N
progressive POS N
disease POS N
was POS N
47%, POS N
21%, POS N
and POS N
13% POS N
at POS N
the POS N
same POS N
dose POS N
levels, POS N
respectively. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
from POS N
start POS N
of POS N
therapy POS N
could POS N
not POS N
be POS N
estimated POS N
for POS N
the POS N
15 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
owing POS N
to POS N
low POS N
relapse POS N
rates POS N
in POS N
2 POS N
patients POS N
(13%); POS N
at POS N
higher POS N
doses POS N
it POS N
was POS N
516 POS N
days. POS N

Eight POS N
(73%) POS N
of POS N
11 POS N
patients POS N
crossing POS N
over POS N
from POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
to POS N
higher POS N
doses POS N
subsequently POS N
responded. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
from POS N
start POS N
of POS N
therapy POS N
could POS N
not POS N
be POS N
estimated POS N
for POS N
the POS N
15 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
owing POS N
to POS N
low POS N
relapse POS N
rates POS N
in POS N
2 POS N
patients POS N
(13%); POS N
at POS N
higher POS N
doses POS N
it POS N
was POS N
516 POS N
days. POS N

The POS N
following POS N
drug-related POS N
adverse POS N
effects POS N
were POS N
reversible POS N
and POS N
treatable: POS N
hypertriglyceridemia POS N
(46 POS N
patients POS N
[79%]), POS N
hypercholesterolemia POS N
(28 POS N
patients POS N
[48%]), POS N
headache POS N
(27 POS N
patients POS N
[47%]), POS N
central POS N
hypothyroidism POS N
(23 POS N
patients POS N
[40%]), POS N
asthenia POS N
(21 POS N
patients POS N
[36%]), POS N
and POS N
leukopenia POS N
(16 POS N
patients POS N
[28%]). POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
from POS N
start POS N
of POS N
therapy POS N
could POS N
not POS N
be POS N
estimated POS N
for POS N
the POS N
15 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
owing POS N
to POS N
low POS N
relapse POS N
rates POS N
in POS N
2 POS N
patients POS N
(13%); POS N
at POS N
higher POS N
doses POS N
it POS N
was POS N
516 POS N
days. POS N

No POS N
cases POS N
of POS N
drug-related POS N
neutropenic POS N
fever, POS N
sepsis, POS N
or POS N
death POS N
occurred. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
from POS N
start POS N
of POS N
therapy POS N
could POS N
not POS N
be POS N
estimated POS N
for POS N
the POS N
15 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
owing POS N
to POS N
low POS N
relapse POS N
rates POS N
in POS N
2 POS N
patients POS N
(13%); POS N
at POS N
higher POS N
doses POS N
it POS N
was POS N
516 POS N
days. POS N

Pancreatitis POS N
occurred POS N
in POS N
3 POS N
patients POS N
with POS N
triglyceride POS N
levels POS N
higher POS N
than POS N
14.69 POS N
mmol/L POS N
(1300 POS N
mg/dL), POS N
all POS N
of POS N
whom POS N
were POS N
taking POS N
300 POS N
mg/m(2) POS N
or POS N
more POS N
of POS N
oral POS N
bexarotene POS N
per POS N
day. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
from POS N
start POS N
of POS N
therapy POS N
could POS N
not POS N
be POS N
estimated POS N
for POS N
the POS N
15 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
owing POS N
to POS N
low POS N
relapse POS N
rates POS N
in POS N
2 POS N
patients POS N
(13%); POS N
at POS N
higher POS N
doses POS N
it POS N
was POS N
516 POS N
days. POS N

Bexarotene POS N
(Targretin POS N
capsules) POS N
(the POS N
first POS N
retinoid POS N
X POS N
receptor-selective POS N
rexinoid) POS N
was POS N
well POS N
tolerated POS N
and POS N
effective POS N
as POS N
an POS N
oral POS N
treatment POS N
for POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
with POS N
refractory POS N
or POS N
persistent POS N
early-stage POS N
cutaneous POS N
T-cell POS N
lymphoma POS N
at POS N
doses POS N
of POS N
300 POS N
mg/m(2) POS N
per POS N
day. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
from POS N
start POS N
of POS N
therapy POS N
could POS N
not POS N
be POS N
estimated POS N
for POS N
the POS N
15 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
owing POS N
to POS N
low POS N
relapse POS N
rates POS N
in POS N
2 POS N
patients POS N
(13%); POS N
at POS N
higher POS N
doses POS N
it POS N
was POS N
516 POS N
days. POS N

Hypertriglyceridemia POS N
and POS N
hypothyroidism POS N
require POS N
monitoring POS N
but POS N
are POS N
reversible POS N
and POS N
manageable POS N
with POS N
concomitant POS N
medication. POS N

The POS N
following POS N
drug-related POS N
adverse POS N
effects POS N
were POS N
reversible POS N
and POS N
treatable: POS N
hypertriglyceridemia POS N
(46 POS N
patients POS N
[79%]), POS N
hypercholesterolemia POS N
(28 POS N
patients POS N
[48%]), POS N
headache POS N
(27 POS N
patients POS N
[47%]), POS N
central POS N
hypothyroidism POS N
(23 POS N
patients POS N
[40%]), POS N
asthenia POS N
(21 POS N
patients POS N
[36%]), POS N
and POS N
leukopenia POS N
(16 POS N
patients POS N
[28%]). POS N

Responses POS N
(> POS N
or POS N
= POS N
50% POS N
improvement) POS N
were POS N
seen POS N
in POS N
3 POS N
(20%) POS N
of POS N
15 POS N
patients POS N
with POS N
an POS N
initial POS N
dose POS N
at POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0%-40%), POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
35%-72%), POS N
and POS N
10 POS N
(67%) POS N
of POS N
15 POS N
patients POS N
at POS N
above POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
43%-91%). POS N

The POS N
following POS N
drug-related POS N
adverse POS N
effects POS N
were POS N
reversible POS N
and POS N
treatable: POS N
hypertriglyceridemia POS N
(46 POS N
patients POS N
[79%]), POS N
hypercholesterolemia POS N
(28 POS N
patients POS N
[48%]), POS N
headache POS N
(27 POS N
patients POS N
[47%]), POS N
central POS N
hypothyroidism POS N
(23 POS N
patients POS N
[40%]), POS N
asthenia POS N
(21 POS N
patients POS N
[36%]), POS N
and POS N
leukopenia POS N
(16 POS N
patients POS N
[28%]). POS N

The POS N
rate POS N
of POS N
progressive POS N
disease POS N
was POS N
47%, POS N
21%, POS N
and POS N
13% POS N
at POS N
the POS N
same POS N
dose POS N
levels, POS N
respectively. POS N

The POS N
following POS N
drug-related POS N
adverse POS N
effects POS N
were POS N
reversible POS N
and POS N
treatable: POS N
hypertriglyceridemia POS N
(46 POS N
patients POS N
[79%]), POS N
hypercholesterolemia POS N
(28 POS N
patients POS N
[48%]), POS N
headache POS N
(27 POS N
patients POS N
[47%]), POS N
central POS N
hypothyroidism POS N
(23 POS N
patients POS N
[40%]), POS N
asthenia POS N
(21 POS N
patients POS N
[36%]), POS N
and POS N
leukopenia POS N
(16 POS N
patients POS N
[28%]). POS N

Eight POS N
(73%) POS N
of POS N
11 POS N
patients POS N
crossing POS N
over POS N
from POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
to POS N
higher POS N
doses POS N
subsequently POS N
responded. POS N

The POS N
following POS N
drug-related POS N
adverse POS N
effects POS N
were POS N
reversible POS N
and POS N
treatable: POS N
hypertriglyceridemia POS N
(46 POS N
patients POS N
[79%]), POS N
hypercholesterolemia POS N
(28 POS N
patients POS N
[48%]), POS N
headache POS N
(27 POS N
patients POS N
[47%]), POS N
central POS N
hypothyroidism POS N
(23 POS N
patients POS N
[40%]), POS N
asthenia POS N
(21 POS N
patients POS N
[36%]), POS N
and POS N
leukopenia POS N
(16 POS N
patients POS N
[28%]). POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
from POS N
start POS N
of POS N
therapy POS N
could POS N
not POS N
be POS N
estimated POS N
for POS N
the POS N
15 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
owing POS N
to POS N
low POS N
relapse POS N
rates POS N
in POS N
2 POS N
patients POS N
(13%); POS N
at POS N
higher POS N
doses POS N
it POS N
was POS N
516 POS N
days. POS N

The POS N
following POS N
drug-related POS N
adverse POS N
effects POS N
were POS N
reversible POS N
and POS N
treatable: POS N
hypertriglyceridemia POS N
(46 POS N
patients POS N
[79%]), POS N
hypercholesterolemia POS N
(28 POS N
patients POS N
[48%]), POS N
headache POS N
(27 POS N
patients POS N
[47%]), POS N
central POS N
hypothyroidism POS N
(23 POS N
patients POS N
[40%]), POS N
asthenia POS N
(21 POS N
patients POS N
[36%]), POS N
and POS N
leukopenia POS N
(16 POS N
patients POS N
[28%]). POS N

No POS N
cases POS N
of POS N
drug-related POS N
neutropenic POS N
fever, POS N
sepsis, POS N
or POS N
death POS N
occurred. POS N

The POS N
following POS N
drug-related POS N
adverse POS N
effects POS N
were POS N
reversible POS N
and POS N
treatable: POS N
hypertriglyceridemia POS N
(46 POS N
patients POS N
[79%]), POS N
hypercholesterolemia POS N
(28 POS N
patients POS N
[48%]), POS N
headache POS N
(27 POS N
patients POS N
[47%]), POS N
central POS N
hypothyroidism POS N
(23 POS N
patients POS N
[40%]), POS N
asthenia POS N
(21 POS N
patients POS N
[36%]), POS N
and POS N
leukopenia POS N
(16 POS N
patients POS N
[28%]). POS N

Pancreatitis POS N
occurred POS N
in POS N
3 POS N
patients POS N
with POS N
triglyceride POS N
levels POS N
higher POS N
than POS N
14.69 POS N
mmol/L POS N
(1300 POS N
mg/dL), POS N
all POS N
of POS N
whom POS N
were POS N
taking POS N
300 POS N
mg/m(2) POS N
or POS N
more POS N
of POS N
oral POS N
bexarotene POS N
per POS N
day. POS N

The POS N
following POS N
drug-related POS N
adverse POS N
effects POS N
were POS N
reversible POS N
and POS N
treatable: POS N
hypertriglyceridemia POS N
(46 POS N
patients POS N
[79%]), POS N
hypercholesterolemia POS N
(28 POS N
patients POS N
[48%]), POS N
headache POS N
(27 POS N
patients POS N
[47%]), POS N
central POS N
hypothyroidism POS N
(23 POS N
patients POS N
[40%]), POS N
asthenia POS N
(21 POS N
patients POS N
[36%]), POS N
and POS N
leukopenia POS N
(16 POS N
patients POS N
[28%]). POS N

Bexarotene POS N
(Targretin POS N
capsules) POS N
(the POS N
first POS N
retinoid POS N
X POS N
receptor-selective POS N
rexinoid) POS N
was POS N
well POS N
tolerated POS N
and POS N
effective POS N
as POS N
an POS N
oral POS N
treatment POS N
for POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
with POS N
refractory POS N
or POS N
persistent POS N
early-stage POS N
cutaneous POS N
T-cell POS N
lymphoma POS N
at POS N
doses POS N
of POS N
300 POS N
mg/m(2) POS N
per POS N
day. POS N

The POS N
following POS N
drug-related POS N
adverse POS N
effects POS N
were POS N
reversible POS N
and POS N
treatable: POS N
hypertriglyceridemia POS N
(46 POS N
patients POS N
[79%]), POS N
hypercholesterolemia POS N
(28 POS N
patients POS N
[48%]), POS N
headache POS N
(27 POS N
patients POS N
[47%]), POS N
central POS N
hypothyroidism POS N
(23 POS N
patients POS N
[40%]), POS N
asthenia POS N
(21 POS N
patients POS N
[36%]), POS N
and POS N
leukopenia POS N
(16 POS N
patients POS N
[28%]). POS N

Hypertriglyceridemia POS N
and POS N
hypothyroidism POS N
require POS N
monitoring POS N
but POS N
are POS N
reversible POS N
and POS N
manageable POS N
with POS N
concomitant POS N
medication. POS N

No POS N
cases POS N
of POS N
drug-related POS N
neutropenic POS N
fever, POS N
sepsis, POS N
or POS N
death POS N
occurred. POS N

Responses POS N
(> POS N
or POS N
= POS N
50% POS N
improvement) POS N
were POS N
seen POS N
in POS N
3 POS N
(20%) POS N
of POS N
15 POS N
patients POS N
with POS N
an POS N
initial POS N
dose POS N
at POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0%-40%), POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
35%-72%), POS N
and POS N
10 POS N
(67%) POS N
of POS N
15 POS N
patients POS N
at POS N
above POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
43%-91%). POS N

No POS N
cases POS N
of POS N
drug-related POS N
neutropenic POS N
fever, POS N
sepsis, POS N
or POS N
death POS N
occurred. POS N

The POS N
rate POS N
of POS N
progressive POS N
disease POS N
was POS N
47%, POS N
21%, POS N
and POS N
13% POS N
at POS N
the POS N
same POS N
dose POS N
levels, POS N
respectively. POS N

No POS N
cases POS N
of POS N
drug-related POS N
neutropenic POS N
fever, POS N
sepsis, POS N
or POS N
death POS N
occurred. POS N

Eight POS N
(73%) POS N
of POS N
11 POS N
patients POS N
crossing POS N
over POS N
from POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
to POS N
higher POS N
doses POS N
subsequently POS N
responded. POS N

No POS N
cases POS N
of POS N
drug-related POS N
neutropenic POS N
fever, POS N
sepsis, POS N
or POS N
death POS N
occurred. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
from POS N
start POS N
of POS N
therapy POS N
could POS N
not POS N
be POS N
estimated POS N
for POS N
the POS N
15 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
owing POS N
to POS N
low POS N
relapse POS N
rates POS N
in POS N
2 POS N
patients POS N
(13%); POS N
at POS N
higher POS N
doses POS N
it POS N
was POS N
516 POS N
days. POS N

No POS N
cases POS N
of POS N
drug-related POS N
neutropenic POS N
fever, POS N
sepsis, POS N
or POS N
death POS N
occurred. POS N

The POS N
following POS N
drug-related POS N
adverse POS N
effects POS N
were POS N
reversible POS N
and POS N
treatable: POS N
hypertriglyceridemia POS N
(46 POS N
patients POS N
[79%]), POS N
hypercholesterolemia POS N
(28 POS N
patients POS N
[48%]), POS N
headache POS N
(27 POS N
patients POS N
[47%]), POS N
central POS N
hypothyroidism POS N
(23 POS N
patients POS N
[40%]), POS N
asthenia POS N
(21 POS N
patients POS N
[36%]), POS N
and POS N
leukopenia POS N
(16 POS N
patients POS N
[28%]). POS N

No POS N
cases POS N
of POS N
drug-related POS N
neutropenic POS N
fever, POS N
sepsis, POS N
or POS N
death POS N
occurred. POS N

Pancreatitis POS N
occurred POS N
in POS N
3 POS N
patients POS N
with POS N
triglyceride POS N
levels POS N
higher POS N
than POS N
14.69 POS N
mmol/L POS N
(1300 POS N
mg/dL), POS N
all POS N
of POS N
whom POS N
were POS N
taking POS N
300 POS N
mg/m(2) POS N
or POS N
more POS N
of POS N
oral POS N
bexarotene POS N
per POS N
day. POS N

No POS N
cases POS N
of POS N
drug-related POS N
neutropenic POS N
fever, POS N
sepsis, POS N
or POS N
death POS N
occurred. POS N

Bexarotene POS N
(Targretin POS N
capsules) POS N
(the POS N
first POS N
retinoid POS N
X POS N
receptor-selective POS N
rexinoid) POS N
was POS N
well POS N
tolerated POS N
and POS N
effective POS N
as POS N
an POS N
oral POS N
treatment POS N
for POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
with POS N
refractory POS N
or POS N
persistent POS N
early-stage POS N
cutaneous POS N
T-cell POS N
lymphoma POS N
at POS N
doses POS N
of POS N
300 POS N
mg/m(2) POS N
per POS N
day. POS N

No POS N
cases POS N
of POS N
drug-related POS N
neutropenic POS N
fever, POS N
sepsis, POS N
or POS N
death POS N
occurred. POS N

Hypertriglyceridemia POS N
and POS N
hypothyroidism POS N
require POS N
monitoring POS N
but POS N
are POS N
reversible POS N
and POS N
manageable POS N
with POS N
concomitant POS N
medication. POS N

Pancreatitis POS N
occurred POS N
in POS N
3 POS N
patients POS N
with POS N
triglyceride POS N
levels POS N
higher POS N
than POS N
14.69 POS N
mmol/L POS N
(1300 POS N
mg/dL), POS N
all POS N
of POS N
whom POS N
were POS N
taking POS N
300 POS N
mg/m(2) POS N
or POS N
more POS N
of POS N
oral POS N
bexarotene POS N
per POS N
day. POS N

Responses POS N
(> POS N
or POS N
= POS N
50% POS N
improvement) POS N
were POS N
seen POS N
in POS N
3 POS N
(20%) POS N
of POS N
15 POS N
patients POS N
with POS N
an POS N
initial POS N
dose POS N
at POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0%-40%), POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
35%-72%), POS N
and POS N
10 POS N
(67%) POS N
of POS N
15 POS N
patients POS N
at POS N
above POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
43%-91%). POS N

Pancreatitis POS N
occurred POS N
in POS N
3 POS N
patients POS N
with POS N
triglyceride POS N
levels POS N
higher POS N
than POS N
14.69 POS N
mmol/L POS N
(1300 POS N
mg/dL), POS N
all POS N
of POS N
whom POS N
were POS N
taking POS N
300 POS N
mg/m(2) POS N
or POS N
more POS N
of POS N
oral POS N
bexarotene POS N
per POS N
day. POS N

The POS N
rate POS N
of POS N
progressive POS N
disease POS N
was POS N
47%, POS N
21%, POS N
and POS N
13% POS N
at POS N
the POS N
same POS N
dose POS N
levels, POS N
respectively. POS N

Pancreatitis POS N
occurred POS N
in POS N
3 POS N
patients POS N
with POS N
triglyceride POS N
levels POS N
higher POS N
than POS N
14.69 POS N
mmol/L POS N
(1300 POS N
mg/dL), POS N
all POS N
of POS N
whom POS N
were POS N
taking POS N
300 POS N
mg/m(2) POS N
or POS N
more POS N
of POS N
oral POS N
bexarotene POS N
per POS N
day. POS N

Eight POS N
(73%) POS N
of POS N
11 POS N
patients POS N
crossing POS N
over POS N
from POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
to POS N
higher POS N
doses POS N
subsequently POS N
responded. POS N

Pancreatitis POS N
occurred POS N
in POS N
3 POS N
patients POS N
with POS N
triglyceride POS N
levels POS N
higher POS N
than POS N
14.69 POS N
mmol/L POS N
(1300 POS N
mg/dL), POS N
all POS N
of POS N
whom POS N
were POS N
taking POS N
300 POS N
mg/m(2) POS N
or POS N
more POS N
of POS N
oral POS N
bexarotene POS N
per POS N
day. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
from POS N
start POS N
of POS N
therapy POS N
could POS N
not POS N
be POS N
estimated POS N
for POS N
the POS N
15 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
owing POS N
to POS N
low POS N
relapse POS N
rates POS N
in POS N
2 POS N
patients POS N
(13%); POS N
at POS N
higher POS N
doses POS N
it POS N
was POS N
516 POS N
days. POS N

Pancreatitis POS N
occurred POS N
in POS N
3 POS N
patients POS N
with POS N
triglyceride POS N
levels POS N
higher POS N
than POS N
14.69 POS N
mmol/L POS N
(1300 POS N
mg/dL), POS N
all POS N
of POS N
whom POS N
were POS N
taking POS N
300 POS N
mg/m(2) POS N
or POS N
more POS N
of POS N
oral POS N
bexarotene POS N
per POS N
day. POS N

The POS N
following POS N
drug-related POS N
adverse POS N
effects POS N
were POS N
reversible POS N
and POS N
treatable: POS N
hypertriglyceridemia POS N
(46 POS N
patients POS N
[79%]), POS N
hypercholesterolemia POS N
(28 POS N
patients POS N
[48%]), POS N
headache POS N
(27 POS N
patients POS N
[47%]), POS N
central POS N
hypothyroidism POS N
(23 POS N
patients POS N
[40%]), POS N
asthenia POS N
(21 POS N
patients POS N
[36%]), POS N
and POS N
leukopenia POS N
(16 POS N
patients POS N
[28%]). POS N

Pancreatitis POS N
occurred POS N
in POS N
3 POS N
patients POS N
with POS N
triglyceride POS N
levels POS N
higher POS N
than POS N
14.69 POS N
mmol/L POS N
(1300 POS N
mg/dL), POS N
all POS N
of POS N
whom POS N
were POS N
taking POS N
300 POS N
mg/m(2) POS N
or POS N
more POS N
of POS N
oral POS N
bexarotene POS N
per POS N
day. POS N

No POS N
cases POS N
of POS N
drug-related POS N
neutropenic POS N
fever, POS N
sepsis, POS N
or POS N
death POS N
occurred. POS N

Pancreatitis POS N
occurred POS N
in POS N
3 POS N
patients POS N
with POS N
triglyceride POS N
levels POS N
higher POS N
than POS N
14.69 POS N
mmol/L POS N
(1300 POS N
mg/dL), POS N
all POS N
of POS N
whom POS N
were POS N
taking POS N
300 POS N
mg/m(2) POS N
or POS N
more POS N
of POS N
oral POS N
bexarotene POS N
per POS N
day. POS N

Bexarotene POS N
(Targretin POS N
capsules) POS N
(the POS N
first POS N
retinoid POS N
X POS N
receptor-selective POS N
rexinoid) POS N
was POS N
well POS N
tolerated POS N
and POS N
effective POS N
as POS N
an POS N
oral POS N
treatment POS N
for POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
with POS N
refractory POS N
or POS N
persistent POS N
early-stage POS N
cutaneous POS N
T-cell POS N
lymphoma POS N
at POS N
doses POS N
of POS N
300 POS N
mg/m(2) POS N
per POS N
day. POS N

Pancreatitis POS N
occurred POS N
in POS N
3 POS N
patients POS N
with POS N
triglyceride POS N
levels POS N
higher POS N
than POS N
14.69 POS N
mmol/L POS N
(1300 POS N
mg/dL), POS N
all POS N
of POS N
whom POS N
were POS N
taking POS N
300 POS N
mg/m(2) POS N
or POS N
more POS N
of POS N
oral POS N
bexarotene POS N
per POS N
day. POS N

Hypertriglyceridemia POS N
and POS N
hypothyroidism POS N
require POS N
monitoring POS N
but POS N
are POS N
reversible POS N
and POS N
manageable POS N
with POS N
concomitant POS N
medication. POS N

Bexarotene POS N
(Targretin POS N
capsules) POS N
(the POS N
first POS N
retinoid POS N
X POS N
receptor-selective POS N
rexinoid) POS N
was POS N
well POS N
tolerated POS N
and POS N
effective POS N
as POS N
an POS N
oral POS N
treatment POS N
for POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
with POS N
refractory POS N
or POS N
persistent POS N
early-stage POS N
cutaneous POS N
T-cell POS N
lymphoma POS N
at POS N
doses POS N
of POS N
300 POS N
mg/m(2) POS N
per POS N
day. POS N

Responses POS N
(> POS N
or POS N
= POS N
50% POS N
improvement) POS N
were POS N
seen POS N
in POS N
3 POS N
(20%) POS N
of POS N
15 POS N
patients POS N
with POS N
an POS N
initial POS N
dose POS N
at POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0%-40%), POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
35%-72%), POS N
and POS N
10 POS N
(67%) POS N
of POS N
15 POS N
patients POS N
at POS N
above POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
43%-91%). POS N

Bexarotene POS N
(Targretin POS N
capsules) POS N
(the POS N
first POS N
retinoid POS N
X POS N
receptor-selective POS N
rexinoid) POS N
was POS N
well POS N
tolerated POS N
and POS N
effective POS N
as POS N
an POS N
oral POS N
treatment POS N
for POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
with POS N
refractory POS N
or POS N
persistent POS N
early-stage POS N
cutaneous POS N
T-cell POS N
lymphoma POS N
at POS N
doses POS N
of POS N
300 POS N
mg/m(2) POS N
per POS N
day. POS N

The POS N
rate POS N
of POS N
progressive POS N
disease POS N
was POS N
47%, POS N
21%, POS N
and POS N
13% POS N
at POS N
the POS N
same POS N
dose POS N
levels, POS N
respectively. POS N

Bexarotene POS N
(Targretin POS N
capsules) POS N
(the POS N
first POS N
retinoid POS N
X POS N
receptor-selective POS N
rexinoid) POS N
was POS N
well POS N
tolerated POS N
and POS N
effective POS N
as POS N
an POS N
oral POS N
treatment POS N
for POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
with POS N
refractory POS N
or POS N
persistent POS N
early-stage POS N
cutaneous POS N
T-cell POS N
lymphoma POS N
at POS N
doses POS N
of POS N
300 POS N
mg/m(2) POS N
per POS N
day. POS N

Eight POS N
(73%) POS N
of POS N
11 POS N
patients POS N
crossing POS N
over POS N
from POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
to POS N
higher POS N
doses POS N
subsequently POS N
responded. POS N

Bexarotene POS N
(Targretin POS N
capsules) POS N
(the POS N
first POS N
retinoid POS N
X POS N
receptor-selective POS N
rexinoid) POS N
was POS N
well POS N
tolerated POS N
and POS N
effective POS N
as POS N
an POS N
oral POS N
treatment POS N
for POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
with POS N
refractory POS N
or POS N
persistent POS N
early-stage POS N
cutaneous POS N
T-cell POS N
lymphoma POS N
at POS N
doses POS N
of POS N
300 POS N
mg/m(2) POS N
per POS N
day. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
from POS N
start POS N
of POS N
therapy POS N
could POS N
not POS N
be POS N
estimated POS N
for POS N
the POS N
15 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
owing POS N
to POS N
low POS N
relapse POS N
rates POS N
in POS N
2 POS N
patients POS N
(13%); POS N
at POS N
higher POS N
doses POS N
it POS N
was POS N
516 POS N
days. POS N

Bexarotene POS N
(Targretin POS N
capsules) POS N
(the POS N
first POS N
retinoid POS N
X POS N
receptor-selective POS N
rexinoid) POS N
was POS N
well POS N
tolerated POS N
and POS N
effective POS N
as POS N
an POS N
oral POS N
treatment POS N
for POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
with POS N
refractory POS N
or POS N
persistent POS N
early-stage POS N
cutaneous POS N
T-cell POS N
lymphoma POS N
at POS N
doses POS N
of POS N
300 POS N
mg/m(2) POS N
per POS N
day. POS N

The POS N
following POS N
drug-related POS N
adverse POS N
effects POS N
were POS N
reversible POS N
and POS N
treatable: POS N
hypertriglyceridemia POS N
(46 POS N
patients POS N
[79%]), POS N
hypercholesterolemia POS N
(28 POS N
patients POS N
[48%]), POS N
headache POS N
(27 POS N
patients POS N
[47%]), POS N
central POS N
hypothyroidism POS N
(23 POS N
patients POS N
[40%]), POS N
asthenia POS N
(21 POS N
patients POS N
[36%]), POS N
and POS N
leukopenia POS N
(16 POS N
patients POS N
[28%]). POS N

Bexarotene POS N
(Targretin POS N
capsules) POS N
(the POS N
first POS N
retinoid POS N
X POS N
receptor-selective POS N
rexinoid) POS N
was POS N
well POS N
tolerated POS N
and POS N
effective POS N
as POS N
an POS N
oral POS N
treatment POS N
for POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
with POS N
refractory POS N
or POS N
persistent POS N
early-stage POS N
cutaneous POS N
T-cell POS N
lymphoma POS N
at POS N
doses POS N
of POS N
300 POS N
mg/m(2) POS N
per POS N
day. POS N

No POS N
cases POS N
of POS N
drug-related POS N
neutropenic POS N
fever, POS N
sepsis, POS N
or POS N
death POS N
occurred. POS N

Bexarotene POS N
(Targretin POS N
capsules) POS N
(the POS N
first POS N
retinoid POS N
X POS N
receptor-selective POS N
rexinoid) POS N
was POS N
well POS N
tolerated POS N
and POS N
effective POS N
as POS N
an POS N
oral POS N
treatment POS N
for POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
with POS N
refractory POS N
or POS N
persistent POS N
early-stage POS N
cutaneous POS N
T-cell POS N
lymphoma POS N
at POS N
doses POS N
of POS N
300 POS N
mg/m(2) POS N
per POS N
day. POS N

Pancreatitis POS N
occurred POS N
in POS N
3 POS N
patients POS N
with POS N
triglyceride POS N
levels POS N
higher POS N
than POS N
14.69 POS N
mmol/L POS N
(1300 POS N
mg/dL), POS N
all POS N
of POS N
whom POS N
were POS N
taking POS N
300 POS N
mg/m(2) POS N
or POS N
more POS N
of POS N
oral POS N
bexarotene POS N
per POS N
day. POS N

Bexarotene POS N
(Targretin POS N
capsules) POS N
(the POS N
first POS N
retinoid POS N
X POS N
receptor-selective POS N
rexinoid) POS N
was POS N
well POS N
tolerated POS N
and POS N
effective POS N
as POS N
an POS N
oral POS N
treatment POS N
for POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
with POS N
refractory POS N
or POS N
persistent POS N
early-stage POS N
cutaneous POS N
T-cell POS N
lymphoma POS N
at POS N
doses POS N
of POS N
300 POS N
mg/m(2) POS N
per POS N
day. POS N

Hypertriglyceridemia POS N
and POS N
hypothyroidism POS N
require POS N
monitoring POS N
but POS N
are POS N
reversible POS N
and POS N
manageable POS N
with POS N
concomitant POS N
medication. POS N

Hypertriglyceridemia POS N
and POS N
hypothyroidism POS N
require POS N
monitoring POS N
but POS N
are POS N
reversible POS N
and POS N
manageable POS N
with POS N
concomitant POS N
medication. POS N

Responses POS N
(> POS N
or POS N
= POS N
50% POS N
improvement) POS N
were POS N
seen POS N
in POS N
3 POS N
(20%) POS N
of POS N
15 POS N
patients POS N
with POS N
an POS N
initial POS N
dose POS N
at POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0%-40%), POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
35%-72%), POS N
and POS N
10 POS N
(67%) POS N
of POS N
15 POS N
patients POS N
at POS N
above POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
43%-91%). POS N

Hypertriglyceridemia POS N
and POS N
hypothyroidism POS N
require POS N
monitoring POS N
but POS N
are POS N
reversible POS N
and POS N
manageable POS N
with POS N
concomitant POS N
medication. POS N

The POS N
rate POS N
of POS N
progressive POS N
disease POS N
was POS N
47%, POS N
21%, POS N
and POS N
13% POS N
at POS N
the POS N
same POS N
dose POS N
levels, POS N
respectively. POS N

Hypertriglyceridemia POS N
and POS N
hypothyroidism POS N
require POS N
monitoring POS N
but POS N
are POS N
reversible POS N
and POS N
manageable POS N
with POS N
concomitant POS N
medication. POS N

Eight POS N
(73%) POS N
of POS N
11 POS N
patients POS N
crossing POS N
over POS N
from POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
to POS N
higher POS N
doses POS N
subsequently POS N
responded. POS N

Hypertriglyceridemia POS N
and POS N
hypothyroidism POS N
require POS N
monitoring POS N
but POS N
are POS N
reversible POS N
and POS N
manageable POS N
with POS N
concomitant POS N
medication. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
from POS N
start POS N
of POS N
therapy POS N
could POS N
not POS N
be POS N
estimated POS N
for POS N
the POS N
15 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
owing POS N
to POS N
low POS N
relapse POS N
rates POS N
in POS N
2 POS N
patients POS N
(13%); POS N
at POS N
higher POS N
doses POS N
it POS N
was POS N
516 POS N
days. POS N

Hypertriglyceridemia POS N
and POS N
hypothyroidism POS N
require POS N
monitoring POS N
but POS N
are POS N
reversible POS N
and POS N
manageable POS N
with POS N
concomitant POS N
medication. POS N

The POS N
following POS N
drug-related POS N
adverse POS N
effects POS N
were POS N
reversible POS N
and POS N
treatable: POS N
hypertriglyceridemia POS N
(46 POS N
patients POS N
[79%]), POS N
hypercholesterolemia POS N
(28 POS N
patients POS N
[48%]), POS N
headache POS N
(27 POS N
patients POS N
[47%]), POS N
central POS N
hypothyroidism POS N
(23 POS N
patients POS N
[40%]), POS N
asthenia POS N
(21 POS N
patients POS N
[36%]), POS N
and POS N
leukopenia POS N
(16 POS N
patients POS N
[28%]). POS N

Hypertriglyceridemia POS N
and POS N
hypothyroidism POS N
require POS N
monitoring POS N
but POS N
are POS N
reversible POS N
and POS N
manageable POS N
with POS N
concomitant POS N
medication. POS N

No POS N
cases POS N
of POS N
drug-related POS N
neutropenic POS N
fever, POS N
sepsis, POS N
or POS N
death POS N
occurred. POS N

Hypertriglyceridemia POS N
and POS N
hypothyroidism POS N
require POS N
monitoring POS N
but POS N
are POS N
reversible POS N
and POS N
manageable POS N
with POS N
concomitant POS N
medication. POS N

Pancreatitis POS N
occurred POS N
in POS N
3 POS N
patients POS N
with POS N
triglyceride POS N
levels POS N
higher POS N
than POS N
14.69 POS N
mmol/L POS N
(1300 POS N
mg/dL), POS N
all POS N
of POS N
whom POS N
were POS N
taking POS N
300 POS N
mg/m(2) POS N
or POS N
more POS N
of POS N
oral POS N
bexarotene POS N
per POS N
day. POS N

Hypertriglyceridemia POS N
and POS N
hypothyroidism POS N
require POS N
monitoring POS N
but POS N
are POS N
reversible POS N
and POS N
manageable POS N
with POS N
concomitant POS N
medication. POS N

Bexarotene POS N
(Targretin POS N
capsules) POS N
(the POS N
first POS N
retinoid POS N
X POS N
receptor-selective POS N
rexinoid) POS N
was POS N
well POS N
tolerated POS N
and POS N
effective POS N
as POS N
an POS N
oral POS N
treatment POS N
for POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
with POS N
refractory POS N
or POS N
persistent POS N
early-stage POS N
cutaneous POS N
T-cell POS N
lymphoma POS N
at POS N
doses POS N
of POS N
300 POS N
mg/m(2) POS N
per POS N
day. POS N

TDF POS N
monotherapy POS N
was POS N
efficacious POS N
and POS N
safe POS N
for POS N
up POS N
to POS N
144 POS N
weeks, POS N
providing POS N
an POS N
increasing POS N
rate POS N
of POS N
virologic POS N
response POS N
in POS N
heavily POS N
pretreated POS N
patients POS N
with POS N
multidrug-resistant POS N
HBV. POS N

Serum POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
48, POS N
the POS N
primary POS N
efficacy POS N
endpoint, POS N
was POS N
achieved POS N
in POS N
66.3% POS N
in POS N
the POS N
TDF-TDF POS N
group POS N
and POS N
68.0% POS N
in POS N
the POS N
TDF/ETV-TDF POS N
group POS N
(P POS N
= POS N
0.80). POS N

TDF POS N
monotherapy POS N
was POS N
efficacious POS N
and POS N
safe POS N
for POS N
up POS N
to POS N
144 POS N
weeks, POS N
providing POS N
an POS N
increasing POS N
rate POS N
of POS N
virologic POS N
response POS N
in POS N
heavily POS N
pretreated POS N
patients POS N
with POS N
multidrug-resistant POS N
HBV. POS N

At POS N
week POS N
144, POS N
the POS N
proportion POS N
with POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
increased POS N
to POS N
74.5%, POS N
which POS N
was POS N
significantly POS N
higher POS N
compared POS N
with POS N
that POS N
at POS N
week POS N
48 POS N
(P POS N
= POS N
0.03), POS N
without POS N
a POS N
significant POS N
difference POS N
between POS N
groups POS N
(P POS N
= POS N
0.46). POS N

TDF POS N
monotherapy POS N
was POS N
efficacious POS N
and POS N
safe POS N
for POS N
up POS N
to POS N
144 POS N
weeks, POS N
providing POS N
an POS N
increasing POS N
rate POS N
of POS N
virologic POS N
response POS N
in POS N
heavily POS N
pretreated POS N
patients POS N
with POS N
multidrug-resistant POS N
HBV. POS N

By POS N
on-treatment POS N
analysis, POS N
a POS N
total POS N
of POS N
79.4% POS N
had POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
144. POS N

TDF POS N
monotherapy POS N
was POS N
efficacious POS N
and POS N
safe POS N
for POS N
up POS N
to POS N
144 POS N
weeks, POS N
providing POS N
an POS N
increasing POS N
rate POS N
of POS N
virologic POS N
response POS N
in POS N
heavily POS N
pretreated POS N
patients POS N
with POS N
multidrug-resistant POS N
HBV. POS N

Transient POS N
virologic POS N
breakthrough POS N
occurred POS N
in POS N
6 POS N
patients, POS N
which POS N
was POS N
due POS N
to POS N
poor POS N
drug POS N
adherence. POS N

TDF POS N
monotherapy POS N
was POS N
efficacious POS N
and POS N
safe POS N
for POS N
up POS N
to POS N
144 POS N
weeks, POS N
providing POS N
an POS N
increasing POS N
rate POS N
of POS N
virologic POS N
response POS N
in POS N
heavily POS N
pretreated POS N
patients POS N
with POS N
multidrug-resistant POS N
HBV. POS N

At POS N
week POS N
144, POS N
19 POS N
patients POS N
who POS N
had POS N
HBV POS N
DNA POS N
levels POS N
>60 POS N
IU/mL POS N
qualified POS N
for POS N
genotypic POS N
resistance POS N
analysis, POS N
and POS N
6 POS N
retained POS N
some POS N
of POS N
their POS N
baseline POS N
resistance POS N
mutations POS N
of POS N
HBV. POS N

TDF POS N
monotherapy POS N
was POS N
efficacious POS N
and POS N
safe POS N
for POS N
up POS N
to POS N
144 POS N
weeks, POS N
providing POS N
an POS N
increasing POS N
rate POS N
of POS N
virologic POS N
response POS N
in POS N
heavily POS N
pretreated POS N
patients POS N
with POS N
multidrug-resistant POS N
HBV. POS N

No POS N
patients POS N
developed POS N
additional POS N
resistance POS N
mutations POS N
throughout POS N
the POS N
study POS N
period. POS N

Serum POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
48, POS N
the POS N
primary POS N
efficacy POS N
endpoint, POS N
was POS N
achieved POS N
in POS N
66.3% POS N
in POS N
the POS N
TDF-TDF POS N
group POS N
and POS N
68.0% POS N
in POS N
the POS N
TDF/ETV-TDF POS N
group POS N
(P POS N
= POS N
0.80). POS N

TDF POS N
monotherapy POS N
was POS N
efficacious POS N
and POS N
safe POS N
for POS N
up POS N
to POS N
144 POS N
weeks, POS N
providing POS N
an POS N
increasing POS N
rate POS N
of POS N
virologic POS N
response POS N
in POS N
heavily POS N
pretreated POS N
patients POS N
with POS N
multidrug-resistant POS N
HBV. POS N

Serum POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
48, POS N
the POS N
primary POS N
efficacy POS N
endpoint, POS N
was POS N
achieved POS N
in POS N
66.3% POS N
in POS N
the POS N
TDF-TDF POS N
group POS N
and POS N
68.0% POS N
in POS N
the POS N
TDF/ETV-TDF POS N
group POS N
(P POS N
= POS N
0.80). POS N

At POS N
week POS N
144, POS N
the POS N
proportion POS N
with POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
increased POS N
to POS N
74.5%, POS N
which POS N
was POS N
significantly POS N
higher POS N
compared POS N
with POS N
that POS N
at POS N
week POS N
48 POS N
(P POS N
= POS N
0.03), POS N
without POS N
a POS N
significant POS N
difference POS N
between POS N
groups POS N
(P POS N
= POS N
0.46). POS N

Serum POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
48, POS N
the POS N
primary POS N
efficacy POS N
endpoint, POS N
was POS N
achieved POS N
in POS N
66.3% POS N
in POS N
the POS N
TDF-TDF POS N
group POS N
and POS N
68.0% POS N
in POS N
the POS N
TDF/ETV-TDF POS N
group POS N
(P POS N
= POS N
0.80). POS N

By POS N
on-treatment POS N
analysis, POS N
a POS N
total POS N
of POS N
79.4% POS N
had POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
144. POS N

Serum POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
48, POS N
the POS N
primary POS N
efficacy POS N
endpoint, POS N
was POS N
achieved POS N
in POS N
66.3% POS N
in POS N
the POS N
TDF-TDF POS N
group POS N
and POS N
68.0% POS N
in POS N
the POS N
TDF/ETV-TDF POS N
group POS N
(P POS N
= POS N
0.80). POS N

Transient POS N
virologic POS N
breakthrough POS N
occurred POS N
in POS N
6 POS N
patients, POS N
which POS N
was POS N
due POS N
to POS N
poor POS N
drug POS N
adherence. POS N

Serum POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
48, POS N
the POS N
primary POS N
efficacy POS N
endpoint, POS N
was POS N
achieved POS N
in POS N
66.3% POS N
in POS N
the POS N
TDF-TDF POS N
group POS N
and POS N
68.0% POS N
in POS N
the POS N
TDF/ETV-TDF POS N
group POS N
(P POS N
= POS N
0.80). POS N

At POS N
week POS N
144, POS N
19 POS N
patients POS N
who POS N
had POS N
HBV POS N
DNA POS N
levels POS N
>60 POS N
IU/mL POS N
qualified POS N
for POS N
genotypic POS N
resistance POS N
analysis, POS N
and POS N
6 POS N
retained POS N
some POS N
of POS N
their POS N
baseline POS N
resistance POS N
mutations POS N
of POS N
HBV. POS N

Serum POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
48, POS N
the POS N
primary POS N
efficacy POS N
endpoint, POS N
was POS N
achieved POS N
in POS N
66.3% POS N
in POS N
the POS N
TDF-TDF POS N
group POS N
and POS N
68.0% POS N
in POS N
the POS N
TDF/ETV-TDF POS N
group POS N
(P POS N
= POS N
0.80). POS N

No POS N
patients POS N
developed POS N
additional POS N
resistance POS N
mutations POS N
throughout POS N
the POS N
study POS N
period. POS N

At POS N
week POS N
144, POS N
the POS N
proportion POS N
with POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
increased POS N
to POS N
74.5%, POS N
which POS N
was POS N
significantly POS N
higher POS N
compared POS N
with POS N
that POS N
at POS N
week POS N
48 POS N
(P POS N
= POS N
0.03), POS N
without POS N
a POS N
significant POS N
difference POS N
between POS N
groups POS N
(P POS N
= POS N
0.46). POS N

TDF POS N
monotherapy POS N
was POS N
efficacious POS N
and POS N
safe POS N
for POS N
up POS N
to POS N
144 POS N
weeks, POS N
providing POS N
an POS N
increasing POS N
rate POS N
of POS N
virologic POS N
response POS N
in POS N
heavily POS N
pretreated POS N
patients POS N
with POS N
multidrug-resistant POS N
HBV. POS N

At POS N
week POS N
144, POS N
the POS N
proportion POS N
with POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
increased POS N
to POS N
74.5%, POS N
which POS N
was POS N
significantly POS N
higher POS N
compared POS N
with POS N
that POS N
at POS N
week POS N
48 POS N
(P POS N
= POS N
0.03), POS N
without POS N
a POS N
significant POS N
difference POS N
between POS N
groups POS N
(P POS N
= POS N
0.46). POS N

Serum POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
48, POS N
the POS N
primary POS N
efficacy POS N
endpoint, POS N
was POS N
achieved POS N
in POS N
66.3% POS N
in POS N
the POS N
TDF-TDF POS N
group POS N
and POS N
68.0% POS N
in POS N
the POS N
TDF/ETV-TDF POS N
group POS N
(P POS N
= POS N
0.80). POS N

At POS N
week POS N
144, POS N
the POS N
proportion POS N
with POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
increased POS N
to POS N
74.5%, POS N
which POS N
was POS N
significantly POS N
higher POS N
compared POS N
with POS N
that POS N
at POS N
week POS N
48 POS N
(P POS N
= POS N
0.03), POS N
without POS N
a POS N
significant POS N
difference POS N
between POS N
groups POS N
(P POS N
= POS N
0.46). POS N

By POS N
on-treatment POS N
analysis, POS N
a POS N
total POS N
of POS N
79.4% POS N
had POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
144. POS N

At POS N
week POS N
144, POS N
the POS N
proportion POS N
with POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
increased POS N
to POS N
74.5%, POS N
which POS N
was POS N
significantly POS N
higher POS N
compared POS N
with POS N
that POS N
at POS N
week POS N
48 POS N
(P POS N
= POS N
0.03), POS N
without POS N
a POS N
significant POS N
difference POS N
between POS N
groups POS N
(P POS N
= POS N
0.46). POS N

Transient POS N
virologic POS N
breakthrough POS N
occurred POS N
in POS N
6 POS N
patients, POS N
which POS N
was POS N
due POS N
to POS N
poor POS N
drug POS N
adherence. POS N

At POS N
week POS N
144, POS N
the POS N
proportion POS N
with POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
increased POS N
to POS N
74.5%, POS N
which POS N
was POS N
significantly POS N
higher POS N
compared POS N
with POS N
that POS N
at POS N
week POS N
48 POS N
(P POS N
= POS N
0.03), POS N
without POS N
a POS N
significant POS N
difference POS N
between POS N
groups POS N
(P POS N
= POS N
0.46). POS N

At POS N
week POS N
144, POS N
19 POS N
patients POS N
who POS N
had POS N
HBV POS N
DNA POS N
levels POS N
>60 POS N
IU/mL POS N
qualified POS N
for POS N
genotypic POS N
resistance POS N
analysis, POS N
and POS N
6 POS N
retained POS N
some POS N
of POS N
their POS N
baseline POS N
resistance POS N
mutations POS N
of POS N
HBV. POS N

At POS N
week POS N
144, POS N
the POS N
proportion POS N
with POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
increased POS N
to POS N
74.5%, POS N
which POS N
was POS N
significantly POS N
higher POS N
compared POS N
with POS N
that POS N
at POS N
week POS N
48 POS N
(P POS N
= POS N
0.03), POS N
without POS N
a POS N
significant POS N
difference POS N
between POS N
groups POS N
(P POS N
= POS N
0.46). POS N

No POS N
patients POS N
developed POS N
additional POS N
resistance POS N
mutations POS N
throughout POS N
the POS N
study POS N
period. POS N

By POS N
on-treatment POS N
analysis, POS N
a POS N
total POS N
of POS N
79.4% POS N
had POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
144. POS N

TDF POS N
monotherapy POS N
was POS N
efficacious POS N
and POS N
safe POS N
for POS N
up POS N
to POS N
144 POS N
weeks, POS N
providing POS N
an POS N
increasing POS N
rate POS N
of POS N
virologic POS N
response POS N
in POS N
heavily POS N
pretreated POS N
patients POS N
with POS N
multidrug-resistant POS N
HBV. POS N

By POS N
on-treatment POS N
analysis, POS N
a POS N
total POS N
of POS N
79.4% POS N
had POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
144. POS N

Serum POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
48, POS N
the POS N
primary POS N
efficacy POS N
endpoint, POS N
was POS N
achieved POS N
in POS N
66.3% POS N
in POS N
the POS N
TDF-TDF POS N
group POS N
and POS N
68.0% POS N
in POS N
the POS N
TDF/ETV-TDF POS N
group POS N
(P POS N
= POS N
0.80). POS N

By POS N
on-treatment POS N
analysis, POS N
a POS N
total POS N
of POS N
79.4% POS N
had POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
144. POS N

At POS N
week POS N
144, POS N
the POS N
proportion POS N
with POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
increased POS N
to POS N
74.5%, POS N
which POS N
was POS N
significantly POS N
higher POS N
compared POS N
with POS N
that POS N
at POS N
week POS N
48 POS N
(P POS N
= POS N
0.03), POS N
without POS N
a POS N
significant POS N
difference POS N
between POS N
groups POS N
(P POS N
= POS N
0.46). POS N

By POS N
on-treatment POS N
analysis, POS N
a POS N
total POS N
of POS N
79.4% POS N
had POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
144. POS N

Transient POS N
virologic POS N
breakthrough POS N
occurred POS N
in POS N
6 POS N
patients, POS N
which POS N
was POS N
due POS N
to POS N
poor POS N
drug POS N
adherence. POS N

By POS N
on-treatment POS N
analysis, POS N
a POS N
total POS N
of POS N
79.4% POS N
had POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
144. POS N

At POS N
week POS N
144, POS N
19 POS N
patients POS N
who POS N
had POS N
HBV POS N
DNA POS N
levels POS N
>60 POS N
IU/mL POS N
qualified POS N
for POS N
genotypic POS N
resistance POS N
analysis, POS N
and POS N
6 POS N
retained POS N
some POS N
of POS N
their POS N
baseline POS N
resistance POS N
mutations POS N
of POS N
HBV. POS N

By POS N
on-treatment POS N
analysis, POS N
a POS N
total POS N
of POS N
79.4% POS N
had POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
144. POS N

No POS N
patients POS N
developed POS N
additional POS N
resistance POS N
mutations POS N
throughout POS N
the POS N
study POS N
period. POS N

Transient POS N
virologic POS N
breakthrough POS N
occurred POS N
in POS N
6 POS N
patients, POS N
which POS N
was POS N
due POS N
to POS N
poor POS N
drug POS N
adherence. POS N

TDF POS N
monotherapy POS N
was POS N
efficacious POS N
and POS N
safe POS N
for POS N
up POS N
to POS N
144 POS N
weeks, POS N
providing POS N
an POS N
increasing POS N
rate POS N
of POS N
virologic POS N
response POS N
in POS N
heavily POS N
pretreated POS N
patients POS N
with POS N
multidrug-resistant POS N
HBV. POS N

Transient POS N
virologic POS N
breakthrough POS N
occurred POS N
in POS N
6 POS N
patients, POS N
which POS N
was POS N
due POS N
to POS N
poor POS N
drug POS N
adherence. POS N

Serum POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
48, POS N
the POS N
primary POS N
efficacy POS N
endpoint, POS N
was POS N
achieved POS N
in POS N
66.3% POS N
in POS N
the POS N
TDF-TDF POS N
group POS N
and POS N
68.0% POS N
in POS N
the POS N
TDF/ETV-TDF POS N
group POS N
(P POS N
= POS N
0.80). POS N

Transient POS N
virologic POS N
breakthrough POS N
occurred POS N
in POS N
6 POS N
patients, POS N
which POS N
was POS N
due POS N
to POS N
poor POS N
drug POS N
adherence. POS N

At POS N
week POS N
144, POS N
the POS N
proportion POS N
with POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
increased POS N
to POS N
74.5%, POS N
which POS N
was POS N
significantly POS N
higher POS N
compared POS N
with POS N
that POS N
at POS N
week POS N
48 POS N
(P POS N
= POS N
0.03), POS N
without POS N
a POS N
significant POS N
difference POS N
between POS N
groups POS N
(P POS N
= POS N
0.46). POS N

Transient POS N
virologic POS N
breakthrough POS N
occurred POS N
in POS N
6 POS N
patients, POS N
which POS N
was POS N
due POS N
to POS N
poor POS N
drug POS N
adherence. POS N

By POS N
on-treatment POS N
analysis, POS N
a POS N
total POS N
of POS N
79.4% POS N
had POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
144. POS N

Transient POS N
virologic POS N
breakthrough POS N
occurred POS N
in POS N
6 POS N
patients, POS N
which POS N
was POS N
due POS N
to POS N
poor POS N
drug POS N
adherence. POS N

At POS N
week POS N
144, POS N
19 POS N
patients POS N
who POS N
had POS N
HBV POS N
DNA POS N
levels POS N
>60 POS N
IU/mL POS N
qualified POS N
for POS N
genotypic POS N
resistance POS N
analysis, POS N
and POS N
6 POS N
retained POS N
some POS N
of POS N
their POS N
baseline POS N
resistance POS N
mutations POS N
of POS N
HBV. POS N

Transient POS N
virologic POS N
breakthrough POS N
occurred POS N
in POS N
6 POS N
patients, POS N
which POS N
was POS N
due POS N
to POS N
poor POS N
drug POS N
adherence. POS N

No POS N
patients POS N
developed POS N
additional POS N
resistance POS N
mutations POS N
throughout POS N
the POS N
study POS N
period. POS N

At POS N
week POS N
144, POS N
19 POS N
patients POS N
who POS N
had POS N
HBV POS N
DNA POS N
levels POS N
>60 POS N
IU/mL POS N
qualified POS N
for POS N
genotypic POS N
resistance POS N
analysis, POS N
and POS N
6 POS N
retained POS N
some POS N
of POS N
their POS N
baseline POS N
resistance POS N
mutations POS N
of POS N
HBV. POS N

TDF POS N
monotherapy POS N
was POS N
efficacious POS N
and POS N
safe POS N
for POS N
up POS N
to POS N
144 POS N
weeks, POS N
providing POS N
an POS N
increasing POS N
rate POS N
of POS N
virologic POS N
response POS N
in POS N
heavily POS N
pretreated POS N
patients POS N
with POS N
multidrug-resistant POS N
HBV. POS N

At POS N
week POS N
144, POS N
19 POS N
patients POS N
who POS N
had POS N
HBV POS N
DNA POS N
levels POS N
>60 POS N
IU/mL POS N
qualified POS N
for POS N
genotypic POS N
resistance POS N
analysis, POS N
and POS N
6 POS N
retained POS N
some POS N
of POS N
their POS N
baseline POS N
resistance POS N
mutations POS N
of POS N
HBV. POS N

Serum POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
48, POS N
the POS N
primary POS N
efficacy POS N
endpoint, POS N
was POS N
achieved POS N
in POS N
66.3% POS N
in POS N
the POS N
TDF-TDF POS N
group POS N
and POS N
68.0% POS N
in POS N
the POS N
TDF/ETV-TDF POS N
group POS N
(P POS N
= POS N
0.80). POS N

At POS N
week POS N
144, POS N
19 POS N
patients POS N
who POS N
had POS N
HBV POS N
DNA POS N
levels POS N
>60 POS N
IU/mL POS N
qualified POS N
for POS N
genotypic POS N
resistance POS N
analysis, POS N
and POS N
6 POS N
retained POS N
some POS N
of POS N
their POS N
baseline POS N
resistance POS N
mutations POS N
of POS N
HBV. POS N

At POS N
week POS N
144, POS N
the POS N
proportion POS N
with POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
increased POS N
to POS N
74.5%, POS N
which POS N
was POS N
significantly POS N
higher POS N
compared POS N
with POS N
that POS N
at POS N
week POS N
48 POS N
(P POS N
= POS N
0.03), POS N
without POS N
a POS N
significant POS N
difference POS N
between POS N
groups POS N
(P POS N
= POS N
0.46). POS N

At POS N
week POS N
144, POS N
19 POS N
patients POS N
who POS N
had POS N
HBV POS N
DNA POS N
levels POS N
>60 POS N
IU/mL POS N
qualified POS N
for POS N
genotypic POS N
resistance POS N
analysis, POS N
and POS N
6 POS N
retained POS N
some POS N
of POS N
their POS N
baseline POS N
resistance POS N
mutations POS N
of POS N
HBV. POS N

By POS N
on-treatment POS N
analysis, POS N
a POS N
total POS N
of POS N
79.4% POS N
had POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
144. POS N

At POS N
week POS N
144, POS N
19 POS N
patients POS N
who POS N
had POS N
HBV POS N
DNA POS N
levels POS N
>60 POS N
IU/mL POS N
qualified POS N
for POS N
genotypic POS N
resistance POS N
analysis, POS N
and POS N
6 POS N
retained POS N
some POS N
of POS N
their POS N
baseline POS N
resistance POS N
mutations POS N
of POS N
HBV. POS N

Transient POS N
virologic POS N
breakthrough POS N
occurred POS N
in POS N
6 POS N
patients, POS N
which POS N
was POS N
due POS N
to POS N
poor POS N
drug POS N
adherence. POS N

At POS N
week POS N
144, POS N
19 POS N
patients POS N
who POS N
had POS N
HBV POS N
DNA POS N
levels POS N
>60 POS N
IU/mL POS N
qualified POS N
for POS N
genotypic POS N
resistance POS N
analysis, POS N
and POS N
6 POS N
retained POS N
some POS N
of POS N
their POS N
baseline POS N
resistance POS N
mutations POS N
of POS N
HBV. POS N

No POS N
patients POS N
developed POS N
additional POS N
resistance POS N
mutations POS N
throughout POS N
the POS N
study POS N
period. POS N

No POS N
patients POS N
developed POS N
additional POS N
resistance POS N
mutations POS N
throughout POS N
the POS N
study POS N
period. POS N

TDF POS N
monotherapy POS N
was POS N
efficacious POS N
and POS N
safe POS N
for POS N
up POS N
to POS N
144 POS N
weeks, POS N
providing POS N
an POS N
increasing POS N
rate POS N
of POS N
virologic POS N
response POS N
in POS N
heavily POS N
pretreated POS N
patients POS N
with POS N
multidrug-resistant POS N
HBV. POS N

No POS N
patients POS N
developed POS N
additional POS N
resistance POS N
mutations POS N
throughout POS N
the POS N
study POS N
period. POS N

Serum POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
48, POS N
the POS N
primary POS N
efficacy POS N
endpoint, POS N
was POS N
achieved POS N
in POS N
66.3% POS N
in POS N
the POS N
TDF-TDF POS N
group POS N
and POS N
68.0% POS N
in POS N
the POS N
TDF/ETV-TDF POS N
group POS N
(P POS N
= POS N
0.80). POS N

No POS N
patients POS N
developed POS N
additional POS N
resistance POS N
mutations POS N
throughout POS N
the POS N
study POS N
period. POS N

At POS N
week POS N
144, POS N
the POS N
proportion POS N
with POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
increased POS N
to POS N
74.5%, POS N
which POS N
was POS N
significantly POS N
higher POS N
compared POS N
with POS N
that POS N
at POS N
week POS N
48 POS N
(P POS N
= POS N
0.03), POS N
without POS N
a POS N
significant POS N
difference POS N
between POS N
groups POS N
(P POS N
= POS N
0.46). POS N

No POS N
patients POS N
developed POS N
additional POS N
resistance POS N
mutations POS N
throughout POS N
the POS N
study POS N
period. POS N

By POS N
on-treatment POS N
analysis, POS N
a POS N
total POS N
of POS N
79.4% POS N
had POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
144. POS N

No POS N
patients POS N
developed POS N
additional POS N
resistance POS N
mutations POS N
throughout POS N
the POS N
study POS N
period. POS N

Transient POS N
virologic POS N
breakthrough POS N
occurred POS N
in POS N
6 POS N
patients, POS N
which POS N
was POS N
due POS N
to POS N
poor POS N
drug POS N
adherence. POS N

No POS N
patients POS N
developed POS N
additional POS N
resistance POS N
mutations POS N
throughout POS N
the POS N
study POS N
period. POS N

At POS N
week POS N
144, POS N
19 POS N
patients POS N
who POS N
had POS N
HBV POS N
DNA POS N
levels POS N
>60 POS N
IU/mL POS N
qualified POS N
for POS N
genotypic POS N
resistance POS N
analysis, POS N
and POS N
6 POS N
retained POS N
some POS N
of POS N
their POS N
baseline POS N
resistance POS N
mutations POS N
of POS N
HBV. POS N

In POS N
the POS N
primary POS N
intention-to-treat POS N
analysis, POS N
the POS N
effect POS N
of POS N
GLI POS N
encouragement POS N
was POS N
0.95% POS N
weight POS N
loss POS N
at POS N
six POS N
months POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0.13-1.77%; POS N
P = 0.02), POS N
and POS N
1.20% POS N
weight POS N
loss POS N
at POS N
12 months POS N
(95% POS N
CI, POS N
0.05-2.36%; POS N
P = 0.04). POS N

At POS N
12 months, POS N
there POS N
was POS N
a POS N
0.30% POS N
(3.3 mmol/mol) POS N
reduction POS N
in POS N
hemoglobin POS N
A1c, POS N

In POS N
the POS N
primary POS N
intention-to-treat POS N
analysis, POS N
the POS N
effect POS N
of POS N
GLI POS N
encouragement POS N
was POS N
0.95% POS N
weight POS N
loss POS N
at POS N
six POS N
months POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0.13-1.77%; POS N
P = 0.02), POS N
and POS N
1.20% POS N
weight POS N
loss POS N
at POS N
12 months POS N
(95% POS N
CI, POS N
0.05-2.36%; POS N
P = 0.04). POS N

but POS N
this POS N
result POS N
did POS N
not POS N
achieve POS N
statistical POS N
significance POS N
(P = 0.054). POS N

In POS N
the POS N
primary POS N
intention-to-treat POS N
analysis, POS N
the POS N
effect POS N
of POS N
GLI POS N
encouragement POS N
was POS N
0.95% POS N
weight POS N
loss POS N
at POS N
six POS N
months POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0.13-1.77%; POS N
P = 0.02), POS N
and POS N
1.20% POS N
weight POS N
loss POS N
at POS N
12 months POS N
(95% POS N
CI, POS N
0.05-2.36%; POS N
P = 0.04). POS N

In POS N
instrumental POS N
variable POS N
analysis POS N
estimating POS N
effects POS N
among POS N
the POS N
subgroup POS N
of POS N
participants POS N
who POS N
attended POS N
any POS N
GLI POS N
visits, POS N
the POS N
effect POS N
of POS N
GLI POS N
attendance POS N
was POS N
2.30% POS N
weight POS N
loss POS N
at POS N
six POS N
months POS N
(95% POS N
CI, POS N
0.30-4.30%; POS N
P = 0.02), POS N
and POS N
2.07% POS N
weight POS N
loss POS N
at POS N
12 months POS N
(95% POS N
CI, POS N
0.25-3.88%; POS N
P = 0.02). POS N

In POS N
the POS N
primary POS N
intention-to-treat POS N
analysis, POS N
the POS N
effect POS N
of POS N
GLI POS N
encouragement POS N
was POS N
0.95% POS N
weight POS N
loss POS N
at POS N
six POS N
months POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0.13-1.77%; POS N
P = 0.02), POS N
and POS N
1.20% POS N
weight POS N
loss POS N
at POS N
12 months POS N
(95% POS N
CI, POS N
0.05-2.36%; POS N
P = 0.04). POS N

Among POS N
adults POS N
with POS N
type POS N
2 POS N
diabetes, POS N
a POS N
group-based POS N
lifestyle POS N
intervention POS N
in POS N
a POS N
community-based POS N
setting POS N
achieved POS N
modest POS N
weight POS N
loss POS N
at POS N
6 POS N
and POS N
12 months. POS N

At POS N
12 months, POS N
there POS N
was POS N
a POS N
0.30% POS N
(3.3 mmol/mol) POS N
reduction POS N
in POS N
hemoglobin POS N
A1c, POS N

In POS N
the POS N
primary POS N
intention-to-treat POS N
analysis, POS N
the POS N
effect POS N
of POS N
GLI POS N
encouragement POS N
was POS N
0.95% POS N
weight POS N
loss POS N
at POS N
six POS N
months POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0.13-1.77%; POS N
P = 0.02), POS N
and POS N
1.20% POS N
weight POS N
loss POS N
at POS N
12 months POS N
(95% POS N
CI, POS N
0.05-2.36%; POS N
P = 0.04). POS N

At POS N
12 months, POS N
there POS N
was POS N
a POS N
0.30% POS N
(3.3 mmol/mol) POS N
reduction POS N
in POS N
hemoglobin POS N
A1c, POS N

but POS N
this POS N
result POS N
did POS N
not POS N
achieve POS N
statistical POS N
significance POS N
(P = 0.054). POS N

At POS N
12 months, POS N
there POS N
was POS N
a POS N
0.30% POS N
(3.3 mmol/mol) POS N
reduction POS N
in POS N
hemoglobin POS N
A1c, POS N

In POS N
instrumental POS N
variable POS N
analysis POS N
estimating POS N
effects POS N
among POS N
the POS N
subgroup POS N
of POS N
participants POS N
who POS N
attended POS N
any POS N
GLI POS N
visits, POS N
the POS N
effect POS N
of POS N
GLI POS N
attendance POS N
was POS N
2.30% POS N
weight POS N
loss POS N
at POS N
six POS N
months POS N
(95% POS N
CI, POS N
0.30-4.30%; POS N
P = 0.02), POS N
and POS N
2.07% POS N
weight POS N
loss POS N
at POS N
12 months POS N
(95% POS N
CI, POS N
0.25-3.88%; POS N
P = 0.02). POS N

At POS N
12 months, POS N
there POS N
was POS N
a POS N
0.30% POS N
(3.3 mmol/mol) POS N
reduction POS N
in POS N
hemoglobin POS N
A1c, POS N

Among POS N
adults POS N
with POS N
type POS N
2 POS N
diabetes, POS N
a POS N
group-based POS N
lifestyle POS N
intervention POS N
in POS N
a POS N
community-based POS N
setting POS N
achieved POS N
modest POS N
weight POS N
loss POS N
at POS N
6 POS N
and POS N
12 months. POS N

but POS N
this POS N
result POS N
did POS N
not POS N
achieve POS N
statistical POS N
significance POS N
(P = 0.054). POS N

In POS N
the POS N
primary POS N
intention-to-treat POS N
analysis, POS N
the POS N
effect POS N
of POS N
GLI POS N
encouragement POS N
was POS N
0.95% POS N
weight POS N
loss POS N
at POS N
six POS N
months POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0.13-1.77%; POS N
P = 0.02), POS N
and POS N
1.20% POS N
weight POS N
loss POS N
at POS N
12 months POS N
(95% POS N
CI, POS N
0.05-2.36%; POS N
P = 0.04). POS N

but POS N
this POS N
result POS N
did POS N
not POS N
achieve POS N
statistical POS N
significance POS N
(P = 0.054). POS N

At POS N
12 months, POS N
there POS N
was POS N
a POS N
0.30% POS N
(3.3 mmol/mol) POS N
reduction POS N
in POS N
hemoglobin POS N
A1c, POS N

but POS N
this POS N
result POS N
did POS N
not POS N
achieve POS N
statistical POS N
significance POS N
(P = 0.054). POS N

In POS N
instrumental POS N
variable POS N
analysis POS N
estimating POS N
effects POS N
among POS N
the POS N
subgroup POS N
of POS N
participants POS N
who POS N
attended POS N
any POS N
GLI POS N
visits, POS N
the POS N
effect POS N
of POS N
GLI POS N
attendance POS N
was POS N
2.30% POS N
weight POS N
loss POS N
at POS N
six POS N
months POS N
(95% POS N
CI, POS N
0.30-4.30%; POS N
P = 0.02), POS N
and POS N
2.07% POS N
weight POS N
loss POS N
at POS N
12 months POS N
(95% POS N
CI, POS N
0.25-3.88%; POS N
P = 0.02). POS N

but POS N
this POS N
result POS N
did POS N
not POS N
achieve POS N
statistical POS N
significance POS N
(P = 0.054). POS N

Among POS N
adults POS N
with POS N
type POS N
2 POS N
diabetes, POS N
a POS N
group-based POS N
lifestyle POS N
intervention POS N
in POS N
a POS N
community-based POS N
setting POS N
achieved POS N
modest POS N
weight POS N
loss POS N
at POS N
6 POS N
and POS N
12 months. POS N

In POS N
instrumental POS N
variable POS N
analysis POS N
estimating POS N
effects POS N
among POS N
the POS N
subgroup POS N
of POS N
participants POS N
who POS N
attended POS N
any POS N
GLI POS N
visits, POS N
the POS N
effect POS N
of POS N
GLI POS N
attendance POS N
was POS N
2.30% POS N
weight POS N
loss POS N
at POS N
six POS N
months POS N
(95% POS N
CI, POS N
0.30-4.30%; POS N
P = 0.02), POS N
and POS N
2.07% POS N
weight POS N
loss POS N
at POS N
12 months POS N
(95% POS N
CI, POS N
0.25-3.88%; POS N
P = 0.02). POS N

In POS N
the POS N
primary POS N
intention-to-treat POS N
analysis, POS N
the POS N
effect POS N
of POS N
GLI POS N
encouragement POS N
was POS N
0.95% POS N
weight POS N
loss POS N
at POS N
six POS N
months POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0.13-1.77%; POS N
P = 0.02), POS N
and POS N
1.20% POS N
weight POS N
loss POS N
at POS N
12 months POS N
(95% POS N
CI, POS N
0.05-2.36%; POS N
P = 0.04). POS N

In POS N
instrumental POS N
variable POS N
analysis POS N
estimating POS N
effects POS N
among POS N
the POS N
subgroup POS N
of POS N
participants POS N
who POS N
attended POS N
any POS N
GLI POS N
visits, POS N
the POS N
effect POS N
of POS N
GLI POS N
attendance POS N
was POS N
2.30% POS N
weight POS N
loss POS N
at POS N
six POS N
months POS N
(95% POS N
CI, POS N
0.30-4.30%; POS N
P = 0.02), POS N
and POS N
2.07% POS N
weight POS N
loss POS N
at POS N
12 months POS N
(95% POS N
CI, POS N
0.25-3.88%; POS N
P = 0.02). POS N

At POS N
12 months, POS N
there POS N
was POS N
a POS N
0.30% POS N
(3.3 mmol/mol) POS N
reduction POS N
in POS N
hemoglobin POS N
A1c, POS N

In POS N
instrumental POS N
variable POS N
analysis POS N
estimating POS N
effects POS N
among POS N
the POS N
subgroup POS N
of POS N
participants POS N
who POS N
attended POS N
any POS N
GLI POS N
visits, POS N
the POS N
effect POS N
of POS N
GLI POS N
attendance POS N
was POS N
2.30% POS N
weight POS N
loss POS N
at POS N
six POS N
months POS N
(95% POS N
CI, POS N
0.30-4.30%; POS N
P = 0.02), POS N
and POS N
2.07% POS N
weight POS N
loss POS N
at POS N
12 months POS N
(95% POS N
CI, POS N
0.25-3.88%; POS N
P = 0.02). POS N

but POS N
this POS N
result POS N
did POS N
not POS N
achieve POS N
statistical POS N
significance POS N
(P = 0.054). POS N

In POS N
instrumental POS N
variable POS N
analysis POS N
estimating POS N
effects POS N
among POS N
the POS N
subgroup POS N
of POS N
participants POS N
who POS N
attended POS N
any POS N
GLI POS N
visits, POS N
the POS N
effect POS N
of POS N
GLI POS N
attendance POS N
was POS N
2.30% POS N
weight POS N
loss POS N
at POS N
six POS N
months POS N
(95% POS N
CI, POS N
0.30-4.30%; POS N
P = 0.02), POS N
and POS N
2.07% POS N
weight POS N
loss POS N
at POS N
12 months POS N
(95% POS N
CI, POS N
0.25-3.88%; POS N
P = 0.02). POS N

Among POS N
adults POS N
with POS N
type POS N
2 POS N
diabetes, POS N
a POS N
group-based POS N
lifestyle POS N
intervention POS N
in POS N
a POS N
community-based POS N
setting POS N
achieved POS N
modest POS N
weight POS N
loss POS N
at POS N
6 POS N
and POS N
12 months. POS N

Among POS N
adults POS N
with POS N
type POS N
2 POS N
diabetes, POS N
a POS N
group-based POS N
lifestyle POS N
intervention POS N
in POS N
a POS N
community-based POS N
setting POS N
achieved POS N
modest POS N
weight POS N
loss POS N
at POS N
6 POS N
and POS N
12 months. POS N

In POS N
the POS N
primary POS N
intention-to-treat POS N
analysis, POS N
the POS N
effect POS N
of POS N
GLI POS N
encouragement POS N
was POS N
0.95% POS N
weight POS N
loss POS N
at POS N
six POS N
months POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0.13-1.77%; POS N
P = 0.02), POS N
and POS N
1.20% POS N
weight POS N
loss POS N
at POS N
12 months POS N
(95% POS N
CI, POS N
0.05-2.36%; POS N
P = 0.04). POS N

Among POS N
adults POS N
with POS N
type POS N
2 POS N
diabetes, POS N
a POS N
group-based POS N
lifestyle POS N
intervention POS N
in POS N
a POS N
community-based POS N
setting POS N
achieved POS N
modest POS N
weight POS N
loss POS N
at POS N
6 POS N
and POS N
12 months. POS N

At POS N
12 months, POS N
there POS N
was POS N
a POS N
0.30% POS N
(3.3 mmol/mol) POS N
reduction POS N
in POS N
hemoglobin POS N
A1c, POS N

Among POS N
adults POS N
with POS N
type POS N
2 POS N
diabetes, POS N
a POS N
group-based POS N
lifestyle POS N
intervention POS N
in POS N
a POS N
community-based POS N
setting POS N
achieved POS N
modest POS N
weight POS N
loss POS N
at POS N
6 POS N
and POS N
12 months. POS N

but POS N
this POS N
result POS N
did POS N
not POS N
achieve POS N
statistical POS N
significance POS N
(P = 0.054). POS N

Among POS N
adults POS N
with POS N
type POS N
2 POS N
diabetes, POS N
a POS N
group-based POS N
lifestyle POS N
intervention POS N
in POS N
a POS N
community-based POS N
setting POS N
achieved POS N
modest POS N
weight POS N
loss POS N
at POS N
6 POS N
and POS N
12 months. POS N

In POS N
instrumental POS N
variable POS N
analysis POS N
estimating POS N
effects POS N
among POS N
the POS N
subgroup POS N
of POS N
participants POS N
who POS N
attended POS N
any POS N
GLI POS N
visits, POS N
the POS N
effect POS N
of POS N
GLI POS N
attendance POS N
was POS N
2.30% POS N
weight POS N
loss POS N
at POS N
six POS N
months POS N
(95% POS N
CI, POS N
0.30-4.30%; POS N
P = 0.02), POS N
and POS N
2.07% POS N
weight POS N
loss POS N
at POS N
12 months POS N
(95% POS N
CI, POS N
0.25-3.88%; POS N
P = 0.02). POS N

anthracyclines POS N
are POS N
effective POS N
chemotherapeutic POS N
agents POS N
for POS N
treating POS N
B-cell POS N
lymphoma, POS N

adverse POS N
effects, POS N
such POS N
as POS N
bone POS N
marrow POS N
suppression POS N
and POS N
cardiotoxicity, POS N
limit POS N
their POS N
clinical POS N
application. POS N

anthracyclines POS N
are POS N
effective POS N
chemotherapeutic POS N
agents POS N
for POS N
treating POS N
B-cell POS N
lymphoma, POS N

Cumulative POS N
anthracycline POS N
doses POS N
of POS N
253-400 POS N
mg POS N
(HR: POS N
2.35; POS N
95% POS N
CI POS N
1.41-3.91; POS N
p = 0.0010), POS N
401-504 POS N
mg POS N
(HR: POS N
2.26; POS N
95% POS N
CI POS N
1.26-4.05; POS N
p = 0.0063), POS N
and > 504 POS N
mg POS N
(HR: POS N
2.29; POS N
95% POS N
CI POS N
1.25-4.18; POS N
p = 0.0072) POS N
increased POS N
the POS N
incidence POS N
density POS N
of POS N
diabetes POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
(p = 0.0006). POS N

anthracyclines POS N
are POS N
effective POS N
chemotherapeutic POS N
agents POS N
for POS N
treating POS N
B-cell POS N
lymphoma, POS N

Anthracycline POS N
administration POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
incidence POS N
of POS N
diabetes POS N
(HR: POS N
1.75; POS N
95% POS N
CI POS N
1.11-2.75; POS N
p = 0.0163) POS N
after POS N
adjustments POS N
for POS N
age, POS N
gender, POS N
cumulative POS N
dose POS N
of POS N
prednisolone, POS N
and POS N
co-morbidities. POS N

anthracyclines POS N
are POS N
effective POS N
chemotherapeutic POS N
agents POS N
for POS N
treating POS N
B-cell POS N
lymphoma, POS N

The POS N
annual POS N
alteration POS N
of POS N
adapted POS N
diabetes POS N
complications POS N
severity POS N
index POS N
score POS N
was POS N
not POS N
significantly POS N
different POS N
between POS N
B-cell POS N
lymphoma POS N
patients POS N
with POS N
or POS N
without POS N
anthracycline POS N
treatment POS N
(p = 0.4924). POS N

anthracyclines POS N
are POS N
effective POS N
chemotherapeutic POS N
agents POS N
for POS N
treating POS N
B-cell POS N
lymphoma, POS N

Anthracycline POS N
therapy POS N
increases POS N
diabetes POS N
risk POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
in POS N
B-cell POS N
lymphoma POS N
patients. POS N

anthracyclines POS N
are POS N
effective POS N
chemotherapeutic POS N
agents POS N
for POS N
treating POS N
B-cell POS N
lymphoma, POS N

Intensive POS N
blood POS N
glucose POS N
monitoring POS N
and POS N
control POS N
should POS N
be POS N
recommended POS N
for POS N
B-cell POS N
lymphoma POS N
patients POS N
receiving POS N
anthracycline POS N
treatment. POS N

adverse POS N
effects, POS N
such POS N
as POS N
bone POS N
marrow POS N
suppression POS N
and POS N
cardiotoxicity, POS N
limit POS N
their POS N
clinical POS N
application. POS N

anthracyclines POS N
are POS N
effective POS N
chemotherapeutic POS N
agents POS N
for POS N
treating POS N
B-cell POS N
lymphoma, POS N

adverse POS N
effects, POS N
such POS N
as POS N
bone POS N
marrow POS N
suppression POS N
and POS N
cardiotoxicity, POS N
limit POS N
their POS N
clinical POS N
application. POS N

Cumulative POS N
anthracycline POS N
doses POS N
of POS N
253-400 POS N
mg POS N
(HR: POS N
2.35; POS N
95% POS N
CI POS N
1.41-3.91; POS N
p = 0.0010), POS N
401-504 POS N
mg POS N
(HR: POS N
2.26; POS N
95% POS N
CI POS N
1.26-4.05; POS N
p = 0.0063), POS N
and > 504 POS N
mg POS N
(HR: POS N
2.29; POS N
95% POS N
CI POS N
1.25-4.18; POS N
p = 0.0072) POS N
increased POS N
the POS N
incidence POS N
density POS N
of POS N
diabetes POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
(p = 0.0006). POS N

adverse POS N
effects, POS N
such POS N
as POS N
bone POS N
marrow POS N
suppression POS N
and POS N
cardiotoxicity, POS N
limit POS N
their POS N
clinical POS N
application. POS N

Anthracycline POS N
administration POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
incidence POS N
of POS N
diabetes POS N
(HR: POS N
1.75; POS N
95% POS N
CI POS N
1.11-2.75; POS N
p = 0.0163) POS N
after POS N
adjustments POS N
for POS N
age, POS N
gender, POS N
cumulative POS N
dose POS N
of POS N
prednisolone, POS N
and POS N
co-morbidities. POS N

adverse POS N
effects, POS N
such POS N
as POS N
bone POS N
marrow POS N
suppression POS N
and POS N
cardiotoxicity, POS N
limit POS N
their POS N
clinical POS N
application. POS N

The POS N
annual POS N
alteration POS N
of POS N
adapted POS N
diabetes POS N
complications POS N
severity POS N
index POS N
score POS N
was POS N
not POS N
significantly POS N
different POS N
between POS N
B-cell POS N
lymphoma POS N
patients POS N
with POS N
or POS N
without POS N
anthracycline POS N
treatment POS N
(p = 0.4924). POS N

adverse POS N
effects, POS N
such POS N
as POS N
bone POS N
marrow POS N
suppression POS N
and POS N
cardiotoxicity, POS N
limit POS N
their POS N
clinical POS N
application. POS N

Anthracycline POS N
therapy POS N
increases POS N
diabetes POS N
risk POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
in POS N
B-cell POS N
lymphoma POS N
patients. POS N

adverse POS N
effects, POS N
such POS N
as POS N
bone POS N
marrow POS N
suppression POS N
and POS N
cardiotoxicity, POS N
limit POS N
their POS N
clinical POS N
application. POS N

Intensive POS N
blood POS N
glucose POS N
monitoring POS N
and POS N
control POS N
should POS N
be POS N
recommended POS N
for POS N
B-cell POS N
lymphoma POS N
patients POS N
receiving POS N
anthracycline POS N
treatment. POS N

Cumulative POS N
anthracycline POS N
doses POS N
of POS N
253-400 POS N
mg POS N
(HR: POS N
2.35; POS N
95% POS N
CI POS N
1.41-3.91; POS N
p = 0.0010), POS N
401-504 POS N
mg POS N
(HR: POS N
2.26; POS N
95% POS N
CI POS N
1.26-4.05; POS N
p = 0.0063), POS N
and > 504 POS N
mg POS N
(HR: POS N
2.29; POS N
95% POS N
CI POS N
1.25-4.18; POS N
p = 0.0072) POS N
increased POS N
the POS N
incidence POS N
density POS N
of POS N
diabetes POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
(p = 0.0006). POS N

anthracyclines POS N
are POS N
effective POS N
chemotherapeutic POS N
agents POS N
for POS N
treating POS N
B-cell POS N
lymphoma, POS N

Cumulative POS N
anthracycline POS N
doses POS N
of POS N
253-400 POS N
mg POS N
(HR: POS N
2.35; POS N
95% POS N
CI POS N
1.41-3.91; POS N
p = 0.0010), POS N
401-504 POS N
mg POS N
(HR: POS N
2.26; POS N
95% POS N
CI POS N
1.26-4.05; POS N
p = 0.0063), POS N
and > 504 POS N
mg POS N
(HR: POS N
2.29; POS N
95% POS N
CI POS N
1.25-4.18; POS N
p = 0.0072) POS N
increased POS N
the POS N
incidence POS N
density POS N
of POS N
diabetes POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
(p = 0.0006). POS N

adverse POS N
effects, POS N
such POS N
as POS N
bone POS N
marrow POS N
suppression POS N
and POS N
cardiotoxicity, POS N
limit POS N
their POS N
clinical POS N
application. POS N

Cumulative POS N
anthracycline POS N
doses POS N
of POS N
253-400 POS N
mg POS N
(HR: POS N
2.35; POS N
95% POS N
CI POS N
1.41-3.91; POS N
p = 0.0010), POS N
401-504 POS N
mg POS N
(HR: POS N
2.26; POS N
95% POS N
CI POS N
1.26-4.05; POS N
p = 0.0063), POS N
and > 504 POS N
mg POS N
(HR: POS N
2.29; POS N
95% POS N
CI POS N
1.25-4.18; POS N
p = 0.0072) POS N
increased POS N
the POS N
incidence POS N
density POS N
of POS N
diabetes POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
(p = 0.0006). POS N

Anthracycline POS N
administration POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
incidence POS N
of POS N
diabetes POS N
(HR: POS N
1.75; POS N
95% POS N
CI POS N
1.11-2.75; POS N
p = 0.0163) POS N
after POS N
adjustments POS N
for POS N
age, POS N
gender, POS N
cumulative POS N
dose POS N
of POS N
prednisolone, POS N
and POS N
co-morbidities. POS N

Cumulative POS N
anthracycline POS N
doses POS N
of POS N
253-400 POS N
mg POS N
(HR: POS N
2.35; POS N
95% POS N
CI POS N
1.41-3.91; POS N
p = 0.0010), POS N
401-504 POS N
mg POS N
(HR: POS N
2.26; POS N
95% POS N
CI POS N
1.26-4.05; POS N
p = 0.0063), POS N
and > 504 POS N
mg POS N
(HR: POS N
2.29; POS N
95% POS N
CI POS N
1.25-4.18; POS N
p = 0.0072) POS N
increased POS N
the POS N
incidence POS N
density POS N
of POS N
diabetes POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
(p = 0.0006). POS N

The POS N
annual POS N
alteration POS N
of POS N
adapted POS N
diabetes POS N
complications POS N
severity POS N
index POS N
score POS N
was POS N
not POS N
significantly POS N
different POS N
between POS N
B-cell POS N
lymphoma POS N
patients POS N
with POS N
or POS N
without POS N
anthracycline POS N
treatment POS N
(p = 0.4924). POS N

Cumulative POS N
anthracycline POS N
doses POS N
of POS N
253-400 POS N
mg POS N
(HR: POS N
2.35; POS N
95% POS N
CI POS N
1.41-3.91; POS N
p = 0.0010), POS N
401-504 POS N
mg POS N
(HR: POS N
2.26; POS N
95% POS N
CI POS N
1.26-4.05; POS N
p = 0.0063), POS N
and > 504 POS N
mg POS N
(HR: POS N
2.29; POS N
95% POS N
CI POS N
1.25-4.18; POS N
p = 0.0072) POS N
increased POS N
the POS N
incidence POS N
density POS N
of POS N
diabetes POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
(p = 0.0006). POS N

Anthracycline POS N
therapy POS N
increases POS N
diabetes POS N
risk POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
in POS N
B-cell POS N
lymphoma POS N
patients. POS N

Cumulative POS N
anthracycline POS N
doses POS N
of POS N
253-400 POS N
mg POS N
(HR: POS N
2.35; POS N
95% POS N
CI POS N
1.41-3.91; POS N
p = 0.0010), POS N
401-504 POS N
mg POS N
(HR: POS N
2.26; POS N
95% POS N
CI POS N
1.26-4.05; POS N
p = 0.0063), POS N
and > 504 POS N
mg POS N
(HR: POS N
2.29; POS N
95% POS N
CI POS N
1.25-4.18; POS N
p = 0.0072) POS N
increased POS N
the POS N
incidence POS N
density POS N
of POS N
diabetes POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
(p = 0.0006). POS N

Intensive POS N
blood POS N
glucose POS N
monitoring POS N
and POS N
control POS N
should POS N
be POS N
recommended POS N
for POS N
B-cell POS N
lymphoma POS N
patients POS N
receiving POS N
anthracycline POS N
treatment. POS N

Anthracycline POS N
administration POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
incidence POS N
of POS N
diabetes POS N
(HR: POS N
1.75; POS N
95% POS N
CI POS N
1.11-2.75; POS N
p = 0.0163) POS N
after POS N
adjustments POS N
for POS N
age, POS N
gender, POS N
cumulative POS N
dose POS N
of POS N
prednisolone, POS N
and POS N
co-morbidities. POS N

anthracyclines POS N
are POS N
effective POS N
chemotherapeutic POS N
agents POS N
for POS N
treating POS N
B-cell POS N
lymphoma, POS N

Anthracycline POS N
administration POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
incidence POS N
of POS N
diabetes POS N
(HR: POS N
1.75; POS N
95% POS N
CI POS N
1.11-2.75; POS N
p = 0.0163) POS N
after POS N
adjustments POS N
for POS N
age, POS N
gender, POS N
cumulative POS N
dose POS N
of POS N
prednisolone, POS N
and POS N
co-morbidities. POS N

adverse POS N
effects, POS N
such POS N
as POS N
bone POS N
marrow POS N
suppression POS N
and POS N
cardiotoxicity, POS N
limit POS N
their POS N
clinical POS N
application. POS N

Anthracycline POS N
administration POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
incidence POS N
of POS N
diabetes POS N
(HR: POS N
1.75; POS N
95% POS N
CI POS N
1.11-2.75; POS N
p = 0.0163) POS N
after POS N
adjustments POS N
for POS N
age, POS N
gender, POS N
cumulative POS N
dose POS N
of POS N
prednisolone, POS N
and POS N
co-morbidities. POS N

Cumulative POS N
anthracycline POS N
doses POS N
of POS N
253-400 POS N
mg POS N
(HR: POS N
2.35; POS N
95% POS N
CI POS N
1.41-3.91; POS N
p = 0.0010), POS N
401-504 POS N
mg POS N
(HR: POS N
2.26; POS N
95% POS N
CI POS N
1.26-4.05; POS N
p = 0.0063), POS N
and > 504 POS N
mg POS N
(HR: POS N
2.29; POS N
95% POS N
CI POS N
1.25-4.18; POS N
p = 0.0072) POS N
increased POS N
the POS N
incidence POS N
density POS N
of POS N
diabetes POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
(p = 0.0006). POS N

Anthracycline POS N
administration POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
incidence POS N
of POS N
diabetes POS N
(HR: POS N
1.75; POS N
95% POS N
CI POS N
1.11-2.75; POS N
p = 0.0163) POS N
after POS N
adjustments POS N
for POS N
age, POS N
gender, POS N
cumulative POS N
dose POS N
of POS N
prednisolone, POS N
and POS N
co-morbidities. POS N

The POS N
annual POS N
alteration POS N
of POS N
adapted POS N
diabetes POS N
complications POS N
severity POS N
index POS N
score POS N
was POS N
not POS N
significantly POS N
different POS N
between POS N
B-cell POS N
lymphoma POS N
patients POS N
with POS N
or POS N
without POS N
anthracycline POS N
treatment POS N
(p = 0.4924). POS N

Anthracycline POS N
administration POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
incidence POS N
of POS N
diabetes POS N
(HR: POS N
1.75; POS N
95% POS N
CI POS N
1.11-2.75; POS N
p = 0.0163) POS N
after POS N
adjustments POS N
for POS N
age, POS N
gender, POS N
cumulative POS N
dose POS N
of POS N
prednisolone, POS N
and POS N
co-morbidities. POS N

Anthracycline POS N
therapy POS N
increases POS N
diabetes POS N
risk POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
in POS N
B-cell POS N
lymphoma POS N
patients. POS N

Anthracycline POS N
administration POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
incidence POS N
of POS N
diabetes POS N
(HR: POS N
1.75; POS N
95% POS N
CI POS N
1.11-2.75; POS N
p = 0.0163) POS N
after POS N
adjustments POS N
for POS N
age, POS N
gender, POS N
cumulative POS N
dose POS N
of POS N
prednisolone, POS N
and POS N
co-morbidities. POS N

Intensive POS N
blood POS N
glucose POS N
monitoring POS N
and POS N
control POS N
should POS N
be POS N
recommended POS N
for POS N
B-cell POS N
lymphoma POS N
patients POS N
receiving POS N
anthracycline POS N
treatment. POS N

The POS N
annual POS N
alteration POS N
of POS N
adapted POS N
diabetes POS N
complications POS N
severity POS N
index POS N
score POS N
was POS N
not POS N
significantly POS N
different POS N
between POS N
B-cell POS N
lymphoma POS N
patients POS N
with POS N
or POS N
without POS N
anthracycline POS N
treatment POS N
(p = 0.4924). POS N

anthracyclines POS N
are POS N
effective POS N
chemotherapeutic POS N
agents POS N
for POS N
treating POS N
B-cell POS N
lymphoma, POS N

The POS N
annual POS N
alteration POS N
of POS N
adapted POS N
diabetes POS N
complications POS N
severity POS N
index POS N
score POS N
was POS N
not POS N
significantly POS N
different POS N
between POS N
B-cell POS N
lymphoma POS N
patients POS N
with POS N
or POS N
without POS N
anthracycline POS N
treatment POS N
(p = 0.4924). POS N

adverse POS N
effects, POS N
such POS N
as POS N
bone POS N
marrow POS N
suppression POS N
and POS N
cardiotoxicity, POS N
limit POS N
their POS N
clinical POS N
application. POS N

The POS N
annual POS N
alteration POS N
of POS N
adapted POS N
diabetes POS N
complications POS N
severity POS N
index POS N
score POS N
was POS N
not POS N
significantly POS N
different POS N
between POS N
B-cell POS N
lymphoma POS N
patients POS N
with POS N
or POS N
without POS N
anthracycline POS N
treatment POS N
(p = 0.4924). POS N

Cumulative POS N
anthracycline POS N
doses POS N
of POS N
253-400 POS N
mg POS N
(HR: POS N
2.35; POS N
95% POS N
CI POS N
1.41-3.91; POS N
p = 0.0010), POS N
401-504 POS N
mg POS N
(HR: POS N
2.26; POS N
95% POS N
CI POS N
1.26-4.05; POS N
p = 0.0063), POS N
and > 504 POS N
mg POS N
(HR: POS N
2.29; POS N
95% POS N
CI POS N
1.25-4.18; POS N
p = 0.0072) POS N
increased POS N
the POS N
incidence POS N
density POS N
of POS N
diabetes POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
(p = 0.0006). POS N

The POS N
annual POS N
alteration POS N
of POS N
adapted POS N
diabetes POS N
complications POS N
severity POS N
index POS N
score POS N
was POS N
not POS N
significantly POS N
different POS N
between POS N
B-cell POS N
lymphoma POS N
patients POS N
with POS N
or POS N
without POS N
anthracycline POS N
treatment POS N
(p = 0.4924). POS N

Anthracycline POS N
administration POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
incidence POS N
of POS N
diabetes POS N
(HR: POS N
1.75; POS N
95% POS N
CI POS N
1.11-2.75; POS N
p = 0.0163) POS N
after POS N
adjustments POS N
for POS N
age, POS N
gender, POS N
cumulative POS N
dose POS N
of POS N
prednisolone, POS N
and POS N
co-morbidities. POS N

The POS N
annual POS N
alteration POS N
of POS N
adapted POS N
diabetes POS N
complications POS N
severity POS N
index POS N
score POS N
was POS N
not POS N
significantly POS N
different POS N
between POS N
B-cell POS N
lymphoma POS N
patients POS N
with POS N
or POS N
without POS N
anthracycline POS N
treatment POS N
(p = 0.4924). POS N

Anthracycline POS N
therapy POS N
increases POS N
diabetes POS N
risk POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
in POS N
B-cell POS N
lymphoma POS N
patients. POS N

The POS N
annual POS N
alteration POS N
of POS N
adapted POS N
diabetes POS N
complications POS N
severity POS N
index POS N
score POS N
was POS N
not POS N
significantly POS N
different POS N
between POS N
B-cell POS N
lymphoma POS N
patients POS N
with POS N
or POS N
without POS N
anthracycline POS N
treatment POS N
(p = 0.4924). POS N

Intensive POS N
blood POS N
glucose POS N
monitoring POS N
and POS N
control POS N
should POS N
be POS N
recommended POS N
for POS N
B-cell POS N
lymphoma POS N
patients POS N
receiving POS N
anthracycline POS N
treatment. POS N

Anthracycline POS N
therapy POS N
increases POS N
diabetes POS N
risk POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
in POS N
B-cell POS N
lymphoma POS N
patients. POS N

anthracyclines POS N
are POS N
effective POS N
chemotherapeutic POS N
agents POS N
for POS N
treating POS N
B-cell POS N
lymphoma, POS N

Anthracycline POS N
therapy POS N
increases POS N
diabetes POS N
risk POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
in POS N
B-cell POS N
lymphoma POS N
patients. POS N

adverse POS N
effects, POS N
such POS N
as POS N
bone POS N
marrow POS N
suppression POS N
and POS N
cardiotoxicity, POS N
limit POS N
their POS N
clinical POS N
application. POS N

Anthracycline POS N
therapy POS N
increases POS N
diabetes POS N
risk POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
in POS N
B-cell POS N
lymphoma POS N
patients. POS N

Cumulative POS N
anthracycline POS N
doses POS N
of POS N
253-400 POS N
mg POS N
(HR: POS N
2.35; POS N
95% POS N
CI POS N
1.41-3.91; POS N
p = 0.0010), POS N
401-504 POS N
mg POS N
(HR: POS N
2.26; POS N
95% POS N
CI POS N
1.26-4.05; POS N
p = 0.0063), POS N
and > 504 POS N
mg POS N
(HR: POS N
2.29; POS N
95% POS N
CI POS N
1.25-4.18; POS N
p = 0.0072) POS N
increased POS N
the POS N
incidence POS N
density POS N
of POS N
diabetes POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
(p = 0.0006). POS N

Anthracycline POS N
therapy POS N
increases POS N
diabetes POS N
risk POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
in POS N
B-cell POS N
lymphoma POS N
patients. POS N

Anthracycline POS N
administration POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
incidence POS N
of POS N
diabetes POS N
(HR: POS N
1.75; POS N
95% POS N
CI POS N
1.11-2.75; POS N
p = 0.0163) POS N
after POS N
adjustments POS N
for POS N
age, POS N
gender, POS N
cumulative POS N
dose POS N
of POS N
prednisolone, POS N
and POS N
co-morbidities. POS N

Anthracycline POS N
therapy POS N
increases POS N
diabetes POS N
risk POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
in POS N
B-cell POS N
lymphoma POS N
patients. POS N

The POS N
annual POS N
alteration POS N
of POS N
adapted POS N
diabetes POS N
complications POS N
severity POS N
index POS N
score POS N
was POS N
not POS N
significantly POS N
different POS N
between POS N
B-cell POS N
lymphoma POS N
patients POS N
with POS N
or POS N
without POS N
anthracycline POS N
treatment POS N
(p = 0.4924). POS N

Anthracycline POS N
therapy POS N
increases POS N
diabetes POS N
risk POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
in POS N
B-cell POS N
lymphoma POS N
patients. POS N

Intensive POS N
blood POS N
glucose POS N
monitoring POS N
and POS N
control POS N
should POS N
be POS N
recommended POS N
for POS N
B-cell POS N
lymphoma POS N
patients POS N
receiving POS N
anthracycline POS N
treatment. POS N

Intensive POS N
blood POS N
glucose POS N
monitoring POS N
and POS N
control POS N
should POS N
be POS N
recommended POS N
for POS N
B-cell POS N
lymphoma POS N
patients POS N
receiving POS N
anthracycline POS N
treatment. POS N

anthracyclines POS N
are POS N
effective POS N
chemotherapeutic POS N
agents POS N
for POS N
treating POS N
B-cell POS N
lymphoma, POS N

Intensive POS N
blood POS N
glucose POS N
monitoring POS N
and POS N
control POS N
should POS N
be POS N
recommended POS N
for POS N
B-cell POS N
lymphoma POS N
patients POS N
receiving POS N
anthracycline POS N
treatment. POS N

adverse POS N
effects, POS N
such POS N
as POS N
bone POS N
marrow POS N
suppression POS N
and POS N
cardiotoxicity, POS N
limit POS N
their POS N
clinical POS N
application. POS N

Intensive POS N
blood POS N
glucose POS N
monitoring POS N
and POS N
control POS N
should POS N
be POS N
recommended POS N
for POS N
B-cell POS N
lymphoma POS N
patients POS N
receiving POS N
anthracycline POS N
treatment. POS N

Cumulative POS N
anthracycline POS N
doses POS N
of POS N
253-400 POS N
mg POS N
(HR: POS N
2.35; POS N
95% POS N
CI POS N
1.41-3.91; POS N
p = 0.0010), POS N
401-504 POS N
mg POS N
(HR: POS N
2.26; POS N
95% POS N
CI POS N
1.26-4.05; POS N
p = 0.0063), POS N
and > 504 POS N
mg POS N
(HR: POS N
2.29; POS N
95% POS N
CI POS N
1.25-4.18; POS N
p = 0.0072) POS N
increased POS N
the POS N
incidence POS N
density POS N
of POS N
diabetes POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
(p = 0.0006). POS N

Intensive POS N
blood POS N
glucose POS N
monitoring POS N
and POS N
control POS N
should POS N
be POS N
recommended POS N
for POS N
B-cell POS N
lymphoma POS N
patients POS N
receiving POS N
anthracycline POS N
treatment. POS N

Anthracycline POS N
administration POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
incidence POS N
of POS N
diabetes POS N
(HR: POS N
1.75; POS N
95% POS N
CI POS N
1.11-2.75; POS N
p = 0.0163) POS N
after POS N
adjustments POS N
for POS N
age, POS N
gender, POS N
cumulative POS N
dose POS N
of POS N
prednisolone, POS N
and POS N
co-morbidities. POS N

Intensive POS N
blood POS N
glucose POS N
monitoring POS N
and POS N
control POS N
should POS N
be POS N
recommended POS N
for POS N
B-cell POS N
lymphoma POS N
patients POS N
receiving POS N
anthracycline POS N
treatment. POS N

The POS N
annual POS N
alteration POS N
of POS N
adapted POS N
diabetes POS N
complications POS N
severity POS N
index POS N
score POS N
was POS N
not POS N
significantly POS N
different POS N
between POS N
B-cell POS N
lymphoma POS N
patients POS N
with POS N
or POS N
without POS N
anthracycline POS N
treatment POS N
(p = 0.4924). POS N

Intensive POS N
blood POS N
glucose POS N
monitoring POS N
and POS N
control POS N
should POS N
be POS N
recommended POS N
for POS N
B-cell POS N
lymphoma POS N
patients POS N
receiving POS N
anthracycline POS N
treatment. POS N

Anthracycline POS N
therapy POS N
increases POS N
diabetes POS N
risk POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
in POS N
B-cell POS N
lymphoma POS N
patients. POS N

Multiple POS N
studies POS N
have POS N
evaluated POS N
the POS N
hypoglycemic POS N
effect POS N
of POS N
cinnamon POS N
in POS N
patients POS N
with POS N
diabetes POS N
mellitus POS N
(DM) POS N
type POS N
II, POS N
with POS N
conflicting POS N
results. POS N

Cinnamon POS N
supplementation POS N
led POS N
to POS N
improvement POS N
of POS N
all POS N
anthropometric POS N
(BMI, POS N
body POS N
fat, POS N
and POS N
visceral POS N
fat), POS N
glycemic POS N
(FPG, POS N
2hpp, POS N
HbA1C, POS N
Fasting POS N
Insulin, POS N
and POS N
Insulin POS N
Resistance), POS N
and POS N
lipids POS N
(Cholesterol POS N
Total, POS N
LDL-c POS N
and POS N
HDL-c) POS N
outcomes POS N
(except POS N
for POS N
triglycerides POS N
level). POS N

Multiple POS N
studies POS N
have POS N
evaluated POS N
the POS N
hypoglycemic POS N
effect POS N
of POS N
cinnamon POS N
in POS N
patients POS N
with POS N
diabetes POS N
mellitus POS N
(DM) POS N
type POS N
II, POS N
with POS N
conflicting POS N
results. POS N

All POS N
observed POS N
changes POS N
(except POS N
for POS N
Cholesterol POS N
Total POS N
and POS N
LDL-c) POS N
were POS N
significantly POS N
more POS N
prominent POS N
in POS N
patients POS N
with POS N
higher POS N
baseline POS N
BMI POS N
(BMI POS N
≥ POS N
27). POS N

Multiple POS N
studies POS N
have POS N
evaluated POS N
the POS N
hypoglycemic POS N
effect POS N
of POS N
cinnamon POS N
in POS N
patients POS N
with POS N
diabetes POS N
mellitus POS N
(DM) POS N
type POS N
II, POS N
with POS N
conflicting POS N
results. POS N

Based POS N
on POS N
the POS N
study POS N
findings, POS N
cinnamon POS N
may POS N
improve POS N
anthropometric POS N
parameters, POS N
glycemic POS N
indices POS N
and POS N
lipid POS N
profile POS N
of POS N
patients POS N
with POS N
type POS N
II POS N
diabetes. POS N

Multiple POS N
studies POS N
have POS N
evaluated POS N
the POS N
hypoglycemic POS N
effect POS N
of POS N
cinnamon POS N
in POS N
patients POS N
with POS N
diabetes POS N
mellitus POS N
(DM) POS N
type POS N
II, POS N
with POS N
conflicting POS N
results. POS N

These POS N
benefits POS N
are POS N
significantly POS N
more POS N
prominent POS N
in POS N
patients POS N
with POS N
higher POS N
baseline POS N
BMI POS N
(BMI POS N
≥ POS N
27). POS N

Cinnamon POS N
supplementation POS N
led POS N
to POS N
improvement POS N
of POS N
all POS N
anthropometric POS N
(BMI, POS N
body POS N
fat, POS N
and POS N
visceral POS N
fat), POS N
glycemic POS N
(FPG, POS N
2hpp, POS N
HbA1C, POS N
Fasting POS N
Insulin, POS N
and POS N
Insulin POS N
Resistance), POS N
and POS N
lipids POS N
(Cholesterol POS N
Total, POS N
LDL-c POS N
and POS N
HDL-c) POS N
outcomes POS N
(except POS N
for POS N
triglycerides POS N
level). POS N

Multiple POS N
studies POS N
have POS N
evaluated POS N
the POS N
hypoglycemic POS N
effect POS N
of POS N
cinnamon POS N
in POS N
patients POS N
with POS N
diabetes POS N
mellitus POS N
(DM) POS N
type POS N
II, POS N
with POS N
conflicting POS N
results. POS N

Cinnamon POS N
supplementation POS N
led POS N
to POS N
improvement POS N
of POS N
all POS N
anthropometric POS N
(BMI, POS N
body POS N
fat, POS N
and POS N
visceral POS N
fat), POS N
glycemic POS N
(FPG, POS N
2hpp, POS N
HbA1C, POS N
Fasting POS N
Insulin, POS N
and POS N
Insulin POS N
Resistance), POS N
and POS N
lipids POS N
(Cholesterol POS N
Total, POS N
LDL-c POS N
and POS N
HDL-c) POS N
outcomes POS N
(except POS N
for POS N
triglycerides POS N
level). POS N

All POS N
observed POS N
changes POS N
(except POS N
for POS N
Cholesterol POS N
Total POS N
and POS N
LDL-c) POS N
were POS N
significantly POS N
more POS N
prominent POS N
in POS N
patients POS N
with POS N
higher POS N
baseline POS N
BMI POS N
(BMI POS N
≥ POS N
27). POS N

Cinnamon POS N
supplementation POS N
led POS N
to POS N
improvement POS N
of POS N
all POS N
anthropometric POS N
(BMI, POS N
body POS N
fat, POS N
and POS N
visceral POS N
fat), POS N
glycemic POS N
(FPG, POS N
2hpp, POS N
HbA1C, POS N
Fasting POS N
Insulin, POS N
and POS N
Insulin POS N
Resistance), POS N
and POS N
lipids POS N
(Cholesterol POS N
Total, POS N
LDL-c POS N
and POS N
HDL-c) POS N
outcomes POS N
(except POS N
for POS N
triglycerides POS N
level). POS N

Based POS N
on POS N
the POS N
study POS N
findings, POS N
cinnamon POS N
may POS N
improve POS N
anthropometric POS N
parameters, POS N
glycemic POS N
indices POS N
and POS N
lipid POS N
profile POS N
of POS N
patients POS N
with POS N
type POS N
II POS N
diabetes. POS N

Cinnamon POS N
supplementation POS N
led POS N
to POS N
improvement POS N
of POS N
all POS N
anthropometric POS N
(BMI, POS N
body POS N
fat, POS N
and POS N
visceral POS N
fat), POS N
glycemic POS N
(FPG, POS N
2hpp, POS N
HbA1C, POS N
Fasting POS N
Insulin, POS N
and POS N
Insulin POS N
Resistance), POS N
and POS N
lipids POS N
(Cholesterol POS N
Total, POS N
LDL-c POS N
and POS N
HDL-c) POS N
outcomes POS N
(except POS N
for POS N
triglycerides POS N
level). POS N

These POS N
benefits POS N
are POS N
significantly POS N
more POS N
prominent POS N
in POS N
patients POS N
with POS N
higher POS N
baseline POS N
BMI POS N
(BMI POS N
≥ POS N
27). POS N

All POS N
observed POS N
changes POS N
(except POS N
for POS N
Cholesterol POS N
Total POS N
and POS N
LDL-c) POS N
were POS N
significantly POS N
more POS N
prominent POS N
in POS N
patients POS N
with POS N
higher POS N
baseline POS N
BMI POS N
(BMI POS N
≥ POS N
27). POS N

Multiple POS N
studies POS N
have POS N
evaluated POS N
the POS N
hypoglycemic POS N
effect POS N
of POS N
cinnamon POS N
in POS N
patients POS N
with POS N
diabetes POS N
mellitus POS N
(DM) POS N
type POS N
II, POS N
with POS N
conflicting POS N
results. POS N

All POS N
observed POS N
changes POS N
(except POS N
for POS N
Cholesterol POS N
Total POS N
and POS N
LDL-c) POS N
were POS N
significantly POS N
more POS N
prominent POS N
in POS N
patients POS N
with POS N
higher POS N
baseline POS N
BMI POS N
(BMI POS N
≥ POS N
27). POS N

Cinnamon POS N
supplementation POS N
led POS N
to POS N
improvement POS N
of POS N
all POS N
anthropometric POS N
(BMI, POS N
body POS N
fat, POS N
and POS N
visceral POS N
fat), POS N
glycemic POS N
(FPG, POS N
2hpp, POS N
HbA1C, POS N
Fasting POS N
Insulin, POS N
and POS N
Insulin POS N
Resistance), POS N
and POS N
lipids POS N
(Cholesterol POS N
Total, POS N
LDL-c POS N
and POS N
HDL-c) POS N
outcomes POS N
(except POS N
for POS N
triglycerides POS N
level). POS N

All POS N
observed POS N
changes POS N
(except POS N
for POS N
Cholesterol POS N
Total POS N
and POS N
LDL-c) POS N
were POS N
significantly POS N
more POS N
prominent POS N
in POS N
patients POS N
with POS N
higher POS N
baseline POS N
BMI POS N
(BMI POS N
≥ POS N
27). POS N

Based POS N
on POS N
the POS N
study POS N
findings, POS N
cinnamon POS N
may POS N
improve POS N
anthropometric POS N
parameters, POS N
glycemic POS N
indices POS N
and POS N
lipid POS N
profile POS N
of POS N
patients POS N
with POS N
type POS N
II POS N
diabetes. POS N

All POS N
observed POS N
changes POS N
(except POS N
for POS N
Cholesterol POS N
Total POS N
and POS N
LDL-c) POS N
were POS N
significantly POS N
more POS N
prominent POS N
in POS N
patients POS N
with POS N
higher POS N
baseline POS N
BMI POS N
(BMI POS N
≥ POS N
27). POS N

These POS N
benefits POS N
are POS N
significantly POS N
more POS N
prominent POS N
in POS N
patients POS N
with POS N
higher POS N
baseline POS N
BMI POS N
(BMI POS N
≥ POS N
27). POS N

Based POS N
on POS N
the POS N
study POS N
findings, POS N
cinnamon POS N
may POS N
improve POS N
anthropometric POS N
parameters, POS N
glycemic POS N
indices POS N
and POS N
lipid POS N
profile POS N
of POS N
patients POS N
with POS N
type POS N
II POS N
diabetes. POS N

Multiple POS N
studies POS N
have POS N
evaluated POS N
the POS N
hypoglycemic POS N
effect POS N
of POS N
cinnamon POS N
in POS N
patients POS N
with POS N
diabetes POS N
mellitus POS N
(DM) POS N
type POS N
II, POS N
with POS N
conflicting POS N
results. POS N

Based POS N
on POS N
the POS N
study POS N
findings, POS N
cinnamon POS N
may POS N
improve POS N
anthropometric POS N
parameters, POS N
glycemic POS N
indices POS N
and POS N
lipid POS N
profile POS N
of POS N
patients POS N
with POS N
type POS N
II POS N
diabetes. POS N

Cinnamon POS N
supplementation POS N
led POS N
to POS N
improvement POS N
of POS N
all POS N
anthropometric POS N
(BMI, POS N
body POS N
fat, POS N
and POS N
visceral POS N
fat), POS N
glycemic POS N
(FPG, POS N
2hpp, POS N
HbA1C, POS N
Fasting POS N
Insulin, POS N
and POS N
Insulin POS N
Resistance), POS N
and POS N
lipids POS N
(Cholesterol POS N
Total, POS N
LDL-c POS N
and POS N
HDL-c) POS N
outcomes POS N
(except POS N
for POS N
triglycerides POS N
level). POS N

Based POS N
on POS N
the POS N
study POS N
findings, POS N
cinnamon POS N
may POS N
improve POS N
anthropometric POS N
parameters, POS N
glycemic POS N
indices POS N
and POS N
lipid POS N
profile POS N
of POS N
patients POS N
with POS N
type POS N
II POS N
diabetes. POS N

All POS N
observed POS N
changes POS N
(except POS N
for POS N
Cholesterol POS N
Total POS N
and POS N
LDL-c) POS N
were POS N
significantly POS N
more POS N
prominent POS N
in POS N
patients POS N
with POS N
higher POS N
baseline POS N
BMI POS N
(BMI POS N
≥ POS N
27). POS N

Based POS N
on POS N
the POS N
study POS N
findings, POS N
cinnamon POS N
may POS N
improve POS N
anthropometric POS N
parameters, POS N
glycemic POS N
indices POS N
and POS N
lipid POS N
profile POS N
of POS N
patients POS N
with POS N
type POS N
II POS N
diabetes. POS N

These POS N
benefits POS N
are POS N
significantly POS N
more POS N
prominent POS N
in POS N
patients POS N
with POS N
higher POS N
baseline POS N
BMI POS N
(BMI POS N
≥ POS N
27). POS N

These POS N
benefits POS N
are POS N
significantly POS N
more POS N
prominent POS N
in POS N
patients POS N
with POS N
higher POS N
baseline POS N
BMI POS N
(BMI POS N
≥ POS N
27). POS N

Multiple POS N
studies POS N
have POS N
evaluated POS N
the POS N
hypoglycemic POS N
effect POS N
of POS N
cinnamon POS N
in POS N
patients POS N
with POS N
diabetes POS N
mellitus POS N
(DM) POS N
type POS N
II, POS N
with POS N
conflicting POS N
results. POS N

These POS N
benefits POS N
are POS N
significantly POS N
more POS N
prominent POS N
in POS N
patients POS N
with POS N
higher POS N
baseline POS N
BMI POS N
(BMI POS N
≥ POS N
27). POS N

Cinnamon POS N
supplementation POS N
led POS N
to POS N
improvement POS N
of POS N
all POS N
anthropometric POS N
(BMI, POS N
body POS N
fat, POS N
and POS N
visceral POS N
fat), POS N
glycemic POS N
(FPG, POS N
2hpp, POS N
HbA1C, POS N
Fasting POS N
Insulin, POS N
and POS N
Insulin POS N
Resistance), POS N
and POS N
lipids POS N
(Cholesterol POS N
Total, POS N
LDL-c POS N
and POS N
HDL-c) POS N
outcomes POS N
(except POS N
for POS N
triglycerides POS N
level). POS N

These POS N
benefits POS N
are POS N
significantly POS N
more POS N
prominent POS N
in POS N
patients POS N
with POS N
higher POS N
baseline POS N
BMI POS N
(BMI POS N
≥ POS N
27). POS N

All POS N
observed POS N
changes POS N
(except POS N
for POS N
Cholesterol POS N
Total POS N
and POS N
LDL-c) POS N
were POS N
significantly POS N
more POS N
prominent POS N
in POS N
patients POS N
with POS N
higher POS N
baseline POS N
BMI POS N
(BMI POS N
≥ POS N
27). POS N

These POS N
benefits POS N
are POS N
significantly POS N
more POS N
prominent POS N
in POS N
patients POS N
with POS N
higher POS N
baseline POS N
BMI POS N
(BMI POS N
≥ POS N
27). POS N

Based POS N
on POS N
the POS N
study POS N
findings, POS N
cinnamon POS N
may POS N
improve POS N
anthropometric POS N
parameters, POS N
glycemic POS N
indices POS N
and POS N
lipid POS N
profile POS N
of POS N
patients POS N
with POS N
type POS N
II POS N
diabetes. POS N

Efficacy POS N
was POS N
similar POS N
for POS N
the POS N
250- POS N
and POS N
500-mg/d POS N
groups. POS N

Objective POS N
tumor POS N
response POS N
rates POS N
were POS N
18.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
11.5 POS N
to POS N
27.3) POS N
and POS N
19.0% POS N
(95% POS N
CI, POS N
12.1 POS N
to POS N
27.9); POS N
among POS N
evaluable POS N
patients, POS N
symptom POS N
improvement POS N
rates POS N
were POS N
40.3% POS N
(95% POS N
CI, POS N
28.5 POS N
to POS N
53.0) POS N
and POS N
37.0% POS N
(95% POS N
CI, POS N
26.0 POS N
to POS N
49.1); POS N
median POS N
progression-free POS N
survival POS N
times POS N
were POS N
2.7 POS N
and POS N
2.8 POS N
months; POS N
and POS N
median POS N
overall POS N
survival POS N
times POS N
were POS N
7.6 POS N
and POS N
8.0 POS N
months, POS N
respectively. POS N

Efficacy POS N
was POS N
similar POS N
for POS N
the POS N
250- POS N
and POS N
500-mg/d POS N
groups. POS N

Adverse POS N
events POS N
(AEs) POS N
at POS N
both POS N
dose POS N
levels POS N
were POS N
generally POS N
mild POS N
(grade POS N
1 POS N
or POS N
2) POS N
and POS N
consisted POS N
mainly POS N
of POS N
skin POS N
reactions POS N
and POS N
diarrhea. POS N

Efficacy POS N
was POS N
similar POS N
for POS N
the POS N
250- POS N
and POS N
500-mg/d POS N
groups. POS N

Symptom POS N
improvements POS N
were POS N
recorded POS N
for POS N
69.2% POS N
(250 POS N
mg/d) POS N
and POS N
85.7% POS N
(500 POS N
mg/d) POS N
of POS N
patients POS N
with POS N
a POS N
tumor POS N
response. POS N

Efficacy POS N
was POS N
similar POS N
for POS N
the POS N
250- POS N
and POS N
500-mg/d POS N
groups. POS N

Drug-related POS N
toxicities POS N
were POS N
more POS N
frequent POS N
in POS N
the POS N
higher-dose POS N
group. POS N

Efficacy POS N
was POS N
similar POS N
for POS N
the POS N
250- POS N
and POS N
500-mg/d POS N
groups. POS N

Withdrawal POS N
due POS N
to POS N
drug-related POS N
AEs POS N
was POS N
1.9% POS N
and POS N
9.4% POS N
for POS N
patients POS N
receiving POS N
gefitinib POS N
250 POS N
and POS N
500 POS N
mg/d, POS N
respectively. POS N

Efficacy POS N
was POS N
similar POS N
for POS N
the POS N
250- POS N
and POS N
500-mg/d POS N
groups. POS N

Gefitinib POS N
showed POS N
clinically POS N
meaningful POS N
antitumor POS N
activity POS N
and POS N
provided POS N
symptom POS N
relief POS N
as POS N
second- POS N
and POS N
third-line POS N
treatment POS N
in POS N
these POS N
patients. POS N

Efficacy POS N
was POS N
similar POS N
for POS N
the POS N
250- POS N
and POS N
500-mg/d POS N
groups. POS N

At POS N
250 POS N
mg/d, POS N
gefitinib POS N
had POS N
a POS N
favorable POS N
AE POS N
profile. POS N

Efficacy POS N
was POS N
similar POS N
for POS N
the POS N
250- POS N
and POS N
500-mg/d POS N
groups. POS N

Gefitinib POS N
250 POS N
mg/d POS N
is POS N
an POS N
important, POS N
novel POS N
treatment POS N
option POS N
for POS N
patients POS N
with POS N
pretreated POS N
advanced POS N
NSCLC. POS N

Objective POS N
tumor POS N
response POS N
rates POS N
were POS N
18.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
11.5 POS N
to POS N
27.3) POS N
and POS N
19.0% POS N
(95% POS N
CI, POS N
12.1 POS N
to POS N
27.9); POS N
among POS N
evaluable POS N
patients, POS N
symptom POS N
improvement POS N
rates POS N
were POS N
40.3% POS N
(95% POS N
CI, POS N
28.5 POS N
to POS N
53.0) POS N
and POS N
37.0% POS N
(95% POS N
CI, POS N
26.0 POS N
to POS N
49.1); POS N
median POS N
progression-free POS N
survival POS N
times POS N
were POS N
2.7 POS N
and POS N
2.8 POS N
months; POS N
and POS N
median POS N
overall POS N
survival POS N
times POS N
were POS N
7.6 POS N
and POS N
8.0 POS N
months, POS N
respectively. POS N

Efficacy POS N
was POS N
similar POS N
for POS N
the POS N
250- POS N
and POS N
500-mg/d POS N
groups. POS N

Objective POS N
tumor POS N
response POS N
rates POS N
were POS N
18.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
11.5 POS N
to POS N
27.3) POS N
and POS N
19.0% POS N
(95% POS N
CI, POS N
12.1 POS N
to POS N
27.9); POS N
among POS N
evaluable POS N
patients, POS N
symptom POS N
improvement POS N
rates POS N
were POS N
40.3% POS N
(95% POS N
CI, POS N
28.5 POS N
to POS N
53.0) POS N
and POS N
37.0% POS N
(95% POS N
CI, POS N
26.0 POS N
to POS N
49.1); POS N
median POS N
progression-free POS N
survival POS N
times POS N
were POS N
2.7 POS N
and POS N
2.8 POS N
months; POS N
and POS N
median POS N
overall POS N
survival POS N
times POS N
were POS N
7.6 POS N
and POS N
8.0 POS N
months, POS N
respectively. POS N

Adverse POS N
events POS N
(AEs) POS N
at POS N
both POS N
dose POS N
levels POS N
were POS N
generally POS N
mild POS N
(grade POS N
1 POS N
or POS N
2) POS N
and POS N
consisted POS N
mainly POS N
of POS N
skin POS N
reactions POS N
and POS N
diarrhea. POS N

Objective POS N
tumor POS N
response POS N
rates POS N
were POS N
18.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
11.5 POS N
to POS N
27.3) POS N
and POS N
19.0% POS N
(95% POS N
CI, POS N
12.1 POS N
to POS N
27.9); POS N
among POS N
evaluable POS N
patients, POS N
symptom POS N
improvement POS N
rates POS N
were POS N
40.3% POS N
(95% POS N
CI, POS N
28.5 POS N
to POS N
53.0) POS N
and POS N
37.0% POS N
(95% POS N
CI, POS N
26.0 POS N
to POS N
49.1); POS N
median POS N
progression-free POS N
survival POS N
times POS N
were POS N
2.7 POS N
and POS N
2.8 POS N
months; POS N
and POS N
median POS N
overall POS N
survival POS N
times POS N
were POS N
7.6 POS N
and POS N
8.0 POS N
months, POS N
respectively. POS N

Symptom POS N
improvements POS N
were POS N
recorded POS N
for POS N
69.2% POS N
(250 POS N
mg/d) POS N
and POS N
85.7% POS N
(500 POS N
mg/d) POS N
of POS N
patients POS N
with POS N
a POS N
tumor POS N
response. POS N

Objective POS N
tumor POS N
response POS N
rates POS N
were POS N
18.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
11.5 POS N
to POS N
27.3) POS N
and POS N
19.0% POS N
(95% POS N
CI, POS N
12.1 POS N
to POS N
27.9); POS N
among POS N
evaluable POS N
patients, POS N
symptom POS N
improvement POS N
rates POS N
were POS N
40.3% POS N
(95% POS N
CI, POS N
28.5 POS N
to POS N
53.0) POS N
and POS N
37.0% POS N
(95% POS N
CI, POS N
26.0 POS N
to POS N
49.1); POS N
median POS N
progression-free POS N
survival POS N
times POS N
were POS N
2.7 POS N
and POS N
2.8 POS N
months; POS N
and POS N
median POS N
overall POS N
survival POS N
times POS N
were POS N
7.6 POS N
and POS N
8.0 POS N
months, POS N
respectively. POS N

Drug-related POS N
toxicities POS N
were POS N
more POS N
frequent POS N
in POS N
the POS N
higher-dose POS N
group. POS N

Objective POS N
tumor POS N
response POS N
rates POS N
were POS N
18.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
11.5 POS N
to POS N
27.3) POS N
and POS N
19.0% POS N
(95% POS N
CI, POS N
12.1 POS N
to POS N
27.9); POS N
among POS N
evaluable POS N
patients, POS N
symptom POS N
improvement POS N
rates POS N
were POS N
40.3% POS N
(95% POS N
CI, POS N
28.5 POS N
to POS N
53.0) POS N
and POS N
37.0% POS N
(95% POS N
CI, POS N
26.0 POS N
to POS N
49.1); POS N
median POS N
progression-free POS N
survival POS N
times POS N
were POS N
2.7 POS N
and POS N
2.8 POS N
months; POS N
and POS N
median POS N
overall POS N
survival POS N
times POS N
were POS N
7.6 POS N
and POS N
8.0 POS N
months, POS N
respectively. POS N

Withdrawal POS N
due POS N
to POS N
drug-related POS N
AEs POS N
was POS N
1.9% POS N
and POS N
9.4% POS N
for POS N
patients POS N
receiving POS N
gefitinib POS N
250 POS N
and POS N
500 POS N
mg/d, POS N
respectively. POS N

Objective POS N
tumor POS N
response POS N
rates POS N
were POS N
18.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
11.5 POS N
to POS N
27.3) POS N
and POS N
19.0% POS N
(95% POS N
CI, POS N
12.1 POS N
to POS N
27.9); POS N
among POS N
evaluable POS N
patients, POS N
symptom POS N
improvement POS N
rates POS N
were POS N
40.3% POS N
(95% POS N
CI, POS N
28.5 POS N
to POS N
53.0) POS N
and POS N
37.0% POS N
(95% POS N
CI, POS N
26.0 POS N
to POS N
49.1); POS N
median POS N
progression-free POS N
survival POS N
times POS N
were POS N
2.7 POS N
and POS N
2.8 POS N
months; POS N
and POS N
median POS N
overall POS N
survival POS N
times POS N
were POS N
7.6 POS N
and POS N
8.0 POS N
months, POS N
respectively. POS N

Gefitinib POS N
showed POS N
clinically POS N
meaningful POS N
antitumor POS N
activity POS N
and POS N
provided POS N
symptom POS N
relief POS N
as POS N
second- POS N
and POS N
third-line POS N
treatment POS N
in POS N
these POS N
patients. POS N

Objective POS N
tumor POS N
response POS N
rates POS N
were POS N
18.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
11.5 POS N
to POS N
27.3) POS N
and POS N
19.0% POS N
(95% POS N
CI, POS N
12.1 POS N
to POS N
27.9); POS N
among POS N
evaluable POS N
patients, POS N
symptom POS N
improvement POS N
rates POS N
were POS N
40.3% POS N
(95% POS N
CI, POS N
28.5 POS N
to POS N
53.0) POS N
and POS N
37.0% POS N
(95% POS N
CI, POS N
26.0 POS N
to POS N
49.1); POS N
median POS N
progression-free POS N
survival POS N
times POS N
were POS N
2.7 POS N
and POS N
2.8 POS N
months; POS N
and POS N
median POS N
overall POS N
survival POS N
times POS N
were POS N
7.6 POS N
and POS N
8.0 POS N
months, POS N
respectively. POS N

At POS N
250 POS N
mg/d, POS N
gefitinib POS N
had POS N
a POS N
favorable POS N
AE POS N
profile. POS N

Objective POS N
tumor POS N
response POS N
rates POS N
were POS N
18.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
11.5 POS N
to POS N
27.3) POS N
and POS N
19.0% POS N
(95% POS N
CI, POS N
12.1 POS N
to POS N
27.9); POS N
among POS N
evaluable POS N
patients, POS N
symptom POS N
improvement POS N
rates POS N
were POS N
40.3% POS N
(95% POS N
CI, POS N
28.5 POS N
to POS N
53.0) POS N
and POS N
37.0% POS N
(95% POS N
CI, POS N
26.0 POS N
to POS N
49.1); POS N
median POS N
progression-free POS N
survival POS N
times POS N
were POS N
2.7 POS N
and POS N
2.8 POS N
months; POS N
and POS N
median POS N
overall POS N
survival POS N
times POS N
were POS N
7.6 POS N
and POS N
8.0 POS N
months, POS N
respectively. POS N

Gefitinib POS N
250 POS N
mg/d POS N
is POS N
an POS N
important, POS N
novel POS N
treatment POS N
option POS N
for POS N
patients POS N
with POS N
pretreated POS N
advanced POS N
NSCLC. POS N

Adverse POS N
events POS N
(AEs) POS N
at POS N
both POS N
dose POS N
levels POS N
were POS N
generally POS N
mild POS N
(grade POS N
1 POS N
or POS N
2) POS N
and POS N
consisted POS N
mainly POS N
of POS N
skin POS N
reactions POS N
and POS N
diarrhea. POS N

Efficacy POS N
was POS N
similar POS N
for POS N
the POS N
250- POS N
and POS N
500-mg/d POS N
groups. POS N

Adverse POS N
events POS N
(AEs) POS N
at POS N
both POS N
dose POS N
levels POS N
were POS N
generally POS N
mild POS N
(grade POS N
1 POS N
or POS N
2) POS N
and POS N
consisted POS N
mainly POS N
of POS N
skin POS N
reactions POS N
and POS N
diarrhea. POS N

Objective POS N
tumor POS N
response POS N
rates POS N
were POS N
18.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
11.5 POS N
to POS N
27.3) POS N
and POS N
19.0% POS N
(95% POS N
CI, POS N
12.1 POS N
to POS N
27.9); POS N
among POS N
evaluable POS N
patients, POS N
symptom POS N
improvement POS N
rates POS N
were POS N
40.3% POS N
(95% POS N
CI, POS N
28.5 POS N
to POS N
53.0) POS N
and POS N
37.0% POS N
(95% POS N
CI, POS N
26.0 POS N
to POS N
49.1); POS N
median POS N
progression-free POS N
survival POS N
times POS N
were POS N
2.7 POS N
and POS N
2.8 POS N
months; POS N
and POS N
median POS N
overall POS N
survival POS N
times POS N
were POS N
7.6 POS N
and POS N
8.0 POS N
months, POS N
respectively. POS N

Adverse POS N
events POS N
(AEs) POS N
at POS N
both POS N
dose POS N
levels POS N
were POS N
generally POS N
mild POS N
(grade POS N
1 POS N
or POS N
2) POS N
and POS N
consisted POS N
mainly POS N
of POS N
skin POS N
reactions POS N
and POS N
diarrhea. POS N

Symptom POS N
improvements POS N
were POS N
recorded POS N
for POS N
69.2% POS N
(250 POS N
mg/d) POS N
and POS N
85.7% POS N
(500 POS N
mg/d) POS N
of POS N
patients POS N
with POS N
a POS N
tumor POS N
response. POS N

Adverse POS N
events POS N
(AEs) POS N
at POS N
both POS N
dose POS N
levels POS N
were POS N
generally POS N
mild POS N
(grade POS N
1 POS N
or POS N
2) POS N
and POS N
consisted POS N
mainly POS N
of POS N
skin POS N
reactions POS N
and POS N
diarrhea. POS N

Drug-related POS N
toxicities POS N
were POS N
more POS N
frequent POS N
in POS N
the POS N
higher-dose POS N
group. POS N

Adverse POS N
events POS N
(AEs) POS N
at POS N
both POS N
dose POS N
levels POS N
were POS N
generally POS N
mild POS N
(grade POS N
1 POS N
or POS N
2) POS N
and POS N
consisted POS N
mainly POS N
of POS N
skin POS N
reactions POS N
and POS N
diarrhea. POS N

Withdrawal POS N
due POS N
to POS N
drug-related POS N
AEs POS N
was POS N
1.9% POS N
and POS N
9.4% POS N
for POS N
patients POS N
receiving POS N
gefitinib POS N
250 POS N
and POS N
500 POS N
mg/d, POS N
respectively. POS N

Adverse POS N
events POS N
(AEs) POS N
at POS N
both POS N
dose POS N
levels POS N
were POS N
generally POS N
mild POS N
(grade POS N
1 POS N
or POS N
2) POS N
and POS N
consisted POS N
mainly POS N
of POS N
skin POS N
reactions POS N
and POS N
diarrhea. POS N

Gefitinib POS N
showed POS N
clinically POS N
meaningful POS N
antitumor POS N
activity POS N
and POS N
provided POS N
symptom POS N
relief POS N
as POS N
second- POS N
and POS N
third-line POS N
treatment POS N
in POS N
these POS N
patients. POS N

Adverse POS N
events POS N
(AEs) POS N
at POS N
both POS N
dose POS N
levels POS N
were POS N
generally POS N
mild POS N
(grade POS N
1 POS N
or POS N
2) POS N
and POS N
consisted POS N
mainly POS N
of POS N
skin POS N
reactions POS N
and POS N
diarrhea. POS N

At POS N
250 POS N
mg/d, POS N
gefitinib POS N
had POS N
a POS N
favorable POS N
AE POS N
profile. POS N

Adverse POS N
events POS N
(AEs) POS N
at POS N
both POS N
dose POS N
levels POS N
were POS N
generally POS N
mild POS N
(grade POS N
1 POS N
or POS N
2) POS N
and POS N
consisted POS N
mainly POS N
of POS N
skin POS N
reactions POS N
and POS N
diarrhea. POS N

Gefitinib POS N
250 POS N
mg/d POS N
is POS N
an POS N
important, POS N
novel POS N
treatment POS N
option POS N
for POS N
patients POS N
with POS N
pretreated POS N
advanced POS N
NSCLC. POS N

Symptom POS N
improvements POS N
were POS N
recorded POS N
for POS N
69.2% POS N
(250 POS N
mg/d) POS N
and POS N
85.7% POS N
(500 POS N
mg/d) POS N
of POS N
patients POS N
with POS N
a POS N
tumor POS N
response. POS N

Efficacy POS N
was POS N
similar POS N
for POS N
the POS N
250- POS N
and POS N
500-mg/d POS N
groups. POS N

Symptom POS N
improvements POS N
were POS N
recorded POS N
for POS N
69.2% POS N
(250 POS N
mg/d) POS N
and POS N
85.7% POS N
(500 POS N
mg/d) POS N
of POS N
patients POS N
with POS N
a POS N
tumor POS N
response. POS N

Objective POS N
tumor POS N
response POS N
rates POS N
were POS N
18.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
11.5 POS N
to POS N
27.3) POS N
and POS N
19.0% POS N
(95% POS N
CI, POS N
12.1 POS N
to POS N
27.9); POS N
among POS N
evaluable POS N
patients, POS N
symptom POS N
improvement POS N
rates POS N
were POS N
40.3% POS N
(95% POS N
CI, POS N
28.5 POS N
to POS N
53.0) POS N
and POS N
37.0% POS N
(95% POS N
CI, POS N
26.0 POS N
to POS N
49.1); POS N
median POS N
progression-free POS N
survival POS N
times POS N
were POS N
2.7 POS N
and POS N
2.8 POS N
months; POS N
and POS N
median POS N
overall POS N
survival POS N
times POS N
were POS N
7.6 POS N
and POS N
8.0 POS N
months, POS N
respectively. POS N

Symptom POS N
improvements POS N
were POS N
recorded POS N
for POS N
69.2% POS N
(250 POS N
mg/d) POS N
and POS N
85.7% POS N
(500 POS N
mg/d) POS N
of POS N
patients POS N
with POS N
a POS N
tumor POS N
response. POS N

Adverse POS N
events POS N
(AEs) POS N
at POS N
both POS N
dose POS N
levels POS N
were POS N
generally POS N
mild POS N
(grade POS N
1 POS N
or POS N
2) POS N
and POS N
consisted POS N
mainly POS N
of POS N
skin POS N
reactions POS N
and POS N
diarrhea. POS N

Symptom POS N
improvements POS N
were POS N
recorded POS N
for POS N
69.2% POS N
(250 POS N
mg/d) POS N
and POS N
85.7% POS N
(500 POS N
mg/d) POS N
of POS N
patients POS N
with POS N
a POS N
tumor POS N
response. POS N

Drug-related POS N
toxicities POS N
were POS N
more POS N
frequent POS N
in POS N
the POS N
higher-dose POS N
group. POS N

Symptom POS N
improvements POS N
were POS N
recorded POS N
for POS N
69.2% POS N
(250 POS N
mg/d) POS N
and POS N
85.7% POS N
(500 POS N
mg/d) POS N
of POS N
patients POS N
with POS N
a POS N
tumor POS N
response. POS N

Withdrawal POS N
due POS N
to POS N
drug-related POS N
AEs POS N
was POS N
1.9% POS N
and POS N
9.4% POS N
for POS N
patients POS N
receiving POS N
gefitinib POS N
250 POS N
and POS N
500 POS N
mg/d, POS N
respectively. POS N

Symptom POS N
improvements POS N
were POS N
recorded POS N
for POS N
69.2% POS N
(250 POS N
mg/d) POS N
and POS N
85.7% POS N
(500 POS N
mg/d) POS N
of POS N
patients POS N
with POS N
a POS N
tumor POS N
response. POS N

Gefitinib POS N
showed POS N
clinically POS N
meaningful POS N
antitumor POS N
activity POS N
and POS N
provided POS N
symptom POS N
relief POS N
as POS N
second- POS N
and POS N
third-line POS N
treatment POS N
in POS N
these POS N
patients. POS N

Symptom POS N
improvements POS N
were POS N
recorded POS N
for POS N
69.2% POS N
(250 POS N
mg/d) POS N
and POS N
85.7% POS N
(500 POS N
mg/d) POS N
of POS N
patients POS N
with POS N
a POS N
tumor POS N
response. POS N

At POS N
250 POS N
mg/d, POS N
gefitinib POS N
had POS N
a POS N
favorable POS N
AE POS N
profile. POS N

Symptom POS N
improvements POS N
were POS N
recorded POS N
for POS N
69.2% POS N
(250 POS N
mg/d) POS N
and POS N
85.7% POS N
(500 POS N
mg/d) POS N
of POS N
patients POS N
with POS N
a POS N
tumor POS N
response. POS N

Gefitinib POS N
250 POS N
mg/d POS N
is POS N
an POS N
important, POS N
novel POS N
treatment POS N
option POS N
for POS N
patients POS N
with POS N
pretreated POS N
advanced POS N
NSCLC. POS N

Drug-related POS N
toxicities POS N
were POS N
more POS N
frequent POS N
in POS N
the POS N
higher-dose POS N
group. POS N

Efficacy POS N
was POS N
similar POS N
for POS N
the POS N
250- POS N
and POS N
500-mg/d POS N
groups. POS N

Drug-related POS N
toxicities POS N
were POS N
more POS N
frequent POS N
in POS N
the POS N
higher-dose POS N
group. POS N

Objective POS N
tumor POS N
response POS N
rates POS N
were POS N
18.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
11.5 POS N
to POS N
27.3) POS N
and POS N
19.0% POS N
(95% POS N
CI, POS N
12.1 POS N
to POS N
27.9); POS N
among POS N
evaluable POS N
patients, POS N
symptom POS N
improvement POS N
rates POS N
were POS N
40.3% POS N
(95% POS N
CI, POS N
28.5 POS N
to POS N
53.0) POS N
and POS N
37.0% POS N
(95% POS N
CI, POS N
26.0 POS N
to POS N
49.1); POS N
median POS N
progression-free POS N
survival POS N
times POS N
were POS N
2.7 POS N
and POS N
2.8 POS N
months; POS N
and POS N
median POS N
overall POS N
survival POS N
times POS N
were POS N
7.6 POS N
and POS N
8.0 POS N
months, POS N
respectively. POS N

Drug-related POS N
toxicities POS N
were POS N
more POS N
frequent POS N
in POS N
the POS N
higher-dose POS N
group. POS N

Adverse POS N
events POS N
(AEs) POS N
at POS N
both POS N
dose POS N
levels POS N
were POS N
generally POS N
mild POS N
(grade POS N
1 POS N
or POS N
2) POS N
and POS N
consisted POS N
mainly POS N
of POS N
skin POS N
reactions POS N
and POS N
diarrhea. POS N

Drug-related POS N
toxicities POS N
were POS N
more POS N
frequent POS N
in POS N
the POS N
higher-dose POS N
group. POS N

Symptom POS N
improvements POS N
were POS N
recorded POS N
for POS N
69.2% POS N
(250 POS N
mg/d) POS N
and POS N
85.7% POS N
(500 POS N
mg/d) POS N
of POS N
patients POS N
with POS N
a POS N
tumor POS N
response. POS N

Drug-related POS N
toxicities POS N
were POS N
more POS N
frequent POS N
in POS N
the POS N
higher-dose POS N
group. POS N

Withdrawal POS N
due POS N
to POS N
drug-related POS N
AEs POS N
was POS N
1.9% POS N
and POS N
9.4% POS N
for POS N
patients POS N
receiving POS N
gefitinib POS N
250 POS N
and POS N
500 POS N
mg/d, POS N
respectively. POS N

Drug-related POS N
toxicities POS N
were POS N
more POS N
frequent POS N
in POS N
the POS N
higher-dose POS N
group. POS N

Gefitinib POS N
showed POS N
clinically POS N
meaningful POS N
antitumor POS N
activity POS N
and POS N
provided POS N
symptom POS N
relief POS N
as POS N
second- POS N
and POS N
third-line POS N
treatment POS N
in POS N
these POS N
patients. POS N

Drug-related POS N
toxicities POS N
were POS N
more POS N
frequent POS N
in POS N
the POS N
higher-dose POS N
group. POS N

At POS N
250 POS N
mg/d, POS N
gefitinib POS N
had POS N
a POS N
favorable POS N
AE POS N
profile. POS N

Drug-related POS N
toxicities POS N
were POS N
more POS N
frequent POS N
in POS N
the POS N
higher-dose POS N
group. POS N

Gefitinib POS N
250 POS N
mg/d POS N
is POS N
an POS N
important, POS N
novel POS N
treatment POS N
option POS N
for POS N
patients POS N
with POS N
pretreated POS N
advanced POS N
NSCLC. POS N

Withdrawal POS N
due POS N
to POS N
drug-related POS N
AEs POS N
was POS N
1.9% POS N
and POS N
9.4% POS N
for POS N
patients POS N
receiving POS N
gefitinib POS N
250 POS N
and POS N
500 POS N
mg/d, POS N
respectively. POS N

Efficacy POS N
was POS N
similar POS N
for POS N
the POS N
250- POS N
and POS N
500-mg/d POS N
groups. POS N

Withdrawal POS N
due POS N
to POS N
drug-related POS N
AEs POS N
was POS N
1.9% POS N
and POS N
9.4% POS N
for POS N
patients POS N
receiving POS N
gefitinib POS N
250 POS N
and POS N
500 POS N
mg/d, POS N
respectively. POS N

Objective POS N
tumor POS N
response POS N
rates POS N
were POS N
18.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
11.5 POS N
to POS N
27.3) POS N
and POS N
19.0% POS N
(95% POS N
CI, POS N
12.1 POS N
to POS N
27.9); POS N
among POS N
evaluable POS N
patients, POS N
symptom POS N
improvement POS N
rates POS N
were POS N
40.3% POS N
(95% POS N
CI, POS N
28.5 POS N
to POS N
53.0) POS N
and POS N
37.0% POS N
(95% POS N
CI, POS N
26.0 POS N
to POS N
49.1); POS N
median POS N
progression-free POS N
survival POS N
times POS N
were POS N
2.7 POS N
and POS N
2.8 POS N
months; POS N
and POS N
median POS N
overall POS N
survival POS N
times POS N
were POS N
7.6 POS N
and POS N
8.0 POS N
months, POS N
respectively. POS N

Withdrawal POS N
due POS N
to POS N
drug-related POS N
AEs POS N
was POS N
1.9% POS N
and POS N
9.4% POS N
for POS N
patients POS N
receiving POS N
gefitinib POS N
250 POS N
and POS N
500 POS N
mg/d, POS N
respectively. POS N

Adverse POS N
events POS N
(AEs) POS N
at POS N
both POS N
dose POS N
levels POS N
were POS N
generally POS N
mild POS N
(grade POS N
1 POS N
or POS N
2) POS N
and POS N
consisted POS N
mainly POS N
of POS N
skin POS N
reactions POS N
and POS N
diarrhea. POS N

Withdrawal POS N
due POS N
to POS N
drug-related POS N
AEs POS N
was POS N
1.9% POS N
and POS N
9.4% POS N
for POS N
patients POS N
receiving POS N
gefitinib POS N
250 POS N
and POS N
500 POS N
mg/d, POS N
respectively. POS N

Symptom POS N
improvements POS N
were POS N
recorded POS N
for POS N
69.2% POS N
(250 POS N
mg/d) POS N
and POS N
85.7% POS N
(500 POS N
mg/d) POS N
of POS N
patients POS N
with POS N
a POS N
tumor POS N
response. POS N

Withdrawal POS N
due POS N
to POS N
drug-related POS N
AEs POS N
was POS N
1.9% POS N
and POS N
9.4% POS N
for POS N
patients POS N
receiving POS N
gefitinib POS N
250 POS N
and POS N
500 POS N
mg/d, POS N
respectively. POS N

Drug-related POS N
toxicities POS N
were POS N
more POS N
frequent POS N
in POS N
the POS N
higher-dose POS N
group. POS N

Withdrawal POS N
due POS N
to POS N
drug-related POS N
AEs POS N
was POS N
1.9% POS N
and POS N
9.4% POS N
for POS N
patients POS N
receiving POS N
gefitinib POS N
250 POS N
and POS N
500 POS N
mg/d, POS N
respectively. POS N

Gefitinib POS N
showed POS N
clinically POS N
meaningful POS N
antitumor POS N
activity POS N
and POS N
provided POS N
symptom POS N
relief POS N
as POS N
second- POS N
and POS N
third-line POS N
treatment POS N
in POS N
these POS N
patients. POS N

Withdrawal POS N
due POS N
to POS N
drug-related POS N
AEs POS N
was POS N
1.9% POS N
and POS N
9.4% POS N
for POS N
patients POS N
receiving POS N
gefitinib POS N
250 POS N
and POS N
500 POS N
mg/d, POS N
respectively. POS N

At POS N
250 POS N
mg/d, POS N
gefitinib POS N
had POS N
a POS N
favorable POS N
AE POS N
profile. POS N

Withdrawal POS N
due POS N
to POS N
drug-related POS N
AEs POS N
was POS N
1.9% POS N
and POS N
9.4% POS N
for POS N
patients POS N
receiving POS N
gefitinib POS N
250 POS N
and POS N
500 POS N
mg/d, POS N
respectively. POS N

Gefitinib POS N
250 POS N
mg/d POS N
is POS N
an POS N
important, POS N
novel POS N
treatment POS N
option POS N
for POS N
patients POS N
with POS N
pretreated POS N
advanced POS N
NSCLC. POS N

Gefitinib POS N
showed POS N
clinically POS N
meaningful POS N
antitumor POS N
activity POS N
and POS N
provided POS N
symptom POS N
relief POS N
as POS N
second- POS N
and POS N
third-line POS N
treatment POS N
in POS N
these POS N
patients. POS N

Efficacy POS N
was POS N
similar POS N
for POS N
the POS N
250- POS N
and POS N
500-mg/d POS N
groups. POS N

Gefitinib POS N
showed POS N
clinically POS N
meaningful POS N
antitumor POS N
activity POS N
and POS N
provided POS N
symptom POS N
relief POS N
as POS N
second- POS N
and POS N
third-line POS N
treatment POS N
in POS N
these POS N
patients. POS N

Objective POS N
tumor POS N
response POS N
rates POS N
were POS N
18.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
11.5 POS N
to POS N
27.3) POS N
and POS N
19.0% POS N
(95% POS N
CI, POS N
12.1 POS N
to POS N
27.9); POS N
among POS N
evaluable POS N
patients, POS N
symptom POS N
improvement POS N
rates POS N
were POS N
40.3% POS N
(95% POS N
CI, POS N
28.5 POS N
to POS N
53.0) POS N
and POS N
37.0% POS N
(95% POS N
CI, POS N
26.0 POS N
to POS N
49.1); POS N
median POS N
progression-free POS N
survival POS N
times POS N
were POS N
2.7 POS N
and POS N
2.8 POS N
months; POS N
and POS N
median POS N
overall POS N
survival POS N
times POS N
were POS N
7.6 POS N
and POS N
8.0 POS N
months, POS N
respectively. POS N

Gefitinib POS N
showed POS N
clinically POS N
meaningful POS N
antitumor POS N
activity POS N
and POS N
provided POS N
symptom POS N
relief POS N
as POS N
second- POS N
and POS N
third-line POS N
treatment POS N
in POS N
these POS N
patients. POS N

Adverse POS N
events POS N
(AEs) POS N
at POS N
both POS N
dose POS N
levels POS N
were POS N
generally POS N
mild POS N
(grade POS N
1 POS N
or POS N
2) POS N
and POS N
consisted POS N
mainly POS N
of POS N
skin POS N
reactions POS N
and POS N
diarrhea. POS N

Gefitinib POS N
showed POS N
clinically POS N
meaningful POS N
antitumor POS N
activity POS N
and POS N
provided POS N
symptom POS N
relief POS N
as POS N
second- POS N
and POS N
third-line POS N
treatment POS N
in POS N
these POS N
patients. POS N

Symptom POS N
improvements POS N
were POS N
recorded POS N
for POS N
69.2% POS N
(250 POS N
mg/d) POS N
and POS N
85.7% POS N
(500 POS N
mg/d) POS N
of POS N
patients POS N
with POS N
a POS N
tumor POS N
response. POS N

Gefitinib POS N
showed POS N
clinically POS N
meaningful POS N
antitumor POS N
activity POS N
and POS N
provided POS N
symptom POS N
relief POS N
as POS N
second- POS N
and POS N
third-line POS N
treatment POS N
in POS N
these POS N
patients. POS N

Drug-related POS N
toxicities POS N
were POS N
more POS N
frequent POS N
in POS N
the POS N
higher-dose POS N
group. POS N

Gefitinib POS N
showed POS N
clinically POS N
meaningful POS N
antitumor POS N
activity POS N
and POS N
provided POS N
symptom POS N
relief POS N
as POS N
second- POS N
and POS N
third-line POS N
treatment POS N
in POS N
these POS N
patients. POS N

Withdrawal POS N
due POS N
to POS N
drug-related POS N
AEs POS N
was POS N
1.9% POS N
and POS N
9.4% POS N
for POS N
patients POS N
receiving POS N
gefitinib POS N
250 POS N
and POS N
500 POS N
mg/d, POS N
respectively. POS N

Gefitinib POS N
showed POS N
clinically POS N
meaningful POS N
antitumor POS N
activity POS N
and POS N
provided POS N
symptom POS N
relief POS N
as POS N
second- POS N
and POS N
third-line POS N
treatment POS N
in POS N
these POS N
patients. POS N

At POS N
250 POS N
mg/d, POS N
gefitinib POS N
had POS N
a POS N
favorable POS N
AE POS N
profile. POS N

Gefitinib POS N
showed POS N
clinically POS N
meaningful POS N
antitumor POS N
activity POS N
and POS N
provided POS N
symptom POS N
relief POS N
as POS N
second- POS N
and POS N
third-line POS N
treatment POS N
in POS N
these POS N
patients. POS N

Gefitinib POS N
250 POS N
mg/d POS N
is POS N
an POS N
important, POS N
novel POS N
treatment POS N
option POS N
for POS N
patients POS N
with POS N
pretreated POS N
advanced POS N
NSCLC. POS N

At POS N
250 POS N
mg/d, POS N
gefitinib POS N
had POS N
a POS N
favorable POS N
AE POS N
profile. POS N

Efficacy POS N
was POS N
similar POS N
for POS N
the POS N
250- POS N
and POS N
500-mg/d POS N
groups. POS N

At POS N
250 POS N
mg/d, POS N
gefitinib POS N
had POS N
a POS N
favorable POS N
AE POS N
profile. POS N

Objective POS N
tumor POS N
response POS N
rates POS N
were POS N
18.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
11.5 POS N
to POS N
27.3) POS N
and POS N
19.0% POS N
(95% POS N
CI, POS N
12.1 POS N
to POS N
27.9); POS N
among POS N
evaluable POS N
patients, POS N
symptom POS N
improvement POS N
rates POS N
were POS N
40.3% POS N
(95% POS N
CI, POS N
28.5 POS N
to POS N
53.0) POS N
and POS N
37.0% POS N
(95% POS N
CI, POS N
26.0 POS N
to POS N
49.1); POS N
median POS N
progression-free POS N
survival POS N
times POS N
were POS N
2.7 POS N
and POS N
2.8 POS N
months; POS N
and POS N
median POS N
overall POS N
survival POS N
times POS N
were POS N
7.6 POS N
and POS N
8.0 POS N
months, POS N
respectively. POS N

At POS N
250 POS N
mg/d, POS N
gefitinib POS N
had POS N
a POS N
favorable POS N
AE POS N
profile. POS N

Adverse POS N
events POS N
(AEs) POS N
at POS N
both POS N
dose POS N
levels POS N
were POS N
generally POS N
mild POS N
(grade POS N
1 POS N
or POS N
2) POS N
and POS N
consisted POS N
mainly POS N
of POS N
skin POS N
reactions POS N
and POS N
diarrhea. POS N

At POS N
250 POS N
mg/d, POS N
gefitinib POS N
had POS N
a POS N
favorable POS N
AE POS N
profile. POS N

Symptom POS N
improvements POS N
were POS N
recorded POS N
for POS N
69.2% POS N
(250 POS N
mg/d) POS N
and POS N
85.7% POS N
(500 POS N
mg/d) POS N
of POS N
patients POS N
with POS N
a POS N
tumor POS N
response. POS N

At POS N
250 POS N
mg/d, POS N
gefitinib POS N
had POS N
a POS N
favorable POS N
AE POS N
profile. POS N

Drug-related POS N
toxicities POS N
were POS N
more POS N
frequent POS N
in POS N
the POS N
higher-dose POS N
group. POS N

At POS N
250 POS N
mg/d, POS N
gefitinib POS N
had POS N
a POS N
favorable POS N
AE POS N
profile. POS N

Withdrawal POS N
due POS N
to POS N
drug-related POS N
AEs POS N
was POS N
1.9% POS N
and POS N
9.4% POS N
for POS N
patients POS N
receiving POS N
gefitinib POS N
250 POS N
and POS N
500 POS N
mg/d, POS N
respectively. POS N

At POS N
250 POS N
mg/d, POS N
gefitinib POS N
had POS N
a POS N
favorable POS N
AE POS N
profile. POS N

Gefitinib POS N
showed POS N
clinically POS N
meaningful POS N
antitumor POS N
activity POS N
and POS N
provided POS N
symptom POS N
relief POS N
as POS N
second- POS N
and POS N
third-line POS N
treatment POS N
in POS N
these POS N
patients. POS N

At POS N
250 POS N
mg/d, POS N
gefitinib POS N
had POS N
a POS N
favorable POS N
AE POS N
profile. POS N

Gefitinib POS N
250 POS N
mg/d POS N
is POS N
an POS N
important, POS N
novel POS N
treatment POS N
option POS N
for POS N
patients POS N
with POS N
pretreated POS N
advanced POS N
NSCLC. POS N

Gefitinib POS N
250 POS N
mg/d POS N
is POS N
an POS N
important, POS N
novel POS N
treatment POS N
option POS N
for POS N
patients POS N
with POS N
pretreated POS N
advanced POS N
NSCLC. POS N

Efficacy POS N
was POS N
similar POS N
for POS N
the POS N
250- POS N
and POS N
500-mg/d POS N
groups. POS N

Gefitinib POS N
250 POS N
mg/d POS N
is POS N
an POS N
important, POS N
novel POS N
treatment POS N
option POS N
for POS N
patients POS N
with POS N
pretreated POS N
advanced POS N
NSCLC. POS N

Objective POS N
tumor POS N
response POS N
rates POS N
were POS N
18.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
11.5 POS N
to POS N
27.3) POS N
and POS N
19.0% POS N
(95% POS N
CI, POS N
12.1 POS N
to POS N
27.9); POS N
among POS N
evaluable POS N
patients, POS N
symptom POS N
improvement POS N
rates POS N
were POS N
40.3% POS N
(95% POS N
CI, POS N
28.5 POS N
to POS N
53.0) POS N
and POS N
37.0% POS N
(95% POS N
CI, POS N
26.0 POS N
to POS N
49.1); POS N
median POS N
progression-free POS N
survival POS N
times POS N
were POS N
2.7 POS N
and POS N
2.8 POS N
months; POS N
and POS N
median POS N
overall POS N
survival POS N
times POS N
were POS N
7.6 POS N
and POS N
8.0 POS N
months, POS N
respectively. POS N

Gefitinib POS N
250 POS N
mg/d POS N
is POS N
an POS N
important, POS N
novel POS N
treatment POS N
option POS N
for POS N
patients POS N
with POS N
pretreated POS N
advanced POS N
NSCLC. POS N

Adverse POS N
events POS N
(AEs) POS N
at POS N
both POS N
dose POS N
levels POS N
were POS N
generally POS N
mild POS N
(grade POS N
1 POS N
or POS N
2) POS N
and POS N
consisted POS N
mainly POS N
of POS N
skin POS N
reactions POS N
and POS N
diarrhea. POS N

Gefitinib POS N
250 POS N
mg/d POS N
is POS N
an POS N
important, POS N
novel POS N
treatment POS N
option POS N
for POS N
patients POS N
with POS N
pretreated POS N
advanced POS N
NSCLC. POS N

Symptom POS N
improvements POS N
were POS N
recorded POS N
for POS N
69.2% POS N
(250 POS N
mg/d) POS N
and POS N
85.7% POS N
(500 POS N
mg/d) POS N
of POS N
patients POS N
with POS N
a POS N
tumor POS N
response. POS N

Gefitinib POS N
250 POS N
mg/d POS N
is POS N
an POS N
important, POS N
novel POS N
treatment POS N
option POS N
for POS N
patients POS N
with POS N
pretreated POS N
advanced POS N
NSCLC. POS N

Drug-related POS N
toxicities POS N
were POS N
more POS N
frequent POS N
in POS N
the POS N
higher-dose POS N
group. POS N

Gefitinib POS N
250 POS N
mg/d POS N
is POS N
an POS N
important, POS N
novel POS N
treatment POS N
option POS N
for POS N
patients POS N
with POS N
pretreated POS N
advanced POS N
NSCLC. POS N

Withdrawal POS N
due POS N
to POS N
drug-related POS N
AEs POS N
was POS N
1.9% POS N
and POS N
9.4% POS N
for POS N
patients POS N
receiving POS N
gefitinib POS N
250 POS N
and POS N
500 POS N
mg/d, POS N
respectively. POS N

Gefitinib POS N
250 POS N
mg/d POS N
is POS N
an POS N
important, POS N
novel POS N
treatment POS N
option POS N
for POS N
patients POS N
with POS N
pretreated POS N
advanced POS N
NSCLC. POS N

Gefitinib POS N
showed POS N
clinically POS N
meaningful POS N
antitumor POS N
activity POS N
and POS N
provided POS N
symptom POS N
relief POS N
as POS N
second- POS N
and POS N
third-line POS N
treatment POS N
in POS N
these POS N
patients. POS N

Gefitinib POS N
250 POS N
mg/d POS N
is POS N
an POS N
important, POS N
novel POS N
treatment POS N
option POS N
for POS N
patients POS N
with POS N
pretreated POS N
advanced POS N
NSCLC. POS N

At POS N
250 POS N
mg/d, POS N
gefitinib POS N
had POS N
a POS N
favorable POS N
AE POS N
profile. POS N

The POS N
results POS N
highlight POS N
the POS N
need POS N
to POS N
promote POS N
the POS N
benefits POS N
of POS N
this POS N
drug POS N
combination POS N
in POS N
helping POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
and POS N
to POS N
promote POS N
its POS N
application POS N
in POS N
clinical POS N
practices. POS N

After POS N
treatment, POS N
the POS N
levels POS N
of POS N
the POS N
indexes POS N
in POS N
both POS N
groups POS N
(the POS N
combination POS N
treatment POS N
group POS N
vs. POS N
the POS N
entecavir POS N
group) POS N
were POS N
as POS N
follows: POS N
bilirubin POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μmol/L); POS N
International POS N
Normalized POS N
Ratio POS N
(INR) POS N
(1.21±0.8 POS N
vs. POS N
1.14±0.7); POS N
creatinine POS N
(147.3±12.4 POS N
vs. POS N
287.4±21.6 POS N
mg/dL); POS N
GGT POS N
(67.4±23.2 POS N
vs. POS N
88.4±23.7 POS N
U/L); POS N
and POS N
ALT POS N
(63.4±40.8 POS N
vs. POS N
96.5±23.5 POS N
U/L). POS N

The POS N
results POS N
highlight POS N
the POS N
need POS N
to POS N
promote POS N
the POS N
benefits POS N
of POS N
this POS N
drug POS N
combination POS N
in POS N
helping POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
and POS N
to POS N
promote POS N
its POS N
application POS N
in POS N
clinical POS N
practices. POS N

In POS N
comparison POS N
of POS N
the POS N
indexes POS N
of POS N
hepatic POS N
fibrosis POS N
between POS N
the POS N
two POS N
groups, POS N
we POS N
found POS N
the POS N
following POS N
differences: POS N
PCIII POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μg/L); POS N
IV-C POS N
(61.3±18.7 POS N
vs. POS N
74.5±17.9 POS N
μg/L); POS N
HA POS N
(147.3±12.4 POS N
vs. POS N
87.4±31.6 POS N
μg/L); POS N
and POS N
LN POS N
(88.7±13.2 POS N
vs POS N
102.5±23.4 POS N
μg/L). POS N

The POS N
results POS N
highlight POS N
the POS N
need POS N
to POS N
promote POS N
the POS N
benefits POS N
of POS N
this POS N
drug POS N
combination POS N
in POS N
helping POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
and POS N
to POS N
promote POS N
its POS N
application POS N
in POS N
clinical POS N
practices. POS N

The POS N
results POS N
showed POS N
that POS N
the POS N
differences POS N
in POS N
comparison POS N
of POS N
the POS N
indexes POS N
before POS N
and POS N
after POS N
the POS N
treatment POS N
were POS N
statistically POS N
significant POS N
(P<0.05). POS N

The POS N
results POS N
highlight POS N
the POS N
need POS N
to POS N
promote POS N
the POS N
benefits POS N
of POS N
this POS N
drug POS N
combination POS N
in POS N
helping POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
and POS N
to POS N
promote POS N
its POS N
application POS N
in POS N
clinical POS N
practices. POS N

After POS N
treatment, POS N
the POS N
MELD POS N
score POS N
of POS N
patients POS N
in POS N
the POS N
combination POS N
treatment POS N
group POS N
was POS N
significantly POS N
lower POS N
than POS N
that POS N
in POS N
the POS N
entecavir POS N
group POS N
(18.7±3.2 POS N
vs. POS N
22.5±3.4), POS N
with POS N
a POS N
statistically POS N
significant POS N
difference POS N
(P<0.05). POS N

The POS N
results POS N
highlight POS N
the POS N
need POS N
to POS N
promote POS N
the POS N
benefits POS N
of POS N
this POS N
drug POS N
combination POS N
in POS N
helping POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
and POS N
to POS N
promote POS N
its POS N
application POS N
in POS N
clinical POS N
practices. POS N

In POS N
the POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
the POS N
combined POS N
administration POS N
of POS N
entecavir POS N
and POS N
adefovir POS N
dipivoxil POS N
can POS N
significantly POS N
improve POS N
liver POS N
function, POS N
hepatic POS N
fibrosis POS N
and POS N
MELD POS N
scores. POS N

After POS N
treatment, POS N
the POS N
levels POS N
of POS N
the POS N
indexes POS N
in POS N
both POS N
groups POS N
(the POS N
combination POS N
treatment POS N
group POS N
vs. POS N
the POS N
entecavir POS N
group) POS N
were POS N
as POS N
follows: POS N
bilirubin POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μmol/L); POS N
International POS N
Normalized POS N
Ratio POS N
(INR) POS N
(1.21±0.8 POS N
vs. POS N
1.14±0.7); POS N
creatinine POS N
(147.3±12.4 POS N
vs. POS N
287.4±21.6 POS N
mg/dL); POS N
GGT POS N
(67.4±23.2 POS N
vs. POS N
88.4±23.7 POS N
U/L); POS N
and POS N
ALT POS N
(63.4±40.8 POS N
vs. POS N
96.5±23.5 POS N
U/L). POS N

The POS N
results POS N
highlight POS N
the POS N
need POS N
to POS N
promote POS N
the POS N
benefits POS N
of POS N
this POS N
drug POS N
combination POS N
in POS N
helping POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
and POS N
to POS N
promote POS N
its POS N
application POS N
in POS N
clinical POS N
practices. POS N

After POS N
treatment, POS N
the POS N
levels POS N
of POS N
the POS N
indexes POS N
in POS N
both POS N
groups POS N
(the POS N
combination POS N
treatment POS N
group POS N
vs. POS N
the POS N
entecavir POS N
group) POS N
were POS N
as POS N
follows: POS N
bilirubin POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μmol/L); POS N
International POS N
Normalized POS N
Ratio POS N
(INR) POS N
(1.21±0.8 POS N
vs. POS N
1.14±0.7); POS N
creatinine POS N
(147.3±12.4 POS N
vs. POS N
287.4±21.6 POS N
mg/dL); POS N
GGT POS N
(67.4±23.2 POS N
vs. POS N
88.4±23.7 POS N
U/L); POS N
and POS N
ALT POS N
(63.4±40.8 POS N
vs. POS N
96.5±23.5 POS N
U/L). POS N

In POS N
comparison POS N
of POS N
the POS N
indexes POS N
of POS N
hepatic POS N
fibrosis POS N
between POS N
the POS N
two POS N
groups, POS N
we POS N
found POS N
the POS N
following POS N
differences: POS N
PCIII POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μg/L); POS N
IV-C POS N
(61.3±18.7 POS N
vs. POS N
74.5±17.9 POS N
μg/L); POS N
HA POS N
(147.3±12.4 POS N
vs. POS N
87.4±31.6 POS N
μg/L); POS N
and POS N
LN POS N
(88.7±13.2 POS N
vs POS N
102.5±23.4 POS N
μg/L). POS N

After POS N
treatment, POS N
the POS N
levels POS N
of POS N
the POS N
indexes POS N
in POS N
both POS N
groups POS N
(the POS N
combination POS N
treatment POS N
group POS N
vs. POS N
the POS N
entecavir POS N
group) POS N
were POS N
as POS N
follows: POS N
bilirubin POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μmol/L); POS N
International POS N
Normalized POS N
Ratio POS N
(INR) POS N
(1.21±0.8 POS N
vs. POS N
1.14±0.7); POS N
creatinine POS N
(147.3±12.4 POS N
vs. POS N
287.4±21.6 POS N
mg/dL); POS N
GGT POS N
(67.4±23.2 POS N
vs. POS N
88.4±23.7 POS N
U/L); POS N
and POS N
ALT POS N
(63.4±40.8 POS N
vs. POS N
96.5±23.5 POS N
U/L). POS N

The POS N
results POS N
showed POS N
that POS N
the POS N
differences POS N
in POS N
comparison POS N
of POS N
the POS N
indexes POS N
before POS N
and POS N
after POS N
the POS N
treatment POS N
were POS N
statistically POS N
significant POS N
(P<0.05). POS N

After POS N
treatment, POS N
the POS N
levels POS N
of POS N
the POS N
indexes POS N
in POS N
both POS N
groups POS N
(the POS N
combination POS N
treatment POS N
group POS N
vs. POS N
the POS N
entecavir POS N
group) POS N
were POS N
as POS N
follows: POS N
bilirubin POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μmol/L); POS N
International POS N
Normalized POS N
Ratio POS N
(INR) POS N
(1.21±0.8 POS N
vs. POS N
1.14±0.7); POS N
creatinine POS N
(147.3±12.4 POS N
vs. POS N
287.4±21.6 POS N
mg/dL); POS N
GGT POS N
(67.4±23.2 POS N
vs. POS N
88.4±23.7 POS N
U/L); POS N
and POS N
ALT POS N
(63.4±40.8 POS N
vs. POS N
96.5±23.5 POS N
U/L). POS N

After POS N
treatment, POS N
the POS N
MELD POS N
score POS N
of POS N
patients POS N
in POS N
the POS N
combination POS N
treatment POS N
group POS N
was POS N
significantly POS N
lower POS N
than POS N
that POS N
in POS N
the POS N
entecavir POS N
group POS N
(18.7±3.2 POS N
vs. POS N
22.5±3.4), POS N
with POS N
a POS N
statistically POS N
significant POS N
difference POS N
(P<0.05). POS N

After POS N
treatment, POS N
the POS N
levels POS N
of POS N
the POS N
indexes POS N
in POS N
both POS N
groups POS N
(the POS N
combination POS N
treatment POS N
group POS N
vs. POS N
the POS N
entecavir POS N
group) POS N
were POS N
as POS N
follows: POS N
bilirubin POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μmol/L); POS N
International POS N
Normalized POS N
Ratio POS N
(INR) POS N
(1.21±0.8 POS N
vs. POS N
1.14±0.7); POS N
creatinine POS N
(147.3±12.4 POS N
vs. POS N
287.4±21.6 POS N
mg/dL); POS N
GGT POS N
(67.4±23.2 POS N
vs. POS N
88.4±23.7 POS N
U/L); POS N
and POS N
ALT POS N
(63.4±40.8 POS N
vs. POS N
96.5±23.5 POS N
U/L). POS N

In POS N
the POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
the POS N
combined POS N
administration POS N
of POS N
entecavir POS N
and POS N
adefovir POS N
dipivoxil POS N
can POS N
significantly POS N
improve POS N
liver POS N
function, POS N
hepatic POS N
fibrosis POS N
and POS N
MELD POS N
scores. POS N

In POS N
comparison POS N
of POS N
the POS N
indexes POS N
of POS N
hepatic POS N
fibrosis POS N
between POS N
the POS N
two POS N
groups, POS N
we POS N
found POS N
the POS N
following POS N
differences: POS N
PCIII POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μg/L); POS N
IV-C POS N
(61.3±18.7 POS N
vs. POS N
74.5±17.9 POS N
μg/L); POS N
HA POS N
(147.3±12.4 POS N
vs. POS N
87.4±31.6 POS N
μg/L); POS N
and POS N
LN POS N
(88.7±13.2 POS N
vs POS N
102.5±23.4 POS N
μg/L). POS N

The POS N
results POS N
highlight POS N
the POS N
need POS N
to POS N
promote POS N
the POS N
benefits POS N
of POS N
this POS N
drug POS N
combination POS N
in POS N
helping POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
and POS N
to POS N
promote POS N
its POS N
application POS N
in POS N
clinical POS N
practices. POS N

In POS N
comparison POS N
of POS N
the POS N
indexes POS N
of POS N
hepatic POS N
fibrosis POS N
between POS N
the POS N
two POS N
groups, POS N
we POS N
found POS N
the POS N
following POS N
differences: POS N
PCIII POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μg/L); POS N
IV-C POS N
(61.3±18.7 POS N
vs. POS N
74.5±17.9 POS N
μg/L); POS N
HA POS N
(147.3±12.4 POS N
vs. POS N
87.4±31.6 POS N
μg/L); POS N
and POS N
LN POS N
(88.7±13.2 POS N
vs POS N
102.5±23.4 POS N
μg/L). POS N

After POS N
treatment, POS N
the POS N
levels POS N
of POS N
the POS N
indexes POS N
in POS N
both POS N
groups POS N
(the POS N
combination POS N
treatment POS N
group POS N
vs. POS N
the POS N
entecavir POS N
group) POS N
were POS N
as POS N
follows: POS N
bilirubin POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μmol/L); POS N
International POS N
Normalized POS N
Ratio POS N
(INR) POS N
(1.21±0.8 POS N
vs. POS N
1.14±0.7); POS N
creatinine POS N
(147.3±12.4 POS N
vs. POS N
287.4±21.6 POS N
mg/dL); POS N
GGT POS N
(67.4±23.2 POS N
vs. POS N
88.4±23.7 POS N
U/L); POS N
and POS N
ALT POS N
(63.4±40.8 POS N
vs. POS N
96.5±23.5 POS N
U/L). POS N

In POS N
comparison POS N
of POS N
the POS N
indexes POS N
of POS N
hepatic POS N
fibrosis POS N
between POS N
the POS N
two POS N
groups, POS N
we POS N
found POS N
the POS N
following POS N
differences: POS N
PCIII POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μg/L); POS N
IV-C POS N
(61.3±18.7 POS N
vs. POS N
74.5±17.9 POS N
μg/L); POS N
HA POS N
(147.3±12.4 POS N
vs. POS N
87.4±31.6 POS N
μg/L); POS N
and POS N
LN POS N
(88.7±13.2 POS N
vs POS N
102.5±23.4 POS N
μg/L). POS N

The POS N
results POS N
showed POS N
that POS N
the POS N
differences POS N
in POS N
comparison POS N
of POS N
the POS N
indexes POS N
before POS N
and POS N
after POS N
the POS N
treatment POS N
were POS N
statistically POS N
significant POS N
(P<0.05). POS N

In POS N
comparison POS N
of POS N
the POS N
indexes POS N
of POS N
hepatic POS N
fibrosis POS N
between POS N
the POS N
two POS N
groups, POS N
we POS N
found POS N
the POS N
following POS N
differences: POS N
PCIII POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μg/L); POS N
IV-C POS N
(61.3±18.7 POS N
vs. POS N
74.5±17.9 POS N
μg/L); POS N
HA POS N
(147.3±12.4 POS N
vs. POS N
87.4±31.6 POS N
μg/L); POS N
and POS N
LN POS N
(88.7±13.2 POS N
vs POS N
102.5±23.4 POS N
μg/L). POS N

After POS N
treatment, POS N
the POS N
MELD POS N
score POS N
of POS N
patients POS N
in POS N
the POS N
combination POS N
treatment POS N
group POS N
was POS N
significantly POS N
lower POS N
than POS N
that POS N
in POS N
the POS N
entecavir POS N
group POS N
(18.7±3.2 POS N
vs. POS N
22.5±3.4), POS N
with POS N
a POS N
statistically POS N
significant POS N
difference POS N
(P<0.05). POS N

In POS N
comparison POS N
of POS N
the POS N
indexes POS N
of POS N
hepatic POS N
fibrosis POS N
between POS N
the POS N
two POS N
groups, POS N
we POS N
found POS N
the POS N
following POS N
differences: POS N
PCIII POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μg/L); POS N
IV-C POS N
(61.3±18.7 POS N
vs. POS N
74.5±17.9 POS N
μg/L); POS N
HA POS N
(147.3±12.4 POS N
vs. POS N
87.4±31.6 POS N
μg/L); POS N
and POS N
LN POS N
(88.7±13.2 POS N
vs POS N
102.5±23.4 POS N
μg/L). POS N

In POS N
the POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
the POS N
combined POS N
administration POS N
of POS N
entecavir POS N
and POS N
adefovir POS N
dipivoxil POS N
can POS N
significantly POS N
improve POS N
liver POS N
function, POS N
hepatic POS N
fibrosis POS N
and POS N
MELD POS N
scores. POS N

The POS N
results POS N
showed POS N
that POS N
the POS N
differences POS N
in POS N
comparison POS N
of POS N
the POS N
indexes POS N
before POS N
and POS N
after POS N
the POS N
treatment POS N
were POS N
statistically POS N
significant POS N
(P<0.05). POS N

The POS N
results POS N
highlight POS N
the POS N
need POS N
to POS N
promote POS N
the POS N
benefits POS N
of POS N
this POS N
drug POS N
combination POS N
in POS N
helping POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
and POS N
to POS N
promote POS N
its POS N
application POS N
in POS N
clinical POS N
practices. POS N

The POS N
results POS N
showed POS N
that POS N
the POS N
differences POS N
in POS N
comparison POS N
of POS N
the POS N
indexes POS N
before POS N
and POS N
after POS N
the POS N
treatment POS N
were POS N
statistically POS N
significant POS N
(P<0.05). POS N

After POS N
treatment, POS N
the POS N
levels POS N
of POS N
the POS N
indexes POS N
in POS N
both POS N
groups POS N
(the POS N
combination POS N
treatment POS N
group POS N
vs. POS N
the POS N
entecavir POS N
group) POS N
were POS N
as POS N
follows: POS N
bilirubin POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μmol/L); POS N
International POS N
Normalized POS N
Ratio POS N
(INR) POS N
(1.21±0.8 POS N
vs. POS N
1.14±0.7); POS N
creatinine POS N
(147.3±12.4 POS N
vs. POS N
287.4±21.6 POS N
mg/dL); POS N
GGT POS N
(67.4±23.2 POS N
vs. POS N
88.4±23.7 POS N
U/L); POS N
and POS N
ALT POS N
(63.4±40.8 POS N
vs. POS N
96.5±23.5 POS N
U/L). POS N

The POS N
results POS N
showed POS N
that POS N
the POS N
differences POS N
in POS N
comparison POS N
of POS N
the POS N
indexes POS N
before POS N
and POS N
after POS N
the POS N
treatment POS N
were POS N
statistically POS N
significant POS N
(P<0.05). POS N

In POS N
comparison POS N
of POS N
the POS N
indexes POS N
of POS N
hepatic POS N
fibrosis POS N
between POS N
the POS N
two POS N
groups, POS N
we POS N
found POS N
the POS N
following POS N
differences: POS N
PCIII POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μg/L); POS N
IV-C POS N
(61.3±18.7 POS N
vs. POS N
74.5±17.9 POS N
μg/L); POS N
HA POS N
(147.3±12.4 POS N
vs. POS N
87.4±31.6 POS N
μg/L); POS N
and POS N
LN POS N
(88.7±13.2 POS N
vs POS N
102.5±23.4 POS N
μg/L). POS N

The POS N
results POS N
showed POS N
that POS N
the POS N
differences POS N
in POS N
comparison POS N
of POS N
the POS N
indexes POS N
before POS N
and POS N
after POS N
the POS N
treatment POS N
were POS N
statistically POS N
significant POS N
(P<0.05). POS N

After POS N
treatment, POS N
the POS N
MELD POS N
score POS N
of POS N
patients POS N
in POS N
the POS N
combination POS N
treatment POS N
group POS N
was POS N
significantly POS N
lower POS N
than POS N
that POS N
in POS N
the POS N
entecavir POS N
group POS N
(18.7±3.2 POS N
vs. POS N
22.5±3.4), POS N
with POS N
a POS N
statistically POS N
significant POS N
difference POS N
(P<0.05). POS N

The POS N
results POS N
showed POS N
that POS N
the POS N
differences POS N
in POS N
comparison POS N
of POS N
the POS N
indexes POS N
before POS N
and POS N
after POS N
the POS N
treatment POS N
were POS N
statistically POS N
significant POS N
(P<0.05). POS N

In POS N
the POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
the POS N
combined POS N
administration POS N
of POS N
entecavir POS N
and POS N
adefovir POS N
dipivoxil POS N
can POS N
significantly POS N
improve POS N
liver POS N
function, POS N
hepatic POS N
fibrosis POS N
and POS N
MELD POS N
scores. POS N

After POS N
treatment, POS N
the POS N
MELD POS N
score POS N
of POS N
patients POS N
in POS N
the POS N
combination POS N
treatment POS N
group POS N
was POS N
significantly POS N
lower POS N
than POS N
that POS N
in POS N
the POS N
entecavir POS N
group POS N
(18.7±3.2 POS N
vs. POS N
22.5±3.4), POS N
with POS N
a POS N
statistically POS N
significant POS N
difference POS N
(P<0.05). POS N

The POS N
results POS N
highlight POS N
the POS N
need POS N
to POS N
promote POS N
the POS N
benefits POS N
of POS N
this POS N
drug POS N
combination POS N
in POS N
helping POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
and POS N
to POS N
promote POS N
its POS N
application POS N
in POS N
clinical POS N
practices. POS N

After POS N
treatment, POS N
the POS N
MELD POS N
score POS N
of POS N
patients POS N
in POS N
the POS N
combination POS N
treatment POS N
group POS N
was POS N
significantly POS N
lower POS N
than POS N
that POS N
in POS N
the POS N
entecavir POS N
group POS N
(18.7±3.2 POS N
vs. POS N
22.5±3.4), POS N
with POS N
a POS N
statistically POS N
significant POS N
difference POS N
(P<0.05). POS N

After POS N
treatment, POS N
the POS N
levels POS N
of POS N
the POS N
indexes POS N
in POS N
both POS N
groups POS N
(the POS N
combination POS N
treatment POS N
group POS N
vs. POS N
the POS N
entecavir POS N
group) POS N
were POS N
as POS N
follows: POS N
bilirubin POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μmol/L); POS N
International POS N
Normalized POS N
Ratio POS N
(INR) POS N
(1.21±0.8 POS N
vs. POS N
1.14±0.7); POS N
creatinine POS N
(147.3±12.4 POS N
vs. POS N
287.4±21.6 POS N
mg/dL); POS N
GGT POS N
(67.4±23.2 POS N
vs. POS N
88.4±23.7 POS N
U/L); POS N
and POS N
ALT POS N
(63.4±40.8 POS N
vs. POS N
96.5±23.5 POS N
U/L). POS N

After POS N
treatment, POS N
the POS N
MELD POS N
score POS N
of POS N
patients POS N
in POS N
the POS N
combination POS N
treatment POS N
group POS N
was POS N
significantly POS N
lower POS N
than POS N
that POS N
in POS N
the POS N
entecavir POS N
group POS N
(18.7±3.2 POS N
vs. POS N
22.5±3.4), POS N
with POS N
a POS N
statistically POS N
significant POS N
difference POS N
(P<0.05). POS N

In POS N
comparison POS N
of POS N
the POS N
indexes POS N
of POS N
hepatic POS N
fibrosis POS N
between POS N
the POS N
two POS N
groups, POS N
we POS N
found POS N
the POS N
following POS N
differences: POS N
PCIII POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μg/L); POS N
IV-C POS N
(61.3±18.7 POS N
vs. POS N
74.5±17.9 POS N
μg/L); POS N
HA POS N
(147.3±12.4 POS N
vs. POS N
87.4±31.6 POS N
μg/L); POS N
and POS N
LN POS N
(88.7±13.2 POS N
vs POS N
102.5±23.4 POS N
μg/L). POS N

After POS N
treatment, POS N
the POS N
MELD POS N
score POS N
of POS N
patients POS N
in POS N
the POS N
combination POS N
treatment POS N
group POS N
was POS N
significantly POS N
lower POS N
than POS N
that POS N
in POS N
the POS N
entecavir POS N
group POS N
(18.7±3.2 POS N
vs. POS N
22.5±3.4), POS N
with POS N
a POS N
statistically POS N
significant POS N
difference POS N
(P<0.05). POS N

The POS N
results POS N
showed POS N
that POS N
the POS N
differences POS N
in POS N
comparison POS N
of POS N
the POS N
indexes POS N
before POS N
and POS N
after POS N
the POS N
treatment POS N
were POS N
statistically POS N
significant POS N
(P<0.05). POS N

After POS N
treatment, POS N
the POS N
MELD POS N
score POS N
of POS N
patients POS N
in POS N
the POS N
combination POS N
treatment POS N
group POS N
was POS N
significantly POS N
lower POS N
than POS N
that POS N
in POS N
the POS N
entecavir POS N
group POS N
(18.7±3.2 POS N
vs. POS N
22.5±3.4), POS N
with POS N
a POS N
statistically POS N
significant POS N
difference POS N
(P<0.05). POS N

In POS N
the POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
the POS N
combined POS N
administration POS N
of POS N
entecavir POS N
and POS N
adefovir POS N
dipivoxil POS N
can POS N
significantly POS N
improve POS N
liver POS N
function, POS N
hepatic POS N
fibrosis POS N
and POS N
MELD POS N
scores. POS N

In POS N
the POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
the POS N
combined POS N
administration POS N
of POS N
entecavir POS N
and POS N
adefovir POS N
dipivoxil POS N
can POS N
significantly POS N
improve POS N
liver POS N
function, POS N
hepatic POS N
fibrosis POS N
and POS N
MELD POS N
scores. POS N

The POS N
results POS N
highlight POS N
the POS N
need POS N
to POS N
promote POS N
the POS N
benefits POS N
of POS N
this POS N
drug POS N
combination POS N
in POS N
helping POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
and POS N
to POS N
promote POS N
its POS N
application POS N
in POS N
clinical POS N
practices. POS N

In POS N
the POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
the POS N
combined POS N
administration POS N
of POS N
entecavir POS N
and POS N
adefovir POS N
dipivoxil POS N
can POS N
significantly POS N
improve POS N
liver POS N
function, POS N
hepatic POS N
fibrosis POS N
and POS N
MELD POS N
scores. POS N

After POS N
treatment, POS N
the POS N
levels POS N
of POS N
the POS N
indexes POS N
in POS N
both POS N
groups POS N
(the POS N
combination POS N
treatment POS N
group POS N
vs. POS N
the POS N
entecavir POS N
group) POS N
were POS N
as POS N
follows: POS N
bilirubin POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μmol/L); POS N
International POS N
Normalized POS N
Ratio POS N
(INR) POS N
(1.21±0.8 POS N
vs. POS N
1.14±0.7); POS N
creatinine POS N
(147.3±12.4 POS N
vs. POS N
287.4±21.6 POS N
mg/dL); POS N
GGT POS N
(67.4±23.2 POS N
vs. POS N
88.4±23.7 POS N
U/L); POS N
and POS N
ALT POS N
(63.4±40.8 POS N
vs. POS N
96.5±23.5 POS N
U/L). POS N

In POS N
the POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
the POS N
combined POS N
administration POS N
of POS N
entecavir POS N
and POS N
adefovir POS N
dipivoxil POS N
can POS N
significantly POS N
improve POS N
liver POS N
function, POS N
hepatic POS N
fibrosis POS N
and POS N
MELD POS N
scores. POS N

In POS N
comparison POS N
of POS N
the POS N
indexes POS N
of POS N
hepatic POS N
fibrosis POS N
between POS N
the POS N
two POS N
groups, POS N
we POS N
found POS N
the POS N
following POS N
differences: POS N
PCIII POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μg/L); POS N
IV-C POS N
(61.3±18.7 POS N
vs. POS N
74.5±17.9 POS N
μg/L); POS N
HA POS N
(147.3±12.4 POS N
vs. POS N
87.4±31.6 POS N
μg/L); POS N
and POS N
LN POS N
(88.7±13.2 POS N
vs POS N
102.5±23.4 POS N
μg/L). POS N

In POS N
the POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
the POS N
combined POS N
administration POS N
of POS N
entecavir POS N
and POS N
adefovir POS N
dipivoxil POS N
can POS N
significantly POS N
improve POS N
liver POS N
function, POS N
hepatic POS N
fibrosis POS N
and POS N
MELD POS N
scores. POS N

The POS N
results POS N
showed POS N
that POS N
the POS N
differences POS N
in POS N
comparison POS N
of POS N
the POS N
indexes POS N
before POS N
and POS N
after POS N
the POS N
treatment POS N
were POS N
statistically POS N
significant POS N
(P<0.05). POS N

In POS N
the POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
the POS N
combined POS N
administration POS N
of POS N
entecavir POS N
and POS N
adefovir POS N
dipivoxil POS N
can POS N
significantly POS N
improve POS N
liver POS N
function, POS N
hepatic POS N
fibrosis POS N
and POS N
MELD POS N
scores. POS N

After POS N
treatment, POS N
the POS N
MELD POS N
score POS N
of POS N
patients POS N
in POS N
the POS N
combination POS N
treatment POS N
group POS N
was POS N
significantly POS N
lower POS N
than POS N
that POS N
in POS N
the POS N
entecavir POS N
group POS N
(18.7±3.2 POS N
vs. POS N
22.5±3.4), POS N
with POS N
a POS N
statistically POS N
significant POS N
difference POS N
(P<0.05). POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

Risk POS N
of POS N
all POS N
three POS N
outcomes POS N
was POS N
higher POS N
for POS N
participants POS N
with POS N
chronic POS N
kidney POS N
disease POS N
or POS N
frailty. POS N

Older POS N
age POS N
was POS N
also POS N
associated POS N
with POS N
greater POS N
risk POS N
of POS N
syncope, POS N
hypotension, POS N
and POS N
falls, POS N
but POS N
there POS N
was POS N
no POS N
age-by-treatment POS N
interaction POS N
for POS N
any POS N
of POS N
the POS N
SAE POS N
outcomes. POS N

Risk POS N
of POS N
all POS N
three POS N
outcomes POS N
was POS N
higher POS N
for POS N
participants POS N
with POS N
chronic POS N
kidney POS N
disease POS N
or POS N
frailty. POS N

Participants POS N
randomized POS N
to POS N
intensive POS N
SBP POS N
control POS N
had POS N
greater POS N
risk POS N
of POS N
hypotension POS N
and POS N
possibly POS N
syncope, POS N
but POS N
not POS N
falls. POS N

Risk POS N
of POS N
all POS N
three POS N
outcomes POS N
was POS N
higher POS N
for POS N
participants POS N
with POS N
chronic POS N
kidney POS N
disease POS N
or POS N
frailty. POS N

Randomization POS N
to POS N
intensive POS N
SBP POS N
control POS N
was POS N
associated POS N
with POS N
greater POS N
risk POS N
of POS N
an POS N
SAE POS N
involving POS N
hypotension POS N
(hazard POS N
ratio POS N
(HR) POS N
= POS N
1.67, POS N
95% POS N
confidence POS N
interval POS N
(CI) POS N
= POS N
1.21-2.32, POS N
P POS N
= POS N
.002), POS N
and POS N
possibly POS N
syncope POS N
(HR POS N
= POS N
1.32, POS N
95% POS N
CI POS N
= POS N
0.98-1.79, POS N
P POS N
= POS N
.07), POS N
but POS N
not POS N
falls POS N
(HR POS N
= POS N
0.98, POS N
95% POS N
CI POS N
= POS N
0.75-1.29, POS N
P POS N
= POS N
.90). POS N

Older POS N
age POS N
was POS N
also POS N
associated POS N
with POS N
greater POS N
risk POS N
of POS N
syncope, POS N
hypotension, POS N
and POS N
falls, POS N
but POS N
there POS N
was POS N
no POS N
age-by-treatment POS N
interaction POS N
for POS N
any POS N
of POS N
the POS N
SAE POS N
outcomes. POS N

Risk POS N
of POS N
all POS N
three POS N
outcomes POS N
was POS N
higher POS N
for POS N
participants POS N
with POS N
chronic POS N
kidney POS N
disease POS N
or POS N
frailty. POS N

Older POS N
age POS N
was POS N
also POS N
associated POS N
with POS N
greater POS N
risk POS N
of POS N
syncope, POS N
hypotension, POS N
and POS N
falls, POS N
but POS N
there POS N
was POS N
no POS N
age-by-treatment POS N
interaction POS N
for POS N
any POS N
of POS N
the POS N
SAE POS N
outcomes. POS N

Participants POS N
randomized POS N
to POS N
intensive POS N
SBP POS N
control POS N
had POS N
greater POS N
risk POS N
of POS N
hypotension POS N
and POS N
possibly POS N
syncope, POS N
but POS N
not POS N
falls. POS N

Older POS N
age POS N
was POS N
also POS N
associated POS N
with POS N
greater POS N
risk POS N
of POS N
syncope, POS N
hypotension, POS N
and POS N
falls, POS N
but POS N
there POS N
was POS N
no POS N
age-by-treatment POS N
interaction POS N
for POS N
any POS N
of POS N
the POS N
SAE POS N
outcomes. POS N

Randomization POS N
to POS N
intensive POS N
SBP POS N
control POS N
was POS N
associated POS N
with POS N
greater POS N
risk POS N
of POS N
an POS N
SAE POS N
involving POS N
hypotension POS N
(hazard POS N
ratio POS N
(HR) POS N
= POS N
1.67, POS N
95% POS N
confidence POS N
interval POS N
(CI) POS N
= POS N
1.21-2.32, POS N
P POS N
= POS N
.002), POS N
and POS N
possibly POS N
syncope POS N
(HR POS N
= POS N
1.32, POS N
95% POS N
CI POS N
= POS N
0.98-1.79, POS N
P POS N
= POS N
.07), POS N
but POS N
not POS N
falls POS N
(HR POS N
= POS N
0.98, POS N
95% POS N
CI POS N
= POS N
0.75-1.29, POS N
P POS N
= POS N
.90). POS N

Participants POS N
randomized POS N
to POS N
intensive POS N
SBP POS N
control POS N
had POS N
greater POS N
risk POS N
of POS N
hypotension POS N
and POS N
possibly POS N
syncope, POS N
but POS N
not POS N
falls. POS N

Risk POS N
of POS N
all POS N
three POS N
outcomes POS N
was POS N
higher POS N
for POS N
participants POS N
with POS N
chronic POS N
kidney POS N
disease POS N
or POS N
frailty. POS N

Participants POS N
randomized POS N
to POS N
intensive POS N
SBP POS N
control POS N
had POS N
greater POS N
risk POS N
of POS N
hypotension POS N
and POS N
possibly POS N
syncope, POS N
but POS N
not POS N
falls. POS N

Older POS N
age POS N
was POS N
also POS N
associated POS N
with POS N
greater POS N
risk POS N
of POS N
syncope, POS N
hypotension, POS N
and POS N
falls, POS N
but POS N
there POS N
was POS N
no POS N
age-by-treatment POS N
interaction POS N
for POS N
any POS N
of POS N
the POS N
SAE POS N
outcomes. POS N

Participants POS N
randomized POS N
to POS N
intensive POS N
SBP POS N
control POS N
had POS N
greater POS N
risk POS N
of POS N
hypotension POS N
and POS N
possibly POS N
syncope, POS N
but POS N
not POS N
falls. POS N

Randomization POS N
to POS N
intensive POS N
SBP POS N
control POS N
was POS N
associated POS N
with POS N
greater POS N
risk POS N
of POS N
an POS N
SAE POS N
involving POS N
hypotension POS N
(hazard POS N
ratio POS N
(HR) POS N
= POS N
1.67, POS N
95% POS N
confidence POS N
interval POS N
(CI) POS N
= POS N
1.21-2.32, POS N
P POS N
= POS N
.002), POS N
and POS N
possibly POS N
syncope POS N
(HR POS N
= POS N
1.32, POS N
95% POS N
CI POS N
= POS N
0.98-1.79, POS N
P POS N
= POS N
.07), POS N
but POS N
not POS N
falls POS N
(HR POS N
= POS N
0.98, POS N
95% POS N
CI POS N
= POS N
0.75-1.29, POS N
P POS N
= POS N
.90). POS N

Randomization POS N
to POS N
intensive POS N
SBP POS N
control POS N
was POS N
associated POS N
with POS N
greater POS N
risk POS N
of POS N
an POS N
SAE POS N
involving POS N
hypotension POS N
(hazard POS N
ratio POS N
(HR) POS N
= POS N
1.67, POS N
95% POS N
confidence POS N
interval POS N
(CI) POS N
= POS N
1.21-2.32, POS N
P POS N
= POS N
.002), POS N
and POS N
possibly POS N
syncope POS N
(HR POS N
= POS N
1.32, POS N
95% POS N
CI POS N
= POS N
0.98-1.79, POS N
P POS N
= POS N
.07), POS N
but POS N
not POS N
falls POS N
(HR POS N
= POS N
0.98, POS N
95% POS N
CI POS N
= POS N
0.75-1.29, POS N
P POS N
= POS N
.90). POS N

Risk POS N
of POS N
all POS N
three POS N
outcomes POS N
was POS N
higher POS N
for POS N
participants POS N
with POS N
chronic POS N
kidney POS N
disease POS N
or POS N
frailty. POS N

Randomization POS N
to POS N
intensive POS N
SBP POS N
control POS N
was POS N
associated POS N
with POS N
greater POS N
risk POS N
of POS N
an POS N
SAE POS N
involving POS N
hypotension POS N
(hazard POS N
ratio POS N
(HR) POS N
= POS N
1.67, POS N
95% POS N
confidence POS N
interval POS N
(CI) POS N
= POS N
1.21-2.32, POS N
P POS N
= POS N
.002), POS N
and POS N
possibly POS N
syncope POS N
(HR POS N
= POS N
1.32, POS N
95% POS N
CI POS N
= POS N
0.98-1.79, POS N
P POS N
= POS N
.07), POS N
but POS N
not POS N
falls POS N
(HR POS N
= POS N
0.98, POS N
95% POS N
CI POS N
= POS N
0.75-1.29, POS N
P POS N
= POS N
.90). POS N

Older POS N
age POS N
was POS N
also POS N
associated POS N
with POS N
greater POS N
risk POS N
of POS N
syncope, POS N
hypotension, POS N
and POS N
falls, POS N
but POS N
there POS N
was POS N
no POS N
age-by-treatment POS N
interaction POS N
for POS N
any POS N
of POS N
the POS N
SAE POS N
outcomes. POS N

Randomization POS N
to POS N
intensive POS N
SBP POS N
control POS N
was POS N
associated POS N
with POS N
greater POS N
risk POS N
of POS N
an POS N
SAE POS N
involving POS N
hypotension POS N
(hazard POS N
ratio POS N
(HR) POS N
= POS N
1.67, POS N
95% POS N
confidence POS N
interval POS N
(CI) POS N
= POS N
1.21-2.32, POS N
P POS N
= POS N
.002), POS N
and POS N
possibly POS N
syncope POS N
(HR POS N
= POS N
1.32, POS N
95% POS N
CI POS N
= POS N
0.98-1.79, POS N
P POS N
= POS N
.07), POS N
but POS N
not POS N
falls POS N
(HR POS N
= POS N
0.98, POS N
95% POS N
CI POS N
= POS N
0.75-1.29, POS N
P POS N
= POS N
.90). POS N

Participants POS N
randomized POS N
to POS N
intensive POS N
SBP POS N
control POS N
had POS N
greater POS N
risk POS N
of POS N
hypotension POS N
and POS N
possibly POS N
syncope, POS N
but POS N
not POS N
falls. POS N

Severely POS N
immunosuppressed POS N
individuals POS N
with POS N
raised POS N
pretreatment POS N
AST/ALT POS N
or POS N
HBsAg POS N
seropositivity POS N
need POS N
closer POS N
monitoring POS N
for POS N
hepatotoxicity. POS N

Among POS N
426 POS N
participants POS N
(53% POS N
male, POS N
median POS N
age POS N
35 POS N
years, POS N
median POS N
CD4 POS N
count POS N
19 POS N
cells/µL), POS N
31 POS N
developed POS N
hepatotoxicity POS N
(7.3%). POS N

Severely POS N
immunosuppressed POS N
individuals POS N
with POS N
raised POS N
pretreatment POS N
AST/ALT POS N
or POS N
HBsAg POS N
seropositivity POS N
need POS N
closer POS N
monitoring POS N
for POS N
hepatotoxicity. POS N

Raised POS N
pretreatment POS N
AST/ALT POS N
(odds POS N
ratio POS N
[OR] POS N
3.6, POS N
95% POS N
confidence POS N
interval POS N
[CI]: POS N
1.7 POS N
to POS N
7.7) POS N
and POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
seropositivity POS N
at POS N
baseline POS N
(OR POS N
4.7, POS N
95% POS N
CI: POS N
1.7 POS N
to POS N
12.9) POS N
were POS N
significantly POS N
associated POS N
with POS N
an POS N
increased POS N
risk POS N
of POS N
developing POS N
hepatotoxicity. POS N

Severely POS N
immunosuppressed POS N
individuals POS N
with POS N
raised POS N
pretreatment POS N
AST/ALT POS N
or POS N
HBsAg POS N
seropositivity POS N
need POS N
closer POS N
monitoring POS N
for POS N
hepatotoxicity. POS N

Participants POS N
with POS N
both POS N
raised POS N
AST/ALT POS N
and POS N
positive POS N
HBsAg POS N
had POS N
a POS N
higher POS N
risk POS N
(OR POS N
19.9, POS N
95% POS N
CI: POS N
5.3 POS N
to POS N
74.3) POS N
and POS N
earlier POS N
onset POS N
of POS N
hepatotoxicity POS N
than POS N
participants POS N
who POS N
did POS N
not POS N
have POS N
these POS N
conditions POS N
at POS N
baseline. POS N

Severely POS N
immunosuppressed POS N
individuals POS N
with POS N
raised POS N
pretreatment POS N
AST/ALT POS N
or POS N
HBsAg POS N
seropositivity POS N
need POS N
closer POS N
monitoring POS N
for POS N
hepatotoxicity. POS N

The POS N
incidence POS N
of POS N
hepatotoxicity POS N
during POS N
IPT POS N
and POS N
ART POS N
was POS N
high. POS N

Among POS N
426 POS N
participants POS N
(53% POS N
male, POS N
median POS N
age POS N
35 POS N
years, POS N
median POS N
CD4 POS N
count POS N
19 POS N
cells/µL), POS N
31 POS N
developed POS N
hepatotoxicity POS N
(7.3%). POS N

Severely POS N
immunosuppressed POS N
individuals POS N
with POS N
raised POS N
pretreatment POS N
AST/ALT POS N
or POS N
HBsAg POS N
seropositivity POS N
need POS N
closer POS N
monitoring POS N
for POS N
hepatotoxicity. POS N

Among POS N
426 POS N
participants POS N
(53% POS N
male, POS N
median POS N
age POS N
35 POS N
years, POS N
median POS N
CD4 POS N
count POS N
19 POS N
cells/µL), POS N
31 POS N
developed POS N
hepatotoxicity POS N
(7.3%). POS N

Raised POS N
pretreatment POS N
AST/ALT POS N
(odds POS N
ratio POS N
[OR] POS N
3.6, POS N
95% POS N
confidence POS N
interval POS N
[CI]: POS N
1.7 POS N
to POS N
7.7) POS N
and POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
seropositivity POS N
at POS N
baseline POS N
(OR POS N
4.7, POS N
95% POS N
CI: POS N
1.7 POS N
to POS N
12.9) POS N
were POS N
significantly POS N
associated POS N
with POS N
an POS N
increased POS N
risk POS N
of POS N
developing POS N
hepatotoxicity. POS N

Among POS N
426 POS N
participants POS N
(53% POS N
male, POS N
median POS N
age POS N
35 POS N
years, POS N
median POS N
CD4 POS N
count POS N
19 POS N
cells/µL), POS N
31 POS N
developed POS N
hepatotoxicity POS N
(7.3%). POS N

Participants POS N
with POS N
both POS N
raised POS N
AST/ALT POS N
and POS N
positive POS N
HBsAg POS N
had POS N
a POS N
higher POS N
risk POS N
(OR POS N
19.9, POS N
95% POS N
CI: POS N
5.3 POS N
to POS N
74.3) POS N
and POS N
earlier POS N
onset POS N
of POS N
hepatotoxicity POS N
than POS N
participants POS N
who POS N
did POS N
not POS N
have POS N
these POS N
conditions POS N
at POS N
baseline. POS N

Among POS N
426 POS N
participants POS N
(53% POS N
male, POS N
median POS N
age POS N
35 POS N
years, POS N
median POS N
CD4 POS N
count POS N
19 POS N
cells/µL), POS N
31 POS N
developed POS N
hepatotoxicity POS N
(7.3%). POS N

The POS N
incidence POS N
of POS N
hepatotoxicity POS N
during POS N
IPT POS N
and POS N
ART POS N
was POS N
high. POS N

Raised POS N
pretreatment POS N
AST/ALT POS N
(odds POS N
ratio POS N
[OR] POS N
3.6, POS N
95% POS N
confidence POS N
interval POS N
[CI]: POS N
1.7 POS N
to POS N
7.7) POS N
and POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
seropositivity POS N
at POS N
baseline POS N
(OR POS N
4.7, POS N
95% POS N
CI: POS N
1.7 POS N
to POS N
12.9) POS N
were POS N
significantly POS N
associated POS N
with POS N
an POS N
increased POS N
risk POS N
of POS N
developing POS N
hepatotoxicity. POS N

Severely POS N
immunosuppressed POS N
individuals POS N
with POS N
raised POS N
pretreatment POS N
AST/ALT POS N
or POS N
HBsAg POS N
seropositivity POS N
need POS N
closer POS N
monitoring POS N
for POS N
hepatotoxicity. POS N

Raised POS N
pretreatment POS N
AST/ALT POS N
(odds POS N
ratio POS N
[OR] POS N
3.6, POS N
95% POS N
confidence POS N
interval POS N
[CI]: POS N
1.7 POS N
to POS N
7.7) POS N
and POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
seropositivity POS N
at POS N
baseline POS N
(OR POS N
4.7, POS N
95% POS N
CI: POS N
1.7 POS N
to POS N
12.9) POS N
were POS N
significantly POS N
associated POS N
with POS N
an POS N
increased POS N
risk POS N
of POS N
developing POS N
hepatotoxicity. POS N

Among POS N
426 POS N
participants POS N
(53% POS N
male, POS N
median POS N
age POS N
35 POS N
years, POS N
median POS N
CD4 POS N
count POS N
19 POS N
cells/µL), POS N
31 POS N
developed POS N
hepatotoxicity POS N
(7.3%). POS N

Raised POS N
pretreatment POS N
AST/ALT POS N
(odds POS N
ratio POS N
[OR] POS N
3.6, POS N
95% POS N
confidence POS N
interval POS N
[CI]: POS N
1.7 POS N
to POS N
7.7) POS N
and POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
seropositivity POS N
at POS N
baseline POS N
(OR POS N
4.7, POS N
95% POS N
CI: POS N
1.7 POS N
to POS N
12.9) POS N
were POS N
significantly POS N
associated POS N
with POS N
an POS N
increased POS N
risk POS N
of POS N
developing POS N
hepatotoxicity. POS N

Participants POS N
with POS N
both POS N
raised POS N
AST/ALT POS N
and POS N
positive POS N
HBsAg POS N
had POS N
a POS N
higher POS N
risk POS N
(OR POS N
19.9, POS N
95% POS N
CI: POS N
5.3 POS N
to POS N
74.3) POS N
and POS N
earlier POS N
onset POS N
of POS N
hepatotoxicity POS N
than POS N
participants POS N
who POS N
did POS N
not POS N
have POS N
these POS N
conditions POS N
at POS N
baseline. POS N

Raised POS N
pretreatment POS N
AST/ALT POS N
(odds POS N
ratio POS N
[OR] POS N
3.6, POS N
95% POS N
confidence POS N
interval POS N
[CI]: POS N
1.7 POS N
to POS N
7.7) POS N
and POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
seropositivity POS N
at POS N
baseline POS N
(OR POS N
4.7, POS N
95% POS N
CI: POS N
1.7 POS N
to POS N
12.9) POS N
were POS N
significantly POS N
associated POS N
with POS N
an POS N
increased POS N
risk POS N
of POS N
developing POS N
hepatotoxicity. POS N

The POS N
incidence POS N
of POS N
hepatotoxicity POS N
during POS N
IPT POS N
and POS N
ART POS N
was POS N
high. POS N

Participants POS N
with POS N
both POS N
raised POS N
AST/ALT POS N
and POS N
positive POS N
HBsAg POS N
had POS N
a POS N
higher POS N
risk POS N
(OR POS N
19.9, POS N
95% POS N
CI: POS N
5.3 POS N
to POS N
74.3) POS N
and POS N
earlier POS N
onset POS N
of POS N
hepatotoxicity POS N
than POS N
participants POS N
who POS N
did POS N
not POS N
have POS N
these POS N
conditions POS N
at POS N
baseline. POS N

Severely POS N
immunosuppressed POS N
individuals POS N
with POS N
raised POS N
pretreatment POS N
AST/ALT POS N
or POS N
HBsAg POS N
seropositivity POS N
need POS N
closer POS N
monitoring POS N
for POS N
hepatotoxicity. POS N

Participants POS N
with POS N
both POS N
raised POS N
AST/ALT POS N
and POS N
positive POS N
HBsAg POS N
had POS N
a POS N
higher POS N
risk POS N
(OR POS N
19.9, POS N
95% POS N
CI: POS N
5.3 POS N
to POS N
74.3) POS N
and POS N
earlier POS N
onset POS N
of POS N
hepatotoxicity POS N
than POS N
participants POS N
who POS N
did POS N
not POS N
have POS N
these POS N
conditions POS N
at POS N
baseline. POS N

Among POS N
426 POS N
participants POS N
(53% POS N
male, POS N
median POS N
age POS N
35 POS N
years, POS N
median POS N
CD4 POS N
count POS N
19 POS N
cells/µL), POS N
31 POS N
developed POS N
hepatotoxicity POS N
(7.3%). POS N

Participants POS N
with POS N
both POS N
raised POS N
AST/ALT POS N
and POS N
positive POS N
HBsAg POS N
had POS N
a POS N
higher POS N
risk POS N
(OR POS N
19.9, POS N
95% POS N
CI: POS N
5.3 POS N
to POS N
74.3) POS N
and POS N
earlier POS N
onset POS N
of POS N
hepatotoxicity POS N
than POS N
participants POS N
who POS N
did POS N
not POS N
have POS N
these POS N
conditions POS N
at POS N
baseline. POS N

Raised POS N
pretreatment POS N
AST/ALT POS N
(odds POS N
ratio POS N
[OR] POS N
3.6, POS N
95% POS N
confidence POS N
interval POS N
[CI]: POS N
1.7 POS N
to POS N
7.7) POS N
and POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
seropositivity POS N
at POS N
baseline POS N
(OR POS N
4.7, POS N
95% POS N
CI: POS N
1.7 POS N
to POS N
12.9) POS N
were POS N
significantly POS N
associated POS N
with POS N
an POS N
increased POS N
risk POS N
of POS N
developing POS N
hepatotoxicity. POS N

Participants POS N
with POS N
both POS N
raised POS N
AST/ALT POS N
and POS N
positive POS N
HBsAg POS N
had POS N
a POS N
higher POS N
risk POS N
(OR POS N
19.9, POS N
95% POS N
CI: POS N
5.3 POS N
to POS N
74.3) POS N
and POS N
earlier POS N
onset POS N
of POS N
hepatotoxicity POS N
than POS N
participants POS N
who POS N
did POS N
not POS N
have POS N
these POS N
conditions POS N
at POS N
baseline. POS N

The POS N
incidence POS N
of POS N
hepatotoxicity POS N
during POS N
IPT POS N
and POS N
ART POS N
was POS N
high. POS N

The POS N
incidence POS N
of POS N
hepatotoxicity POS N
during POS N
IPT POS N
and POS N
ART POS N
was POS N
high. POS N

Severely POS N
immunosuppressed POS N
individuals POS N
with POS N
raised POS N
pretreatment POS N
AST/ALT POS N
or POS N
HBsAg POS N
seropositivity POS N
need POS N
closer POS N
monitoring POS N
for POS N
hepatotoxicity. POS N

The POS N
incidence POS N
of POS N
hepatotoxicity POS N
during POS N
IPT POS N
and POS N
ART POS N
was POS N
high. POS N

Among POS N
426 POS N
participants POS N
(53% POS N
male, POS N
median POS N
age POS N
35 POS N
years, POS N
median POS N
CD4 POS N
count POS N
19 POS N
cells/µL), POS N
31 POS N
developed POS N
hepatotoxicity POS N
(7.3%). POS N

The POS N
incidence POS N
of POS N
hepatotoxicity POS N
during POS N
IPT POS N
and POS N
ART POS N
was POS N
high. POS N

Raised POS N
pretreatment POS N
AST/ALT POS N
(odds POS N
ratio POS N
[OR] POS N
3.6, POS N
95% POS N
confidence POS N
interval POS N
[CI]: POS N
1.7 POS N
to POS N
7.7) POS N
and POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
seropositivity POS N
at POS N
baseline POS N
(OR POS N
4.7, POS N
95% POS N
CI: POS N
1.7 POS N
to POS N
12.9) POS N
were POS N
significantly POS N
associated POS N
with POS N
an POS N
increased POS N
risk POS N
of POS N
developing POS N
hepatotoxicity. POS N

The POS N
incidence POS N
of POS N
hepatotoxicity POS N
during POS N
IPT POS N
and POS N
ART POS N
was POS N
high. POS N

Participants POS N
with POS N
both POS N
raised POS N
AST/ALT POS N
and POS N
positive POS N
HBsAg POS N
had POS N
a POS N
higher POS N
risk POS N
(OR POS N
19.9, POS N
95% POS N
CI: POS N
5.3 POS N
to POS N
74.3) POS N
and POS N
earlier POS N
onset POS N
of POS N
hepatotoxicity POS N
than POS N
participants POS N
who POS N
did POS N
not POS N
have POS N
these POS N
conditions POS N
at POS N
baseline. POS N

Synbiotic POS N
is POS N
effective POS N
in POS N
reducing POS N
of POS N
blood POS N
pressure POS N
in POS N
women POS N
with POS N
GDM. POS N

No POS N
significant POS N
changes POS N
in POS N
FPG, POS N
insulin POS N
resistance/sensitivity, POS N
lipid POS N
profile POS N
and POS N
TAC POS N
indices POS N
were POS N
seen POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
the POS N
placebo POS N
one POS N
(p > 0.05). POS N

Synbiotic POS N
is POS N
effective POS N
in POS N
reducing POS N
of POS N
blood POS N
pressure POS N
in POS N
women POS N
with POS N
GDM. POS N

Significant POS N
within POS N
group POS N
increases POS N
for POS N
HDL-C POS N
and POS N
TAC POS N
levels POS N
in POS N
synbiotic POS N
group POS N
were POS N
observed POS N
(p < 0.05). POS N

Synbiotic POS N
is POS N
effective POS N
in POS N
reducing POS N
of POS N
blood POS N
pressure POS N
in POS N
women POS N
with POS N
GDM. POS N

LDL-C POS N
showed POS N
significant POS N
increment POS N
in POS N
the POS N
placebo POS N
group POS N
compared POS N
to POS N
the POS N
baseline POS N
of POS N
the POS N
study POS N
(6.9 mg/dL, POS N
p < 0.05). POS N

Synbiotic POS N
is POS N
effective POS N
in POS N
reducing POS N
of POS N
blood POS N
pressure POS N
in POS N
women POS N
with POS N
GDM. POS N

Between POS N
group POS N
comparison POS N
showed POS N
significant POS N
decrease POS N
in POS N
SBP POS N
and POS N
DBP POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
placebo POS N
(-2.5 POS N
vs. POS N
8.6 mmHg, POS N
and POS N
-1.8 POS N
vs. POS N
2.1 mmHg, POS N
p < 0.05). POS N

Synbiotic POS N
is POS N
effective POS N
in POS N
reducing POS N
of POS N
blood POS N
pressure POS N
in POS N
women POS N
with POS N
GDM. POS N

The POS N
results POS N
showed POS N
that, POS N
in POS N
women POS N
with POS N
GDM, POS N
synbiotic POS N
supplementation POS N
had POS N
no POS N
effect POS N
on POS N
FPG POS N
and POS N
insulin POS N
resistance/sensitivity POS N
indices. POS N

Synbiotic POS N
is POS N
effective POS N
in POS N
reducing POS N
of POS N
blood POS N
pressure POS N
in POS N
women POS N
with POS N
GDM. POS N

Lipid POS N
profile POS N
and POS N
TAC POS N
status POS N
may POS N
be POS N
affected POS N
by POS N
synbiotic POS N
supplementation. POS N

No POS N
significant POS N
changes POS N
in POS N
FPG, POS N
insulin POS N
resistance/sensitivity, POS N
lipid POS N
profile POS N
and POS N
TAC POS N
indices POS N
were POS N
seen POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
the POS N
placebo POS N
one POS N
(p > 0.05). POS N

Synbiotic POS N
is POS N
effective POS N
in POS N
reducing POS N
of POS N
blood POS N
pressure POS N
in POS N
women POS N
with POS N
GDM. POS N

No POS N
significant POS N
changes POS N
in POS N
FPG, POS N
insulin POS N
resistance/sensitivity, POS N
lipid POS N
profile POS N
and POS N
TAC POS N
indices POS N
were POS N
seen POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
the POS N
placebo POS N
one POS N
(p > 0.05). POS N

Significant POS N
within POS N
group POS N
increases POS N
for POS N
HDL-C POS N
and POS N
TAC POS N
levels POS N
in POS N
synbiotic POS N
group POS N
were POS N
observed POS N
(p < 0.05). POS N

No POS N
significant POS N
changes POS N
in POS N
FPG, POS N
insulin POS N
resistance/sensitivity, POS N
lipid POS N
profile POS N
and POS N
TAC POS N
indices POS N
were POS N
seen POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
the POS N
placebo POS N
one POS N
(p > 0.05). POS N

LDL-C POS N
showed POS N
significant POS N
increment POS N
in POS N
the POS N
placebo POS N
group POS N
compared POS N
to POS N
the POS N
baseline POS N
of POS N
the POS N
study POS N
(6.9 mg/dL, POS N
p < 0.05). POS N

No POS N
significant POS N
changes POS N
in POS N
FPG, POS N
insulin POS N
resistance/sensitivity, POS N
lipid POS N
profile POS N
and POS N
TAC POS N
indices POS N
were POS N
seen POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
the POS N
placebo POS N
one POS N
(p > 0.05). POS N

Between POS N
group POS N
comparison POS N
showed POS N
significant POS N
decrease POS N
in POS N
SBP POS N
and POS N
DBP POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
placebo POS N
(-2.5 POS N
vs. POS N
8.6 mmHg, POS N
and POS N
-1.8 POS N
vs. POS N
2.1 mmHg, POS N
p < 0.05). POS N

No POS N
significant POS N
changes POS N
in POS N
FPG, POS N
insulin POS N
resistance/sensitivity, POS N
lipid POS N
profile POS N
and POS N
TAC POS N
indices POS N
were POS N
seen POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
the POS N
placebo POS N
one POS N
(p > 0.05). POS N

The POS N
results POS N
showed POS N
that, POS N
in POS N
women POS N
with POS N
GDM, POS N
synbiotic POS N
supplementation POS N
had POS N
no POS N
effect POS N
on POS N
FPG POS N
and POS N
insulin POS N
resistance/sensitivity POS N
indices. POS N

No POS N
significant POS N
changes POS N
in POS N
FPG, POS N
insulin POS N
resistance/sensitivity, POS N
lipid POS N
profile POS N
and POS N
TAC POS N
indices POS N
were POS N
seen POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
the POS N
placebo POS N
one POS N
(p > 0.05). POS N

Lipid POS N
profile POS N
and POS N
TAC POS N
status POS N
may POS N
be POS N
affected POS N
by POS N
synbiotic POS N
supplementation. POS N

Significant POS N
within POS N
group POS N
increases POS N
for POS N
HDL-C POS N
and POS N
TAC POS N
levels POS N
in POS N
synbiotic POS N
group POS N
were POS N
observed POS N
(p < 0.05). POS N

Synbiotic POS N
is POS N
effective POS N
in POS N
reducing POS N
of POS N
blood POS N
pressure POS N
in POS N
women POS N
with POS N
GDM. POS N

Significant POS N
within POS N
group POS N
increases POS N
for POS N
HDL-C POS N
and POS N
TAC POS N
levels POS N
in POS N
synbiotic POS N
group POS N
were POS N
observed POS N
(p < 0.05). POS N

No POS N
significant POS N
changes POS N
in POS N
FPG, POS N
insulin POS N
resistance/sensitivity, POS N
lipid POS N
profile POS N
and POS N
TAC POS N
indices POS N
were POS N
seen POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
the POS N
placebo POS N
one POS N
(p > 0.05). POS N

Significant POS N
within POS N
group POS N
increases POS N
for POS N
HDL-C POS N
and POS N
TAC POS N
levels POS N
in POS N
synbiotic POS N
group POS N
were POS N
observed POS N
(p < 0.05). POS N

LDL-C POS N
showed POS N
significant POS N
increment POS N
in POS N
the POS N
placebo POS N
group POS N
compared POS N
to POS N
the POS N
baseline POS N
of POS N
the POS N
study POS N
(6.9 mg/dL, POS N
p < 0.05). POS N

Significant POS N
within POS N
group POS N
increases POS N
for POS N
HDL-C POS N
and POS N
TAC POS N
levels POS N
in POS N
synbiotic POS N
group POS N
were POS N
observed POS N
(p < 0.05). POS N

Between POS N
group POS N
comparison POS N
showed POS N
significant POS N
decrease POS N
in POS N
SBP POS N
and POS N
DBP POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
placebo POS N
(-2.5 POS N
vs. POS N
8.6 mmHg, POS N
and POS N
-1.8 POS N
vs. POS N
2.1 mmHg, POS N
p < 0.05). POS N

Significant POS N
within POS N
group POS N
increases POS N
for POS N
HDL-C POS N
and POS N
TAC POS N
levels POS N
in POS N
synbiotic POS N
group POS N
were POS N
observed POS N
(p < 0.05). POS N

The POS N
results POS N
showed POS N
that, POS N
in POS N
women POS N
with POS N
GDM, POS N
synbiotic POS N
supplementation POS N
had POS N
no POS N
effect POS N
on POS N
FPG POS N
and POS N
insulin POS N
resistance/sensitivity POS N
indices. POS N

Significant POS N
within POS N
group POS N
increases POS N
for POS N
HDL-C POS N
and POS N
TAC POS N
levels POS N
in POS N
synbiotic POS N
group POS N
were POS N
observed POS N
(p < 0.05). POS N

Lipid POS N
profile POS N
and POS N
TAC POS N
status POS N
may POS N
be POS N
affected POS N
by POS N
synbiotic POS N
supplementation. POS N

LDL-C POS N
showed POS N
significant POS N
increment POS N
in POS N
the POS N
placebo POS N
group POS N
compared POS N
to POS N
the POS N
baseline POS N
of POS N
the POS N
study POS N
(6.9 mg/dL, POS N
p < 0.05). POS N

Synbiotic POS N
is POS N
effective POS N
in POS N
reducing POS N
of POS N
blood POS N
pressure POS N
in POS N
women POS N
with POS N
GDM. POS N

LDL-C POS N
showed POS N
significant POS N
increment POS N
in POS N
the POS N
placebo POS N
group POS N
compared POS N
to POS N
the POS N
baseline POS N
of POS N
the POS N
study POS N
(6.9 mg/dL, POS N
p < 0.05). POS N

No POS N
significant POS N
changes POS N
in POS N
FPG, POS N
insulin POS N
resistance/sensitivity, POS N
lipid POS N
profile POS N
and POS N
TAC POS N
indices POS N
were POS N
seen POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
the POS N
placebo POS N
one POS N
(p > 0.05). POS N

LDL-C POS N
showed POS N
significant POS N
increment POS N
in POS N
the POS N
placebo POS N
group POS N
compared POS N
to POS N
the POS N
baseline POS N
of POS N
the POS N
study POS N
(6.9 mg/dL, POS N
p < 0.05). POS N

Significant POS N
within POS N
group POS N
increases POS N
for POS N
HDL-C POS N
and POS N
TAC POS N
levels POS N
in POS N
synbiotic POS N
group POS N
were POS N
observed POS N
(p < 0.05). POS N

LDL-C POS N
showed POS N
significant POS N
increment POS N
in POS N
the POS N
placebo POS N
group POS N
compared POS N
to POS N
the POS N
baseline POS N
of POS N
the POS N
study POS N
(6.9 mg/dL, POS N
p < 0.05). POS N

Between POS N
group POS N
comparison POS N
showed POS N
significant POS N
decrease POS N
in POS N
SBP POS N
and POS N
DBP POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
placebo POS N
(-2.5 POS N
vs. POS N
8.6 mmHg, POS N
and POS N
-1.8 POS N
vs. POS N
2.1 mmHg, POS N
p < 0.05). POS N

LDL-C POS N
showed POS N
significant POS N
increment POS N
in POS N
the POS N
placebo POS N
group POS N
compared POS N
to POS N
the POS N
baseline POS N
of POS N
the POS N
study POS N
(6.9 mg/dL, POS N
p < 0.05). POS N

The POS N
results POS N
showed POS N
that, POS N
in POS N
women POS N
with POS N
GDM, POS N
synbiotic POS N
supplementation POS N
had POS N
no POS N
effect POS N
on POS N
FPG POS N
and POS N
insulin POS N
resistance/sensitivity POS N
indices. POS N

LDL-C POS N
showed POS N
significant POS N
increment POS N
in POS N
the POS N
placebo POS N
group POS N
compared POS N
to POS N
the POS N
baseline POS N
of POS N
the POS N
study POS N
(6.9 mg/dL, POS N
p < 0.05). POS N

Lipid POS N
profile POS N
and POS N
TAC POS N
status POS N
may POS N
be POS N
affected POS N
by POS N
synbiotic POS N
supplementation. POS N

Between POS N
group POS N
comparison POS N
showed POS N
significant POS N
decrease POS N
in POS N
SBP POS N
and POS N
DBP POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
placebo POS N
(-2.5 POS N
vs. POS N
8.6 mmHg, POS N
and POS N
-1.8 POS N
vs. POS N
2.1 mmHg, POS N
p < 0.05). POS N

Synbiotic POS N
is POS N
effective POS N
in POS N
reducing POS N
of POS N
blood POS N
pressure POS N
in POS N
women POS N
with POS N
GDM. POS N

Between POS N
group POS N
comparison POS N
showed POS N
significant POS N
decrease POS N
in POS N
SBP POS N
and POS N
DBP POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
placebo POS N
(-2.5 POS N
vs. POS N
8.6 mmHg, POS N
and POS N
-1.8 POS N
vs. POS N
2.1 mmHg, POS N
p < 0.05). POS N

No POS N
significant POS N
changes POS N
in POS N
FPG, POS N
insulin POS N
resistance/sensitivity, POS N
lipid POS N
profile POS N
and POS N
TAC POS N
indices POS N
were POS N
seen POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
the POS N
placebo POS N
one POS N
(p > 0.05). POS N

Between POS N
group POS N
comparison POS N
showed POS N
significant POS N
decrease POS N
in POS N
SBP POS N
and POS N
DBP POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
placebo POS N
(-2.5 POS N
vs. POS N
8.6 mmHg, POS N
and POS N
-1.8 POS N
vs. POS N
2.1 mmHg, POS N
p < 0.05). POS N

Significant POS N
within POS N
group POS N
increases POS N
for POS N
HDL-C POS N
and POS N
TAC POS N
levels POS N
in POS N
synbiotic POS N
group POS N
were POS N
observed POS N
(p < 0.05). POS N

Between POS N
group POS N
comparison POS N
showed POS N
significant POS N
decrease POS N
in POS N
SBP POS N
and POS N
DBP POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
placebo POS N
(-2.5 POS N
vs. POS N
8.6 mmHg, POS N
and POS N
-1.8 POS N
vs. POS N
2.1 mmHg, POS N
p < 0.05). POS N

LDL-C POS N
showed POS N
significant POS N
increment POS N
in POS N
the POS N
placebo POS N
group POS N
compared POS N
to POS N
the POS N
baseline POS N
of POS N
the POS N
study POS N
(6.9 mg/dL, POS N
p < 0.05). POS N

Between POS N
group POS N
comparison POS N
showed POS N
significant POS N
decrease POS N
in POS N
SBP POS N
and POS N
DBP POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
placebo POS N
(-2.5 POS N
vs. POS N
8.6 mmHg, POS N
and POS N
-1.8 POS N
vs. POS N
2.1 mmHg, POS N
p < 0.05). POS N

The POS N
results POS N
showed POS N
that, POS N
in POS N
women POS N
with POS N
GDM, POS N
synbiotic POS N
supplementation POS N
had POS N
no POS N
effect POS N
on POS N
FPG POS N
and POS N
insulin POS N
resistance/sensitivity POS N
indices. POS N

Between POS N
group POS N
comparison POS N
showed POS N
significant POS N
decrease POS N
in POS N
SBP POS N
and POS N
DBP POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
placebo POS N
(-2.5 POS N
vs. POS N
8.6 mmHg, POS N
and POS N
-1.8 POS N
vs. POS N
2.1 mmHg, POS N
p < 0.05). POS N

Lipid POS N
profile POS N
and POS N
TAC POS N
status POS N
may POS N
be POS N
affected POS N
by POS N
synbiotic POS N
supplementation. POS N

The POS N
results POS N
showed POS N
that, POS N
in POS N
women POS N
with POS N
GDM, POS N
synbiotic POS N
supplementation POS N
had POS N
no POS N
effect POS N
on POS N
FPG POS N
and POS N
insulin POS N
resistance/sensitivity POS N
indices. POS N

Synbiotic POS N
is POS N
effective POS N
in POS N
reducing POS N
of POS N
blood POS N
pressure POS N
in POS N
women POS N
with POS N
GDM. POS N

The POS N
results POS N
showed POS N
that, POS N
in POS N
women POS N
with POS N
GDM, POS N
synbiotic POS N
supplementation POS N
had POS N
no POS N
effect POS N
on POS N
FPG POS N
and POS N
insulin POS N
resistance/sensitivity POS N
indices. POS N

No POS N
significant POS N
changes POS N
in POS N
FPG, POS N
insulin POS N
resistance/sensitivity, POS N
lipid POS N
profile POS N
and POS N
TAC POS N
indices POS N
were POS N
seen POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
the POS N
placebo POS N
one POS N
(p > 0.05). POS N

The POS N
results POS N
showed POS N
that, POS N
in POS N
women POS N
with POS N
GDM, POS N
synbiotic POS N
supplementation POS N
had POS N
no POS N
effect POS N
on POS N
FPG POS N
and POS N
insulin POS N
resistance/sensitivity POS N
indices. POS N

Significant POS N
within POS N
group POS N
increases POS N
for POS N
HDL-C POS N
and POS N
TAC POS N
levels POS N
in POS N
synbiotic POS N
group POS N
were POS N
observed POS N
(p < 0.05). POS N

The POS N
results POS N
showed POS N
that, POS N
in POS N
women POS N
with POS N
GDM, POS N
synbiotic POS N
supplementation POS N
had POS N
no POS N
effect POS N
on POS N
FPG POS N
and POS N
insulin POS N
resistance/sensitivity POS N
indices. POS N

LDL-C POS N
showed POS N
significant POS N
increment POS N
in POS N
the POS N
placebo POS N
group POS N
compared POS N
to POS N
the POS N
baseline POS N
of POS N
the POS N
study POS N
(6.9 mg/dL, POS N
p < 0.05). POS N

The POS N
results POS N
showed POS N
that, POS N
in POS N
women POS N
with POS N
GDM, POS N
synbiotic POS N
supplementation POS N
had POS N
no POS N
effect POS N
on POS N
FPG POS N
and POS N
insulin POS N
resistance/sensitivity POS N
indices. POS N

Between POS N
group POS N
comparison POS N
showed POS N
significant POS N
decrease POS N
in POS N
SBP POS N
and POS N
DBP POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
placebo POS N
(-2.5 POS N
vs. POS N
8.6 mmHg, POS N
and POS N
-1.8 POS N
vs. POS N
2.1 mmHg, POS N
p < 0.05). POS N

The POS N
results POS N
showed POS N
that, POS N
in POS N
women POS N
with POS N
GDM, POS N
synbiotic POS N
supplementation POS N
had POS N
no POS N
effect POS N
on POS N
FPG POS N
and POS N
insulin POS N
resistance/sensitivity POS N
indices. POS N

Lipid POS N
profile POS N
and POS N
TAC POS N
status POS N
may POS N
be POS N
affected POS N
by POS N
synbiotic POS N
supplementation. POS N

Lipid POS N
profile POS N
and POS N
TAC POS N
status POS N
may POS N
be POS N
affected POS N
by POS N
synbiotic POS N
supplementation. POS N

Synbiotic POS N
is POS N
effective POS N
in POS N
reducing POS N
of POS N
blood POS N
pressure POS N
in POS N
women POS N
with POS N
GDM. POS N

Lipid POS N
profile POS N
and POS N
TAC POS N
status POS N
may POS N
be POS N
affected POS N
by POS N
synbiotic POS N
supplementation. POS N

No POS N
significant POS N
changes POS N
in POS N
FPG, POS N
insulin POS N
resistance/sensitivity, POS N
lipid POS N
profile POS N
and POS N
TAC POS N
indices POS N
were POS N
seen POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
the POS N
placebo POS N
one POS N
(p > 0.05). POS N

Lipid POS N
profile POS N
and POS N
TAC POS N
status POS N
may POS N
be POS N
affected POS N
by POS N
synbiotic POS N
supplementation. POS N

Significant POS N
within POS N
group POS N
increases POS N
for POS N
HDL-C POS N
and POS N
TAC POS N
levels POS N
in POS N
synbiotic POS N
group POS N
were POS N
observed POS N
(p < 0.05). POS N

Lipid POS N
profile POS N
and POS N
TAC POS N
status POS N
may POS N
be POS N
affected POS N
by POS N
synbiotic POS N
supplementation. POS N

LDL-C POS N
showed POS N
significant POS N
increment POS N
in POS N
the POS N
placebo POS N
group POS N
compared POS N
to POS N
the POS N
baseline POS N
of POS N
the POS N
study POS N
(6.9 mg/dL, POS N
p < 0.05). POS N

Lipid POS N
profile POS N
and POS N
TAC POS N
status POS N
may POS N
be POS N
affected POS N
by POS N
synbiotic POS N
supplementation. POS N

Between POS N
group POS N
comparison POS N
showed POS N
significant POS N
decrease POS N
in POS N
SBP POS N
and POS N
DBP POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
placebo POS N
(-2.5 POS N
vs. POS N
8.6 mmHg, POS N
and POS N
-1.8 POS N
vs. POS N
2.1 mmHg, POS N
p < 0.05). POS N

Lipid POS N
profile POS N
and POS N
TAC POS N
status POS N
may POS N
be POS N
affected POS N
by POS N
synbiotic POS N
supplementation. POS N

The POS N
results POS N
showed POS N
that, POS N
in POS N
women POS N
with POS N
GDM, POS N
synbiotic POS N
supplementation POS N
had POS N
no POS N
effect POS N
on POS N
FPG POS N
and POS N
insulin POS N
resistance/sensitivity POS N
indices. POS N

KAMUT POS N
khorasan POS N
is POS N
an POS N
ancient POS N
grain POS N
with POS N
widely POS N
acclaimed POS N
health POS N
benefits. POS N

This POS N
study POS N
suggests POS N
that POS N
a POS N
short-term POS N
replacement POS N
diet POS N
with POS N
ancient POS N
KAMUT POS N
khorasan POS N
products POS N
is POS N
most POS N
effective POS N
in POS N
reducing POS N
metabolic POS N
risk POS N
factors POS N
and POS N
ameliorating POS N
the POS N
liver POS N
profile POS N
in POS N
patients POS N
with POS N
NAFLD. POS N

KAMUT POS N
khorasan POS N
is POS N
an POS N
ancient POS N
grain POS N
with POS N
widely POS N
acclaimed POS N
health POS N
benefits. POS N

significant POS N
improvements POS N
in POS N
the POS N
liver POS N
steatosis POS N
grading, POS N
Doppler POS N
perfusion POS N
index POS N
values, POS N
and POS N
reactive POS N
oxygen POS N
species POS N
(ROS) POS N
production POS N
were POS N
evident POS N
after POS N
consumption POS N
of POS N
both POS N
the POS N
khorasan POS N
and POS N
control POS N
products. POS N

KAMUT POS N
khorasan POS N
is POS N
an POS N
ancient POS N
grain POS N
with POS N
widely POS N
acclaimed POS N
health POS N
benefits. POS N

significant POS N
reductions POS N
in POS N
circulating POS N
proinflammatory POS N
tumor POS N
necrosis POS N
factor-alpha POS N
by POS N
50%, POS N
interleukin POS N
l-receptor POS N
antagonist-alpha POS N
by POS N
37%, POS N
interleukin-8 POS N
by POS N
24%, POS N
and POS N
interferon POS N
gamma POS N
by POS N
24% POS N
were POS N
evident POS N
only POS N
in POS N
participants POS N
who POS N
consumed POS N
the POS N
khorasan POS N
products POS N
(p POS N
< POS N
0.05 POS N
for POS N
all). POS N

KAMUT POS N
khorasan POS N
is POS N
an POS N
ancient POS N
grain POS N
with POS N
widely POS N
acclaimed POS N
health POS N
benefits. POS N

After POS N
the POS N
implementation POS N
of POS N
a POS N
general POS N
linear POS N
model POS N
for POS N
repeated POS N
measurements POS N
adjusted POS N
for POS N
baseline POS N
demographic POS N
details, POS N
risk POS N
factors, POS N
and POS N
medication, POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
was POS N
significantly POS N
reduced POS N
by POS N
12%, POS N
aspartate POS N
aminotransferase POS N
(AST) POS N
by POS N
14%, POS N
alkaline POS N
phosphatase POS N
(ALP) POS N
by POS N
8%, POS N
and POS N
cholesterol POS N
by POS N
6% POS N
only POS N
in POS N
the POS N
khorasan POS N
group POS N
(p POS N
< POS N
0.05 POS N
for POS N
all). POS N

This POS N
study POS N
suggests POS N
that POS N
a POS N
short-term POS N
replacement POS N
diet POS N
with POS N
ancient POS N
KAMUT POS N
khorasan POS N
products POS N
is POS N
most POS N
effective POS N
in POS N
reducing POS N
metabolic POS N
risk POS N
factors POS N
and POS N
ameliorating POS N
the POS N
liver POS N
profile POS N
in POS N
patients POS N
with POS N
NAFLD. POS N

KAMUT POS N
khorasan POS N
is POS N
an POS N
ancient POS N
grain POS N
with POS N
widely POS N
acclaimed POS N
health POS N
benefits. POS N

This POS N
study POS N
suggests POS N
that POS N
a POS N
short-term POS N
replacement POS N
diet POS N
with POS N
ancient POS N
KAMUT POS N
khorasan POS N
products POS N
is POS N
most POS N
effective POS N
in POS N
reducing POS N
metabolic POS N
risk POS N
factors POS N
and POS N
ameliorating POS N
the POS N
liver POS N
profile POS N
in POS N
patients POS N
with POS N
NAFLD. POS N

significant POS N
improvements POS N
in POS N
the POS N
liver POS N
steatosis POS N
grading, POS N
Doppler POS N
perfusion POS N
index POS N
values, POS N
and POS N
reactive POS N
oxygen POS N
species POS N
(ROS) POS N
production POS N
were POS N
evident POS N
after POS N
consumption POS N
of POS N
both POS N
the POS N
khorasan POS N
and POS N
control POS N
products. POS N

This POS N
study POS N
suggests POS N
that POS N
a POS N
short-term POS N
replacement POS N
diet POS N
with POS N
ancient POS N
KAMUT POS N
khorasan POS N
products POS N
is POS N
most POS N
effective POS N
in POS N
reducing POS N
metabolic POS N
risk POS N
factors POS N
and POS N
ameliorating POS N
the POS N
liver POS N
profile POS N
in POS N
patients POS N
with POS N
NAFLD. POS N

significant POS N
reductions POS N
in POS N
circulating POS N
proinflammatory POS N
tumor POS N
necrosis POS N
factor-alpha POS N
by POS N
50%, POS N
interleukin POS N
l-receptor POS N
antagonist-alpha POS N
by POS N
37%, POS N
interleukin-8 POS N
by POS N
24%, POS N
and POS N
interferon POS N
gamma POS N
by POS N
24% POS N
were POS N
evident POS N
only POS N
in POS N
participants POS N
who POS N
consumed POS N
the POS N
khorasan POS N
products POS N
(p POS N
< POS N
0.05 POS N
for POS N
all). POS N

This POS N
study POS N
suggests POS N
that POS N
a POS N
short-term POS N
replacement POS N
diet POS N
with POS N
ancient POS N
KAMUT POS N
khorasan POS N
products POS N
is POS N
most POS N
effective POS N
in POS N
reducing POS N
metabolic POS N
risk POS N
factors POS N
and POS N
ameliorating POS N
the POS N
liver POS N
profile POS N
in POS N
patients POS N
with POS N
NAFLD. POS N

After POS N
the POS N
implementation POS N
of POS N
a POS N
general POS N
linear POS N
model POS N
for POS N
repeated POS N
measurements POS N
adjusted POS N
for POS N
baseline POS N
demographic POS N
details, POS N
risk POS N
factors, POS N
and POS N
medication, POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
was POS N
significantly POS N
reduced POS N
by POS N
12%, POS N
aspartate POS N
aminotransferase POS N
(AST) POS N
by POS N
14%, POS N
alkaline POS N
phosphatase POS N
(ALP) POS N
by POS N
8%, POS N
and POS N
cholesterol POS N
by POS N
6% POS N
only POS N
in POS N
the POS N
khorasan POS N
group POS N
(p POS N
< POS N
0.05 POS N
for POS N
all). POS N

significant POS N
improvements POS N
in POS N
the POS N
liver POS N
steatosis POS N
grading, POS N
Doppler POS N
perfusion POS N
index POS N
values, POS N
and POS N
reactive POS N
oxygen POS N
species POS N
(ROS) POS N
production POS N
were POS N
evident POS N
after POS N
consumption POS N
of POS N
both POS N
the POS N
khorasan POS N
and POS N
control POS N
products. POS N

KAMUT POS N
khorasan POS N
is POS N
an POS N
ancient POS N
grain POS N
with POS N
widely POS N
acclaimed POS N
health POS N
benefits. POS N

significant POS N
improvements POS N
in POS N
the POS N
liver POS N
steatosis POS N
grading, POS N
Doppler POS N
perfusion POS N
index POS N
values, POS N
and POS N
reactive POS N
oxygen POS N
species POS N
(ROS) POS N
production POS N
were POS N
evident POS N
after POS N
consumption POS N
of POS N
both POS N
the POS N
khorasan POS N
and POS N
control POS N
products. POS N

This POS N
study POS N
suggests POS N
that POS N
a POS N
short-term POS N
replacement POS N
diet POS N
with POS N
ancient POS N
KAMUT POS N
khorasan POS N
products POS N
is POS N
most POS N
effective POS N
in POS N
reducing POS N
metabolic POS N
risk POS N
factors POS N
and POS N
ameliorating POS N
the POS N
liver POS N
profile POS N
in POS N
patients POS N
with POS N
NAFLD. POS N

significant POS N
improvements POS N
in POS N
the POS N
liver POS N
steatosis POS N
grading, POS N
Doppler POS N
perfusion POS N
index POS N
values, POS N
and POS N
reactive POS N
oxygen POS N
species POS N
(ROS) POS N
production POS N
were POS N
evident POS N
after POS N
consumption POS N
of POS N
both POS N
the POS N
khorasan POS N
and POS N
control POS N
products. POS N

significant POS N
reductions POS N
in POS N
circulating POS N
proinflammatory POS N
tumor POS N
necrosis POS N
factor-alpha POS N
by POS N
50%, POS N
interleukin POS N
l-receptor POS N
antagonist-alpha POS N
by POS N
37%, POS N
interleukin-8 POS N
by POS N
24%, POS N
and POS N
interferon POS N
gamma POS N
by POS N
24% POS N
were POS N
evident POS N
only POS N
in POS N
participants POS N
who POS N
consumed POS N
the POS N
khorasan POS N
products POS N
(p POS N
< POS N
0.05 POS N
for POS N
all). POS N

significant POS N
improvements POS N
in POS N
the POS N
liver POS N
steatosis POS N
grading, POS N
Doppler POS N
perfusion POS N
index POS N
values, POS N
and POS N
reactive POS N
oxygen POS N
species POS N
(ROS) POS N
production POS N
were POS N
evident POS N
after POS N
consumption POS N
of POS N
both POS N
the POS N
khorasan POS N
and POS N
control POS N
products. POS N

After POS N
the POS N
implementation POS N
of POS N
a POS N
general POS N
linear POS N
model POS N
for POS N
repeated POS N
measurements POS N
adjusted POS N
for POS N
baseline POS N
demographic POS N
details, POS N
risk POS N
factors, POS N
and POS N
medication, POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
was POS N
significantly POS N
reduced POS N
by POS N
12%, POS N
aspartate POS N
aminotransferase POS N
(AST) POS N
by POS N
14%, POS N
alkaline POS N
phosphatase POS N
(ALP) POS N
by POS N
8%, POS N
and POS N
cholesterol POS N
by POS N
6% POS N
only POS N
in POS N
the POS N
khorasan POS N
group POS N
(p POS N
< POS N
0.05 POS N
for POS N
all). POS N

significant POS N
reductions POS N
in POS N
circulating POS N
proinflammatory POS N
tumor POS N
necrosis POS N
factor-alpha POS N
by POS N
50%, POS N
interleukin POS N
l-receptor POS N
antagonist-alpha POS N
by POS N
37%, POS N
interleukin-8 POS N
by POS N
24%, POS N
and POS N
interferon POS N
gamma POS N
by POS N
24% POS N
were POS N
evident POS N
only POS N
in POS N
participants POS N
who POS N
consumed POS N
the POS N
khorasan POS N
products POS N
(p POS N
< POS N
0.05 POS N
for POS N
all). POS N

KAMUT POS N
khorasan POS N
is POS N
an POS N
ancient POS N
grain POS N
with POS N
widely POS N
acclaimed POS N
health POS N
benefits. POS N

significant POS N
reductions POS N
in POS N
circulating POS N
proinflammatory POS N
tumor POS N
necrosis POS N
factor-alpha POS N
by POS N
50%, POS N
interleukin POS N
l-receptor POS N
antagonist-alpha POS N
by POS N
37%, POS N
interleukin-8 POS N
by POS N
24%, POS N
and POS N
interferon POS N
gamma POS N
by POS N
24% POS N
were POS N
evident POS N
only POS N
in POS N
participants POS N
who POS N
consumed POS N
the POS N
khorasan POS N
products POS N
(p POS N
< POS N
0.05 POS N
for POS N
all). POS N

This POS N
study POS N
suggests POS N
that POS N
a POS N
short-term POS N
replacement POS N
diet POS N
with POS N
ancient POS N
KAMUT POS N
khorasan POS N
products POS N
is POS N
most POS N
effective POS N
in POS N
reducing POS N
metabolic POS N
risk POS N
factors POS N
and POS N
ameliorating POS N
the POS N
liver POS N
profile POS N
in POS N
patients POS N
with POS N
NAFLD. POS N

significant POS N
reductions POS N
in POS N
circulating POS N
proinflammatory POS N
tumor POS N
necrosis POS N
factor-alpha POS N
by POS N
50%, POS N
interleukin POS N
l-receptor POS N
antagonist-alpha POS N
by POS N
37%, POS N
interleukin-8 POS N
by POS N
24%, POS N
and POS N
interferon POS N
gamma POS N
by POS N
24% POS N
were POS N
evident POS N
only POS N
in POS N
participants POS N
who POS N
consumed POS N
the POS N
khorasan POS N
products POS N
(p POS N
< POS N
0.05 POS N
for POS N
all). POS N

significant POS N
improvements POS N
in POS N
the POS N
liver POS N
steatosis POS N
grading, POS N
Doppler POS N
perfusion POS N
index POS N
values, POS N
and POS N
reactive POS N
oxygen POS N
species POS N
(ROS) POS N
production POS N
were POS N
evident POS N
after POS N
consumption POS N
of POS N
both POS N
the POS N
khorasan POS N
and POS N
control POS N
products. POS N

significant POS N
reductions POS N
in POS N
circulating POS N
proinflammatory POS N
tumor POS N
necrosis POS N
factor-alpha POS N
by POS N
50%, POS N
interleukin POS N
l-receptor POS N
antagonist-alpha POS N
by POS N
37%, POS N
interleukin-8 POS N
by POS N
24%, POS N
and POS N
interferon POS N
gamma POS N
by POS N
24% POS N
were POS N
evident POS N
only POS N
in POS N
participants POS N
who POS N
consumed POS N
the POS N
khorasan POS N
products POS N
(p POS N
< POS N
0.05 POS N
for POS N
all). POS N

After POS N
the POS N
implementation POS N
of POS N
a POS N
general POS N
linear POS N
model POS N
for POS N
repeated POS N
measurements POS N
adjusted POS N
for POS N
baseline POS N
demographic POS N
details, POS N
risk POS N
factors, POS N
and POS N
medication, POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
was POS N
significantly POS N
reduced POS N
by POS N
12%, POS N
aspartate POS N
aminotransferase POS N
(AST) POS N
by POS N
14%, POS N
alkaline POS N
phosphatase POS N
(ALP) POS N
by POS N
8%, POS N
and POS N
cholesterol POS N
by POS N
6% POS N
only POS N
in POS N
the POS N
khorasan POS N
group POS N
(p POS N
< POS N
0.05 POS N
for POS N
all). POS N

After POS N
the POS N
implementation POS N
of POS N
a POS N
general POS N
linear POS N
model POS N
for POS N
repeated POS N
measurements POS N
adjusted POS N
for POS N
baseline POS N
demographic POS N
details, POS N
risk POS N
factors, POS N
and POS N
medication, POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
was POS N
significantly POS N
reduced POS N
by POS N
12%, POS N
aspartate POS N
aminotransferase POS N
(AST) POS N
by POS N
14%, POS N
alkaline POS N
phosphatase POS N
(ALP) POS N
by POS N
8%, POS N
and POS N
cholesterol POS N
by POS N
6% POS N
only POS N
in POS N
the POS N
khorasan POS N
group POS N
(p POS N
< POS N
0.05 POS N
for POS N
all). POS N

KAMUT POS N
khorasan POS N
is POS N
an POS N
ancient POS N
grain POS N
with POS N
widely POS N
acclaimed POS N
health POS N
benefits. POS N

After POS N
the POS N
implementation POS N
of POS N
a POS N
general POS N
linear POS N
model POS N
for POS N
repeated POS N
measurements POS N
adjusted POS N
for POS N
baseline POS N
demographic POS N
details, POS N
risk POS N
factors, POS N
and POS N
medication, POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
was POS N
significantly POS N
reduced POS N
by POS N
12%, POS N
aspartate POS N
aminotransferase POS N
(AST) POS N
by POS N
14%, POS N
alkaline POS N
phosphatase POS N
(ALP) POS N
by POS N
8%, POS N
and POS N
cholesterol POS N
by POS N
6% POS N
only POS N
in POS N
the POS N
khorasan POS N
group POS N
(p POS N
< POS N
0.05 POS N
for POS N
all). POS N

This POS N
study POS N
suggests POS N
that POS N
a POS N
short-term POS N
replacement POS N
diet POS N
with POS N
ancient POS N
KAMUT POS N
khorasan POS N
products POS N
is POS N
most POS N
effective POS N
in POS N
reducing POS N
metabolic POS N
risk POS N
factors POS N
and POS N
ameliorating POS N
the POS N
liver POS N
profile POS N
in POS N
patients POS N
with POS N
NAFLD. POS N

After POS N
the POS N
implementation POS N
of POS N
a POS N
general POS N
linear POS N
model POS N
for POS N
repeated POS N
measurements POS N
adjusted POS N
for POS N
baseline POS N
demographic POS N
details, POS N
risk POS N
factors, POS N
and POS N
medication, POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
was POS N
significantly POS N
reduced POS N
by POS N
12%, POS N
aspartate POS N
aminotransferase POS N
(AST) POS N
by POS N
14%, POS N
alkaline POS N
phosphatase POS N
(ALP) POS N
by POS N
8%, POS N
and POS N
cholesterol POS N
by POS N
6% POS N
only POS N
in POS N
the POS N
khorasan POS N
group POS N
(p POS N
< POS N
0.05 POS N
for POS N
all). POS N

significant POS N
improvements POS N
in POS N
the POS N
liver POS N
steatosis POS N
grading, POS N
Doppler POS N
perfusion POS N
index POS N
values, POS N
and POS N
reactive POS N
oxygen POS N
species POS N
(ROS) POS N
production POS N
were POS N
evident POS N
after POS N
consumption POS N
of POS N
both POS N
the POS N
khorasan POS N
and POS N
control POS N
products. POS N

After POS N
the POS N
implementation POS N
of POS N
a POS N
general POS N
linear POS N
model POS N
for POS N
repeated POS N
measurements POS N
adjusted POS N
for POS N
baseline POS N
demographic POS N
details, POS N
risk POS N
factors, POS N
and POS N
medication, POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
was POS N
significantly POS N
reduced POS N
by POS N
12%, POS N
aspartate POS N
aminotransferase POS N
(AST) POS N
by POS N
14%, POS N
alkaline POS N
phosphatase POS N
(ALP) POS N
by POS N
8%, POS N
and POS N
cholesterol POS N
by POS N
6% POS N
only POS N
in POS N
the POS N
khorasan POS N
group POS N
(p POS N
< POS N
0.05 POS N
for POS N
all). POS N

significant POS N
reductions POS N
in POS N
circulating POS N
proinflammatory POS N
tumor POS N
necrosis POS N
factor-alpha POS N
by POS N
50%, POS N
interleukin POS N
l-receptor POS N
antagonist-alpha POS N
by POS N
37%, POS N
interleukin-8 POS N
by POS N
24%, POS N
and POS N
interferon POS N
gamma POS N
by POS N
24% POS N
were POS N
evident POS N
only POS N
in POS N
participants POS N
who POS N
consumed POS N
the POS N
khorasan POS N
products POS N
(p POS N
< POS N
0.05 POS N
for POS N
all). POS N

The POS N
results POS N
of POS N
our POS N
study POS N
suggest POS N
that POS N
patients POS N
previously POS N
infected POS N
with POS N
HBV POS N
and POS N
naturally POS N
immune POS N
to POS N
HBV POS N
were POS N
at POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL. POS N

The POS N
results POS N
of POS N
the POS N
multivariable POS N
analysis POS N
showed POS N
that POS N
after POS N
adjustment POS N
for POS N
a POS N
set POS N
of POS N
known POS N
risk POS N
factors, POS N
patients POS N
previously POS N
infected POS N
with POS N
HBV POS N
(HBsAg-seronegative/anti-HBc-seropositive) POS N
and POS N
naturally POS N
immune POS N
to POS N
HBV POS N
(anti-HBs-seropositive/anti-HBc-seropositive) POS N
were POS N
at POS N
significantly POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL POS N
(AOR, POS N
1.497; POS N
95% POS N
CI POS N
1.098-2.042, POS N
P=0.033 POS N
and POS N
AOR, POS N
1.871; POS N
95% POS N
CI POS N
1.302-2.689, POS N
P=0.001, POS N
respectively). POS N

The POS N
results POS N
of POS N
our POS N
study POS N
suggest POS N
that POS N
patients POS N
previously POS N
infected POS N
with POS N
HBV POS N
and POS N
naturally POS N
immune POS N
to POS N
HBV POS N
were POS N
at POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL. POS N

After POS N
adjusting POS N
for POS N
other POS N
factors, POS N
significantly POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL POS N
were POS N
observed POS N
among POS N
cases POS N
who POS N
reported POS N
ever POS N
drinking POS N
alcohol POS N
(AOR, POS N
1.675; POS N
95% POS N
CI POS N
1.054-2.660, POS N
P=0.029). POS N

The POS N
results POS N
of POS N
our POS N
study POS N
suggest POS N
that POS N
patients POS N
previously POS N
infected POS N
with POS N
HBV POS N
and POS N
naturally POS N
immune POS N
to POS N
HBV POS N
were POS N
at POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL. POS N

The POS N
odds POS N
of POS N
ENKTL POS N
diagnosis POS N
were POS N
not POS N
significantly POS N
associated POS N
with POS N
ABO POS N
blood POS N
type, POS N
cigarette POS N
smoking POS N
status POS N
or POS N
family POS N
history POS N
of POS N
cancer. POS N

The POS N
results POS N
of POS N
the POS N
multivariable POS N
analysis POS N
showed POS N
that POS N
after POS N
adjustment POS N
for POS N
a POS N
set POS N
of POS N
known POS N
risk POS N
factors, POS N
patients POS N
previously POS N
infected POS N
with POS N
HBV POS N
(HBsAg-seronegative/anti-HBc-seropositive) POS N
and POS N
naturally POS N
immune POS N
to POS N
HBV POS N
(anti-HBs-seropositive/anti-HBc-seropositive) POS N
were POS N
at POS N
significantly POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL POS N
(AOR, POS N
1.497; POS N
95% POS N
CI POS N
1.098-2.042, POS N
P=0.033 POS N
and POS N
AOR, POS N
1.871; POS N
95% POS N
CI POS N
1.302-2.689, POS N
P=0.001, POS N
respectively). POS N

The POS N
results POS N
of POS N
our POS N
study POS N
suggest POS N
that POS N
patients POS N
previously POS N
infected POS N
with POS N
HBV POS N
and POS N
naturally POS N
immune POS N
to POS N
HBV POS N
were POS N
at POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL. POS N

The POS N
results POS N
of POS N
the POS N
multivariable POS N
analysis POS N
showed POS N
that POS N
after POS N
adjustment POS N
for POS N
a POS N
set POS N
of POS N
known POS N
risk POS N
factors, POS N
patients POS N
previously POS N
infected POS N
with POS N
HBV POS N
(HBsAg-seronegative/anti-HBc-seropositive) POS N
and POS N
naturally POS N
immune POS N
to POS N
HBV POS N
(anti-HBs-seropositive/anti-HBc-seropositive) POS N
were POS N
at POS N
significantly POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL POS N
(AOR, POS N
1.497; POS N
95% POS N
CI POS N
1.098-2.042, POS N
P=0.033 POS N
and POS N
AOR, POS N
1.871; POS N
95% POS N
CI POS N
1.302-2.689, POS N
P=0.001, POS N
respectively). POS N

After POS N
adjusting POS N
for POS N
other POS N
factors, POS N
significantly POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL POS N
were POS N
observed POS N
among POS N
cases POS N
who POS N
reported POS N
ever POS N
drinking POS N
alcohol POS N
(AOR, POS N
1.675; POS N
95% POS N
CI POS N
1.054-2.660, POS N
P=0.029). POS N

The POS N
results POS N
of POS N
the POS N
multivariable POS N
analysis POS N
showed POS N
that POS N
after POS N
adjustment POS N
for POS N
a POS N
set POS N
of POS N
known POS N
risk POS N
factors, POS N
patients POS N
previously POS N
infected POS N
with POS N
HBV POS N
(HBsAg-seronegative/anti-HBc-seropositive) POS N
and POS N
naturally POS N
immune POS N
to POS N
HBV POS N
(anti-HBs-seropositive/anti-HBc-seropositive) POS N
were POS N
at POS N
significantly POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL POS N
(AOR, POS N
1.497; POS N
95% POS N
CI POS N
1.098-2.042, POS N
P=0.033 POS N
and POS N
AOR, POS N
1.871; POS N
95% POS N
CI POS N
1.302-2.689, POS N
P=0.001, POS N
respectively). POS N

The POS N
odds POS N
of POS N
ENKTL POS N
diagnosis POS N
were POS N
not POS N
significantly POS N
associated POS N
with POS N
ABO POS N
blood POS N
type, POS N
cigarette POS N
smoking POS N
status POS N
or POS N
family POS N
history POS N
of POS N
cancer. POS N

After POS N
adjusting POS N
for POS N
other POS N
factors, POS N
significantly POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL POS N
were POS N
observed POS N
among POS N
cases POS N
who POS N
reported POS N
ever POS N
drinking POS N
alcohol POS N
(AOR, POS N
1.675; POS N
95% POS N
CI POS N
1.054-2.660, POS N
P=0.029). POS N

The POS N
results POS N
of POS N
our POS N
study POS N
suggest POS N
that POS N
patients POS N
previously POS N
infected POS N
with POS N
HBV POS N
and POS N
naturally POS N
immune POS N
to POS N
HBV POS N
were POS N
at POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL. POS N

After POS N
adjusting POS N
for POS N
other POS N
factors, POS N
significantly POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL POS N
were POS N
observed POS N
among POS N
cases POS N
who POS N
reported POS N
ever POS N
drinking POS N
alcohol POS N
(AOR, POS N
1.675; POS N
95% POS N
CI POS N
1.054-2.660, POS N
P=0.029). POS N

The POS N
results POS N
of POS N
the POS N
multivariable POS N
analysis POS N
showed POS N
that POS N
after POS N
adjustment POS N
for POS N
a POS N
set POS N
of POS N
known POS N
risk POS N
factors, POS N
patients POS N
previously POS N
infected POS N
with POS N
HBV POS N
(HBsAg-seronegative/anti-HBc-seropositive) POS N
and POS N
naturally POS N
immune POS N
to POS N
HBV POS N
(anti-HBs-seropositive/anti-HBc-seropositive) POS N
were POS N
at POS N
significantly POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL POS N
(AOR, POS N
1.497; POS N
95% POS N
CI POS N
1.098-2.042, POS N
P=0.033 POS N
and POS N
AOR, POS N
1.871; POS N
95% POS N
CI POS N
1.302-2.689, POS N
P=0.001, POS N
respectively). POS N

After POS N
adjusting POS N
for POS N
other POS N
factors, POS N
significantly POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL POS N
were POS N
observed POS N
among POS N
cases POS N
who POS N
reported POS N
ever POS N
drinking POS N
alcohol POS N
(AOR, POS N
1.675; POS N
95% POS N
CI POS N
1.054-2.660, POS N
P=0.029). POS N

The POS N
odds POS N
of POS N
ENKTL POS N
diagnosis POS N
were POS N
not POS N
significantly POS N
associated POS N
with POS N
ABO POS N
blood POS N
type, POS N
cigarette POS N
smoking POS N
status POS N
or POS N
family POS N
history POS N
of POS N
cancer. POS N

The POS N
odds POS N
of POS N
ENKTL POS N
diagnosis POS N
were POS N
not POS N
significantly POS N
associated POS N
with POS N
ABO POS N
blood POS N
type, POS N
cigarette POS N
smoking POS N
status POS N
or POS N
family POS N
history POS N
of POS N
cancer. POS N

The POS N
results POS N
of POS N
our POS N
study POS N
suggest POS N
that POS N
patients POS N
previously POS N
infected POS N
with POS N
HBV POS N
and POS N
naturally POS N
immune POS N
to POS N
HBV POS N
were POS N
at POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL. POS N

The POS N
odds POS N
of POS N
ENKTL POS N
diagnosis POS N
were POS N
not POS N
significantly POS N
associated POS N
with POS N
ABO POS N
blood POS N
type, POS N
cigarette POS N
smoking POS N
status POS N
or POS N
family POS N
history POS N
of POS N
cancer. POS N

The POS N
results POS N
of POS N
the POS N
multivariable POS N
analysis POS N
showed POS N
that POS N
after POS N
adjustment POS N
for POS N
a POS N
set POS N
of POS N
known POS N
risk POS N
factors, POS N
patients POS N
previously POS N
infected POS N
with POS N
HBV POS N
(HBsAg-seronegative/anti-HBc-seropositive) POS N
and POS N
naturally POS N
immune POS N
to POS N
HBV POS N
(anti-HBs-seropositive/anti-HBc-seropositive) POS N
were POS N
at POS N
significantly POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL POS N
(AOR, POS N
1.497; POS N
95% POS N
CI POS N
1.098-2.042, POS N
P=0.033 POS N
and POS N
AOR, POS N
1.871; POS N
95% POS N
CI POS N
1.302-2.689, POS N
P=0.001, POS N
respectively). POS N

The POS N
odds POS N
of POS N
ENKTL POS N
diagnosis POS N
were POS N
not POS N
significantly POS N
associated POS N
with POS N
ABO POS N
blood POS N
type, POS N
cigarette POS N
smoking POS N
status POS N
or POS N
family POS N
history POS N
of POS N
cancer. POS N

After POS N
adjusting POS N
for POS N
other POS N
factors, POS N
significantly POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL POS N
were POS N
observed POS N
among POS N
cases POS N
who POS N
reported POS N
ever POS N
drinking POS N
alcohol POS N
(AOR, POS N
1.675; POS N
95% POS N
CI POS N
1.054-2.660, POS N
P=0.029). POS N

The POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
statistically POS N
significantly POS N
lower POS N
than POS N
the POS N
mean POS N
preoperative POS N
IOP POS N
at POS N
each POS N
follow-up POS N
in POS N
each POS N
group. POS N

At POS N
1 POS N
year, POS N
the POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
significantly POS N
lower POS N
in POS N
group POS N
A. POS N

The POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
statistically POS N
significantly POS N
lower POS N
than POS N
the POS N
mean POS N
preoperative POS N
IOP POS N
at POS N
each POS N
follow-up POS N
in POS N
each POS N
group. POS N

According POS N
to POS N
the POS N
MBGS, POS N
blebs POS N
with POS N
an POS N
ologen POS N
implant POS N
showed POS N
significantly POS N
better POS N
scoring POS N
than POS N
those POS N
with POS N
MMC. POS N

The POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
statistically POS N
significantly POS N
lower POS N
than POS N
the POS N
mean POS N
preoperative POS N
IOP POS N
at POS N
each POS N
follow-up POS N
in POS N
each POS N
group. POS N

AS-OCT POS N
showed POS N
that POS N
ologen-induced POS N
blebs POS N
had POS N
significantly POS N
more POS N
fluid-filled POS N
spaces, POS N
cleavage POS N
planes, POS N
and POS N
less POS N
fibrosis. POS N

The POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
statistically POS N
significantly POS N
lower POS N
than POS N
the POS N
mean POS N
preoperative POS N
IOP POS N
at POS N
each POS N
follow-up POS N
in POS N
each POS N
group. POS N

Ologen POS N
resulted POS N
in POS N
a POS N
lower POS N
long-term POS N
postoperative POS N
IOP, POS N
a POS N
better POS N
bleb POS N
morphology, POS N
and POS N
fewer POS N
complications. POS N

The POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
statistically POS N
significantly POS N
lower POS N
than POS N
the POS N
mean POS N
preoperative POS N
IOP POS N
at POS N
each POS N
follow-up POS N
in POS N
each POS N
group. POS N

Our POS N
results POS N
suggest POS N
that POS N
ologen POS N
may POS N
be POS N
a POS N
useful POS N
alternative POS N
to POS N
MMC POS N
in POS N
JOAG. POS N

At POS N
1 POS N
year, POS N
the POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
significantly POS N
lower POS N
in POS N
group POS N
A. POS N

The POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
statistically POS N
significantly POS N
lower POS N
than POS N
the POS N
mean POS N
preoperative POS N
IOP POS N
at POS N
each POS N
follow-up POS N
in POS N
each POS N
group. POS N

At POS N
1 POS N
year, POS N
the POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
significantly POS N
lower POS N
in POS N
group POS N
A. POS N

According POS N
to POS N
the POS N
MBGS, POS N
blebs POS N
with POS N
an POS N
ologen POS N
implant POS N
showed POS N
significantly POS N
better POS N
scoring POS N
than POS N
those POS N
with POS N
MMC. POS N

At POS N
1 POS N
year, POS N
the POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
significantly POS N
lower POS N
in POS N
group POS N
A. POS N

AS-OCT POS N
showed POS N
that POS N
ologen-induced POS N
blebs POS N
had POS N
significantly POS N
more POS N
fluid-filled POS N
spaces, POS N
cleavage POS N
planes, POS N
and POS N
less POS N
fibrosis. POS N

At POS N
1 POS N
year, POS N
the POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
significantly POS N
lower POS N
in POS N
group POS N
A. POS N

Ologen POS N
resulted POS N
in POS N
a POS N
lower POS N
long-term POS N
postoperative POS N
IOP, POS N
a POS N
better POS N
bleb POS N
morphology, POS N
and POS N
fewer POS N
complications. POS N

At POS N
1 POS N
year, POS N
the POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
significantly POS N
lower POS N
in POS N
group POS N
A. POS N

Our POS N
results POS N
suggest POS N
that POS N
ologen POS N
may POS N
be POS N
a POS N
useful POS N
alternative POS N
to POS N
MMC POS N
in POS N
JOAG. POS N

According POS N
to POS N
the POS N
MBGS, POS N
blebs POS N
with POS N
an POS N
ologen POS N
implant POS N
showed POS N
significantly POS N
better POS N
scoring POS N
than POS N
those POS N
with POS N
MMC. POS N

The POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
statistically POS N
significantly POS N
lower POS N
than POS N
the POS N
mean POS N
preoperative POS N
IOP POS N
at POS N
each POS N
follow-up POS N
in POS N
each POS N
group. POS N

According POS N
to POS N
the POS N
MBGS, POS N
blebs POS N
with POS N
an POS N
ologen POS N
implant POS N
showed POS N
significantly POS N
better POS N
scoring POS N
than POS N
those POS N
with POS N
MMC. POS N

At POS N
1 POS N
year, POS N
the POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
significantly POS N
lower POS N
in POS N
group POS N
A. POS N

According POS N
to POS N
the POS N
MBGS, POS N
blebs POS N
with POS N
an POS N
ologen POS N
implant POS N
showed POS N
significantly POS N
better POS N
scoring POS N
than POS N
those POS N
with POS N
MMC. POS N

AS-OCT POS N
showed POS N
that POS N
ologen-induced POS N
blebs POS N
had POS N
significantly POS N
more POS N
fluid-filled POS N
spaces, POS N
cleavage POS N
planes, POS N
and POS N
less POS N
fibrosis. POS N

According POS N
to POS N
the POS N
MBGS, POS N
blebs POS N
with POS N
an POS N
ologen POS N
implant POS N
showed POS N
significantly POS N
better POS N
scoring POS N
than POS N
those POS N
with POS N
MMC. POS N

Ologen POS N
resulted POS N
in POS N
a POS N
lower POS N
long-term POS N
postoperative POS N
IOP, POS N
a POS N
better POS N
bleb POS N
morphology, POS N
and POS N
fewer POS N
complications. POS N

According POS N
to POS N
the POS N
MBGS, POS N
blebs POS N
with POS N
an POS N
ologen POS N
implant POS N
showed POS N
significantly POS N
better POS N
scoring POS N
than POS N
those POS N
with POS N
MMC. POS N

Our POS N
results POS N
suggest POS N
that POS N
ologen POS N
may POS N
be POS N
a POS N
useful POS N
alternative POS N
to POS N
MMC POS N
in POS N
JOAG. POS N

AS-OCT POS N
showed POS N
that POS N
ologen-induced POS N
blebs POS N
had POS N
significantly POS N
more POS N
fluid-filled POS N
spaces, POS N
cleavage POS N
planes, POS N
and POS N
less POS N
fibrosis. POS N

The POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
statistically POS N
significantly POS N
lower POS N
than POS N
the POS N
mean POS N
preoperative POS N
IOP POS N
at POS N
each POS N
follow-up POS N
in POS N
each POS N
group. POS N

AS-OCT POS N
showed POS N
that POS N
ologen-induced POS N
blebs POS N
had POS N
significantly POS N
more POS N
fluid-filled POS N
spaces, POS N
cleavage POS N
planes, POS N
and POS N
less POS N
fibrosis. POS N

At POS N
1 POS N
year, POS N
the POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
significantly POS N
lower POS N
in POS N
group POS N
A. POS N

AS-OCT POS N
showed POS N
that POS N
ologen-induced POS N
blebs POS N
had POS N
significantly POS N
more POS N
fluid-filled POS N
spaces, POS N
cleavage POS N
planes, POS N
and POS N
less POS N
fibrosis. POS N

According POS N
to POS N
the POS N
MBGS, POS N
blebs POS N
with POS N
an POS N
ologen POS N
implant POS N
showed POS N
significantly POS N
better POS N
scoring POS N
than POS N
those POS N
with POS N
MMC. POS N

AS-OCT POS N
showed POS N
that POS N
ologen-induced POS N
blebs POS N
had POS N
significantly POS N
more POS N
fluid-filled POS N
spaces, POS N
cleavage POS N
planes, POS N
and POS N
less POS N
fibrosis. POS N

Ologen POS N
resulted POS N
in POS N
a POS N
lower POS N
long-term POS N
postoperative POS N
IOP, POS N
a POS N
better POS N
bleb POS N
morphology, POS N
and POS N
fewer POS N
complications. POS N

AS-OCT POS N
showed POS N
that POS N
ologen-induced POS N
blebs POS N
had POS N
significantly POS N
more POS N
fluid-filled POS N
spaces, POS N
cleavage POS N
planes, POS N
and POS N
less POS N
fibrosis. POS N

Our POS N
results POS N
suggest POS N
that POS N
ologen POS N
may POS N
be POS N
a POS N
useful POS N
alternative POS N
to POS N
MMC POS N
in POS N
JOAG. POS N

Ologen POS N
resulted POS N
in POS N
a POS N
lower POS N
long-term POS N
postoperative POS N
IOP, POS N
a POS N
better POS N
bleb POS N
morphology, POS N
and POS N
fewer POS N
complications. POS N

The POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
statistically POS N
significantly POS N
lower POS N
than POS N
the POS N
mean POS N
preoperative POS N
IOP POS N
at POS N
each POS N
follow-up POS N
in POS N
each POS N
group. POS N

Ologen POS N
resulted POS N
in POS N
a POS N
lower POS N
long-term POS N
postoperative POS N
IOP, POS N
a POS N
better POS N
bleb POS N
morphology, POS N
and POS N
fewer POS N
complications. POS N

At POS N
1 POS N
year, POS N
the POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
significantly POS N
lower POS N
in POS N
group POS N
A. POS N

Ologen POS N
resulted POS N
in POS N
a POS N
lower POS N
long-term POS N
postoperative POS N
IOP, POS N
a POS N
better POS N
bleb POS N
morphology, POS N
and POS N
fewer POS N
complications. POS N

According POS N
to POS N
the POS N
MBGS, POS N
blebs POS N
with POS N
an POS N
ologen POS N
implant POS N
showed POS N
significantly POS N
better POS N
scoring POS N
than POS N
those POS N
with POS N
MMC. POS N

Ologen POS N
resulted POS N
in POS N
a POS N
lower POS N
long-term POS N
postoperative POS N
IOP, POS N
a POS N
better POS N
bleb POS N
morphology, POS N
and POS N
fewer POS N
complications. POS N

AS-OCT POS N
showed POS N
that POS N
ologen-induced POS N
blebs POS N
had POS N
significantly POS N
more POS N
fluid-filled POS N
spaces, POS N
cleavage POS N
planes, POS N
and POS N
less POS N
fibrosis. POS N

Ologen POS N
resulted POS N
in POS N
a POS N
lower POS N
long-term POS N
postoperative POS N
IOP, POS N
a POS N
better POS N
bleb POS N
morphology, POS N
and POS N
fewer POS N
complications. POS N

Our POS N
results POS N
suggest POS N
that POS N
ologen POS N
may POS N
be POS N
a POS N
useful POS N
alternative POS N
to POS N
MMC POS N
in POS N
JOAG. POS N

Our POS N
results POS N
suggest POS N
that POS N
ologen POS N
may POS N
be POS N
a POS N
useful POS N
alternative POS N
to POS N
MMC POS N
in POS N
JOAG. POS N

The POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
statistically POS N
significantly POS N
lower POS N
than POS N
the POS N
mean POS N
preoperative POS N
IOP POS N
at POS N
each POS N
follow-up POS N
in POS N
each POS N
group. POS N

Our POS N
results POS N
suggest POS N
that POS N
ologen POS N
may POS N
be POS N
a POS N
useful POS N
alternative POS N
to POS N
MMC POS N
in POS N
JOAG. POS N

At POS N
1 POS N
year, POS N
the POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
significantly POS N
lower POS N
in POS N
group POS N
A. POS N

Our POS N
results POS N
suggest POS N
that POS N
ologen POS N
may POS N
be POS N
a POS N
useful POS N
alternative POS N
to POS N
MMC POS N
in POS N
JOAG. POS N

According POS N
to POS N
the POS N
MBGS, POS N
blebs POS N
with POS N
an POS N
ologen POS N
implant POS N
showed POS N
significantly POS N
better POS N
scoring POS N
than POS N
those POS N
with POS N
MMC. POS N

Our POS N
results POS N
suggest POS N
that POS N
ologen POS N
may POS N
be POS N
a POS N
useful POS N
alternative POS N
to POS N
MMC POS N
in POS N
JOAG. POS N

AS-OCT POS N
showed POS N
that POS N
ologen-induced POS N
blebs POS N
had POS N
significantly POS N
more POS N
fluid-filled POS N
spaces, POS N
cleavage POS N
planes, POS N
and POS N
less POS N
fibrosis. POS N

Our POS N
results POS N
suggest POS N
that POS N
ologen POS N
may POS N
be POS N
a POS N
useful POS N
alternative POS N
to POS N
MMC POS N
in POS N
JOAG. POS N

Ologen POS N
resulted POS N
in POS N
a POS N
lower POS N
long-term POS N
postoperative POS N
IOP, POS N
a POS N
better POS N
bleb POS N
morphology, POS N
and POS N
fewer POS N
complications. POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

In POS N
Group POS N
1 POS N
and POS N
2, POS N
intraocular POS N
pressure POS N
was POS N
well POS N
controlled POS N
to POS N
approximately POS N
14 POS N
mmHg POS N
(9.38-18.46% POS N
decrease). POS N

Generally, POS N
subjective POS N
satisfaction POS N
was POS N
improved POS N
after POS N
changing POS N
from POS N
PT POS N
to POS N
NPT POS N
(p = 0.03) POS N
and POS N
TBUT POS N
using POS N
PT POS N
was POS N
numerically POS N
inferior POS N
to POS N
that POS N
using POS N
NPT POS N
(p = 0.06) POS N
but POS N
not POS N
when POS N
changing POS N
from POS N
NPT POS N
to POS N
PT. POS N

In POS N
Group POS N
1 POS N
and POS N
2, POS N
intraocular POS N
pressure POS N
was POS N
well POS N
controlled POS N
to POS N
approximately POS N
14 POS N
mmHg POS N
(9.38-18.46% POS N
decrease). POS N

Both POS N
preservative POS N
containing POS N
and POS N
preservative-free POS N
0.0015% POS N
tafluprost POS N
reduced POS N
intraocular POS N
pressure POS N
significantly. POS N

In POS N
Group POS N
1 POS N
and POS N
2, POS N
intraocular POS N
pressure POS N
was POS N
well POS N
controlled POS N
to POS N
approximately POS N
14 POS N
mmHg POS N
(9.38-18.46% POS N
decrease). POS N

changing POS N
medication POS N
from POS N
PT POS N
to POS N
NPT POS N
might POS N
improve POS N
subjective POS N
satisfaction POS N
and POS N
tear POS N
break POS N
up POS N
time. POS N

Generally, POS N
subjective POS N
satisfaction POS N
was POS N
improved POS N
after POS N
changing POS N
from POS N
PT POS N
to POS N
NPT POS N
(p = 0.03) POS N
and POS N
TBUT POS N
using POS N
PT POS N
was POS N
numerically POS N
inferior POS N
to POS N
that POS N
using POS N
NPT POS N
(p = 0.06) POS N
but POS N
not POS N
when POS N
changing POS N
from POS N
NPT POS N
to POS N
PT. POS N

In POS N
Group POS N
1 POS N
and POS N
2, POS N
intraocular POS N
pressure POS N
was POS N
well POS N
controlled POS N
to POS N
approximately POS N
14 POS N
mmHg POS N
(9.38-18.46% POS N
decrease). POS N

Generally, POS N
subjective POS N
satisfaction POS N
was POS N
improved POS N
after POS N
changing POS N
from POS N
PT POS N
to POS N
NPT POS N
(p = 0.03) POS N
and POS N
TBUT POS N
using POS N
PT POS N
was POS N
numerically POS N
inferior POS N
to POS N
that POS N
using POS N
NPT POS N
(p = 0.06) POS N
but POS N
not POS N
when POS N
changing POS N
from POS N
NPT POS N
to POS N
PT. POS N

Both POS N
preservative POS N
containing POS N
and POS N
preservative-free POS N
0.0015% POS N
tafluprost POS N
reduced POS N
intraocular POS N
pressure POS N
significantly. POS N

Generally, POS N
subjective POS N
satisfaction POS N
was POS N
improved POS N
after POS N
changing POS N
from POS N
PT POS N
to POS N
NPT POS N
(p = 0.03) POS N
and POS N
TBUT POS N
using POS N
PT POS N
was POS N
numerically POS N
inferior POS N
to POS N
that POS N
using POS N
NPT POS N
(p = 0.06) POS N
but POS N
not POS N
when POS N
changing POS N
from POS N
NPT POS N
to POS N
PT. POS N

changing POS N
medication POS N
from POS N
PT POS N
to POS N
NPT POS N
might POS N
improve POS N
subjective POS N
satisfaction POS N
and POS N
tear POS N
break POS N
up POS N
time. POS N

Both POS N
preservative POS N
containing POS N
and POS N
preservative-free POS N
0.0015% POS N
tafluprost POS N
reduced POS N
intraocular POS N
pressure POS N
significantly. POS N

In POS N
Group POS N
1 POS N
and POS N
2, POS N
intraocular POS N
pressure POS N
was POS N
well POS N
controlled POS N
to POS N
approximately POS N
14 POS N
mmHg POS N
(9.38-18.46% POS N
decrease). POS N

Both POS N
preservative POS N
containing POS N
and POS N
preservative-free POS N
0.0015% POS N
tafluprost POS N
reduced POS N
intraocular POS N
pressure POS N
significantly. POS N

Generally, POS N
subjective POS N
satisfaction POS N
was POS N
improved POS N
after POS N
changing POS N
from POS N
PT POS N
to POS N
NPT POS N
(p = 0.03) POS N
and POS N
TBUT POS N
using POS N
PT POS N
was POS N
numerically POS N
inferior POS N
to POS N
that POS N
using POS N
NPT POS N
(p = 0.06) POS N
but POS N
not POS N
when POS N
changing POS N
from POS N
NPT POS N
to POS N
PT. POS N

Both POS N
preservative POS N
containing POS N
and POS N
preservative-free POS N
0.0015% POS N
tafluprost POS N
reduced POS N
intraocular POS N
pressure POS N
significantly. POS N

changing POS N
medication POS N
from POS N
PT POS N
to POS N
NPT POS N
might POS N
improve POS N
subjective POS N
satisfaction POS N
and POS N
tear POS N
break POS N
up POS N
time. POS N

changing POS N
medication POS N
from POS N
PT POS N
to POS N
NPT POS N
might POS N
improve POS N
subjective POS N
satisfaction POS N
and POS N
tear POS N
break POS N
up POS N
time. POS N

In POS N
Group POS N
1 POS N
and POS N
2, POS N
intraocular POS N
pressure POS N
was POS N
well POS N
controlled POS N
to POS N
approximately POS N
14 POS N
mmHg POS N
(9.38-18.46% POS N
decrease). POS N

changing POS N
medication POS N
from POS N
PT POS N
to POS N
NPT POS N
might POS N
improve POS N
subjective POS N
satisfaction POS N
and POS N
tear POS N
break POS N
up POS N
time. POS N

Generally, POS N
subjective POS N
satisfaction POS N
was POS N
improved POS N
after POS N
changing POS N
from POS N
PT POS N
to POS N
NPT POS N
(p = 0.03) POS N
and POS N
TBUT POS N
using POS N
PT POS N
was POS N
numerically POS N
inferior POS N
to POS N
that POS N
using POS N
NPT POS N
(p = 0.06) POS N
but POS N
not POS N
when POS N
changing POS N
from POS N
NPT POS N
to POS N
PT. POS N

changing POS N
medication POS N
from POS N
PT POS N
to POS N
NPT POS N
might POS N
improve POS N
subjective POS N
satisfaction POS N
and POS N
tear POS N
break POS N
up POS N
time. POS N

Both POS N
preservative POS N
containing POS N
and POS N
preservative-free POS N
0.0015% POS N
tafluprost POS N
reduced POS N
intraocular POS N
pressure POS N
significantly. POS N

There POS N
was POS N
a POS N
significant POS N
difference POS N
in POS N
post-intervention POS N
levels POS N
of POS N
urea, POS N
creatinine, POS N
sodium, POS N
potassium, POS N
calcium, POS N
and POS N
phosphorus POS N
between POS N
the POS N
two POS N
groups. POS N

Appropriate POS N
nutrition POS N
training POS N
via POS N
small-group POS N
method POS N
for POS N
patients POS N
on POS N
hemodialysis POS N
can POS N
impose POS N
positive POS N
effects POS N
on POS N
laboratory POS N
parameters. POS N

Appropriate POS N
nutrition POS N
training POS N
via POS N
small-group POS N
method POS N
for POS N
patients POS N
on POS N
hemodialysis POS N
can POS N
impose POS N
positive POS N
effects POS N
on POS N
laboratory POS N
parameters. POS N

There POS N
was POS N
a POS N
significant POS N
difference POS N
in POS N
post-intervention POS N
levels POS N
of POS N
urea, POS N
creatinine, POS N
sodium, POS N
potassium, POS N
calcium, POS N
and POS N
phosphorus POS N
between POS N
the POS N
two POS N
groups. POS N

In POS N
patients POS N
with POS N
chronic POS N
hepatitis POS N
B, POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
plus POS N
pegylated POS N
interferon POS N
(PEG-IFN) POS N
for POS N
48-weeks POS N
results POS N
in POS N
higher POS N
rates POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
than POS N
either POS N
monotherapy. POS N

Rates POS N
of POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72 POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
TDF/PI-48w POS N
group POS N
(6.5%) POS N
than POS N
in POS N
the POS N
TDF/PI-16w+TDF-32w POS N
(0.5%), POS N
TDF-120w POS N
(0%) POS N
and POS N
PI-48w POS N
(2.2%) POS N
groups POS N
(P POS N
= POS N
0.09). POS N

In POS N
patients POS N
with POS N
chronic POS N
hepatitis POS N
B, POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
plus POS N
pegylated POS N
interferon POS N
(PEG-IFN) POS N
for POS N
48-weeks POS N
results POS N
in POS N
higher POS N
rates POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
than POS N
either POS N
monotherapy. POS N

HBsAg POS N
decline POS N
at POS N
Week POS N
12 POS N
or POS N
24 POS N
of POS N
treatment POS N
was POS N
associated POS N
with POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72 POS N
(P POS N
< POS N
0.001). POS N

In POS N
patients POS N
with POS N
chronic POS N
hepatitis POS N
B, POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
plus POS N
pegylated POS N
interferon POS N
(PEG-IFN) POS N
for POS N
48-weeks POS N
results POS N
in POS N
higher POS N
rates POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
than POS N
either POS N
monotherapy. POS N

HBsAg POS N
decline POS N
>3.5 POS N
log10 POS N
IU/mL POS N
at POS N
Week POS N
24 POS N
in POS N
the POS N
TDF/PI-48w POS N
group POS N
resulted POS N
in POS N
a POS N
positive POS N
predictive POS N
value POS N
of POS N
85% POS N
and POS N
a POS N
negative POS N
predictive POS N
value POS N
of POS N
99% POS N
for POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72. POS N

In POS N
patients POS N
with POS N
chronic POS N
hepatitis POS N
B, POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
plus POS N
pegylated POS N
interferon POS N
(PEG-IFN) POS N
for POS N
48-weeks POS N
results POS N
in POS N
higher POS N
rates POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
than POS N
either POS N
monotherapy. POS N

HBsAg POS N
decline POS N
at POS N
Week POS N
24 POS N
of POS N
TDF POS N
plus POS N
PEG-IFN POS N
combination POS N
therapy POS N
may POS N
identify POS N
patients POS N
who, POS N
after POS N
completing POS N
48 POS N
weeks POS N
of POS N
treatment, POS N
have POS N
a POS N
better POS N
chance POS N
of POS N
achieving POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72. POS N

Rates POS N
of POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72 POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
TDF/PI-48w POS N
group POS N
(6.5%) POS N
than POS N
in POS N
the POS N
TDF/PI-16w+TDF-32w POS N
(0.5%), POS N
TDF-120w POS N
(0%) POS N
and POS N
PI-48w POS N
(2.2%) POS N
groups POS N
(P POS N
= POS N
0.09). POS N

In POS N
patients POS N
with POS N
chronic POS N
hepatitis POS N
B, POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
plus POS N
pegylated POS N
interferon POS N
(PEG-IFN) POS N
for POS N
48-weeks POS N
results POS N
in POS N
higher POS N
rates POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
than POS N
either POS N
monotherapy. POS N

Rates POS N
of POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72 POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
TDF/PI-48w POS N
group POS N
(6.5%) POS N
than POS N
in POS N
the POS N
TDF/PI-16w+TDF-32w POS N
(0.5%), POS N
TDF-120w POS N
(0%) POS N
and POS N
PI-48w POS N
(2.2%) POS N
groups POS N
(P POS N
= POS N
0.09). POS N

HBsAg POS N
decline POS N
at POS N
Week POS N
12 POS N
or POS N
24 POS N
of POS N
treatment POS N
was POS N
associated POS N
with POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72 POS N
(P POS N
< POS N
0.001). POS N

Rates POS N
of POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72 POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
TDF/PI-48w POS N
group POS N
(6.5%) POS N
than POS N
in POS N
the POS N
TDF/PI-16w+TDF-32w POS N
(0.5%), POS N
TDF-120w POS N
(0%) POS N
and POS N
PI-48w POS N
(2.2%) POS N
groups POS N
(P POS N
= POS N
0.09). POS N

HBsAg POS N
decline POS N
>3.5 POS N
log10 POS N
IU/mL POS N
at POS N
Week POS N
24 POS N
in POS N
the POS N
TDF/PI-48w POS N
group POS N
resulted POS N
in POS N
a POS N
positive POS N
predictive POS N
value POS N
of POS N
85% POS N
and POS N
a POS N
negative POS N
predictive POS N
value POS N
of POS N
99% POS N
for POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72. POS N

Rates POS N
of POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72 POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
TDF/PI-48w POS N
group POS N
(6.5%) POS N
than POS N
in POS N
the POS N
TDF/PI-16w+TDF-32w POS N
(0.5%), POS N
TDF-120w POS N
(0%) POS N
and POS N
PI-48w POS N
(2.2%) POS N
groups POS N
(P POS N
= POS N
0.09). POS N

HBsAg POS N
decline POS N
at POS N
Week POS N
24 POS N
of POS N
TDF POS N
plus POS N
PEG-IFN POS N
combination POS N
therapy POS N
may POS N
identify POS N
patients POS N
who, POS N
after POS N
completing POS N
48 POS N
weeks POS N
of POS N
treatment, POS N
have POS N
a POS N
better POS N
chance POS N
of POS N
achieving POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72. POS N

HBsAg POS N
decline POS N
at POS N
Week POS N
12 POS N
or POS N
24 POS N
of POS N
treatment POS N
was POS N
associated POS N
with POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72 POS N
(P POS N
< POS N
0.001). POS N

In POS N
patients POS N
with POS N
chronic POS N
hepatitis POS N
B, POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
plus POS N
pegylated POS N
interferon POS N
(PEG-IFN) POS N
for POS N
48-weeks POS N
results POS N
in POS N
higher POS N
rates POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
than POS N
either POS N
monotherapy. POS N

HBsAg POS N
decline POS N
at POS N
Week POS N
12 POS N
or POS N
24 POS N
of POS N
treatment POS N
was POS N
associated POS N
with POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72 POS N
(P POS N
< POS N
0.001). POS N

Rates POS N
of POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72 POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
TDF/PI-48w POS N
group POS N
(6.5%) POS N
than POS N
in POS N
the POS N
TDF/PI-16w+TDF-32w POS N
(0.5%), POS N
TDF-120w POS N
(0%) POS N
and POS N
PI-48w POS N
(2.2%) POS N
groups POS N
(P POS N
= POS N
0.09). POS N

HBsAg POS N
decline POS N
at POS N
Week POS N
12 POS N
or POS N
24 POS N
of POS N
treatment POS N
was POS N
associated POS N
with POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72 POS N
(P POS N
< POS N
0.001). POS N

HBsAg POS N
decline POS N
>3.5 POS N
log10 POS N
IU/mL POS N
at POS N
Week POS N
24 POS N
in POS N
the POS N
TDF/PI-48w POS N
group POS N
resulted POS N
in POS N
a POS N
positive POS N
predictive POS N
value POS N
of POS N
85% POS N
and POS N
a POS N
negative POS N
predictive POS N
value POS N
of POS N
99% POS N
for POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72. POS N

HBsAg POS N
decline POS N
at POS N
Week POS N
12 POS N
or POS N
24 POS N
of POS N
treatment POS N
was POS N
associated POS N
with POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72 POS N
(P POS N
< POS N
0.001). POS N

HBsAg POS N
decline POS N
at POS N
Week POS N
24 POS N
of POS N
TDF POS N
plus POS N
PEG-IFN POS N
combination POS N
therapy POS N
may POS N
identify POS N
patients POS N
who, POS N
after POS N
completing POS N
48 POS N
weeks POS N
of POS N
treatment, POS N
have POS N
a POS N
better POS N
chance POS N
of POS N
achieving POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72. POS N

HBsAg POS N
decline POS N
>3.5 POS N
log10 POS N
IU/mL POS N
at POS N
Week POS N
24 POS N
in POS N
the POS N
TDF/PI-48w POS N
group POS N
resulted POS N
in POS N
a POS N
positive POS N
predictive POS N
value POS N
of POS N
85% POS N
and POS N
a POS N
negative POS N
predictive POS N
value POS N
of POS N
99% POS N
for POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72. POS N

In POS N
patients POS N
with POS N
chronic POS N
hepatitis POS N
B, POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
plus POS N
pegylated POS N
interferon POS N
(PEG-IFN) POS N
for POS N
48-weeks POS N
results POS N
in POS N
higher POS N
rates POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
than POS N
either POS N
monotherapy. POS N

HBsAg POS N
decline POS N
>3.5 POS N
log10 POS N
IU/mL POS N
at POS N
Week POS N
24 POS N
in POS N
the POS N
TDF/PI-48w POS N
group POS N
resulted POS N
in POS N
a POS N
positive POS N
predictive POS N
value POS N
of POS N
85% POS N
and POS N
a POS N
negative POS N
predictive POS N
value POS N
of POS N
99% POS N
for POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72. POS N

Rates POS N
of POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72 POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
TDF/PI-48w POS N
group POS N
(6.5%) POS N
than POS N
in POS N
the POS N
TDF/PI-16w+TDF-32w POS N
(0.5%), POS N
TDF-120w POS N
(0%) POS N
and POS N
PI-48w POS N
(2.2%) POS N
groups POS N
(P POS N
= POS N
0.09). POS N

HBsAg POS N
decline POS N
>3.5 POS N
log10 POS N
IU/mL POS N
at POS N
Week POS N
24 POS N
in POS N
the POS N
TDF/PI-48w POS N
group POS N
resulted POS N
in POS N
a POS N
positive POS N
predictive POS N
value POS N
of POS N
85% POS N
and POS N
a POS N
negative POS N
predictive POS N
value POS N
of POS N
99% POS N
for POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72. POS N

HBsAg POS N
decline POS N
at POS N
Week POS N
12 POS N
or POS N
24 POS N
of POS N
treatment POS N
was POS N
associated POS N
with POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72 POS N
(P POS N
< POS N
0.001). POS N

HBsAg POS N
decline POS N
>3.5 POS N
log10 POS N
IU/mL POS N
at POS N
Week POS N
24 POS N
in POS N
the POS N
TDF/PI-48w POS N
group POS N
resulted POS N
in POS N
a POS N
positive POS N
predictive POS N
value POS N
of POS N
85% POS N
and POS N
a POS N
negative POS N
predictive POS N
value POS N
of POS N
99% POS N
for POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72. POS N

HBsAg POS N
decline POS N
at POS N
Week POS N
24 POS N
of POS N
TDF POS N
plus POS N
PEG-IFN POS N
combination POS N
therapy POS N
may POS N
identify POS N
patients POS N
who, POS N
after POS N
completing POS N
48 POS N
weeks POS N
of POS N
treatment, POS N
have POS N
a POS N
better POS N
chance POS N
of POS N
achieving POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72. POS N

HBsAg POS N
decline POS N
at POS N
Week POS N
24 POS N
of POS N
TDF POS N
plus POS N
PEG-IFN POS N
combination POS N
therapy POS N
may POS N
identify POS N
patients POS N
who, POS N
after POS N
completing POS N
48 POS N
weeks POS N
of POS N
treatment, POS N
have POS N
a POS N
better POS N
chance POS N
of POS N
achieving POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72. POS N

In POS N
patients POS N
with POS N
chronic POS N
hepatitis POS N
B, POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
plus POS N
pegylated POS N
interferon POS N
(PEG-IFN) POS N
for POS N
48-weeks POS N
results POS N
in POS N
higher POS N
rates POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
than POS N
either POS N
monotherapy. POS N

HBsAg POS N
decline POS N
at POS N
Week POS N
24 POS N
of POS N
TDF POS N
plus POS N
PEG-IFN POS N
combination POS N
therapy POS N
may POS N
identify POS N
patients POS N
who, POS N
after POS N
completing POS N
48 POS N
weeks POS N
of POS N
treatment, POS N
have POS N
a POS N
better POS N
chance POS N
of POS N
achieving POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72. POS N

Rates POS N
of POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72 POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
TDF/PI-48w POS N
group POS N
(6.5%) POS N
than POS N
in POS N
the POS N
TDF/PI-16w+TDF-32w POS N
(0.5%), POS N
TDF-120w POS N
(0%) POS N
and POS N
PI-48w POS N
(2.2%) POS N
groups POS N
(P POS N
= POS N
0.09). POS N

HBsAg POS N
decline POS N
at POS N
Week POS N
24 POS N
of POS N
TDF POS N
plus POS N
PEG-IFN POS N
combination POS N
therapy POS N
may POS N
identify POS N
patients POS N
who, POS N
after POS N
completing POS N
48 POS N
weeks POS N
of POS N
treatment, POS N
have POS N
a POS N
better POS N
chance POS N
of POS N
achieving POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72. POS N

HBsAg POS N
decline POS N
at POS N
Week POS N
12 POS N
or POS N
24 POS N
of POS N
treatment POS N
was POS N
associated POS N
with POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72 POS N
(P POS N
< POS N
0.001). POS N

HBsAg POS N
decline POS N
at POS N
Week POS N
24 POS N
of POS N
TDF POS N
plus POS N
PEG-IFN POS N
combination POS N
therapy POS N
may POS N
identify POS N
patients POS N
who, POS N
after POS N
completing POS N
48 POS N
weeks POS N
of POS N
treatment, POS N
have POS N
a POS N
better POS N
chance POS N
of POS N
achieving POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72. POS N

HBsAg POS N
decline POS N
>3.5 POS N
log10 POS N
IU/mL POS N
at POS N
Week POS N
24 POS N
in POS N
the POS N
TDF/PI-48w POS N
group POS N
resulted POS N
in POS N
a POS N
positive POS N
predictive POS N
value POS N
of POS N
85% POS N
and POS N
a POS N
negative POS N
predictive POS N
value POS N
of POS N
99% POS N
for POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72. POS N

GS-9620 POS N
might POS N
therefore POS N
be POS N
included POS N
in POS N
therapies POS N
to POS N
increase POS N
the POS N
immune POS N
response POS N
to POS N
HBV. POS N

T POS N
cells POS N
collected POS N
at POS N
baseline POS N
before POS N
addition POS N
of POS N
GS-9620, POS N
when POS N
patients POS N
were POS N
receiving POS N
only POS N
nucleos(t)ide POS N
therapy, POS N
had POS N
greater POS N
responses POS N
to POS N
HBV POS N
than POS N
T POS N
cells POS N
from POS N
treatment-naïve POS N
patients, POS N
based POS N
on POS N
cytokine POS N
production POS N
in POS N
response POS N
to POS N
HBV POS N
peptides. POS N

GS-9620 POS N
might POS N
therefore POS N
be POS N
included POS N
in POS N
therapies POS N
to POS N
increase POS N
the POS N
immune POS N
response POS N
to POS N
HBV. POS N

However, POS N
during POS N
or POS N
after POS N
administration POS N
of POS N
GS-9620, POS N
T POS N
cells POS N
produced POS N
higher POS N
levels POS N
of POS N
cytokines POS N
compared POS N
to POS N
baseline. POS N

GS-9620 POS N
might POS N
therefore POS N
be POS N
included POS N
in POS N
therapies POS N
to POS N
increase POS N
the POS N
immune POS N
response POS N
to POS N
HBV. POS N

NK-cell POS N
activation POS N
and POS N
function POS N
increased POS N
after POS N
patients POS N
were POS N
given POS N
GS-9620, POS N
but POS N
the POS N
ability POS N
of POS N
NK POS N
cells POS N
to POS N
suppress POS N
T-cell POS N
responses POS N
was POS N
lower POS N
during POS N
GS-9620 POS N
therapy POS N
than POS N
before. POS N

GS-9620 POS N
might POS N
therefore POS N
be POS N
included POS N
in POS N
therapies POS N
to POS N
increase POS N
the POS N
immune POS N
response POS N
to POS N
HBV. POS N

Changes POS N
in POS N
T-cell POS N
or POS N
NK-cell POS N
function POS N
did POS N
not POS N
correlate POS N
with POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen. POS N

GS-9620 POS N
might POS N
therefore POS N
be POS N
included POS N
in POS N
therapies POS N
to POS N
increase POS N
the POS N
immune POS N
response POS N
to POS N
HBV. POS N

Serum POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
did POS N
not POS N
decrease POS N
significantly POS N
compared POS N
to POS N
baseline POS N
in POS N
patients POS N
given POS N
any POS N
dose POS N
of POS N
GS-9620. POS N

GS-9620 POS N
might POS N
therefore POS N
be POS N
included POS N
in POS N
therapies POS N
to POS N
increase POS N
the POS N
immune POS N
response POS N
to POS N
HBV. POS N

Twelve POS N
weeks POS N
administration POS N
of POS N
GS-9620 POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
serum POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
levels, POS N
but POS N
did POS N
appear POS N
to POS N
increase POS N
T-cell POS N
and POS N
NK-cell POS N
responses POS N
and POS N
reduce POS N
the POS N
ability POS N
of POS N
NK POS N
to POS N
suppress POS N
T POS N
cells. POS N

T POS N
cells POS N
collected POS N
at POS N
baseline POS N
before POS N
addition POS N
of POS N
GS-9620, POS N
when POS N
patients POS N
were POS N
receiving POS N
only POS N
nucleos(t)ide POS N
therapy, POS N
had POS N
greater POS N
responses POS N
to POS N
HBV POS N
than POS N
T POS N
cells POS N
from POS N
treatment-naïve POS N
patients, POS N
based POS N
on POS N
cytokine POS N
production POS N
in POS N
response POS N
to POS N
HBV POS N
peptides. POS N

GS-9620 POS N
might POS N
therefore POS N
be POS N
included POS N
in POS N
therapies POS N
to POS N
increase POS N
the POS N
immune POS N
response POS N
to POS N
HBV. POS N

T POS N
cells POS N
collected POS N
at POS N
baseline POS N
before POS N
addition POS N
of POS N
GS-9620, POS N
when POS N
patients POS N
were POS N
receiving POS N
only POS N
nucleos(t)ide POS N
therapy, POS N
had POS N
greater POS N
responses POS N
to POS N
HBV POS N
than POS N
T POS N
cells POS N
from POS N
treatment-naïve POS N
patients, POS N
based POS N
on POS N
cytokine POS N
production POS N
in POS N
response POS N
to POS N
HBV POS N
peptides. POS N

However, POS N
during POS N
or POS N
after POS N
administration POS N
of POS N
GS-9620, POS N
T POS N
cells POS N
produced POS N
higher POS N
levels POS N
of POS N
cytokines POS N
compared POS N
to POS N
baseline. POS N

T POS N
cells POS N
collected POS N
at POS N
baseline POS N
before POS N
addition POS N
of POS N
GS-9620, POS N
when POS N
patients POS N
were POS N
receiving POS N
only POS N
nucleos(t)ide POS N
therapy, POS N
had POS N
greater POS N
responses POS N
to POS N
HBV POS N
than POS N
T POS N
cells POS N
from POS N
treatment-naïve POS N
patients, POS N
based POS N
on POS N
cytokine POS N
production POS N
in POS N
response POS N
to POS N
HBV POS N
peptides. POS N

NK-cell POS N
activation POS N
and POS N
function POS N
increased POS N
after POS N
patients POS N
were POS N
given POS N
GS-9620, POS N
but POS N
the POS N
ability POS N
of POS N
NK POS N
cells POS N
to POS N
suppress POS N
T-cell POS N
responses POS N
was POS N
lower POS N
during POS N
GS-9620 POS N
therapy POS N
than POS N
before. POS N

T POS N
cells POS N
collected POS N
at POS N
baseline POS N
before POS N
addition POS N
of POS N
GS-9620, POS N
when POS N
patients POS N
were POS N
receiving POS N
only POS N
nucleos(t)ide POS N
therapy, POS N
had POS N
greater POS N
responses POS N
to POS N
HBV POS N
than POS N
T POS N
cells POS N
from POS N
treatment-naïve POS N
patients, POS N
based POS N
on POS N
cytokine POS N
production POS N
in POS N
response POS N
to POS N
HBV POS N
peptides. POS N

Changes POS N
in POS N
T-cell POS N
or POS N
NK-cell POS N
function POS N
did POS N
not POS N
correlate POS N
with POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen. POS N

T POS N
cells POS N
collected POS N
at POS N
baseline POS N
before POS N
addition POS N
of POS N
GS-9620, POS N
when POS N
patients POS N
were POS N
receiving POS N
only POS N
nucleos(t)ide POS N
therapy, POS N
had POS N
greater POS N
responses POS N
to POS N
HBV POS N
than POS N
T POS N
cells POS N
from POS N
treatment-naïve POS N
patients, POS N
based POS N
on POS N
cytokine POS N
production POS N
in POS N
response POS N
to POS N
HBV POS N
peptides. POS N

Serum POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
did POS N
not POS N
decrease POS N
significantly POS N
compared POS N
to POS N
baseline POS N
in POS N
patients POS N
given POS N
any POS N
dose POS N
of POS N
GS-9620. POS N

T POS N
cells POS N
collected POS N
at POS N
baseline POS N
before POS N
addition POS N
of POS N
GS-9620, POS N
when POS N
patients POS N
were POS N
receiving POS N
only POS N
nucleos(t)ide POS N
therapy, POS N
had POS N
greater POS N
responses POS N
to POS N
HBV POS N
than POS N
T POS N
cells POS N
from POS N
treatment-naïve POS N
patients, POS N
based POS N
on POS N
cytokine POS N
production POS N
in POS N
response POS N
to POS N
HBV POS N
peptides. POS N

Twelve POS N
weeks POS N
administration POS N
of POS N
GS-9620 POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
serum POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
levels, POS N
but POS N
did POS N
appear POS N
to POS N
increase POS N
T-cell POS N
and POS N
NK-cell POS N
responses POS N
and POS N
reduce POS N
the POS N
ability POS N
of POS N
NK POS N
to POS N
suppress POS N
T POS N
cells. POS N

However, POS N
during POS N
or POS N
after POS N
administration POS N
of POS N
GS-9620, POS N
T POS N
cells POS N
produced POS N
higher POS N
levels POS N
of POS N
cytokines POS N
compared POS N
to POS N
baseline. POS N

GS-9620 POS N
might POS N
therefore POS N
be POS N
included POS N
in POS N
therapies POS N
to POS N
increase POS N
the POS N
immune POS N
response POS N
to POS N
HBV. POS N

However, POS N
during POS N
or POS N
after POS N
administration POS N
of POS N
GS-9620, POS N
T POS N
cells POS N
produced POS N
higher POS N
levels POS N
of POS N
cytokines POS N
compared POS N
to POS N
baseline. POS N

T POS N
cells POS N
collected POS N
at POS N
baseline POS N
before POS N
addition POS N
of POS N
GS-9620, POS N
when POS N
patients POS N
were POS N
receiving POS N
only POS N
nucleos(t)ide POS N
therapy, POS N
had POS N
greater POS N
responses POS N
to POS N
HBV POS N
than POS N
T POS N
cells POS N
from POS N
treatment-naïve POS N
patients, POS N
based POS N
on POS N
cytokine POS N
production POS N
in POS N
response POS N
to POS N
HBV POS N
peptides. POS N

However, POS N
during POS N
or POS N
after POS N
administration POS N
of POS N
GS-9620, POS N
T POS N
cells POS N
produced POS N
higher POS N
levels POS N
of POS N
cytokines POS N
compared POS N
to POS N
baseline. POS N

NK-cell POS N
activation POS N
and POS N
function POS N
increased POS N
after POS N
patients POS N
were POS N
given POS N
GS-9620, POS N
but POS N
the POS N
ability POS N
of POS N
NK POS N
cells POS N
to POS N
suppress POS N
T-cell POS N
responses POS N
was POS N
lower POS N
during POS N
GS-9620 POS N
therapy POS N
than POS N
before. POS N

However, POS N
during POS N
or POS N
after POS N
administration POS N
of POS N
GS-9620, POS N
T POS N
cells POS N
produced POS N
higher POS N
levels POS N
of POS N
cytokines POS N
compared POS N
to POS N
baseline. POS N

Changes POS N
in POS N
T-cell POS N
or POS N
NK-cell POS N
function POS N
did POS N
not POS N
correlate POS N
with POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen. POS N

However, POS N
during POS N
or POS N
after POS N
administration POS N
of POS N
GS-9620, POS N
T POS N
cells POS N
produced POS N
higher POS N
levels POS N
of POS N
cytokines POS N
compared POS N
to POS N
baseline. POS N

Serum POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
did POS N
not POS N
decrease POS N
significantly POS N
compared POS N
to POS N
baseline POS N
in POS N
patients POS N
given POS N
any POS N
dose POS N
of POS N
GS-9620. POS N

However, POS N
during POS N
or POS N
after POS N
administration POS N
of POS N
GS-9620, POS N
T POS N
cells POS N
produced POS N
higher POS N
levels POS N
of POS N
cytokines POS N
compared POS N
to POS N
baseline. POS N

Twelve POS N
weeks POS N
administration POS N
of POS N
GS-9620 POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
serum POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
levels, POS N
but POS N
did POS N
appear POS N
to POS N
increase POS N
T-cell POS N
and POS N
NK-cell POS N
responses POS N
and POS N
reduce POS N
the POS N
ability POS N
of POS N
NK POS N
to POS N
suppress POS N
T POS N
cells. POS N

NK-cell POS N
activation POS N
and POS N
function POS N
increased POS N
after POS N
patients POS N
were POS N
given POS N
GS-9620, POS N
but POS N
the POS N
ability POS N
of POS N
NK POS N
cells POS N
to POS N
suppress POS N
T-cell POS N
responses POS N
was POS N
lower POS N
during POS N
GS-9620 POS N
therapy POS N
than POS N
before. POS N

GS-9620 POS N
might POS N
therefore POS N
be POS N
included POS N
in POS N
therapies POS N
to POS N
increase POS N
the POS N
immune POS N
response POS N
to POS N
HBV. POS N

NK-cell POS N
activation POS N
and POS N
function POS N
increased POS N
after POS N
patients POS N
were POS N
given POS N
GS-9620, POS N
but POS N
the POS N
ability POS N
of POS N
NK POS N
cells POS N
to POS N
suppress POS N
T-cell POS N
responses POS N
was POS N
lower POS N
during POS N
GS-9620 POS N
therapy POS N
than POS N
before. POS N

T POS N
cells POS N
collected POS N
at POS N
baseline POS N
before POS N
addition POS N
of POS N
GS-9620, POS N
when POS N
patients POS N
were POS N
receiving POS N
only POS N
nucleos(t)ide POS N
therapy, POS N
had POS N
greater POS N
responses POS N
to POS N
HBV POS N
than POS N
T POS N
cells POS N
from POS N
treatment-naïve POS N
patients, POS N
based POS N
on POS N
cytokine POS N
production POS N
in POS N
response POS N
to POS N
HBV POS N
peptides. POS N

NK-cell POS N
activation POS N
and POS N
function POS N
increased POS N
after POS N
patients POS N
were POS N
given POS N
GS-9620, POS N
but POS N
the POS N
ability POS N
of POS N
NK POS N
cells POS N
to POS N
suppress POS N
T-cell POS N
responses POS N
was POS N
lower POS N
during POS N
GS-9620 POS N
therapy POS N
than POS N
before. POS N

However, POS N
during POS N
or POS N
after POS N
administration POS N
of POS N
GS-9620, POS N
T POS N
cells POS N
produced POS N
higher POS N
levels POS N
of POS N
cytokines POS N
compared POS N
to POS N
baseline. POS N

NK-cell POS N
activation POS N
and POS N
function POS N
increased POS N
after POS N
patients POS N
were POS N
given POS N
GS-9620, POS N
but POS N
the POS N
ability POS N
of POS N
NK POS N
cells POS N
to POS N
suppress POS N
T-cell POS N
responses POS N
was POS N
lower POS N
during POS N
GS-9620 POS N
therapy POS N
than POS N
before. POS N

Changes POS N
in POS N
T-cell POS N
or POS N
NK-cell POS N
function POS N
did POS N
not POS N
correlate POS N
with POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen. POS N

NK-cell POS N
activation POS N
and POS N
function POS N
increased POS N
after POS N
patients POS N
were POS N
given POS N
GS-9620, POS N
but POS N
the POS N
ability POS N
of POS N
NK POS N
cells POS N
to POS N
suppress POS N
T-cell POS N
responses POS N
was POS N
lower POS N
during POS N
GS-9620 POS N
therapy POS N
than POS N
before. POS N

Serum POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
did POS N
not POS N
decrease POS N
significantly POS N
compared POS N
to POS N
baseline POS N
in POS N
patients POS N
given POS N
any POS N
dose POS N
of POS N
GS-9620. POS N

NK-cell POS N
activation POS N
and POS N
function POS N
increased POS N
after POS N
patients POS N
were POS N
given POS N
GS-9620, POS N
but POS N
the POS N
ability POS N
of POS N
NK POS N
cells POS N
to POS N
suppress POS N
T-cell POS N
responses POS N
was POS N
lower POS N
during POS N
GS-9620 POS N
therapy POS N
than POS N
before. POS N

Twelve POS N
weeks POS N
administration POS N
of POS N
GS-9620 POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
serum POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
levels, POS N
but POS N
did POS N
appear POS N
to POS N
increase POS N
T-cell POS N
and POS N
NK-cell POS N
responses POS N
and POS N
reduce POS N
the POS N
ability POS N
of POS N
NK POS N
to POS N
suppress POS N
T POS N
cells. POS N

Changes POS N
in POS N
T-cell POS N
or POS N
NK-cell POS N
function POS N
did POS N
not POS N
correlate POS N
with POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen. POS N

GS-9620 POS N
might POS N
therefore POS N
be POS N
included POS N
in POS N
therapies POS N
to POS N
increase POS N
the POS N
immune POS N
response POS N
to POS N
HBV. POS N

Changes POS N
in POS N
T-cell POS N
or POS N
NK-cell POS N
function POS N
did POS N
not POS N
correlate POS N
with POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen. POS N

T POS N
cells POS N
collected POS N
at POS N
baseline POS N
before POS N
addition POS N
of POS N
GS-9620, POS N
when POS N
patients POS N
were POS N
receiving POS N
only POS N
nucleos(t)ide POS N
therapy, POS N
had POS N
greater POS N
responses POS N
to POS N
HBV POS N
than POS N
T POS N
cells POS N
from POS N
treatment-naïve POS N
patients, POS N
based POS N
on POS N
cytokine POS N
production POS N
in POS N
response POS N
to POS N
HBV POS N
peptides. POS N

Changes POS N
in POS N
T-cell POS N
or POS N
NK-cell POS N
function POS N
did POS N
not POS N
correlate POS N
with POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen. POS N

However, POS N
during POS N
or POS N
after POS N
administration POS N
of POS N
GS-9620, POS N
T POS N
cells POS N
produced POS N
higher POS N
levels POS N
of POS N
cytokines POS N
compared POS N
to POS N
baseline. POS N

Changes POS N
in POS N
T-cell POS N
or POS N
NK-cell POS N
function POS N
did POS N
not POS N
correlate POS N
with POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen. POS N

NK-cell POS N
activation POS N
and POS N
function POS N
increased POS N
after POS N
patients POS N
were POS N
given POS N
GS-9620, POS N
but POS N
the POS N
ability POS N
of POS N
NK POS N
cells POS N
to POS N
suppress POS N
T-cell POS N
responses POS N
was POS N
lower POS N
during POS N
GS-9620 POS N
therapy POS N
than POS N
before. POS N

Changes POS N
in POS N
T-cell POS N
or POS N
NK-cell POS N
function POS N
did POS N
not POS N
correlate POS N
with POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen. POS N

Serum POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
did POS N
not POS N
decrease POS N
significantly POS N
compared POS N
to POS N
baseline POS N
in POS N
patients POS N
given POS N
any POS N
dose POS N
of POS N
GS-9620. POS N

Changes POS N
in POS N
T-cell POS N
or POS N
NK-cell POS N
function POS N
did POS N
not POS N
correlate POS N
with POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen. POS N

Twelve POS N
weeks POS N
administration POS N
of POS N
GS-9620 POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
serum POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
levels, POS N
but POS N
did POS N
appear POS N
to POS N
increase POS N
T-cell POS N
and POS N
NK-cell POS N
responses POS N
and POS N
reduce POS N
the POS N
ability POS N
of POS N
NK POS N
to POS N
suppress POS N
T POS N
cells. POS N

Serum POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
did POS N
not POS N
decrease POS N
significantly POS N
compared POS N
to POS N
baseline POS N
in POS N
patients POS N
given POS N
any POS N
dose POS N
of POS N
GS-9620. POS N

GS-9620 POS N
might POS N
therefore POS N
be POS N
included POS N
in POS N
therapies POS N
to POS N
increase POS N
the POS N
immune POS N
response POS N
to POS N
HBV. POS N

Serum POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
did POS N
not POS N
decrease POS N
significantly POS N
compared POS N
to POS N
baseline POS N
in POS N
patients POS N
given POS N
any POS N
dose POS N
of POS N
GS-9620. POS N

T POS N
cells POS N
collected POS N
at POS N
baseline POS N
before POS N
addition POS N
of POS N
GS-9620, POS N
when POS N
patients POS N
were POS N
receiving POS N
only POS N
nucleos(t)ide POS N
therapy, POS N
had POS N
greater POS N
responses POS N
to POS N
HBV POS N
than POS N
T POS N
cells POS N
from POS N
treatment-naïve POS N
patients, POS N
based POS N
on POS N
cytokine POS N
production POS N
in POS N
response POS N
to POS N
HBV POS N
peptides. POS N

Serum POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
did POS N
not POS N
decrease POS N
significantly POS N
compared POS N
to POS N
baseline POS N
in POS N
patients POS N
given POS N
any POS N
dose POS N
of POS N
GS-9620. POS N

However, POS N
during POS N
or POS N
after POS N
administration POS N
of POS N
GS-9620, POS N
T POS N
cells POS N
produced POS N
higher POS N
levels POS N
of POS N
cytokines POS N
compared POS N
to POS N
baseline. POS N

Serum POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
did POS N
not POS N
decrease POS N
significantly POS N
compared POS N
to POS N
baseline POS N
in POS N
patients POS N
given POS N
any POS N
dose POS N
of POS N
GS-9620. POS N

NK-cell POS N
activation POS N
and POS N
function POS N
increased POS N
after POS N
patients POS N
were POS N
given POS N
GS-9620, POS N
but POS N
the POS N
ability POS N
of POS N
NK POS N
cells POS N
to POS N
suppress POS N
T-cell POS N
responses POS N
was POS N
lower POS N
during POS N
GS-9620 POS N
therapy POS N
than POS N
before. POS N

Serum POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
did POS N
not POS N
decrease POS N
significantly POS N
compared POS N
to POS N
baseline POS N
in POS N
patients POS N
given POS N
any POS N
dose POS N
of POS N
GS-9620. POS N

Changes POS N
in POS N
T-cell POS N
or POS N
NK-cell POS N
function POS N
did POS N
not POS N
correlate POS N
with POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen. POS N

Serum POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
did POS N
not POS N
decrease POS N
significantly POS N
compared POS N
to POS N
baseline POS N
in POS N
patients POS N
given POS N
any POS N
dose POS N
of POS N
GS-9620. POS N

Twelve POS N
weeks POS N
administration POS N
of POS N
GS-9620 POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
serum POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
levels, POS N
but POS N
did POS N
appear POS N
to POS N
increase POS N
T-cell POS N
and POS N
NK-cell POS N
responses POS N
and POS N
reduce POS N
the POS N
ability POS N
of POS N
NK POS N
to POS N
suppress POS N
T POS N
cells. POS N

Twelve POS N
weeks POS N
administration POS N
of POS N
GS-9620 POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
serum POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
levels, POS N
but POS N
did POS N
appear POS N
to POS N
increase POS N
T-cell POS N
and POS N
NK-cell POS N
responses POS N
and POS N
reduce POS N
the POS N
ability POS N
of POS N
NK POS N
to POS N
suppress POS N
T POS N
cells. POS N

GS-9620 POS N
might POS N
therefore POS N
be POS N
included POS N
in POS N
therapies POS N
to POS N
increase POS N
the POS N
immune POS N
response POS N
to POS N
HBV. POS N

Twelve POS N
weeks POS N
administration POS N
of POS N
GS-9620 POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
serum POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
levels, POS N
but POS N
did POS N
appear POS N
to POS N
increase POS N
T-cell POS N
and POS N
NK-cell POS N
responses POS N
and POS N
reduce POS N
the POS N
ability POS N
of POS N
NK POS N
to POS N
suppress POS N
T POS N
cells. POS N

T POS N
cells POS N
collected POS N
at POS N
baseline POS N
before POS N
addition POS N
of POS N
GS-9620, POS N
when POS N
patients POS N
were POS N
receiving POS N
only POS N
nucleos(t)ide POS N
therapy, POS N
had POS N
greater POS N
responses POS N
to POS N
HBV POS N
than POS N
T POS N
cells POS N
from POS N
treatment-naïve POS N
patients, POS N
based POS N
on POS N
cytokine POS N
production POS N
in POS N
response POS N
to POS N
HBV POS N
peptides. POS N

Twelve POS N
weeks POS N
administration POS N
of POS N
GS-9620 POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
serum POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
levels, POS N
but POS N
did POS N
appear POS N
to POS N
increase POS N
T-cell POS N
and POS N
NK-cell POS N
responses POS N
and POS N
reduce POS N
the POS N
ability POS N
of POS N
NK POS N
to POS N
suppress POS N
T POS N
cells. POS N

However, POS N
during POS N
or POS N
after POS N
administration POS N
of POS N
GS-9620, POS N
T POS N
cells POS N
produced POS N
higher POS N
levels POS N
of POS N
cytokines POS N
compared POS N
to POS N
baseline. POS N

Twelve POS N
weeks POS N
administration POS N
of POS N
GS-9620 POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
serum POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
levels, POS N
but POS N
did POS N
appear POS N
to POS N
increase POS N
T-cell POS N
and POS N
NK-cell POS N
responses POS N
and POS N
reduce POS N
the POS N
ability POS N
of POS N
NK POS N
to POS N
suppress POS N
T POS N
cells. POS N

NK-cell POS N
activation POS N
and POS N
function POS N
increased POS N
after POS N
patients POS N
were POS N
given POS N
GS-9620, POS N
but POS N
the POS N
ability POS N
of POS N
NK POS N
cells POS N
to POS N
suppress POS N
T-cell POS N
responses POS N
was POS N
lower POS N
during POS N
GS-9620 POS N
therapy POS N
than POS N
before. POS N

Twelve POS N
weeks POS N
administration POS N
of POS N
GS-9620 POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
serum POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
levels, POS N
but POS N
did POS N
appear POS N
to POS N
increase POS N
T-cell POS N
and POS N
NK-cell POS N
responses POS N
and POS N
reduce POS N
the POS N
ability POS N
of POS N
NK POS N
to POS N
suppress POS N
T POS N
cells. POS N

Changes POS N
in POS N
T-cell POS N
or POS N
NK-cell POS N
function POS N
did POS N
not POS N
correlate POS N
with POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen. POS N

Twelve POS N
weeks POS N
administration POS N
of POS N
GS-9620 POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
serum POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
levels, POS N
but POS N
did POS N
appear POS N
to POS N
increase POS N
T-cell POS N
and POS N
NK-cell POS N
responses POS N
and POS N
reduce POS N
the POS N
ability POS N
of POS N
NK POS N
to POS N
suppress POS N
T POS N
cells. POS N

Serum POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
did POS N
not POS N
decrease POS N
significantly POS N
compared POS N
to POS N
baseline POS N
in POS N
patients POS N
given POS N
any POS N
dose POS N
of POS N
GS-9620. POS N

Both POS N
patients POS N
with POS N
objective POS N
response POS N
and POS N
disease POS N
stabilisation POS N
had POS N
clearly POS N
better POS N
symptom POS N
control POS N
than POS N
those POS N
with POS N
disease POS N
progression. POS N

Symptom POS N
control POS N
in POS N
both POS N
arms POS N
was POS N
similar POS N
for POS N
'disease-specific' POS N
symptoms POS N
such POS N
as POS N
cough, POS N
dyspnea, POS N
pain POS N
or POS N
haemoptysis. POS N

Both POS N
patients POS N
with POS N
objective POS N
response POS N
and POS N
disease POS N
stabilisation POS N
had POS N
clearly POS N
better POS N
symptom POS N
control POS N
than POS N
those POS N
with POS N
disease POS N
progression. POS N

Compared POS N
to POS N
PV, POS N
a POS N
significantly POS N
larger POS N
number POS N
of POS N
GEM-patients POS N
had POS N
better POS N
scores POS N
for POS N
'constitutional' POS N
items POS N
such POS N
as POS N
anorexia POS N
(P=0.007), POS N
ability POS N
to POS N
carry POS N
on POS N
with POS N
daily POS N
activities POS N
(P=0.04) POS N
and POS N
overall POS N
impression POS N
of POS N
quality-of-life POS N
(P=0.008). POS N

Both POS N
patients POS N
with POS N
objective POS N
response POS N
and POS N
disease POS N
stabilisation POS N
had POS N
clearly POS N
better POS N
symptom POS N
control POS N
than POS N
those POS N
with POS N
disease POS N
progression. POS N

Symptom POS N
control POS N
was POS N
very POS N
similar POS N
in POS N
younger POS N
(<65 POS N
years) POS N
versus POS N
older POS N
(>/=65 POS N
years) POS N
patients, POS N
and POS N
only POS N
slightly POS N
better POS N
in POS N
those POS N
with POS N
a POS N
Karnofsky POS N
PS POS N
>/=80% POS N
compared POS N
to POS N
those POS N
<80%. POS N

Both POS N
patients POS N
with POS N
objective POS N
response POS N
and POS N
disease POS N
stabilisation POS N
had POS N
clearly POS N
better POS N
symptom POS N
control POS N
than POS N
those POS N
with POS N
disease POS N
progression. POS N

Most POS N
of POS N
the POS N
symptom POS N
improvement POS N
occurred POS N
in POS N
the POS N
first POS N
3 POS N
cycles, POS N
with POS N
some POS N
further POS N
symptom POS N
improvement POS N
in POS N
the POS N
following POS N
cycles POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Both POS N
patients POS N
with POS N
objective POS N
response POS N
and POS N
disease POS N
stabilisation POS N
had POS N
clearly POS N
better POS N
symptom POS N
control POS N
than POS N
those POS N
with POS N
disease POS N
progression. POS N

Both POS N
GEM POS N
and POS N
PV POS N
yield POS N
a POS N
symptom POS N
control POS N
rate POS N
much POS N
higher POS N
than POS N
expected POS N
by POS N
the POS N
objective POS N
tumour POS N
RR. POS N

Both POS N
patients POS N
with POS N
objective POS N
response POS N
and POS N
disease POS N
stabilisation POS N
had POS N
clearly POS N
better POS N
symptom POS N
control POS N
than POS N
those POS N
with POS N
disease POS N
progression. POS N

GEM POS N
is POS N
equally POS N
effective POS N
in POS N
controlling POS N
'disease-specific' POS N
symptoms, POS N
but POS N
superior POS N
in POS N
controlling POS N
'constitutional' POS N
symptoms. POS N

Both POS N
patients POS N
with POS N
objective POS N
response POS N
and POS N
disease POS N
stabilisation POS N
had POS N
clearly POS N
better POS N
symptom POS N
control POS N
than POS N
those POS N
with POS N
disease POS N
progression. POS N

Most POS N
of POS N
the POS N
symptom POS N
control POS N
was POS N
achieved POS N
during POS N
the POS N
first POS N
3 POS N
cycles POS N
of POS N
treatment, POS N
with POS N
some POS N
further POS N
improvement POS N
thereafter POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Symptom POS N
control POS N
in POS N
both POS N
arms POS N
was POS N
similar POS N
for POS N
'disease-specific' POS N
symptoms POS N
such POS N
as POS N
cough, POS N
dyspnea, POS N
pain POS N
or POS N
haemoptysis. POS N

Both POS N
patients POS N
with POS N
objective POS N
response POS N
and POS N
disease POS N
stabilisation POS N
had POS N
clearly POS N
better POS N
symptom POS N
control POS N
than POS N
those POS N
with POS N
disease POS N
progression. POS N

Symptom POS N
control POS N
in POS N
both POS N
arms POS N
was POS N
similar POS N
for POS N
'disease-specific' POS N
symptoms POS N
such POS N
as POS N
cough, POS N
dyspnea, POS N
pain POS N
or POS N
haemoptysis. POS N

Compared POS N
to POS N
PV, POS N
a POS N
significantly POS N
larger POS N
number POS N
of POS N
GEM-patients POS N
had POS N
better POS N
scores POS N
for POS N
'constitutional' POS N
items POS N
such POS N
as POS N
anorexia POS N
(P=0.007), POS N
ability POS N
to POS N
carry POS N
on POS N
with POS N
daily POS N
activities POS N
(P=0.04) POS N
and POS N
overall POS N
impression POS N
of POS N
quality-of-life POS N
(P=0.008). POS N

Symptom POS N
control POS N
in POS N
both POS N
arms POS N
was POS N
similar POS N
for POS N
'disease-specific' POS N
symptoms POS N
such POS N
as POS N
cough, POS N
dyspnea, POS N
pain POS N
or POS N
haemoptysis. POS N

Symptom POS N
control POS N
was POS N
very POS N
similar POS N
in POS N
younger POS N
(<65 POS N
years) POS N
versus POS N
older POS N
(>/=65 POS N
years) POS N
patients, POS N
and POS N
only POS N
slightly POS N
better POS N
in POS N
those POS N
with POS N
a POS N
Karnofsky POS N
PS POS N
>/=80% POS N
compared POS N
to POS N
those POS N
<80%. POS N

Symptom POS N
control POS N
in POS N
both POS N
arms POS N
was POS N
similar POS N
for POS N
'disease-specific' POS N
symptoms POS N
such POS N
as POS N
cough, POS N
dyspnea, POS N
pain POS N
or POS N
haemoptysis. POS N

Most POS N
of POS N
the POS N
symptom POS N
improvement POS N
occurred POS N
in POS N
the POS N
first POS N
3 POS N
cycles, POS N
with POS N
some POS N
further POS N
symptom POS N
improvement POS N
in POS N
the POS N
following POS N
cycles POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Symptom POS N
control POS N
in POS N
both POS N
arms POS N
was POS N
similar POS N
for POS N
'disease-specific' POS N
symptoms POS N
such POS N
as POS N
cough, POS N
dyspnea, POS N
pain POS N
or POS N
haemoptysis. POS N

Both POS N
GEM POS N
and POS N
PV POS N
yield POS N
a POS N
symptom POS N
control POS N
rate POS N
much POS N
higher POS N
than POS N
expected POS N
by POS N
the POS N
objective POS N
tumour POS N
RR. POS N

Symptom POS N
control POS N
in POS N
both POS N
arms POS N
was POS N
similar POS N
for POS N
'disease-specific' POS N
symptoms POS N
such POS N
as POS N
cough, POS N
dyspnea, POS N
pain POS N
or POS N
haemoptysis. POS N

GEM POS N
is POS N
equally POS N
effective POS N
in POS N
controlling POS N
'disease-specific' POS N
symptoms, POS N
but POS N
superior POS N
in POS N
controlling POS N
'constitutional' POS N
symptoms. POS N

Symptom POS N
control POS N
in POS N
both POS N
arms POS N
was POS N
similar POS N
for POS N
'disease-specific' POS N
symptoms POS N
such POS N
as POS N
cough, POS N
dyspnea, POS N
pain POS N
or POS N
haemoptysis. POS N

Most POS N
of POS N
the POS N
symptom POS N
control POS N
was POS N
achieved POS N
during POS N
the POS N
first POS N
3 POS N
cycles POS N
of POS N
treatment, POS N
with POS N
some POS N
further POS N
improvement POS N
thereafter POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Compared POS N
to POS N
PV, POS N
a POS N
significantly POS N
larger POS N
number POS N
of POS N
GEM-patients POS N
had POS N
better POS N
scores POS N
for POS N
'constitutional' POS N
items POS N
such POS N
as POS N
anorexia POS N
(P=0.007), POS N
ability POS N
to POS N
carry POS N
on POS N
with POS N
daily POS N
activities POS N
(P=0.04) POS N
and POS N
overall POS N
impression POS N
of POS N
quality-of-life POS N
(P=0.008). POS N

Both POS N
patients POS N
with POS N
objective POS N
response POS N
and POS N
disease POS N
stabilisation POS N
had POS N
clearly POS N
better POS N
symptom POS N
control POS N
than POS N
those POS N
with POS N
disease POS N
progression. POS N

Compared POS N
to POS N
PV, POS N
a POS N
significantly POS N
larger POS N
number POS N
of POS N
GEM-patients POS N
had POS N
better POS N
scores POS N
for POS N
'constitutional' POS N
items POS N
such POS N
as POS N
anorexia POS N
(P=0.007), POS N
ability POS N
to POS N
carry POS N
on POS N
with POS N
daily POS N
activities POS N
(P=0.04) POS N
and POS N
overall POS N
impression POS N
of POS N
quality-of-life POS N
(P=0.008). POS N

Symptom POS N
control POS N
in POS N
both POS N
arms POS N
was POS N
similar POS N
for POS N
'disease-specific' POS N
symptoms POS N
such POS N
as POS N
cough, POS N
dyspnea, POS N
pain POS N
or POS N
haemoptysis. POS N

Compared POS N
to POS N
PV, POS N
a POS N
significantly POS N
larger POS N
number POS N
of POS N
GEM-patients POS N
had POS N
better POS N
scores POS N
for POS N
'constitutional' POS N
items POS N
such POS N
as POS N
anorexia POS N
(P=0.007), POS N
ability POS N
to POS N
carry POS N
on POS N
with POS N
daily POS N
activities POS N
(P=0.04) POS N
and POS N
overall POS N
impression POS N
of POS N
quality-of-life POS N
(P=0.008). POS N

Symptom POS N
control POS N
was POS N
very POS N
similar POS N
in POS N
younger POS N
(<65 POS N
years) POS N
versus POS N
older POS N
(>/=65 POS N
years) POS N
patients, POS N
and POS N
only POS N
slightly POS N
better POS N
in POS N
those POS N
with POS N
a POS N
Karnofsky POS N
PS POS N
>/=80% POS N
compared POS N
to POS N
those POS N
<80%. POS N

Compared POS N
to POS N
PV, POS N
a POS N
significantly POS N
larger POS N
number POS N
of POS N
GEM-patients POS N
had POS N
better POS N
scores POS N
for POS N
'constitutional' POS N
items POS N
such POS N
as POS N
anorexia POS N
(P=0.007), POS N
ability POS N
to POS N
carry POS N
on POS N
with POS N
daily POS N
activities POS N
(P=0.04) POS N
and POS N
overall POS N
impression POS N
of POS N
quality-of-life POS N
(P=0.008). POS N

Most POS N
of POS N
the POS N
symptom POS N
improvement POS N
occurred POS N
in POS N
the POS N
first POS N
3 POS N
cycles, POS N
with POS N
some POS N
further POS N
symptom POS N
improvement POS N
in POS N
the POS N
following POS N
cycles POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Compared POS N
to POS N
PV, POS N
a POS N
significantly POS N
larger POS N
number POS N
of POS N
GEM-patients POS N
had POS N
better POS N
scores POS N
for POS N
'constitutional' POS N
items POS N
such POS N
as POS N
anorexia POS N
(P=0.007), POS N
ability POS N
to POS N
carry POS N
on POS N
with POS N
daily POS N
activities POS N
(P=0.04) POS N
and POS N
overall POS N
impression POS N
of POS N
quality-of-life POS N
(P=0.008). POS N

Both POS N
GEM POS N
and POS N
PV POS N
yield POS N
a POS N
symptom POS N
control POS N
rate POS N
much POS N
higher POS N
than POS N
expected POS N
by POS N
the POS N
objective POS N
tumour POS N
RR. POS N

Compared POS N
to POS N
PV, POS N
a POS N
significantly POS N
larger POS N
number POS N
of POS N
GEM-patients POS N
had POS N
better POS N
scores POS N
for POS N
'constitutional' POS N
items POS N
such POS N
as POS N
anorexia POS N
(P=0.007), POS N
ability POS N
to POS N
carry POS N
on POS N
with POS N
daily POS N
activities POS N
(P=0.04) POS N
and POS N
overall POS N
impression POS N
of POS N
quality-of-life POS N
(P=0.008). POS N

GEM POS N
is POS N
equally POS N
effective POS N
in POS N
controlling POS N
'disease-specific' POS N
symptoms, POS N
but POS N
superior POS N
in POS N
controlling POS N
'constitutional' POS N
symptoms. POS N

Compared POS N
to POS N
PV, POS N
a POS N
significantly POS N
larger POS N
number POS N
of POS N
GEM-patients POS N
had POS N
better POS N
scores POS N
for POS N
'constitutional' POS N
items POS N
such POS N
as POS N
anorexia POS N
(P=0.007), POS N
ability POS N
to POS N
carry POS N
on POS N
with POS N
daily POS N
activities POS N
(P=0.04) POS N
and POS N
overall POS N
impression POS N
of POS N
quality-of-life POS N
(P=0.008). POS N

Most POS N
of POS N
the POS N
symptom POS N
control POS N
was POS N
achieved POS N
during POS N
the POS N
first POS N
3 POS N
cycles POS N
of POS N
treatment, POS N
with POS N
some POS N
further POS N
improvement POS N
thereafter POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Symptom POS N
control POS N
was POS N
very POS N
similar POS N
in POS N
younger POS N
(<65 POS N
years) POS N
versus POS N
older POS N
(>/=65 POS N
years) POS N
patients, POS N
and POS N
only POS N
slightly POS N
better POS N
in POS N
those POS N
with POS N
a POS N
Karnofsky POS N
PS POS N
>/=80% POS N
compared POS N
to POS N
those POS N
<80%. POS N

Both POS N
patients POS N
with POS N
objective POS N
response POS N
and POS N
disease POS N
stabilisation POS N
had POS N
clearly POS N
better POS N
symptom POS N
control POS N
than POS N
those POS N
with POS N
disease POS N
progression. POS N

Symptom POS N
control POS N
was POS N
very POS N
similar POS N
in POS N
younger POS N
(<65 POS N
years) POS N
versus POS N
older POS N
(>/=65 POS N
years) POS N
patients, POS N
and POS N
only POS N
slightly POS N
better POS N
in POS N
those POS N
with POS N
a POS N
Karnofsky POS N
PS POS N
>/=80% POS N
compared POS N
to POS N
those POS N
<80%. POS N

Symptom POS N
control POS N
in POS N
both POS N
arms POS N
was POS N
similar POS N
for POS N
'disease-specific' POS N
symptoms POS N
such POS N
as POS N
cough, POS N
dyspnea, POS N
pain POS N
or POS N
haemoptysis. POS N

Symptom POS N
control POS N
was POS N
very POS N
similar POS N
in POS N
younger POS N
(<65 POS N
years) POS N
versus POS N
older POS N
(>/=65 POS N
years) POS N
patients, POS N
and POS N
only POS N
slightly POS N
better POS N
in POS N
those POS N
with POS N
a POS N
Karnofsky POS N
PS POS N
>/=80% POS N
compared POS N
to POS N
those POS N
<80%. POS N

Compared POS N
to POS N
PV, POS N
a POS N
significantly POS N
larger POS N
number POS N
of POS N
GEM-patients POS N
had POS N
better POS N
scores POS N
for POS N
'constitutional' POS N
items POS N
such POS N
as POS N
anorexia POS N
(P=0.007), POS N
ability POS N
to POS N
carry POS N
on POS N
with POS N
daily POS N
activities POS N
(P=0.04) POS N
and POS N
overall POS N
impression POS N
of POS N
quality-of-life POS N
(P=0.008). POS N

Symptom POS N
control POS N
was POS N
very POS N
similar POS N
in POS N
younger POS N
(<65 POS N
years) POS N
versus POS N
older POS N
(>/=65 POS N
years) POS N
patients, POS N
and POS N
only POS N
slightly POS N
better POS N
in POS N
those POS N
with POS N
a POS N
Karnofsky POS N
PS POS N
>/=80% POS N
compared POS N
to POS N
those POS N
<80%. POS N

Most POS N
of POS N
the POS N
symptom POS N
improvement POS N
occurred POS N
in POS N
the POS N
first POS N
3 POS N
cycles, POS N
with POS N
some POS N
further POS N
symptom POS N
improvement POS N
in POS N
the POS N
following POS N
cycles POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Symptom POS N
control POS N
was POS N
very POS N
similar POS N
in POS N
younger POS N
(<65 POS N
years) POS N
versus POS N
older POS N
(>/=65 POS N
years) POS N
patients, POS N
and POS N
only POS N
slightly POS N
better POS N
in POS N
those POS N
with POS N
a POS N
Karnofsky POS N
PS POS N
>/=80% POS N
compared POS N
to POS N
those POS N
<80%. POS N

Both POS N
GEM POS N
and POS N
PV POS N
yield POS N
a POS N
symptom POS N
control POS N
rate POS N
much POS N
higher POS N
than POS N
expected POS N
by POS N
the POS N
objective POS N
tumour POS N
RR. POS N

Symptom POS N
control POS N
was POS N
very POS N
similar POS N
in POS N
younger POS N
(<65 POS N
years) POS N
versus POS N
older POS N
(>/=65 POS N
years) POS N
patients, POS N
and POS N
only POS N
slightly POS N
better POS N
in POS N
those POS N
with POS N
a POS N
Karnofsky POS N
PS POS N
>/=80% POS N
compared POS N
to POS N
those POS N
<80%. POS N

GEM POS N
is POS N
equally POS N
effective POS N
in POS N
controlling POS N
'disease-specific' POS N
symptoms, POS N
but POS N
superior POS N
in POS N
controlling POS N
'constitutional' POS N
symptoms. POS N

Symptom POS N
control POS N
was POS N
very POS N
similar POS N
in POS N
younger POS N
(<65 POS N
years) POS N
versus POS N
older POS N
(>/=65 POS N
years) POS N
patients, POS N
and POS N
only POS N
slightly POS N
better POS N
in POS N
those POS N
with POS N
a POS N
Karnofsky POS N
PS POS N
>/=80% POS N
compared POS N
to POS N
those POS N
<80%. POS N

Most POS N
of POS N
the POS N
symptom POS N
control POS N
was POS N
achieved POS N
during POS N
the POS N
first POS N
3 POS N
cycles POS N
of POS N
treatment, POS N
with POS N
some POS N
further POS N
improvement POS N
thereafter POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Most POS N
of POS N
the POS N
symptom POS N
improvement POS N
occurred POS N
in POS N
the POS N
first POS N
3 POS N
cycles, POS N
with POS N
some POS N
further POS N
symptom POS N
improvement POS N
in POS N
the POS N
following POS N
cycles POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Both POS N
patients POS N
with POS N
objective POS N
response POS N
and POS N
disease POS N
stabilisation POS N
had POS N
clearly POS N
better POS N
symptom POS N
control POS N
than POS N
those POS N
with POS N
disease POS N
progression. POS N

Most POS N
of POS N
the POS N
symptom POS N
improvement POS N
occurred POS N
in POS N
the POS N
first POS N
3 POS N
cycles, POS N
with POS N
some POS N
further POS N
symptom POS N
improvement POS N
in POS N
the POS N
following POS N
cycles POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Symptom POS N
control POS N
in POS N
both POS N
arms POS N
was POS N
similar POS N
for POS N
'disease-specific' POS N
symptoms POS N
such POS N
as POS N
cough, POS N
dyspnea, POS N
pain POS N
or POS N
haemoptysis. POS N

Most POS N
of POS N
the POS N
symptom POS N
improvement POS N
occurred POS N
in POS N
the POS N
first POS N
3 POS N
cycles, POS N
with POS N
some POS N
further POS N
symptom POS N
improvement POS N
in POS N
the POS N
following POS N
cycles POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Compared POS N
to POS N
PV, POS N
a POS N
significantly POS N
larger POS N
number POS N
of POS N
GEM-patients POS N
had POS N
better POS N
scores POS N
for POS N
'constitutional' POS N
items POS N
such POS N
as POS N
anorexia POS N
(P=0.007), POS N
ability POS N
to POS N
carry POS N
on POS N
with POS N
daily POS N
activities POS N
(P=0.04) POS N
and POS N
overall POS N
impression POS N
of POS N
quality-of-life POS N
(P=0.008). POS N

Most POS N
of POS N
the POS N
symptom POS N
improvement POS N
occurred POS N
in POS N
the POS N
first POS N
3 POS N
cycles, POS N
with POS N
some POS N
further POS N
symptom POS N
improvement POS N
in POS N
the POS N
following POS N
cycles POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Symptom POS N
control POS N
was POS N
very POS N
similar POS N
in POS N
younger POS N
(<65 POS N
years) POS N
versus POS N
older POS N
(>/=65 POS N
years) POS N
patients, POS N
and POS N
only POS N
slightly POS N
better POS N
in POS N
those POS N
with POS N
a POS N
Karnofsky POS N
PS POS N
>/=80% POS N
compared POS N
to POS N
those POS N
<80%. POS N

Most POS N
of POS N
the POS N
symptom POS N
improvement POS N
occurred POS N
in POS N
the POS N
first POS N
3 POS N
cycles, POS N
with POS N
some POS N
further POS N
symptom POS N
improvement POS N
in POS N
the POS N
following POS N
cycles POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Both POS N
GEM POS N
and POS N
PV POS N
yield POS N
a POS N
symptom POS N
control POS N
rate POS N
much POS N
higher POS N
than POS N
expected POS N
by POS N
the POS N
objective POS N
tumour POS N
RR. POS N

Most POS N
of POS N
the POS N
symptom POS N
improvement POS N
occurred POS N
in POS N
the POS N
first POS N
3 POS N
cycles, POS N
with POS N
some POS N
further POS N
symptom POS N
improvement POS N
in POS N
the POS N
following POS N
cycles POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

GEM POS N
is POS N
equally POS N
effective POS N
in POS N
controlling POS N
'disease-specific' POS N
symptoms, POS N
but POS N
superior POS N
in POS N
controlling POS N
'constitutional' POS N
symptoms. POS N

Most POS N
of POS N
the POS N
symptom POS N
improvement POS N
occurred POS N
in POS N
the POS N
first POS N
3 POS N
cycles, POS N
with POS N
some POS N
further POS N
symptom POS N
improvement POS N
in POS N
the POS N
following POS N
cycles POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Most POS N
of POS N
the POS N
symptom POS N
control POS N
was POS N
achieved POS N
during POS N
the POS N
first POS N
3 POS N
cycles POS N
of POS N
treatment, POS N
with POS N
some POS N
further POS N
improvement POS N
thereafter POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Both POS N
GEM POS N
and POS N
PV POS N
yield POS N
a POS N
symptom POS N
control POS N
rate POS N
much POS N
higher POS N
than POS N
expected POS N
by POS N
the POS N
objective POS N
tumour POS N
RR. POS N

Both POS N
patients POS N
with POS N
objective POS N
response POS N
and POS N
disease POS N
stabilisation POS N
had POS N
clearly POS N
better POS N
symptom POS N
control POS N
than POS N
those POS N
with POS N
disease POS N
progression. POS N

Both POS N
GEM POS N
and POS N
PV POS N
yield POS N
a POS N
symptom POS N
control POS N
rate POS N
much POS N
higher POS N
than POS N
expected POS N
by POS N
the POS N
objective POS N
tumour POS N
RR. POS N

Symptom POS N
control POS N
in POS N
both POS N
arms POS N
was POS N
similar POS N
for POS N
'disease-specific' POS N
symptoms POS N
such POS N
as POS N
cough, POS N
dyspnea, POS N
pain POS N
or POS N
haemoptysis. POS N

Both POS N
GEM POS N
and POS N
PV POS N
yield POS N
a POS N
symptom POS N
control POS N
rate POS N
much POS N
higher POS N
than POS N
expected POS N
by POS N
the POS N
objective POS N
tumour POS N
RR. POS N

Compared POS N
to POS N
PV, POS N
a POS N
significantly POS N
larger POS N
number POS N
of POS N
GEM-patients POS N
had POS N
better POS N
scores POS N
for POS N
'constitutional' POS N
items POS N
such POS N
as POS N
anorexia POS N
(P=0.007), POS N
ability POS N
to POS N
carry POS N
on POS N
with POS N
daily POS N
activities POS N
(P=0.04) POS N
and POS N
overall POS N
impression POS N
of POS N
quality-of-life POS N
(P=0.008). POS N

Both POS N
GEM POS N
and POS N
PV POS N
yield POS N
a POS N
symptom POS N
control POS N
rate POS N
much POS N
higher POS N
than POS N
expected POS N
by POS N
the POS N
objective POS N
tumour POS N
RR. POS N

Symptom POS N
control POS N
was POS N
very POS N
similar POS N
in POS N
younger POS N
(<65 POS N
years) POS N
versus POS N
older POS N
(>/=65 POS N
years) POS N
patients, POS N
and POS N
only POS N
slightly POS N
better POS N
in POS N
those POS N
with POS N
a POS N
Karnofsky POS N
PS POS N
>/=80% POS N
compared POS N
to POS N
those POS N
<80%. POS N

Both POS N
GEM POS N
and POS N
PV POS N
yield POS N
a POS N
symptom POS N
control POS N
rate POS N
much POS N
higher POS N
than POS N
expected POS N
by POS N
the POS N
objective POS N
tumour POS N
RR. POS N

Most POS N
of POS N
the POS N
symptom POS N
improvement POS N
occurred POS N
in POS N
the POS N
first POS N
3 POS N
cycles, POS N
with POS N
some POS N
further POS N
symptom POS N
improvement POS N
in POS N
the POS N
following POS N
cycles POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Both POS N
GEM POS N
and POS N
PV POS N
yield POS N
a POS N
symptom POS N
control POS N
rate POS N
much POS N
higher POS N
than POS N
expected POS N
by POS N
the POS N
objective POS N
tumour POS N
RR. POS N

GEM POS N
is POS N
equally POS N
effective POS N
in POS N
controlling POS N
'disease-specific' POS N
symptoms, POS N
but POS N
superior POS N
in POS N
controlling POS N
'constitutional' POS N
symptoms. POS N

Both POS N
GEM POS N
and POS N
PV POS N
yield POS N
a POS N
symptom POS N
control POS N
rate POS N
much POS N
higher POS N
than POS N
expected POS N
by POS N
the POS N
objective POS N
tumour POS N
RR. POS N

Most POS N
of POS N
the POS N
symptom POS N
control POS N
was POS N
achieved POS N
during POS N
the POS N
first POS N
3 POS N
cycles POS N
of POS N
treatment, POS N
with POS N
some POS N
further POS N
improvement POS N
thereafter POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

GEM POS N
is POS N
equally POS N
effective POS N
in POS N
controlling POS N
'disease-specific' POS N
symptoms, POS N
but POS N
superior POS N
in POS N
controlling POS N
'constitutional' POS N
symptoms. POS N

Both POS N
patients POS N
with POS N
objective POS N
response POS N
and POS N
disease POS N
stabilisation POS N
had POS N
clearly POS N
better POS N
symptom POS N
control POS N
than POS N
those POS N
with POS N
disease POS N
progression. POS N

GEM POS N
is POS N
equally POS N
effective POS N
in POS N
controlling POS N
'disease-specific' POS N
symptoms, POS N
but POS N
superior POS N
in POS N
controlling POS N
'constitutional' POS N
symptoms. POS N

Symptom POS N
control POS N
in POS N
both POS N
arms POS N
was POS N
similar POS N
for POS N
'disease-specific' POS N
symptoms POS N
such POS N
as POS N
cough, POS N
dyspnea, POS N
pain POS N
or POS N
haemoptysis. POS N

GEM POS N
is POS N
equally POS N
effective POS N
in POS N
controlling POS N
'disease-specific' POS N
symptoms, POS N
but POS N
superior POS N
in POS N
controlling POS N
'constitutional' POS N
symptoms. POS N

Compared POS N
to POS N
PV, POS N
a POS N
significantly POS N
larger POS N
number POS N
of POS N
GEM-patients POS N
had POS N
better POS N
scores POS N
for POS N
'constitutional' POS N
items POS N
such POS N
as POS N
anorexia POS N
(P=0.007), POS N
ability POS N
to POS N
carry POS N
on POS N
with POS N
daily POS N
activities POS N
(P=0.04) POS N
and POS N
overall POS N
impression POS N
of POS N
quality-of-life POS N
(P=0.008). POS N

GEM POS N
is POS N
equally POS N
effective POS N
in POS N
controlling POS N
'disease-specific' POS N
symptoms, POS N
but POS N
superior POS N
in POS N
controlling POS N
'constitutional' POS N
symptoms. POS N

Symptom POS N
control POS N
was POS N
very POS N
similar POS N
in POS N
younger POS N
(<65 POS N
years) POS N
versus POS N
older POS N
(>/=65 POS N
years) POS N
patients, POS N
and POS N
only POS N
slightly POS N
better POS N
in POS N
those POS N
with POS N
a POS N
Karnofsky POS N
PS POS N
>/=80% POS N
compared POS N
to POS N
those POS N
<80%. POS N

GEM POS N
is POS N
equally POS N
effective POS N
in POS N
controlling POS N
'disease-specific' POS N
symptoms, POS N
but POS N
superior POS N
in POS N
controlling POS N
'constitutional' POS N
symptoms. POS N

Most POS N
of POS N
the POS N
symptom POS N
improvement POS N
occurred POS N
in POS N
the POS N
first POS N
3 POS N
cycles, POS N
with POS N
some POS N
further POS N
symptom POS N
improvement POS N
in POS N
the POS N
following POS N
cycles POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

GEM POS N
is POS N
equally POS N
effective POS N
in POS N
controlling POS N
'disease-specific' POS N
symptoms, POS N
but POS N
superior POS N
in POS N
controlling POS N
'constitutional' POS N
symptoms. POS N

Both POS N
GEM POS N
and POS N
PV POS N
yield POS N
a POS N
symptom POS N
control POS N
rate POS N
much POS N
higher POS N
than POS N
expected POS N
by POS N
the POS N
objective POS N
tumour POS N
RR. POS N

GEM POS N
is POS N
equally POS N
effective POS N
in POS N
controlling POS N
'disease-specific' POS N
symptoms, POS N
but POS N
superior POS N
in POS N
controlling POS N
'constitutional' POS N
symptoms. POS N

Most POS N
of POS N
the POS N
symptom POS N
control POS N
was POS N
achieved POS N
during POS N
the POS N
first POS N
3 POS N
cycles POS N
of POS N
treatment, POS N
with POS N
some POS N
further POS N
improvement POS N
thereafter POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Most POS N
of POS N
the POS N
symptom POS N
control POS N
was POS N
achieved POS N
during POS N
the POS N
first POS N
3 POS N
cycles POS N
of POS N
treatment, POS N
with POS N
some POS N
further POS N
improvement POS N
thereafter POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Both POS N
patients POS N
with POS N
objective POS N
response POS N
and POS N
disease POS N
stabilisation POS N
had POS N
clearly POS N
better POS N
symptom POS N
control POS N
than POS N
those POS N
with POS N
disease POS N
progression. POS N

Most POS N
of POS N
the POS N
symptom POS N
control POS N
was POS N
achieved POS N
during POS N
the POS N
first POS N
3 POS N
cycles POS N
of POS N
treatment, POS N
with POS N
some POS N
further POS N
improvement POS N
thereafter POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Symptom POS N
control POS N
in POS N
both POS N
arms POS N
was POS N
similar POS N
for POS N
'disease-specific' POS N
symptoms POS N
such POS N
as POS N
cough, POS N
dyspnea, POS N
pain POS N
or POS N
haemoptysis. POS N

Most POS N
of POS N
the POS N
symptom POS N
control POS N
was POS N
achieved POS N
during POS N
the POS N
first POS N
3 POS N
cycles POS N
of POS N
treatment, POS N
with POS N
some POS N
further POS N
improvement POS N
thereafter POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Compared POS N
to POS N
PV, POS N
a POS N
significantly POS N
larger POS N
number POS N
of POS N
GEM-patients POS N
had POS N
better POS N
scores POS N
for POS N
'constitutional' POS N
items POS N
such POS N
as POS N
anorexia POS N
(P=0.007), POS N
ability POS N
to POS N
carry POS N
on POS N
with POS N
daily POS N
activities POS N
(P=0.04) POS N
and POS N
overall POS N
impression POS N
of POS N
quality-of-life POS N
(P=0.008). POS N

Most POS N
of POS N
the POS N
symptom POS N
control POS N
was POS N
achieved POS N
during POS N
the POS N
first POS N
3 POS N
cycles POS N
of POS N
treatment, POS N
with POS N
some POS N
further POS N
improvement POS N
thereafter POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Symptom POS N
control POS N
was POS N
very POS N
similar POS N
in POS N
younger POS N
(<65 POS N
years) POS N
versus POS N
older POS N
(>/=65 POS N
years) POS N
patients, POS N
and POS N
only POS N
slightly POS N
better POS N
in POS N
those POS N
with POS N
a POS N
Karnofsky POS N
PS POS N
>/=80% POS N
compared POS N
to POS N
those POS N
<80%. POS N

Most POS N
of POS N
the POS N
symptom POS N
control POS N
was POS N
achieved POS N
during POS N
the POS N
first POS N
3 POS N
cycles POS N
of POS N
treatment, POS N
with POS N
some POS N
further POS N
improvement POS N
thereafter POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Most POS N
of POS N
the POS N
symptom POS N
improvement POS N
occurred POS N
in POS N
the POS N
first POS N
3 POS N
cycles, POS N
with POS N
some POS N
further POS N
symptom POS N
improvement POS N
in POS N
the POS N
following POS N
cycles POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Most POS N
of POS N
the POS N
symptom POS N
control POS N
was POS N
achieved POS N
during POS N
the POS N
first POS N
3 POS N
cycles POS N
of POS N
treatment, POS N
with POS N
some POS N
further POS N
improvement POS N
thereafter POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Both POS N
GEM POS N
and POS N
PV POS N
yield POS N
a POS N
symptom POS N
control POS N
rate POS N
much POS N
higher POS N
than POS N
expected POS N
by POS N
the POS N
objective POS N
tumour POS N
RR. POS N

Most POS N
of POS N
the POS N
symptom POS N
control POS N
was POS N
achieved POS N
during POS N
the POS N
first POS N
3 POS N
cycles POS N
of POS N
treatment, POS N
with POS N
some POS N
further POS N
improvement POS N
thereafter POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

GEM POS N
is POS N
equally POS N
effective POS N
in POS N
controlling POS N
'disease-specific' POS N
symptoms, POS N
but POS N
superior POS N
in POS N
controlling POS N
'constitutional' POS N
symptoms. POS N

For POS N
the POS N
IMCT POS N
group POS N
and POS N
CPT POS N
groups, POS N
respectively, POS N
the POS N
absolute POS N
success POS N
rates POS N
were POS N
80% POS N
(16/20) POS N
and POS N
60% POS N
(12/20) POS N
(P POS N
< POS N
.001) POS N
and POS N
qualified POS N
success POS N
rates POS N
were POS N
90% POS N
(18/20) POS N
and POS N
70% POS N
(14/20) POS N
(P POS N
< POS N
.001). POS N

Both POS N
procedures POS N
produced POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
IOP, POS N

For POS N
the POS N
IMCT POS N
group POS N
and POS N
CPT POS N
groups, POS N
respectively, POS N
the POS N
absolute POS N
success POS N
rates POS N
were POS N
80% POS N
(16/20) POS N
and POS N
60% POS N
(12/20) POS N
(P POS N
< POS N
.001) POS N
and POS N
qualified POS N
success POS N
rates POS N
were POS N
90% POS N
(18/20) POS N
and POS N
70% POS N
(14/20) POS N
(P POS N
< POS N
.001). POS N

eyes POS N
undergoing POS N
IMCT POS N
achieved POS N
a POS N
lower POS N
IOP POS N
than POS N
CPT POS N
group POS N
eyes POS N
at POS N
12 POS N
months POS N
follow-up POS N
(9.5 POS N
± POS N
2.4 POS N
mm POS N
Hg POS N
and POS N
11.7 POS N
± POS N
2.1 POS N
mm POS N
Hg, POS N
respectively, POS N
P POS N
< POS N
.001). POS N

For POS N
the POS N
IMCT POS N
group POS N
and POS N
CPT POS N
groups, POS N
respectively, POS N
the POS N
absolute POS N
success POS N
rates POS N
were POS N
80% POS N
(16/20) POS N
and POS N
60% POS N
(12/20) POS N
(P POS N
< POS N
.001) POS N
and POS N
qualified POS N
success POS N
rates POS N
were POS N
90% POS N
(18/20) POS N
and POS N
70% POS N
(14/20) POS N
(P POS N
< POS N
.001). POS N

In POS N
primary POS N
congential POS N
glaucoma, POS N
illuminated POS N
microcatheter-assisted POS N
360-degree POS N
circumferential POS N
trabeculotomy POS N
performed POS N
better POS N
than POS N
conventional POS N
partial POS N
trabeculotomy POS N
at POS N
1 POS N
year POS N
follow-up POS N
and POS N
resulted POS N
in POS N
significantly POS N
lower POS N
IOP POS N
measurements. POS N

For POS N
the POS N
IMCT POS N
group POS N
and POS N
CPT POS N
groups, POS N
respectively, POS N
the POS N
absolute POS N
success POS N
rates POS N
were POS N
80% POS N
(16/20) POS N
and POS N
60% POS N
(12/20) POS N
(P POS N
< POS N
.001) POS N
and POS N
qualified POS N
success POS N
rates POS N
were POS N
90% POS N
(18/20) POS N
and POS N
70% POS N
(14/20) POS N
(P POS N
< POS N
.001). POS N

In POS N
the POS N
IMCT POS N
group, POS N
360-degree POS N
cannulation POS N
was POS N
achieved POS N
in POS N
80% POS N
(16/20) POS N
of POS N
eyes. POS N

Both POS N
procedures POS N
produced POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
IOP, POS N

For POS N
the POS N
IMCT POS N
group POS N
and POS N
CPT POS N
groups, POS N
respectively, POS N
the POS N
absolute POS N
success POS N
rates POS N
were POS N
80% POS N
(16/20) POS N
and POS N
60% POS N
(12/20) POS N
(P POS N
< POS N
.001) POS N
and POS N
qualified POS N
success POS N
rates POS N
were POS N
90% POS N
(18/20) POS N
and POS N
70% POS N
(14/20) POS N
(P POS N
< POS N
.001). POS N

Both POS N
procedures POS N
produced POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
IOP, POS N

eyes POS N
undergoing POS N
IMCT POS N
achieved POS N
a POS N
lower POS N
IOP POS N
than POS N
CPT POS N
group POS N
eyes POS N
at POS N
12 POS N
months POS N
follow-up POS N
(9.5 POS N
± POS N
2.4 POS N
mm POS N
Hg POS N
and POS N
11.7 POS N
± POS N
2.1 POS N
mm POS N
Hg, POS N
respectively, POS N
P POS N
< POS N
.001). POS N

Both POS N
procedures POS N
produced POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
IOP, POS N

In POS N
primary POS N
congential POS N
glaucoma, POS N
illuminated POS N
microcatheter-assisted POS N
360-degree POS N
circumferential POS N
trabeculotomy POS N
performed POS N
better POS N
than POS N
conventional POS N
partial POS N
trabeculotomy POS N
at POS N
1 POS N
year POS N
follow-up POS N
and POS N
resulted POS N
in POS N
significantly POS N
lower POS N
IOP POS N
measurements. POS N

Both POS N
procedures POS N
produced POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
IOP, POS N

In POS N
the POS N
IMCT POS N
group, POS N
360-degree POS N
cannulation POS N
was POS N
achieved POS N
in POS N
80% POS N
(16/20) POS N
of POS N
eyes. POS N

eyes POS N
undergoing POS N
IMCT POS N
achieved POS N
a POS N
lower POS N
IOP POS N
than POS N
CPT POS N
group POS N
eyes POS N
at POS N
12 POS N
months POS N
follow-up POS N
(9.5 POS N
± POS N
2.4 POS N
mm POS N
Hg POS N
and POS N
11.7 POS N
± POS N
2.1 POS N
mm POS N
Hg, POS N
respectively, POS N
P POS N
< POS N
.001). POS N

For POS N
the POS N
IMCT POS N
group POS N
and POS N
CPT POS N
groups, POS N
respectively, POS N
the POS N
absolute POS N
success POS N
rates POS N
were POS N
80% POS N
(16/20) POS N
and POS N
60% POS N
(12/20) POS N
(P POS N
< POS N
.001) POS N
and POS N
qualified POS N
success POS N
rates POS N
were POS N
90% POS N
(18/20) POS N
and POS N
70% POS N
(14/20) POS N
(P POS N
< POS N
.001). POS N

eyes POS N
undergoing POS N
IMCT POS N
achieved POS N
a POS N
lower POS N
IOP POS N
than POS N
CPT POS N
group POS N
eyes POS N
at POS N
12 POS N
months POS N
follow-up POS N
(9.5 POS N
± POS N
2.4 POS N
mm POS N
Hg POS N
and POS N
11.7 POS N
± POS N
2.1 POS N
mm POS N
Hg, POS N
respectively, POS N
P POS N
< POS N
.001). POS N

Both POS N
procedures POS N
produced POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
IOP, POS N

eyes POS N
undergoing POS N
IMCT POS N
achieved POS N
a POS N
lower POS N
IOP POS N
than POS N
CPT POS N
group POS N
eyes POS N
at POS N
12 POS N
months POS N
follow-up POS N
(9.5 POS N
± POS N
2.4 POS N
mm POS N
Hg POS N
and POS N
11.7 POS N
± POS N
2.1 POS N
mm POS N
Hg, POS N
respectively, POS N
P POS N
< POS N
.001). POS N

In POS N
primary POS N
congential POS N
glaucoma, POS N
illuminated POS N
microcatheter-assisted POS N
360-degree POS N
circumferential POS N
trabeculotomy POS N
performed POS N
better POS N
than POS N
conventional POS N
partial POS N
trabeculotomy POS N
at POS N
1 POS N
year POS N
follow-up POS N
and POS N
resulted POS N
in POS N
significantly POS N
lower POS N
IOP POS N
measurements. POS N

eyes POS N
undergoing POS N
IMCT POS N
achieved POS N
a POS N
lower POS N
IOP POS N
than POS N
CPT POS N
group POS N
eyes POS N
at POS N
12 POS N
months POS N
follow-up POS N
(9.5 POS N
± POS N
2.4 POS N
mm POS N
Hg POS N
and POS N
11.7 POS N
± POS N
2.1 POS N
mm POS N
Hg, POS N
respectively, POS N
P POS N
< POS N
.001). POS N

In POS N
the POS N
IMCT POS N
group, POS N
360-degree POS N
cannulation POS N
was POS N
achieved POS N
in POS N
80% POS N
(16/20) POS N
of POS N
eyes. POS N

In POS N
primary POS N
congential POS N
glaucoma, POS N
illuminated POS N
microcatheter-assisted POS N
360-degree POS N
circumferential POS N
trabeculotomy POS N
performed POS N
better POS N
than POS N
conventional POS N
partial POS N
trabeculotomy POS N
at POS N
1 POS N
year POS N
follow-up POS N
and POS N
resulted POS N
in POS N
significantly POS N
lower POS N
IOP POS N
measurements. POS N

For POS N
the POS N
IMCT POS N
group POS N
and POS N
CPT POS N
groups, POS N
respectively, POS N
the POS N
absolute POS N
success POS N
rates POS N
were POS N
80% POS N
(16/20) POS N
and POS N
60% POS N
(12/20) POS N
(P POS N
< POS N
.001) POS N
and POS N
qualified POS N
success POS N
rates POS N
were POS N
90% POS N
(18/20) POS N
and POS N
70% POS N
(14/20) POS N
(P POS N
< POS N
.001). POS N

In POS N
primary POS N
congential POS N
glaucoma, POS N
illuminated POS N
microcatheter-assisted POS N
360-degree POS N
circumferential POS N
trabeculotomy POS N
performed POS N
better POS N
than POS N
conventional POS N
partial POS N
trabeculotomy POS N
at POS N
1 POS N
year POS N
follow-up POS N
and POS N
resulted POS N
in POS N
significantly POS N
lower POS N
IOP POS N
measurements. POS N

Both POS N
procedures POS N
produced POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
IOP, POS N

In POS N
primary POS N
congential POS N
glaucoma, POS N
illuminated POS N
microcatheter-assisted POS N
360-degree POS N
circumferential POS N
trabeculotomy POS N
performed POS N
better POS N
than POS N
conventional POS N
partial POS N
trabeculotomy POS N
at POS N
1 POS N
year POS N
follow-up POS N
and POS N
resulted POS N
in POS N
significantly POS N
lower POS N
IOP POS N
measurements. POS N

eyes POS N
undergoing POS N
IMCT POS N
achieved POS N
a POS N
lower POS N
IOP POS N
than POS N
CPT POS N
group POS N
eyes POS N
at POS N
12 POS N
months POS N
follow-up POS N
(9.5 POS N
± POS N
2.4 POS N
mm POS N
Hg POS N
and POS N
11.7 POS N
± POS N
2.1 POS N
mm POS N
Hg, POS N
respectively, POS N
P POS N
< POS N
.001). POS N

In POS N
primary POS N
congential POS N
glaucoma, POS N
illuminated POS N
microcatheter-assisted POS N
360-degree POS N
circumferential POS N
trabeculotomy POS N
performed POS N
better POS N
than POS N
conventional POS N
partial POS N
trabeculotomy POS N
at POS N
1 POS N
year POS N
follow-up POS N
and POS N
resulted POS N
in POS N
significantly POS N
lower POS N
IOP POS N
measurements. POS N

In POS N
the POS N
IMCT POS N
group, POS N
360-degree POS N
cannulation POS N
was POS N
achieved POS N
in POS N
80% POS N
(16/20) POS N
of POS N
eyes. POS N

In POS N
the POS N
IMCT POS N
group, POS N
360-degree POS N
cannulation POS N
was POS N
achieved POS N
in POS N
80% POS N
(16/20) POS N
of POS N
eyes. POS N

For POS N
the POS N
IMCT POS N
group POS N
and POS N
CPT POS N
groups, POS N
respectively, POS N
the POS N
absolute POS N
success POS N
rates POS N
were POS N
80% POS N
(16/20) POS N
and POS N
60% POS N
(12/20) POS N
(P POS N
< POS N
.001) POS N
and POS N
qualified POS N
success POS N
rates POS N
were POS N
90% POS N
(18/20) POS N
and POS N
70% POS N
(14/20) POS N
(P POS N
< POS N
.001). POS N

In POS N
the POS N
IMCT POS N
group, POS N
360-degree POS N
cannulation POS N
was POS N
achieved POS N
in POS N
80% POS N
(16/20) POS N
of POS N
eyes. POS N

Both POS N
procedures POS N
produced POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
IOP, POS N

In POS N
the POS N
IMCT POS N
group, POS N
360-degree POS N
cannulation POS N
was POS N
achieved POS N
in POS N
80% POS N
(16/20) POS N
of POS N
eyes. POS N

eyes POS N
undergoing POS N
IMCT POS N
achieved POS N
a POS N
lower POS N
IOP POS N
than POS N
CPT POS N
group POS N
eyes POS N
at POS N
12 POS N
months POS N
follow-up POS N
(9.5 POS N
± POS N
2.4 POS N
mm POS N
Hg POS N
and POS N
11.7 POS N
± POS N
2.1 POS N
mm POS N
Hg, POS N
respectively, POS N
P POS N
< POS N
.001). POS N

In POS N
the POS N
IMCT POS N
group, POS N
360-degree POS N
cannulation POS N
was POS N
achieved POS N
in POS N
80% POS N
(16/20) POS N
of POS N
eyes. POS N

In POS N
primary POS N
congential POS N
glaucoma, POS N
illuminated POS N
microcatheter-assisted POS N
360-degree POS N
circumferential POS N
trabeculotomy POS N
performed POS N
better POS N
than POS N
conventional POS N
partial POS N
trabeculotomy POS N
at POS N
1 POS N
year POS N
follow-up POS N
and POS N
resulted POS N
in POS N
significantly POS N
lower POS N
IOP POS N
measurements. POS N

Tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
without POS N
TDF POS N
resistance POS N
development POS N
in POS N
CHB POS N
patients POS N
with POS N
LAM-R, POS N
for POS N
up POS N
to POS N
240weeks. POS N

At POS N
week POS N
240, POS N
83.0% POS N
of POS N
patients POS N
in POS N
the POS N
TDF POS N
arm, POS N
and POS N
82.7% POS N
of POS N
patients POS N
in POS N
the POS N
FTC/TDF POS N
treatment POS N
arm POS N
had POS N
HBV POS N
DNA<69IU/ml POS N
(p=0.96). POS N

Tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
without POS N
TDF POS N
resistance POS N
development POS N
in POS N
CHB POS N
patients POS N
with POS N
LAM-R, POS N
for POS N
up POS N
to POS N
240weeks. POS N

Rates POS N
of POS N
normal POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
and POS N
normalised POS N
ALT POS N
were POS N
similar POS N
between POS N
groups POS N
(p=0.41 POS N
and POS N
p=0.97 POS N
respectively). POS N

Tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
without POS N
TDF POS N
resistance POS N
development POS N
in POS N
CHB POS N
patients POS N
with POS N
LAM-R, POS N
for POS N
up POS N
to POS N
240weeks. POS N

Hepatitis POS N
B POS N
e POS N
antigen POS N
loss POS N
and POS N
seroconversion POS N
at POS N
week POS N
240 POS N
were POS N
similar POS N
between POS N
groups, POS N
(p=0.41 POS N
and POS N
p=0.67 POS N
respectively). POS N

Tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
without POS N
TDF POS N
resistance POS N
development POS N
in POS N
CHB POS N
patients POS N
with POS N
LAM-R, POS N
for POS N
up POS N
to POS N
240weeks. POS N

Overall, POS N
six POS N
patients POS N
achieved POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
and POS N
one POS N
patient POS N
(FTC/TDF POS N
arm) POS N
had POS N
HBsAg POS N
seroconversion POS N
by POS N
week POS N
240. POS N

Tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
without POS N
TDF POS N
resistance POS N
development POS N
in POS N
CHB POS N
patients POS N
with POS N
LAM-R, POS N
for POS N
up POS N
to POS N
240weeks. POS N

No POS N
TDF POS N
resistance POS N
was POS N
observed POS N
up POS N
to POS N
week POS N
240. POS N

Tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
without POS N
TDF POS N
resistance POS N
development POS N
in POS N
CHB POS N
patients POS N
with POS N
LAM-R, POS N
for POS N
up POS N
to POS N
240weeks. POS N

Treatment POS N
was POS N
generally POS N
well POS N
tolerated, POS N
and POS N
renal POS N
events POS N
were POS N
mild POS N
and POS N
infrequent POS N
(∼8.6%). POS N

Tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
without POS N
TDF POS N
resistance POS N
development POS N
in POS N
CHB POS N
patients POS N
with POS N
LAM-R, POS N
for POS N
up POS N
to POS N
240weeks. POS N

The POS N
mean POS N
change POS N
in POS N
bone POS N
mineral POS N
density POS N
at POS N
week POS N
240 POS N
was POS N
-0.98% POS N
and POS N
-2.54% POS N
at POS N
the POS N
spine POS N
and POS N
hip, POS N
respectively. POS N

Tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
without POS N
TDF POS N
resistance POS N
development POS N
in POS N
CHB POS N
patients POS N
with POS N
LAM-R, POS N
for POS N
up POS N
to POS N
240weeks. POS N

TDF POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
in POS N
LAM-R POS N
CHB POS N
patients POS N
for POS N
up POS N
to POS N
240 POS N
weeks. POS N

At POS N
week POS N
240, POS N
83.0% POS N
of POS N
patients POS N
in POS N
the POS N
TDF POS N
arm, POS N
and POS N
82.7% POS N
of POS N
patients POS N
in POS N
the POS N
FTC/TDF POS N
treatment POS N
arm POS N
had POS N
HBV POS N
DNA<69IU/ml POS N
(p=0.96). POS N

Tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
without POS N
TDF POS N
resistance POS N
development POS N
in POS N
CHB POS N
patients POS N
with POS N
LAM-R, POS N
for POS N
up POS N
to POS N
240weeks. POS N

At POS N
week POS N
240, POS N
83.0% POS N
of POS N
patients POS N
in POS N
the POS N
TDF POS N
arm, POS N
and POS N
82.7% POS N
of POS N
patients POS N
in POS N
the POS N
FTC/TDF POS N
treatment POS N
arm POS N
had POS N
HBV POS N
DNA<69IU/ml POS N
(p=0.96). POS N

Rates POS N
of POS N
normal POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
and POS N
normalised POS N
ALT POS N
were POS N
similar POS N
between POS N
groups POS N
(p=0.41 POS N
and POS N
p=0.97 POS N
respectively). POS N

At POS N
week POS N
240, POS N
83.0% POS N
of POS N
patients POS N
in POS N
the POS N
TDF POS N
arm, POS N
and POS N
82.7% POS N
of POS N
patients POS N
in POS N
the POS N
FTC/TDF POS N
treatment POS N
arm POS N
had POS N
HBV POS N
DNA<69IU/ml POS N
(p=0.96). POS N

Hepatitis POS N
B POS N
e POS N
antigen POS N
loss POS N
and POS N
seroconversion POS N
at POS N
week POS N
240 POS N
were POS N
similar POS N
between POS N
groups, POS N
(p=0.41 POS N
and POS N
p=0.67 POS N
respectively). POS N

At POS N
week POS N
240, POS N
83.0% POS N
of POS N
patients POS N
in POS N
the POS N
TDF POS N
arm, POS N
and POS N
82.7% POS N
of POS N
patients POS N
in POS N
the POS N
FTC/TDF POS N
treatment POS N
arm POS N
had POS N
HBV POS N
DNA<69IU/ml POS N
(p=0.96). POS N

Overall, POS N
six POS N
patients POS N
achieved POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
and POS N
one POS N
patient POS N
(FTC/TDF POS N
arm) POS N
had POS N
HBsAg POS N
seroconversion POS N
by POS N
week POS N
240. POS N

At POS N
week POS N
240, POS N
83.0% POS N
of POS N
patients POS N
in POS N
the POS N
TDF POS N
arm, POS N
and POS N
82.7% POS N
of POS N
patients POS N
in POS N
the POS N
FTC/TDF POS N
treatment POS N
arm POS N
had POS N
HBV POS N
DNA<69IU/ml POS N
(p=0.96). POS N

No POS N
TDF POS N
resistance POS N
was POS N
observed POS N
up POS N
to POS N
week POS N
240. POS N

At POS N
week POS N
240, POS N
83.0% POS N
of POS N
patients POS N
in POS N
the POS N
TDF POS N
arm, POS N
and POS N
82.7% POS N
of POS N
patients POS N
in POS N
the POS N
FTC/TDF POS N
treatment POS N
arm POS N
had POS N
HBV POS N
DNA<69IU/ml POS N
(p=0.96). POS N

Treatment POS N
was POS N
generally POS N
well POS N
tolerated, POS N
and POS N
renal POS N
events POS N
were POS N
mild POS N
and POS N
infrequent POS N
(∼8.6%). POS N

At POS N
week POS N
240, POS N
83.0% POS N
of POS N
patients POS N
in POS N
the POS N
TDF POS N
arm, POS N
and POS N
82.7% POS N
of POS N
patients POS N
in POS N
the POS N
FTC/TDF POS N
treatment POS N
arm POS N
had POS N
HBV POS N
DNA<69IU/ml POS N
(p=0.96). POS N

The POS N
mean POS N
change POS N
in POS N
bone POS N
mineral POS N
density POS N
at POS N
week POS N
240 POS N
was POS N
-0.98% POS N
and POS N
-2.54% POS N
at POS N
the POS N
spine POS N
and POS N
hip, POS N
respectively. POS N

At POS N
week POS N
240, POS N
83.0% POS N
of POS N
patients POS N
in POS N
the POS N
TDF POS N
arm, POS N
and POS N
82.7% POS N
of POS N
patients POS N
in POS N
the POS N
FTC/TDF POS N
treatment POS N
arm POS N
had POS N
HBV POS N
DNA<69IU/ml POS N
(p=0.96). POS N

TDF POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
in POS N
LAM-R POS N
CHB POS N
patients POS N
for POS N
up POS N
to POS N
240 POS N
weeks. POS N

Rates POS N
of POS N
normal POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
and POS N
normalised POS N
ALT POS N
were POS N
similar POS N
between POS N
groups POS N
(p=0.41 POS N
and POS N
p=0.97 POS N
respectively). POS N

Tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
without POS N
TDF POS N
resistance POS N
development POS N
in POS N
CHB POS N
patients POS N
with POS N
LAM-R, POS N
for POS N
up POS N
to POS N
240weeks. POS N

Rates POS N
of POS N
normal POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
and POS N
normalised POS N
ALT POS N
were POS N
similar POS N
between POS N
groups POS N
(p=0.41 POS N
and POS N
p=0.97 POS N
respectively). POS N

At POS N
week POS N
240, POS N
83.0% POS N
of POS N
patients POS N
in POS N
the POS N
TDF POS N
arm, POS N
and POS N
82.7% POS N
of POS N
patients POS N
in POS N
the POS N
FTC/TDF POS N
treatment POS N
arm POS N
had POS N
HBV POS N
DNA<69IU/ml POS N
(p=0.96). POS N

Rates POS N
of POS N
normal POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
and POS N
normalised POS N
ALT POS N
were POS N
similar POS N
between POS N
groups POS N
(p=0.41 POS N
and POS N
p=0.97 POS N
respectively). POS N

Hepatitis POS N
B POS N
e POS N
antigen POS N
loss POS N
and POS N
seroconversion POS N
at POS N
week POS N
240 POS N
were POS N
similar POS N
between POS N
groups, POS N
(p=0.41 POS N
and POS N
p=0.67 POS N
respectively). POS N

Rates POS N
of POS N
normal POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
and POS N
normalised POS N
ALT POS N
were POS N
similar POS N
between POS N
groups POS N
(p=0.41 POS N
and POS N
p=0.97 POS N
respectively). POS N

Overall, POS N
six POS N
patients POS N
achieved POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
and POS N
one POS N
patient POS N
(FTC/TDF POS N
arm) POS N
had POS N
HBsAg POS N
seroconversion POS N
by POS N
week POS N
240. POS N

Rates POS N
of POS N
normal POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
and POS N
normalised POS N
ALT POS N
were POS N
similar POS N
between POS N
groups POS N
(p=0.41 POS N
and POS N
p=0.97 POS N
respectively). POS N

No POS N
TDF POS N
resistance POS N
was POS N
observed POS N
up POS N
to POS N
week POS N
240. POS N

Rates POS N
of POS N
normal POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
and POS N
normalised POS N
ALT POS N
were POS N
similar POS N
between POS N
groups POS N
(p=0.41 POS N
and POS N
p=0.97 POS N
respectively). POS N

Treatment POS N
was POS N
generally POS N
well POS N
tolerated, POS N
and POS N
renal POS N
events POS N
were POS N
mild POS N
and POS N
infrequent POS N
(∼8.6%). POS N

Rates POS N
of POS N
normal POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
and POS N
normalised POS N
ALT POS N
were POS N
similar POS N
between POS N
groups POS N
(p=0.41 POS N
and POS N
p=0.97 POS N
respectively). POS N

The POS N
mean POS N
change POS N
in POS N
bone POS N
mineral POS N
density POS N
at POS N
week POS N
240 POS N
was POS N
-0.98% POS N
and POS N
-2.54% POS N
at POS N
the POS N
spine POS N
and POS N
hip, POS N
respectively. POS N

Rates POS N
of POS N
normal POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
and POS N
normalised POS N
ALT POS N
were POS N
similar POS N
between POS N
groups POS N
(p=0.41 POS N
and POS N
p=0.97 POS N
respectively). POS N

TDF POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
in POS N
LAM-R POS N
CHB POS N
patients POS N
for POS N
up POS N
to POS N
240 POS N
weeks. POS N

Hepatitis POS N
B POS N
e POS N
antigen POS N
loss POS N
and POS N
seroconversion POS N
at POS N
week POS N
240 POS N
were POS N
similar POS N
between POS N
groups, POS N
(p=0.41 POS N
and POS N
p=0.67 POS N
respectively). POS N

Tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
without POS N
TDF POS N
resistance POS N
development POS N
in POS N
CHB POS N
patients POS N
with POS N
LAM-R, POS N
for POS N
up POS N
to POS N
240weeks. POS N

Hepatitis POS N
B POS N
e POS N
antigen POS N
loss POS N
and POS N
seroconversion POS N
at POS N
week POS N
240 POS N
were POS N
similar POS N
between POS N
groups, POS N
(p=0.41 POS N
and POS N
p=0.67 POS N
respectively). POS N

At POS N
week POS N
240, POS N
83.0% POS N
of POS N
patients POS N
in POS N
the POS N
TDF POS N
arm, POS N
and POS N
82.7% POS N
of POS N
patients POS N
in POS N
the POS N
FTC/TDF POS N
treatment POS N
arm POS N
had POS N
HBV POS N
DNA<69IU/ml POS N
(p=0.96). POS N

Hepatitis POS N
B POS N
e POS N
antigen POS N
loss POS N
and POS N
seroconversion POS N
at POS N
week POS N
240 POS N
were POS N
similar POS N
between POS N
groups, POS N
(p=0.41 POS N
and POS N
p=0.67 POS N
respectively). POS N

Rates POS N
of POS N
normal POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
and POS N
normalised POS N
ALT POS N
were POS N
similar POS N
between POS N
groups POS N
(p=0.41 POS N
and POS N
p=0.97 POS N
respectively). POS N

Hepatitis POS N
B POS N
e POS N
antigen POS N
loss POS N
and POS N
seroconversion POS N
at POS N
week POS N
240 POS N
were POS N
similar POS N
between POS N
groups, POS N
(p=0.41 POS N
and POS N
p=0.67 POS N
respectively). POS N

Overall, POS N
six POS N
patients POS N
achieved POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
and POS N
one POS N
patient POS N
(FTC/TDF POS N
arm) POS N
had POS N
HBsAg POS N
seroconversion POS N
by POS N
week POS N
240. POS N

Hepatitis POS N
B POS N
e POS N
antigen POS N
loss POS N
and POS N
seroconversion POS N
at POS N
week POS N
240 POS N
were POS N
similar POS N
between POS N
groups, POS N
(p=0.41 POS N
and POS N
p=0.67 POS N
respectively). POS N

No POS N
TDF POS N
resistance POS N
was POS N
observed POS N
up POS N
to POS N
week POS N
240. POS N

Hepatitis POS N
B POS N
e POS N
antigen POS N
loss POS N
and POS N
seroconversion POS N
at POS N
week POS N
240 POS N
were POS N
similar POS N
between POS N
groups, POS N
(p=0.41 POS N
and POS N
p=0.67 POS N
respectively). POS N

Treatment POS N
was POS N
generally POS N
well POS N
tolerated, POS N
and POS N
renal POS N
events POS N
were POS N
mild POS N
and POS N
infrequent POS N
(∼8.6%). POS N

Hepatitis POS N
B POS N
e POS N
antigen POS N
loss POS N
and POS N
seroconversion POS N
at POS N
week POS N
240 POS N
were POS N
similar POS N
between POS N
groups, POS N
(p=0.41 POS N
and POS N
p=0.67 POS N
respectively). POS N

The POS N
mean POS N
change POS N
in POS N
bone POS N
mineral POS N
density POS N
at POS N
week POS N
240 POS N
was POS N
-0.98% POS N
and POS N
-2.54% POS N
at POS N
the POS N
spine POS N
and POS N
hip, POS N
respectively. POS N

Hepatitis POS N
B POS N
e POS N
antigen POS N
loss POS N
and POS N
seroconversion POS N
at POS N
week POS N
240 POS N
were POS N
similar POS N
between POS N
groups, POS N
(p=0.41 POS N
and POS N
p=0.67 POS N
respectively). POS N

TDF POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
in POS N
LAM-R POS N
CHB POS N
patients POS N
for POS N
up POS N
to POS N
240 POS N
weeks. POS N

Overall, POS N
six POS N
patients POS N
achieved POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
and POS N
one POS N
patient POS N
(FTC/TDF POS N
arm) POS N
had POS N
HBsAg POS N
seroconversion POS N
by POS N
week POS N
240. POS N

Tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
without POS N
TDF POS N
resistance POS N
development POS N
in POS N
CHB POS N
patients POS N
with POS N
LAM-R, POS N
for POS N
up POS N
to POS N
240weeks. POS N

Overall, POS N
six POS N
patients POS N
achieved POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
and POS N
one POS N
patient POS N
(FTC/TDF POS N
arm) POS N
had POS N
HBsAg POS N
seroconversion POS N
by POS N
week POS N
240. POS N

At POS N
week POS N
240, POS N
83.0% POS N
of POS N
patients POS N
in POS N
the POS N
TDF POS N
arm, POS N
and POS N
82.7% POS N
of POS N
patients POS N
in POS N
the POS N
FTC/TDF POS N
treatment POS N
arm POS N
had POS N
HBV POS N
DNA<69IU/ml POS N
(p=0.96). POS N

Overall, POS N
six POS N
patients POS N
achieved POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
and POS N
one POS N
patient POS N
(FTC/TDF POS N
arm) POS N
had POS N
HBsAg POS N
seroconversion POS N
by POS N
week POS N
240. POS N

Rates POS N
of POS N
normal POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
and POS N
normalised POS N
ALT POS N
were POS N
similar POS N
between POS N
groups POS N
(p=0.41 POS N
and POS N
p=0.97 POS N
respectively). POS N

Overall, POS N
six POS N
patients POS N
achieved POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
and POS N
one POS N
patient POS N
(FTC/TDF POS N
arm) POS N
had POS N
HBsAg POS N
seroconversion POS N
by POS N
week POS N
240. POS N

Hepatitis POS N
B POS N
e POS N
antigen POS N
loss POS N
and POS N
seroconversion POS N
at POS N
week POS N
240 POS N
were POS N
similar POS N
between POS N
groups, POS N
(p=0.41 POS N
and POS N
p=0.67 POS N
respectively). POS N

Overall, POS N
six POS N
patients POS N
achieved POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
and POS N
one POS N
patient POS N
(FTC/TDF POS N
arm) POS N
had POS N
HBsAg POS N
seroconversion POS N
by POS N
week POS N
240. POS N

No POS N
TDF POS N
resistance POS N
was POS N
observed POS N
up POS N
to POS N
week POS N
240. POS N

Overall, POS N
six POS N
patients POS N
achieved POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
and POS N
one POS N
patient POS N
(FTC/TDF POS N
arm) POS N
had POS N
HBsAg POS N
seroconversion POS N
by POS N
week POS N
240. POS N

Treatment POS N
was POS N
generally POS N
well POS N
tolerated, POS N
and POS N
renal POS N
events POS N
were POS N
mild POS N
and POS N
infrequent POS N
(∼8.6%). POS N

Overall, POS N
six POS N
patients POS N
achieved POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
and POS N
one POS N
patient POS N
(FTC/TDF POS N
arm) POS N
had POS N
HBsAg POS N
seroconversion POS N
by POS N
week POS N
240. POS N

The POS N
mean POS N
change POS N
in POS N
bone POS N
mineral POS N
density POS N
at POS N
week POS N
240 POS N
was POS N
-0.98% POS N
and POS N
-2.54% POS N
at POS N
the POS N
spine POS N
and POS N
hip, POS N
respectively. POS N

Overall, POS N
six POS N
patients POS N
achieved POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
and POS N
one POS N
patient POS N
(FTC/TDF POS N
arm) POS N
had POS N
HBsAg POS N
seroconversion POS N
by POS N
week POS N
240. POS N

TDF POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
in POS N
LAM-R POS N
CHB POS N
patients POS N
for POS N
up POS N
to POS N
240 POS N
weeks. POS N

No POS N
TDF POS N
resistance POS N
was POS N
observed POS N
up POS N
to POS N
week POS N
240. POS N

Tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
without POS N
TDF POS N
resistance POS N
development POS N
in POS N
CHB POS N
patients POS N
with POS N
LAM-R, POS N
for POS N
up POS N
to POS N
240weeks. POS N

No POS N
TDF POS N
resistance POS N
was POS N
observed POS N
up POS N
to POS N
week POS N
240. POS N

At POS N
week POS N
240, POS N
83.0% POS N
of POS N
patients POS N
in POS N
the POS N
TDF POS N
arm, POS N
and POS N
82.7% POS N
of POS N
patients POS N
in POS N
the POS N
FTC/TDF POS N
treatment POS N
arm POS N
had POS N
HBV POS N
DNA<69IU/ml POS N
(p=0.96). POS N

No POS N
TDF POS N
resistance POS N
was POS N
observed POS N
up POS N
to POS N
week POS N
240. POS N

Rates POS N
of POS N
normal POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
and POS N
normalised POS N
ALT POS N
were POS N
similar POS N
between POS N
groups POS N
(p=0.41 POS N
and POS N
p=0.97 POS N
respectively). POS N

No POS N
TDF POS N
resistance POS N
was POS N
observed POS N
up POS N
to POS N
week POS N
240. POS N

Hepatitis POS N
B POS N
e POS N
antigen POS N
loss POS N
and POS N
seroconversion POS N
at POS N
week POS N
240 POS N
were POS N
similar POS N
between POS N
groups, POS N
(p=0.41 POS N
and POS N
p=0.67 POS N
respectively). POS N

No POS N
TDF POS N
resistance POS N
was POS N
observed POS N
up POS N
to POS N
week POS N
240. POS N

Overall, POS N
six POS N
patients POS N
achieved POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
and POS N
one POS N
patient POS N
(FTC/TDF POS N
arm) POS N
had POS N
HBsAg POS N
seroconversion POS N
by POS N
week POS N
240. POS N

No POS N
TDF POS N
resistance POS N
was POS N
observed POS N
up POS N
to POS N
week POS N
240. POS N

Treatment POS N
was POS N
generally POS N
well POS N
tolerated, POS N
and POS N
renal POS N
events POS N
were POS N
mild POS N
and POS N
infrequent POS N
(∼8.6%). POS N

No POS N
TDF POS N
resistance POS N
was POS N
observed POS N
up POS N
to POS N
week POS N
240. POS N

The POS N
mean POS N
change POS N
in POS N
bone POS N
mineral POS N
density POS N
at POS N
week POS N
240 POS N
was POS N
-0.98% POS N
and POS N
-2.54% POS N
at POS N
the POS N
spine POS N
and POS N
hip, POS N
respectively. POS N

No POS N
TDF POS N
resistance POS N
was POS N
observed POS N
up POS N
to POS N
week POS N
240. POS N

TDF POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
in POS N
LAM-R POS N
CHB POS N
patients POS N
for POS N
up POS N
to POS N
240 POS N
weeks. POS N

Treatment POS N
was POS N
generally POS N
well POS N
tolerated, POS N
and POS N
renal POS N
events POS N
were POS N
mild POS N
and POS N
infrequent POS N
(∼8.6%). POS N

Tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
without POS N
TDF POS N
resistance POS N
development POS N
in POS N
CHB POS N
patients POS N
with POS N
LAM-R, POS N
for POS N
up POS N
to POS N
240weeks. POS N

Treatment POS N
was POS N
generally POS N
well POS N
tolerated, POS N
and POS N
renal POS N
events POS N
were POS N
mild POS N
and POS N
infrequent POS N
(∼8.6%). POS N

At POS N
week POS N
240, POS N
83.0% POS N
of POS N
patients POS N
in POS N
the POS N
TDF POS N
arm, POS N
and POS N
82.7% POS N
of POS N
patients POS N
in POS N
the POS N
FTC/TDF POS N
treatment POS N
arm POS N
had POS N
HBV POS N
DNA<69IU/ml POS N
(p=0.96). POS N

Treatment POS N
was POS N
generally POS N
well POS N
tolerated, POS N
and POS N
renal POS N
events POS N
were POS N
mild POS N
and POS N
infrequent POS N
(∼8.6%). POS N

Rates POS N
of POS N
normal POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
and POS N
normalised POS N
ALT POS N
were POS N
similar POS N
between POS N
groups POS N
(p=0.41 POS N
and POS N
p=0.97 POS N
respectively). POS N

Treatment POS N
was POS N
generally POS N
well POS N
tolerated, POS N
and POS N
renal POS N
events POS N
were POS N
mild POS N
and POS N
infrequent POS N
(∼8.6%). POS N

Hepatitis POS N
B POS N
e POS N
antigen POS N
loss POS N
and POS N
seroconversion POS N
at POS N
week POS N
240 POS N
were POS N
similar POS N
between POS N
groups, POS N
(p=0.41 POS N
and POS N
p=0.67 POS N
respectively). POS N

Treatment POS N
was POS N
generally POS N
well POS N
tolerated, POS N
and POS N
renal POS N
events POS N
were POS N
mild POS N
and POS N
infrequent POS N
(∼8.6%). POS N

Overall, POS N
six POS N
patients POS N
achieved POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
and POS N
one POS N
patient POS N
(FTC/TDF POS N
arm) POS N
had POS N
HBsAg POS N
seroconversion POS N
by POS N
week POS N
240. POS N

Treatment POS N
was POS N
generally POS N
well POS N
tolerated, POS N
and POS N
renal POS N
events POS N
were POS N
mild POS N
and POS N
infrequent POS N
(∼8.6%). POS N

No POS N
TDF POS N
resistance POS N
was POS N
observed POS N
up POS N
to POS N
week POS N
240. POS N

Treatment POS N
was POS N
generally POS N
well POS N
tolerated, POS N
and POS N
renal POS N
events POS N
were POS N
mild POS N
and POS N
infrequent POS N
(∼8.6%). POS N

The POS N
mean POS N
change POS N
in POS N
bone POS N
mineral POS N
density POS N
at POS N
week POS N
240 POS N
was POS N
-0.98% POS N
and POS N
-2.54% POS N
at POS N
the POS N
spine POS N
and POS N
hip, POS N
respectively. POS N

Treatment POS N
was POS N
generally POS N
well POS N
tolerated, POS N
and POS N
renal POS N
events POS N
were POS N
mild POS N
and POS N
infrequent POS N
(∼8.6%). POS N

TDF POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
in POS N
LAM-R POS N
CHB POS N
patients POS N
for POS N
up POS N
to POS N
240 POS N
weeks. POS N

The POS N
mean POS N
change POS N
in POS N
bone POS N
mineral POS N
density POS N
at POS N
week POS N
240 POS N
was POS N
-0.98% POS N
and POS N
-2.54% POS N
at POS N
the POS N
spine POS N
and POS N
hip, POS N
respectively. POS N

Tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
without POS N
TDF POS N
resistance POS N
development POS N
in POS N
CHB POS N
patients POS N
with POS N
LAM-R, POS N
for POS N
up POS N
to POS N
240weeks. POS N

The POS N
mean POS N
change POS N
in POS N
bone POS N
mineral POS N
density POS N
at POS N
week POS N
240 POS N
was POS N
-0.98% POS N
and POS N
-2.54% POS N
at POS N
the POS N
spine POS N
and POS N
hip, POS N
respectively. POS N

At POS N
week POS N
240, POS N
83.0% POS N
of POS N
patients POS N
in POS N
the POS N
TDF POS N
arm, POS N
and POS N
82.7% POS N
of POS N
patients POS N
in POS N
the POS N
FTC/TDF POS N
treatment POS N
arm POS N
had POS N
HBV POS N
DNA<69IU/ml POS N
(p=0.96). POS N

The POS N
mean POS N
change POS N
in POS N
bone POS N
mineral POS N
density POS N
at POS N
week POS N
240 POS N
was POS N
-0.98% POS N
and POS N
-2.54% POS N
at POS N
the POS N
spine POS N
and POS N
hip, POS N
respectively. POS N

Rates POS N
of POS N
normal POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
and POS N
normalised POS N
ALT POS N
were POS N
similar POS N
between POS N
groups POS N
(p=0.41 POS N
and POS N
p=0.97 POS N
respectively). POS N

The POS N
mean POS N
change POS N
in POS N
bone POS N
mineral POS N
density POS N
at POS N
week POS N
240 POS N
was POS N
-0.98% POS N
and POS N
-2.54% POS N
at POS N
the POS N
spine POS N
and POS N
hip, POS N
respectively. POS N

Hepatitis POS N
B POS N
e POS N
antigen POS N
loss POS N
and POS N
seroconversion POS N
at POS N
week POS N
240 POS N
were POS N
similar POS N
between POS N
groups, POS N
(p=0.41 POS N
and POS N
p=0.67 POS N
respectively). POS N

The POS N
mean POS N
change POS N
in POS N
bone POS N
mineral POS N
density POS N
at POS N
week POS N
240 POS N
was POS N
-0.98% POS N
and POS N
-2.54% POS N
at POS N
the POS N
spine POS N
and POS N
hip, POS N
respectively. POS N

Overall, POS N
six POS N
patients POS N
achieved POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
and POS N
one POS N
patient POS N
(FTC/TDF POS N
arm) POS N
had POS N
HBsAg POS N
seroconversion POS N
by POS N
week POS N
240. POS N

The POS N
mean POS N
change POS N
in POS N
bone POS N
mineral POS N
density POS N
at POS N
week POS N
240 POS N
was POS N
-0.98% POS N
and POS N
-2.54% POS N
at POS N
the POS N
spine POS N
and POS N
hip, POS N
respectively. POS N

No POS N
TDF POS N
resistance POS N
was POS N
observed POS N
up POS N
to POS N
week POS N
240. POS N

The POS N
mean POS N
change POS N
in POS N
bone POS N
mineral POS N
density POS N
at POS N
week POS N
240 POS N
was POS N
-0.98% POS N
and POS N
-2.54% POS N
at POS N
the POS N
spine POS N
and POS N
hip, POS N
respectively. POS N

Treatment POS N
was POS N
generally POS N
well POS N
tolerated, POS N
and POS N
renal POS N
events POS N
were POS N
mild POS N
and POS N
infrequent POS N
(∼8.6%). POS N

The POS N
mean POS N
change POS N
in POS N
bone POS N
mineral POS N
density POS N
at POS N
week POS N
240 POS N
was POS N
-0.98% POS N
and POS N
-2.54% POS N
at POS N
the POS N
spine POS N
and POS N
hip, POS N
respectively. POS N

TDF POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
in POS N
LAM-R POS N
CHB POS N
patients POS N
for POS N
up POS N
to POS N
240 POS N
weeks. POS N

TDF POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
in POS N
LAM-R POS N
CHB POS N
patients POS N
for POS N
up POS N
to POS N
240 POS N
weeks. POS N

Tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
without POS N
TDF POS N
resistance POS N
development POS N
in POS N
CHB POS N
patients POS N
with POS N
LAM-R, POS N
for POS N
up POS N
to POS N
240weeks. POS N

TDF POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
in POS N
LAM-R POS N
CHB POS N
patients POS N
for POS N
up POS N
to POS N
240 POS N
weeks. POS N

At POS N
week POS N
240, POS N
83.0% POS N
of POS N
patients POS N
in POS N
the POS N
TDF POS N
arm, POS N
and POS N
82.7% POS N
of POS N
patients POS N
in POS N
the POS N
FTC/TDF POS N
treatment POS N
arm POS N
had POS N
HBV POS N
DNA<69IU/ml POS N
(p=0.96). POS N

TDF POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
in POS N
LAM-R POS N
CHB POS N
patients POS N
for POS N
up POS N
to POS N
240 POS N
weeks. POS N

Rates POS N
of POS N
normal POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
and POS N
normalised POS N
ALT POS N
were POS N
similar POS N
between POS N
groups POS N
(p=0.41 POS N
and POS N
p=0.97 POS N
respectively). POS N

TDF POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
in POS N
LAM-R POS N
CHB POS N
patients POS N
for POS N
up POS N
to POS N
240 POS N
weeks. POS N

Hepatitis POS N
B POS N
e POS N
antigen POS N
loss POS N
and POS N
seroconversion POS N
at POS N
week POS N
240 POS N
were POS N
similar POS N
between POS N
groups, POS N
(p=0.41 POS N
and POS N
p=0.67 POS N
respectively). POS N

TDF POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
in POS N
LAM-R POS N
CHB POS N
patients POS N
for POS N
up POS N
to POS N
240 POS N
weeks. POS N

Overall, POS N
six POS N
patients POS N
achieved POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
and POS N
one POS N
patient POS N
(FTC/TDF POS N
arm) POS N
had POS N
HBsAg POS N
seroconversion POS N
by POS N
week POS N
240. POS N

TDF POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
in POS N
LAM-R POS N
CHB POS N
patients POS N
for POS N
up POS N
to POS N
240 POS N
weeks. POS N

No POS N
TDF POS N
resistance POS N
was POS N
observed POS N
up POS N
to POS N
week POS N
240. POS N

TDF POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
in POS N
LAM-R POS N
CHB POS N
patients POS N
for POS N
up POS N
to POS N
240 POS N
weeks. POS N

Treatment POS N
was POS N
generally POS N
well POS N
tolerated, POS N
and POS N
renal POS N
events POS N
were POS N
mild POS N
and POS N
infrequent POS N
(∼8.6%). POS N

TDF POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
in POS N
LAM-R POS N
CHB POS N
patients POS N
for POS N
up POS N
to POS N
240 POS N
weeks. POS N

The POS N
mean POS N
change POS N
in POS N
bone POS N
mineral POS N
density POS N
at POS N
week POS N
240 POS N
was POS N
-0.98% POS N
and POS N
-2.54% POS N
at POS N
the POS N
spine POS N
and POS N
hip, POS N
respectively. POS N

Compared POS N
with POS N
baseline, POS N
IOP POS N
drop POS N
at POS N
last POS N
visit POS N
was POS N
11.76±5.51 POS N
and POS N
13.43±5.92 POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.207). POS N

At POS N
last POS N
visit, POS N
complete POS N
success POS N
was POS N
achieved POS N
in POS N
25 POS N
cases POS N
(61%) POS N
of POS N
bevacizumab POS N
group POS N
and POS N
23 POS N
cases POS N
(66%) POS N
of POS N
MMC POS N
group POS N
(P=0.669). POS N

Compared POS N
with POS N
baseline, POS N
IOP POS N
drop POS N
at POS N
last POS N
visit POS N
was POS N
11.76±5.51 POS N
and POS N
13.43±5.92 POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.207). POS N

Early POS N
filtering POS N
bleb POS N
leak POS N
was POS N
more POS N
prevalent POS N
in POS N
bevacizumab POS N
group POS N
(29% POS N
vs. POS N
11%). POS N

Compared POS N
with POS N
baseline, POS N
IOP POS N
drop POS N
at POS N
last POS N
visit POS N
was POS N
11.76±5.51 POS N
and POS N
13.43±5.92 POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.207). POS N

A POS N
single POS N
1.25 mg POS N
dose POS N
of POS N
intracameral POS N
bevacizumab POS N
improves POS N
the POS N
success POS N
of POS N
trabeculectomy POS N
comparable POS N
with POS N
MMC; POS N

Compared POS N
with POS N
baseline, POS N
IOP POS N
drop POS N
at POS N
last POS N
visit POS N
was POS N
11.76±5.51 POS N
and POS N
13.43±5.92 POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.207). POS N

however, POS N
it POS N
increases POS N
the POS N
risk POS N
of POS N
early POS N
filtering POS N
bleb POS N
leakage. POS N

Compared POS N
with POS N
baseline, POS N
IOP POS N
drop POS N
at POS N
last POS N
visit POS N
was POS N
11.76±5.51 POS N
and POS N
13.43±5.92 POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.207). POS N

The POS N
preoperative POS N
IOP POS N
was POS N
29.17±3.94 POS N
and POS N
28.8±4.08 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.689). POS N

Compared POS N
with POS N
baseline, POS N
IOP POS N
drop POS N
at POS N
last POS N
visit POS N
was POS N
11.76±5.51 POS N
and POS N
13.43±5.92 POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.207). POS N

Last POS N
visit POS N
IOP POS N
was POS N
17.41±3.11 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
group POS N
and POS N
15.34±3.62 mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.009). POS N

At POS N
last POS N
visit, POS N
complete POS N
success POS N
was POS N
achieved POS N
in POS N
25 POS N
cases POS N
(61%) POS N
of POS N
bevacizumab POS N
group POS N
and POS N
23 POS N
cases POS N
(66%) POS N
of POS N
MMC POS N
group POS N
(P=0.669). POS N

Compared POS N
with POS N
baseline, POS N
IOP POS N
drop POS N
at POS N
last POS N
visit POS N
was POS N
11.76±5.51 POS N
and POS N
13.43±5.92 POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.207). POS N

At POS N
last POS N
visit, POS N
complete POS N
success POS N
was POS N
achieved POS N
in POS N
25 POS N
cases POS N
(61%) POS N
of POS N
bevacizumab POS N
group POS N
and POS N
23 POS N
cases POS N
(66%) POS N
of POS N
MMC POS N
group POS N
(P=0.669). POS N

Early POS N
filtering POS N
bleb POS N
leak POS N
was POS N
more POS N
prevalent POS N
in POS N
bevacizumab POS N
group POS N
(29% POS N
vs. POS N
11%). POS N

At POS N
last POS N
visit, POS N
complete POS N
success POS N
was POS N
achieved POS N
in POS N
25 POS N
cases POS N
(61%) POS N
of POS N
bevacizumab POS N
group POS N
and POS N
23 POS N
cases POS N
(66%) POS N
of POS N
MMC POS N
group POS N
(P=0.669). POS N

A POS N
single POS N
1.25 mg POS N
dose POS N
of POS N
intracameral POS N
bevacizumab POS N
improves POS N
the POS N
success POS N
of POS N
trabeculectomy POS N
comparable POS N
with POS N
MMC; POS N

At POS N
last POS N
visit, POS N
complete POS N
success POS N
was POS N
achieved POS N
in POS N
25 POS N
cases POS N
(61%) POS N
of POS N
bevacizumab POS N
group POS N
and POS N
23 POS N
cases POS N
(66%) POS N
of POS N
MMC POS N
group POS N
(P=0.669). POS N

however, POS N
it POS N
increases POS N
the POS N
risk POS N
of POS N
early POS N
filtering POS N
bleb POS N
leakage. POS N

At POS N
last POS N
visit, POS N
complete POS N
success POS N
was POS N
achieved POS N
in POS N
25 POS N
cases POS N
(61%) POS N
of POS N
bevacizumab POS N
group POS N
and POS N
23 POS N
cases POS N
(66%) POS N
of POS N
MMC POS N
group POS N
(P=0.669). POS N

The POS N
preoperative POS N
IOP POS N
was POS N
29.17±3.94 POS N
and POS N
28.8±4.08 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.689). POS N

At POS N
last POS N
visit, POS N
complete POS N
success POS N
was POS N
achieved POS N
in POS N
25 POS N
cases POS N
(61%) POS N
of POS N
bevacizumab POS N
group POS N
and POS N
23 POS N
cases POS N
(66%) POS N
of POS N
MMC POS N
group POS N
(P=0.669). POS N

Last POS N
visit POS N
IOP POS N
was POS N
17.41±3.11 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
group POS N
and POS N
15.34±3.62 mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.009). POS N

Early POS N
filtering POS N
bleb POS N
leak POS N
was POS N
more POS N
prevalent POS N
in POS N
bevacizumab POS N
group POS N
(29% POS N
vs. POS N
11%). POS N

Compared POS N
with POS N
baseline, POS N
IOP POS N
drop POS N
at POS N
last POS N
visit POS N
was POS N
11.76±5.51 POS N
and POS N
13.43±5.92 POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.207). POS N

Early POS N
filtering POS N
bleb POS N
leak POS N
was POS N
more POS N
prevalent POS N
in POS N
bevacizumab POS N
group POS N
(29% POS N
vs. POS N
11%). POS N

At POS N
last POS N
visit, POS N
complete POS N
success POS N
was POS N
achieved POS N
in POS N
25 POS N
cases POS N
(61%) POS N
of POS N
bevacizumab POS N
group POS N
and POS N
23 POS N
cases POS N
(66%) POS N
of POS N
MMC POS N
group POS N
(P=0.669). POS N

Early POS N
filtering POS N
bleb POS N
leak POS N
was POS N
more POS N
prevalent POS N
in POS N
bevacizumab POS N
group POS N
(29% POS N
vs. POS N
11%). POS N

A POS N
single POS N
1.25 mg POS N
dose POS N
of POS N
intracameral POS N
bevacizumab POS N
improves POS N
the POS N
success POS N
of POS N
trabeculectomy POS N
comparable POS N
with POS N
MMC; POS N

Early POS N
filtering POS N
bleb POS N
leak POS N
was POS N
more POS N
prevalent POS N
in POS N
bevacizumab POS N
group POS N
(29% POS N
vs. POS N
11%). POS N

however, POS N
it POS N
increases POS N
the POS N
risk POS N
of POS N
early POS N
filtering POS N
bleb POS N
leakage. POS N

Early POS N
filtering POS N
bleb POS N
leak POS N
was POS N
more POS N
prevalent POS N
in POS N
bevacizumab POS N
group POS N
(29% POS N
vs. POS N
11%). POS N

The POS N
preoperative POS N
IOP POS N
was POS N
29.17±3.94 POS N
and POS N
28.8±4.08 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.689). POS N

Early POS N
filtering POS N
bleb POS N
leak POS N
was POS N
more POS N
prevalent POS N
in POS N
bevacizumab POS N
group POS N
(29% POS N
vs. POS N
11%). POS N

Last POS N
visit POS N
IOP POS N
was POS N
17.41±3.11 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
group POS N
and POS N
15.34±3.62 mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.009). POS N

A POS N
single POS N
1.25 mg POS N
dose POS N
of POS N
intracameral POS N
bevacizumab POS N
improves POS N
the POS N
success POS N
of POS N
trabeculectomy POS N
comparable POS N
with POS N
MMC; POS N

Compared POS N
with POS N
baseline, POS N
IOP POS N
drop POS N
at POS N
last POS N
visit POS N
was POS N
11.76±5.51 POS N
and POS N
13.43±5.92 POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.207). POS N

A POS N
single POS N
1.25 mg POS N
dose POS N
of POS N
intracameral POS N
bevacizumab POS N
improves POS N
the POS N
success POS N
of POS N
trabeculectomy POS N
comparable POS N
with POS N
MMC; POS N

At POS N
last POS N
visit, POS N
complete POS N
success POS N
was POS N
achieved POS N
in POS N
25 POS N
cases POS N
(61%) POS N
of POS N
bevacizumab POS N
group POS N
and POS N
23 POS N
cases POS N
(66%) POS N
of POS N
MMC POS N
group POS N
(P=0.669). POS N

A POS N
single POS N
1.25 mg POS N
dose POS N
of POS N
intracameral POS N
bevacizumab POS N
improves POS N
the POS N
success POS N
of POS N
trabeculectomy POS N
comparable POS N
with POS N
MMC; POS N

Early POS N
filtering POS N
bleb POS N
leak POS N
was POS N
more POS N
prevalent POS N
in POS N
bevacizumab POS N
group POS N
(29% POS N
vs. POS N
11%). POS N

A POS N
single POS N
1.25 mg POS N
dose POS N
of POS N
intracameral POS N
bevacizumab POS N
improves POS N
the POS N
success POS N
of POS N
trabeculectomy POS N
comparable POS N
with POS N
MMC; POS N

however, POS N
it POS N
increases POS N
the POS N
risk POS N
of POS N
early POS N
filtering POS N
bleb POS N
leakage. POS N

A POS N
single POS N
1.25 mg POS N
dose POS N
of POS N
intracameral POS N
bevacizumab POS N
improves POS N
the POS N
success POS N
of POS N
trabeculectomy POS N
comparable POS N
with POS N
MMC; POS N

The POS N
preoperative POS N
IOP POS N
was POS N
29.17±3.94 POS N
and POS N
28.8±4.08 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.689). POS N

A POS N
single POS N
1.25 mg POS N
dose POS N
of POS N
intracameral POS N
bevacizumab POS N
improves POS N
the POS N
success POS N
of POS N
trabeculectomy POS N
comparable POS N
with POS N
MMC; POS N

Last POS N
visit POS N
IOP POS N
was POS N
17.41±3.11 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
group POS N
and POS N
15.34±3.62 mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.009). POS N

however, POS N
it POS N
increases POS N
the POS N
risk POS N
of POS N
early POS N
filtering POS N
bleb POS N
leakage. POS N

Compared POS N
with POS N
baseline, POS N
IOP POS N
drop POS N
at POS N
last POS N
visit POS N
was POS N
11.76±5.51 POS N
and POS N
13.43±5.92 POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.207). POS N

however, POS N
it POS N
increases POS N
the POS N
risk POS N
of POS N
early POS N
filtering POS N
bleb POS N
leakage. POS N

At POS N
last POS N
visit, POS N
complete POS N
success POS N
was POS N
achieved POS N
in POS N
25 POS N
cases POS N
(61%) POS N
of POS N
bevacizumab POS N
group POS N
and POS N
23 POS N
cases POS N
(66%) POS N
of POS N
MMC POS N
group POS N
(P=0.669). POS N

however, POS N
it POS N
increases POS N
the POS N
risk POS N
of POS N
early POS N
filtering POS N
bleb POS N
leakage. POS N

Early POS N
filtering POS N
bleb POS N
leak POS N
was POS N
more POS N
prevalent POS N
in POS N
bevacizumab POS N
group POS N
(29% POS N
vs. POS N
11%). POS N

however, POS N
it POS N
increases POS N
the POS N
risk POS N
of POS N
early POS N
filtering POS N
bleb POS N
leakage. POS N

A POS N
single POS N
1.25 mg POS N
dose POS N
of POS N
intracameral POS N
bevacizumab POS N
improves POS N
the POS N
success POS N
of POS N
trabeculectomy POS N
comparable POS N
with POS N
MMC; POS N

however, POS N
it POS N
increases POS N
the POS N
risk POS N
of POS N
early POS N
filtering POS N
bleb POS N
leakage. POS N

The POS N
preoperative POS N
IOP POS N
was POS N
29.17±3.94 POS N
and POS N
28.8±4.08 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.689). POS N

however, POS N
it POS N
increases POS N
the POS N
risk POS N
of POS N
early POS N
filtering POS N
bleb POS N
leakage. POS N

Last POS N
visit POS N
IOP POS N
was POS N
17.41±3.11 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
group POS N
and POS N
15.34±3.62 mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.009). POS N

The POS N
preoperative POS N
IOP POS N
was POS N
29.17±3.94 POS N
and POS N
28.8±4.08 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.689). POS N

Compared POS N
with POS N
baseline, POS N
IOP POS N
drop POS N
at POS N
last POS N
visit POS N
was POS N
11.76±5.51 POS N
and POS N
13.43±5.92 POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.207). POS N

The POS N
preoperative POS N
IOP POS N
was POS N
29.17±3.94 POS N
and POS N
28.8±4.08 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.689). POS N

At POS N
last POS N
visit, POS N
complete POS N
success POS N
was POS N
achieved POS N
in POS N
25 POS N
cases POS N
(61%) POS N
of POS N
bevacizumab POS N
group POS N
and POS N
23 POS N
cases POS N
(66%) POS N
of POS N
MMC POS N
group POS N
(P=0.669). POS N

The POS N
preoperative POS N
IOP POS N
was POS N
29.17±3.94 POS N
and POS N
28.8±4.08 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.689). POS N

Early POS N
filtering POS N
bleb POS N
leak POS N
was POS N
more POS N
prevalent POS N
in POS N
bevacizumab POS N
group POS N
(29% POS N
vs. POS N
11%). POS N

The POS N
preoperative POS N
IOP POS N
was POS N
29.17±3.94 POS N
and POS N
28.8±4.08 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.689). POS N

A POS N
single POS N
1.25 mg POS N
dose POS N
of POS N
intracameral POS N
bevacizumab POS N
improves POS N
the POS N
success POS N
of POS N
trabeculectomy POS N
comparable POS N
with POS N
MMC; POS N

The POS N
preoperative POS N
IOP POS N
was POS N
29.17±3.94 POS N
and POS N
28.8±4.08 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.689). POS N

however, POS N
it POS N
increases POS N
the POS N
risk POS N
of POS N
early POS N
filtering POS N
bleb POS N
leakage. POS N

The POS N
preoperative POS N
IOP POS N
was POS N
29.17±3.94 POS N
and POS N
28.8±4.08 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.689). POS N

Last POS N
visit POS N
IOP POS N
was POS N
17.41±3.11 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
group POS N
and POS N
15.34±3.62 mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.009). POS N

Last POS N
visit POS N
IOP POS N
was POS N
17.41±3.11 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
group POS N
and POS N
15.34±3.62 mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.009). POS N

Compared POS N
with POS N
baseline, POS N
IOP POS N
drop POS N
at POS N
last POS N
visit POS N
was POS N
11.76±5.51 POS N
and POS N
13.43±5.92 POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.207). POS N

Last POS N
visit POS N
IOP POS N
was POS N
17.41±3.11 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
group POS N
and POS N
15.34±3.62 mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.009). POS N

At POS N
last POS N
visit, POS N
complete POS N
success POS N
was POS N
achieved POS N
in POS N
25 POS N
cases POS N
(61%) POS N
of POS N
bevacizumab POS N
group POS N
and POS N
23 POS N
cases POS N
(66%) POS N
of POS N
MMC POS N
group POS N
(P=0.669). POS N

Last POS N
visit POS N
IOP POS N
was POS N
17.41±3.11 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
group POS N
and POS N
15.34±3.62 mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.009). POS N

Early POS N
filtering POS N
bleb POS N
leak POS N
was POS N
more POS N
prevalent POS N
in POS N
bevacizumab POS N
group POS N
(29% POS N
vs. POS N
11%). POS N

Last POS N
visit POS N
IOP POS N
was POS N
17.41±3.11 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
group POS N
and POS N
15.34±3.62 mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.009). POS N

A POS N
single POS N
1.25 mg POS N
dose POS N
of POS N
intracameral POS N
bevacizumab POS N
improves POS N
the POS N
success POS N
of POS N
trabeculectomy POS N
comparable POS N
with POS N
MMC; POS N

Last POS N
visit POS N
IOP POS N
was POS N
17.41±3.11 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
group POS N
and POS N
15.34±3.62 mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.009). POS N

however, POS N
it POS N
increases POS N
the POS N
risk POS N
of POS N
early POS N
filtering POS N
bleb POS N
leakage. POS N

Last POS N
visit POS N
IOP POS N
was POS N
17.41±3.11 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
group POS N
and POS N
15.34±3.62 mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.009). POS N

The POS N
preoperative POS N
IOP POS N
was POS N
29.17±3.94 POS N
and POS N
28.8±4.08 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.689). POS N

Treatment-related POS N
quality POS N
of POS N
life POS N
(QOL) POS N
is POS N
an POS N
important POS N
aspect POS N
of POS N
diabetes POS N
management. POS N

Compared POS N
with POS N
baseline POS N
data, POS N
total POS N
DTR-QOL17 POS N
scores POS N
were POS N
significantly POS N
higher POS N
after POS N
12 POS N
weeks POS N
of POS N
linagliptin POS N
and POS N
voglibose POS N
treatment. POS N

Treatment-related POS N
quality POS N
of POS N
life POS N
(QOL) POS N
is POS N
an POS N
important POS N
aspect POS N
of POS N
diabetes POS N
management. POS N

The POS N
change POS N
in POS N
the POS N
total POS N
DTR-QOL17 POS N
score POS N
and POS N
the POS N
score POS N
of POS N
one POS N
domain, POS N
burden POS N
on POS N
social POS N
activities POS N
and POS N
daily POS N
activities, POS N
was POS N
significantly POS N
greater POS N
in POS N
the POS N
linagliptin POS N
group POS N
than POS N
in POS N
the POS N
voglibose POS N
group. POS N

Treatment-related POS N
quality POS N
of POS N
life POS N
(QOL) POS N
is POS N
an POS N
important POS N
aspect POS N
of POS N
diabetes POS N
management. POS N

In POS N
addition, POS N
only POS N
linagliptin POS N
treatment POS N
was POS N
identified POS N
as POS N
a POS N
factor POS N
associated POS N
with POS N
an POS N
increased POS N
total POS N
DTR-QOL17 POS N
score. POS N

Treatment-related POS N
quality POS N
of POS N
life POS N
(QOL) POS N
is POS N
an POS N
important POS N
aspect POS N
of POS N
diabetes POS N
management. POS N

Linagliptin POS N
is POS N
superior POS N
to POS N
voglibose POS N
in POS N
terms POS N
of POS N
improving POS N
treatment-related POS N
QOL POS N
in POS N
Japanese POS N
patients POS N
with POS N
T2DM. POS N

Compared POS N
with POS N
baseline POS N
data, POS N
total POS N
DTR-QOL17 POS N
scores POS N
were POS N
significantly POS N
higher POS N
after POS N
12 POS N
weeks POS N
of POS N
linagliptin POS N
and POS N
voglibose POS N
treatment. POS N

Treatment-related POS N
quality POS N
of POS N
life POS N
(QOL) POS N
is POS N
an POS N
important POS N
aspect POS N
of POS N
diabetes POS N
management. POS N

Compared POS N
with POS N
baseline POS N
data, POS N
total POS N
DTR-QOL17 POS N
scores POS N
were POS N
significantly POS N
higher POS N
after POS N
12 POS N
weeks POS N
of POS N
linagliptin POS N
and POS N
voglibose POS N
treatment. POS N

The POS N
change POS N
in POS N
the POS N
total POS N
DTR-QOL17 POS N
score POS N
and POS N
the POS N
score POS N
of POS N
one POS N
domain, POS N
burden POS N
on POS N
social POS N
activities POS N
and POS N
daily POS N
activities, POS N
was POS N
significantly POS N
greater POS N
in POS N
the POS N
linagliptin POS N
group POS N
than POS N
in POS N
the POS N
voglibose POS N
group. POS N

Compared POS N
with POS N
baseline POS N
data, POS N
total POS N
DTR-QOL17 POS N
scores POS N
were POS N
significantly POS N
higher POS N
after POS N
12 POS N
weeks POS N
of POS N
linagliptin POS N
and POS N
voglibose POS N
treatment. POS N

In POS N
addition, POS N
only POS N
linagliptin POS N
treatment POS N
was POS N
identified POS N
as POS N
a POS N
factor POS N
associated POS N
with POS N
an POS N
increased POS N
total POS N
DTR-QOL17 POS N
score. POS N

Compared POS N
with POS N
baseline POS N
data, POS N
total POS N
DTR-QOL17 POS N
scores POS N
were POS N
significantly POS N
higher POS N
after POS N
12 POS N
weeks POS N
of POS N
linagliptin POS N
and POS N
voglibose POS N
treatment. POS N

Linagliptin POS N
is POS N
superior POS N
to POS N
voglibose POS N
in POS N
terms POS N
of POS N
improving POS N
treatment-related POS N
QOL POS N
in POS N
Japanese POS N
patients POS N
with POS N
T2DM. POS N

The POS N
change POS N
in POS N
the POS N
total POS N
DTR-QOL17 POS N
score POS N
and POS N
the POS N
score POS N
of POS N
one POS N
domain, POS N
burden POS N
on POS N
social POS N
activities POS N
and POS N
daily POS N
activities, POS N
was POS N
significantly POS N
greater POS N
in POS N
the POS N
linagliptin POS N
group POS N
than POS N
in POS N
the POS N
voglibose POS N
group. POS N

Treatment-related POS N
quality POS N
of POS N
life POS N
(QOL) POS N
is POS N
an POS N
important POS N
aspect POS N
of POS N
diabetes POS N
management. POS N

The POS N
change POS N
in POS N
the POS N
total POS N
DTR-QOL17 POS N
score POS N
and POS N
the POS N
score POS N
of POS N
one POS N
domain, POS N
burden POS N
on POS N
social POS N
activities POS N
and POS N
daily POS N
activities, POS N
was POS N
significantly POS N
greater POS N
in POS N
the POS N
linagliptin POS N
group POS N
than POS N
in POS N
the POS N
voglibose POS N
group. POS N

Compared POS N
with POS N
baseline POS N
data, POS N
total POS N
DTR-QOL17 POS N
scores POS N
were POS N
significantly POS N
higher POS N
after POS N
12 POS N
weeks POS N
of POS N
linagliptin POS N
and POS N
voglibose POS N
treatment. POS N

The POS N
change POS N
in POS N
the POS N
total POS N
DTR-QOL17 POS N
score POS N
and POS N
the POS N
score POS N
of POS N
one POS N
domain, POS N
burden POS N
on POS N
social POS N
activities POS N
and POS N
daily POS N
activities, POS N
was POS N
significantly POS N
greater POS N
in POS N
the POS N
linagliptin POS N
group POS N
than POS N
in POS N
the POS N
voglibose POS N
group. POS N

In POS N
addition, POS N
only POS N
linagliptin POS N
treatment POS N
was POS N
identified POS N
as POS N
a POS N
factor POS N
associated POS N
with POS N
an POS N
increased POS N
total POS N
DTR-QOL17 POS N
score. POS N

The POS N
change POS N
in POS N
the POS N
total POS N
DTR-QOL17 POS N
score POS N
and POS N
the POS N
score POS N
of POS N
one POS N
domain, POS N
burden POS N
on POS N
social POS N
activities POS N
and POS N
daily POS N
activities, POS N
was POS N
significantly POS N
greater POS N
in POS N
the POS N
linagliptin POS N
group POS N
than POS N
in POS N
the POS N
voglibose POS N
group. POS N

Linagliptin POS N
is POS N
superior POS N
to POS N
voglibose POS N
in POS N
terms POS N
of POS N
improving POS N
treatment-related POS N
QOL POS N
in POS N
Japanese POS N
patients POS N
with POS N
T2DM. POS N

In POS N
addition, POS N
only POS N
linagliptin POS N
treatment POS N
was POS N
identified POS N
as POS N
a POS N
factor POS N
associated POS N
with POS N
an POS N
increased POS N
total POS N
DTR-QOL17 POS N
score. POS N

Treatment-related POS N
quality POS N
of POS N
life POS N
(QOL) POS N
is POS N
an POS N
important POS N
aspect POS N
of POS N
diabetes POS N
management. POS N

In POS N
addition, POS N
only POS N
linagliptin POS N
treatment POS N
was POS N
identified POS N
as POS N
a POS N
factor POS N
associated POS N
with POS N
an POS N
increased POS N
total POS N
DTR-QOL17 POS N
score. POS N

Compared POS N
with POS N
baseline POS N
data, POS N
total POS N
DTR-QOL17 POS N
scores POS N
were POS N
significantly POS N
higher POS N
after POS N
12 POS N
weeks POS N
of POS N
linagliptin POS N
and POS N
voglibose POS N
treatment. POS N

In POS N
addition, POS N
only POS N
linagliptin POS N
treatment POS N
was POS N
identified POS N
as POS N
a POS N
factor POS N
associated POS N
with POS N
an POS N
increased POS N
total POS N
DTR-QOL17 POS N
score. POS N

The POS N
change POS N
in POS N
the POS N
total POS N
DTR-QOL17 POS N
score POS N
and POS N
the POS N
score POS N
of POS N
one POS N
domain, POS N
burden POS N
on POS N
social POS N
activities POS N
and POS N
daily POS N
activities, POS N
was POS N
significantly POS N
greater POS N
in POS N
the POS N
linagliptin POS N
group POS N
than POS N
in POS N
the POS N
voglibose POS N
group. POS N

In POS N
addition, POS N
only POS N
linagliptin POS N
treatment POS N
was POS N
identified POS N
as POS N
a POS N
factor POS N
associated POS N
with POS N
an POS N
increased POS N
total POS N
DTR-QOL17 POS N
score. POS N

Linagliptin POS N
is POS N
superior POS N
to POS N
voglibose POS N
in POS N
terms POS N
of POS N
improving POS N
treatment-related POS N
QOL POS N
in POS N
Japanese POS N
patients POS N
with POS N
T2DM. POS N

Linagliptin POS N
is POS N
superior POS N
to POS N
voglibose POS N
in POS N
terms POS N
of POS N
improving POS N
treatment-related POS N
QOL POS N
in POS N
Japanese POS N
patients POS N
with POS N
T2DM. POS N

Treatment-related POS N
quality POS N
of POS N
life POS N
(QOL) POS N
is POS N
an POS N
important POS N
aspect POS N
of POS N
diabetes POS N
management. POS N

Linagliptin POS N
is POS N
superior POS N
to POS N
voglibose POS N
in POS N
terms POS N
of POS N
improving POS N
treatment-related POS N
QOL POS N
in POS N
Japanese POS N
patients POS N
with POS N
T2DM. POS N

Compared POS N
with POS N
baseline POS N
data, POS N
total POS N
DTR-QOL17 POS N
scores POS N
were POS N
significantly POS N
higher POS N
after POS N
12 POS N
weeks POS N
of POS N
linagliptin POS N
and POS N
voglibose POS N
treatment. POS N

Linagliptin POS N
is POS N
superior POS N
to POS N
voglibose POS N
in POS N
terms POS N
of POS N
improving POS N
treatment-related POS N
QOL POS N
in POS N
Japanese POS N
patients POS N
with POS N
T2DM. POS N

The POS N
change POS N
in POS N
the POS N
total POS N
DTR-QOL17 POS N
score POS N
and POS N
the POS N
score POS N
of POS N
one POS N
domain, POS N
burden POS N
on POS N
social POS N
activities POS N
and POS N
daily POS N
activities, POS N
was POS N
significantly POS N
greater POS N
in POS N
the POS N
linagliptin POS N
group POS N
than POS N
in POS N
the POS N
voglibose POS N
group. POS N

Linagliptin POS N
is POS N
superior POS N
to POS N
voglibose POS N
in POS N
terms POS N
of POS N
improving POS N
treatment-related POS N
QOL POS N
in POS N
Japanese POS N
patients POS N
with POS N
T2DM. POS N

In POS N
addition, POS N
only POS N
linagliptin POS N
treatment POS N
was POS N
identified POS N
as POS N
a POS N
factor POS N
associated POS N
with POS N
an POS N
increased POS N
total POS N
DTR-QOL17 POS N
score. POS N

At POS N
6 POS N
months, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
fell POS N
by POS N
27.0 POS N
mm POS N
Hg POS N
(to POS N
125.8 POS N
mm POS N
Hg) POS N
in POS N
the POS N
intervention POS N
group POS N
and POS N
by POS N
9.3 POS N
mm POS N
Hg POS N
(to POS N
145.4 POS N
mm POS N
Hg) POS N
in POS N
the POS N
control POS N
group; POS N
the POS N
mean POS N
reduction POS N
was POS N
21.6 POS N
mm POS N
Hg POS N
greater POS N
with POS N
the POS N
intervention POS N
(95% POS N
confidence POS N
interval, POS N
14.7 POS N
to POS N
28.4; POS N
P<0.001). POS N

A POS N
blood-pressure POS N
level POS N
of POS N
less POS N
than POS N
130/80 POS N
mm POS N
Hg POS N
was POS N
achieved POS N
among POS N
63.6% POS N
of POS N
the POS N
participants POS N
in POS N
the POS N
intervention POS N
group POS N
versus POS N
11.7% POS N
of POS N
the POS N
participants POS N
in POS N
the POS N
control POS N
group POS N
(P<0.001). POS N

At POS N
6 POS N
months, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
fell POS N
by POS N
27.0 POS N
mm POS N
Hg POS N
(to POS N
125.8 POS N
mm POS N
Hg) POS N
in POS N
the POS N
intervention POS N
group POS N
and POS N
by POS N
9.3 POS N
mm POS N
Hg POS N
(to POS N
145.4 POS N
mm POS N
Hg) POS N
in POS N
the POS N
control POS N
group; POS N
the POS N
mean POS N
reduction POS N
was POS N
21.6 POS N
mm POS N
Hg POS N
greater POS N
with POS N
the POS N
intervention POS N
(95% POS N
confidence POS N
interval, POS N
14.7 POS N
to POS N
28.4; POS N
P<0.001). POS N

In POS N
the POS N
intervention POS N
group, POS N
the POS N
rate POS N
of POS N
cohort POS N
retention POS N
was POS N
95%, POS N
and POS N
there POS N
were POS N
few POS N
adverse POS N
events POS N
(three POS N
cases POS N
of POS N
acute POS N
kidney POS N
injury). POS N

At POS N
6 POS N
months, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
fell POS N
by POS N
27.0 POS N
mm POS N
Hg POS N
(to POS N
125.8 POS N
mm POS N
Hg) POS N
in POS N
the POS N
intervention POS N
group POS N
and POS N
by POS N
9.3 POS N
mm POS N
Hg POS N
(to POS N
145.4 POS N
mm POS N
Hg) POS N
in POS N
the POS N
control POS N
group; POS N
the POS N
mean POS N
reduction POS N
was POS N
21.6 POS N
mm POS N
Hg POS N
greater POS N
with POS N
the POS N
intervention POS N
(95% POS N
confidence POS N
interval, POS N
14.7 POS N
to POS N
28.4; POS N
P<0.001). POS N

Among POS N
black POS N
male POS N
barbershop POS N
patrons POS N
with POS N
uncontrolled POS N
hypertension, POS N
health POS N
promotion POS N
by POS N
barbers POS N
resulted POS N
in POS N
larger POS N
blood-pressure POS N
reduction POS N
when POS N
coupled POS N
with POS N
medication POS N
management POS N
in POS N
barbershops POS N
by POS N
specialty-trained POS N
pharmacists. POS N

A POS N
blood-pressure POS N
level POS N
of POS N
less POS N
than POS N
130/80 POS N
mm POS N
Hg POS N
was POS N
achieved POS N
among POS N
63.6% POS N
of POS N
the POS N
participants POS N
in POS N
the POS N
intervention POS N
group POS N
versus POS N
11.7% POS N
of POS N
the POS N
participants POS N
in POS N
the POS N
control POS N
group POS N
(P<0.001). POS N

At POS N
6 POS N
months, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
fell POS N
by POS N
27.0 POS N
mm POS N
Hg POS N
(to POS N
125.8 POS N
mm POS N
Hg) POS N
in POS N
the POS N
intervention POS N
group POS N
and POS N
by POS N
9.3 POS N
mm POS N
Hg POS N
(to POS N
145.4 POS N
mm POS N
Hg) POS N
in POS N
the POS N
control POS N
group; POS N
the POS N
mean POS N
reduction POS N
was POS N
21.6 POS N
mm POS N
Hg POS N
greater POS N
with POS N
the POS N
intervention POS N
(95% POS N
confidence POS N
interval, POS N
14.7 POS N
to POS N
28.4; POS N
P<0.001). POS N

A POS N
blood-pressure POS N
level POS N
of POS N
less POS N
than POS N
130/80 POS N
mm POS N
Hg POS N
was POS N
achieved POS N
among POS N
63.6% POS N
of POS N
the POS N
participants POS N
in POS N
the POS N
intervention POS N
group POS N
versus POS N
11.7% POS N
of POS N
the POS N
participants POS N
in POS N
the POS N
control POS N
group POS N
(P<0.001). POS N

In POS N
the POS N
intervention POS N
group, POS N
the POS N
rate POS N
of POS N
cohort POS N
retention POS N
was POS N
95%, POS N
and POS N
there POS N
were POS N
few POS N
adverse POS N
events POS N
(three POS N
cases POS N
of POS N
acute POS N
kidney POS N
injury). POS N

A POS N
blood-pressure POS N
level POS N
of POS N
less POS N
than POS N
130/80 POS N
mm POS N
Hg POS N
was POS N
achieved POS N
among POS N
63.6% POS N
of POS N
the POS N
participants POS N
in POS N
the POS N
intervention POS N
group POS N
versus POS N
11.7% POS N
of POS N
the POS N
participants POS N
in POS N
the POS N
control POS N
group POS N
(P<0.001). POS N

Among POS N
black POS N
male POS N
barbershop POS N
patrons POS N
with POS N
uncontrolled POS N
hypertension, POS N
health POS N
promotion POS N
by POS N
barbers POS N
resulted POS N
in POS N
larger POS N
blood-pressure POS N
reduction POS N
when POS N
coupled POS N
with POS N
medication POS N
management POS N
in POS N
barbershops POS N
by POS N
specialty-trained POS N
pharmacists. POS N

In POS N
the POS N
intervention POS N
group, POS N
the POS N
rate POS N
of POS N
cohort POS N
retention POS N
was POS N
95%, POS N
and POS N
there POS N
were POS N
few POS N
adverse POS N
events POS N
(three POS N
cases POS N
of POS N
acute POS N
kidney POS N
injury). POS N

At POS N
6 POS N
months, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
fell POS N
by POS N
27.0 POS N
mm POS N
Hg POS N
(to POS N
125.8 POS N
mm POS N
Hg) POS N
in POS N
the POS N
intervention POS N
group POS N
and POS N
by POS N
9.3 POS N
mm POS N
Hg POS N
(to POS N
145.4 POS N
mm POS N
Hg) POS N
in POS N
the POS N
control POS N
group; POS N
the POS N
mean POS N
reduction POS N
was POS N
21.6 POS N
mm POS N
Hg POS N
greater POS N
with POS N
the POS N
intervention POS N
(95% POS N
confidence POS N
interval, POS N
14.7 POS N
to POS N
28.4; POS N
P<0.001). POS N

In POS N
the POS N
intervention POS N
group, POS N
the POS N
rate POS N
of POS N
cohort POS N
retention POS N
was POS N
95%, POS N
and POS N
there POS N
were POS N
few POS N
adverse POS N
events POS N
(three POS N
cases POS N
of POS N
acute POS N
kidney POS N
injury). POS N

A POS N
blood-pressure POS N
level POS N
of POS N
less POS N
than POS N
130/80 POS N
mm POS N
Hg POS N
was POS N
achieved POS N
among POS N
63.6% POS N
of POS N
the POS N
participants POS N
in POS N
the POS N
intervention POS N
group POS N
versus POS N
11.7% POS N
of POS N
the POS N
participants POS N
in POS N
the POS N
control POS N
group POS N
(P<0.001). POS N

In POS N
the POS N
intervention POS N
group, POS N
the POS N
rate POS N
of POS N
cohort POS N
retention POS N
was POS N
95%, POS N
and POS N
there POS N
were POS N
few POS N
adverse POS N
events POS N
(three POS N
cases POS N
of POS N
acute POS N
kidney POS N
injury). POS N

Among POS N
black POS N
male POS N
barbershop POS N
patrons POS N
with POS N
uncontrolled POS N
hypertension, POS N
health POS N
promotion POS N
by POS N
barbers POS N
resulted POS N
in POS N
larger POS N
blood-pressure POS N
reduction POS N
when POS N
coupled POS N
with POS N
medication POS N
management POS N
in POS N
barbershops POS N
by POS N
specialty-trained POS N
pharmacists. POS N

Among POS N
black POS N
male POS N
barbershop POS N
patrons POS N
with POS N
uncontrolled POS N
hypertension, POS N
health POS N
promotion POS N
by POS N
barbers POS N
resulted POS N
in POS N
larger POS N
blood-pressure POS N
reduction POS N
when POS N
coupled POS N
with POS N
medication POS N
management POS N
in POS N
barbershops POS N
by POS N
specialty-trained POS N
pharmacists. POS N

At POS N
6 POS N
months, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
fell POS N
by POS N
27.0 POS N
mm POS N
Hg POS N
(to POS N
125.8 POS N
mm POS N
Hg) POS N
in POS N
the POS N
intervention POS N
group POS N
and POS N
by POS N
9.3 POS N
mm POS N
Hg POS N
(to POS N
145.4 POS N
mm POS N
Hg) POS N
in POS N
the POS N
control POS N
group; POS N
the POS N
mean POS N
reduction POS N
was POS N
21.6 POS N
mm POS N
Hg POS N
greater POS N
with POS N
the POS N
intervention POS N
(95% POS N
confidence POS N
interval, POS N
14.7 POS N
to POS N
28.4; POS N
P<0.001). POS N

Among POS N
black POS N
male POS N
barbershop POS N
patrons POS N
with POS N
uncontrolled POS N
hypertension, POS N
health POS N
promotion POS N
by POS N
barbers POS N
resulted POS N
in POS N
larger POS N
blood-pressure POS N
reduction POS N
when POS N
coupled POS N
with POS N
medication POS N
management POS N
in POS N
barbershops POS N
by POS N
specialty-trained POS N
pharmacists. POS N

A POS N
blood-pressure POS N
level POS N
of POS N
less POS N
than POS N
130/80 POS N
mm POS N
Hg POS N
was POS N
achieved POS N
among POS N
63.6% POS N
of POS N
the POS N
participants POS N
in POS N
the POS N
intervention POS N
group POS N
versus POS N
11.7% POS N
of POS N
the POS N
participants POS N
in POS N
the POS N
control POS N
group POS N
(P<0.001). POS N

Among POS N
black POS N
male POS N
barbershop POS N
patrons POS N
with POS N
uncontrolled POS N
hypertension, POS N
health POS N
promotion POS N
by POS N
barbers POS N
resulted POS N
in POS N
larger POS N
blood-pressure POS N
reduction POS N
when POS N
coupled POS N
with POS N
medication POS N
management POS N
in POS N
barbershops POS N
by POS N
specialty-trained POS N
pharmacists. POS N

In POS N
the POS N
intervention POS N
group, POS N
the POS N
rate POS N
of POS N
cohort POS N
retention POS N
was POS N
95%, POS N
and POS N
there POS N
were POS N
few POS N
adverse POS N
events POS N
(three POS N
cases POS N
of POS N
acute POS N
kidney POS N
injury). POS N

For POS N
several POS N
decades, POS N
both POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
and POS N
preoperative POS N
irradiation POS N
have POS N
been POS N
accepted POS N
treatments POS N
for POS N
patients POS N
with POS N
tumors POS N
of POS N
the POS N
head POS N
and POS N
neck. POS N

Occurrence POS N
of POS N
a POS N
second POS N
carcinoma POS N
was POS N
3 POS N
times POS N
as POS N
frequent POS N
in POS N
the POS N
irradiation POS N
group POS N
(9 POS N
patients) POS N
as POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(3 POS N
patients). POS N

For POS N
several POS N
decades, POS N
both POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
and POS N
preoperative POS N
irradiation POS N
have POS N
been POS N
accepted POS N
treatments POS N
for POS N
patients POS N
with POS N
tumors POS N
of POS N
the POS N
head POS N
and POS N
neck. POS N

the POS N
survival POS N
rates POS N
were POS N
by-and-large POS N
the POS N
same POS N
for POS N
the POS N
two POS N
groups. POS N

For POS N
several POS N
decades, POS N
both POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
and POS N
preoperative POS N
irradiation POS N
have POS N
been POS N
accepted POS N
treatments POS N
for POS N
patients POS N
with POS N
tumors POS N
of POS N
the POS N
head POS N
and POS N
neck. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
the POS N
chemotherapy POS N
group POS N
presented POS N
a POS N
more POS N
favorable POS N
picture. POS N

For POS N
several POS N
decades, POS N
both POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
and POS N
preoperative POS N
irradiation POS N
have POS N
been POS N
accepted POS N
treatments POS N
for POS N
patients POS N
with POS N
tumors POS N
of POS N
the POS N
head POS N
and POS N
neck. POS N

The POS N
long POS N
term POS N
survival POS N
results POS N
subsequent POS N
to POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
or POS N
preoperative POS N
radiotherapy POS N
were POS N
practically POS N
the POS N
same. POS N

For POS N
several POS N
decades, POS N
both POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
and POS N
preoperative POS N
irradiation POS N
have POS N
been POS N
accepted POS N
treatments POS N
for POS N
patients POS N
with POS N
tumors POS N
of POS N
the POS N
head POS N
and POS N
neck. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
patients POS N
who POS N
underwent POS N
intra-arterial POS N
chemotherapy POS N
appeared POS N
to POS N
be POS N
in POS N
a POS N
slightly POS N
more POS N
favorable POS N
situation. POS N

For POS N
several POS N
decades, POS N
both POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
and POS N
preoperative POS N
irradiation POS N
have POS N
been POS N
accepted POS N
treatments POS N
for POS N
patients POS N
with POS N
tumors POS N
of POS N
the POS N
head POS N
and POS N
neck. POS N

After POS N
5 POS N
years, POS N
18 POS N
of POS N
the POS N
47 POS N
patients POS N
who POS N
received POS N
chemotherapy POS N
and POS N
15 POS N
of POS N
the POS N
48 POS N
patients POS N
who POS N
received POS N
irradiation POS N
were POS N
still POS N
alive POS N
and POS N
tumor POS N
free. POS N

For POS N
several POS N
decades, POS N
both POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
and POS N
preoperative POS N
irradiation POS N
have POS N
been POS N
accepted POS N
treatments POS N
for POS N
patients POS N
with POS N
tumors POS N
of POS N
the POS N
head POS N
and POS N
neck. POS N

A POS N
few POS N
more POS N
patients POS N
had POS N
died POS N
of POS N
recurrence POS N
or POS N
regional POS N
metastasis POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(23 POS N
patients) POS N
than POS N
in POS N
the POS N
irradiation POS N
group POS N
(20 POS N
patients). POS N

Occurrence POS N
of POS N
a POS N
second POS N
carcinoma POS N
was POS N
3 POS N
times POS N
as POS N
frequent POS N
in POS N
the POS N
irradiation POS N
group POS N
(9 POS N
patients) POS N
as POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(3 POS N
patients). POS N

For POS N
several POS N
decades, POS N
both POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
and POS N
preoperative POS N
irradiation POS N
have POS N
been POS N
accepted POS N
treatments POS N
for POS N
patients POS N
with POS N
tumors POS N
of POS N
the POS N
head POS N
and POS N
neck. POS N

Occurrence POS N
of POS N
a POS N
second POS N
carcinoma POS N
was POS N
3 POS N
times POS N
as POS N
frequent POS N
in POS N
the POS N
irradiation POS N
group POS N
(9 POS N
patients) POS N
as POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(3 POS N
patients). POS N

the POS N
survival POS N
rates POS N
were POS N
by-and-large POS N
the POS N
same POS N
for POS N
the POS N
two POS N
groups. POS N

Occurrence POS N
of POS N
a POS N
second POS N
carcinoma POS N
was POS N
3 POS N
times POS N
as POS N
frequent POS N
in POS N
the POS N
irradiation POS N
group POS N
(9 POS N
patients) POS N
as POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(3 POS N
patients). POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
the POS N
chemotherapy POS N
group POS N
presented POS N
a POS N
more POS N
favorable POS N
picture. POS N

Occurrence POS N
of POS N
a POS N
second POS N
carcinoma POS N
was POS N
3 POS N
times POS N
as POS N
frequent POS N
in POS N
the POS N
irradiation POS N
group POS N
(9 POS N
patients) POS N
as POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(3 POS N
patients). POS N

The POS N
long POS N
term POS N
survival POS N
results POS N
subsequent POS N
to POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
or POS N
preoperative POS N
radiotherapy POS N
were POS N
practically POS N
the POS N
same. POS N

Occurrence POS N
of POS N
a POS N
second POS N
carcinoma POS N
was POS N
3 POS N
times POS N
as POS N
frequent POS N
in POS N
the POS N
irradiation POS N
group POS N
(9 POS N
patients) POS N
as POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(3 POS N
patients). POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
patients POS N
who POS N
underwent POS N
intra-arterial POS N
chemotherapy POS N
appeared POS N
to POS N
be POS N
in POS N
a POS N
slightly POS N
more POS N
favorable POS N
situation. POS N

Occurrence POS N
of POS N
a POS N
second POS N
carcinoma POS N
was POS N
3 POS N
times POS N
as POS N
frequent POS N
in POS N
the POS N
irradiation POS N
group POS N
(9 POS N
patients) POS N
as POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(3 POS N
patients). POS N

After POS N
5 POS N
years, POS N
18 POS N
of POS N
the POS N
47 POS N
patients POS N
who POS N
received POS N
chemotherapy POS N
and POS N
15 POS N
of POS N
the POS N
48 POS N
patients POS N
who POS N
received POS N
irradiation POS N
were POS N
still POS N
alive POS N
and POS N
tumor POS N
free. POS N

Occurrence POS N
of POS N
a POS N
second POS N
carcinoma POS N
was POS N
3 POS N
times POS N
as POS N
frequent POS N
in POS N
the POS N
irradiation POS N
group POS N
(9 POS N
patients) POS N
as POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(3 POS N
patients). POS N

A POS N
few POS N
more POS N
patients POS N
had POS N
died POS N
of POS N
recurrence POS N
or POS N
regional POS N
metastasis POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(23 POS N
patients) POS N
than POS N
in POS N
the POS N
irradiation POS N
group POS N
(20 POS N
patients). POS N

the POS N
survival POS N
rates POS N
were POS N
by-and-large POS N
the POS N
same POS N
for POS N
the POS N
two POS N
groups. POS N

For POS N
several POS N
decades, POS N
both POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
and POS N
preoperative POS N
irradiation POS N
have POS N
been POS N
accepted POS N
treatments POS N
for POS N
patients POS N
with POS N
tumors POS N
of POS N
the POS N
head POS N
and POS N
neck. POS N

the POS N
survival POS N
rates POS N
were POS N
by-and-large POS N
the POS N
same POS N
for POS N
the POS N
two POS N
groups. POS N

Occurrence POS N
of POS N
a POS N
second POS N
carcinoma POS N
was POS N
3 POS N
times POS N
as POS N
frequent POS N
in POS N
the POS N
irradiation POS N
group POS N
(9 POS N
patients) POS N
as POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(3 POS N
patients). POS N

the POS N
survival POS N
rates POS N
were POS N
by-and-large POS N
the POS N
same POS N
for POS N
the POS N
two POS N
groups. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
the POS N
chemotherapy POS N
group POS N
presented POS N
a POS N
more POS N
favorable POS N
picture. POS N

the POS N
survival POS N
rates POS N
were POS N
by-and-large POS N
the POS N
same POS N
for POS N
the POS N
two POS N
groups. POS N

The POS N
long POS N
term POS N
survival POS N
results POS N
subsequent POS N
to POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
or POS N
preoperative POS N
radiotherapy POS N
were POS N
practically POS N
the POS N
same. POS N

the POS N
survival POS N
rates POS N
were POS N
by-and-large POS N
the POS N
same POS N
for POS N
the POS N
two POS N
groups. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
patients POS N
who POS N
underwent POS N
intra-arterial POS N
chemotherapy POS N
appeared POS N
to POS N
be POS N
in POS N
a POS N
slightly POS N
more POS N
favorable POS N
situation. POS N

the POS N
survival POS N
rates POS N
were POS N
by-and-large POS N
the POS N
same POS N
for POS N
the POS N
two POS N
groups. POS N

After POS N
5 POS N
years, POS N
18 POS N
of POS N
the POS N
47 POS N
patients POS N
who POS N
received POS N
chemotherapy POS N
and POS N
15 POS N
of POS N
the POS N
48 POS N
patients POS N
who POS N
received POS N
irradiation POS N
were POS N
still POS N
alive POS N
and POS N
tumor POS N
free. POS N

the POS N
survival POS N
rates POS N
were POS N
by-and-large POS N
the POS N
same POS N
for POS N
the POS N
two POS N
groups. POS N

A POS N
few POS N
more POS N
patients POS N
had POS N
died POS N
of POS N
recurrence POS N
or POS N
regional POS N
metastasis POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(23 POS N
patients) POS N
than POS N
in POS N
the POS N
irradiation POS N
group POS N
(20 POS N
patients). POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
the POS N
chemotherapy POS N
group POS N
presented POS N
a POS N
more POS N
favorable POS N
picture. POS N

For POS N
several POS N
decades, POS N
both POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
and POS N
preoperative POS N
irradiation POS N
have POS N
been POS N
accepted POS N
treatments POS N
for POS N
patients POS N
with POS N
tumors POS N
of POS N
the POS N
head POS N
and POS N
neck. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
the POS N
chemotherapy POS N
group POS N
presented POS N
a POS N
more POS N
favorable POS N
picture. POS N

Occurrence POS N
of POS N
a POS N
second POS N
carcinoma POS N
was POS N
3 POS N
times POS N
as POS N
frequent POS N
in POS N
the POS N
irradiation POS N
group POS N
(9 POS N
patients) POS N
as POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(3 POS N
patients). POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
the POS N
chemotherapy POS N
group POS N
presented POS N
a POS N
more POS N
favorable POS N
picture. POS N

the POS N
survival POS N
rates POS N
were POS N
by-and-large POS N
the POS N
same POS N
for POS N
the POS N
two POS N
groups. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
the POS N
chemotherapy POS N
group POS N
presented POS N
a POS N
more POS N
favorable POS N
picture. POS N

The POS N
long POS N
term POS N
survival POS N
results POS N
subsequent POS N
to POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
or POS N
preoperative POS N
radiotherapy POS N
were POS N
practically POS N
the POS N
same. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
the POS N
chemotherapy POS N
group POS N
presented POS N
a POS N
more POS N
favorable POS N
picture. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
patients POS N
who POS N
underwent POS N
intra-arterial POS N
chemotherapy POS N
appeared POS N
to POS N
be POS N
in POS N
a POS N
slightly POS N
more POS N
favorable POS N
situation. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
the POS N
chemotherapy POS N
group POS N
presented POS N
a POS N
more POS N
favorable POS N
picture. POS N

After POS N
5 POS N
years, POS N
18 POS N
of POS N
the POS N
47 POS N
patients POS N
who POS N
received POS N
chemotherapy POS N
and POS N
15 POS N
of POS N
the POS N
48 POS N
patients POS N
who POS N
received POS N
irradiation POS N
were POS N
still POS N
alive POS N
and POS N
tumor POS N
free. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
the POS N
chemotherapy POS N
group POS N
presented POS N
a POS N
more POS N
favorable POS N
picture. POS N

A POS N
few POS N
more POS N
patients POS N
had POS N
died POS N
of POS N
recurrence POS N
or POS N
regional POS N
metastasis POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(23 POS N
patients) POS N
than POS N
in POS N
the POS N
irradiation POS N
group POS N
(20 POS N
patients). POS N

The POS N
long POS N
term POS N
survival POS N
results POS N
subsequent POS N
to POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
or POS N
preoperative POS N
radiotherapy POS N
were POS N
practically POS N
the POS N
same. POS N

For POS N
several POS N
decades, POS N
both POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
and POS N
preoperative POS N
irradiation POS N
have POS N
been POS N
accepted POS N
treatments POS N
for POS N
patients POS N
with POS N
tumors POS N
of POS N
the POS N
head POS N
and POS N
neck. POS N

The POS N
long POS N
term POS N
survival POS N
results POS N
subsequent POS N
to POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
or POS N
preoperative POS N
radiotherapy POS N
were POS N
practically POS N
the POS N
same. POS N

Occurrence POS N
of POS N
a POS N
second POS N
carcinoma POS N
was POS N
3 POS N
times POS N
as POS N
frequent POS N
in POS N
the POS N
irradiation POS N
group POS N
(9 POS N
patients) POS N
as POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(3 POS N
patients). POS N

The POS N
long POS N
term POS N
survival POS N
results POS N
subsequent POS N
to POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
or POS N
preoperative POS N
radiotherapy POS N
were POS N
practically POS N
the POS N
same. POS N

the POS N
survival POS N
rates POS N
were POS N
by-and-large POS N
the POS N
same POS N
for POS N
the POS N
two POS N
groups. POS N

The POS N
long POS N
term POS N
survival POS N
results POS N
subsequent POS N
to POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
or POS N
preoperative POS N
radiotherapy POS N
were POS N
practically POS N
the POS N
same. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
the POS N
chemotherapy POS N
group POS N
presented POS N
a POS N
more POS N
favorable POS N
picture. POS N

The POS N
long POS N
term POS N
survival POS N
results POS N
subsequent POS N
to POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
or POS N
preoperative POS N
radiotherapy POS N
were POS N
practically POS N
the POS N
same. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
patients POS N
who POS N
underwent POS N
intra-arterial POS N
chemotherapy POS N
appeared POS N
to POS N
be POS N
in POS N
a POS N
slightly POS N
more POS N
favorable POS N
situation. POS N

The POS N
long POS N
term POS N
survival POS N
results POS N
subsequent POS N
to POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
or POS N
preoperative POS N
radiotherapy POS N
were POS N
practically POS N
the POS N
same. POS N

After POS N
5 POS N
years, POS N
18 POS N
of POS N
the POS N
47 POS N
patients POS N
who POS N
received POS N
chemotherapy POS N
and POS N
15 POS N
of POS N
the POS N
48 POS N
patients POS N
who POS N
received POS N
irradiation POS N
were POS N
still POS N
alive POS N
and POS N
tumor POS N
free. POS N

The POS N
long POS N
term POS N
survival POS N
results POS N
subsequent POS N
to POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
or POS N
preoperative POS N
radiotherapy POS N
were POS N
practically POS N
the POS N
same. POS N

A POS N
few POS N
more POS N
patients POS N
had POS N
died POS N
of POS N
recurrence POS N
or POS N
regional POS N
metastasis POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(23 POS N
patients) POS N
than POS N
in POS N
the POS N
irradiation POS N
group POS N
(20 POS N
patients). POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
patients POS N
who POS N
underwent POS N
intra-arterial POS N
chemotherapy POS N
appeared POS N
to POS N
be POS N
in POS N
a POS N
slightly POS N
more POS N
favorable POS N
situation. POS N

For POS N
several POS N
decades, POS N
both POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
and POS N
preoperative POS N
irradiation POS N
have POS N
been POS N
accepted POS N
treatments POS N
for POS N
patients POS N
with POS N
tumors POS N
of POS N
the POS N
head POS N
and POS N
neck. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
patients POS N
who POS N
underwent POS N
intra-arterial POS N
chemotherapy POS N
appeared POS N
to POS N
be POS N
in POS N
a POS N
slightly POS N
more POS N
favorable POS N
situation. POS N

Occurrence POS N
of POS N
a POS N
second POS N
carcinoma POS N
was POS N
3 POS N
times POS N
as POS N
frequent POS N
in POS N
the POS N
irradiation POS N
group POS N
(9 POS N
patients) POS N
as POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(3 POS N
patients). POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
patients POS N
who POS N
underwent POS N
intra-arterial POS N
chemotherapy POS N
appeared POS N
to POS N
be POS N
in POS N
a POS N
slightly POS N
more POS N
favorable POS N
situation. POS N

the POS N
survival POS N
rates POS N
were POS N
by-and-large POS N
the POS N
same POS N
for POS N
the POS N
two POS N
groups. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
patients POS N
who POS N
underwent POS N
intra-arterial POS N
chemotherapy POS N
appeared POS N
to POS N
be POS N
in POS N
a POS N
slightly POS N
more POS N
favorable POS N
situation. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
the POS N
chemotherapy POS N
group POS N
presented POS N
a POS N
more POS N
favorable POS N
picture. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
patients POS N
who POS N
underwent POS N
intra-arterial POS N
chemotherapy POS N
appeared POS N
to POS N
be POS N
in POS N
a POS N
slightly POS N
more POS N
favorable POS N
situation. POS N

The POS N
long POS N
term POS N
survival POS N
results POS N
subsequent POS N
to POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
or POS N
preoperative POS N
radiotherapy POS N
were POS N
practically POS N
the POS N
same. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
patients POS N
who POS N
underwent POS N
intra-arterial POS N
chemotherapy POS N
appeared POS N
to POS N
be POS N
in POS N
a POS N
slightly POS N
more POS N
favorable POS N
situation. POS N

After POS N
5 POS N
years, POS N
18 POS N
of POS N
the POS N
47 POS N
patients POS N
who POS N
received POS N
chemotherapy POS N
and POS N
15 POS N
of POS N
the POS N
48 POS N
patients POS N
who POS N
received POS N
irradiation POS N
were POS N
still POS N
alive POS N
and POS N
tumor POS N
free. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
patients POS N
who POS N
underwent POS N
intra-arterial POS N
chemotherapy POS N
appeared POS N
to POS N
be POS N
in POS N
a POS N
slightly POS N
more POS N
favorable POS N
situation. POS N

A POS N
few POS N
more POS N
patients POS N
had POS N
died POS N
of POS N
recurrence POS N
or POS N
regional POS N
metastasis POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(23 POS N
patients) POS N
than POS N
in POS N
the POS N
irradiation POS N
group POS N
(20 POS N
patients). POS N

After POS N
5 POS N
years, POS N
18 POS N
of POS N
the POS N
47 POS N
patients POS N
who POS N
received POS N
chemotherapy POS N
and POS N
15 POS N
of POS N
the POS N
48 POS N
patients POS N
who POS N
received POS N
irradiation POS N
were POS N
still POS N
alive POS N
and POS N
tumor POS N
free. POS N

For POS N
several POS N
decades, POS N
both POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
and POS N
preoperative POS N
irradiation POS N
have POS N
been POS N
accepted POS N
treatments POS N
for POS N
patients POS N
with POS N
tumors POS N
of POS N
the POS N
head POS N
and POS N
neck. POS N

After POS N
5 POS N
years, POS N
18 POS N
of POS N
the POS N
47 POS N
patients POS N
who POS N
received POS N
chemotherapy POS N
and POS N
15 POS N
of POS N
the POS N
48 POS N
patients POS N
who POS N
received POS N
irradiation POS N
were POS N
still POS N
alive POS N
and POS N
tumor POS N
free. POS N

Occurrence POS N
of POS N
a POS N
second POS N
carcinoma POS N
was POS N
3 POS N
times POS N
as POS N
frequent POS N
in POS N
the POS N
irradiation POS N
group POS N
(9 POS N
patients) POS N
as POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(3 POS N
patients). POS N

After POS N
5 POS N
years, POS N
18 POS N
of POS N
the POS N
47 POS N
patients POS N
who POS N
received POS N
chemotherapy POS N
and POS N
15 POS N
of POS N
the POS N
48 POS N
patients POS N
who POS N
received POS N
irradiation POS N
were POS N
still POS N
alive POS N
and POS N
tumor POS N
free. POS N

the POS N
survival POS N
rates POS N
were POS N
by-and-large POS N
the POS N
same POS N
for POS N
the POS N
two POS N
groups. POS N

After POS N
5 POS N
years, POS N
18 POS N
of POS N
the POS N
47 POS N
patients POS N
who POS N
received POS N
chemotherapy POS N
and POS N
15 POS N
of POS N
the POS N
48 POS N
patients POS N
who POS N
received POS N
irradiation POS N
were POS N
still POS N
alive POS N
and POS N
tumor POS N
free. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
the POS N
chemotherapy POS N
group POS N
presented POS N
a POS N
more POS N
favorable POS N
picture. POS N

After POS N
5 POS N
years, POS N
18 POS N
of POS N
the POS N
47 POS N
patients POS N
who POS N
received POS N
chemotherapy POS N
and POS N
15 POS N
of POS N
the POS N
48 POS N
patients POS N
who POS N
received POS N
irradiation POS N
were POS N
still POS N
alive POS N
and POS N
tumor POS N
free. POS N

The POS N
long POS N
term POS N
survival POS N
results POS N
subsequent POS N
to POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
or POS N
preoperative POS N
radiotherapy POS N
were POS N
practically POS N
the POS N
same. POS N

After POS N
5 POS N
years, POS N
18 POS N
of POS N
the POS N
47 POS N
patients POS N
who POS N
received POS N
chemotherapy POS N
and POS N
15 POS N
of POS N
the POS N
48 POS N
patients POS N
who POS N
received POS N
irradiation POS N
were POS N
still POS N
alive POS N
and POS N
tumor POS N
free. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
patients POS N
who POS N
underwent POS N
intra-arterial POS N
chemotherapy POS N
appeared POS N
to POS N
be POS N
in POS N
a POS N
slightly POS N
more POS N
favorable POS N
situation. POS N

After POS N
5 POS N
years, POS N
18 POS N
of POS N
the POS N
47 POS N
patients POS N
who POS N
received POS N
chemotherapy POS N
and POS N
15 POS N
of POS N
the POS N
48 POS N
patients POS N
who POS N
received POS N
irradiation POS N
were POS N
still POS N
alive POS N
and POS N
tumor POS N
free. POS N

A POS N
few POS N
more POS N
patients POS N
had POS N
died POS N
of POS N
recurrence POS N
or POS N
regional POS N
metastasis POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(23 POS N
patients) POS N
than POS N
in POS N
the POS N
irradiation POS N
group POS N
(20 POS N
patients). POS N

A POS N
few POS N
more POS N
patients POS N
had POS N
died POS N
of POS N
recurrence POS N
or POS N
regional POS N
metastasis POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(23 POS N
patients) POS N
than POS N
in POS N
the POS N
irradiation POS N
group POS N
(20 POS N
patients). POS N

For POS N
several POS N
decades, POS N
both POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
and POS N
preoperative POS N
irradiation POS N
have POS N
been POS N
accepted POS N
treatments POS N
for POS N
patients POS N
with POS N
tumors POS N
of POS N
the POS N
head POS N
and POS N
neck. POS N

A POS N
few POS N
more POS N
patients POS N
had POS N
died POS N
of POS N
recurrence POS N
or POS N
regional POS N
metastasis POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(23 POS N
patients) POS N
than POS N
in POS N
the POS N
irradiation POS N
group POS N
(20 POS N
patients). POS N

Occurrence POS N
of POS N
a POS N
second POS N
carcinoma POS N
was POS N
3 POS N
times POS N
as POS N
frequent POS N
in POS N
the POS N
irradiation POS N
group POS N
(9 POS N
patients) POS N
as POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(3 POS N
patients). POS N

A POS N
few POS N
more POS N
patients POS N
had POS N
died POS N
of POS N
recurrence POS N
or POS N
regional POS N
metastasis POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(23 POS N
patients) POS N
than POS N
in POS N
the POS N
irradiation POS N
group POS N
(20 POS N
patients). POS N

the POS N
survival POS N
rates POS N
were POS N
by-and-large POS N
the POS N
same POS N
for POS N
the POS N
two POS N
groups. POS N

A POS N
few POS N
more POS N
patients POS N
had POS N
died POS N
of POS N
recurrence POS N
or POS N
regional POS N
metastasis POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(23 POS N
patients) POS N
than POS N
in POS N
the POS N
irradiation POS N
group POS N
(20 POS N
patients). POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
the POS N
chemotherapy POS N
group POS N
presented POS N
a POS N
more POS N
favorable POS N
picture. POS N

A POS N
few POS N
more POS N
patients POS N
had POS N
died POS N
of POS N
recurrence POS N
or POS N
regional POS N
metastasis POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(23 POS N
patients) POS N
than POS N
in POS N
the POS N
irradiation POS N
group POS N
(20 POS N
patients). POS N

The POS N
long POS N
term POS N
survival POS N
results POS N
subsequent POS N
to POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
or POS N
preoperative POS N
radiotherapy POS N
were POS N
practically POS N
the POS N
same. POS N

A POS N
few POS N
more POS N
patients POS N
had POS N
died POS N
of POS N
recurrence POS N
or POS N
regional POS N
metastasis POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(23 POS N
patients) POS N
than POS N
in POS N
the POS N
irradiation POS N
group POS N
(20 POS N
patients). POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
patients POS N
who POS N
underwent POS N
intra-arterial POS N
chemotherapy POS N
appeared POS N
to POS N
be POS N
in POS N
a POS N
slightly POS N
more POS N
favorable POS N
situation. POS N

A POS N
few POS N
more POS N
patients POS N
had POS N
died POS N
of POS N
recurrence POS N
or POS N
regional POS N
metastasis POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(23 POS N
patients) POS N
than POS N
in POS N
the POS N
irradiation POS N
group POS N
(20 POS N
patients). POS N

After POS N
5 POS N
years, POS N
18 POS N
of POS N
the POS N
47 POS N
patients POS N
who POS N
received POS N
chemotherapy POS N
and POS N
15 POS N
of POS N
the POS N
48 POS N
patients POS N
who POS N
received POS N
irradiation POS N
were POS N
still POS N
alive POS N
and POS N
tumor POS N
free. POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
17.3% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
7.9% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.01; POS N
hazard POS N
ratio, POS N
2.59; POS N
95% POS N
confidence POS N
interval, POS N
1.20-5.60). POS N

Postoperative POS N
complications POS N
developed POS N
in POS N
36 POS N
patients POS N
(29%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
48 POS N
patients POS N
(41%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.06). POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
17.3% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
7.9% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.01; POS N
hazard POS N
ratio, POS N
2.59; POS N
95% POS N
confidence POS N
interval, POS N
1.20-5.60). POS N

Serious POS N
complications POS N
requiring POS N
reoperation POS N
or POS N
producing POS N
a POS N
loss POS N
of POS N
2 POS N
Snellen POS N
lines POS N
or POS N
more POS N
occurred POS N
in POS N
1 POS N
patient POS N
(1%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
8 POS N
patients POS N
(7%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.03). POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
17.3% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
7.9% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.01; POS N
hazard POS N
ratio, POS N
2.59; POS N
95% POS N
confidence POS N
interval, POS N
1.20-5.60). POS N

Trabeculectomy POS N
with POS N
MMC POS N
had POS N
a POS N
higher POS N
surgical POS N
success POS N
rate POS N
than POS N
tube POS N
shunt POS N
implantation POS N
after POS N
1 POS N
year POS N
in POS N
the POS N
PTVT POS N
Study. POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
17.3% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
7.9% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.01; POS N
hazard POS N
ratio, POS N
2.59; POS N
95% POS N
confidence POS N
interval, POS N
1.20-5.60). POS N

The POS N
frequency POS N
of POS N
serious POS N
complications POS N
producing POS N
vision POS N
loss POS N
or POS N
requiring POS N
reoperation POS N
was POS N
lower POS N
after POS N
tube POS N
shunt POS N
surgery POS N
relative POS N
to POS N
trabeculectomy POS N
with POS N
MMC. POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
17.3% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
7.9% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.01; POS N
hazard POS N
ratio, POS N
2.59; POS N
95% POS N
confidence POS N
interval, POS N
1.20-5.60). POS N

Lower POS N
IOP POS N
with POS N
use POS N
of POS N
fewer POS N
glaucoma POS N
medications POS N
was POS N
achieved POS N
after POS N
trabeculectomy POS N
with POS N
MMC POS N
compared POS N
with POS N
tube POS N
shunt POS N
surgery POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up. POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
17.3% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
7.9% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.01; POS N
hazard POS N
ratio, POS N
2.59; POS N
95% POS N
confidence POS N
interval, POS N
1.20-5.60). POS N

Mean POS N
± POS N
standard POS N
deviation POS N
IOP POS N
was POS N
13.8±4.1 POS N
mmHg POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
12.4±4.4 POS N
mmHg POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
at POS N
1 POS N
year POS N
(P POS N
= POS N
0.01), POS N
and POS N
the POS N
number POS N
of POS N
glaucoma POS N
medications POS N
was POS N
2.1±1.4 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.9±1.4 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
0.001). POS N

Postoperative POS N
complications POS N
developed POS N
in POS N
36 POS N
patients POS N
(29%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
48 POS N
patients POS N
(41%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.06). POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
17.3% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
7.9% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.01; POS N
hazard POS N
ratio, POS N
2.59; POS N
95% POS N
confidence POS N
interval, POS N
1.20-5.60). POS N

Postoperative POS N
complications POS N
developed POS N
in POS N
36 POS N
patients POS N
(29%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
48 POS N
patients POS N
(41%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.06). POS N

Serious POS N
complications POS N
requiring POS N
reoperation POS N
or POS N
producing POS N
a POS N
loss POS N
of POS N
2 POS N
Snellen POS N
lines POS N
or POS N
more POS N
occurred POS N
in POS N
1 POS N
patient POS N
(1%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
8 POS N
patients POS N
(7%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.03). POS N

Postoperative POS N
complications POS N
developed POS N
in POS N
36 POS N
patients POS N
(29%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
48 POS N
patients POS N
(41%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.06). POS N

Trabeculectomy POS N
with POS N
MMC POS N
had POS N
a POS N
higher POS N
surgical POS N
success POS N
rate POS N
than POS N
tube POS N
shunt POS N
implantation POS N
after POS N
1 POS N
year POS N
in POS N
the POS N
PTVT POS N
Study. POS N

Postoperative POS N
complications POS N
developed POS N
in POS N
36 POS N
patients POS N
(29%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
48 POS N
patients POS N
(41%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.06). POS N

The POS N
frequency POS N
of POS N
serious POS N
complications POS N
producing POS N
vision POS N
loss POS N
or POS N
requiring POS N
reoperation POS N
was POS N
lower POS N
after POS N
tube POS N
shunt POS N
surgery POS N
relative POS N
to POS N
trabeculectomy POS N
with POS N
MMC. POS N

Postoperative POS N
complications POS N
developed POS N
in POS N
36 POS N
patients POS N
(29%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
48 POS N
patients POS N
(41%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.06). POS N

Lower POS N
IOP POS N
with POS N
use POS N
of POS N
fewer POS N
glaucoma POS N
medications POS N
was POS N
achieved POS N
after POS N
trabeculectomy POS N
with POS N
MMC POS N
compared POS N
with POS N
tube POS N
shunt POS N
surgery POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up. POS N

Postoperative POS N
complications POS N
developed POS N
in POS N
36 POS N
patients POS N
(29%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
48 POS N
patients POS N
(41%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.06). POS N

Mean POS N
± POS N
standard POS N
deviation POS N
IOP POS N
was POS N
13.8±4.1 POS N
mmHg POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
12.4±4.4 POS N
mmHg POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
at POS N
1 POS N
year POS N
(P POS N
= POS N
0.01), POS N
and POS N
the POS N
number POS N
of POS N
glaucoma POS N
medications POS N
was POS N
2.1±1.4 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.9±1.4 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
0.001). POS N

Serious POS N
complications POS N
requiring POS N
reoperation POS N
or POS N
producing POS N
a POS N
loss POS N
of POS N
2 POS N
Snellen POS N
lines POS N
or POS N
more POS N
occurred POS N
in POS N
1 POS N
patient POS N
(1%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
8 POS N
patients POS N
(7%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.03). POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
17.3% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
7.9% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.01; POS N
hazard POS N
ratio, POS N
2.59; POS N
95% POS N
confidence POS N
interval, POS N
1.20-5.60). POS N

Serious POS N
complications POS N
requiring POS N
reoperation POS N
or POS N
producing POS N
a POS N
loss POS N
of POS N
2 POS N
Snellen POS N
lines POS N
or POS N
more POS N
occurred POS N
in POS N
1 POS N
patient POS N
(1%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
8 POS N
patients POS N
(7%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.03). POS N

Postoperative POS N
complications POS N
developed POS N
in POS N
36 POS N
patients POS N
(29%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
48 POS N
patients POS N
(41%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.06). POS N

Serious POS N
complications POS N
requiring POS N
reoperation POS N
or POS N
producing POS N
a POS N
loss POS N
of POS N
2 POS N
Snellen POS N
lines POS N
or POS N
more POS N
occurred POS N
in POS N
1 POS N
patient POS N
(1%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
8 POS N
patients POS N
(7%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.03). POS N

Trabeculectomy POS N
with POS N
MMC POS N
had POS N
a POS N
higher POS N
surgical POS N
success POS N
rate POS N
than POS N
tube POS N
shunt POS N
implantation POS N
after POS N
1 POS N
year POS N
in POS N
the POS N
PTVT POS N
Study. POS N

Serious POS N
complications POS N
requiring POS N
reoperation POS N
or POS N
producing POS N
a POS N
loss POS N
of POS N
2 POS N
Snellen POS N
lines POS N
or POS N
more POS N
occurred POS N
in POS N
1 POS N
patient POS N
(1%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
8 POS N
patients POS N
(7%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.03). POS N

The POS N
frequency POS N
of POS N
serious POS N
complications POS N
producing POS N
vision POS N
loss POS N
or POS N
requiring POS N
reoperation POS N
was POS N
lower POS N
after POS N
tube POS N
shunt POS N
surgery POS N
relative POS N
to POS N
trabeculectomy POS N
with POS N
MMC. POS N

Serious POS N
complications POS N
requiring POS N
reoperation POS N
or POS N
producing POS N
a POS N
loss POS N
of POS N
2 POS N
Snellen POS N
lines POS N
or POS N
more POS N
occurred POS N
in POS N
1 POS N
patient POS N
(1%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
8 POS N
patients POS N
(7%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.03). POS N

Lower POS N
IOP POS N
with POS N
use POS N
of POS N
fewer POS N
glaucoma POS N
medications POS N
was POS N
achieved POS N
after POS N
trabeculectomy POS N
with POS N
MMC POS N
compared POS N
with POS N
tube POS N
shunt POS N
surgery POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up. POS N

Serious POS N
complications POS N
requiring POS N
reoperation POS N
or POS N
producing POS N
a POS N
loss POS N
of POS N
2 POS N
Snellen POS N
lines POS N
or POS N
more POS N
occurred POS N
in POS N
1 POS N
patient POS N
(1%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
8 POS N
patients POS N
(7%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.03). POS N

Mean POS N
± POS N
standard POS N
deviation POS N
IOP POS N
was POS N
13.8±4.1 POS N
mmHg POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
12.4±4.4 POS N
mmHg POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
at POS N
1 POS N
year POS N
(P POS N
= POS N
0.01), POS N
and POS N
the POS N
number POS N
of POS N
glaucoma POS N
medications POS N
was POS N
2.1±1.4 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.9±1.4 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
0.001). POS N

Trabeculectomy POS N
with POS N
MMC POS N
had POS N
a POS N
higher POS N
surgical POS N
success POS N
rate POS N
than POS N
tube POS N
shunt POS N
implantation POS N
after POS N
1 POS N
year POS N
in POS N
the POS N
PTVT POS N
Study. POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
17.3% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
7.9% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.01; POS N
hazard POS N
ratio, POS N
2.59; POS N
95% POS N
confidence POS N
interval, POS N
1.20-5.60). POS N

Trabeculectomy POS N
with POS N
MMC POS N
had POS N
a POS N
higher POS N
surgical POS N
success POS N
rate POS N
than POS N
tube POS N
shunt POS N
implantation POS N
after POS N
1 POS N
year POS N
in POS N
the POS N
PTVT POS N
Study. POS N

Postoperative POS N
complications POS N
developed POS N
in POS N
36 POS N
patients POS N
(29%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
48 POS N
patients POS N
(41%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.06). POS N

Trabeculectomy POS N
with POS N
MMC POS N
had POS N
a POS N
higher POS N
surgical POS N
success POS N
rate POS N
than POS N
tube POS N
shunt POS N
implantation POS N
after POS N
1 POS N
year POS N
in POS N
the POS N
PTVT POS N
Study. POS N

Serious POS N
complications POS N
requiring POS N
reoperation POS N
or POS N
producing POS N
a POS N
loss POS N
of POS N
2 POS N
Snellen POS N
lines POS N
or POS N
more POS N
occurred POS N
in POS N
1 POS N
patient POS N
(1%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
8 POS N
patients POS N
(7%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.03). POS N

Trabeculectomy POS N
with POS N
MMC POS N
had POS N
a POS N
higher POS N
surgical POS N
success POS N
rate POS N
than POS N
tube POS N
shunt POS N
implantation POS N
after POS N
1 POS N
year POS N
in POS N
the POS N
PTVT POS N
Study. POS N

The POS N
frequency POS N
of POS N
serious POS N
complications POS N
producing POS N
vision POS N
loss POS N
or POS N
requiring POS N
reoperation POS N
was POS N
lower POS N
after POS N
tube POS N
shunt POS N
surgery POS N
relative POS N
to POS N
trabeculectomy POS N
with POS N
MMC. POS N

Trabeculectomy POS N
with POS N
MMC POS N
had POS N
a POS N
higher POS N
surgical POS N
success POS N
rate POS N
than POS N
tube POS N
shunt POS N
implantation POS N
after POS N
1 POS N
year POS N
in POS N
the POS N
PTVT POS N
Study. POS N

Lower POS N
IOP POS N
with POS N
use POS N
of POS N
fewer POS N
glaucoma POS N
medications POS N
was POS N
achieved POS N
after POS N
trabeculectomy POS N
with POS N
MMC POS N
compared POS N
with POS N
tube POS N
shunt POS N
surgery POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up. POS N

Trabeculectomy POS N
with POS N
MMC POS N
had POS N
a POS N
higher POS N
surgical POS N
success POS N
rate POS N
than POS N
tube POS N
shunt POS N
implantation POS N
after POS N
1 POS N
year POS N
in POS N
the POS N
PTVT POS N
Study. POS N

Mean POS N
± POS N
standard POS N
deviation POS N
IOP POS N
was POS N
13.8±4.1 POS N
mmHg POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
12.4±4.4 POS N
mmHg POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
at POS N
1 POS N
year POS N
(P POS N
= POS N
0.01), POS N
and POS N
the POS N
number POS N
of POS N
glaucoma POS N
medications POS N
was POS N
2.1±1.4 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.9±1.4 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
0.001). POS N

The POS N
frequency POS N
of POS N
serious POS N
complications POS N
producing POS N
vision POS N
loss POS N
or POS N
requiring POS N
reoperation POS N
was POS N
lower POS N
after POS N
tube POS N
shunt POS N
surgery POS N
relative POS N
to POS N
trabeculectomy POS N
with POS N
MMC. POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
17.3% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
7.9% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.01; POS N
hazard POS N
ratio, POS N
2.59; POS N
95% POS N
confidence POS N
interval, POS N
1.20-5.60). POS N

The POS N
frequency POS N
of POS N
serious POS N
complications POS N
producing POS N
vision POS N
loss POS N
or POS N
requiring POS N
reoperation POS N
was POS N
lower POS N
after POS N
tube POS N
shunt POS N
surgery POS N
relative POS N
to POS N
trabeculectomy POS N
with POS N
MMC. POS N

Postoperative POS N
complications POS N
developed POS N
in POS N
36 POS N
patients POS N
(29%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
48 POS N
patients POS N
(41%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.06). POS N

The POS N
frequency POS N
of POS N
serious POS N
complications POS N
producing POS N
vision POS N
loss POS N
or POS N
requiring POS N
reoperation POS N
was POS N
lower POS N
after POS N
tube POS N
shunt POS N
surgery POS N
relative POS N
to POS N
trabeculectomy POS N
with POS N
MMC. POS N

Serious POS N
complications POS N
requiring POS N
reoperation POS N
or POS N
producing POS N
a POS N
loss POS N
of POS N
2 POS N
Snellen POS N
lines POS N
or POS N
more POS N
occurred POS N
in POS N
1 POS N
patient POS N
(1%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
8 POS N
patients POS N
(7%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.03). POS N

The POS N
frequency POS N
of POS N
serious POS N
complications POS N
producing POS N
vision POS N
loss POS N
or POS N
requiring POS N
reoperation POS N
was POS N
lower POS N
after POS N
tube POS N
shunt POS N
surgery POS N
relative POS N
to POS N
trabeculectomy POS N
with POS N
MMC. POS N

Trabeculectomy POS N
with POS N
MMC POS N
had POS N
a POS N
higher POS N
surgical POS N
success POS N
rate POS N
than POS N
tube POS N
shunt POS N
implantation POS N
after POS N
1 POS N
year POS N
in POS N
the POS N
PTVT POS N
Study. POS N

The POS N
frequency POS N
of POS N
serious POS N
complications POS N
producing POS N
vision POS N
loss POS N
or POS N
requiring POS N
reoperation POS N
was POS N
lower POS N
after POS N
tube POS N
shunt POS N
surgery POS N
relative POS N
to POS N
trabeculectomy POS N
with POS N
MMC. POS N

Lower POS N
IOP POS N
with POS N
use POS N
of POS N
fewer POS N
glaucoma POS N
medications POS N
was POS N
achieved POS N
after POS N
trabeculectomy POS N
with POS N
MMC POS N
compared POS N
with POS N
tube POS N
shunt POS N
surgery POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up. POS N

The POS N
frequency POS N
of POS N
serious POS N
complications POS N
producing POS N
vision POS N
loss POS N
or POS N
requiring POS N
reoperation POS N
was POS N
lower POS N
after POS N
tube POS N
shunt POS N
surgery POS N
relative POS N
to POS N
trabeculectomy POS N
with POS N
MMC. POS N

Mean POS N
± POS N
standard POS N
deviation POS N
IOP POS N
was POS N
13.8±4.1 POS N
mmHg POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
12.4±4.4 POS N
mmHg POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
at POS N
1 POS N
year POS N
(P POS N
= POS N
0.01), POS N
and POS N
the POS N
number POS N
of POS N
glaucoma POS N
medications POS N
was POS N
2.1±1.4 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.9±1.4 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
0.001). POS N

Lower POS N
IOP POS N
with POS N
use POS N
of POS N
fewer POS N
glaucoma POS N
medications POS N
was POS N
achieved POS N
after POS N
trabeculectomy POS N
with POS N
MMC POS N
compared POS N
with POS N
tube POS N
shunt POS N
surgery POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up. POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
17.3% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
7.9% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.01; POS N
hazard POS N
ratio, POS N
2.59; POS N
95% POS N
confidence POS N
interval, POS N
1.20-5.60). POS N

Lower POS N
IOP POS N
with POS N
use POS N
of POS N
fewer POS N
glaucoma POS N
medications POS N
was POS N
achieved POS N
after POS N
trabeculectomy POS N
with POS N
MMC POS N
compared POS N
with POS N
tube POS N
shunt POS N
surgery POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up. POS N

Postoperative POS N
complications POS N
developed POS N
in POS N
36 POS N
patients POS N
(29%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
48 POS N
patients POS N
(41%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.06). POS N

Lower POS N
IOP POS N
with POS N
use POS N
of POS N
fewer POS N
glaucoma POS N
medications POS N
was POS N
achieved POS N
after POS N
trabeculectomy POS N
with POS N
MMC POS N
compared POS N
with POS N
tube POS N
shunt POS N
surgery POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up. POS N

Serious POS N
complications POS N
requiring POS N
reoperation POS N
or POS N
producing POS N
a POS N
loss POS N
of POS N
2 POS N
Snellen POS N
lines POS N
or POS N
more POS N
occurred POS N
in POS N
1 POS N
patient POS N
(1%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
8 POS N
patients POS N
(7%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.03). POS N

Lower POS N
IOP POS N
with POS N
use POS N
of POS N
fewer POS N
glaucoma POS N
medications POS N
was POS N
achieved POS N
after POS N
trabeculectomy POS N
with POS N
MMC POS N
compared POS N
with POS N
tube POS N
shunt POS N
surgery POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up. POS N

Trabeculectomy POS N
with POS N
MMC POS N
had POS N
a POS N
higher POS N
surgical POS N
success POS N
rate POS N
than POS N
tube POS N
shunt POS N
implantation POS N
after POS N
1 POS N
year POS N
in POS N
the POS N
PTVT POS N
Study. POS N

Lower POS N
IOP POS N
with POS N
use POS N
of POS N
fewer POS N
glaucoma POS N
medications POS N
was POS N
achieved POS N
after POS N
trabeculectomy POS N
with POS N
MMC POS N
compared POS N
with POS N
tube POS N
shunt POS N
surgery POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up. POS N

The POS N
frequency POS N
of POS N
serious POS N
complications POS N
producing POS N
vision POS N
loss POS N
or POS N
requiring POS N
reoperation POS N
was POS N
lower POS N
after POS N
tube POS N
shunt POS N
surgery POS N
relative POS N
to POS N
trabeculectomy POS N
with POS N
MMC. POS N

Lower POS N
IOP POS N
with POS N
use POS N
of POS N
fewer POS N
glaucoma POS N
medications POS N
was POS N
achieved POS N
after POS N
trabeculectomy POS N
with POS N
MMC POS N
compared POS N
with POS N
tube POS N
shunt POS N
surgery POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up. POS N

Mean POS N
± POS N
standard POS N
deviation POS N
IOP POS N
was POS N
13.8±4.1 POS N
mmHg POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
12.4±4.4 POS N
mmHg POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
at POS N
1 POS N
year POS N
(P POS N
= POS N
0.01), POS N
and POS N
the POS N
number POS N
of POS N
glaucoma POS N
medications POS N
was POS N
2.1±1.4 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.9±1.4 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
0.001). POS N

Mean POS N
± POS N
standard POS N
deviation POS N
IOP POS N
was POS N
13.8±4.1 POS N
mmHg POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
12.4±4.4 POS N
mmHg POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
at POS N
1 POS N
year POS N
(P POS N
= POS N
0.01), POS N
and POS N
the POS N
number POS N
of POS N
glaucoma POS N
medications POS N
was POS N
2.1±1.4 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.9±1.4 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
0.001). POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
17.3% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
7.9% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.01; POS N
hazard POS N
ratio, POS N
2.59; POS N
95% POS N
confidence POS N
interval, POS N
1.20-5.60). POS N

Mean POS N
± POS N
standard POS N
deviation POS N
IOP POS N
was POS N
13.8±4.1 POS N
mmHg POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
12.4±4.4 POS N
mmHg POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
at POS N
1 POS N
year POS N
(P POS N
= POS N
0.01), POS N
and POS N
the POS N
number POS N
of POS N
glaucoma POS N
medications POS N
was POS N
2.1±1.4 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.9±1.4 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
0.001). POS N

Postoperative POS N
complications POS N
developed POS N
in POS N
36 POS N
patients POS N
(29%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
48 POS N
patients POS N
(41%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.06). POS N

Mean POS N
± POS N
standard POS N
deviation POS N
IOP POS N
was POS N
13.8±4.1 POS N
mmHg POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
12.4±4.4 POS N
mmHg POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
at POS N
1 POS N
year POS N
(P POS N
= POS N
0.01), POS N
and POS N
the POS N
number POS N
of POS N
glaucoma POS N
medications POS N
was POS N
2.1±1.4 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.9±1.4 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
0.001). POS N

Serious POS N
complications POS N
requiring POS N
reoperation POS N
or POS N
producing POS N
a POS N
loss POS N
of POS N
2 POS N
Snellen POS N
lines POS N
or POS N
more POS N
occurred POS N
in POS N
1 POS N
patient POS N
(1%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
8 POS N
patients POS N
(7%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.03). POS N

Mean POS N
± POS N
standard POS N
deviation POS N
IOP POS N
was POS N
13.8±4.1 POS N
mmHg POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
12.4±4.4 POS N
mmHg POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
at POS N
1 POS N
year POS N
(P POS N
= POS N
0.01), POS N
and POS N
the POS N
number POS N
of POS N
glaucoma POS N
medications POS N
was POS N
2.1±1.4 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.9±1.4 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
0.001). POS N

Trabeculectomy POS N
with POS N
MMC POS N
had POS N
a POS N
higher POS N
surgical POS N
success POS N
rate POS N
than POS N
tube POS N
shunt POS N
implantation POS N
after POS N
1 POS N
year POS N
in POS N
the POS N
PTVT POS N
Study. POS N

Mean POS N
± POS N
standard POS N
deviation POS N
IOP POS N
was POS N
13.8±4.1 POS N
mmHg POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
12.4±4.4 POS N
mmHg POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
at POS N
1 POS N
year POS N
(P POS N
= POS N
0.01), POS N
and POS N
the POS N
number POS N
of POS N
glaucoma POS N
medications POS N
was POS N
2.1±1.4 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.9±1.4 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
0.001). POS N

The POS N
frequency POS N
of POS N
serious POS N
complications POS N
producing POS N
vision POS N
loss POS N
or POS N
requiring POS N
reoperation POS N
was POS N
lower POS N
after POS N
tube POS N
shunt POS N
surgery POS N
relative POS N
to POS N
trabeculectomy POS N
with POS N
MMC. POS N

Mean POS N
± POS N
standard POS N
deviation POS N
IOP POS N
was POS N
13.8±4.1 POS N
mmHg POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
12.4±4.4 POS N
mmHg POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
at POS N
1 POS N
year POS N
(P POS N
= POS N
0.01), POS N
and POS N
the POS N
number POS N
of POS N
glaucoma POS N
medications POS N
was POS N
2.1±1.4 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.9±1.4 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
0.001). POS N

Lower POS N
IOP POS N
with POS N
use POS N
of POS N
fewer POS N
glaucoma POS N
medications POS N
was POS N
achieved POS N
after POS N
trabeculectomy POS N
with POS N
MMC POS N
compared POS N
with POS N
tube POS N
shunt POS N
surgery POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up. POS N

valsartan/cilnidipine POS N
combination POS N
would POS N
suppress POS N
the POS N
home POS N
morning POS N
blood POS N
pressure POS N
(BP) POS N
surge POS N
(HMBPS) POS N
more POS N
effectively POS N
than POS N
a POS N
valsartan/hydrochlorothiazide POS N
combination POS N
in POS N
patients POS N
with POS N
morning POS N
hypertension POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment POS N
period, POS N
the POS N
changes POS N
in POS N
nocturnal POS N
SBP POS N
and POS N
morning POS N
SBP POS N
from POS N
baseline POS N
were POS N
significant POS N
in POS N
both POS N
the POS N
valsartan/cilnidipine POS N
and POS N
valsartan/hydrochlorothiazide POS N
groups POS N
(P POS N
< POS N
.001): POS N
-5.0 POS N
vs POS N
-10.0 POS N
mm POS N
Hg POS N
(P POS N
= POS N
.035) POS N
and POS N
-10.7 POS N
vs POS N
-13.6 POS N
mm POS N
Hg POS N
(P POS N
= POS N
.142), POS N
respectively. POS N

valsartan/cilnidipine POS N
combination POS N
would POS N
suppress POS N
the POS N
home POS N
morning POS N
blood POS N
pressure POS N
(BP) POS N
surge POS N
(HMBPS) POS N
more POS N
effectively POS N
than POS N
a POS N
valsartan/hydrochlorothiazide POS N
combination POS N
in POS N
patients POS N
with POS N
morning POS N
hypertension POS N

HMBPS POS N
was POS N
significantly POS N
decreased POS N
from POS N
baseline POS N
in POS N
both POS N
groups POS N
(P POS N
< POS N
.001), POS N
but POS N
there POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
two POS N
groups: POS N
14.4 POS N
mm POS N
Hg POS N
vs POS N
14.0 POS N
mm POS N
Hg, POS N
respectively POS N
(P POS N
= POS N
.892). POS N

valsartan/cilnidipine POS N
combination POS N
would POS N
suppress POS N
the POS N
home POS N
morning POS N
blood POS N
pressure POS N
(BP) POS N
surge POS N
(HMBPS) POS N
more POS N
effectively POS N
than POS N
a POS N
valsartan/hydrochlorothiazide POS N
combination POS N
in POS N
patients POS N
with POS N
morning POS N
hypertension POS N

Valsartan/cilnidipine POS N
could POS N
not POS N
significantly POS N
suppress POS N
HMBPS POS N
compared POS N
with POS N
valsartan/hydrochlorothiazide. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment POS N
period, POS N
the POS N
changes POS N
in POS N
nocturnal POS N
SBP POS N
and POS N
morning POS N
SBP POS N
from POS N
baseline POS N
were POS N
significant POS N
in POS N
both POS N
the POS N
valsartan/cilnidipine POS N
and POS N
valsartan/hydrochlorothiazide POS N
groups POS N
(P POS N
< POS N
.001): POS N
-5.0 POS N
vs POS N
-10.0 POS N
mm POS N
Hg POS N
(P POS N
= POS N
.035) POS N
and POS N
-10.7 POS N
vs POS N
-13.6 POS N
mm POS N
Hg POS N
(P POS N
= POS N
.142), POS N
respectively. POS N

valsartan/cilnidipine POS N
combination POS N
would POS N
suppress POS N
the POS N
home POS N
morning POS N
blood POS N
pressure POS N
(BP) POS N
surge POS N
(HMBPS) POS N
more POS N
effectively POS N
than POS N
a POS N
valsartan/hydrochlorothiazide POS N
combination POS N
in POS N
patients POS N
with POS N
morning POS N
hypertension POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment POS N
period, POS N
the POS N
changes POS N
in POS N
nocturnal POS N
SBP POS N
and POS N
morning POS N
SBP POS N
from POS N
baseline POS N
were POS N
significant POS N
in POS N
both POS N
the POS N
valsartan/cilnidipine POS N
and POS N
valsartan/hydrochlorothiazide POS N
groups POS N
(P POS N
< POS N
.001): POS N
-5.0 POS N
vs POS N
-10.0 POS N
mm POS N
Hg POS N
(P POS N
= POS N
.035) POS N
and POS N
-10.7 POS N
vs POS N
-13.6 POS N
mm POS N
Hg POS N
(P POS N
= POS N
.142), POS N
respectively. POS N

HMBPS POS N
was POS N
significantly POS N
decreased POS N
from POS N
baseline POS N
in POS N
both POS N
groups POS N
(P POS N
< POS N
.001), POS N
but POS N
there POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
two POS N
groups: POS N
14.4 POS N
mm POS N
Hg POS N
vs POS N
14.0 POS N
mm POS N
Hg, POS N
respectively POS N
(P POS N
= POS N
.892). POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment POS N
period, POS N
the POS N
changes POS N
in POS N
nocturnal POS N
SBP POS N
and POS N
morning POS N
SBP POS N
from POS N
baseline POS N
were POS N
significant POS N
in POS N
both POS N
the POS N
valsartan/cilnidipine POS N
and POS N
valsartan/hydrochlorothiazide POS N
groups POS N
(P POS N
< POS N
.001): POS N
-5.0 POS N
vs POS N
-10.0 POS N
mm POS N
Hg POS N
(P POS N
= POS N
.035) POS N
and POS N
-10.7 POS N
vs POS N
-13.6 POS N
mm POS N
Hg POS N
(P POS N
= POS N
.142), POS N
respectively. POS N

Valsartan/cilnidipine POS N
could POS N
not POS N
significantly POS N
suppress POS N
HMBPS POS N
compared POS N
with POS N
valsartan/hydrochlorothiazide. POS N

HMBPS POS N
was POS N
significantly POS N
decreased POS N
from POS N
baseline POS N
in POS N
both POS N
groups POS N
(P POS N
< POS N
.001), POS N
but POS N
there POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
two POS N
groups: POS N
14.4 POS N
mm POS N
Hg POS N
vs POS N
14.0 POS N
mm POS N
Hg, POS N
respectively POS N
(P POS N
= POS N
.892). POS N

valsartan/cilnidipine POS N
combination POS N
would POS N
suppress POS N
the POS N
home POS N
morning POS N
blood POS N
pressure POS N
(BP) POS N
surge POS N
(HMBPS) POS N
more POS N
effectively POS N
than POS N
a POS N
valsartan/hydrochlorothiazide POS N
combination POS N
in POS N
patients POS N
with POS N
morning POS N
hypertension POS N

HMBPS POS N
was POS N
significantly POS N
decreased POS N
from POS N
baseline POS N
in POS N
both POS N
groups POS N
(P POS N
< POS N
.001), POS N
but POS N
there POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
two POS N
groups: POS N
14.4 POS N
mm POS N
Hg POS N
vs POS N
14.0 POS N
mm POS N
Hg, POS N
respectively POS N
(P POS N
= POS N
.892). POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment POS N
period, POS N
the POS N
changes POS N
in POS N
nocturnal POS N
SBP POS N
and POS N
morning POS N
SBP POS N
from POS N
baseline POS N
were POS N
significant POS N
in POS N
both POS N
the POS N
valsartan/cilnidipine POS N
and POS N
valsartan/hydrochlorothiazide POS N
groups POS N
(P POS N
< POS N
.001): POS N
-5.0 POS N
vs POS N
-10.0 POS N
mm POS N
Hg POS N
(P POS N
= POS N
.035) POS N
and POS N
-10.7 POS N
vs POS N
-13.6 POS N
mm POS N
Hg POS N
(P POS N
= POS N
.142), POS N
respectively. POS N

HMBPS POS N
was POS N
significantly POS N
decreased POS N
from POS N
baseline POS N
in POS N
both POS N
groups POS N
(P POS N
< POS N
.001), POS N
but POS N
there POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
two POS N
groups: POS N
14.4 POS N
mm POS N
Hg POS N
vs POS N
14.0 POS N
mm POS N
Hg, POS N
respectively POS N
(P POS N
= POS N
.892). POS N

Valsartan/cilnidipine POS N
could POS N
not POS N
significantly POS N
suppress POS N
HMBPS POS N
compared POS N
with POS N
valsartan/hydrochlorothiazide. POS N

Valsartan/cilnidipine POS N
could POS N
not POS N
significantly POS N
suppress POS N
HMBPS POS N
compared POS N
with POS N
valsartan/hydrochlorothiazide. POS N

valsartan/cilnidipine POS N
combination POS N
would POS N
suppress POS N
the POS N
home POS N
morning POS N
blood POS N
pressure POS N
(BP) POS N
surge POS N
(HMBPS) POS N
more POS N
effectively POS N
than POS N
a POS N
valsartan/hydrochlorothiazide POS N
combination POS N
in POS N
patients POS N
with POS N
morning POS N
hypertension POS N

Valsartan/cilnidipine POS N
could POS N
not POS N
significantly POS N
suppress POS N
HMBPS POS N
compared POS N
with POS N
valsartan/hydrochlorothiazide. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment POS N
period, POS N
the POS N
changes POS N
in POS N
nocturnal POS N
SBP POS N
and POS N
morning POS N
SBP POS N
from POS N
baseline POS N
were POS N
significant POS N
in POS N
both POS N
the POS N
valsartan/cilnidipine POS N
and POS N
valsartan/hydrochlorothiazide POS N
groups POS N
(P POS N
< POS N
.001): POS N
-5.0 POS N
vs POS N
-10.0 POS N
mm POS N
Hg POS N
(P POS N
= POS N
.035) POS N
and POS N
-10.7 POS N
vs POS N
-13.6 POS N
mm POS N
Hg POS N
(P POS N
= POS N
.142), POS N
respectively. POS N

Valsartan/cilnidipine POS N
could POS N
not POS N
significantly POS N
suppress POS N
HMBPS POS N
compared POS N
with POS N
valsartan/hydrochlorothiazide. POS N

HMBPS POS N
was POS N
significantly POS N
decreased POS N
from POS N
baseline POS N
in POS N
both POS N
groups POS N
(P POS N
< POS N
.001), POS N
but POS N
there POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
two POS N
groups: POS N
14.4 POS N
mm POS N
Hg POS N
vs POS N
14.0 POS N
mm POS N
Hg, POS N
respectively POS N
(P POS N
= POS N
.892). POS N

In POS N
recent POS N
years, POS N
encouraging POS N
results POS N
of POS N
preoperative POS N
radiotherapy POS N
have POS N
been POS N
reported. POS N

Postoperative POS N
radiochemotherapy POS N
is POS N
recommended POS N
for POS N
patients POS N
with POS N
advanced POS N
disease POS N
(pT3/4 POS N
or POS N
pN+). POS N

In POS N
recent POS N
years, POS N
encouraging POS N
results POS N
of POS N
preoperative POS N
radiotherapy POS N
have POS N
been POS N
reported. POS N

Acute POS N
toxicity POS N
(WHO) POS N
of POS N
radiochemotherapy POS N
was POS N
low, POS N
with POS N
less POS N
than POS N
15% POS N
of POS N
patients POS N
experiencing POS N
Grade POS N
3 POS N
or POS N
higher POS N
toxicity POS N

In POS N
recent POS N
years, POS N
encouraging POS N
results POS N
of POS N
preoperative POS N
radiotherapy POS N
have POS N
been POS N
reported. POS N

The POS N
principal POS N
toxicity POS N
was POS N
diarrhea, POS N
with POS N
12% POS N
in POS N
the POS N
postoperative POS N
radiochemotherapy POS N
arm POS N
and POS N
10% POS N
in POS N
the POS N
preoperative POS N
radiochemotherapy POS N
arm POS N
having POS N
Grade-3, POS N
and POS N
1% POS N
in POS N
either POS N
arm POS N
having POS N
Grade-4 POS N
diarrhea. POS N

In POS N
recent POS N
years, POS N
encouraging POS N
results POS N
of POS N
preoperative POS N
radiotherapy POS N
have POS N
been POS N
reported. POS N

Erythema, POS N
nausea POS N
and POS N
leukopenia POS N
were POS N
the POS N
next POS N
common POS N
toxicities, POS N
with POS N
less POS N
than POS N
3% POS N
of POS N
patients POS N
in POS N
either POS N
arm POS N
suffering POS N
Grade POS N
3 POS N
or POS N
greater POS N
leukopenia POS N
or POS N
nausea. POS N

In POS N
recent POS N
years, POS N
encouraging POS N
results POS N
of POS N
preoperative POS N
radiotherapy POS N
have POS N
been POS N
reported. POS N

Postoperative POS N
complication POS N
rates POS N
were POS N
similar POS N
in POS N
both POS N
arms, POS N
with POS N
12% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
13% POS N
(preoperative POS N
radiochemotherapy) POS N
of POS N
patients, POS N
respectively, POS N
suffering POS N
from POS N
anastomotic POS N
leakage, POS N
4% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
3% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
postoperative POS N
bleeding, POS N
and POS N
6% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
5% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
delayed POS N
wound POS N
healing. POS N

In POS N
recent POS N
years, POS N
encouraging POS N
results POS N
of POS N
preoperative POS N
radiotherapy POS N
have POS N
been POS N
reported. POS N

The POS N
patient POS N
accrual POS N
of POS N
our POS N
trial POS N
is POS N
satisfactory, POS N

In POS N
recent POS N
years, POS N
encouraging POS N
results POS N
of POS N
preoperative POS N
radiotherapy POS N
have POS N
been POS N
reported. POS N

neoadjuvant POS N
radiochemotherapy POS N
is POS N
well POS N
tolerated POS N
and POS N
bears POS N
no POS N
higher POS N
risk POS N
for POS N
postoperative POS N
morbidity. POS N

Postoperative POS N
radiochemotherapy POS N
is POS N
recommended POS N
for POS N
patients POS N
with POS N
advanced POS N
disease POS N
(pT3/4 POS N
or POS N
pN+). POS N

In POS N
recent POS N
years, POS N
encouraging POS N
results POS N
of POS N
preoperative POS N
radiotherapy POS N
have POS N
been POS N
reported. POS N

Postoperative POS N
radiochemotherapy POS N
is POS N
recommended POS N
for POS N
patients POS N
with POS N
advanced POS N
disease POS N
(pT3/4 POS N
or POS N
pN+). POS N

Acute POS N
toxicity POS N
(WHO) POS N
of POS N
radiochemotherapy POS N
was POS N
low, POS N
with POS N
less POS N
than POS N
15% POS N
of POS N
patients POS N
experiencing POS N
Grade POS N
3 POS N
or POS N
higher POS N
toxicity POS N

Postoperative POS N
radiochemotherapy POS N
is POS N
recommended POS N
for POS N
patients POS N
with POS N
advanced POS N
disease POS N
(pT3/4 POS N
or POS N
pN+). POS N

The POS N
principal POS N
toxicity POS N
was POS N
diarrhea, POS N
with POS N
12% POS N
in POS N
the POS N
postoperative POS N
radiochemotherapy POS N
arm POS N
and POS N
10% POS N
in POS N
the POS N
preoperative POS N
radiochemotherapy POS N
arm POS N
having POS N
Grade-3, POS N
and POS N
1% POS N
in POS N
either POS N
arm POS N
having POS N
Grade-4 POS N
diarrhea. POS N

Postoperative POS N
radiochemotherapy POS N
is POS N
recommended POS N
for POS N
patients POS N
with POS N
advanced POS N
disease POS N
(pT3/4 POS N
or POS N
pN+). POS N

Erythema, POS N
nausea POS N
and POS N
leukopenia POS N
were POS N
the POS N
next POS N
common POS N
toxicities, POS N
with POS N
less POS N
than POS N
3% POS N
of POS N
patients POS N
in POS N
either POS N
arm POS N
suffering POS N
Grade POS N
3 POS N
or POS N
greater POS N
leukopenia POS N
or POS N
nausea. POS N

Postoperative POS N
radiochemotherapy POS N
is POS N
recommended POS N
for POS N
patients POS N
with POS N
advanced POS N
disease POS N
(pT3/4 POS N
or POS N
pN+). POS N

Postoperative POS N
complication POS N
rates POS N
were POS N
similar POS N
in POS N
both POS N
arms, POS N
with POS N
12% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
13% POS N
(preoperative POS N
radiochemotherapy) POS N
of POS N
patients, POS N
respectively, POS N
suffering POS N
from POS N
anastomotic POS N
leakage, POS N
4% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
3% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
postoperative POS N
bleeding, POS N
and POS N
6% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
5% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
delayed POS N
wound POS N
healing. POS N

Postoperative POS N
radiochemotherapy POS N
is POS N
recommended POS N
for POS N
patients POS N
with POS N
advanced POS N
disease POS N
(pT3/4 POS N
or POS N
pN+). POS N

The POS N
patient POS N
accrual POS N
of POS N
our POS N
trial POS N
is POS N
satisfactory, POS N

Postoperative POS N
radiochemotherapy POS N
is POS N
recommended POS N
for POS N
patients POS N
with POS N
advanced POS N
disease POS N
(pT3/4 POS N
or POS N
pN+). POS N

neoadjuvant POS N
radiochemotherapy POS N
is POS N
well POS N
tolerated POS N
and POS N
bears POS N
no POS N
higher POS N
risk POS N
for POS N
postoperative POS N
morbidity. POS N

Acute POS N
toxicity POS N
(WHO) POS N
of POS N
radiochemotherapy POS N
was POS N
low, POS N
with POS N
less POS N
than POS N
15% POS N
of POS N
patients POS N
experiencing POS N
Grade POS N
3 POS N
or POS N
higher POS N
toxicity POS N

In POS N
recent POS N
years, POS N
encouraging POS N
results POS N
of POS N
preoperative POS N
radiotherapy POS N
have POS N
been POS N
reported. POS N

Acute POS N
toxicity POS N
(WHO) POS N
of POS N
radiochemotherapy POS N
was POS N
low, POS N
with POS N
less POS N
than POS N
15% POS N
of POS N
patients POS N
experiencing POS N
Grade POS N
3 POS N
or POS N
higher POS N
toxicity POS N

Postoperative POS N
radiochemotherapy POS N
is POS N
recommended POS N
for POS N
patients POS N
with POS N
advanced POS N
disease POS N
(pT3/4 POS N
or POS N
pN+). POS N

Acute POS N
toxicity POS N
(WHO) POS N
of POS N
radiochemotherapy POS N
was POS N
low, POS N
with POS N
less POS N
than POS N
15% POS N
of POS N
patients POS N
experiencing POS N
Grade POS N
3 POS N
or POS N
higher POS N
toxicity POS N

The POS N
principal POS N
toxicity POS N
was POS N
diarrhea, POS N
with POS N
12% POS N
in POS N
the POS N
postoperative POS N
radiochemotherapy POS N
arm POS N
and POS N
10% POS N
in POS N
the POS N
preoperative POS N
radiochemotherapy POS N
arm POS N
having POS N
Grade-3, POS N
and POS N
1% POS N
in POS N
either POS N
arm POS N
having POS N
Grade-4 POS N
diarrhea. POS N

Acute POS N
toxicity POS N
(WHO) POS N
of POS N
radiochemotherapy POS N
was POS N
low, POS N
with POS N
less POS N
than POS N
15% POS N
of POS N
patients POS N
experiencing POS N
Grade POS N
3 POS N
or POS N
higher POS N
toxicity POS N

Erythema, POS N
nausea POS N
and POS N
leukopenia POS N
were POS N
the POS N
next POS N
common POS N
toxicities, POS N
with POS N
less POS N
than POS N
3% POS N
of POS N
patients POS N
in POS N
either POS N
arm POS N
suffering POS N
Grade POS N
3 POS N
or POS N
greater POS N
leukopenia POS N
or POS N
nausea. POS N

Acute POS N
toxicity POS N
(WHO) POS N
of POS N
radiochemotherapy POS N
was POS N
low, POS N
with POS N
less POS N
than POS N
15% POS N
of POS N
patients POS N
experiencing POS N
Grade POS N
3 POS N
or POS N
higher POS N
toxicity POS N

Postoperative POS N
complication POS N
rates POS N
were POS N
similar POS N
in POS N
both POS N
arms, POS N
with POS N
12% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
13% POS N
(preoperative POS N
radiochemotherapy) POS N
of POS N
patients, POS N
respectively, POS N
suffering POS N
from POS N
anastomotic POS N
leakage, POS N
4% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
3% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
postoperative POS N
bleeding, POS N
and POS N
6% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
5% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
delayed POS N
wound POS N
healing. POS N

Acute POS N
toxicity POS N
(WHO) POS N
of POS N
radiochemotherapy POS N
was POS N
low, POS N
with POS N
less POS N
than POS N
15% POS N
of POS N
patients POS N
experiencing POS N
Grade POS N
3 POS N
or POS N
higher POS N
toxicity POS N

The POS N
patient POS N
accrual POS N
of POS N
our POS N
trial POS N
is POS N
satisfactory, POS N

Acute POS N
toxicity POS N
(WHO) POS N
of POS N
radiochemotherapy POS N
was POS N
low, POS N
with POS N
less POS N
than POS N
15% POS N
of POS N
patients POS N
experiencing POS N
Grade POS N
3 POS N
or POS N
higher POS N
toxicity POS N

neoadjuvant POS N
radiochemotherapy POS N
is POS N
well POS N
tolerated POS N
and POS N
bears POS N
no POS N
higher POS N
risk POS N
for POS N
postoperative POS N
morbidity. POS N

The POS N
principal POS N
toxicity POS N
was POS N
diarrhea, POS N
with POS N
12% POS N
in POS N
the POS N
postoperative POS N
radiochemotherapy POS N
arm POS N
and POS N
10% POS N
in POS N
the POS N
preoperative POS N
radiochemotherapy POS N
arm POS N
having POS N
Grade-3, POS N
and POS N
1% POS N
in POS N
either POS N
arm POS N
having POS N
Grade-4 POS N
diarrhea. POS N

In POS N
recent POS N
years, POS N
encouraging POS N
results POS N
of POS N
preoperative POS N
radiotherapy POS N
have POS N
been POS N
reported. POS N

The POS N
principal POS N
toxicity POS N
was POS N
diarrhea, POS N
with POS N
12% POS N
in POS N
the POS N
postoperative POS N
radiochemotherapy POS N
arm POS N
and POS N
10% POS N
in POS N
the POS N
preoperative POS N
radiochemotherapy POS N
arm POS N
having POS N
Grade-3, POS N
and POS N
1% POS N
in POS N
either POS N
arm POS N
having POS N
Grade-4 POS N
diarrhea. POS N

Postoperative POS N
radiochemotherapy POS N
is POS N
recommended POS N
for POS N
patients POS N
with POS N
advanced POS N
disease POS N
(pT3/4 POS N
or POS N
pN+). POS N

The POS N
principal POS N
toxicity POS N
was POS N
diarrhea, POS N
with POS N
12% POS N
in POS N
the POS N
postoperative POS N
radiochemotherapy POS N
arm POS N
and POS N
10% POS N
in POS N
the POS N
preoperative POS N
radiochemotherapy POS N
arm POS N
having POS N
Grade-3, POS N
and POS N
1% POS N
in POS N
either POS N
arm POS N
having POS N
Grade-4 POS N
diarrhea. POS N

Acute POS N
toxicity POS N
(WHO) POS N
of POS N
radiochemotherapy POS N
was POS N
low, POS N
with POS N
less POS N
than POS N
15% POS N
of POS N
patients POS N
experiencing POS N
Grade POS N
3 POS N
or POS N
higher POS N
toxicity POS N

The POS N
principal POS N
toxicity POS N
was POS N
diarrhea, POS N
with POS N
12% POS N
in POS N
the POS N
postoperative POS N
radiochemotherapy POS N
arm POS N
and POS N
10% POS N
in POS N
the POS N
preoperative POS N
radiochemotherapy POS N
arm POS N
having POS N
Grade-3, POS N
and POS N
1% POS N
in POS N
either POS N
arm POS N
having POS N
Grade-4 POS N
diarrhea. POS N

Erythema, POS N
nausea POS N
and POS N
leukopenia POS N
were POS N
the POS N
next POS N
common POS N
toxicities, POS N
with POS N
less POS N
than POS N
3% POS N
of POS N
patients POS N
in POS N
either POS N
arm POS N
suffering POS N
Grade POS N
3 POS N
or POS N
greater POS N
leukopenia POS N
or POS N
nausea. POS N

The POS N
principal POS N
toxicity POS N
was POS N
diarrhea, POS N
with POS N
12% POS N
in POS N
the POS N
postoperative POS N
radiochemotherapy POS N
arm POS N
and POS N
10% POS N
in POS N
the POS N
preoperative POS N
radiochemotherapy POS N
arm POS N
having POS N
Grade-3, POS N
and POS N
1% POS N
in POS N
either POS N
arm POS N
having POS N
Grade-4 POS N
diarrhea. POS N

Postoperative POS N
complication POS N
rates POS N
were POS N
similar POS N
in POS N
both POS N
arms, POS N
with POS N
12% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
13% POS N
(preoperative POS N
radiochemotherapy) POS N
of POS N
patients, POS N
respectively, POS N
suffering POS N
from POS N
anastomotic POS N
leakage, POS N
4% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
3% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
postoperative POS N
bleeding, POS N
and POS N
6% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
5% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
delayed POS N
wound POS N
healing. POS N

The POS N
principal POS N
toxicity POS N
was POS N
diarrhea, POS N
with POS N
12% POS N
in POS N
the POS N
postoperative POS N
radiochemotherapy POS N
arm POS N
and POS N
10% POS N
in POS N
the POS N
preoperative POS N
radiochemotherapy POS N
arm POS N
having POS N
Grade-3, POS N
and POS N
1% POS N
in POS N
either POS N
arm POS N
having POS N
Grade-4 POS N
diarrhea. POS N

The POS N
patient POS N
accrual POS N
of POS N
our POS N
trial POS N
is POS N
satisfactory, POS N

The POS N
principal POS N
toxicity POS N
was POS N
diarrhea, POS N
with POS N
12% POS N
in POS N
the POS N
postoperative POS N
radiochemotherapy POS N
arm POS N
and POS N
10% POS N
in POS N
the POS N
preoperative POS N
radiochemotherapy POS N
arm POS N
having POS N
Grade-3, POS N
and POS N
1% POS N
in POS N
either POS N
arm POS N
having POS N
Grade-4 POS N
diarrhea. POS N

neoadjuvant POS N
radiochemotherapy POS N
is POS N
well POS N
tolerated POS N
and POS N
bears POS N
no POS N
higher POS N
risk POS N
for POS N
postoperative POS N
morbidity. POS N

Erythema, POS N
nausea POS N
and POS N
leukopenia POS N
were POS N
the POS N
next POS N
common POS N
toxicities, POS N
with POS N
less POS N
than POS N
3% POS N
of POS N
patients POS N
in POS N
either POS N
arm POS N
suffering POS N
Grade POS N
3 POS N
or POS N
greater POS N
leukopenia POS N
or POS N
nausea. POS N

In POS N
recent POS N
years, POS N
encouraging POS N
results POS N
of POS N
preoperative POS N
radiotherapy POS N
have POS N
been POS N
reported. POS N

Erythema, POS N
nausea POS N
and POS N
leukopenia POS N
were POS N
the POS N
next POS N
common POS N
toxicities, POS N
with POS N
less POS N
than POS N
3% POS N
of POS N
patients POS N
in POS N
either POS N
arm POS N
suffering POS N
Grade POS N
3 POS N
or POS N
greater POS N
leukopenia POS N
or POS N
nausea. POS N

Postoperative POS N
radiochemotherapy POS N
is POS N
recommended POS N
for POS N
patients POS N
with POS N
advanced POS N
disease POS N
(pT3/4 POS N
or POS N
pN+). POS N

Erythema, POS N
nausea POS N
and POS N
leukopenia POS N
were POS N
the POS N
next POS N
common POS N
toxicities, POS N
with POS N
less POS N
than POS N
3% POS N
of POS N
patients POS N
in POS N
either POS N
arm POS N
suffering POS N
Grade POS N
3 POS N
or POS N
greater POS N
leukopenia POS N
or POS N
nausea. POS N

Acute POS N
toxicity POS N
(WHO) POS N
of POS N
radiochemotherapy POS N
was POS N
low, POS N
with POS N
less POS N
than POS N
15% POS N
of POS N
patients POS N
experiencing POS N
Grade POS N
3 POS N
or POS N
higher POS N
toxicity POS N

Erythema, POS N
nausea POS N
and POS N
leukopenia POS N
were POS N
the POS N
next POS N
common POS N
toxicities, POS N
with POS N
less POS N
than POS N
3% POS N
of POS N
patients POS N
in POS N
either POS N
arm POS N
suffering POS N
Grade POS N
3 POS N
or POS N
greater POS N
leukopenia POS N
or POS N
nausea. POS N

The POS N
principal POS N
toxicity POS N
was POS N
diarrhea, POS N
with POS N
12% POS N
in POS N
the POS N
postoperative POS N
radiochemotherapy POS N
arm POS N
and POS N
10% POS N
in POS N
the POS N
preoperative POS N
radiochemotherapy POS N
arm POS N
having POS N
Grade-3, POS N
and POS N
1% POS N
in POS N
either POS N
arm POS N
having POS N
Grade-4 POS N
diarrhea. POS N

Erythema, POS N
nausea POS N
and POS N
leukopenia POS N
were POS N
the POS N
next POS N
common POS N
toxicities, POS N
with POS N
less POS N
than POS N
3% POS N
of POS N
patients POS N
in POS N
either POS N
arm POS N
suffering POS N
Grade POS N
3 POS N
or POS N
greater POS N
leukopenia POS N
or POS N
nausea. POS N

Postoperative POS N
complication POS N
rates POS N
were POS N
similar POS N
in POS N
both POS N
arms, POS N
with POS N
12% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
13% POS N
(preoperative POS N
radiochemotherapy) POS N
of POS N
patients, POS N
respectively, POS N
suffering POS N
from POS N
anastomotic POS N
leakage, POS N
4% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
3% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
postoperative POS N
bleeding, POS N
and POS N
6% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
5% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
delayed POS N
wound POS N
healing. POS N

Erythema, POS N
nausea POS N
and POS N
leukopenia POS N
were POS N
the POS N
next POS N
common POS N
toxicities, POS N
with POS N
less POS N
than POS N
3% POS N
of POS N
patients POS N
in POS N
either POS N
arm POS N
suffering POS N
Grade POS N
3 POS N
or POS N
greater POS N
leukopenia POS N
or POS N
nausea. POS N

The POS N
patient POS N
accrual POS N
of POS N
our POS N
trial POS N
is POS N
satisfactory, POS N

Erythema, POS N
nausea POS N
and POS N
leukopenia POS N
were POS N
the POS N
next POS N
common POS N
toxicities, POS N
with POS N
less POS N
than POS N
3% POS N
of POS N
patients POS N
in POS N
either POS N
arm POS N
suffering POS N
Grade POS N
3 POS N
or POS N
greater POS N
leukopenia POS N
or POS N
nausea. POS N

neoadjuvant POS N
radiochemotherapy POS N
is POS N
well POS N
tolerated POS N
and POS N
bears POS N
no POS N
higher POS N
risk POS N
for POS N
postoperative POS N
morbidity. POS N

Postoperative POS N
complication POS N
rates POS N
were POS N
similar POS N
in POS N
both POS N
arms, POS N
with POS N
12% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
13% POS N
(preoperative POS N
radiochemotherapy) POS N
of POS N
patients, POS N
respectively, POS N
suffering POS N
from POS N
anastomotic POS N
leakage, POS N
4% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
3% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
postoperative POS N
bleeding, POS N
and POS N
6% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
5% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
delayed POS N
wound POS N
healing. POS N

In POS N
recent POS N
years, POS N
encouraging POS N
results POS N
of POS N
preoperative POS N
radiotherapy POS N
have POS N
been POS N
reported. POS N

Postoperative POS N
complication POS N
rates POS N
were POS N
similar POS N
in POS N
both POS N
arms, POS N
with POS N
12% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
13% POS N
(preoperative POS N
radiochemotherapy) POS N
of POS N
patients, POS N
respectively, POS N
suffering POS N
from POS N
anastomotic POS N
leakage, POS N
4% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
3% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
postoperative POS N
bleeding, POS N
and POS N
6% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
5% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
delayed POS N
wound POS N
healing. POS N

Postoperative POS N
radiochemotherapy POS N
is POS N
recommended POS N
for POS N
patients POS N
with POS N
advanced POS N
disease POS N
(pT3/4 POS N
or POS N
pN+). POS N

Postoperative POS N
complication POS N
rates POS N
were POS N
similar POS N
in POS N
both POS N
arms, POS N
with POS N
12% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
13% POS N
(preoperative POS N
radiochemotherapy) POS N
of POS N
patients, POS N
respectively, POS N
suffering POS N
from POS N
anastomotic POS N
leakage, POS N
4% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
3% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
postoperative POS N
bleeding, POS N
and POS N
6% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
5% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
delayed POS N
wound POS N
healing. POS N

Acute POS N
toxicity POS N
(WHO) POS N
of POS N
radiochemotherapy POS N
was POS N
low, POS N
with POS N
less POS N
than POS N
15% POS N
of POS N
patients POS N
experiencing POS N
Grade POS N
3 POS N
or POS N
higher POS N
toxicity POS N

Postoperative POS N
complication POS N
rates POS N
were POS N
similar POS N
in POS N
both POS N
arms, POS N
with POS N
12% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
13% POS N
(preoperative POS N
radiochemotherapy) POS N
of POS N
patients, POS N
respectively, POS N
suffering POS N
from POS N
anastomotic POS N
leakage, POS N
4% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
3% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
postoperative POS N
bleeding, POS N
and POS N
6% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
5% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
delayed POS N
wound POS N
healing. POS N

The POS N
principal POS N
toxicity POS N
was POS N
diarrhea, POS N
with POS N
12% POS N
in POS N
the POS N
postoperative POS N
radiochemotherapy POS N
arm POS N
and POS N
10% POS N
in POS N
the POS N
preoperative POS N
radiochemotherapy POS N
arm POS N
having POS N
Grade-3, POS N
and POS N
1% POS N
in POS N
either POS N
arm POS N
having POS N
Grade-4 POS N
diarrhea. POS N

Postoperative POS N
complication POS N
rates POS N
were POS N
similar POS N
in POS N
both POS N
arms, POS N
with POS N
12% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
13% POS N
(preoperative POS N
radiochemotherapy) POS N
of POS N
patients, POS N
respectively, POS N
suffering POS N
from POS N
anastomotic POS N
leakage, POS N
4% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
3% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
postoperative POS N
bleeding, POS N
and POS N
6% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
5% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
delayed POS N
wound POS N
healing. POS N

Erythema, POS N
nausea POS N
and POS N
leukopenia POS N
were POS N
the POS N
next POS N
common POS N
toxicities, POS N
with POS N
less POS N
than POS N
3% POS N
of POS N
patients POS N
in POS N
either POS N
arm POS N
suffering POS N
Grade POS N
3 POS N
or POS N
greater POS N
leukopenia POS N
or POS N
nausea. POS N

Postoperative POS N
complication POS N
rates POS N
were POS N
similar POS N
in POS N
both POS N
arms, POS N
with POS N
12% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
13% POS N
(preoperative POS N
radiochemotherapy) POS N
of POS N
patients, POS N
respectively, POS N
suffering POS N
from POS N
anastomotic POS N
leakage, POS N
4% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
3% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
postoperative POS N
bleeding, POS N
and POS N
6% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
5% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
delayed POS N
wound POS N
healing. POS N

The POS N
patient POS N
accrual POS N
of POS N
our POS N
trial POS N
is POS N
satisfactory, POS N

Postoperative POS N
complication POS N
rates POS N
were POS N
similar POS N
in POS N
both POS N
arms, POS N
with POS N
12% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
13% POS N
(preoperative POS N
radiochemotherapy) POS N
of POS N
patients, POS N
respectively, POS N
suffering POS N
from POS N
anastomotic POS N
leakage, POS N
4% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
3% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
postoperative POS N
bleeding, POS N
and POS N
6% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
5% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
delayed POS N
wound POS N
healing. POS N

neoadjuvant POS N
radiochemotherapy POS N
is POS N
well POS N
tolerated POS N
and POS N
bears POS N
no POS N
higher POS N
risk POS N
for POS N
postoperative POS N
morbidity. POS N

The POS N
patient POS N
accrual POS N
of POS N
our POS N
trial POS N
is POS N
satisfactory, POS N

In POS N
recent POS N
years, POS N
encouraging POS N
results POS N
of POS N
preoperative POS N
radiotherapy POS N
have POS N
been POS N
reported. POS N

The POS N
patient POS N
accrual POS N
of POS N
our POS N
trial POS N
is POS N
satisfactory, POS N

Postoperative POS N
radiochemotherapy POS N
is POS N
recommended POS N
for POS N
patients POS N
with POS N
advanced POS N
disease POS N
(pT3/4 POS N
or POS N
pN+). POS N

The POS N
patient POS N
accrual POS N
of POS N
our POS N
trial POS N
is POS N
satisfactory, POS N

Acute POS N
toxicity POS N
(WHO) POS N
of POS N
radiochemotherapy POS N
was POS N
low, POS N
with POS N
less POS N
than POS N
15% POS N
of POS N
patients POS N
experiencing POS N
Grade POS N
3 POS N
or POS N
higher POS N
toxicity POS N

The POS N
patient POS N
accrual POS N
of POS N
our POS N
trial POS N
is POS N
satisfactory, POS N

The POS N
principal POS N
toxicity POS N
was POS N
diarrhea, POS N
with POS N
12% POS N
in POS N
the POS N
postoperative POS N
radiochemotherapy POS N
arm POS N
and POS N
10% POS N
in POS N
the POS N
preoperative POS N
radiochemotherapy POS N
arm POS N
having POS N
Grade-3, POS N
and POS N
1% POS N
in POS N
either POS N
arm POS N
having POS N
Grade-4 POS N
diarrhea. POS N

The POS N
patient POS N
accrual POS N
of POS N
our POS N
trial POS N
is POS N
satisfactory, POS N

Erythema, POS N
nausea POS N
and POS N
leukopenia POS N
were POS N
the POS N
next POS N
common POS N
toxicities, POS N
with POS N
less POS N
than POS N
3% POS N
of POS N
patients POS N
in POS N
either POS N
arm POS N
suffering POS N
Grade POS N
3 POS N
or POS N
greater POS N
leukopenia POS N
or POS N
nausea. POS N

The POS N
patient POS N
accrual POS N
of POS N
our POS N
trial POS N
is POS N
satisfactory, POS N

Postoperative POS N
complication POS N
rates POS N
were POS N
similar POS N
in POS N
both POS N
arms, POS N
with POS N
12% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
13% POS N
(preoperative POS N
radiochemotherapy) POS N
of POS N
patients, POS N
respectively, POS N
suffering POS N
from POS N
anastomotic POS N
leakage, POS N
4% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
3% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
postoperative POS N
bleeding, POS N
and POS N
6% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
5% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
delayed POS N
wound POS N
healing. POS N

The POS N
patient POS N
accrual POS N
of POS N
our POS N
trial POS N
is POS N
satisfactory, POS N

neoadjuvant POS N
radiochemotherapy POS N
is POS N
well POS N
tolerated POS N
and POS N
bears POS N
no POS N
higher POS N
risk POS N
for POS N
postoperative POS N
morbidity. POS N

neoadjuvant POS N
radiochemotherapy POS N
is POS N
well POS N
tolerated POS N
and POS N
bears POS N
no POS N
higher POS N
risk POS N
for POS N
postoperative POS N
morbidity. POS N

In POS N
recent POS N
years, POS N
encouraging POS N
results POS N
of POS N
preoperative POS N
radiotherapy POS N
have POS N
been POS N
reported. POS N

neoadjuvant POS N
radiochemotherapy POS N
is POS N
well POS N
tolerated POS N
and POS N
bears POS N
no POS N
higher POS N
risk POS N
for POS N
postoperative POS N
morbidity. POS N

Postoperative POS N
radiochemotherapy POS N
is POS N
recommended POS N
for POS N
patients POS N
with POS N
advanced POS N
disease POS N
(pT3/4 POS N
or POS N
pN+). POS N

neoadjuvant POS N
radiochemotherapy POS N
is POS N
well POS N
tolerated POS N
and POS N
bears POS N
no POS N
higher POS N
risk POS N
for POS N
postoperative POS N
morbidity. POS N

Acute POS N
toxicity POS N
(WHO) POS N
of POS N
radiochemotherapy POS N
was POS N
low, POS N
with POS N
less POS N
than POS N
15% POS N
of POS N
patients POS N
experiencing POS N
Grade POS N
3 POS N
or POS N
higher POS N
toxicity POS N

neoadjuvant POS N
radiochemotherapy POS N
is POS N
well POS N
tolerated POS N
and POS N
bears POS N
no POS N
higher POS N
risk POS N
for POS N
postoperative POS N
morbidity. POS N

The POS N
principal POS N
toxicity POS N
was POS N
diarrhea, POS N
with POS N
12% POS N
in POS N
the POS N
postoperative POS N
radiochemotherapy POS N
arm POS N
and POS N
10% POS N
in POS N
the POS N
preoperative POS N
radiochemotherapy POS N
arm POS N
having POS N
Grade-3, POS N
and POS N
1% POS N
in POS N
either POS N
arm POS N
having POS N
Grade-4 POS N
diarrhea. POS N

neoadjuvant POS N
radiochemotherapy POS N
is POS N
well POS N
tolerated POS N
and POS N
bears POS N
no POS N
higher POS N
risk POS N
for POS N
postoperative POS N
morbidity. POS N

Erythema, POS N
nausea POS N
and POS N
leukopenia POS N
were POS N
the POS N
next POS N
common POS N
toxicities, POS N
with POS N
less POS N
than POS N
3% POS N
of POS N
patients POS N
in POS N
either POS N
arm POS N
suffering POS N
Grade POS N
3 POS N
or POS N
greater POS N
leukopenia POS N
or POS N
nausea. POS N

neoadjuvant POS N
radiochemotherapy POS N
is POS N
well POS N
tolerated POS N
and POS N
bears POS N
no POS N
higher POS N
risk POS N
for POS N
postoperative POS N
morbidity. POS N

Postoperative POS N
complication POS N
rates POS N
were POS N
similar POS N
in POS N
both POS N
arms, POS N
with POS N
12% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
13% POS N
(preoperative POS N
radiochemotherapy) POS N
of POS N
patients, POS N
respectively, POS N
suffering POS N
from POS N
anastomotic POS N
leakage, POS N
4% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
3% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
postoperative POS N
bleeding, POS N
and POS N
6% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
5% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
delayed POS N
wound POS N
healing. POS N

neoadjuvant POS N
radiochemotherapy POS N
is POS N
well POS N
tolerated POS N
and POS N
bears POS N
no POS N
higher POS N
risk POS N
for POS N
postoperative POS N
morbidity. POS N

The POS N
patient POS N
accrual POS N
of POS N
our POS N
trial POS N
is POS N
satisfactory, POS N

Cardiovascular POS N
complications POS N
are POS N
one POS N
of POS N
main POS N
cause POS N
of POS N
increased POS N
mortality POS N
and POS N
morbidity POS N
among POS N
Diabetes POS N
Mellitus POS N
(DM) POS N
patients. POS N

Eight POS N
weeks POS N
supplementation POS N
with POS N
EPA POS N
led POS N
to POS N
significant POS N
reductions POS N
in POS N
Met POS N
(p < 0.002) POS N
and POS N
Cys POS N
(p < 0.001) POS N
compared POS N
with POS N
the POS N
placebo POS N
(p < 0.06). POS N

Cardiovascular POS N
complications POS N
are POS N
one POS N
of POS N
main POS N
cause POS N
of POS N
increased POS N
mortality POS N
and POS N
morbidity POS N
among POS N
Diabetes POS N
Mellitus POS N
(DM) POS N
patients. POS N

Altered POS N
metabolism POS N
of POS N
sulphur POS N
amino POS N
acids POS N
in POS N
diabetes POS N
reflected POS N
as POS N
increases POS N
in POS N
concentration POS N
of POS N
methionine POS N
and POS N
cysteine/cystine POS N
in POS N
the POS N
blood POS N
which POS N
known POS N
as POS N
a POS N
markers POS N
of POS N
Cardiovascular POS N
Diseases POS N
(CVD). POS N

Cardiovascular POS N
complications POS N
are POS N
one POS N
of POS N
main POS N
cause POS N
of POS N
increased POS N
mortality POS N
and POS N
morbidity POS N
among POS N
Diabetes POS N
Mellitus POS N
(DM) POS N
patients. POS N

compared POS N
to POS N
placebo POS N
a POS N
significant POS N
reduction POS N
in POS N
AIP POS N
were POS N
seen POS N
after POS N
taking POS N
EPA POS N
(p < 0.04). POS N

Cardiovascular POS N
complications POS N
are POS N
one POS N
of POS N
main POS N
cause POS N
of POS N
increased POS N
mortality POS N
and POS N
morbidity POS N
among POS N
Diabetes POS N
Mellitus POS N
(DM) POS N
patients. POS N

EPA POS N
supplementation POS N
in POS N
patients POS N
with POS N
T2DM POS N
for POS N
eight POS N
weeks POS N
had POS N
beneficial POS N
effects POS N
on POS N
Met, POS N
Cys POS N
and POS N
AIP, POS N
which POS N
may POS N
attribute POS N
to POS N
the POS N
prevention POS N
of POS N
vascular POS N
complications POS N
in POS N
the POS N
T2DM POS N
patients. POS N

Eight POS N
weeks POS N
supplementation POS N
with POS N
EPA POS N
led POS N
to POS N
significant POS N
reductions POS N
in POS N
Met POS N
(p < 0.002) POS N
and POS N
Cys POS N
(p < 0.001) POS N
compared POS N
with POS N
the POS N
placebo POS N
(p < 0.06). POS N

Cardiovascular POS N
complications POS N
are POS N
one POS N
of POS N
main POS N
cause POS N
of POS N
increased POS N
mortality POS N
and POS N
morbidity POS N
among POS N
Diabetes POS N
Mellitus POS N
(DM) POS N
patients. POS N

Eight POS N
weeks POS N
supplementation POS N
with POS N
EPA POS N
led POS N
to POS N
significant POS N
reductions POS N
in POS N
Met POS N
(p < 0.002) POS N
and POS N
Cys POS N
(p < 0.001) POS N
compared POS N
with POS N
the POS N
placebo POS N
(p < 0.06). POS N

Altered POS N
metabolism POS N
of POS N
sulphur POS N
amino POS N
acids POS N
in POS N
diabetes POS N
reflected POS N
as POS N
increases POS N
in POS N
concentration POS N
of POS N
methionine POS N
and POS N
cysteine/cystine POS N
in POS N
the POS N
blood POS N
which POS N
known POS N
as POS N
a POS N
markers POS N
of POS N
Cardiovascular POS N
Diseases POS N
(CVD). POS N

Eight POS N
weeks POS N
supplementation POS N
with POS N
EPA POS N
led POS N
to POS N
significant POS N
reductions POS N
in POS N
Met POS N
(p < 0.002) POS N
and POS N
Cys POS N
(p < 0.001) POS N
compared POS N
with POS N
the POS N
placebo POS N
(p < 0.06). POS N

compared POS N
to POS N
placebo POS N
a POS N
significant POS N
reduction POS N
in POS N
AIP POS N
were POS N
seen POS N
after POS N
taking POS N
EPA POS N
(p < 0.04). POS N

Eight POS N
weeks POS N
supplementation POS N
with POS N
EPA POS N
led POS N
to POS N
significant POS N
reductions POS N
in POS N
Met POS N
(p < 0.002) POS N
and POS N
Cys POS N
(p < 0.001) POS N
compared POS N
with POS N
the POS N
placebo POS N
(p < 0.06). POS N

EPA POS N
supplementation POS N
in POS N
patients POS N
with POS N
T2DM POS N
for POS N
eight POS N
weeks POS N
had POS N
beneficial POS N
effects POS N
on POS N
Met, POS N
Cys POS N
and POS N
AIP, POS N
which POS N
may POS N
attribute POS N
to POS N
the POS N
prevention POS N
of POS N
vascular POS N
complications POS N
in POS N
the POS N
T2DM POS N
patients. POS N

Altered POS N
metabolism POS N
of POS N
sulphur POS N
amino POS N
acids POS N
in POS N
diabetes POS N
reflected POS N
as POS N
increases POS N
in POS N
concentration POS N
of POS N
methionine POS N
and POS N
cysteine/cystine POS N
in POS N
the POS N
blood POS N
which POS N
known POS N
as POS N
a POS N
markers POS N
of POS N
Cardiovascular POS N
Diseases POS N
(CVD). POS N

Cardiovascular POS N
complications POS N
are POS N
one POS N
of POS N
main POS N
cause POS N
of POS N
increased POS N
mortality POS N
and POS N
morbidity POS N
among POS N
Diabetes POS N
Mellitus POS N
(DM) POS N
patients. POS N

Altered POS N
metabolism POS N
of POS N
sulphur POS N
amino POS N
acids POS N
in POS N
diabetes POS N
reflected POS N
as POS N
increases POS N
in POS N
concentration POS N
of POS N
methionine POS N
and POS N
cysteine/cystine POS N
in POS N
the POS N
blood POS N
which POS N
known POS N
as POS N
a POS N
markers POS N
of POS N
Cardiovascular POS N
Diseases POS N
(CVD). POS N

Eight POS N
weeks POS N
supplementation POS N
with POS N
EPA POS N
led POS N
to POS N
significant POS N
reductions POS N
in POS N
Met POS N
(p < 0.002) POS N
and POS N
Cys POS N
(p < 0.001) POS N
compared POS N
with POS N
the POS N
placebo POS N
(p < 0.06). POS N

Altered POS N
metabolism POS N
of POS N
sulphur POS N
amino POS N
acids POS N
in POS N
diabetes POS N
reflected POS N
as POS N
increases POS N
in POS N
concentration POS N
of POS N
methionine POS N
and POS N
cysteine/cystine POS N
in POS N
the POS N
blood POS N
which POS N
known POS N
as POS N
a POS N
markers POS N
of POS N
Cardiovascular POS N
Diseases POS N
(CVD). POS N

compared POS N
to POS N
placebo POS N
a POS N
significant POS N
reduction POS N
in POS N
AIP POS N
were POS N
seen POS N
after POS N
taking POS N
EPA POS N
(p < 0.04). POS N

Altered POS N
metabolism POS N
of POS N
sulphur POS N
amino POS N
acids POS N
in POS N
diabetes POS N
reflected POS N
as POS N
increases POS N
in POS N
concentration POS N
of POS N
methionine POS N
and POS N
cysteine/cystine POS N
in POS N
the POS N
blood POS N
which POS N
known POS N
as POS N
a POS N
markers POS N
of POS N
Cardiovascular POS N
Diseases POS N
(CVD). POS N

EPA POS N
supplementation POS N
in POS N
patients POS N
with POS N
T2DM POS N
for POS N
eight POS N
weeks POS N
had POS N
beneficial POS N
effects POS N
on POS N
Met, POS N
Cys POS N
and POS N
AIP, POS N
which POS N
may POS N
attribute POS N
to POS N
the POS N
prevention POS N
of POS N
vascular POS N
complications POS N
in POS N
the POS N
T2DM POS N
patients. POS N

compared POS N
to POS N
placebo POS N
a POS N
significant POS N
reduction POS N
in POS N
AIP POS N
were POS N
seen POS N
after POS N
taking POS N
EPA POS N
(p < 0.04). POS N

Cardiovascular POS N
complications POS N
are POS N
one POS N
of POS N
main POS N
cause POS N
of POS N
increased POS N
mortality POS N
and POS N
morbidity POS N
among POS N
Diabetes POS N
Mellitus POS N
(DM) POS N
patients. POS N

compared POS N
to POS N
placebo POS N
a POS N
significant POS N
reduction POS N
in POS N
AIP POS N
were POS N
seen POS N
after POS N
taking POS N
EPA POS N
(p < 0.04). POS N

Eight POS N
weeks POS N
supplementation POS N
with POS N
EPA POS N
led POS N
to POS N
significant POS N
reductions POS N
in POS N
Met POS N
(p < 0.002) POS N
and POS N
Cys POS N
(p < 0.001) POS N
compared POS N
with POS N
the POS N
placebo POS N
(p < 0.06). POS N

compared POS N
to POS N
placebo POS N
a POS N
significant POS N
reduction POS N
in POS N
AIP POS N
were POS N
seen POS N
after POS N
taking POS N
EPA POS N
(p < 0.04). POS N

Altered POS N
metabolism POS N
of POS N
sulphur POS N
amino POS N
acids POS N
in POS N
diabetes POS N
reflected POS N
as POS N
increases POS N
in POS N
concentration POS N
of POS N
methionine POS N
and POS N
cysteine/cystine POS N
in POS N
the POS N
blood POS N
which POS N
known POS N
as POS N
a POS N
markers POS N
of POS N
Cardiovascular POS N
Diseases POS N
(CVD). POS N

compared POS N
to POS N
placebo POS N
a POS N
significant POS N
reduction POS N
in POS N
AIP POS N
were POS N
seen POS N
after POS N
taking POS N
EPA POS N
(p < 0.04). POS N

EPA POS N
supplementation POS N
in POS N
patients POS N
with POS N
T2DM POS N
for POS N
eight POS N
weeks POS N
had POS N
beneficial POS N
effects POS N
on POS N
Met, POS N
Cys POS N
and POS N
AIP, POS N
which POS N
may POS N
attribute POS N
to POS N
the POS N
prevention POS N
of POS N
vascular POS N
complications POS N
in POS N
the POS N
T2DM POS N
patients. POS N

EPA POS N
supplementation POS N
in POS N
patients POS N
with POS N
T2DM POS N
for POS N
eight POS N
weeks POS N
had POS N
beneficial POS N
effects POS N
on POS N
Met, POS N
Cys POS N
and POS N
AIP, POS N
which POS N
may POS N
attribute POS N
to POS N
the POS N
prevention POS N
of POS N
vascular POS N
complications POS N
in POS N
the POS N
T2DM POS N
patients. POS N

Cardiovascular POS N
complications POS N
are POS N
one POS N
of POS N
main POS N
cause POS N
of POS N
increased POS N
mortality POS N
and POS N
morbidity POS N
among POS N
Diabetes POS N
Mellitus POS N
(DM) POS N
patients. POS N

EPA POS N
supplementation POS N
in POS N
patients POS N
with POS N
T2DM POS N
for POS N
eight POS N
weeks POS N
had POS N
beneficial POS N
effects POS N
on POS N
Met, POS N
Cys POS N
and POS N
AIP, POS N
which POS N
may POS N
attribute POS N
to POS N
the POS N
prevention POS N
of POS N
vascular POS N
complications POS N
in POS N
the POS N
T2DM POS N
patients. POS N

Eight POS N
weeks POS N
supplementation POS N
with POS N
EPA POS N
led POS N
to POS N
significant POS N
reductions POS N
in POS N
Met POS N
(p < 0.002) POS N
and POS N
Cys POS N
(p < 0.001) POS N
compared POS N
with POS N
the POS N
placebo POS N
(p < 0.06). POS N

EPA POS N
supplementation POS N
in POS N
patients POS N
with POS N
T2DM POS N
for POS N
eight POS N
weeks POS N
had POS N
beneficial POS N
effects POS N
on POS N
Met, POS N
Cys POS N
and POS N
AIP, POS N
which POS N
may POS N
attribute POS N
to POS N
the POS N
prevention POS N
of POS N
vascular POS N
complications POS N
in POS N
the POS N
T2DM POS N
patients. POS N

Altered POS N
metabolism POS N
of POS N
sulphur POS N
amino POS N
acids POS N
in POS N
diabetes POS N
reflected POS N
as POS N
increases POS N
in POS N
concentration POS N
of POS N
methionine POS N
and POS N
cysteine/cystine POS N
in POS N
the POS N
blood POS N
which POS N
known POS N
as POS N
a POS N
markers POS N
of POS N
Cardiovascular POS N
Diseases POS N
(CVD). POS N

EPA POS N
supplementation POS N
in POS N
patients POS N
with POS N
T2DM POS N
for POS N
eight POS N
weeks POS N
had POS N
beneficial POS N
effects POS N
on POS N
Met, POS N
Cys POS N
and POS N
AIP, POS N
which POS N
may POS N
attribute POS N
to POS N
the POS N
prevention POS N
of POS N
vascular POS N
complications POS N
in POS N
the POS N
T2DM POS N
patients. POS N

compared POS N
to POS N
placebo POS N
a POS N
significant POS N
reduction POS N
in POS N
AIP POS N
were POS N
seen POS N
after POS N
taking POS N
EPA POS N
(p < 0.04). POS N

Observational POS N
data POS N
support POS N
a POS N
role POS N
for POS N
vitamin POS N
D POS N
in POS N
type POS N
2 POS N
diabetes, POS N

but POS N
evidence POS N
from POS N
trials POS N
is POS N
inconclusive. POS N

Observational POS N
data POS N
support POS N
a POS N
role POS N
for POS N
vitamin POS N
D POS N
in POS N
type POS N
2 POS N
diabetes, POS N

At POS N
week POS N
24, POS N
mean POS N
25(OH)D POS N
changed POS N
by POS N
20.5 POS N
and POS N
-1.6 POS N
ng/mL POS N
in POS N
the POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups, POS N
respectively POS N
(P POS N
< POS N
0.001). POS N

Observational POS N
data POS N
support POS N
a POS N
role POS N
for POS N
vitamin POS N
D POS N
in POS N
type POS N
2 POS N
diabetes, POS N

The POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups POS N
did POS N
not POS N
differ POS N
in POS N
change POS N
in POS N
ISR POS N
or POS N
HbA1c. POS N

Observational POS N
data POS N
support POS N
a POS N
role POS N
for POS N
vitamin POS N
D POS N
in POS N
type POS N
2 POS N
diabetes, POS N

Among POS N
patients POS N
treated POS N
with POS N
lifestyle POS N
only POS N
(n POS N
= POS N
28), POS N
vitamin POS N
D POS N
supplementation POS N
reduced POS N
HbA1c POS N
compared POS N
with POS N
placebo POS N
(-0.1% POS N
vs POS N
0.3%, POS N
respectively; POS N
P POS N
= POS N
0.034) POS N
at POS N
week POS N
24. POS N

Observational POS N
data POS N
support POS N
a POS N
role POS N
for POS N
vitamin POS N
D POS N
in POS N
type POS N
2 POS N
diabetes, POS N

Vitamin POS N
D3 POS N
at POS N
4000 POS N
IU/d POS N
did POS N
not POS N
change POS N
ISR POS N
or POS N
HbA1c POS N
in POS N
patients POS N
with POS N
well-controlled POS N
type POS N
2 POS N
diabetes POS N
on POS N
metformin POS N
not POS N
selected POS N
for POS N
vitamin POS N
D POS N
deficiency. POS N

but POS N
evidence POS N
from POS N
trials POS N
is POS N
inconclusive. POS N

Observational POS N
data POS N
support POS N
a POS N
role POS N
for POS N
vitamin POS N
D POS N
in POS N
type POS N
2 POS N
diabetes, POS N

but POS N
evidence POS N
from POS N
trials POS N
is POS N
inconclusive. POS N

At POS N
week POS N
24, POS N
mean POS N
25(OH)D POS N
changed POS N
by POS N
20.5 POS N
and POS N
-1.6 POS N
ng/mL POS N
in POS N
the POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups, POS N
respectively POS N
(P POS N
< POS N
0.001). POS N

but POS N
evidence POS N
from POS N
trials POS N
is POS N
inconclusive. POS N

The POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups POS N
did POS N
not POS N
differ POS N
in POS N
change POS N
in POS N
ISR POS N
or POS N
HbA1c. POS N

but POS N
evidence POS N
from POS N
trials POS N
is POS N
inconclusive. POS N

Among POS N
patients POS N
treated POS N
with POS N
lifestyle POS N
only POS N
(n POS N
= POS N
28), POS N
vitamin POS N
D POS N
supplementation POS N
reduced POS N
HbA1c POS N
compared POS N
with POS N
placebo POS N
(-0.1% POS N
vs POS N
0.3%, POS N
respectively; POS N
P POS N
= POS N
0.034) POS N
at POS N
week POS N
24. POS N

but POS N
evidence POS N
from POS N
trials POS N
is POS N
inconclusive. POS N

Vitamin POS N
D3 POS N
at POS N
4000 POS N
IU/d POS N
did POS N
not POS N
change POS N
ISR POS N
or POS N
HbA1c POS N
in POS N
patients POS N
with POS N
well-controlled POS N
type POS N
2 POS N
diabetes POS N
on POS N
metformin POS N
not POS N
selected POS N
for POS N
vitamin POS N
D POS N
deficiency. POS N

At POS N
week POS N
24, POS N
mean POS N
25(OH)D POS N
changed POS N
by POS N
20.5 POS N
and POS N
-1.6 POS N
ng/mL POS N
in POS N
the POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups, POS N
respectively POS N
(P POS N
< POS N
0.001). POS N

Observational POS N
data POS N
support POS N
a POS N
role POS N
for POS N
vitamin POS N
D POS N
in POS N
type POS N
2 POS N
diabetes, POS N

At POS N
week POS N
24, POS N
mean POS N
25(OH)D POS N
changed POS N
by POS N
20.5 POS N
and POS N
-1.6 POS N
ng/mL POS N
in POS N
the POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups, POS N
respectively POS N
(P POS N
< POS N
0.001). POS N

but POS N
evidence POS N
from POS N
trials POS N
is POS N
inconclusive. POS N

At POS N
week POS N
24, POS N
mean POS N
25(OH)D POS N
changed POS N
by POS N
20.5 POS N
and POS N
-1.6 POS N
ng/mL POS N
in POS N
the POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups, POS N
respectively POS N
(P POS N
< POS N
0.001). POS N

The POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups POS N
did POS N
not POS N
differ POS N
in POS N
change POS N
in POS N
ISR POS N
or POS N
HbA1c. POS N

At POS N
week POS N
24, POS N
mean POS N
25(OH)D POS N
changed POS N
by POS N
20.5 POS N
and POS N
-1.6 POS N
ng/mL POS N
in POS N
the POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups, POS N
respectively POS N
(P POS N
< POS N
0.001). POS N

Among POS N
patients POS N
treated POS N
with POS N
lifestyle POS N
only POS N
(n POS N
= POS N
28), POS N
vitamin POS N
D POS N
supplementation POS N
reduced POS N
HbA1c POS N
compared POS N
with POS N
placebo POS N
(-0.1% POS N
vs POS N
0.3%, POS N
respectively; POS N
P POS N
= POS N
0.034) POS N
at POS N
week POS N
24. POS N

At POS N
week POS N
24, POS N
mean POS N
25(OH)D POS N
changed POS N
by POS N
20.5 POS N
and POS N
-1.6 POS N
ng/mL POS N
in POS N
the POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups, POS N
respectively POS N
(P POS N
< POS N
0.001). POS N

Vitamin POS N
D3 POS N
at POS N
4000 POS N
IU/d POS N
did POS N
not POS N
change POS N
ISR POS N
or POS N
HbA1c POS N
in POS N
patients POS N
with POS N
well-controlled POS N
type POS N
2 POS N
diabetes POS N
on POS N
metformin POS N
not POS N
selected POS N
for POS N
vitamin POS N
D POS N
deficiency. POS N

The POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups POS N
did POS N
not POS N
differ POS N
in POS N
change POS N
in POS N
ISR POS N
or POS N
HbA1c. POS N

Observational POS N
data POS N
support POS N
a POS N
role POS N
for POS N
vitamin POS N
D POS N
in POS N
type POS N
2 POS N
diabetes, POS N

The POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups POS N
did POS N
not POS N
differ POS N
in POS N
change POS N
in POS N
ISR POS N
or POS N
HbA1c. POS N

but POS N
evidence POS N
from POS N
trials POS N
is POS N
inconclusive. POS N

The POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups POS N
did POS N
not POS N
differ POS N
in POS N
change POS N
in POS N
ISR POS N
or POS N
HbA1c. POS N

At POS N
week POS N
24, POS N
mean POS N
25(OH)D POS N
changed POS N
by POS N
20.5 POS N
and POS N
-1.6 POS N
ng/mL POS N
in POS N
the POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups, POS N
respectively POS N
(P POS N
< POS N
0.001). POS N

The POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups POS N
did POS N
not POS N
differ POS N
in POS N
change POS N
in POS N
ISR POS N
or POS N
HbA1c. POS N

Among POS N
patients POS N
treated POS N
with POS N
lifestyle POS N
only POS N
(n POS N
= POS N
28), POS N
vitamin POS N
D POS N
supplementation POS N
reduced POS N
HbA1c POS N
compared POS N
with POS N
placebo POS N
(-0.1% POS N
vs POS N
0.3%, POS N
respectively; POS N
P POS N
= POS N
0.034) POS N
at POS N
week POS N
24. POS N

The POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups POS N
did POS N
not POS N
differ POS N
in POS N
change POS N
in POS N
ISR POS N
or POS N
HbA1c. POS N

Vitamin POS N
D3 POS N
at POS N
4000 POS N
IU/d POS N
did POS N
not POS N
change POS N
ISR POS N
or POS N
HbA1c POS N
in POS N
patients POS N
with POS N
well-controlled POS N
type POS N
2 POS N
diabetes POS N
on POS N
metformin POS N
not POS N
selected POS N
for POS N
vitamin POS N
D POS N
deficiency. POS N

Among POS N
patients POS N
treated POS N
with POS N
lifestyle POS N
only POS N
(n POS N
= POS N
28), POS N
vitamin POS N
D POS N
supplementation POS N
reduced POS N
HbA1c POS N
compared POS N
with POS N
placebo POS N
(-0.1% POS N
vs POS N
0.3%, POS N
respectively; POS N
P POS N
= POS N
0.034) POS N
at POS N
week POS N
24. POS N

Observational POS N
data POS N
support POS N
a POS N
role POS N
for POS N
vitamin POS N
D POS N
in POS N
type POS N
2 POS N
diabetes, POS N

Among POS N
patients POS N
treated POS N
with POS N
lifestyle POS N
only POS N
(n POS N
= POS N
28), POS N
vitamin POS N
D POS N
supplementation POS N
reduced POS N
HbA1c POS N
compared POS N
with POS N
placebo POS N
(-0.1% POS N
vs POS N
0.3%, POS N
respectively; POS N
P POS N
= POS N
0.034) POS N
at POS N
week POS N
24. POS N

but POS N
evidence POS N
from POS N
trials POS N
is POS N
inconclusive. POS N

Among POS N
patients POS N
treated POS N
with POS N
lifestyle POS N
only POS N
(n POS N
= POS N
28), POS N
vitamin POS N
D POS N
supplementation POS N
reduced POS N
HbA1c POS N
compared POS N
with POS N
placebo POS N
(-0.1% POS N
vs POS N
0.3%, POS N
respectively; POS N
P POS N
= POS N
0.034) POS N
at POS N
week POS N
24. POS N

At POS N
week POS N
24, POS N
mean POS N
25(OH)D POS N
changed POS N
by POS N
20.5 POS N
and POS N
-1.6 POS N
ng/mL POS N
in POS N
the POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups, POS N
respectively POS N
(P POS N
< POS N
0.001). POS N

Among POS N
patients POS N
treated POS N
with POS N
lifestyle POS N
only POS N
(n POS N
= POS N
28), POS N
vitamin POS N
D POS N
supplementation POS N
reduced POS N
HbA1c POS N
compared POS N
with POS N
placebo POS N
(-0.1% POS N
vs POS N
0.3%, POS N
respectively; POS N
P POS N
= POS N
0.034) POS N
at POS N
week POS N
24. POS N

The POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups POS N
did POS N
not POS N
differ POS N
in POS N
change POS N
in POS N
ISR POS N
or POS N
HbA1c. POS N

Among POS N
patients POS N
treated POS N
with POS N
lifestyle POS N
only POS N
(n POS N
= POS N
28), POS N
vitamin POS N
D POS N
supplementation POS N
reduced POS N
HbA1c POS N
compared POS N
with POS N
placebo POS N
(-0.1% POS N
vs POS N
0.3%, POS N
respectively; POS N
P POS N
= POS N
0.034) POS N
at POS N
week POS N
24. POS N

Vitamin POS N
D3 POS N
at POS N
4000 POS N
IU/d POS N
did POS N
not POS N
change POS N
ISR POS N
or POS N
HbA1c POS N
in POS N
patients POS N
with POS N
well-controlled POS N
type POS N
2 POS N
diabetes POS N
on POS N
metformin POS N
not POS N
selected POS N
for POS N
vitamin POS N
D POS N
deficiency. POS N

Vitamin POS N
D3 POS N
at POS N
4000 POS N
IU/d POS N
did POS N
not POS N
change POS N
ISR POS N
or POS N
HbA1c POS N
in POS N
patients POS N
with POS N
well-controlled POS N
type POS N
2 POS N
diabetes POS N
on POS N
metformin POS N
not POS N
selected POS N
for POS N
vitamin POS N
D POS N
deficiency. POS N

Observational POS N
data POS N
support POS N
a POS N
role POS N
for POS N
vitamin POS N
D POS N
in POS N
type POS N
2 POS N
diabetes, POS N

Vitamin POS N
D3 POS N
at POS N
4000 POS N
IU/d POS N
did POS N
not POS N
change POS N
ISR POS N
or POS N
HbA1c POS N
in POS N
patients POS N
with POS N
well-controlled POS N
type POS N
2 POS N
diabetes POS N
on POS N
metformin POS N
not POS N
selected POS N
for POS N
vitamin POS N
D POS N
deficiency. POS N

but POS N
evidence POS N
from POS N
trials POS N
is POS N
inconclusive. POS N

Vitamin POS N
D3 POS N
at POS N
4000 POS N
IU/d POS N
did POS N
not POS N
change POS N
ISR POS N
or POS N
HbA1c POS N
in POS N
patients POS N
with POS N
well-controlled POS N
type POS N
2 POS N
diabetes POS N
on POS N
metformin POS N
not POS N
selected POS N
for POS N
vitamin POS N
D POS N
deficiency. POS N

At POS N
week POS N
24, POS N
mean POS N
25(OH)D POS N
changed POS N
by POS N
20.5 POS N
and POS N
-1.6 POS N
ng/mL POS N
in POS N
the POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups, POS N
respectively POS N
(P POS N
< POS N
0.001). POS N

Vitamin POS N
D3 POS N
at POS N
4000 POS N
IU/d POS N
did POS N
not POS N
change POS N
ISR POS N
or POS N
HbA1c POS N
in POS N
patients POS N
with POS N
well-controlled POS N
type POS N
2 POS N
diabetes POS N
on POS N
metformin POS N
not POS N
selected POS N
for POS N
vitamin POS N
D POS N
deficiency. POS N

The POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups POS N
did POS N
not POS N
differ POS N
in POS N
change POS N
in POS N
ISR POS N
or POS N
HbA1c. POS N

Vitamin POS N
D3 POS N
at POS N
4000 POS N
IU/d POS N
did POS N
not POS N
change POS N
ISR POS N
or POS N
HbA1c POS N
in POS N
patients POS N
with POS N
well-controlled POS N
type POS N
2 POS N
diabetes POS N
on POS N
metformin POS N
not POS N
selected POS N
for POS N
vitamin POS N
D POS N
deficiency. POS N

Among POS N
patients POS N
treated POS N
with POS N
lifestyle POS N
only POS N
(n POS N
= POS N
28), POS N
vitamin POS N
D POS N
supplementation POS N
reduced POS N
HbA1c POS N
compared POS N
with POS N
placebo POS N
(-0.1% POS N
vs POS N
0.3%, POS N
respectively; POS N
P POS N
= POS N
0.034) POS N
at POS N
week POS N
24. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
2-year POS N
follow-up POS N
period, POS N
the POS N
complete POS N
success POS N
and POS N
the POS N
failure POS N
rates POS N
were POS N
67% POS N
and POS N
15%, POS N
respectively, POS N
in POS N
the POS N
microcatheter-assisted POS N
group POS N
versus POS N
47% POS N
and POS N
50% POS N
in POS N
the POS N
rigid POS N
probe POS N
trabeculotomy POS N
group POS N
(p POS N
= POS N
0.006). POS N

There POS N
was POS N
a POS N
tendency POS N
towards POS N
lower POS N
IOP POS N
in POS N
the POS N
microcatheter POS N
group POS N
at POS N
1, POS N
3, POS N
6, POS N
12 POS N
and POS N
24 POS N
months POS N
postoperatively, POS N
with POS N
the POS N
difference POS N
in POS N
IOP POS N
reaching POS N
statistical POS N
significance POS N
at POS N
6 POS N
months POS N
(p POS N
= POS N
0.004). POS N

At POS N
the POS N
end POS N
of POS N
the POS N
2-year POS N
follow-up POS N
period, POS N
the POS N
complete POS N
success POS N
and POS N
the POS N
failure POS N
rates POS N
were POS N
67% POS N
and POS N
15%, POS N
respectively, POS N
in POS N
the POS N
microcatheter-assisted POS N
group POS N
versus POS N
47% POS N
and POS N
50% POS N
in POS N
the POS N
rigid POS N
probe POS N
trabeculotomy POS N
group POS N
(p POS N
= POS N
0.006). POS N

The POS N
mean POS N
survival POS N
time POS N
was POS N
significantly POS N
longer POS N
for POS N
the POS N
microcatheter POS N
group POS N
(p POS N
= POS N
0.01). POS N

At POS N
the POS N
end POS N
of POS N
the POS N
2-year POS N
follow-up POS N
period, POS N
the POS N
complete POS N
success POS N
and POS N
the POS N
failure POS N
rates POS N
were POS N
67% POS N
and POS N
15%, POS N
respectively, POS N
in POS N
the POS N
microcatheter-assisted POS N
group POS N
versus POS N
47% POS N
and POS N
50% POS N
in POS N
the POS N
rigid POS N
probe POS N
trabeculotomy POS N
group POS N
(p POS N
= POS N
0.006). POS N

At POS N
2 POS N
years POS N
postoperatively, POS N
microcatheter-assisted POS N
trabeculotomy POS N
still POS N
yielded POS N
superior POS N
results POS N
in POS N
terms POS N
of POS N
IOP POS N
control POS N
and POS N
success POS N
rates POS N
in POS N
children POS N
with POS N
primary POS N
congenital POS N
glaucoma. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
2-year POS N
follow-up POS N
period, POS N
the POS N
complete POS N
success POS N
and POS N
the POS N
failure POS N
rates POS N
were POS N
67% POS N
and POS N
15%, POS N
respectively, POS N
in POS N
the POS N
microcatheter-assisted POS N
group POS N
versus POS N
47% POS N
and POS N
50% POS N
in POS N
the POS N
rigid POS N
probe POS N
trabeculotomy POS N
group POS N
(p POS N
= POS N
0.006). POS N

The POS N
need POS N
for POS N
reoperation POS N
for POS N
glaucoma POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
microcatheter POS N
group. POS N

There POS N
was POS N
a POS N
tendency POS N
towards POS N
lower POS N
IOP POS N
in POS N
the POS N
microcatheter POS N
group POS N
at POS N
1, POS N
3, POS N
6, POS N
12 POS N
and POS N
24 POS N
months POS N
postoperatively, POS N
with POS N
the POS N
difference POS N
in POS N
IOP POS N
reaching POS N
statistical POS N
significance POS N
at POS N
6 POS N
months POS N
(p POS N
= POS N
0.004). POS N

At POS N
the POS N
end POS N
of POS N
the POS N
2-year POS N
follow-up POS N
period, POS N
the POS N
complete POS N
success POS N
and POS N
the POS N
failure POS N
rates POS N
were POS N
67% POS N
and POS N
15%, POS N
respectively, POS N
in POS N
the POS N
microcatheter-assisted POS N
group POS N
versus POS N
47% POS N
and POS N
50% POS N
in POS N
the POS N
rigid POS N
probe POS N
trabeculotomy POS N
group POS N
(p POS N
= POS N
0.006). POS N

There POS N
was POS N
a POS N
tendency POS N
towards POS N
lower POS N
IOP POS N
in POS N
the POS N
microcatheter POS N
group POS N
at POS N
1, POS N
3, POS N
6, POS N
12 POS N
and POS N
24 POS N
months POS N
postoperatively, POS N
with POS N
the POS N
difference POS N
in POS N
IOP POS N
reaching POS N
statistical POS N
significance POS N
at POS N
6 POS N
months POS N
(p POS N
= POS N
0.004). POS N

The POS N
mean POS N
survival POS N
time POS N
was POS N
significantly POS N
longer POS N
for POS N
the POS N
microcatheter POS N
group POS N
(p POS N
= POS N
0.01). POS N

There POS N
was POS N
a POS N
tendency POS N
towards POS N
lower POS N
IOP POS N
in POS N
the POS N
microcatheter POS N
group POS N
at POS N
1, POS N
3, POS N
6, POS N
12 POS N
and POS N
24 POS N
months POS N
postoperatively, POS N
with POS N
the POS N
difference POS N
in POS N
IOP POS N
reaching POS N
statistical POS N
significance POS N
at POS N
6 POS N
months POS N
(p POS N
= POS N
0.004). POS N

At POS N
2 POS N
years POS N
postoperatively, POS N
microcatheter-assisted POS N
trabeculotomy POS N
still POS N
yielded POS N
superior POS N
results POS N
in POS N
terms POS N
of POS N
IOP POS N
control POS N
and POS N
success POS N
rates POS N
in POS N
children POS N
with POS N
primary POS N
congenital POS N
glaucoma. POS N

There POS N
was POS N
a POS N
tendency POS N
towards POS N
lower POS N
IOP POS N
in POS N
the POS N
microcatheter POS N
group POS N
at POS N
1, POS N
3, POS N
6, POS N
12 POS N
and POS N
24 POS N
months POS N
postoperatively, POS N
with POS N
the POS N
difference POS N
in POS N
IOP POS N
reaching POS N
statistical POS N
significance POS N
at POS N
6 POS N
months POS N
(p POS N
= POS N
0.004). POS N

The POS N
need POS N
for POS N
reoperation POS N
for POS N
glaucoma POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
microcatheter POS N
group. POS N

The POS N
mean POS N
survival POS N
time POS N
was POS N
significantly POS N
longer POS N
for POS N
the POS N
microcatheter POS N
group POS N
(p POS N
= POS N
0.01). POS N

At POS N
the POS N
end POS N
of POS N
the POS N
2-year POS N
follow-up POS N
period, POS N
the POS N
complete POS N
success POS N
and POS N
the POS N
failure POS N
rates POS N
were POS N
67% POS N
and POS N
15%, POS N
respectively, POS N
in POS N
the POS N
microcatheter-assisted POS N
group POS N
versus POS N
47% POS N
and POS N
50% POS N
in POS N
the POS N
rigid POS N
probe POS N
trabeculotomy POS N
group POS N
(p POS N
= POS N
0.006). POS N

The POS N
mean POS N
survival POS N
time POS N
was POS N
significantly POS N
longer POS N
for POS N
the POS N
microcatheter POS N
group POS N
(p POS N
= POS N
0.01). POS N

There POS N
was POS N
a POS N
tendency POS N
towards POS N
lower POS N
IOP POS N
in POS N
the POS N
microcatheter POS N
group POS N
at POS N
1, POS N
3, POS N
6, POS N
12 POS N
and POS N
24 POS N
months POS N
postoperatively, POS N
with POS N
the POS N
difference POS N
in POS N
IOP POS N
reaching POS N
statistical POS N
significance POS N
at POS N
6 POS N
months POS N
(p POS N
= POS N
0.004). POS N

The POS N
mean POS N
survival POS N
time POS N
was POS N
significantly POS N
longer POS N
for POS N
the POS N
microcatheter POS N
group POS N
(p POS N
= POS N
0.01). POS N

At POS N
2 POS N
years POS N
postoperatively, POS N
microcatheter-assisted POS N
trabeculotomy POS N
still POS N
yielded POS N
superior POS N
results POS N
in POS N
terms POS N
of POS N
IOP POS N
control POS N
and POS N
success POS N
rates POS N
in POS N
children POS N
with POS N
primary POS N
congenital POS N
glaucoma. POS N

The POS N
mean POS N
survival POS N
time POS N
was POS N
significantly POS N
longer POS N
for POS N
the POS N
microcatheter POS N
group POS N
(p POS N
= POS N
0.01). POS N

The POS N
need POS N
for POS N
reoperation POS N
for POS N
glaucoma POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
microcatheter POS N
group. POS N

At POS N
2 POS N
years POS N
postoperatively, POS N
microcatheter-assisted POS N
trabeculotomy POS N
still POS N
yielded POS N
superior POS N
results POS N
in POS N
terms POS N
of POS N
IOP POS N
control POS N
and POS N
success POS N
rates POS N
in POS N
children POS N
with POS N
primary POS N
congenital POS N
glaucoma. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
2-year POS N
follow-up POS N
period, POS N
the POS N
complete POS N
success POS N
and POS N
the POS N
failure POS N
rates POS N
were POS N
67% POS N
and POS N
15%, POS N
respectively, POS N
in POS N
the POS N
microcatheter-assisted POS N
group POS N
versus POS N
47% POS N
and POS N
50% POS N
in POS N
the POS N
rigid POS N
probe POS N
trabeculotomy POS N
group POS N
(p POS N
= POS N
0.006). POS N

At POS N
2 POS N
years POS N
postoperatively, POS N
microcatheter-assisted POS N
trabeculotomy POS N
still POS N
yielded POS N
superior POS N
results POS N
in POS N
terms POS N
of POS N
IOP POS N
control POS N
and POS N
success POS N
rates POS N
in POS N
children POS N
with POS N
primary POS N
congenital POS N
glaucoma. POS N

There POS N
was POS N
a POS N
tendency POS N
towards POS N
lower POS N
IOP POS N
in POS N
the POS N
microcatheter POS N
group POS N
at POS N
1, POS N
3, POS N
6, POS N
12 POS N
and POS N
24 POS N
months POS N
postoperatively, POS N
with POS N
the POS N
difference POS N
in POS N
IOP POS N
reaching POS N
statistical POS N
significance POS N
at POS N
6 POS N
months POS N
(p POS N
= POS N
0.004). POS N

At POS N
2 POS N
years POS N
postoperatively, POS N
microcatheter-assisted POS N
trabeculotomy POS N
still POS N
yielded POS N
superior POS N
results POS N
in POS N
terms POS N
of POS N
IOP POS N
control POS N
and POS N
success POS N
rates POS N
in POS N
children POS N
with POS N
primary POS N
congenital POS N
glaucoma. POS N

The POS N
mean POS N
survival POS N
time POS N
was POS N
significantly POS N
longer POS N
for POS N
the POS N
microcatheter POS N
group POS N
(p POS N
= POS N
0.01). POS N

At POS N
2 POS N
years POS N
postoperatively, POS N
microcatheter-assisted POS N
trabeculotomy POS N
still POS N
yielded POS N
superior POS N
results POS N
in POS N
terms POS N
of POS N
IOP POS N
control POS N
and POS N
success POS N
rates POS N
in POS N
children POS N
with POS N
primary POS N
congenital POS N
glaucoma. POS N

The POS N
need POS N
for POS N
reoperation POS N
for POS N
glaucoma POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
microcatheter POS N
group. POS N

The POS N
need POS N
for POS N
reoperation POS N
for POS N
glaucoma POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
microcatheter POS N
group. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
2-year POS N
follow-up POS N
period, POS N
the POS N
complete POS N
success POS N
and POS N
the POS N
failure POS N
rates POS N
were POS N
67% POS N
and POS N
15%, POS N
respectively, POS N
in POS N
the POS N
microcatheter-assisted POS N
group POS N
versus POS N
47% POS N
and POS N
50% POS N
in POS N
the POS N
rigid POS N
probe POS N
trabeculotomy POS N
group POS N
(p POS N
= POS N
0.006). POS N

The POS N
need POS N
for POS N
reoperation POS N
for POS N
glaucoma POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
microcatheter POS N
group. POS N

There POS N
was POS N
a POS N
tendency POS N
towards POS N
lower POS N
IOP POS N
in POS N
the POS N
microcatheter POS N
group POS N
at POS N
1, POS N
3, POS N
6, POS N
12 POS N
and POS N
24 POS N
months POS N
postoperatively, POS N
with POS N
the POS N
difference POS N
in POS N
IOP POS N
reaching POS N
statistical POS N
significance POS N
at POS N
6 POS N
months POS N
(p POS N
= POS N
0.004). POS N

The POS N
need POS N
for POS N
reoperation POS N
for POS N
glaucoma POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
microcatheter POS N
group. POS N

The POS N
mean POS N
survival POS N
time POS N
was POS N
significantly POS N
longer POS N
for POS N
the POS N
microcatheter POS N
group POS N
(p POS N
= POS N
0.01). POS N

The POS N
need POS N
for POS N
reoperation POS N
for POS N
glaucoma POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
microcatheter POS N
group. POS N

At POS N
2 POS N
years POS N
postoperatively, POS N
microcatheter-assisted POS N
trabeculotomy POS N
still POS N
yielded POS N
superior POS N
results POS N
in POS N
terms POS N
of POS N
IOP POS N
control POS N
and POS N
success POS N
rates POS N
in POS N
children POS N
with POS N
primary POS N
congenital POS N
glaucoma. POS N

It POS N
is POS N
concluded POS N
that POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
possesses POS N
as POS N
effective POS N
a POS N
therapeutic POS N
value POS N
in POS N
treating POS N
hepatitis POS N
B POS N
as POS N
allopathic POS N
medicine. POS N

No POS N
significant POS N
difference POS N
was POS N
identified POS N
after POS N
treatment POS N
and POS N
it POS N
was POS N
found POS N
that POS N
the POS N
efficacy POS N
of POS N
Alpha POS N
(Control POS N
drug) POS N
is POS N
same POS N
as POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(Test POS N
drug). POS N

It POS N
is POS N
concluded POS N
that POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
possesses POS N
as POS N
effective POS N
a POS N
therapeutic POS N
value POS N
in POS N
treating POS N
hepatitis POS N
B POS N
as POS N
allopathic POS N
medicine. POS N

The POS N
data POS N
offered POS N
support POS N
to POS N
the POS N
null POS N
hypothesis POS N
and POS N
therefore POS N
research POS N
hypothesis POS N
was POS N
rejected. POS N

It POS N
is POS N
concluded POS N
that POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
possesses POS N
as POS N
effective POS N
a POS N
therapeutic POS N
value POS N
in POS N
treating POS N
hepatitis POS N
B POS N
as POS N
allopathic POS N
medicine. POS N

According POS N
to POS N
the POS N
statistical POS N
analysis POS N
by POS N
chi POS N
square, POS N
hepatitis POS N
B POS N
was POS N
recorded POS N
as POS N
negative POS N
in POS N
26 POS N
patients POS N
(57.77%) POS N
out POS N
of POS N
45 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Interferon POS N
Alpha POS N
(control POS N
therapy) POS N
and POS N
in POS N
27 POS N
patients POS N
(64.28%) POS N
out POS N
of POS N
42 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(test POS N
drug). POS N

It POS N
is POS N
concluded POS N
that POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
possesses POS N
as POS N
effective POS N
a POS N
therapeutic POS N
value POS N
in POS N
treating POS N
hepatitis POS N
B POS N
as POS N
allopathic POS N
medicine. POS N

Comparison POS N
of POS N
the POS N
data POS N
recorded POS N
of POS N
the POS N
patients POS N
was POS N
determined POS N
as POS N
both POS N
drugs POS N
showed POS N
significant POS N
improvement POS N
and POS N
p POS N
value>0.05. POS N

It POS N
is POS N
concluded POS N
that POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
possesses POS N
as POS N
effective POS N
a POS N
therapeutic POS N
value POS N
in POS N
treating POS N
hepatitis POS N
B POS N
as POS N
allopathic POS N
medicine. POS N

The POS N
efficacy POS N
response POS N
is POS N
equal POS N
in POS N
both POS N
drugs POS N
while POS N
test POS N
drug POS N
showed POS N
more POS N
safety POS N
response. POS N

No POS N
significant POS N
difference POS N
was POS N
identified POS N
after POS N
treatment POS N
and POS N
it POS N
was POS N
found POS N
that POS N
the POS N
efficacy POS N
of POS N
Alpha POS N
(Control POS N
drug) POS N
is POS N
same POS N
as POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(Test POS N
drug). POS N

It POS N
is POS N
concluded POS N
that POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
possesses POS N
as POS N
effective POS N
a POS N
therapeutic POS N
value POS N
in POS N
treating POS N
hepatitis POS N
B POS N
as POS N
allopathic POS N
medicine. POS N

No POS N
significant POS N
difference POS N
was POS N
identified POS N
after POS N
treatment POS N
and POS N
it POS N
was POS N
found POS N
that POS N
the POS N
efficacy POS N
of POS N
Alpha POS N
(Control POS N
drug) POS N
is POS N
same POS N
as POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(Test POS N
drug). POS N

The POS N
data POS N
offered POS N
support POS N
to POS N
the POS N
null POS N
hypothesis POS N
and POS N
therefore POS N
research POS N
hypothesis POS N
was POS N
rejected. POS N

No POS N
significant POS N
difference POS N
was POS N
identified POS N
after POS N
treatment POS N
and POS N
it POS N
was POS N
found POS N
that POS N
the POS N
efficacy POS N
of POS N
Alpha POS N
(Control POS N
drug) POS N
is POS N
same POS N
as POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(Test POS N
drug). POS N

According POS N
to POS N
the POS N
statistical POS N
analysis POS N
by POS N
chi POS N
square, POS N
hepatitis POS N
B POS N
was POS N
recorded POS N
as POS N
negative POS N
in POS N
26 POS N
patients POS N
(57.77%) POS N
out POS N
of POS N
45 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Interferon POS N
Alpha POS N
(control POS N
therapy) POS N
and POS N
in POS N
27 POS N
patients POS N
(64.28%) POS N
out POS N
of POS N
42 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(test POS N
drug). POS N

No POS N
significant POS N
difference POS N
was POS N
identified POS N
after POS N
treatment POS N
and POS N
it POS N
was POS N
found POS N
that POS N
the POS N
efficacy POS N
of POS N
Alpha POS N
(Control POS N
drug) POS N
is POS N
same POS N
as POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(Test POS N
drug). POS N

Comparison POS N
of POS N
the POS N
data POS N
recorded POS N
of POS N
the POS N
patients POS N
was POS N
determined POS N
as POS N
both POS N
drugs POS N
showed POS N
significant POS N
improvement POS N
and POS N
p POS N
value>0.05. POS N

No POS N
significant POS N
difference POS N
was POS N
identified POS N
after POS N
treatment POS N
and POS N
it POS N
was POS N
found POS N
that POS N
the POS N
efficacy POS N
of POS N
Alpha POS N
(Control POS N
drug) POS N
is POS N
same POS N
as POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(Test POS N
drug). POS N

The POS N
efficacy POS N
response POS N
is POS N
equal POS N
in POS N
both POS N
drugs POS N
while POS N
test POS N
drug POS N
showed POS N
more POS N
safety POS N
response. POS N

The POS N
data POS N
offered POS N
support POS N
to POS N
the POS N
null POS N
hypothesis POS N
and POS N
therefore POS N
research POS N
hypothesis POS N
was POS N
rejected. POS N

It POS N
is POS N
concluded POS N
that POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
possesses POS N
as POS N
effective POS N
a POS N
therapeutic POS N
value POS N
in POS N
treating POS N
hepatitis POS N
B POS N
as POS N
allopathic POS N
medicine. POS N

The POS N
data POS N
offered POS N
support POS N
to POS N
the POS N
null POS N
hypothesis POS N
and POS N
therefore POS N
research POS N
hypothesis POS N
was POS N
rejected. POS N

No POS N
significant POS N
difference POS N
was POS N
identified POS N
after POS N
treatment POS N
and POS N
it POS N
was POS N
found POS N
that POS N
the POS N
efficacy POS N
of POS N
Alpha POS N
(Control POS N
drug) POS N
is POS N
same POS N
as POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(Test POS N
drug). POS N

The POS N
data POS N
offered POS N
support POS N
to POS N
the POS N
null POS N
hypothesis POS N
and POS N
therefore POS N
research POS N
hypothesis POS N
was POS N
rejected. POS N

According POS N
to POS N
the POS N
statistical POS N
analysis POS N
by POS N
chi POS N
square, POS N
hepatitis POS N
B POS N
was POS N
recorded POS N
as POS N
negative POS N
in POS N
26 POS N
patients POS N
(57.77%) POS N
out POS N
of POS N
45 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Interferon POS N
Alpha POS N
(control POS N
therapy) POS N
and POS N
in POS N
27 POS N
patients POS N
(64.28%) POS N
out POS N
of POS N
42 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(test POS N
drug). POS N

The POS N
data POS N
offered POS N
support POS N
to POS N
the POS N
null POS N
hypothesis POS N
and POS N
therefore POS N
research POS N
hypothesis POS N
was POS N
rejected. POS N

Comparison POS N
of POS N
the POS N
data POS N
recorded POS N
of POS N
the POS N
patients POS N
was POS N
determined POS N
as POS N
both POS N
drugs POS N
showed POS N
significant POS N
improvement POS N
and POS N
p POS N
value>0.05. POS N

The POS N
data POS N
offered POS N
support POS N
to POS N
the POS N
null POS N
hypothesis POS N
and POS N
therefore POS N
research POS N
hypothesis POS N
was POS N
rejected. POS N

The POS N
efficacy POS N
response POS N
is POS N
equal POS N
in POS N
both POS N
drugs POS N
while POS N
test POS N
drug POS N
showed POS N
more POS N
safety POS N
response. POS N

According POS N
to POS N
the POS N
statistical POS N
analysis POS N
by POS N
chi POS N
square, POS N
hepatitis POS N
B POS N
was POS N
recorded POS N
as POS N
negative POS N
in POS N
26 POS N
patients POS N
(57.77%) POS N
out POS N
of POS N
45 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Interferon POS N
Alpha POS N
(control POS N
therapy) POS N
and POS N
in POS N
27 POS N
patients POS N
(64.28%) POS N
out POS N
of POS N
42 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(test POS N
drug). POS N

It POS N
is POS N
concluded POS N
that POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
possesses POS N
as POS N
effective POS N
a POS N
therapeutic POS N
value POS N
in POS N
treating POS N
hepatitis POS N
B POS N
as POS N
allopathic POS N
medicine. POS N

According POS N
to POS N
the POS N
statistical POS N
analysis POS N
by POS N
chi POS N
square, POS N
hepatitis POS N
B POS N
was POS N
recorded POS N
as POS N
negative POS N
in POS N
26 POS N
patients POS N
(57.77%) POS N
out POS N
of POS N
45 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Interferon POS N
Alpha POS N
(control POS N
therapy) POS N
and POS N
in POS N
27 POS N
patients POS N
(64.28%) POS N
out POS N
of POS N
42 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(test POS N
drug). POS N

No POS N
significant POS N
difference POS N
was POS N
identified POS N
after POS N
treatment POS N
and POS N
it POS N
was POS N
found POS N
that POS N
the POS N
efficacy POS N
of POS N
Alpha POS N
(Control POS N
drug) POS N
is POS N
same POS N
as POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(Test POS N
drug). POS N

According POS N
to POS N
the POS N
statistical POS N
analysis POS N
by POS N
chi POS N
square, POS N
hepatitis POS N
B POS N
was POS N
recorded POS N
as POS N
negative POS N
in POS N
26 POS N
patients POS N
(57.77%) POS N
out POS N
of POS N
45 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Interferon POS N
Alpha POS N
(control POS N
therapy) POS N
and POS N
in POS N
27 POS N
patients POS N
(64.28%) POS N
out POS N
of POS N
42 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(test POS N
drug). POS N

The POS N
data POS N
offered POS N
support POS N
to POS N
the POS N
null POS N
hypothesis POS N
and POS N
therefore POS N
research POS N
hypothesis POS N
was POS N
rejected. POS N

According POS N
to POS N
the POS N
statistical POS N
analysis POS N
by POS N
chi POS N
square, POS N
hepatitis POS N
B POS N
was POS N
recorded POS N
as POS N
negative POS N
in POS N
26 POS N
patients POS N
(57.77%) POS N
out POS N
of POS N
45 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Interferon POS N
Alpha POS N
(control POS N
therapy) POS N
and POS N
in POS N
27 POS N
patients POS N
(64.28%) POS N
out POS N
of POS N
42 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(test POS N
drug). POS N

Comparison POS N
of POS N
the POS N
data POS N
recorded POS N
of POS N
the POS N
patients POS N
was POS N
determined POS N
as POS N
both POS N
drugs POS N
showed POS N
significant POS N
improvement POS N
and POS N
p POS N
value>0.05. POS N

According POS N
to POS N
the POS N
statistical POS N
analysis POS N
by POS N
chi POS N
square, POS N
hepatitis POS N
B POS N
was POS N
recorded POS N
as POS N
negative POS N
in POS N
26 POS N
patients POS N
(57.77%) POS N
out POS N
of POS N
45 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Interferon POS N
Alpha POS N
(control POS N
therapy) POS N
and POS N
in POS N
27 POS N
patients POS N
(64.28%) POS N
out POS N
of POS N
42 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(test POS N
drug). POS N

The POS N
efficacy POS N
response POS N
is POS N
equal POS N
in POS N
both POS N
drugs POS N
while POS N
test POS N
drug POS N
showed POS N
more POS N
safety POS N
response. POS N

Comparison POS N
of POS N
the POS N
data POS N
recorded POS N
of POS N
the POS N
patients POS N
was POS N
determined POS N
as POS N
both POS N
drugs POS N
showed POS N
significant POS N
improvement POS N
and POS N
p POS N
value>0.05. POS N

It POS N
is POS N
concluded POS N
that POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
possesses POS N
as POS N
effective POS N
a POS N
therapeutic POS N
value POS N
in POS N
treating POS N
hepatitis POS N
B POS N
as POS N
allopathic POS N
medicine. POS N

Comparison POS N
of POS N
the POS N
data POS N
recorded POS N
of POS N
the POS N
patients POS N
was POS N
determined POS N
as POS N
both POS N
drugs POS N
showed POS N
significant POS N
improvement POS N
and POS N
p POS N
value>0.05. POS N

No POS N
significant POS N
difference POS N
was POS N
identified POS N
after POS N
treatment POS N
and POS N
it POS N
was POS N
found POS N
that POS N
the POS N
efficacy POS N
of POS N
Alpha POS N
(Control POS N
drug) POS N
is POS N
same POS N
as POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(Test POS N
drug). POS N

Comparison POS N
of POS N
the POS N
data POS N
recorded POS N
of POS N
the POS N
patients POS N
was POS N
determined POS N
as POS N
both POS N
drugs POS N
showed POS N
significant POS N
improvement POS N
and POS N
p POS N
value>0.05. POS N

The POS N
data POS N
offered POS N
support POS N
to POS N
the POS N
null POS N
hypothesis POS N
and POS N
therefore POS N
research POS N
hypothesis POS N
was POS N
rejected. POS N

Comparison POS N
of POS N
the POS N
data POS N
recorded POS N
of POS N
the POS N
patients POS N
was POS N
determined POS N
as POS N
both POS N
drugs POS N
showed POS N
significant POS N
improvement POS N
and POS N
p POS N
value>0.05. POS N

According POS N
to POS N
the POS N
statistical POS N
analysis POS N
by POS N
chi POS N
square, POS N
hepatitis POS N
B POS N
was POS N
recorded POS N
as POS N
negative POS N
in POS N
26 POS N
patients POS N
(57.77%) POS N
out POS N
of POS N
45 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Interferon POS N
Alpha POS N
(control POS N
therapy) POS N
and POS N
in POS N
27 POS N
patients POS N
(64.28%) POS N
out POS N
of POS N
42 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(test POS N
drug). POS N

Comparison POS N
of POS N
the POS N
data POS N
recorded POS N
of POS N
the POS N
patients POS N
was POS N
determined POS N
as POS N
both POS N
drugs POS N
showed POS N
significant POS N
improvement POS N
and POS N
p POS N
value>0.05. POS N

The POS N
efficacy POS N
response POS N
is POS N
equal POS N
in POS N
both POS N
drugs POS N
while POS N
test POS N
drug POS N
showed POS N
more POS N
safety POS N
response. POS N

The POS N
efficacy POS N
response POS N
is POS N
equal POS N
in POS N
both POS N
drugs POS N
while POS N
test POS N
drug POS N
showed POS N
more POS N
safety POS N
response. POS N

It POS N
is POS N
concluded POS N
that POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
possesses POS N
as POS N
effective POS N
a POS N
therapeutic POS N
value POS N
in POS N
treating POS N
hepatitis POS N
B POS N
as POS N
allopathic POS N
medicine. POS N

The POS N
efficacy POS N
response POS N
is POS N
equal POS N
in POS N
both POS N
drugs POS N
while POS N
test POS N
drug POS N
showed POS N
more POS N
safety POS N
response. POS N

No POS N
significant POS N
difference POS N
was POS N
identified POS N
after POS N
treatment POS N
and POS N
it POS N
was POS N
found POS N
that POS N
the POS N
efficacy POS N
of POS N
Alpha POS N
(Control POS N
drug) POS N
is POS N
same POS N
as POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(Test POS N
drug). POS N

The POS N
efficacy POS N
response POS N
is POS N
equal POS N
in POS N
both POS N
drugs POS N
while POS N
test POS N
drug POS N
showed POS N
more POS N
safety POS N
response. POS N

The POS N
data POS N
offered POS N
support POS N
to POS N
the POS N
null POS N
hypothesis POS N
and POS N
therefore POS N
research POS N
hypothesis POS N
was POS N
rejected. POS N

The POS N
efficacy POS N
response POS N
is POS N
equal POS N
in POS N
both POS N
drugs POS N
while POS N
test POS N
drug POS N
showed POS N
more POS N
safety POS N
response. POS N

According POS N
to POS N
the POS N
statistical POS N
analysis POS N
by POS N
chi POS N
square, POS N
hepatitis POS N
B POS N
was POS N
recorded POS N
as POS N
negative POS N
in POS N
26 POS N
patients POS N
(57.77%) POS N
out POS N
of POS N
45 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Interferon POS N
Alpha POS N
(control POS N
therapy) POS N
and POS N
in POS N
27 POS N
patients POS N
(64.28%) POS N
out POS N
of POS N
42 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(test POS N
drug). POS N

The POS N
efficacy POS N
response POS N
is POS N
equal POS N
in POS N
both POS N
drugs POS N
while POS N
test POS N
drug POS N
showed POS N
more POS N
safety POS N
response. POS N

Comparison POS N
of POS N
the POS N
data POS N
recorded POS N
of POS N
the POS N
patients POS N
was POS N
determined POS N
as POS N
both POS N
drugs POS N
showed POS N
significant POS N
improvement POS N
and POS N
p POS N
value>0.05. POS N

The POS N
immunosuppressive POS N
drug POS N
rapamycin POS N
may POS N
influence POS N
insulin POS N
sensitivity POS N
in POS N
insulin-responsive POS N
tissues. POS N

This POS N
treatment POS N
may POS N
improve POS N
short-term POS N
ITx POS N
outcomes, POS N
possibly POS N
in POS N
selected POS N
patients POS N
with POS N
T1DM POS N
complicated POS N
by POS N
insulin POS N
resistance. POS N

The POS N
immunosuppressive POS N
drug POS N
rapamycin POS N
may POS N
influence POS N
insulin POS N
sensitivity POS N
in POS N
insulin-responsive POS N
tissues. POS N

Rapamycin POS N
pre-treatment POS N
before POS N
ITx POS N
succeeds POS N
in POS N
reducing POS N
insulin POS N
requirement, POS N
enhancing POS N
hepatic POS N
insulin POS N
sensitivity. POS N

The POS N
immunosuppressive POS N
drug POS N
rapamycin POS N
may POS N
influence POS N
insulin POS N
sensitivity POS N
in POS N
insulin-responsive POS N
tissues. POS N

Hepatic POS N
glucose POS N
production POS N
decreased POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 1.1 ± 1.1 POS N
mg/kg/min, POS N
p = 0.04) POS N
and POS N
after POS N
ITx POS N
(- 1.6 ± 0.6 POS N
mg/kg/min, POS N
p = 0.015), POS N

The POS N
immunosuppressive POS N
drug POS N
rapamycin POS N
may POS N
influence POS N
insulin POS N
sensitivity POS N
in POS N
insulin-responsive POS N
tissues. POS N

no POS N
changes POS N
in POS N
peripheral POS N
glucose POS N
disposal POS N
were POS N
observed. POS N

The POS N
immunosuppressive POS N
drug POS N
rapamycin POS N
may POS N
influence POS N
insulin POS N
sensitivity POS N
in POS N
insulin-responsive POS N
tissues. POS N

Fasting POS N
glucose POS N
and POS N
HbA1c POS N
significantly POS N
decreased POS N
1 POS N
year POS N
after POS N
ITx POS N
in POS N
Group POS N
1 POS N
(HbA1c: POS N
- 2.1 ± 1.4%, POS N
p = 0.002), POS N

The POS N
immunosuppressive POS N
drug POS N
rapamycin POS N
may POS N
influence POS N
insulin POS N
sensitivity POS N
in POS N
insulin-responsive POS N
tissues. POS N

fasting POS N
C-peptide POS N
(+0.5 ± 0.3 POS N
nmol/l, POS N
p = 0.002) POS N
and POS N
SUITO POS N
index POS N
increased POS N
(+57.4 ± 39.7, POS N
p = 0.016), POS N
without POS N
differences POS N
between POS N
the POS N
two POS N
groups. POS N

The POS N
immunosuppressive POS N
drug POS N
rapamycin POS N
may POS N
influence POS N
insulin POS N
sensitivity POS N
in POS N
insulin-responsive POS N
tissues. POS N

DIR POS N
reduction POS N
1 POS N
year POS N
after POS N
ITx POS N
was POS N
greater POS N
in POS N
Group POS N
1 POS N
as POS N
compared POS N
to POS N
Group POS N
2 POS N
(- 37 ± 15 POS N
vs. POS N
- 19 ± 13 POS N
U/day, POS N
p = 0.005) POS N
and POS N
remained POS N
significant POS N
after POS N
adjusting POS N
for POS N
gender, POS N
age, POS N
glucose POS N
and POS N
baseline POS N
HbA1c POS N
(beta = 18.2 ± 5.9, POS N
p = 0.006). POS N

The POS N
immunosuppressive POS N
drug POS N
rapamycin POS N
may POS N
influence POS N
insulin POS N
sensitivity POS N
in POS N
insulin-responsive POS N
tissues. POS N

We POS N
found POS N
a POS N
significant POS N
reduction POS N
in POS N
DIR POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 8 ± 6 POS N
U/day, POS N
mean ± SD, POS N
p < 0.001) POS N
and POS N
1 POS N
year POS N
after POS N
ITx. POS N

This POS N
treatment POS N
may POS N
improve POS N
short-term POS N
ITx POS N
outcomes, POS N
possibly POS N
in POS N
selected POS N
patients POS N
with POS N
T1DM POS N
complicated POS N
by POS N
insulin POS N
resistance. POS N

The POS N
immunosuppressive POS N
drug POS N
rapamycin POS N
may POS N
influence POS N
insulin POS N
sensitivity POS N
in POS N
insulin-responsive POS N
tissues. POS N

This POS N
treatment POS N
may POS N
improve POS N
short-term POS N
ITx POS N
outcomes, POS N
possibly POS N
in POS N
selected POS N
patients POS N
with POS N
T1DM POS N
complicated POS N
by POS N
insulin POS N
resistance. POS N

Rapamycin POS N
pre-treatment POS N
before POS N
ITx POS N
succeeds POS N
in POS N
reducing POS N
insulin POS N
requirement, POS N
enhancing POS N
hepatic POS N
insulin POS N
sensitivity. POS N

This POS N
treatment POS N
may POS N
improve POS N
short-term POS N
ITx POS N
outcomes, POS N
possibly POS N
in POS N
selected POS N
patients POS N
with POS N
T1DM POS N
complicated POS N
by POS N
insulin POS N
resistance. POS N

Hepatic POS N
glucose POS N
production POS N
decreased POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 1.1 ± 1.1 POS N
mg/kg/min, POS N
p = 0.04) POS N
and POS N
after POS N
ITx POS N
(- 1.6 ± 0.6 POS N
mg/kg/min, POS N
p = 0.015), POS N

This POS N
treatment POS N
may POS N
improve POS N
short-term POS N
ITx POS N
outcomes, POS N
possibly POS N
in POS N
selected POS N
patients POS N
with POS N
T1DM POS N
complicated POS N
by POS N
insulin POS N
resistance. POS N

no POS N
changes POS N
in POS N
peripheral POS N
glucose POS N
disposal POS N
were POS N
observed. POS N

This POS N
treatment POS N
may POS N
improve POS N
short-term POS N
ITx POS N
outcomes, POS N
possibly POS N
in POS N
selected POS N
patients POS N
with POS N
T1DM POS N
complicated POS N
by POS N
insulin POS N
resistance. POS N

Fasting POS N
glucose POS N
and POS N
HbA1c POS N
significantly POS N
decreased POS N
1 POS N
year POS N
after POS N
ITx POS N
in POS N
Group POS N
1 POS N
(HbA1c: POS N
- 2.1 ± 1.4%, POS N
p = 0.002), POS N

This POS N
treatment POS N
may POS N
improve POS N
short-term POS N
ITx POS N
outcomes, POS N
possibly POS N
in POS N
selected POS N
patients POS N
with POS N
T1DM POS N
complicated POS N
by POS N
insulin POS N
resistance. POS N

fasting POS N
C-peptide POS N
(+0.5 ± 0.3 POS N
nmol/l, POS N
p = 0.002) POS N
and POS N
SUITO POS N
index POS N
increased POS N
(+57.4 ± 39.7, POS N
p = 0.016), POS N
without POS N
differences POS N
between POS N
the POS N
two POS N
groups. POS N

This POS N
treatment POS N
may POS N
improve POS N
short-term POS N
ITx POS N
outcomes, POS N
possibly POS N
in POS N
selected POS N
patients POS N
with POS N
T1DM POS N
complicated POS N
by POS N
insulin POS N
resistance. POS N

DIR POS N
reduction POS N
1 POS N
year POS N
after POS N
ITx POS N
was POS N
greater POS N
in POS N
Group POS N
1 POS N
as POS N
compared POS N
to POS N
Group POS N
2 POS N
(- 37 ± 15 POS N
vs. POS N
- 19 ± 13 POS N
U/day, POS N
p = 0.005) POS N
and POS N
remained POS N
significant POS N
after POS N
adjusting POS N
for POS N
gender, POS N
age, POS N
glucose POS N
and POS N
baseline POS N
HbA1c POS N
(beta = 18.2 ± 5.9, POS N
p = 0.006). POS N

This POS N
treatment POS N
may POS N
improve POS N
short-term POS N
ITx POS N
outcomes, POS N
possibly POS N
in POS N
selected POS N
patients POS N
with POS N
T1DM POS N
complicated POS N
by POS N
insulin POS N
resistance. POS N

We POS N
found POS N
a POS N
significant POS N
reduction POS N
in POS N
DIR POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 8 ± 6 POS N
U/day, POS N
mean ± SD, POS N
p < 0.001) POS N
and POS N
1 POS N
year POS N
after POS N
ITx. POS N

Rapamycin POS N
pre-treatment POS N
before POS N
ITx POS N
succeeds POS N
in POS N
reducing POS N
insulin POS N
requirement, POS N
enhancing POS N
hepatic POS N
insulin POS N
sensitivity. POS N

The POS N
immunosuppressive POS N
drug POS N
rapamycin POS N
may POS N
influence POS N
insulin POS N
sensitivity POS N
in POS N
insulin-responsive POS N
tissues. POS N

Rapamycin POS N
pre-treatment POS N
before POS N
ITx POS N
succeeds POS N
in POS N
reducing POS N
insulin POS N
requirement, POS N
enhancing POS N
hepatic POS N
insulin POS N
sensitivity. POS N

This POS N
treatment POS N
may POS N
improve POS N
short-term POS N
ITx POS N
outcomes, POS N
possibly POS N
in POS N
selected POS N
patients POS N
with POS N
T1DM POS N
complicated POS N
by POS N
insulin POS N
resistance. POS N

Rapamycin POS N
pre-treatment POS N
before POS N
ITx POS N
succeeds POS N
in POS N
reducing POS N
insulin POS N
requirement, POS N
enhancing POS N
hepatic POS N
insulin POS N
sensitivity. POS N

Hepatic POS N
glucose POS N
production POS N
decreased POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 1.1 ± 1.1 POS N
mg/kg/min, POS N
p = 0.04) POS N
and POS N
after POS N
ITx POS N
(- 1.6 ± 0.6 POS N
mg/kg/min, POS N
p = 0.015), POS N

Rapamycin POS N
pre-treatment POS N
before POS N
ITx POS N
succeeds POS N
in POS N
reducing POS N
insulin POS N
requirement, POS N
enhancing POS N
hepatic POS N
insulin POS N
sensitivity. POS N

no POS N
changes POS N
in POS N
peripheral POS N
glucose POS N
disposal POS N
were POS N
observed. POS N

Rapamycin POS N
pre-treatment POS N
before POS N
ITx POS N
succeeds POS N
in POS N
reducing POS N
insulin POS N
requirement, POS N
enhancing POS N
hepatic POS N
insulin POS N
sensitivity. POS N

Fasting POS N
glucose POS N
and POS N
HbA1c POS N
significantly POS N
decreased POS N
1 POS N
year POS N
after POS N
ITx POS N
in POS N
Group POS N
1 POS N
(HbA1c: POS N
- 2.1 ± 1.4%, POS N
p = 0.002), POS N

Rapamycin POS N
pre-treatment POS N
before POS N
ITx POS N
succeeds POS N
in POS N
reducing POS N
insulin POS N
requirement, POS N
enhancing POS N
hepatic POS N
insulin POS N
sensitivity. POS N

fasting POS N
C-peptide POS N
(+0.5 ± 0.3 POS N
nmol/l, POS N
p = 0.002) POS N
and POS N
SUITO POS N
index POS N
increased POS N
(+57.4 ± 39.7, POS N
p = 0.016), POS N
without POS N
differences POS N
between POS N
the POS N
two POS N
groups. POS N

Rapamycin POS N
pre-treatment POS N
before POS N
ITx POS N
succeeds POS N
in POS N
reducing POS N
insulin POS N
requirement, POS N
enhancing POS N
hepatic POS N
insulin POS N
sensitivity. POS N

DIR POS N
reduction POS N
1 POS N
year POS N
after POS N
ITx POS N
was POS N
greater POS N
in POS N
Group POS N
1 POS N
as POS N
compared POS N
to POS N
Group POS N
2 POS N
(- 37 ± 15 POS N
vs. POS N
- 19 ± 13 POS N
U/day, POS N
p = 0.005) POS N
and POS N
remained POS N
significant POS N
after POS N
adjusting POS N
for POS N
gender, POS N
age, POS N
glucose POS N
and POS N
baseline POS N
HbA1c POS N
(beta = 18.2 ± 5.9, POS N
p = 0.006). POS N

Rapamycin POS N
pre-treatment POS N
before POS N
ITx POS N
succeeds POS N
in POS N
reducing POS N
insulin POS N
requirement, POS N
enhancing POS N
hepatic POS N
insulin POS N
sensitivity. POS N

We POS N
found POS N
a POS N
significant POS N
reduction POS N
in POS N
DIR POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 8 ± 6 POS N
U/day, POS N
mean ± SD, POS N
p < 0.001) POS N
and POS N
1 POS N
year POS N
after POS N
ITx. POS N

Hepatic POS N
glucose POS N
production POS N
decreased POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 1.1 ± 1.1 POS N
mg/kg/min, POS N
p = 0.04) POS N
and POS N
after POS N
ITx POS N
(- 1.6 ± 0.6 POS N
mg/kg/min, POS N
p = 0.015), POS N

The POS N
immunosuppressive POS N
drug POS N
rapamycin POS N
may POS N
influence POS N
insulin POS N
sensitivity POS N
in POS N
insulin-responsive POS N
tissues. POS N

Hepatic POS N
glucose POS N
production POS N
decreased POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 1.1 ± 1.1 POS N
mg/kg/min, POS N
p = 0.04) POS N
and POS N
after POS N
ITx POS N
(- 1.6 ± 0.6 POS N
mg/kg/min, POS N
p = 0.015), POS N

This POS N
treatment POS N
may POS N
improve POS N
short-term POS N
ITx POS N
outcomes, POS N
possibly POS N
in POS N
selected POS N
patients POS N
with POS N
T1DM POS N
complicated POS N
by POS N
insulin POS N
resistance. POS N

Hepatic POS N
glucose POS N
production POS N
decreased POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 1.1 ± 1.1 POS N
mg/kg/min, POS N
p = 0.04) POS N
and POS N
after POS N
ITx POS N
(- 1.6 ± 0.6 POS N
mg/kg/min, POS N
p = 0.015), POS N

Rapamycin POS N
pre-treatment POS N
before POS N
ITx POS N
succeeds POS N
in POS N
reducing POS N
insulin POS N
requirement, POS N
enhancing POS N
hepatic POS N
insulin POS N
sensitivity. POS N

Hepatic POS N
glucose POS N
production POS N
decreased POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 1.1 ± 1.1 POS N
mg/kg/min, POS N
p = 0.04) POS N
and POS N
after POS N
ITx POS N
(- 1.6 ± 0.6 POS N
mg/kg/min, POS N
p = 0.015), POS N

no POS N
changes POS N
in POS N
peripheral POS N
glucose POS N
disposal POS N
were POS N
observed. POS N

Hepatic POS N
glucose POS N
production POS N
decreased POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 1.1 ± 1.1 POS N
mg/kg/min, POS N
p = 0.04) POS N
and POS N
after POS N
ITx POS N
(- 1.6 ± 0.6 POS N
mg/kg/min, POS N
p = 0.015), POS N

Fasting POS N
glucose POS N
and POS N
HbA1c POS N
significantly POS N
decreased POS N
1 POS N
year POS N
after POS N
ITx POS N
in POS N
Group POS N
1 POS N
(HbA1c: POS N
- 2.1 ± 1.4%, POS N
p = 0.002), POS N

Hepatic POS N
glucose POS N
production POS N
decreased POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 1.1 ± 1.1 POS N
mg/kg/min, POS N
p = 0.04) POS N
and POS N
after POS N
ITx POS N
(- 1.6 ± 0.6 POS N
mg/kg/min, POS N
p = 0.015), POS N

fasting POS N
C-peptide POS N
(+0.5 ± 0.3 POS N
nmol/l, POS N
p = 0.002) POS N
and POS N
SUITO POS N
index POS N
increased POS N
(+57.4 ± 39.7, POS N
p = 0.016), POS N
without POS N
differences POS N
between POS N
the POS N
two POS N
groups. POS N

Hepatic POS N
glucose POS N
production POS N
decreased POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 1.1 ± 1.1 POS N
mg/kg/min, POS N
p = 0.04) POS N
and POS N
after POS N
ITx POS N
(- 1.6 ± 0.6 POS N
mg/kg/min, POS N
p = 0.015), POS N

DIR POS N
reduction POS N
1 POS N
year POS N
after POS N
ITx POS N
was POS N
greater POS N
in POS N
Group POS N
1 POS N
as POS N
compared POS N
to POS N
Group POS N
2 POS N
(- 37 ± 15 POS N
vs. POS N
- 19 ± 13 POS N
U/day, POS N
p = 0.005) POS N
and POS N
remained POS N
significant POS N
after POS N
adjusting POS N
for POS N
gender, POS N
age, POS N
glucose POS N
and POS N
baseline POS N
HbA1c POS N
(beta = 18.2 ± 5.9, POS N
p = 0.006). POS N

Hepatic POS N
glucose POS N
production POS N
decreased POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 1.1 ± 1.1 POS N
mg/kg/min, POS N
p = 0.04) POS N
and POS N
after POS N
ITx POS N
(- 1.6 ± 0.6 POS N
mg/kg/min, POS N
p = 0.015), POS N

We POS N
found POS N
a POS N
significant POS N
reduction POS N
in POS N
DIR POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 8 ± 6 POS N
U/day, POS N
mean ± SD, POS N
p < 0.001) POS N
and POS N
1 POS N
year POS N
after POS N
ITx. POS N

no POS N
changes POS N
in POS N
peripheral POS N
glucose POS N
disposal POS N
were POS N
observed. POS N

The POS N
immunosuppressive POS N
drug POS N
rapamycin POS N
may POS N
influence POS N
insulin POS N
sensitivity POS N
in POS N
insulin-responsive POS N
tissues. POS N

no POS N
changes POS N
in POS N
peripheral POS N
glucose POS N
disposal POS N
were POS N
observed. POS N

This POS N
treatment POS N
may POS N
improve POS N
short-term POS N
ITx POS N
outcomes, POS N
possibly POS N
in POS N
selected POS N
patients POS N
with POS N
T1DM POS N
complicated POS N
by POS N
insulin POS N
resistance. POS N

no POS N
changes POS N
in POS N
peripheral POS N
glucose POS N
disposal POS N
were POS N
observed. POS N

Rapamycin POS N
pre-treatment POS N
before POS N
ITx POS N
succeeds POS N
in POS N
reducing POS N
insulin POS N
requirement, POS N
enhancing POS N
hepatic POS N
insulin POS N
sensitivity. POS N

no POS N
changes POS N
in POS N
peripheral POS N
glucose POS N
disposal POS N
were POS N
observed. POS N

Hepatic POS N
glucose POS N
production POS N
decreased POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 1.1 ± 1.1 POS N
mg/kg/min, POS N
p = 0.04) POS N
and POS N
after POS N
ITx POS N
(- 1.6 ± 0.6 POS N
mg/kg/min, POS N
p = 0.015), POS N

no POS N
changes POS N
in POS N
peripheral POS N
glucose POS N
disposal POS N
were POS N
observed. POS N

Fasting POS N
glucose POS N
and POS N
HbA1c POS N
significantly POS N
decreased POS N
1 POS N
year POS N
after POS N
ITx POS N
in POS N
Group POS N
1 POS N
(HbA1c: POS N
- 2.1 ± 1.4%, POS N
p = 0.002), POS N

no POS N
changes POS N
in POS N
peripheral POS N
glucose POS N
disposal POS N
were POS N
observed. POS N

fasting POS N
C-peptide POS N
(+0.5 ± 0.3 POS N
nmol/l, POS N
p = 0.002) POS N
and POS N
SUITO POS N
index POS N
increased POS N
(+57.4 ± 39.7, POS N
p = 0.016), POS N
without POS N
differences POS N
between POS N
the POS N
two POS N
groups. POS N

no POS N
changes POS N
in POS N
peripheral POS N
glucose POS N
disposal POS N
were POS N
observed. POS N

DIR POS N
reduction POS N
1 POS N
year POS N
after POS N
ITx POS N
was POS N
greater POS N
in POS N
Group POS N
1 POS N
as POS N
compared POS N
to POS N
Group POS N
2 POS N
(- 37 ± 15 POS N
vs. POS N
- 19 ± 13 POS N
U/day, POS N
p = 0.005) POS N
and POS N
remained POS N
significant POS N
after POS N
adjusting POS N
for POS N
gender, POS N
age, POS N
glucose POS N
and POS N
baseline POS N
HbA1c POS N
(beta = 18.2 ± 5.9, POS N
p = 0.006). POS N

no POS N
changes POS N
in POS N
peripheral POS N
glucose POS N
disposal POS N
were POS N
observed. POS N

We POS N
found POS N
a POS N
significant POS N
reduction POS N
in POS N
DIR POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 8 ± 6 POS N
U/day, POS N
mean ± SD, POS N
p < 0.001) POS N
and POS N
1 POS N
year POS N
after POS N
ITx. POS N

Fasting POS N
glucose POS N
and POS N
HbA1c POS N
significantly POS N
decreased POS N
1 POS N
year POS N
after POS N
ITx POS N
in POS N
Group POS N
1 POS N
(HbA1c: POS N
- 2.1 ± 1.4%, POS N
p = 0.002), POS N

The POS N
immunosuppressive POS N
drug POS N
rapamycin POS N
may POS N
influence POS N
insulin POS N
sensitivity POS N
in POS N
insulin-responsive POS N
tissues. POS N

Fasting POS N
glucose POS N
and POS N
HbA1c POS N
significantly POS N
decreased POS N
1 POS N
year POS N
after POS N
ITx POS N
in POS N
Group POS N
1 POS N
(HbA1c: POS N
- 2.1 ± 1.4%, POS N
p = 0.002), POS N

This POS N
treatment POS N
may POS N
improve POS N
short-term POS N
ITx POS N
outcomes, POS N
possibly POS N
in POS N
selected POS N
patients POS N
with POS N
T1DM POS N
complicated POS N
by POS N
insulin POS N
resistance. POS N

Fasting POS N
glucose POS N
and POS N
HbA1c POS N
significantly POS N
decreased POS N
1 POS N
year POS N
after POS N
ITx POS N
in POS N
Group POS N
1 POS N
(HbA1c: POS N
- 2.1 ± 1.4%, POS N
p = 0.002), POS N

Rapamycin POS N
pre-treatment POS N
before POS N
ITx POS N
succeeds POS N
in POS N
reducing POS N
insulin POS N
requirement, POS N
enhancing POS N
hepatic POS N
insulin POS N
sensitivity. POS N

Fasting POS N
glucose POS N
and POS N
HbA1c POS N
significantly POS N
decreased POS N
1 POS N
year POS N
after POS N
ITx POS N
in POS N
Group POS N
1 POS N
(HbA1c: POS N
- 2.1 ± 1.4%, POS N
p = 0.002), POS N

Hepatic POS N
glucose POS N
production POS N
decreased POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 1.1 ± 1.1 POS N
mg/kg/min, POS N
p = 0.04) POS N
and POS N
after POS N
ITx POS N
(- 1.6 ± 0.6 POS N
mg/kg/min, POS N
p = 0.015), POS N

Fasting POS N
glucose POS N
and POS N
HbA1c POS N
significantly POS N
decreased POS N
1 POS N
year POS N
after POS N
ITx POS N
in POS N
Group POS N
1 POS N
(HbA1c: POS N
- 2.1 ± 1.4%, POS N
p = 0.002), POS N

no POS N
changes POS N
in POS N
peripheral POS N
glucose POS N
disposal POS N
were POS N
observed. POS N

Fasting POS N
glucose POS N
and POS N
HbA1c POS N
significantly POS N
decreased POS N
1 POS N
year POS N
after POS N
ITx POS N
in POS N
Group POS N
1 POS N
(HbA1c: POS N
- 2.1 ± 1.4%, POS N
p = 0.002), POS N

fasting POS N
C-peptide POS N
(+0.5 ± 0.3 POS N
nmol/l, POS N
p = 0.002) POS N
and POS N
SUITO POS N
index POS N
increased POS N
(+57.4 ± 39.7, POS N
p = 0.016), POS N
without POS N
differences POS N
between POS N
the POS N
two POS N
groups. POS N

Fasting POS N
glucose POS N
and POS N
HbA1c POS N
significantly POS N
decreased POS N
1 POS N
year POS N
after POS N
ITx POS N
in POS N
Group POS N
1 POS N
(HbA1c: POS N
- 2.1 ± 1.4%, POS N
p = 0.002), POS N

DIR POS N
reduction POS N
1 POS N
year POS N
after POS N
ITx POS N
was POS N
greater POS N
in POS N
Group POS N
1 POS N
as POS N
compared POS N
to POS N
Group POS N
2 POS N
(- 37 ± 15 POS N
vs. POS N
- 19 ± 13 POS N
U/day, POS N
p = 0.005) POS N
and POS N
remained POS N
significant POS N
after POS N
adjusting POS N
for POS N
gender, POS N
age, POS N
glucose POS N
and POS N
baseline POS N
HbA1c POS N
(beta = 18.2 ± 5.9, POS N
p = 0.006). POS N

Fasting POS N
glucose POS N
and POS N
HbA1c POS N
significantly POS N
decreased POS N
1 POS N
year POS N
after POS N
ITx POS N
in POS N
Group POS N
1 POS N
(HbA1c: POS N
- 2.1 ± 1.4%, POS N
p = 0.002), POS N

We POS N
found POS N
a POS N
significant POS N
reduction POS N
in POS N
DIR POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 8 ± 6 POS N
U/day, POS N
mean ± SD, POS N
p < 0.001) POS N
and POS N
1 POS N
year POS N
after POS N
ITx. POS N

fasting POS N
C-peptide POS N
(+0.5 ± 0.3 POS N
nmol/l, POS N
p = 0.002) POS N
and POS N
SUITO POS N
index POS N
increased POS N
(+57.4 ± 39.7, POS N
p = 0.016), POS N
without POS N
differences POS N
between POS N
the POS N
two POS N
groups. POS N

The POS N
immunosuppressive POS N
drug POS N
rapamycin POS N
may POS N
influence POS N
insulin POS N
sensitivity POS N
in POS N
insulin-responsive POS N
tissues. POS N

fasting POS N
C-peptide POS N
(+0.5 ± 0.3 POS N
nmol/l, POS N
p = 0.002) POS N
and POS N
SUITO POS N
index POS N
increased POS N
(+57.4 ± 39.7, POS N
p = 0.016), POS N
without POS N
differences POS N
between POS N
the POS N
two POS N
groups. POS N

This POS N
treatment POS N
may POS N
improve POS N
short-term POS N
ITx POS N
outcomes, POS N
possibly POS N
in POS N
selected POS N
patients POS N
with POS N
T1DM POS N
complicated POS N
by POS N
insulin POS N
resistance. POS N

fasting POS N
C-peptide POS N
(+0.5 ± 0.3 POS N
nmol/l, POS N
p = 0.002) POS N
and POS N
SUITO POS N
index POS N
increased POS N
(+57.4 ± 39.7, POS N
p = 0.016), POS N
without POS N
differences POS N
between POS N
the POS N
two POS N
groups. POS N

Rapamycin POS N
pre-treatment POS N
before POS N
ITx POS N
succeeds POS N
in POS N
reducing POS N
insulin POS N
requirement, POS N
enhancing POS N
hepatic POS N
insulin POS N
sensitivity. POS N

fasting POS N
C-peptide POS N
(+0.5 ± 0.3 POS N
nmol/l, POS N
p = 0.002) POS N
and POS N
SUITO POS N
index POS N
increased POS N
(+57.4 ± 39.7, POS N
p = 0.016), POS N
without POS N
differences POS N
between POS N
the POS N
two POS N
groups. POS N

Hepatic POS N
glucose POS N
production POS N
decreased POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 1.1 ± 1.1 POS N
mg/kg/min, POS N
p = 0.04) POS N
and POS N
after POS N
ITx POS N
(- 1.6 ± 0.6 POS N
mg/kg/min, POS N
p = 0.015), POS N

fasting POS N
C-peptide POS N
(+0.5 ± 0.3 POS N
nmol/l, POS N
p = 0.002) POS N
and POS N
SUITO POS N
index POS N
increased POS N
(+57.4 ± 39.7, POS N
p = 0.016), POS N
without POS N
differences POS N
between POS N
the POS N
two POS N
groups. POS N

no POS N
changes POS N
in POS N
peripheral POS N
glucose POS N
disposal POS N
were POS N
observed. POS N

fasting POS N
C-peptide POS N
(+0.5 ± 0.3 POS N
nmol/l, POS N
p = 0.002) POS N
and POS N
SUITO POS N
index POS N
increased POS N
(+57.4 ± 39.7, POS N
p = 0.016), POS N
without POS N
differences POS N
between POS N
the POS N
two POS N
groups. POS N

Fasting POS N
glucose POS N
and POS N
HbA1c POS N
significantly POS N
decreased POS N
1 POS N
year POS N
after POS N
ITx POS N
in POS N
Group POS N
1 POS N
(HbA1c: POS N
- 2.1 ± 1.4%, POS N
p = 0.002), POS N

fasting POS N
C-peptide POS N
(+0.5 ± 0.3 POS N
nmol/l, POS N
p = 0.002) POS N
and POS N
SUITO POS N
index POS N
increased POS N
(+57.4 ± 39.7, POS N
p = 0.016), POS N
without POS N
differences POS N
between POS N
the POS N
two POS N
groups. POS N

DIR POS N
reduction POS N
1 POS N
year POS N
after POS N
ITx POS N
was POS N
greater POS N
in POS N
Group POS N
1 POS N
as POS N
compared POS N
to POS N
Group POS N
2 POS N
(- 37 ± 15 POS N
vs. POS N
- 19 ± 13 POS N
U/day, POS N
p = 0.005) POS N
and POS N
remained POS N
significant POS N
after POS N
adjusting POS N
for POS N
gender, POS N
age, POS N
glucose POS N
and POS N
baseline POS N
HbA1c POS N
(beta = 18.2 ± 5.9, POS N
p = 0.006). POS N

fasting POS N
C-peptide POS N
(+0.5 ± 0.3 POS N
nmol/l, POS N
p = 0.002) POS N
and POS N
SUITO POS N
index POS N
increased POS N
(+57.4 ± 39.7, POS N
p = 0.016), POS N
without POS N
differences POS N
between POS N
the POS N
two POS N
groups. POS N

We POS N
found POS N
a POS N
significant POS N
reduction POS N
in POS N
DIR POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 8 ± 6 POS N
U/day, POS N
mean ± SD, POS N
p < 0.001) POS N
and POS N
1 POS N
year POS N
after POS N
ITx. POS N

DIR POS N
reduction POS N
1 POS N
year POS N
after POS N
ITx POS N
was POS N
greater POS N
in POS N
Group POS N
1 POS N
as POS N
compared POS N
to POS N
Group POS N
2 POS N
(- 37 ± 15 POS N
vs. POS N
- 19 ± 13 POS N
U/day, POS N
p = 0.005) POS N
and POS N
remained POS N
significant POS N
after POS N
adjusting POS N
for POS N
gender, POS N
age, POS N
glucose POS N
and POS N
baseline POS N
HbA1c POS N
(beta = 18.2 ± 5.9, POS N
p = 0.006). POS N

The POS N
immunosuppressive POS N
drug POS N
rapamycin POS N
may POS N
influence POS N
insulin POS N
sensitivity POS N
in POS N
insulin-responsive POS N
tissues. POS N

DIR POS N
reduction POS N
1 POS N
year POS N
after POS N
ITx POS N
was POS N
greater POS N
in POS N
Group POS N
1 POS N
as POS N
compared POS N
to POS N
Group POS N
2 POS N
(- 37 ± 15 POS N
vs. POS N
- 19 ± 13 POS N
U/day, POS N
p = 0.005) POS N
and POS N
remained POS N
significant POS N
after POS N
adjusting POS N
for POS N
gender, POS N
age, POS N
glucose POS N
and POS N
baseline POS N
HbA1c POS N
(beta = 18.2 ± 5.9, POS N
p = 0.006). POS N

This POS N
treatment POS N
may POS N
improve POS N
short-term POS N
ITx POS N
outcomes, POS N
possibly POS N
in POS N
selected POS N
patients POS N
with POS N
T1DM POS N
complicated POS N
by POS N
insulin POS N
resistance. POS N

DIR POS N
reduction POS N
1 POS N
year POS N
after POS N
ITx POS N
was POS N
greater POS N
in POS N
Group POS N
1 POS N
as POS N
compared POS N
to POS N
Group POS N
2 POS N
(- 37 ± 15 POS N
vs. POS N
- 19 ± 13 POS N
U/day, POS N
p = 0.005) POS N
and POS N
remained POS N
significant POS N
after POS N
adjusting POS N
for POS N
gender, POS N
age, POS N
glucose POS N
and POS N
baseline POS N
HbA1c POS N
(beta = 18.2 ± 5.9, POS N
p = 0.006). POS N

Rapamycin POS N
pre-treatment POS N
before POS N
ITx POS N
succeeds POS N
in POS N
reducing POS N
insulin POS N
requirement, POS N
enhancing POS N
hepatic POS N
insulin POS N
sensitivity. POS N

DIR POS N
reduction POS N
1 POS N
year POS N
after POS N
ITx POS N
was POS N
greater POS N
in POS N
Group POS N
1 POS N
as POS N
compared POS N
to POS N
Group POS N
2 POS N
(- 37 ± 15 POS N
vs. POS N
- 19 ± 13 POS N
U/day, POS N
p = 0.005) POS N
and POS N
remained POS N
significant POS N
after POS N
adjusting POS N
for POS N
gender, POS N
age, POS N
glucose POS N
and POS N
baseline POS N
HbA1c POS N
(beta = 18.2 ± 5.9, POS N
p = 0.006). POS N

Hepatic POS N
glucose POS N
production POS N
decreased POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 1.1 ± 1.1 POS N
mg/kg/min, POS N
p = 0.04) POS N
and POS N
after POS N
ITx POS N
(- 1.6 ± 0.6 POS N
mg/kg/min, POS N
p = 0.015), POS N

DIR POS N
reduction POS N
1 POS N
year POS N
after POS N
ITx POS N
was POS N
greater POS N
in POS N
Group POS N
1 POS N
as POS N
compared POS N
to POS N
Group POS N
2 POS N
(- 37 ± 15 POS N
vs. POS N
- 19 ± 13 POS N
U/day, POS N
p = 0.005) POS N
and POS N
remained POS N
significant POS N
after POS N
adjusting POS N
for POS N
gender, POS N
age, POS N
glucose POS N
and POS N
baseline POS N
HbA1c POS N
(beta = 18.2 ± 5.9, POS N
p = 0.006). POS N

no POS N
changes POS N
in POS N
peripheral POS N
glucose POS N
disposal POS N
were POS N
observed. POS N

DIR POS N
reduction POS N
1 POS N
year POS N
after POS N
ITx POS N
was POS N
greater POS N
in POS N
Group POS N
1 POS N
as POS N
compared POS N
to POS N
Group POS N
2 POS N
(- 37 ± 15 POS N
vs. POS N
- 19 ± 13 POS N
U/day, POS N
p = 0.005) POS N
and POS N
remained POS N
significant POS N
after POS N
adjusting POS N
for POS N
gender, POS N
age, POS N
glucose POS N
and POS N
baseline POS N
HbA1c POS N
(beta = 18.2 ± 5.9, POS N
p = 0.006). POS N

Fasting POS N
glucose POS N
and POS N
HbA1c POS N
significantly POS N
decreased POS N
1 POS N
year POS N
after POS N
ITx POS N
in POS N
Group POS N
1 POS N
(HbA1c: POS N
- 2.1 ± 1.4%, POS N
p = 0.002), POS N

DIR POS N
reduction POS N
1 POS N
year POS N
after POS N
ITx POS N
was POS N
greater POS N
in POS N
Group POS N
1 POS N
as POS N
compared POS N
to POS N
Group POS N
2 POS N
(- 37 ± 15 POS N
vs. POS N
- 19 ± 13 POS N
U/day, POS N
p = 0.005) POS N
and POS N
remained POS N
significant POS N
after POS N
adjusting POS N
for POS N
gender, POS N
age, POS N
glucose POS N
and POS N
baseline POS N
HbA1c POS N
(beta = 18.2 ± 5.9, POS N
p = 0.006). POS N

fasting POS N
C-peptide POS N
(+0.5 ± 0.3 POS N
nmol/l, POS N
p = 0.002) POS N
and POS N
SUITO POS N
index POS N
increased POS N
(+57.4 ± 39.7, POS N
p = 0.016), POS N
without POS N
differences POS N
between POS N
the POS N
two POS N
groups. POS N

DIR POS N
reduction POS N
1 POS N
year POS N
after POS N
ITx POS N
was POS N
greater POS N
in POS N
Group POS N
1 POS N
as POS N
compared POS N
to POS N
Group POS N
2 POS N
(- 37 ± 15 POS N
vs. POS N
- 19 ± 13 POS N
U/day, POS N
p = 0.005) POS N
and POS N
remained POS N
significant POS N
after POS N
adjusting POS N
for POS N
gender, POS N
age, POS N
glucose POS N
and POS N
baseline POS N
HbA1c POS N
(beta = 18.2 ± 5.9, POS N
p = 0.006). POS N

We POS N
found POS N
a POS N
significant POS N
reduction POS N
in POS N
DIR POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 8 ± 6 POS N
U/day, POS N
mean ± SD, POS N
p < 0.001) POS N
and POS N
1 POS N
year POS N
after POS N
ITx. POS N

We POS N
found POS N
a POS N
significant POS N
reduction POS N
in POS N
DIR POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 8 ± 6 POS N
U/day, POS N
mean ± SD, POS N
p < 0.001) POS N
and POS N
1 POS N
year POS N
after POS N
ITx. POS N

The POS N
immunosuppressive POS N
drug POS N
rapamycin POS N
may POS N
influence POS N
insulin POS N
sensitivity POS N
in POS N
insulin-responsive POS N
tissues. POS N

We POS N
found POS N
a POS N
significant POS N
reduction POS N
in POS N
DIR POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 8 ± 6 POS N
U/day, POS N
mean ± SD, POS N
p < 0.001) POS N
and POS N
1 POS N
year POS N
after POS N
ITx. POS N

This POS N
treatment POS N
may POS N
improve POS N
short-term POS N
ITx POS N
outcomes, POS N
possibly POS N
in POS N
selected POS N
patients POS N
with POS N
T1DM POS N
complicated POS N
by POS N
insulin POS N
resistance. POS N

We POS N
found POS N
a POS N
significant POS N
reduction POS N
in POS N
DIR POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 8 ± 6 POS N
U/day, POS N
mean ± SD, POS N
p < 0.001) POS N
and POS N
1 POS N
year POS N
after POS N
ITx. POS N

Rapamycin POS N
pre-treatment POS N
before POS N
ITx POS N
succeeds POS N
in POS N
reducing POS N
insulin POS N
requirement, POS N
enhancing POS N
hepatic POS N
insulin POS N
sensitivity. POS N

We POS N
found POS N
a POS N
significant POS N
reduction POS N
in POS N
DIR POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 8 ± 6 POS N
U/day, POS N
mean ± SD, POS N
p < 0.001) POS N
and POS N
1 POS N
year POS N
after POS N
ITx. POS N

Hepatic POS N
glucose POS N
production POS N
decreased POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 1.1 ± 1.1 POS N
mg/kg/min, POS N
p = 0.04) POS N
and POS N
after POS N
ITx POS N
(- 1.6 ± 0.6 POS N
mg/kg/min, POS N
p = 0.015), POS N

We POS N
found POS N
a POS N
significant POS N
reduction POS N
in POS N
DIR POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 8 ± 6 POS N
U/day, POS N
mean ± SD, POS N
p < 0.001) POS N
and POS N
1 POS N
year POS N
after POS N
ITx. POS N

no POS N
changes POS N
in POS N
peripheral POS N
glucose POS N
disposal POS N
were POS N
observed. POS N

We POS N
found POS N
a POS N
significant POS N
reduction POS N
in POS N
DIR POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 8 ± 6 POS N
U/day, POS N
mean ± SD, POS N
p < 0.001) POS N
and POS N
1 POS N
year POS N
after POS N
ITx. POS N

Fasting POS N
glucose POS N
and POS N
HbA1c POS N
significantly POS N
decreased POS N
1 POS N
year POS N
after POS N
ITx POS N
in POS N
Group POS N
1 POS N
(HbA1c: POS N
- 2.1 ± 1.4%, POS N
p = 0.002), POS N

We POS N
found POS N
a POS N
significant POS N
reduction POS N
in POS N
DIR POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 8 ± 6 POS N
U/day, POS N
mean ± SD, POS N
p < 0.001) POS N
and POS N
1 POS N
year POS N
after POS N
ITx. POS N

fasting POS N
C-peptide POS N
(+0.5 ± 0.3 POS N
nmol/l, POS N
p = 0.002) POS N
and POS N
SUITO POS N
index POS N
increased POS N
(+57.4 ± 39.7, POS N
p = 0.016), POS N
without POS N
differences POS N
between POS N
the POS N
two POS N
groups. POS N

We POS N
found POS N
a POS N
significant POS N
reduction POS N
in POS N
DIR POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 8 ± 6 POS N
U/day, POS N
mean ± SD, POS N
p < 0.001) POS N
and POS N
1 POS N
year POS N
after POS N
ITx. POS N

DIR POS N
reduction POS N
1 POS N
year POS N
after POS N
ITx POS N
was POS N
greater POS N
in POS N
Group POS N
1 POS N
as POS N
compared POS N
to POS N
Group POS N
2 POS N
(- 37 ± 15 POS N
vs. POS N
- 19 ± 13 POS N
U/day, POS N
p = 0.005) POS N
and POS N
remained POS N
significant POS N
after POS N
adjusting POS N
for POS N
gender, POS N
age, POS N
glucose POS N
and POS N
baseline POS N
HbA1c POS N
(beta = 18.2 ± 5.9, POS N
p = 0.006). POS N

Hypertension POS N
is POS N
a POS N
generally POS N
accepted POS N
atherogenic POS N
risk POS N
factor. POS N

The POS N
results POS N
showed POS N
that POS N
mean POS N
c-IMT POS N
z-scores POS N
increased POS N
significantly POS N
during POS N
4 POS N
years POS N
(0.002 POS N
± POS N
0.003, POS N
p POS N
< POS N
0.001) POS N
as POS N
well POS N
as POS N
carotid-femoral POS N
PWV POS N
(13.99 POS N
± POS N
2.74, POS N
p POS N
< POS N
0.01) POS N
and POS N
total POS N
cholesterol POS N
(6.97 POS N
± POS N
1.08, POS N
p POS N
< POS N
0.001). POS N

Hypertension POS N
is POS N
a POS N
generally POS N
accepted POS N
atherogenic POS N
risk POS N
factor. POS N

Linear POS N
regression POS N
showed POS N
statistically POS N
significant POS N
associations POS N
between POS N
systolic POS N
blood POS N
pressure, POS N
diastolic POS N
blood POS N
pressure, POS N
C-reactive POS N
protein, POS N
lip-line, POS N
and POS N
heart POS N
rate POS N
with POS N
c-IMT POS N
z-scores POS N
of POS N
>1.5SD POS N
in POS N
the POS N
fully POS N
adjusted POS N
models POS N
and POS N
the POS N
p POS N
values POS N
were POS N
0.000, POS N
0.000, POS N
0.017, POS N
0.001, POS N
and POS N
0.044, POS N
respectively POS N
. POS N

Hypertension POS N
is POS N
a POS N
generally POS N
accepted POS N
atherogenic POS N
risk POS N
factor. POS N

In POS N
a POS N
full-model POS N
logistic POS N
regression, POS N
significant POS N
risk POS N
factors POS N
for POS N
an POS N
increase POS N
in POS N
IMT POS N
of POS N
≥1.5 POS N
z-scores POS N
were POS N
carotid-femoral POS N
PWV POS N
(odds POS N
ratio: POS N
1.119, POS N
confidence POS N
interval: POS N
1.018, POS N
1.230, POS N
p POS N
= POS N
0.020 POS N
< POS N
0.05) POS N
at POS N
first POS N
measurement. POS N

Hypertension POS N
is POS N
a POS N
generally POS N
accepted POS N
atherogenic POS N
risk POS N
factor. POS N

The POS N
conclusion POS N
of POS N
the POS N
study POS N
was POS N
that POS N
longitudinal POS N
c-IMT POS N
measurements POS N
revealed POS N
progression POS N
in POS N
subclinical POS N
atherosclerosis POS N
during POS N
a POS N
four-year POS N
period POS N
in POS N
a POS N
hypertensive POS N
old-aged POS N
cohort. POS N

Hypertension POS N
is POS N
a POS N
generally POS N
accepted POS N
atherogenic POS N
risk POS N
factor. POS N

Systolic POS N
or POS N
diastolic POS N
blood POS N
pressure, POS N
homocysteine, POS N
carotid-femoral POS N
PWV, POS N
and POS N
waistline POS N
were POS N
significantly POS N
related POS N
to POS N
c-IMT POS N
increment. POS N

Hypertension POS N
is POS N
a POS N
generally POS N
accepted POS N
atherogenic POS N
risk POS N
factor. POS N

By POS N
lifestyle POS N
and POS N
medical POS N
intervention POS N
to POS N
control POS N
these POS N
risk POS N
factors POS N
may POS N
prevent POS N
progression POS N
of POS N
c-IMT POS N
in POS N
old-aged POS N
cohort POS N
with POS N
hypertension. POS N

The POS N
results POS N
showed POS N
that POS N
mean POS N
c-IMT POS N
z-scores POS N
increased POS N
significantly POS N
during POS N
4 POS N
years POS N
(0.002 POS N
± POS N
0.003, POS N
p POS N
< POS N
0.001) POS N
as POS N
well POS N
as POS N
carotid-femoral POS N
PWV POS N
(13.99 POS N
± POS N
2.74, POS N
p POS N
< POS N
0.01) POS N
and POS N
total POS N
cholesterol POS N
(6.97 POS N
± POS N
1.08, POS N
p POS N
< POS N
0.001). POS N

Hypertension POS N
is POS N
a POS N
generally POS N
accepted POS N
atherogenic POS N
risk POS N
factor. POS N

The POS N
results POS N
showed POS N
that POS N
mean POS N
c-IMT POS N
z-scores POS N
increased POS N
significantly POS N
during POS N
4 POS N
years POS N
(0.002 POS N
± POS N
0.003, POS N
p POS N
< POS N
0.001) POS N
as POS N
well POS N
as POS N
carotid-femoral POS N
PWV POS N
(13.99 POS N
± POS N
2.74, POS N
p POS N
< POS N
0.01) POS N
and POS N
total POS N
cholesterol POS N
(6.97 POS N
± POS N
1.08, POS N
p POS N
< POS N
0.001). POS N

Linear POS N
regression POS N
showed POS N
statistically POS N
significant POS N
associations POS N
between POS N
systolic POS N
blood POS N
pressure, POS N
diastolic POS N
blood POS N
pressure, POS N
C-reactive POS N
protein, POS N
lip-line, POS N
and POS N
heart POS N
rate POS N
with POS N
c-IMT POS N
z-scores POS N
of POS N
>1.5SD POS N
in POS N
the POS N
fully POS N
adjusted POS N
models POS N
and POS N
the POS N
p POS N
values POS N
were POS N
0.000, POS N
0.000, POS N
0.017, POS N
0.001, POS N
and POS N
0.044, POS N
respectively POS N
. POS N

The POS N
results POS N
showed POS N
that POS N
mean POS N
c-IMT POS N
z-scores POS N
increased POS N
significantly POS N
during POS N
4 POS N
years POS N
(0.002 POS N
± POS N
0.003, POS N
p POS N
< POS N
0.001) POS N
as POS N
well POS N
as POS N
carotid-femoral POS N
PWV POS N
(13.99 POS N
± POS N
2.74, POS N
p POS N
< POS N
0.01) POS N
and POS N
total POS N
cholesterol POS N
(6.97 POS N
± POS N
1.08, POS N
p POS N
< POS N
0.001). POS N

In POS N
a POS N
full-model POS N
logistic POS N
regression, POS N
significant POS N
risk POS N
factors POS N
for POS N
an POS N
increase POS N
in POS N
IMT POS N
of POS N
≥1.5 POS N
z-scores POS N
were POS N
carotid-femoral POS N
PWV POS N
(odds POS N
ratio: POS N
1.119, POS N
confidence POS N
interval: POS N
1.018, POS N
1.230, POS N
p POS N
= POS N
0.020 POS N
< POS N
0.05) POS N
at POS N
first POS N
measurement. POS N

The POS N
results POS N
showed POS N
that POS N
mean POS N
c-IMT POS N
z-scores POS N
increased POS N
significantly POS N
during POS N
4 POS N
years POS N
(0.002 POS N
± POS N
0.003, POS N
p POS N
< POS N
0.001) POS N
as POS N
well POS N
as POS N
carotid-femoral POS N
PWV POS N
(13.99 POS N
± POS N
2.74, POS N
p POS N
< POS N
0.01) POS N
and POS N
total POS N
cholesterol POS N
(6.97 POS N
± POS N
1.08, POS N
p POS N
< POS N
0.001). POS N

The POS N
conclusion POS N
of POS N
the POS N
study POS N
was POS N
that POS N
longitudinal POS N
c-IMT POS N
measurements POS N
revealed POS N
progression POS N
in POS N
subclinical POS N
atherosclerosis POS N
during POS N
a POS N
four-year POS N
period POS N
in POS N
a POS N
hypertensive POS N
old-aged POS N
cohort. POS N

The POS N
results POS N
showed POS N
that POS N
mean POS N
c-IMT POS N
z-scores POS N
increased POS N
significantly POS N
during POS N
4 POS N
years POS N
(0.002 POS N
± POS N
0.003, POS N
p POS N
< POS N
0.001) POS N
as POS N
well POS N
as POS N
carotid-femoral POS N
PWV POS N
(13.99 POS N
± POS N
2.74, POS N
p POS N
< POS N
0.01) POS N
and POS N
total POS N
cholesterol POS N
(6.97 POS N
± POS N
1.08, POS N
p POS N
< POS N
0.001). POS N

Systolic POS N
or POS N
diastolic POS N
blood POS N
pressure, POS N
homocysteine, POS N
carotid-femoral POS N
PWV, POS N
and POS N
waistline POS N
were POS N
significantly POS N
related POS N
to POS N
c-IMT POS N
increment. POS N

The POS N
results POS N
showed POS N
that POS N
mean POS N
c-IMT POS N
z-scores POS N
increased POS N
significantly POS N
during POS N
4 POS N
years POS N
(0.002 POS N
± POS N
0.003, POS N
p POS N
< POS N
0.001) POS N
as POS N
well POS N
as POS N
carotid-femoral POS N
PWV POS N
(13.99 POS N
± POS N
2.74, POS N
p POS N
< POS N
0.01) POS N
and POS N
total POS N
cholesterol POS N
(6.97 POS N
± POS N
1.08, POS N
p POS N
< POS N
0.001). POS N

By POS N
lifestyle POS N
and POS N
medical POS N
intervention POS N
to POS N
control POS N
these POS N
risk POS N
factors POS N
may POS N
prevent POS N
progression POS N
of POS N
c-IMT POS N
in POS N
old-aged POS N
cohort POS N
with POS N
hypertension. POS N

Linear POS N
regression POS N
showed POS N
statistically POS N
significant POS N
associations POS N
between POS N
systolic POS N
blood POS N
pressure, POS N
diastolic POS N
blood POS N
pressure, POS N
C-reactive POS N
protein, POS N
lip-line, POS N
and POS N
heart POS N
rate POS N
with POS N
c-IMT POS N
z-scores POS N
of POS N
>1.5SD POS N
in POS N
the POS N
fully POS N
adjusted POS N
models POS N
and POS N
the POS N
p POS N
values POS N
were POS N
0.000, POS N
0.000, POS N
0.017, POS N
0.001, POS N
and POS N
0.044, POS N
respectively POS N
. POS N

Hypertension POS N
is POS N
a POS N
generally POS N
accepted POS N
atherogenic POS N
risk POS N
factor. POS N

Linear POS N
regression POS N
showed POS N
statistically POS N
significant POS N
associations POS N
between POS N
systolic POS N
blood POS N
pressure, POS N
diastolic POS N
blood POS N
pressure, POS N
C-reactive POS N
protein, POS N
lip-line, POS N
and POS N
heart POS N
rate POS N
with POS N
c-IMT POS N
z-scores POS N
of POS N
>1.5SD POS N
in POS N
the POS N
fully POS N
adjusted POS N
models POS N
and POS N
the POS N
p POS N
values POS N
were POS N
0.000, POS N
0.000, POS N
0.017, POS N
0.001, POS N
and POS N
0.044, POS N
respectively POS N
. POS N

The POS N
results POS N
showed POS N
that POS N
mean POS N
c-IMT POS N
z-scores POS N
increased POS N
significantly POS N
during POS N
4 POS N
years POS N
(0.002 POS N
± POS N
0.003, POS N
p POS N
< POS N
0.001) POS N
as POS N
well POS N
as POS N
carotid-femoral POS N
PWV POS N
(13.99 POS N
± POS N
2.74, POS N
p POS N
< POS N
0.01) POS N
and POS N
total POS N
cholesterol POS N
(6.97 POS N
± POS N
1.08, POS N
p POS N
< POS N
0.001). POS N

Linear POS N
regression POS N
showed POS N
statistically POS N
significant POS N
associations POS N
between POS N
systolic POS N
blood POS N
pressure, POS N
diastolic POS N
blood POS N
pressure, POS N
C-reactive POS N
protein, POS N
lip-line, POS N
and POS N
heart POS N
rate POS N
with POS N
c-IMT POS N
z-scores POS N
of POS N
>1.5SD POS N
in POS N
the POS N
fully POS N
adjusted POS N
models POS N
and POS N
the POS N
p POS N
values POS N
were POS N
0.000, POS N
0.000, POS N
0.017, POS N
0.001, POS N
and POS N
0.044, POS N
respectively POS N
. POS N

In POS N
a POS N
full-model POS N
logistic POS N
regression, POS N
significant POS N
risk POS N
factors POS N
for POS N
an POS N
increase POS N
in POS N
IMT POS N
of POS N
≥1.5 POS N
z-scores POS N
were POS N
carotid-femoral POS N
PWV POS N
(odds POS N
ratio: POS N
1.119, POS N
confidence POS N
interval: POS N
1.018, POS N
1.230, POS N
p POS N
= POS N
0.020 POS N
< POS N
0.05) POS N
at POS N
first POS N
measurement. POS N

Linear POS N
regression POS N
showed POS N
statistically POS N
significant POS N
associations POS N
between POS N
systolic POS N
blood POS N
pressure, POS N
diastolic POS N
blood POS N
pressure, POS N
C-reactive POS N
protein, POS N
lip-line, POS N
and POS N
heart POS N
rate POS N
with POS N
c-IMT POS N
z-scores POS N
of POS N
>1.5SD POS N
in POS N
the POS N
fully POS N
adjusted POS N
models POS N
and POS N
the POS N
p POS N
values POS N
were POS N
0.000, POS N
0.000, POS N
0.017, POS N
0.001, POS N
and POS N
0.044, POS N
respectively POS N
. POS N

The POS N
conclusion POS N
of POS N
the POS N
study POS N
was POS N
that POS N
longitudinal POS N
c-IMT POS N
measurements POS N
revealed POS N
progression POS N
in POS N
subclinical POS N
atherosclerosis POS N
during POS N
a POS N
four-year POS N
period POS N
in POS N
a POS N
hypertensive POS N
old-aged POS N
cohort. POS N

Linear POS N
regression POS N
showed POS N
statistically POS N
significant POS N
associations POS N
between POS N
systolic POS N
blood POS N
pressure, POS N
diastolic POS N
blood POS N
pressure, POS N
C-reactive POS N
protein, POS N
lip-line, POS N
and POS N
heart POS N
rate POS N
with POS N
c-IMT POS N
z-scores POS N
of POS N
>1.5SD POS N
in POS N
the POS N
fully POS N
adjusted POS N
models POS N
and POS N
the POS N
p POS N
values POS N
were POS N
0.000, POS N
0.000, POS N
0.017, POS N
0.001, POS N
and POS N
0.044, POS N
respectively POS N
. POS N

Systolic POS N
or POS N
diastolic POS N
blood POS N
pressure, POS N
homocysteine, POS N
carotid-femoral POS N
PWV, POS N
and POS N
waistline POS N
were POS N
significantly POS N
related POS N
to POS N
c-IMT POS N
increment. POS N

Linear POS N
regression POS N
showed POS N
statistically POS N
significant POS N
associations POS N
between POS N
systolic POS N
blood POS N
pressure, POS N
diastolic POS N
blood POS N
pressure, POS N
C-reactive POS N
protein, POS N
lip-line, POS N
and POS N
heart POS N
rate POS N
with POS N
c-IMT POS N
z-scores POS N
of POS N
>1.5SD POS N
in POS N
the POS N
fully POS N
adjusted POS N
models POS N
and POS N
the POS N
p POS N
values POS N
were POS N
0.000, POS N
0.000, POS N
0.017, POS N
0.001, POS N
and POS N
0.044, POS N
respectively POS N
. POS N

By POS N
lifestyle POS N
and POS N
medical POS N
intervention POS N
to POS N
control POS N
these POS N
risk POS N
factors POS N
may POS N
prevent POS N
progression POS N
of POS N
c-IMT POS N
in POS N
old-aged POS N
cohort POS N
with POS N
hypertension. POS N

In POS N
a POS N
full-model POS N
logistic POS N
regression, POS N
significant POS N
risk POS N
factors POS N
for POS N
an POS N
increase POS N
in POS N
IMT POS N
of POS N
≥1.5 POS N
z-scores POS N
were POS N
carotid-femoral POS N
PWV POS N
(odds POS N
ratio: POS N
1.119, POS N
confidence POS N
interval: POS N
1.018, POS N
1.230, POS N
p POS N
= POS N
0.020 POS N
< POS N
0.05) POS N
at POS N
first POS N
measurement. POS N

Hypertension POS N
is POS N
a POS N
generally POS N
accepted POS N
atherogenic POS N
risk POS N
factor. POS N

In POS N
a POS N
full-model POS N
logistic POS N
regression, POS N
significant POS N
risk POS N
factors POS N
for POS N
an POS N
increase POS N
in POS N
IMT POS N
of POS N
≥1.5 POS N
z-scores POS N
were POS N
carotid-femoral POS N
PWV POS N
(odds POS N
ratio: POS N
1.119, POS N
confidence POS N
interval: POS N
1.018, POS N
1.230, POS N
p POS N
= POS N
0.020 POS N
< POS N
0.05) POS N
at POS N
first POS N
measurement. POS N

The POS N
results POS N
showed POS N
that POS N
mean POS N
c-IMT POS N
z-scores POS N
increased POS N
significantly POS N
during POS N
4 POS N
years POS N
(0.002 POS N
± POS N
0.003, POS N
p POS N
< POS N
0.001) POS N
as POS N
well POS N
as POS N
carotid-femoral POS N
PWV POS N
(13.99 POS N
± POS N
2.74, POS N
p POS N
< POS N
0.01) POS N
and POS N
total POS N
cholesterol POS N
(6.97 POS N
± POS N
1.08, POS N
p POS N
< POS N
0.001). POS N

In POS N
a POS N
full-model POS N
logistic POS N
regression, POS N
significant POS N
risk POS N
factors POS N
for POS N
an POS N
increase POS N
in POS N
IMT POS N
of POS N
≥1.5 POS N
z-scores POS N
were POS N
carotid-femoral POS N
PWV POS N
(odds POS N
ratio: POS N
1.119, POS N
confidence POS N
interval: POS N
1.018, POS N
1.230, POS N
p POS N
= POS N
0.020 POS N
< POS N
0.05) POS N
at POS N
first POS N
measurement. POS N

Linear POS N
regression POS N
showed POS N
statistically POS N
significant POS N
associations POS N
between POS N
systolic POS N
blood POS N
pressure, POS N
diastolic POS N
blood POS N
pressure, POS N
C-reactive POS N
protein, POS N
lip-line, POS N
and POS N
heart POS N
rate POS N
with POS N
c-IMT POS N
z-scores POS N
of POS N
>1.5SD POS N
in POS N
the POS N
fully POS N
adjusted POS N
models POS N
and POS N
the POS N
p POS N
values POS N
were POS N
0.000, POS N
0.000, POS N
0.017, POS N
0.001, POS N
and POS N
0.044, POS N
respectively POS N
. POS N

In POS N
a POS N
full-model POS N
logistic POS N
regression, POS N
significant POS N
risk POS N
factors POS N
for POS N
an POS N
increase POS N
in POS N
IMT POS N
of POS N
≥1.5 POS N
z-scores POS N
were POS N
carotid-femoral POS N
PWV POS N
(odds POS N
ratio: POS N
1.119, POS N
confidence POS N
interval: POS N
1.018, POS N
1.230, POS N
p POS N
= POS N
0.020 POS N
< POS N
0.05) POS N
at POS N
first POS N
measurement. POS N

The POS N
conclusion POS N
of POS N
the POS N
study POS N
was POS N
that POS N
longitudinal POS N
c-IMT POS N
measurements POS N
revealed POS N
progression POS N
in POS N
subclinical POS N
atherosclerosis POS N
during POS N
a POS N
four-year POS N
period POS N
in POS N
a POS N
hypertensive POS N
old-aged POS N
cohort. POS N

In POS N
a POS N
full-model POS N
logistic POS N
regression, POS N
significant POS N
risk POS N
factors POS N
for POS N
an POS N
increase POS N
in POS N
IMT POS N
of POS N
≥1.5 POS N
z-scores POS N
were POS N
carotid-femoral POS N
PWV POS N
(odds POS N
ratio: POS N
1.119, POS N
confidence POS N
interval: POS N
1.018, POS N
1.230, POS N
p POS N
= POS N
0.020 POS N
< POS N
0.05) POS N
at POS N
first POS N
measurement. POS N

Systolic POS N
or POS N
diastolic POS N
blood POS N
pressure, POS N
homocysteine, POS N
carotid-femoral POS N
PWV, POS N
and POS N
waistline POS N
were POS N
significantly POS N
related POS N
to POS N
c-IMT POS N
increment. POS N

In POS N
a POS N
full-model POS N
logistic POS N
regression, POS N
significant POS N
risk POS N
factors POS N
for POS N
an POS N
increase POS N
in POS N
IMT POS N
of POS N
≥1.5 POS N
z-scores POS N
were POS N
carotid-femoral POS N
PWV POS N
(odds POS N
ratio: POS N
1.119, POS N
confidence POS N
interval: POS N
1.018, POS N
1.230, POS N
p POS N
= POS N
0.020 POS N
< POS N
0.05) POS N
at POS N
first POS N
measurement. POS N

By POS N
lifestyle POS N
and POS N
medical POS N
intervention POS N
to POS N
control POS N
these POS N
risk POS N
factors POS N
may POS N
prevent POS N
progression POS N
of POS N
c-IMT POS N
in POS N
old-aged POS N
cohort POS N
with POS N
hypertension. POS N

The POS N
conclusion POS N
of POS N
the POS N
study POS N
was POS N
that POS N
longitudinal POS N
c-IMT POS N
measurements POS N
revealed POS N
progression POS N
in POS N
subclinical POS N
atherosclerosis POS N
during POS N
a POS N
four-year POS N
period POS N
in POS N
a POS N
hypertensive POS N
old-aged POS N
cohort. POS N

Hypertension POS N
is POS N
a POS N
generally POS N
accepted POS N
atherogenic POS N
risk POS N
factor. POS N

The POS N
conclusion POS N
of POS N
the POS N
study POS N
was POS N
that POS N
longitudinal POS N
c-IMT POS N
measurements POS N
revealed POS N
progression POS N
in POS N
subclinical POS N
atherosclerosis POS N
during POS N
a POS N
four-year POS N
period POS N
in POS N
a POS N
hypertensive POS N
old-aged POS N
cohort. POS N

The POS N
results POS N
showed POS N
that POS N
mean POS N
c-IMT POS N
z-scores POS N
increased POS N
significantly POS N
during POS N
4 POS N
years POS N
(0.002 POS N
± POS N
0.003, POS N
p POS N
< POS N
0.001) POS N
as POS N
well POS N
as POS N
carotid-femoral POS N
PWV POS N
(13.99 POS N
± POS N
2.74, POS N
p POS N
< POS N
0.01) POS N
and POS N
total POS N
cholesterol POS N
(6.97 POS N
± POS N
1.08, POS N
p POS N
< POS N
0.001). POS N

The POS N
conclusion POS N
of POS N
the POS N
study POS N
was POS N
that POS N
longitudinal POS N
c-IMT POS N
measurements POS N
revealed POS N
progression POS N
in POS N
subclinical POS N
atherosclerosis POS N
during POS N
a POS N
four-year POS N
period POS N
in POS N
a POS N
hypertensive POS N
old-aged POS N
cohort. POS N

Linear POS N
regression POS N
showed POS N
statistically POS N
significant POS N
associations POS N
between POS N
systolic POS N
blood POS N
pressure, POS N
diastolic POS N
blood POS N
pressure, POS N
C-reactive POS N
protein, POS N
lip-line, POS N
and POS N
heart POS N
rate POS N
with POS N
c-IMT POS N
z-scores POS N
of POS N
>1.5SD POS N
in POS N
the POS N
fully POS N
adjusted POS N
models POS N
and POS N
the POS N
p POS N
values POS N
were POS N
0.000, POS N
0.000, POS N
0.017, POS N
0.001, POS N
and POS N
0.044, POS N
respectively POS N
. POS N

The POS N
conclusion POS N
of POS N
the POS N
study POS N
was POS N
that POS N
longitudinal POS N
c-IMT POS N
measurements POS N
revealed POS N
progression POS N
in POS N
subclinical POS N
atherosclerosis POS N
during POS N
a POS N
four-year POS N
period POS N
in POS N
a POS N
hypertensive POS N
old-aged POS N
cohort. POS N

In POS N
a POS N
full-model POS N
logistic POS N
regression, POS N
significant POS N
risk POS N
factors POS N
for POS N
an POS N
increase POS N
in POS N
IMT POS N
of POS N
≥1.5 POS N
z-scores POS N
were POS N
carotid-femoral POS N
PWV POS N
(odds POS N
ratio: POS N
1.119, POS N
confidence POS N
interval: POS N
1.018, POS N
1.230, POS N
p POS N
= POS N
0.020 POS N
< POS N
0.05) POS N
at POS N
first POS N
measurement. POS N

The POS N
conclusion POS N
of POS N
the POS N
study POS N
was POS N
that POS N
longitudinal POS N
c-IMT POS N
measurements POS N
revealed POS N
progression POS N
in POS N
subclinical POS N
atherosclerosis POS N
during POS N
a POS N
four-year POS N
period POS N
in POS N
a POS N
hypertensive POS N
old-aged POS N
cohort. POS N

Systolic POS N
or POS N
diastolic POS N
blood POS N
pressure, POS N
homocysteine, POS N
carotid-femoral POS N
PWV, POS N
and POS N
waistline POS N
were POS N
significantly POS N
related POS N
to POS N
c-IMT POS N
increment. POS N

The POS N
conclusion POS N
of POS N
the POS N
study POS N
was POS N
that POS N
longitudinal POS N
c-IMT POS N
measurements POS N
revealed POS N
progression POS N
in POS N
subclinical POS N
atherosclerosis POS N
during POS N
a POS N
four-year POS N
period POS N
in POS N
a POS N
hypertensive POS N
old-aged POS N
cohort. POS N

By POS N
lifestyle POS N
and POS N
medical POS N
intervention POS N
to POS N
control POS N
these POS N
risk POS N
factors POS N
may POS N
prevent POS N
progression POS N
of POS N
c-IMT POS N
in POS N
old-aged POS N
cohort POS N
with POS N
hypertension. POS N

Systolic POS N
or POS N
diastolic POS N
blood POS N
pressure, POS N
homocysteine, POS N
carotid-femoral POS N
PWV, POS N
and POS N
waistline POS N
were POS N
significantly POS N
related POS N
to POS N
c-IMT POS N
increment. POS N

Hypertension POS N
is POS N
a POS N
generally POS N
accepted POS N
atherogenic POS N
risk POS N
factor. POS N

Systolic POS N
or POS N
diastolic POS N
blood POS N
pressure, POS N
homocysteine, POS N
carotid-femoral POS N
PWV, POS N
and POS N
waistline POS N
were POS N
significantly POS N
related POS N
to POS N
c-IMT POS N
increment. POS N

The POS N
results POS N
showed POS N
that POS N
mean POS N
c-IMT POS N
z-scores POS N
increased POS N
significantly POS N
during POS N
4 POS N
years POS N
(0.002 POS N
± POS N
0.003, POS N
p POS N
< POS N
0.001) POS N
as POS N
well POS N
as POS N
carotid-femoral POS N
PWV POS N
(13.99 POS N
± POS N
2.74, POS N
p POS N
< POS N
0.01) POS N
and POS N
total POS N
cholesterol POS N
(6.97 POS N
± POS N
1.08, POS N
p POS N
< POS N
0.001). POS N

Systolic POS N
or POS N
diastolic POS N
blood POS N
pressure, POS N
homocysteine, POS N
carotid-femoral POS N
PWV, POS N
and POS N
waistline POS N
were POS N
significantly POS N
related POS N
to POS N
c-IMT POS N
increment. POS N

Linear POS N
regression POS N
showed POS N
statistically POS N
significant POS N
associations POS N
between POS N
systolic POS N
blood POS N
pressure, POS N
diastolic POS N
blood POS N
pressure, POS N
C-reactive POS N
protein, POS N
lip-line, POS N
and POS N
heart POS N
rate POS N
with POS N
c-IMT POS N
z-scores POS N
of POS N
>1.5SD POS N
in POS N
the POS N
fully POS N
adjusted POS N
models POS N
and POS N
the POS N
p POS N
values POS N
were POS N
0.000, POS N
0.000, POS N
0.017, POS N
0.001, POS N
and POS N
0.044, POS N
respectively POS N
. POS N

Systolic POS N
or POS N
diastolic POS N
blood POS N
pressure, POS N
homocysteine, POS N
carotid-femoral POS N
PWV, POS N
and POS N
waistline POS N
were POS N
significantly POS N
related POS N
to POS N
c-IMT POS N
increment. POS N

In POS N
a POS N
full-model POS N
logistic POS N
regression, POS N
significant POS N
risk POS N
factors POS N
for POS N
an POS N
increase POS N
in POS N
IMT POS N
of POS N
≥1.5 POS N
z-scores POS N
were POS N
carotid-femoral POS N
PWV POS N
(odds POS N
ratio: POS N
1.119, POS N
confidence POS N
interval: POS N
1.018, POS N
1.230, POS N
p POS N
= POS N
0.020 POS N
< POS N
0.05) POS N
at POS N
first POS N
measurement. POS N

Systolic POS N
or POS N
diastolic POS N
blood POS N
pressure, POS N
homocysteine, POS N
carotid-femoral POS N
PWV, POS N
and POS N
waistline POS N
were POS N
significantly POS N
related POS N
to POS N
c-IMT POS N
increment. POS N

The POS N
conclusion POS N
of POS N
the POS N
study POS N
was POS N
that POS N
longitudinal POS N
c-IMT POS N
measurements POS N
revealed POS N
progression POS N
in POS N
subclinical POS N
atherosclerosis POS N
during POS N
a POS N
four-year POS N
period POS N
in POS N
a POS N
hypertensive POS N
old-aged POS N
cohort. POS N

Systolic POS N
or POS N
diastolic POS N
blood POS N
pressure, POS N
homocysteine, POS N
carotid-femoral POS N
PWV, POS N
and POS N
waistline POS N
were POS N
significantly POS N
related POS N
to POS N
c-IMT POS N
increment. POS N

By POS N
lifestyle POS N
and POS N
medical POS N
intervention POS N
to POS N
control POS N
these POS N
risk POS N
factors POS N
may POS N
prevent POS N
progression POS N
of POS N
c-IMT POS N
in POS N
old-aged POS N
cohort POS N
with POS N
hypertension. POS N

By POS N
lifestyle POS N
and POS N
medical POS N
intervention POS N
to POS N
control POS N
these POS N
risk POS N
factors POS N
may POS N
prevent POS N
progression POS N
of POS N
c-IMT POS N
in POS N
old-aged POS N
cohort POS N
with POS N
hypertension. POS N

Hypertension POS N
is POS N
a POS N
generally POS N
accepted POS N
atherogenic POS N
risk POS N
factor. POS N

By POS N
lifestyle POS N
and POS N
medical POS N
intervention POS N
to POS N
control POS N
these POS N
risk POS N
factors POS N
may POS N
prevent POS N
progression POS N
of POS N
c-IMT POS N
in POS N
old-aged POS N
cohort POS N
with POS N
hypertension. POS N

The POS N
results POS N
showed POS N
that POS N
mean POS N
c-IMT POS N
z-scores POS N
increased POS N
significantly POS N
during POS N
4 POS N
years POS N
(0.002 POS N
± POS N
0.003, POS N
p POS N
< POS N
0.001) POS N
as POS N
well POS N
as POS N
carotid-femoral POS N
PWV POS N
(13.99 POS N
± POS N
2.74, POS N
p POS N
< POS N
0.01) POS N
and POS N
total POS N
cholesterol POS N
(6.97 POS N
± POS N
1.08, POS N
p POS N
< POS N
0.001). POS N

By POS N
lifestyle POS N
and POS N
medical POS N
intervention POS N
to POS N
control POS N
these POS N
risk POS N
factors POS N
may POS N
prevent POS N
progression POS N
of POS N
c-IMT POS N
in POS N
old-aged POS N
cohort POS N
with POS N
hypertension. POS N

Linear POS N
regression POS N
showed POS N
statistically POS N
significant POS N
associations POS N
between POS N
systolic POS N
blood POS N
pressure, POS N
diastolic POS N
blood POS N
pressure, POS N
C-reactive POS N
protein, POS N
lip-line, POS N
and POS N
heart POS N
rate POS N
with POS N
c-IMT POS N
z-scores POS N
of POS N
>1.5SD POS N
in POS N
the POS N
fully POS N
adjusted POS N
models POS N
and POS N
the POS N
p POS N
values POS N
were POS N
0.000, POS N
0.000, POS N
0.017, POS N
0.001, POS N
and POS N
0.044, POS N
respectively POS N
. POS N

By POS N
lifestyle POS N
and POS N
medical POS N
intervention POS N
to POS N
control POS N
these POS N
risk POS N
factors POS N
may POS N
prevent POS N
progression POS N
of POS N
c-IMT POS N
in POS N
old-aged POS N
cohort POS N
with POS N
hypertension. POS N

In POS N
a POS N
full-model POS N
logistic POS N
regression, POS N
significant POS N
risk POS N
factors POS N
for POS N
an POS N
increase POS N
in POS N
IMT POS N
of POS N
≥1.5 POS N
z-scores POS N
were POS N
carotid-femoral POS N
PWV POS N
(odds POS N
ratio: POS N
1.119, POS N
confidence POS N
interval: POS N
1.018, POS N
1.230, POS N
p POS N
= POS N
0.020 POS N
< POS N
0.05) POS N
at POS N
first POS N
measurement. POS N

By POS N
lifestyle POS N
and POS N
medical POS N
intervention POS N
to POS N
control POS N
these POS N
risk POS N
factors POS N
may POS N
prevent POS N
progression POS N
of POS N
c-IMT POS N
in POS N
old-aged POS N
cohort POS N
with POS N
hypertension. POS N

The POS N
conclusion POS N
of POS N
the POS N
study POS N
was POS N
that POS N
longitudinal POS N
c-IMT POS N
measurements POS N
revealed POS N
progression POS N
in POS N
subclinical POS N
atherosclerosis POS N
during POS N
a POS N
four-year POS N
period POS N
in POS N
a POS N
hypertensive POS N
old-aged POS N
cohort. POS N

By POS N
lifestyle POS N
and POS N
medical POS N
intervention POS N
to POS N
control POS N
these POS N
risk POS N
factors POS N
may POS N
prevent POS N
progression POS N
of POS N
c-IMT POS N
in POS N
old-aged POS N
cohort POS N
with POS N
hypertension. POS N

Systolic POS N
or POS N
diastolic POS N
blood POS N
pressure, POS N
homocysteine, POS N
carotid-femoral POS N
PWV, POS N
and POS N
waistline POS N
were POS N
significantly POS N
related POS N
to POS N
c-IMT POS N
increment. POS N

Larger POS N
sample POS N
size POS N
is POS N
presumably POS N
needed POS N
to POS N
assess POS N
the POS N
effect POS N
of POS N
RIPC POS N
for POS N
patients POS N
with POS N
diabetes POS N
mellitus. POS N

Remote POS N
ischemic POS N
preconditioning POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
acute POS N
kidney POS N
injury POS N
in POS N
non-diabetic POS N
patients POS N
undergoing POS N
PCI. POS N

Larger POS N
sample POS N
size POS N
is POS N
presumably POS N
needed POS N
to POS N
assess POS N
the POS N
effect POS N
of POS N
RIPC POS N
for POS N
patients POS N
with POS N
diabetes POS N
mellitus. POS N

RIPC POS N
significantly POS N
reduced POS N
CIN POS N
incidence POS N
in POS N
the POS N
overall POS N
population POS N
(12.1% POS N
vs. POS N
26.1%, POS N
p=0.01, POS N
with POS N
a POS N
NNT=9) POS N
and POS N
in POS N
non-diabetic POS N
patients POS N
(9.2% POS N
vs. POS N
25.0%, POS N
p=0.02), POS N
but POS N
showed POS N
no POS N
benefit POS N
in POS N
diabetics POS N
(16.7% POS N
vs. POS N
28.2%, POS N
p=0.21). POS N

Larger POS N
sample POS N
size POS N
is POS N
presumably POS N
needed POS N
to POS N
assess POS N
the POS N
effect POS N
of POS N
RIPC POS N
for POS N
patients POS N
with POS N
diabetes POS N
mellitus. POS N

A POS N
trend POS N
for POS N
lower POS N
PMI POS N
was POS N
seen POS N
in POS N
the POS N
intervention POS N
arm POS N
(creatine POS N
kinase POS N
- POS N
muscle POS N
brain POS N
>5 POS N
URL; POS N
8.4% POS N
vs. POS N
16.4%, POS N
p=0.07; POS N
troponin POS N
T POS N
>5 POS N
URL; POS N
27% POS N
vs. POS N
38%, POS N
p=0.21). POS N

Remote POS N
ischemic POS N
preconditioning POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
acute POS N
kidney POS N
injury POS N
in POS N
non-diabetic POS N
patients POS N
undergoing POS N
PCI. POS N

Larger POS N
sample POS N
size POS N
is POS N
presumably POS N
needed POS N
to POS N
assess POS N
the POS N
effect POS N
of POS N
RIPC POS N
for POS N
patients POS N
with POS N
diabetes POS N
mellitus. POS N

Remote POS N
ischemic POS N
preconditioning POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
acute POS N
kidney POS N
injury POS N
in POS N
non-diabetic POS N
patients POS N
undergoing POS N
PCI. POS N

RIPC POS N
significantly POS N
reduced POS N
CIN POS N
incidence POS N
in POS N
the POS N
overall POS N
population POS N
(12.1% POS N
vs. POS N
26.1%, POS N
p=0.01, POS N
with POS N
a POS N
NNT=9) POS N
and POS N
in POS N
non-diabetic POS N
patients POS N
(9.2% POS N
vs. POS N
25.0%, POS N
p=0.02), POS N
but POS N
showed POS N
no POS N
benefit POS N
in POS N
diabetics POS N
(16.7% POS N
vs. POS N
28.2%, POS N
p=0.21). POS N

Remote POS N
ischemic POS N
preconditioning POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
acute POS N
kidney POS N
injury POS N
in POS N
non-diabetic POS N
patients POS N
undergoing POS N
PCI. POS N

A POS N
trend POS N
for POS N
lower POS N
PMI POS N
was POS N
seen POS N
in POS N
the POS N
intervention POS N
arm POS N
(creatine POS N
kinase POS N
- POS N
muscle POS N
brain POS N
>5 POS N
URL; POS N
8.4% POS N
vs. POS N
16.4%, POS N
p=0.07; POS N
troponin POS N
T POS N
>5 POS N
URL; POS N
27% POS N
vs. POS N
38%, POS N
p=0.21). POS N

RIPC POS N
significantly POS N
reduced POS N
CIN POS N
incidence POS N
in POS N
the POS N
overall POS N
population POS N
(12.1% POS N
vs. POS N
26.1%, POS N
p=0.01, POS N
with POS N
a POS N
NNT=9) POS N
and POS N
in POS N
non-diabetic POS N
patients POS N
(9.2% POS N
vs. POS N
25.0%, POS N
p=0.02), POS N
but POS N
showed POS N
no POS N
benefit POS N
in POS N
diabetics POS N
(16.7% POS N
vs. POS N
28.2%, POS N
p=0.21). POS N

Larger POS N
sample POS N
size POS N
is POS N
presumably POS N
needed POS N
to POS N
assess POS N
the POS N
effect POS N
of POS N
RIPC POS N
for POS N
patients POS N
with POS N
diabetes POS N
mellitus. POS N

RIPC POS N
significantly POS N
reduced POS N
CIN POS N
incidence POS N
in POS N
the POS N
overall POS N
population POS N
(12.1% POS N
vs. POS N
26.1%, POS N
p=0.01, POS N
with POS N
a POS N
NNT=9) POS N
and POS N
in POS N
non-diabetic POS N
patients POS N
(9.2% POS N
vs. POS N
25.0%, POS N
p=0.02), POS N
but POS N
showed POS N
no POS N
benefit POS N
in POS N
diabetics POS N
(16.7% POS N
vs. POS N
28.2%, POS N
p=0.21). POS N

Remote POS N
ischemic POS N
preconditioning POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
acute POS N
kidney POS N
injury POS N
in POS N
non-diabetic POS N
patients POS N
undergoing POS N
PCI. POS N

RIPC POS N
significantly POS N
reduced POS N
CIN POS N
incidence POS N
in POS N
the POS N
overall POS N
population POS N
(12.1% POS N
vs. POS N
26.1%, POS N
p=0.01, POS N
with POS N
a POS N
NNT=9) POS N
and POS N
in POS N
non-diabetic POS N
patients POS N
(9.2% POS N
vs. POS N
25.0%, POS N
p=0.02), POS N
but POS N
showed POS N
no POS N
benefit POS N
in POS N
diabetics POS N
(16.7% POS N
vs. POS N
28.2%, POS N
p=0.21). POS N

A POS N
trend POS N
for POS N
lower POS N
PMI POS N
was POS N
seen POS N
in POS N
the POS N
intervention POS N
arm POS N
(creatine POS N
kinase POS N
- POS N
muscle POS N
brain POS N
>5 POS N
URL; POS N
8.4% POS N
vs. POS N
16.4%, POS N
p=0.07; POS N
troponin POS N
T POS N
>5 POS N
URL; POS N
27% POS N
vs. POS N
38%, POS N
p=0.21). POS N

A POS N
trend POS N
for POS N
lower POS N
PMI POS N
was POS N
seen POS N
in POS N
the POS N
intervention POS N
arm POS N
(creatine POS N
kinase POS N
- POS N
muscle POS N
brain POS N
>5 POS N
URL; POS N
8.4% POS N
vs. POS N
16.4%, POS N
p=0.07; POS N
troponin POS N
T POS N
>5 POS N
URL; POS N
27% POS N
vs. POS N
38%, POS N
p=0.21). POS N

Larger POS N
sample POS N
size POS N
is POS N
presumably POS N
needed POS N
to POS N
assess POS N
the POS N
effect POS N
of POS N
RIPC POS N
for POS N
patients POS N
with POS N
diabetes POS N
mellitus. POS N

A POS N
trend POS N
for POS N
lower POS N
PMI POS N
was POS N
seen POS N
in POS N
the POS N
intervention POS N
arm POS N
(creatine POS N
kinase POS N
- POS N
muscle POS N
brain POS N
>5 POS N
URL; POS N
8.4% POS N
vs. POS N
16.4%, POS N
p=0.07; POS N
troponin POS N
T POS N
>5 POS N
URL; POS N
27% POS N
vs. POS N
38%, POS N
p=0.21). POS N

Remote POS N
ischemic POS N
preconditioning POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
acute POS N
kidney POS N
injury POS N
in POS N
non-diabetic POS N
patients POS N
undergoing POS N
PCI. POS N

A POS N
trend POS N
for POS N
lower POS N
PMI POS N
was POS N
seen POS N
in POS N
the POS N
intervention POS N
arm POS N
(creatine POS N
kinase POS N
- POS N
muscle POS N
brain POS N
>5 POS N
URL; POS N
8.4% POS N
vs. POS N
16.4%, POS N
p=0.07; POS N
troponin POS N
T POS N
>5 POS N
URL; POS N
27% POS N
vs. POS N
38%, POS N
p=0.21). POS N

RIPC POS N
significantly POS N
reduced POS N
CIN POS N
incidence POS N
in POS N
the POS N
overall POS N
population POS N
(12.1% POS N
vs. POS N
26.1%, POS N
p=0.01, POS N
with POS N
a POS N
NNT=9) POS N
and POS N
in POS N
non-diabetic POS N
patients POS N
(9.2% POS N
vs. POS N
25.0%, POS N
p=0.02), POS N
but POS N
showed POS N
no POS N
benefit POS N
in POS N
diabetics POS N
(16.7% POS N
vs. POS N
28.2%, POS N
p=0.21). POS N

Vesatolimod POS N
was POS N
safe POS N
and POS N
well-tolerated POS N
in POS N
patients POS N
with POS N
CHB, POS N
demonstrating POS N
consistent POS N
dose-dependent POS N
pharmacodynamic POS N
induction POS N
of POS N
ISG15 POS N
without POS N
significant POS N
systemic POS N
induction POS N
of POS N
IFNα POS N
expression POS N
or POS N
related POS N
symptoms. POS N

Most POS N
(41-80%) POS N
experienced POS N
≥1 POS N
AE POS N
during POS N
the POS N
study POS N
with POS N
the POS N
majority POS N
of POS N
AEs POS N
mild POS N
or POS N
moderate POS N
in POS N
severity. POS N

Vesatolimod POS N
was POS N
safe POS N
and POS N
well-tolerated POS N
in POS N
patients POS N
with POS N
CHB, POS N
demonstrating POS N
consistent POS N
dose-dependent POS N
pharmacodynamic POS N
induction POS N
of POS N
ISG15 POS N
without POS N
significant POS N
systemic POS N
induction POS N
of POS N
IFNα POS N
expression POS N
or POS N
related POS N
symptoms. POS N

No POS N
significant POS N
declines POS N
in POS N
HBsAg POS N
were POS N
observed POS N
at POS N
the POS N
primary POS N
(Week POS N
24) POS N
or POS N
secondary POS N
endpoints POS N
(Weeks POS N
4, POS N
8, POS N
12, POS N
and POS N
48). POS N

Vesatolimod POS N
was POS N
safe POS N
and POS N
well-tolerated POS N
in POS N
patients POS N
with POS N
CHB, POS N
demonstrating POS N
consistent POS N
dose-dependent POS N
pharmacodynamic POS N
induction POS N
of POS N
ISG15 POS N
without POS N
significant POS N
systemic POS N
induction POS N
of POS N
IFNα POS N
expression POS N
or POS N
related POS N
symptoms. POS N

ISG15 POS N
induction POS N
was POS N
dose-dependent POS N
and POS N
consistent POS N
after POS N
repeat POS N
dosing, POS N
returning POS N
closer POS N
to POS N
baseline POS N
by POS N
one POS N
week POS N
after POS N
treatment POS N
at POS N
all POS N
dose POS N
levels; POS N

Vesatolimod POS N
was POS N
safe POS N
and POS N
well-tolerated POS N
in POS N
patients POS N
with POS N
CHB, POS N
demonstrating POS N
consistent POS N
dose-dependent POS N
pharmacodynamic POS N
induction POS N
of POS N
ISG15 POS N
without POS N
significant POS N
systemic POS N
induction POS N
of POS N
IFNα POS N
expression POS N
or POS N
related POS N
symptoms. POS N

no POS N
patient POS N
demonstrated POS N
significant POS N
serum POS N
interferon POS N
alpha POS N
(IFNα) POS N
expression POS N
at POS N
any POS N
timepoint POS N
evaluated. POS N

Vesatolimod POS N
was POS N
safe POS N
and POS N
well-tolerated POS N
in POS N
patients POS N
with POS N
CHB, POS N
demonstrating POS N
consistent POS N
dose-dependent POS N
pharmacodynamic POS N
induction POS N
of POS N
ISG15 POS N
without POS N
significant POS N
systemic POS N
induction POS N
of POS N
IFNα POS N
expression POS N
or POS N
related POS N
symptoms. POS N

Multivariate POS N
analyses POS N
showed POS N
that POS N
≥2-fold POS N
ISG15 POS N
induction POS N
is POS N
associated POS N
with POS N
2- POS N
or POS N
4-mg POS N
vesatolimod POS N
dose POS N
and POS N
female POS N
sex. POS N

Most POS N
(41-80%) POS N
experienced POS N
≥1 POS N
AE POS N
during POS N
the POS N
study POS N
with POS N
the POS N
majority POS N
of POS N
AEs POS N
mild POS N
or POS N
moderate POS N
in POS N
severity. POS N

Vesatolimod POS N
was POS N
safe POS N
and POS N
well-tolerated POS N
in POS N
patients POS N
with POS N
CHB, POS N
demonstrating POS N
consistent POS N
dose-dependent POS N
pharmacodynamic POS N
induction POS N
of POS N
ISG15 POS N
without POS N
significant POS N
systemic POS N
induction POS N
of POS N
IFNα POS N
expression POS N
or POS N
related POS N
symptoms. POS N

Most POS N
(41-80%) POS N
experienced POS N
≥1 POS N
AE POS N
during POS N
the POS N
study POS N
with POS N
the POS N
majority POS N
of POS N
AEs POS N
mild POS N
or POS N
moderate POS N
in POS N
severity. POS N

No POS N
significant POS N
declines POS N
in POS N
HBsAg POS N
were POS N
observed POS N
at POS N
the POS N
primary POS N
(Week POS N
24) POS N
or POS N
secondary POS N
endpoints POS N
(Weeks POS N
4, POS N
8, POS N
12, POS N
and POS N
48). POS N

Most POS N
(41-80%) POS N
experienced POS N
≥1 POS N
AE POS N
during POS N
the POS N
study POS N
with POS N
the POS N
majority POS N
of POS N
AEs POS N
mild POS N
or POS N
moderate POS N
in POS N
severity. POS N

ISG15 POS N
induction POS N
was POS N
dose-dependent POS N
and POS N
consistent POS N
after POS N
repeat POS N
dosing, POS N
returning POS N
closer POS N
to POS N
baseline POS N
by POS N
one POS N
week POS N
after POS N
treatment POS N
at POS N
all POS N
dose POS N
levels; POS N

Most POS N
(41-80%) POS N
experienced POS N
≥1 POS N
AE POS N
during POS N
the POS N
study POS N
with POS N
the POS N
majority POS N
of POS N
AEs POS N
mild POS N
or POS N
moderate POS N
in POS N
severity. POS N

no POS N
patient POS N
demonstrated POS N
significant POS N
serum POS N
interferon POS N
alpha POS N
(IFNα) POS N
expression POS N
at POS N
any POS N
timepoint POS N
evaluated. POS N

Most POS N
(41-80%) POS N
experienced POS N
≥1 POS N
AE POS N
during POS N
the POS N
study POS N
with POS N
the POS N
majority POS N
of POS N
AEs POS N
mild POS N
or POS N
moderate POS N
in POS N
severity. POS N

Multivariate POS N
analyses POS N
showed POS N
that POS N
≥2-fold POS N
ISG15 POS N
induction POS N
is POS N
associated POS N
with POS N
2- POS N
or POS N
4-mg POS N
vesatolimod POS N
dose POS N
and POS N
female POS N
sex. POS N

No POS N
significant POS N
declines POS N
in POS N
HBsAg POS N
were POS N
observed POS N
at POS N
the POS N
primary POS N
(Week POS N
24) POS N
or POS N
secondary POS N
endpoints POS N
(Weeks POS N
4, POS N
8, POS N
12, POS N
and POS N
48). POS N

Vesatolimod POS N
was POS N
safe POS N
and POS N
well-tolerated POS N
in POS N
patients POS N
with POS N
CHB, POS N
demonstrating POS N
consistent POS N
dose-dependent POS N
pharmacodynamic POS N
induction POS N
of POS N
ISG15 POS N
without POS N
significant POS N
systemic POS N
induction POS N
of POS N
IFNα POS N
expression POS N
or POS N
related POS N
symptoms. POS N

No POS N
significant POS N
declines POS N
in POS N
HBsAg POS N
were POS N
observed POS N
at POS N
the POS N
primary POS N
(Week POS N
24) POS N
or POS N
secondary POS N
endpoints POS N
(Weeks POS N
4, POS N
8, POS N
12, POS N
and POS N
48). POS N

Most POS N
(41-80%) POS N
experienced POS N
≥1 POS N
AE POS N
during POS N
the POS N
study POS N
with POS N
the POS N
majority POS N
of POS N
AEs POS N
mild POS N
or POS N
moderate POS N
in POS N
severity. POS N

No POS N
significant POS N
declines POS N
in POS N
HBsAg POS N
were POS N
observed POS N
at POS N
the POS N
primary POS N
(Week POS N
24) POS N
or POS N
secondary POS N
endpoints POS N
(Weeks POS N
4, POS N
8, POS N
12, POS N
and POS N
48). POS N

ISG15 POS N
induction POS N
was POS N
dose-dependent POS N
and POS N
consistent POS N
after POS N
repeat POS N
dosing, POS N
returning POS N
closer POS N
to POS N
baseline POS N
by POS N
one POS N
week POS N
after POS N
treatment POS N
at POS N
all POS N
dose POS N
levels; POS N

No POS N
significant POS N
declines POS N
in POS N
HBsAg POS N
were POS N
observed POS N
at POS N
the POS N
primary POS N
(Week POS N
24) POS N
or POS N
secondary POS N
endpoints POS N
(Weeks POS N
4, POS N
8, POS N
12, POS N
and POS N
48). POS N

no POS N
patient POS N
demonstrated POS N
significant POS N
serum POS N
interferon POS N
alpha POS N
(IFNα) POS N
expression POS N
at POS N
any POS N
timepoint POS N
evaluated. POS N

No POS N
significant POS N
declines POS N
in POS N
HBsAg POS N
were POS N
observed POS N
at POS N
the POS N
primary POS N
(Week POS N
24) POS N
or POS N
secondary POS N
endpoints POS N
(Weeks POS N
4, POS N
8, POS N
12, POS N
and POS N
48). POS N

Multivariate POS N
analyses POS N
showed POS N
that POS N
≥2-fold POS N
ISG15 POS N
induction POS N
is POS N
associated POS N
with POS N
2- POS N
or POS N
4-mg POS N
vesatolimod POS N
dose POS N
and POS N
female POS N
sex. POS N

ISG15 POS N
induction POS N
was POS N
dose-dependent POS N
and POS N
consistent POS N
after POS N
repeat POS N
dosing, POS N
returning POS N
closer POS N
to POS N
baseline POS N
by POS N
one POS N
week POS N
after POS N
treatment POS N
at POS N
all POS N
dose POS N
levels; POS N

Vesatolimod POS N
was POS N
safe POS N
and POS N
well-tolerated POS N
in POS N
patients POS N
with POS N
CHB, POS N
demonstrating POS N
consistent POS N
dose-dependent POS N
pharmacodynamic POS N
induction POS N
of POS N
ISG15 POS N
without POS N
significant POS N
systemic POS N
induction POS N
of POS N
IFNα POS N
expression POS N
or POS N
related POS N
symptoms. POS N

ISG15 POS N
induction POS N
was POS N
dose-dependent POS N
and POS N
consistent POS N
after POS N
repeat POS N
dosing, POS N
returning POS N
closer POS N
to POS N
baseline POS N
by POS N
one POS N
week POS N
after POS N
treatment POS N
at POS N
all POS N
dose POS N
levels; POS N

Most POS N
(41-80%) POS N
experienced POS N
≥1 POS N
AE POS N
during POS N
the POS N
study POS N
with POS N
the POS N
majority POS N
of POS N
AEs POS N
mild POS N
or POS N
moderate POS N
in POS N
severity. POS N

ISG15 POS N
induction POS N
was POS N
dose-dependent POS N
and POS N
consistent POS N
after POS N
repeat POS N
dosing, POS N
returning POS N
closer POS N
to POS N
baseline POS N
by POS N
one POS N
week POS N
after POS N
treatment POS N
at POS N
all POS N
dose POS N
levels; POS N

No POS N
significant POS N
declines POS N
in POS N
HBsAg POS N
were POS N
observed POS N
at POS N
the POS N
primary POS N
(Week POS N
24) POS N
or POS N
secondary POS N
endpoints POS N
(Weeks POS N
4, POS N
8, POS N
12, POS N
and POS N
48). POS N

ISG15 POS N
induction POS N
was POS N
dose-dependent POS N
and POS N
consistent POS N
after POS N
repeat POS N
dosing, POS N
returning POS N
closer POS N
to POS N
baseline POS N
by POS N
one POS N
week POS N
after POS N
treatment POS N
at POS N
all POS N
dose POS N
levels; POS N

no POS N
patient POS N
demonstrated POS N
significant POS N
serum POS N
interferon POS N
alpha POS N
(IFNα) POS N
expression POS N
at POS N
any POS N
timepoint POS N
evaluated. POS N

ISG15 POS N
induction POS N
was POS N
dose-dependent POS N
and POS N
consistent POS N
after POS N
repeat POS N
dosing, POS N
returning POS N
closer POS N
to POS N
baseline POS N
by POS N
one POS N
week POS N
after POS N
treatment POS N
at POS N
all POS N
dose POS N
levels; POS N

Multivariate POS N
analyses POS N
showed POS N
that POS N
≥2-fold POS N
ISG15 POS N
induction POS N
is POS N
associated POS N
with POS N
2- POS N
or POS N
4-mg POS N
vesatolimod POS N
dose POS N
and POS N
female POS N
sex. POS N

no POS N
patient POS N
demonstrated POS N
significant POS N
serum POS N
interferon POS N
alpha POS N
(IFNα) POS N
expression POS N
at POS N
any POS N
timepoint POS N
evaluated. POS N

Vesatolimod POS N
was POS N
safe POS N
and POS N
well-tolerated POS N
in POS N
patients POS N
with POS N
CHB, POS N
demonstrating POS N
consistent POS N
dose-dependent POS N
pharmacodynamic POS N
induction POS N
of POS N
ISG15 POS N
without POS N
significant POS N
systemic POS N
induction POS N
of POS N
IFNα POS N
expression POS N
or POS N
related POS N
symptoms. POS N

no POS N
patient POS N
demonstrated POS N
significant POS N
serum POS N
interferon POS N
alpha POS N
(IFNα) POS N
expression POS N
at POS N
any POS N
timepoint POS N
evaluated. POS N

Most POS N
(41-80%) POS N
experienced POS N
≥1 POS N
AE POS N
during POS N
the POS N
study POS N
with POS N
the POS N
majority POS N
of POS N
AEs POS N
mild POS N
or POS N
moderate POS N
in POS N
severity. POS N

no POS N
patient POS N
demonstrated POS N
significant POS N
serum POS N
interferon POS N
alpha POS N
(IFNα) POS N
expression POS N
at POS N
any POS N
timepoint POS N
evaluated. POS N

No POS N
significant POS N
declines POS N
in POS N
HBsAg POS N
were POS N
observed POS N
at POS N
the POS N
primary POS N
(Week POS N
24) POS N
or POS N
secondary POS N
endpoints POS N
(Weeks POS N
4, POS N
8, POS N
12, POS N
and POS N
48). POS N

no POS N
patient POS N
demonstrated POS N
significant POS N
serum POS N
interferon POS N
alpha POS N
(IFNα) POS N
expression POS N
at POS N
any POS N
timepoint POS N
evaluated. POS N

ISG15 POS N
induction POS N
was POS N
dose-dependent POS N
and POS N
consistent POS N
after POS N
repeat POS N
dosing, POS N
returning POS N
closer POS N
to POS N
baseline POS N
by POS N
one POS N
week POS N
after POS N
treatment POS N
at POS N
all POS N
dose POS N
levels; POS N

no POS N
patient POS N
demonstrated POS N
significant POS N
serum POS N
interferon POS N
alpha POS N
(IFNα) POS N
expression POS N
at POS N
any POS N
timepoint POS N
evaluated. POS N

Multivariate POS N
analyses POS N
showed POS N
that POS N
≥2-fold POS N
ISG15 POS N
induction POS N
is POS N
associated POS N
with POS N
2- POS N
or POS N
4-mg POS N
vesatolimod POS N
dose POS N
and POS N
female POS N
sex. POS N

Multivariate POS N
analyses POS N
showed POS N
that POS N
≥2-fold POS N
ISG15 POS N
induction POS N
is POS N
associated POS N
with POS N
2- POS N
or POS N
4-mg POS N
vesatolimod POS N
dose POS N
and POS N
female POS N
sex. POS N

Vesatolimod POS N
was POS N
safe POS N
and POS N
well-tolerated POS N
in POS N
patients POS N
with POS N
CHB, POS N
demonstrating POS N
consistent POS N
dose-dependent POS N
pharmacodynamic POS N
induction POS N
of POS N
ISG15 POS N
without POS N
significant POS N
systemic POS N
induction POS N
of POS N
IFNα POS N
expression POS N
or POS N
related POS N
symptoms. POS N

Multivariate POS N
analyses POS N
showed POS N
that POS N
≥2-fold POS N
ISG15 POS N
induction POS N
is POS N
associated POS N
with POS N
2- POS N
or POS N
4-mg POS N
vesatolimod POS N
dose POS N
and POS N
female POS N
sex. POS N

Most POS N
(41-80%) POS N
experienced POS N
≥1 POS N
AE POS N
during POS N
the POS N
study POS N
with POS N
the POS N
majority POS N
of POS N
AEs POS N
mild POS N
or POS N
moderate POS N
in POS N
severity. POS N

Multivariate POS N
analyses POS N
showed POS N
that POS N
≥2-fold POS N
ISG15 POS N
induction POS N
is POS N
associated POS N
with POS N
2- POS N
or POS N
4-mg POS N
vesatolimod POS N
dose POS N
and POS N
female POS N
sex. POS N

No POS N
significant POS N
declines POS N
in POS N
HBsAg POS N
were POS N
observed POS N
at POS N
the POS N
primary POS N
(Week POS N
24) POS N
or POS N
secondary POS N
endpoints POS N
(Weeks POS N
4, POS N
8, POS N
12, POS N
and POS N
48). POS N

Multivariate POS N
analyses POS N
showed POS N
that POS N
≥2-fold POS N
ISG15 POS N
induction POS N
is POS N
associated POS N
with POS N
2- POS N
or POS N
4-mg POS N
vesatolimod POS N
dose POS N
and POS N
female POS N
sex. POS N

ISG15 POS N
induction POS N
was POS N
dose-dependent POS N
and POS N
consistent POS N
after POS N
repeat POS N
dosing, POS N
returning POS N
closer POS N
to POS N
baseline POS N
by POS N
one POS N
week POS N
after POS N
treatment POS N
at POS N
all POS N
dose POS N
levels; POS N

Multivariate POS N
analyses POS N
showed POS N
that POS N
≥2-fold POS N
ISG15 POS N
induction POS N
is POS N
associated POS N
with POS N
2- POS N
or POS N
4-mg POS N
vesatolimod POS N
dose POS N
and POS N
female POS N
sex. POS N

no POS N
patient POS N
demonstrated POS N
significant POS N
serum POS N
interferon POS N
alpha POS N
(IFNα) POS N
expression POS N
at POS N
any POS N
timepoint POS N
evaluated. POS N

Transfusion-free POS N
(P POS N
=.0012) POS N
survival POS N
and POS N
transfusion- POS N
and POS N
severe POS N
anemia-free POS N
survival POS N
(P POS N
=.0001) POS N
were POS N
significantly POS N
greater POS N
in POS N
the POS N
epoetin POS N
beta POS N
group POS N
versus POS N
placebo POS N
(Wald POS N
chi(2) POS N
test), POS N
giving POS N
a POS N
relative POS N
risk POS N
reduction POS N
of POS N
43% POS N
and POS N
51%, POS N
respectively. POS N

The POS N
response POS N
rate POS N
was POS N
67% POS N
and POS N
27% POS N
in POS N
the POS N
epoetin POS N
beta POS N
versus POS N
the POS N
placebo POS N
group, POS N
respectively POS N
(P POS N
<.0001). POS N

Transfusion-free POS N
(P POS N
=.0012) POS N
survival POS N
and POS N
transfusion- POS N
and POS N
severe POS N
anemia-free POS N
survival POS N
(P POS N
=.0001) POS N
were POS N
significantly POS N
greater POS N
in POS N
the POS N
epoetin POS N
beta POS N
group POS N
versus POS N
placebo POS N
(Wald POS N
chi(2) POS N
test), POS N
giving POS N
a POS N
relative POS N
risk POS N
reduction POS N
of POS N
43% POS N
and POS N
51%, POS N
respectively. POS N

After POS N
12 POS N
and POS N
16 POS N
weeks POS N
of POS N
treatment, POS N
QOL POS N
significantly POS N
improved POS N
in POS N
the POS N
epoetin POS N
beta POS N
group POS N
compared POS N
with POS N
placebo POS N
(P POS N
<.05); POS N

Transfusion-free POS N
(P POS N
=.0012) POS N
survival POS N
and POS N
transfusion- POS N
and POS N
severe POS N
anemia-free POS N
survival POS N
(P POS N
=.0001) POS N
were POS N
significantly POS N
greater POS N
in POS N
the POS N
epoetin POS N
beta POS N
group POS N
versus POS N
placebo POS N
(Wald POS N
chi(2) POS N
test), POS N
giving POS N
a POS N
relative POS N
risk POS N
reduction POS N
of POS N
43% POS N
and POS N
51%, POS N
respectively. POS N

this POS N
improvement POS N
correlated POS N
with POS N
an POS N
increase POS N
in POS N
Hb POS N
concentration POS N
(> POS N
or POS N
= POS N
2 POS N
g/dL). POS N

Transfusion-free POS N
(P POS N
=.0012) POS N
survival POS N
and POS N
transfusion- POS N
and POS N
severe POS N
anemia-free POS N
survival POS N
(P POS N
=.0001) POS N
were POS N
significantly POS N
greater POS N
in POS N
the POS N
epoetin POS N
beta POS N
group POS N
versus POS N
placebo POS N
(Wald POS N
chi(2) POS N
test), POS N
giving POS N
a POS N
relative POS N
risk POS N
reduction POS N
of POS N
43% POS N
and POS N
51%, POS N
respectively. POS N

Many POS N
severely POS N
anemic POS N
and POS N
transfusion-dependent POS N
patients POS N
with POS N
advanced POS N
MM, POS N
NHL, POS N
and POS N
CLL POS N
and POS N
a POS N
low POS N
performance POS N
status POS N
benefited POS N
from POS N
epoetin POS N
therapy, POS N
with POS N
elimination POS N
of POS N
severe POS N
anemia POS N
and POS N
transfusion POS N
need, POS N
and POS N
improvement POS N
in POS N
QOL. POS N

The POS N
response POS N
rate POS N
was POS N
67% POS N
and POS N
27% POS N
in POS N
the POS N
epoetin POS N
beta POS N
versus POS N
the POS N
placebo POS N
group, POS N
respectively POS N
(P POS N
<.0001). POS N

Transfusion-free POS N
(P POS N
=.0012) POS N
survival POS N
and POS N
transfusion- POS N
and POS N
severe POS N
anemia-free POS N
survival POS N
(P POS N
=.0001) POS N
were POS N
significantly POS N
greater POS N
in POS N
the POS N
epoetin POS N
beta POS N
group POS N
versus POS N
placebo POS N
(Wald POS N
chi(2) POS N
test), POS N
giving POS N
a POS N
relative POS N
risk POS N
reduction POS N
of POS N
43% POS N
and POS N
51%, POS N
respectively. POS N

The POS N
response POS N
rate POS N
was POS N
67% POS N
and POS N
27% POS N
in POS N
the POS N
epoetin POS N
beta POS N
versus POS N
the POS N
placebo POS N
group, POS N
respectively POS N
(P POS N
<.0001). POS N

After POS N
12 POS N
and POS N
16 POS N
weeks POS N
of POS N
treatment, POS N
QOL POS N
significantly POS N
improved POS N
in POS N
the POS N
epoetin POS N
beta POS N
group POS N
compared POS N
with POS N
placebo POS N
(P POS N
<.05); POS N

The POS N
response POS N
rate POS N
was POS N
67% POS N
and POS N
27% POS N
in POS N
the POS N
epoetin POS N
beta POS N
versus POS N
the POS N
placebo POS N
group, POS N
respectively POS N
(P POS N
<.0001). POS N

this POS N
improvement POS N
correlated POS N
with POS N
an POS N
increase POS N
in POS N
Hb POS N
concentration POS N
(> POS N
or POS N
= POS N
2 POS N
g/dL). POS N

The POS N
response POS N
rate POS N
was POS N
67% POS N
and POS N
27% POS N
in POS N
the POS N
epoetin POS N
beta POS N
versus POS N
the POS N
placebo POS N
group, POS N
respectively POS N
(P POS N
<.0001). POS N

Many POS N
severely POS N
anemic POS N
and POS N
transfusion-dependent POS N
patients POS N
with POS N
advanced POS N
MM, POS N
NHL, POS N
and POS N
CLL POS N
and POS N
a POS N
low POS N
performance POS N
status POS N
benefited POS N
from POS N
epoetin POS N
therapy, POS N
with POS N
elimination POS N
of POS N
severe POS N
anemia POS N
and POS N
transfusion POS N
need, POS N
and POS N
improvement POS N
in POS N
QOL. POS N

After POS N
12 POS N
and POS N
16 POS N
weeks POS N
of POS N
treatment, POS N
QOL POS N
significantly POS N
improved POS N
in POS N
the POS N
epoetin POS N
beta POS N
group POS N
compared POS N
with POS N
placebo POS N
(P POS N
<.05); POS N

Transfusion-free POS N
(P POS N
=.0012) POS N
survival POS N
and POS N
transfusion- POS N
and POS N
severe POS N
anemia-free POS N
survival POS N
(P POS N
=.0001) POS N
were POS N
significantly POS N
greater POS N
in POS N
the POS N
epoetin POS N
beta POS N
group POS N
versus POS N
placebo POS N
(Wald POS N
chi(2) POS N
test), POS N
giving POS N
a POS N
relative POS N
risk POS N
reduction POS N
of POS N
43% POS N
and POS N
51%, POS N
respectively. POS N

After POS N
12 POS N
and POS N
16 POS N
weeks POS N
of POS N
treatment, POS N
QOL POS N
significantly POS N
improved POS N
in POS N
the POS N
epoetin POS N
beta POS N
group POS N
compared POS N
with POS N
placebo POS N
(P POS N
<.05); POS N

The POS N
response POS N
rate POS N
was POS N
67% POS N
and POS N
27% POS N
in POS N
the POS N
epoetin POS N
beta POS N
versus POS N
the POS N
placebo POS N
group, POS N
respectively POS N
(P POS N
<.0001). POS N

After POS N
12 POS N
and POS N
16 POS N
weeks POS N
of POS N
treatment, POS N
QOL POS N
significantly POS N
improved POS N
in POS N
the POS N
epoetin POS N
beta POS N
group POS N
compared POS N
with POS N
placebo POS N
(P POS N
<.05); POS N

this POS N
improvement POS N
correlated POS N
with POS N
an POS N
increase POS N
in POS N
Hb POS N
concentration POS N
(> POS N
or POS N
= POS N
2 POS N
g/dL). POS N

After POS N
12 POS N
and POS N
16 POS N
weeks POS N
of POS N
treatment, POS N
QOL POS N
significantly POS N
improved POS N
in POS N
the POS N
epoetin POS N
beta POS N
group POS N
compared POS N
with POS N
placebo POS N
(P POS N
<.05); POS N

Many POS N
severely POS N
anemic POS N
and POS N
transfusion-dependent POS N
patients POS N
with POS N
advanced POS N
MM, POS N
NHL, POS N
and POS N
CLL POS N
and POS N
a POS N
low POS N
performance POS N
status POS N
benefited POS N
from POS N
epoetin POS N
therapy, POS N
with POS N
elimination POS N
of POS N
severe POS N
anemia POS N
and POS N
transfusion POS N
need, POS N
and POS N
improvement POS N
in POS N
QOL. POS N

this POS N
improvement POS N
correlated POS N
with POS N
an POS N
increase POS N
in POS N
Hb POS N
concentration POS N
(> POS N
or POS N
= POS N
2 POS N
g/dL). POS N

Transfusion-free POS N
(P POS N
=.0012) POS N
survival POS N
and POS N
transfusion- POS N
and POS N
severe POS N
anemia-free POS N
survival POS N
(P POS N
=.0001) POS N
were POS N
significantly POS N
greater POS N
in POS N
the POS N
epoetin POS N
beta POS N
group POS N
versus POS N
placebo POS N
(Wald POS N
chi(2) POS N
test), POS N
giving POS N
a POS N
relative POS N
risk POS N
reduction POS N
of POS N
43% POS N
and POS N
51%, POS N
respectively. POS N

this POS N
improvement POS N
correlated POS N
with POS N
an POS N
increase POS N
in POS N
Hb POS N
concentration POS N
(> POS N
or POS N
= POS N
2 POS N
g/dL). POS N

The POS N
response POS N
rate POS N
was POS N
67% POS N
and POS N
27% POS N
in POS N
the POS N
epoetin POS N
beta POS N
versus POS N
the POS N
placebo POS N
group, POS N
respectively POS N
(P POS N
<.0001). POS N

this POS N
improvement POS N
correlated POS N
with POS N
an POS N
increase POS N
in POS N
Hb POS N
concentration POS N
(> POS N
or POS N
= POS N
2 POS N
g/dL). POS N

After POS N
12 POS N
and POS N
16 POS N
weeks POS N
of POS N
treatment, POS N
QOL POS N
significantly POS N
improved POS N
in POS N
the POS N
epoetin POS N
beta POS N
group POS N
compared POS N
with POS N
placebo POS N
(P POS N
<.05); POS N

this POS N
improvement POS N
correlated POS N
with POS N
an POS N
increase POS N
in POS N
Hb POS N
concentration POS N
(> POS N
or POS N
= POS N
2 POS N
g/dL). POS N

Many POS N
severely POS N
anemic POS N
and POS N
transfusion-dependent POS N
patients POS N
with POS N
advanced POS N
MM, POS N
NHL, POS N
and POS N
CLL POS N
and POS N
a POS N
low POS N
performance POS N
status POS N
benefited POS N
from POS N
epoetin POS N
therapy, POS N
with POS N
elimination POS N
of POS N
severe POS N
anemia POS N
and POS N
transfusion POS N
need, POS N
and POS N
improvement POS N
in POS N
QOL. POS N

Many POS N
severely POS N
anemic POS N
and POS N
transfusion-dependent POS N
patients POS N
with POS N
advanced POS N
MM, POS N
NHL, POS N
and POS N
CLL POS N
and POS N
a POS N
low POS N
performance POS N
status POS N
benefited POS N
from POS N
epoetin POS N
therapy, POS N
with POS N
elimination POS N
of POS N
severe POS N
anemia POS N
and POS N
transfusion POS N
need, POS N
and POS N
improvement POS N
in POS N
QOL. POS N

Transfusion-free POS N
(P POS N
=.0012) POS N
survival POS N
and POS N
transfusion- POS N
and POS N
severe POS N
anemia-free POS N
survival POS N
(P POS N
=.0001) POS N
were POS N
significantly POS N
greater POS N
in POS N
the POS N
epoetin POS N
beta POS N
group POS N
versus POS N
placebo POS N
(Wald POS N
chi(2) POS N
test), POS N
giving POS N
a POS N
relative POS N
risk POS N
reduction POS N
of POS N
43% POS N
and POS N
51%, POS N
respectively. POS N

Many POS N
severely POS N
anemic POS N
and POS N
transfusion-dependent POS N
patients POS N
with POS N
advanced POS N
MM, POS N
NHL, POS N
and POS N
CLL POS N
and POS N
a POS N
low POS N
performance POS N
status POS N
benefited POS N
from POS N
epoetin POS N
therapy, POS N
with POS N
elimination POS N
of POS N
severe POS N
anemia POS N
and POS N
transfusion POS N
need, POS N
and POS N
improvement POS N
in POS N
QOL. POS N

The POS N
response POS N
rate POS N
was POS N
67% POS N
and POS N
27% POS N
in POS N
the POS N
epoetin POS N
beta POS N
versus POS N
the POS N
placebo POS N
group, POS N
respectively POS N
(P POS N
<.0001). POS N

Many POS N
severely POS N
anemic POS N
and POS N
transfusion-dependent POS N
patients POS N
with POS N
advanced POS N
MM, POS N
NHL, POS N
and POS N
CLL POS N
and POS N
a POS N
low POS N
performance POS N
status POS N
benefited POS N
from POS N
epoetin POS N
therapy, POS N
with POS N
elimination POS N
of POS N
severe POS N
anemia POS N
and POS N
transfusion POS N
need, POS N
and POS N
improvement POS N
in POS N
QOL. POS N

After POS N
12 POS N
and POS N
16 POS N
weeks POS N
of POS N
treatment, POS N
QOL POS N
significantly POS N
improved POS N
in POS N
the POS N
epoetin POS N
beta POS N
group POS N
compared POS N
with POS N
placebo POS N
(P POS N
<.05); POS N

Many POS N
severely POS N
anemic POS N
and POS N
transfusion-dependent POS N
patients POS N
with POS N
advanced POS N
MM, POS N
NHL, POS N
and POS N
CLL POS N
and POS N
a POS N
low POS N
performance POS N
status POS N
benefited POS N
from POS N
epoetin POS N
therapy, POS N
with POS N
elimination POS N
of POS N
severe POS N
anemia POS N
and POS N
transfusion POS N
need, POS N
and POS N
improvement POS N
in POS N
QOL. POS N

this POS N
improvement POS N
correlated POS N
with POS N
an POS N
increase POS N
in POS N
Hb POS N
concentration POS N
(> POS N
or POS N
= POS N
2 POS N
g/dL). POS N

Compared POS N
with POS N
metformin, POS N
COC POS N
plus POS N
spironolactone POS N
caused POS N
larger POS N
decreases POS N
in POS N
hirsutism POS N
score POS N
(mean POS N
difference POS N
4.6 POS N
points, POS N
95% POS N
CI: POS N
2.6-6.7), POS N
total POS N
testosterone POS N
(1.1 nmol/L, POS N
0.4-1.7), POS N
free POS N
testosterone POS N
(25 pmol/L, POS N
12-39), POS N
androstenedione POS N
(5.5 nmol/L, POS N
1.8-9.2) POS N
and POS N
dehydroepiandrosterone POS N
sulfate POS N
(2.7 μmol/L, POS N
1.4-4.0). POS N

Menstrual POS N
dysfunction POS N
was POS N
less POS N
frequent POS N
with POS N
COC POS N
plus POS N
spironolactone POS N
(OR: POS N
0.06, POS N
95% POS N
CI: POS N
0.02-0.23). POS N

Compared POS N
with POS N
metformin, POS N
COC POS N
plus POS N
spironolactone POS N
caused POS N
larger POS N
decreases POS N
in POS N
hirsutism POS N
score POS N
(mean POS N
difference POS N
4.6 POS N
points, POS N
95% POS N
CI: POS N
2.6-6.7), POS N
total POS N
testosterone POS N
(1.1 nmol/L, POS N
0.4-1.7), POS N
free POS N
testosterone POS N
(25 pmol/L, POS N
12-39), POS N
androstenedione POS N
(5.5 nmol/L, POS N
1.8-9.2) POS N
and POS N
dehydroepiandrosterone POS N
sulfate POS N
(2.7 μmol/L, POS N
1.4-4.0). POS N

No POS N
differences POS N
were POS N
found POS N
in POS N
frequencies POS N
of POS N
abnormal POS N
glucose POS N
tolerance POS N
(OR: POS N
1.7, POS N
95% POS N
CI: POS N
0.7-4.4), POS N
dyslipidemia POS N
(OR: POS N
0.6, POS N
95% POS N
CI: POS N
0.2-1.8) POS N
or POS N
hypertension POS N
(OR: POS N
0.3, POS N
95% POS N
CI: POS N
0.5-2.0). POS N

Compared POS N
with POS N
metformin, POS N
COC POS N
plus POS N
spironolactone POS N
caused POS N
larger POS N
decreases POS N
in POS N
hirsutism POS N
score POS N
(mean POS N
difference POS N
4.6 POS N
points, POS N
95% POS N
CI: POS N
2.6-6.7), POS N
total POS N
testosterone POS N
(1.1 nmol/L, POS N
0.4-1.7), POS N
free POS N
testosterone POS N
(25 pmol/L, POS N
12-39), POS N
androstenedione POS N
(5.5 nmol/L, POS N
1.8-9.2) POS N
and POS N
dehydroepiandrosterone POS N
sulfate POS N
(2.7 μmol/L, POS N
1.4-4.0). POS N

No POS N
major POS N
adverse POS N
events POS N
occurred POS N
and POS N
biochemical POS N
markers POS N
were POS N
similarly POS N
safe POS N
with POS N
both POS N
treatments. POS N

Compared POS N
with POS N
metformin, POS N
COC POS N
plus POS N
spironolactone POS N
caused POS N
larger POS N
decreases POS N
in POS N
hirsutism POS N
score POS N
(mean POS N
difference POS N
4.6 POS N
points, POS N
95% POS N
CI: POS N
2.6-6.7), POS N
total POS N
testosterone POS N
(1.1 nmol/L, POS N
0.4-1.7), POS N
free POS N
testosterone POS N
(25 pmol/L, POS N
12-39), POS N
androstenedione POS N
(5.5 nmol/L, POS N
1.8-9.2) POS N
and POS N
dehydroepiandrosterone POS N
sulfate POS N
(2.7 μmol/L, POS N
1.4-4.0). POS N

COC POS N
plus POS N
spironolactone POS N
was POS N
more POS N
effective POS N
than POS N
metformin POS N
for POS N
symptoms POS N
of POS N
PCOS POS N
showing POS N
similar POS N
safety POS N
and POS N
overall POS N
neutral POS N
effects POS N
on POS N
cardiometabolic POS N
risk POS N
factors. POS N

Menstrual POS N
dysfunction POS N
was POS N
less POS N
frequent POS N
with POS N
COC POS N
plus POS N
spironolactone POS N
(OR: POS N
0.06, POS N
95% POS N
CI: POS N
0.02-0.23). POS N

Compared POS N
with POS N
metformin, POS N
COC POS N
plus POS N
spironolactone POS N
caused POS N
larger POS N
decreases POS N
in POS N
hirsutism POS N
score POS N
(mean POS N
difference POS N
4.6 POS N
points, POS N
95% POS N
CI: POS N
2.6-6.7), POS N
total POS N
testosterone POS N
(1.1 nmol/L, POS N
0.4-1.7), POS N
free POS N
testosterone POS N
(25 pmol/L, POS N
12-39), POS N
androstenedione POS N
(5.5 nmol/L, POS N
1.8-9.2) POS N
and POS N
dehydroepiandrosterone POS N
sulfate POS N
(2.7 μmol/L, POS N
1.4-4.0). POS N

Menstrual POS N
dysfunction POS N
was POS N
less POS N
frequent POS N
with POS N
COC POS N
plus POS N
spironolactone POS N
(OR: POS N
0.06, POS N
95% POS N
CI: POS N
0.02-0.23). POS N

No POS N
differences POS N
were POS N
found POS N
in POS N
frequencies POS N
of POS N
abnormal POS N
glucose POS N
tolerance POS N
(OR: POS N
1.7, POS N
95% POS N
CI: POS N
0.7-4.4), POS N
dyslipidemia POS N
(OR: POS N
0.6, POS N
95% POS N
CI: POS N
0.2-1.8) POS N
or POS N
hypertension POS N
(OR: POS N
0.3, POS N
95% POS N
CI: POS N
0.5-2.0). POS N

Menstrual POS N
dysfunction POS N
was POS N
less POS N
frequent POS N
with POS N
COC POS N
plus POS N
spironolactone POS N
(OR: POS N
0.06, POS N
95% POS N
CI: POS N
0.02-0.23). POS N

No POS N
major POS N
adverse POS N
events POS N
occurred POS N
and POS N
biochemical POS N
markers POS N
were POS N
similarly POS N
safe POS N
with POS N
both POS N
treatments. POS N

Menstrual POS N
dysfunction POS N
was POS N
less POS N
frequent POS N
with POS N
COC POS N
plus POS N
spironolactone POS N
(OR: POS N
0.06, POS N
95% POS N
CI: POS N
0.02-0.23). POS N

COC POS N
plus POS N
spironolactone POS N
was POS N
more POS N
effective POS N
than POS N
metformin POS N
for POS N
symptoms POS N
of POS N
PCOS POS N
showing POS N
similar POS N
safety POS N
and POS N
overall POS N
neutral POS N
effects POS N
on POS N
cardiometabolic POS N
risk POS N
factors. POS N

No POS N
differences POS N
were POS N
found POS N
in POS N
frequencies POS N
of POS N
abnormal POS N
glucose POS N
tolerance POS N
(OR: POS N
1.7, POS N
95% POS N
CI: POS N
0.7-4.4), POS N
dyslipidemia POS N
(OR: POS N
0.6, POS N
95% POS N
CI: POS N
0.2-1.8) POS N
or POS N
hypertension POS N
(OR: POS N
0.3, POS N
95% POS N
CI: POS N
0.5-2.0). POS N

Compared POS N
with POS N
metformin, POS N
COC POS N
plus POS N
spironolactone POS N
caused POS N
larger POS N
decreases POS N
in POS N
hirsutism POS N
score POS N
(mean POS N
difference POS N
4.6 POS N
points, POS N
95% POS N
CI: POS N
2.6-6.7), POS N
total POS N
testosterone POS N
(1.1 nmol/L, POS N
0.4-1.7), POS N
free POS N
testosterone POS N
(25 pmol/L, POS N
12-39), POS N
androstenedione POS N
(5.5 nmol/L, POS N
1.8-9.2) POS N
and POS N
dehydroepiandrosterone POS N
sulfate POS N
(2.7 μmol/L, POS N
1.4-4.0). POS N

No POS N
differences POS N
were POS N
found POS N
in POS N
frequencies POS N
of POS N
abnormal POS N
glucose POS N
tolerance POS N
(OR: POS N
1.7, POS N
95% POS N
CI: POS N
0.7-4.4), POS N
dyslipidemia POS N
(OR: POS N
0.6, POS N
95% POS N
CI: POS N
0.2-1.8) POS N
or POS N
hypertension POS N
(OR: POS N
0.3, POS N
95% POS N
CI: POS N
0.5-2.0). POS N

Menstrual POS N
dysfunction POS N
was POS N
less POS N
frequent POS N
with POS N
COC POS N
plus POS N
spironolactone POS N
(OR: POS N
0.06, POS N
95% POS N
CI: POS N
0.02-0.23). POS N

No POS N
differences POS N
were POS N
found POS N
in POS N
frequencies POS N
of POS N
abnormal POS N
glucose POS N
tolerance POS N
(OR: POS N
1.7, POS N
95% POS N
CI: POS N
0.7-4.4), POS N
dyslipidemia POS N
(OR: POS N
0.6, POS N
95% POS N
CI: POS N
0.2-1.8) POS N
or POS N
hypertension POS N
(OR: POS N
0.3, POS N
95% POS N
CI: POS N
0.5-2.0). POS N

No POS N
major POS N
adverse POS N
events POS N
occurred POS N
and POS N
biochemical POS N
markers POS N
were POS N
similarly POS N
safe POS N
with POS N
both POS N
treatments. POS N

No POS N
differences POS N
were POS N
found POS N
in POS N
frequencies POS N
of POS N
abnormal POS N
glucose POS N
tolerance POS N
(OR: POS N
1.7, POS N
95% POS N
CI: POS N
0.7-4.4), POS N
dyslipidemia POS N
(OR: POS N
0.6, POS N
95% POS N
CI: POS N
0.2-1.8) POS N
or POS N
hypertension POS N
(OR: POS N
0.3, POS N
95% POS N
CI: POS N
0.5-2.0). POS N

COC POS N
plus POS N
spironolactone POS N
was POS N
more POS N
effective POS N
than POS N
metformin POS N
for POS N
symptoms POS N
of POS N
PCOS POS N
showing POS N
similar POS N
safety POS N
and POS N
overall POS N
neutral POS N
effects POS N
on POS N
cardiometabolic POS N
risk POS N
factors. POS N

No POS N
major POS N
adverse POS N
events POS N
occurred POS N
and POS N
biochemical POS N
markers POS N
were POS N
similarly POS N
safe POS N
with POS N
both POS N
treatments. POS N

Compared POS N
with POS N
metformin, POS N
COC POS N
plus POS N
spironolactone POS N
caused POS N
larger POS N
decreases POS N
in POS N
hirsutism POS N
score POS N
(mean POS N
difference POS N
4.6 POS N
points, POS N
95% POS N
CI: POS N
2.6-6.7), POS N
total POS N
testosterone POS N
(1.1 nmol/L, POS N
0.4-1.7), POS N
free POS N
testosterone POS N
(25 pmol/L, POS N
12-39), POS N
androstenedione POS N
(5.5 nmol/L, POS N
1.8-9.2) POS N
and POS N
dehydroepiandrosterone POS N
sulfate POS N
(2.7 μmol/L, POS N
1.4-4.0). POS N

No POS N
major POS N
adverse POS N
events POS N
occurred POS N
and POS N
biochemical POS N
markers POS N
were POS N
similarly POS N
safe POS N
with POS N
both POS N
treatments. POS N

Menstrual POS N
dysfunction POS N
was POS N
less POS N
frequent POS N
with POS N
COC POS N
plus POS N
spironolactone POS N
(OR: POS N
0.06, POS N
95% POS N
CI: POS N
0.02-0.23). POS N

No POS N
major POS N
adverse POS N
events POS N
occurred POS N
and POS N
biochemical POS N
markers POS N
were POS N
similarly POS N
safe POS N
with POS N
both POS N
treatments. POS N

No POS N
differences POS N
were POS N
found POS N
in POS N
frequencies POS N
of POS N
abnormal POS N
glucose POS N
tolerance POS N
(OR: POS N
1.7, POS N
95% POS N
CI: POS N
0.7-4.4), POS N
dyslipidemia POS N
(OR: POS N
0.6, POS N
95% POS N
CI: POS N
0.2-1.8) POS N
or POS N
hypertension POS N
(OR: POS N
0.3, POS N
95% POS N
CI: POS N
0.5-2.0). POS N

No POS N
major POS N
adverse POS N
events POS N
occurred POS N
and POS N
biochemical POS N
markers POS N
were POS N
similarly POS N
safe POS N
with POS N
both POS N
treatments. POS N

COC POS N
plus POS N
spironolactone POS N
was POS N
more POS N
effective POS N
than POS N
metformin POS N
for POS N
symptoms POS N
of POS N
PCOS POS N
showing POS N
similar POS N
safety POS N
and POS N
overall POS N
neutral POS N
effects POS N
on POS N
cardiometabolic POS N
risk POS N
factors. POS N

COC POS N
plus POS N
spironolactone POS N
was POS N
more POS N
effective POS N
than POS N
metformin POS N
for POS N
symptoms POS N
of POS N
PCOS POS N
showing POS N
similar POS N
safety POS N
and POS N
overall POS N
neutral POS N
effects POS N
on POS N
cardiometabolic POS N
risk POS N
factors. POS N

Compared POS N
with POS N
metformin, POS N
COC POS N
plus POS N
spironolactone POS N
caused POS N
larger POS N
decreases POS N
in POS N
hirsutism POS N
score POS N
(mean POS N
difference POS N
4.6 POS N
points, POS N
95% POS N
CI: POS N
2.6-6.7), POS N
total POS N
testosterone POS N
(1.1 nmol/L, POS N
0.4-1.7), POS N
free POS N
testosterone POS N
(25 pmol/L, POS N
12-39), POS N
androstenedione POS N
(5.5 nmol/L, POS N
1.8-9.2) POS N
and POS N
dehydroepiandrosterone POS N
sulfate POS N
(2.7 μmol/L, POS N
1.4-4.0). POS N

COC POS N
plus POS N
spironolactone POS N
was POS N
more POS N
effective POS N
than POS N
metformin POS N
for POS N
symptoms POS N
of POS N
PCOS POS N
showing POS N
similar POS N
safety POS N
and POS N
overall POS N
neutral POS N
effects POS N
on POS N
cardiometabolic POS N
risk POS N
factors. POS N

Menstrual POS N
dysfunction POS N
was POS N
less POS N
frequent POS N
with POS N
COC POS N
plus POS N
spironolactone POS N
(OR: POS N
0.06, POS N
95% POS N
CI: POS N
0.02-0.23). POS N

COC POS N
plus POS N
spironolactone POS N
was POS N
more POS N
effective POS N
than POS N
metformin POS N
for POS N
symptoms POS N
of POS N
PCOS POS N
showing POS N
similar POS N
safety POS N
and POS N
overall POS N
neutral POS N
effects POS N
on POS N
cardiometabolic POS N
risk POS N
factors. POS N

No POS N
differences POS N
were POS N
found POS N
in POS N
frequencies POS N
of POS N
abnormal POS N
glucose POS N
tolerance POS N
(OR: POS N
1.7, POS N
95% POS N
CI: POS N
0.7-4.4), POS N
dyslipidemia POS N
(OR: POS N
0.6, POS N
95% POS N
CI: POS N
0.2-1.8) POS N
or POS N
hypertension POS N
(OR: POS N
0.3, POS N
95% POS N
CI: POS N
0.5-2.0). POS N

COC POS N
plus POS N
spironolactone POS N
was POS N
more POS N
effective POS N
than POS N
metformin POS N
for POS N
symptoms POS N
of POS N
PCOS POS N
showing POS N
similar POS N
safety POS N
and POS N
overall POS N
neutral POS N
effects POS N
on POS N
cardiometabolic POS N
risk POS N
factors. POS N

No POS N
major POS N
adverse POS N
events POS N
occurred POS N
and POS N
biochemical POS N
markers POS N
were POS N
similarly POS N
safe POS N
with POS N
both POS N
treatments. POS N

There POS N
were POS N
no POS N
obvious POS N
differences POS N
in POS N
the POS N
normalization POS N
rate POS N
of POS N
ALT, POS N
negative POS N
conversion POS N
rate POS N
of POS N
HBV POS N
DNA POS N
and POS N
HBeAg, POS N
as POS N
well POS N
as POS N
improvement POS N
in POS N
Child-Pugh POS N
scores POS N
among POS N
the POS N
combination POS N
therapy POS N
group, POS N
12-week POS N
optimized POS N
therapy POS N
group, POS N
and POS N
ETV POS N
monotherapy POS N
group. POS N

For POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group, POS N
only POS N
ALT POS N
levels POS N
revealed POS N
a POS N
significant POS N
improvement. POS N

There POS N
were POS N
no POS N
obvious POS N
differences POS N
in POS N
the POS N
normalization POS N
rate POS N
of POS N
ALT, POS N
negative POS N
conversion POS N
rate POS N
of POS N
HBV POS N
DNA POS N
and POS N
HBeAg, POS N
as POS N
well POS N
as POS N
improvement POS N
in POS N
Child-Pugh POS N
scores POS N
among POS N
the POS N
combination POS N
therapy POS N
group, POS N
12-week POS N
optimized POS N
therapy POS N
group, POS N
and POS N
ETV POS N
monotherapy POS N
group. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment, POS N
the POS N
level POS N
of POS N
alanine POS N
amino-transferase POS N
(ALT), POS N
albumin POS N
(ALB) POS N
and POS N
total POS N
bilirubin POS N
(TBIL) POS N
in POS N
the POS N
combination POS N
therapy POS N
group POS N
and POS N
12-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significantly POS N
improved. POS N

There POS N
were POS N
no POS N
obvious POS N
differences POS N
in POS N
the POS N
normalization POS N
rate POS N
of POS N
ALT, POS N
negative POS N
conversion POS N
rate POS N
of POS N
HBV POS N
DNA POS N
and POS N
HBeAg, POS N
as POS N
well POS N
as POS N
improvement POS N
in POS N
Child-Pugh POS N
scores POS N
among POS N
the POS N
combination POS N
therapy POS N
group, POS N
12-week POS N
optimized POS N
therapy POS N
group, POS N
and POS N
ETV POS N
monotherapy POS N
group. POS N

However, POS N
the POS N
difference POS N
among POS N
these POS N
three POS N
groups POS N
and POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significant. POS N

There POS N
were POS N
no POS N
obvious POS N
differences POS N
in POS N
the POS N
normalization POS N
rate POS N
of POS N
ALT, POS N
negative POS N
conversion POS N
rate POS N
of POS N
HBV POS N
DNA POS N
and POS N
HBeAg, POS N
as POS N
well POS N
as POS N
improvement POS N
in POS N
Child-Pugh POS N
scores POS N
among POS N
the POS N
combination POS N
therapy POS N
group, POS N
12-week POS N
optimized POS N
therapy POS N
group, POS N
and POS N
ETV POS N
monotherapy POS N
group. POS N

Differences POS N
were POS N
not POS N
observed POS N
in POS N
the POS N
HBeAg POS N
seroconversion POS N
between POS N
each POS N
group. POS N

There POS N
were POS N
no POS N
obvious POS N
differences POS N
in POS N
the POS N
normalization POS N
rate POS N
of POS N
ALT, POS N
negative POS N
conversion POS N
rate POS N
of POS N
HBV POS N
DNA POS N
and POS N
HBeAg, POS N
as POS N
well POS N
as POS N
improvement POS N
in POS N
Child-Pugh POS N
scores POS N
among POS N
the POS N
combination POS N
therapy POS N
group, POS N
12-week POS N
optimized POS N
therapy POS N
group, POS N
and POS N
ETV POS N
monotherapy POS N
group. POS N

Differences POS N
in POS N
blood POS N
urea POS N
nitrogen, POS N
serum POS N
creatinine, POS N
creatine POS N
kinase, POS N
or POS N
other POS N
serious POS N
adverse POS N
effects POS N
were POS N
not POS N
observed POS N
in POS N
each POS N
group POS N
at POS N
the POS N
end POS N
of POS N
the POS N
96-week POS N
treatment. POS N

There POS N
were POS N
no POS N
obvious POS N
differences POS N
in POS N
the POS N
normalization POS N
rate POS N
of POS N
ALT, POS N
negative POS N
conversion POS N
rate POS N
of POS N
HBV POS N
DNA POS N
and POS N
HBeAg, POS N
as POS N
well POS N
as POS N
improvement POS N
in POS N
Child-Pugh POS N
scores POS N
among POS N
the POS N
combination POS N
therapy POS N
group, POS N
12-week POS N
optimized POS N
therapy POS N
group, POS N
and POS N
ETV POS N
monotherapy POS N
group. POS N

Combination POS N
therapy POS N
and POS N
early POS N
ADV POS N
addition POS N
were POS N
the POS N
preferred POS N
approaches POS N
in POS N
the POS N
antiviral POS N
strategy POS N
for POS N
the POS N
treatment POS N
of POS N
hepatitis POS N
B-induced POS N
decompensated POS N
cirrhosis. POS N

For POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group, POS N
only POS N
ALT POS N
levels POS N
revealed POS N
a POS N
significant POS N
improvement. POS N

There POS N
were POS N
no POS N
obvious POS N
differences POS N
in POS N
the POS N
normalization POS N
rate POS N
of POS N
ALT, POS N
negative POS N
conversion POS N
rate POS N
of POS N
HBV POS N
DNA POS N
and POS N
HBeAg, POS N
as POS N
well POS N
as POS N
improvement POS N
in POS N
Child-Pugh POS N
scores POS N
among POS N
the POS N
combination POS N
therapy POS N
group, POS N
12-week POS N
optimized POS N
therapy POS N
group, POS N
and POS N
ETV POS N
monotherapy POS N
group. POS N

For POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group, POS N
only POS N
ALT POS N
levels POS N
revealed POS N
a POS N
significant POS N
improvement. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment, POS N
the POS N
level POS N
of POS N
alanine POS N
amino-transferase POS N
(ALT), POS N
albumin POS N
(ALB) POS N
and POS N
total POS N
bilirubin POS N
(TBIL) POS N
in POS N
the POS N
combination POS N
therapy POS N
group POS N
and POS N
12-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significantly POS N
improved. POS N

For POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group, POS N
only POS N
ALT POS N
levels POS N
revealed POS N
a POS N
significant POS N
improvement. POS N

However, POS N
the POS N
difference POS N
among POS N
these POS N
three POS N
groups POS N
and POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significant. POS N

For POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group, POS N
only POS N
ALT POS N
levels POS N
revealed POS N
a POS N
significant POS N
improvement. POS N

Differences POS N
were POS N
not POS N
observed POS N
in POS N
the POS N
HBeAg POS N
seroconversion POS N
between POS N
each POS N
group. POS N

For POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group, POS N
only POS N
ALT POS N
levels POS N
revealed POS N
a POS N
significant POS N
improvement. POS N

Differences POS N
in POS N
blood POS N
urea POS N
nitrogen, POS N
serum POS N
creatinine, POS N
creatine POS N
kinase, POS N
or POS N
other POS N
serious POS N
adverse POS N
effects POS N
were POS N
not POS N
observed POS N
in POS N
each POS N
group POS N
at POS N
the POS N
end POS N
of POS N
the POS N
96-week POS N
treatment. POS N

For POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group, POS N
only POS N
ALT POS N
levels POS N
revealed POS N
a POS N
significant POS N
improvement. POS N

Combination POS N
therapy POS N
and POS N
early POS N
ADV POS N
addition POS N
were POS N
the POS N
preferred POS N
approaches POS N
in POS N
the POS N
antiviral POS N
strategy POS N
for POS N
the POS N
treatment POS N
of POS N
hepatitis POS N
B-induced POS N
decompensated POS N
cirrhosis. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment, POS N
the POS N
level POS N
of POS N
alanine POS N
amino-transferase POS N
(ALT), POS N
albumin POS N
(ALB) POS N
and POS N
total POS N
bilirubin POS N
(TBIL) POS N
in POS N
the POS N
combination POS N
therapy POS N
group POS N
and POS N
12-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significantly POS N
improved. POS N

There POS N
were POS N
no POS N
obvious POS N
differences POS N
in POS N
the POS N
normalization POS N
rate POS N
of POS N
ALT, POS N
negative POS N
conversion POS N
rate POS N
of POS N
HBV POS N
DNA POS N
and POS N
HBeAg, POS N
as POS N
well POS N
as POS N
improvement POS N
in POS N
Child-Pugh POS N
scores POS N
among POS N
the POS N
combination POS N
therapy POS N
group, POS N
12-week POS N
optimized POS N
therapy POS N
group, POS N
and POS N
ETV POS N
monotherapy POS N
group. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment, POS N
the POS N
level POS N
of POS N
alanine POS N
amino-transferase POS N
(ALT), POS N
albumin POS N
(ALB) POS N
and POS N
total POS N
bilirubin POS N
(TBIL) POS N
in POS N
the POS N
combination POS N
therapy POS N
group POS N
and POS N
12-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significantly POS N
improved. POS N

For POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group, POS N
only POS N
ALT POS N
levels POS N
revealed POS N
a POS N
significant POS N
improvement. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment, POS N
the POS N
level POS N
of POS N
alanine POS N
amino-transferase POS N
(ALT), POS N
albumin POS N
(ALB) POS N
and POS N
total POS N
bilirubin POS N
(TBIL) POS N
in POS N
the POS N
combination POS N
therapy POS N
group POS N
and POS N
12-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significantly POS N
improved. POS N

However, POS N
the POS N
difference POS N
among POS N
these POS N
three POS N
groups POS N
and POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significant. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment, POS N
the POS N
level POS N
of POS N
alanine POS N
amino-transferase POS N
(ALT), POS N
albumin POS N
(ALB) POS N
and POS N
total POS N
bilirubin POS N
(TBIL) POS N
in POS N
the POS N
combination POS N
therapy POS N
group POS N
and POS N
12-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significantly POS N
improved. POS N

Differences POS N
were POS N
not POS N
observed POS N
in POS N
the POS N
HBeAg POS N
seroconversion POS N
between POS N
each POS N
group. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment, POS N
the POS N
level POS N
of POS N
alanine POS N
amino-transferase POS N
(ALT), POS N
albumin POS N
(ALB) POS N
and POS N
total POS N
bilirubin POS N
(TBIL) POS N
in POS N
the POS N
combination POS N
therapy POS N
group POS N
and POS N
12-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significantly POS N
improved. POS N

Differences POS N
in POS N
blood POS N
urea POS N
nitrogen, POS N
serum POS N
creatinine, POS N
creatine POS N
kinase, POS N
or POS N
other POS N
serious POS N
adverse POS N
effects POS N
were POS N
not POS N
observed POS N
in POS N
each POS N
group POS N
at POS N
the POS N
end POS N
of POS N
the POS N
96-week POS N
treatment. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment, POS N
the POS N
level POS N
of POS N
alanine POS N
amino-transferase POS N
(ALT), POS N
albumin POS N
(ALB) POS N
and POS N
total POS N
bilirubin POS N
(TBIL) POS N
in POS N
the POS N
combination POS N
therapy POS N
group POS N
and POS N
12-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significantly POS N
improved. POS N

Combination POS N
therapy POS N
and POS N
early POS N
ADV POS N
addition POS N
were POS N
the POS N
preferred POS N
approaches POS N
in POS N
the POS N
antiviral POS N
strategy POS N
for POS N
the POS N
treatment POS N
of POS N
hepatitis POS N
B-induced POS N
decompensated POS N
cirrhosis. POS N

However, POS N
the POS N
difference POS N
among POS N
these POS N
three POS N
groups POS N
and POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significant. POS N

There POS N
were POS N
no POS N
obvious POS N
differences POS N
in POS N
the POS N
normalization POS N
rate POS N
of POS N
ALT, POS N
negative POS N
conversion POS N
rate POS N
of POS N
HBV POS N
DNA POS N
and POS N
HBeAg, POS N
as POS N
well POS N
as POS N
improvement POS N
in POS N
Child-Pugh POS N
scores POS N
among POS N
the POS N
combination POS N
therapy POS N
group, POS N
12-week POS N
optimized POS N
therapy POS N
group, POS N
and POS N
ETV POS N
monotherapy POS N
group. POS N

However, POS N
the POS N
difference POS N
among POS N
these POS N
three POS N
groups POS N
and POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significant. POS N

For POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group, POS N
only POS N
ALT POS N
levels POS N
revealed POS N
a POS N
significant POS N
improvement. POS N

However, POS N
the POS N
difference POS N
among POS N
these POS N
three POS N
groups POS N
and POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significant. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment, POS N
the POS N
level POS N
of POS N
alanine POS N
amino-transferase POS N
(ALT), POS N
albumin POS N
(ALB) POS N
and POS N
total POS N
bilirubin POS N
(TBIL) POS N
in POS N
the POS N
combination POS N
therapy POS N
group POS N
and POS N
12-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significantly POS N
improved. POS N

However, POS N
the POS N
difference POS N
among POS N
these POS N
three POS N
groups POS N
and POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significant. POS N

Differences POS N
were POS N
not POS N
observed POS N
in POS N
the POS N
HBeAg POS N
seroconversion POS N
between POS N
each POS N
group. POS N

However, POS N
the POS N
difference POS N
among POS N
these POS N
three POS N
groups POS N
and POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significant. POS N

Differences POS N
in POS N
blood POS N
urea POS N
nitrogen, POS N
serum POS N
creatinine, POS N
creatine POS N
kinase, POS N
or POS N
other POS N
serious POS N
adverse POS N
effects POS N
were POS N
not POS N
observed POS N
in POS N
each POS N
group POS N
at POS N
the POS N
end POS N
of POS N
the POS N
96-week POS N
treatment. POS N

However, POS N
the POS N
difference POS N
among POS N
these POS N
three POS N
groups POS N
and POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significant. POS N

Combination POS N
therapy POS N
and POS N
early POS N
ADV POS N
addition POS N
were POS N
the POS N
preferred POS N
approaches POS N
in POS N
the POS N
antiviral POS N
strategy POS N
for POS N
the POS N
treatment POS N
of POS N
hepatitis POS N
B-induced POS N
decompensated POS N
cirrhosis. POS N

Differences POS N
were POS N
not POS N
observed POS N
in POS N
the POS N
HBeAg POS N
seroconversion POS N
between POS N
each POS N
group. POS N

There POS N
were POS N
no POS N
obvious POS N
differences POS N
in POS N
the POS N
normalization POS N
rate POS N
of POS N
ALT, POS N
negative POS N
conversion POS N
rate POS N
of POS N
HBV POS N
DNA POS N
and POS N
HBeAg, POS N
as POS N
well POS N
as POS N
improvement POS N
in POS N
Child-Pugh POS N
scores POS N
among POS N
the POS N
combination POS N
therapy POS N
group, POS N
12-week POS N
optimized POS N
therapy POS N
group, POS N
and POS N
ETV POS N
monotherapy POS N
group. POS N

Differences POS N
were POS N
not POS N
observed POS N
in POS N
the POS N
HBeAg POS N
seroconversion POS N
between POS N
each POS N
group. POS N

For POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group, POS N
only POS N
ALT POS N
levels POS N
revealed POS N
a POS N
significant POS N
improvement. POS N

Differences POS N
were POS N
not POS N
observed POS N
in POS N
the POS N
HBeAg POS N
seroconversion POS N
between POS N
each POS N
group. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment, POS N
the POS N
level POS N
of POS N
alanine POS N
amino-transferase POS N
(ALT), POS N
albumin POS N
(ALB) POS N
and POS N
total POS N
bilirubin POS N
(TBIL) POS N
in POS N
the POS N
combination POS N
therapy POS N
group POS N
and POS N
12-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significantly POS N
improved. POS N

Differences POS N
were POS N
not POS N
observed POS N
in POS N
the POS N
HBeAg POS N
seroconversion POS N
between POS N
each POS N
group. POS N

However, POS N
the POS N
difference POS N
among POS N
these POS N
three POS N
groups POS N
and POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significant. POS N

Differences POS N
were POS N
not POS N
observed POS N
in POS N
the POS N
HBeAg POS N
seroconversion POS N
between POS N
each POS N
group. POS N

Differences POS N
in POS N
blood POS N
urea POS N
nitrogen, POS N
serum POS N
creatinine, POS N
creatine POS N
kinase, POS N
or POS N
other POS N
serious POS N
adverse POS N
effects POS N
were POS N
not POS N
observed POS N
in POS N
each POS N
group POS N
at POS N
the POS N
end POS N
of POS N
the POS N
96-week POS N
treatment. POS N

Differences POS N
were POS N
not POS N
observed POS N
in POS N
the POS N
HBeAg POS N
seroconversion POS N
between POS N
each POS N
group. POS N

Combination POS N
therapy POS N
and POS N
early POS N
ADV POS N
addition POS N
were POS N
the POS N
preferred POS N
approaches POS N
in POS N
the POS N
antiviral POS N
strategy POS N
for POS N
the POS N
treatment POS N
of POS N
hepatitis POS N
B-induced POS N
decompensated POS N
cirrhosis. POS N

Differences POS N
in POS N
blood POS N
urea POS N
nitrogen, POS N
serum POS N
creatinine, POS N
creatine POS N
kinase, POS N
or POS N
other POS N
serious POS N
adverse POS N
effects POS N
were POS N
not POS N
observed POS N
in POS N
each POS N
group POS N
at POS N
the POS N
end POS N
of POS N
the POS N
96-week POS N
treatment. POS N

There POS N
were POS N
no POS N
obvious POS N
differences POS N
in POS N
the POS N
normalization POS N
rate POS N
of POS N
ALT, POS N
negative POS N
conversion POS N
rate POS N
of POS N
HBV POS N
DNA POS N
and POS N
HBeAg, POS N
as POS N
well POS N
as POS N
improvement POS N
in POS N
Child-Pugh POS N
scores POS N
among POS N
the POS N
combination POS N
therapy POS N
group, POS N
12-week POS N
optimized POS N
therapy POS N
group, POS N
and POS N
ETV POS N
monotherapy POS N
group. POS N

Differences POS N
in POS N
blood POS N
urea POS N
nitrogen, POS N
serum POS N
creatinine, POS N
creatine POS N
kinase, POS N
or POS N
other POS N
serious POS N
adverse POS N
effects POS N
were POS N
not POS N
observed POS N
in POS N
each POS N
group POS N
at POS N
the POS N
end POS N
of POS N
the POS N
96-week POS N
treatment. POS N

For POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group, POS N
only POS N
ALT POS N
levels POS N
revealed POS N
a POS N
significant POS N
improvement. POS N

Differences POS N
in POS N
blood POS N
urea POS N
nitrogen, POS N
serum POS N
creatinine, POS N
creatine POS N
kinase, POS N
or POS N
other POS N
serious POS N
adverse POS N
effects POS N
were POS N
not POS N
observed POS N
in POS N
each POS N
group POS N
at POS N
the POS N
end POS N
of POS N
the POS N
96-week POS N
treatment. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment, POS N
the POS N
level POS N
of POS N
alanine POS N
amino-transferase POS N
(ALT), POS N
albumin POS N
(ALB) POS N
and POS N
total POS N
bilirubin POS N
(TBIL) POS N
in POS N
the POS N
combination POS N
therapy POS N
group POS N
and POS N
12-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significantly POS N
improved. POS N

Differences POS N
in POS N
blood POS N
urea POS N
nitrogen, POS N
serum POS N
creatinine, POS N
creatine POS N
kinase, POS N
or POS N
other POS N
serious POS N
adverse POS N
effects POS N
were POS N
not POS N
observed POS N
in POS N
each POS N
group POS N
at POS N
the POS N
end POS N
of POS N
the POS N
96-week POS N
treatment. POS N

However, POS N
the POS N
difference POS N
among POS N
these POS N
three POS N
groups POS N
and POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significant. POS N

Differences POS N
in POS N
blood POS N
urea POS N
nitrogen, POS N
serum POS N
creatinine, POS N
creatine POS N
kinase, POS N
or POS N
other POS N
serious POS N
adverse POS N
effects POS N
were POS N
not POS N
observed POS N
in POS N
each POS N
group POS N
at POS N
the POS N
end POS N
of POS N
the POS N
96-week POS N
treatment. POS N

Differences POS N
were POS N
not POS N
observed POS N
in POS N
the POS N
HBeAg POS N
seroconversion POS N
between POS N
each POS N
group. POS N

Differences POS N
in POS N
blood POS N
urea POS N
nitrogen, POS N
serum POS N
creatinine, POS N
creatine POS N
kinase, POS N
or POS N
other POS N
serious POS N
adverse POS N
effects POS N
were POS N
not POS N
observed POS N
in POS N
each POS N
group POS N
at POS N
the POS N
end POS N
of POS N
the POS N
96-week POS N
treatment. POS N

Combination POS N
therapy POS N
and POS N
early POS N
ADV POS N
addition POS N
were POS N
the POS N
preferred POS N
approaches POS N
in POS N
the POS N
antiviral POS N
strategy POS N
for POS N
the POS N
treatment POS N
of POS N
hepatitis POS N
B-induced POS N
decompensated POS N
cirrhosis. POS N

Combination POS N
therapy POS N
and POS N
early POS N
ADV POS N
addition POS N
were POS N
the POS N
preferred POS N
approaches POS N
in POS N
the POS N
antiviral POS N
strategy POS N
for POS N
the POS N
treatment POS N
of POS N
hepatitis POS N
B-induced POS N
decompensated POS N
cirrhosis. POS N

There POS N
were POS N
no POS N
obvious POS N
differences POS N
in POS N
the POS N
normalization POS N
rate POS N
of POS N
ALT, POS N
negative POS N
conversion POS N
rate POS N
of POS N
HBV POS N
DNA POS N
and POS N
HBeAg, POS N
as POS N
well POS N
as POS N
improvement POS N
in POS N
Child-Pugh POS N
scores POS N
among POS N
the POS N
combination POS N
therapy POS N
group, POS N
12-week POS N
optimized POS N
therapy POS N
group, POS N
and POS N
ETV POS N
monotherapy POS N
group. POS N

Combination POS N
therapy POS N
and POS N
early POS N
ADV POS N
addition POS N
were POS N
the POS N
preferred POS N
approaches POS N
in POS N
the POS N
antiviral POS N
strategy POS N
for POS N
the POS N
treatment POS N
of POS N
hepatitis POS N
B-induced POS N
decompensated POS N
cirrhosis. POS N

For POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group, POS N
only POS N
ALT POS N
levels POS N
revealed POS N
a POS N
significant POS N
improvement. POS N

Combination POS N
therapy POS N
and POS N
early POS N
ADV POS N
addition POS N
were POS N
the POS N
preferred POS N
approaches POS N
in POS N
the POS N
antiviral POS N
strategy POS N
for POS N
the POS N
treatment POS N
of POS N
hepatitis POS N
B-induced POS N
decompensated POS N
cirrhosis. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment, POS N
the POS N
level POS N
of POS N
alanine POS N
amino-transferase POS N
(ALT), POS N
albumin POS N
(ALB) POS N
and POS N
total POS N
bilirubin POS N
(TBIL) POS N
in POS N
the POS N
combination POS N
therapy POS N
group POS N
and POS N
12-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significantly POS N
improved. POS N

Combination POS N
therapy POS N
and POS N
early POS N
ADV POS N
addition POS N
were POS N
the POS N
preferred POS N
approaches POS N
in POS N
the POS N
antiviral POS N
strategy POS N
for POS N
the POS N
treatment POS N
of POS N
hepatitis POS N
B-induced POS N
decompensated POS N
cirrhosis. POS N

However, POS N
the POS N
difference POS N
among POS N
these POS N
three POS N
groups POS N
and POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significant. POS N

Combination POS N
therapy POS N
and POS N
early POS N
ADV POS N
addition POS N
were POS N
the POS N
preferred POS N
approaches POS N
in POS N
the POS N
antiviral POS N
strategy POS N
for POS N
the POS N
treatment POS N
of POS N
hepatitis POS N
B-induced POS N
decompensated POS N
cirrhosis. POS N

Differences POS N
were POS N
not POS N
observed POS N
in POS N
the POS N
HBeAg POS N
seroconversion POS N
between POS N
each POS N
group. POS N

Combination POS N
therapy POS N
and POS N
early POS N
ADV POS N
addition POS N
were POS N
the POS N
preferred POS N
approaches POS N
in POS N
the POS N
antiviral POS N
strategy POS N
for POS N
the POS N
treatment POS N
of POS N
hepatitis POS N
B-induced POS N
decompensated POS N
cirrhosis. POS N

Differences POS N
in POS N
blood POS N
urea POS N
nitrogen, POS N
serum POS N
creatinine, POS N
creatine POS N
kinase, POS N
or POS N
other POS N
serious POS N
adverse POS N
effects POS N
were POS N
not POS N
observed POS N
in POS N
each POS N
group POS N
at POS N
the POS N
end POS N
of POS N
the POS N
96-week POS N
treatment. POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

Overall, POS N
6.6% POS N
of POS N
patients POS N
modified POS N
their POS N
initial POS N
treatment, POS N
with POS N
ETV POS N
having POS N
lower POS N
rates POS N
of POS N
treatment POS N
modification POS N
than POS N
other POS N
major POS N
NUCs POS N
(P<0.05). POS N

At POS N
week POS N
52, POS N
the POS N
virologic POS N
response POS N
rate POS N
was POS N
higher POS N
with POS N
ETV POS N
than POS N
with POS N
LAM-based POS N
treatment POS N
(77.0% POS N
versus POS N
61.4%, POS N
P<0.0001). POS N

Overall, POS N
6.6% POS N
of POS N
patients POS N
modified POS N
their POS N
initial POS N
treatment, POS N
with POS N
ETV POS N
having POS N
lower POS N
rates POS N
of POS N
treatment POS N
modification POS N
than POS N
other POS N
major POS N
NUCs POS N
(P<0.05). POS N

LAM-based POS N
treatment POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
probability POS N
of POS N
virologic POS N
breakthrough POS N
and POS N
genotypic POS N
resistance POS N
(21.4% POS N
and POS N
19.6%, POS N
respectively) POS N
than POS N
ETV POS N
(1.6% POS N
and POS N
0.1%, POS N
respectively) POS N
(P<0.0001). POS N

Overall, POS N
6.6% POS N
of POS N
patients POS N
modified POS N
their POS N
initial POS N
treatment, POS N
with POS N
ETV POS N
having POS N
lower POS N
rates POS N
of POS N
treatment POS N
modification POS N
than POS N
other POS N
major POS N
NUCs POS N
(P<0.05). POS N

Treatment-related POS N
adverse POS N
events POS N
or POS N
serious POS N
adverse POS N
events POS N
were POS N
uncommon. POS N

Overall, POS N
6.6% POS N
of POS N
patients POS N
modified POS N
their POS N
initial POS N
treatment, POS N
with POS N
ETV POS N
having POS N
lower POS N
rates POS N
of POS N
treatment POS N
modification POS N
than POS N
other POS N
major POS N
NUCs POS N
(P<0.05). POS N

Consistent POS N
with POS N
clinical POS N
trial POS N
results, POS N
ETV POS N
was POS N
more POS N
effective POS N
than POS N
LAM-based POS N
treatments POS N
in POS N
a POS N
real-world POS N
setting, POS N
with POS N
treatment POS N
modification POS N
being POS N
relatively POS N
low POS N
in POS N
ETV-treated POS N
patients. POS N

At POS N
week POS N
52, POS N
the POS N
virologic POS N
response POS N
rate POS N
was POS N
higher POS N
with POS N
ETV POS N
than POS N
with POS N
LAM-based POS N
treatment POS N
(77.0% POS N
versus POS N
61.4%, POS N
P<0.0001). POS N

Overall, POS N
6.6% POS N
of POS N
patients POS N
modified POS N
their POS N
initial POS N
treatment, POS N
with POS N
ETV POS N
having POS N
lower POS N
rates POS N
of POS N
treatment POS N
modification POS N
than POS N
other POS N
major POS N
NUCs POS N
(P<0.05). POS N

At POS N
week POS N
52, POS N
the POS N
virologic POS N
response POS N
rate POS N
was POS N
higher POS N
with POS N
ETV POS N
than POS N
with POS N
LAM-based POS N
treatment POS N
(77.0% POS N
versus POS N
61.4%, POS N
P<0.0001). POS N

LAM-based POS N
treatment POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
probability POS N
of POS N
virologic POS N
breakthrough POS N
and POS N
genotypic POS N
resistance POS N
(21.4% POS N
and POS N
19.6%, POS N
respectively) POS N
than POS N
ETV POS N
(1.6% POS N
and POS N
0.1%, POS N
respectively) POS N
(P<0.0001). POS N

At POS N
week POS N
52, POS N
the POS N
virologic POS N
response POS N
rate POS N
was POS N
higher POS N
with POS N
ETV POS N
than POS N
with POS N
LAM-based POS N
treatment POS N
(77.0% POS N
versus POS N
61.4%, POS N
P<0.0001). POS N

Treatment-related POS N
adverse POS N
events POS N
or POS N
serious POS N
adverse POS N
events POS N
were POS N
uncommon. POS N

At POS N
week POS N
52, POS N
the POS N
virologic POS N
response POS N
rate POS N
was POS N
higher POS N
with POS N
ETV POS N
than POS N
with POS N
LAM-based POS N
treatment POS N
(77.0% POS N
versus POS N
61.4%, POS N
P<0.0001). POS N

Consistent POS N
with POS N
clinical POS N
trial POS N
results, POS N
ETV POS N
was POS N
more POS N
effective POS N
than POS N
LAM-based POS N
treatments POS N
in POS N
a POS N
real-world POS N
setting, POS N
with POS N
treatment POS N
modification POS N
being POS N
relatively POS N
low POS N
in POS N
ETV-treated POS N
patients. POS N

LAM-based POS N
treatment POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
probability POS N
of POS N
virologic POS N
breakthrough POS N
and POS N
genotypic POS N
resistance POS N
(21.4% POS N
and POS N
19.6%, POS N
respectively) POS N
than POS N
ETV POS N
(1.6% POS N
and POS N
0.1%, POS N
respectively) POS N
(P<0.0001). POS N

Overall, POS N
6.6% POS N
of POS N
patients POS N
modified POS N
their POS N
initial POS N
treatment, POS N
with POS N
ETV POS N
having POS N
lower POS N
rates POS N
of POS N
treatment POS N
modification POS N
than POS N
other POS N
major POS N
NUCs POS N
(P<0.05). POS N

LAM-based POS N
treatment POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
probability POS N
of POS N
virologic POS N
breakthrough POS N
and POS N
genotypic POS N
resistance POS N
(21.4% POS N
and POS N
19.6%, POS N
respectively) POS N
than POS N
ETV POS N
(1.6% POS N
and POS N
0.1%, POS N
respectively) POS N
(P<0.0001). POS N

At POS N
week POS N
52, POS N
the POS N
virologic POS N
response POS N
rate POS N
was POS N
higher POS N
with POS N
ETV POS N
than POS N
with POS N
LAM-based POS N
treatment POS N
(77.0% POS N
versus POS N
61.4%, POS N
P<0.0001). POS N

LAM-based POS N
treatment POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
probability POS N
of POS N
virologic POS N
breakthrough POS N
and POS N
genotypic POS N
resistance POS N
(21.4% POS N
and POS N
19.6%, POS N
respectively) POS N
than POS N
ETV POS N
(1.6% POS N
and POS N
0.1%, POS N
respectively) POS N
(P<0.0001). POS N

Treatment-related POS N
adverse POS N
events POS N
or POS N
serious POS N
adverse POS N
events POS N
were POS N
uncommon. POS N

LAM-based POS N
treatment POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
probability POS N
of POS N
virologic POS N
breakthrough POS N
and POS N
genotypic POS N
resistance POS N
(21.4% POS N
and POS N
19.6%, POS N
respectively) POS N
than POS N
ETV POS N
(1.6% POS N
and POS N
0.1%, POS N
respectively) POS N
(P<0.0001). POS N

Consistent POS N
with POS N
clinical POS N
trial POS N
results, POS N
ETV POS N
was POS N
more POS N
effective POS N
than POS N
LAM-based POS N
treatments POS N
in POS N
a POS N
real-world POS N
setting, POS N
with POS N
treatment POS N
modification POS N
being POS N
relatively POS N
low POS N
in POS N
ETV-treated POS N
patients. POS N

Treatment-related POS N
adverse POS N
events POS N
or POS N
serious POS N
adverse POS N
events POS N
were POS N
uncommon. POS N

Overall, POS N
6.6% POS N
of POS N
patients POS N
modified POS N
their POS N
initial POS N
treatment, POS N
with POS N
ETV POS N
having POS N
lower POS N
rates POS N
of POS N
treatment POS N
modification POS N
than POS N
other POS N
major POS N
NUCs POS N
(P<0.05). POS N

Treatment-related POS N
adverse POS N
events POS N
or POS N
serious POS N
adverse POS N
events POS N
were POS N
uncommon. POS N

At POS N
week POS N
52, POS N
the POS N
virologic POS N
response POS N
rate POS N
was POS N
higher POS N
with POS N
ETV POS N
than POS N
with POS N
LAM-based POS N
treatment POS N
(77.0% POS N
versus POS N
61.4%, POS N
P<0.0001). POS N

Treatment-related POS N
adverse POS N
events POS N
or POS N
serious POS N
adverse POS N
events POS N
were POS N
uncommon. POS N

LAM-based POS N
treatment POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
probability POS N
of POS N
virologic POS N
breakthrough POS N
and POS N
genotypic POS N
resistance POS N
(21.4% POS N
and POS N
19.6%, POS N
respectively) POS N
than POS N
ETV POS N
(1.6% POS N
and POS N
0.1%, POS N
respectively) POS N
(P<0.0001). POS N

Treatment-related POS N
adverse POS N
events POS N
or POS N
serious POS N
adverse POS N
events POS N
were POS N
uncommon. POS N

Consistent POS N
with POS N
clinical POS N
trial POS N
results, POS N
ETV POS N
was POS N
more POS N
effective POS N
than POS N
LAM-based POS N
treatments POS N
in POS N
a POS N
real-world POS N
setting, POS N
with POS N
treatment POS N
modification POS N
being POS N
relatively POS N
low POS N
in POS N
ETV-treated POS N
patients. POS N

Consistent POS N
with POS N
clinical POS N
trial POS N
results, POS N
ETV POS N
was POS N
more POS N
effective POS N
than POS N
LAM-based POS N
treatments POS N
in POS N
a POS N
real-world POS N
setting, POS N
with POS N
treatment POS N
modification POS N
being POS N
relatively POS N
low POS N
in POS N
ETV-treated POS N
patients. POS N

Overall, POS N
6.6% POS N
of POS N
patients POS N
modified POS N
their POS N
initial POS N
treatment, POS N
with POS N
ETV POS N
having POS N
lower POS N
rates POS N
of POS N
treatment POS N
modification POS N
than POS N
other POS N
major POS N
NUCs POS N
(P<0.05). POS N

Consistent POS N
with POS N
clinical POS N
trial POS N
results, POS N
ETV POS N
was POS N
more POS N
effective POS N
than POS N
LAM-based POS N
treatments POS N
in POS N
a POS N
real-world POS N
setting, POS N
with POS N
treatment POS N
modification POS N
being POS N
relatively POS N
low POS N
in POS N
ETV-treated POS N
patients. POS N

At POS N
week POS N
52, POS N
the POS N
virologic POS N
response POS N
rate POS N
was POS N
higher POS N
with POS N
ETV POS N
than POS N
with POS N
LAM-based POS N
treatment POS N
(77.0% POS N
versus POS N
61.4%, POS N
P<0.0001). POS N

Consistent POS N
with POS N
clinical POS N
trial POS N
results, POS N
ETV POS N
was POS N
more POS N
effective POS N
than POS N
LAM-based POS N
treatments POS N
in POS N
a POS N
real-world POS N
setting, POS N
with POS N
treatment POS N
modification POS N
being POS N
relatively POS N
low POS N
in POS N
ETV-treated POS N
patients. POS N

LAM-based POS N
treatment POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
probability POS N
of POS N
virologic POS N
breakthrough POS N
and POS N
genotypic POS N
resistance POS N
(21.4% POS N
and POS N
19.6%, POS N
respectively) POS N
than POS N
ETV POS N
(1.6% POS N
and POS N
0.1%, POS N
respectively) POS N
(P<0.0001). POS N

Consistent POS N
with POS N
clinical POS N
trial POS N
results, POS N
ETV POS N
was POS N
more POS N
effective POS N
than POS N
LAM-based POS N
treatments POS N
in POS N
a POS N
real-world POS N
setting, POS N
with POS N
treatment POS N
modification POS N
being POS N
relatively POS N
low POS N
in POS N
ETV-treated POS N
patients. POS N

Treatment-related POS N
adverse POS N
events POS N
or POS N
serious POS N
adverse POS N
events POS N
were POS N
uncommon. POS N

Chronic POS N
HFHT POS N
compared POS N
with POS N
LFLT POS N
intake POS N
significantly POS N
increased POS N
plasma POS N
theobromine POS N
(p POS N
< POS N
0.0001). POS N

Compared POS N
with POS N
LFLT, POS N
acute POS N
HFHT POS N
intake POS N
significantly POS N
increased POS N
plasma POS N
epicatechin POS N
and POS N
theobromine POS N
(p POS N
< POS N
0.0001), POS N
decreased POS N
AIx POS N
(p POS N
< POS N
0.0001) POS N
and POS N
increased POS N
diastolic POS N
BP POS N
(3.49 POS N
± POS N
3.40 POS N
mmHg POS N
increase POS N
in POS N
HFHT POS N
group POS N
vs POS N
1.55 POS N
± POS N
2.59 POS N
mmHg POS N
increase POS N
in POS N
LFLT POS N
group, POS N
p POS N
= POS N
0.0008). POS N

Chronic POS N
HFHT POS N
compared POS N
with POS N
LFLT POS N
intake POS N
significantly POS N
increased POS N
plasma POS N
theobromine POS N
(p POS N
< POS N
0.0001). POS N

Acute POS N
consumption POS N
of POS N
HFHT, POS N
compared POS N
to POS N
LFLT, POS N
increased POS N
plasma POS N
epicatechin POS N
and POS N
theobromine POS N
concentrations POS N
and POS N
decreased POS N
arterial POS N
stiffness, POS N
with POS N
no POS N
effect POS N
on POS N
endothelial POS N
function POS N
and POS N
a POS N
marginal POS N
increase POS N
in POS N
diastolic POS N
BP. POS N

Chronic POS N
HFHT POS N
compared POS N
with POS N
LFLT POS N
intake POS N
significantly POS N
increased POS N
plasma POS N
theobromine POS N
(p POS N
< POS N
0.0001). POS N

Chronic POS N
HFHT POS N
intake POS N
increased POS N
plasma POS N
theobromine, POS N
though POS N
it POS N
did POS N
not POS N
have POS N
positive POS N
impacts POS N
on POS N
endothelial POS N
function, POS N
arterial POS N
stiffness POS N
or POS N
BP POS N
when POS N
compared POS N
to POS N
LFLT POS N
in POS N
pregnant POS N
women POS N
at POS N
risk POS N
of POS N
PE. POS N

Compared POS N
with POS N
LFLT, POS N
acute POS N
HFHT POS N
intake POS N
significantly POS N
increased POS N
plasma POS N
epicatechin POS N
and POS N
theobromine POS N
(p POS N
< POS N
0.0001), POS N
decreased POS N
AIx POS N
(p POS N
< POS N
0.0001) POS N
and POS N
increased POS N
diastolic POS N
BP POS N
(3.49 POS N
± POS N
3.40 POS N
mmHg POS N
increase POS N
in POS N
HFHT POS N
group POS N
vs POS N
1.55 POS N
± POS N
2.59 POS N
mmHg POS N
increase POS N
in POS N
LFLT POS N
group, POS N
p POS N
= POS N
0.0008). POS N

Chronic POS N
HFHT POS N
compared POS N
with POS N
LFLT POS N
intake POS N
significantly POS N
increased POS N
plasma POS N
theobromine POS N
(p POS N
< POS N
0.0001). POS N

Compared POS N
with POS N
LFLT, POS N
acute POS N
HFHT POS N
intake POS N
significantly POS N
increased POS N
plasma POS N
epicatechin POS N
and POS N
theobromine POS N
(p POS N
< POS N
0.0001), POS N
decreased POS N
AIx POS N
(p POS N
< POS N
0.0001) POS N
and POS N
increased POS N
diastolic POS N
BP POS N
(3.49 POS N
± POS N
3.40 POS N
mmHg POS N
increase POS N
in POS N
HFHT POS N
group POS N
vs POS N
1.55 POS N
± POS N
2.59 POS N
mmHg POS N
increase POS N
in POS N
LFLT POS N
group, POS N
p POS N
= POS N
0.0008). POS N

Acute POS N
consumption POS N
of POS N
HFHT, POS N
compared POS N
to POS N
LFLT, POS N
increased POS N
plasma POS N
epicatechin POS N
and POS N
theobromine POS N
concentrations POS N
and POS N
decreased POS N
arterial POS N
stiffness, POS N
with POS N
no POS N
effect POS N
on POS N
endothelial POS N
function POS N
and POS N
a POS N
marginal POS N
increase POS N
in POS N
diastolic POS N
BP. POS N

Compared POS N
with POS N
LFLT, POS N
acute POS N
HFHT POS N
intake POS N
significantly POS N
increased POS N
plasma POS N
epicatechin POS N
and POS N
theobromine POS N
(p POS N
< POS N
0.0001), POS N
decreased POS N
AIx POS N
(p POS N
< POS N
0.0001) POS N
and POS N
increased POS N
diastolic POS N
BP POS N
(3.49 POS N
± POS N
3.40 POS N
mmHg POS N
increase POS N
in POS N
HFHT POS N
group POS N
vs POS N
1.55 POS N
± POS N
2.59 POS N
mmHg POS N
increase POS N
in POS N
LFLT POS N
group, POS N
p POS N
= POS N
0.0008). POS N

Chronic POS N
HFHT POS N
intake POS N
increased POS N
plasma POS N
theobromine, POS N
though POS N
it POS N
did POS N
not POS N
have POS N
positive POS N
impacts POS N
on POS N
endothelial POS N
function, POS N
arterial POS N
stiffness POS N
or POS N
BP POS N
when POS N
compared POS N
to POS N
LFLT POS N
in POS N
pregnant POS N
women POS N
at POS N
risk POS N
of POS N
PE. POS N

Acute POS N
consumption POS N
of POS N
HFHT, POS N
compared POS N
to POS N
LFLT, POS N
increased POS N
plasma POS N
epicatechin POS N
and POS N
theobromine POS N
concentrations POS N
and POS N
decreased POS N
arterial POS N
stiffness, POS N
with POS N
no POS N
effect POS N
on POS N
endothelial POS N
function POS N
and POS N
a POS N
marginal POS N
increase POS N
in POS N
diastolic POS N
BP. POS N

Chronic POS N
HFHT POS N
compared POS N
with POS N
LFLT POS N
intake POS N
significantly POS N
increased POS N
plasma POS N
theobromine POS N
(p POS N
< POS N
0.0001). POS N

Acute POS N
consumption POS N
of POS N
HFHT, POS N
compared POS N
to POS N
LFLT, POS N
increased POS N
plasma POS N
epicatechin POS N
and POS N
theobromine POS N
concentrations POS N
and POS N
decreased POS N
arterial POS N
stiffness, POS N
with POS N
no POS N
effect POS N
on POS N
endothelial POS N
function POS N
and POS N
a POS N
marginal POS N
increase POS N
in POS N
diastolic POS N
BP. POS N

Compared POS N
with POS N
LFLT, POS N
acute POS N
HFHT POS N
intake POS N
significantly POS N
increased POS N
plasma POS N
epicatechin POS N
and POS N
theobromine POS N
(p POS N
< POS N
0.0001), POS N
decreased POS N
AIx POS N
(p POS N
< POS N
0.0001) POS N
and POS N
increased POS N
diastolic POS N
BP POS N
(3.49 POS N
± POS N
3.40 POS N
mmHg POS N
increase POS N
in POS N
HFHT POS N
group POS N
vs POS N
1.55 POS N
± POS N
2.59 POS N
mmHg POS N
increase POS N
in POS N
LFLT POS N
group, POS N
p POS N
= POS N
0.0008). POS N

Acute POS N
consumption POS N
of POS N
HFHT, POS N
compared POS N
to POS N
LFLT, POS N
increased POS N
plasma POS N
epicatechin POS N
and POS N
theobromine POS N
concentrations POS N
and POS N
decreased POS N
arterial POS N
stiffness, POS N
with POS N
no POS N
effect POS N
on POS N
endothelial POS N
function POS N
and POS N
a POS N
marginal POS N
increase POS N
in POS N
diastolic POS N
BP. POS N

Chronic POS N
HFHT POS N
intake POS N
increased POS N
plasma POS N
theobromine, POS N
though POS N
it POS N
did POS N
not POS N
have POS N
positive POS N
impacts POS N
on POS N
endothelial POS N
function, POS N
arterial POS N
stiffness POS N
or POS N
BP POS N
when POS N
compared POS N
to POS N
LFLT POS N
in POS N
pregnant POS N
women POS N
at POS N
risk POS N
of POS N
PE. POS N

Chronic POS N
HFHT POS N
intake POS N
increased POS N
plasma POS N
theobromine, POS N
though POS N
it POS N
did POS N
not POS N
have POS N
positive POS N
impacts POS N
on POS N
endothelial POS N
function, POS N
arterial POS N
stiffness POS N
or POS N
BP POS N
when POS N
compared POS N
to POS N
LFLT POS N
in POS N
pregnant POS N
women POS N
at POS N
risk POS N
of POS N
PE. POS N

Chronic POS N
HFHT POS N
compared POS N
with POS N
LFLT POS N
intake POS N
significantly POS N
increased POS N
plasma POS N
theobromine POS N
(p POS N
< POS N
0.0001). POS N

Chronic POS N
HFHT POS N
intake POS N
increased POS N
plasma POS N
theobromine, POS N
though POS N
it POS N
did POS N
not POS N
have POS N
positive POS N
impacts POS N
on POS N
endothelial POS N
function, POS N
arterial POS N
stiffness POS N
or POS N
BP POS N
when POS N
compared POS N
to POS N
LFLT POS N
in POS N
pregnant POS N
women POS N
at POS N
risk POS N
of POS N
PE. POS N

Compared POS N
with POS N
LFLT, POS N
acute POS N
HFHT POS N
intake POS N
significantly POS N
increased POS N
plasma POS N
epicatechin POS N
and POS N
theobromine POS N
(p POS N
< POS N
0.0001), POS N
decreased POS N
AIx POS N
(p POS N
< POS N
0.0001) POS N
and POS N
increased POS N
diastolic POS N
BP POS N
(3.49 POS N
± POS N
3.40 POS N
mmHg POS N
increase POS N
in POS N
HFHT POS N
group POS N
vs POS N
1.55 POS N
± POS N
2.59 POS N
mmHg POS N
increase POS N
in POS N
LFLT POS N
group, POS N
p POS N
= POS N
0.0008). POS N

Chronic POS N
HFHT POS N
intake POS N
increased POS N
plasma POS N
theobromine, POS N
though POS N
it POS N
did POS N
not POS N
have POS N
positive POS N
impacts POS N
on POS N
endothelial POS N
function, POS N
arterial POS N
stiffness POS N
or POS N
BP POS N
when POS N
compared POS N
to POS N
LFLT POS N
in POS N
pregnant POS N
women POS N
at POS N
risk POS N
of POS N
PE. POS N

Acute POS N
consumption POS N
of POS N
HFHT, POS N
compared POS N
to POS N
LFLT, POS N
increased POS N
plasma POS N
epicatechin POS N
and POS N
theobromine POS N
concentrations POS N
and POS N
decreased POS N
arterial POS N
stiffness, POS N
with POS N
no POS N
effect POS N
on POS N
endothelial POS N
function POS N
and POS N
a POS N
marginal POS N
increase POS N
in POS N
diastolic POS N
BP. POS N

The POS N
response POS N
rate POS N
was POS N
71% POS N
for POS N
DepoCyt POS N
and POS N
15% POS N
for POS N
ara-C POS N
on POS N
an POS N
intent-to-treat POS N
basis POS N
(P POS N
=.006). POS N

All POS N
of POS N
the POS N
patients POS N
on POS N
the POS N
DepoCyt POS N
arm POS N
but POS N
only POS N
53% POS N
of POS N
those POS N
on POS N
the POS N
ara-C POS N
arm POS N
were POS N
able POS N
to POS N
complete POS N
the POS N
planned POS N
1-month POS N
induction POS N
therapy POS N
regimen. POS N

The POS N
response POS N
rate POS N
was POS N
71% POS N
for POS N
DepoCyt POS N
and POS N
15% POS N
for POS N
ara-C POS N
on POS N
an POS N
intent-to-treat POS N
basis POS N
(P POS N
=.006). POS N

Time POS N
to POS N
neurologic POS N
progression POS N
and POS N
survival POS N
trend POS N
in POS N
favor POS N
of POS N
DepoCyt POS N
(median, POS N
78.5 POS N
v POS N
42 POS N
days POS N
and POS N
99.5 POS N
v POS N
63 POS N
days, POS N
respectively; POS N
P POS N
>.05). POS N

The POS N
response POS N
rate POS N
was POS N
71% POS N
for POS N
DepoCyt POS N
and POS N
15% POS N
for POS N
ara-C POS N
on POS N
an POS N
intent-to-treat POS N
basis POS N
(P POS N
=.006). POS N

DepoCyt POS N
treatment POS N
was POS N
associated POS N
with POS N
an POS N
improved POS N
mean POS N
change POS N
in POS N
Karnofsky POS N
performance POS N
score POS N
at POS N
the POS N
end POS N
of POS N
induction POS N
(P POS N
=.041). POS N

The POS N
response POS N
rate POS N
was POS N
71% POS N
for POS N
DepoCyt POS N
and POS N
15% POS N
for POS N
ara-C POS N
on POS N
an POS N
intent-to-treat POS N
basis POS N
(P POS N
=.006). POS N

The POS N
major POS N
adverse POS N
events POS N
on POS N
both POS N
arms POS N
were POS N
headache POS N
and POS N
arachnoiditis, POS N
which POS N
were POS N
often POS N
caused POS N
by POS N
the POS N
underlying POS N
disease. POS N

The POS N
response POS N
rate POS N
was POS N
71% POS N
for POS N
DepoCyt POS N
and POS N
15% POS N
for POS N
ara-C POS N
on POS N
an POS N
intent-to-treat POS N
basis POS N
(P POS N
=.006). POS N

DepoCyt POS N
injected POS N
once POS N
every POS N
2 POS N
weeks POS N
produced POS N
a POS N
high POS N
response POS N
rate POS N
and POS N
a POS N
better POS N
quality POS N
of POS N
life POS N
as POS N
measured POS N
by POS N
Karnofsky POS N
score POS N
relative POS N
to POS N
that POS N
produced POS N
by POS N
free POS N
ara-C POS N
injected POS N
twice POS N
a POS N
week. POS N

All POS N
of POS N
the POS N
patients POS N
on POS N
the POS N
DepoCyt POS N
arm POS N
but POS N
only POS N
53% POS N
of POS N
those POS N
on POS N
the POS N
ara-C POS N
arm POS N
were POS N
able POS N
to POS N
complete POS N
the POS N
planned POS N
1-month POS N
induction POS N
therapy POS N
regimen. POS N

The POS N
response POS N
rate POS N
was POS N
71% POS N
for POS N
DepoCyt POS N
and POS N
15% POS N
for POS N
ara-C POS N
on POS N
an POS N
intent-to-treat POS N
basis POS N
(P POS N
=.006). POS N

All POS N
of POS N
the POS N
patients POS N
on POS N
the POS N
DepoCyt POS N
arm POS N
but POS N
only POS N
53% POS N
of POS N
those POS N
on POS N
the POS N
ara-C POS N
arm POS N
were POS N
able POS N
to POS N
complete POS N
the POS N
planned POS N
1-month POS N
induction POS N
therapy POS N
regimen. POS N

Time POS N
to POS N
neurologic POS N
progression POS N
and POS N
survival POS N
trend POS N
in POS N
favor POS N
of POS N
DepoCyt POS N
(median, POS N
78.5 POS N
v POS N
42 POS N
days POS N
and POS N
99.5 POS N
v POS N
63 POS N
days, POS N
respectively; POS N
P POS N
>.05). POS N

All POS N
of POS N
the POS N
patients POS N
on POS N
the POS N
DepoCyt POS N
arm POS N
but POS N
only POS N
53% POS N
of POS N
those POS N
on POS N
the POS N
ara-C POS N
arm POS N
were POS N
able POS N
to POS N
complete POS N
the POS N
planned POS N
1-month POS N
induction POS N
therapy POS N
regimen. POS N

DepoCyt POS N
treatment POS N
was POS N
associated POS N
with POS N
an POS N
improved POS N
mean POS N
change POS N
in POS N
Karnofsky POS N
performance POS N
score POS N
at POS N
the POS N
end POS N
of POS N
induction POS N
(P POS N
=.041). POS N

All POS N
of POS N
the POS N
patients POS N
on POS N
the POS N
DepoCyt POS N
arm POS N
but POS N
only POS N
53% POS N
of POS N
those POS N
on POS N
the POS N
ara-C POS N
arm POS N
were POS N
able POS N
to POS N
complete POS N
the POS N
planned POS N
1-month POS N
induction POS N
therapy POS N
regimen. POS N

The POS N
major POS N
adverse POS N
events POS N
on POS N
both POS N
arms POS N
were POS N
headache POS N
and POS N
arachnoiditis, POS N
which POS N
were POS N
often POS N
caused POS N
by POS N
the POS N
underlying POS N
disease. POS N

All POS N
of POS N
the POS N
patients POS N
on POS N
the POS N
DepoCyt POS N
arm POS N
but POS N
only POS N
53% POS N
of POS N
those POS N
on POS N
the POS N
ara-C POS N
arm POS N
were POS N
able POS N
to POS N
complete POS N
the POS N
planned POS N
1-month POS N
induction POS N
therapy POS N
regimen. POS N

DepoCyt POS N
injected POS N
once POS N
every POS N
2 POS N
weeks POS N
produced POS N
a POS N
high POS N
response POS N
rate POS N
and POS N
a POS N
better POS N
quality POS N
of POS N
life POS N
as POS N
measured POS N
by POS N
Karnofsky POS N
score POS N
relative POS N
to POS N
that POS N
produced POS N
by POS N
free POS N
ara-C POS N
injected POS N
twice POS N
a POS N
week. POS N

Time POS N
to POS N
neurologic POS N
progression POS N
and POS N
survival POS N
trend POS N
in POS N
favor POS N
of POS N
DepoCyt POS N
(median, POS N
78.5 POS N
v POS N
42 POS N
days POS N
and POS N
99.5 POS N
v POS N
63 POS N
days, POS N
respectively; POS N
P POS N
>.05). POS N

The POS N
response POS N
rate POS N
was POS N
71% POS N
for POS N
DepoCyt POS N
and POS N
15% POS N
for POS N
ara-C POS N
on POS N
an POS N
intent-to-treat POS N
basis POS N
(P POS N
=.006). POS N

Time POS N
to POS N
neurologic POS N
progression POS N
and POS N
survival POS N
trend POS N
in POS N
favor POS N
of POS N
DepoCyt POS N
(median, POS N
78.5 POS N
v POS N
42 POS N
days POS N
and POS N
99.5 POS N
v POS N
63 POS N
days, POS N
respectively; POS N
P POS N
>.05). POS N

All POS N
of POS N
the POS N
patients POS N
on POS N
the POS N
DepoCyt POS N
arm POS N
but POS N
only POS N
53% POS N
of POS N
those POS N
on POS N
the POS N
ara-C POS N
arm POS N
were POS N
able POS N
to POS N
complete POS N
the POS N
planned POS N
1-month POS N
induction POS N
therapy POS N
regimen. POS N

Time POS N
to POS N
neurologic POS N
progression POS N
and POS N
survival POS N
trend POS N
in POS N
favor POS N
of POS N
DepoCyt POS N
(median, POS N
78.5 POS N
v POS N
42 POS N
days POS N
and POS N
99.5 POS N
v POS N
63 POS N
days, POS N
respectively; POS N
P POS N
>.05). POS N

DepoCyt POS N
treatment POS N
was POS N
associated POS N
with POS N
an POS N
improved POS N
mean POS N
change POS N
in POS N
Karnofsky POS N
performance POS N
score POS N
at POS N
the POS N
end POS N
of POS N
induction POS N
(P POS N
=.041). POS N

Time POS N
to POS N
neurologic POS N
progression POS N
and POS N
survival POS N
trend POS N
in POS N
favor POS N
of POS N
DepoCyt POS N
(median, POS N
78.5 POS N
v POS N
42 POS N
days POS N
and POS N
99.5 POS N
v POS N
63 POS N
days, POS N
respectively; POS N
P POS N
>.05). POS N

The POS N
major POS N
adverse POS N
events POS N
on POS N
both POS N
arms POS N
were POS N
headache POS N
and POS N
arachnoiditis, POS N
which POS N
were POS N
often POS N
caused POS N
by POS N
the POS N
underlying POS N
disease. POS N

Time POS N
to POS N
neurologic POS N
progression POS N
and POS N
survival POS N
trend POS N
in POS N
favor POS N
of POS N
DepoCyt POS N
(median, POS N
78.5 POS N
v POS N
42 POS N
days POS N
and POS N
99.5 POS N
v POS N
63 POS N
days, POS N
respectively; POS N
P POS N
>.05). POS N

DepoCyt POS N
injected POS N
once POS N
every POS N
2 POS N
weeks POS N
produced POS N
a POS N
high POS N
response POS N
rate POS N
and POS N
a POS N
better POS N
quality POS N
of POS N
life POS N
as POS N
measured POS N
by POS N
Karnofsky POS N
score POS N
relative POS N
to POS N
that POS N
produced POS N
by POS N
free POS N
ara-C POS N
injected POS N
twice POS N
a POS N
week. POS N

DepoCyt POS N
treatment POS N
was POS N
associated POS N
with POS N
an POS N
improved POS N
mean POS N
change POS N
in POS N
Karnofsky POS N
performance POS N
score POS N
at POS N
the POS N
end POS N
of POS N
induction POS N
(P POS N
=.041). POS N

The POS N
response POS N
rate POS N
was POS N
71% POS N
for POS N
DepoCyt POS N
and POS N
15% POS N
for POS N
ara-C POS N
on POS N
an POS N
intent-to-treat POS N
basis POS N
(P POS N
=.006). POS N

DepoCyt POS N
treatment POS N
was POS N
associated POS N
with POS N
an POS N
improved POS N
mean POS N
change POS N
in POS N
Karnofsky POS N
performance POS N
score POS N
at POS N
the POS N
end POS N
of POS N
induction POS N
(P POS N
=.041). POS N

All POS N
of POS N
the POS N
patients POS N
on POS N
the POS N
DepoCyt POS N
arm POS N
but POS N
only POS N
53% POS N
of POS N
those POS N
on POS N
the POS N
ara-C POS N
arm POS N
were POS N
able POS N
to POS N
complete POS N
the POS N
planned POS N
1-month POS N
induction POS N
therapy POS N
regimen. POS N

DepoCyt POS N
treatment POS N
was POS N
associated POS N
with POS N
an POS N
improved POS N
mean POS N
change POS N
in POS N
Karnofsky POS N
performance POS N
score POS N
at POS N
the POS N
end POS N
of POS N
induction POS N
(P POS N
=.041). POS N

Time POS N
to POS N
neurologic POS N
progression POS N
and POS N
survival POS N
trend POS N
in POS N
favor POS N
of POS N
DepoCyt POS N
(median, POS N
78.5 POS N
v POS N
42 POS N
days POS N
and POS N
99.5 POS N
v POS N
63 POS N
days, POS N
respectively; POS N
P POS N
>.05). POS N

DepoCyt POS N
treatment POS N
was POS N
associated POS N
with POS N
an POS N
improved POS N
mean POS N
change POS N
in POS N
Karnofsky POS N
performance POS N
score POS N
at POS N
the POS N
end POS N
of POS N
induction POS N
(P POS N
=.041). POS N

The POS N
major POS N
adverse POS N
events POS N
on POS N
both POS N
arms POS N
were POS N
headache POS N
and POS N
arachnoiditis, POS N
which POS N
were POS N
often POS N
caused POS N
by POS N
the POS N
underlying POS N
disease. POS N

DepoCyt POS N
treatment POS N
was POS N
associated POS N
with POS N
an POS N
improved POS N
mean POS N
change POS N
in POS N
Karnofsky POS N
performance POS N
score POS N
at POS N
the POS N
end POS N
of POS N
induction POS N
(P POS N
=.041). POS N

DepoCyt POS N
injected POS N
once POS N
every POS N
2 POS N
weeks POS N
produced POS N
a POS N
high POS N
response POS N
rate POS N
and POS N
a POS N
better POS N
quality POS N
of POS N
life POS N
as POS N
measured POS N
by POS N
Karnofsky POS N
score POS N
relative POS N
to POS N
that POS N
produced POS N
by POS N
free POS N
ara-C POS N
injected POS N
twice POS N
a POS N
week. POS N

The POS N
major POS N
adverse POS N
events POS N
on POS N
both POS N
arms POS N
were POS N
headache POS N
and POS N
arachnoiditis, POS N
which POS N
were POS N
often POS N
caused POS N
by POS N
the POS N
underlying POS N
disease. POS N

The POS N
response POS N
rate POS N
was POS N
71% POS N
for POS N
DepoCyt POS N
and POS N
15% POS N
for POS N
ara-C POS N
on POS N
an POS N
intent-to-treat POS N
basis POS N
(P POS N
=.006). POS N

The POS N
major POS N
adverse POS N
events POS N
on POS N
both POS N
arms POS N
were POS N
headache POS N
and POS N
arachnoiditis, POS N
which POS N
were POS N
often POS N
caused POS N
by POS N
the POS N
underlying POS N
disease. POS N

All POS N
of POS N
the POS N
patients POS N
on POS N
the POS N
DepoCyt POS N
arm POS N
but POS N
only POS N
53% POS N
of POS N
those POS N
on POS N
the POS N
ara-C POS N
arm POS N
were POS N
able POS N
to POS N
complete POS N
the POS N
planned POS N
1-month POS N
induction POS N
therapy POS N
regimen. POS N

The POS N
major POS N
adverse POS N
events POS N
on POS N
both POS N
arms POS N
were POS N
headache POS N
and POS N
arachnoiditis, POS N
which POS N
were POS N
often POS N
caused POS N
by POS N
the POS N
underlying POS N
disease. POS N

Time POS N
to POS N
neurologic POS N
progression POS N
and POS N
survival POS N
trend POS N
in POS N
favor POS N
of POS N
DepoCyt POS N
(median, POS N
78.5 POS N
v POS N
42 POS N
days POS N
and POS N
99.5 POS N
v POS N
63 POS N
days, POS N
respectively; POS N
P POS N
>.05). POS N

The POS N
major POS N
adverse POS N
events POS N
on POS N
both POS N
arms POS N
were POS N
headache POS N
and POS N
arachnoiditis, POS N
which POS N
were POS N
often POS N
caused POS N
by POS N
the POS N
underlying POS N
disease. POS N

DepoCyt POS N
treatment POS N
was POS N
associated POS N
with POS N
an POS N
improved POS N
mean POS N
change POS N
in POS N
Karnofsky POS N
performance POS N
score POS N
at POS N
the POS N
end POS N
of POS N
induction POS N
(P POS N
=.041). POS N

The POS N
major POS N
adverse POS N
events POS N
on POS N
both POS N
arms POS N
were POS N
headache POS N
and POS N
arachnoiditis, POS N
which POS N
were POS N
often POS N
caused POS N
by POS N
the POS N
underlying POS N
disease. POS N

DepoCyt POS N
injected POS N
once POS N
every POS N
2 POS N
weeks POS N
produced POS N
a POS N
high POS N
response POS N
rate POS N
and POS N
a POS N
better POS N
quality POS N
of POS N
life POS N
as POS N
measured POS N
by POS N
Karnofsky POS N
score POS N
relative POS N
to POS N
that POS N
produced POS N
by POS N
free POS N
ara-C POS N
injected POS N
twice POS N
a POS N
week. POS N

DepoCyt POS N
injected POS N
once POS N
every POS N
2 POS N
weeks POS N
produced POS N
a POS N
high POS N
response POS N
rate POS N
and POS N
a POS N
better POS N
quality POS N
of POS N
life POS N
as POS N
measured POS N
by POS N
Karnofsky POS N
score POS N
relative POS N
to POS N
that POS N
produced POS N
by POS N
free POS N
ara-C POS N
injected POS N
twice POS N
a POS N
week. POS N

The POS N
response POS N
rate POS N
was POS N
71% POS N
for POS N
DepoCyt POS N
and POS N
15% POS N
for POS N
ara-C POS N
on POS N
an POS N
intent-to-treat POS N
basis POS N
(P POS N
=.006). POS N

DepoCyt POS N
injected POS N
once POS N
every POS N
2 POS N
weeks POS N
produced POS N
a POS N
high POS N
response POS N
rate POS N
and POS N
a POS N
better POS N
quality POS N
of POS N
life POS N
as POS N
measured POS N
by POS N
Karnofsky POS N
score POS N
relative POS N
to POS N
that POS N
produced POS N
by POS N
free POS N
ara-C POS N
injected POS N
twice POS N
a POS N
week. POS N

All POS N
of POS N
the POS N
patients POS N
on POS N
the POS N
DepoCyt POS N
arm POS N
but POS N
only POS N
53% POS N
of POS N
those POS N
on POS N
the POS N
ara-C POS N
arm POS N
were POS N
able POS N
to POS N
complete POS N
the POS N
planned POS N
1-month POS N
induction POS N
therapy POS N
regimen. POS N

DepoCyt POS N
injected POS N
once POS N
every POS N
2 POS N
weeks POS N
produced POS N
a POS N
high POS N
response POS N
rate POS N
and POS N
a POS N
better POS N
quality POS N
of POS N
life POS N
as POS N
measured POS N
by POS N
Karnofsky POS N
score POS N
relative POS N
to POS N
that POS N
produced POS N
by POS N
free POS N
ara-C POS N
injected POS N
twice POS N
a POS N
week. POS N

Time POS N
to POS N
neurologic POS N
progression POS N
and POS N
survival POS N
trend POS N
in POS N
favor POS N
of POS N
DepoCyt POS N
(median, POS N
78.5 POS N
v POS N
42 POS N
days POS N
and POS N
99.5 POS N
v POS N
63 POS N
days, POS N
respectively; POS N
P POS N
>.05). POS N

DepoCyt POS N
injected POS N
once POS N
every POS N
2 POS N
weeks POS N
produced POS N
a POS N
high POS N
response POS N
rate POS N
and POS N
a POS N
better POS N
quality POS N
of POS N
life POS N
as POS N
measured POS N
by POS N
Karnofsky POS N
score POS N
relative POS N
to POS N
that POS N
produced POS N
by POS N
free POS N
ara-C POS N
injected POS N
twice POS N
a POS N
week. POS N

DepoCyt POS N
treatment POS N
was POS N
associated POS N
with POS N
an POS N
improved POS N
mean POS N
change POS N
in POS N
Karnofsky POS N
performance POS N
score POS N
at POS N
the POS N
end POS N
of POS N
induction POS N
(P POS N
=.041). POS N

DepoCyt POS N
injected POS N
once POS N
every POS N
2 POS N
weeks POS N
produced POS N
a POS N
high POS N
response POS N
rate POS N
and POS N
a POS N
better POS N
quality POS N
of POS N
life POS N
as POS N
measured POS N
by POS N
Karnofsky POS N
score POS N
relative POS N
to POS N
that POS N
produced POS N
by POS N
free POS N
ara-C POS N
injected POS N
twice POS N
a POS N
week. POS N

The POS N
major POS N
adverse POS N
events POS N
on POS N
both POS N
arms POS N
were POS N
headache POS N
and POS N
arachnoiditis, POS N
which POS N
were POS N
often POS N
caused POS N
by POS N
the POS N
underlying POS N
disease. POS N

Larger POS N
studies POS N
using POS N
physiologically POS N
standardized POS N
ginseng POS N
preparations POS N
are POS N
warranted POS N
to POS N
substantiate POS N
the POS N
present POS N
findings POS N
and POS N
to POS N
demonstrate POS N
therapeutic POS N
effectiveness POS N
of POS N
AG. POS N

AG POS N
extract POS N
added POS N
to POS N
conventional POS N
treatment POS N
provided POS N
an POS N
effective POS N
and POS N
safe POS N
adjunct POS N
in POS N
the POS N
management POS N
of POS N
T2DM. POS N

Larger POS N
studies POS N
using POS N
physiologically POS N
standardized POS N
ginseng POS N
preparations POS N
are POS N
warranted POS N
to POS N
substantiate POS N
the POS N
present POS N
findings POS N
and POS N
to POS N
demonstrate POS N
therapeutic POS N
effectiveness POS N
of POS N
AG. POS N

Compared POS N
to POS N
placebo, POS N
AG POS N
significantly POS N
reduced POS N
HbA1c POS N
(- POS N
0.29%; POS N
p = 0.041) POS N
and POS N
fasting POS N
blood POS N
glucose POS N
(- POS N
0.71 POS N
mmol/L; POS N
p = 0.008). POS N

Larger POS N
studies POS N
using POS N
physiologically POS N
standardized POS N
ginseng POS N
preparations POS N
are POS N
warranted POS N
to POS N
substantiate POS N
the POS N
present POS N
findings POS N
and POS N
to POS N
demonstrate POS N
therapeutic POS N
effectiveness POS N
of POS N
AG. POS N

AG POS N
lowered POS N
systolic POS N
blood POS N
pressure POS N
(- POS N
5.6 ± 2.7 POS N
mmHg; POS N
p < 0.001), POS N
increased POS N
NOx POS N
(+ 1.85 ± 2.13 POS N
µmol/L; POS N
p < 0.03), POS N
and POS N
produced POS N
a POS N
mean POS N
percent POS N
end-difference POS N
of POS N
- POS N
12.3 ± 3.9% POS N
in POS N
LDL-C POS N
and POS N
- 13.9 ± 5.8% POS N
in POS N
LDL-C/HDL. POS N

AG POS N
extract POS N
added POS N
to POS N
conventional POS N
treatment POS N
provided POS N
an POS N
effective POS N
and POS N
safe POS N
adjunct POS N
in POS N
the POS N
management POS N
of POS N
T2DM. POS N

Larger POS N
studies POS N
using POS N
physiologically POS N
standardized POS N
ginseng POS N
preparations POS N
are POS N
warranted POS N
to POS N
substantiate POS N
the POS N
present POS N
findings POS N
and POS N
to POS N
demonstrate POS N
therapeutic POS N
effectiveness POS N
of POS N
AG. POS N

AG POS N
extract POS N
added POS N
to POS N
conventional POS N
treatment POS N
provided POS N
an POS N
effective POS N
and POS N
safe POS N
adjunct POS N
in POS N
the POS N
management POS N
of POS N
T2DM. POS N

Compared POS N
to POS N
placebo, POS N
AG POS N
significantly POS N
reduced POS N
HbA1c POS N
(- POS N
0.29%; POS N
p = 0.041) POS N
and POS N
fasting POS N
blood POS N
glucose POS N
(- POS N
0.71 POS N
mmol/L; POS N
p = 0.008). POS N

AG POS N
extract POS N
added POS N
to POS N
conventional POS N
treatment POS N
provided POS N
an POS N
effective POS N
and POS N
safe POS N
adjunct POS N
in POS N
the POS N
management POS N
of POS N
T2DM. POS N

AG POS N
lowered POS N
systolic POS N
blood POS N
pressure POS N
(- POS N
5.6 ± 2.7 POS N
mmHg; POS N
p < 0.001), POS N
increased POS N
NOx POS N
(+ 1.85 ± 2.13 POS N
µmol/L; POS N
p < 0.03), POS N
and POS N
produced POS N
a POS N
mean POS N
percent POS N
end-difference POS N
of POS N
- POS N
12.3 ± 3.9% POS N
in POS N
LDL-C POS N
and POS N
- 13.9 ± 5.8% POS N
in POS N
LDL-C/HDL. POS N

Compared POS N
to POS N
placebo, POS N
AG POS N
significantly POS N
reduced POS N
HbA1c POS N
(- POS N
0.29%; POS N
p = 0.041) POS N
and POS N
fasting POS N
blood POS N
glucose POS N
(- POS N
0.71 POS N
mmol/L; POS N
p = 0.008). POS N

Larger POS N
studies POS N
using POS N
physiologically POS N
standardized POS N
ginseng POS N
preparations POS N
are POS N
warranted POS N
to POS N
substantiate POS N
the POS N
present POS N
findings POS N
and POS N
to POS N
demonstrate POS N
therapeutic POS N
effectiveness POS N
of POS N
AG. POS N

Compared POS N
to POS N
placebo, POS N
AG POS N
significantly POS N
reduced POS N
HbA1c POS N
(- POS N
0.29%; POS N
p = 0.041) POS N
and POS N
fasting POS N
blood POS N
glucose POS N
(- POS N
0.71 POS N
mmol/L; POS N
p = 0.008). POS N

AG POS N
extract POS N
added POS N
to POS N
conventional POS N
treatment POS N
provided POS N
an POS N
effective POS N
and POS N
safe POS N
adjunct POS N
in POS N
the POS N
management POS N
of POS N
T2DM. POS N

Compared POS N
to POS N
placebo, POS N
AG POS N
significantly POS N
reduced POS N
HbA1c POS N
(- POS N
0.29%; POS N
p = 0.041) POS N
and POS N
fasting POS N
blood POS N
glucose POS N
(- POS N
0.71 POS N
mmol/L; POS N
p = 0.008). POS N

AG POS N
lowered POS N
systolic POS N
blood POS N
pressure POS N
(- POS N
5.6 ± 2.7 POS N
mmHg; POS N
p < 0.001), POS N
increased POS N
NOx POS N
(+ 1.85 ± 2.13 POS N
µmol/L; POS N
p < 0.03), POS N
and POS N
produced POS N
a POS N
mean POS N
percent POS N
end-difference POS N
of POS N
- POS N
12.3 ± 3.9% POS N
in POS N
LDL-C POS N
and POS N
- 13.9 ± 5.8% POS N
in POS N
LDL-C/HDL. POS N

AG POS N
lowered POS N
systolic POS N
blood POS N
pressure POS N
(- POS N
5.6 ± 2.7 POS N
mmHg; POS N
p < 0.001), POS N
increased POS N
NOx POS N
(+ 1.85 ± 2.13 POS N
µmol/L; POS N
p < 0.03), POS N
and POS N
produced POS N
a POS N
mean POS N
percent POS N
end-difference POS N
of POS N
- POS N
12.3 ± 3.9% POS N
in POS N
LDL-C POS N
and POS N
- 13.9 ± 5.8% POS N
in POS N
LDL-C/HDL. POS N

Larger POS N
studies POS N
using POS N
physiologically POS N
standardized POS N
ginseng POS N
preparations POS N
are POS N
warranted POS N
to POS N
substantiate POS N
the POS N
present POS N
findings POS N
and POS N
to POS N
demonstrate POS N
therapeutic POS N
effectiveness POS N
of POS N
AG. POS N

AG POS N
lowered POS N
systolic POS N
blood POS N
pressure POS N
(- POS N
5.6 ± 2.7 POS N
mmHg; POS N
p < 0.001), POS N
increased POS N
NOx POS N
(+ 1.85 ± 2.13 POS N
µmol/L; POS N
p < 0.03), POS N
and POS N
produced POS N
a POS N
mean POS N
percent POS N
end-difference POS N
of POS N
- POS N
12.3 ± 3.9% POS N
in POS N
LDL-C POS N
and POS N
- 13.9 ± 5.8% POS N
in POS N
LDL-C/HDL. POS N

AG POS N
extract POS N
added POS N
to POS N
conventional POS N
treatment POS N
provided POS N
an POS N
effective POS N
and POS N
safe POS N
adjunct POS N
in POS N
the POS N
management POS N
of POS N
T2DM. POS N

AG POS N
lowered POS N
systolic POS N
blood POS N
pressure POS N
(- POS N
5.6 ± 2.7 POS N
mmHg; POS N
p < 0.001), POS N
increased POS N
NOx POS N
(+ 1.85 ± 2.13 POS N
µmol/L; POS N
p < 0.03), POS N
and POS N
produced POS N
a POS N
mean POS N
percent POS N
end-difference POS N
of POS N
- POS N
12.3 ± 3.9% POS N
in POS N
LDL-C POS N
and POS N
- 13.9 ± 5.8% POS N
in POS N
LDL-C/HDL. POS N

Compared POS N
to POS N
placebo, POS N
AG POS N
significantly POS N
reduced POS N
HbA1c POS N
(- POS N
0.29%; POS N
p = 0.041) POS N
and POS N
fasting POS N
blood POS N
glucose POS N
(- POS N
0.71 POS N
mmol/L; POS N
p = 0.008). POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

No POS N
significant POS N
differences POS N
were POS N
observed POS N
among POS N
groups POS N
for POS N
HBeAg POS N
seroconversion POS N
(PEG-IFN POS N
alfa-2a+placebo, POS N
36.3%; POS N
PEG-IFN POS N
alfa-2a+ETV, POS N
29.5%; POS N
and POS N
PEG-IFN POS N
alfa-2a+ADV, POS N
27.4%), POS N
HBeAg POS N
loss POS N
(37.4%, POS N
32.2%, POS N
and POS N
28.6%, POS N
respectively) POS N
or POS N
change POS N
in POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
levels POS N
from POS N
baseline POS N
(-0.56 POS N
IU/mL, POS N
-0.60 POS N
IU/mL, POS N
and POS N
-0.41 POS N
IU/mL, POS N
respectively). POS N

However, POS N
hepatitis POS N
B POS N
virus POS N
DNA POS N
levels POS N
were POS N
higher POS N
with POS N
PEG-IFN POS N
alfa-2a+placebo POS N
than POS N
PEG-IFN POS N
alfa+ETV POS N
at POS N
week POS N
64 POS N
(p POS N
= POS N
0.0412), POS N
76 POS N
(p POS N
= POS N
0.0311), POS N
and POS N
88 POS N
(p POS N
= POS N
0.0113), POS N
and POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
normalization POS N
rate POS N
was POS N
higher POS N
with POS N
PEG-IFN POS N
alfa-2a+placebo POS N
than POS N
PEG-IFN POS N
alfa-2a+ADV POS N
(p POS N
= POS N
0.0283) POS N
or POS N
PEG-IFN POS N
alfa-2a+ETV POS N
(p POS N
= POS N
0.0369) POS N
at POS N
week POS N
88. POS N

No POS N
significant POS N
differences POS N
were POS N
observed POS N
among POS N
groups POS N
for POS N
HBeAg POS N
seroconversion POS N
(PEG-IFN POS N
alfa-2a+placebo, POS N
36.3%; POS N
PEG-IFN POS N
alfa-2a+ETV, POS N
29.5%; POS N
and POS N
PEG-IFN POS N
alfa-2a+ADV, POS N
27.4%), POS N
HBeAg POS N
loss POS N
(37.4%, POS N
32.2%, POS N
and POS N
28.6%, POS N
respectively) POS N
or POS N
change POS N
in POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
levels POS N
from POS N
baseline POS N
(-0.56 POS N
IU/mL, POS N
-0.60 POS N
IU/mL, POS N
and POS N
-0.41 POS N
IU/mL, POS N
respectively). POS N

Sub-analysis POS N
of POS N
results POS N
revealed POS N
an POS N
association POS N
between POS N
on-treatment POS N
HBsAg POS N
and POS N
ALT POS N
levels POS N
and POS N
efficacy POS N
48 POS N
weeks POS N
post-treatment. POS N

No POS N
significant POS N
differences POS N
were POS N
observed POS N
among POS N
groups POS N
for POS N
HBeAg POS N
seroconversion POS N
(PEG-IFN POS N
alfa-2a+placebo, POS N
36.3%; POS N
PEG-IFN POS N
alfa-2a+ETV, POS N
29.5%; POS N
and POS N
PEG-IFN POS N
alfa-2a+ADV, POS N
27.4%), POS N
HBeAg POS N
loss POS N
(37.4%, POS N
32.2%, POS N
and POS N
28.6%, POS N
respectively) POS N
or POS N
change POS N
in POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
levels POS N
from POS N
baseline POS N
(-0.56 POS N
IU/mL, POS N
-0.60 POS N
IU/mL, POS N
and POS N
-0.41 POS N
IU/mL, POS N
respectively). POS N

Safety POS N
was POS N
comparable POS N
among POS N
treatment POS N
groups. POS N

No POS N
significant POS N
differences POS N
were POS N
observed POS N
among POS N
groups POS N
for POS N
HBeAg POS N
seroconversion POS N
(PEG-IFN POS N
alfa-2a+placebo, POS N
36.3%; POS N
PEG-IFN POS N
alfa-2a+ETV, POS N
29.5%; POS N
and POS N
PEG-IFN POS N
alfa-2a+ADV, POS N
27.4%), POS N
HBeAg POS N
loss POS N
(37.4%, POS N
32.2%, POS N
and POS N
28.6%, POS N
respectively) POS N
or POS N
change POS N
in POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
levels POS N
from POS N
baseline POS N
(-0.56 POS N
IU/mL, POS N
-0.60 POS N
IU/mL, POS N
and POS N
-0.41 POS N
IU/mL, POS N
respectively). POS N

Pre-therapy POS N
with POS N
ADV POS N
or POS N
ETV POS N
followed POS N
by POS N
PEG-IFN POS N
alfa-2a POS N
is POS N
not POS N
superior POS N
to POS N
PEG-IFN POS N
alfa-2a POS N
monotherapy POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
HBeAg-positive POS N
CHB. POS N

However, POS N
hepatitis POS N
B POS N
virus POS N
DNA POS N
levels POS N
were POS N
higher POS N
with POS N
PEG-IFN POS N
alfa-2a+placebo POS N
than POS N
PEG-IFN POS N
alfa+ETV POS N
at POS N
week POS N
64 POS N
(p POS N
= POS N
0.0412), POS N
76 POS N
(p POS N
= POS N
0.0311), POS N
and POS N
88 POS N
(p POS N
= POS N
0.0113), POS N
and POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
normalization POS N
rate POS N
was POS N
higher POS N
with POS N
PEG-IFN POS N
alfa-2a+placebo POS N
than POS N
PEG-IFN POS N
alfa-2a+ADV POS N
(p POS N
= POS N
0.0283) POS N
or POS N
PEG-IFN POS N
alfa-2a+ETV POS N
(p POS N
= POS N
0.0369) POS N
at POS N
week POS N
88. POS N

No POS N
significant POS N
differences POS N
were POS N
observed POS N
among POS N
groups POS N
for POS N
HBeAg POS N
seroconversion POS N
(PEG-IFN POS N
alfa-2a+placebo, POS N
36.3%; POS N
PEG-IFN POS N
alfa-2a+ETV, POS N
29.5%; POS N
and POS N
PEG-IFN POS N
alfa-2a+ADV, POS N
27.4%), POS N
HBeAg POS N
loss POS N
(37.4%, POS N
32.2%, POS N
and POS N
28.6%, POS N
respectively) POS N
or POS N
change POS N
in POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
levels POS N
from POS N
baseline POS N
(-0.56 POS N
IU/mL, POS N
-0.60 POS N
IU/mL, POS N
and POS N
-0.41 POS N
IU/mL, POS N
respectively). POS N

However, POS N
hepatitis POS N
B POS N
virus POS N
DNA POS N
levels POS N
were POS N
higher POS N
with POS N
PEG-IFN POS N
alfa-2a+placebo POS N
than POS N
PEG-IFN POS N
alfa+ETV POS N
at POS N
week POS N
64 POS N
(p POS N
= POS N
0.0412), POS N
76 POS N
(p POS N
= POS N
0.0311), POS N
and POS N
88 POS N
(p POS N
= POS N
0.0113), POS N
and POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
normalization POS N
rate POS N
was POS N
higher POS N
with POS N
PEG-IFN POS N
alfa-2a+placebo POS N
than POS N
PEG-IFN POS N
alfa-2a+ADV POS N
(p POS N
= POS N
0.0283) POS N
or POS N
PEG-IFN POS N
alfa-2a+ETV POS N
(p POS N
= POS N
0.0369) POS N
at POS N
week POS N
88. POS N

Sub-analysis POS N
of POS N
results POS N
revealed POS N
an POS N
association POS N
between POS N
on-treatment POS N
HBsAg POS N
and POS N
ALT POS N
levels POS N
and POS N
efficacy POS N
48 POS N
weeks POS N
post-treatment. POS N

However, POS N
hepatitis POS N
B POS N
virus POS N
DNA POS N
levels POS N
were POS N
higher POS N
with POS N
PEG-IFN POS N
alfa-2a+placebo POS N
than POS N
PEG-IFN POS N
alfa+ETV POS N
at POS N
week POS N
64 POS N
(p POS N
= POS N
0.0412), POS N
76 POS N
(p POS N
= POS N
0.0311), POS N
and POS N
88 POS N
(p POS N
= POS N
0.0113), POS N
and POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
normalization POS N
rate POS N
was POS N
higher POS N
with POS N
PEG-IFN POS N
alfa-2a+placebo POS N
than POS N
PEG-IFN POS N
alfa-2a+ADV POS N
(p POS N
= POS N
0.0283) POS N
or POS N
PEG-IFN POS N
alfa-2a+ETV POS N
(p POS N
= POS N
0.0369) POS N
at POS N
week POS N
88. POS N

Safety POS N
was POS N
comparable POS N
among POS N
treatment POS N
groups. POS N

However, POS N
hepatitis POS N
B POS N
virus POS N
DNA POS N
levels POS N
were POS N
higher POS N
with POS N
PEG-IFN POS N
alfa-2a+placebo POS N
than POS N
PEG-IFN POS N
alfa+ETV POS N
at POS N
week POS N
64 POS N
(p POS N
= POS N
0.0412), POS N
76 POS N
(p POS N
= POS N
0.0311), POS N
and POS N
88 POS N
(p POS N
= POS N
0.0113), POS N
and POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
normalization POS N
rate POS N
was POS N
higher POS N
with POS N
PEG-IFN POS N
alfa-2a+placebo POS N
than POS N
PEG-IFN POS N
alfa-2a+ADV POS N
(p POS N
= POS N
0.0283) POS N
or POS N
PEG-IFN POS N
alfa-2a+ETV POS N
(p POS N
= POS N
0.0369) POS N
at POS N
week POS N
88. POS N

Pre-therapy POS N
with POS N
ADV POS N
or POS N
ETV POS N
followed POS N
by POS N
PEG-IFN POS N
alfa-2a POS N
is POS N
not POS N
superior POS N
to POS N
PEG-IFN POS N
alfa-2a POS N
monotherapy POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
HBeAg-positive POS N
CHB. POS N

Sub-analysis POS N
of POS N
results POS N
revealed POS N
an POS N
association POS N
between POS N
on-treatment POS N
HBsAg POS N
and POS N
ALT POS N
levels POS N
and POS N
efficacy POS N
48 POS N
weeks POS N
post-treatment. POS N

No POS N
significant POS N
differences POS N
were POS N
observed POS N
among POS N
groups POS N
for POS N
HBeAg POS N
seroconversion POS N
(PEG-IFN POS N
alfa-2a+placebo, POS N
36.3%; POS N
PEG-IFN POS N
alfa-2a+ETV, POS N
29.5%; POS N
and POS N
PEG-IFN POS N
alfa-2a+ADV, POS N
27.4%), POS N
HBeAg POS N
loss POS N
(37.4%, POS N
32.2%, POS N
and POS N
28.6%, POS N
respectively) POS N
or POS N
change POS N
in POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
levels POS N
from POS N
baseline POS N
(-0.56 POS N
IU/mL, POS N
-0.60 POS N
IU/mL, POS N
and POS N
-0.41 POS N
IU/mL, POS N
respectively). POS N

Sub-analysis POS N
of POS N
results POS N
revealed POS N
an POS N
association POS N
between POS N
on-treatment POS N
HBsAg POS N
and POS N
ALT POS N
levels POS N
and POS N
efficacy POS N
48 POS N
weeks POS N
post-treatment. POS N

However, POS N
hepatitis POS N
B POS N
virus POS N
DNA POS N
levels POS N
were POS N
higher POS N
with POS N
PEG-IFN POS N
alfa-2a+placebo POS N
than POS N
PEG-IFN POS N
alfa+ETV POS N
at POS N
week POS N
64 POS N
(p POS N
= POS N
0.0412), POS N
76 POS N
(p POS N
= POS N
0.0311), POS N
and POS N
88 POS N
(p POS N
= POS N
0.0113), POS N
and POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
normalization POS N
rate POS N
was POS N
higher POS N
with POS N
PEG-IFN POS N
alfa-2a+placebo POS N
than POS N
PEG-IFN POS N
alfa-2a+ADV POS N
(p POS N
= POS N
0.0283) POS N
or POS N
PEG-IFN POS N
alfa-2a+ETV POS N
(p POS N
= POS N
0.0369) POS N
at POS N
week POS N
88. POS N

Sub-analysis POS N
of POS N
results POS N
revealed POS N
an POS N
association POS N
between POS N
on-treatment POS N
HBsAg POS N
and POS N
ALT POS N
levels POS N
and POS N
efficacy POS N
48 POS N
weeks POS N
post-treatment. POS N

Safety POS N
was POS N
comparable POS N
among POS N
treatment POS N
groups. POS N

Sub-analysis POS N
of POS N
results POS N
revealed POS N
an POS N
association POS N
between POS N
on-treatment POS N
HBsAg POS N
and POS N
ALT POS N
levels POS N
and POS N
efficacy POS N
48 POS N
weeks POS N
post-treatment. POS N

Pre-therapy POS N
with POS N
ADV POS N
or POS N
ETV POS N
followed POS N
by POS N
PEG-IFN POS N
alfa-2a POS N
is POS N
not POS N
superior POS N
to POS N
PEG-IFN POS N
alfa-2a POS N
monotherapy POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
HBeAg-positive POS N
CHB. POS N

Safety POS N
was POS N
comparable POS N
among POS N
treatment POS N
groups. POS N

No POS N
significant POS N
differences POS N
were POS N
observed POS N
among POS N
groups POS N
for POS N
HBeAg POS N
seroconversion POS N
(PEG-IFN POS N
alfa-2a+placebo, POS N
36.3%; POS N
PEG-IFN POS N
alfa-2a+ETV, POS N
29.5%; POS N
and POS N
PEG-IFN POS N
alfa-2a+ADV, POS N
27.4%), POS N
HBeAg POS N
loss POS N
(37.4%, POS N
32.2%, POS N
and POS N
28.6%, POS N
respectively) POS N
or POS N
change POS N
in POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
levels POS N
from POS N
baseline POS N
(-0.56 POS N
IU/mL, POS N
-0.60 POS N
IU/mL, POS N
and POS N
-0.41 POS N
IU/mL, POS N
respectively). POS N

Safety POS N
was POS N
comparable POS N
among POS N
treatment POS N
groups. POS N

However, POS N
hepatitis POS N
B POS N
virus POS N
DNA POS N
levels POS N
were POS N
higher POS N
with POS N
PEG-IFN POS N
alfa-2a+placebo POS N
than POS N
PEG-IFN POS N
alfa+ETV POS N
at POS N
week POS N
64 POS N
(p POS N
= POS N
0.0412), POS N
76 POS N
(p POS N
= POS N
0.0311), POS N
and POS N
88 POS N
(p POS N
= POS N
0.0113), POS N
and POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
normalization POS N
rate POS N
was POS N
higher POS N
with POS N
PEG-IFN POS N
alfa-2a+placebo POS N
than POS N
PEG-IFN POS N
alfa-2a+ADV POS N
(p POS N
= POS N
0.0283) POS N
or POS N
PEG-IFN POS N
alfa-2a+ETV POS N
(p POS N
= POS N
0.0369) POS N
at POS N
week POS N
88. POS N

Safety POS N
was POS N
comparable POS N
among POS N
treatment POS N
groups. POS N

Sub-analysis POS N
of POS N
results POS N
revealed POS N
an POS N
association POS N
between POS N
on-treatment POS N
HBsAg POS N
and POS N
ALT POS N
levels POS N
and POS N
efficacy POS N
48 POS N
weeks POS N
post-treatment. POS N

Safety POS N
was POS N
comparable POS N
among POS N
treatment POS N
groups. POS N

Pre-therapy POS N
with POS N
ADV POS N
or POS N
ETV POS N
followed POS N
by POS N
PEG-IFN POS N
alfa-2a POS N
is POS N
not POS N
superior POS N
to POS N
PEG-IFN POS N
alfa-2a POS N
monotherapy POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
HBeAg-positive POS N
CHB. POS N

Pre-therapy POS N
with POS N
ADV POS N
or POS N
ETV POS N
followed POS N
by POS N
PEG-IFN POS N
alfa-2a POS N
is POS N
not POS N
superior POS N
to POS N
PEG-IFN POS N
alfa-2a POS N
monotherapy POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
HBeAg-positive POS N
CHB. POS N

No POS N
significant POS N
differences POS N
were POS N
observed POS N
among POS N
groups POS N
for POS N
HBeAg POS N
seroconversion POS N
(PEG-IFN POS N
alfa-2a+placebo, POS N
36.3%; POS N
PEG-IFN POS N
alfa-2a+ETV, POS N
29.5%; POS N
and POS N
PEG-IFN POS N
alfa-2a+ADV, POS N
27.4%), POS N
HBeAg POS N
loss POS N
(37.4%, POS N
32.2%, POS N
and POS N
28.6%, POS N
respectively) POS N
or POS N
change POS N
in POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
levels POS N
from POS N
baseline POS N
(-0.56 POS N
IU/mL, POS N
-0.60 POS N
IU/mL, POS N
and POS N
-0.41 POS N
IU/mL, POS N
respectively). POS N

Pre-therapy POS N
with POS N
ADV POS N
or POS N
ETV POS N
followed POS N
by POS N
PEG-IFN POS N
alfa-2a POS N
is POS N
not POS N
superior POS N
to POS N
PEG-IFN POS N
alfa-2a POS N
monotherapy POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
HBeAg-positive POS N
CHB. POS N

However, POS N
hepatitis POS N
B POS N
virus POS N
DNA POS N
levels POS N
were POS N
higher POS N
with POS N
PEG-IFN POS N
alfa-2a+placebo POS N
than POS N
PEG-IFN POS N
alfa+ETV POS N
at POS N
week POS N
64 POS N
(p POS N
= POS N
0.0412), POS N
76 POS N
(p POS N
= POS N
0.0311), POS N
and POS N
88 POS N
(p POS N
= POS N
0.0113), POS N
and POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
normalization POS N
rate POS N
was POS N
higher POS N
with POS N
PEG-IFN POS N
alfa-2a+placebo POS N
than POS N
PEG-IFN POS N
alfa-2a+ADV POS N
(p POS N
= POS N
0.0283) POS N
or POS N
PEG-IFN POS N
alfa-2a+ETV POS N
(p POS N
= POS N
0.0369) POS N
at POS N
week POS N
88. POS N

Pre-therapy POS N
with POS N
ADV POS N
or POS N
ETV POS N
followed POS N
by POS N
PEG-IFN POS N
alfa-2a POS N
is POS N
not POS N
superior POS N
to POS N
PEG-IFN POS N
alfa-2a POS N
monotherapy POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
HBeAg-positive POS N
CHB. POS N

Sub-analysis POS N
of POS N
results POS N
revealed POS N
an POS N
association POS N
between POS N
on-treatment POS N
HBsAg POS N
and POS N
ALT POS N
levels POS N
and POS N
efficacy POS N
48 POS N
weeks POS N
post-treatment. POS N

Pre-therapy POS N
with POS N
ADV POS N
or POS N
ETV POS N
followed POS N
by POS N
PEG-IFN POS N
alfa-2a POS N
is POS N
not POS N
superior POS N
to POS N
PEG-IFN POS N
alfa-2a POS N
monotherapy POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
HBeAg-positive POS N
CHB. POS N

Safety POS N
was POS N
comparable POS N
among POS N
treatment POS N
groups. POS N

Over POS N
73 POS N
months POS N
after POS N
randomization, POS N
the POS N
fludarabine POS N
group POS N
gained POS N
a POS N
mean POS N
of POS N
45 POS N
days POS N
of POS N
toxicity-free POS N
survival POS N
at POS N
CAP, POS N
and POS N
61 POS N
days POS N
over POS N
ChOP. POS N

The POS N
mean POS N
TWIST POS N
was POS N
27.05 POS N
months POS N
with POS N
CAP, POS N
31.5 POS N
months POS N
with POS N
ChOP POS N
and POS N
32.95 POS N
months POS N
with POS N
fludarabine. POS N

Over POS N
73 POS N
months POS N
after POS N
randomization, POS N
the POS N
fludarabine POS N
group POS N
gained POS N
a POS N
mean POS N
of POS N
45 POS N
days POS N
of POS N
toxicity-free POS N
survival POS N
at POS N
CAP, POS N
and POS N
61 POS N
days POS N
over POS N
ChOP. POS N

The POS N
threshold POS N
analyses POS N
showed POS N
that, POS N
whatever POS N
the POS N
utility POS N
weights, POS N
the POS N
mean POS N
Q-TWIST POS N
was POS N
always POS N
greater POS N
with POS N
ChOP POS N
or POS N
fludarabine POS N
as POS N
compared POS N
to POS N
CAP. POS N

Over POS N
73 POS N
months POS N
after POS N
randomization, POS N
the POS N
fludarabine POS N
group POS N
gained POS N
a POS N
mean POS N
of POS N
45 POS N
days POS N
of POS N
toxicity-free POS N
survival POS N
at POS N
CAP, POS N
and POS N
61 POS N
days POS N
over POS N
ChOP. POS N

Fludarabine POS N
was POS N
consistently POS N
a POS N
better POS N
treatment POS N
than POS N
ChOP, POS N

Over POS N
73 POS N
months POS N
after POS N
randomization, POS N
the POS N
fludarabine POS N
group POS N
gained POS N
a POS N
mean POS N
of POS N
45 POS N
days POS N
of POS N
toxicity-free POS N
survival POS N
at POS N
CAP, POS N
and POS N
61 POS N
days POS N
over POS N
ChOP. POS N

except POS N
in POS N
the POS N
unlikely POS N
case POS N
of POS N
high POS N
utility POS N
weights POS N
attributed POS N
to POS N
toxicity POS N
and POS N
low POS N
utility POS N
weights POS N
attributed POS N
to POS N
treatment. POS N

Over POS N
73 POS N
months POS N
after POS N
randomization, POS N
the POS N
fludarabine POS N
group POS N
gained POS N
a POS N
mean POS N
of POS N
45 POS N
days POS N
of POS N
toxicity-free POS N
survival POS N
at POS N
CAP, POS N
and POS N
61 POS N
days POS N
over POS N
ChOP. POS N

from POS N
a POS N
clinical POS N
point POS N
of POS N
view, POS N
differences POS N
between POS N
ChOP POS N
and POS N
fludarabine POS N
were POS N
moderate POS N
or POS N
event POS N
slight POS N
(mean POS N
difference POS N
in POS N
TWIST POS N
of POS N
1.45 POS N
months). POS N

Over POS N
73 POS N
months POS N
after POS N
randomization, POS N
the POS N
fludarabine POS N
group POS N
gained POS N
a POS N
mean POS N
of POS N
45 POS N
days POS N
of POS N
toxicity-free POS N
survival POS N
at POS N
CAP, POS N
and POS N
61 POS N
days POS N
over POS N
ChOP. POS N

patients POS N
with POS N
advanced POS N
CLL POS N
have POS N
a POS N
moderate POS N
benefit POS N
in POS N
terms POS N
of POS N
Q-TWIST POS N
when POS N
treated POS N
with POS N
fludarabine POS N
over POS N
ChOP. POS N

Over POS N
73 POS N
months POS N
after POS N
randomization, POS N
the POS N
fludarabine POS N
group POS N
gained POS N
a POS N
mean POS N
of POS N
45 POS N
days POS N
of POS N
toxicity-free POS N
survival POS N
at POS N
CAP, POS N
and POS N
61 POS N
days POS N
over POS N
ChOP. POS N

These POS N
two POS N
treatments POS N
are POS N
always POS N
superior POS N
to POS N
CAP. POS N

The POS N
mean POS N
TWIST POS N
was POS N
27.05 POS N
months POS N
with POS N
CAP, POS N
31.5 POS N
months POS N
with POS N
ChOP POS N
and POS N
32.95 POS N
months POS N
with POS N
fludarabine. POS N

Over POS N
73 POS N
months POS N
after POS N
randomization, POS N
the POS N
fludarabine POS N
group POS N
gained POS N
a POS N
mean POS N
of POS N
45 POS N
days POS N
of POS N
toxicity-free POS N
survival POS N
at POS N
CAP, POS N
and POS N
61 POS N
days POS N
over POS N
ChOP. POS N

The POS N
mean POS N
TWIST POS N
was POS N
27.05 POS N
months POS N
with POS N
CAP, POS N
31.5 POS N
months POS N
with POS N
ChOP POS N
and POS N
32.95 POS N
months POS N
with POS N
fludarabine. POS N

The POS N
threshold POS N
analyses POS N
showed POS N
that, POS N
whatever POS N
the POS N
utility POS N
weights, POS N
the POS N
mean POS N
Q-TWIST POS N
was POS N
always POS N
greater POS N
with POS N
ChOP POS N
or POS N
fludarabine POS N
as POS N
compared POS N
to POS N
CAP. POS N

The POS N
mean POS N
TWIST POS N
was POS N
27.05 POS N
months POS N
with POS N
CAP, POS N
31.5 POS N
months POS N
with POS N
ChOP POS N
and POS N
32.95 POS N
months POS N
with POS N
fludarabine. POS N

Fludarabine POS N
was POS N
consistently POS N
a POS N
better POS N
treatment POS N
than POS N
ChOP, POS N

The POS N
mean POS N
TWIST POS N
was POS N
27.05 POS N
months POS N
with POS N
CAP, POS N
31.5 POS N
months POS N
with POS N
ChOP POS N
and POS N
32.95 POS N
months POS N
with POS N
fludarabine. POS N

except POS N
in POS N
the POS N
unlikely POS N
case POS N
of POS N
high POS N
utility POS N
weights POS N
attributed POS N
to POS N
toxicity POS N
and POS N
low POS N
utility POS N
weights POS N
attributed POS N
to POS N
treatment. POS N

The POS N
mean POS N
TWIST POS N
was POS N
27.05 POS N
months POS N
with POS N
CAP, POS N
31.5 POS N
months POS N
with POS N
ChOP POS N
and POS N
32.95 POS N
months POS N
with POS N
fludarabine. POS N

from POS N
a POS N
clinical POS N
point POS N
of POS N
view, POS N
differences POS N
between POS N
ChOP POS N
and POS N
fludarabine POS N
were POS N
moderate POS N
or POS N
event POS N
slight POS N
(mean POS N
difference POS N
in POS N
TWIST POS N
of POS N
1.45 POS N
months). POS N

The POS N
mean POS N
TWIST POS N
was POS N
27.05 POS N
months POS N
with POS N
CAP, POS N
31.5 POS N
months POS N
with POS N
ChOP POS N
and POS N
32.95 POS N
months POS N
with POS N
fludarabine. POS N

patients POS N
with POS N
advanced POS N
CLL POS N
have POS N
a POS N
moderate POS N
benefit POS N
in POS N
terms POS N
of POS N
Q-TWIST POS N
when POS N
treated POS N
with POS N
fludarabine POS N
over POS N
ChOP. POS N

The POS N
mean POS N
TWIST POS N
was POS N
27.05 POS N
months POS N
with POS N
CAP, POS N
31.5 POS N
months POS N
with POS N
ChOP POS N
and POS N
32.95 POS N
months POS N
with POS N
fludarabine. POS N

These POS N
two POS N
treatments POS N
are POS N
always POS N
superior POS N
to POS N
CAP. POS N

The POS N
threshold POS N
analyses POS N
showed POS N
that, POS N
whatever POS N
the POS N
utility POS N
weights, POS N
the POS N
mean POS N
Q-TWIST POS N
was POS N
always POS N
greater POS N
with POS N
ChOP POS N
or POS N
fludarabine POS N
as POS N
compared POS N
to POS N
CAP. POS N

Over POS N
73 POS N
months POS N
after POS N
randomization, POS N
the POS N
fludarabine POS N
group POS N
gained POS N
a POS N
mean POS N
of POS N
45 POS N
days POS N
of POS N
toxicity-free POS N
survival POS N
at POS N
CAP, POS N
and POS N
61 POS N
days POS N
over POS N
ChOP. POS N

The POS N
threshold POS N
analyses POS N
showed POS N
that, POS N
whatever POS N
the POS N
utility POS N
weights, POS N
the POS N
mean POS N
Q-TWIST POS N
was POS N
always POS N
greater POS N
with POS N
ChOP POS N
or POS N
fludarabine POS N
as POS N
compared POS N
to POS N
CAP. POS N

The POS N
mean POS N
TWIST POS N
was POS N
27.05 POS N
months POS N
with POS N
CAP, POS N
31.5 POS N
months POS N
with POS N
ChOP POS N
and POS N
32.95 POS N
months POS N
with POS N
fludarabine. POS N

The POS N
threshold POS N
analyses POS N
showed POS N
that, POS N
whatever POS N
the POS N
utility POS N
weights, POS N
the POS N
mean POS N
Q-TWIST POS N
was POS N
always POS N
greater POS N
with POS N
ChOP POS N
or POS N
fludarabine POS N
as POS N
compared POS N
to POS N
CAP. POS N

Fludarabine POS N
was POS N
consistently POS N
a POS N
better POS N
treatment POS N
than POS N
ChOP, POS N

The POS N
threshold POS N
analyses POS N
showed POS N
that, POS N
whatever POS N
the POS N
utility POS N
weights, POS N
the POS N
mean POS N
Q-TWIST POS N
was POS N
always POS N
greater POS N
with POS N
ChOP POS N
or POS N
fludarabine POS N
as POS N
compared POS N
to POS N
CAP. POS N

except POS N
in POS N
the POS N
unlikely POS N
case POS N
of POS N
high POS N
utility POS N
weights POS N
attributed POS N
to POS N
toxicity POS N
and POS N
low POS N
utility POS N
weights POS N
attributed POS N
to POS N
treatment. POS N

The POS N
threshold POS N
analyses POS N
showed POS N
that, POS N
whatever POS N
the POS N
utility POS N
weights, POS N
the POS N
mean POS N
Q-TWIST POS N
was POS N
always POS N
greater POS N
with POS N
ChOP POS N
or POS N
fludarabine POS N
as POS N
compared POS N
to POS N
CAP. POS N

from POS N
a POS N
clinical POS N
point POS N
of POS N
view, POS N
differences POS N
between POS N
ChOP POS N
and POS N
fludarabine POS N
were POS N
moderate POS N
or POS N
event POS N
slight POS N
(mean POS N
difference POS N
in POS N
TWIST POS N
of POS N
1.45 POS N
months). POS N

The POS N
threshold POS N
analyses POS N
showed POS N
that, POS N
whatever POS N
the POS N
utility POS N
weights, POS N
the POS N
mean POS N
Q-TWIST POS N
was POS N
always POS N
greater POS N
with POS N
ChOP POS N
or POS N
fludarabine POS N
as POS N
compared POS N
to POS N
CAP. POS N

patients POS N
with POS N
advanced POS N
CLL POS N
have POS N
a POS N
moderate POS N
benefit POS N
in POS N
terms POS N
of POS N
Q-TWIST POS N
when POS N
treated POS N
with POS N
fludarabine POS N
over POS N
ChOP. POS N

The POS N
threshold POS N
analyses POS N
showed POS N
that, POS N
whatever POS N
the POS N
utility POS N
weights, POS N
the POS N
mean POS N
Q-TWIST POS N
was POS N
always POS N
greater POS N
with POS N
ChOP POS N
or POS N
fludarabine POS N
as POS N
compared POS N
to POS N
CAP. POS N

These POS N
two POS N
treatments POS N
are POS N
always POS N
superior POS N
to POS N
CAP. POS N

Fludarabine POS N
was POS N
consistently POS N
a POS N
better POS N
treatment POS N
than POS N
ChOP, POS N

Over POS N
73 POS N
months POS N
after POS N
randomization, POS N
the POS N
fludarabine POS N
group POS N
gained POS N
a POS N
mean POS N
of POS N
45 POS N
days POS N
of POS N
toxicity-free POS N
survival POS N
at POS N
CAP, POS N
and POS N
61 POS N
days POS N
over POS N
ChOP. POS N

Fludarabine POS N
was POS N
consistently POS N
a POS N
better POS N
treatment POS N
than POS N
ChOP, POS N

The POS N
mean POS N
TWIST POS N
was POS N
27.05 POS N
months POS N
with POS N
CAP, POS N
31.5 POS N
months POS N
with POS N
ChOP POS N
and POS N
32.95 POS N
months POS N
with POS N
fludarabine. POS N

Fludarabine POS N
was POS N
consistently POS N
a POS N
better POS N
treatment POS N
than POS N
ChOP, POS N

The POS N
threshold POS N
analyses POS N
showed POS N
that, POS N
whatever POS N
the POS N
utility POS N
weights, POS N
the POS N
mean POS N
Q-TWIST POS N
was POS N
always POS N
greater POS N
with POS N
ChOP POS N
or POS N
fludarabine POS N
as POS N
compared POS N
to POS N
CAP. POS N

Fludarabine POS N
was POS N
consistently POS N
a POS N
better POS N
treatment POS N
than POS N
ChOP, POS N

except POS N
in POS N
the POS N
unlikely POS N
case POS N
of POS N
high POS N
utility POS N
weights POS N
attributed POS N
to POS N
toxicity POS N
and POS N
low POS N
utility POS N
weights POS N
attributed POS N
to POS N
treatment. POS N

Fludarabine POS N
was POS N
consistently POS N
a POS N
better POS N
treatment POS N
than POS N
ChOP, POS N

from POS N
a POS N
clinical POS N
point POS N
of POS N
view, POS N
differences POS N
between POS N
ChOP POS N
and POS N
fludarabine POS N
were POS N
moderate POS N
or POS N
event POS N
slight POS N
(mean POS N
difference POS N
in POS N
TWIST POS N
of POS N
1.45 POS N
months). POS N

Fludarabine POS N
was POS N
consistently POS N
a POS N
better POS N
treatment POS N
than POS N
ChOP, POS N

patients POS N
with POS N
advanced POS N
CLL POS N
have POS N
a POS N
moderate POS N
benefit POS N
in POS N
terms POS N
of POS N
Q-TWIST POS N
when POS N
treated POS N
with POS N
fludarabine POS N
over POS N
ChOP. POS N

Fludarabine POS N
was POS N
consistently POS N
a POS N
better POS N
treatment POS N
than POS N
ChOP, POS N

These POS N
two POS N
treatments POS N
are POS N
always POS N
superior POS N
to POS N
CAP. POS N

except POS N
in POS N
the POS N
unlikely POS N
case POS N
of POS N
high POS N
utility POS N
weights POS N
attributed POS N
to POS N
toxicity POS N
and POS N
low POS N
utility POS N
weights POS N
attributed POS N
to POS N
treatment. POS N

Over POS N
73 POS N
months POS N
after POS N
randomization, POS N
the POS N
fludarabine POS N
group POS N
gained POS N
a POS N
mean POS N
of POS N
45 POS N
days POS N
of POS N
toxicity-free POS N
survival POS N
at POS N
CAP, POS N
and POS N
61 POS N
days POS N
over POS N
ChOP. POS N

except POS N
in POS N
the POS N
unlikely POS N
case POS N
of POS N
high POS N
utility POS N
weights POS N
attributed POS N
to POS N
toxicity POS N
and POS N
low POS N
utility POS N
weights POS N
attributed POS N
to POS N
treatment. POS N

The POS N
mean POS N
TWIST POS N
was POS N
27.05 POS N
months POS N
with POS N
CAP, POS N
31.5 POS N
months POS N
with POS N
ChOP POS N
and POS N
32.95 POS N
months POS N
with POS N
fludarabine. POS N

except POS N
in POS N
the POS N
unlikely POS N
case POS N
of POS N
high POS N
utility POS N
weights POS N
attributed POS N
to POS N
toxicity POS N
and POS N
low POS N
utility POS N
weights POS N
attributed POS N
to POS N
treatment. POS N

The POS N
threshold POS N
analyses POS N
showed POS N
that, POS N
whatever POS N
the POS N
utility POS N
weights, POS N
the POS N
mean POS N
Q-TWIST POS N
was POS N
always POS N
greater POS N
with POS N
ChOP POS N
or POS N
fludarabine POS N
as POS N
compared POS N
to POS N
CAP. POS N

except POS N
in POS N
the POS N
unlikely POS N
case POS N
of POS N
high POS N
utility POS N
weights POS N
attributed POS N
to POS N
toxicity POS N
and POS N
low POS N
utility POS N
weights POS N
attributed POS N
to POS N
treatment. POS N

Fludarabine POS N
was POS N
consistently POS N
a POS N
better POS N
treatment POS N
than POS N
ChOP, POS N

except POS N
in POS N
the POS N
unlikely POS N
case POS N
of POS N
high POS N
utility POS N
weights POS N
attributed POS N
to POS N
toxicity POS N
and POS N
low POS N
utility POS N
weights POS N
attributed POS N
to POS N
treatment. POS N

from POS N
a POS N
clinical POS N
point POS N
of POS N
view, POS N
differences POS N
between POS N
ChOP POS N
and POS N
fludarabine POS N
were POS N
moderate POS N
or POS N
event POS N
slight POS N
(mean POS N
difference POS N
in POS N
TWIST POS N
of POS N
1.45 POS N
months). POS N

except POS N
in POS N
the POS N
unlikely POS N
case POS N
of POS N
high POS N
utility POS N
weights POS N
attributed POS N
to POS N
toxicity POS N
and POS N
low POS N
utility POS N
weights POS N
attributed POS N
to POS N
treatment. POS N

patients POS N
with POS N
advanced POS N
CLL POS N
have POS N
a POS N
moderate POS N
benefit POS N
in POS N
terms POS N
of POS N
Q-TWIST POS N
when POS N
treated POS N
with POS N
fludarabine POS N
over POS N
ChOP. POS N

except POS N
in POS N
the POS N
unlikely POS N
case POS N
of POS N
high POS N
utility POS N
weights POS N
attributed POS N
to POS N
toxicity POS N
and POS N
low POS N
utility POS N
weights POS N
attributed POS N
to POS N
treatment. POS N

These POS N
two POS N
treatments POS N
are POS N
always POS N
superior POS N
to POS N
CAP. POS N

from POS N
a POS N
clinical POS N
point POS N
of POS N
view, POS N
differences POS N
between POS N
ChOP POS N
and POS N
fludarabine POS N
were POS N
moderate POS N
or POS N
event POS N
slight POS N
(mean POS N
difference POS N
in POS N
TWIST POS N
of POS N
1.45 POS N
months). POS N

Over POS N
73 POS N
months POS N
after POS N
randomization, POS N
the POS N
fludarabine POS N
group POS N
gained POS N
a POS N
mean POS N
of POS N
45 POS N
days POS N
of POS N
toxicity-free POS N
survival POS N
at POS N
CAP, POS N
and POS N
61 POS N
days POS N
over POS N
ChOP. POS N

from POS N
a POS N
clinical POS N
point POS N
of POS N
view, POS N
differences POS N
between POS N
ChOP POS N
and POS N
fludarabine POS N
were POS N
moderate POS N
or POS N
event POS N
slight POS N
(mean POS N
difference POS N
in POS N
TWIST POS N
of POS N
1.45 POS N
months). POS N

The POS N
mean POS N
TWIST POS N
was POS N
27.05 POS N
months POS N
with POS N
CAP, POS N
31.5 POS N
months POS N
with POS N
ChOP POS N
and POS N
32.95 POS N
months POS N
with POS N
fludarabine. POS N

from POS N
a POS N
clinical POS N
point POS N
of POS N
view, POS N
differences POS N
between POS N
ChOP POS N
and POS N
fludarabine POS N
were POS N
moderate POS N
or POS N
event POS N
slight POS N
(mean POS N
difference POS N
in POS N
TWIST POS N
of POS N
1.45 POS N
months). POS N

The POS N
threshold POS N
analyses POS N
showed POS N
that, POS N
whatever POS N
the POS N
utility POS N
weights, POS N
the POS N
mean POS N
Q-TWIST POS N
was POS N
always POS N
greater POS N
with POS N
ChOP POS N
or POS N
fludarabine POS N
as POS N
compared POS N
to POS N
CAP. POS N

from POS N
a POS N
clinical POS N
point POS N
of POS N
view, POS N
differences POS N
between POS N
ChOP POS N
and POS N
fludarabine POS N
were POS N
moderate POS N
or POS N
event POS N
slight POS N
(mean POS N
difference POS N
in POS N
TWIST POS N
of POS N
1.45 POS N
months). POS N

Fludarabine POS N
was POS N
consistently POS N
a POS N
better POS N
treatment POS N
than POS N
ChOP, POS N

from POS N
a POS N
clinical POS N
point POS N
of POS N
view, POS N
differences POS N
between POS N
ChOP POS N
and POS N
fludarabine POS N
were POS N
moderate POS N
or POS N
event POS N
slight POS N
(mean POS N
difference POS N
in POS N
TWIST POS N
of POS N
1.45 POS N
months). POS N

except POS N
in POS N
the POS N
unlikely POS N
case POS N
of POS N
high POS N
utility POS N
weights POS N
attributed POS N
to POS N
toxicity POS N
and POS N
low POS N
utility POS N
weights POS N
attributed POS N
to POS N
treatment. POS N

from POS N
a POS N
clinical POS N
point POS N
of POS N
view, POS N
differences POS N
between POS N
ChOP POS N
and POS N
fludarabine POS N
were POS N
moderate POS N
or POS N
event POS N
slight POS N
(mean POS N
difference POS N
in POS N
TWIST POS N
of POS N
1.45 POS N
months). POS N

patients POS N
with POS N
advanced POS N
CLL POS N
have POS N
a POS N
moderate POS N
benefit POS N
in POS N
terms POS N
of POS N
Q-TWIST POS N
when POS N
treated POS N
with POS N
fludarabine POS N
over POS N
ChOP. POS N

from POS N
a POS N
clinical POS N
point POS N
of POS N
view, POS N
differences POS N
between POS N
ChOP POS N
and POS N
fludarabine POS N
were POS N
moderate POS N
or POS N
event POS N
slight POS N
(mean POS N
difference POS N
in POS N
TWIST POS N
of POS N
1.45 POS N
months). POS N

These POS N
two POS N
treatments POS N
are POS N
always POS N
superior POS N
to POS N
CAP. POS N

patients POS N
with POS N
advanced POS N
CLL POS N
have POS N
a POS N
moderate POS N
benefit POS N
in POS N
terms POS N
of POS N
Q-TWIST POS N
when POS N
treated POS N
with POS N
fludarabine POS N
over POS N
ChOP. POS N

Over POS N
73 POS N
months POS N
after POS N
randomization, POS N
the POS N
fludarabine POS N
group POS N
gained POS N
a POS N
mean POS N
of POS N
45 POS N
days POS N
of POS N
toxicity-free POS N
survival POS N
at POS N
CAP, POS N
and POS N
61 POS N
days POS N
over POS N
ChOP. POS N

patients POS N
with POS N
advanced POS N
CLL POS N
have POS N
a POS N
moderate POS N
benefit POS N
in POS N
terms POS N
of POS N
Q-TWIST POS N
when POS N
treated POS N
with POS N
fludarabine POS N
over POS N
ChOP. POS N

The POS N
mean POS N
TWIST POS N
was POS N
27.05 POS N
months POS N
with POS N
CAP, POS N
31.5 POS N
months POS N
with POS N
ChOP POS N
and POS N
32.95 POS N
months POS N
with POS N
fludarabine. POS N

patients POS N
with POS N
advanced POS N
CLL POS N
have POS N
a POS N
moderate POS N
benefit POS N
in POS N
terms POS N
of POS N
Q-TWIST POS N
when POS N
treated POS N
with POS N
fludarabine POS N
over POS N
ChOP. POS N

The POS N
threshold POS N
analyses POS N
showed POS N
that, POS N
whatever POS N
the POS N
utility POS N
weights, POS N
the POS N
mean POS N
Q-TWIST POS N
was POS N
always POS N
greater POS N
with POS N
ChOP POS N
or POS N
fludarabine POS N
as POS N
compared POS N
to POS N
CAP. POS N

patients POS N
with POS N
advanced POS N
CLL POS N
have POS N
a POS N
moderate POS N
benefit POS N
in POS N
terms POS N
of POS N
Q-TWIST POS N
when POS N
treated POS N
with POS N
fludarabine POS N
over POS N
ChOP. POS N

Fludarabine POS N
was POS N
consistently POS N
a POS N
better POS N
treatment POS N
than POS N
ChOP, POS N

patients POS N
with POS N
advanced POS N
CLL POS N
have POS N
a POS N
moderate POS N
benefit POS N
in POS N
terms POS N
of POS N
Q-TWIST POS N
when POS N
treated POS N
with POS N
fludarabine POS N
over POS N
ChOP. POS N

except POS N
in POS N
the POS N
unlikely POS N
case POS N
of POS N
high POS N
utility POS N
weights POS N
attributed POS N
to POS N
toxicity POS N
and POS N
low POS N
utility POS N
weights POS N
attributed POS N
to POS N
treatment. POS N

patients POS N
with POS N
advanced POS N
CLL POS N
have POS N
a POS N
moderate POS N
benefit POS N
in POS N
terms POS N
of POS N
Q-TWIST POS N
when POS N
treated POS N
with POS N
fludarabine POS N
over POS N
ChOP. POS N

from POS N
a POS N
clinical POS N
point POS N
of POS N
view, POS N
differences POS N
between POS N
ChOP POS N
and POS N
fludarabine POS N
were POS N
moderate POS N
or POS N
event POS N
slight POS N
(mean POS N
difference POS N
in POS N
TWIST POS N
of POS N
1.45 POS N
months). POS N

patients POS N
with POS N
advanced POS N
CLL POS N
have POS N
a POS N
moderate POS N
benefit POS N
in POS N
terms POS N
of POS N
Q-TWIST POS N
when POS N
treated POS N
with POS N
fludarabine POS N
over POS N
ChOP. POS N

These POS N
two POS N
treatments POS N
are POS N
always POS N
superior POS N
to POS N
CAP. POS N

These POS N
two POS N
treatments POS N
are POS N
always POS N
superior POS N
to POS N
CAP. POS N

Over POS N
73 POS N
months POS N
after POS N
randomization, POS N
the POS N
fludarabine POS N
group POS N
gained POS N
a POS N
mean POS N
of POS N
45 POS N
days POS N
of POS N
toxicity-free POS N
survival POS N
at POS N
CAP, POS N
and POS N
61 POS N
days POS N
over POS N
ChOP. POS N

These POS N
two POS N
treatments POS N
are POS N
always POS N
superior POS N
to POS N
CAP. POS N

The POS N
mean POS N
TWIST POS N
was POS N
27.05 POS N
months POS N
with POS N
CAP, POS N
31.5 POS N
months POS N
with POS N
ChOP POS N
and POS N
32.95 POS N
months POS N
with POS N
fludarabine. POS N

These POS N
two POS N
treatments POS N
are POS N
always POS N
superior POS N
to POS N
CAP. POS N

The POS N
threshold POS N
analyses POS N
showed POS N
that, POS N
whatever POS N
the POS N
utility POS N
weights, POS N
the POS N
mean POS N
Q-TWIST POS N
was POS N
always POS N
greater POS N
with POS N
ChOP POS N
or POS N
fludarabine POS N
as POS N
compared POS N
to POS N
CAP. POS N

These POS N
two POS N
treatments POS N
are POS N
always POS N
superior POS N
to POS N
CAP. POS N

Fludarabine POS N
was POS N
consistently POS N
a POS N
better POS N
treatment POS N
than POS N
ChOP, POS N

These POS N
two POS N
treatments POS N
are POS N
always POS N
superior POS N
to POS N
CAP. POS N

except POS N
in POS N
the POS N
unlikely POS N
case POS N
of POS N
high POS N
utility POS N
weights POS N
attributed POS N
to POS N
toxicity POS N
and POS N
low POS N
utility POS N
weights POS N
attributed POS N
to POS N
treatment. POS N

These POS N
two POS N
treatments POS N
are POS N
always POS N
superior POS N
to POS N
CAP. POS N

from POS N
a POS N
clinical POS N
point POS N
of POS N
view, POS N
differences POS N
between POS N
ChOP POS N
and POS N
fludarabine POS N
were POS N
moderate POS N
or POS N
event POS N
slight POS N
(mean POS N
difference POS N
in POS N
TWIST POS N
of POS N
1.45 POS N
months). POS N

These POS N
two POS N
treatments POS N
are POS N
always POS N
superior POS N
to POS N
CAP. POS N

patients POS N
with POS N
advanced POS N
CLL POS N
have POS N
a POS N
moderate POS N
benefit POS N
in POS N
terms POS N
of POS N
Q-TWIST POS N
when POS N
treated POS N
with POS N
fludarabine POS N
over POS N
ChOP. POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

The POS N
hazard POS N
ratios POS N
for POS N
overall POS N
survival POS N
were POS N
0.88 POS N
(95% POS N
CI POS N
0.70-1.12, POS N
p=0.17) POS N
for POS N
de POS N
Gramont POS N
versus POS N
Lokich, POS N
and POS N
0.99 POS N
(0.79-1.25, POS N
p=0.94) POS N
for POS N
de POS N
Gramont POS N
versus POS N
raltitrexed. POS N

For POS N
the POS N
de POS N
Gramont, POS N
Lokich, POS N
and POS N
raltitrexed POS N
groups, POS N
respectively, POS N
median POS N
survival POS N
was POS N
294, POS N
302, POS N
and POS N
266 POS N
days. POS N

The POS N
hazard POS N
ratios POS N
for POS N
overall POS N
survival POS N
were POS N
0.88 POS N
(95% POS N
CI POS N
0.70-1.12, POS N
p=0.17) POS N
for POS N
de POS N
Gramont POS N
versus POS N
Lokich, POS N
and POS N
0.99 POS N
(0.79-1.25, POS N
p=0.94) POS N
for POS N
de POS N
Gramont POS N
versus POS N
raltitrexed. POS N

An POS N
increase POS N
in POS N
treatment-related POS N
deaths POS N
was POS N
seen POS N
on POS N
raltitrexed POS N
(de POS N
Gramont POS N
one, POS N
Lokich POS N
two, POS N
raltitrexed POS N
18) POS N
due POS N
to POS N
combined POS N
gastrointestinal POS N
and POS N
haematological POS N
toxicity. POS N

The POS N
hazard POS N
ratios POS N
for POS N
overall POS N
survival POS N
were POS N
0.88 POS N
(95% POS N
CI POS N
0.70-1.12, POS N
p=0.17) POS N
for POS N
de POS N
Gramont POS N
versus POS N
Lokich, POS N
and POS N
0.99 POS N
(0.79-1.25, POS N
p=0.94) POS N
for POS N
de POS N
Gramont POS N
versus POS N
raltitrexed. POS N

Patients' POS N
assessment POS N
of POS N
quality POS N
of POS N
life POS N
showed POS N
that POS N
raltitrexed POS N
was POS N
inferior POS N
to POS N
the POS N
fluorouracil-based POS N
regimens, POS N
especially POS N
in POS N
terms POS N
of POS N
palliation POS N
and POS N
functioning. POS N

The POS N
hazard POS N
ratios POS N
for POS N
overall POS N
survival POS N
were POS N
0.88 POS N
(95% POS N
CI POS N
0.70-1.12, POS N
p=0.17) POS N
for POS N
de POS N
Gramont POS N
versus POS N
Lokich, POS N
and POS N
0.99 POS N
(0.79-1.25, POS N
p=0.94) POS N
for POS N
de POS N
Gramont POS N
versus POS N
raltitrexed. POS N

The POS N
deGramont POS N
and POS N
Lokich POS N
regimens POS N
were POS N
similar POS N
in POS N
terms POS N
of POS N
survival, POS N
quality POS N
of POS N
life, POS N
and POS N
response POS N
rates. POS N

The POS N
hazard POS N
ratios POS N
for POS N
overall POS N
survival POS N
were POS N
0.88 POS N
(95% POS N
CI POS N
0.70-1.12, POS N
p=0.17) POS N
for POS N
de POS N
Gramont POS N
versus POS N
Lokich, POS N
and POS N
0.99 POS N
(0.79-1.25, POS N
p=0.94) POS N
for POS N
de POS N
Gramont POS N
versus POS N
raltitrexed. POS N

The POS N
Lokich POS N
regimen POS N
was POS N
associated POS N
with POS N
more POS N
central POS N
line POS N
complications POS N
and POS N
hand-foot POS N
syndrome. POS N

The POS N
hazard POS N
ratios POS N
for POS N
overall POS N
survival POS N
were POS N
0.88 POS N
(95% POS N
CI POS N
0.70-1.12, POS N
p=0.17) POS N
for POS N
de POS N
Gramont POS N
versus POS N
Lokich, POS N
and POS N
0.99 POS N
(0.79-1.25, POS N
p=0.94) POS N
for POS N
de POS N
Gramont POS N
versus POS N
raltitrexed. POS N

Raltitrexed POS N
showed POS N
similar POS N
response POS N
rates POS N
and POS N
overall POS N
survival POS N
to POS N
the POS N
de POS N
Gramont POS N
regimen POS N
and POS N
was POS N
easier POS N
to POS N
administer, POS N

The POS N
hazard POS N
ratios POS N
for POS N
overall POS N
survival POS N
were POS N
0.88 POS N
(95% POS N
CI POS N
0.70-1.12, POS N
p=0.17) POS N
for POS N
de POS N
Gramont POS N
versus POS N
Lokich, POS N
and POS N
0.99 POS N
(0.79-1.25, POS N
p=0.94) POS N
for POS N
de POS N
Gramont POS N
versus POS N
raltitrexed. POS N

but POS N
resulted POS N
in POS N
greater POS N
toxicity POS N
and POS N
inferior POS N
quality POS N
of POS N
life. POS N

For POS N
the POS N
de POS N
Gramont, POS N
Lokich, POS N
and POS N
raltitrexed POS N
groups, POS N
respectively, POS N
median POS N
survival POS N
was POS N
294, POS N
302, POS N
and POS N
266 POS N
days. POS N

The POS N
hazard POS N
ratios POS N
for POS N
overall POS N
survival POS N
were POS N
0.88 POS N
(95% POS N
CI POS N
0.70-1.12, POS N
p=0.17) POS N
for POS N
de POS N
Gramont POS N
versus POS N
Lokich, POS N
and POS N
0.99 POS N
(0.79-1.25, POS N
p=0.94) POS N
for POS N
de POS N
Gramont POS N
versus POS N
raltitrexed. POS N

For POS N
the POS N
de POS N
Gramont, POS N
Lokich, POS N
and POS N
raltitrexed POS N
groups, POS N
respectively, POS N
median POS N
survival POS N
was POS N
294, POS N
302, POS N
and POS N
266 POS N
days. POS N

An POS N
increase POS N
in POS N
treatment-related POS N
deaths POS N
was POS N
seen POS N
on POS N
raltitrexed POS N
(de POS N
Gramont POS N
one, POS N
Lokich POS N
two, POS N
raltitrexed POS N
18) POS N
due POS N
to POS N
combined POS N
gastrointestinal POS N
and POS N
haematological POS N
toxicity. POS N

For POS N
the POS N
de POS N
Gramont, POS N
Lokich, POS N
and POS N
raltitrexed POS N
groups, POS N
respectively, POS N
median POS N
survival POS N
was POS N
294, POS N
302, POS N
and POS N
266 POS N
days. POS N

Patients' POS N
assessment POS N
of POS N
quality POS N
of POS N
life POS N
showed POS N
that POS N
raltitrexed POS N
was POS N
inferior POS N
to POS N
the POS N
fluorouracil-based POS N
regimens, POS N
especially POS N
in POS N
terms POS N
of POS N
palliation POS N
and POS N
functioning. POS N

For POS N
the POS N
de POS N
Gramont, POS N
Lokich, POS N
and POS N
raltitrexed POS N
groups, POS N
respectively, POS N
median POS N
survival POS N
was POS N
294, POS N
302, POS N
and POS N
266 POS N
days. POS N

The POS N
deGramont POS N
and POS N
Lokich POS N
regimens POS N
were POS N
similar POS N
in POS N
terms POS N
of POS N
survival, POS N
quality POS N
of POS N
life, POS N
and POS N
response POS N
rates. POS N

For POS N
the POS N
de POS N
Gramont, POS N
Lokich, POS N
and POS N
raltitrexed POS N
groups, POS N
respectively, POS N
median POS N
survival POS N
was POS N
294, POS N
302, POS N
and POS N
266 POS N
days. POS N

The POS N
Lokich POS N
regimen POS N
was POS N
associated POS N
with POS N
more POS N
central POS N
line POS N
complications POS N
and POS N
hand-foot POS N
syndrome. POS N

For POS N
the POS N
de POS N
Gramont, POS N
Lokich, POS N
and POS N
raltitrexed POS N
groups, POS N
respectively, POS N
median POS N
survival POS N
was POS N
294, POS N
302, POS N
and POS N
266 POS N
days. POS N

Raltitrexed POS N
showed POS N
similar POS N
response POS N
rates POS N
and POS N
overall POS N
survival POS N
to POS N
the POS N
de POS N
Gramont POS N
regimen POS N
and POS N
was POS N
easier POS N
to POS N
administer, POS N

For POS N
the POS N
de POS N
Gramont, POS N
Lokich, POS N
and POS N
raltitrexed POS N
groups, POS N
respectively, POS N
median POS N
survival POS N
was POS N
294, POS N
302, POS N
and POS N
266 POS N
days. POS N

but POS N
resulted POS N
in POS N
greater POS N
toxicity POS N
and POS N
inferior POS N
quality POS N
of POS N
life. POS N

An POS N
increase POS N
in POS N
treatment-related POS N
deaths POS N
was POS N
seen POS N
on POS N
raltitrexed POS N
(de POS N
Gramont POS N
one, POS N
Lokich POS N
two, POS N
raltitrexed POS N
18) POS N
due POS N
to POS N
combined POS N
gastrointestinal POS N
and POS N
haematological POS N
toxicity. POS N

The POS N
hazard POS N
ratios POS N
for POS N
overall POS N
survival POS N
were POS N
0.88 POS N
(95% POS N
CI POS N
0.70-1.12, POS N
p=0.17) POS N
for POS N
de POS N
Gramont POS N
versus POS N
Lokich, POS N
and POS N
0.99 POS N
(0.79-1.25, POS N
p=0.94) POS N
for POS N
de POS N
Gramont POS N
versus POS N
raltitrexed. POS N

An POS N
increase POS N
in POS N
treatment-related POS N
deaths POS N
was POS N
seen POS N
on POS N
raltitrexed POS N
(de POS N
Gramont POS N
one, POS N
Lokich POS N
two, POS N
raltitrexed POS N
18) POS N
due POS N
to POS N
combined POS N
gastrointestinal POS N
and POS N
haematological POS N
toxicity. POS N

For POS N
the POS N
de POS N
Gramont, POS N
Lokich, POS N
and POS N
raltitrexed POS N
groups, POS N
respectively, POS N
median POS N
survival POS N
was POS N
294, POS N
302, POS N
and POS N
266 POS N
days. POS N

An POS N
increase POS N
in POS N
treatment-related POS N
deaths POS N
was POS N
seen POS N
on POS N
raltitrexed POS N
(de POS N
Gramont POS N
one, POS N
Lokich POS N
two, POS N
raltitrexed POS N
18) POS N
due POS N
to POS N
combined POS N
gastrointestinal POS N
and POS N
haematological POS N
toxicity. POS N

Patients' POS N
assessment POS N
of POS N
quality POS N
of POS N
life POS N
showed POS N
that POS N
raltitrexed POS N
was POS N
inferior POS N
to POS N
the POS N
fluorouracil-based POS N
regimens, POS N
especially POS N
in POS N
terms POS N
of POS N
palliation POS N
and POS N
functioning. POS N

An POS N
increase POS N
in POS N
treatment-related POS N
deaths POS N
was POS N
seen POS N
on POS N
raltitrexed POS N
(de POS N
Gramont POS N
one, POS N
Lokich POS N
two, POS N
raltitrexed POS N
18) POS N
due POS N
to POS N
combined POS N
gastrointestinal POS N
and POS N
haematological POS N
toxicity. POS N

The POS N
deGramont POS N
and POS N
Lokich POS N
regimens POS N
were POS N
similar POS N
in POS N
terms POS N
of POS N
survival, POS N
quality POS N
of POS N
life, POS N
and POS N
response POS N
rates. POS N

An POS N
increase POS N
in POS N
treatment-related POS N
deaths POS N
was POS N
seen POS N
on POS N
raltitrexed POS N
(de POS N
Gramont POS N
one, POS N
Lokich POS N
two, POS N
raltitrexed POS N
18) POS N
due POS N
to POS N
combined POS N
gastrointestinal POS N
and POS N
haematological POS N
toxicity. POS N

The POS N
Lokich POS N
regimen POS N
was POS N
associated POS N
with POS N
more POS N
central POS N
line POS N
complications POS N
and POS N
hand-foot POS N
syndrome. POS N

An POS N
increase POS N
in POS N
treatment-related POS N
deaths POS N
was POS N
seen POS N
on POS N
raltitrexed POS N
(de POS N
Gramont POS N
one, POS N
Lokich POS N
two, POS N
raltitrexed POS N
18) POS N
due POS N
to POS N
combined POS N
gastrointestinal POS N
and POS N
haematological POS N
toxicity. POS N

Raltitrexed POS N
showed POS N
similar POS N
response POS N
rates POS N
and POS N
overall POS N
survival POS N
to POS N
the POS N
de POS N
Gramont POS N
regimen POS N
and POS N
was POS N
easier POS N
to POS N
administer, POS N

An POS N
increase POS N
in POS N
treatment-related POS N
deaths POS N
was POS N
seen POS N
on POS N
raltitrexed POS N
(de POS N
Gramont POS N
one, POS N
Lokich POS N
two, POS N
raltitrexed POS N
18) POS N
due POS N
to POS N
combined POS N
gastrointestinal POS N
and POS N
haematological POS N
toxicity. POS N

but POS N
resulted POS N
in POS N
greater POS N
toxicity POS N
and POS N
inferior POS N
quality POS N
of POS N
life. POS N

Patients' POS N
assessment POS N
of POS N
quality POS N
of POS N
life POS N
showed POS N
that POS N
raltitrexed POS N
was POS N
inferior POS N
to POS N
the POS N
fluorouracil-based POS N
regimens, POS N
especially POS N
in POS N
terms POS N
of POS N
palliation POS N
and POS N
functioning. POS N

The POS N
hazard POS N
ratios POS N
for POS N
overall POS N
survival POS N
were POS N
0.88 POS N
(95% POS N
CI POS N
0.70-1.12, POS N
p=0.17) POS N
for POS N
de POS N
Gramont POS N
versus POS N
Lokich, POS N
and POS N
0.99 POS N
(0.79-1.25, POS N
p=0.94) POS N
for POS N
de POS N
Gramont POS N
versus POS N
raltitrexed. POS N

Patients' POS N
assessment POS N
of POS N
quality POS N
of POS N
life POS N
showed POS N
that POS N
raltitrexed POS N
was POS N
inferior POS N
to POS N
the POS N
fluorouracil-based POS N
regimens, POS N
especially POS N
in POS N
terms POS N
of POS N
palliation POS N
and POS N
functioning. POS N

For POS N
the POS N
de POS N
Gramont, POS N
Lokich, POS N
and POS N
raltitrexed POS N
groups, POS N
respectively, POS N
median POS N
survival POS N
was POS N
294, POS N
302, POS N
and POS N
266 POS N
days. POS N

Patients' POS N
assessment POS N
of POS N
quality POS N
of POS N
life POS N
showed POS N
that POS N
raltitrexed POS N
was POS N
inferior POS N
to POS N
the POS N
fluorouracil-based POS N
regimens, POS N
especially POS N
in POS N
terms POS N
of POS N
palliation POS N
and POS N
functioning. POS N

An POS N
increase POS N
in POS N
treatment-related POS N
deaths POS N
was POS N
seen POS N
on POS N
raltitrexed POS N
(de POS N
Gramont POS N
one, POS N
Lokich POS N
two, POS N
raltitrexed POS N
18) POS N
due POS N
to POS N
combined POS N
gastrointestinal POS N
and POS N
haematological POS N
toxicity. POS N

Patients' POS N
assessment POS N
of POS N
quality POS N
of POS N
life POS N
showed POS N
that POS N
raltitrexed POS N
was POS N
inferior POS N
to POS N
the POS N
fluorouracil-based POS N
regimens, POS N
especially POS N
in POS N
terms POS N
of POS N
palliation POS N
and POS N
functioning. POS N

The POS N
deGramont POS N
and POS N
Lokich POS N
regimens POS N
were POS N
similar POS N
in POS N
terms POS N
of POS N
survival, POS N
quality POS N
of POS N
life, POS N
and POS N
response POS N
rates. POS N

Patients' POS N
assessment POS N
of POS N
quality POS N
of POS N
life POS N
showed POS N
that POS N
raltitrexed POS N
was POS N
inferior POS N
to POS N
the POS N
fluorouracil-based POS N
regimens, POS N
especially POS N
in POS N
terms POS N
of POS N
palliation POS N
and POS N
functioning. POS N

The POS N
Lokich POS N
regimen POS N
was POS N
associated POS N
with POS N
more POS N
central POS N
line POS N
complications POS N
and POS N
hand-foot POS N
syndrome. POS N

Patients' POS N
assessment POS N
of POS N
quality POS N
of POS N
life POS N
showed POS N
that POS N
raltitrexed POS N
was POS N
inferior POS N
to POS N
the POS N
fluorouracil-based POS N
regimens, POS N
especially POS N
in POS N
terms POS N
of POS N
palliation POS N
and POS N
functioning. POS N

Raltitrexed POS N
showed POS N
similar POS N
response POS N
rates POS N
and POS N
overall POS N
survival POS N
to POS N
the POS N
de POS N
Gramont POS N
regimen POS N
and POS N
was POS N
easier POS N
to POS N
administer, POS N

Patients' POS N
assessment POS N
of POS N
quality POS N
of POS N
life POS N
showed POS N
that POS N
raltitrexed POS N
was POS N
inferior POS N
to POS N
the POS N
fluorouracil-based POS N
regimens, POS N
especially POS N
in POS N
terms POS N
of POS N
palliation POS N
and POS N
functioning. POS N

but POS N
resulted POS N
in POS N
greater POS N
toxicity POS N
and POS N
inferior POS N
quality POS N
of POS N
life. POS N

The POS N
deGramont POS N
and POS N
Lokich POS N
regimens POS N
were POS N
similar POS N
in POS N
terms POS N
of POS N
survival, POS N
quality POS N
of POS N
life, POS N
and POS N
response POS N
rates. POS N

The POS N
hazard POS N
ratios POS N
for POS N
overall POS N
survival POS N
were POS N
0.88 POS N
(95% POS N
CI POS N
0.70-1.12, POS N
p=0.17) POS N
for POS N
de POS N
Gramont POS N
versus POS N
Lokich, POS N
and POS N
0.99 POS N
(0.79-1.25, POS N
p=0.94) POS N
for POS N
de POS N
Gramont POS N
versus POS N
raltitrexed. POS N

The POS N
deGramont POS N
and POS N
Lokich POS N
regimens POS N
were POS N
similar POS N
in POS N
terms POS N
of POS N
survival, POS N
quality POS N
of POS N
life, POS N
and POS N
response POS N
rates. POS N

For POS N
the POS N
de POS N
Gramont, POS N
Lokich, POS N
and POS N
raltitrexed POS N
groups, POS N
respectively, POS N
median POS N
survival POS N
was POS N
294, POS N
302, POS N
and POS N
266 POS N
days. POS N

The POS N
deGramont POS N
and POS N
Lokich POS N
regimens POS N
were POS N
similar POS N
in POS N
terms POS N
of POS N
survival, POS N
quality POS N
of POS N
life, POS N
and POS N
response POS N
rates. POS N

An POS N
increase POS N
in POS N
treatment-related POS N
deaths POS N
was POS N
seen POS N
on POS N
raltitrexed POS N
(de POS N
Gramont POS N
one, POS N
Lokich POS N
two, POS N
raltitrexed POS N
18) POS N
due POS N
to POS N
combined POS N
gastrointestinal POS N
and POS N
haematological POS N
toxicity. POS N

The POS N
deGramont POS N
and POS N
Lokich POS N
regimens POS N
were POS N
similar POS N
in POS N
terms POS N
of POS N
survival, POS N
quality POS N
of POS N
life, POS N
and POS N
response POS N
rates. POS N

Patients' POS N
assessment POS N
of POS N
quality POS N
of POS N
life POS N
showed POS N
that POS N
raltitrexed POS N
was POS N
inferior POS N
to POS N
the POS N
fluorouracil-based POS N
regimens, POS N
especially POS N
in POS N
terms POS N
of POS N
palliation POS N
and POS N
functioning. POS N

The POS N
deGramont POS N
and POS N
Lokich POS N
regimens POS N
were POS N
similar POS N
in POS N
terms POS N
of POS N
survival, POS N
quality POS N
of POS N
life, POS N
and POS N
response POS N
rates. POS N

The POS N
Lokich POS N
regimen POS N
was POS N
associated POS N
with POS N
more POS N
central POS N
line POS N
complications POS N
and POS N
hand-foot POS N
syndrome. POS N

The POS N
deGramont POS N
and POS N
Lokich POS N
regimens POS N
were POS N
similar POS N
in POS N
terms POS N
of POS N
survival, POS N
quality POS N
of POS N
life, POS N
and POS N
response POS N
rates. POS N

Raltitrexed POS N
showed POS N
similar POS N
response POS N
rates POS N
and POS N
overall POS N
survival POS N
to POS N
the POS N
de POS N
Gramont POS N
regimen POS N
and POS N
was POS N
easier POS N
to POS N
administer, POS N

The POS N
deGramont POS N
and POS N
Lokich POS N
regimens POS N
were POS N
similar POS N
in POS N
terms POS N
of POS N
survival, POS N
quality POS N
of POS N
life, POS N
and POS N
response POS N
rates. POS N

but POS N
resulted POS N
in POS N
greater POS N
toxicity POS N
and POS N
inferior POS N
quality POS N
of POS N
life. POS N

The POS N
Lokich POS N
regimen POS N
was POS N
associated POS N
with POS N
more POS N
central POS N
line POS N
complications POS N
and POS N
hand-foot POS N
syndrome. POS N

The POS N
hazard POS N
ratios POS N
for POS N
overall POS N
survival POS N
were POS N
0.88 POS N
(95% POS N
CI POS N
0.70-1.12, POS N
p=0.17) POS N
for POS N
de POS N
Gramont POS N
versus POS N
Lokich, POS N
and POS N
0.99 POS N
(0.79-1.25, POS N
p=0.94) POS N
for POS N
de POS N
Gramont POS N
versus POS N
raltitrexed. POS N

The POS N
Lokich POS N
regimen POS N
was POS N
associated POS N
with POS N
more POS N
central POS N
line POS N
complications POS N
and POS N
hand-foot POS N
syndrome. POS N

For POS N
the POS N
de POS N
Gramont, POS N
Lokich, POS N
and POS N
raltitrexed POS N
groups, POS N
respectively, POS N
median POS N
survival POS N
was POS N
294, POS N
302, POS N
and POS N
266 POS N
days. POS N

The POS N
Lokich POS N
regimen POS N
was POS N
associated POS N
with POS N
more POS N
central POS N
line POS N
complications POS N
and POS N
hand-foot POS N
syndrome. POS N

An POS N
increase POS N
in POS N
treatment-related POS N
deaths POS N
was POS N
seen POS N
on POS N
raltitrexed POS N
(de POS N
Gramont POS N
one, POS N
Lokich POS N
two, POS N
raltitrexed POS N
18) POS N
due POS N
to POS N
combined POS N
gastrointestinal POS N
and POS N
haematological POS N
toxicity. POS N

The POS N
Lokich POS N
regimen POS N
was POS N
associated POS N
with POS N
more POS N
central POS N
line POS N
complications POS N
and POS N
hand-foot POS N
syndrome. POS N

Patients' POS N
assessment POS N
of POS N
quality POS N
of POS N
life POS N
showed POS N
that POS N
raltitrexed POS N
was POS N
inferior POS N
to POS N
the POS N
fluorouracil-based POS N
regimens, POS N
especially POS N
in POS N
terms POS N
of POS N
palliation POS N
and POS N
functioning. POS N

The POS N
Lokich POS N
regimen POS N
was POS N
associated POS N
with POS N
more POS N
central POS N
line POS N
complications POS N
and POS N
hand-foot POS N
syndrome. POS N

The POS N
deGramont POS N
and POS N
Lokich POS N
regimens POS N
were POS N
similar POS N
in POS N
terms POS N
of POS N
survival, POS N
quality POS N
of POS N
life, POS N
and POS N
response POS N
rates. POS N

The POS N
Lokich POS N
regimen POS N
was POS N
associated POS N
with POS N
more POS N
central POS N
line POS N
complications POS N
and POS N
hand-foot POS N
syndrome. POS N

Raltitrexed POS N
showed POS N
similar POS N
response POS N
rates POS N
and POS N
overall POS N
survival POS N
to POS N
the POS N
de POS N
Gramont POS N
regimen POS N
and POS N
was POS N
easier POS N
to POS N
administer, POS N

The POS N
Lokich POS N
regimen POS N
was POS N
associated POS N
with POS N
more POS N
central POS N
line POS N
complications POS N
and POS N
hand-foot POS N
syndrome. POS N

but POS N
resulted POS N
in POS N
greater POS N
toxicity POS N
and POS N
inferior POS N
quality POS N
of POS N
life. POS N

Raltitrexed POS N
showed POS N
similar POS N
response POS N
rates POS N
and POS N
overall POS N
survival POS N
to POS N
the POS N
de POS N
Gramont POS N
regimen POS N
and POS N
was POS N
easier POS N
to POS N
administer, POS N

The POS N
hazard POS N
ratios POS N
for POS N
overall POS N
survival POS N
were POS N
0.88 POS N
(95% POS N
CI POS N
0.70-1.12, POS N
p=0.17) POS N
for POS N
de POS N
Gramont POS N
versus POS N
Lokich, POS N
and POS N
0.99 POS N
(0.79-1.25, POS N
p=0.94) POS N
for POS N
de POS N
Gramont POS N
versus POS N
raltitrexed. POS N

Raltitrexed POS N
showed POS N
similar POS N
response POS N
rates POS N
and POS N
overall POS N
survival POS N
to POS N
the POS N
de POS N
Gramont POS N
regimen POS N
and POS N
was POS N
easier POS N
to POS N
administer, POS N

For POS N
the POS N
de POS N
Gramont, POS N
Lokich, POS N
and POS N
raltitrexed POS N
groups, POS N
respectively, POS N
median POS N
survival POS N
was POS N
294, POS N
302, POS N
and POS N
266 POS N
days. POS N

Raltitrexed POS N
showed POS N
similar POS N
response POS N
rates POS N
and POS N
overall POS N
survival POS N
to POS N
the POS N
de POS N
Gramont POS N
regimen POS N
and POS N
was POS N
easier POS N
to POS N
administer, POS N

An POS N
increase POS N
in POS N
treatment-related POS N
deaths POS N
was POS N
seen POS N
on POS N
raltitrexed POS N
(de POS N
Gramont POS N
one, POS N
Lokich POS N
two, POS N
raltitrexed POS N
18) POS N
due POS N
to POS N
combined POS N
gastrointestinal POS N
and POS N
haematological POS N
toxicity. POS N

Raltitrexed POS N
showed POS N
similar POS N
response POS N
rates POS N
and POS N
overall POS N
survival POS N
to POS N
the POS N
de POS N
Gramont POS N
regimen POS N
and POS N
was POS N
easier POS N
to POS N
administer, POS N

Patients' POS N
assessment POS N
of POS N
quality POS N
of POS N
life POS N
showed POS N
that POS N
raltitrexed POS N
was POS N
inferior POS N
to POS N
the POS N
fluorouracil-based POS N
regimens, POS N
especially POS N
in POS N
terms POS N
of POS N
palliation POS N
and POS N
functioning. POS N

Raltitrexed POS N
showed POS N
similar POS N
response POS N
rates POS N
and POS N
overall POS N
survival POS N
to POS N
the POS N
de POS N
Gramont POS N
regimen POS N
and POS N
was POS N
easier POS N
to POS N
administer, POS N

The POS N
deGramont POS N
and POS N
Lokich POS N
regimens POS N
were POS N
similar POS N
in POS N
terms POS N
of POS N
survival, POS N
quality POS N
of POS N
life, POS N
and POS N
response POS N
rates. POS N

Raltitrexed POS N
showed POS N
similar POS N
response POS N
rates POS N
and POS N
overall POS N
survival POS N
to POS N
the POS N
de POS N
Gramont POS N
regimen POS N
and POS N
was POS N
easier POS N
to POS N
administer, POS N

The POS N
Lokich POS N
regimen POS N
was POS N
associated POS N
with POS N
more POS N
central POS N
line POS N
complications POS N
and POS N
hand-foot POS N
syndrome. POS N

Raltitrexed POS N
showed POS N
similar POS N
response POS N
rates POS N
and POS N
overall POS N
survival POS N
to POS N
the POS N
de POS N
Gramont POS N
regimen POS N
and POS N
was POS N
easier POS N
to POS N
administer, POS N

but POS N
resulted POS N
in POS N
greater POS N
toxicity POS N
and POS N
inferior POS N
quality POS N
of POS N
life. POS N

but POS N
resulted POS N
in POS N
greater POS N
toxicity POS N
and POS N
inferior POS N
quality POS N
of POS N
life. POS N

The POS N
hazard POS N
ratios POS N
for POS N
overall POS N
survival POS N
were POS N
0.88 POS N
(95% POS N
CI POS N
0.70-1.12, POS N
p=0.17) POS N
for POS N
de POS N
Gramont POS N
versus POS N
Lokich, POS N
and POS N
0.99 POS N
(0.79-1.25, POS N
p=0.94) POS N
for POS N
de POS N
Gramont POS N
versus POS N
raltitrexed. POS N

but POS N
resulted POS N
in POS N
greater POS N
toxicity POS N
and POS N
inferior POS N
quality POS N
of POS N
life. POS N

For POS N
the POS N
de POS N
Gramont, POS N
Lokich, POS N
and POS N
raltitrexed POS N
groups, POS N
respectively, POS N
median POS N
survival POS N
was POS N
294, POS N
302, POS N
and POS N
266 POS N
days. POS N

but POS N
resulted POS N
in POS N
greater POS N
toxicity POS N
and POS N
inferior POS N
quality POS N
of POS N
life. POS N

An POS N
increase POS N
in POS N
treatment-related POS N
deaths POS N
was POS N
seen POS N
on POS N
raltitrexed POS N
(de POS N
Gramont POS N
one, POS N
Lokich POS N
two, POS N
raltitrexed POS N
18) POS N
due POS N
to POS N
combined POS N
gastrointestinal POS N
and POS N
haematological POS N
toxicity. POS N

but POS N
resulted POS N
in POS N
greater POS N
toxicity POS N
and POS N
inferior POS N
quality POS N
of POS N
life. POS N

Patients' POS N
assessment POS N
of POS N
quality POS N
of POS N
life POS N
showed POS N
that POS N
raltitrexed POS N
was POS N
inferior POS N
to POS N
the POS N
fluorouracil-based POS N
regimens, POS N
especially POS N
in POS N
terms POS N
of POS N
palliation POS N
and POS N
functioning. POS N

but POS N
resulted POS N
in POS N
greater POS N
toxicity POS N
and POS N
inferior POS N
quality POS N
of POS N
life. POS N

The POS N
deGramont POS N
and POS N
Lokich POS N
regimens POS N
were POS N
similar POS N
in POS N
terms POS N
of POS N
survival, POS N
quality POS N
of POS N
life, POS N
and POS N
response POS N
rates. POS N

but POS N
resulted POS N
in POS N
greater POS N
toxicity POS N
and POS N
inferior POS N
quality POS N
of POS N
life. POS N

The POS N
Lokich POS N
regimen POS N
was POS N
associated POS N
with POS N
more POS N
central POS N
line POS N
complications POS N
and POS N
hand-foot POS N
syndrome. POS N

but POS N
resulted POS N
in POS N
greater POS N
toxicity POS N
and POS N
inferior POS N
quality POS N
of POS N
life. POS N

Raltitrexed POS N
showed POS N
similar POS N
response POS N
rates POS N
and POS N
overall POS N
survival POS N
to POS N
the POS N
de POS N
Gramont POS N
regimen POS N
and POS N
was POS N
easier POS N
to POS N
administer, POS N

The POS N
mean POS N
(SD) POS N
systolic POS N
BP POS N
decreased POS N
by POS N
8 POS N
(12) POS N
mm POS N
Hg POS N
in POS N
the POS N
standard POS N
group POS N
and POS N
by POS N
27 POS N
(17) POS N
mm POS N
Hg POS N
in POS N
the POS N
intensive POS N
group POS N
(P < .001), POS N
with POS N
mean POS N
(SD) POS N
achieved POS N
pressures POS N
of POS N
141 POS N
(13) POS N
and POS N
126 POS N
(10) POS N
mm POS N
Hg, POS N
respectively. POS N

Change POS N
in POS N
global POS N
perfusion POS N
did POS N
not POS N
differ POS N
between POS N
treatment POS N
groups: POS N
the POS N
mean POS N
(SD) POS N
change POS N
was POS N
-0.5 POS N
(9.4) POS N
mL/min/100 POS N
g POS N
in POS N
the POS N
standard POS N
group POS N
vs POS N
0.7 POS N
(8.6) POS N
mL/min/100 POS N
g POS N
in POS N
the POS N
intensive POS N
group POS N
(partial POS N
η2, POS N
0.004; POS N
95% POS N
CI, POS N
-3.551 POS N
to POS N
5.818; POS N
P = .63). POS N

The POS N
mean POS N
(SD) POS N
systolic POS N
BP POS N
decreased POS N
by POS N
8 POS N
(12) POS N
mm POS N
Hg POS N
in POS N
the POS N
standard POS N
group POS N
and POS N
by POS N
27 POS N
(17) POS N
mm POS N
Hg POS N
in POS N
the POS N
intensive POS N
group POS N
(P < .001), POS N
with POS N
mean POS N
(SD) POS N
achieved POS N
pressures POS N
of POS N
141 POS N
(13) POS N
and POS N
126 POS N
(10) POS N
mm POS N
Hg, POS N
respectively. POS N

No POS N
differences POS N
were POS N
observed POS N
when POS N
the POS N
analysis POS N
examined POS N
gray POS N
or POS N
white POS N
matter POS N
only POS N
or POS N
was POS N
confined POS N
to POS N
those POS N
achieving POS N
target POS N
BP. POS N

The POS N
mean POS N
(SD) POS N
systolic POS N
BP POS N
decreased POS N
by POS N
8 POS N
(12) POS N
mm POS N
Hg POS N
in POS N
the POS N
standard POS N
group POS N
and POS N
by POS N
27 POS N
(17) POS N
mm POS N
Hg POS N
in POS N
the POS N
intensive POS N
group POS N
(P < .001), POS N
with POS N
mean POS N
(SD) POS N
achieved POS N
pressures POS N
of POS N
141 POS N
(13) POS N
and POS N
126 POS N
(10) POS N
mm POS N
Hg, POS N
respectively. POS N

Intensive POS N
BP POS N
lowering POS N
did POS N
not POS N
reduce POS N
cerebral POS N
perfusion POS N
in POS N
severe POS N
small POS N
vessel POS N
disease. POS N

The POS N
mean POS N
(SD) POS N
systolic POS N
BP POS N
decreased POS N
by POS N
8 POS N
(12) POS N
mm POS N
Hg POS N
in POS N
the POS N
standard POS N
group POS N
and POS N
by POS N
27 POS N
(17) POS N
mm POS N
Hg POS N
in POS N
the POS N
intensive POS N
group POS N
(P < .001), POS N
with POS N
mean POS N
(SD) POS N
achieved POS N
pressures POS N
of POS N
141 POS N
(13) POS N
and POS N
126 POS N
(10) POS N
mm POS N
Hg, POS N
respectively. POS N

The POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
differ POS N
between POS N
treatment POS N
groups, POS N
with POS N
a POS N
mean POS N
(SD) POS N
of POS N
0.21 POS N
(0.65) POS N
for POS N
the POS N
standard POS N
group POS N
and POS N
0.32 POS N
(0.75) POS N
for POS N
the POS N
intensive POS N
group POS N
(P = .44). POS N

Change POS N
in POS N
global POS N
perfusion POS N
did POS N
not POS N
differ POS N
between POS N
treatment POS N
groups: POS N
the POS N
mean POS N
(SD) POS N
change POS N
was POS N
-0.5 POS N
(9.4) POS N
mL/min/100 POS N
g POS N
in POS N
the POS N
standard POS N
group POS N
vs POS N
0.7 POS N
(8.6) POS N
mL/min/100 POS N
g POS N
in POS N
the POS N
intensive POS N
group POS N
(partial POS N
η2, POS N
0.004; POS N
95% POS N
CI, POS N
-3.551 POS N
to POS N
5.818; POS N
P = .63). POS N

The POS N
mean POS N
(SD) POS N
systolic POS N
BP POS N
decreased POS N
by POS N
8 POS N
(12) POS N
mm POS N
Hg POS N
in POS N
the POS N
standard POS N
group POS N
and POS N
by POS N
27 POS N
(17) POS N
mm POS N
Hg POS N
in POS N
the POS N
intensive POS N
group POS N
(P < .001), POS N
with POS N
mean POS N
(SD) POS N
achieved POS N
pressures POS N
of POS N
141 POS N
(13) POS N
and POS N
126 POS N
(10) POS N
mm POS N
Hg, POS N
respectively. POS N

Change POS N
in POS N
global POS N
perfusion POS N
did POS N
not POS N
differ POS N
between POS N
treatment POS N
groups: POS N
the POS N
mean POS N
(SD) POS N
change POS N
was POS N
-0.5 POS N
(9.4) POS N
mL/min/100 POS N
g POS N
in POS N
the POS N
standard POS N
group POS N
vs POS N
0.7 POS N
(8.6) POS N
mL/min/100 POS N
g POS N
in POS N
the POS N
intensive POS N
group POS N
(partial POS N
η2, POS N
0.004; POS N
95% POS N
CI, POS N
-3.551 POS N
to POS N
5.818; POS N
P = .63). POS N

No POS N
differences POS N
were POS N
observed POS N
when POS N
the POS N
analysis POS N
examined POS N
gray POS N
or POS N
white POS N
matter POS N
only POS N
or POS N
was POS N
confined POS N
to POS N
those POS N
achieving POS N
target POS N
BP. POS N

Change POS N
in POS N
global POS N
perfusion POS N
did POS N
not POS N
differ POS N
between POS N
treatment POS N
groups: POS N
the POS N
mean POS N
(SD) POS N
change POS N
was POS N
-0.5 POS N
(9.4) POS N
mL/min/100 POS N
g POS N
in POS N
the POS N
standard POS N
group POS N
vs POS N
0.7 POS N
(8.6) POS N
mL/min/100 POS N
g POS N
in POS N
the POS N
intensive POS N
group POS N
(partial POS N
η2, POS N
0.004; POS N
95% POS N
CI, POS N
-3.551 POS N
to POS N
5.818; POS N
P = .63). POS N

Intensive POS N
BP POS N
lowering POS N
did POS N
not POS N
reduce POS N
cerebral POS N
perfusion POS N
in POS N
severe POS N
small POS N
vessel POS N
disease. POS N

Change POS N
in POS N
global POS N
perfusion POS N
did POS N
not POS N
differ POS N
between POS N
treatment POS N
groups: POS N
the POS N
mean POS N
(SD) POS N
change POS N
was POS N
-0.5 POS N
(9.4) POS N
mL/min/100 POS N
g POS N
in POS N
the POS N
standard POS N
group POS N
vs POS N
0.7 POS N
(8.6) POS N
mL/min/100 POS N
g POS N
in POS N
the POS N
intensive POS N
group POS N
(partial POS N
η2, POS N
0.004; POS N
95% POS N
CI, POS N
-3.551 POS N
to POS N
5.818; POS N
P = .63). POS N

The POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
differ POS N
between POS N
treatment POS N
groups, POS N
with POS N
a POS N
mean POS N
(SD) POS N
of POS N
0.21 POS N
(0.65) POS N
for POS N
the POS N
standard POS N
group POS N
and POS N
0.32 POS N
(0.75) POS N
for POS N
the POS N
intensive POS N
group POS N
(P = .44). POS N

No POS N
differences POS N
were POS N
observed POS N
when POS N
the POS N
analysis POS N
examined POS N
gray POS N
or POS N
white POS N
matter POS N
only POS N
or POS N
was POS N
confined POS N
to POS N
those POS N
achieving POS N
target POS N
BP. POS N

The POS N
mean POS N
(SD) POS N
systolic POS N
BP POS N
decreased POS N
by POS N
8 POS N
(12) POS N
mm POS N
Hg POS N
in POS N
the POS N
standard POS N
group POS N
and POS N
by POS N
27 POS N
(17) POS N
mm POS N
Hg POS N
in POS N
the POS N
intensive POS N
group POS N
(P < .001), POS N
with POS N
mean POS N
(SD) POS N
achieved POS N
pressures POS N
of POS N
141 POS N
(13) POS N
and POS N
126 POS N
(10) POS N
mm POS N
Hg, POS N
respectively. POS N

No POS N
differences POS N
were POS N
observed POS N
when POS N
the POS N
analysis POS N
examined POS N
gray POS N
or POS N
white POS N
matter POS N
only POS N
or POS N
was POS N
confined POS N
to POS N
those POS N
achieving POS N
target POS N
BP. POS N

Change POS N
in POS N
global POS N
perfusion POS N
did POS N
not POS N
differ POS N
between POS N
treatment POS N
groups: POS N
the POS N
mean POS N
(SD) POS N
change POS N
was POS N
-0.5 POS N
(9.4) POS N
mL/min/100 POS N
g POS N
in POS N
the POS N
standard POS N
group POS N
vs POS N
0.7 POS N
(8.6) POS N
mL/min/100 POS N
g POS N
in POS N
the POS N
intensive POS N
group POS N
(partial POS N
η2, POS N
0.004; POS N
95% POS N
CI, POS N
-3.551 POS N
to POS N
5.818; POS N
P = .63). POS N

No POS N
differences POS N
were POS N
observed POS N
when POS N
the POS N
analysis POS N
examined POS N
gray POS N
or POS N
white POS N
matter POS N
only POS N
or POS N
was POS N
confined POS N
to POS N
those POS N
achieving POS N
target POS N
BP. POS N

Intensive POS N
BP POS N
lowering POS N
did POS N
not POS N
reduce POS N
cerebral POS N
perfusion POS N
in POS N
severe POS N
small POS N
vessel POS N
disease. POS N

No POS N
differences POS N
were POS N
observed POS N
when POS N
the POS N
analysis POS N
examined POS N
gray POS N
or POS N
white POS N
matter POS N
only POS N
or POS N
was POS N
confined POS N
to POS N
those POS N
achieving POS N
target POS N
BP. POS N

The POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
differ POS N
between POS N
treatment POS N
groups, POS N
with POS N
a POS N
mean POS N
(SD) POS N
of POS N
0.21 POS N
(0.65) POS N
for POS N
the POS N
standard POS N
group POS N
and POS N
0.32 POS N
(0.75) POS N
for POS N
the POS N
intensive POS N
group POS N
(P = .44). POS N

Intensive POS N
BP POS N
lowering POS N
did POS N
not POS N
reduce POS N
cerebral POS N
perfusion POS N
in POS N
severe POS N
small POS N
vessel POS N
disease. POS N

The POS N
mean POS N
(SD) POS N
systolic POS N
BP POS N
decreased POS N
by POS N
8 POS N
(12) POS N
mm POS N
Hg POS N
in POS N
the POS N
standard POS N
group POS N
and POS N
by POS N
27 POS N
(17) POS N
mm POS N
Hg POS N
in POS N
the POS N
intensive POS N
group POS N
(P < .001), POS N
with POS N
mean POS N
(SD) POS N
achieved POS N
pressures POS N
of POS N
141 POS N
(13) POS N
and POS N
126 POS N
(10) POS N
mm POS N
Hg, POS N
respectively. POS N

Intensive POS N
BP POS N
lowering POS N
did POS N
not POS N
reduce POS N
cerebral POS N
perfusion POS N
in POS N
severe POS N
small POS N
vessel POS N
disease. POS N

Change POS N
in POS N
global POS N
perfusion POS N
did POS N
not POS N
differ POS N
between POS N
treatment POS N
groups: POS N
the POS N
mean POS N
(SD) POS N
change POS N
was POS N
-0.5 POS N
(9.4) POS N
mL/min/100 POS N
g POS N
in POS N
the POS N
standard POS N
group POS N
vs POS N
0.7 POS N
(8.6) POS N
mL/min/100 POS N
g POS N
in POS N
the POS N
intensive POS N
group POS N
(partial POS N
η2, POS N
0.004; POS N
95% POS N
CI, POS N
-3.551 POS N
to POS N
5.818; POS N
P = .63). POS N

Intensive POS N
BP POS N
lowering POS N
did POS N
not POS N
reduce POS N
cerebral POS N
perfusion POS N
in POS N
severe POS N
small POS N
vessel POS N
disease. POS N

No POS N
differences POS N
were POS N
observed POS N
when POS N
the POS N
analysis POS N
examined POS N
gray POS N
or POS N
white POS N
matter POS N
only POS N
or POS N
was POS N
confined POS N
to POS N
those POS N
achieving POS N
target POS N
BP. POS N

Intensive POS N
BP POS N
lowering POS N
did POS N
not POS N
reduce POS N
cerebral POS N
perfusion POS N
in POS N
severe POS N
small POS N
vessel POS N
disease. POS N

The POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
differ POS N
between POS N
treatment POS N
groups, POS N
with POS N
a POS N
mean POS N
(SD) POS N
of POS N
0.21 POS N
(0.65) POS N
for POS N
the POS N
standard POS N
group POS N
and POS N
0.32 POS N
(0.75) POS N
for POS N
the POS N
intensive POS N
group POS N
(P = .44). POS N

The POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
differ POS N
between POS N
treatment POS N
groups, POS N
with POS N
a POS N
mean POS N
(SD) POS N
of POS N
0.21 POS N
(0.65) POS N
for POS N
the POS N
standard POS N
group POS N
and POS N
0.32 POS N
(0.75) POS N
for POS N
the POS N
intensive POS N
group POS N
(P = .44). POS N

The POS N
mean POS N
(SD) POS N
systolic POS N
BP POS N
decreased POS N
by POS N
8 POS N
(12) POS N
mm POS N
Hg POS N
in POS N
the POS N
standard POS N
group POS N
and POS N
by POS N
27 POS N
(17) POS N
mm POS N
Hg POS N
in POS N
the POS N
intensive POS N
group POS N
(P < .001), POS N
with POS N
mean POS N
(SD) POS N
achieved POS N
pressures POS N
of POS N
141 POS N
(13) POS N
and POS N
126 POS N
(10) POS N
mm POS N
Hg, POS N
respectively. POS N

The POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
differ POS N
between POS N
treatment POS N
groups, POS N
with POS N
a POS N
mean POS N
(SD) POS N
of POS N
0.21 POS N
(0.65) POS N
for POS N
the POS N
standard POS N
group POS N
and POS N
0.32 POS N
(0.75) POS N
for POS N
the POS N
intensive POS N
group POS N
(P = .44). POS N

Change POS N
in POS N
global POS N
perfusion POS N
did POS N
not POS N
differ POS N
between POS N
treatment POS N
groups: POS N
the POS N
mean POS N
(SD) POS N
change POS N
was POS N
-0.5 POS N
(9.4) POS N
mL/min/100 POS N
g POS N
in POS N
the POS N
standard POS N
group POS N
vs POS N
0.7 POS N
(8.6) POS N
mL/min/100 POS N
g POS N
in POS N
the POS N
intensive POS N
group POS N
(partial POS N
η2, POS N
0.004; POS N
95% POS N
CI, POS N
-3.551 POS N
to POS N
5.818; POS N
P = .63). POS N

The POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
differ POS N
between POS N
treatment POS N
groups, POS N
with POS N
a POS N
mean POS N
(SD) POS N
of POS N
0.21 POS N
(0.65) POS N
for POS N
the POS N
standard POS N
group POS N
and POS N
0.32 POS N
(0.75) POS N
for POS N
the POS N
intensive POS N
group POS N
(P = .44). POS N

No POS N
differences POS N
were POS N
observed POS N
when POS N
the POS N
analysis POS N
examined POS N
gray POS N
or POS N
white POS N
matter POS N
only POS N
or POS N
was POS N
confined POS N
to POS N
those POS N
achieving POS N
target POS N
BP. POS N

The POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
differ POS N
between POS N
treatment POS N
groups, POS N
with POS N
a POS N
mean POS N
(SD) POS N
of POS N
0.21 POS N
(0.65) POS N
for POS N
the POS N
standard POS N
group POS N
and POS N
0.32 POS N
(0.75) POS N
for POS N
the POS N
intensive POS N
group POS N
(P = .44). POS N

Intensive POS N
BP POS N
lowering POS N
did POS N
not POS N
reduce POS N
cerebral POS N
perfusion POS N
in POS N
severe POS N
small POS N
vessel POS N
disease. POS N

At POS N
two POS N
year POS N
follow-up POS N
there POS N
was POS N
a POS N
significant POS N
group POS N
by POS N
time POS N
interaction POS N
showing POS N
lower POS N
Center POS N
for POS N
Epidemiological POS N
Studies-Depression POS N
(CESD) POS N
scores POS N
in POS N
the POS N
SSRI POS N
+ POS N
CCB POS N
group, POS N
F(1,291) POS N
= POS N
4.13, POS N
p POS N
= POS N
0.043, POS N
η2 POS N
p POS N
= POS N
0.014. POS N

Over POS N
ten-years POS N
follow-up, POS N
SSRI POS N
+ POS N
CCB POS N
use POS N
was POS N
associated POS N
with POS N
improved POS N
general POS N
cognitive POS N
function POS N
(Mini-Mental POS N
State POS N
Examination: POS N
β POS N
= POS N
0.97; POS N
95% POS N
CI POS N
0.14 POS N
to POS N
1.81, POS N
p POS N
= POS N
0.023) POS N
and POS N
immediate POS N
visual POS N
memory POS N
(Boston POS N
Visual POS N
Retention POS N
Test: POS N
β POS N
= POS N
0.69; POS N
95% POS N
CI POS N
0.06 POS N
to POS N
1.32, POS N
p POS N
= POS N
0.033). POS N

At POS N
two POS N
year POS N
follow-up POS N
there POS N
was POS N
a POS N
significant POS N
group POS N
by POS N
time POS N
interaction POS N
showing POS N
lower POS N
Center POS N
for POS N
Epidemiological POS N
Studies-Depression POS N
(CESD) POS N
scores POS N
in POS N
the POS N
SSRI POS N
+ POS N
CCB POS N
group, POS N
F(1,291) POS N
= POS N
4.13, POS N
p POS N
= POS N
0.043, POS N
η2 POS N
p POS N
= POS N
0.014. POS N

The POS N
findings POS N
provide POS N
general POS N
population POS N
evidence POS N
that POS N
SSRI POS N
augmentation POS N
with POS N
CCB POS N
may POS N
improve POS N
depression POS N
and POS N
cognitive POS N
function. POS N

Over POS N
ten-years POS N
follow-up, POS N
SSRI POS N
+ POS N
CCB POS N
use POS N
was POS N
associated POS N
with POS N
improved POS N
general POS N
cognitive POS N
function POS N
(Mini-Mental POS N
State POS N
Examination: POS N
β POS N
= POS N
0.97; POS N
95% POS N
CI POS N
0.14 POS N
to POS N
1.81, POS N
p POS N
= POS N
0.023) POS N
and POS N
immediate POS N
visual POS N
memory POS N
(Boston POS N
Visual POS N
Retention POS N
Test: POS N
β POS N
= POS N
0.69; POS N
95% POS N
CI POS N
0.06 POS N
to POS N
1.32, POS N
p POS N
= POS N
0.033). POS N

At POS N
two POS N
year POS N
follow-up POS N
there POS N
was POS N
a POS N
significant POS N
group POS N
by POS N
time POS N
interaction POS N
showing POS N
lower POS N
Center POS N
for POS N
Epidemiological POS N
Studies-Depression POS N
(CESD) POS N
scores POS N
in POS N
the POS N
SSRI POS N
+ POS N
CCB POS N
group, POS N
F(1,291) POS N
= POS N
4.13, POS N
p POS N
= POS N
0.043, POS N
η2 POS N
p POS N
= POS N
0.014. POS N

Over POS N
ten-years POS N
follow-up, POS N
SSRI POS N
+ POS N
CCB POS N
use POS N
was POS N
associated POS N
with POS N
improved POS N
general POS N
cognitive POS N
function POS N
(Mini-Mental POS N
State POS N
Examination: POS N
β POS N
= POS N
0.97; POS N
95% POS N
CI POS N
0.14 POS N
to POS N
1.81, POS N
p POS N
= POS N
0.023) POS N
and POS N
immediate POS N
visual POS N
memory POS N
(Boston POS N
Visual POS N
Retention POS N
Test: POS N
β POS N
= POS N
0.69; POS N
95% POS N
CI POS N
0.06 POS N
to POS N
1.32, POS N
p POS N
= POS N
0.033). POS N

The POS N
findings POS N
provide POS N
general POS N
population POS N
evidence POS N
that POS N
SSRI POS N
augmentation POS N
with POS N
CCB POS N
may POS N
improve POS N
depression POS N
and POS N
cognitive POS N
function. POS N

The POS N
findings POS N
provide POS N
general POS N
population POS N
evidence POS N
that POS N
SSRI POS N
augmentation POS N
with POS N
CCB POS N
may POS N
improve POS N
depression POS N
and POS N
cognitive POS N
function. POS N

At POS N
two POS N
year POS N
follow-up POS N
there POS N
was POS N
a POS N
significant POS N
group POS N
by POS N
time POS N
interaction POS N
showing POS N
lower POS N
Center POS N
for POS N
Epidemiological POS N
Studies-Depression POS N
(CESD) POS N
scores POS N
in POS N
the POS N
SSRI POS N
+ POS N
CCB POS N
group, POS N
F(1,291) POS N
= POS N
4.13, POS N
p POS N
= POS N
0.043, POS N
η2 POS N
p POS N
= POS N
0.014. POS N

The POS N
findings POS N
provide POS N
general POS N
population POS N
evidence POS N
that POS N
SSRI POS N
augmentation POS N
with POS N
CCB POS N
may POS N
improve POS N
depression POS N
and POS N
cognitive POS N
function. POS N

Over POS N
ten-years POS N
follow-up, POS N
SSRI POS N
+ POS N
CCB POS N
use POS N
was POS N
associated POS N
with POS N
improved POS N
general POS N
cognitive POS N
function POS N
(Mini-Mental POS N
State POS N
Examination: POS N
β POS N
= POS N
0.97; POS N
95% POS N
CI POS N
0.14 POS N
to POS N
1.81, POS N
p POS N
= POS N
0.023) POS N
and POS N
immediate POS N
visual POS N
memory POS N
(Boston POS N
Visual POS N
Retention POS N
Test: POS N
β POS N
= POS N
0.69; POS N
95% POS N
CI POS N
0.06 POS N
to POS N
1.32, POS N
p POS N
= POS N
0.033). POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

Symptomatic POS N
hypotension POS N
did POS N
not POS N
develop POS N
in POS N
any POS N
of POS N
the POS N
patients POS N
during POS N
the POS N
wet POS N
session, POS N
compared POS N
to POS N
4 POS N
(40%) POS N
during POS N
the POS N
dry POS N
session. POS N

Systolic POS N
blood POS N
pressure POS N
adjusted POS N
to POS N
ultrafiltration POS N
was POS N
stable POS N
during POS N
the POS N
wet POS N
session, POS N
0.22 POS N
mmHg/15 POS N
min POS N
(95% POS N
CI POS N
-0.27 POS N
to POS N
0.70), POS N
P = 0.38, POS N
and POS N
significantly POS N
decreased POS N
during POS N
the POS N
dry POS N
session, POS N
-0.68 POS N
mmHg/15 POS N
min POS N
(95%CI POS N
-1.24 POS N
to POS N
-0.11), POS N
P = 0.02. POS N

Symptomatic POS N
hypotension POS N
did POS N
not POS N
develop POS N
in POS N
any POS N
of POS N
the POS N
patients POS N
during POS N
the POS N
wet POS N
session, POS N
compared POS N
to POS N
4 POS N
(40%) POS N
during POS N
the POS N
dry POS N
session. POS N

Diastolic POS N
blood POS N
pressure POS N
did POS N
not POS N
change POS N
during POS N
the POS N
sessions. POS N

Symptomatic POS N
hypotension POS N
did POS N
not POS N
develop POS N
in POS N
any POS N
of POS N
the POS N
patients POS N
during POS N
the POS N
wet POS N
session, POS N
compared POS N
to POS N
4 POS N
(40%) POS N
during POS N
the POS N
dry POS N
session. POS N

Mean POS N
atrial POS N
natriuretic POS N
peptide POS N
significantly POS N
increased POS N
in POS N
the POS N
wet POS N
session, POS N
by POS N
31.36 POS N
pgr/mL POS N
(95%CI POS N
8.73-53.99), POS N
P = 0.007, POS N
and POS N
slightly POS N
and POS N
insignificantly POS N
decreased POS N
in POS N
the POS N
dry POS N
session, POS N
by POS N
21.66 POS N
pgr/mL POS N
(95% POS N
CI POS N
-52.59 POS N
to POS N
9.25), POS N
P = 0.167. POS N

Symptomatic POS N
hypotension POS N
did POS N
not POS N
develop POS N
in POS N
any POS N
of POS N
the POS N
patients POS N
during POS N
the POS N
wet POS N
session, POS N
compared POS N
to POS N
4 POS N
(40%) POS N
during POS N
the POS N
dry POS N
session. POS N

Reduced POS N
effective POS N
circulating POS N
volume POS N
is POS N
a POS N
major POS N
cause POS N
for POS N
IDH, POS N
which POS N
can POS N
be POS N
prevented POS N
using POS N
head-out POS N
water POS N
immersion POS N
facilitated POS N
redistribution. POS N

Symptomatic POS N
hypotension POS N
did POS N
not POS N
develop POS N
in POS N
any POS N
of POS N
the POS N
patients POS N
during POS N
the POS N
wet POS N
session, POS N
compared POS N
to POS N
4 POS N
(40%) POS N
during POS N
the POS N
dry POS N
session. POS N

Aldosterone POS N
blood POS N
levels POS N
did POS N
not POS N
change. POS N

Systolic POS N
blood POS N
pressure POS N
adjusted POS N
to POS N
ultrafiltration POS N
was POS N
stable POS N
during POS N
the POS N
wet POS N
session, POS N
0.22 POS N
mmHg/15 POS N
min POS N
(95% POS N
CI POS N
-0.27 POS N
to POS N
0.70), POS N
P = 0.38, POS N
and POS N
significantly POS N
decreased POS N
during POS N
the POS N
dry POS N
session, POS N
-0.68 POS N
mmHg/15 POS N
min POS N
(95%CI POS N
-1.24 POS N
to POS N
-0.11), POS N
P = 0.02. POS N

Symptomatic POS N
hypotension POS N
did POS N
not POS N
develop POS N
in POS N
any POS N
of POS N
the POS N
patients POS N
during POS N
the POS N
wet POS N
session, POS N
compared POS N
to POS N
4 POS N
(40%) POS N
during POS N
the POS N
dry POS N
session. POS N

Systolic POS N
blood POS N
pressure POS N
adjusted POS N
to POS N
ultrafiltration POS N
was POS N
stable POS N
during POS N
the POS N
wet POS N
session, POS N
0.22 POS N
mmHg/15 POS N
min POS N
(95% POS N
CI POS N
-0.27 POS N
to POS N
0.70), POS N
P = 0.38, POS N
and POS N
significantly POS N
decreased POS N
during POS N
the POS N
dry POS N
session, POS N
-0.68 POS N
mmHg/15 POS N
min POS N
(95%CI POS N
-1.24 POS N
to POS N
-0.11), POS N
P = 0.02. POS N

Diastolic POS N
blood POS N
pressure POS N
did POS N
not POS N
change POS N
during POS N
the POS N
sessions. POS N

Systolic POS N
blood POS N
pressure POS N
adjusted POS N
to POS N
ultrafiltration POS N
was POS N
stable POS N
during POS N
the POS N
wet POS N
session, POS N
0.22 POS N
mmHg/15 POS N
min POS N
(95% POS N
CI POS N
-0.27 POS N
to POS N
0.70), POS N
P = 0.38, POS N
and POS N
significantly POS N
decreased POS N
during POS N
the POS N
dry POS N
session, POS N
-0.68 POS N
mmHg/15 POS N
min POS N
(95%CI POS N
-1.24 POS N
to POS N
-0.11), POS N
P = 0.02. POS N

Mean POS N
atrial POS N
natriuretic POS N
peptide POS N
significantly POS N
increased POS N
in POS N
the POS N
wet POS N
session, POS N
by POS N
31.36 POS N
pgr/mL POS N
(95%CI POS N
8.73-53.99), POS N
P = 0.007, POS N
and POS N
slightly POS N
and POS N
insignificantly POS N
decreased POS N
in POS N
the POS N
dry POS N
session, POS N
by POS N
21.66 POS N
pgr/mL POS N
(95% POS N
CI POS N
-52.59 POS N
to POS N
9.25), POS N
P = 0.167. POS N

Systolic POS N
blood POS N
pressure POS N
adjusted POS N
to POS N
ultrafiltration POS N
was POS N
stable POS N
during POS N
the POS N
wet POS N
session, POS N
0.22 POS N
mmHg/15 POS N
min POS N
(95% POS N
CI POS N
-0.27 POS N
to POS N
0.70), POS N
P = 0.38, POS N
and POS N
significantly POS N
decreased POS N
during POS N
the POS N
dry POS N
session, POS N
-0.68 POS N
mmHg/15 POS N
min POS N
(95%CI POS N
-1.24 POS N
to POS N
-0.11), POS N
P = 0.02. POS N

Reduced POS N
effective POS N
circulating POS N
volume POS N
is POS N
a POS N
major POS N
cause POS N
for POS N
IDH, POS N
which POS N
can POS N
be POS N
prevented POS N
using POS N
head-out POS N
water POS N
immersion POS N
facilitated POS N
redistribution. POS N

Systolic POS N
blood POS N
pressure POS N
adjusted POS N
to POS N
ultrafiltration POS N
was POS N
stable POS N
during POS N
the POS N
wet POS N
session, POS N
0.22 POS N
mmHg/15 POS N
min POS N
(95% POS N
CI POS N
-0.27 POS N
to POS N
0.70), POS N
P = 0.38, POS N
and POS N
significantly POS N
decreased POS N
during POS N
the POS N
dry POS N
session, POS N
-0.68 POS N
mmHg/15 POS N
min POS N
(95%CI POS N
-1.24 POS N
to POS N
-0.11), POS N
P = 0.02. POS N

Aldosterone POS N
blood POS N
levels POS N
did POS N
not POS N
change. POS N

Diastolic POS N
blood POS N
pressure POS N
did POS N
not POS N
change POS N
during POS N
the POS N
sessions. POS N

Symptomatic POS N
hypotension POS N
did POS N
not POS N
develop POS N
in POS N
any POS N
of POS N
the POS N
patients POS N
during POS N
the POS N
wet POS N
session, POS N
compared POS N
to POS N
4 POS N
(40%) POS N
during POS N
the POS N
dry POS N
session. POS N

Diastolic POS N
blood POS N
pressure POS N
did POS N
not POS N
change POS N
during POS N
the POS N
sessions. POS N

Systolic POS N
blood POS N
pressure POS N
adjusted POS N
to POS N
ultrafiltration POS N
was POS N
stable POS N
during POS N
the POS N
wet POS N
session, POS N
0.22 POS N
mmHg/15 POS N
min POS N
(95% POS N
CI POS N
-0.27 POS N
to POS N
0.70), POS N
P = 0.38, POS N
and POS N
significantly POS N
decreased POS N
during POS N
the POS N
dry POS N
session, POS N
-0.68 POS N
mmHg/15 POS N
min POS N
(95%CI POS N
-1.24 POS N
to POS N
-0.11), POS N
P = 0.02. POS N

Diastolic POS N
blood POS N
pressure POS N
did POS N
not POS N
change POS N
during POS N
the POS N
sessions. POS N

Mean POS N
atrial POS N
natriuretic POS N
peptide POS N
significantly POS N
increased POS N
in POS N
the POS N
wet POS N
session, POS N
by POS N
31.36 POS N
pgr/mL POS N
(95%CI POS N
8.73-53.99), POS N
P = 0.007, POS N
and POS N
slightly POS N
and POS N
insignificantly POS N
decreased POS N
in POS N
the POS N
dry POS N
session, POS N
by POS N
21.66 POS N
pgr/mL POS N
(95% POS N
CI POS N
-52.59 POS N
to POS N
9.25), POS N
P = 0.167. POS N

Diastolic POS N
blood POS N
pressure POS N
did POS N
not POS N
change POS N
during POS N
the POS N
sessions. POS N

Reduced POS N
effective POS N
circulating POS N
volume POS N
is POS N
a POS N
major POS N
cause POS N
for POS N
IDH, POS N
which POS N
can POS N
be POS N
prevented POS N
using POS N
head-out POS N
water POS N
immersion POS N
facilitated POS N
redistribution. POS N

Diastolic POS N
blood POS N
pressure POS N
did POS N
not POS N
change POS N
during POS N
the POS N
sessions. POS N

Aldosterone POS N
blood POS N
levels POS N
did POS N
not POS N
change. POS N

Mean POS N
atrial POS N
natriuretic POS N
peptide POS N
significantly POS N
increased POS N
in POS N
the POS N
wet POS N
session, POS N
by POS N
31.36 POS N
pgr/mL POS N
(95%CI POS N
8.73-53.99), POS N
P = 0.007, POS N
and POS N
slightly POS N
and POS N
insignificantly POS N
decreased POS N
in POS N
the POS N
dry POS N
session, POS N
by POS N
21.66 POS N
pgr/mL POS N
(95% POS N
CI POS N
-52.59 POS N
to POS N
9.25), POS N
P = 0.167. POS N

Symptomatic POS N
hypotension POS N
did POS N
not POS N
develop POS N
in POS N
any POS N
of POS N
the POS N
patients POS N
during POS N
the POS N
wet POS N
session, POS N
compared POS N
to POS N
4 POS N
(40%) POS N
during POS N
the POS N
dry POS N
session. POS N

Mean POS N
atrial POS N
natriuretic POS N
peptide POS N
significantly POS N
increased POS N
in POS N
the POS N
wet POS N
session, POS N
by POS N
31.36 POS N
pgr/mL POS N
(95%CI POS N
8.73-53.99), POS N
P = 0.007, POS N
and POS N
slightly POS N
and POS N
insignificantly POS N
decreased POS N
in POS N
the POS N
dry POS N
session, POS N
by POS N
21.66 POS N
pgr/mL POS N
(95% POS N
CI POS N
-52.59 POS N
to POS N
9.25), POS N
P = 0.167. POS N

Systolic POS N
blood POS N
pressure POS N
adjusted POS N
to POS N
ultrafiltration POS N
was POS N
stable POS N
during POS N
the POS N
wet POS N
session, POS N
0.22 POS N
mmHg/15 POS N
min POS N
(95% POS N
CI POS N
-0.27 POS N
to POS N
0.70), POS N
P = 0.38, POS N
and POS N
significantly POS N
decreased POS N
during POS N
the POS N
dry POS N
session, POS N
-0.68 POS N
mmHg/15 POS N
min POS N
(95%CI POS N
-1.24 POS N
to POS N
-0.11), POS N
P = 0.02. POS N

Mean POS N
atrial POS N
natriuretic POS N
peptide POS N
significantly POS N
increased POS N
in POS N
the POS N
wet POS N
session, POS N
by POS N
31.36 POS N
pgr/mL POS N
(95%CI POS N
8.73-53.99), POS N
P = 0.007, POS N
and POS N
slightly POS N
and POS N
insignificantly POS N
decreased POS N
in POS N
the POS N
dry POS N
session, POS N
by POS N
21.66 POS N
pgr/mL POS N
(95% POS N
CI POS N
-52.59 POS N
to POS N
9.25), POS N
P = 0.167. POS N

Diastolic POS N
blood POS N
pressure POS N
did POS N
not POS N
change POS N
during POS N
the POS N
sessions. POS N

Mean POS N
atrial POS N
natriuretic POS N
peptide POS N
significantly POS N
increased POS N
in POS N
the POS N
wet POS N
session, POS N
by POS N
31.36 POS N
pgr/mL POS N
(95%CI POS N
8.73-53.99), POS N
P = 0.007, POS N
and POS N
slightly POS N
and POS N
insignificantly POS N
decreased POS N
in POS N
the POS N
dry POS N
session, POS N
by POS N
21.66 POS N
pgr/mL POS N
(95% POS N
CI POS N
-52.59 POS N
to POS N
9.25), POS N
P = 0.167. POS N

Reduced POS N
effective POS N
circulating POS N
volume POS N
is POS N
a POS N
major POS N
cause POS N
for POS N
IDH, POS N
which POS N
can POS N
be POS N
prevented POS N
using POS N
head-out POS N
water POS N
immersion POS N
facilitated POS N
redistribution. POS N

Mean POS N
atrial POS N
natriuretic POS N
peptide POS N
significantly POS N
increased POS N
in POS N
the POS N
wet POS N
session, POS N
by POS N
31.36 POS N
pgr/mL POS N
(95%CI POS N
8.73-53.99), POS N
P = 0.007, POS N
and POS N
slightly POS N
and POS N
insignificantly POS N
decreased POS N
in POS N
the POS N
dry POS N
session, POS N
by POS N
21.66 POS N
pgr/mL POS N
(95% POS N
CI POS N
-52.59 POS N
to POS N
9.25), POS N
P = 0.167. POS N

Aldosterone POS N
blood POS N
levels POS N
did POS N
not POS N
change. POS N

Reduced POS N
effective POS N
circulating POS N
volume POS N
is POS N
a POS N
major POS N
cause POS N
for POS N
IDH, POS N
which POS N
can POS N
be POS N
prevented POS N
using POS N
head-out POS N
water POS N
immersion POS N
facilitated POS N
redistribution. POS N

Symptomatic POS N
hypotension POS N
did POS N
not POS N
develop POS N
in POS N
any POS N
of POS N
the POS N
patients POS N
during POS N
the POS N
wet POS N
session, POS N
compared POS N
to POS N
4 POS N
(40%) POS N
during POS N
the POS N
dry POS N
session. POS N

Reduced POS N
effective POS N
circulating POS N
volume POS N
is POS N
a POS N
major POS N
cause POS N
for POS N
IDH, POS N
which POS N
can POS N
be POS N
prevented POS N
using POS N
head-out POS N
water POS N
immersion POS N
facilitated POS N
redistribution. POS N

Systolic POS N
blood POS N
pressure POS N
adjusted POS N
to POS N
ultrafiltration POS N
was POS N
stable POS N
during POS N
the POS N
wet POS N
session, POS N
0.22 POS N
mmHg/15 POS N
min POS N
(95% POS N
CI POS N
-0.27 POS N
to POS N
0.70), POS N
P = 0.38, POS N
and POS N
significantly POS N
decreased POS N
during POS N
the POS N
dry POS N
session, POS N
-0.68 POS N
mmHg/15 POS N
min POS N
(95%CI POS N
-1.24 POS N
to POS N
-0.11), POS N
P = 0.02. POS N

Reduced POS N
effective POS N
circulating POS N
volume POS N
is POS N
a POS N
major POS N
cause POS N
for POS N
IDH, POS N
which POS N
can POS N
be POS N
prevented POS N
using POS N
head-out POS N
water POS N
immersion POS N
facilitated POS N
redistribution. POS N

Diastolic POS N
blood POS N
pressure POS N
did POS N
not POS N
change POS N
during POS N
the POS N
sessions. POS N

Reduced POS N
effective POS N
circulating POS N
volume POS N
is POS N
a POS N
major POS N
cause POS N
for POS N
IDH, POS N
which POS N
can POS N
be POS N
prevented POS N
using POS N
head-out POS N
water POS N
immersion POS N
facilitated POS N
redistribution. POS N

Mean POS N
atrial POS N
natriuretic POS N
peptide POS N
significantly POS N
increased POS N
in POS N
the POS N
wet POS N
session, POS N
by POS N
31.36 POS N
pgr/mL POS N
(95%CI POS N
8.73-53.99), POS N
P = 0.007, POS N
and POS N
slightly POS N
and POS N
insignificantly POS N
decreased POS N
in POS N
the POS N
dry POS N
session, POS N
by POS N
21.66 POS N
pgr/mL POS N
(95% POS N
CI POS N
-52.59 POS N
to POS N
9.25), POS N
P = 0.167. POS N

Reduced POS N
effective POS N
circulating POS N
volume POS N
is POS N
a POS N
major POS N
cause POS N
for POS N
IDH, POS N
which POS N
can POS N
be POS N
prevented POS N
using POS N
head-out POS N
water POS N
immersion POS N
facilitated POS N
redistribution. POS N

Aldosterone POS N
blood POS N
levels POS N
did POS N
not POS N
change. POS N

Aldosterone POS N
blood POS N
levels POS N
did POS N
not POS N
change. POS N

Symptomatic POS N
hypotension POS N
did POS N
not POS N
develop POS N
in POS N
any POS N
of POS N
the POS N
patients POS N
during POS N
the POS N
wet POS N
session, POS N
compared POS N
to POS N
4 POS N
(40%) POS N
during POS N
the POS N
dry POS N
session. POS N

Aldosterone POS N
blood POS N
levels POS N
did POS N
not POS N
change. POS N

Systolic POS N
blood POS N
pressure POS N
adjusted POS N
to POS N
ultrafiltration POS N
was POS N
stable POS N
during POS N
the POS N
wet POS N
session, POS N
0.22 POS N
mmHg/15 POS N
min POS N
(95% POS N
CI POS N
-0.27 POS N
to POS N
0.70), POS N
P = 0.38, POS N
and POS N
significantly POS N
decreased POS N
during POS N
the POS N
dry POS N
session, POS N
-0.68 POS N
mmHg/15 POS N
min POS N
(95%CI POS N
-1.24 POS N
to POS N
-0.11), POS N
P = 0.02. POS N

Aldosterone POS N
blood POS N
levels POS N
did POS N
not POS N
change. POS N

Diastolic POS N
blood POS N
pressure POS N
did POS N
not POS N
change POS N
during POS N
the POS N
sessions. POS N

Aldosterone POS N
blood POS N
levels POS N
did POS N
not POS N
change. POS N

Mean POS N
atrial POS N
natriuretic POS N
peptide POS N
significantly POS N
increased POS N
in POS N
the POS N
wet POS N
session, POS N
by POS N
31.36 POS N
pgr/mL POS N
(95%CI POS N
8.73-53.99), POS N
P = 0.007, POS N
and POS N
slightly POS N
and POS N
insignificantly POS N
decreased POS N
in POS N
the POS N
dry POS N
session, POS N
by POS N
21.66 POS N
pgr/mL POS N
(95% POS N
CI POS N
-52.59 POS N
to POS N
9.25), POS N
P = 0.167. POS N

Aldosterone POS N
blood POS N
levels POS N
did POS N
not POS N
change. POS N

Reduced POS N
effective POS N
circulating POS N
volume POS N
is POS N
a POS N
major POS N
cause POS N
for POS N
IDH, POS N
which POS N
can POS N
be POS N
prevented POS N
using POS N
head-out POS N
water POS N
immersion POS N
facilitated POS N
redistribution. POS N

Preservative-free POS N
latanoprost POS N
has POS N
the POS N
same POS N
efficacy POS N
as POS N
BPL, POS N
with POS N
improved POS N
local POS N
tolerance. POS N

Upon POS N
instillation, POS N
the POS N
global POS N
subjective POS N
ocular POS N
symptom POS N
score POS N
was POS N
significantly POS N
lower POS N
on POS N
T2345 POS N
than POS N
BPL POS N
on POS N
D42 POS N
(0.15 POS N
vs POS N
0.41; POS N
p=0.001) POS N
and POS N
D84 POS N
(0.18 POS N
vs POS N
0.46; POS N
p=0.001). POS N

Preservative-free POS N
latanoprost POS N
has POS N
the POS N
same POS N
efficacy POS N
as POS N
BPL, POS N
with POS N
improved POS N
local POS N
tolerance. POS N

Moderate POS N
to POS N
severe POS N
conjunctival POS N
hyperaemia POS N
was POS N
less POS N
frequent POS N
on POS N
T2345 POS N
than POS N
on POS N
BPL POS N
at POS N
D42 POS N
(20.2% POS N
vs POS N
30.6%; POS N
p=0.003) POS N
and POS N
D84 POS N
(21.4% POS N
vs POS N
29.1%; POS N
p=0.02). POS N

Preservative-free POS N
latanoprost POS N
has POS N
the POS N
same POS N
efficacy POS N
as POS N
BPL, POS N
with POS N
improved POS N
local POS N
tolerance. POS N

The POS N
most POS N
frequent POS N
ocular POS N
adverse POS N
event, POS N
drug POS N
intolerance, POS N
was POS N
reported POS N
in POS N
1 POS N
(0.5%) POS N
patient POS N
on POS N
T2345 POS N
versus POS N
4 POS N
(2.1%) POS N
patients POS N
on POS N
BPL. POS N

Preservative-free POS N
latanoprost POS N
has POS N
the POS N
same POS N
efficacy POS N
as POS N
BPL, POS N
with POS N
improved POS N
local POS N
tolerance. POS N

Mean POS N
IOP POS N
reduction POS N
(D0-D84) POS N
was POS N
-8.6 POS N
±2.6 POS N
mm POS N
Hg POS N
(-36%) POS N
on POS N
T2345 POS N
and POS N
-9.0 POS N
±2.4 POS N
mm POS N
Hg POS N
(-38%) POS N
on POS N
BPL, POS N
confirming POS N
non-inferiority POS N
of POS N
T2345 POS N
to POS N
BPL. POS N

Upon POS N
instillation, POS N
the POS N
global POS N
subjective POS N
ocular POS N
symptom POS N
score POS N
was POS N
significantly POS N
lower POS N
on POS N
T2345 POS N
than POS N
BPL POS N
on POS N
D42 POS N
(0.15 POS N
vs POS N
0.41; POS N
p=0.001) POS N
and POS N
D84 POS N
(0.18 POS N
vs POS N
0.46; POS N
p=0.001). POS N

Preservative-free POS N
latanoprost POS N
has POS N
the POS N
same POS N
efficacy POS N
as POS N
BPL, POS N
with POS N
improved POS N
local POS N
tolerance. POS N

Upon POS N
instillation, POS N
the POS N
global POS N
subjective POS N
ocular POS N
symptom POS N
score POS N
was POS N
significantly POS N
lower POS N
on POS N
T2345 POS N
than POS N
BPL POS N
on POS N
D42 POS N
(0.15 POS N
vs POS N
0.41; POS N
p=0.001) POS N
and POS N
D84 POS N
(0.18 POS N
vs POS N
0.46; POS N
p=0.001). POS N

Moderate POS N
to POS N
severe POS N
conjunctival POS N
hyperaemia POS N
was POS N
less POS N
frequent POS N
on POS N
T2345 POS N
than POS N
on POS N
BPL POS N
at POS N
D42 POS N
(20.2% POS N
vs POS N
30.6%; POS N
p=0.003) POS N
and POS N
D84 POS N
(21.4% POS N
vs POS N
29.1%; POS N
p=0.02). POS N

Upon POS N
instillation, POS N
the POS N
global POS N
subjective POS N
ocular POS N
symptom POS N
score POS N
was POS N
significantly POS N
lower POS N
on POS N
T2345 POS N
than POS N
BPL POS N
on POS N
D42 POS N
(0.15 POS N
vs POS N
0.41; POS N
p=0.001) POS N
and POS N
D84 POS N
(0.18 POS N
vs POS N
0.46; POS N
p=0.001). POS N

The POS N
most POS N
frequent POS N
ocular POS N
adverse POS N
event, POS N
drug POS N
intolerance, POS N
was POS N
reported POS N
in POS N
1 POS N
(0.5%) POS N
patient POS N
on POS N
T2345 POS N
versus POS N
4 POS N
(2.1%) POS N
patients POS N
on POS N
BPL. POS N

Upon POS N
instillation, POS N
the POS N
global POS N
subjective POS N
ocular POS N
symptom POS N
score POS N
was POS N
significantly POS N
lower POS N
on POS N
T2345 POS N
than POS N
BPL POS N
on POS N
D42 POS N
(0.15 POS N
vs POS N
0.41; POS N
p=0.001) POS N
and POS N
D84 POS N
(0.18 POS N
vs POS N
0.46; POS N
p=0.001). POS N

Mean POS N
IOP POS N
reduction POS N
(D0-D84) POS N
was POS N
-8.6 POS N
±2.6 POS N
mm POS N
Hg POS N
(-36%) POS N
on POS N
T2345 POS N
and POS N
-9.0 POS N
±2.4 POS N
mm POS N
Hg POS N
(-38%) POS N
on POS N
BPL, POS N
confirming POS N
non-inferiority POS N
of POS N
T2345 POS N
to POS N
BPL. POS N

Moderate POS N
to POS N
severe POS N
conjunctival POS N
hyperaemia POS N
was POS N
less POS N
frequent POS N
on POS N
T2345 POS N
than POS N
on POS N
BPL POS N
at POS N
D42 POS N
(20.2% POS N
vs POS N
30.6%; POS N
p=0.003) POS N
and POS N
D84 POS N
(21.4% POS N
vs POS N
29.1%; POS N
p=0.02). POS N

Preservative-free POS N
latanoprost POS N
has POS N
the POS N
same POS N
efficacy POS N
as POS N
BPL, POS N
with POS N
improved POS N
local POS N
tolerance. POS N

Moderate POS N
to POS N
severe POS N
conjunctival POS N
hyperaemia POS N
was POS N
less POS N
frequent POS N
on POS N
T2345 POS N
than POS N
on POS N
BPL POS N
at POS N
D42 POS N
(20.2% POS N
vs POS N
30.6%; POS N
p=0.003) POS N
and POS N
D84 POS N
(21.4% POS N
vs POS N
29.1%; POS N
p=0.02). POS N

Upon POS N
instillation, POS N
the POS N
global POS N
subjective POS N
ocular POS N
symptom POS N
score POS N
was POS N
significantly POS N
lower POS N
on POS N
T2345 POS N
than POS N
BPL POS N
on POS N
D42 POS N
(0.15 POS N
vs POS N
0.41; POS N
p=0.001) POS N
and POS N
D84 POS N
(0.18 POS N
vs POS N
0.46; POS N
p=0.001). POS N

Moderate POS N
to POS N
severe POS N
conjunctival POS N
hyperaemia POS N
was POS N
less POS N
frequent POS N
on POS N
T2345 POS N
than POS N
on POS N
BPL POS N
at POS N
D42 POS N
(20.2% POS N
vs POS N
30.6%; POS N
p=0.003) POS N
and POS N
D84 POS N
(21.4% POS N
vs POS N
29.1%; POS N
p=0.02). POS N

The POS N
most POS N
frequent POS N
ocular POS N
adverse POS N
event, POS N
drug POS N
intolerance, POS N
was POS N
reported POS N
in POS N
1 POS N
(0.5%) POS N
patient POS N
on POS N
T2345 POS N
versus POS N
4 POS N
(2.1%) POS N
patients POS N
on POS N
BPL. POS N

Moderate POS N
to POS N
severe POS N
conjunctival POS N
hyperaemia POS N
was POS N
less POS N
frequent POS N
on POS N
T2345 POS N
than POS N
on POS N
BPL POS N
at POS N
D42 POS N
(20.2% POS N
vs POS N
30.6%; POS N
p=0.003) POS N
and POS N
D84 POS N
(21.4% POS N
vs POS N
29.1%; POS N
p=0.02). POS N

Mean POS N
IOP POS N
reduction POS N
(D0-D84) POS N
was POS N
-8.6 POS N
±2.6 POS N
mm POS N
Hg POS N
(-36%) POS N
on POS N
T2345 POS N
and POS N
-9.0 POS N
±2.4 POS N
mm POS N
Hg POS N
(-38%) POS N
on POS N
BPL, POS N
confirming POS N
non-inferiority POS N
of POS N
T2345 POS N
to POS N
BPL. POS N

The POS N
most POS N
frequent POS N
ocular POS N
adverse POS N
event, POS N
drug POS N
intolerance, POS N
was POS N
reported POS N
in POS N
1 POS N
(0.5%) POS N
patient POS N
on POS N
T2345 POS N
versus POS N
4 POS N
(2.1%) POS N
patients POS N
on POS N
BPL. POS N

Preservative-free POS N
latanoprost POS N
has POS N
the POS N
same POS N
efficacy POS N
as POS N
BPL, POS N
with POS N
improved POS N
local POS N
tolerance. POS N

The POS N
most POS N
frequent POS N
ocular POS N
adverse POS N
event, POS N
drug POS N
intolerance, POS N
was POS N
reported POS N
in POS N
1 POS N
(0.5%) POS N
patient POS N
on POS N
T2345 POS N
versus POS N
4 POS N
(2.1%) POS N
patients POS N
on POS N
BPL. POS N

Upon POS N
instillation, POS N
the POS N
global POS N
subjective POS N
ocular POS N
symptom POS N
score POS N
was POS N
significantly POS N
lower POS N
on POS N
T2345 POS N
than POS N
BPL POS N
on POS N
D42 POS N
(0.15 POS N
vs POS N
0.41; POS N
p=0.001) POS N
and POS N
D84 POS N
(0.18 POS N
vs POS N
0.46; POS N
p=0.001). POS N

The POS N
most POS N
frequent POS N
ocular POS N
adverse POS N
event, POS N
drug POS N
intolerance, POS N
was POS N
reported POS N
in POS N
1 POS N
(0.5%) POS N
patient POS N
on POS N
T2345 POS N
versus POS N
4 POS N
(2.1%) POS N
patients POS N
on POS N
BPL. POS N

Moderate POS N
to POS N
severe POS N
conjunctival POS N
hyperaemia POS N
was POS N
less POS N
frequent POS N
on POS N
T2345 POS N
than POS N
on POS N
BPL POS N
at POS N
D42 POS N
(20.2% POS N
vs POS N
30.6%; POS N
p=0.003) POS N
and POS N
D84 POS N
(21.4% POS N
vs POS N
29.1%; POS N
p=0.02). POS N

The POS N
most POS N
frequent POS N
ocular POS N
adverse POS N
event, POS N
drug POS N
intolerance, POS N
was POS N
reported POS N
in POS N
1 POS N
(0.5%) POS N
patient POS N
on POS N
T2345 POS N
versus POS N
4 POS N
(2.1%) POS N
patients POS N
on POS N
BPL. POS N

Mean POS N
IOP POS N
reduction POS N
(D0-D84) POS N
was POS N
-8.6 POS N
±2.6 POS N
mm POS N
Hg POS N
(-36%) POS N
on POS N
T2345 POS N
and POS N
-9.0 POS N
±2.4 POS N
mm POS N
Hg POS N
(-38%) POS N
on POS N
BPL, POS N
confirming POS N
non-inferiority POS N
of POS N
T2345 POS N
to POS N
BPL. POS N

Mean POS N
IOP POS N
reduction POS N
(D0-D84) POS N
was POS N
-8.6 POS N
±2.6 POS N
mm POS N
Hg POS N
(-36%) POS N
on POS N
T2345 POS N
and POS N
-9.0 POS N
±2.4 POS N
mm POS N
Hg POS N
(-38%) POS N
on POS N
BPL, POS N
confirming POS N
non-inferiority POS N
of POS N
T2345 POS N
to POS N
BPL. POS N

Preservative-free POS N
latanoprost POS N
has POS N
the POS N
same POS N
efficacy POS N
as POS N
BPL, POS N
with POS N
improved POS N
local POS N
tolerance. POS N

Mean POS N
IOP POS N
reduction POS N
(D0-D84) POS N
was POS N
-8.6 POS N
±2.6 POS N
mm POS N
Hg POS N
(-36%) POS N
on POS N
T2345 POS N
and POS N
-9.0 POS N
±2.4 POS N
mm POS N
Hg POS N
(-38%) POS N
on POS N
BPL, POS N
confirming POS N
non-inferiority POS N
of POS N
T2345 POS N
to POS N
BPL. POS N

Upon POS N
instillation, POS N
the POS N
global POS N
subjective POS N
ocular POS N
symptom POS N
score POS N
was POS N
significantly POS N
lower POS N
on POS N
T2345 POS N
than POS N
BPL POS N
on POS N
D42 POS N
(0.15 POS N
vs POS N
0.41; POS N
p=0.001) POS N
and POS N
D84 POS N
(0.18 POS N
vs POS N
0.46; POS N
p=0.001). POS N

Mean POS N
IOP POS N
reduction POS N
(D0-D84) POS N
was POS N
-8.6 POS N
±2.6 POS N
mm POS N
Hg POS N
(-36%) POS N
on POS N
T2345 POS N
and POS N
-9.0 POS N
±2.4 POS N
mm POS N
Hg POS N
(-38%) POS N
on POS N
BPL, POS N
confirming POS N
non-inferiority POS N
of POS N
T2345 POS N
to POS N
BPL. POS N

Moderate POS N
to POS N
severe POS N
conjunctival POS N
hyperaemia POS N
was POS N
less POS N
frequent POS N
on POS N
T2345 POS N
than POS N
on POS N
BPL POS N
at POS N
D42 POS N
(20.2% POS N
vs POS N
30.6%; POS N
p=0.003) POS N
and POS N
D84 POS N
(21.4% POS N
vs POS N
29.1%; POS N
p=0.02). POS N

Mean POS N
IOP POS N
reduction POS N
(D0-D84) POS N
was POS N
-8.6 POS N
±2.6 POS N
mm POS N
Hg POS N
(-36%) POS N
on POS N
T2345 POS N
and POS N
-9.0 POS N
±2.4 POS N
mm POS N
Hg POS N
(-38%) POS N
on POS N
BPL, POS N
confirming POS N
non-inferiority POS N
of POS N
T2345 POS N
to POS N
BPL. POS N

The POS N
most POS N
frequent POS N
ocular POS N
adverse POS N
event, POS N
drug POS N
intolerance, POS N
was POS N
reported POS N
in POS N
1 POS N
(0.5%) POS N
patient POS N
on POS N
T2345 POS N
versus POS N
4 POS N
(2.1%) POS N
patients POS N
on POS N
BPL. POS N

Large-scale POS N
clinical POS N
trials POS N
have POS N
shown POS N
that POS N
incretin-based POS N
therapies POS N
mitigate POS N
albuminuria POS N

but POS N
have POS N
not POS N
shown POS N
beneficial POS N
effects POS N
on POS N
eGFR. POS N

Large-scale POS N
clinical POS N
trials POS N
have POS N
shown POS N
that POS N
incretin-based POS N
therapies POS N
mitigate POS N
albuminuria POS N

Research POS N
on POS N
the POS N
incretin-based POS N
therapies POS N
has POS N
yielded POS N
a POS N
diverse POS N
array POS N
of POS N
direct POS N
effects POS N
throughout POS N
the POS N
body, POS N
which POS N
fuels POS N
speculation POS N
as POS N
to POS N
how POS N
these POS N
drugs POS N
might POS N
benefit POS N
the POS N
diabetic POS N
kidney POS N
and POS N
affect POS N
its POS N
function(s). POS N

Large-scale POS N
clinical POS N
trials POS N
have POS N
shown POS N
that POS N
incretin-based POS N
therapies POS N
mitigate POS N
albuminuria POS N

But POS N
in POS N
vivo POS N
experiments POS N
have POS N
yet POS N
to POS N
confirm POS N
that POS N
the POS N
proposed POS N
mechanisms POS N
underlying POS N
emergent POS N
phenomena, POS N
such POS N
as POS N
proximal POS N
tubular POS N
fluid POS N
reabsorption, POS N
are POS N
the POS N
ones POS N
predicted POS N
by POS N
cell POS N
and POS N
molecular POS N
experiments. POS N

Large-scale POS N
clinical POS N
trials POS N
have POS N
shown POS N
that POS N
incretin-based POS N
therapies POS N
mitigate POS N
albuminuria POS N

There POS N
may POS N
be POS N
salutary POS N
effects POS N
of POS N
incretin-based POS N
treatments POS N
on POS N
the POS N
diabetic POS N
kidney, POS N

Large-scale POS N
clinical POS N
trials POS N
have POS N
shown POS N
that POS N
incretin-based POS N
therapies POS N
mitigate POS N
albuminuria POS N

but POS N
the POS N
system POS N
is POS N
complex POS N
and POS N
not POS N
amenable POS N
to POS N
simple POS N
explanation POS N
or POS N
prior POS N
prediction. POS N

Large-scale POS N
clinical POS N
trials POS N
have POS N
shown POS N
that POS N
incretin-based POS N
therapies POS N
mitigate POS N
albuminuria POS N

This POS N
contrasts POS N
with POS N
the POS N
renal POS N
effects POS N
of POS N
SGLT2 POS N
inhibitors, POS N
which POS N
can POS N
be POS N
explained POS N
concisely. POS N

but POS N
have POS N
not POS N
shown POS N
beneficial POS N
effects POS N
on POS N
eGFR. POS N

Large-scale POS N
clinical POS N
trials POS N
have POS N
shown POS N
that POS N
incretin-based POS N
therapies POS N
mitigate POS N
albuminuria POS N

but POS N
have POS N
not POS N
shown POS N
beneficial POS N
effects POS N
on POS N
eGFR. POS N

Research POS N
on POS N
the POS N
incretin-based POS N
therapies POS N
has POS N
yielded POS N
a POS N
diverse POS N
array POS N
of POS N
direct POS N
effects POS N
throughout POS N
the POS N
body, POS N
which POS N
fuels POS N
speculation POS N
as POS N
to POS N
how POS N
these POS N
drugs POS N
might POS N
benefit POS N
the POS N
diabetic POS N
kidney POS N
and POS N
affect POS N
its POS N
function(s). POS N

but POS N
have POS N
not POS N
shown POS N
beneficial POS N
effects POS N
on POS N
eGFR. POS N

But POS N
in POS N
vivo POS N
experiments POS N
have POS N
yet POS N
to POS N
confirm POS N
that POS N
the POS N
proposed POS N
mechanisms POS N
underlying POS N
emergent POS N
phenomena, POS N
such POS N
as POS N
proximal POS N
tubular POS N
fluid POS N
reabsorption, POS N
are POS N
the POS N
ones POS N
predicted POS N
by POS N
cell POS N
and POS N
molecular POS N
experiments. POS N

but POS N
have POS N
not POS N
shown POS N
beneficial POS N
effects POS N
on POS N
eGFR. POS N

There POS N
may POS N
be POS N
salutary POS N
effects POS N
of POS N
incretin-based POS N
treatments POS N
on POS N
the POS N
diabetic POS N
kidney, POS N

but POS N
have POS N
not POS N
shown POS N
beneficial POS N
effects POS N
on POS N
eGFR. POS N

but POS N
the POS N
system POS N
is POS N
complex POS N
and POS N
not POS N
amenable POS N
to POS N
simple POS N
explanation POS N
or POS N
prior POS N
prediction. POS N

but POS N
have POS N
not POS N
shown POS N
beneficial POS N
effects POS N
on POS N
eGFR. POS N

This POS N
contrasts POS N
with POS N
the POS N
renal POS N
effects POS N
of POS N
SGLT2 POS N
inhibitors, POS N
which POS N
can POS N
be POS N
explained POS N
concisely. POS N

Research POS N
on POS N
the POS N
incretin-based POS N
therapies POS N
has POS N
yielded POS N
a POS N
diverse POS N
array POS N
of POS N
direct POS N
effects POS N
throughout POS N
the POS N
body, POS N
which POS N
fuels POS N
speculation POS N
as POS N
to POS N
how POS N
these POS N
drugs POS N
might POS N
benefit POS N
the POS N
diabetic POS N
kidney POS N
and POS N
affect POS N
its POS N
function(s). POS N

Large-scale POS N
clinical POS N
trials POS N
have POS N
shown POS N
that POS N
incretin-based POS N
therapies POS N
mitigate POS N
albuminuria POS N

Research POS N
on POS N
the POS N
incretin-based POS N
therapies POS N
has POS N
yielded POS N
a POS N
diverse POS N
array POS N
of POS N
direct POS N
effects POS N
throughout POS N
the POS N
body, POS N
which POS N
fuels POS N
speculation POS N
as POS N
to POS N
how POS N
these POS N
drugs POS N
might POS N
benefit POS N
the POS N
diabetic POS N
kidney POS N
and POS N
affect POS N
its POS N
function(s). POS N

but POS N
have POS N
not POS N
shown POS N
beneficial POS N
effects POS N
on POS N
eGFR. POS N

Research POS N
on POS N
the POS N
incretin-based POS N
therapies POS N
has POS N
yielded POS N
a POS N
diverse POS N
array POS N
of POS N
direct POS N
effects POS N
throughout POS N
the POS N
body, POS N
which POS N
fuels POS N
speculation POS N
as POS N
to POS N
how POS N
these POS N
drugs POS N
might POS N
benefit POS N
the POS N
diabetic POS N
kidney POS N
and POS N
affect POS N
its POS N
function(s). POS N

But POS N
in POS N
vivo POS N
experiments POS N
have POS N
yet POS N
to POS N
confirm POS N
that POS N
the POS N
proposed POS N
mechanisms POS N
underlying POS N
emergent POS N
phenomena, POS N
such POS N
as POS N
proximal POS N
tubular POS N
fluid POS N
reabsorption, POS N
are POS N
the POS N
ones POS N
predicted POS N
by POS N
cell POS N
and POS N
molecular POS N
experiments. POS N

Research POS N
on POS N
the POS N
incretin-based POS N
therapies POS N
has POS N
yielded POS N
a POS N
diverse POS N
array POS N
of POS N
direct POS N
effects POS N
throughout POS N
the POS N
body, POS N
which POS N
fuels POS N
speculation POS N
as POS N
to POS N
how POS N
these POS N
drugs POS N
might POS N
benefit POS N
the POS N
diabetic POS N
kidney POS N
and POS N
affect POS N
its POS N
function(s). POS N

There POS N
may POS N
be POS N
salutary POS N
effects POS N
of POS N
incretin-based POS N
treatments POS N
on POS N
the POS N
diabetic POS N
kidney, POS N

Research POS N
on POS N
the POS N
incretin-based POS N
therapies POS N
has POS N
yielded POS N
a POS N
diverse POS N
array POS N
of POS N
direct POS N
effects POS N
throughout POS N
the POS N
body, POS N
which POS N
fuels POS N
speculation POS N
as POS N
to POS N
how POS N
these POS N
drugs POS N
might POS N
benefit POS N
the POS N
diabetic POS N
kidney POS N
and POS N
affect POS N
its POS N
function(s). POS N

but POS N
the POS N
system POS N
is POS N
complex POS N
and POS N
not POS N
amenable POS N
to POS N
simple POS N
explanation POS N
or POS N
prior POS N
prediction. POS N

Research POS N
on POS N
the POS N
incretin-based POS N
therapies POS N
has POS N
yielded POS N
a POS N
diverse POS N
array POS N
of POS N
direct POS N
effects POS N
throughout POS N
the POS N
body, POS N
which POS N
fuels POS N
speculation POS N
as POS N
to POS N
how POS N
these POS N
drugs POS N
might POS N
benefit POS N
the POS N
diabetic POS N
kidney POS N
and POS N
affect POS N
its POS N
function(s). POS N

This POS N
contrasts POS N
with POS N
the POS N
renal POS N
effects POS N
of POS N
SGLT2 POS N
inhibitors, POS N
which POS N
can POS N
be POS N
explained POS N
concisely. POS N

But POS N
in POS N
vivo POS N
experiments POS N
have POS N
yet POS N
to POS N
confirm POS N
that POS N
the POS N
proposed POS N
mechanisms POS N
underlying POS N
emergent POS N
phenomena, POS N
such POS N
as POS N
proximal POS N
tubular POS N
fluid POS N
reabsorption, POS N
are POS N
the POS N
ones POS N
predicted POS N
by POS N
cell POS N
and POS N
molecular POS N
experiments. POS N

Large-scale POS N
clinical POS N
trials POS N
have POS N
shown POS N
that POS N
incretin-based POS N
therapies POS N
mitigate POS N
albuminuria POS N

But POS N
in POS N
vivo POS N
experiments POS N
have POS N
yet POS N
to POS N
confirm POS N
that POS N
the POS N
proposed POS N
mechanisms POS N
underlying POS N
emergent POS N
phenomena, POS N
such POS N
as POS N
proximal POS N
tubular POS N
fluid POS N
reabsorption, POS N
are POS N
the POS N
ones POS N
predicted POS N
by POS N
cell POS N
and POS N
molecular POS N
experiments. POS N

but POS N
have POS N
not POS N
shown POS N
beneficial POS N
effects POS N
on POS N
eGFR. POS N

But POS N
in POS N
vivo POS N
experiments POS N
have POS N
yet POS N
to POS N
confirm POS N
that POS N
the POS N
proposed POS N
mechanisms POS N
underlying POS N
emergent POS N
phenomena, POS N
such POS N
as POS N
proximal POS N
tubular POS N
fluid POS N
reabsorption, POS N
are POS N
the POS N
ones POS N
predicted POS N
by POS N
cell POS N
and POS N
molecular POS N
experiments. POS N

Research POS N
on POS N
the POS N
incretin-based POS N
therapies POS N
has POS N
yielded POS N
a POS N
diverse POS N
array POS N
of POS N
direct POS N
effects POS N
throughout POS N
the POS N
body, POS N
which POS N
fuels POS N
speculation POS N
as POS N
to POS N
how POS N
these POS N
drugs POS N
might POS N
benefit POS N
the POS N
diabetic POS N
kidney POS N
and POS N
affect POS N
its POS N
function(s). POS N

But POS N
in POS N
vivo POS N
experiments POS N
have POS N
yet POS N
to POS N
confirm POS N
that POS N
the POS N
proposed POS N
mechanisms POS N
underlying POS N
emergent POS N
phenomena, POS N
such POS N
as POS N
proximal POS N
tubular POS N
fluid POS N
reabsorption, POS N
are POS N
the POS N
ones POS N
predicted POS N
by POS N
cell POS N
and POS N
molecular POS N
experiments. POS N

There POS N
may POS N
be POS N
salutary POS N
effects POS N
of POS N
incretin-based POS N
treatments POS N
on POS N
the POS N
diabetic POS N
kidney, POS N

But POS N
in POS N
vivo POS N
experiments POS N
have POS N
yet POS N
to POS N
confirm POS N
that POS N
the POS N
proposed POS N
mechanisms POS N
underlying POS N
emergent POS N
phenomena, POS N
such POS N
as POS N
proximal POS N
tubular POS N
fluid POS N
reabsorption, POS N
are POS N
the POS N
ones POS N
predicted POS N
by POS N
cell POS N
and POS N
molecular POS N
experiments. POS N

but POS N
the POS N
system POS N
is POS N
complex POS N
and POS N
not POS N
amenable POS N
to POS N
simple POS N
explanation POS N
or POS N
prior POS N
prediction. POS N

But POS N
in POS N
vivo POS N
experiments POS N
have POS N
yet POS N
to POS N
confirm POS N
that POS N
the POS N
proposed POS N
mechanisms POS N
underlying POS N
emergent POS N
phenomena, POS N
such POS N
as POS N
proximal POS N
tubular POS N
fluid POS N
reabsorption, POS N
are POS N
the POS N
ones POS N
predicted POS N
by POS N
cell POS N
and POS N
molecular POS N
experiments. POS N

This POS N
contrasts POS N
with POS N
the POS N
renal POS N
effects POS N
of POS N
SGLT2 POS N
inhibitors, POS N
which POS N
can POS N
be POS N
explained POS N
concisely. POS N

There POS N
may POS N
be POS N
salutary POS N
effects POS N
of POS N
incretin-based POS N
treatments POS N
on POS N
the POS N
diabetic POS N
kidney, POS N

Large-scale POS N
clinical POS N
trials POS N
have POS N
shown POS N
that POS N
incretin-based POS N
therapies POS N
mitigate POS N
albuminuria POS N

There POS N
may POS N
be POS N
salutary POS N
effects POS N
of POS N
incretin-based POS N
treatments POS N
on POS N
the POS N
diabetic POS N
kidney, POS N

but POS N
have POS N
not POS N
shown POS N
beneficial POS N
effects POS N
on POS N
eGFR. POS N

There POS N
may POS N
be POS N
salutary POS N
effects POS N
of POS N
incretin-based POS N
treatments POS N
on POS N
the POS N
diabetic POS N
kidney, POS N

Research POS N
on POS N
the POS N
incretin-based POS N
therapies POS N
has POS N
yielded POS N
a POS N
diverse POS N
array POS N
of POS N
direct POS N
effects POS N
throughout POS N
the POS N
body, POS N
which POS N
fuels POS N
speculation POS N
as POS N
to POS N
how POS N
these POS N
drugs POS N
might POS N
benefit POS N
the POS N
diabetic POS N
kidney POS N
and POS N
affect POS N
its POS N
function(s). POS N

There POS N
may POS N
be POS N
salutary POS N
effects POS N
of POS N
incretin-based POS N
treatments POS N
on POS N
the POS N
diabetic POS N
kidney, POS N

But POS N
in POS N
vivo POS N
experiments POS N
have POS N
yet POS N
to POS N
confirm POS N
that POS N
the POS N
proposed POS N
mechanisms POS N
underlying POS N
emergent POS N
phenomena, POS N
such POS N
as POS N
proximal POS N
tubular POS N
fluid POS N
reabsorption, POS N
are POS N
the POS N
ones POS N
predicted POS N
by POS N
cell POS N
and POS N
molecular POS N
experiments. POS N

There POS N
may POS N
be POS N
salutary POS N
effects POS N
of POS N
incretin-based POS N
treatments POS N
on POS N
the POS N
diabetic POS N
kidney, POS N

but POS N
the POS N
system POS N
is POS N
complex POS N
and POS N
not POS N
amenable POS N
to POS N
simple POS N
explanation POS N
or POS N
prior POS N
prediction. POS N

There POS N
may POS N
be POS N
salutary POS N
effects POS N
of POS N
incretin-based POS N
treatments POS N
on POS N
the POS N
diabetic POS N
kidney, POS N

This POS N
contrasts POS N
with POS N
the POS N
renal POS N
effects POS N
of POS N
SGLT2 POS N
inhibitors, POS N
which POS N
can POS N
be POS N
explained POS N
concisely. POS N

but POS N
the POS N
system POS N
is POS N
complex POS N
and POS N
not POS N
amenable POS N
to POS N
simple POS N
explanation POS N
or POS N
prior POS N
prediction. POS N

Large-scale POS N
clinical POS N
trials POS N
have POS N
shown POS N
that POS N
incretin-based POS N
therapies POS N
mitigate POS N
albuminuria POS N

but POS N
the POS N
system POS N
is POS N
complex POS N
and POS N
not POS N
amenable POS N
to POS N
simple POS N
explanation POS N
or POS N
prior POS N
prediction. POS N

but POS N
have POS N
not POS N
shown POS N
beneficial POS N
effects POS N
on POS N
eGFR. POS N

but POS N
the POS N
system POS N
is POS N
complex POS N
and POS N
not POS N
amenable POS N
to POS N
simple POS N
explanation POS N
or POS N
prior POS N
prediction. POS N

Research POS N
on POS N
the POS N
incretin-based POS N
therapies POS N
has POS N
yielded POS N
a POS N
diverse POS N
array POS N
of POS N
direct POS N
effects POS N
throughout POS N
the POS N
body, POS N
which POS N
fuels POS N
speculation POS N
as POS N
to POS N
how POS N
these POS N
drugs POS N
might POS N
benefit POS N
the POS N
diabetic POS N
kidney POS N
and POS N
affect POS N
its POS N
function(s). POS N

but POS N
the POS N
system POS N
is POS N
complex POS N
and POS N
not POS N
amenable POS N
to POS N
simple POS N
explanation POS N
or POS N
prior POS N
prediction. POS N

But POS N
in POS N
vivo POS N
experiments POS N
have POS N
yet POS N
to POS N
confirm POS N
that POS N
the POS N
proposed POS N
mechanisms POS N
underlying POS N
emergent POS N
phenomena, POS N
such POS N
as POS N
proximal POS N
tubular POS N
fluid POS N
reabsorption, POS N
are POS N
the POS N
ones POS N
predicted POS N
by POS N
cell POS N
and POS N
molecular POS N
experiments. POS N

but POS N
the POS N
system POS N
is POS N
complex POS N
and POS N
not POS N
amenable POS N
to POS N
simple POS N
explanation POS N
or POS N
prior POS N
prediction. POS N

There POS N
may POS N
be POS N
salutary POS N
effects POS N
of POS N
incretin-based POS N
treatments POS N
on POS N
the POS N
diabetic POS N
kidney, POS N

but POS N
the POS N
system POS N
is POS N
complex POS N
and POS N
not POS N
amenable POS N
to POS N
simple POS N
explanation POS N
or POS N
prior POS N
prediction. POS N

This POS N
contrasts POS N
with POS N
the POS N
renal POS N
effects POS N
of POS N
SGLT2 POS N
inhibitors, POS N
which POS N
can POS N
be POS N
explained POS N
concisely. POS N

This POS N
contrasts POS N
with POS N
the POS N
renal POS N
effects POS N
of POS N
SGLT2 POS N
inhibitors, POS N
which POS N
can POS N
be POS N
explained POS N
concisely. POS N

Large-scale POS N
clinical POS N
trials POS N
have POS N
shown POS N
that POS N
incretin-based POS N
therapies POS N
mitigate POS N
albuminuria POS N

This POS N
contrasts POS N
with POS N
the POS N
renal POS N
effects POS N
of POS N
SGLT2 POS N
inhibitors, POS N
which POS N
can POS N
be POS N
explained POS N
concisely. POS N

but POS N
have POS N
not POS N
shown POS N
beneficial POS N
effects POS N
on POS N
eGFR. POS N

This POS N
contrasts POS N
with POS N
the POS N
renal POS N
effects POS N
of POS N
SGLT2 POS N
inhibitors, POS N
which POS N
can POS N
be POS N
explained POS N
concisely. POS N

Research POS N
on POS N
the POS N
incretin-based POS N
therapies POS N
has POS N
yielded POS N
a POS N
diverse POS N
array POS N
of POS N
direct POS N
effects POS N
throughout POS N
the POS N
body, POS N
which POS N
fuels POS N
speculation POS N
as POS N
to POS N
how POS N
these POS N
drugs POS N
might POS N
benefit POS N
the POS N
diabetic POS N
kidney POS N
and POS N
affect POS N
its POS N
function(s). POS N

This POS N
contrasts POS N
with POS N
the POS N
renal POS N
effects POS N
of POS N
SGLT2 POS N
inhibitors, POS N
which POS N
can POS N
be POS N
explained POS N
concisely. POS N

But POS N
in POS N
vivo POS N
experiments POS N
have POS N
yet POS N
to POS N
confirm POS N
that POS N
the POS N
proposed POS N
mechanisms POS N
underlying POS N
emergent POS N
phenomena, POS N
such POS N
as POS N
proximal POS N
tubular POS N
fluid POS N
reabsorption, POS N
are POS N
the POS N
ones POS N
predicted POS N
by POS N
cell POS N
and POS N
molecular POS N
experiments. POS N

This POS N
contrasts POS N
with POS N
the POS N
renal POS N
effects POS N
of POS N
SGLT2 POS N
inhibitors, POS N
which POS N
can POS N
be POS N
explained POS N
concisely. POS N

There POS N
may POS N
be POS N
salutary POS N
effects POS N
of POS N
incretin-based POS N
treatments POS N
on POS N
the POS N
diabetic POS N
kidney, POS N

This POS N
contrasts POS N
with POS N
the POS N
renal POS N
effects POS N
of POS N
SGLT2 POS N
inhibitors, POS N
which POS N
can POS N
be POS N
explained POS N
concisely. POS N

but POS N
the POS N
system POS N
is POS N
complex POS N
and POS N
not POS N
amenable POS N
to POS N
simple POS N
explanation POS N
or POS N
prior POS N
prediction. POS N

Aortic POS N
systolic POS N
pressure POS N
and POS N
augmentation POS N
index, POS N
assessed POS N
by POS N
radial POS N
artery POS N
oscillatory POS N
tonometry, POS N
were POS N
unaffected POS N
by POS N
CPAP POS N
but POS N
decreased POS N
after POS N
AZT POS N
and POS N
AZT POS N
plus POS N
CPAP POS N
(RM-ANOVA POS N
P POS N
= POS N
.030 POS N
and POS N
.031, POS N
respectively). POS N

The POS N
apnea-hypopnea POS N
index POS N
was POS N
significantly POS N
reduced POS N
in POS N
all POS N
three POS N
treatment POS N
arms, POS N
most POS N
prominently POS N
by POS N
AZT POS N
plus POS N
CPAP POS N
(RM-ANOVA POS N
P POS N
= POS N
.003). POS N

Aortic POS N
systolic POS N
pressure POS N
and POS N
augmentation POS N
index, POS N
assessed POS N
by POS N
radial POS N
artery POS N
oscillatory POS N
tonometry, POS N
were POS N
unaffected POS N
by POS N
CPAP POS N
but POS N
decreased POS N
after POS N
AZT POS N
and POS N
AZT POS N
plus POS N
CPAP POS N
(RM-ANOVA POS N
P POS N
= POS N
.030 POS N
and POS N
.031, POS N
respectively). POS N

The POS N
reduction POS N
of POS N
venous POS N
bicarbonate POS N
concentration POS N
following POS N
AZT POS N
was POS N
correlated POS N
with POS N
the POS N
change POS N
of POS N
apnea-hypopnea POS N
index POS N
(r POS N
= POS N
0.66, POS N
P POS N
= POS N
.013). POS N

Aortic POS N
systolic POS N
pressure POS N
and POS N
augmentation POS N
index, POS N
assessed POS N
by POS N
radial POS N
artery POS N
oscillatory POS N
tonometry, POS N
were POS N
unaffected POS N
by POS N
CPAP POS N
but POS N
decreased POS N
after POS N
AZT POS N
and POS N
AZT POS N
plus POS N
CPAP POS N
(RM-ANOVA POS N
P POS N
= POS N
.030 POS N
and POS N
.031, POS N
respectively). POS N

AZT POS N
reduced POS N
blood POS N
pressure, POS N
vascular POS N
stiffness, POS N
and POS N
sleep-disordered POS N
breathing POS N
in POS N
patients POS N
with POS N
OSA POS N
and POS N
comorbid POS N
hypertension. POS N

Aortic POS N
systolic POS N
pressure POS N
and POS N
augmentation POS N
index, POS N
assessed POS N
by POS N
radial POS N
artery POS N
oscillatory POS N
tonometry, POS N
were POS N
unaffected POS N
by POS N
CPAP POS N
but POS N
decreased POS N
after POS N
AZT POS N
and POS N
AZT POS N
plus POS N
CPAP POS N
(RM-ANOVA POS N
P POS N
= POS N
.030 POS N
and POS N
.031, POS N
respectively). POS N

Carbonic POS N
anhydrase POS N
inhibition POS N
may POS N
constitute POS N
a POS N
potential POS N
target POS N
for POS N
drug POS N
therapy POS N
in POS N
patients POS N
with POS N
sleep POS N
apnea POS N
and POS N
comorbid POS N
hypertension. POS N

The POS N
apnea-hypopnea POS N
index POS N
was POS N
significantly POS N
reduced POS N
in POS N
all POS N
three POS N
treatment POS N
arms, POS N
most POS N
prominently POS N
by POS N
AZT POS N
plus POS N
CPAP POS N
(RM-ANOVA POS N
P POS N
= POS N
.003). POS N

Aortic POS N
systolic POS N
pressure POS N
and POS N
augmentation POS N
index, POS N
assessed POS N
by POS N
radial POS N
artery POS N
oscillatory POS N
tonometry, POS N
were POS N
unaffected POS N
by POS N
CPAP POS N
but POS N
decreased POS N
after POS N
AZT POS N
and POS N
AZT POS N
plus POS N
CPAP POS N
(RM-ANOVA POS N
P POS N
= POS N
.030 POS N
and POS N
.031, POS N
respectively). POS N

The POS N
apnea-hypopnea POS N
index POS N
was POS N
significantly POS N
reduced POS N
in POS N
all POS N
three POS N
treatment POS N
arms, POS N
most POS N
prominently POS N
by POS N
AZT POS N
plus POS N
CPAP POS N
(RM-ANOVA POS N
P POS N
= POS N
.003). POS N

The POS N
reduction POS N
of POS N
venous POS N
bicarbonate POS N
concentration POS N
following POS N
AZT POS N
was POS N
correlated POS N
with POS N
the POS N
change POS N
of POS N
apnea-hypopnea POS N
index POS N
(r POS N
= POS N
0.66, POS N
P POS N
= POS N
.013). POS N

The POS N
apnea-hypopnea POS N
index POS N
was POS N
significantly POS N
reduced POS N
in POS N
all POS N
three POS N
treatment POS N
arms, POS N
most POS N
prominently POS N
by POS N
AZT POS N
plus POS N
CPAP POS N
(RM-ANOVA POS N
P POS N
= POS N
.003). POS N

AZT POS N
reduced POS N
blood POS N
pressure, POS N
vascular POS N
stiffness, POS N
and POS N
sleep-disordered POS N
breathing POS N
in POS N
patients POS N
with POS N
OSA POS N
and POS N
comorbid POS N
hypertension. POS N

The POS N
apnea-hypopnea POS N
index POS N
was POS N
significantly POS N
reduced POS N
in POS N
all POS N
three POS N
treatment POS N
arms, POS N
most POS N
prominently POS N
by POS N
AZT POS N
plus POS N
CPAP POS N
(RM-ANOVA POS N
P POS N
= POS N
.003). POS N

Carbonic POS N
anhydrase POS N
inhibition POS N
may POS N
constitute POS N
a POS N
potential POS N
target POS N
for POS N
drug POS N
therapy POS N
in POS N
patients POS N
with POS N
sleep POS N
apnea POS N
and POS N
comorbid POS N
hypertension. POS N

The POS N
reduction POS N
of POS N
venous POS N
bicarbonate POS N
concentration POS N
following POS N
AZT POS N
was POS N
correlated POS N
with POS N
the POS N
change POS N
of POS N
apnea-hypopnea POS N
index POS N
(r POS N
= POS N
0.66, POS N
P POS N
= POS N
.013). POS N

Aortic POS N
systolic POS N
pressure POS N
and POS N
augmentation POS N
index, POS N
assessed POS N
by POS N
radial POS N
artery POS N
oscillatory POS N
tonometry, POS N
were POS N
unaffected POS N
by POS N
CPAP POS N
but POS N
decreased POS N
after POS N
AZT POS N
and POS N
AZT POS N
plus POS N
CPAP POS N
(RM-ANOVA POS N
P POS N
= POS N
.030 POS N
and POS N
.031, POS N
respectively). POS N

The POS N
reduction POS N
of POS N
venous POS N
bicarbonate POS N
concentration POS N
following POS N
AZT POS N
was POS N
correlated POS N
with POS N
the POS N
change POS N
of POS N
apnea-hypopnea POS N
index POS N
(r POS N
= POS N
0.66, POS N
P POS N
= POS N
.013). POS N

The POS N
apnea-hypopnea POS N
index POS N
was POS N
significantly POS N
reduced POS N
in POS N
all POS N
three POS N
treatment POS N
arms, POS N
most POS N
prominently POS N
by POS N
AZT POS N
plus POS N
CPAP POS N
(RM-ANOVA POS N
P POS N
= POS N
.003). POS N

The POS N
reduction POS N
of POS N
venous POS N
bicarbonate POS N
concentration POS N
following POS N
AZT POS N
was POS N
correlated POS N
with POS N
the POS N
change POS N
of POS N
apnea-hypopnea POS N
index POS N
(r POS N
= POS N
0.66, POS N
P POS N
= POS N
.013). POS N

AZT POS N
reduced POS N
blood POS N
pressure, POS N
vascular POS N
stiffness, POS N
and POS N
sleep-disordered POS N
breathing POS N
in POS N
patients POS N
with POS N
OSA POS N
and POS N
comorbid POS N
hypertension. POS N

The POS N
reduction POS N
of POS N
venous POS N
bicarbonate POS N
concentration POS N
following POS N
AZT POS N
was POS N
correlated POS N
with POS N
the POS N
change POS N
of POS N
apnea-hypopnea POS N
index POS N
(r POS N
= POS N
0.66, POS N
P POS N
= POS N
.013). POS N

Carbonic POS N
anhydrase POS N
inhibition POS N
may POS N
constitute POS N
a POS N
potential POS N
target POS N
for POS N
drug POS N
therapy POS N
in POS N
patients POS N
with POS N
sleep POS N
apnea POS N
and POS N
comorbid POS N
hypertension. POS N

AZT POS N
reduced POS N
blood POS N
pressure, POS N
vascular POS N
stiffness, POS N
and POS N
sleep-disordered POS N
breathing POS N
in POS N
patients POS N
with POS N
OSA POS N
and POS N
comorbid POS N
hypertension. POS N

Aortic POS N
systolic POS N
pressure POS N
and POS N
augmentation POS N
index, POS N
assessed POS N
by POS N
radial POS N
artery POS N
oscillatory POS N
tonometry, POS N
were POS N
unaffected POS N
by POS N
CPAP POS N
but POS N
decreased POS N
after POS N
AZT POS N
and POS N
AZT POS N
plus POS N
CPAP POS N
(RM-ANOVA POS N
P POS N
= POS N
.030 POS N
and POS N
.031, POS N
respectively). POS N

AZT POS N
reduced POS N
blood POS N
pressure, POS N
vascular POS N
stiffness, POS N
and POS N
sleep-disordered POS N
breathing POS N
in POS N
patients POS N
with POS N
OSA POS N
and POS N
comorbid POS N
hypertension. POS N

The POS N
apnea-hypopnea POS N
index POS N
was POS N
significantly POS N
reduced POS N
in POS N
all POS N
three POS N
treatment POS N
arms, POS N
most POS N
prominently POS N
by POS N
AZT POS N
plus POS N
CPAP POS N
(RM-ANOVA POS N
P POS N
= POS N
.003). POS N

AZT POS N
reduced POS N
blood POS N
pressure, POS N
vascular POS N
stiffness, POS N
and POS N
sleep-disordered POS N
breathing POS N
in POS N
patients POS N
with POS N
OSA POS N
and POS N
comorbid POS N
hypertension. POS N

The POS N
reduction POS N
of POS N
venous POS N
bicarbonate POS N
concentration POS N
following POS N
AZT POS N
was POS N
correlated POS N
with POS N
the POS N
change POS N
of POS N
apnea-hypopnea POS N
index POS N
(r POS N
= POS N
0.66, POS N
P POS N
= POS N
.013). POS N

AZT POS N
reduced POS N
blood POS N
pressure, POS N
vascular POS N
stiffness, POS N
and POS N
sleep-disordered POS N
breathing POS N
in POS N
patients POS N
with POS N
OSA POS N
and POS N
comorbid POS N
hypertension. POS N

Carbonic POS N
anhydrase POS N
inhibition POS N
may POS N
constitute POS N
a POS N
potential POS N
target POS N
for POS N
drug POS N
therapy POS N
in POS N
patients POS N
with POS N
sleep POS N
apnea POS N
and POS N
comorbid POS N
hypertension. POS N

Carbonic POS N
anhydrase POS N
inhibition POS N
may POS N
constitute POS N
a POS N
potential POS N
target POS N
for POS N
drug POS N
therapy POS N
in POS N
patients POS N
with POS N
sleep POS N
apnea POS N
and POS N
comorbid POS N
hypertension. POS N

Aortic POS N
systolic POS N
pressure POS N
and POS N
augmentation POS N
index, POS N
assessed POS N
by POS N
radial POS N
artery POS N
oscillatory POS N
tonometry, POS N
were POS N
unaffected POS N
by POS N
CPAP POS N
but POS N
decreased POS N
after POS N
AZT POS N
and POS N
AZT POS N
plus POS N
CPAP POS N
(RM-ANOVA POS N
P POS N
= POS N
.030 POS N
and POS N
.031, POS N
respectively). POS N

Carbonic POS N
anhydrase POS N
inhibition POS N
may POS N
constitute POS N
a POS N
potential POS N
target POS N
for POS N
drug POS N
therapy POS N
in POS N
patients POS N
with POS N
sleep POS N
apnea POS N
and POS N
comorbid POS N
hypertension. POS N

The POS N
apnea-hypopnea POS N
index POS N
was POS N
significantly POS N
reduced POS N
in POS N
all POS N
three POS N
treatment POS N
arms, POS N
most POS N
prominently POS N
by POS N
AZT POS N
plus POS N
CPAP POS N
(RM-ANOVA POS N
P POS N
= POS N
.003). POS N

Carbonic POS N
anhydrase POS N
inhibition POS N
may POS N
constitute POS N
a POS N
potential POS N
target POS N
for POS N
drug POS N
therapy POS N
in POS N
patients POS N
with POS N
sleep POS N
apnea POS N
and POS N
comorbid POS N
hypertension. POS N

The POS N
reduction POS N
of POS N
venous POS N
bicarbonate POS N
concentration POS N
following POS N
AZT POS N
was POS N
correlated POS N
with POS N
the POS N
change POS N
of POS N
apnea-hypopnea POS N
index POS N
(r POS N
= POS N
0.66, POS N
P POS N
= POS N
.013). POS N

Carbonic POS N
anhydrase POS N
inhibition POS N
may POS N
constitute POS N
a POS N
potential POS N
target POS N
for POS N
drug POS N
therapy POS N
in POS N
patients POS N
with POS N
sleep POS N
apnea POS N
and POS N
comorbid POS N
hypertension. POS N

AZT POS N
reduced POS N
blood POS N
pressure, POS N
vascular POS N
stiffness, POS N
and POS N
sleep-disordered POS N
breathing POS N
in POS N
patients POS N
with POS N
OSA POS N
and POS N
comorbid POS N
hypertension. POS N

It POS N
shows POS N
that POS N
a POS N
sequential POS N
combination POS N
of POS N
interferon-α POS N
and POS N
lamivudine POS N
was POS N
beneficial. POS N

Of POS N
the POS N
46 POS N
patients POS N
in POS N
the POS N
treatment POS N
group, POS N
73.91% POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
32.61% POS N
achieved POS N
HBeAg POS N
seroconversion POS N
and POS N
21.74% POS N
lost POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
at POS N
the POS N
endpoint. POS N

It POS N
shows POS N
that POS N
a POS N
sequential POS N
combination POS N
of POS N
interferon-α POS N
and POS N
lamivudine POS N
was POS N
beneficial. POS N

No POS N
LAM POS N
resistance POS N
emerged POS N
at POS N
week POS N
96. POS N

It POS N
shows POS N
that POS N
a POS N
sequential POS N
combination POS N
of POS N
interferon-α POS N
and POS N
lamivudine POS N
was POS N
beneficial. POS N

In POS N
the POS N
control POS N
group, POS N
only POS N
one POS N
(4.35%) POS N
patient POS N
underwent POS N
spontaneous POS N
HBeAg POS N
seroconversion POS N
and POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA POS N
during POS N
observation, POS N
and POS N
moreover, POS N
none POS N
developed POS N
HBsAg POS N
clearance. POS N

It POS N
shows POS N
that POS N
a POS N
sequential POS N
combination POS N
of POS N
interferon-α POS N
and POS N
lamivudine POS N
was POS N
beneficial. POS N

For POS N
all POS N
patients, POS N
no POS N
serious POS N
adverse POS N
events POS N
were POS N
observed. POS N

It POS N
shows POS N
that POS N
a POS N
sequential POS N
combination POS N
of POS N
interferon-α POS N
and POS N
lamivudine POS N
was POS N
beneficial. POS N

Antiviral POS N
treatment POS N
with POS N
a POS N
sequential POS N
combination POS N
of POS N
IFN POS N
and POS N
LAM POS N
resulted POS N
in POS N
a POS N
significant POS N
improvement POS N
in POS N
the POS N
rates POS N
of POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
HBeAg POS N
seroconversion POS N
and POS N
HBsAg POS N
loss POS N
in POS N
children POS N
with POS N
chronic POS N
HBV POS N
infection POS N
and POS N
immune-tolerant POS N
characteristics. POS N

It POS N
shows POS N
that POS N
a POS N
sequential POS N
combination POS N
of POS N
interferon-α POS N
and POS N
lamivudine POS N
was POS N
beneficial. POS N

It POS N
remains POS N
unresolved POS N
how POS N
children POS N
with POS N
immune-tolerant POS N
CHB POS N
should POS N
be POS N
treated. POS N

Of POS N
the POS N
46 POS N
patients POS N
in POS N
the POS N
treatment POS N
group, POS N
73.91% POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
32.61% POS N
achieved POS N
HBeAg POS N
seroconversion POS N
and POS N
21.74% POS N
lost POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
at POS N
the POS N
endpoint. POS N

It POS N
shows POS N
that POS N
a POS N
sequential POS N
combination POS N
of POS N
interferon-α POS N
and POS N
lamivudine POS N
was POS N
beneficial. POS N

Of POS N
the POS N
46 POS N
patients POS N
in POS N
the POS N
treatment POS N
group, POS N
73.91% POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
32.61% POS N
achieved POS N
HBeAg POS N
seroconversion POS N
and POS N
21.74% POS N
lost POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
at POS N
the POS N
endpoint. POS N

No POS N
LAM POS N
resistance POS N
emerged POS N
at POS N
week POS N
96. POS N

Of POS N
the POS N
46 POS N
patients POS N
in POS N
the POS N
treatment POS N
group, POS N
73.91% POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
32.61% POS N
achieved POS N
HBeAg POS N
seroconversion POS N
and POS N
21.74% POS N
lost POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
at POS N
the POS N
endpoint. POS N

In POS N
the POS N
control POS N
group, POS N
only POS N
one POS N
(4.35%) POS N
patient POS N
underwent POS N
spontaneous POS N
HBeAg POS N
seroconversion POS N
and POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA POS N
during POS N
observation, POS N
and POS N
moreover, POS N
none POS N
developed POS N
HBsAg POS N
clearance. POS N

Of POS N
the POS N
46 POS N
patients POS N
in POS N
the POS N
treatment POS N
group, POS N
73.91% POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
32.61% POS N
achieved POS N
HBeAg POS N
seroconversion POS N
and POS N
21.74% POS N
lost POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
at POS N
the POS N
endpoint. POS N

For POS N
all POS N
patients, POS N
no POS N
serious POS N
adverse POS N
events POS N
were POS N
observed. POS N

Of POS N
the POS N
46 POS N
patients POS N
in POS N
the POS N
treatment POS N
group, POS N
73.91% POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
32.61% POS N
achieved POS N
HBeAg POS N
seroconversion POS N
and POS N
21.74% POS N
lost POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
at POS N
the POS N
endpoint. POS N

Antiviral POS N
treatment POS N
with POS N
a POS N
sequential POS N
combination POS N
of POS N
IFN POS N
and POS N
LAM POS N
resulted POS N
in POS N
a POS N
significant POS N
improvement POS N
in POS N
the POS N
rates POS N
of POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
HBeAg POS N
seroconversion POS N
and POS N
HBsAg POS N
loss POS N
in POS N
children POS N
with POS N
chronic POS N
HBV POS N
infection POS N
and POS N
immune-tolerant POS N
characteristics. POS N

Of POS N
the POS N
46 POS N
patients POS N
in POS N
the POS N
treatment POS N
group, POS N
73.91% POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
32.61% POS N
achieved POS N
HBeAg POS N
seroconversion POS N
and POS N
21.74% POS N
lost POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
at POS N
the POS N
endpoint. POS N

It POS N
remains POS N
unresolved POS N
how POS N
children POS N
with POS N
immune-tolerant POS N
CHB POS N
should POS N
be POS N
treated. POS N

No POS N
LAM POS N
resistance POS N
emerged POS N
at POS N
week POS N
96. POS N

It POS N
shows POS N
that POS N
a POS N
sequential POS N
combination POS N
of POS N
interferon-α POS N
and POS N
lamivudine POS N
was POS N
beneficial. POS N

No POS N
LAM POS N
resistance POS N
emerged POS N
at POS N
week POS N
96. POS N

Of POS N
the POS N
46 POS N
patients POS N
in POS N
the POS N
treatment POS N
group, POS N
73.91% POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
32.61% POS N
achieved POS N
HBeAg POS N
seroconversion POS N
and POS N
21.74% POS N
lost POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
at POS N
the POS N
endpoint. POS N

No POS N
LAM POS N
resistance POS N
emerged POS N
at POS N
week POS N
96. POS N

In POS N
the POS N
control POS N
group, POS N
only POS N
one POS N
(4.35%) POS N
patient POS N
underwent POS N
spontaneous POS N
HBeAg POS N
seroconversion POS N
and POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA POS N
during POS N
observation, POS N
and POS N
moreover, POS N
none POS N
developed POS N
HBsAg POS N
clearance. POS N

No POS N
LAM POS N
resistance POS N
emerged POS N
at POS N
week POS N
96. POS N

For POS N
all POS N
patients, POS N
no POS N
serious POS N
adverse POS N
events POS N
were POS N
observed. POS N

No POS N
LAM POS N
resistance POS N
emerged POS N
at POS N
week POS N
96. POS N

Antiviral POS N
treatment POS N
with POS N
a POS N
sequential POS N
combination POS N
of POS N
IFN POS N
and POS N
LAM POS N
resulted POS N
in POS N
a POS N
significant POS N
improvement POS N
in POS N
the POS N
rates POS N
of POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
HBeAg POS N
seroconversion POS N
and POS N
HBsAg POS N
loss POS N
in POS N
children POS N
with POS N
chronic POS N
HBV POS N
infection POS N
and POS N
immune-tolerant POS N
characteristics. POS N

No POS N
LAM POS N
resistance POS N
emerged POS N
at POS N
week POS N
96. POS N

It POS N
remains POS N
unresolved POS N
how POS N
children POS N
with POS N
immune-tolerant POS N
CHB POS N
should POS N
be POS N
treated. POS N

In POS N
the POS N
control POS N
group, POS N
only POS N
one POS N
(4.35%) POS N
patient POS N
underwent POS N
spontaneous POS N
HBeAg POS N
seroconversion POS N
and POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA POS N
during POS N
observation, POS N
and POS N
moreover, POS N
none POS N
developed POS N
HBsAg POS N
clearance. POS N

It POS N
shows POS N
that POS N
a POS N
sequential POS N
combination POS N
of POS N
interferon-α POS N
and POS N
lamivudine POS N
was POS N
beneficial. POS N

In POS N
the POS N
control POS N
group, POS N
only POS N
one POS N
(4.35%) POS N
patient POS N
underwent POS N
spontaneous POS N
HBeAg POS N
seroconversion POS N
and POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA POS N
during POS N
observation, POS N
and POS N
moreover, POS N
none POS N
developed POS N
HBsAg POS N
clearance. POS N

Of POS N
the POS N
46 POS N
patients POS N
in POS N
the POS N
treatment POS N
group, POS N
73.91% POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
32.61% POS N
achieved POS N
HBeAg POS N
seroconversion POS N
and POS N
21.74% POS N
lost POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
at POS N
the POS N
endpoint. POS N

In POS N
the POS N
control POS N
group, POS N
only POS N
one POS N
(4.35%) POS N
patient POS N
underwent POS N
spontaneous POS N
HBeAg POS N
seroconversion POS N
and POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA POS N
during POS N
observation, POS N
and POS N
moreover, POS N
none POS N
developed POS N
HBsAg POS N
clearance. POS N

No POS N
LAM POS N
resistance POS N
emerged POS N
at POS N
week POS N
96. POS N

In POS N
the POS N
control POS N
group, POS N
only POS N
one POS N
(4.35%) POS N
patient POS N
underwent POS N
spontaneous POS N
HBeAg POS N
seroconversion POS N
and POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA POS N
during POS N
observation, POS N
and POS N
moreover, POS N
none POS N
developed POS N
HBsAg POS N
clearance. POS N

For POS N
all POS N
patients, POS N
no POS N
serious POS N
adverse POS N
events POS N
were POS N
observed. POS N

In POS N
the POS N
control POS N
group, POS N
only POS N
one POS N
(4.35%) POS N
patient POS N
underwent POS N
spontaneous POS N
HBeAg POS N
seroconversion POS N
and POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA POS N
during POS N
observation, POS N
and POS N
moreover, POS N
none POS N
developed POS N
HBsAg POS N
clearance. POS N

Antiviral POS N
treatment POS N
with POS N
a POS N
sequential POS N
combination POS N
of POS N
IFN POS N
and POS N
LAM POS N
resulted POS N
in POS N
a POS N
significant POS N
improvement POS N
in POS N
the POS N
rates POS N
of POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
HBeAg POS N
seroconversion POS N
and POS N
HBsAg POS N
loss POS N
in POS N
children POS N
with POS N
chronic POS N
HBV POS N
infection POS N
and POS N
immune-tolerant POS N
characteristics. POS N

In POS N
the POS N
control POS N
group, POS N
only POS N
one POS N
(4.35%) POS N
patient POS N
underwent POS N
spontaneous POS N
HBeAg POS N
seroconversion POS N
and POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA POS N
during POS N
observation, POS N
and POS N
moreover, POS N
none POS N
developed POS N
HBsAg POS N
clearance. POS N

It POS N
remains POS N
unresolved POS N
how POS N
children POS N
with POS N
immune-tolerant POS N
CHB POS N
should POS N
be POS N
treated. POS N

For POS N
all POS N
patients, POS N
no POS N
serious POS N
adverse POS N
events POS N
were POS N
observed. POS N

It POS N
shows POS N
that POS N
a POS N
sequential POS N
combination POS N
of POS N
interferon-α POS N
and POS N
lamivudine POS N
was POS N
beneficial. POS N

For POS N
all POS N
patients, POS N
no POS N
serious POS N
adverse POS N
events POS N
were POS N
observed. POS N

Of POS N
the POS N
46 POS N
patients POS N
in POS N
the POS N
treatment POS N
group, POS N
73.91% POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
32.61% POS N
achieved POS N
HBeAg POS N
seroconversion POS N
and POS N
21.74% POS N
lost POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
at POS N
the POS N
endpoint. POS N

For POS N
all POS N
patients, POS N
no POS N
serious POS N
adverse POS N
events POS N
were POS N
observed. POS N

No POS N
LAM POS N
resistance POS N
emerged POS N
at POS N
week POS N
96. POS N

For POS N
all POS N
patients, POS N
no POS N
serious POS N
adverse POS N
events POS N
were POS N
observed. POS N

In POS N
the POS N
control POS N
group, POS N
only POS N
one POS N
(4.35%) POS N
patient POS N
underwent POS N
spontaneous POS N
HBeAg POS N
seroconversion POS N
and POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA POS N
during POS N
observation, POS N
and POS N
moreover, POS N
none POS N
developed POS N
HBsAg POS N
clearance. POS N

For POS N
all POS N
patients, POS N
no POS N
serious POS N
adverse POS N
events POS N
were POS N
observed. POS N

Antiviral POS N
treatment POS N
with POS N
a POS N
sequential POS N
combination POS N
of POS N
IFN POS N
and POS N
LAM POS N
resulted POS N
in POS N
a POS N
significant POS N
improvement POS N
in POS N
the POS N
rates POS N
of POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
HBeAg POS N
seroconversion POS N
and POS N
HBsAg POS N
loss POS N
in POS N
children POS N
with POS N
chronic POS N
HBV POS N
infection POS N
and POS N
immune-tolerant POS N
characteristics. POS N

For POS N
all POS N
patients, POS N
no POS N
serious POS N
adverse POS N
events POS N
were POS N
observed. POS N

It POS N
remains POS N
unresolved POS N
how POS N
children POS N
with POS N
immune-tolerant POS N
CHB POS N
should POS N
be POS N
treated. POS N

Antiviral POS N
treatment POS N
with POS N
a POS N
sequential POS N
combination POS N
of POS N
IFN POS N
and POS N
LAM POS N
resulted POS N
in POS N
a POS N
significant POS N
improvement POS N
in POS N
the POS N
rates POS N
of POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
HBeAg POS N
seroconversion POS N
and POS N
HBsAg POS N
loss POS N
in POS N
children POS N
with POS N
chronic POS N
HBV POS N
infection POS N
and POS N
immune-tolerant POS N
characteristics. POS N

It POS N
shows POS N
that POS N
a POS N
sequential POS N
combination POS N
of POS N
interferon-α POS N
and POS N
lamivudine POS N
was POS N
beneficial. POS N

Antiviral POS N
treatment POS N
with POS N
a POS N
sequential POS N
combination POS N
of POS N
IFN POS N
and POS N
LAM POS N
resulted POS N
in POS N
a POS N
significant POS N
improvement POS N
in POS N
the POS N
rates POS N
of POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
HBeAg POS N
seroconversion POS N
and POS N
HBsAg POS N
loss POS N
in POS N
children POS N
with POS N
chronic POS N
HBV POS N
infection POS N
and POS N
immune-tolerant POS N
characteristics. POS N

Of POS N
the POS N
46 POS N
patients POS N
in POS N
the POS N
treatment POS N
group, POS N
73.91% POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
32.61% POS N
achieved POS N
HBeAg POS N
seroconversion POS N
and POS N
21.74% POS N
lost POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
at POS N
the POS N
endpoint. POS N

Antiviral POS N
treatment POS N
with POS N
a POS N
sequential POS N
combination POS N
of POS N
IFN POS N
and POS N
LAM POS N
resulted POS N
in POS N
a POS N
significant POS N
improvement POS N
in POS N
the POS N
rates POS N
of POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
HBeAg POS N
seroconversion POS N
and POS N
HBsAg POS N
loss POS N
in POS N
children POS N
with POS N
chronic POS N
HBV POS N
infection POS N
and POS N
immune-tolerant POS N
characteristics. POS N

No POS N
LAM POS N
resistance POS N
emerged POS N
at POS N
week POS N
96. POS N

Antiviral POS N
treatment POS N
with POS N
a POS N
sequential POS N
combination POS N
of POS N
IFN POS N
and POS N
LAM POS N
resulted POS N
in POS N
a POS N
significant POS N
improvement POS N
in POS N
the POS N
rates POS N
of POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
HBeAg POS N
seroconversion POS N
and POS N
HBsAg POS N
loss POS N
in POS N
children POS N
with POS N
chronic POS N
HBV POS N
infection POS N
and POS N
immune-tolerant POS N
characteristics. POS N

In POS N
the POS N
control POS N
group, POS N
only POS N
one POS N
(4.35%) POS N
patient POS N
underwent POS N
spontaneous POS N
HBeAg POS N
seroconversion POS N
and POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA POS N
during POS N
observation, POS N
and POS N
moreover, POS N
none POS N
developed POS N
HBsAg POS N
clearance. POS N

Antiviral POS N
treatment POS N
with POS N
a POS N
sequential POS N
combination POS N
of POS N
IFN POS N
and POS N
LAM POS N
resulted POS N
in POS N
a POS N
significant POS N
improvement POS N
in POS N
the POS N
rates POS N
of POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
HBeAg POS N
seroconversion POS N
and POS N
HBsAg POS N
loss POS N
in POS N
children POS N
with POS N
chronic POS N
HBV POS N
infection POS N
and POS N
immune-tolerant POS N
characteristics. POS N

For POS N
all POS N
patients, POS N
no POS N
serious POS N
adverse POS N
events POS N
were POS N
observed. POS N

Antiviral POS N
treatment POS N
with POS N
a POS N
sequential POS N
combination POS N
of POS N
IFN POS N
and POS N
LAM POS N
resulted POS N
in POS N
a POS N
significant POS N
improvement POS N
in POS N
the POS N
rates POS N
of POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
HBeAg POS N
seroconversion POS N
and POS N
HBsAg POS N
loss POS N
in POS N
children POS N
with POS N
chronic POS N
HBV POS N
infection POS N
and POS N
immune-tolerant POS N
characteristics. POS N

It POS N
remains POS N
unresolved POS N
how POS N
children POS N
with POS N
immune-tolerant POS N
CHB POS N
should POS N
be POS N
treated. POS N

It POS N
remains POS N
unresolved POS N
how POS N
children POS N
with POS N
immune-tolerant POS N
CHB POS N
should POS N
be POS N
treated. POS N

It POS N
shows POS N
that POS N
a POS N
sequential POS N
combination POS N
of POS N
interferon-α POS N
and POS N
lamivudine POS N
was POS N
beneficial. POS N

It POS N
remains POS N
unresolved POS N
how POS N
children POS N
with POS N
immune-tolerant POS N
CHB POS N
should POS N
be POS N
treated. POS N

Of POS N
the POS N
46 POS N
patients POS N
in POS N
the POS N
treatment POS N
group, POS N
73.91% POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
32.61% POS N
achieved POS N
HBeAg POS N
seroconversion POS N
and POS N
21.74% POS N
lost POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
at POS N
the POS N
endpoint. POS N

It POS N
remains POS N
unresolved POS N
how POS N
children POS N
with POS N
immune-tolerant POS N
CHB POS N
should POS N
be POS N
treated. POS N

No POS N
LAM POS N
resistance POS N
emerged POS N
at POS N
week POS N
96. POS N

It POS N
remains POS N
unresolved POS N
how POS N
children POS N
with POS N
immune-tolerant POS N
CHB POS N
should POS N
be POS N
treated. POS N

In POS N
the POS N
control POS N
group, POS N
only POS N
one POS N
(4.35%) POS N
patient POS N
underwent POS N
spontaneous POS N
HBeAg POS N
seroconversion POS N
and POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA POS N
during POS N
observation, POS N
and POS N
moreover, POS N
none POS N
developed POS N
HBsAg POS N
clearance. POS N

It POS N
remains POS N
unresolved POS N
how POS N
children POS N
with POS N
immune-tolerant POS N
CHB POS N
should POS N
be POS N
treated. POS N

For POS N
all POS N
patients, POS N
no POS N
serious POS N
adverse POS N
events POS N
were POS N
observed. POS N

It POS N
remains POS N
unresolved POS N
how POS N
children POS N
with POS N
immune-tolerant POS N
CHB POS N
should POS N
be POS N
treated. POS N

Antiviral POS N
treatment POS N
with POS N
a POS N
sequential POS N
combination POS N
of POS N
IFN POS N
and POS N
LAM POS N
resulted POS N
in POS N
a POS N
significant POS N
improvement POS N
in POS N
the POS N
rates POS N
of POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
HBeAg POS N
seroconversion POS N
and POS N
HBsAg POS N
loss POS N
in POS N
children POS N
with POS N
chronic POS N
HBV POS N
infection POS N
and POS N
immune-tolerant POS N
characteristics. POS N

Spironolactone POS N
could POS N
be POS N
used POS N
as POS N
the POS N
fourth-line POS N
therapy POS N
in POS N
patients POS N
with POS N
resistant POS N
hypertension. POS N

Systolic POS N
BP POS N
was POS N
reduced POS N
from POS N
143.5 POS N
± POS N
8.2 POS N
mmHg POS N
to POS N
137.10 POS N
± POS N
7.57 POS N
mmHg POS N
in POS N
the POS N
intervention POS N
group, POS N
while POS N
it POS N
did POS N
not POS N
change POS N
significantly POS N
in POS N
control POS N
(between POS N
group POS N
treatment POS N
difference POS N
= POS N
-4.5 POS N
mmHg, POS N
p POS N
= POS N
0.004). POS N

Spironolactone POS N
could POS N
be POS N
used POS N
as POS N
the POS N
fourth-line POS N
therapy POS N
in POS N
patients POS N
with POS N
resistant POS N
hypertension. POS N

There POS N
was POS N
no POS N
significant POS N
reduction POS N
of POS N
diastolic POS N
BP POS N
in POS N
the POS N
intervention POS N
group POS N
in POS N
comparison POS N
to POS N
placebo POS N
group POS N
(between POS N
group POS N
treatment POS N
difference POS N
= POS N
-1.3 POS N
mmHg, POS N
p POS N
= POS N
0.099). POS N

Spironolactone POS N
could POS N
be POS N
used POS N
as POS N
the POS N
fourth-line POS N
therapy POS N
in POS N
patients POS N
with POS N
resistant POS N
hypertension. POS N

Short POS N
course POS N
monotherapy POS N
with POS N
low POS N
dose POS N
spironolactone POS N
is POS N
effective POS N
in POS N
reducing POS N
systolic POS N
BP POS N
in POS N
patients POS N
with POS N
stage POS N
I POS N
essential POS N
hypertension. POS N

Systolic POS N
BP POS N
was POS N
reduced POS N
from POS N
143.5 POS N
± POS N
8.2 POS N
mmHg POS N
to POS N
137.10 POS N
± POS N
7.57 POS N
mmHg POS N
in POS N
the POS N
intervention POS N
group, POS N
while POS N
it POS N
did POS N
not POS N
change POS N
significantly POS N
in POS N
control POS N
(between POS N
group POS N
treatment POS N
difference POS N
= POS N
-4.5 POS N
mmHg, POS N
p POS N
= POS N
0.004). POS N

Spironolactone POS N
could POS N
be POS N
used POS N
as POS N
the POS N
fourth-line POS N
therapy POS N
in POS N
patients POS N
with POS N
resistant POS N
hypertension. POS N

Systolic POS N
BP POS N
was POS N
reduced POS N
from POS N
143.5 POS N
± POS N
8.2 POS N
mmHg POS N
to POS N
137.10 POS N
± POS N
7.57 POS N
mmHg POS N
in POS N
the POS N
intervention POS N
group, POS N
while POS N
it POS N
did POS N
not POS N
change POS N
significantly POS N
in POS N
control POS N
(between POS N
group POS N
treatment POS N
difference POS N
= POS N
-4.5 POS N
mmHg, POS N
p POS N
= POS N
0.004). POS N

There POS N
was POS N
no POS N
significant POS N
reduction POS N
of POS N
diastolic POS N
BP POS N
in POS N
the POS N
intervention POS N
group POS N
in POS N
comparison POS N
to POS N
placebo POS N
group POS N
(between POS N
group POS N
treatment POS N
difference POS N
= POS N
-1.3 POS N
mmHg, POS N
p POS N
= POS N
0.099). POS N

Systolic POS N
BP POS N
was POS N
reduced POS N
from POS N
143.5 POS N
± POS N
8.2 POS N
mmHg POS N
to POS N
137.10 POS N
± POS N
7.57 POS N
mmHg POS N
in POS N
the POS N
intervention POS N
group, POS N
while POS N
it POS N
did POS N
not POS N
change POS N
significantly POS N
in POS N
control POS N
(between POS N
group POS N
treatment POS N
difference POS N
= POS N
-4.5 POS N
mmHg, POS N
p POS N
= POS N
0.004). POS N

Short POS N
course POS N
monotherapy POS N
with POS N
low POS N
dose POS N
spironolactone POS N
is POS N
effective POS N
in POS N
reducing POS N
systolic POS N
BP POS N
in POS N
patients POS N
with POS N
stage POS N
I POS N
essential POS N
hypertension. POS N

There POS N
was POS N
no POS N
significant POS N
reduction POS N
of POS N
diastolic POS N
BP POS N
in POS N
the POS N
intervention POS N
group POS N
in POS N
comparison POS N
to POS N
placebo POS N
group POS N
(between POS N
group POS N
treatment POS N
difference POS N
= POS N
-1.3 POS N
mmHg, POS N
p POS N
= POS N
0.099). POS N

Spironolactone POS N
could POS N
be POS N
used POS N
as POS N
the POS N
fourth-line POS N
therapy POS N
in POS N
patients POS N
with POS N
resistant POS N
hypertension. POS N

There POS N
was POS N
no POS N
significant POS N
reduction POS N
of POS N
diastolic POS N
BP POS N
in POS N
the POS N
intervention POS N
group POS N
in POS N
comparison POS N
to POS N
placebo POS N
group POS N
(between POS N
group POS N
treatment POS N
difference POS N
= POS N
-1.3 POS N
mmHg, POS N
p POS N
= POS N
0.099). POS N

Systolic POS N
BP POS N
was POS N
reduced POS N
from POS N
143.5 POS N
± POS N
8.2 POS N
mmHg POS N
to POS N
137.10 POS N
± POS N
7.57 POS N
mmHg POS N
in POS N
the POS N
intervention POS N
group, POS N
while POS N
it POS N
did POS N
not POS N
change POS N
significantly POS N
in POS N
control POS N
(between POS N
group POS N
treatment POS N
difference POS N
= POS N
-4.5 POS N
mmHg, POS N
p POS N
= POS N
0.004). POS N

There POS N
was POS N
no POS N
significant POS N
reduction POS N
of POS N
diastolic POS N
BP POS N
in POS N
the POS N
intervention POS N
group POS N
in POS N
comparison POS N
to POS N
placebo POS N
group POS N
(between POS N
group POS N
treatment POS N
difference POS N
= POS N
-1.3 POS N
mmHg, POS N
p POS N
= POS N
0.099). POS N

Short POS N
course POS N
monotherapy POS N
with POS N
low POS N
dose POS N
spironolactone POS N
is POS N
effective POS N
in POS N
reducing POS N
systolic POS N
BP POS N
in POS N
patients POS N
with POS N
stage POS N
I POS N
essential POS N
hypertension. POS N

Short POS N
course POS N
monotherapy POS N
with POS N
low POS N
dose POS N
spironolactone POS N
is POS N
effective POS N
in POS N
reducing POS N
systolic POS N
BP POS N
in POS N
patients POS N
with POS N
stage POS N
I POS N
essential POS N
hypertension. POS N

Spironolactone POS N
could POS N
be POS N
used POS N
as POS N
the POS N
fourth-line POS N
therapy POS N
in POS N
patients POS N
with POS N
resistant POS N
hypertension. POS N

Short POS N
course POS N
monotherapy POS N
with POS N
low POS N
dose POS N
spironolactone POS N
is POS N
effective POS N
in POS N
reducing POS N
systolic POS N
BP POS N
in POS N
patients POS N
with POS N
stage POS N
I POS N
essential POS N
hypertension. POS N

Systolic POS N
BP POS N
was POS N
reduced POS N
from POS N
143.5 POS N
± POS N
8.2 POS N
mmHg POS N
to POS N
137.10 POS N
± POS N
7.57 POS N
mmHg POS N
in POS N
the POS N
intervention POS N
group, POS N
while POS N
it POS N
did POS N
not POS N
change POS N
significantly POS N
in POS N
control POS N
(between POS N
group POS N
treatment POS N
difference POS N
= POS N
-4.5 POS N
mmHg, POS N
p POS N
= POS N
0.004). POS N

Short POS N
course POS N
monotherapy POS N
with POS N
low POS N
dose POS N
spironolactone POS N
is POS N
effective POS N
in POS N
reducing POS N
systolic POS N
BP POS N
in POS N
patients POS N
with POS N
stage POS N
I POS N
essential POS N
hypertension. POS N

There POS N
was POS N
no POS N
significant POS N
reduction POS N
of POS N
diastolic POS N
BP POS N
in POS N
the POS N
intervention POS N
group POS N
in POS N
comparison POS N
to POS N
placebo POS N
group POS N
(between POS N
group POS N
treatment POS N
difference POS N
= POS N
-1.3 POS N
mmHg, POS N
p POS N
= POS N
0.099). POS N

In POS N
CHEST-1, POS N
riociguat POS N
significantly POS N
improved POS N
RRS POS N
(p POS N
< POS N
0.0001) POS N
and POS N
risk POS N
stratum POS N
(p POS N
< POS N
0.001) POS N
vs POS N
placebo POS N
from POS N
baseline POS N
to POS N
Week POS N
16. POS N

RRS POS N
at POS N
baseline, POS N
and POS N
at POS N
Week POS N
16, POS N
and POS N
change POS N
in POS N
RRS POS N
during POS N
CHEST-1 POS N
were POS N
significantly POS N
associated POS N
with POS N
survival POS N
(hazard POS N
ratios POS N
for POS N
a POS N
1-point POS N
reduction POS N
in POS N
RRS: POS N
0.702, POS N
0.692, POS N
and POS N
0.682, POS N
respectively) POS N
and POS N
clinical POS N
worsening-free POS N
survival POS N
(hazard POS N
ratios: POS N
0.697, POS N
0.719, POS N
and POS N
0.754, POS N
respectively) POS N
over POS N
2 POS N
years POS N
in POS N
CHEST-2. POS N

In POS N
CHEST-1, POS N
riociguat POS N
significantly POS N
improved POS N
RRS POS N
(p POS N
< POS N
0.0001) POS N
and POS N
risk POS N
stratum POS N
(p POS N
< POS N
0.001) POS N
vs POS N
placebo POS N
from POS N
baseline POS N
to POS N
Week POS N
16. POS N

Riociguat POS N
improved POS N
RRS POS N
in POS N
patients POS N
with POS N
inoperable POS N
and POS N
persistent/recurrent POS N
CTEPH. POS N

In POS N
CHEST-1, POS N
riociguat POS N
significantly POS N
improved POS N
RRS POS N
(p POS N
< POS N
0.0001) POS N
and POS N
risk POS N
stratum POS N
(p POS N
< POS N
0.001) POS N
vs POS N
placebo POS N
from POS N
baseline POS N
to POS N
Week POS N
16. POS N

RRS POS N
at POS N
baseline POS N
and POS N
Week POS N
16, POS N
and POS N
change POS N
in POS N
RRS POS N
from POS N
baseline, POS N
predicted POS N
survival POS N
and POS N
clinical POS N
worsening-free POS N
survival. POS N

In POS N
CHEST-1, POS N
riociguat POS N
significantly POS N
improved POS N
RRS POS N
(p POS N
< POS N
0.0001) POS N
and POS N
risk POS N
stratum POS N
(p POS N
< POS N
0.001) POS N
vs POS N
placebo POS N
from POS N
baseline POS N
to POS N
Week POS N
16. POS N

This POS N
analysis POS N
of POS N
RRS POS N
in POS N
patients POS N
with POS N
inoperable POS N
or POS N
persistent/recurrent POS N
CTEPH POS N
suggests POS N
utility POS N
for POS N
the POS N
RRS POS N
in POS N
indications POS N
beyond POS N
PAH. POS N

RRS POS N
at POS N
baseline, POS N
and POS N
at POS N
Week POS N
16, POS N
and POS N
change POS N
in POS N
RRS POS N
during POS N
CHEST-1 POS N
were POS N
significantly POS N
associated POS N
with POS N
survival POS N
(hazard POS N
ratios POS N
for POS N
a POS N
1-point POS N
reduction POS N
in POS N
RRS: POS N
0.702, POS N
0.692, POS N
and POS N
0.682, POS N
respectively) POS N
and POS N
clinical POS N
worsening-free POS N
survival POS N
(hazard POS N
ratios: POS N
0.697, POS N
0.719, POS N
and POS N
0.754, POS N
respectively) POS N
over POS N
2 POS N
years POS N
in POS N
CHEST-2. POS N

In POS N
CHEST-1, POS N
riociguat POS N
significantly POS N
improved POS N
RRS POS N
(p POS N
< POS N
0.0001) POS N
and POS N
risk POS N
stratum POS N
(p POS N
< POS N
0.001) POS N
vs POS N
placebo POS N
from POS N
baseline POS N
to POS N
Week POS N
16. POS N

RRS POS N
at POS N
baseline, POS N
and POS N
at POS N
Week POS N
16, POS N
and POS N
change POS N
in POS N
RRS POS N
during POS N
CHEST-1 POS N
were POS N
significantly POS N
associated POS N
with POS N
survival POS N
(hazard POS N
ratios POS N
for POS N
a POS N
1-point POS N
reduction POS N
in POS N
RRS: POS N
0.702, POS N
0.692, POS N
and POS N
0.682, POS N
respectively) POS N
and POS N
clinical POS N
worsening-free POS N
survival POS N
(hazard POS N
ratios: POS N
0.697, POS N
0.719, POS N
and POS N
0.754, POS N
respectively) POS N
over POS N
2 POS N
years POS N
in POS N
CHEST-2. POS N

Riociguat POS N
improved POS N
RRS POS N
in POS N
patients POS N
with POS N
inoperable POS N
and POS N
persistent/recurrent POS N
CTEPH. POS N

RRS POS N
at POS N
baseline, POS N
and POS N
at POS N
Week POS N
16, POS N
and POS N
change POS N
in POS N
RRS POS N
during POS N
CHEST-1 POS N
were POS N
significantly POS N
associated POS N
with POS N
survival POS N
(hazard POS N
ratios POS N
for POS N
a POS N
1-point POS N
reduction POS N
in POS N
RRS: POS N
0.702, POS N
0.692, POS N
and POS N
0.682, POS N
respectively) POS N
and POS N
clinical POS N
worsening-free POS N
survival POS N
(hazard POS N
ratios: POS N
0.697, POS N
0.719, POS N
and POS N
0.754, POS N
respectively) POS N
over POS N
2 POS N
years POS N
in POS N
CHEST-2. POS N

RRS POS N
at POS N
baseline POS N
and POS N
Week POS N
16, POS N
and POS N
change POS N
in POS N
RRS POS N
from POS N
baseline, POS N
predicted POS N
survival POS N
and POS N
clinical POS N
worsening-free POS N
survival. POS N

RRS POS N
at POS N
baseline, POS N
and POS N
at POS N
Week POS N
16, POS N
and POS N
change POS N
in POS N
RRS POS N
during POS N
CHEST-1 POS N
were POS N
significantly POS N
associated POS N
with POS N
survival POS N
(hazard POS N
ratios POS N
for POS N
a POS N
1-point POS N
reduction POS N
in POS N
RRS: POS N
0.702, POS N
0.692, POS N
and POS N
0.682, POS N
respectively) POS N
and POS N
clinical POS N
worsening-free POS N
survival POS N
(hazard POS N
ratios: POS N
0.697, POS N
0.719, POS N
and POS N
0.754, POS N
respectively) POS N
over POS N
2 POS N
years POS N
in POS N
CHEST-2. POS N

This POS N
analysis POS N
of POS N
RRS POS N
in POS N
patients POS N
with POS N
inoperable POS N
or POS N
persistent/recurrent POS N
CTEPH POS N
suggests POS N
utility POS N
for POS N
the POS N
RRS POS N
in POS N
indications POS N
beyond POS N
PAH. POS N

Riociguat POS N
improved POS N
RRS POS N
in POS N
patients POS N
with POS N
inoperable POS N
and POS N
persistent/recurrent POS N
CTEPH. POS N

In POS N
CHEST-1, POS N
riociguat POS N
significantly POS N
improved POS N
RRS POS N
(p POS N
< POS N
0.0001) POS N
and POS N
risk POS N
stratum POS N
(p POS N
< POS N
0.001) POS N
vs POS N
placebo POS N
from POS N
baseline POS N
to POS N
Week POS N
16. POS N

Riociguat POS N
improved POS N
RRS POS N
in POS N
patients POS N
with POS N
inoperable POS N
and POS N
persistent/recurrent POS N
CTEPH. POS N

RRS POS N
at POS N
baseline, POS N
and POS N
at POS N
Week POS N
16, POS N
and POS N
change POS N
in POS N
RRS POS N
during POS N
CHEST-1 POS N
were POS N
significantly POS N
associated POS N
with POS N
survival POS N
(hazard POS N
ratios POS N
for POS N
a POS N
1-point POS N
reduction POS N
in POS N
RRS: POS N
0.702, POS N
0.692, POS N
and POS N
0.682, POS N
respectively) POS N
and POS N
clinical POS N
worsening-free POS N
survival POS N
(hazard POS N
ratios: POS N
0.697, POS N
0.719, POS N
and POS N
0.754, POS N
respectively) POS N
over POS N
2 POS N
years POS N
in POS N
CHEST-2. POS N

Riociguat POS N
improved POS N
RRS POS N
in POS N
patients POS N
with POS N
inoperable POS N
and POS N
persistent/recurrent POS N
CTEPH. POS N

RRS POS N
at POS N
baseline POS N
and POS N
Week POS N
16, POS N
and POS N
change POS N
in POS N
RRS POS N
from POS N
baseline, POS N
predicted POS N
survival POS N
and POS N
clinical POS N
worsening-free POS N
survival. POS N

Riociguat POS N
improved POS N
RRS POS N
in POS N
patients POS N
with POS N
inoperable POS N
and POS N
persistent/recurrent POS N
CTEPH. POS N

This POS N
analysis POS N
of POS N
RRS POS N
in POS N
patients POS N
with POS N
inoperable POS N
or POS N
persistent/recurrent POS N
CTEPH POS N
suggests POS N
utility POS N
for POS N
the POS N
RRS POS N
in POS N
indications POS N
beyond POS N
PAH. POS N

RRS POS N
at POS N
baseline POS N
and POS N
Week POS N
16, POS N
and POS N
change POS N
in POS N
RRS POS N
from POS N
baseline, POS N
predicted POS N
survival POS N
and POS N
clinical POS N
worsening-free POS N
survival. POS N

In POS N
CHEST-1, POS N
riociguat POS N
significantly POS N
improved POS N
RRS POS N
(p POS N
< POS N
0.0001) POS N
and POS N
risk POS N
stratum POS N
(p POS N
< POS N
0.001) POS N
vs POS N
placebo POS N
from POS N
baseline POS N
to POS N
Week POS N
16. POS N

RRS POS N
at POS N
baseline POS N
and POS N
Week POS N
16, POS N
and POS N
change POS N
in POS N
RRS POS N
from POS N
baseline, POS N
predicted POS N
survival POS N
and POS N
clinical POS N
worsening-free POS N
survival. POS N

RRS POS N
at POS N
baseline, POS N
and POS N
at POS N
Week POS N
16, POS N
and POS N
change POS N
in POS N
RRS POS N
during POS N
CHEST-1 POS N
were POS N
significantly POS N
associated POS N
with POS N
survival POS N
(hazard POS N
ratios POS N
for POS N
a POS N
1-point POS N
reduction POS N
in POS N
RRS: POS N
0.702, POS N
0.692, POS N
and POS N
0.682, POS N
respectively) POS N
and POS N
clinical POS N
worsening-free POS N
survival POS N
(hazard POS N
ratios: POS N
0.697, POS N
0.719, POS N
and POS N
0.754, POS N
respectively) POS N
over POS N
2 POS N
years POS N
in POS N
CHEST-2. POS N

RRS POS N
at POS N
baseline POS N
and POS N
Week POS N
16, POS N
and POS N
change POS N
in POS N
RRS POS N
from POS N
baseline, POS N
predicted POS N
survival POS N
and POS N
clinical POS N
worsening-free POS N
survival. POS N

Riociguat POS N
improved POS N
RRS POS N
in POS N
patients POS N
with POS N
inoperable POS N
and POS N
persistent/recurrent POS N
CTEPH. POS N

RRS POS N
at POS N
baseline POS N
and POS N
Week POS N
16, POS N
and POS N
change POS N
in POS N
RRS POS N
from POS N
baseline, POS N
predicted POS N
survival POS N
and POS N
clinical POS N
worsening-free POS N
survival. POS N

This POS N
analysis POS N
of POS N
RRS POS N
in POS N
patients POS N
with POS N
inoperable POS N
or POS N
persistent/recurrent POS N
CTEPH POS N
suggests POS N
utility POS N
for POS N
the POS N
RRS POS N
in POS N
indications POS N
beyond POS N
PAH. POS N

This POS N
analysis POS N
of POS N
RRS POS N
in POS N
patients POS N
with POS N
inoperable POS N
or POS N
persistent/recurrent POS N
CTEPH POS N
suggests POS N
utility POS N
for POS N
the POS N
RRS POS N
in POS N
indications POS N
beyond POS N
PAH. POS N

In POS N
CHEST-1, POS N
riociguat POS N
significantly POS N
improved POS N
RRS POS N
(p POS N
< POS N
0.0001) POS N
and POS N
risk POS N
stratum POS N
(p POS N
< POS N
0.001) POS N
vs POS N
placebo POS N
from POS N
baseline POS N
to POS N
Week POS N
16. POS N

This POS N
analysis POS N
of POS N
RRS POS N
in POS N
patients POS N
with POS N
inoperable POS N
or POS N
persistent/recurrent POS N
CTEPH POS N
suggests POS N
utility POS N
for POS N
the POS N
RRS POS N
in POS N
indications POS N
beyond POS N
PAH. POS N

RRS POS N
at POS N
baseline, POS N
and POS N
at POS N
Week POS N
16, POS N
and POS N
change POS N
in POS N
RRS POS N
during POS N
CHEST-1 POS N
were POS N
significantly POS N
associated POS N
with POS N
survival POS N
(hazard POS N
ratios POS N
for POS N
a POS N
1-point POS N
reduction POS N
in POS N
RRS: POS N
0.702, POS N
0.692, POS N
and POS N
0.682, POS N
respectively) POS N
and POS N
clinical POS N
worsening-free POS N
survival POS N
(hazard POS N
ratios: POS N
0.697, POS N
0.719, POS N
and POS N
0.754, POS N
respectively) POS N
over POS N
2 POS N
years POS N
in POS N
CHEST-2. POS N

This POS N
analysis POS N
of POS N
RRS POS N
in POS N
patients POS N
with POS N
inoperable POS N
or POS N
persistent/recurrent POS N
CTEPH POS N
suggests POS N
utility POS N
for POS N
the POS N
RRS POS N
in POS N
indications POS N
beyond POS N
PAH. POS N

Riociguat POS N
improved POS N
RRS POS N
in POS N
patients POS N
with POS N
inoperable POS N
and POS N
persistent/recurrent POS N
CTEPH. POS N

This POS N
analysis POS N
of POS N
RRS POS N
in POS N
patients POS N
with POS N
inoperable POS N
or POS N
persistent/recurrent POS N
CTEPH POS N
suggests POS N
utility POS N
for POS N
the POS N
RRS POS N
in POS N
indications POS N
beyond POS N
PAH. POS N

RRS POS N
at POS N
baseline POS N
and POS N
Week POS N
16, POS N
and POS N
change POS N
in POS N
RRS POS N
from POS N
baseline, POS N
predicted POS N
survival POS N
and POS N
clinical POS N
worsening-free POS N
survival. POS N

By POS N
ITT POS N
analysis, POS N
HBV POS N
reactivation POS N
was POS N
0% POS N
(0/33) POS N
in POS N
the POS N
study POS N
group POS N
and POS N
10.7% POS N
(3/28) POS N
in POS N
the POS N
observation POS N
group POS N
(p POS N
= POS N
0.091). POS N

None POS N
of POS N
the POS N
patients POS N
in POS N
either POS N
group POS N
showed POS N
significant POS N
differences POS N
in POS N
liver POS N
function POS N
parameters POS N
between POS N
baseline POS N
and POS N
the POS N
last POS N
follow-up POS N
sample. POS N

By POS N
ITT POS N
analysis, POS N
HBV POS N
reactivation POS N
was POS N
0% POS N
(0/33) POS N
in POS N
the POS N
study POS N
group POS N
and POS N
10.7% POS N
(3/28) POS N
in POS N
the POS N
observation POS N
group POS N
(p POS N
= POS N
0.091). POS N

TDF POS N
was POS N
generally POS N
well POS N
tolerated POS N
and POS N
there POS N
were POS N
no POS N
severe POS N
treatment-related POS N
adverse POS N
events. POS N

By POS N
ITT POS N
analysis, POS N
HBV POS N
reactivation POS N
was POS N
0% POS N
(0/33) POS N
in POS N
the POS N
study POS N
group POS N
and POS N
10.7% POS N
(3/28) POS N
in POS N
the POS N
observation POS N
group POS N
(p POS N
= POS N
0.091). POS N

In POS N
patients POS N
with POS N
hematological POS N
malignancy POS N
and POS N
resolved POS N
hepatitis POS N
B POS N
infection POS N
receiving POS N
RTX-based POS N
regimens, POS N
HBV POS N
reactivation POS N
did POS N
not POS N
occur POS N
in POS N
patients POS N
given POS N
TDF POS N
prophylaxis. POS N

None POS N
of POS N
the POS N
patients POS N
in POS N
either POS N
group POS N
showed POS N
significant POS N
differences POS N
in POS N
liver POS N
function POS N
parameters POS N
between POS N
baseline POS N
and POS N
the POS N
last POS N
follow-up POS N
sample. POS N

By POS N
ITT POS N
analysis, POS N
HBV POS N
reactivation POS N
was POS N
0% POS N
(0/33) POS N
in POS N
the POS N
study POS N
group POS N
and POS N
10.7% POS N
(3/28) POS N
in POS N
the POS N
observation POS N
group POS N
(p POS N
= POS N
0.091). POS N

None POS N
of POS N
the POS N
patients POS N
in POS N
either POS N
group POS N
showed POS N
significant POS N
differences POS N
in POS N
liver POS N
function POS N
parameters POS N
between POS N
baseline POS N
and POS N
the POS N
last POS N
follow-up POS N
sample. POS N

TDF POS N
was POS N
generally POS N
well POS N
tolerated POS N
and POS N
there POS N
were POS N
no POS N
severe POS N
treatment-related POS N
adverse POS N
events. POS N

None POS N
of POS N
the POS N
patients POS N
in POS N
either POS N
group POS N
showed POS N
significant POS N
differences POS N
in POS N
liver POS N
function POS N
parameters POS N
between POS N
baseline POS N
and POS N
the POS N
last POS N
follow-up POS N
sample. POS N

In POS N
patients POS N
with POS N
hematological POS N
malignancy POS N
and POS N
resolved POS N
hepatitis POS N
B POS N
infection POS N
receiving POS N
RTX-based POS N
regimens, POS N
HBV POS N
reactivation POS N
did POS N
not POS N
occur POS N
in POS N
patients POS N
given POS N
TDF POS N
prophylaxis. POS N

TDF POS N
was POS N
generally POS N
well POS N
tolerated POS N
and POS N
there POS N
were POS N
no POS N
severe POS N
treatment-related POS N
adverse POS N
events. POS N

By POS N
ITT POS N
analysis, POS N
HBV POS N
reactivation POS N
was POS N
0% POS N
(0/33) POS N
in POS N
the POS N
study POS N
group POS N
and POS N
10.7% POS N
(3/28) POS N
in POS N
the POS N
observation POS N
group POS N
(p POS N
= POS N
0.091). POS N

TDF POS N
was POS N
generally POS N
well POS N
tolerated POS N
and POS N
there POS N
were POS N
no POS N
severe POS N
treatment-related POS N
adverse POS N
events. POS N

None POS N
of POS N
the POS N
patients POS N
in POS N
either POS N
group POS N
showed POS N
significant POS N
differences POS N
in POS N
liver POS N
function POS N
parameters POS N
between POS N
baseline POS N
and POS N
the POS N
last POS N
follow-up POS N
sample. POS N

TDF POS N
was POS N
generally POS N
well POS N
tolerated POS N
and POS N
there POS N
were POS N
no POS N
severe POS N
treatment-related POS N
adverse POS N
events. POS N

In POS N
patients POS N
with POS N
hematological POS N
malignancy POS N
and POS N
resolved POS N
hepatitis POS N
B POS N
infection POS N
receiving POS N
RTX-based POS N
regimens, POS N
HBV POS N
reactivation POS N
did POS N
not POS N
occur POS N
in POS N
patients POS N
given POS N
TDF POS N
prophylaxis. POS N

In POS N
patients POS N
with POS N
hematological POS N
malignancy POS N
and POS N
resolved POS N
hepatitis POS N
B POS N
infection POS N
receiving POS N
RTX-based POS N
regimens, POS N
HBV POS N
reactivation POS N
did POS N
not POS N
occur POS N
in POS N
patients POS N
given POS N
TDF POS N
prophylaxis. POS N

By POS N
ITT POS N
analysis, POS N
HBV POS N
reactivation POS N
was POS N
0% POS N
(0/33) POS N
in POS N
the POS N
study POS N
group POS N
and POS N
10.7% POS N
(3/28) POS N
in POS N
the POS N
observation POS N
group POS N
(p POS N
= POS N
0.091). POS N

In POS N
patients POS N
with POS N
hematological POS N
malignancy POS N
and POS N
resolved POS N
hepatitis POS N
B POS N
infection POS N
receiving POS N
RTX-based POS N
regimens, POS N
HBV POS N
reactivation POS N
did POS N
not POS N
occur POS N
in POS N
patients POS N
given POS N
TDF POS N
prophylaxis. POS N

None POS N
of POS N
the POS N
patients POS N
in POS N
either POS N
group POS N
showed POS N
significant POS N
differences POS N
in POS N
liver POS N
function POS N
parameters POS N
between POS N
baseline POS N
and POS N
the POS N
last POS N
follow-up POS N
sample. POS N

In POS N
patients POS N
with POS N
hematological POS N
malignancy POS N
and POS N
resolved POS N
hepatitis POS N
B POS N
infection POS N
receiving POS N
RTX-based POS N
regimens, POS N
HBV POS N
reactivation POS N
did POS N
not POS N
occur POS N
in POS N
patients POS N
given POS N
TDF POS N
prophylaxis. POS N

TDF POS N
was POS N
generally POS N
well POS N
tolerated POS N
and POS N
there POS N
were POS N
no POS N
severe POS N
treatment-related POS N
adverse POS N
events. POS N

In POS N
conclusion, POS N
co-infected POS N
patients POS N
with POS N
elevated POS N
HBV-replication POS N
at POS N
ART-initiation POS N
are POS N
more POS N
susceptible POS N
to POS N
HIV-related POS N
morbidity, POS N
especially POS N
invasive POS N
bacterial POS N
diseases, POS N
during POS N
treatment POS N
interruption. POS N

No POS N
increase POS N
in POS N
the POS N
incidence POS N
of POS N
non-HIV-related POS N
morbidity POS N
was POS N
observed POS N
for POS N
co-infected POS N
patients POS N
(P POS N
= POS N
0.5), POS N
even POS N
at POS N
HBV-replication POS N
levels POS N
> POS N
10,000 POS N
copies/mL POS N
(P POS N
= POS N
0.7). POS N

In POS N
conclusion, POS N
co-infected POS N
patients POS N
with POS N
elevated POS N
HBV-replication POS N
at POS N
ART-initiation POS N
are POS N
more POS N
susceptible POS N
to POS N
HIV-related POS N
morbidity, POS N
especially POS N
invasive POS N
bacterial POS N
diseases, POS N
during POS N
treatment POS N
interruption. POS N

The POS N
relative POS N
effect POS N
of POS N
CD4GT POS N
or POS N
2/4-ART POS N
versus POS N
C-ART POS N
was POS N
not POS N
different POS N
between POS N
infection POS N
groups POS N
(P POS N
for POS N
interaction POS N
= POS N
0.4). POS N

In POS N
conclusion, POS N
co-infected POS N
patients POS N
with POS N
elevated POS N
HBV-replication POS N
at POS N
ART-initiation POS N
are POS N
more POS N
susceptible POS N
to POS N
HIV-related POS N
morbidity, POS N
especially POS N
invasive POS N
bacterial POS N
diseases, POS N
during POS N
treatment POS N
interruption. POS N

Incidence POS N
of POS N
bacterial POS N
infections POS N
was POS N
also POS N
highest POS N
in POS N
the POS N
co-infected POS N
group POS N
with POS N
HBV-replication POS N
> POS N
10,000 POS N
copies/mL POS N
(IR POS N
= POS N
12.9 POS N
versus POS N
3.3/100 POS N
person/years POS N
in POS N
HIV POS N
mono-infected POS N
patients, POS N
P POS N
= POS N
0.001). POS N

In POS N
conclusion, POS N
co-infected POS N
patients POS N
with POS N
elevated POS N
HBV-replication POS N
at POS N
ART-initiation POS N
are POS N
more POS N
susceptible POS N
to POS N
HIV-related POS N
morbidity, POS N
especially POS N
invasive POS N
bacterial POS N
diseases, POS N
during POS N
treatment POS N
interruption. POS N

After POS N
a POS N
median POS N
2.0 POS N
year POS N
(range POS N
= POS N
0.2-3.1) POS N
follow-up, POS N
≥ POS N
1 POS N
serious POS N
HIV-related POS N
events POS N
occurred POS N
in POS N
101 POS N
HIV POS N
mono-infected POS N
and POS N
15 POS N
HIV-HBV POS N
co-infected POS N
patients POS N
(IR POS N
= POS N
10.0 POS N
versus POS N
13.2/100 POS N
person/years, POS N
respectively, POS N
P POS N
= POS N
0.3) POS N

No POS N
increase POS N
in POS N
the POS N
incidence POS N
of POS N
non-HIV-related POS N
morbidity POS N
was POS N
observed POS N
for POS N
co-infected POS N
patients POS N
(P POS N
= POS N
0.5), POS N
even POS N
at POS N
HBV-replication POS N
levels POS N
> POS N
10,000 POS N
copies/mL POS N
(P POS N
= POS N
0.7). POS N

In POS N
conclusion, POS N
co-infected POS N
patients POS N
with POS N
elevated POS N
HBV-replication POS N
at POS N
ART-initiation POS N
are POS N
more POS N
susceptible POS N
to POS N
HIV-related POS N
morbidity, POS N
especially POS N
invasive POS N
bacterial POS N
diseases, POS N
during POS N
treatment POS N
interruption. POS N

No POS N
increase POS N
in POS N
the POS N
incidence POS N
of POS N
non-HIV-related POS N
morbidity POS N
was POS N
observed POS N
for POS N
co-infected POS N
patients POS N
(P POS N
= POS N
0.5), POS N
even POS N
at POS N
HBV-replication POS N
levels POS N
> POS N
10,000 POS N
copies/mL POS N
(P POS N
= POS N
0.7). POS N

The POS N
relative POS N
effect POS N
of POS N
CD4GT POS N
or POS N
2/4-ART POS N
versus POS N
C-ART POS N
was POS N
not POS N
different POS N
between POS N
infection POS N
groups POS N
(P POS N
for POS N
interaction POS N
= POS N
0.4). POS N

No POS N
increase POS N
in POS N
the POS N
incidence POS N
of POS N
non-HIV-related POS N
morbidity POS N
was POS N
observed POS N
for POS N
co-infected POS N
patients POS N
(P POS N
= POS N
0.5), POS N
even POS N
at POS N
HBV-replication POS N
levels POS N
> POS N
10,000 POS N
copies/mL POS N
(P POS N
= POS N
0.7). POS N

Incidence POS N
of POS N
bacterial POS N
infections POS N
was POS N
also POS N
highest POS N
in POS N
the POS N
co-infected POS N
group POS N
with POS N
HBV-replication POS N
> POS N
10,000 POS N
copies/mL POS N
(IR POS N
= POS N
12.9 POS N
versus POS N
3.3/100 POS N
person/years POS N
in POS N
HIV POS N
mono-infected POS N
patients, POS N
P POS N
= POS N
0.001). POS N

No POS N
increase POS N
in POS N
the POS N
incidence POS N
of POS N
non-HIV-related POS N
morbidity POS N
was POS N
observed POS N
for POS N
co-infected POS N
patients POS N
(P POS N
= POS N
0.5), POS N
even POS N
at POS N
HBV-replication POS N
levels POS N
> POS N
10,000 POS N
copies/mL POS N
(P POS N
= POS N
0.7). POS N

After POS N
a POS N
median POS N
2.0 POS N
year POS N
(range POS N
= POS N
0.2-3.1) POS N
follow-up, POS N
≥ POS N
1 POS N
serious POS N
HIV-related POS N
events POS N
occurred POS N
in POS N
101 POS N
HIV POS N
mono-infected POS N
and POS N
15 POS N
HIV-HBV POS N
co-infected POS N
patients POS N
(IR POS N
= POS N
10.0 POS N
versus POS N
13.2/100 POS N
person/years, POS N
respectively, POS N
P POS N
= POS N
0.3) POS N

The POS N
relative POS N
effect POS N
of POS N
CD4GT POS N
or POS N
2/4-ART POS N
versus POS N
C-ART POS N
was POS N
not POS N
different POS N
between POS N
infection POS N
groups POS N
(P POS N
for POS N
interaction POS N
= POS N
0.4). POS N

In POS N
conclusion, POS N
co-infected POS N
patients POS N
with POS N
elevated POS N
HBV-replication POS N
at POS N
ART-initiation POS N
are POS N
more POS N
susceptible POS N
to POS N
HIV-related POS N
morbidity, POS N
especially POS N
invasive POS N
bacterial POS N
diseases, POS N
during POS N
treatment POS N
interruption. POS N

The POS N
relative POS N
effect POS N
of POS N
CD4GT POS N
or POS N
2/4-ART POS N
versus POS N
C-ART POS N
was POS N
not POS N
different POS N
between POS N
infection POS N
groups POS N
(P POS N
for POS N
interaction POS N
= POS N
0.4). POS N

No POS N
increase POS N
in POS N
the POS N
incidence POS N
of POS N
non-HIV-related POS N
morbidity POS N
was POS N
observed POS N
for POS N
co-infected POS N
patients POS N
(P POS N
= POS N
0.5), POS N
even POS N
at POS N
HBV-replication POS N
levels POS N
> POS N
10,000 POS N
copies/mL POS N
(P POS N
= POS N
0.7). POS N

The POS N
relative POS N
effect POS N
of POS N
CD4GT POS N
or POS N
2/4-ART POS N
versus POS N
C-ART POS N
was POS N
not POS N
different POS N
between POS N
infection POS N
groups POS N
(P POS N
for POS N
interaction POS N
= POS N
0.4). POS N

Incidence POS N
of POS N
bacterial POS N
infections POS N
was POS N
also POS N
highest POS N
in POS N
the POS N
co-infected POS N
group POS N
with POS N
HBV-replication POS N
> POS N
10,000 POS N
copies/mL POS N
(IR POS N
= POS N
12.9 POS N
versus POS N
3.3/100 POS N
person/years POS N
in POS N
HIV POS N
mono-infected POS N
patients, POS N
P POS N
= POS N
0.001). POS N

The POS N
relative POS N
effect POS N
of POS N
CD4GT POS N
or POS N
2/4-ART POS N
versus POS N
C-ART POS N
was POS N
not POS N
different POS N
between POS N
infection POS N
groups POS N
(P POS N
for POS N
interaction POS N
= POS N
0.4). POS N

After POS N
a POS N
median POS N
2.0 POS N
year POS N
(range POS N
= POS N
0.2-3.1) POS N
follow-up, POS N
≥ POS N
1 POS N
serious POS N
HIV-related POS N
events POS N
occurred POS N
in POS N
101 POS N
HIV POS N
mono-infected POS N
and POS N
15 POS N
HIV-HBV POS N
co-infected POS N
patients POS N
(IR POS N
= POS N
10.0 POS N
versus POS N
13.2/100 POS N
person/years, POS N
respectively, POS N
P POS N
= POS N
0.3) POS N

Incidence POS N
of POS N
bacterial POS N
infections POS N
was POS N
also POS N
highest POS N
in POS N
the POS N
co-infected POS N
group POS N
with POS N
HBV-replication POS N
> POS N
10,000 POS N
copies/mL POS N
(IR POS N
= POS N
12.9 POS N
versus POS N
3.3/100 POS N
person/years POS N
in POS N
HIV POS N
mono-infected POS N
patients, POS N
P POS N
= POS N
0.001). POS N

In POS N
conclusion, POS N
co-infected POS N
patients POS N
with POS N
elevated POS N
HBV-replication POS N
at POS N
ART-initiation POS N
are POS N
more POS N
susceptible POS N
to POS N
HIV-related POS N
morbidity, POS N
especially POS N
invasive POS N
bacterial POS N
diseases, POS N
during POS N
treatment POS N
interruption. POS N

Incidence POS N
of POS N
bacterial POS N
infections POS N
was POS N
also POS N
highest POS N
in POS N
the POS N
co-infected POS N
group POS N
with POS N
HBV-replication POS N
> POS N
10,000 POS N
copies/mL POS N
(IR POS N
= POS N
12.9 POS N
versus POS N
3.3/100 POS N
person/years POS N
in POS N
HIV POS N
mono-infected POS N
patients, POS N
P POS N
= POS N
0.001). POS N

No POS N
increase POS N
in POS N
the POS N
incidence POS N
of POS N
non-HIV-related POS N
morbidity POS N
was POS N
observed POS N
for POS N
co-infected POS N
patients POS N
(P POS N
= POS N
0.5), POS N
even POS N
at POS N
HBV-replication POS N
levels POS N
> POS N
10,000 POS N
copies/mL POS N
(P POS N
= POS N
0.7). POS N

Incidence POS N
of POS N
bacterial POS N
infections POS N
was POS N
also POS N
highest POS N
in POS N
the POS N
co-infected POS N
group POS N
with POS N
HBV-replication POS N
> POS N
10,000 POS N
copies/mL POS N
(IR POS N
= POS N
12.9 POS N
versus POS N
3.3/100 POS N
person/years POS N
in POS N
HIV POS N
mono-infected POS N
patients, POS N
P POS N
= POS N
0.001). POS N

The POS N
relative POS N
effect POS N
of POS N
CD4GT POS N
or POS N
2/4-ART POS N
versus POS N
C-ART POS N
was POS N
not POS N
different POS N
between POS N
infection POS N
groups POS N
(P POS N
for POS N
interaction POS N
= POS N
0.4). POS N

Incidence POS N
of POS N
bacterial POS N
infections POS N
was POS N
also POS N
highest POS N
in POS N
the POS N
co-infected POS N
group POS N
with POS N
HBV-replication POS N
> POS N
10,000 POS N
copies/mL POS N
(IR POS N
= POS N
12.9 POS N
versus POS N
3.3/100 POS N
person/years POS N
in POS N
HIV POS N
mono-infected POS N
patients, POS N
P POS N
= POS N
0.001). POS N

After POS N
a POS N
median POS N
2.0 POS N
year POS N
(range POS N
= POS N
0.2-3.1) POS N
follow-up, POS N
≥ POS N
1 POS N
serious POS N
HIV-related POS N
events POS N
occurred POS N
in POS N
101 POS N
HIV POS N
mono-infected POS N
and POS N
15 POS N
HIV-HBV POS N
co-infected POS N
patients POS N
(IR POS N
= POS N
10.0 POS N
versus POS N
13.2/100 POS N
person/years, POS N
respectively, POS N
P POS N
= POS N
0.3) POS N

After POS N
a POS N
median POS N
2.0 POS N
year POS N
(range POS N
= POS N
0.2-3.1) POS N
follow-up, POS N
≥ POS N
1 POS N
serious POS N
HIV-related POS N
events POS N
occurred POS N
in POS N
101 POS N
HIV POS N
mono-infected POS N
and POS N
15 POS N
HIV-HBV POS N
co-infected POS N
patients POS N
(IR POS N
= POS N
10.0 POS N
versus POS N
13.2/100 POS N
person/years, POS N
respectively, POS N
P POS N
= POS N
0.3) POS N

In POS N
conclusion, POS N
co-infected POS N
patients POS N
with POS N
elevated POS N
HBV-replication POS N
at POS N
ART-initiation POS N
are POS N
more POS N
susceptible POS N
to POS N
HIV-related POS N
morbidity, POS N
especially POS N
invasive POS N
bacterial POS N
diseases, POS N
during POS N
treatment POS N
interruption. POS N

After POS N
a POS N
median POS N
2.0 POS N
year POS N
(range POS N
= POS N
0.2-3.1) POS N
follow-up, POS N
≥ POS N
1 POS N
serious POS N
HIV-related POS N
events POS N
occurred POS N
in POS N
101 POS N
HIV POS N
mono-infected POS N
and POS N
15 POS N
HIV-HBV POS N
co-infected POS N
patients POS N
(IR POS N
= POS N
10.0 POS N
versus POS N
13.2/100 POS N
person/years, POS N
respectively, POS N
P POS N
= POS N
0.3) POS N

No POS N
increase POS N
in POS N
the POS N
incidence POS N
of POS N
non-HIV-related POS N
morbidity POS N
was POS N
observed POS N
for POS N
co-infected POS N
patients POS N
(P POS N
= POS N
0.5), POS N
even POS N
at POS N
HBV-replication POS N
levels POS N
> POS N
10,000 POS N
copies/mL POS N
(P POS N
= POS N
0.7). POS N

After POS N
a POS N
median POS N
2.0 POS N
year POS N
(range POS N
= POS N
0.2-3.1) POS N
follow-up, POS N
≥ POS N
1 POS N
serious POS N
HIV-related POS N
events POS N
occurred POS N
in POS N
101 POS N
HIV POS N
mono-infected POS N
and POS N
15 POS N
HIV-HBV POS N
co-infected POS N
patients POS N
(IR POS N
= POS N
10.0 POS N
versus POS N
13.2/100 POS N
person/years, POS N
respectively, POS N
P POS N
= POS N
0.3) POS N

The POS N
relative POS N
effect POS N
of POS N
CD4GT POS N
or POS N
2/4-ART POS N
versus POS N
C-ART POS N
was POS N
not POS N
different POS N
between POS N
infection POS N
groups POS N
(P POS N
for POS N
interaction POS N
= POS N
0.4). POS N

After POS N
a POS N
median POS N
2.0 POS N
year POS N
(range POS N
= POS N
0.2-3.1) POS N
follow-up, POS N
≥ POS N
1 POS N
serious POS N
HIV-related POS N
events POS N
occurred POS N
in POS N
101 POS N
HIV POS N
mono-infected POS N
and POS N
15 POS N
HIV-HBV POS N
co-infected POS N
patients POS N
(IR POS N
= POS N
10.0 POS N
versus POS N
13.2/100 POS N
person/years, POS N
respectively, POS N
P POS N
= POS N
0.3) POS N

Incidence POS N
of POS N
bacterial POS N
infections POS N
was POS N
also POS N
highest POS N
in POS N
the POS N
co-infected POS N
group POS N
with POS N
HBV-replication POS N
> POS N
10,000 POS N
copies/mL POS N
(IR POS N
= POS N
12.9 POS N
versus POS N
3.3/100 POS N
person/years POS N
in POS N
HIV POS N
mono-infected POS N
patients, POS N
P POS N
= POS N
0.001). POS N

Results POS N
revealed POS N
that POS N
during POS N
daily POS N
consumption POS N
of POS N
fermented POS N
milk POS N
for POS N
5 POS N
wk, POS N
systolic POS N
[(116.55 POS N
± POS N
12.26 POS N
mmHg POS N
vs. POS N
124.77 POS N
± POS N
11.04 POS N
mmHg) POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
(80.7 POS N
± POS N
9 POS N
vs. POS N
84.5 POS N
± POS N
8.5 POS N
mmHg)] POS N
from POS N
the POS N
fermented POS N
milk POS N
group POS N
was POS N
lower POS N
than POS N
the POS N
control POS N
group. POS N

Additionally, POS N
triglyceride, POS N
total POS N
cholesterol, POS N
and POS N
low-density POS N
lipoprotein POS N
in POS N
blood POS N
serum POS N
were POS N
lower POS N
in POS N
the POS N
fermented POS N
milk POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group. POS N

Results POS N
revealed POS N
that POS N
during POS N
daily POS N
consumption POS N
of POS N
fermented POS N
milk POS N
for POS N
5 POS N
wk, POS N
systolic POS N
[(116.55 POS N
± POS N
12.26 POS N
mmHg POS N
vs. POS N
124.77 POS N
± POS N
11.04 POS N
mmHg) POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
(80.7 POS N
± POS N
9 POS N
vs. POS N
84.5 POS N
± POS N
8.5 POS N
mmHg)] POS N
from POS N
the POS N
fermented POS N
milk POS N
group POS N
was POS N
lower POS N
than POS N
the POS N
control POS N
group. POS N

Results POS N
demonstrated POS N
that POS N
daily POS N
consumption POS N
of POS N
fermented POS N
milk POS N
with POS N
Lactococcus POS N
lactis POS N
(NRRL POS N
B-50571) POS N
had POS N
a POS N
blood POS N
pressure-lowering POS N
effect POS N
on POS N
prehypertensive POS N
subjects. POS N

Results POS N
revealed POS N
that POS N
during POS N
daily POS N
consumption POS N
of POS N
fermented POS N
milk POS N
for POS N
5 POS N
wk, POS N
systolic POS N
[(116.55 POS N
± POS N
12.26 POS N
mmHg POS N
vs. POS N
124.77 POS N
± POS N
11.04 POS N
mmHg) POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
(80.7 POS N
± POS N
9 POS N
vs. POS N
84.5 POS N
± POS N
8.5 POS N
mmHg)] POS N
from POS N
the POS N
fermented POS N
milk POS N
group POS N
was POS N
lower POS N
than POS N
the POS N
control POS N
group. POS N

Regular POS N
consumption POS N
of POS N
this POS N
product POS N
may POS N
be POS N
used POS N
as POS N
a POS N
potential POS N
functional POS N
food. POS N

Additionally, POS N
triglyceride, POS N
total POS N
cholesterol, POS N
and POS N
low-density POS N
lipoprotein POS N
in POS N
blood POS N
serum POS N
were POS N
lower POS N
in POS N
the POS N
fermented POS N
milk POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group. POS N

Results POS N
revealed POS N
that POS N
during POS N
daily POS N
consumption POS N
of POS N
fermented POS N
milk POS N
for POS N
5 POS N
wk, POS N
systolic POS N
[(116.55 POS N
± POS N
12.26 POS N
mmHg POS N
vs. POS N
124.77 POS N
± POS N
11.04 POS N
mmHg) POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
(80.7 POS N
± POS N
9 POS N
vs. POS N
84.5 POS N
± POS N
8.5 POS N
mmHg)] POS N
from POS N
the POS N
fermented POS N
milk POS N
group POS N
was POS N
lower POS N
than POS N
the POS N
control POS N
group. POS N

Additionally, POS N
triglyceride, POS N
total POS N
cholesterol, POS N
and POS N
low-density POS N
lipoprotein POS N
in POS N
blood POS N
serum POS N
were POS N
lower POS N
in POS N
the POS N
fermented POS N
milk POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group. POS N

Results POS N
demonstrated POS N
that POS N
daily POS N
consumption POS N
of POS N
fermented POS N
milk POS N
with POS N
Lactococcus POS N
lactis POS N
(NRRL POS N
B-50571) POS N
had POS N
a POS N
blood POS N
pressure-lowering POS N
effect POS N
on POS N
prehypertensive POS N
subjects. POS N

Additionally, POS N
triglyceride, POS N
total POS N
cholesterol, POS N
and POS N
low-density POS N
lipoprotein POS N
in POS N
blood POS N
serum POS N
were POS N
lower POS N
in POS N
the POS N
fermented POS N
milk POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group. POS N

Regular POS N
consumption POS N
of POS N
this POS N
product POS N
may POS N
be POS N
used POS N
as POS N
a POS N
potential POS N
functional POS N
food. POS N

Results POS N
demonstrated POS N
that POS N
daily POS N
consumption POS N
of POS N
fermented POS N
milk POS N
with POS N
Lactococcus POS N
lactis POS N
(NRRL POS N
B-50571) POS N
had POS N
a POS N
blood POS N
pressure-lowering POS N
effect POS N
on POS N
prehypertensive POS N
subjects. POS N

Results POS N
revealed POS N
that POS N
during POS N
daily POS N
consumption POS N
of POS N
fermented POS N
milk POS N
for POS N
5 POS N
wk, POS N
systolic POS N
[(116.55 POS N
± POS N
12.26 POS N
mmHg POS N
vs. POS N
124.77 POS N
± POS N
11.04 POS N
mmHg) POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
(80.7 POS N
± POS N
9 POS N
vs. POS N
84.5 POS N
± POS N
8.5 POS N
mmHg)] POS N
from POS N
the POS N
fermented POS N
milk POS N
group POS N
was POS N
lower POS N
than POS N
the POS N
control POS N
group. POS N

Results POS N
demonstrated POS N
that POS N
daily POS N
consumption POS N
of POS N
fermented POS N
milk POS N
with POS N
Lactococcus POS N
lactis POS N
(NRRL POS N
B-50571) POS N
had POS N
a POS N
blood POS N
pressure-lowering POS N
effect POS N
on POS N
prehypertensive POS N
subjects. POS N

Additionally, POS N
triglyceride, POS N
total POS N
cholesterol, POS N
and POS N
low-density POS N
lipoprotein POS N
in POS N
blood POS N
serum POS N
were POS N
lower POS N
in POS N
the POS N
fermented POS N
milk POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group. POS N

Results POS N
demonstrated POS N
that POS N
daily POS N
consumption POS N
of POS N
fermented POS N
milk POS N
with POS N
Lactococcus POS N
lactis POS N
(NRRL POS N
B-50571) POS N
had POS N
a POS N
blood POS N
pressure-lowering POS N
effect POS N
on POS N
prehypertensive POS N
subjects. POS N

Regular POS N
consumption POS N
of POS N
this POS N
product POS N
may POS N
be POS N
used POS N
as POS N
a POS N
potential POS N
functional POS N
food. POS N

Regular POS N
consumption POS N
of POS N
this POS N
product POS N
may POS N
be POS N
used POS N
as POS N
a POS N
potential POS N
functional POS N
food. POS N

Results POS N
revealed POS N
that POS N
during POS N
daily POS N
consumption POS N
of POS N
fermented POS N
milk POS N
for POS N
5 POS N
wk, POS N
systolic POS N
[(116.55 POS N
± POS N
12.26 POS N
mmHg POS N
vs. POS N
124.77 POS N
± POS N
11.04 POS N
mmHg) POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
(80.7 POS N
± POS N
9 POS N
vs. POS N
84.5 POS N
± POS N
8.5 POS N
mmHg)] POS N
from POS N
the POS N
fermented POS N
milk POS N
group POS N
was POS N
lower POS N
than POS N
the POS N
control POS N
group. POS N

Regular POS N
consumption POS N
of POS N
this POS N
product POS N
may POS N
be POS N
used POS N
as POS N
a POS N
potential POS N
functional POS N
food. POS N

Additionally, POS N
triglyceride, POS N
total POS N
cholesterol, POS N
and POS N
low-density POS N
lipoprotein POS N
in POS N
blood POS N
serum POS N
were POS N
lower POS N
in POS N
the POS N
fermented POS N
milk POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group. POS N

Regular POS N
consumption POS N
of POS N
this POS N
product POS N
may POS N
be POS N
used POS N
as POS N
a POS N
potential POS N
functional POS N
food. POS N

Results POS N
demonstrated POS N
that POS N
daily POS N
consumption POS N
of POS N
fermented POS N
milk POS N
with POS N
Lactococcus POS N
lactis POS N
(NRRL POS N
B-50571) POS N
had POS N
a POS N
blood POS N
pressure-lowering POS N
effect POS N
on POS N
prehypertensive POS N
subjects. POS N

Cutaneous POS N
T-cell POS N
lymphoma POS N
(CTCL) POS N
can POS N
be POS N
associated POS N
with POS N
painful, POS N
pruritic, POS N
disfiguring POS N
lesions. POS N

Composite POS N
FACT-G POS N
and POS N
most POS N
individual POS N
subscale POS N
scores POS N
(physical, POS N
social/family, POS N
emotional, POS N
and POS N
functional POS N
well POS N
being) POS N
in POS N
documented POS N
responders POS N
(n POS N
= POS N
21) POS N
gradually POS N
increased POS N
during POS N
the POS N
study POS N
period, POS N
generally POS N
reaching POS N
statistical POS N
significance POS N
(P POS N
< POS N
0.05) POS N
by POS N
cycle POS N
3, POS N
and POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
= POS N
0.041) POS N
higher POS N
than POS N
the POS N
scores POS N
of POS N
nonresponders POS N
at POS N
endpoint. POS N

Cutaneous POS N
T-cell POS N
lymphoma POS N
(CTCL) POS N
can POS N
be POS N
associated POS N
with POS N
painful, POS N
pruritic, POS N
disfiguring POS N
lesions. POS N

Additionally POS N
for POS N
responders, POS N
assessments POS N
of POS N
skin POS N
severity POS N
and POS N
pruritus POS N
severity POS N
showed POS N
significant POS N
(P POS N
< POS N
or POS N
= POS N
0.05) POS N
improvements POS N
at POS N
study POS N
endpoint POS N
compared POS N
with POS N
baseline. POS N

Cutaneous POS N
T-cell POS N
lymphoma POS N
(CTCL) POS N
can POS N
be POS N
associated POS N
with POS N
painful, POS N
pruritic, POS N
disfiguring POS N
lesions. POS N

Adverse POS N
transfusion-related POS N
events POS N
(eg, POS N
hypersensitivity POS N
reactions, POS N
flu-like POS N
syndrome) POS N
were POS N
common POS N
during POS N
cycles POS N
1 POS N
and POS N
2, POS N
and POS N
vascular-leak POS N
syndrome POS N
occurred POS N
in POS N
25% POS N
of POS N
patients. POS N

Cutaneous POS N
T-cell POS N
lymphoma POS N
(CTCL) POS N
can POS N
be POS N
associated POS N
with POS N
painful, POS N
pruritic, POS N
disfiguring POS N
lesions. POS N

Denileukin POS N
diftitox POS N
was POS N
not POS N
associated POS N
with POS N
any POS N
clinically POS N
significant POS N
myelosuppression. POS N

Cutaneous POS N
T-cell POS N
lymphoma POS N
(CTCL) POS N
can POS N
be POS N
associated POS N
with POS N
painful, POS N
pruritic, POS N
disfiguring POS N
lesions. POS N

Heavily POS N
pretreated POS N
patients POS N
with POS N
advanced POS N
and/or POS N
recurrent POS N
CTCL POS N
who POS N
responded POS N
to POS N
denileukin POS N
diftitox POS N
therapy POS N
showed POS N
significant POS N
improvements POS N
in POS N
self-rated POS N
overall POS N
QOL, POS N
skin POS N
appearance, POS N
and POS N
pruritus POS N
severity. POS N

Composite POS N
FACT-G POS N
and POS N
most POS N
individual POS N
subscale POS N
scores POS N
(physical, POS N
social/family, POS N
emotional, POS N
and POS N
functional POS N
well POS N
being) POS N
in POS N
documented POS N
responders POS N
(n POS N
= POS N
21) POS N
gradually POS N
increased POS N
during POS N
the POS N
study POS N
period, POS N
generally POS N
reaching POS N
statistical POS N
significance POS N
(P POS N
< POS N
0.05) POS N
by POS N
cycle POS N
3, POS N
and POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
= POS N
0.041) POS N
higher POS N
than POS N
the POS N
scores POS N
of POS N
nonresponders POS N
at POS N
endpoint. POS N

Cutaneous POS N
T-cell POS N
lymphoma POS N
(CTCL) POS N
can POS N
be POS N
associated POS N
with POS N
painful, POS N
pruritic, POS N
disfiguring POS N
lesions. POS N

Composite POS N
FACT-G POS N
and POS N
most POS N
individual POS N
subscale POS N
scores POS N
(physical, POS N
social/family, POS N
emotional, POS N
and POS N
functional POS N
well POS N
being) POS N
in POS N
documented POS N
responders POS N
(n POS N
= POS N
21) POS N
gradually POS N
increased POS N
during POS N
the POS N
study POS N
period, POS N
generally POS N
reaching POS N
statistical POS N
significance POS N
(P POS N
< POS N
0.05) POS N
by POS N
cycle POS N
3, POS N
and POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
= POS N
0.041) POS N
higher POS N
than POS N
the POS N
scores POS N
of POS N
nonresponders POS N
at POS N
endpoint. POS N

Additionally POS N
for POS N
responders, POS N
assessments POS N
of POS N
skin POS N
severity POS N
and POS N
pruritus POS N
severity POS N
showed POS N
significant POS N
(P POS N
< POS N
or POS N
= POS N
0.05) POS N
improvements POS N
at POS N
study POS N
endpoint POS N
compared POS N
with POS N
baseline. POS N

Composite POS N
FACT-G POS N
and POS N
most POS N
individual POS N
subscale POS N
scores POS N
(physical, POS N
social/family, POS N
emotional, POS N
and POS N
functional POS N
well POS N
being) POS N
in POS N
documented POS N
responders POS N
(n POS N
= POS N
21) POS N
gradually POS N
increased POS N
during POS N
the POS N
study POS N
period, POS N
generally POS N
reaching POS N
statistical POS N
significance POS N
(P POS N
< POS N
0.05) POS N
by POS N
cycle POS N
3, POS N
and POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
= POS N
0.041) POS N
higher POS N
than POS N
the POS N
scores POS N
of POS N
nonresponders POS N
at POS N
endpoint. POS N

Adverse POS N
transfusion-related POS N
events POS N
(eg, POS N
hypersensitivity POS N
reactions, POS N
flu-like POS N
syndrome) POS N
were POS N
common POS N
during POS N
cycles POS N
1 POS N
and POS N
2, POS N
and POS N
vascular-leak POS N
syndrome POS N
occurred POS N
in POS N
25% POS N
of POS N
patients. POS N

Composite POS N
FACT-G POS N
and POS N
most POS N
individual POS N
subscale POS N
scores POS N
(physical, POS N
social/family, POS N
emotional, POS N
and POS N
functional POS N
well POS N
being) POS N
in POS N
documented POS N
responders POS N
(n POS N
= POS N
21) POS N
gradually POS N
increased POS N
during POS N
the POS N
study POS N
period, POS N
generally POS N
reaching POS N
statistical POS N
significance POS N
(P POS N
< POS N
0.05) POS N
by POS N
cycle POS N
3, POS N
and POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
= POS N
0.041) POS N
higher POS N
than POS N
the POS N
scores POS N
of POS N
nonresponders POS N
at POS N
endpoint. POS N

Denileukin POS N
diftitox POS N
was POS N
not POS N
associated POS N
with POS N
any POS N
clinically POS N
significant POS N
myelosuppression. POS N

Composite POS N
FACT-G POS N
and POS N
most POS N
individual POS N
subscale POS N
scores POS N
(physical, POS N
social/family, POS N
emotional, POS N
and POS N
functional POS N
well POS N
being) POS N
in POS N
documented POS N
responders POS N
(n POS N
= POS N
21) POS N
gradually POS N
increased POS N
during POS N
the POS N
study POS N
period, POS N
generally POS N
reaching POS N
statistical POS N
significance POS N
(P POS N
< POS N
0.05) POS N
by POS N
cycle POS N
3, POS N
and POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
= POS N
0.041) POS N
higher POS N
than POS N
the POS N
scores POS N
of POS N
nonresponders POS N
at POS N
endpoint. POS N

Heavily POS N
pretreated POS N
patients POS N
with POS N
advanced POS N
and/or POS N
recurrent POS N
CTCL POS N
who POS N
responded POS N
to POS N
denileukin POS N
diftitox POS N
therapy POS N
showed POS N
significant POS N
improvements POS N
in POS N
self-rated POS N
overall POS N
QOL, POS N
skin POS N
appearance, POS N
and POS N
pruritus POS N
severity. POS N

Additionally POS N
for POS N
responders, POS N
assessments POS N
of POS N
skin POS N
severity POS N
and POS N
pruritus POS N
severity POS N
showed POS N
significant POS N
(P POS N
< POS N
or POS N
= POS N
0.05) POS N
improvements POS N
at POS N
study POS N
endpoint POS N
compared POS N
with POS N
baseline. POS N

Cutaneous POS N
T-cell POS N
lymphoma POS N
(CTCL) POS N
can POS N
be POS N
associated POS N
with POS N
painful, POS N
pruritic, POS N
disfiguring POS N
lesions. POS N

Additionally POS N
for POS N
responders, POS N
assessments POS N
of POS N
skin POS N
severity POS N
and POS N
pruritus POS N
severity POS N
showed POS N
significant POS N
(P POS N
< POS N
or POS N
= POS N
0.05) POS N
improvements POS N
at POS N
study POS N
endpoint POS N
compared POS N
with POS N
baseline. POS N

Composite POS N
FACT-G POS N
and POS N
most POS N
individual POS N
subscale POS N
scores POS N
(physical, POS N
social/family, POS N
emotional, POS N
and POS N
functional POS N
well POS N
being) POS N
in POS N
documented POS N
responders POS N
(n POS N
= POS N
21) POS N
gradually POS N
increased POS N
during POS N
the POS N
study POS N
period, POS N
generally POS N
reaching POS N
statistical POS N
significance POS N
(P POS N
< POS N
0.05) POS N
by POS N
cycle POS N
3, POS N
and POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
= POS N
0.041) POS N
higher POS N
than POS N
the POS N
scores POS N
of POS N
nonresponders POS N
at POS N
endpoint. POS N

Additionally POS N
for POS N
responders, POS N
assessments POS N
of POS N
skin POS N
severity POS N
and POS N
pruritus POS N
severity POS N
showed POS N
significant POS N
(P POS N
< POS N
or POS N
= POS N
0.05) POS N
improvements POS N
at POS N
study POS N
endpoint POS N
compared POS N
with POS N
baseline. POS N

Adverse POS N
transfusion-related POS N
events POS N
(eg, POS N
hypersensitivity POS N
reactions, POS N
flu-like POS N
syndrome) POS N
were POS N
common POS N
during POS N
cycles POS N
1 POS N
and POS N
2, POS N
and POS N
vascular-leak POS N
syndrome POS N
occurred POS N
in POS N
25% POS N
of POS N
patients. POS N

Additionally POS N
for POS N
responders, POS N
assessments POS N
of POS N
skin POS N
severity POS N
and POS N
pruritus POS N
severity POS N
showed POS N
significant POS N
(P POS N
< POS N
or POS N
= POS N
0.05) POS N
improvements POS N
at POS N
study POS N
endpoint POS N
compared POS N
with POS N
baseline. POS N

Denileukin POS N
diftitox POS N
was POS N
not POS N
associated POS N
with POS N
any POS N
clinically POS N
significant POS N
myelosuppression. POS N

Additionally POS N
for POS N
responders, POS N
assessments POS N
of POS N
skin POS N
severity POS N
and POS N
pruritus POS N
severity POS N
showed POS N
significant POS N
(P POS N
< POS N
or POS N
= POS N
0.05) POS N
improvements POS N
at POS N
study POS N
endpoint POS N
compared POS N
with POS N
baseline. POS N

Heavily POS N
pretreated POS N
patients POS N
with POS N
advanced POS N
and/or POS N
recurrent POS N
CTCL POS N
who POS N
responded POS N
to POS N
denileukin POS N
diftitox POS N
therapy POS N
showed POS N
significant POS N
improvements POS N
in POS N
self-rated POS N
overall POS N
QOL, POS N
skin POS N
appearance, POS N
and POS N
pruritus POS N
severity. POS N

Adverse POS N
transfusion-related POS N
events POS N
(eg, POS N
hypersensitivity POS N
reactions, POS N
flu-like POS N
syndrome) POS N
were POS N
common POS N
during POS N
cycles POS N
1 POS N
and POS N
2, POS N
and POS N
vascular-leak POS N
syndrome POS N
occurred POS N
in POS N
25% POS N
of POS N
patients. POS N

Cutaneous POS N
T-cell POS N
lymphoma POS N
(CTCL) POS N
can POS N
be POS N
associated POS N
with POS N
painful, POS N
pruritic, POS N
disfiguring POS N
lesions. POS N

Adverse POS N
transfusion-related POS N
events POS N
(eg, POS N
hypersensitivity POS N
reactions, POS N
flu-like POS N
syndrome) POS N
were POS N
common POS N
during POS N
cycles POS N
1 POS N
and POS N
2, POS N
and POS N
vascular-leak POS N
syndrome POS N
occurred POS N
in POS N
25% POS N
of POS N
patients. POS N

Composite POS N
FACT-G POS N
and POS N
most POS N
individual POS N
subscale POS N
scores POS N
(physical, POS N
social/family, POS N
emotional, POS N
and POS N
functional POS N
well POS N
being) POS N
in POS N
documented POS N
responders POS N
(n POS N
= POS N
21) POS N
gradually POS N
increased POS N
during POS N
the POS N
study POS N
period, POS N
generally POS N
reaching POS N
statistical POS N
significance POS N
(P POS N
< POS N
0.05) POS N
by POS N
cycle POS N
3, POS N
and POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
= POS N
0.041) POS N
higher POS N
than POS N
the POS N
scores POS N
of POS N
nonresponders POS N
at POS N
endpoint. POS N

Adverse POS N
transfusion-related POS N
events POS N
(eg, POS N
hypersensitivity POS N
reactions, POS N
flu-like POS N
syndrome) POS N
were POS N
common POS N
during POS N
cycles POS N
1 POS N
and POS N
2, POS N
and POS N
vascular-leak POS N
syndrome POS N
occurred POS N
in POS N
25% POS N
of POS N
patients. POS N

Additionally POS N
for POS N
responders, POS N
assessments POS N
of POS N
skin POS N
severity POS N
and POS N
pruritus POS N
severity POS N
showed POS N
significant POS N
(P POS N
< POS N
or POS N
= POS N
0.05) POS N
improvements POS N
at POS N
study POS N
endpoint POS N
compared POS N
with POS N
baseline. POS N

Adverse POS N
transfusion-related POS N
events POS N
(eg, POS N
hypersensitivity POS N
reactions, POS N
flu-like POS N
syndrome) POS N
were POS N
common POS N
during POS N
cycles POS N
1 POS N
and POS N
2, POS N
and POS N
vascular-leak POS N
syndrome POS N
occurred POS N
in POS N
25% POS N
of POS N
patients. POS N

Denileukin POS N
diftitox POS N
was POS N
not POS N
associated POS N
with POS N
any POS N
clinically POS N
significant POS N
myelosuppression. POS N

Adverse POS N
transfusion-related POS N
events POS N
(eg, POS N
hypersensitivity POS N
reactions, POS N
flu-like POS N
syndrome) POS N
were POS N
common POS N
during POS N
cycles POS N
1 POS N
and POS N
2, POS N
and POS N
vascular-leak POS N
syndrome POS N
occurred POS N
in POS N
25% POS N
of POS N
patients. POS N

Heavily POS N
pretreated POS N
patients POS N
with POS N
advanced POS N
and/or POS N
recurrent POS N
CTCL POS N
who POS N
responded POS N
to POS N
denileukin POS N
diftitox POS N
therapy POS N
showed POS N
significant POS N
improvements POS N
in POS N
self-rated POS N
overall POS N
QOL, POS N
skin POS N
appearance, POS N
and POS N
pruritus POS N
severity. POS N

Denileukin POS N
diftitox POS N
was POS N
not POS N
associated POS N
with POS N
any POS N
clinically POS N
significant POS N
myelosuppression. POS N

Cutaneous POS N
T-cell POS N
lymphoma POS N
(CTCL) POS N
can POS N
be POS N
associated POS N
with POS N
painful, POS N
pruritic, POS N
disfiguring POS N
lesions. POS N

Denileukin POS N
diftitox POS N
was POS N
not POS N
associated POS N
with POS N
any POS N
clinically POS N
significant POS N
myelosuppression. POS N

Composite POS N
FACT-G POS N
and POS N
most POS N
individual POS N
subscale POS N
scores POS N
(physical, POS N
social/family, POS N
emotional, POS N
and POS N
functional POS N
well POS N
being) POS N
in POS N
documented POS N
responders POS N
(n POS N
= POS N
21) POS N
gradually POS N
increased POS N
during POS N
the POS N
study POS N
period, POS N
generally POS N
reaching POS N
statistical POS N
significance POS N
(P POS N
< POS N
0.05) POS N
by POS N
cycle POS N
3, POS N
and POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
= POS N
0.041) POS N
higher POS N
than POS N
the POS N
scores POS N
of POS N
nonresponders POS N
at POS N
endpoint. POS N

Denileukin POS N
diftitox POS N
was POS N
not POS N
associated POS N
with POS N
any POS N
clinically POS N
significant POS N
myelosuppression. POS N

Additionally POS N
for POS N
responders, POS N
assessments POS N
of POS N
skin POS N
severity POS N
and POS N
pruritus POS N
severity POS N
showed POS N
significant POS N
(P POS N
< POS N
or POS N
= POS N
0.05) POS N
improvements POS N
at POS N
study POS N
endpoint POS N
compared POS N
with POS N
baseline. POS N

Denileukin POS N
diftitox POS N
was POS N
not POS N
associated POS N
with POS N
any POS N
clinically POS N
significant POS N
myelosuppression. POS N

Adverse POS N
transfusion-related POS N
events POS N
(eg, POS N
hypersensitivity POS N
reactions, POS N
flu-like POS N
syndrome) POS N
were POS N
common POS N
during POS N
cycles POS N
1 POS N
and POS N
2, POS N
and POS N
vascular-leak POS N
syndrome POS N
occurred POS N
in POS N
25% POS N
of POS N
patients. POS N

Denileukin POS N
diftitox POS N
was POS N
not POS N
associated POS N
with POS N
any POS N
clinically POS N
significant POS N
myelosuppression. POS N

Heavily POS N
pretreated POS N
patients POS N
with POS N
advanced POS N
and/or POS N
recurrent POS N
CTCL POS N
who POS N
responded POS N
to POS N
denileukin POS N
diftitox POS N
therapy POS N
showed POS N
significant POS N
improvements POS N
in POS N
self-rated POS N
overall POS N
QOL, POS N
skin POS N
appearance, POS N
and POS N
pruritus POS N
severity. POS N

Heavily POS N
pretreated POS N
patients POS N
with POS N
advanced POS N
and/or POS N
recurrent POS N
CTCL POS N
who POS N
responded POS N
to POS N
denileukin POS N
diftitox POS N
therapy POS N
showed POS N
significant POS N
improvements POS N
in POS N
self-rated POS N
overall POS N
QOL, POS N
skin POS N
appearance, POS N
and POS N
pruritus POS N
severity. POS N

Cutaneous POS N
T-cell POS N
lymphoma POS N
(CTCL) POS N
can POS N
be POS N
associated POS N
with POS N
painful, POS N
pruritic, POS N
disfiguring POS N
lesions. POS N

Heavily POS N
pretreated POS N
patients POS N
with POS N
advanced POS N
and/or POS N
recurrent POS N
CTCL POS N
who POS N
responded POS N
to POS N
denileukin POS N
diftitox POS N
therapy POS N
showed POS N
significant POS N
improvements POS N
in POS N
self-rated POS N
overall POS N
QOL, POS N
skin POS N
appearance, POS N
and POS N
pruritus POS N
severity. POS N

Composite POS N
FACT-G POS N
and POS N
most POS N
individual POS N
subscale POS N
scores POS N
(physical, POS N
social/family, POS N
emotional, POS N
and POS N
functional POS N
well POS N
being) POS N
in POS N
documented POS N
responders POS N
(n POS N
= POS N
21) POS N
gradually POS N
increased POS N
during POS N
the POS N
study POS N
period, POS N
generally POS N
reaching POS N
statistical POS N
significance POS N
(P POS N
< POS N
0.05) POS N
by POS N
cycle POS N
3, POS N
and POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
= POS N
0.041) POS N
higher POS N
than POS N
the POS N
scores POS N
of POS N
nonresponders POS N
at POS N
endpoint. POS N

Heavily POS N
pretreated POS N
patients POS N
with POS N
advanced POS N
and/or POS N
recurrent POS N
CTCL POS N
who POS N
responded POS N
to POS N
denileukin POS N
diftitox POS N
therapy POS N
showed POS N
significant POS N
improvements POS N
in POS N
self-rated POS N
overall POS N
QOL, POS N
skin POS N
appearance, POS N
and POS N
pruritus POS N
severity. POS N

Additionally POS N
for POS N
responders, POS N
assessments POS N
of POS N
skin POS N
severity POS N
and POS N
pruritus POS N
severity POS N
showed POS N
significant POS N
(P POS N
< POS N
or POS N
= POS N
0.05) POS N
improvements POS N
at POS N
study POS N
endpoint POS N
compared POS N
with POS N
baseline. POS N

Heavily POS N
pretreated POS N
patients POS N
with POS N
advanced POS N
and/or POS N
recurrent POS N
CTCL POS N
who POS N
responded POS N
to POS N
denileukin POS N
diftitox POS N
therapy POS N
showed POS N
significant POS N
improvements POS N
in POS N
self-rated POS N
overall POS N
QOL, POS N
skin POS N
appearance, POS N
and POS N
pruritus POS N
severity. POS N

Adverse POS N
transfusion-related POS N
events POS N
(eg, POS N
hypersensitivity POS N
reactions, POS N
flu-like POS N
syndrome) POS N
were POS N
common POS N
during POS N
cycles POS N
1 POS N
and POS N
2, POS N
and POS N
vascular-leak POS N
syndrome POS N
occurred POS N
in POS N
25% POS N
of POS N
patients. POS N

Heavily POS N
pretreated POS N
patients POS N
with POS N
advanced POS N
and/or POS N
recurrent POS N
CTCL POS N
who POS N
responded POS N
to POS N
denileukin POS N
diftitox POS N
therapy POS N
showed POS N
significant POS N
improvements POS N
in POS N
self-rated POS N
overall POS N
QOL, POS N
skin POS N
appearance, POS N
and POS N
pruritus POS N
severity. POS N

Denileukin POS N
diftitox POS N
was POS N
not POS N
associated POS N
with POS N
any POS N
clinically POS N
significant POS N
myelosuppression. POS N

Imatinib POS N
(Gleevec), POS N
a POS N
highly POS N
effective POS N
specific POS N
tyrosine POS N
kinase POS N
inhibitor, POS N
demonstrates POS N
a POS N
better POS N
side POS N
effect POS N
profile POS N
than POS N
interferon-alpha POS N
(IFN), POS N
which POS N
impairs POS N
patients' POS N
quality POS N
of POS N
life POS N
(QoL). POS N

Two POS N
hundred POS N
sixty-one POS N
patients POS N
(50%) POS N
crossed POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib POS N
and POS N
11 POS N
(2%) POS N
crossed POS N
over POS N
from POS N
imatinib POS N
to POS N
IFN. POS N

Imatinib POS N
(Gleevec), POS N
a POS N
highly POS N
effective POS N
specific POS N
tyrosine POS N
kinase POS N
inhibitor, POS N
demonstrates POS N
a POS N
better POS N
side POS N
effect POS N
profile POS N
than POS N
interferon-alpha POS N
(IFN), POS N
which POS N
impairs POS N
patients' POS N
quality POS N
of POS N
life POS N
(QoL). POS N

There POS N
was POS N
a POS N
significant POS N
decline POS N
in POS N
TOI POS N
scores POS N
for POS N
the POS N
IFN POS N
treatment POS N
arm POS N
compared POS N
with POS N
preservation POS N
of POS N
baseline POS N
TOI POS N
scores POS N
in POS N
the POS N
imatinib POS N
arm POS N
(P POS N
<.001, POS N
ITT). POS N

Imatinib POS N
(Gleevec), POS N
a POS N
highly POS N
effective POS N
specific POS N
tyrosine POS N
kinase POS N
inhibitor, POS N
demonstrates POS N
a POS N
better POS N
side POS N
effect POS N
profile POS N
than POS N
interferon-alpha POS N
(IFN), POS N
which POS N
impairs POS N
patients' POS N
quality POS N
of POS N
life POS N
(QoL). POS N

Mean POS N
social/family POS N
and POS N
EWB POS N
scores POS N
were POS N
22.8 POS N
and POS N
19.5, POS N
respectively, POS N
for POS N
imatinib POS N
and POS N
21.6 POS N
and POS N
17.6, POS N
respectively, POS N
for POS N
IFN POS N
(P POS N
<.001, POS N
ITT). POS N

Imatinib POS N
(Gleevec), POS N
a POS N
highly POS N
effective POS N
specific POS N
tyrosine POS N
kinase POS N
inhibitor, POS N
demonstrates POS N
a POS N
better POS N
side POS N
effect POS N
profile POS N
than POS N
interferon-alpha POS N
(IFN), POS N
which POS N
impairs POS N
patients' POS N
quality POS N
of POS N
life POS N
(QoL). POS N

After POS N
crossing POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib, POS N
patients POS N
experienced POS N
a POS N
significant POS N
(P POS N
<.001) POS N
increase POS N
in POS N
TOI POS N
scores. POS N

Imatinib POS N
(Gleevec), POS N
a POS N
highly POS N
effective POS N
specific POS N
tyrosine POS N
kinase POS N
inhibitor, POS N
demonstrates POS N
a POS N
better POS N
side POS N
effect POS N
profile POS N
than POS N
interferon-alpha POS N
(IFN), POS N
which POS N
impairs POS N
patients' POS N
quality POS N
of POS N
life POS N
(QoL). POS N

Imatinib POS N
offers POS N
clear POS N
QoL POS N
advantages POS N
over POS N
IFN POS N
as POS N
first-line POS N
treatment POS N
of POS N
chronic-phase POS N
CML. POS N

Imatinib POS N
(Gleevec), POS N
a POS N
highly POS N
effective POS N
specific POS N
tyrosine POS N
kinase POS N
inhibitor, POS N
demonstrates POS N
a POS N
better POS N
side POS N
effect POS N
profile POS N
than POS N
interferon-alpha POS N
(IFN), POS N
which POS N
impairs POS N
patients' POS N
quality POS N
of POS N
life POS N
(QoL). POS N

patients POS N
who POS N
crossed POS N
over POS N
to POS N
imatinib POS N
reported POS N
higher POS N
QoL POS N
than POS N
those POS N
who POS N
remained POS N
on POS N
IFN. POS N

Two POS N
hundred POS N
sixty-one POS N
patients POS N
(50%) POS N
crossed POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib POS N
and POS N
11 POS N
(2%) POS N
crossed POS N
over POS N
from POS N
imatinib POS N
to POS N
IFN. POS N

Imatinib POS N
(Gleevec), POS N
a POS N
highly POS N
effective POS N
specific POS N
tyrosine POS N
kinase POS N
inhibitor, POS N
demonstrates POS N
a POS N
better POS N
side POS N
effect POS N
profile POS N
than POS N
interferon-alpha POS N
(IFN), POS N
which POS N
impairs POS N
patients' POS N
quality POS N
of POS N
life POS N
(QoL). POS N

Two POS N
hundred POS N
sixty-one POS N
patients POS N
(50%) POS N
crossed POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib POS N
and POS N
11 POS N
(2%) POS N
crossed POS N
over POS N
from POS N
imatinib POS N
to POS N
IFN. POS N

There POS N
was POS N
a POS N
significant POS N
decline POS N
in POS N
TOI POS N
scores POS N
for POS N
the POS N
IFN POS N
treatment POS N
arm POS N
compared POS N
with POS N
preservation POS N
of POS N
baseline POS N
TOI POS N
scores POS N
in POS N
the POS N
imatinib POS N
arm POS N
(P POS N
<.001, POS N
ITT). POS N

Two POS N
hundred POS N
sixty-one POS N
patients POS N
(50%) POS N
crossed POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib POS N
and POS N
11 POS N
(2%) POS N
crossed POS N
over POS N
from POS N
imatinib POS N
to POS N
IFN. POS N

Mean POS N
social/family POS N
and POS N
EWB POS N
scores POS N
were POS N
22.8 POS N
and POS N
19.5, POS N
respectively, POS N
for POS N
imatinib POS N
and POS N
21.6 POS N
and POS N
17.6, POS N
respectively, POS N
for POS N
IFN POS N
(P POS N
<.001, POS N
ITT). POS N

Two POS N
hundred POS N
sixty-one POS N
patients POS N
(50%) POS N
crossed POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib POS N
and POS N
11 POS N
(2%) POS N
crossed POS N
over POS N
from POS N
imatinib POS N
to POS N
IFN. POS N

After POS N
crossing POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib, POS N
patients POS N
experienced POS N
a POS N
significant POS N
(P POS N
<.001) POS N
increase POS N
in POS N
TOI POS N
scores. POS N

Two POS N
hundred POS N
sixty-one POS N
patients POS N
(50%) POS N
crossed POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib POS N
and POS N
11 POS N
(2%) POS N
crossed POS N
over POS N
from POS N
imatinib POS N
to POS N
IFN. POS N

Imatinib POS N
offers POS N
clear POS N
QoL POS N
advantages POS N
over POS N
IFN POS N
as POS N
first-line POS N
treatment POS N
of POS N
chronic-phase POS N
CML. POS N

Two POS N
hundred POS N
sixty-one POS N
patients POS N
(50%) POS N
crossed POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib POS N
and POS N
11 POS N
(2%) POS N
crossed POS N
over POS N
from POS N
imatinib POS N
to POS N
IFN. POS N

patients POS N
who POS N
crossed POS N
over POS N
to POS N
imatinib POS N
reported POS N
higher POS N
QoL POS N
than POS N
those POS N
who POS N
remained POS N
on POS N
IFN. POS N

There POS N
was POS N
a POS N
significant POS N
decline POS N
in POS N
TOI POS N
scores POS N
for POS N
the POS N
IFN POS N
treatment POS N
arm POS N
compared POS N
with POS N
preservation POS N
of POS N
baseline POS N
TOI POS N
scores POS N
in POS N
the POS N
imatinib POS N
arm POS N
(P POS N
<.001, POS N
ITT). POS N

Imatinib POS N
(Gleevec), POS N
a POS N
highly POS N
effective POS N
specific POS N
tyrosine POS N
kinase POS N
inhibitor, POS N
demonstrates POS N
a POS N
better POS N
side POS N
effect POS N
profile POS N
than POS N
interferon-alpha POS N
(IFN), POS N
which POS N
impairs POS N
patients' POS N
quality POS N
of POS N
life POS N
(QoL). POS N

There POS N
was POS N
a POS N
significant POS N
decline POS N
in POS N
TOI POS N
scores POS N
for POS N
the POS N
IFN POS N
treatment POS N
arm POS N
compared POS N
with POS N
preservation POS N
of POS N
baseline POS N
TOI POS N
scores POS N
in POS N
the POS N
imatinib POS N
arm POS N
(P POS N
<.001, POS N
ITT). POS N

Two POS N
hundred POS N
sixty-one POS N
patients POS N
(50%) POS N
crossed POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib POS N
and POS N
11 POS N
(2%) POS N
crossed POS N
over POS N
from POS N
imatinib POS N
to POS N
IFN. POS N

There POS N
was POS N
a POS N
significant POS N
decline POS N
in POS N
TOI POS N
scores POS N
for POS N
the POS N
IFN POS N
treatment POS N
arm POS N
compared POS N
with POS N
preservation POS N
of POS N
baseline POS N
TOI POS N
scores POS N
in POS N
the POS N
imatinib POS N
arm POS N
(P POS N
<.001, POS N
ITT). POS N

Mean POS N
social/family POS N
and POS N
EWB POS N
scores POS N
were POS N
22.8 POS N
and POS N
19.5, POS N
respectively, POS N
for POS N
imatinib POS N
and POS N
21.6 POS N
and POS N
17.6, POS N
respectively, POS N
for POS N
IFN POS N
(P POS N
<.001, POS N
ITT). POS N

There POS N
was POS N
a POS N
significant POS N
decline POS N
in POS N
TOI POS N
scores POS N
for POS N
the POS N
IFN POS N
treatment POS N
arm POS N
compared POS N
with POS N
preservation POS N
of POS N
baseline POS N
TOI POS N
scores POS N
in POS N
the POS N
imatinib POS N
arm POS N
(P POS N
<.001, POS N
ITT). POS N

After POS N
crossing POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib, POS N
patients POS N
experienced POS N
a POS N
significant POS N
(P POS N
<.001) POS N
increase POS N
in POS N
TOI POS N
scores. POS N

There POS N
was POS N
a POS N
significant POS N
decline POS N
in POS N
TOI POS N
scores POS N
for POS N
the POS N
IFN POS N
treatment POS N
arm POS N
compared POS N
with POS N
preservation POS N
of POS N
baseline POS N
TOI POS N
scores POS N
in POS N
the POS N
imatinib POS N
arm POS N
(P POS N
<.001, POS N
ITT). POS N

Imatinib POS N
offers POS N
clear POS N
QoL POS N
advantages POS N
over POS N
IFN POS N
as POS N
first-line POS N
treatment POS N
of POS N
chronic-phase POS N
CML. POS N

There POS N
was POS N
a POS N
significant POS N
decline POS N
in POS N
TOI POS N
scores POS N
for POS N
the POS N
IFN POS N
treatment POS N
arm POS N
compared POS N
with POS N
preservation POS N
of POS N
baseline POS N
TOI POS N
scores POS N
in POS N
the POS N
imatinib POS N
arm POS N
(P POS N
<.001, POS N
ITT). POS N

patients POS N
who POS N
crossed POS N
over POS N
to POS N
imatinib POS N
reported POS N
higher POS N
QoL POS N
than POS N
those POS N
who POS N
remained POS N
on POS N
IFN. POS N

Mean POS N
social/family POS N
and POS N
EWB POS N
scores POS N
were POS N
22.8 POS N
and POS N
19.5, POS N
respectively, POS N
for POS N
imatinib POS N
and POS N
21.6 POS N
and POS N
17.6, POS N
respectively, POS N
for POS N
IFN POS N
(P POS N
<.001, POS N
ITT). POS N

Imatinib POS N
(Gleevec), POS N
a POS N
highly POS N
effective POS N
specific POS N
tyrosine POS N
kinase POS N
inhibitor, POS N
demonstrates POS N
a POS N
better POS N
side POS N
effect POS N
profile POS N
than POS N
interferon-alpha POS N
(IFN), POS N
which POS N
impairs POS N
patients' POS N
quality POS N
of POS N
life POS N
(QoL). POS N

Mean POS N
social/family POS N
and POS N
EWB POS N
scores POS N
were POS N
22.8 POS N
and POS N
19.5, POS N
respectively, POS N
for POS N
imatinib POS N
and POS N
21.6 POS N
and POS N
17.6, POS N
respectively, POS N
for POS N
IFN POS N
(P POS N
<.001, POS N
ITT). POS N

Two POS N
hundred POS N
sixty-one POS N
patients POS N
(50%) POS N
crossed POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib POS N
and POS N
11 POS N
(2%) POS N
crossed POS N
over POS N
from POS N
imatinib POS N
to POS N
IFN. POS N

Mean POS N
social/family POS N
and POS N
EWB POS N
scores POS N
were POS N
22.8 POS N
and POS N
19.5, POS N
respectively, POS N
for POS N
imatinib POS N
and POS N
21.6 POS N
and POS N
17.6, POS N
respectively, POS N
for POS N
IFN POS N
(P POS N
<.001, POS N
ITT). POS N

There POS N
was POS N
a POS N
significant POS N
decline POS N
in POS N
TOI POS N
scores POS N
for POS N
the POS N
IFN POS N
treatment POS N
arm POS N
compared POS N
with POS N
preservation POS N
of POS N
baseline POS N
TOI POS N
scores POS N
in POS N
the POS N
imatinib POS N
arm POS N
(P POS N
<.001, POS N
ITT). POS N

Mean POS N
social/family POS N
and POS N
EWB POS N
scores POS N
were POS N
22.8 POS N
and POS N
19.5, POS N
respectively, POS N
for POS N
imatinib POS N
and POS N
21.6 POS N
and POS N
17.6, POS N
respectively, POS N
for POS N
IFN POS N
(P POS N
<.001, POS N
ITT). POS N

After POS N
crossing POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib, POS N
patients POS N
experienced POS N
a POS N
significant POS N
(P POS N
<.001) POS N
increase POS N
in POS N
TOI POS N
scores. POS N

Mean POS N
social/family POS N
and POS N
EWB POS N
scores POS N
were POS N
22.8 POS N
and POS N
19.5, POS N
respectively, POS N
for POS N
imatinib POS N
and POS N
21.6 POS N
and POS N
17.6, POS N
respectively, POS N
for POS N
IFN POS N
(P POS N
<.001, POS N
ITT). POS N

Imatinib POS N
offers POS N
clear POS N
QoL POS N
advantages POS N
over POS N
IFN POS N
as POS N
first-line POS N
treatment POS N
of POS N
chronic-phase POS N
CML. POS N

Mean POS N
social/family POS N
and POS N
EWB POS N
scores POS N
were POS N
22.8 POS N
and POS N
19.5, POS N
respectively, POS N
for POS N
imatinib POS N
and POS N
21.6 POS N
and POS N
17.6, POS N
respectively, POS N
for POS N
IFN POS N
(P POS N
<.001, POS N
ITT). POS N

patients POS N
who POS N
crossed POS N
over POS N
to POS N
imatinib POS N
reported POS N
higher POS N
QoL POS N
than POS N
those POS N
who POS N
remained POS N
on POS N
IFN. POS N

After POS N
crossing POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib, POS N
patients POS N
experienced POS N
a POS N
significant POS N
(P POS N
<.001) POS N
increase POS N
in POS N
TOI POS N
scores. POS N

Imatinib POS N
(Gleevec), POS N
a POS N
highly POS N
effective POS N
specific POS N
tyrosine POS N
kinase POS N
inhibitor, POS N
demonstrates POS N
a POS N
better POS N
side POS N
effect POS N
profile POS N
than POS N
interferon-alpha POS N
(IFN), POS N
which POS N
impairs POS N
patients' POS N
quality POS N
of POS N
life POS N
(QoL). POS N

After POS N
crossing POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib, POS N
patients POS N
experienced POS N
a POS N
significant POS N
(P POS N
<.001) POS N
increase POS N
in POS N
TOI POS N
scores. POS N

Two POS N
hundred POS N
sixty-one POS N
patients POS N
(50%) POS N
crossed POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib POS N
and POS N
11 POS N
(2%) POS N
crossed POS N
over POS N
from POS N
imatinib POS N
to POS N
IFN. POS N

After POS N
crossing POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib, POS N
patients POS N
experienced POS N
a POS N
significant POS N
(P POS N
<.001) POS N
increase POS N
in POS N
TOI POS N
scores. POS N

There POS N
was POS N
a POS N
significant POS N
decline POS N
in POS N
TOI POS N
scores POS N
for POS N
the POS N
IFN POS N
treatment POS N
arm POS N
compared POS N
with POS N
preservation POS N
of POS N
baseline POS N
TOI POS N
scores POS N
in POS N
the POS N
imatinib POS N
arm POS N
(P POS N
<.001, POS N
ITT). POS N

After POS N
crossing POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib, POS N
patients POS N
experienced POS N
a POS N
significant POS N
(P POS N
<.001) POS N
increase POS N
in POS N
TOI POS N
scores. POS N

Mean POS N
social/family POS N
and POS N
EWB POS N
scores POS N
were POS N
22.8 POS N
and POS N
19.5, POS N
respectively, POS N
for POS N
imatinib POS N
and POS N
21.6 POS N
and POS N
17.6, POS N
respectively, POS N
for POS N
IFN POS N
(P POS N
<.001, POS N
ITT). POS N

After POS N
crossing POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib, POS N
patients POS N
experienced POS N
a POS N
significant POS N
(P POS N
<.001) POS N
increase POS N
in POS N
TOI POS N
scores. POS N

Imatinib POS N
offers POS N
clear POS N
QoL POS N
advantages POS N
over POS N
IFN POS N
as POS N
first-line POS N
treatment POS N
of POS N
chronic-phase POS N
CML. POS N

After POS N
crossing POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib, POS N
patients POS N
experienced POS N
a POS N
significant POS N
(P POS N
<.001) POS N
increase POS N
in POS N
TOI POS N
scores. POS N

patients POS N
who POS N
crossed POS N
over POS N
to POS N
imatinib POS N
reported POS N
higher POS N
QoL POS N
than POS N
those POS N
who POS N
remained POS N
on POS N
IFN. POS N

Imatinib POS N
offers POS N
clear POS N
QoL POS N
advantages POS N
over POS N
IFN POS N
as POS N
first-line POS N
treatment POS N
of POS N
chronic-phase POS N
CML. POS N

Imatinib POS N
(Gleevec), POS N
a POS N
highly POS N
effective POS N
specific POS N
tyrosine POS N
kinase POS N
inhibitor, POS N
demonstrates POS N
a POS N
better POS N
side POS N
effect POS N
profile POS N
than POS N
interferon-alpha POS N
(IFN), POS N
which POS N
impairs POS N
patients' POS N
quality POS N
of POS N
life POS N
(QoL). POS N

Imatinib POS N
offers POS N
clear POS N
QoL POS N
advantages POS N
over POS N
IFN POS N
as POS N
first-line POS N
treatment POS N
of POS N
chronic-phase POS N
CML. POS N

Two POS N
hundred POS N
sixty-one POS N
patients POS N
(50%) POS N
crossed POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib POS N
and POS N
11 POS N
(2%) POS N
crossed POS N
over POS N
from POS N
imatinib POS N
to POS N
IFN. POS N

Imatinib POS N
offers POS N
clear POS N
QoL POS N
advantages POS N
over POS N
IFN POS N
as POS N
first-line POS N
treatment POS N
of POS N
chronic-phase POS N
CML. POS N

There POS N
was POS N
a POS N
significant POS N
decline POS N
in POS N
TOI POS N
scores POS N
for POS N
the POS N
IFN POS N
treatment POS N
arm POS N
compared POS N
with POS N
preservation POS N
of POS N
baseline POS N
TOI POS N
scores POS N
in POS N
the POS N
imatinib POS N
arm POS N
(P POS N
<.001, POS N
ITT). POS N

Imatinib POS N
offers POS N
clear POS N
QoL POS N
advantages POS N
over POS N
IFN POS N
as POS N
first-line POS N
treatment POS N
of POS N
chronic-phase POS N
CML. POS N

Mean POS N
social/family POS N
and POS N
EWB POS N
scores POS N
were POS N
22.8 POS N
and POS N
19.5, POS N
respectively, POS N
for POS N
imatinib POS N
and POS N
21.6 POS N
and POS N
17.6, POS N
respectively, POS N
for POS N
IFN POS N
(P POS N
<.001, POS N
ITT). POS N

Imatinib POS N
offers POS N
clear POS N
QoL POS N
advantages POS N
over POS N
IFN POS N
as POS N
first-line POS N
treatment POS N
of POS N
chronic-phase POS N
CML. POS N

After POS N
crossing POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib, POS N
patients POS N
experienced POS N
a POS N
significant POS N
(P POS N
<.001) POS N
increase POS N
in POS N
TOI POS N
scores. POS N

Imatinib POS N
offers POS N
clear POS N
QoL POS N
advantages POS N
over POS N
IFN POS N
as POS N
first-line POS N
treatment POS N
of POS N
chronic-phase POS N
CML. POS N

patients POS N
who POS N
crossed POS N
over POS N
to POS N
imatinib POS N
reported POS N
higher POS N
QoL POS N
than POS N
those POS N
who POS N
remained POS N
on POS N
IFN. POS N

patients POS N
who POS N
crossed POS N
over POS N
to POS N
imatinib POS N
reported POS N
higher POS N
QoL POS N
than POS N
those POS N
who POS N
remained POS N
on POS N
IFN. POS N

Imatinib POS N
(Gleevec), POS N
a POS N
highly POS N
effective POS N
specific POS N
tyrosine POS N
kinase POS N
inhibitor, POS N
demonstrates POS N
a POS N
better POS N
side POS N
effect POS N
profile POS N
than POS N
interferon-alpha POS N
(IFN), POS N
which POS N
impairs POS N
patients' POS N
quality POS N
of POS N
life POS N
(QoL). POS N

patients POS N
who POS N
crossed POS N
over POS N
to POS N
imatinib POS N
reported POS N
higher POS N
QoL POS N
than POS N
those POS N
who POS N
remained POS N
on POS N
IFN. POS N

Two POS N
hundred POS N
sixty-one POS N
patients POS N
(50%) POS N
crossed POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib POS N
and POS N
11 POS N
(2%) POS N
crossed POS N
over POS N
from POS N
imatinib POS N
to POS N
IFN. POS N

patients POS N
who POS N
crossed POS N
over POS N
to POS N
imatinib POS N
reported POS N
higher POS N
QoL POS N
than POS N
those POS N
who POS N
remained POS N
on POS N
IFN. POS N

There POS N
was POS N
a POS N
significant POS N
decline POS N
in POS N
TOI POS N
scores POS N
for POS N
the POS N
IFN POS N
treatment POS N
arm POS N
compared POS N
with POS N
preservation POS N
of POS N
baseline POS N
TOI POS N
scores POS N
in POS N
the POS N
imatinib POS N
arm POS N
(P POS N
<.001, POS N
ITT). POS N

patients POS N
who POS N
crossed POS N
over POS N
to POS N
imatinib POS N
reported POS N
higher POS N
QoL POS N
than POS N
those POS N
who POS N
remained POS N
on POS N
IFN. POS N

Mean POS N
social/family POS N
and POS N
EWB POS N
scores POS N
were POS N
22.8 POS N
and POS N
19.5, POS N
respectively, POS N
for POS N
imatinib POS N
and POS N
21.6 POS N
and POS N
17.6, POS N
respectively, POS N
for POS N
IFN POS N
(P POS N
<.001, POS N
ITT). POS N

patients POS N
who POS N
crossed POS N
over POS N
to POS N
imatinib POS N
reported POS N
higher POS N
QoL POS N
than POS N
those POS N
who POS N
remained POS N
on POS N
IFN. POS N

After POS N
crossing POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib, POS N
patients POS N
experienced POS N
a POS N
significant POS N
(P POS N
<.001) POS N
increase POS N
in POS N
TOI POS N
scores. POS N

patients POS N
who POS N
crossed POS N
over POS N
to POS N
imatinib POS N
reported POS N
higher POS N
QoL POS N
than POS N
those POS N
who POS N
remained POS N
on POS N
IFN. POS N

Imatinib POS N
offers POS N
clear POS N
QoL POS N
advantages POS N
over POS N
IFN POS N
as POS N
first-line POS N
treatment POS N
of POS N
chronic-phase POS N
CML. POS N

vitamin POS N
C POS N
and/or POS N
E POS N
improve POS N
fasting POS N
blood POS N
sugar POS N
(FBS), POS N
HbA1c, POS N
lipid POS N
profile, POS N
insulin, POS N
homeostasis POS N
model POS N
assessment POS N
of POS N
insulin POS N
resistance POS N
(HOMA-IR), POS N
reduced POS N
glutathione POS N
(GSH); POS N
and POS N
Quantitative POS N
Insulin POS N
Sensitivity POS N
Check POS N
Index POS N
(QISCI) POS N
compared POS N
with POS N
diabetic POS N
patients POS N
group POS N
that POS N
received POS N
placebo. POS N

there POS N
has POS N
been POS N
an POS N
increasing POS N
interest POS N
in POS N
the POS N
influence POS N
of POS N
antioxidant POS N
vitamins POS N
on POS N
the POS N
efficacy POS N
of POS N
oral POS N
hypoglycemic POS N
therapy POS N
in POS N
type POS N
2 POS N
diabetic POS N
patients POS N
(T2DM). POS N

vitamin POS N
C POS N
and/or POS N
E POS N
improve POS N
fasting POS N
blood POS N
sugar POS N
(FBS), POS N
HbA1c, POS N
lipid POS N
profile, POS N
insulin, POS N
homeostasis POS N
model POS N
assessment POS N
of POS N
insulin POS N
resistance POS N
(HOMA-IR), POS N
reduced POS N
glutathione POS N
(GSH); POS N
and POS N
Quantitative POS N
Insulin POS N
Sensitivity POS N
Check POS N
Index POS N
(QISCI) POS N
compared POS N
with POS N
diabetic POS N
patients POS N
group POS N
that POS N
received POS N
placebo. POS N

This POS N
study POS N
provided POS N
additional POS N
evidence POS N
on POS N
the POS N
beneficial POS N
effects POS N
of POS N
supplementing POS N
antioxidant POS N
vitamins POS N
in POS N
T2DM POS N
which POS N
could POS N
improve POS N
the POS N
clinical POS N
condition POS N
and POS N
attenuate POS N
or POS N
prevent POS N
diabetic POS N
pathogenesis POS N
and POS N
complications POS N
that, POS N
secondly POS N
to POS N
poor POS N
glycemic POS N
control, POS N
could POS N
attribute POS N
to POS N
the POS N
imbalance POS N
between POS N
the POS N
decline POS N
in POS N
the POS N
endogenous POS N
antioxidants POS N
and POS N
increasing POS N
production POS N
of POS N
the POS N
reactive POS N
oxygen POS N
species POS N
leading POS N
to POS N
the POS N
oxidant-mediated POS N
damage POS N
present POS N
in POS N
the POS N
diabetic POS N
context. POS N

there POS N
has POS N
been POS N
an POS N
increasing POS N
interest POS N
in POS N
the POS N
influence POS N
of POS N
antioxidant POS N
vitamins POS N
on POS N
the POS N
efficacy POS N
of POS N
oral POS N
hypoglycemic POS N
therapy POS N
in POS N
type POS N
2 POS N
diabetic POS N
patients POS N
(T2DM). POS N

vitamin POS N
C POS N
and/or POS N
E POS N
improve POS N
fasting POS N
blood POS N
sugar POS N
(FBS), POS N
HbA1c, POS N
lipid POS N
profile, POS N
insulin, POS N
homeostasis POS N
model POS N
assessment POS N
of POS N
insulin POS N
resistance POS N
(HOMA-IR), POS N
reduced POS N
glutathione POS N
(GSH); POS N
and POS N
Quantitative POS N
Insulin POS N
Sensitivity POS N
Check POS N
Index POS N
(QISCI) POS N
compared POS N
with POS N
diabetic POS N
patients POS N
group POS N
that POS N
received POS N
placebo. POS N

there POS N
has POS N
been POS N
an POS N
increasing POS N
interest POS N
in POS N
the POS N
influence POS N
of POS N
antioxidant POS N
vitamins POS N
on POS N
the POS N
efficacy POS N
of POS N
oral POS N
hypoglycemic POS N
therapy POS N
in POS N
type POS N
2 POS N
diabetic POS N
patients POS N
(T2DM). POS N

This POS N
study POS N
provided POS N
additional POS N
evidence POS N
on POS N
the POS N
beneficial POS N
effects POS N
of POS N
supplementing POS N
antioxidant POS N
vitamins POS N
in POS N
T2DM POS N
which POS N
could POS N
improve POS N
the POS N
clinical POS N
condition POS N
and POS N
attenuate POS N
or POS N
prevent POS N
diabetic POS N
pathogenesis POS N
and POS N
complications POS N
that, POS N
secondly POS N
to POS N
poor POS N
glycemic POS N
control, POS N
could POS N
attribute POS N
to POS N
the POS N
imbalance POS N
between POS N
the POS N
decline POS N
in POS N
the POS N
endogenous POS N
antioxidants POS N
and POS N
increasing POS N
production POS N
of POS N
the POS N
reactive POS N
oxygen POS N
species POS N
leading POS N
to POS N
the POS N
oxidant-mediated POS N
damage POS N
present POS N
in POS N
the POS N
diabetic POS N
context. POS N

This POS N
study POS N
provided POS N
additional POS N
evidence POS N
on POS N
the POS N
beneficial POS N
effects POS N
of POS N
supplementing POS N
antioxidant POS N
vitamins POS N
in POS N
T2DM POS N
which POS N
could POS N
improve POS N
the POS N
clinical POS N
condition POS N
and POS N
attenuate POS N
or POS N
prevent POS N
diabetic POS N
pathogenesis POS N
and POS N
complications POS N
that, POS N
secondly POS N
to POS N
poor POS N
glycemic POS N
control, POS N
could POS N
attribute POS N
to POS N
the POS N
imbalance POS N
between POS N
the POS N
decline POS N
in POS N
the POS N
endogenous POS N
antioxidants POS N
and POS N
increasing POS N
production POS N
of POS N
the POS N
reactive POS N
oxygen POS N
species POS N
leading POS N
to POS N
the POS N
oxidant-mediated POS N
damage POS N
present POS N
in POS N
the POS N
diabetic POS N
context. POS N

vitamin POS N
C POS N
and/or POS N
E POS N
improve POS N
fasting POS N
blood POS N
sugar POS N
(FBS), POS N
HbA1c, POS N
lipid POS N
profile, POS N
insulin, POS N
homeostasis POS N
model POS N
assessment POS N
of POS N
insulin POS N
resistance POS N
(HOMA-IR), POS N
reduced POS N
glutathione POS N
(GSH); POS N
and POS N
Quantitative POS N
Insulin POS N
Sensitivity POS N
Check POS N
Index POS N
(QISCI) POS N
compared POS N
with POS N
diabetic POS N
patients POS N
group POS N
that POS N
received POS N
placebo. POS N

This POS N
study POS N
provided POS N
additional POS N
evidence POS N
on POS N
the POS N
beneficial POS N
effects POS N
of POS N
supplementing POS N
antioxidant POS N
vitamins POS N
in POS N
T2DM POS N
which POS N
could POS N
improve POS N
the POS N
clinical POS N
condition POS N
and POS N
attenuate POS N
or POS N
prevent POS N
diabetic POS N
pathogenesis POS N
and POS N
complications POS N
that, POS N
secondly POS N
to POS N
poor POS N
glycemic POS N
control, POS N
could POS N
attribute POS N
to POS N
the POS N
imbalance POS N
between POS N
the POS N
decline POS N
in POS N
the POS N
endogenous POS N
antioxidants POS N
and POS N
increasing POS N
production POS N
of POS N
the POS N
reactive POS N
oxygen POS N
species POS N
leading POS N
to POS N
the POS N
oxidant-mediated POS N
damage POS N
present POS N
in POS N
the POS N
diabetic POS N
context. POS N

there POS N
has POS N
been POS N
an POS N
increasing POS N
interest POS N
in POS N
the POS N
influence POS N
of POS N
antioxidant POS N
vitamins POS N
on POS N
the POS N
efficacy POS N
of POS N
oral POS N
hypoglycemic POS N
therapy POS N
in POS N
type POS N
2 POS N
diabetic POS N
patients POS N
(T2DM). POS N

Low POS N
serum POS N
vitamin POS N
D POS N
has POS N
been POS N
associated POS N
with POS N
metabolic POS N
syndrome POS N
and POS N
Non-alcoholic POS N
fatty POS N
liver POS N
disease POS N
(NAFLD). POS N

significant POS N
reduction POS N
of POS N
serum POS N
alkaline POS N
phosphatase POS N
and POS N
GGT POS N
were POS N
seen POS N
with POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
supplementation POS N
from POS N
baseline POS N
levels, POS N

Low POS N
serum POS N
vitamin POS N
D POS N
has POS N
been POS N
associated POS N
with POS N
metabolic POS N
syndrome POS N
and POS N
Non-alcoholic POS N
fatty POS N
liver POS N
disease POS N
(NAFLD). POS N

no POS N
beneficial POS N
effects POS N
was POS N
seen POS N
when POS N
comparing POS N
vitamin POS N
D, POS N
calcitriol POS N
and POS N
placebo POS N
groups POS N
at POS N
the POS N
end POS N
of POS N
trial. POS N

Low POS N
serum POS N
vitamin POS N
D POS N
has POS N
been POS N
associated POS N
with POS N
metabolic POS N
syndrome POS N
and POS N
Non-alcoholic POS N
fatty POS N
liver POS N
disease POS N
(NAFLD). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
placebo, POS N
calcitriol, POS N
vitamin POS N
D POS N
groups POS N
in POS N
terms POS N
of POS N
serum POS N
aminotransferase, POS N
alkaline POS N
phosphatase, POS N
serum POS N
GGT POS N
and POS N
lipid POS N
profile POS N
(P > 0.05). POS N

Low POS N
serum POS N
vitamin POS N
D POS N
has POS N
been POS N
associated POS N
with POS N
metabolic POS N
syndrome POS N
and POS N
Non-alcoholic POS N
fatty POS N
liver POS N
disease POS N
(NAFLD). POS N

Serum POS N
and POS N
gamma POS N
glutamyl POS N
transferase POS N
(GGT) POS N
level POS N
was POS N
also POS N
significantly POS N
decreased POS N
compared POS N
to POS N
the POS N
baseline POS N
levels POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment POS N
with POS N
vitamin POS N
D. POS N

Low POS N
serum POS N
vitamin POS N
D POS N
has POS N
been POS N
associated POS N
with POS N
metabolic POS N
syndrome POS N
and POS N
Non-alcoholic POS N
fatty POS N
liver POS N
disease POS N
(NAFLD). POS N

After POS N
12 POS N
weeks POS N
of POS N
treatment, POS N
serum POS N
alkaline POS N
phosphatase POS N
levels POS N
was POS N
significantly POS N
decreased POS N
from POS N
baseline POS N
levels POS N
in POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
treated POS N
groups POS N
(P < 0.05). POS N

significant POS N
reduction POS N
of POS N
serum POS N
alkaline POS N
phosphatase POS N
and POS N
GGT POS N
were POS N
seen POS N
with POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
supplementation POS N
from POS N
baseline POS N
levels, POS N

Low POS N
serum POS N
vitamin POS N
D POS N
has POS N
been POS N
associated POS N
with POS N
metabolic POS N
syndrome POS N
and POS N
Non-alcoholic POS N
fatty POS N
liver POS N
disease POS N
(NAFLD). POS N

significant POS N
reduction POS N
of POS N
serum POS N
alkaline POS N
phosphatase POS N
and POS N
GGT POS N
were POS N
seen POS N
with POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
supplementation POS N
from POS N
baseline POS N
levels, POS N

no POS N
beneficial POS N
effects POS N
was POS N
seen POS N
when POS N
comparing POS N
vitamin POS N
D, POS N
calcitriol POS N
and POS N
placebo POS N
groups POS N
at POS N
the POS N
end POS N
of POS N
trial. POS N

significant POS N
reduction POS N
of POS N
serum POS N
alkaline POS N
phosphatase POS N
and POS N
GGT POS N
were POS N
seen POS N
with POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
supplementation POS N
from POS N
baseline POS N
levels, POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
placebo, POS N
calcitriol, POS N
vitamin POS N
D POS N
groups POS N
in POS N
terms POS N
of POS N
serum POS N
aminotransferase, POS N
alkaline POS N
phosphatase, POS N
serum POS N
GGT POS N
and POS N
lipid POS N
profile POS N
(P > 0.05). POS N

significant POS N
reduction POS N
of POS N
serum POS N
alkaline POS N
phosphatase POS N
and POS N
GGT POS N
were POS N
seen POS N
with POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
supplementation POS N
from POS N
baseline POS N
levels, POS N

Serum POS N
and POS N
gamma POS N
glutamyl POS N
transferase POS N
(GGT) POS N
level POS N
was POS N
also POS N
significantly POS N
decreased POS N
compared POS N
to POS N
the POS N
baseline POS N
levels POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment POS N
with POS N
vitamin POS N
D. POS N

significant POS N
reduction POS N
of POS N
serum POS N
alkaline POS N
phosphatase POS N
and POS N
GGT POS N
were POS N
seen POS N
with POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
supplementation POS N
from POS N
baseline POS N
levels, POS N

After POS N
12 POS N
weeks POS N
of POS N
treatment, POS N
serum POS N
alkaline POS N
phosphatase POS N
levels POS N
was POS N
significantly POS N
decreased POS N
from POS N
baseline POS N
levels POS N
in POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
treated POS N
groups POS N
(P < 0.05). POS N

no POS N
beneficial POS N
effects POS N
was POS N
seen POS N
when POS N
comparing POS N
vitamin POS N
D, POS N
calcitriol POS N
and POS N
placebo POS N
groups POS N
at POS N
the POS N
end POS N
of POS N
trial. POS N

Low POS N
serum POS N
vitamin POS N
D POS N
has POS N
been POS N
associated POS N
with POS N
metabolic POS N
syndrome POS N
and POS N
Non-alcoholic POS N
fatty POS N
liver POS N
disease POS N
(NAFLD). POS N

no POS N
beneficial POS N
effects POS N
was POS N
seen POS N
when POS N
comparing POS N
vitamin POS N
D, POS N
calcitriol POS N
and POS N
placebo POS N
groups POS N
at POS N
the POS N
end POS N
of POS N
trial. POS N

significant POS N
reduction POS N
of POS N
serum POS N
alkaline POS N
phosphatase POS N
and POS N
GGT POS N
were POS N
seen POS N
with POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
supplementation POS N
from POS N
baseline POS N
levels, POS N

no POS N
beneficial POS N
effects POS N
was POS N
seen POS N
when POS N
comparing POS N
vitamin POS N
D, POS N
calcitriol POS N
and POS N
placebo POS N
groups POS N
at POS N
the POS N
end POS N
of POS N
trial. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
placebo, POS N
calcitriol, POS N
vitamin POS N
D POS N
groups POS N
in POS N
terms POS N
of POS N
serum POS N
aminotransferase, POS N
alkaline POS N
phosphatase, POS N
serum POS N
GGT POS N
and POS N
lipid POS N
profile POS N
(P > 0.05). POS N

no POS N
beneficial POS N
effects POS N
was POS N
seen POS N
when POS N
comparing POS N
vitamin POS N
D, POS N
calcitriol POS N
and POS N
placebo POS N
groups POS N
at POS N
the POS N
end POS N
of POS N
trial. POS N

Serum POS N
and POS N
gamma POS N
glutamyl POS N
transferase POS N
(GGT) POS N
level POS N
was POS N
also POS N
significantly POS N
decreased POS N
compared POS N
to POS N
the POS N
baseline POS N
levels POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment POS N
with POS N
vitamin POS N
D. POS N

no POS N
beneficial POS N
effects POS N
was POS N
seen POS N
when POS N
comparing POS N
vitamin POS N
D, POS N
calcitriol POS N
and POS N
placebo POS N
groups POS N
at POS N
the POS N
end POS N
of POS N
trial. POS N

After POS N
12 POS N
weeks POS N
of POS N
treatment, POS N
serum POS N
alkaline POS N
phosphatase POS N
levels POS N
was POS N
significantly POS N
decreased POS N
from POS N
baseline POS N
levels POS N
in POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
treated POS N
groups POS N
(P < 0.05). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
placebo, POS N
calcitriol, POS N
vitamin POS N
D POS N
groups POS N
in POS N
terms POS N
of POS N
serum POS N
aminotransferase, POS N
alkaline POS N
phosphatase, POS N
serum POS N
GGT POS N
and POS N
lipid POS N
profile POS N
(P > 0.05). POS N

Low POS N
serum POS N
vitamin POS N
D POS N
has POS N
been POS N
associated POS N
with POS N
metabolic POS N
syndrome POS N
and POS N
Non-alcoholic POS N
fatty POS N
liver POS N
disease POS N
(NAFLD). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
placebo, POS N
calcitriol, POS N
vitamin POS N
D POS N
groups POS N
in POS N
terms POS N
of POS N
serum POS N
aminotransferase, POS N
alkaline POS N
phosphatase, POS N
serum POS N
GGT POS N
and POS N
lipid POS N
profile POS N
(P > 0.05). POS N

significant POS N
reduction POS N
of POS N
serum POS N
alkaline POS N
phosphatase POS N
and POS N
GGT POS N
were POS N
seen POS N
with POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
supplementation POS N
from POS N
baseline POS N
levels, POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
placebo, POS N
calcitriol, POS N
vitamin POS N
D POS N
groups POS N
in POS N
terms POS N
of POS N
serum POS N
aminotransferase, POS N
alkaline POS N
phosphatase, POS N
serum POS N
GGT POS N
and POS N
lipid POS N
profile POS N
(P > 0.05). POS N

no POS N
beneficial POS N
effects POS N
was POS N
seen POS N
when POS N
comparing POS N
vitamin POS N
D, POS N
calcitriol POS N
and POS N
placebo POS N
groups POS N
at POS N
the POS N
end POS N
of POS N
trial. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
placebo, POS N
calcitriol, POS N
vitamin POS N
D POS N
groups POS N
in POS N
terms POS N
of POS N
serum POS N
aminotransferase, POS N
alkaline POS N
phosphatase, POS N
serum POS N
GGT POS N
and POS N
lipid POS N
profile POS N
(P > 0.05). POS N

Serum POS N
and POS N
gamma POS N
glutamyl POS N
transferase POS N
(GGT) POS N
level POS N
was POS N
also POS N
significantly POS N
decreased POS N
compared POS N
to POS N
the POS N
baseline POS N
levels POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment POS N
with POS N
vitamin POS N
D. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
placebo, POS N
calcitriol, POS N
vitamin POS N
D POS N
groups POS N
in POS N
terms POS N
of POS N
serum POS N
aminotransferase, POS N
alkaline POS N
phosphatase, POS N
serum POS N
GGT POS N
and POS N
lipid POS N
profile POS N
(P > 0.05). POS N

After POS N
12 POS N
weeks POS N
of POS N
treatment, POS N
serum POS N
alkaline POS N
phosphatase POS N
levels POS N
was POS N
significantly POS N
decreased POS N
from POS N
baseline POS N
levels POS N
in POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
treated POS N
groups POS N
(P < 0.05). POS N

Serum POS N
and POS N
gamma POS N
glutamyl POS N
transferase POS N
(GGT) POS N
level POS N
was POS N
also POS N
significantly POS N
decreased POS N
compared POS N
to POS N
the POS N
baseline POS N
levels POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment POS N
with POS N
vitamin POS N
D. POS N

Low POS N
serum POS N
vitamin POS N
D POS N
has POS N
been POS N
associated POS N
with POS N
metabolic POS N
syndrome POS N
and POS N
Non-alcoholic POS N
fatty POS N
liver POS N
disease POS N
(NAFLD). POS N

Serum POS N
and POS N
gamma POS N
glutamyl POS N
transferase POS N
(GGT) POS N
level POS N
was POS N
also POS N
significantly POS N
decreased POS N
compared POS N
to POS N
the POS N
baseline POS N
levels POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment POS N
with POS N
vitamin POS N
D. POS N

significant POS N
reduction POS N
of POS N
serum POS N
alkaline POS N
phosphatase POS N
and POS N
GGT POS N
were POS N
seen POS N
with POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
supplementation POS N
from POS N
baseline POS N
levels, POS N

Serum POS N
and POS N
gamma POS N
glutamyl POS N
transferase POS N
(GGT) POS N
level POS N
was POS N
also POS N
significantly POS N
decreased POS N
compared POS N
to POS N
the POS N
baseline POS N
levels POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment POS N
with POS N
vitamin POS N
D. POS N

no POS N
beneficial POS N
effects POS N
was POS N
seen POS N
when POS N
comparing POS N
vitamin POS N
D, POS N
calcitriol POS N
and POS N
placebo POS N
groups POS N
at POS N
the POS N
end POS N
of POS N
trial. POS N

Serum POS N
and POS N
gamma POS N
glutamyl POS N
transferase POS N
(GGT) POS N
level POS N
was POS N
also POS N
significantly POS N
decreased POS N
compared POS N
to POS N
the POS N
baseline POS N
levels POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment POS N
with POS N
vitamin POS N
D. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
placebo, POS N
calcitriol, POS N
vitamin POS N
D POS N
groups POS N
in POS N
terms POS N
of POS N
serum POS N
aminotransferase, POS N
alkaline POS N
phosphatase, POS N
serum POS N
GGT POS N
and POS N
lipid POS N
profile POS N
(P > 0.05). POS N

Serum POS N
and POS N
gamma POS N
glutamyl POS N
transferase POS N
(GGT) POS N
level POS N
was POS N
also POS N
significantly POS N
decreased POS N
compared POS N
to POS N
the POS N
baseline POS N
levels POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment POS N
with POS N
vitamin POS N
D. POS N

After POS N
12 POS N
weeks POS N
of POS N
treatment, POS N
serum POS N
alkaline POS N
phosphatase POS N
levels POS N
was POS N
significantly POS N
decreased POS N
from POS N
baseline POS N
levels POS N
in POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
treated POS N
groups POS N
(P < 0.05). POS N

After POS N
12 POS N
weeks POS N
of POS N
treatment, POS N
serum POS N
alkaline POS N
phosphatase POS N
levels POS N
was POS N
significantly POS N
decreased POS N
from POS N
baseline POS N
levels POS N
in POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
treated POS N
groups POS N
(P < 0.05). POS N

Low POS N
serum POS N
vitamin POS N
D POS N
has POS N
been POS N
associated POS N
with POS N
metabolic POS N
syndrome POS N
and POS N
Non-alcoholic POS N
fatty POS N
liver POS N
disease POS N
(NAFLD). POS N

After POS N
12 POS N
weeks POS N
of POS N
treatment, POS N
serum POS N
alkaline POS N
phosphatase POS N
levels POS N
was POS N
significantly POS N
decreased POS N
from POS N
baseline POS N
levels POS N
in POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
treated POS N
groups POS N
(P < 0.05). POS N

significant POS N
reduction POS N
of POS N
serum POS N
alkaline POS N
phosphatase POS N
and POS N
GGT POS N
were POS N
seen POS N
with POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
supplementation POS N
from POS N
baseline POS N
levels, POS N

After POS N
12 POS N
weeks POS N
of POS N
treatment, POS N
serum POS N
alkaline POS N
phosphatase POS N
levels POS N
was POS N
significantly POS N
decreased POS N
from POS N
baseline POS N
levels POS N
in POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
treated POS N
groups POS N
(P < 0.05). POS N

no POS N
beneficial POS N
effects POS N
was POS N
seen POS N
when POS N
comparing POS N
vitamin POS N
D, POS N
calcitriol POS N
and POS N
placebo POS N
groups POS N
at POS N
the POS N
end POS N
of POS N
trial. POS N

After POS N
12 POS N
weeks POS N
of POS N
treatment, POS N
serum POS N
alkaline POS N
phosphatase POS N
levels POS N
was POS N
significantly POS N
decreased POS N
from POS N
baseline POS N
levels POS N
in POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
treated POS N
groups POS N
(P < 0.05). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
placebo, POS N
calcitriol, POS N
vitamin POS N
D POS N
groups POS N
in POS N
terms POS N
of POS N
serum POS N
aminotransferase, POS N
alkaline POS N
phosphatase, POS N
serum POS N
GGT POS N
and POS N
lipid POS N
profile POS N
(P > 0.05). POS N

After POS N
12 POS N
weeks POS N
of POS N
treatment, POS N
serum POS N
alkaline POS N
phosphatase POS N
levels POS N
was POS N
significantly POS N
decreased POS N
from POS N
baseline POS N
levels POS N
in POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
treated POS N
groups POS N
(P < 0.05). POS N

Serum POS N
and POS N
gamma POS N
glutamyl POS N
transferase POS N
(GGT) POS N
level POS N
was POS N
also POS N
significantly POS N
decreased POS N
compared POS N
to POS N
the POS N
baseline POS N
levels POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment POS N
with POS N
vitamin POS N
D. POS N

Compared POS N
with POS N
the POS N
spironolactone POS N
group POS N
(n=95), POS N
the POS N
clonidine POS N
group POS N
(n=92) POS N
presented POS N
similar POS N
rates POS N
of POS N
achieving POS N
the POS N
primary POS N
end POS N
point POS N
(20.5% POS N
versus POS N
20.8%, POS N
respectively; POS N
relative POS N
risk, POS N
1.01 POS N
[0.55-1.88]; POS N
P=1.00). POS N

Secondary POS N
end POS N
point POS N
analysis POS N
showed POS N
similar POS N
office POS N
BP POS N
(33.3% POS N
versus POS N
29.3%) POS N
and POS N
ambulatory POS N
BP POS N
monitoring POS N
(44% POS N
versus POS N
46.2%) POS N
control POS N
for POS N
spironolactone POS N
and POS N
clonidine, POS N
respectively. POS N

Compared POS N
with POS N
the POS N
spironolactone POS N
group POS N
(n=95), POS N
the POS N
clonidine POS N
group POS N
(n=92) POS N
presented POS N
similar POS N
rates POS N
of POS N
achieving POS N
the POS N
primary POS N
end POS N
point POS N
(20.5% POS N
versus POS N
20.8%, POS N
respectively; POS N
relative POS N
risk, POS N
1.01 POS N
[0.55-1.88]; POS N
P=1.00). POS N

spironolactone POS N
promoted POS N
greater POS N
decrease POS N
in POS N
24-h POS N
systolic POS N
and POS N
diastolic POS N
BP POS N
and POS N
diastolic POS N
daytime POS N
ambulatory POS N
BP POS N
than POS N
clonidine. POS N

Compared POS N
with POS N
the POS N
spironolactone POS N
group POS N
(n=95), POS N
the POS N
clonidine POS N
group POS N
(n=92) POS N
presented POS N
similar POS N
rates POS N
of POS N
achieving POS N
the POS N
primary POS N
end POS N
point POS N
(20.5% POS N
versus POS N
20.8%, POS N
respectively; POS N
relative POS N
risk, POS N
1.01 POS N
[0.55-1.88]; POS N
P=1.00). POS N

clonidine POS N
was POS N
not POS N
superior POS N
to POS N
spironolactone POS N
in POS N
true POS N
resistant POS N
hypertensive POS N
patients, POS N
but POS N
the POS N
overall POS N
BP POS N
control POS N
was POS N
low POS N
(≈21%). POS N

Compared POS N
with POS N
the POS N
spironolactone POS N
group POS N
(n=95), POS N
the POS N
clonidine POS N
group POS N
(n=92) POS N
presented POS N
similar POS N
rates POS N
of POS N
achieving POS N
the POS N
primary POS N
end POS N
point POS N
(20.5% POS N
versus POS N
20.8%, POS N
respectively; POS N
relative POS N
risk, POS N
1.01 POS N
[0.55-1.88]; POS N
P=1.00). POS N

spironolactone POS N
is POS N
preferable POS N
for POS N
the POS N
fourth-drug POS N
therapy. POS N

Secondary POS N
end POS N
point POS N
analysis POS N
showed POS N
similar POS N
office POS N
BP POS N
(33.3% POS N
versus POS N
29.3%) POS N
and POS N
ambulatory POS N
BP POS N
monitoring POS N
(44% POS N
versus POS N
46.2%) POS N
control POS N
for POS N
spironolactone POS N
and POS N
clonidine, POS N
respectively. POS N

Compared POS N
with POS N
the POS N
spironolactone POS N
group POS N
(n=95), POS N
the POS N
clonidine POS N
group POS N
(n=92) POS N
presented POS N
similar POS N
rates POS N
of POS N
achieving POS N
the POS N
primary POS N
end POS N
point POS N
(20.5% POS N
versus POS N
20.8%, POS N
respectively; POS N
relative POS N
risk, POS N
1.01 POS N
[0.55-1.88]; POS N
P=1.00). POS N

Secondary POS N
end POS N
point POS N
analysis POS N
showed POS N
similar POS N
office POS N
BP POS N
(33.3% POS N
versus POS N
29.3%) POS N
and POS N
ambulatory POS N
BP POS N
monitoring POS N
(44% POS N
versus POS N
46.2%) POS N
control POS N
for POS N
spironolactone POS N
and POS N
clonidine, POS N
respectively. POS N

spironolactone POS N
promoted POS N
greater POS N
decrease POS N
in POS N
24-h POS N
systolic POS N
and POS N
diastolic POS N
BP POS N
and POS N
diastolic POS N
daytime POS N
ambulatory POS N
BP POS N
than POS N
clonidine. POS N

Secondary POS N
end POS N
point POS N
analysis POS N
showed POS N
similar POS N
office POS N
BP POS N
(33.3% POS N
versus POS N
29.3%) POS N
and POS N
ambulatory POS N
BP POS N
monitoring POS N
(44% POS N
versus POS N
46.2%) POS N
control POS N
for POS N
spironolactone POS N
and POS N
clonidine, POS N
respectively. POS N

clonidine POS N
was POS N
not POS N
superior POS N
to POS N
spironolactone POS N
in POS N
true POS N
resistant POS N
hypertensive POS N
patients, POS N
but POS N
the POS N
overall POS N
BP POS N
control POS N
was POS N
low POS N
(≈21%). POS N

Secondary POS N
end POS N
point POS N
analysis POS N
showed POS N
similar POS N
office POS N
BP POS N
(33.3% POS N
versus POS N
29.3%) POS N
and POS N
ambulatory POS N
BP POS N
monitoring POS N
(44% POS N
versus POS N
46.2%) POS N
control POS N
for POS N
spironolactone POS N
and POS N
clonidine, POS N
respectively. POS N

spironolactone POS N
is POS N
preferable POS N
for POS N
the POS N
fourth-drug POS N
therapy. POS N

spironolactone POS N
promoted POS N
greater POS N
decrease POS N
in POS N
24-h POS N
systolic POS N
and POS N
diastolic POS N
BP POS N
and POS N
diastolic POS N
daytime POS N
ambulatory POS N
BP POS N
than POS N
clonidine. POS N

Compared POS N
with POS N
the POS N
spironolactone POS N
group POS N
(n=95), POS N
the POS N
clonidine POS N
group POS N
(n=92) POS N
presented POS N
similar POS N
rates POS N
of POS N
achieving POS N
the POS N
primary POS N
end POS N
point POS N
(20.5% POS N
versus POS N
20.8%, POS N
respectively; POS N
relative POS N
risk, POS N
1.01 POS N
[0.55-1.88]; POS N
P=1.00). POS N

spironolactone POS N
promoted POS N
greater POS N
decrease POS N
in POS N
24-h POS N
systolic POS N
and POS N
diastolic POS N
BP POS N
and POS N
diastolic POS N
daytime POS N
ambulatory POS N
BP POS N
than POS N
clonidine. POS N

Secondary POS N
end POS N
point POS N
analysis POS N
showed POS N
similar POS N
office POS N
BP POS N
(33.3% POS N
versus POS N
29.3%) POS N
and POS N
ambulatory POS N
BP POS N
monitoring POS N
(44% POS N
versus POS N
46.2%) POS N
control POS N
for POS N
spironolactone POS N
and POS N
clonidine, POS N
respectively. POS N

spironolactone POS N
promoted POS N
greater POS N
decrease POS N
in POS N
24-h POS N
systolic POS N
and POS N
diastolic POS N
BP POS N
and POS N
diastolic POS N
daytime POS N
ambulatory POS N
BP POS N
than POS N
clonidine. POS N

clonidine POS N
was POS N
not POS N
superior POS N
to POS N
spironolactone POS N
in POS N
true POS N
resistant POS N
hypertensive POS N
patients, POS N
but POS N
the POS N
overall POS N
BP POS N
control POS N
was POS N
low POS N
(≈21%). POS N

spironolactone POS N
promoted POS N
greater POS N
decrease POS N
in POS N
24-h POS N
systolic POS N
and POS N
diastolic POS N
BP POS N
and POS N
diastolic POS N
daytime POS N
ambulatory POS N
BP POS N
than POS N
clonidine. POS N

spironolactone POS N
is POS N
preferable POS N
for POS N
the POS N
fourth-drug POS N
therapy. POS N

clonidine POS N
was POS N
not POS N
superior POS N
to POS N
spironolactone POS N
in POS N
true POS N
resistant POS N
hypertensive POS N
patients, POS N
but POS N
the POS N
overall POS N
BP POS N
control POS N
was POS N
low POS N
(≈21%). POS N

Compared POS N
with POS N
the POS N
spironolactone POS N
group POS N
(n=95), POS N
the POS N
clonidine POS N
group POS N
(n=92) POS N
presented POS N
similar POS N
rates POS N
of POS N
achieving POS N
the POS N
primary POS N
end POS N
point POS N
(20.5% POS N
versus POS N
20.8%, POS N
respectively; POS N
relative POS N
risk, POS N
1.01 POS N
[0.55-1.88]; POS N
P=1.00). POS N

clonidine POS N
was POS N
not POS N
superior POS N
to POS N
spironolactone POS N
in POS N
true POS N
resistant POS N
hypertensive POS N
patients, POS N
but POS N
the POS N
overall POS N
BP POS N
control POS N
was POS N
low POS N
(≈21%). POS N

Secondary POS N
end POS N
point POS N
analysis POS N
showed POS N
similar POS N
office POS N
BP POS N
(33.3% POS N
versus POS N
29.3%) POS N
and POS N
ambulatory POS N
BP POS N
monitoring POS N
(44% POS N
versus POS N
46.2%) POS N
control POS N
for POS N
spironolactone POS N
and POS N
clonidine, POS N
respectively. POS N

clonidine POS N
was POS N
not POS N
superior POS N
to POS N
spironolactone POS N
in POS N
true POS N
resistant POS N
hypertensive POS N
patients, POS N
but POS N
the POS N
overall POS N
BP POS N
control POS N
was POS N
low POS N
(≈21%). POS N

spironolactone POS N
promoted POS N
greater POS N
decrease POS N
in POS N
24-h POS N
systolic POS N
and POS N
diastolic POS N
BP POS N
and POS N
diastolic POS N
daytime POS N
ambulatory POS N
BP POS N
than POS N
clonidine. POS N

clonidine POS N
was POS N
not POS N
superior POS N
to POS N
spironolactone POS N
in POS N
true POS N
resistant POS N
hypertensive POS N
patients, POS N
but POS N
the POS N
overall POS N
BP POS N
control POS N
was POS N
low POS N
(≈21%). POS N

spironolactone POS N
is POS N
preferable POS N
for POS N
the POS N
fourth-drug POS N
therapy. POS N

spironolactone POS N
is POS N
preferable POS N
for POS N
the POS N
fourth-drug POS N
therapy. POS N

Compared POS N
with POS N
the POS N
spironolactone POS N
group POS N
(n=95), POS N
the POS N
clonidine POS N
group POS N
(n=92) POS N
presented POS N
similar POS N
rates POS N
of POS N
achieving POS N
the POS N
primary POS N
end POS N
point POS N
(20.5% POS N
versus POS N
20.8%, POS N
respectively; POS N
relative POS N
risk, POS N
1.01 POS N
[0.55-1.88]; POS N
P=1.00). POS N

spironolactone POS N
is POS N
preferable POS N
for POS N
the POS N
fourth-drug POS N
therapy. POS N

Secondary POS N
end POS N
point POS N
analysis POS N
showed POS N
similar POS N
office POS N
BP POS N
(33.3% POS N
versus POS N
29.3%) POS N
and POS N
ambulatory POS N
BP POS N
monitoring POS N
(44% POS N
versus POS N
46.2%) POS N
control POS N
for POS N
spironolactone POS N
and POS N
clonidine, POS N
respectively. POS N

spironolactone POS N
is POS N
preferable POS N
for POS N
the POS N
fourth-drug POS N
therapy. POS N

spironolactone POS N
promoted POS N
greater POS N
decrease POS N
in POS N
24-h POS N
systolic POS N
and POS N
diastolic POS N
BP POS N
and POS N
diastolic POS N
daytime POS N
ambulatory POS N
BP POS N
than POS N
clonidine. POS N

spironolactone POS N
is POS N
preferable POS N
for POS N
the POS N
fourth-drug POS N
therapy. POS N

clonidine POS N
was POS N
not POS N
superior POS N
to POS N
spironolactone POS N
in POS N
true POS N
resistant POS N
hypertensive POS N
patients, POS N
but POS N
the POS N
overall POS N
BP POS N
control POS N
was POS N
low POS N
(≈21%). POS N

Survival POS N
advantage POS N
was POS N
significant POS N
with POS N
regular POS N
surveillance POS N
but POS N
not POS N
with POS N
irregular POS N
surveillance. POS N

Patients POS N
in POS N
the POS N
regular POS N
surveillance POS N
group POS N
were POS N
diagnosed POS N
at POS N
earlier POS N
stages POS N
([very] POS N
early POS N
stage, POS N
64.4%) POS N
than POS N
the POS N
irregular POS N
surveillance POS N
(40.4%) POS N
or POS N
nonsurveillance POS N
(26.9%) POS N
groups POS N
and POS N
had POS N
more POS N
chance POS N
for POS N
curative POS N
treatments POS N
(52.4%) POS N
than POS N
the POS N
irregular POS N
surveillance POS N
(39.4%) POS N
or POS N
nonsurveillance POS N
(23.3%) POS N
groups POS N
(all POS N
P POS N
< POS N
0.001). POS N

Survival POS N
advantage POS N
was POS N
significant POS N
with POS N
regular POS N
surveillance POS N
but POS N
not POS N
with POS N
irregular POS N
surveillance. POS N

Mortality POS N
risk POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
regular POS N
surveillance POS N
group POS N
(adjusted POS N
hazard POS N
ratio POS N
[aHR], POS N
0.69; POS N
95% POS N
[CI], POS N
0.57-0.83) POS N
but POS N
not POS N
in POS N
the POS N
irregular POS N
surveillance POS N
group POS N
(aHR, POS N
0.94; POS N
95% POS N
CI, POS N
0.69-1.28) POS N
compared POS N
with POS N
the POS N
nonsurveillance POS N
group POS N
after POS N
adjusting POS N
for POS N
confounding POS N
factors POS N
and POS N
lead-time. POS N

Survival POS N
advantage POS N
was POS N
significant POS N
with POS N
regular POS N
surveillance POS N
but POS N
not POS N
with POS N
irregular POS N
surveillance. POS N

When POS N
the POS N
subjects POS N
were POS N
restricted POS N
to POS N
cirrhotic POS N
patients POS N
or POS N
Child-Pugh POS N
class POS N
A/B POS N
patients, POS N
similar POS N
results POS N
were POS N
obtained POS N
for POS N
mortality POS N
risk POS N
reduction POS N
between POS N
groups. POS N

Survival POS N
advantage POS N
was POS N
significant POS N
with POS N
regular POS N
surveillance POS N
but POS N
not POS N
with POS N
irregular POS N
surveillance. POS N

HCC POS N
surveillance POS N
was POS N
associated POS N
with POS N
longer POS N
survival POS N
owing POS N
to POS N
earlier POS N
diagnosis POS N
and POS N
curative POS N
treatment. POS N

Patients POS N
in POS N
the POS N
regular POS N
surveillance POS N
group POS N
were POS N
diagnosed POS N
at POS N
earlier POS N
stages POS N
([very] POS N
early POS N
stage, POS N
64.4%) POS N
than POS N
the POS N
irregular POS N
surveillance POS N
(40.4%) POS N
or POS N
nonsurveillance POS N
(26.9%) POS N
groups POS N
and POS N
had POS N
more POS N
chance POS N
for POS N
curative POS N
treatments POS N
(52.4%) POS N
than POS N
the POS N
irregular POS N
surveillance POS N
(39.4%) POS N
or POS N
nonsurveillance POS N
(23.3%) POS N
groups POS N
(all POS N
P POS N
< POS N
0.001). POS N

Survival POS N
advantage POS N
was POS N
significant POS N
with POS N
regular POS N
surveillance POS N
but POS N
not POS N
with POS N
irregular POS N
surveillance. POS N

Patients POS N
in POS N
the POS N
regular POS N
surveillance POS N
group POS N
were POS N
diagnosed POS N
at POS N
earlier POS N
stages POS N
([very] POS N
early POS N
stage, POS N
64.4%) POS N
than POS N
the POS N
irregular POS N
surveillance POS N
(40.4%) POS N
or POS N
nonsurveillance POS N
(26.9%) POS N
groups POS N
and POS N
had POS N
more POS N
chance POS N
for POS N
curative POS N
treatments POS N
(52.4%) POS N
than POS N
the POS N
irregular POS N
surveillance POS N
(39.4%) POS N
or POS N
nonsurveillance POS N
(23.3%) POS N
groups POS N
(all POS N
P POS N
< POS N
0.001). POS N

Mortality POS N
risk POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
regular POS N
surveillance POS N
group POS N
(adjusted POS N
hazard POS N
ratio POS N
[aHR], POS N
0.69; POS N
95% POS N
[CI], POS N
0.57-0.83) POS N
but POS N
not POS N
in POS N
the POS N
irregular POS N
surveillance POS N
group POS N
(aHR, POS N
0.94; POS N
95% POS N
CI, POS N
0.69-1.28) POS N
compared POS N
with POS N
the POS N
nonsurveillance POS N
group POS N
after POS N
adjusting POS N
for POS N
confounding POS N
factors POS N
and POS N
lead-time. POS N

Patients POS N
in POS N
the POS N
regular POS N
surveillance POS N
group POS N
were POS N
diagnosed POS N
at POS N
earlier POS N
stages POS N
([very] POS N
early POS N
stage, POS N
64.4%) POS N
than POS N
the POS N
irregular POS N
surveillance POS N
(40.4%) POS N
or POS N
nonsurveillance POS N
(26.9%) POS N
groups POS N
and POS N
had POS N
more POS N
chance POS N
for POS N
curative POS N
treatments POS N
(52.4%) POS N
than POS N
the POS N
irregular POS N
surveillance POS N
(39.4%) POS N
or POS N
nonsurveillance POS N
(23.3%) POS N
groups POS N
(all POS N
P POS N
< POS N
0.001). POS N

When POS N
the POS N
subjects POS N
were POS N
restricted POS N
to POS N
cirrhotic POS N
patients POS N
or POS N
Child-Pugh POS N
class POS N
A/B POS N
patients, POS N
similar POS N
results POS N
were POS N
obtained POS N
for POS N
mortality POS N
risk POS N
reduction POS N
between POS N
groups. POS N

Patients POS N
in POS N
the POS N
regular POS N
surveillance POS N
group POS N
were POS N
diagnosed POS N
at POS N
earlier POS N
stages POS N
([very] POS N
early POS N
stage, POS N
64.4%) POS N
than POS N
the POS N
irregular POS N
surveillance POS N
(40.4%) POS N
or POS N
nonsurveillance POS N
(26.9%) POS N
groups POS N
and POS N
had POS N
more POS N
chance POS N
for POS N
curative POS N
treatments POS N
(52.4%) POS N
than POS N
the POS N
irregular POS N
surveillance POS N
(39.4%) POS N
or POS N
nonsurveillance POS N
(23.3%) POS N
groups POS N
(all POS N
P POS N
< POS N
0.001). POS N

HCC POS N
surveillance POS N
was POS N
associated POS N
with POS N
longer POS N
survival POS N
owing POS N
to POS N
earlier POS N
diagnosis POS N
and POS N
curative POS N
treatment. POS N

Mortality POS N
risk POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
regular POS N
surveillance POS N
group POS N
(adjusted POS N
hazard POS N
ratio POS N
[aHR], POS N
0.69; POS N
95% POS N
[CI], POS N
0.57-0.83) POS N
but POS N
not POS N
in POS N
the POS N
irregular POS N
surveillance POS N
group POS N
(aHR, POS N
0.94; POS N
95% POS N
CI, POS N
0.69-1.28) POS N
compared POS N
with POS N
the POS N
nonsurveillance POS N
group POS N
after POS N
adjusting POS N
for POS N
confounding POS N
factors POS N
and POS N
lead-time. POS N

Survival POS N
advantage POS N
was POS N
significant POS N
with POS N
regular POS N
surveillance POS N
but POS N
not POS N
with POS N
irregular POS N
surveillance. POS N

Mortality POS N
risk POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
regular POS N
surveillance POS N
group POS N
(adjusted POS N
hazard POS N
ratio POS N
[aHR], POS N
0.69; POS N
95% POS N
[CI], POS N
0.57-0.83) POS N
but POS N
not POS N
in POS N
the POS N
irregular POS N
surveillance POS N
group POS N
(aHR, POS N
0.94; POS N
95% POS N
CI, POS N
0.69-1.28) POS N
compared POS N
with POS N
the POS N
nonsurveillance POS N
group POS N
after POS N
adjusting POS N
for POS N
confounding POS N
factors POS N
and POS N
lead-time. POS N

Patients POS N
in POS N
the POS N
regular POS N
surveillance POS N
group POS N
were POS N
diagnosed POS N
at POS N
earlier POS N
stages POS N
([very] POS N
early POS N
stage, POS N
64.4%) POS N
than POS N
the POS N
irregular POS N
surveillance POS N
(40.4%) POS N
or POS N
nonsurveillance POS N
(26.9%) POS N
groups POS N
and POS N
had POS N
more POS N
chance POS N
for POS N
curative POS N
treatments POS N
(52.4%) POS N
than POS N
the POS N
irregular POS N
surveillance POS N
(39.4%) POS N
or POS N
nonsurveillance POS N
(23.3%) POS N
groups POS N
(all POS N
P POS N
< POS N
0.001). POS N

Mortality POS N
risk POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
regular POS N
surveillance POS N
group POS N
(adjusted POS N
hazard POS N
ratio POS N
[aHR], POS N
0.69; POS N
95% POS N
[CI], POS N
0.57-0.83) POS N
but POS N
not POS N
in POS N
the POS N
irregular POS N
surveillance POS N
group POS N
(aHR, POS N
0.94; POS N
95% POS N
CI, POS N
0.69-1.28) POS N
compared POS N
with POS N
the POS N
nonsurveillance POS N
group POS N
after POS N
adjusting POS N
for POS N
confounding POS N
factors POS N
and POS N
lead-time. POS N

When POS N
the POS N
subjects POS N
were POS N
restricted POS N
to POS N
cirrhotic POS N
patients POS N
or POS N
Child-Pugh POS N
class POS N
A/B POS N
patients, POS N
similar POS N
results POS N
were POS N
obtained POS N
for POS N
mortality POS N
risk POS N
reduction POS N
between POS N
groups. POS N

Mortality POS N
risk POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
regular POS N
surveillance POS N
group POS N
(adjusted POS N
hazard POS N
ratio POS N
[aHR], POS N
0.69; POS N
95% POS N
[CI], POS N
0.57-0.83) POS N
but POS N
not POS N
in POS N
the POS N
irregular POS N
surveillance POS N
group POS N
(aHR, POS N
0.94; POS N
95% POS N
CI, POS N
0.69-1.28) POS N
compared POS N
with POS N
the POS N
nonsurveillance POS N
group POS N
after POS N
adjusting POS N
for POS N
confounding POS N
factors POS N
and POS N
lead-time. POS N

HCC POS N
surveillance POS N
was POS N
associated POS N
with POS N
longer POS N
survival POS N
owing POS N
to POS N
earlier POS N
diagnosis POS N
and POS N
curative POS N
treatment. POS N

When POS N
the POS N
subjects POS N
were POS N
restricted POS N
to POS N
cirrhotic POS N
patients POS N
or POS N
Child-Pugh POS N
class POS N
A/B POS N
patients, POS N
similar POS N
results POS N
were POS N
obtained POS N
for POS N
mortality POS N
risk POS N
reduction POS N
between POS N
groups. POS N

Survival POS N
advantage POS N
was POS N
significant POS N
with POS N
regular POS N
surveillance POS N
but POS N
not POS N
with POS N
irregular POS N
surveillance. POS N

When POS N
the POS N
subjects POS N
were POS N
restricted POS N
to POS N
cirrhotic POS N
patients POS N
or POS N
Child-Pugh POS N
class POS N
A/B POS N
patients, POS N
similar POS N
results POS N
were POS N
obtained POS N
for POS N
mortality POS N
risk POS N
reduction POS N
between POS N
groups. POS N

Patients POS N
in POS N
the POS N
regular POS N
surveillance POS N
group POS N
were POS N
diagnosed POS N
at POS N
earlier POS N
stages POS N
([very] POS N
early POS N
stage, POS N
64.4%) POS N
than POS N
the POS N
irregular POS N
surveillance POS N
(40.4%) POS N
or POS N
nonsurveillance POS N
(26.9%) POS N
groups POS N
and POS N
had POS N
more POS N
chance POS N
for POS N
curative POS N
treatments POS N
(52.4%) POS N
than POS N
the POS N
irregular POS N
surveillance POS N
(39.4%) POS N
or POS N
nonsurveillance POS N
(23.3%) POS N
groups POS N
(all POS N
P POS N
< POS N
0.001). POS N

When POS N
the POS N
subjects POS N
were POS N
restricted POS N
to POS N
cirrhotic POS N
patients POS N
or POS N
Child-Pugh POS N
class POS N
A/B POS N
patients, POS N
similar POS N
results POS N
were POS N
obtained POS N
for POS N
mortality POS N
risk POS N
reduction POS N
between POS N
groups. POS N

Mortality POS N
risk POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
regular POS N
surveillance POS N
group POS N
(adjusted POS N
hazard POS N
ratio POS N
[aHR], POS N
0.69; POS N
95% POS N
[CI], POS N
0.57-0.83) POS N
but POS N
not POS N
in POS N
the POS N
irregular POS N
surveillance POS N
group POS N
(aHR, POS N
0.94; POS N
95% POS N
CI, POS N
0.69-1.28) POS N
compared POS N
with POS N
the POS N
nonsurveillance POS N
group POS N
after POS N
adjusting POS N
for POS N
confounding POS N
factors POS N
and POS N
lead-time. POS N

When POS N
the POS N
subjects POS N
were POS N
restricted POS N
to POS N
cirrhotic POS N
patients POS N
or POS N
Child-Pugh POS N
class POS N
A/B POS N
patients, POS N
similar POS N
results POS N
were POS N
obtained POS N
for POS N
mortality POS N
risk POS N
reduction POS N
between POS N
groups. POS N

HCC POS N
surveillance POS N
was POS N
associated POS N
with POS N
longer POS N
survival POS N
owing POS N
to POS N
earlier POS N
diagnosis POS N
and POS N
curative POS N
treatment. POS N

HCC POS N
surveillance POS N
was POS N
associated POS N
with POS N
longer POS N
survival POS N
owing POS N
to POS N
earlier POS N
diagnosis POS N
and POS N
curative POS N
treatment. POS N

Survival POS N
advantage POS N
was POS N
significant POS N
with POS N
regular POS N
surveillance POS N
but POS N
not POS N
with POS N
irregular POS N
surveillance. POS N

HCC POS N
surveillance POS N
was POS N
associated POS N
with POS N
longer POS N
survival POS N
owing POS N
to POS N
earlier POS N
diagnosis POS N
and POS N
curative POS N
treatment. POS N

Patients POS N
in POS N
the POS N
regular POS N
surveillance POS N
group POS N
were POS N
diagnosed POS N
at POS N
earlier POS N
stages POS N
([very] POS N
early POS N
stage, POS N
64.4%) POS N
than POS N
the POS N
irregular POS N
surveillance POS N
(40.4%) POS N
or POS N
nonsurveillance POS N
(26.9%) POS N
groups POS N
and POS N
had POS N
more POS N
chance POS N
for POS N
curative POS N
treatments POS N
(52.4%) POS N
than POS N
the POS N
irregular POS N
surveillance POS N
(39.4%) POS N
or POS N
nonsurveillance POS N
(23.3%) POS N
groups POS N
(all POS N
P POS N
< POS N
0.001). POS N

HCC POS N
surveillance POS N
was POS N
associated POS N
with POS N
longer POS N
survival POS N
owing POS N
to POS N
earlier POS N
diagnosis POS N
and POS N
curative POS N
treatment. POS N

Mortality POS N
risk POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
regular POS N
surveillance POS N
group POS N
(adjusted POS N
hazard POS N
ratio POS N
[aHR], POS N
0.69; POS N
95% POS N
[CI], POS N
0.57-0.83) POS N
but POS N
not POS N
in POS N
the POS N
irregular POS N
surveillance POS N
group POS N
(aHR, POS N
0.94; POS N
95% POS N
CI, POS N
0.69-1.28) POS N
compared POS N
with POS N
the POS N
nonsurveillance POS N
group POS N
after POS N
adjusting POS N
for POS N
confounding POS N
factors POS N
and POS N
lead-time. POS N

HCC POS N
surveillance POS N
was POS N
associated POS N
with POS N
longer POS N
survival POS N
owing POS N
to POS N
earlier POS N
diagnosis POS N
and POS N
curative POS N
treatment. POS N

When POS N
the POS N
subjects POS N
were POS N
restricted POS N
to POS N
cirrhotic POS N
patients POS N
or POS N
Child-Pugh POS N
class POS N
A/B POS N
patients, POS N
similar POS N
results POS N
were POS N
obtained POS N
for POS N
mortality POS N
risk POS N
reduction POS N
between POS N
groups. POS N

Multivariate POS N
analysis POS N
indicated POS N
a POS N
positive POS N
relationship POS N
between POS N
6MWD POS N
and POS N
the POS N
Physical POS N
Composite POS N
Score POS N
for POS N
QoL POS N
(p=0.004), POS N

negative POS N
relationship POS N
between POS N
delta POS N
SPO2 POS N
and POS N
the POS N
Mental POS N
Composite POS N
Score POS N
(p=0.02), POS N
irrespective POS N
of POS N
other POS N
known POS N
prognostic POS N
factors POS N
(such POS N
as POS N
haemodynamics POS N
at POS N
right POS N
heart POS N
catheterization). POS N

Multivariate POS N
analysis POS N
indicated POS N
a POS N
positive POS N
relationship POS N
between POS N
6MWD POS N
and POS N
the POS N
Physical POS N
Composite POS N
Score POS N
for POS N
QoL POS N
(p=0.004), POS N

Depression POS N
and POS N
Trait-Anxiety POS N
were POS N
associated POS N
with POS N
a POS N
lower POS N
physical POS N
(p=0.001) POS N
and POS N
mental POS N
(p<0.001) POS N
QoL, POS N
respectively. POS N

Multivariate POS N
analysis POS N
indicated POS N
a POS N
positive POS N
relationship POS N
between POS N
6MWD POS N
and POS N
the POS N
Physical POS N
Composite POS N
Score POS N
for POS N
QoL POS N
(p=0.004), POS N

Psychological POS N
factors POS N
impact POS N
the POS N
HRQoL POS N
of POS N
treated POS N
patients. POS N

Multivariate POS N
analysis POS N
indicated POS N
a POS N
positive POS N
relationship POS N
between POS N
6MWD POS N
and POS N
the POS N
Physical POS N
Composite POS N
Score POS N
for POS N
QoL POS N
(p=0.004), POS N

A POS N
longitudinal POS N
and POS N
qualitative POS N
study POS N
should POS N
refine POS N
these POS N
results. POS N

negative POS N
relationship POS N
between POS N
delta POS N
SPO2 POS N
and POS N
the POS N
Mental POS N
Composite POS N
Score POS N
(p=0.02), POS N
irrespective POS N
of POS N
other POS N
known POS N
prognostic POS N
factors POS N
(such POS N
as POS N
haemodynamics POS N
at POS N
right POS N
heart POS N
catheterization). POS N

Multivariate POS N
analysis POS N
indicated POS N
a POS N
positive POS N
relationship POS N
between POS N
6MWD POS N
and POS N
the POS N
Physical POS N
Composite POS N
Score POS N
for POS N
QoL POS N
(p=0.004), POS N

negative POS N
relationship POS N
between POS N
delta POS N
SPO2 POS N
and POS N
the POS N
Mental POS N
Composite POS N
Score POS N
(p=0.02), POS N
irrespective POS N
of POS N
other POS N
known POS N
prognostic POS N
factors POS N
(such POS N
as POS N
haemodynamics POS N
at POS N
right POS N
heart POS N
catheterization). POS N

Depression POS N
and POS N
Trait-Anxiety POS N
were POS N
associated POS N
with POS N
a POS N
lower POS N
physical POS N
(p=0.001) POS N
and POS N
mental POS N
(p<0.001) POS N
QoL, POS N
respectively. POS N

negative POS N
relationship POS N
between POS N
delta POS N
SPO2 POS N
and POS N
the POS N
Mental POS N
Composite POS N
Score POS N
(p=0.02), POS N
irrespective POS N
of POS N
other POS N
known POS N
prognostic POS N
factors POS N
(such POS N
as POS N
haemodynamics POS N
at POS N
right POS N
heart POS N
catheterization). POS N

Psychological POS N
factors POS N
impact POS N
the POS N
HRQoL POS N
of POS N
treated POS N
patients. POS N

negative POS N
relationship POS N
between POS N
delta POS N
SPO2 POS N
and POS N
the POS N
Mental POS N
Composite POS N
Score POS N
(p=0.02), POS N
irrespective POS N
of POS N
other POS N
known POS N
prognostic POS N
factors POS N
(such POS N
as POS N
haemodynamics POS N
at POS N
right POS N
heart POS N
catheterization). POS N

A POS N
longitudinal POS N
and POS N
qualitative POS N
study POS N
should POS N
refine POS N
these POS N
results. POS N

Depression POS N
and POS N
Trait-Anxiety POS N
were POS N
associated POS N
with POS N
a POS N
lower POS N
physical POS N
(p=0.001) POS N
and POS N
mental POS N
(p<0.001) POS N
QoL, POS N
respectively. POS N

Multivariate POS N
analysis POS N
indicated POS N
a POS N
positive POS N
relationship POS N
between POS N
6MWD POS N
and POS N
the POS N
Physical POS N
Composite POS N
Score POS N
for POS N
QoL POS N
(p=0.004), POS N

Depression POS N
and POS N
Trait-Anxiety POS N
were POS N
associated POS N
with POS N
a POS N
lower POS N
physical POS N
(p=0.001) POS N
and POS N
mental POS N
(p<0.001) POS N
QoL, POS N
respectively. POS N

negative POS N
relationship POS N
between POS N
delta POS N
SPO2 POS N
and POS N
the POS N
Mental POS N
Composite POS N
Score POS N
(p=0.02), POS N
irrespective POS N
of POS N
other POS N
known POS N
prognostic POS N
factors POS N
(such POS N
as POS N
haemodynamics POS N
at POS N
right POS N
heart POS N
catheterization). POS N

Depression POS N
and POS N
Trait-Anxiety POS N
were POS N
associated POS N
with POS N
a POS N
lower POS N
physical POS N
(p=0.001) POS N
and POS N
mental POS N
(p<0.001) POS N
QoL, POS N
respectively. POS N

Psychological POS N
factors POS N
impact POS N
the POS N
HRQoL POS N
of POS N
treated POS N
patients. POS N

Depression POS N
and POS N
Trait-Anxiety POS N
were POS N
associated POS N
with POS N
a POS N
lower POS N
physical POS N
(p=0.001) POS N
and POS N
mental POS N
(p<0.001) POS N
QoL, POS N
respectively. POS N

A POS N
longitudinal POS N
and POS N
qualitative POS N
study POS N
should POS N
refine POS N
these POS N
results. POS N

Psychological POS N
factors POS N
impact POS N
the POS N
HRQoL POS N
of POS N
treated POS N
patients. POS N

Multivariate POS N
analysis POS N
indicated POS N
a POS N
positive POS N
relationship POS N
between POS N
6MWD POS N
and POS N
the POS N
Physical POS N
Composite POS N
Score POS N
for POS N
QoL POS N
(p=0.004), POS N

Psychological POS N
factors POS N
impact POS N
the POS N
HRQoL POS N
of POS N
treated POS N
patients. POS N

negative POS N
relationship POS N
between POS N
delta POS N
SPO2 POS N
and POS N
the POS N
Mental POS N
Composite POS N
Score POS N
(p=0.02), POS N
irrespective POS N
of POS N
other POS N
known POS N
prognostic POS N
factors POS N
(such POS N
as POS N
haemodynamics POS N
at POS N
right POS N
heart POS N
catheterization). POS N

Psychological POS N
factors POS N
impact POS N
the POS N
HRQoL POS N
of POS N
treated POS N
patients. POS N

Depression POS N
and POS N
Trait-Anxiety POS N
were POS N
associated POS N
with POS N
a POS N
lower POS N
physical POS N
(p=0.001) POS N
and POS N
mental POS N
(p<0.001) POS N
QoL, POS N
respectively. POS N

Psychological POS N
factors POS N
impact POS N
the POS N
HRQoL POS N
of POS N
treated POS N
patients. POS N

A POS N
longitudinal POS N
and POS N
qualitative POS N
study POS N
should POS N
refine POS N
these POS N
results. POS N

A POS N
longitudinal POS N
and POS N
qualitative POS N
study POS N
should POS N
refine POS N
these POS N
results. POS N

Multivariate POS N
analysis POS N
indicated POS N
a POS N
positive POS N
relationship POS N
between POS N
6MWD POS N
and POS N
the POS N
Physical POS N
Composite POS N
Score POS N
for POS N
QoL POS N
(p=0.004), POS N

A POS N
longitudinal POS N
and POS N
qualitative POS N
study POS N
should POS N
refine POS N
these POS N
results. POS N

negative POS N
relationship POS N
between POS N
delta POS N
SPO2 POS N
and POS N
the POS N
Mental POS N
Composite POS N
Score POS N
(p=0.02), POS N
irrespective POS N
of POS N
other POS N
known POS N
prognostic POS N
factors POS N
(such POS N
as POS N
haemodynamics POS N
at POS N
right POS N
heart POS N
catheterization). POS N

A POS N
longitudinal POS N
and POS N
qualitative POS N
study POS N
should POS N
refine POS N
these POS N
results. POS N

Depression POS N
and POS N
Trait-Anxiety POS N
were POS N
associated POS N
with POS N
a POS N
lower POS N
physical POS N
(p=0.001) POS N
and POS N
mental POS N
(p<0.001) POS N
QoL, POS N
respectively. POS N

A POS N
longitudinal POS N
and POS N
qualitative POS N
study POS N
should POS N
refine POS N
these POS N
results. POS N

Psychological POS N
factors POS N
impact POS N
the POS N
HRQoL POS N
of POS N
treated POS N
patients. POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

iron-containing POS N
multiple POS N
micronutrient POS N
may POS N
reduce POS N
the POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
including POS N
gestational POS N
hypertension POS N
or POS N
preeclampsia. POS N

The POS N
incidence POS N
of POS N
pregnancy-induced POS N
hypertension POS N
was POS N
7.1% POS N
(423/5923), POS N
6.3% POS N
(374/5933) POS N
and POS N
6.3% POS N
(372/5914) POS N
among POS N
the POS N
pregnant POS N
women POS N
who POS N
took POS N
folic POS N
acid POS N
only, POS N
iron-folic POS N
acid POS N
and POS N
multiple POS N
micronutrient POS N
supplements, POS N
respectively. POS N

iron-containing POS N
multiple POS N
micronutrient POS N
may POS N
reduce POS N
the POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
including POS N
gestational POS N
hypertension POS N
or POS N
preeclampsia. POS N

The POS N
adjusted POS N
odds POS N
ratios POS N
associated POS N
with POS N
iron-folic POS N
acid POS N
supplements POS N
and POS N
multiple POS N
micronutrient POS N
supplements POS N
for POS N
pregnancy-induced POS N
hypertension POS N
were POS N
both POS N
nearly POS N
0.88 POS N
(95% POS N
confidence POS N
interval, POS N
0.76-1.02), POS N
compared POS N
with POS N
folic POS N
acid POS N
supplements POS N
only. POS N

iron-containing POS N
multiple POS N
micronutrient POS N
may POS N
reduce POS N
the POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
including POS N
gestational POS N
hypertension POS N
or POS N
preeclampsia. POS N

among POS N
pregnant POS N
women POS N
aged POS N
20-24 POS N
years, POS N
iron-containing POS N
multiple POS N
micronutrient POS N
supplementation POS N
was POS N
associated POS N
with POS N
a POS N
reduced POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
compared POS N
with POS N
folic POS N
acid POS N
supplements POS N
only. POS N

iron-containing POS N
multiple POS N
micronutrient POS N
may POS N
reduce POS N
the POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
including POS N
gestational POS N
hypertension POS N
or POS N
preeclampsia. POS N

Among POS N
pregnant POS N
women POS N
aged POS N
20-24 POS N
years, POS N
iron-folic POS N
acid POS N
(adjusted POS N
odds POS N
ratios: POS N
0.81, POS N
95% POS N
confidence POS N
interval: POS N
0.67-0.96) POS N
or POS N
multiple POS N
micronutrient POS N
supplementation POS N
(adjusted POS N
odds POS N
ratios: POS N
0.83, POS N
95% POS N
confidence POS N
interval: POS N
0.70-0.99) POS N
can POS N
significantly POS N
reduce POS N
the POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
compared POS N
to POS N
folic POS N
acid POS N
supplementation. POS N

The POS N
incidence POS N
of POS N
pregnancy-induced POS N
hypertension POS N
was POS N
7.1% POS N
(423/5923), POS N
6.3% POS N
(374/5933) POS N
and POS N
6.3% POS N
(372/5914) POS N
among POS N
the POS N
pregnant POS N
women POS N
who POS N
took POS N
folic POS N
acid POS N
only, POS N
iron-folic POS N
acid POS N
and POS N
multiple POS N
micronutrient POS N
supplements, POS N
respectively. POS N

iron-containing POS N
multiple POS N
micronutrient POS N
may POS N
reduce POS N
the POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
including POS N
gestational POS N
hypertension POS N
or POS N
preeclampsia. POS N

The POS N
incidence POS N
of POS N
pregnancy-induced POS N
hypertension POS N
was POS N
7.1% POS N
(423/5923), POS N
6.3% POS N
(374/5933) POS N
and POS N
6.3% POS N
(372/5914) POS N
among POS N
the POS N
pregnant POS N
women POS N
who POS N
took POS N
folic POS N
acid POS N
only, POS N
iron-folic POS N
acid POS N
and POS N
multiple POS N
micronutrient POS N
supplements, POS N
respectively. POS N

The POS N
adjusted POS N
odds POS N
ratios POS N
associated POS N
with POS N
iron-folic POS N
acid POS N
supplements POS N
and POS N
multiple POS N
micronutrient POS N
supplements POS N
for POS N
pregnancy-induced POS N
hypertension POS N
were POS N
both POS N
nearly POS N
0.88 POS N
(95% POS N
confidence POS N
interval, POS N
0.76-1.02), POS N
compared POS N
with POS N
folic POS N
acid POS N
supplements POS N
only. POS N

The POS N
incidence POS N
of POS N
pregnancy-induced POS N
hypertension POS N
was POS N
7.1% POS N
(423/5923), POS N
6.3% POS N
(374/5933) POS N
and POS N
6.3% POS N
(372/5914) POS N
among POS N
the POS N
pregnant POS N
women POS N
who POS N
took POS N
folic POS N
acid POS N
only, POS N
iron-folic POS N
acid POS N
and POS N
multiple POS N
micronutrient POS N
supplements, POS N
respectively. POS N

among POS N
pregnant POS N
women POS N
aged POS N
20-24 POS N
years, POS N
iron-containing POS N
multiple POS N
micronutrient POS N
supplementation POS N
was POS N
associated POS N
with POS N
a POS N
reduced POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
compared POS N
with POS N
folic POS N
acid POS N
supplements POS N
only. POS N

The POS N
incidence POS N
of POS N
pregnancy-induced POS N
hypertension POS N
was POS N
7.1% POS N
(423/5923), POS N
6.3% POS N
(374/5933) POS N
and POS N
6.3% POS N
(372/5914) POS N
among POS N
the POS N
pregnant POS N
women POS N
who POS N
took POS N
folic POS N
acid POS N
only, POS N
iron-folic POS N
acid POS N
and POS N
multiple POS N
micronutrient POS N
supplements, POS N
respectively. POS N

Among POS N
pregnant POS N
women POS N
aged POS N
20-24 POS N
years, POS N
iron-folic POS N
acid POS N
(adjusted POS N
odds POS N
ratios: POS N
0.81, POS N
95% POS N
confidence POS N
interval: POS N
0.67-0.96) POS N
or POS N
multiple POS N
micronutrient POS N
supplementation POS N
(adjusted POS N
odds POS N
ratios: POS N
0.83, POS N
95% POS N
confidence POS N
interval: POS N
0.70-0.99) POS N
can POS N
significantly POS N
reduce POS N
the POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
compared POS N
to POS N
folic POS N
acid POS N
supplementation. POS N

The POS N
adjusted POS N
odds POS N
ratios POS N
associated POS N
with POS N
iron-folic POS N
acid POS N
supplements POS N
and POS N
multiple POS N
micronutrient POS N
supplements POS N
for POS N
pregnancy-induced POS N
hypertension POS N
were POS N
both POS N
nearly POS N
0.88 POS N
(95% POS N
confidence POS N
interval, POS N
0.76-1.02), POS N
compared POS N
with POS N
folic POS N
acid POS N
supplements POS N
only. POS N

iron-containing POS N
multiple POS N
micronutrient POS N
may POS N
reduce POS N
the POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
including POS N
gestational POS N
hypertension POS N
or POS N
preeclampsia. POS N

The POS N
adjusted POS N
odds POS N
ratios POS N
associated POS N
with POS N
iron-folic POS N
acid POS N
supplements POS N
and POS N
multiple POS N
micronutrient POS N
supplements POS N
for POS N
pregnancy-induced POS N
hypertension POS N
were POS N
both POS N
nearly POS N
0.88 POS N
(95% POS N
confidence POS N
interval, POS N
0.76-1.02), POS N
compared POS N
with POS N
folic POS N
acid POS N
supplements POS N
only. POS N

The POS N
incidence POS N
of POS N
pregnancy-induced POS N
hypertension POS N
was POS N
7.1% POS N
(423/5923), POS N
6.3% POS N
(374/5933) POS N
and POS N
6.3% POS N
(372/5914) POS N
among POS N
the POS N
pregnant POS N
women POS N
who POS N
took POS N
folic POS N
acid POS N
only, POS N
iron-folic POS N
acid POS N
and POS N
multiple POS N
micronutrient POS N
supplements, POS N
respectively. POS N

The POS N
adjusted POS N
odds POS N
ratios POS N
associated POS N
with POS N
iron-folic POS N
acid POS N
supplements POS N
and POS N
multiple POS N
micronutrient POS N
supplements POS N
for POS N
pregnancy-induced POS N
hypertension POS N
were POS N
both POS N
nearly POS N
0.88 POS N
(95% POS N
confidence POS N
interval, POS N
0.76-1.02), POS N
compared POS N
with POS N
folic POS N
acid POS N
supplements POS N
only. POS N

among POS N
pregnant POS N
women POS N
aged POS N
20-24 POS N
years, POS N
iron-containing POS N
multiple POS N
micronutrient POS N
supplementation POS N
was POS N
associated POS N
with POS N
a POS N
reduced POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
compared POS N
with POS N
folic POS N
acid POS N
supplements POS N
only. POS N

The POS N
adjusted POS N
odds POS N
ratios POS N
associated POS N
with POS N
iron-folic POS N
acid POS N
supplements POS N
and POS N
multiple POS N
micronutrient POS N
supplements POS N
for POS N
pregnancy-induced POS N
hypertension POS N
were POS N
both POS N
nearly POS N
0.88 POS N
(95% POS N
confidence POS N
interval, POS N
0.76-1.02), POS N
compared POS N
with POS N
folic POS N
acid POS N
supplements POS N
only. POS N

Among POS N
pregnant POS N
women POS N
aged POS N
20-24 POS N
years, POS N
iron-folic POS N
acid POS N
(adjusted POS N
odds POS N
ratios: POS N
0.81, POS N
95% POS N
confidence POS N
interval: POS N
0.67-0.96) POS N
or POS N
multiple POS N
micronutrient POS N
supplementation POS N
(adjusted POS N
odds POS N
ratios: POS N
0.83, POS N
95% POS N
confidence POS N
interval: POS N
0.70-0.99) POS N
can POS N
significantly POS N
reduce POS N
the POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
compared POS N
to POS N
folic POS N
acid POS N
supplementation. POS N

among POS N
pregnant POS N
women POS N
aged POS N
20-24 POS N
years, POS N
iron-containing POS N
multiple POS N
micronutrient POS N
supplementation POS N
was POS N
associated POS N
with POS N
a POS N
reduced POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
compared POS N
with POS N
folic POS N
acid POS N
supplements POS N
only. POS N

iron-containing POS N
multiple POS N
micronutrient POS N
may POS N
reduce POS N
the POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
including POS N
gestational POS N
hypertension POS N
or POS N
preeclampsia. POS N

among POS N
pregnant POS N
women POS N
aged POS N
20-24 POS N
years, POS N
iron-containing POS N
multiple POS N
micronutrient POS N
supplementation POS N
was POS N
associated POS N
with POS N
a POS N
reduced POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
compared POS N
with POS N
folic POS N
acid POS N
supplements POS N
only. POS N

The POS N
incidence POS N
of POS N
pregnancy-induced POS N
hypertension POS N
was POS N
7.1% POS N
(423/5923), POS N
6.3% POS N
(374/5933) POS N
and POS N
6.3% POS N
(372/5914) POS N
among POS N
the POS N
pregnant POS N
women POS N
who POS N
took POS N
folic POS N
acid POS N
only, POS N
iron-folic POS N
acid POS N
and POS N
multiple POS N
micronutrient POS N
supplements, POS N
respectively. POS N

among POS N
pregnant POS N
women POS N
aged POS N
20-24 POS N
years, POS N
iron-containing POS N
multiple POS N
micronutrient POS N
supplementation POS N
was POS N
associated POS N
with POS N
a POS N
reduced POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
compared POS N
with POS N
folic POS N
acid POS N
supplements POS N
only. POS N

The POS N
adjusted POS N
odds POS N
ratios POS N
associated POS N
with POS N
iron-folic POS N
acid POS N
supplements POS N
and POS N
multiple POS N
micronutrient POS N
supplements POS N
for POS N
pregnancy-induced POS N
hypertension POS N
were POS N
both POS N
nearly POS N
0.88 POS N
(95% POS N
confidence POS N
interval, POS N
0.76-1.02), POS N
compared POS N
with POS N
folic POS N
acid POS N
supplements POS N
only. POS N

among POS N
pregnant POS N
women POS N
aged POS N
20-24 POS N
years, POS N
iron-containing POS N
multiple POS N
micronutrient POS N
supplementation POS N
was POS N
associated POS N
with POS N
a POS N
reduced POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
compared POS N
with POS N
folic POS N
acid POS N
supplements POS N
only. POS N

Among POS N
pregnant POS N
women POS N
aged POS N
20-24 POS N
years, POS N
iron-folic POS N
acid POS N
(adjusted POS N
odds POS N
ratios: POS N
0.81, POS N
95% POS N
confidence POS N
interval: POS N
0.67-0.96) POS N
or POS N
multiple POS N
micronutrient POS N
supplementation POS N
(adjusted POS N
odds POS N
ratios: POS N
0.83, POS N
95% POS N
confidence POS N
interval: POS N
0.70-0.99) POS N
can POS N
significantly POS N
reduce POS N
the POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
compared POS N
to POS N
folic POS N
acid POS N
supplementation. POS N

Among POS N
pregnant POS N
women POS N
aged POS N
20-24 POS N
years, POS N
iron-folic POS N
acid POS N
(adjusted POS N
odds POS N
ratios: POS N
0.81, POS N
95% POS N
confidence POS N
interval: POS N
0.67-0.96) POS N
or POS N
multiple POS N
micronutrient POS N
supplementation POS N
(adjusted POS N
odds POS N
ratios: POS N
0.83, POS N
95% POS N
confidence POS N
interval: POS N
0.70-0.99) POS N
can POS N
significantly POS N
reduce POS N
the POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
compared POS N
to POS N
folic POS N
acid POS N
supplementation. POS N

iron-containing POS N
multiple POS N
micronutrient POS N
may POS N
reduce POS N
the POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
including POS N
gestational POS N
hypertension POS N
or POS N
preeclampsia. POS N

Among POS N
pregnant POS N
women POS N
aged POS N
20-24 POS N
years, POS N
iron-folic POS N
acid POS N
(adjusted POS N
odds POS N
ratios: POS N
0.81, POS N
95% POS N
confidence POS N
interval: POS N
0.67-0.96) POS N
or POS N
multiple POS N
micronutrient POS N
supplementation POS N
(adjusted POS N
odds POS N
ratios: POS N
0.83, POS N
95% POS N
confidence POS N
interval: POS N
0.70-0.99) POS N
can POS N
significantly POS N
reduce POS N
the POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
compared POS N
to POS N
folic POS N
acid POS N
supplementation. POS N

The POS N
incidence POS N
of POS N
pregnancy-induced POS N
hypertension POS N
was POS N
7.1% POS N
(423/5923), POS N
6.3% POS N
(374/5933) POS N
and POS N
6.3% POS N
(372/5914) POS N
among POS N
the POS N
pregnant POS N
women POS N
who POS N
took POS N
folic POS N
acid POS N
only, POS N
iron-folic POS N
acid POS N
and POS N
multiple POS N
micronutrient POS N
supplements, POS N
respectively. POS N

Among POS N
pregnant POS N
women POS N
aged POS N
20-24 POS N
years, POS N
iron-folic POS N
acid POS N
(adjusted POS N
odds POS N
ratios: POS N
0.81, POS N
95% POS N
confidence POS N
interval: POS N
0.67-0.96) POS N
or POS N
multiple POS N
micronutrient POS N
supplementation POS N
(adjusted POS N
odds POS N
ratios: POS N
0.83, POS N
95% POS N
confidence POS N
interval: POS N
0.70-0.99) POS N
can POS N
significantly POS N
reduce POS N
the POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
compared POS N
to POS N
folic POS N
acid POS N
supplementation. POS N

The POS N
adjusted POS N
odds POS N
ratios POS N
associated POS N
with POS N
iron-folic POS N
acid POS N
supplements POS N
and POS N
multiple POS N
micronutrient POS N
supplements POS N
for POS N
pregnancy-induced POS N
hypertension POS N
were POS N
both POS N
nearly POS N
0.88 POS N
(95% POS N
confidence POS N
interval, POS N
0.76-1.02), POS N
compared POS N
with POS N
folic POS N
acid POS N
supplements POS N
only. POS N

Among POS N
pregnant POS N
women POS N
aged POS N
20-24 POS N
years, POS N
iron-folic POS N
acid POS N
(adjusted POS N
odds POS N
ratios: POS N
0.81, POS N
95% POS N
confidence POS N
interval: POS N
0.67-0.96) POS N
or POS N
multiple POS N
micronutrient POS N
supplementation POS N
(adjusted POS N
odds POS N
ratios: POS N
0.83, POS N
95% POS N
confidence POS N
interval: POS N
0.70-0.99) POS N
can POS N
significantly POS N
reduce POS N
the POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
compared POS N
to POS N
folic POS N
acid POS N
supplementation. POS N

among POS N
pregnant POS N
women POS N
aged POS N
20-24 POS N
years, POS N
iron-containing POS N
multiple POS N
micronutrient POS N
supplementation POS N
was POS N
associated POS N
with POS N
a POS N
reduced POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
compared POS N
with POS N
folic POS N
acid POS N
supplements POS N
only. POS N

At POS N
radical POS N
prostatectomy, POS N
pathological POS N
variables POS N
were POS N
not POS N
significantly POS N
different POS N
in POS N
the POS N
two POS N
groups. POS N

Serum POS N
testosterone POS N
level POS N
was POS N
significantly POS N
higher POS N
(mean POS N
359.2 POS N
compared POS N
to POS N
10.5, POS N
P POS N
< POS N
0.001), POS N

At POS N
radical POS N
prostatectomy, POS N
pathological POS N
variables POS N
were POS N
not POS N
significantly POS N
different POS N
in POS N
the POS N
two POS N
groups. POS N

complete POS N
response POS N
rate POS N
of POS N
PSA POS N
(13% POS N
compared POS N
to POS N
57%, POS N
P POS N
= POS N
0.028) POS N
and POS N
rate POS N
of POS N
downsizing POS N
of POS N
prostate POS N
volume POS N
(mean, POS N
-17.7% POS N
compared POS N
to POS N
-35.4%, POS N
P POS N
= POS N
0.038) POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

At POS N
radical POS N
prostatectomy, POS N
pathological POS N
variables POS N
were POS N
not POS N
significantly POS N
different POS N
in POS N
the POS N
two POS N
groups. POS N

After POS N
neoadjuvant POS N
hormone POS N
therapy, POS N
the POS N
scores POS N
on POS N
the POS N
sexual POS N
problem POS N
domain POS N
of POS N
EORTC-P POS N
(P POS N
= POS N
0.033) POS N
and POS N
sexual POS N
desire POS N
score POS N
of POS N
SMUF POS N
(P POS N
= POS N
0.021) POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

At POS N
radical POS N
prostatectomy, POS N
pathological POS N
variables POS N
were POS N
not POS N
significantly POS N
different POS N
in POS N
the POS N
two POS N
groups. POS N

This POS N
study POS N
suggests POS N
that POS N
flutamide POS N
monotherapy POS N
can POS N
be POS N
an POS N
acceptable POS N
modality POS N
as POS N
an POS N
option POS N
for POS N
neoadjuvant POS N
hormone POS N
therapy. POS N

At POS N
radical POS N
prostatectomy, POS N
pathological POS N
variables POS N
were POS N
not POS N
significantly POS N
different POS N
in POS N
the POS N
two POS N
groups. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
34 POS N
months POS N
after POS N
prostatectomy, POS N
biochemical POS N
failure-free POS N
survival POS N
rate POS N
in POS N
the POS N
flutamide POS N
group POS N
did POS N
not POS N
differ POS N
from POS N
that POS N
in POS N
the POS N
LHRH POS N
group. POS N

Serum POS N
testosterone POS N
level POS N
was POS N
significantly POS N
higher POS N
(mean POS N
359.2 POS N
compared POS N
to POS N
10.5, POS N
P POS N
< POS N
0.001), POS N

At POS N
radical POS N
prostatectomy, POS N
pathological POS N
variables POS N
were POS N
not POS N
significantly POS N
different POS N
in POS N
the POS N
two POS N
groups. POS N

Serum POS N
testosterone POS N
level POS N
was POS N
significantly POS N
higher POS N
(mean POS N
359.2 POS N
compared POS N
to POS N
10.5, POS N
P POS N
< POS N
0.001), POS N

complete POS N
response POS N
rate POS N
of POS N
PSA POS N
(13% POS N
compared POS N
to POS N
57%, POS N
P POS N
= POS N
0.028) POS N
and POS N
rate POS N
of POS N
downsizing POS N
of POS N
prostate POS N
volume POS N
(mean, POS N
-17.7% POS N
compared POS N
to POS N
-35.4%, POS N
P POS N
= POS N
0.038) POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

Serum POS N
testosterone POS N
level POS N
was POS N
significantly POS N
higher POS N
(mean POS N
359.2 POS N
compared POS N
to POS N
10.5, POS N
P POS N
< POS N
0.001), POS N

After POS N
neoadjuvant POS N
hormone POS N
therapy, POS N
the POS N
scores POS N
on POS N
the POS N
sexual POS N
problem POS N
domain POS N
of POS N
EORTC-P POS N
(P POS N
= POS N
0.033) POS N
and POS N
sexual POS N
desire POS N
score POS N
of POS N
SMUF POS N
(P POS N
= POS N
0.021) POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

Serum POS N
testosterone POS N
level POS N
was POS N
significantly POS N
higher POS N
(mean POS N
359.2 POS N
compared POS N
to POS N
10.5, POS N
P POS N
< POS N
0.001), POS N

This POS N
study POS N
suggests POS N
that POS N
flutamide POS N
monotherapy POS N
can POS N
be POS N
an POS N
acceptable POS N
modality POS N
as POS N
an POS N
option POS N
for POS N
neoadjuvant POS N
hormone POS N
therapy. POS N

Serum POS N
testosterone POS N
level POS N
was POS N
significantly POS N
higher POS N
(mean POS N
359.2 POS N
compared POS N
to POS N
10.5, POS N
P POS N
< POS N
0.001), POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
34 POS N
months POS N
after POS N
prostatectomy, POS N
biochemical POS N
failure-free POS N
survival POS N
rate POS N
in POS N
the POS N
flutamide POS N
group POS N
did POS N
not POS N
differ POS N
from POS N
that POS N
in POS N
the POS N
LHRH POS N
group. POS N

complete POS N
response POS N
rate POS N
of POS N
PSA POS N
(13% POS N
compared POS N
to POS N
57%, POS N
P POS N
= POS N
0.028) POS N
and POS N
rate POS N
of POS N
downsizing POS N
of POS N
prostate POS N
volume POS N
(mean, POS N
-17.7% POS N
compared POS N
to POS N
-35.4%, POS N
P POS N
= POS N
0.038) POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

At POS N
radical POS N
prostatectomy, POS N
pathological POS N
variables POS N
were POS N
not POS N
significantly POS N
different POS N
in POS N
the POS N
two POS N
groups. POS N

complete POS N
response POS N
rate POS N
of POS N
PSA POS N
(13% POS N
compared POS N
to POS N
57%, POS N
P POS N
= POS N
0.028) POS N
and POS N
rate POS N
of POS N
downsizing POS N
of POS N
prostate POS N
volume POS N
(mean, POS N
-17.7% POS N
compared POS N
to POS N
-35.4%, POS N
P POS N
= POS N
0.038) POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

Serum POS N
testosterone POS N
level POS N
was POS N
significantly POS N
higher POS N
(mean POS N
359.2 POS N
compared POS N
to POS N
10.5, POS N
P POS N
< POS N
0.001), POS N

complete POS N
response POS N
rate POS N
of POS N
PSA POS N
(13% POS N
compared POS N
to POS N
57%, POS N
P POS N
= POS N
0.028) POS N
and POS N
rate POS N
of POS N
downsizing POS N
of POS N
prostate POS N
volume POS N
(mean, POS N
-17.7% POS N
compared POS N
to POS N
-35.4%, POS N
P POS N
= POS N
0.038) POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

After POS N
neoadjuvant POS N
hormone POS N
therapy, POS N
the POS N
scores POS N
on POS N
the POS N
sexual POS N
problem POS N
domain POS N
of POS N
EORTC-P POS N
(P POS N
= POS N
0.033) POS N
and POS N
sexual POS N
desire POS N
score POS N
of POS N
SMUF POS N
(P POS N
= POS N
0.021) POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

complete POS N
response POS N
rate POS N
of POS N
PSA POS N
(13% POS N
compared POS N
to POS N
57%, POS N
P POS N
= POS N
0.028) POS N
and POS N
rate POS N
of POS N
downsizing POS N
of POS N
prostate POS N
volume POS N
(mean, POS N
-17.7% POS N
compared POS N
to POS N
-35.4%, POS N
P POS N
= POS N
0.038) POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

This POS N
study POS N
suggests POS N
that POS N
flutamide POS N
monotherapy POS N
can POS N
be POS N
an POS N
acceptable POS N
modality POS N
as POS N
an POS N
option POS N
for POS N
neoadjuvant POS N
hormone POS N
therapy. POS N

complete POS N
response POS N
rate POS N
of POS N
PSA POS N
(13% POS N
compared POS N
to POS N
57%, POS N
P POS N
= POS N
0.028) POS N
and POS N
rate POS N
of POS N
downsizing POS N
of POS N
prostate POS N
volume POS N
(mean, POS N
-17.7% POS N
compared POS N
to POS N
-35.4%, POS N
P POS N
= POS N
0.038) POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
34 POS N
months POS N
after POS N
prostatectomy, POS N
biochemical POS N
failure-free POS N
survival POS N
rate POS N
in POS N
the POS N
flutamide POS N
group POS N
did POS N
not POS N
differ POS N
from POS N
that POS N
in POS N
the POS N
LHRH POS N
group. POS N

After POS N
neoadjuvant POS N
hormone POS N
therapy, POS N
the POS N
scores POS N
on POS N
the POS N
sexual POS N
problem POS N
domain POS N
of POS N
EORTC-P POS N
(P POS N
= POS N
0.033) POS N
and POS N
sexual POS N
desire POS N
score POS N
of POS N
SMUF POS N
(P POS N
= POS N
0.021) POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

At POS N
radical POS N
prostatectomy, POS N
pathological POS N
variables POS N
were POS N
not POS N
significantly POS N
different POS N
in POS N
the POS N
two POS N
groups. POS N

After POS N
neoadjuvant POS N
hormone POS N
therapy, POS N
the POS N
scores POS N
on POS N
the POS N
sexual POS N
problem POS N
domain POS N
of POS N
EORTC-P POS N
(P POS N
= POS N
0.033) POS N
and POS N
sexual POS N
desire POS N
score POS N
of POS N
SMUF POS N
(P POS N
= POS N
0.021) POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

Serum POS N
testosterone POS N
level POS N
was POS N
significantly POS N
higher POS N
(mean POS N
359.2 POS N
compared POS N
to POS N
10.5, POS N
P POS N
< POS N
0.001), POS N

After POS N
neoadjuvant POS N
hormone POS N
therapy, POS N
the POS N
scores POS N
on POS N
the POS N
sexual POS N
problem POS N
domain POS N
of POS N
EORTC-P POS N
(P POS N
= POS N
0.033) POS N
and POS N
sexual POS N
desire POS N
score POS N
of POS N
SMUF POS N
(P POS N
= POS N
0.021) POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

complete POS N
response POS N
rate POS N
of POS N
PSA POS N
(13% POS N
compared POS N
to POS N
57%, POS N
P POS N
= POS N
0.028) POS N
and POS N
rate POS N
of POS N
downsizing POS N
of POS N
prostate POS N
volume POS N
(mean, POS N
-17.7% POS N
compared POS N
to POS N
-35.4%, POS N
P POS N
= POS N
0.038) POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

After POS N
neoadjuvant POS N
hormone POS N
therapy, POS N
the POS N
scores POS N
on POS N
the POS N
sexual POS N
problem POS N
domain POS N
of POS N
EORTC-P POS N
(P POS N
= POS N
0.033) POS N
and POS N
sexual POS N
desire POS N
score POS N
of POS N
SMUF POS N
(P POS N
= POS N
0.021) POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

This POS N
study POS N
suggests POS N
that POS N
flutamide POS N
monotherapy POS N
can POS N
be POS N
an POS N
acceptable POS N
modality POS N
as POS N
an POS N
option POS N
for POS N
neoadjuvant POS N
hormone POS N
therapy. POS N

After POS N
neoadjuvant POS N
hormone POS N
therapy, POS N
the POS N
scores POS N
on POS N
the POS N
sexual POS N
problem POS N
domain POS N
of POS N
EORTC-P POS N
(P POS N
= POS N
0.033) POS N
and POS N
sexual POS N
desire POS N
score POS N
of POS N
SMUF POS N
(P POS N
= POS N
0.021) POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
34 POS N
months POS N
after POS N
prostatectomy, POS N
biochemical POS N
failure-free POS N
survival POS N
rate POS N
in POS N
the POS N
flutamide POS N
group POS N
did POS N
not POS N
differ POS N
from POS N
that POS N
in POS N
the POS N
LHRH POS N
group. POS N

This POS N
study POS N
suggests POS N
that POS N
flutamide POS N
monotherapy POS N
can POS N
be POS N
an POS N
acceptable POS N
modality POS N
as POS N
an POS N
option POS N
for POS N
neoadjuvant POS N
hormone POS N
therapy. POS N

At POS N
radical POS N
prostatectomy, POS N
pathological POS N
variables POS N
were POS N
not POS N
significantly POS N
different POS N
in POS N
the POS N
two POS N
groups. POS N

This POS N
study POS N
suggests POS N
that POS N
flutamide POS N
monotherapy POS N
can POS N
be POS N
an POS N
acceptable POS N
modality POS N
as POS N
an POS N
option POS N
for POS N
neoadjuvant POS N
hormone POS N
therapy. POS N

Serum POS N
testosterone POS N
level POS N
was POS N
significantly POS N
higher POS N
(mean POS N
359.2 POS N
compared POS N
to POS N
10.5, POS N
P POS N
< POS N
0.001), POS N

This POS N
study POS N
suggests POS N
that POS N
flutamide POS N
monotherapy POS N
can POS N
be POS N
an POS N
acceptable POS N
modality POS N
as POS N
an POS N
option POS N
for POS N
neoadjuvant POS N
hormone POS N
therapy. POS N

complete POS N
response POS N
rate POS N
of POS N
PSA POS N
(13% POS N
compared POS N
to POS N
57%, POS N
P POS N
= POS N
0.028) POS N
and POS N
rate POS N
of POS N
downsizing POS N
of POS N
prostate POS N
volume POS N
(mean, POS N
-17.7% POS N
compared POS N
to POS N
-35.4%, POS N
P POS N
= POS N
0.038) POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

This POS N
study POS N
suggests POS N
that POS N
flutamide POS N
monotherapy POS N
can POS N
be POS N
an POS N
acceptable POS N
modality POS N
as POS N
an POS N
option POS N
for POS N
neoadjuvant POS N
hormone POS N
therapy. POS N

After POS N
neoadjuvant POS N
hormone POS N
therapy, POS N
the POS N
scores POS N
on POS N
the POS N
sexual POS N
problem POS N
domain POS N
of POS N
EORTC-P POS N
(P POS N
= POS N
0.033) POS N
and POS N
sexual POS N
desire POS N
score POS N
of POS N
SMUF POS N
(P POS N
= POS N
0.021) POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

This POS N
study POS N
suggests POS N
that POS N
flutamide POS N
monotherapy POS N
can POS N
be POS N
an POS N
acceptable POS N
modality POS N
as POS N
an POS N
option POS N
for POS N
neoadjuvant POS N
hormone POS N
therapy. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
34 POS N
months POS N
after POS N
prostatectomy, POS N
biochemical POS N
failure-free POS N
survival POS N
rate POS N
in POS N
the POS N
flutamide POS N
group POS N
did POS N
not POS N
differ POS N
from POS N
that POS N
in POS N
the POS N
LHRH POS N
group. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
34 POS N
months POS N
after POS N
prostatectomy, POS N
biochemical POS N
failure-free POS N
survival POS N
rate POS N
in POS N
the POS N
flutamide POS N
group POS N
did POS N
not POS N
differ POS N
from POS N
that POS N
in POS N
the POS N
LHRH POS N
group. POS N

At POS N
radical POS N
prostatectomy, POS N
pathological POS N
variables POS N
were POS N
not POS N
significantly POS N
different POS N
in POS N
the POS N
two POS N
groups. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
34 POS N
months POS N
after POS N
prostatectomy, POS N
biochemical POS N
failure-free POS N
survival POS N
rate POS N
in POS N
the POS N
flutamide POS N
group POS N
did POS N
not POS N
differ POS N
from POS N
that POS N
in POS N
the POS N
LHRH POS N
group. POS N

Serum POS N
testosterone POS N
level POS N
was POS N
significantly POS N
higher POS N
(mean POS N
359.2 POS N
compared POS N
to POS N
10.5, POS N
P POS N
< POS N
0.001), POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
34 POS N
months POS N
after POS N
prostatectomy, POS N
biochemical POS N
failure-free POS N
survival POS N
rate POS N
in POS N
the POS N
flutamide POS N
group POS N
did POS N
not POS N
differ POS N
from POS N
that POS N
in POS N
the POS N
LHRH POS N
group. POS N

complete POS N
response POS N
rate POS N
of POS N
PSA POS N
(13% POS N
compared POS N
to POS N
57%, POS N
P POS N
= POS N
0.028) POS N
and POS N
rate POS N
of POS N
downsizing POS N
of POS N
prostate POS N
volume POS N
(mean, POS N
-17.7% POS N
compared POS N
to POS N
-35.4%, POS N
P POS N
= POS N
0.038) POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
34 POS N
months POS N
after POS N
prostatectomy, POS N
biochemical POS N
failure-free POS N
survival POS N
rate POS N
in POS N
the POS N
flutamide POS N
group POS N
did POS N
not POS N
differ POS N
from POS N
that POS N
in POS N
the POS N
LHRH POS N
group. POS N

After POS N
neoadjuvant POS N
hormone POS N
therapy, POS N
the POS N
scores POS N
on POS N
the POS N
sexual POS N
problem POS N
domain POS N
of POS N
EORTC-P POS N
(P POS N
= POS N
0.033) POS N
and POS N
sexual POS N
desire POS N
score POS N
of POS N
SMUF POS N
(P POS N
= POS N
0.021) POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
34 POS N
months POS N
after POS N
prostatectomy, POS N
biochemical POS N
failure-free POS N
survival POS N
rate POS N
in POS N
the POS N
flutamide POS N
group POS N
did POS N
not POS N
differ POS N
from POS N
that POS N
in POS N
the POS N
LHRH POS N
group. POS N

This POS N
study POS N
suggests POS N
that POS N
flutamide POS N
monotherapy POS N
can POS N
be POS N
an POS N
acceptable POS N
modality POS N
as POS N
an POS N
option POS N
for POS N
neoadjuvant POS N
hormone POS N
therapy. POS N

Both POS N
treatments POS N
demonstrated POS N
favorable POS N
ocular POS N
tolerability. POS N

Fixed-combination POS N
brimonidine-timolol POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Both POS N
treatments POS N
demonstrated POS N
favorable POS N
ocular POS N
tolerability. POS N

The POS N
percentage POS N
of POS N
patients POS N
achieving POS N
at POS N
least POS N
a POS N
20% POS N
decrease POS N
from POS N
baseline POS N
diurnal POS N
IOP POS N
at POS N
week POS N
12 POS N
was POS N
87.7% POS N
in POS N
the POS N
brimonidine-timolol POS N
group POS N
and POS N
77.3% POS N
in POS N
the POS N
latanoprost POS N
group POS N
(p POS N
= POS N
0.131). POS N

Both POS N
treatments POS N
demonstrated POS N
favorable POS N
ocular POS N
tolerability. POS N

At POS N
week POS N
12, POS N
the POS N
mean POS N
(SD) POS N
diurnal POS N
IOP POS N
was POS N
17.8 POS N
(2.9) POS N
mmHg POS N
with POS N
brimonidine-timolol POS N
and POS N
17.9 POS N
(3.9) POS N
mmHg POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.794). POS N

Both POS N
treatments POS N
demonstrated POS N
favorable POS N
ocular POS N
tolerability. POS N

Measured POS N
biomicroscopic POS N
changes POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
infrequent POS N
in POS N
both POS N
groups. POS N

Fixed-combination POS N
brimonidine-timolol POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Both POS N
treatments POS N
demonstrated POS N
favorable POS N
ocular POS N
tolerability. POS N

Fixed-combination POS N
brimonidine-timolol POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

The POS N
percentage POS N
of POS N
patients POS N
achieving POS N
at POS N
least POS N
a POS N
20% POS N
decrease POS N
from POS N
baseline POS N
diurnal POS N
IOP POS N
at POS N
week POS N
12 POS N
was POS N
87.7% POS N
in POS N
the POS N
brimonidine-timolol POS N
group POS N
and POS N
77.3% POS N
in POS N
the POS N
latanoprost POS N
group POS N
(p POS N
= POS N
0.131). POS N

Fixed-combination POS N
brimonidine-timolol POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

At POS N
week POS N
12, POS N
the POS N
mean POS N
(SD) POS N
diurnal POS N
IOP POS N
was POS N
17.8 POS N
(2.9) POS N
mmHg POS N
with POS N
brimonidine-timolol POS N
and POS N
17.9 POS N
(3.9) POS N
mmHg POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.794). POS N

Fixed-combination POS N
brimonidine-timolol POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Measured POS N
biomicroscopic POS N
changes POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
infrequent POS N
in POS N
both POS N
groups. POS N

The POS N
percentage POS N
of POS N
patients POS N
achieving POS N
at POS N
least POS N
a POS N
20% POS N
decrease POS N
from POS N
baseline POS N
diurnal POS N
IOP POS N
at POS N
week POS N
12 POS N
was POS N
87.7% POS N
in POS N
the POS N
brimonidine-timolol POS N
group POS N
and POS N
77.3% POS N
in POS N
the POS N
latanoprost POS N
group POS N
(p POS N
= POS N
0.131). POS N

Both POS N
treatments POS N
demonstrated POS N
favorable POS N
ocular POS N
tolerability. POS N

The POS N
percentage POS N
of POS N
patients POS N
achieving POS N
at POS N
least POS N
a POS N
20% POS N
decrease POS N
from POS N
baseline POS N
diurnal POS N
IOP POS N
at POS N
week POS N
12 POS N
was POS N
87.7% POS N
in POS N
the POS N
brimonidine-timolol POS N
group POS N
and POS N
77.3% POS N
in POS N
the POS N
latanoprost POS N
group POS N
(p POS N
= POS N
0.131). POS N

Fixed-combination POS N
brimonidine-timolol POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

The POS N
percentage POS N
of POS N
patients POS N
achieving POS N
at POS N
least POS N
a POS N
20% POS N
decrease POS N
from POS N
baseline POS N
diurnal POS N
IOP POS N
at POS N
week POS N
12 POS N
was POS N
87.7% POS N
in POS N
the POS N
brimonidine-timolol POS N
group POS N
and POS N
77.3% POS N
in POS N
the POS N
latanoprost POS N
group POS N
(p POS N
= POS N
0.131). POS N

At POS N
week POS N
12, POS N
the POS N
mean POS N
(SD) POS N
diurnal POS N
IOP POS N
was POS N
17.8 POS N
(2.9) POS N
mmHg POS N
with POS N
brimonidine-timolol POS N
and POS N
17.9 POS N
(3.9) POS N
mmHg POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.794). POS N

The POS N
percentage POS N
of POS N
patients POS N
achieving POS N
at POS N
least POS N
a POS N
20% POS N
decrease POS N
from POS N
baseline POS N
diurnal POS N
IOP POS N
at POS N
week POS N
12 POS N
was POS N
87.7% POS N
in POS N
the POS N
brimonidine-timolol POS N
group POS N
and POS N
77.3% POS N
in POS N
the POS N
latanoprost POS N
group POS N
(p POS N
= POS N
0.131). POS N

Measured POS N
biomicroscopic POS N
changes POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
infrequent POS N
in POS N
both POS N
groups. POS N

At POS N
week POS N
12, POS N
the POS N
mean POS N
(SD) POS N
diurnal POS N
IOP POS N
was POS N
17.8 POS N
(2.9) POS N
mmHg POS N
with POS N
brimonidine-timolol POS N
and POS N
17.9 POS N
(3.9) POS N
mmHg POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.794). POS N

Both POS N
treatments POS N
demonstrated POS N
favorable POS N
ocular POS N
tolerability. POS N

At POS N
week POS N
12, POS N
the POS N
mean POS N
(SD) POS N
diurnal POS N
IOP POS N
was POS N
17.8 POS N
(2.9) POS N
mmHg POS N
with POS N
brimonidine-timolol POS N
and POS N
17.9 POS N
(3.9) POS N
mmHg POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.794). POS N

Fixed-combination POS N
brimonidine-timolol POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

At POS N
week POS N
12, POS N
the POS N
mean POS N
(SD) POS N
diurnal POS N
IOP POS N
was POS N
17.8 POS N
(2.9) POS N
mmHg POS N
with POS N
brimonidine-timolol POS N
and POS N
17.9 POS N
(3.9) POS N
mmHg POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.794). POS N

The POS N
percentage POS N
of POS N
patients POS N
achieving POS N
at POS N
least POS N
a POS N
20% POS N
decrease POS N
from POS N
baseline POS N
diurnal POS N
IOP POS N
at POS N
week POS N
12 POS N
was POS N
87.7% POS N
in POS N
the POS N
brimonidine-timolol POS N
group POS N
and POS N
77.3% POS N
in POS N
the POS N
latanoprost POS N
group POS N
(p POS N
= POS N
0.131). POS N

At POS N
week POS N
12, POS N
the POS N
mean POS N
(SD) POS N
diurnal POS N
IOP POS N
was POS N
17.8 POS N
(2.9) POS N
mmHg POS N
with POS N
brimonidine-timolol POS N
and POS N
17.9 POS N
(3.9) POS N
mmHg POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.794). POS N

Measured POS N
biomicroscopic POS N
changes POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
infrequent POS N
in POS N
both POS N
groups. POS N

Measured POS N
biomicroscopic POS N
changes POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
infrequent POS N
in POS N
both POS N
groups. POS N

Both POS N
treatments POS N
demonstrated POS N
favorable POS N
ocular POS N
tolerability. POS N

Measured POS N
biomicroscopic POS N
changes POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
infrequent POS N
in POS N
both POS N
groups. POS N

Fixed-combination POS N
brimonidine-timolol POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Measured POS N
biomicroscopic POS N
changes POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
infrequent POS N
in POS N
both POS N
groups. POS N

The POS N
percentage POS N
of POS N
patients POS N
achieving POS N
at POS N
least POS N
a POS N
20% POS N
decrease POS N
from POS N
baseline POS N
diurnal POS N
IOP POS N
at POS N
week POS N
12 POS N
was POS N
87.7% POS N
in POS N
the POS N
brimonidine-timolol POS N
group POS N
and POS N
77.3% POS N
in POS N
the POS N
latanoprost POS N
group POS N
(p POS N
= POS N
0.131). POS N

Measured POS N
biomicroscopic POS N
changes POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
infrequent POS N
in POS N
both POS N
groups. POS N

At POS N
week POS N
12, POS N
the POS N
mean POS N
(SD) POS N
diurnal POS N
IOP POS N
was POS N
17.8 POS N
(2.9) POS N
mmHg POS N
with POS N
brimonidine-timolol POS N
and POS N
17.9 POS N
(3.9) POS N
mmHg POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.794). POS N

This POS N
study POS N
suggests POS N
the POS N
possibility POS N
of POS N
Korean POS N
Red POS N
Ginseng POS N
as POS N
a POS N
complementary POS N
therapy POS N
for POS N
chronic POS N
hepatitis POS N
B. POS N

The POS N
non-invasive POS N
fibrosis POS N
serologic POS N
markers POS N
were POS N
further POS N
decreased POS N
in POS N
the POS N
experimental POS N
group, POS N
with POS N
significant POS N
differences POS N
after POS N
treatment POS N
observed POS N
for POS N
hyaluronic POS N
acid POS N
(p = 0.032) POS N
and POS N
transforming POS N
growth POS N
factor-β POS N
(p = 0.008), POS N
but POS N
not POS N
for POS N
type POS N
IV POS N
collagen POS N
(p = 0.174). POS N

This POS N
study POS N
suggests POS N
the POS N
possibility POS N
of POS N
Korean POS N
Red POS N
Ginseng POS N
as POS N
a POS N
complementary POS N
therapy POS N
for POS N
chronic POS N
hepatitis POS N
B. POS N

Differences POS N
in POS N
several POS N
non-invasive POS N
fibrosis POS N
serologic POS N
markers POS N
(type POS N
IV POS N
collagen, POS N
hyaluronic POS N
acid, POS N
transforming POS N
growth POS N
factor-β) POS N
and POS N
in POS N
the POS N
hepatitis POS N
B POS N
virus POS N
DNA POS N
levels POS N
were POS N
compared POS N
between POS N
the POS N
groups. POS N

The POS N
non-invasive POS N
fibrosis POS N
serologic POS N
markers POS N
were POS N
further POS N
decreased POS N
in POS N
the POS N
experimental POS N
group, POS N
with POS N
significant POS N
differences POS N
after POS N
treatment POS N
observed POS N
for POS N
hyaluronic POS N
acid POS N
(p = 0.032) POS N
and POS N
transforming POS N
growth POS N
factor-β POS N
(p = 0.008), POS N
but POS N
not POS N
for POS N
type POS N
IV POS N
collagen POS N
(p = 0.174). POS N

This POS N
study POS N
suggests POS N
the POS N
possibility POS N
of POS N
Korean POS N
Red POS N
Ginseng POS N
as POS N
a POS N
complementary POS N
therapy POS N
for POS N
chronic POS N
hepatitis POS N
B. POS N

The POS N
non-invasive POS N
fibrosis POS N
serologic POS N
markers POS N
were POS N
further POS N
decreased POS N
in POS N
the POS N
experimental POS N
group, POS N
with POS N
significant POS N
differences POS N
after POS N
treatment POS N
observed POS N
for POS N
hyaluronic POS N
acid POS N
(p = 0.032) POS N
and POS N
transforming POS N
growth POS N
factor-β POS N
(p = 0.008), POS N
but POS N
not POS N
for POS N
type POS N
IV POS N
collagen POS N
(p = 0.174). POS N

Differences POS N
in POS N
several POS N
non-invasive POS N
fibrosis POS N
serologic POS N
markers POS N
(type POS N
IV POS N
collagen, POS N
hyaluronic POS N
acid, POS N
transforming POS N
growth POS N
factor-β) POS N
and POS N
in POS N
the POS N
hepatitis POS N
B POS N
virus POS N
DNA POS N
levels POS N
were POS N
compared POS N
between POS N
the POS N
groups. POS N

Differences POS N
in POS N
several POS N
non-invasive POS N
fibrosis POS N
serologic POS N
markers POS N
(type POS N
IV POS N
collagen, POS N
hyaluronic POS N
acid, POS N
transforming POS N
growth POS N
factor-β) POS N
and POS N
in POS N
the POS N
hepatitis POS N
B POS N
virus POS N
DNA POS N
levels POS N
were POS N
compared POS N
between POS N
the POS N
groups. POS N

This POS N
study POS N
suggests POS N
the POS N
possibility POS N
of POS N
Korean POS N
Red POS N
Ginseng POS N
as POS N
a POS N
complementary POS N
therapy POS N
for POS N
chronic POS N
hepatitis POS N
B. POS N

Differences POS N
in POS N
several POS N
non-invasive POS N
fibrosis POS N
serologic POS N
markers POS N
(type POS N
IV POS N
collagen, POS N
hyaluronic POS N
acid, POS N
transforming POS N
growth POS N
factor-β) POS N
and POS N
in POS N
the POS N
hepatitis POS N
B POS N
virus POS N
DNA POS N
levels POS N
were POS N
compared POS N
between POS N
the POS N
groups. POS N

The POS N
non-invasive POS N
fibrosis POS N
serologic POS N
markers POS N
were POS N
further POS N
decreased POS N
in POS N
the POS N
experimental POS N
group, POS N
with POS N
significant POS N
differences POS N
after POS N
treatment POS N
observed POS N
for POS N
hyaluronic POS N
acid POS N
(p = 0.032) POS N
and POS N
transforming POS N
growth POS N
factor-β POS N
(p = 0.008), POS N
but POS N
not POS N
for POS N
type POS N
IV POS N
collagen POS N
(p = 0.174). POS N

Fewer POS N
complications POS N
were POS N
noted POS N
in POS N
eyes POS N
receiving POS N
sclerostomy POS N
(5/29, POS N
17.2%) POS N
as POS N
compared POS N
to POS N
control POS N
group POS N
eyes POS N
(12/31, POS N
38.7%), POS N
though POS N
differences POS N
were POS N
marginally POS N
significant POS N
(P POS N
= POS N
.065). POS N

Four POS N
control POS N
group, POS N
but POS N
no POS N
sclerostomy POS N
group, POS N
eyes POS N
developed POS N
postoperative POS N
uveal POS N
effusions POS N
(P POS N
= POS N
.04). POS N

Fewer POS N
complications POS N
were POS N
noted POS N
in POS N
eyes POS N
receiving POS N
sclerostomy POS N
(5/29, POS N
17.2%) POS N
as POS N
compared POS N
to POS N
control POS N
group POS N
eyes POS N
(12/31, POS N
38.7%), POS N
though POS N
differences POS N
were POS N
marginally POS N
significant POS N
(P POS N
= POS N
.065). POS N

In POS N
multivariable POS N
models, POS N
sclerostomy POS N
decreased POS N
the POS N
odds POS N
of POS N
an POS N
intraoperative POS N
or POS N
postoperative POS N
complication POS N
by POS N
80% POS N
(odds POS N
ratio POS N
[OR] POS N
= POS N
0.2, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
0.04-0.92, POS N
P POS N
= POS N
.039); POS N

Fewer POS N
complications POS N
were POS N
noted POS N
in POS N
eyes POS N
receiving POS N
sclerostomy POS N
(5/29, POS N
17.2%) POS N
as POS N
compared POS N
to POS N
control POS N
group POS N
eyes POS N
(12/31, POS N
38.7%), POS N
though POS N
differences POS N
were POS N
marginally POS N
significant POS N
(P POS N
= POS N
.065). POS N

SICS POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
risk POS N
of POS N
complications POS N
as POS N
compared POS N
to POS N
phacoemulsification POS N
(OR POS N
= POS N
5.95, POS N
95% POS N
CI POS N
= POS N
1.49-23.73, POS N
P POS N
= POS N
.012), POS N
while POS N
high POS N
preoperative POS N
intraocular POS N
pressure POS N
(OR POS N
= POS N
4.54, POS N
95% POS N
CI POS N
= POS N
0.99-20.9, POS N
P POS N
= POS N
.052) POS N
and POS N
greater POS N
lens POS N
thickness POS N
(OR POS N
= POS N
3.38, POS N
95% POS N
CI POS N
= POS N
0.88-12.91, POS N
P POS N
= POS N
.075) POS N
demonstrated POS N
a POS N
marginally POS N
significant POS N
association. POS N

Fewer POS N
complications POS N
were POS N
noted POS N
in POS N
eyes POS N
receiving POS N
sclerostomy POS N
(5/29, POS N
17.2%) POS N
as POS N
compared POS N
to POS N
control POS N
group POS N
eyes POS N
(12/31, POS N
38.7%), POS N
though POS N
differences POS N
were POS N
marginally POS N
significant POS N
(P POS N
= POS N
.065). POS N

Cataract POS N
surgery POS N
in POS N
eyes POS N
with POS N
nanophthalmos POS N
is POS N
associated POS N
with POS N
a POS N
high POS N
risk POS N
for POS N
vision-threatening POS N
complications. POS N

Fewer POS N
complications POS N
were POS N
noted POS N
in POS N
eyes POS N
receiving POS N
sclerostomy POS N
(5/29, POS N
17.2%) POS N
as POS N
compared POS N
to POS N
control POS N
group POS N
eyes POS N
(12/31, POS N
38.7%), POS N
though POS N
differences POS N
were POS N
marginally POS N
significant POS N
(P POS N
= POS N
.065). POS N

Performing POS N
a POS N
simultaneous POS N
prophylactic POS N
sclerostomy POS N
with POS N
cataract POS N
surgery POS N
reduces POS N
complication POS N
rates, POS N
particularly POS N
uveal POS N
effusions. POS N

Fewer POS N
complications POS N
were POS N
noted POS N
in POS N
eyes POS N
receiving POS N
sclerostomy POS N
(5/29, POS N
17.2%) POS N
as POS N
compared POS N
to POS N
control POS N
group POS N
eyes POS N
(12/31, POS N
38.7%), POS N
though POS N
differences POS N
were POS N
marginally POS N
significant POS N
(P POS N
= POS N
.065). POS N

Cataract POS N
surgery POS N
at POS N
earlier POS N
stages POS N
by POS N
phacoemulsification POS N
may POS N
be POS N
more POS N
beneficial POS N
than POS N
undergoing POS N
manual POS N
SICS. POS N

Four POS N
control POS N
group, POS N
but POS N
no POS N
sclerostomy POS N
group, POS N
eyes POS N
developed POS N
postoperative POS N
uveal POS N
effusions POS N
(P POS N
= POS N
.04). POS N

Fewer POS N
complications POS N
were POS N
noted POS N
in POS N
eyes POS N
receiving POS N
sclerostomy POS N
(5/29, POS N
17.2%) POS N
as POS N
compared POS N
to POS N
control POS N
group POS N
eyes POS N
(12/31, POS N
38.7%), POS N
though POS N
differences POS N
were POS N
marginally POS N
significant POS N
(P POS N
= POS N
.065). POS N

Four POS N
control POS N
group, POS N
but POS N
no POS N
sclerostomy POS N
group, POS N
eyes POS N
developed POS N
postoperative POS N
uveal POS N
effusions POS N
(P POS N
= POS N
.04). POS N

In POS N
multivariable POS N
models, POS N
sclerostomy POS N
decreased POS N
the POS N
odds POS N
of POS N
an POS N
intraoperative POS N
or POS N
postoperative POS N
complication POS N
by POS N
80% POS N
(odds POS N
ratio POS N
[OR] POS N
= POS N
0.2, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
0.04-0.92, POS N
P POS N
= POS N
.039); POS N

Four POS N
control POS N
group, POS N
but POS N
no POS N
sclerostomy POS N
group, POS N
eyes POS N
developed POS N
postoperative POS N
uveal POS N
effusions POS N
(P POS N
= POS N
.04). POS N

SICS POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
risk POS N
of POS N
complications POS N
as POS N
compared POS N
to POS N
phacoemulsification POS N
(OR POS N
= POS N
5.95, POS N
95% POS N
CI POS N
= POS N
1.49-23.73, POS N
P POS N
= POS N
.012), POS N
while POS N
high POS N
preoperative POS N
intraocular POS N
pressure POS N
(OR POS N
= POS N
4.54, POS N
95% POS N
CI POS N
= POS N
0.99-20.9, POS N
P POS N
= POS N
.052) POS N
and POS N
greater POS N
lens POS N
thickness POS N
(OR POS N
= POS N
3.38, POS N
95% POS N
CI POS N
= POS N
0.88-12.91, POS N
P POS N
= POS N
.075) POS N
demonstrated POS N
a POS N
marginally POS N
significant POS N
association. POS N

Four POS N
control POS N
group, POS N
but POS N
no POS N
sclerostomy POS N
group, POS N
eyes POS N
developed POS N
postoperative POS N
uveal POS N
effusions POS N
(P POS N
= POS N
.04). POS N

Cataract POS N
surgery POS N
in POS N
eyes POS N
with POS N
nanophthalmos POS N
is POS N
associated POS N
with POS N
a POS N
high POS N
risk POS N
for POS N
vision-threatening POS N
complications. POS N

Four POS N
control POS N
group, POS N
but POS N
no POS N
sclerostomy POS N
group, POS N
eyes POS N
developed POS N
postoperative POS N
uveal POS N
effusions POS N
(P POS N
= POS N
.04). POS N

Performing POS N
a POS N
simultaneous POS N
prophylactic POS N
sclerostomy POS N
with POS N
cataract POS N
surgery POS N
reduces POS N
complication POS N
rates, POS N
particularly POS N
uveal POS N
effusions. POS N

Four POS N
control POS N
group, POS N
but POS N
no POS N
sclerostomy POS N
group, POS N
eyes POS N
developed POS N
postoperative POS N
uveal POS N
effusions POS N
(P POS N
= POS N
.04). POS N

Cataract POS N
surgery POS N
at POS N
earlier POS N
stages POS N
by POS N
phacoemulsification POS N
may POS N
be POS N
more POS N
beneficial POS N
than POS N
undergoing POS N
manual POS N
SICS. POS N

In POS N
multivariable POS N
models, POS N
sclerostomy POS N
decreased POS N
the POS N
odds POS N
of POS N
an POS N
intraoperative POS N
or POS N
postoperative POS N
complication POS N
by POS N
80% POS N
(odds POS N
ratio POS N
[OR] POS N
= POS N
0.2, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
0.04-0.92, POS N
P POS N
= POS N
.039); POS N

Fewer POS N
complications POS N
were POS N
noted POS N
in POS N
eyes POS N
receiving POS N
sclerostomy POS N
(5/29, POS N
17.2%) POS N
as POS N
compared POS N
to POS N
control POS N
group POS N
eyes POS N
(12/31, POS N
38.7%), POS N
though POS N
differences POS N
were POS N
marginally POS N
significant POS N
(P POS N
= POS N
.065). POS N

In POS N
multivariable POS N
models, POS N
sclerostomy POS N
decreased POS N
the POS N
odds POS N
of POS N
an POS N
intraoperative POS N
or POS N
postoperative POS N
complication POS N
by POS N
80% POS N
(odds POS N
ratio POS N
[OR] POS N
= POS N
0.2, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
0.04-0.92, POS N
P POS N
= POS N
.039); POS N

Four POS N
control POS N
group, POS N
but POS N
no POS N
sclerostomy POS N
group, POS N
eyes POS N
developed POS N
postoperative POS N
uveal POS N
effusions POS N
(P POS N
= POS N
.04). POS N

In POS N
multivariable POS N
models, POS N
sclerostomy POS N
decreased POS N
the POS N
odds POS N
of POS N
an POS N
intraoperative POS N
or POS N
postoperative POS N
complication POS N
by POS N
80% POS N
(odds POS N
ratio POS N
[OR] POS N
= POS N
0.2, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
0.04-0.92, POS N
P POS N
= POS N
.039); POS N

SICS POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
risk POS N
of POS N
complications POS N
as POS N
compared POS N
to POS N
phacoemulsification POS N
(OR POS N
= POS N
5.95, POS N
95% POS N
CI POS N
= POS N
1.49-23.73, POS N
P POS N
= POS N
.012), POS N
while POS N
high POS N
preoperative POS N
intraocular POS N
pressure POS N
(OR POS N
= POS N
4.54, POS N
95% POS N
CI POS N
= POS N
0.99-20.9, POS N
P POS N
= POS N
.052) POS N
and POS N
greater POS N
lens POS N
thickness POS N
(OR POS N
= POS N
3.38, POS N
95% POS N
CI POS N
= POS N
0.88-12.91, POS N
P POS N
= POS N
.075) POS N
demonstrated POS N
a POS N
marginally POS N
significant POS N
association. POS N

In POS N
multivariable POS N
models, POS N
sclerostomy POS N
decreased POS N
the POS N
odds POS N
of POS N
an POS N
intraoperative POS N
or POS N
postoperative POS N
complication POS N
by POS N
80% POS N
(odds POS N
ratio POS N
[OR] POS N
= POS N
0.2, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
0.04-0.92, POS N
P POS N
= POS N
.039); POS N

Cataract POS N
surgery POS N
in POS N
eyes POS N
with POS N
nanophthalmos POS N
is POS N
associated POS N
with POS N
a POS N
high POS N
risk POS N
for POS N
vision-threatening POS N
complications. POS N

In POS N
multivariable POS N
models, POS N
sclerostomy POS N
decreased POS N
the POS N
odds POS N
of POS N
an POS N
intraoperative POS N
or POS N
postoperative POS N
complication POS N
by POS N
80% POS N
(odds POS N
ratio POS N
[OR] POS N
= POS N
0.2, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
0.04-0.92, POS N
P POS N
= POS N
.039); POS N

Performing POS N
a POS N
simultaneous POS N
prophylactic POS N
sclerostomy POS N
with POS N
cataract POS N
surgery POS N
reduces POS N
complication POS N
rates, POS N
particularly POS N
uveal POS N
effusions. POS N

In POS N
multivariable POS N
models, POS N
sclerostomy POS N
decreased POS N
the POS N
odds POS N
of POS N
an POS N
intraoperative POS N
or POS N
postoperative POS N
complication POS N
by POS N
80% POS N
(odds POS N
ratio POS N
[OR] POS N
= POS N
0.2, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
0.04-0.92, POS N
P POS N
= POS N
.039); POS N

Cataract POS N
surgery POS N
at POS N
earlier POS N
stages POS N
by POS N
phacoemulsification POS N
may POS N
be POS N
more POS N
beneficial POS N
than POS N
undergoing POS N
manual POS N
SICS. POS N

SICS POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
risk POS N
of POS N
complications POS N
as POS N
compared POS N
to POS N
phacoemulsification POS N
(OR POS N
= POS N
5.95, POS N
95% POS N
CI POS N
= POS N
1.49-23.73, POS N
P POS N
= POS N
.012), POS N
while POS N
high POS N
preoperative POS N
intraocular POS N
pressure POS N
(OR POS N
= POS N
4.54, POS N
95% POS N
CI POS N
= POS N
0.99-20.9, POS N
P POS N
= POS N
.052) POS N
and POS N
greater POS N
lens POS N
thickness POS N
(OR POS N
= POS N
3.38, POS N
95% POS N
CI POS N
= POS N
0.88-12.91, POS N
P POS N
= POS N
.075) POS N
demonstrated POS N
a POS N
marginally POS N
significant POS N
association. POS N

Fewer POS N
complications POS N
were POS N
noted POS N
in POS N
eyes POS N
receiving POS N
sclerostomy POS N
(5/29, POS N
17.2%) POS N
as POS N
compared POS N
to POS N
control POS N
group POS N
eyes POS N
(12/31, POS N
38.7%), POS N
though POS N
differences POS N
were POS N
marginally POS N
significant POS N
(P POS N
= POS N
.065). POS N

SICS POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
risk POS N
of POS N
complications POS N
as POS N
compared POS N
to POS N
phacoemulsification POS N
(OR POS N
= POS N
5.95, POS N
95% POS N
CI POS N
= POS N
1.49-23.73, POS N
P POS N
= POS N
.012), POS N
while POS N
high POS N
preoperative POS N
intraocular POS N
pressure POS N
(OR POS N
= POS N
4.54, POS N
95% POS N
CI POS N
= POS N
0.99-20.9, POS N
P POS N
= POS N
.052) POS N
and POS N
greater POS N
lens POS N
thickness POS N
(OR POS N
= POS N
3.38, POS N
95% POS N
CI POS N
= POS N
0.88-12.91, POS N
P POS N
= POS N
.075) POS N
demonstrated POS N
a POS N
marginally POS N
significant POS N
association. POS N

Four POS N
control POS N
group, POS N
but POS N
no POS N
sclerostomy POS N
group, POS N
eyes POS N
developed POS N
postoperative POS N
uveal POS N
effusions POS N
(P POS N
= POS N
.04). POS N

SICS POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
risk POS N
of POS N
complications POS N
as POS N
compared POS N
to POS N
phacoemulsification POS N
(OR POS N
= POS N
5.95, POS N
95% POS N
CI POS N
= POS N
1.49-23.73, POS N
P POS N
= POS N
.012), POS N
while POS N
high POS N
preoperative POS N
intraocular POS N
pressure POS N
(OR POS N
= POS N
4.54, POS N
95% POS N
CI POS N
= POS N
0.99-20.9, POS N
P POS N
= POS N
.052) POS N
and POS N
greater POS N
lens POS N
thickness POS N
(OR POS N
= POS N
3.38, POS N
95% POS N
CI POS N
= POS N
0.88-12.91, POS N
P POS N
= POS N
.075) POS N
demonstrated POS N
a POS N
marginally POS N
significant POS N
association. POS N

In POS N
multivariable POS N
models, POS N
sclerostomy POS N
decreased POS N
the POS N
odds POS N
of POS N
an POS N
intraoperative POS N
or POS N
postoperative POS N
complication POS N
by POS N
80% POS N
(odds POS N
ratio POS N
[OR] POS N
= POS N
0.2, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
0.04-0.92, POS N
P POS N
= POS N
.039); POS N

SICS POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
risk POS N
of POS N
complications POS N
as POS N
compared POS N
to POS N
phacoemulsification POS N
(OR POS N
= POS N
5.95, POS N
95% POS N
CI POS N
= POS N
1.49-23.73, POS N
P POS N
= POS N
.012), POS N
while POS N
high POS N
preoperative POS N
intraocular POS N
pressure POS N
(OR POS N
= POS N
4.54, POS N
95% POS N
CI POS N
= POS N
0.99-20.9, POS N
P POS N
= POS N
.052) POS N
and POS N
greater POS N
lens POS N
thickness POS N
(OR POS N
= POS N
3.38, POS N
95% POS N
CI POS N
= POS N
0.88-12.91, POS N
P POS N
= POS N
.075) POS N
demonstrated POS N
a POS N
marginally POS N
significant POS N
association. POS N

Cataract POS N
surgery POS N
in POS N
eyes POS N
with POS N
nanophthalmos POS N
is POS N
associated POS N
with POS N
a POS N
high POS N
risk POS N
for POS N
vision-threatening POS N
complications. POS N

SICS POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
risk POS N
of POS N
complications POS N
as POS N
compared POS N
to POS N
phacoemulsification POS N
(OR POS N
= POS N
5.95, POS N
95% POS N
CI POS N
= POS N
1.49-23.73, POS N
P POS N
= POS N
.012), POS N
while POS N
high POS N
preoperative POS N
intraocular POS N
pressure POS N
(OR POS N
= POS N
4.54, POS N
95% POS N
CI POS N
= POS N
0.99-20.9, POS N
P POS N
= POS N
.052) POS N
and POS N
greater POS N
lens POS N
thickness POS N
(OR POS N
= POS N
3.38, POS N
95% POS N
CI POS N
= POS N
0.88-12.91, POS N
P POS N
= POS N
.075) POS N
demonstrated POS N
a POS N
marginally POS N
significant POS N
association. POS N

Performing POS N
a POS N
simultaneous POS N
prophylactic POS N
sclerostomy POS N
with POS N
cataract POS N
surgery POS N
reduces POS N
complication POS N
rates, POS N
particularly POS N
uveal POS N
effusions. POS N

SICS POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
risk POS N
of POS N
complications POS N
as POS N
compared POS N
to POS N
phacoemulsification POS N
(OR POS N
= POS N
5.95, POS N
95% POS N
CI POS N
= POS N
1.49-23.73, POS N
P POS N
= POS N
.012), POS N
while POS N
high POS N
preoperative POS N
intraocular POS N
pressure POS N
(OR POS N
= POS N
4.54, POS N
95% POS N
CI POS N
= POS N
0.99-20.9, POS N
P POS N
= POS N
.052) POS N
and POS N
greater POS N
lens POS N
thickness POS N
(OR POS N
= POS N
3.38, POS N
95% POS N
CI POS N
= POS N
0.88-12.91, POS N
P POS N
= POS N
.075) POS N
demonstrated POS N
a POS N
marginally POS N
significant POS N
association. POS N

Cataract POS N
surgery POS N
at POS N
earlier POS N
stages POS N
by POS N
phacoemulsification POS N
may POS N
be POS N
more POS N
beneficial POS N
than POS N
undergoing POS N
manual POS N
SICS. POS N

Cataract POS N
surgery POS N
in POS N
eyes POS N
with POS N
nanophthalmos POS N
is POS N
associated POS N
with POS N
a POS N
high POS N
risk POS N
for POS N
vision-threatening POS N
complications. POS N

Fewer POS N
complications POS N
were POS N
noted POS N
in POS N
eyes POS N
receiving POS N
sclerostomy POS N
(5/29, POS N
17.2%) POS N
as POS N
compared POS N
to POS N
control POS N
group POS N
eyes POS N
(12/31, POS N
38.7%), POS N
though POS N
differences POS N
were POS N
marginally POS N
significant POS N
(P POS N
= POS N
.065). POS N

Cataract POS N
surgery POS N
in POS N
eyes POS N
with POS N
nanophthalmos POS N
is POS N
associated POS N
with POS N
a POS N
high POS N
risk POS N
for POS N
vision-threatening POS N
complications. POS N

Four POS N
control POS N
group, POS N
but POS N
no POS N
sclerostomy POS N
group, POS N
eyes POS N
developed POS N
postoperative POS N
uveal POS N
effusions POS N
(P POS N
= POS N
.04). POS N

Cataract POS N
surgery POS N
in POS N
eyes POS N
with POS N
nanophthalmos POS N
is POS N
associated POS N
with POS N
a POS N
high POS N
risk POS N
for POS N
vision-threatening POS N
complications. POS N

In POS N
multivariable POS N
models, POS N
sclerostomy POS N
decreased POS N
the POS N
odds POS N
of POS N
an POS N
intraoperative POS N
or POS N
postoperative POS N
complication POS N
by POS N
80% POS N
(odds POS N
ratio POS N
[OR] POS N
= POS N
0.2, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
0.04-0.92, POS N
P POS N
= POS N
.039); POS N

Cataract POS N
surgery POS N
in POS N
eyes POS N
with POS N
nanophthalmos POS N
is POS N
associated POS N
with POS N
a POS N
high POS N
risk POS N
for POS N
vision-threatening POS N
complications. POS N

SICS POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
risk POS N
of POS N
complications POS N
as POS N
compared POS N
to POS N
phacoemulsification POS N
(OR POS N
= POS N
5.95, POS N
95% POS N
CI POS N
= POS N
1.49-23.73, POS N
P POS N
= POS N
.012), POS N
while POS N
high POS N
preoperative POS N
intraocular POS N
pressure POS N
(OR POS N
= POS N
4.54, POS N
95% POS N
CI POS N
= POS N
0.99-20.9, POS N
P POS N
= POS N
.052) POS N
and POS N
greater POS N
lens POS N
thickness POS N
(OR POS N
= POS N
3.38, POS N
95% POS N
CI POS N
= POS N
0.88-12.91, POS N
P POS N
= POS N
.075) POS N
demonstrated POS N
a POS N
marginally POS N
significant POS N
association. POS N

Cataract POS N
surgery POS N
in POS N
eyes POS N
with POS N
nanophthalmos POS N
is POS N
associated POS N
with POS N
a POS N
high POS N
risk POS N
for POS N
vision-threatening POS N
complications. POS N

Performing POS N
a POS N
simultaneous POS N
prophylactic POS N
sclerostomy POS N
with POS N
cataract POS N
surgery POS N
reduces POS N
complication POS N
rates, POS N
particularly POS N
uveal POS N
effusions. POS N

Cataract POS N
surgery POS N
in POS N
eyes POS N
with POS N
nanophthalmos POS N
is POS N
associated POS N
with POS N
a POS N
high POS N
risk POS N
for POS N
vision-threatening POS N
complications. POS N

Cataract POS N
surgery POS N
at POS N
earlier POS N
stages POS N
by POS N
phacoemulsification POS N
may POS N
be POS N
more POS N
beneficial POS N
than POS N
undergoing POS N
manual POS N
SICS. POS N

Performing POS N
a POS N
simultaneous POS N
prophylactic POS N
sclerostomy POS N
with POS N
cataract POS N
surgery POS N
reduces POS N
complication POS N
rates, POS N
particularly POS N
uveal POS N
effusions. POS N

Fewer POS N
complications POS N
were POS N
noted POS N
in POS N
eyes POS N
receiving POS N
sclerostomy POS N
(5/29, POS N
17.2%) POS N
as POS N
compared POS N
to POS N
control POS N
group POS N
eyes POS N
(12/31, POS N
38.7%), POS N
though POS N
differences POS N
were POS N
marginally POS N
significant POS N
(P POS N
= POS N
.065). POS N

Performing POS N
a POS N
simultaneous POS N
prophylactic POS N
sclerostomy POS N
with POS N
cataract POS N
surgery POS N
reduces POS N
complication POS N
rates, POS N
particularly POS N
uveal POS N
effusions. POS N

Four POS N
control POS N
group, POS N
but POS N
no POS N
sclerostomy POS N
group, POS N
eyes POS N
developed POS N
postoperative POS N
uveal POS N
effusions POS N
(P POS N
= POS N
.04). POS N

Performing POS N
a POS N
simultaneous POS N
prophylactic POS N
sclerostomy POS N
with POS N
cataract POS N
surgery POS N
reduces POS N
complication POS N
rates, POS N
particularly POS N
uveal POS N
effusions. POS N

In POS N
multivariable POS N
models, POS N
sclerostomy POS N
decreased POS N
the POS N
odds POS N
of POS N
an POS N
intraoperative POS N
or POS N
postoperative POS N
complication POS N
by POS N
80% POS N
(odds POS N
ratio POS N
[OR] POS N
= POS N
0.2, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
0.04-0.92, POS N
P POS N
= POS N
.039); POS N

Performing POS N
a POS N
simultaneous POS N
prophylactic POS N
sclerostomy POS N
with POS N
cataract POS N
surgery POS N
reduces POS N
complication POS N
rates, POS N
particularly POS N
uveal POS N
effusions. POS N

SICS POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
risk POS N
of POS N
complications POS N
as POS N
compared POS N
to POS N
phacoemulsification POS N
(OR POS N
= POS N
5.95, POS N
95% POS N
CI POS N
= POS N
1.49-23.73, POS N
P POS N
= POS N
.012), POS N
while POS N
high POS N
preoperative POS N
intraocular POS N
pressure POS N
(OR POS N
= POS N
4.54, POS N
95% POS N
CI POS N
= POS N
0.99-20.9, POS N
P POS N
= POS N
.052) POS N
and POS N
greater POS N
lens POS N
thickness POS N
(OR POS N
= POS N
3.38, POS N
95% POS N
CI POS N
= POS N
0.88-12.91, POS N
P POS N
= POS N
.075) POS N
demonstrated POS N
a POS N
marginally POS N
significant POS N
association. POS N

Performing POS N
a POS N
simultaneous POS N
prophylactic POS N
sclerostomy POS N
with POS N
cataract POS N
surgery POS N
reduces POS N
complication POS N
rates, POS N
particularly POS N
uveal POS N
effusions. POS N

Cataract POS N
surgery POS N
in POS N
eyes POS N
with POS N
nanophthalmos POS N
is POS N
associated POS N
with POS N
a POS N
high POS N
risk POS N
for POS N
vision-threatening POS N
complications. POS N

Performing POS N
a POS N
simultaneous POS N
prophylactic POS N
sclerostomy POS N
with POS N
cataract POS N
surgery POS N
reduces POS N
complication POS N
rates, POS N
particularly POS N
uveal POS N
effusions. POS N

Cataract POS N
surgery POS N
at POS N
earlier POS N
stages POS N
by POS N
phacoemulsification POS N
may POS N
be POS N
more POS N
beneficial POS N
than POS N
undergoing POS N
manual POS N
SICS. POS N

Cataract POS N
surgery POS N
at POS N
earlier POS N
stages POS N
by POS N
phacoemulsification POS N
may POS N
be POS N
more POS N
beneficial POS N
than POS N
undergoing POS N
manual POS N
SICS. POS N

Fewer POS N
complications POS N
were POS N
noted POS N
in POS N
eyes POS N
receiving POS N
sclerostomy POS N
(5/29, POS N
17.2%) POS N
as POS N
compared POS N
to POS N
control POS N
group POS N
eyes POS N
(12/31, POS N
38.7%), POS N
though POS N
differences POS N
were POS N
marginally POS N
significant POS N
(P POS N
= POS N
.065). POS N

Cataract POS N
surgery POS N
at POS N
earlier POS N
stages POS N
by POS N
phacoemulsification POS N
may POS N
be POS N
more POS N
beneficial POS N
than POS N
undergoing POS N
manual POS N
SICS. POS N

Four POS N
control POS N
group, POS N
but POS N
no POS N
sclerostomy POS N
group, POS N
eyes POS N
developed POS N
postoperative POS N
uveal POS N
effusions POS N
(P POS N
= POS N
.04). POS N

Cataract POS N
surgery POS N
at POS N
earlier POS N
stages POS N
by POS N
phacoemulsification POS N
may POS N
be POS N
more POS N
beneficial POS N
than POS N
undergoing POS N
manual POS N
SICS. POS N

In POS N
multivariable POS N
models, POS N
sclerostomy POS N
decreased POS N
the POS N
odds POS N
of POS N
an POS N
intraoperative POS N
or POS N
postoperative POS N
complication POS N
by POS N
80% POS N
(odds POS N
ratio POS N
[OR] POS N
= POS N
0.2, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
0.04-0.92, POS N
P POS N
= POS N
.039); POS N

Cataract POS N
surgery POS N
at POS N
earlier POS N
stages POS N
by POS N
phacoemulsification POS N
may POS N
be POS N
more POS N
beneficial POS N
than POS N
undergoing POS N
manual POS N
SICS. POS N

SICS POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
risk POS N
of POS N
complications POS N
as POS N
compared POS N
to POS N
phacoemulsification POS N
(OR POS N
= POS N
5.95, POS N
95% POS N
CI POS N
= POS N
1.49-23.73, POS N
P POS N
= POS N
.012), POS N
while POS N
high POS N
preoperative POS N
intraocular POS N
pressure POS N
(OR POS N
= POS N
4.54, POS N
95% POS N
CI POS N
= POS N
0.99-20.9, POS N
P POS N
= POS N
.052) POS N
and POS N
greater POS N
lens POS N
thickness POS N
(OR POS N
= POS N
3.38, POS N
95% POS N
CI POS N
= POS N
0.88-12.91, POS N
P POS N
= POS N
.075) POS N
demonstrated POS N
a POS N
marginally POS N
significant POS N
association. POS N

Cataract POS N
surgery POS N
at POS N
earlier POS N
stages POS N
by POS N
phacoemulsification POS N
may POS N
be POS N
more POS N
beneficial POS N
than POS N
undergoing POS N
manual POS N
SICS. POS N

Cataract POS N
surgery POS N
in POS N
eyes POS N
with POS N
nanophthalmos POS N
is POS N
associated POS N
with POS N
a POS N
high POS N
risk POS N
for POS N
vision-threatening POS N
complications. POS N

Cataract POS N
surgery POS N
at POS N
earlier POS N
stages POS N
by POS N
phacoemulsification POS N
may POS N
be POS N
more POS N
beneficial POS N
than POS N
undergoing POS N
manual POS N
SICS. POS N

Performing POS N
a POS N
simultaneous POS N
prophylactic POS N
sclerostomy POS N
with POS N
cataract POS N
surgery POS N
reduces POS N
complication POS N
rates, POS N
particularly POS N
uveal POS N
effusions. POS N

Peak POS N
oxygen POS N
consumption POS N
increased POS N
by POS N
0.24 POS N
L/min POS N
in POS N
the POS N
exercise POS N
group, POS N

whereas POS N
it POS N
decreased POS N
by POS N
0.05 POS N
L/min POS N
in POS N
the POS N
control POS N
group POS N
(mean POS N
difference, POS N
0.29 POS N
L/min; POS N
95% POS N
confidence POS N
interval POS N
[CI], POS N
0.18 POS N
to POS N
0.40; POS N
P POS N
<.001). POS N

Peak POS N
oxygen POS N
consumption POS N
increased POS N
by POS N
0.24 POS N
L/min POS N
in POS N
the POS N
exercise POS N
group, POS N

Overall POS N
QOL POS N
increased POS N
by POS N
9.1 POS N
points POS N
in POS N
the POS N
exercise POS N
group POS N
compared POS N
with POS N
0.3 POS N
points POS N
in POS N
the POS N
control POS N
group POS N
(mean POS N
difference, POS N
8.8 POS N
points; POS N
95% POS N
CI, POS N
3.6 POS N
to POS N
14.0; POS N
P POS N
=.001). POS N

Peak POS N
oxygen POS N
consumption POS N
increased POS N
by POS N
0.24 POS N
L/min POS N
in POS N
the POS N
exercise POS N
group, POS N

Pearson POS N
correlations POS N
indicated POS N
that POS N
change POS N
in POS N
peak POS N
oxygen POS N
consumption POS N
correlated POS N
with POS N
change POS N
in POS N
overall POS N
QOL POS N
(r POS N
= POS N
0.45; POS N
P POS N
<.01). POS N

Peak POS N
oxygen POS N
consumption POS N
increased POS N
by POS N
0.24 POS N
L/min POS N
in POS N
the POS N
exercise POS N
group, POS N

Exercise POS N
training POS N
had POS N
beneficial POS N
effects POS N
on POS N
cardiopulmonary POS N
function POS N
and POS N
QOL POS N
in POS N
postmenopausal POS N
breast POS N
cancer POS N
survivors. POS N

whereas POS N
it POS N
decreased POS N
by POS N
0.05 POS N
L/min POS N
in POS N
the POS N
control POS N
group POS N
(mean POS N
difference, POS N
0.29 POS N
L/min; POS N
95% POS N
confidence POS N
interval POS N
[CI], POS N
0.18 POS N
to POS N
0.40; POS N
P POS N
<.001). POS N

Peak POS N
oxygen POS N
consumption POS N
increased POS N
by POS N
0.24 POS N
L/min POS N
in POS N
the POS N
exercise POS N
group, POS N

whereas POS N
it POS N
decreased POS N
by POS N
0.05 POS N
L/min POS N
in POS N
the POS N
control POS N
group POS N
(mean POS N
difference, POS N
0.29 POS N
L/min; POS N
95% POS N
confidence POS N
interval POS N
[CI], POS N
0.18 POS N
to POS N
0.40; POS N
P POS N
<.001). POS N

Overall POS N
QOL POS N
increased POS N
by POS N
9.1 POS N
points POS N
in POS N
the POS N
exercise POS N
group POS N
compared POS N
with POS N
0.3 POS N
points POS N
in POS N
the POS N
control POS N
group POS N
(mean POS N
difference, POS N
8.8 POS N
points; POS N
95% POS N
CI, POS N
3.6 POS N
to POS N
14.0; POS N
P POS N
=.001). POS N

whereas POS N
it POS N
decreased POS N
by POS N
0.05 POS N
L/min POS N
in POS N
the POS N
control POS N
group POS N
(mean POS N
difference, POS N
0.29 POS N
L/min; POS N
95% POS N
confidence POS N
interval POS N
[CI], POS N
0.18 POS N
to POS N
0.40; POS N
P POS N
<.001). POS N

Pearson POS N
correlations POS N
indicated POS N
that POS N
change POS N
in POS N
peak POS N
oxygen POS N
consumption POS N
correlated POS N
with POS N
change POS N
in POS N
overall POS N
QOL POS N
(r POS N
= POS N
0.45; POS N
P POS N
<.01). POS N

whereas POS N
it POS N
decreased POS N
by POS N
0.05 POS N
L/min POS N
in POS N
the POS N
control POS N
group POS N
(mean POS N
difference, POS N
0.29 POS N
L/min; POS N
95% POS N
confidence POS N
interval POS N
[CI], POS N
0.18 POS N
to POS N
0.40; POS N
P POS N
<.001). POS N

Exercise POS N
training POS N
had POS N
beneficial POS N
effects POS N
on POS N
cardiopulmonary POS N
function POS N
and POS N
QOL POS N
in POS N
postmenopausal POS N
breast POS N
cancer POS N
survivors. POS N

Overall POS N
QOL POS N
increased POS N
by POS N
9.1 POS N
points POS N
in POS N
the POS N
exercise POS N
group POS N
compared POS N
with POS N
0.3 POS N
points POS N
in POS N
the POS N
control POS N
group POS N
(mean POS N
difference, POS N
8.8 POS N
points; POS N
95% POS N
CI, POS N
3.6 POS N
to POS N
14.0; POS N
P POS N
=.001). POS N

Peak POS N
oxygen POS N
consumption POS N
increased POS N
by POS N
0.24 POS N
L/min POS N
in POS N
the POS N
exercise POS N
group, POS N

Overall POS N
QOL POS N
increased POS N
by POS N
9.1 POS N
points POS N
in POS N
the POS N
exercise POS N
group POS N
compared POS N
with POS N
0.3 POS N
points POS N
in POS N
the POS N
control POS N
group POS N
(mean POS N
difference, POS N
8.8 POS N
points; POS N
95% POS N
CI, POS N
3.6 POS N
to POS N
14.0; POS N
P POS N
=.001). POS N

whereas POS N
it POS N
decreased POS N
by POS N
0.05 POS N
L/min POS N
in POS N
the POS N
control POS N
group POS N
(mean POS N
difference, POS N
0.29 POS N
L/min; POS N
95% POS N
confidence POS N
interval POS N
[CI], POS N
0.18 POS N
to POS N
0.40; POS N
P POS N
<.001). POS N

Overall POS N
QOL POS N
increased POS N
by POS N
9.1 POS N
points POS N
in POS N
the POS N
exercise POS N
group POS N
compared POS N
with POS N
0.3 POS N
points POS N
in POS N
the POS N
control POS N
group POS N
(mean POS N
difference, POS N
8.8 POS N
points; POS N
95% POS N
CI, POS N
3.6 POS N
to POS N
14.0; POS N
P POS N
=.001). POS N

Pearson POS N
correlations POS N
indicated POS N
that POS N
change POS N
in POS N
peak POS N
oxygen POS N
consumption POS N
correlated POS N
with POS N
change POS N
in POS N
overall POS N
QOL POS N
(r POS N
= POS N
0.45; POS N
P POS N
<.01). POS N

Overall POS N
QOL POS N
increased POS N
by POS N
9.1 POS N
points POS N
in POS N
the POS N
exercise POS N
group POS N
compared POS N
with POS N
0.3 POS N
points POS N
in POS N
the POS N
control POS N
group POS N
(mean POS N
difference, POS N
8.8 POS N
points; POS N
95% POS N
CI, POS N
3.6 POS N
to POS N
14.0; POS N
P POS N
=.001). POS N

Exercise POS N
training POS N
had POS N
beneficial POS N
effects POS N
on POS N
cardiopulmonary POS N
function POS N
and POS N
QOL POS N
in POS N
postmenopausal POS N
breast POS N
cancer POS N
survivors. POS N

Pearson POS N
correlations POS N
indicated POS N
that POS N
change POS N
in POS N
peak POS N
oxygen POS N
consumption POS N
correlated POS N
with POS N
change POS N
in POS N
overall POS N
QOL POS N
(r POS N
= POS N
0.45; POS N
P POS N
<.01). POS N

Peak POS N
oxygen POS N
consumption POS N
increased POS N
by POS N
0.24 POS N
L/min POS N
in POS N
the POS N
exercise POS N
group, POS N

Pearson POS N
correlations POS N
indicated POS N
that POS N
change POS N
in POS N
peak POS N
oxygen POS N
consumption POS N
correlated POS N
with POS N
change POS N
in POS N
overall POS N
QOL POS N
(r POS N
= POS N
0.45; POS N
P POS N
<.01). POS N

whereas POS N
it POS N
decreased POS N
by POS N
0.05 POS N
L/min POS N
in POS N
the POS N
control POS N
group POS N
(mean POS N
difference, POS N
0.29 POS N
L/min; POS N
95% POS N
confidence POS N
interval POS N
[CI], POS N
0.18 POS N
to POS N
0.40; POS N
P POS N
<.001). POS N

Pearson POS N
correlations POS N
indicated POS N
that POS N
change POS N
in POS N
peak POS N
oxygen POS N
consumption POS N
correlated POS N
with POS N
change POS N
in POS N
overall POS N
QOL POS N
(r POS N
= POS N
0.45; POS N
P POS N
<.01). POS N

Overall POS N
QOL POS N
increased POS N
by POS N
9.1 POS N
points POS N
in POS N
the POS N
exercise POS N
group POS N
compared POS N
with POS N
0.3 POS N
points POS N
in POS N
the POS N
control POS N
group POS N
(mean POS N
difference, POS N
8.8 POS N
points; POS N
95% POS N
CI, POS N
3.6 POS N
to POS N
14.0; POS N
P POS N
=.001). POS N

Pearson POS N
correlations POS N
indicated POS N
that POS N
change POS N
in POS N
peak POS N
oxygen POS N
consumption POS N
correlated POS N
with POS N
change POS N
in POS N
overall POS N
QOL POS N
(r POS N
= POS N
0.45; POS N
P POS N
<.01). POS N

Exercise POS N
training POS N
had POS N
beneficial POS N
effects POS N
on POS N
cardiopulmonary POS N
function POS N
and POS N
QOL POS N
in POS N
postmenopausal POS N
breast POS N
cancer POS N
survivors. POS N

Exercise POS N
training POS N
had POS N
beneficial POS N
effects POS N
on POS N
cardiopulmonary POS N
function POS N
and POS N
QOL POS N
in POS N
postmenopausal POS N
breast POS N
cancer POS N
survivors. POS N

Peak POS N
oxygen POS N
consumption POS N
increased POS N
by POS N
0.24 POS N
L/min POS N
in POS N
the POS N
exercise POS N
group, POS N

Exercise POS N
training POS N
had POS N
beneficial POS N
effects POS N
on POS N
cardiopulmonary POS N
function POS N
and POS N
QOL POS N
in POS N
postmenopausal POS N
breast POS N
cancer POS N
survivors. POS N

whereas POS N
it POS N
decreased POS N
by POS N
0.05 POS N
L/min POS N
in POS N
the POS N
control POS N
group POS N
(mean POS N
difference, POS N
0.29 POS N
L/min; POS N
95% POS N
confidence POS N
interval POS N
[CI], POS N
0.18 POS N
to POS N
0.40; POS N
P POS N
<.001). POS N

Exercise POS N
training POS N
had POS N
beneficial POS N
effects POS N
on POS N
cardiopulmonary POS N
function POS N
and POS N
QOL POS N
in POS N
postmenopausal POS N
breast POS N
cancer POS N
survivors. POS N

Overall POS N
QOL POS N
increased POS N
by POS N
9.1 POS N
points POS N
in POS N
the POS N
exercise POS N
group POS N
compared POS N
with POS N
0.3 POS N
points POS N
in POS N
the POS N
control POS N
group POS N
(mean POS N
difference, POS N
8.8 POS N
points; POS N
95% POS N
CI, POS N
3.6 POS N
to POS N
14.0; POS N
P POS N
=.001). POS N

Exercise POS N
training POS N
had POS N
beneficial POS N
effects POS N
on POS N
cardiopulmonary POS N
function POS N
and POS N
QOL POS N
in POS N
postmenopausal POS N
breast POS N
cancer POS N
survivors. POS N

Pearson POS N
correlations POS N
indicated POS N
that POS N
change POS N
in POS N
peak POS N
oxygen POS N
consumption POS N
correlated POS N
with POS N
change POS N
in POS N
overall POS N
QOL POS N
(r POS N
= POS N
0.45; POS N
P POS N
<.01). POS N

Epoetin POS N
alfa, POS N
compared POS N
with POS N
placebo, POS N
significantly POS N
decreased POS N
transfusion POS N
requirements POS N
(P POS N
=.0057) POS N
and POS N
increased POS N
hemoglobin POS N
(P POS N
<.001). POS N

Improvement POS N
of POS N
all POS N
primary POS N
cancer- POS N
and POS N
anemia-specific POS N
QOL POS N
domains, POS N
including POS N
energy POS N
level, POS N
ability POS N
to POS N
do POS N
daily POS N
activities, POS N
and POS N
fatigue, POS N
was POS N
significantly POS N
(P POS N
<.01) POS N
greater POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
placebo POS N
patients. POS N

Epoetin POS N
alfa, POS N
compared POS N
with POS N
placebo, POS N
significantly POS N
decreased POS N
transfusion POS N
requirements POS N
(P POS N
=.0057) POS N
and POS N
increased POS N
hemoglobin POS N
(P POS N
<.001). POS N

Kaplan-Meier POS N
estimates POS N
showed POS N
a POS N
trend POS N
in POS N
overall POS N
survival POS N
favoring POS N
epoetin POS N
alfa POS N
(P POS N
=.13, POS N
log-rank POS N
test), POS N

Epoetin POS N
alfa, POS N
compared POS N
with POS N
placebo, POS N
significantly POS N
decreased POS N
transfusion POS N
requirements POS N
(P POS N
=.0057) POS N
and POS N
increased POS N
hemoglobin POS N
(P POS N
<.001). POS N

Cox POS N
regression POS N
analysis POS N
showed POS N
an POS N
estimated POS N
hazards POS N
ratio POS N
of POS N
1.309 POS N
(P POS N
=.052) POS N
favoring POS N
epoetin POS N
alfa. POS N

Epoetin POS N
alfa, POS N
compared POS N
with POS N
placebo, POS N
significantly POS N
decreased POS N
transfusion POS N
requirements POS N
(P POS N
=.0057) POS N
and POS N
increased POS N
hemoglobin POS N
(P POS N
<.001). POS N

Adverse POS N
events POS N
were POS N
comparable POS N
between POS N
groups. POS N

Epoetin POS N
alfa, POS N
compared POS N
with POS N
placebo, POS N
significantly POS N
decreased POS N
transfusion POS N
requirements POS N
(P POS N
=.0057) POS N
and POS N
increased POS N
hemoglobin POS N
(P POS N
<.001). POS N

Epoetin POS N
alfa POS N
safely POS N
and POS N
effectively POS N
ameliorates POS N
anemia POS N
and POS N
significantly POS N
improves POS N
QOL POS N
in POS N
cancer POS N
patients POS N
receiving POS N
nonplatinum POS N
chemotherapy. POS N

Epoetin POS N
alfa, POS N
compared POS N
with POS N
placebo, POS N
significantly POS N
decreased POS N
transfusion POS N
requirements POS N
(P POS N
=.0057) POS N
and POS N
increased POS N
hemoglobin POS N
(P POS N
<.001). POS N

Encouraging POS N
results POS N
regarding POS N
increased POS N
survival POS N
warrant POS N
another POS N
trial POS N
designed POS N
to POS N
confirm POS N
these POS N
findings. POS N

Improvement POS N
of POS N
all POS N
primary POS N
cancer- POS N
and POS N
anemia-specific POS N
QOL POS N
domains, POS N
including POS N
energy POS N
level, POS N
ability POS N
to POS N
do POS N
daily POS N
activities, POS N
and POS N
fatigue, POS N
was POS N
significantly POS N
(P POS N
<.01) POS N
greater POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
placebo POS N
patients. POS N

Epoetin POS N
alfa, POS N
compared POS N
with POS N
placebo, POS N
significantly POS N
decreased POS N
transfusion POS N
requirements POS N
(P POS N
=.0057) POS N
and POS N
increased POS N
hemoglobin POS N
(P POS N
<.001). POS N

Improvement POS N
of POS N
all POS N
primary POS N
cancer- POS N
and POS N
anemia-specific POS N
QOL POS N
domains, POS N
including POS N
energy POS N
level, POS N
ability POS N
to POS N
do POS N
daily POS N
activities, POS N
and POS N
fatigue, POS N
was POS N
significantly POS N
(P POS N
<.01) POS N
greater POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
placebo POS N
patients. POS N

Kaplan-Meier POS N
estimates POS N
showed POS N
a POS N
trend POS N
in POS N
overall POS N
survival POS N
favoring POS N
epoetin POS N
alfa POS N
(P POS N
=.13, POS N
log-rank POS N
test), POS N

Improvement POS N
of POS N
all POS N
primary POS N
cancer- POS N
and POS N
anemia-specific POS N
QOL POS N
domains, POS N
including POS N
energy POS N
level, POS N
ability POS N
to POS N
do POS N
daily POS N
activities, POS N
and POS N
fatigue, POS N
was POS N
significantly POS N
(P POS N
<.01) POS N
greater POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
placebo POS N
patients. POS N

Cox POS N
regression POS N
analysis POS N
showed POS N
an POS N
estimated POS N
hazards POS N
ratio POS N
of POS N
1.309 POS N
(P POS N
=.052) POS N
favoring POS N
epoetin POS N
alfa. POS N

Improvement POS N
of POS N
all POS N
primary POS N
cancer- POS N
and POS N
anemia-specific POS N
QOL POS N
domains, POS N
including POS N
energy POS N
level, POS N
ability POS N
to POS N
do POS N
daily POS N
activities, POS N
and POS N
fatigue, POS N
was POS N
significantly POS N
(P POS N
<.01) POS N
greater POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
placebo POS N
patients. POS N

Adverse POS N
events POS N
were POS N
comparable POS N
between POS N
groups. POS N

Improvement POS N
of POS N
all POS N
primary POS N
cancer- POS N
and POS N
anemia-specific POS N
QOL POS N
domains, POS N
including POS N
energy POS N
level, POS N
ability POS N
to POS N
do POS N
daily POS N
activities, POS N
and POS N
fatigue, POS N
was POS N
significantly POS N
(P POS N
<.01) POS N
greater POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
placebo POS N
patients. POS N

Epoetin POS N
alfa POS N
safely POS N
and POS N
effectively POS N
ameliorates POS N
anemia POS N
and POS N
significantly POS N
improves POS N
QOL POS N
in POS N
cancer POS N
patients POS N
receiving POS N
nonplatinum POS N
chemotherapy. POS N

Improvement POS N
of POS N
all POS N
primary POS N
cancer- POS N
and POS N
anemia-specific POS N
QOL POS N
domains, POS N
including POS N
energy POS N
level, POS N
ability POS N
to POS N
do POS N
daily POS N
activities, POS N
and POS N
fatigue, POS N
was POS N
significantly POS N
(P POS N
<.01) POS N
greater POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
placebo POS N
patients. POS N

Encouraging POS N
results POS N
regarding POS N
increased POS N
survival POS N
warrant POS N
another POS N
trial POS N
designed POS N
to POS N
confirm POS N
these POS N
findings. POS N

Kaplan-Meier POS N
estimates POS N
showed POS N
a POS N
trend POS N
in POS N
overall POS N
survival POS N
favoring POS N
epoetin POS N
alfa POS N
(P POS N
=.13, POS N
log-rank POS N
test), POS N

Epoetin POS N
alfa, POS N
compared POS N
with POS N
placebo, POS N
significantly POS N
decreased POS N
transfusion POS N
requirements POS N
(P POS N
=.0057) POS N
and POS N
increased POS N
hemoglobin POS N
(P POS N
<.001). POS N

Kaplan-Meier POS N
estimates POS N
showed POS N
a POS N
trend POS N
in POS N
overall POS N
survival POS N
favoring POS N
epoetin POS N
alfa POS N
(P POS N
=.13, POS N
log-rank POS N
test), POS N

Improvement POS N
of POS N
all POS N
primary POS N
cancer- POS N
and POS N
anemia-specific POS N
QOL POS N
domains, POS N
including POS N
energy POS N
level, POS N
ability POS N
to POS N
do POS N
daily POS N
activities, POS N
and POS N
fatigue, POS N
was POS N
significantly POS N
(P POS N
<.01) POS N
greater POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
placebo POS N
patients. POS N

Kaplan-Meier POS N
estimates POS N
showed POS N
a POS N
trend POS N
in POS N
overall POS N
survival POS N
favoring POS N
epoetin POS N
alfa POS N
(P POS N
=.13, POS N
log-rank POS N
test), POS N

Cox POS N
regression POS N
analysis POS N
showed POS N
an POS N
estimated POS N
hazards POS N
ratio POS N
of POS N
1.309 POS N
(P POS N
=.052) POS N
favoring POS N
epoetin POS N
alfa. POS N

Kaplan-Meier POS N
estimates POS N
showed POS N
a POS N
trend POS N
in POS N
overall POS N
survival POS N
favoring POS N
epoetin POS N
alfa POS N
(P POS N
=.13, POS N
log-rank POS N
test), POS N

Adverse POS N
events POS N
were POS N
comparable POS N
between POS N
groups. POS N

Kaplan-Meier POS N
estimates POS N
showed POS N
a POS N
trend POS N
in POS N
overall POS N
survival POS N
favoring POS N
epoetin POS N
alfa POS N
(P POS N
=.13, POS N
log-rank POS N
test), POS N

Epoetin POS N
alfa POS N
safely POS N
and POS N
effectively POS N
ameliorates POS N
anemia POS N
and POS N
significantly POS N
improves POS N
QOL POS N
in POS N
cancer POS N
patients POS N
receiving POS N
nonplatinum POS N
chemotherapy. POS N

Kaplan-Meier POS N
estimates POS N
showed POS N
a POS N
trend POS N
in POS N
overall POS N
survival POS N
favoring POS N
epoetin POS N
alfa POS N
(P POS N
=.13, POS N
log-rank POS N
test), POS N

Encouraging POS N
results POS N
regarding POS N
increased POS N
survival POS N
warrant POS N
another POS N
trial POS N
designed POS N
to POS N
confirm POS N
these POS N
findings. POS N

Cox POS N
regression POS N
analysis POS N
showed POS N
an POS N
estimated POS N
hazards POS N
ratio POS N
of POS N
1.309 POS N
(P POS N
=.052) POS N
favoring POS N
epoetin POS N
alfa. POS N

Epoetin POS N
alfa, POS N
compared POS N
with POS N
placebo, POS N
significantly POS N
decreased POS N
transfusion POS N
requirements POS N
(P POS N
=.0057) POS N
and POS N
increased POS N
hemoglobin POS N
(P POS N
<.001). POS N

Cox POS N
regression POS N
analysis POS N
showed POS N
an POS N
estimated POS N
hazards POS N
ratio POS N
of POS N
1.309 POS N
(P POS N
=.052) POS N
favoring POS N
epoetin POS N
alfa. POS N

Improvement POS N
of POS N
all POS N
primary POS N
cancer- POS N
and POS N
anemia-specific POS N
QOL POS N
domains, POS N
including POS N
energy POS N
level, POS N
ability POS N
to POS N
do POS N
daily POS N
activities, POS N
and POS N
fatigue, POS N
was POS N
significantly POS N
(P POS N
<.01) POS N
greater POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
placebo POS N
patients. POS N

Cox POS N
regression POS N
analysis POS N
showed POS N
an POS N
estimated POS N
hazards POS N
ratio POS N
of POS N
1.309 POS N
(P POS N
=.052) POS N
favoring POS N
epoetin POS N
alfa. POS N

Kaplan-Meier POS N
estimates POS N
showed POS N
a POS N
trend POS N
in POS N
overall POS N
survival POS N
favoring POS N
epoetin POS N
alfa POS N
(P POS N
=.13, POS N
log-rank POS N
test), POS N

Cox POS N
regression POS N
analysis POS N
showed POS N
an POS N
estimated POS N
hazards POS N
ratio POS N
of POS N
1.309 POS N
(P POS N
=.052) POS N
favoring POS N
epoetin POS N
alfa. POS N

Adverse POS N
events POS N
were POS N
comparable POS N
between POS N
groups. POS N

Cox POS N
regression POS N
analysis POS N
showed POS N
an POS N
estimated POS N
hazards POS N
ratio POS N
of POS N
1.309 POS N
(P POS N
=.052) POS N
favoring POS N
epoetin POS N
alfa. POS N

Epoetin POS N
alfa POS N
safely POS N
and POS N
effectively POS N
ameliorates POS N
anemia POS N
and POS N
significantly POS N
improves POS N
QOL POS N
in POS N
cancer POS N
patients POS N
receiving POS N
nonplatinum POS N
chemotherapy. POS N

Cox POS N
regression POS N
analysis POS N
showed POS N
an POS N
estimated POS N
hazards POS N
ratio POS N
of POS N
1.309 POS N
(P POS N
=.052) POS N
favoring POS N
epoetin POS N
alfa. POS N

Encouraging POS N
results POS N
regarding POS N
increased POS N
survival POS N
warrant POS N
another POS N
trial POS N
designed POS N
to POS N
confirm POS N
these POS N
findings. POS N

Adverse POS N
events POS N
were POS N
comparable POS N
between POS N
groups. POS N

Epoetin POS N
alfa, POS N
compared POS N
with POS N
placebo, POS N
significantly POS N
decreased POS N
transfusion POS N
requirements POS N
(P POS N
=.0057) POS N
and POS N
increased POS N
hemoglobin POS N
(P POS N
<.001). POS N

Adverse POS N
events POS N
were POS N
comparable POS N
between POS N
groups. POS N

Improvement POS N
of POS N
all POS N
primary POS N
cancer- POS N
and POS N
anemia-specific POS N
QOL POS N
domains, POS N
including POS N
energy POS N
level, POS N
ability POS N
to POS N
do POS N
daily POS N
activities, POS N
and POS N
fatigue, POS N
was POS N
significantly POS N
(P POS N
<.01) POS N
greater POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
placebo POS N
patients. POS N

Adverse POS N
events POS N
were POS N
comparable POS N
between POS N
groups. POS N

Kaplan-Meier POS N
estimates POS N
showed POS N
a POS N
trend POS N
in POS N
overall POS N
survival POS N
favoring POS N
epoetin POS N
alfa POS N
(P POS N
=.13, POS N
log-rank POS N
test), POS N

Adverse POS N
events POS N
were POS N
comparable POS N
between POS N
groups. POS N

Cox POS N
regression POS N
analysis POS N
showed POS N
an POS N
estimated POS N
hazards POS N
ratio POS N
of POS N
1.309 POS N
(P POS N
=.052) POS N
favoring POS N
epoetin POS N
alfa. POS N

Adverse POS N
events POS N
were POS N
comparable POS N
between POS N
groups. POS N

Epoetin POS N
alfa POS N
safely POS N
and POS N
effectively POS N
ameliorates POS N
anemia POS N
and POS N
significantly POS N
improves POS N
QOL POS N
in POS N
cancer POS N
patients POS N
receiving POS N
nonplatinum POS N
chemotherapy. POS N

Adverse POS N
events POS N
were POS N
comparable POS N
between POS N
groups. POS N

Encouraging POS N
results POS N
regarding POS N
increased POS N
survival POS N
warrant POS N
another POS N
trial POS N
designed POS N
to POS N
confirm POS N
these POS N
findings. POS N

Epoetin POS N
alfa POS N
safely POS N
and POS N
effectively POS N
ameliorates POS N
anemia POS N
and POS N
significantly POS N
improves POS N
QOL POS N
in POS N
cancer POS N
patients POS N
receiving POS N
nonplatinum POS N
chemotherapy. POS N

Epoetin POS N
alfa, POS N
compared POS N
with POS N
placebo, POS N
significantly POS N
decreased POS N
transfusion POS N
requirements POS N
(P POS N
=.0057) POS N
and POS N
increased POS N
hemoglobin POS N
(P POS N
<.001). POS N

Epoetin POS N
alfa POS N
safely POS N
and POS N
effectively POS N
ameliorates POS N
anemia POS N
and POS N
significantly POS N
improves POS N
QOL POS N
in POS N
cancer POS N
patients POS N
receiving POS N
nonplatinum POS N
chemotherapy. POS N

Improvement POS N
of POS N
all POS N
primary POS N
cancer- POS N
and POS N
anemia-specific POS N
QOL POS N
domains, POS N
including POS N
energy POS N
level, POS N
ability POS N
to POS N
do POS N
daily POS N
activities, POS N
and POS N
fatigue, POS N
was POS N
significantly POS N
(P POS N
<.01) POS N
greater POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
placebo POS N
patients. POS N

Epoetin POS N
alfa POS N
safely POS N
and POS N
effectively POS N
ameliorates POS N
anemia POS N
and POS N
significantly POS N
improves POS N
QOL POS N
in POS N
cancer POS N
patients POS N
receiving POS N
nonplatinum POS N
chemotherapy. POS N

Kaplan-Meier POS N
estimates POS N
showed POS N
a POS N
trend POS N
in POS N
overall POS N
survival POS N
favoring POS N
epoetin POS N
alfa POS N
(P POS N
=.13, POS N
log-rank POS N
test), POS N

Epoetin POS N
alfa POS N
safely POS N
and POS N
effectively POS N
ameliorates POS N
anemia POS N
and POS N
significantly POS N
improves POS N
QOL POS N
in POS N
cancer POS N
patients POS N
receiving POS N
nonplatinum POS N
chemotherapy. POS N

Cox POS N
regression POS N
analysis POS N
showed POS N
an POS N
estimated POS N
hazards POS N
ratio POS N
of POS N
1.309 POS N
(P POS N
=.052) POS N
favoring POS N
epoetin POS N
alfa. POS N

Epoetin POS N
alfa POS N
safely POS N
and POS N
effectively POS N
ameliorates POS N
anemia POS N
and POS N
significantly POS N
improves POS N
QOL POS N
in POS N
cancer POS N
patients POS N
receiving POS N
nonplatinum POS N
chemotherapy. POS N

Adverse POS N
events POS N
were POS N
comparable POS N
between POS N
groups. POS N

Epoetin POS N
alfa POS N
safely POS N
and POS N
effectively POS N
ameliorates POS N
anemia POS N
and POS N
significantly POS N
improves POS N
QOL POS N
in POS N
cancer POS N
patients POS N
receiving POS N
nonplatinum POS N
chemotherapy. POS N

Encouraging POS N
results POS N
regarding POS N
increased POS N
survival POS N
warrant POS N
another POS N
trial POS N
designed POS N
to POS N
confirm POS N
these POS N
findings. POS N

Encouraging POS N
results POS N
regarding POS N
increased POS N
survival POS N
warrant POS N
another POS N
trial POS N
designed POS N
to POS N
confirm POS N
these POS N
findings. POS N

Epoetin POS N
alfa, POS N
compared POS N
with POS N
placebo, POS N
significantly POS N
decreased POS N
transfusion POS N
requirements POS N
(P POS N
=.0057) POS N
and POS N
increased POS N
hemoglobin POS N
(P POS N
<.001). POS N

Encouraging POS N
results POS N
regarding POS N
increased POS N
survival POS N
warrant POS N
another POS N
trial POS N
designed POS N
to POS N
confirm POS N
these POS N
findings. POS N

Improvement POS N
of POS N
all POS N
primary POS N
cancer- POS N
and POS N
anemia-specific POS N
QOL POS N
domains, POS N
including POS N
energy POS N
level, POS N
ability POS N
to POS N
do POS N
daily POS N
activities, POS N
and POS N
fatigue, POS N
was POS N
significantly POS N
(P POS N
<.01) POS N
greater POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
placebo POS N
patients. POS N

Encouraging POS N
results POS N
regarding POS N
increased POS N
survival POS N
warrant POS N
another POS N
trial POS N
designed POS N
to POS N
confirm POS N
these POS N
findings. POS N

Kaplan-Meier POS N
estimates POS N
showed POS N
a POS N
trend POS N
in POS N
overall POS N
survival POS N
favoring POS N
epoetin POS N
alfa POS N
(P POS N
=.13, POS N
log-rank POS N
test), POS N

Encouraging POS N
results POS N
regarding POS N
increased POS N
survival POS N
warrant POS N
another POS N
trial POS N
designed POS N
to POS N
confirm POS N
these POS N
findings. POS N

Cox POS N
regression POS N
analysis POS N
showed POS N
an POS N
estimated POS N
hazards POS N
ratio POS N
of POS N
1.309 POS N
(P POS N
=.052) POS N
favoring POS N
epoetin POS N
alfa. POS N

Encouraging POS N
results POS N
regarding POS N
increased POS N
survival POS N
warrant POS N
another POS N
trial POS N
designed POS N
to POS N
confirm POS N
these POS N
findings. POS N

Adverse POS N
events POS N
were POS N
comparable POS N
between POS N
groups. POS N

Encouraging POS N
results POS N
regarding POS N
increased POS N
survival POS N
warrant POS N
another POS N
trial POS N
designed POS N
to POS N
confirm POS N
these POS N
findings. POS N

Epoetin POS N
alfa POS N
safely POS N
and POS N
effectively POS N
ameliorates POS N
anemia POS N
and POS N
significantly POS N
improves POS N
QOL POS N
in POS N
cancer POS N
patients POS N
receiving POS N
nonplatinum POS N
chemotherapy. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
(SBP) POS N
of POS N
the POS N
ISH POS N
LSSalt POS N
group POS N
had POS N
significantly POS N
decreased POS N
by POS N
10.18 POS N
mm POS N
Hg POS N
(95% POS N
confidence POS N
interval POS N
(CI): POS N
3.13 POS N
to POS N
17.2, POS N
P = .006) POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
ISH POS N
NSalt POS N
group, POS N

the POS N
mean POS N
SBP POS N
only POS N
decreased POS N
by POS N
5.10 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-2.02 POS N
to POS N
12.2, POS N
P = .158) POS N
in POS N
the POS N
NISH POS N
LSSalt POS N
group POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
NISH POS N
NSalt POS N
group. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
(SBP) POS N
of POS N
the POS N
ISH POS N
LSSalt POS N
group POS N
had POS N
significantly POS N
decreased POS N
by POS N
10.18 POS N
mm POS N
Hg POS N
(95% POS N
confidence POS N
interval POS N
(CI): POS N
3.13 POS N
to POS N
17.2, POS N
P = .006) POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
ISH POS N
NSalt POS N
group, POS N

The POS N
mean POS N
diastolic POS N
blood POS N
pressure POS N
(DBP) POS N
had POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
ISH POS N
and POS N
NISH POS N
groups. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
(SBP) POS N
of POS N
the POS N
ISH POS N
LSSalt POS N
group POS N
had POS N
significantly POS N
decreased POS N
by POS N
10.18 POS N
mm POS N
Hg POS N
(95% POS N
confidence POS N
interval POS N
(CI): POS N
3.13 POS N
to POS N
17.2, POS N
P = .006) POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
ISH POS N
NSalt POS N
group, POS N

No POS N
obvious POS N
renin POS N
angiotensin POS N
system POS N
activation POS N
was POS N
found POS N
after POS N
LSSalt POS N
intervention. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
(SBP) POS N
of POS N
the POS N
ISH POS N
LSSalt POS N
group POS N
had POS N
significantly POS N
decreased POS N
by POS N
10.18 POS N
mm POS N
Hg POS N
(95% POS N
confidence POS N
interval POS N
(CI): POS N
3.13 POS N
to POS N
17.2, POS N
P = .006) POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
ISH POS N
NSalt POS N
group, POS N

The POS N
present POS N
study POS N
showed POS N
that POS N
the POS N
SBP POS N
of POS N
ISH POS N
patients POS N
was POS N
significantly POS N
decreased POS N
with POS N
the POS N
LSSalt POS N
intervention, POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
(SBP) POS N
of POS N
the POS N
ISH POS N
LSSalt POS N
group POS N
had POS N
significantly POS N
decreased POS N
by POS N
10.18 POS N
mm POS N
Hg POS N
(95% POS N
confidence POS N
interval POS N
(CI): POS N
3.13 POS N
to POS N
17.2, POS N
P = .006) POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
ISH POS N
NSalt POS N
group, POS N

neither POS N
the POS N
SBP POS N
of POS N
the POS N
NISH POS N
patients POS N
nor POS N
the POS N
DBP POS N
of POS N
either POS N
group POS N
were POS N
similarly POS N
decreased, POS N
which POS N
indicated POS N
that POS N
ISH POS N
patients POS N
were POS N
more POS N
sensitive POS N
to POS N
salt POS N
restriction. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
(SBP) POS N
of POS N
the POS N
ISH POS N
LSSalt POS N
group POS N
had POS N
significantly POS N
decreased POS N
by POS N
10.18 POS N
mm POS N
Hg POS N
(95% POS N
confidence POS N
interval POS N
(CI): POS N
3.13 POS N
to POS N
17.2, POS N
P = .006) POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
ISH POS N
NSalt POS N
group, POS N

Regarding POS N
the POS N
urinary POS N
excretion POS N
of POS N
electrolytes POS N
and POS N
blood POS N
biochemical POS N
assays, POS N
the POS N
LSSalt POS N
treatment POS N
had POS N
the POS N
same POS N
effects POS N
on POS N
the POS N
ISH POS N
group POS N
as POS N
on POS N
the POS N
NISH POS N
group. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
(SBP) POS N
of POS N
the POS N
ISH POS N
LSSalt POS N
group POS N
had POS N
significantly POS N
decreased POS N
by POS N
10.18 POS N
mm POS N
Hg POS N
(95% POS N
confidence POS N
interval POS N
(CI): POS N
3.13 POS N
to POS N
17.2, POS N
P = .006) POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
ISH POS N
NSalt POS N
group, POS N

Evidence POS N
has POS N
shown POS N
that POS N
long-term POS N
sodium POS N
reduction POS N
can POS N
not POS N
only POS N
reduce POS N
blood POS N
pressure, POS N
but POS N
also POS N
provide POS N
cardiovascular POS N
benefits. POS N

the POS N
mean POS N
SBP POS N
only POS N
decreased POS N
by POS N
5.10 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-2.02 POS N
to POS N
12.2, POS N
P = .158) POS N
in POS N
the POS N
NISH POS N
LSSalt POS N
group POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
NISH POS N
NSalt POS N
group. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
(SBP) POS N
of POS N
the POS N
ISH POS N
LSSalt POS N
group POS N
had POS N
significantly POS N
decreased POS N
by POS N
10.18 POS N
mm POS N
Hg POS N
(95% POS N
confidence POS N
interval POS N
(CI): POS N
3.13 POS N
to POS N
17.2, POS N
P = .006) POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
ISH POS N
NSalt POS N
group, POS N

the POS N
mean POS N
SBP POS N
only POS N
decreased POS N
by POS N
5.10 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-2.02 POS N
to POS N
12.2, POS N
P = .158) POS N
in POS N
the POS N
NISH POS N
LSSalt POS N
group POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
NISH POS N
NSalt POS N
group. POS N

The POS N
mean POS N
diastolic POS N
blood POS N
pressure POS N
(DBP) POS N
had POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
ISH POS N
and POS N
NISH POS N
groups. POS N

the POS N
mean POS N
SBP POS N
only POS N
decreased POS N
by POS N
5.10 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-2.02 POS N
to POS N
12.2, POS N
P = .158) POS N
in POS N
the POS N
NISH POS N
LSSalt POS N
group POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
NISH POS N
NSalt POS N
group. POS N

No POS N
obvious POS N
renin POS N
angiotensin POS N
system POS N
activation POS N
was POS N
found POS N
after POS N
LSSalt POS N
intervention. POS N

the POS N
mean POS N
SBP POS N
only POS N
decreased POS N
by POS N
5.10 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-2.02 POS N
to POS N
12.2, POS N
P = .158) POS N
in POS N
the POS N
NISH POS N
LSSalt POS N
group POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
NISH POS N
NSalt POS N
group. POS N

The POS N
present POS N
study POS N
showed POS N
that POS N
the POS N
SBP POS N
of POS N
ISH POS N
patients POS N
was POS N
significantly POS N
decreased POS N
with POS N
the POS N
LSSalt POS N
intervention, POS N

the POS N
mean POS N
SBP POS N
only POS N
decreased POS N
by POS N
5.10 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-2.02 POS N
to POS N
12.2, POS N
P = .158) POS N
in POS N
the POS N
NISH POS N
LSSalt POS N
group POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
NISH POS N
NSalt POS N
group. POS N

neither POS N
the POS N
SBP POS N
of POS N
the POS N
NISH POS N
patients POS N
nor POS N
the POS N
DBP POS N
of POS N
either POS N
group POS N
were POS N
similarly POS N
decreased, POS N
which POS N
indicated POS N
that POS N
ISH POS N
patients POS N
were POS N
more POS N
sensitive POS N
to POS N
salt POS N
restriction. POS N

the POS N
mean POS N
SBP POS N
only POS N
decreased POS N
by POS N
5.10 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-2.02 POS N
to POS N
12.2, POS N
P = .158) POS N
in POS N
the POS N
NISH POS N
LSSalt POS N
group POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
NISH POS N
NSalt POS N
group. POS N

Regarding POS N
the POS N
urinary POS N
excretion POS N
of POS N
electrolytes POS N
and POS N
blood POS N
biochemical POS N
assays, POS N
the POS N
LSSalt POS N
treatment POS N
had POS N
the POS N
same POS N
effects POS N
on POS N
the POS N
ISH POS N
group POS N
as POS N
on POS N
the POS N
NISH POS N
group. POS N

the POS N
mean POS N
SBP POS N
only POS N
decreased POS N
by POS N
5.10 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-2.02 POS N
to POS N
12.2, POS N
P = .158) POS N
in POS N
the POS N
NISH POS N
LSSalt POS N
group POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
NISH POS N
NSalt POS N
group. POS N

Evidence POS N
has POS N
shown POS N
that POS N
long-term POS N
sodium POS N
reduction POS N
can POS N
not POS N
only POS N
reduce POS N
blood POS N
pressure, POS N
but POS N
also POS N
provide POS N
cardiovascular POS N
benefits. POS N

The POS N
mean POS N
diastolic POS N
blood POS N
pressure POS N
(DBP) POS N
had POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
ISH POS N
and POS N
NISH POS N
groups. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
(SBP) POS N
of POS N
the POS N
ISH POS N
LSSalt POS N
group POS N
had POS N
significantly POS N
decreased POS N
by POS N
10.18 POS N
mm POS N
Hg POS N
(95% POS N
confidence POS N
interval POS N
(CI): POS N
3.13 POS N
to POS N
17.2, POS N
P = .006) POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
ISH POS N
NSalt POS N
group, POS N

The POS N
mean POS N
diastolic POS N
blood POS N
pressure POS N
(DBP) POS N
had POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
ISH POS N
and POS N
NISH POS N
groups. POS N

the POS N
mean POS N
SBP POS N
only POS N
decreased POS N
by POS N
5.10 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-2.02 POS N
to POS N
12.2, POS N
P = .158) POS N
in POS N
the POS N
NISH POS N
LSSalt POS N
group POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
NISH POS N
NSalt POS N
group. POS N

The POS N
mean POS N
diastolic POS N
blood POS N
pressure POS N
(DBP) POS N
had POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
ISH POS N
and POS N
NISH POS N
groups. POS N

No POS N
obvious POS N
renin POS N
angiotensin POS N
system POS N
activation POS N
was POS N
found POS N
after POS N
LSSalt POS N
intervention. POS N

The POS N
mean POS N
diastolic POS N
blood POS N
pressure POS N
(DBP) POS N
had POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
ISH POS N
and POS N
NISH POS N
groups. POS N

The POS N
present POS N
study POS N
showed POS N
that POS N
the POS N
SBP POS N
of POS N
ISH POS N
patients POS N
was POS N
significantly POS N
decreased POS N
with POS N
the POS N
LSSalt POS N
intervention, POS N

The POS N
mean POS N
diastolic POS N
blood POS N
pressure POS N
(DBP) POS N
had POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
ISH POS N
and POS N
NISH POS N
groups. POS N

neither POS N
the POS N
SBP POS N
of POS N
the POS N
NISH POS N
patients POS N
nor POS N
the POS N
DBP POS N
of POS N
either POS N
group POS N
were POS N
similarly POS N
decreased, POS N
which POS N
indicated POS N
that POS N
ISH POS N
patients POS N
were POS N
more POS N
sensitive POS N
to POS N
salt POS N
restriction. POS N

The POS N
mean POS N
diastolic POS N
blood POS N
pressure POS N
(DBP) POS N
had POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
ISH POS N
and POS N
NISH POS N
groups. POS N

Regarding POS N
the POS N
urinary POS N
excretion POS N
of POS N
electrolytes POS N
and POS N
blood POS N
biochemical POS N
assays, POS N
the POS N
LSSalt POS N
treatment POS N
had POS N
the POS N
same POS N
effects POS N
on POS N
the POS N
ISH POS N
group POS N
as POS N
on POS N
the POS N
NISH POS N
group. POS N

The POS N
mean POS N
diastolic POS N
blood POS N
pressure POS N
(DBP) POS N
had POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
ISH POS N
and POS N
NISH POS N
groups. POS N

Evidence POS N
has POS N
shown POS N
that POS N
long-term POS N
sodium POS N
reduction POS N
can POS N
not POS N
only POS N
reduce POS N
blood POS N
pressure, POS N
but POS N
also POS N
provide POS N
cardiovascular POS N
benefits. POS N

No POS N
obvious POS N
renin POS N
angiotensin POS N
system POS N
activation POS N
was POS N
found POS N
after POS N
LSSalt POS N
intervention. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
(SBP) POS N
of POS N
the POS N
ISH POS N
LSSalt POS N
group POS N
had POS N
significantly POS N
decreased POS N
by POS N
10.18 POS N
mm POS N
Hg POS N
(95% POS N
confidence POS N
interval POS N
(CI): POS N
3.13 POS N
to POS N
17.2, POS N
P = .006) POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
ISH POS N
NSalt POS N
group, POS N

No POS N
obvious POS N
renin POS N
angiotensin POS N
system POS N
activation POS N
was POS N
found POS N
after POS N
LSSalt POS N
intervention. POS N

the POS N
mean POS N
SBP POS N
only POS N
decreased POS N
by POS N
5.10 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-2.02 POS N
to POS N
12.2, POS N
P = .158) POS N
in POS N
the POS N
NISH POS N
LSSalt POS N
group POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
NISH POS N
NSalt POS N
group. POS N

No POS N
obvious POS N
renin POS N
angiotensin POS N
system POS N
activation POS N
was POS N
found POS N
after POS N
LSSalt POS N
intervention. POS N

The POS N
mean POS N
diastolic POS N
blood POS N
pressure POS N
(DBP) POS N
had POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
ISH POS N
and POS N
NISH POS N
groups. POS N

No POS N
obvious POS N
renin POS N
angiotensin POS N
system POS N
activation POS N
was POS N
found POS N
after POS N
LSSalt POS N
intervention. POS N

The POS N
present POS N
study POS N
showed POS N
that POS N
the POS N
SBP POS N
of POS N
ISH POS N
patients POS N
was POS N
significantly POS N
decreased POS N
with POS N
the POS N
LSSalt POS N
intervention, POS N

No POS N
obvious POS N
renin POS N
angiotensin POS N
system POS N
activation POS N
was POS N
found POS N
after POS N
LSSalt POS N
intervention. POS N

neither POS N
the POS N
SBP POS N
of POS N
the POS N
NISH POS N
patients POS N
nor POS N
the POS N
DBP POS N
of POS N
either POS N
group POS N
were POS N
similarly POS N
decreased, POS N
which POS N
indicated POS N
that POS N
ISH POS N
patients POS N
were POS N
more POS N
sensitive POS N
to POS N
salt POS N
restriction. POS N

No POS N
obvious POS N
renin POS N
angiotensin POS N
system POS N
activation POS N
was POS N
found POS N
after POS N
LSSalt POS N
intervention. POS N

Regarding POS N
the POS N
urinary POS N
excretion POS N
of POS N
electrolytes POS N
and POS N
blood POS N
biochemical POS N
assays, POS N
the POS N
LSSalt POS N
treatment POS N
had POS N
the POS N
same POS N
effects POS N
on POS N
the POS N
ISH POS N
group POS N
as POS N
on POS N
the POS N
NISH POS N
group. POS N

No POS N
obvious POS N
renin POS N
angiotensin POS N
system POS N
activation POS N
was POS N
found POS N
after POS N
LSSalt POS N
intervention. POS N

Evidence POS N
has POS N
shown POS N
that POS N
long-term POS N
sodium POS N
reduction POS N
can POS N
not POS N
only POS N
reduce POS N
blood POS N
pressure, POS N
but POS N
also POS N
provide POS N
cardiovascular POS N
benefits. POS N

The POS N
present POS N
study POS N
showed POS N
that POS N
the POS N
SBP POS N
of POS N
ISH POS N
patients POS N
was POS N
significantly POS N
decreased POS N
with POS N
the POS N
LSSalt POS N
intervention, POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
(SBP) POS N
of POS N
the POS N
ISH POS N
LSSalt POS N
group POS N
had POS N
significantly POS N
decreased POS N
by POS N
10.18 POS N
mm POS N
Hg POS N
(95% POS N
confidence POS N
interval POS N
(CI): POS N
3.13 POS N
to POS N
17.2, POS N
P = .006) POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
ISH POS N
NSalt POS N
group, POS N

The POS N
present POS N
study POS N
showed POS N
that POS N
the POS N
SBP POS N
of POS N
ISH POS N
patients POS N
was POS N
significantly POS N
decreased POS N
with POS N
the POS N
LSSalt POS N
intervention, POS N

the POS N
mean POS N
SBP POS N
only POS N
decreased POS N
by POS N
5.10 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-2.02 POS N
to POS N
12.2, POS N
P = .158) POS N
in POS N
the POS N
NISH POS N
LSSalt POS N
group POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
NISH POS N
NSalt POS N
group. POS N

The POS N
present POS N
study POS N
showed POS N
that POS N
the POS N
SBP POS N
of POS N
ISH POS N
patients POS N
was POS N
significantly POS N
decreased POS N
with POS N
the POS N
LSSalt POS N
intervention, POS N

The POS N
mean POS N
diastolic POS N
blood POS N
pressure POS N
(DBP) POS N
had POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
ISH POS N
and POS N
NISH POS N
groups. POS N

The POS N
present POS N
study POS N
showed POS N
that POS N
the POS N
SBP POS N
of POS N
ISH POS N
patients POS N
was POS N
significantly POS N
decreased POS N
with POS N
the POS N
LSSalt POS N
intervention, POS N

No POS N
obvious POS N
renin POS N
angiotensin POS N
system POS N
activation POS N
was POS N
found POS N
after POS N
LSSalt POS N
intervention. POS N

The POS N
present POS N
study POS N
showed POS N
that POS N
the POS N
SBP POS N
of POS N
ISH POS N
patients POS N
was POS N
significantly POS N
decreased POS N
with POS N
the POS N
LSSalt POS N
intervention, POS N

neither POS N
the POS N
SBP POS N
of POS N
the POS N
NISH POS N
patients POS N
nor POS N
the POS N
DBP POS N
of POS N
either POS N
group POS N
were POS N
similarly POS N
decreased, POS N
which POS N
indicated POS N
that POS N
ISH POS N
patients POS N
were POS N
more POS N
sensitive POS N
to POS N
salt POS N
restriction. POS N

The POS N
present POS N
study POS N
showed POS N
that POS N
the POS N
SBP POS N
of POS N
ISH POS N
patients POS N
was POS N
significantly POS N
decreased POS N
with POS N
the POS N
LSSalt POS N
intervention, POS N

Regarding POS N
the POS N
urinary POS N
excretion POS N
of POS N
electrolytes POS N
and POS N
blood POS N
biochemical POS N
assays, POS N
the POS N
LSSalt POS N
treatment POS N
had POS N
the POS N
same POS N
effects POS N
on POS N
the POS N
ISH POS N
group POS N
as POS N
on POS N
the POS N
NISH POS N
group. POS N

The POS N
present POS N
study POS N
showed POS N
that POS N
the POS N
SBP POS N
of POS N
ISH POS N
patients POS N
was POS N
significantly POS N
decreased POS N
with POS N
the POS N
LSSalt POS N
intervention, POS N

Evidence POS N
has POS N
shown POS N
that POS N
long-term POS N
sodium POS N
reduction POS N
can POS N
not POS N
only POS N
reduce POS N
blood POS N
pressure, POS N
but POS N
also POS N
provide POS N
cardiovascular POS N
benefits. POS N

neither POS N
the POS N
SBP POS N
of POS N
the POS N
NISH POS N
patients POS N
nor POS N
the POS N
DBP POS N
of POS N
either POS N
group POS N
were POS N
similarly POS N
decreased, POS N
which POS N
indicated POS N
that POS N
ISH POS N
patients POS N
were POS N
more POS N
sensitive POS N
to POS N
salt POS N
restriction. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
(SBP) POS N
of POS N
the POS N
ISH POS N
LSSalt POS N
group POS N
had POS N
significantly POS N
decreased POS N
by POS N
10.18 POS N
mm POS N
Hg POS N
(95% POS N
confidence POS N
interval POS N
(CI): POS N
3.13 POS N
to POS N
17.2, POS N
P = .006) POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
ISH POS N
NSalt POS N
group, POS N

neither POS N
the POS N
SBP POS N
of POS N
the POS N
NISH POS N
patients POS N
nor POS N
the POS N
DBP POS N
of POS N
either POS N
group POS N
were POS N
similarly POS N
decreased, POS N
which POS N
indicated POS N
that POS N
ISH POS N
patients POS N
were POS N
more POS N
sensitive POS N
to POS N
salt POS N
restriction. POS N

the POS N
mean POS N
SBP POS N
only POS N
decreased POS N
by POS N
5.10 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-2.02 POS N
to POS N
12.2, POS N
P = .158) POS N
in POS N
the POS N
NISH POS N
LSSalt POS N
group POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
NISH POS N
NSalt POS N
group. POS N

neither POS N
the POS N
SBP POS N
of POS N
the POS N
NISH POS N
patients POS N
nor POS N
the POS N
DBP POS N
of POS N
either POS N
group POS N
were POS N
similarly POS N
decreased, POS N
which POS N
indicated POS N
that POS N
ISH POS N
patients POS N
were POS N
more POS N
sensitive POS N
to POS N
salt POS N
restriction. POS N

The POS N
mean POS N
diastolic POS N
blood POS N
pressure POS N
(DBP) POS N
had POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
ISH POS N
and POS N
NISH POS N
groups. POS N

neither POS N
the POS N
SBP POS N
of POS N
the POS N
NISH POS N
patients POS N
nor POS N
the POS N
DBP POS N
of POS N
either POS N
group POS N
were POS N
similarly POS N
decreased, POS N
which POS N
indicated POS N
that POS N
ISH POS N
patients POS N
were POS N
more POS N
sensitive POS N
to POS N
salt POS N
restriction. POS N

No POS N
obvious POS N
renin POS N
angiotensin POS N
system POS N
activation POS N
was POS N
found POS N
after POS N
LSSalt POS N
intervention. POS N

neither POS N
the POS N
SBP POS N
of POS N
the POS N
NISH POS N
patients POS N
nor POS N
the POS N
DBP POS N
of POS N
either POS N
group POS N
were POS N
similarly POS N
decreased, POS N
which POS N
indicated POS N
that POS N
ISH POS N
patients POS N
were POS N
more POS N
sensitive POS N
to POS N
salt POS N
restriction. POS N

The POS N
present POS N
study POS N
showed POS N
that POS N
the POS N
SBP POS N
of POS N
ISH POS N
patients POS N
was POS N
significantly POS N
decreased POS N
with POS N
the POS N
LSSalt POS N
intervention, POS N

neither POS N
the POS N
SBP POS N
of POS N
the POS N
NISH POS N
patients POS N
nor POS N
the POS N
DBP POS N
of POS N
either POS N
group POS N
were POS N
similarly POS N
decreased, POS N
which POS N
indicated POS N
that POS N
ISH POS N
patients POS N
were POS N
more POS N
sensitive POS N
to POS N
salt POS N
restriction. POS N

Regarding POS N
the POS N
urinary POS N
excretion POS N
of POS N
electrolytes POS N
and POS N
blood POS N
biochemical POS N
assays, POS N
the POS N
LSSalt POS N
treatment POS N
had POS N
the POS N
same POS N
effects POS N
on POS N
the POS N
ISH POS N
group POS N
as POS N
on POS N
the POS N
NISH POS N
group. POS N

neither POS N
the POS N
SBP POS N
of POS N
the POS N
NISH POS N
patients POS N
nor POS N
the POS N
DBP POS N
of POS N
either POS N
group POS N
were POS N
similarly POS N
decreased, POS N
which POS N
indicated POS N
that POS N
ISH POS N
patients POS N
were POS N
more POS N
sensitive POS N
to POS N
salt POS N
restriction. POS N

Evidence POS N
has POS N
shown POS N
that POS N
long-term POS N
sodium POS N
reduction POS N
can POS N
not POS N
only POS N
reduce POS N
blood POS N
pressure, POS N
but POS N
also POS N
provide POS N
cardiovascular POS N
benefits. POS N

Regarding POS N
the POS N
urinary POS N
excretion POS N
of POS N
electrolytes POS N
and POS N
blood POS N
biochemical POS N
assays, POS N
the POS N
LSSalt POS N
treatment POS N
had POS N
the POS N
same POS N
effects POS N
on POS N
the POS N
ISH POS N
group POS N
as POS N
on POS N
the POS N
NISH POS N
group. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
(SBP) POS N
of POS N
the POS N
ISH POS N
LSSalt POS N
group POS N
had POS N
significantly POS N
decreased POS N
by POS N
10.18 POS N
mm POS N
Hg POS N
(95% POS N
confidence POS N
interval POS N
(CI): POS N
3.13 POS N
to POS N
17.2, POS N
P = .006) POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
ISH POS N
NSalt POS N
group, POS N

Regarding POS N
the POS N
urinary POS N
excretion POS N
of POS N
electrolytes POS N
and POS N
blood POS N
biochemical POS N
assays, POS N
the POS N
LSSalt POS N
treatment POS N
had POS N
the POS N
same POS N
effects POS N
on POS N
the POS N
ISH POS N
group POS N
as POS N
on POS N
the POS N
NISH POS N
group. POS N

the POS N
mean POS N
SBP POS N
only POS N
decreased POS N
by POS N
5.10 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-2.02 POS N
to POS N
12.2, POS N
P = .158) POS N
in POS N
the POS N
NISH POS N
LSSalt POS N
group POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
NISH POS N
NSalt POS N
group. POS N

Regarding POS N
the POS N
urinary POS N
excretion POS N
of POS N
electrolytes POS N
and POS N
blood POS N
biochemical POS N
assays, POS N
the POS N
LSSalt POS N
treatment POS N
had POS N
the POS N
same POS N
effects POS N
on POS N
the POS N
ISH POS N
group POS N
as POS N
on POS N
the POS N
NISH POS N
group. POS N

The POS N
mean POS N
diastolic POS N
blood POS N
pressure POS N
(DBP) POS N
had POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
ISH POS N
and POS N
NISH POS N
groups. POS N

Regarding POS N
the POS N
urinary POS N
excretion POS N
of POS N
electrolytes POS N
and POS N
blood POS N
biochemical POS N
assays, POS N
the POS N
LSSalt POS N
treatment POS N
had POS N
the POS N
same POS N
effects POS N
on POS N
the POS N
ISH POS N
group POS N
as POS N
on POS N
the POS N
NISH POS N
group. POS N

No POS N
obvious POS N
renin POS N
angiotensin POS N
system POS N
activation POS N
was POS N
found POS N
after POS N
LSSalt POS N
intervention. POS N

Regarding POS N
the POS N
urinary POS N
excretion POS N
of POS N
electrolytes POS N
and POS N
blood POS N
biochemical POS N
assays, POS N
the POS N
LSSalt POS N
treatment POS N
had POS N
the POS N
same POS N
effects POS N
on POS N
the POS N
ISH POS N
group POS N
as POS N
on POS N
the POS N
NISH POS N
group. POS N

The POS N
present POS N
study POS N
showed POS N
that POS N
the POS N
SBP POS N
of POS N
ISH POS N
patients POS N
was POS N
significantly POS N
decreased POS N
with POS N
the POS N
LSSalt POS N
intervention, POS N

Regarding POS N
the POS N
urinary POS N
excretion POS N
of POS N
electrolytes POS N
and POS N
blood POS N
biochemical POS N
assays, POS N
the POS N
LSSalt POS N
treatment POS N
had POS N
the POS N
same POS N
effects POS N
on POS N
the POS N
ISH POS N
group POS N
as POS N
on POS N
the POS N
NISH POS N
group. POS N

neither POS N
the POS N
SBP POS N
of POS N
the POS N
NISH POS N
patients POS N
nor POS N
the POS N
DBP POS N
of POS N
either POS N
group POS N
were POS N
similarly POS N
decreased, POS N
which POS N
indicated POS N
that POS N
ISH POS N
patients POS N
were POS N
more POS N
sensitive POS N
to POS N
salt POS N
restriction. POS N

Regarding POS N
the POS N
urinary POS N
excretion POS N
of POS N
electrolytes POS N
and POS N
blood POS N
biochemical POS N
assays, POS N
the POS N
LSSalt POS N
treatment POS N
had POS N
the POS N
same POS N
effects POS N
on POS N
the POS N
ISH POS N
group POS N
as POS N
on POS N
the POS N
NISH POS N
group. POS N

Evidence POS N
has POS N
shown POS N
that POS N
long-term POS N
sodium POS N
reduction POS N
can POS N
not POS N
only POS N
reduce POS N
blood POS N
pressure, POS N
but POS N
also POS N
provide POS N
cardiovascular POS N
benefits. POS N

Evidence POS N
has POS N
shown POS N
that POS N
long-term POS N
sodium POS N
reduction POS N
can POS N
not POS N
only POS N
reduce POS N
blood POS N
pressure, POS N
but POS N
also POS N
provide POS N
cardiovascular POS N
benefits. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
(SBP) POS N
of POS N
the POS N
ISH POS N
LSSalt POS N
group POS N
had POS N
significantly POS N
decreased POS N
by POS N
10.18 POS N
mm POS N
Hg POS N
(95% POS N
confidence POS N
interval POS N
(CI): POS N
3.13 POS N
to POS N
17.2, POS N
P = .006) POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
ISH POS N
NSalt POS N
group, POS N

Evidence POS N
has POS N
shown POS N
that POS N
long-term POS N
sodium POS N
reduction POS N
can POS N
not POS N
only POS N
reduce POS N
blood POS N
pressure, POS N
but POS N
also POS N
provide POS N
cardiovascular POS N
benefits. POS N

the POS N
mean POS N
SBP POS N
only POS N
decreased POS N
by POS N
5.10 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-2.02 POS N
to POS N
12.2, POS N
P = .158) POS N
in POS N
the POS N
NISH POS N
LSSalt POS N
group POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
NISH POS N
NSalt POS N
group. POS N

Evidence POS N
has POS N
shown POS N
that POS N
long-term POS N
sodium POS N
reduction POS N
can POS N
not POS N
only POS N
reduce POS N
blood POS N
pressure, POS N
but POS N
also POS N
provide POS N
cardiovascular POS N
benefits. POS N

The POS N
mean POS N
diastolic POS N
blood POS N
pressure POS N
(DBP) POS N
had POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
ISH POS N
and POS N
NISH POS N
groups. POS N

Evidence POS N
has POS N
shown POS N
that POS N
long-term POS N
sodium POS N
reduction POS N
can POS N
not POS N
only POS N
reduce POS N
blood POS N
pressure, POS N
but POS N
also POS N
provide POS N
cardiovascular POS N
benefits. POS N

No POS N
obvious POS N
renin POS N
angiotensin POS N
system POS N
activation POS N
was POS N
found POS N
after POS N
LSSalt POS N
intervention. POS N

Evidence POS N
has POS N
shown POS N
that POS N
long-term POS N
sodium POS N
reduction POS N
can POS N
not POS N
only POS N
reduce POS N
blood POS N
pressure, POS N
but POS N
also POS N
provide POS N
cardiovascular POS N
benefits. POS N

The POS N
present POS N
study POS N
showed POS N
that POS N
the POS N
SBP POS N
of POS N
ISH POS N
patients POS N
was POS N
significantly POS N
decreased POS N
with POS N
the POS N
LSSalt POS N
intervention, POS N

Evidence POS N
has POS N
shown POS N
that POS N
long-term POS N
sodium POS N
reduction POS N
can POS N
not POS N
only POS N
reduce POS N
blood POS N
pressure, POS N
but POS N
also POS N
provide POS N
cardiovascular POS N
benefits. POS N

neither POS N
the POS N
SBP POS N
of POS N
the POS N
NISH POS N
patients POS N
nor POS N
the POS N
DBP POS N
of POS N
either POS N
group POS N
were POS N
similarly POS N
decreased, POS N
which POS N
indicated POS N
that POS N
ISH POS N
patients POS N
were POS N
more POS N
sensitive POS N
to POS N
salt POS N
restriction. POS N

Evidence POS N
has POS N
shown POS N
that POS N
long-term POS N
sodium POS N
reduction POS N
can POS N
not POS N
only POS N
reduce POS N
blood POS N
pressure, POS N
but POS N
also POS N
provide POS N
cardiovascular POS N
benefits. POS N

Regarding POS N
the POS N
urinary POS N
excretion POS N
of POS N
electrolytes POS N
and POS N
blood POS N
biochemical POS N
assays, POS N
the POS N
LSSalt POS N
treatment POS N
had POS N
the POS N
same POS N
effects POS N
on POS N
the POS N
ISH POS N
group POS N
as POS N
on POS N
the POS N
NISH POS N
group. POS N

Available POS N
data POS N
indicate POS N
that POS N
dietary POS N
sodium POS N
(as POS N
salt) POS N
relates POS N
directly POS N
to POS N
blood POS N
pressure POS N
(BP). POS N

Normal POS N
weight POS N
and POS N
obese POS N
participants POS N
manifested POS N
significant POS N
positive POS N
relations POS N
to POS N
BP POS N
of POS N
urinary POS N
sodium; POS N
relations POS N
were POS N
weaker POS N
for POS N
overweight POS N
people. POS N

Available POS N
data POS N
indicate POS N
that POS N
dietary POS N
sodium POS N
(as POS N
salt) POS N
relates POS N
directly POS N
to POS N
blood POS N
pressure POS N
(BP). POS N

At POS N
lower POS N
but POS N
not POS N
higher POS N
levels POS N
of POS N
24-hour POS N
sodium POS N
excretion, POS N
potassium POS N
intake POS N
blunted POS N
the POS N
sodium-BP POS N
relation. POS N

Available POS N
data POS N
indicate POS N
that POS N
dietary POS N
sodium POS N
(as POS N
salt) POS N
relates POS N
directly POS N
to POS N
blood POS N
pressure POS N
(BP). POS N

The POS N
adverse POS N
association POS N
of POS N
dietary POS N
sodium POS N
with POS N
BP POS N
is POS N
minimally POS N
attenuated POS N
by POS N
other POS N
dietary POS N
constituents; POS N

Available POS N
data POS N
indicate POS N
that POS N
dietary POS N
sodium POS N
(as POS N
salt) POS N
relates POS N
directly POS N
to POS N
blood POS N
pressure POS N
(BP). POS N

these POS N
findings POS N
underscore POS N
the POS N
importance POS N
of POS N
reducing POS N
salt POS N
intake POS N
for POS N
the POS N
prevention POS N
and POS N
control POS N
of POS N
prehypertension POS N
and POS N
hypertension. POS N

Normal POS N
weight POS N
and POS N
obese POS N
participants POS N
manifested POS N
significant POS N
positive POS N
relations POS N
to POS N
BP POS N
of POS N
urinary POS N
sodium; POS N
relations POS N
were POS N
weaker POS N
for POS N
overweight POS N
people. POS N

Available POS N
data POS N
indicate POS N
that POS N
dietary POS N
sodium POS N
(as POS N
salt) POS N
relates POS N
directly POS N
to POS N
blood POS N
pressure POS N
(BP). POS N

Normal POS N
weight POS N
and POS N
obese POS N
participants POS N
manifested POS N
significant POS N
positive POS N
relations POS N
to POS N
BP POS N
of POS N
urinary POS N
sodium; POS N
relations POS N
were POS N
weaker POS N
for POS N
overweight POS N
people. POS N

At POS N
lower POS N
but POS N
not POS N
higher POS N
levels POS N
of POS N
24-hour POS N
sodium POS N
excretion, POS N
potassium POS N
intake POS N
blunted POS N
the POS N
sodium-BP POS N
relation. POS N

Normal POS N
weight POS N
and POS N
obese POS N
participants POS N
manifested POS N
significant POS N
positive POS N
relations POS N
to POS N
BP POS N
of POS N
urinary POS N
sodium; POS N
relations POS N
were POS N
weaker POS N
for POS N
overweight POS N
people. POS N

The POS N
adverse POS N
association POS N
of POS N
dietary POS N
sodium POS N
with POS N
BP POS N
is POS N
minimally POS N
attenuated POS N
by POS N
other POS N
dietary POS N
constituents; POS N

Normal POS N
weight POS N
and POS N
obese POS N
participants POS N
manifested POS N
significant POS N
positive POS N
relations POS N
to POS N
BP POS N
of POS N
urinary POS N
sodium; POS N
relations POS N
were POS N
weaker POS N
for POS N
overweight POS N
people. POS N

these POS N
findings POS N
underscore POS N
the POS N
importance POS N
of POS N
reducing POS N
salt POS N
intake POS N
for POS N
the POS N
prevention POS N
and POS N
control POS N
of POS N
prehypertension POS N
and POS N
hypertension. POS N

At POS N
lower POS N
but POS N
not POS N
higher POS N
levels POS N
of POS N
24-hour POS N
sodium POS N
excretion, POS N
potassium POS N
intake POS N
blunted POS N
the POS N
sodium-BP POS N
relation. POS N

Available POS N
data POS N
indicate POS N
that POS N
dietary POS N
sodium POS N
(as POS N
salt) POS N
relates POS N
directly POS N
to POS N
blood POS N
pressure POS N
(BP). POS N

At POS N
lower POS N
but POS N
not POS N
higher POS N
levels POS N
of POS N
24-hour POS N
sodium POS N
excretion, POS N
potassium POS N
intake POS N
blunted POS N
the POS N
sodium-BP POS N
relation. POS N

Normal POS N
weight POS N
and POS N
obese POS N
participants POS N
manifested POS N
significant POS N
positive POS N
relations POS N
to POS N
BP POS N
of POS N
urinary POS N
sodium; POS N
relations POS N
were POS N
weaker POS N
for POS N
overweight POS N
people. POS N

At POS N
lower POS N
but POS N
not POS N
higher POS N
levels POS N
of POS N
24-hour POS N
sodium POS N
excretion, POS N
potassium POS N
intake POS N
blunted POS N
the POS N
sodium-BP POS N
relation. POS N

The POS N
adverse POS N
association POS N
of POS N
dietary POS N
sodium POS N
with POS N
BP POS N
is POS N
minimally POS N
attenuated POS N
by POS N
other POS N
dietary POS N
constituents; POS N

At POS N
lower POS N
but POS N
not POS N
higher POS N
levels POS N
of POS N
24-hour POS N
sodium POS N
excretion, POS N
potassium POS N
intake POS N
blunted POS N
the POS N
sodium-BP POS N
relation. POS N

these POS N
findings POS N
underscore POS N
the POS N
importance POS N
of POS N
reducing POS N
salt POS N
intake POS N
for POS N
the POS N
prevention POS N
and POS N
control POS N
of POS N
prehypertension POS N
and POS N
hypertension. POS N

The POS N
adverse POS N
association POS N
of POS N
dietary POS N
sodium POS N
with POS N
BP POS N
is POS N
minimally POS N
attenuated POS N
by POS N
other POS N
dietary POS N
constituents; POS N

Available POS N
data POS N
indicate POS N
that POS N
dietary POS N
sodium POS N
(as POS N
salt) POS N
relates POS N
directly POS N
to POS N
blood POS N
pressure POS N
(BP). POS N

The POS N
adverse POS N
association POS N
of POS N
dietary POS N
sodium POS N
with POS N
BP POS N
is POS N
minimally POS N
attenuated POS N
by POS N
other POS N
dietary POS N
constituents; POS N

Normal POS N
weight POS N
and POS N
obese POS N
participants POS N
manifested POS N
significant POS N
positive POS N
relations POS N
to POS N
BP POS N
of POS N
urinary POS N
sodium; POS N
relations POS N
were POS N
weaker POS N
for POS N
overweight POS N
people. POS N

The POS N
adverse POS N
association POS N
of POS N
dietary POS N
sodium POS N
with POS N
BP POS N
is POS N
minimally POS N
attenuated POS N
by POS N
other POS N
dietary POS N
constituents; POS N

At POS N
lower POS N
but POS N
not POS N
higher POS N
levels POS N
of POS N
24-hour POS N
sodium POS N
excretion, POS N
potassium POS N
intake POS N
blunted POS N
the POS N
sodium-BP POS N
relation. POS N

The POS N
adverse POS N
association POS N
of POS N
dietary POS N
sodium POS N
with POS N
BP POS N
is POS N
minimally POS N
attenuated POS N
by POS N
other POS N
dietary POS N
constituents; POS N

these POS N
findings POS N
underscore POS N
the POS N
importance POS N
of POS N
reducing POS N
salt POS N
intake POS N
for POS N
the POS N
prevention POS N
and POS N
control POS N
of POS N
prehypertension POS N
and POS N
hypertension. POS N

these POS N
findings POS N
underscore POS N
the POS N
importance POS N
of POS N
reducing POS N
salt POS N
intake POS N
for POS N
the POS N
prevention POS N
and POS N
control POS N
of POS N
prehypertension POS N
and POS N
hypertension. POS N

Available POS N
data POS N
indicate POS N
that POS N
dietary POS N
sodium POS N
(as POS N
salt) POS N
relates POS N
directly POS N
to POS N
blood POS N
pressure POS N
(BP). POS N

these POS N
findings POS N
underscore POS N
the POS N
importance POS N
of POS N
reducing POS N
salt POS N
intake POS N
for POS N
the POS N
prevention POS N
and POS N
control POS N
of POS N
prehypertension POS N
and POS N
hypertension. POS N

Normal POS N
weight POS N
and POS N
obese POS N
participants POS N
manifested POS N
significant POS N
positive POS N
relations POS N
to POS N
BP POS N
of POS N
urinary POS N
sodium; POS N
relations POS N
were POS N
weaker POS N
for POS N
overweight POS N
people. POS N

these POS N
findings POS N
underscore POS N
the POS N
importance POS N
of POS N
reducing POS N
salt POS N
intake POS N
for POS N
the POS N
prevention POS N
and POS N
control POS N
of POS N
prehypertension POS N
and POS N
hypertension. POS N

At POS N
lower POS N
but POS N
not POS N
higher POS N
levels POS N
of POS N
24-hour POS N
sodium POS N
excretion, POS N
potassium POS N
intake POS N
blunted POS N
the POS N
sodium-BP POS N
relation. POS N

these POS N
findings POS N
underscore POS N
the POS N
importance POS N
of POS N
reducing POS N
salt POS N
intake POS N
for POS N
the POS N
prevention POS N
and POS N
control POS N
of POS N
prehypertension POS N
and POS N
hypertension. POS N

The POS N
adverse POS N
association POS N
of POS N
dietary POS N
sodium POS N
with POS N
BP POS N
is POS N
minimally POS N
attenuated POS N
by POS N
other POS N
dietary POS N
constituents; POS N

The POS N
data POS N
of POS N
the POS N
full POS N
analysis POS N
set POS N
showed POS N
that POS N
HBeAg POS N
seroconversion POS N
rate POS N
at POS N
week POS N
72 POS N
was POS N
27.32% POS N
in POS N
the POS N
trial POS N
group POS N
and POS N
22.70% POS N
in POS N
the POS N
control POS N
group POS N
with POS N
a POS N
rate POS N
difference POS N
of POS N
4.63% POS N
(95% POS N
CI POS N
-1.54% POS N
to POS N
10.80%, POS N
P POS N
= POS N
0.1493). POS N

The POS N
data POS N
of POS N
the POS N
per-protocol POS N
set POS N
showed POS N
that POS N
HBeAg POS N
seroconversion POS N
rate POS N
at POS N
week POS N
72 POS N
was POS N
30.75% POS N
in POS N
the POS N
trial POS N
group POS N
and POS N
27.14% POS N
in POS N
the POS N
control POS N
group POS N
with POS N
a POS N
rate POS N
difference POS N
of POS N
3.61% POS N
(95% POS N
CI POS N
-3.87% POS N
to POS N
11.09%, POS N
P POS N
= POS N
0.3436). POS N

The POS N
data POS N
of POS N
the POS N
full POS N
analysis POS N
set POS N
showed POS N
that POS N
HBeAg POS N
seroconversion POS N
rate POS N
at POS N
week POS N
72 POS N
was POS N
27.32% POS N
in POS N
the POS N
trial POS N
group POS N
and POS N
22.70% POS N
in POS N
the POS N
control POS N
group POS N
with POS N
a POS N
rate POS N
difference POS N
of POS N
4.63% POS N
(95% POS N
CI POS N
-1.54% POS N
to POS N
10.80%, POS N
P POS N
= POS N
0.1493). POS N

95% POS N
CI POS N
met POS N
the POS N
non-inferiority POS N
criteria, POS N
and POS N
the POS N
trial POS N
group POS N
was POS N
non-inferior POS N
to POS N
the POS N
control POS N
group. POS N

The POS N
data POS N
of POS N
the POS N
full POS N
analysis POS N
set POS N
showed POS N
that POS N
HBeAg POS N
seroconversion POS N
rate POS N
at POS N
week POS N
72 POS N
was POS N
27.32% POS N
in POS N
the POS N
trial POS N
group POS N
and POS N
22.70% POS N
in POS N
the POS N
control POS N
group POS N
with POS N
a POS N
rate POS N
difference POS N
of POS N
4.63% POS N
(95% POS N
CI POS N
-1.54% POS N
to POS N
10.80%, POS N
P POS N
= POS N
0.1493). POS N

The POS N
two POS N
groups POS N
had POS N
similar POS N
incidence POS N
rates POS N
of POS N
adverse POS N
events, POS N
serious POS N
adverse POS N
events, POS N
and POS N
common POS N
adverse POS N
events. POS N

The POS N
data POS N
of POS N
the POS N
full POS N
analysis POS N
set POS N
showed POS N
that POS N
HBeAg POS N
seroconversion POS N
rate POS N
at POS N
week POS N
72 POS N
was POS N
27.32% POS N
in POS N
the POS N
trial POS N
group POS N
and POS N
22.70% POS N
in POS N
the POS N
control POS N
group POS N
with POS N
a POS N
rate POS N
difference POS N
of POS N
4.63% POS N
(95% POS N
CI POS N
-1.54% POS N
to POS N
10.80%, POS N
P POS N
= POS N
0.1493). POS N

In POS N
Peg-IFN-α POS N
regimen POS N
for POS N
HBeAg-positive POS N
CHB POS N
patients, POS N
the POS N
new POS N
drug POS N
Peg-IFN-α-2b POS N
(Y POS N
shape, POS N
40 POS N
kD) POS N
has POS N
comparable POS N
effect POS N
and POS N
safety POS N
to POS N
the POS N
control POS N
drug POS N
Peg-IFN-α-2a. POS N

The POS N
data POS N
of POS N
the POS N
per-protocol POS N
set POS N
showed POS N
that POS N
HBeAg POS N
seroconversion POS N
rate POS N
at POS N
week POS N
72 POS N
was POS N
30.75% POS N
in POS N
the POS N
trial POS N
group POS N
and POS N
27.14% POS N
in POS N
the POS N
control POS N
group POS N
with POS N
a POS N
rate POS N
difference POS N
of POS N
3.61% POS N
(95% POS N
CI POS N
-3.87% POS N
to POS N
11.09%, POS N
P POS N
= POS N
0.3436). POS N

The POS N
data POS N
of POS N
the POS N
full POS N
analysis POS N
set POS N
showed POS N
that POS N
HBeAg POS N
seroconversion POS N
rate POS N
at POS N
week POS N
72 POS N
was POS N
27.32% POS N
in POS N
the POS N
trial POS N
group POS N
and POS N
22.70% POS N
in POS N
the POS N
control POS N
group POS N
with POS N
a POS N
rate POS N
difference POS N
of POS N
4.63% POS N
(95% POS N
CI POS N
-1.54% POS N
to POS N
10.80%, POS N
P POS N
= POS N
0.1493). POS N

The POS N
data POS N
of POS N
the POS N
per-protocol POS N
set POS N
showed POS N
that POS N
HBeAg POS N
seroconversion POS N
rate POS N
at POS N
week POS N
72 POS N
was POS N
30.75% POS N
in POS N
the POS N
trial POS N
group POS N
and POS N
27.14% POS N
in POS N
the POS N
control POS N
group POS N
with POS N
a POS N
rate POS N
difference POS N
of POS N
3.61% POS N
(95% POS N
CI POS N
-3.87% POS N
to POS N
11.09%, POS N
P POS N
= POS N
0.3436). POS N

95% POS N
CI POS N
met POS N
the POS N
non-inferiority POS N
criteria, POS N
and POS N
the POS N
trial POS N
group POS N
was POS N
non-inferior POS N
to POS N
the POS N
control POS N
group. POS N

The POS N
data POS N
of POS N
the POS N
per-protocol POS N
set POS N
showed POS N
that POS N
HBeAg POS N
seroconversion POS N
rate POS N
at POS N
week POS N
72 POS N
was POS N
30.75% POS N
in POS N
the POS N
trial POS N
group POS N
and POS N
27.14% POS N
in POS N
the POS N
control POS N
group POS N
with POS N
a POS N
rate POS N
difference POS N
of POS N
3.61% POS N
(95% POS N
CI POS N
-3.87% POS N
to POS N
11.09%, POS N
P POS N
= POS N
0.3436). POS N

The POS N
two POS N
groups POS N
had POS N
similar POS N
incidence POS N
rates POS N
of POS N
adverse POS N
events, POS N
serious POS N
adverse POS N
events, POS N
and POS N
common POS N
adverse POS N
events. POS N

The POS N
data POS N
of POS N
the POS N
per-protocol POS N
set POS N
showed POS N
that POS N
HBeAg POS N
seroconversion POS N
rate POS N
at POS N
week POS N
72 POS N
was POS N
30.75% POS N
in POS N
the POS N
trial POS N
group POS N
and POS N
27.14% POS N
in POS N
the POS N
control POS N
group POS N
with POS N
a POS N
rate POS N
difference POS N
of POS N
3.61% POS N
(95% POS N
CI POS N
-3.87% POS N
to POS N
11.09%, POS N
P POS N
= POS N
0.3436). POS N

In POS N
Peg-IFN-α POS N
regimen POS N
for POS N
HBeAg-positive POS N
CHB POS N
patients, POS N
the POS N
new POS N
drug POS N
Peg-IFN-α-2b POS N
(Y POS N
shape, POS N
40 POS N
kD) POS N
has POS N
comparable POS N
effect POS N
and POS N
safety POS N
to POS N
the POS N
control POS N
drug POS N
Peg-IFN-α-2a. POS N

95% POS N
CI POS N
met POS N
the POS N
non-inferiority POS N
criteria, POS N
and POS N
the POS N
trial POS N
group POS N
was POS N
non-inferior POS N
to POS N
the POS N
control POS N
group. POS N

The POS N
data POS N
of POS N
the POS N
full POS N
analysis POS N
set POS N
showed POS N
that POS N
HBeAg POS N
seroconversion POS N
rate POS N
at POS N
week POS N
72 POS N
was POS N
27.32% POS N
in POS N
the POS N
trial POS N
group POS N
and POS N
22.70% POS N
in POS N
the POS N
control POS N
group POS N
with POS N
a POS N
rate POS N
difference POS N
of POS N
4.63% POS N
(95% POS N
CI POS N
-1.54% POS N
to POS N
10.80%, POS N
P POS N
= POS N
0.1493). POS N

95% POS N
CI POS N
met POS N
the POS N
non-inferiority POS N
criteria, POS N
and POS N
the POS N
trial POS N
group POS N
was POS N
non-inferior POS N
to POS N
the POS N
control POS N
group. POS N

The POS N
data POS N
of POS N
the POS N
per-protocol POS N
set POS N
showed POS N
that POS N
HBeAg POS N
seroconversion POS N
rate POS N
at POS N
week POS N
72 POS N
was POS N
30.75% POS N
in POS N
the POS N
trial POS N
group POS N
and POS N
27.14% POS N
in POS N
the POS N
control POS N
group POS N
with POS N
a POS N
rate POS N
difference POS N
of POS N
3.61% POS N
(95% POS N
CI POS N
-3.87% POS N
to POS N
11.09%, POS N
P POS N
= POS N
0.3436). POS N

95% POS N
CI POS N
met POS N
the POS N
non-inferiority POS N
criteria, POS N
and POS N
the POS N
trial POS N
group POS N
was POS N
non-inferior POS N
to POS N
the POS N
control POS N
group. POS N

The POS N
two POS N
groups POS N
had POS N
similar POS N
incidence POS N
rates POS N
of POS N
adverse POS N
events, POS N
serious POS N
adverse POS N
events, POS N
and POS N
common POS N
adverse POS N
events. POS N

95% POS N
CI POS N
met POS N
the POS N
non-inferiority POS N
criteria, POS N
and POS N
the POS N
trial POS N
group POS N
was POS N
non-inferior POS N
to POS N
the POS N
control POS N
group. POS N

In POS N
Peg-IFN-α POS N
regimen POS N
for POS N
HBeAg-positive POS N
CHB POS N
patients, POS N
the POS N
new POS N
drug POS N
Peg-IFN-α-2b POS N
(Y POS N
shape, POS N
40 POS N
kD) POS N
has POS N
comparable POS N
effect POS N
and POS N
safety POS N
to POS N
the POS N
control POS N
drug POS N
Peg-IFN-α-2a. POS N

The POS N
two POS N
groups POS N
had POS N
similar POS N
incidence POS N
rates POS N
of POS N
adverse POS N
events, POS N
serious POS N
adverse POS N
events, POS N
and POS N
common POS N
adverse POS N
events. POS N

The POS N
data POS N
of POS N
the POS N
full POS N
analysis POS N
set POS N
showed POS N
that POS N
HBeAg POS N
seroconversion POS N
rate POS N
at POS N
week POS N
72 POS N
was POS N
27.32% POS N
in POS N
the POS N
trial POS N
group POS N
and POS N
22.70% POS N
in POS N
the POS N
control POS N
group POS N
with POS N
a POS N
rate POS N
difference POS N
of POS N
4.63% POS N
(95% POS N
CI POS N
-1.54% POS N
to POS N
10.80%, POS N
P POS N
= POS N
0.1493). POS N

The POS N
two POS N
groups POS N
had POS N
similar POS N
incidence POS N
rates POS N
of POS N
adverse POS N
events, POS N
serious POS N
adverse POS N
events, POS N
and POS N
common POS N
adverse POS N
events. POS N

The POS N
data POS N
of POS N
the POS N
per-protocol POS N
set POS N
showed POS N
that POS N
HBeAg POS N
seroconversion POS N
rate POS N
at POS N
week POS N
72 POS N
was POS N
30.75% POS N
in POS N
the POS N
trial POS N
group POS N
and POS N
27.14% POS N
in POS N
the POS N
control POS N
group POS N
with POS N
a POS N
rate POS N
difference POS N
of POS N
3.61% POS N
(95% POS N
CI POS N
-3.87% POS N
to POS N
11.09%, POS N
P POS N
= POS N
0.3436). POS N

The POS N
two POS N
groups POS N
had POS N
similar POS N
incidence POS N
rates POS N
of POS N
adverse POS N
events, POS N
serious POS N
adverse POS N
events, POS N
and POS N
common POS N
adverse POS N
events. POS N

95% POS N
CI POS N
met POS N
the POS N
non-inferiority POS N
criteria, POS N
and POS N
the POS N
trial POS N
group POS N
was POS N
non-inferior POS N
to POS N
the POS N
control POS N
group. POS N

The POS N
two POS N
groups POS N
had POS N
similar POS N
incidence POS N
rates POS N
of POS N
adverse POS N
events, POS N
serious POS N
adverse POS N
events, POS N
and POS N
common POS N
adverse POS N
events. POS N

In POS N
Peg-IFN-α POS N
regimen POS N
for POS N
HBeAg-positive POS N
CHB POS N
patients, POS N
the POS N
new POS N
drug POS N
Peg-IFN-α-2b POS N
(Y POS N
shape, POS N
40 POS N
kD) POS N
has POS N
comparable POS N
effect POS N
and POS N
safety POS N
to POS N
the POS N
control POS N
drug POS N
Peg-IFN-α-2a. POS N

In POS N
Peg-IFN-α POS N
regimen POS N
for POS N
HBeAg-positive POS N
CHB POS N
patients, POS N
the POS N
new POS N
drug POS N
Peg-IFN-α-2b POS N
(Y POS N
shape, POS N
40 POS N
kD) POS N
has POS N
comparable POS N
effect POS N
and POS N
safety POS N
to POS N
the POS N
control POS N
drug POS N
Peg-IFN-α-2a. POS N

The POS N
data POS N
of POS N
the POS N
full POS N
analysis POS N
set POS N
showed POS N
that POS N
HBeAg POS N
seroconversion POS N
rate POS N
at POS N
week POS N
72 POS N
was POS N
27.32% POS N
in POS N
the POS N
trial POS N
group POS N
and POS N
22.70% POS N
in POS N
the POS N
control POS N
group POS N
with POS N
a POS N
rate POS N
difference POS N
of POS N
4.63% POS N
(95% POS N
CI POS N
-1.54% POS N
to POS N
10.80%, POS N
P POS N
= POS N
0.1493). POS N

In POS N
Peg-IFN-α POS N
regimen POS N
for POS N
HBeAg-positive POS N
CHB POS N
patients, POS N
the POS N
new POS N
drug POS N
Peg-IFN-α-2b POS N
(Y POS N
shape, POS N
40 POS N
kD) POS N
has POS N
comparable POS N
effect POS N
and POS N
safety POS N
to POS N
the POS N
control POS N
drug POS N
Peg-IFN-α-2a. POS N

The POS N
data POS N
of POS N
the POS N
per-protocol POS N
set POS N
showed POS N
that POS N
HBeAg POS N
seroconversion POS N
rate POS N
at POS N
week POS N
72 POS N
was POS N
30.75% POS N
in POS N
the POS N
trial POS N
group POS N
and POS N
27.14% POS N
in POS N
the POS N
control POS N
group POS N
with POS N
a POS N
rate POS N
difference POS N
of POS N
3.61% POS N
(95% POS N
CI POS N
-3.87% POS N
to POS N
11.09%, POS N
P POS N
= POS N
0.3436). POS N

In POS N
Peg-IFN-α POS N
regimen POS N
for POS N
HBeAg-positive POS N
CHB POS N
patients, POS N
the POS N
new POS N
drug POS N
Peg-IFN-α-2b POS N
(Y POS N
shape, POS N
40 POS N
kD) POS N
has POS N
comparable POS N
effect POS N
and POS N
safety POS N
to POS N
the POS N
control POS N
drug POS N
Peg-IFN-α-2a. POS N

95% POS N
CI POS N
met POS N
the POS N
non-inferiority POS N
criteria, POS N
and POS N
the POS N
trial POS N
group POS N
was POS N
non-inferior POS N
to POS N
the POS N
control POS N
group. POS N

In POS N
Peg-IFN-α POS N
regimen POS N
for POS N
HBeAg-positive POS N
CHB POS N
patients, POS N
the POS N
new POS N
drug POS N
Peg-IFN-α-2b POS N
(Y POS N
shape, POS N
40 POS N
kD) POS N
has POS N
comparable POS N
effect POS N
and POS N
safety POS N
to POS N
the POS N
control POS N
drug POS N
Peg-IFN-α-2a. POS N

The POS N
two POS N
groups POS N
had POS N
similar POS N
incidence POS N
rates POS N
of POS N
adverse POS N
events, POS N
serious POS N
adverse POS N
events, POS N
and POS N
common POS N
adverse POS N
events. POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

Fracture POS N
risk POS N
is POS N
increased POS N
in POS N
individuals POS N
with POS N
type POS N
2 POS N
diabetes POS N
(T2D). POS N

The POS N
choice POS N
of POS N
insulin POS N
treatment POS N
is POS N
not POS N
influencing POS N
BTMs, POS N

Fracture POS N
risk POS N
is POS N
increased POS N
in POS N
individuals POS N
with POS N
type POS N
2 POS N
diabetes POS N
(T2D). POS N

metformin POS N
treatment POS N
may POS N
decrease POS N
BTMs, POS N

Fracture POS N
risk POS N
is POS N
increased POS N
in POS N
individuals POS N
with POS N
type POS N
2 POS N
diabetes POS N
(T2D). POS N

improvement POS N
of POS N
glycaemic POS N
control POS N
may POS N
influence POS N
bone POS N
resorption POS N
activity. POS N

Fracture POS N
risk POS N
is POS N
increased POS N
in POS N
individuals POS N
with POS N
type POS N
2 POS N
diabetes POS N
(T2D). POS N

HbA1c POS N
was POS N
inversely POS N
associated POS N
with POS N
CTX POS N
but POS N
not POS N
P1NP. POS N

Fracture POS N
risk POS N
is POS N
increased POS N
in POS N
individuals POS N
with POS N
type POS N
2 POS N
diabetes POS N
(T2D). POS N

Neither POS N
metformin POS N
nor POS N
rosiglitazone POS N
plasma POS N
concentrations POS N
was POS N
associated POS N
with POS N
BTMs. POS N

Fracture POS N
risk POS N
is POS N
increased POS N
in POS N
individuals POS N
with POS N
type POS N
2 POS N
diabetes POS N
(T2D). POS N

Metformin POS N
and POS N
metformin + rosiglitazone POS N
but POS N
not POS N
rosiglitazone POS N
alone POS N
were POS N
associated POS N
with POS N
lower POS N
bone POS N
formation POS N
(PINP). POS N

Fracture POS N
risk POS N
is POS N
increased POS N
in POS N
individuals POS N
with POS N
type POS N
2 POS N
diabetes POS N
(T2D). POS N

Allocation POS N
of POS N
insulin POS N
regimens POS N
was POS N
not POS N
associated POS N
with POS N
different POS N
levels POS N
of POS N
BTMs. POS N

Fracture POS N
risk POS N
is POS N
increased POS N
in POS N
individuals POS N
with POS N
type POS N
2 POS N
diabetes POS N
(T2D). POS N

BTMs POS N
increased POS N
from POS N
baseline POS N
to POS N
month POS N
12 POS N
and POS N
remained POS N
higher POS N
at POS N
month POS N
24, POS N
with POS N
CTX POS N
and POS N
PINP POS N
increasing POS N
28.5% POS N
and POS N
23.0% POS N
(all: POS N
p < 0.001), POS N
respectively. POS N

The POS N
choice POS N
of POS N
insulin POS N
treatment POS N
is POS N
not POS N
influencing POS N
BTMs, POS N

Fracture POS N
risk POS N
is POS N
increased POS N
in POS N
individuals POS N
with POS N
type POS N
2 POS N
diabetes POS N
(T2D). POS N

The POS N
choice POS N
of POS N
insulin POS N
treatment POS N
is POS N
not POS N
influencing POS N
BTMs, POS N

metformin POS N
treatment POS N
may POS N
decrease POS N
BTMs, POS N

The POS N
choice POS N
of POS N
insulin POS N
treatment POS N
is POS N
not POS N
influencing POS N
BTMs, POS N

improvement POS N
of POS N
glycaemic POS N
control POS N
may POS N
influence POS N
bone POS N
resorption POS N
activity. POS N

The POS N
choice POS N
of POS N
insulin POS N
treatment POS N
is POS N
not POS N
influencing POS N
BTMs, POS N

HbA1c POS N
was POS N
inversely POS N
associated POS N
with POS N
CTX POS N
but POS N
not POS N
P1NP. POS N

The POS N
choice POS N
of POS N
insulin POS N
treatment POS N
is POS N
not POS N
influencing POS N
BTMs, POS N

Neither POS N
metformin POS N
nor POS N
rosiglitazone POS N
plasma POS N
concentrations POS N
was POS N
associated POS N
with POS N
BTMs. POS N

The POS N
choice POS N
of POS N
insulin POS N
treatment POS N
is POS N
not POS N
influencing POS N
BTMs, POS N

Metformin POS N
and POS N
metformin + rosiglitazone POS N
but POS N
not POS N
rosiglitazone POS N
alone POS N
were POS N
associated POS N
with POS N
lower POS N
bone POS N
formation POS N
(PINP). POS N

The POS N
choice POS N
of POS N
insulin POS N
treatment POS N
is POS N
not POS N
influencing POS N
BTMs, POS N

Allocation POS N
of POS N
insulin POS N
regimens POS N
was POS N
not POS N
associated POS N
with POS N
different POS N
levels POS N
of POS N
BTMs. POS N

The POS N
choice POS N
of POS N
insulin POS N
treatment POS N
is POS N
not POS N
influencing POS N
BTMs, POS N

BTMs POS N
increased POS N
from POS N
baseline POS N
to POS N
month POS N
12 POS N
and POS N
remained POS N
higher POS N
at POS N
month POS N
24, POS N
with POS N
CTX POS N
and POS N
PINP POS N
increasing POS N
28.5% POS N
and POS N
23.0% POS N
(all: POS N
p < 0.001), POS N
respectively. POS N

metformin POS N
treatment POS N
may POS N
decrease POS N
BTMs, POS N

Fracture POS N
risk POS N
is POS N
increased POS N
in POS N
individuals POS N
with POS N
type POS N
2 POS N
diabetes POS N
(T2D). POS N

metformin POS N
treatment POS N
may POS N
decrease POS N
BTMs, POS N

The POS N
choice POS N
of POS N
insulin POS N
treatment POS N
is POS N
not POS N
influencing POS N
BTMs, POS N

metformin POS N
treatment POS N
may POS N
decrease POS N
BTMs, POS N

improvement POS N
of POS N
glycaemic POS N
control POS N
may POS N
influence POS N
bone POS N
resorption POS N
activity. POS N

metformin POS N
treatment POS N
may POS N
decrease POS N
BTMs, POS N

HbA1c POS N
was POS N
inversely POS N
associated POS N
with POS N
CTX POS N
but POS N
not POS N
P1NP. POS N

metformin POS N
treatment POS N
may POS N
decrease POS N
BTMs, POS N

Neither POS N
metformin POS N
nor POS N
rosiglitazone POS N
plasma POS N
concentrations POS N
was POS N
associated POS N
with POS N
BTMs. POS N

metformin POS N
treatment POS N
may POS N
decrease POS N
BTMs, POS N

Metformin POS N
and POS N
metformin + rosiglitazone POS N
but POS N
not POS N
rosiglitazone POS N
alone POS N
were POS N
associated POS N
with POS N
lower POS N
bone POS N
formation POS N
(PINP). POS N

metformin POS N
treatment POS N
may POS N
decrease POS N
BTMs, POS N

Allocation POS N
of POS N
insulin POS N
regimens POS N
was POS N
not POS N
associated POS N
with POS N
different POS N
levels POS N
of POS N
BTMs. POS N

metformin POS N
treatment POS N
may POS N
decrease POS N
BTMs, POS N

BTMs POS N
increased POS N
from POS N
baseline POS N
to POS N
month POS N
12 POS N
and POS N
remained POS N
higher POS N
at POS N
month POS N
24, POS N
with POS N
CTX POS N
and POS N
PINP POS N
increasing POS N
28.5% POS N
and POS N
23.0% POS N
(all: POS N
p < 0.001), POS N
respectively. POS N

improvement POS N
of POS N
glycaemic POS N
control POS N
may POS N
influence POS N
bone POS N
resorption POS N
activity. POS N

Fracture POS N
risk POS N
is POS N
increased POS N
in POS N
individuals POS N
with POS N
type POS N
2 POS N
diabetes POS N
(T2D). POS N

improvement POS N
of POS N
glycaemic POS N
control POS N
may POS N
influence POS N
bone POS N
resorption POS N
activity. POS N

The POS N
choice POS N
of POS N
insulin POS N
treatment POS N
is POS N
not POS N
influencing POS N
BTMs, POS N

improvement POS N
of POS N
glycaemic POS N
control POS N
may POS N
influence POS N
bone POS N
resorption POS N
activity. POS N

metformin POS N
treatment POS N
may POS N
decrease POS N
BTMs, POS N

improvement POS N
of POS N
glycaemic POS N
control POS N
may POS N
influence POS N
bone POS N
resorption POS N
activity. POS N

HbA1c POS N
was POS N
inversely POS N
associated POS N
with POS N
CTX POS N
but POS N
not POS N
P1NP. POS N

improvement POS N
of POS N
glycaemic POS N
control POS N
may POS N
influence POS N
bone POS N
resorption POS N
activity. POS N

Neither POS N
metformin POS N
nor POS N
rosiglitazone POS N
plasma POS N
concentrations POS N
was POS N
associated POS N
with POS N
BTMs. POS N

improvement POS N
of POS N
glycaemic POS N
control POS N
may POS N
influence POS N
bone POS N
resorption POS N
activity. POS N

Metformin POS N
and POS N
metformin + rosiglitazone POS N
but POS N
not POS N
rosiglitazone POS N
alone POS N
were POS N
associated POS N
with POS N
lower POS N
bone POS N
formation POS N
(PINP). POS N

improvement POS N
of POS N
glycaemic POS N
control POS N
may POS N
influence POS N
bone POS N
resorption POS N
activity. POS N

Allocation POS N
of POS N
insulin POS N
regimens POS N
was POS N
not POS N
associated POS N
with POS N
different POS N
levels POS N
of POS N
BTMs. POS N

improvement POS N
of POS N
glycaemic POS N
control POS N
may POS N
influence POS N
bone POS N
resorption POS N
activity. POS N

BTMs POS N
increased POS N
from POS N
baseline POS N
to POS N
month POS N
12 POS N
and POS N
remained POS N
higher POS N
at POS N
month POS N
24, POS N
with POS N
CTX POS N
and POS N
PINP POS N
increasing POS N
28.5% POS N
and POS N
23.0% POS N
(all: POS N
p < 0.001), POS N
respectively. POS N

HbA1c POS N
was POS N
inversely POS N
associated POS N
with POS N
CTX POS N
but POS N
not POS N
P1NP. POS N

Fracture POS N
risk POS N
is POS N
increased POS N
in POS N
individuals POS N
with POS N
type POS N
2 POS N
diabetes POS N
(T2D). POS N

HbA1c POS N
was POS N
inversely POS N
associated POS N
with POS N
CTX POS N
but POS N
not POS N
P1NP. POS N

The POS N
choice POS N
of POS N
insulin POS N
treatment POS N
is POS N
not POS N
influencing POS N
BTMs, POS N

HbA1c POS N
was POS N
inversely POS N
associated POS N
with POS N
CTX POS N
but POS N
not POS N
P1NP. POS N

metformin POS N
treatment POS N
may POS N
decrease POS N
BTMs, POS N

HbA1c POS N
was POS N
inversely POS N
associated POS N
with POS N
CTX POS N
but POS N
not POS N
P1NP. POS N

improvement POS N
of POS N
glycaemic POS N
control POS N
may POS N
influence POS N
bone POS N
resorption POS N
activity. POS N

HbA1c POS N
was POS N
inversely POS N
associated POS N
with POS N
CTX POS N
but POS N
not POS N
P1NP. POS N

Neither POS N
metformin POS N
nor POS N
rosiglitazone POS N
plasma POS N
concentrations POS N
was POS N
associated POS N
with POS N
BTMs. POS N

HbA1c POS N
was POS N
inversely POS N
associated POS N
with POS N
CTX POS N
but POS N
not POS N
P1NP. POS N

Metformin POS N
and POS N
metformin + rosiglitazone POS N
but POS N
not POS N
rosiglitazone POS N
alone POS N
were POS N
associated POS N
with POS N
lower POS N
bone POS N
formation POS N
(PINP). POS N

HbA1c POS N
was POS N
inversely POS N
associated POS N
with POS N
CTX POS N
but POS N
not POS N
P1NP. POS N

Allocation POS N
of POS N
insulin POS N
regimens POS N
was POS N
not POS N
associated POS N
with POS N
different POS N
levels POS N
of POS N
BTMs. POS N

HbA1c POS N
was POS N
inversely POS N
associated POS N
with POS N
CTX POS N
but POS N
not POS N
P1NP. POS N

BTMs POS N
increased POS N
from POS N
baseline POS N
to POS N
month POS N
12 POS N
and POS N
remained POS N
higher POS N
at POS N
month POS N
24, POS N
with POS N
CTX POS N
and POS N
PINP POS N
increasing POS N
28.5% POS N
and POS N
23.0% POS N
(all: POS N
p < 0.001), POS N
respectively. POS N

Neither POS N
metformin POS N
nor POS N
rosiglitazone POS N
plasma POS N
concentrations POS N
was POS N
associated POS N
with POS N
BTMs. POS N

Fracture POS N
risk POS N
is POS N
increased POS N
in POS N
individuals POS N
with POS N
type POS N
2 POS N
diabetes POS N
(T2D). POS N

Neither POS N
metformin POS N
nor POS N
rosiglitazone POS N
plasma POS N
concentrations POS N
was POS N
associated POS N
with POS N
BTMs. POS N

The POS N
choice POS N
of POS N
insulin POS N
treatment POS N
is POS N
not POS N
influencing POS N
BTMs, POS N

Neither POS N
metformin POS N
nor POS N
rosiglitazone POS N
plasma POS N
concentrations POS N
was POS N
associated POS N
with POS N
BTMs. POS N

metformin POS N
treatment POS N
may POS N
decrease POS N
BTMs, POS N

Neither POS N
metformin POS N
nor POS N
rosiglitazone POS N
plasma POS N
concentrations POS N
was POS N
associated POS N
with POS N
BTMs. POS N

improvement POS N
of POS N
glycaemic POS N
control POS N
may POS N
influence POS N
bone POS N
resorption POS N
activity. POS N

Neither POS N
metformin POS N
nor POS N
rosiglitazone POS N
plasma POS N
concentrations POS N
was POS N
associated POS N
with POS N
BTMs. POS N

HbA1c POS N
was POS N
inversely POS N
associated POS N
with POS N
CTX POS N
but POS N
not POS N
P1NP. POS N

Neither POS N
metformin POS N
nor POS N
rosiglitazone POS N
plasma POS N
concentrations POS N
was POS N
associated POS N
with POS N
BTMs. POS N

Metformin POS N
and POS N
metformin + rosiglitazone POS N
but POS N
not POS N
rosiglitazone POS N
alone POS N
were POS N
associated POS N
with POS N
lower POS N
bone POS N
formation POS N
(PINP). POS N

Neither POS N
metformin POS N
nor POS N
rosiglitazone POS N
plasma POS N
concentrations POS N
was POS N
associated POS N
with POS N
BTMs. POS N

Allocation POS N
of POS N
insulin POS N
regimens POS N
was POS N
not POS N
associated POS N
with POS N
different POS N
levels POS N
of POS N
BTMs. POS N

Neither POS N
metformin POS N
nor POS N
rosiglitazone POS N
plasma POS N
concentrations POS N
was POS N
associated POS N
with POS N
BTMs. POS N

BTMs POS N
increased POS N
from POS N
baseline POS N
to POS N
month POS N
12 POS N
and POS N
remained POS N
higher POS N
at POS N
month POS N
24, POS N
with POS N
CTX POS N
and POS N
PINP POS N
increasing POS N
28.5% POS N
and POS N
23.0% POS N
(all: POS N
p < 0.001), POS N
respectively. POS N

Metformin POS N
and POS N
metformin + rosiglitazone POS N
but POS N
not POS N
rosiglitazone POS N
alone POS N
were POS N
associated POS N
with POS N
lower POS N
bone POS N
formation POS N
(PINP). POS N

Fracture POS N
risk POS N
is POS N
increased POS N
in POS N
individuals POS N
with POS N
type POS N
2 POS N
diabetes POS N
(T2D). POS N

Metformin POS N
and POS N
metformin + rosiglitazone POS N
but POS N
not POS N
rosiglitazone POS N
alone POS N
were POS N
associated POS N
with POS N
lower POS N
bone POS N
formation POS N
(PINP). POS N

The POS N
choice POS N
of POS N
insulin POS N
treatment POS N
is POS N
not POS N
influencing POS N
BTMs, POS N

Metformin POS N
and POS N
metformin + rosiglitazone POS N
but POS N
not POS N
rosiglitazone POS N
alone POS N
were POS N
associated POS N
with POS N
lower POS N
bone POS N
formation POS N
(PINP). POS N

metformin POS N
treatment POS N
may POS N
decrease POS N
BTMs, POS N

Metformin POS N
and POS N
metformin + rosiglitazone POS N
but POS N
not POS N
rosiglitazone POS N
alone POS N
were POS N
associated POS N
with POS N
lower POS N
bone POS N
formation POS N
(PINP). POS N

improvement POS N
of POS N
glycaemic POS N
control POS N
may POS N
influence POS N
bone POS N
resorption POS N
activity. POS N

Metformin POS N
and POS N
metformin + rosiglitazone POS N
but POS N
not POS N
rosiglitazone POS N
alone POS N
were POS N
associated POS N
with POS N
lower POS N
bone POS N
formation POS N
(PINP). POS N

HbA1c POS N
was POS N
inversely POS N
associated POS N
with POS N
CTX POS N
but POS N
not POS N
P1NP. POS N

Metformin POS N
and POS N
metformin + rosiglitazone POS N
but POS N
not POS N
rosiglitazone POS N
alone POS N
were POS N
associated POS N
with POS N
lower POS N
bone POS N
formation POS N
(PINP). POS N

Neither POS N
metformin POS N
nor POS N
rosiglitazone POS N
plasma POS N
concentrations POS N
was POS N
associated POS N
with POS N
BTMs. POS N

Metformin POS N
and POS N
metformin + rosiglitazone POS N
but POS N
not POS N
rosiglitazone POS N
alone POS N
were POS N
associated POS N
with POS N
lower POS N
bone POS N
formation POS N
(PINP). POS N

Allocation POS N
of POS N
insulin POS N
regimens POS N
was POS N
not POS N
associated POS N
with POS N
different POS N
levels POS N
of POS N
BTMs. POS N

Metformin POS N
and POS N
metformin + rosiglitazone POS N
but POS N
not POS N
rosiglitazone POS N
alone POS N
were POS N
associated POS N
with POS N
lower POS N
bone POS N
formation POS N
(PINP). POS N

BTMs POS N
increased POS N
from POS N
baseline POS N
to POS N
month POS N
12 POS N
and POS N
remained POS N
higher POS N
at POS N
month POS N
24, POS N
with POS N
CTX POS N
and POS N
PINP POS N
increasing POS N
28.5% POS N
and POS N
23.0% POS N
(all: POS N
p < 0.001), POS N
respectively. POS N

Allocation POS N
of POS N
insulin POS N
regimens POS N
was POS N
not POS N
associated POS N
with POS N
different POS N
levels POS N
of POS N
BTMs. POS N

Fracture POS N
risk POS N
is POS N
increased POS N
in POS N
individuals POS N
with POS N
type POS N
2 POS N
diabetes POS N
(T2D). POS N

Allocation POS N
of POS N
insulin POS N
regimens POS N
was POS N
not POS N
associated POS N
with POS N
different POS N
levels POS N
of POS N
BTMs. POS N

The POS N
choice POS N
of POS N
insulin POS N
treatment POS N
is POS N
not POS N
influencing POS N
BTMs, POS N

Allocation POS N
of POS N
insulin POS N
regimens POS N
was POS N
not POS N
associated POS N
with POS N
different POS N
levels POS N
of POS N
BTMs. POS N

metformin POS N
treatment POS N
may POS N
decrease POS N
BTMs, POS N

Allocation POS N
of POS N
insulin POS N
regimens POS N
was POS N
not POS N
associated POS N
with POS N
different POS N
levels POS N
of POS N
BTMs. POS N

improvement POS N
of POS N
glycaemic POS N
control POS N
may POS N
influence POS N
bone POS N
resorption POS N
activity. POS N

Allocation POS N
of POS N
insulin POS N
regimens POS N
was POS N
not POS N
associated POS N
with POS N
different POS N
levels POS N
of POS N
BTMs. POS N

HbA1c POS N
was POS N
inversely POS N
associated POS N
with POS N
CTX POS N
but POS N
not POS N
P1NP. POS N

Allocation POS N
of POS N
insulin POS N
regimens POS N
was POS N
not POS N
associated POS N
with POS N
different POS N
levels POS N
of POS N
BTMs. POS N

Neither POS N
metformin POS N
nor POS N
rosiglitazone POS N
plasma POS N
concentrations POS N
was POS N
associated POS N
with POS N
BTMs. POS N

Allocation POS N
of POS N
insulin POS N
regimens POS N
was POS N
not POS N
associated POS N
with POS N
different POS N
levels POS N
of POS N
BTMs. POS N

Metformin POS N
and POS N
metformin + rosiglitazone POS N
but POS N
not POS N
rosiglitazone POS N
alone POS N
were POS N
associated POS N
with POS N
lower POS N
bone POS N
formation POS N
(PINP). POS N

Allocation POS N
of POS N
insulin POS N
regimens POS N
was POS N
not POS N
associated POS N
with POS N
different POS N
levels POS N
of POS N
BTMs. POS N

BTMs POS N
increased POS N
from POS N
baseline POS N
to POS N
month POS N
12 POS N
and POS N
remained POS N
higher POS N
at POS N
month POS N
24, POS N
with POS N
CTX POS N
and POS N
PINP POS N
increasing POS N
28.5% POS N
and POS N
23.0% POS N
(all: POS N
p < 0.001), POS N
respectively. POS N

BTMs POS N
increased POS N
from POS N
baseline POS N
to POS N
month POS N
12 POS N
and POS N
remained POS N
higher POS N
at POS N
month POS N
24, POS N
with POS N
CTX POS N
and POS N
PINP POS N
increasing POS N
28.5% POS N
and POS N
23.0% POS N
(all: POS N
p < 0.001), POS N
respectively. POS N

Fracture POS N
risk POS N
is POS N
increased POS N
in POS N
individuals POS N
with POS N
type POS N
2 POS N
diabetes POS N
(T2D). POS N

BTMs POS N
increased POS N
from POS N
baseline POS N
to POS N
month POS N
12 POS N
and POS N
remained POS N
higher POS N
at POS N
month POS N
24, POS N
with POS N
CTX POS N
and POS N
PINP POS N
increasing POS N
28.5% POS N
and POS N
23.0% POS N
(all: POS N
p < 0.001), POS N
respectively. POS N

The POS N
choice POS N
of POS N
insulin POS N
treatment POS N
is POS N
not POS N
influencing POS N
BTMs, POS N

BTMs POS N
increased POS N
from POS N
baseline POS N
to POS N
month POS N
12 POS N
and POS N
remained POS N
higher POS N
at POS N
month POS N
24, POS N
with POS N
CTX POS N
and POS N
PINP POS N
increasing POS N
28.5% POS N
and POS N
23.0% POS N
(all: POS N
p < 0.001), POS N
respectively. POS N

metformin POS N
treatment POS N
may POS N
decrease POS N
BTMs, POS N

BTMs POS N
increased POS N
from POS N
baseline POS N
to POS N
month POS N
12 POS N
and POS N
remained POS N
higher POS N
at POS N
month POS N
24, POS N
with POS N
CTX POS N
and POS N
PINP POS N
increasing POS N
28.5% POS N
and POS N
23.0% POS N
(all: POS N
p < 0.001), POS N
respectively. POS N

improvement POS N
of POS N
glycaemic POS N
control POS N
may POS N
influence POS N
bone POS N
resorption POS N
activity. POS N

BTMs POS N
increased POS N
from POS N
baseline POS N
to POS N
month POS N
12 POS N
and POS N
remained POS N
higher POS N
at POS N
month POS N
24, POS N
with POS N
CTX POS N
and POS N
PINP POS N
increasing POS N
28.5% POS N
and POS N
23.0% POS N
(all: POS N
p < 0.001), POS N
respectively. POS N

HbA1c POS N
was POS N
inversely POS N
associated POS N
with POS N
CTX POS N
but POS N
not POS N
P1NP. POS N

BTMs POS N
increased POS N
from POS N
baseline POS N
to POS N
month POS N
12 POS N
and POS N
remained POS N
higher POS N
at POS N
month POS N
24, POS N
with POS N
CTX POS N
and POS N
PINP POS N
increasing POS N
28.5% POS N
and POS N
23.0% POS N
(all: POS N
p < 0.001), POS N
respectively. POS N

Neither POS N
metformin POS N
nor POS N
rosiglitazone POS N
plasma POS N
concentrations POS N
was POS N
associated POS N
with POS N
BTMs. POS N

BTMs POS N
increased POS N
from POS N
baseline POS N
to POS N
month POS N
12 POS N
and POS N
remained POS N
higher POS N
at POS N
month POS N
24, POS N
with POS N
CTX POS N
and POS N
PINP POS N
increasing POS N
28.5% POS N
and POS N
23.0% POS N
(all: POS N
p < 0.001), POS N
respectively. POS N

Metformin POS N
and POS N
metformin + rosiglitazone POS N
but POS N
not POS N
rosiglitazone POS N
alone POS N
were POS N
associated POS N
with POS N
lower POS N
bone POS N
formation POS N
(PINP). POS N

BTMs POS N
increased POS N
from POS N
baseline POS N
to POS N
month POS N
12 POS N
and POS N
remained POS N
higher POS N
at POS N
month POS N
24, POS N
with POS N
CTX POS N
and POS N
PINP POS N
increasing POS N
28.5% POS N
and POS N
23.0% POS N
(all: POS N
p < 0.001), POS N
respectively. POS N

Allocation POS N
of POS N
insulin POS N
regimens POS N
was POS N
not POS N
associated POS N
with POS N
different POS N
levels POS N
of POS N
BTMs. POS N

Androgen POS N
deprivation POS N
therapy POS N
is POS N
a POS N
common POS N
treatment POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
that POS N
may POS N
cause POS N
fatigue, POS N
functional POS N
decline, POS N
increased POS N
body POS N
fatness, POS N
and POS N
loss POS N
of POS N
lean POS N
body POS N
tissue. POS N

These POS N
physical POS N
changes POS N
can POS N
negatively POS N
affect POS N
health-related POS N
quality POS N
of POS N
life. POS N

Androgen POS N
deprivation POS N
therapy POS N
is POS N
a POS N
common POS N
treatment POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
that POS N
may POS N
cause POS N
fatigue, POS N
functional POS N
decline, POS N
increased POS N
body POS N
fatness, POS N
and POS N
loss POS N
of POS N
lean POS N
body POS N
tissue. POS N

Resistance POS N
exercise POS N
may POS N
help POS N
to POS N
counter POS N
some POS N
of POS N
these POS N
side POS N
effects POS N
by POS N
reducing POS N
fatigue, POS N
elevating POS N
mood, POS N
building POS N
muscle POS N
mass, POS N
and POS N
reducing POS N
body POS N
fat. POS N

Androgen POS N
deprivation POS N
therapy POS N
is POS N
a POS N
common POS N
treatment POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
that POS N
may POS N
cause POS N
fatigue, POS N
functional POS N
decline, POS N
increased POS N
body POS N
fatness, POS N
and POS N
loss POS N
of POS N
lean POS N
body POS N
tissue. POS N

Men POS N
assigned POS N
to POS N
resistance POS N
exercise POS N
had POS N
less POS N
interference POS N
from POS N
fatigue POS N
on POS N
activities POS N
of POS N
daily POS N
living POS N
(P POS N
=.002) POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
(P POS N
=.001) POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

Androgen POS N
deprivation POS N
therapy POS N
is POS N
a POS N
common POS N
treatment POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
that POS N
may POS N
cause POS N
fatigue, POS N
functional POS N
decline, POS N
increased POS N
body POS N
fatness, POS N
and POS N
loss POS N
of POS N
lean POS N
body POS N
tissue. POS N

Men POS N
in POS N
the POS N
intervention POS N
group POS N
demonstrated POS N
higher POS N
levels POS N
of POS N
upper POS N
body POS N
(P POS N
=.009) POS N
and POS N
lower POS N
body POS N
(P POS N
<.001) POS N
muscular POS N
fitness POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

Androgen POS N
deprivation POS N
therapy POS N
is POS N
a POS N
common POS N
treatment POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
that POS N
may POS N
cause POS N
fatigue, POS N
functional POS N
decline, POS N
increased POS N
body POS N
fatness, POS N
and POS N
loss POS N
of POS N
lean POS N
body POS N
tissue. POS N

The POS N
12-week POS N
resistance POS N
exercise POS N
intervention POS N
did POS N
not POS N
improve POS N
body POS N
composition POS N
as POS N
measured POS N
by POS N
changes POS N
in POS N
body POS N
weight, POS N
body POS N
mass POS N
index, POS N
waist POS N
circumference, POS N
or POS N
subcutaneous POS N
skinfolds. POS N

Androgen POS N
deprivation POS N
therapy POS N
is POS N
a POS N
common POS N
treatment POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
that POS N
may POS N
cause POS N
fatigue, POS N
functional POS N
decline, POS N
increased POS N
body POS N
fatness, POS N
and POS N
loss POS N
of POS N
lean POS N
body POS N
tissue. POS N

Resistance POS N
exercise POS N
reduces POS N
fatigue POS N
and POS N
improves POS N
quality POS N
of POS N
life POS N
and POS N
muscular POS N
fitness POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
receiving POS N
androgen POS N
deprivation POS N
therapy. POS N

Androgen POS N
deprivation POS N
therapy POS N
is POS N
a POS N
common POS N
treatment POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
that POS N
may POS N
cause POS N
fatigue, POS N
functional POS N
decline, POS N
increased POS N
body POS N
fatness, POS N
and POS N
loss POS N
of POS N
lean POS N
body POS N
tissue. POS N

This POS N
form POS N
of POS N
exercise POS N
can POS N
be POS N
an POS N
important POS N
component POS N
of POS N
supportive POS N
care POS N
for POS N
these POS N
patients. POS N

These POS N
physical POS N
changes POS N
can POS N
negatively POS N
affect POS N
health-related POS N
quality POS N
of POS N
life. POS N

Androgen POS N
deprivation POS N
therapy POS N
is POS N
a POS N
common POS N
treatment POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
that POS N
may POS N
cause POS N
fatigue, POS N
functional POS N
decline, POS N
increased POS N
body POS N
fatness, POS N
and POS N
loss POS N
of POS N
lean POS N
body POS N
tissue. POS N

These POS N
physical POS N
changes POS N
can POS N
negatively POS N
affect POS N
health-related POS N
quality POS N
of POS N
life. POS N

Resistance POS N
exercise POS N
may POS N
help POS N
to POS N
counter POS N
some POS N
of POS N
these POS N
side POS N
effects POS N
by POS N
reducing POS N
fatigue, POS N
elevating POS N
mood, POS N
building POS N
muscle POS N
mass, POS N
and POS N
reducing POS N
body POS N
fat. POS N

These POS N
physical POS N
changes POS N
can POS N
negatively POS N
affect POS N
health-related POS N
quality POS N
of POS N
life. POS N

Men POS N
assigned POS N
to POS N
resistance POS N
exercise POS N
had POS N
less POS N
interference POS N
from POS N
fatigue POS N
on POS N
activities POS N
of POS N
daily POS N
living POS N
(P POS N
=.002) POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
(P POS N
=.001) POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

These POS N
physical POS N
changes POS N
can POS N
negatively POS N
affect POS N
health-related POS N
quality POS N
of POS N
life. POS N

Men POS N
in POS N
the POS N
intervention POS N
group POS N
demonstrated POS N
higher POS N
levels POS N
of POS N
upper POS N
body POS N
(P POS N
=.009) POS N
and POS N
lower POS N
body POS N
(P POS N
<.001) POS N
muscular POS N
fitness POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

These POS N
physical POS N
changes POS N
can POS N
negatively POS N
affect POS N
health-related POS N
quality POS N
of POS N
life. POS N

The POS N
12-week POS N
resistance POS N
exercise POS N
intervention POS N
did POS N
not POS N
improve POS N
body POS N
composition POS N
as POS N
measured POS N
by POS N
changes POS N
in POS N
body POS N
weight, POS N
body POS N
mass POS N
index, POS N
waist POS N
circumference, POS N
or POS N
subcutaneous POS N
skinfolds. POS N

These POS N
physical POS N
changes POS N
can POS N
negatively POS N
affect POS N
health-related POS N
quality POS N
of POS N
life. POS N

Resistance POS N
exercise POS N
reduces POS N
fatigue POS N
and POS N
improves POS N
quality POS N
of POS N
life POS N
and POS N
muscular POS N
fitness POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
receiving POS N
androgen POS N
deprivation POS N
therapy. POS N

These POS N
physical POS N
changes POS N
can POS N
negatively POS N
affect POS N
health-related POS N
quality POS N
of POS N
life. POS N

This POS N
form POS N
of POS N
exercise POS N
can POS N
be POS N
an POS N
important POS N
component POS N
of POS N
supportive POS N
care POS N
for POS N
these POS N
patients. POS N

Resistance POS N
exercise POS N
may POS N
help POS N
to POS N
counter POS N
some POS N
of POS N
these POS N
side POS N
effects POS N
by POS N
reducing POS N
fatigue, POS N
elevating POS N
mood, POS N
building POS N
muscle POS N
mass, POS N
and POS N
reducing POS N
body POS N
fat. POS N

Androgen POS N
deprivation POS N
therapy POS N
is POS N
a POS N
common POS N
treatment POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
that POS N
may POS N
cause POS N
fatigue, POS N
functional POS N
decline, POS N
increased POS N
body POS N
fatness, POS N
and POS N
loss POS N
of POS N
lean POS N
body POS N
tissue. POS N

Resistance POS N
exercise POS N
may POS N
help POS N
to POS N
counter POS N
some POS N
of POS N
these POS N
side POS N
effects POS N
by POS N
reducing POS N
fatigue, POS N
elevating POS N
mood, POS N
building POS N
muscle POS N
mass, POS N
and POS N
reducing POS N
body POS N
fat. POS N

These POS N
physical POS N
changes POS N
can POS N
negatively POS N
affect POS N
health-related POS N
quality POS N
of POS N
life. POS N

Resistance POS N
exercise POS N
may POS N
help POS N
to POS N
counter POS N
some POS N
of POS N
these POS N
side POS N
effects POS N
by POS N
reducing POS N
fatigue, POS N
elevating POS N
mood, POS N
building POS N
muscle POS N
mass, POS N
and POS N
reducing POS N
body POS N
fat. POS N

Men POS N
assigned POS N
to POS N
resistance POS N
exercise POS N
had POS N
less POS N
interference POS N
from POS N
fatigue POS N
on POS N
activities POS N
of POS N
daily POS N
living POS N
(P POS N
=.002) POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
(P POS N
=.001) POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

Resistance POS N
exercise POS N
may POS N
help POS N
to POS N
counter POS N
some POS N
of POS N
these POS N
side POS N
effects POS N
by POS N
reducing POS N
fatigue, POS N
elevating POS N
mood, POS N
building POS N
muscle POS N
mass, POS N
and POS N
reducing POS N
body POS N
fat. POS N

Men POS N
in POS N
the POS N
intervention POS N
group POS N
demonstrated POS N
higher POS N
levels POS N
of POS N
upper POS N
body POS N
(P POS N
=.009) POS N
and POS N
lower POS N
body POS N
(P POS N
<.001) POS N
muscular POS N
fitness POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

Resistance POS N
exercise POS N
may POS N
help POS N
to POS N
counter POS N
some POS N
of POS N
these POS N
side POS N
effects POS N
by POS N
reducing POS N
fatigue, POS N
elevating POS N
mood, POS N
building POS N
muscle POS N
mass, POS N
and POS N
reducing POS N
body POS N
fat. POS N

The POS N
12-week POS N
resistance POS N
exercise POS N
intervention POS N
did POS N
not POS N
improve POS N
body POS N
composition POS N
as POS N
measured POS N
by POS N
changes POS N
in POS N
body POS N
weight, POS N
body POS N
mass POS N
index, POS N
waist POS N
circumference, POS N
or POS N
subcutaneous POS N
skinfolds. POS N

Resistance POS N
exercise POS N
may POS N
help POS N
to POS N
counter POS N
some POS N
of POS N
these POS N
side POS N
effects POS N
by POS N
reducing POS N
fatigue, POS N
elevating POS N
mood, POS N
building POS N
muscle POS N
mass, POS N
and POS N
reducing POS N
body POS N
fat. POS N

Resistance POS N
exercise POS N
reduces POS N
fatigue POS N
and POS N
improves POS N
quality POS N
of POS N
life POS N
and POS N
muscular POS N
fitness POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
receiving POS N
androgen POS N
deprivation POS N
therapy. POS N

Resistance POS N
exercise POS N
may POS N
help POS N
to POS N
counter POS N
some POS N
of POS N
these POS N
side POS N
effects POS N
by POS N
reducing POS N
fatigue, POS N
elevating POS N
mood, POS N
building POS N
muscle POS N
mass, POS N
and POS N
reducing POS N
body POS N
fat. POS N

This POS N
form POS N
of POS N
exercise POS N
can POS N
be POS N
an POS N
important POS N
component POS N
of POS N
supportive POS N
care POS N
for POS N
these POS N
patients. POS N

Men POS N
assigned POS N
to POS N
resistance POS N
exercise POS N
had POS N
less POS N
interference POS N
from POS N
fatigue POS N
on POS N
activities POS N
of POS N
daily POS N
living POS N
(P POS N
=.002) POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
(P POS N
=.001) POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

Androgen POS N
deprivation POS N
therapy POS N
is POS N
a POS N
common POS N
treatment POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
that POS N
may POS N
cause POS N
fatigue, POS N
functional POS N
decline, POS N
increased POS N
body POS N
fatness, POS N
and POS N
loss POS N
of POS N
lean POS N
body POS N
tissue. POS N

Men POS N
assigned POS N
to POS N
resistance POS N
exercise POS N
had POS N
less POS N
interference POS N
from POS N
fatigue POS N
on POS N
activities POS N
of POS N
daily POS N
living POS N
(P POS N
=.002) POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
(P POS N
=.001) POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

These POS N
physical POS N
changes POS N
can POS N
negatively POS N
affect POS N
health-related POS N
quality POS N
of POS N
life. POS N

Men POS N
assigned POS N
to POS N
resistance POS N
exercise POS N
had POS N
less POS N
interference POS N
from POS N
fatigue POS N
on POS N
activities POS N
of POS N
daily POS N
living POS N
(P POS N
=.002) POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
(P POS N
=.001) POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

Resistance POS N
exercise POS N
may POS N
help POS N
to POS N
counter POS N
some POS N
of POS N
these POS N
side POS N
effects POS N
by POS N
reducing POS N
fatigue, POS N
elevating POS N
mood, POS N
building POS N
muscle POS N
mass, POS N
and POS N
reducing POS N
body POS N
fat. POS N

Men POS N
assigned POS N
to POS N
resistance POS N
exercise POS N
had POS N
less POS N
interference POS N
from POS N
fatigue POS N
on POS N
activities POS N
of POS N
daily POS N
living POS N
(P POS N
=.002) POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
(P POS N
=.001) POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

Men POS N
in POS N
the POS N
intervention POS N
group POS N
demonstrated POS N
higher POS N
levels POS N
of POS N
upper POS N
body POS N
(P POS N
=.009) POS N
and POS N
lower POS N
body POS N
(P POS N
<.001) POS N
muscular POS N
fitness POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

Men POS N
assigned POS N
to POS N
resistance POS N
exercise POS N
had POS N
less POS N
interference POS N
from POS N
fatigue POS N
on POS N
activities POS N
of POS N
daily POS N
living POS N
(P POS N
=.002) POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
(P POS N
=.001) POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

The POS N
12-week POS N
resistance POS N
exercise POS N
intervention POS N
did POS N
not POS N
improve POS N
body POS N
composition POS N
as POS N
measured POS N
by POS N
changes POS N
in POS N
body POS N
weight, POS N
body POS N
mass POS N
index, POS N
waist POS N
circumference, POS N
or POS N
subcutaneous POS N
skinfolds. POS N

Men POS N
assigned POS N
to POS N
resistance POS N
exercise POS N
had POS N
less POS N
interference POS N
from POS N
fatigue POS N
on POS N
activities POS N
of POS N
daily POS N
living POS N
(P POS N
=.002) POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
(P POS N
=.001) POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

Resistance POS N
exercise POS N
reduces POS N
fatigue POS N
and POS N
improves POS N
quality POS N
of POS N
life POS N
and POS N
muscular POS N
fitness POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
receiving POS N
androgen POS N
deprivation POS N
therapy. POS N

Men POS N
assigned POS N
to POS N
resistance POS N
exercise POS N
had POS N
less POS N
interference POS N
from POS N
fatigue POS N
on POS N
activities POS N
of POS N
daily POS N
living POS N
(P POS N
=.002) POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
(P POS N
=.001) POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

This POS N
form POS N
of POS N
exercise POS N
can POS N
be POS N
an POS N
important POS N
component POS N
of POS N
supportive POS N
care POS N
for POS N
these POS N
patients. POS N

Men POS N
in POS N
the POS N
intervention POS N
group POS N
demonstrated POS N
higher POS N
levels POS N
of POS N
upper POS N
body POS N
(P POS N
=.009) POS N
and POS N
lower POS N
body POS N
(P POS N
<.001) POS N
muscular POS N
fitness POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

Androgen POS N
deprivation POS N
therapy POS N
is POS N
a POS N
common POS N
treatment POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
that POS N
may POS N
cause POS N
fatigue, POS N
functional POS N
decline, POS N
increased POS N
body POS N
fatness, POS N
and POS N
loss POS N
of POS N
lean POS N
body POS N
tissue. POS N

Men POS N
in POS N
the POS N
intervention POS N
group POS N
demonstrated POS N
higher POS N
levels POS N
of POS N
upper POS N
body POS N
(P POS N
=.009) POS N
and POS N
lower POS N
body POS N
(P POS N
<.001) POS N
muscular POS N
fitness POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

These POS N
physical POS N
changes POS N
can POS N
negatively POS N
affect POS N
health-related POS N
quality POS N
of POS N
life. POS N

Men POS N
in POS N
the POS N
intervention POS N
group POS N
demonstrated POS N
higher POS N
levels POS N
of POS N
upper POS N
body POS N
(P POS N
=.009) POS N
and POS N
lower POS N
body POS N
(P POS N
<.001) POS N
muscular POS N
fitness POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

Resistance POS N
exercise POS N
may POS N
help POS N
to POS N
counter POS N
some POS N
of POS N
these POS N
side POS N
effects POS N
by POS N
reducing POS N
fatigue, POS N
elevating POS N
mood, POS N
building POS N
muscle POS N
mass, POS N
and POS N
reducing POS N
body POS N
fat. POS N

Men POS N
in POS N
the POS N
intervention POS N
group POS N
demonstrated POS N
higher POS N
levels POS N
of POS N
upper POS N
body POS N
(P POS N
=.009) POS N
and POS N
lower POS N
body POS N
(P POS N
<.001) POS N
muscular POS N
fitness POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

Men POS N
assigned POS N
to POS N
resistance POS N
exercise POS N
had POS N
less POS N
interference POS N
from POS N
fatigue POS N
on POS N
activities POS N
of POS N
daily POS N
living POS N
(P POS N
=.002) POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
(P POS N
=.001) POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

Men POS N
in POS N
the POS N
intervention POS N
group POS N
demonstrated POS N
higher POS N
levels POS N
of POS N
upper POS N
body POS N
(P POS N
=.009) POS N
and POS N
lower POS N
body POS N
(P POS N
<.001) POS N
muscular POS N
fitness POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

The POS N
12-week POS N
resistance POS N
exercise POS N
intervention POS N
did POS N
not POS N
improve POS N
body POS N
composition POS N
as POS N
measured POS N
by POS N
changes POS N
in POS N
body POS N
weight, POS N
body POS N
mass POS N
index, POS N
waist POS N
circumference, POS N
or POS N
subcutaneous POS N
skinfolds. POS N

Men POS N
in POS N
the POS N
intervention POS N
group POS N
demonstrated POS N
higher POS N
levels POS N
of POS N
upper POS N
body POS N
(P POS N
=.009) POS N
and POS N
lower POS N
body POS N
(P POS N
<.001) POS N
muscular POS N
fitness POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

Resistance POS N
exercise POS N
reduces POS N
fatigue POS N
and POS N
improves POS N
quality POS N
of POS N
life POS N
and POS N
muscular POS N
fitness POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
receiving POS N
androgen POS N
deprivation POS N
therapy. POS N

Men POS N
in POS N
the POS N
intervention POS N
group POS N
demonstrated POS N
higher POS N
levels POS N
of POS N
upper POS N
body POS N
(P POS N
=.009) POS N
and POS N
lower POS N
body POS N
(P POS N
<.001) POS N
muscular POS N
fitness POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

This POS N
form POS N
of POS N
exercise POS N
can POS N
be POS N
an POS N
important POS N
component POS N
of POS N
supportive POS N
care POS N
for POS N
these POS N
patients. POS N

The POS N
12-week POS N
resistance POS N
exercise POS N
intervention POS N
did POS N
not POS N
improve POS N
body POS N
composition POS N
as POS N
measured POS N
by POS N
changes POS N
in POS N
body POS N
weight, POS N
body POS N
mass POS N
index, POS N
waist POS N
circumference, POS N
or POS N
subcutaneous POS N
skinfolds. POS N

Androgen POS N
deprivation POS N
therapy POS N
is POS N
a POS N
common POS N
treatment POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
that POS N
may POS N
cause POS N
fatigue, POS N
functional POS N
decline, POS N
increased POS N
body POS N
fatness, POS N
and POS N
loss POS N
of POS N
lean POS N
body POS N
tissue. POS N

The POS N
12-week POS N
resistance POS N
exercise POS N
intervention POS N
did POS N
not POS N
improve POS N
body POS N
composition POS N
as POS N
measured POS N
by POS N
changes POS N
in POS N
body POS N
weight, POS N
body POS N
mass POS N
index, POS N
waist POS N
circumference, POS N
or POS N
subcutaneous POS N
skinfolds. POS N

These POS N
physical POS N
changes POS N
can POS N
negatively POS N
affect POS N
health-related POS N
quality POS N
of POS N
life. POS N

The POS N
12-week POS N
resistance POS N
exercise POS N
intervention POS N
did POS N
not POS N
improve POS N
body POS N
composition POS N
as POS N
measured POS N
by POS N
changes POS N
in POS N
body POS N
weight, POS N
body POS N
mass POS N
index, POS N
waist POS N
circumference, POS N
or POS N
subcutaneous POS N
skinfolds. POS N

Resistance POS N
exercise POS N
may POS N
help POS N
to POS N
counter POS N
some POS N
of POS N
these POS N
side POS N
effects POS N
by POS N
reducing POS N
fatigue, POS N
elevating POS N
mood, POS N
building POS N
muscle POS N
mass, POS N
and POS N
reducing POS N
body POS N
fat. POS N

The POS N
12-week POS N
resistance POS N
exercise POS N
intervention POS N
did POS N
not POS N
improve POS N
body POS N
composition POS N
as POS N
measured POS N
by POS N
changes POS N
in POS N
body POS N
weight, POS N
body POS N
mass POS N
index, POS N
waist POS N
circumference, POS N
or POS N
subcutaneous POS N
skinfolds. POS N

Men POS N
assigned POS N
to POS N
resistance POS N
exercise POS N
had POS N
less POS N
interference POS N
from POS N
fatigue POS N
on POS N
activities POS N
of POS N
daily POS N
living POS N
(P POS N
=.002) POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
(P POS N
=.001) POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

The POS N
12-week POS N
resistance POS N
exercise POS N
intervention POS N
did POS N
not POS N
improve POS N
body POS N
composition POS N
as POS N
measured POS N
by POS N
changes POS N
in POS N
body POS N
weight, POS N
body POS N
mass POS N
index, POS N
waist POS N
circumference, POS N
or POS N
subcutaneous POS N
skinfolds. POS N

Men POS N
in POS N
the POS N
intervention POS N
group POS N
demonstrated POS N
higher POS N
levels POS N
of POS N
upper POS N
body POS N
(P POS N
=.009) POS N
and POS N
lower POS N
body POS N
(P POS N
<.001) POS N
muscular POS N
fitness POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

The POS N
12-week POS N
resistance POS N
exercise POS N
intervention POS N
did POS N
not POS N
improve POS N
body POS N
composition POS N
as POS N
measured POS N
by POS N
changes POS N
in POS N
body POS N
weight, POS N
body POS N
mass POS N
index, POS N
waist POS N
circumference, POS N
or POS N
subcutaneous POS N
skinfolds. POS N

Resistance POS N
exercise POS N
reduces POS N
fatigue POS N
and POS N
improves POS N
quality POS N
of POS N
life POS N
and POS N
muscular POS N
fitness POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
receiving POS N
androgen POS N
deprivation POS N
therapy. POS N

The POS N
12-week POS N
resistance POS N
exercise POS N
intervention POS N
did POS N
not POS N
improve POS N
body POS N
composition POS N
as POS N
measured POS N
by POS N
changes POS N
in POS N
body POS N
weight, POS N
body POS N
mass POS N
index, POS N
waist POS N
circumference, POS N
or POS N
subcutaneous POS N
skinfolds. POS N

This POS N
form POS N
of POS N
exercise POS N
can POS N
be POS N
an POS N
important POS N
component POS N
of POS N
supportive POS N
care POS N
for POS N
these POS N
patients. POS N

Resistance POS N
exercise POS N
reduces POS N
fatigue POS N
and POS N
improves POS N
quality POS N
of POS N
life POS N
and POS N
muscular POS N
fitness POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
receiving POS N
androgen POS N
deprivation POS N
therapy. POS N

Androgen POS N
deprivation POS N
therapy POS N
is POS N
a POS N
common POS N
treatment POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
that POS N
may POS N
cause POS N
fatigue, POS N
functional POS N
decline, POS N
increased POS N
body POS N
fatness, POS N
and POS N
loss POS N
of POS N
lean POS N
body POS N
tissue. POS N

Resistance POS N
exercise POS N
reduces POS N
fatigue POS N
and POS N
improves POS N
quality POS N
of POS N
life POS N
and POS N
muscular POS N
fitness POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
receiving POS N
androgen POS N
deprivation POS N
therapy. POS N

These POS N
physical POS N
changes POS N
can POS N
negatively POS N
affect POS N
health-related POS N
quality POS N
of POS N
life. POS N

Resistance POS N
exercise POS N
reduces POS N
fatigue POS N
and POS N
improves POS N
quality POS N
of POS N
life POS N
and POS N
muscular POS N
fitness POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
receiving POS N
androgen POS N
deprivation POS N
therapy. POS N

Resistance POS N
exercise POS N
may POS N
help POS N
to POS N
counter POS N
some POS N
of POS N
these POS N
side POS N
effects POS N
by POS N
reducing POS N
fatigue, POS N
elevating POS N
mood, POS N
building POS N
muscle POS N
mass, POS N
and POS N
reducing POS N
body POS N
fat. POS N

Resistance POS N
exercise POS N
reduces POS N
fatigue POS N
and POS N
improves POS N
quality POS N
of POS N
life POS N
and POS N
muscular POS N
fitness POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
receiving POS N
androgen POS N
deprivation POS N
therapy. POS N

Men POS N
assigned POS N
to POS N
resistance POS N
exercise POS N
had POS N
less POS N
interference POS N
from POS N
fatigue POS N
on POS N
activities POS N
of POS N
daily POS N
living POS N
(P POS N
=.002) POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
(P POS N
=.001) POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

Resistance POS N
exercise POS N
reduces POS N
fatigue POS N
and POS N
improves POS N
quality POS N
of POS N
life POS N
and POS N
muscular POS N
fitness POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
receiving POS N
androgen POS N
deprivation POS N
therapy. POS N

Men POS N
in POS N
the POS N
intervention POS N
group POS N
demonstrated POS N
higher POS N
levels POS N
of POS N
upper POS N
body POS N
(P POS N
=.009) POS N
and POS N
lower POS N
body POS N
(P POS N
<.001) POS N
muscular POS N
fitness POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

Resistance POS N
exercise POS N
reduces POS N
fatigue POS N
and POS N
improves POS N
quality POS N
of POS N
life POS N
and POS N
muscular POS N
fitness POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
receiving POS N
androgen POS N
deprivation POS N
therapy. POS N

The POS N
12-week POS N
resistance POS N
exercise POS N
intervention POS N
did POS N
not POS N
improve POS N
body POS N
composition POS N
as POS N
measured POS N
by POS N
changes POS N
in POS N
body POS N
weight, POS N
body POS N
mass POS N
index, POS N
waist POS N
circumference, POS N
or POS N
subcutaneous POS N
skinfolds. POS N

Resistance POS N
exercise POS N
reduces POS N
fatigue POS N
and POS N
improves POS N
quality POS N
of POS N
life POS N
and POS N
muscular POS N
fitness POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
receiving POS N
androgen POS N
deprivation POS N
therapy. POS N

This POS N
form POS N
of POS N
exercise POS N
can POS N
be POS N
an POS N
important POS N
component POS N
of POS N
supportive POS N
care POS N
for POS N
these POS N
patients. POS N

This POS N
form POS N
of POS N
exercise POS N
can POS N
be POS N
an POS N
important POS N
component POS N
of POS N
supportive POS N
care POS N
for POS N
these POS N
patients. POS N

Androgen POS N
deprivation POS N
therapy POS N
is POS N
a POS N
common POS N
treatment POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
that POS N
may POS N
cause POS N
fatigue, POS N
functional POS N
decline, POS N
increased POS N
body POS N
fatness, POS N
and POS N
loss POS N
of POS N
lean POS N
body POS N
tissue. POS N

This POS N
form POS N
of POS N
exercise POS N
can POS N
be POS N
an POS N
important POS N
component POS N
of POS N
supportive POS N
care POS N
for POS N
these POS N
patients. POS N

These POS N
physical POS N
changes POS N
can POS N
negatively POS N
affect POS N
health-related POS N
quality POS N
of POS N
life. POS N

This POS N
form POS N
of POS N
exercise POS N
can POS N
be POS N
an POS N
important POS N
component POS N
of POS N
supportive POS N
care POS N
for POS N
these POS N
patients. POS N

Resistance POS N
exercise POS N
may POS N
help POS N
to POS N
counter POS N
some POS N
of POS N
these POS N
side POS N
effects POS N
by POS N
reducing POS N
fatigue, POS N
elevating POS N
mood, POS N
building POS N
muscle POS N
mass, POS N
and POS N
reducing POS N
body POS N
fat. POS N

This POS N
form POS N
of POS N
exercise POS N
can POS N
be POS N
an POS N
important POS N
component POS N
of POS N
supportive POS N
care POS N
for POS N
these POS N
patients. POS N

Men POS N
assigned POS N
to POS N
resistance POS N
exercise POS N
had POS N
less POS N
interference POS N
from POS N
fatigue POS N
on POS N
activities POS N
of POS N
daily POS N
living POS N
(P POS N
=.002) POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
(P POS N
=.001) POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

This POS N
form POS N
of POS N
exercise POS N
can POS N
be POS N
an POS N
important POS N
component POS N
of POS N
supportive POS N
care POS N
for POS N
these POS N
patients. POS N

Men POS N
in POS N
the POS N
intervention POS N
group POS N
demonstrated POS N
higher POS N
levels POS N
of POS N
upper POS N
body POS N
(P POS N
=.009) POS N
and POS N
lower POS N
body POS N
(P POS N
<.001) POS N
muscular POS N
fitness POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

This POS N
form POS N
of POS N
exercise POS N
can POS N
be POS N
an POS N
important POS N
component POS N
of POS N
supportive POS N
care POS N
for POS N
these POS N
patients. POS N

The POS N
12-week POS N
resistance POS N
exercise POS N
intervention POS N
did POS N
not POS N
improve POS N
body POS N
composition POS N
as POS N
measured POS N
by POS N
changes POS N
in POS N
body POS N
weight, POS N
body POS N
mass POS N
index, POS N
waist POS N
circumference, POS N
or POS N
subcutaneous POS N
skinfolds. POS N

This POS N
form POS N
of POS N
exercise POS N
can POS N
be POS N
an POS N
important POS N
component POS N
of POS N
supportive POS N
care POS N
for POS N
these POS N
patients. POS N

Resistance POS N
exercise POS N
reduces POS N
fatigue POS N
and POS N
improves POS N
quality POS N
of POS N
life POS N
and POS N
muscular POS N
fitness POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
receiving POS N
androgen POS N
deprivation POS N
therapy. POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

Time POS N
with POS N
nocturnal POS N
hypoglycemia, POS N
glucose POS N
levels POS N
<70 mg/dL POS N
was POS N
reduced POS N
by POS N
48% POS N
(10.2 POS N
vs. POS N
19.6 min POS N
each POS N
night, POS N
P < 0.001) POS N
and POS N
glucose POS N
levels POS N
<54 mg/dL POS N
by POS N
65%. POS N
(3.1 POS N
vs. POS N
8.9 min, POS N
P < 0.001). POS N

For POS N
the POS N
corresponding POS N
glucose POS N
cutoffs, POS N
daytime POS N
hypoglycemia POS N
was POS N
reduced POS N
by POS N
40% POS N
(29 POS N
vs. POS N
49 min, POS N
P < 0.001) POS N
and POS N
54% POS N
(8 POS N
vs. POS N
18 min., POS N
P < 0.001), POS N
respectively. POS N

Time POS N
with POS N
nocturnal POS N
hypoglycemia, POS N
glucose POS N
levels POS N
<70 mg/dL POS N
was POS N
reduced POS N
by POS N
48% POS N
(10.2 POS N
vs. POS N
19.6 min POS N
each POS N
night, POS N
P < 0.001) POS N
and POS N
glucose POS N
levels POS N
<54 mg/dL POS N
by POS N
65%. POS N
(3.1 POS N
vs. POS N
8.9 min, POS N
P < 0.001). POS N

Compared POS N
with POS N
SMBG, POS N
CGM POS N
use POS N
improved POS N
hypoglycemia-related POS N
confidence POS N
in POS N
social POS N
situations POS N
(P = 0.016) POS N
and POS N
confidence POS N
in POS N
more POS N
broadly POS N
avoiding POS N
serious POS N
problems POS N
due POS N
to POS N
hypoglycemia POS N
(P = 0.0020). POS N

Time POS N
with POS N
nocturnal POS N
hypoglycemia, POS N
glucose POS N
levels POS N
<70 mg/dL POS N
was POS N
reduced POS N
by POS N
48% POS N
(10.2 POS N
vs. POS N
19.6 min POS N
each POS N
night, POS N
P < 0.001) POS N
and POS N
glucose POS N
levels POS N
<54 mg/dL POS N
by POS N
65%. POS N
(3.1 POS N
vs. POS N
8.9 min, POS N
P < 0.001). POS N

Persons POS N
also POS N
reported POS N
greater POS N
confidence POS N
in POS N
detecting POS N
and POS N
responding POS N
to POS N
decreasing POS N
blood POS N
glucose POS N
levels POS N
(thereby POS N
avoiding POS N
hypoglycemia) POS N
during POS N
CGM POS N
use POS N
(P = 0.0033) POS N

Time POS N
with POS N
nocturnal POS N
hypoglycemia, POS N
glucose POS N
levels POS N
<70 mg/dL POS N
was POS N
reduced POS N
by POS N
48% POS N
(10.2 POS N
vs. POS N
19.6 min POS N
each POS N
night, POS N
P < 0.001) POS N
and POS N
glucose POS N
levels POS N
<54 mg/dL POS N
by POS N
65%. POS N
(3.1 POS N
vs. POS N
8.9 min, POS N
P < 0.001). POS N

indicated POS N
greater POS N
conviction POS N
that POS N
they POS N
could POS N
more POS N
freely POS N
live POS N
their POS N
lives POS N
despite POS N
the POS N
risk POS N
of POS N
hypoglycemia POS N
(P = 0.022). POS N

Time POS N
with POS N
nocturnal POS N
hypoglycemia, POS N
glucose POS N
levels POS N
<70 mg/dL POS N
was POS N
reduced POS N
by POS N
48% POS N
(10.2 POS N
vs. POS N
19.6 min POS N
each POS N
night, POS N
P < 0.001) POS N
and POS N
glucose POS N
levels POS N
<54 mg/dL POS N
by POS N
65%. POS N
(3.1 POS N
vs. POS N
8.9 min, POS N
P < 0.001). POS N

CGM POS N
reduced POS N
time POS N
in POS N
both POS N
nocturnal POS N
and POS N
daytime POS N
hypoglycemia POS N
in POS N
persons POS N
with POS N
type POS N
1 POS N
diabetes POS N
treated POS N
with POS N
MDI POS N
and POS N
improved POS N
hypoglycemia-related POS N
confidence, POS N
especially POS N
in POS N
social POS N
situations, POS N
thus POS N
contributing POS N
to POS N
greater POS N
well-being POS N
and POS N
quality POS N
of POS N
life. POS N

For POS N
the POS N
corresponding POS N
glucose POS N
cutoffs, POS N
daytime POS N
hypoglycemia POS N
was POS N
reduced POS N
by POS N
40% POS N
(29 POS N
vs. POS N
49 min, POS N
P < 0.001) POS N
and POS N
54% POS N
(8 POS N
vs. POS N
18 min., POS N
P < 0.001), POS N
respectively. POS N

Time POS N
with POS N
nocturnal POS N
hypoglycemia, POS N
glucose POS N
levels POS N
<70 mg/dL POS N
was POS N
reduced POS N
by POS N
48% POS N
(10.2 POS N
vs. POS N
19.6 min POS N
each POS N
night, POS N
P < 0.001) POS N
and POS N
glucose POS N
levels POS N
<54 mg/dL POS N
by POS N
65%. POS N
(3.1 POS N
vs. POS N
8.9 min, POS N
P < 0.001). POS N

For POS N
the POS N
corresponding POS N
glucose POS N
cutoffs, POS N
daytime POS N
hypoglycemia POS N
was POS N
reduced POS N
by POS N
40% POS N
(29 POS N
vs. POS N
49 min, POS N
P < 0.001) POS N
and POS N
54% POS N
(8 POS N
vs. POS N
18 min., POS N
P < 0.001), POS N
respectively. POS N

Compared POS N
with POS N
SMBG, POS N
CGM POS N
use POS N
improved POS N
hypoglycemia-related POS N
confidence POS N
in POS N
social POS N
situations POS N
(P = 0.016) POS N
and POS N
confidence POS N
in POS N
more POS N
broadly POS N
avoiding POS N
serious POS N
problems POS N
due POS N
to POS N
hypoglycemia POS N
(P = 0.0020). POS N

For POS N
the POS N
corresponding POS N
glucose POS N
cutoffs, POS N
daytime POS N
hypoglycemia POS N
was POS N
reduced POS N
by POS N
40% POS N
(29 POS N
vs. POS N
49 min, POS N
P < 0.001) POS N
and POS N
54% POS N
(8 POS N
vs. POS N
18 min., POS N
P < 0.001), POS N
respectively. POS N

Persons POS N
also POS N
reported POS N
greater POS N
confidence POS N
in POS N
detecting POS N
and POS N
responding POS N
to POS N
decreasing POS N
blood POS N
glucose POS N
levels POS N
(thereby POS N
avoiding POS N
hypoglycemia) POS N
during POS N
CGM POS N
use POS N
(P = 0.0033) POS N

For POS N
the POS N
corresponding POS N
glucose POS N
cutoffs, POS N
daytime POS N
hypoglycemia POS N
was POS N
reduced POS N
by POS N
40% POS N
(29 POS N
vs. POS N
49 min, POS N
P < 0.001) POS N
and POS N
54% POS N
(8 POS N
vs. POS N
18 min., POS N
P < 0.001), POS N
respectively. POS N

indicated POS N
greater POS N
conviction POS N
that POS N
they POS N
could POS N
more POS N
freely POS N
live POS N
their POS N
lives POS N
despite POS N
the POS N
risk POS N
of POS N
hypoglycemia POS N
(P = 0.022). POS N

For POS N
the POS N
corresponding POS N
glucose POS N
cutoffs, POS N
daytime POS N
hypoglycemia POS N
was POS N
reduced POS N
by POS N
40% POS N
(29 POS N
vs. POS N
49 min, POS N
P < 0.001) POS N
and POS N
54% POS N
(8 POS N
vs. POS N
18 min., POS N
P < 0.001), POS N
respectively. POS N

CGM POS N
reduced POS N
time POS N
in POS N
both POS N
nocturnal POS N
and POS N
daytime POS N
hypoglycemia POS N
in POS N
persons POS N
with POS N
type POS N
1 POS N
diabetes POS N
treated POS N
with POS N
MDI POS N
and POS N
improved POS N
hypoglycemia-related POS N
confidence, POS N
especially POS N
in POS N
social POS N
situations, POS N
thus POS N
contributing POS N
to POS N
greater POS N
well-being POS N
and POS N
quality POS N
of POS N
life. POS N

Compared POS N
with POS N
SMBG, POS N
CGM POS N
use POS N
improved POS N
hypoglycemia-related POS N
confidence POS N
in POS N
social POS N
situations POS N
(P = 0.016) POS N
and POS N
confidence POS N
in POS N
more POS N
broadly POS N
avoiding POS N
serious POS N
problems POS N
due POS N
to POS N
hypoglycemia POS N
(P = 0.0020). POS N

Time POS N
with POS N
nocturnal POS N
hypoglycemia, POS N
glucose POS N
levels POS N
<70 mg/dL POS N
was POS N
reduced POS N
by POS N
48% POS N
(10.2 POS N
vs. POS N
19.6 min POS N
each POS N
night, POS N
P < 0.001) POS N
and POS N
glucose POS N
levels POS N
<54 mg/dL POS N
by POS N
65%. POS N
(3.1 POS N
vs. POS N
8.9 min, POS N
P < 0.001). POS N

Compared POS N
with POS N
SMBG, POS N
CGM POS N
use POS N
improved POS N
hypoglycemia-related POS N
confidence POS N
in POS N
social POS N
situations POS N
(P = 0.016) POS N
and POS N
confidence POS N
in POS N
more POS N
broadly POS N
avoiding POS N
serious POS N
problems POS N
due POS N
to POS N
hypoglycemia POS N
(P = 0.0020). POS N

For POS N
the POS N
corresponding POS N
glucose POS N
cutoffs, POS N
daytime POS N
hypoglycemia POS N
was POS N
reduced POS N
by POS N
40% POS N
(29 POS N
vs. POS N
49 min, POS N
P < 0.001) POS N
and POS N
54% POS N
(8 POS N
vs. POS N
18 min., POS N
P < 0.001), POS N
respectively. POS N

Compared POS N
with POS N
SMBG, POS N
CGM POS N
use POS N
improved POS N
hypoglycemia-related POS N
confidence POS N
in POS N
social POS N
situations POS N
(P = 0.016) POS N
and POS N
confidence POS N
in POS N
more POS N
broadly POS N
avoiding POS N
serious POS N
problems POS N
due POS N
to POS N
hypoglycemia POS N
(P = 0.0020). POS N

Persons POS N
also POS N
reported POS N
greater POS N
confidence POS N
in POS N
detecting POS N
and POS N
responding POS N
to POS N
decreasing POS N
blood POS N
glucose POS N
levels POS N
(thereby POS N
avoiding POS N
hypoglycemia) POS N
during POS N
CGM POS N
use POS N
(P = 0.0033) POS N

Compared POS N
with POS N
SMBG, POS N
CGM POS N
use POS N
improved POS N
hypoglycemia-related POS N
confidence POS N
in POS N
social POS N
situations POS N
(P = 0.016) POS N
and POS N
confidence POS N
in POS N
more POS N
broadly POS N
avoiding POS N
serious POS N
problems POS N
due POS N
to POS N
hypoglycemia POS N
(P = 0.0020). POS N

indicated POS N
greater POS N
conviction POS N
that POS N
they POS N
could POS N
more POS N
freely POS N
live POS N
their POS N
lives POS N
despite POS N
the POS N
risk POS N
of POS N
hypoglycemia POS N
(P = 0.022). POS N

Compared POS N
with POS N
SMBG, POS N
CGM POS N
use POS N
improved POS N
hypoglycemia-related POS N
confidence POS N
in POS N
social POS N
situations POS N
(P = 0.016) POS N
and POS N
confidence POS N
in POS N
more POS N
broadly POS N
avoiding POS N
serious POS N
problems POS N
due POS N
to POS N
hypoglycemia POS N
(P = 0.0020). POS N

CGM POS N
reduced POS N
time POS N
in POS N
both POS N
nocturnal POS N
and POS N
daytime POS N
hypoglycemia POS N
in POS N
persons POS N
with POS N
type POS N
1 POS N
diabetes POS N
treated POS N
with POS N
MDI POS N
and POS N
improved POS N
hypoglycemia-related POS N
confidence, POS N
especially POS N
in POS N
social POS N
situations, POS N
thus POS N
contributing POS N
to POS N
greater POS N
well-being POS N
and POS N
quality POS N
of POS N
life. POS N

Persons POS N
also POS N
reported POS N
greater POS N
confidence POS N
in POS N
detecting POS N
and POS N
responding POS N
to POS N
decreasing POS N
blood POS N
glucose POS N
levels POS N
(thereby POS N
avoiding POS N
hypoglycemia) POS N
during POS N
CGM POS N
use POS N
(P = 0.0033) POS N

Time POS N
with POS N
nocturnal POS N
hypoglycemia, POS N
glucose POS N
levels POS N
<70 mg/dL POS N
was POS N
reduced POS N
by POS N
48% POS N
(10.2 POS N
vs. POS N
19.6 min POS N
each POS N
night, POS N
P < 0.001) POS N
and POS N
glucose POS N
levels POS N
<54 mg/dL POS N
by POS N
65%. POS N
(3.1 POS N
vs. POS N
8.9 min, POS N
P < 0.001). POS N

Persons POS N
also POS N
reported POS N
greater POS N
confidence POS N
in POS N
detecting POS N
and POS N
responding POS N
to POS N
decreasing POS N
blood POS N
glucose POS N
levels POS N
(thereby POS N
avoiding POS N
hypoglycemia) POS N
during POS N
CGM POS N
use POS N
(P = 0.0033) POS N

For POS N
the POS N
corresponding POS N
glucose POS N
cutoffs, POS N
daytime POS N
hypoglycemia POS N
was POS N
reduced POS N
by POS N
40% POS N
(29 POS N
vs. POS N
49 min, POS N
P < 0.001) POS N
and POS N
54% POS N
(8 POS N
vs. POS N
18 min., POS N
P < 0.001), POS N
respectively. POS N

Persons POS N
also POS N
reported POS N
greater POS N
confidence POS N
in POS N
detecting POS N
and POS N
responding POS N
to POS N
decreasing POS N
blood POS N
glucose POS N
levels POS N
(thereby POS N
avoiding POS N
hypoglycemia) POS N
during POS N
CGM POS N
use POS N
(P = 0.0033) POS N

Compared POS N
with POS N
SMBG, POS N
CGM POS N
use POS N
improved POS N
hypoglycemia-related POS N
confidence POS N
in POS N
social POS N
situations POS N
(P = 0.016) POS N
and POS N
confidence POS N
in POS N
more POS N
broadly POS N
avoiding POS N
serious POS N
problems POS N
due POS N
to POS N
hypoglycemia POS N
(P = 0.0020). POS N

Persons POS N
also POS N
reported POS N
greater POS N
confidence POS N
in POS N
detecting POS N
and POS N
responding POS N
to POS N
decreasing POS N
blood POS N
glucose POS N
levels POS N
(thereby POS N
avoiding POS N
hypoglycemia) POS N
during POS N
CGM POS N
use POS N
(P = 0.0033) POS N

indicated POS N
greater POS N
conviction POS N
that POS N
they POS N
could POS N
more POS N
freely POS N
live POS N
their POS N
lives POS N
despite POS N
the POS N
risk POS N
of POS N
hypoglycemia POS N
(P = 0.022). POS N

Persons POS N
also POS N
reported POS N
greater POS N
confidence POS N
in POS N
detecting POS N
and POS N
responding POS N
to POS N
decreasing POS N
blood POS N
glucose POS N
levels POS N
(thereby POS N
avoiding POS N
hypoglycemia) POS N
during POS N
CGM POS N
use POS N
(P = 0.0033) POS N

CGM POS N
reduced POS N
time POS N
in POS N
both POS N
nocturnal POS N
and POS N
daytime POS N
hypoglycemia POS N
in POS N
persons POS N
with POS N
type POS N
1 POS N
diabetes POS N
treated POS N
with POS N
MDI POS N
and POS N
improved POS N
hypoglycemia-related POS N
confidence, POS N
especially POS N
in POS N
social POS N
situations, POS N
thus POS N
contributing POS N
to POS N
greater POS N
well-being POS N
and POS N
quality POS N
of POS N
life. POS N

indicated POS N
greater POS N
conviction POS N
that POS N
they POS N
could POS N
more POS N
freely POS N
live POS N
their POS N
lives POS N
despite POS N
the POS N
risk POS N
of POS N
hypoglycemia POS N
(P = 0.022). POS N

Time POS N
with POS N
nocturnal POS N
hypoglycemia, POS N
glucose POS N
levels POS N
<70 mg/dL POS N
was POS N
reduced POS N
by POS N
48% POS N
(10.2 POS N
vs. POS N
19.6 min POS N
each POS N
night, POS N
P < 0.001) POS N
and POS N
glucose POS N
levels POS N
<54 mg/dL POS N
by POS N
65%. POS N
(3.1 POS N
vs. POS N
8.9 min, POS N
P < 0.001). POS N

indicated POS N
greater POS N
conviction POS N
that POS N
they POS N
could POS N
more POS N
freely POS N
live POS N
their POS N
lives POS N
despite POS N
the POS N
risk POS N
of POS N
hypoglycemia POS N
(P = 0.022). POS N

For POS N
the POS N
corresponding POS N
glucose POS N
cutoffs, POS N
daytime POS N
hypoglycemia POS N
was POS N
reduced POS N
by POS N
40% POS N
(29 POS N
vs. POS N
49 min, POS N
P < 0.001) POS N
and POS N
54% POS N
(8 POS N
vs. POS N
18 min., POS N
P < 0.001), POS N
respectively. POS N

indicated POS N
greater POS N
conviction POS N
that POS N
they POS N
could POS N
more POS N
freely POS N
live POS N
their POS N
lives POS N
despite POS N
the POS N
risk POS N
of POS N
hypoglycemia POS N
(P = 0.022). POS N

Compared POS N
with POS N
SMBG, POS N
CGM POS N
use POS N
improved POS N
hypoglycemia-related POS N
confidence POS N
in POS N
social POS N
situations POS N
(P = 0.016) POS N
and POS N
confidence POS N
in POS N
more POS N
broadly POS N
avoiding POS N
serious POS N
problems POS N
due POS N
to POS N
hypoglycemia POS N
(P = 0.0020). POS N

indicated POS N
greater POS N
conviction POS N
that POS N
they POS N
could POS N
more POS N
freely POS N
live POS N
their POS N
lives POS N
despite POS N
the POS N
risk POS N
of POS N
hypoglycemia POS N
(P = 0.022). POS N

Persons POS N
also POS N
reported POS N
greater POS N
confidence POS N
in POS N
detecting POS N
and POS N
responding POS N
to POS N
decreasing POS N
blood POS N
glucose POS N
levels POS N
(thereby POS N
avoiding POS N
hypoglycemia) POS N
during POS N
CGM POS N
use POS N
(P = 0.0033) POS N

indicated POS N
greater POS N
conviction POS N
that POS N
they POS N
could POS N
more POS N
freely POS N
live POS N
their POS N
lives POS N
despite POS N
the POS N
risk POS N
of POS N
hypoglycemia POS N
(P = 0.022). POS N

CGM POS N
reduced POS N
time POS N
in POS N
both POS N
nocturnal POS N
and POS N
daytime POS N
hypoglycemia POS N
in POS N
persons POS N
with POS N
type POS N
1 POS N
diabetes POS N
treated POS N
with POS N
MDI POS N
and POS N
improved POS N
hypoglycemia-related POS N
confidence, POS N
especially POS N
in POS N
social POS N
situations, POS N
thus POS N
contributing POS N
to POS N
greater POS N
well-being POS N
and POS N
quality POS N
of POS N
life. POS N

CGM POS N
reduced POS N
time POS N
in POS N
both POS N
nocturnal POS N
and POS N
daytime POS N
hypoglycemia POS N
in POS N
persons POS N
with POS N
type POS N
1 POS N
diabetes POS N
treated POS N
with POS N
MDI POS N
and POS N
improved POS N
hypoglycemia-related POS N
confidence, POS N
especially POS N
in POS N
social POS N
situations, POS N
thus POS N
contributing POS N
to POS N
greater POS N
well-being POS N
and POS N
quality POS N
of POS N
life. POS N

Time POS N
with POS N
nocturnal POS N
hypoglycemia, POS N
glucose POS N
levels POS N
<70 mg/dL POS N
was POS N
reduced POS N
by POS N
48% POS N
(10.2 POS N
vs. POS N
19.6 min POS N
each POS N
night, POS N
P < 0.001) POS N
and POS N
glucose POS N
levels POS N
<54 mg/dL POS N
by POS N
65%. POS N
(3.1 POS N
vs. POS N
8.9 min, POS N
P < 0.001). POS N

CGM POS N
reduced POS N
time POS N
in POS N
both POS N
nocturnal POS N
and POS N
daytime POS N
hypoglycemia POS N
in POS N
persons POS N
with POS N
type POS N
1 POS N
diabetes POS N
treated POS N
with POS N
MDI POS N
and POS N
improved POS N
hypoglycemia-related POS N
confidence, POS N
especially POS N
in POS N
social POS N
situations, POS N
thus POS N
contributing POS N
to POS N
greater POS N
well-being POS N
and POS N
quality POS N
of POS N
life. POS N

For POS N
the POS N
corresponding POS N
glucose POS N
cutoffs, POS N
daytime POS N
hypoglycemia POS N
was POS N
reduced POS N
by POS N
40% POS N
(29 POS N
vs. POS N
49 min, POS N
P < 0.001) POS N
and POS N
54% POS N
(8 POS N
vs. POS N
18 min., POS N
P < 0.001), POS N
respectively. POS N

CGM POS N
reduced POS N
time POS N
in POS N
both POS N
nocturnal POS N
and POS N
daytime POS N
hypoglycemia POS N
in POS N
persons POS N
with POS N
type POS N
1 POS N
diabetes POS N
treated POS N
with POS N
MDI POS N
and POS N
improved POS N
hypoglycemia-related POS N
confidence, POS N
especially POS N
in POS N
social POS N
situations, POS N
thus POS N
contributing POS N
to POS N
greater POS N
well-being POS N
and POS N
quality POS N
of POS N
life. POS N

Compared POS N
with POS N
SMBG, POS N
CGM POS N
use POS N
improved POS N
hypoglycemia-related POS N
confidence POS N
in POS N
social POS N
situations POS N
(P = 0.016) POS N
and POS N
confidence POS N
in POS N
more POS N
broadly POS N
avoiding POS N
serious POS N
problems POS N
due POS N
to POS N
hypoglycemia POS N
(P = 0.0020). POS N

CGM POS N
reduced POS N
time POS N
in POS N
both POS N
nocturnal POS N
and POS N
daytime POS N
hypoglycemia POS N
in POS N
persons POS N
with POS N
type POS N
1 POS N
diabetes POS N
treated POS N
with POS N
MDI POS N
and POS N
improved POS N
hypoglycemia-related POS N
confidence, POS N
especially POS N
in POS N
social POS N
situations, POS N
thus POS N
contributing POS N
to POS N
greater POS N
well-being POS N
and POS N
quality POS N
of POS N
life. POS N

Persons POS N
also POS N
reported POS N
greater POS N
confidence POS N
in POS N
detecting POS N
and POS N
responding POS N
to POS N
decreasing POS N
blood POS N
glucose POS N
levels POS N
(thereby POS N
avoiding POS N
hypoglycemia) POS N
during POS N
CGM POS N
use POS N
(P = 0.0033) POS N

CGM POS N
reduced POS N
time POS N
in POS N
both POS N
nocturnal POS N
and POS N
daytime POS N
hypoglycemia POS N
in POS N
persons POS N
with POS N
type POS N
1 POS N
diabetes POS N
treated POS N
with POS N
MDI POS N
and POS N
improved POS N
hypoglycemia-related POS N
confidence, POS N
especially POS N
in POS N
social POS N
situations, POS N
thus POS N
contributing POS N
to POS N
greater POS N
well-being POS N
and POS N
quality POS N
of POS N
life. POS N

indicated POS N
greater POS N
conviction POS N
that POS N
they POS N
could POS N
more POS N
freely POS N
live POS N
their POS N
lives POS N
despite POS N
the POS N
risk POS N
of POS N
hypoglycemia POS N
(P = 0.022). POS N

In POS N
a POS N
setting POS N
in POS N
which POS N
the POS N
rate POS N
of POS N
mother-to-child POS N
HBV POS N
transmission POS N
was POS N
low POS N
with POS N
the POS N
administration POS N
of POS N
hepatitis POS N
B POS N
immune POS N
globulin POS N
and POS N
hepatitis POS N
B POS N
vaccine POS N
in POS N
infants POS N
born POS N
to POS N
HBeAg-positive POS N
mothers, POS N
the POS N
additional POS N
maternal POS N
use POS N
of POS N
TDF POS N
did POS N
not POS N
result POS N
in POS N
a POS N
significantly POS N
lower POS N
rate POS N
of POS N
transmission. POS N

In POS N
the POS N
primary POS N
analysis, POS N
none POS N
of POS N
the POS N
147 POS N
infants POS N
(0%; POS N
95% POS N
confidence POS N
interval POS N
[CI], POS N
0 POS N
to POS N
2) POS N
in POS N
the POS N
TDF POS N
group POS N
were POS N
infected, POS N
as POS N
compared POS N
with POS N
3 POS N
of POS N
147 POS N
(2%; POS N
95% POS N
CI, POS N
0 POS N
to POS N
6) POS N
in POS N
the POS N
placebo POS N
group POS N
(P=0.12). POS N

In POS N
a POS N
setting POS N
in POS N
which POS N
the POS N
rate POS N
of POS N
mother-to-child POS N
HBV POS N
transmission POS N
was POS N
low POS N
with POS N
the POS N
administration POS N
of POS N
hepatitis POS N
B POS N
immune POS N
globulin POS N
and POS N
hepatitis POS N
B POS N
vaccine POS N
in POS N
infants POS N
born POS N
to POS N
HBeAg-positive POS N
mothers, POS N
the POS N
additional POS N
maternal POS N
use POS N
of POS N
TDF POS N
did POS N
not POS N
result POS N
in POS N
a POS N
significantly POS N
lower POS N
rate POS N
of POS N
transmission. POS N

The POS N
rate POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
differ POS N
significantly POS N
between POS N
groups. POS N

In POS N
a POS N
setting POS N
in POS N
which POS N
the POS N
rate POS N
of POS N
mother-to-child POS N
HBV POS N
transmission POS N
was POS N
low POS N
with POS N
the POS N
administration POS N
of POS N
hepatitis POS N
B POS N
immune POS N
globulin POS N
and POS N
hepatitis POS N
B POS N
vaccine POS N
in POS N
infants POS N
born POS N
to POS N
HBeAg-positive POS N
mothers, POS N
the POS N
additional POS N
maternal POS N
use POS N
of POS N
TDF POS N
did POS N
not POS N
result POS N
in POS N
a POS N
significantly POS N
lower POS N
rate POS N
of POS N
transmission. POS N

The POS N
incidence POS N
of POS N
a POS N
maternal POS N
alanine POS N
aminotransferase POS N
level POS N
of POS N
more POS N
than POS N
300 POS N
IU POS N
per POS N
liter POS N
after POS N
discontinuation POS N
of POS N
the POS N
trial POS N
regimen POS N
was POS N
6% POS N
in POS N
the POS N
TDF POS N
group POS N
and POS N
3% POS N
in POS N
the POS N
placebo POS N
group POS N
(P=0.29). POS N

In POS N
the POS N
primary POS N
analysis, POS N
none POS N
of POS N
the POS N
147 POS N
infants POS N
(0%; POS N
95% POS N
confidence POS N
interval POS N
[CI], POS N
0 POS N
to POS N
2) POS N
in POS N
the POS N
TDF POS N
group POS N
were POS N
infected, POS N
as POS N
compared POS N
with POS N
3 POS N
of POS N
147 POS N
(2%; POS N
95% POS N
CI, POS N
0 POS N
to POS N
6) POS N
in POS N
the POS N
placebo POS N
group POS N
(P=0.12). POS N

In POS N
a POS N
setting POS N
in POS N
which POS N
the POS N
rate POS N
of POS N
mother-to-child POS N
HBV POS N
transmission POS N
was POS N
low POS N
with POS N
the POS N
administration POS N
of POS N
hepatitis POS N
B POS N
immune POS N
globulin POS N
and POS N
hepatitis POS N
B POS N
vaccine POS N
in POS N
infants POS N
born POS N
to POS N
HBeAg-positive POS N
mothers, POS N
the POS N
additional POS N
maternal POS N
use POS N
of POS N
TDF POS N
did POS N
not POS N
result POS N
in POS N
a POS N
significantly POS N
lower POS N
rate POS N
of POS N
transmission. POS N

In POS N
the POS N
primary POS N
analysis, POS N
none POS N
of POS N
the POS N
147 POS N
infants POS N
(0%; POS N
95% POS N
confidence POS N
interval POS N
[CI], POS N
0 POS N
to POS N
2) POS N
in POS N
the POS N
TDF POS N
group POS N
were POS N
infected, POS N
as POS N
compared POS N
with POS N
3 POS N
of POS N
147 POS N
(2%; POS N
95% POS N
CI, POS N
0 POS N
to POS N
6) POS N
in POS N
the POS N
placebo POS N
group POS N
(P=0.12). POS N

The POS N
rate POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
differ POS N
significantly POS N
between POS N
groups. POS N

In POS N
the POS N
primary POS N
analysis, POS N
none POS N
of POS N
the POS N
147 POS N
infants POS N
(0%; POS N
95% POS N
confidence POS N
interval POS N
[CI], POS N
0 POS N
to POS N
2) POS N
in POS N
the POS N
TDF POS N
group POS N
were POS N
infected, POS N
as POS N
compared POS N
with POS N
3 POS N
of POS N
147 POS N
(2%; POS N
95% POS N
CI, POS N
0 POS N
to POS N
6) POS N
in POS N
the POS N
placebo POS N
group POS N
(P=0.12). POS N

The POS N
incidence POS N
of POS N
a POS N
maternal POS N
alanine POS N
aminotransferase POS N
level POS N
of POS N
more POS N
than POS N
300 POS N
IU POS N
per POS N
liter POS N
after POS N
discontinuation POS N
of POS N
the POS N
trial POS N
regimen POS N
was POS N
6% POS N
in POS N
the POS N
TDF POS N
group POS N
and POS N
3% POS N
in POS N
the POS N
placebo POS N
group POS N
(P=0.29). POS N

The POS N
rate POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
differ POS N
significantly POS N
between POS N
groups. POS N

In POS N
a POS N
setting POS N
in POS N
which POS N
the POS N
rate POS N
of POS N
mother-to-child POS N
HBV POS N
transmission POS N
was POS N
low POS N
with POS N
the POS N
administration POS N
of POS N
hepatitis POS N
B POS N
immune POS N
globulin POS N
and POS N
hepatitis POS N
B POS N
vaccine POS N
in POS N
infants POS N
born POS N
to POS N
HBeAg-positive POS N
mothers, POS N
the POS N
additional POS N
maternal POS N
use POS N
of POS N
TDF POS N
did POS N
not POS N
result POS N
in POS N
a POS N
significantly POS N
lower POS N
rate POS N
of POS N
transmission. POS N

The POS N
rate POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
differ POS N
significantly POS N
between POS N
groups. POS N

In POS N
the POS N
primary POS N
analysis, POS N
none POS N
of POS N
the POS N
147 POS N
infants POS N
(0%; POS N
95% POS N
confidence POS N
interval POS N
[CI], POS N
0 POS N
to POS N
2) POS N
in POS N
the POS N
TDF POS N
group POS N
were POS N
infected, POS N
as POS N
compared POS N
with POS N
3 POS N
of POS N
147 POS N
(2%; POS N
95% POS N
CI, POS N
0 POS N
to POS N
6) POS N
in POS N
the POS N
placebo POS N
group POS N
(P=0.12). POS N

The POS N
rate POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
differ POS N
significantly POS N
between POS N
groups. POS N

The POS N
incidence POS N
of POS N
a POS N
maternal POS N
alanine POS N
aminotransferase POS N
level POS N
of POS N
more POS N
than POS N
300 POS N
IU POS N
per POS N
liter POS N
after POS N
discontinuation POS N
of POS N
the POS N
trial POS N
regimen POS N
was POS N
6% POS N
in POS N
the POS N
TDF POS N
group POS N
and POS N
3% POS N
in POS N
the POS N
placebo POS N
group POS N
(P=0.29). POS N

The POS N
incidence POS N
of POS N
a POS N
maternal POS N
alanine POS N
aminotransferase POS N
level POS N
of POS N
more POS N
than POS N
300 POS N
IU POS N
per POS N
liter POS N
after POS N
discontinuation POS N
of POS N
the POS N
trial POS N
regimen POS N
was POS N
6% POS N
in POS N
the POS N
TDF POS N
group POS N
and POS N
3% POS N
in POS N
the POS N
placebo POS N
group POS N
(P=0.29). POS N

In POS N
a POS N
setting POS N
in POS N
which POS N
the POS N
rate POS N
of POS N
mother-to-child POS N
HBV POS N
transmission POS N
was POS N
low POS N
with POS N
the POS N
administration POS N
of POS N
hepatitis POS N
B POS N
immune POS N
globulin POS N
and POS N
hepatitis POS N
B POS N
vaccine POS N
in POS N
infants POS N
born POS N
to POS N
HBeAg-positive POS N
mothers, POS N
the POS N
additional POS N
maternal POS N
use POS N
of POS N
TDF POS N
did POS N
not POS N
result POS N
in POS N
a POS N
significantly POS N
lower POS N
rate POS N
of POS N
transmission. POS N

The POS N
incidence POS N
of POS N
a POS N
maternal POS N
alanine POS N
aminotransferase POS N
level POS N
of POS N
more POS N
than POS N
300 POS N
IU POS N
per POS N
liter POS N
after POS N
discontinuation POS N
of POS N
the POS N
trial POS N
regimen POS N
was POS N
6% POS N
in POS N
the POS N
TDF POS N
group POS N
and POS N
3% POS N
in POS N
the POS N
placebo POS N
group POS N
(P=0.29). POS N

In POS N
the POS N
primary POS N
analysis, POS N
none POS N
of POS N
the POS N
147 POS N
infants POS N
(0%; POS N
95% POS N
confidence POS N
interval POS N
[CI], POS N
0 POS N
to POS N
2) POS N
in POS N
the POS N
TDF POS N
group POS N
were POS N
infected, POS N
as POS N
compared POS N
with POS N
3 POS N
of POS N
147 POS N
(2%; POS N
95% POS N
CI, POS N
0 POS N
to POS N
6) POS N
in POS N
the POS N
placebo POS N
group POS N
(P=0.12). POS N

The POS N
incidence POS N
of POS N
a POS N
maternal POS N
alanine POS N
aminotransferase POS N
level POS N
of POS N
more POS N
than POS N
300 POS N
IU POS N
per POS N
liter POS N
after POS N
discontinuation POS N
of POS N
the POS N
trial POS N
regimen POS N
was POS N
6% POS N
in POS N
the POS N
TDF POS N
group POS N
and POS N
3% POS N
in POS N
the POS N
placebo POS N
group POS N
(P=0.29). POS N

The POS N
rate POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
differ POS N
significantly POS N
between POS N
groups. POS N

After POS N
completion POS N
of POS N
chemotherapy, POS N
patients POS N
treated POS N
with POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
significant POS N
improvement POS N
in POS N
fatigue POS N
(P POS N
<.05) POS N
as POS N
compared POS N
with POS N
their POS N
baseline POS N
scores. POS N

Higher POS N
proportions POS N
of POS N
patients POS N
receiving POS N
the POS N
combined POS N
therapy POS N
achieved POS N
improvement POS N
in POS N
global POS N
QOL POS N
(P POS N
<.05) POS N
than POS N
did POS N
patients POS N
treated POS N
with POS N
chemotherapy POS N
alone. POS N

After POS N
completion POS N
of POS N
chemotherapy, POS N
patients POS N
treated POS N
with POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
significant POS N
improvement POS N
in POS N
fatigue POS N
(P POS N
<.05) POS N
as POS N
compared POS N
with POS N
their POS N
baseline POS N
scores. POS N

Higher POS N
proportions POS N
of POS N
the POS N
combined POS N
therapy POS N
group POS N
also POS N
achieved POS N
improvement POS N
in POS N
physical POS N
and POS N
role POS N
functioning POS N
and POS N
in POS N
fatigue POS N
as POS N
compared POS N
with POS N
the POS N
chemotherapy POS N
group, POS N

After POS N
completion POS N
of POS N
chemotherapy, POS N
patients POS N
treated POS N
with POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
significant POS N
improvement POS N
in POS N
fatigue POS N
(P POS N
<.05) POS N
as POS N
compared POS N
with POS N
their POS N
baseline POS N
scores. POS N

There POS N
were POS N
no POS N
differences POS N
in POS N
the POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
two POS N
groups POS N
that POS N
reported POS N
worsening. POS N

After POS N
completion POS N
of POS N
chemotherapy, POS N
patients POS N
treated POS N
with POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
significant POS N
improvement POS N
in POS N
fatigue POS N
(P POS N
<.05) POS N
as POS N
compared POS N
with POS N
their POS N
baseline POS N
scores. POS N

Statistically POS N
significantly POS N
higher POS N
proportions POS N
of POS N
patients POS N
treated POS N
with POS N
a POS N
combination POS N
of POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
improved POS N
global POS N
QOL POS N
than POS N
did POS N
patients POS N
treated POS N
by POS N
chemotherapy POS N
alone. POS N

After POS N
completion POS N
of POS N
chemotherapy, POS N
patients POS N
treated POS N
with POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
significant POS N
improvement POS N
in POS N
fatigue POS N
(P POS N
<.05) POS N
as POS N
compared POS N
with POS N
their POS N
baseline POS N
scores. POS N

but POS N
the POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

Higher POS N
proportions POS N
of POS N
patients POS N
receiving POS N
the POS N
combined POS N
therapy POS N
achieved POS N
improvement POS N
in POS N
global POS N
QOL POS N
(P POS N
<.05) POS N
than POS N
did POS N
patients POS N
treated POS N
with POS N
chemotherapy POS N
alone. POS N

After POS N
completion POS N
of POS N
chemotherapy, POS N
patients POS N
treated POS N
with POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
significant POS N
improvement POS N
in POS N
fatigue POS N
(P POS N
<.05) POS N
as POS N
compared POS N
with POS N
their POS N
baseline POS N
scores. POS N

Higher POS N
proportions POS N
of POS N
patients POS N
receiving POS N
the POS N
combined POS N
therapy POS N
achieved POS N
improvement POS N
in POS N
global POS N
QOL POS N
(P POS N
<.05) POS N
than POS N
did POS N
patients POS N
treated POS N
with POS N
chemotherapy POS N
alone. POS N

Higher POS N
proportions POS N
of POS N
the POS N
combined POS N
therapy POS N
group POS N
also POS N
achieved POS N
improvement POS N
in POS N
physical POS N
and POS N
role POS N
functioning POS N
and POS N
in POS N
fatigue POS N
as POS N
compared POS N
with POS N
the POS N
chemotherapy POS N
group, POS N

Higher POS N
proportions POS N
of POS N
patients POS N
receiving POS N
the POS N
combined POS N
therapy POS N
achieved POS N
improvement POS N
in POS N
global POS N
QOL POS N
(P POS N
<.05) POS N
than POS N
did POS N
patients POS N
treated POS N
with POS N
chemotherapy POS N
alone. POS N

There POS N
were POS N
no POS N
differences POS N
in POS N
the POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
two POS N
groups POS N
that POS N
reported POS N
worsening. POS N

Higher POS N
proportions POS N
of POS N
patients POS N
receiving POS N
the POS N
combined POS N
therapy POS N
achieved POS N
improvement POS N
in POS N
global POS N
QOL POS N
(P POS N
<.05) POS N
than POS N
did POS N
patients POS N
treated POS N
with POS N
chemotherapy POS N
alone. POS N

Statistically POS N
significantly POS N
higher POS N
proportions POS N
of POS N
patients POS N
treated POS N
with POS N
a POS N
combination POS N
of POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
improved POS N
global POS N
QOL POS N
than POS N
did POS N
patients POS N
treated POS N
by POS N
chemotherapy POS N
alone. POS N

Higher POS N
proportions POS N
of POS N
patients POS N
receiving POS N
the POS N
combined POS N
therapy POS N
achieved POS N
improvement POS N
in POS N
global POS N
QOL POS N
(P POS N
<.05) POS N
than POS N
did POS N
patients POS N
treated POS N
with POS N
chemotherapy POS N
alone. POS N

but POS N
the POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

Higher POS N
proportions POS N
of POS N
the POS N
combined POS N
therapy POS N
group POS N
also POS N
achieved POS N
improvement POS N
in POS N
physical POS N
and POS N
role POS N
functioning POS N
and POS N
in POS N
fatigue POS N
as POS N
compared POS N
with POS N
the POS N
chemotherapy POS N
group, POS N

After POS N
completion POS N
of POS N
chemotherapy, POS N
patients POS N
treated POS N
with POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
significant POS N
improvement POS N
in POS N
fatigue POS N
(P POS N
<.05) POS N
as POS N
compared POS N
with POS N
their POS N
baseline POS N
scores. POS N

Higher POS N
proportions POS N
of POS N
the POS N
combined POS N
therapy POS N
group POS N
also POS N
achieved POS N
improvement POS N
in POS N
physical POS N
and POS N
role POS N
functioning POS N
and POS N
in POS N
fatigue POS N
as POS N
compared POS N
with POS N
the POS N
chemotherapy POS N
group, POS N

Higher POS N
proportions POS N
of POS N
patients POS N
receiving POS N
the POS N
combined POS N
therapy POS N
achieved POS N
improvement POS N
in POS N
global POS N
QOL POS N
(P POS N
<.05) POS N
than POS N
did POS N
patients POS N
treated POS N
with POS N
chemotherapy POS N
alone. POS N

Higher POS N
proportions POS N
of POS N
the POS N
combined POS N
therapy POS N
group POS N
also POS N
achieved POS N
improvement POS N
in POS N
physical POS N
and POS N
role POS N
functioning POS N
and POS N
in POS N
fatigue POS N
as POS N
compared POS N
with POS N
the POS N
chemotherapy POS N
group, POS N

There POS N
were POS N
no POS N
differences POS N
in POS N
the POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
two POS N
groups POS N
that POS N
reported POS N
worsening. POS N

Higher POS N
proportions POS N
of POS N
the POS N
combined POS N
therapy POS N
group POS N
also POS N
achieved POS N
improvement POS N
in POS N
physical POS N
and POS N
role POS N
functioning POS N
and POS N
in POS N
fatigue POS N
as POS N
compared POS N
with POS N
the POS N
chemotherapy POS N
group, POS N

Statistically POS N
significantly POS N
higher POS N
proportions POS N
of POS N
patients POS N
treated POS N
with POS N
a POS N
combination POS N
of POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
improved POS N
global POS N
QOL POS N
than POS N
did POS N
patients POS N
treated POS N
by POS N
chemotherapy POS N
alone. POS N

Higher POS N
proportions POS N
of POS N
the POS N
combined POS N
therapy POS N
group POS N
also POS N
achieved POS N
improvement POS N
in POS N
physical POS N
and POS N
role POS N
functioning POS N
and POS N
in POS N
fatigue POS N
as POS N
compared POS N
with POS N
the POS N
chemotherapy POS N
group, POS N

but POS N
the POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

There POS N
were POS N
no POS N
differences POS N
in POS N
the POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
two POS N
groups POS N
that POS N
reported POS N
worsening. POS N

After POS N
completion POS N
of POS N
chemotherapy, POS N
patients POS N
treated POS N
with POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
significant POS N
improvement POS N
in POS N
fatigue POS N
(P POS N
<.05) POS N
as POS N
compared POS N
with POS N
their POS N
baseline POS N
scores. POS N

There POS N
were POS N
no POS N
differences POS N
in POS N
the POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
two POS N
groups POS N
that POS N
reported POS N
worsening. POS N

Higher POS N
proportions POS N
of POS N
patients POS N
receiving POS N
the POS N
combined POS N
therapy POS N
achieved POS N
improvement POS N
in POS N
global POS N
QOL POS N
(P POS N
<.05) POS N
than POS N
did POS N
patients POS N
treated POS N
with POS N
chemotherapy POS N
alone. POS N

There POS N
were POS N
no POS N
differences POS N
in POS N
the POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
two POS N
groups POS N
that POS N
reported POS N
worsening. POS N

Higher POS N
proportions POS N
of POS N
the POS N
combined POS N
therapy POS N
group POS N
also POS N
achieved POS N
improvement POS N
in POS N
physical POS N
and POS N
role POS N
functioning POS N
and POS N
in POS N
fatigue POS N
as POS N
compared POS N
with POS N
the POS N
chemotherapy POS N
group, POS N

There POS N
were POS N
no POS N
differences POS N
in POS N
the POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
two POS N
groups POS N
that POS N
reported POS N
worsening. POS N

Statistically POS N
significantly POS N
higher POS N
proportions POS N
of POS N
patients POS N
treated POS N
with POS N
a POS N
combination POS N
of POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
improved POS N
global POS N
QOL POS N
than POS N
did POS N
patients POS N
treated POS N
by POS N
chemotherapy POS N
alone. POS N

There POS N
were POS N
no POS N
differences POS N
in POS N
the POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
two POS N
groups POS N
that POS N
reported POS N
worsening. POS N

but POS N
the POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

Statistically POS N
significantly POS N
higher POS N
proportions POS N
of POS N
patients POS N
treated POS N
with POS N
a POS N
combination POS N
of POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
improved POS N
global POS N
QOL POS N
than POS N
did POS N
patients POS N
treated POS N
by POS N
chemotherapy POS N
alone. POS N

After POS N
completion POS N
of POS N
chemotherapy, POS N
patients POS N
treated POS N
with POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
significant POS N
improvement POS N
in POS N
fatigue POS N
(P POS N
<.05) POS N
as POS N
compared POS N
with POS N
their POS N
baseline POS N
scores. POS N

Statistically POS N
significantly POS N
higher POS N
proportions POS N
of POS N
patients POS N
treated POS N
with POS N
a POS N
combination POS N
of POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
improved POS N
global POS N
QOL POS N
than POS N
did POS N
patients POS N
treated POS N
by POS N
chemotherapy POS N
alone. POS N

Higher POS N
proportions POS N
of POS N
patients POS N
receiving POS N
the POS N
combined POS N
therapy POS N
achieved POS N
improvement POS N
in POS N
global POS N
QOL POS N
(P POS N
<.05) POS N
than POS N
did POS N
patients POS N
treated POS N
with POS N
chemotherapy POS N
alone. POS N

Statistically POS N
significantly POS N
higher POS N
proportions POS N
of POS N
patients POS N
treated POS N
with POS N
a POS N
combination POS N
of POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
improved POS N
global POS N
QOL POS N
than POS N
did POS N
patients POS N
treated POS N
by POS N
chemotherapy POS N
alone. POS N

Higher POS N
proportions POS N
of POS N
the POS N
combined POS N
therapy POS N
group POS N
also POS N
achieved POS N
improvement POS N
in POS N
physical POS N
and POS N
role POS N
functioning POS N
and POS N
in POS N
fatigue POS N
as POS N
compared POS N
with POS N
the POS N
chemotherapy POS N
group, POS N

Statistically POS N
significantly POS N
higher POS N
proportions POS N
of POS N
patients POS N
treated POS N
with POS N
a POS N
combination POS N
of POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
improved POS N
global POS N
QOL POS N
than POS N
did POS N
patients POS N
treated POS N
by POS N
chemotherapy POS N
alone. POS N

There POS N
were POS N
no POS N
differences POS N
in POS N
the POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
two POS N
groups POS N
that POS N
reported POS N
worsening. POS N

Statistically POS N
significantly POS N
higher POS N
proportions POS N
of POS N
patients POS N
treated POS N
with POS N
a POS N
combination POS N
of POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
improved POS N
global POS N
QOL POS N
than POS N
did POS N
patients POS N
treated POS N
by POS N
chemotherapy POS N
alone. POS N

but POS N
the POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

but POS N
the POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

After POS N
completion POS N
of POS N
chemotherapy, POS N
patients POS N
treated POS N
with POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
significant POS N
improvement POS N
in POS N
fatigue POS N
(P POS N
<.05) POS N
as POS N
compared POS N
with POS N
their POS N
baseline POS N
scores. POS N

but POS N
the POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

Higher POS N
proportions POS N
of POS N
patients POS N
receiving POS N
the POS N
combined POS N
therapy POS N
achieved POS N
improvement POS N
in POS N
global POS N
QOL POS N
(P POS N
<.05) POS N
than POS N
did POS N
patients POS N
treated POS N
with POS N
chemotherapy POS N
alone. POS N

but POS N
the POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

Higher POS N
proportions POS N
of POS N
the POS N
combined POS N
therapy POS N
group POS N
also POS N
achieved POS N
improvement POS N
in POS N
physical POS N
and POS N
role POS N
functioning POS N
and POS N
in POS N
fatigue POS N
as POS N
compared POS N
with POS N
the POS N
chemotherapy POS N
group, POS N

but POS N
the POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

There POS N
were POS N
no POS N
differences POS N
in POS N
the POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
two POS N
groups POS N
that POS N
reported POS N
worsening. POS N

but POS N
the POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

Statistically POS N
significantly POS N
higher POS N
proportions POS N
of POS N
patients POS N
treated POS N
with POS N
a POS N
combination POS N
of POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
improved POS N
global POS N
QOL POS N
than POS N
did POS N
patients POS N
treated POS N
by POS N
chemotherapy POS N
alone. POS N

In POS N
389 POS N
eligible POS N
patients, POS N
the POS N
relative POS N
dose POS N
intensities POS N
(RDIs) POS N
of POS N
cyclophosphamide POS N
(median, POS N
96.3% POS N
v POS N
93.9%; POS N
P POS N
=.01) POS N
and POS N
doxorubicin POS N
(median, POS N
95.4% POS N
v POS N
93.3%; POS N
P POS N
=.04) POS N
were POS N
higher POS N
in POS N
patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF. POS N

The POS N
complete POS N
response POS N
rates POS N
were POS N
55% POS N
and POS N
52% POS N
for POS N
CHOP POS N
and POS N
CHOP POS N
plus POS N
G-CSF, POS N
respectively POS N
(P POS N
=.63). POS N

In POS N
389 POS N
eligible POS N
patients, POS N
the POS N
relative POS N
dose POS N
intensities POS N
(RDIs) POS N
of POS N
cyclophosphamide POS N
(median, POS N
96.3% POS N
v POS N
93.9%; POS N
P POS N
=.01) POS N
and POS N
doxorubicin POS N
(median, POS N
95.4% POS N
v POS N
93.3%; POS N
P POS N
=.04) POS N
were POS N
higher POS N
in POS N
patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF. POS N

The POS N
actuarial POS N
overall POS N
survival POS N
at POS N
5 POS N
years POS N
was POS N
22% POS N
with POS N
CHOP POS N
alone, POS N
compared POS N
with POS N
24% POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(P POS N
=.76), POS N
with POS N
a POS N
median POS N
follow-up POS N
of POS N
33 POS N
months. POS N

In POS N
389 POS N
eligible POS N
patients, POS N
the POS N
relative POS N
dose POS N
intensities POS N
(RDIs) POS N
of POS N
cyclophosphamide POS N
(median, POS N
96.3% POS N
v POS N
93.9%; POS N
P POS N
=.01) POS N
and POS N
doxorubicin POS N
(median, POS N
95.4% POS N
v POS N
93.3%; POS N
P POS N
=.04) POS N
were POS N
higher POS N
in POS N
patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF. POS N

Patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
had POS N
an POS N
identical POS N
incidence POS N
of POS N
infections, POS N
with POS N
World POS N
Health POS N
Organization POS N
grade POS N
3 POS N
to POS N
4 POS N
(34 POS N
of POS N
1,191 POS N
cycles POS N
v POS N
36 POS N
of POS N
1,195 POS N
cycles). POS N

In POS N
389 POS N
eligible POS N
patients, POS N
the POS N
relative POS N
dose POS N
intensities POS N
(RDIs) POS N
of POS N
cyclophosphamide POS N
(median, POS N
96.3% POS N
v POS N
93.9%; POS N
P POS N
=.01) POS N
and POS N
doxorubicin POS N
(median, POS N
95.4% POS N
v POS N
93.3%; POS N
P POS N
=.04) POS N
were POS N
higher POS N
in POS N
patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF. POS N

Only POS N
the POS N
cumulative POS N
days POS N
with POS N
antibiotics POS N
were POS N
fewer POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(median, POS N
0 POS N
v POS N
6 POS N
days; POS N
P POS N
=.006) POS N
than POS N
with POS N
CHOP POS N
alone. POS N

In POS N
389 POS N
eligible POS N
patients, POS N
the POS N
relative POS N
dose POS N
intensities POS N
(RDIs) POS N
of POS N
cyclophosphamide POS N
(median, POS N
96.3% POS N
v POS N
93.9%; POS N
P POS N
=.01) POS N
and POS N
doxorubicin POS N
(median, POS N
95.4% POS N
v POS N
93.3%; POS N
P POS N
=.04) POS N
were POS N
higher POS N
in POS N
patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF. POS N

The POS N
number POS N
of POS N
hospital POS N
admissions POS N
and POS N
the POS N
number POS N
of POS N
days POS N
in POS N
hospital POS N
were POS N
not POS N
different. POS N

In POS N
389 POS N
eligible POS N
patients, POS N
the POS N
relative POS N
dose POS N
intensities POS N
(RDIs) POS N
of POS N
cyclophosphamide POS N
(median, POS N
96.3% POS N
v POS N
93.9%; POS N
P POS N
=.01) POS N
and POS N
doxorubicin POS N
(median, POS N
95.4% POS N
v POS N
93.3%; POS N
P POS N
=.04) POS N
were POS N
higher POS N
in POS N
patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF. POS N

In POS N
elderly POS N
patients, POS N
G-CSF POS N
improved POS N
the POS N
RDI POS N
of POS N
CHOP, POS N

In POS N
389 POS N
eligible POS N
patients, POS N
the POS N
relative POS N
dose POS N
intensities POS N
(RDIs) POS N
of POS N
cyclophosphamide POS N
(median, POS N
96.3% POS N
v POS N
93.9%; POS N
P POS N
=.01) POS N
and POS N
doxorubicin POS N
(median, POS N
95.4% POS N
v POS N
93.3%; POS N
P POS N
=.04) POS N
were POS N
higher POS N
in POS N
patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF. POS N

but POS N
this POS N
did POS N
not POS N
lead POS N
to POS N
a POS N
higher POS N
complete POS N
response POS N
rate POS N
or POS N
better POS N
overall POS N
survival. POS N

In POS N
389 POS N
eligible POS N
patients, POS N
the POS N
relative POS N
dose POS N
intensities POS N
(RDIs) POS N
of POS N
cyclophosphamide POS N
(median, POS N
96.3% POS N
v POS N
93.9%; POS N
P POS N
=.01) POS N
and POS N
doxorubicin POS N
(median, POS N
95.4% POS N
v POS N
93.3%; POS N
P POS N
=.04) POS N
were POS N
higher POS N
in POS N
patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF. POS N

G-CSF POS N
did POS N
not POS N
prevent POS N
serious POS N
infections. POS N

The POS N
complete POS N
response POS N
rates POS N
were POS N
55% POS N
and POS N
52% POS N
for POS N
CHOP POS N
and POS N
CHOP POS N
plus POS N
G-CSF, POS N
respectively POS N
(P POS N
=.63). POS N

In POS N
389 POS N
eligible POS N
patients, POS N
the POS N
relative POS N
dose POS N
intensities POS N
(RDIs) POS N
of POS N
cyclophosphamide POS N
(median, POS N
96.3% POS N
v POS N
93.9%; POS N
P POS N
=.01) POS N
and POS N
doxorubicin POS N
(median, POS N
95.4% POS N
v POS N
93.3%; POS N
P POS N
=.04) POS N
were POS N
higher POS N
in POS N
patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF. POS N

The POS N
complete POS N
response POS N
rates POS N
were POS N
55% POS N
and POS N
52% POS N
for POS N
CHOP POS N
and POS N
CHOP POS N
plus POS N
G-CSF, POS N
respectively POS N
(P POS N
=.63). POS N

The POS N
actuarial POS N
overall POS N
survival POS N
at POS N
5 POS N
years POS N
was POS N
22% POS N
with POS N
CHOP POS N
alone, POS N
compared POS N
with POS N
24% POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(P POS N
=.76), POS N
with POS N
a POS N
median POS N
follow-up POS N
of POS N
33 POS N
months. POS N

The POS N
complete POS N
response POS N
rates POS N
were POS N
55% POS N
and POS N
52% POS N
for POS N
CHOP POS N
and POS N
CHOP POS N
plus POS N
G-CSF, POS N
respectively POS N
(P POS N
=.63). POS N

Patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
had POS N
an POS N
identical POS N
incidence POS N
of POS N
infections, POS N
with POS N
World POS N
Health POS N
Organization POS N
grade POS N
3 POS N
to POS N
4 POS N
(34 POS N
of POS N
1,191 POS N
cycles POS N
v POS N
36 POS N
of POS N
1,195 POS N
cycles). POS N

The POS N
complete POS N
response POS N
rates POS N
were POS N
55% POS N
and POS N
52% POS N
for POS N
CHOP POS N
and POS N
CHOP POS N
plus POS N
G-CSF, POS N
respectively POS N
(P POS N
=.63). POS N

Only POS N
the POS N
cumulative POS N
days POS N
with POS N
antibiotics POS N
were POS N
fewer POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(median, POS N
0 POS N
v POS N
6 POS N
days; POS N
P POS N
=.006) POS N
than POS N
with POS N
CHOP POS N
alone. POS N

The POS N
complete POS N
response POS N
rates POS N
were POS N
55% POS N
and POS N
52% POS N
for POS N
CHOP POS N
and POS N
CHOP POS N
plus POS N
G-CSF, POS N
respectively POS N
(P POS N
=.63). POS N

The POS N
number POS N
of POS N
hospital POS N
admissions POS N
and POS N
the POS N
number POS N
of POS N
days POS N
in POS N
hospital POS N
were POS N
not POS N
different. POS N

The POS N
complete POS N
response POS N
rates POS N
were POS N
55% POS N
and POS N
52% POS N
for POS N
CHOP POS N
and POS N
CHOP POS N
plus POS N
G-CSF, POS N
respectively POS N
(P POS N
=.63). POS N

In POS N
elderly POS N
patients, POS N
G-CSF POS N
improved POS N
the POS N
RDI POS N
of POS N
CHOP, POS N

The POS N
complete POS N
response POS N
rates POS N
were POS N
55% POS N
and POS N
52% POS N
for POS N
CHOP POS N
and POS N
CHOP POS N
plus POS N
G-CSF, POS N
respectively POS N
(P POS N
=.63). POS N

but POS N
this POS N
did POS N
not POS N
lead POS N
to POS N
a POS N
higher POS N
complete POS N
response POS N
rate POS N
or POS N
better POS N
overall POS N
survival. POS N

The POS N
complete POS N
response POS N
rates POS N
were POS N
55% POS N
and POS N
52% POS N
for POS N
CHOP POS N
and POS N
CHOP POS N
plus POS N
G-CSF, POS N
respectively POS N
(P POS N
=.63). POS N

G-CSF POS N
did POS N
not POS N
prevent POS N
serious POS N
infections. POS N

The POS N
actuarial POS N
overall POS N
survival POS N
at POS N
5 POS N
years POS N
was POS N
22% POS N
with POS N
CHOP POS N
alone, POS N
compared POS N
with POS N
24% POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(P POS N
=.76), POS N
with POS N
a POS N
median POS N
follow-up POS N
of POS N
33 POS N
months. POS N

In POS N
389 POS N
eligible POS N
patients, POS N
the POS N
relative POS N
dose POS N
intensities POS N
(RDIs) POS N
of POS N
cyclophosphamide POS N
(median, POS N
96.3% POS N
v POS N
93.9%; POS N
P POS N
=.01) POS N
and POS N
doxorubicin POS N
(median, POS N
95.4% POS N
v POS N
93.3%; POS N
P POS N
=.04) POS N
were POS N
higher POS N
in POS N
patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF. POS N

The POS N
actuarial POS N
overall POS N
survival POS N
at POS N
5 POS N
years POS N
was POS N
22% POS N
with POS N
CHOP POS N
alone, POS N
compared POS N
with POS N
24% POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(P POS N
=.76), POS N
with POS N
a POS N
median POS N
follow-up POS N
of POS N
33 POS N
months. POS N

The POS N
complete POS N
response POS N
rates POS N
were POS N
55% POS N
and POS N
52% POS N
for POS N
CHOP POS N
and POS N
CHOP POS N
plus POS N
G-CSF, POS N
respectively POS N
(P POS N
=.63). POS N

The POS N
actuarial POS N
overall POS N
survival POS N
at POS N
5 POS N
years POS N
was POS N
22% POS N
with POS N
CHOP POS N
alone, POS N
compared POS N
with POS N
24% POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(P POS N
=.76), POS N
with POS N
a POS N
median POS N
follow-up POS N
of POS N
33 POS N
months. POS N

Patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
had POS N
an POS N
identical POS N
incidence POS N
of POS N
infections, POS N
with POS N
World POS N
Health POS N
Organization POS N
grade POS N
3 POS N
to POS N
4 POS N
(34 POS N
of POS N
1,191 POS N
cycles POS N
v POS N
36 POS N
of POS N
1,195 POS N
cycles). POS N

The POS N
actuarial POS N
overall POS N
survival POS N
at POS N
5 POS N
years POS N
was POS N
22% POS N
with POS N
CHOP POS N
alone, POS N
compared POS N
with POS N
24% POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(P POS N
=.76), POS N
with POS N
a POS N
median POS N
follow-up POS N
of POS N
33 POS N
months. POS N

Only POS N
the POS N
cumulative POS N
days POS N
with POS N
antibiotics POS N
were POS N
fewer POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(median, POS N
0 POS N
v POS N
6 POS N
days; POS N
P POS N
=.006) POS N
than POS N
with POS N
CHOP POS N
alone. POS N

The POS N
actuarial POS N
overall POS N
survival POS N
at POS N
5 POS N
years POS N
was POS N
22% POS N
with POS N
CHOP POS N
alone, POS N
compared POS N
with POS N
24% POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(P POS N
=.76), POS N
with POS N
a POS N
median POS N
follow-up POS N
of POS N
33 POS N
months. POS N

The POS N
number POS N
of POS N
hospital POS N
admissions POS N
and POS N
the POS N
number POS N
of POS N
days POS N
in POS N
hospital POS N
were POS N
not POS N
different. POS N

The POS N
actuarial POS N
overall POS N
survival POS N
at POS N
5 POS N
years POS N
was POS N
22% POS N
with POS N
CHOP POS N
alone, POS N
compared POS N
with POS N
24% POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(P POS N
=.76), POS N
with POS N
a POS N
median POS N
follow-up POS N
of POS N
33 POS N
months. POS N

In POS N
elderly POS N
patients, POS N
G-CSF POS N
improved POS N
the POS N
RDI POS N
of POS N
CHOP, POS N

The POS N
actuarial POS N
overall POS N
survival POS N
at POS N
5 POS N
years POS N
was POS N
22% POS N
with POS N
CHOP POS N
alone, POS N
compared POS N
with POS N
24% POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(P POS N
=.76), POS N
with POS N
a POS N
median POS N
follow-up POS N
of POS N
33 POS N
months. POS N

but POS N
this POS N
did POS N
not POS N
lead POS N
to POS N
a POS N
higher POS N
complete POS N
response POS N
rate POS N
or POS N
better POS N
overall POS N
survival. POS N

The POS N
actuarial POS N
overall POS N
survival POS N
at POS N
5 POS N
years POS N
was POS N
22% POS N
with POS N
CHOP POS N
alone, POS N
compared POS N
with POS N
24% POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(P POS N
=.76), POS N
with POS N
a POS N
median POS N
follow-up POS N
of POS N
33 POS N
months. POS N

G-CSF POS N
did POS N
not POS N
prevent POS N
serious POS N
infections. POS N

Patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
had POS N
an POS N
identical POS N
incidence POS N
of POS N
infections, POS N
with POS N
World POS N
Health POS N
Organization POS N
grade POS N
3 POS N
to POS N
4 POS N
(34 POS N
of POS N
1,191 POS N
cycles POS N
v POS N
36 POS N
of POS N
1,195 POS N
cycles). POS N

In POS N
389 POS N
eligible POS N
patients, POS N
the POS N
relative POS N
dose POS N
intensities POS N
(RDIs) POS N
of POS N
cyclophosphamide POS N
(median, POS N
96.3% POS N
v POS N
93.9%; POS N
P POS N
=.01) POS N
and POS N
doxorubicin POS N
(median, POS N
95.4% POS N
v POS N
93.3%; POS N
P POS N
=.04) POS N
were POS N
higher POS N
in POS N
patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF. POS N

Patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
had POS N
an POS N
identical POS N
incidence POS N
of POS N
infections, POS N
with POS N
World POS N
Health POS N
Organization POS N
grade POS N
3 POS N
to POS N
4 POS N
(34 POS N
of POS N
1,191 POS N
cycles POS N
v POS N
36 POS N
of POS N
1,195 POS N
cycles). POS N

The POS N
complete POS N
response POS N
rates POS N
were POS N
55% POS N
and POS N
52% POS N
for POS N
CHOP POS N
and POS N
CHOP POS N
plus POS N
G-CSF, POS N
respectively POS N
(P POS N
=.63). POS N

Patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
had POS N
an POS N
identical POS N
incidence POS N
of POS N
infections, POS N
with POS N
World POS N
Health POS N
Organization POS N
grade POS N
3 POS N
to POS N
4 POS N
(34 POS N
of POS N
1,191 POS N
cycles POS N
v POS N
36 POS N
of POS N
1,195 POS N
cycles). POS N

The POS N
actuarial POS N
overall POS N
survival POS N
at POS N
5 POS N
years POS N
was POS N
22% POS N
with POS N
CHOP POS N
alone, POS N
compared POS N
with POS N
24% POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(P POS N
=.76), POS N
with POS N
a POS N
median POS N
follow-up POS N
of POS N
33 POS N
months. POS N

Patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
had POS N
an POS N
identical POS N
incidence POS N
of POS N
infections, POS N
with POS N
World POS N
Health POS N
Organization POS N
grade POS N
3 POS N
to POS N
4 POS N
(34 POS N
of POS N
1,191 POS N
cycles POS N
v POS N
36 POS N
of POS N
1,195 POS N
cycles). POS N

Only POS N
the POS N
cumulative POS N
days POS N
with POS N
antibiotics POS N
were POS N
fewer POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(median, POS N
0 POS N
v POS N
6 POS N
days; POS N
P POS N
=.006) POS N
than POS N
with POS N
CHOP POS N
alone. POS N

Patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
had POS N
an POS N
identical POS N
incidence POS N
of POS N
infections, POS N
with POS N
World POS N
Health POS N
Organization POS N
grade POS N
3 POS N
to POS N
4 POS N
(34 POS N
of POS N
1,191 POS N
cycles POS N
v POS N
36 POS N
of POS N
1,195 POS N
cycles). POS N

The POS N
number POS N
of POS N
hospital POS N
admissions POS N
and POS N
the POS N
number POS N
of POS N
days POS N
in POS N
hospital POS N
were POS N
not POS N
different. POS N

Patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
had POS N
an POS N
identical POS N
incidence POS N
of POS N
infections, POS N
with POS N
World POS N
Health POS N
Organization POS N
grade POS N
3 POS N
to POS N
4 POS N
(34 POS N
of POS N
1,191 POS N
cycles POS N
v POS N
36 POS N
of POS N
1,195 POS N
cycles). POS N

In POS N
elderly POS N
patients, POS N
G-CSF POS N
improved POS N
the POS N
RDI POS N
of POS N
CHOP, POS N

Patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
had POS N
an POS N
identical POS N
incidence POS N
of POS N
infections, POS N
with POS N
World POS N
Health POS N
Organization POS N
grade POS N
3 POS N
to POS N
4 POS N
(34 POS N
of POS N
1,191 POS N
cycles POS N
v POS N
36 POS N
of POS N
1,195 POS N
cycles). POS N

but POS N
this POS N
did POS N
not POS N
lead POS N
to POS N
a POS N
higher POS N
complete POS N
response POS N
rate POS N
or POS N
better POS N
overall POS N
survival. POS N

Patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
had POS N
an POS N
identical POS N
incidence POS N
of POS N
infections, POS N
with POS N
World POS N
Health POS N
Organization POS N
grade POS N
3 POS N
to POS N
4 POS N
(34 POS N
of POS N
1,191 POS N
cycles POS N
v POS N
36 POS N
of POS N
1,195 POS N
cycles). POS N

G-CSF POS N
did POS N
not POS N
prevent POS N
serious POS N
infections. POS N

Only POS N
the POS N
cumulative POS N
days POS N
with POS N
antibiotics POS N
were POS N
fewer POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(median, POS N
0 POS N
v POS N
6 POS N
days; POS N
P POS N
=.006) POS N
than POS N
with POS N
CHOP POS N
alone. POS N

In POS N
389 POS N
eligible POS N
patients, POS N
the POS N
relative POS N
dose POS N
intensities POS N
(RDIs) POS N
of POS N
cyclophosphamide POS N
(median, POS N
96.3% POS N
v POS N
93.9%; POS N
P POS N
=.01) POS N
and POS N
doxorubicin POS N
(median, POS N
95.4% POS N
v POS N
93.3%; POS N
P POS N
=.04) POS N
were POS N
higher POS N
in POS N
patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF. POS N

Only POS N
the POS N
cumulative POS N
days POS N
with POS N
antibiotics POS N
were POS N
fewer POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(median, POS N
0 POS N
v POS N
6 POS N
days; POS N
P POS N
=.006) POS N
than POS N
with POS N
CHOP POS N
alone. POS N

The POS N
complete POS N
response POS N
rates POS N
were POS N
55% POS N
and POS N
52% POS N
for POS N
CHOP POS N
and POS N
CHOP POS N
plus POS N
G-CSF, POS N
respectively POS N
(P POS N
=.63). POS N

Only POS N
the POS N
cumulative POS N
days POS N
with POS N
antibiotics POS N
were POS N
fewer POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(median, POS N
0 POS N
v POS N
6 POS N
days; POS N
P POS N
=.006) POS N
than POS N
with POS N
CHOP POS N
alone. POS N

The POS N
actuarial POS N
overall POS N
survival POS N
at POS N
5 POS N
years POS N
was POS N
22% POS N
with POS N
CHOP POS N
alone, POS N
compared POS N
with POS N
24% POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(P POS N
=.76), POS N
with POS N
a POS N
median POS N
follow-up POS N
of POS N
33 POS N
months. POS N

Only POS N
the POS N
cumulative POS N
days POS N
with POS N
antibiotics POS N
were POS N
fewer POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(median, POS N
0 POS N
v POS N
6 POS N
days; POS N
P POS N
=.006) POS N
than POS N
with POS N
CHOP POS N
alone. POS N

Patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
had POS N
an POS N
identical POS N
incidence POS N
of POS N
infections, POS N
with POS N
World POS N
Health POS N
Organization POS N
grade POS N
3 POS N
to POS N
4 POS N
(34 POS N
of POS N
1,191 POS N
cycles POS N
v POS N
36 POS N
of POS N
1,195 POS N
cycles). POS N

Only POS N
the POS N
cumulative POS N
days POS N
with POS N
antibiotics POS N
were POS N
fewer POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(median, POS N
0 POS N
v POS N
6 POS N
days; POS N
P POS N
=.006) POS N
than POS N
with POS N
CHOP POS N
alone. POS N

The POS N
number POS N
of POS N
hospital POS N
admissions POS N
and POS N
the POS N
number POS N
of POS N
days POS N
in POS N
hospital POS N
were POS N
not POS N
different. POS N

Only POS N
the POS N
cumulative POS N
days POS N
with POS N
antibiotics POS N
were POS N
fewer POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(median, POS N
0 POS N
v POS N
6 POS N
days; POS N
P POS N
=.006) POS N
than POS N
with POS N
CHOP POS N
alone. POS N

In POS N
elderly POS N
patients, POS N
G-CSF POS N
improved POS N
the POS N
RDI POS N
of POS N
CHOP, POS N

Only POS N
the POS N
cumulative POS N
days POS N
with POS N
antibiotics POS N
were POS N
fewer POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(median, POS N
0 POS N
v POS N
6 POS N
days; POS N
P POS N
=.006) POS N
than POS N
with POS N
CHOP POS N
alone. POS N

but POS N
this POS N
did POS N
not POS N
lead POS N
to POS N
a POS N
higher POS N
complete POS N
response POS N
rate POS N
or POS N
better POS N
overall POS N
survival. POS N

Only POS N
the POS N
cumulative POS N
days POS N
with POS N
antibiotics POS N
were POS N
fewer POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(median, POS N
0 POS N
v POS N
6 POS N
days; POS N
P POS N
=.006) POS N
than POS N
with POS N
CHOP POS N
alone. POS N

G-CSF POS N
did POS N
not POS N
prevent POS N
serious POS N
infections. POS N

The POS N
number POS N
of POS N
hospital POS N
admissions POS N
and POS N
the POS N
number POS N
of POS N
days POS N
in POS N
hospital POS N
were POS N
not POS N
different. POS N

In POS N
389 POS N
eligible POS N
patients, POS N
the POS N
relative POS N
dose POS N
intensities POS N
(RDIs) POS N
of POS N
cyclophosphamide POS N
(median, POS N
96.3% POS N
v POS N
93.9%; POS N
P POS N
=.01) POS N
and POS N
doxorubicin POS N
(median, POS N
95.4% POS N
v POS N
93.3%; POS N
P POS N
=.04) POS N
were POS N
higher POS N
in POS N
patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF. POS N

The POS N
number POS N
of POS N
hospital POS N
admissions POS N
and POS N
the POS N
number POS N
of POS N
days POS N
in POS N
hospital POS N
were POS N
not POS N
different. POS N

The POS N
complete POS N
response POS N
rates POS N
were POS N
55% POS N
and POS N
52% POS N
for POS N
CHOP POS N
and POS N
CHOP POS N
plus POS N
G-CSF, POS N
respectively POS N
(P POS N
=.63). POS N

The POS N
number POS N
of POS N
hospital POS N
admissions POS N
and POS N
the POS N
number POS N
of POS N
days POS N
in POS N
hospital POS N
were POS N
not POS N
different. POS N

The POS N
actuarial POS N
overall POS N
survival POS N
at POS N
5 POS N
years POS N
was POS N
22% POS N
with POS N
CHOP POS N
alone, POS N
compared POS N
with POS N
24% POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(P POS N
=.76), POS N
with POS N
a POS N
median POS N
follow-up POS N
of POS N
33 POS N
months. POS N

The POS N
number POS N
of POS N
hospital POS N
admissions POS N
and POS N
the POS N
number POS N
of POS N
days POS N
in POS N
hospital POS N
were POS N
not POS N
different. POS N

Patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
had POS N
an POS N
identical POS N
incidence POS N
of POS N
infections, POS N
with POS N
World POS N
Health POS N
Organization POS N
grade POS N
3 POS N
to POS N
4 POS N
(34 POS N
of POS N
1,191 POS N
cycles POS N
v POS N
36 POS N
of POS N
1,195 POS N
cycles). POS N

The POS N
number POS N
of POS N
hospital POS N
admissions POS N
and POS N
the POS N
number POS N
of POS N
days POS N
in POS N
hospital POS N
were POS N
not POS N
different. POS N

Only POS N
the POS N
cumulative POS N
days POS N
with POS N
antibiotics POS N
were POS N
fewer POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(median, POS N
0 POS N
v POS N
6 POS N
days; POS N
P POS N
=.006) POS N
than POS N
with POS N
CHOP POS N
alone. POS N

The POS N
number POS N
of POS N
hospital POS N
admissions POS N
and POS N
the POS N
number POS N
of POS N
days POS N
in POS N
hospital POS N
were POS N
not POS N
different. POS N

In POS N
elderly POS N
patients, POS N
G-CSF POS N
improved POS N
the POS N
RDI POS N
of POS N
CHOP, POS N

The POS N
number POS N
of POS N
hospital POS N
admissions POS N
and POS N
the POS N
number POS N
of POS N
days POS N
in POS N
hospital POS N
were POS N
not POS N
different. POS N

but POS N
this POS N
did POS N
not POS N
lead POS N
to POS N
a POS N
higher POS N
complete POS N
response POS N
rate POS N
or POS N
better POS N
overall POS N
survival. POS N

The POS N
number POS N
of POS N
hospital POS N
admissions POS N
and POS N
the POS N
number POS N
of POS N
days POS N
in POS N
hospital POS N
were POS N
not POS N
different. POS N

G-CSF POS N
did POS N
not POS N
prevent POS N
serious POS N
infections. POS N

In POS N
elderly POS N
patients, POS N
G-CSF POS N
improved POS N
the POS N
RDI POS N
of POS N
CHOP, POS N

In POS N
389 POS N
eligible POS N
patients, POS N
the POS N
relative POS N
dose POS N
intensities POS N
(RDIs) POS N
of POS N
cyclophosphamide POS N
(median, POS N
96.3% POS N
v POS N
93.9%; POS N
P POS N
=.01) POS N
and POS N
doxorubicin POS N
(median, POS N
95.4% POS N
v POS N
93.3%; POS N
P POS N
=.04) POS N
were POS N
higher POS N
in POS N
patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF. POS N

In POS N
elderly POS N
patients, POS N
G-CSF POS N
improved POS N
the POS N
RDI POS N
of POS N
CHOP, POS N

The POS N
complete POS N
response POS N
rates POS N
were POS N
55% POS N
and POS N
52% POS N
for POS N
CHOP POS N
and POS N
CHOP POS N
plus POS N
G-CSF, POS N
respectively POS N
(P POS N
=.63). POS N

In POS N
elderly POS N
patients, POS N
G-CSF POS N
improved POS N
the POS N
RDI POS N
of POS N
CHOP, POS N

The POS N
actuarial POS N
overall POS N
survival POS N
at POS N
5 POS N
years POS N
was POS N
22% POS N
with POS N
CHOP POS N
alone, POS N
compared POS N
with POS N
24% POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(P POS N
=.76), POS N
with POS N
a POS N
median POS N
follow-up POS N
of POS N
33 POS N
months. POS N

In POS N
elderly POS N
patients, POS N
G-CSF POS N
improved POS N
the POS N
RDI POS N
of POS N
CHOP, POS N

Patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
had POS N
an POS N
identical POS N
incidence POS N
of POS N
infections, POS N
with POS N
World POS N
Health POS N
Organization POS N
grade POS N
3 POS N
to POS N
4 POS N
(34 POS N
of POS N
1,191 POS N
cycles POS N
v POS N
36 POS N
of POS N
1,195 POS N
cycles). POS N

In POS N
elderly POS N
patients, POS N
G-CSF POS N
improved POS N
the POS N
RDI POS N
of POS N
CHOP, POS N

Only POS N
the POS N
cumulative POS N
days POS N
with POS N
antibiotics POS N
were POS N
fewer POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(median, POS N
0 POS N
v POS N
6 POS N
days; POS N
P POS N
=.006) POS N
than POS N
with POS N
CHOP POS N
alone. POS N

In POS N
elderly POS N
patients, POS N
G-CSF POS N
improved POS N
the POS N
RDI POS N
of POS N
CHOP, POS N

The POS N
number POS N
of POS N
hospital POS N
admissions POS N
and POS N
the POS N
number POS N
of POS N
days POS N
in POS N
hospital POS N
were POS N
not POS N
different. POS N

In POS N
elderly POS N
patients, POS N
G-CSF POS N
improved POS N
the POS N
RDI POS N
of POS N
CHOP, POS N

but POS N
this POS N
did POS N
not POS N
lead POS N
to POS N
a POS N
higher POS N
complete POS N
response POS N
rate POS N
or POS N
better POS N
overall POS N
survival. POS N

In POS N
elderly POS N
patients, POS N
G-CSF POS N
improved POS N
the POS N
RDI POS N
of POS N
CHOP, POS N

G-CSF POS N
did POS N
not POS N
prevent POS N
serious POS N
infections. POS N

but POS N
this POS N
did POS N
not POS N
lead POS N
to POS N
a POS N
higher POS N
complete POS N
response POS N
rate POS N
or POS N
better POS N
overall POS N
survival. POS N

In POS N
389 POS N
eligible POS N
patients, POS N
the POS N
relative POS N
dose POS N
intensities POS N
(RDIs) POS N
of POS N
cyclophosphamide POS N
(median, POS N
96.3% POS N
v POS N
93.9%; POS N
P POS N
=.01) POS N
and POS N
doxorubicin POS N
(median, POS N
95.4% POS N
v POS N
93.3%; POS N
P POS N
=.04) POS N
were POS N
higher POS N
in POS N
patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF. POS N

but POS N
this POS N
did POS N
not POS N
lead POS N
to POS N
a POS N
higher POS N
complete POS N
response POS N
rate POS N
or POS N
better POS N
overall POS N
survival. POS N

The POS N
complete POS N
response POS N
rates POS N
were POS N
55% POS N
and POS N
52% POS N
for POS N
CHOP POS N
and POS N
CHOP POS N
plus POS N
G-CSF, POS N
respectively POS N
(P POS N
=.63). POS N

but POS N
this POS N
did POS N
not POS N
lead POS N
to POS N
a POS N
higher POS N
complete POS N
response POS N
rate POS N
or POS N
better POS N
overall POS N
survival. POS N

The POS N
actuarial POS N
overall POS N
survival POS N
at POS N
5 POS N
years POS N
was POS N
22% POS N
with POS N
CHOP POS N
alone, POS N
compared POS N
with POS N
24% POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(P POS N
=.76), POS N
with POS N
a POS N
median POS N
follow-up POS N
of POS N
33 POS N
months. POS N

but POS N
this POS N
did POS N
not POS N
lead POS N
to POS N
a POS N
higher POS N
complete POS N
response POS N
rate POS N
or POS N
better POS N
overall POS N
survival. POS N

Patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
had POS N
an POS N
identical POS N
incidence POS N
of POS N
infections, POS N
with POS N
World POS N
Health POS N
Organization POS N
grade POS N
3 POS N
to POS N
4 POS N
(34 POS N
of POS N
1,191 POS N
cycles POS N
v POS N
36 POS N
of POS N
1,195 POS N
cycles). POS N

but POS N
this POS N
did POS N
not POS N
lead POS N
to POS N
a POS N
higher POS N
complete POS N
response POS N
rate POS N
or POS N
better POS N
overall POS N
survival. POS N

Only POS N
the POS N
cumulative POS N
days POS N
with POS N
antibiotics POS N
were POS N
fewer POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(median, POS N
0 POS N
v POS N
6 POS N
days; POS N
P POS N
=.006) POS N
than POS N
with POS N
CHOP POS N
alone. POS N

but POS N
this POS N
did POS N
not POS N
lead POS N
to POS N
a POS N
higher POS N
complete POS N
response POS N
rate POS N
or POS N
better POS N
overall POS N
survival. POS N

The POS N
number POS N
of POS N
hospital POS N
admissions POS N
and POS N
the POS N
number POS N
of POS N
days POS N
in POS N
hospital POS N
were POS N
not POS N
different. POS N

but POS N
this POS N
did POS N
not POS N
lead POS N
to POS N
a POS N
higher POS N
complete POS N
response POS N
rate POS N
or POS N
better POS N
overall POS N
survival. POS N

In POS N
elderly POS N
patients, POS N
G-CSF POS N
improved POS N
the POS N
RDI POS N
of POS N
CHOP, POS N

but POS N
this POS N
did POS N
not POS N
lead POS N
to POS N
a POS N
higher POS N
complete POS N
response POS N
rate POS N
or POS N
better POS N
overall POS N
survival. POS N

G-CSF POS N
did POS N
not POS N
prevent POS N
serious POS N
infections. POS N

G-CSF POS N
did POS N
not POS N
prevent POS N
serious POS N
infections. POS N

In POS N
389 POS N
eligible POS N
patients, POS N
the POS N
relative POS N
dose POS N
intensities POS N
(RDIs) POS N
of POS N
cyclophosphamide POS N
(median, POS N
96.3% POS N
v POS N
93.9%; POS N
P POS N
=.01) POS N
and POS N
doxorubicin POS N
(median, POS N
95.4% POS N
v POS N
93.3%; POS N
P POS N
=.04) POS N
were POS N
higher POS N
in POS N
patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF. POS N

G-CSF POS N
did POS N
not POS N
prevent POS N
serious POS N
infections. POS N

The POS N
complete POS N
response POS N
rates POS N
were POS N
55% POS N
and POS N
52% POS N
for POS N
CHOP POS N
and POS N
CHOP POS N
plus POS N
G-CSF, POS N
respectively POS N
(P POS N
=.63). POS N

G-CSF POS N
did POS N
not POS N
prevent POS N
serious POS N
infections. POS N

The POS N
actuarial POS N
overall POS N
survival POS N
at POS N
5 POS N
years POS N
was POS N
22% POS N
with POS N
CHOP POS N
alone, POS N
compared POS N
with POS N
24% POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(P POS N
=.76), POS N
with POS N
a POS N
median POS N
follow-up POS N
of POS N
33 POS N
months. POS N

G-CSF POS N
did POS N
not POS N
prevent POS N
serious POS N
infections. POS N

Patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
had POS N
an POS N
identical POS N
incidence POS N
of POS N
infections, POS N
with POS N
World POS N
Health POS N
Organization POS N
grade POS N
3 POS N
to POS N
4 POS N
(34 POS N
of POS N
1,191 POS N
cycles POS N
v POS N
36 POS N
of POS N
1,195 POS N
cycles). POS N

G-CSF POS N
did POS N
not POS N
prevent POS N
serious POS N
infections. POS N

Only POS N
the POS N
cumulative POS N
days POS N
with POS N
antibiotics POS N
were POS N
fewer POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(median, POS N
0 POS N
v POS N
6 POS N
days; POS N
P POS N
=.006) POS N
than POS N
with POS N
CHOP POS N
alone. POS N

G-CSF POS N
did POS N
not POS N
prevent POS N
serious POS N
infections. POS N

The POS N
number POS N
of POS N
hospital POS N
admissions POS N
and POS N
the POS N
number POS N
of POS N
days POS N
in POS N
hospital POS N
were POS N
not POS N
different. POS N

G-CSF POS N
did POS N
not POS N
prevent POS N
serious POS N
infections. POS N

In POS N
elderly POS N
patients, POS N
G-CSF POS N
improved POS N
the POS N
RDI POS N
of POS N
CHOP, POS N

G-CSF POS N
did POS N
not POS N
prevent POS N
serious POS N
infections. POS N

but POS N
this POS N
did POS N
not POS N
lead POS N
to POS N
a POS N
higher POS N
complete POS N
response POS N
rate POS N
or POS N
better POS N
overall POS N
survival. POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

Methionine POS N
aminopeptidase POS N
2 POS N
(MetAP2) POS N
inhibition POS N
has POS N
been POS N
shown POS N
to POS N
result POS N
in POS N
significant POS N
weight POS N
loss POS N
and POS N
improved POS N
glucose POS N
control. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
across POS N
all POS N
doses POS N
with POS N
most POS N
frequent POS N
adverse POS N
events POS N
of POS N
mild POS N
headache POS N
and POS N
procedural-related POS N
irritation. POS N

Methionine POS N
aminopeptidase POS N
2 POS N
(MetAP2) POS N
inhibition POS N
has POS N
been POS N
shown POS N
to POS N
result POS N
in POS N
significant POS N
weight POS N
loss POS N
and POS N
improved POS N
glucose POS N
control. POS N

All POS N
doses POS N
of POS N
ZGN-1061 POS N
were POS N
rapidly POS N
absorbed POS N
and POS N
cleared, POS N
resulting POS N
in POS N
short POS N
duration POS N
of POS N
exposure POS N
that POS N
is POS N
anticipated POS N
to POS N
minimize POS N
potential POS N
off-drug POS N
target POS N
risks. POS N

Methionine POS N
aminopeptidase POS N
2 POS N
(MetAP2) POS N
inhibition POS N
has POS N
been POS N
shown POS N
to POS N
result POS N
in POS N
significant POS N
weight POS N
loss POS N
and POS N
improved POS N
glucose POS N
control. POS N

Safety POS N
observations POS N
were POS N
consistent POS N
with POS N
SAD POS N
findings. POS N

Methionine POS N
aminopeptidase POS N
2 POS N
(MetAP2) POS N
inhibition POS N
has POS N
been POS N
shown POS N
to POS N
result POS N
in POS N
significant POS N
weight POS N
loss POS N
and POS N
improved POS N
glucose POS N
control. POS N

Efficacy POS N
measures POS N
in POS N
the POS N
MAD POS N
phase POS N
indicated POS N
trends POS N
for POS N
weight POS N
change POS N
(-1.5 POS N
kg POS N
total POS N
ZGN-1061 POS N
vs POS N
-0.2 POS N
kg POS N
placebo) POS N
and POS N
other POS N
biomarker POS N
changes. POS N

Methionine POS N
aminopeptidase POS N
2 POS N
(MetAP2) POS N
inhibition POS N
has POS N
been POS N
shown POS N
to POS N
result POS N
in POS N
significant POS N
weight POS N
loss POS N
and POS N
improved POS N
glucose POS N
control. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
with POS N
no POS N
safety POS N
signals POS N
in POS N
all POS N
doses POS N
tested. POS N

Methionine POS N
aminopeptidase POS N
2 POS N
(MetAP2) POS N
inhibition POS N
has POS N
been POS N
shown POS N
to POS N
result POS N
in POS N
significant POS N
weight POS N
loss POS N
and POS N
improved POS N
glucose POS N
control. POS N

the POS N
desired POS N
pharmacokinetic POS N
profile POS N
and POS N
preliminary POS N
efficacy POS N
observations POS N
with POS N
ZGN-1061 POS N
support POS N
evaluation POS N
in POS N
larger POS N
and POS N
longer POS N
clinical POS N
trials. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
across POS N
all POS N
doses POS N
with POS N
most POS N
frequent POS N
adverse POS N
events POS N
of POS N
mild POS N
headache POS N
and POS N
procedural-related POS N
irritation. POS N

Methionine POS N
aminopeptidase POS N
2 POS N
(MetAP2) POS N
inhibition POS N
has POS N
been POS N
shown POS N
to POS N
result POS N
in POS N
significant POS N
weight POS N
loss POS N
and POS N
improved POS N
glucose POS N
control. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
across POS N
all POS N
doses POS N
with POS N
most POS N
frequent POS N
adverse POS N
events POS N
of POS N
mild POS N
headache POS N
and POS N
procedural-related POS N
irritation. POS N

All POS N
doses POS N
of POS N
ZGN-1061 POS N
were POS N
rapidly POS N
absorbed POS N
and POS N
cleared, POS N
resulting POS N
in POS N
short POS N
duration POS N
of POS N
exposure POS N
that POS N
is POS N
anticipated POS N
to POS N
minimize POS N
potential POS N
off-drug POS N
target POS N
risks. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
across POS N
all POS N
doses POS N
with POS N
most POS N
frequent POS N
adverse POS N
events POS N
of POS N
mild POS N
headache POS N
and POS N
procedural-related POS N
irritation. POS N

Safety POS N
observations POS N
were POS N
consistent POS N
with POS N
SAD POS N
findings. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
across POS N
all POS N
doses POS N
with POS N
most POS N
frequent POS N
adverse POS N
events POS N
of POS N
mild POS N
headache POS N
and POS N
procedural-related POS N
irritation. POS N

Efficacy POS N
measures POS N
in POS N
the POS N
MAD POS N
phase POS N
indicated POS N
trends POS N
for POS N
weight POS N
change POS N
(-1.5 POS N
kg POS N
total POS N
ZGN-1061 POS N
vs POS N
-0.2 POS N
kg POS N
placebo) POS N
and POS N
other POS N
biomarker POS N
changes. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
across POS N
all POS N
doses POS N
with POS N
most POS N
frequent POS N
adverse POS N
events POS N
of POS N
mild POS N
headache POS N
and POS N
procedural-related POS N
irritation. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
with POS N
no POS N
safety POS N
signals POS N
in POS N
all POS N
doses POS N
tested. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
across POS N
all POS N
doses POS N
with POS N
most POS N
frequent POS N
adverse POS N
events POS N
of POS N
mild POS N
headache POS N
and POS N
procedural-related POS N
irritation. POS N

the POS N
desired POS N
pharmacokinetic POS N
profile POS N
and POS N
preliminary POS N
efficacy POS N
observations POS N
with POS N
ZGN-1061 POS N
support POS N
evaluation POS N
in POS N
larger POS N
and POS N
longer POS N
clinical POS N
trials. POS N

All POS N
doses POS N
of POS N
ZGN-1061 POS N
were POS N
rapidly POS N
absorbed POS N
and POS N
cleared, POS N
resulting POS N
in POS N
short POS N
duration POS N
of POS N
exposure POS N
that POS N
is POS N
anticipated POS N
to POS N
minimize POS N
potential POS N
off-drug POS N
target POS N
risks. POS N

Methionine POS N
aminopeptidase POS N
2 POS N
(MetAP2) POS N
inhibition POS N
has POS N
been POS N
shown POS N
to POS N
result POS N
in POS N
significant POS N
weight POS N
loss POS N
and POS N
improved POS N
glucose POS N
control. POS N

All POS N
doses POS N
of POS N
ZGN-1061 POS N
were POS N
rapidly POS N
absorbed POS N
and POS N
cleared, POS N
resulting POS N
in POS N
short POS N
duration POS N
of POS N
exposure POS N
that POS N
is POS N
anticipated POS N
to POS N
minimize POS N
potential POS N
off-drug POS N
target POS N
risks. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
across POS N
all POS N
doses POS N
with POS N
most POS N
frequent POS N
adverse POS N
events POS N
of POS N
mild POS N
headache POS N
and POS N
procedural-related POS N
irritation. POS N

All POS N
doses POS N
of POS N
ZGN-1061 POS N
were POS N
rapidly POS N
absorbed POS N
and POS N
cleared, POS N
resulting POS N
in POS N
short POS N
duration POS N
of POS N
exposure POS N
that POS N
is POS N
anticipated POS N
to POS N
minimize POS N
potential POS N
off-drug POS N
target POS N
risks. POS N

Safety POS N
observations POS N
were POS N
consistent POS N
with POS N
SAD POS N
findings. POS N

All POS N
doses POS N
of POS N
ZGN-1061 POS N
were POS N
rapidly POS N
absorbed POS N
and POS N
cleared, POS N
resulting POS N
in POS N
short POS N
duration POS N
of POS N
exposure POS N
that POS N
is POS N
anticipated POS N
to POS N
minimize POS N
potential POS N
off-drug POS N
target POS N
risks. POS N

Efficacy POS N
measures POS N
in POS N
the POS N
MAD POS N
phase POS N
indicated POS N
trends POS N
for POS N
weight POS N
change POS N
(-1.5 POS N
kg POS N
total POS N
ZGN-1061 POS N
vs POS N
-0.2 POS N
kg POS N
placebo) POS N
and POS N
other POS N
biomarker POS N
changes. POS N

All POS N
doses POS N
of POS N
ZGN-1061 POS N
were POS N
rapidly POS N
absorbed POS N
and POS N
cleared, POS N
resulting POS N
in POS N
short POS N
duration POS N
of POS N
exposure POS N
that POS N
is POS N
anticipated POS N
to POS N
minimize POS N
potential POS N
off-drug POS N
target POS N
risks. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
with POS N
no POS N
safety POS N
signals POS N
in POS N
all POS N
doses POS N
tested. POS N

All POS N
doses POS N
of POS N
ZGN-1061 POS N
were POS N
rapidly POS N
absorbed POS N
and POS N
cleared, POS N
resulting POS N
in POS N
short POS N
duration POS N
of POS N
exposure POS N
that POS N
is POS N
anticipated POS N
to POS N
minimize POS N
potential POS N
off-drug POS N
target POS N
risks. POS N

the POS N
desired POS N
pharmacokinetic POS N
profile POS N
and POS N
preliminary POS N
efficacy POS N
observations POS N
with POS N
ZGN-1061 POS N
support POS N
evaluation POS N
in POS N
larger POS N
and POS N
longer POS N
clinical POS N
trials. POS N

Safety POS N
observations POS N
were POS N
consistent POS N
with POS N
SAD POS N
findings. POS N

Methionine POS N
aminopeptidase POS N
2 POS N
(MetAP2) POS N
inhibition POS N
has POS N
been POS N
shown POS N
to POS N
result POS N
in POS N
significant POS N
weight POS N
loss POS N
and POS N
improved POS N
glucose POS N
control. POS N

Safety POS N
observations POS N
were POS N
consistent POS N
with POS N
SAD POS N
findings. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
across POS N
all POS N
doses POS N
with POS N
most POS N
frequent POS N
adverse POS N
events POS N
of POS N
mild POS N
headache POS N
and POS N
procedural-related POS N
irritation. POS N

Safety POS N
observations POS N
were POS N
consistent POS N
with POS N
SAD POS N
findings. POS N

All POS N
doses POS N
of POS N
ZGN-1061 POS N
were POS N
rapidly POS N
absorbed POS N
and POS N
cleared, POS N
resulting POS N
in POS N
short POS N
duration POS N
of POS N
exposure POS N
that POS N
is POS N
anticipated POS N
to POS N
minimize POS N
potential POS N
off-drug POS N
target POS N
risks. POS N

Safety POS N
observations POS N
were POS N
consistent POS N
with POS N
SAD POS N
findings. POS N

Efficacy POS N
measures POS N
in POS N
the POS N
MAD POS N
phase POS N
indicated POS N
trends POS N
for POS N
weight POS N
change POS N
(-1.5 POS N
kg POS N
total POS N
ZGN-1061 POS N
vs POS N
-0.2 POS N
kg POS N
placebo) POS N
and POS N
other POS N
biomarker POS N
changes. POS N

Safety POS N
observations POS N
were POS N
consistent POS N
with POS N
SAD POS N
findings. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
with POS N
no POS N
safety POS N
signals POS N
in POS N
all POS N
doses POS N
tested. POS N

Safety POS N
observations POS N
were POS N
consistent POS N
with POS N
SAD POS N
findings. POS N

the POS N
desired POS N
pharmacokinetic POS N
profile POS N
and POS N
preliminary POS N
efficacy POS N
observations POS N
with POS N
ZGN-1061 POS N
support POS N
evaluation POS N
in POS N
larger POS N
and POS N
longer POS N
clinical POS N
trials. POS N

Efficacy POS N
measures POS N
in POS N
the POS N
MAD POS N
phase POS N
indicated POS N
trends POS N
for POS N
weight POS N
change POS N
(-1.5 POS N
kg POS N
total POS N
ZGN-1061 POS N
vs POS N
-0.2 POS N
kg POS N
placebo) POS N
and POS N
other POS N
biomarker POS N
changes. POS N

Methionine POS N
aminopeptidase POS N
2 POS N
(MetAP2) POS N
inhibition POS N
has POS N
been POS N
shown POS N
to POS N
result POS N
in POS N
significant POS N
weight POS N
loss POS N
and POS N
improved POS N
glucose POS N
control. POS N

Efficacy POS N
measures POS N
in POS N
the POS N
MAD POS N
phase POS N
indicated POS N
trends POS N
for POS N
weight POS N
change POS N
(-1.5 POS N
kg POS N
total POS N
ZGN-1061 POS N
vs POS N
-0.2 POS N
kg POS N
placebo) POS N
and POS N
other POS N
biomarker POS N
changes. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
across POS N
all POS N
doses POS N
with POS N
most POS N
frequent POS N
adverse POS N
events POS N
of POS N
mild POS N
headache POS N
and POS N
procedural-related POS N
irritation. POS N

Efficacy POS N
measures POS N
in POS N
the POS N
MAD POS N
phase POS N
indicated POS N
trends POS N
for POS N
weight POS N
change POS N
(-1.5 POS N
kg POS N
total POS N
ZGN-1061 POS N
vs POS N
-0.2 POS N
kg POS N
placebo) POS N
and POS N
other POS N
biomarker POS N
changes. POS N

All POS N
doses POS N
of POS N
ZGN-1061 POS N
were POS N
rapidly POS N
absorbed POS N
and POS N
cleared, POS N
resulting POS N
in POS N
short POS N
duration POS N
of POS N
exposure POS N
that POS N
is POS N
anticipated POS N
to POS N
minimize POS N
potential POS N
off-drug POS N
target POS N
risks. POS N

Efficacy POS N
measures POS N
in POS N
the POS N
MAD POS N
phase POS N
indicated POS N
trends POS N
for POS N
weight POS N
change POS N
(-1.5 POS N
kg POS N
total POS N
ZGN-1061 POS N
vs POS N
-0.2 POS N
kg POS N
placebo) POS N
and POS N
other POS N
biomarker POS N
changes. POS N

Safety POS N
observations POS N
were POS N
consistent POS N
with POS N
SAD POS N
findings. POS N

Efficacy POS N
measures POS N
in POS N
the POS N
MAD POS N
phase POS N
indicated POS N
trends POS N
for POS N
weight POS N
change POS N
(-1.5 POS N
kg POS N
total POS N
ZGN-1061 POS N
vs POS N
-0.2 POS N
kg POS N
placebo) POS N
and POS N
other POS N
biomarker POS N
changes. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
with POS N
no POS N
safety POS N
signals POS N
in POS N
all POS N
doses POS N
tested. POS N

Efficacy POS N
measures POS N
in POS N
the POS N
MAD POS N
phase POS N
indicated POS N
trends POS N
for POS N
weight POS N
change POS N
(-1.5 POS N
kg POS N
total POS N
ZGN-1061 POS N
vs POS N
-0.2 POS N
kg POS N
placebo) POS N
and POS N
other POS N
biomarker POS N
changes. POS N

the POS N
desired POS N
pharmacokinetic POS N
profile POS N
and POS N
preliminary POS N
efficacy POS N
observations POS N
with POS N
ZGN-1061 POS N
support POS N
evaluation POS N
in POS N
larger POS N
and POS N
longer POS N
clinical POS N
trials. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
with POS N
no POS N
safety POS N
signals POS N
in POS N
all POS N
doses POS N
tested. POS N

Methionine POS N
aminopeptidase POS N
2 POS N
(MetAP2) POS N
inhibition POS N
has POS N
been POS N
shown POS N
to POS N
result POS N
in POS N
significant POS N
weight POS N
loss POS N
and POS N
improved POS N
glucose POS N
control. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
with POS N
no POS N
safety POS N
signals POS N
in POS N
all POS N
doses POS N
tested. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
across POS N
all POS N
doses POS N
with POS N
most POS N
frequent POS N
adverse POS N
events POS N
of POS N
mild POS N
headache POS N
and POS N
procedural-related POS N
irritation. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
with POS N
no POS N
safety POS N
signals POS N
in POS N
all POS N
doses POS N
tested. POS N

All POS N
doses POS N
of POS N
ZGN-1061 POS N
were POS N
rapidly POS N
absorbed POS N
and POS N
cleared, POS N
resulting POS N
in POS N
short POS N
duration POS N
of POS N
exposure POS N
that POS N
is POS N
anticipated POS N
to POS N
minimize POS N
potential POS N
off-drug POS N
target POS N
risks. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
with POS N
no POS N
safety POS N
signals POS N
in POS N
all POS N
doses POS N
tested. POS N

Safety POS N
observations POS N
were POS N
consistent POS N
with POS N
SAD POS N
findings. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
with POS N
no POS N
safety POS N
signals POS N
in POS N
all POS N
doses POS N
tested. POS N

Efficacy POS N
measures POS N
in POS N
the POS N
MAD POS N
phase POS N
indicated POS N
trends POS N
for POS N
weight POS N
change POS N
(-1.5 POS N
kg POS N
total POS N
ZGN-1061 POS N
vs POS N
-0.2 POS N
kg POS N
placebo) POS N
and POS N
other POS N
biomarker POS N
changes. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
with POS N
no POS N
safety POS N
signals POS N
in POS N
all POS N
doses POS N
tested. POS N

the POS N
desired POS N
pharmacokinetic POS N
profile POS N
and POS N
preliminary POS N
efficacy POS N
observations POS N
with POS N
ZGN-1061 POS N
support POS N
evaluation POS N
in POS N
larger POS N
and POS N
longer POS N
clinical POS N
trials. POS N

the POS N
desired POS N
pharmacokinetic POS N
profile POS N
and POS N
preliminary POS N
efficacy POS N
observations POS N
with POS N
ZGN-1061 POS N
support POS N
evaluation POS N
in POS N
larger POS N
and POS N
longer POS N
clinical POS N
trials. POS N

Methionine POS N
aminopeptidase POS N
2 POS N
(MetAP2) POS N
inhibition POS N
has POS N
been POS N
shown POS N
to POS N
result POS N
in POS N
significant POS N
weight POS N
loss POS N
and POS N
improved POS N
glucose POS N
control. POS N

the POS N
desired POS N
pharmacokinetic POS N
profile POS N
and POS N
preliminary POS N
efficacy POS N
observations POS N
with POS N
ZGN-1061 POS N
support POS N
evaluation POS N
in POS N
larger POS N
and POS N
longer POS N
clinical POS N
trials. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
across POS N
all POS N
doses POS N
with POS N
most POS N
frequent POS N
adverse POS N
events POS N
of POS N
mild POS N
headache POS N
and POS N
procedural-related POS N
irritation. POS N

the POS N
desired POS N
pharmacokinetic POS N
profile POS N
and POS N
preliminary POS N
efficacy POS N
observations POS N
with POS N
ZGN-1061 POS N
support POS N
evaluation POS N
in POS N
larger POS N
and POS N
longer POS N
clinical POS N
trials. POS N

All POS N
doses POS N
of POS N
ZGN-1061 POS N
were POS N
rapidly POS N
absorbed POS N
and POS N
cleared, POS N
resulting POS N
in POS N
short POS N
duration POS N
of POS N
exposure POS N
that POS N
is POS N
anticipated POS N
to POS N
minimize POS N
potential POS N
off-drug POS N
target POS N
risks. POS N

the POS N
desired POS N
pharmacokinetic POS N
profile POS N
and POS N
preliminary POS N
efficacy POS N
observations POS N
with POS N
ZGN-1061 POS N
support POS N
evaluation POS N
in POS N
larger POS N
and POS N
longer POS N
clinical POS N
trials. POS N

Safety POS N
observations POS N
were POS N
consistent POS N
with POS N
SAD POS N
findings. POS N

the POS N
desired POS N
pharmacokinetic POS N
profile POS N
and POS N
preliminary POS N
efficacy POS N
observations POS N
with POS N
ZGN-1061 POS N
support POS N
evaluation POS N
in POS N
larger POS N
and POS N
longer POS N
clinical POS N
trials. POS N

Efficacy POS N
measures POS N
in POS N
the POS N
MAD POS N
phase POS N
indicated POS N
trends POS N
for POS N
weight POS N
change POS N
(-1.5 POS N
kg POS N
total POS N
ZGN-1061 POS N
vs POS N
-0.2 POS N
kg POS N
placebo) POS N
and POS N
other POS N
biomarker POS N
changes. POS N

the POS N
desired POS N
pharmacokinetic POS N
profile POS N
and POS N
preliminary POS N
efficacy POS N
observations POS N
with POS N
ZGN-1061 POS N
support POS N
evaluation POS N
in POS N
larger POS N
and POS N
longer POS N
clinical POS N
trials. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
with POS N
no POS N
safety POS N
signals POS N
in POS N
all POS N
doses POS N
tested. POS N

Complete POS N
success POS N
(defined POS N
as POS N
IOP POS N
<16 POS N
mmHg POS N
on POS N
no POS N
medication) POS N
could POS N
be POS N
achieved POS N
in POS N
85% POS N
eyes POS N
in POS N
study POS N
group POS N
while POS N
it POS N
was POS N
60% POS N
in POS N
control POS N
group POS N
(P POS N
= POS N
0.04). POS N

IOP POS N
reduced POS N
by POS N
71.1% POS N
in POS N
study POS N
group POS N
from POS N
41.9 POS N
± POS N
10.6 POS N
to POS N
12.1 POS N
± POS N
2.7 POS N
mmHg POS N
and POS N
from POS N
40.5 POS N
± POS N
8.5 POS N
to POS N
12.8 POS N
± POS N
4.5 POS N
mmHg POS N
in POS N
control POS N
group, POS N
a POS N
decline POS N
of POS N
68.29%. POS N

Complete POS N
success POS N
(defined POS N
as POS N
IOP POS N
<16 POS N
mmHg POS N
on POS N
no POS N
medication) POS N
could POS N
be POS N
achieved POS N
in POS N
85% POS N
eyes POS N
in POS N
study POS N
group POS N
while POS N
it POS N
was POS N
60% POS N
in POS N
control POS N
group POS N
(P POS N
= POS N
0.04). POS N

Blebs POS N
in POS N
AMT POS N
group POS N
showed POS N
better POS N
bleb POS N
morphology POS N
in POS N
terms POS N
of POS N
significantly POS N
better POS N
extent POS N
(E3) POS N
on POS N
day POS N
1 POS N
(P POS N
= POS N
0.03) POS N
and POS N
better POS N
height POS N
(H2 POS N
and POS N
H3) POS N
(P POS N
= POS N
0.04), POS N
according POS N
to POS N
the POS N
Indiana POS N
Bleb POS N
Appearance POS N
Grading POS N
Scale, POS N
at POS N
all POS N
follow-up POS N
visits POS N
along POS N
with POS N
normal POS N
vascularity. POS N

Complete POS N
success POS N
(defined POS N
as POS N
IOP POS N
<16 POS N
mmHg POS N
on POS N
no POS N
medication) POS N
could POS N
be POS N
achieved POS N
in POS N
85% POS N
eyes POS N
in POS N
study POS N
group POS N
while POS N
it POS N
was POS N
60% POS N
in POS N
control POS N
group POS N
(P POS N
= POS N
0.04). POS N

The POS N
study POS N
group POS N
required POS N
significantly POS N
lesser POS N
(P POS N
= POS N
0.03) POS N
bleb POS N
needlings POS N
as POS N
compared POS N
to POS N
control POS N
group. POS N

Complete POS N
success POS N
(defined POS N
as POS N
IOP POS N
<16 POS N
mmHg POS N
on POS N
no POS N
medication) POS N
could POS N
be POS N
achieved POS N
in POS N
85% POS N
eyes POS N
in POS N
study POS N
group POS N
while POS N
it POS N
was POS N
60% POS N
in POS N
control POS N
group POS N
(P POS N
= POS N
0.04). POS N

Amnion POS N
enhanced POS N
the POS N
efficacy POS N
of POS N
MMC-modulated POS N
trabeculectomy POS N
in POS N
terms POS N
of POS N
eyes POS N
with POS N
complete POS N
success POS N
and POS N
lesser POS N
interventions POS N
such POS N
as POS N
bleb POS N
needling. POS N

Complete POS N
success POS N
(defined POS N
as POS N
IOP POS N
<16 POS N
mmHg POS N
on POS N
no POS N
medication) POS N
could POS N
be POS N
achieved POS N
in POS N
85% POS N
eyes POS N
in POS N
study POS N
group POS N
while POS N
it POS N
was POS N
60% POS N
in POS N
control POS N
group POS N
(P POS N
= POS N
0.04). POS N

This POS N
reiterates POS N
the POS N
role POS N
of POS N
amnion POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
bleb POS N
modulator. POS N

IOP POS N
reduced POS N
by POS N
71.1% POS N
in POS N
study POS N
group POS N
from POS N
41.9 POS N
± POS N
10.6 POS N
to POS N
12.1 POS N
± POS N
2.7 POS N
mmHg POS N
and POS N
from POS N
40.5 POS N
± POS N
8.5 POS N
to POS N
12.8 POS N
± POS N
4.5 POS N
mmHg POS N
in POS N
control POS N
group, POS N
a POS N
decline POS N
of POS N
68.29%. POS N

Complete POS N
success POS N
(defined POS N
as POS N
IOP POS N
<16 POS N
mmHg POS N
on POS N
no POS N
medication) POS N
could POS N
be POS N
achieved POS N
in POS N
85% POS N
eyes POS N
in POS N
study POS N
group POS N
while POS N
it POS N
was POS N
60% POS N
in POS N
control POS N
group POS N
(P POS N
= POS N
0.04). POS N

IOP POS N
reduced POS N
by POS N
71.1% POS N
in POS N
study POS N
group POS N
from POS N
41.9 POS N
± POS N
10.6 POS N
to POS N
12.1 POS N
± POS N
2.7 POS N
mmHg POS N
and POS N
from POS N
40.5 POS N
± POS N
8.5 POS N
to POS N
12.8 POS N
± POS N
4.5 POS N
mmHg POS N
in POS N
control POS N
group, POS N
a POS N
decline POS N
of POS N
68.29%. POS N

Blebs POS N
in POS N
AMT POS N
group POS N
showed POS N
better POS N
bleb POS N
morphology POS N
in POS N
terms POS N
of POS N
significantly POS N
better POS N
extent POS N
(E3) POS N
on POS N
day POS N
1 POS N
(P POS N
= POS N
0.03) POS N
and POS N
better POS N
height POS N
(H2 POS N
and POS N
H3) POS N
(P POS N
= POS N
0.04), POS N
according POS N
to POS N
the POS N
Indiana POS N
Bleb POS N
Appearance POS N
Grading POS N
Scale, POS N
at POS N
all POS N
follow-up POS N
visits POS N
along POS N
with POS N
normal POS N
vascularity. POS N

IOP POS N
reduced POS N
by POS N
71.1% POS N
in POS N
study POS N
group POS N
from POS N
41.9 POS N
± POS N
10.6 POS N
to POS N
12.1 POS N
± POS N
2.7 POS N
mmHg POS N
and POS N
from POS N
40.5 POS N
± POS N
8.5 POS N
to POS N
12.8 POS N
± POS N
4.5 POS N
mmHg POS N
in POS N
control POS N
group, POS N
a POS N
decline POS N
of POS N
68.29%. POS N

The POS N
study POS N
group POS N
required POS N
significantly POS N
lesser POS N
(P POS N
= POS N
0.03) POS N
bleb POS N
needlings POS N
as POS N
compared POS N
to POS N
control POS N
group. POS N

IOP POS N
reduced POS N
by POS N
71.1% POS N
in POS N
study POS N
group POS N
from POS N
41.9 POS N
± POS N
10.6 POS N
to POS N
12.1 POS N
± POS N
2.7 POS N
mmHg POS N
and POS N
from POS N
40.5 POS N
± POS N
8.5 POS N
to POS N
12.8 POS N
± POS N
4.5 POS N
mmHg POS N
in POS N
control POS N
group, POS N
a POS N
decline POS N
of POS N
68.29%. POS N

Amnion POS N
enhanced POS N
the POS N
efficacy POS N
of POS N
MMC-modulated POS N
trabeculectomy POS N
in POS N
terms POS N
of POS N
eyes POS N
with POS N
complete POS N
success POS N
and POS N
lesser POS N
interventions POS N
such POS N
as POS N
bleb POS N
needling. POS N

IOP POS N
reduced POS N
by POS N
71.1% POS N
in POS N
study POS N
group POS N
from POS N
41.9 POS N
± POS N
10.6 POS N
to POS N
12.1 POS N
± POS N
2.7 POS N
mmHg POS N
and POS N
from POS N
40.5 POS N
± POS N
8.5 POS N
to POS N
12.8 POS N
± POS N
4.5 POS N
mmHg POS N
in POS N
control POS N
group, POS N
a POS N
decline POS N
of POS N
68.29%. POS N

This POS N
reiterates POS N
the POS N
role POS N
of POS N
amnion POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
bleb POS N
modulator. POS N

Blebs POS N
in POS N
AMT POS N
group POS N
showed POS N
better POS N
bleb POS N
morphology POS N
in POS N
terms POS N
of POS N
significantly POS N
better POS N
extent POS N
(E3) POS N
on POS N
day POS N
1 POS N
(P POS N
= POS N
0.03) POS N
and POS N
better POS N
height POS N
(H2 POS N
and POS N
H3) POS N
(P POS N
= POS N
0.04), POS N
according POS N
to POS N
the POS N
Indiana POS N
Bleb POS N
Appearance POS N
Grading POS N
Scale, POS N
at POS N
all POS N
follow-up POS N
visits POS N
along POS N
with POS N
normal POS N
vascularity. POS N

Complete POS N
success POS N
(defined POS N
as POS N
IOP POS N
<16 POS N
mmHg POS N
on POS N
no POS N
medication) POS N
could POS N
be POS N
achieved POS N
in POS N
85% POS N
eyes POS N
in POS N
study POS N
group POS N
while POS N
it POS N
was POS N
60% POS N
in POS N
control POS N
group POS N
(P POS N
= POS N
0.04). POS N

Blebs POS N
in POS N
AMT POS N
group POS N
showed POS N
better POS N
bleb POS N
morphology POS N
in POS N
terms POS N
of POS N
significantly POS N
better POS N
extent POS N
(E3) POS N
on POS N
day POS N
1 POS N
(P POS N
= POS N
0.03) POS N
and POS N
better POS N
height POS N
(H2 POS N
and POS N
H3) POS N
(P POS N
= POS N
0.04), POS N
according POS N
to POS N
the POS N
Indiana POS N
Bleb POS N
Appearance POS N
Grading POS N
Scale, POS N
at POS N
all POS N
follow-up POS N
visits POS N
along POS N
with POS N
normal POS N
vascularity. POS N

IOP POS N
reduced POS N
by POS N
71.1% POS N
in POS N
study POS N
group POS N
from POS N
41.9 POS N
± POS N
10.6 POS N
to POS N
12.1 POS N
± POS N
2.7 POS N
mmHg POS N
and POS N
from POS N
40.5 POS N
± POS N
8.5 POS N
to POS N
12.8 POS N
± POS N
4.5 POS N
mmHg POS N
in POS N
control POS N
group, POS N
a POS N
decline POS N
of POS N
68.29%. POS N

Blebs POS N
in POS N
AMT POS N
group POS N
showed POS N
better POS N
bleb POS N
morphology POS N
in POS N
terms POS N
of POS N
significantly POS N
better POS N
extent POS N
(E3) POS N
on POS N
day POS N
1 POS N
(P POS N
= POS N
0.03) POS N
and POS N
better POS N
height POS N
(H2 POS N
and POS N
H3) POS N
(P POS N
= POS N
0.04), POS N
according POS N
to POS N
the POS N
Indiana POS N
Bleb POS N
Appearance POS N
Grading POS N
Scale, POS N
at POS N
all POS N
follow-up POS N
visits POS N
along POS N
with POS N
normal POS N
vascularity. POS N

The POS N
study POS N
group POS N
required POS N
significantly POS N
lesser POS N
(P POS N
= POS N
0.03) POS N
bleb POS N
needlings POS N
as POS N
compared POS N
to POS N
control POS N
group. POS N

Blebs POS N
in POS N
AMT POS N
group POS N
showed POS N
better POS N
bleb POS N
morphology POS N
in POS N
terms POS N
of POS N
significantly POS N
better POS N
extent POS N
(E3) POS N
on POS N
day POS N
1 POS N
(P POS N
= POS N
0.03) POS N
and POS N
better POS N
height POS N
(H2 POS N
and POS N
H3) POS N
(P POS N
= POS N
0.04), POS N
according POS N
to POS N
the POS N
Indiana POS N
Bleb POS N
Appearance POS N
Grading POS N
Scale, POS N
at POS N
all POS N
follow-up POS N
visits POS N
along POS N
with POS N
normal POS N
vascularity. POS N

Amnion POS N
enhanced POS N
the POS N
efficacy POS N
of POS N
MMC-modulated POS N
trabeculectomy POS N
in POS N
terms POS N
of POS N
eyes POS N
with POS N
complete POS N
success POS N
and POS N
lesser POS N
interventions POS N
such POS N
as POS N
bleb POS N
needling. POS N

Blebs POS N
in POS N
AMT POS N
group POS N
showed POS N
better POS N
bleb POS N
morphology POS N
in POS N
terms POS N
of POS N
significantly POS N
better POS N
extent POS N
(E3) POS N
on POS N
day POS N
1 POS N
(P POS N
= POS N
0.03) POS N
and POS N
better POS N
height POS N
(H2 POS N
and POS N
H3) POS N
(P POS N
= POS N
0.04), POS N
according POS N
to POS N
the POS N
Indiana POS N
Bleb POS N
Appearance POS N
Grading POS N
Scale, POS N
at POS N
all POS N
follow-up POS N
visits POS N
along POS N
with POS N
normal POS N
vascularity. POS N

This POS N
reiterates POS N
the POS N
role POS N
of POS N
amnion POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
bleb POS N
modulator. POS N

The POS N
study POS N
group POS N
required POS N
significantly POS N
lesser POS N
(P POS N
= POS N
0.03) POS N
bleb POS N
needlings POS N
as POS N
compared POS N
to POS N
control POS N
group. POS N

Complete POS N
success POS N
(defined POS N
as POS N
IOP POS N
<16 POS N
mmHg POS N
on POS N
no POS N
medication) POS N
could POS N
be POS N
achieved POS N
in POS N
85% POS N
eyes POS N
in POS N
study POS N
group POS N
while POS N
it POS N
was POS N
60% POS N
in POS N
control POS N
group POS N
(P POS N
= POS N
0.04). POS N

The POS N
study POS N
group POS N
required POS N
significantly POS N
lesser POS N
(P POS N
= POS N
0.03) POS N
bleb POS N
needlings POS N
as POS N
compared POS N
to POS N
control POS N
group. POS N

IOP POS N
reduced POS N
by POS N
71.1% POS N
in POS N
study POS N
group POS N
from POS N
41.9 POS N
± POS N
10.6 POS N
to POS N
12.1 POS N
± POS N
2.7 POS N
mmHg POS N
and POS N
from POS N
40.5 POS N
± POS N
8.5 POS N
to POS N
12.8 POS N
± POS N
4.5 POS N
mmHg POS N
in POS N
control POS N
group, POS N
a POS N
decline POS N
of POS N
68.29%. POS N

The POS N
study POS N
group POS N
required POS N
significantly POS N
lesser POS N
(P POS N
= POS N
0.03) POS N
bleb POS N
needlings POS N
as POS N
compared POS N
to POS N
control POS N
group. POS N

Blebs POS N
in POS N
AMT POS N
group POS N
showed POS N
better POS N
bleb POS N
morphology POS N
in POS N
terms POS N
of POS N
significantly POS N
better POS N
extent POS N
(E3) POS N
on POS N
day POS N
1 POS N
(P POS N
= POS N
0.03) POS N
and POS N
better POS N
height POS N
(H2 POS N
and POS N
H3) POS N
(P POS N
= POS N
0.04), POS N
according POS N
to POS N
the POS N
Indiana POS N
Bleb POS N
Appearance POS N
Grading POS N
Scale, POS N
at POS N
all POS N
follow-up POS N
visits POS N
along POS N
with POS N
normal POS N
vascularity. POS N

The POS N
study POS N
group POS N
required POS N
significantly POS N
lesser POS N
(P POS N
= POS N
0.03) POS N
bleb POS N
needlings POS N
as POS N
compared POS N
to POS N
control POS N
group. POS N

Amnion POS N
enhanced POS N
the POS N
efficacy POS N
of POS N
MMC-modulated POS N
trabeculectomy POS N
in POS N
terms POS N
of POS N
eyes POS N
with POS N
complete POS N
success POS N
and POS N
lesser POS N
interventions POS N
such POS N
as POS N
bleb POS N
needling. POS N

The POS N
study POS N
group POS N
required POS N
significantly POS N
lesser POS N
(P POS N
= POS N
0.03) POS N
bleb POS N
needlings POS N
as POS N
compared POS N
to POS N
control POS N
group. POS N

This POS N
reiterates POS N
the POS N
role POS N
of POS N
amnion POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
bleb POS N
modulator. POS N

Amnion POS N
enhanced POS N
the POS N
efficacy POS N
of POS N
MMC-modulated POS N
trabeculectomy POS N
in POS N
terms POS N
of POS N
eyes POS N
with POS N
complete POS N
success POS N
and POS N
lesser POS N
interventions POS N
such POS N
as POS N
bleb POS N
needling. POS N

Complete POS N
success POS N
(defined POS N
as POS N
IOP POS N
<16 POS N
mmHg POS N
on POS N
no POS N
medication) POS N
could POS N
be POS N
achieved POS N
in POS N
85% POS N
eyes POS N
in POS N
study POS N
group POS N
while POS N
it POS N
was POS N
60% POS N
in POS N
control POS N
group POS N
(P POS N
= POS N
0.04). POS N

Amnion POS N
enhanced POS N
the POS N
efficacy POS N
of POS N
MMC-modulated POS N
trabeculectomy POS N
in POS N
terms POS N
of POS N
eyes POS N
with POS N
complete POS N
success POS N
and POS N
lesser POS N
interventions POS N
such POS N
as POS N
bleb POS N
needling. POS N

IOP POS N
reduced POS N
by POS N
71.1% POS N
in POS N
study POS N
group POS N
from POS N
41.9 POS N
± POS N
10.6 POS N
to POS N
12.1 POS N
± POS N
2.7 POS N
mmHg POS N
and POS N
from POS N
40.5 POS N
± POS N
8.5 POS N
to POS N
12.8 POS N
± POS N
4.5 POS N
mmHg POS N
in POS N
control POS N
group, POS N
a POS N
decline POS N
of POS N
68.29%. POS N

Amnion POS N
enhanced POS N
the POS N
efficacy POS N
of POS N
MMC-modulated POS N
trabeculectomy POS N
in POS N
terms POS N
of POS N
eyes POS N
with POS N
complete POS N
success POS N
and POS N
lesser POS N
interventions POS N
such POS N
as POS N
bleb POS N
needling. POS N

Blebs POS N
in POS N
AMT POS N
group POS N
showed POS N
better POS N
bleb POS N
morphology POS N
in POS N
terms POS N
of POS N
significantly POS N
better POS N
extent POS N
(E3) POS N
on POS N
day POS N
1 POS N
(P POS N
= POS N
0.03) POS N
and POS N
better POS N
height POS N
(H2 POS N
and POS N
H3) POS N
(P POS N
= POS N
0.04), POS N
according POS N
to POS N
the POS N
Indiana POS N
Bleb POS N
Appearance POS N
Grading POS N
Scale, POS N
at POS N
all POS N
follow-up POS N
visits POS N
along POS N
with POS N
normal POS N
vascularity. POS N

Amnion POS N
enhanced POS N
the POS N
efficacy POS N
of POS N
MMC-modulated POS N
trabeculectomy POS N
in POS N
terms POS N
of POS N
eyes POS N
with POS N
complete POS N
success POS N
and POS N
lesser POS N
interventions POS N
such POS N
as POS N
bleb POS N
needling. POS N

The POS N
study POS N
group POS N
required POS N
significantly POS N
lesser POS N
(P POS N
= POS N
0.03) POS N
bleb POS N
needlings POS N
as POS N
compared POS N
to POS N
control POS N
group. POS N

Amnion POS N
enhanced POS N
the POS N
efficacy POS N
of POS N
MMC-modulated POS N
trabeculectomy POS N
in POS N
terms POS N
of POS N
eyes POS N
with POS N
complete POS N
success POS N
and POS N
lesser POS N
interventions POS N
such POS N
as POS N
bleb POS N
needling. POS N

This POS N
reiterates POS N
the POS N
role POS N
of POS N
amnion POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
bleb POS N
modulator. POS N

This POS N
reiterates POS N
the POS N
role POS N
of POS N
amnion POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
bleb POS N
modulator. POS N

Complete POS N
success POS N
(defined POS N
as POS N
IOP POS N
<16 POS N
mmHg POS N
on POS N
no POS N
medication) POS N
could POS N
be POS N
achieved POS N
in POS N
85% POS N
eyes POS N
in POS N
study POS N
group POS N
while POS N
it POS N
was POS N
60% POS N
in POS N
control POS N
group POS N
(P POS N
= POS N
0.04). POS N

This POS N
reiterates POS N
the POS N
role POS N
of POS N
amnion POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
bleb POS N
modulator. POS N

IOP POS N
reduced POS N
by POS N
71.1% POS N
in POS N
study POS N
group POS N
from POS N
41.9 POS N
± POS N
10.6 POS N
to POS N
12.1 POS N
± POS N
2.7 POS N
mmHg POS N
and POS N
from POS N
40.5 POS N
± POS N
8.5 POS N
to POS N
12.8 POS N
± POS N
4.5 POS N
mmHg POS N
in POS N
control POS N
group, POS N
a POS N
decline POS N
of POS N
68.29%. POS N

This POS N
reiterates POS N
the POS N
role POS N
of POS N
amnion POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
bleb POS N
modulator. POS N

Blebs POS N
in POS N
AMT POS N
group POS N
showed POS N
better POS N
bleb POS N
morphology POS N
in POS N
terms POS N
of POS N
significantly POS N
better POS N
extent POS N
(E3) POS N
on POS N
day POS N
1 POS N
(P POS N
= POS N
0.03) POS N
and POS N
better POS N
height POS N
(H2 POS N
and POS N
H3) POS N
(P POS N
= POS N
0.04), POS N
according POS N
to POS N
the POS N
Indiana POS N
Bleb POS N
Appearance POS N
Grading POS N
Scale, POS N
at POS N
all POS N
follow-up POS N
visits POS N
along POS N
with POS N
normal POS N
vascularity. POS N

This POS N
reiterates POS N
the POS N
role POS N
of POS N
amnion POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
bleb POS N
modulator. POS N

The POS N
study POS N
group POS N
required POS N
significantly POS N
lesser POS N
(P POS N
= POS N
0.03) POS N
bleb POS N
needlings POS N
as POS N
compared POS N
to POS N
control POS N
group. POS N

This POS N
reiterates POS N
the POS N
role POS N
of POS N
amnion POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
bleb POS N
modulator. POS N

Amnion POS N
enhanced POS N
the POS N
efficacy POS N
of POS N
MMC-modulated POS N
trabeculectomy POS N
in POS N
terms POS N
of POS N
eyes POS N
with POS N
complete POS N
success POS N
and POS N
lesser POS N
interventions POS N
such POS N
as POS N
bleb POS N
needling. POS N

Ca POS N
consumption POS N
during POS N
the POS N
study POS N
was POS N
equivalent POS N
to POS N
1200 POS N
mg/d POS N
during POS N
MD POS N
and POS N
525 POS N
mg/d POS N
during POS N
CD. POS N

There POS N
was POS N
a POS N
greater POS N
reduction POS N
in POS N
WC, POS N
SBP, POS N
DBP POS N
and POS N
LAP POS N
index POS N
after POS N
MD POS N
compared POS N
with POS N
CD. POS N

Ca POS N
consumption POS N
during POS N
the POS N
study POS N
was POS N
equivalent POS N
to POS N
1200 POS N
mg/d POS N
during POS N
MD POS N
and POS N
525 POS N
mg/d POS N
during POS N
CD. POS N

HDL:LDL POS N
ratio POS N
increased POS N
and POS N
total POS N
cholesterol, POS N
LDL-cholesterol, POS N
SBP, POS N
DBP POS N
and POS N
LAP POS N
index POS N
decreased POS N
only POS N
in POS N
MD. POS N

Ca POS N
consumption POS N
during POS N
the POS N
study POS N
was POS N
equivalent POS N
to POS N
1200 POS N
mg/d POS N
during POS N
MD POS N
and POS N
525 POS N
mg/d POS N
during POS N
CD. POS N

The POS N
consumption POS N
of POS N
approximately POS N
1200 POS N
mg POS N
of POS N
Ca/d POS N
(700 POS N
mg POS N
from POS N
fat-free POS N
milk+500mg POS N
from POS N
other POS N
dietary POS N
sources) POS N
associated POS N
with POS N
an POS N
energy-restricted POS N
diet POS N
decreased POS N
some POS N
of POS N
the POS N
MetS POS N
components POS N
and POS N
cardiometabolic POS N
measures POS N
in POS N
adults POS N
with POS N
T2DM. POS N

There POS N
was POS N
a POS N
greater POS N
reduction POS N
in POS N
WC, POS N
SBP, POS N
DBP POS N
and POS N
LAP POS N
index POS N
after POS N
MD POS N
compared POS N
with POS N
CD. POS N

Ca POS N
consumption POS N
during POS N
the POS N
study POS N
was POS N
equivalent POS N
to POS N
1200 POS N
mg/d POS N
during POS N
MD POS N
and POS N
525 POS N
mg/d POS N
during POS N
CD. POS N

There POS N
was POS N
a POS N
greater POS N
reduction POS N
in POS N
WC, POS N
SBP, POS N
DBP POS N
and POS N
LAP POS N
index POS N
after POS N
MD POS N
compared POS N
with POS N
CD. POS N

HDL:LDL POS N
ratio POS N
increased POS N
and POS N
total POS N
cholesterol, POS N
LDL-cholesterol, POS N
SBP, POS N
DBP POS N
and POS N
LAP POS N
index POS N
decreased POS N
only POS N
in POS N
MD. POS N

There POS N
was POS N
a POS N
greater POS N
reduction POS N
in POS N
WC, POS N
SBP, POS N
DBP POS N
and POS N
LAP POS N
index POS N
after POS N
MD POS N
compared POS N
with POS N
CD. POS N

The POS N
consumption POS N
of POS N
approximately POS N
1200 POS N
mg POS N
of POS N
Ca/d POS N
(700 POS N
mg POS N
from POS N
fat-free POS N
milk+500mg POS N
from POS N
other POS N
dietary POS N
sources) POS N
associated POS N
with POS N
an POS N
energy-restricted POS N
diet POS N
decreased POS N
some POS N
of POS N
the POS N
MetS POS N
components POS N
and POS N
cardiometabolic POS N
measures POS N
in POS N
adults POS N
with POS N
T2DM. POS N

HDL:LDL POS N
ratio POS N
increased POS N
and POS N
total POS N
cholesterol, POS N
LDL-cholesterol, POS N
SBP, POS N
DBP POS N
and POS N
LAP POS N
index POS N
decreased POS N
only POS N
in POS N
MD. POS N

Ca POS N
consumption POS N
during POS N
the POS N
study POS N
was POS N
equivalent POS N
to POS N
1200 POS N
mg/d POS N
during POS N
MD POS N
and POS N
525 POS N
mg/d POS N
during POS N
CD. POS N

HDL:LDL POS N
ratio POS N
increased POS N
and POS N
total POS N
cholesterol, POS N
LDL-cholesterol, POS N
SBP, POS N
DBP POS N
and POS N
LAP POS N
index POS N
decreased POS N
only POS N
in POS N
MD. POS N

There POS N
was POS N
a POS N
greater POS N
reduction POS N
in POS N
WC, POS N
SBP, POS N
DBP POS N
and POS N
LAP POS N
index POS N
after POS N
MD POS N
compared POS N
with POS N
CD. POS N

HDL:LDL POS N
ratio POS N
increased POS N
and POS N
total POS N
cholesterol, POS N
LDL-cholesterol, POS N
SBP, POS N
DBP POS N
and POS N
LAP POS N
index POS N
decreased POS N
only POS N
in POS N
MD. POS N

The POS N
consumption POS N
of POS N
approximately POS N
1200 POS N
mg POS N
of POS N
Ca/d POS N
(700 POS N
mg POS N
from POS N
fat-free POS N
milk+500mg POS N
from POS N
other POS N
dietary POS N
sources) POS N
associated POS N
with POS N
an POS N
energy-restricted POS N
diet POS N
decreased POS N
some POS N
of POS N
the POS N
MetS POS N
components POS N
and POS N
cardiometabolic POS N
measures POS N
in POS N
adults POS N
with POS N
T2DM. POS N

The POS N
consumption POS N
of POS N
approximately POS N
1200 POS N
mg POS N
of POS N
Ca/d POS N
(700 POS N
mg POS N
from POS N
fat-free POS N
milk+500mg POS N
from POS N
other POS N
dietary POS N
sources) POS N
associated POS N
with POS N
an POS N
energy-restricted POS N
diet POS N
decreased POS N
some POS N
of POS N
the POS N
MetS POS N
components POS N
and POS N
cardiometabolic POS N
measures POS N
in POS N
adults POS N
with POS N
T2DM. POS N

Ca POS N
consumption POS N
during POS N
the POS N
study POS N
was POS N
equivalent POS N
to POS N
1200 POS N
mg/d POS N
during POS N
MD POS N
and POS N
525 POS N
mg/d POS N
during POS N
CD. POS N

The POS N
consumption POS N
of POS N
approximately POS N
1200 POS N
mg POS N
of POS N
Ca/d POS N
(700 POS N
mg POS N
from POS N
fat-free POS N
milk+500mg POS N
from POS N
other POS N
dietary POS N
sources) POS N
associated POS N
with POS N
an POS N
energy-restricted POS N
diet POS N
decreased POS N
some POS N
of POS N
the POS N
MetS POS N
components POS N
and POS N
cardiometabolic POS N
measures POS N
in POS N
adults POS N
with POS N
T2DM. POS N

There POS N
was POS N
a POS N
greater POS N
reduction POS N
in POS N
WC, POS N
SBP, POS N
DBP POS N
and POS N
LAP POS N
index POS N
after POS N
MD POS N
compared POS N
with POS N
CD. POS N

The POS N
consumption POS N
of POS N
approximately POS N
1200 POS N
mg POS N
of POS N
Ca/d POS N
(700 POS N
mg POS N
from POS N
fat-free POS N
milk+500mg POS N
from POS N
other POS N
dietary POS N
sources) POS N
associated POS N
with POS N
an POS N
energy-restricted POS N
diet POS N
decreased POS N
some POS N
of POS N
the POS N
MetS POS N
components POS N
and POS N
cardiometabolic POS N
measures POS N
in POS N
adults POS N
with POS N
T2DM. POS N

HDL:LDL POS N
ratio POS N
increased POS N
and POS N
total POS N
cholesterol, POS N
LDL-cholesterol, POS N
SBP, POS N
DBP POS N
and POS N
LAP POS N
index POS N
decreased POS N
only POS N
in POS N
MD. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

Changes POS N
in POS N
UACR POS N
category POS N
were POS N
not POS N
different POS N
among POS N
treatment POS N
groups POS N
at POS N
the POS N
52-week POS N
visit POS N
(global POS N
P POS N
= POS N
0.29). POS N

Average POS N
change POS N
in POS N
mean POS N
arterial POS N
pressure POS N
from POS N
baseline POS N
to POS N
2 POS N
years POS N
was POS N
-1.2 POS N
± POS N
15, POS N
-1.8 POS N
± POS N
13.5, POS N
-2.6 POS N
± POS N
14.4 POS N
mm POS N
Hg POS N
in POS N
the POS N
aflibercept, POS N
bevacizumab, POS N
and POS N
ranibizumab POS N
groups, POS N
respectively POS N
(global POS N
P POS N
= POS N
0.69). POS N

Changes POS N
in POS N
UACR POS N
category POS N
were POS N
not POS N
different POS N
among POS N
treatment POS N
groups POS N
at POS N
the POS N
52-week POS N
visit POS N
(global POS N
P POS N
= POS N
0.29). POS N

There POS N
do POS N
not POS N
appear POS N
to POS N
be POS N
treatment POS N
group POS N
differences POS N
for POS N
changes POS N
in POS N
blood POS N
pressure POS N
or POS N
UACR POS N
as POS N
a POS N
reflection POS N
of POS N
kidney POS N
function POS N
in POS N
patients POS N
with POS N
DME POS N
treated POS N
with POS N
aflibercept, POS N
bevacizumab, POS N
or POS N
ranibizumab. POS N

Average POS N
change POS N
in POS N
mean POS N
arterial POS N
pressure POS N
from POS N
baseline POS N
to POS N
2 POS N
years POS N
was POS N
-1.2 POS N
± POS N
15, POS N
-1.8 POS N
± POS N
13.5, POS N
-2.6 POS N
± POS N
14.4 POS N
mm POS N
Hg POS N
in POS N
the POS N
aflibercept, POS N
bevacizumab, POS N
and POS N
ranibizumab POS N
groups, POS N
respectively POS N
(global POS N
P POS N
= POS N
0.69). POS N

Changes POS N
in POS N
UACR POS N
category POS N
were POS N
not POS N
different POS N
among POS N
treatment POS N
groups POS N
at POS N
the POS N
52-week POS N
visit POS N
(global POS N
P POS N
= POS N
0.29). POS N

Average POS N
change POS N
in POS N
mean POS N
arterial POS N
pressure POS N
from POS N
baseline POS N
to POS N
2 POS N
years POS N
was POS N
-1.2 POS N
± POS N
15, POS N
-1.8 POS N
± POS N
13.5, POS N
-2.6 POS N
± POS N
14.4 POS N
mm POS N
Hg POS N
in POS N
the POS N
aflibercept, POS N
bevacizumab, POS N
and POS N
ranibizumab POS N
groups, POS N
respectively POS N
(global POS N
P POS N
= POS N
0.69). POS N

There POS N
do POS N
not POS N
appear POS N
to POS N
be POS N
treatment POS N
group POS N
differences POS N
for POS N
changes POS N
in POS N
blood POS N
pressure POS N
or POS N
UACR POS N
as POS N
a POS N
reflection POS N
of POS N
kidney POS N
function POS N
in POS N
patients POS N
with POS N
DME POS N
treated POS N
with POS N
aflibercept, POS N
bevacizumab, POS N
or POS N
ranibizumab. POS N

There POS N
do POS N
not POS N
appear POS N
to POS N
be POS N
treatment POS N
group POS N
differences POS N
for POS N
changes POS N
in POS N
blood POS N
pressure POS N
or POS N
UACR POS N
as POS N
a POS N
reflection POS N
of POS N
kidney POS N
function POS N
in POS N
patients POS N
with POS N
DME POS N
treated POS N
with POS N
aflibercept, POS N
bevacizumab, POS N
or POS N
ranibizumab. POS N

Changes POS N
in POS N
UACR POS N
category POS N
were POS N
not POS N
different POS N
among POS N
treatment POS N
groups POS N
at POS N
the POS N
52-week POS N
visit POS N
(global POS N
P POS N
= POS N
0.29). POS N

There POS N
do POS N
not POS N
appear POS N
to POS N
be POS N
treatment POS N
group POS N
differences POS N
for POS N
changes POS N
in POS N
blood POS N
pressure POS N
or POS N
UACR POS N
as POS N
a POS N
reflection POS N
of POS N
kidney POS N
function POS N
in POS N
patients POS N
with POS N
DME POS N
treated POS N
with POS N
aflibercept, POS N
bevacizumab, POS N
or POS N
ranibizumab. POS N

Average POS N
change POS N
in POS N
mean POS N
arterial POS N
pressure POS N
from POS N
baseline POS N
to POS N
2 POS N
years POS N
was POS N
-1.2 POS N
± POS N
15, POS N
-1.8 POS N
± POS N
13.5, POS N
-2.6 POS N
± POS N
14.4 POS N
mm POS N
Hg POS N
in POS N
the POS N
aflibercept, POS N
bevacizumab, POS N
and POS N
ranibizumab POS N
groups, POS N
respectively POS N
(global POS N
P POS N
= POS N
0.69). POS N

Topical POS N
brimonidine POS N
showed POS N
an POS N
additive POS N
IOP-lowering POS N
effect POS N
to POS N
topical POS N
PG POS N
analogues, POS N

although POS N
its POS N
IOP-lowering POS N
effect POS N
was POS N
inferior POS N
to POS N
topical POS N
timolol POS N
as POS N
monotherapy. POS N

Topical POS N
brimonidine POS N
showed POS N
an POS N
additive POS N
IOP-lowering POS N
effect POS N
to POS N
topical POS N
PG POS N
analogues, POS N

The POS N
mean POS N
changes POS N
were POS N
-4.7 POS N
+/- POS N
2.1 POS N
(S. POS N
D.) POS N
in POS N
the POS N
timolol POS N
and POS N
-4.0 POS N
+/- POS N
2.0 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
(p POS N
= POS N
0.0138). POS N

Topical POS N
brimonidine POS N
showed POS N
an POS N
additive POS N
IOP-lowering POS N
effect POS N
to POS N
topical POS N
PG POS N
analogues, POS N

The POS N
95% POS N
confidence POS N
interval POS N
of POS N
the POS N
inter-group POS N
difference POS N
was POS N
greater POS N
than POS N
the POS N
pre-determined POS N
criterion POS N
of POS N
non-inferiority POS N
of POS N
brimonidine POS N
to POS N
timolol. POS N

Topical POS N
brimonidine POS N
showed POS N
an POS N
additive POS N
IOP-lowering POS N
effect POS N
to POS N
topical POS N
PG POS N
analogues, POS N

When POS N
added POS N
to POS N
PG POS N
analogues, POS N
the POS N
IOP-lowering POS N
effect POS N
of POS N
brimonidine POS N
(-2.9 POS N
+/- POS N
1.8 POS N
mmHg) POS N
was POS N
greater POS N
than POS N
that POS N
of POS N
the POS N
placebo POS N
(-2.1 POS N
+/- POS N
1.8 POS N
mmHg) POS N
(p POS N
= POS N
0.0010). POS N

although POS N
its POS N
IOP-lowering POS N
effect POS N
was POS N
inferior POS N
to POS N
topical POS N
timolol POS N
as POS N
monotherapy. POS N

Topical POS N
brimonidine POS N
showed POS N
an POS N
additive POS N
IOP-lowering POS N
effect POS N
to POS N
topical POS N
PG POS N
analogues, POS N

although POS N
its POS N
IOP-lowering POS N
effect POS N
was POS N
inferior POS N
to POS N
topical POS N
timolol POS N
as POS N
monotherapy. POS N

The POS N
mean POS N
changes POS N
were POS N
-4.7 POS N
+/- POS N
2.1 POS N
(S. POS N
D.) POS N
in POS N
the POS N
timolol POS N
and POS N
-4.0 POS N
+/- POS N
2.0 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
(p POS N
= POS N
0.0138). POS N

although POS N
its POS N
IOP-lowering POS N
effect POS N
was POS N
inferior POS N
to POS N
topical POS N
timolol POS N
as POS N
monotherapy. POS N

The POS N
95% POS N
confidence POS N
interval POS N
of POS N
the POS N
inter-group POS N
difference POS N
was POS N
greater POS N
than POS N
the POS N
pre-determined POS N
criterion POS N
of POS N
non-inferiority POS N
of POS N
brimonidine POS N
to POS N
timolol. POS N

although POS N
its POS N
IOP-lowering POS N
effect POS N
was POS N
inferior POS N
to POS N
topical POS N
timolol POS N
as POS N
monotherapy. POS N

When POS N
added POS N
to POS N
PG POS N
analogues, POS N
the POS N
IOP-lowering POS N
effect POS N
of POS N
brimonidine POS N
(-2.9 POS N
+/- POS N
1.8 POS N
mmHg) POS N
was POS N
greater POS N
than POS N
that POS N
of POS N
the POS N
placebo POS N
(-2.1 POS N
+/- POS N
1.8 POS N
mmHg) POS N
(p POS N
= POS N
0.0010). POS N

The POS N
mean POS N
changes POS N
were POS N
-4.7 POS N
+/- POS N
2.1 POS N
(S. POS N
D.) POS N
in POS N
the POS N
timolol POS N
and POS N
-4.0 POS N
+/- POS N
2.0 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
(p POS N
= POS N
0.0138). POS N

Topical POS N
brimonidine POS N
showed POS N
an POS N
additive POS N
IOP-lowering POS N
effect POS N
to POS N
topical POS N
PG POS N
analogues, POS N

The POS N
mean POS N
changes POS N
were POS N
-4.7 POS N
+/- POS N
2.1 POS N
(S. POS N
D.) POS N
in POS N
the POS N
timolol POS N
and POS N
-4.0 POS N
+/- POS N
2.0 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
(p POS N
= POS N
0.0138). POS N

although POS N
its POS N
IOP-lowering POS N
effect POS N
was POS N
inferior POS N
to POS N
topical POS N
timolol POS N
as POS N
monotherapy. POS N

The POS N
mean POS N
changes POS N
were POS N
-4.7 POS N
+/- POS N
2.1 POS N
(S. POS N
D.) POS N
in POS N
the POS N
timolol POS N
and POS N
-4.0 POS N
+/- POS N
2.0 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
(p POS N
= POS N
0.0138). POS N

The POS N
95% POS N
confidence POS N
interval POS N
of POS N
the POS N
inter-group POS N
difference POS N
was POS N
greater POS N
than POS N
the POS N
pre-determined POS N
criterion POS N
of POS N
non-inferiority POS N
of POS N
brimonidine POS N
to POS N
timolol. POS N

The POS N
mean POS N
changes POS N
were POS N
-4.7 POS N
+/- POS N
2.1 POS N
(S. POS N
D.) POS N
in POS N
the POS N
timolol POS N
and POS N
-4.0 POS N
+/- POS N
2.0 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
(p POS N
= POS N
0.0138). POS N

When POS N
added POS N
to POS N
PG POS N
analogues, POS N
the POS N
IOP-lowering POS N
effect POS N
of POS N
brimonidine POS N
(-2.9 POS N
+/- POS N
1.8 POS N
mmHg) POS N
was POS N
greater POS N
than POS N
that POS N
of POS N
the POS N
placebo POS N
(-2.1 POS N
+/- POS N
1.8 POS N
mmHg) POS N
(p POS N
= POS N
0.0010). POS N

The POS N
95% POS N
confidence POS N
interval POS N
of POS N
the POS N
inter-group POS N
difference POS N
was POS N
greater POS N
than POS N
the POS N
pre-determined POS N
criterion POS N
of POS N
non-inferiority POS N
of POS N
brimonidine POS N
to POS N
timolol. POS N

Topical POS N
brimonidine POS N
showed POS N
an POS N
additive POS N
IOP-lowering POS N
effect POS N
to POS N
topical POS N
PG POS N
analogues, POS N

The POS N
95% POS N
confidence POS N
interval POS N
of POS N
the POS N
inter-group POS N
difference POS N
was POS N
greater POS N
than POS N
the POS N
pre-determined POS N
criterion POS N
of POS N
non-inferiority POS N
of POS N
brimonidine POS N
to POS N
timolol. POS N

although POS N
its POS N
IOP-lowering POS N
effect POS N
was POS N
inferior POS N
to POS N
topical POS N
timolol POS N
as POS N
monotherapy. POS N

The POS N
95% POS N
confidence POS N
interval POS N
of POS N
the POS N
inter-group POS N
difference POS N
was POS N
greater POS N
than POS N
the POS N
pre-determined POS N
criterion POS N
of POS N
non-inferiority POS N
of POS N
brimonidine POS N
to POS N
timolol. POS N

The POS N
mean POS N
changes POS N
were POS N
-4.7 POS N
+/- POS N
2.1 POS N
(S. POS N
D.) POS N
in POS N
the POS N
timolol POS N
and POS N
-4.0 POS N
+/- POS N
2.0 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
(p POS N
= POS N
0.0138). POS N

The POS N
95% POS N
confidence POS N
interval POS N
of POS N
the POS N
inter-group POS N
difference POS N
was POS N
greater POS N
than POS N
the POS N
pre-determined POS N
criterion POS N
of POS N
non-inferiority POS N
of POS N
brimonidine POS N
to POS N
timolol. POS N

When POS N
added POS N
to POS N
PG POS N
analogues, POS N
the POS N
IOP-lowering POS N
effect POS N
of POS N
brimonidine POS N
(-2.9 POS N
+/- POS N
1.8 POS N
mmHg) POS N
was POS N
greater POS N
than POS N
that POS N
of POS N
the POS N
placebo POS N
(-2.1 POS N
+/- POS N
1.8 POS N
mmHg) POS N
(p POS N
= POS N
0.0010). POS N

When POS N
added POS N
to POS N
PG POS N
analogues, POS N
the POS N
IOP-lowering POS N
effect POS N
of POS N
brimonidine POS N
(-2.9 POS N
+/- POS N
1.8 POS N
mmHg) POS N
was POS N
greater POS N
than POS N
that POS N
of POS N
the POS N
placebo POS N
(-2.1 POS N
+/- POS N
1.8 POS N
mmHg) POS N
(p POS N
= POS N
0.0010). POS N

Topical POS N
brimonidine POS N
showed POS N
an POS N
additive POS N
IOP-lowering POS N
effect POS N
to POS N
topical POS N
PG POS N
analogues, POS N

When POS N
added POS N
to POS N
PG POS N
analogues, POS N
the POS N
IOP-lowering POS N
effect POS N
of POS N
brimonidine POS N
(-2.9 POS N
+/- POS N
1.8 POS N
mmHg) POS N
was POS N
greater POS N
than POS N
that POS N
of POS N
the POS N
placebo POS N
(-2.1 POS N
+/- POS N
1.8 POS N
mmHg) POS N
(p POS N
= POS N
0.0010). POS N

although POS N
its POS N
IOP-lowering POS N
effect POS N
was POS N
inferior POS N
to POS N
topical POS N
timolol POS N
as POS N
monotherapy. POS N

When POS N
added POS N
to POS N
PG POS N
analogues, POS N
the POS N
IOP-lowering POS N
effect POS N
of POS N
brimonidine POS N
(-2.9 POS N
+/- POS N
1.8 POS N
mmHg) POS N
was POS N
greater POS N
than POS N
that POS N
of POS N
the POS N
placebo POS N
(-2.1 POS N
+/- POS N
1.8 POS N
mmHg) POS N
(p POS N
= POS N
0.0010). POS N

The POS N
mean POS N
changes POS N
were POS N
-4.7 POS N
+/- POS N
2.1 POS N
(S. POS N
D.) POS N
in POS N
the POS N
timolol POS N
and POS N
-4.0 POS N
+/- POS N
2.0 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
(p POS N
= POS N
0.0138). POS N

When POS N
added POS N
to POS N
PG POS N
analogues, POS N
the POS N
IOP-lowering POS N
effect POS N
of POS N
brimonidine POS N
(-2.9 POS N
+/- POS N
1.8 POS N
mmHg) POS N
was POS N
greater POS N
than POS N
that POS N
of POS N
the POS N
placebo POS N
(-2.1 POS N
+/- POS N
1.8 POS N
mmHg) POS N
(p POS N
= POS N
0.0010). POS N

The POS N
95% POS N
confidence POS N
interval POS N
of POS N
the POS N
inter-group POS N
difference POS N
was POS N
greater POS N
than POS N
the POS N
pre-determined POS N
criterion POS N
of POS N
non-inferiority POS N
of POS N
brimonidine POS N
to POS N
timolol. POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

After POS N
a POS N
mean POS N
follow-up POS N
period POS N
of POS N
96 POS N
weeks, POS N
the POS N
proportion POS N
of POS N
HBV POS N
reactivation POS N
observed POS N
was POS N
6.8% POS N
(4/58) POS N
in POS N
the POS N
LAM+ADV POS N
group POS N
and POS N
4.5% POS N
(5/111) POS N
in POS N
the POS N
TDF POS N
group POS N
by POS N
using POS N
intention-to-treat POS N
analysis POS N
(difference, POS N
-2.3%; POS N
95% POS N
CI, POS N
-9.84-5.24%). POS N

None POS N
of POS N
the POS N
subjects POS N
in POS N
either POS N
group POS N
experienced POS N
viral POS N
reactivation POS N
based POS N
on POS N
per POS N
protocol POS N
analysis. POS N

After POS N
a POS N
mean POS N
follow-up POS N
period POS N
of POS N
96 POS N
weeks, POS N
the POS N
proportion POS N
of POS N
HBV POS N
reactivation POS N
observed POS N
was POS N
6.8% POS N
(4/58) POS N
in POS N
the POS N
LAM+ADV POS N
group POS N
and POS N
4.5% POS N
(5/111) POS N
in POS N
the POS N
TDF POS N
group POS N
by POS N
using POS N
intention-to-treat POS N
analysis POS N
(difference, POS N
-2.3%; POS N
95% POS N
CI, POS N
-9.84-5.24%). POS N

No POS N
serious POS N
adverse POS N
reactions POS N
were POS N
observed. POS N

After POS N
a POS N
mean POS N
follow-up POS N
period POS N
of POS N
96 POS N
weeks, POS N
the POS N
proportion POS N
of POS N
HBV POS N
reactivation POS N
observed POS N
was POS N
6.8% POS N
(4/58) POS N
in POS N
the POS N
LAM+ADV POS N
group POS N
and POS N
4.5% POS N
(5/111) POS N
in POS N
the POS N
TDF POS N
group POS N
by POS N
using POS N
intention-to-treat POS N
analysis POS N
(difference, POS N
-2.3%; POS N
95% POS N
CI, POS N
-9.84-5.24%). POS N

In POS N
the POS N
subgroup POS N
analysis POS N
for POS N
estimated POS N
glomerular POS N
filtration POS N
rate POS N
(eGFR) POS N
before POS N
and POS N
after POS N
treatment, POS N
decreased POS N
eGFR POS N
was POS N
observed POS N
only POS N
in POS N
the POS N
TDF POS N
group POS N
with POS N
cirrhosis POS N
(85.22 POS N
vs. POS N
79.83 POS N
mL/min/1.73 POS N
m2, POS N
p POS N
= POS N
0.000). POS N

After POS N
a POS N
mean POS N
follow-up POS N
period POS N
of POS N
96 POS N
weeks, POS N
the POS N
proportion POS N
of POS N
HBV POS N
reactivation POS N
observed POS N
was POS N
6.8% POS N
(4/58) POS N
in POS N
the POS N
LAM+ADV POS N
group POS N
and POS N
4.5% POS N
(5/111) POS N
in POS N
the POS N
TDF POS N
group POS N
by POS N
using POS N
intention-to-treat POS N
analysis POS N
(difference, POS N
-2.3%; POS N
95% POS N
CI, POS N
-9.84-5.24%). POS N

Stable POS N
switching POS N
to POS N
TDF POS N
monotherapy POS N
yielded POS N
non-inferior POS N
results POS N
at POS N
96 POS N
weeks POS N
compared POS N
to POS N
the POS N
results POS N
obtained POS N
with POS N
LAM+ADV POS N
combination POS N
therapy POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
CHB POS N
and POS N
undetectable POS N
HBV POS N
DNA. POS N

After POS N
a POS N
mean POS N
follow-up POS N
period POS N
of POS N
96 POS N
weeks, POS N
the POS N
proportion POS N
of POS N
HBV POS N
reactivation POS N
observed POS N
was POS N
6.8% POS N
(4/58) POS N
in POS N
the POS N
LAM+ADV POS N
group POS N
and POS N
4.5% POS N
(5/111) POS N
in POS N
the POS N
TDF POS N
group POS N
by POS N
using POS N
intention-to-treat POS N
analysis POS N
(difference, POS N
-2.3%; POS N
95% POS N
CI, POS N
-9.84-5.24%). POS N

However, POS N
TDF POS N
monotherapy POS N
in POS N
patients POS N
with POS N
cirrhosis POS N
requires POS N
close POS N
attention POS N
with POS N
respect POS N
to POS N
renal POS N
function. POS N

After POS N
a POS N
mean POS N
follow-up POS N
period POS N
of POS N
96 POS N
weeks, POS N
the POS N
proportion POS N
of POS N
HBV POS N
reactivation POS N
observed POS N
was POS N
6.8% POS N
(4/58) POS N
in POS N
the POS N
LAM+ADV POS N
group POS N
and POS N
4.5% POS N
(5/111) POS N
in POS N
the POS N
TDF POS N
group POS N
by POS N
using POS N
intention-to-treat POS N
analysis POS N
(difference, POS N
-2.3%; POS N
95% POS N
CI, POS N
-9.84-5.24%). POS N

The POS N
efficacy POS N
of POS N
switching POS N
to POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
from POS N
lamivudine POS N
(LAM) POS N
plus POS N
adefovir POS N
dipivoxil POS N
(ADV) POS N
combination POS N
therapy POS N
(stable POS N
switching) POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
chronic POS N
hepatitis POS N
B POS N
(CHB) POS N
and POS N
undetectable POS N
hepatitis POS N
B POS N
virus POS N
(HBV) POS N
DNA POS N
is POS N
not POS N
clear. POS N

None POS N
of POS N
the POS N
subjects POS N
in POS N
either POS N
group POS N
experienced POS N
viral POS N
reactivation POS N
based POS N
on POS N
per POS N
protocol POS N
analysis. POS N

After POS N
a POS N
mean POS N
follow-up POS N
period POS N
of POS N
96 POS N
weeks, POS N
the POS N
proportion POS N
of POS N
HBV POS N
reactivation POS N
observed POS N
was POS N
6.8% POS N
(4/58) POS N
in POS N
the POS N
LAM+ADV POS N
group POS N
and POS N
4.5% POS N
(5/111) POS N
in POS N
the POS N
TDF POS N
group POS N
by POS N
using POS N
intention-to-treat POS N
analysis POS N
(difference, POS N
-2.3%; POS N
95% POS N
CI, POS N
-9.84-5.24%). POS N

None POS N
of POS N
the POS N
subjects POS N
in POS N
either POS N
group POS N
experienced POS N
viral POS N
reactivation POS N
based POS N
on POS N
per POS N
protocol POS N
analysis. POS N

No POS N
serious POS N
adverse POS N
reactions POS N
were POS N
observed. POS N

None POS N
of POS N
the POS N
subjects POS N
in POS N
either POS N
group POS N
experienced POS N
viral POS N
reactivation POS N
based POS N
on POS N
per POS N
protocol POS N
analysis. POS N

In POS N
the POS N
subgroup POS N
analysis POS N
for POS N
estimated POS N
glomerular POS N
filtration POS N
rate POS N
(eGFR) POS N
before POS N
and POS N
after POS N
treatment, POS N
decreased POS N
eGFR POS N
was POS N
observed POS N
only POS N
in POS N
the POS N
TDF POS N
group POS N
with POS N
cirrhosis POS N
(85.22 POS N
vs. POS N
79.83 POS N
mL/min/1.73 POS N
m2, POS N
p POS N
= POS N
0.000). POS N

None POS N
of POS N
the POS N
subjects POS N
in POS N
either POS N
group POS N
experienced POS N
viral POS N
reactivation POS N
based POS N
on POS N
per POS N
protocol POS N
analysis. POS N

Stable POS N
switching POS N
to POS N
TDF POS N
monotherapy POS N
yielded POS N
non-inferior POS N
results POS N
at POS N
96 POS N
weeks POS N
compared POS N
to POS N
the POS N
results POS N
obtained POS N
with POS N
LAM+ADV POS N
combination POS N
therapy POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
CHB POS N
and POS N
undetectable POS N
HBV POS N
DNA. POS N

None POS N
of POS N
the POS N
subjects POS N
in POS N
either POS N
group POS N
experienced POS N
viral POS N
reactivation POS N
based POS N
on POS N
per POS N
protocol POS N
analysis. POS N

However, POS N
TDF POS N
monotherapy POS N
in POS N
patients POS N
with POS N
cirrhosis POS N
requires POS N
close POS N
attention POS N
with POS N
respect POS N
to POS N
renal POS N
function. POS N

None POS N
of POS N
the POS N
subjects POS N
in POS N
either POS N
group POS N
experienced POS N
viral POS N
reactivation POS N
based POS N
on POS N
per POS N
protocol POS N
analysis. POS N

The POS N
efficacy POS N
of POS N
switching POS N
to POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
from POS N
lamivudine POS N
(LAM) POS N
plus POS N
adefovir POS N
dipivoxil POS N
(ADV) POS N
combination POS N
therapy POS N
(stable POS N
switching) POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
chronic POS N
hepatitis POS N
B POS N
(CHB) POS N
and POS N
undetectable POS N
hepatitis POS N
B POS N
virus POS N
(HBV) POS N
DNA POS N
is POS N
not POS N
clear. POS N

No POS N
serious POS N
adverse POS N
reactions POS N
were POS N
observed. POS N

After POS N
a POS N
mean POS N
follow-up POS N
period POS N
of POS N
96 POS N
weeks, POS N
the POS N
proportion POS N
of POS N
HBV POS N
reactivation POS N
observed POS N
was POS N
6.8% POS N
(4/58) POS N
in POS N
the POS N
LAM+ADV POS N
group POS N
and POS N
4.5% POS N
(5/111) POS N
in POS N
the POS N
TDF POS N
group POS N
by POS N
using POS N
intention-to-treat POS N
analysis POS N
(difference, POS N
-2.3%; POS N
95% POS N
CI, POS N
-9.84-5.24%). POS N

No POS N
serious POS N
adverse POS N
reactions POS N
were POS N
observed. POS N

None POS N
of POS N
the POS N
subjects POS N
in POS N
either POS N
group POS N
experienced POS N
viral POS N
reactivation POS N
based POS N
on POS N
per POS N
protocol POS N
analysis. POS N

No POS N
serious POS N
adverse POS N
reactions POS N
were POS N
observed. POS N

In POS N
the POS N
subgroup POS N
analysis POS N
for POS N
estimated POS N
glomerular POS N
filtration POS N
rate POS N
(eGFR) POS N
before POS N
and POS N
after POS N
treatment, POS N
decreased POS N
eGFR POS N
was POS N
observed POS N
only POS N
in POS N
the POS N
TDF POS N
group POS N
with POS N
cirrhosis POS N
(85.22 POS N
vs. POS N
79.83 POS N
mL/min/1.73 POS N
m2, POS N
p POS N
= POS N
0.000). POS N

No POS N
serious POS N
adverse POS N
reactions POS N
were POS N
observed. POS N

Stable POS N
switching POS N
to POS N
TDF POS N
monotherapy POS N
yielded POS N
non-inferior POS N
results POS N
at POS N
96 POS N
weeks POS N
compared POS N
to POS N
the POS N
results POS N
obtained POS N
with POS N
LAM+ADV POS N
combination POS N
therapy POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
CHB POS N
and POS N
undetectable POS N
HBV POS N
DNA. POS N

No POS N
serious POS N
adverse POS N
reactions POS N
were POS N
observed. POS N

However, POS N
TDF POS N
monotherapy POS N
in POS N
patients POS N
with POS N
cirrhosis POS N
requires POS N
close POS N
attention POS N
with POS N
respect POS N
to POS N
renal POS N
function. POS N

No POS N
serious POS N
adverse POS N
reactions POS N
were POS N
observed. POS N

The POS N
efficacy POS N
of POS N
switching POS N
to POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
from POS N
lamivudine POS N
(LAM) POS N
plus POS N
adefovir POS N
dipivoxil POS N
(ADV) POS N
combination POS N
therapy POS N
(stable POS N
switching) POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
chronic POS N
hepatitis POS N
B POS N
(CHB) POS N
and POS N
undetectable POS N
hepatitis POS N
B POS N
virus POS N
(HBV) POS N
DNA POS N
is POS N
not POS N
clear. POS N

In POS N
the POS N
subgroup POS N
analysis POS N
for POS N
estimated POS N
glomerular POS N
filtration POS N
rate POS N
(eGFR) POS N
before POS N
and POS N
after POS N
treatment, POS N
decreased POS N
eGFR POS N
was POS N
observed POS N
only POS N
in POS N
the POS N
TDF POS N
group POS N
with POS N
cirrhosis POS N
(85.22 POS N
vs. POS N
79.83 POS N
mL/min/1.73 POS N
m2, POS N
p POS N
= POS N
0.000). POS N

After POS N
a POS N
mean POS N
follow-up POS N
period POS N
of POS N
96 POS N
weeks, POS N
the POS N
proportion POS N
of POS N
HBV POS N
reactivation POS N
observed POS N
was POS N
6.8% POS N
(4/58) POS N
in POS N
the POS N
LAM+ADV POS N
group POS N
and POS N
4.5% POS N
(5/111) POS N
in POS N
the POS N
TDF POS N
group POS N
by POS N
using POS N
intention-to-treat POS N
analysis POS N
(difference, POS N
-2.3%; POS N
95% POS N
CI, POS N
-9.84-5.24%). POS N

In POS N
the POS N
subgroup POS N
analysis POS N
for POS N
estimated POS N
glomerular POS N
filtration POS N
rate POS N
(eGFR) POS N
before POS N
and POS N
after POS N
treatment, POS N
decreased POS N
eGFR POS N
was POS N
observed POS N
only POS N
in POS N
the POS N
TDF POS N
group POS N
with POS N
cirrhosis POS N
(85.22 POS N
vs. POS N
79.83 POS N
mL/min/1.73 POS N
m2, POS N
p POS N
= POS N
0.000). POS N

None POS N
of POS N
the POS N
subjects POS N
in POS N
either POS N
group POS N
experienced POS N
viral POS N
reactivation POS N
based POS N
on POS N
per POS N
protocol POS N
analysis. POS N

In POS N
the POS N
subgroup POS N
analysis POS N
for POS N
estimated POS N
glomerular POS N
filtration POS N
rate POS N
(eGFR) POS N
before POS N
and POS N
after POS N
treatment, POS N
decreased POS N
eGFR POS N
was POS N
observed POS N
only POS N
in POS N
the POS N
TDF POS N
group POS N
with POS N
cirrhosis POS N
(85.22 POS N
vs. POS N
79.83 POS N
mL/min/1.73 POS N
m2, POS N
p POS N
= POS N
0.000). POS N

No POS N
serious POS N
adverse POS N
reactions POS N
were POS N
observed. POS N

In POS N
the POS N
subgroup POS N
analysis POS N
for POS N
estimated POS N
glomerular POS N
filtration POS N
rate POS N
(eGFR) POS N
before POS N
and POS N
after POS N
treatment, POS N
decreased POS N
eGFR POS N
was POS N
observed POS N
only POS N
in POS N
the POS N
TDF POS N
group POS N
with POS N
cirrhosis POS N
(85.22 POS N
vs. POS N
79.83 POS N
mL/min/1.73 POS N
m2, POS N
p POS N
= POS N
0.000). POS N

Stable POS N
switching POS N
to POS N
TDF POS N
monotherapy POS N
yielded POS N
non-inferior POS N
results POS N
at POS N
96 POS N
weeks POS N
compared POS N
to POS N
the POS N
results POS N
obtained POS N
with POS N
LAM+ADV POS N
combination POS N
therapy POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
CHB POS N
and POS N
undetectable POS N
HBV POS N
DNA. POS N

In POS N
the POS N
subgroup POS N
analysis POS N
for POS N
estimated POS N
glomerular POS N
filtration POS N
rate POS N
(eGFR) POS N
before POS N
and POS N
after POS N
treatment, POS N
decreased POS N
eGFR POS N
was POS N
observed POS N
only POS N
in POS N
the POS N
TDF POS N
group POS N
with POS N
cirrhosis POS N
(85.22 POS N
vs. POS N
79.83 POS N
mL/min/1.73 POS N
m2, POS N
p POS N
= POS N
0.000). POS N

However, POS N
TDF POS N
monotherapy POS N
in POS N
patients POS N
with POS N
cirrhosis POS N
requires POS N
close POS N
attention POS N
with POS N
respect POS N
to POS N
renal POS N
function. POS N

In POS N
the POS N
subgroup POS N
analysis POS N
for POS N
estimated POS N
glomerular POS N
filtration POS N
rate POS N
(eGFR) POS N
before POS N
and POS N
after POS N
treatment, POS N
decreased POS N
eGFR POS N
was POS N
observed POS N
only POS N
in POS N
the POS N
TDF POS N
group POS N
with POS N
cirrhosis POS N
(85.22 POS N
vs. POS N
79.83 POS N
mL/min/1.73 POS N
m2, POS N
p POS N
= POS N
0.000). POS N

The POS N
efficacy POS N
of POS N
switching POS N
to POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
from POS N
lamivudine POS N
(LAM) POS N
plus POS N
adefovir POS N
dipivoxil POS N
(ADV) POS N
combination POS N
therapy POS N
(stable POS N
switching) POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
chronic POS N
hepatitis POS N
B POS N
(CHB) POS N
and POS N
undetectable POS N
hepatitis POS N
B POS N
virus POS N
(HBV) POS N
DNA POS N
is POS N
not POS N
clear. POS N

Stable POS N
switching POS N
to POS N
TDF POS N
monotherapy POS N
yielded POS N
non-inferior POS N
results POS N
at POS N
96 POS N
weeks POS N
compared POS N
to POS N
the POS N
results POS N
obtained POS N
with POS N
LAM+ADV POS N
combination POS N
therapy POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
CHB POS N
and POS N
undetectable POS N
HBV POS N
DNA. POS N

After POS N
a POS N
mean POS N
follow-up POS N
period POS N
of POS N
96 POS N
weeks, POS N
the POS N
proportion POS N
of POS N
HBV POS N
reactivation POS N
observed POS N
was POS N
6.8% POS N
(4/58) POS N
in POS N
the POS N
LAM+ADV POS N
group POS N
and POS N
4.5% POS N
(5/111) POS N
in POS N
the POS N
TDF POS N
group POS N
by POS N
using POS N
intention-to-treat POS N
analysis POS N
(difference, POS N
-2.3%; POS N
95% POS N
CI, POS N
-9.84-5.24%). POS N

Stable POS N
switching POS N
to POS N
TDF POS N
monotherapy POS N
yielded POS N
non-inferior POS N
results POS N
at POS N
96 POS N
weeks POS N
compared POS N
to POS N
the POS N
results POS N
obtained POS N
with POS N
LAM+ADV POS N
combination POS N
therapy POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
CHB POS N
and POS N
undetectable POS N
HBV POS N
DNA. POS N

None POS N
of POS N
the POS N
subjects POS N
in POS N
either POS N
group POS N
experienced POS N
viral POS N
reactivation POS N
based POS N
on POS N
per POS N
protocol POS N
analysis. POS N

Stable POS N
switching POS N
to POS N
TDF POS N
monotherapy POS N
yielded POS N
non-inferior POS N
results POS N
at POS N
96 POS N
weeks POS N
compared POS N
to POS N
the POS N
results POS N
obtained POS N
with POS N
LAM+ADV POS N
combination POS N
therapy POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
CHB POS N
and POS N
undetectable POS N
HBV POS N
DNA. POS N

No POS N
serious POS N
adverse POS N
reactions POS N
were POS N
observed. POS N

Stable POS N
switching POS N
to POS N
TDF POS N
monotherapy POS N
yielded POS N
non-inferior POS N
results POS N
at POS N
96 POS N
weeks POS N
compared POS N
to POS N
the POS N
results POS N
obtained POS N
with POS N
LAM+ADV POS N
combination POS N
therapy POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
CHB POS N
and POS N
undetectable POS N
HBV POS N
DNA. POS N

In POS N
the POS N
subgroup POS N
analysis POS N
for POS N
estimated POS N
glomerular POS N
filtration POS N
rate POS N
(eGFR) POS N
before POS N
and POS N
after POS N
treatment, POS N
decreased POS N
eGFR POS N
was POS N
observed POS N
only POS N
in POS N
the POS N
TDF POS N
group POS N
with POS N
cirrhosis POS N
(85.22 POS N
vs. POS N
79.83 POS N
mL/min/1.73 POS N
m2, POS N
p POS N
= POS N
0.000). POS N

Stable POS N
switching POS N
to POS N
TDF POS N
monotherapy POS N
yielded POS N
non-inferior POS N
results POS N
at POS N
96 POS N
weeks POS N
compared POS N
to POS N
the POS N
results POS N
obtained POS N
with POS N
LAM+ADV POS N
combination POS N
therapy POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
CHB POS N
and POS N
undetectable POS N
HBV POS N
DNA. POS N

However, POS N
TDF POS N
monotherapy POS N
in POS N
patients POS N
with POS N
cirrhosis POS N
requires POS N
close POS N
attention POS N
with POS N
respect POS N
to POS N
renal POS N
function. POS N

Stable POS N
switching POS N
to POS N
TDF POS N
monotherapy POS N
yielded POS N
non-inferior POS N
results POS N
at POS N
96 POS N
weeks POS N
compared POS N
to POS N
the POS N
results POS N
obtained POS N
with POS N
LAM+ADV POS N
combination POS N
therapy POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
CHB POS N
and POS N
undetectable POS N
HBV POS N
DNA. POS N

The POS N
efficacy POS N
of POS N
switching POS N
to POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
from POS N
lamivudine POS N
(LAM) POS N
plus POS N
adefovir POS N
dipivoxil POS N
(ADV) POS N
combination POS N
therapy POS N
(stable POS N
switching) POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
chronic POS N
hepatitis POS N
B POS N
(CHB) POS N
and POS N
undetectable POS N
hepatitis POS N
B POS N
virus POS N
(HBV) POS N
DNA POS N
is POS N
not POS N
clear. POS N

However, POS N
TDF POS N
monotherapy POS N
in POS N
patients POS N
with POS N
cirrhosis POS N
requires POS N
close POS N
attention POS N
with POS N
respect POS N
to POS N
renal POS N
function. POS N

After POS N
a POS N
mean POS N
follow-up POS N
period POS N
of POS N
96 POS N
weeks, POS N
the POS N
proportion POS N
of POS N
HBV POS N
reactivation POS N
observed POS N
was POS N
6.8% POS N
(4/58) POS N
in POS N
the POS N
LAM+ADV POS N
group POS N
and POS N
4.5% POS N
(5/111) POS N
in POS N
the POS N
TDF POS N
group POS N
by POS N
using POS N
intention-to-treat POS N
analysis POS N
(difference, POS N
-2.3%; POS N
95% POS N
CI, POS N
-9.84-5.24%). POS N

However, POS N
TDF POS N
monotherapy POS N
in POS N
patients POS N
with POS N
cirrhosis POS N
requires POS N
close POS N
attention POS N
with POS N
respect POS N
to POS N
renal POS N
function. POS N

None POS N
of POS N
the POS N
subjects POS N
in POS N
either POS N
group POS N
experienced POS N
viral POS N
reactivation POS N
based POS N
on POS N
per POS N
protocol POS N
analysis. POS N

However, POS N
TDF POS N
monotherapy POS N
in POS N
patients POS N
with POS N
cirrhosis POS N
requires POS N
close POS N
attention POS N
with POS N
respect POS N
to POS N
renal POS N
function. POS N

No POS N
serious POS N
adverse POS N
reactions POS N
were POS N
observed. POS N

However, POS N
TDF POS N
monotherapy POS N
in POS N
patients POS N
with POS N
cirrhosis POS N
requires POS N
close POS N
attention POS N
with POS N
respect POS N
to POS N
renal POS N
function. POS N

In POS N
the POS N
subgroup POS N
analysis POS N
for POS N
estimated POS N
glomerular POS N
filtration POS N
rate POS N
(eGFR) POS N
before POS N
and POS N
after POS N
treatment, POS N
decreased POS N
eGFR POS N
was POS N
observed POS N
only POS N
in POS N
the POS N
TDF POS N
group POS N
with POS N
cirrhosis POS N
(85.22 POS N
vs. POS N
79.83 POS N
mL/min/1.73 POS N
m2, POS N
p POS N
= POS N
0.000). POS N

However, POS N
TDF POS N
monotherapy POS N
in POS N
patients POS N
with POS N
cirrhosis POS N
requires POS N
close POS N
attention POS N
with POS N
respect POS N
to POS N
renal POS N
function. POS N

Stable POS N
switching POS N
to POS N
TDF POS N
monotherapy POS N
yielded POS N
non-inferior POS N
results POS N
at POS N
96 POS N
weeks POS N
compared POS N
to POS N
the POS N
results POS N
obtained POS N
with POS N
LAM+ADV POS N
combination POS N
therapy POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
CHB POS N
and POS N
undetectable POS N
HBV POS N
DNA. POS N

However, POS N
TDF POS N
monotherapy POS N
in POS N
patients POS N
with POS N
cirrhosis POS N
requires POS N
close POS N
attention POS N
with POS N
respect POS N
to POS N
renal POS N
function. POS N

The POS N
efficacy POS N
of POS N
switching POS N
to POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
from POS N
lamivudine POS N
(LAM) POS N
plus POS N
adefovir POS N
dipivoxil POS N
(ADV) POS N
combination POS N
therapy POS N
(stable POS N
switching) POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
chronic POS N
hepatitis POS N
B POS N
(CHB) POS N
and POS N
undetectable POS N
hepatitis POS N
B POS N
virus POS N
(HBV) POS N
DNA POS N
is POS N
not POS N
clear. POS N

The POS N
efficacy POS N
of POS N
switching POS N
to POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
from POS N
lamivudine POS N
(LAM) POS N
plus POS N
adefovir POS N
dipivoxil POS N
(ADV) POS N
combination POS N
therapy POS N
(stable POS N
switching) POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
chronic POS N
hepatitis POS N
B POS N
(CHB) POS N
and POS N
undetectable POS N
hepatitis POS N
B POS N
virus POS N
(HBV) POS N
DNA POS N
is POS N
not POS N
clear. POS N

After POS N
a POS N
mean POS N
follow-up POS N
period POS N
of POS N
96 POS N
weeks, POS N
the POS N
proportion POS N
of POS N
HBV POS N
reactivation POS N
observed POS N
was POS N
6.8% POS N
(4/58) POS N
in POS N
the POS N
LAM+ADV POS N
group POS N
and POS N
4.5% POS N
(5/111) POS N
in POS N
the POS N
TDF POS N
group POS N
by POS N
using POS N
intention-to-treat POS N
analysis POS N
(difference, POS N
-2.3%; POS N
95% POS N
CI, POS N
-9.84-5.24%). POS N

The POS N
efficacy POS N
of POS N
switching POS N
to POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
from POS N
lamivudine POS N
(LAM) POS N
plus POS N
adefovir POS N
dipivoxil POS N
(ADV) POS N
combination POS N
therapy POS N
(stable POS N
switching) POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
chronic POS N
hepatitis POS N
B POS N
(CHB) POS N
and POS N
undetectable POS N
hepatitis POS N
B POS N
virus POS N
(HBV) POS N
DNA POS N
is POS N
not POS N
clear. POS N

None POS N
of POS N
the POS N
subjects POS N
in POS N
either POS N
group POS N
experienced POS N
viral POS N
reactivation POS N
based POS N
on POS N
per POS N
protocol POS N
analysis. POS N

The POS N
efficacy POS N
of POS N
switching POS N
to POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
from POS N
lamivudine POS N
(LAM) POS N
plus POS N
adefovir POS N
dipivoxil POS N
(ADV) POS N
combination POS N
therapy POS N
(stable POS N
switching) POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
chronic POS N
hepatitis POS N
B POS N
(CHB) POS N
and POS N
undetectable POS N
hepatitis POS N
B POS N
virus POS N
(HBV) POS N
DNA POS N
is POS N
not POS N
clear. POS N

No POS N
serious POS N
adverse POS N
reactions POS N
were POS N
observed. POS N

The POS N
efficacy POS N
of POS N
switching POS N
to POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
from POS N
lamivudine POS N
(LAM) POS N
plus POS N
adefovir POS N
dipivoxil POS N
(ADV) POS N
combination POS N
therapy POS N
(stable POS N
switching) POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
chronic POS N
hepatitis POS N
B POS N
(CHB) POS N
and POS N
undetectable POS N
hepatitis POS N
B POS N
virus POS N
(HBV) POS N
DNA POS N
is POS N
not POS N
clear. POS N

In POS N
the POS N
subgroup POS N
analysis POS N
for POS N
estimated POS N
glomerular POS N
filtration POS N
rate POS N
(eGFR) POS N
before POS N
and POS N
after POS N
treatment, POS N
decreased POS N
eGFR POS N
was POS N
observed POS N
only POS N
in POS N
the POS N
TDF POS N
group POS N
with POS N
cirrhosis POS N
(85.22 POS N
vs. POS N
79.83 POS N
mL/min/1.73 POS N
m2, POS N
p POS N
= POS N
0.000). POS N

The POS N
efficacy POS N
of POS N
switching POS N
to POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
from POS N
lamivudine POS N
(LAM) POS N
plus POS N
adefovir POS N
dipivoxil POS N
(ADV) POS N
combination POS N
therapy POS N
(stable POS N
switching) POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
chronic POS N
hepatitis POS N
B POS N
(CHB) POS N
and POS N
undetectable POS N
hepatitis POS N
B POS N
virus POS N
(HBV) POS N
DNA POS N
is POS N
not POS N
clear. POS N

Stable POS N
switching POS N
to POS N
TDF POS N
monotherapy POS N
yielded POS N
non-inferior POS N
results POS N
at POS N
96 POS N
weeks POS N
compared POS N
to POS N
the POS N
results POS N
obtained POS N
with POS N
LAM+ADV POS N
combination POS N
therapy POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
CHB POS N
and POS N
undetectable POS N
HBV POS N
DNA. POS N

The POS N
efficacy POS N
of POS N
switching POS N
to POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
from POS N
lamivudine POS N
(LAM) POS N
plus POS N
adefovir POS N
dipivoxil POS N
(ADV) POS N
combination POS N
therapy POS N
(stable POS N
switching) POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
chronic POS N
hepatitis POS N
B POS N
(CHB) POS N
and POS N
undetectable POS N
hepatitis POS N
B POS N
virus POS N
(HBV) POS N
DNA POS N
is POS N
not POS N
clear. POS N

However, POS N
TDF POS N
monotherapy POS N
in POS N
patients POS N
with POS N
cirrhosis POS N
requires POS N
close POS N
attention POS N
with POS N
respect POS N
to POS N
renal POS N
function. POS N

Ocular POS N
irritation POS N
was POS N
frequently POS N
seen POS N
in POS N
DTFC POS N
group. POS N

Intra-ocular POS N
pressure POS N
(IOP) POS N
change POS N
from POS N
baseline POS N
at POS N
9 POS N
AM/11 POS N
AM POS N
pooled POS N
over POS N
the POS N
8 POS N
weeks POS N
was POS N
-3.3/-3.3 POS N
mmHg POS N
in POS N
the POS N
BTFC POS N
group POS N
and POS N
-2.9/-3.4 POS N
mmHg POS N
in POS N
the POS N
DTFC POS N
group, POS N

Ocular POS N
irritation POS N
was POS N
frequently POS N
seen POS N
in POS N
DTFC POS N
group. POS N

blurred POS N
vision POS N
was POS N
frequently POS N
seen POS N
in POS N
BTFC POS N
group, POS N

Ocular POS N
irritation POS N
was POS N
frequently POS N
seen POS N
in POS N
DTFC POS N
group. POS N

Non-inferiority POS N
of POS N
BTFC POS N
to POS N
DTFC POS N
in POS N
IOP POS N
reduction POS N
was POS N
demonstrated POS N
after POS N
adding POS N
onto POS N
PGA POS N
therapy POS N
in POS N
Japanese POS N
OAG/OH POS N
patients. POS N

Ocular POS N
irritation POS N
was POS N
frequently POS N
seen POS N
in POS N
DTFC POS N
group. POS N

the POS N
score POS N
of POS N
blurred POS N
vision POS N
was POS N
transiently POS N
higher POS N
in POS N
BTFC POS N
than POS N
DTFC, POS N

Ocular POS N
irritation POS N
was POS N
frequently POS N
seen POS N
in POS N
DTFC POS N
group. POS N

BTFC POS N
can POS N
be POS N
considered POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
agent POS N
for POS N
glaucoma POS N
treatment. POS N

Ocular POS N
irritation POS N
was POS N
frequently POS N
seen POS N
in POS N
DTFC POS N
group. POS N

treatment POS N
difference POS N
decreased POS N
and POS N
disappeared POS N
with POS N
time. POS N

Ocular POS N
irritation POS N
was POS N
frequently POS N
seen POS N
in POS N
DTFC POS N
group. POS N

No POS N
noteworthy POS N
issue POS N
was POS N
observed POS N
in POS N
other POS N
safety POS N
outcome. POS N

Intra-ocular POS N
pressure POS N
(IOP) POS N
change POS N
from POS N
baseline POS N
at POS N
9 POS N
AM/11 POS N
AM POS N
pooled POS N
over POS N
the POS N
8 POS N
weeks POS N
was POS N
-3.3/-3.3 POS N
mmHg POS N
in POS N
the POS N
BTFC POS N
group POS N
and POS N
-2.9/-3.4 POS N
mmHg POS N
in POS N
the POS N
DTFC POS N
group, POS N

Ocular POS N
irritation POS N
was POS N
frequently POS N
seen POS N
in POS N
DTFC POS N
group. POS N

Intra-ocular POS N
pressure POS N
(IOP) POS N
change POS N
from POS N
baseline POS N
at POS N
9 POS N
AM/11 POS N
AM POS N
pooled POS N
over POS N
the POS N
8 POS N
weeks POS N
was POS N
-3.3/-3.3 POS N
mmHg POS N
in POS N
the POS N
BTFC POS N
group POS N
and POS N
-2.9/-3.4 POS N
mmHg POS N
in POS N
the POS N
DTFC POS N
group, POS N

blurred POS N
vision POS N
was POS N
frequently POS N
seen POS N
in POS N
BTFC POS N
group, POS N

Intra-ocular POS N
pressure POS N
(IOP) POS N
change POS N
from POS N
baseline POS N
at POS N
9 POS N
AM/11 POS N
AM POS N
pooled POS N
over POS N
the POS N
8 POS N
weeks POS N
was POS N
-3.3/-3.3 POS N
mmHg POS N
in POS N
the POS N
BTFC POS N
group POS N
and POS N
-2.9/-3.4 POS N
mmHg POS N
in POS N
the POS N
DTFC POS N
group, POS N

Non-inferiority POS N
of POS N
BTFC POS N
to POS N
DTFC POS N
in POS N
IOP POS N
reduction POS N
was POS N
demonstrated POS N
after POS N
adding POS N
onto POS N
PGA POS N
therapy POS N
in POS N
Japanese POS N
OAG/OH POS N
patients. POS N

Intra-ocular POS N
pressure POS N
(IOP) POS N
change POS N
from POS N
baseline POS N
at POS N
9 POS N
AM/11 POS N
AM POS N
pooled POS N
over POS N
the POS N
8 POS N
weeks POS N
was POS N
-3.3/-3.3 POS N
mmHg POS N
in POS N
the POS N
BTFC POS N
group POS N
and POS N
-2.9/-3.4 POS N
mmHg POS N
in POS N
the POS N
DTFC POS N
group, POS N

the POS N
score POS N
of POS N
blurred POS N
vision POS N
was POS N
transiently POS N
higher POS N
in POS N
BTFC POS N
than POS N
DTFC, POS N

Intra-ocular POS N
pressure POS N
(IOP) POS N
change POS N
from POS N
baseline POS N
at POS N
9 POS N
AM/11 POS N
AM POS N
pooled POS N
over POS N
the POS N
8 POS N
weeks POS N
was POS N
-3.3/-3.3 POS N
mmHg POS N
in POS N
the POS N
BTFC POS N
group POS N
and POS N
-2.9/-3.4 POS N
mmHg POS N
in POS N
the POS N
DTFC POS N
group, POS N

BTFC POS N
can POS N
be POS N
considered POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
agent POS N
for POS N
glaucoma POS N
treatment. POS N

Intra-ocular POS N
pressure POS N
(IOP) POS N
change POS N
from POS N
baseline POS N
at POS N
9 POS N
AM/11 POS N
AM POS N
pooled POS N
over POS N
the POS N
8 POS N
weeks POS N
was POS N
-3.3/-3.3 POS N
mmHg POS N
in POS N
the POS N
BTFC POS N
group POS N
and POS N
-2.9/-3.4 POS N
mmHg POS N
in POS N
the POS N
DTFC POS N
group, POS N

treatment POS N
difference POS N
decreased POS N
and POS N
disappeared POS N
with POS N
time. POS N

Intra-ocular POS N
pressure POS N
(IOP) POS N
change POS N
from POS N
baseline POS N
at POS N
9 POS N
AM/11 POS N
AM POS N
pooled POS N
over POS N
the POS N
8 POS N
weeks POS N
was POS N
-3.3/-3.3 POS N
mmHg POS N
in POS N
the POS N
BTFC POS N
group POS N
and POS N
-2.9/-3.4 POS N
mmHg POS N
in POS N
the POS N
DTFC POS N
group, POS N

No POS N
noteworthy POS N
issue POS N
was POS N
observed POS N
in POS N
other POS N
safety POS N
outcome. POS N

blurred POS N
vision POS N
was POS N
frequently POS N
seen POS N
in POS N
BTFC POS N
group, POS N

Ocular POS N
irritation POS N
was POS N
frequently POS N
seen POS N
in POS N
DTFC POS N
group. POS N

blurred POS N
vision POS N
was POS N
frequently POS N
seen POS N
in POS N
BTFC POS N
group, POS N

Intra-ocular POS N
pressure POS N
(IOP) POS N
change POS N
from POS N
baseline POS N
at POS N
9 POS N
AM/11 POS N
AM POS N
pooled POS N
over POS N
the POS N
8 POS N
weeks POS N
was POS N
-3.3/-3.3 POS N
mmHg POS N
in POS N
the POS N
BTFC POS N
group POS N
and POS N
-2.9/-3.4 POS N
mmHg POS N
in POS N
the POS N
DTFC POS N
group, POS N

blurred POS N
vision POS N
was POS N
frequently POS N
seen POS N
in POS N
BTFC POS N
group, POS N

Non-inferiority POS N
of POS N
BTFC POS N
to POS N
DTFC POS N
in POS N
IOP POS N
reduction POS N
was POS N
demonstrated POS N
after POS N
adding POS N
onto POS N
PGA POS N
therapy POS N
in POS N
Japanese POS N
OAG/OH POS N
patients. POS N

blurred POS N
vision POS N
was POS N
frequently POS N
seen POS N
in POS N
BTFC POS N
group, POS N

the POS N
score POS N
of POS N
blurred POS N
vision POS N
was POS N
transiently POS N
higher POS N
in POS N
BTFC POS N
than POS N
DTFC, POS N

blurred POS N
vision POS N
was POS N
frequently POS N
seen POS N
in POS N
BTFC POS N
group, POS N

BTFC POS N
can POS N
be POS N
considered POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
agent POS N
for POS N
glaucoma POS N
treatment. POS N

blurred POS N
vision POS N
was POS N
frequently POS N
seen POS N
in POS N
BTFC POS N
group, POS N

treatment POS N
difference POS N
decreased POS N
and POS N
disappeared POS N
with POS N
time. POS N

blurred POS N
vision POS N
was POS N
frequently POS N
seen POS N
in POS N
BTFC POS N
group, POS N

No POS N
noteworthy POS N
issue POS N
was POS N
observed POS N
in POS N
other POS N
safety POS N
outcome. POS N

Non-inferiority POS N
of POS N
BTFC POS N
to POS N
DTFC POS N
in POS N
IOP POS N
reduction POS N
was POS N
demonstrated POS N
after POS N
adding POS N
onto POS N
PGA POS N
therapy POS N
in POS N
Japanese POS N
OAG/OH POS N
patients. POS N

Ocular POS N
irritation POS N
was POS N
frequently POS N
seen POS N
in POS N
DTFC POS N
group. POS N

Non-inferiority POS N
of POS N
BTFC POS N
to POS N
DTFC POS N
in POS N
IOP POS N
reduction POS N
was POS N
demonstrated POS N
after POS N
adding POS N
onto POS N
PGA POS N
therapy POS N
in POS N
Japanese POS N
OAG/OH POS N
patients. POS N

Intra-ocular POS N
pressure POS N
(IOP) POS N
change POS N
from POS N
baseline POS N
at POS N
9 POS N
AM/11 POS N
AM POS N
pooled POS N
over POS N
the POS N
8 POS N
weeks POS N
was POS N
-3.3/-3.3 POS N
mmHg POS N
in POS N
the POS N
BTFC POS N
group POS N
and POS N
-2.9/-3.4 POS N
mmHg POS N
in POS N
the POS N
DTFC POS N
group, POS N

Non-inferiority POS N
of POS N
BTFC POS N
to POS N
DTFC POS N
in POS N
IOP POS N
reduction POS N
was POS N
demonstrated POS N
after POS N
adding POS N
onto POS N
PGA POS N
therapy POS N
in POS N
Japanese POS N
OAG/OH POS N
patients. POS N

blurred POS N
vision POS N
was POS N
frequently POS N
seen POS N
in POS N
BTFC POS N
group, POS N

Non-inferiority POS N
of POS N
BTFC POS N
to POS N
DTFC POS N
in POS N
IOP POS N
reduction POS N
was POS N
demonstrated POS N
after POS N
adding POS N
onto POS N
PGA POS N
therapy POS N
in POS N
Japanese POS N
OAG/OH POS N
patients. POS N

the POS N
score POS N
of POS N
blurred POS N
vision POS N
was POS N
transiently POS N
higher POS N
in POS N
BTFC POS N
than POS N
DTFC, POS N

Non-inferiority POS N
of POS N
BTFC POS N
to POS N
DTFC POS N
in POS N
IOP POS N
reduction POS N
was POS N
demonstrated POS N
after POS N
adding POS N
onto POS N
PGA POS N
therapy POS N
in POS N
Japanese POS N
OAG/OH POS N
patients. POS N

BTFC POS N
can POS N
be POS N
considered POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
agent POS N
for POS N
glaucoma POS N
treatment. POS N

Non-inferiority POS N
of POS N
BTFC POS N
to POS N
DTFC POS N
in POS N
IOP POS N
reduction POS N
was POS N
demonstrated POS N
after POS N
adding POS N
onto POS N
PGA POS N
therapy POS N
in POS N
Japanese POS N
OAG/OH POS N
patients. POS N

treatment POS N
difference POS N
decreased POS N
and POS N
disappeared POS N
with POS N
time. POS N

Non-inferiority POS N
of POS N
BTFC POS N
to POS N
DTFC POS N
in POS N
IOP POS N
reduction POS N
was POS N
demonstrated POS N
after POS N
adding POS N
onto POS N
PGA POS N
therapy POS N
in POS N
Japanese POS N
OAG/OH POS N
patients. POS N

No POS N
noteworthy POS N
issue POS N
was POS N
observed POS N
in POS N
other POS N
safety POS N
outcome. POS N

the POS N
score POS N
of POS N
blurred POS N
vision POS N
was POS N
transiently POS N
higher POS N
in POS N
BTFC POS N
than POS N
DTFC, POS N

Ocular POS N
irritation POS N
was POS N
frequently POS N
seen POS N
in POS N
DTFC POS N
group. POS N

the POS N
score POS N
of POS N
blurred POS N
vision POS N
was POS N
transiently POS N
higher POS N
in POS N
BTFC POS N
than POS N
DTFC, POS N

Intra-ocular POS N
pressure POS N
(IOP) POS N
change POS N
from POS N
baseline POS N
at POS N
9 POS N
AM/11 POS N
AM POS N
pooled POS N
over POS N
the POS N
8 POS N
weeks POS N
was POS N
-3.3/-3.3 POS N
mmHg POS N
in POS N
the POS N
BTFC POS N
group POS N
and POS N
-2.9/-3.4 POS N
mmHg POS N
in POS N
the POS N
DTFC POS N
group, POS N

the POS N
score POS N
of POS N
blurred POS N
vision POS N
was POS N
transiently POS N
higher POS N
in POS N
BTFC POS N
than POS N
DTFC, POS N

blurred POS N
vision POS N
was POS N
frequently POS N
seen POS N
in POS N
BTFC POS N
group, POS N

the POS N
score POS N
of POS N
blurred POS N
vision POS N
was POS N
transiently POS N
higher POS N
in POS N
BTFC POS N
than POS N
DTFC, POS N

Non-inferiority POS N
of POS N
BTFC POS N
to POS N
DTFC POS N
in POS N
IOP POS N
reduction POS N
was POS N
demonstrated POS N
after POS N
adding POS N
onto POS N
PGA POS N
therapy POS N
in POS N
Japanese POS N
OAG/OH POS N
patients. POS N

the POS N
score POS N
of POS N
blurred POS N
vision POS N
was POS N
transiently POS N
higher POS N
in POS N
BTFC POS N
than POS N
DTFC, POS N

BTFC POS N
can POS N
be POS N
considered POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
agent POS N
for POS N
glaucoma POS N
treatment. POS N

the POS N
score POS N
of POS N
blurred POS N
vision POS N
was POS N
transiently POS N
higher POS N
in POS N
BTFC POS N
than POS N
DTFC, POS N

treatment POS N
difference POS N
decreased POS N
and POS N
disappeared POS N
with POS N
time. POS N

the POS N
score POS N
of POS N
blurred POS N
vision POS N
was POS N
transiently POS N
higher POS N
in POS N
BTFC POS N
than POS N
DTFC, POS N

No POS N
noteworthy POS N
issue POS N
was POS N
observed POS N
in POS N
other POS N
safety POS N
outcome. POS N

BTFC POS N
can POS N
be POS N
considered POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
agent POS N
for POS N
glaucoma POS N
treatment. POS N

Ocular POS N
irritation POS N
was POS N
frequently POS N
seen POS N
in POS N
DTFC POS N
group. POS N

BTFC POS N
can POS N
be POS N
considered POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
agent POS N
for POS N
glaucoma POS N
treatment. POS N

Intra-ocular POS N
pressure POS N
(IOP) POS N
change POS N
from POS N
baseline POS N
at POS N
9 POS N
AM/11 POS N
AM POS N
pooled POS N
over POS N
the POS N
8 POS N
weeks POS N
was POS N
-3.3/-3.3 POS N
mmHg POS N
in POS N
the POS N
BTFC POS N
group POS N
and POS N
-2.9/-3.4 POS N
mmHg POS N
in POS N
the POS N
DTFC POS N
group, POS N

BTFC POS N
can POS N
be POS N
considered POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
agent POS N
for POS N
glaucoma POS N
treatment. POS N

blurred POS N
vision POS N
was POS N
frequently POS N
seen POS N
in POS N
BTFC POS N
group, POS N

BTFC POS N
can POS N
be POS N
considered POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
agent POS N
for POS N
glaucoma POS N
treatment. POS N

Non-inferiority POS N
of POS N
BTFC POS N
to POS N
DTFC POS N
in POS N
IOP POS N
reduction POS N
was POS N
demonstrated POS N
after POS N
adding POS N
onto POS N
PGA POS N
therapy POS N
in POS N
Japanese POS N
OAG/OH POS N
patients. POS N

BTFC POS N
can POS N
be POS N
considered POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
agent POS N
for POS N
glaucoma POS N
treatment. POS N

the POS N
score POS N
of POS N
blurred POS N
vision POS N
was POS N
transiently POS N
higher POS N
in POS N
BTFC POS N
than POS N
DTFC, POS N

BTFC POS N
can POS N
be POS N
considered POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
agent POS N
for POS N
glaucoma POS N
treatment. POS N

treatment POS N
difference POS N
decreased POS N
and POS N
disappeared POS N
with POS N
time. POS N

BTFC POS N
can POS N
be POS N
considered POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
agent POS N
for POS N
glaucoma POS N
treatment. POS N

No POS N
noteworthy POS N
issue POS N
was POS N
observed POS N
in POS N
other POS N
safety POS N
outcome. POS N

treatment POS N
difference POS N
decreased POS N
and POS N
disappeared POS N
with POS N
time. POS N

Ocular POS N
irritation POS N
was POS N
frequently POS N
seen POS N
in POS N
DTFC POS N
group. POS N

treatment POS N
difference POS N
decreased POS N
and POS N
disappeared POS N
with POS N
time. POS N

Intra-ocular POS N
pressure POS N
(IOP) POS N
change POS N
from POS N
baseline POS N
at POS N
9 POS N
AM/11 POS N
AM POS N
pooled POS N
over POS N
the POS N
8 POS N
weeks POS N
was POS N
-3.3/-3.3 POS N
mmHg POS N
in POS N
the POS N
BTFC POS N
group POS N
and POS N
-2.9/-3.4 POS N
mmHg POS N
in POS N
the POS N
DTFC POS N
group, POS N

treatment POS N
difference POS N
decreased POS N
and POS N
disappeared POS N
with POS N
time. POS N

blurred POS N
vision POS N
was POS N
frequently POS N
seen POS N
in POS N
BTFC POS N
group, POS N

treatment POS N
difference POS N
decreased POS N
and POS N
disappeared POS N
with POS N
time. POS N

Non-inferiority POS N
of POS N
BTFC POS N
to POS N
DTFC POS N
in POS N
IOP POS N
reduction POS N
was POS N
demonstrated POS N
after POS N
adding POS N
onto POS N
PGA POS N
therapy POS N
in POS N
Japanese POS N
OAG/OH POS N
patients. POS N

treatment POS N
difference POS N
decreased POS N
and POS N
disappeared POS N
with POS N
time. POS N

the POS N
score POS N
of POS N
blurred POS N
vision POS N
was POS N
transiently POS N
higher POS N
in POS N
BTFC POS N
than POS N
DTFC, POS N

treatment POS N
difference POS N
decreased POS N
and POS N
disappeared POS N
with POS N
time. POS N

BTFC POS N
can POS N
be POS N
considered POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
agent POS N
for POS N
glaucoma POS N
treatment. POS N

treatment POS N
difference POS N
decreased POS N
and POS N
disappeared POS N
with POS N
time. POS N

No POS N
noteworthy POS N
issue POS N
was POS N
observed POS N
in POS N
other POS N
safety POS N
outcome. POS N

No POS N
noteworthy POS N
issue POS N
was POS N
observed POS N
in POS N
other POS N
safety POS N
outcome. POS N

Ocular POS N
irritation POS N
was POS N
frequently POS N
seen POS N
in POS N
DTFC POS N
group. POS N

No POS N
noteworthy POS N
issue POS N
was POS N
observed POS N
in POS N
other POS N
safety POS N
outcome. POS N

Intra-ocular POS N
pressure POS N
(IOP) POS N
change POS N
from POS N
baseline POS N
at POS N
9 POS N
AM/11 POS N
AM POS N
pooled POS N
over POS N
the POS N
8 POS N
weeks POS N
was POS N
-3.3/-3.3 POS N
mmHg POS N
in POS N
the POS N
BTFC POS N
group POS N
and POS N
-2.9/-3.4 POS N
mmHg POS N
in POS N
the POS N
DTFC POS N
group, POS N

No POS N
noteworthy POS N
issue POS N
was POS N
observed POS N
in POS N
other POS N
safety POS N
outcome. POS N

blurred POS N
vision POS N
was POS N
frequently POS N
seen POS N
in POS N
BTFC POS N
group, POS N

No POS N
noteworthy POS N
issue POS N
was POS N
observed POS N
in POS N
other POS N
safety POS N
outcome. POS N

Non-inferiority POS N
of POS N
BTFC POS N
to POS N
DTFC POS N
in POS N
IOP POS N
reduction POS N
was POS N
demonstrated POS N
after POS N
adding POS N
onto POS N
PGA POS N
therapy POS N
in POS N
Japanese POS N
OAG/OH POS N
patients. POS N

No POS N
noteworthy POS N
issue POS N
was POS N
observed POS N
in POS N
other POS N
safety POS N
outcome. POS N

the POS N
score POS N
of POS N
blurred POS N
vision POS N
was POS N
transiently POS N
higher POS N
in POS N
BTFC POS N
than POS N
DTFC, POS N

No POS N
noteworthy POS N
issue POS N
was POS N
observed POS N
in POS N
other POS N
safety POS N
outcome. POS N

BTFC POS N
can POS N
be POS N
considered POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
agent POS N
for POS N
glaucoma POS N
treatment. POS N

No POS N
noteworthy POS N
issue POS N
was POS N
observed POS N
in POS N
other POS N
safety POS N
outcome. POS N

treatment POS N
difference POS N
decreased POS N
and POS N
disappeared POS N
with POS N
time. POS N

In POS N
sildenafil POS N
versus POS N
placebo POS N
arms, POS N
week-12 POS N
6MWD POS N
increases POS N
were POS N
similar POS N
(least POS N
squares POS N
mean POS N
difference POS N
[sildenafil-placebo], POS N
-2.4 POS N
m POS N
[90% POS N
CI: POS N
-21.8 POS N
to POS N
17.1 POS N
m]; POS N
P POS N
= POS N
0.6); POS N
mean POS N
± POS N
SD POS N
changes POS N
from POS N
baseline POS N
were POS N
26.4 POS N
± POS N
45.7 POS N
versus POS N
11.8 POS N
± POS N
57.4 POS N
m, POS N
respectively, POS N
in POS N
IPAH POS N
(65% POS N
of POS N
population) POS N
and POS N
-18.3 POS N
± POS N
82.0 POS N
versus POS N
17.5 POS N
± POS N
59.1 POS N
m POS N
in POS N
APAH-CTD POS N
(35% POS N
of POS N
population). POS N

Changes POS N
in POS N
WHO POS N
functional POS N
class POS N
and POS N
Borg POS N
dyspnoea POS N
score POS N
and POS N
incidence POS N
of POS N
clinical POS N
worsening POS N
did POS N
not POS N
differ. POS N

In POS N
sildenafil POS N
versus POS N
placebo POS N
arms, POS N
week-12 POS N
6MWD POS N
increases POS N
were POS N
similar POS N
(least POS N
squares POS N
mean POS N
difference POS N
[sildenafil-placebo], POS N
-2.4 POS N
m POS N
[90% POS N
CI: POS N
-21.8 POS N
to POS N
17.1 POS N
m]; POS N
P POS N
= POS N
0.6); POS N
mean POS N
± POS N
SD POS N
changes POS N
from POS N
baseline POS N
were POS N
26.4 POS N
± POS N
45.7 POS N
versus POS N
11.8 POS N
± POS N
57.4 POS N
m, POS N
respectively, POS N
in POS N
IPAH POS N
(65% POS N
of POS N
population) POS N
and POS N
-18.3 POS N
± POS N
82.0 POS N
versus POS N
17.5 POS N
± POS N
59.1 POS N
m POS N
in POS N
APAH-CTD POS N
(35% POS N
of POS N
population). POS N

Headache, POS N
diarrhoea, POS N
and POS N
flushing POS N
were POS N
more POS N
common POS N
with POS N
sildenafil. POS N

In POS N
sildenafil POS N
versus POS N
placebo POS N
arms, POS N
week-12 POS N
6MWD POS N
increases POS N
were POS N
similar POS N
(least POS N
squares POS N
mean POS N
difference POS N
[sildenafil-placebo], POS N
-2.4 POS N
m POS N
[90% POS N
CI: POS N
-21.8 POS N
to POS N
17.1 POS N
m]; POS N
P POS N
= POS N
0.6); POS N
mean POS N
± POS N
SD POS N
changes POS N
from POS N
baseline POS N
were POS N
26.4 POS N
± POS N
45.7 POS N
versus POS N
11.8 POS N
± POS N
57.4 POS N
m, POS N
respectively, POS N
in POS N
IPAH POS N
(65% POS N
of POS N
population) POS N
and POS N
-18.3 POS N
± POS N
82.0 POS N
versus POS N
17.5 POS N
± POS N
59.1 POS N
m POS N
in POS N
APAH-CTD POS N
(35% POS N
of POS N
population). POS N

Sildenafil, POS N
in POS N
addition POS N
to POS N
stable POS N
(≥3 POS N
months) POS N
bosentan POS N
therapy, POS N
had POS N
no POS N
benefit POS N
over POS N
placebo POS N
for POS N
12-week POS N
change POS N
from POS N
baseline POS N
in POS N
6MWD. POS N

Changes POS N
in POS N
WHO POS N
functional POS N
class POS N
and POS N
Borg POS N
dyspnoea POS N
score POS N
and POS N
incidence POS N
of POS N
clinical POS N
worsening POS N
did POS N
not POS N
differ. POS N

In POS N
sildenafil POS N
versus POS N
placebo POS N
arms, POS N
week-12 POS N
6MWD POS N
increases POS N
were POS N
similar POS N
(least POS N
squares POS N
mean POS N
difference POS N
[sildenafil-placebo], POS N
-2.4 POS N
m POS N
[90% POS N
CI: POS N
-21.8 POS N
to POS N
17.1 POS N
m]; POS N
P POS N
= POS N
0.6); POS N
mean POS N
± POS N
SD POS N
changes POS N
from POS N
baseline POS N
were POS N
26.4 POS N
± POS N
45.7 POS N
versus POS N
11.8 POS N
± POS N
57.4 POS N
m, POS N
respectively, POS N
in POS N
IPAH POS N
(65% POS N
of POS N
population) POS N
and POS N
-18.3 POS N
± POS N
82.0 POS N
versus POS N
17.5 POS N
± POS N
59.1 POS N
m POS N
in POS N
APAH-CTD POS N
(35% POS N
of POS N
population). POS N

Changes POS N
in POS N
WHO POS N
functional POS N
class POS N
and POS N
Borg POS N
dyspnoea POS N
score POS N
and POS N
incidence POS N
of POS N
clinical POS N
worsening POS N
did POS N
not POS N
differ. POS N

Headache, POS N
diarrhoea, POS N
and POS N
flushing POS N
were POS N
more POS N
common POS N
with POS N
sildenafil. POS N

Changes POS N
in POS N
WHO POS N
functional POS N
class POS N
and POS N
Borg POS N
dyspnoea POS N
score POS N
and POS N
incidence POS N
of POS N
clinical POS N
worsening POS N
did POS N
not POS N
differ. POS N

Sildenafil, POS N
in POS N
addition POS N
to POS N
stable POS N
(≥3 POS N
months) POS N
bosentan POS N
therapy, POS N
had POS N
no POS N
benefit POS N
over POS N
placebo POS N
for POS N
12-week POS N
change POS N
from POS N
baseline POS N
in POS N
6MWD. POS N

Headache, POS N
diarrhoea, POS N
and POS N
flushing POS N
were POS N
more POS N
common POS N
with POS N
sildenafil. POS N

In POS N
sildenafil POS N
versus POS N
placebo POS N
arms, POS N
week-12 POS N
6MWD POS N
increases POS N
were POS N
similar POS N
(least POS N
squares POS N
mean POS N
difference POS N
[sildenafil-placebo], POS N
-2.4 POS N
m POS N
[90% POS N
CI: POS N
-21.8 POS N
to POS N
17.1 POS N
m]; POS N
P POS N
= POS N
0.6); POS N
mean POS N
± POS N
SD POS N
changes POS N
from POS N
baseline POS N
were POS N
26.4 POS N
± POS N
45.7 POS N
versus POS N
11.8 POS N
± POS N
57.4 POS N
m, POS N
respectively, POS N
in POS N
IPAH POS N
(65% POS N
of POS N
population) POS N
and POS N
-18.3 POS N
± POS N
82.0 POS N
versus POS N
17.5 POS N
± POS N
59.1 POS N
m POS N
in POS N
APAH-CTD POS N
(35% POS N
of POS N
population). POS N

Headache, POS N
diarrhoea, POS N
and POS N
flushing POS N
were POS N
more POS N
common POS N
with POS N
sildenafil. POS N

Changes POS N
in POS N
WHO POS N
functional POS N
class POS N
and POS N
Borg POS N
dyspnoea POS N
score POS N
and POS N
incidence POS N
of POS N
clinical POS N
worsening POS N
did POS N
not POS N
differ. POS N

Headache, POS N
diarrhoea, POS N
and POS N
flushing POS N
were POS N
more POS N
common POS N
with POS N
sildenafil. POS N

Sildenafil, POS N
in POS N
addition POS N
to POS N
stable POS N
(≥3 POS N
months) POS N
bosentan POS N
therapy, POS N
had POS N
no POS N
benefit POS N
over POS N
placebo POS N
for POS N
12-week POS N
change POS N
from POS N
baseline POS N
in POS N
6MWD. POS N

Sildenafil, POS N
in POS N
addition POS N
to POS N
stable POS N
(≥3 POS N
months) POS N
bosentan POS N
therapy, POS N
had POS N
no POS N
benefit POS N
over POS N
placebo POS N
for POS N
12-week POS N
change POS N
from POS N
baseline POS N
in POS N
6MWD. POS N

In POS N
sildenafil POS N
versus POS N
placebo POS N
arms, POS N
week-12 POS N
6MWD POS N
increases POS N
were POS N
similar POS N
(least POS N
squares POS N
mean POS N
difference POS N
[sildenafil-placebo], POS N
-2.4 POS N
m POS N
[90% POS N
CI: POS N
-21.8 POS N
to POS N
17.1 POS N
m]; POS N
P POS N
= POS N
0.6); POS N
mean POS N
± POS N
SD POS N
changes POS N
from POS N
baseline POS N
were POS N
26.4 POS N
± POS N
45.7 POS N
versus POS N
11.8 POS N
± POS N
57.4 POS N
m, POS N
respectively, POS N
in POS N
IPAH POS N
(65% POS N
of POS N
population) POS N
and POS N
-18.3 POS N
± POS N
82.0 POS N
versus POS N
17.5 POS N
± POS N
59.1 POS N
m POS N
in POS N
APAH-CTD POS N
(35% POS N
of POS N
population). POS N

Sildenafil, POS N
in POS N
addition POS N
to POS N
stable POS N
(≥3 POS N
months) POS N
bosentan POS N
therapy, POS N
had POS N
no POS N
benefit POS N
over POS N
placebo POS N
for POS N
12-week POS N
change POS N
from POS N
baseline POS N
in POS N
6MWD. POS N

Changes POS N
in POS N
WHO POS N
functional POS N
class POS N
and POS N
Borg POS N
dyspnoea POS N
score POS N
and POS N
incidence POS N
of POS N
clinical POS N
worsening POS N
did POS N
not POS N
differ. POS N

Sildenafil, POS N
in POS N
addition POS N
to POS N
stable POS N
(≥3 POS N
months) POS N
bosentan POS N
therapy, POS N
had POS N
no POS N
benefit POS N
over POS N
placebo POS N
for POS N
12-week POS N
change POS N
from POS N
baseline POS N
in POS N
6MWD. POS N

Headache, POS N
diarrhoea, POS N
and POS N
flushing POS N
were POS N
more POS N
common POS N
with POS N
sildenafil. POS N

Responses POS N
(> POS N
or POS N
= POS N
50% POS N
improvement) POS N
were POS N
seen POS N
in POS N
3 POS N
(20%) POS N
of POS N
15 POS N
patients POS N
with POS N
an POS N
initial POS N
dose POS N
at POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0%-40%), POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
35%-72%), POS N
and POS N
10 POS N
(67%) POS N
of POS N
15 POS N
patients POS N
at POS N
above POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
43%-91%). POS N

The POS N
rate POS N
of POS N
progressive POS N
disease POS N
was POS N
47%, POS N
21%, POS N
and POS N
13% POS N
at POS N
the POS N
same POS N
dose POS N
levels, POS N
respectively. POS N

Responses POS N
(> POS N
or POS N
= POS N
50% POS N
improvement) POS N
were POS N
seen POS N
in POS N
3 POS N
(20%) POS N
of POS N
15 POS N
patients POS N
with POS N
an POS N
initial POS N
dose POS N
at POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0%-40%), POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
35%-72%), POS N
and POS N
10 POS N
(67%) POS N
of POS N
15 POS N
patients POS N
at POS N
above POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
43%-91%). POS N

Eight POS N
(73%) POS N
of POS N
11 POS N
patients POS N
crossing POS N
over POS N
from POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
to POS N
higher POS N
doses POS N
subsequently POS N
responded. POS N

Responses POS N
(> POS N
or POS N
= POS N
50% POS N
improvement) POS N
were POS N
seen POS N
in POS N
3 POS N
(20%) POS N
of POS N
15 POS N
patients POS N
with POS N
an POS N
initial POS N
dose POS N
at POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0%-40%), POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
35%-72%), POS N
and POS N
10 POS N
(67%) POS N
of POS N
15 POS N
patients POS N
at POS N
above POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
43%-91%). POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
from POS N
start POS N
of POS N
therapy POS N
could POS N
not POS N
be POS N
estimated POS N
for POS N
the POS N
15 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
owing POS N
to POS N
low POS N
relapse POS N
rates POS N
in POS N
2 POS N
patients POS N
(13%); POS N
at POS N
higher POS N
doses POS N
it POS N
was POS N
516 POS N
days. POS N

Responses POS N
(> POS N
or POS N
= POS N
50% POS N
improvement) POS N
were POS N
seen POS N
in POS N
3 POS N
(20%) POS N
of POS N
15 POS N
patients POS N
with POS N
an POS N
initial POS N
dose POS N
at POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0%-40%), POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
35%-72%), POS N
and POS N
10 POS N
(67%) POS N
of POS N
15 POS N
patients POS N
at POS N
above POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
43%-91%). POS N

The POS N
following POS N
drug-related POS N
adverse POS N
effects POS N
were POS N
reversible POS N
and POS N
treatable: POS N
hypertriglyceridemia POS N
(46 POS N
patients POS N
[79%]), POS N
hypercholesterolemia POS N
(28 POS N
patients POS N
[48%]), POS N
headache POS N
(27 POS N
patients POS N
[47%]), POS N
central POS N
hypothyroidism POS N
(23 POS N
patients POS N
[40%]), POS N
asthenia POS N
(21 POS N
patients POS N
[36%]), POS N
and POS N
leukopenia POS N
(16 POS N
patients POS N
[28%]). POS N

Responses POS N
(> POS N
or POS N
= POS N
50% POS N
improvement) POS N
were POS N
seen POS N
in POS N
3 POS N
(20%) POS N
of POS N
15 POS N
patients POS N
with POS N
an POS N
initial POS N
dose POS N
at POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0%-40%), POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
35%-72%), POS N
and POS N
10 POS N
(67%) POS N
of POS N
15 POS N
patients POS N
at POS N
above POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
43%-91%). POS N

No POS N
cases POS N
of POS N
drug-related POS N
neutropenic POS N
fever, POS N
sepsis, POS N
or POS N
death POS N
occurred. POS N

Responses POS N
(> POS N
or POS N
= POS N
50% POS N
improvement) POS N
were POS N
seen POS N
in POS N
3 POS N
(20%) POS N
of POS N
15 POS N
patients POS N
with POS N
an POS N
initial POS N
dose POS N
at POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0%-40%), POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
35%-72%), POS N
and POS N
10 POS N
(67%) POS N
of POS N
15 POS N
patients POS N
at POS N
above POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
43%-91%). POS N

Pancreatitis POS N
occurred POS N
in POS N
3 POS N
patients POS N
with POS N
triglyceride POS N
levels POS N
higher POS N
than POS N
14.69 POS N
mmol/L POS N
(1300 POS N
mg/dL), POS N
all POS N
of POS N
whom POS N
were POS N
taking POS N
300 POS N
mg/m(2) POS N
or POS N
more POS N
of POS N
oral POS N
bexarotene POS N
per POS N
day. POS N

Responses POS N
(> POS N
or POS N
= POS N
50% POS N
improvement) POS N
were POS N
seen POS N
in POS N
3 POS N
(20%) POS N
of POS N
15 POS N
patients POS N
with POS N
an POS N
initial POS N
dose POS N
at POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0%-40%), POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
35%-72%), POS N
and POS N
10 POS N
(67%) POS N
of POS N
15 POS N
patients POS N
at POS N
above POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
43%-91%). POS N

Bexarotene POS N
(Targretin POS N
capsules) POS N
(the POS N
first POS N
retinoid POS N
X POS N
receptor-selective POS N
rexinoid) POS N
was POS N
well POS N
tolerated POS N
and POS N
effective POS N
as POS N
an POS N
oral POS N
treatment POS N
for POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
with POS N
refractory POS N
or POS N
persistent POS N
early-stage POS N
cutaneous POS N
T-cell POS N
lymphoma POS N
at POS N
doses POS N
of POS N
300 POS N
mg/m(2) POS N
per POS N
day. POS N

Responses POS N
(> POS N
or POS N
= POS N
50% POS N
improvement) POS N
were POS N
seen POS N
in POS N
3 POS N
(20%) POS N
of POS N
15 POS N
patients POS N
with POS N
an POS N
initial POS N
dose POS N
at POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0%-40%), POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
35%-72%), POS N
and POS N
10 POS N
(67%) POS N
of POS N
15 POS N
patients POS N
at POS N
above POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
43%-91%). POS N

Hypertriglyceridemia POS N
and POS N
hypothyroidism POS N
require POS N
monitoring POS N
but POS N
are POS N
reversible POS N
and POS N
manageable POS N
with POS N
concomitant POS N
medication. POS N

The POS N
rate POS N
of POS N
progressive POS N
disease POS N
was POS N
47%, POS N
21%, POS N
and POS N
13% POS N
at POS N
the POS N
same POS N
dose POS N
levels, POS N
respectively. POS N

Responses POS N
(> POS N
or POS N
= POS N
50% POS N
improvement) POS N
were POS N
seen POS N
in POS N
3 POS N
(20%) POS N
of POS N
15 POS N
patients POS N
with POS N
an POS N
initial POS N
dose POS N
at POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0%-40%), POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
35%-72%), POS N
and POS N
10 POS N
(67%) POS N
of POS N
15 POS N
patients POS N
at POS N
above POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
43%-91%). POS N

The POS N
rate POS N
of POS N
progressive POS N
disease POS N
was POS N
47%, POS N
21%, POS N
and POS N
13% POS N
at POS N
the POS N
same POS N
dose POS N
levels, POS N
respectively. POS N

Eight POS N
(73%) POS N
of POS N
11 POS N
patients POS N
crossing POS N
over POS N
from POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
to POS N
higher POS N
doses POS N
subsequently POS N
responded. POS N

The POS N
rate POS N
of POS N
progressive POS N
disease POS N
was POS N
47%, POS N
21%, POS N
and POS N
13% POS N
at POS N
the POS N
same POS N
dose POS N
levels, POS N
respectively. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
from POS N
start POS N
of POS N
therapy POS N
could POS N
not POS N
be POS N
estimated POS N
for POS N
the POS N
15 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
owing POS N
to POS N
low POS N
relapse POS N
rates POS N
in POS N
2 POS N
patients POS N
(13%); POS N
at POS N
higher POS N
doses POS N
it POS N
was POS N
516 POS N
days. POS N

The POS N
rate POS N
of POS N
progressive POS N
disease POS N
was POS N
47%, POS N
21%, POS N
and POS N
13% POS N
at POS N
the POS N
same POS N
dose POS N
levels, POS N
respectively. POS N

The POS N
following POS N
drug-related POS N
adverse POS N
effects POS N
were POS N
reversible POS N
and POS N
treatable: POS N
hypertriglyceridemia POS N
(46 POS N
patients POS N
[79%]), POS N
hypercholesterolemia POS N
(28 POS N
patients POS N
[48%]), POS N
headache POS N
(27 POS N
patients POS N
[47%]), POS N
central POS N
hypothyroidism POS N
(23 POS N
patients POS N
[40%]), POS N
asthenia POS N
(21 POS N
patients POS N
[36%]), POS N
and POS N
leukopenia POS N
(16 POS N
patients POS N
[28%]). POS N

The POS N
rate POS N
of POS N
progressive POS N
disease POS N
was POS N
47%, POS N
21%, POS N
and POS N
13% POS N
at POS N
the POS N
same POS N
dose POS N
levels, POS N
respectively. POS N

No POS N
cases POS N
of POS N
drug-related POS N
neutropenic POS N
fever, POS N
sepsis, POS N
or POS N
death POS N
occurred. POS N

The POS N
rate POS N
of POS N
progressive POS N
disease POS N
was POS N
47%, POS N
21%, POS N
and POS N
13% POS N
at POS N
the POS N
same POS N
dose POS N
levels, POS N
respectively. POS N

Pancreatitis POS N
occurred POS N
in POS N
3 POS N
patients POS N
with POS N
triglyceride POS N
levels POS N
higher POS N
than POS N
14.69 POS N
mmol/L POS N
(1300 POS N
mg/dL), POS N
all POS N
of POS N
whom POS N
were POS N
taking POS N
300 POS N
mg/m(2) POS N
or POS N
more POS N
of POS N
oral POS N
bexarotene POS N
per POS N
day. POS N

The POS N
rate POS N
of POS N
progressive POS N
disease POS N
was POS N
47%, POS N
21%, POS N
and POS N
13% POS N
at POS N
the POS N
same POS N
dose POS N
levels, POS N
respectively. POS N

Bexarotene POS N
(Targretin POS N
capsules) POS N
(the POS N
first POS N
retinoid POS N
X POS N
receptor-selective POS N
rexinoid) POS N
was POS N
well POS N
tolerated POS N
and POS N
effective POS N
as POS N
an POS N
oral POS N
treatment POS N
for POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
with POS N
refractory POS N
or POS N
persistent POS N
early-stage POS N
cutaneous POS N
T-cell POS N
lymphoma POS N
at POS N
doses POS N
of POS N
300 POS N
mg/m(2) POS N
per POS N
day. POS N

The POS N
rate POS N
of POS N
progressive POS N
disease POS N
was POS N
47%, POS N
21%, POS N
and POS N
13% POS N
at POS N
the POS N
same POS N
dose POS N
levels, POS N
respectively. POS N

Hypertriglyceridemia POS N
and POS N
hypothyroidism POS N
require POS N
monitoring POS N
but POS N
are POS N
reversible POS N
and POS N
manageable POS N
with POS N
concomitant POS N
medication. POS N

Eight POS N
(73%) POS N
of POS N
11 POS N
patients POS N
crossing POS N
over POS N
from POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
to POS N
higher POS N
doses POS N
subsequently POS N
responded. POS N

Responses POS N
(> POS N
or POS N
= POS N
50% POS N
improvement) POS N
were POS N
seen POS N
in POS N
3 POS N
(20%) POS N
of POS N
15 POS N
patients POS N
with POS N
an POS N
initial POS N
dose POS N
at POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0%-40%), POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
35%-72%), POS N
and POS N
10 POS N
(67%) POS N
of POS N
15 POS N
patients POS N
at POS N
above POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
43%-91%). POS N

Eight POS N
(73%) POS N
of POS N
11 POS N
patients POS N
crossing POS N
over POS N
from POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
to POS N
higher POS N
doses POS N
subsequently POS N
responded. POS N

The POS N
rate POS N
of POS N
progressive POS N
disease POS N
was POS N
47%, POS N
21%, POS N
and POS N
13% POS N
at POS N
the POS N
same POS N
dose POS N
levels, POS N
respectively. POS N

Eight POS N
(73%) POS N
of POS N
11 POS N
patients POS N
crossing POS N
over POS N
from POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
to POS N
higher POS N
doses POS N
subsequently POS N
responded. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
from POS N
start POS N
of POS N
therapy POS N
could POS N
not POS N
be POS N
estimated POS N
for POS N
the POS N
15 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
owing POS N
to POS N
low POS N
relapse POS N
rates POS N
in POS N
2 POS N
patients POS N
(13%); POS N
at POS N
higher POS N
doses POS N
it POS N
was POS N
516 POS N
days. POS N

Eight POS N
(73%) POS N
of POS N
11 POS N
patients POS N
crossing POS N
over POS N
from POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
to POS N
higher POS N
doses POS N
subsequently POS N
responded. POS N

The POS N
following POS N
drug-related POS N
adverse POS N
effects POS N
were POS N
reversible POS N
and POS N
treatable: POS N
hypertriglyceridemia POS N
(46 POS N
patients POS N
[79%]), POS N
hypercholesterolemia POS N
(28 POS N
patients POS N
[48%]), POS N
headache POS N
(27 POS N
patients POS N
[47%]), POS N
central POS N
hypothyroidism POS N
(23 POS N
patients POS N
[40%]), POS N
asthenia POS N
(21 POS N
patients POS N
[36%]), POS N
and POS N
leukopenia POS N
(16 POS N
patients POS N
[28%]). POS N

Eight POS N
(73%) POS N
of POS N
11 POS N
patients POS N
crossing POS N
over POS N
from POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
to POS N
higher POS N
doses POS N
subsequently POS N
responded. POS N

No POS N
cases POS N
of POS N
drug-related POS N
neutropenic POS N
fever, POS N
sepsis, POS N
or POS N
death POS N
occurred. POS N

Eight POS N
(73%) POS N
of POS N
11 POS N
patients POS N
crossing POS N
over POS N
from POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
to POS N
higher POS N
doses POS N
subsequently POS N
responded. POS N

Pancreatitis POS N
occurred POS N
in POS N
3 POS N
patients POS N
with POS N
triglyceride POS N
levels POS N
higher POS N
than POS N
14.69 POS N
mmol/L POS N
(1300 POS N
mg/dL), POS N
all POS N
of POS N
whom POS N
were POS N
taking POS N
300 POS N
mg/m(2) POS N
or POS N
more POS N
of POS N
oral POS N
bexarotene POS N
per POS N
day. POS N

Eight POS N
(73%) POS N
of POS N
11 POS N
patients POS N
crossing POS N
over POS N
from POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
to POS N
higher POS N
doses POS N
subsequently POS N
responded. POS N

Bexarotene POS N
(Targretin POS N
capsules) POS N
(the POS N
first POS N
retinoid POS N
X POS N
receptor-selective POS N
rexinoid) POS N
was POS N
well POS N
tolerated POS N
and POS N
effective POS N
as POS N
an POS N
oral POS N
treatment POS N
for POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
with POS N
refractory POS N
or POS N
persistent POS N
early-stage POS N
cutaneous POS N
T-cell POS N
lymphoma POS N
at POS N
doses POS N
of POS N
300 POS N
mg/m(2) POS N
per POS N
day. POS N

Eight POS N
(73%) POS N
of POS N
11 POS N
patients POS N
crossing POS N
over POS N
from POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
to POS N
higher POS N
doses POS N
subsequently POS N
responded. POS N

Hypertriglyceridemia POS N
and POS N
hypothyroidism POS N
require POS N
monitoring POS N
but POS N
are POS N
reversible POS N
and POS N
manageable POS N
with POS N
concomitant POS N
medication. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
from POS N
start POS N
of POS N
therapy POS N
could POS N
not POS N
be POS N
estimated POS N
for POS N
the POS N
15 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
owing POS N
to POS N
low POS N
relapse POS N
rates POS N
in POS N
2 POS N
patients POS N
(13%); POS N
at POS N
higher POS N
doses POS N
it POS N
was POS N
516 POS N
days. POS N

Responses POS N
(> POS N
or POS N
= POS N
50% POS N
improvement) POS N
were POS N
seen POS N
in POS N
3 POS N
(20%) POS N
of POS N
15 POS N
patients POS N
with POS N
an POS N
initial POS N
dose POS N
at POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0%-40%), POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
35%-72%), POS N
and POS N
10 POS N
(67%) POS N
of POS N
15 POS N
patients POS N
at POS N
above POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
43%-91%). POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
from POS N
start POS N
of POS N
therapy POS N
could POS N
not POS N
be POS N
estimated POS N
for POS N
the POS N
15 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
owing POS N
to POS N
low POS N
relapse POS N
rates POS N
in POS N
2 POS N
patients POS N
(13%); POS N
at POS N
higher POS N
doses POS N
it POS N
was POS N
516 POS N
days. POS N

The POS N
rate POS N
of POS N
progressive POS N
disease POS N
was POS N
47%, POS N
21%, POS N
and POS N
13% POS N
at POS N
the POS N
same POS N
dose POS N
levels, POS N
respectively. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
from POS N
start POS N
of POS N
therapy POS N
could POS N
not POS N
be POS N
estimated POS N
for POS N
the POS N
15 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
owing POS N
to POS N
low POS N
relapse POS N
rates POS N
in POS N
2 POS N
patients POS N
(13%); POS N
at POS N
higher POS N
doses POS N
it POS N
was POS N
516 POS N
days. POS N

Eight POS N
(73%) POS N
of POS N
11 POS N
patients POS N
crossing POS N
over POS N
from POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
to POS N
higher POS N
doses POS N
subsequently POS N
responded. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
from POS N
start POS N
of POS N
therapy POS N
could POS N
not POS N
be POS N
estimated POS N
for POS N
the POS N
15 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
owing POS N
to POS N
low POS N
relapse POS N
rates POS N
in POS N
2 POS N
patients POS N
(13%); POS N
at POS N
higher POS N
doses POS N
it POS N
was POS N
516 POS N
days. POS N

The POS N
following POS N
drug-related POS N
adverse POS N
effects POS N
were POS N
reversible POS N
and POS N
treatable: POS N
hypertriglyceridemia POS N
(46 POS N
patients POS N
[79%]), POS N
hypercholesterolemia POS N
(28 POS N
patients POS N
[48%]), POS N
headache POS N
(27 POS N
patients POS N
[47%]), POS N
central POS N
hypothyroidism POS N
(23 POS N
patients POS N
[40%]), POS N
asthenia POS N
(21 POS N
patients POS N
[36%]), POS N
and POS N
leukopenia POS N
(16 POS N
patients POS N
[28%]). POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
from POS N
start POS N
of POS N
therapy POS N
could POS N
not POS N
be POS N
estimated POS N
for POS N
the POS N
15 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
owing POS N
to POS N
low POS N
relapse POS N
rates POS N
in POS N
2 POS N
patients POS N
(13%); POS N
at POS N
higher POS N
doses POS N
it POS N
was POS N
516 POS N
days. POS N

No POS N
cases POS N
of POS N
drug-related POS N
neutropenic POS N
fever, POS N
sepsis, POS N
or POS N
death POS N
occurred. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
from POS N
start POS N
of POS N
therapy POS N
could POS N
not POS N
be POS N
estimated POS N
for POS N
the POS N
15 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
owing POS N
to POS N
low POS N
relapse POS N
rates POS N
in POS N
2 POS N
patients POS N
(13%); POS N
at POS N
higher POS N
doses POS N
it POS N
was POS N
516 POS N
days. POS N

Pancreatitis POS N
occurred POS N
in POS N
3 POS N
patients POS N
with POS N
triglyceride POS N
levels POS N
higher POS N
than POS N
14.69 POS N
mmol/L POS N
(1300 POS N
mg/dL), POS N
all POS N
of POS N
whom POS N
were POS N
taking POS N
300 POS N
mg/m(2) POS N
or POS N
more POS N
of POS N
oral POS N
bexarotene POS N
per POS N
day. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
from POS N
start POS N
of POS N
therapy POS N
could POS N
not POS N
be POS N
estimated POS N
for POS N
the POS N
15 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
owing POS N
to POS N
low POS N
relapse POS N
rates POS N
in POS N
2 POS N
patients POS N
(13%); POS N
at POS N
higher POS N
doses POS N
it POS N
was POS N
516 POS N
days. POS N

Bexarotene POS N
(Targretin POS N
capsules) POS N
(the POS N
first POS N
retinoid POS N
X POS N
receptor-selective POS N
rexinoid) POS N
was POS N
well POS N
tolerated POS N
and POS N
effective POS N
as POS N
an POS N
oral POS N
treatment POS N
for POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
with POS N
refractory POS N
or POS N
persistent POS N
early-stage POS N
cutaneous POS N
T-cell POS N
lymphoma POS N
at POS N
doses POS N
of POS N
300 POS N
mg/m(2) POS N
per POS N
day. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
from POS N
start POS N
of POS N
therapy POS N
could POS N
not POS N
be POS N
estimated POS N
for POS N
the POS N
15 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
owing POS N
to POS N
low POS N
relapse POS N
rates POS N
in POS N
2 POS N
patients POS N
(13%); POS N
at POS N
higher POS N
doses POS N
it POS N
was POS N
516 POS N
days. POS N

Hypertriglyceridemia POS N
and POS N
hypothyroidism POS N
require POS N
monitoring POS N
but POS N
are POS N
reversible POS N
and POS N
manageable POS N
with POS N
concomitant POS N
medication. POS N

The POS N
following POS N
drug-related POS N
adverse POS N
effects POS N
were POS N
reversible POS N
and POS N
treatable: POS N
hypertriglyceridemia POS N
(46 POS N
patients POS N
[79%]), POS N
hypercholesterolemia POS N
(28 POS N
patients POS N
[48%]), POS N
headache POS N
(27 POS N
patients POS N
[47%]), POS N
central POS N
hypothyroidism POS N
(23 POS N
patients POS N
[40%]), POS N
asthenia POS N
(21 POS N
patients POS N
[36%]), POS N
and POS N
leukopenia POS N
(16 POS N
patients POS N
[28%]). POS N

Responses POS N
(> POS N
or POS N
= POS N
50% POS N
improvement) POS N
were POS N
seen POS N
in POS N
3 POS N
(20%) POS N
of POS N
15 POS N
patients POS N
with POS N
an POS N
initial POS N
dose POS N
at POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0%-40%), POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
35%-72%), POS N
and POS N
10 POS N
(67%) POS N
of POS N
15 POS N
patients POS N
at POS N
above POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
43%-91%). POS N

The POS N
following POS N
drug-related POS N
adverse POS N
effects POS N
were POS N
reversible POS N
and POS N
treatable: POS N
hypertriglyceridemia POS N
(46 POS N
patients POS N
[79%]), POS N
hypercholesterolemia POS N
(28 POS N
patients POS N
[48%]), POS N
headache POS N
(27 POS N
patients POS N
[47%]), POS N
central POS N
hypothyroidism POS N
(23 POS N
patients POS N
[40%]), POS N
asthenia POS N
(21 POS N
patients POS N
[36%]), POS N
and POS N
leukopenia POS N
(16 POS N
patients POS N
[28%]). POS N

The POS N
rate POS N
of POS N
progressive POS N
disease POS N
was POS N
47%, POS N
21%, POS N
and POS N
13% POS N
at POS N
the POS N
same POS N
dose POS N
levels, POS N
respectively. POS N

The POS N
following POS N
drug-related POS N
adverse POS N
effects POS N
were POS N
reversible POS N
and POS N
treatable: POS N
hypertriglyceridemia POS N
(46 POS N
patients POS N
[79%]), POS N
hypercholesterolemia POS N
(28 POS N
patients POS N
[48%]), POS N
headache POS N
(27 POS N
patients POS N
[47%]), POS N
central POS N
hypothyroidism POS N
(23 POS N
patients POS N
[40%]), POS N
asthenia POS N
(21 POS N
patients POS N
[36%]), POS N
and POS N
leukopenia POS N
(16 POS N
patients POS N
[28%]). POS N

Eight POS N
(73%) POS N
of POS N
11 POS N
patients POS N
crossing POS N
over POS N
from POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
to POS N
higher POS N
doses POS N
subsequently POS N
responded. POS N

The POS N
following POS N
drug-related POS N
adverse POS N
effects POS N
were POS N
reversible POS N
and POS N
treatable: POS N
hypertriglyceridemia POS N
(46 POS N
patients POS N
[79%]), POS N
hypercholesterolemia POS N
(28 POS N
patients POS N
[48%]), POS N
headache POS N
(27 POS N
patients POS N
[47%]), POS N
central POS N
hypothyroidism POS N
(23 POS N
patients POS N
[40%]), POS N
asthenia POS N
(21 POS N
patients POS N
[36%]), POS N
and POS N
leukopenia POS N
(16 POS N
patients POS N
[28%]). POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
from POS N
start POS N
of POS N
therapy POS N
could POS N
not POS N
be POS N
estimated POS N
for POS N
the POS N
15 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
owing POS N
to POS N
low POS N
relapse POS N
rates POS N
in POS N
2 POS N
patients POS N
(13%); POS N
at POS N
higher POS N
doses POS N
it POS N
was POS N
516 POS N
days. POS N

The POS N
following POS N
drug-related POS N
adverse POS N
effects POS N
were POS N
reversible POS N
and POS N
treatable: POS N
hypertriglyceridemia POS N
(46 POS N
patients POS N
[79%]), POS N
hypercholesterolemia POS N
(28 POS N
patients POS N
[48%]), POS N
headache POS N
(27 POS N
patients POS N
[47%]), POS N
central POS N
hypothyroidism POS N
(23 POS N
patients POS N
[40%]), POS N
asthenia POS N
(21 POS N
patients POS N
[36%]), POS N
and POS N
leukopenia POS N
(16 POS N
patients POS N
[28%]). POS N

No POS N
cases POS N
of POS N
drug-related POS N
neutropenic POS N
fever, POS N
sepsis, POS N
or POS N
death POS N
occurred. POS N

The POS N
following POS N
drug-related POS N
adverse POS N
effects POS N
were POS N
reversible POS N
and POS N
treatable: POS N
hypertriglyceridemia POS N
(46 POS N
patients POS N
[79%]), POS N
hypercholesterolemia POS N
(28 POS N
patients POS N
[48%]), POS N
headache POS N
(27 POS N
patients POS N
[47%]), POS N
central POS N
hypothyroidism POS N
(23 POS N
patients POS N
[40%]), POS N
asthenia POS N
(21 POS N
patients POS N
[36%]), POS N
and POS N
leukopenia POS N
(16 POS N
patients POS N
[28%]). POS N

Pancreatitis POS N
occurred POS N
in POS N
3 POS N
patients POS N
with POS N
triglyceride POS N
levels POS N
higher POS N
than POS N
14.69 POS N
mmol/L POS N
(1300 POS N
mg/dL), POS N
all POS N
of POS N
whom POS N
were POS N
taking POS N
300 POS N
mg/m(2) POS N
or POS N
more POS N
of POS N
oral POS N
bexarotene POS N
per POS N
day. POS N

The POS N
following POS N
drug-related POS N
adverse POS N
effects POS N
were POS N
reversible POS N
and POS N
treatable: POS N
hypertriglyceridemia POS N
(46 POS N
patients POS N
[79%]), POS N
hypercholesterolemia POS N
(28 POS N
patients POS N
[48%]), POS N
headache POS N
(27 POS N
patients POS N
[47%]), POS N
central POS N
hypothyroidism POS N
(23 POS N
patients POS N
[40%]), POS N
asthenia POS N
(21 POS N
patients POS N
[36%]), POS N
and POS N
leukopenia POS N
(16 POS N
patients POS N
[28%]). POS N

Bexarotene POS N
(Targretin POS N
capsules) POS N
(the POS N
first POS N
retinoid POS N
X POS N
receptor-selective POS N
rexinoid) POS N
was POS N
well POS N
tolerated POS N
and POS N
effective POS N
as POS N
an POS N
oral POS N
treatment POS N
for POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
with POS N
refractory POS N
or POS N
persistent POS N
early-stage POS N
cutaneous POS N
T-cell POS N
lymphoma POS N
at POS N
doses POS N
of POS N
300 POS N
mg/m(2) POS N
per POS N
day. POS N

The POS N
following POS N
drug-related POS N
adverse POS N
effects POS N
were POS N
reversible POS N
and POS N
treatable: POS N
hypertriglyceridemia POS N
(46 POS N
patients POS N
[79%]), POS N
hypercholesterolemia POS N
(28 POS N
patients POS N
[48%]), POS N
headache POS N
(27 POS N
patients POS N
[47%]), POS N
central POS N
hypothyroidism POS N
(23 POS N
patients POS N
[40%]), POS N
asthenia POS N
(21 POS N
patients POS N
[36%]), POS N
and POS N
leukopenia POS N
(16 POS N
patients POS N
[28%]). POS N

Hypertriglyceridemia POS N
and POS N
hypothyroidism POS N
require POS N
monitoring POS N
but POS N
are POS N
reversible POS N
and POS N
manageable POS N
with POS N
concomitant POS N
medication. POS N

No POS N
cases POS N
of POS N
drug-related POS N
neutropenic POS N
fever, POS N
sepsis, POS N
or POS N
death POS N
occurred. POS N

Responses POS N
(> POS N
or POS N
= POS N
50% POS N
improvement) POS N
were POS N
seen POS N
in POS N
3 POS N
(20%) POS N
of POS N
15 POS N
patients POS N
with POS N
an POS N
initial POS N
dose POS N
at POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0%-40%), POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
35%-72%), POS N
and POS N
10 POS N
(67%) POS N
of POS N
15 POS N
patients POS N
at POS N
above POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
43%-91%). POS N

No POS N
cases POS N
of POS N
drug-related POS N
neutropenic POS N
fever, POS N
sepsis, POS N
or POS N
death POS N
occurred. POS N

The POS N
rate POS N
of POS N
progressive POS N
disease POS N
was POS N
47%, POS N
21%, POS N
and POS N
13% POS N
at POS N
the POS N
same POS N
dose POS N
levels, POS N
respectively. POS N

No POS N
cases POS N
of POS N
drug-related POS N
neutropenic POS N
fever, POS N
sepsis, POS N
or POS N
death POS N
occurred. POS N

Eight POS N
(73%) POS N
of POS N
11 POS N
patients POS N
crossing POS N
over POS N
from POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
to POS N
higher POS N
doses POS N
subsequently POS N
responded. POS N

No POS N
cases POS N
of POS N
drug-related POS N
neutropenic POS N
fever, POS N
sepsis, POS N
or POS N
death POS N
occurred. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
from POS N
start POS N
of POS N
therapy POS N
could POS N
not POS N
be POS N
estimated POS N
for POS N
the POS N
15 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
owing POS N
to POS N
low POS N
relapse POS N
rates POS N
in POS N
2 POS N
patients POS N
(13%); POS N
at POS N
higher POS N
doses POS N
it POS N
was POS N
516 POS N
days. POS N

No POS N
cases POS N
of POS N
drug-related POS N
neutropenic POS N
fever, POS N
sepsis, POS N
or POS N
death POS N
occurred. POS N

The POS N
following POS N
drug-related POS N
adverse POS N
effects POS N
were POS N
reversible POS N
and POS N
treatable: POS N
hypertriglyceridemia POS N
(46 POS N
patients POS N
[79%]), POS N
hypercholesterolemia POS N
(28 POS N
patients POS N
[48%]), POS N
headache POS N
(27 POS N
patients POS N
[47%]), POS N
central POS N
hypothyroidism POS N
(23 POS N
patients POS N
[40%]), POS N
asthenia POS N
(21 POS N
patients POS N
[36%]), POS N
and POS N
leukopenia POS N
(16 POS N
patients POS N
[28%]). POS N

No POS N
cases POS N
of POS N
drug-related POS N
neutropenic POS N
fever, POS N
sepsis, POS N
or POS N
death POS N
occurred. POS N

Pancreatitis POS N
occurred POS N
in POS N
3 POS N
patients POS N
with POS N
triglyceride POS N
levels POS N
higher POS N
than POS N
14.69 POS N
mmol/L POS N
(1300 POS N
mg/dL), POS N
all POS N
of POS N
whom POS N
were POS N
taking POS N
300 POS N
mg/m(2) POS N
or POS N
more POS N
of POS N
oral POS N
bexarotene POS N
per POS N
day. POS N

No POS N
cases POS N
of POS N
drug-related POS N
neutropenic POS N
fever, POS N
sepsis, POS N
or POS N
death POS N
occurred. POS N

Bexarotene POS N
(Targretin POS N
capsules) POS N
(the POS N
first POS N
retinoid POS N
X POS N
receptor-selective POS N
rexinoid) POS N
was POS N
well POS N
tolerated POS N
and POS N
effective POS N
as POS N
an POS N
oral POS N
treatment POS N
for POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
with POS N
refractory POS N
or POS N
persistent POS N
early-stage POS N
cutaneous POS N
T-cell POS N
lymphoma POS N
at POS N
doses POS N
of POS N
300 POS N
mg/m(2) POS N
per POS N
day. POS N

No POS N
cases POS N
of POS N
drug-related POS N
neutropenic POS N
fever, POS N
sepsis, POS N
or POS N
death POS N
occurred. POS N

Hypertriglyceridemia POS N
and POS N
hypothyroidism POS N
require POS N
monitoring POS N
but POS N
are POS N
reversible POS N
and POS N
manageable POS N
with POS N
concomitant POS N
medication. POS N

Pancreatitis POS N
occurred POS N
in POS N
3 POS N
patients POS N
with POS N
triglyceride POS N
levels POS N
higher POS N
than POS N
14.69 POS N
mmol/L POS N
(1300 POS N
mg/dL), POS N
all POS N
of POS N
whom POS N
were POS N
taking POS N
300 POS N
mg/m(2) POS N
or POS N
more POS N
of POS N
oral POS N
bexarotene POS N
per POS N
day. POS N

Responses POS N
(> POS N
or POS N
= POS N
50% POS N
improvement) POS N
were POS N
seen POS N
in POS N
3 POS N
(20%) POS N
of POS N
15 POS N
patients POS N
with POS N
an POS N
initial POS N
dose POS N
at POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0%-40%), POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
35%-72%), POS N
and POS N
10 POS N
(67%) POS N
of POS N
15 POS N
patients POS N
at POS N
above POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
43%-91%). POS N

Pancreatitis POS N
occurred POS N
in POS N
3 POS N
patients POS N
with POS N
triglyceride POS N
levels POS N
higher POS N
than POS N
14.69 POS N
mmol/L POS N
(1300 POS N
mg/dL), POS N
all POS N
of POS N
whom POS N
were POS N
taking POS N
300 POS N
mg/m(2) POS N
or POS N
more POS N
of POS N
oral POS N
bexarotene POS N
per POS N
day. POS N

The POS N
rate POS N
of POS N
progressive POS N
disease POS N
was POS N
47%, POS N
21%, POS N
and POS N
13% POS N
at POS N
the POS N
same POS N
dose POS N
levels, POS N
respectively. POS N

Pancreatitis POS N
occurred POS N
in POS N
3 POS N
patients POS N
with POS N
triglyceride POS N
levels POS N
higher POS N
than POS N
14.69 POS N
mmol/L POS N
(1300 POS N
mg/dL), POS N
all POS N
of POS N
whom POS N
were POS N
taking POS N
300 POS N
mg/m(2) POS N
or POS N
more POS N
of POS N
oral POS N
bexarotene POS N
per POS N
day. POS N

Eight POS N
(73%) POS N
of POS N
11 POS N
patients POS N
crossing POS N
over POS N
from POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
to POS N
higher POS N
doses POS N
subsequently POS N
responded. POS N

Pancreatitis POS N
occurred POS N
in POS N
3 POS N
patients POS N
with POS N
triglyceride POS N
levels POS N
higher POS N
than POS N
14.69 POS N
mmol/L POS N
(1300 POS N
mg/dL), POS N
all POS N
of POS N
whom POS N
were POS N
taking POS N
300 POS N
mg/m(2) POS N
or POS N
more POS N
of POS N
oral POS N
bexarotene POS N
per POS N
day. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
from POS N
start POS N
of POS N
therapy POS N
could POS N
not POS N
be POS N
estimated POS N
for POS N
the POS N
15 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
owing POS N
to POS N
low POS N
relapse POS N
rates POS N
in POS N
2 POS N
patients POS N
(13%); POS N
at POS N
higher POS N
doses POS N
it POS N
was POS N
516 POS N
days. POS N

Pancreatitis POS N
occurred POS N
in POS N
3 POS N
patients POS N
with POS N
triglyceride POS N
levels POS N
higher POS N
than POS N
14.69 POS N
mmol/L POS N
(1300 POS N
mg/dL), POS N
all POS N
of POS N
whom POS N
were POS N
taking POS N
300 POS N
mg/m(2) POS N
or POS N
more POS N
of POS N
oral POS N
bexarotene POS N
per POS N
day. POS N

The POS N
following POS N
drug-related POS N
adverse POS N
effects POS N
were POS N
reversible POS N
and POS N
treatable: POS N
hypertriglyceridemia POS N
(46 POS N
patients POS N
[79%]), POS N
hypercholesterolemia POS N
(28 POS N
patients POS N
[48%]), POS N
headache POS N
(27 POS N
patients POS N
[47%]), POS N
central POS N
hypothyroidism POS N
(23 POS N
patients POS N
[40%]), POS N
asthenia POS N
(21 POS N
patients POS N
[36%]), POS N
and POS N
leukopenia POS N
(16 POS N
patients POS N
[28%]). POS N

Pancreatitis POS N
occurred POS N
in POS N
3 POS N
patients POS N
with POS N
triglyceride POS N
levels POS N
higher POS N
than POS N
14.69 POS N
mmol/L POS N
(1300 POS N
mg/dL), POS N
all POS N
of POS N
whom POS N
were POS N
taking POS N
300 POS N
mg/m(2) POS N
or POS N
more POS N
of POS N
oral POS N
bexarotene POS N
per POS N
day. POS N

No POS N
cases POS N
of POS N
drug-related POS N
neutropenic POS N
fever, POS N
sepsis, POS N
or POS N
death POS N
occurred. POS N

Pancreatitis POS N
occurred POS N
in POS N
3 POS N
patients POS N
with POS N
triglyceride POS N
levels POS N
higher POS N
than POS N
14.69 POS N
mmol/L POS N
(1300 POS N
mg/dL), POS N
all POS N
of POS N
whom POS N
were POS N
taking POS N
300 POS N
mg/m(2) POS N
or POS N
more POS N
of POS N
oral POS N
bexarotene POS N
per POS N
day. POS N

Bexarotene POS N
(Targretin POS N
capsules) POS N
(the POS N
first POS N
retinoid POS N
X POS N
receptor-selective POS N
rexinoid) POS N
was POS N
well POS N
tolerated POS N
and POS N
effective POS N
as POS N
an POS N
oral POS N
treatment POS N
for POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
with POS N
refractory POS N
or POS N
persistent POS N
early-stage POS N
cutaneous POS N
T-cell POS N
lymphoma POS N
at POS N
doses POS N
of POS N
300 POS N
mg/m(2) POS N
per POS N
day. POS N

Pancreatitis POS N
occurred POS N
in POS N
3 POS N
patients POS N
with POS N
triglyceride POS N
levels POS N
higher POS N
than POS N
14.69 POS N
mmol/L POS N
(1300 POS N
mg/dL), POS N
all POS N
of POS N
whom POS N
were POS N
taking POS N
300 POS N
mg/m(2) POS N
or POS N
more POS N
of POS N
oral POS N
bexarotene POS N
per POS N
day. POS N

Hypertriglyceridemia POS N
and POS N
hypothyroidism POS N
require POS N
monitoring POS N
but POS N
are POS N
reversible POS N
and POS N
manageable POS N
with POS N
concomitant POS N
medication. POS N

Bexarotene POS N
(Targretin POS N
capsules) POS N
(the POS N
first POS N
retinoid POS N
X POS N
receptor-selective POS N
rexinoid) POS N
was POS N
well POS N
tolerated POS N
and POS N
effective POS N
as POS N
an POS N
oral POS N
treatment POS N
for POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
with POS N
refractory POS N
or POS N
persistent POS N
early-stage POS N
cutaneous POS N
T-cell POS N
lymphoma POS N
at POS N
doses POS N
of POS N
300 POS N
mg/m(2) POS N
per POS N
day. POS N

Responses POS N
(> POS N
or POS N
= POS N
50% POS N
improvement) POS N
were POS N
seen POS N
in POS N
3 POS N
(20%) POS N
of POS N
15 POS N
patients POS N
with POS N
an POS N
initial POS N
dose POS N
at POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0%-40%), POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
35%-72%), POS N
and POS N
10 POS N
(67%) POS N
of POS N
15 POS N
patients POS N
at POS N
above POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
43%-91%). POS N

Bexarotene POS N
(Targretin POS N
capsules) POS N
(the POS N
first POS N
retinoid POS N
X POS N
receptor-selective POS N
rexinoid) POS N
was POS N
well POS N
tolerated POS N
and POS N
effective POS N
as POS N
an POS N
oral POS N
treatment POS N
for POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
with POS N
refractory POS N
or POS N
persistent POS N
early-stage POS N
cutaneous POS N
T-cell POS N
lymphoma POS N
at POS N
doses POS N
of POS N
300 POS N
mg/m(2) POS N
per POS N
day. POS N

The POS N
rate POS N
of POS N
progressive POS N
disease POS N
was POS N
47%, POS N
21%, POS N
and POS N
13% POS N
at POS N
the POS N
same POS N
dose POS N
levels, POS N
respectively. POS N

Bexarotene POS N
(Targretin POS N
capsules) POS N
(the POS N
first POS N
retinoid POS N
X POS N
receptor-selective POS N
rexinoid) POS N
was POS N
well POS N
tolerated POS N
and POS N
effective POS N
as POS N
an POS N
oral POS N
treatment POS N
for POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
with POS N
refractory POS N
or POS N
persistent POS N
early-stage POS N
cutaneous POS N
T-cell POS N
lymphoma POS N
at POS N
doses POS N
of POS N
300 POS N
mg/m(2) POS N
per POS N
day. POS N

Eight POS N
(73%) POS N
of POS N
11 POS N
patients POS N
crossing POS N
over POS N
from POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
to POS N
higher POS N
doses POS N
subsequently POS N
responded. POS N

Bexarotene POS N
(Targretin POS N
capsules) POS N
(the POS N
first POS N
retinoid POS N
X POS N
receptor-selective POS N
rexinoid) POS N
was POS N
well POS N
tolerated POS N
and POS N
effective POS N
as POS N
an POS N
oral POS N
treatment POS N
for POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
with POS N
refractory POS N
or POS N
persistent POS N
early-stage POS N
cutaneous POS N
T-cell POS N
lymphoma POS N
at POS N
doses POS N
of POS N
300 POS N
mg/m(2) POS N
per POS N
day. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
from POS N
start POS N
of POS N
therapy POS N
could POS N
not POS N
be POS N
estimated POS N
for POS N
the POS N
15 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
owing POS N
to POS N
low POS N
relapse POS N
rates POS N
in POS N
2 POS N
patients POS N
(13%); POS N
at POS N
higher POS N
doses POS N
it POS N
was POS N
516 POS N
days. POS N

Bexarotene POS N
(Targretin POS N
capsules) POS N
(the POS N
first POS N
retinoid POS N
X POS N
receptor-selective POS N
rexinoid) POS N
was POS N
well POS N
tolerated POS N
and POS N
effective POS N
as POS N
an POS N
oral POS N
treatment POS N
for POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
with POS N
refractory POS N
or POS N
persistent POS N
early-stage POS N
cutaneous POS N
T-cell POS N
lymphoma POS N
at POS N
doses POS N
of POS N
300 POS N
mg/m(2) POS N
per POS N
day. POS N

The POS N
following POS N
drug-related POS N
adverse POS N
effects POS N
were POS N
reversible POS N
and POS N
treatable: POS N
hypertriglyceridemia POS N
(46 POS N
patients POS N
[79%]), POS N
hypercholesterolemia POS N
(28 POS N
patients POS N
[48%]), POS N
headache POS N
(27 POS N
patients POS N
[47%]), POS N
central POS N
hypothyroidism POS N
(23 POS N
patients POS N
[40%]), POS N
asthenia POS N
(21 POS N
patients POS N
[36%]), POS N
and POS N
leukopenia POS N
(16 POS N
patients POS N
[28%]). POS N

Bexarotene POS N
(Targretin POS N
capsules) POS N
(the POS N
first POS N
retinoid POS N
X POS N
receptor-selective POS N
rexinoid) POS N
was POS N
well POS N
tolerated POS N
and POS N
effective POS N
as POS N
an POS N
oral POS N
treatment POS N
for POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
with POS N
refractory POS N
or POS N
persistent POS N
early-stage POS N
cutaneous POS N
T-cell POS N
lymphoma POS N
at POS N
doses POS N
of POS N
300 POS N
mg/m(2) POS N
per POS N
day. POS N

No POS N
cases POS N
of POS N
drug-related POS N
neutropenic POS N
fever, POS N
sepsis, POS N
or POS N
death POS N
occurred. POS N

Bexarotene POS N
(Targretin POS N
capsules) POS N
(the POS N
first POS N
retinoid POS N
X POS N
receptor-selective POS N
rexinoid) POS N
was POS N
well POS N
tolerated POS N
and POS N
effective POS N
as POS N
an POS N
oral POS N
treatment POS N
for POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
with POS N
refractory POS N
or POS N
persistent POS N
early-stage POS N
cutaneous POS N
T-cell POS N
lymphoma POS N
at POS N
doses POS N
of POS N
300 POS N
mg/m(2) POS N
per POS N
day. POS N

Pancreatitis POS N
occurred POS N
in POS N
3 POS N
patients POS N
with POS N
triglyceride POS N
levels POS N
higher POS N
than POS N
14.69 POS N
mmol/L POS N
(1300 POS N
mg/dL), POS N
all POS N
of POS N
whom POS N
were POS N
taking POS N
300 POS N
mg/m(2) POS N
or POS N
more POS N
of POS N
oral POS N
bexarotene POS N
per POS N
day. POS N

Bexarotene POS N
(Targretin POS N
capsules) POS N
(the POS N
first POS N
retinoid POS N
X POS N
receptor-selective POS N
rexinoid) POS N
was POS N
well POS N
tolerated POS N
and POS N
effective POS N
as POS N
an POS N
oral POS N
treatment POS N
for POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
with POS N
refractory POS N
or POS N
persistent POS N
early-stage POS N
cutaneous POS N
T-cell POS N
lymphoma POS N
at POS N
doses POS N
of POS N
300 POS N
mg/m(2) POS N
per POS N
day. POS N

Hypertriglyceridemia POS N
and POS N
hypothyroidism POS N
require POS N
monitoring POS N
but POS N
are POS N
reversible POS N
and POS N
manageable POS N
with POS N
concomitant POS N
medication. POS N

Hypertriglyceridemia POS N
and POS N
hypothyroidism POS N
require POS N
monitoring POS N
but POS N
are POS N
reversible POS N
and POS N
manageable POS N
with POS N
concomitant POS N
medication. POS N

Responses POS N
(> POS N
or POS N
= POS N
50% POS N
improvement) POS N
were POS N
seen POS N
in POS N
3 POS N
(20%) POS N
of POS N
15 POS N
patients POS N
with POS N
an POS N
initial POS N
dose POS N
at POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0%-40%), POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
35%-72%), POS N
and POS N
10 POS N
(67%) POS N
of POS N
15 POS N
patients POS N
at POS N
above POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
(95% POS N
CI, POS N
43%-91%). POS N

Hypertriglyceridemia POS N
and POS N
hypothyroidism POS N
require POS N
monitoring POS N
but POS N
are POS N
reversible POS N
and POS N
manageable POS N
with POS N
concomitant POS N
medication. POS N

The POS N
rate POS N
of POS N
progressive POS N
disease POS N
was POS N
47%, POS N
21%, POS N
and POS N
13% POS N
at POS N
the POS N
same POS N
dose POS N
levels, POS N
respectively. POS N

Hypertriglyceridemia POS N
and POS N
hypothyroidism POS N
require POS N
monitoring POS N
but POS N
are POS N
reversible POS N
and POS N
manageable POS N
with POS N
concomitant POS N
medication. POS N

Eight POS N
(73%) POS N
of POS N
11 POS N
patients POS N
crossing POS N
over POS N
from POS N
6.5 POS N
mg/m(2) POS N
per POS N
day POS N
to POS N
higher POS N
doses POS N
subsequently POS N
responded. POS N

Hypertriglyceridemia POS N
and POS N
hypothyroidism POS N
require POS N
monitoring POS N
but POS N
are POS N
reversible POS N
and POS N
manageable POS N
with POS N
concomitant POS N
medication. POS N

The POS N
median POS N
duration POS N
of POS N
response POS N
from POS N
start POS N
of POS N
therapy POS N
could POS N
not POS N
be POS N
estimated POS N
for POS N
the POS N
15 POS N
patients POS N
at POS N
300 POS N
mg/m(2) POS N
per POS N
day POS N
owing POS N
to POS N
low POS N
relapse POS N
rates POS N
in POS N
2 POS N
patients POS N
(13%); POS N
at POS N
higher POS N
doses POS N
it POS N
was POS N
516 POS N
days. POS N

Hypertriglyceridemia POS N
and POS N
hypothyroidism POS N
require POS N
monitoring POS N
but POS N
are POS N
reversible POS N
and POS N
manageable POS N
with POS N
concomitant POS N
medication. POS N

The POS N
following POS N
drug-related POS N
adverse POS N
effects POS N
were POS N
reversible POS N
and POS N
treatable: POS N
hypertriglyceridemia POS N
(46 POS N
patients POS N
[79%]), POS N
hypercholesterolemia POS N
(28 POS N
patients POS N
[48%]), POS N
headache POS N
(27 POS N
patients POS N
[47%]), POS N
central POS N
hypothyroidism POS N
(23 POS N
patients POS N
[40%]), POS N
asthenia POS N
(21 POS N
patients POS N
[36%]), POS N
and POS N
leukopenia POS N
(16 POS N
patients POS N
[28%]). POS N

Hypertriglyceridemia POS N
and POS N
hypothyroidism POS N
require POS N
monitoring POS N
but POS N
are POS N
reversible POS N
and POS N
manageable POS N
with POS N
concomitant POS N
medication. POS N

No POS N
cases POS N
of POS N
drug-related POS N
neutropenic POS N
fever, POS N
sepsis, POS N
or POS N
death POS N
occurred. POS N

Hypertriglyceridemia POS N
and POS N
hypothyroidism POS N
require POS N
monitoring POS N
but POS N
are POS N
reversible POS N
and POS N
manageable POS N
with POS N
concomitant POS N
medication. POS N

Pancreatitis POS N
occurred POS N
in POS N
3 POS N
patients POS N
with POS N
triglyceride POS N
levels POS N
higher POS N
than POS N
14.69 POS N
mmol/L POS N
(1300 POS N
mg/dL), POS N
all POS N
of POS N
whom POS N
were POS N
taking POS N
300 POS N
mg/m(2) POS N
or POS N
more POS N
of POS N
oral POS N
bexarotene POS N
per POS N
day. POS N

Hypertriglyceridemia POS N
and POS N
hypothyroidism POS N
require POS N
monitoring POS N
but POS N
are POS N
reversible POS N
and POS N
manageable POS N
with POS N
concomitant POS N
medication. POS N

Bexarotene POS N
(Targretin POS N
capsules) POS N
(the POS N
first POS N
retinoid POS N
X POS N
receptor-selective POS N
rexinoid) POS N
was POS N
well POS N
tolerated POS N
and POS N
effective POS N
as POS N
an POS N
oral POS N
treatment POS N
for POS N
15 POS N
(54%) POS N
of POS N
28 POS N
patients POS N
with POS N
refractory POS N
or POS N
persistent POS N
early-stage POS N
cutaneous POS N
T-cell POS N
lymphoma POS N
at POS N
doses POS N
of POS N
300 POS N
mg/m(2) POS N
per POS N
day. POS N

TDF POS N
monotherapy POS N
was POS N
efficacious POS N
and POS N
safe POS N
for POS N
up POS N
to POS N
144 POS N
weeks, POS N
providing POS N
an POS N
increasing POS N
rate POS N
of POS N
virologic POS N
response POS N
in POS N
heavily POS N
pretreated POS N
patients POS N
with POS N
multidrug-resistant POS N
HBV. POS N

Serum POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
48, POS N
the POS N
primary POS N
efficacy POS N
endpoint, POS N
was POS N
achieved POS N
in POS N
66.3% POS N
in POS N
the POS N
TDF-TDF POS N
group POS N
and POS N
68.0% POS N
in POS N
the POS N
TDF/ETV-TDF POS N
group POS N
(P POS N
= POS N
0.80). POS N

TDF POS N
monotherapy POS N
was POS N
efficacious POS N
and POS N
safe POS N
for POS N
up POS N
to POS N
144 POS N
weeks, POS N
providing POS N
an POS N
increasing POS N
rate POS N
of POS N
virologic POS N
response POS N
in POS N
heavily POS N
pretreated POS N
patients POS N
with POS N
multidrug-resistant POS N
HBV. POS N

At POS N
week POS N
144, POS N
the POS N
proportion POS N
with POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
increased POS N
to POS N
74.5%, POS N
which POS N
was POS N
significantly POS N
higher POS N
compared POS N
with POS N
that POS N
at POS N
week POS N
48 POS N
(P POS N
= POS N
0.03), POS N
without POS N
a POS N
significant POS N
difference POS N
between POS N
groups POS N
(P POS N
= POS N
0.46). POS N

TDF POS N
monotherapy POS N
was POS N
efficacious POS N
and POS N
safe POS N
for POS N
up POS N
to POS N
144 POS N
weeks, POS N
providing POS N
an POS N
increasing POS N
rate POS N
of POS N
virologic POS N
response POS N
in POS N
heavily POS N
pretreated POS N
patients POS N
with POS N
multidrug-resistant POS N
HBV. POS N

By POS N
on-treatment POS N
analysis, POS N
a POS N
total POS N
of POS N
79.4% POS N
had POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
144. POS N

TDF POS N
monotherapy POS N
was POS N
efficacious POS N
and POS N
safe POS N
for POS N
up POS N
to POS N
144 POS N
weeks, POS N
providing POS N
an POS N
increasing POS N
rate POS N
of POS N
virologic POS N
response POS N
in POS N
heavily POS N
pretreated POS N
patients POS N
with POS N
multidrug-resistant POS N
HBV. POS N

Transient POS N
virologic POS N
breakthrough POS N
occurred POS N
in POS N
6 POS N
patients, POS N
which POS N
was POS N
due POS N
to POS N
poor POS N
drug POS N
adherence. POS N

TDF POS N
monotherapy POS N
was POS N
efficacious POS N
and POS N
safe POS N
for POS N
up POS N
to POS N
144 POS N
weeks, POS N
providing POS N
an POS N
increasing POS N
rate POS N
of POS N
virologic POS N
response POS N
in POS N
heavily POS N
pretreated POS N
patients POS N
with POS N
multidrug-resistant POS N
HBV. POS N

At POS N
week POS N
144, POS N
19 POS N
patients POS N
who POS N
had POS N
HBV POS N
DNA POS N
levels POS N
>60 POS N
IU/mL POS N
qualified POS N
for POS N
genotypic POS N
resistance POS N
analysis, POS N
and POS N
6 POS N
retained POS N
some POS N
of POS N
their POS N
baseline POS N
resistance POS N
mutations POS N
of POS N
HBV. POS N

TDF POS N
monotherapy POS N
was POS N
efficacious POS N
and POS N
safe POS N
for POS N
up POS N
to POS N
144 POS N
weeks, POS N
providing POS N
an POS N
increasing POS N
rate POS N
of POS N
virologic POS N
response POS N
in POS N
heavily POS N
pretreated POS N
patients POS N
with POS N
multidrug-resistant POS N
HBV. POS N

No POS N
patients POS N
developed POS N
additional POS N
resistance POS N
mutations POS N
throughout POS N
the POS N
study POS N
period. POS N

Serum POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
48, POS N
the POS N
primary POS N
efficacy POS N
endpoint, POS N
was POS N
achieved POS N
in POS N
66.3% POS N
in POS N
the POS N
TDF-TDF POS N
group POS N
and POS N
68.0% POS N
in POS N
the POS N
TDF/ETV-TDF POS N
group POS N
(P POS N
= POS N
0.80). POS N

TDF POS N
monotherapy POS N
was POS N
efficacious POS N
and POS N
safe POS N
for POS N
up POS N
to POS N
144 POS N
weeks, POS N
providing POS N
an POS N
increasing POS N
rate POS N
of POS N
virologic POS N
response POS N
in POS N
heavily POS N
pretreated POS N
patients POS N
with POS N
multidrug-resistant POS N
HBV. POS N

Serum POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
48, POS N
the POS N
primary POS N
efficacy POS N
endpoint, POS N
was POS N
achieved POS N
in POS N
66.3% POS N
in POS N
the POS N
TDF-TDF POS N
group POS N
and POS N
68.0% POS N
in POS N
the POS N
TDF/ETV-TDF POS N
group POS N
(P POS N
= POS N
0.80). POS N

At POS N
week POS N
144, POS N
the POS N
proportion POS N
with POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
increased POS N
to POS N
74.5%, POS N
which POS N
was POS N
significantly POS N
higher POS N
compared POS N
with POS N
that POS N
at POS N
week POS N
48 POS N
(P POS N
= POS N
0.03), POS N
without POS N
a POS N
significant POS N
difference POS N
between POS N
groups POS N
(P POS N
= POS N
0.46). POS N

Serum POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
48, POS N
the POS N
primary POS N
efficacy POS N
endpoint, POS N
was POS N
achieved POS N
in POS N
66.3% POS N
in POS N
the POS N
TDF-TDF POS N
group POS N
and POS N
68.0% POS N
in POS N
the POS N
TDF/ETV-TDF POS N
group POS N
(P POS N
= POS N
0.80). POS N

By POS N
on-treatment POS N
analysis, POS N
a POS N
total POS N
of POS N
79.4% POS N
had POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
144. POS N

Serum POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
48, POS N
the POS N
primary POS N
efficacy POS N
endpoint, POS N
was POS N
achieved POS N
in POS N
66.3% POS N
in POS N
the POS N
TDF-TDF POS N
group POS N
and POS N
68.0% POS N
in POS N
the POS N
TDF/ETV-TDF POS N
group POS N
(P POS N
= POS N
0.80). POS N

Transient POS N
virologic POS N
breakthrough POS N
occurred POS N
in POS N
6 POS N
patients, POS N
which POS N
was POS N
due POS N
to POS N
poor POS N
drug POS N
adherence. POS N

Serum POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
48, POS N
the POS N
primary POS N
efficacy POS N
endpoint, POS N
was POS N
achieved POS N
in POS N
66.3% POS N
in POS N
the POS N
TDF-TDF POS N
group POS N
and POS N
68.0% POS N
in POS N
the POS N
TDF/ETV-TDF POS N
group POS N
(P POS N
= POS N
0.80). POS N

At POS N
week POS N
144, POS N
19 POS N
patients POS N
who POS N
had POS N
HBV POS N
DNA POS N
levels POS N
>60 POS N
IU/mL POS N
qualified POS N
for POS N
genotypic POS N
resistance POS N
analysis, POS N
and POS N
6 POS N
retained POS N
some POS N
of POS N
their POS N
baseline POS N
resistance POS N
mutations POS N
of POS N
HBV. POS N

Serum POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
48, POS N
the POS N
primary POS N
efficacy POS N
endpoint, POS N
was POS N
achieved POS N
in POS N
66.3% POS N
in POS N
the POS N
TDF-TDF POS N
group POS N
and POS N
68.0% POS N
in POS N
the POS N
TDF/ETV-TDF POS N
group POS N
(P POS N
= POS N
0.80). POS N

No POS N
patients POS N
developed POS N
additional POS N
resistance POS N
mutations POS N
throughout POS N
the POS N
study POS N
period. POS N

At POS N
week POS N
144, POS N
the POS N
proportion POS N
with POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
increased POS N
to POS N
74.5%, POS N
which POS N
was POS N
significantly POS N
higher POS N
compared POS N
with POS N
that POS N
at POS N
week POS N
48 POS N
(P POS N
= POS N
0.03), POS N
without POS N
a POS N
significant POS N
difference POS N
between POS N
groups POS N
(P POS N
= POS N
0.46). POS N

TDF POS N
monotherapy POS N
was POS N
efficacious POS N
and POS N
safe POS N
for POS N
up POS N
to POS N
144 POS N
weeks, POS N
providing POS N
an POS N
increasing POS N
rate POS N
of POS N
virologic POS N
response POS N
in POS N
heavily POS N
pretreated POS N
patients POS N
with POS N
multidrug-resistant POS N
HBV. POS N

At POS N
week POS N
144, POS N
the POS N
proportion POS N
with POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
increased POS N
to POS N
74.5%, POS N
which POS N
was POS N
significantly POS N
higher POS N
compared POS N
with POS N
that POS N
at POS N
week POS N
48 POS N
(P POS N
= POS N
0.03), POS N
without POS N
a POS N
significant POS N
difference POS N
between POS N
groups POS N
(P POS N
= POS N
0.46). POS N

Serum POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
48, POS N
the POS N
primary POS N
efficacy POS N
endpoint, POS N
was POS N
achieved POS N
in POS N
66.3% POS N
in POS N
the POS N
TDF-TDF POS N
group POS N
and POS N
68.0% POS N
in POS N
the POS N
TDF/ETV-TDF POS N
group POS N
(P POS N
= POS N
0.80). POS N

At POS N
week POS N
144, POS N
the POS N
proportion POS N
with POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
increased POS N
to POS N
74.5%, POS N
which POS N
was POS N
significantly POS N
higher POS N
compared POS N
with POS N
that POS N
at POS N
week POS N
48 POS N
(P POS N
= POS N
0.03), POS N
without POS N
a POS N
significant POS N
difference POS N
between POS N
groups POS N
(P POS N
= POS N
0.46). POS N

By POS N
on-treatment POS N
analysis, POS N
a POS N
total POS N
of POS N
79.4% POS N
had POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
144. POS N

At POS N
week POS N
144, POS N
the POS N
proportion POS N
with POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
increased POS N
to POS N
74.5%, POS N
which POS N
was POS N
significantly POS N
higher POS N
compared POS N
with POS N
that POS N
at POS N
week POS N
48 POS N
(P POS N
= POS N
0.03), POS N
without POS N
a POS N
significant POS N
difference POS N
between POS N
groups POS N
(P POS N
= POS N
0.46). POS N

Transient POS N
virologic POS N
breakthrough POS N
occurred POS N
in POS N
6 POS N
patients, POS N
which POS N
was POS N
due POS N
to POS N
poor POS N
drug POS N
adherence. POS N

At POS N
week POS N
144, POS N
the POS N
proportion POS N
with POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
increased POS N
to POS N
74.5%, POS N
which POS N
was POS N
significantly POS N
higher POS N
compared POS N
with POS N
that POS N
at POS N
week POS N
48 POS N
(P POS N
= POS N
0.03), POS N
without POS N
a POS N
significant POS N
difference POS N
between POS N
groups POS N
(P POS N
= POS N
0.46). POS N

At POS N
week POS N
144, POS N
19 POS N
patients POS N
who POS N
had POS N
HBV POS N
DNA POS N
levels POS N
>60 POS N
IU/mL POS N
qualified POS N
for POS N
genotypic POS N
resistance POS N
analysis, POS N
and POS N
6 POS N
retained POS N
some POS N
of POS N
their POS N
baseline POS N
resistance POS N
mutations POS N
of POS N
HBV. POS N

At POS N
week POS N
144, POS N
the POS N
proportion POS N
with POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
increased POS N
to POS N
74.5%, POS N
which POS N
was POS N
significantly POS N
higher POS N
compared POS N
with POS N
that POS N
at POS N
week POS N
48 POS N
(P POS N
= POS N
0.03), POS N
without POS N
a POS N
significant POS N
difference POS N
between POS N
groups POS N
(P POS N
= POS N
0.46). POS N

No POS N
patients POS N
developed POS N
additional POS N
resistance POS N
mutations POS N
throughout POS N
the POS N
study POS N
period. POS N

By POS N
on-treatment POS N
analysis, POS N
a POS N
total POS N
of POS N
79.4% POS N
had POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
144. POS N

TDF POS N
monotherapy POS N
was POS N
efficacious POS N
and POS N
safe POS N
for POS N
up POS N
to POS N
144 POS N
weeks, POS N
providing POS N
an POS N
increasing POS N
rate POS N
of POS N
virologic POS N
response POS N
in POS N
heavily POS N
pretreated POS N
patients POS N
with POS N
multidrug-resistant POS N
HBV. POS N

By POS N
on-treatment POS N
analysis, POS N
a POS N
total POS N
of POS N
79.4% POS N
had POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
144. POS N

Serum POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
48, POS N
the POS N
primary POS N
efficacy POS N
endpoint, POS N
was POS N
achieved POS N
in POS N
66.3% POS N
in POS N
the POS N
TDF-TDF POS N
group POS N
and POS N
68.0% POS N
in POS N
the POS N
TDF/ETV-TDF POS N
group POS N
(P POS N
= POS N
0.80). POS N

By POS N
on-treatment POS N
analysis, POS N
a POS N
total POS N
of POS N
79.4% POS N
had POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
144. POS N

At POS N
week POS N
144, POS N
the POS N
proportion POS N
with POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
increased POS N
to POS N
74.5%, POS N
which POS N
was POS N
significantly POS N
higher POS N
compared POS N
with POS N
that POS N
at POS N
week POS N
48 POS N
(P POS N
= POS N
0.03), POS N
without POS N
a POS N
significant POS N
difference POS N
between POS N
groups POS N
(P POS N
= POS N
0.46). POS N

By POS N
on-treatment POS N
analysis, POS N
a POS N
total POS N
of POS N
79.4% POS N
had POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
144. POS N

Transient POS N
virologic POS N
breakthrough POS N
occurred POS N
in POS N
6 POS N
patients, POS N
which POS N
was POS N
due POS N
to POS N
poor POS N
drug POS N
adherence. POS N

By POS N
on-treatment POS N
analysis, POS N
a POS N
total POS N
of POS N
79.4% POS N
had POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
144. POS N

At POS N
week POS N
144, POS N
19 POS N
patients POS N
who POS N
had POS N
HBV POS N
DNA POS N
levels POS N
>60 POS N
IU/mL POS N
qualified POS N
for POS N
genotypic POS N
resistance POS N
analysis, POS N
and POS N
6 POS N
retained POS N
some POS N
of POS N
their POS N
baseline POS N
resistance POS N
mutations POS N
of POS N
HBV. POS N

By POS N
on-treatment POS N
analysis, POS N
a POS N
total POS N
of POS N
79.4% POS N
had POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
144. POS N

No POS N
patients POS N
developed POS N
additional POS N
resistance POS N
mutations POS N
throughout POS N
the POS N
study POS N
period. POS N

Transient POS N
virologic POS N
breakthrough POS N
occurred POS N
in POS N
6 POS N
patients, POS N
which POS N
was POS N
due POS N
to POS N
poor POS N
drug POS N
adherence. POS N

TDF POS N
monotherapy POS N
was POS N
efficacious POS N
and POS N
safe POS N
for POS N
up POS N
to POS N
144 POS N
weeks, POS N
providing POS N
an POS N
increasing POS N
rate POS N
of POS N
virologic POS N
response POS N
in POS N
heavily POS N
pretreated POS N
patients POS N
with POS N
multidrug-resistant POS N
HBV. POS N

Transient POS N
virologic POS N
breakthrough POS N
occurred POS N
in POS N
6 POS N
patients, POS N
which POS N
was POS N
due POS N
to POS N
poor POS N
drug POS N
adherence. POS N

Serum POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
48, POS N
the POS N
primary POS N
efficacy POS N
endpoint, POS N
was POS N
achieved POS N
in POS N
66.3% POS N
in POS N
the POS N
TDF-TDF POS N
group POS N
and POS N
68.0% POS N
in POS N
the POS N
TDF/ETV-TDF POS N
group POS N
(P POS N
= POS N
0.80). POS N

Transient POS N
virologic POS N
breakthrough POS N
occurred POS N
in POS N
6 POS N
patients, POS N
which POS N
was POS N
due POS N
to POS N
poor POS N
drug POS N
adherence. POS N

At POS N
week POS N
144, POS N
the POS N
proportion POS N
with POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
increased POS N
to POS N
74.5%, POS N
which POS N
was POS N
significantly POS N
higher POS N
compared POS N
with POS N
that POS N
at POS N
week POS N
48 POS N
(P POS N
= POS N
0.03), POS N
without POS N
a POS N
significant POS N
difference POS N
between POS N
groups POS N
(P POS N
= POS N
0.46). POS N

Transient POS N
virologic POS N
breakthrough POS N
occurred POS N
in POS N
6 POS N
patients, POS N
which POS N
was POS N
due POS N
to POS N
poor POS N
drug POS N
adherence. POS N

By POS N
on-treatment POS N
analysis, POS N
a POS N
total POS N
of POS N
79.4% POS N
had POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
144. POS N

Transient POS N
virologic POS N
breakthrough POS N
occurred POS N
in POS N
6 POS N
patients, POS N
which POS N
was POS N
due POS N
to POS N
poor POS N
drug POS N
adherence. POS N

At POS N
week POS N
144, POS N
19 POS N
patients POS N
who POS N
had POS N
HBV POS N
DNA POS N
levels POS N
>60 POS N
IU/mL POS N
qualified POS N
for POS N
genotypic POS N
resistance POS N
analysis, POS N
and POS N
6 POS N
retained POS N
some POS N
of POS N
their POS N
baseline POS N
resistance POS N
mutations POS N
of POS N
HBV. POS N

Transient POS N
virologic POS N
breakthrough POS N
occurred POS N
in POS N
6 POS N
patients, POS N
which POS N
was POS N
due POS N
to POS N
poor POS N
drug POS N
adherence. POS N

No POS N
patients POS N
developed POS N
additional POS N
resistance POS N
mutations POS N
throughout POS N
the POS N
study POS N
period. POS N

At POS N
week POS N
144, POS N
19 POS N
patients POS N
who POS N
had POS N
HBV POS N
DNA POS N
levels POS N
>60 POS N
IU/mL POS N
qualified POS N
for POS N
genotypic POS N
resistance POS N
analysis, POS N
and POS N
6 POS N
retained POS N
some POS N
of POS N
their POS N
baseline POS N
resistance POS N
mutations POS N
of POS N
HBV. POS N

TDF POS N
monotherapy POS N
was POS N
efficacious POS N
and POS N
safe POS N
for POS N
up POS N
to POS N
144 POS N
weeks, POS N
providing POS N
an POS N
increasing POS N
rate POS N
of POS N
virologic POS N
response POS N
in POS N
heavily POS N
pretreated POS N
patients POS N
with POS N
multidrug-resistant POS N
HBV. POS N

At POS N
week POS N
144, POS N
19 POS N
patients POS N
who POS N
had POS N
HBV POS N
DNA POS N
levels POS N
>60 POS N
IU/mL POS N
qualified POS N
for POS N
genotypic POS N
resistance POS N
analysis, POS N
and POS N
6 POS N
retained POS N
some POS N
of POS N
their POS N
baseline POS N
resistance POS N
mutations POS N
of POS N
HBV. POS N

Serum POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
48, POS N
the POS N
primary POS N
efficacy POS N
endpoint, POS N
was POS N
achieved POS N
in POS N
66.3% POS N
in POS N
the POS N
TDF-TDF POS N
group POS N
and POS N
68.0% POS N
in POS N
the POS N
TDF/ETV-TDF POS N
group POS N
(P POS N
= POS N
0.80). POS N

At POS N
week POS N
144, POS N
19 POS N
patients POS N
who POS N
had POS N
HBV POS N
DNA POS N
levels POS N
>60 POS N
IU/mL POS N
qualified POS N
for POS N
genotypic POS N
resistance POS N
analysis, POS N
and POS N
6 POS N
retained POS N
some POS N
of POS N
their POS N
baseline POS N
resistance POS N
mutations POS N
of POS N
HBV. POS N

At POS N
week POS N
144, POS N
the POS N
proportion POS N
with POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
increased POS N
to POS N
74.5%, POS N
which POS N
was POS N
significantly POS N
higher POS N
compared POS N
with POS N
that POS N
at POS N
week POS N
48 POS N
(P POS N
= POS N
0.03), POS N
without POS N
a POS N
significant POS N
difference POS N
between POS N
groups POS N
(P POS N
= POS N
0.46). POS N

At POS N
week POS N
144, POS N
19 POS N
patients POS N
who POS N
had POS N
HBV POS N
DNA POS N
levels POS N
>60 POS N
IU/mL POS N
qualified POS N
for POS N
genotypic POS N
resistance POS N
analysis, POS N
and POS N
6 POS N
retained POS N
some POS N
of POS N
their POS N
baseline POS N
resistance POS N
mutations POS N
of POS N
HBV. POS N

By POS N
on-treatment POS N
analysis, POS N
a POS N
total POS N
of POS N
79.4% POS N
had POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
144. POS N

At POS N
week POS N
144, POS N
19 POS N
patients POS N
who POS N
had POS N
HBV POS N
DNA POS N
levels POS N
>60 POS N
IU/mL POS N
qualified POS N
for POS N
genotypic POS N
resistance POS N
analysis, POS N
and POS N
6 POS N
retained POS N
some POS N
of POS N
their POS N
baseline POS N
resistance POS N
mutations POS N
of POS N
HBV. POS N

Transient POS N
virologic POS N
breakthrough POS N
occurred POS N
in POS N
6 POS N
patients, POS N
which POS N
was POS N
due POS N
to POS N
poor POS N
drug POS N
adherence. POS N

At POS N
week POS N
144, POS N
19 POS N
patients POS N
who POS N
had POS N
HBV POS N
DNA POS N
levels POS N
>60 POS N
IU/mL POS N
qualified POS N
for POS N
genotypic POS N
resistance POS N
analysis, POS N
and POS N
6 POS N
retained POS N
some POS N
of POS N
their POS N
baseline POS N
resistance POS N
mutations POS N
of POS N
HBV. POS N

No POS N
patients POS N
developed POS N
additional POS N
resistance POS N
mutations POS N
throughout POS N
the POS N
study POS N
period. POS N

No POS N
patients POS N
developed POS N
additional POS N
resistance POS N
mutations POS N
throughout POS N
the POS N
study POS N
period. POS N

TDF POS N
monotherapy POS N
was POS N
efficacious POS N
and POS N
safe POS N
for POS N
up POS N
to POS N
144 POS N
weeks, POS N
providing POS N
an POS N
increasing POS N
rate POS N
of POS N
virologic POS N
response POS N
in POS N
heavily POS N
pretreated POS N
patients POS N
with POS N
multidrug-resistant POS N
HBV. POS N

No POS N
patients POS N
developed POS N
additional POS N
resistance POS N
mutations POS N
throughout POS N
the POS N
study POS N
period. POS N

Serum POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
48, POS N
the POS N
primary POS N
efficacy POS N
endpoint, POS N
was POS N
achieved POS N
in POS N
66.3% POS N
in POS N
the POS N
TDF-TDF POS N
group POS N
and POS N
68.0% POS N
in POS N
the POS N
TDF/ETV-TDF POS N
group POS N
(P POS N
= POS N
0.80). POS N

No POS N
patients POS N
developed POS N
additional POS N
resistance POS N
mutations POS N
throughout POS N
the POS N
study POS N
period. POS N

At POS N
week POS N
144, POS N
the POS N
proportion POS N
with POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
increased POS N
to POS N
74.5%, POS N
which POS N
was POS N
significantly POS N
higher POS N
compared POS N
with POS N
that POS N
at POS N
week POS N
48 POS N
(P POS N
= POS N
0.03), POS N
without POS N
a POS N
significant POS N
difference POS N
between POS N
groups POS N
(P POS N
= POS N
0.46). POS N

No POS N
patients POS N
developed POS N
additional POS N
resistance POS N
mutations POS N
throughout POS N
the POS N
study POS N
period. POS N

By POS N
on-treatment POS N
analysis, POS N
a POS N
total POS N
of POS N
79.4% POS N
had POS N
HBV POS N
DNA POS N
<15 POS N
IU/mL POS N
at POS N
week POS N
144. POS N

No POS N
patients POS N
developed POS N
additional POS N
resistance POS N
mutations POS N
throughout POS N
the POS N
study POS N
period. POS N

Transient POS N
virologic POS N
breakthrough POS N
occurred POS N
in POS N
6 POS N
patients, POS N
which POS N
was POS N
due POS N
to POS N
poor POS N
drug POS N
adherence. POS N

No POS N
patients POS N
developed POS N
additional POS N
resistance POS N
mutations POS N
throughout POS N
the POS N
study POS N
period. POS N

At POS N
week POS N
144, POS N
19 POS N
patients POS N
who POS N
had POS N
HBV POS N
DNA POS N
levels POS N
>60 POS N
IU/mL POS N
qualified POS N
for POS N
genotypic POS N
resistance POS N
analysis, POS N
and POS N
6 POS N
retained POS N
some POS N
of POS N
their POS N
baseline POS N
resistance POS N
mutations POS N
of POS N
HBV. POS N

In POS N
the POS N
primary POS N
intention-to-treat POS N
analysis, POS N
the POS N
effect POS N
of POS N
GLI POS N
encouragement POS N
was POS N
0.95% POS N
weight POS N
loss POS N
at POS N
six POS N
months POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0.13-1.77%; POS N
P = 0.02), POS N
and POS N
1.20% POS N
weight POS N
loss POS N
at POS N
12 months POS N
(95% POS N
CI, POS N
0.05-2.36%; POS N
P = 0.04). POS N

At POS N
12 months, POS N
there POS N
was POS N
a POS N
0.30% POS N
(3.3 mmol/mol) POS N
reduction POS N
in POS N
hemoglobin POS N
A1c, POS N

In POS N
the POS N
primary POS N
intention-to-treat POS N
analysis, POS N
the POS N
effect POS N
of POS N
GLI POS N
encouragement POS N
was POS N
0.95% POS N
weight POS N
loss POS N
at POS N
six POS N
months POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0.13-1.77%; POS N
P = 0.02), POS N
and POS N
1.20% POS N
weight POS N
loss POS N
at POS N
12 months POS N
(95% POS N
CI, POS N
0.05-2.36%; POS N
P = 0.04). POS N

but POS N
this POS N
result POS N
did POS N
not POS N
achieve POS N
statistical POS N
significance POS N
(P = 0.054). POS N

In POS N
the POS N
primary POS N
intention-to-treat POS N
analysis, POS N
the POS N
effect POS N
of POS N
GLI POS N
encouragement POS N
was POS N
0.95% POS N
weight POS N
loss POS N
at POS N
six POS N
months POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0.13-1.77%; POS N
P = 0.02), POS N
and POS N
1.20% POS N
weight POS N
loss POS N
at POS N
12 months POS N
(95% POS N
CI, POS N
0.05-2.36%; POS N
P = 0.04). POS N

In POS N
instrumental POS N
variable POS N
analysis POS N
estimating POS N
effects POS N
among POS N
the POS N
subgroup POS N
of POS N
participants POS N
who POS N
attended POS N
any POS N
GLI POS N
visits, POS N
the POS N
effect POS N
of POS N
GLI POS N
attendance POS N
was POS N
2.30% POS N
weight POS N
loss POS N
at POS N
six POS N
months POS N
(95% POS N
CI, POS N
0.30-4.30%; POS N
P = 0.02), POS N
and POS N
2.07% POS N
weight POS N
loss POS N
at POS N
12 months POS N
(95% POS N
CI, POS N
0.25-3.88%; POS N
P = 0.02). POS N

In POS N
the POS N
primary POS N
intention-to-treat POS N
analysis, POS N
the POS N
effect POS N
of POS N
GLI POS N
encouragement POS N
was POS N
0.95% POS N
weight POS N
loss POS N
at POS N
six POS N
months POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0.13-1.77%; POS N
P = 0.02), POS N
and POS N
1.20% POS N
weight POS N
loss POS N
at POS N
12 months POS N
(95% POS N
CI, POS N
0.05-2.36%; POS N
P = 0.04). POS N

Among POS N
adults POS N
with POS N
type POS N
2 POS N
diabetes, POS N
a POS N
group-based POS N
lifestyle POS N
intervention POS N
in POS N
a POS N
community-based POS N
setting POS N
achieved POS N
modest POS N
weight POS N
loss POS N
at POS N
6 POS N
and POS N
12 months. POS N

At POS N
12 months, POS N
there POS N
was POS N
a POS N
0.30% POS N
(3.3 mmol/mol) POS N
reduction POS N
in POS N
hemoglobin POS N
A1c, POS N

In POS N
the POS N
primary POS N
intention-to-treat POS N
analysis, POS N
the POS N
effect POS N
of POS N
GLI POS N
encouragement POS N
was POS N
0.95% POS N
weight POS N
loss POS N
at POS N
six POS N
months POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0.13-1.77%; POS N
P = 0.02), POS N
and POS N
1.20% POS N
weight POS N
loss POS N
at POS N
12 months POS N
(95% POS N
CI, POS N
0.05-2.36%; POS N
P = 0.04). POS N

At POS N
12 months, POS N
there POS N
was POS N
a POS N
0.30% POS N
(3.3 mmol/mol) POS N
reduction POS N
in POS N
hemoglobin POS N
A1c, POS N

but POS N
this POS N
result POS N
did POS N
not POS N
achieve POS N
statistical POS N
significance POS N
(P = 0.054). POS N

At POS N
12 months, POS N
there POS N
was POS N
a POS N
0.30% POS N
(3.3 mmol/mol) POS N
reduction POS N
in POS N
hemoglobin POS N
A1c, POS N

In POS N
instrumental POS N
variable POS N
analysis POS N
estimating POS N
effects POS N
among POS N
the POS N
subgroup POS N
of POS N
participants POS N
who POS N
attended POS N
any POS N
GLI POS N
visits, POS N
the POS N
effect POS N
of POS N
GLI POS N
attendance POS N
was POS N
2.30% POS N
weight POS N
loss POS N
at POS N
six POS N
months POS N
(95% POS N
CI, POS N
0.30-4.30%; POS N
P = 0.02), POS N
and POS N
2.07% POS N
weight POS N
loss POS N
at POS N
12 months POS N
(95% POS N
CI, POS N
0.25-3.88%; POS N
P = 0.02). POS N

At POS N
12 months, POS N
there POS N
was POS N
a POS N
0.30% POS N
(3.3 mmol/mol) POS N
reduction POS N
in POS N
hemoglobin POS N
A1c, POS N

Among POS N
adults POS N
with POS N
type POS N
2 POS N
diabetes, POS N
a POS N
group-based POS N
lifestyle POS N
intervention POS N
in POS N
a POS N
community-based POS N
setting POS N
achieved POS N
modest POS N
weight POS N
loss POS N
at POS N
6 POS N
and POS N
12 months. POS N

but POS N
this POS N
result POS N
did POS N
not POS N
achieve POS N
statistical POS N
significance POS N
(P = 0.054). POS N

In POS N
the POS N
primary POS N
intention-to-treat POS N
analysis, POS N
the POS N
effect POS N
of POS N
GLI POS N
encouragement POS N
was POS N
0.95% POS N
weight POS N
loss POS N
at POS N
six POS N
months POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0.13-1.77%; POS N
P = 0.02), POS N
and POS N
1.20% POS N
weight POS N
loss POS N
at POS N
12 months POS N
(95% POS N
CI, POS N
0.05-2.36%; POS N
P = 0.04). POS N

but POS N
this POS N
result POS N
did POS N
not POS N
achieve POS N
statistical POS N
significance POS N
(P = 0.054). POS N

At POS N
12 months, POS N
there POS N
was POS N
a POS N
0.30% POS N
(3.3 mmol/mol) POS N
reduction POS N
in POS N
hemoglobin POS N
A1c, POS N

but POS N
this POS N
result POS N
did POS N
not POS N
achieve POS N
statistical POS N
significance POS N
(P = 0.054). POS N

In POS N
instrumental POS N
variable POS N
analysis POS N
estimating POS N
effects POS N
among POS N
the POS N
subgroup POS N
of POS N
participants POS N
who POS N
attended POS N
any POS N
GLI POS N
visits, POS N
the POS N
effect POS N
of POS N
GLI POS N
attendance POS N
was POS N
2.30% POS N
weight POS N
loss POS N
at POS N
six POS N
months POS N
(95% POS N
CI, POS N
0.30-4.30%; POS N
P = 0.02), POS N
and POS N
2.07% POS N
weight POS N
loss POS N
at POS N
12 months POS N
(95% POS N
CI, POS N
0.25-3.88%; POS N
P = 0.02). POS N

but POS N
this POS N
result POS N
did POS N
not POS N
achieve POS N
statistical POS N
significance POS N
(P = 0.054). POS N

Among POS N
adults POS N
with POS N
type POS N
2 POS N
diabetes, POS N
a POS N
group-based POS N
lifestyle POS N
intervention POS N
in POS N
a POS N
community-based POS N
setting POS N
achieved POS N
modest POS N
weight POS N
loss POS N
at POS N
6 POS N
and POS N
12 months. POS N

In POS N
instrumental POS N
variable POS N
analysis POS N
estimating POS N
effects POS N
among POS N
the POS N
subgroup POS N
of POS N
participants POS N
who POS N
attended POS N
any POS N
GLI POS N
visits, POS N
the POS N
effect POS N
of POS N
GLI POS N
attendance POS N
was POS N
2.30% POS N
weight POS N
loss POS N
at POS N
six POS N
months POS N
(95% POS N
CI, POS N
0.30-4.30%; POS N
P = 0.02), POS N
and POS N
2.07% POS N
weight POS N
loss POS N
at POS N
12 months POS N
(95% POS N
CI, POS N
0.25-3.88%; POS N
P = 0.02). POS N

In POS N
the POS N
primary POS N
intention-to-treat POS N
analysis, POS N
the POS N
effect POS N
of POS N
GLI POS N
encouragement POS N
was POS N
0.95% POS N
weight POS N
loss POS N
at POS N
six POS N
months POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0.13-1.77%; POS N
P = 0.02), POS N
and POS N
1.20% POS N
weight POS N
loss POS N
at POS N
12 months POS N
(95% POS N
CI, POS N
0.05-2.36%; POS N
P = 0.04). POS N

In POS N
instrumental POS N
variable POS N
analysis POS N
estimating POS N
effects POS N
among POS N
the POS N
subgroup POS N
of POS N
participants POS N
who POS N
attended POS N
any POS N
GLI POS N
visits, POS N
the POS N
effect POS N
of POS N
GLI POS N
attendance POS N
was POS N
2.30% POS N
weight POS N
loss POS N
at POS N
six POS N
months POS N
(95% POS N
CI, POS N
0.30-4.30%; POS N
P = 0.02), POS N
and POS N
2.07% POS N
weight POS N
loss POS N
at POS N
12 months POS N
(95% POS N
CI, POS N
0.25-3.88%; POS N
P = 0.02). POS N

At POS N
12 months, POS N
there POS N
was POS N
a POS N
0.30% POS N
(3.3 mmol/mol) POS N
reduction POS N
in POS N
hemoglobin POS N
A1c, POS N

In POS N
instrumental POS N
variable POS N
analysis POS N
estimating POS N
effects POS N
among POS N
the POS N
subgroup POS N
of POS N
participants POS N
who POS N
attended POS N
any POS N
GLI POS N
visits, POS N
the POS N
effect POS N
of POS N
GLI POS N
attendance POS N
was POS N
2.30% POS N
weight POS N
loss POS N
at POS N
six POS N
months POS N
(95% POS N
CI, POS N
0.30-4.30%; POS N
P = 0.02), POS N
and POS N
2.07% POS N
weight POS N
loss POS N
at POS N
12 months POS N
(95% POS N
CI, POS N
0.25-3.88%; POS N
P = 0.02). POS N

but POS N
this POS N
result POS N
did POS N
not POS N
achieve POS N
statistical POS N
significance POS N
(P = 0.054). POS N

In POS N
instrumental POS N
variable POS N
analysis POS N
estimating POS N
effects POS N
among POS N
the POS N
subgroup POS N
of POS N
participants POS N
who POS N
attended POS N
any POS N
GLI POS N
visits, POS N
the POS N
effect POS N
of POS N
GLI POS N
attendance POS N
was POS N
2.30% POS N
weight POS N
loss POS N
at POS N
six POS N
months POS N
(95% POS N
CI, POS N
0.30-4.30%; POS N
P = 0.02), POS N
and POS N
2.07% POS N
weight POS N
loss POS N
at POS N
12 months POS N
(95% POS N
CI, POS N
0.25-3.88%; POS N
P = 0.02). POS N

Among POS N
adults POS N
with POS N
type POS N
2 POS N
diabetes, POS N
a POS N
group-based POS N
lifestyle POS N
intervention POS N
in POS N
a POS N
community-based POS N
setting POS N
achieved POS N
modest POS N
weight POS N
loss POS N
at POS N
6 POS N
and POS N
12 months. POS N

Among POS N
adults POS N
with POS N
type POS N
2 POS N
diabetes, POS N
a POS N
group-based POS N
lifestyle POS N
intervention POS N
in POS N
a POS N
community-based POS N
setting POS N
achieved POS N
modest POS N
weight POS N
loss POS N
at POS N
6 POS N
and POS N
12 months. POS N

In POS N
the POS N
primary POS N
intention-to-treat POS N
analysis, POS N
the POS N
effect POS N
of POS N
GLI POS N
encouragement POS N
was POS N
0.95% POS N
weight POS N
loss POS N
at POS N
six POS N
months POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
0.13-1.77%; POS N
P = 0.02), POS N
and POS N
1.20% POS N
weight POS N
loss POS N
at POS N
12 months POS N
(95% POS N
CI, POS N
0.05-2.36%; POS N
P = 0.04). POS N

Among POS N
adults POS N
with POS N
type POS N
2 POS N
diabetes, POS N
a POS N
group-based POS N
lifestyle POS N
intervention POS N
in POS N
a POS N
community-based POS N
setting POS N
achieved POS N
modest POS N
weight POS N
loss POS N
at POS N
6 POS N
and POS N
12 months. POS N

At POS N
12 months, POS N
there POS N
was POS N
a POS N
0.30% POS N
(3.3 mmol/mol) POS N
reduction POS N
in POS N
hemoglobin POS N
A1c, POS N

Among POS N
adults POS N
with POS N
type POS N
2 POS N
diabetes, POS N
a POS N
group-based POS N
lifestyle POS N
intervention POS N
in POS N
a POS N
community-based POS N
setting POS N
achieved POS N
modest POS N
weight POS N
loss POS N
at POS N
6 POS N
and POS N
12 months. POS N

but POS N
this POS N
result POS N
did POS N
not POS N
achieve POS N
statistical POS N
significance POS N
(P = 0.054). POS N

Among POS N
adults POS N
with POS N
type POS N
2 POS N
diabetes, POS N
a POS N
group-based POS N
lifestyle POS N
intervention POS N
in POS N
a POS N
community-based POS N
setting POS N
achieved POS N
modest POS N
weight POS N
loss POS N
at POS N
6 POS N
and POS N
12 months. POS N

In POS N
instrumental POS N
variable POS N
analysis POS N
estimating POS N
effects POS N
among POS N
the POS N
subgroup POS N
of POS N
participants POS N
who POS N
attended POS N
any POS N
GLI POS N
visits, POS N
the POS N
effect POS N
of POS N
GLI POS N
attendance POS N
was POS N
2.30% POS N
weight POS N
loss POS N
at POS N
six POS N
months POS N
(95% POS N
CI, POS N
0.30-4.30%; POS N
P = 0.02), POS N
and POS N
2.07% POS N
weight POS N
loss POS N
at POS N
12 months POS N
(95% POS N
CI, POS N
0.25-3.88%; POS N
P = 0.02). POS N

anthracyclines POS N
are POS N
effective POS N
chemotherapeutic POS N
agents POS N
for POS N
treating POS N
B-cell POS N
lymphoma, POS N

adverse POS N
effects, POS N
such POS N
as POS N
bone POS N
marrow POS N
suppression POS N
and POS N
cardiotoxicity, POS N
limit POS N
their POS N
clinical POS N
application. POS N

anthracyclines POS N
are POS N
effective POS N
chemotherapeutic POS N
agents POS N
for POS N
treating POS N
B-cell POS N
lymphoma, POS N

Cumulative POS N
anthracycline POS N
doses POS N
of POS N
253-400 POS N
mg POS N
(HR: POS N
2.35; POS N
95% POS N
CI POS N
1.41-3.91; POS N
p = 0.0010), POS N
401-504 POS N
mg POS N
(HR: POS N
2.26; POS N
95% POS N
CI POS N
1.26-4.05; POS N
p = 0.0063), POS N
and > 504 POS N
mg POS N
(HR: POS N
2.29; POS N
95% POS N
CI POS N
1.25-4.18; POS N
p = 0.0072) POS N
increased POS N
the POS N
incidence POS N
density POS N
of POS N
diabetes POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
(p = 0.0006). POS N

anthracyclines POS N
are POS N
effective POS N
chemotherapeutic POS N
agents POS N
for POS N
treating POS N
B-cell POS N
lymphoma, POS N

Anthracycline POS N
administration POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
incidence POS N
of POS N
diabetes POS N
(HR: POS N
1.75; POS N
95% POS N
CI POS N
1.11-2.75; POS N
p = 0.0163) POS N
after POS N
adjustments POS N
for POS N
age, POS N
gender, POS N
cumulative POS N
dose POS N
of POS N
prednisolone, POS N
and POS N
co-morbidities. POS N

anthracyclines POS N
are POS N
effective POS N
chemotherapeutic POS N
agents POS N
for POS N
treating POS N
B-cell POS N
lymphoma, POS N

The POS N
annual POS N
alteration POS N
of POS N
adapted POS N
diabetes POS N
complications POS N
severity POS N
index POS N
score POS N
was POS N
not POS N
significantly POS N
different POS N
between POS N
B-cell POS N
lymphoma POS N
patients POS N
with POS N
or POS N
without POS N
anthracycline POS N
treatment POS N
(p = 0.4924). POS N

anthracyclines POS N
are POS N
effective POS N
chemotherapeutic POS N
agents POS N
for POS N
treating POS N
B-cell POS N
lymphoma, POS N

Anthracycline POS N
therapy POS N
increases POS N
diabetes POS N
risk POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
in POS N
B-cell POS N
lymphoma POS N
patients. POS N

anthracyclines POS N
are POS N
effective POS N
chemotherapeutic POS N
agents POS N
for POS N
treating POS N
B-cell POS N
lymphoma, POS N

Intensive POS N
blood POS N
glucose POS N
monitoring POS N
and POS N
control POS N
should POS N
be POS N
recommended POS N
for POS N
B-cell POS N
lymphoma POS N
patients POS N
receiving POS N
anthracycline POS N
treatment. POS N

adverse POS N
effects, POS N
such POS N
as POS N
bone POS N
marrow POS N
suppression POS N
and POS N
cardiotoxicity, POS N
limit POS N
their POS N
clinical POS N
application. POS N

anthracyclines POS N
are POS N
effective POS N
chemotherapeutic POS N
agents POS N
for POS N
treating POS N
B-cell POS N
lymphoma, POS N

adverse POS N
effects, POS N
such POS N
as POS N
bone POS N
marrow POS N
suppression POS N
and POS N
cardiotoxicity, POS N
limit POS N
their POS N
clinical POS N
application. POS N

Cumulative POS N
anthracycline POS N
doses POS N
of POS N
253-400 POS N
mg POS N
(HR: POS N
2.35; POS N
95% POS N
CI POS N
1.41-3.91; POS N
p = 0.0010), POS N
401-504 POS N
mg POS N
(HR: POS N
2.26; POS N
95% POS N
CI POS N
1.26-4.05; POS N
p = 0.0063), POS N
and > 504 POS N
mg POS N
(HR: POS N
2.29; POS N
95% POS N
CI POS N
1.25-4.18; POS N
p = 0.0072) POS N
increased POS N
the POS N
incidence POS N
density POS N
of POS N
diabetes POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
(p = 0.0006). POS N

adverse POS N
effects, POS N
such POS N
as POS N
bone POS N
marrow POS N
suppression POS N
and POS N
cardiotoxicity, POS N
limit POS N
their POS N
clinical POS N
application. POS N

Anthracycline POS N
administration POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
incidence POS N
of POS N
diabetes POS N
(HR: POS N
1.75; POS N
95% POS N
CI POS N
1.11-2.75; POS N
p = 0.0163) POS N
after POS N
adjustments POS N
for POS N
age, POS N
gender, POS N
cumulative POS N
dose POS N
of POS N
prednisolone, POS N
and POS N
co-morbidities. POS N

adverse POS N
effects, POS N
such POS N
as POS N
bone POS N
marrow POS N
suppression POS N
and POS N
cardiotoxicity, POS N
limit POS N
their POS N
clinical POS N
application. POS N

The POS N
annual POS N
alteration POS N
of POS N
adapted POS N
diabetes POS N
complications POS N
severity POS N
index POS N
score POS N
was POS N
not POS N
significantly POS N
different POS N
between POS N
B-cell POS N
lymphoma POS N
patients POS N
with POS N
or POS N
without POS N
anthracycline POS N
treatment POS N
(p = 0.4924). POS N

adverse POS N
effects, POS N
such POS N
as POS N
bone POS N
marrow POS N
suppression POS N
and POS N
cardiotoxicity, POS N
limit POS N
their POS N
clinical POS N
application. POS N

Anthracycline POS N
therapy POS N
increases POS N
diabetes POS N
risk POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
in POS N
B-cell POS N
lymphoma POS N
patients. POS N

adverse POS N
effects, POS N
such POS N
as POS N
bone POS N
marrow POS N
suppression POS N
and POS N
cardiotoxicity, POS N
limit POS N
their POS N
clinical POS N
application. POS N

Intensive POS N
blood POS N
glucose POS N
monitoring POS N
and POS N
control POS N
should POS N
be POS N
recommended POS N
for POS N
B-cell POS N
lymphoma POS N
patients POS N
receiving POS N
anthracycline POS N
treatment. POS N

Cumulative POS N
anthracycline POS N
doses POS N
of POS N
253-400 POS N
mg POS N
(HR: POS N
2.35; POS N
95% POS N
CI POS N
1.41-3.91; POS N
p = 0.0010), POS N
401-504 POS N
mg POS N
(HR: POS N
2.26; POS N
95% POS N
CI POS N
1.26-4.05; POS N
p = 0.0063), POS N
and > 504 POS N
mg POS N
(HR: POS N
2.29; POS N
95% POS N
CI POS N
1.25-4.18; POS N
p = 0.0072) POS N
increased POS N
the POS N
incidence POS N
density POS N
of POS N
diabetes POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
(p = 0.0006). POS N

anthracyclines POS N
are POS N
effective POS N
chemotherapeutic POS N
agents POS N
for POS N
treating POS N
B-cell POS N
lymphoma, POS N

Cumulative POS N
anthracycline POS N
doses POS N
of POS N
253-400 POS N
mg POS N
(HR: POS N
2.35; POS N
95% POS N
CI POS N
1.41-3.91; POS N
p = 0.0010), POS N
401-504 POS N
mg POS N
(HR: POS N
2.26; POS N
95% POS N
CI POS N
1.26-4.05; POS N
p = 0.0063), POS N
and > 504 POS N
mg POS N
(HR: POS N
2.29; POS N
95% POS N
CI POS N
1.25-4.18; POS N
p = 0.0072) POS N
increased POS N
the POS N
incidence POS N
density POS N
of POS N
diabetes POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
(p = 0.0006). POS N

adverse POS N
effects, POS N
such POS N
as POS N
bone POS N
marrow POS N
suppression POS N
and POS N
cardiotoxicity, POS N
limit POS N
their POS N
clinical POS N
application. POS N

Cumulative POS N
anthracycline POS N
doses POS N
of POS N
253-400 POS N
mg POS N
(HR: POS N
2.35; POS N
95% POS N
CI POS N
1.41-3.91; POS N
p = 0.0010), POS N
401-504 POS N
mg POS N
(HR: POS N
2.26; POS N
95% POS N
CI POS N
1.26-4.05; POS N
p = 0.0063), POS N
and > 504 POS N
mg POS N
(HR: POS N
2.29; POS N
95% POS N
CI POS N
1.25-4.18; POS N
p = 0.0072) POS N
increased POS N
the POS N
incidence POS N
density POS N
of POS N
diabetes POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
(p = 0.0006). POS N

Anthracycline POS N
administration POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
incidence POS N
of POS N
diabetes POS N
(HR: POS N
1.75; POS N
95% POS N
CI POS N
1.11-2.75; POS N
p = 0.0163) POS N
after POS N
adjustments POS N
for POS N
age, POS N
gender, POS N
cumulative POS N
dose POS N
of POS N
prednisolone, POS N
and POS N
co-morbidities. POS N

Cumulative POS N
anthracycline POS N
doses POS N
of POS N
253-400 POS N
mg POS N
(HR: POS N
2.35; POS N
95% POS N
CI POS N
1.41-3.91; POS N
p = 0.0010), POS N
401-504 POS N
mg POS N
(HR: POS N
2.26; POS N
95% POS N
CI POS N
1.26-4.05; POS N
p = 0.0063), POS N
and > 504 POS N
mg POS N
(HR: POS N
2.29; POS N
95% POS N
CI POS N
1.25-4.18; POS N
p = 0.0072) POS N
increased POS N
the POS N
incidence POS N
density POS N
of POS N
diabetes POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
(p = 0.0006). POS N

The POS N
annual POS N
alteration POS N
of POS N
adapted POS N
diabetes POS N
complications POS N
severity POS N
index POS N
score POS N
was POS N
not POS N
significantly POS N
different POS N
between POS N
B-cell POS N
lymphoma POS N
patients POS N
with POS N
or POS N
without POS N
anthracycline POS N
treatment POS N
(p = 0.4924). POS N

Cumulative POS N
anthracycline POS N
doses POS N
of POS N
253-400 POS N
mg POS N
(HR: POS N
2.35; POS N
95% POS N
CI POS N
1.41-3.91; POS N
p = 0.0010), POS N
401-504 POS N
mg POS N
(HR: POS N
2.26; POS N
95% POS N
CI POS N
1.26-4.05; POS N
p = 0.0063), POS N
and > 504 POS N
mg POS N
(HR: POS N
2.29; POS N
95% POS N
CI POS N
1.25-4.18; POS N
p = 0.0072) POS N
increased POS N
the POS N
incidence POS N
density POS N
of POS N
diabetes POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
(p = 0.0006). POS N

Anthracycline POS N
therapy POS N
increases POS N
diabetes POS N
risk POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
in POS N
B-cell POS N
lymphoma POS N
patients. POS N

Cumulative POS N
anthracycline POS N
doses POS N
of POS N
253-400 POS N
mg POS N
(HR: POS N
2.35; POS N
95% POS N
CI POS N
1.41-3.91; POS N
p = 0.0010), POS N
401-504 POS N
mg POS N
(HR: POS N
2.26; POS N
95% POS N
CI POS N
1.26-4.05; POS N
p = 0.0063), POS N
and > 504 POS N
mg POS N
(HR: POS N
2.29; POS N
95% POS N
CI POS N
1.25-4.18; POS N
p = 0.0072) POS N
increased POS N
the POS N
incidence POS N
density POS N
of POS N
diabetes POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
(p = 0.0006). POS N

Intensive POS N
blood POS N
glucose POS N
monitoring POS N
and POS N
control POS N
should POS N
be POS N
recommended POS N
for POS N
B-cell POS N
lymphoma POS N
patients POS N
receiving POS N
anthracycline POS N
treatment. POS N

Anthracycline POS N
administration POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
incidence POS N
of POS N
diabetes POS N
(HR: POS N
1.75; POS N
95% POS N
CI POS N
1.11-2.75; POS N
p = 0.0163) POS N
after POS N
adjustments POS N
for POS N
age, POS N
gender, POS N
cumulative POS N
dose POS N
of POS N
prednisolone, POS N
and POS N
co-morbidities. POS N

anthracyclines POS N
are POS N
effective POS N
chemotherapeutic POS N
agents POS N
for POS N
treating POS N
B-cell POS N
lymphoma, POS N

Anthracycline POS N
administration POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
incidence POS N
of POS N
diabetes POS N
(HR: POS N
1.75; POS N
95% POS N
CI POS N
1.11-2.75; POS N
p = 0.0163) POS N
after POS N
adjustments POS N
for POS N
age, POS N
gender, POS N
cumulative POS N
dose POS N
of POS N
prednisolone, POS N
and POS N
co-morbidities. POS N

adverse POS N
effects, POS N
such POS N
as POS N
bone POS N
marrow POS N
suppression POS N
and POS N
cardiotoxicity, POS N
limit POS N
their POS N
clinical POS N
application. POS N

Anthracycline POS N
administration POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
incidence POS N
of POS N
diabetes POS N
(HR: POS N
1.75; POS N
95% POS N
CI POS N
1.11-2.75; POS N
p = 0.0163) POS N
after POS N
adjustments POS N
for POS N
age, POS N
gender, POS N
cumulative POS N
dose POS N
of POS N
prednisolone, POS N
and POS N
co-morbidities. POS N

Cumulative POS N
anthracycline POS N
doses POS N
of POS N
253-400 POS N
mg POS N
(HR: POS N
2.35; POS N
95% POS N
CI POS N
1.41-3.91; POS N
p = 0.0010), POS N
401-504 POS N
mg POS N
(HR: POS N
2.26; POS N
95% POS N
CI POS N
1.26-4.05; POS N
p = 0.0063), POS N
and > 504 POS N
mg POS N
(HR: POS N
2.29; POS N
95% POS N
CI POS N
1.25-4.18; POS N
p = 0.0072) POS N
increased POS N
the POS N
incidence POS N
density POS N
of POS N
diabetes POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
(p = 0.0006). POS N

Anthracycline POS N
administration POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
incidence POS N
of POS N
diabetes POS N
(HR: POS N
1.75; POS N
95% POS N
CI POS N
1.11-2.75; POS N
p = 0.0163) POS N
after POS N
adjustments POS N
for POS N
age, POS N
gender, POS N
cumulative POS N
dose POS N
of POS N
prednisolone, POS N
and POS N
co-morbidities. POS N

The POS N
annual POS N
alteration POS N
of POS N
adapted POS N
diabetes POS N
complications POS N
severity POS N
index POS N
score POS N
was POS N
not POS N
significantly POS N
different POS N
between POS N
B-cell POS N
lymphoma POS N
patients POS N
with POS N
or POS N
without POS N
anthracycline POS N
treatment POS N
(p = 0.4924). POS N

Anthracycline POS N
administration POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
incidence POS N
of POS N
diabetes POS N
(HR: POS N
1.75; POS N
95% POS N
CI POS N
1.11-2.75; POS N
p = 0.0163) POS N
after POS N
adjustments POS N
for POS N
age, POS N
gender, POS N
cumulative POS N
dose POS N
of POS N
prednisolone, POS N
and POS N
co-morbidities. POS N

Anthracycline POS N
therapy POS N
increases POS N
diabetes POS N
risk POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
in POS N
B-cell POS N
lymphoma POS N
patients. POS N

Anthracycline POS N
administration POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
incidence POS N
of POS N
diabetes POS N
(HR: POS N
1.75; POS N
95% POS N
CI POS N
1.11-2.75; POS N
p = 0.0163) POS N
after POS N
adjustments POS N
for POS N
age, POS N
gender, POS N
cumulative POS N
dose POS N
of POS N
prednisolone, POS N
and POS N
co-morbidities. POS N

Intensive POS N
blood POS N
glucose POS N
monitoring POS N
and POS N
control POS N
should POS N
be POS N
recommended POS N
for POS N
B-cell POS N
lymphoma POS N
patients POS N
receiving POS N
anthracycline POS N
treatment. POS N

The POS N
annual POS N
alteration POS N
of POS N
adapted POS N
diabetes POS N
complications POS N
severity POS N
index POS N
score POS N
was POS N
not POS N
significantly POS N
different POS N
between POS N
B-cell POS N
lymphoma POS N
patients POS N
with POS N
or POS N
without POS N
anthracycline POS N
treatment POS N
(p = 0.4924). POS N

anthracyclines POS N
are POS N
effective POS N
chemotherapeutic POS N
agents POS N
for POS N
treating POS N
B-cell POS N
lymphoma, POS N

The POS N
annual POS N
alteration POS N
of POS N
adapted POS N
diabetes POS N
complications POS N
severity POS N
index POS N
score POS N
was POS N
not POS N
significantly POS N
different POS N
between POS N
B-cell POS N
lymphoma POS N
patients POS N
with POS N
or POS N
without POS N
anthracycline POS N
treatment POS N
(p = 0.4924). POS N

adverse POS N
effects, POS N
such POS N
as POS N
bone POS N
marrow POS N
suppression POS N
and POS N
cardiotoxicity, POS N
limit POS N
their POS N
clinical POS N
application. POS N

The POS N
annual POS N
alteration POS N
of POS N
adapted POS N
diabetes POS N
complications POS N
severity POS N
index POS N
score POS N
was POS N
not POS N
significantly POS N
different POS N
between POS N
B-cell POS N
lymphoma POS N
patients POS N
with POS N
or POS N
without POS N
anthracycline POS N
treatment POS N
(p = 0.4924). POS N

Cumulative POS N
anthracycline POS N
doses POS N
of POS N
253-400 POS N
mg POS N
(HR: POS N
2.35; POS N
95% POS N
CI POS N
1.41-3.91; POS N
p = 0.0010), POS N
401-504 POS N
mg POS N
(HR: POS N
2.26; POS N
95% POS N
CI POS N
1.26-4.05; POS N
p = 0.0063), POS N
and > 504 POS N
mg POS N
(HR: POS N
2.29; POS N
95% POS N
CI POS N
1.25-4.18; POS N
p = 0.0072) POS N
increased POS N
the POS N
incidence POS N
density POS N
of POS N
diabetes POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
(p = 0.0006). POS N

The POS N
annual POS N
alteration POS N
of POS N
adapted POS N
diabetes POS N
complications POS N
severity POS N
index POS N
score POS N
was POS N
not POS N
significantly POS N
different POS N
between POS N
B-cell POS N
lymphoma POS N
patients POS N
with POS N
or POS N
without POS N
anthracycline POS N
treatment POS N
(p = 0.4924). POS N

Anthracycline POS N
administration POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
incidence POS N
of POS N
diabetes POS N
(HR: POS N
1.75; POS N
95% POS N
CI POS N
1.11-2.75; POS N
p = 0.0163) POS N
after POS N
adjustments POS N
for POS N
age, POS N
gender, POS N
cumulative POS N
dose POS N
of POS N
prednisolone, POS N
and POS N
co-morbidities. POS N

The POS N
annual POS N
alteration POS N
of POS N
adapted POS N
diabetes POS N
complications POS N
severity POS N
index POS N
score POS N
was POS N
not POS N
significantly POS N
different POS N
between POS N
B-cell POS N
lymphoma POS N
patients POS N
with POS N
or POS N
without POS N
anthracycline POS N
treatment POS N
(p = 0.4924). POS N

Anthracycline POS N
therapy POS N
increases POS N
diabetes POS N
risk POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
in POS N
B-cell POS N
lymphoma POS N
patients. POS N

The POS N
annual POS N
alteration POS N
of POS N
adapted POS N
diabetes POS N
complications POS N
severity POS N
index POS N
score POS N
was POS N
not POS N
significantly POS N
different POS N
between POS N
B-cell POS N
lymphoma POS N
patients POS N
with POS N
or POS N
without POS N
anthracycline POS N
treatment POS N
(p = 0.4924). POS N

Intensive POS N
blood POS N
glucose POS N
monitoring POS N
and POS N
control POS N
should POS N
be POS N
recommended POS N
for POS N
B-cell POS N
lymphoma POS N
patients POS N
receiving POS N
anthracycline POS N
treatment. POS N

Anthracycline POS N
therapy POS N
increases POS N
diabetes POS N
risk POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
in POS N
B-cell POS N
lymphoma POS N
patients. POS N

anthracyclines POS N
are POS N
effective POS N
chemotherapeutic POS N
agents POS N
for POS N
treating POS N
B-cell POS N
lymphoma, POS N

Anthracycline POS N
therapy POS N
increases POS N
diabetes POS N
risk POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
in POS N
B-cell POS N
lymphoma POS N
patients. POS N

adverse POS N
effects, POS N
such POS N
as POS N
bone POS N
marrow POS N
suppression POS N
and POS N
cardiotoxicity, POS N
limit POS N
their POS N
clinical POS N
application. POS N

Anthracycline POS N
therapy POS N
increases POS N
diabetes POS N
risk POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
in POS N
B-cell POS N
lymphoma POS N
patients. POS N

Cumulative POS N
anthracycline POS N
doses POS N
of POS N
253-400 POS N
mg POS N
(HR: POS N
2.35; POS N
95% POS N
CI POS N
1.41-3.91; POS N
p = 0.0010), POS N
401-504 POS N
mg POS N
(HR: POS N
2.26; POS N
95% POS N
CI POS N
1.26-4.05; POS N
p = 0.0063), POS N
and > 504 POS N
mg POS N
(HR: POS N
2.29; POS N
95% POS N
CI POS N
1.25-4.18; POS N
p = 0.0072) POS N
increased POS N
the POS N
incidence POS N
density POS N
of POS N
diabetes POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
(p = 0.0006). POS N

Anthracycline POS N
therapy POS N
increases POS N
diabetes POS N
risk POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
in POS N
B-cell POS N
lymphoma POS N
patients. POS N

Anthracycline POS N
administration POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
incidence POS N
of POS N
diabetes POS N
(HR: POS N
1.75; POS N
95% POS N
CI POS N
1.11-2.75; POS N
p = 0.0163) POS N
after POS N
adjustments POS N
for POS N
age, POS N
gender, POS N
cumulative POS N
dose POS N
of POS N
prednisolone, POS N
and POS N
co-morbidities. POS N

Anthracycline POS N
therapy POS N
increases POS N
diabetes POS N
risk POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
in POS N
B-cell POS N
lymphoma POS N
patients. POS N

The POS N
annual POS N
alteration POS N
of POS N
adapted POS N
diabetes POS N
complications POS N
severity POS N
index POS N
score POS N
was POS N
not POS N
significantly POS N
different POS N
between POS N
B-cell POS N
lymphoma POS N
patients POS N
with POS N
or POS N
without POS N
anthracycline POS N
treatment POS N
(p = 0.4924). POS N

Anthracycline POS N
therapy POS N
increases POS N
diabetes POS N
risk POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
in POS N
B-cell POS N
lymphoma POS N
patients. POS N

Intensive POS N
blood POS N
glucose POS N
monitoring POS N
and POS N
control POS N
should POS N
be POS N
recommended POS N
for POS N
B-cell POS N
lymphoma POS N
patients POS N
receiving POS N
anthracycline POS N
treatment. POS N

Intensive POS N
blood POS N
glucose POS N
monitoring POS N
and POS N
control POS N
should POS N
be POS N
recommended POS N
for POS N
B-cell POS N
lymphoma POS N
patients POS N
receiving POS N
anthracycline POS N
treatment. POS N

anthracyclines POS N
are POS N
effective POS N
chemotherapeutic POS N
agents POS N
for POS N
treating POS N
B-cell POS N
lymphoma, POS N

Intensive POS N
blood POS N
glucose POS N
monitoring POS N
and POS N
control POS N
should POS N
be POS N
recommended POS N
for POS N
B-cell POS N
lymphoma POS N
patients POS N
receiving POS N
anthracycline POS N
treatment. POS N

adverse POS N
effects, POS N
such POS N
as POS N
bone POS N
marrow POS N
suppression POS N
and POS N
cardiotoxicity, POS N
limit POS N
their POS N
clinical POS N
application. POS N

Intensive POS N
blood POS N
glucose POS N
monitoring POS N
and POS N
control POS N
should POS N
be POS N
recommended POS N
for POS N
B-cell POS N
lymphoma POS N
patients POS N
receiving POS N
anthracycline POS N
treatment. POS N

Cumulative POS N
anthracycline POS N
doses POS N
of POS N
253-400 POS N
mg POS N
(HR: POS N
2.35; POS N
95% POS N
CI POS N
1.41-3.91; POS N
p = 0.0010), POS N
401-504 POS N
mg POS N
(HR: POS N
2.26; POS N
95% POS N
CI POS N
1.26-4.05; POS N
p = 0.0063), POS N
and > 504 POS N
mg POS N
(HR: POS N
2.29; POS N
95% POS N
CI POS N
1.25-4.18; POS N
p = 0.0072) POS N
increased POS N
the POS N
incidence POS N
density POS N
of POS N
diabetes POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
(p = 0.0006). POS N

Intensive POS N
blood POS N
glucose POS N
monitoring POS N
and POS N
control POS N
should POS N
be POS N
recommended POS N
for POS N
B-cell POS N
lymphoma POS N
patients POS N
receiving POS N
anthracycline POS N
treatment. POS N

Anthracycline POS N
administration POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
incidence POS N
of POS N
diabetes POS N
(HR: POS N
1.75; POS N
95% POS N
CI POS N
1.11-2.75; POS N
p = 0.0163) POS N
after POS N
adjustments POS N
for POS N
age, POS N
gender, POS N
cumulative POS N
dose POS N
of POS N
prednisolone, POS N
and POS N
co-morbidities. POS N

Intensive POS N
blood POS N
glucose POS N
monitoring POS N
and POS N
control POS N
should POS N
be POS N
recommended POS N
for POS N
B-cell POS N
lymphoma POS N
patients POS N
receiving POS N
anthracycline POS N
treatment. POS N

The POS N
annual POS N
alteration POS N
of POS N
adapted POS N
diabetes POS N
complications POS N
severity POS N
index POS N
score POS N
was POS N
not POS N
significantly POS N
different POS N
between POS N
B-cell POS N
lymphoma POS N
patients POS N
with POS N
or POS N
without POS N
anthracycline POS N
treatment POS N
(p = 0.4924). POS N

Intensive POS N
blood POS N
glucose POS N
monitoring POS N
and POS N
control POS N
should POS N
be POS N
recommended POS N
for POS N
B-cell POS N
lymphoma POS N
patients POS N
receiving POS N
anthracycline POS N
treatment. POS N

Anthracycline POS N
therapy POS N
increases POS N
diabetes POS N
risk POS N
in POS N
a POS N
dose-dependent POS N
manner POS N
in POS N
B-cell POS N
lymphoma POS N
patients. POS N

Multiple POS N
studies POS N
have POS N
evaluated POS N
the POS N
hypoglycemic POS N
effect POS N
of POS N
cinnamon POS N
in POS N
patients POS N
with POS N
diabetes POS N
mellitus POS N
(DM) POS N
type POS N
II, POS N
with POS N
conflicting POS N
results. POS N

Cinnamon POS N
supplementation POS N
led POS N
to POS N
improvement POS N
of POS N
all POS N
anthropometric POS N
(BMI, POS N
body POS N
fat, POS N
and POS N
visceral POS N
fat), POS N
glycemic POS N
(FPG, POS N
2hpp, POS N
HbA1C, POS N
Fasting POS N
Insulin, POS N
and POS N
Insulin POS N
Resistance), POS N
and POS N
lipids POS N
(Cholesterol POS N
Total, POS N
LDL-c POS N
and POS N
HDL-c) POS N
outcomes POS N
(except POS N
for POS N
triglycerides POS N
level). POS N

Multiple POS N
studies POS N
have POS N
evaluated POS N
the POS N
hypoglycemic POS N
effect POS N
of POS N
cinnamon POS N
in POS N
patients POS N
with POS N
diabetes POS N
mellitus POS N
(DM) POS N
type POS N
II, POS N
with POS N
conflicting POS N
results. POS N

All POS N
observed POS N
changes POS N
(except POS N
for POS N
Cholesterol POS N
Total POS N
and POS N
LDL-c) POS N
were POS N
significantly POS N
more POS N
prominent POS N
in POS N
patients POS N
with POS N
higher POS N
baseline POS N
BMI POS N
(BMI POS N
≥ POS N
27). POS N

Multiple POS N
studies POS N
have POS N
evaluated POS N
the POS N
hypoglycemic POS N
effect POS N
of POS N
cinnamon POS N
in POS N
patients POS N
with POS N
diabetes POS N
mellitus POS N
(DM) POS N
type POS N
II, POS N
with POS N
conflicting POS N
results. POS N

Based POS N
on POS N
the POS N
study POS N
findings, POS N
cinnamon POS N
may POS N
improve POS N
anthropometric POS N
parameters, POS N
glycemic POS N
indices POS N
and POS N
lipid POS N
profile POS N
of POS N
patients POS N
with POS N
type POS N
II POS N
diabetes. POS N

Multiple POS N
studies POS N
have POS N
evaluated POS N
the POS N
hypoglycemic POS N
effect POS N
of POS N
cinnamon POS N
in POS N
patients POS N
with POS N
diabetes POS N
mellitus POS N
(DM) POS N
type POS N
II, POS N
with POS N
conflicting POS N
results. POS N

These POS N
benefits POS N
are POS N
significantly POS N
more POS N
prominent POS N
in POS N
patients POS N
with POS N
higher POS N
baseline POS N
BMI POS N
(BMI POS N
≥ POS N
27). POS N

Cinnamon POS N
supplementation POS N
led POS N
to POS N
improvement POS N
of POS N
all POS N
anthropometric POS N
(BMI, POS N
body POS N
fat, POS N
and POS N
visceral POS N
fat), POS N
glycemic POS N
(FPG, POS N
2hpp, POS N
HbA1C, POS N
Fasting POS N
Insulin, POS N
and POS N
Insulin POS N
Resistance), POS N
and POS N
lipids POS N
(Cholesterol POS N
Total, POS N
LDL-c POS N
and POS N
HDL-c) POS N
outcomes POS N
(except POS N
for POS N
triglycerides POS N
level). POS N

Multiple POS N
studies POS N
have POS N
evaluated POS N
the POS N
hypoglycemic POS N
effect POS N
of POS N
cinnamon POS N
in POS N
patients POS N
with POS N
diabetes POS N
mellitus POS N
(DM) POS N
type POS N
II, POS N
with POS N
conflicting POS N
results. POS N

Cinnamon POS N
supplementation POS N
led POS N
to POS N
improvement POS N
of POS N
all POS N
anthropometric POS N
(BMI, POS N
body POS N
fat, POS N
and POS N
visceral POS N
fat), POS N
glycemic POS N
(FPG, POS N
2hpp, POS N
HbA1C, POS N
Fasting POS N
Insulin, POS N
and POS N
Insulin POS N
Resistance), POS N
and POS N
lipids POS N
(Cholesterol POS N
Total, POS N
LDL-c POS N
and POS N
HDL-c) POS N
outcomes POS N
(except POS N
for POS N
triglycerides POS N
level). POS N

All POS N
observed POS N
changes POS N
(except POS N
for POS N
Cholesterol POS N
Total POS N
and POS N
LDL-c) POS N
were POS N
significantly POS N
more POS N
prominent POS N
in POS N
patients POS N
with POS N
higher POS N
baseline POS N
BMI POS N
(BMI POS N
≥ POS N
27). POS N

Cinnamon POS N
supplementation POS N
led POS N
to POS N
improvement POS N
of POS N
all POS N
anthropometric POS N
(BMI, POS N
body POS N
fat, POS N
and POS N
visceral POS N
fat), POS N
glycemic POS N
(FPG, POS N
2hpp, POS N
HbA1C, POS N
Fasting POS N
Insulin, POS N
and POS N
Insulin POS N
Resistance), POS N
and POS N
lipids POS N
(Cholesterol POS N
Total, POS N
LDL-c POS N
and POS N
HDL-c) POS N
outcomes POS N
(except POS N
for POS N
triglycerides POS N
level). POS N

Based POS N
on POS N
the POS N
study POS N
findings, POS N
cinnamon POS N
may POS N
improve POS N
anthropometric POS N
parameters, POS N
glycemic POS N
indices POS N
and POS N
lipid POS N
profile POS N
of POS N
patients POS N
with POS N
type POS N
II POS N
diabetes. POS N

Cinnamon POS N
supplementation POS N
led POS N
to POS N
improvement POS N
of POS N
all POS N
anthropometric POS N
(BMI, POS N
body POS N
fat, POS N
and POS N
visceral POS N
fat), POS N
glycemic POS N
(FPG, POS N
2hpp, POS N
HbA1C, POS N
Fasting POS N
Insulin, POS N
and POS N
Insulin POS N
Resistance), POS N
and POS N
lipids POS N
(Cholesterol POS N
Total, POS N
LDL-c POS N
and POS N
HDL-c) POS N
outcomes POS N
(except POS N
for POS N
triglycerides POS N
level). POS N

These POS N
benefits POS N
are POS N
significantly POS N
more POS N
prominent POS N
in POS N
patients POS N
with POS N
higher POS N
baseline POS N
BMI POS N
(BMI POS N
≥ POS N
27). POS N

All POS N
observed POS N
changes POS N
(except POS N
for POS N
Cholesterol POS N
Total POS N
and POS N
LDL-c) POS N
were POS N
significantly POS N
more POS N
prominent POS N
in POS N
patients POS N
with POS N
higher POS N
baseline POS N
BMI POS N
(BMI POS N
≥ POS N
27). POS N

Multiple POS N
studies POS N
have POS N
evaluated POS N
the POS N
hypoglycemic POS N
effect POS N
of POS N
cinnamon POS N
in POS N
patients POS N
with POS N
diabetes POS N
mellitus POS N
(DM) POS N
type POS N
II, POS N
with POS N
conflicting POS N
results. POS N

All POS N
observed POS N
changes POS N
(except POS N
for POS N
Cholesterol POS N
Total POS N
and POS N
LDL-c) POS N
were POS N
significantly POS N
more POS N
prominent POS N
in POS N
patients POS N
with POS N
higher POS N
baseline POS N
BMI POS N
(BMI POS N
≥ POS N
27). POS N

Cinnamon POS N
supplementation POS N
led POS N
to POS N
improvement POS N
of POS N
all POS N
anthropometric POS N
(BMI, POS N
body POS N
fat, POS N
and POS N
visceral POS N
fat), POS N
glycemic POS N
(FPG, POS N
2hpp, POS N
HbA1C, POS N
Fasting POS N
Insulin, POS N
and POS N
Insulin POS N
Resistance), POS N
and POS N
lipids POS N
(Cholesterol POS N
Total, POS N
LDL-c POS N
and POS N
HDL-c) POS N
outcomes POS N
(except POS N
for POS N
triglycerides POS N
level). POS N

All POS N
observed POS N
changes POS N
(except POS N
for POS N
Cholesterol POS N
Total POS N
and POS N
LDL-c) POS N
were POS N
significantly POS N
more POS N
prominent POS N
in POS N
patients POS N
with POS N
higher POS N
baseline POS N
BMI POS N
(BMI POS N
≥ POS N
27). POS N

Based POS N
on POS N
the POS N
study POS N
findings, POS N
cinnamon POS N
may POS N
improve POS N
anthropometric POS N
parameters, POS N
glycemic POS N
indices POS N
and POS N
lipid POS N
profile POS N
of POS N
patients POS N
with POS N
type POS N
II POS N
diabetes. POS N

All POS N
observed POS N
changes POS N
(except POS N
for POS N
Cholesterol POS N
Total POS N
and POS N
LDL-c) POS N
were POS N
significantly POS N
more POS N
prominent POS N
in POS N
patients POS N
with POS N
higher POS N
baseline POS N
BMI POS N
(BMI POS N
≥ POS N
27). POS N

These POS N
benefits POS N
are POS N
significantly POS N
more POS N
prominent POS N
in POS N
patients POS N
with POS N
higher POS N
baseline POS N
BMI POS N
(BMI POS N
≥ POS N
27). POS N

Based POS N
on POS N
the POS N
study POS N
findings, POS N
cinnamon POS N
may POS N
improve POS N
anthropometric POS N
parameters, POS N
glycemic POS N
indices POS N
and POS N
lipid POS N
profile POS N
of POS N
patients POS N
with POS N
type POS N
II POS N
diabetes. POS N

Multiple POS N
studies POS N
have POS N
evaluated POS N
the POS N
hypoglycemic POS N
effect POS N
of POS N
cinnamon POS N
in POS N
patients POS N
with POS N
diabetes POS N
mellitus POS N
(DM) POS N
type POS N
II, POS N
with POS N
conflicting POS N
results. POS N

Based POS N
on POS N
the POS N
study POS N
findings, POS N
cinnamon POS N
may POS N
improve POS N
anthropometric POS N
parameters, POS N
glycemic POS N
indices POS N
and POS N
lipid POS N
profile POS N
of POS N
patients POS N
with POS N
type POS N
II POS N
diabetes. POS N

Cinnamon POS N
supplementation POS N
led POS N
to POS N
improvement POS N
of POS N
all POS N
anthropometric POS N
(BMI, POS N
body POS N
fat, POS N
and POS N
visceral POS N
fat), POS N
glycemic POS N
(FPG, POS N
2hpp, POS N
HbA1C, POS N
Fasting POS N
Insulin, POS N
and POS N
Insulin POS N
Resistance), POS N
and POS N
lipids POS N
(Cholesterol POS N
Total, POS N
LDL-c POS N
and POS N
HDL-c) POS N
outcomes POS N
(except POS N
for POS N
triglycerides POS N
level). POS N

Based POS N
on POS N
the POS N
study POS N
findings, POS N
cinnamon POS N
may POS N
improve POS N
anthropometric POS N
parameters, POS N
glycemic POS N
indices POS N
and POS N
lipid POS N
profile POS N
of POS N
patients POS N
with POS N
type POS N
II POS N
diabetes. POS N

All POS N
observed POS N
changes POS N
(except POS N
for POS N
Cholesterol POS N
Total POS N
and POS N
LDL-c) POS N
were POS N
significantly POS N
more POS N
prominent POS N
in POS N
patients POS N
with POS N
higher POS N
baseline POS N
BMI POS N
(BMI POS N
≥ POS N
27). POS N

Based POS N
on POS N
the POS N
study POS N
findings, POS N
cinnamon POS N
may POS N
improve POS N
anthropometric POS N
parameters, POS N
glycemic POS N
indices POS N
and POS N
lipid POS N
profile POS N
of POS N
patients POS N
with POS N
type POS N
II POS N
diabetes. POS N

These POS N
benefits POS N
are POS N
significantly POS N
more POS N
prominent POS N
in POS N
patients POS N
with POS N
higher POS N
baseline POS N
BMI POS N
(BMI POS N
≥ POS N
27). POS N

These POS N
benefits POS N
are POS N
significantly POS N
more POS N
prominent POS N
in POS N
patients POS N
with POS N
higher POS N
baseline POS N
BMI POS N
(BMI POS N
≥ POS N
27). POS N

Multiple POS N
studies POS N
have POS N
evaluated POS N
the POS N
hypoglycemic POS N
effect POS N
of POS N
cinnamon POS N
in POS N
patients POS N
with POS N
diabetes POS N
mellitus POS N
(DM) POS N
type POS N
II, POS N
with POS N
conflicting POS N
results. POS N

These POS N
benefits POS N
are POS N
significantly POS N
more POS N
prominent POS N
in POS N
patients POS N
with POS N
higher POS N
baseline POS N
BMI POS N
(BMI POS N
≥ POS N
27). POS N

Cinnamon POS N
supplementation POS N
led POS N
to POS N
improvement POS N
of POS N
all POS N
anthropometric POS N
(BMI, POS N
body POS N
fat, POS N
and POS N
visceral POS N
fat), POS N
glycemic POS N
(FPG, POS N
2hpp, POS N
HbA1C, POS N
Fasting POS N
Insulin, POS N
and POS N
Insulin POS N
Resistance), POS N
and POS N
lipids POS N
(Cholesterol POS N
Total, POS N
LDL-c POS N
and POS N
HDL-c) POS N
outcomes POS N
(except POS N
for POS N
triglycerides POS N
level). POS N

These POS N
benefits POS N
are POS N
significantly POS N
more POS N
prominent POS N
in POS N
patients POS N
with POS N
higher POS N
baseline POS N
BMI POS N
(BMI POS N
≥ POS N
27). POS N

All POS N
observed POS N
changes POS N
(except POS N
for POS N
Cholesterol POS N
Total POS N
and POS N
LDL-c) POS N
were POS N
significantly POS N
more POS N
prominent POS N
in POS N
patients POS N
with POS N
higher POS N
baseline POS N
BMI POS N
(BMI POS N
≥ POS N
27). POS N

These POS N
benefits POS N
are POS N
significantly POS N
more POS N
prominent POS N
in POS N
patients POS N
with POS N
higher POS N
baseline POS N
BMI POS N
(BMI POS N
≥ POS N
27). POS N

Based POS N
on POS N
the POS N
study POS N
findings, POS N
cinnamon POS N
may POS N
improve POS N
anthropometric POS N
parameters, POS N
glycemic POS N
indices POS N
and POS N
lipid POS N
profile POS N
of POS N
patients POS N
with POS N
type POS N
II POS N
diabetes. POS N

Efficacy POS N
was POS N
similar POS N
for POS N
the POS N
250- POS N
and POS N
500-mg/d POS N
groups. POS N

Objective POS N
tumor POS N
response POS N
rates POS N
were POS N
18.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
11.5 POS N
to POS N
27.3) POS N
and POS N
19.0% POS N
(95% POS N
CI, POS N
12.1 POS N
to POS N
27.9); POS N
among POS N
evaluable POS N
patients, POS N
symptom POS N
improvement POS N
rates POS N
were POS N
40.3% POS N
(95% POS N
CI, POS N
28.5 POS N
to POS N
53.0) POS N
and POS N
37.0% POS N
(95% POS N
CI, POS N
26.0 POS N
to POS N
49.1); POS N
median POS N
progression-free POS N
survival POS N
times POS N
were POS N
2.7 POS N
and POS N
2.8 POS N
months; POS N
and POS N
median POS N
overall POS N
survival POS N
times POS N
were POS N
7.6 POS N
and POS N
8.0 POS N
months, POS N
respectively. POS N

Efficacy POS N
was POS N
similar POS N
for POS N
the POS N
250- POS N
and POS N
500-mg/d POS N
groups. POS N

Adverse POS N
events POS N
(AEs) POS N
at POS N
both POS N
dose POS N
levels POS N
were POS N
generally POS N
mild POS N
(grade POS N
1 POS N
or POS N
2) POS N
and POS N
consisted POS N
mainly POS N
of POS N
skin POS N
reactions POS N
and POS N
diarrhea. POS N

Efficacy POS N
was POS N
similar POS N
for POS N
the POS N
250- POS N
and POS N
500-mg/d POS N
groups. POS N

Symptom POS N
improvements POS N
were POS N
recorded POS N
for POS N
69.2% POS N
(250 POS N
mg/d) POS N
and POS N
85.7% POS N
(500 POS N
mg/d) POS N
of POS N
patients POS N
with POS N
a POS N
tumor POS N
response. POS N

Efficacy POS N
was POS N
similar POS N
for POS N
the POS N
250- POS N
and POS N
500-mg/d POS N
groups. POS N

Drug-related POS N
toxicities POS N
were POS N
more POS N
frequent POS N
in POS N
the POS N
higher-dose POS N
group. POS N

Efficacy POS N
was POS N
similar POS N
for POS N
the POS N
250- POS N
and POS N
500-mg/d POS N
groups. POS N

Withdrawal POS N
due POS N
to POS N
drug-related POS N
AEs POS N
was POS N
1.9% POS N
and POS N
9.4% POS N
for POS N
patients POS N
receiving POS N
gefitinib POS N
250 POS N
and POS N
500 POS N
mg/d, POS N
respectively. POS N

Efficacy POS N
was POS N
similar POS N
for POS N
the POS N
250- POS N
and POS N
500-mg/d POS N
groups. POS N

Gefitinib POS N
showed POS N
clinically POS N
meaningful POS N
antitumor POS N
activity POS N
and POS N
provided POS N
symptom POS N
relief POS N
as POS N
second- POS N
and POS N
third-line POS N
treatment POS N
in POS N
these POS N
patients. POS N

Efficacy POS N
was POS N
similar POS N
for POS N
the POS N
250- POS N
and POS N
500-mg/d POS N
groups. POS N

At POS N
250 POS N
mg/d, POS N
gefitinib POS N
had POS N
a POS N
favorable POS N
AE POS N
profile. POS N

Efficacy POS N
was POS N
similar POS N
for POS N
the POS N
250- POS N
and POS N
500-mg/d POS N
groups. POS N

Gefitinib POS N
250 POS N
mg/d POS N
is POS N
an POS N
important, POS N
novel POS N
treatment POS N
option POS N
for POS N
patients POS N
with POS N
pretreated POS N
advanced POS N
NSCLC. POS N

Objective POS N
tumor POS N
response POS N
rates POS N
were POS N
18.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
11.5 POS N
to POS N
27.3) POS N
and POS N
19.0% POS N
(95% POS N
CI, POS N
12.1 POS N
to POS N
27.9); POS N
among POS N
evaluable POS N
patients, POS N
symptom POS N
improvement POS N
rates POS N
were POS N
40.3% POS N
(95% POS N
CI, POS N
28.5 POS N
to POS N
53.0) POS N
and POS N
37.0% POS N
(95% POS N
CI, POS N
26.0 POS N
to POS N
49.1); POS N
median POS N
progression-free POS N
survival POS N
times POS N
were POS N
2.7 POS N
and POS N
2.8 POS N
months; POS N
and POS N
median POS N
overall POS N
survival POS N
times POS N
were POS N
7.6 POS N
and POS N
8.0 POS N
months, POS N
respectively. POS N

Efficacy POS N
was POS N
similar POS N
for POS N
the POS N
250- POS N
and POS N
500-mg/d POS N
groups. POS N

Objective POS N
tumor POS N
response POS N
rates POS N
were POS N
18.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
11.5 POS N
to POS N
27.3) POS N
and POS N
19.0% POS N
(95% POS N
CI, POS N
12.1 POS N
to POS N
27.9); POS N
among POS N
evaluable POS N
patients, POS N
symptom POS N
improvement POS N
rates POS N
were POS N
40.3% POS N
(95% POS N
CI, POS N
28.5 POS N
to POS N
53.0) POS N
and POS N
37.0% POS N
(95% POS N
CI, POS N
26.0 POS N
to POS N
49.1); POS N
median POS N
progression-free POS N
survival POS N
times POS N
were POS N
2.7 POS N
and POS N
2.8 POS N
months; POS N
and POS N
median POS N
overall POS N
survival POS N
times POS N
were POS N
7.6 POS N
and POS N
8.0 POS N
months, POS N
respectively. POS N

Adverse POS N
events POS N
(AEs) POS N
at POS N
both POS N
dose POS N
levels POS N
were POS N
generally POS N
mild POS N
(grade POS N
1 POS N
or POS N
2) POS N
and POS N
consisted POS N
mainly POS N
of POS N
skin POS N
reactions POS N
and POS N
diarrhea. POS N

Objective POS N
tumor POS N
response POS N
rates POS N
were POS N
18.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
11.5 POS N
to POS N
27.3) POS N
and POS N
19.0% POS N
(95% POS N
CI, POS N
12.1 POS N
to POS N
27.9); POS N
among POS N
evaluable POS N
patients, POS N
symptom POS N
improvement POS N
rates POS N
were POS N
40.3% POS N
(95% POS N
CI, POS N
28.5 POS N
to POS N
53.0) POS N
and POS N
37.0% POS N
(95% POS N
CI, POS N
26.0 POS N
to POS N
49.1); POS N
median POS N
progression-free POS N
survival POS N
times POS N
were POS N
2.7 POS N
and POS N
2.8 POS N
months; POS N
and POS N
median POS N
overall POS N
survival POS N
times POS N
were POS N
7.6 POS N
and POS N
8.0 POS N
months, POS N
respectively. POS N

Symptom POS N
improvements POS N
were POS N
recorded POS N
for POS N
69.2% POS N
(250 POS N
mg/d) POS N
and POS N
85.7% POS N
(500 POS N
mg/d) POS N
of POS N
patients POS N
with POS N
a POS N
tumor POS N
response. POS N

Objective POS N
tumor POS N
response POS N
rates POS N
were POS N
18.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
11.5 POS N
to POS N
27.3) POS N
and POS N
19.0% POS N
(95% POS N
CI, POS N
12.1 POS N
to POS N
27.9); POS N
among POS N
evaluable POS N
patients, POS N
symptom POS N
improvement POS N
rates POS N
were POS N
40.3% POS N
(95% POS N
CI, POS N
28.5 POS N
to POS N
53.0) POS N
and POS N
37.0% POS N
(95% POS N
CI, POS N
26.0 POS N
to POS N
49.1); POS N
median POS N
progression-free POS N
survival POS N
times POS N
were POS N
2.7 POS N
and POS N
2.8 POS N
months; POS N
and POS N
median POS N
overall POS N
survival POS N
times POS N
were POS N
7.6 POS N
and POS N
8.0 POS N
months, POS N
respectively. POS N

Drug-related POS N
toxicities POS N
were POS N
more POS N
frequent POS N
in POS N
the POS N
higher-dose POS N
group. POS N

Objective POS N
tumor POS N
response POS N
rates POS N
were POS N
18.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
11.5 POS N
to POS N
27.3) POS N
and POS N
19.0% POS N
(95% POS N
CI, POS N
12.1 POS N
to POS N
27.9); POS N
among POS N
evaluable POS N
patients, POS N
symptom POS N
improvement POS N
rates POS N
were POS N
40.3% POS N
(95% POS N
CI, POS N
28.5 POS N
to POS N
53.0) POS N
and POS N
37.0% POS N
(95% POS N
CI, POS N
26.0 POS N
to POS N
49.1); POS N
median POS N
progression-free POS N
survival POS N
times POS N
were POS N
2.7 POS N
and POS N
2.8 POS N
months; POS N
and POS N
median POS N
overall POS N
survival POS N
times POS N
were POS N
7.6 POS N
and POS N
8.0 POS N
months, POS N
respectively. POS N

Withdrawal POS N
due POS N
to POS N
drug-related POS N
AEs POS N
was POS N
1.9% POS N
and POS N
9.4% POS N
for POS N
patients POS N
receiving POS N
gefitinib POS N
250 POS N
and POS N
500 POS N
mg/d, POS N
respectively. POS N

Objective POS N
tumor POS N
response POS N
rates POS N
were POS N
18.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
11.5 POS N
to POS N
27.3) POS N
and POS N
19.0% POS N
(95% POS N
CI, POS N
12.1 POS N
to POS N
27.9); POS N
among POS N
evaluable POS N
patients, POS N
symptom POS N
improvement POS N
rates POS N
were POS N
40.3% POS N
(95% POS N
CI, POS N
28.5 POS N
to POS N
53.0) POS N
and POS N
37.0% POS N
(95% POS N
CI, POS N
26.0 POS N
to POS N
49.1); POS N
median POS N
progression-free POS N
survival POS N
times POS N
were POS N
2.7 POS N
and POS N
2.8 POS N
months; POS N
and POS N
median POS N
overall POS N
survival POS N
times POS N
were POS N
7.6 POS N
and POS N
8.0 POS N
months, POS N
respectively. POS N

Gefitinib POS N
showed POS N
clinically POS N
meaningful POS N
antitumor POS N
activity POS N
and POS N
provided POS N
symptom POS N
relief POS N
as POS N
second- POS N
and POS N
third-line POS N
treatment POS N
in POS N
these POS N
patients. POS N

Objective POS N
tumor POS N
response POS N
rates POS N
were POS N
18.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
11.5 POS N
to POS N
27.3) POS N
and POS N
19.0% POS N
(95% POS N
CI, POS N
12.1 POS N
to POS N
27.9); POS N
among POS N
evaluable POS N
patients, POS N
symptom POS N
improvement POS N
rates POS N
were POS N
40.3% POS N
(95% POS N
CI, POS N
28.5 POS N
to POS N
53.0) POS N
and POS N
37.0% POS N
(95% POS N
CI, POS N
26.0 POS N
to POS N
49.1); POS N
median POS N
progression-free POS N
survival POS N
times POS N
were POS N
2.7 POS N
and POS N
2.8 POS N
months; POS N
and POS N
median POS N
overall POS N
survival POS N
times POS N
were POS N
7.6 POS N
and POS N
8.0 POS N
months, POS N
respectively. POS N

At POS N
250 POS N
mg/d, POS N
gefitinib POS N
had POS N
a POS N
favorable POS N
AE POS N
profile. POS N

Objective POS N
tumor POS N
response POS N
rates POS N
were POS N
18.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
11.5 POS N
to POS N
27.3) POS N
and POS N
19.0% POS N
(95% POS N
CI, POS N
12.1 POS N
to POS N
27.9); POS N
among POS N
evaluable POS N
patients, POS N
symptom POS N
improvement POS N
rates POS N
were POS N
40.3% POS N
(95% POS N
CI, POS N
28.5 POS N
to POS N
53.0) POS N
and POS N
37.0% POS N
(95% POS N
CI, POS N
26.0 POS N
to POS N
49.1); POS N
median POS N
progression-free POS N
survival POS N
times POS N
were POS N
2.7 POS N
and POS N
2.8 POS N
months; POS N
and POS N
median POS N
overall POS N
survival POS N
times POS N
were POS N
7.6 POS N
and POS N
8.0 POS N
months, POS N
respectively. POS N

Gefitinib POS N
250 POS N
mg/d POS N
is POS N
an POS N
important, POS N
novel POS N
treatment POS N
option POS N
for POS N
patients POS N
with POS N
pretreated POS N
advanced POS N
NSCLC. POS N

Adverse POS N
events POS N
(AEs) POS N
at POS N
both POS N
dose POS N
levels POS N
were POS N
generally POS N
mild POS N
(grade POS N
1 POS N
or POS N
2) POS N
and POS N
consisted POS N
mainly POS N
of POS N
skin POS N
reactions POS N
and POS N
diarrhea. POS N

Efficacy POS N
was POS N
similar POS N
for POS N
the POS N
250- POS N
and POS N
500-mg/d POS N
groups. POS N

Adverse POS N
events POS N
(AEs) POS N
at POS N
both POS N
dose POS N
levels POS N
were POS N
generally POS N
mild POS N
(grade POS N
1 POS N
or POS N
2) POS N
and POS N
consisted POS N
mainly POS N
of POS N
skin POS N
reactions POS N
and POS N
diarrhea. POS N

Objective POS N
tumor POS N
response POS N
rates POS N
were POS N
18.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
11.5 POS N
to POS N
27.3) POS N
and POS N
19.0% POS N
(95% POS N
CI, POS N
12.1 POS N
to POS N
27.9); POS N
among POS N
evaluable POS N
patients, POS N
symptom POS N
improvement POS N
rates POS N
were POS N
40.3% POS N
(95% POS N
CI, POS N
28.5 POS N
to POS N
53.0) POS N
and POS N
37.0% POS N
(95% POS N
CI, POS N
26.0 POS N
to POS N
49.1); POS N
median POS N
progression-free POS N
survival POS N
times POS N
were POS N
2.7 POS N
and POS N
2.8 POS N
months; POS N
and POS N
median POS N
overall POS N
survival POS N
times POS N
were POS N
7.6 POS N
and POS N
8.0 POS N
months, POS N
respectively. POS N

Adverse POS N
events POS N
(AEs) POS N
at POS N
both POS N
dose POS N
levels POS N
were POS N
generally POS N
mild POS N
(grade POS N
1 POS N
or POS N
2) POS N
and POS N
consisted POS N
mainly POS N
of POS N
skin POS N
reactions POS N
and POS N
diarrhea. POS N

Symptom POS N
improvements POS N
were POS N
recorded POS N
for POS N
69.2% POS N
(250 POS N
mg/d) POS N
and POS N
85.7% POS N
(500 POS N
mg/d) POS N
of POS N
patients POS N
with POS N
a POS N
tumor POS N
response. POS N

Adverse POS N
events POS N
(AEs) POS N
at POS N
both POS N
dose POS N
levels POS N
were POS N
generally POS N
mild POS N
(grade POS N
1 POS N
or POS N
2) POS N
and POS N
consisted POS N
mainly POS N
of POS N
skin POS N
reactions POS N
and POS N
diarrhea. POS N

Drug-related POS N
toxicities POS N
were POS N
more POS N
frequent POS N
in POS N
the POS N
higher-dose POS N
group. POS N

Adverse POS N
events POS N
(AEs) POS N
at POS N
both POS N
dose POS N
levels POS N
were POS N
generally POS N
mild POS N
(grade POS N
1 POS N
or POS N
2) POS N
and POS N
consisted POS N
mainly POS N
of POS N
skin POS N
reactions POS N
and POS N
diarrhea. POS N

Withdrawal POS N
due POS N
to POS N
drug-related POS N
AEs POS N
was POS N
1.9% POS N
and POS N
9.4% POS N
for POS N
patients POS N
receiving POS N
gefitinib POS N
250 POS N
and POS N
500 POS N
mg/d, POS N
respectively. POS N

Adverse POS N
events POS N
(AEs) POS N
at POS N
both POS N
dose POS N
levels POS N
were POS N
generally POS N
mild POS N
(grade POS N
1 POS N
or POS N
2) POS N
and POS N
consisted POS N
mainly POS N
of POS N
skin POS N
reactions POS N
and POS N
diarrhea. POS N

Gefitinib POS N
showed POS N
clinically POS N
meaningful POS N
antitumor POS N
activity POS N
and POS N
provided POS N
symptom POS N
relief POS N
as POS N
second- POS N
and POS N
third-line POS N
treatment POS N
in POS N
these POS N
patients. POS N

Adverse POS N
events POS N
(AEs) POS N
at POS N
both POS N
dose POS N
levels POS N
were POS N
generally POS N
mild POS N
(grade POS N
1 POS N
or POS N
2) POS N
and POS N
consisted POS N
mainly POS N
of POS N
skin POS N
reactions POS N
and POS N
diarrhea. POS N

At POS N
250 POS N
mg/d, POS N
gefitinib POS N
had POS N
a POS N
favorable POS N
AE POS N
profile. POS N

Adverse POS N
events POS N
(AEs) POS N
at POS N
both POS N
dose POS N
levels POS N
were POS N
generally POS N
mild POS N
(grade POS N
1 POS N
or POS N
2) POS N
and POS N
consisted POS N
mainly POS N
of POS N
skin POS N
reactions POS N
and POS N
diarrhea. POS N

Gefitinib POS N
250 POS N
mg/d POS N
is POS N
an POS N
important, POS N
novel POS N
treatment POS N
option POS N
for POS N
patients POS N
with POS N
pretreated POS N
advanced POS N
NSCLC. POS N

Symptom POS N
improvements POS N
were POS N
recorded POS N
for POS N
69.2% POS N
(250 POS N
mg/d) POS N
and POS N
85.7% POS N
(500 POS N
mg/d) POS N
of POS N
patients POS N
with POS N
a POS N
tumor POS N
response. POS N

Efficacy POS N
was POS N
similar POS N
for POS N
the POS N
250- POS N
and POS N
500-mg/d POS N
groups. POS N

Symptom POS N
improvements POS N
were POS N
recorded POS N
for POS N
69.2% POS N
(250 POS N
mg/d) POS N
and POS N
85.7% POS N
(500 POS N
mg/d) POS N
of POS N
patients POS N
with POS N
a POS N
tumor POS N
response. POS N

Objective POS N
tumor POS N
response POS N
rates POS N
were POS N
18.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
11.5 POS N
to POS N
27.3) POS N
and POS N
19.0% POS N
(95% POS N
CI, POS N
12.1 POS N
to POS N
27.9); POS N
among POS N
evaluable POS N
patients, POS N
symptom POS N
improvement POS N
rates POS N
were POS N
40.3% POS N
(95% POS N
CI, POS N
28.5 POS N
to POS N
53.0) POS N
and POS N
37.0% POS N
(95% POS N
CI, POS N
26.0 POS N
to POS N
49.1); POS N
median POS N
progression-free POS N
survival POS N
times POS N
were POS N
2.7 POS N
and POS N
2.8 POS N
months; POS N
and POS N
median POS N
overall POS N
survival POS N
times POS N
were POS N
7.6 POS N
and POS N
8.0 POS N
months, POS N
respectively. POS N

Symptom POS N
improvements POS N
were POS N
recorded POS N
for POS N
69.2% POS N
(250 POS N
mg/d) POS N
and POS N
85.7% POS N
(500 POS N
mg/d) POS N
of POS N
patients POS N
with POS N
a POS N
tumor POS N
response. POS N

Adverse POS N
events POS N
(AEs) POS N
at POS N
both POS N
dose POS N
levels POS N
were POS N
generally POS N
mild POS N
(grade POS N
1 POS N
or POS N
2) POS N
and POS N
consisted POS N
mainly POS N
of POS N
skin POS N
reactions POS N
and POS N
diarrhea. POS N

Symptom POS N
improvements POS N
were POS N
recorded POS N
for POS N
69.2% POS N
(250 POS N
mg/d) POS N
and POS N
85.7% POS N
(500 POS N
mg/d) POS N
of POS N
patients POS N
with POS N
a POS N
tumor POS N
response. POS N

Drug-related POS N
toxicities POS N
were POS N
more POS N
frequent POS N
in POS N
the POS N
higher-dose POS N
group. POS N

Symptom POS N
improvements POS N
were POS N
recorded POS N
for POS N
69.2% POS N
(250 POS N
mg/d) POS N
and POS N
85.7% POS N
(500 POS N
mg/d) POS N
of POS N
patients POS N
with POS N
a POS N
tumor POS N
response. POS N

Withdrawal POS N
due POS N
to POS N
drug-related POS N
AEs POS N
was POS N
1.9% POS N
and POS N
9.4% POS N
for POS N
patients POS N
receiving POS N
gefitinib POS N
250 POS N
and POS N
500 POS N
mg/d, POS N
respectively. POS N

Symptom POS N
improvements POS N
were POS N
recorded POS N
for POS N
69.2% POS N
(250 POS N
mg/d) POS N
and POS N
85.7% POS N
(500 POS N
mg/d) POS N
of POS N
patients POS N
with POS N
a POS N
tumor POS N
response. POS N

Gefitinib POS N
showed POS N
clinically POS N
meaningful POS N
antitumor POS N
activity POS N
and POS N
provided POS N
symptom POS N
relief POS N
as POS N
second- POS N
and POS N
third-line POS N
treatment POS N
in POS N
these POS N
patients. POS N

Symptom POS N
improvements POS N
were POS N
recorded POS N
for POS N
69.2% POS N
(250 POS N
mg/d) POS N
and POS N
85.7% POS N
(500 POS N
mg/d) POS N
of POS N
patients POS N
with POS N
a POS N
tumor POS N
response. POS N

At POS N
250 POS N
mg/d, POS N
gefitinib POS N
had POS N
a POS N
favorable POS N
AE POS N
profile. POS N

Symptom POS N
improvements POS N
were POS N
recorded POS N
for POS N
69.2% POS N
(250 POS N
mg/d) POS N
and POS N
85.7% POS N
(500 POS N
mg/d) POS N
of POS N
patients POS N
with POS N
a POS N
tumor POS N
response. POS N

Gefitinib POS N
250 POS N
mg/d POS N
is POS N
an POS N
important, POS N
novel POS N
treatment POS N
option POS N
for POS N
patients POS N
with POS N
pretreated POS N
advanced POS N
NSCLC. POS N

Drug-related POS N
toxicities POS N
were POS N
more POS N
frequent POS N
in POS N
the POS N
higher-dose POS N
group. POS N

Efficacy POS N
was POS N
similar POS N
for POS N
the POS N
250- POS N
and POS N
500-mg/d POS N
groups. POS N

Drug-related POS N
toxicities POS N
were POS N
more POS N
frequent POS N
in POS N
the POS N
higher-dose POS N
group. POS N

Objective POS N
tumor POS N
response POS N
rates POS N
were POS N
18.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
11.5 POS N
to POS N
27.3) POS N
and POS N
19.0% POS N
(95% POS N
CI, POS N
12.1 POS N
to POS N
27.9); POS N
among POS N
evaluable POS N
patients, POS N
symptom POS N
improvement POS N
rates POS N
were POS N
40.3% POS N
(95% POS N
CI, POS N
28.5 POS N
to POS N
53.0) POS N
and POS N
37.0% POS N
(95% POS N
CI, POS N
26.0 POS N
to POS N
49.1); POS N
median POS N
progression-free POS N
survival POS N
times POS N
were POS N
2.7 POS N
and POS N
2.8 POS N
months; POS N
and POS N
median POS N
overall POS N
survival POS N
times POS N
were POS N
7.6 POS N
and POS N
8.0 POS N
months, POS N
respectively. POS N

Drug-related POS N
toxicities POS N
were POS N
more POS N
frequent POS N
in POS N
the POS N
higher-dose POS N
group. POS N

Adverse POS N
events POS N
(AEs) POS N
at POS N
both POS N
dose POS N
levels POS N
were POS N
generally POS N
mild POS N
(grade POS N
1 POS N
or POS N
2) POS N
and POS N
consisted POS N
mainly POS N
of POS N
skin POS N
reactions POS N
and POS N
diarrhea. POS N

Drug-related POS N
toxicities POS N
were POS N
more POS N
frequent POS N
in POS N
the POS N
higher-dose POS N
group. POS N

Symptom POS N
improvements POS N
were POS N
recorded POS N
for POS N
69.2% POS N
(250 POS N
mg/d) POS N
and POS N
85.7% POS N
(500 POS N
mg/d) POS N
of POS N
patients POS N
with POS N
a POS N
tumor POS N
response. POS N

Drug-related POS N
toxicities POS N
were POS N
more POS N
frequent POS N
in POS N
the POS N
higher-dose POS N
group. POS N

Withdrawal POS N
due POS N
to POS N
drug-related POS N
AEs POS N
was POS N
1.9% POS N
and POS N
9.4% POS N
for POS N
patients POS N
receiving POS N
gefitinib POS N
250 POS N
and POS N
500 POS N
mg/d, POS N
respectively. POS N

Drug-related POS N
toxicities POS N
were POS N
more POS N
frequent POS N
in POS N
the POS N
higher-dose POS N
group. POS N

Gefitinib POS N
showed POS N
clinically POS N
meaningful POS N
antitumor POS N
activity POS N
and POS N
provided POS N
symptom POS N
relief POS N
as POS N
second- POS N
and POS N
third-line POS N
treatment POS N
in POS N
these POS N
patients. POS N

Drug-related POS N
toxicities POS N
were POS N
more POS N
frequent POS N
in POS N
the POS N
higher-dose POS N
group. POS N

At POS N
250 POS N
mg/d, POS N
gefitinib POS N
had POS N
a POS N
favorable POS N
AE POS N
profile. POS N

Drug-related POS N
toxicities POS N
were POS N
more POS N
frequent POS N
in POS N
the POS N
higher-dose POS N
group. POS N

Gefitinib POS N
250 POS N
mg/d POS N
is POS N
an POS N
important, POS N
novel POS N
treatment POS N
option POS N
for POS N
patients POS N
with POS N
pretreated POS N
advanced POS N
NSCLC. POS N

Withdrawal POS N
due POS N
to POS N
drug-related POS N
AEs POS N
was POS N
1.9% POS N
and POS N
9.4% POS N
for POS N
patients POS N
receiving POS N
gefitinib POS N
250 POS N
and POS N
500 POS N
mg/d, POS N
respectively. POS N

Efficacy POS N
was POS N
similar POS N
for POS N
the POS N
250- POS N
and POS N
500-mg/d POS N
groups. POS N

Withdrawal POS N
due POS N
to POS N
drug-related POS N
AEs POS N
was POS N
1.9% POS N
and POS N
9.4% POS N
for POS N
patients POS N
receiving POS N
gefitinib POS N
250 POS N
and POS N
500 POS N
mg/d, POS N
respectively. POS N

Objective POS N
tumor POS N
response POS N
rates POS N
were POS N
18.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
11.5 POS N
to POS N
27.3) POS N
and POS N
19.0% POS N
(95% POS N
CI, POS N
12.1 POS N
to POS N
27.9); POS N
among POS N
evaluable POS N
patients, POS N
symptom POS N
improvement POS N
rates POS N
were POS N
40.3% POS N
(95% POS N
CI, POS N
28.5 POS N
to POS N
53.0) POS N
and POS N
37.0% POS N
(95% POS N
CI, POS N
26.0 POS N
to POS N
49.1); POS N
median POS N
progression-free POS N
survival POS N
times POS N
were POS N
2.7 POS N
and POS N
2.8 POS N
months; POS N
and POS N
median POS N
overall POS N
survival POS N
times POS N
were POS N
7.6 POS N
and POS N
8.0 POS N
months, POS N
respectively. POS N

Withdrawal POS N
due POS N
to POS N
drug-related POS N
AEs POS N
was POS N
1.9% POS N
and POS N
9.4% POS N
for POS N
patients POS N
receiving POS N
gefitinib POS N
250 POS N
and POS N
500 POS N
mg/d, POS N
respectively. POS N

Adverse POS N
events POS N
(AEs) POS N
at POS N
both POS N
dose POS N
levels POS N
were POS N
generally POS N
mild POS N
(grade POS N
1 POS N
or POS N
2) POS N
and POS N
consisted POS N
mainly POS N
of POS N
skin POS N
reactions POS N
and POS N
diarrhea. POS N

Withdrawal POS N
due POS N
to POS N
drug-related POS N
AEs POS N
was POS N
1.9% POS N
and POS N
9.4% POS N
for POS N
patients POS N
receiving POS N
gefitinib POS N
250 POS N
and POS N
500 POS N
mg/d, POS N
respectively. POS N

Symptom POS N
improvements POS N
were POS N
recorded POS N
for POS N
69.2% POS N
(250 POS N
mg/d) POS N
and POS N
85.7% POS N
(500 POS N
mg/d) POS N
of POS N
patients POS N
with POS N
a POS N
tumor POS N
response. POS N

Withdrawal POS N
due POS N
to POS N
drug-related POS N
AEs POS N
was POS N
1.9% POS N
and POS N
9.4% POS N
for POS N
patients POS N
receiving POS N
gefitinib POS N
250 POS N
and POS N
500 POS N
mg/d, POS N
respectively. POS N

Drug-related POS N
toxicities POS N
were POS N
more POS N
frequent POS N
in POS N
the POS N
higher-dose POS N
group. POS N

Withdrawal POS N
due POS N
to POS N
drug-related POS N
AEs POS N
was POS N
1.9% POS N
and POS N
9.4% POS N
for POS N
patients POS N
receiving POS N
gefitinib POS N
250 POS N
and POS N
500 POS N
mg/d, POS N
respectively. POS N

Gefitinib POS N
showed POS N
clinically POS N
meaningful POS N
antitumor POS N
activity POS N
and POS N
provided POS N
symptom POS N
relief POS N
as POS N
second- POS N
and POS N
third-line POS N
treatment POS N
in POS N
these POS N
patients. POS N

Withdrawal POS N
due POS N
to POS N
drug-related POS N
AEs POS N
was POS N
1.9% POS N
and POS N
9.4% POS N
for POS N
patients POS N
receiving POS N
gefitinib POS N
250 POS N
and POS N
500 POS N
mg/d, POS N
respectively. POS N

At POS N
250 POS N
mg/d, POS N
gefitinib POS N
had POS N
a POS N
favorable POS N
AE POS N
profile. POS N

Withdrawal POS N
due POS N
to POS N
drug-related POS N
AEs POS N
was POS N
1.9% POS N
and POS N
9.4% POS N
for POS N
patients POS N
receiving POS N
gefitinib POS N
250 POS N
and POS N
500 POS N
mg/d, POS N
respectively. POS N

Gefitinib POS N
250 POS N
mg/d POS N
is POS N
an POS N
important, POS N
novel POS N
treatment POS N
option POS N
for POS N
patients POS N
with POS N
pretreated POS N
advanced POS N
NSCLC. POS N

Gefitinib POS N
showed POS N
clinically POS N
meaningful POS N
antitumor POS N
activity POS N
and POS N
provided POS N
symptom POS N
relief POS N
as POS N
second- POS N
and POS N
third-line POS N
treatment POS N
in POS N
these POS N
patients. POS N

Efficacy POS N
was POS N
similar POS N
for POS N
the POS N
250- POS N
and POS N
500-mg/d POS N
groups. POS N

Gefitinib POS N
showed POS N
clinically POS N
meaningful POS N
antitumor POS N
activity POS N
and POS N
provided POS N
symptom POS N
relief POS N
as POS N
second- POS N
and POS N
third-line POS N
treatment POS N
in POS N
these POS N
patients. POS N

Objective POS N
tumor POS N
response POS N
rates POS N
were POS N
18.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
11.5 POS N
to POS N
27.3) POS N
and POS N
19.0% POS N
(95% POS N
CI, POS N
12.1 POS N
to POS N
27.9); POS N
among POS N
evaluable POS N
patients, POS N
symptom POS N
improvement POS N
rates POS N
were POS N
40.3% POS N
(95% POS N
CI, POS N
28.5 POS N
to POS N
53.0) POS N
and POS N
37.0% POS N
(95% POS N
CI, POS N
26.0 POS N
to POS N
49.1); POS N
median POS N
progression-free POS N
survival POS N
times POS N
were POS N
2.7 POS N
and POS N
2.8 POS N
months; POS N
and POS N
median POS N
overall POS N
survival POS N
times POS N
were POS N
7.6 POS N
and POS N
8.0 POS N
months, POS N
respectively. POS N

Gefitinib POS N
showed POS N
clinically POS N
meaningful POS N
antitumor POS N
activity POS N
and POS N
provided POS N
symptom POS N
relief POS N
as POS N
second- POS N
and POS N
third-line POS N
treatment POS N
in POS N
these POS N
patients. POS N

Adverse POS N
events POS N
(AEs) POS N
at POS N
both POS N
dose POS N
levels POS N
were POS N
generally POS N
mild POS N
(grade POS N
1 POS N
or POS N
2) POS N
and POS N
consisted POS N
mainly POS N
of POS N
skin POS N
reactions POS N
and POS N
diarrhea. POS N

Gefitinib POS N
showed POS N
clinically POS N
meaningful POS N
antitumor POS N
activity POS N
and POS N
provided POS N
symptom POS N
relief POS N
as POS N
second- POS N
and POS N
third-line POS N
treatment POS N
in POS N
these POS N
patients. POS N

Symptom POS N
improvements POS N
were POS N
recorded POS N
for POS N
69.2% POS N
(250 POS N
mg/d) POS N
and POS N
85.7% POS N
(500 POS N
mg/d) POS N
of POS N
patients POS N
with POS N
a POS N
tumor POS N
response. POS N

Gefitinib POS N
showed POS N
clinically POS N
meaningful POS N
antitumor POS N
activity POS N
and POS N
provided POS N
symptom POS N
relief POS N
as POS N
second- POS N
and POS N
third-line POS N
treatment POS N
in POS N
these POS N
patients. POS N

Drug-related POS N
toxicities POS N
were POS N
more POS N
frequent POS N
in POS N
the POS N
higher-dose POS N
group. POS N

Gefitinib POS N
showed POS N
clinically POS N
meaningful POS N
antitumor POS N
activity POS N
and POS N
provided POS N
symptom POS N
relief POS N
as POS N
second- POS N
and POS N
third-line POS N
treatment POS N
in POS N
these POS N
patients. POS N

Withdrawal POS N
due POS N
to POS N
drug-related POS N
AEs POS N
was POS N
1.9% POS N
and POS N
9.4% POS N
for POS N
patients POS N
receiving POS N
gefitinib POS N
250 POS N
and POS N
500 POS N
mg/d, POS N
respectively. POS N

Gefitinib POS N
showed POS N
clinically POS N
meaningful POS N
antitumor POS N
activity POS N
and POS N
provided POS N
symptom POS N
relief POS N
as POS N
second- POS N
and POS N
third-line POS N
treatment POS N
in POS N
these POS N
patients. POS N

At POS N
250 POS N
mg/d, POS N
gefitinib POS N
had POS N
a POS N
favorable POS N
AE POS N
profile. POS N

Gefitinib POS N
showed POS N
clinically POS N
meaningful POS N
antitumor POS N
activity POS N
and POS N
provided POS N
symptom POS N
relief POS N
as POS N
second- POS N
and POS N
third-line POS N
treatment POS N
in POS N
these POS N
patients. POS N

Gefitinib POS N
250 POS N
mg/d POS N
is POS N
an POS N
important, POS N
novel POS N
treatment POS N
option POS N
for POS N
patients POS N
with POS N
pretreated POS N
advanced POS N
NSCLC. POS N

At POS N
250 POS N
mg/d, POS N
gefitinib POS N
had POS N
a POS N
favorable POS N
AE POS N
profile. POS N

Efficacy POS N
was POS N
similar POS N
for POS N
the POS N
250- POS N
and POS N
500-mg/d POS N
groups. POS N

At POS N
250 POS N
mg/d, POS N
gefitinib POS N
had POS N
a POS N
favorable POS N
AE POS N
profile. POS N

Objective POS N
tumor POS N
response POS N
rates POS N
were POS N
18.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
11.5 POS N
to POS N
27.3) POS N
and POS N
19.0% POS N
(95% POS N
CI, POS N
12.1 POS N
to POS N
27.9); POS N
among POS N
evaluable POS N
patients, POS N
symptom POS N
improvement POS N
rates POS N
were POS N
40.3% POS N
(95% POS N
CI, POS N
28.5 POS N
to POS N
53.0) POS N
and POS N
37.0% POS N
(95% POS N
CI, POS N
26.0 POS N
to POS N
49.1); POS N
median POS N
progression-free POS N
survival POS N
times POS N
were POS N
2.7 POS N
and POS N
2.8 POS N
months; POS N
and POS N
median POS N
overall POS N
survival POS N
times POS N
were POS N
7.6 POS N
and POS N
8.0 POS N
months, POS N
respectively. POS N

At POS N
250 POS N
mg/d, POS N
gefitinib POS N
had POS N
a POS N
favorable POS N
AE POS N
profile. POS N

Adverse POS N
events POS N
(AEs) POS N
at POS N
both POS N
dose POS N
levels POS N
were POS N
generally POS N
mild POS N
(grade POS N
1 POS N
or POS N
2) POS N
and POS N
consisted POS N
mainly POS N
of POS N
skin POS N
reactions POS N
and POS N
diarrhea. POS N

At POS N
250 POS N
mg/d, POS N
gefitinib POS N
had POS N
a POS N
favorable POS N
AE POS N
profile. POS N

Symptom POS N
improvements POS N
were POS N
recorded POS N
for POS N
69.2% POS N
(250 POS N
mg/d) POS N
and POS N
85.7% POS N
(500 POS N
mg/d) POS N
of POS N
patients POS N
with POS N
a POS N
tumor POS N
response. POS N

At POS N
250 POS N
mg/d, POS N
gefitinib POS N
had POS N
a POS N
favorable POS N
AE POS N
profile. POS N

Drug-related POS N
toxicities POS N
were POS N
more POS N
frequent POS N
in POS N
the POS N
higher-dose POS N
group. POS N

At POS N
250 POS N
mg/d, POS N
gefitinib POS N
had POS N
a POS N
favorable POS N
AE POS N
profile. POS N

Withdrawal POS N
due POS N
to POS N
drug-related POS N
AEs POS N
was POS N
1.9% POS N
and POS N
9.4% POS N
for POS N
patients POS N
receiving POS N
gefitinib POS N
250 POS N
and POS N
500 POS N
mg/d, POS N
respectively. POS N

At POS N
250 POS N
mg/d, POS N
gefitinib POS N
had POS N
a POS N
favorable POS N
AE POS N
profile. POS N

Gefitinib POS N
showed POS N
clinically POS N
meaningful POS N
antitumor POS N
activity POS N
and POS N
provided POS N
symptom POS N
relief POS N
as POS N
second- POS N
and POS N
third-line POS N
treatment POS N
in POS N
these POS N
patients. POS N

At POS N
250 POS N
mg/d, POS N
gefitinib POS N
had POS N
a POS N
favorable POS N
AE POS N
profile. POS N

Gefitinib POS N
250 POS N
mg/d POS N
is POS N
an POS N
important, POS N
novel POS N
treatment POS N
option POS N
for POS N
patients POS N
with POS N
pretreated POS N
advanced POS N
NSCLC. POS N

Gefitinib POS N
250 POS N
mg/d POS N
is POS N
an POS N
important, POS N
novel POS N
treatment POS N
option POS N
for POS N
patients POS N
with POS N
pretreated POS N
advanced POS N
NSCLC. POS N

Efficacy POS N
was POS N
similar POS N
for POS N
the POS N
250- POS N
and POS N
500-mg/d POS N
groups. POS N

Gefitinib POS N
250 POS N
mg/d POS N
is POS N
an POS N
important, POS N
novel POS N
treatment POS N
option POS N
for POS N
patients POS N
with POS N
pretreated POS N
advanced POS N
NSCLC. POS N

Objective POS N
tumor POS N
response POS N
rates POS N
were POS N
18.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI], POS N
11.5 POS N
to POS N
27.3) POS N
and POS N
19.0% POS N
(95% POS N
CI, POS N
12.1 POS N
to POS N
27.9); POS N
among POS N
evaluable POS N
patients, POS N
symptom POS N
improvement POS N
rates POS N
were POS N
40.3% POS N
(95% POS N
CI, POS N
28.5 POS N
to POS N
53.0) POS N
and POS N
37.0% POS N
(95% POS N
CI, POS N
26.0 POS N
to POS N
49.1); POS N
median POS N
progression-free POS N
survival POS N
times POS N
were POS N
2.7 POS N
and POS N
2.8 POS N
months; POS N
and POS N
median POS N
overall POS N
survival POS N
times POS N
were POS N
7.6 POS N
and POS N
8.0 POS N
months, POS N
respectively. POS N

Gefitinib POS N
250 POS N
mg/d POS N
is POS N
an POS N
important, POS N
novel POS N
treatment POS N
option POS N
for POS N
patients POS N
with POS N
pretreated POS N
advanced POS N
NSCLC. POS N

Adverse POS N
events POS N
(AEs) POS N
at POS N
both POS N
dose POS N
levels POS N
were POS N
generally POS N
mild POS N
(grade POS N
1 POS N
or POS N
2) POS N
and POS N
consisted POS N
mainly POS N
of POS N
skin POS N
reactions POS N
and POS N
diarrhea. POS N

Gefitinib POS N
250 POS N
mg/d POS N
is POS N
an POS N
important, POS N
novel POS N
treatment POS N
option POS N
for POS N
patients POS N
with POS N
pretreated POS N
advanced POS N
NSCLC. POS N

Symptom POS N
improvements POS N
were POS N
recorded POS N
for POS N
69.2% POS N
(250 POS N
mg/d) POS N
and POS N
85.7% POS N
(500 POS N
mg/d) POS N
of POS N
patients POS N
with POS N
a POS N
tumor POS N
response. POS N

Gefitinib POS N
250 POS N
mg/d POS N
is POS N
an POS N
important, POS N
novel POS N
treatment POS N
option POS N
for POS N
patients POS N
with POS N
pretreated POS N
advanced POS N
NSCLC. POS N

Drug-related POS N
toxicities POS N
were POS N
more POS N
frequent POS N
in POS N
the POS N
higher-dose POS N
group. POS N

Gefitinib POS N
250 POS N
mg/d POS N
is POS N
an POS N
important, POS N
novel POS N
treatment POS N
option POS N
for POS N
patients POS N
with POS N
pretreated POS N
advanced POS N
NSCLC. POS N

Withdrawal POS N
due POS N
to POS N
drug-related POS N
AEs POS N
was POS N
1.9% POS N
and POS N
9.4% POS N
for POS N
patients POS N
receiving POS N
gefitinib POS N
250 POS N
and POS N
500 POS N
mg/d, POS N
respectively. POS N

Gefitinib POS N
250 POS N
mg/d POS N
is POS N
an POS N
important, POS N
novel POS N
treatment POS N
option POS N
for POS N
patients POS N
with POS N
pretreated POS N
advanced POS N
NSCLC. POS N

Gefitinib POS N
showed POS N
clinically POS N
meaningful POS N
antitumor POS N
activity POS N
and POS N
provided POS N
symptom POS N
relief POS N
as POS N
second- POS N
and POS N
third-line POS N
treatment POS N
in POS N
these POS N
patients. POS N

Gefitinib POS N
250 POS N
mg/d POS N
is POS N
an POS N
important, POS N
novel POS N
treatment POS N
option POS N
for POS N
patients POS N
with POS N
pretreated POS N
advanced POS N
NSCLC. POS N

At POS N
250 POS N
mg/d, POS N
gefitinib POS N
had POS N
a POS N
favorable POS N
AE POS N
profile. POS N

The POS N
results POS N
highlight POS N
the POS N
need POS N
to POS N
promote POS N
the POS N
benefits POS N
of POS N
this POS N
drug POS N
combination POS N
in POS N
helping POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
and POS N
to POS N
promote POS N
its POS N
application POS N
in POS N
clinical POS N
practices. POS N

After POS N
treatment, POS N
the POS N
levels POS N
of POS N
the POS N
indexes POS N
in POS N
both POS N
groups POS N
(the POS N
combination POS N
treatment POS N
group POS N
vs. POS N
the POS N
entecavir POS N
group) POS N
were POS N
as POS N
follows: POS N
bilirubin POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μmol/L); POS N
International POS N
Normalized POS N
Ratio POS N
(INR) POS N
(1.21±0.8 POS N
vs. POS N
1.14±0.7); POS N
creatinine POS N
(147.3±12.4 POS N
vs. POS N
287.4±21.6 POS N
mg/dL); POS N
GGT POS N
(67.4±23.2 POS N
vs. POS N
88.4±23.7 POS N
U/L); POS N
and POS N
ALT POS N
(63.4±40.8 POS N
vs. POS N
96.5±23.5 POS N
U/L). POS N

The POS N
results POS N
highlight POS N
the POS N
need POS N
to POS N
promote POS N
the POS N
benefits POS N
of POS N
this POS N
drug POS N
combination POS N
in POS N
helping POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
and POS N
to POS N
promote POS N
its POS N
application POS N
in POS N
clinical POS N
practices. POS N

In POS N
comparison POS N
of POS N
the POS N
indexes POS N
of POS N
hepatic POS N
fibrosis POS N
between POS N
the POS N
two POS N
groups, POS N
we POS N
found POS N
the POS N
following POS N
differences: POS N
PCIII POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μg/L); POS N
IV-C POS N
(61.3±18.7 POS N
vs. POS N
74.5±17.9 POS N
μg/L); POS N
HA POS N
(147.3±12.4 POS N
vs. POS N
87.4±31.6 POS N
μg/L); POS N
and POS N
LN POS N
(88.7±13.2 POS N
vs POS N
102.5±23.4 POS N
μg/L). POS N

The POS N
results POS N
highlight POS N
the POS N
need POS N
to POS N
promote POS N
the POS N
benefits POS N
of POS N
this POS N
drug POS N
combination POS N
in POS N
helping POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
and POS N
to POS N
promote POS N
its POS N
application POS N
in POS N
clinical POS N
practices. POS N

The POS N
results POS N
showed POS N
that POS N
the POS N
differences POS N
in POS N
comparison POS N
of POS N
the POS N
indexes POS N
before POS N
and POS N
after POS N
the POS N
treatment POS N
were POS N
statistically POS N
significant POS N
(P<0.05). POS N

The POS N
results POS N
highlight POS N
the POS N
need POS N
to POS N
promote POS N
the POS N
benefits POS N
of POS N
this POS N
drug POS N
combination POS N
in POS N
helping POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
and POS N
to POS N
promote POS N
its POS N
application POS N
in POS N
clinical POS N
practices. POS N

After POS N
treatment, POS N
the POS N
MELD POS N
score POS N
of POS N
patients POS N
in POS N
the POS N
combination POS N
treatment POS N
group POS N
was POS N
significantly POS N
lower POS N
than POS N
that POS N
in POS N
the POS N
entecavir POS N
group POS N
(18.7±3.2 POS N
vs. POS N
22.5±3.4), POS N
with POS N
a POS N
statistically POS N
significant POS N
difference POS N
(P<0.05). POS N

The POS N
results POS N
highlight POS N
the POS N
need POS N
to POS N
promote POS N
the POS N
benefits POS N
of POS N
this POS N
drug POS N
combination POS N
in POS N
helping POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
and POS N
to POS N
promote POS N
its POS N
application POS N
in POS N
clinical POS N
practices. POS N

In POS N
the POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
the POS N
combined POS N
administration POS N
of POS N
entecavir POS N
and POS N
adefovir POS N
dipivoxil POS N
can POS N
significantly POS N
improve POS N
liver POS N
function, POS N
hepatic POS N
fibrosis POS N
and POS N
MELD POS N
scores. POS N

After POS N
treatment, POS N
the POS N
levels POS N
of POS N
the POS N
indexes POS N
in POS N
both POS N
groups POS N
(the POS N
combination POS N
treatment POS N
group POS N
vs. POS N
the POS N
entecavir POS N
group) POS N
were POS N
as POS N
follows: POS N
bilirubin POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μmol/L); POS N
International POS N
Normalized POS N
Ratio POS N
(INR) POS N
(1.21±0.8 POS N
vs. POS N
1.14±0.7); POS N
creatinine POS N
(147.3±12.4 POS N
vs. POS N
287.4±21.6 POS N
mg/dL); POS N
GGT POS N
(67.4±23.2 POS N
vs. POS N
88.4±23.7 POS N
U/L); POS N
and POS N
ALT POS N
(63.4±40.8 POS N
vs. POS N
96.5±23.5 POS N
U/L). POS N

The POS N
results POS N
highlight POS N
the POS N
need POS N
to POS N
promote POS N
the POS N
benefits POS N
of POS N
this POS N
drug POS N
combination POS N
in POS N
helping POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
and POS N
to POS N
promote POS N
its POS N
application POS N
in POS N
clinical POS N
practices. POS N

After POS N
treatment, POS N
the POS N
levels POS N
of POS N
the POS N
indexes POS N
in POS N
both POS N
groups POS N
(the POS N
combination POS N
treatment POS N
group POS N
vs. POS N
the POS N
entecavir POS N
group) POS N
were POS N
as POS N
follows: POS N
bilirubin POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μmol/L); POS N
International POS N
Normalized POS N
Ratio POS N
(INR) POS N
(1.21±0.8 POS N
vs. POS N
1.14±0.7); POS N
creatinine POS N
(147.3±12.4 POS N
vs. POS N
287.4±21.6 POS N
mg/dL); POS N
GGT POS N
(67.4±23.2 POS N
vs. POS N
88.4±23.7 POS N
U/L); POS N
and POS N
ALT POS N
(63.4±40.8 POS N
vs. POS N
96.5±23.5 POS N
U/L). POS N

In POS N
comparison POS N
of POS N
the POS N
indexes POS N
of POS N
hepatic POS N
fibrosis POS N
between POS N
the POS N
two POS N
groups, POS N
we POS N
found POS N
the POS N
following POS N
differences: POS N
PCIII POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μg/L); POS N
IV-C POS N
(61.3±18.7 POS N
vs. POS N
74.5±17.9 POS N
μg/L); POS N
HA POS N
(147.3±12.4 POS N
vs. POS N
87.4±31.6 POS N
μg/L); POS N
and POS N
LN POS N
(88.7±13.2 POS N
vs POS N
102.5±23.4 POS N
μg/L). POS N

After POS N
treatment, POS N
the POS N
levels POS N
of POS N
the POS N
indexes POS N
in POS N
both POS N
groups POS N
(the POS N
combination POS N
treatment POS N
group POS N
vs. POS N
the POS N
entecavir POS N
group) POS N
were POS N
as POS N
follows: POS N
bilirubin POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μmol/L); POS N
International POS N
Normalized POS N
Ratio POS N
(INR) POS N
(1.21±0.8 POS N
vs. POS N
1.14±0.7); POS N
creatinine POS N
(147.3±12.4 POS N
vs. POS N
287.4±21.6 POS N
mg/dL); POS N
GGT POS N
(67.4±23.2 POS N
vs. POS N
88.4±23.7 POS N
U/L); POS N
and POS N
ALT POS N
(63.4±40.8 POS N
vs. POS N
96.5±23.5 POS N
U/L). POS N

The POS N
results POS N
showed POS N
that POS N
the POS N
differences POS N
in POS N
comparison POS N
of POS N
the POS N
indexes POS N
before POS N
and POS N
after POS N
the POS N
treatment POS N
were POS N
statistically POS N
significant POS N
(P<0.05). POS N

After POS N
treatment, POS N
the POS N
levels POS N
of POS N
the POS N
indexes POS N
in POS N
both POS N
groups POS N
(the POS N
combination POS N
treatment POS N
group POS N
vs. POS N
the POS N
entecavir POS N
group) POS N
were POS N
as POS N
follows: POS N
bilirubin POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μmol/L); POS N
International POS N
Normalized POS N
Ratio POS N
(INR) POS N
(1.21±0.8 POS N
vs. POS N
1.14±0.7); POS N
creatinine POS N
(147.3±12.4 POS N
vs. POS N
287.4±21.6 POS N
mg/dL); POS N
GGT POS N
(67.4±23.2 POS N
vs. POS N
88.4±23.7 POS N
U/L); POS N
and POS N
ALT POS N
(63.4±40.8 POS N
vs. POS N
96.5±23.5 POS N
U/L). POS N

After POS N
treatment, POS N
the POS N
MELD POS N
score POS N
of POS N
patients POS N
in POS N
the POS N
combination POS N
treatment POS N
group POS N
was POS N
significantly POS N
lower POS N
than POS N
that POS N
in POS N
the POS N
entecavir POS N
group POS N
(18.7±3.2 POS N
vs. POS N
22.5±3.4), POS N
with POS N
a POS N
statistically POS N
significant POS N
difference POS N
(P<0.05). POS N

After POS N
treatment, POS N
the POS N
levels POS N
of POS N
the POS N
indexes POS N
in POS N
both POS N
groups POS N
(the POS N
combination POS N
treatment POS N
group POS N
vs. POS N
the POS N
entecavir POS N
group) POS N
were POS N
as POS N
follows: POS N
bilirubin POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μmol/L); POS N
International POS N
Normalized POS N
Ratio POS N
(INR) POS N
(1.21±0.8 POS N
vs. POS N
1.14±0.7); POS N
creatinine POS N
(147.3±12.4 POS N
vs. POS N
287.4±21.6 POS N
mg/dL); POS N
GGT POS N
(67.4±23.2 POS N
vs. POS N
88.4±23.7 POS N
U/L); POS N
and POS N
ALT POS N
(63.4±40.8 POS N
vs. POS N
96.5±23.5 POS N
U/L). POS N

In POS N
the POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
the POS N
combined POS N
administration POS N
of POS N
entecavir POS N
and POS N
adefovir POS N
dipivoxil POS N
can POS N
significantly POS N
improve POS N
liver POS N
function, POS N
hepatic POS N
fibrosis POS N
and POS N
MELD POS N
scores. POS N

In POS N
comparison POS N
of POS N
the POS N
indexes POS N
of POS N
hepatic POS N
fibrosis POS N
between POS N
the POS N
two POS N
groups, POS N
we POS N
found POS N
the POS N
following POS N
differences: POS N
PCIII POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μg/L); POS N
IV-C POS N
(61.3±18.7 POS N
vs. POS N
74.5±17.9 POS N
μg/L); POS N
HA POS N
(147.3±12.4 POS N
vs. POS N
87.4±31.6 POS N
μg/L); POS N
and POS N
LN POS N
(88.7±13.2 POS N
vs POS N
102.5±23.4 POS N
μg/L). POS N

The POS N
results POS N
highlight POS N
the POS N
need POS N
to POS N
promote POS N
the POS N
benefits POS N
of POS N
this POS N
drug POS N
combination POS N
in POS N
helping POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
and POS N
to POS N
promote POS N
its POS N
application POS N
in POS N
clinical POS N
practices. POS N

In POS N
comparison POS N
of POS N
the POS N
indexes POS N
of POS N
hepatic POS N
fibrosis POS N
between POS N
the POS N
two POS N
groups, POS N
we POS N
found POS N
the POS N
following POS N
differences: POS N
PCIII POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μg/L); POS N
IV-C POS N
(61.3±18.7 POS N
vs. POS N
74.5±17.9 POS N
μg/L); POS N
HA POS N
(147.3±12.4 POS N
vs. POS N
87.4±31.6 POS N
μg/L); POS N
and POS N
LN POS N
(88.7±13.2 POS N
vs POS N
102.5±23.4 POS N
μg/L). POS N

After POS N
treatment, POS N
the POS N
levels POS N
of POS N
the POS N
indexes POS N
in POS N
both POS N
groups POS N
(the POS N
combination POS N
treatment POS N
group POS N
vs. POS N
the POS N
entecavir POS N
group) POS N
were POS N
as POS N
follows: POS N
bilirubin POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μmol/L); POS N
International POS N
Normalized POS N
Ratio POS N
(INR) POS N
(1.21±0.8 POS N
vs. POS N
1.14±0.7); POS N
creatinine POS N
(147.3±12.4 POS N
vs. POS N
287.4±21.6 POS N
mg/dL); POS N
GGT POS N
(67.4±23.2 POS N
vs. POS N
88.4±23.7 POS N
U/L); POS N
and POS N
ALT POS N
(63.4±40.8 POS N
vs. POS N
96.5±23.5 POS N
U/L). POS N

In POS N
comparison POS N
of POS N
the POS N
indexes POS N
of POS N
hepatic POS N
fibrosis POS N
between POS N
the POS N
two POS N
groups, POS N
we POS N
found POS N
the POS N
following POS N
differences: POS N
PCIII POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μg/L); POS N
IV-C POS N
(61.3±18.7 POS N
vs. POS N
74.5±17.9 POS N
μg/L); POS N
HA POS N
(147.3±12.4 POS N
vs. POS N
87.4±31.6 POS N
μg/L); POS N
and POS N
LN POS N
(88.7±13.2 POS N
vs POS N
102.5±23.4 POS N
μg/L). POS N

The POS N
results POS N
showed POS N
that POS N
the POS N
differences POS N
in POS N
comparison POS N
of POS N
the POS N
indexes POS N
before POS N
and POS N
after POS N
the POS N
treatment POS N
were POS N
statistically POS N
significant POS N
(P<0.05). POS N

In POS N
comparison POS N
of POS N
the POS N
indexes POS N
of POS N
hepatic POS N
fibrosis POS N
between POS N
the POS N
two POS N
groups, POS N
we POS N
found POS N
the POS N
following POS N
differences: POS N
PCIII POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μg/L); POS N
IV-C POS N
(61.3±18.7 POS N
vs. POS N
74.5±17.9 POS N
μg/L); POS N
HA POS N
(147.3±12.4 POS N
vs. POS N
87.4±31.6 POS N
μg/L); POS N
and POS N
LN POS N
(88.7±13.2 POS N
vs POS N
102.5±23.4 POS N
μg/L). POS N

After POS N
treatment, POS N
the POS N
MELD POS N
score POS N
of POS N
patients POS N
in POS N
the POS N
combination POS N
treatment POS N
group POS N
was POS N
significantly POS N
lower POS N
than POS N
that POS N
in POS N
the POS N
entecavir POS N
group POS N
(18.7±3.2 POS N
vs. POS N
22.5±3.4), POS N
with POS N
a POS N
statistically POS N
significant POS N
difference POS N
(P<0.05). POS N

In POS N
comparison POS N
of POS N
the POS N
indexes POS N
of POS N
hepatic POS N
fibrosis POS N
between POS N
the POS N
two POS N
groups, POS N
we POS N
found POS N
the POS N
following POS N
differences: POS N
PCIII POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μg/L); POS N
IV-C POS N
(61.3±18.7 POS N
vs. POS N
74.5±17.9 POS N
μg/L); POS N
HA POS N
(147.3±12.4 POS N
vs. POS N
87.4±31.6 POS N
μg/L); POS N
and POS N
LN POS N
(88.7±13.2 POS N
vs POS N
102.5±23.4 POS N
μg/L). POS N

In POS N
the POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
the POS N
combined POS N
administration POS N
of POS N
entecavir POS N
and POS N
adefovir POS N
dipivoxil POS N
can POS N
significantly POS N
improve POS N
liver POS N
function, POS N
hepatic POS N
fibrosis POS N
and POS N
MELD POS N
scores. POS N

The POS N
results POS N
showed POS N
that POS N
the POS N
differences POS N
in POS N
comparison POS N
of POS N
the POS N
indexes POS N
before POS N
and POS N
after POS N
the POS N
treatment POS N
were POS N
statistically POS N
significant POS N
(P<0.05). POS N

The POS N
results POS N
highlight POS N
the POS N
need POS N
to POS N
promote POS N
the POS N
benefits POS N
of POS N
this POS N
drug POS N
combination POS N
in POS N
helping POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
and POS N
to POS N
promote POS N
its POS N
application POS N
in POS N
clinical POS N
practices. POS N

The POS N
results POS N
showed POS N
that POS N
the POS N
differences POS N
in POS N
comparison POS N
of POS N
the POS N
indexes POS N
before POS N
and POS N
after POS N
the POS N
treatment POS N
were POS N
statistically POS N
significant POS N
(P<0.05). POS N

After POS N
treatment, POS N
the POS N
levels POS N
of POS N
the POS N
indexes POS N
in POS N
both POS N
groups POS N
(the POS N
combination POS N
treatment POS N
group POS N
vs. POS N
the POS N
entecavir POS N
group) POS N
were POS N
as POS N
follows: POS N
bilirubin POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μmol/L); POS N
International POS N
Normalized POS N
Ratio POS N
(INR) POS N
(1.21±0.8 POS N
vs. POS N
1.14±0.7); POS N
creatinine POS N
(147.3±12.4 POS N
vs. POS N
287.4±21.6 POS N
mg/dL); POS N
GGT POS N
(67.4±23.2 POS N
vs. POS N
88.4±23.7 POS N
U/L); POS N
and POS N
ALT POS N
(63.4±40.8 POS N
vs. POS N
96.5±23.5 POS N
U/L). POS N

The POS N
results POS N
showed POS N
that POS N
the POS N
differences POS N
in POS N
comparison POS N
of POS N
the POS N
indexes POS N
before POS N
and POS N
after POS N
the POS N
treatment POS N
were POS N
statistically POS N
significant POS N
(P<0.05). POS N

In POS N
comparison POS N
of POS N
the POS N
indexes POS N
of POS N
hepatic POS N
fibrosis POS N
between POS N
the POS N
two POS N
groups, POS N
we POS N
found POS N
the POS N
following POS N
differences: POS N
PCIII POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μg/L); POS N
IV-C POS N
(61.3±18.7 POS N
vs. POS N
74.5±17.9 POS N
μg/L); POS N
HA POS N
(147.3±12.4 POS N
vs. POS N
87.4±31.6 POS N
μg/L); POS N
and POS N
LN POS N
(88.7±13.2 POS N
vs POS N
102.5±23.4 POS N
μg/L). POS N

The POS N
results POS N
showed POS N
that POS N
the POS N
differences POS N
in POS N
comparison POS N
of POS N
the POS N
indexes POS N
before POS N
and POS N
after POS N
the POS N
treatment POS N
were POS N
statistically POS N
significant POS N
(P<0.05). POS N

After POS N
treatment, POS N
the POS N
MELD POS N
score POS N
of POS N
patients POS N
in POS N
the POS N
combination POS N
treatment POS N
group POS N
was POS N
significantly POS N
lower POS N
than POS N
that POS N
in POS N
the POS N
entecavir POS N
group POS N
(18.7±3.2 POS N
vs. POS N
22.5±3.4), POS N
with POS N
a POS N
statistically POS N
significant POS N
difference POS N
(P<0.05). POS N

The POS N
results POS N
showed POS N
that POS N
the POS N
differences POS N
in POS N
comparison POS N
of POS N
the POS N
indexes POS N
before POS N
and POS N
after POS N
the POS N
treatment POS N
were POS N
statistically POS N
significant POS N
(P<0.05). POS N

In POS N
the POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
the POS N
combined POS N
administration POS N
of POS N
entecavir POS N
and POS N
adefovir POS N
dipivoxil POS N
can POS N
significantly POS N
improve POS N
liver POS N
function, POS N
hepatic POS N
fibrosis POS N
and POS N
MELD POS N
scores. POS N

After POS N
treatment, POS N
the POS N
MELD POS N
score POS N
of POS N
patients POS N
in POS N
the POS N
combination POS N
treatment POS N
group POS N
was POS N
significantly POS N
lower POS N
than POS N
that POS N
in POS N
the POS N
entecavir POS N
group POS N
(18.7±3.2 POS N
vs. POS N
22.5±3.4), POS N
with POS N
a POS N
statistically POS N
significant POS N
difference POS N
(P<0.05). POS N

The POS N
results POS N
highlight POS N
the POS N
need POS N
to POS N
promote POS N
the POS N
benefits POS N
of POS N
this POS N
drug POS N
combination POS N
in POS N
helping POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
and POS N
to POS N
promote POS N
its POS N
application POS N
in POS N
clinical POS N
practices. POS N

After POS N
treatment, POS N
the POS N
MELD POS N
score POS N
of POS N
patients POS N
in POS N
the POS N
combination POS N
treatment POS N
group POS N
was POS N
significantly POS N
lower POS N
than POS N
that POS N
in POS N
the POS N
entecavir POS N
group POS N
(18.7±3.2 POS N
vs. POS N
22.5±3.4), POS N
with POS N
a POS N
statistically POS N
significant POS N
difference POS N
(P<0.05). POS N

After POS N
treatment, POS N
the POS N
levels POS N
of POS N
the POS N
indexes POS N
in POS N
both POS N
groups POS N
(the POS N
combination POS N
treatment POS N
group POS N
vs. POS N
the POS N
entecavir POS N
group) POS N
were POS N
as POS N
follows: POS N
bilirubin POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μmol/L); POS N
International POS N
Normalized POS N
Ratio POS N
(INR) POS N
(1.21±0.8 POS N
vs. POS N
1.14±0.7); POS N
creatinine POS N
(147.3±12.4 POS N
vs. POS N
287.4±21.6 POS N
mg/dL); POS N
GGT POS N
(67.4±23.2 POS N
vs. POS N
88.4±23.7 POS N
U/L); POS N
and POS N
ALT POS N
(63.4±40.8 POS N
vs. POS N
96.5±23.5 POS N
U/L). POS N

After POS N
treatment, POS N
the POS N
MELD POS N
score POS N
of POS N
patients POS N
in POS N
the POS N
combination POS N
treatment POS N
group POS N
was POS N
significantly POS N
lower POS N
than POS N
that POS N
in POS N
the POS N
entecavir POS N
group POS N
(18.7±3.2 POS N
vs. POS N
22.5±3.4), POS N
with POS N
a POS N
statistically POS N
significant POS N
difference POS N
(P<0.05). POS N

In POS N
comparison POS N
of POS N
the POS N
indexes POS N
of POS N
hepatic POS N
fibrosis POS N
between POS N
the POS N
two POS N
groups, POS N
we POS N
found POS N
the POS N
following POS N
differences: POS N
PCIII POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μg/L); POS N
IV-C POS N
(61.3±18.7 POS N
vs. POS N
74.5±17.9 POS N
μg/L); POS N
HA POS N
(147.3±12.4 POS N
vs. POS N
87.4±31.6 POS N
μg/L); POS N
and POS N
LN POS N
(88.7±13.2 POS N
vs POS N
102.5±23.4 POS N
μg/L). POS N

After POS N
treatment, POS N
the POS N
MELD POS N
score POS N
of POS N
patients POS N
in POS N
the POS N
combination POS N
treatment POS N
group POS N
was POS N
significantly POS N
lower POS N
than POS N
that POS N
in POS N
the POS N
entecavir POS N
group POS N
(18.7±3.2 POS N
vs. POS N
22.5±3.4), POS N
with POS N
a POS N
statistically POS N
significant POS N
difference POS N
(P<0.05). POS N

The POS N
results POS N
showed POS N
that POS N
the POS N
differences POS N
in POS N
comparison POS N
of POS N
the POS N
indexes POS N
before POS N
and POS N
after POS N
the POS N
treatment POS N
were POS N
statistically POS N
significant POS N
(P<0.05). POS N

After POS N
treatment, POS N
the POS N
MELD POS N
score POS N
of POS N
patients POS N
in POS N
the POS N
combination POS N
treatment POS N
group POS N
was POS N
significantly POS N
lower POS N
than POS N
that POS N
in POS N
the POS N
entecavir POS N
group POS N
(18.7±3.2 POS N
vs. POS N
22.5±3.4), POS N
with POS N
a POS N
statistically POS N
significant POS N
difference POS N
(P<0.05). POS N

In POS N
the POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
the POS N
combined POS N
administration POS N
of POS N
entecavir POS N
and POS N
adefovir POS N
dipivoxil POS N
can POS N
significantly POS N
improve POS N
liver POS N
function, POS N
hepatic POS N
fibrosis POS N
and POS N
MELD POS N
scores. POS N

In POS N
the POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
the POS N
combined POS N
administration POS N
of POS N
entecavir POS N
and POS N
adefovir POS N
dipivoxil POS N
can POS N
significantly POS N
improve POS N
liver POS N
function, POS N
hepatic POS N
fibrosis POS N
and POS N
MELD POS N
scores. POS N

The POS N
results POS N
highlight POS N
the POS N
need POS N
to POS N
promote POS N
the POS N
benefits POS N
of POS N
this POS N
drug POS N
combination POS N
in POS N
helping POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
and POS N
to POS N
promote POS N
its POS N
application POS N
in POS N
clinical POS N
practices. POS N

In POS N
the POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
the POS N
combined POS N
administration POS N
of POS N
entecavir POS N
and POS N
adefovir POS N
dipivoxil POS N
can POS N
significantly POS N
improve POS N
liver POS N
function, POS N
hepatic POS N
fibrosis POS N
and POS N
MELD POS N
scores. POS N

After POS N
treatment, POS N
the POS N
levels POS N
of POS N
the POS N
indexes POS N
in POS N
both POS N
groups POS N
(the POS N
combination POS N
treatment POS N
group POS N
vs. POS N
the POS N
entecavir POS N
group) POS N
were POS N
as POS N
follows: POS N
bilirubin POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μmol/L); POS N
International POS N
Normalized POS N
Ratio POS N
(INR) POS N
(1.21±0.8 POS N
vs. POS N
1.14±0.7); POS N
creatinine POS N
(147.3±12.4 POS N
vs. POS N
287.4±21.6 POS N
mg/dL); POS N
GGT POS N
(67.4±23.2 POS N
vs. POS N
88.4±23.7 POS N
U/L); POS N
and POS N
ALT POS N
(63.4±40.8 POS N
vs. POS N
96.5±23.5 POS N
U/L). POS N

In POS N
the POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
the POS N
combined POS N
administration POS N
of POS N
entecavir POS N
and POS N
adefovir POS N
dipivoxil POS N
can POS N
significantly POS N
improve POS N
liver POS N
function, POS N
hepatic POS N
fibrosis POS N
and POS N
MELD POS N
scores. POS N

In POS N
comparison POS N
of POS N
the POS N
indexes POS N
of POS N
hepatic POS N
fibrosis POS N
between POS N
the POS N
two POS N
groups, POS N
we POS N
found POS N
the POS N
following POS N
differences: POS N
PCIII POS N
(67.5±7.7 POS N
vs. POS N
82.4±13.5 POS N
μg/L); POS N
IV-C POS N
(61.3±18.7 POS N
vs. POS N
74.5±17.9 POS N
μg/L); POS N
HA POS N
(147.3±12.4 POS N
vs. POS N
87.4±31.6 POS N
μg/L); POS N
and POS N
LN POS N
(88.7±13.2 POS N
vs POS N
102.5±23.4 POS N
μg/L). POS N

In POS N
the POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
the POS N
combined POS N
administration POS N
of POS N
entecavir POS N
and POS N
adefovir POS N
dipivoxil POS N
can POS N
significantly POS N
improve POS N
liver POS N
function, POS N
hepatic POS N
fibrosis POS N
and POS N
MELD POS N
scores. POS N

The POS N
results POS N
showed POS N
that POS N
the POS N
differences POS N
in POS N
comparison POS N
of POS N
the POS N
indexes POS N
before POS N
and POS N
after POS N
the POS N
treatment POS N
were POS N
statistically POS N
significant POS N
(P<0.05). POS N

In POS N
the POS N
chronic POS N
hepatitis POS N
B POS N
patients POS N
with POS N
interferon POS N
resistance, POS N
the POS N
combined POS N
administration POS N
of POS N
entecavir POS N
and POS N
adefovir POS N
dipivoxil POS N
can POS N
significantly POS N
improve POS N
liver POS N
function, POS N
hepatic POS N
fibrosis POS N
and POS N
MELD POS N
scores. POS N

After POS N
treatment, POS N
the POS N
MELD POS N
score POS N
of POS N
patients POS N
in POS N
the POS N
combination POS N
treatment POS N
group POS N
was POS N
significantly POS N
lower POS N
than POS N
that POS N
in POS N
the POS N
entecavir POS N
group POS N
(18.7±3.2 POS N
vs. POS N
22.5±3.4), POS N
with POS N
a POS N
statistically POS N
significant POS N
difference POS N
(P<0.05). POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

Low POS N
anterior POS N
resection POS N
with POS N
coloanal POS N
anastomosis POS N
prevents POS N
a POS N
definitive POS N
stoma POS N
in POS N
patients POS N
with POS N
distal POS N
rectal POS N
cancer. POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

However, POS N
imperative POS N
stool POS N
urge, POS N
stool POS N
fragmentation, POS N
prolonged POS N
stooling POS N
sessions, POS N
and POS N
minor POS N
problems POS N
of POS N
incontinence POS N
are POS N
frequently POS N
observed POS N
in POS N
the POS N
postoperative POS N
situation POS N
and POS N
negatively POS N
affect POS N
quality POS N
of POS N
life. POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

problems POS N
with POS N
continence POS N
for POS N
liquids POS N
or POS N
gas POS N
occurred POS N
less POS N
frequently POS N
in POS N
the POS N
colonic POS N
J-pouch POS N
group POS N
6 POS N
months POS N
after POS N
surgery. POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

The POS N
frequency POS N
of POS N
bowel POS N
movements POS N
was POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
(2.5 POS N
per POS N
day) POS N
than POS N
in POS N
the POS N
coloanal POS N
group POS N
(4.7 POS N
per POS N
day). POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

in POS N
a POS N
manometric POS N
study POS N
at POS N
the POS N
same POS N
postoperative POS N
point, POS N
neorectal POS N
capacity POS N
was POS N
decreased POS N
to POS N
a POS N
similar POS N
degree POS N
in POS N
both POS N
groups POS N
compared POS N
with POS N
the POS N
preoperative POS N
rectal POS N
volume. POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

the POS N
expected POS N
and POS N
postulated POS N
reservoir POS N
effect POS N
could POS N
not POS N
be POS N
achieved POS N
by POS N
forming POS N
a POS N
5-cm POS N
colonic POS N
J-pouch. POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

The POS N
colonic POS N
J-pouch POS N
was POS N
superior POS N
with POS N
regard POS N
to POS N
continence POS N
for POS N
gas POS N
and POS N
liquids POS N
compared POS N
with POS N
a POS N
straight POS N
coloanal POS N
anastomosis. POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

stool POS N
frequency POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
J-pouch POS N
group POS N
than POS N
in POS N
the POS N
coloanal POS N
reconstruction POS N
group. POS N

because POS N
neorectal POS N
capacity POS N
decreased POS N
equally POS N
in POS N
both POS N
groups, POS N

we POS N
speculate POS N
that POS N
the POS N
advantage POS N
of POS N
the POS N
colonic POS N
J-pouch POS N
is POS N
not POS N
in POS N
the POS N
creation POS N
of POS N
a POS N
larger POS N
neorectal POS N
reservoir POS N
but POS N
rather POS N
may POS N
be POS N
related POS N
to POS N
decreased POS N
motility. POS N

Risk POS N
of POS N
all POS N
three POS N
outcomes POS N
was POS N
higher POS N
for POS N
participants POS N
with POS N
chronic POS N
kidney POS N
disease POS N
or POS N
frailty. POS N

Older POS N
age POS N
was POS N
also POS N
associated POS N
with POS N
greater POS N
risk POS N
of POS N
syncope, POS N
hypotension, POS N
and POS N
falls, POS N
but POS N
there POS N
was POS N
no POS N
age-by-treatment POS N
interaction POS N
for POS N
any POS N
of POS N
the POS N
SAE POS N
outcomes. POS N

Risk POS N
of POS N
all POS N
three POS N
outcomes POS N
was POS N
higher POS N
for POS N
participants POS N
with POS N
chronic POS N
kidney POS N
disease POS N
or POS N
frailty. POS N

Participants POS N
randomized POS N
to POS N
intensive POS N
SBP POS N
control POS N
had POS N
greater POS N
risk POS N
of POS N
hypotension POS N
and POS N
possibly POS N
syncope, POS N
but POS N
not POS N
falls. POS N

Risk POS N
of POS N
all POS N
three POS N
outcomes POS N
was POS N
higher POS N
for POS N
participants POS N
with POS N
chronic POS N
kidney POS N
disease POS N
or POS N
frailty. POS N

Randomization POS N
to POS N
intensive POS N
SBP POS N
control POS N
was POS N
associated POS N
with POS N
greater POS N
risk POS N
of POS N
an POS N
SAE POS N
involving POS N
hypotension POS N
(hazard POS N
ratio POS N
(HR) POS N
= POS N
1.67, POS N
95% POS N
confidence POS N
interval POS N
(CI) POS N
= POS N
1.21-2.32, POS N
P POS N
= POS N
.002), POS N
and POS N
possibly POS N
syncope POS N
(HR POS N
= POS N
1.32, POS N
95% POS N
CI POS N
= POS N
0.98-1.79, POS N
P POS N
= POS N
.07), POS N
but POS N
not POS N
falls POS N
(HR POS N
= POS N
0.98, POS N
95% POS N
CI POS N
= POS N
0.75-1.29, POS N
P POS N
= POS N
.90). POS N

Older POS N
age POS N
was POS N
also POS N
associated POS N
with POS N
greater POS N
risk POS N
of POS N
syncope, POS N
hypotension, POS N
and POS N
falls, POS N
but POS N
there POS N
was POS N
no POS N
age-by-treatment POS N
interaction POS N
for POS N
any POS N
of POS N
the POS N
SAE POS N
outcomes. POS N

Risk POS N
of POS N
all POS N
three POS N
outcomes POS N
was POS N
higher POS N
for POS N
participants POS N
with POS N
chronic POS N
kidney POS N
disease POS N
or POS N
frailty. POS N

Older POS N
age POS N
was POS N
also POS N
associated POS N
with POS N
greater POS N
risk POS N
of POS N
syncope, POS N
hypotension, POS N
and POS N
falls, POS N
but POS N
there POS N
was POS N
no POS N
age-by-treatment POS N
interaction POS N
for POS N
any POS N
of POS N
the POS N
SAE POS N
outcomes. POS N

Participants POS N
randomized POS N
to POS N
intensive POS N
SBP POS N
control POS N
had POS N
greater POS N
risk POS N
of POS N
hypotension POS N
and POS N
possibly POS N
syncope, POS N
but POS N
not POS N
falls. POS N

Older POS N
age POS N
was POS N
also POS N
associated POS N
with POS N
greater POS N
risk POS N
of POS N
syncope, POS N
hypotension, POS N
and POS N
falls, POS N
but POS N
there POS N
was POS N
no POS N
age-by-treatment POS N
interaction POS N
for POS N
any POS N
of POS N
the POS N
SAE POS N
outcomes. POS N

Randomization POS N
to POS N
intensive POS N
SBP POS N
control POS N
was POS N
associated POS N
with POS N
greater POS N
risk POS N
of POS N
an POS N
SAE POS N
involving POS N
hypotension POS N
(hazard POS N
ratio POS N
(HR) POS N
= POS N
1.67, POS N
95% POS N
confidence POS N
interval POS N
(CI) POS N
= POS N
1.21-2.32, POS N
P POS N
= POS N
.002), POS N
and POS N
possibly POS N
syncope POS N
(HR POS N
= POS N
1.32, POS N
95% POS N
CI POS N
= POS N
0.98-1.79, POS N
P POS N
= POS N
.07), POS N
but POS N
not POS N
falls POS N
(HR POS N
= POS N
0.98, POS N
95% POS N
CI POS N
= POS N
0.75-1.29, POS N
P POS N
= POS N
.90). POS N

Participants POS N
randomized POS N
to POS N
intensive POS N
SBP POS N
control POS N
had POS N
greater POS N
risk POS N
of POS N
hypotension POS N
and POS N
possibly POS N
syncope, POS N
but POS N
not POS N
falls. POS N

Risk POS N
of POS N
all POS N
three POS N
outcomes POS N
was POS N
higher POS N
for POS N
participants POS N
with POS N
chronic POS N
kidney POS N
disease POS N
or POS N
frailty. POS N

Participants POS N
randomized POS N
to POS N
intensive POS N
SBP POS N
control POS N
had POS N
greater POS N
risk POS N
of POS N
hypotension POS N
and POS N
possibly POS N
syncope, POS N
but POS N
not POS N
falls. POS N

Older POS N
age POS N
was POS N
also POS N
associated POS N
with POS N
greater POS N
risk POS N
of POS N
syncope, POS N
hypotension, POS N
and POS N
falls, POS N
but POS N
there POS N
was POS N
no POS N
age-by-treatment POS N
interaction POS N
for POS N
any POS N
of POS N
the POS N
SAE POS N
outcomes. POS N

Participants POS N
randomized POS N
to POS N
intensive POS N
SBP POS N
control POS N
had POS N
greater POS N
risk POS N
of POS N
hypotension POS N
and POS N
possibly POS N
syncope, POS N
but POS N
not POS N
falls. POS N

Randomization POS N
to POS N
intensive POS N
SBP POS N
control POS N
was POS N
associated POS N
with POS N
greater POS N
risk POS N
of POS N
an POS N
SAE POS N
involving POS N
hypotension POS N
(hazard POS N
ratio POS N
(HR) POS N
= POS N
1.67, POS N
95% POS N
confidence POS N
interval POS N
(CI) POS N
= POS N
1.21-2.32, POS N
P POS N
= POS N
.002), POS N
and POS N
possibly POS N
syncope POS N
(HR POS N
= POS N
1.32, POS N
95% POS N
CI POS N
= POS N
0.98-1.79, POS N
P POS N
= POS N
.07), POS N
but POS N
not POS N
falls POS N
(HR POS N
= POS N
0.98, POS N
95% POS N
CI POS N
= POS N
0.75-1.29, POS N
P POS N
= POS N
.90). POS N

Randomization POS N
to POS N
intensive POS N
SBP POS N
control POS N
was POS N
associated POS N
with POS N
greater POS N
risk POS N
of POS N
an POS N
SAE POS N
involving POS N
hypotension POS N
(hazard POS N
ratio POS N
(HR) POS N
= POS N
1.67, POS N
95% POS N
confidence POS N
interval POS N
(CI) POS N
= POS N
1.21-2.32, POS N
P POS N
= POS N
.002), POS N
and POS N
possibly POS N
syncope POS N
(HR POS N
= POS N
1.32, POS N
95% POS N
CI POS N
= POS N
0.98-1.79, POS N
P POS N
= POS N
.07), POS N
but POS N
not POS N
falls POS N
(HR POS N
= POS N
0.98, POS N
95% POS N
CI POS N
= POS N
0.75-1.29, POS N
P POS N
= POS N
.90). POS N

Risk POS N
of POS N
all POS N
three POS N
outcomes POS N
was POS N
higher POS N
for POS N
participants POS N
with POS N
chronic POS N
kidney POS N
disease POS N
or POS N
frailty. POS N

Randomization POS N
to POS N
intensive POS N
SBP POS N
control POS N
was POS N
associated POS N
with POS N
greater POS N
risk POS N
of POS N
an POS N
SAE POS N
involving POS N
hypotension POS N
(hazard POS N
ratio POS N
(HR) POS N
= POS N
1.67, POS N
95% POS N
confidence POS N
interval POS N
(CI) POS N
= POS N
1.21-2.32, POS N
P POS N
= POS N
.002), POS N
and POS N
possibly POS N
syncope POS N
(HR POS N
= POS N
1.32, POS N
95% POS N
CI POS N
= POS N
0.98-1.79, POS N
P POS N
= POS N
.07), POS N
but POS N
not POS N
falls POS N
(HR POS N
= POS N
0.98, POS N
95% POS N
CI POS N
= POS N
0.75-1.29, POS N
P POS N
= POS N
.90). POS N

Older POS N
age POS N
was POS N
also POS N
associated POS N
with POS N
greater POS N
risk POS N
of POS N
syncope, POS N
hypotension, POS N
and POS N
falls, POS N
but POS N
there POS N
was POS N
no POS N
age-by-treatment POS N
interaction POS N
for POS N
any POS N
of POS N
the POS N
SAE POS N
outcomes. POS N

Randomization POS N
to POS N
intensive POS N
SBP POS N
control POS N
was POS N
associated POS N
with POS N
greater POS N
risk POS N
of POS N
an POS N
SAE POS N
involving POS N
hypotension POS N
(hazard POS N
ratio POS N
(HR) POS N
= POS N
1.67, POS N
95% POS N
confidence POS N
interval POS N
(CI) POS N
= POS N
1.21-2.32, POS N
P POS N
= POS N
.002), POS N
and POS N
possibly POS N
syncope POS N
(HR POS N
= POS N
1.32, POS N
95% POS N
CI POS N
= POS N
0.98-1.79, POS N
P POS N
= POS N
.07), POS N
but POS N
not POS N
falls POS N
(HR POS N
= POS N
0.98, POS N
95% POS N
CI POS N
= POS N
0.75-1.29, POS N
P POS N
= POS N
.90). POS N

Participants POS N
randomized POS N
to POS N
intensive POS N
SBP POS N
control POS N
had POS N
greater POS N
risk POS N
of POS N
hypotension POS N
and POS N
possibly POS N
syncope, POS N
but POS N
not POS N
falls. POS N

Severely POS N
immunosuppressed POS N
individuals POS N
with POS N
raised POS N
pretreatment POS N
AST/ALT POS N
or POS N
HBsAg POS N
seropositivity POS N
need POS N
closer POS N
monitoring POS N
for POS N
hepatotoxicity. POS N

Among POS N
426 POS N
participants POS N
(53% POS N
male, POS N
median POS N
age POS N
35 POS N
years, POS N
median POS N
CD4 POS N
count POS N
19 POS N
cells/µL), POS N
31 POS N
developed POS N
hepatotoxicity POS N
(7.3%). POS N

Severely POS N
immunosuppressed POS N
individuals POS N
with POS N
raised POS N
pretreatment POS N
AST/ALT POS N
or POS N
HBsAg POS N
seropositivity POS N
need POS N
closer POS N
monitoring POS N
for POS N
hepatotoxicity. POS N

Raised POS N
pretreatment POS N
AST/ALT POS N
(odds POS N
ratio POS N
[OR] POS N
3.6, POS N
95% POS N
confidence POS N
interval POS N
[CI]: POS N
1.7 POS N
to POS N
7.7) POS N
and POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
seropositivity POS N
at POS N
baseline POS N
(OR POS N
4.7, POS N
95% POS N
CI: POS N
1.7 POS N
to POS N
12.9) POS N
were POS N
significantly POS N
associated POS N
with POS N
an POS N
increased POS N
risk POS N
of POS N
developing POS N
hepatotoxicity. POS N

Severely POS N
immunosuppressed POS N
individuals POS N
with POS N
raised POS N
pretreatment POS N
AST/ALT POS N
or POS N
HBsAg POS N
seropositivity POS N
need POS N
closer POS N
monitoring POS N
for POS N
hepatotoxicity. POS N

Participants POS N
with POS N
both POS N
raised POS N
AST/ALT POS N
and POS N
positive POS N
HBsAg POS N
had POS N
a POS N
higher POS N
risk POS N
(OR POS N
19.9, POS N
95% POS N
CI: POS N
5.3 POS N
to POS N
74.3) POS N
and POS N
earlier POS N
onset POS N
of POS N
hepatotoxicity POS N
than POS N
participants POS N
who POS N
did POS N
not POS N
have POS N
these POS N
conditions POS N
at POS N
baseline. POS N

Severely POS N
immunosuppressed POS N
individuals POS N
with POS N
raised POS N
pretreatment POS N
AST/ALT POS N
or POS N
HBsAg POS N
seropositivity POS N
need POS N
closer POS N
monitoring POS N
for POS N
hepatotoxicity. POS N

The POS N
incidence POS N
of POS N
hepatotoxicity POS N
during POS N
IPT POS N
and POS N
ART POS N
was POS N
high. POS N

Among POS N
426 POS N
participants POS N
(53% POS N
male, POS N
median POS N
age POS N
35 POS N
years, POS N
median POS N
CD4 POS N
count POS N
19 POS N
cells/µL), POS N
31 POS N
developed POS N
hepatotoxicity POS N
(7.3%). POS N

Severely POS N
immunosuppressed POS N
individuals POS N
with POS N
raised POS N
pretreatment POS N
AST/ALT POS N
or POS N
HBsAg POS N
seropositivity POS N
need POS N
closer POS N
monitoring POS N
for POS N
hepatotoxicity. POS N

Among POS N
426 POS N
participants POS N
(53% POS N
male, POS N
median POS N
age POS N
35 POS N
years, POS N
median POS N
CD4 POS N
count POS N
19 POS N
cells/µL), POS N
31 POS N
developed POS N
hepatotoxicity POS N
(7.3%). POS N

Raised POS N
pretreatment POS N
AST/ALT POS N
(odds POS N
ratio POS N
[OR] POS N
3.6, POS N
95% POS N
confidence POS N
interval POS N
[CI]: POS N
1.7 POS N
to POS N
7.7) POS N
and POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
seropositivity POS N
at POS N
baseline POS N
(OR POS N
4.7, POS N
95% POS N
CI: POS N
1.7 POS N
to POS N
12.9) POS N
were POS N
significantly POS N
associated POS N
with POS N
an POS N
increased POS N
risk POS N
of POS N
developing POS N
hepatotoxicity. POS N

Among POS N
426 POS N
participants POS N
(53% POS N
male, POS N
median POS N
age POS N
35 POS N
years, POS N
median POS N
CD4 POS N
count POS N
19 POS N
cells/µL), POS N
31 POS N
developed POS N
hepatotoxicity POS N
(7.3%). POS N

Participants POS N
with POS N
both POS N
raised POS N
AST/ALT POS N
and POS N
positive POS N
HBsAg POS N
had POS N
a POS N
higher POS N
risk POS N
(OR POS N
19.9, POS N
95% POS N
CI: POS N
5.3 POS N
to POS N
74.3) POS N
and POS N
earlier POS N
onset POS N
of POS N
hepatotoxicity POS N
than POS N
participants POS N
who POS N
did POS N
not POS N
have POS N
these POS N
conditions POS N
at POS N
baseline. POS N

Among POS N
426 POS N
participants POS N
(53% POS N
male, POS N
median POS N
age POS N
35 POS N
years, POS N
median POS N
CD4 POS N
count POS N
19 POS N
cells/µL), POS N
31 POS N
developed POS N
hepatotoxicity POS N
(7.3%). POS N

The POS N
incidence POS N
of POS N
hepatotoxicity POS N
during POS N
IPT POS N
and POS N
ART POS N
was POS N
high. POS N

Raised POS N
pretreatment POS N
AST/ALT POS N
(odds POS N
ratio POS N
[OR] POS N
3.6, POS N
95% POS N
confidence POS N
interval POS N
[CI]: POS N
1.7 POS N
to POS N
7.7) POS N
and POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
seropositivity POS N
at POS N
baseline POS N
(OR POS N
4.7, POS N
95% POS N
CI: POS N
1.7 POS N
to POS N
12.9) POS N
were POS N
significantly POS N
associated POS N
with POS N
an POS N
increased POS N
risk POS N
of POS N
developing POS N
hepatotoxicity. POS N

Severely POS N
immunosuppressed POS N
individuals POS N
with POS N
raised POS N
pretreatment POS N
AST/ALT POS N
or POS N
HBsAg POS N
seropositivity POS N
need POS N
closer POS N
monitoring POS N
for POS N
hepatotoxicity. POS N

Raised POS N
pretreatment POS N
AST/ALT POS N
(odds POS N
ratio POS N
[OR] POS N
3.6, POS N
95% POS N
confidence POS N
interval POS N
[CI]: POS N
1.7 POS N
to POS N
7.7) POS N
and POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
seropositivity POS N
at POS N
baseline POS N
(OR POS N
4.7, POS N
95% POS N
CI: POS N
1.7 POS N
to POS N
12.9) POS N
were POS N
significantly POS N
associated POS N
with POS N
an POS N
increased POS N
risk POS N
of POS N
developing POS N
hepatotoxicity. POS N

Among POS N
426 POS N
participants POS N
(53% POS N
male, POS N
median POS N
age POS N
35 POS N
years, POS N
median POS N
CD4 POS N
count POS N
19 POS N
cells/µL), POS N
31 POS N
developed POS N
hepatotoxicity POS N
(7.3%). POS N

Raised POS N
pretreatment POS N
AST/ALT POS N
(odds POS N
ratio POS N
[OR] POS N
3.6, POS N
95% POS N
confidence POS N
interval POS N
[CI]: POS N
1.7 POS N
to POS N
7.7) POS N
and POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
seropositivity POS N
at POS N
baseline POS N
(OR POS N
4.7, POS N
95% POS N
CI: POS N
1.7 POS N
to POS N
12.9) POS N
were POS N
significantly POS N
associated POS N
with POS N
an POS N
increased POS N
risk POS N
of POS N
developing POS N
hepatotoxicity. POS N

Participants POS N
with POS N
both POS N
raised POS N
AST/ALT POS N
and POS N
positive POS N
HBsAg POS N
had POS N
a POS N
higher POS N
risk POS N
(OR POS N
19.9, POS N
95% POS N
CI: POS N
5.3 POS N
to POS N
74.3) POS N
and POS N
earlier POS N
onset POS N
of POS N
hepatotoxicity POS N
than POS N
participants POS N
who POS N
did POS N
not POS N
have POS N
these POS N
conditions POS N
at POS N
baseline. POS N

Raised POS N
pretreatment POS N
AST/ALT POS N
(odds POS N
ratio POS N
[OR] POS N
3.6, POS N
95% POS N
confidence POS N
interval POS N
[CI]: POS N
1.7 POS N
to POS N
7.7) POS N
and POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
seropositivity POS N
at POS N
baseline POS N
(OR POS N
4.7, POS N
95% POS N
CI: POS N
1.7 POS N
to POS N
12.9) POS N
were POS N
significantly POS N
associated POS N
with POS N
an POS N
increased POS N
risk POS N
of POS N
developing POS N
hepatotoxicity. POS N

The POS N
incidence POS N
of POS N
hepatotoxicity POS N
during POS N
IPT POS N
and POS N
ART POS N
was POS N
high. POS N

Participants POS N
with POS N
both POS N
raised POS N
AST/ALT POS N
and POS N
positive POS N
HBsAg POS N
had POS N
a POS N
higher POS N
risk POS N
(OR POS N
19.9, POS N
95% POS N
CI: POS N
5.3 POS N
to POS N
74.3) POS N
and POS N
earlier POS N
onset POS N
of POS N
hepatotoxicity POS N
than POS N
participants POS N
who POS N
did POS N
not POS N
have POS N
these POS N
conditions POS N
at POS N
baseline. POS N

Severely POS N
immunosuppressed POS N
individuals POS N
with POS N
raised POS N
pretreatment POS N
AST/ALT POS N
or POS N
HBsAg POS N
seropositivity POS N
need POS N
closer POS N
monitoring POS N
for POS N
hepatotoxicity. POS N

Participants POS N
with POS N
both POS N
raised POS N
AST/ALT POS N
and POS N
positive POS N
HBsAg POS N
had POS N
a POS N
higher POS N
risk POS N
(OR POS N
19.9, POS N
95% POS N
CI: POS N
5.3 POS N
to POS N
74.3) POS N
and POS N
earlier POS N
onset POS N
of POS N
hepatotoxicity POS N
than POS N
participants POS N
who POS N
did POS N
not POS N
have POS N
these POS N
conditions POS N
at POS N
baseline. POS N

Among POS N
426 POS N
participants POS N
(53% POS N
male, POS N
median POS N
age POS N
35 POS N
years, POS N
median POS N
CD4 POS N
count POS N
19 POS N
cells/µL), POS N
31 POS N
developed POS N
hepatotoxicity POS N
(7.3%). POS N

Participants POS N
with POS N
both POS N
raised POS N
AST/ALT POS N
and POS N
positive POS N
HBsAg POS N
had POS N
a POS N
higher POS N
risk POS N
(OR POS N
19.9, POS N
95% POS N
CI: POS N
5.3 POS N
to POS N
74.3) POS N
and POS N
earlier POS N
onset POS N
of POS N
hepatotoxicity POS N
than POS N
participants POS N
who POS N
did POS N
not POS N
have POS N
these POS N
conditions POS N
at POS N
baseline. POS N

Raised POS N
pretreatment POS N
AST/ALT POS N
(odds POS N
ratio POS N
[OR] POS N
3.6, POS N
95% POS N
confidence POS N
interval POS N
[CI]: POS N
1.7 POS N
to POS N
7.7) POS N
and POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
seropositivity POS N
at POS N
baseline POS N
(OR POS N
4.7, POS N
95% POS N
CI: POS N
1.7 POS N
to POS N
12.9) POS N
were POS N
significantly POS N
associated POS N
with POS N
an POS N
increased POS N
risk POS N
of POS N
developing POS N
hepatotoxicity. POS N

Participants POS N
with POS N
both POS N
raised POS N
AST/ALT POS N
and POS N
positive POS N
HBsAg POS N
had POS N
a POS N
higher POS N
risk POS N
(OR POS N
19.9, POS N
95% POS N
CI: POS N
5.3 POS N
to POS N
74.3) POS N
and POS N
earlier POS N
onset POS N
of POS N
hepatotoxicity POS N
than POS N
participants POS N
who POS N
did POS N
not POS N
have POS N
these POS N
conditions POS N
at POS N
baseline. POS N

The POS N
incidence POS N
of POS N
hepatotoxicity POS N
during POS N
IPT POS N
and POS N
ART POS N
was POS N
high. POS N

The POS N
incidence POS N
of POS N
hepatotoxicity POS N
during POS N
IPT POS N
and POS N
ART POS N
was POS N
high. POS N

Severely POS N
immunosuppressed POS N
individuals POS N
with POS N
raised POS N
pretreatment POS N
AST/ALT POS N
or POS N
HBsAg POS N
seropositivity POS N
need POS N
closer POS N
monitoring POS N
for POS N
hepatotoxicity. POS N

The POS N
incidence POS N
of POS N
hepatotoxicity POS N
during POS N
IPT POS N
and POS N
ART POS N
was POS N
high. POS N

Among POS N
426 POS N
participants POS N
(53% POS N
male, POS N
median POS N
age POS N
35 POS N
years, POS N
median POS N
CD4 POS N
count POS N
19 POS N
cells/µL), POS N
31 POS N
developed POS N
hepatotoxicity POS N
(7.3%). POS N

The POS N
incidence POS N
of POS N
hepatotoxicity POS N
during POS N
IPT POS N
and POS N
ART POS N
was POS N
high. POS N

Raised POS N
pretreatment POS N
AST/ALT POS N
(odds POS N
ratio POS N
[OR] POS N
3.6, POS N
95% POS N
confidence POS N
interval POS N
[CI]: POS N
1.7 POS N
to POS N
7.7) POS N
and POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
seropositivity POS N
at POS N
baseline POS N
(OR POS N
4.7, POS N
95% POS N
CI: POS N
1.7 POS N
to POS N
12.9) POS N
were POS N
significantly POS N
associated POS N
with POS N
an POS N
increased POS N
risk POS N
of POS N
developing POS N
hepatotoxicity. POS N

The POS N
incidence POS N
of POS N
hepatotoxicity POS N
during POS N
IPT POS N
and POS N
ART POS N
was POS N
high. POS N

Participants POS N
with POS N
both POS N
raised POS N
AST/ALT POS N
and POS N
positive POS N
HBsAg POS N
had POS N
a POS N
higher POS N
risk POS N
(OR POS N
19.9, POS N
95% POS N
CI: POS N
5.3 POS N
to POS N
74.3) POS N
and POS N
earlier POS N
onset POS N
of POS N
hepatotoxicity POS N
than POS N
participants POS N
who POS N
did POS N
not POS N
have POS N
these POS N
conditions POS N
at POS N
baseline. POS N

Synbiotic POS N
is POS N
effective POS N
in POS N
reducing POS N
of POS N
blood POS N
pressure POS N
in POS N
women POS N
with POS N
GDM. POS N

No POS N
significant POS N
changes POS N
in POS N
FPG, POS N
insulin POS N
resistance/sensitivity, POS N
lipid POS N
profile POS N
and POS N
TAC POS N
indices POS N
were POS N
seen POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
the POS N
placebo POS N
one POS N
(p > 0.05). POS N

Synbiotic POS N
is POS N
effective POS N
in POS N
reducing POS N
of POS N
blood POS N
pressure POS N
in POS N
women POS N
with POS N
GDM. POS N

Significant POS N
within POS N
group POS N
increases POS N
for POS N
HDL-C POS N
and POS N
TAC POS N
levels POS N
in POS N
synbiotic POS N
group POS N
were POS N
observed POS N
(p < 0.05). POS N

Synbiotic POS N
is POS N
effective POS N
in POS N
reducing POS N
of POS N
blood POS N
pressure POS N
in POS N
women POS N
with POS N
GDM. POS N

LDL-C POS N
showed POS N
significant POS N
increment POS N
in POS N
the POS N
placebo POS N
group POS N
compared POS N
to POS N
the POS N
baseline POS N
of POS N
the POS N
study POS N
(6.9 mg/dL, POS N
p < 0.05). POS N

Synbiotic POS N
is POS N
effective POS N
in POS N
reducing POS N
of POS N
blood POS N
pressure POS N
in POS N
women POS N
with POS N
GDM. POS N

Between POS N
group POS N
comparison POS N
showed POS N
significant POS N
decrease POS N
in POS N
SBP POS N
and POS N
DBP POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
placebo POS N
(-2.5 POS N
vs. POS N
8.6 mmHg, POS N
and POS N
-1.8 POS N
vs. POS N
2.1 mmHg, POS N
p < 0.05). POS N

Synbiotic POS N
is POS N
effective POS N
in POS N
reducing POS N
of POS N
blood POS N
pressure POS N
in POS N
women POS N
with POS N
GDM. POS N

The POS N
results POS N
showed POS N
that, POS N
in POS N
women POS N
with POS N
GDM, POS N
synbiotic POS N
supplementation POS N
had POS N
no POS N
effect POS N
on POS N
FPG POS N
and POS N
insulin POS N
resistance/sensitivity POS N
indices. POS N

Synbiotic POS N
is POS N
effective POS N
in POS N
reducing POS N
of POS N
blood POS N
pressure POS N
in POS N
women POS N
with POS N
GDM. POS N

Lipid POS N
profile POS N
and POS N
TAC POS N
status POS N
may POS N
be POS N
affected POS N
by POS N
synbiotic POS N
supplementation. POS N

No POS N
significant POS N
changes POS N
in POS N
FPG, POS N
insulin POS N
resistance/sensitivity, POS N
lipid POS N
profile POS N
and POS N
TAC POS N
indices POS N
were POS N
seen POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
the POS N
placebo POS N
one POS N
(p > 0.05). POS N

Synbiotic POS N
is POS N
effective POS N
in POS N
reducing POS N
of POS N
blood POS N
pressure POS N
in POS N
women POS N
with POS N
GDM. POS N

No POS N
significant POS N
changes POS N
in POS N
FPG, POS N
insulin POS N
resistance/sensitivity, POS N
lipid POS N
profile POS N
and POS N
TAC POS N
indices POS N
were POS N
seen POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
the POS N
placebo POS N
one POS N
(p > 0.05). POS N

Significant POS N
within POS N
group POS N
increases POS N
for POS N
HDL-C POS N
and POS N
TAC POS N
levels POS N
in POS N
synbiotic POS N
group POS N
were POS N
observed POS N
(p < 0.05). POS N

No POS N
significant POS N
changes POS N
in POS N
FPG, POS N
insulin POS N
resistance/sensitivity, POS N
lipid POS N
profile POS N
and POS N
TAC POS N
indices POS N
were POS N
seen POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
the POS N
placebo POS N
one POS N
(p > 0.05). POS N

LDL-C POS N
showed POS N
significant POS N
increment POS N
in POS N
the POS N
placebo POS N
group POS N
compared POS N
to POS N
the POS N
baseline POS N
of POS N
the POS N
study POS N
(6.9 mg/dL, POS N
p < 0.05). POS N

No POS N
significant POS N
changes POS N
in POS N
FPG, POS N
insulin POS N
resistance/sensitivity, POS N
lipid POS N
profile POS N
and POS N
TAC POS N
indices POS N
were POS N
seen POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
the POS N
placebo POS N
one POS N
(p > 0.05). POS N

Between POS N
group POS N
comparison POS N
showed POS N
significant POS N
decrease POS N
in POS N
SBP POS N
and POS N
DBP POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
placebo POS N
(-2.5 POS N
vs. POS N
8.6 mmHg, POS N
and POS N
-1.8 POS N
vs. POS N
2.1 mmHg, POS N
p < 0.05). POS N

No POS N
significant POS N
changes POS N
in POS N
FPG, POS N
insulin POS N
resistance/sensitivity, POS N
lipid POS N
profile POS N
and POS N
TAC POS N
indices POS N
were POS N
seen POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
the POS N
placebo POS N
one POS N
(p > 0.05). POS N

The POS N
results POS N
showed POS N
that, POS N
in POS N
women POS N
with POS N
GDM, POS N
synbiotic POS N
supplementation POS N
had POS N
no POS N
effect POS N
on POS N
FPG POS N
and POS N
insulin POS N
resistance/sensitivity POS N
indices. POS N

No POS N
significant POS N
changes POS N
in POS N
FPG, POS N
insulin POS N
resistance/sensitivity, POS N
lipid POS N
profile POS N
and POS N
TAC POS N
indices POS N
were POS N
seen POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
the POS N
placebo POS N
one POS N
(p > 0.05). POS N

Lipid POS N
profile POS N
and POS N
TAC POS N
status POS N
may POS N
be POS N
affected POS N
by POS N
synbiotic POS N
supplementation. POS N

Significant POS N
within POS N
group POS N
increases POS N
for POS N
HDL-C POS N
and POS N
TAC POS N
levels POS N
in POS N
synbiotic POS N
group POS N
were POS N
observed POS N
(p < 0.05). POS N

Synbiotic POS N
is POS N
effective POS N
in POS N
reducing POS N
of POS N
blood POS N
pressure POS N
in POS N
women POS N
with POS N
GDM. POS N

Significant POS N
within POS N
group POS N
increases POS N
for POS N
HDL-C POS N
and POS N
TAC POS N
levels POS N
in POS N
synbiotic POS N
group POS N
were POS N
observed POS N
(p < 0.05). POS N

No POS N
significant POS N
changes POS N
in POS N
FPG, POS N
insulin POS N
resistance/sensitivity, POS N
lipid POS N
profile POS N
and POS N
TAC POS N
indices POS N
were POS N
seen POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
the POS N
placebo POS N
one POS N
(p > 0.05). POS N

Significant POS N
within POS N
group POS N
increases POS N
for POS N
HDL-C POS N
and POS N
TAC POS N
levels POS N
in POS N
synbiotic POS N
group POS N
were POS N
observed POS N
(p < 0.05). POS N

LDL-C POS N
showed POS N
significant POS N
increment POS N
in POS N
the POS N
placebo POS N
group POS N
compared POS N
to POS N
the POS N
baseline POS N
of POS N
the POS N
study POS N
(6.9 mg/dL, POS N
p < 0.05). POS N

Significant POS N
within POS N
group POS N
increases POS N
for POS N
HDL-C POS N
and POS N
TAC POS N
levels POS N
in POS N
synbiotic POS N
group POS N
were POS N
observed POS N
(p < 0.05). POS N

Between POS N
group POS N
comparison POS N
showed POS N
significant POS N
decrease POS N
in POS N
SBP POS N
and POS N
DBP POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
placebo POS N
(-2.5 POS N
vs. POS N
8.6 mmHg, POS N
and POS N
-1.8 POS N
vs. POS N
2.1 mmHg, POS N
p < 0.05). POS N

Significant POS N
within POS N
group POS N
increases POS N
for POS N
HDL-C POS N
and POS N
TAC POS N
levels POS N
in POS N
synbiotic POS N
group POS N
were POS N
observed POS N
(p < 0.05). POS N

The POS N
results POS N
showed POS N
that, POS N
in POS N
women POS N
with POS N
GDM, POS N
synbiotic POS N
supplementation POS N
had POS N
no POS N
effect POS N
on POS N
FPG POS N
and POS N
insulin POS N
resistance/sensitivity POS N
indices. POS N

Significant POS N
within POS N
group POS N
increases POS N
for POS N
HDL-C POS N
and POS N
TAC POS N
levels POS N
in POS N
synbiotic POS N
group POS N
were POS N
observed POS N
(p < 0.05). POS N

Lipid POS N
profile POS N
and POS N
TAC POS N
status POS N
may POS N
be POS N
affected POS N
by POS N
synbiotic POS N
supplementation. POS N

LDL-C POS N
showed POS N
significant POS N
increment POS N
in POS N
the POS N
placebo POS N
group POS N
compared POS N
to POS N
the POS N
baseline POS N
of POS N
the POS N
study POS N
(6.9 mg/dL, POS N
p < 0.05). POS N

Synbiotic POS N
is POS N
effective POS N
in POS N
reducing POS N
of POS N
blood POS N
pressure POS N
in POS N
women POS N
with POS N
GDM. POS N

LDL-C POS N
showed POS N
significant POS N
increment POS N
in POS N
the POS N
placebo POS N
group POS N
compared POS N
to POS N
the POS N
baseline POS N
of POS N
the POS N
study POS N
(6.9 mg/dL, POS N
p < 0.05). POS N

No POS N
significant POS N
changes POS N
in POS N
FPG, POS N
insulin POS N
resistance/sensitivity, POS N
lipid POS N
profile POS N
and POS N
TAC POS N
indices POS N
were POS N
seen POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
the POS N
placebo POS N
one POS N
(p > 0.05). POS N

LDL-C POS N
showed POS N
significant POS N
increment POS N
in POS N
the POS N
placebo POS N
group POS N
compared POS N
to POS N
the POS N
baseline POS N
of POS N
the POS N
study POS N
(6.9 mg/dL, POS N
p < 0.05). POS N

Significant POS N
within POS N
group POS N
increases POS N
for POS N
HDL-C POS N
and POS N
TAC POS N
levels POS N
in POS N
synbiotic POS N
group POS N
were POS N
observed POS N
(p < 0.05). POS N

LDL-C POS N
showed POS N
significant POS N
increment POS N
in POS N
the POS N
placebo POS N
group POS N
compared POS N
to POS N
the POS N
baseline POS N
of POS N
the POS N
study POS N
(6.9 mg/dL, POS N
p < 0.05). POS N

Between POS N
group POS N
comparison POS N
showed POS N
significant POS N
decrease POS N
in POS N
SBP POS N
and POS N
DBP POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
placebo POS N
(-2.5 POS N
vs. POS N
8.6 mmHg, POS N
and POS N
-1.8 POS N
vs. POS N
2.1 mmHg, POS N
p < 0.05). POS N

LDL-C POS N
showed POS N
significant POS N
increment POS N
in POS N
the POS N
placebo POS N
group POS N
compared POS N
to POS N
the POS N
baseline POS N
of POS N
the POS N
study POS N
(6.9 mg/dL, POS N
p < 0.05). POS N

The POS N
results POS N
showed POS N
that, POS N
in POS N
women POS N
with POS N
GDM, POS N
synbiotic POS N
supplementation POS N
had POS N
no POS N
effect POS N
on POS N
FPG POS N
and POS N
insulin POS N
resistance/sensitivity POS N
indices. POS N

LDL-C POS N
showed POS N
significant POS N
increment POS N
in POS N
the POS N
placebo POS N
group POS N
compared POS N
to POS N
the POS N
baseline POS N
of POS N
the POS N
study POS N
(6.9 mg/dL, POS N
p < 0.05). POS N

Lipid POS N
profile POS N
and POS N
TAC POS N
status POS N
may POS N
be POS N
affected POS N
by POS N
synbiotic POS N
supplementation. POS N

Between POS N
group POS N
comparison POS N
showed POS N
significant POS N
decrease POS N
in POS N
SBP POS N
and POS N
DBP POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
placebo POS N
(-2.5 POS N
vs. POS N
8.6 mmHg, POS N
and POS N
-1.8 POS N
vs. POS N
2.1 mmHg, POS N
p < 0.05). POS N

Synbiotic POS N
is POS N
effective POS N
in POS N
reducing POS N
of POS N
blood POS N
pressure POS N
in POS N
women POS N
with POS N
GDM. POS N

Between POS N
group POS N
comparison POS N
showed POS N
significant POS N
decrease POS N
in POS N
SBP POS N
and POS N
DBP POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
placebo POS N
(-2.5 POS N
vs. POS N
8.6 mmHg, POS N
and POS N
-1.8 POS N
vs. POS N
2.1 mmHg, POS N
p < 0.05). POS N

No POS N
significant POS N
changes POS N
in POS N
FPG, POS N
insulin POS N
resistance/sensitivity, POS N
lipid POS N
profile POS N
and POS N
TAC POS N
indices POS N
were POS N
seen POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
the POS N
placebo POS N
one POS N
(p > 0.05). POS N

Between POS N
group POS N
comparison POS N
showed POS N
significant POS N
decrease POS N
in POS N
SBP POS N
and POS N
DBP POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
placebo POS N
(-2.5 POS N
vs. POS N
8.6 mmHg, POS N
and POS N
-1.8 POS N
vs. POS N
2.1 mmHg, POS N
p < 0.05). POS N

Significant POS N
within POS N
group POS N
increases POS N
for POS N
HDL-C POS N
and POS N
TAC POS N
levels POS N
in POS N
synbiotic POS N
group POS N
were POS N
observed POS N
(p < 0.05). POS N

Between POS N
group POS N
comparison POS N
showed POS N
significant POS N
decrease POS N
in POS N
SBP POS N
and POS N
DBP POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
placebo POS N
(-2.5 POS N
vs. POS N
8.6 mmHg, POS N
and POS N
-1.8 POS N
vs. POS N
2.1 mmHg, POS N
p < 0.05). POS N

LDL-C POS N
showed POS N
significant POS N
increment POS N
in POS N
the POS N
placebo POS N
group POS N
compared POS N
to POS N
the POS N
baseline POS N
of POS N
the POS N
study POS N
(6.9 mg/dL, POS N
p < 0.05). POS N

Between POS N
group POS N
comparison POS N
showed POS N
significant POS N
decrease POS N
in POS N
SBP POS N
and POS N
DBP POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
placebo POS N
(-2.5 POS N
vs. POS N
8.6 mmHg, POS N
and POS N
-1.8 POS N
vs. POS N
2.1 mmHg, POS N
p < 0.05). POS N

The POS N
results POS N
showed POS N
that, POS N
in POS N
women POS N
with POS N
GDM, POS N
synbiotic POS N
supplementation POS N
had POS N
no POS N
effect POS N
on POS N
FPG POS N
and POS N
insulin POS N
resistance/sensitivity POS N
indices. POS N

Between POS N
group POS N
comparison POS N
showed POS N
significant POS N
decrease POS N
in POS N
SBP POS N
and POS N
DBP POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
placebo POS N
(-2.5 POS N
vs. POS N
8.6 mmHg, POS N
and POS N
-1.8 POS N
vs. POS N
2.1 mmHg, POS N
p < 0.05). POS N

Lipid POS N
profile POS N
and POS N
TAC POS N
status POS N
may POS N
be POS N
affected POS N
by POS N
synbiotic POS N
supplementation. POS N

The POS N
results POS N
showed POS N
that, POS N
in POS N
women POS N
with POS N
GDM, POS N
synbiotic POS N
supplementation POS N
had POS N
no POS N
effect POS N
on POS N
FPG POS N
and POS N
insulin POS N
resistance/sensitivity POS N
indices. POS N

Synbiotic POS N
is POS N
effective POS N
in POS N
reducing POS N
of POS N
blood POS N
pressure POS N
in POS N
women POS N
with POS N
GDM. POS N

The POS N
results POS N
showed POS N
that, POS N
in POS N
women POS N
with POS N
GDM, POS N
synbiotic POS N
supplementation POS N
had POS N
no POS N
effect POS N
on POS N
FPG POS N
and POS N
insulin POS N
resistance/sensitivity POS N
indices. POS N

No POS N
significant POS N
changes POS N
in POS N
FPG, POS N
insulin POS N
resistance/sensitivity, POS N
lipid POS N
profile POS N
and POS N
TAC POS N
indices POS N
were POS N
seen POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
the POS N
placebo POS N
one POS N
(p > 0.05). POS N

The POS N
results POS N
showed POS N
that, POS N
in POS N
women POS N
with POS N
GDM, POS N
synbiotic POS N
supplementation POS N
had POS N
no POS N
effect POS N
on POS N
FPG POS N
and POS N
insulin POS N
resistance/sensitivity POS N
indices. POS N

Significant POS N
within POS N
group POS N
increases POS N
for POS N
HDL-C POS N
and POS N
TAC POS N
levels POS N
in POS N
synbiotic POS N
group POS N
were POS N
observed POS N
(p < 0.05). POS N

The POS N
results POS N
showed POS N
that, POS N
in POS N
women POS N
with POS N
GDM, POS N
synbiotic POS N
supplementation POS N
had POS N
no POS N
effect POS N
on POS N
FPG POS N
and POS N
insulin POS N
resistance/sensitivity POS N
indices. POS N

LDL-C POS N
showed POS N
significant POS N
increment POS N
in POS N
the POS N
placebo POS N
group POS N
compared POS N
to POS N
the POS N
baseline POS N
of POS N
the POS N
study POS N
(6.9 mg/dL, POS N
p < 0.05). POS N

The POS N
results POS N
showed POS N
that, POS N
in POS N
women POS N
with POS N
GDM, POS N
synbiotic POS N
supplementation POS N
had POS N
no POS N
effect POS N
on POS N
FPG POS N
and POS N
insulin POS N
resistance/sensitivity POS N
indices. POS N

Between POS N
group POS N
comparison POS N
showed POS N
significant POS N
decrease POS N
in POS N
SBP POS N
and POS N
DBP POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
placebo POS N
(-2.5 POS N
vs. POS N
8.6 mmHg, POS N
and POS N
-1.8 POS N
vs. POS N
2.1 mmHg, POS N
p < 0.05). POS N

The POS N
results POS N
showed POS N
that, POS N
in POS N
women POS N
with POS N
GDM, POS N
synbiotic POS N
supplementation POS N
had POS N
no POS N
effect POS N
on POS N
FPG POS N
and POS N
insulin POS N
resistance/sensitivity POS N
indices. POS N

Lipid POS N
profile POS N
and POS N
TAC POS N
status POS N
may POS N
be POS N
affected POS N
by POS N
synbiotic POS N
supplementation. POS N

Lipid POS N
profile POS N
and POS N
TAC POS N
status POS N
may POS N
be POS N
affected POS N
by POS N
synbiotic POS N
supplementation. POS N

Synbiotic POS N
is POS N
effective POS N
in POS N
reducing POS N
of POS N
blood POS N
pressure POS N
in POS N
women POS N
with POS N
GDM. POS N

Lipid POS N
profile POS N
and POS N
TAC POS N
status POS N
may POS N
be POS N
affected POS N
by POS N
synbiotic POS N
supplementation. POS N

No POS N
significant POS N
changes POS N
in POS N
FPG, POS N
insulin POS N
resistance/sensitivity, POS N
lipid POS N
profile POS N
and POS N
TAC POS N
indices POS N
were POS N
seen POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
the POS N
placebo POS N
one POS N
(p > 0.05). POS N

Lipid POS N
profile POS N
and POS N
TAC POS N
status POS N
may POS N
be POS N
affected POS N
by POS N
synbiotic POS N
supplementation. POS N

Significant POS N
within POS N
group POS N
increases POS N
for POS N
HDL-C POS N
and POS N
TAC POS N
levels POS N
in POS N
synbiotic POS N
group POS N
were POS N
observed POS N
(p < 0.05). POS N

Lipid POS N
profile POS N
and POS N
TAC POS N
status POS N
may POS N
be POS N
affected POS N
by POS N
synbiotic POS N
supplementation. POS N

LDL-C POS N
showed POS N
significant POS N
increment POS N
in POS N
the POS N
placebo POS N
group POS N
compared POS N
to POS N
the POS N
baseline POS N
of POS N
the POS N
study POS N
(6.9 mg/dL, POS N
p < 0.05). POS N

Lipid POS N
profile POS N
and POS N
TAC POS N
status POS N
may POS N
be POS N
affected POS N
by POS N
synbiotic POS N
supplementation. POS N

Between POS N
group POS N
comparison POS N
showed POS N
significant POS N
decrease POS N
in POS N
SBP POS N
and POS N
DBP POS N
in POS N
synbiotic POS N
group POS N
compared POS N
to POS N
placebo POS N
(-2.5 POS N
vs. POS N
8.6 mmHg, POS N
and POS N
-1.8 POS N
vs. POS N
2.1 mmHg, POS N
p < 0.05). POS N

Lipid POS N
profile POS N
and POS N
TAC POS N
status POS N
may POS N
be POS N
affected POS N
by POS N
synbiotic POS N
supplementation. POS N

The POS N
results POS N
showed POS N
that, POS N
in POS N
women POS N
with POS N
GDM, POS N
synbiotic POS N
supplementation POS N
had POS N
no POS N
effect POS N
on POS N
FPG POS N
and POS N
insulin POS N
resistance/sensitivity POS N
indices. POS N

KAMUT POS N
khorasan POS N
is POS N
an POS N
ancient POS N
grain POS N
with POS N
widely POS N
acclaimed POS N
health POS N
benefits. POS N

This POS N
study POS N
suggests POS N
that POS N
a POS N
short-term POS N
replacement POS N
diet POS N
with POS N
ancient POS N
KAMUT POS N
khorasan POS N
products POS N
is POS N
most POS N
effective POS N
in POS N
reducing POS N
metabolic POS N
risk POS N
factors POS N
and POS N
ameliorating POS N
the POS N
liver POS N
profile POS N
in POS N
patients POS N
with POS N
NAFLD. POS N

KAMUT POS N
khorasan POS N
is POS N
an POS N
ancient POS N
grain POS N
with POS N
widely POS N
acclaimed POS N
health POS N
benefits. POS N

significant POS N
improvements POS N
in POS N
the POS N
liver POS N
steatosis POS N
grading, POS N
Doppler POS N
perfusion POS N
index POS N
values, POS N
and POS N
reactive POS N
oxygen POS N
species POS N
(ROS) POS N
production POS N
were POS N
evident POS N
after POS N
consumption POS N
of POS N
both POS N
the POS N
khorasan POS N
and POS N
control POS N
products. POS N

KAMUT POS N
khorasan POS N
is POS N
an POS N
ancient POS N
grain POS N
with POS N
widely POS N
acclaimed POS N
health POS N
benefits. POS N

significant POS N
reductions POS N
in POS N
circulating POS N
proinflammatory POS N
tumor POS N
necrosis POS N
factor-alpha POS N
by POS N
50%, POS N
interleukin POS N
l-receptor POS N
antagonist-alpha POS N
by POS N
37%, POS N
interleukin-8 POS N
by POS N
24%, POS N
and POS N
interferon POS N
gamma POS N
by POS N
24% POS N
were POS N
evident POS N
only POS N
in POS N
participants POS N
who POS N
consumed POS N
the POS N
khorasan POS N
products POS N
(p POS N
< POS N
0.05 POS N
for POS N
all). POS N

KAMUT POS N
khorasan POS N
is POS N
an POS N
ancient POS N
grain POS N
with POS N
widely POS N
acclaimed POS N
health POS N
benefits. POS N

After POS N
the POS N
implementation POS N
of POS N
a POS N
general POS N
linear POS N
model POS N
for POS N
repeated POS N
measurements POS N
adjusted POS N
for POS N
baseline POS N
demographic POS N
details, POS N
risk POS N
factors, POS N
and POS N
medication, POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
was POS N
significantly POS N
reduced POS N
by POS N
12%, POS N
aspartate POS N
aminotransferase POS N
(AST) POS N
by POS N
14%, POS N
alkaline POS N
phosphatase POS N
(ALP) POS N
by POS N
8%, POS N
and POS N
cholesterol POS N
by POS N
6% POS N
only POS N
in POS N
the POS N
khorasan POS N
group POS N
(p POS N
< POS N
0.05 POS N
for POS N
all). POS N

This POS N
study POS N
suggests POS N
that POS N
a POS N
short-term POS N
replacement POS N
diet POS N
with POS N
ancient POS N
KAMUT POS N
khorasan POS N
products POS N
is POS N
most POS N
effective POS N
in POS N
reducing POS N
metabolic POS N
risk POS N
factors POS N
and POS N
ameliorating POS N
the POS N
liver POS N
profile POS N
in POS N
patients POS N
with POS N
NAFLD. POS N

KAMUT POS N
khorasan POS N
is POS N
an POS N
ancient POS N
grain POS N
with POS N
widely POS N
acclaimed POS N
health POS N
benefits. POS N

This POS N
study POS N
suggests POS N
that POS N
a POS N
short-term POS N
replacement POS N
diet POS N
with POS N
ancient POS N
KAMUT POS N
khorasan POS N
products POS N
is POS N
most POS N
effective POS N
in POS N
reducing POS N
metabolic POS N
risk POS N
factors POS N
and POS N
ameliorating POS N
the POS N
liver POS N
profile POS N
in POS N
patients POS N
with POS N
NAFLD. POS N

significant POS N
improvements POS N
in POS N
the POS N
liver POS N
steatosis POS N
grading, POS N
Doppler POS N
perfusion POS N
index POS N
values, POS N
and POS N
reactive POS N
oxygen POS N
species POS N
(ROS) POS N
production POS N
were POS N
evident POS N
after POS N
consumption POS N
of POS N
both POS N
the POS N
khorasan POS N
and POS N
control POS N
products. POS N

This POS N
study POS N
suggests POS N
that POS N
a POS N
short-term POS N
replacement POS N
diet POS N
with POS N
ancient POS N
KAMUT POS N
khorasan POS N
products POS N
is POS N
most POS N
effective POS N
in POS N
reducing POS N
metabolic POS N
risk POS N
factors POS N
and POS N
ameliorating POS N
the POS N
liver POS N
profile POS N
in POS N
patients POS N
with POS N
NAFLD. POS N

significant POS N
reductions POS N
in POS N
circulating POS N
proinflammatory POS N
tumor POS N
necrosis POS N
factor-alpha POS N
by POS N
50%, POS N
interleukin POS N
l-receptor POS N
antagonist-alpha POS N
by POS N
37%, POS N
interleukin-8 POS N
by POS N
24%, POS N
and POS N
interferon POS N
gamma POS N
by POS N
24% POS N
were POS N
evident POS N
only POS N
in POS N
participants POS N
who POS N
consumed POS N
the POS N
khorasan POS N
products POS N
(p POS N
< POS N
0.05 POS N
for POS N
all). POS N

This POS N
study POS N
suggests POS N
that POS N
a POS N
short-term POS N
replacement POS N
diet POS N
with POS N
ancient POS N
KAMUT POS N
khorasan POS N
products POS N
is POS N
most POS N
effective POS N
in POS N
reducing POS N
metabolic POS N
risk POS N
factors POS N
and POS N
ameliorating POS N
the POS N
liver POS N
profile POS N
in POS N
patients POS N
with POS N
NAFLD. POS N

After POS N
the POS N
implementation POS N
of POS N
a POS N
general POS N
linear POS N
model POS N
for POS N
repeated POS N
measurements POS N
adjusted POS N
for POS N
baseline POS N
demographic POS N
details, POS N
risk POS N
factors, POS N
and POS N
medication, POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
was POS N
significantly POS N
reduced POS N
by POS N
12%, POS N
aspartate POS N
aminotransferase POS N
(AST) POS N
by POS N
14%, POS N
alkaline POS N
phosphatase POS N
(ALP) POS N
by POS N
8%, POS N
and POS N
cholesterol POS N
by POS N
6% POS N
only POS N
in POS N
the POS N
khorasan POS N
group POS N
(p POS N
< POS N
0.05 POS N
for POS N
all). POS N

significant POS N
improvements POS N
in POS N
the POS N
liver POS N
steatosis POS N
grading, POS N
Doppler POS N
perfusion POS N
index POS N
values, POS N
and POS N
reactive POS N
oxygen POS N
species POS N
(ROS) POS N
production POS N
were POS N
evident POS N
after POS N
consumption POS N
of POS N
both POS N
the POS N
khorasan POS N
and POS N
control POS N
products. POS N

KAMUT POS N
khorasan POS N
is POS N
an POS N
ancient POS N
grain POS N
with POS N
widely POS N
acclaimed POS N
health POS N
benefits. POS N

significant POS N
improvements POS N
in POS N
the POS N
liver POS N
steatosis POS N
grading, POS N
Doppler POS N
perfusion POS N
index POS N
values, POS N
and POS N
reactive POS N
oxygen POS N
species POS N
(ROS) POS N
production POS N
were POS N
evident POS N
after POS N
consumption POS N
of POS N
both POS N
the POS N
khorasan POS N
and POS N
control POS N
products. POS N

This POS N
study POS N
suggests POS N
that POS N
a POS N
short-term POS N
replacement POS N
diet POS N
with POS N
ancient POS N
KAMUT POS N
khorasan POS N
products POS N
is POS N
most POS N
effective POS N
in POS N
reducing POS N
metabolic POS N
risk POS N
factors POS N
and POS N
ameliorating POS N
the POS N
liver POS N
profile POS N
in POS N
patients POS N
with POS N
NAFLD. POS N

significant POS N
improvements POS N
in POS N
the POS N
liver POS N
steatosis POS N
grading, POS N
Doppler POS N
perfusion POS N
index POS N
values, POS N
and POS N
reactive POS N
oxygen POS N
species POS N
(ROS) POS N
production POS N
were POS N
evident POS N
after POS N
consumption POS N
of POS N
both POS N
the POS N
khorasan POS N
and POS N
control POS N
products. POS N

significant POS N
reductions POS N
in POS N
circulating POS N
proinflammatory POS N
tumor POS N
necrosis POS N
factor-alpha POS N
by POS N
50%, POS N
interleukin POS N
l-receptor POS N
antagonist-alpha POS N
by POS N
37%, POS N
interleukin-8 POS N
by POS N
24%, POS N
and POS N
interferon POS N
gamma POS N
by POS N
24% POS N
were POS N
evident POS N
only POS N
in POS N
participants POS N
who POS N
consumed POS N
the POS N
khorasan POS N
products POS N
(p POS N
< POS N
0.05 POS N
for POS N
all). POS N

significant POS N
improvements POS N
in POS N
the POS N
liver POS N
steatosis POS N
grading, POS N
Doppler POS N
perfusion POS N
index POS N
values, POS N
and POS N
reactive POS N
oxygen POS N
species POS N
(ROS) POS N
production POS N
were POS N
evident POS N
after POS N
consumption POS N
of POS N
both POS N
the POS N
khorasan POS N
and POS N
control POS N
products. POS N

After POS N
the POS N
implementation POS N
of POS N
a POS N
general POS N
linear POS N
model POS N
for POS N
repeated POS N
measurements POS N
adjusted POS N
for POS N
baseline POS N
demographic POS N
details, POS N
risk POS N
factors, POS N
and POS N
medication, POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
was POS N
significantly POS N
reduced POS N
by POS N
12%, POS N
aspartate POS N
aminotransferase POS N
(AST) POS N
by POS N
14%, POS N
alkaline POS N
phosphatase POS N
(ALP) POS N
by POS N
8%, POS N
and POS N
cholesterol POS N
by POS N
6% POS N
only POS N
in POS N
the POS N
khorasan POS N
group POS N
(p POS N
< POS N
0.05 POS N
for POS N
all). POS N

significant POS N
reductions POS N
in POS N
circulating POS N
proinflammatory POS N
tumor POS N
necrosis POS N
factor-alpha POS N
by POS N
50%, POS N
interleukin POS N
l-receptor POS N
antagonist-alpha POS N
by POS N
37%, POS N
interleukin-8 POS N
by POS N
24%, POS N
and POS N
interferon POS N
gamma POS N
by POS N
24% POS N
were POS N
evident POS N
only POS N
in POS N
participants POS N
who POS N
consumed POS N
the POS N
khorasan POS N
products POS N
(p POS N
< POS N
0.05 POS N
for POS N
all). POS N

KAMUT POS N
khorasan POS N
is POS N
an POS N
ancient POS N
grain POS N
with POS N
widely POS N
acclaimed POS N
health POS N
benefits. POS N

significant POS N
reductions POS N
in POS N
circulating POS N
proinflammatory POS N
tumor POS N
necrosis POS N
factor-alpha POS N
by POS N
50%, POS N
interleukin POS N
l-receptor POS N
antagonist-alpha POS N
by POS N
37%, POS N
interleukin-8 POS N
by POS N
24%, POS N
and POS N
interferon POS N
gamma POS N
by POS N
24% POS N
were POS N
evident POS N
only POS N
in POS N
participants POS N
who POS N
consumed POS N
the POS N
khorasan POS N
products POS N
(p POS N
< POS N
0.05 POS N
for POS N
all). POS N

This POS N
study POS N
suggests POS N
that POS N
a POS N
short-term POS N
replacement POS N
diet POS N
with POS N
ancient POS N
KAMUT POS N
khorasan POS N
products POS N
is POS N
most POS N
effective POS N
in POS N
reducing POS N
metabolic POS N
risk POS N
factors POS N
and POS N
ameliorating POS N
the POS N
liver POS N
profile POS N
in POS N
patients POS N
with POS N
NAFLD. POS N

significant POS N
reductions POS N
in POS N
circulating POS N
proinflammatory POS N
tumor POS N
necrosis POS N
factor-alpha POS N
by POS N
50%, POS N
interleukin POS N
l-receptor POS N
antagonist-alpha POS N
by POS N
37%, POS N
interleukin-8 POS N
by POS N
24%, POS N
and POS N
interferon POS N
gamma POS N
by POS N
24% POS N
were POS N
evident POS N
only POS N
in POS N
participants POS N
who POS N
consumed POS N
the POS N
khorasan POS N
products POS N
(p POS N
< POS N
0.05 POS N
for POS N
all). POS N

significant POS N
improvements POS N
in POS N
the POS N
liver POS N
steatosis POS N
grading, POS N
Doppler POS N
perfusion POS N
index POS N
values, POS N
and POS N
reactive POS N
oxygen POS N
species POS N
(ROS) POS N
production POS N
were POS N
evident POS N
after POS N
consumption POS N
of POS N
both POS N
the POS N
khorasan POS N
and POS N
control POS N
products. POS N

significant POS N
reductions POS N
in POS N
circulating POS N
proinflammatory POS N
tumor POS N
necrosis POS N
factor-alpha POS N
by POS N
50%, POS N
interleukin POS N
l-receptor POS N
antagonist-alpha POS N
by POS N
37%, POS N
interleukin-8 POS N
by POS N
24%, POS N
and POS N
interferon POS N
gamma POS N
by POS N
24% POS N
were POS N
evident POS N
only POS N
in POS N
participants POS N
who POS N
consumed POS N
the POS N
khorasan POS N
products POS N
(p POS N
< POS N
0.05 POS N
for POS N
all). POS N

After POS N
the POS N
implementation POS N
of POS N
a POS N
general POS N
linear POS N
model POS N
for POS N
repeated POS N
measurements POS N
adjusted POS N
for POS N
baseline POS N
demographic POS N
details, POS N
risk POS N
factors, POS N
and POS N
medication, POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
was POS N
significantly POS N
reduced POS N
by POS N
12%, POS N
aspartate POS N
aminotransferase POS N
(AST) POS N
by POS N
14%, POS N
alkaline POS N
phosphatase POS N
(ALP) POS N
by POS N
8%, POS N
and POS N
cholesterol POS N
by POS N
6% POS N
only POS N
in POS N
the POS N
khorasan POS N
group POS N
(p POS N
< POS N
0.05 POS N
for POS N
all). POS N

After POS N
the POS N
implementation POS N
of POS N
a POS N
general POS N
linear POS N
model POS N
for POS N
repeated POS N
measurements POS N
adjusted POS N
for POS N
baseline POS N
demographic POS N
details, POS N
risk POS N
factors, POS N
and POS N
medication, POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
was POS N
significantly POS N
reduced POS N
by POS N
12%, POS N
aspartate POS N
aminotransferase POS N
(AST) POS N
by POS N
14%, POS N
alkaline POS N
phosphatase POS N
(ALP) POS N
by POS N
8%, POS N
and POS N
cholesterol POS N
by POS N
6% POS N
only POS N
in POS N
the POS N
khorasan POS N
group POS N
(p POS N
< POS N
0.05 POS N
for POS N
all). POS N

KAMUT POS N
khorasan POS N
is POS N
an POS N
ancient POS N
grain POS N
with POS N
widely POS N
acclaimed POS N
health POS N
benefits. POS N

After POS N
the POS N
implementation POS N
of POS N
a POS N
general POS N
linear POS N
model POS N
for POS N
repeated POS N
measurements POS N
adjusted POS N
for POS N
baseline POS N
demographic POS N
details, POS N
risk POS N
factors, POS N
and POS N
medication, POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
was POS N
significantly POS N
reduced POS N
by POS N
12%, POS N
aspartate POS N
aminotransferase POS N
(AST) POS N
by POS N
14%, POS N
alkaline POS N
phosphatase POS N
(ALP) POS N
by POS N
8%, POS N
and POS N
cholesterol POS N
by POS N
6% POS N
only POS N
in POS N
the POS N
khorasan POS N
group POS N
(p POS N
< POS N
0.05 POS N
for POS N
all). POS N

This POS N
study POS N
suggests POS N
that POS N
a POS N
short-term POS N
replacement POS N
diet POS N
with POS N
ancient POS N
KAMUT POS N
khorasan POS N
products POS N
is POS N
most POS N
effective POS N
in POS N
reducing POS N
metabolic POS N
risk POS N
factors POS N
and POS N
ameliorating POS N
the POS N
liver POS N
profile POS N
in POS N
patients POS N
with POS N
NAFLD. POS N

After POS N
the POS N
implementation POS N
of POS N
a POS N
general POS N
linear POS N
model POS N
for POS N
repeated POS N
measurements POS N
adjusted POS N
for POS N
baseline POS N
demographic POS N
details, POS N
risk POS N
factors, POS N
and POS N
medication, POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
was POS N
significantly POS N
reduced POS N
by POS N
12%, POS N
aspartate POS N
aminotransferase POS N
(AST) POS N
by POS N
14%, POS N
alkaline POS N
phosphatase POS N
(ALP) POS N
by POS N
8%, POS N
and POS N
cholesterol POS N
by POS N
6% POS N
only POS N
in POS N
the POS N
khorasan POS N
group POS N
(p POS N
< POS N
0.05 POS N
for POS N
all). POS N

significant POS N
improvements POS N
in POS N
the POS N
liver POS N
steatosis POS N
grading, POS N
Doppler POS N
perfusion POS N
index POS N
values, POS N
and POS N
reactive POS N
oxygen POS N
species POS N
(ROS) POS N
production POS N
were POS N
evident POS N
after POS N
consumption POS N
of POS N
both POS N
the POS N
khorasan POS N
and POS N
control POS N
products. POS N

After POS N
the POS N
implementation POS N
of POS N
a POS N
general POS N
linear POS N
model POS N
for POS N
repeated POS N
measurements POS N
adjusted POS N
for POS N
baseline POS N
demographic POS N
details, POS N
risk POS N
factors, POS N
and POS N
medication, POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
was POS N
significantly POS N
reduced POS N
by POS N
12%, POS N
aspartate POS N
aminotransferase POS N
(AST) POS N
by POS N
14%, POS N
alkaline POS N
phosphatase POS N
(ALP) POS N
by POS N
8%, POS N
and POS N
cholesterol POS N
by POS N
6% POS N
only POS N
in POS N
the POS N
khorasan POS N
group POS N
(p POS N
< POS N
0.05 POS N
for POS N
all). POS N

significant POS N
reductions POS N
in POS N
circulating POS N
proinflammatory POS N
tumor POS N
necrosis POS N
factor-alpha POS N
by POS N
50%, POS N
interleukin POS N
l-receptor POS N
antagonist-alpha POS N
by POS N
37%, POS N
interleukin-8 POS N
by POS N
24%, POS N
and POS N
interferon POS N
gamma POS N
by POS N
24% POS N
were POS N
evident POS N
only POS N
in POS N
participants POS N
who POS N
consumed POS N
the POS N
khorasan POS N
products POS N
(p POS N
< POS N
0.05 POS N
for POS N
all). POS N

The POS N
results POS N
of POS N
our POS N
study POS N
suggest POS N
that POS N
patients POS N
previously POS N
infected POS N
with POS N
HBV POS N
and POS N
naturally POS N
immune POS N
to POS N
HBV POS N
were POS N
at POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL. POS N

The POS N
results POS N
of POS N
the POS N
multivariable POS N
analysis POS N
showed POS N
that POS N
after POS N
adjustment POS N
for POS N
a POS N
set POS N
of POS N
known POS N
risk POS N
factors, POS N
patients POS N
previously POS N
infected POS N
with POS N
HBV POS N
(HBsAg-seronegative/anti-HBc-seropositive) POS N
and POS N
naturally POS N
immune POS N
to POS N
HBV POS N
(anti-HBs-seropositive/anti-HBc-seropositive) POS N
were POS N
at POS N
significantly POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL POS N
(AOR, POS N
1.497; POS N
95% POS N
CI POS N
1.098-2.042, POS N
P=0.033 POS N
and POS N
AOR, POS N
1.871; POS N
95% POS N
CI POS N
1.302-2.689, POS N
P=0.001, POS N
respectively). POS N

The POS N
results POS N
of POS N
our POS N
study POS N
suggest POS N
that POS N
patients POS N
previously POS N
infected POS N
with POS N
HBV POS N
and POS N
naturally POS N
immune POS N
to POS N
HBV POS N
were POS N
at POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL. POS N

After POS N
adjusting POS N
for POS N
other POS N
factors, POS N
significantly POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL POS N
were POS N
observed POS N
among POS N
cases POS N
who POS N
reported POS N
ever POS N
drinking POS N
alcohol POS N
(AOR, POS N
1.675; POS N
95% POS N
CI POS N
1.054-2.660, POS N
P=0.029). POS N

The POS N
results POS N
of POS N
our POS N
study POS N
suggest POS N
that POS N
patients POS N
previously POS N
infected POS N
with POS N
HBV POS N
and POS N
naturally POS N
immune POS N
to POS N
HBV POS N
were POS N
at POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL. POS N

The POS N
odds POS N
of POS N
ENKTL POS N
diagnosis POS N
were POS N
not POS N
significantly POS N
associated POS N
with POS N
ABO POS N
blood POS N
type, POS N
cigarette POS N
smoking POS N
status POS N
or POS N
family POS N
history POS N
of POS N
cancer. POS N

The POS N
results POS N
of POS N
the POS N
multivariable POS N
analysis POS N
showed POS N
that POS N
after POS N
adjustment POS N
for POS N
a POS N
set POS N
of POS N
known POS N
risk POS N
factors, POS N
patients POS N
previously POS N
infected POS N
with POS N
HBV POS N
(HBsAg-seronegative/anti-HBc-seropositive) POS N
and POS N
naturally POS N
immune POS N
to POS N
HBV POS N
(anti-HBs-seropositive/anti-HBc-seropositive) POS N
were POS N
at POS N
significantly POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL POS N
(AOR, POS N
1.497; POS N
95% POS N
CI POS N
1.098-2.042, POS N
P=0.033 POS N
and POS N
AOR, POS N
1.871; POS N
95% POS N
CI POS N
1.302-2.689, POS N
P=0.001, POS N
respectively). POS N

The POS N
results POS N
of POS N
our POS N
study POS N
suggest POS N
that POS N
patients POS N
previously POS N
infected POS N
with POS N
HBV POS N
and POS N
naturally POS N
immune POS N
to POS N
HBV POS N
were POS N
at POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL. POS N

The POS N
results POS N
of POS N
the POS N
multivariable POS N
analysis POS N
showed POS N
that POS N
after POS N
adjustment POS N
for POS N
a POS N
set POS N
of POS N
known POS N
risk POS N
factors, POS N
patients POS N
previously POS N
infected POS N
with POS N
HBV POS N
(HBsAg-seronegative/anti-HBc-seropositive) POS N
and POS N
naturally POS N
immune POS N
to POS N
HBV POS N
(anti-HBs-seropositive/anti-HBc-seropositive) POS N
were POS N
at POS N
significantly POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL POS N
(AOR, POS N
1.497; POS N
95% POS N
CI POS N
1.098-2.042, POS N
P=0.033 POS N
and POS N
AOR, POS N
1.871; POS N
95% POS N
CI POS N
1.302-2.689, POS N
P=0.001, POS N
respectively). POS N

After POS N
adjusting POS N
for POS N
other POS N
factors, POS N
significantly POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL POS N
were POS N
observed POS N
among POS N
cases POS N
who POS N
reported POS N
ever POS N
drinking POS N
alcohol POS N
(AOR, POS N
1.675; POS N
95% POS N
CI POS N
1.054-2.660, POS N
P=0.029). POS N

The POS N
results POS N
of POS N
the POS N
multivariable POS N
analysis POS N
showed POS N
that POS N
after POS N
adjustment POS N
for POS N
a POS N
set POS N
of POS N
known POS N
risk POS N
factors, POS N
patients POS N
previously POS N
infected POS N
with POS N
HBV POS N
(HBsAg-seronegative/anti-HBc-seropositive) POS N
and POS N
naturally POS N
immune POS N
to POS N
HBV POS N
(anti-HBs-seropositive/anti-HBc-seropositive) POS N
were POS N
at POS N
significantly POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL POS N
(AOR, POS N
1.497; POS N
95% POS N
CI POS N
1.098-2.042, POS N
P=0.033 POS N
and POS N
AOR, POS N
1.871; POS N
95% POS N
CI POS N
1.302-2.689, POS N
P=0.001, POS N
respectively). POS N

The POS N
odds POS N
of POS N
ENKTL POS N
diagnosis POS N
were POS N
not POS N
significantly POS N
associated POS N
with POS N
ABO POS N
blood POS N
type, POS N
cigarette POS N
smoking POS N
status POS N
or POS N
family POS N
history POS N
of POS N
cancer. POS N

After POS N
adjusting POS N
for POS N
other POS N
factors, POS N
significantly POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL POS N
were POS N
observed POS N
among POS N
cases POS N
who POS N
reported POS N
ever POS N
drinking POS N
alcohol POS N
(AOR, POS N
1.675; POS N
95% POS N
CI POS N
1.054-2.660, POS N
P=0.029). POS N

The POS N
results POS N
of POS N
our POS N
study POS N
suggest POS N
that POS N
patients POS N
previously POS N
infected POS N
with POS N
HBV POS N
and POS N
naturally POS N
immune POS N
to POS N
HBV POS N
were POS N
at POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL. POS N

After POS N
adjusting POS N
for POS N
other POS N
factors, POS N
significantly POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL POS N
were POS N
observed POS N
among POS N
cases POS N
who POS N
reported POS N
ever POS N
drinking POS N
alcohol POS N
(AOR, POS N
1.675; POS N
95% POS N
CI POS N
1.054-2.660, POS N
P=0.029). POS N

The POS N
results POS N
of POS N
the POS N
multivariable POS N
analysis POS N
showed POS N
that POS N
after POS N
adjustment POS N
for POS N
a POS N
set POS N
of POS N
known POS N
risk POS N
factors, POS N
patients POS N
previously POS N
infected POS N
with POS N
HBV POS N
(HBsAg-seronegative/anti-HBc-seropositive) POS N
and POS N
naturally POS N
immune POS N
to POS N
HBV POS N
(anti-HBs-seropositive/anti-HBc-seropositive) POS N
were POS N
at POS N
significantly POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL POS N
(AOR, POS N
1.497; POS N
95% POS N
CI POS N
1.098-2.042, POS N
P=0.033 POS N
and POS N
AOR, POS N
1.871; POS N
95% POS N
CI POS N
1.302-2.689, POS N
P=0.001, POS N
respectively). POS N

After POS N
adjusting POS N
for POS N
other POS N
factors, POS N
significantly POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL POS N
were POS N
observed POS N
among POS N
cases POS N
who POS N
reported POS N
ever POS N
drinking POS N
alcohol POS N
(AOR, POS N
1.675; POS N
95% POS N
CI POS N
1.054-2.660, POS N
P=0.029). POS N

The POS N
odds POS N
of POS N
ENKTL POS N
diagnosis POS N
were POS N
not POS N
significantly POS N
associated POS N
with POS N
ABO POS N
blood POS N
type, POS N
cigarette POS N
smoking POS N
status POS N
or POS N
family POS N
history POS N
of POS N
cancer. POS N

The POS N
odds POS N
of POS N
ENKTL POS N
diagnosis POS N
were POS N
not POS N
significantly POS N
associated POS N
with POS N
ABO POS N
blood POS N
type, POS N
cigarette POS N
smoking POS N
status POS N
or POS N
family POS N
history POS N
of POS N
cancer. POS N

The POS N
results POS N
of POS N
our POS N
study POS N
suggest POS N
that POS N
patients POS N
previously POS N
infected POS N
with POS N
HBV POS N
and POS N
naturally POS N
immune POS N
to POS N
HBV POS N
were POS N
at POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL. POS N

The POS N
odds POS N
of POS N
ENKTL POS N
diagnosis POS N
were POS N
not POS N
significantly POS N
associated POS N
with POS N
ABO POS N
blood POS N
type, POS N
cigarette POS N
smoking POS N
status POS N
or POS N
family POS N
history POS N
of POS N
cancer. POS N

The POS N
results POS N
of POS N
the POS N
multivariable POS N
analysis POS N
showed POS N
that POS N
after POS N
adjustment POS N
for POS N
a POS N
set POS N
of POS N
known POS N
risk POS N
factors, POS N
patients POS N
previously POS N
infected POS N
with POS N
HBV POS N
(HBsAg-seronegative/anti-HBc-seropositive) POS N
and POS N
naturally POS N
immune POS N
to POS N
HBV POS N
(anti-HBs-seropositive/anti-HBc-seropositive) POS N
were POS N
at POS N
significantly POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL POS N
(AOR, POS N
1.497; POS N
95% POS N
CI POS N
1.098-2.042, POS N
P=0.033 POS N
and POS N
AOR, POS N
1.871; POS N
95% POS N
CI POS N
1.302-2.689, POS N
P=0.001, POS N
respectively). POS N

The POS N
odds POS N
of POS N
ENKTL POS N
diagnosis POS N
were POS N
not POS N
significantly POS N
associated POS N
with POS N
ABO POS N
blood POS N
type, POS N
cigarette POS N
smoking POS N
status POS N
or POS N
family POS N
history POS N
of POS N
cancer. POS N

After POS N
adjusting POS N
for POS N
other POS N
factors, POS N
significantly POS N
greater POS N
odds POS N
of POS N
being POS N
diagnosed POS N
with POS N
ENKTL POS N
were POS N
observed POS N
among POS N
cases POS N
who POS N
reported POS N
ever POS N
drinking POS N
alcohol POS N
(AOR, POS N
1.675; POS N
95% POS N
CI POS N
1.054-2.660, POS N
P=0.029). POS N

The POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
statistically POS N
significantly POS N
lower POS N
than POS N
the POS N
mean POS N
preoperative POS N
IOP POS N
at POS N
each POS N
follow-up POS N
in POS N
each POS N
group. POS N

At POS N
1 POS N
year, POS N
the POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
significantly POS N
lower POS N
in POS N
group POS N
A. POS N

The POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
statistically POS N
significantly POS N
lower POS N
than POS N
the POS N
mean POS N
preoperative POS N
IOP POS N
at POS N
each POS N
follow-up POS N
in POS N
each POS N
group. POS N

According POS N
to POS N
the POS N
MBGS, POS N
blebs POS N
with POS N
an POS N
ologen POS N
implant POS N
showed POS N
significantly POS N
better POS N
scoring POS N
than POS N
those POS N
with POS N
MMC. POS N

The POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
statistically POS N
significantly POS N
lower POS N
than POS N
the POS N
mean POS N
preoperative POS N
IOP POS N
at POS N
each POS N
follow-up POS N
in POS N
each POS N
group. POS N

AS-OCT POS N
showed POS N
that POS N
ologen-induced POS N
blebs POS N
had POS N
significantly POS N
more POS N
fluid-filled POS N
spaces, POS N
cleavage POS N
planes, POS N
and POS N
less POS N
fibrosis. POS N

The POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
statistically POS N
significantly POS N
lower POS N
than POS N
the POS N
mean POS N
preoperative POS N
IOP POS N
at POS N
each POS N
follow-up POS N
in POS N
each POS N
group. POS N

Ologen POS N
resulted POS N
in POS N
a POS N
lower POS N
long-term POS N
postoperative POS N
IOP, POS N
a POS N
better POS N
bleb POS N
morphology, POS N
and POS N
fewer POS N
complications. POS N

The POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
statistically POS N
significantly POS N
lower POS N
than POS N
the POS N
mean POS N
preoperative POS N
IOP POS N
at POS N
each POS N
follow-up POS N
in POS N
each POS N
group. POS N

Our POS N
results POS N
suggest POS N
that POS N
ologen POS N
may POS N
be POS N
a POS N
useful POS N
alternative POS N
to POS N
MMC POS N
in POS N
JOAG. POS N

At POS N
1 POS N
year, POS N
the POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
significantly POS N
lower POS N
in POS N
group POS N
A. POS N

The POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
statistically POS N
significantly POS N
lower POS N
than POS N
the POS N
mean POS N
preoperative POS N
IOP POS N
at POS N
each POS N
follow-up POS N
in POS N
each POS N
group. POS N

At POS N
1 POS N
year, POS N
the POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
significantly POS N
lower POS N
in POS N
group POS N
A. POS N

According POS N
to POS N
the POS N
MBGS, POS N
blebs POS N
with POS N
an POS N
ologen POS N
implant POS N
showed POS N
significantly POS N
better POS N
scoring POS N
than POS N
those POS N
with POS N
MMC. POS N

At POS N
1 POS N
year, POS N
the POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
significantly POS N
lower POS N
in POS N
group POS N
A. POS N

AS-OCT POS N
showed POS N
that POS N
ologen-induced POS N
blebs POS N
had POS N
significantly POS N
more POS N
fluid-filled POS N
spaces, POS N
cleavage POS N
planes, POS N
and POS N
less POS N
fibrosis. POS N

At POS N
1 POS N
year, POS N
the POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
significantly POS N
lower POS N
in POS N
group POS N
A. POS N

Ologen POS N
resulted POS N
in POS N
a POS N
lower POS N
long-term POS N
postoperative POS N
IOP, POS N
a POS N
better POS N
bleb POS N
morphology, POS N
and POS N
fewer POS N
complications. POS N

At POS N
1 POS N
year, POS N
the POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
significantly POS N
lower POS N
in POS N
group POS N
A. POS N

Our POS N
results POS N
suggest POS N
that POS N
ologen POS N
may POS N
be POS N
a POS N
useful POS N
alternative POS N
to POS N
MMC POS N
in POS N
JOAG. POS N

According POS N
to POS N
the POS N
MBGS, POS N
blebs POS N
with POS N
an POS N
ologen POS N
implant POS N
showed POS N
significantly POS N
better POS N
scoring POS N
than POS N
those POS N
with POS N
MMC. POS N

The POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
statistically POS N
significantly POS N
lower POS N
than POS N
the POS N
mean POS N
preoperative POS N
IOP POS N
at POS N
each POS N
follow-up POS N
in POS N
each POS N
group. POS N

According POS N
to POS N
the POS N
MBGS, POS N
blebs POS N
with POS N
an POS N
ologen POS N
implant POS N
showed POS N
significantly POS N
better POS N
scoring POS N
than POS N
those POS N
with POS N
MMC. POS N

At POS N
1 POS N
year, POS N
the POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
significantly POS N
lower POS N
in POS N
group POS N
A. POS N

According POS N
to POS N
the POS N
MBGS, POS N
blebs POS N
with POS N
an POS N
ologen POS N
implant POS N
showed POS N
significantly POS N
better POS N
scoring POS N
than POS N
those POS N
with POS N
MMC. POS N

AS-OCT POS N
showed POS N
that POS N
ologen-induced POS N
blebs POS N
had POS N
significantly POS N
more POS N
fluid-filled POS N
spaces, POS N
cleavage POS N
planes, POS N
and POS N
less POS N
fibrosis. POS N

According POS N
to POS N
the POS N
MBGS, POS N
blebs POS N
with POS N
an POS N
ologen POS N
implant POS N
showed POS N
significantly POS N
better POS N
scoring POS N
than POS N
those POS N
with POS N
MMC. POS N

Ologen POS N
resulted POS N
in POS N
a POS N
lower POS N
long-term POS N
postoperative POS N
IOP, POS N
a POS N
better POS N
bleb POS N
morphology, POS N
and POS N
fewer POS N
complications. POS N

According POS N
to POS N
the POS N
MBGS, POS N
blebs POS N
with POS N
an POS N
ologen POS N
implant POS N
showed POS N
significantly POS N
better POS N
scoring POS N
than POS N
those POS N
with POS N
MMC. POS N

Our POS N
results POS N
suggest POS N
that POS N
ologen POS N
may POS N
be POS N
a POS N
useful POS N
alternative POS N
to POS N
MMC POS N
in POS N
JOAG. POS N

AS-OCT POS N
showed POS N
that POS N
ologen-induced POS N
blebs POS N
had POS N
significantly POS N
more POS N
fluid-filled POS N
spaces, POS N
cleavage POS N
planes, POS N
and POS N
less POS N
fibrosis. POS N

The POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
statistically POS N
significantly POS N
lower POS N
than POS N
the POS N
mean POS N
preoperative POS N
IOP POS N
at POS N
each POS N
follow-up POS N
in POS N
each POS N
group. POS N

AS-OCT POS N
showed POS N
that POS N
ologen-induced POS N
blebs POS N
had POS N
significantly POS N
more POS N
fluid-filled POS N
spaces, POS N
cleavage POS N
planes, POS N
and POS N
less POS N
fibrosis. POS N

At POS N
1 POS N
year, POS N
the POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
significantly POS N
lower POS N
in POS N
group POS N
A. POS N

AS-OCT POS N
showed POS N
that POS N
ologen-induced POS N
blebs POS N
had POS N
significantly POS N
more POS N
fluid-filled POS N
spaces, POS N
cleavage POS N
planes, POS N
and POS N
less POS N
fibrosis. POS N

According POS N
to POS N
the POS N
MBGS, POS N
blebs POS N
with POS N
an POS N
ologen POS N
implant POS N
showed POS N
significantly POS N
better POS N
scoring POS N
than POS N
those POS N
with POS N
MMC. POS N

AS-OCT POS N
showed POS N
that POS N
ologen-induced POS N
blebs POS N
had POS N
significantly POS N
more POS N
fluid-filled POS N
spaces, POS N
cleavage POS N
planes, POS N
and POS N
less POS N
fibrosis. POS N

Ologen POS N
resulted POS N
in POS N
a POS N
lower POS N
long-term POS N
postoperative POS N
IOP, POS N
a POS N
better POS N
bleb POS N
morphology, POS N
and POS N
fewer POS N
complications. POS N

AS-OCT POS N
showed POS N
that POS N
ologen-induced POS N
blebs POS N
had POS N
significantly POS N
more POS N
fluid-filled POS N
spaces, POS N
cleavage POS N
planes, POS N
and POS N
less POS N
fibrosis. POS N

Our POS N
results POS N
suggest POS N
that POS N
ologen POS N
may POS N
be POS N
a POS N
useful POS N
alternative POS N
to POS N
MMC POS N
in POS N
JOAG. POS N

Ologen POS N
resulted POS N
in POS N
a POS N
lower POS N
long-term POS N
postoperative POS N
IOP, POS N
a POS N
better POS N
bleb POS N
morphology, POS N
and POS N
fewer POS N
complications. POS N

The POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
statistically POS N
significantly POS N
lower POS N
than POS N
the POS N
mean POS N
preoperative POS N
IOP POS N
at POS N
each POS N
follow-up POS N
in POS N
each POS N
group. POS N

Ologen POS N
resulted POS N
in POS N
a POS N
lower POS N
long-term POS N
postoperative POS N
IOP, POS N
a POS N
better POS N
bleb POS N
morphology, POS N
and POS N
fewer POS N
complications. POS N

At POS N
1 POS N
year, POS N
the POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
significantly POS N
lower POS N
in POS N
group POS N
A. POS N

Ologen POS N
resulted POS N
in POS N
a POS N
lower POS N
long-term POS N
postoperative POS N
IOP, POS N
a POS N
better POS N
bleb POS N
morphology, POS N
and POS N
fewer POS N
complications. POS N

According POS N
to POS N
the POS N
MBGS, POS N
blebs POS N
with POS N
an POS N
ologen POS N
implant POS N
showed POS N
significantly POS N
better POS N
scoring POS N
than POS N
those POS N
with POS N
MMC. POS N

Ologen POS N
resulted POS N
in POS N
a POS N
lower POS N
long-term POS N
postoperative POS N
IOP, POS N
a POS N
better POS N
bleb POS N
morphology, POS N
and POS N
fewer POS N
complications. POS N

AS-OCT POS N
showed POS N
that POS N
ologen-induced POS N
blebs POS N
had POS N
significantly POS N
more POS N
fluid-filled POS N
spaces, POS N
cleavage POS N
planes, POS N
and POS N
less POS N
fibrosis. POS N

Ologen POS N
resulted POS N
in POS N
a POS N
lower POS N
long-term POS N
postoperative POS N
IOP, POS N
a POS N
better POS N
bleb POS N
morphology, POS N
and POS N
fewer POS N
complications. POS N

Our POS N
results POS N
suggest POS N
that POS N
ologen POS N
may POS N
be POS N
a POS N
useful POS N
alternative POS N
to POS N
MMC POS N
in POS N
JOAG. POS N

Our POS N
results POS N
suggest POS N
that POS N
ologen POS N
may POS N
be POS N
a POS N
useful POS N
alternative POS N
to POS N
MMC POS N
in POS N
JOAG. POS N

The POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
statistically POS N
significantly POS N
lower POS N
than POS N
the POS N
mean POS N
preoperative POS N
IOP POS N
at POS N
each POS N
follow-up POS N
in POS N
each POS N
group. POS N

Our POS N
results POS N
suggest POS N
that POS N
ologen POS N
may POS N
be POS N
a POS N
useful POS N
alternative POS N
to POS N
MMC POS N
in POS N
JOAG. POS N

At POS N
1 POS N
year, POS N
the POS N
mean POS N
postoperative POS N
IOP POS N
was POS N
significantly POS N
lower POS N
in POS N
group POS N
A. POS N

Our POS N
results POS N
suggest POS N
that POS N
ologen POS N
may POS N
be POS N
a POS N
useful POS N
alternative POS N
to POS N
MMC POS N
in POS N
JOAG. POS N

According POS N
to POS N
the POS N
MBGS, POS N
blebs POS N
with POS N
an POS N
ologen POS N
implant POS N
showed POS N
significantly POS N
better POS N
scoring POS N
than POS N
those POS N
with POS N
MMC. POS N

Our POS N
results POS N
suggest POS N
that POS N
ologen POS N
may POS N
be POS N
a POS N
useful POS N
alternative POS N
to POS N
MMC POS N
in POS N
JOAG. POS N

AS-OCT POS N
showed POS N
that POS N
ologen-induced POS N
blebs POS N
had POS N
significantly POS N
more POS N
fluid-filled POS N
spaces, POS N
cleavage POS N
planes, POS N
and POS N
less POS N
fibrosis. POS N

Our POS N
results POS N
suggest POS N
that POS N
ologen POS N
may POS N
be POS N
a POS N
useful POS N
alternative POS N
to POS N
MMC POS N
in POS N
JOAG. POS N

Ologen POS N
resulted POS N
in POS N
a POS N
lower POS N
long-term POS N
postoperative POS N
IOP, POS N
a POS N
better POS N
bleb POS N
morphology, POS N
and POS N
fewer POS N
complications. POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

Trabeculectomy POS N
is POS N
more POS N
effective POS N
than POS N
phacoemulsification POS N
in POS N
reducing POS N
dependence POS N
on POS N
glaucoma POS N
drugs, POS N
but POS N
is POS N
associated POS N
with POS N
more POS N
complications. POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

Both POS N
phacoemulsification POS N
and POS N
trabeculectomy POS N
are POS N
effective POS N
in POS N
reducing POS N
IOP POS N
in POS N
medically POS N
uncontrolled POS N
CACG POS N
eyes POS N
without POS N
cataract. POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

Eight POS N
(33%) POS N
of POS N
24 POS N
trabeculectomy POS N
eyes POS N
demonstrated POS N
cataract POS N
during POS N
follow-up. POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

trabeculectomy POS N
was POS N
associated POS N
with POS N
significantly POS N
more POS N
surgical POS N
complications POS N
than POS N
phacoemulsification POS N
(46% POS N
vs POS N
4%; POS N
P=0.001). POS N

Phacoemulsification POS N
and POS N
trabeculectomy POS N
resulted POS N
in POS N
significant POS N
and POS N
comparable POS N
IOP POS N
reduction POS N
at POS N
24 POS N
months POS N
after POS N
surgery POS N
(reduction POS N
of POS N
8.4 POS N
mmHg POS N
or POS N
34% POS N
for POS N
phacoemulsification POS N
vs POS N
8.9 POS N
mmHg POS N
or POS N
36% POS N
for POS N
trabeculectomy; POS N
P=0.76). POS N

Over POS N
first POS N
24 POS N
months, POS N
trabeculectomy-treated POS N
eyes POS N
required POS N
on POS N
average POS N
1.1 POS N
fewer POS N
drugs POS N
than POS N
phacoemulsification-treated POS N
eyes POS N
(P<0.001). POS N

In POS N
Group POS N
1 POS N
and POS N
2, POS N
intraocular POS N
pressure POS N
was POS N
well POS N
controlled POS N
to POS N
approximately POS N
14 POS N
mmHg POS N
(9.38-18.46% POS N
decrease). POS N

Generally, POS N
subjective POS N
satisfaction POS N
was POS N
improved POS N
after POS N
changing POS N
from POS N
PT POS N
to POS N
NPT POS N
(p = 0.03) POS N
and POS N
TBUT POS N
using POS N
PT POS N
was POS N
numerically POS N
inferior POS N
to POS N
that POS N
using POS N
NPT POS N
(p = 0.06) POS N
but POS N
not POS N
when POS N
changing POS N
from POS N
NPT POS N
to POS N
PT. POS N

In POS N
Group POS N
1 POS N
and POS N
2, POS N
intraocular POS N
pressure POS N
was POS N
well POS N
controlled POS N
to POS N
approximately POS N
14 POS N
mmHg POS N
(9.38-18.46% POS N
decrease). POS N

Both POS N
preservative POS N
containing POS N
and POS N
preservative-free POS N
0.0015% POS N
tafluprost POS N
reduced POS N
intraocular POS N
pressure POS N
significantly. POS N

In POS N
Group POS N
1 POS N
and POS N
2, POS N
intraocular POS N
pressure POS N
was POS N
well POS N
controlled POS N
to POS N
approximately POS N
14 POS N
mmHg POS N
(9.38-18.46% POS N
decrease). POS N

changing POS N
medication POS N
from POS N
PT POS N
to POS N
NPT POS N
might POS N
improve POS N
subjective POS N
satisfaction POS N
and POS N
tear POS N
break POS N
up POS N
time. POS N

Generally, POS N
subjective POS N
satisfaction POS N
was POS N
improved POS N
after POS N
changing POS N
from POS N
PT POS N
to POS N
NPT POS N
(p = 0.03) POS N
and POS N
TBUT POS N
using POS N
PT POS N
was POS N
numerically POS N
inferior POS N
to POS N
that POS N
using POS N
NPT POS N
(p = 0.06) POS N
but POS N
not POS N
when POS N
changing POS N
from POS N
NPT POS N
to POS N
PT. POS N

In POS N
Group POS N
1 POS N
and POS N
2, POS N
intraocular POS N
pressure POS N
was POS N
well POS N
controlled POS N
to POS N
approximately POS N
14 POS N
mmHg POS N
(9.38-18.46% POS N
decrease). POS N

Generally, POS N
subjective POS N
satisfaction POS N
was POS N
improved POS N
after POS N
changing POS N
from POS N
PT POS N
to POS N
NPT POS N
(p = 0.03) POS N
and POS N
TBUT POS N
using POS N
PT POS N
was POS N
numerically POS N
inferior POS N
to POS N
that POS N
using POS N
NPT POS N
(p = 0.06) POS N
but POS N
not POS N
when POS N
changing POS N
from POS N
NPT POS N
to POS N
PT. POS N

Both POS N
preservative POS N
containing POS N
and POS N
preservative-free POS N
0.0015% POS N
tafluprost POS N
reduced POS N
intraocular POS N
pressure POS N
significantly. POS N

Generally, POS N
subjective POS N
satisfaction POS N
was POS N
improved POS N
after POS N
changing POS N
from POS N
PT POS N
to POS N
NPT POS N
(p = 0.03) POS N
and POS N
TBUT POS N
using POS N
PT POS N
was POS N
numerically POS N
inferior POS N
to POS N
that POS N
using POS N
NPT POS N
(p = 0.06) POS N
but POS N
not POS N
when POS N
changing POS N
from POS N
NPT POS N
to POS N
PT. POS N

changing POS N
medication POS N
from POS N
PT POS N
to POS N
NPT POS N
might POS N
improve POS N
subjective POS N
satisfaction POS N
and POS N
tear POS N
break POS N
up POS N
time. POS N

Both POS N
preservative POS N
containing POS N
and POS N
preservative-free POS N
0.0015% POS N
tafluprost POS N
reduced POS N
intraocular POS N
pressure POS N
significantly. POS N

In POS N
Group POS N
1 POS N
and POS N
2, POS N
intraocular POS N
pressure POS N
was POS N
well POS N
controlled POS N
to POS N
approximately POS N
14 POS N
mmHg POS N
(9.38-18.46% POS N
decrease). POS N

Both POS N
preservative POS N
containing POS N
and POS N
preservative-free POS N
0.0015% POS N
tafluprost POS N
reduced POS N
intraocular POS N
pressure POS N
significantly. POS N

Generally, POS N
subjective POS N
satisfaction POS N
was POS N
improved POS N
after POS N
changing POS N
from POS N
PT POS N
to POS N
NPT POS N
(p = 0.03) POS N
and POS N
TBUT POS N
using POS N
PT POS N
was POS N
numerically POS N
inferior POS N
to POS N
that POS N
using POS N
NPT POS N
(p = 0.06) POS N
but POS N
not POS N
when POS N
changing POS N
from POS N
NPT POS N
to POS N
PT. POS N

Both POS N
preservative POS N
containing POS N
and POS N
preservative-free POS N
0.0015% POS N
tafluprost POS N
reduced POS N
intraocular POS N
pressure POS N
significantly. POS N

changing POS N
medication POS N
from POS N
PT POS N
to POS N
NPT POS N
might POS N
improve POS N
subjective POS N
satisfaction POS N
and POS N
tear POS N
break POS N
up POS N
time. POS N

changing POS N
medication POS N
from POS N
PT POS N
to POS N
NPT POS N
might POS N
improve POS N
subjective POS N
satisfaction POS N
and POS N
tear POS N
break POS N
up POS N
time. POS N

In POS N
Group POS N
1 POS N
and POS N
2, POS N
intraocular POS N
pressure POS N
was POS N
well POS N
controlled POS N
to POS N
approximately POS N
14 POS N
mmHg POS N
(9.38-18.46% POS N
decrease). POS N

changing POS N
medication POS N
from POS N
PT POS N
to POS N
NPT POS N
might POS N
improve POS N
subjective POS N
satisfaction POS N
and POS N
tear POS N
break POS N
up POS N
time. POS N

Generally, POS N
subjective POS N
satisfaction POS N
was POS N
improved POS N
after POS N
changing POS N
from POS N
PT POS N
to POS N
NPT POS N
(p = 0.03) POS N
and POS N
TBUT POS N
using POS N
PT POS N
was POS N
numerically POS N
inferior POS N
to POS N
that POS N
using POS N
NPT POS N
(p = 0.06) POS N
but POS N
not POS N
when POS N
changing POS N
from POS N
NPT POS N
to POS N
PT. POS N

changing POS N
medication POS N
from POS N
PT POS N
to POS N
NPT POS N
might POS N
improve POS N
subjective POS N
satisfaction POS N
and POS N
tear POS N
break POS N
up POS N
time. POS N

Both POS N
preservative POS N
containing POS N
and POS N
preservative-free POS N
0.0015% POS N
tafluprost POS N
reduced POS N
intraocular POS N
pressure POS N
significantly. POS N

There POS N
was POS N
a POS N
significant POS N
difference POS N
in POS N
post-intervention POS N
levels POS N
of POS N
urea, POS N
creatinine, POS N
sodium, POS N
potassium, POS N
calcium, POS N
and POS N
phosphorus POS N
between POS N
the POS N
two POS N
groups. POS N

Appropriate POS N
nutrition POS N
training POS N
via POS N
small-group POS N
method POS N
for POS N
patients POS N
on POS N
hemodialysis POS N
can POS N
impose POS N
positive POS N
effects POS N
on POS N
laboratory POS N
parameters. POS N

Appropriate POS N
nutrition POS N
training POS N
via POS N
small-group POS N
method POS N
for POS N
patients POS N
on POS N
hemodialysis POS N
can POS N
impose POS N
positive POS N
effects POS N
on POS N
laboratory POS N
parameters. POS N

There POS N
was POS N
a POS N
significant POS N
difference POS N
in POS N
post-intervention POS N
levels POS N
of POS N
urea, POS N
creatinine, POS N
sodium, POS N
potassium, POS N
calcium, POS N
and POS N
phosphorus POS N
between POS N
the POS N
two POS N
groups. POS N

In POS N
patients POS N
with POS N
chronic POS N
hepatitis POS N
B, POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
plus POS N
pegylated POS N
interferon POS N
(PEG-IFN) POS N
for POS N
48-weeks POS N
results POS N
in POS N
higher POS N
rates POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
than POS N
either POS N
monotherapy. POS N

Rates POS N
of POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72 POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
TDF/PI-48w POS N
group POS N
(6.5%) POS N
than POS N
in POS N
the POS N
TDF/PI-16w+TDF-32w POS N
(0.5%), POS N
TDF-120w POS N
(0%) POS N
and POS N
PI-48w POS N
(2.2%) POS N
groups POS N
(P POS N
= POS N
0.09). POS N

In POS N
patients POS N
with POS N
chronic POS N
hepatitis POS N
B, POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
plus POS N
pegylated POS N
interferon POS N
(PEG-IFN) POS N
for POS N
48-weeks POS N
results POS N
in POS N
higher POS N
rates POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
than POS N
either POS N
monotherapy. POS N

HBsAg POS N
decline POS N
at POS N
Week POS N
12 POS N
or POS N
24 POS N
of POS N
treatment POS N
was POS N
associated POS N
with POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72 POS N
(P POS N
< POS N
0.001). POS N

In POS N
patients POS N
with POS N
chronic POS N
hepatitis POS N
B, POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
plus POS N
pegylated POS N
interferon POS N
(PEG-IFN) POS N
for POS N
48-weeks POS N
results POS N
in POS N
higher POS N
rates POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
than POS N
either POS N
monotherapy. POS N

HBsAg POS N
decline POS N
>3.5 POS N
log10 POS N
IU/mL POS N
at POS N
Week POS N
24 POS N
in POS N
the POS N
TDF/PI-48w POS N
group POS N
resulted POS N
in POS N
a POS N
positive POS N
predictive POS N
value POS N
of POS N
85% POS N
and POS N
a POS N
negative POS N
predictive POS N
value POS N
of POS N
99% POS N
for POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72. POS N

In POS N
patients POS N
with POS N
chronic POS N
hepatitis POS N
B, POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
plus POS N
pegylated POS N
interferon POS N
(PEG-IFN) POS N
for POS N
48-weeks POS N
results POS N
in POS N
higher POS N
rates POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
than POS N
either POS N
monotherapy. POS N

HBsAg POS N
decline POS N
at POS N
Week POS N
24 POS N
of POS N
TDF POS N
plus POS N
PEG-IFN POS N
combination POS N
therapy POS N
may POS N
identify POS N
patients POS N
who, POS N
after POS N
completing POS N
48 POS N
weeks POS N
of POS N
treatment, POS N
have POS N
a POS N
better POS N
chance POS N
of POS N
achieving POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72. POS N

Rates POS N
of POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72 POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
TDF/PI-48w POS N
group POS N
(6.5%) POS N
than POS N
in POS N
the POS N
TDF/PI-16w+TDF-32w POS N
(0.5%), POS N
TDF-120w POS N
(0%) POS N
and POS N
PI-48w POS N
(2.2%) POS N
groups POS N
(P POS N
= POS N
0.09). POS N

In POS N
patients POS N
with POS N
chronic POS N
hepatitis POS N
B, POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
plus POS N
pegylated POS N
interferon POS N
(PEG-IFN) POS N
for POS N
48-weeks POS N
results POS N
in POS N
higher POS N
rates POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
than POS N
either POS N
monotherapy. POS N

Rates POS N
of POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72 POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
TDF/PI-48w POS N
group POS N
(6.5%) POS N
than POS N
in POS N
the POS N
TDF/PI-16w+TDF-32w POS N
(0.5%), POS N
TDF-120w POS N
(0%) POS N
and POS N
PI-48w POS N
(2.2%) POS N
groups POS N
(P POS N
= POS N
0.09). POS N

HBsAg POS N
decline POS N
at POS N
Week POS N
12 POS N
or POS N
24 POS N
of POS N
treatment POS N
was POS N
associated POS N
with POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72 POS N
(P POS N
< POS N
0.001). POS N

Rates POS N
of POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72 POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
TDF/PI-48w POS N
group POS N
(6.5%) POS N
than POS N
in POS N
the POS N
TDF/PI-16w+TDF-32w POS N
(0.5%), POS N
TDF-120w POS N
(0%) POS N
and POS N
PI-48w POS N
(2.2%) POS N
groups POS N
(P POS N
= POS N
0.09). POS N

HBsAg POS N
decline POS N
>3.5 POS N
log10 POS N
IU/mL POS N
at POS N
Week POS N
24 POS N
in POS N
the POS N
TDF/PI-48w POS N
group POS N
resulted POS N
in POS N
a POS N
positive POS N
predictive POS N
value POS N
of POS N
85% POS N
and POS N
a POS N
negative POS N
predictive POS N
value POS N
of POS N
99% POS N
for POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72. POS N

Rates POS N
of POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72 POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
TDF/PI-48w POS N
group POS N
(6.5%) POS N
than POS N
in POS N
the POS N
TDF/PI-16w+TDF-32w POS N
(0.5%), POS N
TDF-120w POS N
(0%) POS N
and POS N
PI-48w POS N
(2.2%) POS N
groups POS N
(P POS N
= POS N
0.09). POS N

HBsAg POS N
decline POS N
at POS N
Week POS N
24 POS N
of POS N
TDF POS N
plus POS N
PEG-IFN POS N
combination POS N
therapy POS N
may POS N
identify POS N
patients POS N
who, POS N
after POS N
completing POS N
48 POS N
weeks POS N
of POS N
treatment, POS N
have POS N
a POS N
better POS N
chance POS N
of POS N
achieving POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72. POS N

HBsAg POS N
decline POS N
at POS N
Week POS N
12 POS N
or POS N
24 POS N
of POS N
treatment POS N
was POS N
associated POS N
with POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72 POS N
(P POS N
< POS N
0.001). POS N

In POS N
patients POS N
with POS N
chronic POS N
hepatitis POS N
B, POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
plus POS N
pegylated POS N
interferon POS N
(PEG-IFN) POS N
for POS N
48-weeks POS N
results POS N
in POS N
higher POS N
rates POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
than POS N
either POS N
monotherapy. POS N

HBsAg POS N
decline POS N
at POS N
Week POS N
12 POS N
or POS N
24 POS N
of POS N
treatment POS N
was POS N
associated POS N
with POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72 POS N
(P POS N
< POS N
0.001). POS N

Rates POS N
of POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72 POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
TDF/PI-48w POS N
group POS N
(6.5%) POS N
than POS N
in POS N
the POS N
TDF/PI-16w+TDF-32w POS N
(0.5%), POS N
TDF-120w POS N
(0%) POS N
and POS N
PI-48w POS N
(2.2%) POS N
groups POS N
(P POS N
= POS N
0.09). POS N

HBsAg POS N
decline POS N
at POS N
Week POS N
12 POS N
or POS N
24 POS N
of POS N
treatment POS N
was POS N
associated POS N
with POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72 POS N
(P POS N
< POS N
0.001). POS N

HBsAg POS N
decline POS N
>3.5 POS N
log10 POS N
IU/mL POS N
at POS N
Week POS N
24 POS N
in POS N
the POS N
TDF/PI-48w POS N
group POS N
resulted POS N
in POS N
a POS N
positive POS N
predictive POS N
value POS N
of POS N
85% POS N
and POS N
a POS N
negative POS N
predictive POS N
value POS N
of POS N
99% POS N
for POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72. POS N

HBsAg POS N
decline POS N
at POS N
Week POS N
12 POS N
or POS N
24 POS N
of POS N
treatment POS N
was POS N
associated POS N
with POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72 POS N
(P POS N
< POS N
0.001). POS N

HBsAg POS N
decline POS N
at POS N
Week POS N
24 POS N
of POS N
TDF POS N
plus POS N
PEG-IFN POS N
combination POS N
therapy POS N
may POS N
identify POS N
patients POS N
who, POS N
after POS N
completing POS N
48 POS N
weeks POS N
of POS N
treatment, POS N
have POS N
a POS N
better POS N
chance POS N
of POS N
achieving POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72. POS N

HBsAg POS N
decline POS N
>3.5 POS N
log10 POS N
IU/mL POS N
at POS N
Week POS N
24 POS N
in POS N
the POS N
TDF/PI-48w POS N
group POS N
resulted POS N
in POS N
a POS N
positive POS N
predictive POS N
value POS N
of POS N
85% POS N
and POS N
a POS N
negative POS N
predictive POS N
value POS N
of POS N
99% POS N
for POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72. POS N

In POS N
patients POS N
with POS N
chronic POS N
hepatitis POS N
B, POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
plus POS N
pegylated POS N
interferon POS N
(PEG-IFN) POS N
for POS N
48-weeks POS N
results POS N
in POS N
higher POS N
rates POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
than POS N
either POS N
monotherapy. POS N

HBsAg POS N
decline POS N
>3.5 POS N
log10 POS N
IU/mL POS N
at POS N
Week POS N
24 POS N
in POS N
the POS N
TDF/PI-48w POS N
group POS N
resulted POS N
in POS N
a POS N
positive POS N
predictive POS N
value POS N
of POS N
85% POS N
and POS N
a POS N
negative POS N
predictive POS N
value POS N
of POS N
99% POS N
for POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72. POS N

Rates POS N
of POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72 POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
TDF/PI-48w POS N
group POS N
(6.5%) POS N
than POS N
in POS N
the POS N
TDF/PI-16w+TDF-32w POS N
(0.5%), POS N
TDF-120w POS N
(0%) POS N
and POS N
PI-48w POS N
(2.2%) POS N
groups POS N
(P POS N
= POS N
0.09). POS N

HBsAg POS N
decline POS N
>3.5 POS N
log10 POS N
IU/mL POS N
at POS N
Week POS N
24 POS N
in POS N
the POS N
TDF/PI-48w POS N
group POS N
resulted POS N
in POS N
a POS N
positive POS N
predictive POS N
value POS N
of POS N
85% POS N
and POS N
a POS N
negative POS N
predictive POS N
value POS N
of POS N
99% POS N
for POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72. POS N

HBsAg POS N
decline POS N
at POS N
Week POS N
12 POS N
or POS N
24 POS N
of POS N
treatment POS N
was POS N
associated POS N
with POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72 POS N
(P POS N
< POS N
0.001). POS N

HBsAg POS N
decline POS N
>3.5 POS N
log10 POS N
IU/mL POS N
at POS N
Week POS N
24 POS N
in POS N
the POS N
TDF/PI-48w POS N
group POS N
resulted POS N
in POS N
a POS N
positive POS N
predictive POS N
value POS N
of POS N
85% POS N
and POS N
a POS N
negative POS N
predictive POS N
value POS N
of POS N
99% POS N
for POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72. POS N

HBsAg POS N
decline POS N
at POS N
Week POS N
24 POS N
of POS N
TDF POS N
plus POS N
PEG-IFN POS N
combination POS N
therapy POS N
may POS N
identify POS N
patients POS N
who, POS N
after POS N
completing POS N
48 POS N
weeks POS N
of POS N
treatment, POS N
have POS N
a POS N
better POS N
chance POS N
of POS N
achieving POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72. POS N

HBsAg POS N
decline POS N
at POS N
Week POS N
24 POS N
of POS N
TDF POS N
plus POS N
PEG-IFN POS N
combination POS N
therapy POS N
may POS N
identify POS N
patients POS N
who, POS N
after POS N
completing POS N
48 POS N
weeks POS N
of POS N
treatment, POS N
have POS N
a POS N
better POS N
chance POS N
of POS N
achieving POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72. POS N

In POS N
patients POS N
with POS N
chronic POS N
hepatitis POS N
B, POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
plus POS N
pegylated POS N
interferon POS N
(PEG-IFN) POS N
for POS N
48-weeks POS N
results POS N
in POS N
higher POS N
rates POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
than POS N
either POS N
monotherapy. POS N

HBsAg POS N
decline POS N
at POS N
Week POS N
24 POS N
of POS N
TDF POS N
plus POS N
PEG-IFN POS N
combination POS N
therapy POS N
may POS N
identify POS N
patients POS N
who, POS N
after POS N
completing POS N
48 POS N
weeks POS N
of POS N
treatment, POS N
have POS N
a POS N
better POS N
chance POS N
of POS N
achieving POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72. POS N

Rates POS N
of POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72 POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
TDF/PI-48w POS N
group POS N
(6.5%) POS N
than POS N
in POS N
the POS N
TDF/PI-16w+TDF-32w POS N
(0.5%), POS N
TDF-120w POS N
(0%) POS N
and POS N
PI-48w POS N
(2.2%) POS N
groups POS N
(P POS N
= POS N
0.09). POS N

HBsAg POS N
decline POS N
at POS N
Week POS N
24 POS N
of POS N
TDF POS N
plus POS N
PEG-IFN POS N
combination POS N
therapy POS N
may POS N
identify POS N
patients POS N
who, POS N
after POS N
completing POS N
48 POS N
weeks POS N
of POS N
treatment, POS N
have POS N
a POS N
better POS N
chance POS N
of POS N
achieving POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72. POS N

HBsAg POS N
decline POS N
at POS N
Week POS N
12 POS N
or POS N
24 POS N
of POS N
treatment POS N
was POS N
associated POS N
with POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72 POS N
(P POS N
< POS N
0.001). POS N

HBsAg POS N
decline POS N
at POS N
Week POS N
24 POS N
of POS N
TDF POS N
plus POS N
PEG-IFN POS N
combination POS N
therapy POS N
may POS N
identify POS N
patients POS N
who, POS N
after POS N
completing POS N
48 POS N
weeks POS N
of POS N
treatment, POS N
have POS N
a POS N
better POS N
chance POS N
of POS N
achieving POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72. POS N

HBsAg POS N
decline POS N
>3.5 POS N
log10 POS N
IU/mL POS N
at POS N
Week POS N
24 POS N
in POS N
the POS N
TDF/PI-48w POS N
group POS N
resulted POS N
in POS N
a POS N
positive POS N
predictive POS N
value POS N
of POS N
85% POS N
and POS N
a POS N
negative POS N
predictive POS N
value POS N
of POS N
99% POS N
for POS N
HBsAg POS N
loss POS N
at POS N
Week POS N
72. POS N

GS-9620 POS N
might POS N
therefore POS N
be POS N
included POS N
in POS N
therapies POS N
to POS N
increase POS N
the POS N
immune POS N
response POS N
to POS N
HBV. POS N

T POS N
cells POS N
collected POS N
at POS N
baseline POS N
before POS N
addition POS N
of POS N
GS-9620, POS N
when POS N
patients POS N
were POS N
receiving POS N
only POS N
nucleos(t)ide POS N
therapy, POS N
had POS N
greater POS N
responses POS N
to POS N
HBV POS N
than POS N
T POS N
cells POS N
from POS N
treatment-naïve POS N
patients, POS N
based POS N
on POS N
cytokine POS N
production POS N
in POS N
response POS N
to POS N
HBV POS N
peptides. POS N

GS-9620 POS N
might POS N
therefore POS N
be POS N
included POS N
in POS N
therapies POS N
to POS N
increase POS N
the POS N
immune POS N
response POS N
to POS N
HBV. POS N

However, POS N
during POS N
or POS N
after POS N
administration POS N
of POS N
GS-9620, POS N
T POS N
cells POS N
produced POS N
higher POS N
levels POS N
of POS N
cytokines POS N
compared POS N
to POS N
baseline. POS N

GS-9620 POS N
might POS N
therefore POS N
be POS N
included POS N
in POS N
therapies POS N
to POS N
increase POS N
the POS N
immune POS N
response POS N
to POS N
HBV. POS N

NK-cell POS N
activation POS N
and POS N
function POS N
increased POS N
after POS N
patients POS N
were POS N
given POS N
GS-9620, POS N
but POS N
the POS N
ability POS N
of POS N
NK POS N
cells POS N
to POS N
suppress POS N
T-cell POS N
responses POS N
was POS N
lower POS N
during POS N
GS-9620 POS N
therapy POS N
than POS N
before. POS N

GS-9620 POS N
might POS N
therefore POS N
be POS N
included POS N
in POS N
therapies POS N
to POS N
increase POS N
the POS N
immune POS N
response POS N
to POS N
HBV. POS N

Changes POS N
in POS N
T-cell POS N
or POS N
NK-cell POS N
function POS N
did POS N
not POS N
correlate POS N
with POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen. POS N

GS-9620 POS N
might POS N
therefore POS N
be POS N
included POS N
in POS N
therapies POS N
to POS N
increase POS N
the POS N
immune POS N
response POS N
to POS N
HBV. POS N

Serum POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
did POS N
not POS N
decrease POS N
significantly POS N
compared POS N
to POS N
baseline POS N
in POS N
patients POS N
given POS N
any POS N
dose POS N
of POS N
GS-9620. POS N

GS-9620 POS N
might POS N
therefore POS N
be POS N
included POS N
in POS N
therapies POS N
to POS N
increase POS N
the POS N
immune POS N
response POS N
to POS N
HBV. POS N

Twelve POS N
weeks POS N
administration POS N
of POS N
GS-9620 POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
serum POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
levels, POS N
but POS N
did POS N
appear POS N
to POS N
increase POS N
T-cell POS N
and POS N
NK-cell POS N
responses POS N
and POS N
reduce POS N
the POS N
ability POS N
of POS N
NK POS N
to POS N
suppress POS N
T POS N
cells. POS N

T POS N
cells POS N
collected POS N
at POS N
baseline POS N
before POS N
addition POS N
of POS N
GS-9620, POS N
when POS N
patients POS N
were POS N
receiving POS N
only POS N
nucleos(t)ide POS N
therapy, POS N
had POS N
greater POS N
responses POS N
to POS N
HBV POS N
than POS N
T POS N
cells POS N
from POS N
treatment-naïve POS N
patients, POS N
based POS N
on POS N
cytokine POS N
production POS N
in POS N
response POS N
to POS N
HBV POS N
peptides. POS N

GS-9620 POS N
might POS N
therefore POS N
be POS N
included POS N
in POS N
therapies POS N
to POS N
increase POS N
the POS N
immune POS N
response POS N
to POS N
HBV. POS N

T POS N
cells POS N
collected POS N
at POS N
baseline POS N
before POS N
addition POS N
of POS N
GS-9620, POS N
when POS N
patients POS N
were POS N
receiving POS N
only POS N
nucleos(t)ide POS N
therapy, POS N
had POS N
greater POS N
responses POS N
to POS N
HBV POS N
than POS N
T POS N
cells POS N
from POS N
treatment-naïve POS N
patients, POS N
based POS N
on POS N
cytokine POS N
production POS N
in POS N
response POS N
to POS N
HBV POS N
peptides. POS N

However, POS N
during POS N
or POS N
after POS N
administration POS N
of POS N
GS-9620, POS N
T POS N
cells POS N
produced POS N
higher POS N
levels POS N
of POS N
cytokines POS N
compared POS N
to POS N
baseline. POS N

T POS N
cells POS N
collected POS N
at POS N
baseline POS N
before POS N
addition POS N
of POS N
GS-9620, POS N
when POS N
patients POS N
were POS N
receiving POS N
only POS N
nucleos(t)ide POS N
therapy, POS N
had POS N
greater POS N
responses POS N
to POS N
HBV POS N
than POS N
T POS N
cells POS N
from POS N
treatment-naïve POS N
patients, POS N
based POS N
on POS N
cytokine POS N
production POS N
in POS N
response POS N
to POS N
HBV POS N
peptides. POS N

NK-cell POS N
activation POS N
and POS N
function POS N
increased POS N
after POS N
patients POS N
were POS N
given POS N
GS-9620, POS N
but POS N
the POS N
ability POS N
of POS N
NK POS N
cells POS N
to POS N
suppress POS N
T-cell POS N
responses POS N
was POS N
lower POS N
during POS N
GS-9620 POS N
therapy POS N
than POS N
before. POS N

T POS N
cells POS N
collected POS N
at POS N
baseline POS N
before POS N
addition POS N
of POS N
GS-9620, POS N
when POS N
patients POS N
were POS N
receiving POS N
only POS N
nucleos(t)ide POS N
therapy, POS N
had POS N
greater POS N
responses POS N
to POS N
HBV POS N
than POS N
T POS N
cells POS N
from POS N
treatment-naïve POS N
patients, POS N
based POS N
on POS N
cytokine POS N
production POS N
in POS N
response POS N
to POS N
HBV POS N
peptides. POS N

Changes POS N
in POS N
T-cell POS N
or POS N
NK-cell POS N
function POS N
did POS N
not POS N
correlate POS N
with POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen. POS N

T POS N
cells POS N
collected POS N
at POS N
baseline POS N
before POS N
addition POS N
of POS N
GS-9620, POS N
when POS N
patients POS N
were POS N
receiving POS N
only POS N
nucleos(t)ide POS N
therapy, POS N
had POS N
greater POS N
responses POS N
to POS N
HBV POS N
than POS N
T POS N
cells POS N
from POS N
treatment-naïve POS N
patients, POS N
based POS N
on POS N
cytokine POS N
production POS N
in POS N
response POS N
to POS N
HBV POS N
peptides. POS N

Serum POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
did POS N
not POS N
decrease POS N
significantly POS N
compared POS N
to POS N
baseline POS N
in POS N
patients POS N
given POS N
any POS N
dose POS N
of POS N
GS-9620. POS N

T POS N
cells POS N
collected POS N
at POS N
baseline POS N
before POS N
addition POS N
of POS N
GS-9620, POS N
when POS N
patients POS N
were POS N
receiving POS N
only POS N
nucleos(t)ide POS N
therapy, POS N
had POS N
greater POS N
responses POS N
to POS N
HBV POS N
than POS N
T POS N
cells POS N
from POS N
treatment-naïve POS N
patients, POS N
based POS N
on POS N
cytokine POS N
production POS N
in POS N
response POS N
to POS N
HBV POS N
peptides. POS N

Twelve POS N
weeks POS N
administration POS N
of POS N
GS-9620 POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
serum POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
levels, POS N
but POS N
did POS N
appear POS N
to POS N
increase POS N
T-cell POS N
and POS N
NK-cell POS N
responses POS N
and POS N
reduce POS N
the POS N
ability POS N
of POS N
NK POS N
to POS N
suppress POS N
T POS N
cells. POS N

However, POS N
during POS N
or POS N
after POS N
administration POS N
of POS N
GS-9620, POS N
T POS N
cells POS N
produced POS N
higher POS N
levels POS N
of POS N
cytokines POS N
compared POS N
to POS N
baseline. POS N

GS-9620 POS N
might POS N
therefore POS N
be POS N
included POS N
in POS N
therapies POS N
to POS N
increase POS N
the POS N
immune POS N
response POS N
to POS N
HBV. POS N

However, POS N
during POS N
or POS N
after POS N
administration POS N
of POS N
GS-9620, POS N
T POS N
cells POS N
produced POS N
higher POS N
levels POS N
of POS N
cytokines POS N
compared POS N
to POS N
baseline. POS N

T POS N
cells POS N
collected POS N
at POS N
baseline POS N
before POS N
addition POS N
of POS N
GS-9620, POS N
when POS N
patients POS N
were POS N
receiving POS N
only POS N
nucleos(t)ide POS N
therapy, POS N
had POS N
greater POS N
responses POS N
to POS N
HBV POS N
than POS N
T POS N
cells POS N
from POS N
treatment-naïve POS N
patients, POS N
based POS N
on POS N
cytokine POS N
production POS N
in POS N
response POS N
to POS N
HBV POS N
peptides. POS N

However, POS N
during POS N
or POS N
after POS N
administration POS N
of POS N
GS-9620, POS N
T POS N
cells POS N
produced POS N
higher POS N
levels POS N
of POS N
cytokines POS N
compared POS N
to POS N
baseline. POS N

NK-cell POS N
activation POS N
and POS N
function POS N
increased POS N
after POS N
patients POS N
were POS N
given POS N
GS-9620, POS N
but POS N
the POS N
ability POS N
of POS N
NK POS N
cells POS N
to POS N
suppress POS N
T-cell POS N
responses POS N
was POS N
lower POS N
during POS N
GS-9620 POS N
therapy POS N
than POS N
before. POS N

However, POS N
during POS N
or POS N
after POS N
administration POS N
of POS N
GS-9620, POS N
T POS N
cells POS N
produced POS N
higher POS N
levels POS N
of POS N
cytokines POS N
compared POS N
to POS N
baseline. POS N

Changes POS N
in POS N
T-cell POS N
or POS N
NK-cell POS N
function POS N
did POS N
not POS N
correlate POS N
with POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen. POS N

However, POS N
during POS N
or POS N
after POS N
administration POS N
of POS N
GS-9620, POS N
T POS N
cells POS N
produced POS N
higher POS N
levels POS N
of POS N
cytokines POS N
compared POS N
to POS N
baseline. POS N

Serum POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
did POS N
not POS N
decrease POS N
significantly POS N
compared POS N
to POS N
baseline POS N
in POS N
patients POS N
given POS N
any POS N
dose POS N
of POS N
GS-9620. POS N

However, POS N
during POS N
or POS N
after POS N
administration POS N
of POS N
GS-9620, POS N
T POS N
cells POS N
produced POS N
higher POS N
levels POS N
of POS N
cytokines POS N
compared POS N
to POS N
baseline. POS N

Twelve POS N
weeks POS N
administration POS N
of POS N
GS-9620 POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
serum POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
levels, POS N
but POS N
did POS N
appear POS N
to POS N
increase POS N
T-cell POS N
and POS N
NK-cell POS N
responses POS N
and POS N
reduce POS N
the POS N
ability POS N
of POS N
NK POS N
to POS N
suppress POS N
T POS N
cells. POS N

NK-cell POS N
activation POS N
and POS N
function POS N
increased POS N
after POS N
patients POS N
were POS N
given POS N
GS-9620, POS N
but POS N
the POS N
ability POS N
of POS N
NK POS N
cells POS N
to POS N
suppress POS N
T-cell POS N
responses POS N
was POS N
lower POS N
during POS N
GS-9620 POS N
therapy POS N
than POS N
before. POS N

GS-9620 POS N
might POS N
therefore POS N
be POS N
included POS N
in POS N
therapies POS N
to POS N
increase POS N
the POS N
immune POS N
response POS N
to POS N
HBV. POS N

NK-cell POS N
activation POS N
and POS N
function POS N
increased POS N
after POS N
patients POS N
were POS N
given POS N
GS-9620, POS N
but POS N
the POS N
ability POS N
of POS N
NK POS N
cells POS N
to POS N
suppress POS N
T-cell POS N
responses POS N
was POS N
lower POS N
during POS N
GS-9620 POS N
therapy POS N
than POS N
before. POS N

T POS N
cells POS N
collected POS N
at POS N
baseline POS N
before POS N
addition POS N
of POS N
GS-9620, POS N
when POS N
patients POS N
were POS N
receiving POS N
only POS N
nucleos(t)ide POS N
therapy, POS N
had POS N
greater POS N
responses POS N
to POS N
HBV POS N
than POS N
T POS N
cells POS N
from POS N
treatment-naïve POS N
patients, POS N
based POS N
on POS N
cytokine POS N
production POS N
in POS N
response POS N
to POS N
HBV POS N
peptides. POS N

NK-cell POS N
activation POS N
and POS N
function POS N
increased POS N
after POS N
patients POS N
were POS N
given POS N
GS-9620, POS N
but POS N
the POS N
ability POS N
of POS N
NK POS N
cells POS N
to POS N
suppress POS N
T-cell POS N
responses POS N
was POS N
lower POS N
during POS N
GS-9620 POS N
therapy POS N
than POS N
before. POS N

However, POS N
during POS N
or POS N
after POS N
administration POS N
of POS N
GS-9620, POS N
T POS N
cells POS N
produced POS N
higher POS N
levels POS N
of POS N
cytokines POS N
compared POS N
to POS N
baseline. POS N

NK-cell POS N
activation POS N
and POS N
function POS N
increased POS N
after POS N
patients POS N
were POS N
given POS N
GS-9620, POS N
but POS N
the POS N
ability POS N
of POS N
NK POS N
cells POS N
to POS N
suppress POS N
T-cell POS N
responses POS N
was POS N
lower POS N
during POS N
GS-9620 POS N
therapy POS N
than POS N
before. POS N

Changes POS N
in POS N
T-cell POS N
or POS N
NK-cell POS N
function POS N
did POS N
not POS N
correlate POS N
with POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen. POS N

NK-cell POS N
activation POS N
and POS N
function POS N
increased POS N
after POS N
patients POS N
were POS N
given POS N
GS-9620, POS N
but POS N
the POS N
ability POS N
of POS N
NK POS N
cells POS N
to POS N
suppress POS N
T-cell POS N
responses POS N
was POS N
lower POS N
during POS N
GS-9620 POS N
therapy POS N
than POS N
before. POS N

Serum POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
did POS N
not POS N
decrease POS N
significantly POS N
compared POS N
to POS N
baseline POS N
in POS N
patients POS N
given POS N
any POS N
dose POS N
of POS N
GS-9620. POS N

NK-cell POS N
activation POS N
and POS N
function POS N
increased POS N
after POS N
patients POS N
were POS N
given POS N
GS-9620, POS N
but POS N
the POS N
ability POS N
of POS N
NK POS N
cells POS N
to POS N
suppress POS N
T-cell POS N
responses POS N
was POS N
lower POS N
during POS N
GS-9620 POS N
therapy POS N
than POS N
before. POS N

Twelve POS N
weeks POS N
administration POS N
of POS N
GS-9620 POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
serum POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
levels, POS N
but POS N
did POS N
appear POS N
to POS N
increase POS N
T-cell POS N
and POS N
NK-cell POS N
responses POS N
and POS N
reduce POS N
the POS N
ability POS N
of POS N
NK POS N
to POS N
suppress POS N
T POS N
cells. POS N

Changes POS N
in POS N
T-cell POS N
or POS N
NK-cell POS N
function POS N
did POS N
not POS N
correlate POS N
with POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen. POS N

GS-9620 POS N
might POS N
therefore POS N
be POS N
included POS N
in POS N
therapies POS N
to POS N
increase POS N
the POS N
immune POS N
response POS N
to POS N
HBV. POS N

Changes POS N
in POS N
T-cell POS N
or POS N
NK-cell POS N
function POS N
did POS N
not POS N
correlate POS N
with POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen. POS N

T POS N
cells POS N
collected POS N
at POS N
baseline POS N
before POS N
addition POS N
of POS N
GS-9620, POS N
when POS N
patients POS N
were POS N
receiving POS N
only POS N
nucleos(t)ide POS N
therapy, POS N
had POS N
greater POS N
responses POS N
to POS N
HBV POS N
than POS N
T POS N
cells POS N
from POS N
treatment-naïve POS N
patients, POS N
based POS N
on POS N
cytokine POS N
production POS N
in POS N
response POS N
to POS N
HBV POS N
peptides. POS N

Changes POS N
in POS N
T-cell POS N
or POS N
NK-cell POS N
function POS N
did POS N
not POS N
correlate POS N
with POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen. POS N

However, POS N
during POS N
or POS N
after POS N
administration POS N
of POS N
GS-9620, POS N
T POS N
cells POS N
produced POS N
higher POS N
levels POS N
of POS N
cytokines POS N
compared POS N
to POS N
baseline. POS N

Changes POS N
in POS N
T-cell POS N
or POS N
NK-cell POS N
function POS N
did POS N
not POS N
correlate POS N
with POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen. POS N

NK-cell POS N
activation POS N
and POS N
function POS N
increased POS N
after POS N
patients POS N
were POS N
given POS N
GS-9620, POS N
but POS N
the POS N
ability POS N
of POS N
NK POS N
cells POS N
to POS N
suppress POS N
T-cell POS N
responses POS N
was POS N
lower POS N
during POS N
GS-9620 POS N
therapy POS N
than POS N
before. POS N

Changes POS N
in POS N
T-cell POS N
or POS N
NK-cell POS N
function POS N
did POS N
not POS N
correlate POS N
with POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen. POS N

Serum POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
did POS N
not POS N
decrease POS N
significantly POS N
compared POS N
to POS N
baseline POS N
in POS N
patients POS N
given POS N
any POS N
dose POS N
of POS N
GS-9620. POS N

Changes POS N
in POS N
T-cell POS N
or POS N
NK-cell POS N
function POS N
did POS N
not POS N
correlate POS N
with POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen. POS N

Twelve POS N
weeks POS N
administration POS N
of POS N
GS-9620 POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
serum POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
levels, POS N
but POS N
did POS N
appear POS N
to POS N
increase POS N
T-cell POS N
and POS N
NK-cell POS N
responses POS N
and POS N
reduce POS N
the POS N
ability POS N
of POS N
NK POS N
to POS N
suppress POS N
T POS N
cells. POS N

Serum POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
did POS N
not POS N
decrease POS N
significantly POS N
compared POS N
to POS N
baseline POS N
in POS N
patients POS N
given POS N
any POS N
dose POS N
of POS N
GS-9620. POS N

GS-9620 POS N
might POS N
therefore POS N
be POS N
included POS N
in POS N
therapies POS N
to POS N
increase POS N
the POS N
immune POS N
response POS N
to POS N
HBV. POS N

Serum POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
did POS N
not POS N
decrease POS N
significantly POS N
compared POS N
to POS N
baseline POS N
in POS N
patients POS N
given POS N
any POS N
dose POS N
of POS N
GS-9620. POS N

T POS N
cells POS N
collected POS N
at POS N
baseline POS N
before POS N
addition POS N
of POS N
GS-9620, POS N
when POS N
patients POS N
were POS N
receiving POS N
only POS N
nucleos(t)ide POS N
therapy, POS N
had POS N
greater POS N
responses POS N
to POS N
HBV POS N
than POS N
T POS N
cells POS N
from POS N
treatment-naïve POS N
patients, POS N
based POS N
on POS N
cytokine POS N
production POS N
in POS N
response POS N
to POS N
HBV POS N
peptides. POS N

Serum POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
did POS N
not POS N
decrease POS N
significantly POS N
compared POS N
to POS N
baseline POS N
in POS N
patients POS N
given POS N
any POS N
dose POS N
of POS N
GS-9620. POS N

However, POS N
during POS N
or POS N
after POS N
administration POS N
of POS N
GS-9620, POS N
T POS N
cells POS N
produced POS N
higher POS N
levels POS N
of POS N
cytokines POS N
compared POS N
to POS N
baseline. POS N

Serum POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
did POS N
not POS N
decrease POS N
significantly POS N
compared POS N
to POS N
baseline POS N
in POS N
patients POS N
given POS N
any POS N
dose POS N
of POS N
GS-9620. POS N

NK-cell POS N
activation POS N
and POS N
function POS N
increased POS N
after POS N
patients POS N
were POS N
given POS N
GS-9620, POS N
but POS N
the POS N
ability POS N
of POS N
NK POS N
cells POS N
to POS N
suppress POS N
T-cell POS N
responses POS N
was POS N
lower POS N
during POS N
GS-9620 POS N
therapy POS N
than POS N
before. POS N

Serum POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
did POS N
not POS N
decrease POS N
significantly POS N
compared POS N
to POS N
baseline POS N
in POS N
patients POS N
given POS N
any POS N
dose POS N
of POS N
GS-9620. POS N

Changes POS N
in POS N
T-cell POS N
or POS N
NK-cell POS N
function POS N
did POS N
not POS N
correlate POS N
with POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen. POS N

Serum POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
did POS N
not POS N
decrease POS N
significantly POS N
compared POS N
to POS N
baseline POS N
in POS N
patients POS N
given POS N
any POS N
dose POS N
of POS N
GS-9620. POS N

Twelve POS N
weeks POS N
administration POS N
of POS N
GS-9620 POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
serum POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
levels, POS N
but POS N
did POS N
appear POS N
to POS N
increase POS N
T-cell POS N
and POS N
NK-cell POS N
responses POS N
and POS N
reduce POS N
the POS N
ability POS N
of POS N
NK POS N
to POS N
suppress POS N
T POS N
cells. POS N

Twelve POS N
weeks POS N
administration POS N
of POS N
GS-9620 POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
serum POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
levels, POS N
but POS N
did POS N
appear POS N
to POS N
increase POS N
T-cell POS N
and POS N
NK-cell POS N
responses POS N
and POS N
reduce POS N
the POS N
ability POS N
of POS N
NK POS N
to POS N
suppress POS N
T POS N
cells. POS N

GS-9620 POS N
might POS N
therefore POS N
be POS N
included POS N
in POS N
therapies POS N
to POS N
increase POS N
the POS N
immune POS N
response POS N
to POS N
HBV. POS N

Twelve POS N
weeks POS N
administration POS N
of POS N
GS-9620 POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
serum POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
levels, POS N
but POS N
did POS N
appear POS N
to POS N
increase POS N
T-cell POS N
and POS N
NK-cell POS N
responses POS N
and POS N
reduce POS N
the POS N
ability POS N
of POS N
NK POS N
to POS N
suppress POS N
T POS N
cells. POS N

T POS N
cells POS N
collected POS N
at POS N
baseline POS N
before POS N
addition POS N
of POS N
GS-9620, POS N
when POS N
patients POS N
were POS N
receiving POS N
only POS N
nucleos(t)ide POS N
therapy, POS N
had POS N
greater POS N
responses POS N
to POS N
HBV POS N
than POS N
T POS N
cells POS N
from POS N
treatment-naïve POS N
patients, POS N
based POS N
on POS N
cytokine POS N
production POS N
in POS N
response POS N
to POS N
HBV POS N
peptides. POS N

Twelve POS N
weeks POS N
administration POS N
of POS N
GS-9620 POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
serum POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
levels, POS N
but POS N
did POS N
appear POS N
to POS N
increase POS N
T-cell POS N
and POS N
NK-cell POS N
responses POS N
and POS N
reduce POS N
the POS N
ability POS N
of POS N
NK POS N
to POS N
suppress POS N
T POS N
cells. POS N

However, POS N
during POS N
or POS N
after POS N
administration POS N
of POS N
GS-9620, POS N
T POS N
cells POS N
produced POS N
higher POS N
levels POS N
of POS N
cytokines POS N
compared POS N
to POS N
baseline. POS N

Twelve POS N
weeks POS N
administration POS N
of POS N
GS-9620 POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
serum POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
levels, POS N
but POS N
did POS N
appear POS N
to POS N
increase POS N
T-cell POS N
and POS N
NK-cell POS N
responses POS N
and POS N
reduce POS N
the POS N
ability POS N
of POS N
NK POS N
to POS N
suppress POS N
T POS N
cells. POS N

NK-cell POS N
activation POS N
and POS N
function POS N
increased POS N
after POS N
patients POS N
were POS N
given POS N
GS-9620, POS N
but POS N
the POS N
ability POS N
of POS N
NK POS N
cells POS N
to POS N
suppress POS N
T-cell POS N
responses POS N
was POS N
lower POS N
during POS N
GS-9620 POS N
therapy POS N
than POS N
before. POS N

Twelve POS N
weeks POS N
administration POS N
of POS N
GS-9620 POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
serum POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
levels, POS N
but POS N
did POS N
appear POS N
to POS N
increase POS N
T-cell POS N
and POS N
NK-cell POS N
responses POS N
and POS N
reduce POS N
the POS N
ability POS N
of POS N
NK POS N
to POS N
suppress POS N
T POS N
cells. POS N

Changes POS N
in POS N
T-cell POS N
or POS N
NK-cell POS N
function POS N
did POS N
not POS N
correlate POS N
with POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen. POS N

Twelve POS N
weeks POS N
administration POS N
of POS N
GS-9620 POS N
had POS N
no POS N
significant POS N
effect POS N
on POS N
serum POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
levels, POS N
but POS N
did POS N
appear POS N
to POS N
increase POS N
T-cell POS N
and POS N
NK-cell POS N
responses POS N
and POS N
reduce POS N
the POS N
ability POS N
of POS N
NK POS N
to POS N
suppress POS N
T POS N
cells. POS N

Serum POS N
levels POS N
of POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
did POS N
not POS N
decrease POS N
significantly POS N
compared POS N
to POS N
baseline POS N
in POS N
patients POS N
given POS N
any POS N
dose POS N
of POS N
GS-9620. POS N

Both POS N
patients POS N
with POS N
objective POS N
response POS N
and POS N
disease POS N
stabilisation POS N
had POS N
clearly POS N
better POS N
symptom POS N
control POS N
than POS N
those POS N
with POS N
disease POS N
progression. POS N

Symptom POS N
control POS N
in POS N
both POS N
arms POS N
was POS N
similar POS N
for POS N
'disease-specific' POS N
symptoms POS N
such POS N
as POS N
cough, POS N
dyspnea, POS N
pain POS N
or POS N
haemoptysis. POS N

Both POS N
patients POS N
with POS N
objective POS N
response POS N
and POS N
disease POS N
stabilisation POS N
had POS N
clearly POS N
better POS N
symptom POS N
control POS N
than POS N
those POS N
with POS N
disease POS N
progression. POS N

Compared POS N
to POS N
PV, POS N
a POS N
significantly POS N
larger POS N
number POS N
of POS N
GEM-patients POS N
had POS N
better POS N
scores POS N
for POS N
'constitutional' POS N
items POS N
such POS N
as POS N
anorexia POS N
(P=0.007), POS N
ability POS N
to POS N
carry POS N
on POS N
with POS N
daily POS N
activities POS N
(P=0.04) POS N
and POS N
overall POS N
impression POS N
of POS N
quality-of-life POS N
(P=0.008). POS N

Both POS N
patients POS N
with POS N
objective POS N
response POS N
and POS N
disease POS N
stabilisation POS N
had POS N
clearly POS N
better POS N
symptom POS N
control POS N
than POS N
those POS N
with POS N
disease POS N
progression. POS N

Symptom POS N
control POS N
was POS N
very POS N
similar POS N
in POS N
younger POS N
(<65 POS N
years) POS N
versus POS N
older POS N
(>/=65 POS N
years) POS N
patients, POS N
and POS N
only POS N
slightly POS N
better POS N
in POS N
those POS N
with POS N
a POS N
Karnofsky POS N
PS POS N
>/=80% POS N
compared POS N
to POS N
those POS N
<80%. POS N

Both POS N
patients POS N
with POS N
objective POS N
response POS N
and POS N
disease POS N
stabilisation POS N
had POS N
clearly POS N
better POS N
symptom POS N
control POS N
than POS N
those POS N
with POS N
disease POS N
progression. POS N

Most POS N
of POS N
the POS N
symptom POS N
improvement POS N
occurred POS N
in POS N
the POS N
first POS N
3 POS N
cycles, POS N
with POS N
some POS N
further POS N
symptom POS N
improvement POS N
in POS N
the POS N
following POS N
cycles POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Both POS N
patients POS N
with POS N
objective POS N
response POS N
and POS N
disease POS N
stabilisation POS N
had POS N
clearly POS N
better POS N
symptom POS N
control POS N
than POS N
those POS N
with POS N
disease POS N
progression. POS N

Both POS N
GEM POS N
and POS N
PV POS N
yield POS N
a POS N
symptom POS N
control POS N
rate POS N
much POS N
higher POS N
than POS N
expected POS N
by POS N
the POS N
objective POS N
tumour POS N
RR. POS N

Both POS N
patients POS N
with POS N
objective POS N
response POS N
and POS N
disease POS N
stabilisation POS N
had POS N
clearly POS N
better POS N
symptom POS N
control POS N
than POS N
those POS N
with POS N
disease POS N
progression. POS N

GEM POS N
is POS N
equally POS N
effective POS N
in POS N
controlling POS N
'disease-specific' POS N
symptoms, POS N
but POS N
superior POS N
in POS N
controlling POS N
'constitutional' POS N
symptoms. POS N

Both POS N
patients POS N
with POS N
objective POS N
response POS N
and POS N
disease POS N
stabilisation POS N
had POS N
clearly POS N
better POS N
symptom POS N
control POS N
than POS N
those POS N
with POS N
disease POS N
progression. POS N

Most POS N
of POS N
the POS N
symptom POS N
control POS N
was POS N
achieved POS N
during POS N
the POS N
first POS N
3 POS N
cycles POS N
of POS N
treatment, POS N
with POS N
some POS N
further POS N
improvement POS N
thereafter POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Symptom POS N
control POS N
in POS N
both POS N
arms POS N
was POS N
similar POS N
for POS N
'disease-specific' POS N
symptoms POS N
such POS N
as POS N
cough, POS N
dyspnea, POS N
pain POS N
or POS N
haemoptysis. POS N

Both POS N
patients POS N
with POS N
objective POS N
response POS N
and POS N
disease POS N
stabilisation POS N
had POS N
clearly POS N
better POS N
symptom POS N
control POS N
than POS N
those POS N
with POS N
disease POS N
progression. POS N

Symptom POS N
control POS N
in POS N
both POS N
arms POS N
was POS N
similar POS N
for POS N
'disease-specific' POS N
symptoms POS N
such POS N
as POS N
cough, POS N
dyspnea, POS N
pain POS N
or POS N
haemoptysis. POS N

Compared POS N
to POS N
PV, POS N
a POS N
significantly POS N
larger POS N
number POS N
of POS N
GEM-patients POS N
had POS N
better POS N
scores POS N
for POS N
'constitutional' POS N
items POS N
such POS N
as POS N
anorexia POS N
(P=0.007), POS N
ability POS N
to POS N
carry POS N
on POS N
with POS N
daily POS N
activities POS N
(P=0.04) POS N
and POS N
overall POS N
impression POS N
of POS N
quality-of-life POS N
(P=0.008). POS N

Symptom POS N
control POS N
in POS N
both POS N
arms POS N
was POS N
similar POS N
for POS N
'disease-specific' POS N
symptoms POS N
such POS N
as POS N
cough, POS N
dyspnea, POS N
pain POS N
or POS N
haemoptysis. POS N

Symptom POS N
control POS N
was POS N
very POS N
similar POS N
in POS N
younger POS N
(<65 POS N
years) POS N
versus POS N
older POS N
(>/=65 POS N
years) POS N
patients, POS N
and POS N
only POS N
slightly POS N
better POS N
in POS N
those POS N
with POS N
a POS N
Karnofsky POS N
PS POS N
>/=80% POS N
compared POS N
to POS N
those POS N
<80%. POS N

Symptom POS N
control POS N
in POS N
both POS N
arms POS N
was POS N
similar POS N
for POS N
'disease-specific' POS N
symptoms POS N
such POS N
as POS N
cough, POS N
dyspnea, POS N
pain POS N
or POS N
haemoptysis. POS N

Most POS N
of POS N
the POS N
symptom POS N
improvement POS N
occurred POS N
in POS N
the POS N
first POS N
3 POS N
cycles, POS N
with POS N
some POS N
further POS N
symptom POS N
improvement POS N
in POS N
the POS N
following POS N
cycles POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Symptom POS N
control POS N
in POS N
both POS N
arms POS N
was POS N
similar POS N
for POS N
'disease-specific' POS N
symptoms POS N
such POS N
as POS N
cough, POS N
dyspnea, POS N
pain POS N
or POS N
haemoptysis. POS N

Both POS N
GEM POS N
and POS N
PV POS N
yield POS N
a POS N
symptom POS N
control POS N
rate POS N
much POS N
higher POS N
than POS N
expected POS N
by POS N
the POS N
objective POS N
tumour POS N
RR. POS N

Symptom POS N
control POS N
in POS N
both POS N
arms POS N
was POS N
similar POS N
for POS N
'disease-specific' POS N
symptoms POS N
such POS N
as POS N
cough, POS N
dyspnea, POS N
pain POS N
or POS N
haemoptysis. POS N

GEM POS N
is POS N
equally POS N
effective POS N
in POS N
controlling POS N
'disease-specific' POS N
symptoms, POS N
but POS N
superior POS N
in POS N
controlling POS N
'constitutional' POS N
symptoms. POS N

Symptom POS N
control POS N
in POS N
both POS N
arms POS N
was POS N
similar POS N
for POS N
'disease-specific' POS N
symptoms POS N
such POS N
as POS N
cough, POS N
dyspnea, POS N
pain POS N
or POS N
haemoptysis. POS N

Most POS N
of POS N
the POS N
symptom POS N
control POS N
was POS N
achieved POS N
during POS N
the POS N
first POS N
3 POS N
cycles POS N
of POS N
treatment, POS N
with POS N
some POS N
further POS N
improvement POS N
thereafter POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Compared POS N
to POS N
PV, POS N
a POS N
significantly POS N
larger POS N
number POS N
of POS N
GEM-patients POS N
had POS N
better POS N
scores POS N
for POS N
'constitutional' POS N
items POS N
such POS N
as POS N
anorexia POS N
(P=0.007), POS N
ability POS N
to POS N
carry POS N
on POS N
with POS N
daily POS N
activities POS N
(P=0.04) POS N
and POS N
overall POS N
impression POS N
of POS N
quality-of-life POS N
(P=0.008). POS N

Both POS N
patients POS N
with POS N
objective POS N
response POS N
and POS N
disease POS N
stabilisation POS N
had POS N
clearly POS N
better POS N
symptom POS N
control POS N
than POS N
those POS N
with POS N
disease POS N
progression. POS N

Compared POS N
to POS N
PV, POS N
a POS N
significantly POS N
larger POS N
number POS N
of POS N
GEM-patients POS N
had POS N
better POS N
scores POS N
for POS N
'constitutional' POS N
items POS N
such POS N
as POS N
anorexia POS N
(P=0.007), POS N
ability POS N
to POS N
carry POS N
on POS N
with POS N
daily POS N
activities POS N
(P=0.04) POS N
and POS N
overall POS N
impression POS N
of POS N
quality-of-life POS N
(P=0.008). POS N

Symptom POS N
control POS N
in POS N
both POS N
arms POS N
was POS N
similar POS N
for POS N
'disease-specific' POS N
symptoms POS N
such POS N
as POS N
cough, POS N
dyspnea, POS N
pain POS N
or POS N
haemoptysis. POS N

Compared POS N
to POS N
PV, POS N
a POS N
significantly POS N
larger POS N
number POS N
of POS N
GEM-patients POS N
had POS N
better POS N
scores POS N
for POS N
'constitutional' POS N
items POS N
such POS N
as POS N
anorexia POS N
(P=0.007), POS N
ability POS N
to POS N
carry POS N
on POS N
with POS N
daily POS N
activities POS N
(P=0.04) POS N
and POS N
overall POS N
impression POS N
of POS N
quality-of-life POS N
(P=0.008). POS N

Symptom POS N
control POS N
was POS N
very POS N
similar POS N
in POS N
younger POS N
(<65 POS N
years) POS N
versus POS N
older POS N
(>/=65 POS N
years) POS N
patients, POS N
and POS N
only POS N
slightly POS N
better POS N
in POS N
those POS N
with POS N
a POS N
Karnofsky POS N
PS POS N
>/=80% POS N
compared POS N
to POS N
those POS N
<80%. POS N

Compared POS N
to POS N
PV, POS N
a POS N
significantly POS N
larger POS N
number POS N
of POS N
GEM-patients POS N
had POS N
better POS N
scores POS N
for POS N
'constitutional' POS N
items POS N
such POS N
as POS N
anorexia POS N
(P=0.007), POS N
ability POS N
to POS N
carry POS N
on POS N
with POS N
daily POS N
activities POS N
(P=0.04) POS N
and POS N
overall POS N
impression POS N
of POS N
quality-of-life POS N
(P=0.008). POS N

Most POS N
of POS N
the POS N
symptom POS N
improvement POS N
occurred POS N
in POS N
the POS N
first POS N
3 POS N
cycles, POS N
with POS N
some POS N
further POS N
symptom POS N
improvement POS N
in POS N
the POS N
following POS N
cycles POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Compared POS N
to POS N
PV, POS N
a POS N
significantly POS N
larger POS N
number POS N
of POS N
GEM-patients POS N
had POS N
better POS N
scores POS N
for POS N
'constitutional' POS N
items POS N
such POS N
as POS N
anorexia POS N
(P=0.007), POS N
ability POS N
to POS N
carry POS N
on POS N
with POS N
daily POS N
activities POS N
(P=0.04) POS N
and POS N
overall POS N
impression POS N
of POS N
quality-of-life POS N
(P=0.008). POS N

Both POS N
GEM POS N
and POS N
PV POS N
yield POS N
a POS N
symptom POS N
control POS N
rate POS N
much POS N
higher POS N
than POS N
expected POS N
by POS N
the POS N
objective POS N
tumour POS N
RR. POS N

Compared POS N
to POS N
PV, POS N
a POS N
significantly POS N
larger POS N
number POS N
of POS N
GEM-patients POS N
had POS N
better POS N
scores POS N
for POS N
'constitutional' POS N
items POS N
such POS N
as POS N
anorexia POS N
(P=0.007), POS N
ability POS N
to POS N
carry POS N
on POS N
with POS N
daily POS N
activities POS N
(P=0.04) POS N
and POS N
overall POS N
impression POS N
of POS N
quality-of-life POS N
(P=0.008). POS N

GEM POS N
is POS N
equally POS N
effective POS N
in POS N
controlling POS N
'disease-specific' POS N
symptoms, POS N
but POS N
superior POS N
in POS N
controlling POS N
'constitutional' POS N
symptoms. POS N

Compared POS N
to POS N
PV, POS N
a POS N
significantly POS N
larger POS N
number POS N
of POS N
GEM-patients POS N
had POS N
better POS N
scores POS N
for POS N
'constitutional' POS N
items POS N
such POS N
as POS N
anorexia POS N
(P=0.007), POS N
ability POS N
to POS N
carry POS N
on POS N
with POS N
daily POS N
activities POS N
(P=0.04) POS N
and POS N
overall POS N
impression POS N
of POS N
quality-of-life POS N
(P=0.008). POS N

Most POS N
of POS N
the POS N
symptom POS N
control POS N
was POS N
achieved POS N
during POS N
the POS N
first POS N
3 POS N
cycles POS N
of POS N
treatment, POS N
with POS N
some POS N
further POS N
improvement POS N
thereafter POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Symptom POS N
control POS N
was POS N
very POS N
similar POS N
in POS N
younger POS N
(<65 POS N
years) POS N
versus POS N
older POS N
(>/=65 POS N
years) POS N
patients, POS N
and POS N
only POS N
slightly POS N
better POS N
in POS N
those POS N
with POS N
a POS N
Karnofsky POS N
PS POS N
>/=80% POS N
compared POS N
to POS N
those POS N
<80%. POS N

Both POS N
patients POS N
with POS N
objective POS N
response POS N
and POS N
disease POS N
stabilisation POS N
had POS N
clearly POS N
better POS N
symptom POS N
control POS N
than POS N
those POS N
with POS N
disease POS N
progression. POS N

Symptom POS N
control POS N
was POS N
very POS N
similar POS N
in POS N
younger POS N
(<65 POS N
years) POS N
versus POS N
older POS N
(>/=65 POS N
years) POS N
patients, POS N
and POS N
only POS N
slightly POS N
better POS N
in POS N
those POS N
with POS N
a POS N
Karnofsky POS N
PS POS N
>/=80% POS N
compared POS N
to POS N
those POS N
<80%. POS N

Symptom POS N
control POS N
in POS N
both POS N
arms POS N
was POS N
similar POS N
for POS N
'disease-specific' POS N
symptoms POS N
such POS N
as POS N
cough, POS N
dyspnea, POS N
pain POS N
or POS N
haemoptysis. POS N

Symptom POS N
control POS N
was POS N
very POS N
similar POS N
in POS N
younger POS N
(<65 POS N
years) POS N
versus POS N
older POS N
(>/=65 POS N
years) POS N
patients, POS N
and POS N
only POS N
slightly POS N
better POS N
in POS N
those POS N
with POS N
a POS N
Karnofsky POS N
PS POS N
>/=80% POS N
compared POS N
to POS N
those POS N
<80%. POS N

Compared POS N
to POS N
PV, POS N
a POS N
significantly POS N
larger POS N
number POS N
of POS N
GEM-patients POS N
had POS N
better POS N
scores POS N
for POS N
'constitutional' POS N
items POS N
such POS N
as POS N
anorexia POS N
(P=0.007), POS N
ability POS N
to POS N
carry POS N
on POS N
with POS N
daily POS N
activities POS N
(P=0.04) POS N
and POS N
overall POS N
impression POS N
of POS N
quality-of-life POS N
(P=0.008). POS N

Symptom POS N
control POS N
was POS N
very POS N
similar POS N
in POS N
younger POS N
(<65 POS N
years) POS N
versus POS N
older POS N
(>/=65 POS N
years) POS N
patients, POS N
and POS N
only POS N
slightly POS N
better POS N
in POS N
those POS N
with POS N
a POS N
Karnofsky POS N
PS POS N
>/=80% POS N
compared POS N
to POS N
those POS N
<80%. POS N

Most POS N
of POS N
the POS N
symptom POS N
improvement POS N
occurred POS N
in POS N
the POS N
first POS N
3 POS N
cycles, POS N
with POS N
some POS N
further POS N
symptom POS N
improvement POS N
in POS N
the POS N
following POS N
cycles POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Symptom POS N
control POS N
was POS N
very POS N
similar POS N
in POS N
younger POS N
(<65 POS N
years) POS N
versus POS N
older POS N
(>/=65 POS N
years) POS N
patients, POS N
and POS N
only POS N
slightly POS N
better POS N
in POS N
those POS N
with POS N
a POS N
Karnofsky POS N
PS POS N
>/=80% POS N
compared POS N
to POS N
those POS N
<80%. POS N

Both POS N
GEM POS N
and POS N
PV POS N
yield POS N
a POS N
symptom POS N
control POS N
rate POS N
much POS N
higher POS N
than POS N
expected POS N
by POS N
the POS N
objective POS N
tumour POS N
RR. POS N

Symptom POS N
control POS N
was POS N
very POS N
similar POS N
in POS N
younger POS N
(<65 POS N
years) POS N
versus POS N
older POS N
(>/=65 POS N
years) POS N
patients, POS N
and POS N
only POS N
slightly POS N
better POS N
in POS N
those POS N
with POS N
a POS N
Karnofsky POS N
PS POS N
>/=80% POS N
compared POS N
to POS N
those POS N
<80%. POS N

GEM POS N
is POS N
equally POS N
effective POS N
in POS N
controlling POS N
'disease-specific' POS N
symptoms, POS N
but POS N
superior POS N
in POS N
controlling POS N
'constitutional' POS N
symptoms. POS N

Symptom POS N
control POS N
was POS N
very POS N
similar POS N
in POS N
younger POS N
(<65 POS N
years) POS N
versus POS N
older POS N
(>/=65 POS N
years) POS N
patients, POS N
and POS N
only POS N
slightly POS N
better POS N
in POS N
those POS N
with POS N
a POS N
Karnofsky POS N
PS POS N
>/=80% POS N
compared POS N
to POS N
those POS N
<80%. POS N

Most POS N
of POS N
the POS N
symptom POS N
control POS N
was POS N
achieved POS N
during POS N
the POS N
first POS N
3 POS N
cycles POS N
of POS N
treatment, POS N
with POS N
some POS N
further POS N
improvement POS N
thereafter POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Most POS N
of POS N
the POS N
symptom POS N
improvement POS N
occurred POS N
in POS N
the POS N
first POS N
3 POS N
cycles, POS N
with POS N
some POS N
further POS N
symptom POS N
improvement POS N
in POS N
the POS N
following POS N
cycles POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Both POS N
patients POS N
with POS N
objective POS N
response POS N
and POS N
disease POS N
stabilisation POS N
had POS N
clearly POS N
better POS N
symptom POS N
control POS N
than POS N
those POS N
with POS N
disease POS N
progression. POS N

Most POS N
of POS N
the POS N
symptom POS N
improvement POS N
occurred POS N
in POS N
the POS N
first POS N
3 POS N
cycles, POS N
with POS N
some POS N
further POS N
symptom POS N
improvement POS N
in POS N
the POS N
following POS N
cycles POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Symptom POS N
control POS N
in POS N
both POS N
arms POS N
was POS N
similar POS N
for POS N
'disease-specific' POS N
symptoms POS N
such POS N
as POS N
cough, POS N
dyspnea, POS N
pain POS N
or POS N
haemoptysis. POS N

Most POS N
of POS N
the POS N
symptom POS N
improvement POS N
occurred POS N
in POS N
the POS N
first POS N
3 POS N
cycles, POS N
with POS N
some POS N
further POS N
symptom POS N
improvement POS N
in POS N
the POS N
following POS N
cycles POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Compared POS N
to POS N
PV, POS N
a POS N
significantly POS N
larger POS N
number POS N
of POS N
GEM-patients POS N
had POS N
better POS N
scores POS N
for POS N
'constitutional' POS N
items POS N
such POS N
as POS N
anorexia POS N
(P=0.007), POS N
ability POS N
to POS N
carry POS N
on POS N
with POS N
daily POS N
activities POS N
(P=0.04) POS N
and POS N
overall POS N
impression POS N
of POS N
quality-of-life POS N
(P=0.008). POS N

Most POS N
of POS N
the POS N
symptom POS N
improvement POS N
occurred POS N
in POS N
the POS N
first POS N
3 POS N
cycles, POS N
with POS N
some POS N
further POS N
symptom POS N
improvement POS N
in POS N
the POS N
following POS N
cycles POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Symptom POS N
control POS N
was POS N
very POS N
similar POS N
in POS N
younger POS N
(<65 POS N
years) POS N
versus POS N
older POS N
(>/=65 POS N
years) POS N
patients, POS N
and POS N
only POS N
slightly POS N
better POS N
in POS N
those POS N
with POS N
a POS N
Karnofsky POS N
PS POS N
>/=80% POS N
compared POS N
to POS N
those POS N
<80%. POS N

Most POS N
of POS N
the POS N
symptom POS N
improvement POS N
occurred POS N
in POS N
the POS N
first POS N
3 POS N
cycles, POS N
with POS N
some POS N
further POS N
symptom POS N
improvement POS N
in POS N
the POS N
following POS N
cycles POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Both POS N
GEM POS N
and POS N
PV POS N
yield POS N
a POS N
symptom POS N
control POS N
rate POS N
much POS N
higher POS N
than POS N
expected POS N
by POS N
the POS N
objective POS N
tumour POS N
RR. POS N

Most POS N
of POS N
the POS N
symptom POS N
improvement POS N
occurred POS N
in POS N
the POS N
first POS N
3 POS N
cycles, POS N
with POS N
some POS N
further POS N
symptom POS N
improvement POS N
in POS N
the POS N
following POS N
cycles POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

GEM POS N
is POS N
equally POS N
effective POS N
in POS N
controlling POS N
'disease-specific' POS N
symptoms, POS N
but POS N
superior POS N
in POS N
controlling POS N
'constitutional' POS N
symptoms. POS N

Most POS N
of POS N
the POS N
symptom POS N
improvement POS N
occurred POS N
in POS N
the POS N
first POS N
3 POS N
cycles, POS N
with POS N
some POS N
further POS N
symptom POS N
improvement POS N
in POS N
the POS N
following POS N
cycles POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Most POS N
of POS N
the POS N
symptom POS N
control POS N
was POS N
achieved POS N
during POS N
the POS N
first POS N
3 POS N
cycles POS N
of POS N
treatment, POS N
with POS N
some POS N
further POS N
improvement POS N
thereafter POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Both POS N
GEM POS N
and POS N
PV POS N
yield POS N
a POS N
symptom POS N
control POS N
rate POS N
much POS N
higher POS N
than POS N
expected POS N
by POS N
the POS N
objective POS N
tumour POS N
RR. POS N

Both POS N
patients POS N
with POS N
objective POS N
response POS N
and POS N
disease POS N
stabilisation POS N
had POS N
clearly POS N
better POS N
symptom POS N
control POS N
than POS N
those POS N
with POS N
disease POS N
progression. POS N

Both POS N
GEM POS N
and POS N
PV POS N
yield POS N
a POS N
symptom POS N
control POS N
rate POS N
much POS N
higher POS N
than POS N
expected POS N
by POS N
the POS N
objective POS N
tumour POS N
RR. POS N

Symptom POS N
control POS N
in POS N
both POS N
arms POS N
was POS N
similar POS N
for POS N
'disease-specific' POS N
symptoms POS N
such POS N
as POS N
cough, POS N
dyspnea, POS N
pain POS N
or POS N
haemoptysis. POS N

Both POS N
GEM POS N
and POS N
PV POS N
yield POS N
a POS N
symptom POS N
control POS N
rate POS N
much POS N
higher POS N
than POS N
expected POS N
by POS N
the POS N
objective POS N
tumour POS N
RR. POS N

Compared POS N
to POS N
PV, POS N
a POS N
significantly POS N
larger POS N
number POS N
of POS N
GEM-patients POS N
had POS N
better POS N
scores POS N
for POS N
'constitutional' POS N
items POS N
such POS N
as POS N
anorexia POS N
(P=0.007), POS N
ability POS N
to POS N
carry POS N
on POS N
with POS N
daily POS N
activities POS N
(P=0.04) POS N
and POS N
overall POS N
impression POS N
of POS N
quality-of-life POS N
(P=0.008). POS N

Both POS N
GEM POS N
and POS N
PV POS N
yield POS N
a POS N
symptom POS N
control POS N
rate POS N
much POS N
higher POS N
than POS N
expected POS N
by POS N
the POS N
objective POS N
tumour POS N
RR. POS N

Symptom POS N
control POS N
was POS N
very POS N
similar POS N
in POS N
younger POS N
(<65 POS N
years) POS N
versus POS N
older POS N
(>/=65 POS N
years) POS N
patients, POS N
and POS N
only POS N
slightly POS N
better POS N
in POS N
those POS N
with POS N
a POS N
Karnofsky POS N
PS POS N
>/=80% POS N
compared POS N
to POS N
those POS N
<80%. POS N

Both POS N
GEM POS N
and POS N
PV POS N
yield POS N
a POS N
symptom POS N
control POS N
rate POS N
much POS N
higher POS N
than POS N
expected POS N
by POS N
the POS N
objective POS N
tumour POS N
RR. POS N

Most POS N
of POS N
the POS N
symptom POS N
improvement POS N
occurred POS N
in POS N
the POS N
first POS N
3 POS N
cycles, POS N
with POS N
some POS N
further POS N
symptom POS N
improvement POS N
in POS N
the POS N
following POS N
cycles POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Both POS N
GEM POS N
and POS N
PV POS N
yield POS N
a POS N
symptom POS N
control POS N
rate POS N
much POS N
higher POS N
than POS N
expected POS N
by POS N
the POS N
objective POS N
tumour POS N
RR. POS N

GEM POS N
is POS N
equally POS N
effective POS N
in POS N
controlling POS N
'disease-specific' POS N
symptoms, POS N
but POS N
superior POS N
in POS N
controlling POS N
'constitutional' POS N
symptoms. POS N

Both POS N
GEM POS N
and POS N
PV POS N
yield POS N
a POS N
symptom POS N
control POS N
rate POS N
much POS N
higher POS N
than POS N
expected POS N
by POS N
the POS N
objective POS N
tumour POS N
RR. POS N

Most POS N
of POS N
the POS N
symptom POS N
control POS N
was POS N
achieved POS N
during POS N
the POS N
first POS N
3 POS N
cycles POS N
of POS N
treatment, POS N
with POS N
some POS N
further POS N
improvement POS N
thereafter POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

GEM POS N
is POS N
equally POS N
effective POS N
in POS N
controlling POS N
'disease-specific' POS N
symptoms, POS N
but POS N
superior POS N
in POS N
controlling POS N
'constitutional' POS N
symptoms. POS N

Both POS N
patients POS N
with POS N
objective POS N
response POS N
and POS N
disease POS N
stabilisation POS N
had POS N
clearly POS N
better POS N
symptom POS N
control POS N
than POS N
those POS N
with POS N
disease POS N
progression. POS N

GEM POS N
is POS N
equally POS N
effective POS N
in POS N
controlling POS N
'disease-specific' POS N
symptoms, POS N
but POS N
superior POS N
in POS N
controlling POS N
'constitutional' POS N
symptoms. POS N

Symptom POS N
control POS N
in POS N
both POS N
arms POS N
was POS N
similar POS N
for POS N
'disease-specific' POS N
symptoms POS N
such POS N
as POS N
cough, POS N
dyspnea, POS N
pain POS N
or POS N
haemoptysis. POS N

GEM POS N
is POS N
equally POS N
effective POS N
in POS N
controlling POS N
'disease-specific' POS N
symptoms, POS N
but POS N
superior POS N
in POS N
controlling POS N
'constitutional' POS N
symptoms. POS N

Compared POS N
to POS N
PV, POS N
a POS N
significantly POS N
larger POS N
number POS N
of POS N
GEM-patients POS N
had POS N
better POS N
scores POS N
for POS N
'constitutional' POS N
items POS N
such POS N
as POS N
anorexia POS N
(P=0.007), POS N
ability POS N
to POS N
carry POS N
on POS N
with POS N
daily POS N
activities POS N
(P=0.04) POS N
and POS N
overall POS N
impression POS N
of POS N
quality-of-life POS N
(P=0.008). POS N

GEM POS N
is POS N
equally POS N
effective POS N
in POS N
controlling POS N
'disease-specific' POS N
symptoms, POS N
but POS N
superior POS N
in POS N
controlling POS N
'constitutional' POS N
symptoms. POS N

Symptom POS N
control POS N
was POS N
very POS N
similar POS N
in POS N
younger POS N
(<65 POS N
years) POS N
versus POS N
older POS N
(>/=65 POS N
years) POS N
patients, POS N
and POS N
only POS N
slightly POS N
better POS N
in POS N
those POS N
with POS N
a POS N
Karnofsky POS N
PS POS N
>/=80% POS N
compared POS N
to POS N
those POS N
<80%. POS N

GEM POS N
is POS N
equally POS N
effective POS N
in POS N
controlling POS N
'disease-specific' POS N
symptoms, POS N
but POS N
superior POS N
in POS N
controlling POS N
'constitutional' POS N
symptoms. POS N

Most POS N
of POS N
the POS N
symptom POS N
improvement POS N
occurred POS N
in POS N
the POS N
first POS N
3 POS N
cycles, POS N
with POS N
some POS N
further POS N
symptom POS N
improvement POS N
in POS N
the POS N
following POS N
cycles POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

GEM POS N
is POS N
equally POS N
effective POS N
in POS N
controlling POS N
'disease-specific' POS N
symptoms, POS N
but POS N
superior POS N
in POS N
controlling POS N
'constitutional' POS N
symptoms. POS N

Both POS N
GEM POS N
and POS N
PV POS N
yield POS N
a POS N
symptom POS N
control POS N
rate POS N
much POS N
higher POS N
than POS N
expected POS N
by POS N
the POS N
objective POS N
tumour POS N
RR. POS N

GEM POS N
is POS N
equally POS N
effective POS N
in POS N
controlling POS N
'disease-specific' POS N
symptoms, POS N
but POS N
superior POS N
in POS N
controlling POS N
'constitutional' POS N
symptoms. POS N

Most POS N
of POS N
the POS N
symptom POS N
control POS N
was POS N
achieved POS N
during POS N
the POS N
first POS N
3 POS N
cycles POS N
of POS N
treatment, POS N
with POS N
some POS N
further POS N
improvement POS N
thereafter POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Most POS N
of POS N
the POS N
symptom POS N
control POS N
was POS N
achieved POS N
during POS N
the POS N
first POS N
3 POS N
cycles POS N
of POS N
treatment, POS N
with POS N
some POS N
further POS N
improvement POS N
thereafter POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Both POS N
patients POS N
with POS N
objective POS N
response POS N
and POS N
disease POS N
stabilisation POS N
had POS N
clearly POS N
better POS N
symptom POS N
control POS N
than POS N
those POS N
with POS N
disease POS N
progression. POS N

Most POS N
of POS N
the POS N
symptom POS N
control POS N
was POS N
achieved POS N
during POS N
the POS N
first POS N
3 POS N
cycles POS N
of POS N
treatment, POS N
with POS N
some POS N
further POS N
improvement POS N
thereafter POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Symptom POS N
control POS N
in POS N
both POS N
arms POS N
was POS N
similar POS N
for POS N
'disease-specific' POS N
symptoms POS N
such POS N
as POS N
cough, POS N
dyspnea, POS N
pain POS N
or POS N
haemoptysis. POS N

Most POS N
of POS N
the POS N
symptom POS N
control POS N
was POS N
achieved POS N
during POS N
the POS N
first POS N
3 POS N
cycles POS N
of POS N
treatment, POS N
with POS N
some POS N
further POS N
improvement POS N
thereafter POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Compared POS N
to POS N
PV, POS N
a POS N
significantly POS N
larger POS N
number POS N
of POS N
GEM-patients POS N
had POS N
better POS N
scores POS N
for POS N
'constitutional' POS N
items POS N
such POS N
as POS N
anorexia POS N
(P=0.007), POS N
ability POS N
to POS N
carry POS N
on POS N
with POS N
daily POS N
activities POS N
(P=0.04) POS N
and POS N
overall POS N
impression POS N
of POS N
quality-of-life POS N
(P=0.008). POS N

Most POS N
of POS N
the POS N
symptom POS N
control POS N
was POS N
achieved POS N
during POS N
the POS N
first POS N
3 POS N
cycles POS N
of POS N
treatment, POS N
with POS N
some POS N
further POS N
improvement POS N
thereafter POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Symptom POS N
control POS N
was POS N
very POS N
similar POS N
in POS N
younger POS N
(<65 POS N
years) POS N
versus POS N
older POS N
(>/=65 POS N
years) POS N
patients, POS N
and POS N
only POS N
slightly POS N
better POS N
in POS N
those POS N
with POS N
a POS N
Karnofsky POS N
PS POS N
>/=80% POS N
compared POS N
to POS N
those POS N
<80%. POS N

Most POS N
of POS N
the POS N
symptom POS N
control POS N
was POS N
achieved POS N
during POS N
the POS N
first POS N
3 POS N
cycles POS N
of POS N
treatment, POS N
with POS N
some POS N
further POS N
improvement POS N
thereafter POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Most POS N
of POS N
the POS N
symptom POS N
improvement POS N
occurred POS N
in POS N
the POS N
first POS N
3 POS N
cycles, POS N
with POS N
some POS N
further POS N
symptom POS N
improvement POS N
in POS N
the POS N
following POS N
cycles POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Most POS N
of POS N
the POS N
symptom POS N
control POS N
was POS N
achieved POS N
during POS N
the POS N
first POS N
3 POS N
cycles POS N
of POS N
treatment, POS N
with POS N
some POS N
further POS N
improvement POS N
thereafter POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

Both POS N
GEM POS N
and POS N
PV POS N
yield POS N
a POS N
symptom POS N
control POS N
rate POS N
much POS N
higher POS N
than POS N
expected POS N
by POS N
the POS N
objective POS N
tumour POS N
RR. POS N

Most POS N
of POS N
the POS N
symptom POS N
control POS N
was POS N
achieved POS N
during POS N
the POS N
first POS N
3 POS N
cycles POS N
of POS N
treatment, POS N
with POS N
some POS N
further POS N
improvement POS N
thereafter POS N
in POS N
the POS N
GEM-arm POS N
only. POS N

GEM POS N
is POS N
equally POS N
effective POS N
in POS N
controlling POS N
'disease-specific' POS N
symptoms, POS N
but POS N
superior POS N
in POS N
controlling POS N
'constitutional' POS N
symptoms. POS N

For POS N
the POS N
IMCT POS N
group POS N
and POS N
CPT POS N
groups, POS N
respectively, POS N
the POS N
absolute POS N
success POS N
rates POS N
were POS N
80% POS N
(16/20) POS N
and POS N
60% POS N
(12/20) POS N
(P POS N
< POS N
.001) POS N
and POS N
qualified POS N
success POS N
rates POS N
were POS N
90% POS N
(18/20) POS N
and POS N
70% POS N
(14/20) POS N
(P POS N
< POS N
.001). POS N

Both POS N
procedures POS N
produced POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
IOP, POS N

For POS N
the POS N
IMCT POS N
group POS N
and POS N
CPT POS N
groups, POS N
respectively, POS N
the POS N
absolute POS N
success POS N
rates POS N
were POS N
80% POS N
(16/20) POS N
and POS N
60% POS N
(12/20) POS N
(P POS N
< POS N
.001) POS N
and POS N
qualified POS N
success POS N
rates POS N
were POS N
90% POS N
(18/20) POS N
and POS N
70% POS N
(14/20) POS N
(P POS N
< POS N
.001). POS N

eyes POS N
undergoing POS N
IMCT POS N
achieved POS N
a POS N
lower POS N
IOP POS N
than POS N
CPT POS N
group POS N
eyes POS N
at POS N
12 POS N
months POS N
follow-up POS N
(9.5 POS N
± POS N
2.4 POS N
mm POS N
Hg POS N
and POS N
11.7 POS N
± POS N
2.1 POS N
mm POS N
Hg, POS N
respectively, POS N
P POS N
< POS N
.001). POS N

For POS N
the POS N
IMCT POS N
group POS N
and POS N
CPT POS N
groups, POS N
respectively, POS N
the POS N
absolute POS N
success POS N
rates POS N
were POS N
80% POS N
(16/20) POS N
and POS N
60% POS N
(12/20) POS N
(P POS N
< POS N
.001) POS N
and POS N
qualified POS N
success POS N
rates POS N
were POS N
90% POS N
(18/20) POS N
and POS N
70% POS N
(14/20) POS N
(P POS N
< POS N
.001). POS N

In POS N
primary POS N
congential POS N
glaucoma, POS N
illuminated POS N
microcatheter-assisted POS N
360-degree POS N
circumferential POS N
trabeculotomy POS N
performed POS N
better POS N
than POS N
conventional POS N
partial POS N
trabeculotomy POS N
at POS N
1 POS N
year POS N
follow-up POS N
and POS N
resulted POS N
in POS N
significantly POS N
lower POS N
IOP POS N
measurements. POS N

For POS N
the POS N
IMCT POS N
group POS N
and POS N
CPT POS N
groups, POS N
respectively, POS N
the POS N
absolute POS N
success POS N
rates POS N
were POS N
80% POS N
(16/20) POS N
and POS N
60% POS N
(12/20) POS N
(P POS N
< POS N
.001) POS N
and POS N
qualified POS N
success POS N
rates POS N
were POS N
90% POS N
(18/20) POS N
and POS N
70% POS N
(14/20) POS N
(P POS N
< POS N
.001). POS N

In POS N
the POS N
IMCT POS N
group, POS N
360-degree POS N
cannulation POS N
was POS N
achieved POS N
in POS N
80% POS N
(16/20) POS N
of POS N
eyes. POS N

Both POS N
procedures POS N
produced POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
IOP, POS N

For POS N
the POS N
IMCT POS N
group POS N
and POS N
CPT POS N
groups, POS N
respectively, POS N
the POS N
absolute POS N
success POS N
rates POS N
were POS N
80% POS N
(16/20) POS N
and POS N
60% POS N
(12/20) POS N
(P POS N
< POS N
.001) POS N
and POS N
qualified POS N
success POS N
rates POS N
were POS N
90% POS N
(18/20) POS N
and POS N
70% POS N
(14/20) POS N
(P POS N
< POS N
.001). POS N

Both POS N
procedures POS N
produced POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
IOP, POS N

eyes POS N
undergoing POS N
IMCT POS N
achieved POS N
a POS N
lower POS N
IOP POS N
than POS N
CPT POS N
group POS N
eyes POS N
at POS N
12 POS N
months POS N
follow-up POS N
(9.5 POS N
± POS N
2.4 POS N
mm POS N
Hg POS N
and POS N
11.7 POS N
± POS N
2.1 POS N
mm POS N
Hg, POS N
respectively, POS N
P POS N
< POS N
.001). POS N

Both POS N
procedures POS N
produced POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
IOP, POS N

In POS N
primary POS N
congential POS N
glaucoma, POS N
illuminated POS N
microcatheter-assisted POS N
360-degree POS N
circumferential POS N
trabeculotomy POS N
performed POS N
better POS N
than POS N
conventional POS N
partial POS N
trabeculotomy POS N
at POS N
1 POS N
year POS N
follow-up POS N
and POS N
resulted POS N
in POS N
significantly POS N
lower POS N
IOP POS N
measurements. POS N

Both POS N
procedures POS N
produced POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
IOP, POS N

In POS N
the POS N
IMCT POS N
group, POS N
360-degree POS N
cannulation POS N
was POS N
achieved POS N
in POS N
80% POS N
(16/20) POS N
of POS N
eyes. POS N

eyes POS N
undergoing POS N
IMCT POS N
achieved POS N
a POS N
lower POS N
IOP POS N
than POS N
CPT POS N
group POS N
eyes POS N
at POS N
12 POS N
months POS N
follow-up POS N
(9.5 POS N
± POS N
2.4 POS N
mm POS N
Hg POS N
and POS N
11.7 POS N
± POS N
2.1 POS N
mm POS N
Hg, POS N
respectively, POS N
P POS N
< POS N
.001). POS N

For POS N
the POS N
IMCT POS N
group POS N
and POS N
CPT POS N
groups, POS N
respectively, POS N
the POS N
absolute POS N
success POS N
rates POS N
were POS N
80% POS N
(16/20) POS N
and POS N
60% POS N
(12/20) POS N
(P POS N
< POS N
.001) POS N
and POS N
qualified POS N
success POS N
rates POS N
were POS N
90% POS N
(18/20) POS N
and POS N
70% POS N
(14/20) POS N
(P POS N
< POS N
.001). POS N

eyes POS N
undergoing POS N
IMCT POS N
achieved POS N
a POS N
lower POS N
IOP POS N
than POS N
CPT POS N
group POS N
eyes POS N
at POS N
12 POS N
months POS N
follow-up POS N
(9.5 POS N
± POS N
2.4 POS N
mm POS N
Hg POS N
and POS N
11.7 POS N
± POS N
2.1 POS N
mm POS N
Hg, POS N
respectively, POS N
P POS N
< POS N
.001). POS N

Both POS N
procedures POS N
produced POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
IOP, POS N

eyes POS N
undergoing POS N
IMCT POS N
achieved POS N
a POS N
lower POS N
IOP POS N
than POS N
CPT POS N
group POS N
eyes POS N
at POS N
12 POS N
months POS N
follow-up POS N
(9.5 POS N
± POS N
2.4 POS N
mm POS N
Hg POS N
and POS N
11.7 POS N
± POS N
2.1 POS N
mm POS N
Hg, POS N
respectively, POS N
P POS N
< POS N
.001). POS N

In POS N
primary POS N
congential POS N
glaucoma, POS N
illuminated POS N
microcatheter-assisted POS N
360-degree POS N
circumferential POS N
trabeculotomy POS N
performed POS N
better POS N
than POS N
conventional POS N
partial POS N
trabeculotomy POS N
at POS N
1 POS N
year POS N
follow-up POS N
and POS N
resulted POS N
in POS N
significantly POS N
lower POS N
IOP POS N
measurements. POS N

eyes POS N
undergoing POS N
IMCT POS N
achieved POS N
a POS N
lower POS N
IOP POS N
than POS N
CPT POS N
group POS N
eyes POS N
at POS N
12 POS N
months POS N
follow-up POS N
(9.5 POS N
± POS N
2.4 POS N
mm POS N
Hg POS N
and POS N
11.7 POS N
± POS N
2.1 POS N
mm POS N
Hg, POS N
respectively, POS N
P POS N
< POS N
.001). POS N

In POS N
the POS N
IMCT POS N
group, POS N
360-degree POS N
cannulation POS N
was POS N
achieved POS N
in POS N
80% POS N
(16/20) POS N
of POS N
eyes. POS N

In POS N
primary POS N
congential POS N
glaucoma, POS N
illuminated POS N
microcatheter-assisted POS N
360-degree POS N
circumferential POS N
trabeculotomy POS N
performed POS N
better POS N
than POS N
conventional POS N
partial POS N
trabeculotomy POS N
at POS N
1 POS N
year POS N
follow-up POS N
and POS N
resulted POS N
in POS N
significantly POS N
lower POS N
IOP POS N
measurements. POS N

For POS N
the POS N
IMCT POS N
group POS N
and POS N
CPT POS N
groups, POS N
respectively, POS N
the POS N
absolute POS N
success POS N
rates POS N
were POS N
80% POS N
(16/20) POS N
and POS N
60% POS N
(12/20) POS N
(P POS N
< POS N
.001) POS N
and POS N
qualified POS N
success POS N
rates POS N
were POS N
90% POS N
(18/20) POS N
and POS N
70% POS N
(14/20) POS N
(P POS N
< POS N
.001). POS N

In POS N
primary POS N
congential POS N
glaucoma, POS N
illuminated POS N
microcatheter-assisted POS N
360-degree POS N
circumferential POS N
trabeculotomy POS N
performed POS N
better POS N
than POS N
conventional POS N
partial POS N
trabeculotomy POS N
at POS N
1 POS N
year POS N
follow-up POS N
and POS N
resulted POS N
in POS N
significantly POS N
lower POS N
IOP POS N
measurements. POS N

Both POS N
procedures POS N
produced POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
IOP, POS N

In POS N
primary POS N
congential POS N
glaucoma, POS N
illuminated POS N
microcatheter-assisted POS N
360-degree POS N
circumferential POS N
trabeculotomy POS N
performed POS N
better POS N
than POS N
conventional POS N
partial POS N
trabeculotomy POS N
at POS N
1 POS N
year POS N
follow-up POS N
and POS N
resulted POS N
in POS N
significantly POS N
lower POS N
IOP POS N
measurements. POS N

eyes POS N
undergoing POS N
IMCT POS N
achieved POS N
a POS N
lower POS N
IOP POS N
than POS N
CPT POS N
group POS N
eyes POS N
at POS N
12 POS N
months POS N
follow-up POS N
(9.5 POS N
± POS N
2.4 POS N
mm POS N
Hg POS N
and POS N
11.7 POS N
± POS N
2.1 POS N
mm POS N
Hg, POS N
respectively, POS N
P POS N
< POS N
.001). POS N

In POS N
primary POS N
congential POS N
glaucoma, POS N
illuminated POS N
microcatheter-assisted POS N
360-degree POS N
circumferential POS N
trabeculotomy POS N
performed POS N
better POS N
than POS N
conventional POS N
partial POS N
trabeculotomy POS N
at POS N
1 POS N
year POS N
follow-up POS N
and POS N
resulted POS N
in POS N
significantly POS N
lower POS N
IOP POS N
measurements. POS N

In POS N
the POS N
IMCT POS N
group, POS N
360-degree POS N
cannulation POS N
was POS N
achieved POS N
in POS N
80% POS N
(16/20) POS N
of POS N
eyes. POS N

In POS N
the POS N
IMCT POS N
group, POS N
360-degree POS N
cannulation POS N
was POS N
achieved POS N
in POS N
80% POS N
(16/20) POS N
of POS N
eyes. POS N

For POS N
the POS N
IMCT POS N
group POS N
and POS N
CPT POS N
groups, POS N
respectively, POS N
the POS N
absolute POS N
success POS N
rates POS N
were POS N
80% POS N
(16/20) POS N
and POS N
60% POS N
(12/20) POS N
(P POS N
< POS N
.001) POS N
and POS N
qualified POS N
success POS N
rates POS N
were POS N
90% POS N
(18/20) POS N
and POS N
70% POS N
(14/20) POS N
(P POS N
< POS N
.001). POS N

In POS N
the POS N
IMCT POS N
group, POS N
360-degree POS N
cannulation POS N
was POS N
achieved POS N
in POS N
80% POS N
(16/20) POS N
of POS N
eyes. POS N

Both POS N
procedures POS N
produced POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
IOP, POS N

In POS N
the POS N
IMCT POS N
group, POS N
360-degree POS N
cannulation POS N
was POS N
achieved POS N
in POS N
80% POS N
(16/20) POS N
of POS N
eyes. POS N

eyes POS N
undergoing POS N
IMCT POS N
achieved POS N
a POS N
lower POS N
IOP POS N
than POS N
CPT POS N
group POS N
eyes POS N
at POS N
12 POS N
months POS N
follow-up POS N
(9.5 POS N
± POS N
2.4 POS N
mm POS N
Hg POS N
and POS N
11.7 POS N
± POS N
2.1 POS N
mm POS N
Hg, POS N
respectively, POS N
P POS N
< POS N
.001). POS N

In POS N
the POS N
IMCT POS N
group, POS N
360-degree POS N
cannulation POS N
was POS N
achieved POS N
in POS N
80% POS N
(16/20) POS N
of POS N
eyes. POS N

In POS N
primary POS N
congential POS N
glaucoma, POS N
illuminated POS N
microcatheter-assisted POS N
360-degree POS N
circumferential POS N
trabeculotomy POS N
performed POS N
better POS N
than POS N
conventional POS N
partial POS N
trabeculotomy POS N
at POS N
1 POS N
year POS N
follow-up POS N
and POS N
resulted POS N
in POS N
significantly POS N
lower POS N
IOP POS N
measurements. POS N

Tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
without POS N
TDF POS N
resistance POS N
development POS N
in POS N
CHB POS N
patients POS N
with POS N
LAM-R, POS N
for POS N
up POS N
to POS N
240weeks. POS N

At POS N
week POS N
240, POS N
83.0% POS N
of POS N
patients POS N
in POS N
the POS N
TDF POS N
arm, POS N
and POS N
82.7% POS N
of POS N
patients POS N
in POS N
the POS N
FTC/TDF POS N
treatment POS N
arm POS N
had POS N
HBV POS N
DNA<69IU/ml POS N
(p=0.96). POS N

Tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
without POS N
TDF POS N
resistance POS N
development POS N
in POS N
CHB POS N
patients POS N
with POS N
LAM-R, POS N
for POS N
up POS N
to POS N
240weeks. POS N

Rates POS N
of POS N
normal POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
and POS N
normalised POS N
ALT POS N
were POS N
similar POS N
between POS N
groups POS N
(p=0.41 POS N
and POS N
p=0.97 POS N
respectively). POS N

Tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
without POS N
TDF POS N
resistance POS N
development POS N
in POS N
CHB POS N
patients POS N
with POS N
LAM-R, POS N
for POS N
up POS N
to POS N
240weeks. POS N

Hepatitis POS N
B POS N
e POS N
antigen POS N
loss POS N
and POS N
seroconversion POS N
at POS N
week POS N
240 POS N
were POS N
similar POS N
between POS N
groups, POS N
(p=0.41 POS N
and POS N
p=0.67 POS N
respectively). POS N

Tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
without POS N
TDF POS N
resistance POS N
development POS N
in POS N
CHB POS N
patients POS N
with POS N
LAM-R, POS N
for POS N
up POS N
to POS N
240weeks. POS N

Overall, POS N
six POS N
patients POS N
achieved POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
and POS N
one POS N
patient POS N
(FTC/TDF POS N
arm) POS N
had POS N
HBsAg POS N
seroconversion POS N
by POS N
week POS N
240. POS N

Tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
without POS N
TDF POS N
resistance POS N
development POS N
in POS N
CHB POS N
patients POS N
with POS N
LAM-R, POS N
for POS N
up POS N
to POS N
240weeks. POS N

No POS N
TDF POS N
resistance POS N
was POS N
observed POS N
up POS N
to POS N
week POS N
240. POS N

Tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
without POS N
TDF POS N
resistance POS N
development POS N
in POS N
CHB POS N
patients POS N
with POS N
LAM-R, POS N
for POS N
up POS N
to POS N
240weeks. POS N

Treatment POS N
was POS N
generally POS N
well POS N
tolerated, POS N
and POS N
renal POS N
events POS N
were POS N
mild POS N
and POS N
infrequent POS N
(∼8.6%). POS N

Tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
without POS N
TDF POS N
resistance POS N
development POS N
in POS N
CHB POS N
patients POS N
with POS N
LAM-R, POS N
for POS N
up POS N
to POS N
240weeks. POS N

The POS N
mean POS N
change POS N
in POS N
bone POS N
mineral POS N
density POS N
at POS N
week POS N
240 POS N
was POS N
-0.98% POS N
and POS N
-2.54% POS N
at POS N
the POS N
spine POS N
and POS N
hip, POS N
respectively. POS N

Tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
without POS N
TDF POS N
resistance POS N
development POS N
in POS N
CHB POS N
patients POS N
with POS N
LAM-R, POS N
for POS N
up POS N
to POS N
240weeks. POS N

TDF POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
in POS N
LAM-R POS N
CHB POS N
patients POS N
for POS N
up POS N
to POS N
240 POS N
weeks. POS N

At POS N
week POS N
240, POS N
83.0% POS N
of POS N
patients POS N
in POS N
the POS N
TDF POS N
arm, POS N
and POS N
82.7% POS N
of POS N
patients POS N
in POS N
the POS N
FTC/TDF POS N
treatment POS N
arm POS N
had POS N
HBV POS N
DNA<69IU/ml POS N
(p=0.96). POS N

Tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
without POS N
TDF POS N
resistance POS N
development POS N
in POS N
CHB POS N
patients POS N
with POS N
LAM-R, POS N
for POS N
up POS N
to POS N
240weeks. POS N

At POS N
week POS N
240, POS N
83.0% POS N
of POS N
patients POS N
in POS N
the POS N
TDF POS N
arm, POS N
and POS N
82.7% POS N
of POS N
patients POS N
in POS N
the POS N
FTC/TDF POS N
treatment POS N
arm POS N
had POS N
HBV POS N
DNA<69IU/ml POS N
(p=0.96). POS N

Rates POS N
of POS N
normal POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
and POS N
normalised POS N
ALT POS N
were POS N
similar POS N
between POS N
groups POS N
(p=0.41 POS N
and POS N
p=0.97 POS N
respectively). POS N

At POS N
week POS N
240, POS N
83.0% POS N
of POS N
patients POS N
in POS N
the POS N
TDF POS N
arm, POS N
and POS N
82.7% POS N
of POS N
patients POS N
in POS N
the POS N
FTC/TDF POS N
treatment POS N
arm POS N
had POS N
HBV POS N
DNA<69IU/ml POS N
(p=0.96). POS N

Hepatitis POS N
B POS N
e POS N
antigen POS N
loss POS N
and POS N
seroconversion POS N
at POS N
week POS N
240 POS N
were POS N
similar POS N
between POS N
groups, POS N
(p=0.41 POS N
and POS N
p=0.67 POS N
respectively). POS N

At POS N
week POS N
240, POS N
83.0% POS N
of POS N
patients POS N
in POS N
the POS N
TDF POS N
arm, POS N
and POS N
82.7% POS N
of POS N
patients POS N
in POS N
the POS N
FTC/TDF POS N
treatment POS N
arm POS N
had POS N
HBV POS N
DNA<69IU/ml POS N
(p=0.96). POS N

Overall, POS N
six POS N
patients POS N
achieved POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
and POS N
one POS N
patient POS N
(FTC/TDF POS N
arm) POS N
had POS N
HBsAg POS N
seroconversion POS N
by POS N
week POS N
240. POS N

At POS N
week POS N
240, POS N
83.0% POS N
of POS N
patients POS N
in POS N
the POS N
TDF POS N
arm, POS N
and POS N
82.7% POS N
of POS N
patients POS N
in POS N
the POS N
FTC/TDF POS N
treatment POS N
arm POS N
had POS N
HBV POS N
DNA<69IU/ml POS N
(p=0.96). POS N

No POS N
TDF POS N
resistance POS N
was POS N
observed POS N
up POS N
to POS N
week POS N
240. POS N

At POS N
week POS N
240, POS N
83.0% POS N
of POS N
patients POS N
in POS N
the POS N
TDF POS N
arm, POS N
and POS N
82.7% POS N
of POS N
patients POS N
in POS N
the POS N
FTC/TDF POS N
treatment POS N
arm POS N
had POS N
HBV POS N
DNA<69IU/ml POS N
(p=0.96). POS N

Treatment POS N
was POS N
generally POS N
well POS N
tolerated, POS N
and POS N
renal POS N
events POS N
were POS N
mild POS N
and POS N
infrequent POS N
(∼8.6%). POS N

At POS N
week POS N
240, POS N
83.0% POS N
of POS N
patients POS N
in POS N
the POS N
TDF POS N
arm, POS N
and POS N
82.7% POS N
of POS N
patients POS N
in POS N
the POS N
FTC/TDF POS N
treatment POS N
arm POS N
had POS N
HBV POS N
DNA<69IU/ml POS N
(p=0.96). POS N

The POS N
mean POS N
change POS N
in POS N
bone POS N
mineral POS N
density POS N
at POS N
week POS N
240 POS N
was POS N
-0.98% POS N
and POS N
-2.54% POS N
at POS N
the POS N
spine POS N
and POS N
hip, POS N
respectively. POS N

At POS N
week POS N
240, POS N
83.0% POS N
of POS N
patients POS N
in POS N
the POS N
TDF POS N
arm, POS N
and POS N
82.7% POS N
of POS N
patients POS N
in POS N
the POS N
FTC/TDF POS N
treatment POS N
arm POS N
had POS N
HBV POS N
DNA<69IU/ml POS N
(p=0.96). POS N

TDF POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
in POS N
LAM-R POS N
CHB POS N
patients POS N
for POS N
up POS N
to POS N
240 POS N
weeks. POS N

Rates POS N
of POS N
normal POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
and POS N
normalised POS N
ALT POS N
were POS N
similar POS N
between POS N
groups POS N
(p=0.41 POS N
and POS N
p=0.97 POS N
respectively). POS N

Tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
without POS N
TDF POS N
resistance POS N
development POS N
in POS N
CHB POS N
patients POS N
with POS N
LAM-R, POS N
for POS N
up POS N
to POS N
240weeks. POS N

Rates POS N
of POS N
normal POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
and POS N
normalised POS N
ALT POS N
were POS N
similar POS N
between POS N
groups POS N
(p=0.41 POS N
and POS N
p=0.97 POS N
respectively). POS N

At POS N
week POS N
240, POS N
83.0% POS N
of POS N
patients POS N
in POS N
the POS N
TDF POS N
arm, POS N
and POS N
82.7% POS N
of POS N
patients POS N
in POS N
the POS N
FTC/TDF POS N
treatment POS N
arm POS N
had POS N
HBV POS N
DNA<69IU/ml POS N
(p=0.96). POS N

Rates POS N
of POS N
normal POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
and POS N
normalised POS N
ALT POS N
were POS N
similar POS N
between POS N
groups POS N
(p=0.41 POS N
and POS N
p=0.97 POS N
respectively). POS N

Hepatitis POS N
B POS N
e POS N
antigen POS N
loss POS N
and POS N
seroconversion POS N
at POS N
week POS N
240 POS N
were POS N
similar POS N
between POS N
groups, POS N
(p=0.41 POS N
and POS N
p=0.67 POS N
respectively). POS N

Rates POS N
of POS N
normal POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
and POS N
normalised POS N
ALT POS N
were POS N
similar POS N
between POS N
groups POS N
(p=0.41 POS N
and POS N
p=0.97 POS N
respectively). POS N

Overall, POS N
six POS N
patients POS N
achieved POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
and POS N
one POS N
patient POS N
(FTC/TDF POS N
arm) POS N
had POS N
HBsAg POS N
seroconversion POS N
by POS N
week POS N
240. POS N

Rates POS N
of POS N
normal POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
and POS N
normalised POS N
ALT POS N
were POS N
similar POS N
between POS N
groups POS N
(p=0.41 POS N
and POS N
p=0.97 POS N
respectively). POS N

No POS N
TDF POS N
resistance POS N
was POS N
observed POS N
up POS N
to POS N
week POS N
240. POS N

Rates POS N
of POS N
normal POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
and POS N
normalised POS N
ALT POS N
were POS N
similar POS N
between POS N
groups POS N
(p=0.41 POS N
and POS N
p=0.97 POS N
respectively). POS N

Treatment POS N
was POS N
generally POS N
well POS N
tolerated, POS N
and POS N
renal POS N
events POS N
were POS N
mild POS N
and POS N
infrequent POS N
(∼8.6%). POS N

Rates POS N
of POS N
normal POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
and POS N
normalised POS N
ALT POS N
were POS N
similar POS N
between POS N
groups POS N
(p=0.41 POS N
and POS N
p=0.97 POS N
respectively). POS N

The POS N
mean POS N
change POS N
in POS N
bone POS N
mineral POS N
density POS N
at POS N
week POS N
240 POS N
was POS N
-0.98% POS N
and POS N
-2.54% POS N
at POS N
the POS N
spine POS N
and POS N
hip, POS N
respectively. POS N

Rates POS N
of POS N
normal POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
and POS N
normalised POS N
ALT POS N
were POS N
similar POS N
between POS N
groups POS N
(p=0.41 POS N
and POS N
p=0.97 POS N
respectively). POS N

TDF POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
in POS N
LAM-R POS N
CHB POS N
patients POS N
for POS N
up POS N
to POS N
240 POS N
weeks. POS N

Hepatitis POS N
B POS N
e POS N
antigen POS N
loss POS N
and POS N
seroconversion POS N
at POS N
week POS N
240 POS N
were POS N
similar POS N
between POS N
groups, POS N
(p=0.41 POS N
and POS N
p=0.67 POS N
respectively). POS N

Tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
without POS N
TDF POS N
resistance POS N
development POS N
in POS N
CHB POS N
patients POS N
with POS N
LAM-R, POS N
for POS N
up POS N
to POS N
240weeks. POS N

Hepatitis POS N
B POS N
e POS N
antigen POS N
loss POS N
and POS N
seroconversion POS N
at POS N
week POS N
240 POS N
were POS N
similar POS N
between POS N
groups, POS N
(p=0.41 POS N
and POS N
p=0.67 POS N
respectively). POS N

At POS N
week POS N
240, POS N
83.0% POS N
of POS N
patients POS N
in POS N
the POS N
TDF POS N
arm, POS N
and POS N
82.7% POS N
of POS N
patients POS N
in POS N
the POS N
FTC/TDF POS N
treatment POS N
arm POS N
had POS N
HBV POS N
DNA<69IU/ml POS N
(p=0.96). POS N

Hepatitis POS N
B POS N
e POS N
antigen POS N
loss POS N
and POS N
seroconversion POS N
at POS N
week POS N
240 POS N
were POS N
similar POS N
between POS N
groups, POS N
(p=0.41 POS N
and POS N
p=0.67 POS N
respectively). POS N

Rates POS N
of POS N
normal POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
and POS N
normalised POS N
ALT POS N
were POS N
similar POS N
between POS N
groups POS N
(p=0.41 POS N
and POS N
p=0.97 POS N
respectively). POS N

Hepatitis POS N
B POS N
e POS N
antigen POS N
loss POS N
and POS N
seroconversion POS N
at POS N
week POS N
240 POS N
were POS N
similar POS N
between POS N
groups, POS N
(p=0.41 POS N
and POS N
p=0.67 POS N
respectively). POS N

Overall, POS N
six POS N
patients POS N
achieved POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
and POS N
one POS N
patient POS N
(FTC/TDF POS N
arm) POS N
had POS N
HBsAg POS N
seroconversion POS N
by POS N
week POS N
240. POS N

Hepatitis POS N
B POS N
e POS N
antigen POS N
loss POS N
and POS N
seroconversion POS N
at POS N
week POS N
240 POS N
were POS N
similar POS N
between POS N
groups, POS N
(p=0.41 POS N
and POS N
p=0.67 POS N
respectively). POS N

No POS N
TDF POS N
resistance POS N
was POS N
observed POS N
up POS N
to POS N
week POS N
240. POS N

Hepatitis POS N
B POS N
e POS N
antigen POS N
loss POS N
and POS N
seroconversion POS N
at POS N
week POS N
240 POS N
were POS N
similar POS N
between POS N
groups, POS N
(p=0.41 POS N
and POS N
p=0.67 POS N
respectively). POS N

Treatment POS N
was POS N
generally POS N
well POS N
tolerated, POS N
and POS N
renal POS N
events POS N
were POS N
mild POS N
and POS N
infrequent POS N
(∼8.6%). POS N

Hepatitis POS N
B POS N
e POS N
antigen POS N
loss POS N
and POS N
seroconversion POS N
at POS N
week POS N
240 POS N
were POS N
similar POS N
between POS N
groups, POS N
(p=0.41 POS N
and POS N
p=0.67 POS N
respectively). POS N

The POS N
mean POS N
change POS N
in POS N
bone POS N
mineral POS N
density POS N
at POS N
week POS N
240 POS N
was POS N
-0.98% POS N
and POS N
-2.54% POS N
at POS N
the POS N
spine POS N
and POS N
hip, POS N
respectively. POS N

Hepatitis POS N
B POS N
e POS N
antigen POS N
loss POS N
and POS N
seroconversion POS N
at POS N
week POS N
240 POS N
were POS N
similar POS N
between POS N
groups, POS N
(p=0.41 POS N
and POS N
p=0.67 POS N
respectively). POS N

TDF POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
in POS N
LAM-R POS N
CHB POS N
patients POS N
for POS N
up POS N
to POS N
240 POS N
weeks. POS N

Overall, POS N
six POS N
patients POS N
achieved POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
and POS N
one POS N
patient POS N
(FTC/TDF POS N
arm) POS N
had POS N
HBsAg POS N
seroconversion POS N
by POS N
week POS N
240. POS N

Tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
without POS N
TDF POS N
resistance POS N
development POS N
in POS N
CHB POS N
patients POS N
with POS N
LAM-R, POS N
for POS N
up POS N
to POS N
240weeks. POS N

Overall, POS N
six POS N
patients POS N
achieved POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
and POS N
one POS N
patient POS N
(FTC/TDF POS N
arm) POS N
had POS N
HBsAg POS N
seroconversion POS N
by POS N
week POS N
240. POS N

At POS N
week POS N
240, POS N
83.0% POS N
of POS N
patients POS N
in POS N
the POS N
TDF POS N
arm, POS N
and POS N
82.7% POS N
of POS N
patients POS N
in POS N
the POS N
FTC/TDF POS N
treatment POS N
arm POS N
had POS N
HBV POS N
DNA<69IU/ml POS N
(p=0.96). POS N

Overall, POS N
six POS N
patients POS N
achieved POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
and POS N
one POS N
patient POS N
(FTC/TDF POS N
arm) POS N
had POS N
HBsAg POS N
seroconversion POS N
by POS N
week POS N
240. POS N

Rates POS N
of POS N
normal POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
and POS N
normalised POS N
ALT POS N
were POS N
similar POS N
between POS N
groups POS N
(p=0.41 POS N
and POS N
p=0.97 POS N
respectively). POS N

Overall, POS N
six POS N
patients POS N
achieved POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
and POS N
one POS N
patient POS N
(FTC/TDF POS N
arm) POS N
had POS N
HBsAg POS N
seroconversion POS N
by POS N
week POS N
240. POS N

Hepatitis POS N
B POS N
e POS N
antigen POS N
loss POS N
and POS N
seroconversion POS N
at POS N
week POS N
240 POS N
were POS N
similar POS N
between POS N
groups, POS N
(p=0.41 POS N
and POS N
p=0.67 POS N
respectively). POS N

Overall, POS N
six POS N
patients POS N
achieved POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
and POS N
one POS N
patient POS N
(FTC/TDF POS N
arm) POS N
had POS N
HBsAg POS N
seroconversion POS N
by POS N
week POS N
240. POS N

No POS N
TDF POS N
resistance POS N
was POS N
observed POS N
up POS N
to POS N
week POS N
240. POS N

Overall, POS N
six POS N
patients POS N
achieved POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
and POS N
one POS N
patient POS N
(FTC/TDF POS N
arm) POS N
had POS N
HBsAg POS N
seroconversion POS N
by POS N
week POS N
240. POS N

Treatment POS N
was POS N
generally POS N
well POS N
tolerated, POS N
and POS N
renal POS N
events POS N
were POS N
mild POS N
and POS N
infrequent POS N
(∼8.6%). POS N

Overall, POS N
six POS N
patients POS N
achieved POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
and POS N
one POS N
patient POS N
(FTC/TDF POS N
arm) POS N
had POS N
HBsAg POS N
seroconversion POS N
by POS N
week POS N
240. POS N

The POS N
mean POS N
change POS N
in POS N
bone POS N
mineral POS N
density POS N
at POS N
week POS N
240 POS N
was POS N
-0.98% POS N
and POS N
-2.54% POS N
at POS N
the POS N
spine POS N
and POS N
hip, POS N
respectively. POS N

Overall, POS N
six POS N
patients POS N
achieved POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
and POS N
one POS N
patient POS N
(FTC/TDF POS N
arm) POS N
had POS N
HBsAg POS N
seroconversion POS N
by POS N
week POS N
240. POS N

TDF POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
in POS N
LAM-R POS N
CHB POS N
patients POS N
for POS N
up POS N
to POS N
240 POS N
weeks. POS N

No POS N
TDF POS N
resistance POS N
was POS N
observed POS N
up POS N
to POS N
week POS N
240. POS N

Tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
without POS N
TDF POS N
resistance POS N
development POS N
in POS N
CHB POS N
patients POS N
with POS N
LAM-R, POS N
for POS N
up POS N
to POS N
240weeks. POS N

No POS N
TDF POS N
resistance POS N
was POS N
observed POS N
up POS N
to POS N
week POS N
240. POS N

At POS N
week POS N
240, POS N
83.0% POS N
of POS N
patients POS N
in POS N
the POS N
TDF POS N
arm, POS N
and POS N
82.7% POS N
of POS N
patients POS N
in POS N
the POS N
FTC/TDF POS N
treatment POS N
arm POS N
had POS N
HBV POS N
DNA<69IU/ml POS N
(p=0.96). POS N

No POS N
TDF POS N
resistance POS N
was POS N
observed POS N
up POS N
to POS N
week POS N
240. POS N

Rates POS N
of POS N
normal POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
and POS N
normalised POS N
ALT POS N
were POS N
similar POS N
between POS N
groups POS N
(p=0.41 POS N
and POS N
p=0.97 POS N
respectively). POS N

No POS N
TDF POS N
resistance POS N
was POS N
observed POS N
up POS N
to POS N
week POS N
240. POS N

Hepatitis POS N
B POS N
e POS N
antigen POS N
loss POS N
and POS N
seroconversion POS N
at POS N
week POS N
240 POS N
were POS N
similar POS N
between POS N
groups, POS N
(p=0.41 POS N
and POS N
p=0.67 POS N
respectively). POS N

No POS N
TDF POS N
resistance POS N
was POS N
observed POS N
up POS N
to POS N
week POS N
240. POS N

Overall, POS N
six POS N
patients POS N
achieved POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
and POS N
one POS N
patient POS N
(FTC/TDF POS N
arm) POS N
had POS N
HBsAg POS N
seroconversion POS N
by POS N
week POS N
240. POS N

No POS N
TDF POS N
resistance POS N
was POS N
observed POS N
up POS N
to POS N
week POS N
240. POS N

Treatment POS N
was POS N
generally POS N
well POS N
tolerated, POS N
and POS N
renal POS N
events POS N
were POS N
mild POS N
and POS N
infrequent POS N
(∼8.6%). POS N

No POS N
TDF POS N
resistance POS N
was POS N
observed POS N
up POS N
to POS N
week POS N
240. POS N

The POS N
mean POS N
change POS N
in POS N
bone POS N
mineral POS N
density POS N
at POS N
week POS N
240 POS N
was POS N
-0.98% POS N
and POS N
-2.54% POS N
at POS N
the POS N
spine POS N
and POS N
hip, POS N
respectively. POS N

No POS N
TDF POS N
resistance POS N
was POS N
observed POS N
up POS N
to POS N
week POS N
240. POS N

TDF POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
in POS N
LAM-R POS N
CHB POS N
patients POS N
for POS N
up POS N
to POS N
240 POS N
weeks. POS N

Treatment POS N
was POS N
generally POS N
well POS N
tolerated, POS N
and POS N
renal POS N
events POS N
were POS N
mild POS N
and POS N
infrequent POS N
(∼8.6%). POS N

Tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
without POS N
TDF POS N
resistance POS N
development POS N
in POS N
CHB POS N
patients POS N
with POS N
LAM-R, POS N
for POS N
up POS N
to POS N
240weeks. POS N

Treatment POS N
was POS N
generally POS N
well POS N
tolerated, POS N
and POS N
renal POS N
events POS N
were POS N
mild POS N
and POS N
infrequent POS N
(∼8.6%). POS N

At POS N
week POS N
240, POS N
83.0% POS N
of POS N
patients POS N
in POS N
the POS N
TDF POS N
arm, POS N
and POS N
82.7% POS N
of POS N
patients POS N
in POS N
the POS N
FTC/TDF POS N
treatment POS N
arm POS N
had POS N
HBV POS N
DNA<69IU/ml POS N
(p=0.96). POS N

Treatment POS N
was POS N
generally POS N
well POS N
tolerated, POS N
and POS N
renal POS N
events POS N
were POS N
mild POS N
and POS N
infrequent POS N
(∼8.6%). POS N

Rates POS N
of POS N
normal POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
and POS N
normalised POS N
ALT POS N
were POS N
similar POS N
between POS N
groups POS N
(p=0.41 POS N
and POS N
p=0.97 POS N
respectively). POS N

Treatment POS N
was POS N
generally POS N
well POS N
tolerated, POS N
and POS N
renal POS N
events POS N
were POS N
mild POS N
and POS N
infrequent POS N
(∼8.6%). POS N

Hepatitis POS N
B POS N
e POS N
antigen POS N
loss POS N
and POS N
seroconversion POS N
at POS N
week POS N
240 POS N
were POS N
similar POS N
between POS N
groups, POS N
(p=0.41 POS N
and POS N
p=0.67 POS N
respectively). POS N

Treatment POS N
was POS N
generally POS N
well POS N
tolerated, POS N
and POS N
renal POS N
events POS N
were POS N
mild POS N
and POS N
infrequent POS N
(∼8.6%). POS N

Overall, POS N
six POS N
patients POS N
achieved POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
and POS N
one POS N
patient POS N
(FTC/TDF POS N
arm) POS N
had POS N
HBsAg POS N
seroconversion POS N
by POS N
week POS N
240. POS N

Treatment POS N
was POS N
generally POS N
well POS N
tolerated, POS N
and POS N
renal POS N
events POS N
were POS N
mild POS N
and POS N
infrequent POS N
(∼8.6%). POS N

No POS N
TDF POS N
resistance POS N
was POS N
observed POS N
up POS N
to POS N
week POS N
240. POS N

Treatment POS N
was POS N
generally POS N
well POS N
tolerated, POS N
and POS N
renal POS N
events POS N
were POS N
mild POS N
and POS N
infrequent POS N
(∼8.6%). POS N

The POS N
mean POS N
change POS N
in POS N
bone POS N
mineral POS N
density POS N
at POS N
week POS N
240 POS N
was POS N
-0.98% POS N
and POS N
-2.54% POS N
at POS N
the POS N
spine POS N
and POS N
hip, POS N
respectively. POS N

Treatment POS N
was POS N
generally POS N
well POS N
tolerated, POS N
and POS N
renal POS N
events POS N
were POS N
mild POS N
and POS N
infrequent POS N
(∼8.6%). POS N

TDF POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
in POS N
LAM-R POS N
CHB POS N
patients POS N
for POS N
up POS N
to POS N
240 POS N
weeks. POS N

The POS N
mean POS N
change POS N
in POS N
bone POS N
mineral POS N
density POS N
at POS N
week POS N
240 POS N
was POS N
-0.98% POS N
and POS N
-2.54% POS N
at POS N
the POS N
spine POS N
and POS N
hip, POS N
respectively. POS N

Tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
without POS N
TDF POS N
resistance POS N
development POS N
in POS N
CHB POS N
patients POS N
with POS N
LAM-R, POS N
for POS N
up POS N
to POS N
240weeks. POS N

The POS N
mean POS N
change POS N
in POS N
bone POS N
mineral POS N
density POS N
at POS N
week POS N
240 POS N
was POS N
-0.98% POS N
and POS N
-2.54% POS N
at POS N
the POS N
spine POS N
and POS N
hip, POS N
respectively. POS N

At POS N
week POS N
240, POS N
83.0% POS N
of POS N
patients POS N
in POS N
the POS N
TDF POS N
arm, POS N
and POS N
82.7% POS N
of POS N
patients POS N
in POS N
the POS N
FTC/TDF POS N
treatment POS N
arm POS N
had POS N
HBV POS N
DNA<69IU/ml POS N
(p=0.96). POS N

The POS N
mean POS N
change POS N
in POS N
bone POS N
mineral POS N
density POS N
at POS N
week POS N
240 POS N
was POS N
-0.98% POS N
and POS N
-2.54% POS N
at POS N
the POS N
spine POS N
and POS N
hip, POS N
respectively. POS N

Rates POS N
of POS N
normal POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
and POS N
normalised POS N
ALT POS N
were POS N
similar POS N
between POS N
groups POS N
(p=0.41 POS N
and POS N
p=0.97 POS N
respectively). POS N

The POS N
mean POS N
change POS N
in POS N
bone POS N
mineral POS N
density POS N
at POS N
week POS N
240 POS N
was POS N
-0.98% POS N
and POS N
-2.54% POS N
at POS N
the POS N
spine POS N
and POS N
hip, POS N
respectively. POS N

Hepatitis POS N
B POS N
e POS N
antigen POS N
loss POS N
and POS N
seroconversion POS N
at POS N
week POS N
240 POS N
were POS N
similar POS N
between POS N
groups, POS N
(p=0.41 POS N
and POS N
p=0.67 POS N
respectively). POS N

The POS N
mean POS N
change POS N
in POS N
bone POS N
mineral POS N
density POS N
at POS N
week POS N
240 POS N
was POS N
-0.98% POS N
and POS N
-2.54% POS N
at POS N
the POS N
spine POS N
and POS N
hip, POS N
respectively. POS N

Overall, POS N
six POS N
patients POS N
achieved POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
and POS N
one POS N
patient POS N
(FTC/TDF POS N
arm) POS N
had POS N
HBsAg POS N
seroconversion POS N
by POS N
week POS N
240. POS N

The POS N
mean POS N
change POS N
in POS N
bone POS N
mineral POS N
density POS N
at POS N
week POS N
240 POS N
was POS N
-0.98% POS N
and POS N
-2.54% POS N
at POS N
the POS N
spine POS N
and POS N
hip, POS N
respectively. POS N

No POS N
TDF POS N
resistance POS N
was POS N
observed POS N
up POS N
to POS N
week POS N
240. POS N

The POS N
mean POS N
change POS N
in POS N
bone POS N
mineral POS N
density POS N
at POS N
week POS N
240 POS N
was POS N
-0.98% POS N
and POS N
-2.54% POS N
at POS N
the POS N
spine POS N
and POS N
hip, POS N
respectively. POS N

Treatment POS N
was POS N
generally POS N
well POS N
tolerated, POS N
and POS N
renal POS N
events POS N
were POS N
mild POS N
and POS N
infrequent POS N
(∼8.6%). POS N

The POS N
mean POS N
change POS N
in POS N
bone POS N
mineral POS N
density POS N
at POS N
week POS N
240 POS N
was POS N
-0.98% POS N
and POS N
-2.54% POS N
at POS N
the POS N
spine POS N
and POS N
hip, POS N
respectively. POS N

TDF POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
in POS N
LAM-R POS N
CHB POS N
patients POS N
for POS N
up POS N
to POS N
240 POS N
weeks. POS N

TDF POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
in POS N
LAM-R POS N
CHB POS N
patients POS N
for POS N
up POS N
to POS N
240 POS N
weeks. POS N

Tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
without POS N
TDF POS N
resistance POS N
development POS N
in POS N
CHB POS N
patients POS N
with POS N
LAM-R, POS N
for POS N
up POS N
to POS N
240weeks. POS N

TDF POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
in POS N
LAM-R POS N
CHB POS N
patients POS N
for POS N
up POS N
to POS N
240 POS N
weeks. POS N

At POS N
week POS N
240, POS N
83.0% POS N
of POS N
patients POS N
in POS N
the POS N
TDF POS N
arm, POS N
and POS N
82.7% POS N
of POS N
patients POS N
in POS N
the POS N
FTC/TDF POS N
treatment POS N
arm POS N
had POS N
HBV POS N
DNA<69IU/ml POS N
(p=0.96). POS N

TDF POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
in POS N
LAM-R POS N
CHB POS N
patients POS N
for POS N
up POS N
to POS N
240 POS N
weeks. POS N

Rates POS N
of POS N
normal POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
and POS N
normalised POS N
ALT POS N
were POS N
similar POS N
between POS N
groups POS N
(p=0.41 POS N
and POS N
p=0.97 POS N
respectively). POS N

TDF POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
in POS N
LAM-R POS N
CHB POS N
patients POS N
for POS N
up POS N
to POS N
240 POS N
weeks. POS N

Hepatitis POS N
B POS N
e POS N
antigen POS N
loss POS N
and POS N
seroconversion POS N
at POS N
week POS N
240 POS N
were POS N
similar POS N
between POS N
groups, POS N
(p=0.41 POS N
and POS N
p=0.67 POS N
respectively). POS N

TDF POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
in POS N
LAM-R POS N
CHB POS N
patients POS N
for POS N
up POS N
to POS N
240 POS N
weeks. POS N

Overall, POS N
six POS N
patients POS N
achieved POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
loss POS N
and POS N
one POS N
patient POS N
(FTC/TDF POS N
arm) POS N
had POS N
HBsAg POS N
seroconversion POS N
by POS N
week POS N
240. POS N

TDF POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
in POS N
LAM-R POS N
CHB POS N
patients POS N
for POS N
up POS N
to POS N
240 POS N
weeks. POS N

No POS N
TDF POS N
resistance POS N
was POS N
observed POS N
up POS N
to POS N
week POS N
240. POS N

TDF POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
in POS N
LAM-R POS N
CHB POS N
patients POS N
for POS N
up POS N
to POS N
240 POS N
weeks. POS N

Treatment POS N
was POS N
generally POS N
well POS N
tolerated, POS N
and POS N
renal POS N
events POS N
were POS N
mild POS N
and POS N
infrequent POS N
(∼8.6%). POS N

TDF POS N
monotherapy POS N
was POS N
effective POS N
and POS N
well POS N
tolerated POS N
in POS N
LAM-R POS N
CHB POS N
patients POS N
for POS N
up POS N
to POS N
240 POS N
weeks. POS N

The POS N
mean POS N
change POS N
in POS N
bone POS N
mineral POS N
density POS N
at POS N
week POS N
240 POS N
was POS N
-0.98% POS N
and POS N
-2.54% POS N
at POS N
the POS N
spine POS N
and POS N
hip, POS N
respectively. POS N

Compared POS N
with POS N
baseline, POS N
IOP POS N
drop POS N
at POS N
last POS N
visit POS N
was POS N
11.76±5.51 POS N
and POS N
13.43±5.92 POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.207). POS N

At POS N
last POS N
visit, POS N
complete POS N
success POS N
was POS N
achieved POS N
in POS N
25 POS N
cases POS N
(61%) POS N
of POS N
bevacizumab POS N
group POS N
and POS N
23 POS N
cases POS N
(66%) POS N
of POS N
MMC POS N
group POS N
(P=0.669). POS N

Compared POS N
with POS N
baseline, POS N
IOP POS N
drop POS N
at POS N
last POS N
visit POS N
was POS N
11.76±5.51 POS N
and POS N
13.43±5.92 POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.207). POS N

Early POS N
filtering POS N
bleb POS N
leak POS N
was POS N
more POS N
prevalent POS N
in POS N
bevacizumab POS N
group POS N
(29% POS N
vs. POS N
11%). POS N

Compared POS N
with POS N
baseline, POS N
IOP POS N
drop POS N
at POS N
last POS N
visit POS N
was POS N
11.76±5.51 POS N
and POS N
13.43±5.92 POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.207). POS N

A POS N
single POS N
1.25 mg POS N
dose POS N
of POS N
intracameral POS N
bevacizumab POS N
improves POS N
the POS N
success POS N
of POS N
trabeculectomy POS N
comparable POS N
with POS N
MMC; POS N

Compared POS N
with POS N
baseline, POS N
IOP POS N
drop POS N
at POS N
last POS N
visit POS N
was POS N
11.76±5.51 POS N
and POS N
13.43±5.92 POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.207). POS N

however, POS N
it POS N
increases POS N
the POS N
risk POS N
of POS N
early POS N
filtering POS N
bleb POS N
leakage. POS N

Compared POS N
with POS N
baseline, POS N
IOP POS N
drop POS N
at POS N
last POS N
visit POS N
was POS N
11.76±5.51 POS N
and POS N
13.43±5.92 POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.207). POS N

The POS N
preoperative POS N
IOP POS N
was POS N
29.17±3.94 POS N
and POS N
28.8±4.08 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.689). POS N

Compared POS N
with POS N
baseline, POS N
IOP POS N
drop POS N
at POS N
last POS N
visit POS N
was POS N
11.76±5.51 POS N
and POS N
13.43±5.92 POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.207). POS N

Last POS N
visit POS N
IOP POS N
was POS N
17.41±3.11 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
group POS N
and POS N
15.34±3.62 mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.009). POS N

At POS N
last POS N
visit, POS N
complete POS N
success POS N
was POS N
achieved POS N
in POS N
25 POS N
cases POS N
(61%) POS N
of POS N
bevacizumab POS N
group POS N
and POS N
23 POS N
cases POS N
(66%) POS N
of POS N
MMC POS N
group POS N
(P=0.669). POS N

Compared POS N
with POS N
baseline, POS N
IOP POS N
drop POS N
at POS N
last POS N
visit POS N
was POS N
11.76±5.51 POS N
and POS N
13.43±5.92 POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.207). POS N

At POS N
last POS N
visit, POS N
complete POS N
success POS N
was POS N
achieved POS N
in POS N
25 POS N
cases POS N
(61%) POS N
of POS N
bevacizumab POS N
group POS N
and POS N
23 POS N
cases POS N
(66%) POS N
of POS N
MMC POS N
group POS N
(P=0.669). POS N

Early POS N
filtering POS N
bleb POS N
leak POS N
was POS N
more POS N
prevalent POS N
in POS N
bevacizumab POS N
group POS N
(29% POS N
vs. POS N
11%). POS N

At POS N
last POS N
visit, POS N
complete POS N
success POS N
was POS N
achieved POS N
in POS N
25 POS N
cases POS N
(61%) POS N
of POS N
bevacizumab POS N
group POS N
and POS N
23 POS N
cases POS N
(66%) POS N
of POS N
MMC POS N
group POS N
(P=0.669). POS N

A POS N
single POS N
1.25 mg POS N
dose POS N
of POS N
intracameral POS N
bevacizumab POS N
improves POS N
the POS N
success POS N
of POS N
trabeculectomy POS N
comparable POS N
with POS N
MMC; POS N

At POS N
last POS N
visit, POS N
complete POS N
success POS N
was POS N
achieved POS N
in POS N
25 POS N
cases POS N
(61%) POS N
of POS N
bevacizumab POS N
group POS N
and POS N
23 POS N
cases POS N
(66%) POS N
of POS N
MMC POS N
group POS N
(P=0.669). POS N

however, POS N
it POS N
increases POS N
the POS N
risk POS N
of POS N
early POS N
filtering POS N
bleb POS N
leakage. POS N

At POS N
last POS N
visit, POS N
complete POS N
success POS N
was POS N
achieved POS N
in POS N
25 POS N
cases POS N
(61%) POS N
of POS N
bevacizumab POS N
group POS N
and POS N
23 POS N
cases POS N
(66%) POS N
of POS N
MMC POS N
group POS N
(P=0.669). POS N

The POS N
preoperative POS N
IOP POS N
was POS N
29.17±3.94 POS N
and POS N
28.8±4.08 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.689). POS N

At POS N
last POS N
visit, POS N
complete POS N
success POS N
was POS N
achieved POS N
in POS N
25 POS N
cases POS N
(61%) POS N
of POS N
bevacizumab POS N
group POS N
and POS N
23 POS N
cases POS N
(66%) POS N
of POS N
MMC POS N
group POS N
(P=0.669). POS N

Last POS N
visit POS N
IOP POS N
was POS N
17.41±3.11 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
group POS N
and POS N
15.34±3.62 mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.009). POS N

Early POS N
filtering POS N
bleb POS N
leak POS N
was POS N
more POS N
prevalent POS N
in POS N
bevacizumab POS N
group POS N
(29% POS N
vs. POS N
11%). POS N

Compared POS N
with POS N
baseline, POS N
IOP POS N
drop POS N
at POS N
last POS N
visit POS N
was POS N
11.76±5.51 POS N
and POS N
13.43±5.92 POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.207). POS N

Early POS N
filtering POS N
bleb POS N
leak POS N
was POS N
more POS N
prevalent POS N
in POS N
bevacizumab POS N
group POS N
(29% POS N
vs. POS N
11%). POS N

At POS N
last POS N
visit, POS N
complete POS N
success POS N
was POS N
achieved POS N
in POS N
25 POS N
cases POS N
(61%) POS N
of POS N
bevacizumab POS N
group POS N
and POS N
23 POS N
cases POS N
(66%) POS N
of POS N
MMC POS N
group POS N
(P=0.669). POS N

Early POS N
filtering POS N
bleb POS N
leak POS N
was POS N
more POS N
prevalent POS N
in POS N
bevacizumab POS N
group POS N
(29% POS N
vs. POS N
11%). POS N

A POS N
single POS N
1.25 mg POS N
dose POS N
of POS N
intracameral POS N
bevacizumab POS N
improves POS N
the POS N
success POS N
of POS N
trabeculectomy POS N
comparable POS N
with POS N
MMC; POS N

Early POS N
filtering POS N
bleb POS N
leak POS N
was POS N
more POS N
prevalent POS N
in POS N
bevacizumab POS N
group POS N
(29% POS N
vs. POS N
11%). POS N

however, POS N
it POS N
increases POS N
the POS N
risk POS N
of POS N
early POS N
filtering POS N
bleb POS N
leakage. POS N

Early POS N
filtering POS N
bleb POS N
leak POS N
was POS N
more POS N
prevalent POS N
in POS N
bevacizumab POS N
group POS N
(29% POS N
vs. POS N
11%). POS N

The POS N
preoperative POS N
IOP POS N
was POS N
29.17±3.94 POS N
and POS N
28.8±4.08 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.689). POS N

Early POS N
filtering POS N
bleb POS N
leak POS N
was POS N
more POS N
prevalent POS N
in POS N
bevacizumab POS N
group POS N
(29% POS N
vs. POS N
11%). POS N

Last POS N
visit POS N
IOP POS N
was POS N
17.41±3.11 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
group POS N
and POS N
15.34±3.62 mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.009). POS N

A POS N
single POS N
1.25 mg POS N
dose POS N
of POS N
intracameral POS N
bevacizumab POS N
improves POS N
the POS N
success POS N
of POS N
trabeculectomy POS N
comparable POS N
with POS N
MMC; POS N

Compared POS N
with POS N
baseline, POS N
IOP POS N
drop POS N
at POS N
last POS N
visit POS N
was POS N
11.76±5.51 POS N
and POS N
13.43±5.92 POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.207). POS N

A POS N
single POS N
1.25 mg POS N
dose POS N
of POS N
intracameral POS N
bevacizumab POS N
improves POS N
the POS N
success POS N
of POS N
trabeculectomy POS N
comparable POS N
with POS N
MMC; POS N

At POS N
last POS N
visit, POS N
complete POS N
success POS N
was POS N
achieved POS N
in POS N
25 POS N
cases POS N
(61%) POS N
of POS N
bevacizumab POS N
group POS N
and POS N
23 POS N
cases POS N
(66%) POS N
of POS N
MMC POS N
group POS N
(P=0.669). POS N

A POS N
single POS N
1.25 mg POS N
dose POS N
of POS N
intracameral POS N
bevacizumab POS N
improves POS N
the POS N
success POS N
of POS N
trabeculectomy POS N
comparable POS N
with POS N
MMC; POS N

Early POS N
filtering POS N
bleb POS N
leak POS N
was POS N
more POS N
prevalent POS N
in POS N
bevacizumab POS N
group POS N
(29% POS N
vs. POS N
11%). POS N

A POS N
single POS N
1.25 mg POS N
dose POS N
of POS N
intracameral POS N
bevacizumab POS N
improves POS N
the POS N
success POS N
of POS N
trabeculectomy POS N
comparable POS N
with POS N
MMC; POS N

however, POS N
it POS N
increases POS N
the POS N
risk POS N
of POS N
early POS N
filtering POS N
bleb POS N
leakage. POS N

A POS N
single POS N
1.25 mg POS N
dose POS N
of POS N
intracameral POS N
bevacizumab POS N
improves POS N
the POS N
success POS N
of POS N
trabeculectomy POS N
comparable POS N
with POS N
MMC; POS N

The POS N
preoperative POS N
IOP POS N
was POS N
29.17±3.94 POS N
and POS N
28.8±4.08 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.689). POS N

A POS N
single POS N
1.25 mg POS N
dose POS N
of POS N
intracameral POS N
bevacizumab POS N
improves POS N
the POS N
success POS N
of POS N
trabeculectomy POS N
comparable POS N
with POS N
MMC; POS N

Last POS N
visit POS N
IOP POS N
was POS N
17.41±3.11 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
group POS N
and POS N
15.34±3.62 mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.009). POS N

however, POS N
it POS N
increases POS N
the POS N
risk POS N
of POS N
early POS N
filtering POS N
bleb POS N
leakage. POS N

Compared POS N
with POS N
baseline, POS N
IOP POS N
drop POS N
at POS N
last POS N
visit POS N
was POS N
11.76±5.51 POS N
and POS N
13.43±5.92 POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.207). POS N

however, POS N
it POS N
increases POS N
the POS N
risk POS N
of POS N
early POS N
filtering POS N
bleb POS N
leakage. POS N

At POS N
last POS N
visit, POS N
complete POS N
success POS N
was POS N
achieved POS N
in POS N
25 POS N
cases POS N
(61%) POS N
of POS N
bevacizumab POS N
group POS N
and POS N
23 POS N
cases POS N
(66%) POS N
of POS N
MMC POS N
group POS N
(P=0.669). POS N

however, POS N
it POS N
increases POS N
the POS N
risk POS N
of POS N
early POS N
filtering POS N
bleb POS N
leakage. POS N

Early POS N
filtering POS N
bleb POS N
leak POS N
was POS N
more POS N
prevalent POS N
in POS N
bevacizumab POS N
group POS N
(29% POS N
vs. POS N
11%). POS N

however, POS N
it POS N
increases POS N
the POS N
risk POS N
of POS N
early POS N
filtering POS N
bleb POS N
leakage. POS N

A POS N
single POS N
1.25 mg POS N
dose POS N
of POS N
intracameral POS N
bevacizumab POS N
improves POS N
the POS N
success POS N
of POS N
trabeculectomy POS N
comparable POS N
with POS N
MMC; POS N

however, POS N
it POS N
increases POS N
the POS N
risk POS N
of POS N
early POS N
filtering POS N
bleb POS N
leakage. POS N

The POS N
preoperative POS N
IOP POS N
was POS N
29.17±3.94 POS N
and POS N
28.8±4.08 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.689). POS N

however, POS N
it POS N
increases POS N
the POS N
risk POS N
of POS N
early POS N
filtering POS N
bleb POS N
leakage. POS N

Last POS N
visit POS N
IOP POS N
was POS N
17.41±3.11 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
group POS N
and POS N
15.34±3.62 mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.009). POS N

The POS N
preoperative POS N
IOP POS N
was POS N
29.17±3.94 POS N
and POS N
28.8±4.08 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.689). POS N

Compared POS N
with POS N
baseline, POS N
IOP POS N
drop POS N
at POS N
last POS N
visit POS N
was POS N
11.76±5.51 POS N
and POS N
13.43±5.92 POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.207). POS N

The POS N
preoperative POS N
IOP POS N
was POS N
29.17±3.94 POS N
and POS N
28.8±4.08 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.689). POS N

At POS N
last POS N
visit, POS N
complete POS N
success POS N
was POS N
achieved POS N
in POS N
25 POS N
cases POS N
(61%) POS N
of POS N
bevacizumab POS N
group POS N
and POS N
23 POS N
cases POS N
(66%) POS N
of POS N
MMC POS N
group POS N
(P=0.669). POS N

The POS N
preoperative POS N
IOP POS N
was POS N
29.17±3.94 POS N
and POS N
28.8±4.08 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.689). POS N

Early POS N
filtering POS N
bleb POS N
leak POS N
was POS N
more POS N
prevalent POS N
in POS N
bevacizumab POS N
group POS N
(29% POS N
vs. POS N
11%). POS N

The POS N
preoperative POS N
IOP POS N
was POS N
29.17±3.94 POS N
and POS N
28.8±4.08 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.689). POS N

A POS N
single POS N
1.25 mg POS N
dose POS N
of POS N
intracameral POS N
bevacizumab POS N
improves POS N
the POS N
success POS N
of POS N
trabeculectomy POS N
comparable POS N
with POS N
MMC; POS N

The POS N
preoperative POS N
IOP POS N
was POS N
29.17±3.94 POS N
and POS N
28.8±4.08 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.689). POS N

however, POS N
it POS N
increases POS N
the POS N
risk POS N
of POS N
early POS N
filtering POS N
bleb POS N
leakage. POS N

The POS N
preoperative POS N
IOP POS N
was POS N
29.17±3.94 POS N
and POS N
28.8±4.08 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.689). POS N

Last POS N
visit POS N
IOP POS N
was POS N
17.41±3.11 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
group POS N
and POS N
15.34±3.62 mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.009). POS N

Last POS N
visit POS N
IOP POS N
was POS N
17.41±3.11 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
group POS N
and POS N
15.34±3.62 mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.009). POS N

Compared POS N
with POS N
baseline, POS N
IOP POS N
drop POS N
at POS N
last POS N
visit POS N
was POS N
11.76±5.51 POS N
and POS N
13.43±5.92 POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.207). POS N

Last POS N
visit POS N
IOP POS N
was POS N
17.41±3.11 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
group POS N
and POS N
15.34±3.62 mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.009). POS N

At POS N
last POS N
visit, POS N
complete POS N
success POS N
was POS N
achieved POS N
in POS N
25 POS N
cases POS N
(61%) POS N
of POS N
bevacizumab POS N
group POS N
and POS N
23 POS N
cases POS N
(66%) POS N
of POS N
MMC POS N
group POS N
(P=0.669). POS N

Last POS N
visit POS N
IOP POS N
was POS N
17.41±3.11 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
group POS N
and POS N
15.34±3.62 mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.009). POS N

Early POS N
filtering POS N
bleb POS N
leak POS N
was POS N
more POS N
prevalent POS N
in POS N
bevacizumab POS N
group POS N
(29% POS N
vs. POS N
11%). POS N

Last POS N
visit POS N
IOP POS N
was POS N
17.41±3.11 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
group POS N
and POS N
15.34±3.62 mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.009). POS N

A POS N
single POS N
1.25 mg POS N
dose POS N
of POS N
intracameral POS N
bevacizumab POS N
improves POS N
the POS N
success POS N
of POS N
trabeculectomy POS N
comparable POS N
with POS N
MMC; POS N

Last POS N
visit POS N
IOP POS N
was POS N
17.41±3.11 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
group POS N
and POS N
15.34±3.62 mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.009). POS N

however, POS N
it POS N
increases POS N
the POS N
risk POS N
of POS N
early POS N
filtering POS N
bleb POS N
leakage. POS N

Last POS N
visit POS N
IOP POS N
was POS N
17.41±3.11 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
group POS N
and POS N
15.34±3.62 mm POS N
Hg POS N
in POS N
the POS N
MMC POS N
group POS N
(P<0.009). POS N

The POS N
preoperative POS N
IOP POS N
was POS N
29.17±3.94 POS N
and POS N
28.8±4.08 mm Hg POS N
in POS N
the POS N
bevacizumab POS N
and POS N
MMC POS N
groups, POS N
respectively POS N
(P=0.689). POS N

Treatment-related POS N
quality POS N
of POS N
life POS N
(QOL) POS N
is POS N
an POS N
important POS N
aspect POS N
of POS N
diabetes POS N
management. POS N

Compared POS N
with POS N
baseline POS N
data, POS N
total POS N
DTR-QOL17 POS N
scores POS N
were POS N
significantly POS N
higher POS N
after POS N
12 POS N
weeks POS N
of POS N
linagliptin POS N
and POS N
voglibose POS N
treatment. POS N

Treatment-related POS N
quality POS N
of POS N
life POS N
(QOL) POS N
is POS N
an POS N
important POS N
aspect POS N
of POS N
diabetes POS N
management. POS N

The POS N
change POS N
in POS N
the POS N
total POS N
DTR-QOL17 POS N
score POS N
and POS N
the POS N
score POS N
of POS N
one POS N
domain, POS N
burden POS N
on POS N
social POS N
activities POS N
and POS N
daily POS N
activities, POS N
was POS N
significantly POS N
greater POS N
in POS N
the POS N
linagliptin POS N
group POS N
than POS N
in POS N
the POS N
voglibose POS N
group. POS N

Treatment-related POS N
quality POS N
of POS N
life POS N
(QOL) POS N
is POS N
an POS N
important POS N
aspect POS N
of POS N
diabetes POS N
management. POS N

In POS N
addition, POS N
only POS N
linagliptin POS N
treatment POS N
was POS N
identified POS N
as POS N
a POS N
factor POS N
associated POS N
with POS N
an POS N
increased POS N
total POS N
DTR-QOL17 POS N
score. POS N

Treatment-related POS N
quality POS N
of POS N
life POS N
(QOL) POS N
is POS N
an POS N
important POS N
aspect POS N
of POS N
diabetes POS N
management. POS N

Linagliptin POS N
is POS N
superior POS N
to POS N
voglibose POS N
in POS N
terms POS N
of POS N
improving POS N
treatment-related POS N
QOL POS N
in POS N
Japanese POS N
patients POS N
with POS N
T2DM. POS N

Compared POS N
with POS N
baseline POS N
data, POS N
total POS N
DTR-QOL17 POS N
scores POS N
were POS N
significantly POS N
higher POS N
after POS N
12 POS N
weeks POS N
of POS N
linagliptin POS N
and POS N
voglibose POS N
treatment. POS N

Treatment-related POS N
quality POS N
of POS N
life POS N
(QOL) POS N
is POS N
an POS N
important POS N
aspect POS N
of POS N
diabetes POS N
management. POS N

Compared POS N
with POS N
baseline POS N
data, POS N
total POS N
DTR-QOL17 POS N
scores POS N
were POS N
significantly POS N
higher POS N
after POS N
12 POS N
weeks POS N
of POS N
linagliptin POS N
and POS N
voglibose POS N
treatment. POS N

The POS N
change POS N
in POS N
the POS N
total POS N
DTR-QOL17 POS N
score POS N
and POS N
the POS N
score POS N
of POS N
one POS N
domain, POS N
burden POS N
on POS N
social POS N
activities POS N
and POS N
daily POS N
activities, POS N
was POS N
significantly POS N
greater POS N
in POS N
the POS N
linagliptin POS N
group POS N
than POS N
in POS N
the POS N
voglibose POS N
group. POS N

Compared POS N
with POS N
baseline POS N
data, POS N
total POS N
DTR-QOL17 POS N
scores POS N
were POS N
significantly POS N
higher POS N
after POS N
12 POS N
weeks POS N
of POS N
linagliptin POS N
and POS N
voglibose POS N
treatment. POS N

In POS N
addition, POS N
only POS N
linagliptin POS N
treatment POS N
was POS N
identified POS N
as POS N
a POS N
factor POS N
associated POS N
with POS N
an POS N
increased POS N
total POS N
DTR-QOL17 POS N
score. POS N

Compared POS N
with POS N
baseline POS N
data, POS N
total POS N
DTR-QOL17 POS N
scores POS N
were POS N
significantly POS N
higher POS N
after POS N
12 POS N
weeks POS N
of POS N
linagliptin POS N
and POS N
voglibose POS N
treatment. POS N

Linagliptin POS N
is POS N
superior POS N
to POS N
voglibose POS N
in POS N
terms POS N
of POS N
improving POS N
treatment-related POS N
QOL POS N
in POS N
Japanese POS N
patients POS N
with POS N
T2DM. POS N

The POS N
change POS N
in POS N
the POS N
total POS N
DTR-QOL17 POS N
score POS N
and POS N
the POS N
score POS N
of POS N
one POS N
domain, POS N
burden POS N
on POS N
social POS N
activities POS N
and POS N
daily POS N
activities, POS N
was POS N
significantly POS N
greater POS N
in POS N
the POS N
linagliptin POS N
group POS N
than POS N
in POS N
the POS N
voglibose POS N
group. POS N

Treatment-related POS N
quality POS N
of POS N
life POS N
(QOL) POS N
is POS N
an POS N
important POS N
aspect POS N
of POS N
diabetes POS N
management. POS N

The POS N
change POS N
in POS N
the POS N
total POS N
DTR-QOL17 POS N
score POS N
and POS N
the POS N
score POS N
of POS N
one POS N
domain, POS N
burden POS N
on POS N
social POS N
activities POS N
and POS N
daily POS N
activities, POS N
was POS N
significantly POS N
greater POS N
in POS N
the POS N
linagliptin POS N
group POS N
than POS N
in POS N
the POS N
voglibose POS N
group. POS N

Compared POS N
with POS N
baseline POS N
data, POS N
total POS N
DTR-QOL17 POS N
scores POS N
were POS N
significantly POS N
higher POS N
after POS N
12 POS N
weeks POS N
of POS N
linagliptin POS N
and POS N
voglibose POS N
treatment. POS N

The POS N
change POS N
in POS N
the POS N
total POS N
DTR-QOL17 POS N
score POS N
and POS N
the POS N
score POS N
of POS N
one POS N
domain, POS N
burden POS N
on POS N
social POS N
activities POS N
and POS N
daily POS N
activities, POS N
was POS N
significantly POS N
greater POS N
in POS N
the POS N
linagliptin POS N
group POS N
than POS N
in POS N
the POS N
voglibose POS N
group. POS N

In POS N
addition, POS N
only POS N
linagliptin POS N
treatment POS N
was POS N
identified POS N
as POS N
a POS N
factor POS N
associated POS N
with POS N
an POS N
increased POS N
total POS N
DTR-QOL17 POS N
score. POS N

The POS N
change POS N
in POS N
the POS N
total POS N
DTR-QOL17 POS N
score POS N
and POS N
the POS N
score POS N
of POS N
one POS N
domain, POS N
burden POS N
on POS N
social POS N
activities POS N
and POS N
daily POS N
activities, POS N
was POS N
significantly POS N
greater POS N
in POS N
the POS N
linagliptin POS N
group POS N
than POS N
in POS N
the POS N
voglibose POS N
group. POS N

Linagliptin POS N
is POS N
superior POS N
to POS N
voglibose POS N
in POS N
terms POS N
of POS N
improving POS N
treatment-related POS N
QOL POS N
in POS N
Japanese POS N
patients POS N
with POS N
T2DM. POS N

In POS N
addition, POS N
only POS N
linagliptin POS N
treatment POS N
was POS N
identified POS N
as POS N
a POS N
factor POS N
associated POS N
with POS N
an POS N
increased POS N
total POS N
DTR-QOL17 POS N
score. POS N

Treatment-related POS N
quality POS N
of POS N
life POS N
(QOL) POS N
is POS N
an POS N
important POS N
aspect POS N
of POS N
diabetes POS N
management. POS N

In POS N
addition, POS N
only POS N
linagliptin POS N
treatment POS N
was POS N
identified POS N
as POS N
a POS N
factor POS N
associated POS N
with POS N
an POS N
increased POS N
total POS N
DTR-QOL17 POS N
score. POS N

Compared POS N
with POS N
baseline POS N
data, POS N
total POS N
DTR-QOL17 POS N
scores POS N
were POS N
significantly POS N
higher POS N
after POS N
12 POS N
weeks POS N
of POS N
linagliptin POS N
and POS N
voglibose POS N
treatment. POS N

In POS N
addition, POS N
only POS N
linagliptin POS N
treatment POS N
was POS N
identified POS N
as POS N
a POS N
factor POS N
associated POS N
with POS N
an POS N
increased POS N
total POS N
DTR-QOL17 POS N
score. POS N

The POS N
change POS N
in POS N
the POS N
total POS N
DTR-QOL17 POS N
score POS N
and POS N
the POS N
score POS N
of POS N
one POS N
domain, POS N
burden POS N
on POS N
social POS N
activities POS N
and POS N
daily POS N
activities, POS N
was POS N
significantly POS N
greater POS N
in POS N
the POS N
linagliptin POS N
group POS N
than POS N
in POS N
the POS N
voglibose POS N
group. POS N

In POS N
addition, POS N
only POS N
linagliptin POS N
treatment POS N
was POS N
identified POS N
as POS N
a POS N
factor POS N
associated POS N
with POS N
an POS N
increased POS N
total POS N
DTR-QOL17 POS N
score. POS N

Linagliptin POS N
is POS N
superior POS N
to POS N
voglibose POS N
in POS N
terms POS N
of POS N
improving POS N
treatment-related POS N
QOL POS N
in POS N
Japanese POS N
patients POS N
with POS N
T2DM. POS N

Linagliptin POS N
is POS N
superior POS N
to POS N
voglibose POS N
in POS N
terms POS N
of POS N
improving POS N
treatment-related POS N
QOL POS N
in POS N
Japanese POS N
patients POS N
with POS N
T2DM. POS N

Treatment-related POS N
quality POS N
of POS N
life POS N
(QOL) POS N
is POS N
an POS N
important POS N
aspect POS N
of POS N
diabetes POS N
management. POS N

Linagliptin POS N
is POS N
superior POS N
to POS N
voglibose POS N
in POS N
terms POS N
of POS N
improving POS N
treatment-related POS N
QOL POS N
in POS N
Japanese POS N
patients POS N
with POS N
T2DM. POS N

Compared POS N
with POS N
baseline POS N
data, POS N
total POS N
DTR-QOL17 POS N
scores POS N
were POS N
significantly POS N
higher POS N
after POS N
12 POS N
weeks POS N
of POS N
linagliptin POS N
and POS N
voglibose POS N
treatment. POS N

Linagliptin POS N
is POS N
superior POS N
to POS N
voglibose POS N
in POS N
terms POS N
of POS N
improving POS N
treatment-related POS N
QOL POS N
in POS N
Japanese POS N
patients POS N
with POS N
T2DM. POS N

The POS N
change POS N
in POS N
the POS N
total POS N
DTR-QOL17 POS N
score POS N
and POS N
the POS N
score POS N
of POS N
one POS N
domain, POS N
burden POS N
on POS N
social POS N
activities POS N
and POS N
daily POS N
activities, POS N
was POS N
significantly POS N
greater POS N
in POS N
the POS N
linagliptin POS N
group POS N
than POS N
in POS N
the POS N
voglibose POS N
group. POS N

Linagliptin POS N
is POS N
superior POS N
to POS N
voglibose POS N
in POS N
terms POS N
of POS N
improving POS N
treatment-related POS N
QOL POS N
in POS N
Japanese POS N
patients POS N
with POS N
T2DM. POS N

In POS N
addition, POS N
only POS N
linagliptin POS N
treatment POS N
was POS N
identified POS N
as POS N
a POS N
factor POS N
associated POS N
with POS N
an POS N
increased POS N
total POS N
DTR-QOL17 POS N
score. POS N

At POS N
6 POS N
months, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
fell POS N
by POS N
27.0 POS N
mm POS N
Hg POS N
(to POS N
125.8 POS N
mm POS N
Hg) POS N
in POS N
the POS N
intervention POS N
group POS N
and POS N
by POS N
9.3 POS N
mm POS N
Hg POS N
(to POS N
145.4 POS N
mm POS N
Hg) POS N
in POS N
the POS N
control POS N
group; POS N
the POS N
mean POS N
reduction POS N
was POS N
21.6 POS N
mm POS N
Hg POS N
greater POS N
with POS N
the POS N
intervention POS N
(95% POS N
confidence POS N
interval, POS N
14.7 POS N
to POS N
28.4; POS N
P<0.001). POS N

A POS N
blood-pressure POS N
level POS N
of POS N
less POS N
than POS N
130/80 POS N
mm POS N
Hg POS N
was POS N
achieved POS N
among POS N
63.6% POS N
of POS N
the POS N
participants POS N
in POS N
the POS N
intervention POS N
group POS N
versus POS N
11.7% POS N
of POS N
the POS N
participants POS N
in POS N
the POS N
control POS N
group POS N
(P<0.001). POS N

At POS N
6 POS N
months, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
fell POS N
by POS N
27.0 POS N
mm POS N
Hg POS N
(to POS N
125.8 POS N
mm POS N
Hg) POS N
in POS N
the POS N
intervention POS N
group POS N
and POS N
by POS N
9.3 POS N
mm POS N
Hg POS N
(to POS N
145.4 POS N
mm POS N
Hg) POS N
in POS N
the POS N
control POS N
group; POS N
the POS N
mean POS N
reduction POS N
was POS N
21.6 POS N
mm POS N
Hg POS N
greater POS N
with POS N
the POS N
intervention POS N
(95% POS N
confidence POS N
interval, POS N
14.7 POS N
to POS N
28.4; POS N
P<0.001). POS N

In POS N
the POS N
intervention POS N
group, POS N
the POS N
rate POS N
of POS N
cohort POS N
retention POS N
was POS N
95%, POS N
and POS N
there POS N
were POS N
few POS N
adverse POS N
events POS N
(three POS N
cases POS N
of POS N
acute POS N
kidney POS N
injury). POS N

At POS N
6 POS N
months, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
fell POS N
by POS N
27.0 POS N
mm POS N
Hg POS N
(to POS N
125.8 POS N
mm POS N
Hg) POS N
in POS N
the POS N
intervention POS N
group POS N
and POS N
by POS N
9.3 POS N
mm POS N
Hg POS N
(to POS N
145.4 POS N
mm POS N
Hg) POS N
in POS N
the POS N
control POS N
group; POS N
the POS N
mean POS N
reduction POS N
was POS N
21.6 POS N
mm POS N
Hg POS N
greater POS N
with POS N
the POS N
intervention POS N
(95% POS N
confidence POS N
interval, POS N
14.7 POS N
to POS N
28.4; POS N
P<0.001). POS N

Among POS N
black POS N
male POS N
barbershop POS N
patrons POS N
with POS N
uncontrolled POS N
hypertension, POS N
health POS N
promotion POS N
by POS N
barbers POS N
resulted POS N
in POS N
larger POS N
blood-pressure POS N
reduction POS N
when POS N
coupled POS N
with POS N
medication POS N
management POS N
in POS N
barbershops POS N
by POS N
specialty-trained POS N
pharmacists. POS N

A POS N
blood-pressure POS N
level POS N
of POS N
less POS N
than POS N
130/80 POS N
mm POS N
Hg POS N
was POS N
achieved POS N
among POS N
63.6% POS N
of POS N
the POS N
participants POS N
in POS N
the POS N
intervention POS N
group POS N
versus POS N
11.7% POS N
of POS N
the POS N
participants POS N
in POS N
the POS N
control POS N
group POS N
(P<0.001). POS N

At POS N
6 POS N
months, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
fell POS N
by POS N
27.0 POS N
mm POS N
Hg POS N
(to POS N
125.8 POS N
mm POS N
Hg) POS N
in POS N
the POS N
intervention POS N
group POS N
and POS N
by POS N
9.3 POS N
mm POS N
Hg POS N
(to POS N
145.4 POS N
mm POS N
Hg) POS N
in POS N
the POS N
control POS N
group; POS N
the POS N
mean POS N
reduction POS N
was POS N
21.6 POS N
mm POS N
Hg POS N
greater POS N
with POS N
the POS N
intervention POS N
(95% POS N
confidence POS N
interval, POS N
14.7 POS N
to POS N
28.4; POS N
P<0.001). POS N

A POS N
blood-pressure POS N
level POS N
of POS N
less POS N
than POS N
130/80 POS N
mm POS N
Hg POS N
was POS N
achieved POS N
among POS N
63.6% POS N
of POS N
the POS N
participants POS N
in POS N
the POS N
intervention POS N
group POS N
versus POS N
11.7% POS N
of POS N
the POS N
participants POS N
in POS N
the POS N
control POS N
group POS N
(P<0.001). POS N

In POS N
the POS N
intervention POS N
group, POS N
the POS N
rate POS N
of POS N
cohort POS N
retention POS N
was POS N
95%, POS N
and POS N
there POS N
were POS N
few POS N
adverse POS N
events POS N
(three POS N
cases POS N
of POS N
acute POS N
kidney POS N
injury). POS N

A POS N
blood-pressure POS N
level POS N
of POS N
less POS N
than POS N
130/80 POS N
mm POS N
Hg POS N
was POS N
achieved POS N
among POS N
63.6% POS N
of POS N
the POS N
participants POS N
in POS N
the POS N
intervention POS N
group POS N
versus POS N
11.7% POS N
of POS N
the POS N
participants POS N
in POS N
the POS N
control POS N
group POS N
(P<0.001). POS N

Among POS N
black POS N
male POS N
barbershop POS N
patrons POS N
with POS N
uncontrolled POS N
hypertension, POS N
health POS N
promotion POS N
by POS N
barbers POS N
resulted POS N
in POS N
larger POS N
blood-pressure POS N
reduction POS N
when POS N
coupled POS N
with POS N
medication POS N
management POS N
in POS N
barbershops POS N
by POS N
specialty-trained POS N
pharmacists. POS N

In POS N
the POS N
intervention POS N
group, POS N
the POS N
rate POS N
of POS N
cohort POS N
retention POS N
was POS N
95%, POS N
and POS N
there POS N
were POS N
few POS N
adverse POS N
events POS N
(three POS N
cases POS N
of POS N
acute POS N
kidney POS N
injury). POS N

At POS N
6 POS N
months, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
fell POS N
by POS N
27.0 POS N
mm POS N
Hg POS N
(to POS N
125.8 POS N
mm POS N
Hg) POS N
in POS N
the POS N
intervention POS N
group POS N
and POS N
by POS N
9.3 POS N
mm POS N
Hg POS N
(to POS N
145.4 POS N
mm POS N
Hg) POS N
in POS N
the POS N
control POS N
group; POS N
the POS N
mean POS N
reduction POS N
was POS N
21.6 POS N
mm POS N
Hg POS N
greater POS N
with POS N
the POS N
intervention POS N
(95% POS N
confidence POS N
interval, POS N
14.7 POS N
to POS N
28.4; POS N
P<0.001). POS N

In POS N
the POS N
intervention POS N
group, POS N
the POS N
rate POS N
of POS N
cohort POS N
retention POS N
was POS N
95%, POS N
and POS N
there POS N
were POS N
few POS N
adverse POS N
events POS N
(three POS N
cases POS N
of POS N
acute POS N
kidney POS N
injury). POS N

A POS N
blood-pressure POS N
level POS N
of POS N
less POS N
than POS N
130/80 POS N
mm POS N
Hg POS N
was POS N
achieved POS N
among POS N
63.6% POS N
of POS N
the POS N
participants POS N
in POS N
the POS N
intervention POS N
group POS N
versus POS N
11.7% POS N
of POS N
the POS N
participants POS N
in POS N
the POS N
control POS N
group POS N
(P<0.001). POS N

In POS N
the POS N
intervention POS N
group, POS N
the POS N
rate POS N
of POS N
cohort POS N
retention POS N
was POS N
95%, POS N
and POS N
there POS N
were POS N
few POS N
adverse POS N
events POS N
(three POS N
cases POS N
of POS N
acute POS N
kidney POS N
injury). POS N

Among POS N
black POS N
male POS N
barbershop POS N
patrons POS N
with POS N
uncontrolled POS N
hypertension, POS N
health POS N
promotion POS N
by POS N
barbers POS N
resulted POS N
in POS N
larger POS N
blood-pressure POS N
reduction POS N
when POS N
coupled POS N
with POS N
medication POS N
management POS N
in POS N
barbershops POS N
by POS N
specialty-trained POS N
pharmacists. POS N

Among POS N
black POS N
male POS N
barbershop POS N
patrons POS N
with POS N
uncontrolled POS N
hypertension, POS N
health POS N
promotion POS N
by POS N
barbers POS N
resulted POS N
in POS N
larger POS N
blood-pressure POS N
reduction POS N
when POS N
coupled POS N
with POS N
medication POS N
management POS N
in POS N
barbershops POS N
by POS N
specialty-trained POS N
pharmacists. POS N

At POS N
6 POS N
months, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
fell POS N
by POS N
27.0 POS N
mm POS N
Hg POS N
(to POS N
125.8 POS N
mm POS N
Hg) POS N
in POS N
the POS N
intervention POS N
group POS N
and POS N
by POS N
9.3 POS N
mm POS N
Hg POS N
(to POS N
145.4 POS N
mm POS N
Hg) POS N
in POS N
the POS N
control POS N
group; POS N
the POS N
mean POS N
reduction POS N
was POS N
21.6 POS N
mm POS N
Hg POS N
greater POS N
with POS N
the POS N
intervention POS N
(95% POS N
confidence POS N
interval, POS N
14.7 POS N
to POS N
28.4; POS N
P<0.001). POS N

Among POS N
black POS N
male POS N
barbershop POS N
patrons POS N
with POS N
uncontrolled POS N
hypertension, POS N
health POS N
promotion POS N
by POS N
barbers POS N
resulted POS N
in POS N
larger POS N
blood-pressure POS N
reduction POS N
when POS N
coupled POS N
with POS N
medication POS N
management POS N
in POS N
barbershops POS N
by POS N
specialty-trained POS N
pharmacists. POS N

A POS N
blood-pressure POS N
level POS N
of POS N
less POS N
than POS N
130/80 POS N
mm POS N
Hg POS N
was POS N
achieved POS N
among POS N
63.6% POS N
of POS N
the POS N
participants POS N
in POS N
the POS N
intervention POS N
group POS N
versus POS N
11.7% POS N
of POS N
the POS N
participants POS N
in POS N
the POS N
control POS N
group POS N
(P<0.001). POS N

Among POS N
black POS N
male POS N
barbershop POS N
patrons POS N
with POS N
uncontrolled POS N
hypertension, POS N
health POS N
promotion POS N
by POS N
barbers POS N
resulted POS N
in POS N
larger POS N
blood-pressure POS N
reduction POS N
when POS N
coupled POS N
with POS N
medication POS N
management POS N
in POS N
barbershops POS N
by POS N
specialty-trained POS N
pharmacists. POS N

In POS N
the POS N
intervention POS N
group, POS N
the POS N
rate POS N
of POS N
cohort POS N
retention POS N
was POS N
95%, POS N
and POS N
there POS N
were POS N
few POS N
adverse POS N
events POS N
(three POS N
cases POS N
of POS N
acute POS N
kidney POS N
injury). POS N

For POS N
several POS N
decades, POS N
both POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
and POS N
preoperative POS N
irradiation POS N
have POS N
been POS N
accepted POS N
treatments POS N
for POS N
patients POS N
with POS N
tumors POS N
of POS N
the POS N
head POS N
and POS N
neck. POS N

Occurrence POS N
of POS N
a POS N
second POS N
carcinoma POS N
was POS N
3 POS N
times POS N
as POS N
frequent POS N
in POS N
the POS N
irradiation POS N
group POS N
(9 POS N
patients) POS N
as POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(3 POS N
patients). POS N

For POS N
several POS N
decades, POS N
both POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
and POS N
preoperative POS N
irradiation POS N
have POS N
been POS N
accepted POS N
treatments POS N
for POS N
patients POS N
with POS N
tumors POS N
of POS N
the POS N
head POS N
and POS N
neck. POS N

the POS N
survival POS N
rates POS N
were POS N
by-and-large POS N
the POS N
same POS N
for POS N
the POS N
two POS N
groups. POS N

For POS N
several POS N
decades, POS N
both POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
and POS N
preoperative POS N
irradiation POS N
have POS N
been POS N
accepted POS N
treatments POS N
for POS N
patients POS N
with POS N
tumors POS N
of POS N
the POS N
head POS N
and POS N
neck. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
the POS N
chemotherapy POS N
group POS N
presented POS N
a POS N
more POS N
favorable POS N
picture. POS N

For POS N
several POS N
decades, POS N
both POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
and POS N
preoperative POS N
irradiation POS N
have POS N
been POS N
accepted POS N
treatments POS N
for POS N
patients POS N
with POS N
tumors POS N
of POS N
the POS N
head POS N
and POS N
neck. POS N

The POS N
long POS N
term POS N
survival POS N
results POS N
subsequent POS N
to POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
or POS N
preoperative POS N
radiotherapy POS N
were POS N
practically POS N
the POS N
same. POS N

For POS N
several POS N
decades, POS N
both POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
and POS N
preoperative POS N
irradiation POS N
have POS N
been POS N
accepted POS N
treatments POS N
for POS N
patients POS N
with POS N
tumors POS N
of POS N
the POS N
head POS N
and POS N
neck. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
patients POS N
who POS N
underwent POS N
intra-arterial POS N
chemotherapy POS N
appeared POS N
to POS N
be POS N
in POS N
a POS N
slightly POS N
more POS N
favorable POS N
situation. POS N

For POS N
several POS N
decades, POS N
both POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
and POS N
preoperative POS N
irradiation POS N
have POS N
been POS N
accepted POS N
treatments POS N
for POS N
patients POS N
with POS N
tumors POS N
of POS N
the POS N
head POS N
and POS N
neck. POS N

After POS N
5 POS N
years, POS N
18 POS N
of POS N
the POS N
47 POS N
patients POS N
who POS N
received POS N
chemotherapy POS N
and POS N
15 POS N
of POS N
the POS N
48 POS N
patients POS N
who POS N
received POS N
irradiation POS N
were POS N
still POS N
alive POS N
and POS N
tumor POS N
free. POS N

For POS N
several POS N
decades, POS N
both POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
and POS N
preoperative POS N
irradiation POS N
have POS N
been POS N
accepted POS N
treatments POS N
for POS N
patients POS N
with POS N
tumors POS N
of POS N
the POS N
head POS N
and POS N
neck. POS N

A POS N
few POS N
more POS N
patients POS N
had POS N
died POS N
of POS N
recurrence POS N
or POS N
regional POS N
metastasis POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(23 POS N
patients) POS N
than POS N
in POS N
the POS N
irradiation POS N
group POS N
(20 POS N
patients). POS N

Occurrence POS N
of POS N
a POS N
second POS N
carcinoma POS N
was POS N
3 POS N
times POS N
as POS N
frequent POS N
in POS N
the POS N
irradiation POS N
group POS N
(9 POS N
patients) POS N
as POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(3 POS N
patients). POS N

For POS N
several POS N
decades, POS N
both POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
and POS N
preoperative POS N
irradiation POS N
have POS N
been POS N
accepted POS N
treatments POS N
for POS N
patients POS N
with POS N
tumors POS N
of POS N
the POS N
head POS N
and POS N
neck. POS N

Occurrence POS N
of POS N
a POS N
second POS N
carcinoma POS N
was POS N
3 POS N
times POS N
as POS N
frequent POS N
in POS N
the POS N
irradiation POS N
group POS N
(9 POS N
patients) POS N
as POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(3 POS N
patients). POS N

the POS N
survival POS N
rates POS N
were POS N
by-and-large POS N
the POS N
same POS N
for POS N
the POS N
two POS N
groups. POS N

Occurrence POS N
of POS N
a POS N
second POS N
carcinoma POS N
was POS N
3 POS N
times POS N
as POS N
frequent POS N
in POS N
the POS N
irradiation POS N
group POS N
(9 POS N
patients) POS N
as POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(3 POS N
patients). POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
the POS N
chemotherapy POS N
group POS N
presented POS N
a POS N
more POS N
favorable POS N
picture. POS N

Occurrence POS N
of POS N
a POS N
second POS N
carcinoma POS N
was POS N
3 POS N
times POS N
as POS N
frequent POS N
in POS N
the POS N
irradiation POS N
group POS N
(9 POS N
patients) POS N
as POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(3 POS N
patients). POS N

The POS N
long POS N
term POS N
survival POS N
results POS N
subsequent POS N
to POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
or POS N
preoperative POS N
radiotherapy POS N
were POS N
practically POS N
the POS N
same. POS N

Occurrence POS N
of POS N
a POS N
second POS N
carcinoma POS N
was POS N
3 POS N
times POS N
as POS N
frequent POS N
in POS N
the POS N
irradiation POS N
group POS N
(9 POS N
patients) POS N
as POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(3 POS N
patients). POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
patients POS N
who POS N
underwent POS N
intra-arterial POS N
chemotherapy POS N
appeared POS N
to POS N
be POS N
in POS N
a POS N
slightly POS N
more POS N
favorable POS N
situation. POS N

Occurrence POS N
of POS N
a POS N
second POS N
carcinoma POS N
was POS N
3 POS N
times POS N
as POS N
frequent POS N
in POS N
the POS N
irradiation POS N
group POS N
(9 POS N
patients) POS N
as POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(3 POS N
patients). POS N

After POS N
5 POS N
years, POS N
18 POS N
of POS N
the POS N
47 POS N
patients POS N
who POS N
received POS N
chemotherapy POS N
and POS N
15 POS N
of POS N
the POS N
48 POS N
patients POS N
who POS N
received POS N
irradiation POS N
were POS N
still POS N
alive POS N
and POS N
tumor POS N
free. POS N

Occurrence POS N
of POS N
a POS N
second POS N
carcinoma POS N
was POS N
3 POS N
times POS N
as POS N
frequent POS N
in POS N
the POS N
irradiation POS N
group POS N
(9 POS N
patients) POS N
as POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(3 POS N
patients). POS N

A POS N
few POS N
more POS N
patients POS N
had POS N
died POS N
of POS N
recurrence POS N
or POS N
regional POS N
metastasis POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(23 POS N
patients) POS N
than POS N
in POS N
the POS N
irradiation POS N
group POS N
(20 POS N
patients). POS N

the POS N
survival POS N
rates POS N
were POS N
by-and-large POS N
the POS N
same POS N
for POS N
the POS N
two POS N
groups. POS N

For POS N
several POS N
decades, POS N
both POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
and POS N
preoperative POS N
irradiation POS N
have POS N
been POS N
accepted POS N
treatments POS N
for POS N
patients POS N
with POS N
tumors POS N
of POS N
the POS N
head POS N
and POS N
neck. POS N

the POS N
survival POS N
rates POS N
were POS N
by-and-large POS N
the POS N
same POS N
for POS N
the POS N
two POS N
groups. POS N

Occurrence POS N
of POS N
a POS N
second POS N
carcinoma POS N
was POS N
3 POS N
times POS N
as POS N
frequent POS N
in POS N
the POS N
irradiation POS N
group POS N
(9 POS N
patients) POS N
as POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(3 POS N
patients). POS N

the POS N
survival POS N
rates POS N
were POS N
by-and-large POS N
the POS N
same POS N
for POS N
the POS N
two POS N
groups. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
the POS N
chemotherapy POS N
group POS N
presented POS N
a POS N
more POS N
favorable POS N
picture. POS N

the POS N
survival POS N
rates POS N
were POS N
by-and-large POS N
the POS N
same POS N
for POS N
the POS N
two POS N
groups. POS N

The POS N
long POS N
term POS N
survival POS N
results POS N
subsequent POS N
to POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
or POS N
preoperative POS N
radiotherapy POS N
were POS N
practically POS N
the POS N
same. POS N

the POS N
survival POS N
rates POS N
were POS N
by-and-large POS N
the POS N
same POS N
for POS N
the POS N
two POS N
groups. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
patients POS N
who POS N
underwent POS N
intra-arterial POS N
chemotherapy POS N
appeared POS N
to POS N
be POS N
in POS N
a POS N
slightly POS N
more POS N
favorable POS N
situation. POS N

the POS N
survival POS N
rates POS N
were POS N
by-and-large POS N
the POS N
same POS N
for POS N
the POS N
two POS N
groups. POS N

After POS N
5 POS N
years, POS N
18 POS N
of POS N
the POS N
47 POS N
patients POS N
who POS N
received POS N
chemotherapy POS N
and POS N
15 POS N
of POS N
the POS N
48 POS N
patients POS N
who POS N
received POS N
irradiation POS N
were POS N
still POS N
alive POS N
and POS N
tumor POS N
free. POS N

the POS N
survival POS N
rates POS N
were POS N
by-and-large POS N
the POS N
same POS N
for POS N
the POS N
two POS N
groups. POS N

A POS N
few POS N
more POS N
patients POS N
had POS N
died POS N
of POS N
recurrence POS N
or POS N
regional POS N
metastasis POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(23 POS N
patients) POS N
than POS N
in POS N
the POS N
irradiation POS N
group POS N
(20 POS N
patients). POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
the POS N
chemotherapy POS N
group POS N
presented POS N
a POS N
more POS N
favorable POS N
picture. POS N

For POS N
several POS N
decades, POS N
both POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
and POS N
preoperative POS N
irradiation POS N
have POS N
been POS N
accepted POS N
treatments POS N
for POS N
patients POS N
with POS N
tumors POS N
of POS N
the POS N
head POS N
and POS N
neck. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
the POS N
chemotherapy POS N
group POS N
presented POS N
a POS N
more POS N
favorable POS N
picture. POS N

Occurrence POS N
of POS N
a POS N
second POS N
carcinoma POS N
was POS N
3 POS N
times POS N
as POS N
frequent POS N
in POS N
the POS N
irradiation POS N
group POS N
(9 POS N
patients) POS N
as POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(3 POS N
patients). POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
the POS N
chemotherapy POS N
group POS N
presented POS N
a POS N
more POS N
favorable POS N
picture. POS N

the POS N
survival POS N
rates POS N
were POS N
by-and-large POS N
the POS N
same POS N
for POS N
the POS N
two POS N
groups. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
the POS N
chemotherapy POS N
group POS N
presented POS N
a POS N
more POS N
favorable POS N
picture. POS N

The POS N
long POS N
term POS N
survival POS N
results POS N
subsequent POS N
to POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
or POS N
preoperative POS N
radiotherapy POS N
were POS N
practically POS N
the POS N
same. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
the POS N
chemotherapy POS N
group POS N
presented POS N
a POS N
more POS N
favorable POS N
picture. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
patients POS N
who POS N
underwent POS N
intra-arterial POS N
chemotherapy POS N
appeared POS N
to POS N
be POS N
in POS N
a POS N
slightly POS N
more POS N
favorable POS N
situation. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
the POS N
chemotherapy POS N
group POS N
presented POS N
a POS N
more POS N
favorable POS N
picture. POS N

After POS N
5 POS N
years, POS N
18 POS N
of POS N
the POS N
47 POS N
patients POS N
who POS N
received POS N
chemotherapy POS N
and POS N
15 POS N
of POS N
the POS N
48 POS N
patients POS N
who POS N
received POS N
irradiation POS N
were POS N
still POS N
alive POS N
and POS N
tumor POS N
free. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
the POS N
chemotherapy POS N
group POS N
presented POS N
a POS N
more POS N
favorable POS N
picture. POS N

A POS N
few POS N
more POS N
patients POS N
had POS N
died POS N
of POS N
recurrence POS N
or POS N
regional POS N
metastasis POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(23 POS N
patients) POS N
than POS N
in POS N
the POS N
irradiation POS N
group POS N
(20 POS N
patients). POS N

The POS N
long POS N
term POS N
survival POS N
results POS N
subsequent POS N
to POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
or POS N
preoperative POS N
radiotherapy POS N
were POS N
practically POS N
the POS N
same. POS N

For POS N
several POS N
decades, POS N
both POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
and POS N
preoperative POS N
irradiation POS N
have POS N
been POS N
accepted POS N
treatments POS N
for POS N
patients POS N
with POS N
tumors POS N
of POS N
the POS N
head POS N
and POS N
neck. POS N

The POS N
long POS N
term POS N
survival POS N
results POS N
subsequent POS N
to POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
or POS N
preoperative POS N
radiotherapy POS N
were POS N
practically POS N
the POS N
same. POS N

Occurrence POS N
of POS N
a POS N
second POS N
carcinoma POS N
was POS N
3 POS N
times POS N
as POS N
frequent POS N
in POS N
the POS N
irradiation POS N
group POS N
(9 POS N
patients) POS N
as POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(3 POS N
patients). POS N

The POS N
long POS N
term POS N
survival POS N
results POS N
subsequent POS N
to POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
or POS N
preoperative POS N
radiotherapy POS N
were POS N
practically POS N
the POS N
same. POS N

the POS N
survival POS N
rates POS N
were POS N
by-and-large POS N
the POS N
same POS N
for POS N
the POS N
two POS N
groups. POS N

The POS N
long POS N
term POS N
survival POS N
results POS N
subsequent POS N
to POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
or POS N
preoperative POS N
radiotherapy POS N
were POS N
practically POS N
the POS N
same. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
the POS N
chemotherapy POS N
group POS N
presented POS N
a POS N
more POS N
favorable POS N
picture. POS N

The POS N
long POS N
term POS N
survival POS N
results POS N
subsequent POS N
to POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
or POS N
preoperative POS N
radiotherapy POS N
were POS N
practically POS N
the POS N
same. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
patients POS N
who POS N
underwent POS N
intra-arterial POS N
chemotherapy POS N
appeared POS N
to POS N
be POS N
in POS N
a POS N
slightly POS N
more POS N
favorable POS N
situation. POS N

The POS N
long POS N
term POS N
survival POS N
results POS N
subsequent POS N
to POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
or POS N
preoperative POS N
radiotherapy POS N
were POS N
practically POS N
the POS N
same. POS N

After POS N
5 POS N
years, POS N
18 POS N
of POS N
the POS N
47 POS N
patients POS N
who POS N
received POS N
chemotherapy POS N
and POS N
15 POS N
of POS N
the POS N
48 POS N
patients POS N
who POS N
received POS N
irradiation POS N
were POS N
still POS N
alive POS N
and POS N
tumor POS N
free. POS N

The POS N
long POS N
term POS N
survival POS N
results POS N
subsequent POS N
to POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
or POS N
preoperative POS N
radiotherapy POS N
were POS N
practically POS N
the POS N
same. POS N

A POS N
few POS N
more POS N
patients POS N
had POS N
died POS N
of POS N
recurrence POS N
or POS N
regional POS N
metastasis POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(23 POS N
patients) POS N
than POS N
in POS N
the POS N
irradiation POS N
group POS N
(20 POS N
patients). POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
patients POS N
who POS N
underwent POS N
intra-arterial POS N
chemotherapy POS N
appeared POS N
to POS N
be POS N
in POS N
a POS N
slightly POS N
more POS N
favorable POS N
situation. POS N

For POS N
several POS N
decades, POS N
both POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
and POS N
preoperative POS N
irradiation POS N
have POS N
been POS N
accepted POS N
treatments POS N
for POS N
patients POS N
with POS N
tumors POS N
of POS N
the POS N
head POS N
and POS N
neck. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
patients POS N
who POS N
underwent POS N
intra-arterial POS N
chemotherapy POS N
appeared POS N
to POS N
be POS N
in POS N
a POS N
slightly POS N
more POS N
favorable POS N
situation. POS N

Occurrence POS N
of POS N
a POS N
second POS N
carcinoma POS N
was POS N
3 POS N
times POS N
as POS N
frequent POS N
in POS N
the POS N
irradiation POS N
group POS N
(9 POS N
patients) POS N
as POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(3 POS N
patients). POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
patients POS N
who POS N
underwent POS N
intra-arterial POS N
chemotherapy POS N
appeared POS N
to POS N
be POS N
in POS N
a POS N
slightly POS N
more POS N
favorable POS N
situation. POS N

the POS N
survival POS N
rates POS N
were POS N
by-and-large POS N
the POS N
same POS N
for POS N
the POS N
two POS N
groups. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
patients POS N
who POS N
underwent POS N
intra-arterial POS N
chemotherapy POS N
appeared POS N
to POS N
be POS N
in POS N
a POS N
slightly POS N
more POS N
favorable POS N
situation. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
the POS N
chemotherapy POS N
group POS N
presented POS N
a POS N
more POS N
favorable POS N
picture. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
patients POS N
who POS N
underwent POS N
intra-arterial POS N
chemotherapy POS N
appeared POS N
to POS N
be POS N
in POS N
a POS N
slightly POS N
more POS N
favorable POS N
situation. POS N

The POS N
long POS N
term POS N
survival POS N
results POS N
subsequent POS N
to POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
or POS N
preoperative POS N
radiotherapy POS N
were POS N
practically POS N
the POS N
same. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
patients POS N
who POS N
underwent POS N
intra-arterial POS N
chemotherapy POS N
appeared POS N
to POS N
be POS N
in POS N
a POS N
slightly POS N
more POS N
favorable POS N
situation. POS N

After POS N
5 POS N
years, POS N
18 POS N
of POS N
the POS N
47 POS N
patients POS N
who POS N
received POS N
chemotherapy POS N
and POS N
15 POS N
of POS N
the POS N
48 POS N
patients POS N
who POS N
received POS N
irradiation POS N
were POS N
still POS N
alive POS N
and POS N
tumor POS N
free. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
patients POS N
who POS N
underwent POS N
intra-arterial POS N
chemotherapy POS N
appeared POS N
to POS N
be POS N
in POS N
a POS N
slightly POS N
more POS N
favorable POS N
situation. POS N

A POS N
few POS N
more POS N
patients POS N
had POS N
died POS N
of POS N
recurrence POS N
or POS N
regional POS N
metastasis POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(23 POS N
patients) POS N
than POS N
in POS N
the POS N
irradiation POS N
group POS N
(20 POS N
patients). POS N

After POS N
5 POS N
years, POS N
18 POS N
of POS N
the POS N
47 POS N
patients POS N
who POS N
received POS N
chemotherapy POS N
and POS N
15 POS N
of POS N
the POS N
48 POS N
patients POS N
who POS N
received POS N
irradiation POS N
were POS N
still POS N
alive POS N
and POS N
tumor POS N
free. POS N

For POS N
several POS N
decades, POS N
both POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
and POS N
preoperative POS N
irradiation POS N
have POS N
been POS N
accepted POS N
treatments POS N
for POS N
patients POS N
with POS N
tumors POS N
of POS N
the POS N
head POS N
and POS N
neck. POS N

After POS N
5 POS N
years, POS N
18 POS N
of POS N
the POS N
47 POS N
patients POS N
who POS N
received POS N
chemotherapy POS N
and POS N
15 POS N
of POS N
the POS N
48 POS N
patients POS N
who POS N
received POS N
irradiation POS N
were POS N
still POS N
alive POS N
and POS N
tumor POS N
free. POS N

Occurrence POS N
of POS N
a POS N
second POS N
carcinoma POS N
was POS N
3 POS N
times POS N
as POS N
frequent POS N
in POS N
the POS N
irradiation POS N
group POS N
(9 POS N
patients) POS N
as POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(3 POS N
patients). POS N

After POS N
5 POS N
years, POS N
18 POS N
of POS N
the POS N
47 POS N
patients POS N
who POS N
received POS N
chemotherapy POS N
and POS N
15 POS N
of POS N
the POS N
48 POS N
patients POS N
who POS N
received POS N
irradiation POS N
were POS N
still POS N
alive POS N
and POS N
tumor POS N
free. POS N

the POS N
survival POS N
rates POS N
were POS N
by-and-large POS N
the POS N
same POS N
for POS N
the POS N
two POS N
groups. POS N

After POS N
5 POS N
years, POS N
18 POS N
of POS N
the POS N
47 POS N
patients POS N
who POS N
received POS N
chemotherapy POS N
and POS N
15 POS N
of POS N
the POS N
48 POS N
patients POS N
who POS N
received POS N
irradiation POS N
were POS N
still POS N
alive POS N
and POS N
tumor POS N
free. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
the POS N
chemotherapy POS N
group POS N
presented POS N
a POS N
more POS N
favorable POS N
picture. POS N

After POS N
5 POS N
years, POS N
18 POS N
of POS N
the POS N
47 POS N
patients POS N
who POS N
received POS N
chemotherapy POS N
and POS N
15 POS N
of POS N
the POS N
48 POS N
patients POS N
who POS N
received POS N
irradiation POS N
were POS N
still POS N
alive POS N
and POS N
tumor POS N
free. POS N

The POS N
long POS N
term POS N
survival POS N
results POS N
subsequent POS N
to POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
or POS N
preoperative POS N
radiotherapy POS N
were POS N
practically POS N
the POS N
same. POS N

After POS N
5 POS N
years, POS N
18 POS N
of POS N
the POS N
47 POS N
patients POS N
who POS N
received POS N
chemotherapy POS N
and POS N
15 POS N
of POS N
the POS N
48 POS N
patients POS N
who POS N
received POS N
irradiation POS N
were POS N
still POS N
alive POS N
and POS N
tumor POS N
free. POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
patients POS N
who POS N
underwent POS N
intra-arterial POS N
chemotherapy POS N
appeared POS N
to POS N
be POS N
in POS N
a POS N
slightly POS N
more POS N
favorable POS N
situation. POS N

After POS N
5 POS N
years, POS N
18 POS N
of POS N
the POS N
47 POS N
patients POS N
who POS N
received POS N
chemotherapy POS N
and POS N
15 POS N
of POS N
the POS N
48 POS N
patients POS N
who POS N
received POS N
irradiation POS N
were POS N
still POS N
alive POS N
and POS N
tumor POS N
free. POS N

A POS N
few POS N
more POS N
patients POS N
had POS N
died POS N
of POS N
recurrence POS N
or POS N
regional POS N
metastasis POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(23 POS N
patients) POS N
than POS N
in POS N
the POS N
irradiation POS N
group POS N
(20 POS N
patients). POS N

A POS N
few POS N
more POS N
patients POS N
had POS N
died POS N
of POS N
recurrence POS N
or POS N
regional POS N
metastasis POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(23 POS N
patients) POS N
than POS N
in POS N
the POS N
irradiation POS N
group POS N
(20 POS N
patients). POS N

For POS N
several POS N
decades, POS N
both POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
and POS N
preoperative POS N
irradiation POS N
have POS N
been POS N
accepted POS N
treatments POS N
for POS N
patients POS N
with POS N
tumors POS N
of POS N
the POS N
head POS N
and POS N
neck. POS N

A POS N
few POS N
more POS N
patients POS N
had POS N
died POS N
of POS N
recurrence POS N
or POS N
regional POS N
metastasis POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(23 POS N
patients) POS N
than POS N
in POS N
the POS N
irradiation POS N
group POS N
(20 POS N
patients). POS N

Occurrence POS N
of POS N
a POS N
second POS N
carcinoma POS N
was POS N
3 POS N
times POS N
as POS N
frequent POS N
in POS N
the POS N
irradiation POS N
group POS N
(9 POS N
patients) POS N
as POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(3 POS N
patients). POS N

A POS N
few POS N
more POS N
patients POS N
had POS N
died POS N
of POS N
recurrence POS N
or POS N
regional POS N
metastasis POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(23 POS N
patients) POS N
than POS N
in POS N
the POS N
irradiation POS N
group POS N
(20 POS N
patients). POS N

the POS N
survival POS N
rates POS N
were POS N
by-and-large POS N
the POS N
same POS N
for POS N
the POS N
two POS N
groups. POS N

A POS N
few POS N
more POS N
patients POS N
had POS N
died POS N
of POS N
recurrence POS N
or POS N
regional POS N
metastasis POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(23 POS N
patients) POS N
than POS N
in POS N
the POS N
irradiation POS N
group POS N
(20 POS N
patients). POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
the POS N
chemotherapy POS N
group POS N
presented POS N
a POS N
more POS N
favorable POS N
picture. POS N

A POS N
few POS N
more POS N
patients POS N
had POS N
died POS N
of POS N
recurrence POS N
or POS N
regional POS N
metastasis POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(23 POS N
patients) POS N
than POS N
in POS N
the POS N
irradiation POS N
group POS N
(20 POS N
patients). POS N

The POS N
long POS N
term POS N
survival POS N
results POS N
subsequent POS N
to POS N
preoperative POS N
intra-arterial POS N
chemotherapy POS N
or POS N
preoperative POS N
radiotherapy POS N
were POS N
practically POS N
the POS N
same. POS N

A POS N
few POS N
more POS N
patients POS N
had POS N
died POS N
of POS N
recurrence POS N
or POS N
regional POS N
metastasis POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(23 POS N
patients) POS N
than POS N
in POS N
the POS N
irradiation POS N
group POS N
(20 POS N
patients). POS N

Regarding POS N
postoperative POS N
quality POS N
of POS N
life, POS N
patients POS N
who POS N
underwent POS N
intra-arterial POS N
chemotherapy POS N
appeared POS N
to POS N
be POS N
in POS N
a POS N
slightly POS N
more POS N
favorable POS N
situation. POS N

A POS N
few POS N
more POS N
patients POS N
had POS N
died POS N
of POS N
recurrence POS N
or POS N
regional POS N
metastasis POS N
in POS N
the POS N
chemotherapy POS N
group POS N
(23 POS N
patients) POS N
than POS N
in POS N
the POS N
irradiation POS N
group POS N
(20 POS N
patients). POS N

After POS N
5 POS N
years, POS N
18 POS N
of POS N
the POS N
47 POS N
patients POS N
who POS N
received POS N
chemotherapy POS N
and POS N
15 POS N
of POS N
the POS N
48 POS N
patients POS N
who POS N
received POS N
irradiation POS N
were POS N
still POS N
alive POS N
and POS N
tumor POS N
free. POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
17.3% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
7.9% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.01; POS N
hazard POS N
ratio, POS N
2.59; POS N
95% POS N
confidence POS N
interval, POS N
1.20-5.60). POS N

Postoperative POS N
complications POS N
developed POS N
in POS N
36 POS N
patients POS N
(29%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
48 POS N
patients POS N
(41%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.06). POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
17.3% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
7.9% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.01; POS N
hazard POS N
ratio, POS N
2.59; POS N
95% POS N
confidence POS N
interval, POS N
1.20-5.60). POS N

Serious POS N
complications POS N
requiring POS N
reoperation POS N
or POS N
producing POS N
a POS N
loss POS N
of POS N
2 POS N
Snellen POS N
lines POS N
or POS N
more POS N
occurred POS N
in POS N
1 POS N
patient POS N
(1%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
8 POS N
patients POS N
(7%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.03). POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
17.3% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
7.9% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.01; POS N
hazard POS N
ratio, POS N
2.59; POS N
95% POS N
confidence POS N
interval, POS N
1.20-5.60). POS N

Trabeculectomy POS N
with POS N
MMC POS N
had POS N
a POS N
higher POS N
surgical POS N
success POS N
rate POS N
than POS N
tube POS N
shunt POS N
implantation POS N
after POS N
1 POS N
year POS N
in POS N
the POS N
PTVT POS N
Study. POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
17.3% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
7.9% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.01; POS N
hazard POS N
ratio, POS N
2.59; POS N
95% POS N
confidence POS N
interval, POS N
1.20-5.60). POS N

The POS N
frequency POS N
of POS N
serious POS N
complications POS N
producing POS N
vision POS N
loss POS N
or POS N
requiring POS N
reoperation POS N
was POS N
lower POS N
after POS N
tube POS N
shunt POS N
surgery POS N
relative POS N
to POS N
trabeculectomy POS N
with POS N
MMC. POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
17.3% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
7.9% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.01; POS N
hazard POS N
ratio, POS N
2.59; POS N
95% POS N
confidence POS N
interval, POS N
1.20-5.60). POS N

Lower POS N
IOP POS N
with POS N
use POS N
of POS N
fewer POS N
glaucoma POS N
medications POS N
was POS N
achieved POS N
after POS N
trabeculectomy POS N
with POS N
MMC POS N
compared POS N
with POS N
tube POS N
shunt POS N
surgery POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up. POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
17.3% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
7.9% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.01; POS N
hazard POS N
ratio, POS N
2.59; POS N
95% POS N
confidence POS N
interval, POS N
1.20-5.60). POS N

Mean POS N
± POS N
standard POS N
deviation POS N
IOP POS N
was POS N
13.8±4.1 POS N
mmHg POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
12.4±4.4 POS N
mmHg POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
at POS N
1 POS N
year POS N
(P POS N
= POS N
0.01), POS N
and POS N
the POS N
number POS N
of POS N
glaucoma POS N
medications POS N
was POS N
2.1±1.4 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.9±1.4 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
0.001). POS N

Postoperative POS N
complications POS N
developed POS N
in POS N
36 POS N
patients POS N
(29%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
48 POS N
patients POS N
(41%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.06). POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
17.3% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
7.9% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.01; POS N
hazard POS N
ratio, POS N
2.59; POS N
95% POS N
confidence POS N
interval, POS N
1.20-5.60). POS N

Postoperative POS N
complications POS N
developed POS N
in POS N
36 POS N
patients POS N
(29%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
48 POS N
patients POS N
(41%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.06). POS N

Serious POS N
complications POS N
requiring POS N
reoperation POS N
or POS N
producing POS N
a POS N
loss POS N
of POS N
2 POS N
Snellen POS N
lines POS N
or POS N
more POS N
occurred POS N
in POS N
1 POS N
patient POS N
(1%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
8 POS N
patients POS N
(7%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.03). POS N

Postoperative POS N
complications POS N
developed POS N
in POS N
36 POS N
patients POS N
(29%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
48 POS N
patients POS N
(41%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.06). POS N

Trabeculectomy POS N
with POS N
MMC POS N
had POS N
a POS N
higher POS N
surgical POS N
success POS N
rate POS N
than POS N
tube POS N
shunt POS N
implantation POS N
after POS N
1 POS N
year POS N
in POS N
the POS N
PTVT POS N
Study. POS N

Postoperative POS N
complications POS N
developed POS N
in POS N
36 POS N
patients POS N
(29%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
48 POS N
patients POS N
(41%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.06). POS N

The POS N
frequency POS N
of POS N
serious POS N
complications POS N
producing POS N
vision POS N
loss POS N
or POS N
requiring POS N
reoperation POS N
was POS N
lower POS N
after POS N
tube POS N
shunt POS N
surgery POS N
relative POS N
to POS N
trabeculectomy POS N
with POS N
MMC. POS N

Postoperative POS N
complications POS N
developed POS N
in POS N
36 POS N
patients POS N
(29%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
48 POS N
patients POS N
(41%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.06). POS N

Lower POS N
IOP POS N
with POS N
use POS N
of POS N
fewer POS N
glaucoma POS N
medications POS N
was POS N
achieved POS N
after POS N
trabeculectomy POS N
with POS N
MMC POS N
compared POS N
with POS N
tube POS N
shunt POS N
surgery POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up. POS N

Postoperative POS N
complications POS N
developed POS N
in POS N
36 POS N
patients POS N
(29%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
48 POS N
patients POS N
(41%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.06). POS N

Mean POS N
± POS N
standard POS N
deviation POS N
IOP POS N
was POS N
13.8±4.1 POS N
mmHg POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
12.4±4.4 POS N
mmHg POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
at POS N
1 POS N
year POS N
(P POS N
= POS N
0.01), POS N
and POS N
the POS N
number POS N
of POS N
glaucoma POS N
medications POS N
was POS N
2.1±1.4 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.9±1.4 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
0.001). POS N

Serious POS N
complications POS N
requiring POS N
reoperation POS N
or POS N
producing POS N
a POS N
loss POS N
of POS N
2 POS N
Snellen POS N
lines POS N
or POS N
more POS N
occurred POS N
in POS N
1 POS N
patient POS N
(1%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
8 POS N
patients POS N
(7%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.03). POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
17.3% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
7.9% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.01; POS N
hazard POS N
ratio, POS N
2.59; POS N
95% POS N
confidence POS N
interval, POS N
1.20-5.60). POS N

Serious POS N
complications POS N
requiring POS N
reoperation POS N
or POS N
producing POS N
a POS N
loss POS N
of POS N
2 POS N
Snellen POS N
lines POS N
or POS N
more POS N
occurred POS N
in POS N
1 POS N
patient POS N
(1%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
8 POS N
patients POS N
(7%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.03). POS N

Postoperative POS N
complications POS N
developed POS N
in POS N
36 POS N
patients POS N
(29%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
48 POS N
patients POS N
(41%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.06). POS N

Serious POS N
complications POS N
requiring POS N
reoperation POS N
or POS N
producing POS N
a POS N
loss POS N
of POS N
2 POS N
Snellen POS N
lines POS N
or POS N
more POS N
occurred POS N
in POS N
1 POS N
patient POS N
(1%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
8 POS N
patients POS N
(7%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.03). POS N

Trabeculectomy POS N
with POS N
MMC POS N
had POS N
a POS N
higher POS N
surgical POS N
success POS N
rate POS N
than POS N
tube POS N
shunt POS N
implantation POS N
after POS N
1 POS N
year POS N
in POS N
the POS N
PTVT POS N
Study. POS N

Serious POS N
complications POS N
requiring POS N
reoperation POS N
or POS N
producing POS N
a POS N
loss POS N
of POS N
2 POS N
Snellen POS N
lines POS N
or POS N
more POS N
occurred POS N
in POS N
1 POS N
patient POS N
(1%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
8 POS N
patients POS N
(7%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.03). POS N

The POS N
frequency POS N
of POS N
serious POS N
complications POS N
producing POS N
vision POS N
loss POS N
or POS N
requiring POS N
reoperation POS N
was POS N
lower POS N
after POS N
tube POS N
shunt POS N
surgery POS N
relative POS N
to POS N
trabeculectomy POS N
with POS N
MMC. POS N

Serious POS N
complications POS N
requiring POS N
reoperation POS N
or POS N
producing POS N
a POS N
loss POS N
of POS N
2 POS N
Snellen POS N
lines POS N
or POS N
more POS N
occurred POS N
in POS N
1 POS N
patient POS N
(1%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
8 POS N
patients POS N
(7%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.03). POS N

Lower POS N
IOP POS N
with POS N
use POS N
of POS N
fewer POS N
glaucoma POS N
medications POS N
was POS N
achieved POS N
after POS N
trabeculectomy POS N
with POS N
MMC POS N
compared POS N
with POS N
tube POS N
shunt POS N
surgery POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up. POS N

Serious POS N
complications POS N
requiring POS N
reoperation POS N
or POS N
producing POS N
a POS N
loss POS N
of POS N
2 POS N
Snellen POS N
lines POS N
or POS N
more POS N
occurred POS N
in POS N
1 POS N
patient POS N
(1%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
8 POS N
patients POS N
(7%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.03). POS N

Mean POS N
± POS N
standard POS N
deviation POS N
IOP POS N
was POS N
13.8±4.1 POS N
mmHg POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
12.4±4.4 POS N
mmHg POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
at POS N
1 POS N
year POS N
(P POS N
= POS N
0.01), POS N
and POS N
the POS N
number POS N
of POS N
glaucoma POS N
medications POS N
was POS N
2.1±1.4 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.9±1.4 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
0.001). POS N

Trabeculectomy POS N
with POS N
MMC POS N
had POS N
a POS N
higher POS N
surgical POS N
success POS N
rate POS N
than POS N
tube POS N
shunt POS N
implantation POS N
after POS N
1 POS N
year POS N
in POS N
the POS N
PTVT POS N
Study. POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
17.3% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
7.9% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.01; POS N
hazard POS N
ratio, POS N
2.59; POS N
95% POS N
confidence POS N
interval, POS N
1.20-5.60). POS N

Trabeculectomy POS N
with POS N
MMC POS N
had POS N
a POS N
higher POS N
surgical POS N
success POS N
rate POS N
than POS N
tube POS N
shunt POS N
implantation POS N
after POS N
1 POS N
year POS N
in POS N
the POS N
PTVT POS N
Study. POS N

Postoperative POS N
complications POS N
developed POS N
in POS N
36 POS N
patients POS N
(29%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
48 POS N
patients POS N
(41%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.06). POS N

Trabeculectomy POS N
with POS N
MMC POS N
had POS N
a POS N
higher POS N
surgical POS N
success POS N
rate POS N
than POS N
tube POS N
shunt POS N
implantation POS N
after POS N
1 POS N
year POS N
in POS N
the POS N
PTVT POS N
Study. POS N

Serious POS N
complications POS N
requiring POS N
reoperation POS N
or POS N
producing POS N
a POS N
loss POS N
of POS N
2 POS N
Snellen POS N
lines POS N
or POS N
more POS N
occurred POS N
in POS N
1 POS N
patient POS N
(1%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
8 POS N
patients POS N
(7%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.03). POS N

Trabeculectomy POS N
with POS N
MMC POS N
had POS N
a POS N
higher POS N
surgical POS N
success POS N
rate POS N
than POS N
tube POS N
shunt POS N
implantation POS N
after POS N
1 POS N
year POS N
in POS N
the POS N
PTVT POS N
Study. POS N

The POS N
frequency POS N
of POS N
serious POS N
complications POS N
producing POS N
vision POS N
loss POS N
or POS N
requiring POS N
reoperation POS N
was POS N
lower POS N
after POS N
tube POS N
shunt POS N
surgery POS N
relative POS N
to POS N
trabeculectomy POS N
with POS N
MMC. POS N

Trabeculectomy POS N
with POS N
MMC POS N
had POS N
a POS N
higher POS N
surgical POS N
success POS N
rate POS N
than POS N
tube POS N
shunt POS N
implantation POS N
after POS N
1 POS N
year POS N
in POS N
the POS N
PTVT POS N
Study. POS N

Lower POS N
IOP POS N
with POS N
use POS N
of POS N
fewer POS N
glaucoma POS N
medications POS N
was POS N
achieved POS N
after POS N
trabeculectomy POS N
with POS N
MMC POS N
compared POS N
with POS N
tube POS N
shunt POS N
surgery POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up. POS N

Trabeculectomy POS N
with POS N
MMC POS N
had POS N
a POS N
higher POS N
surgical POS N
success POS N
rate POS N
than POS N
tube POS N
shunt POS N
implantation POS N
after POS N
1 POS N
year POS N
in POS N
the POS N
PTVT POS N
Study. POS N

Mean POS N
± POS N
standard POS N
deviation POS N
IOP POS N
was POS N
13.8±4.1 POS N
mmHg POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
12.4±4.4 POS N
mmHg POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
at POS N
1 POS N
year POS N
(P POS N
= POS N
0.01), POS N
and POS N
the POS N
number POS N
of POS N
glaucoma POS N
medications POS N
was POS N
2.1±1.4 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.9±1.4 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
0.001). POS N

The POS N
frequency POS N
of POS N
serious POS N
complications POS N
producing POS N
vision POS N
loss POS N
or POS N
requiring POS N
reoperation POS N
was POS N
lower POS N
after POS N
tube POS N
shunt POS N
surgery POS N
relative POS N
to POS N
trabeculectomy POS N
with POS N
MMC. POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
17.3% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
7.9% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.01; POS N
hazard POS N
ratio, POS N
2.59; POS N
95% POS N
confidence POS N
interval, POS N
1.20-5.60). POS N

The POS N
frequency POS N
of POS N
serious POS N
complications POS N
producing POS N
vision POS N
loss POS N
or POS N
requiring POS N
reoperation POS N
was POS N
lower POS N
after POS N
tube POS N
shunt POS N
surgery POS N
relative POS N
to POS N
trabeculectomy POS N
with POS N
MMC. POS N

Postoperative POS N
complications POS N
developed POS N
in POS N
36 POS N
patients POS N
(29%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
48 POS N
patients POS N
(41%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.06). POS N

The POS N
frequency POS N
of POS N
serious POS N
complications POS N
producing POS N
vision POS N
loss POS N
or POS N
requiring POS N
reoperation POS N
was POS N
lower POS N
after POS N
tube POS N
shunt POS N
surgery POS N
relative POS N
to POS N
trabeculectomy POS N
with POS N
MMC. POS N

Serious POS N
complications POS N
requiring POS N
reoperation POS N
or POS N
producing POS N
a POS N
loss POS N
of POS N
2 POS N
Snellen POS N
lines POS N
or POS N
more POS N
occurred POS N
in POS N
1 POS N
patient POS N
(1%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
8 POS N
patients POS N
(7%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.03). POS N

The POS N
frequency POS N
of POS N
serious POS N
complications POS N
producing POS N
vision POS N
loss POS N
or POS N
requiring POS N
reoperation POS N
was POS N
lower POS N
after POS N
tube POS N
shunt POS N
surgery POS N
relative POS N
to POS N
trabeculectomy POS N
with POS N
MMC. POS N

Trabeculectomy POS N
with POS N
MMC POS N
had POS N
a POS N
higher POS N
surgical POS N
success POS N
rate POS N
than POS N
tube POS N
shunt POS N
implantation POS N
after POS N
1 POS N
year POS N
in POS N
the POS N
PTVT POS N
Study. POS N

The POS N
frequency POS N
of POS N
serious POS N
complications POS N
producing POS N
vision POS N
loss POS N
or POS N
requiring POS N
reoperation POS N
was POS N
lower POS N
after POS N
tube POS N
shunt POS N
surgery POS N
relative POS N
to POS N
trabeculectomy POS N
with POS N
MMC. POS N

Lower POS N
IOP POS N
with POS N
use POS N
of POS N
fewer POS N
glaucoma POS N
medications POS N
was POS N
achieved POS N
after POS N
trabeculectomy POS N
with POS N
MMC POS N
compared POS N
with POS N
tube POS N
shunt POS N
surgery POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up. POS N

The POS N
frequency POS N
of POS N
serious POS N
complications POS N
producing POS N
vision POS N
loss POS N
or POS N
requiring POS N
reoperation POS N
was POS N
lower POS N
after POS N
tube POS N
shunt POS N
surgery POS N
relative POS N
to POS N
trabeculectomy POS N
with POS N
MMC. POS N

Mean POS N
± POS N
standard POS N
deviation POS N
IOP POS N
was POS N
13.8±4.1 POS N
mmHg POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
12.4±4.4 POS N
mmHg POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
at POS N
1 POS N
year POS N
(P POS N
= POS N
0.01), POS N
and POS N
the POS N
number POS N
of POS N
glaucoma POS N
medications POS N
was POS N
2.1±1.4 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.9±1.4 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
0.001). POS N

Lower POS N
IOP POS N
with POS N
use POS N
of POS N
fewer POS N
glaucoma POS N
medications POS N
was POS N
achieved POS N
after POS N
trabeculectomy POS N
with POS N
MMC POS N
compared POS N
with POS N
tube POS N
shunt POS N
surgery POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up. POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
17.3% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
7.9% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.01; POS N
hazard POS N
ratio, POS N
2.59; POS N
95% POS N
confidence POS N
interval, POS N
1.20-5.60). POS N

Lower POS N
IOP POS N
with POS N
use POS N
of POS N
fewer POS N
glaucoma POS N
medications POS N
was POS N
achieved POS N
after POS N
trabeculectomy POS N
with POS N
MMC POS N
compared POS N
with POS N
tube POS N
shunt POS N
surgery POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up. POS N

Postoperative POS N
complications POS N
developed POS N
in POS N
36 POS N
patients POS N
(29%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
48 POS N
patients POS N
(41%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.06). POS N

Lower POS N
IOP POS N
with POS N
use POS N
of POS N
fewer POS N
glaucoma POS N
medications POS N
was POS N
achieved POS N
after POS N
trabeculectomy POS N
with POS N
MMC POS N
compared POS N
with POS N
tube POS N
shunt POS N
surgery POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up. POS N

Serious POS N
complications POS N
requiring POS N
reoperation POS N
or POS N
producing POS N
a POS N
loss POS N
of POS N
2 POS N
Snellen POS N
lines POS N
or POS N
more POS N
occurred POS N
in POS N
1 POS N
patient POS N
(1%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
8 POS N
patients POS N
(7%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.03). POS N

Lower POS N
IOP POS N
with POS N
use POS N
of POS N
fewer POS N
glaucoma POS N
medications POS N
was POS N
achieved POS N
after POS N
trabeculectomy POS N
with POS N
MMC POS N
compared POS N
with POS N
tube POS N
shunt POS N
surgery POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up. POS N

Trabeculectomy POS N
with POS N
MMC POS N
had POS N
a POS N
higher POS N
surgical POS N
success POS N
rate POS N
than POS N
tube POS N
shunt POS N
implantation POS N
after POS N
1 POS N
year POS N
in POS N
the POS N
PTVT POS N
Study. POS N

Lower POS N
IOP POS N
with POS N
use POS N
of POS N
fewer POS N
glaucoma POS N
medications POS N
was POS N
achieved POS N
after POS N
trabeculectomy POS N
with POS N
MMC POS N
compared POS N
with POS N
tube POS N
shunt POS N
surgery POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up. POS N

The POS N
frequency POS N
of POS N
serious POS N
complications POS N
producing POS N
vision POS N
loss POS N
or POS N
requiring POS N
reoperation POS N
was POS N
lower POS N
after POS N
tube POS N
shunt POS N
surgery POS N
relative POS N
to POS N
trabeculectomy POS N
with POS N
MMC. POS N

Lower POS N
IOP POS N
with POS N
use POS N
of POS N
fewer POS N
glaucoma POS N
medications POS N
was POS N
achieved POS N
after POS N
trabeculectomy POS N
with POS N
MMC POS N
compared POS N
with POS N
tube POS N
shunt POS N
surgery POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up. POS N

Mean POS N
± POS N
standard POS N
deviation POS N
IOP POS N
was POS N
13.8±4.1 POS N
mmHg POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
12.4±4.4 POS N
mmHg POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
at POS N
1 POS N
year POS N
(P POS N
= POS N
0.01), POS N
and POS N
the POS N
number POS N
of POS N
glaucoma POS N
medications POS N
was POS N
2.1±1.4 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.9±1.4 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
0.001). POS N

Mean POS N
± POS N
standard POS N
deviation POS N
IOP POS N
was POS N
13.8±4.1 POS N
mmHg POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
12.4±4.4 POS N
mmHg POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
at POS N
1 POS N
year POS N
(P POS N
= POS N
0.01), POS N
and POS N
the POS N
number POS N
of POS N
glaucoma POS N
medications POS N
was POS N
2.1±1.4 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.9±1.4 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
0.001). POS N

The POS N
cumulative POS N
probability POS N
of POS N
failure POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up POS N
was POS N
17.3% POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
7.9% POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.01; POS N
hazard POS N
ratio, POS N
2.59; POS N
95% POS N
confidence POS N
interval, POS N
1.20-5.60). POS N

Mean POS N
± POS N
standard POS N
deviation POS N
IOP POS N
was POS N
13.8±4.1 POS N
mmHg POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
12.4±4.4 POS N
mmHg POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
at POS N
1 POS N
year POS N
(P POS N
= POS N
0.01), POS N
and POS N
the POS N
number POS N
of POS N
glaucoma POS N
medications POS N
was POS N
2.1±1.4 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.9±1.4 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
0.001). POS N

Postoperative POS N
complications POS N
developed POS N
in POS N
36 POS N
patients POS N
(29%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
48 POS N
patients POS N
(41%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.06). POS N

Mean POS N
± POS N
standard POS N
deviation POS N
IOP POS N
was POS N
13.8±4.1 POS N
mmHg POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
12.4±4.4 POS N
mmHg POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
at POS N
1 POS N
year POS N
(P POS N
= POS N
0.01), POS N
and POS N
the POS N
number POS N
of POS N
glaucoma POS N
medications POS N
was POS N
2.1±1.4 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.9±1.4 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
0.001). POS N

Serious POS N
complications POS N
requiring POS N
reoperation POS N
or POS N
producing POS N
a POS N
loss POS N
of POS N
2 POS N
Snellen POS N
lines POS N
or POS N
more POS N
occurred POS N
in POS N
1 POS N
patient POS N
(1%) POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
8 POS N
patients POS N
(7%) POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
= POS N
0.03). POS N

Mean POS N
± POS N
standard POS N
deviation POS N
IOP POS N
was POS N
13.8±4.1 POS N
mmHg POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
12.4±4.4 POS N
mmHg POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
at POS N
1 POS N
year POS N
(P POS N
= POS N
0.01), POS N
and POS N
the POS N
number POS N
of POS N
glaucoma POS N
medications POS N
was POS N
2.1±1.4 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.9±1.4 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
0.001). POS N

Trabeculectomy POS N
with POS N
MMC POS N
had POS N
a POS N
higher POS N
surgical POS N
success POS N
rate POS N
than POS N
tube POS N
shunt POS N
implantation POS N
after POS N
1 POS N
year POS N
in POS N
the POS N
PTVT POS N
Study. POS N

Mean POS N
± POS N
standard POS N
deviation POS N
IOP POS N
was POS N
13.8±4.1 POS N
mmHg POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
12.4±4.4 POS N
mmHg POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
at POS N
1 POS N
year POS N
(P POS N
= POS N
0.01), POS N
and POS N
the POS N
number POS N
of POS N
glaucoma POS N
medications POS N
was POS N
2.1±1.4 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.9±1.4 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
0.001). POS N

The POS N
frequency POS N
of POS N
serious POS N
complications POS N
producing POS N
vision POS N
loss POS N
or POS N
requiring POS N
reoperation POS N
was POS N
lower POS N
after POS N
tube POS N
shunt POS N
surgery POS N
relative POS N
to POS N
trabeculectomy POS N
with POS N
MMC. POS N

Mean POS N
± POS N
standard POS N
deviation POS N
IOP POS N
was POS N
13.8±4.1 POS N
mmHg POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
12.4±4.4 POS N
mmHg POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
at POS N
1 POS N
year POS N
(P POS N
= POS N
0.01), POS N
and POS N
the POS N
number POS N
of POS N
glaucoma POS N
medications POS N
was POS N
2.1±1.4 POS N
in POS N
the POS N
tube POS N
group POS N
and POS N
0.9±1.4 POS N
in POS N
the POS N
trabeculectomy POS N
group POS N
(P POS N
< POS N
0.001). POS N

Lower POS N
IOP POS N
with POS N
use POS N
of POS N
fewer POS N
glaucoma POS N
medications POS N
was POS N
achieved POS N
after POS N
trabeculectomy POS N
with POS N
MMC POS N
compared POS N
with POS N
tube POS N
shunt POS N
surgery POS N
during POS N
the POS N
first POS N
year POS N
of POS N
follow-up. POS N

valsartan/cilnidipine POS N
combination POS N
would POS N
suppress POS N
the POS N
home POS N
morning POS N
blood POS N
pressure POS N
(BP) POS N
surge POS N
(HMBPS) POS N
more POS N
effectively POS N
than POS N
a POS N
valsartan/hydrochlorothiazide POS N
combination POS N
in POS N
patients POS N
with POS N
morning POS N
hypertension POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment POS N
period, POS N
the POS N
changes POS N
in POS N
nocturnal POS N
SBP POS N
and POS N
morning POS N
SBP POS N
from POS N
baseline POS N
were POS N
significant POS N
in POS N
both POS N
the POS N
valsartan/cilnidipine POS N
and POS N
valsartan/hydrochlorothiazide POS N
groups POS N
(P POS N
< POS N
.001): POS N
-5.0 POS N
vs POS N
-10.0 POS N
mm POS N
Hg POS N
(P POS N
= POS N
.035) POS N
and POS N
-10.7 POS N
vs POS N
-13.6 POS N
mm POS N
Hg POS N
(P POS N
= POS N
.142), POS N
respectively. POS N

valsartan/cilnidipine POS N
combination POS N
would POS N
suppress POS N
the POS N
home POS N
morning POS N
blood POS N
pressure POS N
(BP) POS N
surge POS N
(HMBPS) POS N
more POS N
effectively POS N
than POS N
a POS N
valsartan/hydrochlorothiazide POS N
combination POS N
in POS N
patients POS N
with POS N
morning POS N
hypertension POS N

HMBPS POS N
was POS N
significantly POS N
decreased POS N
from POS N
baseline POS N
in POS N
both POS N
groups POS N
(P POS N
< POS N
.001), POS N
but POS N
there POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
two POS N
groups: POS N
14.4 POS N
mm POS N
Hg POS N
vs POS N
14.0 POS N
mm POS N
Hg, POS N
respectively POS N
(P POS N
= POS N
.892). POS N

valsartan/cilnidipine POS N
combination POS N
would POS N
suppress POS N
the POS N
home POS N
morning POS N
blood POS N
pressure POS N
(BP) POS N
surge POS N
(HMBPS) POS N
more POS N
effectively POS N
than POS N
a POS N
valsartan/hydrochlorothiazide POS N
combination POS N
in POS N
patients POS N
with POS N
morning POS N
hypertension POS N

Valsartan/cilnidipine POS N
could POS N
not POS N
significantly POS N
suppress POS N
HMBPS POS N
compared POS N
with POS N
valsartan/hydrochlorothiazide. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment POS N
period, POS N
the POS N
changes POS N
in POS N
nocturnal POS N
SBP POS N
and POS N
morning POS N
SBP POS N
from POS N
baseline POS N
were POS N
significant POS N
in POS N
both POS N
the POS N
valsartan/cilnidipine POS N
and POS N
valsartan/hydrochlorothiazide POS N
groups POS N
(P POS N
< POS N
.001): POS N
-5.0 POS N
vs POS N
-10.0 POS N
mm POS N
Hg POS N
(P POS N
= POS N
.035) POS N
and POS N
-10.7 POS N
vs POS N
-13.6 POS N
mm POS N
Hg POS N
(P POS N
= POS N
.142), POS N
respectively. POS N

valsartan/cilnidipine POS N
combination POS N
would POS N
suppress POS N
the POS N
home POS N
morning POS N
blood POS N
pressure POS N
(BP) POS N
surge POS N
(HMBPS) POS N
more POS N
effectively POS N
than POS N
a POS N
valsartan/hydrochlorothiazide POS N
combination POS N
in POS N
patients POS N
with POS N
morning POS N
hypertension POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment POS N
period, POS N
the POS N
changes POS N
in POS N
nocturnal POS N
SBP POS N
and POS N
morning POS N
SBP POS N
from POS N
baseline POS N
were POS N
significant POS N
in POS N
both POS N
the POS N
valsartan/cilnidipine POS N
and POS N
valsartan/hydrochlorothiazide POS N
groups POS N
(P POS N
< POS N
.001): POS N
-5.0 POS N
vs POS N
-10.0 POS N
mm POS N
Hg POS N
(P POS N
= POS N
.035) POS N
and POS N
-10.7 POS N
vs POS N
-13.6 POS N
mm POS N
Hg POS N
(P POS N
= POS N
.142), POS N
respectively. POS N

HMBPS POS N
was POS N
significantly POS N
decreased POS N
from POS N
baseline POS N
in POS N
both POS N
groups POS N
(P POS N
< POS N
.001), POS N
but POS N
there POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
two POS N
groups: POS N
14.4 POS N
mm POS N
Hg POS N
vs POS N
14.0 POS N
mm POS N
Hg, POS N
respectively POS N
(P POS N
= POS N
.892). POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment POS N
period, POS N
the POS N
changes POS N
in POS N
nocturnal POS N
SBP POS N
and POS N
morning POS N
SBP POS N
from POS N
baseline POS N
were POS N
significant POS N
in POS N
both POS N
the POS N
valsartan/cilnidipine POS N
and POS N
valsartan/hydrochlorothiazide POS N
groups POS N
(P POS N
< POS N
.001): POS N
-5.0 POS N
vs POS N
-10.0 POS N
mm POS N
Hg POS N
(P POS N
= POS N
.035) POS N
and POS N
-10.7 POS N
vs POS N
-13.6 POS N
mm POS N
Hg POS N
(P POS N
= POS N
.142), POS N
respectively. POS N

Valsartan/cilnidipine POS N
could POS N
not POS N
significantly POS N
suppress POS N
HMBPS POS N
compared POS N
with POS N
valsartan/hydrochlorothiazide. POS N

HMBPS POS N
was POS N
significantly POS N
decreased POS N
from POS N
baseline POS N
in POS N
both POS N
groups POS N
(P POS N
< POS N
.001), POS N
but POS N
there POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
two POS N
groups: POS N
14.4 POS N
mm POS N
Hg POS N
vs POS N
14.0 POS N
mm POS N
Hg, POS N
respectively POS N
(P POS N
= POS N
.892). POS N

valsartan/cilnidipine POS N
combination POS N
would POS N
suppress POS N
the POS N
home POS N
morning POS N
blood POS N
pressure POS N
(BP) POS N
surge POS N
(HMBPS) POS N
more POS N
effectively POS N
than POS N
a POS N
valsartan/hydrochlorothiazide POS N
combination POS N
in POS N
patients POS N
with POS N
morning POS N
hypertension POS N

HMBPS POS N
was POS N
significantly POS N
decreased POS N
from POS N
baseline POS N
in POS N
both POS N
groups POS N
(P POS N
< POS N
.001), POS N
but POS N
there POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
two POS N
groups: POS N
14.4 POS N
mm POS N
Hg POS N
vs POS N
14.0 POS N
mm POS N
Hg, POS N
respectively POS N
(P POS N
= POS N
.892). POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment POS N
period, POS N
the POS N
changes POS N
in POS N
nocturnal POS N
SBP POS N
and POS N
morning POS N
SBP POS N
from POS N
baseline POS N
were POS N
significant POS N
in POS N
both POS N
the POS N
valsartan/cilnidipine POS N
and POS N
valsartan/hydrochlorothiazide POS N
groups POS N
(P POS N
< POS N
.001): POS N
-5.0 POS N
vs POS N
-10.0 POS N
mm POS N
Hg POS N
(P POS N
= POS N
.035) POS N
and POS N
-10.7 POS N
vs POS N
-13.6 POS N
mm POS N
Hg POS N
(P POS N
= POS N
.142), POS N
respectively. POS N

HMBPS POS N
was POS N
significantly POS N
decreased POS N
from POS N
baseline POS N
in POS N
both POS N
groups POS N
(P POS N
< POS N
.001), POS N
but POS N
there POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
two POS N
groups: POS N
14.4 POS N
mm POS N
Hg POS N
vs POS N
14.0 POS N
mm POS N
Hg, POS N
respectively POS N
(P POS N
= POS N
.892). POS N

Valsartan/cilnidipine POS N
could POS N
not POS N
significantly POS N
suppress POS N
HMBPS POS N
compared POS N
with POS N
valsartan/hydrochlorothiazide. POS N

Valsartan/cilnidipine POS N
could POS N
not POS N
significantly POS N
suppress POS N
HMBPS POS N
compared POS N
with POS N
valsartan/hydrochlorothiazide. POS N

valsartan/cilnidipine POS N
combination POS N
would POS N
suppress POS N
the POS N
home POS N
morning POS N
blood POS N
pressure POS N
(BP) POS N
surge POS N
(HMBPS) POS N
more POS N
effectively POS N
than POS N
a POS N
valsartan/hydrochlorothiazide POS N
combination POS N
in POS N
patients POS N
with POS N
morning POS N
hypertension POS N

Valsartan/cilnidipine POS N
could POS N
not POS N
significantly POS N
suppress POS N
HMBPS POS N
compared POS N
with POS N
valsartan/hydrochlorothiazide. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment POS N
period, POS N
the POS N
changes POS N
in POS N
nocturnal POS N
SBP POS N
and POS N
morning POS N
SBP POS N
from POS N
baseline POS N
were POS N
significant POS N
in POS N
both POS N
the POS N
valsartan/cilnidipine POS N
and POS N
valsartan/hydrochlorothiazide POS N
groups POS N
(P POS N
< POS N
.001): POS N
-5.0 POS N
vs POS N
-10.0 POS N
mm POS N
Hg POS N
(P POS N
= POS N
.035) POS N
and POS N
-10.7 POS N
vs POS N
-13.6 POS N
mm POS N
Hg POS N
(P POS N
= POS N
.142), POS N
respectively. POS N

Valsartan/cilnidipine POS N
could POS N
not POS N
significantly POS N
suppress POS N
HMBPS POS N
compared POS N
with POS N
valsartan/hydrochlorothiazide. POS N

HMBPS POS N
was POS N
significantly POS N
decreased POS N
from POS N
baseline POS N
in POS N
both POS N
groups POS N
(P POS N
< POS N
.001), POS N
but POS N
there POS N
was POS N
no POS N
significant POS N
difference POS N
between POS N
the POS N
two POS N
groups: POS N
14.4 POS N
mm POS N
Hg POS N
vs POS N
14.0 POS N
mm POS N
Hg, POS N
respectively POS N
(P POS N
= POS N
.892). POS N

In POS N
recent POS N
years, POS N
encouraging POS N
results POS N
of POS N
preoperative POS N
radiotherapy POS N
have POS N
been POS N
reported. POS N

Postoperative POS N
radiochemotherapy POS N
is POS N
recommended POS N
for POS N
patients POS N
with POS N
advanced POS N
disease POS N
(pT3/4 POS N
or POS N
pN+). POS N

In POS N
recent POS N
years, POS N
encouraging POS N
results POS N
of POS N
preoperative POS N
radiotherapy POS N
have POS N
been POS N
reported. POS N

Acute POS N
toxicity POS N
(WHO) POS N
of POS N
radiochemotherapy POS N
was POS N
low, POS N
with POS N
less POS N
than POS N
15% POS N
of POS N
patients POS N
experiencing POS N
Grade POS N
3 POS N
or POS N
higher POS N
toxicity POS N

In POS N
recent POS N
years, POS N
encouraging POS N
results POS N
of POS N
preoperative POS N
radiotherapy POS N
have POS N
been POS N
reported. POS N

The POS N
principal POS N
toxicity POS N
was POS N
diarrhea, POS N
with POS N
12% POS N
in POS N
the POS N
postoperative POS N
radiochemotherapy POS N
arm POS N
and POS N
10% POS N
in POS N
the POS N
preoperative POS N
radiochemotherapy POS N
arm POS N
having POS N
Grade-3, POS N
and POS N
1% POS N
in POS N
either POS N
arm POS N
having POS N
Grade-4 POS N
diarrhea. POS N

In POS N
recent POS N
years, POS N
encouraging POS N
results POS N
of POS N
preoperative POS N
radiotherapy POS N
have POS N
been POS N
reported. POS N

Erythema, POS N
nausea POS N
and POS N
leukopenia POS N
were POS N
the POS N
next POS N
common POS N
toxicities, POS N
with POS N
less POS N
than POS N
3% POS N
of POS N
patients POS N
in POS N
either POS N
arm POS N
suffering POS N
Grade POS N
3 POS N
or POS N
greater POS N
leukopenia POS N
or POS N
nausea. POS N

In POS N
recent POS N
years, POS N
encouraging POS N
results POS N
of POS N
preoperative POS N
radiotherapy POS N
have POS N
been POS N
reported. POS N

Postoperative POS N
complication POS N
rates POS N
were POS N
similar POS N
in POS N
both POS N
arms, POS N
with POS N
12% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
13% POS N
(preoperative POS N
radiochemotherapy) POS N
of POS N
patients, POS N
respectively, POS N
suffering POS N
from POS N
anastomotic POS N
leakage, POS N
4% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
3% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
postoperative POS N
bleeding, POS N
and POS N
6% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
5% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
delayed POS N
wound POS N
healing. POS N

In POS N
recent POS N
years, POS N
encouraging POS N
results POS N
of POS N
preoperative POS N
radiotherapy POS N
have POS N
been POS N
reported. POS N

The POS N
patient POS N
accrual POS N
of POS N
our POS N
trial POS N
is POS N
satisfactory, POS N

In POS N
recent POS N
years, POS N
encouraging POS N
results POS N
of POS N
preoperative POS N
radiotherapy POS N
have POS N
been POS N
reported. POS N

neoadjuvant POS N
radiochemotherapy POS N
is POS N
well POS N
tolerated POS N
and POS N
bears POS N
no POS N
higher POS N
risk POS N
for POS N
postoperative POS N
morbidity. POS N

Postoperative POS N
radiochemotherapy POS N
is POS N
recommended POS N
for POS N
patients POS N
with POS N
advanced POS N
disease POS N
(pT3/4 POS N
or POS N
pN+). POS N

In POS N
recent POS N
years, POS N
encouraging POS N
results POS N
of POS N
preoperative POS N
radiotherapy POS N
have POS N
been POS N
reported. POS N

Postoperative POS N
radiochemotherapy POS N
is POS N
recommended POS N
for POS N
patients POS N
with POS N
advanced POS N
disease POS N
(pT3/4 POS N
or POS N
pN+). POS N

Acute POS N
toxicity POS N
(WHO) POS N
of POS N
radiochemotherapy POS N
was POS N
low, POS N
with POS N
less POS N
than POS N
15% POS N
of POS N
patients POS N
experiencing POS N
Grade POS N
3 POS N
or POS N
higher POS N
toxicity POS N

Postoperative POS N
radiochemotherapy POS N
is POS N
recommended POS N
for POS N
patients POS N
with POS N
advanced POS N
disease POS N
(pT3/4 POS N
or POS N
pN+). POS N

The POS N
principal POS N
toxicity POS N
was POS N
diarrhea, POS N
with POS N
12% POS N
in POS N
the POS N
postoperative POS N
radiochemotherapy POS N
arm POS N
and POS N
10% POS N
in POS N
the POS N
preoperative POS N
radiochemotherapy POS N
arm POS N
having POS N
Grade-3, POS N
and POS N
1% POS N
in POS N
either POS N
arm POS N
having POS N
Grade-4 POS N
diarrhea. POS N

Postoperative POS N
radiochemotherapy POS N
is POS N
recommended POS N
for POS N
patients POS N
with POS N
advanced POS N
disease POS N
(pT3/4 POS N
or POS N
pN+). POS N

Erythema, POS N
nausea POS N
and POS N
leukopenia POS N
were POS N
the POS N
next POS N
common POS N
toxicities, POS N
with POS N
less POS N
than POS N
3% POS N
of POS N
patients POS N
in POS N
either POS N
arm POS N
suffering POS N
Grade POS N
3 POS N
or POS N
greater POS N
leukopenia POS N
or POS N
nausea. POS N

Postoperative POS N
radiochemotherapy POS N
is POS N
recommended POS N
for POS N
patients POS N
with POS N
advanced POS N
disease POS N
(pT3/4 POS N
or POS N
pN+). POS N

Postoperative POS N
complication POS N
rates POS N
were POS N
similar POS N
in POS N
both POS N
arms, POS N
with POS N
12% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
13% POS N
(preoperative POS N
radiochemotherapy) POS N
of POS N
patients, POS N
respectively, POS N
suffering POS N
from POS N
anastomotic POS N
leakage, POS N
4% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
3% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
postoperative POS N
bleeding, POS N
and POS N
6% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
5% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
delayed POS N
wound POS N
healing. POS N

Postoperative POS N
radiochemotherapy POS N
is POS N
recommended POS N
for POS N
patients POS N
with POS N
advanced POS N
disease POS N
(pT3/4 POS N
or POS N
pN+). POS N

The POS N
patient POS N
accrual POS N
of POS N
our POS N
trial POS N
is POS N
satisfactory, POS N

Postoperative POS N
radiochemotherapy POS N
is POS N
recommended POS N
for POS N
patients POS N
with POS N
advanced POS N
disease POS N
(pT3/4 POS N
or POS N
pN+). POS N

neoadjuvant POS N
radiochemotherapy POS N
is POS N
well POS N
tolerated POS N
and POS N
bears POS N
no POS N
higher POS N
risk POS N
for POS N
postoperative POS N
morbidity. POS N

Acute POS N
toxicity POS N
(WHO) POS N
of POS N
radiochemotherapy POS N
was POS N
low, POS N
with POS N
less POS N
than POS N
15% POS N
of POS N
patients POS N
experiencing POS N
Grade POS N
3 POS N
or POS N
higher POS N
toxicity POS N

In POS N
recent POS N
years, POS N
encouraging POS N
results POS N
of POS N
preoperative POS N
radiotherapy POS N
have POS N
been POS N
reported. POS N

Acute POS N
toxicity POS N
(WHO) POS N
of POS N
radiochemotherapy POS N
was POS N
low, POS N
with POS N
less POS N
than POS N
15% POS N
of POS N
patients POS N
experiencing POS N
Grade POS N
3 POS N
or POS N
higher POS N
toxicity POS N

Postoperative POS N
radiochemotherapy POS N
is POS N
recommended POS N
for POS N
patients POS N
with POS N
advanced POS N
disease POS N
(pT3/4 POS N
or POS N
pN+). POS N

Acute POS N
toxicity POS N
(WHO) POS N
of POS N
radiochemotherapy POS N
was POS N
low, POS N
with POS N
less POS N
than POS N
15% POS N
of POS N
patients POS N
experiencing POS N
Grade POS N
3 POS N
or POS N
higher POS N
toxicity POS N

The POS N
principal POS N
toxicity POS N
was POS N
diarrhea, POS N
with POS N
12% POS N
in POS N
the POS N
postoperative POS N
radiochemotherapy POS N
arm POS N
and POS N
10% POS N
in POS N
the POS N
preoperative POS N
radiochemotherapy POS N
arm POS N
having POS N
Grade-3, POS N
and POS N
1% POS N
in POS N
either POS N
arm POS N
having POS N
Grade-4 POS N
diarrhea. POS N

Acute POS N
toxicity POS N
(WHO) POS N
of POS N
radiochemotherapy POS N
was POS N
low, POS N
with POS N
less POS N
than POS N
15% POS N
of POS N
patients POS N
experiencing POS N
Grade POS N
3 POS N
or POS N
higher POS N
toxicity POS N

Erythema, POS N
nausea POS N
and POS N
leukopenia POS N
were POS N
the POS N
next POS N
common POS N
toxicities, POS N
with POS N
less POS N
than POS N
3% POS N
of POS N
patients POS N
in POS N
either POS N
arm POS N
suffering POS N
Grade POS N
3 POS N
or POS N
greater POS N
leukopenia POS N
or POS N
nausea. POS N

Acute POS N
toxicity POS N
(WHO) POS N
of POS N
radiochemotherapy POS N
was POS N
low, POS N
with POS N
less POS N
than POS N
15% POS N
of POS N
patients POS N
experiencing POS N
Grade POS N
3 POS N
or POS N
higher POS N
toxicity POS N

Postoperative POS N
complication POS N
rates POS N
were POS N
similar POS N
in POS N
both POS N
arms, POS N
with POS N
12% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
13% POS N
(preoperative POS N
radiochemotherapy) POS N
of POS N
patients, POS N
respectively, POS N
suffering POS N
from POS N
anastomotic POS N
leakage, POS N
4% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
3% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
postoperative POS N
bleeding, POS N
and POS N
6% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
5% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
delayed POS N
wound POS N
healing. POS N

Acute POS N
toxicity POS N
(WHO) POS N
of POS N
radiochemotherapy POS N
was POS N
low, POS N
with POS N
less POS N
than POS N
15% POS N
of POS N
patients POS N
experiencing POS N
Grade POS N
3 POS N
or POS N
higher POS N
toxicity POS N

The POS N
patient POS N
accrual POS N
of POS N
our POS N
trial POS N
is POS N
satisfactory, POS N

Acute POS N
toxicity POS N
(WHO) POS N
of POS N
radiochemotherapy POS N
was POS N
low, POS N
with POS N
less POS N
than POS N
15% POS N
of POS N
patients POS N
experiencing POS N
Grade POS N
3 POS N
or POS N
higher POS N
toxicity POS N

neoadjuvant POS N
radiochemotherapy POS N
is POS N
well POS N
tolerated POS N
and POS N
bears POS N
no POS N
higher POS N
risk POS N
for POS N
postoperative POS N
morbidity. POS N

The POS N
principal POS N
toxicity POS N
was POS N
diarrhea, POS N
with POS N
12% POS N
in POS N
the POS N
postoperative POS N
radiochemotherapy POS N
arm POS N
and POS N
10% POS N
in POS N
the POS N
preoperative POS N
radiochemotherapy POS N
arm POS N
having POS N
Grade-3, POS N
and POS N
1% POS N
in POS N
either POS N
arm POS N
having POS N
Grade-4 POS N
diarrhea. POS N

In POS N
recent POS N
years, POS N
encouraging POS N
results POS N
of POS N
preoperative POS N
radiotherapy POS N
have POS N
been POS N
reported. POS N

The POS N
principal POS N
toxicity POS N
was POS N
diarrhea, POS N
with POS N
12% POS N
in POS N
the POS N
postoperative POS N
radiochemotherapy POS N
arm POS N
and POS N
10% POS N
in POS N
the POS N
preoperative POS N
radiochemotherapy POS N
arm POS N
having POS N
Grade-3, POS N
and POS N
1% POS N
in POS N
either POS N
arm POS N
having POS N
Grade-4 POS N
diarrhea. POS N

Postoperative POS N
radiochemotherapy POS N
is POS N
recommended POS N
for POS N
patients POS N
with POS N
advanced POS N
disease POS N
(pT3/4 POS N
or POS N
pN+). POS N

The POS N
principal POS N
toxicity POS N
was POS N
diarrhea, POS N
with POS N
12% POS N
in POS N
the POS N
postoperative POS N
radiochemotherapy POS N
arm POS N
and POS N
10% POS N
in POS N
the POS N
preoperative POS N
radiochemotherapy POS N
arm POS N
having POS N
Grade-3, POS N
and POS N
1% POS N
in POS N
either POS N
arm POS N
having POS N
Grade-4 POS N
diarrhea. POS N

Acute POS N
toxicity POS N
(WHO) POS N
of POS N
radiochemotherapy POS N
was POS N
low, POS N
with POS N
less POS N
than POS N
15% POS N
of POS N
patients POS N
experiencing POS N
Grade POS N
3 POS N
or POS N
higher POS N
toxicity POS N

The POS N
principal POS N
toxicity POS N
was POS N
diarrhea, POS N
with POS N
12% POS N
in POS N
the POS N
postoperative POS N
radiochemotherapy POS N
arm POS N
and POS N
10% POS N
in POS N
the POS N
preoperative POS N
radiochemotherapy POS N
arm POS N
having POS N
Grade-3, POS N
and POS N
1% POS N
in POS N
either POS N
arm POS N
having POS N
Grade-4 POS N
diarrhea. POS N

Erythema, POS N
nausea POS N
and POS N
leukopenia POS N
were POS N
the POS N
next POS N
common POS N
toxicities, POS N
with POS N
less POS N
than POS N
3% POS N
of POS N
patients POS N
in POS N
either POS N
arm POS N
suffering POS N
Grade POS N
3 POS N
or POS N
greater POS N
leukopenia POS N
or POS N
nausea. POS N

The POS N
principal POS N
toxicity POS N
was POS N
diarrhea, POS N
with POS N
12% POS N
in POS N
the POS N
postoperative POS N
radiochemotherapy POS N
arm POS N
and POS N
10% POS N
in POS N
the POS N
preoperative POS N
radiochemotherapy POS N
arm POS N
having POS N
Grade-3, POS N
and POS N
1% POS N
in POS N
either POS N
arm POS N
having POS N
Grade-4 POS N
diarrhea. POS N

Postoperative POS N
complication POS N
rates POS N
were POS N
similar POS N
in POS N
both POS N
arms, POS N
with POS N
12% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
13% POS N
(preoperative POS N
radiochemotherapy) POS N
of POS N
patients, POS N
respectively, POS N
suffering POS N
from POS N
anastomotic POS N
leakage, POS N
4% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
3% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
postoperative POS N
bleeding, POS N
and POS N
6% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
5% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
delayed POS N
wound POS N
healing. POS N

The POS N
principal POS N
toxicity POS N
was POS N
diarrhea, POS N
with POS N
12% POS N
in POS N
the POS N
postoperative POS N
radiochemotherapy POS N
arm POS N
and POS N
10% POS N
in POS N
the POS N
preoperative POS N
radiochemotherapy POS N
arm POS N
having POS N
Grade-3, POS N
and POS N
1% POS N
in POS N
either POS N
arm POS N
having POS N
Grade-4 POS N
diarrhea. POS N

The POS N
patient POS N
accrual POS N
of POS N
our POS N
trial POS N
is POS N
satisfactory, POS N

The POS N
principal POS N
toxicity POS N
was POS N
diarrhea, POS N
with POS N
12% POS N
in POS N
the POS N
postoperative POS N
radiochemotherapy POS N
arm POS N
and POS N
10% POS N
in POS N
the POS N
preoperative POS N
radiochemotherapy POS N
arm POS N
having POS N
Grade-3, POS N
and POS N
1% POS N
in POS N
either POS N
arm POS N
having POS N
Grade-4 POS N
diarrhea. POS N

neoadjuvant POS N
radiochemotherapy POS N
is POS N
well POS N
tolerated POS N
and POS N
bears POS N
no POS N
higher POS N
risk POS N
for POS N
postoperative POS N
morbidity. POS N

Erythema, POS N
nausea POS N
and POS N
leukopenia POS N
were POS N
the POS N
next POS N
common POS N
toxicities, POS N
with POS N
less POS N
than POS N
3% POS N
of POS N
patients POS N
in POS N
either POS N
arm POS N
suffering POS N
Grade POS N
3 POS N
or POS N
greater POS N
leukopenia POS N
or POS N
nausea. POS N

In POS N
recent POS N
years, POS N
encouraging POS N
results POS N
of POS N
preoperative POS N
radiotherapy POS N
have POS N
been POS N
reported. POS N

Erythema, POS N
nausea POS N
and POS N
leukopenia POS N
were POS N
the POS N
next POS N
common POS N
toxicities, POS N
with POS N
less POS N
than POS N
3% POS N
of POS N
patients POS N
in POS N
either POS N
arm POS N
suffering POS N
Grade POS N
3 POS N
or POS N
greater POS N
leukopenia POS N
or POS N
nausea. POS N

Postoperative POS N
radiochemotherapy POS N
is POS N
recommended POS N
for POS N
patients POS N
with POS N
advanced POS N
disease POS N
(pT3/4 POS N
or POS N
pN+). POS N

Erythema, POS N
nausea POS N
and POS N
leukopenia POS N
were POS N
the POS N
next POS N
common POS N
toxicities, POS N
with POS N
less POS N
than POS N
3% POS N
of POS N
patients POS N
in POS N
either POS N
arm POS N
suffering POS N
Grade POS N
3 POS N
or POS N
greater POS N
leukopenia POS N
or POS N
nausea. POS N

Acute POS N
toxicity POS N
(WHO) POS N
of POS N
radiochemotherapy POS N
was POS N
low, POS N
with POS N
less POS N
than POS N
15% POS N
of POS N
patients POS N
experiencing POS N
Grade POS N
3 POS N
or POS N
higher POS N
toxicity POS N

Erythema, POS N
nausea POS N
and POS N
leukopenia POS N
were POS N
the POS N
next POS N
common POS N
toxicities, POS N
with POS N
less POS N
than POS N
3% POS N
of POS N
patients POS N
in POS N
either POS N
arm POS N
suffering POS N
Grade POS N
3 POS N
or POS N
greater POS N
leukopenia POS N
or POS N
nausea. POS N

The POS N
principal POS N
toxicity POS N
was POS N
diarrhea, POS N
with POS N
12% POS N
in POS N
the POS N
postoperative POS N
radiochemotherapy POS N
arm POS N
and POS N
10% POS N
in POS N
the POS N
preoperative POS N
radiochemotherapy POS N
arm POS N
having POS N
Grade-3, POS N
and POS N
1% POS N
in POS N
either POS N
arm POS N
having POS N
Grade-4 POS N
diarrhea. POS N

Erythema, POS N
nausea POS N
and POS N
leukopenia POS N
were POS N
the POS N
next POS N
common POS N
toxicities, POS N
with POS N
less POS N
than POS N
3% POS N
of POS N
patients POS N
in POS N
either POS N
arm POS N
suffering POS N
Grade POS N
3 POS N
or POS N
greater POS N
leukopenia POS N
or POS N
nausea. POS N

Postoperative POS N
complication POS N
rates POS N
were POS N
similar POS N
in POS N
both POS N
arms, POS N
with POS N
12% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
13% POS N
(preoperative POS N
radiochemotherapy) POS N
of POS N
patients, POS N
respectively, POS N
suffering POS N
from POS N
anastomotic POS N
leakage, POS N
4% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
3% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
postoperative POS N
bleeding, POS N
and POS N
6% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
5% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
delayed POS N
wound POS N
healing. POS N

Erythema, POS N
nausea POS N
and POS N
leukopenia POS N
were POS N
the POS N
next POS N
common POS N
toxicities, POS N
with POS N
less POS N
than POS N
3% POS N
of POS N
patients POS N
in POS N
either POS N
arm POS N
suffering POS N
Grade POS N
3 POS N
or POS N
greater POS N
leukopenia POS N
or POS N
nausea. POS N

The POS N
patient POS N
accrual POS N
of POS N
our POS N
trial POS N
is POS N
satisfactory, POS N

Erythema, POS N
nausea POS N
and POS N
leukopenia POS N
were POS N
the POS N
next POS N
common POS N
toxicities, POS N
with POS N
less POS N
than POS N
3% POS N
of POS N
patients POS N
in POS N
either POS N
arm POS N
suffering POS N
Grade POS N
3 POS N
or POS N
greater POS N
leukopenia POS N
or POS N
nausea. POS N

neoadjuvant POS N
radiochemotherapy POS N
is POS N
well POS N
tolerated POS N
and POS N
bears POS N
no POS N
higher POS N
risk POS N
for POS N
postoperative POS N
morbidity. POS N

Postoperative POS N
complication POS N
rates POS N
were POS N
similar POS N
in POS N
both POS N
arms, POS N
with POS N
12% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
13% POS N
(preoperative POS N
radiochemotherapy) POS N
of POS N
patients, POS N
respectively, POS N
suffering POS N
from POS N
anastomotic POS N
leakage, POS N
4% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
3% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
postoperative POS N
bleeding, POS N
and POS N
6% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
5% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
delayed POS N
wound POS N
healing. POS N

In POS N
recent POS N
years, POS N
encouraging POS N
results POS N
of POS N
preoperative POS N
radiotherapy POS N
have POS N
been POS N
reported. POS N

Postoperative POS N
complication POS N
rates POS N
were POS N
similar POS N
in POS N
both POS N
arms, POS N
with POS N
12% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
13% POS N
(preoperative POS N
radiochemotherapy) POS N
of POS N
patients, POS N
respectively, POS N
suffering POS N
from POS N
anastomotic POS N
leakage, POS N
4% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
3% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
postoperative POS N
bleeding, POS N
and POS N
6% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
5% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
delayed POS N
wound POS N
healing. POS N

Postoperative POS N
radiochemotherapy POS N
is POS N
recommended POS N
for POS N
patients POS N
with POS N
advanced POS N
disease POS N
(pT3/4 POS N
or POS N
pN+). POS N

Postoperative POS N
complication POS N
rates POS N
were POS N
similar POS N
in POS N
both POS N
arms, POS N
with POS N
12% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
13% POS N
(preoperative POS N
radiochemotherapy) POS N
of POS N
patients, POS N
respectively, POS N
suffering POS N
from POS N
anastomotic POS N
leakage, POS N
4% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
3% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
postoperative POS N
bleeding, POS N
and POS N
6% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
5% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
delayed POS N
wound POS N
healing. POS N

Acute POS N
toxicity POS N
(WHO) POS N
of POS N
radiochemotherapy POS N
was POS N
low, POS N
with POS N
less POS N
than POS N
15% POS N
of POS N
patients POS N
experiencing POS N
Grade POS N
3 POS N
or POS N
higher POS N
toxicity POS N

Postoperative POS N
complication POS N
rates POS N
were POS N
similar POS N
in POS N
both POS N
arms, POS N
with POS N
12% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
13% POS N
(preoperative POS N
radiochemotherapy) POS N
of POS N
patients, POS N
respectively, POS N
suffering POS N
from POS N
anastomotic POS N
leakage, POS N
4% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
3% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
postoperative POS N
bleeding, POS N
and POS N
6% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
5% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
delayed POS N
wound POS N
healing. POS N

The POS N
principal POS N
toxicity POS N
was POS N
diarrhea, POS N
with POS N
12% POS N
in POS N
the POS N
postoperative POS N
radiochemotherapy POS N
arm POS N
and POS N
10% POS N
in POS N
the POS N
preoperative POS N
radiochemotherapy POS N
arm POS N
having POS N
Grade-3, POS N
and POS N
1% POS N
in POS N
either POS N
arm POS N
having POS N
Grade-4 POS N
diarrhea. POS N

Postoperative POS N
complication POS N
rates POS N
were POS N
similar POS N
in POS N
both POS N
arms, POS N
with POS N
12% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
13% POS N
(preoperative POS N
radiochemotherapy) POS N
of POS N
patients, POS N
respectively, POS N
suffering POS N
from POS N
anastomotic POS N
leakage, POS N
4% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
3% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
postoperative POS N
bleeding, POS N
and POS N
6% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
5% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
delayed POS N
wound POS N
healing. POS N

Erythema, POS N
nausea POS N
and POS N
leukopenia POS N
were POS N
the POS N
next POS N
common POS N
toxicities, POS N
with POS N
less POS N
than POS N
3% POS N
of POS N
patients POS N
in POS N
either POS N
arm POS N
suffering POS N
Grade POS N
3 POS N
or POS N
greater POS N
leukopenia POS N
or POS N
nausea. POS N

Postoperative POS N
complication POS N
rates POS N
were POS N
similar POS N
in POS N
both POS N
arms, POS N
with POS N
12% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
13% POS N
(preoperative POS N
radiochemotherapy) POS N
of POS N
patients, POS N
respectively, POS N
suffering POS N
from POS N
anastomotic POS N
leakage, POS N
4% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
3% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
postoperative POS N
bleeding, POS N
and POS N
6% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
5% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
delayed POS N
wound POS N
healing. POS N

The POS N
patient POS N
accrual POS N
of POS N
our POS N
trial POS N
is POS N
satisfactory, POS N

Postoperative POS N
complication POS N
rates POS N
were POS N
similar POS N
in POS N
both POS N
arms, POS N
with POS N
12% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
13% POS N
(preoperative POS N
radiochemotherapy) POS N
of POS N
patients, POS N
respectively, POS N
suffering POS N
from POS N
anastomotic POS N
leakage, POS N
4% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
3% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
postoperative POS N
bleeding, POS N
and POS N
6% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
5% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
delayed POS N
wound POS N
healing. POS N

neoadjuvant POS N
radiochemotherapy POS N
is POS N
well POS N
tolerated POS N
and POS N
bears POS N
no POS N
higher POS N
risk POS N
for POS N
postoperative POS N
morbidity. POS N

The POS N
patient POS N
accrual POS N
of POS N
our POS N
trial POS N
is POS N
satisfactory, POS N

In POS N
recent POS N
years, POS N
encouraging POS N
results POS N
of POS N
preoperative POS N
radiotherapy POS N
have POS N
been POS N
reported. POS N

The POS N
patient POS N
accrual POS N
of POS N
our POS N
trial POS N
is POS N
satisfactory, POS N

Postoperative POS N
radiochemotherapy POS N
is POS N
recommended POS N
for POS N
patients POS N
with POS N
advanced POS N
disease POS N
(pT3/4 POS N
or POS N
pN+). POS N

The POS N
patient POS N
accrual POS N
of POS N
our POS N
trial POS N
is POS N
satisfactory, POS N

Acute POS N
toxicity POS N
(WHO) POS N
of POS N
radiochemotherapy POS N
was POS N
low, POS N
with POS N
less POS N
than POS N
15% POS N
of POS N
patients POS N
experiencing POS N
Grade POS N
3 POS N
or POS N
higher POS N
toxicity POS N

The POS N
patient POS N
accrual POS N
of POS N
our POS N
trial POS N
is POS N
satisfactory, POS N

The POS N
principal POS N
toxicity POS N
was POS N
diarrhea, POS N
with POS N
12% POS N
in POS N
the POS N
postoperative POS N
radiochemotherapy POS N
arm POS N
and POS N
10% POS N
in POS N
the POS N
preoperative POS N
radiochemotherapy POS N
arm POS N
having POS N
Grade-3, POS N
and POS N
1% POS N
in POS N
either POS N
arm POS N
having POS N
Grade-4 POS N
diarrhea. POS N

The POS N
patient POS N
accrual POS N
of POS N
our POS N
trial POS N
is POS N
satisfactory, POS N

Erythema, POS N
nausea POS N
and POS N
leukopenia POS N
were POS N
the POS N
next POS N
common POS N
toxicities, POS N
with POS N
less POS N
than POS N
3% POS N
of POS N
patients POS N
in POS N
either POS N
arm POS N
suffering POS N
Grade POS N
3 POS N
or POS N
greater POS N
leukopenia POS N
or POS N
nausea. POS N

The POS N
patient POS N
accrual POS N
of POS N
our POS N
trial POS N
is POS N
satisfactory, POS N

Postoperative POS N
complication POS N
rates POS N
were POS N
similar POS N
in POS N
both POS N
arms, POS N
with POS N
12% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
13% POS N
(preoperative POS N
radiochemotherapy) POS N
of POS N
patients, POS N
respectively, POS N
suffering POS N
from POS N
anastomotic POS N
leakage, POS N
4% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
3% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
postoperative POS N
bleeding, POS N
and POS N
6% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
5% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
delayed POS N
wound POS N
healing. POS N

The POS N
patient POS N
accrual POS N
of POS N
our POS N
trial POS N
is POS N
satisfactory, POS N

neoadjuvant POS N
radiochemotherapy POS N
is POS N
well POS N
tolerated POS N
and POS N
bears POS N
no POS N
higher POS N
risk POS N
for POS N
postoperative POS N
morbidity. POS N

neoadjuvant POS N
radiochemotherapy POS N
is POS N
well POS N
tolerated POS N
and POS N
bears POS N
no POS N
higher POS N
risk POS N
for POS N
postoperative POS N
morbidity. POS N

In POS N
recent POS N
years, POS N
encouraging POS N
results POS N
of POS N
preoperative POS N
radiotherapy POS N
have POS N
been POS N
reported. POS N

neoadjuvant POS N
radiochemotherapy POS N
is POS N
well POS N
tolerated POS N
and POS N
bears POS N
no POS N
higher POS N
risk POS N
for POS N
postoperative POS N
morbidity. POS N

Postoperative POS N
radiochemotherapy POS N
is POS N
recommended POS N
for POS N
patients POS N
with POS N
advanced POS N
disease POS N
(pT3/4 POS N
or POS N
pN+). POS N

neoadjuvant POS N
radiochemotherapy POS N
is POS N
well POS N
tolerated POS N
and POS N
bears POS N
no POS N
higher POS N
risk POS N
for POS N
postoperative POS N
morbidity. POS N

Acute POS N
toxicity POS N
(WHO) POS N
of POS N
radiochemotherapy POS N
was POS N
low, POS N
with POS N
less POS N
than POS N
15% POS N
of POS N
patients POS N
experiencing POS N
Grade POS N
3 POS N
or POS N
higher POS N
toxicity POS N

neoadjuvant POS N
radiochemotherapy POS N
is POS N
well POS N
tolerated POS N
and POS N
bears POS N
no POS N
higher POS N
risk POS N
for POS N
postoperative POS N
morbidity. POS N

The POS N
principal POS N
toxicity POS N
was POS N
diarrhea, POS N
with POS N
12% POS N
in POS N
the POS N
postoperative POS N
radiochemotherapy POS N
arm POS N
and POS N
10% POS N
in POS N
the POS N
preoperative POS N
radiochemotherapy POS N
arm POS N
having POS N
Grade-3, POS N
and POS N
1% POS N
in POS N
either POS N
arm POS N
having POS N
Grade-4 POS N
diarrhea. POS N

neoadjuvant POS N
radiochemotherapy POS N
is POS N
well POS N
tolerated POS N
and POS N
bears POS N
no POS N
higher POS N
risk POS N
for POS N
postoperative POS N
morbidity. POS N

Erythema, POS N
nausea POS N
and POS N
leukopenia POS N
were POS N
the POS N
next POS N
common POS N
toxicities, POS N
with POS N
less POS N
than POS N
3% POS N
of POS N
patients POS N
in POS N
either POS N
arm POS N
suffering POS N
Grade POS N
3 POS N
or POS N
greater POS N
leukopenia POS N
or POS N
nausea. POS N

neoadjuvant POS N
radiochemotherapy POS N
is POS N
well POS N
tolerated POS N
and POS N
bears POS N
no POS N
higher POS N
risk POS N
for POS N
postoperative POS N
morbidity. POS N

Postoperative POS N
complication POS N
rates POS N
were POS N
similar POS N
in POS N
both POS N
arms, POS N
with POS N
12% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
13% POS N
(preoperative POS N
radiochemotherapy) POS N
of POS N
patients, POS N
respectively, POS N
suffering POS N
from POS N
anastomotic POS N
leakage, POS N
4% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
3% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
postoperative POS N
bleeding, POS N
and POS N
6% POS N
(postoperative POS N
radiochemotherapy) POS N
and POS N
5% POS N
(preoperative POS N
radiochemotherapy) POS N
from POS N
delayed POS N
wound POS N
healing. POS N

neoadjuvant POS N
radiochemotherapy POS N
is POS N
well POS N
tolerated POS N
and POS N
bears POS N
no POS N
higher POS N
risk POS N
for POS N
postoperative POS N
morbidity. POS N

The POS N
patient POS N
accrual POS N
of POS N
our POS N
trial POS N
is POS N
satisfactory, POS N

Cardiovascular POS N
complications POS N
are POS N
one POS N
of POS N
main POS N
cause POS N
of POS N
increased POS N
mortality POS N
and POS N
morbidity POS N
among POS N
Diabetes POS N
Mellitus POS N
(DM) POS N
patients. POS N

Eight POS N
weeks POS N
supplementation POS N
with POS N
EPA POS N
led POS N
to POS N
significant POS N
reductions POS N
in POS N
Met POS N
(p < 0.002) POS N
and POS N
Cys POS N
(p < 0.001) POS N
compared POS N
with POS N
the POS N
placebo POS N
(p < 0.06). POS N

Cardiovascular POS N
complications POS N
are POS N
one POS N
of POS N
main POS N
cause POS N
of POS N
increased POS N
mortality POS N
and POS N
morbidity POS N
among POS N
Diabetes POS N
Mellitus POS N
(DM) POS N
patients. POS N

Altered POS N
metabolism POS N
of POS N
sulphur POS N
amino POS N
acids POS N
in POS N
diabetes POS N
reflected POS N
as POS N
increases POS N
in POS N
concentration POS N
of POS N
methionine POS N
and POS N
cysteine/cystine POS N
in POS N
the POS N
blood POS N
which POS N
known POS N
as POS N
a POS N
markers POS N
of POS N
Cardiovascular POS N
Diseases POS N
(CVD). POS N

Cardiovascular POS N
complications POS N
are POS N
one POS N
of POS N
main POS N
cause POS N
of POS N
increased POS N
mortality POS N
and POS N
morbidity POS N
among POS N
Diabetes POS N
Mellitus POS N
(DM) POS N
patients. POS N

compared POS N
to POS N
placebo POS N
a POS N
significant POS N
reduction POS N
in POS N
AIP POS N
were POS N
seen POS N
after POS N
taking POS N
EPA POS N
(p < 0.04). POS N

Cardiovascular POS N
complications POS N
are POS N
one POS N
of POS N
main POS N
cause POS N
of POS N
increased POS N
mortality POS N
and POS N
morbidity POS N
among POS N
Diabetes POS N
Mellitus POS N
(DM) POS N
patients. POS N

EPA POS N
supplementation POS N
in POS N
patients POS N
with POS N
T2DM POS N
for POS N
eight POS N
weeks POS N
had POS N
beneficial POS N
effects POS N
on POS N
Met, POS N
Cys POS N
and POS N
AIP, POS N
which POS N
may POS N
attribute POS N
to POS N
the POS N
prevention POS N
of POS N
vascular POS N
complications POS N
in POS N
the POS N
T2DM POS N
patients. POS N

Eight POS N
weeks POS N
supplementation POS N
with POS N
EPA POS N
led POS N
to POS N
significant POS N
reductions POS N
in POS N
Met POS N
(p < 0.002) POS N
and POS N
Cys POS N
(p < 0.001) POS N
compared POS N
with POS N
the POS N
placebo POS N
(p < 0.06). POS N

Cardiovascular POS N
complications POS N
are POS N
one POS N
of POS N
main POS N
cause POS N
of POS N
increased POS N
mortality POS N
and POS N
morbidity POS N
among POS N
Diabetes POS N
Mellitus POS N
(DM) POS N
patients. POS N

Eight POS N
weeks POS N
supplementation POS N
with POS N
EPA POS N
led POS N
to POS N
significant POS N
reductions POS N
in POS N
Met POS N
(p < 0.002) POS N
and POS N
Cys POS N
(p < 0.001) POS N
compared POS N
with POS N
the POS N
placebo POS N
(p < 0.06). POS N

Altered POS N
metabolism POS N
of POS N
sulphur POS N
amino POS N
acids POS N
in POS N
diabetes POS N
reflected POS N
as POS N
increases POS N
in POS N
concentration POS N
of POS N
methionine POS N
and POS N
cysteine/cystine POS N
in POS N
the POS N
blood POS N
which POS N
known POS N
as POS N
a POS N
markers POS N
of POS N
Cardiovascular POS N
Diseases POS N
(CVD). POS N

Eight POS N
weeks POS N
supplementation POS N
with POS N
EPA POS N
led POS N
to POS N
significant POS N
reductions POS N
in POS N
Met POS N
(p < 0.002) POS N
and POS N
Cys POS N
(p < 0.001) POS N
compared POS N
with POS N
the POS N
placebo POS N
(p < 0.06). POS N

compared POS N
to POS N
placebo POS N
a POS N
significant POS N
reduction POS N
in POS N
AIP POS N
were POS N
seen POS N
after POS N
taking POS N
EPA POS N
(p < 0.04). POS N

Eight POS N
weeks POS N
supplementation POS N
with POS N
EPA POS N
led POS N
to POS N
significant POS N
reductions POS N
in POS N
Met POS N
(p < 0.002) POS N
and POS N
Cys POS N
(p < 0.001) POS N
compared POS N
with POS N
the POS N
placebo POS N
(p < 0.06). POS N

EPA POS N
supplementation POS N
in POS N
patients POS N
with POS N
T2DM POS N
for POS N
eight POS N
weeks POS N
had POS N
beneficial POS N
effects POS N
on POS N
Met, POS N
Cys POS N
and POS N
AIP, POS N
which POS N
may POS N
attribute POS N
to POS N
the POS N
prevention POS N
of POS N
vascular POS N
complications POS N
in POS N
the POS N
T2DM POS N
patients. POS N

Altered POS N
metabolism POS N
of POS N
sulphur POS N
amino POS N
acids POS N
in POS N
diabetes POS N
reflected POS N
as POS N
increases POS N
in POS N
concentration POS N
of POS N
methionine POS N
and POS N
cysteine/cystine POS N
in POS N
the POS N
blood POS N
which POS N
known POS N
as POS N
a POS N
markers POS N
of POS N
Cardiovascular POS N
Diseases POS N
(CVD). POS N

Cardiovascular POS N
complications POS N
are POS N
one POS N
of POS N
main POS N
cause POS N
of POS N
increased POS N
mortality POS N
and POS N
morbidity POS N
among POS N
Diabetes POS N
Mellitus POS N
(DM) POS N
patients. POS N

Altered POS N
metabolism POS N
of POS N
sulphur POS N
amino POS N
acids POS N
in POS N
diabetes POS N
reflected POS N
as POS N
increases POS N
in POS N
concentration POS N
of POS N
methionine POS N
and POS N
cysteine/cystine POS N
in POS N
the POS N
blood POS N
which POS N
known POS N
as POS N
a POS N
markers POS N
of POS N
Cardiovascular POS N
Diseases POS N
(CVD). POS N

Eight POS N
weeks POS N
supplementation POS N
with POS N
EPA POS N
led POS N
to POS N
significant POS N
reductions POS N
in POS N
Met POS N
(p < 0.002) POS N
and POS N
Cys POS N
(p < 0.001) POS N
compared POS N
with POS N
the POS N
placebo POS N
(p < 0.06). POS N

Altered POS N
metabolism POS N
of POS N
sulphur POS N
amino POS N
acids POS N
in POS N
diabetes POS N
reflected POS N
as POS N
increases POS N
in POS N
concentration POS N
of POS N
methionine POS N
and POS N
cysteine/cystine POS N
in POS N
the POS N
blood POS N
which POS N
known POS N
as POS N
a POS N
markers POS N
of POS N
Cardiovascular POS N
Diseases POS N
(CVD). POS N

compared POS N
to POS N
placebo POS N
a POS N
significant POS N
reduction POS N
in POS N
AIP POS N
were POS N
seen POS N
after POS N
taking POS N
EPA POS N
(p < 0.04). POS N

Altered POS N
metabolism POS N
of POS N
sulphur POS N
amino POS N
acids POS N
in POS N
diabetes POS N
reflected POS N
as POS N
increases POS N
in POS N
concentration POS N
of POS N
methionine POS N
and POS N
cysteine/cystine POS N
in POS N
the POS N
blood POS N
which POS N
known POS N
as POS N
a POS N
markers POS N
of POS N
Cardiovascular POS N
Diseases POS N
(CVD). POS N

EPA POS N
supplementation POS N
in POS N
patients POS N
with POS N
T2DM POS N
for POS N
eight POS N
weeks POS N
had POS N
beneficial POS N
effects POS N
on POS N
Met, POS N
Cys POS N
and POS N
AIP, POS N
which POS N
may POS N
attribute POS N
to POS N
the POS N
prevention POS N
of POS N
vascular POS N
complications POS N
in POS N
the POS N
T2DM POS N
patients. POS N

compared POS N
to POS N
placebo POS N
a POS N
significant POS N
reduction POS N
in POS N
AIP POS N
were POS N
seen POS N
after POS N
taking POS N
EPA POS N
(p < 0.04). POS N

Cardiovascular POS N
complications POS N
are POS N
one POS N
of POS N
main POS N
cause POS N
of POS N
increased POS N
mortality POS N
and POS N
morbidity POS N
among POS N
Diabetes POS N
Mellitus POS N
(DM) POS N
patients. POS N

compared POS N
to POS N
placebo POS N
a POS N
significant POS N
reduction POS N
in POS N
AIP POS N
were POS N
seen POS N
after POS N
taking POS N
EPA POS N
(p < 0.04). POS N

Eight POS N
weeks POS N
supplementation POS N
with POS N
EPA POS N
led POS N
to POS N
significant POS N
reductions POS N
in POS N
Met POS N
(p < 0.002) POS N
and POS N
Cys POS N
(p < 0.001) POS N
compared POS N
with POS N
the POS N
placebo POS N
(p < 0.06). POS N

compared POS N
to POS N
placebo POS N
a POS N
significant POS N
reduction POS N
in POS N
AIP POS N
were POS N
seen POS N
after POS N
taking POS N
EPA POS N
(p < 0.04). POS N

Altered POS N
metabolism POS N
of POS N
sulphur POS N
amino POS N
acids POS N
in POS N
diabetes POS N
reflected POS N
as POS N
increases POS N
in POS N
concentration POS N
of POS N
methionine POS N
and POS N
cysteine/cystine POS N
in POS N
the POS N
blood POS N
which POS N
known POS N
as POS N
a POS N
markers POS N
of POS N
Cardiovascular POS N
Diseases POS N
(CVD). POS N

compared POS N
to POS N
placebo POS N
a POS N
significant POS N
reduction POS N
in POS N
AIP POS N
were POS N
seen POS N
after POS N
taking POS N
EPA POS N
(p < 0.04). POS N

EPA POS N
supplementation POS N
in POS N
patients POS N
with POS N
T2DM POS N
for POS N
eight POS N
weeks POS N
had POS N
beneficial POS N
effects POS N
on POS N
Met, POS N
Cys POS N
and POS N
AIP, POS N
which POS N
may POS N
attribute POS N
to POS N
the POS N
prevention POS N
of POS N
vascular POS N
complications POS N
in POS N
the POS N
T2DM POS N
patients. POS N

EPA POS N
supplementation POS N
in POS N
patients POS N
with POS N
T2DM POS N
for POS N
eight POS N
weeks POS N
had POS N
beneficial POS N
effects POS N
on POS N
Met, POS N
Cys POS N
and POS N
AIP, POS N
which POS N
may POS N
attribute POS N
to POS N
the POS N
prevention POS N
of POS N
vascular POS N
complications POS N
in POS N
the POS N
T2DM POS N
patients. POS N

Cardiovascular POS N
complications POS N
are POS N
one POS N
of POS N
main POS N
cause POS N
of POS N
increased POS N
mortality POS N
and POS N
morbidity POS N
among POS N
Diabetes POS N
Mellitus POS N
(DM) POS N
patients. POS N

EPA POS N
supplementation POS N
in POS N
patients POS N
with POS N
T2DM POS N
for POS N
eight POS N
weeks POS N
had POS N
beneficial POS N
effects POS N
on POS N
Met, POS N
Cys POS N
and POS N
AIP, POS N
which POS N
may POS N
attribute POS N
to POS N
the POS N
prevention POS N
of POS N
vascular POS N
complications POS N
in POS N
the POS N
T2DM POS N
patients. POS N

Eight POS N
weeks POS N
supplementation POS N
with POS N
EPA POS N
led POS N
to POS N
significant POS N
reductions POS N
in POS N
Met POS N
(p < 0.002) POS N
and POS N
Cys POS N
(p < 0.001) POS N
compared POS N
with POS N
the POS N
placebo POS N
(p < 0.06). POS N

EPA POS N
supplementation POS N
in POS N
patients POS N
with POS N
T2DM POS N
for POS N
eight POS N
weeks POS N
had POS N
beneficial POS N
effects POS N
on POS N
Met, POS N
Cys POS N
and POS N
AIP, POS N
which POS N
may POS N
attribute POS N
to POS N
the POS N
prevention POS N
of POS N
vascular POS N
complications POS N
in POS N
the POS N
T2DM POS N
patients. POS N

Altered POS N
metabolism POS N
of POS N
sulphur POS N
amino POS N
acids POS N
in POS N
diabetes POS N
reflected POS N
as POS N
increases POS N
in POS N
concentration POS N
of POS N
methionine POS N
and POS N
cysteine/cystine POS N
in POS N
the POS N
blood POS N
which POS N
known POS N
as POS N
a POS N
markers POS N
of POS N
Cardiovascular POS N
Diseases POS N
(CVD). POS N

EPA POS N
supplementation POS N
in POS N
patients POS N
with POS N
T2DM POS N
for POS N
eight POS N
weeks POS N
had POS N
beneficial POS N
effects POS N
on POS N
Met, POS N
Cys POS N
and POS N
AIP, POS N
which POS N
may POS N
attribute POS N
to POS N
the POS N
prevention POS N
of POS N
vascular POS N
complications POS N
in POS N
the POS N
T2DM POS N
patients. POS N

compared POS N
to POS N
placebo POS N
a POS N
significant POS N
reduction POS N
in POS N
AIP POS N
were POS N
seen POS N
after POS N
taking POS N
EPA POS N
(p < 0.04). POS N

Observational POS N
data POS N
support POS N
a POS N
role POS N
for POS N
vitamin POS N
D POS N
in POS N
type POS N
2 POS N
diabetes, POS N

but POS N
evidence POS N
from POS N
trials POS N
is POS N
inconclusive. POS N

Observational POS N
data POS N
support POS N
a POS N
role POS N
for POS N
vitamin POS N
D POS N
in POS N
type POS N
2 POS N
diabetes, POS N

At POS N
week POS N
24, POS N
mean POS N
25(OH)D POS N
changed POS N
by POS N
20.5 POS N
and POS N
-1.6 POS N
ng/mL POS N
in POS N
the POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups, POS N
respectively POS N
(P POS N
< POS N
0.001). POS N

Observational POS N
data POS N
support POS N
a POS N
role POS N
for POS N
vitamin POS N
D POS N
in POS N
type POS N
2 POS N
diabetes, POS N

The POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups POS N
did POS N
not POS N
differ POS N
in POS N
change POS N
in POS N
ISR POS N
or POS N
HbA1c. POS N

Observational POS N
data POS N
support POS N
a POS N
role POS N
for POS N
vitamin POS N
D POS N
in POS N
type POS N
2 POS N
diabetes, POS N

Among POS N
patients POS N
treated POS N
with POS N
lifestyle POS N
only POS N
(n POS N
= POS N
28), POS N
vitamin POS N
D POS N
supplementation POS N
reduced POS N
HbA1c POS N
compared POS N
with POS N
placebo POS N
(-0.1% POS N
vs POS N
0.3%, POS N
respectively; POS N
P POS N
= POS N
0.034) POS N
at POS N
week POS N
24. POS N

Observational POS N
data POS N
support POS N
a POS N
role POS N
for POS N
vitamin POS N
D POS N
in POS N
type POS N
2 POS N
diabetes, POS N

Vitamin POS N
D3 POS N
at POS N
4000 POS N
IU/d POS N
did POS N
not POS N
change POS N
ISR POS N
or POS N
HbA1c POS N
in POS N
patients POS N
with POS N
well-controlled POS N
type POS N
2 POS N
diabetes POS N
on POS N
metformin POS N
not POS N
selected POS N
for POS N
vitamin POS N
D POS N
deficiency. POS N

but POS N
evidence POS N
from POS N
trials POS N
is POS N
inconclusive. POS N

Observational POS N
data POS N
support POS N
a POS N
role POS N
for POS N
vitamin POS N
D POS N
in POS N
type POS N
2 POS N
diabetes, POS N

but POS N
evidence POS N
from POS N
trials POS N
is POS N
inconclusive. POS N

At POS N
week POS N
24, POS N
mean POS N
25(OH)D POS N
changed POS N
by POS N
20.5 POS N
and POS N
-1.6 POS N
ng/mL POS N
in POS N
the POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups, POS N
respectively POS N
(P POS N
< POS N
0.001). POS N

but POS N
evidence POS N
from POS N
trials POS N
is POS N
inconclusive. POS N

The POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups POS N
did POS N
not POS N
differ POS N
in POS N
change POS N
in POS N
ISR POS N
or POS N
HbA1c. POS N

but POS N
evidence POS N
from POS N
trials POS N
is POS N
inconclusive. POS N

Among POS N
patients POS N
treated POS N
with POS N
lifestyle POS N
only POS N
(n POS N
= POS N
28), POS N
vitamin POS N
D POS N
supplementation POS N
reduced POS N
HbA1c POS N
compared POS N
with POS N
placebo POS N
(-0.1% POS N
vs POS N
0.3%, POS N
respectively; POS N
P POS N
= POS N
0.034) POS N
at POS N
week POS N
24. POS N

but POS N
evidence POS N
from POS N
trials POS N
is POS N
inconclusive. POS N

Vitamin POS N
D3 POS N
at POS N
4000 POS N
IU/d POS N
did POS N
not POS N
change POS N
ISR POS N
or POS N
HbA1c POS N
in POS N
patients POS N
with POS N
well-controlled POS N
type POS N
2 POS N
diabetes POS N
on POS N
metformin POS N
not POS N
selected POS N
for POS N
vitamin POS N
D POS N
deficiency. POS N

At POS N
week POS N
24, POS N
mean POS N
25(OH)D POS N
changed POS N
by POS N
20.5 POS N
and POS N
-1.6 POS N
ng/mL POS N
in POS N
the POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups, POS N
respectively POS N
(P POS N
< POS N
0.001). POS N

Observational POS N
data POS N
support POS N
a POS N
role POS N
for POS N
vitamin POS N
D POS N
in POS N
type POS N
2 POS N
diabetes, POS N

At POS N
week POS N
24, POS N
mean POS N
25(OH)D POS N
changed POS N
by POS N
20.5 POS N
and POS N
-1.6 POS N
ng/mL POS N
in POS N
the POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups, POS N
respectively POS N
(P POS N
< POS N
0.001). POS N

but POS N
evidence POS N
from POS N
trials POS N
is POS N
inconclusive. POS N

At POS N
week POS N
24, POS N
mean POS N
25(OH)D POS N
changed POS N
by POS N
20.5 POS N
and POS N
-1.6 POS N
ng/mL POS N
in POS N
the POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups, POS N
respectively POS N
(P POS N
< POS N
0.001). POS N

The POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups POS N
did POS N
not POS N
differ POS N
in POS N
change POS N
in POS N
ISR POS N
or POS N
HbA1c. POS N

At POS N
week POS N
24, POS N
mean POS N
25(OH)D POS N
changed POS N
by POS N
20.5 POS N
and POS N
-1.6 POS N
ng/mL POS N
in POS N
the POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups, POS N
respectively POS N
(P POS N
< POS N
0.001). POS N

Among POS N
patients POS N
treated POS N
with POS N
lifestyle POS N
only POS N
(n POS N
= POS N
28), POS N
vitamin POS N
D POS N
supplementation POS N
reduced POS N
HbA1c POS N
compared POS N
with POS N
placebo POS N
(-0.1% POS N
vs POS N
0.3%, POS N
respectively; POS N
P POS N
= POS N
0.034) POS N
at POS N
week POS N
24. POS N

At POS N
week POS N
24, POS N
mean POS N
25(OH)D POS N
changed POS N
by POS N
20.5 POS N
and POS N
-1.6 POS N
ng/mL POS N
in POS N
the POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups, POS N
respectively POS N
(P POS N
< POS N
0.001). POS N

Vitamin POS N
D3 POS N
at POS N
4000 POS N
IU/d POS N
did POS N
not POS N
change POS N
ISR POS N
or POS N
HbA1c POS N
in POS N
patients POS N
with POS N
well-controlled POS N
type POS N
2 POS N
diabetes POS N
on POS N
metformin POS N
not POS N
selected POS N
for POS N
vitamin POS N
D POS N
deficiency. POS N

The POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups POS N
did POS N
not POS N
differ POS N
in POS N
change POS N
in POS N
ISR POS N
or POS N
HbA1c. POS N

Observational POS N
data POS N
support POS N
a POS N
role POS N
for POS N
vitamin POS N
D POS N
in POS N
type POS N
2 POS N
diabetes, POS N

The POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups POS N
did POS N
not POS N
differ POS N
in POS N
change POS N
in POS N
ISR POS N
or POS N
HbA1c. POS N

but POS N
evidence POS N
from POS N
trials POS N
is POS N
inconclusive. POS N

The POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups POS N
did POS N
not POS N
differ POS N
in POS N
change POS N
in POS N
ISR POS N
or POS N
HbA1c. POS N

At POS N
week POS N
24, POS N
mean POS N
25(OH)D POS N
changed POS N
by POS N
20.5 POS N
and POS N
-1.6 POS N
ng/mL POS N
in POS N
the POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups, POS N
respectively POS N
(P POS N
< POS N
0.001). POS N

The POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups POS N
did POS N
not POS N
differ POS N
in POS N
change POS N
in POS N
ISR POS N
or POS N
HbA1c. POS N

Among POS N
patients POS N
treated POS N
with POS N
lifestyle POS N
only POS N
(n POS N
= POS N
28), POS N
vitamin POS N
D POS N
supplementation POS N
reduced POS N
HbA1c POS N
compared POS N
with POS N
placebo POS N
(-0.1% POS N
vs POS N
0.3%, POS N
respectively; POS N
P POS N
= POS N
0.034) POS N
at POS N
week POS N
24. POS N

The POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups POS N
did POS N
not POS N
differ POS N
in POS N
change POS N
in POS N
ISR POS N
or POS N
HbA1c. POS N

Vitamin POS N
D3 POS N
at POS N
4000 POS N
IU/d POS N
did POS N
not POS N
change POS N
ISR POS N
or POS N
HbA1c POS N
in POS N
patients POS N
with POS N
well-controlled POS N
type POS N
2 POS N
diabetes POS N
on POS N
metformin POS N
not POS N
selected POS N
for POS N
vitamin POS N
D POS N
deficiency. POS N

Among POS N
patients POS N
treated POS N
with POS N
lifestyle POS N
only POS N
(n POS N
= POS N
28), POS N
vitamin POS N
D POS N
supplementation POS N
reduced POS N
HbA1c POS N
compared POS N
with POS N
placebo POS N
(-0.1% POS N
vs POS N
0.3%, POS N
respectively; POS N
P POS N
= POS N
0.034) POS N
at POS N
week POS N
24. POS N

Observational POS N
data POS N
support POS N
a POS N
role POS N
for POS N
vitamin POS N
D POS N
in POS N
type POS N
2 POS N
diabetes, POS N

Among POS N
patients POS N
treated POS N
with POS N
lifestyle POS N
only POS N
(n POS N
= POS N
28), POS N
vitamin POS N
D POS N
supplementation POS N
reduced POS N
HbA1c POS N
compared POS N
with POS N
placebo POS N
(-0.1% POS N
vs POS N
0.3%, POS N
respectively; POS N
P POS N
= POS N
0.034) POS N
at POS N
week POS N
24. POS N

but POS N
evidence POS N
from POS N
trials POS N
is POS N
inconclusive. POS N

Among POS N
patients POS N
treated POS N
with POS N
lifestyle POS N
only POS N
(n POS N
= POS N
28), POS N
vitamin POS N
D POS N
supplementation POS N
reduced POS N
HbA1c POS N
compared POS N
with POS N
placebo POS N
(-0.1% POS N
vs POS N
0.3%, POS N
respectively; POS N
P POS N
= POS N
0.034) POS N
at POS N
week POS N
24. POS N

At POS N
week POS N
24, POS N
mean POS N
25(OH)D POS N
changed POS N
by POS N
20.5 POS N
and POS N
-1.6 POS N
ng/mL POS N
in POS N
the POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups, POS N
respectively POS N
(P POS N
< POS N
0.001). POS N

Among POS N
patients POS N
treated POS N
with POS N
lifestyle POS N
only POS N
(n POS N
= POS N
28), POS N
vitamin POS N
D POS N
supplementation POS N
reduced POS N
HbA1c POS N
compared POS N
with POS N
placebo POS N
(-0.1% POS N
vs POS N
0.3%, POS N
respectively; POS N
P POS N
= POS N
0.034) POS N
at POS N
week POS N
24. POS N

The POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups POS N
did POS N
not POS N
differ POS N
in POS N
change POS N
in POS N
ISR POS N
or POS N
HbA1c. POS N

Among POS N
patients POS N
treated POS N
with POS N
lifestyle POS N
only POS N
(n POS N
= POS N
28), POS N
vitamin POS N
D POS N
supplementation POS N
reduced POS N
HbA1c POS N
compared POS N
with POS N
placebo POS N
(-0.1% POS N
vs POS N
0.3%, POS N
respectively; POS N
P POS N
= POS N
0.034) POS N
at POS N
week POS N
24. POS N

Vitamin POS N
D3 POS N
at POS N
4000 POS N
IU/d POS N
did POS N
not POS N
change POS N
ISR POS N
or POS N
HbA1c POS N
in POS N
patients POS N
with POS N
well-controlled POS N
type POS N
2 POS N
diabetes POS N
on POS N
metformin POS N
not POS N
selected POS N
for POS N
vitamin POS N
D POS N
deficiency. POS N

Vitamin POS N
D3 POS N
at POS N
4000 POS N
IU/d POS N
did POS N
not POS N
change POS N
ISR POS N
or POS N
HbA1c POS N
in POS N
patients POS N
with POS N
well-controlled POS N
type POS N
2 POS N
diabetes POS N
on POS N
metformin POS N
not POS N
selected POS N
for POS N
vitamin POS N
D POS N
deficiency. POS N

Observational POS N
data POS N
support POS N
a POS N
role POS N
for POS N
vitamin POS N
D POS N
in POS N
type POS N
2 POS N
diabetes, POS N

Vitamin POS N
D3 POS N
at POS N
4000 POS N
IU/d POS N
did POS N
not POS N
change POS N
ISR POS N
or POS N
HbA1c POS N
in POS N
patients POS N
with POS N
well-controlled POS N
type POS N
2 POS N
diabetes POS N
on POS N
metformin POS N
not POS N
selected POS N
for POS N
vitamin POS N
D POS N
deficiency. POS N

but POS N
evidence POS N
from POS N
trials POS N
is POS N
inconclusive. POS N

Vitamin POS N
D3 POS N
at POS N
4000 POS N
IU/d POS N
did POS N
not POS N
change POS N
ISR POS N
or POS N
HbA1c POS N
in POS N
patients POS N
with POS N
well-controlled POS N
type POS N
2 POS N
diabetes POS N
on POS N
metformin POS N
not POS N
selected POS N
for POS N
vitamin POS N
D POS N
deficiency. POS N

At POS N
week POS N
24, POS N
mean POS N
25(OH)D POS N
changed POS N
by POS N
20.5 POS N
and POS N
-1.6 POS N
ng/mL POS N
in POS N
the POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups, POS N
respectively POS N
(P POS N
< POS N
0.001). POS N

Vitamin POS N
D3 POS N
at POS N
4000 POS N
IU/d POS N
did POS N
not POS N
change POS N
ISR POS N
or POS N
HbA1c POS N
in POS N
patients POS N
with POS N
well-controlled POS N
type POS N
2 POS N
diabetes POS N
on POS N
metformin POS N
not POS N
selected POS N
for POS N
vitamin POS N
D POS N
deficiency. POS N

The POS N
vitamin POS N
D POS N
and POS N
placebo POS N
groups POS N
did POS N
not POS N
differ POS N
in POS N
change POS N
in POS N
ISR POS N
or POS N
HbA1c. POS N

Vitamin POS N
D3 POS N
at POS N
4000 POS N
IU/d POS N
did POS N
not POS N
change POS N
ISR POS N
or POS N
HbA1c POS N
in POS N
patients POS N
with POS N
well-controlled POS N
type POS N
2 POS N
diabetes POS N
on POS N
metformin POS N
not POS N
selected POS N
for POS N
vitamin POS N
D POS N
deficiency. POS N

Among POS N
patients POS N
treated POS N
with POS N
lifestyle POS N
only POS N
(n POS N
= POS N
28), POS N
vitamin POS N
D POS N
supplementation POS N
reduced POS N
HbA1c POS N
compared POS N
with POS N
placebo POS N
(-0.1% POS N
vs POS N
0.3%, POS N
respectively; POS N
P POS N
= POS N
0.034) POS N
at POS N
week POS N
24. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
2-year POS N
follow-up POS N
period, POS N
the POS N
complete POS N
success POS N
and POS N
the POS N
failure POS N
rates POS N
were POS N
67% POS N
and POS N
15%, POS N
respectively, POS N
in POS N
the POS N
microcatheter-assisted POS N
group POS N
versus POS N
47% POS N
and POS N
50% POS N
in POS N
the POS N
rigid POS N
probe POS N
trabeculotomy POS N
group POS N
(p POS N
= POS N
0.006). POS N

There POS N
was POS N
a POS N
tendency POS N
towards POS N
lower POS N
IOP POS N
in POS N
the POS N
microcatheter POS N
group POS N
at POS N
1, POS N
3, POS N
6, POS N
12 POS N
and POS N
24 POS N
months POS N
postoperatively, POS N
with POS N
the POS N
difference POS N
in POS N
IOP POS N
reaching POS N
statistical POS N
significance POS N
at POS N
6 POS N
months POS N
(p POS N
= POS N
0.004). POS N

At POS N
the POS N
end POS N
of POS N
the POS N
2-year POS N
follow-up POS N
period, POS N
the POS N
complete POS N
success POS N
and POS N
the POS N
failure POS N
rates POS N
were POS N
67% POS N
and POS N
15%, POS N
respectively, POS N
in POS N
the POS N
microcatheter-assisted POS N
group POS N
versus POS N
47% POS N
and POS N
50% POS N
in POS N
the POS N
rigid POS N
probe POS N
trabeculotomy POS N
group POS N
(p POS N
= POS N
0.006). POS N

The POS N
mean POS N
survival POS N
time POS N
was POS N
significantly POS N
longer POS N
for POS N
the POS N
microcatheter POS N
group POS N
(p POS N
= POS N
0.01). POS N

At POS N
the POS N
end POS N
of POS N
the POS N
2-year POS N
follow-up POS N
period, POS N
the POS N
complete POS N
success POS N
and POS N
the POS N
failure POS N
rates POS N
were POS N
67% POS N
and POS N
15%, POS N
respectively, POS N
in POS N
the POS N
microcatheter-assisted POS N
group POS N
versus POS N
47% POS N
and POS N
50% POS N
in POS N
the POS N
rigid POS N
probe POS N
trabeculotomy POS N
group POS N
(p POS N
= POS N
0.006). POS N

At POS N
2 POS N
years POS N
postoperatively, POS N
microcatheter-assisted POS N
trabeculotomy POS N
still POS N
yielded POS N
superior POS N
results POS N
in POS N
terms POS N
of POS N
IOP POS N
control POS N
and POS N
success POS N
rates POS N
in POS N
children POS N
with POS N
primary POS N
congenital POS N
glaucoma. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
2-year POS N
follow-up POS N
period, POS N
the POS N
complete POS N
success POS N
and POS N
the POS N
failure POS N
rates POS N
were POS N
67% POS N
and POS N
15%, POS N
respectively, POS N
in POS N
the POS N
microcatheter-assisted POS N
group POS N
versus POS N
47% POS N
and POS N
50% POS N
in POS N
the POS N
rigid POS N
probe POS N
trabeculotomy POS N
group POS N
(p POS N
= POS N
0.006). POS N

The POS N
need POS N
for POS N
reoperation POS N
for POS N
glaucoma POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
microcatheter POS N
group. POS N

There POS N
was POS N
a POS N
tendency POS N
towards POS N
lower POS N
IOP POS N
in POS N
the POS N
microcatheter POS N
group POS N
at POS N
1, POS N
3, POS N
6, POS N
12 POS N
and POS N
24 POS N
months POS N
postoperatively, POS N
with POS N
the POS N
difference POS N
in POS N
IOP POS N
reaching POS N
statistical POS N
significance POS N
at POS N
6 POS N
months POS N
(p POS N
= POS N
0.004). POS N

At POS N
the POS N
end POS N
of POS N
the POS N
2-year POS N
follow-up POS N
period, POS N
the POS N
complete POS N
success POS N
and POS N
the POS N
failure POS N
rates POS N
were POS N
67% POS N
and POS N
15%, POS N
respectively, POS N
in POS N
the POS N
microcatheter-assisted POS N
group POS N
versus POS N
47% POS N
and POS N
50% POS N
in POS N
the POS N
rigid POS N
probe POS N
trabeculotomy POS N
group POS N
(p POS N
= POS N
0.006). POS N

There POS N
was POS N
a POS N
tendency POS N
towards POS N
lower POS N
IOP POS N
in POS N
the POS N
microcatheter POS N
group POS N
at POS N
1, POS N
3, POS N
6, POS N
12 POS N
and POS N
24 POS N
months POS N
postoperatively, POS N
with POS N
the POS N
difference POS N
in POS N
IOP POS N
reaching POS N
statistical POS N
significance POS N
at POS N
6 POS N
months POS N
(p POS N
= POS N
0.004). POS N

The POS N
mean POS N
survival POS N
time POS N
was POS N
significantly POS N
longer POS N
for POS N
the POS N
microcatheter POS N
group POS N
(p POS N
= POS N
0.01). POS N

There POS N
was POS N
a POS N
tendency POS N
towards POS N
lower POS N
IOP POS N
in POS N
the POS N
microcatheter POS N
group POS N
at POS N
1, POS N
3, POS N
6, POS N
12 POS N
and POS N
24 POS N
months POS N
postoperatively, POS N
with POS N
the POS N
difference POS N
in POS N
IOP POS N
reaching POS N
statistical POS N
significance POS N
at POS N
6 POS N
months POS N
(p POS N
= POS N
0.004). POS N

At POS N
2 POS N
years POS N
postoperatively, POS N
microcatheter-assisted POS N
trabeculotomy POS N
still POS N
yielded POS N
superior POS N
results POS N
in POS N
terms POS N
of POS N
IOP POS N
control POS N
and POS N
success POS N
rates POS N
in POS N
children POS N
with POS N
primary POS N
congenital POS N
glaucoma. POS N

There POS N
was POS N
a POS N
tendency POS N
towards POS N
lower POS N
IOP POS N
in POS N
the POS N
microcatheter POS N
group POS N
at POS N
1, POS N
3, POS N
6, POS N
12 POS N
and POS N
24 POS N
months POS N
postoperatively, POS N
with POS N
the POS N
difference POS N
in POS N
IOP POS N
reaching POS N
statistical POS N
significance POS N
at POS N
6 POS N
months POS N
(p POS N
= POS N
0.004). POS N

The POS N
need POS N
for POS N
reoperation POS N
for POS N
glaucoma POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
microcatheter POS N
group. POS N

The POS N
mean POS N
survival POS N
time POS N
was POS N
significantly POS N
longer POS N
for POS N
the POS N
microcatheter POS N
group POS N
(p POS N
= POS N
0.01). POS N

At POS N
the POS N
end POS N
of POS N
the POS N
2-year POS N
follow-up POS N
period, POS N
the POS N
complete POS N
success POS N
and POS N
the POS N
failure POS N
rates POS N
were POS N
67% POS N
and POS N
15%, POS N
respectively, POS N
in POS N
the POS N
microcatheter-assisted POS N
group POS N
versus POS N
47% POS N
and POS N
50% POS N
in POS N
the POS N
rigid POS N
probe POS N
trabeculotomy POS N
group POS N
(p POS N
= POS N
0.006). POS N

The POS N
mean POS N
survival POS N
time POS N
was POS N
significantly POS N
longer POS N
for POS N
the POS N
microcatheter POS N
group POS N
(p POS N
= POS N
0.01). POS N

There POS N
was POS N
a POS N
tendency POS N
towards POS N
lower POS N
IOP POS N
in POS N
the POS N
microcatheter POS N
group POS N
at POS N
1, POS N
3, POS N
6, POS N
12 POS N
and POS N
24 POS N
months POS N
postoperatively, POS N
with POS N
the POS N
difference POS N
in POS N
IOP POS N
reaching POS N
statistical POS N
significance POS N
at POS N
6 POS N
months POS N
(p POS N
= POS N
0.004). POS N

The POS N
mean POS N
survival POS N
time POS N
was POS N
significantly POS N
longer POS N
for POS N
the POS N
microcatheter POS N
group POS N
(p POS N
= POS N
0.01). POS N

At POS N
2 POS N
years POS N
postoperatively, POS N
microcatheter-assisted POS N
trabeculotomy POS N
still POS N
yielded POS N
superior POS N
results POS N
in POS N
terms POS N
of POS N
IOP POS N
control POS N
and POS N
success POS N
rates POS N
in POS N
children POS N
with POS N
primary POS N
congenital POS N
glaucoma. POS N

The POS N
mean POS N
survival POS N
time POS N
was POS N
significantly POS N
longer POS N
for POS N
the POS N
microcatheter POS N
group POS N
(p POS N
= POS N
0.01). POS N

The POS N
need POS N
for POS N
reoperation POS N
for POS N
glaucoma POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
microcatheter POS N
group. POS N

At POS N
2 POS N
years POS N
postoperatively, POS N
microcatheter-assisted POS N
trabeculotomy POS N
still POS N
yielded POS N
superior POS N
results POS N
in POS N
terms POS N
of POS N
IOP POS N
control POS N
and POS N
success POS N
rates POS N
in POS N
children POS N
with POS N
primary POS N
congenital POS N
glaucoma. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
2-year POS N
follow-up POS N
period, POS N
the POS N
complete POS N
success POS N
and POS N
the POS N
failure POS N
rates POS N
were POS N
67% POS N
and POS N
15%, POS N
respectively, POS N
in POS N
the POS N
microcatheter-assisted POS N
group POS N
versus POS N
47% POS N
and POS N
50% POS N
in POS N
the POS N
rigid POS N
probe POS N
trabeculotomy POS N
group POS N
(p POS N
= POS N
0.006). POS N

At POS N
2 POS N
years POS N
postoperatively, POS N
microcatheter-assisted POS N
trabeculotomy POS N
still POS N
yielded POS N
superior POS N
results POS N
in POS N
terms POS N
of POS N
IOP POS N
control POS N
and POS N
success POS N
rates POS N
in POS N
children POS N
with POS N
primary POS N
congenital POS N
glaucoma. POS N

There POS N
was POS N
a POS N
tendency POS N
towards POS N
lower POS N
IOP POS N
in POS N
the POS N
microcatheter POS N
group POS N
at POS N
1, POS N
3, POS N
6, POS N
12 POS N
and POS N
24 POS N
months POS N
postoperatively, POS N
with POS N
the POS N
difference POS N
in POS N
IOP POS N
reaching POS N
statistical POS N
significance POS N
at POS N
6 POS N
months POS N
(p POS N
= POS N
0.004). POS N

At POS N
2 POS N
years POS N
postoperatively, POS N
microcatheter-assisted POS N
trabeculotomy POS N
still POS N
yielded POS N
superior POS N
results POS N
in POS N
terms POS N
of POS N
IOP POS N
control POS N
and POS N
success POS N
rates POS N
in POS N
children POS N
with POS N
primary POS N
congenital POS N
glaucoma. POS N

The POS N
mean POS N
survival POS N
time POS N
was POS N
significantly POS N
longer POS N
for POS N
the POS N
microcatheter POS N
group POS N
(p POS N
= POS N
0.01). POS N

At POS N
2 POS N
years POS N
postoperatively, POS N
microcatheter-assisted POS N
trabeculotomy POS N
still POS N
yielded POS N
superior POS N
results POS N
in POS N
terms POS N
of POS N
IOP POS N
control POS N
and POS N
success POS N
rates POS N
in POS N
children POS N
with POS N
primary POS N
congenital POS N
glaucoma. POS N

The POS N
need POS N
for POS N
reoperation POS N
for POS N
glaucoma POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
microcatheter POS N
group. POS N

The POS N
need POS N
for POS N
reoperation POS N
for POS N
glaucoma POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
microcatheter POS N
group. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
2-year POS N
follow-up POS N
period, POS N
the POS N
complete POS N
success POS N
and POS N
the POS N
failure POS N
rates POS N
were POS N
67% POS N
and POS N
15%, POS N
respectively, POS N
in POS N
the POS N
microcatheter-assisted POS N
group POS N
versus POS N
47% POS N
and POS N
50% POS N
in POS N
the POS N
rigid POS N
probe POS N
trabeculotomy POS N
group POS N
(p POS N
= POS N
0.006). POS N

The POS N
need POS N
for POS N
reoperation POS N
for POS N
glaucoma POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
microcatheter POS N
group. POS N

There POS N
was POS N
a POS N
tendency POS N
towards POS N
lower POS N
IOP POS N
in POS N
the POS N
microcatheter POS N
group POS N
at POS N
1, POS N
3, POS N
6, POS N
12 POS N
and POS N
24 POS N
months POS N
postoperatively, POS N
with POS N
the POS N
difference POS N
in POS N
IOP POS N
reaching POS N
statistical POS N
significance POS N
at POS N
6 POS N
months POS N
(p POS N
= POS N
0.004). POS N

The POS N
need POS N
for POS N
reoperation POS N
for POS N
glaucoma POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
microcatheter POS N
group. POS N

The POS N
mean POS N
survival POS N
time POS N
was POS N
significantly POS N
longer POS N
for POS N
the POS N
microcatheter POS N
group POS N
(p POS N
= POS N
0.01). POS N

The POS N
need POS N
for POS N
reoperation POS N
for POS N
glaucoma POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
microcatheter POS N
group. POS N

At POS N
2 POS N
years POS N
postoperatively, POS N
microcatheter-assisted POS N
trabeculotomy POS N
still POS N
yielded POS N
superior POS N
results POS N
in POS N
terms POS N
of POS N
IOP POS N
control POS N
and POS N
success POS N
rates POS N
in POS N
children POS N
with POS N
primary POS N
congenital POS N
glaucoma. POS N

It POS N
is POS N
concluded POS N
that POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
possesses POS N
as POS N
effective POS N
a POS N
therapeutic POS N
value POS N
in POS N
treating POS N
hepatitis POS N
B POS N
as POS N
allopathic POS N
medicine. POS N

No POS N
significant POS N
difference POS N
was POS N
identified POS N
after POS N
treatment POS N
and POS N
it POS N
was POS N
found POS N
that POS N
the POS N
efficacy POS N
of POS N
Alpha POS N
(Control POS N
drug) POS N
is POS N
same POS N
as POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(Test POS N
drug). POS N

It POS N
is POS N
concluded POS N
that POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
possesses POS N
as POS N
effective POS N
a POS N
therapeutic POS N
value POS N
in POS N
treating POS N
hepatitis POS N
B POS N
as POS N
allopathic POS N
medicine. POS N

The POS N
data POS N
offered POS N
support POS N
to POS N
the POS N
null POS N
hypothesis POS N
and POS N
therefore POS N
research POS N
hypothesis POS N
was POS N
rejected. POS N

It POS N
is POS N
concluded POS N
that POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
possesses POS N
as POS N
effective POS N
a POS N
therapeutic POS N
value POS N
in POS N
treating POS N
hepatitis POS N
B POS N
as POS N
allopathic POS N
medicine. POS N

According POS N
to POS N
the POS N
statistical POS N
analysis POS N
by POS N
chi POS N
square, POS N
hepatitis POS N
B POS N
was POS N
recorded POS N
as POS N
negative POS N
in POS N
26 POS N
patients POS N
(57.77%) POS N
out POS N
of POS N
45 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Interferon POS N
Alpha POS N
(control POS N
therapy) POS N
and POS N
in POS N
27 POS N
patients POS N
(64.28%) POS N
out POS N
of POS N
42 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(test POS N
drug). POS N

It POS N
is POS N
concluded POS N
that POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
possesses POS N
as POS N
effective POS N
a POS N
therapeutic POS N
value POS N
in POS N
treating POS N
hepatitis POS N
B POS N
as POS N
allopathic POS N
medicine. POS N

Comparison POS N
of POS N
the POS N
data POS N
recorded POS N
of POS N
the POS N
patients POS N
was POS N
determined POS N
as POS N
both POS N
drugs POS N
showed POS N
significant POS N
improvement POS N
and POS N
p POS N
value>0.05. POS N

It POS N
is POS N
concluded POS N
that POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
possesses POS N
as POS N
effective POS N
a POS N
therapeutic POS N
value POS N
in POS N
treating POS N
hepatitis POS N
B POS N
as POS N
allopathic POS N
medicine. POS N

The POS N
efficacy POS N
response POS N
is POS N
equal POS N
in POS N
both POS N
drugs POS N
while POS N
test POS N
drug POS N
showed POS N
more POS N
safety POS N
response. POS N

No POS N
significant POS N
difference POS N
was POS N
identified POS N
after POS N
treatment POS N
and POS N
it POS N
was POS N
found POS N
that POS N
the POS N
efficacy POS N
of POS N
Alpha POS N
(Control POS N
drug) POS N
is POS N
same POS N
as POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(Test POS N
drug). POS N

It POS N
is POS N
concluded POS N
that POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
possesses POS N
as POS N
effective POS N
a POS N
therapeutic POS N
value POS N
in POS N
treating POS N
hepatitis POS N
B POS N
as POS N
allopathic POS N
medicine. POS N

No POS N
significant POS N
difference POS N
was POS N
identified POS N
after POS N
treatment POS N
and POS N
it POS N
was POS N
found POS N
that POS N
the POS N
efficacy POS N
of POS N
Alpha POS N
(Control POS N
drug) POS N
is POS N
same POS N
as POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(Test POS N
drug). POS N

The POS N
data POS N
offered POS N
support POS N
to POS N
the POS N
null POS N
hypothesis POS N
and POS N
therefore POS N
research POS N
hypothesis POS N
was POS N
rejected. POS N

No POS N
significant POS N
difference POS N
was POS N
identified POS N
after POS N
treatment POS N
and POS N
it POS N
was POS N
found POS N
that POS N
the POS N
efficacy POS N
of POS N
Alpha POS N
(Control POS N
drug) POS N
is POS N
same POS N
as POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(Test POS N
drug). POS N

According POS N
to POS N
the POS N
statistical POS N
analysis POS N
by POS N
chi POS N
square, POS N
hepatitis POS N
B POS N
was POS N
recorded POS N
as POS N
negative POS N
in POS N
26 POS N
patients POS N
(57.77%) POS N
out POS N
of POS N
45 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Interferon POS N
Alpha POS N
(control POS N
therapy) POS N
and POS N
in POS N
27 POS N
patients POS N
(64.28%) POS N
out POS N
of POS N
42 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(test POS N
drug). POS N

No POS N
significant POS N
difference POS N
was POS N
identified POS N
after POS N
treatment POS N
and POS N
it POS N
was POS N
found POS N
that POS N
the POS N
efficacy POS N
of POS N
Alpha POS N
(Control POS N
drug) POS N
is POS N
same POS N
as POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(Test POS N
drug). POS N

Comparison POS N
of POS N
the POS N
data POS N
recorded POS N
of POS N
the POS N
patients POS N
was POS N
determined POS N
as POS N
both POS N
drugs POS N
showed POS N
significant POS N
improvement POS N
and POS N
p POS N
value>0.05. POS N

No POS N
significant POS N
difference POS N
was POS N
identified POS N
after POS N
treatment POS N
and POS N
it POS N
was POS N
found POS N
that POS N
the POS N
efficacy POS N
of POS N
Alpha POS N
(Control POS N
drug) POS N
is POS N
same POS N
as POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(Test POS N
drug). POS N

The POS N
efficacy POS N
response POS N
is POS N
equal POS N
in POS N
both POS N
drugs POS N
while POS N
test POS N
drug POS N
showed POS N
more POS N
safety POS N
response. POS N

The POS N
data POS N
offered POS N
support POS N
to POS N
the POS N
null POS N
hypothesis POS N
and POS N
therefore POS N
research POS N
hypothesis POS N
was POS N
rejected. POS N

It POS N
is POS N
concluded POS N
that POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
possesses POS N
as POS N
effective POS N
a POS N
therapeutic POS N
value POS N
in POS N
treating POS N
hepatitis POS N
B POS N
as POS N
allopathic POS N
medicine. POS N

The POS N
data POS N
offered POS N
support POS N
to POS N
the POS N
null POS N
hypothesis POS N
and POS N
therefore POS N
research POS N
hypothesis POS N
was POS N
rejected. POS N

No POS N
significant POS N
difference POS N
was POS N
identified POS N
after POS N
treatment POS N
and POS N
it POS N
was POS N
found POS N
that POS N
the POS N
efficacy POS N
of POS N
Alpha POS N
(Control POS N
drug) POS N
is POS N
same POS N
as POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(Test POS N
drug). POS N

The POS N
data POS N
offered POS N
support POS N
to POS N
the POS N
null POS N
hypothesis POS N
and POS N
therefore POS N
research POS N
hypothesis POS N
was POS N
rejected. POS N

According POS N
to POS N
the POS N
statistical POS N
analysis POS N
by POS N
chi POS N
square, POS N
hepatitis POS N
B POS N
was POS N
recorded POS N
as POS N
negative POS N
in POS N
26 POS N
patients POS N
(57.77%) POS N
out POS N
of POS N
45 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Interferon POS N
Alpha POS N
(control POS N
therapy) POS N
and POS N
in POS N
27 POS N
patients POS N
(64.28%) POS N
out POS N
of POS N
42 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(test POS N
drug). POS N

The POS N
data POS N
offered POS N
support POS N
to POS N
the POS N
null POS N
hypothesis POS N
and POS N
therefore POS N
research POS N
hypothesis POS N
was POS N
rejected. POS N

Comparison POS N
of POS N
the POS N
data POS N
recorded POS N
of POS N
the POS N
patients POS N
was POS N
determined POS N
as POS N
both POS N
drugs POS N
showed POS N
significant POS N
improvement POS N
and POS N
p POS N
value>0.05. POS N

The POS N
data POS N
offered POS N
support POS N
to POS N
the POS N
null POS N
hypothesis POS N
and POS N
therefore POS N
research POS N
hypothesis POS N
was POS N
rejected. POS N

The POS N
efficacy POS N
response POS N
is POS N
equal POS N
in POS N
both POS N
drugs POS N
while POS N
test POS N
drug POS N
showed POS N
more POS N
safety POS N
response. POS N

According POS N
to POS N
the POS N
statistical POS N
analysis POS N
by POS N
chi POS N
square, POS N
hepatitis POS N
B POS N
was POS N
recorded POS N
as POS N
negative POS N
in POS N
26 POS N
patients POS N
(57.77%) POS N
out POS N
of POS N
45 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Interferon POS N
Alpha POS N
(control POS N
therapy) POS N
and POS N
in POS N
27 POS N
patients POS N
(64.28%) POS N
out POS N
of POS N
42 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(test POS N
drug). POS N

It POS N
is POS N
concluded POS N
that POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
possesses POS N
as POS N
effective POS N
a POS N
therapeutic POS N
value POS N
in POS N
treating POS N
hepatitis POS N
B POS N
as POS N
allopathic POS N
medicine. POS N

According POS N
to POS N
the POS N
statistical POS N
analysis POS N
by POS N
chi POS N
square, POS N
hepatitis POS N
B POS N
was POS N
recorded POS N
as POS N
negative POS N
in POS N
26 POS N
patients POS N
(57.77%) POS N
out POS N
of POS N
45 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Interferon POS N
Alpha POS N
(control POS N
therapy) POS N
and POS N
in POS N
27 POS N
patients POS N
(64.28%) POS N
out POS N
of POS N
42 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(test POS N
drug). POS N

No POS N
significant POS N
difference POS N
was POS N
identified POS N
after POS N
treatment POS N
and POS N
it POS N
was POS N
found POS N
that POS N
the POS N
efficacy POS N
of POS N
Alpha POS N
(Control POS N
drug) POS N
is POS N
same POS N
as POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(Test POS N
drug). POS N

According POS N
to POS N
the POS N
statistical POS N
analysis POS N
by POS N
chi POS N
square, POS N
hepatitis POS N
B POS N
was POS N
recorded POS N
as POS N
negative POS N
in POS N
26 POS N
patients POS N
(57.77%) POS N
out POS N
of POS N
45 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Interferon POS N
Alpha POS N
(control POS N
therapy) POS N
and POS N
in POS N
27 POS N
patients POS N
(64.28%) POS N
out POS N
of POS N
42 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(test POS N
drug). POS N

The POS N
data POS N
offered POS N
support POS N
to POS N
the POS N
null POS N
hypothesis POS N
and POS N
therefore POS N
research POS N
hypothesis POS N
was POS N
rejected. POS N

According POS N
to POS N
the POS N
statistical POS N
analysis POS N
by POS N
chi POS N
square, POS N
hepatitis POS N
B POS N
was POS N
recorded POS N
as POS N
negative POS N
in POS N
26 POS N
patients POS N
(57.77%) POS N
out POS N
of POS N
45 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Interferon POS N
Alpha POS N
(control POS N
therapy) POS N
and POS N
in POS N
27 POS N
patients POS N
(64.28%) POS N
out POS N
of POS N
42 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(test POS N
drug). POS N

Comparison POS N
of POS N
the POS N
data POS N
recorded POS N
of POS N
the POS N
patients POS N
was POS N
determined POS N
as POS N
both POS N
drugs POS N
showed POS N
significant POS N
improvement POS N
and POS N
p POS N
value>0.05. POS N

According POS N
to POS N
the POS N
statistical POS N
analysis POS N
by POS N
chi POS N
square, POS N
hepatitis POS N
B POS N
was POS N
recorded POS N
as POS N
negative POS N
in POS N
26 POS N
patients POS N
(57.77%) POS N
out POS N
of POS N
45 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Interferon POS N
Alpha POS N
(control POS N
therapy) POS N
and POS N
in POS N
27 POS N
patients POS N
(64.28%) POS N
out POS N
of POS N
42 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(test POS N
drug). POS N

The POS N
efficacy POS N
response POS N
is POS N
equal POS N
in POS N
both POS N
drugs POS N
while POS N
test POS N
drug POS N
showed POS N
more POS N
safety POS N
response. POS N

Comparison POS N
of POS N
the POS N
data POS N
recorded POS N
of POS N
the POS N
patients POS N
was POS N
determined POS N
as POS N
both POS N
drugs POS N
showed POS N
significant POS N
improvement POS N
and POS N
p POS N
value>0.05. POS N

It POS N
is POS N
concluded POS N
that POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
possesses POS N
as POS N
effective POS N
a POS N
therapeutic POS N
value POS N
in POS N
treating POS N
hepatitis POS N
B POS N
as POS N
allopathic POS N
medicine. POS N

Comparison POS N
of POS N
the POS N
data POS N
recorded POS N
of POS N
the POS N
patients POS N
was POS N
determined POS N
as POS N
both POS N
drugs POS N
showed POS N
significant POS N
improvement POS N
and POS N
p POS N
value>0.05. POS N

No POS N
significant POS N
difference POS N
was POS N
identified POS N
after POS N
treatment POS N
and POS N
it POS N
was POS N
found POS N
that POS N
the POS N
efficacy POS N
of POS N
Alpha POS N
(Control POS N
drug) POS N
is POS N
same POS N
as POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(Test POS N
drug). POS N

Comparison POS N
of POS N
the POS N
data POS N
recorded POS N
of POS N
the POS N
patients POS N
was POS N
determined POS N
as POS N
both POS N
drugs POS N
showed POS N
significant POS N
improvement POS N
and POS N
p POS N
value>0.05. POS N

The POS N
data POS N
offered POS N
support POS N
to POS N
the POS N
null POS N
hypothesis POS N
and POS N
therefore POS N
research POS N
hypothesis POS N
was POS N
rejected. POS N

Comparison POS N
of POS N
the POS N
data POS N
recorded POS N
of POS N
the POS N
patients POS N
was POS N
determined POS N
as POS N
both POS N
drugs POS N
showed POS N
significant POS N
improvement POS N
and POS N
p POS N
value>0.05. POS N

According POS N
to POS N
the POS N
statistical POS N
analysis POS N
by POS N
chi POS N
square, POS N
hepatitis POS N
B POS N
was POS N
recorded POS N
as POS N
negative POS N
in POS N
26 POS N
patients POS N
(57.77%) POS N
out POS N
of POS N
45 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Interferon POS N
Alpha POS N
(control POS N
therapy) POS N
and POS N
in POS N
27 POS N
patients POS N
(64.28%) POS N
out POS N
of POS N
42 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(test POS N
drug). POS N

Comparison POS N
of POS N
the POS N
data POS N
recorded POS N
of POS N
the POS N
patients POS N
was POS N
determined POS N
as POS N
both POS N
drugs POS N
showed POS N
significant POS N
improvement POS N
and POS N
p POS N
value>0.05. POS N

The POS N
efficacy POS N
response POS N
is POS N
equal POS N
in POS N
both POS N
drugs POS N
while POS N
test POS N
drug POS N
showed POS N
more POS N
safety POS N
response. POS N

The POS N
efficacy POS N
response POS N
is POS N
equal POS N
in POS N
both POS N
drugs POS N
while POS N
test POS N
drug POS N
showed POS N
more POS N
safety POS N
response. POS N

It POS N
is POS N
concluded POS N
that POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
possesses POS N
as POS N
effective POS N
a POS N
therapeutic POS N
value POS N
in POS N
treating POS N
hepatitis POS N
B POS N
as POS N
allopathic POS N
medicine. POS N

The POS N
efficacy POS N
response POS N
is POS N
equal POS N
in POS N
both POS N
drugs POS N
while POS N
test POS N
drug POS N
showed POS N
more POS N
safety POS N
response. POS N

No POS N
significant POS N
difference POS N
was POS N
identified POS N
after POS N
treatment POS N
and POS N
it POS N
was POS N
found POS N
that POS N
the POS N
efficacy POS N
of POS N
Alpha POS N
(Control POS N
drug) POS N
is POS N
same POS N
as POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(Test POS N
drug). POS N

The POS N
efficacy POS N
response POS N
is POS N
equal POS N
in POS N
both POS N
drugs POS N
while POS N
test POS N
drug POS N
showed POS N
more POS N
safety POS N
response. POS N

The POS N
data POS N
offered POS N
support POS N
to POS N
the POS N
null POS N
hypothesis POS N
and POS N
therefore POS N
research POS N
hypothesis POS N
was POS N
rejected. POS N

The POS N
efficacy POS N
response POS N
is POS N
equal POS N
in POS N
both POS N
drugs POS N
while POS N
test POS N
drug POS N
showed POS N
more POS N
safety POS N
response. POS N

According POS N
to POS N
the POS N
statistical POS N
analysis POS N
by POS N
chi POS N
square, POS N
hepatitis POS N
B POS N
was POS N
recorded POS N
as POS N
negative POS N
in POS N
26 POS N
patients POS N
(57.77%) POS N
out POS N
of POS N
45 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Interferon POS N
Alpha POS N
(control POS N
therapy) POS N
and POS N
in POS N
27 POS N
patients POS N
(64.28%) POS N
out POS N
of POS N
42 POS N
patients POS N
by POS N
the POS N
use POS N
of POS N
Safoof POS N
akseer POS N
e POS N
jigar POS N
(test POS N
drug). POS N

The POS N
efficacy POS N
response POS N
is POS N
equal POS N
in POS N
both POS N
drugs POS N
while POS N
test POS N
drug POS N
showed POS N
more POS N
safety POS N
response. POS N

Comparison POS N
of POS N
the POS N
data POS N
recorded POS N
of POS N
the POS N
patients POS N
was POS N
determined POS N
as POS N
both POS N
drugs POS N
showed POS N
significant POS N
improvement POS N
and POS N
p POS N
value>0.05. POS N

The POS N
immunosuppressive POS N
drug POS N
rapamycin POS N
may POS N
influence POS N
insulin POS N
sensitivity POS N
in POS N
insulin-responsive POS N
tissues. POS N

This POS N
treatment POS N
may POS N
improve POS N
short-term POS N
ITx POS N
outcomes, POS N
possibly POS N
in POS N
selected POS N
patients POS N
with POS N
T1DM POS N
complicated POS N
by POS N
insulin POS N
resistance. POS N

The POS N
immunosuppressive POS N
drug POS N
rapamycin POS N
may POS N
influence POS N
insulin POS N
sensitivity POS N
in POS N
insulin-responsive POS N
tissues. POS N

Rapamycin POS N
pre-treatment POS N
before POS N
ITx POS N
succeeds POS N
in POS N
reducing POS N
insulin POS N
requirement, POS N
enhancing POS N
hepatic POS N
insulin POS N
sensitivity. POS N

The POS N
immunosuppressive POS N
drug POS N
rapamycin POS N
may POS N
influence POS N
insulin POS N
sensitivity POS N
in POS N
insulin-responsive POS N
tissues. POS N

Hepatic POS N
glucose POS N
production POS N
decreased POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 1.1 ± 1.1 POS N
mg/kg/min, POS N
p = 0.04) POS N
and POS N
after POS N
ITx POS N
(- 1.6 ± 0.6 POS N
mg/kg/min, POS N
p = 0.015), POS N

The POS N
immunosuppressive POS N
drug POS N
rapamycin POS N
may POS N
influence POS N
insulin POS N
sensitivity POS N
in POS N
insulin-responsive POS N
tissues. POS N

no POS N
changes POS N
in POS N
peripheral POS N
glucose POS N
disposal POS N
were POS N
observed. POS N

The POS N
immunosuppressive POS N
drug POS N
rapamycin POS N
may POS N
influence POS N
insulin POS N
sensitivity POS N
in POS N
insulin-responsive POS N
tissues. POS N

Fasting POS N
glucose POS N
and POS N
HbA1c POS N
significantly POS N
decreased POS N
1 POS N
year POS N
after POS N
ITx POS N
in POS N
Group POS N
1 POS N
(HbA1c: POS N
- 2.1 ± 1.4%, POS N
p = 0.002), POS N

The POS N
immunosuppressive POS N
drug POS N
rapamycin POS N
may POS N
influence POS N
insulin POS N
sensitivity POS N
in POS N
insulin-responsive POS N
tissues. POS N

fasting POS N
C-peptide POS N
(+0.5 ± 0.3 POS N
nmol/l, POS N
p = 0.002) POS N
and POS N
SUITO POS N
index POS N
increased POS N
(+57.4 ± 39.7, POS N
p = 0.016), POS N
without POS N
differences POS N
between POS N
the POS N
two POS N
groups. POS N

The POS N
immunosuppressive POS N
drug POS N
rapamycin POS N
may POS N
influence POS N
insulin POS N
sensitivity POS N
in POS N
insulin-responsive POS N
tissues. POS N

DIR POS N
reduction POS N
1 POS N
year POS N
after POS N
ITx POS N
was POS N
greater POS N
in POS N
Group POS N
1 POS N
as POS N
compared POS N
to POS N
Group POS N
2 POS N
(- 37 ± 15 POS N
vs. POS N
- 19 ± 13 POS N
U/day, POS N
p = 0.005) POS N
and POS N
remained POS N
significant POS N
after POS N
adjusting POS N
for POS N
gender, POS N
age, POS N
glucose POS N
and POS N
baseline POS N
HbA1c POS N
(beta = 18.2 ± 5.9, POS N
p = 0.006). POS N

The POS N
immunosuppressive POS N
drug POS N
rapamycin POS N
may POS N
influence POS N
insulin POS N
sensitivity POS N
in POS N
insulin-responsive POS N
tissues. POS N

We POS N
found POS N
a POS N
significant POS N
reduction POS N
in POS N
DIR POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 8 ± 6 POS N
U/day, POS N
mean ± SD, POS N
p < 0.001) POS N
and POS N
1 POS N
year POS N
after POS N
ITx. POS N

This POS N
treatment POS N
may POS N
improve POS N
short-term POS N
ITx POS N
outcomes, POS N
possibly POS N
in POS N
selected POS N
patients POS N
with POS N
T1DM POS N
complicated POS N
by POS N
insulin POS N
resistance. POS N

The POS N
immunosuppressive POS N
drug POS N
rapamycin POS N
may POS N
influence POS N
insulin POS N
sensitivity POS N
in POS N
insulin-responsive POS N
tissues. POS N

This POS N
treatment POS N
may POS N
improve POS N
short-term POS N
ITx POS N
outcomes, POS N
possibly POS N
in POS N
selected POS N
patients POS N
with POS N
T1DM POS N
complicated POS N
by POS N
insulin POS N
resistance. POS N

Rapamycin POS N
pre-treatment POS N
before POS N
ITx POS N
succeeds POS N
in POS N
reducing POS N
insulin POS N
requirement, POS N
enhancing POS N
hepatic POS N
insulin POS N
sensitivity. POS N

This POS N
treatment POS N
may POS N
improve POS N
short-term POS N
ITx POS N
outcomes, POS N
possibly POS N
in POS N
selected POS N
patients POS N
with POS N
T1DM POS N
complicated POS N
by POS N
insulin POS N
resistance. POS N

Hepatic POS N
glucose POS N
production POS N
decreased POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 1.1 ± 1.1 POS N
mg/kg/min, POS N
p = 0.04) POS N
and POS N
after POS N
ITx POS N
(- 1.6 ± 0.6 POS N
mg/kg/min, POS N
p = 0.015), POS N

This POS N
treatment POS N
may POS N
improve POS N
short-term POS N
ITx POS N
outcomes, POS N
possibly POS N
in POS N
selected POS N
patients POS N
with POS N
T1DM POS N
complicated POS N
by POS N
insulin POS N
resistance. POS N

no POS N
changes POS N
in POS N
peripheral POS N
glucose POS N
disposal POS N
were POS N
observed. POS N

This POS N
treatment POS N
may POS N
improve POS N
short-term POS N
ITx POS N
outcomes, POS N
possibly POS N
in POS N
selected POS N
patients POS N
with POS N
T1DM POS N
complicated POS N
by POS N
insulin POS N
resistance. POS N

Fasting POS N
glucose POS N
and POS N
HbA1c POS N
significantly POS N
decreased POS N
1 POS N
year POS N
after POS N
ITx POS N
in POS N
Group POS N
1 POS N
(HbA1c: POS N
- 2.1 ± 1.4%, POS N
p = 0.002), POS N

This POS N
treatment POS N
may POS N
improve POS N
short-term POS N
ITx POS N
outcomes, POS N
possibly POS N
in POS N
selected POS N
patients POS N
with POS N
T1DM POS N
complicated POS N
by POS N
insulin POS N
resistance. POS N

fasting POS N
C-peptide POS N
(+0.5 ± 0.3 POS N
nmol/l, POS N
p = 0.002) POS N
and POS N
SUITO POS N
index POS N
increased POS N
(+57.4 ± 39.7, POS N
p = 0.016), POS N
without POS N
differences POS N
between POS N
the POS N
two POS N
groups. POS N

This POS N
treatment POS N
may POS N
improve POS N
short-term POS N
ITx POS N
outcomes, POS N
possibly POS N
in POS N
selected POS N
patients POS N
with POS N
T1DM POS N
complicated POS N
by POS N
insulin POS N
resistance. POS N

DIR POS N
reduction POS N
1 POS N
year POS N
after POS N
ITx POS N
was POS N
greater POS N
in POS N
Group POS N
1 POS N
as POS N
compared POS N
to POS N
Group POS N
2 POS N
(- 37 ± 15 POS N
vs. POS N
- 19 ± 13 POS N
U/day, POS N
p = 0.005) POS N
and POS N
remained POS N
significant POS N
after POS N
adjusting POS N
for POS N
gender, POS N
age, POS N
glucose POS N
and POS N
baseline POS N
HbA1c POS N
(beta = 18.2 ± 5.9, POS N
p = 0.006). POS N

This POS N
treatment POS N
may POS N
improve POS N
short-term POS N
ITx POS N
outcomes, POS N
possibly POS N
in POS N
selected POS N
patients POS N
with POS N
T1DM POS N
complicated POS N
by POS N
insulin POS N
resistance. POS N

We POS N
found POS N
a POS N
significant POS N
reduction POS N
in POS N
DIR POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 8 ± 6 POS N
U/day, POS N
mean ± SD, POS N
p < 0.001) POS N
and POS N
1 POS N
year POS N
after POS N
ITx. POS N

Rapamycin POS N
pre-treatment POS N
before POS N
ITx POS N
succeeds POS N
in POS N
reducing POS N
insulin POS N
requirement, POS N
enhancing POS N
hepatic POS N
insulin POS N
sensitivity. POS N

The POS N
immunosuppressive POS N
drug POS N
rapamycin POS N
may POS N
influence POS N
insulin POS N
sensitivity POS N
in POS N
insulin-responsive POS N
tissues. POS N

Rapamycin POS N
pre-treatment POS N
before POS N
ITx POS N
succeeds POS N
in POS N
reducing POS N
insulin POS N
requirement, POS N
enhancing POS N
hepatic POS N
insulin POS N
sensitivity. POS N

This POS N
treatment POS N
may POS N
improve POS N
short-term POS N
ITx POS N
outcomes, POS N
possibly POS N
in POS N
selected POS N
patients POS N
with POS N
T1DM POS N
complicated POS N
by POS N
insulin POS N
resistance. POS N

Rapamycin POS N
pre-treatment POS N
before POS N
ITx POS N
succeeds POS N
in POS N
reducing POS N
insulin POS N
requirement, POS N
enhancing POS N
hepatic POS N
insulin POS N
sensitivity. POS N

Hepatic POS N
glucose POS N
production POS N
decreased POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 1.1 ± 1.1 POS N
mg/kg/min, POS N
p = 0.04) POS N
and POS N
after POS N
ITx POS N
(- 1.6 ± 0.6 POS N
mg/kg/min, POS N
p = 0.015), POS N

Rapamycin POS N
pre-treatment POS N
before POS N
ITx POS N
succeeds POS N
in POS N
reducing POS N
insulin POS N
requirement, POS N
enhancing POS N
hepatic POS N
insulin POS N
sensitivity. POS N

no POS N
changes POS N
in POS N
peripheral POS N
glucose POS N
disposal POS N
were POS N
observed. POS N

Rapamycin POS N
pre-treatment POS N
before POS N
ITx POS N
succeeds POS N
in POS N
reducing POS N
insulin POS N
requirement, POS N
enhancing POS N
hepatic POS N
insulin POS N
sensitivity. POS N

Fasting POS N
glucose POS N
and POS N
HbA1c POS N
significantly POS N
decreased POS N
1 POS N
year POS N
after POS N
ITx POS N
in POS N
Group POS N
1 POS N
(HbA1c: POS N
- 2.1 ± 1.4%, POS N
p = 0.002), POS N

Rapamycin POS N
pre-treatment POS N
before POS N
ITx POS N
succeeds POS N
in POS N
reducing POS N
insulin POS N
requirement, POS N
enhancing POS N
hepatic POS N
insulin POS N
sensitivity. POS N

fasting POS N
C-peptide POS N
(+0.5 ± 0.3 POS N
nmol/l, POS N
p = 0.002) POS N
and POS N
SUITO POS N
index POS N
increased POS N
(+57.4 ± 39.7, POS N
p = 0.016), POS N
without POS N
differences POS N
between POS N
the POS N
two POS N
groups. POS N

Rapamycin POS N
pre-treatment POS N
before POS N
ITx POS N
succeeds POS N
in POS N
reducing POS N
insulin POS N
requirement, POS N
enhancing POS N
hepatic POS N
insulin POS N
sensitivity. POS N

DIR POS N
reduction POS N
1 POS N
year POS N
after POS N
ITx POS N
was POS N
greater POS N
in POS N
Group POS N
1 POS N
as POS N
compared POS N
to POS N
Group POS N
2 POS N
(- 37 ± 15 POS N
vs. POS N
- 19 ± 13 POS N
U/day, POS N
p = 0.005) POS N
and POS N
remained POS N
significant POS N
after POS N
adjusting POS N
for POS N
gender, POS N
age, POS N
glucose POS N
and POS N
baseline POS N
HbA1c POS N
(beta = 18.2 ± 5.9, POS N
p = 0.006). POS N

Rapamycin POS N
pre-treatment POS N
before POS N
ITx POS N
succeeds POS N
in POS N
reducing POS N
insulin POS N
requirement, POS N
enhancing POS N
hepatic POS N
insulin POS N
sensitivity. POS N

We POS N
found POS N
a POS N
significant POS N
reduction POS N
in POS N
DIR POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 8 ± 6 POS N
U/day, POS N
mean ± SD, POS N
p < 0.001) POS N
and POS N
1 POS N
year POS N
after POS N
ITx. POS N

Hepatic POS N
glucose POS N
production POS N
decreased POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 1.1 ± 1.1 POS N
mg/kg/min, POS N
p = 0.04) POS N
and POS N
after POS N
ITx POS N
(- 1.6 ± 0.6 POS N
mg/kg/min, POS N
p = 0.015), POS N

The POS N
immunosuppressive POS N
drug POS N
rapamycin POS N
may POS N
influence POS N
insulin POS N
sensitivity POS N
in POS N
insulin-responsive POS N
tissues. POS N

Hepatic POS N
glucose POS N
production POS N
decreased POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 1.1 ± 1.1 POS N
mg/kg/min, POS N
p = 0.04) POS N
and POS N
after POS N
ITx POS N
(- 1.6 ± 0.6 POS N
mg/kg/min, POS N
p = 0.015), POS N

This POS N
treatment POS N
may POS N
improve POS N
short-term POS N
ITx POS N
outcomes, POS N
possibly POS N
in POS N
selected POS N
patients POS N
with POS N
T1DM POS N
complicated POS N
by POS N
insulin POS N
resistance. POS N

Hepatic POS N
glucose POS N
production POS N
decreased POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 1.1 ± 1.1 POS N
mg/kg/min, POS N
p = 0.04) POS N
and POS N
after POS N
ITx POS N
(- 1.6 ± 0.6 POS N
mg/kg/min, POS N
p = 0.015), POS N

Rapamycin POS N
pre-treatment POS N
before POS N
ITx POS N
succeeds POS N
in POS N
reducing POS N
insulin POS N
requirement, POS N
enhancing POS N
hepatic POS N
insulin POS N
sensitivity. POS N

Hepatic POS N
glucose POS N
production POS N
decreased POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 1.1 ± 1.1 POS N
mg/kg/min, POS N
p = 0.04) POS N
and POS N
after POS N
ITx POS N
(- 1.6 ± 0.6 POS N
mg/kg/min, POS N
p = 0.015), POS N

no POS N
changes POS N
in POS N
peripheral POS N
glucose POS N
disposal POS N
were POS N
observed. POS N

Hepatic POS N
glucose POS N
production POS N
decreased POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 1.1 ± 1.1 POS N
mg/kg/min, POS N
p = 0.04) POS N
and POS N
after POS N
ITx POS N
(- 1.6 ± 0.6 POS N
mg/kg/min, POS N
p = 0.015), POS N

Fasting POS N
glucose POS N
and POS N
HbA1c POS N
significantly POS N
decreased POS N
1 POS N
year POS N
after POS N
ITx POS N
in POS N
Group POS N
1 POS N
(HbA1c: POS N
- 2.1 ± 1.4%, POS N
p = 0.002), POS N

Hepatic POS N
glucose POS N
production POS N
decreased POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 1.1 ± 1.1 POS N
mg/kg/min, POS N
p = 0.04) POS N
and POS N
after POS N
ITx POS N
(- 1.6 ± 0.6 POS N
mg/kg/min, POS N
p = 0.015), POS N

fasting POS N
C-peptide POS N
(+0.5 ± 0.3 POS N
nmol/l, POS N
p = 0.002) POS N
and POS N
SUITO POS N
index POS N
increased POS N
(+57.4 ± 39.7, POS N
p = 0.016), POS N
without POS N
differences POS N
between POS N
the POS N
two POS N
groups. POS N

Hepatic POS N
glucose POS N
production POS N
decreased POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 1.1 ± 1.1 POS N
mg/kg/min, POS N
p = 0.04) POS N
and POS N
after POS N
ITx POS N
(- 1.6 ± 0.6 POS N
mg/kg/min, POS N
p = 0.015), POS N

DIR POS N
reduction POS N
1 POS N
year POS N
after POS N
ITx POS N
was POS N
greater POS N
in POS N
Group POS N
1 POS N
as POS N
compared POS N
to POS N
Group POS N
2 POS N
(- 37 ± 15 POS N
vs. POS N
- 19 ± 13 POS N
U/day, POS N
p = 0.005) POS N
and POS N
remained POS N
significant POS N
after POS N
adjusting POS N
for POS N
gender, POS N
age, POS N
glucose POS N
and POS N
baseline POS N
HbA1c POS N
(beta = 18.2 ± 5.9, POS N
p = 0.006). POS N

Hepatic POS N
glucose POS N
production POS N
decreased POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 1.1 ± 1.1 POS N
mg/kg/min, POS N
p = 0.04) POS N
and POS N
after POS N
ITx POS N
(- 1.6 ± 0.6 POS N
mg/kg/min, POS N
p = 0.015), POS N

We POS N
found POS N
a POS N
significant POS N
reduction POS N
in POS N
DIR POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 8 ± 6 POS N
U/day, POS N
mean ± SD, POS N
p < 0.001) POS N
and POS N
1 POS N
year POS N
after POS N
ITx. POS N

no POS N
changes POS N
in POS N
peripheral POS N
glucose POS N
disposal POS N
were POS N
observed. POS N

The POS N
immunosuppressive POS N
drug POS N
rapamycin POS N
may POS N
influence POS N
insulin POS N
sensitivity POS N
in POS N
insulin-responsive POS N
tissues. POS N

no POS N
changes POS N
in POS N
peripheral POS N
glucose POS N
disposal POS N
were POS N
observed. POS N

This POS N
treatment POS N
may POS N
improve POS N
short-term POS N
ITx POS N
outcomes, POS N
possibly POS N
in POS N
selected POS N
patients POS N
with POS N
T1DM POS N
complicated POS N
by POS N
insulin POS N
resistance. POS N

no POS N
changes POS N
in POS N
peripheral POS N
glucose POS N
disposal POS N
were POS N
observed. POS N

Rapamycin POS N
pre-treatment POS N
before POS N
ITx POS N
succeeds POS N
in POS N
reducing POS N
insulin POS N
requirement, POS N
enhancing POS N
hepatic POS N
insulin POS N
sensitivity. POS N

no POS N
changes POS N
in POS N
peripheral POS N
glucose POS N
disposal POS N
were POS N
observed. POS N

Hepatic POS N
glucose POS N
production POS N
decreased POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 1.1 ± 1.1 POS N
mg/kg/min, POS N
p = 0.04) POS N
and POS N
after POS N
ITx POS N
(- 1.6 ± 0.6 POS N
mg/kg/min, POS N
p = 0.015), POS N

no POS N
changes POS N
in POS N
peripheral POS N
glucose POS N
disposal POS N
were POS N
observed. POS N

Fasting POS N
glucose POS N
and POS N
HbA1c POS N
significantly POS N
decreased POS N
1 POS N
year POS N
after POS N
ITx POS N
in POS N
Group POS N
1 POS N
(HbA1c: POS N
- 2.1 ± 1.4%, POS N
p = 0.002), POS N

no POS N
changes POS N
in POS N
peripheral POS N
glucose POS N
disposal POS N
were POS N
observed. POS N

fasting POS N
C-peptide POS N
(+0.5 ± 0.3 POS N
nmol/l, POS N
p = 0.002) POS N
and POS N
SUITO POS N
index POS N
increased POS N
(+57.4 ± 39.7, POS N
p = 0.016), POS N
without POS N
differences POS N
between POS N
the POS N
two POS N
groups. POS N

no POS N
changes POS N
in POS N
peripheral POS N
glucose POS N
disposal POS N
were POS N
observed. POS N

DIR POS N
reduction POS N
1 POS N
year POS N
after POS N
ITx POS N
was POS N
greater POS N
in POS N
Group POS N
1 POS N
as POS N
compared POS N
to POS N
Group POS N
2 POS N
(- 37 ± 15 POS N
vs. POS N
- 19 ± 13 POS N
U/day, POS N
p = 0.005) POS N
and POS N
remained POS N
significant POS N
after POS N
adjusting POS N
for POS N
gender, POS N
age, POS N
glucose POS N
and POS N
baseline POS N
HbA1c POS N
(beta = 18.2 ± 5.9, POS N
p = 0.006). POS N

no POS N
changes POS N
in POS N
peripheral POS N
glucose POS N
disposal POS N
were POS N
observed. POS N

We POS N
found POS N
a POS N
significant POS N
reduction POS N
in POS N
DIR POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 8 ± 6 POS N
U/day, POS N
mean ± SD, POS N
p < 0.001) POS N
and POS N
1 POS N
year POS N
after POS N
ITx. POS N

Fasting POS N
glucose POS N
and POS N
HbA1c POS N
significantly POS N
decreased POS N
1 POS N
year POS N
after POS N
ITx POS N
in POS N
Group POS N
1 POS N
(HbA1c: POS N
- 2.1 ± 1.4%, POS N
p = 0.002), POS N

The POS N
immunosuppressive POS N
drug POS N
rapamycin POS N
may POS N
influence POS N
insulin POS N
sensitivity POS N
in POS N
insulin-responsive POS N
tissues. POS N

Fasting POS N
glucose POS N
and POS N
HbA1c POS N
significantly POS N
decreased POS N
1 POS N
year POS N
after POS N
ITx POS N
in POS N
Group POS N
1 POS N
(HbA1c: POS N
- 2.1 ± 1.4%, POS N
p = 0.002), POS N

This POS N
treatment POS N
may POS N
improve POS N
short-term POS N
ITx POS N
outcomes, POS N
possibly POS N
in POS N
selected POS N
patients POS N
with POS N
T1DM POS N
complicated POS N
by POS N
insulin POS N
resistance. POS N

Fasting POS N
glucose POS N
and POS N
HbA1c POS N
significantly POS N
decreased POS N
1 POS N
year POS N
after POS N
ITx POS N
in POS N
Group POS N
1 POS N
(HbA1c: POS N
- 2.1 ± 1.4%, POS N
p = 0.002), POS N

Rapamycin POS N
pre-treatment POS N
before POS N
ITx POS N
succeeds POS N
in POS N
reducing POS N
insulin POS N
requirement, POS N
enhancing POS N
hepatic POS N
insulin POS N
sensitivity. POS N

Fasting POS N
glucose POS N
and POS N
HbA1c POS N
significantly POS N
decreased POS N
1 POS N
year POS N
after POS N
ITx POS N
in POS N
Group POS N
1 POS N
(HbA1c: POS N
- 2.1 ± 1.4%, POS N
p = 0.002), POS N

Hepatic POS N
glucose POS N
production POS N
decreased POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 1.1 ± 1.1 POS N
mg/kg/min, POS N
p = 0.04) POS N
and POS N
after POS N
ITx POS N
(- 1.6 ± 0.6 POS N
mg/kg/min, POS N
p = 0.015), POS N

Fasting POS N
glucose POS N
and POS N
HbA1c POS N
significantly POS N
decreased POS N
1 POS N
year POS N
after POS N
ITx POS N
in POS N
Group POS N
1 POS N
(HbA1c: POS N
- 2.1 ± 1.4%, POS N
p = 0.002), POS N

no POS N
changes POS N
in POS N
peripheral POS N
glucose POS N
disposal POS N
were POS N
observed. POS N

Fasting POS N
glucose POS N
and POS N
HbA1c POS N
significantly POS N
decreased POS N
1 POS N
year POS N
after POS N
ITx POS N
in POS N
Group POS N
1 POS N
(HbA1c: POS N
- 2.1 ± 1.4%, POS N
p = 0.002), POS N

fasting POS N
C-peptide POS N
(+0.5 ± 0.3 POS N
nmol/l, POS N
p = 0.002) POS N
and POS N
SUITO POS N
index POS N
increased POS N
(+57.4 ± 39.7, POS N
p = 0.016), POS N
without POS N
differences POS N
between POS N
the POS N
two POS N
groups. POS N

Fasting POS N
glucose POS N
and POS N
HbA1c POS N
significantly POS N
decreased POS N
1 POS N
year POS N
after POS N
ITx POS N
in POS N
Group POS N
1 POS N
(HbA1c: POS N
- 2.1 ± 1.4%, POS N
p = 0.002), POS N

DIR POS N
reduction POS N
1 POS N
year POS N
after POS N
ITx POS N
was POS N
greater POS N
in POS N
Group POS N
1 POS N
as POS N
compared POS N
to POS N
Group POS N
2 POS N
(- 37 ± 15 POS N
vs. POS N
- 19 ± 13 POS N
U/day, POS N
p = 0.005) POS N
and POS N
remained POS N
significant POS N
after POS N
adjusting POS N
for POS N
gender, POS N
age, POS N
glucose POS N
and POS N
baseline POS N
HbA1c POS N
(beta = 18.2 ± 5.9, POS N
p = 0.006). POS N

Fasting POS N
glucose POS N
and POS N
HbA1c POS N
significantly POS N
decreased POS N
1 POS N
year POS N
after POS N
ITx POS N
in POS N
Group POS N
1 POS N
(HbA1c: POS N
- 2.1 ± 1.4%, POS N
p = 0.002), POS N

We POS N
found POS N
a POS N
significant POS N
reduction POS N
in POS N
DIR POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 8 ± 6 POS N
U/day, POS N
mean ± SD, POS N
p < 0.001) POS N
and POS N
1 POS N
year POS N
after POS N
ITx. POS N

fasting POS N
C-peptide POS N
(+0.5 ± 0.3 POS N
nmol/l, POS N
p = 0.002) POS N
and POS N
SUITO POS N
index POS N
increased POS N
(+57.4 ± 39.7, POS N
p = 0.016), POS N
without POS N
differences POS N
between POS N
the POS N
two POS N
groups. POS N

The POS N
immunosuppressive POS N
drug POS N
rapamycin POS N
may POS N
influence POS N
insulin POS N
sensitivity POS N
in POS N
insulin-responsive POS N
tissues. POS N

fasting POS N
C-peptide POS N
(+0.5 ± 0.3 POS N
nmol/l, POS N
p = 0.002) POS N
and POS N
SUITO POS N
index POS N
increased POS N
(+57.4 ± 39.7, POS N
p = 0.016), POS N
without POS N
differences POS N
between POS N
the POS N
two POS N
groups. POS N

This POS N
treatment POS N
may POS N
improve POS N
short-term POS N
ITx POS N
outcomes, POS N
possibly POS N
in POS N
selected POS N
patients POS N
with POS N
T1DM POS N
complicated POS N
by POS N
insulin POS N
resistance. POS N

fasting POS N
C-peptide POS N
(+0.5 ± 0.3 POS N
nmol/l, POS N
p = 0.002) POS N
and POS N
SUITO POS N
index POS N
increased POS N
(+57.4 ± 39.7, POS N
p = 0.016), POS N
without POS N
differences POS N
between POS N
the POS N
two POS N
groups. POS N

Rapamycin POS N
pre-treatment POS N
before POS N
ITx POS N
succeeds POS N
in POS N
reducing POS N
insulin POS N
requirement, POS N
enhancing POS N
hepatic POS N
insulin POS N
sensitivity. POS N

fasting POS N
C-peptide POS N
(+0.5 ± 0.3 POS N
nmol/l, POS N
p = 0.002) POS N
and POS N
SUITO POS N
index POS N
increased POS N
(+57.4 ± 39.7, POS N
p = 0.016), POS N
without POS N
differences POS N
between POS N
the POS N
two POS N
groups. POS N

Hepatic POS N
glucose POS N
production POS N
decreased POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 1.1 ± 1.1 POS N
mg/kg/min, POS N
p = 0.04) POS N
and POS N
after POS N
ITx POS N
(- 1.6 ± 0.6 POS N
mg/kg/min, POS N
p = 0.015), POS N

fasting POS N
C-peptide POS N
(+0.5 ± 0.3 POS N
nmol/l, POS N
p = 0.002) POS N
and POS N
SUITO POS N
index POS N
increased POS N
(+57.4 ± 39.7, POS N
p = 0.016), POS N
without POS N
differences POS N
between POS N
the POS N
two POS N
groups. POS N

no POS N
changes POS N
in POS N
peripheral POS N
glucose POS N
disposal POS N
were POS N
observed. POS N

fasting POS N
C-peptide POS N
(+0.5 ± 0.3 POS N
nmol/l, POS N
p = 0.002) POS N
and POS N
SUITO POS N
index POS N
increased POS N
(+57.4 ± 39.7, POS N
p = 0.016), POS N
without POS N
differences POS N
between POS N
the POS N
two POS N
groups. POS N

Fasting POS N
glucose POS N
and POS N
HbA1c POS N
significantly POS N
decreased POS N
1 POS N
year POS N
after POS N
ITx POS N
in POS N
Group POS N
1 POS N
(HbA1c: POS N
- 2.1 ± 1.4%, POS N
p = 0.002), POS N

fasting POS N
C-peptide POS N
(+0.5 ± 0.3 POS N
nmol/l, POS N
p = 0.002) POS N
and POS N
SUITO POS N
index POS N
increased POS N
(+57.4 ± 39.7, POS N
p = 0.016), POS N
without POS N
differences POS N
between POS N
the POS N
two POS N
groups. POS N

DIR POS N
reduction POS N
1 POS N
year POS N
after POS N
ITx POS N
was POS N
greater POS N
in POS N
Group POS N
1 POS N
as POS N
compared POS N
to POS N
Group POS N
2 POS N
(- 37 ± 15 POS N
vs. POS N
- 19 ± 13 POS N
U/day, POS N
p = 0.005) POS N
and POS N
remained POS N
significant POS N
after POS N
adjusting POS N
for POS N
gender, POS N
age, POS N
glucose POS N
and POS N
baseline POS N
HbA1c POS N
(beta = 18.2 ± 5.9, POS N
p = 0.006). POS N

fasting POS N
C-peptide POS N
(+0.5 ± 0.3 POS N
nmol/l, POS N
p = 0.002) POS N
and POS N
SUITO POS N
index POS N
increased POS N
(+57.4 ± 39.7, POS N
p = 0.016), POS N
without POS N
differences POS N
between POS N
the POS N
two POS N
groups. POS N

We POS N
found POS N
a POS N
significant POS N
reduction POS N
in POS N
DIR POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 8 ± 6 POS N
U/day, POS N
mean ± SD, POS N
p < 0.001) POS N
and POS N
1 POS N
year POS N
after POS N
ITx. POS N

DIR POS N
reduction POS N
1 POS N
year POS N
after POS N
ITx POS N
was POS N
greater POS N
in POS N
Group POS N
1 POS N
as POS N
compared POS N
to POS N
Group POS N
2 POS N
(- 37 ± 15 POS N
vs. POS N
- 19 ± 13 POS N
U/day, POS N
p = 0.005) POS N
and POS N
remained POS N
significant POS N
after POS N
adjusting POS N
for POS N
gender, POS N
age, POS N
glucose POS N
and POS N
baseline POS N
HbA1c POS N
(beta = 18.2 ± 5.9, POS N
p = 0.006). POS N

The POS N
immunosuppressive POS N
drug POS N
rapamycin POS N
may POS N
influence POS N
insulin POS N
sensitivity POS N
in POS N
insulin-responsive POS N
tissues. POS N

DIR POS N
reduction POS N
1 POS N
year POS N
after POS N
ITx POS N
was POS N
greater POS N
in POS N
Group POS N
1 POS N
as POS N
compared POS N
to POS N
Group POS N
2 POS N
(- 37 ± 15 POS N
vs. POS N
- 19 ± 13 POS N
U/day, POS N
p = 0.005) POS N
and POS N
remained POS N
significant POS N
after POS N
adjusting POS N
for POS N
gender, POS N
age, POS N
glucose POS N
and POS N
baseline POS N
HbA1c POS N
(beta = 18.2 ± 5.9, POS N
p = 0.006). POS N

This POS N
treatment POS N
may POS N
improve POS N
short-term POS N
ITx POS N
outcomes, POS N
possibly POS N
in POS N
selected POS N
patients POS N
with POS N
T1DM POS N
complicated POS N
by POS N
insulin POS N
resistance. POS N

DIR POS N
reduction POS N
1 POS N
year POS N
after POS N
ITx POS N
was POS N
greater POS N
in POS N
Group POS N
1 POS N
as POS N
compared POS N
to POS N
Group POS N
2 POS N
(- 37 ± 15 POS N
vs. POS N
- 19 ± 13 POS N
U/day, POS N
p = 0.005) POS N
and POS N
remained POS N
significant POS N
after POS N
adjusting POS N
for POS N
gender, POS N
age, POS N
glucose POS N
and POS N
baseline POS N
HbA1c POS N
(beta = 18.2 ± 5.9, POS N
p = 0.006). POS N

Rapamycin POS N
pre-treatment POS N
before POS N
ITx POS N
succeeds POS N
in POS N
reducing POS N
insulin POS N
requirement, POS N
enhancing POS N
hepatic POS N
insulin POS N
sensitivity. POS N

DIR POS N
reduction POS N
1 POS N
year POS N
after POS N
ITx POS N
was POS N
greater POS N
in POS N
Group POS N
1 POS N
as POS N
compared POS N
to POS N
Group POS N
2 POS N
(- 37 ± 15 POS N
vs. POS N
- 19 ± 13 POS N
U/day, POS N
p = 0.005) POS N
and POS N
remained POS N
significant POS N
after POS N
adjusting POS N
for POS N
gender, POS N
age, POS N
glucose POS N
and POS N
baseline POS N
HbA1c POS N
(beta = 18.2 ± 5.9, POS N
p = 0.006). POS N

Hepatic POS N
glucose POS N
production POS N
decreased POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 1.1 ± 1.1 POS N
mg/kg/min, POS N
p = 0.04) POS N
and POS N
after POS N
ITx POS N
(- 1.6 ± 0.6 POS N
mg/kg/min, POS N
p = 0.015), POS N

DIR POS N
reduction POS N
1 POS N
year POS N
after POS N
ITx POS N
was POS N
greater POS N
in POS N
Group POS N
1 POS N
as POS N
compared POS N
to POS N
Group POS N
2 POS N
(- 37 ± 15 POS N
vs. POS N
- 19 ± 13 POS N
U/day, POS N
p = 0.005) POS N
and POS N
remained POS N
significant POS N
after POS N
adjusting POS N
for POS N
gender, POS N
age, POS N
glucose POS N
and POS N
baseline POS N
HbA1c POS N
(beta = 18.2 ± 5.9, POS N
p = 0.006). POS N

no POS N
changes POS N
in POS N
peripheral POS N
glucose POS N
disposal POS N
were POS N
observed. POS N

DIR POS N
reduction POS N
1 POS N
year POS N
after POS N
ITx POS N
was POS N
greater POS N
in POS N
Group POS N
1 POS N
as POS N
compared POS N
to POS N
Group POS N
2 POS N
(- 37 ± 15 POS N
vs. POS N
- 19 ± 13 POS N
U/day, POS N
p = 0.005) POS N
and POS N
remained POS N
significant POS N
after POS N
adjusting POS N
for POS N
gender, POS N
age, POS N
glucose POS N
and POS N
baseline POS N
HbA1c POS N
(beta = 18.2 ± 5.9, POS N
p = 0.006). POS N

Fasting POS N
glucose POS N
and POS N
HbA1c POS N
significantly POS N
decreased POS N
1 POS N
year POS N
after POS N
ITx POS N
in POS N
Group POS N
1 POS N
(HbA1c: POS N
- 2.1 ± 1.4%, POS N
p = 0.002), POS N

DIR POS N
reduction POS N
1 POS N
year POS N
after POS N
ITx POS N
was POS N
greater POS N
in POS N
Group POS N
1 POS N
as POS N
compared POS N
to POS N
Group POS N
2 POS N
(- 37 ± 15 POS N
vs. POS N
- 19 ± 13 POS N
U/day, POS N
p = 0.005) POS N
and POS N
remained POS N
significant POS N
after POS N
adjusting POS N
for POS N
gender, POS N
age, POS N
glucose POS N
and POS N
baseline POS N
HbA1c POS N
(beta = 18.2 ± 5.9, POS N
p = 0.006). POS N

fasting POS N
C-peptide POS N
(+0.5 ± 0.3 POS N
nmol/l, POS N
p = 0.002) POS N
and POS N
SUITO POS N
index POS N
increased POS N
(+57.4 ± 39.7, POS N
p = 0.016), POS N
without POS N
differences POS N
between POS N
the POS N
two POS N
groups. POS N

DIR POS N
reduction POS N
1 POS N
year POS N
after POS N
ITx POS N
was POS N
greater POS N
in POS N
Group POS N
1 POS N
as POS N
compared POS N
to POS N
Group POS N
2 POS N
(- 37 ± 15 POS N
vs. POS N
- 19 ± 13 POS N
U/day, POS N
p = 0.005) POS N
and POS N
remained POS N
significant POS N
after POS N
adjusting POS N
for POS N
gender, POS N
age, POS N
glucose POS N
and POS N
baseline POS N
HbA1c POS N
(beta = 18.2 ± 5.9, POS N
p = 0.006). POS N

We POS N
found POS N
a POS N
significant POS N
reduction POS N
in POS N
DIR POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 8 ± 6 POS N
U/day, POS N
mean ± SD, POS N
p < 0.001) POS N
and POS N
1 POS N
year POS N
after POS N
ITx. POS N

We POS N
found POS N
a POS N
significant POS N
reduction POS N
in POS N
DIR POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 8 ± 6 POS N
U/day, POS N
mean ± SD, POS N
p < 0.001) POS N
and POS N
1 POS N
year POS N
after POS N
ITx. POS N

The POS N
immunosuppressive POS N
drug POS N
rapamycin POS N
may POS N
influence POS N
insulin POS N
sensitivity POS N
in POS N
insulin-responsive POS N
tissues. POS N

We POS N
found POS N
a POS N
significant POS N
reduction POS N
in POS N
DIR POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 8 ± 6 POS N
U/day, POS N
mean ± SD, POS N
p < 0.001) POS N
and POS N
1 POS N
year POS N
after POS N
ITx. POS N

This POS N
treatment POS N
may POS N
improve POS N
short-term POS N
ITx POS N
outcomes, POS N
possibly POS N
in POS N
selected POS N
patients POS N
with POS N
T1DM POS N
complicated POS N
by POS N
insulin POS N
resistance. POS N

We POS N
found POS N
a POS N
significant POS N
reduction POS N
in POS N
DIR POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 8 ± 6 POS N
U/day, POS N
mean ± SD, POS N
p < 0.001) POS N
and POS N
1 POS N
year POS N
after POS N
ITx. POS N

Rapamycin POS N
pre-treatment POS N
before POS N
ITx POS N
succeeds POS N
in POS N
reducing POS N
insulin POS N
requirement, POS N
enhancing POS N
hepatic POS N
insulin POS N
sensitivity. POS N

We POS N
found POS N
a POS N
significant POS N
reduction POS N
in POS N
DIR POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 8 ± 6 POS N
U/day, POS N
mean ± SD, POS N
p < 0.001) POS N
and POS N
1 POS N
year POS N
after POS N
ITx. POS N

Hepatic POS N
glucose POS N
production POS N
decreased POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 1.1 ± 1.1 POS N
mg/kg/min, POS N
p = 0.04) POS N
and POS N
after POS N
ITx POS N
(- 1.6 ± 0.6 POS N
mg/kg/min, POS N
p = 0.015), POS N

We POS N
found POS N
a POS N
significant POS N
reduction POS N
in POS N
DIR POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 8 ± 6 POS N
U/day, POS N
mean ± SD, POS N
p < 0.001) POS N
and POS N
1 POS N
year POS N
after POS N
ITx. POS N

no POS N
changes POS N
in POS N
peripheral POS N
glucose POS N
disposal POS N
were POS N
observed. POS N

We POS N
found POS N
a POS N
significant POS N
reduction POS N
in POS N
DIR POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 8 ± 6 POS N
U/day, POS N
mean ± SD, POS N
p < 0.001) POS N
and POS N
1 POS N
year POS N
after POS N
ITx. POS N

Fasting POS N
glucose POS N
and POS N
HbA1c POS N
significantly POS N
decreased POS N
1 POS N
year POS N
after POS N
ITx POS N
in POS N
Group POS N
1 POS N
(HbA1c: POS N
- 2.1 ± 1.4%, POS N
p = 0.002), POS N

We POS N
found POS N
a POS N
significant POS N
reduction POS N
in POS N
DIR POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 8 ± 6 POS N
U/day, POS N
mean ± SD, POS N
p < 0.001) POS N
and POS N
1 POS N
year POS N
after POS N
ITx. POS N

fasting POS N
C-peptide POS N
(+0.5 ± 0.3 POS N
nmol/l, POS N
p = 0.002) POS N
and POS N
SUITO POS N
index POS N
increased POS N
(+57.4 ± 39.7, POS N
p = 0.016), POS N
without POS N
differences POS N
between POS N
the POS N
two POS N
groups. POS N

We POS N
found POS N
a POS N
significant POS N
reduction POS N
in POS N
DIR POS N
after POS N
rapamycin POS N
pre-treatment POS N
(- 8 ± 6 POS N
U/day, POS N
mean ± SD, POS N
p < 0.001) POS N
and POS N
1 POS N
year POS N
after POS N
ITx. POS N

DIR POS N
reduction POS N
1 POS N
year POS N
after POS N
ITx POS N
was POS N
greater POS N
in POS N
Group POS N
1 POS N
as POS N
compared POS N
to POS N
Group POS N
2 POS N
(- 37 ± 15 POS N
vs. POS N
- 19 ± 13 POS N
U/day, POS N
p = 0.005) POS N
and POS N
remained POS N
significant POS N
after POS N
adjusting POS N
for POS N
gender, POS N
age, POS N
glucose POS N
and POS N
baseline POS N
HbA1c POS N
(beta = 18.2 ± 5.9, POS N
p = 0.006). POS N

Hypertension POS N
is POS N
a POS N
generally POS N
accepted POS N
atherogenic POS N
risk POS N
factor. POS N

The POS N
results POS N
showed POS N
that POS N
mean POS N
c-IMT POS N
z-scores POS N
increased POS N
significantly POS N
during POS N
4 POS N
years POS N
(0.002 POS N
± POS N
0.003, POS N
p POS N
< POS N
0.001) POS N
as POS N
well POS N
as POS N
carotid-femoral POS N
PWV POS N
(13.99 POS N
± POS N
2.74, POS N
p POS N
< POS N
0.01) POS N
and POS N
total POS N
cholesterol POS N
(6.97 POS N
± POS N
1.08, POS N
p POS N
< POS N
0.001). POS N

Hypertension POS N
is POS N
a POS N
generally POS N
accepted POS N
atherogenic POS N
risk POS N
factor. POS N

Linear POS N
regression POS N
showed POS N
statistically POS N
significant POS N
associations POS N
between POS N
systolic POS N
blood POS N
pressure, POS N
diastolic POS N
blood POS N
pressure, POS N
C-reactive POS N
protein, POS N
lip-line, POS N
and POS N
heart POS N
rate POS N
with POS N
c-IMT POS N
z-scores POS N
of POS N
>1.5SD POS N
in POS N
the POS N
fully POS N
adjusted POS N
models POS N
and POS N
the POS N
p POS N
values POS N
were POS N
0.000, POS N
0.000, POS N
0.017, POS N
0.001, POS N
and POS N
0.044, POS N
respectively POS N
. POS N

Hypertension POS N
is POS N
a POS N
generally POS N
accepted POS N
atherogenic POS N
risk POS N
factor. POS N

In POS N
a POS N
full-model POS N
logistic POS N
regression, POS N
significant POS N
risk POS N
factors POS N
for POS N
an POS N
increase POS N
in POS N
IMT POS N
of POS N
≥1.5 POS N
z-scores POS N
were POS N
carotid-femoral POS N
PWV POS N
(odds POS N
ratio: POS N
1.119, POS N
confidence POS N
interval: POS N
1.018, POS N
1.230, POS N
p POS N
= POS N
0.020 POS N
< POS N
0.05) POS N
at POS N
first POS N
measurement. POS N

Hypertension POS N
is POS N
a POS N
generally POS N
accepted POS N
atherogenic POS N
risk POS N
factor. POS N

The POS N
conclusion POS N
of POS N
the POS N
study POS N
was POS N
that POS N
longitudinal POS N
c-IMT POS N
measurements POS N
revealed POS N
progression POS N
in POS N
subclinical POS N
atherosclerosis POS N
during POS N
a POS N
four-year POS N
period POS N
in POS N
a POS N
hypertensive POS N
old-aged POS N
cohort. POS N

Hypertension POS N
is POS N
a POS N
generally POS N
accepted POS N
atherogenic POS N
risk POS N
factor. POS N

Systolic POS N
or POS N
diastolic POS N
blood POS N
pressure, POS N
homocysteine, POS N
carotid-femoral POS N
PWV, POS N
and POS N
waistline POS N
were POS N
significantly POS N
related POS N
to POS N
c-IMT POS N
increment. POS N

Hypertension POS N
is POS N
a POS N
generally POS N
accepted POS N
atherogenic POS N
risk POS N
factor. POS N

By POS N
lifestyle POS N
and POS N
medical POS N
intervention POS N
to POS N
control POS N
these POS N
risk POS N
factors POS N
may POS N
prevent POS N
progression POS N
of POS N
c-IMT POS N
in POS N
old-aged POS N
cohort POS N
with POS N
hypertension. POS N

The POS N
results POS N
showed POS N
that POS N
mean POS N
c-IMT POS N
z-scores POS N
increased POS N
significantly POS N
during POS N
4 POS N
years POS N
(0.002 POS N
± POS N
0.003, POS N
p POS N
< POS N
0.001) POS N
as POS N
well POS N
as POS N
carotid-femoral POS N
PWV POS N
(13.99 POS N
± POS N
2.74, POS N
p POS N
< POS N
0.01) POS N
and POS N
total POS N
cholesterol POS N
(6.97 POS N
± POS N
1.08, POS N
p POS N
< POS N
0.001). POS N

Hypertension POS N
is POS N
a POS N
generally POS N
accepted POS N
atherogenic POS N
risk POS N
factor. POS N

The POS N
results POS N
showed POS N
that POS N
mean POS N
c-IMT POS N
z-scores POS N
increased POS N
significantly POS N
during POS N
4 POS N
years POS N
(0.002 POS N
± POS N
0.003, POS N
p POS N
< POS N
0.001) POS N
as POS N
well POS N
as POS N
carotid-femoral POS N
PWV POS N
(13.99 POS N
± POS N
2.74, POS N
p POS N
< POS N
0.01) POS N
and POS N
total POS N
cholesterol POS N
(6.97 POS N
± POS N
1.08, POS N
p POS N
< POS N
0.001). POS N

Linear POS N
regression POS N
showed POS N
statistically POS N
significant POS N
associations POS N
between POS N
systolic POS N
blood POS N
pressure, POS N
diastolic POS N
blood POS N
pressure, POS N
C-reactive POS N
protein, POS N
lip-line, POS N
and POS N
heart POS N
rate POS N
with POS N
c-IMT POS N
z-scores POS N
of POS N
>1.5SD POS N
in POS N
the POS N
fully POS N
adjusted POS N
models POS N
and POS N
the POS N
p POS N
values POS N
were POS N
0.000, POS N
0.000, POS N
0.017, POS N
0.001, POS N
and POS N
0.044, POS N
respectively POS N
. POS N

The POS N
results POS N
showed POS N
that POS N
mean POS N
c-IMT POS N
z-scores POS N
increased POS N
significantly POS N
during POS N
4 POS N
years POS N
(0.002 POS N
± POS N
0.003, POS N
p POS N
< POS N
0.001) POS N
as POS N
well POS N
as POS N
carotid-femoral POS N
PWV POS N
(13.99 POS N
± POS N
2.74, POS N
p POS N
< POS N
0.01) POS N
and POS N
total POS N
cholesterol POS N
(6.97 POS N
± POS N
1.08, POS N
p POS N
< POS N
0.001). POS N

In POS N
a POS N
full-model POS N
logistic POS N
regression, POS N
significant POS N
risk POS N
factors POS N
for POS N
an POS N
increase POS N
in POS N
IMT POS N
of POS N
≥1.5 POS N
z-scores POS N
were POS N
carotid-femoral POS N
PWV POS N
(odds POS N
ratio: POS N
1.119, POS N
confidence POS N
interval: POS N
1.018, POS N
1.230, POS N
p POS N
= POS N
0.020 POS N
< POS N
0.05) POS N
at POS N
first POS N
measurement. POS N

The POS N
results POS N
showed POS N
that POS N
mean POS N
c-IMT POS N
z-scores POS N
increased POS N
significantly POS N
during POS N
4 POS N
years POS N
(0.002 POS N
± POS N
0.003, POS N
p POS N
< POS N
0.001) POS N
as POS N
well POS N
as POS N
carotid-femoral POS N
PWV POS N
(13.99 POS N
± POS N
2.74, POS N
p POS N
< POS N
0.01) POS N
and POS N
total POS N
cholesterol POS N
(6.97 POS N
± POS N
1.08, POS N
p POS N
< POS N
0.001). POS N

The POS N
conclusion POS N
of POS N
the POS N
study POS N
was POS N
that POS N
longitudinal POS N
c-IMT POS N
measurements POS N
revealed POS N
progression POS N
in POS N
subclinical POS N
atherosclerosis POS N
during POS N
a POS N
four-year POS N
period POS N
in POS N
a POS N
hypertensive POS N
old-aged POS N
cohort. POS N

The POS N
results POS N
showed POS N
that POS N
mean POS N
c-IMT POS N
z-scores POS N
increased POS N
significantly POS N
during POS N
4 POS N
years POS N
(0.002 POS N
± POS N
0.003, POS N
p POS N
< POS N
0.001) POS N
as POS N
well POS N
as POS N
carotid-femoral POS N
PWV POS N
(13.99 POS N
± POS N
2.74, POS N
p POS N
< POS N
0.01) POS N
and POS N
total POS N
cholesterol POS N
(6.97 POS N
± POS N
1.08, POS N
p POS N
< POS N
0.001). POS N

Systolic POS N
or POS N
diastolic POS N
blood POS N
pressure, POS N
homocysteine, POS N
carotid-femoral POS N
PWV, POS N
and POS N
waistline POS N
were POS N
significantly POS N
related POS N
to POS N
c-IMT POS N
increment. POS N

The POS N
results POS N
showed POS N
that POS N
mean POS N
c-IMT POS N
z-scores POS N
increased POS N
significantly POS N
during POS N
4 POS N
years POS N
(0.002 POS N
± POS N
0.003, POS N
p POS N
< POS N
0.001) POS N
as POS N
well POS N
as POS N
carotid-femoral POS N
PWV POS N
(13.99 POS N
± POS N
2.74, POS N
p POS N
< POS N
0.01) POS N
and POS N
total POS N
cholesterol POS N
(6.97 POS N
± POS N
1.08, POS N
p POS N
< POS N
0.001). POS N

By POS N
lifestyle POS N
and POS N
medical POS N
intervention POS N
to POS N
control POS N
these POS N
risk POS N
factors POS N
may POS N
prevent POS N
progression POS N
of POS N
c-IMT POS N
in POS N
old-aged POS N
cohort POS N
with POS N
hypertension. POS N

Linear POS N
regression POS N
showed POS N
statistically POS N
significant POS N
associations POS N
between POS N
systolic POS N
blood POS N
pressure, POS N
diastolic POS N
blood POS N
pressure, POS N
C-reactive POS N
protein, POS N
lip-line, POS N
and POS N
heart POS N
rate POS N
with POS N
c-IMT POS N
z-scores POS N
of POS N
>1.5SD POS N
in POS N
the POS N
fully POS N
adjusted POS N
models POS N
and POS N
the POS N
p POS N
values POS N
were POS N
0.000, POS N
0.000, POS N
0.017, POS N
0.001, POS N
and POS N
0.044, POS N
respectively POS N
. POS N

Hypertension POS N
is POS N
a POS N
generally POS N
accepted POS N
atherogenic POS N
risk POS N
factor. POS N

Linear POS N
regression POS N
showed POS N
statistically POS N
significant POS N
associations POS N
between POS N
systolic POS N
blood POS N
pressure, POS N
diastolic POS N
blood POS N
pressure, POS N
C-reactive POS N
protein, POS N
lip-line, POS N
and POS N
heart POS N
rate POS N
with POS N
c-IMT POS N
z-scores POS N
of POS N
>1.5SD POS N
in POS N
the POS N
fully POS N
adjusted POS N
models POS N
and POS N
the POS N
p POS N
values POS N
were POS N
0.000, POS N
0.000, POS N
0.017, POS N
0.001, POS N
and POS N
0.044, POS N
respectively POS N
. POS N

The POS N
results POS N
showed POS N
that POS N
mean POS N
c-IMT POS N
z-scores POS N
increased POS N
significantly POS N
during POS N
4 POS N
years POS N
(0.002 POS N
± POS N
0.003, POS N
p POS N
< POS N
0.001) POS N
as POS N
well POS N
as POS N
carotid-femoral POS N
PWV POS N
(13.99 POS N
± POS N
2.74, POS N
p POS N
< POS N
0.01) POS N
and POS N
total POS N
cholesterol POS N
(6.97 POS N
± POS N
1.08, POS N
p POS N
< POS N
0.001). POS N

Linear POS N
regression POS N
showed POS N
statistically POS N
significant POS N
associations POS N
between POS N
systolic POS N
blood POS N
pressure, POS N
diastolic POS N
blood POS N
pressure, POS N
C-reactive POS N
protein, POS N
lip-line, POS N
and POS N
heart POS N
rate POS N
with POS N
c-IMT POS N
z-scores POS N
of POS N
>1.5SD POS N
in POS N
the POS N
fully POS N
adjusted POS N
models POS N
and POS N
the POS N
p POS N
values POS N
were POS N
0.000, POS N
0.000, POS N
0.017, POS N
0.001, POS N
and POS N
0.044, POS N
respectively POS N
. POS N

In POS N
a POS N
full-model POS N
logistic POS N
regression, POS N
significant POS N
risk POS N
factors POS N
for POS N
an POS N
increase POS N
in POS N
IMT POS N
of POS N
≥1.5 POS N
z-scores POS N
were POS N
carotid-femoral POS N
PWV POS N
(odds POS N
ratio: POS N
1.119, POS N
confidence POS N
interval: POS N
1.018, POS N
1.230, POS N
p POS N
= POS N
0.020 POS N
< POS N
0.05) POS N
at POS N
first POS N
measurement. POS N

Linear POS N
regression POS N
showed POS N
statistically POS N
significant POS N
associations POS N
between POS N
systolic POS N
blood POS N
pressure, POS N
diastolic POS N
blood POS N
pressure, POS N
C-reactive POS N
protein, POS N
lip-line, POS N
and POS N
heart POS N
rate POS N
with POS N
c-IMT POS N
z-scores POS N
of POS N
>1.5SD POS N
in POS N
the POS N
fully POS N
adjusted POS N
models POS N
and POS N
the POS N
p POS N
values POS N
were POS N
0.000, POS N
0.000, POS N
0.017, POS N
0.001, POS N
and POS N
0.044, POS N
respectively POS N
. POS N

The POS N
conclusion POS N
of POS N
the POS N
study POS N
was POS N
that POS N
longitudinal POS N
c-IMT POS N
measurements POS N
revealed POS N
progression POS N
in POS N
subclinical POS N
atherosclerosis POS N
during POS N
a POS N
four-year POS N
period POS N
in POS N
a POS N
hypertensive POS N
old-aged POS N
cohort. POS N

Linear POS N
regression POS N
showed POS N
statistically POS N
significant POS N
associations POS N
between POS N
systolic POS N
blood POS N
pressure, POS N
diastolic POS N
blood POS N
pressure, POS N
C-reactive POS N
protein, POS N
lip-line, POS N
and POS N
heart POS N
rate POS N
with POS N
c-IMT POS N
z-scores POS N
of POS N
>1.5SD POS N
in POS N
the POS N
fully POS N
adjusted POS N
models POS N
and POS N
the POS N
p POS N
values POS N
were POS N
0.000, POS N
0.000, POS N
0.017, POS N
0.001, POS N
and POS N
0.044, POS N
respectively POS N
. POS N

Systolic POS N
or POS N
diastolic POS N
blood POS N
pressure, POS N
homocysteine, POS N
carotid-femoral POS N
PWV, POS N
and POS N
waistline POS N
were POS N
significantly POS N
related POS N
to POS N
c-IMT POS N
increment. POS N

Linear POS N
regression POS N
showed POS N
statistically POS N
significant POS N
associations POS N
between POS N
systolic POS N
blood POS N
pressure, POS N
diastolic POS N
blood POS N
pressure, POS N
C-reactive POS N
protein, POS N
lip-line, POS N
and POS N
heart POS N
rate POS N
with POS N
c-IMT POS N
z-scores POS N
of POS N
>1.5SD POS N
in POS N
the POS N
fully POS N
adjusted POS N
models POS N
and POS N
the POS N
p POS N
values POS N
were POS N
0.000, POS N
0.000, POS N
0.017, POS N
0.001, POS N
and POS N
0.044, POS N
respectively POS N
. POS N

By POS N
lifestyle POS N
and POS N
medical POS N
intervention POS N
to POS N
control POS N
these POS N
risk POS N
factors POS N
may POS N
prevent POS N
progression POS N
of POS N
c-IMT POS N
in POS N
old-aged POS N
cohort POS N
with POS N
hypertension. POS N

In POS N
a POS N
full-model POS N
logistic POS N
regression, POS N
significant POS N
risk POS N
factors POS N
for POS N
an POS N
increase POS N
in POS N
IMT POS N
of POS N
≥1.5 POS N
z-scores POS N
were POS N
carotid-femoral POS N
PWV POS N
(odds POS N
ratio: POS N
1.119, POS N
confidence POS N
interval: POS N
1.018, POS N
1.230, POS N
p POS N
= POS N
0.020 POS N
< POS N
0.05) POS N
at POS N
first POS N
measurement. POS N

Hypertension POS N
is POS N
a POS N
generally POS N
accepted POS N
atherogenic POS N
risk POS N
factor. POS N

In POS N
a POS N
full-model POS N
logistic POS N
regression, POS N
significant POS N
risk POS N
factors POS N
for POS N
an POS N
increase POS N
in POS N
IMT POS N
of POS N
≥1.5 POS N
z-scores POS N
were POS N
carotid-femoral POS N
PWV POS N
(odds POS N
ratio: POS N
1.119, POS N
confidence POS N
interval: POS N
1.018, POS N
1.230, POS N
p POS N
= POS N
0.020 POS N
< POS N
0.05) POS N
at POS N
first POS N
measurement. POS N

The POS N
results POS N
showed POS N
that POS N
mean POS N
c-IMT POS N
z-scores POS N
increased POS N
significantly POS N
during POS N
4 POS N
years POS N
(0.002 POS N
± POS N
0.003, POS N
p POS N
< POS N
0.001) POS N
as POS N
well POS N
as POS N
carotid-femoral POS N
PWV POS N
(13.99 POS N
± POS N
2.74, POS N
p POS N
< POS N
0.01) POS N
and POS N
total POS N
cholesterol POS N
(6.97 POS N
± POS N
1.08, POS N
p POS N
< POS N
0.001). POS N

In POS N
a POS N
full-model POS N
logistic POS N
regression, POS N
significant POS N
risk POS N
factors POS N
for POS N
an POS N
increase POS N
in POS N
IMT POS N
of POS N
≥1.5 POS N
z-scores POS N
were POS N
carotid-femoral POS N
PWV POS N
(odds POS N
ratio: POS N
1.119, POS N
confidence POS N
interval: POS N
1.018, POS N
1.230, POS N
p POS N
= POS N
0.020 POS N
< POS N
0.05) POS N
at POS N
first POS N
measurement. POS N

Linear POS N
regression POS N
showed POS N
statistically POS N
significant POS N
associations POS N
between POS N
systolic POS N
blood POS N
pressure, POS N
diastolic POS N
blood POS N
pressure, POS N
C-reactive POS N
protein, POS N
lip-line, POS N
and POS N
heart POS N
rate POS N
with POS N
c-IMT POS N
z-scores POS N
of POS N
>1.5SD POS N
in POS N
the POS N
fully POS N
adjusted POS N
models POS N
and POS N
the POS N
p POS N
values POS N
were POS N
0.000, POS N
0.000, POS N
0.017, POS N
0.001, POS N
and POS N
0.044, POS N
respectively POS N
. POS N

In POS N
a POS N
full-model POS N
logistic POS N
regression, POS N
significant POS N
risk POS N
factors POS N
for POS N
an POS N
increase POS N
in POS N
IMT POS N
of POS N
≥1.5 POS N
z-scores POS N
were POS N
carotid-femoral POS N
PWV POS N
(odds POS N
ratio: POS N
1.119, POS N
confidence POS N
interval: POS N
1.018, POS N
1.230, POS N
p POS N
= POS N
0.020 POS N
< POS N
0.05) POS N
at POS N
first POS N
measurement. POS N

The POS N
conclusion POS N
of POS N
the POS N
study POS N
was POS N
that POS N
longitudinal POS N
c-IMT POS N
measurements POS N
revealed POS N
progression POS N
in POS N
subclinical POS N
atherosclerosis POS N
during POS N
a POS N
four-year POS N
period POS N
in POS N
a POS N
hypertensive POS N
old-aged POS N
cohort. POS N

In POS N
a POS N
full-model POS N
logistic POS N
regression, POS N
significant POS N
risk POS N
factors POS N
for POS N
an POS N
increase POS N
in POS N
IMT POS N
of POS N
≥1.5 POS N
z-scores POS N
were POS N
carotid-femoral POS N
PWV POS N
(odds POS N
ratio: POS N
1.119, POS N
confidence POS N
interval: POS N
1.018, POS N
1.230, POS N
p POS N
= POS N
0.020 POS N
< POS N
0.05) POS N
at POS N
first POS N
measurement. POS N

Systolic POS N
or POS N
diastolic POS N
blood POS N
pressure, POS N
homocysteine, POS N
carotid-femoral POS N
PWV, POS N
and POS N
waistline POS N
were POS N
significantly POS N
related POS N
to POS N
c-IMT POS N
increment. POS N

In POS N
a POS N
full-model POS N
logistic POS N
regression, POS N
significant POS N
risk POS N
factors POS N
for POS N
an POS N
increase POS N
in POS N
IMT POS N
of POS N
≥1.5 POS N
z-scores POS N
were POS N
carotid-femoral POS N
PWV POS N
(odds POS N
ratio: POS N
1.119, POS N
confidence POS N
interval: POS N
1.018, POS N
1.230, POS N
p POS N
= POS N
0.020 POS N
< POS N
0.05) POS N
at POS N
first POS N
measurement. POS N

By POS N
lifestyle POS N
and POS N
medical POS N
intervention POS N
to POS N
control POS N
these POS N
risk POS N
factors POS N
may POS N
prevent POS N
progression POS N
of POS N
c-IMT POS N
in POS N
old-aged POS N
cohort POS N
with POS N
hypertension. POS N

The POS N
conclusion POS N
of POS N
the POS N
study POS N
was POS N
that POS N
longitudinal POS N
c-IMT POS N
measurements POS N
revealed POS N
progression POS N
in POS N
subclinical POS N
atherosclerosis POS N
during POS N
a POS N
four-year POS N
period POS N
in POS N
a POS N
hypertensive POS N
old-aged POS N
cohort. POS N

Hypertension POS N
is POS N
a POS N
generally POS N
accepted POS N
atherogenic POS N
risk POS N
factor. POS N

The POS N
conclusion POS N
of POS N
the POS N
study POS N
was POS N
that POS N
longitudinal POS N
c-IMT POS N
measurements POS N
revealed POS N
progression POS N
in POS N
subclinical POS N
atherosclerosis POS N
during POS N
a POS N
four-year POS N
period POS N
in POS N
a POS N
hypertensive POS N
old-aged POS N
cohort. POS N

The POS N
results POS N
showed POS N
that POS N
mean POS N
c-IMT POS N
z-scores POS N
increased POS N
significantly POS N
during POS N
4 POS N
years POS N
(0.002 POS N
± POS N
0.003, POS N
p POS N
< POS N
0.001) POS N
as POS N
well POS N
as POS N
carotid-femoral POS N
PWV POS N
(13.99 POS N
± POS N
2.74, POS N
p POS N
< POS N
0.01) POS N
and POS N
total POS N
cholesterol POS N
(6.97 POS N
± POS N
1.08, POS N
p POS N
< POS N
0.001). POS N

The POS N
conclusion POS N
of POS N
the POS N
study POS N
was POS N
that POS N
longitudinal POS N
c-IMT POS N
measurements POS N
revealed POS N
progression POS N
in POS N
subclinical POS N
atherosclerosis POS N
during POS N
a POS N
four-year POS N
period POS N
in POS N
a POS N
hypertensive POS N
old-aged POS N
cohort. POS N

Linear POS N
regression POS N
showed POS N
statistically POS N
significant POS N
associations POS N
between POS N
systolic POS N
blood POS N
pressure, POS N
diastolic POS N
blood POS N
pressure, POS N
C-reactive POS N
protein, POS N
lip-line, POS N
and POS N
heart POS N
rate POS N
with POS N
c-IMT POS N
z-scores POS N
of POS N
>1.5SD POS N
in POS N
the POS N
fully POS N
adjusted POS N
models POS N
and POS N
the POS N
p POS N
values POS N
were POS N
0.000, POS N
0.000, POS N
0.017, POS N
0.001, POS N
and POS N
0.044, POS N
respectively POS N
. POS N

The POS N
conclusion POS N
of POS N
the POS N
study POS N
was POS N
that POS N
longitudinal POS N
c-IMT POS N
measurements POS N
revealed POS N
progression POS N
in POS N
subclinical POS N
atherosclerosis POS N
during POS N
a POS N
four-year POS N
period POS N
in POS N
a POS N
hypertensive POS N
old-aged POS N
cohort. POS N

In POS N
a POS N
full-model POS N
logistic POS N
regression, POS N
significant POS N
risk POS N
factors POS N
for POS N
an POS N
increase POS N
in POS N
IMT POS N
of POS N
≥1.5 POS N
z-scores POS N
were POS N
carotid-femoral POS N
PWV POS N
(odds POS N
ratio: POS N
1.119, POS N
confidence POS N
interval: POS N
1.018, POS N
1.230, POS N
p POS N
= POS N
0.020 POS N
< POS N
0.05) POS N
at POS N
first POS N
measurement. POS N

The POS N
conclusion POS N
of POS N
the POS N
study POS N
was POS N
that POS N
longitudinal POS N
c-IMT POS N
measurements POS N
revealed POS N
progression POS N
in POS N
subclinical POS N
atherosclerosis POS N
during POS N
a POS N
four-year POS N
period POS N
in POS N
a POS N
hypertensive POS N
old-aged POS N
cohort. POS N

Systolic POS N
or POS N
diastolic POS N
blood POS N
pressure, POS N
homocysteine, POS N
carotid-femoral POS N
PWV, POS N
and POS N
waistline POS N
were POS N
significantly POS N
related POS N
to POS N
c-IMT POS N
increment. POS N

The POS N
conclusion POS N
of POS N
the POS N
study POS N
was POS N
that POS N
longitudinal POS N
c-IMT POS N
measurements POS N
revealed POS N
progression POS N
in POS N
subclinical POS N
atherosclerosis POS N
during POS N
a POS N
four-year POS N
period POS N
in POS N
a POS N
hypertensive POS N
old-aged POS N
cohort. POS N

By POS N
lifestyle POS N
and POS N
medical POS N
intervention POS N
to POS N
control POS N
these POS N
risk POS N
factors POS N
may POS N
prevent POS N
progression POS N
of POS N
c-IMT POS N
in POS N
old-aged POS N
cohort POS N
with POS N
hypertension. POS N

Systolic POS N
or POS N
diastolic POS N
blood POS N
pressure, POS N
homocysteine, POS N
carotid-femoral POS N
PWV, POS N
and POS N
waistline POS N
were POS N
significantly POS N
related POS N
to POS N
c-IMT POS N
increment. POS N

Hypertension POS N
is POS N
a POS N
generally POS N
accepted POS N
atherogenic POS N
risk POS N
factor. POS N

Systolic POS N
or POS N
diastolic POS N
blood POS N
pressure, POS N
homocysteine, POS N
carotid-femoral POS N
PWV, POS N
and POS N
waistline POS N
were POS N
significantly POS N
related POS N
to POS N
c-IMT POS N
increment. POS N

The POS N
results POS N
showed POS N
that POS N
mean POS N
c-IMT POS N
z-scores POS N
increased POS N
significantly POS N
during POS N
4 POS N
years POS N
(0.002 POS N
± POS N
0.003, POS N
p POS N
< POS N
0.001) POS N
as POS N
well POS N
as POS N
carotid-femoral POS N
PWV POS N
(13.99 POS N
± POS N
2.74, POS N
p POS N
< POS N
0.01) POS N
and POS N
total POS N
cholesterol POS N
(6.97 POS N
± POS N
1.08, POS N
p POS N
< POS N
0.001). POS N

Systolic POS N
or POS N
diastolic POS N
blood POS N
pressure, POS N
homocysteine, POS N
carotid-femoral POS N
PWV, POS N
and POS N
waistline POS N
were POS N
significantly POS N
related POS N
to POS N
c-IMT POS N
increment. POS N

Linear POS N
regression POS N
showed POS N
statistically POS N
significant POS N
associations POS N
between POS N
systolic POS N
blood POS N
pressure, POS N
diastolic POS N
blood POS N
pressure, POS N
C-reactive POS N
protein, POS N
lip-line, POS N
and POS N
heart POS N
rate POS N
with POS N
c-IMT POS N
z-scores POS N
of POS N
>1.5SD POS N
in POS N
the POS N
fully POS N
adjusted POS N
models POS N
and POS N
the POS N
p POS N
values POS N
were POS N
0.000, POS N
0.000, POS N
0.017, POS N
0.001, POS N
and POS N
0.044, POS N
respectively POS N
. POS N

Systolic POS N
or POS N
diastolic POS N
blood POS N
pressure, POS N
homocysteine, POS N
carotid-femoral POS N
PWV, POS N
and POS N
waistline POS N
were POS N
significantly POS N
related POS N
to POS N
c-IMT POS N
increment. POS N

In POS N
a POS N
full-model POS N
logistic POS N
regression, POS N
significant POS N
risk POS N
factors POS N
for POS N
an POS N
increase POS N
in POS N
IMT POS N
of POS N
≥1.5 POS N
z-scores POS N
were POS N
carotid-femoral POS N
PWV POS N
(odds POS N
ratio: POS N
1.119, POS N
confidence POS N
interval: POS N
1.018, POS N
1.230, POS N
p POS N
= POS N
0.020 POS N
< POS N
0.05) POS N
at POS N
first POS N
measurement. POS N

Systolic POS N
or POS N
diastolic POS N
blood POS N
pressure, POS N
homocysteine, POS N
carotid-femoral POS N
PWV, POS N
and POS N
waistline POS N
were POS N
significantly POS N
related POS N
to POS N
c-IMT POS N
increment. POS N

The POS N
conclusion POS N
of POS N
the POS N
study POS N
was POS N
that POS N
longitudinal POS N
c-IMT POS N
measurements POS N
revealed POS N
progression POS N
in POS N
subclinical POS N
atherosclerosis POS N
during POS N
a POS N
four-year POS N
period POS N
in POS N
a POS N
hypertensive POS N
old-aged POS N
cohort. POS N

Systolic POS N
or POS N
diastolic POS N
blood POS N
pressure, POS N
homocysteine, POS N
carotid-femoral POS N
PWV, POS N
and POS N
waistline POS N
were POS N
significantly POS N
related POS N
to POS N
c-IMT POS N
increment. POS N

By POS N
lifestyle POS N
and POS N
medical POS N
intervention POS N
to POS N
control POS N
these POS N
risk POS N
factors POS N
may POS N
prevent POS N
progression POS N
of POS N
c-IMT POS N
in POS N
old-aged POS N
cohort POS N
with POS N
hypertension. POS N

By POS N
lifestyle POS N
and POS N
medical POS N
intervention POS N
to POS N
control POS N
these POS N
risk POS N
factors POS N
may POS N
prevent POS N
progression POS N
of POS N
c-IMT POS N
in POS N
old-aged POS N
cohort POS N
with POS N
hypertension. POS N

Hypertension POS N
is POS N
a POS N
generally POS N
accepted POS N
atherogenic POS N
risk POS N
factor. POS N

By POS N
lifestyle POS N
and POS N
medical POS N
intervention POS N
to POS N
control POS N
these POS N
risk POS N
factors POS N
may POS N
prevent POS N
progression POS N
of POS N
c-IMT POS N
in POS N
old-aged POS N
cohort POS N
with POS N
hypertension. POS N

The POS N
results POS N
showed POS N
that POS N
mean POS N
c-IMT POS N
z-scores POS N
increased POS N
significantly POS N
during POS N
4 POS N
years POS N
(0.002 POS N
± POS N
0.003, POS N
p POS N
< POS N
0.001) POS N
as POS N
well POS N
as POS N
carotid-femoral POS N
PWV POS N
(13.99 POS N
± POS N
2.74, POS N
p POS N
< POS N
0.01) POS N
and POS N
total POS N
cholesterol POS N
(6.97 POS N
± POS N
1.08, POS N
p POS N
< POS N
0.001). POS N

By POS N
lifestyle POS N
and POS N
medical POS N
intervention POS N
to POS N
control POS N
these POS N
risk POS N
factors POS N
may POS N
prevent POS N
progression POS N
of POS N
c-IMT POS N
in POS N
old-aged POS N
cohort POS N
with POS N
hypertension. POS N

Linear POS N
regression POS N
showed POS N
statistically POS N
significant POS N
associations POS N
between POS N
systolic POS N
blood POS N
pressure, POS N
diastolic POS N
blood POS N
pressure, POS N
C-reactive POS N
protein, POS N
lip-line, POS N
and POS N
heart POS N
rate POS N
with POS N
c-IMT POS N
z-scores POS N
of POS N
>1.5SD POS N
in POS N
the POS N
fully POS N
adjusted POS N
models POS N
and POS N
the POS N
p POS N
values POS N
were POS N
0.000, POS N
0.000, POS N
0.017, POS N
0.001, POS N
and POS N
0.044, POS N
respectively POS N
. POS N

By POS N
lifestyle POS N
and POS N
medical POS N
intervention POS N
to POS N
control POS N
these POS N
risk POS N
factors POS N
may POS N
prevent POS N
progression POS N
of POS N
c-IMT POS N
in POS N
old-aged POS N
cohort POS N
with POS N
hypertension. POS N

In POS N
a POS N
full-model POS N
logistic POS N
regression, POS N
significant POS N
risk POS N
factors POS N
for POS N
an POS N
increase POS N
in POS N
IMT POS N
of POS N
≥1.5 POS N
z-scores POS N
were POS N
carotid-femoral POS N
PWV POS N
(odds POS N
ratio: POS N
1.119, POS N
confidence POS N
interval: POS N
1.018, POS N
1.230, POS N
p POS N
= POS N
0.020 POS N
< POS N
0.05) POS N
at POS N
first POS N
measurement. POS N

By POS N
lifestyle POS N
and POS N
medical POS N
intervention POS N
to POS N
control POS N
these POS N
risk POS N
factors POS N
may POS N
prevent POS N
progression POS N
of POS N
c-IMT POS N
in POS N
old-aged POS N
cohort POS N
with POS N
hypertension. POS N

The POS N
conclusion POS N
of POS N
the POS N
study POS N
was POS N
that POS N
longitudinal POS N
c-IMT POS N
measurements POS N
revealed POS N
progression POS N
in POS N
subclinical POS N
atherosclerosis POS N
during POS N
a POS N
four-year POS N
period POS N
in POS N
a POS N
hypertensive POS N
old-aged POS N
cohort. POS N

By POS N
lifestyle POS N
and POS N
medical POS N
intervention POS N
to POS N
control POS N
these POS N
risk POS N
factors POS N
may POS N
prevent POS N
progression POS N
of POS N
c-IMT POS N
in POS N
old-aged POS N
cohort POS N
with POS N
hypertension. POS N

Systolic POS N
or POS N
diastolic POS N
blood POS N
pressure, POS N
homocysteine, POS N
carotid-femoral POS N
PWV, POS N
and POS N
waistline POS N
were POS N
significantly POS N
related POS N
to POS N
c-IMT POS N
increment. POS N

Larger POS N
sample POS N
size POS N
is POS N
presumably POS N
needed POS N
to POS N
assess POS N
the POS N
effect POS N
of POS N
RIPC POS N
for POS N
patients POS N
with POS N
diabetes POS N
mellitus. POS N

Remote POS N
ischemic POS N
preconditioning POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
acute POS N
kidney POS N
injury POS N
in POS N
non-diabetic POS N
patients POS N
undergoing POS N
PCI. POS N

Larger POS N
sample POS N
size POS N
is POS N
presumably POS N
needed POS N
to POS N
assess POS N
the POS N
effect POS N
of POS N
RIPC POS N
for POS N
patients POS N
with POS N
diabetes POS N
mellitus. POS N

RIPC POS N
significantly POS N
reduced POS N
CIN POS N
incidence POS N
in POS N
the POS N
overall POS N
population POS N
(12.1% POS N
vs. POS N
26.1%, POS N
p=0.01, POS N
with POS N
a POS N
NNT=9) POS N
and POS N
in POS N
non-diabetic POS N
patients POS N
(9.2% POS N
vs. POS N
25.0%, POS N
p=0.02), POS N
but POS N
showed POS N
no POS N
benefit POS N
in POS N
diabetics POS N
(16.7% POS N
vs. POS N
28.2%, POS N
p=0.21). POS N

Larger POS N
sample POS N
size POS N
is POS N
presumably POS N
needed POS N
to POS N
assess POS N
the POS N
effect POS N
of POS N
RIPC POS N
for POS N
patients POS N
with POS N
diabetes POS N
mellitus. POS N

A POS N
trend POS N
for POS N
lower POS N
PMI POS N
was POS N
seen POS N
in POS N
the POS N
intervention POS N
arm POS N
(creatine POS N
kinase POS N
- POS N
muscle POS N
brain POS N
>5 POS N
URL; POS N
8.4% POS N
vs. POS N
16.4%, POS N
p=0.07; POS N
troponin POS N
T POS N
>5 POS N
URL; POS N
27% POS N
vs. POS N
38%, POS N
p=0.21). POS N

Remote POS N
ischemic POS N
preconditioning POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
acute POS N
kidney POS N
injury POS N
in POS N
non-diabetic POS N
patients POS N
undergoing POS N
PCI. POS N

Larger POS N
sample POS N
size POS N
is POS N
presumably POS N
needed POS N
to POS N
assess POS N
the POS N
effect POS N
of POS N
RIPC POS N
for POS N
patients POS N
with POS N
diabetes POS N
mellitus. POS N

Remote POS N
ischemic POS N
preconditioning POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
acute POS N
kidney POS N
injury POS N
in POS N
non-diabetic POS N
patients POS N
undergoing POS N
PCI. POS N

RIPC POS N
significantly POS N
reduced POS N
CIN POS N
incidence POS N
in POS N
the POS N
overall POS N
population POS N
(12.1% POS N
vs. POS N
26.1%, POS N
p=0.01, POS N
with POS N
a POS N
NNT=9) POS N
and POS N
in POS N
non-diabetic POS N
patients POS N
(9.2% POS N
vs. POS N
25.0%, POS N
p=0.02), POS N
but POS N
showed POS N
no POS N
benefit POS N
in POS N
diabetics POS N
(16.7% POS N
vs. POS N
28.2%, POS N
p=0.21). POS N

Remote POS N
ischemic POS N
preconditioning POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
acute POS N
kidney POS N
injury POS N
in POS N
non-diabetic POS N
patients POS N
undergoing POS N
PCI. POS N

A POS N
trend POS N
for POS N
lower POS N
PMI POS N
was POS N
seen POS N
in POS N
the POS N
intervention POS N
arm POS N
(creatine POS N
kinase POS N
- POS N
muscle POS N
brain POS N
>5 POS N
URL; POS N
8.4% POS N
vs. POS N
16.4%, POS N
p=0.07; POS N
troponin POS N
T POS N
>5 POS N
URL; POS N
27% POS N
vs. POS N
38%, POS N
p=0.21). POS N

RIPC POS N
significantly POS N
reduced POS N
CIN POS N
incidence POS N
in POS N
the POS N
overall POS N
population POS N
(12.1% POS N
vs. POS N
26.1%, POS N
p=0.01, POS N
with POS N
a POS N
NNT=9) POS N
and POS N
in POS N
non-diabetic POS N
patients POS N
(9.2% POS N
vs. POS N
25.0%, POS N
p=0.02), POS N
but POS N
showed POS N
no POS N
benefit POS N
in POS N
diabetics POS N
(16.7% POS N
vs. POS N
28.2%, POS N
p=0.21). POS N

Larger POS N
sample POS N
size POS N
is POS N
presumably POS N
needed POS N
to POS N
assess POS N
the POS N
effect POS N
of POS N
RIPC POS N
for POS N
patients POS N
with POS N
diabetes POS N
mellitus. POS N

RIPC POS N
significantly POS N
reduced POS N
CIN POS N
incidence POS N
in POS N
the POS N
overall POS N
population POS N
(12.1% POS N
vs. POS N
26.1%, POS N
p=0.01, POS N
with POS N
a POS N
NNT=9) POS N
and POS N
in POS N
non-diabetic POS N
patients POS N
(9.2% POS N
vs. POS N
25.0%, POS N
p=0.02), POS N
but POS N
showed POS N
no POS N
benefit POS N
in POS N
diabetics POS N
(16.7% POS N
vs. POS N
28.2%, POS N
p=0.21). POS N

Remote POS N
ischemic POS N
preconditioning POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
acute POS N
kidney POS N
injury POS N
in POS N
non-diabetic POS N
patients POS N
undergoing POS N
PCI. POS N

RIPC POS N
significantly POS N
reduced POS N
CIN POS N
incidence POS N
in POS N
the POS N
overall POS N
population POS N
(12.1% POS N
vs. POS N
26.1%, POS N
p=0.01, POS N
with POS N
a POS N
NNT=9) POS N
and POS N
in POS N
non-diabetic POS N
patients POS N
(9.2% POS N
vs. POS N
25.0%, POS N
p=0.02), POS N
but POS N
showed POS N
no POS N
benefit POS N
in POS N
diabetics POS N
(16.7% POS N
vs. POS N
28.2%, POS N
p=0.21). POS N

A POS N
trend POS N
for POS N
lower POS N
PMI POS N
was POS N
seen POS N
in POS N
the POS N
intervention POS N
arm POS N
(creatine POS N
kinase POS N
- POS N
muscle POS N
brain POS N
>5 POS N
URL; POS N
8.4% POS N
vs. POS N
16.4%, POS N
p=0.07; POS N
troponin POS N
T POS N
>5 POS N
URL; POS N
27% POS N
vs. POS N
38%, POS N
p=0.21). POS N

A POS N
trend POS N
for POS N
lower POS N
PMI POS N
was POS N
seen POS N
in POS N
the POS N
intervention POS N
arm POS N
(creatine POS N
kinase POS N
- POS N
muscle POS N
brain POS N
>5 POS N
URL; POS N
8.4% POS N
vs. POS N
16.4%, POS N
p=0.07; POS N
troponin POS N
T POS N
>5 POS N
URL; POS N
27% POS N
vs. POS N
38%, POS N
p=0.21). POS N

Larger POS N
sample POS N
size POS N
is POS N
presumably POS N
needed POS N
to POS N
assess POS N
the POS N
effect POS N
of POS N
RIPC POS N
for POS N
patients POS N
with POS N
diabetes POS N
mellitus. POS N

A POS N
trend POS N
for POS N
lower POS N
PMI POS N
was POS N
seen POS N
in POS N
the POS N
intervention POS N
arm POS N
(creatine POS N
kinase POS N
- POS N
muscle POS N
brain POS N
>5 POS N
URL; POS N
8.4% POS N
vs. POS N
16.4%, POS N
p=0.07; POS N
troponin POS N
T POS N
>5 POS N
URL; POS N
27% POS N
vs. POS N
38%, POS N
p=0.21). POS N

Remote POS N
ischemic POS N
preconditioning POS N
significantly POS N
reduces POS N
the POS N
incidence POS N
of POS N
acute POS N
kidney POS N
injury POS N
in POS N
non-diabetic POS N
patients POS N
undergoing POS N
PCI. POS N

A POS N
trend POS N
for POS N
lower POS N
PMI POS N
was POS N
seen POS N
in POS N
the POS N
intervention POS N
arm POS N
(creatine POS N
kinase POS N
- POS N
muscle POS N
brain POS N
>5 POS N
URL; POS N
8.4% POS N
vs. POS N
16.4%, POS N
p=0.07; POS N
troponin POS N
T POS N
>5 POS N
URL; POS N
27% POS N
vs. POS N
38%, POS N
p=0.21). POS N

RIPC POS N
significantly POS N
reduced POS N
CIN POS N
incidence POS N
in POS N
the POS N
overall POS N
population POS N
(12.1% POS N
vs. POS N
26.1%, POS N
p=0.01, POS N
with POS N
a POS N
NNT=9) POS N
and POS N
in POS N
non-diabetic POS N
patients POS N
(9.2% POS N
vs. POS N
25.0%, POS N
p=0.02), POS N
but POS N
showed POS N
no POS N
benefit POS N
in POS N
diabetics POS N
(16.7% POS N
vs. POS N
28.2%, POS N
p=0.21). POS N

Vesatolimod POS N
was POS N
safe POS N
and POS N
well-tolerated POS N
in POS N
patients POS N
with POS N
CHB, POS N
demonstrating POS N
consistent POS N
dose-dependent POS N
pharmacodynamic POS N
induction POS N
of POS N
ISG15 POS N
without POS N
significant POS N
systemic POS N
induction POS N
of POS N
IFNα POS N
expression POS N
or POS N
related POS N
symptoms. POS N

Most POS N
(41-80%) POS N
experienced POS N
≥1 POS N
AE POS N
during POS N
the POS N
study POS N
with POS N
the POS N
majority POS N
of POS N
AEs POS N
mild POS N
or POS N
moderate POS N
in POS N
severity. POS N

Vesatolimod POS N
was POS N
safe POS N
and POS N
well-tolerated POS N
in POS N
patients POS N
with POS N
CHB, POS N
demonstrating POS N
consistent POS N
dose-dependent POS N
pharmacodynamic POS N
induction POS N
of POS N
ISG15 POS N
without POS N
significant POS N
systemic POS N
induction POS N
of POS N
IFNα POS N
expression POS N
or POS N
related POS N
symptoms. POS N

No POS N
significant POS N
declines POS N
in POS N
HBsAg POS N
were POS N
observed POS N
at POS N
the POS N
primary POS N
(Week POS N
24) POS N
or POS N
secondary POS N
endpoints POS N
(Weeks POS N
4, POS N
8, POS N
12, POS N
and POS N
48). POS N

Vesatolimod POS N
was POS N
safe POS N
and POS N
well-tolerated POS N
in POS N
patients POS N
with POS N
CHB, POS N
demonstrating POS N
consistent POS N
dose-dependent POS N
pharmacodynamic POS N
induction POS N
of POS N
ISG15 POS N
without POS N
significant POS N
systemic POS N
induction POS N
of POS N
IFNα POS N
expression POS N
or POS N
related POS N
symptoms. POS N

ISG15 POS N
induction POS N
was POS N
dose-dependent POS N
and POS N
consistent POS N
after POS N
repeat POS N
dosing, POS N
returning POS N
closer POS N
to POS N
baseline POS N
by POS N
one POS N
week POS N
after POS N
treatment POS N
at POS N
all POS N
dose POS N
levels; POS N

Vesatolimod POS N
was POS N
safe POS N
and POS N
well-tolerated POS N
in POS N
patients POS N
with POS N
CHB, POS N
demonstrating POS N
consistent POS N
dose-dependent POS N
pharmacodynamic POS N
induction POS N
of POS N
ISG15 POS N
without POS N
significant POS N
systemic POS N
induction POS N
of POS N
IFNα POS N
expression POS N
or POS N
related POS N
symptoms. POS N

no POS N
patient POS N
demonstrated POS N
significant POS N
serum POS N
interferon POS N
alpha POS N
(IFNα) POS N
expression POS N
at POS N
any POS N
timepoint POS N
evaluated. POS N

Vesatolimod POS N
was POS N
safe POS N
and POS N
well-tolerated POS N
in POS N
patients POS N
with POS N
CHB, POS N
demonstrating POS N
consistent POS N
dose-dependent POS N
pharmacodynamic POS N
induction POS N
of POS N
ISG15 POS N
without POS N
significant POS N
systemic POS N
induction POS N
of POS N
IFNα POS N
expression POS N
or POS N
related POS N
symptoms. POS N

Multivariate POS N
analyses POS N
showed POS N
that POS N
≥2-fold POS N
ISG15 POS N
induction POS N
is POS N
associated POS N
with POS N
2- POS N
or POS N
4-mg POS N
vesatolimod POS N
dose POS N
and POS N
female POS N
sex. POS N

Most POS N
(41-80%) POS N
experienced POS N
≥1 POS N
AE POS N
during POS N
the POS N
study POS N
with POS N
the POS N
majority POS N
of POS N
AEs POS N
mild POS N
or POS N
moderate POS N
in POS N
severity. POS N

Vesatolimod POS N
was POS N
safe POS N
and POS N
well-tolerated POS N
in POS N
patients POS N
with POS N
CHB, POS N
demonstrating POS N
consistent POS N
dose-dependent POS N
pharmacodynamic POS N
induction POS N
of POS N
ISG15 POS N
without POS N
significant POS N
systemic POS N
induction POS N
of POS N
IFNα POS N
expression POS N
or POS N
related POS N
symptoms. POS N

Most POS N
(41-80%) POS N
experienced POS N
≥1 POS N
AE POS N
during POS N
the POS N
study POS N
with POS N
the POS N
majority POS N
of POS N
AEs POS N
mild POS N
or POS N
moderate POS N
in POS N
severity. POS N

No POS N
significant POS N
declines POS N
in POS N
HBsAg POS N
were POS N
observed POS N
at POS N
the POS N
primary POS N
(Week POS N
24) POS N
or POS N
secondary POS N
endpoints POS N
(Weeks POS N
4, POS N
8, POS N
12, POS N
and POS N
48). POS N

Most POS N
(41-80%) POS N
experienced POS N
≥1 POS N
AE POS N
during POS N
the POS N
study POS N
with POS N
the POS N
majority POS N
of POS N
AEs POS N
mild POS N
or POS N
moderate POS N
in POS N
severity. POS N

ISG15 POS N
induction POS N
was POS N
dose-dependent POS N
and POS N
consistent POS N
after POS N
repeat POS N
dosing, POS N
returning POS N
closer POS N
to POS N
baseline POS N
by POS N
one POS N
week POS N
after POS N
treatment POS N
at POS N
all POS N
dose POS N
levels; POS N

Most POS N
(41-80%) POS N
experienced POS N
≥1 POS N
AE POS N
during POS N
the POS N
study POS N
with POS N
the POS N
majority POS N
of POS N
AEs POS N
mild POS N
or POS N
moderate POS N
in POS N
severity. POS N

no POS N
patient POS N
demonstrated POS N
significant POS N
serum POS N
interferon POS N
alpha POS N
(IFNα) POS N
expression POS N
at POS N
any POS N
timepoint POS N
evaluated. POS N

Most POS N
(41-80%) POS N
experienced POS N
≥1 POS N
AE POS N
during POS N
the POS N
study POS N
with POS N
the POS N
majority POS N
of POS N
AEs POS N
mild POS N
or POS N
moderate POS N
in POS N
severity. POS N

Multivariate POS N
analyses POS N
showed POS N
that POS N
≥2-fold POS N
ISG15 POS N
induction POS N
is POS N
associated POS N
with POS N
2- POS N
or POS N
4-mg POS N
vesatolimod POS N
dose POS N
and POS N
female POS N
sex. POS N

No POS N
significant POS N
declines POS N
in POS N
HBsAg POS N
were POS N
observed POS N
at POS N
the POS N
primary POS N
(Week POS N
24) POS N
or POS N
secondary POS N
endpoints POS N
(Weeks POS N
4, POS N
8, POS N
12, POS N
and POS N
48). POS N

Vesatolimod POS N
was POS N
safe POS N
and POS N
well-tolerated POS N
in POS N
patients POS N
with POS N
CHB, POS N
demonstrating POS N
consistent POS N
dose-dependent POS N
pharmacodynamic POS N
induction POS N
of POS N
ISG15 POS N
without POS N
significant POS N
systemic POS N
induction POS N
of POS N
IFNα POS N
expression POS N
or POS N
related POS N
symptoms. POS N

No POS N
significant POS N
declines POS N
in POS N
HBsAg POS N
were POS N
observed POS N
at POS N
the POS N
primary POS N
(Week POS N
24) POS N
or POS N
secondary POS N
endpoints POS N
(Weeks POS N
4, POS N
8, POS N
12, POS N
and POS N
48). POS N

Most POS N
(41-80%) POS N
experienced POS N
≥1 POS N
AE POS N
during POS N
the POS N
study POS N
with POS N
the POS N
majority POS N
of POS N
AEs POS N
mild POS N
or POS N
moderate POS N
in POS N
severity. POS N

No POS N
significant POS N
declines POS N
in POS N
HBsAg POS N
were POS N
observed POS N
at POS N
the POS N
primary POS N
(Week POS N
24) POS N
or POS N
secondary POS N
endpoints POS N
(Weeks POS N
4, POS N
8, POS N
12, POS N
and POS N
48). POS N

ISG15 POS N
induction POS N
was POS N
dose-dependent POS N
and POS N
consistent POS N
after POS N
repeat POS N
dosing, POS N
returning POS N
closer POS N
to POS N
baseline POS N
by POS N
one POS N
week POS N
after POS N
treatment POS N
at POS N
all POS N
dose POS N
levels; POS N

No POS N
significant POS N
declines POS N
in POS N
HBsAg POS N
were POS N
observed POS N
at POS N
the POS N
primary POS N
(Week POS N
24) POS N
or POS N
secondary POS N
endpoints POS N
(Weeks POS N
4, POS N
8, POS N
12, POS N
and POS N
48). POS N

no POS N
patient POS N
demonstrated POS N
significant POS N
serum POS N
interferon POS N
alpha POS N
(IFNα) POS N
expression POS N
at POS N
any POS N
timepoint POS N
evaluated. POS N

No POS N
significant POS N
declines POS N
in POS N
HBsAg POS N
were POS N
observed POS N
at POS N
the POS N
primary POS N
(Week POS N
24) POS N
or POS N
secondary POS N
endpoints POS N
(Weeks POS N
4, POS N
8, POS N
12, POS N
and POS N
48). POS N

Multivariate POS N
analyses POS N
showed POS N
that POS N
≥2-fold POS N
ISG15 POS N
induction POS N
is POS N
associated POS N
with POS N
2- POS N
or POS N
4-mg POS N
vesatolimod POS N
dose POS N
and POS N
female POS N
sex. POS N

ISG15 POS N
induction POS N
was POS N
dose-dependent POS N
and POS N
consistent POS N
after POS N
repeat POS N
dosing, POS N
returning POS N
closer POS N
to POS N
baseline POS N
by POS N
one POS N
week POS N
after POS N
treatment POS N
at POS N
all POS N
dose POS N
levels; POS N

Vesatolimod POS N
was POS N
safe POS N
and POS N
well-tolerated POS N
in POS N
patients POS N
with POS N
CHB, POS N
demonstrating POS N
consistent POS N
dose-dependent POS N
pharmacodynamic POS N
induction POS N
of POS N
ISG15 POS N
without POS N
significant POS N
systemic POS N
induction POS N
of POS N
IFNα POS N
expression POS N
or POS N
related POS N
symptoms. POS N

ISG15 POS N
induction POS N
was POS N
dose-dependent POS N
and POS N
consistent POS N
after POS N
repeat POS N
dosing, POS N
returning POS N
closer POS N
to POS N
baseline POS N
by POS N
one POS N
week POS N
after POS N
treatment POS N
at POS N
all POS N
dose POS N
levels; POS N

Most POS N
(41-80%) POS N
experienced POS N
≥1 POS N
AE POS N
during POS N
the POS N
study POS N
with POS N
the POS N
majority POS N
of POS N
AEs POS N
mild POS N
or POS N
moderate POS N
in POS N
severity. POS N

ISG15 POS N
induction POS N
was POS N
dose-dependent POS N
and POS N
consistent POS N
after POS N
repeat POS N
dosing, POS N
returning POS N
closer POS N
to POS N
baseline POS N
by POS N
one POS N
week POS N
after POS N
treatment POS N
at POS N
all POS N
dose POS N
levels; POS N

No POS N
significant POS N
declines POS N
in POS N
HBsAg POS N
were POS N
observed POS N
at POS N
the POS N
primary POS N
(Week POS N
24) POS N
or POS N
secondary POS N
endpoints POS N
(Weeks POS N
4, POS N
8, POS N
12, POS N
and POS N
48). POS N

ISG15 POS N
induction POS N
was POS N
dose-dependent POS N
and POS N
consistent POS N
after POS N
repeat POS N
dosing, POS N
returning POS N
closer POS N
to POS N
baseline POS N
by POS N
one POS N
week POS N
after POS N
treatment POS N
at POS N
all POS N
dose POS N
levels; POS N

no POS N
patient POS N
demonstrated POS N
significant POS N
serum POS N
interferon POS N
alpha POS N
(IFNα) POS N
expression POS N
at POS N
any POS N
timepoint POS N
evaluated. POS N

ISG15 POS N
induction POS N
was POS N
dose-dependent POS N
and POS N
consistent POS N
after POS N
repeat POS N
dosing, POS N
returning POS N
closer POS N
to POS N
baseline POS N
by POS N
one POS N
week POS N
after POS N
treatment POS N
at POS N
all POS N
dose POS N
levels; POS N

Multivariate POS N
analyses POS N
showed POS N
that POS N
≥2-fold POS N
ISG15 POS N
induction POS N
is POS N
associated POS N
with POS N
2- POS N
or POS N
4-mg POS N
vesatolimod POS N
dose POS N
and POS N
female POS N
sex. POS N

no POS N
patient POS N
demonstrated POS N
significant POS N
serum POS N
interferon POS N
alpha POS N
(IFNα) POS N
expression POS N
at POS N
any POS N
timepoint POS N
evaluated. POS N

Vesatolimod POS N
was POS N
safe POS N
and POS N
well-tolerated POS N
in POS N
patients POS N
with POS N
CHB, POS N
demonstrating POS N
consistent POS N
dose-dependent POS N
pharmacodynamic POS N
induction POS N
of POS N
ISG15 POS N
without POS N
significant POS N
systemic POS N
induction POS N
of POS N
IFNα POS N
expression POS N
or POS N
related POS N
symptoms. POS N

no POS N
patient POS N
demonstrated POS N
significant POS N
serum POS N
interferon POS N
alpha POS N
(IFNα) POS N
expression POS N
at POS N
any POS N
timepoint POS N
evaluated. POS N

Most POS N
(41-80%) POS N
experienced POS N
≥1 POS N
AE POS N
during POS N
the POS N
study POS N
with POS N
the POS N
majority POS N
of POS N
AEs POS N
mild POS N
or POS N
moderate POS N
in POS N
severity. POS N

no POS N
patient POS N
demonstrated POS N
significant POS N
serum POS N
interferon POS N
alpha POS N
(IFNα) POS N
expression POS N
at POS N
any POS N
timepoint POS N
evaluated. POS N

No POS N
significant POS N
declines POS N
in POS N
HBsAg POS N
were POS N
observed POS N
at POS N
the POS N
primary POS N
(Week POS N
24) POS N
or POS N
secondary POS N
endpoints POS N
(Weeks POS N
4, POS N
8, POS N
12, POS N
and POS N
48). POS N

no POS N
patient POS N
demonstrated POS N
significant POS N
serum POS N
interferon POS N
alpha POS N
(IFNα) POS N
expression POS N
at POS N
any POS N
timepoint POS N
evaluated. POS N

ISG15 POS N
induction POS N
was POS N
dose-dependent POS N
and POS N
consistent POS N
after POS N
repeat POS N
dosing, POS N
returning POS N
closer POS N
to POS N
baseline POS N
by POS N
one POS N
week POS N
after POS N
treatment POS N
at POS N
all POS N
dose POS N
levels; POS N

no POS N
patient POS N
demonstrated POS N
significant POS N
serum POS N
interferon POS N
alpha POS N
(IFNα) POS N
expression POS N
at POS N
any POS N
timepoint POS N
evaluated. POS N

Multivariate POS N
analyses POS N
showed POS N
that POS N
≥2-fold POS N
ISG15 POS N
induction POS N
is POS N
associated POS N
with POS N
2- POS N
or POS N
4-mg POS N
vesatolimod POS N
dose POS N
and POS N
female POS N
sex. POS N

Multivariate POS N
analyses POS N
showed POS N
that POS N
≥2-fold POS N
ISG15 POS N
induction POS N
is POS N
associated POS N
with POS N
2- POS N
or POS N
4-mg POS N
vesatolimod POS N
dose POS N
and POS N
female POS N
sex. POS N

Vesatolimod POS N
was POS N
safe POS N
and POS N
well-tolerated POS N
in POS N
patients POS N
with POS N
CHB, POS N
demonstrating POS N
consistent POS N
dose-dependent POS N
pharmacodynamic POS N
induction POS N
of POS N
ISG15 POS N
without POS N
significant POS N
systemic POS N
induction POS N
of POS N
IFNα POS N
expression POS N
or POS N
related POS N
symptoms. POS N

Multivariate POS N
analyses POS N
showed POS N
that POS N
≥2-fold POS N
ISG15 POS N
induction POS N
is POS N
associated POS N
with POS N
2- POS N
or POS N
4-mg POS N
vesatolimod POS N
dose POS N
and POS N
female POS N
sex. POS N

Most POS N
(41-80%) POS N
experienced POS N
≥1 POS N
AE POS N
during POS N
the POS N
study POS N
with POS N
the POS N
majority POS N
of POS N
AEs POS N
mild POS N
or POS N
moderate POS N
in POS N
severity. POS N

Multivariate POS N
analyses POS N
showed POS N
that POS N
≥2-fold POS N
ISG15 POS N
induction POS N
is POS N
associated POS N
with POS N
2- POS N
or POS N
4-mg POS N
vesatolimod POS N
dose POS N
and POS N
female POS N
sex. POS N

No POS N
significant POS N
declines POS N
in POS N
HBsAg POS N
were POS N
observed POS N
at POS N
the POS N
primary POS N
(Week POS N
24) POS N
or POS N
secondary POS N
endpoints POS N
(Weeks POS N
4, POS N
8, POS N
12, POS N
and POS N
48). POS N

Multivariate POS N
analyses POS N
showed POS N
that POS N
≥2-fold POS N
ISG15 POS N
induction POS N
is POS N
associated POS N
with POS N
2- POS N
or POS N
4-mg POS N
vesatolimod POS N
dose POS N
and POS N
female POS N
sex. POS N

ISG15 POS N
induction POS N
was POS N
dose-dependent POS N
and POS N
consistent POS N
after POS N
repeat POS N
dosing, POS N
returning POS N
closer POS N
to POS N
baseline POS N
by POS N
one POS N
week POS N
after POS N
treatment POS N
at POS N
all POS N
dose POS N
levels; POS N

Multivariate POS N
analyses POS N
showed POS N
that POS N
≥2-fold POS N
ISG15 POS N
induction POS N
is POS N
associated POS N
with POS N
2- POS N
or POS N
4-mg POS N
vesatolimod POS N
dose POS N
and POS N
female POS N
sex. POS N

no POS N
patient POS N
demonstrated POS N
significant POS N
serum POS N
interferon POS N
alpha POS N
(IFNα) POS N
expression POS N
at POS N
any POS N
timepoint POS N
evaluated. POS N

Transfusion-free POS N
(P POS N
=.0012) POS N
survival POS N
and POS N
transfusion- POS N
and POS N
severe POS N
anemia-free POS N
survival POS N
(P POS N
=.0001) POS N
were POS N
significantly POS N
greater POS N
in POS N
the POS N
epoetin POS N
beta POS N
group POS N
versus POS N
placebo POS N
(Wald POS N
chi(2) POS N
test), POS N
giving POS N
a POS N
relative POS N
risk POS N
reduction POS N
of POS N
43% POS N
and POS N
51%, POS N
respectively. POS N

The POS N
response POS N
rate POS N
was POS N
67% POS N
and POS N
27% POS N
in POS N
the POS N
epoetin POS N
beta POS N
versus POS N
the POS N
placebo POS N
group, POS N
respectively POS N
(P POS N
<.0001). POS N

Transfusion-free POS N
(P POS N
=.0012) POS N
survival POS N
and POS N
transfusion- POS N
and POS N
severe POS N
anemia-free POS N
survival POS N
(P POS N
=.0001) POS N
were POS N
significantly POS N
greater POS N
in POS N
the POS N
epoetin POS N
beta POS N
group POS N
versus POS N
placebo POS N
(Wald POS N
chi(2) POS N
test), POS N
giving POS N
a POS N
relative POS N
risk POS N
reduction POS N
of POS N
43% POS N
and POS N
51%, POS N
respectively. POS N

After POS N
12 POS N
and POS N
16 POS N
weeks POS N
of POS N
treatment, POS N
QOL POS N
significantly POS N
improved POS N
in POS N
the POS N
epoetin POS N
beta POS N
group POS N
compared POS N
with POS N
placebo POS N
(P POS N
<.05); POS N

Transfusion-free POS N
(P POS N
=.0012) POS N
survival POS N
and POS N
transfusion- POS N
and POS N
severe POS N
anemia-free POS N
survival POS N
(P POS N
=.0001) POS N
were POS N
significantly POS N
greater POS N
in POS N
the POS N
epoetin POS N
beta POS N
group POS N
versus POS N
placebo POS N
(Wald POS N
chi(2) POS N
test), POS N
giving POS N
a POS N
relative POS N
risk POS N
reduction POS N
of POS N
43% POS N
and POS N
51%, POS N
respectively. POS N

this POS N
improvement POS N
correlated POS N
with POS N
an POS N
increase POS N
in POS N
Hb POS N
concentration POS N
(> POS N
or POS N
= POS N
2 POS N
g/dL). POS N

Transfusion-free POS N
(P POS N
=.0012) POS N
survival POS N
and POS N
transfusion- POS N
and POS N
severe POS N
anemia-free POS N
survival POS N
(P POS N
=.0001) POS N
were POS N
significantly POS N
greater POS N
in POS N
the POS N
epoetin POS N
beta POS N
group POS N
versus POS N
placebo POS N
(Wald POS N
chi(2) POS N
test), POS N
giving POS N
a POS N
relative POS N
risk POS N
reduction POS N
of POS N
43% POS N
and POS N
51%, POS N
respectively. POS N

Many POS N
severely POS N
anemic POS N
and POS N
transfusion-dependent POS N
patients POS N
with POS N
advanced POS N
MM, POS N
NHL, POS N
and POS N
CLL POS N
and POS N
a POS N
low POS N
performance POS N
status POS N
benefited POS N
from POS N
epoetin POS N
therapy, POS N
with POS N
elimination POS N
of POS N
severe POS N
anemia POS N
and POS N
transfusion POS N
need, POS N
and POS N
improvement POS N
in POS N
QOL. POS N

The POS N
response POS N
rate POS N
was POS N
67% POS N
and POS N
27% POS N
in POS N
the POS N
epoetin POS N
beta POS N
versus POS N
the POS N
placebo POS N
group, POS N
respectively POS N
(P POS N
<.0001). POS N

Transfusion-free POS N
(P POS N
=.0012) POS N
survival POS N
and POS N
transfusion- POS N
and POS N
severe POS N
anemia-free POS N
survival POS N
(P POS N
=.0001) POS N
were POS N
significantly POS N
greater POS N
in POS N
the POS N
epoetin POS N
beta POS N
group POS N
versus POS N
placebo POS N
(Wald POS N
chi(2) POS N
test), POS N
giving POS N
a POS N
relative POS N
risk POS N
reduction POS N
of POS N
43% POS N
and POS N
51%, POS N
respectively. POS N

The POS N
response POS N
rate POS N
was POS N
67% POS N
and POS N
27% POS N
in POS N
the POS N
epoetin POS N
beta POS N
versus POS N
the POS N
placebo POS N
group, POS N
respectively POS N
(P POS N
<.0001). POS N

After POS N
12 POS N
and POS N
16 POS N
weeks POS N
of POS N
treatment, POS N
QOL POS N
significantly POS N
improved POS N
in POS N
the POS N
epoetin POS N
beta POS N
group POS N
compared POS N
with POS N
placebo POS N
(P POS N
<.05); POS N

The POS N
response POS N
rate POS N
was POS N
67% POS N
and POS N
27% POS N
in POS N
the POS N
epoetin POS N
beta POS N
versus POS N
the POS N
placebo POS N
group, POS N
respectively POS N
(P POS N
<.0001). POS N

this POS N
improvement POS N
correlated POS N
with POS N
an POS N
increase POS N
in POS N
Hb POS N
concentration POS N
(> POS N
or POS N
= POS N
2 POS N
g/dL). POS N

The POS N
response POS N
rate POS N
was POS N
67% POS N
and POS N
27% POS N
in POS N
the POS N
epoetin POS N
beta POS N
versus POS N
the POS N
placebo POS N
group, POS N
respectively POS N
(P POS N
<.0001). POS N

Many POS N
severely POS N
anemic POS N
and POS N
transfusion-dependent POS N
patients POS N
with POS N
advanced POS N
MM, POS N
NHL, POS N
and POS N
CLL POS N
and POS N
a POS N
low POS N
performance POS N
status POS N
benefited POS N
from POS N
epoetin POS N
therapy, POS N
with POS N
elimination POS N
of POS N
severe POS N
anemia POS N
and POS N
transfusion POS N
need, POS N
and POS N
improvement POS N
in POS N
QOL. POS N

After POS N
12 POS N
and POS N
16 POS N
weeks POS N
of POS N
treatment, POS N
QOL POS N
significantly POS N
improved POS N
in POS N
the POS N
epoetin POS N
beta POS N
group POS N
compared POS N
with POS N
placebo POS N
(P POS N
<.05); POS N

Transfusion-free POS N
(P POS N
=.0012) POS N
survival POS N
and POS N
transfusion- POS N
and POS N
severe POS N
anemia-free POS N
survival POS N
(P POS N
=.0001) POS N
were POS N
significantly POS N
greater POS N
in POS N
the POS N
epoetin POS N
beta POS N
group POS N
versus POS N
placebo POS N
(Wald POS N
chi(2) POS N
test), POS N
giving POS N
a POS N
relative POS N
risk POS N
reduction POS N
of POS N
43% POS N
and POS N
51%, POS N
respectively. POS N

After POS N
12 POS N
and POS N
16 POS N
weeks POS N
of POS N
treatment, POS N
QOL POS N
significantly POS N
improved POS N
in POS N
the POS N
epoetin POS N
beta POS N
group POS N
compared POS N
with POS N
placebo POS N
(P POS N
<.05); POS N

The POS N
response POS N
rate POS N
was POS N
67% POS N
and POS N
27% POS N
in POS N
the POS N
epoetin POS N
beta POS N
versus POS N
the POS N
placebo POS N
group, POS N
respectively POS N
(P POS N
<.0001). POS N

After POS N
12 POS N
and POS N
16 POS N
weeks POS N
of POS N
treatment, POS N
QOL POS N
significantly POS N
improved POS N
in POS N
the POS N
epoetin POS N
beta POS N
group POS N
compared POS N
with POS N
placebo POS N
(P POS N
<.05); POS N

this POS N
improvement POS N
correlated POS N
with POS N
an POS N
increase POS N
in POS N
Hb POS N
concentration POS N
(> POS N
or POS N
= POS N
2 POS N
g/dL). POS N

After POS N
12 POS N
and POS N
16 POS N
weeks POS N
of POS N
treatment, POS N
QOL POS N
significantly POS N
improved POS N
in POS N
the POS N
epoetin POS N
beta POS N
group POS N
compared POS N
with POS N
placebo POS N
(P POS N
<.05); POS N

Many POS N
severely POS N
anemic POS N
and POS N
transfusion-dependent POS N
patients POS N
with POS N
advanced POS N
MM, POS N
NHL, POS N
and POS N
CLL POS N
and POS N
a POS N
low POS N
performance POS N
status POS N
benefited POS N
from POS N
epoetin POS N
therapy, POS N
with POS N
elimination POS N
of POS N
severe POS N
anemia POS N
and POS N
transfusion POS N
need, POS N
and POS N
improvement POS N
in POS N
QOL. POS N

this POS N
improvement POS N
correlated POS N
with POS N
an POS N
increase POS N
in POS N
Hb POS N
concentration POS N
(> POS N
or POS N
= POS N
2 POS N
g/dL). POS N

Transfusion-free POS N
(P POS N
=.0012) POS N
survival POS N
and POS N
transfusion- POS N
and POS N
severe POS N
anemia-free POS N
survival POS N
(P POS N
=.0001) POS N
were POS N
significantly POS N
greater POS N
in POS N
the POS N
epoetin POS N
beta POS N
group POS N
versus POS N
placebo POS N
(Wald POS N
chi(2) POS N
test), POS N
giving POS N
a POS N
relative POS N
risk POS N
reduction POS N
of POS N
43% POS N
and POS N
51%, POS N
respectively. POS N

this POS N
improvement POS N
correlated POS N
with POS N
an POS N
increase POS N
in POS N
Hb POS N
concentration POS N
(> POS N
or POS N
= POS N
2 POS N
g/dL). POS N

The POS N
response POS N
rate POS N
was POS N
67% POS N
and POS N
27% POS N
in POS N
the POS N
epoetin POS N
beta POS N
versus POS N
the POS N
placebo POS N
group, POS N
respectively POS N
(P POS N
<.0001). POS N

this POS N
improvement POS N
correlated POS N
with POS N
an POS N
increase POS N
in POS N
Hb POS N
concentration POS N
(> POS N
or POS N
= POS N
2 POS N
g/dL). POS N

After POS N
12 POS N
and POS N
16 POS N
weeks POS N
of POS N
treatment, POS N
QOL POS N
significantly POS N
improved POS N
in POS N
the POS N
epoetin POS N
beta POS N
group POS N
compared POS N
with POS N
placebo POS N
(P POS N
<.05); POS N

this POS N
improvement POS N
correlated POS N
with POS N
an POS N
increase POS N
in POS N
Hb POS N
concentration POS N
(> POS N
or POS N
= POS N
2 POS N
g/dL). POS N

Many POS N
severely POS N
anemic POS N
and POS N
transfusion-dependent POS N
patients POS N
with POS N
advanced POS N
MM, POS N
NHL, POS N
and POS N
CLL POS N
and POS N
a POS N
low POS N
performance POS N
status POS N
benefited POS N
from POS N
epoetin POS N
therapy, POS N
with POS N
elimination POS N
of POS N
severe POS N
anemia POS N
and POS N
transfusion POS N
need, POS N
and POS N
improvement POS N
in POS N
QOL. POS N

Many POS N
severely POS N
anemic POS N
and POS N
transfusion-dependent POS N
patients POS N
with POS N
advanced POS N
MM, POS N
NHL, POS N
and POS N
CLL POS N
and POS N
a POS N
low POS N
performance POS N
status POS N
benefited POS N
from POS N
epoetin POS N
therapy, POS N
with POS N
elimination POS N
of POS N
severe POS N
anemia POS N
and POS N
transfusion POS N
need, POS N
and POS N
improvement POS N
in POS N
QOL. POS N

Transfusion-free POS N
(P POS N
=.0012) POS N
survival POS N
and POS N
transfusion- POS N
and POS N
severe POS N
anemia-free POS N
survival POS N
(P POS N
=.0001) POS N
were POS N
significantly POS N
greater POS N
in POS N
the POS N
epoetin POS N
beta POS N
group POS N
versus POS N
placebo POS N
(Wald POS N
chi(2) POS N
test), POS N
giving POS N
a POS N
relative POS N
risk POS N
reduction POS N
of POS N
43% POS N
and POS N
51%, POS N
respectively. POS N

Many POS N
severely POS N
anemic POS N
and POS N
transfusion-dependent POS N
patients POS N
with POS N
advanced POS N
MM, POS N
NHL, POS N
and POS N
CLL POS N
and POS N
a POS N
low POS N
performance POS N
status POS N
benefited POS N
from POS N
epoetin POS N
therapy, POS N
with POS N
elimination POS N
of POS N
severe POS N
anemia POS N
and POS N
transfusion POS N
need, POS N
and POS N
improvement POS N
in POS N
QOL. POS N

The POS N
response POS N
rate POS N
was POS N
67% POS N
and POS N
27% POS N
in POS N
the POS N
epoetin POS N
beta POS N
versus POS N
the POS N
placebo POS N
group, POS N
respectively POS N
(P POS N
<.0001). POS N

Many POS N
severely POS N
anemic POS N
and POS N
transfusion-dependent POS N
patients POS N
with POS N
advanced POS N
MM, POS N
NHL, POS N
and POS N
CLL POS N
and POS N
a POS N
low POS N
performance POS N
status POS N
benefited POS N
from POS N
epoetin POS N
therapy, POS N
with POS N
elimination POS N
of POS N
severe POS N
anemia POS N
and POS N
transfusion POS N
need, POS N
and POS N
improvement POS N
in POS N
QOL. POS N

After POS N
12 POS N
and POS N
16 POS N
weeks POS N
of POS N
treatment, POS N
QOL POS N
significantly POS N
improved POS N
in POS N
the POS N
epoetin POS N
beta POS N
group POS N
compared POS N
with POS N
placebo POS N
(P POS N
<.05); POS N

Many POS N
severely POS N
anemic POS N
and POS N
transfusion-dependent POS N
patients POS N
with POS N
advanced POS N
MM, POS N
NHL, POS N
and POS N
CLL POS N
and POS N
a POS N
low POS N
performance POS N
status POS N
benefited POS N
from POS N
epoetin POS N
therapy, POS N
with POS N
elimination POS N
of POS N
severe POS N
anemia POS N
and POS N
transfusion POS N
need, POS N
and POS N
improvement POS N
in POS N
QOL. POS N

this POS N
improvement POS N
correlated POS N
with POS N
an POS N
increase POS N
in POS N
Hb POS N
concentration POS N
(> POS N
or POS N
= POS N
2 POS N
g/dL). POS N

Compared POS N
with POS N
metformin, POS N
COC POS N
plus POS N
spironolactone POS N
caused POS N
larger POS N
decreases POS N
in POS N
hirsutism POS N
score POS N
(mean POS N
difference POS N
4.6 POS N
points, POS N
95% POS N
CI: POS N
2.6-6.7), POS N
total POS N
testosterone POS N
(1.1 nmol/L, POS N
0.4-1.7), POS N
free POS N
testosterone POS N
(25 pmol/L, POS N
12-39), POS N
androstenedione POS N
(5.5 nmol/L, POS N
1.8-9.2) POS N
and POS N
dehydroepiandrosterone POS N
sulfate POS N
(2.7 μmol/L, POS N
1.4-4.0). POS N

Menstrual POS N
dysfunction POS N
was POS N
less POS N
frequent POS N
with POS N
COC POS N
plus POS N
spironolactone POS N
(OR: POS N
0.06, POS N
95% POS N
CI: POS N
0.02-0.23). POS N

Compared POS N
with POS N
metformin, POS N
COC POS N
plus POS N
spironolactone POS N
caused POS N
larger POS N
decreases POS N
in POS N
hirsutism POS N
score POS N
(mean POS N
difference POS N
4.6 POS N
points, POS N
95% POS N
CI: POS N
2.6-6.7), POS N
total POS N
testosterone POS N
(1.1 nmol/L, POS N
0.4-1.7), POS N
free POS N
testosterone POS N
(25 pmol/L, POS N
12-39), POS N
androstenedione POS N
(5.5 nmol/L, POS N
1.8-9.2) POS N
and POS N
dehydroepiandrosterone POS N
sulfate POS N
(2.7 μmol/L, POS N
1.4-4.0). POS N

No POS N
differences POS N
were POS N
found POS N
in POS N
frequencies POS N
of POS N
abnormal POS N
glucose POS N
tolerance POS N
(OR: POS N
1.7, POS N
95% POS N
CI: POS N
0.7-4.4), POS N
dyslipidemia POS N
(OR: POS N
0.6, POS N
95% POS N
CI: POS N
0.2-1.8) POS N
or POS N
hypertension POS N
(OR: POS N
0.3, POS N
95% POS N
CI: POS N
0.5-2.0). POS N

Compared POS N
with POS N
metformin, POS N
COC POS N
plus POS N
spironolactone POS N
caused POS N
larger POS N
decreases POS N
in POS N
hirsutism POS N
score POS N
(mean POS N
difference POS N
4.6 POS N
points, POS N
95% POS N
CI: POS N
2.6-6.7), POS N
total POS N
testosterone POS N
(1.1 nmol/L, POS N
0.4-1.7), POS N
free POS N
testosterone POS N
(25 pmol/L, POS N
12-39), POS N
androstenedione POS N
(5.5 nmol/L, POS N
1.8-9.2) POS N
and POS N
dehydroepiandrosterone POS N
sulfate POS N
(2.7 μmol/L, POS N
1.4-4.0). POS N

No POS N
major POS N
adverse POS N
events POS N
occurred POS N
and POS N
biochemical POS N
markers POS N
were POS N
similarly POS N
safe POS N
with POS N
both POS N
treatments. POS N

Compared POS N
with POS N
metformin, POS N
COC POS N
plus POS N
spironolactone POS N
caused POS N
larger POS N
decreases POS N
in POS N
hirsutism POS N
score POS N
(mean POS N
difference POS N
4.6 POS N
points, POS N
95% POS N
CI: POS N
2.6-6.7), POS N
total POS N
testosterone POS N
(1.1 nmol/L, POS N
0.4-1.7), POS N
free POS N
testosterone POS N
(25 pmol/L, POS N
12-39), POS N
androstenedione POS N
(5.5 nmol/L, POS N
1.8-9.2) POS N
and POS N
dehydroepiandrosterone POS N
sulfate POS N
(2.7 μmol/L, POS N
1.4-4.0). POS N

COC POS N
plus POS N
spironolactone POS N
was POS N
more POS N
effective POS N
than POS N
metformin POS N
for POS N
symptoms POS N
of POS N
PCOS POS N
showing POS N
similar POS N
safety POS N
and POS N
overall POS N
neutral POS N
effects POS N
on POS N
cardiometabolic POS N
risk POS N
factors. POS N

Menstrual POS N
dysfunction POS N
was POS N
less POS N
frequent POS N
with POS N
COC POS N
plus POS N
spironolactone POS N
(OR: POS N
0.06, POS N
95% POS N
CI: POS N
0.02-0.23). POS N

Compared POS N
with POS N
metformin, POS N
COC POS N
plus POS N
spironolactone POS N
caused POS N
larger POS N
decreases POS N
in POS N
hirsutism POS N
score POS N
(mean POS N
difference POS N
4.6 POS N
points, POS N
95% POS N
CI: POS N
2.6-6.7), POS N
total POS N
testosterone POS N
(1.1 nmol/L, POS N
0.4-1.7), POS N
free POS N
testosterone POS N
(25 pmol/L, POS N
12-39), POS N
androstenedione POS N
(5.5 nmol/L, POS N
1.8-9.2) POS N
and POS N
dehydroepiandrosterone POS N
sulfate POS N
(2.7 μmol/L, POS N
1.4-4.0). POS N

Menstrual POS N
dysfunction POS N
was POS N
less POS N
frequent POS N
with POS N
COC POS N
plus POS N
spironolactone POS N
(OR: POS N
0.06, POS N
95% POS N
CI: POS N
0.02-0.23). POS N

No POS N
differences POS N
were POS N
found POS N
in POS N
frequencies POS N
of POS N
abnormal POS N
glucose POS N
tolerance POS N
(OR: POS N
1.7, POS N
95% POS N
CI: POS N
0.7-4.4), POS N
dyslipidemia POS N
(OR: POS N
0.6, POS N
95% POS N
CI: POS N
0.2-1.8) POS N
or POS N
hypertension POS N
(OR: POS N
0.3, POS N
95% POS N
CI: POS N
0.5-2.0). POS N

Menstrual POS N
dysfunction POS N
was POS N
less POS N
frequent POS N
with POS N
COC POS N
plus POS N
spironolactone POS N
(OR: POS N
0.06, POS N
95% POS N
CI: POS N
0.02-0.23). POS N

No POS N
major POS N
adverse POS N
events POS N
occurred POS N
and POS N
biochemical POS N
markers POS N
were POS N
similarly POS N
safe POS N
with POS N
both POS N
treatments. POS N

Menstrual POS N
dysfunction POS N
was POS N
less POS N
frequent POS N
with POS N
COC POS N
plus POS N
spironolactone POS N
(OR: POS N
0.06, POS N
95% POS N
CI: POS N
0.02-0.23). POS N

COC POS N
plus POS N
spironolactone POS N
was POS N
more POS N
effective POS N
than POS N
metformin POS N
for POS N
symptoms POS N
of POS N
PCOS POS N
showing POS N
similar POS N
safety POS N
and POS N
overall POS N
neutral POS N
effects POS N
on POS N
cardiometabolic POS N
risk POS N
factors. POS N

No POS N
differences POS N
were POS N
found POS N
in POS N
frequencies POS N
of POS N
abnormal POS N
glucose POS N
tolerance POS N
(OR: POS N
1.7, POS N
95% POS N
CI: POS N
0.7-4.4), POS N
dyslipidemia POS N
(OR: POS N
0.6, POS N
95% POS N
CI: POS N
0.2-1.8) POS N
or POS N
hypertension POS N
(OR: POS N
0.3, POS N
95% POS N
CI: POS N
0.5-2.0). POS N

Compared POS N
with POS N
metformin, POS N
COC POS N
plus POS N
spironolactone POS N
caused POS N
larger POS N
decreases POS N
in POS N
hirsutism POS N
score POS N
(mean POS N
difference POS N
4.6 POS N
points, POS N
95% POS N
CI: POS N
2.6-6.7), POS N
total POS N
testosterone POS N
(1.1 nmol/L, POS N
0.4-1.7), POS N
free POS N
testosterone POS N
(25 pmol/L, POS N
12-39), POS N
androstenedione POS N
(5.5 nmol/L, POS N
1.8-9.2) POS N
and POS N
dehydroepiandrosterone POS N
sulfate POS N
(2.7 μmol/L, POS N
1.4-4.0). POS N

No POS N
differences POS N
were POS N
found POS N
in POS N
frequencies POS N
of POS N
abnormal POS N
glucose POS N
tolerance POS N
(OR: POS N
1.7, POS N
95% POS N
CI: POS N
0.7-4.4), POS N
dyslipidemia POS N
(OR: POS N
0.6, POS N
95% POS N
CI: POS N
0.2-1.8) POS N
or POS N
hypertension POS N
(OR: POS N
0.3, POS N
95% POS N
CI: POS N
0.5-2.0). POS N

Menstrual POS N
dysfunction POS N
was POS N
less POS N
frequent POS N
with POS N
COC POS N
plus POS N
spironolactone POS N
(OR: POS N
0.06, POS N
95% POS N
CI: POS N
0.02-0.23). POS N

No POS N
differences POS N
were POS N
found POS N
in POS N
frequencies POS N
of POS N
abnormal POS N
glucose POS N
tolerance POS N
(OR: POS N
1.7, POS N
95% POS N
CI: POS N
0.7-4.4), POS N
dyslipidemia POS N
(OR: POS N
0.6, POS N
95% POS N
CI: POS N
0.2-1.8) POS N
or POS N
hypertension POS N
(OR: POS N
0.3, POS N
95% POS N
CI: POS N
0.5-2.0). POS N

No POS N
major POS N
adverse POS N
events POS N
occurred POS N
and POS N
biochemical POS N
markers POS N
were POS N
similarly POS N
safe POS N
with POS N
both POS N
treatments. POS N

No POS N
differences POS N
were POS N
found POS N
in POS N
frequencies POS N
of POS N
abnormal POS N
glucose POS N
tolerance POS N
(OR: POS N
1.7, POS N
95% POS N
CI: POS N
0.7-4.4), POS N
dyslipidemia POS N
(OR: POS N
0.6, POS N
95% POS N
CI: POS N
0.2-1.8) POS N
or POS N
hypertension POS N
(OR: POS N
0.3, POS N
95% POS N
CI: POS N
0.5-2.0). POS N

COC POS N
plus POS N
spironolactone POS N
was POS N
more POS N
effective POS N
than POS N
metformin POS N
for POS N
symptoms POS N
of POS N
PCOS POS N
showing POS N
similar POS N
safety POS N
and POS N
overall POS N
neutral POS N
effects POS N
on POS N
cardiometabolic POS N
risk POS N
factors. POS N

No POS N
major POS N
adverse POS N
events POS N
occurred POS N
and POS N
biochemical POS N
markers POS N
were POS N
similarly POS N
safe POS N
with POS N
both POS N
treatments. POS N

Compared POS N
with POS N
metformin, POS N
COC POS N
plus POS N
spironolactone POS N
caused POS N
larger POS N
decreases POS N
in POS N
hirsutism POS N
score POS N
(mean POS N
difference POS N
4.6 POS N
points, POS N
95% POS N
CI: POS N
2.6-6.7), POS N
total POS N
testosterone POS N
(1.1 nmol/L, POS N
0.4-1.7), POS N
free POS N
testosterone POS N
(25 pmol/L, POS N
12-39), POS N
androstenedione POS N
(5.5 nmol/L, POS N
1.8-9.2) POS N
and POS N
dehydroepiandrosterone POS N
sulfate POS N
(2.7 μmol/L, POS N
1.4-4.0). POS N

No POS N
major POS N
adverse POS N
events POS N
occurred POS N
and POS N
biochemical POS N
markers POS N
were POS N
similarly POS N
safe POS N
with POS N
both POS N
treatments. POS N

Menstrual POS N
dysfunction POS N
was POS N
less POS N
frequent POS N
with POS N
COC POS N
plus POS N
spironolactone POS N
(OR: POS N
0.06, POS N
95% POS N
CI: POS N
0.02-0.23). POS N

No POS N
major POS N
adverse POS N
events POS N
occurred POS N
and POS N
biochemical POS N
markers POS N
were POS N
similarly POS N
safe POS N
with POS N
both POS N
treatments. POS N

No POS N
differences POS N
were POS N
found POS N
in POS N
frequencies POS N
of POS N
abnormal POS N
glucose POS N
tolerance POS N
(OR: POS N
1.7, POS N
95% POS N
CI: POS N
0.7-4.4), POS N
dyslipidemia POS N
(OR: POS N
0.6, POS N
95% POS N
CI: POS N
0.2-1.8) POS N
or POS N
hypertension POS N
(OR: POS N
0.3, POS N
95% POS N
CI: POS N
0.5-2.0). POS N

No POS N
major POS N
adverse POS N
events POS N
occurred POS N
and POS N
biochemical POS N
markers POS N
were POS N
similarly POS N
safe POS N
with POS N
both POS N
treatments. POS N

COC POS N
plus POS N
spironolactone POS N
was POS N
more POS N
effective POS N
than POS N
metformin POS N
for POS N
symptoms POS N
of POS N
PCOS POS N
showing POS N
similar POS N
safety POS N
and POS N
overall POS N
neutral POS N
effects POS N
on POS N
cardiometabolic POS N
risk POS N
factors. POS N

COC POS N
plus POS N
spironolactone POS N
was POS N
more POS N
effective POS N
than POS N
metformin POS N
for POS N
symptoms POS N
of POS N
PCOS POS N
showing POS N
similar POS N
safety POS N
and POS N
overall POS N
neutral POS N
effects POS N
on POS N
cardiometabolic POS N
risk POS N
factors. POS N

Compared POS N
with POS N
metformin, POS N
COC POS N
plus POS N
spironolactone POS N
caused POS N
larger POS N
decreases POS N
in POS N
hirsutism POS N
score POS N
(mean POS N
difference POS N
4.6 POS N
points, POS N
95% POS N
CI: POS N
2.6-6.7), POS N
total POS N
testosterone POS N
(1.1 nmol/L, POS N
0.4-1.7), POS N
free POS N
testosterone POS N
(25 pmol/L, POS N
12-39), POS N
androstenedione POS N
(5.5 nmol/L, POS N
1.8-9.2) POS N
and POS N
dehydroepiandrosterone POS N
sulfate POS N
(2.7 μmol/L, POS N
1.4-4.0). POS N

COC POS N
plus POS N
spironolactone POS N
was POS N
more POS N
effective POS N
than POS N
metformin POS N
for POS N
symptoms POS N
of POS N
PCOS POS N
showing POS N
similar POS N
safety POS N
and POS N
overall POS N
neutral POS N
effects POS N
on POS N
cardiometabolic POS N
risk POS N
factors. POS N

Menstrual POS N
dysfunction POS N
was POS N
less POS N
frequent POS N
with POS N
COC POS N
plus POS N
spironolactone POS N
(OR: POS N
0.06, POS N
95% POS N
CI: POS N
0.02-0.23). POS N

COC POS N
plus POS N
spironolactone POS N
was POS N
more POS N
effective POS N
than POS N
metformin POS N
for POS N
symptoms POS N
of POS N
PCOS POS N
showing POS N
similar POS N
safety POS N
and POS N
overall POS N
neutral POS N
effects POS N
on POS N
cardiometabolic POS N
risk POS N
factors. POS N

No POS N
differences POS N
were POS N
found POS N
in POS N
frequencies POS N
of POS N
abnormal POS N
glucose POS N
tolerance POS N
(OR: POS N
1.7, POS N
95% POS N
CI: POS N
0.7-4.4), POS N
dyslipidemia POS N
(OR: POS N
0.6, POS N
95% POS N
CI: POS N
0.2-1.8) POS N
or POS N
hypertension POS N
(OR: POS N
0.3, POS N
95% POS N
CI: POS N
0.5-2.0). POS N

COC POS N
plus POS N
spironolactone POS N
was POS N
more POS N
effective POS N
than POS N
metformin POS N
for POS N
symptoms POS N
of POS N
PCOS POS N
showing POS N
similar POS N
safety POS N
and POS N
overall POS N
neutral POS N
effects POS N
on POS N
cardiometabolic POS N
risk POS N
factors. POS N

No POS N
major POS N
adverse POS N
events POS N
occurred POS N
and POS N
biochemical POS N
markers POS N
were POS N
similarly POS N
safe POS N
with POS N
both POS N
treatments. POS N

There POS N
were POS N
no POS N
obvious POS N
differences POS N
in POS N
the POS N
normalization POS N
rate POS N
of POS N
ALT, POS N
negative POS N
conversion POS N
rate POS N
of POS N
HBV POS N
DNA POS N
and POS N
HBeAg, POS N
as POS N
well POS N
as POS N
improvement POS N
in POS N
Child-Pugh POS N
scores POS N
among POS N
the POS N
combination POS N
therapy POS N
group, POS N
12-week POS N
optimized POS N
therapy POS N
group, POS N
and POS N
ETV POS N
monotherapy POS N
group. POS N

For POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group, POS N
only POS N
ALT POS N
levels POS N
revealed POS N
a POS N
significant POS N
improvement. POS N

There POS N
were POS N
no POS N
obvious POS N
differences POS N
in POS N
the POS N
normalization POS N
rate POS N
of POS N
ALT, POS N
negative POS N
conversion POS N
rate POS N
of POS N
HBV POS N
DNA POS N
and POS N
HBeAg, POS N
as POS N
well POS N
as POS N
improvement POS N
in POS N
Child-Pugh POS N
scores POS N
among POS N
the POS N
combination POS N
therapy POS N
group, POS N
12-week POS N
optimized POS N
therapy POS N
group, POS N
and POS N
ETV POS N
monotherapy POS N
group. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment, POS N
the POS N
level POS N
of POS N
alanine POS N
amino-transferase POS N
(ALT), POS N
albumin POS N
(ALB) POS N
and POS N
total POS N
bilirubin POS N
(TBIL) POS N
in POS N
the POS N
combination POS N
therapy POS N
group POS N
and POS N
12-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significantly POS N
improved. POS N

There POS N
were POS N
no POS N
obvious POS N
differences POS N
in POS N
the POS N
normalization POS N
rate POS N
of POS N
ALT, POS N
negative POS N
conversion POS N
rate POS N
of POS N
HBV POS N
DNA POS N
and POS N
HBeAg, POS N
as POS N
well POS N
as POS N
improvement POS N
in POS N
Child-Pugh POS N
scores POS N
among POS N
the POS N
combination POS N
therapy POS N
group, POS N
12-week POS N
optimized POS N
therapy POS N
group, POS N
and POS N
ETV POS N
monotherapy POS N
group. POS N

However, POS N
the POS N
difference POS N
among POS N
these POS N
three POS N
groups POS N
and POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significant. POS N

There POS N
were POS N
no POS N
obvious POS N
differences POS N
in POS N
the POS N
normalization POS N
rate POS N
of POS N
ALT, POS N
negative POS N
conversion POS N
rate POS N
of POS N
HBV POS N
DNA POS N
and POS N
HBeAg, POS N
as POS N
well POS N
as POS N
improvement POS N
in POS N
Child-Pugh POS N
scores POS N
among POS N
the POS N
combination POS N
therapy POS N
group, POS N
12-week POS N
optimized POS N
therapy POS N
group, POS N
and POS N
ETV POS N
monotherapy POS N
group. POS N

Differences POS N
were POS N
not POS N
observed POS N
in POS N
the POS N
HBeAg POS N
seroconversion POS N
between POS N
each POS N
group. POS N

There POS N
were POS N
no POS N
obvious POS N
differences POS N
in POS N
the POS N
normalization POS N
rate POS N
of POS N
ALT, POS N
negative POS N
conversion POS N
rate POS N
of POS N
HBV POS N
DNA POS N
and POS N
HBeAg, POS N
as POS N
well POS N
as POS N
improvement POS N
in POS N
Child-Pugh POS N
scores POS N
among POS N
the POS N
combination POS N
therapy POS N
group, POS N
12-week POS N
optimized POS N
therapy POS N
group, POS N
and POS N
ETV POS N
monotherapy POS N
group. POS N

Differences POS N
in POS N
blood POS N
urea POS N
nitrogen, POS N
serum POS N
creatinine, POS N
creatine POS N
kinase, POS N
or POS N
other POS N
serious POS N
adverse POS N
effects POS N
were POS N
not POS N
observed POS N
in POS N
each POS N
group POS N
at POS N
the POS N
end POS N
of POS N
the POS N
96-week POS N
treatment. POS N

There POS N
were POS N
no POS N
obvious POS N
differences POS N
in POS N
the POS N
normalization POS N
rate POS N
of POS N
ALT, POS N
negative POS N
conversion POS N
rate POS N
of POS N
HBV POS N
DNA POS N
and POS N
HBeAg, POS N
as POS N
well POS N
as POS N
improvement POS N
in POS N
Child-Pugh POS N
scores POS N
among POS N
the POS N
combination POS N
therapy POS N
group, POS N
12-week POS N
optimized POS N
therapy POS N
group, POS N
and POS N
ETV POS N
monotherapy POS N
group. POS N

Combination POS N
therapy POS N
and POS N
early POS N
ADV POS N
addition POS N
were POS N
the POS N
preferred POS N
approaches POS N
in POS N
the POS N
antiviral POS N
strategy POS N
for POS N
the POS N
treatment POS N
of POS N
hepatitis POS N
B-induced POS N
decompensated POS N
cirrhosis. POS N

For POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group, POS N
only POS N
ALT POS N
levels POS N
revealed POS N
a POS N
significant POS N
improvement. POS N

There POS N
were POS N
no POS N
obvious POS N
differences POS N
in POS N
the POS N
normalization POS N
rate POS N
of POS N
ALT, POS N
negative POS N
conversion POS N
rate POS N
of POS N
HBV POS N
DNA POS N
and POS N
HBeAg, POS N
as POS N
well POS N
as POS N
improvement POS N
in POS N
Child-Pugh POS N
scores POS N
among POS N
the POS N
combination POS N
therapy POS N
group, POS N
12-week POS N
optimized POS N
therapy POS N
group, POS N
and POS N
ETV POS N
monotherapy POS N
group. POS N

For POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group, POS N
only POS N
ALT POS N
levels POS N
revealed POS N
a POS N
significant POS N
improvement. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment, POS N
the POS N
level POS N
of POS N
alanine POS N
amino-transferase POS N
(ALT), POS N
albumin POS N
(ALB) POS N
and POS N
total POS N
bilirubin POS N
(TBIL) POS N
in POS N
the POS N
combination POS N
therapy POS N
group POS N
and POS N
12-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significantly POS N
improved. POS N

For POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group, POS N
only POS N
ALT POS N
levels POS N
revealed POS N
a POS N
significant POS N
improvement. POS N

However, POS N
the POS N
difference POS N
among POS N
these POS N
three POS N
groups POS N
and POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significant. POS N

For POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group, POS N
only POS N
ALT POS N
levels POS N
revealed POS N
a POS N
significant POS N
improvement. POS N

Differences POS N
were POS N
not POS N
observed POS N
in POS N
the POS N
HBeAg POS N
seroconversion POS N
between POS N
each POS N
group. POS N

For POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group, POS N
only POS N
ALT POS N
levels POS N
revealed POS N
a POS N
significant POS N
improvement. POS N

Differences POS N
in POS N
blood POS N
urea POS N
nitrogen, POS N
serum POS N
creatinine, POS N
creatine POS N
kinase, POS N
or POS N
other POS N
serious POS N
adverse POS N
effects POS N
were POS N
not POS N
observed POS N
in POS N
each POS N
group POS N
at POS N
the POS N
end POS N
of POS N
the POS N
96-week POS N
treatment. POS N

For POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group, POS N
only POS N
ALT POS N
levels POS N
revealed POS N
a POS N
significant POS N
improvement. POS N

Combination POS N
therapy POS N
and POS N
early POS N
ADV POS N
addition POS N
were POS N
the POS N
preferred POS N
approaches POS N
in POS N
the POS N
antiviral POS N
strategy POS N
for POS N
the POS N
treatment POS N
of POS N
hepatitis POS N
B-induced POS N
decompensated POS N
cirrhosis. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment, POS N
the POS N
level POS N
of POS N
alanine POS N
amino-transferase POS N
(ALT), POS N
albumin POS N
(ALB) POS N
and POS N
total POS N
bilirubin POS N
(TBIL) POS N
in POS N
the POS N
combination POS N
therapy POS N
group POS N
and POS N
12-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significantly POS N
improved. POS N

There POS N
were POS N
no POS N
obvious POS N
differences POS N
in POS N
the POS N
normalization POS N
rate POS N
of POS N
ALT, POS N
negative POS N
conversion POS N
rate POS N
of POS N
HBV POS N
DNA POS N
and POS N
HBeAg, POS N
as POS N
well POS N
as POS N
improvement POS N
in POS N
Child-Pugh POS N
scores POS N
among POS N
the POS N
combination POS N
therapy POS N
group, POS N
12-week POS N
optimized POS N
therapy POS N
group, POS N
and POS N
ETV POS N
monotherapy POS N
group. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment, POS N
the POS N
level POS N
of POS N
alanine POS N
amino-transferase POS N
(ALT), POS N
albumin POS N
(ALB) POS N
and POS N
total POS N
bilirubin POS N
(TBIL) POS N
in POS N
the POS N
combination POS N
therapy POS N
group POS N
and POS N
12-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significantly POS N
improved. POS N

For POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group, POS N
only POS N
ALT POS N
levels POS N
revealed POS N
a POS N
significant POS N
improvement. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment, POS N
the POS N
level POS N
of POS N
alanine POS N
amino-transferase POS N
(ALT), POS N
albumin POS N
(ALB) POS N
and POS N
total POS N
bilirubin POS N
(TBIL) POS N
in POS N
the POS N
combination POS N
therapy POS N
group POS N
and POS N
12-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significantly POS N
improved. POS N

However, POS N
the POS N
difference POS N
among POS N
these POS N
three POS N
groups POS N
and POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significant. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment, POS N
the POS N
level POS N
of POS N
alanine POS N
amino-transferase POS N
(ALT), POS N
albumin POS N
(ALB) POS N
and POS N
total POS N
bilirubin POS N
(TBIL) POS N
in POS N
the POS N
combination POS N
therapy POS N
group POS N
and POS N
12-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significantly POS N
improved. POS N

Differences POS N
were POS N
not POS N
observed POS N
in POS N
the POS N
HBeAg POS N
seroconversion POS N
between POS N
each POS N
group. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment, POS N
the POS N
level POS N
of POS N
alanine POS N
amino-transferase POS N
(ALT), POS N
albumin POS N
(ALB) POS N
and POS N
total POS N
bilirubin POS N
(TBIL) POS N
in POS N
the POS N
combination POS N
therapy POS N
group POS N
and POS N
12-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significantly POS N
improved. POS N

Differences POS N
in POS N
blood POS N
urea POS N
nitrogen, POS N
serum POS N
creatinine, POS N
creatine POS N
kinase, POS N
or POS N
other POS N
serious POS N
adverse POS N
effects POS N
were POS N
not POS N
observed POS N
in POS N
each POS N
group POS N
at POS N
the POS N
end POS N
of POS N
the POS N
96-week POS N
treatment. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment, POS N
the POS N
level POS N
of POS N
alanine POS N
amino-transferase POS N
(ALT), POS N
albumin POS N
(ALB) POS N
and POS N
total POS N
bilirubin POS N
(TBIL) POS N
in POS N
the POS N
combination POS N
therapy POS N
group POS N
and POS N
12-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significantly POS N
improved. POS N

Combination POS N
therapy POS N
and POS N
early POS N
ADV POS N
addition POS N
were POS N
the POS N
preferred POS N
approaches POS N
in POS N
the POS N
antiviral POS N
strategy POS N
for POS N
the POS N
treatment POS N
of POS N
hepatitis POS N
B-induced POS N
decompensated POS N
cirrhosis. POS N

However, POS N
the POS N
difference POS N
among POS N
these POS N
three POS N
groups POS N
and POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significant. POS N

There POS N
were POS N
no POS N
obvious POS N
differences POS N
in POS N
the POS N
normalization POS N
rate POS N
of POS N
ALT, POS N
negative POS N
conversion POS N
rate POS N
of POS N
HBV POS N
DNA POS N
and POS N
HBeAg, POS N
as POS N
well POS N
as POS N
improvement POS N
in POS N
Child-Pugh POS N
scores POS N
among POS N
the POS N
combination POS N
therapy POS N
group, POS N
12-week POS N
optimized POS N
therapy POS N
group, POS N
and POS N
ETV POS N
monotherapy POS N
group. POS N

However, POS N
the POS N
difference POS N
among POS N
these POS N
three POS N
groups POS N
and POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significant. POS N

For POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group, POS N
only POS N
ALT POS N
levels POS N
revealed POS N
a POS N
significant POS N
improvement. POS N

However, POS N
the POS N
difference POS N
among POS N
these POS N
three POS N
groups POS N
and POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significant. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment, POS N
the POS N
level POS N
of POS N
alanine POS N
amino-transferase POS N
(ALT), POS N
albumin POS N
(ALB) POS N
and POS N
total POS N
bilirubin POS N
(TBIL) POS N
in POS N
the POS N
combination POS N
therapy POS N
group POS N
and POS N
12-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significantly POS N
improved. POS N

However, POS N
the POS N
difference POS N
among POS N
these POS N
three POS N
groups POS N
and POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significant. POS N

Differences POS N
were POS N
not POS N
observed POS N
in POS N
the POS N
HBeAg POS N
seroconversion POS N
between POS N
each POS N
group. POS N

However, POS N
the POS N
difference POS N
among POS N
these POS N
three POS N
groups POS N
and POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significant. POS N

Differences POS N
in POS N
blood POS N
urea POS N
nitrogen, POS N
serum POS N
creatinine, POS N
creatine POS N
kinase, POS N
or POS N
other POS N
serious POS N
adverse POS N
effects POS N
were POS N
not POS N
observed POS N
in POS N
each POS N
group POS N
at POS N
the POS N
end POS N
of POS N
the POS N
96-week POS N
treatment. POS N

However, POS N
the POS N
difference POS N
among POS N
these POS N
three POS N
groups POS N
and POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significant. POS N

Combination POS N
therapy POS N
and POS N
early POS N
ADV POS N
addition POS N
were POS N
the POS N
preferred POS N
approaches POS N
in POS N
the POS N
antiviral POS N
strategy POS N
for POS N
the POS N
treatment POS N
of POS N
hepatitis POS N
B-induced POS N
decompensated POS N
cirrhosis. POS N

Differences POS N
were POS N
not POS N
observed POS N
in POS N
the POS N
HBeAg POS N
seroconversion POS N
between POS N
each POS N
group. POS N

There POS N
were POS N
no POS N
obvious POS N
differences POS N
in POS N
the POS N
normalization POS N
rate POS N
of POS N
ALT, POS N
negative POS N
conversion POS N
rate POS N
of POS N
HBV POS N
DNA POS N
and POS N
HBeAg, POS N
as POS N
well POS N
as POS N
improvement POS N
in POS N
Child-Pugh POS N
scores POS N
among POS N
the POS N
combination POS N
therapy POS N
group, POS N
12-week POS N
optimized POS N
therapy POS N
group, POS N
and POS N
ETV POS N
monotherapy POS N
group. POS N

Differences POS N
were POS N
not POS N
observed POS N
in POS N
the POS N
HBeAg POS N
seroconversion POS N
between POS N
each POS N
group. POS N

For POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group, POS N
only POS N
ALT POS N
levels POS N
revealed POS N
a POS N
significant POS N
improvement. POS N

Differences POS N
were POS N
not POS N
observed POS N
in POS N
the POS N
HBeAg POS N
seroconversion POS N
between POS N
each POS N
group. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment, POS N
the POS N
level POS N
of POS N
alanine POS N
amino-transferase POS N
(ALT), POS N
albumin POS N
(ALB) POS N
and POS N
total POS N
bilirubin POS N
(TBIL) POS N
in POS N
the POS N
combination POS N
therapy POS N
group POS N
and POS N
12-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significantly POS N
improved. POS N

Differences POS N
were POS N
not POS N
observed POS N
in POS N
the POS N
HBeAg POS N
seroconversion POS N
between POS N
each POS N
group. POS N

However, POS N
the POS N
difference POS N
among POS N
these POS N
three POS N
groups POS N
and POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significant. POS N

Differences POS N
were POS N
not POS N
observed POS N
in POS N
the POS N
HBeAg POS N
seroconversion POS N
between POS N
each POS N
group. POS N

Differences POS N
in POS N
blood POS N
urea POS N
nitrogen, POS N
serum POS N
creatinine, POS N
creatine POS N
kinase, POS N
or POS N
other POS N
serious POS N
adverse POS N
effects POS N
were POS N
not POS N
observed POS N
in POS N
each POS N
group POS N
at POS N
the POS N
end POS N
of POS N
the POS N
96-week POS N
treatment. POS N

Differences POS N
were POS N
not POS N
observed POS N
in POS N
the POS N
HBeAg POS N
seroconversion POS N
between POS N
each POS N
group. POS N

Combination POS N
therapy POS N
and POS N
early POS N
ADV POS N
addition POS N
were POS N
the POS N
preferred POS N
approaches POS N
in POS N
the POS N
antiviral POS N
strategy POS N
for POS N
the POS N
treatment POS N
of POS N
hepatitis POS N
B-induced POS N
decompensated POS N
cirrhosis. POS N

Differences POS N
in POS N
blood POS N
urea POS N
nitrogen, POS N
serum POS N
creatinine, POS N
creatine POS N
kinase, POS N
or POS N
other POS N
serious POS N
adverse POS N
effects POS N
were POS N
not POS N
observed POS N
in POS N
each POS N
group POS N
at POS N
the POS N
end POS N
of POS N
the POS N
96-week POS N
treatment. POS N

There POS N
were POS N
no POS N
obvious POS N
differences POS N
in POS N
the POS N
normalization POS N
rate POS N
of POS N
ALT, POS N
negative POS N
conversion POS N
rate POS N
of POS N
HBV POS N
DNA POS N
and POS N
HBeAg, POS N
as POS N
well POS N
as POS N
improvement POS N
in POS N
Child-Pugh POS N
scores POS N
among POS N
the POS N
combination POS N
therapy POS N
group, POS N
12-week POS N
optimized POS N
therapy POS N
group, POS N
and POS N
ETV POS N
monotherapy POS N
group. POS N

Differences POS N
in POS N
blood POS N
urea POS N
nitrogen, POS N
serum POS N
creatinine, POS N
creatine POS N
kinase, POS N
or POS N
other POS N
serious POS N
adverse POS N
effects POS N
were POS N
not POS N
observed POS N
in POS N
each POS N
group POS N
at POS N
the POS N
end POS N
of POS N
the POS N
96-week POS N
treatment. POS N

For POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group, POS N
only POS N
ALT POS N
levels POS N
revealed POS N
a POS N
significant POS N
improvement. POS N

Differences POS N
in POS N
blood POS N
urea POS N
nitrogen, POS N
serum POS N
creatinine, POS N
creatine POS N
kinase, POS N
or POS N
other POS N
serious POS N
adverse POS N
effects POS N
were POS N
not POS N
observed POS N
in POS N
each POS N
group POS N
at POS N
the POS N
end POS N
of POS N
the POS N
96-week POS N
treatment. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment, POS N
the POS N
level POS N
of POS N
alanine POS N
amino-transferase POS N
(ALT), POS N
albumin POS N
(ALB) POS N
and POS N
total POS N
bilirubin POS N
(TBIL) POS N
in POS N
the POS N
combination POS N
therapy POS N
group POS N
and POS N
12-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significantly POS N
improved. POS N

Differences POS N
in POS N
blood POS N
urea POS N
nitrogen, POS N
serum POS N
creatinine, POS N
creatine POS N
kinase, POS N
or POS N
other POS N
serious POS N
adverse POS N
effects POS N
were POS N
not POS N
observed POS N
in POS N
each POS N
group POS N
at POS N
the POS N
end POS N
of POS N
the POS N
96-week POS N
treatment. POS N

However, POS N
the POS N
difference POS N
among POS N
these POS N
three POS N
groups POS N
and POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significant. POS N

Differences POS N
in POS N
blood POS N
urea POS N
nitrogen, POS N
serum POS N
creatinine, POS N
creatine POS N
kinase, POS N
or POS N
other POS N
serious POS N
adverse POS N
effects POS N
were POS N
not POS N
observed POS N
in POS N
each POS N
group POS N
at POS N
the POS N
end POS N
of POS N
the POS N
96-week POS N
treatment. POS N

Differences POS N
were POS N
not POS N
observed POS N
in POS N
the POS N
HBeAg POS N
seroconversion POS N
between POS N
each POS N
group. POS N

Differences POS N
in POS N
blood POS N
urea POS N
nitrogen, POS N
serum POS N
creatinine, POS N
creatine POS N
kinase, POS N
or POS N
other POS N
serious POS N
adverse POS N
effects POS N
were POS N
not POS N
observed POS N
in POS N
each POS N
group POS N
at POS N
the POS N
end POS N
of POS N
the POS N
96-week POS N
treatment. POS N

Combination POS N
therapy POS N
and POS N
early POS N
ADV POS N
addition POS N
were POS N
the POS N
preferred POS N
approaches POS N
in POS N
the POS N
antiviral POS N
strategy POS N
for POS N
the POS N
treatment POS N
of POS N
hepatitis POS N
B-induced POS N
decompensated POS N
cirrhosis. POS N

Combination POS N
therapy POS N
and POS N
early POS N
ADV POS N
addition POS N
were POS N
the POS N
preferred POS N
approaches POS N
in POS N
the POS N
antiviral POS N
strategy POS N
for POS N
the POS N
treatment POS N
of POS N
hepatitis POS N
B-induced POS N
decompensated POS N
cirrhosis. POS N

There POS N
were POS N
no POS N
obvious POS N
differences POS N
in POS N
the POS N
normalization POS N
rate POS N
of POS N
ALT, POS N
negative POS N
conversion POS N
rate POS N
of POS N
HBV POS N
DNA POS N
and POS N
HBeAg, POS N
as POS N
well POS N
as POS N
improvement POS N
in POS N
Child-Pugh POS N
scores POS N
among POS N
the POS N
combination POS N
therapy POS N
group, POS N
12-week POS N
optimized POS N
therapy POS N
group, POS N
and POS N
ETV POS N
monotherapy POS N
group. POS N

Combination POS N
therapy POS N
and POS N
early POS N
ADV POS N
addition POS N
were POS N
the POS N
preferred POS N
approaches POS N
in POS N
the POS N
antiviral POS N
strategy POS N
for POS N
the POS N
treatment POS N
of POS N
hepatitis POS N
B-induced POS N
decompensated POS N
cirrhosis. POS N

For POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group, POS N
only POS N
ALT POS N
levels POS N
revealed POS N
a POS N
significant POS N
improvement. POS N

Combination POS N
therapy POS N
and POS N
early POS N
ADV POS N
addition POS N
were POS N
the POS N
preferred POS N
approaches POS N
in POS N
the POS N
antiviral POS N
strategy POS N
for POS N
the POS N
treatment POS N
of POS N
hepatitis POS N
B-induced POS N
decompensated POS N
cirrhosis. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
treatment, POS N
the POS N
level POS N
of POS N
alanine POS N
amino-transferase POS N
(ALT), POS N
albumin POS N
(ALB) POS N
and POS N
total POS N
bilirubin POS N
(TBIL) POS N
in POS N
the POS N
combination POS N
therapy POS N
group POS N
and POS N
12-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significantly POS N
improved. POS N

Combination POS N
therapy POS N
and POS N
early POS N
ADV POS N
addition POS N
were POS N
the POS N
preferred POS N
approaches POS N
in POS N
the POS N
antiviral POS N
strategy POS N
for POS N
the POS N
treatment POS N
of POS N
hepatitis POS N
B-induced POS N
decompensated POS N
cirrhosis. POS N

However, POS N
the POS N
difference POS N
among POS N
these POS N
three POS N
groups POS N
and POS N
the POS N
24-week POS N
optimized POS N
therapy POS N
group POS N
were POS N
significant. POS N

Combination POS N
therapy POS N
and POS N
early POS N
ADV POS N
addition POS N
were POS N
the POS N
preferred POS N
approaches POS N
in POS N
the POS N
antiviral POS N
strategy POS N
for POS N
the POS N
treatment POS N
of POS N
hepatitis POS N
B-induced POS N
decompensated POS N
cirrhosis. POS N

Differences POS N
were POS N
not POS N
observed POS N
in POS N
the POS N
HBeAg POS N
seroconversion POS N
between POS N
each POS N
group. POS N

Combination POS N
therapy POS N
and POS N
early POS N
ADV POS N
addition POS N
were POS N
the POS N
preferred POS N
approaches POS N
in POS N
the POS N
antiviral POS N
strategy POS N
for POS N
the POS N
treatment POS N
of POS N
hepatitis POS N
B-induced POS N
decompensated POS N
cirrhosis. POS N

Differences POS N
in POS N
blood POS N
urea POS N
nitrogen, POS N
serum POS N
creatinine, POS N
creatine POS N
kinase, POS N
or POS N
other POS N
serious POS N
adverse POS N
effects POS N
were POS N
not POS N
observed POS N
in POS N
each POS N
group POS N
at POS N
the POS N
end POS N
of POS N
the POS N
96-week POS N
treatment. POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

The POS N
technique POS N
of POS N
releasable POS N
sutures POS N
for POS N
trabeculectomy POS N
used POS N
in POS N
this POS N
study POS N
did POS N
not POS N
demonstrate POS N
significant POS N
advantages POS N
over POS N
standard POS N
trabeculectomy. POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

There POS N
was POS N
no POS N
difference POS N
in POS N
the POS N
occurrence POS N
of POS N
shallow POS N
chamber, POS N
choroidal POS N
detachment, POS N
macular POS N
edema, POS N
additional POS N
surgery, POS N
or POS N
hyphema POS N
(P=0.56 POS N
to POS N
1.0). POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

The POS N
incidence POS N
of POS N
transient POS N
hypotony POS N
was POS N
higher POS N
in POS N
S POS N
group POS N
(20.4%) POS N
than POS N
the POS N
R POS N
group POS N
(9.1%) POS N
(P=0.046); POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

hypotony POS N
recovered POS N
in POS N
80.8% POS N
(21/26) POS N
within POS N
1 POS N
week. POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

The POS N
IOP POS N
in POS N
the POS N
first POS N
week POS N
after POS N
trabeculectomy POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
R POS N
group: POS N
day POS N
1, POS N
17.3 POS N
± POS N
8.6 POS N
versus POS N
12.7 POS N
± POS N
6.0 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
3, POS N
18.0 POS N
± POS N
7.3 POS N
versus POS N
12.9 POS N
± POS N
6.3 POS N
mm POS N
Hg POS N
(P<0.001); POS N
day POS N
7, POS N
14.8 POS N
± POS N
6.3 POS N
versus POS N
12.0 POS N
± POS N
4.9 POS N
mm POS N
Hg POS N
(P=0.001), POS N

Releasable POS N
sutures POS N
were POS N
associated POS N
with POS N
some POS N
decrease POS N
in POS N
visual POS N
acuity POS N
and POS N
increase POS N
in POS N
postoperative POS N
complaints. POS N

no POS N
difference POS N
was POS N
observed POS N
after POS N
the POS N
second POS N
week POS N
(P=0.659 POS N
to POS N
0.753). POS N

Overall, POS N
6.6% POS N
of POS N
patients POS N
modified POS N
their POS N
initial POS N
treatment, POS N
with POS N
ETV POS N
having POS N
lower POS N
rates POS N
of POS N
treatment POS N
modification POS N
than POS N
other POS N
major POS N
NUCs POS N
(P<0.05). POS N

At POS N
week POS N
52, POS N
the POS N
virologic POS N
response POS N
rate POS N
was POS N
higher POS N
with POS N
ETV POS N
than POS N
with POS N
LAM-based POS N
treatment POS N
(77.0% POS N
versus POS N
61.4%, POS N
P<0.0001). POS N

Overall, POS N
6.6% POS N
of POS N
patients POS N
modified POS N
their POS N
initial POS N
treatment, POS N
with POS N
ETV POS N
having POS N
lower POS N
rates POS N
of POS N
treatment POS N
modification POS N
than POS N
other POS N
major POS N
NUCs POS N
(P<0.05). POS N

LAM-based POS N
treatment POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
probability POS N
of POS N
virologic POS N
breakthrough POS N
and POS N
genotypic POS N
resistance POS N
(21.4% POS N
and POS N
19.6%, POS N
respectively) POS N
than POS N
ETV POS N
(1.6% POS N
and POS N
0.1%, POS N
respectively) POS N
(P<0.0001). POS N

Overall, POS N
6.6% POS N
of POS N
patients POS N
modified POS N
their POS N
initial POS N
treatment, POS N
with POS N
ETV POS N
having POS N
lower POS N
rates POS N
of POS N
treatment POS N
modification POS N
than POS N
other POS N
major POS N
NUCs POS N
(P<0.05). POS N

Treatment-related POS N
adverse POS N
events POS N
or POS N
serious POS N
adverse POS N
events POS N
were POS N
uncommon. POS N

Overall, POS N
6.6% POS N
of POS N
patients POS N
modified POS N
their POS N
initial POS N
treatment, POS N
with POS N
ETV POS N
having POS N
lower POS N
rates POS N
of POS N
treatment POS N
modification POS N
than POS N
other POS N
major POS N
NUCs POS N
(P<0.05). POS N

Consistent POS N
with POS N
clinical POS N
trial POS N
results, POS N
ETV POS N
was POS N
more POS N
effective POS N
than POS N
LAM-based POS N
treatments POS N
in POS N
a POS N
real-world POS N
setting, POS N
with POS N
treatment POS N
modification POS N
being POS N
relatively POS N
low POS N
in POS N
ETV-treated POS N
patients. POS N

At POS N
week POS N
52, POS N
the POS N
virologic POS N
response POS N
rate POS N
was POS N
higher POS N
with POS N
ETV POS N
than POS N
with POS N
LAM-based POS N
treatment POS N
(77.0% POS N
versus POS N
61.4%, POS N
P<0.0001). POS N

Overall, POS N
6.6% POS N
of POS N
patients POS N
modified POS N
their POS N
initial POS N
treatment, POS N
with POS N
ETV POS N
having POS N
lower POS N
rates POS N
of POS N
treatment POS N
modification POS N
than POS N
other POS N
major POS N
NUCs POS N
(P<0.05). POS N

At POS N
week POS N
52, POS N
the POS N
virologic POS N
response POS N
rate POS N
was POS N
higher POS N
with POS N
ETV POS N
than POS N
with POS N
LAM-based POS N
treatment POS N
(77.0% POS N
versus POS N
61.4%, POS N
P<0.0001). POS N

LAM-based POS N
treatment POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
probability POS N
of POS N
virologic POS N
breakthrough POS N
and POS N
genotypic POS N
resistance POS N
(21.4% POS N
and POS N
19.6%, POS N
respectively) POS N
than POS N
ETV POS N
(1.6% POS N
and POS N
0.1%, POS N
respectively) POS N
(P<0.0001). POS N

At POS N
week POS N
52, POS N
the POS N
virologic POS N
response POS N
rate POS N
was POS N
higher POS N
with POS N
ETV POS N
than POS N
with POS N
LAM-based POS N
treatment POS N
(77.0% POS N
versus POS N
61.4%, POS N
P<0.0001). POS N

Treatment-related POS N
adverse POS N
events POS N
or POS N
serious POS N
adverse POS N
events POS N
were POS N
uncommon. POS N

At POS N
week POS N
52, POS N
the POS N
virologic POS N
response POS N
rate POS N
was POS N
higher POS N
with POS N
ETV POS N
than POS N
with POS N
LAM-based POS N
treatment POS N
(77.0% POS N
versus POS N
61.4%, POS N
P<0.0001). POS N

Consistent POS N
with POS N
clinical POS N
trial POS N
results, POS N
ETV POS N
was POS N
more POS N
effective POS N
than POS N
LAM-based POS N
treatments POS N
in POS N
a POS N
real-world POS N
setting, POS N
with POS N
treatment POS N
modification POS N
being POS N
relatively POS N
low POS N
in POS N
ETV-treated POS N
patients. POS N

LAM-based POS N
treatment POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
probability POS N
of POS N
virologic POS N
breakthrough POS N
and POS N
genotypic POS N
resistance POS N
(21.4% POS N
and POS N
19.6%, POS N
respectively) POS N
than POS N
ETV POS N
(1.6% POS N
and POS N
0.1%, POS N
respectively) POS N
(P<0.0001). POS N

Overall, POS N
6.6% POS N
of POS N
patients POS N
modified POS N
their POS N
initial POS N
treatment, POS N
with POS N
ETV POS N
having POS N
lower POS N
rates POS N
of POS N
treatment POS N
modification POS N
than POS N
other POS N
major POS N
NUCs POS N
(P<0.05). POS N

LAM-based POS N
treatment POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
probability POS N
of POS N
virologic POS N
breakthrough POS N
and POS N
genotypic POS N
resistance POS N
(21.4% POS N
and POS N
19.6%, POS N
respectively) POS N
than POS N
ETV POS N
(1.6% POS N
and POS N
0.1%, POS N
respectively) POS N
(P<0.0001). POS N

At POS N
week POS N
52, POS N
the POS N
virologic POS N
response POS N
rate POS N
was POS N
higher POS N
with POS N
ETV POS N
than POS N
with POS N
LAM-based POS N
treatment POS N
(77.0% POS N
versus POS N
61.4%, POS N
P<0.0001). POS N

LAM-based POS N
treatment POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
probability POS N
of POS N
virologic POS N
breakthrough POS N
and POS N
genotypic POS N
resistance POS N
(21.4% POS N
and POS N
19.6%, POS N
respectively) POS N
than POS N
ETV POS N
(1.6% POS N
and POS N
0.1%, POS N
respectively) POS N
(P<0.0001). POS N

Treatment-related POS N
adverse POS N
events POS N
or POS N
serious POS N
adverse POS N
events POS N
were POS N
uncommon. POS N

LAM-based POS N
treatment POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
probability POS N
of POS N
virologic POS N
breakthrough POS N
and POS N
genotypic POS N
resistance POS N
(21.4% POS N
and POS N
19.6%, POS N
respectively) POS N
than POS N
ETV POS N
(1.6% POS N
and POS N
0.1%, POS N
respectively) POS N
(P<0.0001). POS N

Consistent POS N
with POS N
clinical POS N
trial POS N
results, POS N
ETV POS N
was POS N
more POS N
effective POS N
than POS N
LAM-based POS N
treatments POS N
in POS N
a POS N
real-world POS N
setting, POS N
with POS N
treatment POS N
modification POS N
being POS N
relatively POS N
low POS N
in POS N
ETV-treated POS N
patients. POS N

Treatment-related POS N
adverse POS N
events POS N
or POS N
serious POS N
adverse POS N
events POS N
were POS N
uncommon. POS N

Overall, POS N
6.6% POS N
of POS N
patients POS N
modified POS N
their POS N
initial POS N
treatment, POS N
with POS N
ETV POS N
having POS N
lower POS N
rates POS N
of POS N
treatment POS N
modification POS N
than POS N
other POS N
major POS N
NUCs POS N
(P<0.05). POS N

Treatment-related POS N
adverse POS N
events POS N
or POS N
serious POS N
adverse POS N
events POS N
were POS N
uncommon. POS N

At POS N
week POS N
52, POS N
the POS N
virologic POS N
response POS N
rate POS N
was POS N
higher POS N
with POS N
ETV POS N
than POS N
with POS N
LAM-based POS N
treatment POS N
(77.0% POS N
versus POS N
61.4%, POS N
P<0.0001). POS N

Treatment-related POS N
adverse POS N
events POS N
or POS N
serious POS N
adverse POS N
events POS N
were POS N
uncommon. POS N

LAM-based POS N
treatment POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
probability POS N
of POS N
virologic POS N
breakthrough POS N
and POS N
genotypic POS N
resistance POS N
(21.4% POS N
and POS N
19.6%, POS N
respectively) POS N
than POS N
ETV POS N
(1.6% POS N
and POS N
0.1%, POS N
respectively) POS N
(P<0.0001). POS N

Treatment-related POS N
adverse POS N
events POS N
or POS N
serious POS N
adverse POS N
events POS N
were POS N
uncommon. POS N

Consistent POS N
with POS N
clinical POS N
trial POS N
results, POS N
ETV POS N
was POS N
more POS N
effective POS N
than POS N
LAM-based POS N
treatments POS N
in POS N
a POS N
real-world POS N
setting, POS N
with POS N
treatment POS N
modification POS N
being POS N
relatively POS N
low POS N
in POS N
ETV-treated POS N
patients. POS N

Consistent POS N
with POS N
clinical POS N
trial POS N
results, POS N
ETV POS N
was POS N
more POS N
effective POS N
than POS N
LAM-based POS N
treatments POS N
in POS N
a POS N
real-world POS N
setting, POS N
with POS N
treatment POS N
modification POS N
being POS N
relatively POS N
low POS N
in POS N
ETV-treated POS N
patients. POS N

Overall, POS N
6.6% POS N
of POS N
patients POS N
modified POS N
their POS N
initial POS N
treatment, POS N
with POS N
ETV POS N
having POS N
lower POS N
rates POS N
of POS N
treatment POS N
modification POS N
than POS N
other POS N
major POS N
NUCs POS N
(P<0.05). POS N

Consistent POS N
with POS N
clinical POS N
trial POS N
results, POS N
ETV POS N
was POS N
more POS N
effective POS N
than POS N
LAM-based POS N
treatments POS N
in POS N
a POS N
real-world POS N
setting, POS N
with POS N
treatment POS N
modification POS N
being POS N
relatively POS N
low POS N
in POS N
ETV-treated POS N
patients. POS N

At POS N
week POS N
52, POS N
the POS N
virologic POS N
response POS N
rate POS N
was POS N
higher POS N
with POS N
ETV POS N
than POS N
with POS N
LAM-based POS N
treatment POS N
(77.0% POS N
versus POS N
61.4%, POS N
P<0.0001). POS N

Consistent POS N
with POS N
clinical POS N
trial POS N
results, POS N
ETV POS N
was POS N
more POS N
effective POS N
than POS N
LAM-based POS N
treatments POS N
in POS N
a POS N
real-world POS N
setting, POS N
with POS N
treatment POS N
modification POS N
being POS N
relatively POS N
low POS N
in POS N
ETV-treated POS N
patients. POS N

LAM-based POS N
treatment POS N
was POS N
associated POS N
with POS N
a POS N
higher POS N
probability POS N
of POS N
virologic POS N
breakthrough POS N
and POS N
genotypic POS N
resistance POS N
(21.4% POS N
and POS N
19.6%, POS N
respectively) POS N
than POS N
ETV POS N
(1.6% POS N
and POS N
0.1%, POS N
respectively) POS N
(P<0.0001). POS N

Consistent POS N
with POS N
clinical POS N
trial POS N
results, POS N
ETV POS N
was POS N
more POS N
effective POS N
than POS N
LAM-based POS N
treatments POS N
in POS N
a POS N
real-world POS N
setting, POS N
with POS N
treatment POS N
modification POS N
being POS N
relatively POS N
low POS N
in POS N
ETV-treated POS N
patients. POS N

Treatment-related POS N
adverse POS N
events POS N
or POS N
serious POS N
adverse POS N
events POS N
were POS N
uncommon. POS N

Chronic POS N
HFHT POS N
compared POS N
with POS N
LFLT POS N
intake POS N
significantly POS N
increased POS N
plasma POS N
theobromine POS N
(p POS N
< POS N
0.0001). POS N

Compared POS N
with POS N
LFLT, POS N
acute POS N
HFHT POS N
intake POS N
significantly POS N
increased POS N
plasma POS N
epicatechin POS N
and POS N
theobromine POS N
(p POS N
< POS N
0.0001), POS N
decreased POS N
AIx POS N
(p POS N
< POS N
0.0001) POS N
and POS N
increased POS N
diastolic POS N
BP POS N
(3.49 POS N
± POS N
3.40 POS N
mmHg POS N
increase POS N
in POS N
HFHT POS N
group POS N
vs POS N
1.55 POS N
± POS N
2.59 POS N
mmHg POS N
increase POS N
in POS N
LFLT POS N
group, POS N
p POS N
= POS N
0.0008). POS N

Chronic POS N
HFHT POS N
compared POS N
with POS N
LFLT POS N
intake POS N
significantly POS N
increased POS N
plasma POS N
theobromine POS N
(p POS N
< POS N
0.0001). POS N

Acute POS N
consumption POS N
of POS N
HFHT, POS N
compared POS N
to POS N
LFLT, POS N
increased POS N
plasma POS N
epicatechin POS N
and POS N
theobromine POS N
concentrations POS N
and POS N
decreased POS N
arterial POS N
stiffness, POS N
with POS N
no POS N
effect POS N
on POS N
endothelial POS N
function POS N
and POS N
a POS N
marginal POS N
increase POS N
in POS N
diastolic POS N
BP. POS N

Chronic POS N
HFHT POS N
compared POS N
with POS N
LFLT POS N
intake POS N
significantly POS N
increased POS N
plasma POS N
theobromine POS N
(p POS N
< POS N
0.0001). POS N

Chronic POS N
HFHT POS N
intake POS N
increased POS N
plasma POS N
theobromine, POS N
though POS N
it POS N
did POS N
not POS N
have POS N
positive POS N
impacts POS N
on POS N
endothelial POS N
function, POS N
arterial POS N
stiffness POS N
or POS N
BP POS N
when POS N
compared POS N
to POS N
LFLT POS N
in POS N
pregnant POS N
women POS N
at POS N
risk POS N
of POS N
PE. POS N

Compared POS N
with POS N
LFLT, POS N
acute POS N
HFHT POS N
intake POS N
significantly POS N
increased POS N
plasma POS N
epicatechin POS N
and POS N
theobromine POS N
(p POS N
< POS N
0.0001), POS N
decreased POS N
AIx POS N
(p POS N
< POS N
0.0001) POS N
and POS N
increased POS N
diastolic POS N
BP POS N
(3.49 POS N
± POS N
3.40 POS N
mmHg POS N
increase POS N
in POS N
HFHT POS N
group POS N
vs POS N
1.55 POS N
± POS N
2.59 POS N
mmHg POS N
increase POS N
in POS N
LFLT POS N
group, POS N
p POS N
= POS N
0.0008). POS N

Chronic POS N
HFHT POS N
compared POS N
with POS N
LFLT POS N
intake POS N
significantly POS N
increased POS N
plasma POS N
theobromine POS N
(p POS N
< POS N
0.0001). POS N

Compared POS N
with POS N
LFLT, POS N
acute POS N
HFHT POS N
intake POS N
significantly POS N
increased POS N
plasma POS N
epicatechin POS N
and POS N
theobromine POS N
(p POS N
< POS N
0.0001), POS N
decreased POS N
AIx POS N
(p POS N
< POS N
0.0001) POS N
and POS N
increased POS N
diastolic POS N
BP POS N
(3.49 POS N
± POS N
3.40 POS N
mmHg POS N
increase POS N
in POS N
HFHT POS N
group POS N
vs POS N
1.55 POS N
± POS N
2.59 POS N
mmHg POS N
increase POS N
in POS N
LFLT POS N
group, POS N
p POS N
= POS N
0.0008). POS N

Acute POS N
consumption POS N
of POS N
HFHT, POS N
compared POS N
to POS N
LFLT, POS N
increased POS N
plasma POS N
epicatechin POS N
and POS N
theobromine POS N
concentrations POS N
and POS N
decreased POS N
arterial POS N
stiffness, POS N
with POS N
no POS N
effect POS N
on POS N
endothelial POS N
function POS N
and POS N
a POS N
marginal POS N
increase POS N
in POS N
diastolic POS N
BP. POS N

Compared POS N
with POS N
LFLT, POS N
acute POS N
HFHT POS N
intake POS N
significantly POS N
increased POS N
plasma POS N
epicatechin POS N
and POS N
theobromine POS N
(p POS N
< POS N
0.0001), POS N
decreased POS N
AIx POS N
(p POS N
< POS N
0.0001) POS N
and POS N
increased POS N
diastolic POS N
BP POS N
(3.49 POS N
± POS N
3.40 POS N
mmHg POS N
increase POS N
in POS N
HFHT POS N
group POS N
vs POS N
1.55 POS N
± POS N
2.59 POS N
mmHg POS N
increase POS N
in POS N
LFLT POS N
group, POS N
p POS N
= POS N
0.0008). POS N

Chronic POS N
HFHT POS N
intake POS N
increased POS N
plasma POS N
theobromine, POS N
though POS N
it POS N
did POS N
not POS N
have POS N
positive POS N
impacts POS N
on POS N
endothelial POS N
function, POS N
arterial POS N
stiffness POS N
or POS N
BP POS N
when POS N
compared POS N
to POS N
LFLT POS N
in POS N
pregnant POS N
women POS N
at POS N
risk POS N
of POS N
PE. POS N

Acute POS N
consumption POS N
of POS N
HFHT, POS N
compared POS N
to POS N
LFLT, POS N
increased POS N
plasma POS N
epicatechin POS N
and POS N
theobromine POS N
concentrations POS N
and POS N
decreased POS N
arterial POS N
stiffness, POS N
with POS N
no POS N
effect POS N
on POS N
endothelial POS N
function POS N
and POS N
a POS N
marginal POS N
increase POS N
in POS N
diastolic POS N
BP. POS N

Chronic POS N
HFHT POS N
compared POS N
with POS N
LFLT POS N
intake POS N
significantly POS N
increased POS N
plasma POS N
theobromine POS N
(p POS N
< POS N
0.0001). POS N

Acute POS N
consumption POS N
of POS N
HFHT, POS N
compared POS N
to POS N
LFLT, POS N
increased POS N
plasma POS N
epicatechin POS N
and POS N
theobromine POS N
concentrations POS N
and POS N
decreased POS N
arterial POS N
stiffness, POS N
with POS N
no POS N
effect POS N
on POS N
endothelial POS N
function POS N
and POS N
a POS N
marginal POS N
increase POS N
in POS N
diastolic POS N
BP. POS N

Compared POS N
with POS N
LFLT, POS N
acute POS N
HFHT POS N
intake POS N
significantly POS N
increased POS N
plasma POS N
epicatechin POS N
and POS N
theobromine POS N
(p POS N
< POS N
0.0001), POS N
decreased POS N
AIx POS N
(p POS N
< POS N
0.0001) POS N
and POS N
increased POS N
diastolic POS N
BP POS N
(3.49 POS N
± POS N
3.40 POS N
mmHg POS N
increase POS N
in POS N
HFHT POS N
group POS N
vs POS N
1.55 POS N
± POS N
2.59 POS N
mmHg POS N
increase POS N
in POS N
LFLT POS N
group, POS N
p POS N
= POS N
0.0008). POS N

Acute POS N
consumption POS N
of POS N
HFHT, POS N
compared POS N
to POS N
LFLT, POS N
increased POS N
plasma POS N
epicatechin POS N
and POS N
theobromine POS N
concentrations POS N
and POS N
decreased POS N
arterial POS N
stiffness, POS N
with POS N
no POS N
effect POS N
on POS N
endothelial POS N
function POS N
and POS N
a POS N
marginal POS N
increase POS N
in POS N
diastolic POS N
BP. POS N

Chronic POS N
HFHT POS N
intake POS N
increased POS N
plasma POS N
theobromine, POS N
though POS N
it POS N
did POS N
not POS N
have POS N
positive POS N
impacts POS N
on POS N
endothelial POS N
function, POS N
arterial POS N
stiffness POS N
or POS N
BP POS N
when POS N
compared POS N
to POS N
LFLT POS N
in POS N
pregnant POS N
women POS N
at POS N
risk POS N
of POS N
PE. POS N

Chronic POS N
HFHT POS N
intake POS N
increased POS N
plasma POS N
theobromine, POS N
though POS N
it POS N
did POS N
not POS N
have POS N
positive POS N
impacts POS N
on POS N
endothelial POS N
function, POS N
arterial POS N
stiffness POS N
or POS N
BP POS N
when POS N
compared POS N
to POS N
LFLT POS N
in POS N
pregnant POS N
women POS N
at POS N
risk POS N
of POS N
PE. POS N

Chronic POS N
HFHT POS N
compared POS N
with POS N
LFLT POS N
intake POS N
significantly POS N
increased POS N
plasma POS N
theobromine POS N
(p POS N
< POS N
0.0001). POS N

Chronic POS N
HFHT POS N
intake POS N
increased POS N
plasma POS N
theobromine, POS N
though POS N
it POS N
did POS N
not POS N
have POS N
positive POS N
impacts POS N
on POS N
endothelial POS N
function, POS N
arterial POS N
stiffness POS N
or POS N
BP POS N
when POS N
compared POS N
to POS N
LFLT POS N
in POS N
pregnant POS N
women POS N
at POS N
risk POS N
of POS N
PE. POS N

Compared POS N
with POS N
LFLT, POS N
acute POS N
HFHT POS N
intake POS N
significantly POS N
increased POS N
plasma POS N
epicatechin POS N
and POS N
theobromine POS N
(p POS N
< POS N
0.0001), POS N
decreased POS N
AIx POS N
(p POS N
< POS N
0.0001) POS N
and POS N
increased POS N
diastolic POS N
BP POS N
(3.49 POS N
± POS N
3.40 POS N
mmHg POS N
increase POS N
in POS N
HFHT POS N
group POS N
vs POS N
1.55 POS N
± POS N
2.59 POS N
mmHg POS N
increase POS N
in POS N
LFLT POS N
group, POS N
p POS N
= POS N
0.0008). POS N

Chronic POS N
HFHT POS N
intake POS N
increased POS N
plasma POS N
theobromine, POS N
though POS N
it POS N
did POS N
not POS N
have POS N
positive POS N
impacts POS N
on POS N
endothelial POS N
function, POS N
arterial POS N
stiffness POS N
or POS N
BP POS N
when POS N
compared POS N
to POS N
LFLT POS N
in POS N
pregnant POS N
women POS N
at POS N
risk POS N
of POS N
PE. POS N

Acute POS N
consumption POS N
of POS N
HFHT, POS N
compared POS N
to POS N
LFLT, POS N
increased POS N
plasma POS N
epicatechin POS N
and POS N
theobromine POS N
concentrations POS N
and POS N
decreased POS N
arterial POS N
stiffness, POS N
with POS N
no POS N
effect POS N
on POS N
endothelial POS N
function POS N
and POS N
a POS N
marginal POS N
increase POS N
in POS N
diastolic POS N
BP. POS N

The POS N
response POS N
rate POS N
was POS N
71% POS N
for POS N
DepoCyt POS N
and POS N
15% POS N
for POS N
ara-C POS N
on POS N
an POS N
intent-to-treat POS N
basis POS N
(P POS N
=.006). POS N

All POS N
of POS N
the POS N
patients POS N
on POS N
the POS N
DepoCyt POS N
arm POS N
but POS N
only POS N
53% POS N
of POS N
those POS N
on POS N
the POS N
ara-C POS N
arm POS N
were POS N
able POS N
to POS N
complete POS N
the POS N
planned POS N
1-month POS N
induction POS N
therapy POS N
regimen. POS N

The POS N
response POS N
rate POS N
was POS N
71% POS N
for POS N
DepoCyt POS N
and POS N
15% POS N
for POS N
ara-C POS N
on POS N
an POS N
intent-to-treat POS N
basis POS N
(P POS N
=.006). POS N

Time POS N
to POS N
neurologic POS N
progression POS N
and POS N
survival POS N
trend POS N
in POS N
favor POS N
of POS N
DepoCyt POS N
(median, POS N
78.5 POS N
v POS N
42 POS N
days POS N
and POS N
99.5 POS N
v POS N
63 POS N
days, POS N
respectively; POS N
P POS N
>.05). POS N

The POS N
response POS N
rate POS N
was POS N
71% POS N
for POS N
DepoCyt POS N
and POS N
15% POS N
for POS N
ara-C POS N
on POS N
an POS N
intent-to-treat POS N
basis POS N
(P POS N
=.006). POS N

DepoCyt POS N
treatment POS N
was POS N
associated POS N
with POS N
an POS N
improved POS N
mean POS N
change POS N
in POS N
Karnofsky POS N
performance POS N
score POS N
at POS N
the POS N
end POS N
of POS N
induction POS N
(P POS N
=.041). POS N

The POS N
response POS N
rate POS N
was POS N
71% POS N
for POS N
DepoCyt POS N
and POS N
15% POS N
for POS N
ara-C POS N
on POS N
an POS N
intent-to-treat POS N
basis POS N
(P POS N
=.006). POS N

The POS N
major POS N
adverse POS N
events POS N
on POS N
both POS N
arms POS N
were POS N
headache POS N
and POS N
arachnoiditis, POS N
which POS N
were POS N
often POS N
caused POS N
by POS N
the POS N
underlying POS N
disease. POS N

The POS N
response POS N
rate POS N
was POS N
71% POS N
for POS N
DepoCyt POS N
and POS N
15% POS N
for POS N
ara-C POS N
on POS N
an POS N
intent-to-treat POS N
basis POS N
(P POS N
=.006). POS N

DepoCyt POS N
injected POS N
once POS N
every POS N
2 POS N
weeks POS N
produced POS N
a POS N
high POS N
response POS N
rate POS N
and POS N
a POS N
better POS N
quality POS N
of POS N
life POS N
as POS N
measured POS N
by POS N
Karnofsky POS N
score POS N
relative POS N
to POS N
that POS N
produced POS N
by POS N
free POS N
ara-C POS N
injected POS N
twice POS N
a POS N
week. POS N

All POS N
of POS N
the POS N
patients POS N
on POS N
the POS N
DepoCyt POS N
arm POS N
but POS N
only POS N
53% POS N
of POS N
those POS N
on POS N
the POS N
ara-C POS N
arm POS N
were POS N
able POS N
to POS N
complete POS N
the POS N
planned POS N
1-month POS N
induction POS N
therapy POS N
regimen. POS N

The POS N
response POS N
rate POS N
was POS N
71% POS N
for POS N
DepoCyt POS N
and POS N
15% POS N
for POS N
ara-C POS N
on POS N
an POS N
intent-to-treat POS N
basis POS N
(P POS N
=.006). POS N

All POS N
of POS N
the POS N
patients POS N
on POS N
the POS N
DepoCyt POS N
arm POS N
but POS N
only POS N
53% POS N
of POS N
those POS N
on POS N
the POS N
ara-C POS N
arm POS N
were POS N
able POS N
to POS N
complete POS N
the POS N
planned POS N
1-month POS N
induction POS N
therapy POS N
regimen. POS N

Time POS N
to POS N
neurologic POS N
progression POS N
and POS N
survival POS N
trend POS N
in POS N
favor POS N
of POS N
DepoCyt POS N
(median, POS N
78.5 POS N
v POS N
42 POS N
days POS N
and POS N
99.5 POS N
v POS N
63 POS N
days, POS N
respectively; POS N
P POS N
>.05). POS N

All POS N
of POS N
the POS N
patients POS N
on POS N
the POS N
DepoCyt POS N
arm POS N
but POS N
only POS N
53% POS N
of POS N
those POS N
on POS N
the POS N
ara-C POS N
arm POS N
were POS N
able POS N
to POS N
complete POS N
the POS N
planned POS N
1-month POS N
induction POS N
therapy POS N
regimen. POS N

DepoCyt POS N
treatment POS N
was POS N
associated POS N
with POS N
an POS N
improved POS N
mean POS N
change POS N
in POS N
Karnofsky POS N
performance POS N
score POS N
at POS N
the POS N
end POS N
of POS N
induction POS N
(P POS N
=.041). POS N

All POS N
of POS N
the POS N
patients POS N
on POS N
the POS N
DepoCyt POS N
arm POS N
but POS N
only POS N
53% POS N
of POS N
those POS N
on POS N
the POS N
ara-C POS N
arm POS N
were POS N
able POS N
to POS N
complete POS N
the POS N
planned POS N
1-month POS N
induction POS N
therapy POS N
regimen. POS N

The POS N
major POS N
adverse POS N
events POS N
on POS N
both POS N
arms POS N
were POS N
headache POS N
and POS N
arachnoiditis, POS N
which POS N
were POS N
often POS N
caused POS N
by POS N
the POS N
underlying POS N
disease. POS N

All POS N
of POS N
the POS N
patients POS N
on POS N
the POS N
DepoCyt POS N
arm POS N
but POS N
only POS N
53% POS N
of POS N
those POS N
on POS N
the POS N
ara-C POS N
arm POS N
were POS N
able POS N
to POS N
complete POS N
the POS N
planned POS N
1-month POS N
induction POS N
therapy POS N
regimen. POS N

DepoCyt POS N
injected POS N
once POS N
every POS N
2 POS N
weeks POS N
produced POS N
a POS N
high POS N
response POS N
rate POS N
and POS N
a POS N
better POS N
quality POS N
of POS N
life POS N
as POS N
measured POS N
by POS N
Karnofsky POS N
score POS N
relative POS N
to POS N
that POS N
produced POS N
by POS N
free POS N
ara-C POS N
injected POS N
twice POS N
a POS N
week. POS N

Time POS N
to POS N
neurologic POS N
progression POS N
and POS N
survival POS N
trend POS N
in POS N
favor POS N
of POS N
DepoCyt POS N
(median, POS N
78.5 POS N
v POS N
42 POS N
days POS N
and POS N
99.5 POS N
v POS N
63 POS N
days, POS N
respectively; POS N
P POS N
>.05). POS N

The POS N
response POS N
rate POS N
was POS N
71% POS N
for POS N
DepoCyt POS N
and POS N
15% POS N
for POS N
ara-C POS N
on POS N
an POS N
intent-to-treat POS N
basis POS N
(P POS N
=.006). POS N

Time POS N
to POS N
neurologic POS N
progression POS N
and POS N
survival POS N
trend POS N
in POS N
favor POS N
of POS N
DepoCyt POS N
(median, POS N
78.5 POS N
v POS N
42 POS N
days POS N
and POS N
99.5 POS N
v POS N
63 POS N
days, POS N
respectively; POS N
P POS N
>.05). POS N

All POS N
of POS N
the POS N
patients POS N
on POS N
the POS N
DepoCyt POS N
arm POS N
but POS N
only POS N
53% POS N
of POS N
those POS N
on POS N
the POS N
ara-C POS N
arm POS N
were POS N
able POS N
to POS N
complete POS N
the POS N
planned POS N
1-month POS N
induction POS N
therapy POS N
regimen. POS N

Time POS N
to POS N
neurologic POS N
progression POS N
and POS N
survival POS N
trend POS N
in POS N
favor POS N
of POS N
DepoCyt POS N
(median, POS N
78.5 POS N
v POS N
42 POS N
days POS N
and POS N
99.5 POS N
v POS N
63 POS N
days, POS N
respectively; POS N
P POS N
>.05). POS N

DepoCyt POS N
treatment POS N
was POS N
associated POS N
with POS N
an POS N
improved POS N
mean POS N
change POS N
in POS N
Karnofsky POS N
performance POS N
score POS N
at POS N
the POS N
end POS N
of POS N
induction POS N
(P POS N
=.041). POS N

Time POS N
to POS N
neurologic POS N
progression POS N
and POS N
survival POS N
trend POS N
in POS N
favor POS N
of POS N
DepoCyt POS N
(median, POS N
78.5 POS N
v POS N
42 POS N
days POS N
and POS N
99.5 POS N
v POS N
63 POS N
days, POS N
respectively; POS N
P POS N
>.05). POS N

The POS N
major POS N
adverse POS N
events POS N
on POS N
both POS N
arms POS N
were POS N
headache POS N
and POS N
arachnoiditis, POS N
which POS N
were POS N
often POS N
caused POS N
by POS N
the POS N
underlying POS N
disease. POS N

Time POS N
to POS N
neurologic POS N
progression POS N
and POS N
survival POS N
trend POS N
in POS N
favor POS N
of POS N
DepoCyt POS N
(median, POS N
78.5 POS N
v POS N
42 POS N
days POS N
and POS N
99.5 POS N
v POS N
63 POS N
days, POS N
respectively; POS N
P POS N
>.05). POS N

DepoCyt POS N
injected POS N
once POS N
every POS N
2 POS N
weeks POS N
produced POS N
a POS N
high POS N
response POS N
rate POS N
and POS N
a POS N
better POS N
quality POS N
of POS N
life POS N
as POS N
measured POS N
by POS N
Karnofsky POS N
score POS N
relative POS N
to POS N
that POS N
produced POS N
by POS N
free POS N
ara-C POS N
injected POS N
twice POS N
a POS N
week. POS N

DepoCyt POS N
treatment POS N
was POS N
associated POS N
with POS N
an POS N
improved POS N
mean POS N
change POS N
in POS N
Karnofsky POS N
performance POS N
score POS N
at POS N
the POS N
end POS N
of POS N
induction POS N
(P POS N
=.041). POS N

The POS N
response POS N
rate POS N
was POS N
71% POS N
for POS N
DepoCyt POS N
and POS N
15% POS N
for POS N
ara-C POS N
on POS N
an POS N
intent-to-treat POS N
basis POS N
(P POS N
=.006). POS N

DepoCyt POS N
treatment POS N
was POS N
associated POS N
with POS N
an POS N
improved POS N
mean POS N
change POS N
in POS N
Karnofsky POS N
performance POS N
score POS N
at POS N
the POS N
end POS N
of POS N
induction POS N
(P POS N
=.041). POS N

All POS N
of POS N
the POS N
patients POS N
on POS N
the POS N
DepoCyt POS N
arm POS N
but POS N
only POS N
53% POS N
of POS N
those POS N
on POS N
the POS N
ara-C POS N
arm POS N
were POS N
able POS N
to POS N
complete POS N
the POS N
planned POS N
1-month POS N
induction POS N
therapy POS N
regimen. POS N

DepoCyt POS N
treatment POS N
was POS N
associated POS N
with POS N
an POS N
improved POS N
mean POS N
change POS N
in POS N
Karnofsky POS N
performance POS N
score POS N
at POS N
the POS N
end POS N
of POS N
induction POS N
(P POS N
=.041). POS N

Time POS N
to POS N
neurologic POS N
progression POS N
and POS N
survival POS N
trend POS N
in POS N
favor POS N
of POS N
DepoCyt POS N
(median, POS N
78.5 POS N
v POS N
42 POS N
days POS N
and POS N
99.5 POS N
v POS N
63 POS N
days, POS N
respectively; POS N
P POS N
>.05). POS N

DepoCyt POS N
treatment POS N
was POS N
associated POS N
with POS N
an POS N
improved POS N
mean POS N
change POS N
in POS N
Karnofsky POS N
performance POS N
score POS N
at POS N
the POS N
end POS N
of POS N
induction POS N
(P POS N
=.041). POS N

The POS N
major POS N
adverse POS N
events POS N
on POS N
both POS N
arms POS N
were POS N
headache POS N
and POS N
arachnoiditis, POS N
which POS N
were POS N
often POS N
caused POS N
by POS N
the POS N
underlying POS N
disease. POS N

DepoCyt POS N
treatment POS N
was POS N
associated POS N
with POS N
an POS N
improved POS N
mean POS N
change POS N
in POS N
Karnofsky POS N
performance POS N
score POS N
at POS N
the POS N
end POS N
of POS N
induction POS N
(P POS N
=.041). POS N

DepoCyt POS N
injected POS N
once POS N
every POS N
2 POS N
weeks POS N
produced POS N
a POS N
high POS N
response POS N
rate POS N
and POS N
a POS N
better POS N
quality POS N
of POS N
life POS N
as POS N
measured POS N
by POS N
Karnofsky POS N
score POS N
relative POS N
to POS N
that POS N
produced POS N
by POS N
free POS N
ara-C POS N
injected POS N
twice POS N
a POS N
week. POS N

The POS N
major POS N
adverse POS N
events POS N
on POS N
both POS N
arms POS N
were POS N
headache POS N
and POS N
arachnoiditis, POS N
which POS N
were POS N
often POS N
caused POS N
by POS N
the POS N
underlying POS N
disease. POS N

The POS N
response POS N
rate POS N
was POS N
71% POS N
for POS N
DepoCyt POS N
and POS N
15% POS N
for POS N
ara-C POS N
on POS N
an POS N
intent-to-treat POS N
basis POS N
(P POS N
=.006). POS N

The POS N
major POS N
adverse POS N
events POS N
on POS N
both POS N
arms POS N
were POS N
headache POS N
and POS N
arachnoiditis, POS N
which POS N
were POS N
often POS N
caused POS N
by POS N
the POS N
underlying POS N
disease. POS N

All POS N
of POS N
the POS N
patients POS N
on POS N
the POS N
DepoCyt POS N
arm POS N
but POS N
only POS N
53% POS N
of POS N
those POS N
on POS N
the POS N
ara-C POS N
arm POS N
were POS N
able POS N
to POS N
complete POS N
the POS N
planned POS N
1-month POS N
induction POS N
therapy POS N
regimen. POS N

The POS N
major POS N
adverse POS N
events POS N
on POS N
both POS N
arms POS N
were POS N
headache POS N
and POS N
arachnoiditis, POS N
which POS N
were POS N
often POS N
caused POS N
by POS N
the POS N
underlying POS N
disease. POS N

Time POS N
to POS N
neurologic POS N
progression POS N
and POS N
survival POS N
trend POS N
in POS N
favor POS N
of POS N
DepoCyt POS N
(median, POS N
78.5 POS N
v POS N
42 POS N
days POS N
and POS N
99.5 POS N
v POS N
63 POS N
days, POS N
respectively; POS N
P POS N
>.05). POS N

The POS N
major POS N
adverse POS N
events POS N
on POS N
both POS N
arms POS N
were POS N
headache POS N
and POS N
arachnoiditis, POS N
which POS N
were POS N
often POS N
caused POS N
by POS N
the POS N
underlying POS N
disease. POS N

DepoCyt POS N
treatment POS N
was POS N
associated POS N
with POS N
an POS N
improved POS N
mean POS N
change POS N
in POS N
Karnofsky POS N
performance POS N
score POS N
at POS N
the POS N
end POS N
of POS N
induction POS N
(P POS N
=.041). POS N

The POS N
major POS N
adverse POS N
events POS N
on POS N
both POS N
arms POS N
were POS N
headache POS N
and POS N
arachnoiditis, POS N
which POS N
were POS N
often POS N
caused POS N
by POS N
the POS N
underlying POS N
disease. POS N

DepoCyt POS N
injected POS N
once POS N
every POS N
2 POS N
weeks POS N
produced POS N
a POS N
high POS N
response POS N
rate POS N
and POS N
a POS N
better POS N
quality POS N
of POS N
life POS N
as POS N
measured POS N
by POS N
Karnofsky POS N
score POS N
relative POS N
to POS N
that POS N
produced POS N
by POS N
free POS N
ara-C POS N
injected POS N
twice POS N
a POS N
week. POS N

DepoCyt POS N
injected POS N
once POS N
every POS N
2 POS N
weeks POS N
produced POS N
a POS N
high POS N
response POS N
rate POS N
and POS N
a POS N
better POS N
quality POS N
of POS N
life POS N
as POS N
measured POS N
by POS N
Karnofsky POS N
score POS N
relative POS N
to POS N
that POS N
produced POS N
by POS N
free POS N
ara-C POS N
injected POS N
twice POS N
a POS N
week. POS N

The POS N
response POS N
rate POS N
was POS N
71% POS N
for POS N
DepoCyt POS N
and POS N
15% POS N
for POS N
ara-C POS N
on POS N
an POS N
intent-to-treat POS N
basis POS N
(P POS N
=.006). POS N

DepoCyt POS N
injected POS N
once POS N
every POS N
2 POS N
weeks POS N
produced POS N
a POS N
high POS N
response POS N
rate POS N
and POS N
a POS N
better POS N
quality POS N
of POS N
life POS N
as POS N
measured POS N
by POS N
Karnofsky POS N
score POS N
relative POS N
to POS N
that POS N
produced POS N
by POS N
free POS N
ara-C POS N
injected POS N
twice POS N
a POS N
week. POS N

All POS N
of POS N
the POS N
patients POS N
on POS N
the POS N
DepoCyt POS N
arm POS N
but POS N
only POS N
53% POS N
of POS N
those POS N
on POS N
the POS N
ara-C POS N
arm POS N
were POS N
able POS N
to POS N
complete POS N
the POS N
planned POS N
1-month POS N
induction POS N
therapy POS N
regimen. POS N

DepoCyt POS N
injected POS N
once POS N
every POS N
2 POS N
weeks POS N
produced POS N
a POS N
high POS N
response POS N
rate POS N
and POS N
a POS N
better POS N
quality POS N
of POS N
life POS N
as POS N
measured POS N
by POS N
Karnofsky POS N
score POS N
relative POS N
to POS N
that POS N
produced POS N
by POS N
free POS N
ara-C POS N
injected POS N
twice POS N
a POS N
week. POS N

Time POS N
to POS N
neurologic POS N
progression POS N
and POS N
survival POS N
trend POS N
in POS N
favor POS N
of POS N
DepoCyt POS N
(median, POS N
78.5 POS N
v POS N
42 POS N
days POS N
and POS N
99.5 POS N
v POS N
63 POS N
days, POS N
respectively; POS N
P POS N
>.05). POS N

DepoCyt POS N
injected POS N
once POS N
every POS N
2 POS N
weeks POS N
produced POS N
a POS N
high POS N
response POS N
rate POS N
and POS N
a POS N
better POS N
quality POS N
of POS N
life POS N
as POS N
measured POS N
by POS N
Karnofsky POS N
score POS N
relative POS N
to POS N
that POS N
produced POS N
by POS N
free POS N
ara-C POS N
injected POS N
twice POS N
a POS N
week. POS N

DepoCyt POS N
treatment POS N
was POS N
associated POS N
with POS N
an POS N
improved POS N
mean POS N
change POS N
in POS N
Karnofsky POS N
performance POS N
score POS N
at POS N
the POS N
end POS N
of POS N
induction POS N
(P POS N
=.041). POS N

DepoCyt POS N
injected POS N
once POS N
every POS N
2 POS N
weeks POS N
produced POS N
a POS N
high POS N
response POS N
rate POS N
and POS N
a POS N
better POS N
quality POS N
of POS N
life POS N
as POS N
measured POS N
by POS N
Karnofsky POS N
score POS N
relative POS N
to POS N
that POS N
produced POS N
by POS N
free POS N
ara-C POS N
injected POS N
twice POS N
a POS N
week. POS N

The POS N
major POS N
adverse POS N
events POS N
on POS N
both POS N
arms POS N
were POS N
headache POS N
and POS N
arachnoiditis, POS N
which POS N
were POS N
often POS N
caused POS N
by POS N
the POS N
underlying POS N
disease. POS N

Larger POS N
studies POS N
using POS N
physiologically POS N
standardized POS N
ginseng POS N
preparations POS N
are POS N
warranted POS N
to POS N
substantiate POS N
the POS N
present POS N
findings POS N
and POS N
to POS N
demonstrate POS N
therapeutic POS N
effectiveness POS N
of POS N
AG. POS N

AG POS N
extract POS N
added POS N
to POS N
conventional POS N
treatment POS N
provided POS N
an POS N
effective POS N
and POS N
safe POS N
adjunct POS N
in POS N
the POS N
management POS N
of POS N
T2DM. POS N

Larger POS N
studies POS N
using POS N
physiologically POS N
standardized POS N
ginseng POS N
preparations POS N
are POS N
warranted POS N
to POS N
substantiate POS N
the POS N
present POS N
findings POS N
and POS N
to POS N
demonstrate POS N
therapeutic POS N
effectiveness POS N
of POS N
AG. POS N

Compared POS N
to POS N
placebo, POS N
AG POS N
significantly POS N
reduced POS N
HbA1c POS N
(- POS N
0.29%; POS N
p = 0.041) POS N
and POS N
fasting POS N
blood POS N
glucose POS N
(- POS N
0.71 POS N
mmol/L; POS N
p = 0.008). POS N

Larger POS N
studies POS N
using POS N
physiologically POS N
standardized POS N
ginseng POS N
preparations POS N
are POS N
warranted POS N
to POS N
substantiate POS N
the POS N
present POS N
findings POS N
and POS N
to POS N
demonstrate POS N
therapeutic POS N
effectiveness POS N
of POS N
AG. POS N

AG POS N
lowered POS N
systolic POS N
blood POS N
pressure POS N
(- POS N
5.6 ± 2.7 POS N
mmHg; POS N
p < 0.001), POS N
increased POS N
NOx POS N
(+ 1.85 ± 2.13 POS N
µmol/L; POS N
p < 0.03), POS N
and POS N
produced POS N
a POS N
mean POS N
percent POS N
end-difference POS N
of POS N
- POS N
12.3 ± 3.9% POS N
in POS N
LDL-C POS N
and POS N
- 13.9 ± 5.8% POS N
in POS N
LDL-C/HDL. POS N

AG POS N
extract POS N
added POS N
to POS N
conventional POS N
treatment POS N
provided POS N
an POS N
effective POS N
and POS N
safe POS N
adjunct POS N
in POS N
the POS N
management POS N
of POS N
T2DM. POS N

Larger POS N
studies POS N
using POS N
physiologically POS N
standardized POS N
ginseng POS N
preparations POS N
are POS N
warranted POS N
to POS N
substantiate POS N
the POS N
present POS N
findings POS N
and POS N
to POS N
demonstrate POS N
therapeutic POS N
effectiveness POS N
of POS N
AG. POS N

AG POS N
extract POS N
added POS N
to POS N
conventional POS N
treatment POS N
provided POS N
an POS N
effective POS N
and POS N
safe POS N
adjunct POS N
in POS N
the POS N
management POS N
of POS N
T2DM. POS N

Compared POS N
to POS N
placebo, POS N
AG POS N
significantly POS N
reduced POS N
HbA1c POS N
(- POS N
0.29%; POS N
p = 0.041) POS N
and POS N
fasting POS N
blood POS N
glucose POS N
(- POS N
0.71 POS N
mmol/L; POS N
p = 0.008). POS N

AG POS N
extract POS N
added POS N
to POS N
conventional POS N
treatment POS N
provided POS N
an POS N
effective POS N
and POS N
safe POS N
adjunct POS N
in POS N
the POS N
management POS N
of POS N
T2DM. POS N

AG POS N
lowered POS N
systolic POS N
blood POS N
pressure POS N
(- POS N
5.6 ± 2.7 POS N
mmHg; POS N
p < 0.001), POS N
increased POS N
NOx POS N
(+ 1.85 ± 2.13 POS N
µmol/L; POS N
p < 0.03), POS N
and POS N
produced POS N
a POS N
mean POS N
percent POS N
end-difference POS N
of POS N
- POS N
12.3 ± 3.9% POS N
in POS N
LDL-C POS N
and POS N
- 13.9 ± 5.8% POS N
in POS N
LDL-C/HDL. POS N

Compared POS N
to POS N
placebo, POS N
AG POS N
significantly POS N
reduced POS N
HbA1c POS N
(- POS N
0.29%; POS N
p = 0.041) POS N
and POS N
fasting POS N
blood POS N
glucose POS N
(- POS N
0.71 POS N
mmol/L; POS N
p = 0.008). POS N

Larger POS N
studies POS N
using POS N
physiologically POS N
standardized POS N
ginseng POS N
preparations POS N
are POS N
warranted POS N
to POS N
substantiate POS N
the POS N
present POS N
findings POS N
and POS N
to POS N
demonstrate POS N
therapeutic POS N
effectiveness POS N
of POS N
AG. POS N

Compared POS N
to POS N
placebo, POS N
AG POS N
significantly POS N
reduced POS N
HbA1c POS N
(- POS N
0.29%; POS N
p = 0.041) POS N
and POS N
fasting POS N
blood POS N
glucose POS N
(- POS N
0.71 POS N
mmol/L; POS N
p = 0.008). POS N

AG POS N
extract POS N
added POS N
to POS N
conventional POS N
treatment POS N
provided POS N
an POS N
effective POS N
and POS N
safe POS N
adjunct POS N
in POS N
the POS N
management POS N
of POS N
T2DM. POS N

Compared POS N
to POS N
placebo, POS N
AG POS N
significantly POS N
reduced POS N
HbA1c POS N
(- POS N
0.29%; POS N
p = 0.041) POS N
and POS N
fasting POS N
blood POS N
glucose POS N
(- POS N
0.71 POS N
mmol/L; POS N
p = 0.008). POS N

AG POS N
lowered POS N
systolic POS N
blood POS N
pressure POS N
(- POS N
5.6 ± 2.7 POS N
mmHg; POS N
p < 0.001), POS N
increased POS N
NOx POS N
(+ 1.85 ± 2.13 POS N
µmol/L; POS N
p < 0.03), POS N
and POS N
produced POS N
a POS N
mean POS N
percent POS N
end-difference POS N
of POS N
- POS N
12.3 ± 3.9% POS N
in POS N
LDL-C POS N
and POS N
- 13.9 ± 5.8% POS N
in POS N
LDL-C/HDL. POS N

AG POS N
lowered POS N
systolic POS N
blood POS N
pressure POS N
(- POS N
5.6 ± 2.7 POS N
mmHg; POS N
p < 0.001), POS N
increased POS N
NOx POS N
(+ 1.85 ± 2.13 POS N
µmol/L; POS N
p < 0.03), POS N
and POS N
produced POS N
a POS N
mean POS N
percent POS N
end-difference POS N
of POS N
- POS N
12.3 ± 3.9% POS N
in POS N
LDL-C POS N
and POS N
- 13.9 ± 5.8% POS N
in POS N
LDL-C/HDL. POS N

Larger POS N
studies POS N
using POS N
physiologically POS N
standardized POS N
ginseng POS N
preparations POS N
are POS N
warranted POS N
to POS N
substantiate POS N
the POS N
present POS N
findings POS N
and POS N
to POS N
demonstrate POS N
therapeutic POS N
effectiveness POS N
of POS N
AG. POS N

AG POS N
lowered POS N
systolic POS N
blood POS N
pressure POS N
(- POS N
5.6 ± 2.7 POS N
mmHg; POS N
p < 0.001), POS N
increased POS N
NOx POS N
(+ 1.85 ± 2.13 POS N
µmol/L; POS N
p < 0.03), POS N
and POS N
produced POS N
a POS N
mean POS N
percent POS N
end-difference POS N
of POS N
- POS N
12.3 ± 3.9% POS N
in POS N
LDL-C POS N
and POS N
- 13.9 ± 5.8% POS N
in POS N
LDL-C/HDL. POS N

AG POS N
extract POS N
added POS N
to POS N
conventional POS N
treatment POS N
provided POS N
an POS N
effective POS N
and POS N
safe POS N
adjunct POS N
in POS N
the POS N
management POS N
of POS N
T2DM. POS N

AG POS N
lowered POS N
systolic POS N
blood POS N
pressure POS N
(- POS N
5.6 ± 2.7 POS N
mmHg; POS N
p < 0.001), POS N
increased POS N
NOx POS N
(+ 1.85 ± 2.13 POS N
µmol/L; POS N
p < 0.03), POS N
and POS N
produced POS N
a POS N
mean POS N
percent POS N
end-difference POS N
of POS N
- POS N
12.3 ± 3.9% POS N
in POS N
LDL-C POS N
and POS N
- 13.9 ± 5.8% POS N
in POS N
LDL-C/HDL. POS N

Compared POS N
to POS N
placebo, POS N
AG POS N
significantly POS N
reduced POS N
HbA1c POS N
(- POS N
0.29%; POS N
p = 0.041) POS N
and POS N
fasting POS N
blood POS N
glucose POS N
(- POS N
0.71 POS N
mmol/L; POS N
p = 0.008). POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
effective POS N
IOP POS N
reduction POS N
that POS N
was POS N
greater POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

patients POS N
were POS N
more POS N
likely POS N
to POS N
achieve POS N
lower POS N
target POS N
pressures POS N
with POS N
BTFC POS N
than POS N
with POS N
TTFC. POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

Both POS N
drops POS N
provided POS N
statistically POS N
significant POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
at POS N
all POS N
visits POS N
(P<0.001). POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

BTFC POS N
provided POS N
greater POS N
significant POS N
mean POS N
IOP POS N
reductions POS N
from POS N
baseline POS N
than POS N
TTFC POS N
at POS N
each POS N
visit POS N
(P<0.001). POS N

IOPs POS N
at POS N
2 POS N
weeks POS N
were POS N
18 POS N
mm POS N
Hg POS N
in POS N
36 POS N
(90.8%) POS N
versus POS N
22 POS N
(55%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
28 POS N
(70%) POS N
versus POS N
16 POS N
(40%) POS N
eyes POS N
(P<0.001), POS N
and POS N
at POS N
6 POS N
months, POS N
18 POS N
mm POS N
Hg POS N
in POS N
38 POS N
(95%) POS N
versus POS N
28 POS N
(70%) POS N
eyes POS N
and POS N
16 POS N
mm POS N
Hg POS N
in POS N
30 POS N
(75%) POS N
versus POS N
18 POS N
(45%) POS N
eyes POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively POS N
(P<0.001). POS N

Mean POS N
IOP POS N
reductions POS N
were POS N
11.34 POS N
and POS N
6.42 POS N
mm POS N
Hg POS N
at POS N
2 POS N
weeks POS N
(P=0.000), POS N
and POS N
11.17 POS N
and POS N
7.89 POS N
mmHg POS N
at POS N
6 POS N
months POS N
(P=0.001) POS N
for POS N
BTFC POS N
and POS N
TTFC, POS N
respectively. POS N

No POS N
significant POS N
differences POS N
were POS N
observed POS N
among POS N
groups POS N
for POS N
HBeAg POS N
seroconversion POS N
(PEG-IFN POS N
alfa-2a+placebo, POS N
36.3%; POS N
PEG-IFN POS N
alfa-2a+ETV, POS N
29.5%; POS N
and POS N
PEG-IFN POS N
alfa-2a+ADV, POS N
27.4%), POS N
HBeAg POS N
loss POS N
(37.4%, POS N
32.2%, POS N
and POS N
28.6%, POS N
respectively) POS N
or POS N
change POS N
in POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
levels POS N
from POS N
baseline POS N
(-0.56 POS N
IU/mL, POS N
-0.60 POS N
IU/mL, POS N
and POS N
-0.41 POS N
IU/mL, POS N
respectively). POS N

However, POS N
hepatitis POS N
B POS N
virus POS N
DNA POS N
levels POS N
were POS N
higher POS N
with POS N
PEG-IFN POS N
alfa-2a+placebo POS N
than POS N
PEG-IFN POS N
alfa+ETV POS N
at POS N
week POS N
64 POS N
(p POS N
= POS N
0.0412), POS N
76 POS N
(p POS N
= POS N
0.0311), POS N
and POS N
88 POS N
(p POS N
= POS N
0.0113), POS N
and POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
normalization POS N
rate POS N
was POS N
higher POS N
with POS N
PEG-IFN POS N
alfa-2a+placebo POS N
than POS N
PEG-IFN POS N
alfa-2a+ADV POS N
(p POS N
= POS N
0.0283) POS N
or POS N
PEG-IFN POS N
alfa-2a+ETV POS N
(p POS N
= POS N
0.0369) POS N
at POS N
week POS N
88. POS N

No POS N
significant POS N
differences POS N
were POS N
observed POS N
among POS N
groups POS N
for POS N
HBeAg POS N
seroconversion POS N
(PEG-IFN POS N
alfa-2a+placebo, POS N
36.3%; POS N
PEG-IFN POS N
alfa-2a+ETV, POS N
29.5%; POS N
and POS N
PEG-IFN POS N
alfa-2a+ADV, POS N
27.4%), POS N
HBeAg POS N
loss POS N
(37.4%, POS N
32.2%, POS N
and POS N
28.6%, POS N
respectively) POS N
or POS N
change POS N
in POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
levels POS N
from POS N
baseline POS N
(-0.56 POS N
IU/mL, POS N
-0.60 POS N
IU/mL, POS N
and POS N
-0.41 POS N
IU/mL, POS N
respectively). POS N

Sub-analysis POS N
of POS N
results POS N
revealed POS N
an POS N
association POS N
between POS N
on-treatment POS N
HBsAg POS N
and POS N
ALT POS N
levels POS N
and POS N
efficacy POS N
48 POS N
weeks POS N
post-treatment. POS N

No POS N
significant POS N
differences POS N
were POS N
observed POS N
among POS N
groups POS N
for POS N
HBeAg POS N
seroconversion POS N
(PEG-IFN POS N
alfa-2a+placebo, POS N
36.3%; POS N
PEG-IFN POS N
alfa-2a+ETV, POS N
29.5%; POS N
and POS N
PEG-IFN POS N
alfa-2a+ADV, POS N
27.4%), POS N
HBeAg POS N
loss POS N
(37.4%, POS N
32.2%, POS N
and POS N
28.6%, POS N
respectively) POS N
or POS N
change POS N
in POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
levels POS N
from POS N
baseline POS N
(-0.56 POS N
IU/mL, POS N
-0.60 POS N
IU/mL, POS N
and POS N
-0.41 POS N
IU/mL, POS N
respectively). POS N

Safety POS N
was POS N
comparable POS N
among POS N
treatment POS N
groups. POS N

No POS N
significant POS N
differences POS N
were POS N
observed POS N
among POS N
groups POS N
for POS N
HBeAg POS N
seroconversion POS N
(PEG-IFN POS N
alfa-2a+placebo, POS N
36.3%; POS N
PEG-IFN POS N
alfa-2a+ETV, POS N
29.5%; POS N
and POS N
PEG-IFN POS N
alfa-2a+ADV, POS N
27.4%), POS N
HBeAg POS N
loss POS N
(37.4%, POS N
32.2%, POS N
and POS N
28.6%, POS N
respectively) POS N
or POS N
change POS N
in POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
levels POS N
from POS N
baseline POS N
(-0.56 POS N
IU/mL, POS N
-0.60 POS N
IU/mL, POS N
and POS N
-0.41 POS N
IU/mL, POS N
respectively). POS N

Pre-therapy POS N
with POS N
ADV POS N
or POS N
ETV POS N
followed POS N
by POS N
PEG-IFN POS N
alfa-2a POS N
is POS N
not POS N
superior POS N
to POS N
PEG-IFN POS N
alfa-2a POS N
monotherapy POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
HBeAg-positive POS N
CHB. POS N

However, POS N
hepatitis POS N
B POS N
virus POS N
DNA POS N
levels POS N
were POS N
higher POS N
with POS N
PEG-IFN POS N
alfa-2a+placebo POS N
than POS N
PEG-IFN POS N
alfa+ETV POS N
at POS N
week POS N
64 POS N
(p POS N
= POS N
0.0412), POS N
76 POS N
(p POS N
= POS N
0.0311), POS N
and POS N
88 POS N
(p POS N
= POS N
0.0113), POS N
and POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
normalization POS N
rate POS N
was POS N
higher POS N
with POS N
PEG-IFN POS N
alfa-2a+placebo POS N
than POS N
PEG-IFN POS N
alfa-2a+ADV POS N
(p POS N
= POS N
0.0283) POS N
or POS N
PEG-IFN POS N
alfa-2a+ETV POS N
(p POS N
= POS N
0.0369) POS N
at POS N
week POS N
88. POS N

No POS N
significant POS N
differences POS N
were POS N
observed POS N
among POS N
groups POS N
for POS N
HBeAg POS N
seroconversion POS N
(PEG-IFN POS N
alfa-2a+placebo, POS N
36.3%; POS N
PEG-IFN POS N
alfa-2a+ETV, POS N
29.5%; POS N
and POS N
PEG-IFN POS N
alfa-2a+ADV, POS N
27.4%), POS N
HBeAg POS N
loss POS N
(37.4%, POS N
32.2%, POS N
and POS N
28.6%, POS N
respectively) POS N
or POS N
change POS N
in POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
levels POS N
from POS N
baseline POS N
(-0.56 POS N
IU/mL, POS N
-0.60 POS N
IU/mL, POS N
and POS N
-0.41 POS N
IU/mL, POS N
respectively). POS N

However, POS N
hepatitis POS N
B POS N
virus POS N
DNA POS N
levels POS N
were POS N
higher POS N
with POS N
PEG-IFN POS N
alfa-2a+placebo POS N
than POS N
PEG-IFN POS N
alfa+ETV POS N
at POS N
week POS N
64 POS N
(p POS N
= POS N
0.0412), POS N
76 POS N
(p POS N
= POS N
0.0311), POS N
and POS N
88 POS N
(p POS N
= POS N
0.0113), POS N
and POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
normalization POS N
rate POS N
was POS N
higher POS N
with POS N
PEG-IFN POS N
alfa-2a+placebo POS N
than POS N
PEG-IFN POS N
alfa-2a+ADV POS N
(p POS N
= POS N
0.0283) POS N
or POS N
PEG-IFN POS N
alfa-2a+ETV POS N
(p POS N
= POS N
0.0369) POS N
at POS N
week POS N
88. POS N

Sub-analysis POS N
of POS N
results POS N
revealed POS N
an POS N
association POS N
between POS N
on-treatment POS N
HBsAg POS N
and POS N
ALT POS N
levels POS N
and POS N
efficacy POS N
48 POS N
weeks POS N
post-treatment. POS N

However, POS N
hepatitis POS N
B POS N
virus POS N
DNA POS N
levels POS N
were POS N
higher POS N
with POS N
PEG-IFN POS N
alfa-2a+placebo POS N
than POS N
PEG-IFN POS N
alfa+ETV POS N
at POS N
week POS N
64 POS N
(p POS N
= POS N
0.0412), POS N
76 POS N
(p POS N
= POS N
0.0311), POS N
and POS N
88 POS N
(p POS N
= POS N
0.0113), POS N
and POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
normalization POS N
rate POS N
was POS N
higher POS N
with POS N
PEG-IFN POS N
alfa-2a+placebo POS N
than POS N
PEG-IFN POS N
alfa-2a+ADV POS N
(p POS N
= POS N
0.0283) POS N
or POS N
PEG-IFN POS N
alfa-2a+ETV POS N
(p POS N
= POS N
0.0369) POS N
at POS N
week POS N
88. POS N

Safety POS N
was POS N
comparable POS N
among POS N
treatment POS N
groups. POS N

However, POS N
hepatitis POS N
B POS N
virus POS N
DNA POS N
levels POS N
were POS N
higher POS N
with POS N
PEG-IFN POS N
alfa-2a+placebo POS N
than POS N
PEG-IFN POS N
alfa+ETV POS N
at POS N
week POS N
64 POS N
(p POS N
= POS N
0.0412), POS N
76 POS N
(p POS N
= POS N
0.0311), POS N
and POS N
88 POS N
(p POS N
= POS N
0.0113), POS N
and POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
normalization POS N
rate POS N
was POS N
higher POS N
with POS N
PEG-IFN POS N
alfa-2a+placebo POS N
than POS N
PEG-IFN POS N
alfa-2a+ADV POS N
(p POS N
= POS N
0.0283) POS N
or POS N
PEG-IFN POS N
alfa-2a+ETV POS N
(p POS N
= POS N
0.0369) POS N
at POS N
week POS N
88. POS N

Pre-therapy POS N
with POS N
ADV POS N
or POS N
ETV POS N
followed POS N
by POS N
PEG-IFN POS N
alfa-2a POS N
is POS N
not POS N
superior POS N
to POS N
PEG-IFN POS N
alfa-2a POS N
monotherapy POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
HBeAg-positive POS N
CHB. POS N

Sub-analysis POS N
of POS N
results POS N
revealed POS N
an POS N
association POS N
between POS N
on-treatment POS N
HBsAg POS N
and POS N
ALT POS N
levels POS N
and POS N
efficacy POS N
48 POS N
weeks POS N
post-treatment. POS N

No POS N
significant POS N
differences POS N
were POS N
observed POS N
among POS N
groups POS N
for POS N
HBeAg POS N
seroconversion POS N
(PEG-IFN POS N
alfa-2a+placebo, POS N
36.3%; POS N
PEG-IFN POS N
alfa-2a+ETV, POS N
29.5%; POS N
and POS N
PEG-IFN POS N
alfa-2a+ADV, POS N
27.4%), POS N
HBeAg POS N
loss POS N
(37.4%, POS N
32.2%, POS N
and POS N
28.6%, POS N
respectively) POS N
or POS N
change POS N
in POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
levels POS N
from POS N
baseline POS N
(-0.56 POS N
IU/mL, POS N
-0.60 POS N
IU/mL, POS N
and POS N
-0.41 POS N
IU/mL, POS N
respectively). POS N

Sub-analysis POS N
of POS N
results POS N
revealed POS N
an POS N
association POS N
between POS N
on-treatment POS N
HBsAg POS N
and POS N
ALT POS N
levels POS N
and POS N
efficacy POS N
48 POS N
weeks POS N
post-treatment. POS N

However, POS N
hepatitis POS N
B POS N
virus POS N
DNA POS N
levels POS N
were POS N
higher POS N
with POS N
PEG-IFN POS N
alfa-2a+placebo POS N
than POS N
PEG-IFN POS N
alfa+ETV POS N
at POS N
week POS N
64 POS N
(p POS N
= POS N
0.0412), POS N
76 POS N
(p POS N
= POS N
0.0311), POS N
and POS N
88 POS N
(p POS N
= POS N
0.0113), POS N
and POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
normalization POS N
rate POS N
was POS N
higher POS N
with POS N
PEG-IFN POS N
alfa-2a+placebo POS N
than POS N
PEG-IFN POS N
alfa-2a+ADV POS N
(p POS N
= POS N
0.0283) POS N
or POS N
PEG-IFN POS N
alfa-2a+ETV POS N
(p POS N
= POS N
0.0369) POS N
at POS N
week POS N
88. POS N

Sub-analysis POS N
of POS N
results POS N
revealed POS N
an POS N
association POS N
between POS N
on-treatment POS N
HBsAg POS N
and POS N
ALT POS N
levels POS N
and POS N
efficacy POS N
48 POS N
weeks POS N
post-treatment. POS N

Safety POS N
was POS N
comparable POS N
among POS N
treatment POS N
groups. POS N

Sub-analysis POS N
of POS N
results POS N
revealed POS N
an POS N
association POS N
between POS N
on-treatment POS N
HBsAg POS N
and POS N
ALT POS N
levels POS N
and POS N
efficacy POS N
48 POS N
weeks POS N
post-treatment. POS N

Pre-therapy POS N
with POS N
ADV POS N
or POS N
ETV POS N
followed POS N
by POS N
PEG-IFN POS N
alfa-2a POS N
is POS N
not POS N
superior POS N
to POS N
PEG-IFN POS N
alfa-2a POS N
monotherapy POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
HBeAg-positive POS N
CHB. POS N

Safety POS N
was POS N
comparable POS N
among POS N
treatment POS N
groups. POS N

No POS N
significant POS N
differences POS N
were POS N
observed POS N
among POS N
groups POS N
for POS N
HBeAg POS N
seroconversion POS N
(PEG-IFN POS N
alfa-2a+placebo, POS N
36.3%; POS N
PEG-IFN POS N
alfa-2a+ETV, POS N
29.5%; POS N
and POS N
PEG-IFN POS N
alfa-2a+ADV, POS N
27.4%), POS N
HBeAg POS N
loss POS N
(37.4%, POS N
32.2%, POS N
and POS N
28.6%, POS N
respectively) POS N
or POS N
change POS N
in POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
levels POS N
from POS N
baseline POS N
(-0.56 POS N
IU/mL, POS N
-0.60 POS N
IU/mL, POS N
and POS N
-0.41 POS N
IU/mL, POS N
respectively). POS N

Safety POS N
was POS N
comparable POS N
among POS N
treatment POS N
groups. POS N

However, POS N
hepatitis POS N
B POS N
virus POS N
DNA POS N
levels POS N
were POS N
higher POS N
with POS N
PEG-IFN POS N
alfa-2a+placebo POS N
than POS N
PEG-IFN POS N
alfa+ETV POS N
at POS N
week POS N
64 POS N
(p POS N
= POS N
0.0412), POS N
76 POS N
(p POS N
= POS N
0.0311), POS N
and POS N
88 POS N
(p POS N
= POS N
0.0113), POS N
and POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
normalization POS N
rate POS N
was POS N
higher POS N
with POS N
PEG-IFN POS N
alfa-2a+placebo POS N
than POS N
PEG-IFN POS N
alfa-2a+ADV POS N
(p POS N
= POS N
0.0283) POS N
or POS N
PEG-IFN POS N
alfa-2a+ETV POS N
(p POS N
= POS N
0.0369) POS N
at POS N
week POS N
88. POS N

Safety POS N
was POS N
comparable POS N
among POS N
treatment POS N
groups. POS N

Sub-analysis POS N
of POS N
results POS N
revealed POS N
an POS N
association POS N
between POS N
on-treatment POS N
HBsAg POS N
and POS N
ALT POS N
levels POS N
and POS N
efficacy POS N
48 POS N
weeks POS N
post-treatment. POS N

Safety POS N
was POS N
comparable POS N
among POS N
treatment POS N
groups. POS N

Pre-therapy POS N
with POS N
ADV POS N
or POS N
ETV POS N
followed POS N
by POS N
PEG-IFN POS N
alfa-2a POS N
is POS N
not POS N
superior POS N
to POS N
PEG-IFN POS N
alfa-2a POS N
monotherapy POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
HBeAg-positive POS N
CHB. POS N

Pre-therapy POS N
with POS N
ADV POS N
or POS N
ETV POS N
followed POS N
by POS N
PEG-IFN POS N
alfa-2a POS N
is POS N
not POS N
superior POS N
to POS N
PEG-IFN POS N
alfa-2a POS N
monotherapy POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
HBeAg-positive POS N
CHB. POS N

No POS N
significant POS N
differences POS N
were POS N
observed POS N
among POS N
groups POS N
for POS N
HBeAg POS N
seroconversion POS N
(PEG-IFN POS N
alfa-2a+placebo, POS N
36.3%; POS N
PEG-IFN POS N
alfa-2a+ETV, POS N
29.5%; POS N
and POS N
PEG-IFN POS N
alfa-2a+ADV, POS N
27.4%), POS N
HBeAg POS N
loss POS N
(37.4%, POS N
32.2%, POS N
and POS N
28.6%, POS N
respectively) POS N
or POS N
change POS N
in POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
levels POS N
from POS N
baseline POS N
(-0.56 POS N
IU/mL, POS N
-0.60 POS N
IU/mL, POS N
and POS N
-0.41 POS N
IU/mL, POS N
respectively). POS N

Pre-therapy POS N
with POS N
ADV POS N
or POS N
ETV POS N
followed POS N
by POS N
PEG-IFN POS N
alfa-2a POS N
is POS N
not POS N
superior POS N
to POS N
PEG-IFN POS N
alfa-2a POS N
monotherapy POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
HBeAg-positive POS N
CHB. POS N

However, POS N
hepatitis POS N
B POS N
virus POS N
DNA POS N
levels POS N
were POS N
higher POS N
with POS N
PEG-IFN POS N
alfa-2a+placebo POS N
than POS N
PEG-IFN POS N
alfa+ETV POS N
at POS N
week POS N
64 POS N
(p POS N
= POS N
0.0412), POS N
76 POS N
(p POS N
= POS N
0.0311), POS N
and POS N
88 POS N
(p POS N
= POS N
0.0113), POS N
and POS N
alanine POS N
aminotransferase POS N
(ALT) POS N
normalization POS N
rate POS N
was POS N
higher POS N
with POS N
PEG-IFN POS N
alfa-2a+placebo POS N
than POS N
PEG-IFN POS N
alfa-2a+ADV POS N
(p POS N
= POS N
0.0283) POS N
or POS N
PEG-IFN POS N
alfa-2a+ETV POS N
(p POS N
= POS N
0.0369) POS N
at POS N
week POS N
88. POS N

Pre-therapy POS N
with POS N
ADV POS N
or POS N
ETV POS N
followed POS N
by POS N
PEG-IFN POS N
alfa-2a POS N
is POS N
not POS N
superior POS N
to POS N
PEG-IFN POS N
alfa-2a POS N
monotherapy POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
HBeAg-positive POS N
CHB. POS N

Sub-analysis POS N
of POS N
results POS N
revealed POS N
an POS N
association POS N
between POS N
on-treatment POS N
HBsAg POS N
and POS N
ALT POS N
levels POS N
and POS N
efficacy POS N
48 POS N
weeks POS N
post-treatment. POS N

Pre-therapy POS N
with POS N
ADV POS N
or POS N
ETV POS N
followed POS N
by POS N
PEG-IFN POS N
alfa-2a POS N
is POS N
not POS N
superior POS N
to POS N
PEG-IFN POS N
alfa-2a POS N
monotherapy POS N
in POS N
Taiwanese POS N
patients POS N
with POS N
HBeAg-positive POS N
CHB. POS N

Safety POS N
was POS N
comparable POS N
among POS N
treatment POS N
groups. POS N

Over POS N
73 POS N
months POS N
after POS N
randomization, POS N
the POS N
fludarabine POS N
group POS N
gained POS N
a POS N
mean POS N
of POS N
45 POS N
days POS N
of POS N
toxicity-free POS N
survival POS N
at POS N
CAP, POS N
and POS N
61 POS N
days POS N
over POS N
ChOP. POS N

The POS N
mean POS N
TWIST POS N
was POS N
27.05 POS N
months POS N
with POS N
CAP, POS N
31.5 POS N
months POS N
with POS N
ChOP POS N
and POS N
32.95 POS N
months POS N
with POS N
fludarabine. POS N

Over POS N
73 POS N
months POS N
after POS N
randomization, POS N
the POS N
fludarabine POS N
group POS N
gained POS N
a POS N
mean POS N
of POS N
45 POS N
days POS N
of POS N
toxicity-free POS N
survival POS N
at POS N
CAP, POS N
and POS N
61 POS N
days POS N
over POS N
ChOP. POS N

The POS N
threshold POS N
analyses POS N
showed POS N
that, POS N
whatever POS N
the POS N
utility POS N
weights, POS N
the POS N
mean POS N
Q-TWIST POS N
was POS N
always POS N
greater POS N
with POS N
ChOP POS N
or POS N
fludarabine POS N
as POS N
compared POS N
to POS N
CAP. POS N

Over POS N
73 POS N
months POS N
after POS N
randomization, POS N
the POS N
fludarabine POS N
group POS N
gained POS N
a POS N
mean POS N
of POS N
45 POS N
days POS N
of POS N
toxicity-free POS N
survival POS N
at POS N
CAP, POS N
and POS N
61 POS N
days POS N
over POS N
ChOP. POS N

Fludarabine POS N
was POS N
consistently POS N
a POS N
better POS N
treatment POS N
than POS N
ChOP, POS N

Over POS N
73 POS N
months POS N
after POS N
randomization, POS N
the POS N
fludarabine POS N
group POS N
gained POS N
a POS N
mean POS N
of POS N
45 POS N
days POS N
of POS N
toxicity-free POS N
survival POS N
at POS N
CAP, POS N
and POS N
61 POS N
days POS N
over POS N
ChOP. POS N

except POS N
in POS N
the POS N
unlikely POS N
case POS N
of POS N
high POS N
utility POS N
weights POS N
attributed POS N
to POS N
toxicity POS N
and POS N
low POS N
utility POS N
weights POS N
attributed POS N
to POS N
treatment. POS N

Over POS N
73 POS N
months POS N
after POS N
randomization, POS N
the POS N
fludarabine POS N
group POS N
gained POS N
a POS N
mean POS N
of POS N
45 POS N
days POS N
of POS N
toxicity-free POS N
survival POS N
at POS N
CAP, POS N
and POS N
61 POS N
days POS N
over POS N
ChOP. POS N

from POS N
a POS N
clinical POS N
point POS N
of POS N
view, POS N
differences POS N
between POS N
ChOP POS N
and POS N
fludarabine POS N
were POS N
moderate POS N
or POS N
event POS N
slight POS N
(mean POS N
difference POS N
in POS N
TWIST POS N
of POS N
1.45 POS N
months). POS N

Over POS N
73 POS N
months POS N
after POS N
randomization, POS N
the POS N
fludarabine POS N
group POS N
gained POS N
a POS N
mean POS N
of POS N
45 POS N
days POS N
of POS N
toxicity-free POS N
survival POS N
at POS N
CAP, POS N
and POS N
61 POS N
days POS N
over POS N
ChOP. POS N

patients POS N
with POS N
advanced POS N
CLL POS N
have POS N
a POS N
moderate POS N
benefit POS N
in POS N
terms POS N
of POS N
Q-TWIST POS N
when POS N
treated POS N
with POS N
fludarabine POS N
over POS N
ChOP. POS N

Over POS N
73 POS N
months POS N
after POS N
randomization, POS N
the POS N
fludarabine POS N
group POS N
gained POS N
a POS N
mean POS N
of POS N
45 POS N
days POS N
of POS N
toxicity-free POS N
survival POS N
at POS N
CAP, POS N
and POS N
61 POS N
days POS N
over POS N
ChOP. POS N

These POS N
two POS N
treatments POS N
are POS N
always POS N
superior POS N
to POS N
CAP. POS N

The POS N
mean POS N
TWIST POS N
was POS N
27.05 POS N
months POS N
with POS N
CAP, POS N
31.5 POS N
months POS N
with POS N
ChOP POS N
and POS N
32.95 POS N
months POS N
with POS N
fludarabine. POS N

Over POS N
73 POS N
months POS N
after POS N
randomization, POS N
the POS N
fludarabine POS N
group POS N
gained POS N
a POS N
mean POS N
of POS N
45 POS N
days POS N
of POS N
toxicity-free POS N
survival POS N
at POS N
CAP, POS N
and POS N
61 POS N
days POS N
over POS N
ChOP. POS N

The POS N
mean POS N
TWIST POS N
was POS N
27.05 POS N
months POS N
with POS N
CAP, POS N
31.5 POS N
months POS N
with POS N
ChOP POS N
and POS N
32.95 POS N
months POS N
with POS N
fludarabine. POS N

The POS N
threshold POS N
analyses POS N
showed POS N
that, POS N
whatever POS N
the POS N
utility POS N
weights, POS N
the POS N
mean POS N
Q-TWIST POS N
was POS N
always POS N
greater POS N
with POS N
ChOP POS N
or POS N
fludarabine POS N
as POS N
compared POS N
to POS N
CAP. POS N

The POS N
mean POS N
TWIST POS N
was POS N
27.05 POS N
months POS N
with POS N
CAP, POS N
31.5 POS N
months POS N
with POS N
ChOP POS N
and POS N
32.95 POS N
months POS N
with POS N
fludarabine. POS N

Fludarabine POS N
was POS N
consistently POS N
a POS N
better POS N
treatment POS N
than POS N
ChOP, POS N

The POS N
mean POS N
TWIST POS N
was POS N
27.05 POS N
months POS N
with POS N
CAP, POS N
31.5 POS N
months POS N
with POS N
ChOP POS N
and POS N
32.95 POS N
months POS N
with POS N
fludarabine. POS N

except POS N
in POS N
the POS N
unlikely POS N
case POS N
of POS N
high POS N
utility POS N
weights POS N
attributed POS N
to POS N
toxicity POS N
and POS N
low POS N
utility POS N
weights POS N
attributed POS N
to POS N
treatment. POS N

The POS N
mean POS N
TWIST POS N
was POS N
27.05 POS N
months POS N
with POS N
CAP, POS N
31.5 POS N
months POS N
with POS N
ChOP POS N
and POS N
32.95 POS N
months POS N
with POS N
fludarabine. POS N

from POS N
a POS N
clinical POS N
point POS N
of POS N
view, POS N
differences POS N
between POS N
ChOP POS N
and POS N
fludarabine POS N
were POS N
moderate POS N
or POS N
event POS N
slight POS N
(mean POS N
difference POS N
in POS N
TWIST POS N
of POS N
1.45 POS N
months). POS N

The POS N
mean POS N
TWIST POS N
was POS N
27.05 POS N
months POS N
with POS N
CAP, POS N
31.5 POS N
months POS N
with POS N
ChOP POS N
and POS N
32.95 POS N
months POS N
with POS N
fludarabine. POS N

patients POS N
with POS N
advanced POS N
CLL POS N
have POS N
a POS N
moderate POS N
benefit POS N
in POS N
terms POS N
of POS N
Q-TWIST POS N
when POS N
treated POS N
with POS N
fludarabine POS N
over POS N
ChOP. POS N

The POS N
mean POS N
TWIST POS N
was POS N
27.05 POS N
months POS N
with POS N
CAP, POS N
31.5 POS N
months POS N
with POS N
ChOP POS N
and POS N
32.95 POS N
months POS N
with POS N
fludarabine. POS N

These POS N
two POS N
treatments POS N
are POS N
always POS N
superior POS N
to POS N
CAP. POS N

The POS N
threshold POS N
analyses POS N
showed POS N
that, POS N
whatever POS N
the POS N
utility POS N
weights, POS N
the POS N
mean POS N
Q-TWIST POS N
was POS N
always POS N
greater POS N
with POS N
ChOP POS N
or POS N
fludarabine POS N
as POS N
compared POS N
to POS N
CAP. POS N

Over POS N
73 POS N
months POS N
after POS N
randomization, POS N
the POS N
fludarabine POS N
group POS N
gained POS N
a POS N
mean POS N
of POS N
45 POS N
days POS N
of POS N
toxicity-free POS N
survival POS N
at POS N
CAP, POS N
and POS N
61 POS N
days POS N
over POS N
ChOP. POS N

The POS N
threshold POS N
analyses POS N
showed POS N
that, POS N
whatever POS N
the POS N
utility POS N
weights, POS N
the POS N
mean POS N
Q-TWIST POS N
was POS N
always POS N
greater POS N
with POS N
ChOP POS N
or POS N
fludarabine POS N
as POS N
compared POS N
to POS N
CAP. POS N

The POS N
mean POS N
TWIST POS N
was POS N
27.05 POS N
months POS N
with POS N
CAP, POS N
31.5 POS N
months POS N
with POS N
ChOP POS N
and POS N
32.95 POS N
months POS N
with POS N
fludarabine. POS N

The POS N
threshold POS N
analyses POS N
showed POS N
that, POS N
whatever POS N
the POS N
utility POS N
weights, POS N
the POS N
mean POS N
Q-TWIST POS N
was POS N
always POS N
greater POS N
with POS N
ChOP POS N
or POS N
fludarabine POS N
as POS N
compared POS N
to POS N
CAP. POS N

Fludarabine POS N
was POS N
consistently POS N
a POS N
better POS N
treatment POS N
than POS N
ChOP, POS N

The POS N
threshold POS N
analyses POS N
showed POS N
that, POS N
whatever POS N
the POS N
utility POS N
weights, POS N
the POS N
mean POS N
Q-TWIST POS N
was POS N
always POS N
greater POS N
with POS N
ChOP POS N
or POS N
fludarabine POS N
as POS N
compared POS N
to POS N
CAP. POS N

except POS N
in POS N
the POS N
unlikely POS N
case POS N
of POS N
high POS N
utility POS N
weights POS N
attributed POS N
to POS N
toxicity POS N
and POS N
low POS N
utility POS N
weights POS N
attributed POS N
to POS N
treatment. POS N

The POS N
threshold POS N
analyses POS N
showed POS N
that, POS N
whatever POS N
the POS N
utility POS N
weights, POS N
the POS N
mean POS N
Q-TWIST POS N
was POS N
always POS N
greater POS N
with POS N
ChOP POS N
or POS N
fludarabine POS N
as POS N
compared POS N
to POS N
CAP. POS N

from POS N
a POS N
clinical POS N
point POS N
of POS N
view, POS N
differences POS N
between POS N
ChOP POS N
and POS N
fludarabine POS N
were POS N
moderate POS N
or POS N
event POS N
slight POS N
(mean POS N
difference POS N
in POS N
TWIST POS N
of POS N
1.45 POS N
months). POS N

The POS N
threshold POS N
analyses POS N
showed POS N
that, POS N
whatever POS N
the POS N
utility POS N
weights, POS N
the POS N
mean POS N
Q-TWIST POS N
was POS N
always POS N
greater POS N
with POS N
ChOP POS N
or POS N
fludarabine POS N
as POS N
compared POS N
to POS N
CAP. POS N

patients POS N
with POS N
advanced POS N
CLL POS N
have POS N
a POS N
moderate POS N
benefit POS N
in POS N
terms POS N
of POS N
Q-TWIST POS N
when POS N
treated POS N
with POS N
fludarabine POS N
over POS N
ChOP. POS N

The POS N
threshold POS N
analyses POS N
showed POS N
that, POS N
whatever POS N
the POS N
utility POS N
weights, POS N
the POS N
mean POS N
Q-TWIST POS N
was POS N
always POS N
greater POS N
with POS N
ChOP POS N
or POS N
fludarabine POS N
as POS N
compared POS N
to POS N
CAP. POS N

These POS N
two POS N
treatments POS N
are POS N
always POS N
superior POS N
to POS N
CAP. POS N

Fludarabine POS N
was POS N
consistently POS N
a POS N
better POS N
treatment POS N
than POS N
ChOP, POS N

Over POS N
73 POS N
months POS N
after POS N
randomization, POS N
the POS N
fludarabine POS N
group POS N
gained POS N
a POS N
mean POS N
of POS N
45 POS N
days POS N
of POS N
toxicity-free POS N
survival POS N
at POS N
CAP, POS N
and POS N
61 POS N
days POS N
over POS N
ChOP. POS N

Fludarabine POS N
was POS N
consistently POS N
a POS N
better POS N
treatment POS N
than POS N
ChOP, POS N

The POS N
mean POS N
TWIST POS N
was POS N
27.05 POS N
months POS N
with POS N
CAP, POS N
31.5 POS N
months POS N
with POS N
ChOP POS N
and POS N
32.95 POS N
months POS N
with POS N
fludarabine. POS N

Fludarabine POS N
was POS N
consistently POS N
a POS N
better POS N
treatment POS N
than POS N
ChOP, POS N

The POS N
threshold POS N
analyses POS N
showed POS N
that, POS N
whatever POS N
the POS N
utility POS N
weights, POS N
the POS N
mean POS N
Q-TWIST POS N
was POS N
always POS N
greater POS N
with POS N
ChOP POS N
or POS N
fludarabine POS N
as POS N
compared POS N
to POS N
CAP. POS N

Fludarabine POS N
was POS N
consistently POS N
a POS N
better POS N
treatment POS N
than POS N
ChOP, POS N

except POS N
in POS N
the POS N
unlikely POS N
case POS N
of POS N
high POS N
utility POS N
weights POS N
attributed POS N
to POS N
toxicity POS N
and POS N
low POS N
utility POS N
weights POS N
attributed POS N
to POS N
treatment. POS N

Fludarabine POS N
was POS N
consistently POS N
a POS N
better POS N
treatment POS N
than POS N
ChOP, POS N

from POS N
a POS N
clinical POS N
point POS N
of POS N
view, POS N
differences POS N
between POS N
ChOP POS N
and POS N
fludarabine POS N
were POS N
moderate POS N
or POS N
event POS N
slight POS N
(mean POS N
difference POS N
in POS N
TWIST POS N
of POS N
1.45 POS N
months). POS N

Fludarabine POS N
was POS N
consistently POS N
a POS N
better POS N
treatment POS N
than POS N
ChOP, POS N

patients POS N
with POS N
advanced POS N
CLL POS N
have POS N
a POS N
moderate POS N
benefit POS N
in POS N
terms POS N
of POS N
Q-TWIST POS N
when POS N
treated POS N
with POS N
fludarabine POS N
over POS N
ChOP. POS N

Fludarabine POS N
was POS N
consistently POS N
a POS N
better POS N
treatment POS N
than POS N
ChOP, POS N

These POS N
two POS N
treatments POS N
are POS N
always POS N
superior POS N
to POS N
CAP. POS N

except POS N
in POS N
the POS N
unlikely POS N
case POS N
of POS N
high POS N
utility POS N
weights POS N
attributed POS N
to POS N
toxicity POS N
and POS N
low POS N
utility POS N
weights POS N
attributed POS N
to POS N
treatment. POS N

Over POS N
73 POS N
months POS N
after POS N
randomization, POS N
the POS N
fludarabine POS N
group POS N
gained POS N
a POS N
mean POS N
of POS N
45 POS N
days POS N
of POS N
toxicity-free POS N
survival POS N
at POS N
CAP, POS N
and POS N
61 POS N
days POS N
over POS N
ChOP. POS N

except POS N
in POS N
the POS N
unlikely POS N
case POS N
of POS N
high POS N
utility POS N
weights POS N
attributed POS N
to POS N
toxicity POS N
and POS N
low POS N
utility POS N
weights POS N
attributed POS N
to POS N
treatment. POS N

The POS N
mean POS N
TWIST POS N
was POS N
27.05 POS N
months POS N
with POS N
CAP, POS N
31.5 POS N
months POS N
with POS N
ChOP POS N
and POS N
32.95 POS N
months POS N
with POS N
fludarabine. POS N

except POS N
in POS N
the POS N
unlikely POS N
case POS N
of POS N
high POS N
utility POS N
weights POS N
attributed POS N
to POS N
toxicity POS N
and POS N
low POS N
utility POS N
weights POS N
attributed POS N
to POS N
treatment. POS N

The POS N
threshold POS N
analyses POS N
showed POS N
that, POS N
whatever POS N
the POS N
utility POS N
weights, POS N
the POS N
mean POS N
Q-TWIST POS N
was POS N
always POS N
greater POS N
with POS N
ChOP POS N
or POS N
fludarabine POS N
as POS N
compared POS N
to POS N
CAP. POS N

except POS N
in POS N
the POS N
unlikely POS N
case POS N
of POS N
high POS N
utility POS N
weights POS N
attributed POS N
to POS N
toxicity POS N
and POS N
low POS N
utility POS N
weights POS N
attributed POS N
to POS N
treatment. POS N

Fludarabine POS N
was POS N
consistently POS N
a POS N
better POS N
treatment POS N
than POS N
ChOP, POS N

except POS N
in POS N
the POS N
unlikely POS N
case POS N
of POS N
high POS N
utility POS N
weights POS N
attributed POS N
to POS N
toxicity POS N
and POS N
low POS N
utility POS N
weights POS N
attributed POS N
to POS N
treatment. POS N

from POS N
a POS N
clinical POS N
point POS N
of POS N
view, POS N
differences POS N
between POS N
ChOP POS N
and POS N
fludarabine POS N
were POS N
moderate POS N
or POS N
event POS N
slight POS N
(mean POS N
difference POS N
in POS N
TWIST POS N
of POS N
1.45 POS N
months). POS N

except POS N
in POS N
the POS N
unlikely POS N
case POS N
of POS N
high POS N
utility POS N
weights POS N
attributed POS N
to POS N
toxicity POS N
and POS N
low POS N
utility POS N
weights POS N
attributed POS N
to POS N
treatment. POS N

patients POS N
with POS N
advanced POS N
CLL POS N
have POS N
a POS N
moderate POS N
benefit POS N
in POS N
terms POS N
of POS N
Q-TWIST POS N
when POS N
treated POS N
with POS N
fludarabine POS N
over POS N
ChOP. POS N

except POS N
in POS N
the POS N
unlikely POS N
case POS N
of POS N
high POS N
utility POS N
weights POS N
attributed POS N
to POS N
toxicity POS N
and POS N
low POS N
utility POS N
weights POS N
attributed POS N
to POS N
treatment. POS N

These POS N
two POS N
treatments POS N
are POS N
always POS N
superior POS N
to POS N
CAP. POS N

from POS N
a POS N
clinical POS N
point POS N
of POS N
view, POS N
differences POS N
between POS N
ChOP POS N
and POS N
fludarabine POS N
were POS N
moderate POS N
or POS N
event POS N
slight POS N
(mean POS N
difference POS N
in POS N
TWIST POS N
of POS N
1.45 POS N
months). POS N

Over POS N
73 POS N
months POS N
after POS N
randomization, POS N
the POS N
fludarabine POS N
group POS N
gained POS N
a POS N
mean POS N
of POS N
45 POS N
days POS N
of POS N
toxicity-free POS N
survival POS N
at POS N
CAP, POS N
and POS N
61 POS N
days POS N
over POS N
ChOP. POS N

from POS N
a POS N
clinical POS N
point POS N
of POS N
view, POS N
differences POS N
between POS N
ChOP POS N
and POS N
fludarabine POS N
were POS N
moderate POS N
or POS N
event POS N
slight POS N
(mean POS N
difference POS N
in POS N
TWIST POS N
of POS N
1.45 POS N
months). POS N

The POS N
mean POS N
TWIST POS N
was POS N
27.05 POS N
months POS N
with POS N
CAP, POS N
31.5 POS N
months POS N
with POS N
ChOP POS N
and POS N
32.95 POS N
months POS N
with POS N
fludarabine. POS N

from POS N
a POS N
clinical POS N
point POS N
of POS N
view, POS N
differences POS N
between POS N
ChOP POS N
and POS N
fludarabine POS N
were POS N
moderate POS N
or POS N
event POS N
slight POS N
(mean POS N
difference POS N
in POS N
TWIST POS N
of POS N
1.45 POS N
months). POS N

The POS N
threshold POS N
analyses POS N
showed POS N
that, POS N
whatever POS N
the POS N
utility POS N
weights, POS N
the POS N
mean POS N
Q-TWIST POS N
was POS N
always POS N
greater POS N
with POS N
ChOP POS N
or POS N
fludarabine POS N
as POS N
compared POS N
to POS N
CAP. POS N

from POS N
a POS N
clinical POS N
point POS N
of POS N
view, POS N
differences POS N
between POS N
ChOP POS N
and POS N
fludarabine POS N
were POS N
moderate POS N
or POS N
event POS N
slight POS N
(mean POS N
difference POS N
in POS N
TWIST POS N
of POS N
1.45 POS N
months). POS N

Fludarabine POS N
was POS N
consistently POS N
a POS N
better POS N
treatment POS N
than POS N
ChOP, POS N

from POS N
a POS N
clinical POS N
point POS N
of POS N
view, POS N
differences POS N
between POS N
ChOP POS N
and POS N
fludarabine POS N
were POS N
moderate POS N
or POS N
event POS N
slight POS N
(mean POS N
difference POS N
in POS N
TWIST POS N
of POS N
1.45 POS N
months). POS N

except POS N
in POS N
the POS N
unlikely POS N
case POS N
of POS N
high POS N
utility POS N
weights POS N
attributed POS N
to POS N
toxicity POS N
and POS N
low POS N
utility POS N
weights POS N
attributed POS N
to POS N
treatment. POS N

from POS N
a POS N
clinical POS N
point POS N
of POS N
view, POS N
differences POS N
between POS N
ChOP POS N
and POS N
fludarabine POS N
were POS N
moderate POS N
or POS N
event POS N
slight POS N
(mean POS N
difference POS N
in POS N
TWIST POS N
of POS N
1.45 POS N
months). POS N

patients POS N
with POS N
advanced POS N
CLL POS N
have POS N
a POS N
moderate POS N
benefit POS N
in POS N
terms POS N
of POS N
Q-TWIST POS N
when POS N
treated POS N
with POS N
fludarabine POS N
over POS N
ChOP. POS N

from POS N
a POS N
clinical POS N
point POS N
of POS N
view, POS N
differences POS N
between POS N
ChOP POS N
and POS N
fludarabine POS N
were POS N
moderate POS N
or POS N
event POS N
slight POS N
(mean POS N
difference POS N
in POS N
TWIST POS N
of POS N
1.45 POS N
months). POS N

These POS N
two POS N
treatments POS N
are POS N
always POS N
superior POS N
to POS N
CAP. POS N

patients POS N
with POS N
advanced POS N
CLL POS N
have POS N
a POS N
moderate POS N
benefit POS N
in POS N
terms POS N
of POS N
Q-TWIST POS N
when POS N
treated POS N
with POS N
fludarabine POS N
over POS N
ChOP. POS N

Over POS N
73 POS N
months POS N
after POS N
randomization, POS N
the POS N
fludarabine POS N
group POS N
gained POS N
a POS N
mean POS N
of POS N
45 POS N
days POS N
of POS N
toxicity-free POS N
survival POS N
at POS N
CAP, POS N
and POS N
61 POS N
days POS N
over POS N
ChOP. POS N

patients POS N
with POS N
advanced POS N
CLL POS N
have POS N
a POS N
moderate POS N
benefit POS N
in POS N
terms POS N
of POS N
Q-TWIST POS N
when POS N
treated POS N
with POS N
fludarabine POS N
over POS N
ChOP. POS N

The POS N
mean POS N
TWIST POS N
was POS N
27.05 POS N
months POS N
with POS N
CAP, POS N
31.5 POS N
months POS N
with POS N
ChOP POS N
and POS N
32.95 POS N
months POS N
with POS N
fludarabine. POS N

patients POS N
with POS N
advanced POS N
CLL POS N
have POS N
a POS N
moderate POS N
benefit POS N
in POS N
terms POS N
of POS N
Q-TWIST POS N
when POS N
treated POS N
with POS N
fludarabine POS N
over POS N
ChOP. POS N

The POS N
threshold POS N
analyses POS N
showed POS N
that, POS N
whatever POS N
the POS N
utility POS N
weights, POS N
the POS N
mean POS N
Q-TWIST POS N
was POS N
always POS N
greater POS N
with POS N
ChOP POS N
or POS N
fludarabine POS N
as POS N
compared POS N
to POS N
CAP. POS N

patients POS N
with POS N
advanced POS N
CLL POS N
have POS N
a POS N
moderate POS N
benefit POS N
in POS N
terms POS N
of POS N
Q-TWIST POS N
when POS N
treated POS N
with POS N
fludarabine POS N
over POS N
ChOP. POS N

Fludarabine POS N
was POS N
consistently POS N
a POS N
better POS N
treatment POS N
than POS N
ChOP, POS N

patients POS N
with POS N
advanced POS N
CLL POS N
have POS N
a POS N
moderate POS N
benefit POS N
in POS N
terms POS N
of POS N
Q-TWIST POS N
when POS N
treated POS N
with POS N
fludarabine POS N
over POS N
ChOP. POS N

except POS N
in POS N
the POS N
unlikely POS N
case POS N
of POS N
high POS N
utility POS N
weights POS N
attributed POS N
to POS N
toxicity POS N
and POS N
low POS N
utility POS N
weights POS N
attributed POS N
to POS N
treatment. POS N

patients POS N
with POS N
advanced POS N
CLL POS N
have POS N
a POS N
moderate POS N
benefit POS N
in POS N
terms POS N
of POS N
Q-TWIST POS N
when POS N
treated POS N
with POS N
fludarabine POS N
over POS N
ChOP. POS N

from POS N
a POS N
clinical POS N
point POS N
of POS N
view, POS N
differences POS N
between POS N
ChOP POS N
and POS N
fludarabine POS N
were POS N
moderate POS N
or POS N
event POS N
slight POS N
(mean POS N
difference POS N
in POS N
TWIST POS N
of POS N
1.45 POS N
months). POS N

patients POS N
with POS N
advanced POS N
CLL POS N
have POS N
a POS N
moderate POS N
benefit POS N
in POS N
terms POS N
of POS N
Q-TWIST POS N
when POS N
treated POS N
with POS N
fludarabine POS N
over POS N
ChOP. POS N

These POS N
two POS N
treatments POS N
are POS N
always POS N
superior POS N
to POS N
CAP. POS N

These POS N
two POS N
treatments POS N
are POS N
always POS N
superior POS N
to POS N
CAP. POS N

Over POS N
73 POS N
months POS N
after POS N
randomization, POS N
the POS N
fludarabine POS N
group POS N
gained POS N
a POS N
mean POS N
of POS N
45 POS N
days POS N
of POS N
toxicity-free POS N
survival POS N
at POS N
CAP, POS N
and POS N
61 POS N
days POS N
over POS N
ChOP. POS N

These POS N
two POS N
treatments POS N
are POS N
always POS N
superior POS N
to POS N
CAP. POS N

The POS N
mean POS N
TWIST POS N
was POS N
27.05 POS N
months POS N
with POS N
CAP, POS N
31.5 POS N
months POS N
with POS N
ChOP POS N
and POS N
32.95 POS N
months POS N
with POS N
fludarabine. POS N

These POS N
two POS N
treatments POS N
are POS N
always POS N
superior POS N
to POS N
CAP. POS N

The POS N
threshold POS N
analyses POS N
showed POS N
that, POS N
whatever POS N
the POS N
utility POS N
weights, POS N
the POS N
mean POS N
Q-TWIST POS N
was POS N
always POS N
greater POS N
with POS N
ChOP POS N
or POS N
fludarabine POS N
as POS N
compared POS N
to POS N
CAP. POS N

These POS N
two POS N
treatments POS N
are POS N
always POS N
superior POS N
to POS N
CAP. POS N

Fludarabine POS N
was POS N
consistently POS N
a POS N
better POS N
treatment POS N
than POS N
ChOP, POS N

These POS N
two POS N
treatments POS N
are POS N
always POS N
superior POS N
to POS N
CAP. POS N

except POS N
in POS N
the POS N
unlikely POS N
case POS N
of POS N
high POS N
utility POS N
weights POS N
attributed POS N
to POS N
toxicity POS N
and POS N
low POS N
utility POS N
weights POS N
attributed POS N
to POS N
treatment. POS N

These POS N
two POS N
treatments POS N
are POS N
always POS N
superior POS N
to POS N
CAP. POS N

from POS N
a POS N
clinical POS N
point POS N
of POS N
view, POS N
differences POS N
between POS N
ChOP POS N
and POS N
fludarabine POS N
were POS N
moderate POS N
or POS N
event POS N
slight POS N
(mean POS N
difference POS N
in POS N
TWIST POS N
of POS N
1.45 POS N
months). POS N

These POS N
two POS N
treatments POS N
are POS N
always POS N
superior POS N
to POS N
CAP. POS N

patients POS N
with POS N
advanced POS N
CLL POS N
have POS N
a POS N
moderate POS N
benefit POS N
in POS N
terms POS N
of POS N
Q-TWIST POS N
when POS N
treated POS N
with POS N
fludarabine POS N
over POS N
ChOP. POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

a POS N
6-week POS N
treatment POS N
with POS N
LT POS N
or POS N
BT POS N
was POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP. POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

none POS N
of POS N
the POS N
administered POS N
drugs POS N
induced POS N
a POS N
significant POS N
effect POS N
on POS N
ocular POS N
blood POS N
flow POS N
parameters. POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

Both POS N
drugs POS N
were POS N
equally POS N
effective POS N
in POS N
reducing POS N
IOP POS N
(LT: POS N
-35.0% POS N
±10.0%; POS N
BT: POS N
-33.6% POS N
±8.8%, POS N
P=0.463 POS N
between POS N
groups). POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

no POS N
difference POS N
in POS N
ocular POS N
perfusion POS N
pressure POS N
was POS N
observed POS N
between POS N
the POS N
2 POS N
treatment POS N
groups POS N
(P=0.1, POS N
between POS N
groups). POS N

no POS N
effect POS N
on POS N
flow POS N
velocities POS N
in POS N
the POS N
retrobulbar POS N
vessels POS N
was POS N
seen POS N
with POS N
either POS N
of POS N
the POS N
2 POS N
treatments. POS N

Neither POS N
LT POS N
nor POS N
BT POS N
altered POS N
ONHBF POS N
(P=0.4, POS N
baseline POS N
vs. POS N
treatment) POS N

The POS N
hazard POS N
ratios POS N
for POS N
overall POS N
survival POS N
were POS N
0.88 POS N
(95% POS N
CI POS N
0.70-1.12, POS N
p=0.17) POS N
for POS N
de POS N
Gramont POS N
versus POS N
Lokich, POS N
and POS N
0.99 POS N
(0.79-1.25, POS N
p=0.94) POS N
for POS N
de POS N
Gramont POS N
versus POS N
raltitrexed. POS N

For POS N
the POS N
de POS N
Gramont, POS N
Lokich, POS N
and POS N
raltitrexed POS N
groups, POS N
respectively, POS N
median POS N
survival POS N
was POS N
294, POS N
302, POS N
and POS N
266 POS N
days. POS N

The POS N
hazard POS N
ratios POS N
for POS N
overall POS N
survival POS N
were POS N
0.88 POS N
(95% POS N
CI POS N
0.70-1.12, POS N
p=0.17) POS N
for POS N
de POS N
Gramont POS N
versus POS N
Lokich, POS N
and POS N
0.99 POS N
(0.79-1.25, POS N
p=0.94) POS N
for POS N
de POS N
Gramont POS N
versus POS N
raltitrexed. POS N

An POS N
increase POS N
in POS N
treatment-related POS N
deaths POS N
was POS N
seen POS N
on POS N
raltitrexed POS N
(de POS N
Gramont POS N
one, POS N
Lokich POS N
two, POS N
raltitrexed POS N
18) POS N
due POS N
to POS N
combined POS N
gastrointestinal POS N
and POS N
haematological POS N
toxicity. POS N

The POS N
hazard POS N
ratios POS N
for POS N
overall POS N
survival POS N
were POS N
0.88 POS N
(95% POS N
CI POS N
0.70-1.12, POS N
p=0.17) POS N
for POS N
de POS N
Gramont POS N
versus POS N
Lokich, POS N
and POS N
0.99 POS N
(0.79-1.25, POS N
p=0.94) POS N
for POS N
de POS N
Gramont POS N
versus POS N
raltitrexed. POS N

Patients' POS N
assessment POS N
of POS N
quality POS N
of POS N
life POS N
showed POS N
that POS N
raltitrexed POS N
was POS N
inferior POS N
to POS N
the POS N
fluorouracil-based POS N
regimens, POS N
especially POS N
in POS N
terms POS N
of POS N
palliation POS N
and POS N
functioning. POS N

The POS N
hazard POS N
ratios POS N
for POS N
overall POS N
survival POS N
were POS N
0.88 POS N
(95% POS N
CI POS N
0.70-1.12, POS N
p=0.17) POS N
for POS N
de POS N
Gramont POS N
versus POS N
Lokich, POS N
and POS N
0.99 POS N
(0.79-1.25, POS N
p=0.94) POS N
for POS N
de POS N
Gramont POS N
versus POS N
raltitrexed. POS N

The POS N
deGramont POS N
and POS N
Lokich POS N
regimens POS N
were POS N
similar POS N
in POS N
terms POS N
of POS N
survival, POS N
quality POS N
of POS N
life, POS N
and POS N
response POS N
rates. POS N

The POS N
hazard POS N
ratios POS N
for POS N
overall POS N
survival POS N
were POS N
0.88 POS N
(95% POS N
CI POS N
0.70-1.12, POS N
p=0.17) POS N
for POS N
de POS N
Gramont POS N
versus POS N
Lokich, POS N
and POS N
0.99 POS N
(0.79-1.25, POS N
p=0.94) POS N
for POS N
de POS N
Gramont POS N
versus POS N
raltitrexed. POS N

The POS N
Lokich POS N
regimen POS N
was POS N
associated POS N
with POS N
more POS N
central POS N
line POS N
complications POS N
and POS N
hand-foot POS N
syndrome. POS N

The POS N
hazard POS N
ratios POS N
for POS N
overall POS N
survival POS N
were POS N
0.88 POS N
(95% POS N
CI POS N
0.70-1.12, POS N
p=0.17) POS N
for POS N
de POS N
Gramont POS N
versus POS N
Lokich, POS N
and POS N
0.99 POS N
(0.79-1.25, POS N
p=0.94) POS N
for POS N
de POS N
Gramont POS N
versus POS N
raltitrexed. POS N

Raltitrexed POS N
showed POS N
similar POS N
response POS N
rates POS N
and POS N
overall POS N
survival POS N
to POS N
the POS N
de POS N
Gramont POS N
regimen POS N
and POS N
was POS N
easier POS N
to POS N
administer, POS N

The POS N
hazard POS N
ratios POS N
for POS N
overall POS N
survival POS N
were POS N
0.88 POS N
(95% POS N
CI POS N
0.70-1.12, POS N
p=0.17) POS N
for POS N
de POS N
Gramont POS N
versus POS N
Lokich, POS N
and POS N
0.99 POS N
(0.79-1.25, POS N
p=0.94) POS N
for POS N
de POS N
Gramont POS N
versus POS N
raltitrexed. POS N

but POS N
resulted POS N
in POS N
greater POS N
toxicity POS N
and POS N
inferior POS N
quality POS N
of POS N
life. POS N

For POS N
the POS N
de POS N
Gramont, POS N
Lokich, POS N
and POS N
raltitrexed POS N
groups, POS N
respectively, POS N
median POS N
survival POS N
was POS N
294, POS N
302, POS N
and POS N
266 POS N
days. POS N

The POS N
hazard POS N
ratios POS N
for POS N
overall POS N
survival POS N
were POS N
0.88 POS N
(95% POS N
CI POS N
0.70-1.12, POS N
p=0.17) POS N
for POS N
de POS N
Gramont POS N
versus POS N
Lokich, POS N
and POS N
0.99 POS N
(0.79-1.25, POS N
p=0.94) POS N
for POS N
de POS N
Gramont POS N
versus POS N
raltitrexed. POS N

For POS N
the POS N
de POS N
Gramont, POS N
Lokich, POS N
and POS N
raltitrexed POS N
groups, POS N
respectively, POS N
median POS N
survival POS N
was POS N
294, POS N
302, POS N
and POS N
266 POS N
days. POS N

An POS N
increase POS N
in POS N
treatment-related POS N
deaths POS N
was POS N
seen POS N
on POS N
raltitrexed POS N
(de POS N
Gramont POS N
one, POS N
Lokich POS N
two, POS N
raltitrexed POS N
18) POS N
due POS N
to POS N
combined POS N
gastrointestinal POS N
and POS N
haematological POS N
toxicity. POS N

For POS N
the POS N
de POS N
Gramont, POS N
Lokich, POS N
and POS N
raltitrexed POS N
groups, POS N
respectively, POS N
median POS N
survival POS N
was POS N
294, POS N
302, POS N
and POS N
266 POS N
days. POS N

Patients' POS N
assessment POS N
of POS N
quality POS N
of POS N
life POS N
showed POS N
that POS N
raltitrexed POS N
was POS N
inferior POS N
to POS N
the POS N
fluorouracil-based POS N
regimens, POS N
especially POS N
in POS N
terms POS N
of POS N
palliation POS N
and POS N
functioning. POS N

For POS N
the POS N
de POS N
Gramont, POS N
Lokich, POS N
and POS N
raltitrexed POS N
groups, POS N
respectively, POS N
median POS N
survival POS N
was POS N
294, POS N
302, POS N
and POS N
266 POS N
days. POS N

The POS N
deGramont POS N
and POS N
Lokich POS N
regimens POS N
were POS N
similar POS N
in POS N
terms POS N
of POS N
survival, POS N
quality POS N
of POS N
life, POS N
and POS N
response POS N
rates. POS N

For POS N
the POS N
de POS N
Gramont, POS N
Lokich, POS N
and POS N
raltitrexed POS N
groups, POS N
respectively, POS N
median POS N
survival POS N
was POS N
294, POS N
302, POS N
and POS N
266 POS N
days. POS N

The POS N
Lokich POS N
regimen POS N
was POS N
associated POS N
with POS N
more POS N
central POS N
line POS N
complications POS N
and POS N
hand-foot POS N
syndrome. POS N

For POS N
the POS N
de POS N
Gramont, POS N
Lokich, POS N
and POS N
raltitrexed POS N
groups, POS N
respectively, POS N
median POS N
survival POS N
was POS N
294, POS N
302, POS N
and POS N
266 POS N
days. POS N

Raltitrexed POS N
showed POS N
similar POS N
response POS N
rates POS N
and POS N
overall POS N
survival POS N
to POS N
the POS N
de POS N
Gramont POS N
regimen POS N
and POS N
was POS N
easier POS N
to POS N
administer, POS N

For POS N
the POS N
de POS N
Gramont, POS N
Lokich, POS N
and POS N
raltitrexed POS N
groups, POS N
respectively, POS N
median POS N
survival POS N
was POS N
294, POS N
302, POS N
and POS N
266 POS N
days. POS N

but POS N
resulted POS N
in POS N
greater POS N
toxicity POS N
and POS N
inferior POS N
quality POS N
of POS N
life. POS N

An POS N
increase POS N
in POS N
treatment-related POS N
deaths POS N
was POS N
seen POS N
on POS N
raltitrexed POS N
(de POS N
Gramont POS N
one, POS N
Lokich POS N
two, POS N
raltitrexed POS N
18) POS N
due POS N
to POS N
combined POS N
gastrointestinal POS N
and POS N
haematological POS N
toxicity. POS N

The POS N
hazard POS N
ratios POS N
for POS N
overall POS N
survival POS N
were POS N
0.88 POS N
(95% POS N
CI POS N
0.70-1.12, POS N
p=0.17) POS N
for POS N
de POS N
Gramont POS N
versus POS N
Lokich, POS N
and POS N
0.99 POS N
(0.79-1.25, POS N
p=0.94) POS N
for POS N
de POS N
Gramont POS N
versus POS N
raltitrexed. POS N

An POS N
increase POS N
in POS N
treatment-related POS N
deaths POS N
was POS N
seen POS N
on POS N
raltitrexed POS N
(de POS N
Gramont POS N
one, POS N
Lokich POS N
two, POS N
raltitrexed POS N
18) POS N
due POS N
to POS N
combined POS N
gastrointestinal POS N
and POS N
haematological POS N
toxicity. POS N

For POS N
the POS N
de POS N
Gramont, POS N
Lokich, POS N
and POS N
raltitrexed POS N
groups, POS N
respectively, POS N
median POS N
survival POS N
was POS N
294, POS N
302, POS N
and POS N
266 POS N
days. POS N

An POS N
increase POS N
in POS N
treatment-related POS N
deaths POS N
was POS N
seen POS N
on POS N
raltitrexed POS N
(de POS N
Gramont POS N
one, POS N
Lokich POS N
two, POS N
raltitrexed POS N
18) POS N
due POS N
to POS N
combined POS N
gastrointestinal POS N
and POS N
haematological POS N
toxicity. POS N

Patients' POS N
assessment POS N
of POS N
quality POS N
of POS N
life POS N
showed POS N
that POS N
raltitrexed POS N
was POS N
inferior POS N
to POS N
the POS N
fluorouracil-based POS N
regimens, POS N
especially POS N
in POS N
terms POS N
of POS N
palliation POS N
and POS N
functioning. POS N

An POS N
increase POS N
in POS N
treatment-related POS N
deaths POS N
was POS N
seen POS N
on POS N
raltitrexed POS N
(de POS N
Gramont POS N
one, POS N
Lokich POS N
two, POS N
raltitrexed POS N
18) POS N
due POS N
to POS N
combined POS N
gastrointestinal POS N
and POS N
haematological POS N
toxicity. POS N

The POS N
deGramont POS N
and POS N
Lokich POS N
regimens POS N
were POS N
similar POS N
in POS N
terms POS N
of POS N
survival, POS N
quality POS N
of POS N
life, POS N
and POS N
response POS N
rates. POS N

An POS N
increase POS N
in POS N
treatment-related POS N
deaths POS N
was POS N
seen POS N
on POS N
raltitrexed POS N
(de POS N
Gramont POS N
one, POS N
Lokich POS N
two, POS N
raltitrexed POS N
18) POS N
due POS N
to POS N
combined POS N
gastrointestinal POS N
and POS N
haematological POS N
toxicity. POS N

The POS N
Lokich POS N
regimen POS N
was POS N
associated POS N
with POS N
more POS N
central POS N
line POS N
complications POS N
and POS N
hand-foot POS N
syndrome. POS N

An POS N
increase POS N
in POS N
treatment-related POS N
deaths POS N
was POS N
seen POS N
on POS N
raltitrexed POS N
(de POS N
Gramont POS N
one, POS N
Lokich POS N
two, POS N
raltitrexed POS N
18) POS N
due POS N
to POS N
combined POS N
gastrointestinal POS N
and POS N
haematological POS N
toxicity. POS N

Raltitrexed POS N
showed POS N
similar POS N
response POS N
rates POS N
and POS N
overall POS N
survival POS N
to POS N
the POS N
de POS N
Gramont POS N
regimen POS N
and POS N
was POS N
easier POS N
to POS N
administer, POS N

An POS N
increase POS N
in POS N
treatment-related POS N
deaths POS N
was POS N
seen POS N
on POS N
raltitrexed POS N
(de POS N
Gramont POS N
one, POS N
Lokich POS N
two, POS N
raltitrexed POS N
18) POS N
due POS N
to POS N
combined POS N
gastrointestinal POS N
and POS N
haematological POS N
toxicity. POS N

but POS N
resulted POS N
in POS N
greater POS N
toxicity POS N
and POS N
inferior POS N
quality POS N
of POS N
life. POS N

Patients' POS N
assessment POS N
of POS N
quality POS N
of POS N
life POS N
showed POS N
that POS N
raltitrexed POS N
was POS N
inferior POS N
to POS N
the POS N
fluorouracil-based POS N
regimens, POS N
especially POS N
in POS N
terms POS N
of POS N
palliation POS N
and POS N
functioning. POS N

The POS N
hazard POS N
ratios POS N
for POS N
overall POS N
survival POS N
were POS N
0.88 POS N
(95% POS N
CI POS N
0.70-1.12, POS N
p=0.17) POS N
for POS N
de POS N
Gramont POS N
versus POS N
Lokich, POS N
and POS N
0.99 POS N
(0.79-1.25, POS N
p=0.94) POS N
for POS N
de POS N
Gramont POS N
versus POS N
raltitrexed. POS N

Patients' POS N
assessment POS N
of POS N
quality POS N
of POS N
life POS N
showed POS N
that POS N
raltitrexed POS N
was POS N
inferior POS N
to POS N
the POS N
fluorouracil-based POS N
regimens, POS N
especially POS N
in POS N
terms POS N
of POS N
palliation POS N
and POS N
functioning. POS N

For POS N
the POS N
de POS N
Gramont, POS N
Lokich, POS N
and POS N
raltitrexed POS N
groups, POS N
respectively, POS N
median POS N
survival POS N
was POS N
294, POS N
302, POS N
and POS N
266 POS N
days. POS N

Patients' POS N
assessment POS N
of POS N
quality POS N
of POS N
life POS N
showed POS N
that POS N
raltitrexed POS N
was POS N
inferior POS N
to POS N
the POS N
fluorouracil-based POS N
regimens, POS N
especially POS N
in POS N
terms POS N
of POS N
palliation POS N
and POS N
functioning. POS N

An POS N
increase POS N
in POS N
treatment-related POS N
deaths POS N
was POS N
seen POS N
on POS N
raltitrexed POS N
(de POS N
Gramont POS N
one, POS N
Lokich POS N
two, POS N
raltitrexed POS N
18) POS N
due POS N
to POS N
combined POS N
gastrointestinal POS N
and POS N
haematological POS N
toxicity. POS N

Patients' POS N
assessment POS N
of POS N
quality POS N
of POS N
life POS N
showed POS N
that POS N
raltitrexed POS N
was POS N
inferior POS N
to POS N
the POS N
fluorouracil-based POS N
regimens, POS N
especially POS N
in POS N
terms POS N
of POS N
palliation POS N
and POS N
functioning. POS N

The POS N
deGramont POS N
and POS N
Lokich POS N
regimens POS N
were POS N
similar POS N
in POS N
terms POS N
of POS N
survival, POS N
quality POS N
of POS N
life, POS N
and POS N
response POS N
rates. POS N

Patients' POS N
assessment POS N
of POS N
quality POS N
of POS N
life POS N
showed POS N
that POS N
raltitrexed POS N
was POS N
inferior POS N
to POS N
the POS N
fluorouracil-based POS N
regimens, POS N
especially POS N
in POS N
terms POS N
of POS N
palliation POS N
and POS N
functioning. POS N

The POS N
Lokich POS N
regimen POS N
was POS N
associated POS N
with POS N
more POS N
central POS N
line POS N
complications POS N
and POS N
hand-foot POS N
syndrome. POS N

Patients' POS N
assessment POS N
of POS N
quality POS N
of POS N
life POS N
showed POS N
that POS N
raltitrexed POS N
was POS N
inferior POS N
to POS N
the POS N
fluorouracil-based POS N
regimens, POS N
especially POS N
in POS N
terms POS N
of POS N
palliation POS N
and POS N
functioning. POS N

Raltitrexed POS N
showed POS N
similar POS N
response POS N
rates POS N
and POS N
overall POS N
survival POS N
to POS N
the POS N
de POS N
Gramont POS N
regimen POS N
and POS N
was POS N
easier POS N
to POS N
administer, POS N

Patients' POS N
assessment POS N
of POS N
quality POS N
of POS N
life POS N
showed POS N
that POS N
raltitrexed POS N
was POS N
inferior POS N
to POS N
the POS N
fluorouracil-based POS N
regimens, POS N
especially POS N
in POS N
terms POS N
of POS N
palliation POS N
and POS N
functioning. POS N

but POS N
resulted POS N
in POS N
greater POS N
toxicity POS N
and POS N
inferior POS N
quality POS N
of POS N
life. POS N

The POS N
deGramont POS N
and POS N
Lokich POS N
regimens POS N
were POS N
similar POS N
in POS N
terms POS N
of POS N
survival, POS N
quality POS N
of POS N
life, POS N
and POS N
response POS N
rates. POS N

The POS N
hazard POS N
ratios POS N
for POS N
overall POS N
survival POS N
were POS N
0.88 POS N
(95% POS N
CI POS N
0.70-1.12, POS N
p=0.17) POS N
for POS N
de POS N
Gramont POS N
versus POS N
Lokich, POS N
and POS N
0.99 POS N
(0.79-1.25, POS N
p=0.94) POS N
for POS N
de POS N
Gramont POS N
versus POS N
raltitrexed. POS N

The POS N
deGramont POS N
and POS N
Lokich POS N
regimens POS N
were POS N
similar POS N
in POS N
terms POS N
of POS N
survival, POS N
quality POS N
of POS N
life, POS N
and POS N
response POS N
rates. POS N

For POS N
the POS N
de POS N
Gramont, POS N
Lokich, POS N
and POS N
raltitrexed POS N
groups, POS N
respectively, POS N
median POS N
survival POS N
was POS N
294, POS N
302, POS N
and POS N
266 POS N
days. POS N

The POS N
deGramont POS N
and POS N
Lokich POS N
regimens POS N
were POS N
similar POS N
in POS N
terms POS N
of POS N
survival, POS N
quality POS N
of POS N
life, POS N
and POS N
response POS N
rates. POS N

An POS N
increase POS N
in POS N
treatment-related POS N
deaths POS N
was POS N
seen POS N
on POS N
raltitrexed POS N
(de POS N
Gramont POS N
one, POS N
Lokich POS N
two, POS N
raltitrexed POS N
18) POS N
due POS N
to POS N
combined POS N
gastrointestinal POS N
and POS N
haematological POS N
toxicity. POS N

The POS N
deGramont POS N
and POS N
Lokich POS N
regimens POS N
were POS N
similar POS N
in POS N
terms POS N
of POS N
survival, POS N
quality POS N
of POS N
life, POS N
and POS N
response POS N
rates. POS N

Patients' POS N
assessment POS N
of POS N
quality POS N
of POS N
life POS N
showed POS N
that POS N
raltitrexed POS N
was POS N
inferior POS N
to POS N
the POS N
fluorouracil-based POS N
regimens, POS N
especially POS N
in POS N
terms POS N
of POS N
palliation POS N
and POS N
functioning. POS N

The POS N
deGramont POS N
and POS N
Lokich POS N
regimens POS N
were POS N
similar POS N
in POS N
terms POS N
of POS N
survival, POS N
quality POS N
of POS N
life, POS N
and POS N
response POS N
rates. POS N

The POS N
Lokich POS N
regimen POS N
was POS N
associated POS N
with POS N
more POS N
central POS N
line POS N
complications POS N
and POS N
hand-foot POS N
syndrome. POS N

The POS N
deGramont POS N
and POS N
Lokich POS N
regimens POS N
were POS N
similar POS N
in POS N
terms POS N
of POS N
survival, POS N
quality POS N
of POS N
life, POS N
and POS N
response POS N
rates. POS N

Raltitrexed POS N
showed POS N
similar POS N
response POS N
rates POS N
and POS N
overall POS N
survival POS N
to POS N
the POS N
de POS N
Gramont POS N
regimen POS N
and POS N
was POS N
easier POS N
to POS N
administer, POS N

The POS N
deGramont POS N
and POS N
Lokich POS N
regimens POS N
were POS N
similar POS N
in POS N
terms POS N
of POS N
survival, POS N
quality POS N
of POS N
life, POS N
and POS N
response POS N
rates. POS N

but POS N
resulted POS N
in POS N
greater POS N
toxicity POS N
and POS N
inferior POS N
quality POS N
of POS N
life. POS N

The POS N
Lokich POS N
regimen POS N
was POS N
associated POS N
with POS N
more POS N
central POS N
line POS N
complications POS N
and POS N
hand-foot POS N
syndrome. POS N

The POS N
hazard POS N
ratios POS N
for POS N
overall POS N
survival POS N
were POS N
0.88 POS N
(95% POS N
CI POS N
0.70-1.12, POS N
p=0.17) POS N
for POS N
de POS N
Gramont POS N
versus POS N
Lokich, POS N
and POS N
0.99 POS N
(0.79-1.25, POS N
p=0.94) POS N
for POS N
de POS N
Gramont POS N
versus POS N
raltitrexed. POS N

The POS N
Lokich POS N
regimen POS N
was POS N
associated POS N
with POS N
more POS N
central POS N
line POS N
complications POS N
and POS N
hand-foot POS N
syndrome. POS N

For POS N
the POS N
de POS N
Gramont, POS N
Lokich, POS N
and POS N
raltitrexed POS N
groups, POS N
respectively, POS N
median POS N
survival POS N
was POS N
294, POS N
302, POS N
and POS N
266 POS N
days. POS N

The POS N
Lokich POS N
regimen POS N
was POS N
associated POS N
with POS N
more POS N
central POS N
line POS N
complications POS N
and POS N
hand-foot POS N
syndrome. POS N

An POS N
increase POS N
in POS N
treatment-related POS N
deaths POS N
was POS N
seen POS N
on POS N
raltitrexed POS N
(de POS N
Gramont POS N
one, POS N
Lokich POS N
two, POS N
raltitrexed POS N
18) POS N
due POS N
to POS N
combined POS N
gastrointestinal POS N
and POS N
haematological POS N
toxicity. POS N

The POS N
Lokich POS N
regimen POS N
was POS N
associated POS N
with POS N
more POS N
central POS N
line POS N
complications POS N
and POS N
hand-foot POS N
syndrome. POS N

Patients' POS N
assessment POS N
of POS N
quality POS N
of POS N
life POS N
showed POS N
that POS N
raltitrexed POS N
was POS N
inferior POS N
to POS N
the POS N
fluorouracil-based POS N
regimens, POS N
especially POS N
in POS N
terms POS N
of POS N
palliation POS N
and POS N
functioning. POS N

The POS N
Lokich POS N
regimen POS N
was POS N
associated POS N
with POS N
more POS N
central POS N
line POS N
complications POS N
and POS N
hand-foot POS N
syndrome. POS N

The POS N
deGramont POS N
and POS N
Lokich POS N
regimens POS N
were POS N
similar POS N
in POS N
terms POS N
of POS N
survival, POS N
quality POS N
of POS N
life, POS N
and POS N
response POS N
rates. POS N

The POS N
Lokich POS N
regimen POS N
was POS N
associated POS N
with POS N
more POS N
central POS N
line POS N
complications POS N
and POS N
hand-foot POS N
syndrome. POS N

Raltitrexed POS N
showed POS N
similar POS N
response POS N
rates POS N
and POS N
overall POS N
survival POS N
to POS N
the POS N
de POS N
Gramont POS N
regimen POS N
and POS N
was POS N
easier POS N
to POS N
administer, POS N

The POS N
Lokich POS N
regimen POS N
was POS N
associated POS N
with POS N
more POS N
central POS N
line POS N
complications POS N
and POS N
hand-foot POS N
syndrome. POS N

but POS N
resulted POS N
in POS N
greater POS N
toxicity POS N
and POS N
inferior POS N
quality POS N
of POS N
life. POS N

Raltitrexed POS N
showed POS N
similar POS N
response POS N
rates POS N
and POS N
overall POS N
survival POS N
to POS N
the POS N
de POS N
Gramont POS N
regimen POS N
and POS N
was POS N
easier POS N
to POS N
administer, POS N

The POS N
hazard POS N
ratios POS N
for POS N
overall POS N
survival POS N
were POS N
0.88 POS N
(95% POS N
CI POS N
0.70-1.12, POS N
p=0.17) POS N
for POS N
de POS N
Gramont POS N
versus POS N
Lokich, POS N
and POS N
0.99 POS N
(0.79-1.25, POS N
p=0.94) POS N
for POS N
de POS N
Gramont POS N
versus POS N
raltitrexed. POS N

Raltitrexed POS N
showed POS N
similar POS N
response POS N
rates POS N
and POS N
overall POS N
survival POS N
to POS N
the POS N
de POS N
Gramont POS N
regimen POS N
and POS N
was POS N
easier POS N
to POS N
administer, POS N

For POS N
the POS N
de POS N
Gramont, POS N
Lokich, POS N
and POS N
raltitrexed POS N
groups, POS N
respectively, POS N
median POS N
survival POS N
was POS N
294, POS N
302, POS N
and POS N
266 POS N
days. POS N

Raltitrexed POS N
showed POS N
similar POS N
response POS N
rates POS N
and POS N
overall POS N
survival POS N
to POS N
the POS N
de POS N
Gramont POS N
regimen POS N
and POS N
was POS N
easier POS N
to POS N
administer, POS N

An POS N
increase POS N
in POS N
treatment-related POS N
deaths POS N
was POS N
seen POS N
on POS N
raltitrexed POS N
(de POS N
Gramont POS N
one, POS N
Lokich POS N
two, POS N
raltitrexed POS N
18) POS N
due POS N
to POS N
combined POS N
gastrointestinal POS N
and POS N
haematological POS N
toxicity. POS N

Raltitrexed POS N
showed POS N
similar POS N
response POS N
rates POS N
and POS N
overall POS N
survival POS N
to POS N
the POS N
de POS N
Gramont POS N
regimen POS N
and POS N
was POS N
easier POS N
to POS N
administer, POS N

Patients' POS N
assessment POS N
of POS N
quality POS N
of POS N
life POS N
showed POS N
that POS N
raltitrexed POS N
was POS N
inferior POS N
to POS N
the POS N
fluorouracil-based POS N
regimens, POS N
especially POS N
in POS N
terms POS N
of POS N
palliation POS N
and POS N
functioning. POS N

Raltitrexed POS N
showed POS N
similar POS N
response POS N
rates POS N
and POS N
overall POS N
survival POS N
to POS N
the POS N
de POS N
Gramont POS N
regimen POS N
and POS N
was POS N
easier POS N
to POS N
administer, POS N

The POS N
deGramont POS N
and POS N
Lokich POS N
regimens POS N
were POS N
similar POS N
in POS N
terms POS N
of POS N
survival, POS N
quality POS N
of POS N
life, POS N
and POS N
response POS N
rates. POS N

Raltitrexed POS N
showed POS N
similar POS N
response POS N
rates POS N
and POS N
overall POS N
survival POS N
to POS N
the POS N
de POS N
Gramont POS N
regimen POS N
and POS N
was POS N
easier POS N
to POS N
administer, POS N

The POS N
Lokich POS N
regimen POS N
was POS N
associated POS N
with POS N
more POS N
central POS N
line POS N
complications POS N
and POS N
hand-foot POS N
syndrome. POS N

Raltitrexed POS N
showed POS N
similar POS N
response POS N
rates POS N
and POS N
overall POS N
survival POS N
to POS N
the POS N
de POS N
Gramont POS N
regimen POS N
and POS N
was POS N
easier POS N
to POS N
administer, POS N

but POS N
resulted POS N
in POS N
greater POS N
toxicity POS N
and POS N
inferior POS N
quality POS N
of POS N
life. POS N

but POS N
resulted POS N
in POS N
greater POS N
toxicity POS N
and POS N
inferior POS N
quality POS N
of POS N
life. POS N

The POS N
hazard POS N
ratios POS N
for POS N
overall POS N
survival POS N
were POS N
0.88 POS N
(95% POS N
CI POS N
0.70-1.12, POS N
p=0.17) POS N
for POS N
de POS N
Gramont POS N
versus POS N
Lokich, POS N
and POS N
0.99 POS N
(0.79-1.25, POS N
p=0.94) POS N
for POS N
de POS N
Gramont POS N
versus POS N
raltitrexed. POS N

but POS N
resulted POS N
in POS N
greater POS N
toxicity POS N
and POS N
inferior POS N
quality POS N
of POS N
life. POS N

For POS N
the POS N
de POS N
Gramont, POS N
Lokich, POS N
and POS N
raltitrexed POS N
groups, POS N
respectively, POS N
median POS N
survival POS N
was POS N
294, POS N
302, POS N
and POS N
266 POS N
days. POS N

but POS N
resulted POS N
in POS N
greater POS N
toxicity POS N
and POS N
inferior POS N
quality POS N
of POS N
life. POS N

An POS N
increase POS N
in POS N
treatment-related POS N
deaths POS N
was POS N
seen POS N
on POS N
raltitrexed POS N
(de POS N
Gramont POS N
one, POS N
Lokich POS N
two, POS N
raltitrexed POS N
18) POS N
due POS N
to POS N
combined POS N
gastrointestinal POS N
and POS N
haematological POS N
toxicity. POS N

but POS N
resulted POS N
in POS N
greater POS N
toxicity POS N
and POS N
inferior POS N
quality POS N
of POS N
life. POS N

Patients' POS N
assessment POS N
of POS N
quality POS N
of POS N
life POS N
showed POS N
that POS N
raltitrexed POS N
was POS N
inferior POS N
to POS N
the POS N
fluorouracil-based POS N
regimens, POS N
especially POS N
in POS N
terms POS N
of POS N
palliation POS N
and POS N
functioning. POS N

but POS N
resulted POS N
in POS N
greater POS N
toxicity POS N
and POS N
inferior POS N
quality POS N
of POS N
life. POS N

The POS N
deGramont POS N
and POS N
Lokich POS N
regimens POS N
were POS N
similar POS N
in POS N
terms POS N
of POS N
survival, POS N
quality POS N
of POS N
life, POS N
and POS N
response POS N
rates. POS N

but POS N
resulted POS N
in POS N
greater POS N
toxicity POS N
and POS N
inferior POS N
quality POS N
of POS N
life. POS N

The POS N
Lokich POS N
regimen POS N
was POS N
associated POS N
with POS N
more POS N
central POS N
line POS N
complications POS N
and POS N
hand-foot POS N
syndrome. POS N

but POS N
resulted POS N
in POS N
greater POS N
toxicity POS N
and POS N
inferior POS N
quality POS N
of POS N
life. POS N

Raltitrexed POS N
showed POS N
similar POS N
response POS N
rates POS N
and POS N
overall POS N
survival POS N
to POS N
the POS N
de POS N
Gramont POS N
regimen POS N
and POS N
was POS N
easier POS N
to POS N
administer, POS N

The POS N
mean POS N
(SD) POS N
systolic POS N
BP POS N
decreased POS N
by POS N
8 POS N
(12) POS N
mm POS N
Hg POS N
in POS N
the POS N
standard POS N
group POS N
and POS N
by POS N
27 POS N
(17) POS N
mm POS N
Hg POS N
in POS N
the POS N
intensive POS N
group POS N
(P < .001), POS N
with POS N
mean POS N
(SD) POS N
achieved POS N
pressures POS N
of POS N
141 POS N
(13) POS N
and POS N
126 POS N
(10) POS N
mm POS N
Hg, POS N
respectively. POS N

Change POS N
in POS N
global POS N
perfusion POS N
did POS N
not POS N
differ POS N
between POS N
treatment POS N
groups: POS N
the POS N
mean POS N
(SD) POS N
change POS N
was POS N
-0.5 POS N
(9.4) POS N
mL/min/100 POS N
g POS N
in POS N
the POS N
standard POS N
group POS N
vs POS N
0.7 POS N
(8.6) POS N
mL/min/100 POS N
g POS N
in POS N
the POS N
intensive POS N
group POS N
(partial POS N
η2, POS N
0.004; POS N
95% POS N
CI, POS N
-3.551 POS N
to POS N
5.818; POS N
P = .63). POS N

The POS N
mean POS N
(SD) POS N
systolic POS N
BP POS N
decreased POS N
by POS N
8 POS N
(12) POS N
mm POS N
Hg POS N
in POS N
the POS N
standard POS N
group POS N
and POS N
by POS N
27 POS N
(17) POS N
mm POS N
Hg POS N
in POS N
the POS N
intensive POS N
group POS N
(P < .001), POS N
with POS N
mean POS N
(SD) POS N
achieved POS N
pressures POS N
of POS N
141 POS N
(13) POS N
and POS N
126 POS N
(10) POS N
mm POS N
Hg, POS N
respectively. POS N

No POS N
differences POS N
were POS N
observed POS N
when POS N
the POS N
analysis POS N
examined POS N
gray POS N
or POS N
white POS N
matter POS N
only POS N
or POS N
was POS N
confined POS N
to POS N
those POS N
achieving POS N
target POS N
BP. POS N

The POS N
mean POS N
(SD) POS N
systolic POS N
BP POS N
decreased POS N
by POS N
8 POS N
(12) POS N
mm POS N
Hg POS N
in POS N
the POS N
standard POS N
group POS N
and POS N
by POS N
27 POS N
(17) POS N
mm POS N
Hg POS N
in POS N
the POS N
intensive POS N
group POS N
(P < .001), POS N
with POS N
mean POS N
(SD) POS N
achieved POS N
pressures POS N
of POS N
141 POS N
(13) POS N
and POS N
126 POS N
(10) POS N
mm POS N
Hg, POS N
respectively. POS N

Intensive POS N
BP POS N
lowering POS N
did POS N
not POS N
reduce POS N
cerebral POS N
perfusion POS N
in POS N
severe POS N
small POS N
vessel POS N
disease. POS N

The POS N
mean POS N
(SD) POS N
systolic POS N
BP POS N
decreased POS N
by POS N
8 POS N
(12) POS N
mm POS N
Hg POS N
in POS N
the POS N
standard POS N
group POS N
and POS N
by POS N
27 POS N
(17) POS N
mm POS N
Hg POS N
in POS N
the POS N
intensive POS N
group POS N
(P < .001), POS N
with POS N
mean POS N
(SD) POS N
achieved POS N
pressures POS N
of POS N
141 POS N
(13) POS N
and POS N
126 POS N
(10) POS N
mm POS N
Hg, POS N
respectively. POS N

The POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
differ POS N
between POS N
treatment POS N
groups, POS N
with POS N
a POS N
mean POS N
(SD) POS N
of POS N
0.21 POS N
(0.65) POS N
for POS N
the POS N
standard POS N
group POS N
and POS N
0.32 POS N
(0.75) POS N
for POS N
the POS N
intensive POS N
group POS N
(P = .44). POS N

Change POS N
in POS N
global POS N
perfusion POS N
did POS N
not POS N
differ POS N
between POS N
treatment POS N
groups: POS N
the POS N
mean POS N
(SD) POS N
change POS N
was POS N
-0.5 POS N
(9.4) POS N
mL/min/100 POS N
g POS N
in POS N
the POS N
standard POS N
group POS N
vs POS N
0.7 POS N
(8.6) POS N
mL/min/100 POS N
g POS N
in POS N
the POS N
intensive POS N
group POS N
(partial POS N
η2, POS N
0.004; POS N
95% POS N
CI, POS N
-3.551 POS N
to POS N
5.818; POS N
P = .63). POS N

The POS N
mean POS N
(SD) POS N
systolic POS N
BP POS N
decreased POS N
by POS N
8 POS N
(12) POS N
mm POS N
Hg POS N
in POS N
the POS N
standard POS N
group POS N
and POS N
by POS N
27 POS N
(17) POS N
mm POS N
Hg POS N
in POS N
the POS N
intensive POS N
group POS N
(P < .001), POS N
with POS N
mean POS N
(SD) POS N
achieved POS N
pressures POS N
of POS N
141 POS N
(13) POS N
and POS N
126 POS N
(10) POS N
mm POS N
Hg, POS N
respectively. POS N

Change POS N
in POS N
global POS N
perfusion POS N
did POS N
not POS N
differ POS N
between POS N
treatment POS N
groups: POS N
the POS N
mean POS N
(SD) POS N
change POS N
was POS N
-0.5 POS N
(9.4) POS N
mL/min/100 POS N
g POS N
in POS N
the POS N
standard POS N
group POS N
vs POS N
0.7 POS N
(8.6) POS N
mL/min/100 POS N
g POS N
in POS N
the POS N
intensive POS N
group POS N
(partial POS N
η2, POS N
0.004; POS N
95% POS N
CI, POS N
-3.551 POS N
to POS N
5.818; POS N
P = .63). POS N

No POS N
differences POS N
were POS N
observed POS N
when POS N
the POS N
analysis POS N
examined POS N
gray POS N
or POS N
white POS N
matter POS N
only POS N
or POS N
was POS N
confined POS N
to POS N
those POS N
achieving POS N
target POS N
BP. POS N

Change POS N
in POS N
global POS N
perfusion POS N
did POS N
not POS N
differ POS N
between POS N
treatment POS N
groups: POS N
the POS N
mean POS N
(SD) POS N
change POS N
was POS N
-0.5 POS N
(9.4) POS N
mL/min/100 POS N
g POS N
in POS N
the POS N
standard POS N
group POS N
vs POS N
0.7 POS N
(8.6) POS N
mL/min/100 POS N
g POS N
in POS N
the POS N
intensive POS N
group POS N
(partial POS N
η2, POS N
0.004; POS N
95% POS N
CI, POS N
-3.551 POS N
to POS N
5.818; POS N
P = .63). POS N

Intensive POS N
BP POS N
lowering POS N
did POS N
not POS N
reduce POS N
cerebral POS N
perfusion POS N
in POS N
severe POS N
small POS N
vessel POS N
disease. POS N

Change POS N
in POS N
global POS N
perfusion POS N
did POS N
not POS N
differ POS N
between POS N
treatment POS N
groups: POS N
the POS N
mean POS N
(SD) POS N
change POS N
was POS N
-0.5 POS N
(9.4) POS N
mL/min/100 POS N
g POS N
in POS N
the POS N
standard POS N
group POS N
vs POS N
0.7 POS N
(8.6) POS N
mL/min/100 POS N
g POS N
in POS N
the POS N
intensive POS N
group POS N
(partial POS N
η2, POS N
0.004; POS N
95% POS N
CI, POS N
-3.551 POS N
to POS N
5.818; POS N
P = .63). POS N

The POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
differ POS N
between POS N
treatment POS N
groups, POS N
with POS N
a POS N
mean POS N
(SD) POS N
of POS N
0.21 POS N
(0.65) POS N
for POS N
the POS N
standard POS N
group POS N
and POS N
0.32 POS N
(0.75) POS N
for POS N
the POS N
intensive POS N
group POS N
(P = .44). POS N

No POS N
differences POS N
were POS N
observed POS N
when POS N
the POS N
analysis POS N
examined POS N
gray POS N
or POS N
white POS N
matter POS N
only POS N
or POS N
was POS N
confined POS N
to POS N
those POS N
achieving POS N
target POS N
BP. POS N

The POS N
mean POS N
(SD) POS N
systolic POS N
BP POS N
decreased POS N
by POS N
8 POS N
(12) POS N
mm POS N
Hg POS N
in POS N
the POS N
standard POS N
group POS N
and POS N
by POS N
27 POS N
(17) POS N
mm POS N
Hg POS N
in POS N
the POS N
intensive POS N
group POS N
(P < .001), POS N
with POS N
mean POS N
(SD) POS N
achieved POS N
pressures POS N
of POS N
141 POS N
(13) POS N
and POS N
126 POS N
(10) POS N
mm POS N
Hg, POS N
respectively. POS N

No POS N
differences POS N
were POS N
observed POS N
when POS N
the POS N
analysis POS N
examined POS N
gray POS N
or POS N
white POS N
matter POS N
only POS N
or POS N
was POS N
confined POS N
to POS N
those POS N
achieving POS N
target POS N
BP. POS N

Change POS N
in POS N
global POS N
perfusion POS N
did POS N
not POS N
differ POS N
between POS N
treatment POS N
groups: POS N
the POS N
mean POS N
(SD) POS N
change POS N
was POS N
-0.5 POS N
(9.4) POS N
mL/min/100 POS N
g POS N
in POS N
the POS N
standard POS N
group POS N
vs POS N
0.7 POS N
(8.6) POS N
mL/min/100 POS N
g POS N
in POS N
the POS N
intensive POS N
group POS N
(partial POS N
η2, POS N
0.004; POS N
95% POS N
CI, POS N
-3.551 POS N
to POS N
5.818; POS N
P = .63). POS N

No POS N
differences POS N
were POS N
observed POS N
when POS N
the POS N
analysis POS N
examined POS N
gray POS N
or POS N
white POS N
matter POS N
only POS N
or POS N
was POS N
confined POS N
to POS N
those POS N
achieving POS N
target POS N
BP. POS N

Intensive POS N
BP POS N
lowering POS N
did POS N
not POS N
reduce POS N
cerebral POS N
perfusion POS N
in POS N
severe POS N
small POS N
vessel POS N
disease. POS N

No POS N
differences POS N
were POS N
observed POS N
when POS N
the POS N
analysis POS N
examined POS N
gray POS N
or POS N
white POS N
matter POS N
only POS N
or POS N
was POS N
confined POS N
to POS N
those POS N
achieving POS N
target POS N
BP. POS N

The POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
differ POS N
between POS N
treatment POS N
groups, POS N
with POS N
a POS N
mean POS N
(SD) POS N
of POS N
0.21 POS N
(0.65) POS N
for POS N
the POS N
standard POS N
group POS N
and POS N
0.32 POS N
(0.75) POS N
for POS N
the POS N
intensive POS N
group POS N
(P = .44). POS N

Intensive POS N
BP POS N
lowering POS N
did POS N
not POS N
reduce POS N
cerebral POS N
perfusion POS N
in POS N
severe POS N
small POS N
vessel POS N
disease. POS N

The POS N
mean POS N
(SD) POS N
systolic POS N
BP POS N
decreased POS N
by POS N
8 POS N
(12) POS N
mm POS N
Hg POS N
in POS N
the POS N
standard POS N
group POS N
and POS N
by POS N
27 POS N
(17) POS N
mm POS N
Hg POS N
in POS N
the POS N
intensive POS N
group POS N
(P < .001), POS N
with POS N
mean POS N
(SD) POS N
achieved POS N
pressures POS N
of POS N
141 POS N
(13) POS N
and POS N
126 POS N
(10) POS N
mm POS N
Hg, POS N
respectively. POS N

Intensive POS N
BP POS N
lowering POS N
did POS N
not POS N
reduce POS N
cerebral POS N
perfusion POS N
in POS N
severe POS N
small POS N
vessel POS N
disease. POS N

Change POS N
in POS N
global POS N
perfusion POS N
did POS N
not POS N
differ POS N
between POS N
treatment POS N
groups: POS N
the POS N
mean POS N
(SD) POS N
change POS N
was POS N
-0.5 POS N
(9.4) POS N
mL/min/100 POS N
g POS N
in POS N
the POS N
standard POS N
group POS N
vs POS N
0.7 POS N
(8.6) POS N
mL/min/100 POS N
g POS N
in POS N
the POS N
intensive POS N
group POS N
(partial POS N
η2, POS N
0.004; POS N
95% POS N
CI, POS N
-3.551 POS N
to POS N
5.818; POS N
P = .63). POS N

Intensive POS N
BP POS N
lowering POS N
did POS N
not POS N
reduce POS N
cerebral POS N
perfusion POS N
in POS N
severe POS N
small POS N
vessel POS N
disease. POS N

No POS N
differences POS N
were POS N
observed POS N
when POS N
the POS N
analysis POS N
examined POS N
gray POS N
or POS N
white POS N
matter POS N
only POS N
or POS N
was POS N
confined POS N
to POS N
those POS N
achieving POS N
target POS N
BP. POS N

Intensive POS N
BP POS N
lowering POS N
did POS N
not POS N
reduce POS N
cerebral POS N
perfusion POS N
in POS N
severe POS N
small POS N
vessel POS N
disease. POS N

The POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
differ POS N
between POS N
treatment POS N
groups, POS N
with POS N
a POS N
mean POS N
(SD) POS N
of POS N
0.21 POS N
(0.65) POS N
for POS N
the POS N
standard POS N
group POS N
and POS N
0.32 POS N
(0.75) POS N
for POS N
the POS N
intensive POS N
group POS N
(P = .44). POS N

The POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
differ POS N
between POS N
treatment POS N
groups, POS N
with POS N
a POS N
mean POS N
(SD) POS N
of POS N
0.21 POS N
(0.65) POS N
for POS N
the POS N
standard POS N
group POS N
and POS N
0.32 POS N
(0.75) POS N
for POS N
the POS N
intensive POS N
group POS N
(P = .44). POS N

The POS N
mean POS N
(SD) POS N
systolic POS N
BP POS N
decreased POS N
by POS N
8 POS N
(12) POS N
mm POS N
Hg POS N
in POS N
the POS N
standard POS N
group POS N
and POS N
by POS N
27 POS N
(17) POS N
mm POS N
Hg POS N
in POS N
the POS N
intensive POS N
group POS N
(P < .001), POS N
with POS N
mean POS N
(SD) POS N
achieved POS N
pressures POS N
of POS N
141 POS N
(13) POS N
and POS N
126 POS N
(10) POS N
mm POS N
Hg, POS N
respectively. POS N

The POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
differ POS N
between POS N
treatment POS N
groups, POS N
with POS N
a POS N
mean POS N
(SD) POS N
of POS N
0.21 POS N
(0.65) POS N
for POS N
the POS N
standard POS N
group POS N
and POS N
0.32 POS N
(0.75) POS N
for POS N
the POS N
intensive POS N
group POS N
(P = .44). POS N

Change POS N
in POS N
global POS N
perfusion POS N
did POS N
not POS N
differ POS N
between POS N
treatment POS N
groups: POS N
the POS N
mean POS N
(SD) POS N
change POS N
was POS N
-0.5 POS N
(9.4) POS N
mL/min/100 POS N
g POS N
in POS N
the POS N
standard POS N
group POS N
vs POS N
0.7 POS N
(8.6) POS N
mL/min/100 POS N
g POS N
in POS N
the POS N
intensive POS N
group POS N
(partial POS N
η2, POS N
0.004; POS N
95% POS N
CI, POS N
-3.551 POS N
to POS N
5.818; POS N
P = .63). POS N

The POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
differ POS N
between POS N
treatment POS N
groups, POS N
with POS N
a POS N
mean POS N
(SD) POS N
of POS N
0.21 POS N
(0.65) POS N
for POS N
the POS N
standard POS N
group POS N
and POS N
0.32 POS N
(0.75) POS N
for POS N
the POS N
intensive POS N
group POS N
(P = .44). POS N

No POS N
differences POS N
were POS N
observed POS N
when POS N
the POS N
analysis POS N
examined POS N
gray POS N
or POS N
white POS N
matter POS N
only POS N
or POS N
was POS N
confined POS N
to POS N
those POS N
achieving POS N
target POS N
BP. POS N

The POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
differ POS N
between POS N
treatment POS N
groups, POS N
with POS N
a POS N
mean POS N
(SD) POS N
of POS N
0.21 POS N
(0.65) POS N
for POS N
the POS N
standard POS N
group POS N
and POS N
0.32 POS N
(0.75) POS N
for POS N
the POS N
intensive POS N
group POS N
(P = .44). POS N

Intensive POS N
BP POS N
lowering POS N
did POS N
not POS N
reduce POS N
cerebral POS N
perfusion POS N
in POS N
severe POS N
small POS N
vessel POS N
disease. POS N

At POS N
two POS N
year POS N
follow-up POS N
there POS N
was POS N
a POS N
significant POS N
group POS N
by POS N
time POS N
interaction POS N
showing POS N
lower POS N
Center POS N
for POS N
Epidemiological POS N
Studies-Depression POS N
(CESD) POS N
scores POS N
in POS N
the POS N
SSRI POS N
+ POS N
CCB POS N
group, POS N
F(1,291) POS N
= POS N
4.13, POS N
p POS N
= POS N
0.043, POS N
η2 POS N
p POS N
= POS N
0.014. POS N

Over POS N
ten-years POS N
follow-up, POS N
SSRI POS N
+ POS N
CCB POS N
use POS N
was POS N
associated POS N
with POS N
improved POS N
general POS N
cognitive POS N
function POS N
(Mini-Mental POS N
State POS N
Examination: POS N
β POS N
= POS N
0.97; POS N
95% POS N
CI POS N
0.14 POS N
to POS N
1.81, POS N
p POS N
= POS N
0.023) POS N
and POS N
immediate POS N
visual POS N
memory POS N
(Boston POS N
Visual POS N
Retention POS N
Test: POS N
β POS N
= POS N
0.69; POS N
95% POS N
CI POS N
0.06 POS N
to POS N
1.32, POS N
p POS N
= POS N
0.033). POS N

At POS N
two POS N
year POS N
follow-up POS N
there POS N
was POS N
a POS N
significant POS N
group POS N
by POS N
time POS N
interaction POS N
showing POS N
lower POS N
Center POS N
for POS N
Epidemiological POS N
Studies-Depression POS N
(CESD) POS N
scores POS N
in POS N
the POS N
SSRI POS N
+ POS N
CCB POS N
group, POS N
F(1,291) POS N
= POS N
4.13, POS N
p POS N
= POS N
0.043, POS N
η2 POS N
p POS N
= POS N
0.014. POS N

The POS N
findings POS N
provide POS N
general POS N
population POS N
evidence POS N
that POS N
SSRI POS N
augmentation POS N
with POS N
CCB POS N
may POS N
improve POS N
depression POS N
and POS N
cognitive POS N
function. POS N

Over POS N
ten-years POS N
follow-up, POS N
SSRI POS N
+ POS N
CCB POS N
use POS N
was POS N
associated POS N
with POS N
improved POS N
general POS N
cognitive POS N
function POS N
(Mini-Mental POS N
State POS N
Examination: POS N
β POS N
= POS N
0.97; POS N
95% POS N
CI POS N
0.14 POS N
to POS N
1.81, POS N
p POS N
= POS N
0.023) POS N
and POS N
immediate POS N
visual POS N
memory POS N
(Boston POS N
Visual POS N
Retention POS N
Test: POS N
β POS N
= POS N
0.69; POS N
95% POS N
CI POS N
0.06 POS N
to POS N
1.32, POS N
p POS N
= POS N
0.033). POS N

At POS N
two POS N
year POS N
follow-up POS N
there POS N
was POS N
a POS N
significant POS N
group POS N
by POS N
time POS N
interaction POS N
showing POS N
lower POS N
Center POS N
for POS N
Epidemiological POS N
Studies-Depression POS N
(CESD) POS N
scores POS N
in POS N
the POS N
SSRI POS N
+ POS N
CCB POS N
group, POS N
F(1,291) POS N
= POS N
4.13, POS N
p POS N
= POS N
0.043, POS N
η2 POS N
p POS N
= POS N
0.014. POS N

Over POS N
ten-years POS N
follow-up, POS N
SSRI POS N
+ POS N
CCB POS N
use POS N
was POS N
associated POS N
with POS N
improved POS N
general POS N
cognitive POS N
function POS N
(Mini-Mental POS N
State POS N
Examination: POS N
β POS N
= POS N
0.97; POS N
95% POS N
CI POS N
0.14 POS N
to POS N
1.81, POS N
p POS N
= POS N
0.023) POS N
and POS N
immediate POS N
visual POS N
memory POS N
(Boston POS N
Visual POS N
Retention POS N
Test: POS N
β POS N
= POS N
0.69; POS N
95% POS N
CI POS N
0.06 POS N
to POS N
1.32, POS N
p POS N
= POS N
0.033). POS N

The POS N
findings POS N
provide POS N
general POS N
population POS N
evidence POS N
that POS N
SSRI POS N
augmentation POS N
with POS N
CCB POS N
may POS N
improve POS N
depression POS N
and POS N
cognitive POS N
function. POS N

The POS N
findings POS N
provide POS N
general POS N
population POS N
evidence POS N
that POS N
SSRI POS N
augmentation POS N
with POS N
CCB POS N
may POS N
improve POS N
depression POS N
and POS N
cognitive POS N
function. POS N

At POS N
two POS N
year POS N
follow-up POS N
there POS N
was POS N
a POS N
significant POS N
group POS N
by POS N
time POS N
interaction POS N
showing POS N
lower POS N
Center POS N
for POS N
Epidemiological POS N
Studies-Depression POS N
(CESD) POS N
scores POS N
in POS N
the POS N
SSRI POS N
+ POS N
CCB POS N
group, POS N
F(1,291) POS N
= POS N
4.13, POS N
p POS N
= POS N
0.043, POS N
η2 POS N
p POS N
= POS N
0.014. POS N

The POS N
findings POS N
provide POS N
general POS N
population POS N
evidence POS N
that POS N
SSRI POS N
augmentation POS N
with POS N
CCB POS N
may POS N
improve POS N
depression POS N
and POS N
cognitive POS N
function. POS N

Over POS N
ten-years POS N
follow-up, POS N
SSRI POS N
+ POS N
CCB POS N
use POS N
was POS N
associated POS N
with POS N
improved POS N
general POS N
cognitive POS N
function POS N
(Mini-Mental POS N
State POS N
Examination: POS N
β POS N
= POS N
0.97; POS N
95% POS N
CI POS N
0.14 POS N
to POS N
1.81, POS N
p POS N
= POS N
0.023) POS N
and POS N
immediate POS N
visual POS N
memory POS N
(Boston POS N
Visual POS N
Retention POS N
Test: POS N
β POS N
= POS N
0.69; POS N
95% POS N
CI POS N
0.06 POS N
to POS N
1.32, POS N
p POS N
= POS N
0.033). POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

At POS N
the POS N
last POS N
follow-up POS N
visit, POS N
mean POS N
pre-operative POS N
IOP POS N
decreased POS N
from POS N
31.1 POS N
(± POS N
14.2) POS N
to POS N
16.2 POS N
(± POS N
1.5) POS N
mm POS N
Hg POS N
after POS N
trabeculectomy, POS N
and POS N
from POS N
28.1 POS N
(± POS N
9.0) POS N
to POS N
15.7 POS N
(± POS N
1.8) POS N
mm POS N
Hg POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

The POS N
mean POS N
number POS N
of POS N
anti-glaucoma POS N
medicines POS N
prescribed POS N
at POS N
the POS N
last POS N
follow-up POS N
decreased POS N
from POS N
3.7 POS N
pre-operatively POS N
(both POS N
groups) POS N
to POS N
0.9 POS N
after POS N
trabeculectomy POS N
vs POS N
0.3 POS N
after POS N
Ex-PRESS POS N
implantation POS N
(P=0.001). POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

Complete POS N
success POS N
rates POS N
(5<IOP<18 POS N
mm POS N
Hg POS N
without POS N
medications) POS N
were POS N
higher POS N
with POS N
Ex-PRESS POS N
compared POS N
with POS N
trabeculectomy POS N
(P=0.0024). POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

Postoperative POS N
complications POS N
were POS N
more POS N
frequent POS N
after POS N
trabeculectomy POS N
(33%) POS N
compared POS N
with POS N
Ex-PRESS POS N
(20%), POS N
with POS N
four POS N
trabeculectomy POS N
eyes POS N
(27%) POS N
needing POS N
postoperative POS N
interventions, POS N
compared POS N
with POS N
none POS N
with POS N
Ex-PRESS. POS N

the POS N
Ex-PRESS POS N
group POS N
had POS N
a POS N
lower POS N
rate POS N
of POS N
complications, POS N
fewer POS N
postoperative POS N
interventions, POS N
and POS N
needed POS N
less POS N
glaucoma POS N
medications. POS N

Trabeculectomy POS N
and POS N
Ex-PRESS POS N
implantation POS N
provided POS N
similar POS N
IOP POS N
control, POS N

Symptomatic POS N
hypotension POS N
did POS N
not POS N
develop POS N
in POS N
any POS N
of POS N
the POS N
patients POS N
during POS N
the POS N
wet POS N
session, POS N
compared POS N
to POS N
4 POS N
(40%) POS N
during POS N
the POS N
dry POS N
session. POS N

Systolic POS N
blood POS N
pressure POS N
adjusted POS N
to POS N
ultrafiltration POS N
was POS N
stable POS N
during POS N
the POS N
wet POS N
session, POS N
0.22 POS N
mmHg/15 POS N
min POS N
(95% POS N
CI POS N
-0.27 POS N
to POS N
0.70), POS N
P = 0.38, POS N
and POS N
significantly POS N
decreased POS N
during POS N
the POS N
dry POS N
session, POS N
-0.68 POS N
mmHg/15 POS N
min POS N
(95%CI POS N
-1.24 POS N
to POS N
-0.11), POS N
P = 0.02. POS N

Symptomatic POS N
hypotension POS N
did POS N
not POS N
develop POS N
in POS N
any POS N
of POS N
the POS N
patients POS N
during POS N
the POS N
wet POS N
session, POS N
compared POS N
to POS N
4 POS N
(40%) POS N
during POS N
the POS N
dry POS N
session. POS N

Diastolic POS N
blood POS N
pressure POS N
did POS N
not POS N
change POS N
during POS N
the POS N
sessions. POS N

Symptomatic POS N
hypotension POS N
did POS N
not POS N
develop POS N
in POS N
any POS N
of POS N
the POS N
patients POS N
during POS N
the POS N
wet POS N
session, POS N
compared POS N
to POS N
4 POS N
(40%) POS N
during POS N
the POS N
dry POS N
session. POS N

Mean POS N
atrial POS N
natriuretic POS N
peptide POS N
significantly POS N
increased POS N
in POS N
the POS N
wet POS N
session, POS N
by POS N
31.36 POS N
pgr/mL POS N
(95%CI POS N
8.73-53.99), POS N
P = 0.007, POS N
and POS N
slightly POS N
and POS N
insignificantly POS N
decreased POS N
in POS N
the POS N
dry POS N
session, POS N
by POS N
21.66 POS N
pgr/mL POS N
(95% POS N
CI POS N
-52.59 POS N
to POS N
9.25), POS N
P = 0.167. POS N

Symptomatic POS N
hypotension POS N
did POS N
not POS N
develop POS N
in POS N
any POS N
of POS N
the POS N
patients POS N
during POS N
the POS N
wet POS N
session, POS N
compared POS N
to POS N
4 POS N
(40%) POS N
during POS N
the POS N
dry POS N
session. POS N

Reduced POS N
effective POS N
circulating POS N
volume POS N
is POS N
a POS N
major POS N
cause POS N
for POS N
IDH, POS N
which POS N
can POS N
be POS N
prevented POS N
using POS N
head-out POS N
water POS N
immersion POS N
facilitated POS N
redistribution. POS N

Symptomatic POS N
hypotension POS N
did POS N
not POS N
develop POS N
in POS N
any POS N
of POS N
the POS N
patients POS N
during POS N
the POS N
wet POS N
session, POS N
compared POS N
to POS N
4 POS N
(40%) POS N
during POS N
the POS N
dry POS N
session. POS N

Aldosterone POS N
blood POS N
levels POS N
did POS N
not POS N
change. POS N

Systolic POS N
blood POS N
pressure POS N
adjusted POS N
to POS N
ultrafiltration POS N
was POS N
stable POS N
during POS N
the POS N
wet POS N
session, POS N
0.22 POS N
mmHg/15 POS N
min POS N
(95% POS N
CI POS N
-0.27 POS N
to POS N
0.70), POS N
P = 0.38, POS N
and POS N
significantly POS N
decreased POS N
during POS N
the POS N
dry POS N
session, POS N
-0.68 POS N
mmHg/15 POS N
min POS N
(95%CI POS N
-1.24 POS N
to POS N
-0.11), POS N
P = 0.02. POS N

Symptomatic POS N
hypotension POS N
did POS N
not POS N
develop POS N
in POS N
any POS N
of POS N
the POS N
patients POS N
during POS N
the POS N
wet POS N
session, POS N
compared POS N
to POS N
4 POS N
(40%) POS N
during POS N
the POS N
dry POS N
session. POS N

Systolic POS N
blood POS N
pressure POS N
adjusted POS N
to POS N
ultrafiltration POS N
was POS N
stable POS N
during POS N
the POS N
wet POS N
session, POS N
0.22 POS N
mmHg/15 POS N
min POS N
(95% POS N
CI POS N
-0.27 POS N
to POS N
0.70), POS N
P = 0.38, POS N
and POS N
significantly POS N
decreased POS N
during POS N
the POS N
dry POS N
session, POS N
-0.68 POS N
mmHg/15 POS N
min POS N
(95%CI POS N
-1.24 POS N
to POS N
-0.11), POS N
P = 0.02. POS N

Diastolic POS N
blood POS N
pressure POS N
did POS N
not POS N
change POS N
during POS N
the POS N
sessions. POS N

Systolic POS N
blood POS N
pressure POS N
adjusted POS N
to POS N
ultrafiltration POS N
was POS N
stable POS N
during POS N
the POS N
wet POS N
session, POS N
0.22 POS N
mmHg/15 POS N
min POS N
(95% POS N
CI POS N
-0.27 POS N
to POS N
0.70), POS N
P = 0.38, POS N
and POS N
significantly POS N
decreased POS N
during POS N
the POS N
dry POS N
session, POS N
-0.68 POS N
mmHg/15 POS N
min POS N
(95%CI POS N
-1.24 POS N
to POS N
-0.11), POS N
P = 0.02. POS N

Mean POS N
atrial POS N
natriuretic POS N
peptide POS N
significantly POS N
increased POS N
in POS N
the POS N
wet POS N
session, POS N
by POS N
31.36 POS N
pgr/mL POS N
(95%CI POS N
8.73-53.99), POS N
P = 0.007, POS N
and POS N
slightly POS N
and POS N
insignificantly POS N
decreased POS N
in POS N
the POS N
dry POS N
session, POS N
by POS N
21.66 POS N
pgr/mL POS N
(95% POS N
CI POS N
-52.59 POS N
to POS N
9.25), POS N
P = 0.167. POS N

Systolic POS N
blood POS N
pressure POS N
adjusted POS N
to POS N
ultrafiltration POS N
was POS N
stable POS N
during POS N
the POS N
wet POS N
session, POS N
0.22 POS N
mmHg/15 POS N
min POS N
(95% POS N
CI POS N
-0.27 POS N
to POS N
0.70), POS N
P = 0.38, POS N
and POS N
significantly POS N
decreased POS N
during POS N
the POS N
dry POS N
session, POS N
-0.68 POS N
mmHg/15 POS N
min POS N
(95%CI POS N
-1.24 POS N
to POS N
-0.11), POS N
P = 0.02. POS N

Reduced POS N
effective POS N
circulating POS N
volume POS N
is POS N
a POS N
major POS N
cause POS N
for POS N
IDH, POS N
which POS N
can POS N
be POS N
prevented POS N
using POS N
head-out POS N
water POS N
immersion POS N
facilitated POS N
redistribution. POS N

Systolic POS N
blood POS N
pressure POS N
adjusted POS N
to POS N
ultrafiltration POS N
was POS N
stable POS N
during POS N
the POS N
wet POS N
session, POS N
0.22 POS N
mmHg/15 POS N
min POS N
(95% POS N
CI POS N
-0.27 POS N
to POS N
0.70), POS N
P = 0.38, POS N
and POS N
significantly POS N
decreased POS N
during POS N
the POS N
dry POS N
session, POS N
-0.68 POS N
mmHg/15 POS N
min POS N
(95%CI POS N
-1.24 POS N
to POS N
-0.11), POS N
P = 0.02. POS N

Aldosterone POS N
blood POS N
levels POS N
did POS N
not POS N
change. POS N

Diastolic POS N
blood POS N
pressure POS N
did POS N
not POS N
change POS N
during POS N
the POS N
sessions. POS N

Symptomatic POS N
hypotension POS N
did POS N
not POS N
develop POS N
in POS N
any POS N
of POS N
the POS N
patients POS N
during POS N
the POS N
wet POS N
session, POS N
compared POS N
to POS N
4 POS N
(40%) POS N
during POS N
the POS N
dry POS N
session. POS N

Diastolic POS N
blood POS N
pressure POS N
did POS N
not POS N
change POS N
during POS N
the POS N
sessions. POS N

Systolic POS N
blood POS N
pressure POS N
adjusted POS N
to POS N
ultrafiltration POS N
was POS N
stable POS N
during POS N
the POS N
wet POS N
session, POS N
0.22 POS N
mmHg/15 POS N
min POS N
(95% POS N
CI POS N
-0.27 POS N
to POS N
0.70), POS N
P = 0.38, POS N
and POS N
significantly POS N
decreased POS N
during POS N
the POS N
dry POS N
session, POS N
-0.68 POS N
mmHg/15 POS N
min POS N
(95%CI POS N
-1.24 POS N
to POS N
-0.11), POS N
P = 0.02. POS N

Diastolic POS N
blood POS N
pressure POS N
did POS N
not POS N
change POS N
during POS N
the POS N
sessions. POS N

Mean POS N
atrial POS N
natriuretic POS N
peptide POS N
significantly POS N
increased POS N
in POS N
the POS N
wet POS N
session, POS N
by POS N
31.36 POS N
pgr/mL POS N
(95%CI POS N
8.73-53.99), POS N
P = 0.007, POS N
and POS N
slightly POS N
and POS N
insignificantly POS N
decreased POS N
in POS N
the POS N
dry POS N
session, POS N
by POS N
21.66 POS N
pgr/mL POS N
(95% POS N
CI POS N
-52.59 POS N
to POS N
9.25), POS N
P = 0.167. POS N

Diastolic POS N
blood POS N
pressure POS N
did POS N
not POS N
change POS N
during POS N
the POS N
sessions. POS N

Reduced POS N
effective POS N
circulating POS N
volume POS N
is POS N
a POS N
major POS N
cause POS N
for POS N
IDH, POS N
which POS N
can POS N
be POS N
prevented POS N
using POS N
head-out POS N
water POS N
immersion POS N
facilitated POS N
redistribution. POS N

Diastolic POS N
blood POS N
pressure POS N
did POS N
not POS N
change POS N
during POS N
the POS N
sessions. POS N

Aldosterone POS N
blood POS N
levels POS N
did POS N
not POS N
change. POS N

Mean POS N
atrial POS N
natriuretic POS N
peptide POS N
significantly POS N
increased POS N
in POS N
the POS N
wet POS N
session, POS N
by POS N
31.36 POS N
pgr/mL POS N
(95%CI POS N
8.73-53.99), POS N
P = 0.007, POS N
and POS N
slightly POS N
and POS N
insignificantly POS N
decreased POS N
in POS N
the POS N
dry POS N
session, POS N
by POS N
21.66 POS N
pgr/mL POS N
(95% POS N
CI POS N
-52.59 POS N
to POS N
9.25), POS N
P = 0.167. POS N

Symptomatic POS N
hypotension POS N
did POS N
not POS N
develop POS N
in POS N
any POS N
of POS N
the POS N
patients POS N
during POS N
the POS N
wet POS N
session, POS N
compared POS N
to POS N
4 POS N
(40%) POS N
during POS N
the POS N
dry POS N
session. POS N

Mean POS N
atrial POS N
natriuretic POS N
peptide POS N
significantly POS N
increased POS N
in POS N
the POS N
wet POS N
session, POS N
by POS N
31.36 POS N
pgr/mL POS N
(95%CI POS N
8.73-53.99), POS N
P = 0.007, POS N
and POS N
slightly POS N
and POS N
insignificantly POS N
decreased POS N
in POS N
the POS N
dry POS N
session, POS N
by POS N
21.66 POS N
pgr/mL POS N
(95% POS N
CI POS N
-52.59 POS N
to POS N
9.25), POS N
P = 0.167. POS N

Systolic POS N
blood POS N
pressure POS N
adjusted POS N
to POS N
ultrafiltration POS N
was POS N
stable POS N
during POS N
the POS N
wet POS N
session, POS N
0.22 POS N
mmHg/15 POS N
min POS N
(95% POS N
CI POS N
-0.27 POS N
to POS N
0.70), POS N
P = 0.38, POS N
and POS N
significantly POS N
decreased POS N
during POS N
the POS N
dry POS N
session, POS N
-0.68 POS N
mmHg/15 POS N
min POS N
(95%CI POS N
-1.24 POS N
to POS N
-0.11), POS N
P = 0.02. POS N

Mean POS N
atrial POS N
natriuretic POS N
peptide POS N
significantly POS N
increased POS N
in POS N
the POS N
wet POS N
session, POS N
by POS N
31.36 POS N
pgr/mL POS N
(95%CI POS N
8.73-53.99), POS N
P = 0.007, POS N
and POS N
slightly POS N
and POS N
insignificantly POS N
decreased POS N
in POS N
the POS N
dry POS N
session, POS N
by POS N
21.66 POS N
pgr/mL POS N
(95% POS N
CI POS N
-52.59 POS N
to POS N
9.25), POS N
P = 0.167. POS N

Diastolic POS N
blood POS N
pressure POS N
did POS N
not POS N
change POS N
during POS N
the POS N
sessions. POS N

Mean POS N
atrial POS N
natriuretic POS N
peptide POS N
significantly POS N
increased POS N
in POS N
the POS N
wet POS N
session, POS N
by POS N
31.36 POS N
pgr/mL POS N
(95%CI POS N
8.73-53.99), POS N
P = 0.007, POS N
and POS N
slightly POS N
and POS N
insignificantly POS N
decreased POS N
in POS N
the POS N
dry POS N
session, POS N
by POS N
21.66 POS N
pgr/mL POS N
(95% POS N
CI POS N
-52.59 POS N
to POS N
9.25), POS N
P = 0.167. POS N

Reduced POS N
effective POS N
circulating POS N
volume POS N
is POS N
a POS N
major POS N
cause POS N
for POS N
IDH, POS N
which POS N
can POS N
be POS N
prevented POS N
using POS N
head-out POS N
water POS N
immersion POS N
facilitated POS N
redistribution. POS N

Mean POS N
atrial POS N
natriuretic POS N
peptide POS N
significantly POS N
increased POS N
in POS N
the POS N
wet POS N
session, POS N
by POS N
31.36 POS N
pgr/mL POS N
(95%CI POS N
8.73-53.99), POS N
P = 0.007, POS N
and POS N
slightly POS N
and POS N
insignificantly POS N
decreased POS N
in POS N
the POS N
dry POS N
session, POS N
by POS N
21.66 POS N
pgr/mL POS N
(95% POS N
CI POS N
-52.59 POS N
to POS N
9.25), POS N
P = 0.167. POS N

Aldosterone POS N
blood POS N
levels POS N
did POS N
not POS N
change. POS N

Reduced POS N
effective POS N
circulating POS N
volume POS N
is POS N
a POS N
major POS N
cause POS N
for POS N
IDH, POS N
which POS N
can POS N
be POS N
prevented POS N
using POS N
head-out POS N
water POS N
immersion POS N
facilitated POS N
redistribution. POS N

Symptomatic POS N
hypotension POS N
did POS N
not POS N
develop POS N
in POS N
any POS N
of POS N
the POS N
patients POS N
during POS N
the POS N
wet POS N
session, POS N
compared POS N
to POS N
4 POS N
(40%) POS N
during POS N
the POS N
dry POS N
session. POS N

Reduced POS N
effective POS N
circulating POS N
volume POS N
is POS N
a POS N
major POS N
cause POS N
for POS N
IDH, POS N
which POS N
can POS N
be POS N
prevented POS N
using POS N
head-out POS N
water POS N
immersion POS N
facilitated POS N
redistribution. POS N

Systolic POS N
blood POS N
pressure POS N
adjusted POS N
to POS N
ultrafiltration POS N
was POS N
stable POS N
during POS N
the POS N
wet POS N
session, POS N
0.22 POS N
mmHg/15 POS N
min POS N
(95% POS N
CI POS N
-0.27 POS N
to POS N
0.70), POS N
P = 0.38, POS N
and POS N
significantly POS N
decreased POS N
during POS N
the POS N
dry POS N
session, POS N
-0.68 POS N
mmHg/15 POS N
min POS N
(95%CI POS N
-1.24 POS N
to POS N
-0.11), POS N
P = 0.02. POS N

Reduced POS N
effective POS N
circulating POS N
volume POS N
is POS N
a POS N
major POS N
cause POS N
for POS N
IDH, POS N
which POS N
can POS N
be POS N
prevented POS N
using POS N
head-out POS N
water POS N
immersion POS N
facilitated POS N
redistribution. POS N

Diastolic POS N
blood POS N
pressure POS N
did POS N
not POS N
change POS N
during POS N
the POS N
sessions. POS N

Reduced POS N
effective POS N
circulating POS N
volume POS N
is POS N
a POS N
major POS N
cause POS N
for POS N
IDH, POS N
which POS N
can POS N
be POS N
prevented POS N
using POS N
head-out POS N
water POS N
immersion POS N
facilitated POS N
redistribution. POS N

Mean POS N
atrial POS N
natriuretic POS N
peptide POS N
significantly POS N
increased POS N
in POS N
the POS N
wet POS N
session, POS N
by POS N
31.36 POS N
pgr/mL POS N
(95%CI POS N
8.73-53.99), POS N
P = 0.007, POS N
and POS N
slightly POS N
and POS N
insignificantly POS N
decreased POS N
in POS N
the POS N
dry POS N
session, POS N
by POS N
21.66 POS N
pgr/mL POS N
(95% POS N
CI POS N
-52.59 POS N
to POS N
9.25), POS N
P = 0.167. POS N

Reduced POS N
effective POS N
circulating POS N
volume POS N
is POS N
a POS N
major POS N
cause POS N
for POS N
IDH, POS N
which POS N
can POS N
be POS N
prevented POS N
using POS N
head-out POS N
water POS N
immersion POS N
facilitated POS N
redistribution. POS N

Aldosterone POS N
blood POS N
levels POS N
did POS N
not POS N
change. POS N

Aldosterone POS N
blood POS N
levels POS N
did POS N
not POS N
change. POS N

Symptomatic POS N
hypotension POS N
did POS N
not POS N
develop POS N
in POS N
any POS N
of POS N
the POS N
patients POS N
during POS N
the POS N
wet POS N
session, POS N
compared POS N
to POS N
4 POS N
(40%) POS N
during POS N
the POS N
dry POS N
session. POS N

Aldosterone POS N
blood POS N
levels POS N
did POS N
not POS N
change. POS N

Systolic POS N
blood POS N
pressure POS N
adjusted POS N
to POS N
ultrafiltration POS N
was POS N
stable POS N
during POS N
the POS N
wet POS N
session, POS N
0.22 POS N
mmHg/15 POS N
min POS N
(95% POS N
CI POS N
-0.27 POS N
to POS N
0.70), POS N
P = 0.38, POS N
and POS N
significantly POS N
decreased POS N
during POS N
the POS N
dry POS N
session, POS N
-0.68 POS N
mmHg/15 POS N
min POS N
(95%CI POS N
-1.24 POS N
to POS N
-0.11), POS N
P = 0.02. POS N

Aldosterone POS N
blood POS N
levels POS N
did POS N
not POS N
change. POS N

Diastolic POS N
blood POS N
pressure POS N
did POS N
not POS N
change POS N
during POS N
the POS N
sessions. POS N

Aldosterone POS N
blood POS N
levels POS N
did POS N
not POS N
change. POS N

Mean POS N
atrial POS N
natriuretic POS N
peptide POS N
significantly POS N
increased POS N
in POS N
the POS N
wet POS N
session, POS N
by POS N
31.36 POS N
pgr/mL POS N
(95%CI POS N
8.73-53.99), POS N
P = 0.007, POS N
and POS N
slightly POS N
and POS N
insignificantly POS N
decreased POS N
in POS N
the POS N
dry POS N
session, POS N
by POS N
21.66 POS N
pgr/mL POS N
(95% POS N
CI POS N
-52.59 POS N
to POS N
9.25), POS N
P = 0.167. POS N

Aldosterone POS N
blood POS N
levels POS N
did POS N
not POS N
change. POS N

Reduced POS N
effective POS N
circulating POS N
volume POS N
is POS N
a POS N
major POS N
cause POS N
for POS N
IDH, POS N
which POS N
can POS N
be POS N
prevented POS N
using POS N
head-out POS N
water POS N
immersion POS N
facilitated POS N
redistribution. POS N

Preservative-free POS N
latanoprost POS N
has POS N
the POS N
same POS N
efficacy POS N
as POS N
BPL, POS N
with POS N
improved POS N
local POS N
tolerance. POS N

Upon POS N
instillation, POS N
the POS N
global POS N
subjective POS N
ocular POS N
symptom POS N
score POS N
was POS N
significantly POS N
lower POS N
on POS N
T2345 POS N
than POS N
BPL POS N
on POS N
D42 POS N
(0.15 POS N
vs POS N
0.41; POS N
p=0.001) POS N
and POS N
D84 POS N
(0.18 POS N
vs POS N
0.46; POS N
p=0.001). POS N

Preservative-free POS N
latanoprost POS N
has POS N
the POS N
same POS N
efficacy POS N
as POS N
BPL, POS N
with POS N
improved POS N
local POS N
tolerance. POS N

Moderate POS N
to POS N
severe POS N
conjunctival POS N
hyperaemia POS N
was POS N
less POS N
frequent POS N
on POS N
T2345 POS N
than POS N
on POS N
BPL POS N
at POS N
D42 POS N
(20.2% POS N
vs POS N
30.6%; POS N
p=0.003) POS N
and POS N
D84 POS N
(21.4% POS N
vs POS N
29.1%; POS N
p=0.02). POS N

Preservative-free POS N
latanoprost POS N
has POS N
the POS N
same POS N
efficacy POS N
as POS N
BPL, POS N
with POS N
improved POS N
local POS N
tolerance. POS N

The POS N
most POS N
frequent POS N
ocular POS N
adverse POS N
event, POS N
drug POS N
intolerance, POS N
was POS N
reported POS N
in POS N
1 POS N
(0.5%) POS N
patient POS N
on POS N
T2345 POS N
versus POS N
4 POS N
(2.1%) POS N
patients POS N
on POS N
BPL. POS N

Preservative-free POS N
latanoprost POS N
has POS N
the POS N
same POS N
efficacy POS N
as POS N
BPL, POS N
with POS N
improved POS N
local POS N
tolerance. POS N

Mean POS N
IOP POS N
reduction POS N
(D0-D84) POS N
was POS N
-8.6 POS N
±2.6 POS N
mm POS N
Hg POS N
(-36%) POS N
on POS N
T2345 POS N
and POS N
-9.0 POS N
±2.4 POS N
mm POS N
Hg POS N
(-38%) POS N
on POS N
BPL, POS N
confirming POS N
non-inferiority POS N
of POS N
T2345 POS N
to POS N
BPL. POS N

Upon POS N
instillation, POS N
the POS N
global POS N
subjective POS N
ocular POS N
symptom POS N
score POS N
was POS N
significantly POS N
lower POS N
on POS N
T2345 POS N
than POS N
BPL POS N
on POS N
D42 POS N
(0.15 POS N
vs POS N
0.41; POS N
p=0.001) POS N
and POS N
D84 POS N
(0.18 POS N
vs POS N
0.46; POS N
p=0.001). POS N

Preservative-free POS N
latanoprost POS N
has POS N
the POS N
same POS N
efficacy POS N
as POS N
BPL, POS N
with POS N
improved POS N
local POS N
tolerance. POS N

Upon POS N
instillation, POS N
the POS N
global POS N
subjective POS N
ocular POS N
symptom POS N
score POS N
was POS N
significantly POS N
lower POS N
on POS N
T2345 POS N
than POS N
BPL POS N
on POS N
D42 POS N
(0.15 POS N
vs POS N
0.41; POS N
p=0.001) POS N
and POS N
D84 POS N
(0.18 POS N
vs POS N
0.46; POS N
p=0.001). POS N

Moderate POS N
to POS N
severe POS N
conjunctival POS N
hyperaemia POS N
was POS N
less POS N
frequent POS N
on POS N
T2345 POS N
than POS N
on POS N
BPL POS N
at POS N
D42 POS N
(20.2% POS N
vs POS N
30.6%; POS N
p=0.003) POS N
and POS N
D84 POS N
(21.4% POS N
vs POS N
29.1%; POS N
p=0.02). POS N

Upon POS N
instillation, POS N
the POS N
global POS N
subjective POS N
ocular POS N
symptom POS N
score POS N
was POS N
significantly POS N
lower POS N
on POS N
T2345 POS N
than POS N
BPL POS N
on POS N
D42 POS N
(0.15 POS N
vs POS N
0.41; POS N
p=0.001) POS N
and POS N
D84 POS N
(0.18 POS N
vs POS N
0.46; POS N
p=0.001). POS N

The POS N
most POS N
frequent POS N
ocular POS N
adverse POS N
event, POS N
drug POS N
intolerance, POS N
was POS N
reported POS N
in POS N
1 POS N
(0.5%) POS N
patient POS N
on POS N
T2345 POS N
versus POS N
4 POS N
(2.1%) POS N
patients POS N
on POS N
BPL. POS N

Upon POS N
instillation, POS N
the POS N
global POS N
subjective POS N
ocular POS N
symptom POS N
score POS N
was POS N
significantly POS N
lower POS N
on POS N
T2345 POS N
than POS N
BPL POS N
on POS N
D42 POS N
(0.15 POS N
vs POS N
0.41; POS N
p=0.001) POS N
and POS N
D84 POS N
(0.18 POS N
vs POS N
0.46; POS N
p=0.001). POS N

Mean POS N
IOP POS N
reduction POS N
(D0-D84) POS N
was POS N
-8.6 POS N
±2.6 POS N
mm POS N
Hg POS N
(-36%) POS N
on POS N
T2345 POS N
and POS N
-9.0 POS N
±2.4 POS N
mm POS N
Hg POS N
(-38%) POS N
on POS N
BPL, POS N
confirming POS N
non-inferiority POS N
of POS N
T2345 POS N
to POS N
BPL. POS N

Moderate POS N
to POS N
severe POS N
conjunctival POS N
hyperaemia POS N
was POS N
less POS N
frequent POS N
on POS N
T2345 POS N
than POS N
on POS N
BPL POS N
at POS N
D42 POS N
(20.2% POS N
vs POS N
30.6%; POS N
p=0.003) POS N
and POS N
D84 POS N
(21.4% POS N
vs POS N
29.1%; POS N
p=0.02). POS N

Preservative-free POS N
latanoprost POS N
has POS N
the POS N
same POS N
efficacy POS N
as POS N
BPL, POS N
with POS N
improved POS N
local POS N
tolerance. POS N

Moderate POS N
to POS N
severe POS N
conjunctival POS N
hyperaemia POS N
was POS N
less POS N
frequent POS N
on POS N
T2345 POS N
than POS N
on POS N
BPL POS N
at POS N
D42 POS N
(20.2% POS N
vs POS N
30.6%; POS N
p=0.003) POS N
and POS N
D84 POS N
(21.4% POS N
vs POS N
29.1%; POS N
p=0.02). POS N

Upon POS N
instillation, POS N
the POS N
global POS N
subjective POS N
ocular POS N
symptom POS N
score POS N
was POS N
significantly POS N
lower POS N
on POS N
T2345 POS N
than POS N
BPL POS N
on POS N
D42 POS N
(0.15 POS N
vs POS N
0.41; POS N
p=0.001) POS N
and POS N
D84 POS N
(0.18 POS N
vs POS N
0.46; POS N
p=0.001). POS N

Moderate POS N
to POS N
severe POS N
conjunctival POS N
hyperaemia POS N
was POS N
less POS N
frequent POS N
on POS N
T2345 POS N
than POS N
on POS N
BPL POS N
at POS N
D42 POS N
(20.2% POS N
vs POS N
30.6%; POS N
p=0.003) POS N
and POS N
D84 POS N
(21.4% POS N
vs POS N
29.1%; POS N
p=0.02). POS N

The POS N
most POS N
frequent POS N
ocular POS N
adverse POS N
event, POS N
drug POS N
intolerance, POS N
was POS N
reported POS N
in POS N
1 POS N
(0.5%) POS N
patient POS N
on POS N
T2345 POS N
versus POS N
4 POS N
(2.1%) POS N
patients POS N
on POS N
BPL. POS N

Moderate POS N
to POS N
severe POS N
conjunctival POS N
hyperaemia POS N
was POS N
less POS N
frequent POS N
on POS N
T2345 POS N
than POS N
on POS N
BPL POS N
at POS N
D42 POS N
(20.2% POS N
vs POS N
30.6%; POS N
p=0.003) POS N
and POS N
D84 POS N
(21.4% POS N
vs POS N
29.1%; POS N
p=0.02). POS N

Mean POS N
IOP POS N
reduction POS N
(D0-D84) POS N
was POS N
-8.6 POS N
±2.6 POS N
mm POS N
Hg POS N
(-36%) POS N
on POS N
T2345 POS N
and POS N
-9.0 POS N
±2.4 POS N
mm POS N
Hg POS N
(-38%) POS N
on POS N
BPL, POS N
confirming POS N
non-inferiority POS N
of POS N
T2345 POS N
to POS N
BPL. POS N

The POS N
most POS N
frequent POS N
ocular POS N
adverse POS N
event, POS N
drug POS N
intolerance, POS N
was POS N
reported POS N
in POS N
1 POS N
(0.5%) POS N
patient POS N
on POS N
T2345 POS N
versus POS N
4 POS N
(2.1%) POS N
patients POS N
on POS N
BPL. POS N

Preservative-free POS N
latanoprost POS N
has POS N
the POS N
same POS N
efficacy POS N
as POS N
BPL, POS N
with POS N
improved POS N
local POS N
tolerance. POS N

The POS N
most POS N
frequent POS N
ocular POS N
adverse POS N
event, POS N
drug POS N
intolerance, POS N
was POS N
reported POS N
in POS N
1 POS N
(0.5%) POS N
patient POS N
on POS N
T2345 POS N
versus POS N
4 POS N
(2.1%) POS N
patients POS N
on POS N
BPL. POS N

Upon POS N
instillation, POS N
the POS N
global POS N
subjective POS N
ocular POS N
symptom POS N
score POS N
was POS N
significantly POS N
lower POS N
on POS N
T2345 POS N
than POS N
BPL POS N
on POS N
D42 POS N
(0.15 POS N
vs POS N
0.41; POS N
p=0.001) POS N
and POS N
D84 POS N
(0.18 POS N
vs POS N
0.46; POS N
p=0.001). POS N

The POS N
most POS N
frequent POS N
ocular POS N
adverse POS N
event, POS N
drug POS N
intolerance, POS N
was POS N
reported POS N
in POS N
1 POS N
(0.5%) POS N
patient POS N
on POS N
T2345 POS N
versus POS N
4 POS N
(2.1%) POS N
patients POS N
on POS N
BPL. POS N

Moderate POS N
to POS N
severe POS N
conjunctival POS N
hyperaemia POS N
was POS N
less POS N
frequent POS N
on POS N
T2345 POS N
than POS N
on POS N
BPL POS N
at POS N
D42 POS N
(20.2% POS N
vs POS N
30.6%; POS N
p=0.003) POS N
and POS N
D84 POS N
(21.4% POS N
vs POS N
29.1%; POS N
p=0.02). POS N

The POS N
most POS N
frequent POS N
ocular POS N
adverse POS N
event, POS N
drug POS N
intolerance, POS N
was POS N
reported POS N
in POS N
1 POS N
(0.5%) POS N
patient POS N
on POS N
T2345 POS N
versus POS N
4 POS N
(2.1%) POS N
patients POS N
on POS N
BPL. POS N

Mean POS N
IOP POS N
reduction POS N
(D0-D84) POS N
was POS N
-8.6 POS N
±2.6 POS N
mm POS N
Hg POS N
(-36%) POS N
on POS N
T2345 POS N
and POS N
-9.0 POS N
±2.4 POS N
mm POS N
Hg POS N
(-38%) POS N
on POS N
BPL, POS N
confirming POS N
non-inferiority POS N
of POS N
T2345 POS N
to POS N
BPL. POS N

Mean POS N
IOP POS N
reduction POS N
(D0-D84) POS N
was POS N
-8.6 POS N
±2.6 POS N
mm POS N
Hg POS N
(-36%) POS N
on POS N
T2345 POS N
and POS N
-9.0 POS N
±2.4 POS N
mm POS N
Hg POS N
(-38%) POS N
on POS N
BPL, POS N
confirming POS N
non-inferiority POS N
of POS N
T2345 POS N
to POS N
BPL. POS N

Preservative-free POS N
latanoprost POS N
has POS N
the POS N
same POS N
efficacy POS N
as POS N
BPL, POS N
with POS N
improved POS N
local POS N
tolerance. POS N

Mean POS N
IOP POS N
reduction POS N
(D0-D84) POS N
was POS N
-8.6 POS N
±2.6 POS N
mm POS N
Hg POS N
(-36%) POS N
on POS N
T2345 POS N
and POS N
-9.0 POS N
±2.4 POS N
mm POS N
Hg POS N
(-38%) POS N
on POS N
BPL, POS N
confirming POS N
non-inferiority POS N
of POS N
T2345 POS N
to POS N
BPL. POS N

Upon POS N
instillation, POS N
the POS N
global POS N
subjective POS N
ocular POS N
symptom POS N
score POS N
was POS N
significantly POS N
lower POS N
on POS N
T2345 POS N
than POS N
BPL POS N
on POS N
D42 POS N
(0.15 POS N
vs POS N
0.41; POS N
p=0.001) POS N
and POS N
D84 POS N
(0.18 POS N
vs POS N
0.46; POS N
p=0.001). POS N

Mean POS N
IOP POS N
reduction POS N
(D0-D84) POS N
was POS N
-8.6 POS N
±2.6 POS N
mm POS N
Hg POS N
(-36%) POS N
on POS N
T2345 POS N
and POS N
-9.0 POS N
±2.4 POS N
mm POS N
Hg POS N
(-38%) POS N
on POS N
BPL, POS N
confirming POS N
non-inferiority POS N
of POS N
T2345 POS N
to POS N
BPL. POS N

Moderate POS N
to POS N
severe POS N
conjunctival POS N
hyperaemia POS N
was POS N
less POS N
frequent POS N
on POS N
T2345 POS N
than POS N
on POS N
BPL POS N
at POS N
D42 POS N
(20.2% POS N
vs POS N
30.6%; POS N
p=0.003) POS N
and POS N
D84 POS N
(21.4% POS N
vs POS N
29.1%; POS N
p=0.02). POS N

Mean POS N
IOP POS N
reduction POS N
(D0-D84) POS N
was POS N
-8.6 POS N
±2.6 POS N
mm POS N
Hg POS N
(-36%) POS N
on POS N
T2345 POS N
and POS N
-9.0 POS N
±2.4 POS N
mm POS N
Hg POS N
(-38%) POS N
on POS N
BPL, POS N
confirming POS N
non-inferiority POS N
of POS N
T2345 POS N
to POS N
BPL. POS N

The POS N
most POS N
frequent POS N
ocular POS N
adverse POS N
event, POS N
drug POS N
intolerance, POS N
was POS N
reported POS N
in POS N
1 POS N
(0.5%) POS N
patient POS N
on POS N
T2345 POS N
versus POS N
4 POS N
(2.1%) POS N
patients POS N
on POS N
BPL. POS N

Large-scale POS N
clinical POS N
trials POS N
have POS N
shown POS N
that POS N
incretin-based POS N
therapies POS N
mitigate POS N
albuminuria POS N

but POS N
have POS N
not POS N
shown POS N
beneficial POS N
effects POS N
on POS N
eGFR. POS N

Large-scale POS N
clinical POS N
trials POS N
have POS N
shown POS N
that POS N
incretin-based POS N
therapies POS N
mitigate POS N
albuminuria POS N

Research POS N
on POS N
the POS N
incretin-based POS N
therapies POS N
has POS N
yielded POS N
a POS N
diverse POS N
array POS N
of POS N
direct POS N
effects POS N
throughout POS N
the POS N
body, POS N
which POS N
fuels POS N
speculation POS N
as POS N
to POS N
how POS N
these POS N
drugs POS N
might POS N
benefit POS N
the POS N
diabetic POS N
kidney POS N
and POS N
affect POS N
its POS N
function(s). POS N

Large-scale POS N
clinical POS N
trials POS N
have POS N
shown POS N
that POS N
incretin-based POS N
therapies POS N
mitigate POS N
albuminuria POS N

But POS N
in POS N
vivo POS N
experiments POS N
have POS N
yet POS N
to POS N
confirm POS N
that POS N
the POS N
proposed POS N
mechanisms POS N
underlying POS N
emergent POS N
phenomena, POS N
such POS N
as POS N
proximal POS N
tubular POS N
fluid POS N
reabsorption, POS N
are POS N
the POS N
ones POS N
predicted POS N
by POS N
cell POS N
and POS N
molecular POS N
experiments. POS N

Large-scale POS N
clinical POS N
trials POS N
have POS N
shown POS N
that POS N
incretin-based POS N
therapies POS N
mitigate POS N
albuminuria POS N

There POS N
may POS N
be POS N
salutary POS N
effects POS N
of POS N
incretin-based POS N
treatments POS N
on POS N
the POS N
diabetic POS N
kidney, POS N

Large-scale POS N
clinical POS N
trials POS N
have POS N
shown POS N
that POS N
incretin-based POS N
therapies POS N
mitigate POS N
albuminuria POS N

but POS N
the POS N
system POS N
is POS N
complex POS N
and POS N
not POS N
amenable POS N
to POS N
simple POS N
explanation POS N
or POS N
prior POS N
prediction. POS N

Large-scale POS N
clinical POS N
trials POS N
have POS N
shown POS N
that POS N
incretin-based POS N
therapies POS N
mitigate POS N
albuminuria POS N

This POS N
contrasts POS N
with POS N
the POS N
renal POS N
effects POS N
of POS N
SGLT2 POS N
inhibitors, POS N
which POS N
can POS N
be POS N
explained POS N
concisely. POS N

but POS N
have POS N
not POS N
shown POS N
beneficial POS N
effects POS N
on POS N
eGFR. POS N

Large-scale POS N
clinical POS N
trials POS N
have POS N
shown POS N
that POS N
incretin-based POS N
therapies POS N
mitigate POS N
albuminuria POS N

but POS N
have POS N
not POS N
shown POS N
beneficial POS N
effects POS N
on POS N
eGFR. POS N

Research POS N
on POS N
the POS N
incretin-based POS N
therapies POS N
has POS N
yielded POS N
a POS N
diverse POS N
array POS N
of POS N
direct POS N
effects POS N
throughout POS N
the POS N
body, POS N
which POS N
fuels POS N
speculation POS N
as POS N
to POS N
how POS N
these POS N
drugs POS N
might POS N
benefit POS N
the POS N
diabetic POS N
kidney POS N
and POS N
affect POS N
its POS N
function(s). POS N

but POS N
have POS N
not POS N
shown POS N
beneficial POS N
effects POS N
on POS N
eGFR. POS N

But POS N
in POS N
vivo POS N
experiments POS N
have POS N
yet POS N
to POS N
confirm POS N
that POS N
the POS N
proposed POS N
mechanisms POS N
underlying POS N
emergent POS N
phenomena, POS N
such POS N
as POS N
proximal POS N
tubular POS N
fluid POS N
reabsorption, POS N
are POS N
the POS N
ones POS N
predicted POS N
by POS N
cell POS N
and POS N
molecular POS N
experiments. POS N

but POS N
have POS N
not POS N
shown POS N
beneficial POS N
effects POS N
on POS N
eGFR. POS N

There POS N
may POS N
be POS N
salutary POS N
effects POS N
of POS N
incretin-based POS N
treatments POS N
on POS N
the POS N
diabetic POS N
kidney, POS N

but POS N
have POS N
not POS N
shown POS N
beneficial POS N
effects POS N
on POS N
eGFR. POS N

but POS N
the POS N
system POS N
is POS N
complex POS N
and POS N
not POS N
amenable POS N
to POS N
simple POS N
explanation POS N
or POS N
prior POS N
prediction. POS N

but POS N
have POS N
not POS N
shown POS N
beneficial POS N
effects POS N
on POS N
eGFR. POS N

This POS N
contrasts POS N
with POS N
the POS N
renal POS N
effects POS N
of POS N
SGLT2 POS N
inhibitors, POS N
which POS N
can POS N
be POS N
explained POS N
concisely. POS N

Research POS N
on POS N
the POS N
incretin-based POS N
therapies POS N
has POS N
yielded POS N
a POS N
diverse POS N
array POS N
of POS N
direct POS N
effects POS N
throughout POS N
the POS N
body, POS N
which POS N
fuels POS N
speculation POS N
as POS N
to POS N
how POS N
these POS N
drugs POS N
might POS N
benefit POS N
the POS N
diabetic POS N
kidney POS N
and POS N
affect POS N
its POS N
function(s). POS N

Large-scale POS N
clinical POS N
trials POS N
have POS N
shown POS N
that POS N
incretin-based POS N
therapies POS N
mitigate POS N
albuminuria POS N

Research POS N
on POS N
the POS N
incretin-based POS N
therapies POS N
has POS N
yielded POS N
a POS N
diverse POS N
array POS N
of POS N
direct POS N
effects POS N
throughout POS N
the POS N
body, POS N
which POS N
fuels POS N
speculation POS N
as POS N
to POS N
how POS N
these POS N
drugs POS N
might POS N
benefit POS N
the POS N
diabetic POS N
kidney POS N
and POS N
affect POS N
its POS N
function(s). POS N

but POS N
have POS N
not POS N
shown POS N
beneficial POS N
effects POS N
on POS N
eGFR. POS N

Research POS N
on POS N
the POS N
incretin-based POS N
therapies POS N
has POS N
yielded POS N
a POS N
diverse POS N
array POS N
of POS N
direct POS N
effects POS N
throughout POS N
the POS N
body, POS N
which POS N
fuels POS N
speculation POS N
as POS N
to POS N
how POS N
these POS N
drugs POS N
might POS N
benefit POS N
the POS N
diabetic POS N
kidney POS N
and POS N
affect POS N
its POS N
function(s). POS N

But POS N
in POS N
vivo POS N
experiments POS N
have POS N
yet POS N
to POS N
confirm POS N
that POS N
the POS N
proposed POS N
mechanisms POS N
underlying POS N
emergent POS N
phenomena, POS N
such POS N
as POS N
proximal POS N
tubular POS N
fluid POS N
reabsorption, POS N
are POS N
the POS N
ones POS N
predicted POS N
by POS N
cell POS N
and POS N
molecular POS N
experiments. POS N

Research POS N
on POS N
the POS N
incretin-based POS N
therapies POS N
has POS N
yielded POS N
a POS N
diverse POS N
array POS N
of POS N
direct POS N
effects POS N
throughout POS N
the POS N
body, POS N
which POS N
fuels POS N
speculation POS N
as POS N
to POS N
how POS N
these POS N
drugs POS N
might POS N
benefit POS N
the POS N
diabetic POS N
kidney POS N
and POS N
affect POS N
its POS N
function(s). POS N

There POS N
may POS N
be POS N
salutary POS N
effects POS N
of POS N
incretin-based POS N
treatments POS N
on POS N
the POS N
diabetic POS N
kidney, POS N

Research POS N
on POS N
the POS N
incretin-based POS N
therapies POS N
has POS N
yielded POS N
a POS N
diverse POS N
array POS N
of POS N
direct POS N
effects POS N
throughout POS N
the POS N
body, POS N
which POS N
fuels POS N
speculation POS N
as POS N
to POS N
how POS N
these POS N
drugs POS N
might POS N
benefit POS N
the POS N
diabetic POS N
kidney POS N
and POS N
affect POS N
its POS N
function(s). POS N

but POS N
the POS N
system POS N
is POS N
complex POS N
and POS N
not POS N
amenable POS N
to POS N
simple POS N
explanation POS N
or POS N
prior POS N
prediction. POS N

Research POS N
on POS N
the POS N
incretin-based POS N
therapies POS N
has POS N
yielded POS N
a POS N
diverse POS N
array POS N
of POS N
direct POS N
effects POS N
throughout POS N
the POS N
body, POS N
which POS N
fuels POS N
speculation POS N
as POS N
to POS N
how POS N
these POS N
drugs POS N
might POS N
benefit POS N
the POS N
diabetic POS N
kidney POS N
and POS N
affect POS N
its POS N
function(s). POS N

This POS N
contrasts POS N
with POS N
the POS N
renal POS N
effects POS N
of POS N
SGLT2 POS N
inhibitors, POS N
which POS N
can POS N
be POS N
explained POS N
concisely. POS N

But POS N
in POS N
vivo POS N
experiments POS N
have POS N
yet POS N
to POS N
confirm POS N
that POS N
the POS N
proposed POS N
mechanisms POS N
underlying POS N
emergent POS N
phenomena, POS N
such POS N
as POS N
proximal POS N
tubular POS N
fluid POS N
reabsorption, POS N
are POS N
the POS N
ones POS N
predicted POS N
by POS N
cell POS N
and POS N
molecular POS N
experiments. POS N

Large-scale POS N
clinical POS N
trials POS N
have POS N
shown POS N
that POS N
incretin-based POS N
therapies POS N
mitigate POS N
albuminuria POS N

But POS N
in POS N
vivo POS N
experiments POS N
have POS N
yet POS N
to POS N
confirm POS N
that POS N
the POS N
proposed POS N
mechanisms POS N
underlying POS N
emergent POS N
phenomena, POS N
such POS N
as POS N
proximal POS N
tubular POS N
fluid POS N
reabsorption, POS N
are POS N
the POS N
ones POS N
predicted POS N
by POS N
cell POS N
and POS N
molecular POS N
experiments. POS N

but POS N
have POS N
not POS N
shown POS N
beneficial POS N
effects POS N
on POS N
eGFR. POS N

But POS N
in POS N
vivo POS N
experiments POS N
have POS N
yet POS N
to POS N
confirm POS N
that POS N
the POS N
proposed POS N
mechanisms POS N
underlying POS N
emergent POS N
phenomena, POS N
such POS N
as POS N
proximal POS N
tubular POS N
fluid POS N
reabsorption, POS N
are POS N
the POS N
ones POS N
predicted POS N
by POS N
cell POS N
and POS N
molecular POS N
experiments. POS N

Research POS N
on POS N
the POS N
incretin-based POS N
therapies POS N
has POS N
yielded POS N
a POS N
diverse POS N
array POS N
of POS N
direct POS N
effects POS N
throughout POS N
the POS N
body, POS N
which POS N
fuels POS N
speculation POS N
as POS N
to POS N
how POS N
these POS N
drugs POS N
might POS N
benefit POS N
the POS N
diabetic POS N
kidney POS N
and POS N
affect POS N
its POS N
function(s). POS N

But POS N
in POS N
vivo POS N
experiments POS N
have POS N
yet POS N
to POS N
confirm POS N
that POS N
the POS N
proposed POS N
mechanisms POS N
underlying POS N
emergent POS N
phenomena, POS N
such POS N
as POS N
proximal POS N
tubular POS N
fluid POS N
reabsorption, POS N
are POS N
the POS N
ones POS N
predicted POS N
by POS N
cell POS N
and POS N
molecular POS N
experiments. POS N

There POS N
may POS N
be POS N
salutary POS N
effects POS N
of POS N
incretin-based POS N
treatments POS N
on POS N
the POS N
diabetic POS N
kidney, POS N

But POS N
in POS N
vivo POS N
experiments POS N
have POS N
yet POS N
to POS N
confirm POS N
that POS N
the POS N
proposed POS N
mechanisms POS N
underlying POS N
emergent POS N
phenomena, POS N
such POS N
as POS N
proximal POS N
tubular POS N
fluid POS N
reabsorption, POS N
are POS N
the POS N
ones POS N
predicted POS N
by POS N
cell POS N
and POS N
molecular POS N
experiments. POS N

but POS N
the POS N
system POS N
is POS N
complex POS N
and POS N
not POS N
amenable POS N
to POS N
simple POS N
explanation POS N
or POS N
prior POS N
prediction. POS N

But POS N
in POS N
vivo POS N
experiments POS N
have POS N
yet POS N
to POS N
confirm POS N
that POS N
the POS N
proposed POS N
mechanisms POS N
underlying POS N
emergent POS N
phenomena, POS N
such POS N
as POS N
proximal POS N
tubular POS N
fluid POS N
reabsorption, POS N
are POS N
the POS N
ones POS N
predicted POS N
by POS N
cell POS N
and POS N
molecular POS N
experiments. POS N

This POS N
contrasts POS N
with POS N
the POS N
renal POS N
effects POS N
of POS N
SGLT2 POS N
inhibitors, POS N
which POS N
can POS N
be POS N
explained POS N
concisely. POS N

There POS N
may POS N
be POS N
salutary POS N
effects POS N
of POS N
incretin-based POS N
treatments POS N
on POS N
the POS N
diabetic POS N
kidney, POS N

Large-scale POS N
clinical POS N
trials POS N
have POS N
shown POS N
that POS N
incretin-based POS N
therapies POS N
mitigate POS N
albuminuria POS N

There POS N
may POS N
be POS N
salutary POS N
effects POS N
of POS N
incretin-based POS N
treatments POS N
on POS N
the POS N
diabetic POS N
kidney, POS N

but POS N
have POS N
not POS N
shown POS N
beneficial POS N
effects POS N
on POS N
eGFR. POS N

There POS N
may POS N
be POS N
salutary POS N
effects POS N
of POS N
incretin-based POS N
treatments POS N
on POS N
the POS N
diabetic POS N
kidney, POS N

Research POS N
on POS N
the POS N
incretin-based POS N
therapies POS N
has POS N
yielded POS N
a POS N
diverse POS N
array POS N
of POS N
direct POS N
effects POS N
throughout POS N
the POS N
body, POS N
which POS N
fuels POS N
speculation POS N
as POS N
to POS N
how POS N
these POS N
drugs POS N
might POS N
benefit POS N
the POS N
diabetic POS N
kidney POS N
and POS N
affect POS N
its POS N
function(s). POS N

There POS N
may POS N
be POS N
salutary POS N
effects POS N
of POS N
incretin-based POS N
treatments POS N
on POS N
the POS N
diabetic POS N
kidney, POS N

But POS N
in POS N
vivo POS N
experiments POS N
have POS N
yet POS N
to POS N
confirm POS N
that POS N
the POS N
proposed POS N
mechanisms POS N
underlying POS N
emergent POS N
phenomena, POS N
such POS N
as POS N
proximal POS N
tubular POS N
fluid POS N
reabsorption, POS N
are POS N
the POS N
ones POS N
predicted POS N
by POS N
cell POS N
and POS N
molecular POS N
experiments. POS N

There POS N
may POS N
be POS N
salutary POS N
effects POS N
of POS N
incretin-based POS N
treatments POS N
on POS N
the POS N
diabetic POS N
kidney, POS N

but POS N
the POS N
system POS N
is POS N
complex POS N
and POS N
not POS N
amenable POS N
to POS N
simple POS N
explanation POS N
or POS N
prior POS N
prediction. POS N

There POS N
may POS N
be POS N
salutary POS N
effects POS N
of POS N
incretin-based POS N
treatments POS N
on POS N
the POS N
diabetic POS N
kidney, POS N

This POS N
contrasts POS N
with POS N
the POS N
renal POS N
effects POS N
of POS N
SGLT2 POS N
inhibitors, POS N
which POS N
can POS N
be POS N
explained POS N
concisely. POS N

but POS N
the POS N
system POS N
is POS N
complex POS N
and POS N
not POS N
amenable POS N
to POS N
simple POS N
explanation POS N
or POS N
prior POS N
prediction. POS N

Large-scale POS N
clinical POS N
trials POS N
have POS N
shown POS N
that POS N
incretin-based POS N
therapies POS N
mitigate POS N
albuminuria POS N

but POS N
the POS N
system POS N
is POS N
complex POS N
and POS N
not POS N
amenable POS N
to POS N
simple POS N
explanation POS N
or POS N
prior POS N
prediction. POS N

but POS N
have POS N
not POS N
shown POS N
beneficial POS N
effects POS N
on POS N
eGFR. POS N

but POS N
the POS N
system POS N
is POS N
complex POS N
and POS N
not POS N
amenable POS N
to POS N
simple POS N
explanation POS N
or POS N
prior POS N
prediction. POS N

Research POS N
on POS N
the POS N
incretin-based POS N
therapies POS N
has POS N
yielded POS N
a POS N
diverse POS N
array POS N
of POS N
direct POS N
effects POS N
throughout POS N
the POS N
body, POS N
which POS N
fuels POS N
speculation POS N
as POS N
to POS N
how POS N
these POS N
drugs POS N
might POS N
benefit POS N
the POS N
diabetic POS N
kidney POS N
and POS N
affect POS N
its POS N
function(s). POS N

but POS N
the POS N
system POS N
is POS N
complex POS N
and POS N
not POS N
amenable POS N
to POS N
simple POS N
explanation POS N
or POS N
prior POS N
prediction. POS N

But POS N
in POS N
vivo POS N
experiments POS N
have POS N
yet POS N
to POS N
confirm POS N
that POS N
the POS N
proposed POS N
mechanisms POS N
underlying POS N
emergent POS N
phenomena, POS N
such POS N
as POS N
proximal POS N
tubular POS N
fluid POS N
reabsorption, POS N
are POS N
the POS N
ones POS N
predicted POS N
by POS N
cell POS N
and POS N
molecular POS N
experiments. POS N

but POS N
the POS N
system POS N
is POS N
complex POS N
and POS N
not POS N
amenable POS N
to POS N
simple POS N
explanation POS N
or POS N
prior POS N
prediction. POS N

There POS N
may POS N
be POS N
salutary POS N
effects POS N
of POS N
incretin-based POS N
treatments POS N
on POS N
the POS N
diabetic POS N
kidney, POS N

but POS N
the POS N
system POS N
is POS N
complex POS N
and POS N
not POS N
amenable POS N
to POS N
simple POS N
explanation POS N
or POS N
prior POS N
prediction. POS N

This POS N
contrasts POS N
with POS N
the POS N
renal POS N
effects POS N
of POS N
SGLT2 POS N
inhibitors, POS N
which POS N
can POS N
be POS N
explained POS N
concisely. POS N

This POS N
contrasts POS N
with POS N
the POS N
renal POS N
effects POS N
of POS N
SGLT2 POS N
inhibitors, POS N
which POS N
can POS N
be POS N
explained POS N
concisely. POS N

Large-scale POS N
clinical POS N
trials POS N
have POS N
shown POS N
that POS N
incretin-based POS N
therapies POS N
mitigate POS N
albuminuria POS N

This POS N
contrasts POS N
with POS N
the POS N
renal POS N
effects POS N
of POS N
SGLT2 POS N
inhibitors, POS N
which POS N
can POS N
be POS N
explained POS N
concisely. POS N

but POS N
have POS N
not POS N
shown POS N
beneficial POS N
effects POS N
on POS N
eGFR. POS N

This POS N
contrasts POS N
with POS N
the POS N
renal POS N
effects POS N
of POS N
SGLT2 POS N
inhibitors, POS N
which POS N
can POS N
be POS N
explained POS N
concisely. POS N

Research POS N
on POS N
the POS N
incretin-based POS N
therapies POS N
has POS N
yielded POS N
a POS N
diverse POS N
array POS N
of POS N
direct POS N
effects POS N
throughout POS N
the POS N
body, POS N
which POS N
fuels POS N
speculation POS N
as POS N
to POS N
how POS N
these POS N
drugs POS N
might POS N
benefit POS N
the POS N
diabetic POS N
kidney POS N
and POS N
affect POS N
its POS N
function(s). POS N

This POS N
contrasts POS N
with POS N
the POS N
renal POS N
effects POS N
of POS N
SGLT2 POS N
inhibitors, POS N
which POS N
can POS N
be POS N
explained POS N
concisely. POS N

But POS N
in POS N
vivo POS N
experiments POS N
have POS N
yet POS N
to POS N
confirm POS N
that POS N
the POS N
proposed POS N
mechanisms POS N
underlying POS N
emergent POS N
phenomena, POS N
such POS N
as POS N
proximal POS N
tubular POS N
fluid POS N
reabsorption, POS N
are POS N
the POS N
ones POS N
predicted POS N
by POS N
cell POS N
and POS N
molecular POS N
experiments. POS N

This POS N
contrasts POS N
with POS N
the POS N
renal POS N
effects POS N
of POS N
SGLT2 POS N
inhibitors, POS N
which POS N
can POS N
be POS N
explained POS N
concisely. POS N

There POS N
may POS N
be POS N
salutary POS N
effects POS N
of POS N
incretin-based POS N
treatments POS N
on POS N
the POS N
diabetic POS N
kidney, POS N

This POS N
contrasts POS N
with POS N
the POS N
renal POS N
effects POS N
of POS N
SGLT2 POS N
inhibitors, POS N
which POS N
can POS N
be POS N
explained POS N
concisely. POS N

but POS N
the POS N
system POS N
is POS N
complex POS N
and POS N
not POS N
amenable POS N
to POS N
simple POS N
explanation POS N
or POS N
prior POS N
prediction. POS N

Aortic POS N
systolic POS N
pressure POS N
and POS N
augmentation POS N
index, POS N
assessed POS N
by POS N
radial POS N
artery POS N
oscillatory POS N
tonometry, POS N
were POS N
unaffected POS N
by POS N
CPAP POS N
but POS N
decreased POS N
after POS N
AZT POS N
and POS N
AZT POS N
plus POS N
CPAP POS N
(RM-ANOVA POS N
P POS N
= POS N
.030 POS N
and POS N
.031, POS N
respectively). POS N

The POS N
apnea-hypopnea POS N
index POS N
was POS N
significantly POS N
reduced POS N
in POS N
all POS N
three POS N
treatment POS N
arms, POS N
most POS N
prominently POS N
by POS N
AZT POS N
plus POS N
CPAP POS N
(RM-ANOVA POS N
P POS N
= POS N
.003). POS N

Aortic POS N
systolic POS N
pressure POS N
and POS N
augmentation POS N
index, POS N
assessed POS N
by POS N
radial POS N
artery POS N
oscillatory POS N
tonometry, POS N
were POS N
unaffected POS N
by POS N
CPAP POS N
but POS N
decreased POS N
after POS N
AZT POS N
and POS N
AZT POS N
plus POS N
CPAP POS N
(RM-ANOVA POS N
P POS N
= POS N
.030 POS N
and POS N
.031, POS N
respectively). POS N

The POS N
reduction POS N
of POS N
venous POS N
bicarbonate POS N
concentration POS N
following POS N
AZT POS N
was POS N
correlated POS N
with POS N
the POS N
change POS N
of POS N
apnea-hypopnea POS N
index POS N
(r POS N
= POS N
0.66, POS N
P POS N
= POS N
.013). POS N

Aortic POS N
systolic POS N
pressure POS N
and POS N
augmentation POS N
index, POS N
assessed POS N
by POS N
radial POS N
artery POS N
oscillatory POS N
tonometry, POS N
were POS N
unaffected POS N
by POS N
CPAP POS N
but POS N
decreased POS N
after POS N
AZT POS N
and POS N
AZT POS N
plus POS N
CPAP POS N
(RM-ANOVA POS N
P POS N
= POS N
.030 POS N
and POS N
.031, POS N
respectively). POS N

AZT POS N
reduced POS N
blood POS N
pressure, POS N
vascular POS N
stiffness, POS N
and POS N
sleep-disordered POS N
breathing POS N
in POS N
patients POS N
with POS N
OSA POS N
and POS N
comorbid POS N
hypertension. POS N

Aortic POS N
systolic POS N
pressure POS N
and POS N
augmentation POS N
index, POS N
assessed POS N
by POS N
radial POS N
artery POS N
oscillatory POS N
tonometry, POS N
were POS N
unaffected POS N
by POS N
CPAP POS N
but POS N
decreased POS N
after POS N
AZT POS N
and POS N
AZT POS N
plus POS N
CPAP POS N
(RM-ANOVA POS N
P POS N
= POS N
.030 POS N
and POS N
.031, POS N
respectively). POS N

Carbonic POS N
anhydrase POS N
inhibition POS N
may POS N
constitute POS N
a POS N
potential POS N
target POS N
for POS N
drug POS N
therapy POS N
in POS N
patients POS N
with POS N
sleep POS N
apnea POS N
and POS N
comorbid POS N
hypertension. POS N

The POS N
apnea-hypopnea POS N
index POS N
was POS N
significantly POS N
reduced POS N
in POS N
all POS N
three POS N
treatment POS N
arms, POS N
most POS N
prominently POS N
by POS N
AZT POS N
plus POS N
CPAP POS N
(RM-ANOVA POS N
P POS N
= POS N
.003). POS N

Aortic POS N
systolic POS N
pressure POS N
and POS N
augmentation POS N
index, POS N
assessed POS N
by POS N
radial POS N
artery POS N
oscillatory POS N
tonometry, POS N
were POS N
unaffected POS N
by POS N
CPAP POS N
but POS N
decreased POS N
after POS N
AZT POS N
and POS N
AZT POS N
plus POS N
CPAP POS N
(RM-ANOVA POS N
P POS N
= POS N
.030 POS N
and POS N
.031, POS N
respectively). POS N

The POS N
apnea-hypopnea POS N
index POS N
was POS N
significantly POS N
reduced POS N
in POS N
all POS N
three POS N
treatment POS N
arms, POS N
most POS N
prominently POS N
by POS N
AZT POS N
plus POS N
CPAP POS N
(RM-ANOVA POS N
P POS N
= POS N
.003). POS N

The POS N
reduction POS N
of POS N
venous POS N
bicarbonate POS N
concentration POS N
following POS N
AZT POS N
was POS N
correlated POS N
with POS N
the POS N
change POS N
of POS N
apnea-hypopnea POS N
index POS N
(r POS N
= POS N
0.66, POS N
P POS N
= POS N
.013). POS N

The POS N
apnea-hypopnea POS N
index POS N
was POS N
significantly POS N
reduced POS N
in POS N
all POS N
three POS N
treatment POS N
arms, POS N
most POS N
prominently POS N
by POS N
AZT POS N
plus POS N
CPAP POS N
(RM-ANOVA POS N
P POS N
= POS N
.003). POS N

AZT POS N
reduced POS N
blood POS N
pressure, POS N
vascular POS N
stiffness, POS N
and POS N
sleep-disordered POS N
breathing POS N
in POS N
patients POS N
with POS N
OSA POS N
and POS N
comorbid POS N
hypertension. POS N

The POS N
apnea-hypopnea POS N
index POS N
was POS N
significantly POS N
reduced POS N
in POS N
all POS N
three POS N
treatment POS N
arms, POS N
most POS N
prominently POS N
by POS N
AZT POS N
plus POS N
CPAP POS N
(RM-ANOVA POS N
P POS N
= POS N
.003). POS N

Carbonic POS N
anhydrase POS N
inhibition POS N
may POS N
constitute POS N
a POS N
potential POS N
target POS N
for POS N
drug POS N
therapy POS N
in POS N
patients POS N
with POS N
sleep POS N
apnea POS N
and POS N
comorbid POS N
hypertension. POS N

The POS N
reduction POS N
of POS N
venous POS N
bicarbonate POS N
concentration POS N
following POS N
AZT POS N
was POS N
correlated POS N
with POS N
the POS N
change POS N
of POS N
apnea-hypopnea POS N
index POS N
(r POS N
= POS N
0.66, POS N
P POS N
= POS N
.013). POS N

Aortic POS N
systolic POS N
pressure POS N
and POS N
augmentation POS N
index, POS N
assessed POS N
by POS N
radial POS N
artery POS N
oscillatory POS N
tonometry, POS N
were POS N
unaffected POS N
by POS N
CPAP POS N
but POS N
decreased POS N
after POS N
AZT POS N
and POS N
AZT POS N
plus POS N
CPAP POS N
(RM-ANOVA POS N
P POS N
= POS N
.030 POS N
and POS N
.031, POS N
respectively). POS N

The POS N
reduction POS N
of POS N
venous POS N
bicarbonate POS N
concentration POS N
following POS N
AZT POS N
was POS N
correlated POS N
with POS N
the POS N
change POS N
of POS N
apnea-hypopnea POS N
index POS N
(r POS N
= POS N
0.66, POS N
P POS N
= POS N
.013). POS N

The POS N
apnea-hypopnea POS N
index POS N
was POS N
significantly POS N
reduced POS N
in POS N
all POS N
three POS N
treatment POS N
arms, POS N
most POS N
prominently POS N
by POS N
AZT POS N
plus POS N
CPAP POS N
(RM-ANOVA POS N
P POS N
= POS N
.003). POS N

The POS N
reduction POS N
of POS N
venous POS N
bicarbonate POS N
concentration POS N
following POS N
AZT POS N
was POS N
correlated POS N
with POS N
the POS N
change POS N
of POS N
apnea-hypopnea POS N
index POS N
(r POS N
= POS N
0.66, POS N
P POS N
= POS N
.013). POS N

AZT POS N
reduced POS N
blood POS N
pressure, POS N
vascular POS N
stiffness, POS N
and POS N
sleep-disordered POS N
breathing POS N
in POS N
patients POS N
with POS N
OSA POS N
and POS N
comorbid POS N
hypertension. POS N

The POS N
reduction POS N
of POS N
venous POS N
bicarbonate POS N
concentration POS N
following POS N
AZT POS N
was POS N
correlated POS N
with POS N
the POS N
change POS N
of POS N
apnea-hypopnea POS N
index POS N
(r POS N
= POS N
0.66, POS N
P POS N
= POS N
.013). POS N

Carbonic POS N
anhydrase POS N
inhibition POS N
may POS N
constitute POS N
a POS N
potential POS N
target POS N
for POS N
drug POS N
therapy POS N
in POS N
patients POS N
with POS N
sleep POS N
apnea POS N
and POS N
comorbid POS N
hypertension. POS N

AZT POS N
reduced POS N
blood POS N
pressure, POS N
vascular POS N
stiffness, POS N
and POS N
sleep-disordered POS N
breathing POS N
in POS N
patients POS N
with POS N
OSA POS N
and POS N
comorbid POS N
hypertension. POS N

Aortic POS N
systolic POS N
pressure POS N
and POS N
augmentation POS N
index, POS N
assessed POS N
by POS N
radial POS N
artery POS N
oscillatory POS N
tonometry, POS N
were POS N
unaffected POS N
by POS N
CPAP POS N
but POS N
decreased POS N
after POS N
AZT POS N
and POS N
AZT POS N
plus POS N
CPAP POS N
(RM-ANOVA POS N
P POS N
= POS N
.030 POS N
and POS N
.031, POS N
respectively). POS N

AZT POS N
reduced POS N
blood POS N
pressure, POS N
vascular POS N
stiffness, POS N
and POS N
sleep-disordered POS N
breathing POS N
in POS N
patients POS N
with POS N
OSA POS N
and POS N
comorbid POS N
hypertension. POS N

The POS N
apnea-hypopnea POS N
index POS N
was POS N
significantly POS N
reduced POS N
in POS N
all POS N
three POS N
treatment POS N
arms, POS N
most POS N
prominently POS N
by POS N
AZT POS N
plus POS N
CPAP POS N
(RM-ANOVA POS N
P POS N
= POS N
.003). POS N

AZT POS N
reduced POS N
blood POS N
pressure, POS N
vascular POS N
stiffness, POS N
and POS N
sleep-disordered POS N
breathing POS N
in POS N
patients POS N
with POS N
OSA POS N
and POS N
comorbid POS N
hypertension. POS N

The POS N
reduction POS N
of POS N
venous POS N
bicarbonate POS N
concentration POS N
following POS N
AZT POS N
was POS N
correlated POS N
with POS N
the POS N
change POS N
of POS N
apnea-hypopnea POS N
index POS N
(r POS N
= POS N
0.66, POS N
P POS N
= POS N
.013). POS N

AZT POS N
reduced POS N
blood POS N
pressure, POS N
vascular POS N
stiffness, POS N
and POS N
sleep-disordered POS N
breathing POS N
in POS N
patients POS N
with POS N
OSA POS N
and POS N
comorbid POS N
hypertension. POS N

Carbonic POS N
anhydrase POS N
inhibition POS N
may POS N
constitute POS N
a POS N
potential POS N
target POS N
for POS N
drug POS N
therapy POS N
in POS N
patients POS N
with POS N
sleep POS N
apnea POS N
and POS N
comorbid POS N
hypertension. POS N

Carbonic POS N
anhydrase POS N
inhibition POS N
may POS N
constitute POS N
a POS N
potential POS N
target POS N
for POS N
drug POS N
therapy POS N
in POS N
patients POS N
with POS N
sleep POS N
apnea POS N
and POS N
comorbid POS N
hypertension. POS N

Aortic POS N
systolic POS N
pressure POS N
and POS N
augmentation POS N
index, POS N
assessed POS N
by POS N
radial POS N
artery POS N
oscillatory POS N
tonometry, POS N
were POS N
unaffected POS N
by POS N
CPAP POS N
but POS N
decreased POS N
after POS N
AZT POS N
and POS N
AZT POS N
plus POS N
CPAP POS N
(RM-ANOVA POS N
P POS N
= POS N
.030 POS N
and POS N
.031, POS N
respectively). POS N

Carbonic POS N
anhydrase POS N
inhibition POS N
may POS N
constitute POS N
a POS N
potential POS N
target POS N
for POS N
drug POS N
therapy POS N
in POS N
patients POS N
with POS N
sleep POS N
apnea POS N
and POS N
comorbid POS N
hypertension. POS N

The POS N
apnea-hypopnea POS N
index POS N
was POS N
significantly POS N
reduced POS N
in POS N
all POS N
three POS N
treatment POS N
arms, POS N
most POS N
prominently POS N
by POS N
AZT POS N
plus POS N
CPAP POS N
(RM-ANOVA POS N
P POS N
= POS N
.003). POS N

Carbonic POS N
anhydrase POS N
inhibition POS N
may POS N
constitute POS N
a POS N
potential POS N
target POS N
for POS N
drug POS N
therapy POS N
in POS N
patients POS N
with POS N
sleep POS N
apnea POS N
and POS N
comorbid POS N
hypertension. POS N

The POS N
reduction POS N
of POS N
venous POS N
bicarbonate POS N
concentration POS N
following POS N
AZT POS N
was POS N
correlated POS N
with POS N
the POS N
change POS N
of POS N
apnea-hypopnea POS N
index POS N
(r POS N
= POS N
0.66, POS N
P POS N
= POS N
.013). POS N

Carbonic POS N
anhydrase POS N
inhibition POS N
may POS N
constitute POS N
a POS N
potential POS N
target POS N
for POS N
drug POS N
therapy POS N
in POS N
patients POS N
with POS N
sleep POS N
apnea POS N
and POS N
comorbid POS N
hypertension. POS N

AZT POS N
reduced POS N
blood POS N
pressure, POS N
vascular POS N
stiffness, POS N
and POS N
sleep-disordered POS N
breathing POS N
in POS N
patients POS N
with POS N
OSA POS N
and POS N
comorbid POS N
hypertension. POS N

It POS N
shows POS N
that POS N
a POS N
sequential POS N
combination POS N
of POS N
interferon-α POS N
and POS N
lamivudine POS N
was POS N
beneficial. POS N

Of POS N
the POS N
46 POS N
patients POS N
in POS N
the POS N
treatment POS N
group, POS N
73.91% POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
32.61% POS N
achieved POS N
HBeAg POS N
seroconversion POS N
and POS N
21.74% POS N
lost POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
at POS N
the POS N
endpoint. POS N

It POS N
shows POS N
that POS N
a POS N
sequential POS N
combination POS N
of POS N
interferon-α POS N
and POS N
lamivudine POS N
was POS N
beneficial. POS N

No POS N
LAM POS N
resistance POS N
emerged POS N
at POS N
week POS N
96. POS N

It POS N
shows POS N
that POS N
a POS N
sequential POS N
combination POS N
of POS N
interferon-α POS N
and POS N
lamivudine POS N
was POS N
beneficial. POS N

In POS N
the POS N
control POS N
group, POS N
only POS N
one POS N
(4.35%) POS N
patient POS N
underwent POS N
spontaneous POS N
HBeAg POS N
seroconversion POS N
and POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA POS N
during POS N
observation, POS N
and POS N
moreover, POS N
none POS N
developed POS N
HBsAg POS N
clearance. POS N

It POS N
shows POS N
that POS N
a POS N
sequential POS N
combination POS N
of POS N
interferon-α POS N
and POS N
lamivudine POS N
was POS N
beneficial. POS N

For POS N
all POS N
patients, POS N
no POS N
serious POS N
adverse POS N
events POS N
were POS N
observed. POS N

It POS N
shows POS N
that POS N
a POS N
sequential POS N
combination POS N
of POS N
interferon-α POS N
and POS N
lamivudine POS N
was POS N
beneficial. POS N

Antiviral POS N
treatment POS N
with POS N
a POS N
sequential POS N
combination POS N
of POS N
IFN POS N
and POS N
LAM POS N
resulted POS N
in POS N
a POS N
significant POS N
improvement POS N
in POS N
the POS N
rates POS N
of POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
HBeAg POS N
seroconversion POS N
and POS N
HBsAg POS N
loss POS N
in POS N
children POS N
with POS N
chronic POS N
HBV POS N
infection POS N
and POS N
immune-tolerant POS N
characteristics. POS N

It POS N
shows POS N
that POS N
a POS N
sequential POS N
combination POS N
of POS N
interferon-α POS N
and POS N
lamivudine POS N
was POS N
beneficial. POS N

It POS N
remains POS N
unresolved POS N
how POS N
children POS N
with POS N
immune-tolerant POS N
CHB POS N
should POS N
be POS N
treated. POS N

Of POS N
the POS N
46 POS N
patients POS N
in POS N
the POS N
treatment POS N
group, POS N
73.91% POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
32.61% POS N
achieved POS N
HBeAg POS N
seroconversion POS N
and POS N
21.74% POS N
lost POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
at POS N
the POS N
endpoint. POS N

It POS N
shows POS N
that POS N
a POS N
sequential POS N
combination POS N
of POS N
interferon-α POS N
and POS N
lamivudine POS N
was POS N
beneficial. POS N

Of POS N
the POS N
46 POS N
patients POS N
in POS N
the POS N
treatment POS N
group, POS N
73.91% POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
32.61% POS N
achieved POS N
HBeAg POS N
seroconversion POS N
and POS N
21.74% POS N
lost POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
at POS N
the POS N
endpoint. POS N

No POS N
LAM POS N
resistance POS N
emerged POS N
at POS N
week POS N
96. POS N

Of POS N
the POS N
46 POS N
patients POS N
in POS N
the POS N
treatment POS N
group, POS N
73.91% POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
32.61% POS N
achieved POS N
HBeAg POS N
seroconversion POS N
and POS N
21.74% POS N
lost POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
at POS N
the POS N
endpoint. POS N

In POS N
the POS N
control POS N
group, POS N
only POS N
one POS N
(4.35%) POS N
patient POS N
underwent POS N
spontaneous POS N
HBeAg POS N
seroconversion POS N
and POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA POS N
during POS N
observation, POS N
and POS N
moreover, POS N
none POS N
developed POS N
HBsAg POS N
clearance. POS N

Of POS N
the POS N
46 POS N
patients POS N
in POS N
the POS N
treatment POS N
group, POS N
73.91% POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
32.61% POS N
achieved POS N
HBeAg POS N
seroconversion POS N
and POS N
21.74% POS N
lost POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
at POS N
the POS N
endpoint. POS N

For POS N
all POS N
patients, POS N
no POS N
serious POS N
adverse POS N
events POS N
were POS N
observed. POS N

Of POS N
the POS N
46 POS N
patients POS N
in POS N
the POS N
treatment POS N
group, POS N
73.91% POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
32.61% POS N
achieved POS N
HBeAg POS N
seroconversion POS N
and POS N
21.74% POS N
lost POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
at POS N
the POS N
endpoint. POS N

Antiviral POS N
treatment POS N
with POS N
a POS N
sequential POS N
combination POS N
of POS N
IFN POS N
and POS N
LAM POS N
resulted POS N
in POS N
a POS N
significant POS N
improvement POS N
in POS N
the POS N
rates POS N
of POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
HBeAg POS N
seroconversion POS N
and POS N
HBsAg POS N
loss POS N
in POS N
children POS N
with POS N
chronic POS N
HBV POS N
infection POS N
and POS N
immune-tolerant POS N
characteristics. POS N

Of POS N
the POS N
46 POS N
patients POS N
in POS N
the POS N
treatment POS N
group, POS N
73.91% POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
32.61% POS N
achieved POS N
HBeAg POS N
seroconversion POS N
and POS N
21.74% POS N
lost POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
at POS N
the POS N
endpoint. POS N

It POS N
remains POS N
unresolved POS N
how POS N
children POS N
with POS N
immune-tolerant POS N
CHB POS N
should POS N
be POS N
treated. POS N

No POS N
LAM POS N
resistance POS N
emerged POS N
at POS N
week POS N
96. POS N

It POS N
shows POS N
that POS N
a POS N
sequential POS N
combination POS N
of POS N
interferon-α POS N
and POS N
lamivudine POS N
was POS N
beneficial. POS N

No POS N
LAM POS N
resistance POS N
emerged POS N
at POS N
week POS N
96. POS N

Of POS N
the POS N
46 POS N
patients POS N
in POS N
the POS N
treatment POS N
group, POS N
73.91% POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
32.61% POS N
achieved POS N
HBeAg POS N
seroconversion POS N
and POS N
21.74% POS N
lost POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
at POS N
the POS N
endpoint. POS N

No POS N
LAM POS N
resistance POS N
emerged POS N
at POS N
week POS N
96. POS N

In POS N
the POS N
control POS N
group, POS N
only POS N
one POS N
(4.35%) POS N
patient POS N
underwent POS N
spontaneous POS N
HBeAg POS N
seroconversion POS N
and POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA POS N
during POS N
observation, POS N
and POS N
moreover, POS N
none POS N
developed POS N
HBsAg POS N
clearance. POS N

No POS N
LAM POS N
resistance POS N
emerged POS N
at POS N
week POS N
96. POS N

For POS N
all POS N
patients, POS N
no POS N
serious POS N
adverse POS N
events POS N
were POS N
observed. POS N

No POS N
LAM POS N
resistance POS N
emerged POS N
at POS N
week POS N
96. POS N

Antiviral POS N
treatment POS N
with POS N
a POS N
sequential POS N
combination POS N
of POS N
IFN POS N
and POS N
LAM POS N
resulted POS N
in POS N
a POS N
significant POS N
improvement POS N
in POS N
the POS N
rates POS N
of POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
HBeAg POS N
seroconversion POS N
and POS N
HBsAg POS N
loss POS N
in POS N
children POS N
with POS N
chronic POS N
HBV POS N
infection POS N
and POS N
immune-tolerant POS N
characteristics. POS N

No POS N
LAM POS N
resistance POS N
emerged POS N
at POS N
week POS N
96. POS N

It POS N
remains POS N
unresolved POS N
how POS N
children POS N
with POS N
immune-tolerant POS N
CHB POS N
should POS N
be POS N
treated. POS N

In POS N
the POS N
control POS N
group, POS N
only POS N
one POS N
(4.35%) POS N
patient POS N
underwent POS N
spontaneous POS N
HBeAg POS N
seroconversion POS N
and POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA POS N
during POS N
observation, POS N
and POS N
moreover, POS N
none POS N
developed POS N
HBsAg POS N
clearance. POS N

It POS N
shows POS N
that POS N
a POS N
sequential POS N
combination POS N
of POS N
interferon-α POS N
and POS N
lamivudine POS N
was POS N
beneficial. POS N

In POS N
the POS N
control POS N
group, POS N
only POS N
one POS N
(4.35%) POS N
patient POS N
underwent POS N
spontaneous POS N
HBeAg POS N
seroconversion POS N
and POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA POS N
during POS N
observation, POS N
and POS N
moreover, POS N
none POS N
developed POS N
HBsAg POS N
clearance. POS N

Of POS N
the POS N
46 POS N
patients POS N
in POS N
the POS N
treatment POS N
group, POS N
73.91% POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
32.61% POS N
achieved POS N
HBeAg POS N
seroconversion POS N
and POS N
21.74% POS N
lost POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
at POS N
the POS N
endpoint. POS N

In POS N
the POS N
control POS N
group, POS N
only POS N
one POS N
(4.35%) POS N
patient POS N
underwent POS N
spontaneous POS N
HBeAg POS N
seroconversion POS N
and POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA POS N
during POS N
observation, POS N
and POS N
moreover, POS N
none POS N
developed POS N
HBsAg POS N
clearance. POS N

No POS N
LAM POS N
resistance POS N
emerged POS N
at POS N
week POS N
96. POS N

In POS N
the POS N
control POS N
group, POS N
only POS N
one POS N
(4.35%) POS N
patient POS N
underwent POS N
spontaneous POS N
HBeAg POS N
seroconversion POS N
and POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA POS N
during POS N
observation, POS N
and POS N
moreover, POS N
none POS N
developed POS N
HBsAg POS N
clearance. POS N

For POS N
all POS N
patients, POS N
no POS N
serious POS N
adverse POS N
events POS N
were POS N
observed. POS N

In POS N
the POS N
control POS N
group, POS N
only POS N
one POS N
(4.35%) POS N
patient POS N
underwent POS N
spontaneous POS N
HBeAg POS N
seroconversion POS N
and POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA POS N
during POS N
observation, POS N
and POS N
moreover, POS N
none POS N
developed POS N
HBsAg POS N
clearance. POS N

Antiviral POS N
treatment POS N
with POS N
a POS N
sequential POS N
combination POS N
of POS N
IFN POS N
and POS N
LAM POS N
resulted POS N
in POS N
a POS N
significant POS N
improvement POS N
in POS N
the POS N
rates POS N
of POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
HBeAg POS N
seroconversion POS N
and POS N
HBsAg POS N
loss POS N
in POS N
children POS N
with POS N
chronic POS N
HBV POS N
infection POS N
and POS N
immune-tolerant POS N
characteristics. POS N

In POS N
the POS N
control POS N
group, POS N
only POS N
one POS N
(4.35%) POS N
patient POS N
underwent POS N
spontaneous POS N
HBeAg POS N
seroconversion POS N
and POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA POS N
during POS N
observation, POS N
and POS N
moreover, POS N
none POS N
developed POS N
HBsAg POS N
clearance. POS N

It POS N
remains POS N
unresolved POS N
how POS N
children POS N
with POS N
immune-tolerant POS N
CHB POS N
should POS N
be POS N
treated. POS N

For POS N
all POS N
patients, POS N
no POS N
serious POS N
adverse POS N
events POS N
were POS N
observed. POS N

It POS N
shows POS N
that POS N
a POS N
sequential POS N
combination POS N
of POS N
interferon-α POS N
and POS N
lamivudine POS N
was POS N
beneficial. POS N

For POS N
all POS N
patients, POS N
no POS N
serious POS N
adverse POS N
events POS N
were POS N
observed. POS N

Of POS N
the POS N
46 POS N
patients POS N
in POS N
the POS N
treatment POS N
group, POS N
73.91% POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
32.61% POS N
achieved POS N
HBeAg POS N
seroconversion POS N
and POS N
21.74% POS N
lost POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
at POS N
the POS N
endpoint. POS N

For POS N
all POS N
patients, POS N
no POS N
serious POS N
adverse POS N
events POS N
were POS N
observed. POS N

No POS N
LAM POS N
resistance POS N
emerged POS N
at POS N
week POS N
96. POS N

For POS N
all POS N
patients, POS N
no POS N
serious POS N
adverse POS N
events POS N
were POS N
observed. POS N

In POS N
the POS N
control POS N
group, POS N
only POS N
one POS N
(4.35%) POS N
patient POS N
underwent POS N
spontaneous POS N
HBeAg POS N
seroconversion POS N
and POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA POS N
during POS N
observation, POS N
and POS N
moreover, POS N
none POS N
developed POS N
HBsAg POS N
clearance. POS N

For POS N
all POS N
patients, POS N
no POS N
serious POS N
adverse POS N
events POS N
were POS N
observed. POS N

Antiviral POS N
treatment POS N
with POS N
a POS N
sequential POS N
combination POS N
of POS N
IFN POS N
and POS N
LAM POS N
resulted POS N
in POS N
a POS N
significant POS N
improvement POS N
in POS N
the POS N
rates POS N
of POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
HBeAg POS N
seroconversion POS N
and POS N
HBsAg POS N
loss POS N
in POS N
children POS N
with POS N
chronic POS N
HBV POS N
infection POS N
and POS N
immune-tolerant POS N
characteristics. POS N

For POS N
all POS N
patients, POS N
no POS N
serious POS N
adverse POS N
events POS N
were POS N
observed. POS N

It POS N
remains POS N
unresolved POS N
how POS N
children POS N
with POS N
immune-tolerant POS N
CHB POS N
should POS N
be POS N
treated. POS N

Antiviral POS N
treatment POS N
with POS N
a POS N
sequential POS N
combination POS N
of POS N
IFN POS N
and POS N
LAM POS N
resulted POS N
in POS N
a POS N
significant POS N
improvement POS N
in POS N
the POS N
rates POS N
of POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
HBeAg POS N
seroconversion POS N
and POS N
HBsAg POS N
loss POS N
in POS N
children POS N
with POS N
chronic POS N
HBV POS N
infection POS N
and POS N
immune-tolerant POS N
characteristics. POS N

It POS N
shows POS N
that POS N
a POS N
sequential POS N
combination POS N
of POS N
interferon-α POS N
and POS N
lamivudine POS N
was POS N
beneficial. POS N

Antiviral POS N
treatment POS N
with POS N
a POS N
sequential POS N
combination POS N
of POS N
IFN POS N
and POS N
LAM POS N
resulted POS N
in POS N
a POS N
significant POS N
improvement POS N
in POS N
the POS N
rates POS N
of POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
HBeAg POS N
seroconversion POS N
and POS N
HBsAg POS N
loss POS N
in POS N
children POS N
with POS N
chronic POS N
HBV POS N
infection POS N
and POS N
immune-tolerant POS N
characteristics. POS N

Of POS N
the POS N
46 POS N
patients POS N
in POS N
the POS N
treatment POS N
group, POS N
73.91% POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
32.61% POS N
achieved POS N
HBeAg POS N
seroconversion POS N
and POS N
21.74% POS N
lost POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
at POS N
the POS N
endpoint. POS N

Antiviral POS N
treatment POS N
with POS N
a POS N
sequential POS N
combination POS N
of POS N
IFN POS N
and POS N
LAM POS N
resulted POS N
in POS N
a POS N
significant POS N
improvement POS N
in POS N
the POS N
rates POS N
of POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
HBeAg POS N
seroconversion POS N
and POS N
HBsAg POS N
loss POS N
in POS N
children POS N
with POS N
chronic POS N
HBV POS N
infection POS N
and POS N
immune-tolerant POS N
characteristics. POS N

No POS N
LAM POS N
resistance POS N
emerged POS N
at POS N
week POS N
96. POS N

Antiviral POS N
treatment POS N
with POS N
a POS N
sequential POS N
combination POS N
of POS N
IFN POS N
and POS N
LAM POS N
resulted POS N
in POS N
a POS N
significant POS N
improvement POS N
in POS N
the POS N
rates POS N
of POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
HBeAg POS N
seroconversion POS N
and POS N
HBsAg POS N
loss POS N
in POS N
children POS N
with POS N
chronic POS N
HBV POS N
infection POS N
and POS N
immune-tolerant POS N
characteristics. POS N

In POS N
the POS N
control POS N
group, POS N
only POS N
one POS N
(4.35%) POS N
patient POS N
underwent POS N
spontaneous POS N
HBeAg POS N
seroconversion POS N
and POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA POS N
during POS N
observation, POS N
and POS N
moreover, POS N
none POS N
developed POS N
HBsAg POS N
clearance. POS N

Antiviral POS N
treatment POS N
with POS N
a POS N
sequential POS N
combination POS N
of POS N
IFN POS N
and POS N
LAM POS N
resulted POS N
in POS N
a POS N
significant POS N
improvement POS N
in POS N
the POS N
rates POS N
of POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
HBeAg POS N
seroconversion POS N
and POS N
HBsAg POS N
loss POS N
in POS N
children POS N
with POS N
chronic POS N
HBV POS N
infection POS N
and POS N
immune-tolerant POS N
characteristics. POS N

For POS N
all POS N
patients, POS N
no POS N
serious POS N
adverse POS N
events POS N
were POS N
observed. POS N

Antiviral POS N
treatment POS N
with POS N
a POS N
sequential POS N
combination POS N
of POS N
IFN POS N
and POS N
LAM POS N
resulted POS N
in POS N
a POS N
significant POS N
improvement POS N
in POS N
the POS N
rates POS N
of POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
HBeAg POS N
seroconversion POS N
and POS N
HBsAg POS N
loss POS N
in POS N
children POS N
with POS N
chronic POS N
HBV POS N
infection POS N
and POS N
immune-tolerant POS N
characteristics. POS N

It POS N
remains POS N
unresolved POS N
how POS N
children POS N
with POS N
immune-tolerant POS N
CHB POS N
should POS N
be POS N
treated. POS N

It POS N
remains POS N
unresolved POS N
how POS N
children POS N
with POS N
immune-tolerant POS N
CHB POS N
should POS N
be POS N
treated. POS N

It POS N
shows POS N
that POS N
a POS N
sequential POS N
combination POS N
of POS N
interferon-α POS N
and POS N
lamivudine POS N
was POS N
beneficial. POS N

It POS N
remains POS N
unresolved POS N
how POS N
children POS N
with POS N
immune-tolerant POS N
CHB POS N
should POS N
be POS N
treated. POS N

Of POS N
the POS N
46 POS N
patients POS N
in POS N
the POS N
treatment POS N
group, POS N
73.91% POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
32.61% POS N
achieved POS N
HBeAg POS N
seroconversion POS N
and POS N
21.74% POS N
lost POS N
hepatitis POS N
B POS N
surface POS N
antigen POS N
(HBsAg) POS N
at POS N
the POS N
endpoint. POS N

It POS N
remains POS N
unresolved POS N
how POS N
children POS N
with POS N
immune-tolerant POS N
CHB POS N
should POS N
be POS N
treated. POS N

No POS N
LAM POS N
resistance POS N
emerged POS N
at POS N
week POS N
96. POS N

It POS N
remains POS N
unresolved POS N
how POS N
children POS N
with POS N
immune-tolerant POS N
CHB POS N
should POS N
be POS N
treated. POS N

In POS N
the POS N
control POS N
group, POS N
only POS N
one POS N
(4.35%) POS N
patient POS N
underwent POS N
spontaneous POS N
HBeAg POS N
seroconversion POS N
and POS N
had POS N
undetectable POS N
serum POS N
HBV POS N
DNA POS N
during POS N
observation, POS N
and POS N
moreover, POS N
none POS N
developed POS N
HBsAg POS N
clearance. POS N

It POS N
remains POS N
unresolved POS N
how POS N
children POS N
with POS N
immune-tolerant POS N
CHB POS N
should POS N
be POS N
treated. POS N

For POS N
all POS N
patients, POS N
no POS N
serious POS N
adverse POS N
events POS N
were POS N
observed. POS N

It POS N
remains POS N
unresolved POS N
how POS N
children POS N
with POS N
immune-tolerant POS N
CHB POS N
should POS N
be POS N
treated. POS N

Antiviral POS N
treatment POS N
with POS N
a POS N
sequential POS N
combination POS N
of POS N
IFN POS N
and POS N
LAM POS N
resulted POS N
in POS N
a POS N
significant POS N
improvement POS N
in POS N
the POS N
rates POS N
of POS N
undetectable POS N
serum POS N
HBV POS N
DNA, POS N
HBeAg POS N
seroconversion POS N
and POS N
HBsAg POS N
loss POS N
in POS N
children POS N
with POS N
chronic POS N
HBV POS N
infection POS N
and POS N
immune-tolerant POS N
characteristics. POS N

Spironolactone POS N
could POS N
be POS N
used POS N
as POS N
the POS N
fourth-line POS N
therapy POS N
in POS N
patients POS N
with POS N
resistant POS N
hypertension. POS N

Systolic POS N
BP POS N
was POS N
reduced POS N
from POS N
143.5 POS N
± POS N
8.2 POS N
mmHg POS N
to POS N
137.10 POS N
± POS N
7.57 POS N
mmHg POS N
in POS N
the POS N
intervention POS N
group, POS N
while POS N
it POS N
did POS N
not POS N
change POS N
significantly POS N
in POS N
control POS N
(between POS N
group POS N
treatment POS N
difference POS N
= POS N
-4.5 POS N
mmHg, POS N
p POS N
= POS N
0.004). POS N

Spironolactone POS N
could POS N
be POS N
used POS N
as POS N
the POS N
fourth-line POS N
therapy POS N
in POS N
patients POS N
with POS N
resistant POS N
hypertension. POS N

There POS N
was POS N
no POS N
significant POS N
reduction POS N
of POS N
diastolic POS N
BP POS N
in POS N
the POS N
intervention POS N
group POS N
in POS N
comparison POS N
to POS N
placebo POS N
group POS N
(between POS N
group POS N
treatment POS N
difference POS N
= POS N
-1.3 POS N
mmHg, POS N
p POS N
= POS N
0.099). POS N

Spironolactone POS N
could POS N
be POS N
used POS N
as POS N
the POS N
fourth-line POS N
therapy POS N
in POS N
patients POS N
with POS N
resistant POS N
hypertension. POS N

Short POS N
course POS N
monotherapy POS N
with POS N
low POS N
dose POS N
spironolactone POS N
is POS N
effective POS N
in POS N
reducing POS N
systolic POS N
BP POS N
in POS N
patients POS N
with POS N
stage POS N
I POS N
essential POS N
hypertension. POS N

Systolic POS N
BP POS N
was POS N
reduced POS N
from POS N
143.5 POS N
± POS N
8.2 POS N
mmHg POS N
to POS N
137.10 POS N
± POS N
7.57 POS N
mmHg POS N
in POS N
the POS N
intervention POS N
group, POS N
while POS N
it POS N
did POS N
not POS N
change POS N
significantly POS N
in POS N
control POS N
(between POS N
group POS N
treatment POS N
difference POS N
= POS N
-4.5 POS N
mmHg, POS N
p POS N
= POS N
0.004). POS N

Spironolactone POS N
could POS N
be POS N
used POS N
as POS N
the POS N
fourth-line POS N
therapy POS N
in POS N
patients POS N
with POS N
resistant POS N
hypertension. POS N

Systolic POS N
BP POS N
was POS N
reduced POS N
from POS N
143.5 POS N
± POS N
8.2 POS N
mmHg POS N
to POS N
137.10 POS N
± POS N
7.57 POS N
mmHg POS N
in POS N
the POS N
intervention POS N
group, POS N
while POS N
it POS N
did POS N
not POS N
change POS N
significantly POS N
in POS N
control POS N
(between POS N
group POS N
treatment POS N
difference POS N
= POS N
-4.5 POS N
mmHg, POS N
p POS N
= POS N
0.004). POS N

There POS N
was POS N
no POS N
significant POS N
reduction POS N
of POS N
diastolic POS N
BP POS N
in POS N
the POS N
intervention POS N
group POS N
in POS N
comparison POS N
to POS N
placebo POS N
group POS N
(between POS N
group POS N
treatment POS N
difference POS N
= POS N
-1.3 POS N
mmHg, POS N
p POS N
= POS N
0.099). POS N

Systolic POS N
BP POS N
was POS N
reduced POS N
from POS N
143.5 POS N
± POS N
8.2 POS N
mmHg POS N
to POS N
137.10 POS N
± POS N
7.57 POS N
mmHg POS N
in POS N
the POS N
intervention POS N
group, POS N
while POS N
it POS N
did POS N
not POS N
change POS N
significantly POS N
in POS N
control POS N
(between POS N
group POS N
treatment POS N
difference POS N
= POS N
-4.5 POS N
mmHg, POS N
p POS N
= POS N
0.004). POS N

Short POS N
course POS N
monotherapy POS N
with POS N
low POS N
dose POS N
spironolactone POS N
is POS N
effective POS N
in POS N
reducing POS N
systolic POS N
BP POS N
in POS N
patients POS N
with POS N
stage POS N
I POS N
essential POS N
hypertension. POS N

There POS N
was POS N
no POS N
significant POS N
reduction POS N
of POS N
diastolic POS N
BP POS N
in POS N
the POS N
intervention POS N
group POS N
in POS N
comparison POS N
to POS N
placebo POS N
group POS N
(between POS N
group POS N
treatment POS N
difference POS N
= POS N
-1.3 POS N
mmHg, POS N
p POS N
= POS N
0.099). POS N

Spironolactone POS N
could POS N
be POS N
used POS N
as POS N
the POS N
fourth-line POS N
therapy POS N
in POS N
patients POS N
with POS N
resistant POS N
hypertension. POS N

There POS N
was POS N
no POS N
significant POS N
reduction POS N
of POS N
diastolic POS N
BP POS N
in POS N
the POS N
intervention POS N
group POS N
in POS N
comparison POS N
to POS N
placebo POS N
group POS N
(between POS N
group POS N
treatment POS N
difference POS N
= POS N
-1.3 POS N
mmHg, POS N
p POS N
= POS N
0.099). POS N

Systolic POS N
BP POS N
was POS N
reduced POS N
from POS N
143.5 POS N
± POS N
8.2 POS N
mmHg POS N
to POS N
137.10 POS N
± POS N
7.57 POS N
mmHg POS N
in POS N
the POS N
intervention POS N
group, POS N
while POS N
it POS N
did POS N
not POS N
change POS N
significantly POS N
in POS N
control POS N
(between POS N
group POS N
treatment POS N
difference POS N
= POS N
-4.5 POS N
mmHg, POS N
p POS N
= POS N
0.004). POS N

There POS N
was POS N
no POS N
significant POS N
reduction POS N
of POS N
diastolic POS N
BP POS N
in POS N
the POS N
intervention POS N
group POS N
in POS N
comparison POS N
to POS N
placebo POS N
group POS N
(between POS N
group POS N
treatment POS N
difference POS N
= POS N
-1.3 POS N
mmHg, POS N
p POS N
= POS N
0.099). POS N

Short POS N
course POS N
monotherapy POS N
with POS N
low POS N
dose POS N
spironolactone POS N
is POS N
effective POS N
in POS N
reducing POS N
systolic POS N
BP POS N
in POS N
patients POS N
with POS N
stage POS N
I POS N
essential POS N
hypertension. POS N

Short POS N
course POS N
monotherapy POS N
with POS N
low POS N
dose POS N
spironolactone POS N
is POS N
effective POS N
in POS N
reducing POS N
systolic POS N
BP POS N
in POS N
patients POS N
with POS N
stage POS N
I POS N
essential POS N
hypertension. POS N

Spironolactone POS N
could POS N
be POS N
used POS N
as POS N
the POS N
fourth-line POS N
therapy POS N
in POS N
patients POS N
with POS N
resistant POS N
hypertension. POS N

Short POS N
course POS N
monotherapy POS N
with POS N
low POS N
dose POS N
spironolactone POS N
is POS N
effective POS N
in POS N
reducing POS N
systolic POS N
BP POS N
in POS N
patients POS N
with POS N
stage POS N
I POS N
essential POS N
hypertension. POS N

Systolic POS N
BP POS N
was POS N
reduced POS N
from POS N
143.5 POS N
± POS N
8.2 POS N
mmHg POS N
to POS N
137.10 POS N
± POS N
7.57 POS N
mmHg POS N
in POS N
the POS N
intervention POS N
group, POS N
while POS N
it POS N
did POS N
not POS N
change POS N
significantly POS N
in POS N
control POS N
(between POS N
group POS N
treatment POS N
difference POS N
= POS N
-4.5 POS N
mmHg, POS N
p POS N
= POS N
0.004). POS N

Short POS N
course POS N
monotherapy POS N
with POS N
low POS N
dose POS N
spironolactone POS N
is POS N
effective POS N
in POS N
reducing POS N
systolic POS N
BP POS N
in POS N
patients POS N
with POS N
stage POS N
I POS N
essential POS N
hypertension. POS N

There POS N
was POS N
no POS N
significant POS N
reduction POS N
of POS N
diastolic POS N
BP POS N
in POS N
the POS N
intervention POS N
group POS N
in POS N
comparison POS N
to POS N
placebo POS N
group POS N
(between POS N
group POS N
treatment POS N
difference POS N
= POS N
-1.3 POS N
mmHg, POS N
p POS N
= POS N
0.099). POS N

In POS N
CHEST-1, POS N
riociguat POS N
significantly POS N
improved POS N
RRS POS N
(p POS N
< POS N
0.0001) POS N
and POS N
risk POS N
stratum POS N
(p POS N
< POS N
0.001) POS N
vs POS N
placebo POS N
from POS N
baseline POS N
to POS N
Week POS N
16. POS N

RRS POS N
at POS N
baseline, POS N
and POS N
at POS N
Week POS N
16, POS N
and POS N
change POS N
in POS N
RRS POS N
during POS N
CHEST-1 POS N
were POS N
significantly POS N
associated POS N
with POS N
survival POS N
(hazard POS N
ratios POS N
for POS N
a POS N
1-point POS N
reduction POS N
in POS N
RRS: POS N
0.702, POS N
0.692, POS N
and POS N
0.682, POS N
respectively) POS N
and POS N
clinical POS N
worsening-free POS N
survival POS N
(hazard POS N
ratios: POS N
0.697, POS N
0.719, POS N
and POS N
0.754, POS N
respectively) POS N
over POS N
2 POS N
years POS N
in POS N
CHEST-2. POS N

In POS N
CHEST-1, POS N
riociguat POS N
significantly POS N
improved POS N
RRS POS N
(p POS N
< POS N
0.0001) POS N
and POS N
risk POS N
stratum POS N
(p POS N
< POS N
0.001) POS N
vs POS N
placebo POS N
from POS N
baseline POS N
to POS N
Week POS N
16. POS N

Riociguat POS N
improved POS N
RRS POS N
in POS N
patients POS N
with POS N
inoperable POS N
and POS N
persistent/recurrent POS N
CTEPH. POS N

In POS N
CHEST-1, POS N
riociguat POS N
significantly POS N
improved POS N
RRS POS N
(p POS N
< POS N
0.0001) POS N
and POS N
risk POS N
stratum POS N
(p POS N
< POS N
0.001) POS N
vs POS N
placebo POS N
from POS N
baseline POS N
to POS N
Week POS N
16. POS N

RRS POS N
at POS N
baseline POS N
and POS N
Week POS N
16, POS N
and POS N
change POS N
in POS N
RRS POS N
from POS N
baseline, POS N
predicted POS N
survival POS N
and POS N
clinical POS N
worsening-free POS N
survival. POS N

In POS N
CHEST-1, POS N
riociguat POS N
significantly POS N
improved POS N
RRS POS N
(p POS N
< POS N
0.0001) POS N
and POS N
risk POS N
stratum POS N
(p POS N
< POS N
0.001) POS N
vs POS N
placebo POS N
from POS N
baseline POS N
to POS N
Week POS N
16. POS N

This POS N
analysis POS N
of POS N
RRS POS N
in POS N
patients POS N
with POS N
inoperable POS N
or POS N
persistent/recurrent POS N
CTEPH POS N
suggests POS N
utility POS N
for POS N
the POS N
RRS POS N
in POS N
indications POS N
beyond POS N
PAH. POS N

RRS POS N
at POS N
baseline, POS N
and POS N
at POS N
Week POS N
16, POS N
and POS N
change POS N
in POS N
RRS POS N
during POS N
CHEST-1 POS N
were POS N
significantly POS N
associated POS N
with POS N
survival POS N
(hazard POS N
ratios POS N
for POS N
a POS N
1-point POS N
reduction POS N
in POS N
RRS: POS N
0.702, POS N
0.692, POS N
and POS N
0.682, POS N
respectively) POS N
and POS N
clinical POS N
worsening-free POS N
survival POS N
(hazard POS N
ratios: POS N
0.697, POS N
0.719, POS N
and POS N
0.754, POS N
respectively) POS N
over POS N
2 POS N
years POS N
in POS N
CHEST-2. POS N

In POS N
CHEST-1, POS N
riociguat POS N
significantly POS N
improved POS N
RRS POS N
(p POS N
< POS N
0.0001) POS N
and POS N
risk POS N
stratum POS N
(p POS N
< POS N
0.001) POS N
vs POS N
placebo POS N
from POS N
baseline POS N
to POS N
Week POS N
16. POS N

RRS POS N
at POS N
baseline, POS N
and POS N
at POS N
Week POS N
16, POS N
and POS N
change POS N
in POS N
RRS POS N
during POS N
CHEST-1 POS N
were POS N
significantly POS N
associated POS N
with POS N
survival POS N
(hazard POS N
ratios POS N
for POS N
a POS N
1-point POS N
reduction POS N
in POS N
RRS: POS N
0.702, POS N
0.692, POS N
and POS N
0.682, POS N
respectively) POS N
and POS N
clinical POS N
worsening-free POS N
survival POS N
(hazard POS N
ratios: POS N
0.697, POS N
0.719, POS N
and POS N
0.754, POS N
respectively) POS N
over POS N
2 POS N
years POS N
in POS N
CHEST-2. POS N

Riociguat POS N
improved POS N
RRS POS N
in POS N
patients POS N
with POS N
inoperable POS N
and POS N
persistent/recurrent POS N
CTEPH. POS N

RRS POS N
at POS N
baseline, POS N
and POS N
at POS N
Week POS N
16, POS N
and POS N
change POS N
in POS N
RRS POS N
during POS N
CHEST-1 POS N
were POS N
significantly POS N
associated POS N
with POS N
survival POS N
(hazard POS N
ratios POS N
for POS N
a POS N
1-point POS N
reduction POS N
in POS N
RRS: POS N
0.702, POS N
0.692, POS N
and POS N
0.682, POS N
respectively) POS N
and POS N
clinical POS N
worsening-free POS N
survival POS N
(hazard POS N
ratios: POS N
0.697, POS N
0.719, POS N
and POS N
0.754, POS N
respectively) POS N
over POS N
2 POS N
years POS N
in POS N
CHEST-2. POS N

RRS POS N
at POS N
baseline POS N
and POS N
Week POS N
16, POS N
and POS N
change POS N
in POS N
RRS POS N
from POS N
baseline, POS N
predicted POS N
survival POS N
and POS N
clinical POS N
worsening-free POS N
survival. POS N

RRS POS N
at POS N
baseline, POS N
and POS N
at POS N
Week POS N
16, POS N
and POS N
change POS N
in POS N
RRS POS N
during POS N
CHEST-1 POS N
were POS N
significantly POS N
associated POS N
with POS N
survival POS N
(hazard POS N
ratios POS N
for POS N
a POS N
1-point POS N
reduction POS N
in POS N
RRS: POS N
0.702, POS N
0.692, POS N
and POS N
0.682, POS N
respectively) POS N
and POS N
clinical POS N
worsening-free POS N
survival POS N
(hazard POS N
ratios: POS N
0.697, POS N
0.719, POS N
and POS N
0.754, POS N
respectively) POS N
over POS N
2 POS N
years POS N
in POS N
CHEST-2. POS N

This POS N
analysis POS N
of POS N
RRS POS N
in POS N
patients POS N
with POS N
inoperable POS N
or POS N
persistent/recurrent POS N
CTEPH POS N
suggests POS N
utility POS N
for POS N
the POS N
RRS POS N
in POS N
indications POS N
beyond POS N
PAH. POS N

Riociguat POS N
improved POS N
RRS POS N
in POS N
patients POS N
with POS N
inoperable POS N
and POS N
persistent/recurrent POS N
CTEPH. POS N

In POS N
CHEST-1, POS N
riociguat POS N
significantly POS N
improved POS N
RRS POS N
(p POS N
< POS N
0.0001) POS N
and POS N
risk POS N
stratum POS N
(p POS N
< POS N
0.001) POS N
vs POS N
placebo POS N
from POS N
baseline POS N
to POS N
Week POS N
16. POS N

Riociguat POS N
improved POS N
RRS POS N
in POS N
patients POS N
with POS N
inoperable POS N
and POS N
persistent/recurrent POS N
CTEPH. POS N

RRS POS N
at POS N
baseline, POS N
and POS N
at POS N
Week POS N
16, POS N
and POS N
change POS N
in POS N
RRS POS N
during POS N
CHEST-1 POS N
were POS N
significantly POS N
associated POS N
with POS N
survival POS N
(hazard POS N
ratios POS N
for POS N
a POS N
1-point POS N
reduction POS N
in POS N
RRS: POS N
0.702, POS N
0.692, POS N
and POS N
0.682, POS N
respectively) POS N
and POS N
clinical POS N
worsening-free POS N
survival POS N
(hazard POS N
ratios: POS N
0.697, POS N
0.719, POS N
and POS N
0.754, POS N
respectively) POS N
over POS N
2 POS N
years POS N
in POS N
CHEST-2. POS N

Riociguat POS N
improved POS N
RRS POS N
in POS N
patients POS N
with POS N
inoperable POS N
and POS N
persistent/recurrent POS N
CTEPH. POS N

RRS POS N
at POS N
baseline POS N
and POS N
Week POS N
16, POS N
and POS N
change POS N
in POS N
RRS POS N
from POS N
baseline, POS N
predicted POS N
survival POS N
and POS N
clinical POS N
worsening-free POS N
survival. POS N

Riociguat POS N
improved POS N
RRS POS N
in POS N
patients POS N
with POS N
inoperable POS N
and POS N
persistent/recurrent POS N
CTEPH. POS N

This POS N
analysis POS N
of POS N
RRS POS N
in POS N
patients POS N
with POS N
inoperable POS N
or POS N
persistent/recurrent POS N
CTEPH POS N
suggests POS N
utility POS N
for POS N
the POS N
RRS POS N
in POS N
indications POS N
beyond POS N
PAH. POS N

RRS POS N
at POS N
baseline POS N
and POS N
Week POS N
16, POS N
and POS N
change POS N
in POS N
RRS POS N
from POS N
baseline, POS N
predicted POS N
survival POS N
and POS N
clinical POS N
worsening-free POS N
survival. POS N

In POS N
CHEST-1, POS N
riociguat POS N
significantly POS N
improved POS N
RRS POS N
(p POS N
< POS N
0.0001) POS N
and POS N
risk POS N
stratum POS N
(p POS N
< POS N
0.001) POS N
vs POS N
placebo POS N
from POS N
baseline POS N
to POS N
Week POS N
16. POS N

RRS POS N
at POS N
baseline POS N
and POS N
Week POS N
16, POS N
and POS N
change POS N
in POS N
RRS POS N
from POS N
baseline, POS N
predicted POS N
survival POS N
and POS N
clinical POS N
worsening-free POS N
survival. POS N

RRS POS N
at POS N
baseline, POS N
and POS N
at POS N
Week POS N
16, POS N
and POS N
change POS N
in POS N
RRS POS N
during POS N
CHEST-1 POS N
were POS N
significantly POS N
associated POS N
with POS N
survival POS N
(hazard POS N
ratios POS N
for POS N
a POS N
1-point POS N
reduction POS N
in POS N
RRS: POS N
0.702, POS N
0.692, POS N
and POS N
0.682, POS N
respectively) POS N
and POS N
clinical POS N
worsening-free POS N
survival POS N
(hazard POS N
ratios: POS N
0.697, POS N
0.719, POS N
and POS N
0.754, POS N
respectively) POS N
over POS N
2 POS N
years POS N
in POS N
CHEST-2. POS N

RRS POS N
at POS N
baseline POS N
and POS N
Week POS N
16, POS N
and POS N
change POS N
in POS N
RRS POS N
from POS N
baseline, POS N
predicted POS N
survival POS N
and POS N
clinical POS N
worsening-free POS N
survival. POS N

Riociguat POS N
improved POS N
RRS POS N
in POS N
patients POS N
with POS N
inoperable POS N
and POS N
persistent/recurrent POS N
CTEPH. POS N

RRS POS N
at POS N
baseline POS N
and POS N
Week POS N
16, POS N
and POS N
change POS N
in POS N
RRS POS N
from POS N
baseline, POS N
predicted POS N
survival POS N
and POS N
clinical POS N
worsening-free POS N
survival. POS N

This POS N
analysis POS N
of POS N
RRS POS N
in POS N
patients POS N
with POS N
inoperable POS N
or POS N
persistent/recurrent POS N
CTEPH POS N
suggests POS N
utility POS N
for POS N
the POS N
RRS POS N
in POS N
indications POS N
beyond POS N
PAH. POS N

This POS N
analysis POS N
of POS N
RRS POS N
in POS N
patients POS N
with POS N
inoperable POS N
or POS N
persistent/recurrent POS N
CTEPH POS N
suggests POS N
utility POS N
for POS N
the POS N
RRS POS N
in POS N
indications POS N
beyond POS N
PAH. POS N

In POS N
CHEST-1, POS N
riociguat POS N
significantly POS N
improved POS N
RRS POS N
(p POS N
< POS N
0.0001) POS N
and POS N
risk POS N
stratum POS N
(p POS N
< POS N
0.001) POS N
vs POS N
placebo POS N
from POS N
baseline POS N
to POS N
Week POS N
16. POS N

This POS N
analysis POS N
of POS N
RRS POS N
in POS N
patients POS N
with POS N
inoperable POS N
or POS N
persistent/recurrent POS N
CTEPH POS N
suggests POS N
utility POS N
for POS N
the POS N
RRS POS N
in POS N
indications POS N
beyond POS N
PAH. POS N

RRS POS N
at POS N
baseline, POS N
and POS N
at POS N
Week POS N
16, POS N
and POS N
change POS N
in POS N
RRS POS N
during POS N
CHEST-1 POS N
were POS N
significantly POS N
associated POS N
with POS N
survival POS N
(hazard POS N
ratios POS N
for POS N
a POS N
1-point POS N
reduction POS N
in POS N
RRS: POS N
0.702, POS N
0.692, POS N
and POS N
0.682, POS N
respectively) POS N
and POS N
clinical POS N
worsening-free POS N
survival POS N
(hazard POS N
ratios: POS N
0.697, POS N
0.719, POS N
and POS N
0.754, POS N
respectively) POS N
over POS N
2 POS N
years POS N
in POS N
CHEST-2. POS N

This POS N
analysis POS N
of POS N
RRS POS N
in POS N
patients POS N
with POS N
inoperable POS N
or POS N
persistent/recurrent POS N
CTEPH POS N
suggests POS N
utility POS N
for POS N
the POS N
RRS POS N
in POS N
indications POS N
beyond POS N
PAH. POS N

Riociguat POS N
improved POS N
RRS POS N
in POS N
patients POS N
with POS N
inoperable POS N
and POS N
persistent/recurrent POS N
CTEPH. POS N

This POS N
analysis POS N
of POS N
RRS POS N
in POS N
patients POS N
with POS N
inoperable POS N
or POS N
persistent/recurrent POS N
CTEPH POS N
suggests POS N
utility POS N
for POS N
the POS N
RRS POS N
in POS N
indications POS N
beyond POS N
PAH. POS N

RRS POS N
at POS N
baseline POS N
and POS N
Week POS N
16, POS N
and POS N
change POS N
in POS N
RRS POS N
from POS N
baseline, POS N
predicted POS N
survival POS N
and POS N
clinical POS N
worsening-free POS N
survival. POS N

By POS N
ITT POS N
analysis, POS N
HBV POS N
reactivation POS N
was POS N
0% POS N
(0/33) POS N
in POS N
the POS N
study POS N
group POS N
and POS N
10.7% POS N
(3/28) POS N
in POS N
the POS N
observation POS N
group POS N
(p POS N
= POS N
0.091). POS N

None POS N
of POS N
the POS N
patients POS N
in POS N
either POS N
group POS N
showed POS N
significant POS N
differences POS N
in POS N
liver POS N
function POS N
parameters POS N
between POS N
baseline POS N
and POS N
the POS N
last POS N
follow-up POS N
sample. POS N

By POS N
ITT POS N
analysis, POS N
HBV POS N
reactivation POS N
was POS N
0% POS N
(0/33) POS N
in POS N
the POS N
study POS N
group POS N
and POS N
10.7% POS N
(3/28) POS N
in POS N
the POS N
observation POS N
group POS N
(p POS N
= POS N
0.091). POS N

TDF POS N
was POS N
generally POS N
well POS N
tolerated POS N
and POS N
there POS N
were POS N
no POS N
severe POS N
treatment-related POS N
adverse POS N
events. POS N

By POS N
ITT POS N
analysis, POS N
HBV POS N
reactivation POS N
was POS N
0% POS N
(0/33) POS N
in POS N
the POS N
study POS N
group POS N
and POS N
10.7% POS N
(3/28) POS N
in POS N
the POS N
observation POS N
group POS N
(p POS N
= POS N
0.091). POS N

In POS N
patients POS N
with POS N
hematological POS N
malignancy POS N
and POS N
resolved POS N
hepatitis POS N
B POS N
infection POS N
receiving POS N
RTX-based POS N
regimens, POS N
HBV POS N
reactivation POS N
did POS N
not POS N
occur POS N
in POS N
patients POS N
given POS N
TDF POS N
prophylaxis. POS N

None POS N
of POS N
the POS N
patients POS N
in POS N
either POS N
group POS N
showed POS N
significant POS N
differences POS N
in POS N
liver POS N
function POS N
parameters POS N
between POS N
baseline POS N
and POS N
the POS N
last POS N
follow-up POS N
sample. POS N

By POS N
ITT POS N
analysis, POS N
HBV POS N
reactivation POS N
was POS N
0% POS N
(0/33) POS N
in POS N
the POS N
study POS N
group POS N
and POS N
10.7% POS N
(3/28) POS N
in POS N
the POS N
observation POS N
group POS N
(p POS N
= POS N
0.091). POS N

None POS N
of POS N
the POS N
patients POS N
in POS N
either POS N
group POS N
showed POS N
significant POS N
differences POS N
in POS N
liver POS N
function POS N
parameters POS N
between POS N
baseline POS N
and POS N
the POS N
last POS N
follow-up POS N
sample. POS N

TDF POS N
was POS N
generally POS N
well POS N
tolerated POS N
and POS N
there POS N
were POS N
no POS N
severe POS N
treatment-related POS N
adverse POS N
events. POS N

None POS N
of POS N
the POS N
patients POS N
in POS N
either POS N
group POS N
showed POS N
significant POS N
differences POS N
in POS N
liver POS N
function POS N
parameters POS N
between POS N
baseline POS N
and POS N
the POS N
last POS N
follow-up POS N
sample. POS N

In POS N
patients POS N
with POS N
hematological POS N
malignancy POS N
and POS N
resolved POS N
hepatitis POS N
B POS N
infection POS N
receiving POS N
RTX-based POS N
regimens, POS N
HBV POS N
reactivation POS N
did POS N
not POS N
occur POS N
in POS N
patients POS N
given POS N
TDF POS N
prophylaxis. POS N

TDF POS N
was POS N
generally POS N
well POS N
tolerated POS N
and POS N
there POS N
were POS N
no POS N
severe POS N
treatment-related POS N
adverse POS N
events. POS N

By POS N
ITT POS N
analysis, POS N
HBV POS N
reactivation POS N
was POS N
0% POS N
(0/33) POS N
in POS N
the POS N
study POS N
group POS N
and POS N
10.7% POS N
(3/28) POS N
in POS N
the POS N
observation POS N
group POS N
(p POS N
= POS N
0.091). POS N

TDF POS N
was POS N
generally POS N
well POS N
tolerated POS N
and POS N
there POS N
were POS N
no POS N
severe POS N
treatment-related POS N
adverse POS N
events. POS N

None POS N
of POS N
the POS N
patients POS N
in POS N
either POS N
group POS N
showed POS N
significant POS N
differences POS N
in POS N
liver POS N
function POS N
parameters POS N
between POS N
baseline POS N
and POS N
the POS N
last POS N
follow-up POS N
sample. POS N

TDF POS N
was POS N
generally POS N
well POS N
tolerated POS N
and POS N
there POS N
were POS N
no POS N
severe POS N
treatment-related POS N
adverse POS N
events. POS N

In POS N
patients POS N
with POS N
hematological POS N
malignancy POS N
and POS N
resolved POS N
hepatitis POS N
B POS N
infection POS N
receiving POS N
RTX-based POS N
regimens, POS N
HBV POS N
reactivation POS N
did POS N
not POS N
occur POS N
in POS N
patients POS N
given POS N
TDF POS N
prophylaxis. POS N

In POS N
patients POS N
with POS N
hematological POS N
malignancy POS N
and POS N
resolved POS N
hepatitis POS N
B POS N
infection POS N
receiving POS N
RTX-based POS N
regimens, POS N
HBV POS N
reactivation POS N
did POS N
not POS N
occur POS N
in POS N
patients POS N
given POS N
TDF POS N
prophylaxis. POS N

By POS N
ITT POS N
analysis, POS N
HBV POS N
reactivation POS N
was POS N
0% POS N
(0/33) POS N
in POS N
the POS N
study POS N
group POS N
and POS N
10.7% POS N
(3/28) POS N
in POS N
the POS N
observation POS N
group POS N
(p POS N
= POS N
0.091). POS N

In POS N
patients POS N
with POS N
hematological POS N
malignancy POS N
and POS N
resolved POS N
hepatitis POS N
B POS N
infection POS N
receiving POS N
RTX-based POS N
regimens, POS N
HBV POS N
reactivation POS N
did POS N
not POS N
occur POS N
in POS N
patients POS N
given POS N
TDF POS N
prophylaxis. POS N

None POS N
of POS N
the POS N
patients POS N
in POS N
either POS N
group POS N
showed POS N
significant POS N
differences POS N
in POS N
liver POS N
function POS N
parameters POS N
between POS N
baseline POS N
and POS N
the POS N
last POS N
follow-up POS N
sample. POS N

In POS N
patients POS N
with POS N
hematological POS N
malignancy POS N
and POS N
resolved POS N
hepatitis POS N
B POS N
infection POS N
receiving POS N
RTX-based POS N
regimens, POS N
HBV POS N
reactivation POS N
did POS N
not POS N
occur POS N
in POS N
patients POS N
given POS N
TDF POS N
prophylaxis. POS N

TDF POS N
was POS N
generally POS N
well POS N
tolerated POS N
and POS N
there POS N
were POS N
no POS N
severe POS N
treatment-related POS N
adverse POS N
events. POS N

In POS N
conclusion, POS N
co-infected POS N
patients POS N
with POS N
elevated POS N
HBV-replication POS N
at POS N
ART-initiation POS N
are POS N
more POS N
susceptible POS N
to POS N
HIV-related POS N
morbidity, POS N
especially POS N
invasive POS N
bacterial POS N
diseases, POS N
during POS N
treatment POS N
interruption. POS N

No POS N
increase POS N
in POS N
the POS N
incidence POS N
of POS N
non-HIV-related POS N
morbidity POS N
was POS N
observed POS N
for POS N
co-infected POS N
patients POS N
(P POS N
= POS N
0.5), POS N
even POS N
at POS N
HBV-replication POS N
levels POS N
> POS N
10,000 POS N
copies/mL POS N
(P POS N
= POS N
0.7). POS N

In POS N
conclusion, POS N
co-infected POS N
patients POS N
with POS N
elevated POS N
HBV-replication POS N
at POS N
ART-initiation POS N
are POS N
more POS N
susceptible POS N
to POS N
HIV-related POS N
morbidity, POS N
especially POS N
invasive POS N
bacterial POS N
diseases, POS N
during POS N
treatment POS N
interruption. POS N

The POS N
relative POS N
effect POS N
of POS N
CD4GT POS N
or POS N
2/4-ART POS N
versus POS N
C-ART POS N
was POS N
not POS N
different POS N
between POS N
infection POS N
groups POS N
(P POS N
for POS N
interaction POS N
= POS N
0.4). POS N

In POS N
conclusion, POS N
co-infected POS N
patients POS N
with POS N
elevated POS N
HBV-replication POS N
at POS N
ART-initiation POS N
are POS N
more POS N
susceptible POS N
to POS N
HIV-related POS N
morbidity, POS N
especially POS N
invasive POS N
bacterial POS N
diseases, POS N
during POS N
treatment POS N
interruption. POS N

Incidence POS N
of POS N
bacterial POS N
infections POS N
was POS N
also POS N
highest POS N
in POS N
the POS N
co-infected POS N
group POS N
with POS N
HBV-replication POS N
> POS N
10,000 POS N
copies/mL POS N
(IR POS N
= POS N
12.9 POS N
versus POS N
3.3/100 POS N
person/years POS N
in POS N
HIV POS N
mono-infected POS N
patients, POS N
P POS N
= POS N
0.001). POS N

In POS N
conclusion, POS N
co-infected POS N
patients POS N
with POS N
elevated POS N
HBV-replication POS N
at POS N
ART-initiation POS N
are POS N
more POS N
susceptible POS N
to POS N
HIV-related POS N
morbidity, POS N
especially POS N
invasive POS N
bacterial POS N
diseases, POS N
during POS N
treatment POS N
interruption. POS N

After POS N
a POS N
median POS N
2.0 POS N
year POS N
(range POS N
= POS N
0.2-3.1) POS N
follow-up, POS N
≥ POS N
1 POS N
serious POS N
HIV-related POS N
events POS N
occurred POS N
in POS N
101 POS N
HIV POS N
mono-infected POS N
and POS N
15 POS N
HIV-HBV POS N
co-infected POS N
patients POS N
(IR POS N
= POS N
10.0 POS N
versus POS N
13.2/100 POS N
person/years, POS N
respectively, POS N
P POS N
= POS N
0.3) POS N

No POS N
increase POS N
in POS N
the POS N
incidence POS N
of POS N
non-HIV-related POS N
morbidity POS N
was POS N
observed POS N
for POS N
co-infected POS N
patients POS N
(P POS N
= POS N
0.5), POS N
even POS N
at POS N
HBV-replication POS N
levels POS N
> POS N
10,000 POS N
copies/mL POS N
(P POS N
= POS N
0.7). POS N

In POS N
conclusion, POS N
co-infected POS N
patients POS N
with POS N
elevated POS N
HBV-replication POS N
at POS N
ART-initiation POS N
are POS N
more POS N
susceptible POS N
to POS N
HIV-related POS N
morbidity, POS N
especially POS N
invasive POS N
bacterial POS N
diseases, POS N
during POS N
treatment POS N
interruption. POS N

No POS N
increase POS N
in POS N
the POS N
incidence POS N
of POS N
non-HIV-related POS N
morbidity POS N
was POS N
observed POS N
for POS N
co-infected POS N
patients POS N
(P POS N
= POS N
0.5), POS N
even POS N
at POS N
HBV-replication POS N
levels POS N
> POS N
10,000 POS N
copies/mL POS N
(P POS N
= POS N
0.7). POS N

The POS N
relative POS N
effect POS N
of POS N
CD4GT POS N
or POS N
2/4-ART POS N
versus POS N
C-ART POS N
was POS N
not POS N
different POS N
between POS N
infection POS N
groups POS N
(P POS N
for POS N
interaction POS N
= POS N
0.4). POS N

No POS N
increase POS N
in POS N
the POS N
incidence POS N
of POS N
non-HIV-related POS N
morbidity POS N
was POS N
observed POS N
for POS N
co-infected POS N
patients POS N
(P POS N
= POS N
0.5), POS N
even POS N
at POS N
HBV-replication POS N
levels POS N
> POS N
10,000 POS N
copies/mL POS N
(P POS N
= POS N
0.7). POS N

Incidence POS N
of POS N
bacterial POS N
infections POS N
was POS N
also POS N
highest POS N
in POS N
the POS N
co-infected POS N
group POS N
with POS N
HBV-replication POS N
> POS N
10,000 POS N
copies/mL POS N
(IR POS N
= POS N
12.9 POS N
versus POS N
3.3/100 POS N
person/years POS N
in POS N
HIV POS N
mono-infected POS N
patients, POS N
P POS N
= POS N
0.001). POS N

No POS N
increase POS N
in POS N
the POS N
incidence POS N
of POS N
non-HIV-related POS N
morbidity POS N
was POS N
observed POS N
for POS N
co-infected POS N
patients POS N
(P POS N
= POS N
0.5), POS N
even POS N
at POS N
HBV-replication POS N
levels POS N
> POS N
10,000 POS N
copies/mL POS N
(P POS N
= POS N
0.7). POS N

After POS N
a POS N
median POS N
2.0 POS N
year POS N
(range POS N
= POS N
0.2-3.1) POS N
follow-up, POS N
≥ POS N
1 POS N
serious POS N
HIV-related POS N
events POS N
occurred POS N
in POS N
101 POS N
HIV POS N
mono-infected POS N
and POS N
15 POS N
HIV-HBV POS N
co-infected POS N
patients POS N
(IR POS N
= POS N
10.0 POS N
versus POS N
13.2/100 POS N
person/years, POS N
respectively, POS N
P POS N
= POS N
0.3) POS N

The POS N
relative POS N
effect POS N
of POS N
CD4GT POS N
or POS N
2/4-ART POS N
versus POS N
C-ART POS N
was POS N
not POS N
different POS N
between POS N
infection POS N
groups POS N
(P POS N
for POS N
interaction POS N
= POS N
0.4). POS N

In POS N
conclusion, POS N
co-infected POS N
patients POS N
with POS N
elevated POS N
HBV-replication POS N
at POS N
ART-initiation POS N
are POS N
more POS N
susceptible POS N
to POS N
HIV-related POS N
morbidity, POS N
especially POS N
invasive POS N
bacterial POS N
diseases, POS N
during POS N
treatment POS N
interruption. POS N

The POS N
relative POS N
effect POS N
of POS N
CD4GT POS N
or POS N
2/4-ART POS N
versus POS N
C-ART POS N
was POS N
not POS N
different POS N
between POS N
infection POS N
groups POS N
(P POS N
for POS N
interaction POS N
= POS N
0.4). POS N

No POS N
increase POS N
in POS N
the POS N
incidence POS N
of POS N
non-HIV-related POS N
morbidity POS N
was POS N
observed POS N
for POS N
co-infected POS N
patients POS N
(P POS N
= POS N
0.5), POS N
even POS N
at POS N
HBV-replication POS N
levels POS N
> POS N
10,000 POS N
copies/mL POS N
(P POS N
= POS N
0.7). POS N

The POS N
relative POS N
effect POS N
of POS N
CD4GT POS N
or POS N
2/4-ART POS N
versus POS N
C-ART POS N
was POS N
not POS N
different POS N
between POS N
infection POS N
groups POS N
(P POS N
for POS N
interaction POS N
= POS N
0.4). POS N

Incidence POS N
of POS N
bacterial POS N
infections POS N
was POS N
also POS N
highest POS N
in POS N
the POS N
co-infected POS N
group POS N
with POS N
HBV-replication POS N
> POS N
10,000 POS N
copies/mL POS N
(IR POS N
= POS N
12.9 POS N
versus POS N
3.3/100 POS N
person/years POS N
in POS N
HIV POS N
mono-infected POS N
patients, POS N
P POS N
= POS N
0.001). POS N

The POS N
relative POS N
effect POS N
of POS N
CD4GT POS N
or POS N
2/4-ART POS N
versus POS N
C-ART POS N
was POS N
not POS N
different POS N
between POS N
infection POS N
groups POS N
(P POS N
for POS N
interaction POS N
= POS N
0.4). POS N

After POS N
a POS N
median POS N
2.0 POS N
year POS N
(range POS N
= POS N
0.2-3.1) POS N
follow-up, POS N
≥ POS N
1 POS N
serious POS N
HIV-related POS N
events POS N
occurred POS N
in POS N
101 POS N
HIV POS N
mono-infected POS N
and POS N
15 POS N
HIV-HBV POS N
co-infected POS N
patients POS N
(IR POS N
= POS N
10.0 POS N
versus POS N
13.2/100 POS N
person/years, POS N
respectively, POS N
P POS N
= POS N
0.3) POS N

Incidence POS N
of POS N
bacterial POS N
infections POS N
was POS N
also POS N
highest POS N
in POS N
the POS N
co-infected POS N
group POS N
with POS N
HBV-replication POS N
> POS N
10,000 POS N
copies/mL POS N
(IR POS N
= POS N
12.9 POS N
versus POS N
3.3/100 POS N
person/years POS N
in POS N
HIV POS N
mono-infected POS N
patients, POS N
P POS N
= POS N
0.001). POS N

In POS N
conclusion, POS N
co-infected POS N
patients POS N
with POS N
elevated POS N
HBV-replication POS N
at POS N
ART-initiation POS N
are POS N
more POS N
susceptible POS N
to POS N
HIV-related POS N
morbidity, POS N
especially POS N
invasive POS N
bacterial POS N
diseases, POS N
during POS N
treatment POS N
interruption. POS N

Incidence POS N
of POS N
bacterial POS N
infections POS N
was POS N
also POS N
highest POS N
in POS N
the POS N
co-infected POS N
group POS N
with POS N
HBV-replication POS N
> POS N
10,000 POS N
copies/mL POS N
(IR POS N
= POS N
12.9 POS N
versus POS N
3.3/100 POS N
person/years POS N
in POS N
HIV POS N
mono-infected POS N
patients, POS N
P POS N
= POS N
0.001). POS N

No POS N
increase POS N
in POS N
the POS N
incidence POS N
of POS N
non-HIV-related POS N
morbidity POS N
was POS N
observed POS N
for POS N
co-infected POS N
patients POS N
(P POS N
= POS N
0.5), POS N
even POS N
at POS N
HBV-replication POS N
levels POS N
> POS N
10,000 POS N
copies/mL POS N
(P POS N
= POS N
0.7). POS N

Incidence POS N
of POS N
bacterial POS N
infections POS N
was POS N
also POS N
highest POS N
in POS N
the POS N
co-infected POS N
group POS N
with POS N
HBV-replication POS N
> POS N
10,000 POS N
copies/mL POS N
(IR POS N
= POS N
12.9 POS N
versus POS N
3.3/100 POS N
person/years POS N
in POS N
HIV POS N
mono-infected POS N
patients, POS N
P POS N
= POS N
0.001). POS N

The POS N
relative POS N
effect POS N
of POS N
CD4GT POS N
or POS N
2/4-ART POS N
versus POS N
C-ART POS N
was POS N
not POS N
different POS N
between POS N
infection POS N
groups POS N
(P POS N
for POS N
interaction POS N
= POS N
0.4). POS N

Incidence POS N
of POS N
bacterial POS N
infections POS N
was POS N
also POS N
highest POS N
in POS N
the POS N
co-infected POS N
group POS N
with POS N
HBV-replication POS N
> POS N
10,000 POS N
copies/mL POS N
(IR POS N
= POS N
12.9 POS N
versus POS N
3.3/100 POS N
person/years POS N
in POS N
HIV POS N
mono-infected POS N
patients, POS N
P POS N
= POS N
0.001). POS N

After POS N
a POS N
median POS N
2.0 POS N
year POS N
(range POS N
= POS N
0.2-3.1) POS N
follow-up, POS N
≥ POS N
1 POS N
serious POS N
HIV-related POS N
events POS N
occurred POS N
in POS N
101 POS N
HIV POS N
mono-infected POS N
and POS N
15 POS N
HIV-HBV POS N
co-infected POS N
patients POS N
(IR POS N
= POS N
10.0 POS N
versus POS N
13.2/100 POS N
person/years, POS N
respectively, POS N
P POS N
= POS N
0.3) POS N

After POS N
a POS N
median POS N
2.0 POS N
year POS N
(range POS N
= POS N
0.2-3.1) POS N
follow-up, POS N
≥ POS N
1 POS N
serious POS N
HIV-related POS N
events POS N
occurred POS N
in POS N
101 POS N
HIV POS N
mono-infected POS N
and POS N
15 POS N
HIV-HBV POS N
co-infected POS N
patients POS N
(IR POS N
= POS N
10.0 POS N
versus POS N
13.2/100 POS N
person/years, POS N
respectively, POS N
P POS N
= POS N
0.3) POS N

In POS N
conclusion, POS N
co-infected POS N
patients POS N
with POS N
elevated POS N
HBV-replication POS N
at POS N
ART-initiation POS N
are POS N
more POS N
susceptible POS N
to POS N
HIV-related POS N
morbidity, POS N
especially POS N
invasive POS N
bacterial POS N
diseases, POS N
during POS N
treatment POS N
interruption. POS N

After POS N
a POS N
median POS N
2.0 POS N
year POS N
(range POS N
= POS N
0.2-3.1) POS N
follow-up, POS N
≥ POS N
1 POS N
serious POS N
HIV-related POS N
events POS N
occurred POS N
in POS N
101 POS N
HIV POS N
mono-infected POS N
and POS N
15 POS N
HIV-HBV POS N
co-infected POS N
patients POS N
(IR POS N
= POS N
10.0 POS N
versus POS N
13.2/100 POS N
person/years, POS N
respectively, POS N
P POS N
= POS N
0.3) POS N

No POS N
increase POS N
in POS N
the POS N
incidence POS N
of POS N
non-HIV-related POS N
morbidity POS N
was POS N
observed POS N
for POS N
co-infected POS N
patients POS N
(P POS N
= POS N
0.5), POS N
even POS N
at POS N
HBV-replication POS N
levels POS N
> POS N
10,000 POS N
copies/mL POS N
(P POS N
= POS N
0.7). POS N

After POS N
a POS N
median POS N
2.0 POS N
year POS N
(range POS N
= POS N
0.2-3.1) POS N
follow-up, POS N
≥ POS N
1 POS N
serious POS N
HIV-related POS N
events POS N
occurred POS N
in POS N
101 POS N
HIV POS N
mono-infected POS N
and POS N
15 POS N
HIV-HBV POS N
co-infected POS N
patients POS N
(IR POS N
= POS N
10.0 POS N
versus POS N
13.2/100 POS N
person/years, POS N
respectively, POS N
P POS N
= POS N
0.3) POS N

The POS N
relative POS N
effect POS N
of POS N
CD4GT POS N
or POS N
2/4-ART POS N
versus POS N
C-ART POS N
was POS N
not POS N
different POS N
between POS N
infection POS N
groups POS N
(P POS N
for POS N
interaction POS N
= POS N
0.4). POS N

After POS N
a POS N
median POS N
2.0 POS N
year POS N
(range POS N
= POS N
0.2-3.1) POS N
follow-up, POS N
≥ POS N
1 POS N
serious POS N
HIV-related POS N
events POS N
occurred POS N
in POS N
101 POS N
HIV POS N
mono-infected POS N
and POS N
15 POS N
HIV-HBV POS N
co-infected POS N
patients POS N
(IR POS N
= POS N
10.0 POS N
versus POS N
13.2/100 POS N
person/years, POS N
respectively, POS N
P POS N
= POS N
0.3) POS N

Incidence POS N
of POS N
bacterial POS N
infections POS N
was POS N
also POS N
highest POS N
in POS N
the POS N
co-infected POS N
group POS N
with POS N
HBV-replication POS N
> POS N
10,000 POS N
copies/mL POS N
(IR POS N
= POS N
12.9 POS N
versus POS N
3.3/100 POS N
person/years POS N
in POS N
HIV POS N
mono-infected POS N
patients, POS N
P POS N
= POS N
0.001). POS N

Results POS N
revealed POS N
that POS N
during POS N
daily POS N
consumption POS N
of POS N
fermented POS N
milk POS N
for POS N
5 POS N
wk, POS N
systolic POS N
[(116.55 POS N
± POS N
12.26 POS N
mmHg POS N
vs. POS N
124.77 POS N
± POS N
11.04 POS N
mmHg) POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
(80.7 POS N
± POS N
9 POS N
vs. POS N
84.5 POS N
± POS N
8.5 POS N
mmHg)] POS N
from POS N
the POS N
fermented POS N
milk POS N
group POS N
was POS N
lower POS N
than POS N
the POS N
control POS N
group. POS N

Additionally, POS N
triglyceride, POS N
total POS N
cholesterol, POS N
and POS N
low-density POS N
lipoprotein POS N
in POS N
blood POS N
serum POS N
were POS N
lower POS N
in POS N
the POS N
fermented POS N
milk POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group. POS N

Results POS N
revealed POS N
that POS N
during POS N
daily POS N
consumption POS N
of POS N
fermented POS N
milk POS N
for POS N
5 POS N
wk, POS N
systolic POS N
[(116.55 POS N
± POS N
12.26 POS N
mmHg POS N
vs. POS N
124.77 POS N
± POS N
11.04 POS N
mmHg) POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
(80.7 POS N
± POS N
9 POS N
vs. POS N
84.5 POS N
± POS N
8.5 POS N
mmHg)] POS N
from POS N
the POS N
fermented POS N
milk POS N
group POS N
was POS N
lower POS N
than POS N
the POS N
control POS N
group. POS N

Results POS N
demonstrated POS N
that POS N
daily POS N
consumption POS N
of POS N
fermented POS N
milk POS N
with POS N
Lactococcus POS N
lactis POS N
(NRRL POS N
B-50571) POS N
had POS N
a POS N
blood POS N
pressure-lowering POS N
effect POS N
on POS N
prehypertensive POS N
subjects. POS N

Results POS N
revealed POS N
that POS N
during POS N
daily POS N
consumption POS N
of POS N
fermented POS N
milk POS N
for POS N
5 POS N
wk, POS N
systolic POS N
[(116.55 POS N
± POS N
12.26 POS N
mmHg POS N
vs. POS N
124.77 POS N
± POS N
11.04 POS N
mmHg) POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
(80.7 POS N
± POS N
9 POS N
vs. POS N
84.5 POS N
± POS N
8.5 POS N
mmHg)] POS N
from POS N
the POS N
fermented POS N
milk POS N
group POS N
was POS N
lower POS N
than POS N
the POS N
control POS N
group. POS N

Regular POS N
consumption POS N
of POS N
this POS N
product POS N
may POS N
be POS N
used POS N
as POS N
a POS N
potential POS N
functional POS N
food. POS N

Additionally, POS N
triglyceride, POS N
total POS N
cholesterol, POS N
and POS N
low-density POS N
lipoprotein POS N
in POS N
blood POS N
serum POS N
were POS N
lower POS N
in POS N
the POS N
fermented POS N
milk POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group. POS N

Results POS N
revealed POS N
that POS N
during POS N
daily POS N
consumption POS N
of POS N
fermented POS N
milk POS N
for POS N
5 POS N
wk, POS N
systolic POS N
[(116.55 POS N
± POS N
12.26 POS N
mmHg POS N
vs. POS N
124.77 POS N
± POS N
11.04 POS N
mmHg) POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
(80.7 POS N
± POS N
9 POS N
vs. POS N
84.5 POS N
± POS N
8.5 POS N
mmHg)] POS N
from POS N
the POS N
fermented POS N
milk POS N
group POS N
was POS N
lower POS N
than POS N
the POS N
control POS N
group. POS N

Additionally, POS N
triglyceride, POS N
total POS N
cholesterol, POS N
and POS N
low-density POS N
lipoprotein POS N
in POS N
blood POS N
serum POS N
were POS N
lower POS N
in POS N
the POS N
fermented POS N
milk POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group. POS N

Results POS N
demonstrated POS N
that POS N
daily POS N
consumption POS N
of POS N
fermented POS N
milk POS N
with POS N
Lactococcus POS N
lactis POS N
(NRRL POS N
B-50571) POS N
had POS N
a POS N
blood POS N
pressure-lowering POS N
effect POS N
on POS N
prehypertensive POS N
subjects. POS N

Additionally, POS N
triglyceride, POS N
total POS N
cholesterol, POS N
and POS N
low-density POS N
lipoprotein POS N
in POS N
blood POS N
serum POS N
were POS N
lower POS N
in POS N
the POS N
fermented POS N
milk POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group. POS N

Regular POS N
consumption POS N
of POS N
this POS N
product POS N
may POS N
be POS N
used POS N
as POS N
a POS N
potential POS N
functional POS N
food. POS N

Results POS N
demonstrated POS N
that POS N
daily POS N
consumption POS N
of POS N
fermented POS N
milk POS N
with POS N
Lactococcus POS N
lactis POS N
(NRRL POS N
B-50571) POS N
had POS N
a POS N
blood POS N
pressure-lowering POS N
effect POS N
on POS N
prehypertensive POS N
subjects. POS N

Results POS N
revealed POS N
that POS N
during POS N
daily POS N
consumption POS N
of POS N
fermented POS N
milk POS N
for POS N
5 POS N
wk, POS N
systolic POS N
[(116.55 POS N
± POS N
12.26 POS N
mmHg POS N
vs. POS N
124.77 POS N
± POS N
11.04 POS N
mmHg) POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
(80.7 POS N
± POS N
9 POS N
vs. POS N
84.5 POS N
± POS N
8.5 POS N
mmHg)] POS N
from POS N
the POS N
fermented POS N
milk POS N
group POS N
was POS N
lower POS N
than POS N
the POS N
control POS N
group. POS N

Results POS N
demonstrated POS N
that POS N
daily POS N
consumption POS N
of POS N
fermented POS N
milk POS N
with POS N
Lactococcus POS N
lactis POS N
(NRRL POS N
B-50571) POS N
had POS N
a POS N
blood POS N
pressure-lowering POS N
effect POS N
on POS N
prehypertensive POS N
subjects. POS N

Additionally, POS N
triglyceride, POS N
total POS N
cholesterol, POS N
and POS N
low-density POS N
lipoprotein POS N
in POS N
blood POS N
serum POS N
were POS N
lower POS N
in POS N
the POS N
fermented POS N
milk POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group. POS N

Results POS N
demonstrated POS N
that POS N
daily POS N
consumption POS N
of POS N
fermented POS N
milk POS N
with POS N
Lactococcus POS N
lactis POS N
(NRRL POS N
B-50571) POS N
had POS N
a POS N
blood POS N
pressure-lowering POS N
effect POS N
on POS N
prehypertensive POS N
subjects. POS N

Regular POS N
consumption POS N
of POS N
this POS N
product POS N
may POS N
be POS N
used POS N
as POS N
a POS N
potential POS N
functional POS N
food. POS N

Regular POS N
consumption POS N
of POS N
this POS N
product POS N
may POS N
be POS N
used POS N
as POS N
a POS N
potential POS N
functional POS N
food. POS N

Results POS N
revealed POS N
that POS N
during POS N
daily POS N
consumption POS N
of POS N
fermented POS N
milk POS N
for POS N
5 POS N
wk, POS N
systolic POS N
[(116.55 POS N
± POS N
12.26 POS N
mmHg POS N
vs. POS N
124.77 POS N
± POS N
11.04 POS N
mmHg) POS N
and POS N
diastolic POS N
blood POS N
pressure POS N
(80.7 POS N
± POS N
9 POS N
vs. POS N
84.5 POS N
± POS N
8.5 POS N
mmHg)] POS N
from POS N
the POS N
fermented POS N
milk POS N
group POS N
was POS N
lower POS N
than POS N
the POS N
control POS N
group. POS N

Regular POS N
consumption POS N
of POS N
this POS N
product POS N
may POS N
be POS N
used POS N
as POS N
a POS N
potential POS N
functional POS N
food. POS N

Additionally, POS N
triglyceride, POS N
total POS N
cholesterol, POS N
and POS N
low-density POS N
lipoprotein POS N
in POS N
blood POS N
serum POS N
were POS N
lower POS N
in POS N
the POS N
fermented POS N
milk POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group. POS N

Regular POS N
consumption POS N
of POS N
this POS N
product POS N
may POS N
be POS N
used POS N
as POS N
a POS N
potential POS N
functional POS N
food. POS N

Results POS N
demonstrated POS N
that POS N
daily POS N
consumption POS N
of POS N
fermented POS N
milk POS N
with POS N
Lactococcus POS N
lactis POS N
(NRRL POS N
B-50571) POS N
had POS N
a POS N
blood POS N
pressure-lowering POS N
effect POS N
on POS N
prehypertensive POS N
subjects. POS N

Cutaneous POS N
T-cell POS N
lymphoma POS N
(CTCL) POS N
can POS N
be POS N
associated POS N
with POS N
painful, POS N
pruritic, POS N
disfiguring POS N
lesions. POS N

Composite POS N
FACT-G POS N
and POS N
most POS N
individual POS N
subscale POS N
scores POS N
(physical, POS N
social/family, POS N
emotional, POS N
and POS N
functional POS N
well POS N
being) POS N
in POS N
documented POS N
responders POS N
(n POS N
= POS N
21) POS N
gradually POS N
increased POS N
during POS N
the POS N
study POS N
period, POS N
generally POS N
reaching POS N
statistical POS N
significance POS N
(P POS N
< POS N
0.05) POS N
by POS N
cycle POS N
3, POS N
and POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
= POS N
0.041) POS N
higher POS N
than POS N
the POS N
scores POS N
of POS N
nonresponders POS N
at POS N
endpoint. POS N

Cutaneous POS N
T-cell POS N
lymphoma POS N
(CTCL) POS N
can POS N
be POS N
associated POS N
with POS N
painful, POS N
pruritic, POS N
disfiguring POS N
lesions. POS N

Additionally POS N
for POS N
responders, POS N
assessments POS N
of POS N
skin POS N
severity POS N
and POS N
pruritus POS N
severity POS N
showed POS N
significant POS N
(P POS N
< POS N
or POS N
= POS N
0.05) POS N
improvements POS N
at POS N
study POS N
endpoint POS N
compared POS N
with POS N
baseline. POS N

Cutaneous POS N
T-cell POS N
lymphoma POS N
(CTCL) POS N
can POS N
be POS N
associated POS N
with POS N
painful, POS N
pruritic, POS N
disfiguring POS N
lesions. POS N

Adverse POS N
transfusion-related POS N
events POS N
(eg, POS N
hypersensitivity POS N
reactions, POS N
flu-like POS N
syndrome) POS N
were POS N
common POS N
during POS N
cycles POS N
1 POS N
and POS N
2, POS N
and POS N
vascular-leak POS N
syndrome POS N
occurred POS N
in POS N
25% POS N
of POS N
patients. POS N

Cutaneous POS N
T-cell POS N
lymphoma POS N
(CTCL) POS N
can POS N
be POS N
associated POS N
with POS N
painful, POS N
pruritic, POS N
disfiguring POS N
lesions. POS N

Denileukin POS N
diftitox POS N
was POS N
not POS N
associated POS N
with POS N
any POS N
clinically POS N
significant POS N
myelosuppression. POS N

Cutaneous POS N
T-cell POS N
lymphoma POS N
(CTCL) POS N
can POS N
be POS N
associated POS N
with POS N
painful, POS N
pruritic, POS N
disfiguring POS N
lesions. POS N

Heavily POS N
pretreated POS N
patients POS N
with POS N
advanced POS N
and/or POS N
recurrent POS N
CTCL POS N
who POS N
responded POS N
to POS N
denileukin POS N
diftitox POS N
therapy POS N
showed POS N
significant POS N
improvements POS N
in POS N
self-rated POS N
overall POS N
QOL, POS N
skin POS N
appearance, POS N
and POS N
pruritus POS N
severity. POS N

Composite POS N
FACT-G POS N
and POS N
most POS N
individual POS N
subscale POS N
scores POS N
(physical, POS N
social/family, POS N
emotional, POS N
and POS N
functional POS N
well POS N
being) POS N
in POS N
documented POS N
responders POS N
(n POS N
= POS N
21) POS N
gradually POS N
increased POS N
during POS N
the POS N
study POS N
period, POS N
generally POS N
reaching POS N
statistical POS N
significance POS N
(P POS N
< POS N
0.05) POS N
by POS N
cycle POS N
3, POS N
and POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
= POS N
0.041) POS N
higher POS N
than POS N
the POS N
scores POS N
of POS N
nonresponders POS N
at POS N
endpoint. POS N

Cutaneous POS N
T-cell POS N
lymphoma POS N
(CTCL) POS N
can POS N
be POS N
associated POS N
with POS N
painful, POS N
pruritic, POS N
disfiguring POS N
lesions. POS N

Composite POS N
FACT-G POS N
and POS N
most POS N
individual POS N
subscale POS N
scores POS N
(physical, POS N
social/family, POS N
emotional, POS N
and POS N
functional POS N
well POS N
being) POS N
in POS N
documented POS N
responders POS N
(n POS N
= POS N
21) POS N
gradually POS N
increased POS N
during POS N
the POS N
study POS N
period, POS N
generally POS N
reaching POS N
statistical POS N
significance POS N
(P POS N
< POS N
0.05) POS N
by POS N
cycle POS N
3, POS N
and POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
= POS N
0.041) POS N
higher POS N
than POS N
the POS N
scores POS N
of POS N
nonresponders POS N
at POS N
endpoint. POS N

Additionally POS N
for POS N
responders, POS N
assessments POS N
of POS N
skin POS N
severity POS N
and POS N
pruritus POS N
severity POS N
showed POS N
significant POS N
(P POS N
< POS N
or POS N
= POS N
0.05) POS N
improvements POS N
at POS N
study POS N
endpoint POS N
compared POS N
with POS N
baseline. POS N

Composite POS N
FACT-G POS N
and POS N
most POS N
individual POS N
subscale POS N
scores POS N
(physical, POS N
social/family, POS N
emotional, POS N
and POS N
functional POS N
well POS N
being) POS N
in POS N
documented POS N
responders POS N
(n POS N
= POS N
21) POS N
gradually POS N
increased POS N
during POS N
the POS N
study POS N
period, POS N
generally POS N
reaching POS N
statistical POS N
significance POS N
(P POS N
< POS N
0.05) POS N
by POS N
cycle POS N
3, POS N
and POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
= POS N
0.041) POS N
higher POS N
than POS N
the POS N
scores POS N
of POS N
nonresponders POS N
at POS N
endpoint. POS N

Adverse POS N
transfusion-related POS N
events POS N
(eg, POS N
hypersensitivity POS N
reactions, POS N
flu-like POS N
syndrome) POS N
were POS N
common POS N
during POS N
cycles POS N
1 POS N
and POS N
2, POS N
and POS N
vascular-leak POS N
syndrome POS N
occurred POS N
in POS N
25% POS N
of POS N
patients. POS N

Composite POS N
FACT-G POS N
and POS N
most POS N
individual POS N
subscale POS N
scores POS N
(physical, POS N
social/family, POS N
emotional, POS N
and POS N
functional POS N
well POS N
being) POS N
in POS N
documented POS N
responders POS N
(n POS N
= POS N
21) POS N
gradually POS N
increased POS N
during POS N
the POS N
study POS N
period, POS N
generally POS N
reaching POS N
statistical POS N
significance POS N
(P POS N
< POS N
0.05) POS N
by POS N
cycle POS N
3, POS N
and POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
= POS N
0.041) POS N
higher POS N
than POS N
the POS N
scores POS N
of POS N
nonresponders POS N
at POS N
endpoint. POS N

Denileukin POS N
diftitox POS N
was POS N
not POS N
associated POS N
with POS N
any POS N
clinically POS N
significant POS N
myelosuppression. POS N

Composite POS N
FACT-G POS N
and POS N
most POS N
individual POS N
subscale POS N
scores POS N
(physical, POS N
social/family, POS N
emotional, POS N
and POS N
functional POS N
well POS N
being) POS N
in POS N
documented POS N
responders POS N
(n POS N
= POS N
21) POS N
gradually POS N
increased POS N
during POS N
the POS N
study POS N
period, POS N
generally POS N
reaching POS N
statistical POS N
significance POS N
(P POS N
< POS N
0.05) POS N
by POS N
cycle POS N
3, POS N
and POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
= POS N
0.041) POS N
higher POS N
than POS N
the POS N
scores POS N
of POS N
nonresponders POS N
at POS N
endpoint. POS N

Heavily POS N
pretreated POS N
patients POS N
with POS N
advanced POS N
and/or POS N
recurrent POS N
CTCL POS N
who POS N
responded POS N
to POS N
denileukin POS N
diftitox POS N
therapy POS N
showed POS N
significant POS N
improvements POS N
in POS N
self-rated POS N
overall POS N
QOL, POS N
skin POS N
appearance, POS N
and POS N
pruritus POS N
severity. POS N

Additionally POS N
for POS N
responders, POS N
assessments POS N
of POS N
skin POS N
severity POS N
and POS N
pruritus POS N
severity POS N
showed POS N
significant POS N
(P POS N
< POS N
or POS N
= POS N
0.05) POS N
improvements POS N
at POS N
study POS N
endpoint POS N
compared POS N
with POS N
baseline. POS N

Cutaneous POS N
T-cell POS N
lymphoma POS N
(CTCL) POS N
can POS N
be POS N
associated POS N
with POS N
painful, POS N
pruritic, POS N
disfiguring POS N
lesions. POS N

Additionally POS N
for POS N
responders, POS N
assessments POS N
of POS N
skin POS N
severity POS N
and POS N
pruritus POS N
severity POS N
showed POS N
significant POS N
(P POS N
< POS N
or POS N
= POS N
0.05) POS N
improvements POS N
at POS N
study POS N
endpoint POS N
compared POS N
with POS N
baseline. POS N

Composite POS N
FACT-G POS N
and POS N
most POS N
individual POS N
subscale POS N
scores POS N
(physical, POS N
social/family, POS N
emotional, POS N
and POS N
functional POS N
well POS N
being) POS N
in POS N
documented POS N
responders POS N
(n POS N
= POS N
21) POS N
gradually POS N
increased POS N
during POS N
the POS N
study POS N
period, POS N
generally POS N
reaching POS N
statistical POS N
significance POS N
(P POS N
< POS N
0.05) POS N
by POS N
cycle POS N
3, POS N
and POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
= POS N
0.041) POS N
higher POS N
than POS N
the POS N
scores POS N
of POS N
nonresponders POS N
at POS N
endpoint. POS N

Additionally POS N
for POS N
responders, POS N
assessments POS N
of POS N
skin POS N
severity POS N
and POS N
pruritus POS N
severity POS N
showed POS N
significant POS N
(P POS N
< POS N
or POS N
= POS N
0.05) POS N
improvements POS N
at POS N
study POS N
endpoint POS N
compared POS N
with POS N
baseline. POS N

Adverse POS N
transfusion-related POS N
events POS N
(eg, POS N
hypersensitivity POS N
reactions, POS N
flu-like POS N
syndrome) POS N
were POS N
common POS N
during POS N
cycles POS N
1 POS N
and POS N
2, POS N
and POS N
vascular-leak POS N
syndrome POS N
occurred POS N
in POS N
25% POS N
of POS N
patients. POS N

Additionally POS N
for POS N
responders, POS N
assessments POS N
of POS N
skin POS N
severity POS N
and POS N
pruritus POS N
severity POS N
showed POS N
significant POS N
(P POS N
< POS N
or POS N
= POS N
0.05) POS N
improvements POS N
at POS N
study POS N
endpoint POS N
compared POS N
with POS N
baseline. POS N

Denileukin POS N
diftitox POS N
was POS N
not POS N
associated POS N
with POS N
any POS N
clinically POS N
significant POS N
myelosuppression. POS N

Additionally POS N
for POS N
responders, POS N
assessments POS N
of POS N
skin POS N
severity POS N
and POS N
pruritus POS N
severity POS N
showed POS N
significant POS N
(P POS N
< POS N
or POS N
= POS N
0.05) POS N
improvements POS N
at POS N
study POS N
endpoint POS N
compared POS N
with POS N
baseline. POS N

Heavily POS N
pretreated POS N
patients POS N
with POS N
advanced POS N
and/or POS N
recurrent POS N
CTCL POS N
who POS N
responded POS N
to POS N
denileukin POS N
diftitox POS N
therapy POS N
showed POS N
significant POS N
improvements POS N
in POS N
self-rated POS N
overall POS N
QOL, POS N
skin POS N
appearance, POS N
and POS N
pruritus POS N
severity. POS N

Adverse POS N
transfusion-related POS N
events POS N
(eg, POS N
hypersensitivity POS N
reactions, POS N
flu-like POS N
syndrome) POS N
were POS N
common POS N
during POS N
cycles POS N
1 POS N
and POS N
2, POS N
and POS N
vascular-leak POS N
syndrome POS N
occurred POS N
in POS N
25% POS N
of POS N
patients. POS N

Cutaneous POS N
T-cell POS N
lymphoma POS N
(CTCL) POS N
can POS N
be POS N
associated POS N
with POS N
painful, POS N
pruritic, POS N
disfiguring POS N
lesions. POS N

Adverse POS N
transfusion-related POS N
events POS N
(eg, POS N
hypersensitivity POS N
reactions, POS N
flu-like POS N
syndrome) POS N
were POS N
common POS N
during POS N
cycles POS N
1 POS N
and POS N
2, POS N
and POS N
vascular-leak POS N
syndrome POS N
occurred POS N
in POS N
25% POS N
of POS N
patients. POS N

Composite POS N
FACT-G POS N
and POS N
most POS N
individual POS N
subscale POS N
scores POS N
(physical, POS N
social/family, POS N
emotional, POS N
and POS N
functional POS N
well POS N
being) POS N
in POS N
documented POS N
responders POS N
(n POS N
= POS N
21) POS N
gradually POS N
increased POS N
during POS N
the POS N
study POS N
period, POS N
generally POS N
reaching POS N
statistical POS N
significance POS N
(P POS N
< POS N
0.05) POS N
by POS N
cycle POS N
3, POS N
and POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
= POS N
0.041) POS N
higher POS N
than POS N
the POS N
scores POS N
of POS N
nonresponders POS N
at POS N
endpoint. POS N

Adverse POS N
transfusion-related POS N
events POS N
(eg, POS N
hypersensitivity POS N
reactions, POS N
flu-like POS N
syndrome) POS N
were POS N
common POS N
during POS N
cycles POS N
1 POS N
and POS N
2, POS N
and POS N
vascular-leak POS N
syndrome POS N
occurred POS N
in POS N
25% POS N
of POS N
patients. POS N

Additionally POS N
for POS N
responders, POS N
assessments POS N
of POS N
skin POS N
severity POS N
and POS N
pruritus POS N
severity POS N
showed POS N
significant POS N
(P POS N
< POS N
or POS N
= POS N
0.05) POS N
improvements POS N
at POS N
study POS N
endpoint POS N
compared POS N
with POS N
baseline. POS N

Adverse POS N
transfusion-related POS N
events POS N
(eg, POS N
hypersensitivity POS N
reactions, POS N
flu-like POS N
syndrome) POS N
were POS N
common POS N
during POS N
cycles POS N
1 POS N
and POS N
2, POS N
and POS N
vascular-leak POS N
syndrome POS N
occurred POS N
in POS N
25% POS N
of POS N
patients. POS N

Denileukin POS N
diftitox POS N
was POS N
not POS N
associated POS N
with POS N
any POS N
clinically POS N
significant POS N
myelosuppression. POS N

Adverse POS N
transfusion-related POS N
events POS N
(eg, POS N
hypersensitivity POS N
reactions, POS N
flu-like POS N
syndrome) POS N
were POS N
common POS N
during POS N
cycles POS N
1 POS N
and POS N
2, POS N
and POS N
vascular-leak POS N
syndrome POS N
occurred POS N
in POS N
25% POS N
of POS N
patients. POS N

Heavily POS N
pretreated POS N
patients POS N
with POS N
advanced POS N
and/or POS N
recurrent POS N
CTCL POS N
who POS N
responded POS N
to POS N
denileukin POS N
diftitox POS N
therapy POS N
showed POS N
significant POS N
improvements POS N
in POS N
self-rated POS N
overall POS N
QOL, POS N
skin POS N
appearance, POS N
and POS N
pruritus POS N
severity. POS N

Denileukin POS N
diftitox POS N
was POS N
not POS N
associated POS N
with POS N
any POS N
clinically POS N
significant POS N
myelosuppression. POS N

Cutaneous POS N
T-cell POS N
lymphoma POS N
(CTCL) POS N
can POS N
be POS N
associated POS N
with POS N
painful, POS N
pruritic, POS N
disfiguring POS N
lesions. POS N

Denileukin POS N
diftitox POS N
was POS N
not POS N
associated POS N
with POS N
any POS N
clinically POS N
significant POS N
myelosuppression. POS N

Composite POS N
FACT-G POS N
and POS N
most POS N
individual POS N
subscale POS N
scores POS N
(physical, POS N
social/family, POS N
emotional, POS N
and POS N
functional POS N
well POS N
being) POS N
in POS N
documented POS N
responders POS N
(n POS N
= POS N
21) POS N
gradually POS N
increased POS N
during POS N
the POS N
study POS N
period, POS N
generally POS N
reaching POS N
statistical POS N
significance POS N
(P POS N
< POS N
0.05) POS N
by POS N
cycle POS N
3, POS N
and POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
= POS N
0.041) POS N
higher POS N
than POS N
the POS N
scores POS N
of POS N
nonresponders POS N
at POS N
endpoint. POS N

Denileukin POS N
diftitox POS N
was POS N
not POS N
associated POS N
with POS N
any POS N
clinically POS N
significant POS N
myelosuppression. POS N

Additionally POS N
for POS N
responders, POS N
assessments POS N
of POS N
skin POS N
severity POS N
and POS N
pruritus POS N
severity POS N
showed POS N
significant POS N
(P POS N
< POS N
or POS N
= POS N
0.05) POS N
improvements POS N
at POS N
study POS N
endpoint POS N
compared POS N
with POS N
baseline. POS N

Denileukin POS N
diftitox POS N
was POS N
not POS N
associated POS N
with POS N
any POS N
clinically POS N
significant POS N
myelosuppression. POS N

Adverse POS N
transfusion-related POS N
events POS N
(eg, POS N
hypersensitivity POS N
reactions, POS N
flu-like POS N
syndrome) POS N
were POS N
common POS N
during POS N
cycles POS N
1 POS N
and POS N
2, POS N
and POS N
vascular-leak POS N
syndrome POS N
occurred POS N
in POS N
25% POS N
of POS N
patients. POS N

Denileukin POS N
diftitox POS N
was POS N
not POS N
associated POS N
with POS N
any POS N
clinically POS N
significant POS N
myelosuppression. POS N

Heavily POS N
pretreated POS N
patients POS N
with POS N
advanced POS N
and/or POS N
recurrent POS N
CTCL POS N
who POS N
responded POS N
to POS N
denileukin POS N
diftitox POS N
therapy POS N
showed POS N
significant POS N
improvements POS N
in POS N
self-rated POS N
overall POS N
QOL, POS N
skin POS N
appearance, POS N
and POS N
pruritus POS N
severity. POS N

Heavily POS N
pretreated POS N
patients POS N
with POS N
advanced POS N
and/or POS N
recurrent POS N
CTCL POS N
who POS N
responded POS N
to POS N
denileukin POS N
diftitox POS N
therapy POS N
showed POS N
significant POS N
improvements POS N
in POS N
self-rated POS N
overall POS N
QOL, POS N
skin POS N
appearance, POS N
and POS N
pruritus POS N
severity. POS N

Cutaneous POS N
T-cell POS N
lymphoma POS N
(CTCL) POS N
can POS N
be POS N
associated POS N
with POS N
painful, POS N
pruritic, POS N
disfiguring POS N
lesions. POS N

Heavily POS N
pretreated POS N
patients POS N
with POS N
advanced POS N
and/or POS N
recurrent POS N
CTCL POS N
who POS N
responded POS N
to POS N
denileukin POS N
diftitox POS N
therapy POS N
showed POS N
significant POS N
improvements POS N
in POS N
self-rated POS N
overall POS N
QOL, POS N
skin POS N
appearance, POS N
and POS N
pruritus POS N
severity. POS N

Composite POS N
FACT-G POS N
and POS N
most POS N
individual POS N
subscale POS N
scores POS N
(physical, POS N
social/family, POS N
emotional, POS N
and POS N
functional POS N
well POS N
being) POS N
in POS N
documented POS N
responders POS N
(n POS N
= POS N
21) POS N
gradually POS N
increased POS N
during POS N
the POS N
study POS N
period, POS N
generally POS N
reaching POS N
statistical POS N
significance POS N
(P POS N
< POS N
0.05) POS N
by POS N
cycle POS N
3, POS N
and POS N
were POS N
significantly POS N
(P POS N
< POS N
or POS N
= POS N
0.041) POS N
higher POS N
than POS N
the POS N
scores POS N
of POS N
nonresponders POS N
at POS N
endpoint. POS N

Heavily POS N
pretreated POS N
patients POS N
with POS N
advanced POS N
and/or POS N
recurrent POS N
CTCL POS N
who POS N
responded POS N
to POS N
denileukin POS N
diftitox POS N
therapy POS N
showed POS N
significant POS N
improvements POS N
in POS N
self-rated POS N
overall POS N
QOL, POS N
skin POS N
appearance, POS N
and POS N
pruritus POS N
severity. POS N

Additionally POS N
for POS N
responders, POS N
assessments POS N
of POS N
skin POS N
severity POS N
and POS N
pruritus POS N
severity POS N
showed POS N
significant POS N
(P POS N
< POS N
or POS N
= POS N
0.05) POS N
improvements POS N
at POS N
study POS N
endpoint POS N
compared POS N
with POS N
baseline. POS N

Heavily POS N
pretreated POS N
patients POS N
with POS N
advanced POS N
and/or POS N
recurrent POS N
CTCL POS N
who POS N
responded POS N
to POS N
denileukin POS N
diftitox POS N
therapy POS N
showed POS N
significant POS N
improvements POS N
in POS N
self-rated POS N
overall POS N
QOL, POS N
skin POS N
appearance, POS N
and POS N
pruritus POS N
severity. POS N

Adverse POS N
transfusion-related POS N
events POS N
(eg, POS N
hypersensitivity POS N
reactions, POS N
flu-like POS N
syndrome) POS N
were POS N
common POS N
during POS N
cycles POS N
1 POS N
and POS N
2, POS N
and POS N
vascular-leak POS N
syndrome POS N
occurred POS N
in POS N
25% POS N
of POS N
patients. POS N

Heavily POS N
pretreated POS N
patients POS N
with POS N
advanced POS N
and/or POS N
recurrent POS N
CTCL POS N
who POS N
responded POS N
to POS N
denileukin POS N
diftitox POS N
therapy POS N
showed POS N
significant POS N
improvements POS N
in POS N
self-rated POS N
overall POS N
QOL, POS N
skin POS N
appearance, POS N
and POS N
pruritus POS N
severity. POS N

Denileukin POS N
diftitox POS N
was POS N
not POS N
associated POS N
with POS N
any POS N
clinically POS N
significant POS N
myelosuppression. POS N

Imatinib POS N
(Gleevec), POS N
a POS N
highly POS N
effective POS N
specific POS N
tyrosine POS N
kinase POS N
inhibitor, POS N
demonstrates POS N
a POS N
better POS N
side POS N
effect POS N
profile POS N
than POS N
interferon-alpha POS N
(IFN), POS N
which POS N
impairs POS N
patients' POS N
quality POS N
of POS N
life POS N
(QoL). POS N

Two POS N
hundred POS N
sixty-one POS N
patients POS N
(50%) POS N
crossed POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib POS N
and POS N
11 POS N
(2%) POS N
crossed POS N
over POS N
from POS N
imatinib POS N
to POS N
IFN. POS N

Imatinib POS N
(Gleevec), POS N
a POS N
highly POS N
effective POS N
specific POS N
tyrosine POS N
kinase POS N
inhibitor, POS N
demonstrates POS N
a POS N
better POS N
side POS N
effect POS N
profile POS N
than POS N
interferon-alpha POS N
(IFN), POS N
which POS N
impairs POS N
patients' POS N
quality POS N
of POS N
life POS N
(QoL). POS N

There POS N
was POS N
a POS N
significant POS N
decline POS N
in POS N
TOI POS N
scores POS N
for POS N
the POS N
IFN POS N
treatment POS N
arm POS N
compared POS N
with POS N
preservation POS N
of POS N
baseline POS N
TOI POS N
scores POS N
in POS N
the POS N
imatinib POS N
arm POS N
(P POS N
<.001, POS N
ITT). POS N

Imatinib POS N
(Gleevec), POS N
a POS N
highly POS N
effective POS N
specific POS N
tyrosine POS N
kinase POS N
inhibitor, POS N
demonstrates POS N
a POS N
better POS N
side POS N
effect POS N
profile POS N
than POS N
interferon-alpha POS N
(IFN), POS N
which POS N
impairs POS N
patients' POS N
quality POS N
of POS N
life POS N
(QoL). POS N

Mean POS N
social/family POS N
and POS N
EWB POS N
scores POS N
were POS N
22.8 POS N
and POS N
19.5, POS N
respectively, POS N
for POS N
imatinib POS N
and POS N
21.6 POS N
and POS N
17.6, POS N
respectively, POS N
for POS N
IFN POS N
(P POS N
<.001, POS N
ITT). POS N

Imatinib POS N
(Gleevec), POS N
a POS N
highly POS N
effective POS N
specific POS N
tyrosine POS N
kinase POS N
inhibitor, POS N
demonstrates POS N
a POS N
better POS N
side POS N
effect POS N
profile POS N
than POS N
interferon-alpha POS N
(IFN), POS N
which POS N
impairs POS N
patients' POS N
quality POS N
of POS N
life POS N
(QoL). POS N

After POS N
crossing POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib, POS N
patients POS N
experienced POS N
a POS N
significant POS N
(P POS N
<.001) POS N
increase POS N
in POS N
TOI POS N
scores. POS N

Imatinib POS N
(Gleevec), POS N
a POS N
highly POS N
effective POS N
specific POS N
tyrosine POS N
kinase POS N
inhibitor, POS N
demonstrates POS N
a POS N
better POS N
side POS N
effect POS N
profile POS N
than POS N
interferon-alpha POS N
(IFN), POS N
which POS N
impairs POS N
patients' POS N
quality POS N
of POS N
life POS N
(QoL). POS N

Imatinib POS N
offers POS N
clear POS N
QoL POS N
advantages POS N
over POS N
IFN POS N
as POS N
first-line POS N
treatment POS N
of POS N
chronic-phase POS N
CML. POS N

Imatinib POS N
(Gleevec), POS N
a POS N
highly POS N
effective POS N
specific POS N
tyrosine POS N
kinase POS N
inhibitor, POS N
demonstrates POS N
a POS N
better POS N
side POS N
effect POS N
profile POS N
than POS N
interferon-alpha POS N
(IFN), POS N
which POS N
impairs POS N
patients' POS N
quality POS N
of POS N
life POS N
(QoL). POS N

patients POS N
who POS N
crossed POS N
over POS N
to POS N
imatinib POS N
reported POS N
higher POS N
QoL POS N
than POS N
those POS N
who POS N
remained POS N
on POS N
IFN. POS N

Two POS N
hundred POS N
sixty-one POS N
patients POS N
(50%) POS N
crossed POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib POS N
and POS N
11 POS N
(2%) POS N
crossed POS N
over POS N
from POS N
imatinib POS N
to POS N
IFN. POS N

Imatinib POS N
(Gleevec), POS N
a POS N
highly POS N
effective POS N
specific POS N
tyrosine POS N
kinase POS N
inhibitor, POS N
demonstrates POS N
a POS N
better POS N
side POS N
effect POS N
profile POS N
than POS N
interferon-alpha POS N
(IFN), POS N
which POS N
impairs POS N
patients' POS N
quality POS N
of POS N
life POS N
(QoL). POS N

Two POS N
hundred POS N
sixty-one POS N
patients POS N
(50%) POS N
crossed POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib POS N
and POS N
11 POS N
(2%) POS N
crossed POS N
over POS N
from POS N
imatinib POS N
to POS N
IFN. POS N

There POS N
was POS N
a POS N
significant POS N
decline POS N
in POS N
TOI POS N
scores POS N
for POS N
the POS N
IFN POS N
treatment POS N
arm POS N
compared POS N
with POS N
preservation POS N
of POS N
baseline POS N
TOI POS N
scores POS N
in POS N
the POS N
imatinib POS N
arm POS N
(P POS N
<.001, POS N
ITT). POS N

Two POS N
hundred POS N
sixty-one POS N
patients POS N
(50%) POS N
crossed POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib POS N
and POS N
11 POS N
(2%) POS N
crossed POS N
over POS N
from POS N
imatinib POS N
to POS N
IFN. POS N

Mean POS N
social/family POS N
and POS N
EWB POS N
scores POS N
were POS N
22.8 POS N
and POS N
19.5, POS N
respectively, POS N
for POS N
imatinib POS N
and POS N
21.6 POS N
and POS N
17.6, POS N
respectively, POS N
for POS N
IFN POS N
(P POS N
<.001, POS N
ITT). POS N

Two POS N
hundred POS N
sixty-one POS N
patients POS N
(50%) POS N
crossed POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib POS N
and POS N
11 POS N
(2%) POS N
crossed POS N
over POS N
from POS N
imatinib POS N
to POS N
IFN. POS N

After POS N
crossing POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib, POS N
patients POS N
experienced POS N
a POS N
significant POS N
(P POS N
<.001) POS N
increase POS N
in POS N
TOI POS N
scores. POS N

Two POS N
hundred POS N
sixty-one POS N
patients POS N
(50%) POS N
crossed POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib POS N
and POS N
11 POS N
(2%) POS N
crossed POS N
over POS N
from POS N
imatinib POS N
to POS N
IFN. POS N

Imatinib POS N
offers POS N
clear POS N
QoL POS N
advantages POS N
over POS N
IFN POS N
as POS N
first-line POS N
treatment POS N
of POS N
chronic-phase POS N
CML. POS N

Two POS N
hundred POS N
sixty-one POS N
patients POS N
(50%) POS N
crossed POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib POS N
and POS N
11 POS N
(2%) POS N
crossed POS N
over POS N
from POS N
imatinib POS N
to POS N
IFN. POS N

patients POS N
who POS N
crossed POS N
over POS N
to POS N
imatinib POS N
reported POS N
higher POS N
QoL POS N
than POS N
those POS N
who POS N
remained POS N
on POS N
IFN. POS N

There POS N
was POS N
a POS N
significant POS N
decline POS N
in POS N
TOI POS N
scores POS N
for POS N
the POS N
IFN POS N
treatment POS N
arm POS N
compared POS N
with POS N
preservation POS N
of POS N
baseline POS N
TOI POS N
scores POS N
in POS N
the POS N
imatinib POS N
arm POS N
(P POS N
<.001, POS N
ITT). POS N

Imatinib POS N
(Gleevec), POS N
a POS N
highly POS N
effective POS N
specific POS N
tyrosine POS N
kinase POS N
inhibitor, POS N
demonstrates POS N
a POS N
better POS N
side POS N
effect POS N
profile POS N
than POS N
interferon-alpha POS N
(IFN), POS N
which POS N
impairs POS N
patients' POS N
quality POS N
of POS N
life POS N
(QoL). POS N

There POS N
was POS N
a POS N
significant POS N
decline POS N
in POS N
TOI POS N
scores POS N
for POS N
the POS N
IFN POS N
treatment POS N
arm POS N
compared POS N
with POS N
preservation POS N
of POS N
baseline POS N
TOI POS N
scores POS N
in POS N
the POS N
imatinib POS N
arm POS N
(P POS N
<.001, POS N
ITT). POS N

Two POS N
hundred POS N
sixty-one POS N
patients POS N
(50%) POS N
crossed POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib POS N
and POS N
11 POS N
(2%) POS N
crossed POS N
over POS N
from POS N
imatinib POS N
to POS N
IFN. POS N

There POS N
was POS N
a POS N
significant POS N
decline POS N
in POS N
TOI POS N
scores POS N
for POS N
the POS N
IFN POS N
treatment POS N
arm POS N
compared POS N
with POS N
preservation POS N
of POS N
baseline POS N
TOI POS N
scores POS N
in POS N
the POS N
imatinib POS N
arm POS N
(P POS N
<.001, POS N
ITT). POS N

Mean POS N
social/family POS N
and POS N
EWB POS N
scores POS N
were POS N
22.8 POS N
and POS N
19.5, POS N
respectively, POS N
for POS N
imatinib POS N
and POS N
21.6 POS N
and POS N
17.6, POS N
respectively, POS N
for POS N
IFN POS N
(P POS N
<.001, POS N
ITT). POS N

There POS N
was POS N
a POS N
significant POS N
decline POS N
in POS N
TOI POS N
scores POS N
for POS N
the POS N
IFN POS N
treatment POS N
arm POS N
compared POS N
with POS N
preservation POS N
of POS N
baseline POS N
TOI POS N
scores POS N
in POS N
the POS N
imatinib POS N
arm POS N
(P POS N
<.001, POS N
ITT). POS N

After POS N
crossing POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib, POS N
patients POS N
experienced POS N
a POS N
significant POS N
(P POS N
<.001) POS N
increase POS N
in POS N
TOI POS N
scores. POS N

There POS N
was POS N
a POS N
significant POS N
decline POS N
in POS N
TOI POS N
scores POS N
for POS N
the POS N
IFN POS N
treatment POS N
arm POS N
compared POS N
with POS N
preservation POS N
of POS N
baseline POS N
TOI POS N
scores POS N
in POS N
the POS N
imatinib POS N
arm POS N
(P POS N
<.001, POS N
ITT). POS N

Imatinib POS N
offers POS N
clear POS N
QoL POS N
advantages POS N
over POS N
IFN POS N
as POS N
first-line POS N
treatment POS N
of POS N
chronic-phase POS N
CML. POS N

There POS N
was POS N
a POS N
significant POS N
decline POS N
in POS N
TOI POS N
scores POS N
for POS N
the POS N
IFN POS N
treatment POS N
arm POS N
compared POS N
with POS N
preservation POS N
of POS N
baseline POS N
TOI POS N
scores POS N
in POS N
the POS N
imatinib POS N
arm POS N
(P POS N
<.001, POS N
ITT). POS N

patients POS N
who POS N
crossed POS N
over POS N
to POS N
imatinib POS N
reported POS N
higher POS N
QoL POS N
than POS N
those POS N
who POS N
remained POS N
on POS N
IFN. POS N

Mean POS N
social/family POS N
and POS N
EWB POS N
scores POS N
were POS N
22.8 POS N
and POS N
19.5, POS N
respectively, POS N
for POS N
imatinib POS N
and POS N
21.6 POS N
and POS N
17.6, POS N
respectively, POS N
for POS N
IFN POS N
(P POS N
<.001, POS N
ITT). POS N

Imatinib POS N
(Gleevec), POS N
a POS N
highly POS N
effective POS N
specific POS N
tyrosine POS N
kinase POS N
inhibitor, POS N
demonstrates POS N
a POS N
better POS N
side POS N
effect POS N
profile POS N
than POS N
interferon-alpha POS N
(IFN), POS N
which POS N
impairs POS N
patients' POS N
quality POS N
of POS N
life POS N
(QoL). POS N

Mean POS N
social/family POS N
and POS N
EWB POS N
scores POS N
were POS N
22.8 POS N
and POS N
19.5, POS N
respectively, POS N
for POS N
imatinib POS N
and POS N
21.6 POS N
and POS N
17.6, POS N
respectively, POS N
for POS N
IFN POS N
(P POS N
<.001, POS N
ITT). POS N

Two POS N
hundred POS N
sixty-one POS N
patients POS N
(50%) POS N
crossed POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib POS N
and POS N
11 POS N
(2%) POS N
crossed POS N
over POS N
from POS N
imatinib POS N
to POS N
IFN. POS N

Mean POS N
social/family POS N
and POS N
EWB POS N
scores POS N
were POS N
22.8 POS N
and POS N
19.5, POS N
respectively, POS N
for POS N
imatinib POS N
and POS N
21.6 POS N
and POS N
17.6, POS N
respectively, POS N
for POS N
IFN POS N
(P POS N
<.001, POS N
ITT). POS N

There POS N
was POS N
a POS N
significant POS N
decline POS N
in POS N
TOI POS N
scores POS N
for POS N
the POS N
IFN POS N
treatment POS N
arm POS N
compared POS N
with POS N
preservation POS N
of POS N
baseline POS N
TOI POS N
scores POS N
in POS N
the POS N
imatinib POS N
arm POS N
(P POS N
<.001, POS N
ITT). POS N

Mean POS N
social/family POS N
and POS N
EWB POS N
scores POS N
were POS N
22.8 POS N
and POS N
19.5, POS N
respectively, POS N
for POS N
imatinib POS N
and POS N
21.6 POS N
and POS N
17.6, POS N
respectively, POS N
for POS N
IFN POS N
(P POS N
<.001, POS N
ITT). POS N

After POS N
crossing POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib, POS N
patients POS N
experienced POS N
a POS N
significant POS N
(P POS N
<.001) POS N
increase POS N
in POS N
TOI POS N
scores. POS N

Mean POS N
social/family POS N
and POS N
EWB POS N
scores POS N
were POS N
22.8 POS N
and POS N
19.5, POS N
respectively, POS N
for POS N
imatinib POS N
and POS N
21.6 POS N
and POS N
17.6, POS N
respectively, POS N
for POS N
IFN POS N
(P POS N
<.001, POS N
ITT). POS N

Imatinib POS N
offers POS N
clear POS N
QoL POS N
advantages POS N
over POS N
IFN POS N
as POS N
first-line POS N
treatment POS N
of POS N
chronic-phase POS N
CML. POS N

Mean POS N
social/family POS N
and POS N
EWB POS N
scores POS N
were POS N
22.8 POS N
and POS N
19.5, POS N
respectively, POS N
for POS N
imatinib POS N
and POS N
21.6 POS N
and POS N
17.6, POS N
respectively, POS N
for POS N
IFN POS N
(P POS N
<.001, POS N
ITT). POS N

patients POS N
who POS N
crossed POS N
over POS N
to POS N
imatinib POS N
reported POS N
higher POS N
QoL POS N
than POS N
those POS N
who POS N
remained POS N
on POS N
IFN. POS N

After POS N
crossing POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib, POS N
patients POS N
experienced POS N
a POS N
significant POS N
(P POS N
<.001) POS N
increase POS N
in POS N
TOI POS N
scores. POS N

Imatinib POS N
(Gleevec), POS N
a POS N
highly POS N
effective POS N
specific POS N
tyrosine POS N
kinase POS N
inhibitor, POS N
demonstrates POS N
a POS N
better POS N
side POS N
effect POS N
profile POS N
than POS N
interferon-alpha POS N
(IFN), POS N
which POS N
impairs POS N
patients' POS N
quality POS N
of POS N
life POS N
(QoL). POS N

After POS N
crossing POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib, POS N
patients POS N
experienced POS N
a POS N
significant POS N
(P POS N
<.001) POS N
increase POS N
in POS N
TOI POS N
scores. POS N

Two POS N
hundred POS N
sixty-one POS N
patients POS N
(50%) POS N
crossed POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib POS N
and POS N
11 POS N
(2%) POS N
crossed POS N
over POS N
from POS N
imatinib POS N
to POS N
IFN. POS N

After POS N
crossing POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib, POS N
patients POS N
experienced POS N
a POS N
significant POS N
(P POS N
<.001) POS N
increase POS N
in POS N
TOI POS N
scores. POS N

There POS N
was POS N
a POS N
significant POS N
decline POS N
in POS N
TOI POS N
scores POS N
for POS N
the POS N
IFN POS N
treatment POS N
arm POS N
compared POS N
with POS N
preservation POS N
of POS N
baseline POS N
TOI POS N
scores POS N
in POS N
the POS N
imatinib POS N
arm POS N
(P POS N
<.001, POS N
ITT). POS N

After POS N
crossing POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib, POS N
patients POS N
experienced POS N
a POS N
significant POS N
(P POS N
<.001) POS N
increase POS N
in POS N
TOI POS N
scores. POS N

Mean POS N
social/family POS N
and POS N
EWB POS N
scores POS N
were POS N
22.8 POS N
and POS N
19.5, POS N
respectively, POS N
for POS N
imatinib POS N
and POS N
21.6 POS N
and POS N
17.6, POS N
respectively, POS N
for POS N
IFN POS N
(P POS N
<.001, POS N
ITT). POS N

After POS N
crossing POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib, POS N
patients POS N
experienced POS N
a POS N
significant POS N
(P POS N
<.001) POS N
increase POS N
in POS N
TOI POS N
scores. POS N

Imatinib POS N
offers POS N
clear POS N
QoL POS N
advantages POS N
over POS N
IFN POS N
as POS N
first-line POS N
treatment POS N
of POS N
chronic-phase POS N
CML. POS N

After POS N
crossing POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib, POS N
patients POS N
experienced POS N
a POS N
significant POS N
(P POS N
<.001) POS N
increase POS N
in POS N
TOI POS N
scores. POS N

patients POS N
who POS N
crossed POS N
over POS N
to POS N
imatinib POS N
reported POS N
higher POS N
QoL POS N
than POS N
those POS N
who POS N
remained POS N
on POS N
IFN. POS N

Imatinib POS N
offers POS N
clear POS N
QoL POS N
advantages POS N
over POS N
IFN POS N
as POS N
first-line POS N
treatment POS N
of POS N
chronic-phase POS N
CML. POS N

Imatinib POS N
(Gleevec), POS N
a POS N
highly POS N
effective POS N
specific POS N
tyrosine POS N
kinase POS N
inhibitor, POS N
demonstrates POS N
a POS N
better POS N
side POS N
effect POS N
profile POS N
than POS N
interferon-alpha POS N
(IFN), POS N
which POS N
impairs POS N
patients' POS N
quality POS N
of POS N
life POS N
(QoL). POS N

Imatinib POS N
offers POS N
clear POS N
QoL POS N
advantages POS N
over POS N
IFN POS N
as POS N
first-line POS N
treatment POS N
of POS N
chronic-phase POS N
CML. POS N

Two POS N
hundred POS N
sixty-one POS N
patients POS N
(50%) POS N
crossed POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib POS N
and POS N
11 POS N
(2%) POS N
crossed POS N
over POS N
from POS N
imatinib POS N
to POS N
IFN. POS N

Imatinib POS N
offers POS N
clear POS N
QoL POS N
advantages POS N
over POS N
IFN POS N
as POS N
first-line POS N
treatment POS N
of POS N
chronic-phase POS N
CML. POS N

There POS N
was POS N
a POS N
significant POS N
decline POS N
in POS N
TOI POS N
scores POS N
for POS N
the POS N
IFN POS N
treatment POS N
arm POS N
compared POS N
with POS N
preservation POS N
of POS N
baseline POS N
TOI POS N
scores POS N
in POS N
the POS N
imatinib POS N
arm POS N
(P POS N
<.001, POS N
ITT). POS N

Imatinib POS N
offers POS N
clear POS N
QoL POS N
advantages POS N
over POS N
IFN POS N
as POS N
first-line POS N
treatment POS N
of POS N
chronic-phase POS N
CML. POS N

Mean POS N
social/family POS N
and POS N
EWB POS N
scores POS N
were POS N
22.8 POS N
and POS N
19.5, POS N
respectively, POS N
for POS N
imatinib POS N
and POS N
21.6 POS N
and POS N
17.6, POS N
respectively, POS N
for POS N
IFN POS N
(P POS N
<.001, POS N
ITT). POS N

Imatinib POS N
offers POS N
clear POS N
QoL POS N
advantages POS N
over POS N
IFN POS N
as POS N
first-line POS N
treatment POS N
of POS N
chronic-phase POS N
CML. POS N

After POS N
crossing POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib, POS N
patients POS N
experienced POS N
a POS N
significant POS N
(P POS N
<.001) POS N
increase POS N
in POS N
TOI POS N
scores. POS N

Imatinib POS N
offers POS N
clear POS N
QoL POS N
advantages POS N
over POS N
IFN POS N
as POS N
first-line POS N
treatment POS N
of POS N
chronic-phase POS N
CML. POS N

patients POS N
who POS N
crossed POS N
over POS N
to POS N
imatinib POS N
reported POS N
higher POS N
QoL POS N
than POS N
those POS N
who POS N
remained POS N
on POS N
IFN. POS N

patients POS N
who POS N
crossed POS N
over POS N
to POS N
imatinib POS N
reported POS N
higher POS N
QoL POS N
than POS N
those POS N
who POS N
remained POS N
on POS N
IFN. POS N

Imatinib POS N
(Gleevec), POS N
a POS N
highly POS N
effective POS N
specific POS N
tyrosine POS N
kinase POS N
inhibitor, POS N
demonstrates POS N
a POS N
better POS N
side POS N
effect POS N
profile POS N
than POS N
interferon-alpha POS N
(IFN), POS N
which POS N
impairs POS N
patients' POS N
quality POS N
of POS N
life POS N
(QoL). POS N

patients POS N
who POS N
crossed POS N
over POS N
to POS N
imatinib POS N
reported POS N
higher POS N
QoL POS N
than POS N
those POS N
who POS N
remained POS N
on POS N
IFN. POS N

Two POS N
hundred POS N
sixty-one POS N
patients POS N
(50%) POS N
crossed POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib POS N
and POS N
11 POS N
(2%) POS N
crossed POS N
over POS N
from POS N
imatinib POS N
to POS N
IFN. POS N

patients POS N
who POS N
crossed POS N
over POS N
to POS N
imatinib POS N
reported POS N
higher POS N
QoL POS N
than POS N
those POS N
who POS N
remained POS N
on POS N
IFN. POS N

There POS N
was POS N
a POS N
significant POS N
decline POS N
in POS N
TOI POS N
scores POS N
for POS N
the POS N
IFN POS N
treatment POS N
arm POS N
compared POS N
with POS N
preservation POS N
of POS N
baseline POS N
TOI POS N
scores POS N
in POS N
the POS N
imatinib POS N
arm POS N
(P POS N
<.001, POS N
ITT). POS N

patients POS N
who POS N
crossed POS N
over POS N
to POS N
imatinib POS N
reported POS N
higher POS N
QoL POS N
than POS N
those POS N
who POS N
remained POS N
on POS N
IFN. POS N

Mean POS N
social/family POS N
and POS N
EWB POS N
scores POS N
were POS N
22.8 POS N
and POS N
19.5, POS N
respectively, POS N
for POS N
imatinib POS N
and POS N
21.6 POS N
and POS N
17.6, POS N
respectively, POS N
for POS N
IFN POS N
(P POS N
<.001, POS N
ITT). POS N

patients POS N
who POS N
crossed POS N
over POS N
to POS N
imatinib POS N
reported POS N
higher POS N
QoL POS N
than POS N
those POS N
who POS N
remained POS N
on POS N
IFN. POS N

After POS N
crossing POS N
over POS N
from POS N
IFN POS N
to POS N
imatinib, POS N
patients POS N
experienced POS N
a POS N
significant POS N
(P POS N
<.001) POS N
increase POS N
in POS N
TOI POS N
scores. POS N

patients POS N
who POS N
crossed POS N
over POS N
to POS N
imatinib POS N
reported POS N
higher POS N
QoL POS N
than POS N
those POS N
who POS N
remained POS N
on POS N
IFN. POS N

Imatinib POS N
offers POS N
clear POS N
QoL POS N
advantages POS N
over POS N
IFN POS N
as POS N
first-line POS N
treatment POS N
of POS N
chronic-phase POS N
CML. POS N

vitamin POS N
C POS N
and/or POS N
E POS N
improve POS N
fasting POS N
blood POS N
sugar POS N
(FBS), POS N
HbA1c, POS N
lipid POS N
profile, POS N
insulin, POS N
homeostasis POS N
model POS N
assessment POS N
of POS N
insulin POS N
resistance POS N
(HOMA-IR), POS N
reduced POS N
glutathione POS N
(GSH); POS N
and POS N
Quantitative POS N
Insulin POS N
Sensitivity POS N
Check POS N
Index POS N
(QISCI) POS N
compared POS N
with POS N
diabetic POS N
patients POS N
group POS N
that POS N
received POS N
placebo. POS N

there POS N
has POS N
been POS N
an POS N
increasing POS N
interest POS N
in POS N
the POS N
influence POS N
of POS N
antioxidant POS N
vitamins POS N
on POS N
the POS N
efficacy POS N
of POS N
oral POS N
hypoglycemic POS N
therapy POS N
in POS N
type POS N
2 POS N
diabetic POS N
patients POS N
(T2DM). POS N

vitamin POS N
C POS N
and/or POS N
E POS N
improve POS N
fasting POS N
blood POS N
sugar POS N
(FBS), POS N
HbA1c, POS N
lipid POS N
profile, POS N
insulin, POS N
homeostasis POS N
model POS N
assessment POS N
of POS N
insulin POS N
resistance POS N
(HOMA-IR), POS N
reduced POS N
glutathione POS N
(GSH); POS N
and POS N
Quantitative POS N
Insulin POS N
Sensitivity POS N
Check POS N
Index POS N
(QISCI) POS N
compared POS N
with POS N
diabetic POS N
patients POS N
group POS N
that POS N
received POS N
placebo. POS N

This POS N
study POS N
provided POS N
additional POS N
evidence POS N
on POS N
the POS N
beneficial POS N
effects POS N
of POS N
supplementing POS N
antioxidant POS N
vitamins POS N
in POS N
T2DM POS N
which POS N
could POS N
improve POS N
the POS N
clinical POS N
condition POS N
and POS N
attenuate POS N
or POS N
prevent POS N
diabetic POS N
pathogenesis POS N
and POS N
complications POS N
that, POS N
secondly POS N
to POS N
poor POS N
glycemic POS N
control, POS N
could POS N
attribute POS N
to POS N
the POS N
imbalance POS N
between POS N
the POS N
decline POS N
in POS N
the POS N
endogenous POS N
antioxidants POS N
and POS N
increasing POS N
production POS N
of POS N
the POS N
reactive POS N
oxygen POS N
species POS N
leading POS N
to POS N
the POS N
oxidant-mediated POS N
damage POS N
present POS N
in POS N
the POS N
diabetic POS N
context. POS N

there POS N
has POS N
been POS N
an POS N
increasing POS N
interest POS N
in POS N
the POS N
influence POS N
of POS N
antioxidant POS N
vitamins POS N
on POS N
the POS N
efficacy POS N
of POS N
oral POS N
hypoglycemic POS N
therapy POS N
in POS N
type POS N
2 POS N
diabetic POS N
patients POS N
(T2DM). POS N

vitamin POS N
C POS N
and/or POS N
E POS N
improve POS N
fasting POS N
blood POS N
sugar POS N
(FBS), POS N
HbA1c, POS N
lipid POS N
profile, POS N
insulin, POS N
homeostasis POS N
model POS N
assessment POS N
of POS N
insulin POS N
resistance POS N
(HOMA-IR), POS N
reduced POS N
glutathione POS N
(GSH); POS N
and POS N
Quantitative POS N
Insulin POS N
Sensitivity POS N
Check POS N
Index POS N
(QISCI) POS N
compared POS N
with POS N
diabetic POS N
patients POS N
group POS N
that POS N
received POS N
placebo. POS N

there POS N
has POS N
been POS N
an POS N
increasing POS N
interest POS N
in POS N
the POS N
influence POS N
of POS N
antioxidant POS N
vitamins POS N
on POS N
the POS N
efficacy POS N
of POS N
oral POS N
hypoglycemic POS N
therapy POS N
in POS N
type POS N
2 POS N
diabetic POS N
patients POS N
(T2DM). POS N

This POS N
study POS N
provided POS N
additional POS N
evidence POS N
on POS N
the POS N
beneficial POS N
effects POS N
of POS N
supplementing POS N
antioxidant POS N
vitamins POS N
in POS N
T2DM POS N
which POS N
could POS N
improve POS N
the POS N
clinical POS N
condition POS N
and POS N
attenuate POS N
or POS N
prevent POS N
diabetic POS N
pathogenesis POS N
and POS N
complications POS N
that, POS N
secondly POS N
to POS N
poor POS N
glycemic POS N
control, POS N
could POS N
attribute POS N
to POS N
the POS N
imbalance POS N
between POS N
the POS N
decline POS N
in POS N
the POS N
endogenous POS N
antioxidants POS N
and POS N
increasing POS N
production POS N
of POS N
the POS N
reactive POS N
oxygen POS N
species POS N
leading POS N
to POS N
the POS N
oxidant-mediated POS N
damage POS N
present POS N
in POS N
the POS N
diabetic POS N
context. POS N

This POS N
study POS N
provided POS N
additional POS N
evidence POS N
on POS N
the POS N
beneficial POS N
effects POS N
of POS N
supplementing POS N
antioxidant POS N
vitamins POS N
in POS N
T2DM POS N
which POS N
could POS N
improve POS N
the POS N
clinical POS N
condition POS N
and POS N
attenuate POS N
or POS N
prevent POS N
diabetic POS N
pathogenesis POS N
and POS N
complications POS N
that, POS N
secondly POS N
to POS N
poor POS N
glycemic POS N
control, POS N
could POS N
attribute POS N
to POS N
the POS N
imbalance POS N
between POS N
the POS N
decline POS N
in POS N
the POS N
endogenous POS N
antioxidants POS N
and POS N
increasing POS N
production POS N
of POS N
the POS N
reactive POS N
oxygen POS N
species POS N
leading POS N
to POS N
the POS N
oxidant-mediated POS N
damage POS N
present POS N
in POS N
the POS N
diabetic POS N
context. POS N

vitamin POS N
C POS N
and/or POS N
E POS N
improve POS N
fasting POS N
blood POS N
sugar POS N
(FBS), POS N
HbA1c, POS N
lipid POS N
profile, POS N
insulin, POS N
homeostasis POS N
model POS N
assessment POS N
of POS N
insulin POS N
resistance POS N
(HOMA-IR), POS N
reduced POS N
glutathione POS N
(GSH); POS N
and POS N
Quantitative POS N
Insulin POS N
Sensitivity POS N
Check POS N
Index POS N
(QISCI) POS N
compared POS N
with POS N
diabetic POS N
patients POS N
group POS N
that POS N
received POS N
placebo. POS N

This POS N
study POS N
provided POS N
additional POS N
evidence POS N
on POS N
the POS N
beneficial POS N
effects POS N
of POS N
supplementing POS N
antioxidant POS N
vitamins POS N
in POS N
T2DM POS N
which POS N
could POS N
improve POS N
the POS N
clinical POS N
condition POS N
and POS N
attenuate POS N
or POS N
prevent POS N
diabetic POS N
pathogenesis POS N
and POS N
complications POS N
that, POS N
secondly POS N
to POS N
poor POS N
glycemic POS N
control, POS N
could POS N
attribute POS N
to POS N
the POS N
imbalance POS N
between POS N
the POS N
decline POS N
in POS N
the POS N
endogenous POS N
antioxidants POS N
and POS N
increasing POS N
production POS N
of POS N
the POS N
reactive POS N
oxygen POS N
species POS N
leading POS N
to POS N
the POS N
oxidant-mediated POS N
damage POS N
present POS N
in POS N
the POS N
diabetic POS N
context. POS N

there POS N
has POS N
been POS N
an POS N
increasing POS N
interest POS N
in POS N
the POS N
influence POS N
of POS N
antioxidant POS N
vitamins POS N
on POS N
the POS N
efficacy POS N
of POS N
oral POS N
hypoglycemic POS N
therapy POS N
in POS N
type POS N
2 POS N
diabetic POS N
patients POS N
(T2DM). POS N

Low POS N
serum POS N
vitamin POS N
D POS N
has POS N
been POS N
associated POS N
with POS N
metabolic POS N
syndrome POS N
and POS N
Non-alcoholic POS N
fatty POS N
liver POS N
disease POS N
(NAFLD). POS N

significant POS N
reduction POS N
of POS N
serum POS N
alkaline POS N
phosphatase POS N
and POS N
GGT POS N
were POS N
seen POS N
with POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
supplementation POS N
from POS N
baseline POS N
levels, POS N

Low POS N
serum POS N
vitamin POS N
D POS N
has POS N
been POS N
associated POS N
with POS N
metabolic POS N
syndrome POS N
and POS N
Non-alcoholic POS N
fatty POS N
liver POS N
disease POS N
(NAFLD). POS N

no POS N
beneficial POS N
effects POS N
was POS N
seen POS N
when POS N
comparing POS N
vitamin POS N
D, POS N
calcitriol POS N
and POS N
placebo POS N
groups POS N
at POS N
the POS N
end POS N
of POS N
trial. POS N

Low POS N
serum POS N
vitamin POS N
D POS N
has POS N
been POS N
associated POS N
with POS N
metabolic POS N
syndrome POS N
and POS N
Non-alcoholic POS N
fatty POS N
liver POS N
disease POS N
(NAFLD). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
placebo, POS N
calcitriol, POS N
vitamin POS N
D POS N
groups POS N
in POS N
terms POS N
of POS N
serum POS N
aminotransferase, POS N
alkaline POS N
phosphatase, POS N
serum POS N
GGT POS N
and POS N
lipid POS N
profile POS N
(P > 0.05). POS N

Low POS N
serum POS N
vitamin POS N
D POS N
has POS N
been POS N
associated POS N
with POS N
metabolic POS N
syndrome POS N
and POS N
Non-alcoholic POS N
fatty POS N
liver POS N
disease POS N
(NAFLD). POS N

Serum POS N
and POS N
gamma POS N
glutamyl POS N
transferase POS N
(GGT) POS N
level POS N
was POS N
also POS N
significantly POS N
decreased POS N
compared POS N
to POS N
the POS N
baseline POS N
levels POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment POS N
with POS N
vitamin POS N
D. POS N

Low POS N
serum POS N
vitamin POS N
D POS N
has POS N
been POS N
associated POS N
with POS N
metabolic POS N
syndrome POS N
and POS N
Non-alcoholic POS N
fatty POS N
liver POS N
disease POS N
(NAFLD). POS N

After POS N
12 POS N
weeks POS N
of POS N
treatment, POS N
serum POS N
alkaline POS N
phosphatase POS N
levels POS N
was POS N
significantly POS N
decreased POS N
from POS N
baseline POS N
levels POS N
in POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
treated POS N
groups POS N
(P < 0.05). POS N

significant POS N
reduction POS N
of POS N
serum POS N
alkaline POS N
phosphatase POS N
and POS N
GGT POS N
were POS N
seen POS N
with POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
supplementation POS N
from POS N
baseline POS N
levels, POS N

Low POS N
serum POS N
vitamin POS N
D POS N
has POS N
been POS N
associated POS N
with POS N
metabolic POS N
syndrome POS N
and POS N
Non-alcoholic POS N
fatty POS N
liver POS N
disease POS N
(NAFLD). POS N

significant POS N
reduction POS N
of POS N
serum POS N
alkaline POS N
phosphatase POS N
and POS N
GGT POS N
were POS N
seen POS N
with POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
supplementation POS N
from POS N
baseline POS N
levels, POS N

no POS N
beneficial POS N
effects POS N
was POS N
seen POS N
when POS N
comparing POS N
vitamin POS N
D, POS N
calcitriol POS N
and POS N
placebo POS N
groups POS N
at POS N
the POS N
end POS N
of POS N
trial. POS N

significant POS N
reduction POS N
of POS N
serum POS N
alkaline POS N
phosphatase POS N
and POS N
GGT POS N
were POS N
seen POS N
with POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
supplementation POS N
from POS N
baseline POS N
levels, POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
placebo, POS N
calcitriol, POS N
vitamin POS N
D POS N
groups POS N
in POS N
terms POS N
of POS N
serum POS N
aminotransferase, POS N
alkaline POS N
phosphatase, POS N
serum POS N
GGT POS N
and POS N
lipid POS N
profile POS N
(P > 0.05). POS N

significant POS N
reduction POS N
of POS N
serum POS N
alkaline POS N
phosphatase POS N
and POS N
GGT POS N
were POS N
seen POS N
with POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
supplementation POS N
from POS N
baseline POS N
levels, POS N

Serum POS N
and POS N
gamma POS N
glutamyl POS N
transferase POS N
(GGT) POS N
level POS N
was POS N
also POS N
significantly POS N
decreased POS N
compared POS N
to POS N
the POS N
baseline POS N
levels POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment POS N
with POS N
vitamin POS N
D. POS N

significant POS N
reduction POS N
of POS N
serum POS N
alkaline POS N
phosphatase POS N
and POS N
GGT POS N
were POS N
seen POS N
with POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
supplementation POS N
from POS N
baseline POS N
levels, POS N

After POS N
12 POS N
weeks POS N
of POS N
treatment, POS N
serum POS N
alkaline POS N
phosphatase POS N
levels POS N
was POS N
significantly POS N
decreased POS N
from POS N
baseline POS N
levels POS N
in POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
treated POS N
groups POS N
(P < 0.05). POS N

no POS N
beneficial POS N
effects POS N
was POS N
seen POS N
when POS N
comparing POS N
vitamin POS N
D, POS N
calcitriol POS N
and POS N
placebo POS N
groups POS N
at POS N
the POS N
end POS N
of POS N
trial. POS N

Low POS N
serum POS N
vitamin POS N
D POS N
has POS N
been POS N
associated POS N
with POS N
metabolic POS N
syndrome POS N
and POS N
Non-alcoholic POS N
fatty POS N
liver POS N
disease POS N
(NAFLD). POS N

no POS N
beneficial POS N
effects POS N
was POS N
seen POS N
when POS N
comparing POS N
vitamin POS N
D, POS N
calcitriol POS N
and POS N
placebo POS N
groups POS N
at POS N
the POS N
end POS N
of POS N
trial. POS N

significant POS N
reduction POS N
of POS N
serum POS N
alkaline POS N
phosphatase POS N
and POS N
GGT POS N
were POS N
seen POS N
with POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
supplementation POS N
from POS N
baseline POS N
levels, POS N

no POS N
beneficial POS N
effects POS N
was POS N
seen POS N
when POS N
comparing POS N
vitamin POS N
D, POS N
calcitriol POS N
and POS N
placebo POS N
groups POS N
at POS N
the POS N
end POS N
of POS N
trial. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
placebo, POS N
calcitriol, POS N
vitamin POS N
D POS N
groups POS N
in POS N
terms POS N
of POS N
serum POS N
aminotransferase, POS N
alkaline POS N
phosphatase, POS N
serum POS N
GGT POS N
and POS N
lipid POS N
profile POS N
(P > 0.05). POS N

no POS N
beneficial POS N
effects POS N
was POS N
seen POS N
when POS N
comparing POS N
vitamin POS N
D, POS N
calcitriol POS N
and POS N
placebo POS N
groups POS N
at POS N
the POS N
end POS N
of POS N
trial. POS N

Serum POS N
and POS N
gamma POS N
glutamyl POS N
transferase POS N
(GGT) POS N
level POS N
was POS N
also POS N
significantly POS N
decreased POS N
compared POS N
to POS N
the POS N
baseline POS N
levels POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment POS N
with POS N
vitamin POS N
D. POS N

no POS N
beneficial POS N
effects POS N
was POS N
seen POS N
when POS N
comparing POS N
vitamin POS N
D, POS N
calcitriol POS N
and POS N
placebo POS N
groups POS N
at POS N
the POS N
end POS N
of POS N
trial. POS N

After POS N
12 POS N
weeks POS N
of POS N
treatment, POS N
serum POS N
alkaline POS N
phosphatase POS N
levels POS N
was POS N
significantly POS N
decreased POS N
from POS N
baseline POS N
levels POS N
in POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
treated POS N
groups POS N
(P < 0.05). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
placebo, POS N
calcitriol, POS N
vitamin POS N
D POS N
groups POS N
in POS N
terms POS N
of POS N
serum POS N
aminotransferase, POS N
alkaline POS N
phosphatase, POS N
serum POS N
GGT POS N
and POS N
lipid POS N
profile POS N
(P > 0.05). POS N

Low POS N
serum POS N
vitamin POS N
D POS N
has POS N
been POS N
associated POS N
with POS N
metabolic POS N
syndrome POS N
and POS N
Non-alcoholic POS N
fatty POS N
liver POS N
disease POS N
(NAFLD). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
placebo, POS N
calcitriol, POS N
vitamin POS N
D POS N
groups POS N
in POS N
terms POS N
of POS N
serum POS N
aminotransferase, POS N
alkaline POS N
phosphatase, POS N
serum POS N
GGT POS N
and POS N
lipid POS N
profile POS N
(P > 0.05). POS N

significant POS N
reduction POS N
of POS N
serum POS N
alkaline POS N
phosphatase POS N
and POS N
GGT POS N
were POS N
seen POS N
with POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
supplementation POS N
from POS N
baseline POS N
levels, POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
placebo, POS N
calcitriol, POS N
vitamin POS N
D POS N
groups POS N
in POS N
terms POS N
of POS N
serum POS N
aminotransferase, POS N
alkaline POS N
phosphatase, POS N
serum POS N
GGT POS N
and POS N
lipid POS N
profile POS N
(P > 0.05). POS N

no POS N
beneficial POS N
effects POS N
was POS N
seen POS N
when POS N
comparing POS N
vitamin POS N
D, POS N
calcitriol POS N
and POS N
placebo POS N
groups POS N
at POS N
the POS N
end POS N
of POS N
trial. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
placebo, POS N
calcitriol, POS N
vitamin POS N
D POS N
groups POS N
in POS N
terms POS N
of POS N
serum POS N
aminotransferase, POS N
alkaline POS N
phosphatase, POS N
serum POS N
GGT POS N
and POS N
lipid POS N
profile POS N
(P > 0.05). POS N

Serum POS N
and POS N
gamma POS N
glutamyl POS N
transferase POS N
(GGT) POS N
level POS N
was POS N
also POS N
significantly POS N
decreased POS N
compared POS N
to POS N
the POS N
baseline POS N
levels POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment POS N
with POS N
vitamin POS N
D. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
placebo, POS N
calcitriol, POS N
vitamin POS N
D POS N
groups POS N
in POS N
terms POS N
of POS N
serum POS N
aminotransferase, POS N
alkaline POS N
phosphatase, POS N
serum POS N
GGT POS N
and POS N
lipid POS N
profile POS N
(P > 0.05). POS N

After POS N
12 POS N
weeks POS N
of POS N
treatment, POS N
serum POS N
alkaline POS N
phosphatase POS N
levels POS N
was POS N
significantly POS N
decreased POS N
from POS N
baseline POS N
levels POS N
in POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
treated POS N
groups POS N
(P < 0.05). POS N

Serum POS N
and POS N
gamma POS N
glutamyl POS N
transferase POS N
(GGT) POS N
level POS N
was POS N
also POS N
significantly POS N
decreased POS N
compared POS N
to POS N
the POS N
baseline POS N
levels POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment POS N
with POS N
vitamin POS N
D. POS N

Low POS N
serum POS N
vitamin POS N
D POS N
has POS N
been POS N
associated POS N
with POS N
metabolic POS N
syndrome POS N
and POS N
Non-alcoholic POS N
fatty POS N
liver POS N
disease POS N
(NAFLD). POS N

Serum POS N
and POS N
gamma POS N
glutamyl POS N
transferase POS N
(GGT) POS N
level POS N
was POS N
also POS N
significantly POS N
decreased POS N
compared POS N
to POS N
the POS N
baseline POS N
levels POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment POS N
with POS N
vitamin POS N
D. POS N

significant POS N
reduction POS N
of POS N
serum POS N
alkaline POS N
phosphatase POS N
and POS N
GGT POS N
were POS N
seen POS N
with POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
supplementation POS N
from POS N
baseline POS N
levels, POS N

Serum POS N
and POS N
gamma POS N
glutamyl POS N
transferase POS N
(GGT) POS N
level POS N
was POS N
also POS N
significantly POS N
decreased POS N
compared POS N
to POS N
the POS N
baseline POS N
levels POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment POS N
with POS N
vitamin POS N
D. POS N

no POS N
beneficial POS N
effects POS N
was POS N
seen POS N
when POS N
comparing POS N
vitamin POS N
D, POS N
calcitriol POS N
and POS N
placebo POS N
groups POS N
at POS N
the POS N
end POS N
of POS N
trial. POS N

Serum POS N
and POS N
gamma POS N
glutamyl POS N
transferase POS N
(GGT) POS N
level POS N
was POS N
also POS N
significantly POS N
decreased POS N
compared POS N
to POS N
the POS N
baseline POS N
levels POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment POS N
with POS N
vitamin POS N
D. POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
placebo, POS N
calcitriol, POS N
vitamin POS N
D POS N
groups POS N
in POS N
terms POS N
of POS N
serum POS N
aminotransferase, POS N
alkaline POS N
phosphatase, POS N
serum POS N
GGT POS N
and POS N
lipid POS N
profile POS N
(P > 0.05). POS N

Serum POS N
and POS N
gamma POS N
glutamyl POS N
transferase POS N
(GGT) POS N
level POS N
was POS N
also POS N
significantly POS N
decreased POS N
compared POS N
to POS N
the POS N
baseline POS N
levels POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment POS N
with POS N
vitamin POS N
D. POS N

After POS N
12 POS N
weeks POS N
of POS N
treatment, POS N
serum POS N
alkaline POS N
phosphatase POS N
levels POS N
was POS N
significantly POS N
decreased POS N
from POS N
baseline POS N
levels POS N
in POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
treated POS N
groups POS N
(P < 0.05). POS N

After POS N
12 POS N
weeks POS N
of POS N
treatment, POS N
serum POS N
alkaline POS N
phosphatase POS N
levels POS N
was POS N
significantly POS N
decreased POS N
from POS N
baseline POS N
levels POS N
in POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
treated POS N
groups POS N
(P < 0.05). POS N

Low POS N
serum POS N
vitamin POS N
D POS N
has POS N
been POS N
associated POS N
with POS N
metabolic POS N
syndrome POS N
and POS N
Non-alcoholic POS N
fatty POS N
liver POS N
disease POS N
(NAFLD). POS N

After POS N
12 POS N
weeks POS N
of POS N
treatment, POS N
serum POS N
alkaline POS N
phosphatase POS N
levels POS N
was POS N
significantly POS N
decreased POS N
from POS N
baseline POS N
levels POS N
in POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
treated POS N
groups POS N
(P < 0.05). POS N

significant POS N
reduction POS N
of POS N
serum POS N
alkaline POS N
phosphatase POS N
and POS N
GGT POS N
were POS N
seen POS N
with POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
supplementation POS N
from POS N
baseline POS N
levels, POS N

After POS N
12 POS N
weeks POS N
of POS N
treatment, POS N
serum POS N
alkaline POS N
phosphatase POS N
levels POS N
was POS N
significantly POS N
decreased POS N
from POS N
baseline POS N
levels POS N
in POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
treated POS N
groups POS N
(P < 0.05). POS N

no POS N
beneficial POS N
effects POS N
was POS N
seen POS N
when POS N
comparing POS N
vitamin POS N
D, POS N
calcitriol POS N
and POS N
placebo POS N
groups POS N
at POS N
the POS N
end POS N
of POS N
trial. POS N

After POS N
12 POS N
weeks POS N
of POS N
treatment, POS N
serum POS N
alkaline POS N
phosphatase POS N
levels POS N
was POS N
significantly POS N
decreased POS N
from POS N
baseline POS N
levels POS N
in POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
treated POS N
groups POS N
(P < 0.05). POS N

There POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
between POS N
placebo, POS N
calcitriol, POS N
vitamin POS N
D POS N
groups POS N
in POS N
terms POS N
of POS N
serum POS N
aminotransferase, POS N
alkaline POS N
phosphatase, POS N
serum POS N
GGT POS N
and POS N
lipid POS N
profile POS N
(P > 0.05). POS N

After POS N
12 POS N
weeks POS N
of POS N
treatment, POS N
serum POS N
alkaline POS N
phosphatase POS N
levels POS N
was POS N
significantly POS N
decreased POS N
from POS N
baseline POS N
levels POS N
in POS N
vitamin POS N
D POS N
and POS N
calcitriol POS N
treated POS N
groups POS N
(P < 0.05). POS N

Serum POS N
and POS N
gamma POS N
glutamyl POS N
transferase POS N
(GGT) POS N
level POS N
was POS N
also POS N
significantly POS N
decreased POS N
compared POS N
to POS N
the POS N
baseline POS N
levels POS N
after POS N
12 POS N
weeks POS N
of POS N
treatment POS N
with POS N
vitamin POS N
D. POS N

Compared POS N
with POS N
the POS N
spironolactone POS N
group POS N
(n=95), POS N
the POS N
clonidine POS N
group POS N
(n=92) POS N
presented POS N
similar POS N
rates POS N
of POS N
achieving POS N
the POS N
primary POS N
end POS N
point POS N
(20.5% POS N
versus POS N
20.8%, POS N
respectively; POS N
relative POS N
risk, POS N
1.01 POS N
[0.55-1.88]; POS N
P=1.00). POS N

Secondary POS N
end POS N
point POS N
analysis POS N
showed POS N
similar POS N
office POS N
BP POS N
(33.3% POS N
versus POS N
29.3%) POS N
and POS N
ambulatory POS N
BP POS N
monitoring POS N
(44% POS N
versus POS N
46.2%) POS N
control POS N
for POS N
spironolactone POS N
and POS N
clonidine, POS N
respectively. POS N

Compared POS N
with POS N
the POS N
spironolactone POS N
group POS N
(n=95), POS N
the POS N
clonidine POS N
group POS N
(n=92) POS N
presented POS N
similar POS N
rates POS N
of POS N
achieving POS N
the POS N
primary POS N
end POS N
point POS N
(20.5% POS N
versus POS N
20.8%, POS N
respectively; POS N
relative POS N
risk, POS N
1.01 POS N
[0.55-1.88]; POS N
P=1.00). POS N

spironolactone POS N
promoted POS N
greater POS N
decrease POS N
in POS N
24-h POS N
systolic POS N
and POS N
diastolic POS N
BP POS N
and POS N
diastolic POS N
daytime POS N
ambulatory POS N
BP POS N
than POS N
clonidine. POS N

Compared POS N
with POS N
the POS N
spironolactone POS N
group POS N
(n=95), POS N
the POS N
clonidine POS N
group POS N
(n=92) POS N
presented POS N
similar POS N
rates POS N
of POS N
achieving POS N
the POS N
primary POS N
end POS N
point POS N
(20.5% POS N
versus POS N
20.8%, POS N
respectively; POS N
relative POS N
risk, POS N
1.01 POS N
[0.55-1.88]; POS N
P=1.00). POS N

clonidine POS N
was POS N
not POS N
superior POS N
to POS N
spironolactone POS N
in POS N
true POS N
resistant POS N
hypertensive POS N
patients, POS N
but POS N
the POS N
overall POS N
BP POS N
control POS N
was POS N
low POS N
(≈21%). POS N

Compared POS N
with POS N
the POS N
spironolactone POS N
group POS N
(n=95), POS N
the POS N
clonidine POS N
group POS N
(n=92) POS N
presented POS N
similar POS N
rates POS N
of POS N
achieving POS N
the POS N
primary POS N
end POS N
point POS N
(20.5% POS N
versus POS N
20.8%, POS N
respectively; POS N
relative POS N
risk, POS N
1.01 POS N
[0.55-1.88]; POS N
P=1.00). POS N

spironolactone POS N
is POS N
preferable POS N
for POS N
the POS N
fourth-drug POS N
therapy. POS N

Secondary POS N
end POS N
point POS N
analysis POS N
showed POS N
similar POS N
office POS N
BP POS N
(33.3% POS N
versus POS N
29.3%) POS N
and POS N
ambulatory POS N
BP POS N
monitoring POS N
(44% POS N
versus POS N
46.2%) POS N
control POS N
for POS N
spironolactone POS N
and POS N
clonidine, POS N
respectively. POS N

Compared POS N
with POS N
the POS N
spironolactone POS N
group POS N
(n=95), POS N
the POS N
clonidine POS N
group POS N
(n=92) POS N
presented POS N
similar POS N
rates POS N
of POS N
achieving POS N
the POS N
primary POS N
end POS N
point POS N
(20.5% POS N
versus POS N
20.8%, POS N
respectively; POS N
relative POS N
risk, POS N
1.01 POS N
[0.55-1.88]; POS N
P=1.00). POS N

Secondary POS N
end POS N
point POS N
analysis POS N
showed POS N
similar POS N
office POS N
BP POS N
(33.3% POS N
versus POS N
29.3%) POS N
and POS N
ambulatory POS N
BP POS N
monitoring POS N
(44% POS N
versus POS N
46.2%) POS N
control POS N
for POS N
spironolactone POS N
and POS N
clonidine, POS N
respectively. POS N

spironolactone POS N
promoted POS N
greater POS N
decrease POS N
in POS N
24-h POS N
systolic POS N
and POS N
diastolic POS N
BP POS N
and POS N
diastolic POS N
daytime POS N
ambulatory POS N
BP POS N
than POS N
clonidine. POS N

Secondary POS N
end POS N
point POS N
analysis POS N
showed POS N
similar POS N
office POS N
BP POS N
(33.3% POS N
versus POS N
29.3%) POS N
and POS N
ambulatory POS N
BP POS N
monitoring POS N
(44% POS N
versus POS N
46.2%) POS N
control POS N
for POS N
spironolactone POS N
and POS N
clonidine, POS N
respectively. POS N

clonidine POS N
was POS N
not POS N
superior POS N
to POS N
spironolactone POS N
in POS N
true POS N
resistant POS N
hypertensive POS N
patients, POS N
but POS N
the POS N
overall POS N
BP POS N
control POS N
was POS N
low POS N
(≈21%). POS N

Secondary POS N
end POS N
point POS N
analysis POS N
showed POS N
similar POS N
office POS N
BP POS N
(33.3% POS N
versus POS N
29.3%) POS N
and POS N
ambulatory POS N
BP POS N
monitoring POS N
(44% POS N
versus POS N
46.2%) POS N
control POS N
for POS N
spironolactone POS N
and POS N
clonidine, POS N
respectively. POS N

spironolactone POS N
is POS N
preferable POS N
for POS N
the POS N
fourth-drug POS N
therapy. POS N

spironolactone POS N
promoted POS N
greater POS N
decrease POS N
in POS N
24-h POS N
systolic POS N
and POS N
diastolic POS N
BP POS N
and POS N
diastolic POS N
daytime POS N
ambulatory POS N
BP POS N
than POS N
clonidine. POS N

Compared POS N
with POS N
the POS N
spironolactone POS N
group POS N
(n=95), POS N
the POS N
clonidine POS N
group POS N
(n=92) POS N
presented POS N
similar POS N
rates POS N
of POS N
achieving POS N
the POS N
primary POS N
end POS N
point POS N
(20.5% POS N
versus POS N
20.8%, POS N
respectively; POS N
relative POS N
risk, POS N
1.01 POS N
[0.55-1.88]; POS N
P=1.00). POS N

spironolactone POS N
promoted POS N
greater POS N
decrease POS N
in POS N
24-h POS N
systolic POS N
and POS N
diastolic POS N
BP POS N
and POS N
diastolic POS N
daytime POS N
ambulatory POS N
BP POS N
than POS N
clonidine. POS N

Secondary POS N
end POS N
point POS N
analysis POS N
showed POS N
similar POS N
office POS N
BP POS N
(33.3% POS N
versus POS N
29.3%) POS N
and POS N
ambulatory POS N
BP POS N
monitoring POS N
(44% POS N
versus POS N
46.2%) POS N
control POS N
for POS N
spironolactone POS N
and POS N
clonidine, POS N
respectively. POS N

spironolactone POS N
promoted POS N
greater POS N
decrease POS N
in POS N
24-h POS N
systolic POS N
and POS N
diastolic POS N
BP POS N
and POS N
diastolic POS N
daytime POS N
ambulatory POS N
BP POS N
than POS N
clonidine. POS N

clonidine POS N
was POS N
not POS N
superior POS N
to POS N
spironolactone POS N
in POS N
true POS N
resistant POS N
hypertensive POS N
patients, POS N
but POS N
the POS N
overall POS N
BP POS N
control POS N
was POS N
low POS N
(≈21%). POS N

spironolactone POS N
promoted POS N
greater POS N
decrease POS N
in POS N
24-h POS N
systolic POS N
and POS N
diastolic POS N
BP POS N
and POS N
diastolic POS N
daytime POS N
ambulatory POS N
BP POS N
than POS N
clonidine. POS N

spironolactone POS N
is POS N
preferable POS N
for POS N
the POS N
fourth-drug POS N
therapy. POS N

clonidine POS N
was POS N
not POS N
superior POS N
to POS N
spironolactone POS N
in POS N
true POS N
resistant POS N
hypertensive POS N
patients, POS N
but POS N
the POS N
overall POS N
BP POS N
control POS N
was POS N
low POS N
(≈21%). POS N

Compared POS N
with POS N
the POS N
spironolactone POS N
group POS N
(n=95), POS N
the POS N
clonidine POS N
group POS N
(n=92) POS N
presented POS N
similar POS N
rates POS N
of POS N
achieving POS N
the POS N
primary POS N
end POS N
point POS N
(20.5% POS N
versus POS N
20.8%, POS N
respectively; POS N
relative POS N
risk, POS N
1.01 POS N
[0.55-1.88]; POS N
P=1.00). POS N

clonidine POS N
was POS N
not POS N
superior POS N
to POS N
spironolactone POS N
in POS N
true POS N
resistant POS N
hypertensive POS N
patients, POS N
but POS N
the POS N
overall POS N
BP POS N
control POS N
was POS N
low POS N
(≈21%). POS N

Secondary POS N
end POS N
point POS N
analysis POS N
showed POS N
similar POS N
office POS N
BP POS N
(33.3% POS N
versus POS N
29.3%) POS N
and POS N
ambulatory POS N
BP POS N
monitoring POS N
(44% POS N
versus POS N
46.2%) POS N
control POS N
for POS N
spironolactone POS N
and POS N
clonidine, POS N
respectively. POS N

clonidine POS N
was POS N
not POS N
superior POS N
to POS N
spironolactone POS N
in POS N
true POS N
resistant POS N
hypertensive POS N
patients, POS N
but POS N
the POS N
overall POS N
BP POS N
control POS N
was POS N
low POS N
(≈21%). POS N

spironolactone POS N
promoted POS N
greater POS N
decrease POS N
in POS N
24-h POS N
systolic POS N
and POS N
diastolic POS N
BP POS N
and POS N
diastolic POS N
daytime POS N
ambulatory POS N
BP POS N
than POS N
clonidine. POS N

clonidine POS N
was POS N
not POS N
superior POS N
to POS N
spironolactone POS N
in POS N
true POS N
resistant POS N
hypertensive POS N
patients, POS N
but POS N
the POS N
overall POS N
BP POS N
control POS N
was POS N
low POS N
(≈21%). POS N

spironolactone POS N
is POS N
preferable POS N
for POS N
the POS N
fourth-drug POS N
therapy. POS N

spironolactone POS N
is POS N
preferable POS N
for POS N
the POS N
fourth-drug POS N
therapy. POS N

Compared POS N
with POS N
the POS N
spironolactone POS N
group POS N
(n=95), POS N
the POS N
clonidine POS N
group POS N
(n=92) POS N
presented POS N
similar POS N
rates POS N
of POS N
achieving POS N
the POS N
primary POS N
end POS N
point POS N
(20.5% POS N
versus POS N
20.8%, POS N
respectively; POS N
relative POS N
risk, POS N
1.01 POS N
[0.55-1.88]; POS N
P=1.00). POS N

spironolactone POS N
is POS N
preferable POS N
for POS N
the POS N
fourth-drug POS N
therapy. POS N

Secondary POS N
end POS N
point POS N
analysis POS N
showed POS N
similar POS N
office POS N
BP POS N
(33.3% POS N
versus POS N
29.3%) POS N
and POS N
ambulatory POS N
BP POS N
monitoring POS N
(44% POS N
versus POS N
46.2%) POS N
control POS N
for POS N
spironolactone POS N
and POS N
clonidine, POS N
respectively. POS N

spironolactone POS N
is POS N
preferable POS N
for POS N
the POS N
fourth-drug POS N
therapy. POS N

spironolactone POS N
promoted POS N
greater POS N
decrease POS N
in POS N
24-h POS N
systolic POS N
and POS N
diastolic POS N
BP POS N
and POS N
diastolic POS N
daytime POS N
ambulatory POS N
BP POS N
than POS N
clonidine. POS N

spironolactone POS N
is POS N
preferable POS N
for POS N
the POS N
fourth-drug POS N
therapy. POS N

clonidine POS N
was POS N
not POS N
superior POS N
to POS N
spironolactone POS N
in POS N
true POS N
resistant POS N
hypertensive POS N
patients, POS N
but POS N
the POS N
overall POS N
BP POS N
control POS N
was POS N
low POS N
(≈21%). POS N

Survival POS N
advantage POS N
was POS N
significant POS N
with POS N
regular POS N
surveillance POS N
but POS N
not POS N
with POS N
irregular POS N
surveillance. POS N

Patients POS N
in POS N
the POS N
regular POS N
surveillance POS N
group POS N
were POS N
diagnosed POS N
at POS N
earlier POS N
stages POS N
([very] POS N
early POS N
stage, POS N
64.4%) POS N
than POS N
the POS N
irregular POS N
surveillance POS N
(40.4%) POS N
or POS N
nonsurveillance POS N
(26.9%) POS N
groups POS N
and POS N
had POS N
more POS N
chance POS N
for POS N
curative POS N
treatments POS N
(52.4%) POS N
than POS N
the POS N
irregular POS N
surveillance POS N
(39.4%) POS N
or POS N
nonsurveillance POS N
(23.3%) POS N
groups POS N
(all POS N
P POS N
< POS N
0.001). POS N

Survival POS N
advantage POS N
was POS N
significant POS N
with POS N
regular POS N
surveillance POS N
but POS N
not POS N
with POS N
irregular POS N
surveillance. POS N

Mortality POS N
risk POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
regular POS N
surveillance POS N
group POS N
(adjusted POS N
hazard POS N
ratio POS N
[aHR], POS N
0.69; POS N
95% POS N
[CI], POS N
0.57-0.83) POS N
but POS N
not POS N
in POS N
the POS N
irregular POS N
surveillance POS N
group POS N
(aHR, POS N
0.94; POS N
95% POS N
CI, POS N
0.69-1.28) POS N
compared POS N
with POS N
the POS N
nonsurveillance POS N
group POS N
after POS N
adjusting POS N
for POS N
confounding POS N
factors POS N
and POS N
lead-time. POS N

Survival POS N
advantage POS N
was POS N
significant POS N
with POS N
regular POS N
surveillance POS N
but POS N
not POS N
with POS N
irregular POS N
surveillance. POS N

When POS N
the POS N
subjects POS N
were POS N
restricted POS N
to POS N
cirrhotic POS N
patients POS N
or POS N
Child-Pugh POS N
class POS N
A/B POS N
patients, POS N
similar POS N
results POS N
were POS N
obtained POS N
for POS N
mortality POS N
risk POS N
reduction POS N
between POS N
groups. POS N

Survival POS N
advantage POS N
was POS N
significant POS N
with POS N
regular POS N
surveillance POS N
but POS N
not POS N
with POS N
irregular POS N
surveillance. POS N

HCC POS N
surveillance POS N
was POS N
associated POS N
with POS N
longer POS N
survival POS N
owing POS N
to POS N
earlier POS N
diagnosis POS N
and POS N
curative POS N
treatment. POS N

Patients POS N
in POS N
the POS N
regular POS N
surveillance POS N
group POS N
were POS N
diagnosed POS N
at POS N
earlier POS N
stages POS N
([very] POS N
early POS N
stage, POS N
64.4%) POS N
than POS N
the POS N
irregular POS N
surveillance POS N
(40.4%) POS N
or POS N
nonsurveillance POS N
(26.9%) POS N
groups POS N
and POS N
had POS N
more POS N
chance POS N
for POS N
curative POS N
treatments POS N
(52.4%) POS N
than POS N
the POS N
irregular POS N
surveillance POS N
(39.4%) POS N
or POS N
nonsurveillance POS N
(23.3%) POS N
groups POS N
(all POS N
P POS N
< POS N
0.001). POS N

Survival POS N
advantage POS N
was POS N
significant POS N
with POS N
regular POS N
surveillance POS N
but POS N
not POS N
with POS N
irregular POS N
surveillance. POS N

Patients POS N
in POS N
the POS N
regular POS N
surveillance POS N
group POS N
were POS N
diagnosed POS N
at POS N
earlier POS N
stages POS N
([very] POS N
early POS N
stage, POS N
64.4%) POS N
than POS N
the POS N
irregular POS N
surveillance POS N
(40.4%) POS N
or POS N
nonsurveillance POS N
(26.9%) POS N
groups POS N
and POS N
had POS N
more POS N
chance POS N
for POS N
curative POS N
treatments POS N
(52.4%) POS N
than POS N
the POS N
irregular POS N
surveillance POS N
(39.4%) POS N
or POS N
nonsurveillance POS N
(23.3%) POS N
groups POS N
(all POS N
P POS N
< POS N
0.001). POS N

Mortality POS N
risk POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
regular POS N
surveillance POS N
group POS N
(adjusted POS N
hazard POS N
ratio POS N
[aHR], POS N
0.69; POS N
95% POS N
[CI], POS N
0.57-0.83) POS N
but POS N
not POS N
in POS N
the POS N
irregular POS N
surveillance POS N
group POS N
(aHR, POS N
0.94; POS N
95% POS N
CI, POS N
0.69-1.28) POS N
compared POS N
with POS N
the POS N
nonsurveillance POS N
group POS N
after POS N
adjusting POS N
for POS N
confounding POS N
factors POS N
and POS N
lead-time. POS N

Patients POS N
in POS N
the POS N
regular POS N
surveillance POS N
group POS N
were POS N
diagnosed POS N
at POS N
earlier POS N
stages POS N
([very] POS N
early POS N
stage, POS N
64.4%) POS N
than POS N
the POS N
irregular POS N
surveillance POS N
(40.4%) POS N
or POS N
nonsurveillance POS N
(26.9%) POS N
groups POS N
and POS N
had POS N
more POS N
chance POS N
for POS N
curative POS N
treatments POS N
(52.4%) POS N
than POS N
the POS N
irregular POS N
surveillance POS N
(39.4%) POS N
or POS N
nonsurveillance POS N
(23.3%) POS N
groups POS N
(all POS N
P POS N
< POS N
0.001). POS N

When POS N
the POS N
subjects POS N
were POS N
restricted POS N
to POS N
cirrhotic POS N
patients POS N
or POS N
Child-Pugh POS N
class POS N
A/B POS N
patients, POS N
similar POS N
results POS N
were POS N
obtained POS N
for POS N
mortality POS N
risk POS N
reduction POS N
between POS N
groups. POS N

Patients POS N
in POS N
the POS N
regular POS N
surveillance POS N
group POS N
were POS N
diagnosed POS N
at POS N
earlier POS N
stages POS N
([very] POS N
early POS N
stage, POS N
64.4%) POS N
than POS N
the POS N
irregular POS N
surveillance POS N
(40.4%) POS N
or POS N
nonsurveillance POS N
(26.9%) POS N
groups POS N
and POS N
had POS N
more POS N
chance POS N
for POS N
curative POS N
treatments POS N
(52.4%) POS N
than POS N
the POS N
irregular POS N
surveillance POS N
(39.4%) POS N
or POS N
nonsurveillance POS N
(23.3%) POS N
groups POS N
(all POS N
P POS N
< POS N
0.001). POS N

HCC POS N
surveillance POS N
was POS N
associated POS N
with POS N
longer POS N
survival POS N
owing POS N
to POS N
earlier POS N
diagnosis POS N
and POS N
curative POS N
treatment. POS N

Mortality POS N
risk POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
regular POS N
surveillance POS N
group POS N
(adjusted POS N
hazard POS N
ratio POS N
[aHR], POS N
0.69; POS N
95% POS N
[CI], POS N
0.57-0.83) POS N
but POS N
not POS N
in POS N
the POS N
irregular POS N
surveillance POS N
group POS N
(aHR, POS N
0.94; POS N
95% POS N
CI, POS N
0.69-1.28) POS N
compared POS N
with POS N
the POS N
nonsurveillance POS N
group POS N
after POS N
adjusting POS N
for POS N
confounding POS N
factors POS N
and POS N
lead-time. POS N

Survival POS N
advantage POS N
was POS N
significant POS N
with POS N
regular POS N
surveillance POS N
but POS N
not POS N
with POS N
irregular POS N
surveillance. POS N

Mortality POS N
risk POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
regular POS N
surveillance POS N
group POS N
(adjusted POS N
hazard POS N
ratio POS N
[aHR], POS N
0.69; POS N
95% POS N
[CI], POS N
0.57-0.83) POS N
but POS N
not POS N
in POS N
the POS N
irregular POS N
surveillance POS N
group POS N
(aHR, POS N
0.94; POS N
95% POS N
CI, POS N
0.69-1.28) POS N
compared POS N
with POS N
the POS N
nonsurveillance POS N
group POS N
after POS N
adjusting POS N
for POS N
confounding POS N
factors POS N
and POS N
lead-time. POS N

Patients POS N
in POS N
the POS N
regular POS N
surveillance POS N
group POS N
were POS N
diagnosed POS N
at POS N
earlier POS N
stages POS N
([very] POS N
early POS N
stage, POS N
64.4%) POS N
than POS N
the POS N
irregular POS N
surveillance POS N
(40.4%) POS N
or POS N
nonsurveillance POS N
(26.9%) POS N
groups POS N
and POS N
had POS N
more POS N
chance POS N
for POS N
curative POS N
treatments POS N
(52.4%) POS N
than POS N
the POS N
irregular POS N
surveillance POS N
(39.4%) POS N
or POS N
nonsurveillance POS N
(23.3%) POS N
groups POS N
(all POS N
P POS N
< POS N
0.001). POS N

Mortality POS N
risk POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
regular POS N
surveillance POS N
group POS N
(adjusted POS N
hazard POS N
ratio POS N
[aHR], POS N
0.69; POS N
95% POS N
[CI], POS N
0.57-0.83) POS N
but POS N
not POS N
in POS N
the POS N
irregular POS N
surveillance POS N
group POS N
(aHR, POS N
0.94; POS N
95% POS N
CI, POS N
0.69-1.28) POS N
compared POS N
with POS N
the POS N
nonsurveillance POS N
group POS N
after POS N
adjusting POS N
for POS N
confounding POS N
factors POS N
and POS N
lead-time. POS N

When POS N
the POS N
subjects POS N
were POS N
restricted POS N
to POS N
cirrhotic POS N
patients POS N
or POS N
Child-Pugh POS N
class POS N
A/B POS N
patients, POS N
similar POS N
results POS N
were POS N
obtained POS N
for POS N
mortality POS N
risk POS N
reduction POS N
between POS N
groups. POS N

Mortality POS N
risk POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
regular POS N
surveillance POS N
group POS N
(adjusted POS N
hazard POS N
ratio POS N
[aHR], POS N
0.69; POS N
95% POS N
[CI], POS N
0.57-0.83) POS N
but POS N
not POS N
in POS N
the POS N
irregular POS N
surveillance POS N
group POS N
(aHR, POS N
0.94; POS N
95% POS N
CI, POS N
0.69-1.28) POS N
compared POS N
with POS N
the POS N
nonsurveillance POS N
group POS N
after POS N
adjusting POS N
for POS N
confounding POS N
factors POS N
and POS N
lead-time. POS N

HCC POS N
surveillance POS N
was POS N
associated POS N
with POS N
longer POS N
survival POS N
owing POS N
to POS N
earlier POS N
diagnosis POS N
and POS N
curative POS N
treatment. POS N

When POS N
the POS N
subjects POS N
were POS N
restricted POS N
to POS N
cirrhotic POS N
patients POS N
or POS N
Child-Pugh POS N
class POS N
A/B POS N
patients, POS N
similar POS N
results POS N
were POS N
obtained POS N
for POS N
mortality POS N
risk POS N
reduction POS N
between POS N
groups. POS N

Survival POS N
advantage POS N
was POS N
significant POS N
with POS N
regular POS N
surveillance POS N
but POS N
not POS N
with POS N
irregular POS N
surveillance. POS N

When POS N
the POS N
subjects POS N
were POS N
restricted POS N
to POS N
cirrhotic POS N
patients POS N
or POS N
Child-Pugh POS N
class POS N
A/B POS N
patients, POS N
similar POS N
results POS N
were POS N
obtained POS N
for POS N
mortality POS N
risk POS N
reduction POS N
between POS N
groups. POS N

Patients POS N
in POS N
the POS N
regular POS N
surveillance POS N
group POS N
were POS N
diagnosed POS N
at POS N
earlier POS N
stages POS N
([very] POS N
early POS N
stage, POS N
64.4%) POS N
than POS N
the POS N
irregular POS N
surveillance POS N
(40.4%) POS N
or POS N
nonsurveillance POS N
(26.9%) POS N
groups POS N
and POS N
had POS N
more POS N
chance POS N
for POS N
curative POS N
treatments POS N
(52.4%) POS N
than POS N
the POS N
irregular POS N
surveillance POS N
(39.4%) POS N
or POS N
nonsurveillance POS N
(23.3%) POS N
groups POS N
(all POS N
P POS N
< POS N
0.001). POS N

When POS N
the POS N
subjects POS N
were POS N
restricted POS N
to POS N
cirrhotic POS N
patients POS N
or POS N
Child-Pugh POS N
class POS N
A/B POS N
patients, POS N
similar POS N
results POS N
were POS N
obtained POS N
for POS N
mortality POS N
risk POS N
reduction POS N
between POS N
groups. POS N

Mortality POS N
risk POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
regular POS N
surveillance POS N
group POS N
(adjusted POS N
hazard POS N
ratio POS N
[aHR], POS N
0.69; POS N
95% POS N
[CI], POS N
0.57-0.83) POS N
but POS N
not POS N
in POS N
the POS N
irregular POS N
surveillance POS N
group POS N
(aHR, POS N
0.94; POS N
95% POS N
CI, POS N
0.69-1.28) POS N
compared POS N
with POS N
the POS N
nonsurveillance POS N
group POS N
after POS N
adjusting POS N
for POS N
confounding POS N
factors POS N
and POS N
lead-time. POS N

When POS N
the POS N
subjects POS N
were POS N
restricted POS N
to POS N
cirrhotic POS N
patients POS N
or POS N
Child-Pugh POS N
class POS N
A/B POS N
patients, POS N
similar POS N
results POS N
were POS N
obtained POS N
for POS N
mortality POS N
risk POS N
reduction POS N
between POS N
groups. POS N

HCC POS N
surveillance POS N
was POS N
associated POS N
with POS N
longer POS N
survival POS N
owing POS N
to POS N
earlier POS N
diagnosis POS N
and POS N
curative POS N
treatment. POS N

HCC POS N
surveillance POS N
was POS N
associated POS N
with POS N
longer POS N
survival POS N
owing POS N
to POS N
earlier POS N
diagnosis POS N
and POS N
curative POS N
treatment. POS N

Survival POS N
advantage POS N
was POS N
significant POS N
with POS N
regular POS N
surveillance POS N
but POS N
not POS N
with POS N
irregular POS N
surveillance. POS N

HCC POS N
surveillance POS N
was POS N
associated POS N
with POS N
longer POS N
survival POS N
owing POS N
to POS N
earlier POS N
diagnosis POS N
and POS N
curative POS N
treatment. POS N

Patients POS N
in POS N
the POS N
regular POS N
surveillance POS N
group POS N
were POS N
diagnosed POS N
at POS N
earlier POS N
stages POS N
([very] POS N
early POS N
stage, POS N
64.4%) POS N
than POS N
the POS N
irregular POS N
surveillance POS N
(40.4%) POS N
or POS N
nonsurveillance POS N
(26.9%) POS N
groups POS N
and POS N
had POS N
more POS N
chance POS N
for POS N
curative POS N
treatments POS N
(52.4%) POS N
than POS N
the POS N
irregular POS N
surveillance POS N
(39.4%) POS N
or POS N
nonsurveillance POS N
(23.3%) POS N
groups POS N
(all POS N
P POS N
< POS N
0.001). POS N

HCC POS N
surveillance POS N
was POS N
associated POS N
with POS N
longer POS N
survival POS N
owing POS N
to POS N
earlier POS N
diagnosis POS N
and POS N
curative POS N
treatment. POS N

Mortality POS N
risk POS N
was POS N
significantly POS N
lower POS N
in POS N
the POS N
regular POS N
surveillance POS N
group POS N
(adjusted POS N
hazard POS N
ratio POS N
[aHR], POS N
0.69; POS N
95% POS N
[CI], POS N
0.57-0.83) POS N
but POS N
not POS N
in POS N
the POS N
irregular POS N
surveillance POS N
group POS N
(aHR, POS N
0.94; POS N
95% POS N
CI, POS N
0.69-1.28) POS N
compared POS N
with POS N
the POS N
nonsurveillance POS N
group POS N
after POS N
adjusting POS N
for POS N
confounding POS N
factors POS N
and POS N
lead-time. POS N

HCC POS N
surveillance POS N
was POS N
associated POS N
with POS N
longer POS N
survival POS N
owing POS N
to POS N
earlier POS N
diagnosis POS N
and POS N
curative POS N
treatment. POS N

When POS N
the POS N
subjects POS N
were POS N
restricted POS N
to POS N
cirrhotic POS N
patients POS N
or POS N
Child-Pugh POS N
class POS N
A/B POS N
patients, POS N
similar POS N
results POS N
were POS N
obtained POS N
for POS N
mortality POS N
risk POS N
reduction POS N
between POS N
groups. POS N

Multivariate POS N
analysis POS N
indicated POS N
a POS N
positive POS N
relationship POS N
between POS N
6MWD POS N
and POS N
the POS N
Physical POS N
Composite POS N
Score POS N
for POS N
QoL POS N
(p=0.004), POS N

negative POS N
relationship POS N
between POS N
delta POS N
SPO2 POS N
and POS N
the POS N
Mental POS N
Composite POS N
Score POS N
(p=0.02), POS N
irrespective POS N
of POS N
other POS N
known POS N
prognostic POS N
factors POS N
(such POS N
as POS N
haemodynamics POS N
at POS N
right POS N
heart POS N
catheterization). POS N

Multivariate POS N
analysis POS N
indicated POS N
a POS N
positive POS N
relationship POS N
between POS N
6MWD POS N
and POS N
the POS N
Physical POS N
Composite POS N
Score POS N
for POS N
QoL POS N
(p=0.004), POS N

Depression POS N
and POS N
Trait-Anxiety POS N
were POS N
associated POS N
with POS N
a POS N
lower POS N
physical POS N
(p=0.001) POS N
and POS N
mental POS N
(p<0.001) POS N
QoL, POS N
respectively. POS N

Multivariate POS N
analysis POS N
indicated POS N
a POS N
positive POS N
relationship POS N
between POS N
6MWD POS N
and POS N
the POS N
Physical POS N
Composite POS N
Score POS N
for POS N
QoL POS N
(p=0.004), POS N

Psychological POS N
factors POS N
impact POS N
the POS N
HRQoL POS N
of POS N
treated POS N
patients. POS N

Multivariate POS N
analysis POS N
indicated POS N
a POS N
positive POS N
relationship POS N
between POS N
6MWD POS N
and POS N
the POS N
Physical POS N
Composite POS N
Score POS N
for POS N
QoL POS N
(p=0.004), POS N

A POS N
longitudinal POS N
and POS N
qualitative POS N
study POS N
should POS N
refine POS N
these POS N
results. POS N

negative POS N
relationship POS N
between POS N
delta POS N
SPO2 POS N
and POS N
the POS N
Mental POS N
Composite POS N
Score POS N
(p=0.02), POS N
irrespective POS N
of POS N
other POS N
known POS N
prognostic POS N
factors POS N
(such POS N
as POS N
haemodynamics POS N
at POS N
right POS N
heart POS N
catheterization). POS N

Multivariate POS N
analysis POS N
indicated POS N
a POS N
positive POS N
relationship POS N
between POS N
6MWD POS N
and POS N
the POS N
Physical POS N
Composite POS N
Score POS N
for POS N
QoL POS N
(p=0.004), POS N

negative POS N
relationship POS N
between POS N
delta POS N
SPO2 POS N
and POS N
the POS N
Mental POS N
Composite POS N
Score POS N
(p=0.02), POS N
irrespective POS N
of POS N
other POS N
known POS N
prognostic POS N
factors POS N
(such POS N
as POS N
haemodynamics POS N
at POS N
right POS N
heart POS N
catheterization). POS N

Depression POS N
and POS N
Trait-Anxiety POS N
were POS N
associated POS N
with POS N
a POS N
lower POS N
physical POS N
(p=0.001) POS N
and POS N
mental POS N
(p<0.001) POS N
QoL, POS N
respectively. POS N

negative POS N
relationship POS N
between POS N
delta POS N
SPO2 POS N
and POS N
the POS N
Mental POS N
Composite POS N
Score POS N
(p=0.02), POS N
irrespective POS N
of POS N
other POS N
known POS N
prognostic POS N
factors POS N
(such POS N
as POS N
haemodynamics POS N
at POS N
right POS N
heart POS N
catheterization). POS N

Psychological POS N
factors POS N
impact POS N
the POS N
HRQoL POS N
of POS N
treated POS N
patients. POS N

negative POS N
relationship POS N
between POS N
delta POS N
SPO2 POS N
and POS N
the POS N
Mental POS N
Composite POS N
Score POS N
(p=0.02), POS N
irrespective POS N
of POS N
other POS N
known POS N
prognostic POS N
factors POS N
(such POS N
as POS N
haemodynamics POS N
at POS N
right POS N
heart POS N
catheterization). POS N

A POS N
longitudinal POS N
and POS N
qualitative POS N
study POS N
should POS N
refine POS N
these POS N
results. POS N

Depression POS N
and POS N
Trait-Anxiety POS N
were POS N
associated POS N
with POS N
a POS N
lower POS N
physical POS N
(p=0.001) POS N
and POS N
mental POS N
(p<0.001) POS N
QoL, POS N
respectively. POS N

Multivariate POS N
analysis POS N
indicated POS N
a POS N
positive POS N
relationship POS N
between POS N
6MWD POS N
and POS N
the POS N
Physical POS N
Composite POS N
Score POS N
for POS N
QoL POS N
(p=0.004), POS N

Depression POS N
and POS N
Trait-Anxiety POS N
were POS N
associated POS N
with POS N
a POS N
lower POS N
physical POS N
(p=0.001) POS N
and POS N
mental POS N
(p<0.001) POS N
QoL, POS N
respectively. POS N

negative POS N
relationship POS N
between POS N
delta POS N
SPO2 POS N
and POS N
the POS N
Mental POS N
Composite POS N
Score POS N
(p=0.02), POS N
irrespective POS N
of POS N
other POS N
known POS N
prognostic POS N
factors POS N
(such POS N
as POS N
haemodynamics POS N
at POS N
right POS N
heart POS N
catheterization). POS N

Depression POS N
and POS N
Trait-Anxiety POS N
were POS N
associated POS N
with POS N
a POS N
lower POS N
physical POS N
(p=0.001) POS N
and POS N
mental POS N
(p<0.001) POS N
QoL, POS N
respectively. POS N

Psychological POS N
factors POS N
impact POS N
the POS N
HRQoL POS N
of POS N
treated POS N
patients. POS N

Depression POS N
and POS N
Trait-Anxiety POS N
were POS N
associated POS N
with POS N
a POS N
lower POS N
physical POS N
(p=0.001) POS N
and POS N
mental POS N
(p<0.001) POS N
QoL, POS N
respectively. POS N

A POS N
longitudinal POS N
and POS N
qualitative POS N
study POS N
should POS N
refine POS N
these POS N
results. POS N

Psychological POS N
factors POS N
impact POS N
the POS N
HRQoL POS N
of POS N
treated POS N
patients. POS N

Multivariate POS N
analysis POS N
indicated POS N
a POS N
positive POS N
relationship POS N
between POS N
6MWD POS N
and POS N
the POS N
Physical POS N
Composite POS N
Score POS N
for POS N
QoL POS N
(p=0.004), POS N

Psychological POS N
factors POS N
impact POS N
the POS N
HRQoL POS N
of POS N
treated POS N
patients. POS N

negative POS N
relationship POS N
between POS N
delta POS N
SPO2 POS N
and POS N
the POS N
Mental POS N
Composite POS N
Score POS N
(p=0.02), POS N
irrespective POS N
of POS N
other POS N
known POS N
prognostic POS N
factors POS N
(such POS N
as POS N
haemodynamics POS N
at POS N
right POS N
heart POS N
catheterization). POS N

Psychological POS N
factors POS N
impact POS N
the POS N
HRQoL POS N
of POS N
treated POS N
patients. POS N

Depression POS N
and POS N
Trait-Anxiety POS N
were POS N
associated POS N
with POS N
a POS N
lower POS N
physical POS N
(p=0.001) POS N
and POS N
mental POS N
(p<0.001) POS N
QoL, POS N
respectively. POS N

Psychological POS N
factors POS N
impact POS N
the POS N
HRQoL POS N
of POS N
treated POS N
patients. POS N

A POS N
longitudinal POS N
and POS N
qualitative POS N
study POS N
should POS N
refine POS N
these POS N
results. POS N

A POS N
longitudinal POS N
and POS N
qualitative POS N
study POS N
should POS N
refine POS N
these POS N
results. POS N

Multivariate POS N
analysis POS N
indicated POS N
a POS N
positive POS N
relationship POS N
between POS N
6MWD POS N
and POS N
the POS N
Physical POS N
Composite POS N
Score POS N
for POS N
QoL POS N
(p=0.004), POS N

A POS N
longitudinal POS N
and POS N
qualitative POS N
study POS N
should POS N
refine POS N
these POS N
results. POS N

negative POS N
relationship POS N
between POS N
delta POS N
SPO2 POS N
and POS N
the POS N
Mental POS N
Composite POS N
Score POS N
(p=0.02), POS N
irrespective POS N
of POS N
other POS N
known POS N
prognostic POS N
factors POS N
(such POS N
as POS N
haemodynamics POS N
at POS N
right POS N
heart POS N
catheterization). POS N

A POS N
longitudinal POS N
and POS N
qualitative POS N
study POS N
should POS N
refine POS N
these POS N
results. POS N

Depression POS N
and POS N
Trait-Anxiety POS N
were POS N
associated POS N
with POS N
a POS N
lower POS N
physical POS N
(p=0.001) POS N
and POS N
mental POS N
(p<0.001) POS N
QoL, POS N
respectively. POS N

A POS N
longitudinal POS N
and POS N
qualitative POS N
study POS N
should POS N
refine POS N
these POS N
results. POS N

Psychological POS N
factors POS N
impact POS N
the POS N
HRQoL POS N
of POS N
treated POS N
patients. POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

Patients POS N
treated POS N
with POS N
DC POS N
had POS N
a POS N
median POS N
survival POS N
of POS N
11.3 POS N
v POS N
10.1 POS N
months POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.044; POS N
hazard POS N
ratio, POS N
1.183 POS N
[97.2% POS N
confidence POS N
interval, POS N
0.989 POS N
to POS N
1.416]). POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

The POS N
2-year POS N
survival POS N
rate POS N
was POS N
21% POS N
for POS N
DC-treated POS N
patients POS N
and POS N
14% POS N
for POS N
VC-treated POS N
patients. POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

Overall POS N
response POS N
rate POS N
was POS N
31.6% POS N
for POS N
DC-treated POS N
patients POS N
v POS N
24.5% POS N
for POS N
VC-treated POS N
patients POS N
(P POS N
=.029). POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

Median POS N
survival POS N
(9.4 POS N
v POS N
9.9 POS N
months POS N
[for POS N
VC]; POS N
P POS N
=.657; POS N
hazard POS N
ratio, POS N
1.048 POS N
[97.2 POS N
confidence POS N
interval, POS N
0.877 POS N
to POS N
1.253]) POS N
and POS N
response POS N
(23.9%) POS N
with POS N
DCb POS N
were POS N
similar POS N
to POS N
those POS N
results POS N
for POS N
VC. POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

Neutropenia, POS N
thrombocytopenia, POS N
infection, POS N
and POS N
febrile POS N
neutropenia POS N
were POS N
similar POS N
with POS N
all POS N
three POS N
regimens. POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

Grade POS N
3 POS N
to POS N
4 POS N
anemia, POS N
nausea, POS N
and POS N
vomiting POS N
were POS N
more POS N
common POS N
(P POS N
<.01) POS N
with POS N
VC POS N
than POS N
with POS N
DC POS N
or POS N
DCb. POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

Patients POS N
treated POS N
with POS N
either POS N
docetaxel POS N
regimen POS N
had POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC-treated POS N
patients, POS N
who POS N
experienced POS N
deterioration POS N
in POS N
QoL. POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

DC POS N
resulted POS N
in POS N
a POS N
more POS N
favorable POS N
overall POS N
response POS N
and POS N
survival POS N
rate POS N
than POS N
VC. POS N

These POS N
findings POS N
demonstrate POS N
that POS N
a POS N
docetaxel POS N
plus POS N
platinum POS N
combination POS N
is POS N
an POS N
effective POS N
treatment POS N
option POS N
with POS N
a POS N
favorable POS N
therapeutic POS N
index POS N
for POS N
first-line POS N
treatment POS N
of POS N
advanced POS N
or POS N
metastatic POS N
NSCLC. POS N

Both POS N
DC POS N
and POS N
DCb POS N
were POS N
better POS N
tolerated POS N
and POS N
provided POS N
patients POS N
with POS N
consistently POS N
improved POS N
QoL POS N
compared POS N
with POS N
VC. POS N

iron-containing POS N
multiple POS N
micronutrient POS N
may POS N
reduce POS N
the POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
including POS N
gestational POS N
hypertension POS N
or POS N
preeclampsia. POS N

The POS N
incidence POS N
of POS N
pregnancy-induced POS N
hypertension POS N
was POS N
7.1% POS N
(423/5923), POS N
6.3% POS N
(374/5933) POS N
and POS N
6.3% POS N
(372/5914) POS N
among POS N
the POS N
pregnant POS N
women POS N
who POS N
took POS N
folic POS N
acid POS N
only, POS N
iron-folic POS N
acid POS N
and POS N
multiple POS N
micronutrient POS N
supplements, POS N
respectively. POS N

iron-containing POS N
multiple POS N
micronutrient POS N
may POS N
reduce POS N
the POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
including POS N
gestational POS N
hypertension POS N
or POS N
preeclampsia. POS N

The POS N
adjusted POS N
odds POS N
ratios POS N
associated POS N
with POS N
iron-folic POS N
acid POS N
supplements POS N
and POS N
multiple POS N
micronutrient POS N
supplements POS N
for POS N
pregnancy-induced POS N
hypertension POS N
were POS N
both POS N
nearly POS N
0.88 POS N
(95% POS N
confidence POS N
interval, POS N
0.76-1.02), POS N
compared POS N
with POS N
folic POS N
acid POS N
supplements POS N
only. POS N

iron-containing POS N
multiple POS N
micronutrient POS N
may POS N
reduce POS N
the POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
including POS N
gestational POS N
hypertension POS N
or POS N
preeclampsia. POS N

among POS N
pregnant POS N
women POS N
aged POS N
20-24 POS N
years, POS N
iron-containing POS N
multiple POS N
micronutrient POS N
supplementation POS N
was POS N
associated POS N
with POS N
a POS N
reduced POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
compared POS N
with POS N
folic POS N
acid POS N
supplements POS N
only. POS N

iron-containing POS N
multiple POS N
micronutrient POS N
may POS N
reduce POS N
the POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
including POS N
gestational POS N
hypertension POS N
or POS N
preeclampsia. POS N

Among POS N
pregnant POS N
women POS N
aged POS N
20-24 POS N
years, POS N
iron-folic POS N
acid POS N
(adjusted POS N
odds POS N
ratios: POS N
0.81, POS N
95% POS N
confidence POS N
interval: POS N
0.67-0.96) POS N
or POS N
multiple POS N
micronutrient POS N
supplementation POS N
(adjusted POS N
odds POS N
ratios: POS N
0.83, POS N
95% POS N
confidence POS N
interval: POS N
0.70-0.99) POS N
can POS N
significantly POS N
reduce POS N
the POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
compared POS N
to POS N
folic POS N
acid POS N
supplementation. POS N

The POS N
incidence POS N
of POS N
pregnancy-induced POS N
hypertension POS N
was POS N
7.1% POS N
(423/5923), POS N
6.3% POS N
(374/5933) POS N
and POS N
6.3% POS N
(372/5914) POS N
among POS N
the POS N
pregnant POS N
women POS N
who POS N
took POS N
folic POS N
acid POS N
only, POS N
iron-folic POS N
acid POS N
and POS N
multiple POS N
micronutrient POS N
supplements, POS N
respectively. POS N

iron-containing POS N
multiple POS N
micronutrient POS N
may POS N
reduce POS N
the POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
including POS N
gestational POS N
hypertension POS N
or POS N
preeclampsia. POS N

The POS N
incidence POS N
of POS N
pregnancy-induced POS N
hypertension POS N
was POS N
7.1% POS N
(423/5923), POS N
6.3% POS N
(374/5933) POS N
and POS N
6.3% POS N
(372/5914) POS N
among POS N
the POS N
pregnant POS N
women POS N
who POS N
took POS N
folic POS N
acid POS N
only, POS N
iron-folic POS N
acid POS N
and POS N
multiple POS N
micronutrient POS N
supplements, POS N
respectively. POS N

The POS N
adjusted POS N
odds POS N
ratios POS N
associated POS N
with POS N
iron-folic POS N
acid POS N
supplements POS N
and POS N
multiple POS N
micronutrient POS N
supplements POS N
for POS N
pregnancy-induced POS N
hypertension POS N
were POS N
both POS N
nearly POS N
0.88 POS N
(95% POS N
confidence POS N
interval, POS N
0.76-1.02), POS N
compared POS N
with POS N
folic POS N
acid POS N
supplements POS N
only. POS N

The POS N
incidence POS N
of POS N
pregnancy-induced POS N
hypertension POS N
was POS N
7.1% POS N
(423/5923), POS N
6.3% POS N
(374/5933) POS N
and POS N
6.3% POS N
(372/5914) POS N
among POS N
the POS N
pregnant POS N
women POS N
who POS N
took POS N
folic POS N
acid POS N
only, POS N
iron-folic POS N
acid POS N
and POS N
multiple POS N
micronutrient POS N
supplements, POS N
respectively. POS N

among POS N
pregnant POS N
women POS N
aged POS N
20-24 POS N
years, POS N
iron-containing POS N
multiple POS N
micronutrient POS N
supplementation POS N
was POS N
associated POS N
with POS N
a POS N
reduced POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
compared POS N
with POS N
folic POS N
acid POS N
supplements POS N
only. POS N

The POS N
incidence POS N
of POS N
pregnancy-induced POS N
hypertension POS N
was POS N
7.1% POS N
(423/5923), POS N
6.3% POS N
(374/5933) POS N
and POS N
6.3% POS N
(372/5914) POS N
among POS N
the POS N
pregnant POS N
women POS N
who POS N
took POS N
folic POS N
acid POS N
only, POS N
iron-folic POS N
acid POS N
and POS N
multiple POS N
micronutrient POS N
supplements, POS N
respectively. POS N

Among POS N
pregnant POS N
women POS N
aged POS N
20-24 POS N
years, POS N
iron-folic POS N
acid POS N
(adjusted POS N
odds POS N
ratios: POS N
0.81, POS N
95% POS N
confidence POS N
interval: POS N
0.67-0.96) POS N
or POS N
multiple POS N
micronutrient POS N
supplementation POS N
(adjusted POS N
odds POS N
ratios: POS N
0.83, POS N
95% POS N
confidence POS N
interval: POS N
0.70-0.99) POS N
can POS N
significantly POS N
reduce POS N
the POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
compared POS N
to POS N
folic POS N
acid POS N
supplementation. POS N

The POS N
adjusted POS N
odds POS N
ratios POS N
associated POS N
with POS N
iron-folic POS N
acid POS N
supplements POS N
and POS N
multiple POS N
micronutrient POS N
supplements POS N
for POS N
pregnancy-induced POS N
hypertension POS N
were POS N
both POS N
nearly POS N
0.88 POS N
(95% POS N
confidence POS N
interval, POS N
0.76-1.02), POS N
compared POS N
with POS N
folic POS N
acid POS N
supplements POS N
only. POS N

iron-containing POS N
multiple POS N
micronutrient POS N
may POS N
reduce POS N
the POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
including POS N
gestational POS N
hypertension POS N
or POS N
preeclampsia. POS N

The POS N
adjusted POS N
odds POS N
ratios POS N
associated POS N
with POS N
iron-folic POS N
acid POS N
supplements POS N
and POS N
multiple POS N
micronutrient POS N
supplements POS N
for POS N
pregnancy-induced POS N
hypertension POS N
were POS N
both POS N
nearly POS N
0.88 POS N
(95% POS N
confidence POS N
interval, POS N
0.76-1.02), POS N
compared POS N
with POS N
folic POS N
acid POS N
supplements POS N
only. POS N

The POS N
incidence POS N
of POS N
pregnancy-induced POS N
hypertension POS N
was POS N
7.1% POS N
(423/5923), POS N
6.3% POS N
(374/5933) POS N
and POS N
6.3% POS N
(372/5914) POS N
among POS N
the POS N
pregnant POS N
women POS N
who POS N
took POS N
folic POS N
acid POS N
only, POS N
iron-folic POS N
acid POS N
and POS N
multiple POS N
micronutrient POS N
supplements, POS N
respectively. POS N

The POS N
adjusted POS N
odds POS N
ratios POS N
associated POS N
with POS N
iron-folic POS N
acid POS N
supplements POS N
and POS N
multiple POS N
micronutrient POS N
supplements POS N
for POS N
pregnancy-induced POS N
hypertension POS N
were POS N
both POS N
nearly POS N
0.88 POS N
(95% POS N
confidence POS N
interval, POS N
0.76-1.02), POS N
compared POS N
with POS N
folic POS N
acid POS N
supplements POS N
only. POS N

among POS N
pregnant POS N
women POS N
aged POS N
20-24 POS N
years, POS N
iron-containing POS N
multiple POS N
micronutrient POS N
supplementation POS N
was POS N
associated POS N
with POS N
a POS N
reduced POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
compared POS N
with POS N
folic POS N
acid POS N
supplements POS N
only. POS N

The POS N
adjusted POS N
odds POS N
ratios POS N
associated POS N
with POS N
iron-folic POS N
acid POS N
supplements POS N
and POS N
multiple POS N
micronutrient POS N
supplements POS N
for POS N
pregnancy-induced POS N
hypertension POS N
were POS N
both POS N
nearly POS N
0.88 POS N
(95% POS N
confidence POS N
interval, POS N
0.76-1.02), POS N
compared POS N
with POS N
folic POS N
acid POS N
supplements POS N
only. POS N

Among POS N
pregnant POS N
women POS N
aged POS N
20-24 POS N
years, POS N
iron-folic POS N
acid POS N
(adjusted POS N
odds POS N
ratios: POS N
0.81, POS N
95% POS N
confidence POS N
interval: POS N
0.67-0.96) POS N
or POS N
multiple POS N
micronutrient POS N
supplementation POS N
(adjusted POS N
odds POS N
ratios: POS N
0.83, POS N
95% POS N
confidence POS N
interval: POS N
0.70-0.99) POS N
can POS N
significantly POS N
reduce POS N
the POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
compared POS N
to POS N
folic POS N
acid POS N
supplementation. POS N

among POS N
pregnant POS N
women POS N
aged POS N
20-24 POS N
years, POS N
iron-containing POS N
multiple POS N
micronutrient POS N
supplementation POS N
was POS N
associated POS N
with POS N
a POS N
reduced POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
compared POS N
with POS N
folic POS N
acid POS N
supplements POS N
only. POS N

iron-containing POS N
multiple POS N
micronutrient POS N
may POS N
reduce POS N
the POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
including POS N
gestational POS N
hypertension POS N
or POS N
preeclampsia. POS N

among POS N
pregnant POS N
women POS N
aged POS N
20-24 POS N
years, POS N
iron-containing POS N
multiple POS N
micronutrient POS N
supplementation POS N
was POS N
associated POS N
with POS N
a POS N
reduced POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
compared POS N
with POS N
folic POS N
acid POS N
supplements POS N
only. POS N

The POS N
incidence POS N
of POS N
pregnancy-induced POS N
hypertension POS N
was POS N
7.1% POS N
(423/5923), POS N
6.3% POS N
(374/5933) POS N
and POS N
6.3% POS N
(372/5914) POS N
among POS N
the POS N
pregnant POS N
women POS N
who POS N
took POS N
folic POS N
acid POS N
only, POS N
iron-folic POS N
acid POS N
and POS N
multiple POS N
micronutrient POS N
supplements, POS N
respectively. POS N

among POS N
pregnant POS N
women POS N
aged POS N
20-24 POS N
years, POS N
iron-containing POS N
multiple POS N
micronutrient POS N
supplementation POS N
was POS N
associated POS N
with POS N
a POS N
reduced POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
compared POS N
with POS N
folic POS N
acid POS N
supplements POS N
only. POS N

The POS N
adjusted POS N
odds POS N
ratios POS N
associated POS N
with POS N
iron-folic POS N
acid POS N
supplements POS N
and POS N
multiple POS N
micronutrient POS N
supplements POS N
for POS N
pregnancy-induced POS N
hypertension POS N
were POS N
both POS N
nearly POS N
0.88 POS N
(95% POS N
confidence POS N
interval, POS N
0.76-1.02), POS N
compared POS N
with POS N
folic POS N
acid POS N
supplements POS N
only. POS N

among POS N
pregnant POS N
women POS N
aged POS N
20-24 POS N
years, POS N
iron-containing POS N
multiple POS N
micronutrient POS N
supplementation POS N
was POS N
associated POS N
with POS N
a POS N
reduced POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
compared POS N
with POS N
folic POS N
acid POS N
supplements POS N
only. POS N

Among POS N
pregnant POS N
women POS N
aged POS N
20-24 POS N
years, POS N
iron-folic POS N
acid POS N
(adjusted POS N
odds POS N
ratios: POS N
0.81, POS N
95% POS N
confidence POS N
interval: POS N
0.67-0.96) POS N
or POS N
multiple POS N
micronutrient POS N
supplementation POS N
(adjusted POS N
odds POS N
ratios: POS N
0.83, POS N
95% POS N
confidence POS N
interval: POS N
0.70-0.99) POS N
can POS N
significantly POS N
reduce POS N
the POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
compared POS N
to POS N
folic POS N
acid POS N
supplementation. POS N

Among POS N
pregnant POS N
women POS N
aged POS N
20-24 POS N
years, POS N
iron-folic POS N
acid POS N
(adjusted POS N
odds POS N
ratios: POS N
0.81, POS N
95% POS N
confidence POS N
interval: POS N
0.67-0.96) POS N
or POS N
multiple POS N
micronutrient POS N
supplementation POS N
(adjusted POS N
odds POS N
ratios: POS N
0.83, POS N
95% POS N
confidence POS N
interval: POS N
0.70-0.99) POS N
can POS N
significantly POS N
reduce POS N
the POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
compared POS N
to POS N
folic POS N
acid POS N
supplementation. POS N

iron-containing POS N
multiple POS N
micronutrient POS N
may POS N
reduce POS N
the POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
including POS N
gestational POS N
hypertension POS N
or POS N
preeclampsia. POS N

Among POS N
pregnant POS N
women POS N
aged POS N
20-24 POS N
years, POS N
iron-folic POS N
acid POS N
(adjusted POS N
odds POS N
ratios: POS N
0.81, POS N
95% POS N
confidence POS N
interval: POS N
0.67-0.96) POS N
or POS N
multiple POS N
micronutrient POS N
supplementation POS N
(adjusted POS N
odds POS N
ratios: POS N
0.83, POS N
95% POS N
confidence POS N
interval: POS N
0.70-0.99) POS N
can POS N
significantly POS N
reduce POS N
the POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
compared POS N
to POS N
folic POS N
acid POS N
supplementation. POS N

The POS N
incidence POS N
of POS N
pregnancy-induced POS N
hypertension POS N
was POS N
7.1% POS N
(423/5923), POS N
6.3% POS N
(374/5933) POS N
and POS N
6.3% POS N
(372/5914) POS N
among POS N
the POS N
pregnant POS N
women POS N
who POS N
took POS N
folic POS N
acid POS N
only, POS N
iron-folic POS N
acid POS N
and POS N
multiple POS N
micronutrient POS N
supplements, POS N
respectively. POS N

Among POS N
pregnant POS N
women POS N
aged POS N
20-24 POS N
years, POS N
iron-folic POS N
acid POS N
(adjusted POS N
odds POS N
ratios: POS N
0.81, POS N
95% POS N
confidence POS N
interval: POS N
0.67-0.96) POS N
or POS N
multiple POS N
micronutrient POS N
supplementation POS N
(adjusted POS N
odds POS N
ratios: POS N
0.83, POS N
95% POS N
confidence POS N
interval: POS N
0.70-0.99) POS N
can POS N
significantly POS N
reduce POS N
the POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
compared POS N
to POS N
folic POS N
acid POS N
supplementation. POS N

The POS N
adjusted POS N
odds POS N
ratios POS N
associated POS N
with POS N
iron-folic POS N
acid POS N
supplements POS N
and POS N
multiple POS N
micronutrient POS N
supplements POS N
for POS N
pregnancy-induced POS N
hypertension POS N
were POS N
both POS N
nearly POS N
0.88 POS N
(95% POS N
confidence POS N
interval, POS N
0.76-1.02), POS N
compared POS N
with POS N
folic POS N
acid POS N
supplements POS N
only. POS N

Among POS N
pregnant POS N
women POS N
aged POS N
20-24 POS N
years, POS N
iron-folic POS N
acid POS N
(adjusted POS N
odds POS N
ratios: POS N
0.81, POS N
95% POS N
confidence POS N
interval: POS N
0.67-0.96) POS N
or POS N
multiple POS N
micronutrient POS N
supplementation POS N
(adjusted POS N
odds POS N
ratios: POS N
0.83, POS N
95% POS N
confidence POS N
interval: POS N
0.70-0.99) POS N
can POS N
significantly POS N
reduce POS N
the POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
compared POS N
to POS N
folic POS N
acid POS N
supplementation. POS N

among POS N
pregnant POS N
women POS N
aged POS N
20-24 POS N
years, POS N
iron-containing POS N
multiple POS N
micronutrient POS N
supplementation POS N
was POS N
associated POS N
with POS N
a POS N
reduced POS N
risk POS N
of POS N
pregnancy-induced POS N
hypertension POS N
compared POS N
with POS N
folic POS N
acid POS N
supplements POS N
only. POS N

At POS N
radical POS N
prostatectomy, POS N
pathological POS N
variables POS N
were POS N
not POS N
significantly POS N
different POS N
in POS N
the POS N
two POS N
groups. POS N

Serum POS N
testosterone POS N
level POS N
was POS N
significantly POS N
higher POS N
(mean POS N
359.2 POS N
compared POS N
to POS N
10.5, POS N
P POS N
< POS N
0.001), POS N

At POS N
radical POS N
prostatectomy, POS N
pathological POS N
variables POS N
were POS N
not POS N
significantly POS N
different POS N
in POS N
the POS N
two POS N
groups. POS N

complete POS N
response POS N
rate POS N
of POS N
PSA POS N
(13% POS N
compared POS N
to POS N
57%, POS N
P POS N
= POS N
0.028) POS N
and POS N
rate POS N
of POS N
downsizing POS N
of POS N
prostate POS N
volume POS N
(mean, POS N
-17.7% POS N
compared POS N
to POS N
-35.4%, POS N
P POS N
= POS N
0.038) POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

At POS N
radical POS N
prostatectomy, POS N
pathological POS N
variables POS N
were POS N
not POS N
significantly POS N
different POS N
in POS N
the POS N
two POS N
groups. POS N

After POS N
neoadjuvant POS N
hormone POS N
therapy, POS N
the POS N
scores POS N
on POS N
the POS N
sexual POS N
problem POS N
domain POS N
of POS N
EORTC-P POS N
(P POS N
= POS N
0.033) POS N
and POS N
sexual POS N
desire POS N
score POS N
of POS N
SMUF POS N
(P POS N
= POS N
0.021) POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

At POS N
radical POS N
prostatectomy, POS N
pathological POS N
variables POS N
were POS N
not POS N
significantly POS N
different POS N
in POS N
the POS N
two POS N
groups. POS N

This POS N
study POS N
suggests POS N
that POS N
flutamide POS N
monotherapy POS N
can POS N
be POS N
an POS N
acceptable POS N
modality POS N
as POS N
an POS N
option POS N
for POS N
neoadjuvant POS N
hormone POS N
therapy. POS N

At POS N
radical POS N
prostatectomy, POS N
pathological POS N
variables POS N
were POS N
not POS N
significantly POS N
different POS N
in POS N
the POS N
two POS N
groups. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
34 POS N
months POS N
after POS N
prostatectomy, POS N
biochemical POS N
failure-free POS N
survival POS N
rate POS N
in POS N
the POS N
flutamide POS N
group POS N
did POS N
not POS N
differ POS N
from POS N
that POS N
in POS N
the POS N
LHRH POS N
group. POS N

Serum POS N
testosterone POS N
level POS N
was POS N
significantly POS N
higher POS N
(mean POS N
359.2 POS N
compared POS N
to POS N
10.5, POS N
P POS N
< POS N
0.001), POS N

At POS N
radical POS N
prostatectomy, POS N
pathological POS N
variables POS N
were POS N
not POS N
significantly POS N
different POS N
in POS N
the POS N
two POS N
groups. POS N

Serum POS N
testosterone POS N
level POS N
was POS N
significantly POS N
higher POS N
(mean POS N
359.2 POS N
compared POS N
to POS N
10.5, POS N
P POS N
< POS N
0.001), POS N

complete POS N
response POS N
rate POS N
of POS N
PSA POS N
(13% POS N
compared POS N
to POS N
57%, POS N
P POS N
= POS N
0.028) POS N
and POS N
rate POS N
of POS N
downsizing POS N
of POS N
prostate POS N
volume POS N
(mean, POS N
-17.7% POS N
compared POS N
to POS N
-35.4%, POS N
P POS N
= POS N
0.038) POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

Serum POS N
testosterone POS N
level POS N
was POS N
significantly POS N
higher POS N
(mean POS N
359.2 POS N
compared POS N
to POS N
10.5, POS N
P POS N
< POS N
0.001), POS N

After POS N
neoadjuvant POS N
hormone POS N
therapy, POS N
the POS N
scores POS N
on POS N
the POS N
sexual POS N
problem POS N
domain POS N
of POS N
EORTC-P POS N
(P POS N
= POS N
0.033) POS N
and POS N
sexual POS N
desire POS N
score POS N
of POS N
SMUF POS N
(P POS N
= POS N
0.021) POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

Serum POS N
testosterone POS N
level POS N
was POS N
significantly POS N
higher POS N
(mean POS N
359.2 POS N
compared POS N
to POS N
10.5, POS N
P POS N
< POS N
0.001), POS N

This POS N
study POS N
suggests POS N
that POS N
flutamide POS N
monotherapy POS N
can POS N
be POS N
an POS N
acceptable POS N
modality POS N
as POS N
an POS N
option POS N
for POS N
neoadjuvant POS N
hormone POS N
therapy. POS N

Serum POS N
testosterone POS N
level POS N
was POS N
significantly POS N
higher POS N
(mean POS N
359.2 POS N
compared POS N
to POS N
10.5, POS N
P POS N
< POS N
0.001), POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
34 POS N
months POS N
after POS N
prostatectomy, POS N
biochemical POS N
failure-free POS N
survival POS N
rate POS N
in POS N
the POS N
flutamide POS N
group POS N
did POS N
not POS N
differ POS N
from POS N
that POS N
in POS N
the POS N
LHRH POS N
group. POS N

complete POS N
response POS N
rate POS N
of POS N
PSA POS N
(13% POS N
compared POS N
to POS N
57%, POS N
P POS N
= POS N
0.028) POS N
and POS N
rate POS N
of POS N
downsizing POS N
of POS N
prostate POS N
volume POS N
(mean, POS N
-17.7% POS N
compared POS N
to POS N
-35.4%, POS N
P POS N
= POS N
0.038) POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

At POS N
radical POS N
prostatectomy, POS N
pathological POS N
variables POS N
were POS N
not POS N
significantly POS N
different POS N
in POS N
the POS N
two POS N
groups. POS N

complete POS N
response POS N
rate POS N
of POS N
PSA POS N
(13% POS N
compared POS N
to POS N
57%, POS N
P POS N
= POS N
0.028) POS N
and POS N
rate POS N
of POS N
downsizing POS N
of POS N
prostate POS N
volume POS N
(mean, POS N
-17.7% POS N
compared POS N
to POS N
-35.4%, POS N
P POS N
= POS N
0.038) POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

Serum POS N
testosterone POS N
level POS N
was POS N
significantly POS N
higher POS N
(mean POS N
359.2 POS N
compared POS N
to POS N
10.5, POS N
P POS N
< POS N
0.001), POS N

complete POS N
response POS N
rate POS N
of POS N
PSA POS N
(13% POS N
compared POS N
to POS N
57%, POS N
P POS N
= POS N
0.028) POS N
and POS N
rate POS N
of POS N
downsizing POS N
of POS N
prostate POS N
volume POS N
(mean, POS N
-17.7% POS N
compared POS N
to POS N
-35.4%, POS N
P POS N
= POS N
0.038) POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

After POS N
neoadjuvant POS N
hormone POS N
therapy, POS N
the POS N
scores POS N
on POS N
the POS N
sexual POS N
problem POS N
domain POS N
of POS N
EORTC-P POS N
(P POS N
= POS N
0.033) POS N
and POS N
sexual POS N
desire POS N
score POS N
of POS N
SMUF POS N
(P POS N
= POS N
0.021) POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

complete POS N
response POS N
rate POS N
of POS N
PSA POS N
(13% POS N
compared POS N
to POS N
57%, POS N
P POS N
= POS N
0.028) POS N
and POS N
rate POS N
of POS N
downsizing POS N
of POS N
prostate POS N
volume POS N
(mean, POS N
-17.7% POS N
compared POS N
to POS N
-35.4%, POS N
P POS N
= POS N
0.038) POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

This POS N
study POS N
suggests POS N
that POS N
flutamide POS N
monotherapy POS N
can POS N
be POS N
an POS N
acceptable POS N
modality POS N
as POS N
an POS N
option POS N
for POS N
neoadjuvant POS N
hormone POS N
therapy. POS N

complete POS N
response POS N
rate POS N
of POS N
PSA POS N
(13% POS N
compared POS N
to POS N
57%, POS N
P POS N
= POS N
0.028) POS N
and POS N
rate POS N
of POS N
downsizing POS N
of POS N
prostate POS N
volume POS N
(mean, POS N
-17.7% POS N
compared POS N
to POS N
-35.4%, POS N
P POS N
= POS N
0.038) POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
34 POS N
months POS N
after POS N
prostatectomy, POS N
biochemical POS N
failure-free POS N
survival POS N
rate POS N
in POS N
the POS N
flutamide POS N
group POS N
did POS N
not POS N
differ POS N
from POS N
that POS N
in POS N
the POS N
LHRH POS N
group. POS N

After POS N
neoadjuvant POS N
hormone POS N
therapy, POS N
the POS N
scores POS N
on POS N
the POS N
sexual POS N
problem POS N
domain POS N
of POS N
EORTC-P POS N
(P POS N
= POS N
0.033) POS N
and POS N
sexual POS N
desire POS N
score POS N
of POS N
SMUF POS N
(P POS N
= POS N
0.021) POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

At POS N
radical POS N
prostatectomy, POS N
pathological POS N
variables POS N
were POS N
not POS N
significantly POS N
different POS N
in POS N
the POS N
two POS N
groups. POS N

After POS N
neoadjuvant POS N
hormone POS N
therapy, POS N
the POS N
scores POS N
on POS N
the POS N
sexual POS N
problem POS N
domain POS N
of POS N
EORTC-P POS N
(P POS N
= POS N
0.033) POS N
and POS N
sexual POS N
desire POS N
score POS N
of POS N
SMUF POS N
(P POS N
= POS N
0.021) POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

Serum POS N
testosterone POS N
level POS N
was POS N
significantly POS N
higher POS N
(mean POS N
359.2 POS N
compared POS N
to POS N
10.5, POS N
P POS N
< POS N
0.001), POS N

After POS N
neoadjuvant POS N
hormone POS N
therapy, POS N
the POS N
scores POS N
on POS N
the POS N
sexual POS N
problem POS N
domain POS N
of POS N
EORTC-P POS N
(P POS N
= POS N
0.033) POS N
and POS N
sexual POS N
desire POS N
score POS N
of POS N
SMUF POS N
(P POS N
= POS N
0.021) POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

complete POS N
response POS N
rate POS N
of POS N
PSA POS N
(13% POS N
compared POS N
to POS N
57%, POS N
P POS N
= POS N
0.028) POS N
and POS N
rate POS N
of POS N
downsizing POS N
of POS N
prostate POS N
volume POS N
(mean, POS N
-17.7% POS N
compared POS N
to POS N
-35.4%, POS N
P POS N
= POS N
0.038) POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

After POS N
neoadjuvant POS N
hormone POS N
therapy, POS N
the POS N
scores POS N
on POS N
the POS N
sexual POS N
problem POS N
domain POS N
of POS N
EORTC-P POS N
(P POS N
= POS N
0.033) POS N
and POS N
sexual POS N
desire POS N
score POS N
of POS N
SMUF POS N
(P POS N
= POS N
0.021) POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

This POS N
study POS N
suggests POS N
that POS N
flutamide POS N
monotherapy POS N
can POS N
be POS N
an POS N
acceptable POS N
modality POS N
as POS N
an POS N
option POS N
for POS N
neoadjuvant POS N
hormone POS N
therapy. POS N

After POS N
neoadjuvant POS N
hormone POS N
therapy, POS N
the POS N
scores POS N
on POS N
the POS N
sexual POS N
problem POS N
domain POS N
of POS N
EORTC-P POS N
(P POS N
= POS N
0.033) POS N
and POS N
sexual POS N
desire POS N
score POS N
of POS N
SMUF POS N
(P POS N
= POS N
0.021) POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
34 POS N
months POS N
after POS N
prostatectomy, POS N
biochemical POS N
failure-free POS N
survival POS N
rate POS N
in POS N
the POS N
flutamide POS N
group POS N
did POS N
not POS N
differ POS N
from POS N
that POS N
in POS N
the POS N
LHRH POS N
group. POS N

This POS N
study POS N
suggests POS N
that POS N
flutamide POS N
monotherapy POS N
can POS N
be POS N
an POS N
acceptable POS N
modality POS N
as POS N
an POS N
option POS N
for POS N
neoadjuvant POS N
hormone POS N
therapy. POS N

At POS N
radical POS N
prostatectomy, POS N
pathological POS N
variables POS N
were POS N
not POS N
significantly POS N
different POS N
in POS N
the POS N
two POS N
groups. POS N

This POS N
study POS N
suggests POS N
that POS N
flutamide POS N
monotherapy POS N
can POS N
be POS N
an POS N
acceptable POS N
modality POS N
as POS N
an POS N
option POS N
for POS N
neoadjuvant POS N
hormone POS N
therapy. POS N

Serum POS N
testosterone POS N
level POS N
was POS N
significantly POS N
higher POS N
(mean POS N
359.2 POS N
compared POS N
to POS N
10.5, POS N
P POS N
< POS N
0.001), POS N

This POS N
study POS N
suggests POS N
that POS N
flutamide POS N
monotherapy POS N
can POS N
be POS N
an POS N
acceptable POS N
modality POS N
as POS N
an POS N
option POS N
for POS N
neoadjuvant POS N
hormone POS N
therapy. POS N

complete POS N
response POS N
rate POS N
of POS N
PSA POS N
(13% POS N
compared POS N
to POS N
57%, POS N
P POS N
= POS N
0.028) POS N
and POS N
rate POS N
of POS N
downsizing POS N
of POS N
prostate POS N
volume POS N
(mean, POS N
-17.7% POS N
compared POS N
to POS N
-35.4%, POS N
P POS N
= POS N
0.038) POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

This POS N
study POS N
suggests POS N
that POS N
flutamide POS N
monotherapy POS N
can POS N
be POS N
an POS N
acceptable POS N
modality POS N
as POS N
an POS N
option POS N
for POS N
neoadjuvant POS N
hormone POS N
therapy. POS N

After POS N
neoadjuvant POS N
hormone POS N
therapy, POS N
the POS N
scores POS N
on POS N
the POS N
sexual POS N
problem POS N
domain POS N
of POS N
EORTC-P POS N
(P POS N
= POS N
0.033) POS N
and POS N
sexual POS N
desire POS N
score POS N
of POS N
SMUF POS N
(P POS N
= POS N
0.021) POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

This POS N
study POS N
suggests POS N
that POS N
flutamide POS N
monotherapy POS N
can POS N
be POS N
an POS N
acceptable POS N
modality POS N
as POS N
an POS N
option POS N
for POS N
neoadjuvant POS N
hormone POS N
therapy. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
34 POS N
months POS N
after POS N
prostatectomy, POS N
biochemical POS N
failure-free POS N
survival POS N
rate POS N
in POS N
the POS N
flutamide POS N
group POS N
did POS N
not POS N
differ POS N
from POS N
that POS N
in POS N
the POS N
LHRH POS N
group. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
34 POS N
months POS N
after POS N
prostatectomy, POS N
biochemical POS N
failure-free POS N
survival POS N
rate POS N
in POS N
the POS N
flutamide POS N
group POS N
did POS N
not POS N
differ POS N
from POS N
that POS N
in POS N
the POS N
LHRH POS N
group. POS N

At POS N
radical POS N
prostatectomy, POS N
pathological POS N
variables POS N
were POS N
not POS N
significantly POS N
different POS N
in POS N
the POS N
two POS N
groups. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
34 POS N
months POS N
after POS N
prostatectomy, POS N
biochemical POS N
failure-free POS N
survival POS N
rate POS N
in POS N
the POS N
flutamide POS N
group POS N
did POS N
not POS N
differ POS N
from POS N
that POS N
in POS N
the POS N
LHRH POS N
group. POS N

Serum POS N
testosterone POS N
level POS N
was POS N
significantly POS N
higher POS N
(mean POS N
359.2 POS N
compared POS N
to POS N
10.5, POS N
P POS N
< POS N
0.001), POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
34 POS N
months POS N
after POS N
prostatectomy, POS N
biochemical POS N
failure-free POS N
survival POS N
rate POS N
in POS N
the POS N
flutamide POS N
group POS N
did POS N
not POS N
differ POS N
from POS N
that POS N
in POS N
the POS N
LHRH POS N
group. POS N

complete POS N
response POS N
rate POS N
of POS N
PSA POS N
(13% POS N
compared POS N
to POS N
57%, POS N
P POS N
= POS N
0.028) POS N
and POS N
rate POS N
of POS N
downsizing POS N
of POS N
prostate POS N
volume POS N
(mean, POS N
-17.7% POS N
compared POS N
to POS N
-35.4%, POS N
P POS N
= POS N
0.038) POS N
were POS N
significantly POS N
lower POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
34 POS N
months POS N
after POS N
prostatectomy, POS N
biochemical POS N
failure-free POS N
survival POS N
rate POS N
in POS N
the POS N
flutamide POS N
group POS N
did POS N
not POS N
differ POS N
from POS N
that POS N
in POS N
the POS N
LHRH POS N
group. POS N

After POS N
neoadjuvant POS N
hormone POS N
therapy, POS N
the POS N
scores POS N
on POS N
the POS N
sexual POS N
problem POS N
domain POS N
of POS N
EORTC-P POS N
(P POS N
= POS N
0.033) POS N
and POS N
sexual POS N
desire POS N
score POS N
of POS N
SMUF POS N
(P POS N
= POS N
0.021) POS N
were POS N
significantly POS N
higher POS N
in POS N
the POS N
flutamide POS N
group POS N
than POS N
in POS N
the POS N
LHRH POS N
group. POS N

At POS N
a POS N
median POS N
follow-up POS N
of POS N
34 POS N
months POS N
after POS N
prostatectomy, POS N
biochemical POS N
failure-free POS N
survival POS N
rate POS N
in POS N
the POS N
flutamide POS N
group POS N
did POS N
not POS N
differ POS N
from POS N
that POS N
in POS N
the POS N
LHRH POS N
group. POS N

This POS N
study POS N
suggests POS N
that POS N
flutamide POS N
monotherapy POS N
can POS N
be POS N
an POS N
acceptable POS N
modality POS N
as POS N
an POS N
option POS N
for POS N
neoadjuvant POS N
hormone POS N
therapy. POS N

Both POS N
treatments POS N
demonstrated POS N
favorable POS N
ocular POS N
tolerability. POS N

Fixed-combination POS N
brimonidine-timolol POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Both POS N
treatments POS N
demonstrated POS N
favorable POS N
ocular POS N
tolerability. POS N

The POS N
percentage POS N
of POS N
patients POS N
achieving POS N
at POS N
least POS N
a POS N
20% POS N
decrease POS N
from POS N
baseline POS N
diurnal POS N
IOP POS N
at POS N
week POS N
12 POS N
was POS N
87.7% POS N
in POS N
the POS N
brimonidine-timolol POS N
group POS N
and POS N
77.3% POS N
in POS N
the POS N
latanoprost POS N
group POS N
(p POS N
= POS N
0.131). POS N

Both POS N
treatments POS N
demonstrated POS N
favorable POS N
ocular POS N
tolerability. POS N

At POS N
week POS N
12, POS N
the POS N
mean POS N
(SD) POS N
diurnal POS N
IOP POS N
was POS N
17.8 POS N
(2.9) POS N
mmHg POS N
with POS N
brimonidine-timolol POS N
and POS N
17.9 POS N
(3.9) POS N
mmHg POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.794). POS N

Both POS N
treatments POS N
demonstrated POS N
favorable POS N
ocular POS N
tolerability. POS N

Measured POS N
biomicroscopic POS N
changes POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
infrequent POS N
in POS N
both POS N
groups. POS N

Fixed-combination POS N
brimonidine-timolol POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Both POS N
treatments POS N
demonstrated POS N
favorable POS N
ocular POS N
tolerability. POS N

Fixed-combination POS N
brimonidine-timolol POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

The POS N
percentage POS N
of POS N
patients POS N
achieving POS N
at POS N
least POS N
a POS N
20% POS N
decrease POS N
from POS N
baseline POS N
diurnal POS N
IOP POS N
at POS N
week POS N
12 POS N
was POS N
87.7% POS N
in POS N
the POS N
brimonidine-timolol POS N
group POS N
and POS N
77.3% POS N
in POS N
the POS N
latanoprost POS N
group POS N
(p POS N
= POS N
0.131). POS N

Fixed-combination POS N
brimonidine-timolol POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

At POS N
week POS N
12, POS N
the POS N
mean POS N
(SD) POS N
diurnal POS N
IOP POS N
was POS N
17.8 POS N
(2.9) POS N
mmHg POS N
with POS N
brimonidine-timolol POS N
and POS N
17.9 POS N
(3.9) POS N
mmHg POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.794). POS N

Fixed-combination POS N
brimonidine-timolol POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Measured POS N
biomicroscopic POS N
changes POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
infrequent POS N
in POS N
both POS N
groups. POS N

The POS N
percentage POS N
of POS N
patients POS N
achieving POS N
at POS N
least POS N
a POS N
20% POS N
decrease POS N
from POS N
baseline POS N
diurnal POS N
IOP POS N
at POS N
week POS N
12 POS N
was POS N
87.7% POS N
in POS N
the POS N
brimonidine-timolol POS N
group POS N
and POS N
77.3% POS N
in POS N
the POS N
latanoprost POS N
group POS N
(p POS N
= POS N
0.131). POS N

Both POS N
treatments POS N
demonstrated POS N
favorable POS N
ocular POS N
tolerability. POS N

The POS N
percentage POS N
of POS N
patients POS N
achieving POS N
at POS N
least POS N
a POS N
20% POS N
decrease POS N
from POS N
baseline POS N
diurnal POS N
IOP POS N
at POS N
week POS N
12 POS N
was POS N
87.7% POS N
in POS N
the POS N
brimonidine-timolol POS N
group POS N
and POS N
77.3% POS N
in POS N
the POS N
latanoprost POS N
group POS N
(p POS N
= POS N
0.131). POS N

Fixed-combination POS N
brimonidine-timolol POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

The POS N
percentage POS N
of POS N
patients POS N
achieving POS N
at POS N
least POS N
a POS N
20% POS N
decrease POS N
from POS N
baseline POS N
diurnal POS N
IOP POS N
at POS N
week POS N
12 POS N
was POS N
87.7% POS N
in POS N
the POS N
brimonidine-timolol POS N
group POS N
and POS N
77.3% POS N
in POS N
the POS N
latanoprost POS N
group POS N
(p POS N
= POS N
0.131). POS N

At POS N
week POS N
12, POS N
the POS N
mean POS N
(SD) POS N
diurnal POS N
IOP POS N
was POS N
17.8 POS N
(2.9) POS N
mmHg POS N
with POS N
brimonidine-timolol POS N
and POS N
17.9 POS N
(3.9) POS N
mmHg POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.794). POS N

The POS N
percentage POS N
of POS N
patients POS N
achieving POS N
at POS N
least POS N
a POS N
20% POS N
decrease POS N
from POS N
baseline POS N
diurnal POS N
IOP POS N
at POS N
week POS N
12 POS N
was POS N
87.7% POS N
in POS N
the POS N
brimonidine-timolol POS N
group POS N
and POS N
77.3% POS N
in POS N
the POS N
latanoprost POS N
group POS N
(p POS N
= POS N
0.131). POS N

Measured POS N
biomicroscopic POS N
changes POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
infrequent POS N
in POS N
both POS N
groups. POS N

At POS N
week POS N
12, POS N
the POS N
mean POS N
(SD) POS N
diurnal POS N
IOP POS N
was POS N
17.8 POS N
(2.9) POS N
mmHg POS N
with POS N
brimonidine-timolol POS N
and POS N
17.9 POS N
(3.9) POS N
mmHg POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.794). POS N

Both POS N
treatments POS N
demonstrated POS N
favorable POS N
ocular POS N
tolerability. POS N

At POS N
week POS N
12, POS N
the POS N
mean POS N
(SD) POS N
diurnal POS N
IOP POS N
was POS N
17.8 POS N
(2.9) POS N
mmHg POS N
with POS N
brimonidine-timolol POS N
and POS N
17.9 POS N
(3.9) POS N
mmHg POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.794). POS N

Fixed-combination POS N
brimonidine-timolol POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

At POS N
week POS N
12, POS N
the POS N
mean POS N
(SD) POS N
diurnal POS N
IOP POS N
was POS N
17.8 POS N
(2.9) POS N
mmHg POS N
with POS N
brimonidine-timolol POS N
and POS N
17.9 POS N
(3.9) POS N
mmHg POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.794). POS N

The POS N
percentage POS N
of POS N
patients POS N
achieving POS N
at POS N
least POS N
a POS N
20% POS N
decrease POS N
from POS N
baseline POS N
diurnal POS N
IOP POS N
at POS N
week POS N
12 POS N
was POS N
87.7% POS N
in POS N
the POS N
brimonidine-timolol POS N
group POS N
and POS N
77.3% POS N
in POS N
the POS N
latanoprost POS N
group POS N
(p POS N
= POS N
0.131). POS N

At POS N
week POS N
12, POS N
the POS N
mean POS N
(SD) POS N
diurnal POS N
IOP POS N
was POS N
17.8 POS N
(2.9) POS N
mmHg POS N
with POS N
brimonidine-timolol POS N
and POS N
17.9 POS N
(3.9) POS N
mmHg POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.794). POS N

Measured POS N
biomicroscopic POS N
changes POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
infrequent POS N
in POS N
both POS N
groups. POS N

Measured POS N
biomicroscopic POS N
changes POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
infrequent POS N
in POS N
both POS N
groups. POS N

Both POS N
treatments POS N
demonstrated POS N
favorable POS N
ocular POS N
tolerability. POS N

Measured POS N
biomicroscopic POS N
changes POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
infrequent POS N
in POS N
both POS N
groups. POS N

Fixed-combination POS N
brimonidine-timolol POS N
was POS N
as POS N
effective POS N
as POS N
latanoprost POS N
in POS N
reducing POS N
IOP POS N
in POS N
patients POS N
with POS N
glaucoma POS N
or POS N
ocular POS N
hypertension. POS N

Measured POS N
biomicroscopic POS N
changes POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
infrequent POS N
in POS N
both POS N
groups. POS N

The POS N
percentage POS N
of POS N
patients POS N
achieving POS N
at POS N
least POS N
a POS N
20% POS N
decrease POS N
from POS N
baseline POS N
diurnal POS N
IOP POS N
at POS N
week POS N
12 POS N
was POS N
87.7% POS N
in POS N
the POS N
brimonidine-timolol POS N
group POS N
and POS N
77.3% POS N
in POS N
the POS N
latanoprost POS N
group POS N
(p POS N
= POS N
0.131). POS N

Measured POS N
biomicroscopic POS N
changes POS N
from POS N
baseline POS N
to POS N
week POS N
12 POS N
were POS N
infrequent POS N
in POS N
both POS N
groups. POS N

At POS N
week POS N
12, POS N
the POS N
mean POS N
(SD) POS N
diurnal POS N
IOP POS N
was POS N
17.8 POS N
(2.9) POS N
mmHg POS N
with POS N
brimonidine-timolol POS N
and POS N
17.9 POS N
(3.9) POS N
mmHg POS N
with POS N
latanoprost POS N
(p POS N
= POS N
0.794). POS N

This POS N
study POS N
suggests POS N
the POS N
possibility POS N
of POS N
Korean POS N
Red POS N
Ginseng POS N
as POS N
a POS N
complementary POS N
therapy POS N
for POS N
chronic POS N
hepatitis POS N
B. POS N

The POS N
non-invasive POS N
fibrosis POS N
serologic POS N
markers POS N
were POS N
further POS N
decreased POS N
in POS N
the POS N
experimental POS N
group, POS N
with POS N
significant POS N
differences POS N
after POS N
treatment POS N
observed POS N
for POS N
hyaluronic POS N
acid POS N
(p = 0.032) POS N
and POS N
transforming POS N
growth POS N
factor-β POS N
(p = 0.008), POS N
but POS N
not POS N
for POS N
type POS N
IV POS N
collagen POS N
(p = 0.174). POS N

This POS N
study POS N
suggests POS N
the POS N
possibility POS N
of POS N
Korean POS N
Red POS N
Ginseng POS N
as POS N
a POS N
complementary POS N
therapy POS N
for POS N
chronic POS N
hepatitis POS N
B. POS N

Differences POS N
in POS N
several POS N
non-invasive POS N
fibrosis POS N
serologic POS N
markers POS N
(type POS N
IV POS N
collagen, POS N
hyaluronic POS N
acid, POS N
transforming POS N
growth POS N
factor-β) POS N
and POS N
in POS N
the POS N
hepatitis POS N
B POS N
virus POS N
DNA POS N
levels POS N
were POS N
compared POS N
between POS N
the POS N
groups. POS N

The POS N
non-invasive POS N
fibrosis POS N
serologic POS N
markers POS N
were POS N
further POS N
decreased POS N
in POS N
the POS N
experimental POS N
group, POS N
with POS N
significant POS N
differences POS N
after POS N
treatment POS N
observed POS N
for POS N
hyaluronic POS N
acid POS N
(p = 0.032) POS N
and POS N
transforming POS N
growth POS N
factor-β POS N
(p = 0.008), POS N
but POS N
not POS N
for POS N
type POS N
IV POS N
collagen POS N
(p = 0.174). POS N

This POS N
study POS N
suggests POS N
the POS N
possibility POS N
of POS N
Korean POS N
Red POS N
Ginseng POS N
as POS N
a POS N
complementary POS N
therapy POS N
for POS N
chronic POS N
hepatitis POS N
B. POS N

The POS N
non-invasive POS N
fibrosis POS N
serologic POS N
markers POS N
were POS N
further POS N
decreased POS N
in POS N
the POS N
experimental POS N
group, POS N
with POS N
significant POS N
differences POS N
after POS N
treatment POS N
observed POS N
for POS N
hyaluronic POS N
acid POS N
(p = 0.032) POS N
and POS N
transforming POS N
growth POS N
factor-β POS N
(p = 0.008), POS N
but POS N
not POS N
for POS N
type POS N
IV POS N
collagen POS N
(p = 0.174). POS N

Differences POS N
in POS N
several POS N
non-invasive POS N
fibrosis POS N
serologic POS N
markers POS N
(type POS N
IV POS N
collagen, POS N
hyaluronic POS N
acid, POS N
transforming POS N
growth POS N
factor-β) POS N
and POS N
in POS N
the POS N
hepatitis POS N
B POS N
virus POS N
DNA POS N
levels POS N
were POS N
compared POS N
between POS N
the POS N
groups. POS N

Differences POS N
in POS N
several POS N
non-invasive POS N
fibrosis POS N
serologic POS N
markers POS N
(type POS N
IV POS N
collagen, POS N
hyaluronic POS N
acid, POS N
transforming POS N
growth POS N
factor-β) POS N
and POS N
in POS N
the POS N
hepatitis POS N
B POS N
virus POS N
DNA POS N
levels POS N
were POS N
compared POS N
between POS N
the POS N
groups. POS N

This POS N
study POS N
suggests POS N
the POS N
possibility POS N
of POS N
Korean POS N
Red POS N
Ginseng POS N
as POS N
a POS N
complementary POS N
therapy POS N
for POS N
chronic POS N
hepatitis POS N
B. POS N

Differences POS N
in POS N
several POS N
non-invasive POS N
fibrosis POS N
serologic POS N
markers POS N
(type POS N
IV POS N
collagen, POS N
hyaluronic POS N
acid, POS N
transforming POS N
growth POS N
factor-β) POS N
and POS N
in POS N
the POS N
hepatitis POS N
B POS N
virus POS N
DNA POS N
levels POS N
were POS N
compared POS N
between POS N
the POS N
groups. POS N

The POS N
non-invasive POS N
fibrosis POS N
serologic POS N
markers POS N
were POS N
further POS N
decreased POS N
in POS N
the POS N
experimental POS N
group, POS N
with POS N
significant POS N
differences POS N
after POS N
treatment POS N
observed POS N
for POS N
hyaluronic POS N
acid POS N
(p = 0.032) POS N
and POS N
transforming POS N
growth POS N
factor-β POS N
(p = 0.008), POS N
but POS N
not POS N
for POS N
type POS N
IV POS N
collagen POS N
(p = 0.174). POS N

Fewer POS N
complications POS N
were POS N
noted POS N
in POS N
eyes POS N
receiving POS N
sclerostomy POS N
(5/29, POS N
17.2%) POS N
as POS N
compared POS N
to POS N
control POS N
group POS N
eyes POS N
(12/31, POS N
38.7%), POS N
though POS N
differences POS N
were POS N
marginally POS N
significant POS N
(P POS N
= POS N
.065). POS N

Four POS N
control POS N
group, POS N
but POS N
no POS N
sclerostomy POS N
group, POS N
eyes POS N
developed POS N
postoperative POS N
uveal POS N
effusions POS N
(P POS N
= POS N
.04). POS N

Fewer POS N
complications POS N
were POS N
noted POS N
in POS N
eyes POS N
receiving POS N
sclerostomy POS N
(5/29, POS N
17.2%) POS N
as POS N
compared POS N
to POS N
control POS N
group POS N
eyes POS N
(12/31, POS N
38.7%), POS N
though POS N
differences POS N
were POS N
marginally POS N
significant POS N
(P POS N
= POS N
.065). POS N

In POS N
multivariable POS N
models, POS N
sclerostomy POS N
decreased POS N
the POS N
odds POS N
of POS N
an POS N
intraoperative POS N
or POS N
postoperative POS N
complication POS N
by POS N
80% POS N
(odds POS N
ratio POS N
[OR] POS N
= POS N
0.2, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
0.04-0.92, POS N
P POS N
= POS N
.039); POS N

Fewer POS N
complications POS N
were POS N
noted POS N
in POS N
eyes POS N
receiving POS N
sclerostomy POS N
(5/29, POS N
17.2%) POS N
as POS N
compared POS N
to POS N
control POS N
group POS N
eyes POS N
(12/31, POS N
38.7%), POS N
though POS N
differences POS N
were POS N
marginally POS N
significant POS N
(P POS N
= POS N
.065). POS N

SICS POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
risk POS N
of POS N
complications POS N
as POS N
compared POS N
to POS N
phacoemulsification POS N
(OR POS N
= POS N
5.95, POS N
95% POS N
CI POS N
= POS N
1.49-23.73, POS N
P POS N
= POS N
.012), POS N
while POS N
high POS N
preoperative POS N
intraocular POS N
pressure POS N
(OR POS N
= POS N
4.54, POS N
95% POS N
CI POS N
= POS N
0.99-20.9, POS N
P POS N
= POS N
.052) POS N
and POS N
greater POS N
lens POS N
thickness POS N
(OR POS N
= POS N
3.38, POS N
95% POS N
CI POS N
= POS N
0.88-12.91, POS N
P POS N
= POS N
.075) POS N
demonstrated POS N
a POS N
marginally POS N
significant POS N
association. POS N

Fewer POS N
complications POS N
were POS N
noted POS N
in POS N
eyes POS N
receiving POS N
sclerostomy POS N
(5/29, POS N
17.2%) POS N
as POS N
compared POS N
to POS N
control POS N
group POS N
eyes POS N
(12/31, POS N
38.7%), POS N
though POS N
differences POS N
were POS N
marginally POS N
significant POS N
(P POS N
= POS N
.065). POS N

Cataract POS N
surgery POS N
in POS N
eyes POS N
with POS N
nanophthalmos POS N
is POS N
associated POS N
with POS N
a POS N
high POS N
risk POS N
for POS N
vision-threatening POS N
complications. POS N

Fewer POS N
complications POS N
were POS N
noted POS N
in POS N
eyes POS N
receiving POS N
sclerostomy POS N
(5/29, POS N
17.2%) POS N
as POS N
compared POS N
to POS N
control POS N
group POS N
eyes POS N
(12/31, POS N
38.7%), POS N
though POS N
differences POS N
were POS N
marginally POS N
significant POS N
(P POS N
= POS N
.065). POS N

Performing POS N
a POS N
simultaneous POS N
prophylactic POS N
sclerostomy POS N
with POS N
cataract POS N
surgery POS N
reduces POS N
complication POS N
rates, POS N
particularly POS N
uveal POS N
effusions. POS N

Fewer POS N
complications POS N
were POS N
noted POS N
in POS N
eyes POS N
receiving POS N
sclerostomy POS N
(5/29, POS N
17.2%) POS N
as POS N
compared POS N
to POS N
control POS N
group POS N
eyes POS N
(12/31, POS N
38.7%), POS N
though POS N
differences POS N
were POS N
marginally POS N
significant POS N
(P POS N
= POS N
.065). POS N

Cataract POS N
surgery POS N
at POS N
earlier POS N
stages POS N
by POS N
phacoemulsification POS N
may POS N
be POS N
more POS N
beneficial POS N
than POS N
undergoing POS N
manual POS N
SICS. POS N

Four POS N
control POS N
group, POS N
but POS N
no POS N
sclerostomy POS N
group, POS N
eyes POS N
developed POS N
postoperative POS N
uveal POS N
effusions POS N
(P POS N
= POS N
.04). POS N

Fewer POS N
complications POS N
were POS N
noted POS N
in POS N
eyes POS N
receiving POS N
sclerostomy POS N
(5/29, POS N
17.2%) POS N
as POS N
compared POS N
to POS N
control POS N
group POS N
eyes POS N
(12/31, POS N
38.7%), POS N
though POS N
differences POS N
were POS N
marginally POS N
significant POS N
(P POS N
= POS N
.065). POS N

Four POS N
control POS N
group, POS N
but POS N
no POS N
sclerostomy POS N
group, POS N
eyes POS N
developed POS N
postoperative POS N
uveal POS N
effusions POS N
(P POS N
= POS N
.04). POS N

In POS N
multivariable POS N
models, POS N
sclerostomy POS N
decreased POS N
the POS N
odds POS N
of POS N
an POS N
intraoperative POS N
or POS N
postoperative POS N
complication POS N
by POS N
80% POS N
(odds POS N
ratio POS N
[OR] POS N
= POS N
0.2, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
0.04-0.92, POS N
P POS N
= POS N
.039); POS N

Four POS N
control POS N
group, POS N
but POS N
no POS N
sclerostomy POS N
group, POS N
eyes POS N
developed POS N
postoperative POS N
uveal POS N
effusions POS N
(P POS N
= POS N
.04). POS N

SICS POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
risk POS N
of POS N
complications POS N
as POS N
compared POS N
to POS N
phacoemulsification POS N
(OR POS N
= POS N
5.95, POS N
95% POS N
CI POS N
= POS N
1.49-23.73, POS N
P POS N
= POS N
.012), POS N
while POS N
high POS N
preoperative POS N
intraocular POS N
pressure POS N
(OR POS N
= POS N
4.54, POS N
95% POS N
CI POS N
= POS N
0.99-20.9, POS N
P POS N
= POS N
.052) POS N
and POS N
greater POS N
lens POS N
thickness POS N
(OR POS N
= POS N
3.38, POS N
95% POS N
CI POS N
= POS N
0.88-12.91, POS N
P POS N
= POS N
.075) POS N
demonstrated POS N
a POS N
marginally POS N
significant POS N
association. POS N

Four POS N
control POS N
group, POS N
but POS N
no POS N
sclerostomy POS N
group, POS N
eyes POS N
developed POS N
postoperative POS N
uveal POS N
effusions POS N
(P POS N
= POS N
.04). POS N

Cataract POS N
surgery POS N
in POS N
eyes POS N
with POS N
nanophthalmos POS N
is POS N
associated POS N
with POS N
a POS N
high POS N
risk POS N
for POS N
vision-threatening POS N
complications. POS N

Four POS N
control POS N
group, POS N
but POS N
no POS N
sclerostomy POS N
group, POS N
eyes POS N
developed POS N
postoperative POS N
uveal POS N
effusions POS N
(P POS N
= POS N
.04). POS N

Performing POS N
a POS N
simultaneous POS N
prophylactic POS N
sclerostomy POS N
with POS N
cataract POS N
surgery POS N
reduces POS N
complication POS N
rates, POS N
particularly POS N
uveal POS N
effusions. POS N

Four POS N
control POS N
group, POS N
but POS N
no POS N
sclerostomy POS N
group, POS N
eyes POS N
developed POS N
postoperative POS N
uveal POS N
effusions POS N
(P POS N
= POS N
.04). POS N

Cataract POS N
surgery POS N
at POS N
earlier POS N
stages POS N
by POS N
phacoemulsification POS N
may POS N
be POS N
more POS N
beneficial POS N
than POS N
undergoing POS N
manual POS N
SICS. POS N

In POS N
multivariable POS N
models, POS N
sclerostomy POS N
decreased POS N
the POS N
odds POS N
of POS N
an POS N
intraoperative POS N
or POS N
postoperative POS N
complication POS N
by POS N
80% POS N
(odds POS N
ratio POS N
[OR] POS N
= POS N
0.2, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
0.04-0.92, POS N
P POS N
= POS N
.039); POS N

Fewer POS N
complications POS N
were POS N
noted POS N
in POS N
eyes POS N
receiving POS N
sclerostomy POS N
(5/29, POS N
17.2%) POS N
as POS N
compared POS N
to POS N
control POS N
group POS N
eyes POS N
(12/31, POS N
38.7%), POS N
though POS N
differences POS N
were POS N
marginally POS N
significant POS N
(P POS N
= POS N
.065). POS N

In POS N
multivariable POS N
models, POS N
sclerostomy POS N
decreased POS N
the POS N
odds POS N
of POS N
an POS N
intraoperative POS N
or POS N
postoperative POS N
complication POS N
by POS N
80% POS N
(odds POS N
ratio POS N
[OR] POS N
= POS N
0.2, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
0.04-0.92, POS N
P POS N
= POS N
.039); POS N

Four POS N
control POS N
group, POS N
but POS N
no POS N
sclerostomy POS N
group, POS N
eyes POS N
developed POS N
postoperative POS N
uveal POS N
effusions POS N
(P POS N
= POS N
.04). POS N

In POS N
multivariable POS N
models, POS N
sclerostomy POS N
decreased POS N
the POS N
odds POS N
of POS N
an POS N
intraoperative POS N
or POS N
postoperative POS N
complication POS N
by POS N
80% POS N
(odds POS N
ratio POS N
[OR] POS N
= POS N
0.2, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
0.04-0.92, POS N
P POS N
= POS N
.039); POS N

SICS POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
risk POS N
of POS N
complications POS N
as POS N
compared POS N
to POS N
phacoemulsification POS N
(OR POS N
= POS N
5.95, POS N
95% POS N
CI POS N
= POS N
1.49-23.73, POS N
P POS N
= POS N
.012), POS N
while POS N
high POS N
preoperative POS N
intraocular POS N
pressure POS N
(OR POS N
= POS N
4.54, POS N
95% POS N
CI POS N
= POS N
0.99-20.9, POS N
P POS N
= POS N
.052) POS N
and POS N
greater POS N
lens POS N
thickness POS N
(OR POS N
= POS N
3.38, POS N
95% POS N
CI POS N
= POS N
0.88-12.91, POS N
P POS N
= POS N
.075) POS N
demonstrated POS N
a POS N
marginally POS N
significant POS N
association. POS N

In POS N
multivariable POS N
models, POS N
sclerostomy POS N
decreased POS N
the POS N
odds POS N
of POS N
an POS N
intraoperative POS N
or POS N
postoperative POS N
complication POS N
by POS N
80% POS N
(odds POS N
ratio POS N
[OR] POS N
= POS N
0.2, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
0.04-0.92, POS N
P POS N
= POS N
.039); POS N

Cataract POS N
surgery POS N
in POS N
eyes POS N
with POS N
nanophthalmos POS N
is POS N
associated POS N
with POS N
a POS N
high POS N
risk POS N
for POS N
vision-threatening POS N
complications. POS N

In POS N
multivariable POS N
models, POS N
sclerostomy POS N
decreased POS N
the POS N
odds POS N
of POS N
an POS N
intraoperative POS N
or POS N
postoperative POS N
complication POS N
by POS N
80% POS N
(odds POS N
ratio POS N
[OR] POS N
= POS N
0.2, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
0.04-0.92, POS N
P POS N
= POS N
.039); POS N

Performing POS N
a POS N
simultaneous POS N
prophylactic POS N
sclerostomy POS N
with POS N
cataract POS N
surgery POS N
reduces POS N
complication POS N
rates, POS N
particularly POS N
uveal POS N
effusions. POS N

In POS N
multivariable POS N
models, POS N
sclerostomy POS N
decreased POS N
the POS N
odds POS N
of POS N
an POS N
intraoperative POS N
or POS N
postoperative POS N
complication POS N
by POS N
80% POS N
(odds POS N
ratio POS N
[OR] POS N
= POS N
0.2, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
0.04-0.92, POS N
P POS N
= POS N
.039); POS N

Cataract POS N
surgery POS N
at POS N
earlier POS N
stages POS N
by POS N
phacoemulsification POS N
may POS N
be POS N
more POS N
beneficial POS N
than POS N
undergoing POS N
manual POS N
SICS. POS N

SICS POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
risk POS N
of POS N
complications POS N
as POS N
compared POS N
to POS N
phacoemulsification POS N
(OR POS N
= POS N
5.95, POS N
95% POS N
CI POS N
= POS N
1.49-23.73, POS N
P POS N
= POS N
.012), POS N
while POS N
high POS N
preoperative POS N
intraocular POS N
pressure POS N
(OR POS N
= POS N
4.54, POS N
95% POS N
CI POS N
= POS N
0.99-20.9, POS N
P POS N
= POS N
.052) POS N
and POS N
greater POS N
lens POS N
thickness POS N
(OR POS N
= POS N
3.38, POS N
95% POS N
CI POS N
= POS N
0.88-12.91, POS N
P POS N
= POS N
.075) POS N
demonstrated POS N
a POS N
marginally POS N
significant POS N
association. POS N

Fewer POS N
complications POS N
were POS N
noted POS N
in POS N
eyes POS N
receiving POS N
sclerostomy POS N
(5/29, POS N
17.2%) POS N
as POS N
compared POS N
to POS N
control POS N
group POS N
eyes POS N
(12/31, POS N
38.7%), POS N
though POS N
differences POS N
were POS N
marginally POS N
significant POS N
(P POS N
= POS N
.065). POS N

SICS POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
risk POS N
of POS N
complications POS N
as POS N
compared POS N
to POS N
phacoemulsification POS N
(OR POS N
= POS N
5.95, POS N
95% POS N
CI POS N
= POS N
1.49-23.73, POS N
P POS N
= POS N
.012), POS N
while POS N
high POS N
preoperative POS N
intraocular POS N
pressure POS N
(OR POS N
= POS N
4.54, POS N
95% POS N
CI POS N
= POS N
0.99-20.9, POS N
P POS N
= POS N
.052) POS N
and POS N
greater POS N
lens POS N
thickness POS N
(OR POS N
= POS N
3.38, POS N
95% POS N
CI POS N
= POS N
0.88-12.91, POS N
P POS N
= POS N
.075) POS N
demonstrated POS N
a POS N
marginally POS N
significant POS N
association. POS N

Four POS N
control POS N
group, POS N
but POS N
no POS N
sclerostomy POS N
group, POS N
eyes POS N
developed POS N
postoperative POS N
uveal POS N
effusions POS N
(P POS N
= POS N
.04). POS N

SICS POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
risk POS N
of POS N
complications POS N
as POS N
compared POS N
to POS N
phacoemulsification POS N
(OR POS N
= POS N
5.95, POS N
95% POS N
CI POS N
= POS N
1.49-23.73, POS N
P POS N
= POS N
.012), POS N
while POS N
high POS N
preoperative POS N
intraocular POS N
pressure POS N
(OR POS N
= POS N
4.54, POS N
95% POS N
CI POS N
= POS N
0.99-20.9, POS N
P POS N
= POS N
.052) POS N
and POS N
greater POS N
lens POS N
thickness POS N
(OR POS N
= POS N
3.38, POS N
95% POS N
CI POS N
= POS N
0.88-12.91, POS N
P POS N
= POS N
.075) POS N
demonstrated POS N
a POS N
marginally POS N
significant POS N
association. POS N

In POS N
multivariable POS N
models, POS N
sclerostomy POS N
decreased POS N
the POS N
odds POS N
of POS N
an POS N
intraoperative POS N
or POS N
postoperative POS N
complication POS N
by POS N
80% POS N
(odds POS N
ratio POS N
[OR] POS N
= POS N
0.2, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
0.04-0.92, POS N
P POS N
= POS N
.039); POS N

SICS POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
risk POS N
of POS N
complications POS N
as POS N
compared POS N
to POS N
phacoemulsification POS N
(OR POS N
= POS N
5.95, POS N
95% POS N
CI POS N
= POS N
1.49-23.73, POS N
P POS N
= POS N
.012), POS N
while POS N
high POS N
preoperative POS N
intraocular POS N
pressure POS N
(OR POS N
= POS N
4.54, POS N
95% POS N
CI POS N
= POS N
0.99-20.9, POS N
P POS N
= POS N
.052) POS N
and POS N
greater POS N
lens POS N
thickness POS N
(OR POS N
= POS N
3.38, POS N
95% POS N
CI POS N
= POS N
0.88-12.91, POS N
P POS N
= POS N
.075) POS N
demonstrated POS N
a POS N
marginally POS N
significant POS N
association. POS N

Cataract POS N
surgery POS N
in POS N
eyes POS N
with POS N
nanophthalmos POS N
is POS N
associated POS N
with POS N
a POS N
high POS N
risk POS N
for POS N
vision-threatening POS N
complications. POS N

SICS POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
risk POS N
of POS N
complications POS N
as POS N
compared POS N
to POS N
phacoemulsification POS N
(OR POS N
= POS N
5.95, POS N
95% POS N
CI POS N
= POS N
1.49-23.73, POS N
P POS N
= POS N
.012), POS N
while POS N
high POS N
preoperative POS N
intraocular POS N
pressure POS N
(OR POS N
= POS N
4.54, POS N
95% POS N
CI POS N
= POS N
0.99-20.9, POS N
P POS N
= POS N
.052) POS N
and POS N
greater POS N
lens POS N
thickness POS N
(OR POS N
= POS N
3.38, POS N
95% POS N
CI POS N
= POS N
0.88-12.91, POS N
P POS N
= POS N
.075) POS N
demonstrated POS N
a POS N
marginally POS N
significant POS N
association. POS N

Performing POS N
a POS N
simultaneous POS N
prophylactic POS N
sclerostomy POS N
with POS N
cataract POS N
surgery POS N
reduces POS N
complication POS N
rates, POS N
particularly POS N
uveal POS N
effusions. POS N

SICS POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
risk POS N
of POS N
complications POS N
as POS N
compared POS N
to POS N
phacoemulsification POS N
(OR POS N
= POS N
5.95, POS N
95% POS N
CI POS N
= POS N
1.49-23.73, POS N
P POS N
= POS N
.012), POS N
while POS N
high POS N
preoperative POS N
intraocular POS N
pressure POS N
(OR POS N
= POS N
4.54, POS N
95% POS N
CI POS N
= POS N
0.99-20.9, POS N
P POS N
= POS N
.052) POS N
and POS N
greater POS N
lens POS N
thickness POS N
(OR POS N
= POS N
3.38, POS N
95% POS N
CI POS N
= POS N
0.88-12.91, POS N
P POS N
= POS N
.075) POS N
demonstrated POS N
a POS N
marginally POS N
significant POS N
association. POS N

Cataract POS N
surgery POS N
at POS N
earlier POS N
stages POS N
by POS N
phacoemulsification POS N
may POS N
be POS N
more POS N
beneficial POS N
than POS N
undergoing POS N
manual POS N
SICS. POS N

Cataract POS N
surgery POS N
in POS N
eyes POS N
with POS N
nanophthalmos POS N
is POS N
associated POS N
with POS N
a POS N
high POS N
risk POS N
for POS N
vision-threatening POS N
complications. POS N

Fewer POS N
complications POS N
were POS N
noted POS N
in POS N
eyes POS N
receiving POS N
sclerostomy POS N
(5/29, POS N
17.2%) POS N
as POS N
compared POS N
to POS N
control POS N
group POS N
eyes POS N
(12/31, POS N
38.7%), POS N
though POS N
differences POS N
were POS N
marginally POS N
significant POS N
(P POS N
= POS N
.065). POS N

Cataract POS N
surgery POS N
in POS N
eyes POS N
with POS N
nanophthalmos POS N
is POS N
associated POS N
with POS N
a POS N
high POS N
risk POS N
for POS N
vision-threatening POS N
complications. POS N

Four POS N
control POS N
group, POS N
but POS N
no POS N
sclerostomy POS N
group, POS N
eyes POS N
developed POS N
postoperative POS N
uveal POS N
effusions POS N
(P POS N
= POS N
.04). POS N

Cataract POS N
surgery POS N
in POS N
eyes POS N
with POS N
nanophthalmos POS N
is POS N
associated POS N
with POS N
a POS N
high POS N
risk POS N
for POS N
vision-threatening POS N
complications. POS N

In POS N
multivariable POS N
models, POS N
sclerostomy POS N
decreased POS N
the POS N
odds POS N
of POS N
an POS N
intraoperative POS N
or POS N
postoperative POS N
complication POS N
by POS N
80% POS N
(odds POS N
ratio POS N
[OR] POS N
= POS N
0.2, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
0.04-0.92, POS N
P POS N
= POS N
.039); POS N

Cataract POS N
surgery POS N
in POS N
eyes POS N
with POS N
nanophthalmos POS N
is POS N
associated POS N
with POS N
a POS N
high POS N
risk POS N
for POS N
vision-threatening POS N
complications. POS N

SICS POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
risk POS N
of POS N
complications POS N
as POS N
compared POS N
to POS N
phacoemulsification POS N
(OR POS N
= POS N
5.95, POS N
95% POS N
CI POS N
= POS N
1.49-23.73, POS N
P POS N
= POS N
.012), POS N
while POS N
high POS N
preoperative POS N
intraocular POS N
pressure POS N
(OR POS N
= POS N
4.54, POS N
95% POS N
CI POS N
= POS N
0.99-20.9, POS N
P POS N
= POS N
.052) POS N
and POS N
greater POS N
lens POS N
thickness POS N
(OR POS N
= POS N
3.38, POS N
95% POS N
CI POS N
= POS N
0.88-12.91, POS N
P POS N
= POS N
.075) POS N
demonstrated POS N
a POS N
marginally POS N
significant POS N
association. POS N

Cataract POS N
surgery POS N
in POS N
eyes POS N
with POS N
nanophthalmos POS N
is POS N
associated POS N
with POS N
a POS N
high POS N
risk POS N
for POS N
vision-threatening POS N
complications. POS N

Performing POS N
a POS N
simultaneous POS N
prophylactic POS N
sclerostomy POS N
with POS N
cataract POS N
surgery POS N
reduces POS N
complication POS N
rates, POS N
particularly POS N
uveal POS N
effusions. POS N

Cataract POS N
surgery POS N
in POS N
eyes POS N
with POS N
nanophthalmos POS N
is POS N
associated POS N
with POS N
a POS N
high POS N
risk POS N
for POS N
vision-threatening POS N
complications. POS N

Cataract POS N
surgery POS N
at POS N
earlier POS N
stages POS N
by POS N
phacoemulsification POS N
may POS N
be POS N
more POS N
beneficial POS N
than POS N
undergoing POS N
manual POS N
SICS. POS N

Performing POS N
a POS N
simultaneous POS N
prophylactic POS N
sclerostomy POS N
with POS N
cataract POS N
surgery POS N
reduces POS N
complication POS N
rates, POS N
particularly POS N
uveal POS N
effusions. POS N

Fewer POS N
complications POS N
were POS N
noted POS N
in POS N
eyes POS N
receiving POS N
sclerostomy POS N
(5/29, POS N
17.2%) POS N
as POS N
compared POS N
to POS N
control POS N
group POS N
eyes POS N
(12/31, POS N
38.7%), POS N
though POS N
differences POS N
were POS N
marginally POS N
significant POS N
(P POS N
= POS N
.065). POS N

Performing POS N
a POS N
simultaneous POS N
prophylactic POS N
sclerostomy POS N
with POS N
cataract POS N
surgery POS N
reduces POS N
complication POS N
rates, POS N
particularly POS N
uveal POS N
effusions. POS N

Four POS N
control POS N
group, POS N
but POS N
no POS N
sclerostomy POS N
group, POS N
eyes POS N
developed POS N
postoperative POS N
uveal POS N
effusions POS N
(P POS N
= POS N
.04). POS N

Performing POS N
a POS N
simultaneous POS N
prophylactic POS N
sclerostomy POS N
with POS N
cataract POS N
surgery POS N
reduces POS N
complication POS N
rates, POS N
particularly POS N
uveal POS N
effusions. POS N

In POS N
multivariable POS N
models, POS N
sclerostomy POS N
decreased POS N
the POS N
odds POS N
of POS N
an POS N
intraoperative POS N
or POS N
postoperative POS N
complication POS N
by POS N
80% POS N
(odds POS N
ratio POS N
[OR] POS N
= POS N
0.2, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
0.04-0.92, POS N
P POS N
= POS N
.039); POS N

Performing POS N
a POS N
simultaneous POS N
prophylactic POS N
sclerostomy POS N
with POS N
cataract POS N
surgery POS N
reduces POS N
complication POS N
rates, POS N
particularly POS N
uveal POS N
effusions. POS N

SICS POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
risk POS N
of POS N
complications POS N
as POS N
compared POS N
to POS N
phacoemulsification POS N
(OR POS N
= POS N
5.95, POS N
95% POS N
CI POS N
= POS N
1.49-23.73, POS N
P POS N
= POS N
.012), POS N
while POS N
high POS N
preoperative POS N
intraocular POS N
pressure POS N
(OR POS N
= POS N
4.54, POS N
95% POS N
CI POS N
= POS N
0.99-20.9, POS N
P POS N
= POS N
.052) POS N
and POS N
greater POS N
lens POS N
thickness POS N
(OR POS N
= POS N
3.38, POS N
95% POS N
CI POS N
= POS N
0.88-12.91, POS N
P POS N
= POS N
.075) POS N
demonstrated POS N
a POS N
marginally POS N
significant POS N
association. POS N

Performing POS N
a POS N
simultaneous POS N
prophylactic POS N
sclerostomy POS N
with POS N
cataract POS N
surgery POS N
reduces POS N
complication POS N
rates, POS N
particularly POS N
uveal POS N
effusions. POS N

Cataract POS N
surgery POS N
in POS N
eyes POS N
with POS N
nanophthalmos POS N
is POS N
associated POS N
with POS N
a POS N
high POS N
risk POS N
for POS N
vision-threatening POS N
complications. POS N

Performing POS N
a POS N
simultaneous POS N
prophylactic POS N
sclerostomy POS N
with POS N
cataract POS N
surgery POS N
reduces POS N
complication POS N
rates, POS N
particularly POS N
uveal POS N
effusions. POS N

Cataract POS N
surgery POS N
at POS N
earlier POS N
stages POS N
by POS N
phacoemulsification POS N
may POS N
be POS N
more POS N
beneficial POS N
than POS N
undergoing POS N
manual POS N
SICS. POS N

Cataract POS N
surgery POS N
at POS N
earlier POS N
stages POS N
by POS N
phacoemulsification POS N
may POS N
be POS N
more POS N
beneficial POS N
than POS N
undergoing POS N
manual POS N
SICS. POS N

Fewer POS N
complications POS N
were POS N
noted POS N
in POS N
eyes POS N
receiving POS N
sclerostomy POS N
(5/29, POS N
17.2%) POS N
as POS N
compared POS N
to POS N
control POS N
group POS N
eyes POS N
(12/31, POS N
38.7%), POS N
though POS N
differences POS N
were POS N
marginally POS N
significant POS N
(P POS N
= POS N
.065). POS N

Cataract POS N
surgery POS N
at POS N
earlier POS N
stages POS N
by POS N
phacoemulsification POS N
may POS N
be POS N
more POS N
beneficial POS N
than POS N
undergoing POS N
manual POS N
SICS. POS N

Four POS N
control POS N
group, POS N
but POS N
no POS N
sclerostomy POS N
group, POS N
eyes POS N
developed POS N
postoperative POS N
uveal POS N
effusions POS N
(P POS N
= POS N
.04). POS N

Cataract POS N
surgery POS N
at POS N
earlier POS N
stages POS N
by POS N
phacoemulsification POS N
may POS N
be POS N
more POS N
beneficial POS N
than POS N
undergoing POS N
manual POS N
SICS. POS N

In POS N
multivariable POS N
models, POS N
sclerostomy POS N
decreased POS N
the POS N
odds POS N
of POS N
an POS N
intraoperative POS N
or POS N
postoperative POS N
complication POS N
by POS N
80% POS N
(odds POS N
ratio POS N
[OR] POS N
= POS N
0.2, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
0.04-0.92, POS N
P POS N
= POS N
.039); POS N

Cataract POS N
surgery POS N
at POS N
earlier POS N
stages POS N
by POS N
phacoemulsification POS N
may POS N
be POS N
more POS N
beneficial POS N
than POS N
undergoing POS N
manual POS N
SICS. POS N

SICS POS N
was POS N
associated POS N
with POS N
a POS N
significantly POS N
higher POS N
risk POS N
of POS N
complications POS N
as POS N
compared POS N
to POS N
phacoemulsification POS N
(OR POS N
= POS N
5.95, POS N
95% POS N
CI POS N
= POS N
1.49-23.73, POS N
P POS N
= POS N
.012), POS N
while POS N
high POS N
preoperative POS N
intraocular POS N
pressure POS N
(OR POS N
= POS N
4.54, POS N
95% POS N
CI POS N
= POS N
0.99-20.9, POS N
P POS N
= POS N
.052) POS N
and POS N
greater POS N
lens POS N
thickness POS N
(OR POS N
= POS N
3.38, POS N
95% POS N
CI POS N
= POS N
0.88-12.91, POS N
P POS N
= POS N
.075) POS N
demonstrated POS N
a POS N
marginally POS N
significant POS N
association. POS N

Cataract POS N
surgery POS N
at POS N
earlier POS N
stages POS N
by POS N
phacoemulsification POS N
may POS N
be POS N
more POS N
beneficial POS N
than POS N
undergoing POS N
manual POS N
SICS. POS N

Cataract POS N
surgery POS N
in POS N
eyes POS N
with POS N
nanophthalmos POS N
is POS N
associated POS N
with POS N
a POS N
high POS N
risk POS N
for POS N
vision-threatening POS N
complications. POS N

Cataract POS N
surgery POS N
at POS N
earlier POS N
stages POS N
by POS N
phacoemulsification POS N
may POS N
be POS N
more POS N
beneficial POS N
than POS N
undergoing POS N
manual POS N
SICS. POS N

Performing POS N
a POS N
simultaneous POS N
prophylactic POS N
sclerostomy POS N
with POS N
cataract POS N
surgery POS N
reduces POS N
complication POS N
rates, POS N
particularly POS N
uveal POS N
effusions. POS N

Peak POS N
oxygen POS N
consumption POS N
increased POS N
by POS N
0.24 POS N
L/min POS N
in POS N
the POS N
exercise POS N
group, POS N

whereas POS N
it POS N
decreased POS N
by POS N
0.05 POS N
L/min POS N
in POS N
the POS N
control POS N
group POS N
(mean POS N
difference, POS N
0.29 POS N
L/min; POS N
95% POS N
confidence POS N
interval POS N
[CI], POS N
0.18 POS N
to POS N
0.40; POS N
P POS N
<.001). POS N

Peak POS N
oxygen POS N
consumption POS N
increased POS N
by POS N
0.24 POS N
L/min POS N
in POS N
the POS N
exercise POS N
group, POS N

Overall POS N
QOL POS N
increased POS N
by POS N
9.1 POS N
points POS N
in POS N
the POS N
exercise POS N
group POS N
compared POS N
with POS N
0.3 POS N
points POS N
in POS N
the POS N
control POS N
group POS N
(mean POS N
difference, POS N
8.8 POS N
points; POS N
95% POS N
CI, POS N
3.6 POS N
to POS N
14.0; POS N
P POS N
=.001). POS N

Peak POS N
oxygen POS N
consumption POS N
increased POS N
by POS N
0.24 POS N
L/min POS N
in POS N
the POS N
exercise POS N
group, POS N

Pearson POS N
correlations POS N
indicated POS N
that POS N
change POS N
in POS N
peak POS N
oxygen POS N
consumption POS N
correlated POS N
with POS N
change POS N
in POS N
overall POS N
QOL POS N
(r POS N
= POS N
0.45; POS N
P POS N
<.01). POS N

Peak POS N
oxygen POS N
consumption POS N
increased POS N
by POS N
0.24 POS N
L/min POS N
in POS N
the POS N
exercise POS N
group, POS N

Exercise POS N
training POS N
had POS N
beneficial POS N
effects POS N
on POS N
cardiopulmonary POS N
function POS N
and POS N
QOL POS N
in POS N
postmenopausal POS N
breast POS N
cancer POS N
survivors. POS N

whereas POS N
it POS N
decreased POS N
by POS N
0.05 POS N
L/min POS N
in POS N
the POS N
control POS N
group POS N
(mean POS N
difference, POS N
0.29 POS N
L/min; POS N
95% POS N
confidence POS N
interval POS N
[CI], POS N
0.18 POS N
to POS N
0.40; POS N
P POS N
<.001). POS N

Peak POS N
oxygen POS N
consumption POS N
increased POS N
by POS N
0.24 POS N
L/min POS N
in POS N
the POS N
exercise POS N
group, POS N

whereas POS N
it POS N
decreased POS N
by POS N
0.05 POS N
L/min POS N
in POS N
the POS N
control POS N
group POS N
(mean POS N
difference, POS N
0.29 POS N
L/min; POS N
95% POS N
confidence POS N
interval POS N
[CI], POS N
0.18 POS N
to POS N
0.40; POS N
P POS N
<.001). POS N

Overall POS N
QOL POS N
increased POS N
by POS N
9.1 POS N
points POS N
in POS N
the POS N
exercise POS N
group POS N
compared POS N
with POS N
0.3 POS N
points POS N
in POS N
the POS N
control POS N
group POS N
(mean POS N
difference, POS N
8.8 POS N
points; POS N
95% POS N
CI, POS N
3.6 POS N
to POS N
14.0; POS N
P POS N
=.001). POS N

whereas POS N
it POS N
decreased POS N
by POS N
0.05 POS N
L/min POS N
in POS N
the POS N
control POS N
group POS N
(mean POS N
difference, POS N
0.29 POS N
L/min; POS N
95% POS N
confidence POS N
interval POS N
[CI], POS N
0.18 POS N
to POS N
0.40; POS N
P POS N
<.001). POS N

Pearson POS N
correlations POS N
indicated POS N
that POS N
change POS N
in POS N
peak POS N
oxygen POS N
consumption POS N
correlated POS N
with POS N
change POS N
in POS N
overall POS N
QOL POS N
(r POS N
= POS N
0.45; POS N
P POS N
<.01). POS N

whereas POS N
it POS N
decreased POS N
by POS N
0.05 POS N
L/min POS N
in POS N
the POS N
control POS N
group POS N
(mean POS N
difference, POS N
0.29 POS N
L/min; POS N
95% POS N
confidence POS N
interval POS N
[CI], POS N
0.18 POS N
to POS N
0.40; POS N
P POS N
<.001). POS N

Exercise POS N
training POS N
had POS N
beneficial POS N
effects POS N
on POS N
cardiopulmonary POS N
function POS N
and POS N
QOL POS N
in POS N
postmenopausal POS N
breast POS N
cancer POS N
survivors. POS N

Overall POS N
QOL POS N
increased POS N
by POS N
9.1 POS N
points POS N
in POS N
the POS N
exercise POS N
group POS N
compared POS N
with POS N
0.3 POS N
points POS N
in POS N
the POS N
control POS N
group POS N
(mean POS N
difference, POS N
8.8 POS N
points; POS N
95% POS N
CI, POS N
3.6 POS N
to POS N
14.0; POS N
P POS N
=.001). POS N

Peak POS N
oxygen POS N
consumption POS N
increased POS N
by POS N
0.24 POS N
L/min POS N
in POS N
the POS N
exercise POS N
group, POS N

Overall POS N
QOL POS N
increased POS N
by POS N
9.1 POS N
points POS N
in POS N
the POS N
exercise POS N
group POS N
compared POS N
with POS N
0.3 POS N
points POS N
in POS N
the POS N
control POS N
group POS N
(mean POS N
difference, POS N
8.8 POS N
points; POS N
95% POS N
CI, POS N
3.6 POS N
to POS N
14.0; POS N
P POS N
=.001). POS N

whereas POS N
it POS N
decreased POS N
by POS N
0.05 POS N
L/min POS N
in POS N
the POS N
control POS N
group POS N
(mean POS N
difference, POS N
0.29 POS N
L/min; POS N
95% POS N
confidence POS N
interval POS N
[CI], POS N
0.18 POS N
to POS N
0.40; POS N
P POS N
<.001). POS N

Overall POS N
QOL POS N
increased POS N
by POS N
9.1 POS N
points POS N
in POS N
the POS N
exercise POS N
group POS N
compared POS N
with POS N
0.3 POS N
points POS N
in POS N
the POS N
control POS N
group POS N
(mean POS N
difference, POS N
8.8 POS N
points; POS N
95% POS N
CI, POS N
3.6 POS N
to POS N
14.0; POS N
P POS N
=.001). POS N

Pearson POS N
correlations POS N
indicated POS N
that POS N
change POS N
in POS N
peak POS N
oxygen POS N
consumption POS N
correlated POS N
with POS N
change POS N
in POS N
overall POS N
QOL POS N
(r POS N
= POS N
0.45; POS N
P POS N
<.01). POS N

Overall POS N
QOL POS N
increased POS N
by POS N
9.1 POS N
points POS N
in POS N
the POS N
exercise POS N
group POS N
compared POS N
with POS N
0.3 POS N
points POS N
in POS N
the POS N
control POS N
group POS N
(mean POS N
difference, POS N
8.8 POS N
points; POS N
95% POS N
CI, POS N
3.6 POS N
to POS N
14.0; POS N
P POS N
=.001). POS N

Exercise POS N
training POS N
had POS N
beneficial POS N
effects POS N
on POS N
cardiopulmonary POS N
function POS N
and POS N
QOL POS N
in POS N
postmenopausal POS N
breast POS N
cancer POS N
survivors. POS N

Pearson POS N
correlations POS N
indicated POS N
that POS N
change POS N
in POS N
peak POS N
oxygen POS N
consumption POS N
correlated POS N
with POS N
change POS N
in POS N
overall POS N
QOL POS N
(r POS N
= POS N
0.45; POS N
P POS N
<.01). POS N

Peak POS N
oxygen POS N
consumption POS N
increased POS N
by POS N
0.24 POS N
L/min POS N
in POS N
the POS N
exercise POS N
group, POS N

Pearson POS N
correlations POS N
indicated POS N
that POS N
change POS N
in POS N
peak POS N
oxygen POS N
consumption POS N
correlated POS N
with POS N
change POS N
in POS N
overall POS N
QOL POS N
(r POS N
= POS N
0.45; POS N
P POS N
<.01). POS N

whereas POS N
it POS N
decreased POS N
by POS N
0.05 POS N
L/min POS N
in POS N
the POS N
control POS N
group POS N
(mean POS N
difference, POS N
0.29 POS N
L/min; POS N
95% POS N
confidence POS N
interval POS N
[CI], POS N
0.18 POS N
to POS N
0.40; POS N
P POS N
<.001). POS N

Pearson POS N
correlations POS N
indicated POS N
that POS N
change POS N
in POS N
peak POS N
oxygen POS N
consumption POS N
correlated POS N
with POS N
change POS N
in POS N
overall POS N
QOL POS N
(r POS N
= POS N
0.45; POS N
P POS N
<.01). POS N

Overall POS N
QOL POS N
increased POS N
by POS N
9.1 POS N
points POS N
in POS N
the POS N
exercise POS N
group POS N
compared POS N
with POS N
0.3 POS N
points POS N
in POS N
the POS N
control POS N
group POS N
(mean POS N
difference, POS N
8.8 POS N
points; POS N
95% POS N
CI, POS N
3.6 POS N
to POS N
14.0; POS N
P POS N
=.001). POS N

Pearson POS N
correlations POS N
indicated POS N
that POS N
change POS N
in POS N
peak POS N
oxygen POS N
consumption POS N
correlated POS N
with POS N
change POS N
in POS N
overall POS N
QOL POS N
(r POS N
= POS N
0.45; POS N
P POS N
<.01). POS N

Exercise POS N
training POS N
had POS N
beneficial POS N
effects POS N
on POS N
cardiopulmonary POS N
function POS N
and POS N
QOL POS N
in POS N
postmenopausal POS N
breast POS N
cancer POS N
survivors. POS N

Exercise POS N
training POS N
had POS N
beneficial POS N
effects POS N
on POS N
cardiopulmonary POS N
function POS N
and POS N
QOL POS N
in POS N
postmenopausal POS N
breast POS N
cancer POS N
survivors. POS N

Peak POS N
oxygen POS N
consumption POS N
increased POS N
by POS N
0.24 POS N
L/min POS N
in POS N
the POS N
exercise POS N
group, POS N

Exercise POS N
training POS N
had POS N
beneficial POS N
effects POS N
on POS N
cardiopulmonary POS N
function POS N
and POS N
QOL POS N
in POS N
postmenopausal POS N
breast POS N
cancer POS N
survivors. POS N

whereas POS N
it POS N
decreased POS N
by POS N
0.05 POS N
L/min POS N
in POS N
the POS N
control POS N
group POS N
(mean POS N
difference, POS N
0.29 POS N
L/min; POS N
95% POS N
confidence POS N
interval POS N
[CI], POS N
0.18 POS N
to POS N
0.40; POS N
P POS N
<.001). POS N

Exercise POS N
training POS N
had POS N
beneficial POS N
effects POS N
on POS N
cardiopulmonary POS N
function POS N
and POS N
QOL POS N
in POS N
postmenopausal POS N
breast POS N
cancer POS N
survivors. POS N

Overall POS N
QOL POS N
increased POS N
by POS N
9.1 POS N
points POS N
in POS N
the POS N
exercise POS N
group POS N
compared POS N
with POS N
0.3 POS N
points POS N
in POS N
the POS N
control POS N
group POS N
(mean POS N
difference, POS N
8.8 POS N
points; POS N
95% POS N
CI, POS N
3.6 POS N
to POS N
14.0; POS N
P POS N
=.001). POS N

Exercise POS N
training POS N
had POS N
beneficial POS N
effects POS N
on POS N
cardiopulmonary POS N
function POS N
and POS N
QOL POS N
in POS N
postmenopausal POS N
breast POS N
cancer POS N
survivors. POS N

Pearson POS N
correlations POS N
indicated POS N
that POS N
change POS N
in POS N
peak POS N
oxygen POS N
consumption POS N
correlated POS N
with POS N
change POS N
in POS N
overall POS N
QOL POS N
(r POS N
= POS N
0.45; POS N
P POS N
<.01). POS N

Epoetin POS N
alfa, POS N
compared POS N
with POS N
placebo, POS N
significantly POS N
decreased POS N
transfusion POS N
requirements POS N
(P POS N
=.0057) POS N
and POS N
increased POS N
hemoglobin POS N
(P POS N
<.001). POS N

Improvement POS N
of POS N
all POS N
primary POS N
cancer- POS N
and POS N
anemia-specific POS N
QOL POS N
domains, POS N
including POS N
energy POS N
level, POS N
ability POS N
to POS N
do POS N
daily POS N
activities, POS N
and POS N
fatigue, POS N
was POS N
significantly POS N
(P POS N
<.01) POS N
greater POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
placebo POS N
patients. POS N

Epoetin POS N
alfa, POS N
compared POS N
with POS N
placebo, POS N
significantly POS N
decreased POS N
transfusion POS N
requirements POS N
(P POS N
=.0057) POS N
and POS N
increased POS N
hemoglobin POS N
(P POS N
<.001). POS N

Kaplan-Meier POS N
estimates POS N
showed POS N
a POS N
trend POS N
in POS N
overall POS N
survival POS N
favoring POS N
epoetin POS N
alfa POS N
(P POS N
=.13, POS N
log-rank POS N
test), POS N

Epoetin POS N
alfa, POS N
compared POS N
with POS N
placebo, POS N
significantly POS N
decreased POS N
transfusion POS N
requirements POS N
(P POS N
=.0057) POS N
and POS N
increased POS N
hemoglobin POS N
(P POS N
<.001). POS N

Cox POS N
regression POS N
analysis POS N
showed POS N
an POS N
estimated POS N
hazards POS N
ratio POS N
of POS N
1.309 POS N
(P POS N
=.052) POS N
favoring POS N
epoetin POS N
alfa. POS N

Epoetin POS N
alfa, POS N
compared POS N
with POS N
placebo, POS N
significantly POS N
decreased POS N
transfusion POS N
requirements POS N
(P POS N
=.0057) POS N
and POS N
increased POS N
hemoglobin POS N
(P POS N
<.001). POS N

Adverse POS N
events POS N
were POS N
comparable POS N
between POS N
groups. POS N

Epoetin POS N
alfa, POS N
compared POS N
with POS N
placebo, POS N
significantly POS N
decreased POS N
transfusion POS N
requirements POS N
(P POS N
=.0057) POS N
and POS N
increased POS N
hemoglobin POS N
(P POS N
<.001). POS N

Epoetin POS N
alfa POS N
safely POS N
and POS N
effectively POS N
ameliorates POS N
anemia POS N
and POS N
significantly POS N
improves POS N
QOL POS N
in POS N
cancer POS N
patients POS N
receiving POS N
nonplatinum POS N
chemotherapy. POS N

Epoetin POS N
alfa, POS N
compared POS N
with POS N
placebo, POS N
significantly POS N
decreased POS N
transfusion POS N
requirements POS N
(P POS N
=.0057) POS N
and POS N
increased POS N
hemoglobin POS N
(P POS N
<.001). POS N

Encouraging POS N
results POS N
regarding POS N
increased POS N
survival POS N
warrant POS N
another POS N
trial POS N
designed POS N
to POS N
confirm POS N
these POS N
findings. POS N

Improvement POS N
of POS N
all POS N
primary POS N
cancer- POS N
and POS N
anemia-specific POS N
QOL POS N
domains, POS N
including POS N
energy POS N
level, POS N
ability POS N
to POS N
do POS N
daily POS N
activities, POS N
and POS N
fatigue, POS N
was POS N
significantly POS N
(P POS N
<.01) POS N
greater POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
placebo POS N
patients. POS N

Epoetin POS N
alfa, POS N
compared POS N
with POS N
placebo, POS N
significantly POS N
decreased POS N
transfusion POS N
requirements POS N
(P POS N
=.0057) POS N
and POS N
increased POS N
hemoglobin POS N
(P POS N
<.001). POS N

Improvement POS N
of POS N
all POS N
primary POS N
cancer- POS N
and POS N
anemia-specific POS N
QOL POS N
domains, POS N
including POS N
energy POS N
level, POS N
ability POS N
to POS N
do POS N
daily POS N
activities, POS N
and POS N
fatigue, POS N
was POS N
significantly POS N
(P POS N
<.01) POS N
greater POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
placebo POS N
patients. POS N

Kaplan-Meier POS N
estimates POS N
showed POS N
a POS N
trend POS N
in POS N
overall POS N
survival POS N
favoring POS N
epoetin POS N
alfa POS N
(P POS N
=.13, POS N
log-rank POS N
test), POS N

Improvement POS N
of POS N
all POS N
primary POS N
cancer- POS N
and POS N
anemia-specific POS N
QOL POS N
domains, POS N
including POS N
energy POS N
level, POS N
ability POS N
to POS N
do POS N
daily POS N
activities, POS N
and POS N
fatigue, POS N
was POS N
significantly POS N
(P POS N
<.01) POS N
greater POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
placebo POS N
patients. POS N

Cox POS N
regression POS N
analysis POS N
showed POS N
an POS N
estimated POS N
hazards POS N
ratio POS N
of POS N
1.309 POS N
(P POS N
=.052) POS N
favoring POS N
epoetin POS N
alfa. POS N

Improvement POS N
of POS N
all POS N
primary POS N
cancer- POS N
and POS N
anemia-specific POS N
QOL POS N
domains, POS N
including POS N
energy POS N
level, POS N
ability POS N
to POS N
do POS N
daily POS N
activities, POS N
and POS N
fatigue, POS N
was POS N
significantly POS N
(P POS N
<.01) POS N
greater POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
placebo POS N
patients. POS N

Adverse POS N
events POS N
were POS N
comparable POS N
between POS N
groups. POS N

Improvement POS N
of POS N
all POS N
primary POS N
cancer- POS N
and POS N
anemia-specific POS N
QOL POS N
domains, POS N
including POS N
energy POS N
level, POS N
ability POS N
to POS N
do POS N
daily POS N
activities, POS N
and POS N
fatigue, POS N
was POS N
significantly POS N
(P POS N
<.01) POS N
greater POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
placebo POS N
patients. POS N

Epoetin POS N
alfa POS N
safely POS N
and POS N
effectively POS N
ameliorates POS N
anemia POS N
and POS N
significantly POS N
improves POS N
QOL POS N
in POS N
cancer POS N
patients POS N
receiving POS N
nonplatinum POS N
chemotherapy. POS N

Improvement POS N
of POS N
all POS N
primary POS N
cancer- POS N
and POS N
anemia-specific POS N
QOL POS N
domains, POS N
including POS N
energy POS N
level, POS N
ability POS N
to POS N
do POS N
daily POS N
activities, POS N
and POS N
fatigue, POS N
was POS N
significantly POS N
(P POS N
<.01) POS N
greater POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
placebo POS N
patients. POS N

Encouraging POS N
results POS N
regarding POS N
increased POS N
survival POS N
warrant POS N
another POS N
trial POS N
designed POS N
to POS N
confirm POS N
these POS N
findings. POS N

Kaplan-Meier POS N
estimates POS N
showed POS N
a POS N
trend POS N
in POS N
overall POS N
survival POS N
favoring POS N
epoetin POS N
alfa POS N
(P POS N
=.13, POS N
log-rank POS N
test), POS N

Epoetin POS N
alfa, POS N
compared POS N
with POS N
placebo, POS N
significantly POS N
decreased POS N
transfusion POS N
requirements POS N
(P POS N
=.0057) POS N
and POS N
increased POS N
hemoglobin POS N
(P POS N
<.001). POS N

Kaplan-Meier POS N
estimates POS N
showed POS N
a POS N
trend POS N
in POS N
overall POS N
survival POS N
favoring POS N
epoetin POS N
alfa POS N
(P POS N
=.13, POS N
log-rank POS N
test), POS N

Improvement POS N
of POS N
all POS N
primary POS N
cancer- POS N
and POS N
anemia-specific POS N
QOL POS N
domains, POS N
including POS N
energy POS N
level, POS N
ability POS N
to POS N
do POS N
daily POS N
activities, POS N
and POS N
fatigue, POS N
was POS N
significantly POS N
(P POS N
<.01) POS N
greater POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
placebo POS N
patients. POS N

Kaplan-Meier POS N
estimates POS N
showed POS N
a POS N
trend POS N
in POS N
overall POS N
survival POS N
favoring POS N
epoetin POS N
alfa POS N
(P POS N
=.13, POS N
log-rank POS N
test), POS N

Cox POS N
regression POS N
analysis POS N
showed POS N
an POS N
estimated POS N
hazards POS N
ratio POS N
of POS N
1.309 POS N
(P POS N
=.052) POS N
favoring POS N
epoetin POS N
alfa. POS N

Kaplan-Meier POS N
estimates POS N
showed POS N
a POS N
trend POS N
in POS N
overall POS N
survival POS N
favoring POS N
epoetin POS N
alfa POS N
(P POS N
=.13, POS N
log-rank POS N
test), POS N

Adverse POS N
events POS N
were POS N
comparable POS N
between POS N
groups. POS N

Kaplan-Meier POS N
estimates POS N
showed POS N
a POS N
trend POS N
in POS N
overall POS N
survival POS N
favoring POS N
epoetin POS N
alfa POS N
(P POS N
=.13, POS N
log-rank POS N
test), POS N

Epoetin POS N
alfa POS N
safely POS N
and POS N
effectively POS N
ameliorates POS N
anemia POS N
and POS N
significantly POS N
improves POS N
QOL POS N
in POS N
cancer POS N
patients POS N
receiving POS N
nonplatinum POS N
chemotherapy. POS N

Kaplan-Meier POS N
estimates POS N
showed POS N
a POS N
trend POS N
in POS N
overall POS N
survival POS N
favoring POS N
epoetin POS N
alfa POS N
(P POS N
=.13, POS N
log-rank POS N
test), POS N

Encouraging POS N
results POS N
regarding POS N
increased POS N
survival POS N
warrant POS N
another POS N
trial POS N
designed POS N
to POS N
confirm POS N
these POS N
findings. POS N

Cox POS N
regression POS N
analysis POS N
showed POS N
an POS N
estimated POS N
hazards POS N
ratio POS N
of POS N
1.309 POS N
(P POS N
=.052) POS N
favoring POS N
epoetin POS N
alfa. POS N

Epoetin POS N
alfa, POS N
compared POS N
with POS N
placebo, POS N
significantly POS N
decreased POS N
transfusion POS N
requirements POS N
(P POS N
=.0057) POS N
and POS N
increased POS N
hemoglobin POS N
(P POS N
<.001). POS N

Cox POS N
regression POS N
analysis POS N
showed POS N
an POS N
estimated POS N
hazards POS N
ratio POS N
of POS N
1.309 POS N
(P POS N
=.052) POS N
favoring POS N
epoetin POS N
alfa. POS N

Improvement POS N
of POS N
all POS N
primary POS N
cancer- POS N
and POS N
anemia-specific POS N
QOL POS N
domains, POS N
including POS N
energy POS N
level, POS N
ability POS N
to POS N
do POS N
daily POS N
activities, POS N
and POS N
fatigue, POS N
was POS N
significantly POS N
(P POS N
<.01) POS N
greater POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
placebo POS N
patients. POS N

Cox POS N
regression POS N
analysis POS N
showed POS N
an POS N
estimated POS N
hazards POS N
ratio POS N
of POS N
1.309 POS N
(P POS N
=.052) POS N
favoring POS N
epoetin POS N
alfa. POS N

Kaplan-Meier POS N
estimates POS N
showed POS N
a POS N
trend POS N
in POS N
overall POS N
survival POS N
favoring POS N
epoetin POS N
alfa POS N
(P POS N
=.13, POS N
log-rank POS N
test), POS N

Cox POS N
regression POS N
analysis POS N
showed POS N
an POS N
estimated POS N
hazards POS N
ratio POS N
of POS N
1.309 POS N
(P POS N
=.052) POS N
favoring POS N
epoetin POS N
alfa. POS N

Adverse POS N
events POS N
were POS N
comparable POS N
between POS N
groups. POS N

Cox POS N
regression POS N
analysis POS N
showed POS N
an POS N
estimated POS N
hazards POS N
ratio POS N
of POS N
1.309 POS N
(P POS N
=.052) POS N
favoring POS N
epoetin POS N
alfa. POS N

Epoetin POS N
alfa POS N
safely POS N
and POS N
effectively POS N
ameliorates POS N
anemia POS N
and POS N
significantly POS N
improves POS N
QOL POS N
in POS N
cancer POS N
patients POS N
receiving POS N
nonplatinum POS N
chemotherapy. POS N

Cox POS N
regression POS N
analysis POS N
showed POS N
an POS N
estimated POS N
hazards POS N
ratio POS N
of POS N
1.309 POS N
(P POS N
=.052) POS N
favoring POS N
epoetin POS N
alfa. POS N

Encouraging POS N
results POS N
regarding POS N
increased POS N
survival POS N
warrant POS N
another POS N
trial POS N
designed POS N
to POS N
confirm POS N
these POS N
findings. POS N

Adverse POS N
events POS N
were POS N
comparable POS N
between POS N
groups. POS N

Epoetin POS N
alfa, POS N
compared POS N
with POS N
placebo, POS N
significantly POS N
decreased POS N
transfusion POS N
requirements POS N
(P POS N
=.0057) POS N
and POS N
increased POS N
hemoglobin POS N
(P POS N
<.001). POS N

Adverse POS N
events POS N
were POS N
comparable POS N
between POS N
groups. POS N

Improvement POS N
of POS N
all POS N
primary POS N
cancer- POS N
and POS N
anemia-specific POS N
QOL POS N
domains, POS N
including POS N
energy POS N
level, POS N
ability POS N
to POS N
do POS N
daily POS N
activities, POS N
and POS N
fatigue, POS N
was POS N
significantly POS N
(P POS N
<.01) POS N
greater POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
placebo POS N
patients. POS N

Adverse POS N
events POS N
were POS N
comparable POS N
between POS N
groups. POS N

Kaplan-Meier POS N
estimates POS N
showed POS N
a POS N
trend POS N
in POS N
overall POS N
survival POS N
favoring POS N
epoetin POS N
alfa POS N
(P POS N
=.13, POS N
log-rank POS N
test), POS N

Adverse POS N
events POS N
were POS N
comparable POS N
between POS N
groups. POS N

Cox POS N
regression POS N
analysis POS N
showed POS N
an POS N
estimated POS N
hazards POS N
ratio POS N
of POS N
1.309 POS N
(P POS N
=.052) POS N
favoring POS N
epoetin POS N
alfa. POS N

Adverse POS N
events POS N
were POS N
comparable POS N
between POS N
groups. POS N

Epoetin POS N
alfa POS N
safely POS N
and POS N
effectively POS N
ameliorates POS N
anemia POS N
and POS N
significantly POS N
improves POS N
QOL POS N
in POS N
cancer POS N
patients POS N
receiving POS N
nonplatinum POS N
chemotherapy. POS N

Adverse POS N
events POS N
were POS N
comparable POS N
between POS N
groups. POS N

Encouraging POS N
results POS N
regarding POS N
increased POS N
survival POS N
warrant POS N
another POS N
trial POS N
designed POS N
to POS N
confirm POS N
these POS N
findings. POS N

Epoetin POS N
alfa POS N
safely POS N
and POS N
effectively POS N
ameliorates POS N
anemia POS N
and POS N
significantly POS N
improves POS N
QOL POS N
in POS N
cancer POS N
patients POS N
receiving POS N
nonplatinum POS N
chemotherapy. POS N

Epoetin POS N
alfa, POS N
compared POS N
with POS N
placebo, POS N
significantly POS N
decreased POS N
transfusion POS N
requirements POS N
(P POS N
=.0057) POS N
and POS N
increased POS N
hemoglobin POS N
(P POS N
<.001). POS N

Epoetin POS N
alfa POS N
safely POS N
and POS N
effectively POS N
ameliorates POS N
anemia POS N
and POS N
significantly POS N
improves POS N
QOL POS N
in POS N
cancer POS N
patients POS N
receiving POS N
nonplatinum POS N
chemotherapy. POS N

Improvement POS N
of POS N
all POS N
primary POS N
cancer- POS N
and POS N
anemia-specific POS N
QOL POS N
domains, POS N
including POS N
energy POS N
level, POS N
ability POS N
to POS N
do POS N
daily POS N
activities, POS N
and POS N
fatigue, POS N
was POS N
significantly POS N
(P POS N
<.01) POS N
greater POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
placebo POS N
patients. POS N

Epoetin POS N
alfa POS N
safely POS N
and POS N
effectively POS N
ameliorates POS N
anemia POS N
and POS N
significantly POS N
improves POS N
QOL POS N
in POS N
cancer POS N
patients POS N
receiving POS N
nonplatinum POS N
chemotherapy. POS N

Kaplan-Meier POS N
estimates POS N
showed POS N
a POS N
trend POS N
in POS N
overall POS N
survival POS N
favoring POS N
epoetin POS N
alfa POS N
(P POS N
=.13, POS N
log-rank POS N
test), POS N

Epoetin POS N
alfa POS N
safely POS N
and POS N
effectively POS N
ameliorates POS N
anemia POS N
and POS N
significantly POS N
improves POS N
QOL POS N
in POS N
cancer POS N
patients POS N
receiving POS N
nonplatinum POS N
chemotherapy. POS N

Cox POS N
regression POS N
analysis POS N
showed POS N
an POS N
estimated POS N
hazards POS N
ratio POS N
of POS N
1.309 POS N
(P POS N
=.052) POS N
favoring POS N
epoetin POS N
alfa. POS N

Epoetin POS N
alfa POS N
safely POS N
and POS N
effectively POS N
ameliorates POS N
anemia POS N
and POS N
significantly POS N
improves POS N
QOL POS N
in POS N
cancer POS N
patients POS N
receiving POS N
nonplatinum POS N
chemotherapy. POS N

Adverse POS N
events POS N
were POS N
comparable POS N
between POS N
groups. POS N

Epoetin POS N
alfa POS N
safely POS N
and POS N
effectively POS N
ameliorates POS N
anemia POS N
and POS N
significantly POS N
improves POS N
QOL POS N
in POS N
cancer POS N
patients POS N
receiving POS N
nonplatinum POS N
chemotherapy. POS N

Encouraging POS N
results POS N
regarding POS N
increased POS N
survival POS N
warrant POS N
another POS N
trial POS N
designed POS N
to POS N
confirm POS N
these POS N
findings. POS N

Encouraging POS N
results POS N
regarding POS N
increased POS N
survival POS N
warrant POS N
another POS N
trial POS N
designed POS N
to POS N
confirm POS N
these POS N
findings. POS N

Epoetin POS N
alfa, POS N
compared POS N
with POS N
placebo, POS N
significantly POS N
decreased POS N
transfusion POS N
requirements POS N
(P POS N
=.0057) POS N
and POS N
increased POS N
hemoglobin POS N
(P POS N
<.001). POS N

Encouraging POS N
results POS N
regarding POS N
increased POS N
survival POS N
warrant POS N
another POS N
trial POS N
designed POS N
to POS N
confirm POS N
these POS N
findings. POS N

Improvement POS N
of POS N
all POS N
primary POS N
cancer- POS N
and POS N
anemia-specific POS N
QOL POS N
domains, POS N
including POS N
energy POS N
level, POS N
ability POS N
to POS N
do POS N
daily POS N
activities, POS N
and POS N
fatigue, POS N
was POS N
significantly POS N
(P POS N
<.01) POS N
greater POS N
for POS N
epoetin POS N
alfa POS N
versus POS N
placebo POS N
patients. POS N

Encouraging POS N
results POS N
regarding POS N
increased POS N
survival POS N
warrant POS N
another POS N
trial POS N
designed POS N
to POS N
confirm POS N
these POS N
findings. POS N

Kaplan-Meier POS N
estimates POS N
showed POS N
a POS N
trend POS N
in POS N
overall POS N
survival POS N
favoring POS N
epoetin POS N
alfa POS N
(P POS N
=.13, POS N
log-rank POS N
test), POS N

Encouraging POS N
results POS N
regarding POS N
increased POS N
survival POS N
warrant POS N
another POS N
trial POS N
designed POS N
to POS N
confirm POS N
these POS N
findings. POS N

Cox POS N
regression POS N
analysis POS N
showed POS N
an POS N
estimated POS N
hazards POS N
ratio POS N
of POS N
1.309 POS N
(P POS N
=.052) POS N
favoring POS N
epoetin POS N
alfa. POS N

Encouraging POS N
results POS N
regarding POS N
increased POS N
survival POS N
warrant POS N
another POS N
trial POS N
designed POS N
to POS N
confirm POS N
these POS N
findings. POS N

Adverse POS N
events POS N
were POS N
comparable POS N
between POS N
groups. POS N

Encouraging POS N
results POS N
regarding POS N
increased POS N
survival POS N
warrant POS N
another POS N
trial POS N
designed POS N
to POS N
confirm POS N
these POS N
findings. POS N

Epoetin POS N
alfa POS N
safely POS N
and POS N
effectively POS N
ameliorates POS N
anemia POS N
and POS N
significantly POS N
improves POS N
QOL POS N
in POS N
cancer POS N
patients POS N
receiving POS N
nonplatinum POS N
chemotherapy. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
(SBP) POS N
of POS N
the POS N
ISH POS N
LSSalt POS N
group POS N
had POS N
significantly POS N
decreased POS N
by POS N
10.18 POS N
mm POS N
Hg POS N
(95% POS N
confidence POS N
interval POS N
(CI): POS N
3.13 POS N
to POS N
17.2, POS N
P = .006) POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
ISH POS N
NSalt POS N
group, POS N

the POS N
mean POS N
SBP POS N
only POS N
decreased POS N
by POS N
5.10 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-2.02 POS N
to POS N
12.2, POS N
P = .158) POS N
in POS N
the POS N
NISH POS N
LSSalt POS N
group POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
NISH POS N
NSalt POS N
group. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
(SBP) POS N
of POS N
the POS N
ISH POS N
LSSalt POS N
group POS N
had POS N
significantly POS N
decreased POS N
by POS N
10.18 POS N
mm POS N
Hg POS N
(95% POS N
confidence POS N
interval POS N
(CI): POS N
3.13 POS N
to POS N
17.2, POS N
P = .006) POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
ISH POS N
NSalt POS N
group, POS N

The POS N
mean POS N
diastolic POS N
blood POS N
pressure POS N
(DBP) POS N
had POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
ISH POS N
and POS N
NISH POS N
groups. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
(SBP) POS N
of POS N
the POS N
ISH POS N
LSSalt POS N
group POS N
had POS N
significantly POS N
decreased POS N
by POS N
10.18 POS N
mm POS N
Hg POS N
(95% POS N
confidence POS N
interval POS N
(CI): POS N
3.13 POS N
to POS N
17.2, POS N
P = .006) POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
ISH POS N
NSalt POS N
group, POS N

No POS N
obvious POS N
renin POS N
angiotensin POS N
system POS N
activation POS N
was POS N
found POS N
after POS N
LSSalt POS N
intervention. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
(SBP) POS N
of POS N
the POS N
ISH POS N
LSSalt POS N
group POS N
had POS N
significantly POS N
decreased POS N
by POS N
10.18 POS N
mm POS N
Hg POS N
(95% POS N
confidence POS N
interval POS N
(CI): POS N
3.13 POS N
to POS N
17.2, POS N
P = .006) POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
ISH POS N
NSalt POS N
group, POS N

The POS N
present POS N
study POS N
showed POS N
that POS N
the POS N
SBP POS N
of POS N
ISH POS N
patients POS N
was POS N
significantly POS N
decreased POS N
with POS N
the POS N
LSSalt POS N
intervention, POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
(SBP) POS N
of POS N
the POS N
ISH POS N
LSSalt POS N
group POS N
had POS N
significantly POS N
decreased POS N
by POS N
10.18 POS N
mm POS N
Hg POS N
(95% POS N
confidence POS N
interval POS N
(CI): POS N
3.13 POS N
to POS N
17.2, POS N
P = .006) POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
ISH POS N
NSalt POS N
group, POS N

neither POS N
the POS N
SBP POS N
of POS N
the POS N
NISH POS N
patients POS N
nor POS N
the POS N
DBP POS N
of POS N
either POS N
group POS N
were POS N
similarly POS N
decreased, POS N
which POS N
indicated POS N
that POS N
ISH POS N
patients POS N
were POS N
more POS N
sensitive POS N
to POS N
salt POS N
restriction. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
(SBP) POS N
of POS N
the POS N
ISH POS N
LSSalt POS N
group POS N
had POS N
significantly POS N
decreased POS N
by POS N
10.18 POS N
mm POS N
Hg POS N
(95% POS N
confidence POS N
interval POS N
(CI): POS N
3.13 POS N
to POS N
17.2, POS N
P = .006) POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
ISH POS N
NSalt POS N
group, POS N

Regarding POS N
the POS N
urinary POS N
excretion POS N
of POS N
electrolytes POS N
and POS N
blood POS N
biochemical POS N
assays, POS N
the POS N
LSSalt POS N
treatment POS N
had POS N
the POS N
same POS N
effects POS N
on POS N
the POS N
ISH POS N
group POS N
as POS N
on POS N
the POS N
NISH POS N
group. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
(SBP) POS N
of POS N
the POS N
ISH POS N
LSSalt POS N
group POS N
had POS N
significantly POS N
decreased POS N
by POS N
10.18 POS N
mm POS N
Hg POS N
(95% POS N
confidence POS N
interval POS N
(CI): POS N
3.13 POS N
to POS N
17.2, POS N
P = .006) POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
ISH POS N
NSalt POS N
group, POS N

Evidence POS N
has POS N
shown POS N
that POS N
long-term POS N
sodium POS N
reduction POS N
can POS N
not POS N
only POS N
reduce POS N
blood POS N
pressure, POS N
but POS N
also POS N
provide POS N
cardiovascular POS N
benefits. POS N

the POS N
mean POS N
SBP POS N
only POS N
decreased POS N
by POS N
5.10 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-2.02 POS N
to POS N
12.2, POS N
P = .158) POS N
in POS N
the POS N
NISH POS N
LSSalt POS N
group POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
NISH POS N
NSalt POS N
group. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
(SBP) POS N
of POS N
the POS N
ISH POS N
LSSalt POS N
group POS N
had POS N
significantly POS N
decreased POS N
by POS N
10.18 POS N
mm POS N
Hg POS N
(95% POS N
confidence POS N
interval POS N
(CI): POS N
3.13 POS N
to POS N
17.2, POS N
P = .006) POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
ISH POS N
NSalt POS N
group, POS N

the POS N
mean POS N
SBP POS N
only POS N
decreased POS N
by POS N
5.10 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-2.02 POS N
to POS N
12.2, POS N
P = .158) POS N
in POS N
the POS N
NISH POS N
LSSalt POS N
group POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
NISH POS N
NSalt POS N
group. POS N

The POS N
mean POS N
diastolic POS N
blood POS N
pressure POS N
(DBP) POS N
had POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
ISH POS N
and POS N
NISH POS N
groups. POS N

the POS N
mean POS N
SBP POS N
only POS N
decreased POS N
by POS N
5.10 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-2.02 POS N
to POS N
12.2, POS N
P = .158) POS N
in POS N
the POS N
NISH POS N
LSSalt POS N
group POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
NISH POS N
NSalt POS N
group. POS N

No POS N
obvious POS N
renin POS N
angiotensin POS N
system POS N
activation POS N
was POS N
found POS N
after POS N
LSSalt POS N
intervention. POS N

the POS N
mean POS N
SBP POS N
only POS N
decreased POS N
by POS N
5.10 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-2.02 POS N
to POS N
12.2, POS N
P = .158) POS N
in POS N
the POS N
NISH POS N
LSSalt POS N
group POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
NISH POS N
NSalt POS N
group. POS N

The POS N
present POS N
study POS N
showed POS N
that POS N
the POS N
SBP POS N
of POS N
ISH POS N
patients POS N
was POS N
significantly POS N
decreased POS N
with POS N
the POS N
LSSalt POS N
intervention, POS N

the POS N
mean POS N
SBP POS N
only POS N
decreased POS N
by POS N
5.10 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-2.02 POS N
to POS N
12.2, POS N
P = .158) POS N
in POS N
the POS N
NISH POS N
LSSalt POS N
group POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
NISH POS N
NSalt POS N
group. POS N

neither POS N
the POS N
SBP POS N
of POS N
the POS N
NISH POS N
patients POS N
nor POS N
the POS N
DBP POS N
of POS N
either POS N
group POS N
were POS N
similarly POS N
decreased, POS N
which POS N
indicated POS N
that POS N
ISH POS N
patients POS N
were POS N
more POS N
sensitive POS N
to POS N
salt POS N
restriction. POS N

the POS N
mean POS N
SBP POS N
only POS N
decreased POS N
by POS N
5.10 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-2.02 POS N
to POS N
12.2, POS N
P = .158) POS N
in POS N
the POS N
NISH POS N
LSSalt POS N
group POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
NISH POS N
NSalt POS N
group. POS N

Regarding POS N
the POS N
urinary POS N
excretion POS N
of POS N
electrolytes POS N
and POS N
blood POS N
biochemical POS N
assays, POS N
the POS N
LSSalt POS N
treatment POS N
had POS N
the POS N
same POS N
effects POS N
on POS N
the POS N
ISH POS N
group POS N
as POS N
on POS N
the POS N
NISH POS N
group. POS N

the POS N
mean POS N
SBP POS N
only POS N
decreased POS N
by POS N
5.10 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-2.02 POS N
to POS N
12.2, POS N
P = .158) POS N
in POS N
the POS N
NISH POS N
LSSalt POS N
group POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
NISH POS N
NSalt POS N
group. POS N

Evidence POS N
has POS N
shown POS N
that POS N
long-term POS N
sodium POS N
reduction POS N
can POS N
not POS N
only POS N
reduce POS N
blood POS N
pressure, POS N
but POS N
also POS N
provide POS N
cardiovascular POS N
benefits. POS N

The POS N
mean POS N
diastolic POS N
blood POS N
pressure POS N
(DBP) POS N
had POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
ISH POS N
and POS N
NISH POS N
groups. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
(SBP) POS N
of POS N
the POS N
ISH POS N
LSSalt POS N
group POS N
had POS N
significantly POS N
decreased POS N
by POS N
10.18 POS N
mm POS N
Hg POS N
(95% POS N
confidence POS N
interval POS N
(CI): POS N
3.13 POS N
to POS N
17.2, POS N
P = .006) POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
ISH POS N
NSalt POS N
group, POS N

The POS N
mean POS N
diastolic POS N
blood POS N
pressure POS N
(DBP) POS N
had POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
ISH POS N
and POS N
NISH POS N
groups. POS N

the POS N
mean POS N
SBP POS N
only POS N
decreased POS N
by POS N
5.10 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-2.02 POS N
to POS N
12.2, POS N
P = .158) POS N
in POS N
the POS N
NISH POS N
LSSalt POS N
group POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
NISH POS N
NSalt POS N
group. POS N

The POS N
mean POS N
diastolic POS N
blood POS N
pressure POS N
(DBP) POS N
had POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
ISH POS N
and POS N
NISH POS N
groups. POS N

No POS N
obvious POS N
renin POS N
angiotensin POS N
system POS N
activation POS N
was POS N
found POS N
after POS N
LSSalt POS N
intervention. POS N

The POS N
mean POS N
diastolic POS N
blood POS N
pressure POS N
(DBP) POS N
had POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
ISH POS N
and POS N
NISH POS N
groups. POS N

The POS N
present POS N
study POS N
showed POS N
that POS N
the POS N
SBP POS N
of POS N
ISH POS N
patients POS N
was POS N
significantly POS N
decreased POS N
with POS N
the POS N
LSSalt POS N
intervention, POS N

The POS N
mean POS N
diastolic POS N
blood POS N
pressure POS N
(DBP) POS N
had POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
ISH POS N
and POS N
NISH POS N
groups. POS N

neither POS N
the POS N
SBP POS N
of POS N
the POS N
NISH POS N
patients POS N
nor POS N
the POS N
DBP POS N
of POS N
either POS N
group POS N
were POS N
similarly POS N
decreased, POS N
which POS N
indicated POS N
that POS N
ISH POS N
patients POS N
were POS N
more POS N
sensitive POS N
to POS N
salt POS N
restriction. POS N

The POS N
mean POS N
diastolic POS N
blood POS N
pressure POS N
(DBP) POS N
had POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
ISH POS N
and POS N
NISH POS N
groups. POS N

Regarding POS N
the POS N
urinary POS N
excretion POS N
of POS N
electrolytes POS N
and POS N
blood POS N
biochemical POS N
assays, POS N
the POS N
LSSalt POS N
treatment POS N
had POS N
the POS N
same POS N
effects POS N
on POS N
the POS N
ISH POS N
group POS N
as POS N
on POS N
the POS N
NISH POS N
group. POS N

The POS N
mean POS N
diastolic POS N
blood POS N
pressure POS N
(DBP) POS N
had POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
ISH POS N
and POS N
NISH POS N
groups. POS N

Evidence POS N
has POS N
shown POS N
that POS N
long-term POS N
sodium POS N
reduction POS N
can POS N
not POS N
only POS N
reduce POS N
blood POS N
pressure, POS N
but POS N
also POS N
provide POS N
cardiovascular POS N
benefits. POS N

No POS N
obvious POS N
renin POS N
angiotensin POS N
system POS N
activation POS N
was POS N
found POS N
after POS N
LSSalt POS N
intervention. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
(SBP) POS N
of POS N
the POS N
ISH POS N
LSSalt POS N
group POS N
had POS N
significantly POS N
decreased POS N
by POS N
10.18 POS N
mm POS N
Hg POS N
(95% POS N
confidence POS N
interval POS N
(CI): POS N
3.13 POS N
to POS N
17.2, POS N
P = .006) POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
ISH POS N
NSalt POS N
group, POS N

No POS N
obvious POS N
renin POS N
angiotensin POS N
system POS N
activation POS N
was POS N
found POS N
after POS N
LSSalt POS N
intervention. POS N

the POS N
mean POS N
SBP POS N
only POS N
decreased POS N
by POS N
5.10 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-2.02 POS N
to POS N
12.2, POS N
P = .158) POS N
in POS N
the POS N
NISH POS N
LSSalt POS N
group POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
NISH POS N
NSalt POS N
group. POS N

No POS N
obvious POS N
renin POS N
angiotensin POS N
system POS N
activation POS N
was POS N
found POS N
after POS N
LSSalt POS N
intervention. POS N

The POS N
mean POS N
diastolic POS N
blood POS N
pressure POS N
(DBP) POS N
had POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
ISH POS N
and POS N
NISH POS N
groups. POS N

No POS N
obvious POS N
renin POS N
angiotensin POS N
system POS N
activation POS N
was POS N
found POS N
after POS N
LSSalt POS N
intervention. POS N

The POS N
present POS N
study POS N
showed POS N
that POS N
the POS N
SBP POS N
of POS N
ISH POS N
patients POS N
was POS N
significantly POS N
decreased POS N
with POS N
the POS N
LSSalt POS N
intervention, POS N

No POS N
obvious POS N
renin POS N
angiotensin POS N
system POS N
activation POS N
was POS N
found POS N
after POS N
LSSalt POS N
intervention. POS N

neither POS N
the POS N
SBP POS N
of POS N
the POS N
NISH POS N
patients POS N
nor POS N
the POS N
DBP POS N
of POS N
either POS N
group POS N
were POS N
similarly POS N
decreased, POS N
which POS N
indicated POS N
that POS N
ISH POS N
patients POS N
were POS N
more POS N
sensitive POS N
to POS N
salt POS N
restriction. POS N

No POS N
obvious POS N
renin POS N
angiotensin POS N
system POS N
activation POS N
was POS N
found POS N
after POS N
LSSalt POS N
intervention. POS N

Regarding POS N
the POS N
urinary POS N
excretion POS N
of POS N
electrolytes POS N
and POS N
blood POS N
biochemical POS N
assays, POS N
the POS N
LSSalt POS N
treatment POS N
had POS N
the POS N
same POS N
effects POS N
on POS N
the POS N
ISH POS N
group POS N
as POS N
on POS N
the POS N
NISH POS N
group. POS N

No POS N
obvious POS N
renin POS N
angiotensin POS N
system POS N
activation POS N
was POS N
found POS N
after POS N
LSSalt POS N
intervention. POS N

Evidence POS N
has POS N
shown POS N
that POS N
long-term POS N
sodium POS N
reduction POS N
can POS N
not POS N
only POS N
reduce POS N
blood POS N
pressure, POS N
but POS N
also POS N
provide POS N
cardiovascular POS N
benefits. POS N

The POS N
present POS N
study POS N
showed POS N
that POS N
the POS N
SBP POS N
of POS N
ISH POS N
patients POS N
was POS N
significantly POS N
decreased POS N
with POS N
the POS N
LSSalt POS N
intervention, POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
(SBP) POS N
of POS N
the POS N
ISH POS N
LSSalt POS N
group POS N
had POS N
significantly POS N
decreased POS N
by POS N
10.18 POS N
mm POS N
Hg POS N
(95% POS N
confidence POS N
interval POS N
(CI): POS N
3.13 POS N
to POS N
17.2, POS N
P = .006) POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
ISH POS N
NSalt POS N
group, POS N

The POS N
present POS N
study POS N
showed POS N
that POS N
the POS N
SBP POS N
of POS N
ISH POS N
patients POS N
was POS N
significantly POS N
decreased POS N
with POS N
the POS N
LSSalt POS N
intervention, POS N

the POS N
mean POS N
SBP POS N
only POS N
decreased POS N
by POS N
5.10 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-2.02 POS N
to POS N
12.2, POS N
P = .158) POS N
in POS N
the POS N
NISH POS N
LSSalt POS N
group POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
NISH POS N
NSalt POS N
group. POS N

The POS N
present POS N
study POS N
showed POS N
that POS N
the POS N
SBP POS N
of POS N
ISH POS N
patients POS N
was POS N
significantly POS N
decreased POS N
with POS N
the POS N
LSSalt POS N
intervention, POS N

The POS N
mean POS N
diastolic POS N
blood POS N
pressure POS N
(DBP) POS N
had POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
ISH POS N
and POS N
NISH POS N
groups. POS N

The POS N
present POS N
study POS N
showed POS N
that POS N
the POS N
SBP POS N
of POS N
ISH POS N
patients POS N
was POS N
significantly POS N
decreased POS N
with POS N
the POS N
LSSalt POS N
intervention, POS N

No POS N
obvious POS N
renin POS N
angiotensin POS N
system POS N
activation POS N
was POS N
found POS N
after POS N
LSSalt POS N
intervention. POS N

The POS N
present POS N
study POS N
showed POS N
that POS N
the POS N
SBP POS N
of POS N
ISH POS N
patients POS N
was POS N
significantly POS N
decreased POS N
with POS N
the POS N
LSSalt POS N
intervention, POS N

neither POS N
the POS N
SBP POS N
of POS N
the POS N
NISH POS N
patients POS N
nor POS N
the POS N
DBP POS N
of POS N
either POS N
group POS N
were POS N
similarly POS N
decreased, POS N
which POS N
indicated POS N
that POS N
ISH POS N
patients POS N
were POS N
more POS N
sensitive POS N
to POS N
salt POS N
restriction. POS N

The POS N
present POS N
study POS N
showed POS N
that POS N
the POS N
SBP POS N
of POS N
ISH POS N
patients POS N
was POS N
significantly POS N
decreased POS N
with POS N
the POS N
LSSalt POS N
intervention, POS N

Regarding POS N
the POS N
urinary POS N
excretion POS N
of POS N
electrolytes POS N
and POS N
blood POS N
biochemical POS N
assays, POS N
the POS N
LSSalt POS N
treatment POS N
had POS N
the POS N
same POS N
effects POS N
on POS N
the POS N
ISH POS N
group POS N
as POS N
on POS N
the POS N
NISH POS N
group. POS N

The POS N
present POS N
study POS N
showed POS N
that POS N
the POS N
SBP POS N
of POS N
ISH POS N
patients POS N
was POS N
significantly POS N
decreased POS N
with POS N
the POS N
LSSalt POS N
intervention, POS N

Evidence POS N
has POS N
shown POS N
that POS N
long-term POS N
sodium POS N
reduction POS N
can POS N
not POS N
only POS N
reduce POS N
blood POS N
pressure, POS N
but POS N
also POS N
provide POS N
cardiovascular POS N
benefits. POS N

neither POS N
the POS N
SBP POS N
of POS N
the POS N
NISH POS N
patients POS N
nor POS N
the POS N
DBP POS N
of POS N
either POS N
group POS N
were POS N
similarly POS N
decreased, POS N
which POS N
indicated POS N
that POS N
ISH POS N
patients POS N
were POS N
more POS N
sensitive POS N
to POS N
salt POS N
restriction. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
(SBP) POS N
of POS N
the POS N
ISH POS N
LSSalt POS N
group POS N
had POS N
significantly POS N
decreased POS N
by POS N
10.18 POS N
mm POS N
Hg POS N
(95% POS N
confidence POS N
interval POS N
(CI): POS N
3.13 POS N
to POS N
17.2, POS N
P = .006) POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
ISH POS N
NSalt POS N
group, POS N

neither POS N
the POS N
SBP POS N
of POS N
the POS N
NISH POS N
patients POS N
nor POS N
the POS N
DBP POS N
of POS N
either POS N
group POS N
were POS N
similarly POS N
decreased, POS N
which POS N
indicated POS N
that POS N
ISH POS N
patients POS N
were POS N
more POS N
sensitive POS N
to POS N
salt POS N
restriction. POS N

the POS N
mean POS N
SBP POS N
only POS N
decreased POS N
by POS N
5.10 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-2.02 POS N
to POS N
12.2, POS N
P = .158) POS N
in POS N
the POS N
NISH POS N
LSSalt POS N
group POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
NISH POS N
NSalt POS N
group. POS N

neither POS N
the POS N
SBP POS N
of POS N
the POS N
NISH POS N
patients POS N
nor POS N
the POS N
DBP POS N
of POS N
either POS N
group POS N
were POS N
similarly POS N
decreased, POS N
which POS N
indicated POS N
that POS N
ISH POS N
patients POS N
were POS N
more POS N
sensitive POS N
to POS N
salt POS N
restriction. POS N

The POS N
mean POS N
diastolic POS N
blood POS N
pressure POS N
(DBP) POS N
had POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
ISH POS N
and POS N
NISH POS N
groups. POS N

neither POS N
the POS N
SBP POS N
of POS N
the POS N
NISH POS N
patients POS N
nor POS N
the POS N
DBP POS N
of POS N
either POS N
group POS N
were POS N
similarly POS N
decreased, POS N
which POS N
indicated POS N
that POS N
ISH POS N
patients POS N
were POS N
more POS N
sensitive POS N
to POS N
salt POS N
restriction. POS N

No POS N
obvious POS N
renin POS N
angiotensin POS N
system POS N
activation POS N
was POS N
found POS N
after POS N
LSSalt POS N
intervention. POS N

neither POS N
the POS N
SBP POS N
of POS N
the POS N
NISH POS N
patients POS N
nor POS N
the POS N
DBP POS N
of POS N
either POS N
group POS N
were POS N
similarly POS N
decreased, POS N
which POS N
indicated POS N
that POS N
ISH POS N
patients POS N
were POS N
more POS N
sensitive POS N
to POS N
salt POS N
restriction. POS N

The POS N
present POS N
study POS N
showed POS N
that POS N
the POS N
SBP POS N
of POS N
ISH POS N
patients POS N
was POS N
significantly POS N
decreased POS N
with POS N
the POS N
LSSalt POS N
intervention, POS N

neither POS N
the POS N
SBP POS N
of POS N
the POS N
NISH POS N
patients POS N
nor POS N
the POS N
DBP POS N
of POS N
either POS N
group POS N
were POS N
similarly POS N
decreased, POS N
which POS N
indicated POS N
that POS N
ISH POS N
patients POS N
were POS N
more POS N
sensitive POS N
to POS N
salt POS N
restriction. POS N

Regarding POS N
the POS N
urinary POS N
excretion POS N
of POS N
electrolytes POS N
and POS N
blood POS N
biochemical POS N
assays, POS N
the POS N
LSSalt POS N
treatment POS N
had POS N
the POS N
same POS N
effects POS N
on POS N
the POS N
ISH POS N
group POS N
as POS N
on POS N
the POS N
NISH POS N
group. POS N

neither POS N
the POS N
SBP POS N
of POS N
the POS N
NISH POS N
patients POS N
nor POS N
the POS N
DBP POS N
of POS N
either POS N
group POS N
were POS N
similarly POS N
decreased, POS N
which POS N
indicated POS N
that POS N
ISH POS N
patients POS N
were POS N
more POS N
sensitive POS N
to POS N
salt POS N
restriction. POS N

Evidence POS N
has POS N
shown POS N
that POS N
long-term POS N
sodium POS N
reduction POS N
can POS N
not POS N
only POS N
reduce POS N
blood POS N
pressure, POS N
but POS N
also POS N
provide POS N
cardiovascular POS N
benefits. POS N

Regarding POS N
the POS N
urinary POS N
excretion POS N
of POS N
electrolytes POS N
and POS N
blood POS N
biochemical POS N
assays, POS N
the POS N
LSSalt POS N
treatment POS N
had POS N
the POS N
same POS N
effects POS N
on POS N
the POS N
ISH POS N
group POS N
as POS N
on POS N
the POS N
NISH POS N
group. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
(SBP) POS N
of POS N
the POS N
ISH POS N
LSSalt POS N
group POS N
had POS N
significantly POS N
decreased POS N
by POS N
10.18 POS N
mm POS N
Hg POS N
(95% POS N
confidence POS N
interval POS N
(CI): POS N
3.13 POS N
to POS N
17.2, POS N
P = .006) POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
ISH POS N
NSalt POS N
group, POS N

Regarding POS N
the POS N
urinary POS N
excretion POS N
of POS N
electrolytes POS N
and POS N
blood POS N
biochemical POS N
assays, POS N
the POS N
LSSalt POS N
treatment POS N
had POS N
the POS N
same POS N
effects POS N
on POS N
the POS N
ISH POS N
group POS N
as POS N
on POS N
the POS N
NISH POS N
group. POS N

the POS N
mean POS N
SBP POS N
only POS N
decreased POS N
by POS N
5.10 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-2.02 POS N
to POS N
12.2, POS N
P = .158) POS N
in POS N
the POS N
NISH POS N
LSSalt POS N
group POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
NISH POS N
NSalt POS N
group. POS N

Regarding POS N
the POS N
urinary POS N
excretion POS N
of POS N
electrolytes POS N
and POS N
blood POS N
biochemical POS N
assays, POS N
the POS N
LSSalt POS N
treatment POS N
had POS N
the POS N
same POS N
effects POS N
on POS N
the POS N
ISH POS N
group POS N
as POS N
on POS N
the POS N
NISH POS N
group. POS N

The POS N
mean POS N
diastolic POS N
blood POS N
pressure POS N
(DBP) POS N
had POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
ISH POS N
and POS N
NISH POS N
groups. POS N

Regarding POS N
the POS N
urinary POS N
excretion POS N
of POS N
electrolytes POS N
and POS N
blood POS N
biochemical POS N
assays, POS N
the POS N
LSSalt POS N
treatment POS N
had POS N
the POS N
same POS N
effects POS N
on POS N
the POS N
ISH POS N
group POS N
as POS N
on POS N
the POS N
NISH POS N
group. POS N

No POS N
obvious POS N
renin POS N
angiotensin POS N
system POS N
activation POS N
was POS N
found POS N
after POS N
LSSalt POS N
intervention. POS N

Regarding POS N
the POS N
urinary POS N
excretion POS N
of POS N
electrolytes POS N
and POS N
blood POS N
biochemical POS N
assays, POS N
the POS N
LSSalt POS N
treatment POS N
had POS N
the POS N
same POS N
effects POS N
on POS N
the POS N
ISH POS N
group POS N
as POS N
on POS N
the POS N
NISH POS N
group. POS N

The POS N
present POS N
study POS N
showed POS N
that POS N
the POS N
SBP POS N
of POS N
ISH POS N
patients POS N
was POS N
significantly POS N
decreased POS N
with POS N
the POS N
LSSalt POS N
intervention, POS N

Regarding POS N
the POS N
urinary POS N
excretion POS N
of POS N
electrolytes POS N
and POS N
blood POS N
biochemical POS N
assays, POS N
the POS N
LSSalt POS N
treatment POS N
had POS N
the POS N
same POS N
effects POS N
on POS N
the POS N
ISH POS N
group POS N
as POS N
on POS N
the POS N
NISH POS N
group. POS N

neither POS N
the POS N
SBP POS N
of POS N
the POS N
NISH POS N
patients POS N
nor POS N
the POS N
DBP POS N
of POS N
either POS N
group POS N
were POS N
similarly POS N
decreased, POS N
which POS N
indicated POS N
that POS N
ISH POS N
patients POS N
were POS N
more POS N
sensitive POS N
to POS N
salt POS N
restriction. POS N

Regarding POS N
the POS N
urinary POS N
excretion POS N
of POS N
electrolytes POS N
and POS N
blood POS N
biochemical POS N
assays, POS N
the POS N
LSSalt POS N
treatment POS N
had POS N
the POS N
same POS N
effects POS N
on POS N
the POS N
ISH POS N
group POS N
as POS N
on POS N
the POS N
NISH POS N
group. POS N

Evidence POS N
has POS N
shown POS N
that POS N
long-term POS N
sodium POS N
reduction POS N
can POS N
not POS N
only POS N
reduce POS N
blood POS N
pressure, POS N
but POS N
also POS N
provide POS N
cardiovascular POS N
benefits. POS N

Evidence POS N
has POS N
shown POS N
that POS N
long-term POS N
sodium POS N
reduction POS N
can POS N
not POS N
only POS N
reduce POS N
blood POS N
pressure, POS N
but POS N
also POS N
provide POS N
cardiovascular POS N
benefits. POS N

At POS N
the POS N
end POS N
of POS N
the POS N
study, POS N
the POS N
mean POS N
systolic POS N
blood POS N
pressure POS N
(SBP) POS N
of POS N
the POS N
ISH POS N
LSSalt POS N
group POS N
had POS N
significantly POS N
decreased POS N
by POS N
10.18 POS N
mm POS N
Hg POS N
(95% POS N
confidence POS N
interval POS N
(CI): POS N
3.13 POS N
to POS N
17.2, POS N
P = .006) POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
ISH POS N
NSalt POS N
group, POS N

Evidence POS N
has POS N
shown POS N
that POS N
long-term POS N
sodium POS N
reduction POS N
can POS N
not POS N
only POS N
reduce POS N
blood POS N
pressure, POS N
but POS N
also POS N
provide POS N
cardiovascular POS N
benefits. POS N

the POS N
mean POS N
SBP POS N
only POS N
decreased POS N
by POS N
5.10 POS N
mm POS N
Hg POS N
(95% POS N
CI: POS N
-2.02 POS N
to POS N
12.2, POS N
P = .158) POS N
in POS N
the POS N
NISH POS N
LSSalt POS N
group POS N
compared POS N
with POS N
that POS N
of POS N
the POS N
NISH POS N
NSalt POS N
group. POS N

Evidence POS N
has POS N
shown POS N
that POS N
long-term POS N
sodium POS N
reduction POS N
can POS N
not POS N
only POS N
reduce POS N
blood POS N
pressure, POS N
but POS N
also POS N
provide POS N
cardiovascular POS N
benefits. POS N

The POS N
mean POS N
diastolic POS N
blood POS N
pressure POS N
(DBP) POS N
had POS N
no POS N
significant POS N
differences POS N
in POS N
the POS N
ISH POS N
and POS N
NISH POS N
groups. POS N

Evidence POS N
has POS N
shown POS N
that POS N
long-term POS N
sodium POS N
reduction POS N
can POS N
not POS N
only POS N
reduce POS N
blood POS N
pressure, POS N
but POS N
also POS N
provide POS N
cardiovascular POS N
benefits. POS N

No POS N
obvious POS N
renin POS N
angiotensin POS N
system POS N
activation POS N
was POS N
found POS N
after POS N
LSSalt POS N
intervention. POS N

Evidence POS N
has POS N
shown POS N
that POS N
long-term POS N
sodium POS N
reduction POS N
can POS N
not POS N
only POS N
reduce POS N
blood POS N
pressure, POS N
but POS N
also POS N
provide POS N
cardiovascular POS N
benefits. POS N

The POS N
present POS N
study POS N
showed POS N
that POS N
the POS N
SBP POS N
of POS N
ISH POS N
patients POS N
was POS N
significantly POS N
decreased POS N
with POS N
the POS N
LSSalt POS N
intervention, POS N

Evidence POS N
has POS N
shown POS N
that POS N
long-term POS N
sodium POS N
reduction POS N
can POS N
not POS N
only POS N
reduce POS N
blood POS N
pressure, POS N
but POS N
also POS N
provide POS N
cardiovascular POS N
benefits. POS N

neither POS N
the POS N
SBP POS N
of POS N
the POS N
NISH POS N
patients POS N
nor POS N
the POS N
DBP POS N
of POS N
either POS N
group POS N
were POS N
similarly POS N
decreased, POS N
which POS N
indicated POS N
that POS N
ISH POS N
patients POS N
were POS N
more POS N
sensitive POS N
to POS N
salt POS N
restriction. POS N

Evidence POS N
has POS N
shown POS N
that POS N
long-term POS N
sodium POS N
reduction POS N
can POS N
not POS N
only POS N
reduce POS N
blood POS N
pressure, POS N
but POS N
also POS N
provide POS N
cardiovascular POS N
benefits. POS N

Regarding POS N
the POS N
urinary POS N
excretion POS N
of POS N
electrolytes POS N
and POS N
blood POS N
biochemical POS N
assays, POS N
the POS N
LSSalt POS N
treatment POS N
had POS N
the POS N
same POS N
effects POS N
on POS N
the POS N
ISH POS N
group POS N
as POS N
on POS N
the POS N
NISH POS N
group. POS N

Available POS N
data POS N
indicate POS N
that POS N
dietary POS N
sodium POS N
(as POS N
salt) POS N
relates POS N
directly POS N
to POS N
blood POS N
pressure POS N
(BP). POS N

Normal POS N
weight POS N
and POS N
obese POS N
participants POS N
manifested POS N
significant POS N
positive POS N
relations POS N
to POS N
BP POS N
of POS N
urinary POS N
sodium; POS N
relations POS N
were POS N
weaker POS N
for POS N
overweight POS N
people. POS N

Available POS N
data POS N
indicate POS N
that POS N
dietary POS N
sodium POS N
(as POS N
salt) POS N
relates POS N
directly POS N
to POS N
blood POS N
pressure POS N
(BP). POS N

At POS N
lower POS N
but POS N
not POS N
higher POS N
levels POS N
of POS N
24-hour POS N
sodium POS N
excretion, POS N
potassium POS N
intake POS N
blunted POS N
the POS N
sodium-BP POS N
relation. POS N

Available POS N
data POS N
indicate POS N
that POS N
dietary POS N
sodium POS N
(as POS N
salt) POS N
relates POS N
directly POS N
to POS N
blood POS N
pressure POS N
(BP). POS N

The POS N
adverse POS N
association POS N
of POS N
dietary POS N
sodium POS N
with POS N
BP POS N
is POS N
minimally POS N
attenuated POS N
by POS N
other POS N
dietary POS N
constituents; POS N

Available POS N
data POS N
indicate POS N
that POS N
dietary POS N
sodium POS N
(as POS N
salt) POS N
relates POS N
directly POS N
to POS N
blood POS N
pressure POS N
(BP). POS N

these POS N
findings POS N
underscore POS N
the POS N
importance POS N
of POS N
reducing POS N
salt POS N
intake POS N
for POS N
the POS N
prevention POS N
and POS N
control POS N
of POS N
prehypertension POS N
and POS N
hypertension. POS N

Normal POS N
weight POS N
and POS N
obese POS N
participants POS N
manifested POS N
significant POS N
positive POS N
relations POS N
to POS N
BP POS N
of POS N
urinary POS N
sodium; POS N
relations POS N
were POS N
weaker POS N
for POS N
overweight POS N
people. POS N

Available POS N
data POS N
indicate POS N
that POS N
dietary POS N
sodium POS N
(as POS N
salt) POS N
relates POS N
directly POS N
to POS N
blood POS N
pressure POS N
(BP). POS N

Normal POS N
weight POS N
and POS N
obese POS N
participants POS N
manifested POS N
significant POS N
positive POS N
relations POS N
to POS N
BP POS N
of POS N
urinary POS N
sodium; POS N
relations POS N
were POS N
weaker POS N
for POS N
overweight POS N
people. POS N

At POS N
lower POS N
but POS N
not POS N
higher POS N
levels POS N
of POS N
24-hour POS N
sodium POS N
excretion, POS N
potassium POS N
intake POS N
blunted POS N
the POS N
sodium-BP POS N
relation. POS N

Normal POS N
weight POS N
and POS N
obese POS N
participants POS N
manifested POS N
significant POS N
positive POS N
relations POS N
to POS N
BP POS N
of POS N
urinary POS N
sodium; POS N
relations POS N
were POS N
weaker POS N
for POS N
overweight POS N
people. POS N

The POS N
adverse POS N
association POS N
of POS N
dietary POS N
sodium POS N
with POS N
BP POS N
is POS N
minimally POS N
attenuated POS N
by POS N
other POS N
dietary POS N
constituents; POS N

Normal POS N
weight POS N
and POS N
obese POS N
participants POS N
manifested POS N
significant POS N
positive POS N
relations POS N
to POS N
BP POS N
of POS N
urinary POS N
sodium; POS N
relations POS N
were POS N
weaker POS N
for POS N
overweight POS N
people. POS N

these POS N
findings POS N
underscore POS N
the POS N
importance POS N
of POS N
reducing POS N
salt POS N
intake POS N
for POS N
the POS N
prevention POS N
and POS N
control POS N
of POS N
prehypertension POS N
and POS N
hypertension. POS N

At POS N
lower POS N
but POS N
not POS N
higher POS N
levels POS N
of POS N
24-hour POS N
sodium POS N
excretion, POS N
potassium POS N
intake POS N
blunted POS N
the POS N
sodium-BP POS N
relation. POS N

Available POS N
data POS N
indicate POS N
that POS N
dietary POS N
sodium POS N
(as POS N
salt) POS N
relates POS N
directly POS N
to POS N
blood POS N
pressure POS N
(BP). POS N

At POS N
lower POS N
but POS N
not POS N
higher POS N
levels POS N
of POS N
24-hour POS N
sodium POS N
excretion, POS N
potassium POS N
intake POS N
blunted POS N
the POS N
sodium-BP POS N
relation. POS N

Normal POS N
weight POS N
and POS N
obese POS N
participants POS N
manifested POS N
significant POS N
positive POS N
relations POS N
to POS N
BP POS N
of POS N
urinary POS N
sodium; POS N
relations POS N
were POS N
weaker POS N
for POS N
overweight POS N
people. POS N

At POS N
lower POS N
but POS N
not POS N
higher POS N
levels POS N
of POS N
24-hour POS N
sodium POS N
excretion, POS N
potassium POS N
intake POS N
blunted POS N
the POS N
sodium-BP POS N
relation. POS N

The POS N
adverse POS N
association POS N
of POS N
dietary POS N
sodium POS N
with POS N
BP POS N
is POS N
minimally POS N
attenuated POS N
by POS N
other POS N
dietary POS N
constituents; POS N

At POS N
lower POS N
but POS N
not POS N
higher POS N
levels POS N
of POS N
24-hour POS N
sodium POS N
excretion, POS N
potassium POS N
intake POS N
blunted POS N
the POS N
sodium-BP POS N
relation. POS N

these POS N
findings POS N
underscore POS N
the POS N
importance POS N
of POS N
reducing POS N
salt POS N
intake POS N
for POS N
the POS N
prevention POS N
and POS N
control POS N
of POS N
prehypertension POS N
and POS N
hypertension. POS N

The POS N
adverse POS N
association POS N
of POS N
dietary POS N
sodium POS N
with POS N
BP POS N
is POS N
minimally POS N
attenuated POS N
by POS N
other POS N
dietary POS N
constituents; POS N

Available POS N
data POS N
indicate POS N
that POS N
dietary POS N
sodium POS N
(as POS N
salt) POS N
relates POS N
directly POS N
to POS N
blood POS N
pressure POS N
(BP). POS N

The POS N
adverse POS N
association POS N
of POS N
dietary POS N
sodium POS N
with POS N
BP POS N
is POS N
minimally POS N
attenuated POS N
by POS N
other POS N
dietary POS N
constituents; POS N

Normal POS N
weight POS N
and POS N
obese POS N
participants POS N
manifested POS N
significant POS N
positive POS N
relations POS N
to POS N
BP POS N
of POS N
urinary POS N
sodium; POS N
relations POS N
were POS N
weaker POS N
for POS N
overweight POS N
people. POS N

The POS N
adverse POS N
association POS N
of POS N
dietary POS N
sodium POS N
with POS N
BP POS N
is POS N
minimally POS N
attenuated POS N
by POS N
other POS N
dietary POS N
constituents; POS N

At POS N
lower POS N
but POS N
not POS N
higher POS N
levels POS N
of POS N
24-hour POS N
sodium POS N
excretion, POS N
potassium POS N
intake POS N
blunted POS N
the POS N
sodium-BP POS N
relation. POS N

The POS N
adverse POS N
association POS N
of POS N
dietary POS N
sodium POS N
with POS N
BP POS N
is POS N
minimally POS N
attenuated POS N
by POS N
other POS N
dietary POS N
constituents; POS N

these POS N
findings POS N
underscore POS N
the POS N
importance POS N
of POS N
reducing POS N
salt POS N
intake POS N
for POS N
the POS N
prevention POS N
and POS N
control POS N
of POS N
prehypertension POS N
and POS N
hypertension. POS N

these POS N
findings POS N
underscore POS N
the POS N
importance POS N
of POS N
reducing POS N
salt POS N
intake POS N
for POS N
the POS N
prevention POS N
and POS N
control POS N
of POS N
prehypertension POS N
and POS N
hypertension. POS N

Available POS N
data POS N
indicate POS N
that POS N
dietary POS N
sodium POS N
(as POS N
salt) POS N
relates POS N
directly POS N
to POS N
blood POS N
pressure POS N
(BP). POS N

these POS N
findings POS N
underscore POS N
the POS N
importance POS N
of POS N
reducing POS N
salt POS N
intake POS N
for POS N
the POS N
prevention POS N
and POS N
control POS N
of POS N
prehypertension POS N
and POS N
hypertension. POS N

Normal POS N
weight POS N
and POS N
obese POS N
participants POS N
manifested POS N
significant POS N
positive POS N
relations POS N
to POS N
BP POS N
of POS N
urinary POS N
sodium; POS N
relations POS N
were POS N
weaker POS N
for POS N
overweight POS N
people. POS N

these POS N
findings POS N
underscore POS N
the POS N
importance POS N
of POS N
reducing POS N
salt POS N
intake POS N
for POS N
the POS N
prevention POS N
and POS N
control POS N
of POS N
prehypertension POS N
and POS N
hypertension. POS N

At POS N
lower POS N
but POS N
not POS N
higher POS N
levels POS N
of POS N
24-hour POS N
sodium POS N
excretion, POS N
potassium POS N
intake POS N
blunted POS N
the POS N
sodium-BP POS N
relation. POS N

these POS N
findings POS N
underscore POS N
the POS N
importance POS N
of POS N
reducing POS N
salt POS N
intake POS N
for POS N
the POS N
prevention POS N
and POS N
control POS N
of POS N
prehypertension POS N
and POS N
hypertension. POS N

The POS N
adverse POS N
association POS N
of POS N
dietary POS N
sodium POS N
with POS N
BP POS N
is POS N
minimally POS N
attenuated POS N
by POS N
other POS N
dietary POS N
constituents; POS N

The POS N
data POS N
of POS N
the POS N
full POS N
analysis POS N
set POS N
showed POS N
that POS N
HBeAg POS N
seroconversion POS N
rate POS N
at POS N
week POS N
72 POS N
was POS N
27.32% POS N
in POS N
the POS N
trial POS N
group POS N
and POS N
22.70% POS N
in POS N
the POS N
control POS N
group POS N
with POS N
a POS N
rate POS N
difference POS N
of POS N
4.63% POS N
(95% POS N
CI POS N
-1.54% POS N
to POS N
10.80%, POS N
P POS N
= POS N
0.1493). POS N

The POS N
data POS N
of POS N
the POS N
per-protocol POS N
set POS N
showed POS N
that POS N
HBeAg POS N
seroconversion POS N
rate POS N
at POS N
week POS N
72 POS N
was POS N
30.75% POS N
in POS N
the POS N
trial POS N
group POS N
and POS N
27.14% POS N
in POS N
the POS N
control POS N
group POS N
with POS N
a POS N
rate POS N
difference POS N
of POS N
3.61% POS N
(95% POS N
CI POS N
-3.87% POS N
to POS N
11.09%, POS N
P POS N
= POS N
0.3436). POS N

The POS N
data POS N
of POS N
the POS N
full POS N
analysis POS N
set POS N
showed POS N
that POS N
HBeAg POS N
seroconversion POS N
rate POS N
at POS N
week POS N
72 POS N
was POS N
27.32% POS N
in POS N
the POS N
trial POS N
group POS N
and POS N
22.70% POS N
in POS N
the POS N
control POS N
group POS N
with POS N
a POS N
rate POS N
difference POS N
of POS N
4.63% POS N
(95% POS N
CI POS N
-1.54% POS N
to POS N
10.80%, POS N
P POS N
= POS N
0.1493). POS N

95% POS N
CI POS N
met POS N
the POS N
non-inferiority POS N
criteria, POS N
and POS N
the POS N
trial POS N
group POS N
was POS N
non-inferior POS N
to POS N
the POS N
control POS N
group. POS N

The POS N
data POS N
of POS N
the POS N
full POS N
analysis POS N
set POS N
showed POS N
that POS N
HBeAg POS N
seroconversion POS N
rate POS N
at POS N
week POS N
72 POS N
was POS N
27.32% POS N
in POS N
the POS N
trial POS N
group POS N
and POS N
22.70% POS N
in POS N
the POS N
control POS N
group POS N
with POS N
a POS N
rate POS N
difference POS N
of POS N
4.63% POS N
(95% POS N
CI POS N
-1.54% POS N
to POS N
10.80%, POS N
P POS N
= POS N
0.1493). POS N

The POS N
two POS N
groups POS N
had POS N
similar POS N
incidence POS N
rates POS N
of POS N
adverse POS N
events, POS N
serious POS N
adverse POS N
events, POS N
and POS N
common POS N
adverse POS N
events. POS N

The POS N
data POS N
of POS N
the POS N
full POS N
analysis POS N
set POS N
showed POS N
that POS N
HBeAg POS N
seroconversion POS N
rate POS N
at POS N
week POS N
72 POS N
was POS N
27.32% POS N
in POS N
the POS N
trial POS N
group POS N
and POS N
22.70% POS N
in POS N
the POS N
control POS N
group POS N
with POS N
a POS N
rate POS N
difference POS N
of POS N
4.63% POS N
(95% POS N
CI POS N
-1.54% POS N
to POS N
10.80%, POS N
P POS N
= POS N
0.1493). POS N

In POS N
Peg-IFN-α POS N
regimen POS N
for POS N
HBeAg-positive POS N
CHB POS N
patients, POS N
the POS N
new POS N
drug POS N
Peg-IFN-α-2b POS N
(Y POS N
shape, POS N
40 POS N
kD) POS N
has POS N
comparable POS N
effect POS N
and POS N
safety POS N
to POS N
the POS N
control POS N
drug POS N
Peg-IFN-α-2a. POS N

The POS N
data POS N
of POS N
the POS N
per-protocol POS N
set POS N
showed POS N
that POS N
HBeAg POS N
seroconversion POS N
rate POS N
at POS N
week POS N
72 POS N
was POS N
30.75% POS N
in POS N
the POS N
trial POS N
group POS N
and POS N
27.14% POS N
in POS N
the POS N
control POS N
group POS N
with POS N
a POS N
rate POS N
difference POS N
of POS N
3.61% POS N
(95% POS N
CI POS N
-3.87% POS N
to POS N
11.09%, POS N
P POS N
= POS N
0.3436). POS N

The POS N
data POS N
of POS N
the POS N
full POS N
analysis POS N
set POS N
showed POS N
that POS N
HBeAg POS N
seroconversion POS N
rate POS N
at POS N
week POS N
72 POS N
was POS N
27.32% POS N
in POS N
the POS N
trial POS N
group POS N
and POS N
22.70% POS N
in POS N
the POS N
control POS N
group POS N
with POS N
a POS N
rate POS N
difference POS N
of POS N
4.63% POS N
(95% POS N
CI POS N
-1.54% POS N
to POS N
10.80%, POS N
P POS N
= POS N
0.1493). POS N

The POS N
data POS N
of POS N
the POS N
per-protocol POS N
set POS N
showed POS N
that POS N
HBeAg POS N
seroconversion POS N
rate POS N
at POS N
week POS N
72 POS N
was POS N
30.75% POS N
in POS N
the POS N
trial POS N
group POS N
and POS N
27.14% POS N
in POS N
the POS N
control POS N
group POS N
with POS N
a POS N
rate POS N
difference POS N
of POS N
3.61% POS N
(95% POS N
CI POS N
-3.87% POS N
to POS N
11.09%, POS N
P POS N
= POS N
0.3436). POS N

95% POS N
CI POS N
met POS N
the POS N
non-inferiority POS N
criteria, POS N
and POS N
the POS N
trial POS N
group POS N
was POS N
non-inferior POS N
to POS N
the POS N
control POS N
group. POS N

The POS N
data POS N
of POS N
the POS N
per-protocol POS N
set POS N
showed POS N
that POS N
HBeAg POS N
seroconversion POS N
rate POS N
at POS N
week POS N
72 POS N
was POS N
30.75% POS N
in POS N
the POS N
trial POS N
group POS N
and POS N
27.14% POS N
in POS N
the POS N
control POS N
group POS N
with POS N
a POS N
rate POS N
difference POS N
of POS N
3.61% POS N
(95% POS N
CI POS N
-3.87% POS N
to POS N
11.09%, POS N
P POS N
= POS N
0.3436). POS N

The POS N
two POS N
groups POS N
had POS N
similar POS N
incidence POS N
rates POS N
of POS N
adverse POS N
events, POS N
serious POS N
adverse POS N
events, POS N
and POS N
common POS N
adverse POS N
events. POS N

The POS N
data POS N
of POS N
the POS N
per-protocol POS N
set POS N
showed POS N
that POS N
HBeAg POS N
seroconversion POS N
rate POS N
at POS N
week POS N
72 POS N
was POS N
30.75% POS N
in POS N
the POS N
trial POS N
group POS N
and POS N
27.14% POS N
in POS N
the POS N
control POS N
group POS N
with POS N
a POS N
rate POS N
difference POS N
of POS N
3.61% POS N
(95% POS N
CI POS N
-3.87% POS N
to POS N
11.09%, POS N
P POS N
= POS N
0.3436). POS N

In POS N
Peg-IFN-α POS N
regimen POS N
for POS N
HBeAg-positive POS N
CHB POS N
patients, POS N
the POS N
new POS N
drug POS N
Peg-IFN-α-2b POS N
(Y POS N
shape, POS N
40 POS N
kD) POS N
has POS N
comparable POS N
effect POS N
and POS N
safety POS N
to POS N
the POS N
control POS N
drug POS N
Peg-IFN-α-2a. POS N

95% POS N
CI POS N
met POS N
the POS N
non-inferiority POS N
criteria, POS N
and POS N
the POS N
trial POS N
group POS N
was POS N
non-inferior POS N
to POS N
the POS N
control POS N
group. POS N

The POS N
data POS N
of POS N
the POS N
full POS N
analysis POS N
set POS N
showed POS N
that POS N
HBeAg POS N
seroconversion POS N
rate POS N
at POS N
week POS N
72 POS N
was POS N
27.32% POS N
in POS N
the POS N
trial POS N
group POS N
and POS N
22.70% POS N
in POS N
the POS N
control POS N
group POS N
with POS N
a POS N
rate POS N
difference POS N
of POS N
4.63% POS N
(95% POS N
CI POS N
-1.54% POS N
to POS N
10.80%, POS N
P POS N
= POS N
0.1493). POS N

95% POS N
CI POS N
met POS N
the POS N
non-inferiority POS N
criteria, POS N
and POS N
the POS N
trial POS N
group POS N
was POS N
non-inferior POS N
to POS N
the POS N
control POS N
group. POS N

The POS N
data POS N
of POS N
the POS N
per-protocol POS N
set POS N
showed POS N
that POS N
HBeAg POS N
seroconversion POS N
rate POS N
at POS N
week POS N
72 POS N
was POS N
30.75% POS N
in POS N
the POS N
trial POS N
group POS N
and POS N
27.14% POS N
in POS N
the POS N
control POS N
group POS N
with POS N
a POS N
rate POS N
difference POS N
of POS N
3.61% POS N
(95% POS N
CI POS N
-3.87% POS N
to POS N
11.09%, POS N
P POS N
= POS N
0.3436). POS N

95% POS N
CI POS N
met POS N
the POS N
non-inferiority POS N
criteria, POS N
and POS N
the POS N
trial POS N
group POS N
was POS N
non-inferior POS N
to POS N
the POS N
control POS N
group. POS N

The POS N
two POS N
groups POS N
had POS N
similar POS N
incidence POS N
rates POS N
of POS N
adverse POS N
events, POS N
serious POS N
adverse POS N
events, POS N
and POS N
common POS N
adverse POS N
events. POS N

95% POS N
CI POS N
met POS N
the POS N
non-inferiority POS N
criteria, POS N
and POS N
the POS N
trial POS N
group POS N
was POS N
non-inferior POS N
to POS N
the POS N
control POS N
group. POS N

In POS N
Peg-IFN-α POS N
regimen POS N
for POS N
HBeAg-positive POS N
CHB POS N
patients, POS N
the POS N
new POS N
drug POS N
Peg-IFN-α-2b POS N
(Y POS N
shape, POS N
40 POS N
kD) POS N
has POS N
comparable POS N
effect POS N
and POS N
safety POS N
to POS N
the POS N
control POS N
drug POS N
Peg-IFN-α-2a. POS N

The POS N
two POS N
groups POS N
had POS N
similar POS N
incidence POS N
rates POS N
of POS N
adverse POS N
events, POS N
serious POS N
adverse POS N
events, POS N
and POS N
common POS N
adverse POS N
events. POS N

The POS N
data POS N
of POS N
the POS N
full POS N
analysis POS N
set POS N
showed POS N
that POS N
HBeAg POS N
seroconversion POS N
rate POS N
at POS N
week POS N
72 POS N
was POS N
27.32% POS N
in POS N
the POS N
trial POS N
group POS N
and POS N
22.70% POS N
in POS N
the POS N
control POS N
group POS N
with POS N
a POS N
rate POS N
difference POS N
of POS N
4.63% POS N
(95% POS N
CI POS N
-1.54% POS N
to POS N
10.80%, POS N
P POS N
= POS N
0.1493). POS N

The POS N
two POS N
groups POS N
had POS N
similar POS N
incidence POS N
rates POS N
of POS N
adverse POS N
events, POS N
serious POS N
adverse POS N
events, POS N
and POS N
common POS N
adverse POS N
events. POS N

The POS N
data POS N
of POS N
the POS N
per-protocol POS N
set POS N
showed POS N
that POS N
HBeAg POS N
seroconversion POS N
rate POS N
at POS N
week POS N
72 POS N
was POS N
30.75% POS N
in POS N
the POS N
trial POS N
group POS N
and POS N
27.14% POS N
in POS N
the POS N
control POS N
group POS N
with POS N
a POS N
rate POS N
difference POS N
of POS N
3.61% POS N
(95% POS N
CI POS N
-3.87% POS N
to POS N
11.09%, POS N
P POS N
= POS N
0.3436). POS N

The POS N
two POS N
groups POS N
had POS N
similar POS N
incidence POS N
rates POS N
of POS N
adverse POS N
events, POS N
serious POS N
adverse POS N
events, POS N
and POS N
common POS N
adverse POS N
events. POS N

95% POS N
CI POS N
met POS N
the POS N
non-inferiority POS N
criteria, POS N
and POS N
the POS N
trial POS N
group POS N
was POS N
non-inferior POS N
to POS N
the POS N
control POS N
group. POS N

The POS N
two POS N
groups POS N
had POS N
similar POS N
incidence POS N
rates POS N
of POS N
adverse POS N
events, POS N
serious POS N
adverse POS N
events, POS N
and POS N
common POS N
adverse POS N
events. POS N

In POS N
Peg-IFN-α POS N
regimen POS N
for POS N
HBeAg-positive POS N
CHB POS N
patients, POS N
the POS N
new POS N
drug POS N
Peg-IFN-α-2b POS N
(Y POS N
shape, POS N
40 POS N
kD) POS N
has POS N
comparable POS N
effect POS N
and POS N
safety POS N
to POS N
the POS N
control POS N
drug POS N
Peg-IFN-α-2a. POS N

In POS N
Peg-IFN-α POS N
regimen POS N
for POS N
HBeAg-positive POS N
CHB POS N
patients, POS N
the POS N
new POS N
drug POS N
Peg-IFN-α-2b POS N
(Y POS N
shape, POS N
40 POS N
kD) POS N
has POS N
comparable POS N
effect POS N
and POS N
safety POS N
to POS N
the POS N
control POS N
drug POS N
Peg-IFN-α-2a. POS N

The POS N
data POS N
of POS N
the POS N
full POS N
analysis POS N
set POS N
showed POS N
that POS N
HBeAg POS N
seroconversion POS N
rate POS N
at POS N
week POS N
72 POS N
was POS N
27.32% POS N
in POS N
the POS N
trial POS N
group POS N
and POS N
22.70% POS N
in POS N
the POS N
control POS N
group POS N
with POS N
a POS N
rate POS N
difference POS N
of POS N
4.63% POS N
(95% POS N
CI POS N
-1.54% POS N
to POS N
10.80%, POS N
P POS N
= POS N
0.1493). POS N

In POS N
Peg-IFN-α POS N
regimen POS N
for POS N
HBeAg-positive POS N
CHB POS N
patients, POS N
the POS N
new POS N
drug POS N
Peg-IFN-α-2b POS N
(Y POS N
shape, POS N
40 POS N
kD) POS N
has POS N
comparable POS N
effect POS N
and POS N
safety POS N
to POS N
the POS N
control POS N
drug POS N
Peg-IFN-α-2a. POS N

The POS N
data POS N
of POS N
the POS N
per-protocol POS N
set POS N
showed POS N
that POS N
HBeAg POS N
seroconversion POS N
rate POS N
at POS N
week POS N
72 POS N
was POS N
30.75% POS N
in POS N
the POS N
trial POS N
group POS N
and POS N
27.14% POS N
in POS N
the POS N
control POS N
group POS N
with POS N
a POS N
rate POS N
difference POS N
of POS N
3.61% POS N
(95% POS N
CI POS N
-3.87% POS N
to POS N
11.09%, POS N
P POS N
= POS N
0.3436). POS N

In POS N
Peg-IFN-α POS N
regimen POS N
for POS N
HBeAg-positive POS N
CHB POS N
patients, POS N
the POS N
new POS N
drug POS N
Peg-IFN-α-2b POS N
(Y POS N
shape, POS N
40 POS N
kD) POS N
has POS N
comparable POS N
effect POS N
and POS N
safety POS N
to POS N
the POS N
control POS N
drug POS N
Peg-IFN-α-2a. POS N

95% POS N
CI POS N
met POS N
the POS N
non-inferiority POS N
criteria, POS N
and POS N
the POS N
trial POS N
group POS N
was POS N
non-inferior POS N
to POS N
the POS N
control POS N
group. POS N

In POS N
Peg-IFN-α POS N
regimen POS N
for POS N
HBeAg-positive POS N
CHB POS N
patients, POS N
the POS N
new POS N
drug POS N
Peg-IFN-α-2b POS N
(Y POS N
shape, POS N
40 POS N
kD) POS N
has POS N
comparable POS N
effect POS N
and POS N
safety POS N
to POS N
the POS N
control POS N
drug POS N
Peg-IFN-α-2a. POS N

The POS N
two POS N
groups POS N
had POS N
similar POS N
incidence POS N
rates POS N
of POS N
adverse POS N
events, POS N
serious POS N
adverse POS N
events, POS N
and POS N
common POS N
adverse POS N
events. POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

The POS N
overall POS N
response POS N
rate POS N
was POS N
8.4% POS N
(95% POS N
confidence POS N
interval POS N
[CI]) POS N
3.2% POS N
to POS N
13.7% POS N
for POS N
patients POS N
treated POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
compared POS N
with POS N
17.6%; POS N
95% POS N
CI POS N
10.3% POS N
to POS N
25.1% POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.04). POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

Median POS N
failure-free POS N
survival POS N
was POS N
2.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
3.8 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.14). POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

Median POS N
survival POS N
was POS N
5.1 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
and POS N
6.5 POS N
months POS N
for POS N
PVI POS N
5-FU POS N
plus POS N
MMC POS N
(P POS N
=.34). POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

Toxicities POS N
in POS N
both POS N
arms POS N
were POS N
mild. POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

There POS N
was POS N
an POS N
increased POS N
incidence POS N
of POS N
neutropenia POS N
in POS N
the POS N
5-FU POS N
plus POS N
MMC POS N
arm POS N
(P POS N
<.01), POS N
although POS N
no POS N
differences POS N
in POS N
infection POS N
were POS N
seen. POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

No POS N
patients POS N
developed POS N
hemolytic POS N
uremic POS N
syndrome. POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

Global POS N
QOL POS N
improved POS N
significantly POS N
after POS N
24 POS N
weeks POS N
of POS N
treatment POS N
compared POS N
with POS N
baseline POS N
for POS N
patients POS N
receiving POS N
5-FU POS N
plus POS N
MMC, POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

although POS N
there POS N
was POS N
no POS N
statistically POS N
significant POS N
difference POS N
in POS N
QOL POS N
between POS N
arms. POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

These POS N
results POS N
emphasize POS N
the POS N
importance POS N
of POS N
chemotherapy POS N
in POS N
this POS N
setting POS N
and POS N
the POS N
continuing POS N
value POS N
of POS N
the POS N
fluoropyrimidines POS N
in POS N
pancreatic POS N
cancer. POS N

but POS N
this POS N
did POS N
not POS N
translate POS N
into POS N
a POS N
survival POS N
advantage. POS N

PVI POS N
5-FU POS N
plus POS N
MMC POS N
resulted POS N
in POS N
a POS N
superior POS N
response POS N
rate POS N
in POS N
comparison POS N
with POS N
PVI POS N
5-FU POS N
alone POS N
in POS N
advanced POS N
pancreatic POS N
cancer, POS N

Fracture POS N
risk POS N
is POS N
increased POS N
in POS N
individuals POS N
with POS N
type POS N
2 POS N
diabetes POS N
(T2D). POS N

The POS N
choice POS N
of POS N
insulin POS N
treatment POS N
is POS N
not POS N
influencing POS N
BTMs, POS N

Fracture POS N
risk POS N
is POS N
increased POS N
in POS N
individuals POS N
with POS N
type POS N
2 POS N
diabetes POS N
(T2D). POS N

metformin POS N
treatment POS N
may POS N
decrease POS N
BTMs, POS N

Fracture POS N
risk POS N
is POS N
increased POS N
in POS N
individuals POS N
with POS N
type POS N
2 POS N
diabetes POS N
(T2D). POS N

improvement POS N
of POS N
glycaemic POS N
control POS N
may POS N
influence POS N
bone POS N
resorption POS N
activity. POS N

Fracture POS N
risk POS N
is POS N
increased POS N
in POS N
individuals POS N
with POS N
type POS N
2 POS N
diabetes POS N
(T2D). POS N

HbA1c POS N
was POS N
inversely POS N
associated POS N
with POS N
CTX POS N
but POS N
not POS N
P1NP. POS N

Fracture POS N
risk POS N
is POS N
increased POS N
in POS N
individuals POS N
with POS N
type POS N
2 POS N
diabetes POS N
(T2D). POS N

Neither POS N
metformin POS N
nor POS N
rosiglitazone POS N
plasma POS N
concentrations POS N
was POS N
associated POS N
with POS N
BTMs. POS N

Fracture POS N
risk POS N
is POS N
increased POS N
in POS N
individuals POS N
with POS N
type POS N
2 POS N
diabetes POS N
(T2D). POS N

Metformin POS N
and POS N
metformin + rosiglitazone POS N
but POS N
not POS N
rosiglitazone POS N
alone POS N
were POS N
associated POS N
with POS N
lower POS N
bone POS N
formation POS N
(PINP). POS N

Fracture POS N
risk POS N
is POS N
increased POS N
in POS N
individuals POS N
with POS N
type POS N
2 POS N
diabetes POS N
(T2D). POS N

Allocation POS N
of POS N
insulin POS N
regimens POS N
was POS N
not POS N
associated POS N
with POS N
different POS N
levels POS N
of POS N
BTMs. POS N

Fracture POS N
risk POS N
is POS N
increased POS N
in POS N
individuals POS N
with POS N
type POS N
2 POS N
diabetes POS N
(T2D). POS N

BTMs POS N
increased POS N
from POS N
baseline POS N
to POS N
month POS N
12 POS N
and POS N
remained POS N
higher POS N
at POS N
month POS N
24, POS N
with POS N
CTX POS N
and POS N
PINP POS N
increasing POS N
28.5% POS N
and POS N
23.0% POS N
(all: POS N
p < 0.001), POS N
respectively. POS N

The POS N
choice POS N
of POS N
insulin POS N
treatment POS N
is POS N
not POS N
influencing POS N
BTMs, POS N

Fracture POS N
risk POS N
is POS N
increased POS N
in POS N
individuals POS N
with POS N
type POS N
2 POS N
diabetes POS N
(T2D). POS N

The POS N
choice POS N
of POS N
insulin POS N
treatment POS N
is POS N
not POS N
influencing POS N
BTMs, POS N

metformin POS N
treatment POS N
may POS N
decrease POS N
BTMs, POS N

The POS N
choice POS N
of POS N
insulin POS N
treatment POS N
is POS N
not POS N
influencing POS N
BTMs, POS N

improvement POS N
of POS N
glycaemic POS N
control POS N
may POS N
influence POS N
bone POS N
resorption POS N
activity. POS N

The POS N
choice POS N
of POS N
insulin POS N
treatment POS N
is POS N
not POS N
influencing POS N
BTMs, POS N

HbA1c POS N
was POS N
inversely POS N
associated POS N
with POS N
CTX POS N
but POS N
not POS N
P1NP. POS N

The POS N
choice POS N
of POS N
insulin POS N
treatment POS N
is POS N
not POS N
influencing POS N
BTMs, POS N

Neither POS N
metformin POS N
nor POS N
rosiglitazone POS N
plasma POS N
concentrations POS N
was POS N
associated POS N
with POS N
BTMs. POS N

The POS N
choice POS N
of POS N
insulin POS N
treatment POS N
is POS N
not POS N
influencing POS N
BTMs, POS N

Metformin POS N
and POS N
metformin + rosiglitazone POS N
but POS N
not POS N
rosiglitazone POS N
alone POS N
were POS N
associated POS N
with POS N
lower POS N
bone POS N
formation POS N
(PINP). POS N

The POS N
choice POS N
of POS N
insulin POS N
treatment POS N
is POS N
not POS N
influencing POS N
BTMs, POS N

Allocation POS N
of POS N
insulin POS N
regimens POS N
was POS N
not POS N
associated POS N
with POS N
different POS N
levels POS N
of POS N
BTMs. POS N

The POS N
choice POS N
of POS N
insulin POS N
treatment POS N
is POS N
not POS N
influencing POS N
BTMs, POS N

BTMs POS N
increased POS N
from POS N
baseline POS N
to POS N
month POS N
12 POS N
and POS N
remained POS N
higher POS N
at POS N
month POS N
24, POS N
with POS N
CTX POS N
and POS N
PINP POS N
increasing POS N
28.5% POS N
and POS N
23.0% POS N
(all: POS N
p < 0.001), POS N
respectively. POS N

metformin POS N
treatment POS N
may POS N
decrease POS N
BTMs, POS N

Fracture POS N
risk POS N
is POS N
increased POS N
in POS N
individuals POS N
with POS N
type POS N
2 POS N
diabetes POS N
(T2D). POS N

metformin POS N
treatment POS N
may POS N
decrease POS N
BTMs, POS N

The POS N
choice POS N
of POS N
insulin POS N
treatment POS N
is POS N
not POS N
influencing POS N
BTMs, POS N

metformin POS N
treatment POS N
may POS N
decrease POS N
BTMs, POS N

improvement POS N
of POS N
glycaemic POS N
control POS N
may POS N
influence POS N
bone POS N
resorption POS N
activity. POS N

metformin POS N
treatment POS N
may POS N
decrease POS N
BTMs, POS N

HbA1c POS N
was POS N
inversely POS N
associated POS N
with POS N
CTX POS N
but POS N
not POS N
P1NP. POS N

metformin POS N
treatment POS N
may POS N
decrease POS N
BTMs, POS N

Neither POS N
metformin POS N
nor POS N
rosiglitazone POS N
plasma POS N
concentrations POS N
was POS N
associated POS N
with POS N
BTMs. POS N

metformin POS N
treatment POS N
may POS N
decrease POS N
BTMs, POS N

Metformin POS N
and POS N
metformin + rosiglitazone POS N
but POS N
not POS N
rosiglitazone POS N
alone POS N
were POS N
associated POS N
with POS N
lower POS N
bone POS N
formation POS N
(PINP). POS N

metformin POS N
treatment POS N
may POS N
decrease POS N
BTMs, POS N

Allocation POS N
of POS N
insulin POS N
regimens POS N
was POS N
not POS N
associated POS N
with POS N
different POS N
levels POS N
of POS N
BTMs. POS N

metformin POS N
treatment POS N
may POS N
decrease POS N
BTMs, POS N

BTMs POS N
increased POS N
from POS N
baseline POS N
to POS N
month POS N
12 POS N
and POS N
remained POS N
higher POS N
at POS N
month POS N
24, POS N
with POS N
CTX POS N
and POS N
PINP POS N
increasing POS N
28.5% POS N
and POS N
23.0% POS N
(all: POS N
p < 0.001), POS N
respectively. POS N

improvement POS N
of POS N
glycaemic POS N
control POS N
may POS N
influence POS N
bone POS N
resorption POS N
activity. POS N

Fracture POS N
risk POS N
is POS N
increased POS N
in POS N
individuals POS N
with POS N
type POS N
2 POS N
diabetes POS N
(T2D). POS N

improvement POS N
of POS N
glycaemic POS N
control POS N
may POS N
influence POS N
bone POS N
resorption POS N
activity. POS N

The POS N
choice POS N
of POS N
insulin POS N
treatment POS N
is POS N
not POS N
influencing POS N
BTMs, POS N

improvement POS N
of POS N
glycaemic POS N
control POS N
may POS N
influence POS N
bone POS N
resorption POS N
activity. POS N

metformin POS N
treatment POS N
may POS N
decrease POS N
BTMs, POS N

improvement POS N
of POS N
glycaemic POS N
control POS N
may POS N
influence POS N
bone POS N
resorption POS N
activity. POS N

HbA1c POS N
was POS N
inversely POS N
associated POS N
with POS N
CTX POS N
but POS N
not POS N
P1NP. POS N

improvement POS N
of POS N
glycaemic POS N
control POS N
may POS N
influence POS N
bone POS N
resorption POS N
activity. POS N

Neither POS N
metformin POS N
nor POS N
rosiglitazone POS N
plasma POS N
concentrations POS N
was POS N
associated POS N
with POS N
BTMs. POS N

improvement POS N
of POS N
glycaemic POS N
control POS N
may POS N
influence POS N
bone POS N
resorption POS N
activity. POS N

Metformin POS N
and POS N
metformin + rosiglitazone POS N
but POS N
not POS N
rosiglitazone POS N
alone POS N
were POS N
associated POS N
with POS N
lower POS N
bone POS N
formation POS N
(PINP). POS N

improvement POS N
of POS N
glycaemic POS N
control POS N
may POS N
influence POS N
bone POS N
resorption POS N
activity. POS N

Allocation POS N
of POS N
insulin POS N
regimens POS N
was POS N
not POS N
associated POS N
with POS N
different POS N
levels POS N
of POS N
BTMs. POS N

improvement POS N
of POS N
glycaemic POS N
control POS N
may POS N
influence POS N
bone POS N
resorption POS N
activity. POS N

BTMs POS N
increased POS N
from POS N
baseline POS N
to POS N
month POS N
12 POS N
and POS N
remained POS N
higher POS N
at POS N
month POS N
24, POS N
with POS N
CTX POS N
and POS N
PINP POS N
increasing POS N
28.5% POS N
and POS N
23.0% POS N
(all: POS N
p < 0.001), POS N
respectively. POS N

HbA1c POS N
was POS N
inversely POS N
associated POS N
with POS N
CTX POS N
but POS N
not POS N
P1NP. POS N

Fracture POS N
risk POS N
is POS N
increased POS N
in POS N
individuals POS N
with POS N
type POS N
2 POS N
diabetes POS N
(T2D). POS N

HbA1c POS N
was POS N
inversely POS N
associated POS N
with POS N
CTX POS N
but POS N
not POS N
P1NP. POS N

The POS N
choice POS N
of POS N
insulin POS N
treatment POS N
is POS N
not POS N
influencing POS N
BTMs, POS N

HbA1c POS N
was POS N
inversely POS N
associated POS N
with POS N
CTX POS N
but POS N
not POS N
P1NP. POS N

metformin POS N
treatment POS N
may POS N
decrease POS N
BTMs, POS N

HbA1c POS N
was POS N
inversely POS N
associated POS N
with POS N
CTX POS N
but POS N
not POS N
P1NP. POS N

improvement POS N
of POS N
glycaemic POS N
control POS N
may POS N
influence POS N
bone POS N
resorption POS N
activity. POS N

HbA1c POS N
was POS N
inversely POS N
associated POS N
with POS N
CTX POS N
but POS N
not POS N
P1NP. POS N

Neither POS N
metformin POS N
nor POS N
rosiglitazone POS N
plasma POS N
concentrations POS N
was POS N
associated POS N
with POS N
BTMs. POS N

HbA1c POS N
was POS N
inversely POS N
associated POS N
with POS N
CTX POS N
but POS N
not POS N
P1NP. POS N

Metformin POS N
and POS N
metformin + rosiglitazone POS N
but POS N
not POS N
rosiglitazone POS N
alone POS N
were POS N
associated POS N
with POS N
lower POS N
bone POS N
formation POS N
(PINP). POS N

HbA1c POS N
was POS N
inversely POS N
associated POS N
with POS N
CTX POS N
but POS N
not POS N
P1NP. POS N

Allocation POS N
of POS N
insulin POS N
regimens POS N
was POS N
not POS N
associated POS N
with POS N
different POS N
levels POS N
of POS N
BTMs. POS N

HbA1c POS N
was POS N
inversely POS N
associated POS N
with POS N
CTX POS N
but POS N
not POS N
P1NP. POS N

BTMs POS N
increased POS N
from POS N
baseline POS N
to POS N
month POS N
12 POS N
and POS N
remained POS N
higher POS N
at POS N
month POS N
24, POS N
with POS N
CTX POS N
and POS N
PINP POS N
increasing POS N
28.5% POS N
and POS N
23.0% POS N
(all: POS N
p < 0.001), POS N
respectively. POS N

Neither POS N
metformin POS N
nor POS N
rosiglitazone POS N
plasma POS N
concentrations POS N
was POS N
associated POS N
with POS N
BTMs. POS N

Fracture POS N
risk POS N
is POS N
increased POS N
in POS N
individuals POS N
with POS N
type POS N
2 POS N
diabetes POS N
(T2D). POS N

Neither POS N
metformin POS N
nor POS N
rosiglitazone POS N
plasma POS N
concentrations POS N
was POS N
associated POS N
with POS N
BTMs. POS N

The POS N
choice POS N
of POS N
insulin POS N
treatment POS N
is POS N
not POS N
influencing POS N
BTMs, POS N

Neither POS N
metformin POS N
nor POS N
rosiglitazone POS N
plasma POS N
concentrations POS N
was POS N
associated POS N
with POS N
BTMs. POS N

metformin POS N
treatment POS N
may POS N
decrease POS N
BTMs, POS N

Neither POS N
metformin POS N
nor POS N
rosiglitazone POS N
plasma POS N
concentrations POS N
was POS N
associated POS N
with POS N
BTMs. POS N

improvement POS N
of POS N
glycaemic POS N
control POS N
may POS N
influence POS N
bone POS N
resorption POS N
activity. POS N

Neither POS N
metformin POS N
nor POS N
rosiglitazone POS N
plasma POS N
concentrations POS N
was POS N
associated POS N
with POS N
BTMs. POS N

HbA1c POS N
was POS N
inversely POS N
associated POS N
with POS N
CTX POS N
but POS N
not POS N
P1NP. POS N

Neither POS N
metformin POS N
nor POS N
rosiglitazone POS N
plasma POS N
concentrations POS N
was POS N
associated POS N
with POS N
BTMs. POS N

Metformin POS N
and POS N
metformin + rosiglitazone POS N
but POS N
not POS N
rosiglitazone POS N
alone POS N
were POS N
associated POS N
with POS N
lower POS N
bone POS N
formation POS N
(PINP). POS N

Neither POS N
metformin POS N
nor POS N
rosiglitazone POS N
plasma POS N
concentrations POS N
was POS N
associated POS N
with POS N
BTMs. POS N

Allocation POS N
of POS N
insulin POS N
regimens POS N
was POS N
not POS N
associated POS N
with POS N
different POS N
levels POS N
of POS N
BTMs. POS N

Neither POS N
metformin POS N
nor POS N
rosiglitazone POS N
plasma POS N
concentrations POS N
was POS N
associated POS N
with POS N
BTMs. POS N

BTMs POS N
increased POS N
from POS N
baseline POS N
to POS N
month POS N
12 POS N
and POS N
remained POS N
higher POS N
at POS N
month POS N
24, POS N
with POS N
CTX POS N
and POS N
PINP POS N
increasing POS N
28.5% POS N
and POS N
23.0% POS N
(all: POS N
p < 0.001), POS N
respectively. POS N

Metformin POS N
and POS N
metformin + rosiglitazone POS N
but POS N
not POS N
rosiglitazone POS N
alone POS N
were POS N
associated POS N
with POS N
lower POS N
bone POS N
formation POS N
(PINP). POS N

Fracture POS N
risk POS N
is POS N
increased POS N
in POS N
individuals POS N
with POS N
type POS N
2 POS N
diabetes POS N
(T2D). POS N

Metformin POS N
and POS N
metformin + rosiglitazone POS N
but POS N
not POS N
rosiglitazone POS N
alone POS N
were POS N
associated POS N
with POS N
lower POS N
bone POS N
formation POS N
(PINP). POS N

The POS N
choice POS N
of POS N
insulin POS N
treatment POS N
is POS N
not POS N
influencing POS N
BTMs, POS N

Metformin POS N
and POS N
metformin + rosiglitazone POS N
but POS N
not POS N
rosiglitazone POS N
alone POS N
were POS N
associated POS N
with POS N
lower POS N
bone POS N
formation POS N
(PINP). POS N

metformin POS N
treatment POS N
may POS N
decrease POS N
BTMs, POS N

Metformin POS N
and POS N
metformin + rosiglitazone POS N
but POS N
not POS N
rosiglitazone POS N
alone POS N
were POS N
associated POS N
with POS N
lower POS N
bone POS N
formation POS N
(PINP). POS N

improvement POS N
of POS N
glycaemic POS N
control POS N
may POS N
influence POS N
bone POS N
resorption POS N
activity. POS N

Metformin POS N
and POS N
metformin + rosiglitazone POS N
but POS N
not POS N
rosiglitazone POS N
alone POS N
were POS N
associated POS N
with POS N
lower POS N
bone POS N
formation POS N
(PINP). POS N

HbA1c POS N
was POS N
inversely POS N
associated POS N
with POS N
CTX POS N
but POS N
not POS N
P1NP. POS N

Metformin POS N
and POS N
metformin + rosiglitazone POS N
but POS N
not POS N
rosiglitazone POS N
alone POS N
were POS N
associated POS N
with POS N
lower POS N
bone POS N
formation POS N
(PINP). POS N

Neither POS N
metformin POS N
nor POS N
rosiglitazone POS N
plasma POS N
concentrations POS N
was POS N
associated POS N
with POS N
BTMs. POS N

Metformin POS N
and POS N
metformin + rosiglitazone POS N
but POS N
not POS N
rosiglitazone POS N
alone POS N
were POS N
associated POS N
with POS N
lower POS N
bone POS N
formation POS N
(PINP). POS N

Allocation POS N
of POS N
insulin POS N
regimens POS N
was POS N
not POS N
associated POS N
with POS N
different POS N
levels POS N
of POS N
BTMs. POS N

Metformin POS N
and POS N
metformin + rosiglitazone POS N
but POS N
not POS N
rosiglitazone POS N
alone POS N
were POS N
associated POS N
with POS N
lower POS N
bone POS N
formation POS N
(PINP). POS N

BTMs POS N
increased POS N
from POS N
baseline POS N
to POS N
month POS N
12 POS N
and POS N
remained POS N
higher POS N
at POS N
month POS N
24, POS N
with POS N
CTX POS N
and POS N
PINP POS N
increasing POS N
28.5% POS N
and POS N
23.0% POS N
(all: POS N
p < 0.001), POS N
respectively. POS N

Allocation POS N
of POS N
insulin POS N
regimens POS N
was POS N
not POS N
associated POS N
with POS N
different POS N
levels POS N
of POS N
BTMs. POS N

Fracture POS N
risk POS N
is POS N
increased POS N
in POS N
individuals POS N
with POS N
type POS N
2 POS N
diabetes POS N
(T2D). POS N

Allocation POS N
of POS N
insulin POS N
regimens POS N
was POS N
not POS N
associated POS N
with POS N
different POS N
levels POS N
of POS N
BTMs. POS N

The POS N
choice POS N
of POS N
insulin POS N
treatment POS N
is POS N
not POS N
influencing POS N
BTMs, POS N

Allocation POS N
of POS N
insulin POS N
regimens POS N
was POS N
not POS N
associated POS N
with POS N
different POS N
levels POS N
of POS N
BTMs. POS N

metformin POS N
treatment POS N
may POS N
decrease POS N
BTMs, POS N

Allocation POS N
of POS N
insulin POS N
regimens POS N
was POS N
not POS N
associated POS N
with POS N
different POS N
levels POS N
of POS N
BTMs. POS N

improvement POS N
of POS N
glycaemic POS N
control POS N
may POS N
influence POS N
bone POS N
resorption POS N
activity. POS N

Allocation POS N
of POS N
insulin POS N
regimens POS N
was POS N
not POS N
associated POS N
with POS N
different POS N
levels POS N
of POS N
BTMs. POS N

HbA1c POS N
was POS N
inversely POS N
associated POS N
with POS N
CTX POS N
but POS N
not POS N
P1NP. POS N

Allocation POS N
of POS N
insulin POS N
regimens POS N
was POS N
not POS N
associated POS N
with POS N
different POS N
levels POS N
of POS N
BTMs. POS N

Neither POS N
metformin POS N
nor POS N
rosiglitazone POS N
plasma POS N
concentrations POS N
was POS N
associated POS N
with POS N
BTMs. POS N

Allocation POS N
of POS N
insulin POS N
regimens POS N
was POS N
not POS N
associated POS N
with POS N
different POS N
levels POS N
of POS N
BTMs. POS N

Metformin POS N
and POS N
metformin + rosiglitazone POS N
but POS N
not POS N
rosiglitazone POS N
alone POS N
were POS N
associated POS N
with POS N
lower POS N
bone POS N
formation POS N
(PINP). POS N

Allocation POS N
of POS N
insulin POS N
regimens POS N
was POS N
not POS N
associated POS N
with POS N
different POS N
levels POS N
of POS N
BTMs. POS N

BTMs POS N
increased POS N
from POS N
baseline POS N
to POS N
month POS N
12 POS N
and POS N
remained POS N
higher POS N
at POS N
month POS N
24, POS N
with POS N
CTX POS N
and POS N
PINP POS N
increasing POS N
28.5% POS N
and POS N
23.0% POS N
(all: POS N
p < 0.001), POS N
respectively. POS N

BTMs POS N
increased POS N
from POS N
baseline POS N
to POS N
month POS N
12 POS N
and POS N
remained POS N
higher POS N
at POS N
month POS N
24, POS N
with POS N
CTX POS N
and POS N
PINP POS N
increasing POS N
28.5% POS N
and POS N
23.0% POS N
(all: POS N
p < 0.001), POS N
respectively. POS N

Fracture POS N
risk POS N
is POS N
increased POS N
in POS N
individuals POS N
with POS N
type POS N
2 POS N
diabetes POS N
(T2D). POS N

BTMs POS N
increased POS N
from POS N
baseline POS N
to POS N
month POS N
12 POS N
and POS N
remained POS N
higher POS N
at POS N
month POS N
24, POS N
with POS N
CTX POS N
and POS N
PINP POS N
increasing POS N
28.5% POS N
and POS N
23.0% POS N
(all: POS N
p < 0.001), POS N
respectively. POS N

The POS N
choice POS N
of POS N
insulin POS N
treatment POS N
is POS N
not POS N
influencing POS N
BTMs, POS N

BTMs POS N
increased POS N
from POS N
baseline POS N
to POS N
month POS N
12 POS N
and POS N
remained POS N
higher POS N
at POS N
month POS N
24, POS N
with POS N
CTX POS N
and POS N
PINP POS N
increasing POS N
28.5% POS N
and POS N
23.0% POS N
(all: POS N
p < 0.001), POS N
respectively. POS N

metformin POS N
treatment POS N
may POS N
decrease POS N
BTMs, POS N

BTMs POS N
increased POS N
from POS N
baseline POS N
to POS N
month POS N
12 POS N
and POS N
remained POS N
higher POS N
at POS N
month POS N
24, POS N
with POS N
CTX POS N
and POS N
PINP POS N
increasing POS N
28.5% POS N
and POS N
23.0% POS N
(all: POS N
p < 0.001), POS N
respectively. POS N

improvement POS N
of POS N
glycaemic POS N
control POS N
may POS N
influence POS N
bone POS N
resorption POS N
activity. POS N

BTMs POS N
increased POS N
from POS N
baseline POS N
to POS N
month POS N
12 POS N
and POS N
remained POS N
higher POS N
at POS N
month POS N
24, POS N
with POS N
CTX POS N
and POS N
PINP POS N
increasing POS N
28.5% POS N
and POS N
23.0% POS N
(all: POS N
p < 0.001), POS N
respectively. POS N

HbA1c POS N
was POS N
inversely POS N
associated POS N
with POS N
CTX POS N
but POS N
not POS N
P1NP. POS N

BTMs POS N
increased POS N
from POS N
baseline POS N
to POS N
month POS N
12 POS N
and POS N
remained POS N
higher POS N
at POS N
month POS N
24, POS N
with POS N
CTX POS N
and POS N
PINP POS N
increasing POS N
28.5% POS N
and POS N
23.0% POS N
(all: POS N
p < 0.001), POS N
respectively. POS N

Neither POS N
metformin POS N
nor POS N
rosiglitazone POS N
plasma POS N
concentrations POS N
was POS N
associated POS N
with POS N
BTMs. POS N

BTMs POS N
increased POS N
from POS N
baseline POS N
to POS N
month POS N
12 POS N
and POS N
remained POS N
higher POS N
at POS N
month POS N
24, POS N
with POS N
CTX POS N
and POS N
PINP POS N
increasing POS N
28.5% POS N
and POS N
23.0% POS N
(all: POS N
p < 0.001), POS N
respectively. POS N

Metformin POS N
and POS N
metformin + rosiglitazone POS N
but POS N
not POS N
rosiglitazone POS N
alone POS N
were POS N
associated POS N
with POS N
lower POS N
bone POS N
formation POS N
(PINP). POS N

BTMs POS N
increased POS N
from POS N
baseline POS N
to POS N
month POS N
12 POS N
and POS N
remained POS N
higher POS N
at POS N
month POS N
24, POS N
with POS N
CTX POS N
and POS N
PINP POS N
increasing POS N
28.5% POS N
and POS N
23.0% POS N
(all: POS N
p < 0.001), POS N
respectively. POS N

Allocation POS N
of POS N
insulin POS N
regimens POS N
was POS N
not POS N
associated POS N
with POS N
different POS N
levels POS N
of POS N
BTMs. POS N

Androgen POS N
deprivation POS N
therapy POS N
is POS N
a POS N
common POS N
treatment POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
that POS N
may POS N
cause POS N
fatigue, POS N
functional POS N
decline, POS N
increased POS N
body POS N
fatness, POS N
and POS N
loss POS N
of POS N
lean POS N
body POS N
tissue. POS N

These POS N
physical POS N
changes POS N
can POS N
negatively POS N
affect POS N
health-related POS N
quality POS N
of POS N
life. POS N

Androgen POS N
deprivation POS N
therapy POS N
is POS N
a POS N
common POS N
treatment POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
that POS N
may POS N
cause POS N
fatigue, POS N
functional POS N
decline, POS N
increased POS N
body POS N
fatness, POS N
and POS N
loss POS N
of POS N
lean POS N
body POS N
tissue. POS N

Resistance POS N
exercise POS N
may POS N
help POS N
to POS N
counter POS N
some POS N
of POS N
these POS N
side POS N
effects POS N
by POS N
reducing POS N
fatigue, POS N
elevating POS N
mood, POS N
building POS N
muscle POS N
mass, POS N
and POS N
reducing POS N
body POS N
fat. POS N

Androgen POS N
deprivation POS N
therapy POS N
is POS N
a POS N
common POS N
treatment POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
that POS N
may POS N
cause POS N
fatigue, POS N
functional POS N
decline, POS N
increased POS N
body POS N
fatness, POS N
and POS N
loss POS N
of POS N
lean POS N
body POS N
tissue. POS N

Men POS N
assigned POS N
to POS N
resistance POS N
exercise POS N
had POS N
less POS N
interference POS N
from POS N
fatigue POS N
on POS N
activities POS N
of POS N
daily POS N
living POS N
(P POS N
=.002) POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
(P POS N
=.001) POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

Androgen POS N
deprivation POS N
therapy POS N
is POS N
a POS N
common POS N
treatment POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
that POS N
may POS N
cause POS N
fatigue, POS N
functional POS N
decline, POS N
increased POS N
body POS N
fatness, POS N
and POS N
loss POS N
of POS N
lean POS N
body POS N
tissue. POS N

Men POS N
in POS N
the POS N
intervention POS N
group POS N
demonstrated POS N
higher POS N
levels POS N
of POS N
upper POS N
body POS N
(P POS N
=.009) POS N
and POS N
lower POS N
body POS N
(P POS N
<.001) POS N
muscular POS N
fitness POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

Androgen POS N
deprivation POS N
therapy POS N
is POS N
a POS N
common POS N
treatment POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
that POS N
may POS N
cause POS N
fatigue, POS N
functional POS N
decline, POS N
increased POS N
body POS N
fatness, POS N
and POS N
loss POS N
of POS N
lean POS N
body POS N
tissue. POS N

The POS N
12-week POS N
resistance POS N
exercise POS N
intervention POS N
did POS N
not POS N
improve POS N
body POS N
composition POS N
as POS N
measured POS N
by POS N
changes POS N
in POS N
body POS N
weight, POS N
body POS N
mass POS N
index, POS N
waist POS N
circumference, POS N
or POS N
subcutaneous POS N
skinfolds. POS N

Androgen POS N
deprivation POS N
therapy POS N
is POS N
a POS N
common POS N
treatment POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
that POS N
may POS N
cause POS N
fatigue, POS N
functional POS N
decline, POS N
increased POS N
body POS N
fatness, POS N
and POS N
loss POS N
of POS N
lean POS N
body POS N
tissue. POS N

Resistance POS N
exercise POS N
reduces POS N
fatigue POS N
and POS N
improves POS N
quality POS N
of POS N
life POS N
and POS N
muscular POS N
fitness POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
receiving POS N
androgen POS N
deprivation POS N
therapy. POS N

Androgen POS N
deprivation POS N
therapy POS N
is POS N
a POS N
common POS N
treatment POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
that POS N
may POS N
cause POS N
fatigue, POS N
functional POS N
decline, POS N
increased POS N
body POS N
fatness, POS N
and POS N
loss POS N
of POS N
lean POS N
body POS N
tissue. POS N

This POS N
form POS N
of POS N
exercise POS N
can POS N
be POS N
an POS N
important POS N
component POS N
of POS N
supportive POS N
care POS N
for POS N
these POS N
patients. POS N

These POS N
physical POS N
changes POS N
can POS N
negatively POS N
affect POS N
health-related POS N
quality POS N
of POS N
life. POS N

Androgen POS N
deprivation POS N
therapy POS N
is POS N
a POS N
common POS N
treatment POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
that POS N
may POS N
cause POS N
fatigue, POS N
functional POS N
decline, POS N
increased POS N
body POS N
fatness, POS N
and POS N
loss POS N
of POS N
lean POS N
body POS N
tissue. POS N

These POS N
physical POS N
changes POS N
can POS N
negatively POS N
affect POS N
health-related POS N
quality POS N
of POS N
life. POS N

Resistance POS N
exercise POS N
may POS N
help POS N
to POS N
counter POS N
some POS N
of POS N
these POS N
side POS N
effects POS N
by POS N
reducing POS N
fatigue, POS N
elevating POS N
mood, POS N
building POS N
muscle POS N
mass, POS N
and POS N
reducing POS N
body POS N
fat. POS N

These POS N
physical POS N
changes POS N
can POS N
negatively POS N
affect POS N
health-related POS N
quality POS N
of POS N
life. POS N

Men POS N
assigned POS N
to POS N
resistance POS N
exercise POS N
had POS N
less POS N
interference POS N
from POS N
fatigue POS N
on POS N
activities POS N
of POS N
daily POS N
living POS N
(P POS N
=.002) POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
(P POS N
=.001) POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

These POS N
physical POS N
changes POS N
can POS N
negatively POS N
affect POS N
health-related POS N
quality POS N
of POS N
life. POS N

Men POS N
in POS N
the POS N
intervention POS N
group POS N
demonstrated POS N
higher POS N
levels POS N
of POS N
upper POS N
body POS N
(P POS N
=.009) POS N
and POS N
lower POS N
body POS N
(P POS N
<.001) POS N
muscular POS N
fitness POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

These POS N
physical POS N
changes POS N
can POS N
negatively POS N
affect POS N
health-related POS N
quality POS N
of POS N
life. POS N

The POS N
12-week POS N
resistance POS N
exercise POS N
intervention POS N
did POS N
not POS N
improve POS N
body POS N
composition POS N
as POS N
measured POS N
by POS N
changes POS N
in POS N
body POS N
weight, POS N
body POS N
mass POS N
index, POS N
waist POS N
circumference, POS N
or POS N
subcutaneous POS N
skinfolds. POS N

These POS N
physical POS N
changes POS N
can POS N
negatively POS N
affect POS N
health-related POS N
quality POS N
of POS N
life. POS N

Resistance POS N
exercise POS N
reduces POS N
fatigue POS N
and POS N
improves POS N
quality POS N
of POS N
life POS N
and POS N
muscular POS N
fitness POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
receiving POS N
androgen POS N
deprivation POS N
therapy. POS N

These POS N
physical POS N
changes POS N
can POS N
negatively POS N
affect POS N
health-related POS N
quality POS N
of POS N
life. POS N

This POS N
form POS N
of POS N
exercise POS N
can POS N
be POS N
an POS N
important POS N
component POS N
of POS N
supportive POS N
care POS N
for POS N
these POS N
patients. POS N

Resistance POS N
exercise POS N
may POS N
help POS N
to POS N
counter POS N
some POS N
of POS N
these POS N
side POS N
effects POS N
by POS N
reducing POS N
fatigue, POS N
elevating POS N
mood, POS N
building POS N
muscle POS N
mass, POS N
and POS N
reducing POS N
body POS N
fat. POS N

Androgen POS N
deprivation POS N
therapy POS N
is POS N
a POS N
common POS N
treatment POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
that POS N
may POS N
cause POS N
fatigue, POS N
functional POS N
decline, POS N
increased POS N
body POS N
fatness, POS N
and POS N
loss POS N
of POS N
lean POS N
body POS N
tissue. POS N

Resistance POS N
exercise POS N
may POS N
help POS N
to POS N
counter POS N
some POS N
of POS N
these POS N
side POS N
effects POS N
by POS N
reducing POS N
fatigue, POS N
elevating POS N
mood, POS N
building POS N
muscle POS N
mass, POS N
and POS N
reducing POS N
body POS N
fat. POS N

These POS N
physical POS N
changes POS N
can POS N
negatively POS N
affect POS N
health-related POS N
quality POS N
of POS N
life. POS N

Resistance POS N
exercise POS N
may POS N
help POS N
to POS N
counter POS N
some POS N
of POS N
these POS N
side POS N
effects POS N
by POS N
reducing POS N
fatigue, POS N
elevating POS N
mood, POS N
building POS N
muscle POS N
mass, POS N
and POS N
reducing POS N
body POS N
fat. POS N

Men POS N
assigned POS N
to POS N
resistance POS N
exercise POS N
had POS N
less POS N
interference POS N
from POS N
fatigue POS N
on POS N
activities POS N
of POS N
daily POS N
living POS N
(P POS N
=.002) POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
(P POS N
=.001) POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

Resistance POS N
exercise POS N
may POS N
help POS N
to POS N
counter POS N
some POS N
of POS N
these POS N
side POS N
effects POS N
by POS N
reducing POS N
fatigue, POS N
elevating POS N
mood, POS N
building POS N
muscle POS N
mass, POS N
and POS N
reducing POS N
body POS N
fat. POS N

Men POS N
in POS N
the POS N
intervention POS N
group POS N
demonstrated POS N
higher POS N
levels POS N
of POS N
upper POS N
body POS N
(P POS N
=.009) POS N
and POS N
lower POS N
body POS N
(P POS N
<.001) POS N
muscular POS N
fitness POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

Resistance POS N
exercise POS N
may POS N
help POS N
to POS N
counter POS N
some POS N
of POS N
these POS N
side POS N
effects POS N
by POS N
reducing POS N
fatigue, POS N
elevating POS N
mood, POS N
building POS N
muscle POS N
mass, POS N
and POS N
reducing POS N
body POS N
fat. POS N

The POS N
12-week POS N
resistance POS N
exercise POS N
intervention POS N
did POS N
not POS N
improve POS N
body POS N
composition POS N
as POS N
measured POS N
by POS N
changes POS N
in POS N
body POS N
weight, POS N
body POS N
mass POS N
index, POS N
waist POS N
circumference, POS N
or POS N
subcutaneous POS N
skinfolds. POS N

Resistance POS N
exercise POS N
may POS N
help POS N
to POS N
counter POS N
some POS N
of POS N
these POS N
side POS N
effects POS N
by POS N
reducing POS N
fatigue, POS N
elevating POS N
mood, POS N
building POS N
muscle POS N
mass, POS N
and POS N
reducing POS N
body POS N
fat. POS N

Resistance POS N
exercise POS N
reduces POS N
fatigue POS N
and POS N
improves POS N
quality POS N
of POS N
life POS N
and POS N
muscular POS N
fitness POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
receiving POS N
androgen POS N
deprivation POS N
therapy. POS N

Resistance POS N
exercise POS N
may POS N
help POS N
to POS N
counter POS N
some POS N
of POS N
these POS N
side POS N
effects POS N
by POS N
reducing POS N
fatigue, POS N
elevating POS N
mood, POS N
building POS N
muscle POS N
mass, POS N
and POS N
reducing POS N
body POS N
fat. POS N

This POS N
form POS N
of POS N
exercise POS N
can POS N
be POS N
an POS N
important POS N
component POS N
of POS N
supportive POS N
care POS N
for POS N
these POS N
patients. POS N

Men POS N
assigned POS N
to POS N
resistance POS N
exercise POS N
had POS N
less POS N
interference POS N
from POS N
fatigue POS N
on POS N
activities POS N
of POS N
daily POS N
living POS N
(P POS N
=.002) POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
(P POS N
=.001) POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

Androgen POS N
deprivation POS N
therapy POS N
is POS N
a POS N
common POS N
treatment POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
that POS N
may POS N
cause POS N
fatigue, POS N
functional POS N
decline, POS N
increased POS N
body POS N
fatness, POS N
and POS N
loss POS N
of POS N
lean POS N
body POS N
tissue. POS N

Men POS N
assigned POS N
to POS N
resistance POS N
exercise POS N
had POS N
less POS N
interference POS N
from POS N
fatigue POS N
on POS N
activities POS N
of POS N
daily POS N
living POS N
(P POS N
=.002) POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
(P POS N
=.001) POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

These POS N
physical POS N
changes POS N
can POS N
negatively POS N
affect POS N
health-related POS N
quality POS N
of POS N
life. POS N

Men POS N
assigned POS N
to POS N
resistance POS N
exercise POS N
had POS N
less POS N
interference POS N
from POS N
fatigue POS N
on POS N
activities POS N
of POS N
daily POS N
living POS N
(P POS N
=.002) POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
(P POS N
=.001) POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

Resistance POS N
exercise POS N
may POS N
help POS N
to POS N
counter POS N
some POS N
of POS N
these POS N
side POS N
effects POS N
by POS N
reducing POS N
fatigue, POS N
elevating POS N
mood, POS N
building POS N
muscle POS N
mass, POS N
and POS N
reducing POS N
body POS N
fat. POS N

Men POS N
assigned POS N
to POS N
resistance POS N
exercise POS N
had POS N
less POS N
interference POS N
from POS N
fatigue POS N
on POS N
activities POS N
of POS N
daily POS N
living POS N
(P POS N
=.002) POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
(P POS N
=.001) POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

Men POS N
in POS N
the POS N
intervention POS N
group POS N
demonstrated POS N
higher POS N
levels POS N
of POS N
upper POS N
body POS N
(P POS N
=.009) POS N
and POS N
lower POS N
body POS N
(P POS N
<.001) POS N
muscular POS N
fitness POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

Men POS N
assigned POS N
to POS N
resistance POS N
exercise POS N
had POS N
less POS N
interference POS N
from POS N
fatigue POS N
on POS N
activities POS N
of POS N
daily POS N
living POS N
(P POS N
=.002) POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
(P POS N
=.001) POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

The POS N
12-week POS N
resistance POS N
exercise POS N
intervention POS N
did POS N
not POS N
improve POS N
body POS N
composition POS N
as POS N
measured POS N
by POS N
changes POS N
in POS N
body POS N
weight, POS N
body POS N
mass POS N
index, POS N
waist POS N
circumference, POS N
or POS N
subcutaneous POS N
skinfolds. POS N

Men POS N
assigned POS N
to POS N
resistance POS N
exercise POS N
had POS N
less POS N
interference POS N
from POS N
fatigue POS N
on POS N
activities POS N
of POS N
daily POS N
living POS N
(P POS N
=.002) POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
(P POS N
=.001) POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

Resistance POS N
exercise POS N
reduces POS N
fatigue POS N
and POS N
improves POS N
quality POS N
of POS N
life POS N
and POS N
muscular POS N
fitness POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
receiving POS N
androgen POS N
deprivation POS N
therapy. POS N

Men POS N
assigned POS N
to POS N
resistance POS N
exercise POS N
had POS N
less POS N
interference POS N
from POS N
fatigue POS N
on POS N
activities POS N
of POS N
daily POS N
living POS N
(P POS N
=.002) POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
(P POS N
=.001) POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

This POS N
form POS N
of POS N
exercise POS N
can POS N
be POS N
an POS N
important POS N
component POS N
of POS N
supportive POS N
care POS N
for POS N
these POS N
patients. POS N

Men POS N
in POS N
the POS N
intervention POS N
group POS N
demonstrated POS N
higher POS N
levels POS N
of POS N
upper POS N
body POS N
(P POS N
=.009) POS N
and POS N
lower POS N
body POS N
(P POS N
<.001) POS N
muscular POS N
fitness POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

Androgen POS N
deprivation POS N
therapy POS N
is POS N
a POS N
common POS N
treatment POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
that POS N
may POS N
cause POS N
fatigue, POS N
functional POS N
decline, POS N
increased POS N
body POS N
fatness, POS N
and POS N
loss POS N
of POS N
lean POS N
body POS N
tissue. POS N

Men POS N
in POS N
the POS N
intervention POS N
group POS N
demonstrated POS N
higher POS N
levels POS N
of POS N
upper POS N
body POS N
(P POS N
=.009) POS N
and POS N
lower POS N
body POS N
(P POS N
<.001) POS N
muscular POS N
fitness POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

These POS N
physical POS N
changes POS N
can POS N
negatively POS N
affect POS N
health-related POS N
quality POS N
of POS N
life. POS N

Men POS N
in POS N
the POS N
intervention POS N
group POS N
demonstrated POS N
higher POS N
levels POS N
of POS N
upper POS N
body POS N
(P POS N
=.009) POS N
and POS N
lower POS N
body POS N
(P POS N
<.001) POS N
muscular POS N
fitness POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

Resistance POS N
exercise POS N
may POS N
help POS N
to POS N
counter POS N
some POS N
of POS N
these POS N
side POS N
effects POS N
by POS N
reducing POS N
fatigue, POS N
elevating POS N
mood, POS N
building POS N
muscle POS N
mass, POS N
and POS N
reducing POS N
body POS N
fat. POS N

Men POS N
in POS N
the POS N
intervention POS N
group POS N
demonstrated POS N
higher POS N
levels POS N
of POS N
upper POS N
body POS N
(P POS N
=.009) POS N
and POS N
lower POS N
body POS N
(P POS N
<.001) POS N
muscular POS N
fitness POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

Men POS N
assigned POS N
to POS N
resistance POS N
exercise POS N
had POS N
less POS N
interference POS N
from POS N
fatigue POS N
on POS N
activities POS N
of POS N
daily POS N
living POS N
(P POS N
=.002) POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
(P POS N
=.001) POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

Men POS N
in POS N
the POS N
intervention POS N
group POS N
demonstrated POS N
higher POS N
levels POS N
of POS N
upper POS N
body POS N
(P POS N
=.009) POS N
and POS N
lower POS N
body POS N
(P POS N
<.001) POS N
muscular POS N
fitness POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

The POS N
12-week POS N
resistance POS N
exercise POS N
intervention POS N
did POS N
not POS N
improve POS N
body POS N
composition POS N
as POS N
measured POS N
by POS N
changes POS N
in POS N
body POS N
weight, POS N
body POS N
mass POS N
index, POS N
waist POS N
circumference, POS N
or POS N
subcutaneous POS N
skinfolds. POS N

Men POS N
in POS N
the POS N
intervention POS N
group POS N
demonstrated POS N
higher POS N
levels POS N
of POS N
upper POS N
body POS N
(P POS N
=.009) POS N
and POS N
lower POS N
body POS N
(P POS N
<.001) POS N
muscular POS N
fitness POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

Resistance POS N
exercise POS N
reduces POS N
fatigue POS N
and POS N
improves POS N
quality POS N
of POS N
life POS N
and POS N
muscular POS N
fitness POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
receiving POS N
androgen POS N
deprivation POS N
therapy. POS N

Men POS N
in POS N
the POS N
intervention POS N
group POS N
demonstrated POS N
higher POS N
levels POS N
of POS N
upper POS N
body POS N
(P POS N
=.009) POS N
and POS N
lower POS N
body POS N
(P POS N
<.001) POS N
muscular POS N
fitness POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

This POS N
form POS N
of POS N
exercise POS N
can POS N
be POS N
an POS N
important POS N
component POS N
of POS N
supportive POS N
care POS N
for POS N
these POS N
patients. POS N

The POS N
12-week POS N
resistance POS N
exercise POS N
intervention POS N
did POS N
not POS N
improve POS N
body POS N
composition POS N
as POS N
measured POS N
by POS N
changes POS N
in POS N
body POS N
weight, POS N
body POS N
mass POS N
index, POS N
waist POS N
circumference, POS N
or POS N
subcutaneous POS N
skinfolds. POS N

Androgen POS N
deprivation POS N
therapy POS N
is POS N
a POS N
common POS N
treatment POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
that POS N
may POS N
cause POS N
fatigue, POS N
functional POS N
decline, POS N
increased POS N
body POS N
fatness, POS N
and POS N
loss POS N
of POS N
lean POS N
body POS N
tissue. POS N

The POS N
12-week POS N
resistance POS N
exercise POS N
intervention POS N
did POS N
not POS N
improve POS N
body POS N
composition POS N
as POS N
measured POS N
by POS N
changes POS N
in POS N
body POS N
weight, POS N
body POS N
mass POS N
index, POS N
waist POS N
circumference, POS N
or POS N
subcutaneous POS N
skinfolds. POS N

These POS N
physical POS N
changes POS N
can POS N
negatively POS N
affect POS N
health-related POS N
quality POS N
of POS N
life. POS N

The POS N
12-week POS N
resistance POS N
exercise POS N
intervention POS N
did POS N
not POS N
improve POS N
body POS N
composition POS N
as POS N
measured POS N
by POS N
changes POS N
in POS N
body POS N
weight, POS N
body POS N
mass POS N
index, POS N
waist POS N
circumference, POS N
or POS N
subcutaneous POS N
skinfolds. POS N

Resistance POS N
exercise POS N
may POS N
help POS N
to POS N
counter POS N
some POS N
of POS N
these POS N
side POS N
effects POS N
by POS N
reducing POS N
fatigue, POS N
elevating POS N
mood, POS N
building POS N
muscle POS N
mass, POS N
and POS N
reducing POS N
body POS N
fat. POS N

The POS N
12-week POS N
resistance POS N
exercise POS N
intervention POS N
did POS N
not POS N
improve POS N
body POS N
composition POS N
as POS N
measured POS N
by POS N
changes POS N
in POS N
body POS N
weight, POS N
body POS N
mass POS N
index, POS N
waist POS N
circumference, POS N
or POS N
subcutaneous POS N
skinfolds. POS N

Men POS N
assigned POS N
to POS N
resistance POS N
exercise POS N
had POS N
less POS N
interference POS N
from POS N
fatigue POS N
on POS N
activities POS N
of POS N
daily POS N
living POS N
(P POS N
=.002) POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
(P POS N
=.001) POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

The POS N
12-week POS N
resistance POS N
exercise POS N
intervention POS N
did POS N
not POS N
improve POS N
body POS N
composition POS N
as POS N
measured POS N
by POS N
changes POS N
in POS N
body POS N
weight, POS N
body POS N
mass POS N
index, POS N
waist POS N
circumference, POS N
or POS N
subcutaneous POS N
skinfolds. POS N

Men POS N
in POS N
the POS N
intervention POS N
group POS N
demonstrated POS N
higher POS N
levels POS N
of POS N
upper POS N
body POS N
(P POS N
=.009) POS N
and POS N
lower POS N
body POS N
(P POS N
<.001) POS N
muscular POS N
fitness POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

The POS N
12-week POS N
resistance POS N
exercise POS N
intervention POS N
did POS N
not POS N
improve POS N
body POS N
composition POS N
as POS N
measured POS N
by POS N
changes POS N
in POS N
body POS N
weight, POS N
body POS N
mass POS N
index, POS N
waist POS N
circumference, POS N
or POS N
subcutaneous POS N
skinfolds. POS N

Resistance POS N
exercise POS N
reduces POS N
fatigue POS N
and POS N
improves POS N
quality POS N
of POS N
life POS N
and POS N
muscular POS N
fitness POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
receiving POS N
androgen POS N
deprivation POS N
therapy. POS N

The POS N
12-week POS N
resistance POS N
exercise POS N
intervention POS N
did POS N
not POS N
improve POS N
body POS N
composition POS N
as POS N
measured POS N
by POS N
changes POS N
in POS N
body POS N
weight, POS N
body POS N
mass POS N
index, POS N
waist POS N
circumference, POS N
or POS N
subcutaneous POS N
skinfolds. POS N

This POS N
form POS N
of POS N
exercise POS N
can POS N
be POS N
an POS N
important POS N
component POS N
of POS N
supportive POS N
care POS N
for POS N
these POS N
patients. POS N

Resistance POS N
exercise POS N
reduces POS N
fatigue POS N
and POS N
improves POS N
quality POS N
of POS N
life POS N
and POS N
muscular POS N
fitness POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
receiving POS N
androgen POS N
deprivation POS N
therapy. POS N

Androgen POS N
deprivation POS N
therapy POS N
is POS N
a POS N
common POS N
treatment POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
that POS N
may POS N
cause POS N
fatigue, POS N
functional POS N
decline, POS N
increased POS N
body POS N
fatness, POS N
and POS N
loss POS N
of POS N
lean POS N
body POS N
tissue. POS N

Resistance POS N
exercise POS N
reduces POS N
fatigue POS N
and POS N
improves POS N
quality POS N
of POS N
life POS N
and POS N
muscular POS N
fitness POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
receiving POS N
androgen POS N
deprivation POS N
therapy. POS N

These POS N
physical POS N
changes POS N
can POS N
negatively POS N
affect POS N
health-related POS N
quality POS N
of POS N
life. POS N

Resistance POS N
exercise POS N
reduces POS N
fatigue POS N
and POS N
improves POS N
quality POS N
of POS N
life POS N
and POS N
muscular POS N
fitness POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
receiving POS N
androgen POS N
deprivation POS N
therapy. POS N

Resistance POS N
exercise POS N
may POS N
help POS N
to POS N
counter POS N
some POS N
of POS N
these POS N
side POS N
effects POS N
by POS N
reducing POS N
fatigue, POS N
elevating POS N
mood, POS N
building POS N
muscle POS N
mass, POS N
and POS N
reducing POS N
body POS N
fat. POS N

Resistance POS N
exercise POS N
reduces POS N
fatigue POS N
and POS N
improves POS N
quality POS N
of POS N
life POS N
and POS N
muscular POS N
fitness POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
receiving POS N
androgen POS N
deprivation POS N
therapy. POS N

Men POS N
assigned POS N
to POS N
resistance POS N
exercise POS N
had POS N
less POS N
interference POS N
from POS N
fatigue POS N
on POS N
activities POS N
of POS N
daily POS N
living POS N
(P POS N
=.002) POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
(P POS N
=.001) POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

Resistance POS N
exercise POS N
reduces POS N
fatigue POS N
and POS N
improves POS N
quality POS N
of POS N
life POS N
and POS N
muscular POS N
fitness POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
receiving POS N
androgen POS N
deprivation POS N
therapy. POS N

Men POS N
in POS N
the POS N
intervention POS N
group POS N
demonstrated POS N
higher POS N
levels POS N
of POS N
upper POS N
body POS N
(P POS N
=.009) POS N
and POS N
lower POS N
body POS N
(P POS N
<.001) POS N
muscular POS N
fitness POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

Resistance POS N
exercise POS N
reduces POS N
fatigue POS N
and POS N
improves POS N
quality POS N
of POS N
life POS N
and POS N
muscular POS N
fitness POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
receiving POS N
androgen POS N
deprivation POS N
therapy. POS N

The POS N
12-week POS N
resistance POS N
exercise POS N
intervention POS N
did POS N
not POS N
improve POS N
body POS N
composition POS N
as POS N
measured POS N
by POS N
changes POS N
in POS N
body POS N
weight, POS N
body POS N
mass POS N
index, POS N
waist POS N
circumference, POS N
or POS N
subcutaneous POS N
skinfolds. POS N

Resistance POS N
exercise POS N
reduces POS N
fatigue POS N
and POS N
improves POS N
quality POS N
of POS N
life POS N
and POS N
muscular POS N
fitness POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
receiving POS N
androgen POS N
deprivation POS N
therapy. POS N

This POS N
form POS N
of POS N
exercise POS N
can POS N
be POS N
an POS N
important POS N
component POS N
of POS N
supportive POS N
care POS N
for POS N
these POS N
patients. POS N

This POS N
form POS N
of POS N
exercise POS N
can POS N
be POS N
an POS N
important POS N
component POS N
of POS N
supportive POS N
care POS N
for POS N
these POS N
patients. POS N

Androgen POS N
deprivation POS N
therapy POS N
is POS N
a POS N
common POS N
treatment POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
that POS N
may POS N
cause POS N
fatigue, POS N
functional POS N
decline, POS N
increased POS N
body POS N
fatness, POS N
and POS N
loss POS N
of POS N
lean POS N
body POS N
tissue. POS N

This POS N
form POS N
of POS N
exercise POS N
can POS N
be POS N
an POS N
important POS N
component POS N
of POS N
supportive POS N
care POS N
for POS N
these POS N
patients. POS N

These POS N
physical POS N
changes POS N
can POS N
negatively POS N
affect POS N
health-related POS N
quality POS N
of POS N
life. POS N

This POS N
form POS N
of POS N
exercise POS N
can POS N
be POS N
an POS N
important POS N
component POS N
of POS N
supportive POS N
care POS N
for POS N
these POS N
patients. POS N

Resistance POS N
exercise POS N
may POS N
help POS N
to POS N
counter POS N
some POS N
of POS N
these POS N
side POS N
effects POS N
by POS N
reducing POS N
fatigue, POS N
elevating POS N
mood, POS N
building POS N
muscle POS N
mass, POS N
and POS N
reducing POS N
body POS N
fat. POS N

This POS N
form POS N
of POS N
exercise POS N
can POS N
be POS N
an POS N
important POS N
component POS N
of POS N
supportive POS N
care POS N
for POS N
these POS N
patients. POS N

Men POS N
assigned POS N
to POS N
resistance POS N
exercise POS N
had POS N
less POS N
interference POS N
from POS N
fatigue POS N
on POS N
activities POS N
of POS N
daily POS N
living POS N
(P POS N
=.002) POS N
and POS N
higher POS N
quality POS N
of POS N
life POS N
(P POS N
=.001) POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

This POS N
form POS N
of POS N
exercise POS N
can POS N
be POS N
an POS N
important POS N
component POS N
of POS N
supportive POS N
care POS N
for POS N
these POS N
patients. POS N

Men POS N
in POS N
the POS N
intervention POS N
group POS N
demonstrated POS N
higher POS N
levels POS N
of POS N
upper POS N
body POS N
(P POS N
=.009) POS N
and POS N
lower POS N
body POS N
(P POS N
<.001) POS N
muscular POS N
fitness POS N
than POS N
men POS N
in POS N
the POS N
control POS N
group. POS N

This POS N
form POS N
of POS N
exercise POS N
can POS N
be POS N
an POS N
important POS N
component POS N
of POS N
supportive POS N
care POS N
for POS N
these POS N
patients. POS N

The POS N
12-week POS N
resistance POS N
exercise POS N
intervention POS N
did POS N
not POS N
improve POS N
body POS N
composition POS N
as POS N
measured POS N
by POS N
changes POS N
in POS N
body POS N
weight, POS N
body POS N
mass POS N
index, POS N
waist POS N
circumference, POS N
or POS N
subcutaneous POS N
skinfolds. POS N

This POS N
form POS N
of POS N
exercise POS N
can POS N
be POS N
an POS N
important POS N
component POS N
of POS N
supportive POS N
care POS N
for POS N
these POS N
patients. POS N

Resistance POS N
exercise POS N
reduces POS N
fatigue POS N
and POS N
improves POS N
quality POS N
of POS N
life POS N
and POS N
muscular POS N
fitness POS N
in POS N
men POS N
with POS N
prostate POS N
cancer POS N
receiving POS N
androgen POS N
deprivation POS N
therapy. POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

The POS N
current POS N
results POS N
and POS N
large POS N
number POS N
of POS N
drop-outs POS N
in POS N
the POS N
brimonidine POS N
0.2% POS N
arm POS N
suggest POS N
that POS N
more POS N
research POS N
is POS N
necessary POS N
before POS N
altering POS N
clinical POS N
practice POS N
paradigms. POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

This POS N
suggests POS N
that POS N
the POS N
beneficial POS N
effect POS N
of POS N
randomization POS N
to POS N
the POS N
brimonidine POS N
arm POS N
was POS N
independent POS N
of POS N
possible POS N
differences POS N
in POS N
ocular POS N
perfusion POS N
pressures POS N
between POS N
the POS N
2 POS N
treatment POS N
arms. POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

Eyes POS N
randomized POS N
to POS N
timolol POS N
progressed POS N
faster POS N
than POS N
those POS N
randomized POS N
to POS N
brimonidine POS N
(mean POS N
rates POS N
of POS N
progression, POS N
-0.38 POS N
 POS N
0.9 POS N
vs POS N
0.02 POS N
 POS N
0.7 POS N
dB/y, POS N
P POS N
< POS N
.01). POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

randomization POS N
to POS N
brimonidine POS N
revealed POS N
a POS N
protective POS N
effect POS N
(HR POS N
= POS N
0.26, POS N
95% POS N
CI POS N
= POS N
0.12 POS N
to POS N
0.55, POS N
P POS N
< POS N
.001). POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

randomization POS N
to POS N
brimonidine POS N
0.2% POS N
was POS N
protective POS N
compared POS N
to POS N
timolol POS N
0.5%, POS N

older POS N
age POS N
(hazard POS N
ratio POS N
[HR] POS N
= POS N
1.41/decade POS N
older, POS N
95% POS N
confidence POS N
interval POS N
[CI] POS N
= POS N
1.05 POS N
to POS N
1.90, POS N
P POS N
= POS N
.022), POS N
use POS N
of POS N
systemic POS N
antihypertensives POS N
(HR POS N
= POS N
2.53, POS N
95% POS N
CI POS N
= POS N
1.32 POS N
to POS N
4.87, POS N
P POS N
= POS N
.005), POS N
and POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
(HR POS N
= POS N
1.21/mm POS N
Hg POS N
lower, POS N
95% POS N
CI POS N
= POS N
1.12 POS N
to POS N
1.31, POS N
P POS N
< POS N
.001) POS N
were POS N
associated POS N
with POS N
progression POS N

ower POS N
mean POS N
ocular POS N
perfusion POS N
pressure POS N
increased POS N
the POS N
risk POS N
for POS N
reaching POS N
a POS N
progression POS N
outcome POS N
in POS N
the POS N
Low-pressure POS N
Glaucoma POS N
Treatment POS N
Study. POS N

Time POS N
with POS N
nocturnal POS N
hypoglycemia, POS N
glucose POS N
levels POS N
<70 mg/dL POS N
was POS N
reduced POS N
by POS N
48% POS N
(10.2 POS N
vs. POS N
19.6 min POS N
each POS N
night, POS N
P < 0.001) POS N
and POS N
glucose POS N
levels POS N
<54 mg/dL POS N
by POS N
65%. POS N
(3.1 POS N
vs. POS N
8.9 min, POS N
P < 0.001). POS N

For POS N
the POS N
corresponding POS N
glucose POS N
cutoffs, POS N
daytime POS N
hypoglycemia POS N
was POS N
reduced POS N
by POS N
40% POS N
(29 POS N
vs. POS N
49 min, POS N
P < 0.001) POS N
and POS N
54% POS N
(8 POS N
vs. POS N
18 min., POS N
P < 0.001), POS N
respectively. POS N

Time POS N
with POS N
nocturnal POS N
hypoglycemia, POS N
glucose POS N
levels POS N
<70 mg/dL POS N
was POS N
reduced POS N
by POS N
48% POS N
(10.2 POS N
vs. POS N
19.6 min POS N
each POS N
night, POS N
P < 0.001) POS N
and POS N
glucose POS N
levels POS N
<54 mg/dL POS N
by POS N
65%. POS N
(3.1 POS N
vs. POS N
8.9 min, POS N
P < 0.001). POS N

Compared POS N
with POS N
SMBG, POS N
CGM POS N
use POS N
improved POS N
hypoglycemia-related POS N
confidence POS N
in POS N
social POS N
situations POS N
(P = 0.016) POS N
and POS N
confidence POS N
in POS N
more POS N
broadly POS N
avoiding POS N
serious POS N
problems POS N
due POS N
to POS N
hypoglycemia POS N
(P = 0.0020). POS N

Time POS N
with POS N
nocturnal POS N
hypoglycemia, POS N
glucose POS N
levels POS N
<70 mg/dL POS N
was POS N
reduced POS N
by POS N
48% POS N
(10.2 POS N
vs. POS N
19.6 min POS N
each POS N
night, POS N
P < 0.001) POS N
and POS N
glucose POS N
levels POS N
<54 mg/dL POS N
by POS N
65%. POS N
(3.1 POS N
vs. POS N
8.9 min, POS N
P < 0.001). POS N

Persons POS N
also POS N
reported POS N
greater POS N
confidence POS N
in POS N
detecting POS N
and POS N
responding POS N
to POS N
decreasing POS N
blood POS N
glucose POS N
levels POS N
(thereby POS N
avoiding POS N
hypoglycemia) POS N
during POS N
CGM POS N
use POS N
(P = 0.0033) POS N

Time POS N
with POS N
nocturnal POS N
hypoglycemia, POS N
glucose POS N
levels POS N
<70 mg/dL POS N
was POS N
reduced POS N
by POS N
48% POS N
(10.2 POS N
vs. POS N
19.6 min POS N
each POS N
night, POS N
P < 0.001) POS N
and POS N
glucose POS N
levels POS N
<54 mg/dL POS N
by POS N
65%. POS N
(3.1 POS N
vs. POS N
8.9 min, POS N
P < 0.001). POS N

indicated POS N
greater POS N
conviction POS N
that POS N
they POS N
could POS N
more POS N
freely POS N
live POS N
their POS N
lives POS N
despite POS N
the POS N
risk POS N
of POS N
hypoglycemia POS N
(P = 0.022). POS N

Time POS N
with POS N
nocturnal POS N
hypoglycemia, POS N
glucose POS N
levels POS N
<70 mg/dL POS N
was POS N
reduced POS N
by POS N
48% POS N
(10.2 POS N
vs. POS N
19.6 min POS N
each POS N
night, POS N
P < 0.001) POS N
and POS N
glucose POS N
levels POS N
<54 mg/dL POS N
by POS N
65%. POS N
(3.1 POS N
vs. POS N
8.9 min, POS N
P < 0.001). POS N

CGM POS N
reduced POS N
time POS N
in POS N
both POS N
nocturnal POS N
and POS N
daytime POS N
hypoglycemia POS N
in POS N
persons POS N
with POS N
type POS N
1 POS N
diabetes POS N
treated POS N
with POS N
MDI POS N
and POS N
improved POS N
hypoglycemia-related POS N
confidence, POS N
especially POS N
in POS N
social POS N
situations, POS N
thus POS N
contributing POS N
to POS N
greater POS N
well-being POS N
and POS N
quality POS N
of POS N
life. POS N

For POS N
the POS N
corresponding POS N
glucose POS N
cutoffs, POS N
daytime POS N
hypoglycemia POS N
was POS N
reduced POS N
by POS N
40% POS N
(29 POS N
vs. POS N
49 min, POS N
P < 0.001) POS N
and POS N
54% POS N
(8 POS N
vs. POS N
18 min., POS N
P < 0.001), POS N
respectively. POS N

Time POS N
with POS N
nocturnal POS N
hypoglycemia, POS N
glucose POS N
levels POS N
<70 mg/dL POS N
was POS N
reduced POS N
by POS N
48% POS N
(10.2 POS N
vs. POS N
19.6 min POS N
each POS N
night, POS N
P < 0.001) POS N
and POS N
glucose POS N
levels POS N
<54 mg/dL POS N
by POS N
65%. POS N
(3.1 POS N
vs. POS N
8.9 min, POS N
P < 0.001). POS N

For POS N
the POS N
corresponding POS N
glucose POS N
cutoffs, POS N
daytime POS N
hypoglycemia POS N
was POS N
reduced POS N
by POS N
40% POS N
(29 POS N
vs. POS N
49 min, POS N
P < 0.001) POS N
and POS N
54% POS N
(8 POS N
vs. POS N
18 min., POS N
P < 0.001), POS N
respectively. POS N

Compared POS N
with POS N
SMBG, POS N
CGM POS N
use POS N
improved POS N
hypoglycemia-related POS N
confidence POS N
in POS N
social POS N
situations POS N
(P = 0.016) POS N
and POS N
confidence POS N
in POS N
more POS N
broadly POS N
avoiding POS N
serious POS N
problems POS N
due POS N
to POS N
hypoglycemia POS N
(P = 0.0020). POS N

For POS N
the POS N
corresponding POS N
glucose POS N
cutoffs, POS N
daytime POS N
hypoglycemia POS N
was POS N
reduced POS N
by POS N
40% POS N
(29 POS N
vs. POS N
49 min, POS N
P < 0.001) POS N
and POS N
54% POS N
(8 POS N
vs. POS N
18 min., POS N
P < 0.001), POS N
respectively. POS N

Persons POS N
also POS N
reported POS N
greater POS N
confidence POS N
in POS N
detecting POS N
and POS N
responding POS N
to POS N
decreasing POS N
blood POS N
glucose POS N
levels POS N
(thereby POS N
avoiding POS N
hypoglycemia) POS N
during POS N
CGM POS N
use POS N
(P = 0.0033) POS N

For POS N
the POS N
corresponding POS N
glucose POS N
cutoffs, POS N
daytime POS N
hypoglycemia POS N
was POS N
reduced POS N
by POS N
40% POS N
(29 POS N
vs. POS N
49 min, POS N
P < 0.001) POS N
and POS N
54% POS N
(8 POS N
vs. POS N
18 min., POS N
P < 0.001), POS N
respectively. POS N

indicated POS N
greater POS N
conviction POS N
that POS N
they POS N
could POS N
more POS N
freely POS N
live POS N
their POS N
lives POS N
despite POS N
the POS N
risk POS N
of POS N
hypoglycemia POS N
(P = 0.022). POS N

For POS N
the POS N
corresponding POS N
glucose POS N
cutoffs, POS N
daytime POS N
hypoglycemia POS N
was POS N
reduced POS N
by POS N
40% POS N
(29 POS N
vs. POS N
49 min, POS N
P < 0.001) POS N
and POS N
54% POS N
(8 POS N
vs. POS N
18 min., POS N
P < 0.001), POS N
respectively. POS N

CGM POS N
reduced POS N
time POS N
in POS N
both POS N
nocturnal POS N
and POS N
daytime POS N
hypoglycemia POS N
in POS N
persons POS N
with POS N
type POS N
1 POS N
diabetes POS N
treated POS N
with POS N
MDI POS N
and POS N
improved POS N
hypoglycemia-related POS N
confidence, POS N
especially POS N
in POS N
social POS N
situations, POS N
thus POS N
contributing POS N
to POS N
greater POS N
well-being POS N
and POS N
quality POS N
of POS N
life. POS N

Compared POS N
with POS N
SMBG, POS N
CGM POS N
use POS N
improved POS N
hypoglycemia-related POS N
confidence POS N
in POS N
social POS N
situations POS N
(P = 0.016) POS N
and POS N
confidence POS N
in POS N
more POS N
broadly POS N
avoiding POS N
serious POS N
problems POS N
due POS N
to POS N
hypoglycemia POS N
(P = 0.0020). POS N

Time POS N
with POS N
nocturnal POS N
hypoglycemia, POS N
glucose POS N
levels POS N
<70 mg/dL POS N
was POS N
reduced POS N
by POS N
48% POS N
(10.2 POS N
vs. POS N
19.6 min POS N
each POS N
night, POS N
P < 0.001) POS N
and POS N
glucose POS N
levels POS N
<54 mg/dL POS N
by POS N
65%. POS N
(3.1 POS N
vs. POS N
8.9 min, POS N
P < 0.001). POS N

Compared POS N
with POS N
SMBG, POS N
CGM POS N
use POS N
improved POS N
hypoglycemia-related POS N
confidence POS N
in POS N
social POS N
situations POS N
(P = 0.016) POS N
and POS N
confidence POS N
in POS N
more POS N
broadly POS N
avoiding POS N
serious POS N
problems POS N
due POS N
to POS N
hypoglycemia POS N
(P = 0.0020). POS N

For POS N
the POS N
corresponding POS N
glucose POS N
cutoffs, POS N
daytime POS N
hypoglycemia POS N
was POS N
reduced POS N
by POS N
40% POS N
(29 POS N
vs. POS N
49 min, POS N
P < 0.001) POS N
and POS N
54% POS N
(8 POS N
vs. POS N
18 min., POS N
P < 0.001), POS N
respectively. POS N

Compared POS N
with POS N
SMBG, POS N
CGM POS N
use POS N
improved POS N
hypoglycemia-related POS N
confidence POS N
in POS N
social POS N
situations POS N
(P = 0.016) POS N
and POS N
confidence POS N
in POS N
more POS N
broadly POS N
avoiding POS N
serious POS N
problems POS N
due POS N
to POS N
hypoglycemia POS N
(P = 0.0020). POS N

Persons POS N
also POS N
reported POS N
greater POS N
confidence POS N
in POS N
detecting POS N
and POS N
responding POS N
to POS N
decreasing POS N
blood POS N
glucose POS N
levels POS N
(thereby POS N
avoiding POS N
hypoglycemia) POS N
during POS N
CGM POS N
use POS N
(P = 0.0033) POS N

Compared POS N
with POS N
SMBG, POS N
CGM POS N
use POS N
improved POS N
hypoglycemia-related POS N
confidence POS N
in POS N
social POS N
situations POS N
(P = 0.016) POS N
and POS N
confidence POS N
in POS N
more POS N
broadly POS N
avoiding POS N
serious POS N
problems POS N
due POS N
to POS N
hypoglycemia POS N
(P = 0.0020). POS N

indicated POS N
greater POS N
conviction POS N
that POS N
they POS N
could POS N
more POS N
freely POS N
live POS N
their POS N
lives POS N
despite POS N
the POS N
risk POS N
of POS N
hypoglycemia POS N
(P = 0.022). POS N

Compared POS N
with POS N
SMBG, POS N
CGM POS N
use POS N
improved POS N
hypoglycemia-related POS N
confidence POS N
in POS N
social POS N
situations POS N
(P = 0.016) POS N
and POS N
confidence POS N
in POS N
more POS N
broadly POS N
avoiding POS N
serious POS N
problems POS N
due POS N
to POS N
hypoglycemia POS N
(P = 0.0020). POS N

CGM POS N
reduced POS N
time POS N
in POS N
both POS N
nocturnal POS N
and POS N
daytime POS N
hypoglycemia POS N
in POS N
persons POS N
with POS N
type POS N
1 POS N
diabetes POS N
treated POS N
with POS N
MDI POS N
and POS N
improved POS N
hypoglycemia-related POS N
confidence, POS N
especially POS N
in POS N
social POS N
situations, POS N
thus POS N
contributing POS N
to POS N
greater POS N
well-being POS N
and POS N
quality POS N
of POS N
life. POS N

Persons POS N
also POS N
reported POS N
greater POS N
confidence POS N
in POS N
detecting POS N
and POS N
responding POS N
to POS N
decreasing POS N
blood POS N
glucose POS N
levels POS N
(thereby POS N
avoiding POS N
hypoglycemia) POS N
during POS N
CGM POS N
use POS N
(P = 0.0033) POS N

Time POS N
with POS N
nocturnal POS N
hypoglycemia, POS N
glucose POS N
levels POS N
<70 mg/dL POS N
was POS N
reduced POS N
by POS N
48% POS N
(10.2 POS N
vs. POS N
19.6 min POS N
each POS N
night, POS N
P < 0.001) POS N
and POS N
glucose POS N
levels POS N
<54 mg/dL POS N
by POS N
65%. POS N
(3.1 POS N
vs. POS N
8.9 min, POS N
P < 0.001). POS N

Persons POS N
also POS N
reported POS N
greater POS N
confidence POS N
in POS N
detecting POS N
and POS N
responding POS N
to POS N
decreasing POS N
blood POS N
glucose POS N
levels POS N
(thereby POS N
avoiding POS N
hypoglycemia) POS N
during POS N
CGM POS N
use POS N
(P = 0.0033) POS N

For POS N
the POS N
corresponding POS N
glucose POS N
cutoffs, POS N
daytime POS N
hypoglycemia POS N
was POS N
reduced POS N
by POS N
40% POS N
(29 POS N
vs. POS N
49 min, POS N
P < 0.001) POS N
and POS N
54% POS N
(8 POS N
vs. POS N
18 min., POS N
P < 0.001), POS N
respectively. POS N

Persons POS N
also POS N
reported POS N
greater POS N
confidence POS N
in POS N
detecting POS N
and POS N
responding POS N
to POS N
decreasing POS N
blood POS N
glucose POS N
levels POS N
(thereby POS N
avoiding POS N
hypoglycemia) POS N
during POS N
CGM POS N
use POS N
(P = 0.0033) POS N

Compared POS N
with POS N
SMBG, POS N
CGM POS N
use POS N
improved POS N
hypoglycemia-related POS N
confidence POS N
in POS N
social POS N
situations POS N
(P = 0.016) POS N
and POS N
confidence POS N
in POS N
more POS N
broadly POS N
avoiding POS N
serious POS N
problems POS N
due POS N
to POS N
hypoglycemia POS N
(P = 0.0020). POS N

Persons POS N
also POS N
reported POS N
greater POS N
confidence POS N
in POS N
detecting POS N
and POS N
responding POS N
to POS N
decreasing POS N
blood POS N
glucose POS N
levels POS N
(thereby POS N
avoiding POS N
hypoglycemia) POS N
during POS N
CGM POS N
use POS N
(P = 0.0033) POS N

indicated POS N
greater POS N
conviction POS N
that POS N
they POS N
could POS N
more POS N
freely POS N
live POS N
their POS N
lives POS N
despite POS N
the POS N
risk POS N
of POS N
hypoglycemia POS N
(P = 0.022). POS N

Persons POS N
also POS N
reported POS N
greater POS N
confidence POS N
in POS N
detecting POS N
and POS N
responding POS N
to POS N
decreasing POS N
blood POS N
glucose POS N
levels POS N
(thereby POS N
avoiding POS N
hypoglycemia) POS N
during POS N
CGM POS N
use POS N
(P = 0.0033) POS N

CGM POS N
reduced POS N
time POS N
in POS N
both POS N
nocturnal POS N
and POS N
daytime POS N
hypoglycemia POS N
in POS N
persons POS N
with POS N
type POS N
1 POS N
diabetes POS N
treated POS N
with POS N
MDI POS N
and POS N
improved POS N
hypoglycemia-related POS N
confidence, POS N
especially POS N
in POS N
social POS N
situations, POS N
thus POS N
contributing POS N
to POS N
greater POS N
well-being POS N
and POS N
quality POS N
of POS N
life. POS N

indicated POS N
greater POS N
conviction POS N
that POS N
they POS N
could POS N
more POS N
freely POS N
live POS N
their POS N
lives POS N
despite POS N
the POS N
risk POS N
of POS N
hypoglycemia POS N
(P = 0.022). POS N

Time POS N
with POS N
nocturnal POS N
hypoglycemia, POS N
glucose POS N
levels POS N
<70 mg/dL POS N
was POS N
reduced POS N
by POS N
48% POS N
(10.2 POS N
vs. POS N
19.6 min POS N
each POS N
night, POS N
P < 0.001) POS N
and POS N
glucose POS N
levels POS N
<54 mg/dL POS N
by POS N
65%. POS N
(3.1 POS N
vs. POS N
8.9 min, POS N
P < 0.001). POS N

indicated POS N
greater POS N
conviction POS N
that POS N
they POS N
could POS N
more POS N
freely POS N
live POS N
their POS N
lives POS N
despite POS N
the POS N
risk POS N
of POS N
hypoglycemia POS N
(P = 0.022). POS N

For POS N
the POS N
corresponding POS N
glucose POS N
cutoffs, POS N
daytime POS N
hypoglycemia POS N
was POS N
reduced POS N
by POS N
40% POS N
(29 POS N
vs. POS N
49 min, POS N
P < 0.001) POS N
and POS N
54% POS N
(8 POS N
vs. POS N
18 min., POS N
P < 0.001), POS N
respectively. POS N

indicated POS N
greater POS N
conviction POS N
that POS N
they POS N
could POS N
more POS N
freely POS N
live POS N
their POS N
lives POS N
despite POS N
the POS N
risk POS N
of POS N
hypoglycemia POS N
(P = 0.022). POS N

Compared POS N
with POS N
SMBG, POS N
CGM POS N
use POS N
improved POS N
hypoglycemia-related POS N
confidence POS N
in POS N
social POS N
situations POS N
(P = 0.016) POS N
and POS N
confidence POS N
in POS N
more POS N
broadly POS N
avoiding POS N
serious POS N
problems POS N
due POS N
to POS N
hypoglycemia POS N
(P = 0.0020). POS N

indicated POS N
greater POS N
conviction POS N
that POS N
they POS N
could POS N
more POS N
freely POS N
live POS N
their POS N
lives POS N
despite POS N
the POS N
risk POS N
of POS N
hypoglycemia POS N
(P = 0.022). POS N

Persons POS N
also POS N
reported POS N
greater POS N
confidence POS N
in POS N
detecting POS N
and POS N
responding POS N
to POS N
decreasing POS N
blood POS N
glucose POS N
levels POS N
(thereby POS N
avoiding POS N
hypoglycemia) POS N
during POS N
CGM POS N
use POS N
(P = 0.0033) POS N

indicated POS N
greater POS N
conviction POS N
that POS N
they POS N
could POS N
more POS N
freely POS N
live POS N
their POS N
lives POS N
despite POS N
the POS N
risk POS N
of POS N
hypoglycemia POS N
(P = 0.022). POS N

CGM POS N
reduced POS N
time POS N
in POS N
both POS N
nocturnal POS N
and POS N
daytime POS N
hypoglycemia POS N
in POS N
persons POS N
with POS N
type POS N
1 POS N
diabetes POS N
treated POS N
with POS N
MDI POS N
and POS N
improved POS N
hypoglycemia-related POS N
confidence, POS N
especially POS N
in POS N
social POS N
situations, POS N
thus POS N
contributing POS N
to POS N
greater POS N
well-being POS N
and POS N
quality POS N
of POS N
life. POS N

CGM POS N
reduced POS N
time POS N
in POS N
both POS N
nocturnal POS N
and POS N
daytime POS N
hypoglycemia POS N
in POS N
persons POS N
with POS N
type POS N
1 POS N
diabetes POS N
treated POS N
with POS N
MDI POS N
and POS N
improved POS N
hypoglycemia-related POS N
confidence, POS N
especially POS N
in POS N
social POS N
situations, POS N
thus POS N
contributing POS N
to POS N
greater POS N
well-being POS N
and POS N
quality POS N
of POS N
life. POS N

Time POS N
with POS N
nocturnal POS N
hypoglycemia, POS N
glucose POS N
levels POS N
<70 mg/dL POS N
was POS N
reduced POS N
by POS N
48% POS N
(10.2 POS N
vs. POS N
19.6 min POS N
each POS N
night, POS N
P < 0.001) POS N
and POS N
glucose POS N
levels POS N
<54 mg/dL POS N
by POS N
65%. POS N
(3.1 POS N
vs. POS N
8.9 min, POS N
P < 0.001). POS N

CGM POS N
reduced POS N
time POS N
in POS N
both POS N
nocturnal POS N
and POS N
daytime POS N
hypoglycemia POS N
in POS N
persons POS N
with POS N
type POS N
1 POS N
diabetes POS N
treated POS N
with POS N
MDI POS N
and POS N
improved POS N
hypoglycemia-related POS N
confidence, POS N
especially POS N
in POS N
social POS N
situations, POS N
thus POS N
contributing POS N
to POS N
greater POS N
well-being POS N
and POS N
quality POS N
of POS N
life. POS N

For POS N
the POS N
corresponding POS N
glucose POS N
cutoffs, POS N
daytime POS N
hypoglycemia POS N
was POS N
reduced POS N
by POS N
40% POS N
(29 POS N
vs. POS N
49 min, POS N
P < 0.001) POS N
and POS N
54% POS N
(8 POS N
vs. POS N
18 min., POS N
P < 0.001), POS N
respectively. POS N

CGM POS N
reduced POS N
time POS N
in POS N
both POS N
nocturnal POS N
and POS N
daytime POS N
hypoglycemia POS N
in POS N
persons POS N
with POS N
type POS N
1 POS N
diabetes POS N
treated POS N
with POS N
MDI POS N
and POS N
improved POS N
hypoglycemia-related POS N
confidence, POS N
especially POS N
in POS N
social POS N
situations, POS N
thus POS N
contributing POS N
to POS N
greater POS N
well-being POS N
and POS N
quality POS N
of POS N
life. POS N

Compared POS N
with POS N
SMBG, POS N
CGM POS N
use POS N
improved POS N
hypoglycemia-related POS N
confidence POS N
in POS N
social POS N
situations POS N
(P = 0.016) POS N
and POS N
confidence POS N
in POS N
more POS N
broadly POS N
avoiding POS N
serious POS N
problems POS N
due POS N
to POS N
hypoglycemia POS N
(P = 0.0020). POS N

CGM POS N
reduced POS N
time POS N
in POS N
both POS N
nocturnal POS N
and POS N
daytime POS N
hypoglycemia POS N
in POS N
persons POS N
with POS N
type POS N
1 POS N
diabetes POS N
treated POS N
with POS N
MDI POS N
and POS N
improved POS N
hypoglycemia-related POS N
confidence, POS N
especially POS N
in POS N
social POS N
situations, POS N
thus POS N
contributing POS N
to POS N
greater POS N
well-being POS N
and POS N
quality POS N
of POS N
life. POS N

Persons POS N
also POS N
reported POS N
greater POS N
confidence POS N
in POS N
detecting POS N
and POS N
responding POS N
to POS N
decreasing POS N
blood POS N
glucose POS N
levels POS N
(thereby POS N
avoiding POS N
hypoglycemia) POS N
during POS N
CGM POS N
use POS N
(P = 0.0033) POS N

CGM POS N
reduced POS N
time POS N
in POS N
both POS N
nocturnal POS N
and POS N
daytime POS N
hypoglycemia POS N
in POS N
persons POS N
with POS N
type POS N
1 POS N
diabetes POS N
treated POS N
with POS N
MDI POS N
and POS N
improved POS N
hypoglycemia-related POS N
confidence, POS N
especially POS N
in POS N
social POS N
situations, POS N
thus POS N
contributing POS N
to POS N
greater POS N
well-being POS N
and POS N
quality POS N
of POS N
life. POS N

indicated POS N
greater POS N
conviction POS N
that POS N
they POS N
could POS N
more POS N
freely POS N
live POS N
their POS N
lives POS N
despite POS N
the POS N
risk POS N
of POS N
hypoglycemia POS N
(P = 0.022). POS N

In POS N
a POS N
setting POS N
in POS N
which POS N
the POS N
rate POS N
of POS N
mother-to-child POS N
HBV POS N
transmission POS N
was POS N
low POS N
with POS N
the POS N
administration POS N
of POS N
hepatitis POS N
B POS N
immune POS N
globulin POS N
and POS N
hepatitis POS N
B POS N
vaccine POS N
in POS N
infants POS N
born POS N
to POS N
HBeAg-positive POS N
mothers, POS N
the POS N
additional POS N
maternal POS N
use POS N
of POS N
TDF POS N
did POS N
not POS N
result POS N
in POS N
a POS N
significantly POS N
lower POS N
rate POS N
of POS N
transmission. POS N

In POS N
the POS N
primary POS N
analysis, POS N
none POS N
of POS N
the POS N
147 POS N
infants POS N
(0%; POS N
95% POS N
confidence POS N
interval POS N
[CI], POS N
0 POS N
to POS N
2) POS N
in POS N
the POS N
TDF POS N
group POS N
were POS N
infected, POS N
as POS N
compared POS N
with POS N
3 POS N
of POS N
147 POS N
(2%; POS N
95% POS N
CI, POS N
0 POS N
to POS N
6) POS N
in POS N
the POS N
placebo POS N
group POS N
(P=0.12). POS N

In POS N
a POS N
setting POS N
in POS N
which POS N
the POS N
rate POS N
of POS N
mother-to-child POS N
HBV POS N
transmission POS N
was POS N
low POS N
with POS N
the POS N
administration POS N
of POS N
hepatitis POS N
B POS N
immune POS N
globulin POS N
and POS N
hepatitis POS N
B POS N
vaccine POS N
in POS N
infants POS N
born POS N
to POS N
HBeAg-positive POS N
mothers, POS N
the POS N
additional POS N
maternal POS N
use POS N
of POS N
TDF POS N
did POS N
not POS N
result POS N
in POS N
a POS N
significantly POS N
lower POS N
rate POS N
of POS N
transmission. POS N

The POS N
rate POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
differ POS N
significantly POS N
between POS N
groups. POS N

In POS N
a POS N
setting POS N
in POS N
which POS N
the POS N
rate POS N
of POS N
mother-to-child POS N
HBV POS N
transmission POS N
was POS N
low POS N
with POS N
the POS N
administration POS N
of POS N
hepatitis POS N
B POS N
immune POS N
globulin POS N
and POS N
hepatitis POS N
B POS N
vaccine POS N
in POS N
infants POS N
born POS N
to POS N
HBeAg-positive POS N
mothers, POS N
the POS N
additional POS N
maternal POS N
use POS N
of POS N
TDF POS N
did POS N
not POS N
result POS N
in POS N
a POS N
significantly POS N
lower POS N
rate POS N
of POS N
transmission. POS N

The POS N
incidence POS N
of POS N
a POS N
maternal POS N
alanine POS N
aminotransferase POS N
level POS N
of POS N
more POS N
than POS N
300 POS N
IU POS N
per POS N
liter POS N
after POS N
discontinuation POS N
of POS N
the POS N
trial POS N
regimen POS N
was POS N
6% POS N
in POS N
the POS N
TDF POS N
group POS N
and POS N
3% POS N
in POS N
the POS N
placebo POS N
group POS N
(P=0.29). POS N

In POS N
the POS N
primary POS N
analysis, POS N
none POS N
of POS N
the POS N
147 POS N
infants POS N
(0%; POS N
95% POS N
confidence POS N
interval POS N
[CI], POS N
0 POS N
to POS N
2) POS N
in POS N
the POS N
TDF POS N
group POS N
were POS N
infected, POS N
as POS N
compared POS N
with POS N
3 POS N
of POS N
147 POS N
(2%; POS N
95% POS N
CI, POS N
0 POS N
to POS N
6) POS N
in POS N
the POS N
placebo POS N
group POS N
(P=0.12). POS N

In POS N
a POS N
setting POS N
in POS N
which POS N
the POS N
rate POS N
of POS N
mother-to-child POS N
HBV POS N
transmission POS N
was POS N
low POS N
with POS N
the POS N
administration POS N
of POS N
hepatitis POS N
B POS N
immune POS N
globulin POS N
and POS N
hepatitis POS N
B POS N
vaccine POS N
in POS N
infants POS N
born POS N
to POS N
HBeAg-positive POS N
mothers, POS N
the POS N
additional POS N
maternal POS N
use POS N
of POS N
TDF POS N
did POS N
not POS N
result POS N
in POS N
a POS N
significantly POS N
lower POS N
rate POS N
of POS N
transmission. POS N

In POS N
the POS N
primary POS N
analysis, POS N
none POS N
of POS N
the POS N
147 POS N
infants POS N
(0%; POS N
95% POS N
confidence POS N
interval POS N
[CI], POS N
0 POS N
to POS N
2) POS N
in POS N
the POS N
TDF POS N
group POS N
were POS N
infected, POS N
as POS N
compared POS N
with POS N
3 POS N
of POS N
147 POS N
(2%; POS N
95% POS N
CI, POS N
0 POS N
to POS N
6) POS N
in POS N
the POS N
placebo POS N
group POS N
(P=0.12). POS N

The POS N
rate POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
differ POS N
significantly POS N
between POS N
groups. POS N

In POS N
the POS N
primary POS N
analysis, POS N
none POS N
of POS N
the POS N
147 POS N
infants POS N
(0%; POS N
95% POS N
confidence POS N
interval POS N
[CI], POS N
0 POS N
to POS N
2) POS N
in POS N
the POS N
TDF POS N
group POS N
were POS N
infected, POS N
as POS N
compared POS N
with POS N
3 POS N
of POS N
147 POS N
(2%; POS N
95% POS N
CI, POS N
0 POS N
to POS N
6) POS N
in POS N
the POS N
placebo POS N
group POS N
(P=0.12). POS N

The POS N
incidence POS N
of POS N
a POS N
maternal POS N
alanine POS N
aminotransferase POS N
level POS N
of POS N
more POS N
than POS N
300 POS N
IU POS N
per POS N
liter POS N
after POS N
discontinuation POS N
of POS N
the POS N
trial POS N
regimen POS N
was POS N
6% POS N
in POS N
the POS N
TDF POS N
group POS N
and POS N
3% POS N
in POS N
the POS N
placebo POS N
group POS N
(P=0.29). POS N

The POS N
rate POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
differ POS N
significantly POS N
between POS N
groups. POS N

In POS N
a POS N
setting POS N
in POS N
which POS N
the POS N
rate POS N
of POS N
mother-to-child POS N
HBV POS N
transmission POS N
was POS N
low POS N
with POS N
the POS N
administration POS N
of POS N
hepatitis POS N
B POS N
immune POS N
globulin POS N
and POS N
hepatitis POS N
B POS N
vaccine POS N
in POS N
infants POS N
born POS N
to POS N
HBeAg-positive POS N
mothers, POS N
the POS N
additional POS N
maternal POS N
use POS N
of POS N
TDF POS N
did POS N
not POS N
result POS N
in POS N
a POS N
significantly POS N
lower POS N
rate POS N
of POS N
transmission. POS N

The POS N
rate POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
differ POS N
significantly POS N
between POS N
groups. POS N

In POS N
the POS N
primary POS N
analysis, POS N
none POS N
of POS N
the POS N
147 POS N
infants POS N
(0%; POS N
95% POS N
confidence POS N
interval POS N
[CI], POS N
0 POS N
to POS N
2) POS N
in POS N
the POS N
TDF POS N
group POS N
were POS N
infected, POS N
as POS N
compared POS N
with POS N
3 POS N
of POS N
147 POS N
(2%; POS N
95% POS N
CI, POS N
0 POS N
to POS N
6) POS N
in POS N
the POS N
placebo POS N
group POS N
(P=0.12). POS N

The POS N
rate POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
differ POS N
significantly POS N
between POS N
groups. POS N

The POS N
incidence POS N
of POS N
a POS N
maternal POS N
alanine POS N
aminotransferase POS N
level POS N
of POS N
more POS N
than POS N
300 POS N
IU POS N
per POS N
liter POS N
after POS N
discontinuation POS N
of POS N
the POS N
trial POS N
regimen POS N
was POS N
6% POS N
in POS N
the POS N
TDF POS N
group POS N
and POS N
3% POS N
in POS N
the POS N
placebo POS N
group POS N
(P=0.29). POS N

The POS N
incidence POS N
of POS N
a POS N
maternal POS N
alanine POS N
aminotransferase POS N
level POS N
of POS N
more POS N
than POS N
300 POS N
IU POS N
per POS N
liter POS N
after POS N
discontinuation POS N
of POS N
the POS N
trial POS N
regimen POS N
was POS N
6% POS N
in POS N
the POS N
TDF POS N
group POS N
and POS N
3% POS N
in POS N
the POS N
placebo POS N
group POS N
(P=0.29). POS N

In POS N
a POS N
setting POS N
in POS N
which POS N
the POS N
rate POS N
of POS N
mother-to-child POS N
HBV POS N
transmission POS N
was POS N
low POS N
with POS N
the POS N
administration POS N
of POS N
hepatitis POS N
B POS N
immune POS N
globulin POS N
and POS N
hepatitis POS N
B POS N
vaccine POS N
in POS N
infants POS N
born POS N
to POS N
HBeAg-positive POS N
mothers, POS N
the POS N
additional POS N
maternal POS N
use POS N
of POS N
TDF POS N
did POS N
not POS N
result POS N
in POS N
a POS N
significantly POS N
lower POS N
rate POS N
of POS N
transmission. POS N

The POS N
incidence POS N
of POS N
a POS N
maternal POS N
alanine POS N
aminotransferase POS N
level POS N
of POS N
more POS N
than POS N
300 POS N
IU POS N
per POS N
liter POS N
after POS N
discontinuation POS N
of POS N
the POS N
trial POS N
regimen POS N
was POS N
6% POS N
in POS N
the POS N
TDF POS N
group POS N
and POS N
3% POS N
in POS N
the POS N
placebo POS N
group POS N
(P=0.29). POS N

In POS N
the POS N
primary POS N
analysis, POS N
none POS N
of POS N
the POS N
147 POS N
infants POS N
(0%; POS N
95% POS N
confidence POS N
interval POS N
[CI], POS N
0 POS N
to POS N
2) POS N
in POS N
the POS N
TDF POS N
group POS N
were POS N
infected, POS N
as POS N
compared POS N
with POS N
3 POS N
of POS N
147 POS N
(2%; POS N
95% POS N
CI, POS N
0 POS N
to POS N
6) POS N
in POS N
the POS N
placebo POS N
group POS N
(P=0.12). POS N

The POS N
incidence POS N
of POS N
a POS N
maternal POS N
alanine POS N
aminotransferase POS N
level POS N
of POS N
more POS N
than POS N
300 POS N
IU POS N
per POS N
liter POS N
after POS N
discontinuation POS N
of POS N
the POS N
trial POS N
regimen POS N
was POS N
6% POS N
in POS N
the POS N
TDF POS N
group POS N
and POS N
3% POS N
in POS N
the POS N
placebo POS N
group POS N
(P=0.29). POS N

The POS N
rate POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
differ POS N
significantly POS N
between POS N
groups. POS N

After POS N
completion POS N
of POS N
chemotherapy, POS N
patients POS N
treated POS N
with POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
significant POS N
improvement POS N
in POS N
fatigue POS N
(P POS N
<.05) POS N
as POS N
compared POS N
with POS N
their POS N
baseline POS N
scores. POS N

Higher POS N
proportions POS N
of POS N
patients POS N
receiving POS N
the POS N
combined POS N
therapy POS N
achieved POS N
improvement POS N
in POS N
global POS N
QOL POS N
(P POS N
<.05) POS N
than POS N
did POS N
patients POS N
treated POS N
with POS N
chemotherapy POS N
alone. POS N

After POS N
completion POS N
of POS N
chemotherapy, POS N
patients POS N
treated POS N
with POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
significant POS N
improvement POS N
in POS N
fatigue POS N
(P POS N
<.05) POS N
as POS N
compared POS N
with POS N
their POS N
baseline POS N
scores. POS N

Higher POS N
proportions POS N
of POS N
the POS N
combined POS N
therapy POS N
group POS N
also POS N
achieved POS N
improvement POS N
in POS N
physical POS N
and POS N
role POS N
functioning POS N
and POS N
in POS N
fatigue POS N
as POS N
compared POS N
with POS N
the POS N
chemotherapy POS N
group, POS N

After POS N
completion POS N
of POS N
chemotherapy, POS N
patients POS N
treated POS N
with POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
significant POS N
improvement POS N
in POS N
fatigue POS N
(P POS N
<.05) POS N
as POS N
compared POS N
with POS N
their POS N
baseline POS N
scores. POS N

There POS N
were POS N
no POS N
differences POS N
in POS N
the POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
two POS N
groups POS N
that POS N
reported POS N
worsening. POS N

After POS N
completion POS N
of POS N
chemotherapy, POS N
patients POS N
treated POS N
with POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
significant POS N
improvement POS N
in POS N
fatigue POS N
(P POS N
<.05) POS N
as POS N
compared POS N
with POS N
their POS N
baseline POS N
scores. POS N

Statistically POS N
significantly POS N
higher POS N
proportions POS N
of POS N
patients POS N
treated POS N
with POS N
a POS N
combination POS N
of POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
improved POS N
global POS N
QOL POS N
than POS N
did POS N
patients POS N
treated POS N
by POS N
chemotherapy POS N
alone. POS N

After POS N
completion POS N
of POS N
chemotherapy, POS N
patients POS N
treated POS N
with POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
significant POS N
improvement POS N
in POS N
fatigue POS N
(P POS N
<.05) POS N
as POS N
compared POS N
with POS N
their POS N
baseline POS N
scores. POS N

but POS N
the POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

Higher POS N
proportions POS N
of POS N
patients POS N
receiving POS N
the POS N
combined POS N
therapy POS N
achieved POS N
improvement POS N
in POS N
global POS N
QOL POS N
(P POS N
<.05) POS N
than POS N
did POS N
patients POS N
treated POS N
with POS N
chemotherapy POS N
alone. POS N

After POS N
completion POS N
of POS N
chemotherapy, POS N
patients POS N
treated POS N
with POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
significant POS N
improvement POS N
in POS N
fatigue POS N
(P POS N
<.05) POS N
as POS N
compared POS N
with POS N
their POS N
baseline POS N
scores. POS N

Higher POS N
proportions POS N
of POS N
patients POS N
receiving POS N
the POS N
combined POS N
therapy POS N
achieved POS N
improvement POS N
in POS N
global POS N
QOL POS N
(P POS N
<.05) POS N
than POS N
did POS N
patients POS N
treated POS N
with POS N
chemotherapy POS N
alone. POS N

Higher POS N
proportions POS N
of POS N
the POS N
combined POS N
therapy POS N
group POS N
also POS N
achieved POS N
improvement POS N
in POS N
physical POS N
and POS N
role POS N
functioning POS N
and POS N
in POS N
fatigue POS N
as POS N
compared POS N
with POS N
the POS N
chemotherapy POS N
group, POS N

Higher POS N
proportions POS N
of POS N
patients POS N
receiving POS N
the POS N
combined POS N
therapy POS N
achieved POS N
improvement POS N
in POS N
global POS N
QOL POS N
(P POS N
<.05) POS N
than POS N
did POS N
patients POS N
treated POS N
with POS N
chemotherapy POS N
alone. POS N

There POS N
were POS N
no POS N
differences POS N
in POS N
the POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
two POS N
groups POS N
that POS N
reported POS N
worsening. POS N

Higher POS N
proportions POS N
of POS N
patients POS N
receiving POS N
the POS N
combined POS N
therapy POS N
achieved POS N
improvement POS N
in POS N
global POS N
QOL POS N
(P POS N
<.05) POS N
than POS N
did POS N
patients POS N
treated POS N
with POS N
chemotherapy POS N
alone. POS N

Statistically POS N
significantly POS N
higher POS N
proportions POS N
of POS N
patients POS N
treated POS N
with POS N
a POS N
combination POS N
of POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
improved POS N
global POS N
QOL POS N
than POS N
did POS N
patients POS N
treated POS N
by POS N
chemotherapy POS N
alone. POS N

Higher POS N
proportions POS N
of POS N
patients POS N
receiving POS N
the POS N
combined POS N
therapy POS N
achieved POS N
improvement POS N
in POS N
global POS N
QOL POS N
(P POS N
<.05) POS N
than POS N
did POS N
patients POS N
treated POS N
with POS N
chemotherapy POS N
alone. POS N

but POS N
the POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

Higher POS N
proportions POS N
of POS N
the POS N
combined POS N
therapy POS N
group POS N
also POS N
achieved POS N
improvement POS N
in POS N
physical POS N
and POS N
role POS N
functioning POS N
and POS N
in POS N
fatigue POS N
as POS N
compared POS N
with POS N
the POS N
chemotherapy POS N
group, POS N

After POS N
completion POS N
of POS N
chemotherapy, POS N
patients POS N
treated POS N
with POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
significant POS N
improvement POS N
in POS N
fatigue POS N
(P POS N
<.05) POS N
as POS N
compared POS N
with POS N
their POS N
baseline POS N
scores. POS N

Higher POS N
proportions POS N
of POS N
the POS N
combined POS N
therapy POS N
group POS N
also POS N
achieved POS N
improvement POS N
in POS N
physical POS N
and POS N
role POS N
functioning POS N
and POS N
in POS N
fatigue POS N
as POS N
compared POS N
with POS N
the POS N
chemotherapy POS N
group, POS N

Higher POS N
proportions POS N
of POS N
patients POS N
receiving POS N
the POS N
combined POS N
therapy POS N
achieved POS N
improvement POS N
in POS N
global POS N
QOL POS N
(P POS N
<.05) POS N
than POS N
did POS N
patients POS N
treated POS N
with POS N
chemotherapy POS N
alone. POS N

Higher POS N
proportions POS N
of POS N
the POS N
combined POS N
therapy POS N
group POS N
also POS N
achieved POS N
improvement POS N
in POS N
physical POS N
and POS N
role POS N
functioning POS N
and POS N
in POS N
fatigue POS N
as POS N
compared POS N
with POS N
the POS N
chemotherapy POS N
group, POS N

There POS N
were POS N
no POS N
differences POS N
in POS N
the POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
two POS N
groups POS N
that POS N
reported POS N
worsening. POS N

Higher POS N
proportions POS N
of POS N
the POS N
combined POS N
therapy POS N
group POS N
also POS N
achieved POS N
improvement POS N
in POS N
physical POS N
and POS N
role POS N
functioning POS N
and POS N
in POS N
fatigue POS N
as POS N
compared POS N
with POS N
the POS N
chemotherapy POS N
group, POS N

Statistically POS N
significantly POS N
higher POS N
proportions POS N
of POS N
patients POS N
treated POS N
with POS N
a POS N
combination POS N
of POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
improved POS N
global POS N
QOL POS N
than POS N
did POS N
patients POS N
treated POS N
by POS N
chemotherapy POS N
alone. POS N

Higher POS N
proportions POS N
of POS N
the POS N
combined POS N
therapy POS N
group POS N
also POS N
achieved POS N
improvement POS N
in POS N
physical POS N
and POS N
role POS N
functioning POS N
and POS N
in POS N
fatigue POS N
as POS N
compared POS N
with POS N
the POS N
chemotherapy POS N
group, POS N

but POS N
the POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

There POS N
were POS N
no POS N
differences POS N
in POS N
the POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
two POS N
groups POS N
that POS N
reported POS N
worsening. POS N

After POS N
completion POS N
of POS N
chemotherapy, POS N
patients POS N
treated POS N
with POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
significant POS N
improvement POS N
in POS N
fatigue POS N
(P POS N
<.05) POS N
as POS N
compared POS N
with POS N
their POS N
baseline POS N
scores. POS N

There POS N
were POS N
no POS N
differences POS N
in POS N
the POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
two POS N
groups POS N
that POS N
reported POS N
worsening. POS N

Higher POS N
proportions POS N
of POS N
patients POS N
receiving POS N
the POS N
combined POS N
therapy POS N
achieved POS N
improvement POS N
in POS N
global POS N
QOL POS N
(P POS N
<.05) POS N
than POS N
did POS N
patients POS N
treated POS N
with POS N
chemotherapy POS N
alone. POS N

There POS N
were POS N
no POS N
differences POS N
in POS N
the POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
two POS N
groups POS N
that POS N
reported POS N
worsening. POS N

Higher POS N
proportions POS N
of POS N
the POS N
combined POS N
therapy POS N
group POS N
also POS N
achieved POS N
improvement POS N
in POS N
physical POS N
and POS N
role POS N
functioning POS N
and POS N
in POS N
fatigue POS N
as POS N
compared POS N
with POS N
the POS N
chemotherapy POS N
group, POS N

There POS N
were POS N
no POS N
differences POS N
in POS N
the POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
two POS N
groups POS N
that POS N
reported POS N
worsening. POS N

Statistically POS N
significantly POS N
higher POS N
proportions POS N
of POS N
patients POS N
treated POS N
with POS N
a POS N
combination POS N
of POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
improved POS N
global POS N
QOL POS N
than POS N
did POS N
patients POS N
treated POS N
by POS N
chemotherapy POS N
alone. POS N

There POS N
were POS N
no POS N
differences POS N
in POS N
the POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
two POS N
groups POS N
that POS N
reported POS N
worsening. POS N

but POS N
the POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

Statistically POS N
significantly POS N
higher POS N
proportions POS N
of POS N
patients POS N
treated POS N
with POS N
a POS N
combination POS N
of POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
improved POS N
global POS N
QOL POS N
than POS N
did POS N
patients POS N
treated POS N
by POS N
chemotherapy POS N
alone. POS N

After POS N
completion POS N
of POS N
chemotherapy, POS N
patients POS N
treated POS N
with POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
significant POS N
improvement POS N
in POS N
fatigue POS N
(P POS N
<.05) POS N
as POS N
compared POS N
with POS N
their POS N
baseline POS N
scores. POS N

Statistically POS N
significantly POS N
higher POS N
proportions POS N
of POS N
patients POS N
treated POS N
with POS N
a POS N
combination POS N
of POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
improved POS N
global POS N
QOL POS N
than POS N
did POS N
patients POS N
treated POS N
by POS N
chemotherapy POS N
alone. POS N

Higher POS N
proportions POS N
of POS N
patients POS N
receiving POS N
the POS N
combined POS N
therapy POS N
achieved POS N
improvement POS N
in POS N
global POS N
QOL POS N
(P POS N
<.05) POS N
than POS N
did POS N
patients POS N
treated POS N
with POS N
chemotherapy POS N
alone. POS N

Statistically POS N
significantly POS N
higher POS N
proportions POS N
of POS N
patients POS N
treated POS N
with POS N
a POS N
combination POS N
of POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
improved POS N
global POS N
QOL POS N
than POS N
did POS N
patients POS N
treated POS N
by POS N
chemotherapy POS N
alone. POS N

Higher POS N
proportions POS N
of POS N
the POS N
combined POS N
therapy POS N
group POS N
also POS N
achieved POS N
improvement POS N
in POS N
physical POS N
and POS N
role POS N
functioning POS N
and POS N
in POS N
fatigue POS N
as POS N
compared POS N
with POS N
the POS N
chemotherapy POS N
group, POS N

Statistically POS N
significantly POS N
higher POS N
proportions POS N
of POS N
patients POS N
treated POS N
with POS N
a POS N
combination POS N
of POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
improved POS N
global POS N
QOL POS N
than POS N
did POS N
patients POS N
treated POS N
by POS N
chemotherapy POS N
alone. POS N

There POS N
were POS N
no POS N
differences POS N
in POS N
the POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
two POS N
groups POS N
that POS N
reported POS N
worsening. POS N

Statistically POS N
significantly POS N
higher POS N
proportions POS N
of POS N
patients POS N
treated POS N
with POS N
a POS N
combination POS N
of POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
improved POS N
global POS N
QOL POS N
than POS N
did POS N
patients POS N
treated POS N
by POS N
chemotherapy POS N
alone. POS N

but POS N
the POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

but POS N
the POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

After POS N
completion POS N
of POS N
chemotherapy, POS N
patients POS N
treated POS N
with POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
significant POS N
improvement POS N
in POS N
fatigue POS N
(P POS N
<.05) POS N
as POS N
compared POS N
with POS N
their POS N
baseline POS N
scores. POS N

but POS N
the POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

Higher POS N
proportions POS N
of POS N
patients POS N
receiving POS N
the POS N
combined POS N
therapy POS N
achieved POS N
improvement POS N
in POS N
global POS N
QOL POS N
(P POS N
<.05) POS N
than POS N
did POS N
patients POS N
treated POS N
with POS N
chemotherapy POS N
alone. POS N

but POS N
the POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

Higher POS N
proportions POS N
of POS N
the POS N
combined POS N
therapy POS N
group POS N
also POS N
achieved POS N
improvement POS N
in POS N
physical POS N
and POS N
role POS N
functioning POS N
and POS N
in POS N
fatigue POS N
as POS N
compared POS N
with POS N
the POS N
chemotherapy POS N
group, POS N

but POS N
the POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

There POS N
were POS N
no POS N
differences POS N
in POS N
the POS N
proportions POS N
of POS N
patients POS N
in POS N
the POS N
two POS N
groups POS N
that POS N
reported POS N
worsening. POS N

but POS N
the POS N
differences POS N
were POS N
not POS N
statistically POS N
significant. POS N

Statistically POS N
significantly POS N
higher POS N
proportions POS N
of POS N
patients POS N
treated POS N
with POS N
a POS N
combination POS N
of POS N
trastuzumab POS N
and POS N
chemotherapy POS N
reported POS N
improved POS N
global POS N
QOL POS N
than POS N
did POS N
patients POS N
treated POS N
by POS N
chemotherapy POS N
alone. POS N

In POS N
389 POS N
eligible POS N
patients, POS N
the POS N
relative POS N
dose POS N
intensities POS N
(RDIs) POS N
of POS N
cyclophosphamide POS N
(median, POS N
96.3% POS N
v POS N
93.9%; POS N
P POS N
=.01) POS N
and POS N
doxorubicin POS N
(median, POS N
95.4% POS N
v POS N
93.3%; POS N
P POS N
=.04) POS N
were POS N
higher POS N
in POS N
patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF. POS N

The POS N
complete POS N
response POS N
rates POS N
were POS N
55% POS N
and POS N
52% POS N
for POS N
CHOP POS N
and POS N
CHOP POS N
plus POS N
G-CSF, POS N
respectively POS N
(P POS N
=.63). POS N

In POS N
389 POS N
eligible POS N
patients, POS N
the POS N
relative POS N
dose POS N
intensities POS N
(RDIs) POS N
of POS N
cyclophosphamide POS N
(median, POS N
96.3% POS N
v POS N
93.9%; POS N
P POS N
=.01) POS N
and POS N
doxorubicin POS N
(median, POS N
95.4% POS N
v POS N
93.3%; POS N
P POS N
=.04) POS N
were POS N
higher POS N
in POS N
patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF. POS N

The POS N
actuarial POS N
overall POS N
survival POS N
at POS N
5 POS N
years POS N
was POS N
22% POS N
with POS N
CHOP POS N
alone, POS N
compared POS N
with POS N
24% POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(P POS N
=.76), POS N
with POS N
a POS N
median POS N
follow-up POS N
of POS N
33 POS N
months. POS N

In POS N
389 POS N
eligible POS N
patients, POS N
the POS N
relative POS N
dose POS N
intensities POS N
(RDIs) POS N
of POS N
cyclophosphamide POS N
(median, POS N
96.3% POS N
v POS N
93.9%; POS N
P POS N
=.01) POS N
and POS N
doxorubicin POS N
(median, POS N
95.4% POS N
v POS N
93.3%; POS N
P POS N
=.04) POS N
were POS N
higher POS N
in POS N
patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF. POS N

Patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
had POS N
an POS N
identical POS N
incidence POS N
of POS N
infections, POS N
with POS N
World POS N
Health POS N
Organization POS N
grade POS N
3 POS N
to POS N
4 POS N
(34 POS N
of POS N
1,191 POS N
cycles POS N
v POS N
36 POS N
of POS N
1,195 POS N
cycles). POS N

In POS N
389 POS N
eligible POS N
patients, POS N
the POS N
relative POS N
dose POS N
intensities POS N
(RDIs) POS N
of POS N
cyclophosphamide POS N
(median, POS N
96.3% POS N
v POS N
93.9%; POS N
P POS N
=.01) POS N
and POS N
doxorubicin POS N
(median, POS N
95.4% POS N
v POS N
93.3%; POS N
P POS N
=.04) POS N
were POS N
higher POS N
in POS N
patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF. POS N

Only POS N
the POS N
cumulative POS N
days POS N
with POS N
antibiotics POS N
were POS N
fewer POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(median, POS N
0 POS N
v POS N
6 POS N
days; POS N
P POS N
=.006) POS N
than POS N
with POS N
CHOP POS N
alone. POS N

In POS N
389 POS N
eligible POS N
patients, POS N
the POS N
relative POS N
dose POS N
intensities POS N
(RDIs) POS N
of POS N
cyclophosphamide POS N
(median, POS N
96.3% POS N
v POS N
93.9%; POS N
P POS N
=.01) POS N
and POS N
doxorubicin POS N
(median, POS N
95.4% POS N
v POS N
93.3%; POS N
P POS N
=.04) POS N
were POS N
higher POS N
in POS N
patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF. POS N

The POS N
number POS N
of POS N
hospital POS N
admissions POS N
and POS N
the POS N
number POS N
of POS N
days POS N
in POS N
hospital POS N
were POS N
not POS N
different. POS N

In POS N
389 POS N
eligible POS N
patients, POS N
the POS N
relative POS N
dose POS N
intensities POS N
(RDIs) POS N
of POS N
cyclophosphamide POS N
(median, POS N
96.3% POS N
v POS N
93.9%; POS N
P POS N
=.01) POS N
and POS N
doxorubicin POS N
(median, POS N
95.4% POS N
v POS N
93.3%; POS N
P POS N
=.04) POS N
were POS N
higher POS N
in POS N
patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF. POS N

In POS N
elderly POS N
patients, POS N
G-CSF POS N
improved POS N
the POS N
RDI POS N
of POS N
CHOP, POS N

In POS N
389 POS N
eligible POS N
patients, POS N
the POS N
relative POS N
dose POS N
intensities POS N
(RDIs) POS N
of POS N
cyclophosphamide POS N
(median, POS N
96.3% POS N
v POS N
93.9%; POS N
P POS N
=.01) POS N
and POS N
doxorubicin POS N
(median, POS N
95.4% POS N
v POS N
93.3%; POS N
P POS N
=.04) POS N
were POS N
higher POS N
in POS N
patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF. POS N

but POS N
this POS N
did POS N
not POS N
lead POS N
to POS N
a POS N
higher POS N
complete POS N
response POS N
rate POS N
or POS N
better POS N
overall POS N
survival. POS N

In POS N
389 POS N
eligible POS N
patients, POS N
the POS N
relative POS N
dose POS N
intensities POS N
(RDIs) POS N
of POS N
cyclophosphamide POS N
(median, POS N
96.3% POS N
v POS N
93.9%; POS N
P POS N
=.01) POS N
and POS N
doxorubicin POS N
(median, POS N
95.4% POS N
v POS N
93.3%; POS N
P POS N
=.04) POS N
were POS N
higher POS N
in POS N
patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF. POS N

G-CSF POS N
did POS N
not POS N
prevent POS N
serious POS N
infections. POS N

The POS N
complete POS N
response POS N
rates POS N
were POS N
55% POS N
and POS N
52% POS N
for POS N
CHOP POS N
and POS N
CHOP POS N
plus POS N
G-CSF, POS N
respectively POS N
(P POS N
=.63). POS N

In POS N
389 POS N
eligible POS N
patients, POS N
the POS N
relative POS N
dose POS N
intensities POS N
(RDIs) POS N
of POS N
cyclophosphamide POS N
(median, POS N
96.3% POS N
v POS N
93.9%; POS N
P POS N
=.01) POS N
and POS N
doxorubicin POS N
(median, POS N
95.4% POS N
v POS N
93.3%; POS N
P POS N
=.04) POS N
were POS N
higher POS N
in POS N
patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF. POS N

The POS N
complete POS N
response POS N
rates POS N
were POS N
55% POS N
and POS N
52% POS N
for POS N
CHOP POS N
and POS N
CHOP POS N
plus POS N
G-CSF, POS N
respectively POS N
(P POS N
=.63). POS N

The POS N
actuarial POS N
overall POS N
survival POS N
at POS N
5 POS N
years POS N
was POS N
22% POS N
with POS N
CHOP POS N
alone, POS N
compared POS N
with POS N
24% POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(P POS N
=.76), POS N
with POS N
a POS N
median POS N
follow-up POS N
of POS N
33 POS N
months. POS N

The POS N
complete POS N
response POS N
rates POS N
were POS N
55% POS N
and POS N
52% POS N
for POS N
CHOP POS N
and POS N
CHOP POS N
plus POS N
G-CSF, POS N
respectively POS N
(P POS N
=.63). POS N

Patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
had POS N
an POS N
identical POS N
incidence POS N
of POS N
infections, POS N
with POS N
World POS N
Health POS N
Organization POS N
grade POS N
3 POS N
to POS N
4 POS N
(34 POS N
of POS N
1,191 POS N
cycles POS N
v POS N
36 POS N
of POS N
1,195 POS N
cycles). POS N

The POS N
complete POS N
response POS N
rates POS N
were POS N
55% POS N
and POS N
52% POS N
for POS N
CHOP POS N
and POS N
CHOP POS N
plus POS N
G-CSF, POS N
respectively POS N
(P POS N
=.63). POS N

Only POS N
the POS N
cumulative POS N
days POS N
with POS N
antibiotics POS N
were POS N
fewer POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(median, POS N
0 POS N
v POS N
6 POS N
days; POS N
P POS N
=.006) POS N
than POS N
with POS N
CHOP POS N
alone. POS N

The POS N
complete POS N
response POS N
rates POS N
were POS N
55% POS N
and POS N
52% POS N
for POS N
CHOP POS N
and POS N
CHOP POS N
plus POS N
G-CSF, POS N
respectively POS N
(P POS N
=.63). POS N

The POS N
number POS N
of POS N
hospital POS N
admissions POS N
and POS N
the POS N
number POS N
of POS N
days POS N
in POS N
hospital POS N
were POS N
not POS N
different. POS N

The POS N
complete POS N
response POS N
rates POS N
were POS N
55% POS N
and POS N
52% POS N
for POS N
CHOP POS N
and POS N
CHOP POS N
plus POS N
G-CSF, POS N
respectively POS N
(P POS N
=.63). POS N

In POS N
elderly POS N
patients, POS N
G-CSF POS N
improved POS N
the POS N
RDI POS N
of POS N
CHOP, POS N

The POS N
complete POS N
response POS N
rates POS N
were POS N
55% POS N
and POS N
52% POS N
for POS N
CHOP POS N
and POS N
CHOP POS N
plus POS N
G-CSF, POS N
respectively POS N
(P POS N
=.63). POS N

but POS N
this POS N
did POS N
not POS N
lead POS N
to POS N
a POS N
higher POS N
complete POS N
response POS N
rate POS N
or POS N
better POS N
overall POS N
survival. POS N

The POS N
complete POS N
response POS N
rates POS N
were POS N
55% POS N
and POS N
52% POS N
for POS N
CHOP POS N
and POS N
CHOP POS N
plus POS N
G-CSF, POS N
respectively POS N
(P POS N
=.63). POS N

G-CSF POS N
did POS N
not POS N
prevent POS N
serious POS N
infections. POS N

The POS N
actuarial POS N
overall POS N
survival POS N
at POS N
5 POS N
years POS N
was POS N
22% POS N
with POS N
CHOP POS N
alone, POS N
compared POS N
with POS N
24% POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(P POS N
=.76), POS N
with POS N
a POS N
median POS N
follow-up POS N
of POS N
33 POS N
months. POS N

In POS N
389 POS N
eligible POS N
patients, POS N
the POS N
relative POS N
dose POS N
intensities POS N
(RDIs) POS N
of POS N
cyclophosphamide POS N
(median, POS N
96.3% POS N
v POS N
93.9%; POS N
P POS N
=.01) POS N
and POS N
doxorubicin POS N
(median, POS N
95.4% POS N
v POS N
93.3%; POS N
P POS N
=.04) POS N
were POS N
higher POS N
in POS N
patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF. POS N

The POS N
actuarial POS N
overall POS N
survival POS N
at POS N
5 POS N
years POS N
was POS N
22% POS N
with POS N
CHOP POS N
alone, POS N
compared POS N
with POS N
24% POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(P POS N
=.76), POS N
with POS N
a POS N
median POS N
follow-up POS N
of POS N
33 POS N
months. POS N

The POS N
complete POS N
response POS N
rates POS N
were POS N
55% POS N
and POS N
52% POS N
for POS N
CHOP POS N
and POS N
CHOP POS N
plus POS N
G-CSF, POS N
respectively POS N
(P POS N
=.63). POS N

The POS N
actuarial POS N
overall POS N
survival POS N
at POS N
5 POS N
years POS N
was POS N
22% POS N
with POS N
CHOP POS N
alone, POS N
compared POS N
with POS N
24% POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(P POS N
=.76), POS N
with POS N
a POS N
median POS N
follow-up POS N
of POS N
33 POS N
months. POS N

Patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
had POS N
an POS N
identical POS N
incidence POS N
of POS N
infections, POS N
with POS N
World POS N
Health POS N
Organization POS N
grade POS N
3 POS N
to POS N
4 POS N
(34 POS N
of POS N
1,191 POS N
cycles POS N
v POS N
36 POS N
of POS N
1,195 POS N
cycles). POS N

The POS N
actuarial POS N
overall POS N
survival POS N
at POS N
5 POS N
years POS N
was POS N
22% POS N
with POS N
CHOP POS N
alone, POS N
compared POS N
with POS N
24% POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(P POS N
=.76), POS N
with POS N
a POS N
median POS N
follow-up POS N
of POS N
33 POS N
months. POS N

Only POS N
the POS N
cumulative POS N
days POS N
with POS N
antibiotics POS N
were POS N
fewer POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(median, POS N
0 POS N
v POS N
6 POS N
days; POS N
P POS N
=.006) POS N
than POS N
with POS N
CHOP POS N
alone. POS N

The POS N
actuarial POS N
overall POS N
survival POS N
at POS N
5 POS N
years POS N
was POS N
22% POS N
with POS N
CHOP POS N
alone, POS N
compared POS N
with POS N
24% POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(P POS N
=.76), POS N
with POS N
a POS N
median POS N
follow-up POS N
of POS N
33 POS N
months. POS N

The POS N
number POS N
of POS N
hospital POS N
admissions POS N
and POS N
the POS N
number POS N
of POS N
days POS N
in POS N
hospital POS N
were POS N
not POS N
different. POS N

The POS N
actuarial POS N
overall POS N
survival POS N
at POS N
5 POS N
years POS N
was POS N
22% POS N
with POS N
CHOP POS N
alone, POS N
compared POS N
with POS N
24% POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(P POS N
=.76), POS N
with POS N
a POS N
median POS N
follow-up POS N
of POS N
33 POS N
months. POS N

In POS N
elderly POS N
patients, POS N
G-CSF POS N
improved POS N
the POS N
RDI POS N
of POS N
CHOP, POS N

The POS N
actuarial POS N
overall POS N
survival POS N
at POS N
5 POS N
years POS N
was POS N
22% POS N
with POS N
CHOP POS N
alone, POS N
compared POS N
with POS N
24% POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(P POS N
=.76), POS N
with POS N
a POS N
median POS N
follow-up POS N
of POS N
33 POS N
months. POS N

but POS N
this POS N
did POS N
not POS N
lead POS N
to POS N
a POS N
higher POS N
complete POS N
response POS N
rate POS N
or POS N
better POS N
overall POS N
survival. POS N

The POS N
actuarial POS N
overall POS N
survival POS N
at POS N
5 POS N
years POS N
was POS N
22% POS N
with POS N
CHOP POS N
alone, POS N
compared POS N
with POS N
24% POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(P POS N
=.76), POS N
with POS N
a POS N
median POS N
follow-up POS N
of POS N
33 POS N
months. POS N

G-CSF POS N
did POS N
not POS N
prevent POS N
serious POS N
infections. POS N

Patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
had POS N
an POS N
identical POS N
incidence POS N
of POS N
infections, POS N
with POS N
World POS N
Health POS N
Organization POS N
grade POS N
3 POS N
to POS N
4 POS N
(34 POS N
of POS N
1,191 POS N
cycles POS N
v POS N
36 POS N
of POS N
1,195 POS N
cycles). POS N

In POS N
389 POS N
eligible POS N
patients, POS N
the POS N
relative POS N
dose POS N
intensities POS N
(RDIs) POS N
of POS N
cyclophosphamide POS N
(median, POS N
96.3% POS N
v POS N
93.9%; POS N
P POS N
=.01) POS N
and POS N
doxorubicin POS N
(median, POS N
95.4% POS N
v POS N
93.3%; POS N
P POS N
=.04) POS N
were POS N
higher POS N
in POS N
patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF. POS N

Patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
had POS N
an POS N
identical POS N
incidence POS N
of POS N
infections, POS N
with POS N
World POS N
Health POS N
Organization POS N
grade POS N
3 POS N
to POS N
4 POS N
(34 POS N
of POS N
1,191 POS N
cycles POS N
v POS N
36 POS N
of POS N
1,195 POS N
cycles). POS N

The POS N
complete POS N
response POS N
rates POS N
were POS N
55% POS N
and POS N
52% POS N
for POS N
CHOP POS N
and POS N
CHOP POS N
plus POS N
G-CSF, POS N
respectively POS N
(P POS N
=.63). POS N

Patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
had POS N
an POS N
identical POS N
incidence POS N
of POS N
infections, POS N
with POS N
World POS N
Health POS N
Organization POS N
grade POS N
3 POS N
to POS N
4 POS N
(34 POS N
of POS N
1,191 POS N
cycles POS N
v POS N
36 POS N
of POS N
1,195 POS N
cycles). POS N

The POS N
actuarial POS N
overall POS N
survival POS N
at POS N
5 POS N
years POS N
was POS N
22% POS N
with POS N
CHOP POS N
alone, POS N
compared POS N
with POS N
24% POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(P POS N
=.76), POS N
with POS N
a POS N
median POS N
follow-up POS N
of POS N
33 POS N
months. POS N

Patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
had POS N
an POS N
identical POS N
incidence POS N
of POS N
infections, POS N
with POS N
World POS N
Health POS N
Organization POS N
grade POS N
3 POS N
to POS N
4 POS N
(34 POS N
of POS N
1,191 POS N
cycles POS N
v POS N
36 POS N
of POS N
1,195 POS N
cycles). POS N

Only POS N
the POS N
cumulative POS N
days POS N
with POS N
antibiotics POS N
were POS N
fewer POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(median, POS N
0 POS N
v POS N
6 POS N
days; POS N
P POS N
=.006) POS N
than POS N
with POS N
CHOP POS N
alone. POS N

Patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
had POS N
an POS N
identical POS N
incidence POS N
of POS N
infections, POS N
with POS N
World POS N
Health POS N
Organization POS N
grade POS N
3 POS N
to POS N
4 POS N
(34 POS N
of POS N
1,191 POS N
cycles POS N
v POS N
36 POS N
of POS N
1,195 POS N
cycles). POS N

The POS N
number POS N
of POS N
hospital POS N
admissions POS N
and POS N
the POS N
number POS N
of POS N
days POS N
in POS N
hospital POS N
were POS N
not POS N
different. POS N

Patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
had POS N
an POS N
identical POS N
incidence POS N
of POS N
infections, POS N
with POS N
World POS N
Health POS N
Organization POS N
grade POS N
3 POS N
to POS N
4 POS N
(34 POS N
of POS N
1,191 POS N
cycles POS N
v POS N
36 POS N
of POS N
1,195 POS N
cycles). POS N

In POS N
elderly POS N
patients, POS N
G-CSF POS N
improved POS N
the POS N
RDI POS N
of POS N
CHOP, POS N

Patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
had POS N
an POS N
identical POS N
incidence POS N
of POS N
infections, POS N
with POS N
World POS N
Health POS N
Organization POS N
grade POS N
3 POS N
to POS N
4 POS N
(34 POS N
of POS N
1,191 POS N
cycles POS N
v POS N
36 POS N
of POS N
1,195 POS N
cycles). POS N

but POS N
this POS N
did POS N
not POS N
lead POS N
to POS N
a POS N
higher POS N
complete POS N
response POS N
rate POS N
or POS N
better POS N
overall POS N
survival. POS N

Patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
had POS N
an POS N
identical POS N
incidence POS N
of POS N
infections, POS N
with POS N
World POS N
Health POS N
Organization POS N
grade POS N
3 POS N
to POS N
4 POS N
(34 POS N
of POS N
1,191 POS N
cycles POS N
v POS N
36 POS N
of POS N
1,195 POS N
cycles). POS N

G-CSF POS N
did POS N
not POS N
prevent POS N
serious POS N
infections. POS N

Only POS N
the POS N
cumulative POS N
days POS N
with POS N
antibiotics POS N
were POS N
fewer POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(median, POS N
0 POS N
v POS N
6 POS N
days; POS N
P POS N
=.006) POS N
than POS N
with POS N
CHOP POS N
alone. POS N

In POS N
389 POS N
eligible POS N
patients, POS N
the POS N
relative POS N
dose POS N
intensities POS N
(RDIs) POS N
of POS N
cyclophosphamide POS N
(median, POS N
96.3% POS N
v POS N
93.9%; POS N
P POS N
=.01) POS N
and POS N
doxorubicin POS N
(median, POS N
95.4% POS N
v POS N
93.3%; POS N
P POS N
=.04) POS N
were POS N
higher POS N
in POS N
patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF. POS N

Only POS N
the POS N
cumulative POS N
days POS N
with POS N
antibiotics POS N
were POS N
fewer POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(median, POS N
0 POS N
v POS N
6 POS N
days; POS N
P POS N
=.006) POS N
than POS N
with POS N
CHOP POS N
alone. POS N

The POS N
complete POS N
response POS N
rates POS N
were POS N
55% POS N
and POS N
52% POS N
for POS N
CHOP POS N
and POS N
CHOP POS N
plus POS N
G-CSF, POS N
respectively POS N
(P POS N
=.63). POS N

Only POS N
the POS N
cumulative POS N
days POS N
with POS N
antibiotics POS N
were POS N
fewer POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(median, POS N
0 POS N
v POS N
6 POS N
days; POS N
P POS N
=.006) POS N
than POS N
with POS N
CHOP POS N
alone. POS N

The POS N
actuarial POS N
overall POS N
survival POS N
at POS N
5 POS N
years POS N
was POS N
22% POS N
with POS N
CHOP POS N
alone, POS N
compared POS N
with POS N
24% POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(P POS N
=.76), POS N
with POS N
a POS N
median POS N
follow-up POS N
of POS N
33 POS N
months. POS N

Only POS N
the POS N
cumulative POS N
days POS N
with POS N
antibiotics POS N
were POS N
fewer POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(median, POS N
0 POS N
v POS N
6 POS N
days; POS N
P POS N
=.006) POS N
than POS N
with POS N
CHOP POS N
alone. POS N

Patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
had POS N
an POS N
identical POS N
incidence POS N
of POS N
infections, POS N
with POS N
World POS N
Health POS N
Organization POS N
grade POS N
3 POS N
to POS N
4 POS N
(34 POS N
of POS N
1,191 POS N
cycles POS N
v POS N
36 POS N
of POS N
1,195 POS N
cycles). POS N

Only POS N
the POS N
cumulative POS N
days POS N
with POS N
antibiotics POS N
were POS N
fewer POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(median, POS N
0 POS N
v POS N
6 POS N
days; POS N
P POS N
=.006) POS N
than POS N
with POS N
CHOP POS N
alone. POS N

The POS N
number POS N
of POS N
hospital POS N
admissions POS N
and POS N
the POS N
number POS N
of POS N
days POS N
in POS N
hospital POS N
were POS N
not POS N
different. POS N

Only POS N
the POS N
cumulative POS N
days POS N
with POS N
antibiotics POS N
were POS N
fewer POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(median, POS N
0 POS N
v POS N
6 POS N
days; POS N
P POS N
=.006) POS N
than POS N
with POS N
CHOP POS N
alone. POS N

In POS N
elderly POS N
patients, POS N
G-CSF POS N
improved POS N
the POS N
RDI POS N
of POS N
CHOP, POS N

Only POS N
the POS N
cumulative POS N
days POS N
with POS N
antibiotics POS N
were POS N
fewer POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(median, POS N
0 POS N
v POS N
6 POS N
days; POS N
P POS N
=.006) POS N
than POS N
with POS N
CHOP POS N
alone. POS N

but POS N
this POS N
did POS N
not POS N
lead POS N
to POS N
a POS N
higher POS N
complete POS N
response POS N
rate POS N
or POS N
better POS N
overall POS N
survival. POS N

Only POS N
the POS N
cumulative POS N
days POS N
with POS N
antibiotics POS N
were POS N
fewer POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(median, POS N
0 POS N
v POS N
6 POS N
days; POS N
P POS N
=.006) POS N
than POS N
with POS N
CHOP POS N
alone. POS N

G-CSF POS N
did POS N
not POS N
prevent POS N
serious POS N
infections. POS N

The POS N
number POS N
of POS N
hospital POS N
admissions POS N
and POS N
the POS N
number POS N
of POS N
days POS N
in POS N
hospital POS N
were POS N
not POS N
different. POS N

In POS N
389 POS N
eligible POS N
patients, POS N
the POS N
relative POS N
dose POS N
intensities POS N
(RDIs) POS N
of POS N
cyclophosphamide POS N
(median, POS N
96.3% POS N
v POS N
93.9%; POS N
P POS N
=.01) POS N
and POS N
doxorubicin POS N
(median, POS N
95.4% POS N
v POS N
93.3%; POS N
P POS N
=.04) POS N
were POS N
higher POS N
in POS N
patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF. POS N

The POS N
number POS N
of POS N
hospital POS N
admissions POS N
and POS N
the POS N
number POS N
of POS N
days POS N
in POS N
hospital POS N
were POS N
not POS N
different. POS N

The POS N
complete POS N
response POS N
rates POS N
were POS N
55% POS N
and POS N
52% POS N
for POS N
CHOP POS N
and POS N
CHOP POS N
plus POS N
G-CSF, POS N
respectively POS N
(P POS N
=.63). POS N

The POS N
number POS N
of POS N
hospital POS N
admissions POS N
and POS N
the POS N
number POS N
of POS N
days POS N
in POS N
hospital POS N
were POS N
not POS N
different. POS N

The POS N
actuarial POS N
overall POS N
survival POS N
at POS N
5 POS N
years POS N
was POS N
22% POS N
with POS N
CHOP POS N
alone, POS N
compared POS N
with POS N
24% POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(P POS N
=.76), POS N
with POS N
a POS N
median POS N
follow-up POS N
of POS N
33 POS N
months. POS N

The POS N
number POS N
of POS N
hospital POS N
admissions POS N
and POS N
the POS N
number POS N
of POS N
days POS N
in POS N
hospital POS N
were POS N
not POS N
different. POS N

Patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
had POS N
an POS N
identical POS N
incidence POS N
of POS N
infections, POS N
with POS N
World POS N
Health POS N
Organization POS N
grade POS N
3 POS N
to POS N
4 POS N
(34 POS N
of POS N
1,191 POS N
cycles POS N
v POS N
36 POS N
of POS N
1,195 POS N
cycles). POS N

The POS N
number POS N
of POS N
hospital POS N
admissions POS N
and POS N
the POS N
number POS N
of POS N
days POS N
in POS N
hospital POS N
were POS N
not POS N
different. POS N

Only POS N
the POS N
cumulative POS N
days POS N
with POS N
antibiotics POS N
were POS N
fewer POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(median, POS N
0 POS N
v POS N
6 POS N
days; POS N
P POS N
=.006) POS N
than POS N
with POS N
CHOP POS N
alone. POS N

The POS N
number POS N
of POS N
hospital POS N
admissions POS N
and POS N
the POS N
number POS N
of POS N
days POS N
in POS N
hospital POS N
were POS N
not POS N
different. POS N

In POS N
elderly POS N
patients, POS N
G-CSF POS N
improved POS N
the POS N
RDI POS N
of POS N
CHOP, POS N

The POS N
number POS N
of POS N
hospital POS N
admissions POS N
and POS N
the POS N
number POS N
of POS N
days POS N
in POS N
hospital POS N
were POS N
not POS N
different. POS N

but POS N
this POS N
did POS N
not POS N
lead POS N
to POS N
a POS N
higher POS N
complete POS N
response POS N
rate POS N
or POS N
better POS N
overall POS N
survival. POS N

The POS N
number POS N
of POS N
hospital POS N
admissions POS N
and POS N
the POS N
number POS N
of POS N
days POS N
in POS N
hospital POS N
were POS N
not POS N
different. POS N

G-CSF POS N
did POS N
not POS N
prevent POS N
serious POS N
infections. POS N

In POS N
elderly POS N
patients, POS N
G-CSF POS N
improved POS N
the POS N
RDI POS N
of POS N
CHOP, POS N

In POS N
389 POS N
eligible POS N
patients, POS N
the POS N
relative POS N
dose POS N
intensities POS N
(RDIs) POS N
of POS N
cyclophosphamide POS N
(median, POS N
96.3% POS N
v POS N
93.9%; POS N
P POS N
=.01) POS N
and POS N
doxorubicin POS N
(median, POS N
95.4% POS N
v POS N
93.3%; POS N
P POS N
=.04) POS N
were POS N
higher POS N
in POS N
patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF. POS N

In POS N
elderly POS N
patients, POS N
G-CSF POS N
improved POS N
the POS N
RDI POS N
of POS N
CHOP, POS N

The POS N
complete POS N
response POS N
rates POS N
were POS N
55% POS N
and POS N
52% POS N
for POS N
CHOP POS N
and POS N
CHOP POS N
plus POS N
G-CSF, POS N
respectively POS N
(P POS N
=.63). POS N

In POS N
elderly POS N
patients, POS N
G-CSF POS N
improved POS N
the POS N
RDI POS N
of POS N
CHOP, POS N

The POS N
actuarial POS N
overall POS N
survival POS N
at POS N
5 POS N
years POS N
was POS N
22% POS N
with POS N
CHOP POS N
alone, POS N
compared POS N
with POS N
24% POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(P POS N
=.76), POS N
with POS N
a POS N
median POS N
follow-up POS N
of POS N
33 POS N
months. POS N

In POS N
elderly POS N
patients, POS N
G-CSF POS N
improved POS N
the POS N
RDI POS N
of POS N
CHOP, POS N

Patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
had POS N
an POS N
identical POS N
incidence POS N
of POS N
infections, POS N
with POS N
World POS N
Health POS N
Organization POS N
grade POS N
3 POS N
to POS N
4 POS N
(34 POS N
of POS N
1,191 POS N
cycles POS N
v POS N
36 POS N
of POS N
1,195 POS N
cycles). POS N

In POS N
elderly POS N
patients, POS N
G-CSF POS N
improved POS N
the POS N
RDI POS N
of POS N
CHOP, POS N

Only POS N
the POS N
cumulative POS N
days POS N
with POS N
antibiotics POS N
were POS N
fewer POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(median, POS N
0 POS N
v POS N
6 POS N
days; POS N
P POS N
=.006) POS N
than POS N
with POS N
CHOP POS N
alone. POS N

In POS N
elderly POS N
patients, POS N
G-CSF POS N
improved POS N
the POS N
RDI POS N
of POS N
CHOP, POS N

The POS N
number POS N
of POS N
hospital POS N
admissions POS N
and POS N
the POS N
number POS N
of POS N
days POS N
in POS N
hospital POS N
were POS N
not POS N
different. POS N

In POS N
elderly POS N
patients, POS N
G-CSF POS N
improved POS N
the POS N
RDI POS N
of POS N
CHOP, POS N

but POS N
this POS N
did POS N
not POS N
lead POS N
to POS N
a POS N
higher POS N
complete POS N
response POS N
rate POS N
or POS N
better POS N
overall POS N
survival. POS N

In POS N
elderly POS N
patients, POS N
G-CSF POS N
improved POS N
the POS N
RDI POS N
of POS N
CHOP, POS N

G-CSF POS N
did POS N
not POS N
prevent POS N
serious POS N
infections. POS N

but POS N
this POS N
did POS N
not POS N
lead POS N
to POS N
a POS N
higher POS N
complete POS N
response POS N
rate POS N
or POS N
better POS N
overall POS N
survival. POS N

In POS N
389 POS N
eligible POS N
patients, POS N
the POS N
relative POS N
dose POS N
intensities POS N
(RDIs) POS N
of POS N
cyclophosphamide POS N
(median, POS N
96.3% POS N
v POS N
93.9%; POS N
P POS N
=.01) POS N
and POS N
doxorubicin POS N
(median, POS N
95.4% POS N
v POS N
93.3%; POS N
P POS N
=.04) POS N
were POS N
higher POS N
in POS N
patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF. POS N

but POS N
this POS N
did POS N
not POS N
lead POS N
to POS N
a POS N
higher POS N
complete POS N
response POS N
rate POS N
or POS N
better POS N
overall POS N
survival. POS N

The POS N
complete POS N
response POS N
rates POS N
were POS N
55% POS N
and POS N
52% POS N
for POS N
CHOP POS N
and POS N
CHOP POS N
plus POS N
G-CSF, POS N
respectively POS N
(P POS N
=.63). POS N

but POS N
this POS N
did POS N
not POS N
lead POS N
to POS N
a POS N
higher POS N
complete POS N
response POS N
rate POS N
or POS N
better POS N
overall POS N
survival. POS N

The POS N
actuarial POS N
overall POS N
survival POS N
at POS N
5 POS N
years POS N
was POS N
22% POS N
with POS N
CHOP POS N
alone, POS N
compared POS N
with POS N
24% POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(P POS N
=.76), POS N
with POS N
a POS N
median POS N
follow-up POS N
of POS N
33 POS N
months. POS N

but POS N
this POS N
did POS N
not POS N
lead POS N
to POS N
a POS N
higher POS N
complete POS N
response POS N
rate POS N
or POS N
better POS N
overall POS N
survival. POS N

Patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
had POS N
an POS N
identical POS N
incidence POS N
of POS N
infections, POS N
with POS N
World POS N
Health POS N
Organization POS N
grade POS N
3 POS N
to POS N
4 POS N
(34 POS N
of POS N
1,191 POS N
cycles POS N
v POS N
36 POS N
of POS N
1,195 POS N
cycles). POS N

but POS N
this POS N
did POS N
not POS N
lead POS N
to POS N
a POS N
higher POS N
complete POS N
response POS N
rate POS N
or POS N
better POS N
overall POS N
survival. POS N

Only POS N
the POS N
cumulative POS N
days POS N
with POS N
antibiotics POS N
were POS N
fewer POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(median, POS N
0 POS N
v POS N
6 POS N
days; POS N
P POS N
=.006) POS N
than POS N
with POS N
CHOP POS N
alone. POS N

but POS N
this POS N
did POS N
not POS N
lead POS N
to POS N
a POS N
higher POS N
complete POS N
response POS N
rate POS N
or POS N
better POS N
overall POS N
survival. POS N

The POS N
number POS N
of POS N
hospital POS N
admissions POS N
and POS N
the POS N
number POS N
of POS N
days POS N
in POS N
hospital POS N
were POS N
not POS N
different. POS N

but POS N
this POS N
did POS N
not POS N
lead POS N
to POS N
a POS N
higher POS N
complete POS N
response POS N
rate POS N
or POS N
better POS N
overall POS N
survival. POS N

In POS N
elderly POS N
patients, POS N
G-CSF POS N
improved POS N
the POS N
RDI POS N
of POS N
CHOP, POS N

but POS N
this POS N
did POS N
not POS N
lead POS N
to POS N
a POS N
higher POS N
complete POS N
response POS N
rate POS N
or POS N
better POS N
overall POS N
survival. POS N

G-CSF POS N
did POS N
not POS N
prevent POS N
serious POS N
infections. POS N

G-CSF POS N
did POS N
not POS N
prevent POS N
serious POS N
infections. POS N

In POS N
389 POS N
eligible POS N
patients, POS N
the POS N
relative POS N
dose POS N
intensities POS N
(RDIs) POS N
of POS N
cyclophosphamide POS N
(median, POS N
96.3% POS N
v POS N
93.9%; POS N
P POS N
=.01) POS N
and POS N
doxorubicin POS N
(median, POS N
95.4% POS N
v POS N
93.3%; POS N
P POS N
=.04) POS N
were POS N
higher POS N
in POS N
patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF. POS N

G-CSF POS N
did POS N
not POS N
prevent POS N
serious POS N
infections. POS N

The POS N
complete POS N
response POS N
rates POS N
were POS N
55% POS N
and POS N
52% POS N
for POS N
CHOP POS N
and POS N
CHOP POS N
plus POS N
G-CSF, POS N
respectively POS N
(P POS N
=.63). POS N

G-CSF POS N
did POS N
not POS N
prevent POS N
serious POS N
infections. POS N

The POS N
actuarial POS N
overall POS N
survival POS N
at POS N
5 POS N
years POS N
was POS N
22% POS N
with POS N
CHOP POS N
alone, POS N
compared POS N
with POS N
24% POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(P POS N
=.76), POS N
with POS N
a POS N
median POS N
follow-up POS N
of POS N
33 POS N
months. POS N

G-CSF POS N
did POS N
not POS N
prevent POS N
serious POS N
infections. POS N

Patients POS N
treated POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
had POS N
an POS N
identical POS N
incidence POS N
of POS N
infections, POS N
with POS N
World POS N
Health POS N
Organization POS N
grade POS N
3 POS N
to POS N
4 POS N
(34 POS N
of POS N
1,191 POS N
cycles POS N
v POS N
36 POS N
of POS N
1,195 POS N
cycles). POS N

G-CSF POS N
did POS N
not POS N
prevent POS N
serious POS N
infections. POS N

Only POS N
the POS N
cumulative POS N
days POS N
with POS N
antibiotics POS N
were POS N
fewer POS N
with POS N
CHOP POS N
plus POS N
G-CSF POS N
(median, POS N
0 POS N
v POS N
6 POS N
days; POS N
P POS N
=.006) POS N
than POS N
with POS N
CHOP POS N
alone. POS N

G-CSF POS N
did POS N
not POS N
prevent POS N
serious POS N
infections. POS N

The POS N
number POS N
of POS N
hospital POS N
admissions POS N
and POS N
the POS N
number POS N
of POS N
days POS N
in POS N
hospital POS N
were POS N
not POS N
different. POS N

G-CSF POS N
did POS N
not POS N
prevent POS N
serious POS N
infections. POS N

In POS N
elderly POS N
patients, POS N
G-CSF POS N
improved POS N
the POS N
RDI POS N
of POS N
CHOP, POS N

G-CSF POS N
did POS N
not POS N
prevent POS N
serious POS N
infections. POS N

but POS N
this POS N
did POS N
not POS N
lead POS N
to POS N
a POS N
higher POS N
complete POS N
response POS N
rate POS N
or POS N
better POS N
overall POS N
survival. POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

eyes POS N
in POS N
the POS N
SLT POS N
and POS N
the POS N
travoprost POS N
groups POS N
achieved POS N
a POS N
significant POS N
reduction POS N
in POS N
IOP POS N
compared POS N
with POS N
the POS N
baseline POS N
IOP POS N
values POS N
(-3.7 mm POS N
Hg POS N
[P = 0.002] POS N
vs POS N
-4.1 mm POS N
Hg POS N
[P < 0.001], POS N
respectively). POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

Ninety-six POS N
percent POS N
of POS N
NTG POS N
eyes POS N
in POS N
the POS N
travoprost POS N
group, POS N
and POS N
82% POS N
of POS N
eyes POS N
in POS N
the POS N
SLT POS N
group POS N
had POS N
IOP POS N
fluctuations POS N
<3 mm POS N
Hg POS N
(P = 0.01). POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

Success POS N
in POS N
fluctuation POS N
reduction POS N
was POS N
75% POS N
and POS N
92% POS N
for POS N
the POS N
SLT POS N
and POS N
travoprost POS N
groups, POS N
respectively POS N
(P = 0.005). POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

the POS N
SLT's POS N
effect POS N
was POS N
significant POS N
only POS N
during POS N
the POS N
nighttime. POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

The POS N
effect POS N
of POS N
travoprost POS N
on POS N
IOP POS N
reduction POS N
in POS N
POAG POS N
and POS N
NTG POS N
patients POS N
was POS N
significant POS N
both POS N
during POS N
the POS N
daytime POS N
and POS N
the POS N
nighttime, POS N

travoprost POS N
better POS N
controls POS N
IOP POS N
fluctuations POS N
than POS N
SLT, POS N
especially POS N
during POS N
the POS N
daytime. POS N

Both POS N
travoprost POS N
and POS N
SLT POS N
can POS N
significantly POS N
reduce POS N
the POS N
IOP POS N
in POS N
patients POS N
with POS N
POAG POS N
and POS N
NTG. POS N

Methionine POS N
aminopeptidase POS N
2 POS N
(MetAP2) POS N
inhibition POS N
has POS N
been POS N
shown POS N
to POS N
result POS N
in POS N
significant POS N
weight POS N
loss POS N
and POS N
improved POS N
glucose POS N
control. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
across POS N
all POS N
doses POS N
with POS N
most POS N
frequent POS N
adverse POS N
events POS N
of POS N
mild POS N
headache POS N
and POS N
procedural-related POS N
irritation. POS N

Methionine POS N
aminopeptidase POS N
2 POS N
(MetAP2) POS N
inhibition POS N
has POS N
been POS N
shown POS N
to POS N
result POS N
in POS N
significant POS N
weight POS N
loss POS N
and POS N
improved POS N
glucose POS N
control. POS N

All POS N
doses POS N
of POS N
ZGN-1061 POS N
were POS N
rapidly POS N
absorbed POS N
and POS N
cleared, POS N
resulting POS N
in POS N
short POS N
duration POS N
of POS N
exposure POS N
that POS N
is POS N
anticipated POS N
to POS N
minimize POS N
potential POS N
off-drug POS N
target POS N
risks. POS N

Methionine POS N
aminopeptidase POS N
2 POS N
(MetAP2) POS N
inhibition POS N
has POS N
been POS N
shown POS N
to POS N
result POS N
in POS N
significant POS N
weight POS N
loss POS N
and POS N
improved POS N
glucose POS N
control. POS N

Safety POS N
observations POS N
were POS N
consistent POS N
with POS N
SAD POS N
findings. POS N

Methionine POS N
aminopeptidase POS N
2 POS N
(MetAP2) POS N
inhibition POS N
has POS N
been POS N
shown POS N
to POS N
result POS N
in POS N
significant POS N
weight POS N
loss POS N
and POS N
improved POS N
glucose POS N
control. POS N

Efficacy POS N
measures POS N
in POS N
the POS N
MAD POS N
phase POS N
indicated POS N
trends POS N
for POS N
weight POS N
change POS N
(-1.5 POS N
kg POS N
total POS N
ZGN-1061 POS N
vs POS N
-0.2 POS N
kg POS N
placebo) POS N
and POS N
other POS N
biomarker POS N
changes. POS N

Methionine POS N
aminopeptidase POS N
2 POS N
(MetAP2) POS N
inhibition POS N
has POS N
been POS N
shown POS N
to POS N
result POS N
in POS N
significant POS N
weight POS N
loss POS N
and POS N
improved POS N
glucose POS N
control. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
with POS N
no POS N
safety POS N
signals POS N
in POS N
all POS N
doses POS N
tested. POS N

Methionine POS N
aminopeptidase POS N
2 POS N
(MetAP2) POS N
inhibition POS N
has POS N
been POS N
shown POS N
to POS N
result POS N
in POS N
significant POS N
weight POS N
loss POS N
and POS N
improved POS N
glucose POS N
control. POS N

the POS N
desired POS N
pharmacokinetic POS N
profile POS N
and POS N
preliminary POS N
efficacy POS N
observations POS N
with POS N
ZGN-1061 POS N
support POS N
evaluation POS N
in POS N
larger POS N
and POS N
longer POS N
clinical POS N
trials. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
across POS N
all POS N
doses POS N
with POS N
most POS N
frequent POS N
adverse POS N
events POS N
of POS N
mild POS N
headache POS N
and POS N
procedural-related POS N
irritation. POS N

Methionine POS N
aminopeptidase POS N
2 POS N
(MetAP2) POS N
inhibition POS N
has POS N
been POS N
shown POS N
to POS N
result POS N
in POS N
significant POS N
weight POS N
loss POS N
and POS N
improved POS N
glucose POS N
control. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
across POS N
all POS N
doses POS N
with POS N
most POS N
frequent POS N
adverse POS N
events POS N
of POS N
mild POS N
headache POS N
and POS N
procedural-related POS N
irritation. POS N

All POS N
doses POS N
of POS N
ZGN-1061 POS N
were POS N
rapidly POS N
absorbed POS N
and POS N
cleared, POS N
resulting POS N
in POS N
short POS N
duration POS N
of POS N
exposure POS N
that POS N
is POS N
anticipated POS N
to POS N
minimize POS N
potential POS N
off-drug POS N
target POS N
risks. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
across POS N
all POS N
doses POS N
with POS N
most POS N
frequent POS N
adverse POS N
events POS N
of POS N
mild POS N
headache POS N
and POS N
procedural-related POS N
irritation. POS N

Safety POS N
observations POS N
were POS N
consistent POS N
with POS N
SAD POS N
findings. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
across POS N
all POS N
doses POS N
with POS N
most POS N
frequent POS N
adverse POS N
events POS N
of POS N
mild POS N
headache POS N
and POS N
procedural-related POS N
irritation. POS N

Efficacy POS N
measures POS N
in POS N
the POS N
MAD POS N
phase POS N
indicated POS N
trends POS N
for POS N
weight POS N
change POS N
(-1.5 POS N
kg POS N
total POS N
ZGN-1061 POS N
vs POS N
-0.2 POS N
kg POS N
placebo) POS N
and POS N
other POS N
biomarker POS N
changes. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
across POS N
all POS N
doses POS N
with POS N
most POS N
frequent POS N
adverse POS N
events POS N
of POS N
mild POS N
headache POS N
and POS N
procedural-related POS N
irritation. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
with POS N
no POS N
safety POS N
signals POS N
in POS N
all POS N
doses POS N
tested. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
across POS N
all POS N
doses POS N
with POS N
most POS N
frequent POS N
adverse POS N
events POS N
of POS N
mild POS N
headache POS N
and POS N
procedural-related POS N
irritation. POS N

the POS N
desired POS N
pharmacokinetic POS N
profile POS N
and POS N
preliminary POS N
efficacy POS N
observations POS N
with POS N
ZGN-1061 POS N
support POS N
evaluation POS N
in POS N
larger POS N
and POS N
longer POS N
clinical POS N
trials. POS N

All POS N
doses POS N
of POS N
ZGN-1061 POS N
were POS N
rapidly POS N
absorbed POS N
and POS N
cleared, POS N
resulting POS N
in POS N
short POS N
duration POS N
of POS N
exposure POS N
that POS N
is POS N
anticipated POS N
to POS N
minimize POS N
potential POS N
off-drug POS N
target POS N
risks. POS N

Methionine POS N
aminopeptidase POS N
2 POS N
(MetAP2) POS N
inhibition POS N
has POS N
been POS N
shown POS N
to POS N
result POS N
in POS N
significant POS N
weight POS N
loss POS N
and POS N
improved POS N
glucose POS N
control. POS N

All POS N
doses POS N
of POS N
ZGN-1061 POS N
were POS N
rapidly POS N
absorbed POS N
and POS N
cleared, POS N
resulting POS N
in POS N
short POS N
duration POS N
of POS N
exposure POS N
that POS N
is POS N
anticipated POS N
to POS N
minimize POS N
potential POS N
off-drug POS N
target POS N
risks. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
across POS N
all POS N
doses POS N
with POS N
most POS N
frequent POS N
adverse POS N
events POS N
of POS N
mild POS N
headache POS N
and POS N
procedural-related POS N
irritation. POS N

All POS N
doses POS N
of POS N
ZGN-1061 POS N
were POS N
rapidly POS N
absorbed POS N
and POS N
cleared, POS N
resulting POS N
in POS N
short POS N
duration POS N
of POS N
exposure POS N
that POS N
is POS N
anticipated POS N
to POS N
minimize POS N
potential POS N
off-drug POS N
target POS N
risks. POS N

Safety POS N
observations POS N
were POS N
consistent POS N
with POS N
SAD POS N
findings. POS N

All POS N
doses POS N
of POS N
ZGN-1061 POS N
were POS N
rapidly POS N
absorbed POS N
and POS N
cleared, POS N
resulting POS N
in POS N
short POS N
duration POS N
of POS N
exposure POS N
that POS N
is POS N
anticipated POS N
to POS N
minimize POS N
potential POS N
off-drug POS N
target POS N
risks. POS N

Efficacy POS N
measures POS N
in POS N
the POS N
MAD POS N
phase POS N
indicated POS N
trends POS N
for POS N
weight POS N
change POS N
(-1.5 POS N
kg POS N
total POS N
ZGN-1061 POS N
vs POS N
-0.2 POS N
kg POS N
placebo) POS N
and POS N
other POS N
biomarker POS N
changes. POS N

All POS N
doses POS N
of POS N
ZGN-1061 POS N
were POS N
rapidly POS N
absorbed POS N
and POS N
cleared, POS N
resulting POS N
in POS N
short POS N
duration POS N
of POS N
exposure POS N
that POS N
is POS N
anticipated POS N
to POS N
minimize POS N
potential POS N
off-drug POS N
target POS N
risks. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
with POS N
no POS N
safety POS N
signals POS N
in POS N
all POS N
doses POS N
tested. POS N

All POS N
doses POS N
of POS N
ZGN-1061 POS N
were POS N
rapidly POS N
absorbed POS N
and POS N
cleared, POS N
resulting POS N
in POS N
short POS N
duration POS N
of POS N
exposure POS N
that POS N
is POS N
anticipated POS N
to POS N
minimize POS N
potential POS N
off-drug POS N
target POS N
risks. POS N

the POS N
desired POS N
pharmacokinetic POS N
profile POS N
and POS N
preliminary POS N
efficacy POS N
observations POS N
with POS N
ZGN-1061 POS N
support POS N
evaluation POS N
in POS N
larger POS N
and POS N
longer POS N
clinical POS N
trials. POS N

Safety POS N
observations POS N
were POS N
consistent POS N
with POS N
SAD POS N
findings. POS N

Methionine POS N
aminopeptidase POS N
2 POS N
(MetAP2) POS N
inhibition POS N
has POS N
been POS N
shown POS N
to POS N
result POS N
in POS N
significant POS N
weight POS N
loss POS N
and POS N
improved POS N
glucose POS N
control. POS N

Safety POS N
observations POS N
were POS N
consistent POS N
with POS N
SAD POS N
findings. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
across POS N
all POS N
doses POS N
with POS N
most POS N
frequent POS N
adverse POS N
events POS N
of POS N
mild POS N
headache POS N
and POS N
procedural-related POS N
irritation. POS N

Safety POS N
observations POS N
were POS N
consistent POS N
with POS N
SAD POS N
findings. POS N

All POS N
doses POS N
of POS N
ZGN-1061 POS N
were POS N
rapidly POS N
absorbed POS N
and POS N
cleared, POS N
resulting POS N
in POS N
short POS N
duration POS N
of POS N
exposure POS N
that POS N
is POS N
anticipated POS N
to POS N
minimize POS N
potential POS N
off-drug POS N
target POS N
risks. POS N

Safety POS N
observations POS N
were POS N
consistent POS N
with POS N
SAD POS N
findings. POS N

Efficacy POS N
measures POS N
in POS N
the POS N
MAD POS N
phase POS N
indicated POS N
trends POS N
for POS N
weight POS N
change POS N
(-1.5 POS N
kg POS N
total POS N
ZGN-1061 POS N
vs POS N
-0.2 POS N
kg POS N
placebo) POS N
and POS N
other POS N
biomarker POS N
changes. POS N

Safety POS N
observations POS N
were POS N
consistent POS N
with POS N
SAD POS N
findings. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
with POS N
no POS N
safety POS N
signals POS N
in POS N
all POS N
doses POS N
tested. POS N

Safety POS N
observations POS N
were POS N
consistent POS N
with POS N
SAD POS N
findings. POS N

the POS N
desired POS N
pharmacokinetic POS N
profile POS N
and POS N
preliminary POS N
efficacy POS N
observations POS N
with POS N
ZGN-1061 POS N
support POS N
evaluation POS N
in POS N
larger POS N
and POS N
longer POS N
clinical POS N
trials. POS N

Efficacy POS N
measures POS N
in POS N
the POS N
MAD POS N
phase POS N
indicated POS N
trends POS N
for POS N
weight POS N
change POS N
(-1.5 POS N
kg POS N
total POS N
ZGN-1061 POS N
vs POS N
-0.2 POS N
kg POS N
placebo) POS N
and POS N
other POS N
biomarker POS N
changes. POS N

Methionine POS N
aminopeptidase POS N
2 POS N
(MetAP2) POS N
inhibition POS N
has POS N
been POS N
shown POS N
to POS N
result POS N
in POS N
significant POS N
weight POS N
loss POS N
and POS N
improved POS N
glucose POS N
control. POS N

Efficacy POS N
measures POS N
in POS N
the POS N
MAD POS N
phase POS N
indicated POS N
trends POS N
for POS N
weight POS N
change POS N
(-1.5 POS N
kg POS N
total POS N
ZGN-1061 POS N
vs POS N
-0.2 POS N
kg POS N
placebo) POS N
and POS N
other POS N
biomarker POS N
changes. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
across POS N
all POS N
doses POS N
with POS N
most POS N
frequent POS N
adverse POS N
events POS N
of POS N
mild POS N
headache POS N
and POS N
procedural-related POS N
irritation. POS N

Efficacy POS N
measures POS N
in POS N
the POS N
MAD POS N
phase POS N
indicated POS N
trends POS N
for POS N
weight POS N
change POS N
(-1.5 POS N
kg POS N
total POS N
ZGN-1061 POS N
vs POS N
-0.2 POS N
kg POS N
placebo) POS N
and POS N
other POS N
biomarker POS N
changes. POS N

All POS N
doses POS N
of POS N
ZGN-1061 POS N
were POS N
rapidly POS N
absorbed POS N
and POS N
cleared, POS N
resulting POS N
in POS N
short POS N
duration POS N
of POS N
exposure POS N
that POS N
is POS N
anticipated POS N
to POS N
minimize POS N
potential POS N
off-drug POS N
target POS N
risks. POS N

Efficacy POS N
measures POS N
in POS N
the POS N
MAD POS N
phase POS N
indicated POS N
trends POS N
for POS N
weight POS N
change POS N
(-1.5 POS N
kg POS N
total POS N
ZGN-1061 POS N
vs POS N
-0.2 POS N
kg POS N
placebo) POS N
and POS N
other POS N
biomarker POS N
changes. POS N

Safety POS N
observations POS N
were POS N
consistent POS N
with POS N
SAD POS N
findings. POS N

Efficacy POS N
measures POS N
in POS N
the POS N
MAD POS N
phase POS N
indicated POS N
trends POS N
for POS N
weight POS N
change POS N
(-1.5 POS N
kg POS N
total POS N
ZGN-1061 POS N
vs POS N
-0.2 POS N
kg POS N
placebo) POS N
and POS N
other POS N
biomarker POS N
changes. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
with POS N
no POS N
safety POS N
signals POS N
in POS N
all POS N
doses POS N
tested. POS N

Efficacy POS N
measures POS N
in POS N
the POS N
MAD POS N
phase POS N
indicated POS N
trends POS N
for POS N
weight POS N
change POS N
(-1.5 POS N
kg POS N
total POS N
ZGN-1061 POS N
vs POS N
-0.2 POS N
kg POS N
placebo) POS N
and POS N
other POS N
biomarker POS N
changes. POS N

the POS N
desired POS N
pharmacokinetic POS N
profile POS N
and POS N
preliminary POS N
efficacy POS N
observations POS N
with POS N
ZGN-1061 POS N
support POS N
evaluation POS N
in POS N
larger POS N
and POS N
longer POS N
clinical POS N
trials. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
with POS N
no POS N
safety POS N
signals POS N
in POS N
all POS N
doses POS N
tested. POS N

Methionine POS N
aminopeptidase POS N
2 POS N
(MetAP2) POS N
inhibition POS N
has POS N
been POS N
shown POS N
to POS N
result POS N
in POS N
significant POS N
weight POS N
loss POS N
and POS N
improved POS N
glucose POS N
control. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
with POS N
no POS N
safety POS N
signals POS N
in POS N
all POS N
doses POS N
tested. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
across POS N
all POS N
doses POS N
with POS N
most POS N
frequent POS N
adverse POS N
events POS N
of POS N
mild POS N
headache POS N
and POS N
procedural-related POS N
irritation. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
with POS N
no POS N
safety POS N
signals POS N
in POS N
all POS N
doses POS N
tested. POS N

All POS N
doses POS N
of POS N
ZGN-1061 POS N
were POS N
rapidly POS N
absorbed POS N
and POS N
cleared, POS N
resulting POS N
in POS N
short POS N
duration POS N
of POS N
exposure POS N
that POS N
is POS N
anticipated POS N
to POS N
minimize POS N
potential POS N
off-drug POS N
target POS N
risks. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
with POS N
no POS N
safety POS N
signals POS N
in POS N
all POS N
doses POS N
tested. POS N

Safety POS N
observations POS N
were POS N
consistent POS N
with POS N
SAD POS N
findings. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
with POS N
no POS N
safety POS N
signals POS N
in POS N
all POS N
doses POS N
tested. POS N

Efficacy POS N
measures POS N
in POS N
the POS N
MAD POS N
phase POS N
indicated POS N
trends POS N
for POS N
weight POS N
change POS N
(-1.5 POS N
kg POS N
total POS N
ZGN-1061 POS N
vs POS N
-0.2 POS N
kg POS N
placebo) POS N
and POS N
other POS N
biomarker POS N
changes. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
with POS N
no POS N
safety POS N
signals POS N
in POS N
all POS N
doses POS N
tested. POS N

the POS N
desired POS N
pharmacokinetic POS N
profile POS N
and POS N
preliminary POS N
efficacy POS N
observations POS N
with POS N
ZGN-1061 POS N
support POS N
evaluation POS N
in POS N
larger POS N
and POS N
longer POS N
clinical POS N
trials. POS N

the POS N
desired POS N
pharmacokinetic POS N
profile POS N
and POS N
preliminary POS N
efficacy POS N
observations POS N
with POS N
ZGN-1061 POS N
support POS N
evaluation POS N
in POS N
larger POS N
and POS N
longer POS N
clinical POS N
trials. POS N

Methionine POS N
aminopeptidase POS N
2 POS N
(MetAP2) POS N
inhibition POS N
has POS N
been POS N
shown POS N
to POS N
result POS N
in POS N
significant POS N
weight POS N
loss POS N
and POS N
improved POS N
glucose POS N
control. POS N

the POS N
desired POS N
pharmacokinetic POS N
profile POS N
and POS N
preliminary POS N
efficacy POS N
observations POS N
with POS N
ZGN-1061 POS N
support POS N
evaluation POS N
in POS N
larger POS N
and POS N
longer POS N
clinical POS N
trials. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
across POS N
all POS N
doses POS N
with POS N
most POS N
frequent POS N
adverse POS N
events POS N
of POS N
mild POS N
headache POS N
and POS N
procedural-related POS N
irritation. POS N

the POS N
desired POS N
pharmacokinetic POS N
profile POS N
and POS N
preliminary POS N
efficacy POS N
observations POS N
with POS N
ZGN-1061 POS N
support POS N
evaluation POS N
in POS N
larger POS N
and POS N
longer POS N
clinical POS N
trials. POS N

All POS N
doses POS N
of POS N
ZGN-1061 POS N
were POS N
rapidly POS N
absorbed POS N
and POS N
cleared, POS N
resulting POS N
in POS N
short POS N
duration POS N
of POS N
exposure POS N
that POS N
is POS N
anticipated POS N
to POS N
minimize POS N
potential POS N
off-drug POS N
target POS N
risks. POS N

the POS N
desired POS N
pharmacokinetic POS N
profile POS N
and POS N
preliminary POS N
efficacy POS N
observations POS N
with POS N
ZGN-1061 POS N
support POS N
evaluation POS N
in POS N
larger POS N
and POS N
longer POS N
clinical POS N
trials. POS N

Safety POS N
observations POS N
were POS N
consistent POS N
with POS N
SAD POS N
findings. POS N

the POS N
desired POS N
pharmacokinetic POS N
profile POS N
and POS N
preliminary POS N
efficacy POS N
observations POS N
with POS N
ZGN-1061 POS N
support POS N
evaluation POS N
in POS N
larger POS N
and POS N
longer POS N
clinical POS N
trials. POS N

Efficacy POS N
measures POS N
in POS N
the POS N
MAD POS N
phase POS N
indicated POS N
trends POS N
for POS N
weight POS N
change POS N
(-1.5 POS N
kg POS N
total POS N
ZGN-1061 POS N
vs POS N
-0.2 POS N
kg POS N
placebo) POS N
and POS N
other POS N
biomarker POS N
changes. POS N

the POS N
desired POS N
pharmacokinetic POS N
profile POS N
and POS N
preliminary POS N
efficacy POS N
observations POS N
with POS N
ZGN-1061 POS N
support POS N
evaluation POS N
in POS N
larger POS N
and POS N
longer POS N
clinical POS N
trials. POS N

ZGN-1061 POS N
was POS N
well POS N
tolerated POS N
with POS N
no POS N
safety POS N
signals POS N
in POS N
all POS N
doses POS N
tested. POS N

Complete POS N
success POS N
(defined POS N
as POS N
IOP POS N
<16 POS N
mmHg POS N
on POS N
no POS N
medication) POS N
could POS N
be POS N
achieved POS N
in POS N
85% POS N
eyes POS N
in POS N
study POS N
group POS N
while POS N
it POS N
was POS N
60% POS N
in POS N
control POS N
group POS N
(P POS N
= POS N
0.04). POS N

IOP POS N
reduced POS N
by POS N
71.1% POS N
in POS N
study POS N
group POS N
from POS N
41.9 POS N
± POS N
10.6 POS N
to POS N
12.1 POS N
± POS N
2.7 POS N
mmHg POS N
and POS N
from POS N
40.5 POS N
± POS N
8.5 POS N
to POS N
12.8 POS N
± POS N
4.5 POS N
mmHg POS N
in POS N
control POS N
group, POS N
a POS N
decline POS N
of POS N
68.29%. POS N

Complete POS N
success POS N
(defined POS N
as POS N
IOP POS N
<16 POS N
mmHg POS N
on POS N
no POS N
medication) POS N
could POS N
be POS N
achieved POS N
in POS N
85% POS N
eyes POS N
in POS N
study POS N
group POS N
while POS N
it POS N
was POS N
60% POS N
in POS N
control POS N
group POS N
(P POS N
= POS N
0.04). POS N

Blebs POS N
in POS N
AMT POS N
group POS N
showed POS N
better POS N
bleb POS N
morphology POS N
in POS N
terms POS N
of POS N
significantly POS N
better POS N
extent POS N
(E3) POS N
on POS N
day POS N
1 POS N
(P POS N
= POS N
0.03) POS N
and POS N
better POS N
height POS N
(H2 POS N
and POS N
H3) POS N
(P POS N
= POS N
0.04), POS N
according POS N
to POS N
the POS N
Indiana POS N
Bleb POS N
Appearance POS N
Grading POS N
Scale, POS N
at POS N
all POS N
follow-up POS N
visits POS N
along POS N
with POS N
normal POS N
vascularity. POS N

Complete POS N
success POS N
(defined POS N
as POS N
IOP POS N
<16 POS N
mmHg POS N
on POS N
no POS N
medication) POS N
could POS N
be POS N
achieved POS N
in POS N
85% POS N
eyes POS N
in POS N
study POS N
group POS N
while POS N
it POS N
was POS N
60% POS N
in POS N
control POS N
group POS N
(P POS N
= POS N
0.04). POS N

The POS N
study POS N
group POS N
required POS N
significantly POS N
lesser POS N
(P POS N
= POS N
0.03) POS N
bleb POS N
needlings POS N
as POS N
compared POS N
to POS N
control POS N
group. POS N

Complete POS N
success POS N
(defined POS N
as POS N
IOP POS N
<16 POS N
mmHg POS N
on POS N
no POS N
medication) POS N
could POS N
be POS N
achieved POS N
in POS N
85% POS N
eyes POS N
in POS N
study POS N
group POS N
while POS N
it POS N
was POS N
60% POS N
in POS N
control POS N
group POS N
(P POS N
= POS N
0.04). POS N

Amnion POS N
enhanced POS N
the POS N
efficacy POS N
of POS N
MMC-modulated POS N
trabeculectomy POS N
in POS N
terms POS N
of POS N
eyes POS N
with POS N
complete POS N
success POS N
and POS N
lesser POS N
interventions POS N
such POS N
as POS N
bleb POS N
needling. POS N

Complete POS N
success POS N
(defined POS N
as POS N
IOP POS N
<16 POS N
mmHg POS N
on POS N
no POS N
medication) POS N
could POS N
be POS N
achieved POS N
in POS N
85% POS N
eyes POS N
in POS N
study POS N
group POS N
while POS N
it POS N
was POS N
60% POS N
in POS N
control POS N
group POS N
(P POS N
= POS N
0.04). POS N

This POS N
reiterates POS N
the POS N
role POS N
of POS N
amnion POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
bleb POS N
modulator. POS N

IOP POS N
reduced POS N
by POS N
71.1% POS N
in POS N
study POS N
group POS N
from POS N
41.9 POS N
± POS N
10.6 POS N
to POS N
12.1 POS N
± POS N
2.7 POS N
mmHg POS N
and POS N
from POS N
40.5 POS N
± POS N
8.5 POS N
to POS N
12.8 POS N
± POS N
4.5 POS N
mmHg POS N
in POS N
control POS N
group, POS N
a POS N
decline POS N
of POS N
68.29%. POS N

Complete POS N
success POS N
(defined POS N
as POS N
IOP POS N
<16 POS N
mmHg POS N
on POS N
no POS N
medication) POS N
could POS N
be POS N
achieved POS N
in POS N
85% POS N
eyes POS N
in POS N
study POS N
group POS N
while POS N
it POS N
was POS N
60% POS N
in POS N
control POS N
group POS N
(P POS N
= POS N
0.04). POS N

IOP POS N
reduced POS N
by POS N
71.1% POS N
in POS N
study POS N
group POS N
from POS N
41.9 POS N
± POS N
10.6 POS N
to POS N
12.1 POS N
± POS N
2.7 POS N
mmHg POS N
and POS N
from POS N
40.5 POS N
± POS N
8.5 POS N
to POS N
12.8 POS N
± POS N
4.5 POS N
mmHg POS N
in POS N
control POS N
group, POS N
a POS N
decline POS N
of POS N
68.29%. POS N

Blebs POS N
in POS N
AMT POS N
group POS N
showed POS N
better POS N
bleb POS N
morphology POS N
in POS N
terms POS N
of POS N
significantly POS N
better POS N
extent POS N
(E3) POS N
on POS N
day POS N
1 POS N
(P POS N
= POS N
0.03) POS N
and POS N
better POS N
height POS N
(H2 POS N
and POS N
H3) POS N
(P POS N
= POS N
0.04), POS N
according POS N
to POS N
the POS N
Indiana POS N
Bleb POS N
Appearance POS N
Grading POS N
Scale, POS N
at POS N
all POS N
follow-up POS N
visits POS N
along POS N
with POS N
normal POS N
vascularity. POS N

IOP POS N
reduced POS N
by POS N
71.1% POS N
in POS N
study POS N
group POS N
from POS N
41.9 POS N
± POS N
10.6 POS N
to POS N
12.1 POS N
± POS N
2.7 POS N
mmHg POS N
and POS N
from POS N
40.5 POS N
± POS N
8.5 POS N
to POS N
12.8 POS N
± POS N
4.5 POS N
mmHg POS N
in POS N
control POS N
group, POS N
a POS N
decline POS N
of POS N
68.29%. POS N

The POS N
study POS N
group POS N
required POS N
significantly POS N
lesser POS N
(P POS N
= POS N
0.03) POS N
bleb POS N
needlings POS N
as POS N
compared POS N
to POS N
control POS N
group. POS N

IOP POS N
reduced POS N
by POS N
71.1% POS N
in POS N
study POS N
group POS N
from POS N
41.9 POS N
± POS N
10.6 POS N
to POS N
12.1 POS N
± POS N
2.7 POS N
mmHg POS N
and POS N
from POS N
40.5 POS N
± POS N
8.5 POS N
to POS N
12.8 POS N
± POS N
4.5 POS N
mmHg POS N
in POS N
control POS N
group, POS N
a POS N
decline POS N
of POS N
68.29%. POS N

Amnion POS N
enhanced POS N
the POS N
efficacy POS N
of POS N
MMC-modulated POS N
trabeculectomy POS N
in POS N
terms POS N
of POS N
eyes POS N
with POS N
complete POS N
success POS N
and POS N
lesser POS N
interventions POS N
such POS N
as POS N
bleb POS N
needling. POS N

IOP POS N
reduced POS N
by POS N
71.1% POS N
in POS N
study POS N
group POS N
from POS N
41.9 POS N
± POS N
10.6 POS N
to POS N
12.1 POS N
± POS N
2.7 POS N
mmHg POS N
and POS N
from POS N
40.5 POS N
± POS N
8.5 POS N
to POS N
12.8 POS N
± POS N
4.5 POS N
mmHg POS N
in POS N
control POS N
group, POS N
a POS N
decline POS N
of POS N
68.29%. POS N

This POS N
reiterates POS N
the POS N
role POS N
of POS N
amnion POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
bleb POS N
modulator. POS N

Blebs POS N
in POS N
AMT POS N
group POS N
showed POS N
better POS N
bleb POS N
morphology POS N
in POS N
terms POS N
of POS N
significantly POS N
better POS N
extent POS N
(E3) POS N
on POS N
day POS N
1 POS N
(P POS N
= POS N
0.03) POS N
and POS N
better POS N
height POS N
(H2 POS N
and POS N
H3) POS N
(P POS N
= POS N
0.04), POS N
according POS N
to POS N
the POS N
Indiana POS N
Bleb POS N
Appearance POS N
Grading POS N
Scale, POS N
at POS N
all POS N
follow-up POS N
visits POS N
along POS N
with POS N
normal POS N
vascularity. POS N

Complete POS N
success POS N
(defined POS N
as POS N
IOP POS N
<16 POS N
mmHg POS N
on POS N
no POS N
medication) POS N
could POS N
be POS N
achieved POS N
in POS N
85% POS N
eyes POS N
in POS N
study POS N
group POS N
while POS N
it POS N
was POS N
60% POS N
in POS N
control POS N
group POS N
(P POS N
= POS N
0.04). POS N

Blebs POS N
in POS N
AMT POS N
group POS N
showed POS N
better POS N
bleb POS N
morphology POS N
in POS N
terms POS N
of POS N
significantly POS N
better POS N
extent POS N
(E3) POS N
on POS N
day POS N
1 POS N
(P POS N
= POS N
0.03) POS N
and POS N
better POS N
height POS N
(H2 POS N
and POS N
H3) POS N
(P POS N
= POS N
0.04), POS N
according POS N
to POS N
the POS N
Indiana POS N
Bleb POS N
Appearance POS N
Grading POS N
Scale, POS N
at POS N
all POS N
follow-up POS N
visits POS N
along POS N
with POS N
normal POS N
vascularity. POS N

IOP POS N
reduced POS N
by POS N
71.1% POS N
in POS N
study POS N
group POS N
from POS N
41.9 POS N
± POS N
10.6 POS N
to POS N
12.1 POS N
± POS N
2.7 POS N
mmHg POS N
and POS N
from POS N
40.5 POS N
± POS N
8.5 POS N
to POS N
12.8 POS N
± POS N
4.5 POS N
mmHg POS N
in POS N
control POS N
group, POS N
a POS N
decline POS N
of POS N
68.29%. POS N

Blebs POS N
in POS N
AMT POS N
group POS N
showed POS N
better POS N
bleb POS N
morphology POS N
in POS N
terms POS N
of POS N
significantly POS N
better POS N
extent POS N
(E3) POS N
on POS N
day POS N
1 POS N
(P POS N
= POS N
0.03) POS N
and POS N
better POS N
height POS N
(H2 POS N
and POS N
H3) POS N
(P POS N
= POS N
0.04), POS N
according POS N
to POS N
the POS N
Indiana POS N
Bleb POS N
Appearance POS N
Grading POS N
Scale, POS N
at POS N
all POS N
follow-up POS N
visits POS N
along POS N
with POS N
normal POS N
vascularity. POS N

The POS N
study POS N
group POS N
required POS N
significantly POS N
lesser POS N
(P POS N
= POS N
0.03) POS N
bleb POS N
needlings POS N
as POS N
compared POS N
to POS N
control POS N
group. POS N

Blebs POS N
in POS N
AMT POS N
group POS N
showed POS N
better POS N
bleb POS N
morphology POS N
in POS N
terms POS N
of POS N
significantly POS N
better POS N
extent POS N
(E3) POS N
on POS N
day POS N
1 POS N
(P POS N
= POS N
0.03) POS N
and POS N
better POS N
height POS N
(H2 POS N
and POS N
H3) POS N
(P POS N
= POS N
0.04), POS N
according POS N
to POS N
the POS N
Indiana POS N
Bleb POS N
Appearance POS N
Grading POS N
Scale, POS N
at POS N
all POS N
follow-up POS N
visits POS N
along POS N
with POS N
normal POS N
vascularity. POS N

Amnion POS N
enhanced POS N
the POS N
efficacy POS N
of POS N
MMC-modulated POS N
trabeculectomy POS N
in POS N
terms POS N
of POS N
eyes POS N
with POS N
complete POS N
success POS N
and POS N
lesser POS N
interventions POS N
such POS N
as POS N
bleb POS N
needling. POS N

Blebs POS N
in POS N
AMT POS N
group POS N
showed POS N
better POS N
bleb POS N
morphology POS N
in POS N
terms POS N
of POS N
significantly POS N
better POS N
extent POS N
(E3) POS N
on POS N
day POS N
1 POS N
(P POS N
= POS N
0.03) POS N
and POS N
better POS N
height POS N
(H2 POS N
and POS N
H3) POS N
(P POS N
= POS N
0.04), POS N
according POS N
to POS N
the POS N
Indiana POS N
Bleb POS N
Appearance POS N
Grading POS N
Scale, POS N
at POS N
all POS N
follow-up POS N
visits POS N
along POS N
with POS N
normal POS N
vascularity. POS N

This POS N
reiterates POS N
the POS N
role POS N
of POS N
amnion POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
bleb POS N
modulator. POS N

The POS N
study POS N
group POS N
required POS N
significantly POS N
lesser POS N
(P POS N
= POS N
0.03) POS N
bleb POS N
needlings POS N
as POS N
compared POS N
to POS N
control POS N
group. POS N

Complete POS N
success POS N
(defined POS N
as POS N
IOP POS N
<16 POS N
mmHg POS N
on POS N
no POS N
medication) POS N
could POS N
be POS N
achieved POS N
in POS N
85% POS N
eyes POS N
in POS N
study POS N
group POS N
while POS N
it POS N
was POS N
60% POS N
in POS N
control POS N
group POS N
(P POS N
= POS N
0.04). POS N

The POS N
study POS N
group POS N
required POS N
significantly POS N
lesser POS N
(P POS N
= POS N
0.03) POS N
bleb POS N
needlings POS N
as POS N
compared POS N
to POS N
control POS N
group. POS N

IOP POS N
reduced POS N
by POS N
71.1% POS N
in POS N
study POS N
group POS N
from POS N
41.9 POS N
± POS N
10.6 POS N
to POS N
12.1 POS N
± POS N
2.7 POS N
mmHg POS N
and POS N
from POS N
40.5 POS N
± POS N
8.5 POS N
to POS N
12.8 POS N
± POS N
4.5 POS N
mmHg POS N
in POS N
control POS N
group, POS N
a POS N
decline POS N
of POS N
68.29%. POS N

The POS N
study POS N
group POS N
required POS N
significantly POS N
lesser POS N
(P POS N
= POS N
0.03) POS N
bleb POS N
needlings POS N
as POS N
compared POS N
to POS N
control POS N
group. POS N

Blebs POS N
in POS N
AMT POS N
group POS N
showed POS N
better POS N
bleb POS N
morphology POS N
in POS N
terms POS N
of POS N
significantly POS N
better POS N
extent POS N
(E3) POS N
on POS N
day POS N
1 POS N
(P POS N
= POS N
0.03) POS N
and POS N
better POS N
height POS N
(H2 POS N
and POS N
H3) POS N
(P POS N
= POS N
0.04), POS N
according POS N
to POS N
the POS N
Indiana POS N
Bleb POS N
Appearance POS N
Grading POS N
Scale, POS N
at POS N
all POS N
follow-up POS N
visits POS N
along POS N
with POS N
normal POS N
vascularity. POS N

The POS N
study POS N
group POS N
required POS N
significantly POS N
lesser POS N
(P POS N
= POS N
0.03) POS N
bleb POS N
needlings POS N
as POS N
compared POS N
to POS N
control POS N
group. POS N

Amnion POS N
enhanced POS N
the POS N
efficacy POS N
of POS N
MMC-modulated POS N
trabeculectomy POS N
in POS N
terms POS N
of POS N
eyes POS N
with POS N
complete POS N
success POS N
and POS N
lesser POS N
interventions POS N
such POS N
as POS N
bleb POS N
needling. POS N

The POS N
study POS N
group POS N
required POS N
significantly POS N
lesser POS N
(P POS N
= POS N
0.03) POS N
bleb POS N
needlings POS N
as POS N
compared POS N
to POS N
control POS N
group. POS N

This POS N
reiterates POS N
the POS N
role POS N
of POS N
amnion POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
bleb POS N
modulator. POS N

Amnion POS N
enhanced POS N
the POS N
efficacy POS N
of POS N
MMC-modulated POS N
trabeculectomy POS N
in POS N
terms POS N
of POS N
eyes POS N
with POS N
complete POS N
success POS N
and POS N
lesser POS N
interventions POS N
such POS N
as POS N
bleb POS N
needling. POS N

Complete POS N
success POS N
(defined POS N
as POS N
IOP POS N
<16 POS N
mmHg POS N
on POS N
no POS N
medication) POS N
could POS N
be POS N
achieved POS N
in POS N
85% POS N
eyes POS N
in POS N
study POS N
group POS N
while POS N
it POS N
was POS N
60% POS N
in POS N
control POS N
group POS N
(P POS N
= POS N
0.04). POS N

Amnion POS N
enhanced POS N
the POS N
efficacy POS N
of POS N
MMC-modulated POS N
trabeculectomy POS N
in POS N
terms POS N
of POS N
eyes POS N
with POS N
complete POS N
success POS N
and POS N
lesser POS N
interventions POS N
such POS N
as POS N
bleb POS N
needling. POS N

IOP POS N
reduced POS N
by POS N
71.1% POS N
in POS N
study POS N
group POS N
from POS N
41.9 POS N
± POS N
10.6 POS N
to POS N
12.1 POS N
± POS N
2.7 POS N
mmHg POS N
and POS N
from POS N
40.5 POS N
± POS N
8.5 POS N
to POS N
12.8 POS N
± POS N
4.5 POS N
mmHg POS N
in POS N
control POS N
group, POS N
a POS N
decline POS N
of POS N
68.29%. POS N

Amnion POS N
enhanced POS N
the POS N
efficacy POS N
of POS N
MMC-modulated POS N
trabeculectomy POS N
in POS N
terms POS N
of POS N
eyes POS N
with POS N
complete POS N
success POS N
and POS N
lesser POS N
interventions POS N
such POS N
as POS N
bleb POS N
needling. POS N

Blebs POS N
in POS N
AMT POS N
group POS N
showed POS N
better POS N
bleb POS N
morphology POS N
in POS N
terms POS N
of POS N
significantly POS N
better POS N
extent POS N
(E3) POS N
on POS N
day POS N
1 POS N
(P POS N
= POS N
0.03) POS N
and POS N
better POS N
height POS N
(H2 POS N
and POS N
H3) POS N
(P POS N
= POS N
0.04), POS N
according POS N
to POS N
the POS N
Indiana POS N
Bleb POS N
Appearance POS N
Grading POS N
Scale, POS N
at POS N
all POS N
follow-up POS N
visits POS N
along POS N
with POS N
normal POS N
vascularity. POS N

Amnion POS N
enhanced POS N
the POS N
efficacy POS N
of POS N
MMC-modulated POS N
trabeculectomy POS N
in POS N
terms POS N
of POS N
eyes POS N
with POS N
complete POS N
success POS N
and POS N
lesser POS N
interventions POS N
such POS N
as POS N
bleb POS N
needling. POS N

The POS N
study POS N
group POS N
required POS N
significantly POS N
lesser POS N
(P POS N
= POS N
0.03) POS N
bleb POS N
needlings POS N
as POS N
compared POS N
to POS N
control POS N
group. POS N

Amnion POS N
enhanced POS N
the POS N
efficacy POS N
of POS N
MMC-modulated POS N
trabeculectomy POS N
in POS N
terms POS N
of POS N
eyes POS N
with POS N
complete POS N
success POS N
and POS N
lesser POS N
interventions POS N
such POS N
as POS N
bleb POS N
needling. POS N

This POS N
reiterates POS N
the POS N
role POS N
of POS N
amnion POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
bleb POS N
modulator. POS N

This POS N
reiterates POS N
the POS N
role POS N
of POS N
amnion POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
bleb POS N
modulator. POS N

Complete POS N
success POS N
(defined POS N
as POS N
IOP POS N
<16 POS N
mmHg POS N
on POS N
no POS N
medication) POS N
could POS N
be POS N
achieved POS N
in POS N
85% POS N
eyes POS N
in POS N
study POS N
group POS N
while POS N
it POS N
was POS N
60% POS N
in POS N
control POS N
group POS N
(P POS N
= POS N
0.04). POS N

This POS N
reiterates POS N
the POS N
role POS N
of POS N
amnion POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
bleb POS N
modulator. POS N

IOP POS N
reduced POS N
by POS N
71.1% POS N
in POS N
study POS N
group POS N
from POS N
41.9 POS N
± POS N
10.6 POS N
to POS N
12.1 POS N
± POS N
2.7 POS N
mmHg POS N
and POS N
from POS N
40.5 POS N
± POS N
8.5 POS N
to POS N
12.8 POS N
± POS N
4.5 POS N
mmHg POS N
in POS N
control POS N
group, POS N
a POS N
decline POS N
of POS N
68.29%. POS N

This POS N
reiterates POS N
the POS N
role POS N
of POS N
amnion POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
bleb POS N
modulator. POS N

Blebs POS N
in POS N
AMT POS N
group POS N
showed POS N
better POS N
bleb POS N
morphology POS N
in POS N
terms POS N
of POS N
significantly POS N
better POS N
extent POS N
(E3) POS N
on POS N
day POS N
1 POS N
(P POS N
= POS N
0.03) POS N
and POS N
better POS N
height POS N
(H2 POS N
and POS N
H3) POS N
(P POS N
= POS N
0.04), POS N
according POS N
to POS N
the POS N
Indiana POS N
Bleb POS N
Appearance POS N
Grading POS N
Scale, POS N
at POS N
all POS N
follow-up POS N
visits POS N
along POS N
with POS N
normal POS N
vascularity. POS N

This POS N
reiterates POS N
the POS N
role POS N
of POS N
amnion POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
bleb POS N
modulator. POS N

The POS N
study POS N
group POS N
required POS N
significantly POS N
lesser POS N
(P POS N
= POS N
0.03) POS N
bleb POS N
needlings POS N
as POS N
compared POS N
to POS N
control POS N
group. POS N

This POS N
reiterates POS N
the POS N
role POS N
of POS N
amnion POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
bleb POS N
modulator. POS N

Amnion POS N
enhanced POS N
the POS N
efficacy POS N
of POS N
MMC-modulated POS N
trabeculectomy POS N
in POS N
terms POS N
of POS N
eyes POS N
with POS N
complete POS N
success POS N
and POS N
lesser POS N
interventions POS N
such POS N
as POS N
bleb POS N
needling. POS N

Ca POS N
consumption POS N
during POS N
the POS N
study POS N
was POS N
equivalent POS N
to POS N
1200 POS N
mg/d POS N
during POS N
MD POS N
and POS N
525 POS N
mg/d POS N
during POS N
CD. POS N

There POS N
was POS N
a POS N
greater POS N
reduction POS N
in POS N
WC, POS N
SBP, POS N
DBP POS N
and POS N
LAP POS N
index POS N
after POS N
MD POS N
compared POS N
with POS N
CD. POS N

Ca POS N
consumption POS N
during POS N
the POS N
study POS N
was POS N
equivalent POS N
to POS N
1200 POS N
mg/d POS N
during POS N
MD POS N
and POS N
525 POS N
mg/d POS N
during POS N
CD. POS N

HDL:LDL POS N
ratio POS N
increased POS N
and POS N
total POS N
cholesterol, POS N
LDL-cholesterol, POS N
SBP, POS N
DBP POS N
and POS N
LAP POS N
index POS N
decreased POS N
only POS N
in POS N
MD. POS N

Ca POS N
consumption POS N
during POS N
the POS N
study POS N
was POS N
equivalent POS N
to POS N
1200 POS N
mg/d POS N
during POS N
MD POS N
and POS N
525 POS N
mg/d POS N
during POS N
CD. POS N

The POS N
consumption POS N
of POS N
approximately POS N
1200 POS N
mg POS N
of POS N
Ca/d POS N
(700 POS N
mg POS N
from POS N
fat-free POS N
milk+500mg POS N
from POS N
other POS N
dietary POS N
sources) POS N
associated POS N
with POS N
an POS N
energy-restricted POS N
diet POS N
decreased POS N
some POS N
of POS N
the POS N
MetS POS N
components POS N
and POS N
cardiometabolic POS N
measures POS N
in POS N
adults POS N
with POS N
T2DM. POS N

There POS N
was POS N
a POS N
greater POS N
reduction POS N
in POS N
WC, POS N
SBP, POS N
DBP POS N
and POS N
LAP POS N
index POS N
after POS N
MD POS N
compared POS N
with POS N
CD. POS N

Ca POS N
consumption POS N
during POS N
the POS N
study POS N
was POS N
equivalent POS N
to POS N
1200 POS N
mg/d POS N
during POS N
MD POS N
and POS N
525 POS N
mg/d POS N
during POS N
CD. POS N

There POS N
was POS N
a POS N
greater POS N
reduction POS N
in POS N
WC, POS N
SBP, POS N
DBP POS N
and POS N
LAP POS N
index POS N
after POS N
MD POS N
compared POS N
with POS N
CD. POS N

HDL:LDL POS N
ratio POS N
increased POS N
and POS N
total POS N
cholesterol, POS N
LDL-cholesterol, POS N
SBP, POS N
DBP POS N
and POS N
LAP POS N
index POS N
decreased POS N
only POS N
in POS N
MD. POS N

There POS N
was POS N
a POS N
greater POS N
reduction POS N
in POS N
WC, POS N
SBP, POS N
DBP POS N
and POS N
LAP POS N
index POS N
after POS N
MD POS N
compared POS N
with POS N
CD. POS N

The POS N
consumption POS N
of POS N
approximately POS N
1200 POS N
mg POS N
of POS N
Ca/d POS N
(700 POS N
mg POS N
from POS N
fat-free POS N
milk+500mg POS N
from POS N
other POS N
dietary POS N
sources) POS N
associated POS N
with POS N
an POS N
energy-restricted POS N
diet POS N
decreased POS N
some POS N
of POS N
the POS N
MetS POS N
components POS N
and POS N
cardiometabolic POS N
measures POS N
in POS N
adults POS N
with POS N
T2DM. POS N

HDL:LDL POS N
ratio POS N
increased POS N
and POS N
total POS N
cholesterol, POS N
LDL-cholesterol, POS N
SBP, POS N
DBP POS N
and POS N
LAP POS N
index POS N
decreased POS N
only POS N
in POS N
MD. POS N

Ca POS N
consumption POS N
during POS N
the POS N
study POS N
was POS N
equivalent POS N
to POS N
1200 POS N
mg/d POS N
during POS N
MD POS N
and POS N
525 POS N
mg/d POS N
during POS N
CD. POS N

HDL:LDL POS N
ratio POS N
increased POS N
and POS N
total POS N
cholesterol, POS N
LDL-cholesterol, POS N
SBP, POS N
DBP POS N
and POS N
LAP POS N
index POS N
decreased POS N
only POS N
in POS N
MD. POS N

There POS N
was POS N
a POS N
greater POS N
reduction POS N
in POS N
WC, POS N
SBP, POS N
DBP POS N
and POS N
LAP POS N
index POS N
after POS N
MD POS N
compared POS N
with POS N
CD. POS N

HDL:LDL POS N
ratio POS N
increased POS N
and POS N
total POS N
cholesterol, POS N
LDL-cholesterol, POS N
SBP, POS N
DBP POS N
and POS N
LAP POS N
index POS N
decreased POS N
only POS N
in POS N
MD. POS N

The POS N
consumption POS N
of POS N
approximately POS N
1200 POS N
mg POS N
of POS N
Ca/d POS N
(700 POS N
mg POS N
from POS N
fat-free POS N
milk+500mg POS N
from POS N
other POS N
dietary POS N
sources) POS N
associated POS N
with POS N
an POS N
energy-restricted POS N
diet POS N
decreased POS N
some POS N
of POS N
the POS N
MetS POS N
components POS N
and POS N
cardiometabolic POS N
measures POS N
in POS N
adults POS N
with POS N
T2DM. POS N

The POS N
consumption POS N
of POS N
approximately POS N
1200 POS N
mg POS N
of POS N
Ca/d POS N
(700 POS N
mg POS N
from POS N
fat-free POS N
milk+500mg POS N
from POS N
other POS N
dietary POS N
sources) POS N
associated POS N
with POS N
an POS N
energy-restricted POS N
diet POS N
decreased POS N
some POS N
of POS N
the POS N
MetS POS N
components POS N
and POS N
cardiometabolic POS N
measures POS N
in POS N
adults POS N
with POS N
T2DM. POS N

Ca POS N
consumption POS N
during POS N
the POS N
study POS N
was POS N
equivalent POS N
to POS N
1200 POS N
mg/d POS N
during POS N
MD POS N
and POS N
525 POS N
mg/d POS N
during POS N
CD. POS N

The POS N
consumption POS N
of POS N
approximately POS N
1200 POS N
mg POS N
of POS N
Ca/d POS N
(700 POS N
mg POS N
from POS N
fat-free POS N
milk+500mg POS N
from POS N
other POS N
dietary POS N
sources) POS N
associated POS N
with POS N
an POS N
energy-restricted POS N
diet POS N
decreased POS N
some POS N
of POS N
the POS N
MetS POS N
components POS N
and POS N
cardiometabolic POS N
measures POS N
in POS N
adults POS N
with POS N
T2DM. POS N

There POS N
was POS N
a POS N
greater POS N
reduction POS N
in POS N
WC, POS N
SBP, POS N
DBP POS N
and POS N
LAP POS N
index POS N
after POS N
MD POS N
compared POS N
with POS N
CD. POS N

The POS N
consumption POS N
of POS N
approximately POS N
1200 POS N
mg POS N
of POS N
Ca/d POS N
(700 POS N
mg POS N
from POS N
fat-free POS N
milk+500mg POS N
from POS N
other POS N
dietary POS N
sources) POS N
associated POS N
with POS N
an POS N
energy-restricted POS N
diet POS N
decreased POS N
some POS N
of POS N
the POS N
MetS POS N
components POS N
and POS N
cardiometabolic POS N
measures POS N
in POS N
adults POS N
with POS N
T2DM. POS N

HDL:LDL POS N
ratio POS N
increased POS N
and POS N
total POS N
cholesterol, POS N
LDL-cholesterol, POS N
SBP, POS N
DBP POS N
and POS N
LAP POS N
index POS N
decreased POS N
only POS N
in POS N
MD. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

Sodium POS N
nitrite POS N
has POS N
been POS N
reported POS N
to POS N
be POS N
effective POS N
in POS N
reducing POS N
chronic POS N
peripheral POS N
pain. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

There POS N
were POS N
no POS N
reports POS N
of POS N
treatment-related POS N
headaches. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

The POS N
number POS N
of POS N
subjects POS N
reporting POS N
adverse POS N
events POS N
and POS N
the POS N
number POS N
of POS N
adverse POS N
events POS N
did POS N
not POS N
change POS N
with POS N
dose. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

In POS N
the POS N
NPSI POS N
assessment, POS N
patients POS N
in POS N
the POS N
40 POS N
mg POS N
and POS N
80 POS N
mg POS N
dose POS N
group POS N
reported POS N
a POS N
12.7% POS N
and POS N
22.0% POS N
reduction POS N
in POS N
pain, POS N
respectively, POS N
compared POS N
to POS N
an POS N
8.4% POS N
reduction POS N
by POS N
patients POS N
in POS N
the POS N
placebo POS N
group. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

the POS N
40 POS N
mg POS N
dosing POS N
group POS N
reported POS N
the POS N
greatest POS N
reduction POS N
in POS N
pain POS N
using POS N
the POS N
McGill POS N
Pain POS N
index POS N
and POS N
via POS N
patient POS N
logs POS N
of POS N
daily POS N
pain POS N
scores, POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

the POS N
mean POS N
of POS N
pain POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
the POS N
40 POS N
mg POS N
group POS N
dropped POS N
by POS N
day POS N
41 POS N
and POS N
generally POS N
stayed POS N
lower POS N
than POS N
the POS N
mean POS N
of POS N
scores POS N
reported POS N
by POS N
subjects POS N
in POS N
either POS N
of POS N
the POS N
other POS N
two POS N
groups. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

Patients POS N
in POS N
the POS N
80 POS N
mg POS N
SR-nitrite POS N
group POS N
had POS N
an POS N
improvement POS N
in POS N
both POS N
Nerve POS N
Sensory POS N
Conductance POS N
and POS N
Nerve POS N
Sensory POS N
Velocity. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

No POS N
changes POS N
were POS N
observed POS N
in POS N
HbA1c POS N
levels POS N
or POS N
PulseOx. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

In POS N
a POS N
previous POS N
study POS N
of POS N
patients POS N
with POS N
peripheral POS N
arterial POS N
disease POS N
(PAD), POS N
40 POS N
mg POS N
BID POS N
treatment POS N
led POS N
to POS N
a POS N
statistically POS N
significant POS N
reduction POS N
in POS N
reported POS N
pain, POS N
similar POS N
trends POS N
were POS N
observed POS N
at POS N
the POS N
end POS N
of POS N
the POS N
trial POS N
period POS N
for POS N
most POS N
of POS N
the POS N
pain POS N
questionnaires POS N
used POS N
in POS N
the POS N
study. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

The POS N
ability POS N
to POS N
alleviate POS N
pain POS N
with POS N
BID POS N
treatment POS N
of POS N
SR-nitrite POS N
offers POS N
promise POS N
for POS N
a POS N
new POS N
non-addictive, POS N
non-sedating POS N
treatment POS N
of POS N
chronic POS N
pain POS N
and POS N
warrants POS N
further POS N
study. POS N

Sustained POS N
release POS N
sodium POS N
nitrite POS N
prevents POS N
the POS N
prevalent POS N
reports POS N
of POS N
headaches POS N
by POS N
patients POS N
treated POS N
with POS N
an POS N
immediate POS N
release POS N
formulation POS N
of POS N
sodium POS N
nitrite. POS N

The POS N
80 POS N
mg POS N
BID POS N
treatment POS N
had POS N
the POS N
more POS N
pronounced POS N
affect POS N
on POS N
bioactivity POS N
(quantitative POS N
sensory POS N
testing), POS N
which POS N
was POS N
similar POS N
to POS N
the POS N
PAD POS N
study, POS N
where POS N
this POS N
dose POS N
group POS N
had POS N
the POS N
greatest POS N
improvement POS N
in POS N
FMD POS N
{AU: POS N
spell POS N
out POS N
FMD}. POS N

Changes POS N
in POS N
UACR POS N
category POS N
were POS N
not POS N
different POS N
among POS N
treatment POS N
groups POS N
at POS N
the POS N
52-week POS N
visit POS N
(global POS N
P POS N
= POS N
0.29). POS N

Average POS N
change POS N
in POS N
mean POS N
arterial POS N
pressure POS N
from POS N
baseline POS N
to POS N
2 POS N
years POS N
was POS N
-1.2 POS N
± POS N
15, POS N
-1.8 POS N
± POS N
13.5, POS N
-2.6 POS N
± POS N
14.4 POS N
mm POS N
Hg POS N
in POS N
the POS N
aflibercept, POS N
bevacizumab, POS N
and POS N
ranibizumab POS N
groups, POS N
respectively POS N
(global POS N
P POS N
= POS N
0.69). POS N

Changes POS N
in POS N
UACR POS N
category POS N
were POS N
not POS N
different POS N
among POS N
treatment POS N
groups POS N
at POS N
the POS N
52-week POS N
visit POS N
(global POS N
P POS N
= POS N
0.29). POS N

There POS N
do POS N
not POS N
appear POS N
to POS N
be POS N
treatment POS N
group POS N
differences POS N
for POS N
changes POS N
in POS N
blood POS N
pressure POS N
or POS N
UACR POS N
as POS N
a POS N
reflection POS N
of POS N
kidney POS N
function POS N
in POS N
patients POS N
with POS N
DME POS N
treated POS N
with POS N
aflibercept, POS N
bevacizumab, POS N
or POS N
ranibizumab. POS N

Average POS N
change POS N
in POS N
mean POS N
arterial POS N
pressure POS N
from POS N
baseline POS N
to POS N
2 POS N
years POS N
was POS N
-1.2 POS N
± POS N
15, POS N
-1.8 POS N
± POS N
13.5, POS N
-2.6 POS N
± POS N
14.4 POS N
mm POS N
Hg POS N
in POS N
the POS N
aflibercept, POS N
bevacizumab, POS N
and POS N
ranibizumab POS N
groups, POS N
respectively POS N
(global POS N
P POS N
= POS N
0.69). POS N

Changes POS N
in POS N
UACR POS N
category POS N
were POS N
not POS N
different POS N
among POS N
treatment POS N
groups POS N
at POS N
the POS N
52-week POS N
visit POS N
(global POS N
P POS N
= POS N
0.29). POS N

Average POS N
change POS N
in POS N
mean POS N
arterial POS N
pressure POS N
from POS N
baseline POS N
to POS N
2 POS N
years POS N
was POS N
-1.2 POS N
± POS N
15, POS N
-1.8 POS N
± POS N
13.5, POS N
-2.6 POS N
± POS N
14.4 POS N
mm POS N
Hg POS N
in POS N
the POS N
aflibercept, POS N
bevacizumab, POS N
and POS N
ranibizumab POS N
groups, POS N
respectively POS N
(global POS N
P POS N
= POS N
0.69). POS N

There POS N
do POS N
not POS N
appear POS N
to POS N
be POS N
treatment POS N
group POS N
differences POS N
for POS N
changes POS N
in POS N
blood POS N
pressure POS N
or POS N
UACR POS N
as POS N
a POS N
reflection POS N
of POS N
kidney POS N
function POS N
in POS N
patients POS N
with POS N
DME POS N
treated POS N
with POS N
aflibercept, POS N
bevacizumab, POS N
or POS N
ranibizumab. POS N

There POS N
do POS N
not POS N
appear POS N
to POS N
be POS N
treatment POS N
group POS N
differences POS N
for POS N
changes POS N
in POS N
blood POS N
pressure POS N
or POS N
UACR POS N
as POS N
a POS N
reflection POS N
of POS N
kidney POS N
function POS N
in POS N
patients POS N
with POS N
DME POS N
treated POS N
with POS N
aflibercept, POS N
bevacizumab, POS N
or POS N
ranibizumab. POS N

Changes POS N
in POS N
UACR POS N
category POS N
were POS N
not POS N
different POS N
among POS N
treatment POS N
groups POS N
at POS N
the POS N
52-week POS N
visit POS N
(global POS N
P POS N
= POS N
0.29). POS N

There POS N
do POS N
not POS N
appear POS N
to POS N
be POS N
treatment POS N
group POS N
differences POS N
for POS N
changes POS N
in POS N
blood POS N
pressure POS N
or POS N
UACR POS N
as POS N
a POS N
reflection POS N
of POS N
kidney POS N
function POS N
in POS N
patients POS N
with POS N
DME POS N
treated POS N
with POS N
aflibercept, POS N
bevacizumab, POS N
or POS N
ranibizumab. POS N

Average POS N
change POS N
in POS N
mean POS N
arterial POS N
pressure POS N
from POS N
baseline POS N
to POS N
2 POS N
years POS N
was POS N
-1.2 POS N
± POS N
15, POS N
-1.8 POS N
± POS N
13.5, POS N
-2.6 POS N
± POS N
14.4 POS N
mm POS N
Hg POS N
in POS N
the POS N
aflibercept, POS N
bevacizumab, POS N
and POS N
ranibizumab POS N
groups, POS N
respectively POS N
(global POS N
P POS N
= POS N
0.69). POS N

Topical POS N
brimonidine POS N
showed POS N
an POS N
additive POS N
IOP-lowering POS N
effect POS N
to POS N
topical POS N
PG POS N
analogues, POS N

although POS N
its POS N
IOP-lowering POS N
effect POS N
was POS N
inferior POS N
to POS N
topical POS N
timolol POS N
as POS N
monotherapy. POS N

Topical POS N
brimonidine POS N
showed POS N
an POS N
additive POS N
IOP-lowering POS N
effect POS N
to POS N
topical POS N
PG POS N
analogues, POS N

The POS N
mean POS N
changes POS N
were POS N
-4.7 POS N
+/- POS N
2.1 POS N
(S. POS N
D.) POS N
in POS N
the POS N
timolol POS N
and POS N
-4.0 POS N
+/- POS N
2.0 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
(p POS N
= POS N
0.0138). POS N

Topical POS N
brimonidine POS N
showed POS N
an POS N
additive POS N
IOP-lowering POS N
effect POS N
to POS N
topical POS N
PG POS N
analogues, POS N

The POS N
95% POS N
confidence POS N
interval POS N
of POS N
the POS N
inter-group POS N
difference POS N
was POS N
greater POS N
than POS N
the POS N
pre-determined POS N
criterion POS N
of POS N
non-inferiority POS N
of POS N
brimonidine POS N
to POS N
timolol. POS N

Topical POS N
brimonidine POS N
showed POS N
an POS N
additive POS N
IOP-lowering POS N
effect POS N
to POS N
topical POS N
PG POS N
analogues, POS N

When POS N
added POS N
to POS N
PG POS N
analogues, POS N
the POS N
IOP-lowering POS N
effect POS N
of POS N
brimonidine POS N
(-2.9 POS N
+/- POS N
1.8 POS N
mmHg) POS N
was POS N
greater POS N
than POS N
that POS N
of POS N
the POS N
placebo POS N
(-2.1 POS N
+/- POS N
1.8 POS N
mmHg) POS N
(p POS N
= POS N
0.0010). POS N

although POS N
its POS N
IOP-lowering POS N
effect POS N
was POS N
inferior POS N
to POS N
topical POS N
timolol POS N
as POS N
monotherapy. POS N

Topical POS N
brimonidine POS N
showed POS N
an POS N
additive POS N
IOP-lowering POS N
effect POS N
to POS N
topical POS N
PG POS N
analogues, POS N

although POS N
its POS N
IOP-lowering POS N
effect POS N
was POS N
inferior POS N
to POS N
topical POS N
timolol POS N
as POS N
monotherapy. POS N

The POS N
mean POS N
changes POS N
were POS N
-4.7 POS N
+/- POS N
2.1 POS N
(S. POS N
D.) POS N
in POS N
the POS N
timolol POS N
and POS N
-4.0 POS N
+/- POS N
2.0 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
(p POS N
= POS N
0.0138). POS N

although POS N
its POS N
IOP-lowering POS N
effect POS N
was POS N
inferior POS N
to POS N
topical POS N
timolol POS N
as POS N
monotherapy. POS N

The POS N
95% POS N
confidence POS N
interval POS N
of POS N
the POS N
inter-group POS N
difference POS N
was POS N
greater POS N
than POS N
the POS N
pre-determined POS N
criterion POS N
of POS N
non-inferiority POS N
of POS N
brimonidine POS N
to POS N
timolol. POS N

although POS N
its POS N
IOP-lowering POS N
effect POS N
was POS N
inferior POS N
to POS N
topical POS N
timolol POS N
as POS N
monotherapy. POS N

When POS N
added POS N
to POS N
PG POS N
analogues, POS N
the POS N
IOP-lowering POS N
effect POS N
of POS N
brimonidine POS N
(-2.9 POS N
+/- POS N
1.8 POS N
mmHg) POS N
was POS N
greater POS N
than POS N
that POS N
of POS N
the POS N
placebo POS N
(-2.1 POS N
+/- POS N
1.8 POS N
mmHg) POS N
(p POS N
= POS N
0.0010). POS N

The POS N
mean POS N
changes POS N
were POS N
-4.7 POS N
+/- POS N
2.1 POS N
(S. POS N
D.) POS N
in POS N
the POS N
timolol POS N
and POS N
-4.0 POS N
+/- POS N
2.0 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
(p POS N
= POS N
0.0138). POS N

Topical POS N
brimonidine POS N
showed POS N
an POS N
additive POS N
IOP-lowering POS N
effect POS N
to POS N
topical POS N
PG POS N
analogues, POS N

The POS N
mean POS N
changes POS N
were POS N
-4.7 POS N
+/- POS N
2.1 POS N
(S. POS N
D.) POS N
in POS N
the POS N
timolol POS N
and POS N
-4.0 POS N
+/- POS N
2.0 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
(p POS N
= POS N
0.0138). POS N

although POS N
its POS N
IOP-lowering POS N
effect POS N
was POS N
inferior POS N
to POS N
topical POS N
timolol POS N
as POS N
monotherapy. POS N

The POS N
mean POS N
changes POS N
were POS N
-4.7 POS N
+/- POS N
2.1 POS N
(S. POS N
D.) POS N
in POS N
the POS N
timolol POS N
and POS N
-4.0 POS N
+/- POS N
2.0 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
(p POS N
= POS N
0.0138). POS N

The POS N
95% POS N
confidence POS N
interval POS N
of POS N
the POS N
inter-group POS N
difference POS N
was POS N
greater POS N
than POS N
the POS N
pre-determined POS N
criterion POS N
of POS N
non-inferiority POS N
of POS N
brimonidine POS N
to POS N
timolol. POS N

The POS N
mean POS N
changes POS N
were POS N
-4.7 POS N
+/- POS N
2.1 POS N
(S. POS N
D.) POS N
in POS N
the POS N
timolol POS N
and POS N
-4.0 POS N
+/- POS N
2.0 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
(p POS N
= POS N
0.0138). POS N

When POS N
added POS N
to POS N
PG POS N
analogues, POS N
the POS N
IOP-lowering POS N
effect POS N
of POS N
brimonidine POS N
(-2.9 POS N
+/- POS N
1.8 POS N
mmHg) POS N
was POS N
greater POS N
than POS N
that POS N
of POS N
the POS N
placebo POS N
(-2.1 POS N
+/- POS N
1.8 POS N
mmHg) POS N
(p POS N
= POS N
0.0010). POS N

The POS N
95% POS N
confidence POS N
interval POS N
of POS N
the POS N
inter-group POS N
difference POS N
was POS N
greater POS N
than POS N
the POS N
pre-determined POS N
criterion POS N
of POS N
non-inferiority POS N
of POS N
brimonidine POS N
to POS N
timolol. POS N

Topical POS N
brimonidine POS N
showed POS N
an POS N
additive POS N
IOP-lowering POS N
effect POS N
to POS N
topical POS N
PG POS N
analogues, POS N

The POS N
95% POS N
confidence POS N
interval POS N
of POS N
the POS N
inter-group POS N
difference POS N
was POS N
greater POS N
than POS N
the POS N
pre-determined POS N
criterion POS N
of POS N
non-inferiority POS N
of POS N
brimonidine POS N
to POS N
timolol. POS N

although POS N
its POS N
IOP-lowering POS N
effect POS N
was POS N
inferior POS N
to POS N
topical POS N
timolol POS N
as POS N
monotherapy. POS N

The POS N
95% POS N
confidence POS N
interval POS N
of POS N
the POS N
inter-group POS N
difference POS N
was POS N
greater POS N
than POS N
the POS N
pre-determined POS N
criterion POS N
of POS N
non-inferiority POS N
of POS N
brimonidine POS N
to POS N
timolol. POS N

The POS N
mean POS N
changes POS N
were POS N
-4.7 POS N
+/- POS N
2.1 POS N
(S. POS N
D.) POS N
in POS N
the POS N
timolol POS N
and POS N
-4.0 POS N
+/- POS N
2.0 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
(p POS N
= POS N
0.0138). POS N

The POS N
95% POS N
confidence POS N
interval POS N
of POS N
the POS N
inter-group POS N
difference POS N
was POS N
greater POS N
than POS N
the POS N
pre-determined POS N
criterion POS N
of POS N
non-inferiority POS N
of POS N
brimonidine POS N
to POS N
timolol. POS N

When POS N
added POS N
to POS N
PG POS N
analogues, POS N
the POS N
IOP-lowering POS N
effect POS N
of POS N
brimonidine POS N
(-2.9 POS N
+/- POS N
1.8 POS N
mmHg) POS N
was POS N
greater POS N
than POS N
that POS N
of POS N
the POS N
placebo POS N
(-2.1 POS N
+/- POS N
1.8 POS N
mmHg) POS N
(p POS N
= POS N
0.0010). POS N

When POS N
added POS N
to POS N
PG POS N
analogues, POS N
the POS N
IOP-lowering POS N
effect POS N
of POS N
brimonidine POS N
(-2.9 POS N
+/- POS N
1.8 POS N
mmHg) POS N
was POS N
greater POS N
than POS N
that POS N
of POS N
the POS N
placebo POS N
(-2.1 POS N
+/- POS N
1.8 POS N
mmHg) POS N
(p POS N
= POS N
0.0010). POS N

Topical POS N
brimonidine POS N
showed POS N
an POS N
additive POS N
IOP-lowering POS N
effect POS N
to POS N
topical POS N
PG POS N
analogues, POS N

When POS N
added POS N
to POS N
PG POS N
analogues, POS N
the POS N
IOP-lowering POS N
effect POS N
of POS N
brimonidine POS N
(-2.9 POS N
+/- POS N
1.8 POS N
mmHg) POS N
was POS N
greater POS N
than POS N
that POS N
of POS N
the POS N
placebo POS N
(-2.1 POS N
+/- POS N
1.8 POS N
mmHg) POS N
(p POS N
= POS N
0.0010). POS N

although POS N
its POS N
IOP-lowering POS N
effect POS N
was POS N
inferior POS N
to POS N
topical POS N
timolol POS N
as POS N
monotherapy. POS N

When POS N
added POS N
to POS N
PG POS N
analogues, POS N
the POS N
IOP-lowering POS N
effect POS N
of POS N
brimonidine POS N
(-2.9 POS N
+/- POS N
1.8 POS N
mmHg) POS N
was POS N
greater POS N
than POS N
that POS N
of POS N
the POS N
placebo POS N
(-2.1 POS N
+/- POS N
1.8 POS N
mmHg) POS N
(p POS N
= POS N
0.0010). POS N

The POS N
mean POS N
changes POS N
were POS N
-4.7 POS N
+/- POS N
2.1 POS N
(S. POS N
D.) POS N
in POS N
the POS N
timolol POS N
and POS N
-4.0 POS N
+/- POS N
2.0 POS N
mmHg POS N
in POS N
the POS N
brimonidine POS N
group POS N
(p POS N
= POS N
0.0138). POS N

When POS N
added POS N
to POS N
PG POS N
analogues, POS N
the POS N
IOP-lowering POS N
effect POS N
of POS N
brimonidine POS N
(-2.9 POS N
+/- POS N
1.8 POS N
mmHg) POS N
was POS N
greater POS N
than POS N
that POS N
of POS N
the POS N
placebo POS N
(-2.1 POS N
+/- POS N
1.8 POS N
mmHg) POS N
(p POS N
= POS N
0.0010). POS N

The POS N
95% POS N
confidence POS N
interval POS N
of POS N
the POS N
inter-group POS N
difference POS N
was POS N
greater POS N
than POS N
the POS N
pre-determined POS N
criterion POS N
of POS N
non-inferiority POS N
of POS N
brimonidine POS N
to POS N
timolol. POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

Both POS N
groups POS N
had POS N
a POS N
similar POS N
favorable POS N
long-term POS N
safety POS N
profile. POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

The POS N
incidence POS N
of POS N
adverse POS N
events POS N
was POS N
low POS N
in POS N
both POS N
groups POS N
through POS N
24 POS N
months POS N
of POS N
follow-up. POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

At POS N
24 POS N
months, POS N
the POS N
proportion POS N
of POS N
patients POS N
with POS N
an POS N
IOP POS N
of POS N
21 POS N
mm POS N
Hg POS N
or POS N
lower POS N
without POS N
ocular POS N
hypotensive POS N
medications POS N
was POS N
significantly POS N
higher POS N
in POS N
the POS N
stent POS N
group POS N
than POS N
in POS N
the POS N
control POS N
group POS N
(P=.036). POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

the POS N
mean POS N
IOP POS N
was POS N
stable POS N
between POS N
12 POS N
months POS N
and POS N
24 POS N
months POS N
(17.0 POS N
mm POS N
Hg POS N
± POS N
2.8 POS N
[SD] POS N
and POS N
17.1 POS N
± POS N
2.9 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
stent POS N
group POS N
but POS N
increased POS N
(17.0 POS N
± POS N
3.1 POS N
mm POS N
Hg POS N
to POS N
17.8 POS N
± POS N
3.3 POS N
mm POS N
Hg, POS N
respectively) POS N
in POS N
the POS N
control POS N
group. POS N

Patients POS N
with POS N
combined POS N
single POS N
trabecular POS N
micro-bypass POS N
stent POS N
and POS N
cataract POS N
surgery POS N
had POS N
significantly POS N
better POS N
IOP POS N
control POS N
on POS N
no POS N
medication POS N
through POS N
24 POS N
months POS N
than POS N
patients POS N
having POS N
cataract POS N
surgery POS N
alone. POS N

Ocular POS N
hypotensive POS N
medication POS N
was POS N
statistically POS N
significantly POS N
lower POS N
in POS N
the POS N
stent POS N
group POS N
at POS N
12 POS N
months; POS N
it POS N
was POS N
also POS N
lower POS N
at POS N
24 POS N
months, POS N
although POS N
the POS N
difference POS N
was POS N
no POS N
longer POS N
statistically POS N
significant. POS N

After POS N
a POS N
mean POS N
follow-up POS N
period POS N
of POS N
96 POS N
weeks, POS N
the POS N
proportion POS N
of POS N
HBV POS N
reactivation POS N
observed POS N
was POS N
6.8% POS N
(4/58) POS N
in POS N
the POS N
LAM+ADV POS N
group POS N
and POS N
4.5% POS N
(5/111) POS N
in POS N
the POS N
TDF POS N
group POS N
by POS N
using POS N
intention-to-treat POS N
analysis POS N
(difference, POS N
-2.3%; POS N
95% POS N
CI, POS N
-9.84-5.24%). POS N

None POS N
of POS N
the POS N
subjects POS N
in POS N
either POS N
group POS N
experienced POS N
viral POS N
reactivation POS N
based POS N
on POS N
per POS N
protocol POS N
analysis. POS N

After POS N
a POS N
mean POS N
follow-up POS N
period POS N
of POS N
96 POS N
weeks, POS N
the POS N
proportion POS N
of POS N
HBV POS N
reactivation POS N
observed POS N
was POS N
6.8% POS N
(4/58) POS N
in POS N
the POS N
LAM+ADV POS N
group POS N
and POS N
4.5% POS N
(5/111) POS N
in POS N
the POS N
TDF POS N
group POS N
by POS N
using POS N
intention-to-treat POS N
analysis POS N
(difference, POS N
-2.3%; POS N
95% POS N
CI, POS N
-9.84-5.24%). POS N

No POS N
serious POS N
adverse POS N
reactions POS N
were POS N
observed. POS N

After POS N
a POS N
mean POS N
follow-up POS N
period POS N
of POS N
96 POS N
weeks, POS N
the POS N
proportion POS N
of POS N
HBV POS N
reactivation POS N
observed POS N
was POS N
6.8% POS N
(4/58) POS N
in POS N
the POS N
LAM+ADV POS N
group POS N
and POS N
4.5% POS N
(5/111) POS N
in POS N
the POS N
TDF POS N
group POS N
by POS N
using POS N
intention-to-treat POS N
analysis POS N
(difference, POS N
-2.3%; POS N
95% POS N
CI, POS N
-9.84-5.24%). POS N

In POS N
the POS N
subgroup POS N
analysis POS N
for POS N
estimated POS N
glomerular POS N
filtration POS N
rate POS N
(eGFR) POS N
before POS N
and POS N
after POS N
treatment, POS N
decreased POS N
eGFR POS N
was POS N
observed POS N
only POS N
in POS N
the POS N
TDF POS N
group POS N
with POS N
cirrhosis POS N
(85.22 POS N
vs. POS N
79.83 POS N
mL/min/1.73 POS N
m2, POS N
p POS N
= POS N
0.000). POS N

After POS N
a POS N
mean POS N
follow-up POS N
period POS N
of POS N
96 POS N
weeks, POS N
the POS N
proportion POS N
of POS N
HBV POS N
reactivation POS N
observed POS N
was POS N
6.8% POS N
(4/58) POS N
in POS N
the POS N
LAM+ADV POS N
group POS N
and POS N
4.5% POS N
(5/111) POS N
in POS N
the POS N
TDF POS N
group POS N
by POS N
using POS N
intention-to-treat POS N
analysis POS N
(difference, POS N
-2.3%; POS N
95% POS N
CI, POS N
-9.84-5.24%). POS N

Stable POS N
switching POS N
to POS N
TDF POS N
monotherapy POS N
yielded POS N
non-inferior POS N
results POS N
at POS N
96 POS N
weeks POS N
compared POS N
to POS N
the POS N
results POS N
obtained POS N
with POS N
LAM+ADV POS N
combination POS N
therapy POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
CHB POS N
and POS N
undetectable POS N
HBV POS N
DNA. POS N

After POS N
a POS N
mean POS N
follow-up POS N
period POS N
of POS N
96 POS N
weeks, POS N
the POS N
proportion POS N
of POS N
HBV POS N
reactivation POS N
observed POS N
was POS N
6.8% POS N
(4/58) POS N
in POS N
the POS N
LAM+ADV POS N
group POS N
and POS N
4.5% POS N
(5/111) POS N
in POS N
the POS N
TDF POS N
group POS N
by POS N
using POS N
intention-to-treat POS N
analysis POS N
(difference, POS N
-2.3%; POS N
95% POS N
CI, POS N
-9.84-5.24%). POS N

However, POS N
TDF POS N
monotherapy POS N
in POS N
patients POS N
with POS N
cirrhosis POS N
requires POS N
close POS N
attention POS N
with POS N
respect POS N
to POS N
renal POS N
function. POS N

After POS N
a POS N
mean POS N
follow-up POS N
period POS N
of POS N
96 POS N
weeks, POS N
the POS N
proportion POS N
of POS N
HBV POS N
reactivation POS N
observed POS N
was POS N
6.8% POS N
(4/58) POS N
in POS N
the POS N
LAM+ADV POS N
group POS N
and POS N
4.5% POS N
(5/111) POS N
in POS N
the POS N
TDF POS N
group POS N
by POS N
using POS N
intention-to-treat POS N
analysis POS N
(difference, POS N
-2.3%; POS N
95% POS N
CI, POS N
-9.84-5.24%). POS N

The POS N
efficacy POS N
of POS N
switching POS N
to POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
from POS N
lamivudine POS N
(LAM) POS N
plus POS N
adefovir POS N
dipivoxil POS N
(ADV) POS N
combination POS N
therapy POS N
(stable POS N
switching) POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
chronic POS N
hepatitis POS N
B POS N
(CHB) POS N
and POS N
undetectable POS N
hepatitis POS N
B POS N
virus POS N
(HBV) POS N
DNA POS N
is POS N
not POS N
clear. POS N

None POS N
of POS N
the POS N
subjects POS N
in POS N
either POS N
group POS N
experienced POS N
viral POS N
reactivation POS N
based POS N
on POS N
per POS N
protocol POS N
analysis. POS N

After POS N
a POS N
mean POS N
follow-up POS N
period POS N
of POS N
96 POS N
weeks, POS N
the POS N
proportion POS N
of POS N
HBV POS N
reactivation POS N
observed POS N
was POS N
6.8% POS N
(4/58) POS N
in POS N
the POS N
LAM+ADV POS N
group POS N
and POS N
4.5% POS N
(5/111) POS N
in POS N
the POS N
TDF POS N
group POS N
by POS N
using POS N
intention-to-treat POS N
analysis POS N
(difference, POS N
-2.3%; POS N
95% POS N
CI, POS N
-9.84-5.24%). POS N

None POS N
of POS N
the POS N
subjects POS N
in POS N
either POS N
group POS N
experienced POS N
viral POS N
reactivation POS N
based POS N
on POS N
per POS N
protocol POS N
analysis. POS N

No POS N
serious POS N
adverse POS N
reactions POS N
were POS N
observed. POS N

None POS N
of POS N
the POS N
subjects POS N
in POS N
either POS N
group POS N
experienced POS N
viral POS N
reactivation POS N
based POS N
on POS N
per POS N
protocol POS N
analysis. POS N

In POS N
the POS N
subgroup POS N
analysis POS N
for POS N
estimated POS N
glomerular POS N
filtration POS N
rate POS N
(eGFR) POS N
before POS N
and POS N
after POS N
treatment, POS N
decreased POS N
eGFR POS N
was POS N
observed POS N
only POS N
in POS N
the POS N
TDF POS N
group POS N
with POS N
cirrhosis POS N
(85.22 POS N
vs. POS N
79.83 POS N
mL/min/1.73 POS N
m2, POS N
p POS N
= POS N
0.000). POS N

None POS N
of POS N
the POS N
subjects POS N
in POS N
either POS N
group POS N
experienced POS N
viral POS N
reactivation POS N
based POS N
on POS N
per POS N
protocol POS N
analysis. POS N

Stable POS N
switching POS N
to POS N
TDF POS N
monotherapy POS N
yielded POS N
non-inferior POS N
results POS N
at POS N
96 POS N
weeks POS N
compared POS N
to POS N
the POS N
results POS N
obtained POS N
with POS N
LAM+ADV POS N
combination POS N
therapy POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
CHB POS N
and POS N
undetectable POS N
HBV POS N
DNA. POS N

None POS N
of POS N
the POS N
subjects POS N
in POS N
either POS N
group POS N
experienced POS N
viral POS N
reactivation POS N
based POS N
on POS N
per POS N
protocol POS N
analysis. POS N

However, POS N
TDF POS N
monotherapy POS N
in POS N
patients POS N
with POS N
cirrhosis POS N
requires POS N
close POS N
attention POS N
with POS N
respect POS N
to POS N
renal POS N
function. POS N

None POS N
of POS N
the POS N
subjects POS N
in POS N
either POS N
group POS N
experienced POS N
viral POS N
reactivation POS N
based POS N
on POS N
per POS N
protocol POS N
analysis. POS N

The POS N
efficacy POS N
of POS N
switching POS N
to POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
from POS N
lamivudine POS N
(LAM) POS N
plus POS N
adefovir POS N
dipivoxil POS N
(ADV) POS N
combination POS N
therapy POS N
(stable POS N
switching) POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
chronic POS N
hepatitis POS N
B POS N
(CHB) POS N
and POS N
undetectable POS N
hepatitis POS N
B POS N
virus POS N
(HBV) POS N
DNA POS N
is POS N
not POS N
clear. POS N

No POS N
serious POS N
adverse POS N
reactions POS N
were POS N
observed. POS N

After POS N
a POS N
mean POS N
follow-up POS N
period POS N
of POS N
96 POS N
weeks, POS N
the POS N
proportion POS N
of POS N
HBV POS N
reactivation POS N
observed POS N
was POS N
6.8% POS N
(4/58) POS N
in POS N
the POS N
LAM+ADV POS N
group POS N
and POS N
4.5% POS N
(5/111) POS N
in POS N
the POS N
TDF POS N
group POS N
by POS N
using POS N
intention-to-treat POS N
analysis POS N
(difference, POS N
-2.3%; POS N
95% POS N
CI, POS N
-9.84-5.24%). POS N

No POS N
serious POS N
adverse POS N
reactions POS N
were POS N
observed. POS N

None POS N
of POS N
the POS N
subjects POS N
in POS N
either POS N
group POS N
experienced POS N
viral POS N
reactivation POS N
based POS N
on POS N
per POS N
protocol POS N
analysis. POS N

No POS N
serious POS N
adverse POS N
reactions POS N
were POS N
observed. POS N

In POS N
the POS N
subgroup POS N
analysis POS N
for POS N
estimated POS N
glomerular POS N
filtration POS N
rate POS N
(eGFR) POS N
before POS N
and POS N
after POS N
treatment, POS N
decreased POS N
eGFR POS N
was POS N
observed POS N
only POS N
in POS N
the POS N
TDF POS N
group POS N
with POS N
cirrhosis POS N
(85.22 POS N
vs. POS N
79.83 POS N
mL/min/1.73 POS N
m2, POS N
p POS N
= POS N
0.000). POS N

No POS N
serious POS N
adverse POS N
reactions POS N
were POS N
observed. POS N

Stable POS N
switching POS N
to POS N
TDF POS N
monotherapy POS N
yielded POS N
non-inferior POS N
results POS N
at POS N
96 POS N
weeks POS N
compared POS N
to POS N
the POS N
results POS N
obtained POS N
with POS N
LAM+ADV POS N
combination POS N
therapy POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
CHB POS N
and POS N
undetectable POS N
HBV POS N
DNA. POS N

No POS N
serious POS N
adverse POS N
reactions POS N
were POS N
observed. POS N

However, POS N
TDF POS N
monotherapy POS N
in POS N
patients POS N
with POS N
cirrhosis POS N
requires POS N
close POS N
attention POS N
with POS N
respect POS N
to POS N
renal POS N
function. POS N

No POS N
serious POS N
adverse POS N
reactions POS N
were POS N
observed. POS N

The POS N
efficacy POS N
of POS N
switching POS N
to POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
from POS N
lamivudine POS N
(LAM) POS N
plus POS N
adefovir POS N
dipivoxil POS N
(ADV) POS N
combination POS N
therapy POS N
(stable POS N
switching) POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
chronic POS N
hepatitis POS N
B POS N
(CHB) POS N
and POS N
undetectable POS N
hepatitis POS N
B POS N
virus POS N
(HBV) POS N
DNA POS N
is POS N
not POS N
clear. POS N

In POS N
the POS N
subgroup POS N
analysis POS N
for POS N
estimated POS N
glomerular POS N
filtration POS N
rate POS N
(eGFR) POS N
before POS N
and POS N
after POS N
treatment, POS N
decreased POS N
eGFR POS N
was POS N
observed POS N
only POS N
in POS N
the POS N
TDF POS N
group POS N
with POS N
cirrhosis POS N
(85.22 POS N
vs. POS N
79.83 POS N
mL/min/1.73 POS N
m2, POS N
p POS N
= POS N
0.000). POS N

After POS N
a POS N
mean POS N
follow-up POS N
period POS N
of POS N
96 POS N
weeks, POS N
the POS N
proportion POS N
of POS N
HBV POS N
reactivation POS N
observed POS N
was POS N
6.8% POS N
(4/58) POS N
in POS N
the POS N
LAM+ADV POS N
group POS N
and POS N
4.5% POS N
(5/111) POS N
in POS N
the POS N
TDF POS N
group POS N
by POS N
using POS N
intention-to-treat POS N
analysis POS N
(difference, POS N
-2.3%; POS N
95% POS N
CI, POS N
-9.84-5.24%). POS N

In POS N
the POS N
subgroup POS N
analysis POS N
for POS N
estimated POS N
glomerular POS N
filtration POS N
rate POS N
(eGFR) POS N
before POS N
and POS N
after POS N
treatment, POS N
decreased POS N
eGFR POS N
was POS N
observed POS N
only POS N
in POS N
the POS N
TDF POS N
group POS N
with POS N
cirrhosis POS N
(85.22 POS N
vs. POS N
79.83 POS N
mL/min/1.73 POS N
m2, POS N
p POS N
= POS N
0.000). POS N

None POS N
of POS N
the POS N
subjects POS N
in POS N
either POS N
group POS N
experienced POS N
viral POS N
reactivation POS N
based POS N
on POS N
per POS N
protocol POS N
analysis. POS N

In POS N
the POS N
subgroup POS N
analysis POS N
for POS N
estimated POS N
glomerular POS N
filtration POS N
rate POS N
(eGFR) POS N
before POS N
and POS N
after POS N
treatment, POS N
decreased POS N
eGFR POS N
was POS N
observed POS N
only POS N
in POS N
the POS N
TDF POS N
group POS N
with POS N
cirrhosis POS N
(85.22 POS N
vs. POS N
79.83 POS N
mL/min/1.73 POS N
m2, POS N
p POS N
= POS N
0.000). POS N

No POS N
serious POS N
adverse POS N
reactions POS N
were POS N
observed. POS N

In POS N
the POS N
subgroup POS N
analysis POS N
for POS N
estimated POS N
glomerular POS N
filtration POS N
rate POS N
(eGFR) POS N
before POS N
and POS N
after POS N
treatment, POS N
decreased POS N
eGFR POS N
was POS N
observed POS N
only POS N
in POS N
the POS N
TDF POS N
group POS N
with POS N
cirrhosis POS N
(85.22 POS N
vs. POS N
79.83 POS N
mL/min/1.73 POS N
m2, POS N
p POS N
= POS N
0.000). POS N

Stable POS N
switching POS N
to POS N
TDF POS N
monotherapy POS N
yielded POS N
non-inferior POS N
results POS N
at POS N
96 POS N
weeks POS N
compared POS N
to POS N
the POS N
results POS N
obtained POS N
with POS N
LAM+ADV POS N
combination POS N
therapy POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
CHB POS N
and POS N
undetectable POS N
HBV POS N
DNA. POS N

In POS N
the POS N
subgroup POS N
analysis POS N
for POS N
estimated POS N
glomerular POS N
filtration POS N
rate POS N
(eGFR) POS N
before POS N
and POS N
after POS N
treatment, POS N
decreased POS N
eGFR POS N
was POS N
observed POS N
only POS N
in POS N
the POS N
TDF POS N
group POS N
with POS N
cirrhosis POS N
(85.22 POS N
vs. POS N
79.83 POS N
mL/min/1.73 POS N
m2, POS N
p POS N
= POS N
0.000). POS N

However, POS N
TDF POS N
monotherapy POS N
in POS N
patients POS N
with POS N
cirrhosis POS N
requires POS N
close POS N
attention POS N
with POS N
respect POS N
to POS N
renal POS N
function. POS N

In POS N
the POS N
subgroup POS N
analysis POS N
for POS N
estimated POS N
glomerular POS N
filtration POS N
rate POS N
(eGFR) POS N
before POS N
and POS N
after POS N
treatment, POS N
decreased POS N
eGFR POS N
was POS N
observed POS N
only POS N
in POS N
the POS N
TDF POS N
group POS N
with POS N
cirrhosis POS N
(85.22 POS N
vs. POS N
79.83 POS N
mL/min/1.73 POS N
m2, POS N
p POS N
= POS N
0.000). POS N

The POS N
efficacy POS N
of POS N
switching POS N
to POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
from POS N
lamivudine POS N
(LAM) POS N
plus POS N
adefovir POS N
dipivoxil POS N
(ADV) POS N
combination POS N
therapy POS N
(stable POS N
switching) POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
chronic POS N
hepatitis POS N
B POS N
(CHB) POS N
and POS N
undetectable POS N
hepatitis POS N
B POS N
virus POS N
(HBV) POS N
DNA POS N
is POS N
not POS N
clear. POS N

Stable POS N
switching POS N
to POS N
TDF POS N
monotherapy POS N
yielded POS N
non-inferior POS N
results POS N
at POS N
96 POS N
weeks POS N
compared POS N
to POS N
the POS N
results POS N
obtained POS N
with POS N
LAM+ADV POS N
combination POS N
therapy POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
CHB POS N
and POS N
undetectable POS N
HBV POS N
DNA. POS N

After POS N
a POS N
mean POS N
follow-up POS N
period POS N
of POS N
96 POS N
weeks, POS N
the POS N
proportion POS N
of POS N
HBV POS N
reactivation POS N
observed POS N
was POS N
6.8% POS N
(4/58) POS N
in POS N
the POS N
LAM+ADV POS N
group POS N
and POS N
4.5% POS N
(5/111) POS N
in POS N
the POS N
TDF POS N
group POS N
by POS N
using POS N
intention-to-treat POS N
analysis POS N
(difference, POS N
-2.3%; POS N
95% POS N
CI, POS N
-9.84-5.24%). POS N

Stable POS N
switching POS N
to POS N
TDF POS N
monotherapy POS N
yielded POS N
non-inferior POS N
results POS N
at POS N
96 POS N
weeks POS N
compared POS N
to POS N
the POS N
results POS N
obtained POS N
with POS N
LAM+ADV POS N
combination POS N
therapy POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
CHB POS N
and POS N
undetectable POS N
HBV POS N
DNA. POS N

None POS N
of POS N
the POS N
subjects POS N
in POS N
either POS N
group POS N
experienced POS N
viral POS N
reactivation POS N
based POS N
on POS N
per POS N
protocol POS N
analysis. POS N

Stable POS N
switching POS N
to POS N
TDF POS N
monotherapy POS N
yielded POS N
non-inferior POS N
results POS N
at POS N
96 POS N
weeks POS N
compared POS N
to POS N
the POS N
results POS N
obtained POS N
with POS N
LAM+ADV POS N
combination POS N
therapy POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
CHB POS N
and POS N
undetectable POS N
HBV POS N
DNA. POS N

No POS N
serious POS N
adverse POS N
reactions POS N
were POS N
observed. POS N

Stable POS N
switching POS N
to POS N
TDF POS N
monotherapy POS N
yielded POS N
non-inferior POS N
results POS N
at POS N
96 POS N
weeks POS N
compared POS N
to POS N
the POS N
results POS N
obtained POS N
with POS N
LAM+ADV POS N
combination POS N
therapy POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
CHB POS N
and POS N
undetectable POS N
HBV POS N
DNA. POS N

In POS N
the POS N
subgroup POS N
analysis POS N
for POS N
estimated POS N
glomerular POS N
filtration POS N
rate POS N
(eGFR) POS N
before POS N
and POS N
after POS N
treatment, POS N
decreased POS N
eGFR POS N
was POS N
observed POS N
only POS N
in POS N
the POS N
TDF POS N
group POS N
with POS N
cirrhosis POS N
(85.22 POS N
vs. POS N
79.83 POS N
mL/min/1.73 POS N
m2, POS N
p POS N
= POS N
0.000). POS N

Stable POS N
switching POS N
to POS N
TDF POS N
monotherapy POS N
yielded POS N
non-inferior POS N
results POS N
at POS N
96 POS N
weeks POS N
compared POS N
to POS N
the POS N
results POS N
obtained POS N
with POS N
LAM+ADV POS N
combination POS N
therapy POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
CHB POS N
and POS N
undetectable POS N
HBV POS N
DNA. POS N

However, POS N
TDF POS N
monotherapy POS N
in POS N
patients POS N
with POS N
cirrhosis POS N
requires POS N
close POS N
attention POS N
with POS N
respect POS N
to POS N
renal POS N
function. POS N

Stable POS N
switching POS N
to POS N
TDF POS N
monotherapy POS N
yielded POS N
non-inferior POS N
results POS N
at POS N
96 POS N
weeks POS N
compared POS N
to POS N
the POS N
results POS N
obtained POS N
with POS N
LAM+ADV POS N
combination POS N
therapy POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
CHB POS N
and POS N
undetectable POS N
HBV POS N
DNA. POS N

The POS N
efficacy POS N
of POS N
switching POS N
to POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
from POS N
lamivudine POS N
(LAM) POS N
plus POS N
adefovir POS N
dipivoxil POS N
(ADV) POS N
combination POS N
therapy POS N
(stable POS N
switching) POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
chronic POS N
hepatitis POS N
B POS N
(CHB) POS N
and POS N
undetectable POS N
hepatitis POS N
B POS N
virus POS N
(HBV) POS N
DNA POS N
is POS N
not POS N
clear. POS N

However, POS N
TDF POS N
monotherapy POS N
in POS N
patients POS N
with POS N
cirrhosis POS N
requires POS N
close POS N
attention POS N
with POS N
respect POS N
to POS N
renal POS N
function. POS N

After POS N
a POS N
mean POS N
follow-up POS N
period POS N
of POS N
96 POS N
weeks, POS N
the POS N
proportion POS N
of POS N
HBV POS N
reactivation POS N
observed POS N
was POS N
6.8% POS N
(4/58) POS N
in POS N
the POS N
LAM+ADV POS N
group POS N
and POS N
4.5% POS N
(5/111) POS N
in POS N
the POS N
TDF POS N
group POS N
by POS N
using POS N
intention-to-treat POS N
analysis POS N
(difference, POS N
-2.3%; POS N
95% POS N
CI, POS N
-9.84-5.24%). POS N

However, POS N
TDF POS N
monotherapy POS N
in POS N
patients POS N
with POS N
cirrhosis POS N
requires POS N
close POS N
attention POS N
with POS N
respect POS N
to POS N
renal POS N
function. POS N

None POS N
of POS N
the POS N
subjects POS N
in POS N
either POS N
group POS N
experienced POS N
viral POS N
reactivation POS N
based POS N
on POS N
per POS N
protocol POS N
analysis. POS N

However, POS N
TDF POS N
monotherapy POS N
in POS N
patients POS N
with POS N
cirrhosis POS N
requires POS N
close POS N
attention POS N
with POS N
respect POS N
to POS N
renal POS N
function. POS N

No POS N
serious POS N
adverse POS N
reactions POS N
were POS N
observed. POS N

However, POS N
TDF POS N
monotherapy POS N
in POS N
patients POS N
with POS N
cirrhosis POS N
requires POS N
close POS N
attention POS N
with POS N
respect POS N
to POS N
renal POS N
function. POS N

In POS N
the POS N
subgroup POS N
analysis POS N
for POS N
estimated POS N
glomerular POS N
filtration POS N
rate POS N
(eGFR) POS N
before POS N
and POS N
after POS N
treatment, POS N
decreased POS N
eGFR POS N
was POS N
observed POS N
only POS N
in POS N
the POS N
TDF POS N
group POS N
with POS N
cirrhosis POS N
(85.22 POS N
vs. POS N
79.83 POS N
mL/min/1.73 POS N
m2, POS N
p POS N
= POS N
0.000). POS N

However, POS N
TDF POS N
monotherapy POS N
in POS N
patients POS N
with POS N
cirrhosis POS N
requires POS N
close POS N
attention POS N
with POS N
respect POS N
to POS N
renal POS N
function. POS N

Stable POS N
switching POS N
to POS N
TDF POS N
monotherapy POS N
yielded POS N
non-inferior POS N
results POS N
at POS N
96 POS N
weeks POS N
compared POS N
to POS N
the POS N
results POS N
obtained POS N
with POS N
LAM+ADV POS N
combination POS N
therapy POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
CHB POS N
and POS N
undetectable POS N
HBV POS N
DNA. POS N

However, POS N
TDF POS N
monotherapy POS N
in POS N
patients POS N
with POS N
cirrhosis POS N
requires POS N
close POS N
attention POS N
with POS N
respect POS N
to POS N
renal POS N
function. POS N

The POS N
efficacy POS N
of POS N
switching POS N
to POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
from POS N
lamivudine POS N
(LAM) POS N
plus POS N
adefovir POS N
dipivoxil POS N
(ADV) POS N
combination POS N
therapy POS N
(stable POS N
switching) POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
chronic POS N
hepatitis POS N
B POS N
(CHB) POS N
and POS N
undetectable POS N
hepatitis POS N
B POS N
virus POS N
(HBV) POS N
DNA POS N
is POS N
not POS N
clear. POS N

The POS N
efficacy POS N
of POS N
switching POS N
to POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
from POS N
lamivudine POS N
(LAM) POS N
plus POS N
adefovir POS N
dipivoxil POS N
(ADV) POS N
combination POS N
therapy POS N
(stable POS N
switching) POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
chronic POS N
hepatitis POS N
B POS N
(CHB) POS N
and POS N
undetectable POS N
hepatitis POS N
B POS N
virus POS N
(HBV) POS N
DNA POS N
is POS N
not POS N
clear. POS N

After POS N
a POS N
mean POS N
follow-up POS N
period POS N
of POS N
96 POS N
weeks, POS N
the POS N
proportion POS N
of POS N
HBV POS N
reactivation POS N
observed POS N
was POS N
6.8% POS N
(4/58) POS N
in POS N
the POS N
LAM+ADV POS N
group POS N
and POS N
4.5% POS N
(5/111) POS N
in POS N
the POS N
TDF POS N
group POS N
by POS N
using POS N
intention-to-treat POS N
analysis POS N
(difference, POS N
-2.3%; POS N
95% POS N
CI, POS N
-9.84-5.24%). POS N

The POS N
efficacy POS N
of POS N
switching POS N
to POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
from POS N
lamivudine POS N
(LAM) POS N
plus POS N
adefovir POS N
dipivoxil POS N
(ADV) POS N
combination POS N
therapy POS N
(stable POS N
switching) POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
chronic POS N
hepatitis POS N
B POS N
(CHB) POS N
and POS N
undetectable POS N
hepatitis POS N
B POS N
virus POS N
(HBV) POS N
DNA POS N
is POS N
not POS N
clear. POS N

None POS N
of POS N
the POS N
subjects POS N
in POS N
either POS N
group POS N
experienced POS N
viral POS N
reactivation POS N
based POS N
on POS N
per POS N
protocol POS N
analysis. POS N

The POS N
efficacy POS N
of POS N
switching POS N
to POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
from POS N
lamivudine POS N
(LAM) POS N
plus POS N
adefovir POS N
dipivoxil POS N
(ADV) POS N
combination POS N
therapy POS N
(stable POS N
switching) POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
chronic POS N
hepatitis POS N
B POS N
(CHB) POS N
and POS N
undetectable POS N
hepatitis POS N
B POS N
virus POS N
(HBV) POS N
DNA POS N
is POS N
not POS N
clear. POS N

No POS N
serious POS N
adverse POS N
reactions POS N
were POS N
observed. POS N

The POS N
efficacy POS N
of POS N
switching POS N
to POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
from POS N
lamivudine POS N
(LAM) POS N
plus POS N
adefovir POS N
dipivoxil POS N
(ADV) POS N
combination POS N
therapy POS N
(stable POS N
switching) POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
chronic POS N
hepatitis POS N
B POS N
(CHB) POS N
and POS N
undetectable POS N
hepatitis POS N
B POS N
virus POS N
(HBV) POS N
DNA POS N
is POS N
not POS N
clear. POS N

In POS N
the POS N
subgroup POS N
analysis POS N
for POS N
estimated POS N
glomerular POS N
filtration POS N
rate POS N
(eGFR) POS N
before POS N
and POS N
after POS N
treatment, POS N
decreased POS N
eGFR POS N
was POS N
observed POS N
only POS N
in POS N
the POS N
TDF POS N
group POS N
with POS N
cirrhosis POS N
(85.22 POS N
vs. POS N
79.83 POS N
mL/min/1.73 POS N
m2, POS N
p POS N
= POS N
0.000). POS N

The POS N
efficacy POS N
of POS N
switching POS N
to POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
from POS N
lamivudine POS N
(LAM) POS N
plus POS N
adefovir POS N
dipivoxil POS N
(ADV) POS N
combination POS N
therapy POS N
(stable POS N
switching) POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
chronic POS N
hepatitis POS N
B POS N
(CHB) POS N
and POS N
undetectable POS N
hepatitis POS N
B POS N
virus POS N
(HBV) POS N
DNA POS N
is POS N
not POS N
clear. POS N

Stable POS N
switching POS N
to POS N
TDF POS N
monotherapy POS N
yielded POS N
non-inferior POS N
results POS N
at POS N
96 POS N
weeks POS N
compared POS N
to POS N
the POS N
results POS N
obtained POS N
with POS N
LAM+ADV POS N
combination POS N
therapy POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
CHB POS N
and POS N
undetectable POS N
HBV POS N
DNA. POS N

The POS N
efficacy POS N
of POS N
switching POS N
to POS N
tenofovir POS N
disoproxil POS N
fumarate POS N
(TDF) POS N
monotherapy POS N
from POS N
lamivudine POS N
(LAM) POS N
plus POS N
adefovir POS N
dipivoxil POS N
(ADV) POS N
combination POS N
therapy POS N
(stable POS N
switching) POS N
in POS N
patients POS N
with POS N
LAM-resistant POS N
chronic POS N
hepatitis POS N
B POS N
(CHB) POS N
and POS N
undetectable POS N
hepatitis POS N
B POS N
virus POS N
(HBV) POS N
DNA POS N
is POS N
not POS N
clear. POS N

However, POS N
TDF POS N
monotherapy POS N
in POS N
patients POS N
with POS N
cirrhosis POS N
requires POS N
close POS N
attention POS N
with POS N
respect POS N
to POS N
renal POS N
function. POS N

Ocular POS N
irritation POS N
was POS N
frequently POS N
seen POS N
in POS N
DTFC POS N
group. POS N

Intra-ocular POS N
pressure POS N
(IOP) POS N
change POS N
from POS N
baseline POS N
at POS N
9 POS N
AM/11 POS N
AM POS N
pooled POS N
over POS N
the POS N
8 POS N
weeks POS N
was POS N
-3.3/-3.3 POS N
mmHg POS N
in POS N
the POS N
BTFC POS N
group POS N
and POS N
-2.9/-3.4 POS N
mmHg POS N
in POS N
the POS N
DTFC POS N
group, POS N

Ocular POS N
irritation POS N
was POS N
frequently POS N
seen POS N
in POS N
DTFC POS N
group. POS N

blurred POS N
vision POS N
was POS N
frequently POS N
seen POS N
in POS N
BTFC POS N
group, POS N

Ocular POS N
irritation POS N
was POS N
frequently POS N
seen POS N
in POS N
DTFC POS N
group. POS N

Non-inferiority POS N
of POS N
BTFC POS N
to POS N
DTFC POS N
in POS N
IOP POS N
reduction POS N
was POS N
demonstrated POS N
after POS N
adding POS N
onto POS N
PGA POS N
therapy POS N
in POS N
Japanese POS N
OAG/OH POS N
patients. POS N

Ocular POS N
irritation POS N
was POS N
frequently POS N
seen POS N
in POS N
DTFC POS N
group. POS N

the POS N
score POS N
of POS N
blurred POS N
vision POS N
was POS N
transiently POS N
higher POS N
in POS N
BTFC POS N
than POS N
DTFC, POS N

Ocular POS N
irritation POS N
was POS N
frequently POS N
seen POS N
in POS N
DTFC POS N
group. POS N

BTFC POS N
can POS N
be POS N
considered POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
agent POS N
for POS N
glaucoma POS N
treatment. POS N

Ocular POS N
irritation POS N
was POS N
frequently POS N
seen POS N
in POS N
DTFC POS N
group. POS N

treatment POS N
difference POS N
decreased POS N
and POS N
disappeared POS N
with POS N
time. POS N

Ocular POS N
irritation POS N
was POS N
frequently POS N
seen POS N
in POS N
DTFC POS N
group. POS N

No POS N
noteworthy POS N
issue POS N
was POS N
observed POS N
in POS N
other POS N
safety POS N
outcome. POS N

Intra-ocular POS N
pressure POS N
(IOP) POS N
change POS N
from POS N
baseline POS N
at POS N
9 POS N
AM/11 POS N
AM POS N
pooled POS N
over POS N
the POS N
8 POS N
weeks POS N
was POS N
-3.3/-3.3 POS N
mmHg POS N
in POS N
the POS N
BTFC POS N
group POS N
and POS N
-2.9/-3.4 POS N
mmHg POS N
in POS N
the POS N
DTFC POS N
group, POS N

Ocular POS N
irritation POS N
was POS N
frequently POS N
seen POS N
in POS N
DTFC POS N
group. POS N

Intra-ocular POS N
pressure POS N
(IOP) POS N
change POS N
from POS N
baseline POS N
at POS N
9 POS N
AM/11 POS N
AM POS N
pooled POS N
over POS N
the POS N
8 POS N
weeks POS N
was POS N
-3.3/-3.3 POS N
mmHg POS N
in POS N
the POS N
BTFC POS N
group POS N
and POS N
-2.9/-3.4 POS N
mmHg POS N
in POS N
the POS N
DTFC POS N
group, POS N

blurred POS N
vision POS N
was POS N
frequently POS N
seen POS N
in POS N
BTFC POS N
group, POS N

Intra-ocular POS N
pressure POS N
(IOP) POS N
change POS N
from POS N
baseline POS N
at POS N
9 POS N
AM/11 POS N
AM POS N
pooled POS N
over POS N
the POS N
8 POS N
weeks POS N
was POS N
-3.3/-3.3 POS N
mmHg POS N
in POS N
the POS N
BTFC POS N
group POS N
and POS N
-2.9/-3.4 POS N
mmHg POS N
in POS N
the POS N
DTFC POS N
group, POS N

Non-inferiority POS N
of POS N
BTFC POS N
to POS N
DTFC POS N
in POS N
IOP POS N
reduction POS N
was POS N
demonstrated POS N
after POS N
adding POS N
onto POS N
PGA POS N
therapy POS N
in POS N
Japanese POS N
OAG/OH POS N
patients. POS N

Intra-ocular POS N
pressure POS N
(IOP) POS N
change POS N
from POS N
baseline POS N
at POS N
9 POS N
AM/11 POS N
AM POS N
pooled POS N
over POS N
the POS N
8 POS N
weeks POS N
was POS N
-3.3/-3.3 POS N
mmHg POS N
in POS N
the POS N
BTFC POS N
group POS N
and POS N
-2.9/-3.4 POS N
mmHg POS N
in POS N
the POS N
DTFC POS N
group, POS N

the POS N
score POS N
of POS N
blurred POS N
vision POS N
was POS N
transiently POS N
higher POS N
in POS N
BTFC POS N
than POS N
DTFC, POS N

Intra-ocular POS N
pressure POS N
(IOP) POS N
change POS N
from POS N
baseline POS N
at POS N
9 POS N
AM/11 POS N
AM POS N
pooled POS N
over POS N
the POS N
8 POS N
weeks POS N
was POS N
-3.3/-3.3 POS N
mmHg POS N
in POS N
the POS N
BTFC POS N
group POS N
and POS N
-2.9/-3.4 POS N
mmHg POS N
in POS N
the POS N
DTFC POS N
group, POS N

BTFC POS N
can POS N
be POS N
considered POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
agent POS N
for POS N
glaucoma POS N
treatment. POS N

Intra-ocular POS N
pressure POS N
(IOP) POS N
change POS N
from POS N
baseline POS N
at POS N
9 POS N
AM/11 POS N
AM POS N
pooled POS N
over POS N
the POS N
8 POS N
weeks POS N
was POS N
-3.3/-3.3 POS N
mmHg POS N
in POS N
the POS N
BTFC POS N
group POS N
and POS N
-2.9/-3.4 POS N
mmHg POS N
in POS N
the POS N
DTFC POS N
group, POS N

treatment POS N
difference POS N
decreased POS N
and POS N
disappeared POS N
with POS N
time. POS N

Intra-ocular POS N
pressure POS N
(IOP) POS N
change POS N
from POS N
baseline POS N
at POS N
9 POS N
AM/11 POS N
AM POS N
pooled POS N
over POS N
the POS N
8 POS N
weeks POS N
was POS N
-3.3/-3.3 POS N
mmHg POS N
in POS N
the POS N
BTFC POS N
group POS N
and POS N
-2.9/-3.4 POS N
mmHg POS N
in POS N
the POS N
DTFC POS N
group, POS N

No POS N
noteworthy POS N
issue POS N
was POS N
observed POS N
in POS N
other POS N
safety POS N
outcome. POS N

blurred POS N
vision POS N
was POS N
frequently POS N
seen POS N
in POS N
BTFC POS N
group, POS N

Ocular POS N
irritation POS N
was POS N
frequently POS N
seen POS N
in POS N
DTFC POS N
group. POS N

blurred POS N
vision POS N
was POS N
frequently POS N
seen POS N
in POS N
BTFC POS N
group, POS N

Intra-ocular POS N
pressure POS N
(IOP) POS N
change POS N
from POS N
baseline POS N
at POS N
9 POS N
AM/11 POS N
AM POS N
pooled POS N
over POS N
the POS N
8 POS N
weeks POS N
was POS N
-3.3/-3.3 POS N
mmHg POS N
in POS N
the POS N
BTFC POS N
group POS N
and POS N
-2.9/-3.4 POS N
mmHg POS N
in POS N
the POS N
DTFC POS N
group, POS N

blurred POS N
vision POS N
was POS N
frequently POS N
seen POS N
in POS N
BTFC POS N
group, POS N

Non-inferiority POS N
of POS N
BTFC POS N
to POS N
DTFC POS N
in POS N
IOP POS N
reduction POS N
was POS N
demonstrated POS N
after POS N
adding POS N
onto POS N
PGA POS N
therapy POS N
in POS N
Japanese POS N
OAG/OH POS N
patients. POS N

blurred POS N
vision POS N
was POS N
frequently POS N
seen POS N
in POS N
BTFC POS N
group, POS N

the POS N
score POS N
of POS N
blurred POS N
vision POS N
was POS N
transiently POS N
higher POS N
in POS N
BTFC POS N
than POS N
DTFC, POS N

blurred POS N
vision POS N
was POS N
frequently POS N
seen POS N
in POS N
BTFC POS N
group, POS N

BTFC POS N
can POS N
be POS N
considered POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
agent POS N
for POS N
glaucoma POS N
treatment. POS N

blurred POS N
vision POS N
was POS N
frequently POS N
seen POS N
in POS N
BTFC POS N
group, POS N

treatment POS N
difference POS N
decreased POS N
and POS N
disappeared POS N
with POS N
time. POS N

blurred POS N
vision POS N
was POS N
frequently POS N
seen POS N
in POS N
BTFC POS N
group, POS N

No POS N
noteworthy POS N
issue POS N
was POS N
observed POS N
in POS N
other POS N
safety POS N
outcome. POS N

Non-inferiority POS N
of POS N
BTFC POS N
to POS N
DTFC POS N
in POS N
IOP POS N
reduction POS N
was POS N
demonstrated POS N
after POS N
adding POS N
onto POS N
PGA POS N
therapy POS N
in POS N
Japanese POS N
OAG/OH POS N
patients. POS N

Ocular POS N
irritation POS N
was POS N
frequently POS N
seen POS N
in POS N
DTFC POS N
group. POS N

Non-inferiority POS N
of POS N
BTFC POS N
to POS N
DTFC POS N
in POS N
IOP POS N
reduction POS N
was POS N
demonstrated POS N
after POS N
adding POS N
onto POS N
PGA POS N
therapy POS N
in POS N
Japanese POS N
OAG/OH POS N
patients. POS N

Intra-ocular POS N
pressure POS N
(IOP) POS N
change POS N
from POS N
baseline POS N
at POS N
9 POS N
AM/11 POS N
AM POS N
pooled POS N
over POS N
the POS N
8 POS N
weeks POS N
was POS N
-3.3/-3.3 POS N
mmHg POS N
in POS N
the POS N
BTFC POS N
group POS N
and POS N
-2.9/-3.4 POS N
mmHg POS N
in POS N
the POS N
DTFC POS N
group, POS N

Non-inferiority POS N
of POS N
BTFC POS N
to POS N
DTFC POS N
in POS N
IOP POS N
reduction POS N
was POS N
demonstrated POS N
after POS N
adding POS N
onto POS N
PGA POS N
therapy POS N
in POS N
Japanese POS N
OAG/OH POS N
patients. POS N

blurred POS N
vision POS N
was POS N
frequently POS N
seen POS N
in POS N
BTFC POS N
group, POS N

Non-inferiority POS N
of POS N
BTFC POS N
to POS N
DTFC POS N
in POS N
IOP POS N
reduction POS N
was POS N
demonstrated POS N
after POS N
adding POS N
onto POS N
PGA POS N
therapy POS N
in POS N
Japanese POS N
OAG/OH POS N
patients. POS N

the POS N
score POS N
of POS N
blurred POS N
vision POS N
was POS N
transiently POS N
higher POS N
in POS N
BTFC POS N
than POS N
DTFC, POS N

Non-inferiority POS N
of POS N
BTFC POS N
to POS N
DTFC POS N
in POS N
IOP POS N
reduction POS N
was POS N
demonstrated POS N
after POS N
adding POS N
onto POS N
PGA POS N
therapy POS N
in POS N
Japanese POS N
OAG/OH POS N
patients. POS N

BTFC POS N
can POS N
be POS N
considered POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
agent POS N
for POS N
glaucoma POS N
treatment. POS N

Non-inferiority POS N
of POS N
BTFC POS N
to POS N
DTFC POS N
in POS N
IOP POS N
reduction POS N
was POS N
demonstrated POS N
after POS N
adding POS N
onto POS N
PGA POS N
therapy POS N
in POS N
Japanese POS N
OAG/OH POS N
patients. POS N

treatment POS N
difference POS N
decreased POS N
and POS N
disappeared POS N
with POS N
time. POS N

Non-inferiority POS N
of POS N
BTFC POS N
to POS N
DTFC POS N
in POS N
IOP POS N
reduction POS N
was POS N
demonstrated POS N
after POS N
adding POS N
onto POS N
PGA POS N
therapy POS N
in POS N
Japanese POS N
OAG/OH POS N
patients. POS N

No POS N
noteworthy POS N
issue POS N
was POS N
observed POS N
in POS N
other POS N
safety POS N
outcome. POS N

the POS N
score POS N
of POS N
blurred POS N
vision POS N
was POS N
transiently POS N
higher POS N
in POS N
BTFC POS N
than POS N
DTFC, POS N

Ocular POS N
irritation POS N
was POS N
frequently POS N
seen POS N
in POS N
DTFC POS N
group. POS N

the POS N
score POS N
of POS N
blurred POS N
vision POS N
was POS N
transiently POS N
higher POS N
in POS N
BTFC POS N
than POS N
DTFC, POS N

Intra-ocular POS N
pressure POS N
(IOP) POS N
change POS N
from POS N
baseline POS N
at POS N
9 POS N
AM/11 POS N
AM POS N
pooled POS N
over POS N
the POS N
8 POS N
weeks POS N
was POS N
-3.3/-3.3 POS N
mmHg POS N
in POS N
the POS N
BTFC POS N
group POS N
and POS N
-2.9/-3.4 POS N
mmHg POS N
in POS N
the POS N
DTFC POS N
group, POS N

the POS N
score POS N
of POS N
blurred POS N
vision POS N
was POS N
transiently POS N
higher POS N
in POS N
BTFC POS N
than POS N
DTFC, POS N

blurred POS N
vision POS N
was POS N
frequently POS N
seen POS N
in POS N
BTFC POS N
group, POS N

the POS N
score POS N
of POS N
blurred POS N
vision POS N
was POS N
transiently POS N
higher POS N
in POS N
BTFC POS N
than POS N
DTFC, POS N

Non-inferiority POS N
of POS N
BTFC POS N
to POS N
DTFC POS N
in POS N
IOP POS N
reduction POS N
was POS N
demonstrated POS N
after POS N
adding POS N
onto POS N
PGA POS N
therapy POS N
in POS N
Japanese POS N
OAG/OH POS N
patients. POS N

the POS N
score POS N
of POS N
blurred POS N
vision POS N
was POS N
transiently POS N
higher POS N
in POS N
BTFC POS N
than POS N
DTFC, POS N

BTFC POS N
can POS N
be POS N
considered POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
agent POS N
for POS N
glaucoma POS N
treatment. POS N

the POS N
score POS N
of POS N
blurred POS N
vision POS N
was POS N
transiently POS N
higher POS N
in POS N
BTFC POS N
than POS N
DTFC, POS N

treatment POS N
difference POS N
decreased POS N
and POS N
disappeared POS N
with POS N
time. POS N

the POS N
score POS N
of POS N
blurred POS N
vision POS N
was POS N
transiently POS N
higher POS N
in POS N
BTFC POS N
than POS N
DTFC, POS N

No POS N
noteworthy POS N
issue POS N
was POS N
observed POS N
in POS N
other POS N
safety POS N
outcome. POS N

BTFC POS N
can POS N
be POS N
considered POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
agent POS N
for POS N
glaucoma POS N
treatment. POS N

Ocular POS N
irritation POS N
was POS N
frequently POS N
seen POS N
in POS N
DTFC POS N
group. POS N

BTFC POS N
can POS N
be POS N
considered POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
agent POS N
for POS N
glaucoma POS N
treatment. POS N

Intra-ocular POS N
pressure POS N
(IOP) POS N
change POS N
from POS N
baseline POS N
at POS N
9 POS N
AM/11 POS N
AM POS N
pooled POS N
over POS N
the POS N
8 POS N
weeks POS N
was POS N
-3.3/-3.3 POS N
mmHg POS N
in POS N
the POS N
BTFC POS N
group POS N
and POS N
-2.9/-3.4 POS N
mmHg POS N
in POS N
the POS N
DTFC POS N
group, POS N

BTFC POS N
can POS N
be POS N
considered POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
agent POS N
for POS N
glaucoma POS N
treatment. POS N

blurred POS N
vision POS N
was POS N
frequently POS N
seen POS N
in POS N
BTFC POS N
group, POS N

BTFC POS N
can POS N
be POS N
considered POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
agent POS N
for POS N
glaucoma POS N
treatment. POS N

Non-inferiority POS N
of POS N
BTFC POS N
to POS N
DTFC POS N
in POS N
IOP POS N
reduction POS N
was POS N
demonstrated POS N
after POS N
adding POS N
onto POS N
PGA POS N
therapy POS N
in POS N
Japanese POS N
OAG/OH POS N
patients. POS N

BTFC POS N
can POS N
be POS N
considered POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
agent POS N
for POS N
glaucoma POS N
treatment. POS N

the POS N
score POS N
of POS N
blurred POS N
vision POS N
was POS N
transiently POS N
higher POS N
in POS N
BTFC POS N
than POS N
DTFC, POS N

BTFC POS N
can POS N
be POS N
considered POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
agent POS N
for POS N
glaucoma POS N
treatment. POS N

treatment POS N
difference POS N
decreased POS N
and POS N
disappeared POS N
with POS N
time. POS N

BTFC POS N
can POS N
be POS N
considered POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
agent POS N
for POS N
glaucoma POS N
treatment. POS N

No POS N
noteworthy POS N
issue POS N
was POS N
observed POS N
in POS N
other POS N
safety POS N
outcome. POS N

treatment POS N
difference POS N
decreased POS N
and POS N
disappeared POS N
with POS N
time. POS N

Ocular POS N
irritation POS N
was POS N
frequently POS N
seen POS N
in POS N
DTFC POS N
group. POS N

treatment POS N
difference POS N
decreased POS N
and POS N
disappeared POS N
with POS N
time. POS N

Intra-ocular POS N
pressure POS N
(IOP) POS N
change POS N
from POS N
baseline POS N
at POS N
9 POS N
AM/11 POS N
AM POS N
pooled POS N
over POS N
the POS N
8 POS N
weeks POS N
was POS N
-3.3/-3.3 POS N
mmHg POS N
in POS N
the POS N
BTFC POS N
group POS N
and POS N
-2.9/-3.4 POS N
mmHg POS N
in POS N
the POS N
DTFC POS N
group, POS N

treatment POS N
difference POS N
decreased POS N
and POS N
disappeared POS N
with POS N
time. POS N

blurred POS N
vision POS N
was POS N
frequently POS N
seen POS N
in POS N
BTFC POS N
group, POS N

treatment POS N
difference POS N
decreased POS N
and POS N
disappeared POS N
with POS N
time. POS N

Non-inferiority POS N
of POS N
BTFC POS N
to POS N
DTFC POS N
in POS N
IOP POS N
reduction POS N
was POS N
demonstrated POS N
after POS N
adding POS N
onto POS N
PGA POS N
therapy POS N
in POS N
Japanese POS N
OAG/OH POS N
patients. POS N

treatment POS N
difference POS N
decreased POS N
and POS N
disappeared POS N
with POS N
time. POS N

the POS N
score POS N
of POS N
blurred POS N
vision POS N
was POS N
transiently POS N
higher POS N
in POS N
BTFC POS N
than POS N
DTFC, POS N

treatment POS N
difference POS N
decreased POS N
and POS N
disappeared POS N
with POS N
time. POS N

BTFC POS N
can POS N
be POS N
considered POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
agent POS N
for POS N
glaucoma POS N
treatment. POS N

treatment POS N
difference POS N
decreased POS N
and POS N
disappeared POS N
with POS N
time. POS N

No POS N
noteworthy POS N
issue POS N
was POS N
observed POS N
in POS N
other POS N
safety POS N
outcome. POS N

No POS N
noteworthy POS N
issue POS N
was POS N
observed POS N
in POS N
other POS N
safety POS N
outcome. POS N

Ocular POS N
irritation POS N
was POS N
frequently POS N
seen POS N
in POS N
DTFC POS N
group. POS N

No POS N
noteworthy POS N
issue POS N
was POS N
observed POS N
in POS N
other POS N
safety POS N
outcome. POS N

Intra-ocular POS N
pressure POS N
(IOP) POS N
change POS N
from POS N
baseline POS N
at POS N
9 POS N
AM/11 POS N
AM POS N
pooled POS N
over POS N
the POS N
8 POS N
weeks POS N
was POS N
-3.3/-3.3 POS N
mmHg POS N
in POS N
the POS N
BTFC POS N
group POS N
and POS N
-2.9/-3.4 POS N
mmHg POS N
in POS N
the POS N
DTFC POS N
group, POS N

No POS N
noteworthy POS N
issue POS N
was POS N
observed POS N
in POS N
other POS N
safety POS N
outcome. POS N

blurred POS N
vision POS N
was POS N
frequently POS N
seen POS N
in POS N
BTFC POS N
group, POS N

No POS N
noteworthy POS N
issue POS N
was POS N
observed POS N
in POS N
other POS N
safety POS N
outcome. POS N

Non-inferiority POS N
of POS N
BTFC POS N
to POS N
DTFC POS N
in POS N
IOP POS N
reduction POS N
was POS N
demonstrated POS N
after POS N
adding POS N
onto POS N
PGA POS N
therapy POS N
in POS N
Japanese POS N
OAG/OH POS N
patients. POS N

No POS N
noteworthy POS N
issue POS N
was POS N
observed POS N
in POS N
other POS N
safety POS N
outcome. POS N

the POS N
score POS N
of POS N
blurred POS N
vision POS N
was POS N
transiently POS N
higher POS N
in POS N
BTFC POS N
than POS N
DTFC, POS N

No POS N
noteworthy POS N
issue POS N
was POS N
observed POS N
in POS N
other POS N
safety POS N
outcome. POS N

BTFC POS N
can POS N
be POS N
considered POS N
as POS N
a POS N
safe POS N
and POS N
effective POS N
agent POS N
for POS N
glaucoma POS N
treatment. POS N

No POS N
noteworthy POS N
issue POS N
was POS N
observed POS N
in POS N
other POS N
safety POS N
outcome. POS N

treatment POS N
difference POS N
decreased POS N
and POS N
disappeared POS N
with POS N
time. POS N

